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values were always normal. Patient #4 showed partial response in the CT-scan after 6 
weeks of treatment, and benefit was confirmed later on by CT-scan after 12 weeks; he 
reported a clinical benefit for decrease of fatigue and chest pain; his basal Magnesium 
value was lower than normal and it has been always abnormal at every further blood 
check during PD-L1 treatment. Patient #5 showed partial response in the CT-scan after 6 
weeks of treatment; she reported a clinical benefit for decrease of fatigue and increase 
of appetite; her basal Magnesium value was lower than normal and she continued to have 
low magnesemia at every further blood check during anti-PD-L1 treatment. Conclusion: 
evaluation of response may be difficult with immune checkpoint inhibitors and in one 
case we performed a biopsy to study tumor infiltrating lymphocytes to decide whether 
pseudoprogression or real progression. Data about PDL1 expression were not available 
because patients in a clinical trial. In our experience lower basal Magnesium value may 
predict a clinical benefit with anti-PD-L1, although we do not know its possible explanation. 
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Background: Recent reports have suggested an association between non-small cell 
lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) gene mutations. 
Other studies have indicated that EGFR signaling can activate PD-L1 expression and 
immune escape in mutant EGFR driven NSCLC. Furthermore PD-L1 expression is down-
regulated by EGFR TKI. In this study, we aim to determine the association between 
tumoral and immune cell PDL1 expression and clinical characteristics and outcome 
in EGFR mutant NSCLC patients treated with first line EGFR TKI. Methods: Tumors 
from 90 patients with advanced stage NSCLC with EGFR mutations and treated with 
first line EGFR TKI were analyzed. Double staining for CD3 and PDL1 was performed 
by immunohistochemistry. PDL1 expression in tumour membrane, and PDL1 and 
CD3 expression in tumor and stromal immune cells were segmented and quantified 
using the Vectra slide imaging system (Perkin Elmer, Waltham, MA). Results: The 
median age of patients was 62 (range 34-88) years, 64 (71%) were female, 69 (77%) 
were never smokers, and 43 (48%) harbored EGFR exon 19 deletion. Most immune 
cells were CD3-ve and PDL1-ve in the tumor (median 99%) and stroma (median 86%). 
PDL1 tumor membrane expression was associated with PDL1 expression in CD3+ve 
immune in the tumor and stroma. There was no association between PDL1 or CD3 
expression with response rate or time to progression. Conclusion: This is the first 
study to characterize PDL1 expression in immune cells in advanced stage NSCLC 
harboring EGFR mutations. PDL1+ve immune cells are rare in this patient population. 
PDL1 expression in tumor membrane and immune cells may not be associated with 
outcome in NSCLC patients harboring EGFR mutations and treated with EGFR TKIs. 
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Omachi1, Norio Okamoto2, Hidekazu Suzuki2, Kyoichi Okishio3, Tomonori Hirashima2, 
Shinji Atagi3 1Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai/Japan, 2Thoracic 
Oncology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino/
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Background: Good efficacy and survival was observed in patients with advanced non-
small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation. And 
the phase II study treated with gefitinib plus carboplatin and S-1 previously demonstrated 
the good efficacy in terms of progression free survival (PFS) and response rate (RR) 
as the first-line treatment of advanced NSCLC harboring activating EGFR mutations. 
Methods: This trial was multi-center, open rabel, single arm trial. All patients had a 
dvanced non-small cell lung cancer (Stage IIIB / IV) harboring activating mutations.A 
total of 35 patients received carboplatin on day 1 plus oral S-1 on days 1–14 and 
gefitinib daily. Updated results and subgroup analysis according to EGFR mutations 
are presented. Results: All patients had lung adenocarcinoma with activating EGFR 
mutations, namely, deletion (exon 19; n = 22), L858R (exon 21; n = 12), and T790M/
L858R (exons 20 and 21; n = 1). Almost all patients had stage IV disease. The updated 
analysis revealed response rate of 85.7 %, a median PFS of 17.6 months (95% CI: 13.4 - 
23.0 months), and a median overall survival (OS) was not reached (95% CI: 27.8 months 
-). Response rate and median PFS and median OS were 90.9 %, 18.7 months (95% CI: 
15.5 - 28.4 months) and not reached (95% CI: 27.8 months -) in the exon 19 del+ arm, 
and 83.3 %, 13.4 months (95% CI: 6.2 - 18.5 months), and 27.9 months (95% CI: 10.1 
- 32.4 months) in the exon 21 (L858R) arm. The common toxicities related to gefitinib 
were skin rash, elevated transaminase and diarrhea. And the common toxicity in the 
present trial was neutropenia. No interstitial lung disease or treatment-related deaths 
occurred. Conclusion: This triplet chemotherapy showed good efficacy and prolonged 
PFS. And this analysis showed the different efficacy in terms of PFS and OS of gefitinib plus 
carboplatin plus S-1 in patients with advanced NSCLC between EGFR mutation subtypes. 
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P1.01-001 Pembrolizumab for Advanced NSCLC: Patterns of Response and 
Progression Jenny H. Lee1, John J. Park1, Val Gebski2, Raymond Tangunan3, Matthew 
M. Chan4, Bo Gao1, Rina Hui1 1Department of Medical Oncology, Crown Princess Mary 
Cancer Centre, Westmead Hospital, Sydney/NSW/Australia, 2Nhmrc Clinical Trials Centre, 
University of Sydney, Sydney/NSW/Australia, 3Clinical Trials Unit, Crown Princess Mary 
Cancer Centre, Westmead Hospital, Sydney/NSW/Australia, 4Department of Medical 
Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford/NSW/Australia
Background: Anti-PD1 therapy has activity in patients with NSCLC, as assessed by 
RECIST or immune-related response criteria (irRC) on selected index lesions. Baseline 
tumour size was reported as an independent predictor of response to pembrolizumab 
in melanoma, but little is known about NSCLC. Tumour burden varies depending on 
number and size of lesions. We investigate the relationship of treatment response 
and baseline disease burden using comprehensive lesion-specific analysis on imaging 
at a single centre from a large multicentre Phase I study. Methods: Clinicopathologic 
characteristics of patients with advanced NSCLC enrolled from May 2012 to April 2014 
at Westmead Hospital on the phase I pembrolizumab (MK-3475) KEYNOTE-001 were 
collected, including age, ethnicity, smoking status, histopathology (squamous or non-
squamous), stage and prior treatments. Patients were treated with pembrolizumab 
until disease progression determined by irRC on index lesions or intolerable toxicity. 
Bi-dimensional measurements of individual lesions on computed tomography scans at 
baseline, week 9 and thereafter were performed. Every metastasis ≥5mm (up to 30 
lesions per organ, excluding bone) and every lymph node ≥15mm in the short axis were 
assessed. Overall response was determined by change in sum of the product of longest 
perpendicular diameters (SPD) and categorised as complete response (CR, 100% 
reduction SPD), partial response (PR, ≥50% reduction SPD), progressive disease (PD, 
≥25% increase in SPD) or stable disease (SD, neither CR/PR/PD) using comprehensive 
lesion-specific analysis. Results: Of 25 evaluable patients with at least one post-baseline 
imaging, 12 were treatment-naïve, 21 were PD-L1 positive (>1% staining of cells) 
determined by prototype assay using 22C3 antibody and 4 were unknown. A total of 
226 lesions were evaluated, 196 at baseline and 22 new lesions by first scan. Objective 
response (OR, ≥50% reduction SPD) was achieved in 9/25 patients (36%) by first scan, 
with 1 out of the 9 patients subsequently achieving CR. The patients with treatment 
response by first scan had a lower median number of lesions at baseline, 4.0 (range 2-8) 
vs 8.5 (range 4-30) and a lower median SPD per patient at baseline, 2516 vs 4178.5 
Clinical benefit (CR/PR/SD) occurred in 15/25 patients (60%) with median treatment 
duration of 18.4 months (range 2.8 – 33.5 months). At the time of analysis on 11 April 
2015, 10/25 patients were still receiving ongoing treatment. Clinical benefit was seen in 
14/17 Caucasians and 1/8 non-Caucasians; 14/16 current or former smokers and 1/9 
non-smokers. However, all Asians but one were non-smokers and this ex-smoker was 
the only Asian patient who achieved SD as best response. No differences were found in 
histopathology, stage, number of prior treatments or age. Conclusion:Fewer lesions or 
lower tumour burden at baseline as determined by comprehensive lesion-specific analysis 
may predict treatment response to anti-PD1 in advanced NSCLC. More responses were 
also observed in Caucasians and current or former smokers. Due to small sample size, 
these results need to be interpreted with caution and warrant further investigation. 
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P1.01-002 Response Evaluation and Predictors in NSCLC During Treatment 
with AntiPD-L1 Alessandra Bearz, Eleonora Berto, Luca Cancian, Tiziana Perin, Ivana 
Sartor, Umberto Tirelli Medical Oncology, CRO-IRCCS, Aviano/Italy
Background: Treatment of metastatic NSCLC patients with immune-checkpoint 
medicine is intriguing for the potential efficacy, even in difficult setting such as 
smokers or squamous-carcinoma; however it may be difficult to evaluate the clinical 
response due to the lack of reliable immuno-monitoring markers and the possibility 
of radiological pseudo-progression. Methods: not applicable Results: Herein we 
report five cases treated with antiPD-L1(MPDL3280A, Genentech): four patients were 
male and one female, all of them were ex-smokers, affected by metastatic NSCLC; 4 
adeno- and 1 squamous cell carcinoma- in progression after one cycle of platin-based 
combined chemotherapy, median age 60 yrs (58-64), renal function after cisplatin was 
normal. They received anti-PD-L1 i.v. every 3 weeks in a clinical trial. Two patients had 
progression of disease, while 3 patients showed a clinical benefit. Patient #1 had stable 
disease at the pleural and right lung disease in the CT-scan after 6 weeks of treatment. 
He had low Magnesium values at basal and at every further control during PD-L1 therapy. 
Patient #2 showed progression of mediastinal lymph nodes and liver metastases in 
the CT scan after 6 weeks of treatment and progression was confirmed by CT-scans 
4 and 8 weeks later; eventually a biopsy of the liver metastasis confirmed that there 
was a massive neoplastic invasion with tumor infiltrating lymphocytes (Tils) <5%. His 
basal Magnesium values were always normal. He stopped anti-PD-L1 therapy due to 
progression. Patient #3 had a volumetric increase of bilateral lung nodules in the CT-scan 
after 6 weeks while mediastinal lymph nodes were stable; lung nodules again and lymph 
nodes were both in progression 12 weeks later. His basal and further on Magnesium 
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for disease progression wich is followed by second-line therapy in proper patients. 
Maintenance therapy were introduced, with either biologic or chemotherapeutic agents, 
given after first line treatment, trying to prevent progression and increasing progression-
free survival (PFS). Ten years ago, somatic mutations in epidermal growth factor receptor 
(EGFR) were identified in patients with NSCLC, those targeted agents, used previously as 
maintenance, were seen to inactivate specific mutated proteins, and treatment of them 
has changed. For patients with lung adenocarcinoma and activating EGFR mutations 
who received EGFR TKIs median overall survival (OS) ranges between 24 and 30 
months contrasts with the plateau of 10 months reached with first line platinum-based 
chemotherapy in populations not selected by molecular profiling. Methods: We analyze 
all patients attended in our hospital with NSCLC, who had received EGFR-TKI since 2010. 
Continuous variables were summarized as arithmetic means, medians and standard 
deviations. Categorical variables were reported as proportions with 95% confidence 
intervals (95% CI). OS were measured from the day of EGFR TKI treatment to the date of 
death and analyzed with the Kaplan-Meier technique, Results: The amount of patients 
were 53. EGFR mutation was detected in 46 (86,8%) patients. The median patient age 
was 62.8 ± 19 years, 58.5% were women, 41.5 % had a history of non-smoking and 73% 
had adenocarcinoma histology. Six types of EGFR gene mutations were found: delection 
in exon 19, exon 18 (G719), exon 20(T790 and S768I),exon 21 (L861Q and L858R). There 
were 17 (32%) patients with exon 19 delection, 7 (13.2%) patients with exon 18 G719 
mutation, 4 (7.5%) and 13 (24.5%) patients with exon 21 L861Q and L858R respectively, 
4 (7.5%) with double mutation (two combinations of G719 and L861Q, one combination 
of G719 plus S768I, and one combination of delection in 19 exon and T790 mutation). 
Delection in exon 19 and L858R exon 21 mutations were higher in non-smoking patients 
(31.8% and 40.9%) and in women (35.5% and 32.3%). Mutations in exon 18 (G719) and 
delection in exon 19 -also- were higher in patients with smoking history (19.4% and 29%) 
and in men (18.2% and 22.7%). 79.2% received ITK as first line treatment and 1.9% 
as maintenance therapy. 50.9% had erlotinib, 43.4% had gefitinib and 3.8% received 
dacomitinib. 13 patients (24.5%) have recieved further lines of therapy including: 
chemotherapy, immunotherapy and second generation EGFR TKIs. Prognosis was worse 
in unkwoun mutations and in wild type tumors. OS was 25.8 months [11.4-40.2; IC 
95%] Conclusion: Treatment of patients with advanced NSCLC should be individualized, 
based on the molecular and histological features of tumours. When harbouring an 
activating EGFR mutation, first-line treatment should be with an EGFR TKI. Any avalilable 
agent can be used, until data from comparative studies may better guide TKI selection. 
Keywords: EGFR- tyrosine kinase inhibitors, non-small cell lung cancer, EGFR- mutations, 
Targeted agents
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Radiotherapy and Oncology, Skopje/Macedonia, 2Lung Department, University Clinic of 
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Background: As regards lung cancer patients who have relapse on platinum-based 
chemotherapy, there is a significant need for effective, well-tolerated treatment. Targeted 
agents such as orally active epidermal growth factor receptor EGFR tyrosine kinase 
inhibitor TKI (Erlotinib-Tarceva) and (Gefitinib-Iressa) offered a new therapeutic approach. 
Discovering of somatic EGFR mutations in some patients with NSCLC was a very significant 
breakthrough in the understanding of this disease. EGFR mutations occur almost within 
exons 18-21 of the gene of the receptor. The aim of this study was to evaluate tumor 
response, QoL and adverse effects of erlotinib, as a second line therapy for patients with 
EGFR mutation in NSCLC, after failure on previous first line therapy. Methods: During 
the year 2010-2011, 5 patients were enrolled in this study for testing EGFR mutations, 
after conditions for testing were created in Macedonia. We screened 5 patients for 
EGFR mutations by direct sequencing of axons 18 to 21, by retrospective analyzed their 
previous biopsy samples. Three of the patients were men and two of the patients were 
women. Previous smokers were two of males and one male and both female were never-
smokers. All of the patients who were enrolled in the study were with histological proven 
adenocarcionoma. Patients started with erlotinib 150 mg, one tablet per day, after 
failure on previous first line platinum based chemotherapy, with or without surgery and 
radiotherapy. Assessment of tumor response was according RECIST criteria on the follow-
up visits every 4 weeks. We analyzed tumor response from the beginning with erlotinib 
until tumor progression or detected severe toxicity. Assessment was performed only 
for those patients with EGFR mutations. Assessment of QoL was performed by patient’s 
subjective answers, as subjective improvement and without subjective improvements. 
Adverse effects were performed according to WHO criteria. Results: Tissue was available 
for all 5 cases, two (40%) of which were found to harbor an EGFR mutation, identified 
axon 19 deletions. The both two patients responded to therapy. Complete response 
was seen in female patient for 37 months. Progressive disease was reason to stop 
with erlotinib after 37 mounts and start with third line therapy. Partial response in male 
patient was assessed for 30 mounts and is still in follow up. This patient is still alive with 
good condition. The two patients reported subjective improvements during treatment 
with erlotinib. Skin rash was grade 2-3, and diarrhea was grade1-2. Both patients 
complained for hair loss, but without complete alopecia. Conclusion: Considering our 
clinical results, we recommend target therapy with erlotinib for patients with NSCLC and 
EGFR mutations as a second line treatment. Our excellent results encouraged to require 
prospective tissue procurement for all patients in Macedonia. This may in fact require 
a shift in diagnostic practice, from the current emphasis on fine-needle aspiration, 
which often provides insufficient material for molecular analysis, to obtaining more 
substantial biopsies and to provide this treatment as a first line for selected patients. 
Keywords: epidermal growth factor receptor mutation, erlotinib for second line therapy, 
Tumor response, Adverse effects
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P1.01-005 Early versus Late Brain Metastases in Wild Type and Mutation 
Positive EGFR Patients Ren Yuan1, Andrew Yamada2, Britta Weber3, Cheryl Ho2 
1Diagnostic Radiology, BC Cancer Agency, Vancouver/BC/Canada, 2Medical Oncology, BC 
Cancer Agency, Vancouver/BC/Canada, 3Aarhus University Hospital, Aarhus/Denmark
Background: Brain metastasis (BM) in NSCLC is a negative prognostic indicator. 
Historically, the median survival from diagnosis of BM has been reported as 6 m. The 
prognostic significance of BM however, may be altered in the setting of EGFR mutated 
disease. The timing of BM development may also influence survival outcomes. We 
evaluated the difference between early (<= 6 months from diagnosis) versus late (> 
6 months) BM, in EGFR wild type (WT) and mutant (MT) with respect to radiographic 
patterns and the impact on survival. Methods: The British Columbia Cancer Agency 
provides cancer care to a population of 4.6 million. A retrospective study was conducted 
of referred patients with stage IV non squamous NSCLC who underwent whole brain 
radiotherapy and/or surgical resection of brain metastasis with known EGFR mutation 
status from Mar 2010 - Dec 2012. The data was analyzed by WT and MT, early and 
late BM groups to characterize the radiographic patterns and overall survival (OS) from 
initial NSCLC diagnosis (dx) and BM dx. Results: 430 patients were identified: 327 WT 
patients (206 early vs 121 late) and 103 MT (65 early vs 38 late). Pattern of BM in 
WT early vs late showed no difference in size of largest BM, number of metastases, 
cerebral edema. Leptomeningeal disease was more frequent in WT late disease (2% vs 
8% p=0.01). Pattern of BM in MT early vs late showed no difference in size of largest 
BM, cerebral edema or leptomeningeal disease. There was a trend to miliary pattern 
disease in MT late BM (p=0.058). Median OS from initial dx in EGFR WT was early: 7.1 
m vs late: 24.9 m (p<0.001) and OS from BM dx early: 6.3 m vs late: 4.9 m (p=0.67). 
Median OS from initial dx in EGFR MT was early: 19.9 m vs late: 25.6 m (p=0.39) and 
OS from BM dx early: 19.2 m vs late: 3.9 m (p<0.001). Cox proportional hazards (CPH) 
model showed in the EGFR WT receipt of chemotherapy and late BM were associated 
with better survival. CPH in EGFR MT demonstrated that good PS and systemic 
treatment but not BM timing were predictive of better outcomes. Conclusion: Brain 
metastases in EGFR WT disease is a significant negative prognostic indicator with 
early dx associated with poor survival. In contrast, in EGFR mutation positive disease, 
the overall survival from diagnosis is the same regardless of the development 
of early or late brain metastases. This outcome may reflect the importance of 
systemic control and the penetrance of EGFR TKIs across the blood brain barrier. 
Keywords: EGFR, brain metastasis, timing, TKI
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P1.01-006 Targeted Drug Selection for Advanced NSCLC Treatment Jun Ni, 
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Academy of Medical Sciences, Department of Respiratory Medicine, Beijing/China
Background: The efficacy of traditional cytotoxic drugs that treat the Advanced Non-Small 
Cell Lung Cancer (ANSCLC) has reached a plateau. Recently, the targeted therapy has 
become a new option for ANSCLC treatment. The most representative targeted therapy is 
tyrosine kinase inhibitor (TKI) aimed at the genetic mutations of epidermal growth factor 
(EGFR). Currently, three TKI drugs, namely Gefitinib, Erlotinib, and Icotinib, are available 
in Chinese market. This article compared the molecular structure，pharmacokinetic 
parameters, clinical data, adverse reactions, and contraindications of the three drugs to 
guide the optimal selection in clinical practice. Methods: Not Applicable. Results: Not 
Applicable. Conclusion: Presently the pros and cons of the three drugs are inconclusive. 
Taken together, TKI can be used as the first-line drug among patients with EGFR mutations. 
Of these TKIs, Gefitinib is convenient and safe with fair tolerability, and consequently 
recommended. Icotinib needs to be administered t.i.d without meal. However, in 
ICOGEN study, it was safer than Gefitinib, and therefore also recommended. Erlotinib 
needs to be taken without meal, requires quitting smoke and has narrow therapeutic 
windows. The occurrence rate and severity of its adverse reactions are relatively high. 
Therefore Erlotinib is not recommended. Among the non-selective patients, TKI can 
be used as the second- or third-line treatment. Erlotinib apparently has better survival 
benefit and therefore is recommended. Icotinib has certain efficacy among the Acian 
female non-smokers with adenocarcinoma or lung adenocarcinoma. Its safety and 
tolerability are the best. Therefore, Icotinib is the next recommended drug. Gefitinib 
only has certain efficacies among the Asian female nonsmoking lung adenocarcinoma 
patients, and therefore is recommended to only the appropriate population. 
Keywords: Targeted drug therapy, Optimal Selection, Advanced Non-Small Cell Lung 
Cancer
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-17:00
P1.01-007 Treatment with EGFR-TKIs  in Non Small Cell Lung Cancer Patients. 
The Impact of EGFR Mutations Teresa Garcia Manrique, Rosario Carrillo De 
Albornoz, Ana Milena Vargas, M.Carmen Alamo De La Gala, Ana Maria Grueso Lopez, 
M.Mar Barros Perez, David Vicente Baz Medical Oncology, Hospital Virgen Macarena, 
Seville/Spain
Background: Patients with advanced stage of non small cell lung cancer (NSCLC) 
have been treated with few platinum-doublets in first-line. Most of them are observed 
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The Grade 2 or worse common adverse events (AEs) included skin rash in 17 patients 
(35%), diarrhea in 19 (39%) and mucositis in 15 (31%). Of these, number of patients who 
developed ≥ Grade 2 AEs within the first week was 5 (10%; skin rash), 12 (25%; diarrhea) 
and 4 (8%; mucositis). As for objective response, 21 (43%) of the 49 had partial response. 
In association with AEs and antitumor effect, those who had Grade 2 or worse skin rash 
within the first week tended to have better tumor response as compared with those who 
did not have (80% vs. 39%; p = 0.077). Conclusion: Our small study demonstrated that 
early development of skin rash might predict the response to afatinib monotherapy. 
Keywords: lung cancer, afatinib, skin rash
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P1.01-009 Combination of Angiogenesis Inhibitor and EGFR-TKIs in Advanced 
NSCLC Patients Who Developed Acquired Resistance Xia Song, Ruifen Tian, 
Yi Guo, Rong Wang, Xia Zhang, Wei Guo, Haibo Zhu Department of Pulmonary Oncology, 
Shanxi Cancer Hospital, Taiyuan/China
Background: Several randomized clinical trials have shown that erlotinib and 
Bevacizumab combination improved the survival of patients with EGFR mutation-
positive Non-small cell lung cancer（NSCLC）. The aim of this study was to evaluate 
the clinical activity of another angiogenesis inhibitor Endostar (rh-endostatin) in 
combination with continued EGFR-TKIs (including erlotinib, gefitinib and Icotinib) for 
advanced NSCLC patients who have developed acquired resistance to prior EGFR-TKIs 
treatment. Methods: Advanced NSCLC patients with disease progression who had partial 
or complete response to prior EGFR-TKIs treatment received 2-8cycles of Endostar plus 
EGFR-TKIs. Endostar was administered at a dose of 15mg q.d intravenously for 14 days, 
each at 3-week intervals; combined with continued EGFR-TKIs (erlotinib 150mg PO daily, 
or gefitinib 250mg PO daily or Icotinib 125mg PO t.i.d); until unacceptable toxicity or 
disease progression. The response was assessed using Southwest Oncology Group 
(SWOG) criteria after 6 weeks. Results: A total of 17 NSCLC evaluable patients were 
enrolled, including 9 women and 8 men. The presence of EGFR status were exon 21 
L858R point mutation in 7 cases, exon 19 deletion in 5 cases, wild type in 2 cases 
and unknown in 3 cases. Median number of treatment cycles was four. It showed a 
76.47% (13/17) disease control rate and had a prolonged stabilization of disease (>6 
months). Median PFS was 6.9 Months. Treatment benefit and overall survival was noted 
both in activating EGFR mutation patients, EGFR stated unknown patients and even 
in wild type patients. One stage VI patient with EGFR wild type, developed resistance 
after 6 months 2nd line erlotinib treatment, received 8 cycles of Endstar and erlotinib 
combination, and had 46 months overall survival time. Endostar in combination with 
EGFR-TKIs were generally well tolerated. The most common adverse events were rash 
35.29% (6/17), decreased appetite 29.41% (5/17), dry skin29.41% (5/17). No grade 3 or 
greater adverse events were seen in this study. Conclusion: Endostar with the addition 
of continuation of EGFR-TKIs has demonstrated promising clinical activity in NSCLC 
patients selected for acquired resistance to previous use of EGFR-TKIs. Treatment with 
this combination exhibited a good safety profile. Our results strengthen the evidence that 
angiogenesis inhibitor may be a valid option for NSCLC patients who have progressed on 
EGFR-TKIs. The optimal clinical combination and activity warrants further investigation. 
Keywords: Angiogenesis Inhibitor, EGFR-TKIs, NSCLC, Acquired resistance
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P1.01-010 Development of Skin Rash within the First Week Is a Potential 
Surrogate Marker of Effect in Afatinib for EGFR Mutant NSCLC Kenichiro 
Kudo1, Katsuyuki Hotta1, Akihiro Bessho2, Shinobu Hosokawa2, Kazuya Nishii2, Naoyuki 
Nogami3, Toshiyuki Kozuki3, Shoichi Kuyama4, Koji Inoue5, Shingo Harita6, Toshiaki 
Okada6, Kenichi Gemba7, Masanori Fujii8, Nagio Takigawa9, Naohiro Oda1, Mitsune 
Tanimoto1, Katsuyuki Kiura1 1Respiratory Medicine, Okayama University Hospital, Okayama/
Japan, 2Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama-Shi/
Japan, 3Pulmonary Medicine, National Hospital Organization, Shikoku Cancer Center, 
Matsuyama/Japan, 45. Department of Respiratory Medicine, NHO Iwakuni Medical Center, 
Iwakuni/Japan, 56. Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 
Matsuyama/Japan, 6Medicine, Chugoku Central Hospital, Fukuyama/Japan, 7National Hospital 
Organization, Fukuyama Medical Center, Fukuyama/Japan, 89. Department of Respiratory 
Medicine, Kobe Red Cross Hospital, Kobe/Japan, 9General Internal Medicine, Kawasaki 
Medical School, Okayama/Japan
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) 
are now key agents in EGFR-mutant non-small-cell lung cancer (NSCLC). In gefitinib 
or erlotinib monotherapy, its efficacy could be predicted by development of skin 
rash, however, it has not been fully evaluated if this is similarly the case with afatinib 
monotherapy. Methods: We retrospectively studied consecutive 49 patients with EGFR-
mutant NSCLC who received afatinib therapy between 2009 and 2015. Relationship with 
several toxicities and tumor response was examined. Results:
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Background: Liver metastases appear in 20-30% of patients diagnosed with non-small 
cell lung cancer (NSCLC) and represent a poor prognosis feature of NSCLC and a possibly 
more treatment-resistant condition. Potential clinical outcome differences in NSCLC 
patients with liver metastases harboring molecular alterations in EGFR, KRAS and EML4-
ALK genes are still to be determined. This study aims to evaluate the incidence of liver 
metastasis in a single population and look for potential correlations between molecular 
profile, liver infiltration and response to treatment. response to Liver metastases appear 
in 20-30% of patients diagnosed with non-small cell lung cancer (NSCLC) and represent 
a poor prognosis feature of NSCLC and a possibly more treatment-resistant condition. 
Potential clinical outcome differences in NSCLC patients with liver metastases harboring 
molecular alterations in EGFR, KRAS and EML4-ALK genes are still to be determined. 
This study aims to evaluate the incidence of liver metastasis in a single population and 
look for potential correlations between molecular profile, liver infiltration and response to 
treatment. Methods: A total of 236 consecutive stage IV NSCLC patients treated at the 
Clínica Universidad de Navarra were analyzed. Results: At onset, liver metastases were 
present in 16.9% of patients conferring them a shorter overall survival (OS) compared to 
those with different metastatic locations excluding liver infiltration (10 mo. vs. 21 mo.; 
p =0.001). Patients with EGFR wild-type tumors receiving standard chemotherapy and 
showing no liver involvement presented a superior median OS compared to those with 
liver metastases (23 mo. vs 13 mo.; p=0.001). Conversely, patients with EGFR-mutated 
tumors treated with EGFR tirosin-kinase inhibitors (TKI’s) presented no significant 
differences in OS regardless of liver involvement (median OS not reached vs. 25 mo; 
p=0.81). Conclusion:Overall, liver metastases at onset negatively impact OS of NSCLC 
patients. EGFR TKIs however, may reverse the effects of an initial negative prognosis 
in first-line treatment of EGFR mutated tumors and, more interestingly, in patients with 
EGFR wild-type NCSLC receiving EGFR TKIs after progression to chemotherapy. Table 1. 
Multivariate regression model.
Variable HR p
Sex 1.28 0.32
Age 1 0.9
N 1.28 0.06
EGFR 0.24 0.001
TKIs (after progression) 0.44 0.03
Liver metastases at onset 1.5 0.28
Liver metastases during disease 1.28 0.43
Bone metastases at onset 1.6 0.22
Bone metastases during disease 1.19 0.64
Skin metastases at onset 2.2 0.31
Adrenal metastases at onset 1.37 0.29
 
 
Keywords: Liver Metastasis, Epidermal growth factor receptor, Tyrosin Kinase Inhibitors, 
non-small cell lung cancer
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P1.01-014 Long Term Clinical Benefit of EGFR wt in Advanced NSCLC Patients 
Treated for Long Time with Salvage Erlotinib. A Retrospective Analysis  
Athanasios Kotsakis, Alexandra Voutsina, Aristea Kalikaki, Nikolaos Kentepozidis, 
Filippos Koinis, Athanassios Pallis, Panayiotis Katsaounis, Kostas Kalbakis, K. E 
Dermitzaki, Dora Hatzidaki, Vassilis Georgoulias Hellenic Oncology Research Group 
(Horg), Athens/Greece
Background: Erlotinib (E) has been approved for the management of NSCLC patients 
(pts) after failure of the first or subsequent line of chemotherapy. Although the efficacy 
of E is clearly associated with the presence of drivers EGFR mutations, there is a 
subset of pts with EGFR wild type (EGFR wt) tumors who impressively respond. We 
retrospectively analyzed the clinical and pathological characteristics of a group of pts 
with unresectable EGFR wt NSCLC treated for a prolonged period with salvage (≥ 2nd line 
setting) E. Methods: Patients with unresectable EGFRwt NSCLC who received ≥ 2nd line 
treatment with E without disease progression for at least 6 months, were sought from 
the database of HORG. Pts with available tumor material were molecularly (KRAS, BRAF, 
PI3K, HER2 mutations and ALK-EML4 translocation) characterized. Results: Among 
1450 pts treated in different HORG’s collaborating centers (from 2004-2013), 44 
(3.03%) received E for >6months (median: 10.1 mo; range, 6.0-36.5). 17 were women, 
57% had no history of smoking, 42 had a PS (ECOG) of 0-1; 16% had squamous cell 
histology and 73% adenocarcinoma. KRAS mutations were detected in 20.5% (9/42 
tested) of the pts, PI3K mutations in 9% (3/30 tested) and ALK-EML4 translocation in 
9.5% (2/21 tested); there was no patient with HER2 or BRAF mutated tumor. 11(25%) 
pts experienced a partial response and 26 (59%) stable disease (Tumor growth control 
rate 84%). The median PFS and OS was 10.1 (6.0-40.6) and 24.1 (6.0- 89.1) months, 
respectively. Pts with KRAS wt tumors had a significantly (p=0.018) better OS compared 
to pts with KRAS mutant tumors. There was a trend of improved PFS (p=0.083) and OS 
(p=0.053) in favor of pts with adenocarcinoma compared to pts with squamous cell 
carcinoma. Conclusion: Treatment with E significantly improves the clinical outcome 
in a subset of NSCLC pts with EGFR wt tumors. Pts with non-squamous pathology and 
no smoking history seem to benefit most from such therapy. KRAS mutation was the 
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P1.01-011 Response to Erlotinib in Metastatic Lung Adenocarcinoma with a 
Rare Double Epidermal Growth Factor Receptor (EGFR) Mutation Syed H.R. 
Jafri1, Angel Blanco1, Bonnie A. Labdi2, Shan Guo1 1Internal Medicine, Division of Oncology, 
UT Houston Medical School, Houston/TX/United States of America, 2Department of 
Pharmacy Service, Memorial Hermann Texas Medical Center, Houston/TX/United States of 
America
Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is approved as a 
first line treatment in patients with metastatic lung cancer with EGFR exon 19 deletions 
or exon 21 (L858R) substitution mutations. Here we are reporting use of erlotinib in a 
patient with a rare double EGFR mutation Methods: Case history: Patient is a 52 years 
old Hispanic female with12 packs/year history of smoking who quit few years prior to 
diagnosis. She was evaluated for gradually worsening vision of one year duration and 
regular headaches for one month. MRI brain showed a 2 cm cystic lesion in right posterior 
temporal /parietal region. She underwent surgical resection which showed metastatic 
adenocarcinoma cells positive for CAM 5.2, CK 7, napsin and TTF-1 and negative for CK 
20 consistent with lung primary. Staging PET/CT scan showed increased FDG uptake in 
a left upper lobe 2.5 cm perihilar mass (SUV 12.3) with several satellite lesions and hilar 
nodal metastasis giving her a final stage of T3N2M1. Next generation sequencing: 
Resected metastatic brain lesion was sent for next generation sequencing which showed 
presence of EGFR p.L858R and p.H870R mutations and increased EGFR copy number. 
Other mutations identified included Tp53 p.R175H and CDKN2Ap.H83Y. Tumor was 
negative for KRAS mutation. EML4-ALK and ROS1 rearrangement were also negative by 
FISH. Results: Treatment: Patient received adjuvant gamma knife to the tumor bed of 
resected brain lesion and in consideration of her oligometastatic disease was started 
on concurrent thoracic chemo-radiotherapy. She received a total of 60 Gy radiation to 
the chest with 2 cycles of cisplatin-etoposide. At the completion of chemo-radiotherapy 
re-staging CT scan chest and abdomen showed no improvement in chest disease with 
appearance of new metastatic lesion in liver. MRI brain done at that time also showed 
a new metastatic lesion in parietal calvarial bone for which she received whole brain 
radiation therapy. At that time she was stared on erlotinib at 150mg/day. Initially patient 
had poor tolerance to erlotinib with excessive vomiting. Erlotinib dose was reduced to 
150mg every other day and once tolerance improved the dose was gradually increased 
back to 150mg/day. Re-stating CT scan at 2 months showed partial response in primary 
thoracic tumor as well as almost complete resolution of metastatic lesion in liver. Patient 
remains on erlotinib at 150mg/day and most recent re-staging CT scan chest /abdomen 
as well as MRI brain performed 7 months after starting erlotinib show stable disease. 
Conclusion: Previous reports have shown poor response to EGFR TKI in patients with 
double EGFR (L858R + p.H870R) mutation (1,2).This case report shows poor response 
of platinum doublet chemotherapy but good response to EGFR TKI eroltinib in a patient 
with double EGFR (L858R + p.870R) mutation.References: 1. Pas TD, et al. Activity of 
Epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small 
cell lung cancer harboring rare epidermal growth factor receptor mutations. Journal 
of Thoracic Oncology.2011.6(11)1895-1901 2. Tam IY,et al. Double EGFR mutants 
containing rare EGFR mutant types show reduced in vitro response to gefitinib compared 
with common activating missense mutations. Mol Cancer Ther. (2009); 8(8):2142-51 
Keywords: Erlotinib, rare EGFR mutation, lung adenocarcinoma
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P1.01-012 Kinase Domain Mutation Positive Lung Cancers Are Sensitive to 
Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete 
Treatment Lei Yu1, Liang Chen2 1Department of Thoracic Surgery, Beijing Tongren 
Hospital, Capital Medical University, Beijing City/China, 2National Institute of Biological 
Sciences, Beijing, Beijing City/China
Background: Lung cancer is the global leading cause of cancer-related deaths. A 
significant portion of lung cancer patients harbor kinase domain mutations in the 
epidermal growth factor receptor (EGFR). While EGFR tyrosine kinase inhibitors 
(TKI) effectively shrink tumors harboring mutant EGFR, clinical efficacy is limited by 
the development of TKI resistance. As such, effective alternatives are desperately 
needed. Methods: We have been treating M1a lung cancer patients through intrapleural 
perfusion with hyperthermic chemotherapy (IPHC) followed by cycles of systemic 
chemotherapy (we termed this procedure IPHC complete treatment, IPHC-CT). Tumor 
shrinkage was analyzed in mutant EGFR-positive patients after IPHC-CT treatment. 
Furthermore, patient-derived cell lines driven by mutant EGFR were treated with 
hyperthermic chemotherapy to study the mechanisms of effect of IPHC-CT on cancer 
cells. Results: Tumor shrinkage was detected in patients whose tumor harbored EGFR 
kinase domain mutation. Hyperthermia and cisplatin synergistically downregulated EGFR 
protein levels in tumor cells, which ultimately elicited apoptosis. Conclusion: IPHC-
CT is effective in treating EGFR kinase domain mutation positive lung cancer patients. 
Keywords: Kinase domain mutation, intrapleural perfusion, hyperthermic chemotherapy
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P1.01-013 EGFR Mutations and Targeted Treatment Reverse the Bad Prognosis 
of Stage IV NSCLC Associated to Liver Metastasis Eduardo Castanon1, Christian 
Rolfo2, David Viñal1, Ines Lopez1, Juan P. Fusco1, Patricia Martin1, Leire Zubiri1, Jose 
I. Echeveste3, Ignacio Gil-Bazo1 1Oncology, Clinica Universidad de Navarra, Pamplona/
Spain, 2Thoracic Oncology, Multidisciplinary Oncology Centre Antwerp, University Hospital 
Antwerp, Edegem/Belgium, 3Pathology, Clinica Universidad de Navarra, Pamplona/Spain
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P1.01-017 Two Cases of NSCLC with EGFR Exon 20 Insertions with Major 
Clinical Response to Cetuximab-Containing Therapies Chad M. Vanderbilt1, Erin 
C. Fulchiero2, Robert J. Hoyer3, Dara L. Aisner1, Robert C. Doebele4 1Department of 
Pathology, University of Colorado Som, Aurora/CO/United States of America, 2Department 
of Internal Medicine, University of Colorado Som, Aurora/CO/United States of 
America, 3Medical Oncology & Hematology, Memorial Hospital, Colorado Springs/CO/United 
States of America, 4Division of Medical Oncology, University of Colorado Som, Aurora/CO/
United States of America
Background: Lung tumors with EGFR Exon 20 mutations, particularly insertions 
between the amino acids Y764 and V774, present a major challenge for treatment. 
These mutations are known to confer resistance to current EGFR specific tyrosine kinase 
inhibitors (TKI). The mechanism of this resistance is described by Yasuda et al. as a 
“wedge” formed by the aberrant amino acids locking the C-helix in an inward, active 
position. This structural aberration prevents the TKI from accessing the critical pocket 
within the protein and inhibiting kinase activity. Without the ability to treat these tumors 
with TKIs, alternate treatments need to be pursued. Methods: We present, as index cases, 
two patients with metastatic lung adenocarcinomas demonstrating TKI unresponsive 
insertions in exon 20. Both patients had exuberant clinical and radiographic responses 
to cetuximab, an EGFR specific monoclonal antibody. Results: The first patient is a 39 
year old male never-smoker with lung adenocarcinoma. The disease had progressed 
prior to molecular identification of the EGFR mutation, and the patient developed bilateral 
lung disease and metastatic lymph node and brain lesions. An exon 20 EGFR mutation 
(p.N771_P772insPHGH c.2313_2314insCCCCACGGGCAC) was identified. Following 4th 
line therapy with combination chemiotherapy plus cetuximab, the tumor burden was 
dramatically decreased and the patient had markedly improved functional status with the 
ability to return to employment. The second patient is a 71 year old male never-smoker 
with lung adenocarcinoma. The disease progressed and the patient developed widely 
metastatic disease. An exon 20 EGFR mutation (P770_N771insNPP) was identified. The 
patient was treated with combination cetuximab and afatinib therapy and experienced 
a dramatic decrease in lung and metastatic tumor burden with improved functional 
status. Conclusion: Cetuximab-containing therapeutic regimens may be a viable therapy 
for what previously have been considered treatment resistant molecular insults. Additional 
cases of these mutations and treatment with cetuximab are needed to demonstrate that 
these results are reproducible and that they warrant study in prospective clinical trials. 
Keywords: EGFR Exon 20 Insertion, Cetuximab, TKI resistant mutation
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P1.01-018 Response Rate and Outcomes in Crizotinib Treated Advanced ALK-
Positive NSCLC Patients Keith L. Davis1, James A. Kaye2, Shrividya Iyer3 1RTI Health 
Solutions, Research Triangle Park/NC/United States of America, 2RTI Health Solutions, 
Waltham/MA/United States of America, 3Pfizer Inc, New York/NY/United States of America
Background: Crizotinib is an oral small-molecule tyrosine kinase inhibitor, which was 
approved in the United States (US) in August of 2011 for the treatment of anaplastic 
lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). In clinical 
studies, crizotinib has demonstrated robust response rates and significantly greater 
efficacy than chemotherapy. However, there is currently limited data on crizotinib 
treatment and related outcomes in real-world practice settings. The main objective of 
the current study was to assess the treatment patterns and outcomes of ALK-positive 
advanced NSCLC patients treated with crizotinib in regular clinical practice. Methods: 
Physicians in the US (N= 107) and Canada (N= 40) were recruited from cancer centers/
teaching hospitals (48%) or free standing oncology clinics (47%), to abstract data 
retrospectively from medical records of adult (≥18 years) patients diagnosed with ALK-
positive advanced NSCLC and treated with crizotinib as first or later line therapy between 
August 1, 2011, and March 31, 2013 (for the US) or April 1, 2012 and March 31, 2013 
(for Canada) in non-clinical trial settings. IRB approval was obtained. A secure web-based 
form was used by physicians to abstract data and all patient data were de-identified 
and anonymous. Descriptive analyses were conducted to assess treatment patterns 
and objective response rate (ORR). Progression-free survival (PFS) and overall survival 
(OS) were descriptively analyzed using the Kaplan-Meier method. Results: Data were 
extracted from 212 patient records in US (N=147) and Canada (N=65). The mean (SD) 
patient age was 58.9 (9.5) years and a majority were male (69%), Caucasian (79%), 
current or former smokers (67%), ECOG status 0 or 1 (75%), adenocarcinoma histology 
(90%) and initially diagnosed at the metastatic stage (71%). Cough, fatigue, and dyspnea 
were the most common symptoms present (71%, 65%, and 55%, respectively) at the 
time of metastatic NSCLC diagnosis. Approximately 65% (n=137) of patients initiated 
crizotinib as first-line therapy and the mean ± SD duration of crizotinib treatment was 8.7 
± 4.9 months. Approximately 37% of the patients were deceased at time of medical record 
abstraction. Disease progression following initial response was the most frequently 
reported (59%) reason for treatment discontinuation and 35% received additional 
systemic chemotherapy post-crizotinib. Approximately 90% of patients had no changes 
(reduction or escalation) in crizotinib dose. Among patients experiencing progression 
during crizotinib treatment, the most common sites of progressive metastases were 
liver (35%), bone (30%), and contralateral lung (28%). The crizotinib ORR was estimated 
to be 66% for the overall cohort (69% first line and 60% for later line). The median 
(95% CI) PFS from crizotinib initiation was 9.5 (8.7, 10.1) months in the overall cohort. 
Median (95% CI) OS from crizotinib initiation was 23.4 (19.5, ‒) months for the overall 
cohort. Based on Kaplan-Meier estimation, 1- and 2-year survival rates from crizotinib 
initiation were 82% and 49%, respectively. Conclusion: Response rates in patients 
treated with crizotinib in real world settings seem to align with data reported previously 
from clinical studies. Median OS in patients treated with crizotinib in the real world 
only molecular alteration correlated with the clinical outcome. Further molecular analysis 
of these pts could help to more appropriately define this particular group of patients. 
Keywords: EGFR, wt, metastatic, NSCLC
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P1.01-015 Clinical-Pathological and Survival Analysis of Patients with 
Advanced NSCLC and EGFR Mutation Treated With a Drug Therapy Anti-T790M  
Jesús Corral, Antonio Cervera, Pilar Maiquez, Miriam Alonso, Maria Dolores Mediano, 
Maria José Flor, Lucia Jiménez University Hospital Virgen Del Rocio, Seville/Spain
Background: Multiple phase III trials have demonstrated the benefit in terms of RR and 
PFS of the EGFR TKIs versus platinum-based chemotherapy in patients with advanced 
NSCLC and EGFR mutation. Median PFS of these patients ranges from 9-13 months, 
time where a new therapy approach is needed, the most commonly chemotherapy 
nowadays. The main resistance mechanism described in this clinical situation is the 
development of T790M resistance mutation. There are no comparative efficacy data 
among chemotherapy and T790M targeted therapies. Our research included data from 
15 patients treated in our Institution Phase I Unit with a T790M inhibitor analyzing the 
effectiveness according to their clinical features and mutational profile (T790M carriers 
or not) Methods: Descriptive clinico-pathological and efficacy analysis from October 
2013 to March 2015 of patients with advanced NSCLC and EGFR mutation in progression 
and receiving T790M targeted therapy in the context of a phase I clinical trial performed 
in our Clinica Trial Unit. Results: Fifteen patients were included. The median age resulted 
60 years (range 37-80 years) with a proportion of 8 (55%)/7 (45%) female/men. The 
entire study population was Caucasian and had an histological diagnosis of stage IV 
NSCLC with the presence of activating mutation of EGFR (66% L848R and del19 44%). In 
relation to smoking exposition, most of the patients were past-smokers (55%) or active 
(13%). All patients received a specific T790M inhibitor, 7 of them (45%) with a confirmed 
T790M mutation by local and/or local analysis. The average of prior lines of therapy 
before the experimental T790M inhibitor was 1,9. No grade 3/4 toxicities were reported. 
After an average follow up of 17 months, PFS of the overall population was 4,73 months, 
with a statistically significance difference between T790M positive patients (8,14 
months) versus negative or unknown (1,8 months). We have no outcome at present of 
the OS for the active treatment of most the patients. Conclusion: Despite the limitation 
of the number of patients and follow-up time, our research suggested a clear survival 
benefit with the T790M inhibitor in the context of advanced NSCLC patients harboring 
T790M resistance mutation versus non in progression after EGFR TKI first line therapy. 
Keywords: T790M, inhibition, phase I unit, NSCLC
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P1.01-016 Treatment Outcomes among Elderly Lung Cancer Patients > 65 
Years following Clinical Use of EGFR Tyrosine Kinase Inhibitor Wan-Teck Lim1, 
Li-Lian Kwok2, Daniel S.-W. Tan1, Chee-Keong Toh1, Eng Huat Tan1, Mei-Kim Ang1, 
Ravindran Kanesvaran1 1Department of Medical Oncology, National Cancer Center, 
Singapore/Singapore, 2Division of Clinical Trials and Epidemiology, National Cancer Center, 
Singapore/Singapore
Background: Elderly patients (pts) with lung cancer pose significant challenges in 
cancer treatment because of concurrent comorbidities and age. We examined treatment 
patterns and outcomes in elderly pts with advanced lung cancer prior to and after 
introduction of epidermal growth factor receptor (EGFR) inhibitors into clinical use. 
Methods: Clinical data for pts > 65 yrs derived from two databases, cohort 1(1998-
2003) and cohort 2(2004-current), were used. Demographics, clinical characteristics 
and treatment outcomes were compared between these 2 cohorts with stage III/IV 
lung cancer. Chi-square and Mann-Whitney-U tests were used to compare differences 
between cohorts. Overall survival (OS) from the time from diagnosis to death from any 
cause was estimated using Kaplan-Meier method and differences were defined using 
the logrank test. Pairwise comparisons were analyzed with Sidak’s adjustment applied 
to account for multiple testing. The Cox proportional hazards model was used to model 
the association between survival end-points and patient cohort, with the resulting 
hazard ratios assessed using the Wald test. The proportional hazards assumption was 
verified by fitting an alternative model with inclusion of a covariate-by-time interaction 
term and inspection of the p-value of the interaction term for categorical variables. A 
2-sided p-value of <.05 was considered statistically significant. Results: There were 
397 pts (cohort 1) and 1584 pts (cohort 2) with complete data for analysis. The median 
age of diagnosis was not significantly different between the cohorts (72.5 yrs vs 72.8 
yrs), p: 0.252. Median follow-up times were comparable. Cohort 1 had poorer ECOG 
at diagnosis, more males and a higher proportion of current smokers. For cohort 1, 
cytotoxic chemotherapy was standard of care and EGFR TKI use was minimal. In contrast, 
for cohort 2, 50% of pts received EGFR TKI monotherapy in 1st line, 30% of pts in 2nd line 
and 33.3% of pts in 3rdline and beyond. There was a significant difference in OS between 
the both cohorts (p <.001), HR 0.75 in favor of cohort 2. Specifically women, good ECOG, 
never smoker status, and adenocarcinoma were associated with significantly reduced 
hazard of death. Conclusion: Routine EGFR TKI use in elderly > 65 yrs of age clinical 
setting has improved OS over the last decade. This benefit is reflected in the reduced 
hazards of death for specific patient subsets. Elderly pts where 
targeted therapies are indicated should not be deprived of therapy. 
Keywords: lung cancer, Tyrosine kinase inhibitors, treatment outcomes, elderly
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P1.01-021 Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese 
Patients Shaohua Cui1, Yizhuo Zhao1, Aiqin Gu1, Xiaoxiao Ge1, Yanyan Song2, 
Wei Zhang1, Yuqing Lou1, Lili Dong1, Baohui Han1, Liyan Jiang1 1Department of 
Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/
China, 2Department of Biostatistics, Shanghai Jiao Tong University, School of Medicine, 
Shanghai/China
Background: Anaplastic lymphoma kinase (ALK) is a new tyrosine kinase target that has 
been validated recently in NSCLC. Crizotinib, an oral, small-molecule, tyrosine kinase 
inhibitor that targets ALK, MET and ROS-1, has been reported to be particularly effective 
and to have acceptable toxicity in advanced anaplastic lymphoma kinase (ALK) -positive 
non-small-cell lung cancer (NSCLC). In a phase 1, open-label, multicenter trial evaluating 
the efficacy and adverse event profile of crizotinib in a cohort of 82 ALK-positive lung 
cancer patients, treatment for a mean duration of 6.4 months achieved an overall 
response rate (ORR) of 57%, and the estimated probability of 6-months’ progression-free 
survival (PFS) was 72%. Mild gastrointestinal disturbances were the main adverse effects 
observed in this study. Subsequently, updated data from a study involving 143 patients 
confirmed the durable response and tolerable adverse effect profile of crizotinib in 
patients with ALK-positive NSCLC. Methods: A total of 72 patients with ALK-positive 
NSCLC who received crizotinib between June 1, 2013 and October 15, 2014 at Shanghai 
Chest Hospital, Shanghai JiaoTong University, were prospectively enrolled in the study. 
All were histologically diagnosed and staged as clinically advanced (stage IV, or stage IIIB 
with pleural effusion) NSCLC. All patients received oral crizotinib 250 mg twice daily in 
28-day cycles. The tumor response was assessed after the first cycle of crizotinib 
therapy and subsequently after every 2 cycles using the Response Evaluation Criteria in 
Solid Tumors (RECIST), version 1.0. Tolerability was assessed at least twice per cycle 
until crizotinib was discontinued. Results: The patients tended to be young (mean age 55 
years, range 31-83 years), never or light smokers (smoking index <400), and to have an 
adenocarcinoma histology. Most (49/72; 68.1%) had received previous anticancer 
treatment before crizotinib therapy. Sixty-seven patients (93%) were able to be assessed 
for efficacy. The objective response rate (ORR) and disease control rate (DCR) were 
52.2% (95% CI 40.5%-63.9%) and 64.2% (95% CI 52.75%-75.7%), respectively. The 
estimated median progression-free survival (PFS) for all 67 patients was 10.3 months 
(95% CI 8.6-12.0 months). Mild visual disturbances, nausea, vomiting, diarrhea and 
constipation were the most commonly reported adverse effects.
 
Conclusion: crizotinib was well tolerated and showed promising efficacy in 
Chinese patients with ALK-positive, advanced NSCLC. Further prospective, 
multicenter studies with a larger sample size are needed to confirm these findings. 
Keywords: Anaplastic lymphoma kinase, efficacy, Non-small-cell lung cancer, crizotinib
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P1.01-022 Radiologic Features of Advanced ALK-Rearranged Lung Cancer 
Kakeru Hisakane, Eri Sugiyama, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, 
Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Koichi Goto Thoracic Oncology, National 
Cancer Center Hospital East, Kashiwa, Chiba/Japan
Background: Reportedly, the radiologic features of most primary resectable lung 
cancers harboring an anaplastic lymphoma kinase (ALK) -fusion do not exhibit a ground-
glass opacity (GGO) component when viewed using CT. However, little is known about the 
features of advanced ALK-rearranged lung cancer. Methods: The radiologic features of 
21 advanced ALK-positive lung cancers treated at the National Cancer Center Hospital 
East between January 2012 and June 2014 were retrospectively investigated. ALK-fusion 
was confirmed using IHC and FISH or RT-PCR methods. The primary tumor’s diameter 
settings examined here was approximately 2 years from crizotinib treatment initiation. 
Keywords: crizotinib, lung cancer, outcomes, response rates
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P1.01-019 Czech Experience with Crizotinib in the Personalized Treatment of 
NSCLC Vitezslav Kolek1, Milos Pesek2, Jana Skrickova3, Ivona Grygarkova1, Jaromir 
Roubec4, Leona Koubkova5, Marketa Cernovska6, Karel Hejduk7, Jana Skrickova8 
1Respiratory Medicine, University Hospital, Olomouc/Czech Republic, 2Pulmonary Medicine, 
University Hospital, Plzen/Czech Republic, 3Pulmonary Medicine, University Hospital, 
Brno/Czech Republic, 4Pulmonary Medicine, University Hospital, Ostrava/Czech Republic, 
5Pulmonary Medicine, University Hospital,, Praha/Czech Republic, 6Pulmonary Medicine, 
Thomayer Memorial Hospital, Prague/Czech Republic, 7Biostatistics, Iba Institute, Brno/
Czech Republic, 8Institute of Biostatistics and Analyses, Masaryk University Brno, Brno/
Czech Republic
Background: Crizotinib is a highly selective drug used in the treatment of anaplastic 
lymphoma kinase (ALK) gene re-arrangement positive non-small cell lung cancer 
(NSCLC). In the Czech Republic it was used in frame of compassionate cases program 
and now is reimbursed in pretreated tumors with EML 4/ALK gen translocation verified by 
FISH and/or IHC testing. The recommended dose is 250 mg bid/ day. Crizotinib is used 
since 2011, data are evaluated according to the National Reference Centre Registry. 
Methods: Present study evaluates 26 patients (pts), 14 males,12 females with mean 
age 60 (31- 75) years. Out of them 11 (42.3%) were non-smokers, 8 (30.8%) ex-smokers 
and 7 (26.9 %) smokers. All of them had NSCLC with EML4/ALK gene translocation, 
23 had adenocarcinoma, two NOS and one patient had adenosquamous cancer. Stage 
in the time of treatment was IIIB in 3 and IV in 23 pts. Crizotinib was applied in 2nd 
ĺine in 17 pts, 3rd line in 5 pts, 4th line in 3 pts, 5th in one patient. PS was 0 in 3 pts, 
1 in 20 pts and 2 in 3 pts. Results: On the date of evaluation, 14 pts continued the 
treatment, 6 died and 6 stopped treatment due to progression. Crizotinib effectiveness 
was assessed in 15 pts: CR in 3 (20%) pts, PR in 3 (20%) pts, SD in 5 (33.3 %) pts, 
DP in 4 (26.7 %) pts. CR was associated with long response duration (10.7, 31.8, 34.1 
months). Grade 3 adverse events (gastrointenstinal discomfort and liver disease) were 
observed in two (7.7 %) pts, grade 2 problems with visus appeared in two patients. 
Dose of crizotinib was reduced in 3 pts. Median of progression free survival was 15 
months, median of overall survival was not reached. Conclusion: Interim analysis 
of present series shows, that crizotinib has very good tolerability and promising 
effectiveness even in heavily pretreated patients with EML4/ALK gene translocation. 
Long term survival analysis is running. Supported by national grant IGA MZ ČR NT/13569 
Keywords: ALK gene, crizotinib, survival, advanced NSCLC
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P1.01-020 Symptoms of Bone and Liver Metastases in Patients with ALK+ Non-
Small Cell Lung Cancer (NSCLC) Annie Guerin1, Medha Sasane2, Roy Nitulescu1, Jie 
Zhang2, Kenneth W. Culver2, Eric Q. Wu3, Alexander R. Macalalad3, Anand Dalal2 1Analysis 
Group, Inc., Montreal/QC/Canada, 2Novartis Pharmaceuticals Corporation, East Hanover/NJ/
United States of America, 3Analysis Group, Inc., Boston/MA/United States of America
Background: Among patients with ALK+ NSCLC who develop metastases, common 
metastatic sites include brain, bones, and liver. Although the symptomatic profile 
of ALK+ NSCLC patients with brain metastases is well documented, information remains 
limited for patients with bone metastases or liver metastases. Methods: Data from 2 
large US administrative claims databases—IMS LifeLink Health Plan Claims (01/2001 – 
03/2014) and Truven Health Analytics MarketScan (01/2002 – 09/2012)—were pooled 
for this retrospective study. Among adult patients with a lung cancer diagnosis, ALK+ 
NSCLC patients were identified based on prescription fills for crizotinib. Patients 
were analyzed if they had ≥60 days of follow-up before and ≥30 days after the bone 
metastasis or liver metastasis diagnosis date. Results: A total of 231 ALK+ NSCLC 
patients were selected: 191 had bone metastasis and 104 had liver metastasis. For the 
bone metastasis sample, median age was 54.9 years, 39.3% were male, and median 
time from first lung cancer diagnosis to the bone metastasis diagnosis was 30 days. 
The frequency of symptoms frequently associated with bone metastasis increased 
after bone metastasis diagnosis compared to before. Common skeletal-related events 
included pathologic fractures (before: 0.5% vs. after: 12.6%), spinal cord compression 
(2.6% vs. 5.2%), and bone radiation therapy (12.6% vs. 62.3%).Other common symptoms 
were weakness/fatigue (before: 24.6% vs. after: 46.6%), anemia (10.5% vs. 33.0%), back 
pain (8.4% vs. 22.5%), bowel dysfunction (6.8% vs. 20.9%), and neoplasm-related pain 
(0.0% vs. 14.1%). For the liver metastasis sample, median age was 54.0 years, 42.3% 
were male, and median time from first lung cancer diagnosis to first liver metastasis 
diagnosis was 151 days. The frequency of symptoms frequently associated with liver 
metastasis also increased compared to before liver metastasis diagnosis, where 
most common symptoms were nausea/vomiting (before: 21.2% vs. after: 42.3%), 
abdominal pain (20.2% vs. 34.6%), fever/sweating (6.7% vs. 27.9%), edema (6.7% vs. 
25.0%), jaundice (0.0% vs. 3.8%), and fatigue (29.8% vs. 46.2%). Conclusion: ALK+ 
NSCLC patients experience an increased symptomatic burden after developing bone 
metastasis or liver metastasis. Further research is warranted to analyze the impact of the 
symptomatic burden on patient quality of life and other outcomes as well as the potential 
benefit of instituting second-generation ALK-inhibitors earlier in the treatment course. 
Keywords: ALK, ALK Inhibitor, non-small cell lung cancer, Metastatic Disease
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injected.Cumulative doses of chemotherapeutic agents was as folows- Bevacizumab 
-87480 mg; EC145(Vintafolide) - 90 mg, Carboplatin 3700 mg, Paclitaxel -2508 mg, 
Docetaxel -1710 mg. Baseline renal function described by glomerular filtration rate 
(GFR) was 78 ml/min and during treatment GFR never dropped below ml/min. Patient 
developped sensory peripheral neuropathy, CTC grade 2.Use of ACE inhibitor therapy 
due to arterial hypertension has been initiated.No other clinically significant toxicity 
has been observed, including myelotoxicity and renal toxicity other than non-significant 
transient proteinuria. Conclusion: By presenting this case report we would like to 
bring attention to long -term survival in patient with metastatic NSCLC treated with two 
lines of chemotherapy that included taxane and targeted molecular therapy. Despite 
potentially nephrotoxic regimens and rigorous iodine- based CT disease monitoring 
scans no significant toxicity has been observed. A matter of discussion is a significance 
of ACE inhibitor for renal protection in contrast-and chemotherapy -induced toxicity. 
Keywords: toxicity, clinical trials, long survival, lung adenocarcinoma
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P1.01-025 Radical Resection for Supraclavicular Lymph Node Metastasis 
(N3-Stage IIIB) Adenocarcinoma of the Lung Jun Zhang, Changyu Wang, Shichun 
Xie, Xueshan Qiu China Medical University Lung Cancer Center, The First Hospital of China 
Medical University, Shenyang/China
Background: In China, lung cancer is increasing rapidly, of which 80% are non-
small cell lung cancer, and most belong to Stage IIIB and IV when diagnosed, losing 
opportunity of surgery, and the prognosis is worse, the average survival time is about 
6-12 months. Recently we perform radical resection for part N3-Stage IIIB non-small 
cell lung cancer, hope to improve the prognosis of these patients. A typical case is 
discussed here. Methods: Case1: Man, aged 43 in Dec 2012, found right supraclavicular 
lymph node swollen, CT showed right lower lobe tumor 7X6X5cm3, invading right 
inferior pulmonary vein and pericardium, regional and mediastinal lymph node 
11,10,7,4R,3,2R,1R swollen badly; right supraclavicular lymph node biopsy revealed the 
diagnosis of lung adenocarcinoma; no other distant metastasis was found in brain, liver, 
and bone; cT3-4N3M0 Stage IIIB, which is usually contraindication of surgery. Three 
cycles’ preoperative chemotherapy of Pemetrexed and cisplatin (DDP) was conducted, 
the lung tumor shrunk 1/3, mediastinal lymph node shrunk significantly, and the right 
supraclavicular lymph node disappeared. PET-CT showed right lower lobe tumor and 
part mediastinal lymph node positive, however, showed negative in the neck and other 
part of the body; cT2aN1-2M0 Stage IIA-IIIA, prepared for operation. Results: Standard 
“large-incision” right posterolateral thoracotomy was performed, pleural adhesion, 
tissue edema, fragile, easily broken, easy bleeding were encountered. Right lower lobe 
lobectomy, systematic lymph node dissection including No.2R,3A,3P,4R,7,9,10,11,12 
group lymph node and surrounding adipose tissue were en block dissected. Tumor 
size 4X4X3cm3, postoperative pathology diagnosed as lung adenocarcinoma, No.12 
lymph node metastasis, others were negative, pT2aN1M0 Stage IIA. Two cycles’ 
postoperative chemotherapy was followed. Regular follow-up showed the patient 
recovered very well. Now he is in his 3rd year postoperatively, living a healthy man’s 
life. CT, Ultrasound, ECT, and blood tumor markers’ test showed no sign of recurrence 
and metastasis. Conclusion: Part supraclavicular lymph node metastasis N3-Stage IIIB 
non-small cell lung cancer, if prepared carefully, could gain the opportunity of receiving 
surgical resection, could achieve a much more better prognosis, even to get cured as usual 
Stage IA-IIIA lung cancer patients who receive regular radical resection of lung cancer. 
Keywords: supraclavicular lymph node metastasis, N3 Stage IIIB, preoperative 
chemotherapy, lung cancer
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P1.01-026 Post-Treatment Effects of Lung Cancer on Spinal Fracture Malcolm 
O. Tagbarha Public Health, University of Abuja, Abuja/Nigeria
Background: Studies have shown the relationship between cancers and bone diseases. 
Observations have also shown that the spine, rib and pelvis are more susceptible to cancer 
for riches in marrow that fosters tumor growth. We particularly examined the relationship 
with spinal fractures and cancer Methods: The medical records of more than 100 lung 
cancer survivors were assessed from six Teaching Hospitals in Eastern (Ethiopia and 
Tanzania) and Southern African countries from 2003-2013. We checked for osteolytic 
lesions and osteoblastic lesion as the patients have undergone several kinds of screening 
during and after cancer treatment including DXA (Dual-energy X-ray Absorptiometry), 
plain X-ray or magnetic resonance imaging (MRI) to screen for metastatic bone disease 
Results: We found that an estimated 30-40% of the lung cancer patients developed bone 
metastases and disrupted the balance between bone breakdown and repair which caused 
reduction of bone in some areas and increased density in others. As a result, the bone 
was weakened and became more prone to spinal fracture after treatment Conclusion: 
As lung cancer has spread thereby causing spinal fractures, treatment needs to be 
focused on disease control with chemotherapy. The treatment of bone metastases 
will be primarily dependent on an effective treatment against lung cancer itself 
Keywords: bone metastases, lung cancer, spinal fracture, bone diseases
and characteristics (i.e., presence of a GGO component, notch, spiculation, and pleural 
indentation) as viewed using CT and the SUVmax observed using PET before treatment 
were evaluated. The radiologic features of 181 EGFR/ALK-negative non-sq NSCLCs 
treated during the same period were also evaluated as a control group. In addition, 
sites of distant metastases were evaluated. Results: The median age of patients 
with ALK-positive lung cancer was 58 years (range, 25-83 years). Of the 21 patients, 
8 (39%) were female and 11 (52%) were never-smokers. The proportion of primary 
tumors smaller than 3 cm was significantly higher among the ALK-positive tumors 
than among the EGFR/ALK-negative tumors (48% vs. 21%, P = 0.01). Notches (71% 
vs. 41%, P = 0.01) and pleural indentations (81% vs. 55%, P = 0.03) were significantly 
more common among the ALK-positive tumors than among the EGFR/ALK-negative 
tumors. No significant differences in peripheral GGO (4.8% vs. 6.1%, P = 1.00) and 
spiculation (71.4% vs. 54.7%, P = 0.17) were observed. The median SUVmax values of 
the primary tumors were not significantly different (9.33 [range 4.56-28.81] vs. 10.54 
[range 1.20-38.18], P = 0.91). Regarding the sites of distant metastases, liver (33% vs. 
8%, P < 0.03) and pleural dissemination (48% vs. 24%, P = 0.03) were more frequent 
among patients with ALK-positive tumors than among patients with EGFR/ALK-negative 
tumors. Conclusion: We identified the radiologic features of advanced ALK-positive lung 
cancer, which include smaller-sized primary tumors and higher frequencies of notch 
and pleural indentation, compared with EGFR/ALK-negative tumors. These findings 
might be useful for the selection of patients with advanced ALK-positive lung cancer. 
Keywords: site of distant metastases, advanced ALK-rearranged lung cancer, Radiologic 
features
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P1.01-023 Discrepancy of ALK Status in Lung Adenocarcinoma Subtypes 
According to the IALSC/ATS/ERS Classification in Chinese Patients Shun Lu1, 
Yongfeng Yu2 1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao 
Tong University, Shanghai/China, 2Shanghai Lung Cancer Center, Shanghai Chest Hospital, 
Shanghai Jiaotong University, Shanghai/China
Background: This study aimed to determine the relationship between ALK status and 
predominant subtype, according to the IALSC/ATS/ERS classification. Methods: A 
reclassification of 638 surgically resected adenocarcinomas was performed in Shanghai 
Chest Hospital. ALK Status was detected by immunohistochemistry (Ventana Medical 
Systems) in these patients.All of the cases were confirmed by two independent 
pathologists. Results: The most prevalent subtype was acinar predominant (46.0%), followed 
by papillary predominant (25.2%), solid predominant (9.2%), micropapillary predominant 
(8.7%), variants of invasive adenocarcinoma (5.5%), lepidic predominant(5.3%), minimally 
invasive adenocarcinoma(2.0%), and adenocarcinoma in situ(1.0%). ALK positive was 
identified in 29 of 638 tumors (4.5%). The ALK positive frequencies were: 3.0%(8/284) 
for acinar predominant, 1.9%(3/156) for papillary predominant, 12.3%(7/57) for solid 
predominant, 5.3%(3/54) for micropapillary predominant, 17.6%(6/34) for variants of 
invasive adenocarcinoma, 3.0%(1/33) for lepidic predominant, 7.7%(1/13) for minimally 
invasive adenocarcinoma, and 0%(0/7) for adenocarcinoma in situ, respectively. 
ALK positive was significantly associated with the solid predominant subtype 
(p=0.003) and variants of invasive adenocarcinoma(p=0.0002). Conclusion: The 
ALK positive frequencies of solid predominant subtype and variants 
of invasive adenocarcinoma were higher than other subtypes. 
Keywords: lung adenocarcinoma, histologic classification, ALK status
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P1.01-024 Case Report of a Patient with Non-Small Cell Cancer Treated in Two 
Consecutive Randomized Clinical Trilas. Safety of Imaging Procedures 
Ewa Chmielowska1, Maciej Studzinski2, Marcin Świezynski3, Przemyslaw Szlezak4 
1Clinical Oncology, Oncoogy Center, Bydgoszcz/Poland, 2Oddział Kliniczny Onkologii 
Chemioterapiii, Szpital Onkologiczno Kliniczny Magodent, Warszawa/Poland, 3Clinical 
Oncology, Oncology Center, Bydgoszcz/Poland, 4Radiology, Oncology Center, Bydgoszcz/
Poland
Background: Severala rates for patients with adenocarcinoma of the lung who cannot 
be treated with targeted therapies due to lack of EGFR gene mutation or EML4-ALK 
translocation are relatively poor. Clinical trials with a new compounds pose a chance to 
improve treatment outcome, but also expose patients to many additional and potentially 
risky-related diagnostic procedures Methods: Case study analysis of 57 - years old 
male patient diagnosed in 2008 with metastatic adenocarcinoma of lung cT2N0M1. 
Patient was in good condition without any significant comorbidities.Patient has been 
qualified to A6181058 clinical trial- he received 6 cycles of Paclitaxel and Carboplatin 
chemotherapy with subsequent maintenance therapyconsisting of 72 Bevacizumab 
infusions.Partial remission has been achived with reduction of tumor size by 60%. 
Subsequently, due to disease progression, patient have been enrolled into another 
clinical trial - EC-FV-07 - 9 cycles of Docetaxel and 26 injections of folate receptor 
inhibitor EC145 has been applied. After 71 months since treatment initiationdisease has 
progressed.Upon disease progression paliative radiotherapy has been started. During 
treatment period, because of clinical trial scheduling requirements, contrast-enhanced 
computed tomography ( CE-CT)scans were performed every 6 to 8 weeks. During whole 
disease course neither lung cancer itselfnor applied treatment did not impaire patient’s 
daily activity. Aim of this report is to analyse a disease course and risks of repeated 
contrast enhanced computed tomography in patient treated with potentially nepfotoxic 
drug with long lasting maintenace treatment. Results: During seven years of treatment 
contrast-enhanced chest CT scans has been performed 57 times. Effective radiation 
dose patient has received was 395mSv and 4560 mg of iodine-based contrast was 
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Netherlands, 8Department of Radiation Oncology, Leiden University Medical Center, Leiden/
Netherlands, 9Department of Radiation Oncology, Radboud University Nijmegen Medical 
Center, Nijmegen/Netherlands, 10Department of Radiation Oncology, Catharina Hospital, 
Eindhoven/Netherlands, 11Department of Radiation Oncology, Medical Center Haaglanden, 
The Hague/Netherlands, 12Department of Radiation Oncology, University Medical Center 
Utrecht, Utrecht/Netherlands, 13Department of Radiation Oncology, Medical Center 
Alkmaar, Alkmaar/Netherlands, 14Department of Radiation Oncology, Medical Spectrum 
Twente, Enschede/Netherlands, 15Department of Radiation Oncology, Radiotherapy Institute 
Friesland, Leeuwarden/Netherlands
Background: The Dutch Radiotherapy Lung Audit (DLRA) is an outcome registration 
that provides the local health professionals with an instrument to compare and improve 
their lung cancer treatments. It ensures transparency regarding clinical outcome, quality 
and safety of lung cancer treatments in the radiotherapy departments throughout the 
Netherlands. Patients receiving thoracic radiation treatment with curative intent for 
(primary or recurrent) stage I-IIIB Non-Small Cell Lung Cancer (NSCLC) were included 
in the registry. The results of the DLRA on the first fully registered year, 2014, are 
reported. Methods: Information collected included patient, tumor and treatment 
characteristics, the incidence and severity of acute toxicity, mortality within three 
months after radical radiation treatment and the time interval between diagnostic 
work-up and start of the radiotherapy. The adherence to the waiting time (time between 
referral and start of the irradiation) and throughput time (time between planning CT 
scan and start of the irradiation) guidelines were registered and analyzed, as well as 
the use of modern treatment techniques such as stereotactic irradiation and image-
guided radiotherapy. Results: 14 out of 21 radiotherapy institutes included patients 
in the DLRA database. A total of 1350 patients were entered from January-December 
2014. Patients were treated with concurrent (32%) or sequential chemoradiation(20%), 
radiotherapy only (13%) or stereotactic ablative body radiotherapy (SABR [35%]). On 
a patient record level, there was a high level of completeness. The mean age was 69 
years (range 32-91, 59% males). Charlson comorbidity index ≥ 2 was present in 42% 
of patients. Most patients (45%) were cN+ with 20% cT4 tumors. Fifty eight percent 
of all patients started irradiation within 21 days after referral (range 0-89%). For 68% 
of the patients SABR started within 10 days after the planning-CT scan was acquired 
(range 17-100%) (fig 1). There was no correlation between the number of patients 
treated and the throughput times. Most patients received IMRT or VMAT irradiation. 
All registered patients had position verification during irradiation, mostly 3D (94%). 
Three-month (calculated from the end of RT) acute esophagus toxicity (grade≥ III) and 
pneumonitis (grade≥ II) of concurrent treatment were 12.4% and 3.9%, 6.1% and 4.1% 
for sequential chemoradiation, 3.3% and 4.3% for radiotherapy only, and 0.4% and 
2.3% for SABR, respectively. Three-month mortality rates were 8.2%, 8.5%, 9.6%, 
and 1.7%, respectively. Conclusion: The Dutch Radiotherapy Lung Audit on outcomes 
after (chemo)radiotherapy is directed towards an improvement of care for lung 
cancer patients. There’s room for improvement in the waiting and throughput times. 
Keywords: non-small cell lung cancer, Clinical audit, waiting times, throughput times
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-17:00
P1.01-030 Curable Bulky T4 Right Lower Lobe Tumours Invading Diaphragm 
and Liver: A Distinct Entity? Noelle O’Rourke1, Fiona Roberts2 1Clinical Oncology, 
Beatson West of Scotland Cancer Centre, Glasgow/United Kingdom, 2Pathology, Southern 
General Hospital, Glasgow/United Kingdom
Background: One third of patients with non-small cell lung cancer present with 
unresectable stage III disease. The median survival for all stage III(A and B) tumours 
with optimal chemoradiation in published series ranges 17-24 months. Using platinum 
doublet neoadjuvant chemotherapy as primary treatment the expected response rate is 
modest at 30-40%. In patients presenting with bulky T4 tumours with direct extension 
to diaphragm and beyond into liver, the expected outlook would be extremely poor. We 
report here a series of four such cases over a five year period in our practice which 
challenge our understanding of this disease Methods: Our regional lung cancer network 
presents all new patients at multidisciplinary tumour meetings to agree staging and 
management plan. We record data on all new patients registered with demographic 
data, performance status, results of staging and pathology investigations, treatment 
proposed, treatment delivered and outcomes in terms of progression free and overall 
survival. Results: Between January 2009 and end 2013 we recorded four cases of 
bulky right lower lobe lung cancers which showed radiological evidence of invasion 
into diaphragm (1 case) or beyond to liver (3 cases). There were 2 men and 2 women 
with ages 34, 51, 52 and 68. Three had squamous carcinoma and in one tumour was 
poorly differentiated, no subtype. Two were staged radiologically T4N2 and two were 
T4N0 but both with gross visible extension into liver. All patients were fit and received 
induction chemotherapy (2 carboplatin/paclitaxel and 2 cisplatin/vinorelbine). All had 
extraordinary responses to chemotherapy and proceeded to microscopically complete 
surgical resection. One patient had no viable tumour at operation including within the 
necessary liver resection. Another had only necrosis in the liver but small area viable 
residual tumour at right hilum and proceeded to post-op radiotherapy. All are alive with no 
evidence of recurrence with follow-up ranging 22, 34, 64 and 71 months Conclusion: This 
series although small is remarkable for the exquisite chemosensitivity of locally very 
advanced squamous cancers which have been apparently cured by neoadjuvant 
chemotherapy and surgical resection. We are undertaking additional pathological 
analysis of these specimens to determine whether there is a linking characteristic. 
Keywords: Bulky T4, liver, neoadjuvant chemotherapy
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P1.01-027 Prognostic Impact of Cytological Fluid Tumor Markers in Non-Small 
Cell Lung Cancer Arthur Cho1, Jin Hur2, Yoo Jin Hong2, Hye-Jeong Lee2, Young Jin 
Kim2, Sae Rom Hong2, Young Joo Suh2, Dong Jin Im2, Yun Jung Kim2, Jae Seok Lee3, 
Hyo Sup Shim3, Byoung Wook Choi2 1Nuclear Medicine, Yuhs, Seoul/Korea, 2Diagnostic 
Radiology, Yuhs, Seoul/Korea, 3Pathology, Yuhs, Seoul/Korea
Background: Serum tumor markers CYFRA 21-1, CEA, and squamous cell carcinoma 
antigen (SCCA) are useful in non-small cell lung cancer (NSCLC) diagnosis and prognosis. 
Cytologic tumor markers obtained during needle aspiration biopsy (NAB) of lung lesions 
help in NSCLC diagnosis. This study investigated the incremental prognostic value of 
cytologic tumor markers compared to serum tumor markers. Methods: This prospective 
study included 253 patients diagnosed with NSCLC by NAB with cytologic tumor marker 
analysis. Cytologic CYFRA 21-1, CEA, SCCA and serum counterparts were followed 
up for survival analysis. Optimal cut-off values for each tumor marker were obtained 
for overall survival (OS) and progression free survival (PFS) analysis. Results: All 
patients were followed up for median 22.8 months. Using cut-off value of 0.44ng/ml 
for C-SCCA, 2.0ng/ml for S-SCCA, and 3.3ng/ml for S-CYFRA, multivariate analysis 
revealed that high S-CYFRA (Hazard ratio (HR): 1.573), high S-SCCA (HR: 1.999), 
and high C-SCCA (HR: 1.744) were independent predictive factors for OS. The 3 year 
overall survival was 55% vs 80% for high and low C-SCCA. Conclusion: Cytologic 
tumor markers are poor prognostic factor in NSCLC patients as serum tumor 
markers, with C-SCCA showing a strong prognostic factor for overall survival. 
Keywords: cytologic tumor marker, serum tumor marker, NSCLC, Prognosis
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P1.01-028 Pathological Characteristics of Lung Cancer Patients in Colombian 
Coffe Zone Gustavo Rojas1, Marco Kimmel1, Jaime A. Echeverri F2, German A. 
Moreno1, Jose W. Martinez1, Paula Londno1 1Oncologos Del Occidente S.A., Pereira/
Colombia, 2Pulmonary Medicine, Oncologos Del Occidente, Pereira/Colombia
Background: During 1998 and 2013 at the “Colombian Coffee Zone” (conformed by 
three states Caldas, Quindio, and Risaralda) had an increase of 105 mortality cases of 
Bronchi and lung malignant tumors, as reported in death certificates. Methods: This 
is an observational, descriptive study, that was made in patients at Clínica Oncologos 
del Occidente in the year 2014. Information was taken from the Clinical History 
Administration System (SAHICO). Thereafter, pending data was collected, by phone calls 
to patients or patient’s family, according to every case. Patients were interviewed to 
know their actual performance status and, in case of death, date and basic cause of 
death was asked Results: SAHICO reported 178 patients with lung cancer. From these 
patients, 33 did not have a correct diagnosis. Basically, they did not have a histology 
report. This happens in patients that consulted with a clinical presentation compatible 
with a pulmonary origin neoplasia and radiologist reports concluding thorax tumors, 
which had a lung dependency. But patients had a very low performance status, because 
they did not assist to the second appointment or never started treatment; finally they 
died by the disease. The prevalence of these tumors was slightly more common in men. 
50% of the patients were between 60.7 and 74 years old. The median age was 69.1 
years for males and 64.1 for women. This age median differences were statistically 
significant (F=9,121 p value=0,003). Also, 90.8% of the patients were from urban 
areas. 85.3% of tumors treated during 2014 corresponded to NSCLC, meanwhile 10% 
were Small Cell lung cancer. It was also observed a relationship of 1.7 patients with 
Squamous cellular carcinoma for every patient with Adenocarcinoma. 28 patients 
were tested for the EGFR mutation analysis, from these, 5 were mutated. Squamous 
cellular carcinoma patients were older than Adenocarcinoma patients. Besides this, 
patients with Small cell had a Media and Median age higher than the squamous cellular 
carcinoma. Although, Squamous cellular tumor patients were more frequent, the median 
survival time was inferior to adenocarcinoma patients and the Non-Small cell lung 
cancer. And neuroendocrine tumor patients had also a longer survival than Squamous 
cellular patients. Conclusion: Pathological characteristics of Lung cancer patients in 
Colombian Coffee Zone are in general similar than the other latitudes, predominating 
the squamous cellular carcinoma and with an incidence around 10% of the small cell 
carcinoma; it is striking the sex relationship close than 1:1, presumably for the early 
incorporation of the female population to smoking habit and to others known risk 
factors like the expose to combustion biomass smoke. The epidermic growth factor 
receptor (EGFR) mutation was observed in same proportion than in other studies. 
Keywords: Lung Neoplasms, Surveillance, Survival, Carcinoma Bronchogenic
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P1.01-029 Dutch Radiotherapy Lung Audit: Results of 2014 Jose Belderbos1, 
E. Troost2, M Ten Berge3, Iris Walraven1, B. Reymen2, C. Tissing-Tan4, J. Widder5, F. 
Koppe6, E. Vonk7, I. Coremans8, J. Bussink9, K. De Jaeger10, N. Van Der Voort Van 
Zyp11, S. El Sharouni12, H. Knol13, J. Peer-Valstar14, A. Van Der Wel15 1Department of 
Radiation Oncology, The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, 
Amsterdam/Netherlands, 2Department of Radiation Oncology (Maastro Clinic), Maastricht 
University Medical Center, Maastricht/Netherlands, 3Department of Surgery, Leiden 
University Medical Center, Leiden/Netherlands, 4Department of Radiation Oncology, 
Institute for Radiation Oncology Arnhem, Arnhem/Netherlands, 5Department of Radiation 
Oncology, University Medical Center Groningen, Groningen/Netherlands, 6Department of 
Radiation Oncology, Verbeeten Institute, Tilburg/Netherlands, 7Department of Radiation 
Oncology, Radiotherapeutisch Instituut Stedendriehoek En Omstreken (Riso), Deventer/
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41 female were enrolled in our study. The average age was 62 years old. Metastasis 
occurred during early stage (less than 2 years postoperatively) in 45 patients, and during 
late stage (more than 2 years postoperatively) in 49 patients. Single organ metastasis 
and multiple organ metastasis were found in 85 and 9 patients separately. the most 
popular metastatic site was pulmonary, and then bone and brain. The overall survival 
(OS) of all included patients was 41.5%. The median survival time was 43 months and 
29 months for single metastasis and multiple metastasis groups separately. There was 
signifi cant difference in the OS between GS and GM group (45.9% Vs 0, P＜0.001). The 
median survival time was 50 months and 32 months for early metastatic patients and 
late metastatic patients separately. Signifi cant difference could be in the OS between 
GS and GM group (53.3% Vs 30.6%, COX P=0.130, Breslow P=0.014). Cox regression 
showed age TNM stage (P=0.003), and single organ metastasis (P＜0.001) were 
signifi cant prognostic factors for NSCLC. Conclusion: Lung, bone, and brain were the 
most popular metastatic organ for postoperative NSCLC. The presence of multiple organ 
metastases could be identifi ed as an independent poor prognostic factor in NSCLC. 
Keywords: non-small cell lung cancer, Prognosis, metastasis
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P1.01-034 Is There A “Physician Effect” in Medical Oncology? Hannah 
Jonker1, Khalid Al-Baimani2, Tinghua Zhang3, Glenwood Goss1, Scott A. Laurie1, Garth 
Nicholas2, Paul Wheatley-Price2 1Medical Oncology, The Ottawa Hospital Cancer Centre, 
University of Ottawa, Ottawa/ON/Canada, 2Medical Oncology, The Ottawa Hospital Cancer 
Centre, University of Ottawa, Ottawa/Canada, 3Ottawa Hospital Research Institute, Ottawa/
Canada
Background: Non-small cell lung cancer (NSCLC) is the commonest cause of cancer 
death globally, with a 5-year survival of 16%. Known prognostic factors include stage, 
performance status (PS) and gender, but does the choice of physician affect patient 
outcome? We assessed practice variations of four medical oncologists treating advanced 
NSCLC, investigating this impact on overall survival (OS). Methods: Following ethics 
approval, a retrospective analysis was undertaken of all newly diagnosed stage 4 NSCLC 
patients seen in out-patient consultation at our institution between 2009 and 2012. All 
physicians accepted unselected lung cancer referrals and all patients are included. 
Baseline demographics, systemic therapy received, reasons for not receiving therapy, 
and OS data were collected. Cox regression analyses (univariate and multivariate) were 
employed to assess determinants of OS. The physicians were blinded to the 
results. Results: Overall 528 patients were included. Baseline characteristics are shown 
in table 1. A signifi cant variation was noted in the proportion receiving any systemic 
chemotherapy (p≤0.01) [D(60%), L(65%), R(43%), M(52%)] (Figure 1A). However OS was 
not statistically signifi cantly different among all patients (p=0.47), among treated 
patients (p=0.18) or among untreated patients (p=0.22)(Table and Figure 1B). In 
multivariate analysis, factors associated with survival were PS (p<0.01), weight loss 
(<5%, ≥5%)(p<0.01), WBC (<11, ≥11)(p=0.0588) and platelets (<400, ≥400)(p=0.0374).
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P1.01-031 Feasibility of Median Sternotomy Approach for Locally Advanced 
Lung Cancer Hiroki Sato, Takeshi Kurosaki, Shinji Otani, Yuho Maki, Kentaro 
Miyoshi, Hiromasa Yamamoto, Seiichiro Sugimoto, Junichi Soh, Masaomi Yamane, 
Shinichi Toyooka, Takahiro Oto, Shinichiro Miyoshi Departments of Thoracic, Breast and 
Endocrinological Surgery, Okayama University Graduate School of Medicine, Okayama/Japan
Background: Trimodality therapy is one of therapeutic options for local advanced 
lung cancer. While a posterolateral thoracotomy was used as the standard approach, 
a median sternotomy with or without transverse thoracotomy is applied if necessary. 
In our institution, we have applied median approach for patients who need dissection 
of contralateral mediastinal lymph nodes or clamp of great vessels, mainly pulmonary 
artery, for a safe resection. The purpose of this study was to evaluate the feasibility and 
clinical outcome of median sternotomy approach for locally advanced lung cancer after 
chemoradiotherapy. Methods: Between March 2002 and December 2014, 35 non-small-
cell lung cancer patients underwent radical surgery with median sternotomy approach 
after induction chemoradiotherapy . The medical records were reviewed to investigate 
clinical outcomes including perioperative complications. Results: The median patient 
age was 59 years (range: 41–77 years). There were 28 men and 7 women in the series. 
The histological subtype was adenocarcinoma in 21 patients, squamous cell carcinoma 
in 14. 16 patients had stage IIIA disease, and 19 had stage IIIB disease. The median 
postoperative hospital stay was 23 days. As notable perioperative complications, 12 
patients revealed tachycardia that needs medication, 6 pneumonia, 3 radiation-induced 
pneumonitis, one wound ablation, one bronchial stump fi stula, and one chylothorax. 
All of them were manageable. There was no treatment-related death in this cohort. As 
patients’ survival, the 3-year and 5-year overall survival rates were 77.7 % and 67.1 %, 
respectively. The 1-year and 3-year recurrence-free survival rates were 75.4 % and 63.4 %, 
respectively. Conclusion: Our experience indicates that median sternotomy approach for 
locally advanced lung cancer after ChRT is feasible procedure after chemoradiotherapy. 
Keywords: median sternotomy, induction chemoradiotherapy, locally advanced lung 
cancer
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P1.01-032 Surgical Resection for Lung Adenocarcinoma after Afatinib 
Treatment Hirofumi Suzuki1, Motohiro Nishimura1, Asuka Okada2, Junichi Shimada3
1Thoracic Suregery, Saiseikai Suita Hospital, Osaka/Japan, 2Respiratory Medicine, Saiseikai 
Suita Hospital, Osaka/Japan, 3Thoracic Suregery, Kyoto Prefectural University of Medicine, 
Kyoto/Japan
Background: Afatinib, an irreversible ErbB family blocker, has shown superiority to 
chemotherapy in patients with epidermal growth factor receptor gene (EGFR) mutated 
non-small cell lung cancer. However, there has been no report about the preoperative 
Afatinib treatment. We report a case of surgical resection for lung adenocarcinoma after 
Afatinib treatment. Methods: A 33-year-old female with a chronic cough was referred to 
our hospital because of an abnormality on a chest radiograph. Computed Tomography 
(CT) displayed consolidation in left lower lobe. On bronchoscopic examination, her 
disease was diagnosed as adenocarcinoma of the lung, harboring EGFR mutation 
(exson19 deletions). Contrast-enhanced brain magnetic resonance imaging showed 4 
brain metastases. Positron emission topography (PET) revealed abnormal accumulation 
in left lower lobe, lymph nodes (station 1, 4R, 5) and plevis. Her clinical staging was 
IV (T4N3M1b). Stereotactic radiotherapy for brain metastases (total 35Gy:7Gy/fraction) 
was done, and Afatinib was administered for 6 months. Results: These treatments 
resulted in a down-stage (T1aN0M1b) ; CT showed that the consolidation shrank and a 
single nodule (20mm) remained in S8 of left lower lobe. 3 of the brain metastases lost 
and the rest one diminished. PET revealed slight FDG uptake only in the nodule in S8 but 
not regional lymph node or in a distant site. We performed surgical resection for the 
nodule. Pathological examination revealed no cancer rest. The postoperative course was 
uneventful. She has been continuing Afatinib for 3 months without any recurrence after the 
surgery. Conclusion: We report the fi rst case, to our knowledge, of a patient who obtained 
signifi cant response to Afatinib and was proved no cancer rest by surgical resection. 
Although more observation period for this patient and prospective study are needed, this 
report provides insight into the effi cacy of surgical resection after Afatinib treatment. 
Keywords: afatinib, Surgical resection, lung adenocarcinoma, preoperative treatment
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P1.01-033 Multiple Organ Metastasis Could Be Identifi ed as Poor Prognostic 
Factors for NSCLC Zhenrong Zhang, Deruo Liu, Hongxiang Feng China-Japan 
Friendship Hospital, Beijing/China
Background: Metastatic spread of cancer to distant organs is the reason for
most cancer deaths.Lung cancer frequently metastasize to bone, brain, lung, andliver, 
causing a shorter survival. Therefore, increased knowledgeof metastatic patterns 
is crucial in the treatment of patients. In this article, we evaluate the prognostic 
signifi cance of postoperative metastasis organ in NSCLC. Methods: The relationship 
between postoperative metastasis and survival was investigated. Patients who 
underwent curative lobectomy and pathologically diagnosed with NSCLC between 
2005.1 and 2011.12 were included in our study. SPSS 20.0 software was used for 
analysis. Survival rates were calculated using Kaplan-Meier survival plots and analyzed 
using the Cox regression. The variables with statistical signifi cance in univariate analysis 
were included in multivariate analysis. Signifi cant difference between groups could be 
found if p value was less than 0.05. Results: Finally 94 patients including 53 male and 
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metastasis. Methods: treating painful none small cell lung cancer (NSCLC) rib metastasis. 
Methods radiofrequency ablation procedures were completed in 12 patients with painful 
rib metastasis. Patient age ranged from 66 to 83 years (mean 74.8 years, Standard 
Deviation (SD) =5.3).Pathology: squamous-carcinoma 4 cases, adeno-carcinoma 7 
cases and large cell carcinoma 1 case. Pain causing neoplasm size, pain levels pre- and 
post-procedure (as assessed using the Visual Analog Scale), time length and target 
temperature of radiofrequency ablation (RFA) treatments were documented.
 
 
Results: Radiofrequency ablation (RFA) procedures were performed with 100% technical 
success. The mean pre-procedure and post-procedure pain, as measured by the Visual 
Analog Scale (VAS), was 7.9 (SD=0.90) and 3.4 (SD=0.99) respectively. No symptomatic 
complications occurred. Non-symptomatic complications included 1 case of pneumothorax, 
1case of hemoptysis. Conclusion: RFA appears to be safe, practical and effective in the 
palliative treatment of none small cell lung cancer (NSCLC) chest wall painful metastasis. 
Keywords: palliative treatment, rib painful metastasis, Radiofrequency ablation, none 
small cell lung cancer
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P1.01-037 Successful Treatment of Non-Small Cell Lung Cancer with 
Erlotinib throughout Pregnancy Yongli Ji1, Joanna Schwartz2, Alan Hardford3, 
Jon Ramsey4, Julie Phillips5, Claire Verschraegen6 1University of Vermont Cancer 
Center, Burlington, Vt/United States of America, 2Albany College of Pharmacy, Albany/
United States of America, 3Dartmouth-Hitchcock Medical Center, Lebanon/NH/United 
States of America, 4University of Vermont Cancer Center, Burlington/United States of 
America, 5Maternal Fetal Medicine, University of Vermont Medical Center, Burlington, Vt/VT/
United States of America, 6University of Vermont Cancer Center, Burlington/VT/United States 
of America
Background: Erlotinib is the standard of care for epidermal growth factor receptor 
(EGFR) mutated lung adenocarcinomas in the USA. However, in pregnant patients with 
lung cancer, chemotherapy is recommended, irrespective of EGFR mutations, given the 
lack of experience and uncertainty for fetus’ safety with Erlotinib. Methods: A patient, 
with twin pregnancy after in-vitro fertilization, was intentionally treated with Erlotinib. 
Pharmacokinetics of Erlotinib and its active metabolite (OSI240) were measured 
in mother’s plasma and twins’ cord blood which were collected at delivery. Times of 
gestation, fetal growth, transplacental pharmacokinetics of Erlotinib, and cancer outcome 
were recorded. The pharmacovigilance of Erlotinib during pregnancy was analyzed by 
accessing Roche/Genentech global database. Results: A 47 year old woman, ten-weeks 
pregnant with twins, was diagnosed with stage 4 lung cancer which harbored an exon 19 
deletion. She had brain metastases which were treated with stereotactic surgery during 
Demographic Overall (n=528)
Physi-
cian R 
(n=137)
Physi-
cian M 
(n=118)
Physi-
cian D 
(n=115)
Physi-
cian L 
(n=158)
p-value
Median Age 68 70 68 67 67 0.23
Gender 
(male) 55% 58% 58% 49% 56% 0.42
PS (0-1) 50% 47% 48% 50% 55% 0.01
Hg (<100) 6% 11% 3% 4% 4% 0.01
LDH (<250) 28% 21% 30% 27% 33% 0.09
Platelets 
(<400) 71% 64% 75% 78% 70% 0.12
Weight loss 
(>5%) 48% 49% 48% 46% 49% 0.87
WBC (<11) 62% 56% 68% 68% 60% 0.11
Received ≥ 1 
line systemic 
therapy
55% 43% 52% 60% 65% <0.01
 
Conclusion: While practice size and proportion of patient treated did vary between 
oncologists, these did not translate into significantly different survival. There were 
statistically significant differences in the distribution of baseline characteristics 
between the 4 oncologists and this could cause the differences in proportion of 
patients treated. We hypothesize that as long as the oncologists are well trained 
and display good practice, survival is not dependant on the individual. This 
research does not measure other valuable characteristics or outcomes such as 
rapport, compassion, and quality of life, which may differ between physicians. 
Keywords: outcome, advanced, NSCLC, physician
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P1.01-035 Clinico-Epidemiological Features and Survival Outcome in Patients 
with NSCLC: Ain Shams Clinical Oncology Department 5-Year Data Ahmed A. 
Nagy, Mohamed Kelney Clinical Oncology and Nuclear Medicine, Ain Shams University 
Faculty of Medicine, Cairo/Egypt
Background: Primary lung cancer is the most common malignant neoplasm worldwide. 
In spite of the fact that in Egypt, according to various institutional and hospital-based 
data, bronchogenic carcinoma is the fifth most common malignancy among males the 
seventh most common cancer in females, its incidence continues to increase with no 
improvement in treatment outcome. This study aims to analyze the epidemiological 
factors and clinicopathological features of NSCLC in egyptian patients and evaluate the 
various lines of treatment and their impact on survival. Methods: This study included the 
examination and analysis of data collected retrospectively from the medical records of 
504 patients diagnosed with NSCLC who were treated at Department of Clinical Oncology 
and Nuclear Medicine, Ain Shams University, Cairo-Egypt in the period from January 
2008 till December 2012. Results: The median age of the cohort was 59 years (Range 
33-80)with male predominance (74.4%) and 59.1% were of urban residence. The most 
common symptom at presentation was dyspnea (49.2%). Most patients were stage IV 
at presentation (73.2%) and adenocarcinoma was the most common histology (52.6%). 
About 85% of the patients received active treatment. The Median PFS after first,second 
and third lines was 3, 4 and 2 months respectively and the median OS was 8 months. 
Factors which were associated with a statistically significant difference in median 
OS were age <60 years versus ≥ 60 years (10 and 7 months respectively, p<0.001), 
female versus male gender (10 and 8 months respectively, p<0.001), urban versus rural 
residence (9 and 8 months respectively , p=0.03), smokers versus non-smokers (8 and 
10 months respectively, p<0.001), patients presenting with non-neurological symptoms 
and those presenting with neurological symptoms (9 and 6 months respectively, p< 
0.001) and the receiving treatment versus no treatment (10 and 5 months respectively, 
, p<0.001). Cox regression analysis showed that the factors that were associated 
with shorter OS were age≥ 60 years, not receiving any line of treatment, patients 
presenting with neurological symptoms and male gender. Conclusion: This study 
shows that the active treatment of patients with NSCLC continues to have an important 
impact on survival. The fact that rural residence could be associated with worse OS 
warrants further investigation. We recommend large multicentric prospective studies 
comparing multimodality treatment approaches and including quality of life assessment. 
Keywords: NSCLC, Adenocarcinoma
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P1.01-036 RFA for Palliative Treatment of NSCLC Rib Painful Metastasis: 
Experience in 12 Patients Hu Mu Thoracic Surgery Department, Xuanwu Hospital Capital 
Mediacl University, Beijing/China
Background: Painful rib metastasis is common in NSCLC. Pain sometimes was partially 
or totally refractory to analgesic medications or the side-effects of medication were 
unacceptable. We report the safety and efficacy of a new method: radiofrequency 
ablation in treating painful none small cell lung cancer (NSCLC) rib 
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renal transplanted patients was 1.89/1000 person-years for the 2008-2012 period. Our 
cohort was mainly formed of male smokers around 60 years old, all current or former 
smokers. 43% were diagnosed by routine exams. Histopathological distribution was 
different with more squamous cell carcinoma. As expected, hypertension and ischemic 
heart disease were more prevalent but the other comorbidities and characteristics 
were the same in both groups. 60% had a stage IV cancer. Surgery was performed 
as often as in controls if the stage allowed it and advanced stage received full dose 
chemotherapy. Palliative care only was given to 20% of the patients. Hospitalization 
for infectious complications was somewhat higher in the cases group but global 
survival was similar. Conclusion: Kidney transplant recipients are likely to develop 
lung cancer. Despite frequent radiologic examinations, the majority of patients had 
advanced stage disease at diagnosis. Therapeutic management and prognosis did not 
differ between patients and control. As current or past smoking habit was present in 
all cases, a screening strategy should focus on smokers in this high-risk population. 
Our study was not designed to determine if other risks factors could be identified. 
Keywords: lung cancer, Kidney transplantation
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P1.01-040 Determining Completeness of Case Ascertainment to the 
Victorian Lung Cancer Registry: A Quantitative Case Finding Audit Rob Stirling1, 
Peta Mclaughlin1, Meera Senthuren1, Baki Billah1, Lise Hales2, Mark Molloy3, Chris Bain2, 
Sue Evans1 1Epidemiology and Preventative Medicine, Monash University, Melbourne/VIC/
Australia, 2Health Information Services, Alfred Health, Melbourne/VIC/Australia, 3Health 
Information Services, Epworth Health, Richmond/VIC/Australia
Background: The Victorian Lung Cancer Registry (VLCR) pilot project aims to recruit all 
lung cancer cases diagnosed across participating Victorian sites. Case ascertainment 
derives from institutional ICD-10 coding. A quantitative, case finding audit was employed 
to evaluate the case ascertainment methodology and assess capture completeness 
at a Victorian public and private metropolitan hospital. Methods: Lists of lung cancer 
patients recorded for the period 01/07/2011 and 30/06/2012 were requested from 
institutional departments including; Radiotherapy, Palliative Care, Day Procedure Unit, 
Oncology Lung Multidisciplinary Team Meeting (MDM), Cardiothoracic Surgery (CTS), 
Pathology and the Victorian Cancer Registry (VCR). Comparisons were made between 
VLCR administrative capture versus clinical capture achieved by the use of clinical 
databases compared with mandated VCR capture. Results: The VLCR registered 125 
new cases in Site A and 100 in Site B. A total of 10 (7.5%) patients in Site A and 13 (11%) 
patients in Site B had not been recruited by the registry. Investigations indicated that the 
underreporting of these cases was attributed to:
• Use of the ICD10 R91 Code (when lung cancer is suspected but not confirmed)
• Non coded patients (e.g. day admissions, direct admission to palliative care or 
MDM)
Conclusion: The completeness of capture of incident cancers occurring in a population 
and included in a registry database is a vital attribute of a cancer registry. Current 
capture is approximately 90% and inclusion of the R code and an attempt to capture un-
coded patients will ensure registry incidence rates are close to their true value.
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P1.01-041 Prognostic Significance of CT Emphysema Score in Patients with 
Advanced Squamous Cell Carcinoma of the Lung Young Saing Kim1, Eun Young 
Kim2, Min Young Baek1, Hee Kyung Ahn1, Eun Kyung Cho1 1Division of Hematology and 
Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon/
Korea, 2Radiology, Gachon University Gil Medical Center, Incheon/Korea
Background: Although the contribution of emphysema to lung cancer risk has been 
recognized, no study has focused the prognostic impact of CT emphysema score for 
advanced stage of lung cancer. The aim of our study was to analyze the prognostic value 
of CT emphysema score in patients with advanced squamous cell carcinoma of the lung 
(SCCL). Methods: We analyzed 84 consecutive patients with advanced stage (stage IIIB 
and IV) of SCCL who underwent palliative chemotherapy. The severity of emphysema was 
semi-quantitatively scored using baseline chest CT images according to the Goddard 
scoring system, ranging from 0 to 24. Data on clinical characteristics and survival were 
retrospectively collected. Survival was estimated by the Kaplan-Meier method and 
compared with the log-rank test. A multivariable Cox proportional hazard model was used 
to identify prognostic factors. Results: Most patients were male (89%) and current/ex-
smokers (90%). The median CT emphysema score was five (range, 0 to 22). In univariable 
analysis, patients with higher CT emphysema score (> 6) showed a trend toward poor 
survival (6.3 months vs. 11.4 months in those with lower score, p=0.076). In the multivariable 
model, higher CT emphysema score was a significant independent prognostic factor for 
poor survival (HR,1.85; 95% CI, 1.14 to 3.00; p=0.012) along with response to first-line 
therapy (p=0.001) and second-line therapy (p<0.001). Conclusion: The CT emphysema 
score is significantly associated with poor prognosis in patients with advanced SCCL. 
Keywords: CT emphysema score, Squamous cell carcinoma, Prognosis
the first trimester. Erlotinib -150 mg daily - was intentionally administered at the start of 
the second trimester. She was treated for 130 days. Growth retardation was noted in 
one fetus at week 33 and delivery was planned at week 37 by cesarean section. Drug 
concentrations in mother’s plasma and twins’cord blood are shown in the table. Erlotinib 
and its metabolite cross the placenta, but only at 10-25% of blood concentrations. Side 
effects included a lower than expected birth weight (87% of normal) and transaminitis in 
both newborns that resolved within 3 months. The mother sustains an ongoing partial 
response to Erlotinib with minor skin rash and fatigue from treatment. The infants are 
normal at 10 months. Table 1. Erlotinib Concentrations in Mother and Twins
Sample
Erlotinib 
concentration 
(ng/mL)
%
OSI-420 
concentration 
(ng/mL)
%
Newborn 
weight 
(g)
Mother plasma 54.31 100 16.25 100 -
Newborn A cord 13.67 25.2 2.12 13.0 2353
Newborn B cord 12.18 22.4 1.5 9.2 2438
OSI-420, Desmethyl-Erlotinib.  
Conclusion: Erlotinib administration is feasible during late pregnancy and yields 
improved cancer outcome. Keywords: lung cancer, Erlotinib, Pregnancy
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P1.01-038 Endosonographic vs Surgical Staging for Mediastinal Nodal 
Staging of Lung Cancer: A Systematic Review Prakash Balakrishnan1, Casey Lo2, 
Sean Galvin2, Barry Mahon2 1Cardiothoracic Department, Wellington Regional Hospital, 
Wellington/New Zealand, 2Cardiothoracic Surgery, Wellington Regional Hospital, Wellington/
New Zealand
Background: Endosonographic staging techniques mainly endoscopic (EUS-FNA) or 
endobronchial (EBUS-TBNA) with needle aspiration modalities has been increasingly 
described and used in many established centres since the early year 2000 as 1st line 
mediastinal staging compared to surgical staging (video / cervical mediastinoscopy) 
. Its minimally-invasive nature , with low complications rate , excellent diagnostic 
accuracy and ultimately cost-effectiveness are some of the main deciding factors 
involved .The aim of this review is to evaluate the diagnostic yield of endosonographic 
staging compared to surgical staging for mediastinal lymphadenopathy in lung cancer 
patients. Methods: A thorough extensive electronic literature database search in 
PUBMED ,EMBASE ,MEDLINE and ISI web of Science was conducted systematically , 
emphasizing endosonographic staging modalities vs surgical staging ,ranging from year 
2000 up to April 2015 . These search engines were not confined to English-literature 
language only . Lung cancer patients were identified as a separate unit of analysis ,as 
well as these endosonographic staging methods at the level of mediastinum and its 
diagnostic yield ( positive lymph nodes) were clustered in a different analysis group. In 
this review , the methodological analysis used was the Quality Assessment of Diagnostic 
Accuracy Study (QUADAS-2) as a tool to allow transparent rating of potential bias and 
application of primary diagnostic accuracy study. The primary end-point was the number 
of positive successful mediastinal nodal biopsies ,which was grouped according to the 
American Thoracic Society (ATS) classification . Results: A total of 10 major trials & 
reviews pertaining to this topic were extensively reviewed . Approximately nearly 1000 
patients were grouped in this study ,who underwent either EUS-FNA staging with or 
without EBUS-TBNA and mediastinoscopy following diagnosis of lung cancer , either in a 
small or large , single or multiple centres across the world . The sensitivity , specificity 
, positive (PPV) & negative predictive values (NPV) and diagnostic accuracy or yield 
for endosonographic staging vs surgical staging modalities were cross-examined 
. Conclusion: According to the systematic analysis , these groups are moving forward 
for endosonographic (EUS-FNA or EBUS-TBNA) modalities compared to solely surgical 
staging (mediastinoscopy) in most cases . It seems to be a more promising ,successful 
& cost-effective method for sampling mediastinal nodes in lung cancer patients . 
Keywords: Endoscopic ultrasound-guided fine needle-aspiration, lung cancer, 
endobronchial ultrasound-guided transbronchial needle aspiration, lymphadenopathy
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P1.01-039 Lung Cancer in Kidney Transplant Recipients: A Case-Control 
Retrospective Study of 30 Patients Claire R. Gazaniol1, Séverine Fraboulet2, Louis-
Jean Couderc2, Henri Kreis3, Raphaël Borie4, Leila Tricot2, Dany Anglicheau3, Marie-Ange 
Massiani2, Pierre Bonnette2, Hélène Doubre2, Francois Mellot2, Gaelle Pelle2, Edouard 
Sage2, Patricia Moisson2, Michel Delahousse2, Magali Colombat2, Alain Chapelier2, Leila 
Zemoura2, Philippe Puyo2, Elisabeth Longchampt2, Christophe Legendre3, Sylvie Friard2, 
Emilie Catherinot2 1Hôpital Foch, Suresnes/France, 2Hopital Foch, Suresnes/France, 3Hôpital 
Necker, Paris/France, 4Hôpital Bichat, Paris/France
Background: Kidney transplantation has dramatically increased during last decades. As 
significant progress has been made in the prevention and treatment of infections, cancer 
has become a major cause of concern. Limited data exist about lung cancer after kidney 
transplantation. Methods: The data from 2003 to 2012 of all transplanted patients with 
lung cancer in three French kidney transplant centers were retrospectively reviewed. 
30 cases were included. Lung cancer incidence was determined in two centers for the 
2008-2012 period. Each case was matched with two controls. Controls were patients 
without solid organ transplantation matched with the cases for age (<30; 30-50; 50-65; 
>65 years), gender and diagnosis date of lung cancer. Results: Lung cancer incidence in 
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treatments were calculated using National Health System (NHS) direct costs and 12 
months time-horizon. Effectiveness was estimated as Progression Free Survival (PFS). 
The Incremental Cost-Effectiveness Ratio (ICER) was calculated and pharma-economic 
analysis was performed setting the Willingness To Pay (WTP) threshold value at 40,000€ 
per free-disease month gained. The reliability of results was assessed by a probabilistic 
sensitivity analysis based on “Monte Carlo” method (10,000 simulations) changing the 
costs and effectiveness variables simultaneously. Number and grade of adverse events 
were used to determine the tolerability profile. Results: The average cost per patient 
was 10,278.38€ (arm A) and 8,659.53€ (arm B). Related ICER was 4,496.80€ per 
free-disease month gained and 53,961.73€ per year gained (over the WTP threshold). 
The scatterplot generated in the sensitivity analysis indicated that higher densities of 
ICERs, calculated for each simulation, took place at the cross over of the Cartesian axes 
indicating that there is no clear prevalence of treatment cost-effectiveness. Moreover, the 
Cost-Effectiveness Acceptability Curve (CEAC) was calculated. This curve demonstrated 
that treatment A had 35% of probability to be cost-effectiveness. Conclusion: This 
preliminary evaluation, conducted in a subgroup of pts, suggests the relevance of 
pharmacoeconomic analysis within a clinical trial looking at the best way to identify a 
tailored treatment in non-oncogene addicted NSCLC pts. Further data will be collected 
in a larger simple size. Personalised chemotherapy is a potential method addressing 
both the optimisation of the effectiveness of therapeutic agents and the minimisation of 
adverse events, objectives even more relevant for elderly and fragile patients, given the 
possibility to optimize the use of scarce resources available.
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P1.01-045 Drug Fever After Cancer Chemotherapy Is Most Commonly 
Observed on Post-Treatment Days 3-4 Minoru Fukuda1, Daiki Ogawara2, Shiro 
Ueno3, Yoshihiro Ohue4, Hiroshi Gyotoku5, Hiroaki Senju5, Shinnosuke Takemoto5, 
Hiroyuki Yamaguchi5, Katsumi Nakatomi5, Yoichi Nakamura5, Takuya Honda1, Kazuma 
Kobayashi1, Daisuke Nakamura1, Hideyuki Hayashi1, Mikio Oka4, Kazuto Ashizawa1 
1Clinical Oncology Center, Nagasaki University Hospital, Nagasaki/Japan, 2Internal Medicine, 
Isahaya General Hospital, Isahaya/Japan, 3Ikeda Hospital, Kagoshima/Japan, 4Respiratory 
Medicine, Kawasaki Medical School, Okayama/Japan,5Respiratory Medicine, Nagasaki 
University Hospital, Nagasaki/Japan
Background: Fever during cancer chemotherapy is require attention using antibiotics to 
prevention severe infection. On the other hand, it should be avoid using antibiotics to non-
infectious fever such as drug and tumor fever with the object of development of resistant 
bacteria, exacerbation of drug fever, and medical economics. Methods: Retrospectively, 
1,016 consecutive cycles of cancer chemotherapy were analyzed. Fever was defined as a 
temperature of ≥37.5°C. Age, sex, tumor histology, the treatment regimen, the timing of 
fever onset, the number of days for which the fever persisted, the cause of the fever, and 
the presence or absence of radiotherapy were examined. Results: Seventy-four percent 
of the patients (748 of 1016) were males, the patients’ median age was 68 years (range: 
from 29 to 88 years), and lung cancer was the most common disease (93%). Fevers 
occurred in 36% of cycles (367 of 1016) including 37% of those involving males and 32% 
of those involving females. There was no difference in the frequency of fever among the 
sexes (p=0.146). The incidence of fever according to age were 33% (≤60), 41% (61-65), 
36% (66-70), 33% (71-75), 41% (76-80), and 33% (≥81); it did not differ significantly with 
age (p=0.424). In incidence of fever according to the drugs administered, gemcitabine 
was the drug that was most frequently associated with fever (41%; 43/106), followed by 
irinotecan (40%; 108/272), amrubicin (39%; 29/75), and docetaxel (36%; 47/131). Post-
treatment days 4 (8.3%), 3 (6.8%), and 12 (6.7%) were the days on which fever was most 
common. The distribution of fever exhibited a bimodal distribution; i.e., whilst it peaked 
on post-treatment days 3 and 4; otherwise, it generally gradually increased until day 12 
and then gradually decreased. The peak on post-treatment days 3-4 was considered 
to be due to adverse drug reactions, and the latter peak was considered to represent 
neutropenic or infection-based fevers. Fevers occurred on post-treatment days 3-4 in 11% 
of all cycles (113 of 1016) including 11% (84 of 748) of the cycles involving males and 11% 
(29 of 268) of those involving females. The incidence of fever on post-treatment days 3-4 
according to age were 12% (≤60), 13% (61-65), 10% (66-70), 8% (71-75), 13% (76-80), 
and 10% (≥81); however, this parameter did not differ significantly with age (p=0.427). 
The incidence of fever on post-treatment days 3-4, gemcitabine was the drug that was 
most commonly associated with fever (20%), followed by docetaxel (18%), nedaplatin 
(12%), and carboplatin (11%). The patients’ fevers were caused by infections (47%), 
adverse drug reactions (24%), unknown causes (19%), and tumors (7%). The causative 
infections included febrile neutropenia (50%), pneumonia (18%), unidentified infections 
(9%), and colitis (7%). The incidence of fever was significantly higher among the patients 
treated with radiotherapy than among those that did not receive radiotherapy (46% vs. 
34%, p=0.001). Conclusion: The febrile episodes that occurred on post-treatment days 
3-4 were considered to represent adverse drug reactions after cancer chemotherapy. 
Physicians should be aware of this feature of chemotherapy-associated fever and 
avoid unnecessary examination and treatments including prescribing antibiotics. 
Keywords: drug fever, Radiotherapy, cancer chemotherapy
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P1.01-046 Characteristics of Complete Remission Cases in Advanced Non-
Small Cell Lung Cancer Takuya Aoki1, Kazuki Harada1, Jun Tanaka1, Masako Sato1, 
Yukihiro Horio1, Hiroto Takiguchi1, Hiromi Tomomatsu1, Katsuyoshi Tomomatsu1, 
Takahisa Takihara1, Kyoko Niimi1, Naoki Hayama1, Tsuyoshi Oguma1, Takeshi Akiba2, 
Tetsuya Komatsu2, Tomoki Nakagawa3, Rhota Masuda3, Hitoshi Itoh4, Hiroshi Kajiwara4, 
Jun Nishiyama5, Tetsuya Urano1, Etsuo Kunieda2, Naoya Nakamura4, Atsushi Tsugu5, 
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P1.01-042 Maintenance Therapy with Pemetrexed after Induction Therapy with 
Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma Ho-Kee 
Yum, I-Nae Park Department of Internal Medicine, Seoul Paik Hospital INJE University, Seoul, 
Korea, Seoul/Korea
Background: Recently, continuation maintenance with Pemetrexed after induction 
therapy with pemetrexed plus cisplatin for advanced pulmonary adenocarcinoma has 
been approved in Korea. Therefore we retrospectively evaluated the activity and feasibility 
of continuation maintenance with Pemetrexed in Korean patients. Methods: Stage 
IIIB/V patients with pulmonary adenocarcinoma were evaluated from 2006 to 2015 
April. We analyzed 12 cases with maintenance therapy with Pemetrexed. All patients 
received an induction phase which consisted of 4-6 cycles of induction pemetrexed 
(500 mg/m2) plus cisplatin (75 mg/m2) on day 1 of a 21-day cycle and maintenance 
therapy with pemetrexed (500 mg/m2) every 21 days) plus best supportive care until 
disease progression. Results: Mean age was 61 years; 9 were men. Median number 
of total pemetrexed cycles was 18 (8-42). The mean overall survival time and the mean 
progression free survival were 46±12.3 months and 21.1±5.8 months, respectively. 
The median overall survival time and the median progression free survival were 
29±20.8 months and 12±7.1 months, respectively. Discontinuations due to drug-
related adverse events occurred in one (8%) patients. Conclusion: Continuation 
maintenance with pemetrexed is an effective and well tolerated treatment option for 
patients with advanced pulmonary adenocarcinoma with good performance status who 
have not progressed after induction therapy with pemetrexed plus cisplatin in Korea. 
Keywords: pemetrexed, advanced lung ca
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P1.01-043 Prognostic Factors in the First-Line Chemotherapy of Advanced 
Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 
2 Shinobu Hosokawa, Akihiro Bessho, Kazuya Nishii, Nobuaki Fukamatsu, Yoshiko 
Ogata, Makoto Sakugawa Department of Respiratory Medicine, Japanese Red Cross 
Okayama Hospital, Okayama/Japan
Background: To evaluate prognostic factors in the first-line chemotherapy of advanced 
non-squamous non-small cell lung cancer patients with Eastern Cooperative Oncology 
Group(ECOG) performance status(PS) 2. Methods: We retrospectively analyzed clinical 
and laboratory characteristics of patients with advanced non-squamous non-small 
cell lung cancer patients with ECOG PS 2 who received the first-line chemotherapy 
in our institute. We examined the various clinical values such as gender, age, clinical 
stage, histology, immunohistochemistry, chemotherapy regimen, underlying diseases, 
metastasis sites, data of blood test. Results: A total of 31 patients aged 45 to 80 years 
(median 65) were treated from August 2006 to February 2015(male/female;23/8, 
adenocarcinoma/non-small cell carcinoma;15/16). They were received single agent or 
combination chemotherapy(carboplatin and pemetrexed(CP);17, others;14). In univariate 
analysis, median survival times were 9.56 months in adenocarcinoma vs 3.26 months 
in non-small cell carcinoma(P=0.0011) , 16.77months in Thyroid Transcription Factor-
1(TTF-1) expression positive(n=10) vs 4.96 months in TTF-1 expression negative(n=9)
(P=0.0166), 2.59 months in 7.0ng/ml and over of CYFRA21-1 vs 9.56 months under 7.0ng/
ml of CYFRA21-1(P=0.0236), 8.53 months in CP vs 2.20 months in others(P=0.0003). 
Objective response rates were 29.4% in CP and 0% in others. Conclusion: Our results 
show that patients who were diagnosed adenocarcinoma pathologically had significantly 
better prognosis than the others, and CP may attributes to good prognosis of the patients 
with advanced non-squamous non-small cell lung cancer patients with ECOG PS 2. 
Keywords: Prognostic factors, performance status 2, Advanced Non-Small Cell Lung 
Cancer
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P1.01-044 Cost-Effectiveness of Chemotherapy Based on the Tumor Genetic 
Profile in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Federica 
Capano1, Tiziana Vavala2, Valentina Monica2, Teresa Mele2, Andrea Filieri1, Carlotta 
Lerda1, Daniela Ielo1, Paolo Cortesi3, Silvia Novello2 1Pharmacy, Aou San Luigi, Orbassano 
(Turin)/Italy, 2Department of Oncology, University of Turin, Orbassano/Italy, 3Research Centre 
on Public Health (Cesp), University of Milan-Bicocca, Monza/Italy
Background: Platinum-Based chemotherapy is still the cornerstone in the treatment 
of Non-Small Cell Lung Cancer (NSCLC), in non oncogene-addicted patients (pts). 
Therapeutic algorithm is established on the basis of patient and disease characteristics, 
such as histology and radiologic features. Pharmagenomic-driven trials are investigating 
the role of different markers in predicting efficacy and toxicity in NSCLC pts. A better 
selection of a right therapy for the right patient would improve outcomes ameliorating 
tolerability and optimize the resources available. The aim of the present study is to carry 
out a cost-effectiveness analysis, in order to evaluate the economic efficiency of 1st 
line chemotherapy within a clinical trial (EPIC eudract N 2012-001194-81), in elderly 
pts affected from advanced NSCLC, looking at efficacy and tolerability. Methods: The 
study population consisted in Elderly Patients Individualized Chemotherapy (EPIC) trial 
enrolled at San Luigi Hospital (Orbassano-Italy, coordinating centre) from July 2012 to 
August 2014. Main recruitment criteria: chemotherapy-naïve pts diagnosed with stage IV 
NSCLC, aged≥70 years, no activating EGFR mutations. We evaluated 48 pts randomised 
(2:1 ratio) to receive pharmacogenomics-driven chemotherapy assessed according 
to the genetic profile of primary tumours based on expression of ERCC1, RRM1 and 
TS evaluated by “Real-Time PCR” (arm A) or standard chemotherapy (arm B). Costs of 
S419Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-17:00
P1.01-048 Cost-Effectiveness of Pemetrexed for Advanced Non-Squamous 
Non-Small Cell Lung Cancer (nsNSCLC) in Patients Treated in a Spanish 
Institution Xabier Mielgo Rubio1, Ruth Martínez Cabañes2, Alejandro Velastegui1, 
Adriana Rosero1, Leticia Ruiz-Giménez1, Cristina Aguayo1, Maria Garcia Ferron1, Jorge 
Silva1, Elia Perez Fernandez3, Carlos Jara1 1Medical Oncology, Hospital Universitario 
Fundación Alcorcón, Alcorcón/Spain, 2Medical Oncology Research Unit, Hospital 
Universitario Fundación Alcorcón, Alcorcón/Spain, 3Research Unit, Hospital Universitario 
Fundación Alcorcón, Alcorcón/Spain
Background: Pemetrexed (Pem) is a widespread used drug as standard treatment 
option in patients diagnosed of nsNSCLC in different settings: first line combined with 
platinum, maintenance or second line treatment. The aim of this study is to assess 
the cost-effectiveness of Pem-based chemotherapy in routine clinical practice from 
the perspective of the Spanish National Health System. Methods: We evaluated 
retrospectively clinical outcomes, in terms of overall survival (OS) and progression free 
survival (PFS), in patients diagnosed of advanced nsNSCLC from 2005 to 2014 who were 
treated with Pem-based chemotherapy, and we performed a cost-effectiveness analysis. 
We assessed the cost-effectivenss of the use of Pem-based treatment in routine clinical 
practice calculating the cost per life years gained (LYG) from the first time the patient 
received Pem, based on the price established in Spain and the number of cycles received. 
We calculated OS from the start date of Pem to the death or last contact with the patient, 
and PFS from the start date of Pem to first tumor progression after Pem. Results: 114 
patients treated with Pem-based chemotherapy were reviewed, 78.9% men and 
21.1% women. Mean age at diagnosis was 64 (range 36-81). 80.7% were smokers or 
former smokers. 90.4% were stage IV and 9.6% IIIB. The predominant histology was 
adenocarcinoma (69.3%), followed by large cell carcinoma (22.8%), NSCLC-NOS (7%) 
and pleomorphic carcinoma (0.9%). 59.6% of patients received Pem in first-line and/or 
maintenance (1L - Maint.), and 40.3% in second or successive lines. The majority of them 
had a good functional status; ECOG 0 25,4% and 1 59,6%. Median number of received 
Pem cycles was 5 (range 1-39). Median number of treatment lines was 3 (range 1-8). 
Clinical outcomes: 68.6% obtained clinical benefit (46.1% stable disease, 21.5% partial 
response, and 1% complete response). Median progression free survival (PFS) was 
5.16 months in 1L- Maint., and 4.55 months in second or successive lines (p = 0,278). 
Median OS was significantly better in 1L – Maint. setting than in second or successive 
lines (17.8 vs 9.8 months (p = 0,033)). The mean cost of Pem-based chemotherapy per 
LYG was 18988 euros in 1L-Maint. setting and 17095 euros in second or successive 
lines. Conclusion: From the perspective of the Spanish National Health System, Pem-
based chemotherapy was cost-effective in both first line and/or maintenance setting, 
and second or successive treatment lines in our patients. The cost per life year gained 
(LYG) from treatment with Pem was below the standard threshold of 30000 euros. 
Keywords: pemetrexed, Cost-effectiveness, Life Years Gained (LYG), non squamous Non 
Small Cell Lung Cancer
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P1.01-049 Feasibility of Cisplatin plus Etoposide for Non-Small Cell Lung 
Cancer Associated with Interstitial Lung Disease on Chest Computed 
Tomography Masafumi Yamaguchi1, Takashi Seto1, Akio Furuya2, Hinichiro 
Shimamatsu1, Gouji Toyokawa1, Kaname Nosaki1, Fumihiko Hirai1, Mitsuhiro Takenoyama 
Takenoyama1, Yukito Ichinose1 1Department of Thoracic Oncology, National Kyusyu Cancer 
Center, Fukuoka City/Japan, 2Department of Diagnostic Imaging and Nuclear Medicine, 
National Kyusyu Cancer Center, Fukuoka City/Japan
Background: Despite the recent remarkable progress in chemotherapy (CTx) regimens, 
the application of CTx for non-small cell lung cancer (NSCLC) associated with interstitial 
lung disease (ILD) remains challenging because of the possibility of acute deterioration 
of the underlying ILD, which can lead to severe respiratory insufficiency, thus decreasing 
the life expectancy of the patient. To date, no acceptable CTx regimen for patients with 
ILD has been established. We herein assessed our series of non-small cell lung cancer 
patients with ILD treated with cisplatin and etoposide (PE). Methods: Unresectable 
NSCLC patients with ILD detected on chest computed tomography (CT) who received PE 
at our department between December 2006 and December 2013 were retrospectively 
reviewed. ILD was defined as interstitial opacity on CT, as confirmed by an independent 
radiologist. Overall survival (OS) was defined as the time from the start date of any 
treatment to the date of death from any cause. Progression-free survival (PFS) was 
defined as the time from the start date of PE to disease progression or cancer-related 
death. Results: A total of 32 NSCLC patients with ILD were evaluated. There were 31 males 
and one female, with a median age of 66 (53-79) years. The ECOG performance status 
was 0/1/2 in 17/13/2 patients. Seventeen patients had adenocarcinoma, six patients 
had squamous cell carcinoma and nine patients had NSCLC. Three patients experienced 
post-surgical recurrence. The clinical stage was IIB/IIIA/IIIB//IV in 2/5/8/17 patients. 
The subtypes of ILD classified according to the CT appearance were the usual interstitial 
pneumonia pattern in 22 patients and a non-specific interstitial pneumonia pattern and 
previous drug-induced pneumonia in five patients each. Oral steroids were administered 
concomitant with CTx in two patients. Twenty-four patients received PE as the first-line 
CTx, while the other eight patients received PE after more than two regimens of CTx. Grade 
3/4 hematological toxicity of leukopenia was noted in 15 (46.9%) patients, neutropenia 
was observed in 24 (75.0%) patients, thrombocytopenia occurred in four (12.5%) 
patients and anemia was detected in six (18.8%) patients. Grade 3 febrile neutropenia 
was recorded in six (19.4%) patients, grade 3 and 4 acute myocardial infarction occurred 
in one patient each and grade 3 cerebral infarction occurred in one patient. Two patients 
experienced grade 2 worsening of ILD and successfully recovered. The response rate 
was PR/SD/PD in 10/19/2 patients, and one patient could not be evaluated because 
Asano1 1Internal Medicine, Tokai University School of Medicine, Isehara/Japan, 2Radiation 
Oncology, Tokai University School of Medicine, Isehara/Japan, 3Thoracic Surgery, Tokai 
University School of Medicine, Isehara/Japan, 4Pathology, Tokai University School of 
Medicine, Isehara/Japan, 5Neurosurgery, Tokai University School of Medicine, Isehara/
Japan, 6Immunology and Microbiology, University of Colorado School of Medicine, Aurora/
CO/United States of America
Background: Various types of chemotherapies have been extensively investigated in 
advanced non-small cell lung cancer (NSCLC). Although median survival times have been 
getting long, the outcomes remain poor. This study aimed to analyze the characteristics 
of those with complete remission among advanced NSCLC patients. Methods: Based 
on our hospital database, 1,699 patients who were registered as lung cancer between 
August 2004 and April 2011 were examined, and Stage III or IV NSCLC patients, whose 
treatment began between September 2004 and April 2011, were retrospectively 
evaluated at September 2014. We defined complete remission as a continuous complete 
response observed in spite of the treatment initiation over three years ago, regardless 
of treatment continuation. Results: Seven patients were observed. Two patients were 
at stage IIIA, one at stage IIIB, and four at stage IV. The treatment modalities included 
cytotoxic chemotherapy only (one patient), chemotherapy and EGFR-TKI followed 
by surgery (one patient), radiosurgery for brain metastasis followed by surgery and 
chemotherapy (one patient), and chemoradiation (four patients). Three patients had 
adenocarcinoma, three squamous cell carcinoma, and one large-cell carcinoma. The 
numbers according to survival time since the date of treatment initiation were two 
(between three and four years), three (between four and five years), and two (over five 
years). All cases had complications of inflammatory diseases. In case 1, an acquired 
immunological response against lung cancer was suggested. The patient had rheumatoid 
arthritis and stage IV adenocarcinoma with massive pleural effusion, treatment was only 
1 course of vinorelbine, and sepsis occurred after chemotherapy. After that, complete 
remission has been achieved. Acquired cancer immunity was also suggested in case 2, 
who had stage IV adenocarcinoma with cardiac tamponade. Pericardial drainage was 
done and three courses of cisplatin and gemcitabine were administered, followed by 
EGFR-TKI. Gefitinib have continuously been used for four years, however the tumor in 
the right upper lobe had gradually getting large. The tumor was resected, while EGFR 
mutation was negative and many inflammatory cell infiltrations were observed. In case 
3, oligo-metastatic states have been controlled by surgery and radiation. The patient 
had stage IV large cell carcinoma with a brain metastasis, the primary pulmonary lesion 
was surgically removed after cyber-knife therapy. Chemotherapies were started. Oligo-
metastatic new brain lesions were firstly cyber-knife therapies, and the relapsed or 
new lesions were removed by brain surgeries. After the brain surgery, encephalitis and 
meningitis developed. Many inflammatory cells were observed around and inside the 
brain tumor. Finally, the brain tumors and the pleural dissemination disappeared. In case 
4, who had stage IIIA adenocarcinoma with bulky N2, PET-assisted three-dimensional 
conformal radiation therapy was used to control oligo-metastases. The tissue types of 
chemoradiation-induced complete remission were squamous cell carcinoma in three 
patients and adenocarcinoma in one patient. Conclusion: These results suggest that 
complete remission can be achieved for several types of advanced NSCLC by employing 
combinations of treatment modalities. Oligo-metastatic states could be controlled by 
surgery and radiation therapies with or without chemotherapies. The acquired immune 
response against lung cancer might be important to induce complete remission. 
Keywords: Advanced Non-Small Cell Lung Cancer, complete remmision, Tumor 
immunology, Oligo-matastatic states
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P1.01-047 Pemetrexed in Treating Advanced NSCLC Mivael Olivera, Roxana 
Ticona, Gerson Mejia, Jhoana Muniz, Luis Mas Medical Oncology, Instituto Nacional de 
Enfermedades Neoplasicas, Lima/Peru
Background: In advanced NSCLC, the goal of maintenance therapy is to prolong 
overall survival of first line platinum based combination chemotherapy. Maintenance 
Pemetrexed was associated with statistically and clinically significant improvement 
in both PFS ans OS. Objective was to determine the response rate, progression-free 
survival (PFS), overall survival (OS). Methods: Between January 2011 until July 
2014, Peruvian patients with advanced NSCLC (IIIB, IVA) received four to six cycles of 
Carboplatin (AUC 6) - Pemetrexed 500mg/m2 day 1. Patients who achieved a complete 
response (CR), partial response (PR) o stable diase (SD) were to received maintenance 
Pemetrexed (500mg/m2 day 1) in 21 day cycles until disease progression. All patients 
recevied vitamin B12, Folic acid supplement. Results: 83 patients received induction 
chemotherapy and maintenance therapy, median age was 61 years (26 - 84), > 70 
years 15.7%, female:male 1.5, no smoking:smoking 2.6, exposure to wood smoke 
25 (30.1%), ECOG 1 98.8%, EC IIIB 8.4%, EC IV 91.6%, hystology Adenocarcinoma 
100%. Sites of metastasis: pleural 36 (43.4%), bone 20 (24.1%), brain 7 (8.4%), liver 4 
(4.8%). 40 (48.2%) received 4 cycles, 27 (32.5%) 6 cycles of induction chemotherapy; 
median of cycles of maintenance 5 cycles (1-16). Response to treatment: 4 (4.8%) RC, 
42 (50.6%) RP, 30 (36.1%) DS, 7 (8.4%) PD. The median time to progression was 11 
months, estimated PFS was 86.5%, 39.6%, 13.8% at 6, 12, 30 months respectively. 
The estimated OS was 68.8%, 51.4% and 41.5% at 12, 24 and 30 months respectively, 
median time to OS was 28 months. None variables are significantly associated with 
OS. Conclusion: Induction chemotherapy and maintenance therapy with Pemetrexed 
improves PFS and OS in patients with advanced lung cancer without compromising the 
quality of life. There is a need for better ways of identifying patients most likely to benefit. 
Keywords: PFS and OS, pemetrexed, advanced NSCLC, maintenance
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cell carcinoma. 13 were performed as second line chemotherapy, 6 were as third line 
and 6 were forth or later line. EGFR mutation status was positive in 5 patients (20.0%) 
and they all received EGFR-TKI in their serial chemotherapy. One achieved complete 
response (CR), 7 reached a stage of partial responses (PR), 10 maintained stable disease 
(SD) and 7 suffered progressive diseases (PD). The overall response rate (ORR) was 
32.0% and disease control rate (DCR) was 72.0%. The median PFS was 4.8 months 
and median OS was 29.0 months. Common treatment related adverse events were 
myelosuppression, baldness, peripheral neuropathy and gastrointestinal symptoms, 
most of which were grade 1 to 2. Grade 3-4 neutropenia was present in 6 patients 
(24.0%), thrombocytopenia and anemia in 2 patients (8.0%), respectively. No patients 
experienced grade 3-4 neuropathy. The need of a dose reduction was 26.9% because of 
toxicity, but there were no adverse effects of grade 5. Conclusion: Nab-paclitaxel plus 
CBDCA as second or later phase chemotherapy offers a small but significant survival 
benefits for the patients with recurrent and advanced NSCLC, and its adverse effects 
are tolerable. Further studies including prospective studies of this regimen are required. 
Keywords: nab-paclitaxel, late phase chemotherapy, carboplatin
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P1.01-052 Retreatment with Platinum-Based Regimen for Patients with 
Metastatic NSCLC Is a Reasonable Therapy Rachel L. Mitchell1, Mary J. Fidler1, 
Sanjib Basu1, Philip Bonomi1, Shruthi Melinamani1, Audrey Kam2, Marta Batus1 
1Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago/United 
States of America, 2Internal Medicine, Rush University Medical Center, Chicago/United States 
of America
Background: Standard first-line therapy in stage IV NSCLC patients remains a platinum-
based regimen. Currently, there are limited FDA approved agents for second line therapy 
following progressive disease. The purpose of this study was to evaluate the response 
to retreatment with platinum-based regimens upon progression in a group of platinum-
sensitive patients. Methods: Patients with stage IV NSCLC previously treated with a 
platinum-based first-line regimen were retrospectively reviewed. We examined the 
outcomes of 52 patients retreated with a platinum-based regimen upon progression 
between February 2002 and March 2015. Patients were evaluated for response rate, 
progression free survival, overall survival and platinum reactions. Results: Of the 52 
patients reviewed, 31 were women (59.6%) and 21 were men (40.4%). Median age was 
62.6 (range 42-89) and adenocarcinoma was the most prevalent histology (86.5%). The 
response rate for retreatment was 21.15%. A notable 57.69% of patients had stable 
disease. The median PFS for the first line platinum regimen was 9.2 months (CI 95%; 
6.28-12.13) and for the retreatment was 4.8 months (CI 95%; 3.17-6.42). The median OS 
from diagnosis was 23.31 months (CI 95%; 11.76-34.85). A platinum reaction was noted 
in 9 of the patients (17.3%) though none were fatal. Conclusion: Patients with prolonged 
PFS with frontline chemotherapy appear to benefit from retreatment with a platinum-
based regimen. This cohort demonstrated by a PFS of 4.8 months upon retreatment. 
Patients with prolonged progression free survivals with frontline chemotherapy may 
be reasonable candidates to consider for retreatment with a platinum-based regimen. 
Keywords: Platinum, metastatic, NSCLC, Retreatment
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P1.01-053 Thiol - Disulfide Ratio (TDR) in Blood as a Predictive in Vitro 
Test for Individualized Targeted Therapy Choice in Patients with Advanced 
NSCLC Oleksandr O. Obodnikov1, Genadiy V. Didenko2, Oleksandr V. Parshikov3 
1Thoracic Surgery and Pulmonology, P.L.Shupik National Medical Academy of Postgraduate 
Education, Kiev/Ukraine, 2Biotherapy of Cancer, R.Y.Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology, Kiev/Ukraine,3Experimental Treatment, Institute of 
Pharmacology and Toxicology, Kiev/Ukraine
Background: Despite the available positive results of targeted therapy (TT) in clinical 
oncology, more and more actual is a problem of preliminary screening of patients with 
solid tumors to whom TT will bring success. TDR is an integrated indicator of redox 
balance in biological cells which reflects dynamics of activity of a set of the thiol-
containing cellular enzymes. It is known that the TDR level in a blood of cancer patients 
has a direct correlation with TDR in cancer cells. It assumes possibility of use change 
of TDR in a blood under the influence of drugs for indirect research of influence on 
biochemical processes in tumor cells. The possibility of prognosis of clinical efficacy 
and choice of effective targeting agents by means of TDR-test in blood in vitro in patients 
with advanced NSCLC was the purpose of the study. Methods: Between 09/11 and 
10/14 we enrolled 52 treated patients (M/F - 44/8) with advanced NSCLC (stage IIIB/
IV - 44/8); adenocarcinoma -21, squamous-cell carcinoma - 27, large-cell carcinoma 
- 4. The median number of prior chemotherapy regimens was 3 (range 1-6), median 
performance status - 1 (range 0 -3). Prior before TT course, patient’s blood was tested 
in vitro with targeting agents: erlotinib, gefitinib, cetuximab, trastuzumab, bevacizumab; 
the respons was evaluated on the dynamics of TDR during 24- our incubation. All the 
patients received two 4-week courses of treatment: the standard TT (control group, 
n=25) or such targeting agent susceptibility to which was confirmed by the TDR-test 
(study group, n=27). Clinical respons was evaluated by RECIST. Results: After the end of 
treatment, the analysis of in vitro TDR reactions on the targeted agents tested showed 
direct correlation with the clinical results. According to the TDR-test, a portion of effective 
drugs was 50% - 100% in 92% of the patients, whose treatment resulted in regression 
or stabilization of disease. At the same time, in 94% of the patients, whose treatment 
resulted in progression of disease, a portion of effective agents was only 0 - 49%. Among 
the two groups of patients, objective clinical effects were observed in 7(26%) pts [(PR - 
7(26%) pts, 95% CI: 11,6 - 55,2%), SD - 16(59%) pts, PD - 4(15%) pts)] in the study group 
of an adverse event. The median PFS was 3.9 months, the one-year PFS was 12.8% 
and the two-year PFS was 4.3%. Additionally, the median OS for all patients was 11.2 
months, the one-year OS was 46.2% and the two-year OS was 14.2%. Conclusion: PE 
treatment for unresectable NSCLC associated with ILD was demonstrated to be relatively 
safe in our series, with an acceptable tumor response and OS. However, careful patient 
selection and management during CTx are required. The limitation of the current 
analysis is its retrospective nature and the fact that there was a single arm of CTx 
therapy. Hence, future prospective comparisons of other CTx regimens are warranted. 
Keywords: Interstitial pneumonia, cisplatin and etposide, NSCLC
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P1.01-050 Clinical Features of Non-Squamous Non-Small-Cell Lung Cancer 
Patients Treated with Long-Term Pemetrexed Kenichiro Hirai, Hiroshi Yokouchi, 
Keisuke Azuma, Hiroyuki Minemura, Satoko Sekine, Kenya Kanazawa, Yoshinori Tanino, 
Mitsuru Munakata Department of Pulmonary Medicine, Fukushima Medical University, 
Fukushima/Japan
Background: It has been generally accepted that pemetrexed (PEM) with platinum 
followed by PEM maintenance therapy is a standard first-line treatment for patients 
with advanced non-squamous non-small cell lung cancer (NS-NSCLC). The number of 
patients treated with long-term use of PEM is increasing, and thus we should know the 
clinical features including side effects in those patients. Belen et al. reported that skin 
toxicities were related to PEM maintenance therapy, while Jean et al. demonstrated 
that 7.8% of patients receiving maintenance PEM had grade 1/2 edema in the 
PARAMOUNT trial. Further investigation into clarifying the clinical features of these 
patients is required. Methods: We retrospectively reviewed the charts of 13 patients 
with advanced NS-NSCLC who had been treated with long-term PEM (10 and more 
courses) in our hospital between July 2009 and December 2014. Results: All patients 
had adenocarcinoma. The median age was 63 years (range: 39-72). Six patients were 
male, and six were never-smokers. All but one patient were classified as clinical stage 
IV. Six patients harbored EGFR mutation and one patient had ALK gene rearrangement. 
Twelve patients received PEM with platinum (cisplatin; seven patients, carboplatin; 
five patients), and one patient received PEM alone. The median number of courses of 
PEM was 16 (range: 10-21). Grade 3/4 non-hematological toxicities observed in the 13 
patients were anorexia (8%), nausea (8%), and dizziness (15%). Grade 3/4 hematological 
toxicities observed were neutropenia (46%), anemia (15%), and thrombocytopenia 
(15%). Two patients had peripheral skin edema; one patient developed eyelid edema 
at 21 cycles of PEM, and the other developed limb edema and pleural fluid at 20 cycles 
of PEM. Four patients underwent PEM beyond RECIST PD following platinum-based 
doublet chemotherapy regimen (CDDP+PEM; 2, CBDCA+PEM; 2). Initial response by the 
induction chemotherapy was PR in two patients and SD in two patients. The PD sites were 
lungs in two patients, bone in one patient and adrenal gland in one patient. The median 
post progression survival (PPS) of each of the four patients was 205.5 days (range; 68-
330). All the four patients underwent PEM until “clinical” PD. Progressive sites were lungs 
in two patients, bone in one patient and esophagus in one patient. The median duration 
between RECIST PD and clinical PD was 100.5 days (range; 35-210). Conclusion: The 
differential profile of adverse effects, including dizziness and edema, driven by 
long-term PEM compared with those by conventional use of PEM suggested that we 
should cautiously select supportive therapies for NSCLC patients who are being 
treated with long-term PEM. Continuation of PEM beyond PD can be in consideration 
for selective patients with NS-NSCLC, as observed in patients treated with EGFR-TKI. 
Keywords: Long-term, Beyond PD, pemetrexed, NS-NSCLC
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P1.01-051 Efficiency of Nab-Paclitaxel as a Late Phase Chemotherapy for 
NSCLC Mitsunori Higuchi1, Hironori Takagi2, Yuki Owada1, Takuya Inoue1, Yuzuru 
Watanabe1, Mitsuro Fukuhara1, Takumi Yamaura1, Satoshi Muto1, Naoyuki Okabe1, Yuki 
Matsumura1, Takeo Hasegawa2, Atsushi Yonechi3, Jun Osugi1, Mika Hoshino1, Yutaka 
Shio4, Koichi Fujiu5, Ryuzo Kanno6, Akio Ohishi6, Hiroyuki Suzuki1 1Chest Surgery, 
Fukushima Medical University, Fukushima/Japan, 2Shirakawa Kousei General Hospital, 
Shirakawa/Japan, 3Takeda General Hospital, Aizuwakamatsu/Japan, 4Fukushima Rosai 
Hospital, Iwaki/Japan, 5Southern Tohoku General Hospital, Koriyama/Japan, 6Fukushima Red 
Cross Hospital, Fukushima/Japan
Background: Nanoparticle albumin-bound (nab) paclitaxel is a biologically interactive 
nanoparticle, combining albumin with paclitaxel and has a better toxicity profile 
compared to solvent-based paclitaxel. Recently some studies are reported which show 
the efficacy of nab-paclitaxel as first line chemotherapy for non-small cell lung cancer 
(NSCLC), but rarely reported until today to elucidate the efficacy of nab-paclitaxel 
with carboplatin (CBDCA) as second or later phase chemotherapy for NSCLC. We 
here evaluate the efficiency and feasibility of nab-paclitaxel plus CBDCA as second 
or later phase chemotherapy in patients with recurrent or advanced NSCLC in this 
study. Methods: Twenty-five patients with recurrence after radical surgery for NSCLC 
and unresectable stage IIIB/IV NSCLC who had received previous chemotherapies were 
treated with nab-paclitaxel 70mg/m2 intravenously on day1, 8, and 15 with CBDCA area 
under the concentration-time curve of 4 (AUC4) intravenously on day1, every 28 days. 
Progression-free (PFS) and overall survival (OS) rates were calculated by means of Kaplan-
Meier analysis and statistical significance between the groups was analyzed by using 
log-rank tests. Disease control rates and toxicity were also evaluated. Disease response 
in all of the patients was monitored after two cycles of chemotherapy. Results: Of 
25 patients who participated in this study, 9 were recurrent and 16 were advanced 
case. 13 were adenocarcinoma, 11 were squamous cell carcinoma and 1 was large 
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were not statistically signifi cant. There was no imbalance in terms of second-line therapy 
between KRAS mt vs wt patients. There was no difference in study endpoints according to 
KRAS mutation status observed in patients who received taxane-based chemotherapy as 
fi rst line treatment. There was also no difference in survival outcomes according to fi rst-
line treatment regimen used when patients were stratifi ed according to KRAS mutation 
status. Conclusion: KRAS mutation status is not correlated with treatment outcomes in 
patients with advanced lung adenocarcinoma receiving fi rst-line cytotoxic chemotherapy. 
Keywords: KRAS, NSCLC, pemetrexed
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P1.01-056 A Prospective Audit on Toxicity for Platinum-Based Chemotherapy 
in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A West of Scotland 
Analysis Clinton W. Ali1, John Mcphelim2, Fiona Maclean3, Mamta Kumari1, Steven 
Cadwallader4, Jonathan Hicks1 1Oncology, Beatson West of Scotland Cancer Centre, 
Glasgow/United Kingdom, 2Hairmyres Hospital, Glasgow/United Kingdom, 3Southern General 
Hospital, Glasgow/United Kingdom, 4Independant Medical Writer, London/United Kingdom
Background: The current standard of care for patients with Stage IIIB/IV NSCLC with no 
activating Epidermal Growth Factor Receptor (EGFR) mutations recommends platinum 
(carboplatin or cisplatin) doublet chemotherapy in patients who are performance status 
0-2. Although a number of options are available, evidence from Phase 3 Randomised 
Controlled Trials have previously shown no differences in survival outcomes in non-
pemetrexed based regimens. We set out to prospectively audit toxicity and effi cacy of 
four commonly offered platinum-based doublets in the West of Scotland with a view to 
making comparative conclusions from our data. Methods: Patients undergoing fi rst line 
palliative chemotherapy with a platinum doublet in two lung cancer clinics in the West of 
Scotland (Glasgow and Lanarkshire) between July 2014 and April 2015 were included. 
Baseline demographics were obtained and entered into a common database. On each 
attendance for chemotherapy pre-assessment, toxicity data was recorded using CTC 
version 4.0 and prospectively entered into the database. Requirements for admission to 
hospital and the need for blood and platelet transfusions were also recorded. Results:To 
date 54 patients have been included. The median number of chemotherapy cycles was 
2.7(150). 55% (30) of patients were male and 45% (24) female, with the majority sub-
type being adenocarcinomas. The most commonly prescribed agent with platinum was 
pemetrexed (52%) followed by gemcitabine (24%) and vinorelbine (22%). The use of 
paclitaxel was lower than anticipated (2%). Toxicity data is available for all 54 patients 
(see table 1). Survival outcomes will be reported subsequently along with ongoing 
collated data on toxicity in additional patients in this prospective audit. Table 1
.  
Conclusion: First line treatment of advanced NSCLC with platinum doublets in the 
West of Scotland is generally well tolerated. Toxicities exceeding Grade 2 were 
uncommon with any of the 4 platinum doublets. However, hospital admission was 
more likely in those receiving pemetrexed or vinorelbine doublets. The need for blood 
transfusion was more common in doublets containing pemetrexed or gemcitabine. 
Keywords: non-small cell lung cancer
versus 2(8)% pts [(PR - 2(8)% pts, 95% CI: 3,3 - 16,2%); SD - 8(32%) pts, PD - 15(60%) 
pts.)] in the control group; grade 3 and 4 toxicity was experienced by 1(4,0%) pt and 
2(8%) pts, respectively, - in the control group, and by 1(3,7%) pt and 0, respectively, - in 
the study group. Sensitivity of the method used to choice effi cacious targeting agent 
amounted to 91,8%, specifi city (selectivity) was 94,5% in forecasting the cases resistant 
to targeting agent. Conclusion: The determination of individual sensitivity to targeted 
agents in patient’s blood in vitro by means of TDR- test is an effective method both for 
forecasting clinical effi cacy of the treatment and for individual choice of TT in patients 
with advanced NSCLC. These fi ndings need futher validation in additional clinical studies. 
Keywords: Advanced NSCLC, Individualized therapy, Targeted therapy, Thiol-Disulfi de 
Ratio
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P1.01-054 To Analyse the Effi cacy and Toxicity Profi le of Continuation 
Maintenance Pemetrexed in Advanced NSCLC: An Indian Data Ullas Batra, 
Pankaj Goyal, Mohit Agarwal, Kumardeep D. Choydhary, Dinesh Doval Medical Oncology, 
Rajiv Gandhi Cancer Institute and Research Centre, Delhi/India
Background: Continuation maintenance therapy with pemetrexed has been proved to be 
well tolerated ,offers an overall survival benefi t and reduced risk of disease progression in 
Phase III Paramount trial. Based on same it is approved as a category 1 recommendation for 
patients with nonsquamous advanced lung cancer, who do not progress after pemetrexed 
plus platinum induction regimen. However there is lack of data from Indian subcontinent. 
Here we report the data from a tertiary care cancer centre in North India Methods: - 
In all 280 patients were registered as advanced non squamous lung cancer(stage 
IV) between JAN 14 to DEC 14. Subsequently 96 patients received pemetrexed plus 
platinum based initial chemotherapy. 46 patients with no disease progression and ECOG 
PS 0 or 1 received maintenance pemetrexed (500 mg/m2 on day 1 of 21 day cycles). 
Statistical tests were applied to calculate progression free survival. Toxicity profi le was 
evaluated Results: The mean number of maintenance cycles was 9.5. Pemetrexed 
maintenance therapy resulted in progression free survival (PFS) of 5.4 months. PFS 
on pemetrexed was consistent for all patient subgroups, including induction response: 
complete/partial responders (n-24 ) and stable disease (n-22 ). 3 patients developed grade 
3 or 4 toxicity as to cause a delay in cycles.2 patients also developed renal dysfunction 
during maintenance therapy. 7 patients continue to receive pemetrexed maintenance till 
date. Conclusion: Pemetrexed continuation maintenance therapy is well-tolerated and 
offers benefi ts consistent with Paramount trial, demonstrating that it is an effi cacious 
treatment strategy for Indian patients with advanced nonsquamous NSCLC and good 
performance status who do not progress during pemetrexed-platinum induction therapy 
Keywords: continuation maintenance pemetrexed NSCLC
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P1.01-055 Prognostic Impact of KRAS Mutational Status in Patients with 
Advanced Lung Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy 
Arpita Desai1, Xiangyun He2, Shipra Gandhi1, Chong Wang3, Alison Meagher4, Grace K. 
Dy2 1Department of Medicine, State University of New York at Buffalo, Buffalo/NY/United 
States of America, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo/NY/
United States of America, 3Center for Personalized Medicine, Roswell Park Cancer Institute, 
Buffalo/NY/United States of America, 4Department of Pharmacy, Roswell Park Cancer 
Institute, Buffalo/NY/United States of America
Background: KRAS mutations are among the most commonly encountered mutations in 
lung adenocarcinoma. Although differential outcomes from cytotoxic agents according 
to histology have been shown in lung adenocarcinoma, the prognostic and predictive 
impact of KRAS mutational status is controversial. Recently, a study identifi ed greater 
dependency on folate metabolism pathways in KRAS mutant (mt) compared to KRAS 
wildtype (wt) NSCLC (Moran et al, Mol Cancer Ther 2014, 6:1611-24). We sought 
to evaluate the clinical outcomes of patients with lung adenocarcinoma to fi rst-line 
cytotoxic chemotherapy according to KRAS mutational status. Methods: This IRB-
approved retrospective study involved patients from Roswell Park Cancer Institute 
(RPCI) diagnosed with inoperable stage III or IV lung adenocarcinoma from January 1, 
2012 to December 31, 2013. Patients with documented KRAS mutational status who 
received chemotherapy were eligible. Patients with EGFR mutation or ALK translocation 
were excluded. The objective response (OR) to chemotherapy was assessed using 
RECIST version 1.1 criteria. The primary end points were Progression Free survival 
(PFS) and Overall Survival (OS). Secondary endpoint was the time to achieve OR. OS 
was estimated by the Kaplan-Meier method and compared using the Log-rank method. 
The association between study endpoints and variables of interest (age, gender, 
stage, ECOG performance status [PS], KRAS mutation status) were conducted with 
univariate and multiple Cox models. SAS version 9.4 (SAS Institute, Cary, NC) were 
used for statistical analyses. All tests were two-sided and performed at a nominal 
signifi cance level of 0.05. Results: A total of 123 patients were eligible for this 
analysis. In our study, 53 (42%) patients carried KRAS mutations. Majority of patients 
had stage IV cancer at presentation (74%). There was no difference in distribution of 
KRAS mutation status by the stage of disease at presentation. The most common 
fi rst-line chemotherapy regimen was pemetrexed-based platinum combination (85%). 
When pemetrexed-based regimen was utilized as fi rst-line therapy, univariate analysis 
showed correlation between KRAS status, gender, stage and PS with OS, favoring KRAS 
wt, female, stage III and PS 0, respectively. After controlling for other related covariates, 
only gender, stage and PS remain independently associated with better OS. Patients 
with KRAS wt had a longer median OS compared to KRAS mt patients (414 vs 249 days, 
p=0.027). PFS and time to OR were similarly better in KRAS wt group although these 
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P1.01-058 Impact of Low-Grade Toxicity on Lung Cancer Patient Willingness 
to Undergo Treatment with Novel Agents Emily H. Castellanos, Hillary Drexler, 
Sheau-Chiann Chen, Leora Horn Vanderbilt University Medical Center, Nashville/TN/United 
States of America
Background: Targeted therapies have shown clinical benefit in the treatment of solid 
tumors. The route, frequency, and duration of administration of these agents as well as 
toxicity profiles differ significantly from traditional cytotoxic chemotherapy. Many studies 
of targeted therapies report significant numbers of grade 1 or 2 toxicities, which are 
often regarded as clinically insignificant. We sought to explore whether anticipation of 
low-grade toxicities and dosing convenience would affect lung cancer patient willingness 
to undergo therapy. Methods: 101 lung cancer patients were surveyed at the Vanderbilt 
Ingram Cancer Center regarding willingness to comply with treatment based on 
anticipated efficacy, dosing convenience, and toxicity profiles. All toxicities described 
were CTCAE V.4.0 grade 1 and 2. Willingness to comply with treatment depending 
upon toxicity, anticipated benefit, and dosing convenience were compared. Results: A 
substantial number of patients professed unwillingness to undergo treatment due to 
anticipation of chronic grade 1 and 2 toxicities (Table 1). Gastrointestinal (anorexia, 
nausea, vomiting, diarrhea, or dysgeusia) and constitutional toxicity (fatigue) had a 
stronger negative impact on patient willingness to undergo therapy than dermatologic 
toxicity (rash, hand-foot syndrome, or acne). Willingness to tolerate toxicities correlated 
with expected benefit in life expectancy and chance of cure. Lengthy travel distance for 
treatment also negatively impacted willingness to undergo treatment.
Table 1: Percentage of lung cancer patients who stated that they would be unwilling 
to receive treatment by toxicity type and grade.
Adverse Effect Unwilling to Receive Treatment
Grade 1 Dermatologic Toxicity 5.2%
Grade 1 Gastrointestinal Toxicity 9.5%
Grade 1 Constitutional Toxicity 6.8%
Grade 2 Dermatologic Toxicity 8.7%
Grade 2 Gastrointestinal Toxicity 18.1%
Grade 2 Constitutional Toxicity 19.4%
 
Conclusion: Anticipation of chronic low grade toxicities and dosing inconvenience 
has a negative impact on patient willingness to be treated, which may affect 
patient adherence and outcomes from therapy. Long-term tolerability should 
be considered when developing and using novel agents in lung cancer patients. 
Keywords: toxicity, NSCLC
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P1.01-059 Steps to Improve NSCLC Patient Outcomes Utilizing Mobile Apps 
- Survey Findings Corey J. Langer1, Patty Peterson2, Elaine Rudell3 1Hematology/
Oncology, University of Pennsylvania Health System, Philadelphia/PA/United States 
of America, 2Projects in Knowledge, Livingston/United States of America, 3Projects in 
Knowledge, Livingston/NJ/United States of America
Background: Integration of mobile devices/health-related apps into medical practice 
is transforming healthcare. For clinicians treating NSCLC, the addition of a new app, 
NSCLC @Point of Care, and its patient companion app, are practice-based tools 
designed to provide content at the time it is actually needed and the ability to sync 
with patient data, potentially enabling better decisions, outcomes and care. This 
survey assesses how this mobile dashboard is used in the NSCLC setting, its effect 
as a learning tool, and how it can improve patient outcomes. Methods: To assess 
how clinicians utilize the NSCLC @Point of Care dashboard and patient companion 
app, Projects In Knowledge, the CME provider, sent an online survey to its proprietary 
database of over 53,000 clinicians caring for NSCLC patients. Respondents reported: 
demographic information, use of EMR technology, frequency and reasons for accessing 
the NSCLC @Point of Care app, interest in tracking patient-reported data, and use of 
patient-reported data in institutional EMR reports. Results: Overall findings show a large 
number of responding clinicians use EMR technology, access the NSCLC @Point of 
Care App daily for relevant disease/treatment-specific information, and want to track 
patient-reported data. The survey demonstrates many clinicians are in agreement that 
the clinician app, NSCLC @Point of Care, and its companion app will not only provide 
important disease- and treatment-specific information that they need and can access 
at point of care, but also improve communication of critical and accurate patient 
data in real-time to ensure optimal interventions and patient outcomes, incorporate 
patient-reported data from the companion app into EMRs and believe this maneuver 
can streamline time efficiencies in practice. Conclusion: Management of NSCLC, a 
leading cause of cancer-related mortality, is evolving so rapidly that it is difficult for 
clinicians to keep current and integrate new improved treatment strategies into practice. 
Many clinicians surveyed believe the NSCLC @Point of Care dashboard provides 
a desirable approach for busy clinicians to access information needed to support 
practice change and improve patient outcomes through point of care accessibility. 
Keywords: NSCLC, @Point of Care, patient-reported data, patient companion app
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P1.01-057 Gemcitabine plus Platinum versus Other Platinum Doublets in 
Squamous NSCLC Giorgio V.V. Scagliotti1, Joseph A. Treat2, Rafael Rosell3, Cong 
Xu4, Baoyue Li4, Haidong Chi4, Mauro Orlando5, Caicun Zhou6 1Thoracic Oncology Unit, 
University of Turin, Turin/Italy, 2Eli Lilly and Company, Global Med Affairs & Late Phase Prod 
Dev, Indianapolis/IN/United States of America, 3Hospital Germans Trias I Pujol, Catalan 
Institute of Oncology, Barcelona/Spain, 4Lilly China, Shanghai/China, 5Emerging Markets, Eli 
Lilly Interamérica Inc., Buenos Aires/Argentina, 6Department of Medical Oncology, Shanghai 
Pulmonary Hospital, Tongji University School of Medicine, Shanghai/China
Background: Squamous cell carcinoma is the second most common histologic subtype 
of non-small-cell lung cancer (NSCLC). Platinum-based doublet chemotherapy regimens 
remain the basis of front-line systemic treatment. Most studies in NSCLC included all 
histologic subtypes. Here we present a pooled analysis of gemcitabine in combination 
with cisplatin or carboplatin, specifically focusing on patients with squamous NSCLC, 
from three studies for which individual patient data are available. The objective of this 
analysis was to evaluate the efficacy of first-line gemcitabine plus platinum (GP) compared 
with other regimens plus platinum (OP). Methods: This analysis included squamous 
NSCLC patients from three randomized, open-label, phase III studies of gemcitabine: 1) 
gemcitabine plus cisplatin versus etoposide plus cisplatin (n=61), 2) gemcitabine plus 
carboplatin versus paclitaxel plus carboplatin (n=128), and 3) gemcitabine plus cisplatin 
versus pemetrexed plus cisplatin (n=473). Patients were grouped into the GP subgroup 
(n=324) or the OP subgroup (n=338). Efficacy measures included overall response rate 
(ORR), overall survival (OS), and time to disease progression (TTP). Stratified (by study) 
Cox proportional hazard regression models were used to analyze OS and TTP by random 
assignment factors to identify potential prognostic factors and explore their predictive 
value. Results: Baseline characteristics were similar between the GP and OP groups. 
Median OS was 9.72 months for GP versus 9.33 months for OP (HR=0.898, p=0.223) 
(Figure 1). There was a significant difference in median TTP (5.52 months for GP versus 
4.73 months for OP; HR=0.792, p=0.008) (Figure 2). ORR was 31.5% for GP, and 27.2% 
for OP (p=0.229). Cox regression model identified three prognostic factors for OS: 
Eastern Cooperative Oncology Group performance status, prior radiotherapy, and body 
mass index. 
Figure 1. Kaplan–Meier estimates of overall survival 
Figure 2. Kaplan–Meier estimates of time to disease progression
 
Conclusion: This pooled analysis further confirmed the efficacy of 
gemcitabine plus platinum as first-line treatment of squamous NSCLC. 
Keywords: Gemcitabine, squamous NSCLC, Non-small-cell lung cancer, Platinum
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P1.01-062 Rash as a Marker for the Efficacy of Necitumumab in the SQUIRE 
Study Philip Bonomi1, Patrick Peterson2, Mark A. Socinski3, Martin Reck4, Luis 
Paz-Ares5, Barbara Melosky6, Carlos Mayo7, Coleman Obasaju2, Nick Thatcher8 1Rush 
University Medical Center, Chicago/IL/United States of America, 2Eli Lilly and Company, 
Indianapolis/United States of America, 3University of Pittsburgh, Pittsburgh/PA/United States 
of America, 4Center of Pulmonology and Thoracic Surgery, Lungenclinic Grosshansdorf, 
Grosshansdorf/Germany, 5University Hospital Virgen Del Rocio, Seville/Spain, 6British 
Columbia Cancer Agency, Vancouver/BC/Canada, 7Eli Lilly and Company, Bridgewater/NJ/
United States of America,8The Christie Hospital, Manchester/United Kingdom
Background: SQUIRE, a randomized, phase III study (n=1,093), demonstrated that the 
addition of the EGFR monoclonal antibody necitumumab (N) to gemcitabine-cisplatin 
(GC) improved overall survival in patients with stage IV squamous NSCLC. Rash is an 
established class side-effect associated with EGFR-targeting agents. Previous studies 
have suggested a positive association between rash and clinical outcomes with EGFR-
targeted therapy. Methods: Pre-emptive treatment for rash was not allowed per protocol 
until completion of the first cycle of study therapy. For the purpose of this analysis, 
patients randomized to the N+GC arm were categorized and grouped according 
to whether or not they experienced rash during the first two cycles of study therapy. 
Patients who died or were lost to follow-up before completing two cycles of study therapy 
were not included in this analysis. Overall survival (OS) and progression-free survival 
(PFS) were measured from the date of randomization, with parameters estimated using 
the Kaplan-Meier method. Hazard ratios and 95% CIs between subgroups were estimated 
from stratified Cox proportional hazards models, with comparisons between arms using 
a stratified log-rank test. Results: 505 patients were evaluable in the N+GC arm at the 
end of cycle 2 of which 69% experienced rash during cycle 1 and/or cycle 2. Patients 
experiencing rash in the N+GC arm had improved OS (HR=0.738, p=0.0001) and PFS 
(HR=0.808, p=0.0066) compared with patients in the GC arm. Patients experiencing 
rash in the N+GC arm had improved OS (HR=0.656, p=0.0001) compared with patients 
in the N+GC arm who did not experience rash. The difference in PFS between patients in 
the N+GC arm experiencing rash versus those not experiencing rash was not statistically 
significant. Median PFS and OS for patients experiencing rash in the N+GC arm was 6.2 
mo and 13.6 mo respectively, as compared to 5.6 and 10.2 mo for patients in the N+GC 
arm without rash and 5.6 and 10.6 mo for patients in the GC arm.
Patients alive and under follow-up after Cycle 2
N+GC with 
rash N=350
N+GC no rash 
N=155 GC N=508
Overall Survival, mo (CI) 13.6 mo (11.6, 15.2)
10.2 (8.7, 
11.6) 10.6 (9.5, 11.9)
HR* (95% CI) 0.656 (0.529, 0.813) 0.738 (0.631, 0.864)
Stratified log-rank p value* 0.0001 0.0001
PFS, mo (CI) 6.2 mo (5.7, 6.9) 5.6 (5.0, 5.7) 5.6 (5.3, 5.6)
HR* (95% CI) 0.867 (0.693, 1.084) 0.808 (0.692, 0.942)
Stratified log-rank p value* 0.2127 0.0066
 
*In comparison to the N+GC group with rash Conclusion: Rash occurring 
during the first two cycles of treatment with necitumumab (N+GC) is 
associated with improved OS in patients with advanced squamous NSCLC. 
Keywords: Necitumumab, rash, efficacy, overall survival
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P1.01-063 Efficacy and Safety of Erlotinib in Squamous Cell Lung Cancer 
Marko Jakopovic1, Branka Cucevic1, Sanja Plestina1, Suzana Kukulj1, Mihovil Roglic1, 
Silvana Smojver-Jezek1, Nabil Chalfe1, Marta Korsic1, Gzim Redzepi2, Luka Brcic3, Filip 
Popovic2, Sonja Badovinac2, Miroslav Samarzija2 1University Hospital Centre Zagreb, 
Zagreb/Croatia, 2University Hospital Center Zagreb, Zagreb/Croatia, 3Institute of Pathology, 
Medical University Graz, Graz/Austria
Background: Erlotinib is epidermal growth factor receptor (EGFR) tyrosine-kinase 
inhibitor which showed efficacy and tolerability in patients with advanced non-small 
cell lung cancer (NSCLC), especially in patients which harbor activating mutations in 
EGFR. However, erlotinib also showed efficafy in patient with unknown or wild type EGFR 
mutation status. The iam of the study was to determine safety and efficacy of erlotinib 
in patients with advanced (stage IIIB and IV) squamous NSCLC. Methods: patients with 
advanced squamous NSCLC who had failed prior chemotherapy were treated with oral 
erlotinib 150 mg daily until disease progression or unaccaptable toxicity. Data was 
analyzed retrospectively. Results: a total of 122 patients (107 men and 15 women, 
mean age 62±8 years) with advanced squamous NSCLC were enrolled in the study from 
2006 to 2012 in 14 centers throughout Croatia. More than 50% of patients were active 
smokers at time of enrollment. Most of the patients had performance status ECOG 1 
and 2 (91%). Vast majority of patients were treated with erlotinib in third line setting. 
After cycle 2, 10% of patients had partial response (PR), and 45% of patients had stable 
diseases. In total, 55% of patients had disease control after cycle 2. Progression free 
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P1.01-060 Value Based Health Care Analysis for Lung Cancer Patients 
Ben Van Den Borne, Daphne Dumoulin Pulmonary Diseases, Catharina Ziekenhuis, 
Eindhoven/Netherlands
Background: ‘Care for Outcome’ is a Value Based Health Care project of Santeon (a 
cooperation of six leading, top clinical hospitals spread across the Netherlands) in 
which outcome measures for lung cancer are being measured and reported on a yearly 
base. In this observational study we report differences in outcome of the 6 participating 
hospitals. Methods: In this retrospective study, data of all lung cancer patients from 
the Santeon hospitals who were diagnosed between 1-1-2008 and 31-12-2012 was 
analysed. Primary endpoint in this analysis is mortality. Logistic regression analysis 
was performed to identify correlating factors for outcome. Results: Data of 5922 lung 
cancer patients was collected. Of these, 3584 (61%) patients had stage IIIB or IV disease. 
Tumour stage, performance status, age, co morbidity and treatment with or without 
chemotherapy correlated significantly with survival. Of these factors, treatment with or 
without chemotherapy had the highest correlation The percentage of patients receiving 
chemotherapy was significantly different between hospitals, ranging from 36% to 59% 
(mean 47,6%). The median survival of patients treated with or without chemotherapy 
(excluding those who died within 45 days and therefore passing the ‘immortal time bias’ 
effect) was 124 (95%CI 116-132) and 295 (95%CI 281-309) days (p<0.001) respectively. 
The difference persisted after correction for tumour stage, performance state, age and 
co morbidity. Conclusion: There is a strong variation between hospitals in the percentage 
of patients with stage IIIB / IV lung cancer receiving chemotherapy. Our data indicate 
that chemotherapy is an independent prognostic factor for survival.Santeon’s ‘Care 
for Outcome’ team for lung cancer: Onze Lieve Vrouwe Gasthuis, Amsterdam: A.A.J. 
Smit, MD PhD, St Lucas Andreas Hospital, Amsterdam: H.J. Smit, MD PhD, Catharina 
Hospital, Eindhoven: D.W. Dumoulin, MD; B.E.E.M. van den Borne, MD PhD, Medisch 
Spectrum Twente, Enschede: A.J. Polman MD, Martini Hospital, Groningen: J.W.G. 
van Putten, MD PhD, Antonius Hospital, Nieuwegein: G.J.M. Herder MD PhD; F.M.N.H. 
Schramel MD PhD; W.F. van den Bosch PhD, Canisius Hospital, Nijmegen: A. Termeer MD 
Keywords: Value Based Health Care, chemotherapy, non-small cell lung cancer, survival
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P1.01-061 The Chicago Thoracic Oncology Database Consortium: A Multi-Site 
Database Initiative Brian M. Won1, George B. Carey2, Yi-Hung Carol Tan1, James 
Wallace3, Mark Kozloff3, Thomas Hensing4, Ravi Salgia5 1Medicine, University of Chicago, 
Chicago/IL/United States of America, 2The Perelman School of Medicine, University of 
Pennsylvania, Philadelphia/PA/United States of America, 3Ingalls Memorial Hospital, Harvey/
IL/United States of America,4Section of Hematology/Oncology, Northshore University Health 
System, Evanston/IL/United States of America, 5Medicine, Section of Hematology/Oncology, 
University of Chicago, Chicago/IL/United States of America
Background: An increasing amount of clinical data is available to biomedical researchers, 
but specifically designed databases and informatics infrastructures are needed to handle 
this data effectively. Multiple research groups should be able to pool and share this data 
in an efficient manner. The Chicago Thoracic Oncology Database Consortium (CTODC) 
was created to standardize data collection and facilitate the pooling and sharing of 
data at institutions throughout Chicago and across the world. Methods: The Salgia 
Laboratory has implemented the Thoracic Oncology Program Database Project (TOPDP) 
Microsoft Access, the TORP Velos, and the TORP REDCap databases for translational 
research efforts. Standard operating procedures (SOPs) were created that document 
the construction and proper utilization of these databases. These SOPs have been 
made available freely to other institutions that have implemented their own databases 
patterned on these SOPs. In order to evaluate the effectiveness of this consortium, 
we have performed an investigation examining patients receiving erlotinib at three 
institutions belonging to the CTODC: The University of Chicago Medical Center, Ingalls 
Health System, and NorthShore University Health System. Results: A cohort of 373 
lung cancer patients who are taking erlotinib was identified by querying data from all 
three institutions of the consortium. The patients’ demographic and clinical data were 
compiled. In addition, the EGFR statuses of patients were analyzed, showing that out of 
the 70 patients that were tested, 55 had mutations while 15 did not have any mutations. 
The overall survival and duration of treatment were calculated from the data that was 
provided. It was shown that patients with an EGFR mutation had longer duration of erlotinib 
treatment and longer overall survival compared to patients who received erlotinib and 
were EGFR wild type. Conclusion: The investigation described herein demonstrates the 
successful data collection from multiple institutions in the context of a collaborative 
effort. However, the investigation identified many challenges in this type of collaboration, 
such as difficulty of transferring data between institutions and potential duplication of 
patient data. Overall, these issues do not lessen the findings of the investigation or the 
effectiveness of the CTODC. With greater cooperation and communication between 
institutions of the consortium, these issues can be readily resolved. The data presented 
here can be utilized as the basis for further collaborative efforts and/or development 
of a larger, more streamlined collection of databases within the consortium. 
Keywords: consortium, Erlotinib, EGFR, database
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this combination as first-line therapy of patients with metastatic Sq-NSCLC. 
Keywords: Necitumumab, advanced Sq-NSCLC
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P1.01-065 Bevacizumab Combined with Chemotherapy in the Treatment 
of Advanced NSCLC Patients Hong Tao, Zhe Liu, Junfang Tang, Mingzhi Li, Liang Shi, 
Wei Wu Oncology, Beijing Chest Hospital，Capital Medical University, Beijing/China
Background: Bevacizumab is a monoclonal antibody which selectively binds to human 
vascular endothelia growth factor（VEGF）.The combination of bevacizumab with 
chemotherapy has been one of the choices for advanced non-squamous non-small cell 
lung cancer（NSNSCLC） patients.In this study we evaluate the efficacy,safety and 
imaging findings of bevacizumab plus chemotheray in patients with advanced NSNSCLC.
In addition, the mutation status of EGFR gene and KRAS gene were 
detected. Methods: Patients adimitted in the hospital were treated with bevacizumab 
(15mg/kg or 7.5mg/kg, d1) plus chemotherapy(paclitaxel 175mg/m2, d1, carboplatin 
AUC=5 or 6, d1) with 3 weeks in one cycle,up to 6 cycles,followed with maintenance 
therapy of bevacizumab(15mg/kg or 7.5 mg/kg, d1) till disease progression. Efficacy, 
safety, tumoral cavitation, therapeutic outcome of malignant pleural effusion and EGFR, 
KRAS mutation status were analysed. Results:
 
Fig. Imaging changes of pleural effusion before and after treatment. A: Baseline CT 
of the chest showed plenty of pleural effusion on left side;B: Follow-up CT scan after 
4 cycles of therapy demonstrated the pleural effusion had disappeared. 26 Patients 
were collected.They were all treated with bevacizumab plus chemotherapy.17 patients 
received maintenance therapy.The median cycle number of chemotherapy was 6, and 
that of bevacizumab was 8.Partial response(PR), stable disease(SD) and progressive 
disease(PD) rates were 53.8%, 42.3% and 3.8%，respectively. The median progression 
free survival(PFS) and overall survival(OS) were11.0 and 25.8 months respectively. 
Out of 26 patients, 15.4% developed cavitation after treatment.2 years and 3 years 
survivle rates of cavitation group were lightly higher than those of non-cavitation 
group(75.0% vs 44.4%, P=0.293, 25.0% vs 12.5%, P=0.509, respectively). Of the 
13 patients with malignant pleural effusion, disease control rate of malignant pleural 
effusion was 100%: complete response(CR) rate was 38.5% and SD rate was 61.5%. 
EGFR gene ststus were detected in 11 patients. 36.4% showed sensitive mutation. 
The PR rate of EGFR mutation positive group was higher than that of mutation negitive 
group (75% vs 28.6%, P=0.262),but not statistically. KRAS mutation has not been 
found in all the 10 patients whose samsples were capable of being detected. Common 
adverse effects included myelosuppression, digestive symptoms,epistaxis, ect. Special 
adverse effects were also observed such as hemoptysis,hypertension,proteinuria 
etc. Most adverse effects were mild and controllable. Conclusion: Bevacizumab 
with chemotherapy is a promising and safe treatment for patients with NSNSCLC. It 
was also effective in controlling malignant pleural effusion. Tumoral cavitation were 
found, but the clinical significance was indeterminate. The relationship of EGFR gene 
status and efficacy of bevacizumab-based chemotheray is subject to further research. 
Keywords: bevacizumab, efficacy, Cavitation, malignant pleural effusion
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P1.01-066 Maintenance Bevacizumab after Chemotherapy with Bevacizumab 
in First Line Treatment of Lung Cancer. A Single Institution Experience Malika 
Gamaz Bensaou, Nabila Gheroufella, Maria Gherbi, Kamel Bouzid Medical Oncology, 
Pierre and Marie Curie Center, Algiers/Algeria
Background: Lung cancer is the first cancer in term of incidence and mortality for 
men in Algeria and a majority of the patients are stage IIIB or IV at the diagnostic. 
Bevacizumab + chemotherapy as first line followed by continuation maintenance 
with bevacizumab showed in many phase III randomized trial, an increase of PFS and 
overall survival. The purpose of this study is the evaluation of efficacy and toxicity of 
patient after continuation maintenance with bevacizumab in stage IIIB and IV for no 
squamous lung cancer in single institution. Methods: A retrospective study including 
all patients seen between September 2013 and April 2015, at department of medical 
oncology in Algiers. • Patients should have advanced or metastatic non squamous 
survival (PFS) was 3.7 months in overall population. Statistically significant differences in 
PFS were recorded according to response to treatment; patients with PR after two cycles 
had PFS of 6.2 months comparing to patients with progressive disease (PFS 2.0 months, 
p<0.001). Patients with better ECOG status (ECOG 1 and 2) had trend to improved PFS 
(3.8 vs 1.9 months) compared to ECOG 2 and patients with rash after cycle 2 also showed 
trend to improved PFS (4.1 vs 2.4 months) compared to no rash. There were no grade 3 
and 4 toxicities noticed during the study. Overall survival in our study was meaningfully 
prolonged. Conclusion: erlotinib as a single agent showed efficacy in treatment of 
patients with squamous cell lung cancer without significant toxicities. The best predictive 
factor of response to treatment was response to erlotinib after 2 months of treatment. 
Keywords: Erlotinib, squamous, non-small cell lung cancer
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P1.01-064 A Phase II Study of Gemcitabine-Cisplatin plus Necitumumab for 
Stage IV Sq-NSCLC Jesús Corral1, Santiago Ponce2, Joachim G. Aerts3, Chun-Ming 
Tsai4, Desiree Hao5, Jacques Cadranel6, J Thaddeus Beck7, Sang-We Kim8, Rocio 
Varea9, Grace Chao9, Susana Barriga9, Luis Paz-Ares1 1Hospital Virgen Del Rocio, Sevilal/
Spain, 2Medical Oncology Department, 12 de Octubre´ Hospital, Madrid/Spain, 3Amphia 
Ziekenhuis, Breda/Netherlands, 4Taipei Veterans General Hospital, Taipei/Taiwan, 5Tom 
Baker Cancer Centre/ University of Calgary, Alberta/AB/Canada, 6Hôpital Tenon, Paris/
France, 7Highlands Oncology Group, Fayetteville/AR/United States of America, 8Asan Medical 
Center, Seoul/Korea, 9Eli Lilly and Company, Indianapolis/IN/United States of America
Background: To report the efficacy and safety results from a study of necitumumab 
(N), manufactured under process D, modified from Process C, used in the pivotal 
SQUIRE study, in combination with gemcitabine (G) plus cisplatin (C) as first-line 
treatment in patients with advanced squamous non-small cell lung cancer (Sq-NSCLC). 
(NCT01788566) Methods: This was an open-label, single-arm, multicenter, phase II 
study in patients with advanced Sq-NSCLC. Patients were enrolled who were aged ≥18 
years and had measurable, pathologically confirmed stage IV Sq-NSCLC without prior 
chemotherapy. Patients had ECOG-PS 0-1, adequate organ function, and life expectancy 
of ≥12 weeks. Patients received N (800 mg iv, Days 1 and 8) plus GC (G=1250 mg/m² 
iv, Days 1 and 8; C=75 mg/m² iv, Day 1) each 3-week cycle for up to 6 cycles. Patients 
with at least stable disease (SD) could continue to receive N alone until progressive 
disease (PD) or other discontinuation criteria. Primary endpoint was objective response 
rate (ORR) based on RECIST1.1. Secondary endpoints included overall survival (OS), 
progression-free survival (PFS), disease control rate (DCR), change in tumor size (CTS; 
% improvement in lesions), and safety. Results: Patients (N=61), median age 65 years, 
heavy metastatic disease burden; approximately 70% of the patients had metastases to 
≥ 2 organ systems. Efficacy results, including an ORR of 48.1% are shown in the Table. 
Survival and PFS findings were similar to those reported in the SQUIRE study in the 
GC+N arm (SQUIRE results: median OS of 11.5 months, 1-year survival rate of 47.7%, 
and median PFS of 5.7 months). Median duration of treatment was 12 weeks (4 cycles) 
for G and C and 16 weeks (5 cycles) for N; the median relative dose intensity was 85% 
for G and 93% for C and N. Twenty-eight (46%) patients continued on single-agent N 
(median: 4 cycles). Skin reactions (n=49; 80.3%) and hypomagnesemia (n=21; 34.4%) 
were the most commonly reported adverse events of special interest (AESIs, all grades). 
AESI ≥ Grade 3 were skin reactions (n=8; 13.1%), thromboembolic events (n=7; 11.5%), 
hypomagnesemia (n=6; 9.8%), and hypersensitivity/ IRR (n=3; 4.9%). There were 27 
deaths (20 due to PD and 7 due to AEs [5 had no causal relationship to study drug]) at 
the time of data cut-off.
Table. Efficacy Results
N=61
ORR*† (CR+PR), n (%) [95% CI] 26/54 (48.1)† [34.34–62.16]
CR 0
PR, n (%) 26/54 (48.1)†
SD 18 (29.5)
PD 9 (14.8)
Not evaluable 1 (1.6)
Not assessable 7 (11.5)
DCR CR+PR+SD, n (%) [95% CI] 44 (81.5)† [68.57–90.75]
Median OS, months (95% CI) 11.7 [7.59–NA]
1-year survival rate, % (95% CI) 47.6% [30.20–63.08]
Median PFS, months (95% CI) 5.6 [3.68–6.87]
Median CTS, (%) 42.1
*Assessed by investigators
†Patients who had a post-baseline radiological 
assessment, n=54
Conclusion: The efficacy results and the safety profile, with N 
manufactured under process D, are consistent with what is expected for 
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There have been no in-field failures in the SBRT arm. There has been one death due to 
disease progression in the maintenance chemotherapy arm. No patients have suffered 
a grade 3 or higher adverse event related to protocol therapy. Conclusion: This study 
demonstrates the feasibility of enrolling patients with limited metastatic lung cancer 
to a randomized trial of local therapy following first-line chemotherapy. To date, all 
patients have tolerated the administration of SBRT to multiple sites in between first-
line and maintenance chemotherapy without any grade 3 or higher adverse events. 
Continued follow-up will be necessary to determine the efficacy of the experimental arm. 
Keywords: Oligometastases, SBRT, maintenance
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P1.01-069 Reasons for Discontinuation of Treatment with Bevacizumab in 
Patients with Non-Progressing NSCLC - Retrospective Study Peter Berzinec1, 
Maria Cerna2, Peter Kasan3, Helena Kuzmova1, Gabriela Chowaniecova1, Marian Martak3, 
Milada Vesela3, Lucia Denkova3, Lucia Dolakova1, Milan Kroslak1, Zdenka Cavarova1 
1Specialised Hospital of St Zoerardus Zobor, Nitra/Slovak Republic, 2Slovak Medical 
University, Bratislava/Slovak Republic, 3University Hospital, Bratislava/Slovak Republic
Background: In general, bevacizumab is well-tolerated treatment in patients with 
advanced, metastatic non-squamous NSCLC. Despite this, permanent discontinuations 
of bevacizumab occur also before progressive disease (PD), both in clinical trials and 
in clinical practice. Purpose of this study was to find out the reasons for permanent 
discontinuation of bevacizumab before PD in patients treated in two centers in the Slovak 
republic. Methods: In this retrospective study, approved by the Ethics Committee 
of the Specialized Hospital of St Zoerardus Zobor, the institutional databases were 
searched for patients with advanced NSCLC treated with bevacizumab between 2007 
and 2013. Results: Altogether 161 patients were included into the analysis. Patients’ 
characteristics: M/W: 99/62, age: median 61 years (32 - 83), histologically /cytologically 
confirmed NSCLC: adenocarcinoma/large cell/adenosquamous: 158/2/1. Number of 
cycles with bevacizumab (induction and maintenance): median 8 (1 - 52), PFS: median 
7 months (1 - 42). Bevacizumab was permanently discontinued before PD in 28 of 161 
patients (17,4%), in 18 of 161 (11,2%) due to undesirable effects - Table 1. Table 1: 
Reasons for permanent discontinuation of bevacizumab in non-progressing NSCLC
Undesirable effects N Other reasons N
Cavitation 3 Lost to FU 2
Pneumothoraces 3 Molecular testing, start of TKI 2
Cerebrovascular event 2 Patients’ preference 2
Gastrointestinal perforation 2 Car accident, death 1
Hypertensive crisis 2 Planned surgery 1
Pneumonia 2 Traumatic fractures 1
Proteinuria 2 Other 1
Thrombotic event 2
All 18 All 10
 
Conclusion: Permanent discontinuation of bevacizumab in non-progressing 
NSCLC was seen in this study in the similar rate as in the larger trials (Wozniak AJ 
et al. Clin Oncol [Coll Radiol]. 2015, 27:187-96.) However, some differences are 
in the type of undesirable effects, which are in part also chemotherapy related. 
Keywords: NSCLC, bevacizumab, discontinuation
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P1.01-070 KRAS Mutations: Does It Mean No Erlotinib? Margarida Dias1, Rita 
Linhas1, José Carlos Machado2, Luís Cirnes2, Ana Gonçalves1, Sérgio Campainha1, Sara 
Conde1, Ana Barroso1 1Pulmonology, Centro Hospitalar Vila Nova de Gaia Espinho, Vila Nova 
de Gaia/Portugal, 2Ipatimup, Porto/Portugal
Background: KRAS mutations are the most common mutations in non-small cell lung 
cancer (NSCLC). Theoretically those patients are resistant to tyrosine kinase inhibitors, 
but studies are contradictory. The aim of this study was to compare second-line 
chemotherapy with docetaxel and erlotinib in patients with NSCLC, EGFR wild-type, 
depending on their KRAS status. Methods: We included 47 patients diagnosed with 
NSCLC, EGFR wild type, followed in a Lung Cancer Unit and treated with docetaxel or 
erlotinib as second-line chemotherapy. KRAS mutations in exon 12 and 13 were screened. 
Patients were divided in two arms: docetaxel arm and erlotinib arm. Time to progression 
to each second-line chemotherapy and overall survival after second-line chemotherapy 
was compared between patients with KRAS mutations and KRAS wild-type. In patients 
with KRAS mutations, time to progression and overall survival after second-line 
chemotherapy was compared between docetaxel and erlotinib. Results: 87% were male, 
mean age 65±11 years, 77% smokers or ex-smokers, 81% non-squamous tumors, 70% 
stage IV at diagnosis. Analyzing all patients, there was no statistical difference regarding 
the time to progression and overall survival between patients with or without KRAS. 14 
patients were in docetaxel arm and 33 patients in erlotinib arm. There were no statistical 
differences between arms regarding gender, smoking status, performance status and 
(adenocarcinoma and carcinoma with large cell) lung cancer, and received 4 cycles of 
induction chemotherapy with platine + pemetrexed + bevacizumab. • All patients with 
response or stable disease received bevacizumab as maintenance therapy, evaluation 
by CT scan was done every three cycles. Results: Twenty (3 F and 17 M) patients were 
enrolled, and all are evaluable for response and toxicity. Median age was 61.5 years 
(range m 31 years – M 74 years). Histology was adenocarcinoma in 19 patients and 
carcinoma with large cell in 1 patient. Sixteen (16) patients had IV stage and four (4) 
patients had IIIB stage disease. Response rate (1 CR, 4 PR) was seen in 5 patients (25 
%), Stable Disease (SD) was achieved in 5 patients (25 %) and Progressive Disease 
(PD) in 10 patients (50 %). Among the 20 patients who achieved 4 cycles of induction 
bitherapy + bevacizumab, 10 patients (50 %) underwent for maintenance therapy. All 
the ten patients received the first three cycle of maintenance with bevacizumab and 
well tolerated without toxicity. At this time, two patients achieved one year maintenance 
with stabilization of disease. One of them developed hypertension and is under 
treatment. Conclusion: Bevacizumab was well tolerated in first line treatment and as 
maintenance, for patients with advanced or metastatic non-squamous lung cancer. 
Keywords: NSCLC, non squamous carcinoma, bevacizumab, maintenance
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P1.01-067 Epidermal Growth Factor Receptor Gene Amplification in Patients 
with Advanced-Stage NSCLC Ondrej Fiala1, Milos Pesek2, Jindrich Finek1, Marek 
Minarik3, Lucie Benesova4, Zbynek Bortlicek5, Ondrej Topolcan6 1Department of Oncology 
and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University, 
Pilsen/Czech Republic, 2Department of Pneumology, Medical School and Teaching Hospital 
in Pilsen, Charles University, Pilsen/Czech Republic, 3Center for Applied Genomics of 
Solid Tumours, Genomac Research Institute, Prague, Czech Republic, Pilsen/Czech 
Republic, 4Center for Applied Genomics of Solid Tumours, Genomac Research Institute, 
Prague/Czech Republic, 5Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk 
University, Brno/Czech Republic, 6Department of Nuclear Medicine, Medical School and 
Teaching Hospital in Pilsen, Charles University, Pilsen/Czech Republic
Background: Tyrozine kinase inhibitors (TKI) targeting epidermal growth factor 
receptor (EGFR) represent a novel effective tools in management of advanced-
stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and 
predictive role of EGFR gene amplification in patients with advanced-stage NSCLC 
treated with EGFR-TKIs. Methods: The study included 290 patients with advanced-
stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) 
and Polymerase chain reaction (PCR) were used for detection of EGFR mutations 
and EGFR gene amplification, respectively. Results: EGFR amplification was detected 
in 26 (9.0%) patients. EGFR amplification was found more frequent in patients 
harboring EGFR mutation (p < 0.001). No significant corelation between EGFR gene 
amplification and survival was observed. Conclusion: The presence of EGFR gene 
amplification is associated with EGFR gene mutations. EGFR gene amplification is 
not a feasible predictive biomarker for the treatment with EGFR-TKIs in patients with 
advanced-stage NSCLC. This study is supported by Ministry of Health, Czech Republic - 
conceptual development of research organization Faculty Hospital in Pilsen - FNPl, 00669806 
and by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund. 
Keywords: EGFR, amplification, NSCLC, EGFR-TKI
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P1.01-068 Randomized Trial of Maintenance Chemotherapy Versus SBRT 
plus Maintenance Chemotherapy for Advanced NSCLC - Feasibility and Early 
Outcomes Zabi Wardak1, David E. Gerber2, Chul Ahn3, Randall S. Hughes2, Grace Raja2, 
Saad Khan2, Jonathan E. Dowell2, Lorraine Pelosof2, Suprabha Pulipparacharuvil1, Robert 
D. Timmerman1, Hak Choy1, Puneeth Iyengar1 1Radiation Oncology, UT Southwestern, 
Dallas/TX/United States of America, 2Hematology/Oncology, UT Southwestern, Dallas/
TX/United States of America, 3Biostatistics, UT Southwestern, Dallas/TX/United States of 
America
Background: Following first-line chemotherapy, maintenance therapy regimens have 
shown modest yet statistically significant benefits in progression free survival (PFS). To 
date, there have been no completed, prospective randomized trials examining the role 
of locally aggressive therapy in limited metastastic, advanced stage non-small cell lung 
cancer (NSCLC). We hypothesized that stereotactic body radiotherapy (SBRT) prior to 
maintenance chemotherapy would further improve PFS. This trial also serves to provide 
prospective survival data for a population with limited metastatic NSCLC. Methods: This 
is a two-arm randomized phase II trial. Eligible patients have stable disease or partial 
response with limited metastatic disease (defined by six or fewer sites amenable to 
SBRT) after treatment with up to 6 cycles of first line platinum doublet chemotherapy. 
Patients are then randomized to investigator’s choice maintenance chemotherapy alone 
or SBRT to all amenable sites followed by maintenance chemotherapy. The primary 
endpoint of the study is PFS, with 36 patients required to demonstrate an increase 
from 4 months in the control arm to 10 months in the experimental arm, with 80% 
statistical power and a 2-sided significance level of 0.10. Results: Since May 2014, 11 
patients have been enrolled (5 to SBRT + maintenance arm; 6 to maintenance arm). 
The median number of first-line chemotherapy cycles was four, with the most common 
regimen carboplatin/paclitaxel followed by carboplatin/pemetrexed. The median 
number of maintenance chemotherapy cycles was six, the most common agent being 
pemetrexed followed by bevacizumab. The median number of sites treated with SBRT 
were two, with the lung the most common anatomic location followed by the adrenal 
gland. Five patients have progressed to date, three in the maintenance chemotherapy 
arm and two in the SBRT + maintenance chemotherapy arm. Progression in the 
maintenance alone arm occurred in original sites of disease in two of three patients. 
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These results are similar to previous findings in non-small cell lung cancer (NSCLC). As 
multiple microRNAs from the same family are downregulated in MPM, we investigated 
whether a single synthetic mimic based on the consensus sequence of the entire family 
could restore activity of the entire family. Methods: Novel microRNA mimics based on 
the consensus sequence of the miR-15/107 group were designed (con15/107.1 to 4). 
The effects on growth, migration, target regulation, drug sensitivity and angiogenesis 
of the con15/107 mimics were compared with native miR-15 and miR-16 mimics using 
standard assays in MPM and lung cancer cell lines in vitro. The regulation of specific 
target genes was assessed by RT-qPCR, Western blot and luciferase reporter assays. 
Global gene regulation was assessed by proteomics. Activity of con15/107 mimics 
was investigated in vivo in xenograft models in nude mice. Results: The consensus 
mimics inhibited growth and migration of MPM and lung cancer cell lines in vitro, and 
effects were greater than with native miR-15 or miR-16 mimics. Growth inhibition was 
associated with an induction of apoptosis, and downregulation of predicted targets of 
the mimics. Target gene interactions were confirmed with 3’UTR reporter constructs, 
and proteomics identified a number of candidate genes involved in consensus mimic-
induced growth inhibition. Consensus mimics also sensitized multiple MPM and 
lung cancer cell lines to chemotherapy agents, and inhibited angiogenic activity in 
endothelial cells. In a xenograft model, the consensus mimic con15/107.2, packaged 
in bacterially-derived, EGFR antibody-targeted, EDVTMnanocells, inhibited MPM tumor 
growth in vivo. Conclusion: The novel con15/107 mimics based on the consensus 
sequence of the miR-15/107 group have greater activity than native miR-15 or miR-
16 mimics in vitro and are active in vivo. Increased activity correlates to greater 
target gene downregulation. These preclinical studies support a Phase I clinical 
trial has been initiated for patients with MPM or NSCLC failing standard therapy. This 
represents the first trial of microRNA replacement as a therapy for thoracic cancer. 
Keywords: malignant pleural mesothelioma, non small cell lung cancer, microRNA
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P1.01-073 MET and Invasive Function in NSCLC Tamara Mirzapoiazova, Carol Tan, 
Patrick Singleton, Ravi Salgia Department of Medicine, University of Chicago, Chicago/
United States of America
Background: There is molecular heterogeneity of lung cancers, especially non-
small cell lung cancer (NSCLC). Even though pathways such as EGFR and ALK are 
understood much more, we are beginning to understand the role of MET receptor 
tyrosine kinase (RTK). The initial trial of EGFR with MET inhibitor was no better than 
single agent, we strongly believe that it is a subset of MET abnormalities that lead to 
the pathogenesis of lung cancer. In order to better define this, we are studying the MET 
function in invasion of NSCLC. We are utilizing the novel ECIS method to study biological 
behavior. Methods: Immunofluorescence of Met/pMet staining was performed with the 
following antibodies: c-MET (NovusBio) and p-METet (Tyr1230,1234,1235, Invitrogen). 
Immunoblot analyses of MET/pMET and related signal transduction molecules were 
performed on H1993 (MET amplified cell line) and A549 (KRAS mutated cell line, with 
activated MET) cell lysates. ECIS instrument (Applied Biophysics Inc) was used for 
motility assay and proliferation assay. Confluent cell monolayer was electrically abrased 
at 6V for 30 seconds. Impedance and resistance of the cell layer were immediately 
recorded for a period of up to 20 hours. For proliferation assay cells were seeded in 
8W10E plates without or with inhibitors. Impedance and resistance were measured 
for 48 hours at 15 kHz. MET inhibitors were also utilized in the study. Results: In our 
study we investigated the inhibition potential of MET inhibitors. Staining with MET 
antibody resulted in nuclear and perinuclear staining of both of the cell lines. HGF 
treatment (100 nM, 20 min) increased nuclear staining. p-MET also increased in the 
presence of HGF and had plasma membrane, perinuclear and nuclear pattern. 48 hours 
pre-incubation with MET inhibitors reduced cellular MET staining and abolished MET 
phosphorylation. Moreover immunoblotting assay demonstrated significant reduction of 
MET phosphorylation in untreated and HGF treated cells. We measured biological activity 
of the cells in the presence of inhibitors. MET inhibitors significantly reduced growth 
rate compared with untreated cells as assessed by electrical resistance measurement. 
Next we did ECIS based wound-healing assay for a quantitative determination of MET 
inhibitors on migration potential of NSCLC cells. Voltage pulse led to drastic decrease 
of cell resistance. MET inhibitors delayed for 35% return to resistance value of the 
resting cells. Conclusion: MET inhibitors reduced NSCLC cell motility, migration 
and invasion. Novel MET inhibitors can be used for therapeutic intervention against 
NSCLC. The nuclear localization of MET is a novle function and needs to be explored 
further. ECIS also is a novel technique to study the biology of epithelial cancers. 
Keywords: NSCLC, MET/pMET, RON/pRON, ECIS
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P1.01-074 Phase III Study of WBRT with or without Erlotinib for Brain 
Metastasis NSCLC Zhen-Zhou Yang1, Rong-Qing Li2, Bo Zhu3 1Daping Hospital and 
the Research Institute of Surgery of the Third Military Medical University, Chongqing/
China, 2Radiation Oncology, The First Affiliated Hospital of Kunming Medical College, 
Kunming/China, 3Cancer Center of People’S Liberation Army, Xinqiao Hospital, Third Military 
Medical University, Chongqing/China
Background: More effective treatment strategies are required for pts with brain 
metastasis (BM) from non-small cell lung cancer although whole-brain radiotherapy 
(WBRT) remains the standard treatment. Erlotinib, an effective TKI in EGFR mutant 
NSCLC, has shown evidence of intracranial accumulation, and has been proven with well 
tolerability and favorable objective response rate (71%) when concurrent with WBRT. 
One phase II study (n=80) reported no advantage in median neurological PFS or OS for 
stage at diagnosis. Patients in docetaxel group were younger (60±9 years vs. 67±11 
years, p=0.027). In docetaxel arm, 3 patients had KRAS mutations. We found no statistical 
differences between patients with or without mutations regarding time to progression 
and overall survival after docetaxel. In erlotinib arm, 7 patients had KRAS mutations. We 
found no statistical differences between patients with or without mutations regarding time 
to progression and overall survival after erlotinib. In patients with KRAS mutations, time 
to progression tends to be slightly higher in erlotinib arm (2 vs. 1 month, p=0.088) and 
overall survival after second-line chemotherapy seems to be similar. Conclusion: Unlike 
what is reported in some studies, we found no differences concerning KRAS status with 
respect to overall survival and time to progression. Moreover, it seems that there are 
no differences between docetaxel and erlotinib in second-line treatment. This questions 
the non-use of erlotinib in second-line treatment of KRAS mutated NSCLC patients. 
Keywords: KRAS mutations, Erlotinib, docetaxel, non-small cell lung cancer
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P1.01-071 Long-Term Tolerability Among IRESSA Clinical Access Program 
(ICAP) Participants in the United States (US) Paul A. Bunn, Jr1, Katherine 
Pisters2, Ira Gore3, Elisabeth F. Croft4, Diana Devincenzo5, Dara Stein6, Klaus 
Freivogel7, Frangiscos Sifakis4, Fred R. Hirsch1 1University of Colorado Cancer Center, 
Aurora/CO/United States of America, 2Department of Thoracic Head and Neck Medical 
Oncology, University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 3Alabama Oncology - St. Vincent’S Birmingham, Birmingham/AL/United States of 
America, 4Astrazeneca, Lp, Gaithersburg/MD/United States of America, 5Astrazeneca, Lp, 
Wilmington/DE/United States of America, 6United Biosource Corporation, Chevychase/MD/
United States of America, 7United Biosource Corporation, Munich/Germany
Background: Following the gefitinib (IRESSA®) NDA voluntary withdrawal, which 
previously had allowed for limited commercial distribution of IRESSA, gefitinib became 
available under the IRESSA Clinical Access Program (ICAP) in June 2011. The ICAP 
continued to provide drug access to patients who were benefiting or had benefited from 
treatment with gefitinib through restricted distribution (2005-2011) or through a clinical 
trial that was IRB approved prior to June 2005. ICAP participants constitute a unique 
subset of cancer patients in whom long-term use of gefitinib can be studied. Consequently, 
this is the first study to describe long-term safety and tolerability data for an EGFR TKI 
in cancer patients outside of the clinical trial setting. Methods: This study utilizes 2 
data sources: (1) retrospective patient medical chart review of demographics, including 
safety and tolerability of prolonged treatment with gefitinib as part of the ICAP; and (2) 
retrospective review of serious adverse event (SAE) reports in the AstraZeneca safety 
database, as all ICAP investigators are responsible, per protocol, for reporting all SAEs 
observed for ICAP participants. Results: A total of 188 patients were enrolled in the ICAP 
from 134 sites across the US; 94 patients (50.0%) remain on active treatment. This study 
aims to include as many sites and patients as feasible. Currently, 46 sites representing 
77 patients have agreed to participate; site enrollment and data collection are ongoing. 
As of July 16, 2015, chart abstractions of 16 patients were completed. These patients 
have a median age of 68.0 years, are predominantly female (75.0%), non-Hispanic white 
(87.5%), with a confirmed NSCLC diagnosis (93.8%). More patients received gefitinib in 
second line (43.8%) followed by first line (37.5%) and third line (18.8%). Median gefitinib 
duration prior to ICAP initiation was 11.3 years (range 9.1-13.9 years), with median 
gefitinib duration as part of the ICAP being an additional 3.5 years (range: 0.3-3.8 years). 
During the ICAP, 93.8% of patients (95% CI: 87.9-99.6) did not experience any dose 
reductions, interruptions, or discontinuation due to gefitinib-related adverse events. 
The AstraZeneca Safety Database showed 123 SAEs reported from 54 ICAP patients 
as of February 26, 2015. The majority of SAEs were consistent with underlying disease 
conditions and were considered unrelated to gefitinib therapy by investigators. 5.6% of 
patients (3/54) had potentially causally related SAEs as determined by investigators: one 
patient had procedure-related bronchitis, lung infection, and exacerbation of preexisting 
COPD with a fatal outcome; one patient experienced interstitial lung disease, pulmonary 
alveolar hemorrhage, and acute respiratory and renal failure (patient recovered with 
sequelae); and one patient developed dermatitis acneiform and pruritus. Of the remaining 
51 patients, 20 had fatal outcomes (39.2%). The majority of fatalities (12) had insufficient 
information to assess cause of death and may have had other alternative causes, 
including underlying or concurrent diseases (6) and possible disease progression (2). 
Conclusion: Characterization of long-term gefitinib use among this 
subset of NSCLC patients indicates acceptable long-term tolerability and 
indicates that some patients have long-term (>10 year) benefit. Clinical 
and genetic features associated with long-term benefit need further study. 
Keywords: gefitinib, Long-term, NSCLC, EGFR
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P1.01-072 Targeted Delivery of a Synthetic microRNA-Based Mimic to Treat 
Thoracic Cancers Glen Reid1, Yuen Y. Cheng1, Kadir Sarun1, Marissa Williams2, 
Michaela B. Kirschner2, Andrej Despotovski2, Nancy Mugridge3, Jocelyn Weiss4, 
Himanshu Brahmbhatt3, Jennifer Macdiarmid3, Mark Molloy5, Ruby Lin2, Nico Van 
Zandwijk2 1Asbestos Diseases Research Institute, Sydney/NSW/Australia, 2Asbestos 
Diseases Research Institute, Sydney/Australia, 3Engeneic Ltd, Sydney/NSW/
Australia, 4Engeneic Ltd, Sydney/Australia, 5Australian Proteome Analysis Facility, Macquarie 
University, Sydney/NSW/Australia
Background: MicroRNA expression is commonly suppressed in cancer, contributing to 
tumor cell biology. Recently we demonstrated that multiple members of the miR-15/16 
family are downregulated and have tumor suppressor functions in malignant pleural 
mesothelioma (MPM), an asbestos-related cancer for which few treatments are available. 
S427Copyright © 2015 by the International Association for the Study of Lung Cancer
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cells and cytokines to better understand the immunotherapeutic mechanism.
Results: Trial in progress Conclusion: Trial in progress
Keywords: Non-small-cell lung cancer; Bavituximab; Immunotherapy; phosphatidylserine
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P1.01-076 TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib 
in EGFR-Mutant NSCLC Ross Camidge1, Federico Cappuzzo2, Jowell Go3, Jeffrey 
Isaacson4, Jason Litten3, Keunchil Park5, David R. Spigel6, Alexander Spira7, Alain 
Vergnenegre8, Jürgen Wolf9, James Chih-Hsin Yang10, Tony Mok11 1Medicine, University 
of Colorado, Denver/United States of America, 2Ospedali Riuniti, Ancona/Italy, 3Clovis 
Oncology, Sanfrancisco/CA/United States of America, 4Clovis Oncology, Boulder/CO/
United States of America, 5Division of Hematology-Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/Korea, 6Sarah 
Cannon Research Institute/Tennessee Oncology, Pllc, Nashville/TN/United States of 
America, 7Virginia Cancer Specialists, Fairfax/VA/United States of America, 8CHU de 
Limoges, Limoges/France, 9Universitaetsklinik Köln, Köln/Germany, 10Department of 
Oncology, National Taiwan University Hospital, Graduate Institute of Oncology & Cancer 
Research Center, National Taiwan University, Taipei/Taiwan, 11The Chinese University of Hong 
Kong, Hong Kong/China
Background: Activating EGFR mutations including the L858R mutation and exon 19 
deletions (del19) are key drivers of non-small cell lung cancer (NSCLC) in 10%–15% 
of patients of European and 30%–35% of Asian descent.1 Acquired resistance to 
fi rst-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib can be driven 
by additional EGFR mutations, with exon 20 T790M accounting for 50%–60% of 
cases.2 Rociletinib (CO-1686) was designed to inhibit T790M as well as L858R and 
del19 while sparing wild-type EGFR and has demonstrated response rates up to 67% in 
patients with T790M mutations who had progressed on fi rst or later line EGFR inhibitor 
therapy. Rociletinib continues to be well tolerated by patients in ongoing studies.3 Given 
that T790M mutated subclones commonly emerge during treatment with existing EGFR 
inhibitors, early targeting of T790M along with initial activating mutations is a rational 
approach to delay progression. Methods: TIGER-1 (NCT02186301) is a randomized, 
open label study of rociletinib vs erlotinib in patients with mutant EGFR NSCLC. Patients 
with histologically or cytologically confi rmed metastatic or unresectable locally 
advanced treatment-naive NSCLC (no prior therapy in the metastatic setting and no 
CNS disease), with documentation of ≥1 activating EGFR mutation (excluding exon 20 
insertions) and biopsy within 60 days will be enrolled in this 2-part study. All patients will 
be randomized 1:1 to rociletinib (500 mg twice daily) or erlotinib (150 mg once daily) 
and treated until death, qualifying adverse events or disease progression. Patients will 
be stratifi ed by sensitizing EGFR mutation (T790M, del19, L858R, or other) and territory 
(Asian vs non-Asian geography). The same patient eligibility criteria will be used for the 
Phase 2 and Phase 3 portions of TIGER-1. The phase 2 portion is currently enrolling 
and will transition to the Phase 3 portion upon enrollment of the 201st patient. The 
maturing Phase 2 dataset will contribute to decision-making rules for the Phase 3 interim 
analyses. The Phase 3 portion will incorporate larger cohorts; the fi nal sample sizes 
will be determined by interim analyses where the chances of success will be estimated 
at pre-planned enrollment milestones. The primary endpoint is PFS; secondary effi cacy 
endpoints include objective response rate, duration of response, disease control rate and 
overall survival. Safety will be assessed via standard adverse event reporting. PFS and 
OS will be summarized with Kaplan-Meier plots. The stratifi ed log-rank and hazard ratio 
will compare PFS distributions for rociletinib- vs erlotinib-treated patients. Enrollment 
is ongoing. 1. Herbst R et al. N Engl J Med. 2008 2. Yu H et al. Clin Cancer Res. 2013 
3. Sequist LV J Clin Oncol. 2014 Results: Not applicable Conclusion: Not applicable 
Keywords: T790M, rociletinib, EGFR, NSCLC
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC
MONDAY, SEPTEMBER 7, 2015 - 09:30-17:00
P1.01-077 First-Line Nivolumab + Nab-Paclitaxel + Carboplatin (C) in 
Advanced NSCLC David Waterhouse1, William Derosa2, Cindy Duval Fraser3, Martin 
Gutierrez4, Amy Ko3, Teng Jin Ong3, Daniel Pierce3, Sotirous Stergiopoulos3, Karen 
Kelly5 1Oncology Hematology Care, Blue Ash/OH/United States of America, 2Regional Cancer 
Care Associates, Llc-Morristown Carol G. Simon Cancer Center, Morristown/NJ/United States 
of America, 3Celgene Corporation, Summit/NJ/United States of America, 4John Theuer 
Cancer Center, Hackensack/NJ/United States of America, 5University of California, Davis 
Comprehensive Cancer Center, Sacramento/CA/United States of America
Background: Nivolumab, an anti-PD-1 inhibitor, has demonstrated anti-tumor activity 
in several solid tumors and is approved for unresectable/metastatic melanoma 
and disease progression following ipilimumab, and if BRAF V600 mutation positive, a 
BRAF inhibitor; and for metastatic squamous NSCLC in patients with progression on/
after platinum-based chemotherapy. Combining a taxane, which can act as a cytotoxic 
and an immunomodulator, with an immune checkpoint inhibitor has demonstrated 
improved outcomes over chemotherapy alone in NSCLC. First-line nivolumab and 
solvent-based paclitaxel plus C (sb-P/C) resulted in a 43% overall response rate and 
a median progression-free survival of 31 weeks in an interim analyses from a phase I 
trial in patients with advanced NSCLC (Antonia et al. Presented at ASCO 2014 [Abstract 
8113]). nab -Paclitaxel (nab -P) based therapy has demonstrated improved effi cacy over 
standard treatment in pancreatic and breast cancers, and nab -P plus carboplatin (nab -
P/C) signifi cantly improved the primary endpoint (ORR) vs sb-P/C in a phase III trial of 
patients with advanced NSCLC (Socinski et al. J Clin Oncol. 2012;30:2055-2062) and 
does not requires immunosuppressive premedication. This phase I, open-label, 6-arm, 
multicenter trial, will evaluate safety of nivolumab with nab -P in 3 cancer types: advanced 
NSCLC (+ C), advanced pancreatic cancer (± gemcitabine), and metastatic breast 
concurrent erlotinib (100mg/d) and WBRT (20 Gy/5f) in pts with predominantly EGFR wild-
type NSCLC compared to WBRT alone, while another single arm phase II study (n=40) 
found that pre-treatment with erlotinib (150mg/d for 1 wk) followed by concurrently with 
WBRT (35 Gy/12f) could extend median OS to 11.8 months in all population and 19.1 
months in EGFR mut pts. The optimal administration schedule for erlotinib concurrent 
with WBRT for BM NSCLC is controversial, which should be confi rmed in a randomized 
controlled trial in a more larger population. This phase III trial is to investigate the effi cacy 
and safety of erlotinib pre-treatment followed by combination of erlotinib and WBRT in 
comparison to WBRT alone in multiple BM NSCLC pts. Methods: This was an open-
labeled, randomized, multicenter phase III clinical trial. Pts, aged≥18 and KPS≥70, with 
at least two BMs of NSCLC from 7 medical centers were recruited began in August 
2013. Pts with previous use of EGFR-TKI need to withdraw≥4 weeks if assigned to the 
experimental arm. ARMs for detection of EGFR mutation in tumor tissue is mandatory. 
The major exclusion criteria included previous brain radiotherapy, or any uncontrolled 
or symptomatic major medical illnesses or neurologic/psychiatric illnesses. The 
enrolled pts would be randomly assigned to either erlotinib (150mg/day) concurrent 
WBRT (2.0Gy/day, 5 days/week, total dose 40Gy) or WBRT alone group with a 1:1 
allocation (Fig.1). Only pts with EGFR sensitive mutation will continue to use erlotinib until 
disease progression or intolerable adverse events. The primary endpoint is the time to 
neurologic progression (TTP), defi ned as evidence of progression of brain metastasis 
(The total of longest diameter more than 20% enhanced area in MRI) or of emergency 
of new intracranial metastases. The secondary endpoints include, OS, ORR and QoL and 
subgroup analyses. Till February 12, 2015, 125 of planned 224 pts have been enrolled. 
This study is registered in clnicaltrials.gov (NCT01887795).
  
Results: not applicable Conclusion: not applicable Keywords: Erlotinib, whole-brain 
radiotherapy, Brain metastasis, NSCLC
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P1.01-075 Phase III, Randomized, Double-Blind Trial of Bavituximab Plus 
Docetaxel in Previously Treated Stage IIIb/IV Non-Squamous NSCLC (SUNRISE) 
David R. Spigel1, Joseph Shan2, Alberto Chiappori3, Ulrich Keilholz4, Martin Reck5, 
Martin Edelman6, Manuel Domine7, Keunchil Park8, Tae Won Jang9, Wu-Chou Su10, Rachel 
E. Sanborn11, Leora Horn12, Rebecca Heist13, Paul Mainwaring14, David E. Gerber15 
1Sarah Cannon Research Institute/Tennessee Oncology, Pllc, Nashville/TN/United States 
of America, 2Peregrine Pharmaceuticals Inc, Tustin/CA/United States of America, 3Thoracic 
Oncology, H. Lee Moffi tt Cancer Center and Research Institute, Inc, Tampa/FL/United States 
of America, 4Charité - Universitätsmedizin Berlin, Berlin/Germany, 5Lungclinic Grosshansdorf, 
Grosshansdorf/Germany, 6University of Maryland Medical Center, Baltimore/MD/United 
States of America, 7Oncology, Hospital Universitario- Fundacion Jimenez Diaz, Madrid/
Spain, 8Samsung Medical Center, Seoul/Korea, 9Kosin University Medical College, Pusan/
Korea, 10National Cheng Kung University Hospital, Taipei/Taiwan, 11Medical Oncology, 
Providence Portland Medical Center, Portland/OR/United States of America, 12Vanderbilt-
Ingram Cancer Center, Nashville/TN/United States of America, 13Massachusetss 
General Hospital Cancer Center, Harvard Medical School, Boston/MA/United States of 
America, 14Icon Cancer Foundation, Milton/Australia, 15UT Southwestern, Dallas/TX/United 
States of America
Background: Exposed phosphatidylserine (PS) in the tumor microenvironment is highly 
immunosuppressive. PS binding to PS receptors on myeloid derived suppressor cells 
(MDSC) and M2 macrophages leads to production of anti-infl ammatory cytokines such as 
TGF-β and IL-10. Bavituximab, a fi rst-in-class PS-targeting monoclonal antibody, counters 
these effects, resulting in production of pro-infl ammatory cytokines such as TNF-α and 
IL-12, maturation of dendritic cells and induction of tumor specifi c cytotoxic T lymphocyte 
(CTL) immunity. Docetaxel has also been shown to suppress MDSCs while increasing 
tumor antigens and T-cell mediated cytotoxicity, thereby enhancing bavituximab’s 
immunomodulatory effects. In a prior double-blind Phase II trial in 2nd line non-squamous 
non-small cell lung cancer, bavituximab 3 mg/kg plus docetaxel was well-tolerated and 
demonstrated 60% improvement (11.7 vs 7.3 month) in median overall survival (OS) 
compared to control. Methods: SUNRISE is a Phase III, double-blind trial where patients 
with previously treated Stage IIIb/IV non-squamous, non-small cell lung cancer are 
randomized in a 1:1 ratio to receive up to six 21-day cycles of docetaxel in combination 
with either weekly 3 mg/kg bavituximab or placebo, followed by maintenance with 
weekly bavituximab or placebo until progression or toxicity. Patients will be stratifi ed by 
region (North America, Europe, or Rest of World), disease stage (IIIb or IV), and previous 
maintenance/targeted therapy (yes or no). This trial was initiated in December 2013 and 
accrual of 582 patients across 160+ sites in 14 countries is planned over 24 months.
The primary endpoint is OS and two interim analyses are planned. Secondary 
endpoints include progression-free survival (PFS), overall response rate (ORR) 
and safety. Radiographic tumor response is centrally assessed every two 
cycles during combination therapy and every nine weeks during maintenance. 
Exploratory analysis will include the assessment of changes in circulating immune 
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P1.01-079 Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as 
First-Line Therapy for NSCLC Shirish Gadgeel1, Leena Gandhi2, Hossein Borghaei3, 
Mark A. Socinski4, Matthew A. Gubens5, James Stevenson6, Lecia V. Sequist7, 
James Chih-Hsin Yang8, Vassiliki Papadimitrakopoulou9, Jennifer Bourque10, Robert 
D. Bachman10, Joy Yang Ge10, Ellie Im10, Amita Patnaik11 1Karmanos Cancer Institute/
Wayne State University, Detroit/MI/United States of America, 2Dana-Farber Cancer Institute, 
Boston/MA/United States of America, 3Fox Chase Cancer Center, Philadelphia/PA/United 
States of America, 4University of Pittsburgh Cancer Insitute, Pittsburgh/PA/United States 
of America, 5University of California, San Francisco, San Francisco/CA/United States 
of America, 6Cleveland Clinic, Cleveland/OH/United States of America, 7Massachusetts 
General Hospital, Boston/MA/United States of America, 8National Taiwan University, Taipei/
Taiwan, 9University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 10Merck & Co., Inc., Kenilworth/NJ/United States of America, 11South Texas 
Accelerated Research Therapeutics, San Antonio/TX/United States of America
Background: Platinum doublet chemotherapy with or without bevacizumab is the 
standard first-line therapy for patients with advanced NSCLC without EGFR sensitizing 
mutations or ALK rearrangement. Pembrolizumab (MK-3475), a humanized monoclonal 
antibody against PD-1 designed to block the interaction of PD-1 with its ligands PD-L1 
and PD-L2, has shown efficacy and a manageable toxicity profile in patients with NSCLC 
treated at doses ranging from 2 mg/kg every 3 weeks to 10 mg/kg every 2 weeks. In 
45 patients with treatment-naive advanced NSCLC treated in KEYNOTE-001, single-agent 
pembrolizumab has demonstrated a response rate of 26%. Methods: KEYNOTE-021 
(ClinicalTrials.gov, NCT02039674) is an international, open-label, multi-arm, phase 1/2 
trial of pembrolizumab for advanced NSCLC. After establishing the safety and tolerability 
of pembrolizumab plus carboplatin and pemetrexed in phase 1, a randomized phase 2 
cohort comparing the efficacy of pembrolizumab plus carboplatin and pemetrexed with 
that of carboplatin and pemetrexed has been initiated. Key eligibility criteria for this cohort 
are previously untreated stage IIIB/IV nonsquamous NSCLC, no sensitizing EGFR mutation 
or ALK rearrangement, and ECOG PS 0-1. Patients will be randomly assigned in a 1:1 ratio 
to receive pembrolizumab 200 mg Q3W plus carboplatin and pemetrexed at standard 
doses or carboplatin and pemetrexed alone. Randomization will be stratified by PD-
L1 expression determined by immunohistochemistry at a central laboratory (positive 
[membranous expression in ≥1% of tumor cells] vs negative). Pembrolizumab will be 
given for 24 months or until progression, intolerable toxicity, or investigator decision. 
Pembrolizumab may be continued beyond radiographic progression in eligible patients. 
Carboplatin and pemetrexed will be given for 4 cycles followed by maintenance 
pemetrexed, alone or with pembrolizumab. Patients allocated to the chemotherapy-
alone arm who experience progression may cross over to the pembrolizumab arm 
of the study. AEs will be monitored throughout treatment and for 30 days thereafter. 
Response will be assessed every 6 weeks for the first 18 weeks, then every 9 weeks 
in year 1 and every 12 weeks in year 2. Survival follow-up will occur every 3 months 
after discontinuation of study treatment. Primary end point is progression-free survival 
(RECIST v1.1, central review); secondary end points include overall survival, objective 
response rate, and correlation of PD-L1 expression with antitumor activity. This cohort 
is currently enrolling patients. Results: Not applicable. Conclusion: Not applicable. 
Keywords: pembrolizumab
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P1.01-080 Treatment Rationale and Study Design for the Phase 3 JUNIPER 
Study: Abemaciclib vs Erlotinib in Patients with Stage IV NSCLC and KRAS 
Mutation Jonathan W. Goldman1, Peipei Shi2, Martin Reck3, Luis Paz-Ares4, Andrew 
Koustenis2 1University of California at Los Angeles Medical Center, Santa Monica/
CA/United States of America, 2Eli Lilly and Company, Indianapolis/IN/United States of 
America, 3Department of Thoracic Oncology, Lungen Clinic Grosshansdorf, Airway Research 
Center, North (Arcn), Grosshansdorf/Germany, 4Hospital Universitario Doce de Octubre, 
Madrid/Spain
Background: Abemaciclib (LY2835219) is a potent, selective small molecule inhibitor 
of CDK4/6, which has been shown to inhibit cell cycle progression by preventing the 
phosphorylation and functional inactivation of the Rb tumor-suppressor protein. Cell 
cycle dysfunction due to abnormalities in the CDK4/6 pathway occurs in NSCLC. KRAS 
mutant xenografts predict for greater sensitivity to CDK4/6 inhibitors. In a phase 1 study 
with abemaciclib (Goldman ASCO 2014), 16 patients with KRAS mutant tumors (N=29) 
had a response of stable disease (SD) or better (disease control rate [DCR]=55.2%), 
and 9 patients with KRAS wild-type tumors (N=24) had a response of SD or better 
(DCR=37.5%). Methods: JUNIPER (NCT02152631) is a randomized, phase 3 study of 
abemaciclib (200 mg orally q12hrs) + best supportive care (BSC) versus erlotinib (150 
mg orally q24hrs) + BSC in patients with stage IV NSCLC whose tumors have detectable 
KRAS mutations and who have progressed after platinum-based chemotherapy and 
one other prior therapy or who are not eligible for further chemotherapy. About 550 
patients will be randomized to abemaciclib or erlotinib 3:2 ratio using following factors: 
number of prior chemotherapy regimens (1 vs. 2), ECOG PS (0 vs. 1), gender (male vs. 
female) and KRAS mutation (G12C vs. others). This design has 80% power to detect 
overall survival (OS) hazard ratio (HR) of 0.75 (type I error 0.045) and progression-
free survival (PFS) HR of 0.67 (type I error 0.005). Erlotinib was chosen as the control 
arm, as it is the only agent indicated for both 2nd and 3rd line therapy in advanced 
NSCLC. Treatment will continue until disease progression or unacceptable toxicity 
occurs, with assessments every 28 days, followed by short-term and long-term follow-
up. Primary objectives are to compare OS and PFS of the treatment arms. Enrollment 
began December 2014. If the primary objectives are achieved, this study will provide 
results on an alternative treatment option, abemaciclib + BSC, for patients with 
cancer; 2 arms in each disease. The study design for the NSCLC portion is described 
below. Methods: Eligibility criteria include histologically/cytologically confirmed 
stage IIIB/IV NSCLC, no prior chemotherapy for metastatic disease, prior adjuvant 
chemotherapy allowed providing completion >12 months before study entry, ECOG PS 
0-1, adequate organ function, and preexisting peripheral neuropathy grade <2. NSCLC 
patients will be treated in 2 arms: 4 cycles of nab -P 100 mg/m2on days 1, 8, and 15 
plus C AUC 6 on day 1 of a 21 day cycle with nivolumab 5 mg/kg on day 15 starting 
at cycle 1 or the same nab -P/C regimen with nivolumab 5 mg/kg on day 15 starting at 
cycle 3. In both arms, nivolumab monotherapy will begin at cycle 5. Part 1 will assess 
the dose-limiting toxicities (DLTs) of the nivolumab dose with nab -P/C (≈ 6 patients/arm). 
If deemed safe, the treatment arms may be expanded using the recommended part 
2 dose with an additional ≈ 14 patients/arm (total of 20 nivolumab-treated patients/
arm) to further assess safety and tolerability as well as anti-tumor activity. Patients will 
be allowed to continue nivolumab treatment beyond RECIST 1.1 disease progression 
(physician discretion). ClinicalTrials.gov number NCT02309177.
 . 
Results: Not applicable Conclusion: Not applicable Keywords: nab-paclitaxel, NSCLC, 
Nivolumab, carboplatin
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P1.01-078 Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1-Strong-
Positive NSCLC Julie R. Brahmer1, Maya Gottfried2, Xiaoyun Li3, Margaret Smith3, 
Reshma A. Rangwala3, Mary E. O’Brien4 1The Sidney Kimmel Comprehensive Cancer Center 
at Johns Hopkins, Baltimore/MD/United States of America, 2Meir Medical Center, Kfar-Saba/
Israel, 3Merck & Co., Inc., Kenilworth/NJ/United States of America, 4The Royal Marsden 
Hospital, London/United Kingdom
Background: Platinum-doublet chemotherapy with or without maintenance 
therapy is the standard-of-care first-line therapy for patients with NSCLC that do not 
harbor EGFR sensitizing mutations or ALK translocations. Most patients experience 
disease progression despite treatment with chemotherapy, with median overall survival 
<12 months. Pembrolizumab (MK-3475), a humanized monoclonal antibody against PD-1, 
has demonstrated a manageable safety profile and robust antitumor activity as first-
line therapy in patients with advanced NSCLC enrolled in the phase 1b KEYNOTE-001 
study. Improved efficacy was observed in patients whose tumors strongly expressed 
PD-L1 (ie, showed membranous staining in ≥50% of tumor cells). The international, 
open-label, phase 3 KEYNOTE-024 trial (ClinicalTrials.gov identifier NCT02142738) is 
designed to assess the efficacy and safety of pembrolizumab with those of standard-
of-care platinum-doublet chemotherapy in patients with treatment-naive metastatic 
NSCLC and PD-L1 expression in ≥50% of tumor cells. Methods: Patients aged ≥18 
years with previously untreated advanced NSCLC without EGFR sensitizing mutations 
or ALK translocations, membranous PD-L1 expression in ≥50% of tumor cells, 
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1, no active 
autoimmune disease, or history of interstitial lung disease are eligible. PD-L1 expression 
is determined by immunohistochemistry in newly collected tumor samples at a central 
laboratory. Patients are randomly assigned in a 1:1 ratio to receive a 200-mg fixed dose 
of intravenous pembrolizumab every 3 weeks (Q3W) or investigator’s choice of up to 6 
cycles of gemcitabine 1250 mg/m2 plus cisplatin 75 mg/m2, gemcitabine 1250 mg/
m2 plus carboplatin AUC 5 or 6, pemetrexed 500 mg/m2 plus carboplatin AUC 5 or 6, 
pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2, or paclitaxel 200 mg/m2 plus carboplatin 
AUC 5 or 6; patients with nonsquamous histology may receive pemetrexed 500 mg/
m2 Q3W maintenance therapy. Randomization is stratified by ECOG PS (0 vs 1), histology 
(squamous vs nonsquamous), and region (East Asia vs non-East Asia). Pembrolizumab 
will be given for up to 35 cycles or until disease progression, intolerable toxicity, or 
patient withdrawal. Eligible patients may remain on pembrolizumab therapy after initial 
radiographic disease progression. Patients who complete 35 cycles of pembrolizumab 
or who stop treatment after achieving complete response may be eligible for 1 year 
of pembrolizumab retreatment. Crossover to pembrolizumab is permitted for patients 
who progress on chemotherapy. Tumor imaging is performed every 9 weeks; response 
is assessed per RECIST v1.1 by independent central review and by modified RECIST by 
investigator review. Adverse events will be collected throughout the study and for 30 days 
(90 days for serious adverse events) thereafter; all toxicities will be graded according 
to NCI CTCAE v4.0. The primary end point is progression-free survival per RECIST 1.1 by 
central review; secondary end points are overall response rate per RECIST 1.1, overall 
survival, and safety. Enrollment is ongoing and will continue until approximately 300 
patients are assigned to treatment. Results: Not applicable. Conclusion: Not applicable. 
Keywords: pembrolizumab
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within the setting of PD. For both sub-studies, an interim analysis for OS (and also PFS for 
Sub-study B) will be performed. Eligible patients include patients (PS of 0-1) with locally 
advanced or metastatic NSCLC, who have received at least 2 prior treatment regimens 
including 1 platinum-based chemotherapy. Patients with brain metastases or spinal cord 
compression are excluded unless asymptomatic, treated and stable off steroids. Patients 
with known EGFR activating mutations or ALK rearrangements are not eligible, nor patients 
previously exposed to any anti-PD-1 or anti-PD-L1 antibody. The primary objective is to 
assess PFS (per RECIST 1.1 as assessed by the Blinded Independent Central Review) 
and OS of M (PD-L1-positive) and M+T (PD-L1-negative), compared with SoC, in sub-
study A and B, respectively. Secondary objectives include proportion of patients alive 
at 12 months, objective response rate, duration of response, PFS at 6 and 12 months, 
safety, tolerability, pharmacokinetics, immunogenicity and health-related QoL. Tumor 
assessments are performed every 8 weeks (first 48 weeks) then every 12 weeks. A 
confirmatory scan is required following the initial demonstration of PD. Recruitment in the 
study is ongoing since January 2015. Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, MEDI4736, tremelimumab, PD-L1
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P1.01-083 Phase 2 Study of MEDI4736 in Patients with PD-L1+ Locally 
Advanced or Metastatic Stage IIIb-IV NSCLC Treated with ≥ 2 Prior Regimens 
(ATLANTIC) Marina C. Garassino1, Fabrice Barlesi2, Jamie Chaft3, Kelvin Shi4, Ramy 
Ibrahim4, Paul Stockman5, Marc Ballas4, Naiyer A. Rizvi6 1Fondazione Irccs Istituto 
Nazionale Dei Tumori, Milano/Italy, 2Aix Marseille University-Assistance Publique Hôpitaux de 
Marseille, Marseille/France, 3Memorial Sloan-Kettering Cancer Center, New York/NY/United 
States of America, 4Astrazeneca, Gaithersburg/MD/United States of America, 5Astrazeneca, 
Macclesfield/United Kingdom, 6Columbia University Medical Center, New York/NY/United 
States of America
Background: The role of third and further line therapies in advanced NSCLC is 
contentious both for patients harboring EGFR mutations and ALK translocations and for 
patients without activating mutations. Recent studies have demonstrated that activation 
of the EGFR pathway induces PD-L1 expression, thereby facilitating evasion of the host’s 
anti-tumor immune response as a potential mechanism of targeted therapy resistance. 
This evidence suggests a promising and inadequately explored role of immunotherapy 
in this particular setting of patients in whom only targeted agents were considered of 
unique interest. For the ~85% of patients with non-squamous NSCLC without ALK/EGFR 
aberrations, single agent chemotherapy represents the only option with its associated 
poor results and chemotherapy-related toxicities. Many cancers co-opt the programmed 
cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway to evade immune-
mediated tumor rejection. Encouraging clinical activity against several tumor types 
has been seen for anti-PD-L1/PD-1 monoclonal antibodies (mAbs), including the proven 
benefit of nivolumab in advanced refractory squamous NSCLC. MEDI4736 is a human 
IgG1 mAb that blocks PD-L1 binding to PD-1 and CD-80 with high affinity and selectivity. 
Evidence of clinical activity for MEDI4736 in NSCLC has been observed in a Phase 1 
study (Study 1108, NCT01693562), with initial data indicating that PD-L1 expression 
is associated with a higher objective response rate (ORR). A clinical development 
program of MEDI4736 in NSCLC is underway. Here we describe the ATLANTIC study 
(NCT02087423). Methods: In this Phase 2, open-label, international, multicenter, non-
comparative study, the efficacy and safety of MEDI4736 (10 mg/kg IV every 2 weeks 
for up to 12 months) is being assessed in patients with PD-L1+ locally advanced or 
metastatic NSCLC (Stage IIIb–IV). The present study design includes three patient 
cohorts: 1) Cohort 1 (n=≥94): patients with EGFR mutations or ALK alterations; 2) 
Cohort 2 (n=≥94): patients with wild-type EGFR and ALK; 3) Cohort 3 (n=≥94): patients 
with wild-type EGFR/ALK and ≥90% of tumor cells PD-L1+. Cohorts 1 and 2 include 
patients whose tumor tissue samples have ≥25% of tumor cells with membrane staining 
for PD-L1. The PD-L1 status was tested according to the VENTANA proprietary assay. 
At the time the study was conceived, patients were initially included regardless of PD-L1 
status. However, based on the observation that PD-L1 expression may enrich response 
to MEDI4736 (Study 1108), the trial was amended accordingly to include PD-L1+ tumors 
only. Eligible patients must have an ECOG Performance Status of 0 or 1, and have received 
≥2 prior systemic treatment regimens, including one platinum-based chemotherapy and 
a tyrosine kinase inhibitor if EGFR or ALK positive. The primary outcome measure is ORR 
(RECIST v1.1), based on independent central review. Secondary outcome measures will 
further assess efficacy (including disease control rate, duration of response, progression-
free survival and overall survival), safety (CTCAE v4.03), tolerability, pharmacokinetics, 
and immunogenicity of MEDI4736. Patients will be recruited at ~100–150 sites across 
North America, Asia, and Europe. Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, MEDI4736, PD-L1, Immunotherapy
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P1.01-084 A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-
Negative, Advanced NSCLC Progressing on an EGFR TKI Stephen V. Liu1, Charu 
Aggarawal2, Corey Carter3, David E. Gerber4, Barbara J. Gitlitz5, Leora Horn6, Benjamin 
J. Solomon7, Thomas E. Stinchcombe8, Liza Villaruz9, Howard West10, Stew Kroll11, 
Tillman Pearce11, Ross Camidge12 1Lombardi Cancer Center, Georgetown University 
Hospital Cancer Center, Washington/DC/United States of America, 2Abramson Cancer 
Center, Univ of Penn Hospital, Philadelphia/PA/United States of America, 3Oncology, Walter 
Reed National Military Med Ctr, Bethesda/MD/United States of America, 4UT Southwestern, 
Dallas/TX/United States of America, 5Oncology, Usc Norris Comprehensive Cancer 
Center, Los Angeles/CA/United States of America, 6Vanderbilt-Ingram Cancer Center, 
Nashville/TN/United States of America, 7Peter Maccallum Cancer Centre, Melbourne/
ACT/Australia, 8Oncology, Unc Lineberger Cancer Center, Chapel Hill/NC/United States of 
NSCLC whose tumors have detectable KRAS mutations, currently a patient population 
with few treatment options. Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, CDK4, CDK6, KRAS
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P1.01-081 Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small 
Cell Lung Cancer: A 2-Part Phase 3 Study (HER3-Lung) Wallace L. Akerley1, 
Joachim Von Pawel2, Berta Moritz3, Ling Zhang4, Susan Macintyre4, Wenqin Feng4, 
Dale Shuster4, Shuquan Chen4, Catherine Copigneaux4, Luis Paz Ares5 1Huntsman 
Cancer Institute, Salt Lake City/UT/United States of America, 2Asklepios Fachkliniken 
München-Gauting, Gauting/Germany, 3Cesar Central European Society for Anticancer Drug 
Research, Vienna/Austria, 4Daiichi Sankyo Pharma Development, Edison/NJ/United States of 
America, 5University Hospital Virgen Del Rocío, Seville/Spain
Background: Patritumab (P) is a fully human monoclonal antibody directed against 
human epidermal growth factor receptor 3 (HER3) that blocks activation by the ligand, 
heregulin (HRG), and induces receptor internalization. A Phase 2 study (NCT01211483) 
demonstrated that addition of P to erlotinib (E) increased progression-free survival 
(PFS) for the subgroup of advanced non–small cell lung cancer (NSCLC) patients with 
high HRG mRNA expression (HRG-high); a generally similar safety profile was seen 
with P+E compared with E monotherapy. To confirm these results, P+E vs. E is being 
investigated in a 2-part Phase 3 study designed to further evaluate the predictiveness 
of the HRG biomarker in patients with advanced NSCLC (https://clinicaltrials.gov/
ct2/show/NCT02134015). Methods: HER3-Lung is randomized, placebo-controlled, 
double-blind, 2-part (A and B), Phase 3 study. Part A will enroll subjects with any HRG 
expression (limited to approximately one-third of subjects with HRG-low expression) to 
confirm efficacy of P+E vs. E in HRG-high disease and to possibly refine the cut-off level 
of HRG expression. The primary endpoint of Part A is PFS and secondary endpoints are 
objective response rate, overall survival, and safety. Part B will enroll subjects with HRG-
high disease, defined as having a cut-off based upon the results of Part A and previous 
Phase 2 results. Part B is designed to independently provide pivotal confirmation of 
the efficacy and safety of P+E vs. E in the biomarker-defined population (n=600). The 
primary endpoint of Part B is overall survival. For both Part A and Part B, subjects must be 
aged ≥20 years with advanced NSCLC previously treated with 1 or 2 systemic therapies, 
and if adenocarcinoma histology, wild-type for EGFR and ALK. Tissue assessable for 
HRG expression must be available from archival or recently collected tumor sample. For 
Part A, subjects will be stratified by histology subtype, Eastern Cooperative Oncology 
Group performance status (0, 1) and best response to the most recent systemic therapy. 
Within each stratum, patients will be randomized 1:1 to P (18 mg/kg intravenous loading 
dose, then 9 mg/kg maintenance dose every 3 weeks) + E (150 mg/day orally) or 
placebo + E. Patients will be treated until disease progression, unacceptable toxicity, or 
withdrawal of consent. Results: Recruitment commenced in April 2014, and enrollment 
of Part A is ongoing. Investigational sites are located in Europe, United States and 
Canada. Conclusion: This study employs an innovative design to confirm efficacy in 
HRG-selected subjects while evaluating the expression cut-off before pivotal confirmation 
of efficacy and safety in the HRG-high subpopulation of EGFR wild-type NSCLC. 
Keywords: Advanced non–small cell lung cancer, Heregulin biomarker, Phase 3 study, 
Patritumab
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P1.01-082 A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± 
Tremelimumab (T), vs Standard of Care (SoC), in Patients with Advanced 
NSCLC (ARCTIC) David Planchard1, Mikhail Shtivelband2, Benjamin P. Levy3, Maen 
Hussein4, Kelvin Shi5, Ramy Ibrahim5, Marc Ballas5, Jean-Charles Soria1 
1Gustave Roussy, Villejuif/France, 2Ironwood Cancer and Research Center, Chandler/
AZ/United States of America, 3Mount Sinai Health Systems, New York/NY/United 
States of America, 4Florida Cancer Specialists, St. Petersburg/FL/United States of 
America, 5Astrazeneca, Gaithersburg/MD/United States of America
Background: M is a human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) 
binding to programmed cell death-1 and CD-80 with high affinity and selectivity, and T is 
a selective human IgG2 mAb inhibitor of cytotoxic T-lymphocyte antigen-4 (CTLA-4). Both 
PD-L1 and CTLA-4 are regulators, or checkpoints, of T-cell activation. PD-L1 expression 
may be associated with greater clinical benefit of anti-PD-1/PD-L1 agents. Thus, the 
subset of patients with PD-L1-negative tumors represent a cohort with limited therapeutic 
options, and may benefit from the combination of M+T. Preclinical data, including mouse 
models of transplantable solid tumors, suggest that targeting both pathways may have 
synergistic antitumor activity. Emerging pharmacokinetics, pharmacodynamics, safety 
and efficacy data from a phase Ib study of M+T in advanced NSCLC (NCT02000947) 
has determined the appropriate dose for this combination. Methods: This randomized, 
open label, multi-center, phase III study (NCT02352948) is designed to evaluate the 
efficacy and safety of M (10mg/kg once every 2 weeks [Q2W] for up to 12 months) 
vs SoC (gemcitabine 1000 mg/m2 iv Days 1, 8, and 15, vinorelbine 30 mg/m2 iv on 
Days 1, 8, 15 and 22 or erlotinib 150 mg once daily, on a 4-weekly schedule until PD at 
the investigator’s discretion) in NSCLC patients with PD-L1-positive tumors (based on 
archival tumor sample or recent biopsy) (Sub-study A), and the combination of M+T (M 
20mg/kg + T 1mg/kg Q4W for 12 weeks then M alone 10mg/kg Q2W for 34 weeks) vs 
M or T (10mg/kg Q4W for 24 weeks then Q12W for 24 weeks) vs SoC in NSCLC patients 
with PD-L1-negative tumors (Sub-study B). PD-L1-positive is defined as ≥25% of tumor 
cells with membrane staining based on central assessment. Approximately 300 patients 
will be randomized 1:1 in Sub-study A and approximately 600 patients in a 3:2:2:1 ratio 
(M+T or SoC or M or T) in Sub-study B. Retreatment with immune-therapy is allowed 
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and/or additional immunological biomarkers will also be assessed. Patients may 
continue treatment until unacceptable toxicity, disease progression, discontinuation at 
the discretion of the investigator, or consent withdrawal. MTD and/or RDE estimation will 
be based on the probability of dose-limiting toxicities using an adaptive Bayesian logistic 
regression model guided by the escalation with overdose control principle and an overall 
assessment of safety and tolerability data. Tumor responses will be assessed per RECIST 
v1.1 by investigator assessment. Results: Not available Conclusion: Not available 
Keywords: Ceritinib, Nivolumab, ALK, NSCLC
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-17:00
P1.01-086 TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib 
vs Chemotherapy in NSCLC James Chih-Hsin Yang1, Sanjay Popat2, Lyudmila 
Bazhenova3, Collin M. Blakely4, Robert Dichman5, Enriqueta Felip6, Frank Griesinger7, 
Harry J.M. Groen8, Sarada Gurubhagavatula9, Joseph W. Leach10, Silvia Novello11, 
Maurice Perol12, Ravindranath Patel13, Karen Reckamp14, Panos Georgiou15, Emiko 
Miyamoto16, Jeffrey Isaacson17, Heather A. Wakelee18 1National Taiwan University, 
Taipei City/Taiwan, 2Royal Marsden Hospital, London/United Kingdom, 3Internal Medicine, 
Division of Hematology-Oncology, University of California San Diego, La Jolla/United States 
of America, 4Medicine, UCSF, San Francisco/United States of America, 5Central Coast 
Medical Oncology Corporation, Santa Maria/CA/United States of America, 6Vall D’Hebron 
University Hospital and Vall D’Hebron Institute of Oncology (Vhio), Barcelona/Spain, 7Pius-
Hospital Oldenburg, Oldenburg/Germany, 8Department of Pulmonary Diseases, University 
Medical Center Groningen, Groningen/Netherlands, 9Regional Cancer Care Associates, 
Morristown/NJ/United States of America, 10Virginia Piper Cancer Institute, Minneapolis/
MN/United States of America, 11Department of Oncology, University of Turin, Aou San 
Luigi, Orbassano/Italy, 12Department of Medical Oncology, Léon Bérard Cancer Center, 
Lyon/France, 13Comprehensive Blood and Cancer Center, Bakersfield/CA/United States of 
America, 14Medical Oncology and Therapeutics Research, City of Hope, Duarte/CA/United 
States of America, 15Clovis Oncology, Chelmsford/United Kingdom, 16Clovis Oncology, San 
Francisco/CA/United States of America, 17Clovis Oncology, Boulder/CO/United States of 
America, 18Department of Medicine, Division of Oncology, Stanford University, Stanford/CA/
United States of America
Background: Rociletinib (CO-1686) is a novel, oral, irreversible tyrosine kinase inhibitor 
for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-
small cell lung cancer (NSCLC) that has demonstrated efficacy against the activating 
mutations (L858R and Del19) and the dominant acquired resistance mutation (T790M), 
while sparing wild-type EGFR. TIGER-X, a Phase I/II dose-ranging trial, has provided 
evidence that rociletinib is associated with durable response and is well tolerated in 
patients with NSCLC and positive T790M status following progression on a TKI.1 Efficacy 
has also been noted for patients with T790M negative status in TIGER-X.2 TIGER-3 is 
designed to investigate single agent rociletinib vs chemotherapy in patients who have 
failed EGFR therapy and platinum-based doublet chemotherapy, which is a setting of 
acquired resistance and high unmet need for targeted therapeutic options. TIGER-3 will 
evaluate patients with T790M positive and negative status based on tumor biopsies 
and plasma, and biomarkers of response and/or resistance. Methods: Patients with 
histologically or cytologically confirmed metastatic or unresectable locally advanced 
NSCLC, with radiological progression on the most recent therapy will be enrolled in this 
phase 3, randomized, open-label study (NCT02322281). Patients must have documented 
evidence of a tumor with ≥1 EGFR activating mutations excluding exon 20 insertion, 
and prior treatment with an EGFR TKI and platinum-containing doublet chemotherapy. 
Patients will be randomized 1:1 to receive rociletinib twice daily (500 mg) or single 
agent cytotoxic chemotherapy (investigator choice specified before randomization) until 
disease progression according to RECIST 1.1. Patients will be stratified by presence or 
absence of brain metastases, ECOG performance status (0 vs 1), and race (Asian vs non-
Asian). The primary endpoint is progression-free survival (PFS). Secondary endpoints 
include safety, objective response rates, duration of response, disease control rate, 
and overall survival. Kaplan-Meier methodology will assess time to event variables. The 
stratified log-rank and the hazard ratio will be used for comparing PFS distributions. Serial 
assessment of safety will be carried out based on standard adverse event reporting. 
Planned enrolment is 600 patients; enrolment has been open since March 2015.
• Sequist LV J Clin Oncol. 2014
• Soria J-C EORTC-NCI-AACR 2014
Results: Not applicable Conclusion: Not applicable Keywords: rociletinib, EGFR, 
T790M, NSCLC
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P1.01-087 A Phase I Study of Chloroquine with Carboplatin and Gemcitabine 
in Advanced Solid Tumors and NSCLC Nagla Abdel Karim1, El Mustapha Bahassi2, 
Ahmed Khaled1, Mahmoud Shehata2, Trisha Wise-Draper2, Sue O’Gara2, John Morris2 
1Internal Medicine/Division of Hematology/Oncology, The University of Cincinnati, Ohio/
OH/United States of America, 2Internal Medicine/Division of Hematology/Oncology, The 
University of Cincinnati, Ohio/United States of America
Background: Autophagy is the catabolic degradation of cellular constituents that can 
promote cancer cell survival by maintaining cellular energy levels during periods of stress, 
including exposure to radiation or chemotherapy. The antimalarial, chloroquine (CQ), has 
received attention as an inhibitor of autophagy. The lysosomotropic properties of CQ 
are probably responsible for many of its biological effects. Manipulation of autophagy 
is a potentially exciting area for the development of new cancer treatments. Recently, 
accumulating evidence suggest that CQ can effectively sensitize cancer cells to the cell-
America, 9Oncology, Univ of Pittsburgh School of Medicine, Pittsburgh/PA/United States 
of America, 10Swedish Cancer Institute, Seattle/WA/United States of America, 11Clinical, 
Threshold Pharmaceutical, Inc., South San Francisco/CA/United States of America, 12Medical 
Oncology, University of Colorado, Denver/CO/United States of America
Background: While EGFR-TKI therapy is initially effective for patients with EGFR-mutant 
NSCLC, eventual resistance to EFGR-TKI therapy is expected. For patients with nonT790M 
resistance to EGFR-TKIs, the optimal treatment is unclear. Sensitizing mutations in 
EGFR are often heterozygous with co-expression of both wild type (WT) and mutant 
EGFR. Tumor hypoxia upregulates WT EGFR signaling through several HIF-dependent 
mechanisms. Clinical studies indicate that EGFR-mutant NSCLC with WT EGFR present 
is associated with a poorer response to EGFR-TKIs. NSCLC is known to be a hypoxic 
tumor; thus, hypoxia-induced activation of WT EGFR signaling may be a mechanism of 
EGFR-TKI resistance. TH-4000 is a clinical-stage hypoxia-activated prodrug that releases 
an irreversible pan-ErbB TKI targeting WT EGFR, mutant EGFR and HER2. Hypoxic tumor 
targeting using TH-4000 may allow a greater therapeutic index with greater intratumoral 
TKI levels and less dose-limiting systemic toxicity seen with current EGFR-TKIs. In 
xenograft models of EGFR-mutant NSCLC that coexpress WT EGFR, TH-4000 reverses 
resistance to current EGFR-TKIs, and is effective as a singleagent. A Phase 1 study was 
conducted in patients with advanced solid tumors; the maximum tolerated dose (MTD) 
of TH-4000 administered as a 1-hour weekly intravenous (IV) infusion was established at 
150 mg/m2. The most common treatment-related adverse events were dose-dependent 
and included rash, QT prolongation, nausea, infusion reaction, vomiting, diarrhea and 
fatigue. Methods: A multicenter Phase 2 trial was initiated to evaluate the safety and 
activity of TH-4000 as a singleagent in patients with EGFRmutant, T790M-negative 
Stage IV NSCLC progressing on an EGFR TKI. Hypoxia PET imaging with [18F]-HX4 and 
molecular analyses of tumor tissue and plasma are incorporated in the study design to 
identify potential predictors of response to treatment. The primary endpoint is response 
rate. Secondary endpoints include progression-free survival, duration of response, 
overall survival, pharmacokinetics and safety, as well as evaluation of imaging, serum, 
and tissue biomarkers that may be associated with tumor response. Up to 37 patients 
will be enrolled with recurrent EGFR-mutant Stage IV NSCLC which has progressed 
while on treatment with EGFR-TKI, absence of EGFR T790M mutation, measureable 
disease according to RECIST 1.1, and ECOG performance status 0-1. Eligible patients 
must also have adequate pre-therapy tumor tissue available to enable tumor biomarker 
assessment. TH-4000 (150 mg/m2) is administered weekly by IV infusion over 60 
minutes. The study design incorporates a Simon two-stage design (alpha = 0.10; beta 
= 0.10). Recruitment is ongoing. Results: Not applicable Conclusion: Not applicable 
Keywords: wild-type EGFR, tumor microenvironment, tyrosine kinase inhibitor, T790M-
negative
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P1.01-085 A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in 
Patients with ALK+ NSCLC Alice Shaw1, Herbert Loong2, Daniel S.-W. Tan3, Kerry 
Griscti4, Haitao Gao4, Friedrich Finckenstein5, Jeffrey Scott4, Johan Vansteenkiste6 
1Massachusetts General Hospital, Boston/United States of America, 2The Chinese University 
of Hong Kong, Hong Kong/Hong Kong, 3National Cancer Centre, Singapore, Singapore/
Singapore, 4Novartis Pharma, East Hanover/NJ/United States of America, 5Bristol-Myers 
Squibb Co, Princeton/NJ/United States of America, 6University Hospital Ku Leuven, Leuven/
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Background: Ceritinib is a novel, highly selective, orally active and potent tyrosine kinase 
inhibitor of anaplastic lymphoma kinase (ALK), and has demonstrated clinical efficacy in 
ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) (ASCEND-1; NCT01283516). 
Nivolumab is a fully human, immunoglobulin G4 programmed cell death protein-1 (PD-
1) immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 
ligands (PD-L1 and PD-L2), thereby promoting antitumor T-cell function, and is approved 
by the United States Food and Drug Administration for treatment of squamous NSCLC 
patients with progression following platinum doublet (Checkmate-017; NCT01642004). 
Nivolumab in combination with chemotherapy, other immune modulators and molecular 
targeted therapy has shown promising preliminary results in Stage IIIB/IV NSCLC patients 
(CheckMate-012; NCT01454102). The demonstrated efficacy of ceritinib in ALK+ NSCLC, 
and nivolumab in Stage IIIB/IV NSCLC, provides a rationale to study ceritinib in combination 
with nivolumab in patients with ALK+ NSCLC. Methods: In this prospective, open-label, 
multicenter phase 1B study (CLDK378A2120C; NCT02393625), the primary objectives 
are to determine the maximum tolerated dose (MTD) and/or recommended dose for 
expansion (RDE) and to evaluate the preliminary efficacy, based on overall response 
rate of ceritinib in combination with a fixed dose of nivolumab in adult stage IIIB/IV ALK+ 
NSCLC patients. Secondary objectives include evaluating duration of response, disease 
control rate, time to response, progression-free survival, overall intracranial response 
rate for patients with baseline measurable brain metastases, overall survival, and safety 
profile. In dose escalation phase, patients may have had ≥ 1 prior ALK inhibitors (except 
ceritinib) or prior chemotherapy regimens. In expansion phase, there will be 2 arms: 1) 
ALK-inhibitor pre-treated patients with 0 or 1 prior chemotherapies; 2) ALK-inhibitor naïve 
patients with 0 or 1 prior chemotherapies. Other key inclusion criteria are: presence 
of ≥ 1 measurable lesion as defined by Response Evaluation Criteria In Solid Tumors 
(RECIST) 1.1, and a World Health Organization performance status 0-1. Patients with 
asymptomatic, untreated brain metastases at baseline are allowed. Dose-escalation 
phase will consist of successive cohorts of patients (3 to 6) receiving increasing doses of 
ceritinib (starting dose: 450 mg/d with a low-fat meal; 28-day cycles) plus nivolumab (3 
mg/kg Q2W) and will enroll a minimum of 12 patients. In expansion phase, approximately 
60 patients will be allocated to arms 1 and 2 (30 in each arm) and treated with ceritinib 
at MTD/RDE plus nivolumab (3 mg/kg Q2W). Material required for central assessment 
of ALK rearrangement must be either archival tissue or, preferably, a fresh biopsy. Apart 
from ALK rearrangement, potential predictive markers of PD-L1 and PD-L2 expression 
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predictors after complete resection in patients with pathological stage 1 NSCLC were 
age (over 75 years), lymph/vascular invasion, stage 1B and high serum concentration 
of SLX. Furthermore, SLX is potentially useful to predict distant metastasis. Adjuvant 
chemotherapy might be considered in patients who are positive for these predictive factors. 
Keywords: stage1 NSCLC, recurrence, SLX, predictive factor
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P1.02-002 Interstitial Lung Disease (ILD) Associated Cancer Genesis Is Noble 
Predictor for Patients with Non-Small Cell Lung Cancer and ILD Ryo Miyata, 
Mitsugu Omasa, Ryo Fujimoto, Hiroyuki Ishikawa, Yosuke Otake, Minoru Aoki 
Department of Thoracic Surgery, Nishi-Kobe Medical Center, Kobe, Hyogo/Japan
Background: Interstitial lung diseases (ILDs) are at increased risk of developing lung 
cancer. The purpose of this study is to evaluate the survival and predictors of survival 
after surgical resection in patients with non-small cell lung cancer (NSCLC) and 
ILDs. Methods: We retrospectively analyzed data from 55 patients with NSCLC with a 
clinical diagnosis of ILD who underwent pulmonary resection between 1994 and 2010 at 
our institution. Kaplan-Meier analysis and Cox proportional hazards regression analysis 
were used. Results: Male patients (94.5%) and smokers (98.2%) were in majority. The 
overall 5-year survival was 15.4%. The 5-year survivals were 9.1% and 31.6% for patients 
with a predicted percent vital capacity of 80% or less and a predicted percent vital 
capacity greater than 80%, respectively (log-rank test, P = .036). The 5-year survival 
of patients in which NSCLC was developed in the ILD positive background was 15.4%. 
On the other hand, the 5-year survival of patients in which NSCLC was developed in the 
ILD negative background was 47.5% (P = .033). Surgical procedures had an association 
with survival (P = .051), the 5-year survival were 0% and 31.3% in the wedge resection 
and segmentectomy / lobectomy groups, respectively. Multivariable analysis revealed 
that lower predicted percent vital capacity, ILD-associated cancer genesis, and non-
anatomical pulmonary resection were independent poor prognostic factor for survival. 
Carbon monoxide diffusing capacity and Krebs von den Lungen-6 (KL-6) were not 
included in the analysis because of missing data more than 5%. Conclusion: Anatomical 
resection is recommended for patients with NSCLC and ILD with predicted percent 
vital capacity greater than 80%. ILD-associated cancer genesis is noble predictor for 
patients with a clinical diagnosis of ILD who underwent pulmonary resection for NSCLC. 
Keywords: prognostic factor, lung cancer, interstitial lung diease, cancer genesis
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P1.02-003 Accuracy of Clinical and Pathologic Staging of Non-Small Cell 
Lung Cancer in a Residency Education Program Mariam J. Almarashda, Stephen 
A. Deppen, Joe B. Putnam, Jr. Thoracic Surgery, Vanderbilt University Medical Center, 
Nashville/TN/United States of America
Background: Accurate non-small cell lung cancer (NSCLC) clinical staging (CS) guides 
treatment options and prognosis. In addition, clinical and quality improvement registries 
incorporate CS and pathological staging (PS) for patients undergoing pulmonary 
resection. In residency education programs, CS and PS for NSCLC patients are essential 
educational components of thoracic surgical care. To determine the accuracy of CS by 
our house staff, we prospectively collected CS of patients who were treated by lobectomy 
(traditionally entered by our house staff) and compared those results to CS and PS in our 
cancer registry for accuracy and concordance. Methods: We conducted a retrospective 
analysis of prospectively collected clinical data between January 2005 and December 
2014. Only patients with NSCLC who underwent anatomic pulmonary resection were 
included. We compared accuracy and Kappa score of preoperative CS entered by our 
house staff with the CS and PS obtained by our institutional cancer registry. Results: A 
total of 915 patients underwent pulmonary resection operation for known or suspected 
lung cancer. 582 patients underwent lobectomy, segmentectomy, or sleeve resection for 
non-small cell lung cancer. The mean age at time of surgery was 65 years (95%CI: 64, 66), 
and 316 (56%) were women. Histology included adenocarcinoma, 292 (50%); squamous, 
181, (31%); carcinoid, 40, (7%); large cell, 36, (6%); and others, NOS 30 (5%). CS by 
house staff compared to registry CS had 49% agreement and (expected agreement at 
random was 27% given 7 possible staging choices; Kappa score of interrater reliability of 
the 7 possible staging levels was 0.31). Agreement was significantly better than random 
(p<0.001) but Kappa score was relatively low. CS by house staff was compared to final 
PS had 52% agreement of an expected 28% and a Kappa score of 0.34. Final pathological 
stage by the author [MJA] or pathologist compared to cancer registry final pathology had 
87% agreement and Kappa 0.83. House staff clinical nodal staging accuracy compared 
to pathological nodal staging had a higher absolute agreement (73%) than tumor staging 
(67%); however, due to fewer levels of nodal disease, higher agreement was expected 
in nodal staging. Adjusted level of agreement measured by Kappa score was lower in 
nodal staging, (0.14) compared to moderate agreement in tumor staging, Kappa 0.48. 
Registry CS absolute agreement for lymph nodes (66%) and tumor (63%) compared 
to PS was slightly lower than that of house staff (73% nodal and 67% tumor staging). 
This was largely due to the greater number of unstaged cancers (n=105) found in the 
registry. Conclusion: The cancer registry generally under stages the patient’s CS 
compared to the PS. In addition, CS by trainees was only accurate in 52% of patients. 
The clinical nodal status had the lowest agreement (42%) after adjusting for the number 
of choices available by both our house staff and the cancer registry. Additional attention 
in trainee education, especially in the area of clinical nodal staging is necessary for 
improving CS and subsequent clinical decision making for our patients with NSCLC. 
Keywords: NSCLC, Accuracy, Staging, Education
killing effects of ionizing radiation and chemotherapeutic agents, thus suggesting its use 
as a sensitizer for conventional therapies. Hypothesis: CQ may sensitize chemotherapy-
resistant tumor cells by inhibiting autophagy and enhance tumor response and survival 
of patients with solid tumors. Patients with non small cell lung cancer (NSCLC) squamous 
cell carcinoma subtype will be enrolled and followed for possible improved outcome 
with the addition of choloroquine to platinum doublet especially agents as Bevacuzimab 
can not be added to their standard doublet therapy. Patients with other advanced 
solid tumors will be eligible as long as carboplatin and Gemcitabine are considered an 
acceptable therapeutic option. 
Methods:
Dose Level Patients(N) CQ mg/dl D-7-D21
Carboplatin 
AUC D1
Gemcitabine 
mg/m2 D1 
&D8
1 3-6 50 5 1,000
2 3-6 100 5 1,000
3 3-6 150 5 1,000
4 3-6 200 5 1,000
Expansion 
cohort 10-12 MTD 5 1,000
 
Primary Objectives: The aim of this phase I study is to determine the adverse events (AE) 
and maximum tolerated dose (MTD) associated with adding chloroquine (CQ) to carboplatin 
and gemcitabine (CG) in patients with previously treated advanced solid tumors. 
Secondary Objectives: To estimate overall response rate (ORR), progression-free survival 
(PFS), and overall survival (OS); to determine the pharmacokinetics of CQ in combination 
with CG, and its effect on tumor burden by measurement of circulating tumor cells (CTCs). 
Methods: A single institution phase I dose-escalation study. Patients with advanced solid 
malignancies with no available standard of care treatment options, and ECOG performance 
status 0-2 are eligible. Sequential cohorts of 3-6 patients will be treated with escalating daily 
doses of oral CQ in addition to carboplatin and gemcitabine (Table 1). The study is ongoing 
and patient accrual is in the first cohort. Results: Not applicable Conclusion: Not applicable 
Keywords: phase I Clinical trial in progress, Carboplatin and Gemcitabine, Choloroquine, 
Autophagy
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P1.02-001 Predictive Factors of Distant and Local Recurrence in Patients with 
Surgically Resected Stage 1 NSCLC Shinjiro Mizuguchi, Nobuhiro Izumi, Hiroko Oka-
Yamamoto, Satoshi Okada, Michihito Toda, Kantaro Hara, Noritoshi Nishiyama Osaka 
City University, Osaka/Japan
Background: Surgical treatment is the most efficient therapy for early non-small lung 
cancer (NSCLC). However, after radical surgery many patients relapse or progress to 
systemic disease, even in stage I NSCLC. The objective of this study was to examine the 
recurrence predictors, especially focused on location of recurrence (local or distant), in 
patients who underwent potentially curative resection for stage 1NSCLC. Methods: The 
study included 371 consecutive patients who underwent lobectomy with radical 
mediastinum lymph node dissection from 1998 to 2011 without any preoperative 
therapy. For analysis of recurrence, 342 patients were enrolled after excluding patients 
with non-cancer related death or loss of their follow-up within 3 years of resection. 
Disease recurrence at the surgical margin, ipsilateral pleural dissemination, ipsilateral 
hilum, and/or mediastinum was considered as local recurrence. The median follow-
up was 62 months. There were 205 males and 137 females with a median age of 69 
years. Two hundred and forty-four patients had adenocarcinoma, 86 had squamous cell 
carcinoma, and 12 had other types. On pathologic staging 194 patients were in stage 
IA and 148 in stage IB. Lymph/vascular invasion were detected in 123, moderate/poor 
degree of tumor differentiation in 210, and 129 were non-smokers. The patients were 
divided into two groups: recurrence (n = 70) and non-recurrence (n = 272) within 3 
years. Results:The 1, 3, and 5-year overall survival was 97%, 85% and 74%, respectively. 
Postoperative recurrence within 1, 2 and 3 years was observed in 26 (7.1%), 58 (16.6%) 
and 70 (20.4%) patients, respectively. Recurrence in local tissue only within 1, 2 and 3 
years was observed in 4 (15%), 14 (24%) and 17 (24%) cases, respectively. Age, sex, 
smoking history, pathologic stage (IB), lymphatic/vascular invasion, and the degree 
of tumor differentiation were also significantly different between recurrence and non-
recurrence group. Regarding tumor markers, the serum concentrations of SLX, CEA 
and CYFRA21-1 in the recurrence group were significantly higher than those in the non-
recurrence group (p = 0.003, 0.030, and 0.006, respectively). By multivariate analysis, 
independent predictors of recurrence within 3 years were age more than 75 years (HR 
2.51; 1.27–4.96), lymph/vascular invasion (HR 1.95; 1.06–3.63), stage IB (vs IA; HR 2.17; 
1.14–4.18) and SLX (HR 1.04; 1.01-1.08). Although the rate of distant recurrence within 
3 years was higher in stage IB (p = 0.032), there was no significant difference in age, 
sex, smoking history, lymphatic/vascular invasion, degree of tumor differentiation, CEA 
and CYFRA between distant and local recurrence group. The serum tumor marker SLX 
was also significantly higher in the distant metastasis group than in the local recurrence 
group (mean 29.8 and 21.4U/ml, respectively; p = 0.007) Conclusion: Early recurrence 
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Conclusion: Not cardiovascular but respiratory complications following lung cancer 
surgery might have the negative predictor in the incidence of cancer recurrence. Severe 
inflammation induced by postoperative complications might be associated with high 
incidence of cancer recurrence. 
Keywords: postoperative complication, cancer recurrence, surgical inflammation, lung 
cancer surgery
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P1.02-006 Visceral Pleural Invasion Was Common in Larger (> 2 cm) Ground 
Glass Nodules, but Showed No Aggressive Prognostic Impact Lilan Zhao1, 
Huikang Xie2, Junyan Zha1, Ke Fei1, Chang Chen3 1Department of General Thoracic Surgery, 
Shanghai Pulmonary Hospital, Shanghai/China, 2Department of Pathology, Shanghai 
Pulmonary Hospital, Tongji University School of Medicine, Shanghai/China, 3Department 
of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 
Shanghai/China
Background: Visceral pleural invasion (VPI) had been demonstrated as an aggressive 
sign in solid-density non-small-cell lung cancers. However, its incidence and clinical 
relevance in ground glass nodules (GGNs) has not been clarified. The present study aims 
to investigate the clinical, radiological and pathological features of GGNs in patients 
with VPI. Methods: All consecutive surgically treated patients with solitary GGNs 
between 2008 and 2013 were retrospectively reviewed. Inclusion criteria were defined 
as: lesions < 3 cm and pleura abutting on computed tomography scan; pathologically 
confirmed non-small cell lung cancers. Patients with and without VPI were compared 
for clinical, radiological and pathologic parameters and survival. Results: A total of 
121 patients were enrolled and 38 had pathologically proven VPI. The median patient 
age was 61 years old (range, 30-81 years old) and 45 (37.2%) patients were male. The 
mean follow-up duration was 30 months. The incidence of VPI was 43.9% (25/57) if 
the tumor diameter was > 2.0 cm and 20.3% (13/64) in < 2.0 cm (p=0.005). It was 
20.9% (9/43) in pure GGNs and 37.2% (29/78) in part-solid GGNs (p=0.065). In cases 
with pleura indentation the incidence was 37.5% (24/64). In lepidic predominant, acinar 
predominant, papillary predominant and mucinous variant adenocarcinomas, the VPI 
rate was 44.7%, 84.60%, 52.9% and 100%, respectively (p=0.07). There were five 
lymph node involvement cases and three death cases due to distant metastasis. There 
was no statistical difference in 3-year overall survival between patients with VPI and 
without, nor between pure (all alive) and part-solid GGNs (p=0.956). Conclusion: VPI 
was more commonly seen in large (> 2 cm) GGNs and those with pleural indentations. 
Histologically it was more frequently seen when acinar was also predominant. Although 
commonly taken as an aggressive sign predictive of poor prognosis, the presence of 
VPI in GGNs may be associated with less prognostic significance. Therefore, upgrading 
of the TNM stage on the basis of VPI for such patients needs further verification. 
Keywords: non-small cell lung cancer, ground-glass nodules, visceral pleural invasion
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P1.02-007 The Histologic Subtype of Lung Adenocarcinoma Should Not Deter 
Sublobar Resection for Patients with Clinical Stage IA Lung Cancer Mohamed 
Kamel1, Navneet Narula2, Brendon Stiles1, Abu Nasar1, Galal Ghaly1, Mohamed 
Rahouma1, Jeffery Port1, Paul Lee1, Subroto Paul1, Nasser Altorki1 1Thoracic Division of 
Cardiothoracic Surgery Department, Weill Cornell Medical College, New York/NY/United 
States of America, 2Pathology Department, Weill Cornell Medical College, New York/NY/
United States of America
Background: The International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society pathological classification of lung 
cancer allows for a more comprehensive understanding of the prognostic factors 
associated with subtypes of lung adenocarcinoma. Micropapillary and solid (MIP/SOL) 
subtypes have been associated with higher recurrence rates. Some have therefore 
suggested that sublobar resection (SLR) should be considered a compromise procedure 
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P1.02-004 Accurate Assessment of Vessel Invasion Using D2-40 and Victoria 
Blue Predicts Recurrence in Patients with Pathological Stage I NSCLC 
Satoshi Okada, Shinjiro Mizuguchi, Nobuhiro Izumi, Hiroko Oka-Yamamoto, Michihito 
Toda, Kantaro Hara, Noritoshi Nishiyama Osaka City University Hospital, Osaka/Japan
Background: It is difficult to estimate lymphatic vessel invasion (LVI) and blood vessel 
invasion (BVI) by Hematoxylin-Eosin (HE) staining for lung cancer specimens. The aim 
of this study was to compare HE with D2-40 and Victoria blue staining for detection of 
LVI and BVI, respectively, and to assess the relationship between these measurements 
and recurrence in patients with pathological stage I non-small cell lung cancer 
(NSCLC). Methods: We retrospectively analyzed 251 patients who underwent complete 
resection for pathological stage I NSCLC from 1997 to 2008. This study included 152 
males and 99 females with a median age of 69 years (range, 20–93 years). Using criteria 
detailed in the seventh edition of the TNM classification for lung cancer, 129 cases were 
pathological stage IA and 122 cases were IB. Histologically, 175 adenocarcinomas, 67 
squamous cell carcinomas, and 9 other subtypes of carcinomas were found. There were 
81 well-differentiated carcinomas and 170 moderate or poorly differentiated carcinomas. 
The median follow-up across the cohort was 70.2 months and the 5-year survival rate 
was 72.2%. The paraffin-embedded sections were stained with HE, D2-40, and Victoria 
blue. Specimens with each staining were reevaluated and classified into three grades 
according to numbers of vessel invasion in one section: Ly0/V0, no invasion; Ly1/V1, 
one or two invasions; and Ly2/V2, more than three invasions. Results:Assessment of 
vessel invasion by HE revealed the following distribution of LVI grades: Ly0=125 (49.8%); 
Ly1=104 (41.4%); Ly2=22 (8.8%), and BVI grades: V0=224 (89.2%); V1=24 (9.6%); and 
V2=3 (1.2%). In contrast, segregation of patients according to reassessment of LVI 
and BVI by D2-40 and Victoria blue, respectively, resulted in the following distributions: 
Ly0=177 (70.5%); Ly1=53 (21.1%); Ly2=21 (8.4%); V0=186 (74.1%); V1=53 (21.1%); 
and V2=12 (4.8%). After reassessment using D2-40 and Victoria blue, 50% (11 of 22) 
of Ly2 cases by HE changed to Ly0, and 22.7% (5 of 22) of Ly2 cases by HE changed 
to Ly1, 66% (2 of 3) of V2 cases by HE changed to V0 and V1, respectively. According 
to accurate assessment of vessel invasion using D2-40 and Victoria blue, there was no 
significant difference in disease-free survival between patients who were negative and 
positive for LVI or BVI (p=0.1062 and 0.1849, respectively); however, when patients 
were divided according to the intensity of LVI/BVI (Ly0&1/V0&1 vs. Ly2/V2), there was 
a significant difference in disease-free survival (p=0.0281 and p<0.0001, respectively). 
A recurrence of lung cancer was discovered in 50 patients (19.9%) within 3 years. On 
multivariate analysis, the independent recurrence factors were pleural invasion (HR 
2.64; 1.40–4.86) and V2 based on Victoria blue (HR 8.54; 3.46–19.1). Conclusion: Our 
study suggests that accurate reassessment of LVI and BVI using D2-40 and Victoria 
blue staining, used to assess not only presence but also intensity, is important to 
predict the postoperative recurrence in patients with pathological stage I NSCLC. 
If the predictive factors of pleural invasion and V2 based on Victoria blue staining 
were recognized, adjuvant chemotherapy might be considered for these patients. 
Keywords: pathological stage I NSCLC, lymphatic invasion, blood vessel invasion, 
recurrence
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P1.02-005 Impact of Postoperative Complications on Cancer Recurrence 
following Lung Cancer Surgery Takashi Nojiri1, Masayoshi Inoue1, Yasushi Shintani1, 
Yukiyasu Takeuchi2, Hajime Maeda2, Toshimitsu Hamasaki3, Meinoshin Okumura1 
1General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita/
Japan, 2General Thoracic Surgery, National Hospital Organization Toneyama Hospital, 
Toyonaka/Japan, 3Clinical Research and Development, National Cerebral and Cardiovascular 
Center, Suita/Japan
Background: Recent studies indicate that postoperative complications after various 
types of cancer surgery are associated with poor cancer-specific survival. Postoperative 
complications induce severe inflammatory reaction during the perioperative period. 
Emerging evidence suggests that systemic inflammation can accelerate the adhesion 
of circulating tumor cells to the vascular endothelium of distant organs, which is the 
first step of extravasation in hematogenous metastasis. The objective of this study 
was to investigate the impact of postoperative cardiopulmonary complications on 
cancer recurrence after lung cancer surgery. Methods: From a prospective database 
of 675 consecutive patients who underwent a lung cancer surgery between April 
2007 and March 2012, we retrospectively analyzed medical charts of all patients 
with curative surgery. The primary endpoint was the incidence of cancer recurrence 
after surgery between the patients with and without postoperative cardiopulmonary 
complications. Perioperative white blood cell counts and C-reactive protein levels were 
also compared. Results: Postoperative cardiovascular or respiratory complications 
were identified in 98 (15%) or 30 (4%) patients, respectively. There were no significant 
differences in the incidence of cancer recurrence between the patients with postoperative 
cardiovascular complications and without cardiopulmonary complications (23% vs. 19%; 
p = 0.26). In contrast, there was significantly higher incidence of cancer recurrence in 
those with postoperative respiratory complications than those without cardiopulmonary 
complications (42% vs. 19%; p < 0.05). Multiple regression analysis adjusted age, sex, 
and pathological staging showed the similar tendency, however there was no significant 
difference. There were significantly higher levels of white blood cell counts and C-reactive 
protein levels in the acute phase after surgery in those with postoperative respiratory 
complications than those without.
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same mutation (KRAS G12C, KRAS G12D, KRAS G12F), and 8 had different mutations. 
Table 1: Multiple Lung Cancer: Molecular Data
Conclusion: Martini-Melamed criteria and comprehensive pathologic assessment, 
are currently used to diagnose MLCs. Assuming separate MLC lesions harbor distinct 
molecularly defi ned clones, paired molecular testing using limited panels is not suffi cient 
to diagnose MLCs. Concordant molecular profi les do not necessarily defi ne whether a 
lesion is an MLC or a metastatic lesion. Paired prospective testing of suspected MLC 
lesions including broader molecular tests such as DNA, RNA, protein expression and 
immune correlates, may advance our understanding of the biology of these tumors. 
Keywords: multiple lung cancers, diagnostic molecular pathology, non-small cell lung 
cancer, clonality
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P1.02-009 Prognostic Value of New IASLC/ATS/RES Lung Adenocarcinoma 
Classifi cation on Dominate Tumor in Synchronous Multiple Primary 
Adenocarcinomas Chien-Sheng Huang1, Po-Kuei Hsu1, Yu-Chao Yu1, Chun-Ku Chen2, 
Yi-Chen Yeh3, Mei-Han Wu2, Chih-Cheng Hsieh1, Han-Shui Hsu1, Teh-Ying Chou3, Yu-Chung 
Wu1, Biing-Shiun Huang1, Wen-Hu Hsu1 1Division of Thoracic Surgery, Department of 
Surgery, Taipei Veterans General Hospital, Taipei/Taiwan, 2Department of Radiology, Taipei 
Veterans General Hospital, Taipei/Taiwan, 3Department of Pathology, Taipei Veterans General 
Hospital, Taipei/Taiwan
Background: The prognostic roles of the dominate tumor and tumor combination 
pattern in synchronous multiple primary adenocarcinoma (SMPADCs) remain 
unclear. Methods: The predominant histologic pattern of each tumor among SMPADCs 
was determined according to the new IASLC/ATS/ERS classifi cation system. For 
recurrence analysis, each tumor was further divided into low, intermediate and high 
grade prognostic group. The dominate tumor (DT) was representative of the highest 
prognostic grade in each SMPADCs. Results: From 2004 to 2012, there were 108 
consecutive nodal-negative patients who underwent surgery for SMPADCs in a tertiary 
referral center. The median follow-up time was 52.4 months. During follow-up, 38 (35.2%) 
patients developed recurrence. The pattern of recurrence included local recurrence only 
in 8 patients (21.1%), distal metastasis only in 11 (28.9%), and both local recurrence and 
distal metastasis in 19 (50.0%). In multivariate analysis, the percentage of recurrence 
was signifi cantly higher in older age (p=0.002; odds ratio 6.324) and DT presented with 
radiologic solid-appearance (vs. pure- , Mixed-GGNs, p=0.032; odds ratio 7.041). In 
addition, there was no tumor recurrence identifi ed in 17 DTs presented with radiologic 
pure GGN and 6 DTs in low grade prognostic group. The 5-year overall and disease-
free survival of SMPADCs determined by DT in low, intermittent and high grade were 
100%, 84.6%, 32.5% (p<0.001) and 100%, 73.9%, 23.3%, respectively (p<0.001). 
Compared to low/intermediate grade, DT in high grade had signifi cantly worse overall 
survival (p=0.007; hazard ratio 4.313) and disease-free survival (p=0.045; hazard ratio 
2.360) in multivariate analysis. For further combination pattern analysis, high grade 
DT combined with high grade 2nd dominate tumor had signifi cantly worse disease-free 
survival than that combined with intermediate and low grade 2nd dominate tumors.
in patients with MIP or SOL tumors. We conducted this study to examine the effect of the 
resection type [lobectomy (LO) or SLR] on oncological outcomes of patients with MIP/
SOL. Methods: A retrospective review of a prospective database (2000-2014) was 
performed to identify patients with clinical stage IA adenocarcinoma, excluding pure 
ground glass opacities. Propensity score matching (age, gender, FEV1%, and clinical 
tumor size) was done to obtain balanced cohorts of patients undergoing LO and SLR. The 
presence of MIP and/or SOL components (≥5%) was assessed by a single pathologist to 
avoid inter-observer bias. The SLR group of patients had more comorbidities. Therefore, 
deaths from causes other than lung cancer were censored and freedom from recurrence 
was used to assess oncological outcomes. Survival analysis was done using the Kaplan 
Meier method. Multivariable analysis (MVA) was done using Cox regression. Results: This 
study included 300 patients (150 LO vs. 150 SLR, including 77 segmentectomy and 73 
wedge resection). Patients undergoing SLR had higher Charlson comorbidity index 
(P=0.002) and lower DLco% (P=0.01). Patients undergoing LO were more likely to have 
nodal assessment (99% vs. 85%,P<0.001). Otherwise, no differences in the 
clinicopathological characteristics were found between the two groups. The presence of 
≥5% MIP and/or SOL components was found in 135 patients; LO (58), SLR (77). The 
3-year probability of freedom from recurrence in the whole cohort was: MIP (77%), 
synchronous MIP/SOL (76%), and SOL (61%), compared to 86% freedom from recurrence 
for other pathological subtypes (median follow-up 41 months). The probability of freedom 
from recurrence in patients with MIP/SOL subtypes showed a trend favoring the LO group 
(P=0.092). However, when we excluded patients with SLR with resection margin <1 cm 
(n=64), there was no difference between LO (80%-72%) and SLR (81%-75%) at 3 and 5 
years respectively (P=0.812)(Fig.1). Also, the type of resection (LO/SLR) was not 
associated with higher recurrence rates in the MVA of the whole cohort.
Conclusion: SLR can be safely performed in clinical stage-IA lung adenocarcinoma, 
regardless of the histological subtype, provided that a resection margin >1 cm is obtained. 
Keywords: lobectomy, Histological Subtype, stage I, Sublobar
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P1.02-008 Diagnostic Molecular Testing in Multiple Lung Cancers Jarushka 
Naidoo1, Kaitlin Woo2, Camelia S. Sima3, William D. Travis4, Maria E. Arcila5, David J. 
Finley6, Valerie Rusch7, David R. Jones8, Mark G. Kris1, Marjorie G. Zauderer9 1Thoracic 
Oncology, Memorial Sloan Kettering Cancer Center, New York/NY/United States of 
America, 2Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New 
York/United States of America, 3Epidemiology and Biostatistics, Memorial Sloan Kettering 
Cancer Center, New York/NY/United States of America, 4Pathology, Memorial Sloan 
Kettering Cancer Center, New York/United States of America, 5Department of Pathology - 
Molecular Diagnostics, Memoria Sloan Kettering Cancer Center, New York/United States 
of America, 6Thoracic Surgery, Dartmouth-Hitchcock Medical Center, New Hampshire/NH/
United States of America, 7Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New 
York/NY/United States of America, 8Thoracic Surgery, Memorial Sloan Kettering Cancer, New 
York/NY/United States of America, 9Medicine/Thoracic Oncology, Mskcc, New York/NY/
United States of America
Background: Multiple lung cancers (MLCs) are determined using the Martini-Melamed 
clinical criteria, and comprehensive pathologic assessment. The underlying biology 
for why MLCs develop is not known. Herein, we evaluate clinicopathologic data for 
patients with MLCs, and report clonality between MLC lesions using diagnostic 
molecular testing. Methods: After IRB approval, we conducted a retrospective review 
of all patients who underwent an R0 resection for stage IA-IIIA LC from 2008-2013 in 
our institution. Patients with carcinoid tumors, adenocarcinoma-in-situ, multiple ground-
glass opacities, intrapulmonary metastases, and cancers not originating from the lung, 
were excluded. MLCs were defi ned using Martini-Melamed criteria, and comprehensive 
pathologic assessment. Clinico-pathologic data was collected for patients with MLCs, 
including available diagnostic molecular data from sizing assays, Sanger sequencing and 
mass spectrometry genotyping (Sequenom). Results: 2352 pts were identifi ed: one LC 
(n=2238), recurrent LC (n=348), MLC (n=113). In patients with MLCs, adenocarcinoma 
histology (n=97) was associated with improved OS (p=0.049) compared to squamous 
histology (n=13, other n=3). Paired diagnostic molecular pathology was available 
in 51 patients with adequate tissue from MLCs. MLC pairs stratifi ed by mutation 
type are depicted in Table 1. In 49 patients, both MLCs were adenocarcinomas (20= 
extended panel: sizing assays/Sanger sequencing/Sequenom, 29=limited panel: EGFR/
KRAS sizing assay/Sanger sequencing): 51% (n=25/49) had concordant molecular 
results, suggesting a common tumor clone, and 49% (n=24/49) had discordant results. 
In 1 patient, one MLC was an adenocarcinoma and the other was a squamous carcinoma, 
and had discordant molecular results by limited panel testing. In 1 patient, both MLCs 
were squamous carcinomas, and had concordant molecular results by limited panel 
testing. In patients where MLCs both had a KRAS mutation (n=11), 3 pairs had the 
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percentage of postoperative FEV1.0 (%ppoFEV1), and estimated postoperative 
epoFEV1/m2 (epoFEV1/m2). Results: The mean %FEV1 in spirometry was significantly 
higher in patients with lung cancer than in patients with infectious lung disease (79.5% 
vs 67.0%; p=0.01). The rate of perfusion to the operative lung was significantly higher 
in patients with lung cancer than in patients with infectious lung disease (35.8% vs. 
19.3%; p<0.01). Consequently, the mean %ppoFEV1 was not significantly different 
between the two groups (51.8% vs 50.6%; p=0.72). Body surface area of lung cancer 
patients was larger than that of infectious lung disease patients (1.65m2 vs 1.50m2; 
p<0.01). The mean calculated epoFEV1/m2 after pneumonectomy in patients with 
lung cancer and in patients with infectious lung disease were 869ml/m2 and 993ml/
m2 (p=0.05), respectively. Conclusion: Preoperative %FEV1 in patients with lung cancer 
was higher than that in patients with infectious lung disease. However, %ppoFEV1.0 
and epoFEV1/m2 after pneumonectomy were not different between the two groups. 
These differences were caused by destructive feature of infectious lung diseases. 
Keywords: lung infectious disease, pneumonectomy, Pulmonary Function, lung cancer
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P1.02-011 The Discordance of Two Major Diagnostic Criteria for Chronic 
Obstructive Pulmonary Disease Affects Lung Cancer Prognosis after Resection 
Masaya Yotsukura1, Takashi Ohtsuka1, Yasoo Sugiura1, Yuichiro Hayashi2, Ikuo 
Kamiyama1, Hisao Asamura1 1Division of Thoracic Surgery, Keio University School of 
Medicine, Tokyo/Japan, 2Department of Pathology, Keio University Hospital, Tokyo/Japan
Background: Chronic obstructive pulmonary disease (COPD) has been reported to 
be associated with the development of lung cancer and poor prognosis after curative 
surgery for early-stage non-small cell lung cancer (NSCLC). The Global Initiative for 
Chronic Obstructive Lung Disease defines COPD as a fixed post-bronchodilator ratio of 
forced expiratory volume in 1 second and forced vital capacity (FEV1/FVC) below 0.7. 
Age-dependent cut-off values below the lower fifth percentile (LLN) of this ratio derived 
from the general population have been proposed as an alternative. In patients with 
obstruction according to the LLN cut-off point but not according to the fixed cut-off point, 
the prognosis after curative surgery for NSCLC is not known. Methods: We enrolled 556 
patients with FEV1/FVC ≥0.7 who underwent curative surgical resection for pathological 
stage I or II NSCLC in our institute between January 2002 and December 2012. The 
post-surgical prognosis was compared between patients with obstruction (obstructed 
patients) and without obstruction (non-obstructed patients) according to the LLN cut-off 
point, using a Cox regression hazards model. Results: Of the 556 patients, 42 (7.6%) 
met the criteria of the LLN cut-off point. The 5-year recurrence-free rate was significantly 
lower in the obstructed patients (54.4%) than in the non-obstructed patients (77.1%), in 
univariate analysis (p < 0.01). The 5-year overall survival rate was also significantly lower in 
the obstructed patients (64.0%) than in the non-obstructed patients (91.1%), in univariate 
analysis (p < 0.01). Multivariate analysis showed that the obstructed patients had a poor 
recurrence-free (p = 0.05) and overall survival (p < 0.01) probability. Conclusion: Even 
if COPD is not diagnosed according to the fixed cut-off point, those who meet the 
criteria of the LLN cut-off point have a poor prognosis after curative surgery for NSCLC. 
Keywords: Early-stage lung cancer, Thoracic Surgery, Chronic obstructive pulmonary 
disease
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P1.02-012 Study for Prognostic Impact of Tumor Volume Instead of Tumor 
Size for T Staging in NSCLCancer Doosang Kim1, Jungeun Kim2, Hyungho Park2 
1Thoracic and Cardio-Vascular Surgery, Veterans Health Service Medical Center, Seoul/
Korea, 2Veterans Health Service Medical Center, Seoul/Korea
Background: Size criteria have been used as a gold standard for a long time in 
cancer staging of all kinds of solid tumors. However, real tumor mass is usually 
neither spherical, nor symmetrical in shape. Therefore, single dimension length of 
tumor does not stand for the tumor volume exactly. We conducted the feasibility test 
of volume criteria for T staging. Methods: From April 1998 to April 2015, 425 lung 
tumor masses were resected. Among them, 187 masses of completely resected 
(R0) pT1a,1b,2a,2bN0M0 were enrolled for study. Their survival data were used for 
comparing log-rank statistics between size-based T(s) stage and volume-based T(v) 
stage. Tumor volumes were calculated from two-to-three dimension lengths of tumor 
from biopsy specimen. Results: Overall log-rank statistics was p=0.4377 and there 
was no detectable numerical order for trend among pT1a~pT2b in size-based T(s) 
stage. However, overall log-rank was p=0.1153 and log-rank for trend was p=0.0241 
in volume-based T(v) stage. Cut-off values for volume T stage were selected as V1 (less 
than 2cc), V2 (more than 2cc and less than 4cc), V3 (more than 4cc and less than 9cc) 
and V4 (more than 9cc) from log-rank statistics. Conclusion:Volume-based T(v) stage 
shows better discrimination power comparing size-based T(s) stage in T1-2N0 NSCLCa. 
Keywords: T staging, volume staging
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P1.02-013 The New Interventional Technique by Photodynamic Therapy Using 
Composite-Type Optical Fiberscope of 1.0 mm in Diameter Jitsuo Usuda Thoracic 
Surgery, Nippon Medical School, Tokyo/Japan
Background: Ground-glass opacity (GGO) nodules at peripheral parenchyma of 
the lung noted at thin –section computed tomography (CT) scan have shown to 
have a histopathologic relationship with atypical adenomatous hyperplasia (AAH) 
Conclusion:
Risks analysis of disease-free survival
Variables HR p value HR p value
Age 3.212 0.001 2.228 0.026
Gender 1.552 0.182 -- --
Smoking Hx 1.443 0.270 -- --
Preop CEA 1.640 0.217 -- --
Tumor size 2.108 0.024 0.967 0.927
Radiologic appearance 10.814 0.001 3.911 0.086
Pleural invasion 2.069 0.050 0.930 0.869
TNM stage 3.405 0.021 1.334 0.669
Histologic differentiation 4.170 <0.001 1.840 0.118
Angiolymphatic invasion 4.089 <0.001 1.773 0.175
Subtyping predominate 5.399 <0.001 2.360 0.045
Tumor distribution 0.523 0.146 -- --
Same lobe 1.269 0.481 -- --
Adjuvant chemotherapy 1.855 0.072 1.391 0.360
Similar CHS 1.251 0.521 -- --
 
DT analyzed with prognostic grouping of the IASLC/ATS/RES histological 
classification was an independent risk factor regarding to overall and 
disease-free survivals in complete resected nodal-negative SMPADCs. 
Keywords: synchronous primary lung cancers, New lung adenocarcinoma classification, 
recurrent pattern, dominate tumor
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P1.02-010 What Is the Difference between Lung Cancer and Infectious 
Lung Disease in Predicted Postoperative Pulmonary Function after 
Pneumonectomy? Takayuki Nakagawa, Kiyomi Shimoda, Miyako Hiramatsu, Tsutomu 
Yoshida, Yuji Shiraishi Chest Surgery Division, Respiratory Disease Center, Fukujuji Hospital, 
Japan Anti-Tuberculosis Association, Tokyo/Japan
Background: Clinical guideline recommends that spirometry and/or lung perfusion 
scan be performed for patients undergoing pneumonectomy. Unlike in patients with lung 
cancer, the affected lungs to be resected have been destroyed due to inflammatory 
changes in patients with infectious lung diseases. This study was aimed to assess 
whether there is any difference in predicted postoperative pulmonary function between 
patients with lung cancer and patients with infectious lung disease. Methods: The study 
was done on 55 patients undergoing pneumonectomy from January 2005 to February 
2015, including 22 patients with lung cancer (three right, 19 left) and 33 patients with 
infectious lung disease (13 right, 20 left). Infectious diseases included 10 pulmonary 
aspergillosis, 15 multidrug-resistant tuberculosis (MDR-TB), and 8 non-tuberculosis 
mycobacterial (NTM) infections. In all cases, predicted postoperative pulmonary function 
was evaluated by spirometry and quantitative lung perfusion scan before operation. We 
analyzed the differences in patient characteristics and pulmonary function between the 
two groups, such as percentage of forced expiratory volume in one second (%FEV1), 
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Table 1
Variables Hazard ratio (95% CI) p-value
Extracapsular spread Yes vs no 1.47 (1.00, 2.17) 0.049
Pleural invasion PL1 vs PL0 1.37 (0.97, 1.93) 0.002
PL2 vs PL0 1.08 (0.63, 1.85)
PL3 vs PL0 2.42 (1.53, 3.83)
T stage 1b vs 1a 1.04 (0.61, 1.79) 0.006
2a vs 1a 1.30 (0.81, 2.08)
2b vs 1a 1.63 (0.95, 2.81)
3 vs 1a 2.17 (1.28, 3.66)
4 vs 1a 2.99 (1.46, 6.11)
N stage N1 vs N0 1.30 (0.91, 1.87) 0.005
N2 vs N0 1.80 (1.26, 2.58)
 
Conclusion: Pathological T-stage and N-stage are well established predictors of 
prognosis and inform decisions around adjuvant chemotherapy. Extra-capsular 
nodal disease and pleural invasion (PL3) are additional independent predictors 
of survival. The presence of these pathological findings in resected NSCLC may 
help in the decision making around adjuvant therapy, the appropriate intensity of 
surveillance programs and the design or stratification of adjuvant therapy trials. 
Keywords: Adjuvant chemotherapy NSCLC, NSCLC surgery, NSCLC recurrence, NSCLC 
survival
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P1.02-016 Prevalence of Preoperative DVT in Japanese Patients Who 
Underwent Thoracic Surgery by Intensive Screeng Toshiki Takemoto, Yuichi 
Sesumi, Yoshihisa Kobayashi, Katsuaki Sato, Masato Chiba, Masaki Shimoji, Kenichi 
Suda, Kenji Tomizawa, Masahiro Sakaguchi, Tetsuya Mitsudomi Division of Thoracic 
Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama/Japan
Background: Pulmonary thromboembolism (PTE) is a well-recognized potentially fatal 
complication after thoracic surgery. In Japan, PTE had been relatively uncommon. 
However, it has recently been increasing probably due to changes in lifestyle. Therefore 
the first guideline for the prevention of venous thromboembolism (VTE) were published in 
February 2004 in Japan. In this guideline, the patients with history of VTE are classified 
as highest risk group for PTE. Recently, it has been reported that the presence of normal 
D-dimer levels can exclude acute-phase deep vein thrombosis (DVT). Therefore, in our 
institution, DVT had been intensively screened by measuring preoperative D-dimer. The 
objective of this study was to investigate prevalence of preoperative DVT in Japanese 
patients scheduled for thoracic surgery. Methods: A total of 276 patients who underwent 
thoracic surgery from June 2013 through July 2014 in our institution were reviewed. The 
patients who were deemed high-risk for DVT (those with elevated preoperative D-dimer 
(≧1.0µg/ml), with past history of thrombosis, or with varicose veins in their lower 
extremities) were defined as preoperative screening positive. They were examined with 
venous ultrasonography of lower extremities. Those with DVT underwent contrast-
and adenocarcinoma (AIS) which is newly classified by International Association 
for the study of Lung Cancer (IASLC). We hypothesize that those early lung cancers 
in peripheral parenchyma such as AIS, do not need surgical resection may be curred 
by interventional approach such as Photodynamic therapy (PDT). For peripheral type 
early lung cancer, it is unable to observe using bronchoscopy nor to treat by PDT. 
Therefore, we have developed a new minimally invasive laser device using a 1.0 mm in 
diameter composite-type optical fiberscope (COF), which could transmit laser energy 
and images for observation in parallel, consisting a laser Doppler blood-flow meter. The 
use of COF technology was previously used in the field of atomic energy. It enables 
the acquisition of an image while simultaneously performing laser treatment such as 
PDT, measuring the blood-flow, estimating the irradiational distance. Methods: In this 
study, we aimed to develop a new endoscopical treatment for peripheral parenchymal 
cancer by NPe6-PDT and a COF. We administered NPe6, 10mg/kg to pigs and we 
observed the peripheral parenchyma through the bronchus using COF. One h after the 
administration of NPe6, we irradiated 664 nm-laser (120 mW, 100J) for normal lesion of 
the peripheral lung using COF. Seven days after PDT, we extracted lungs and examined 
pathologically. Results: We were able to introduce the 1.0 mm COF into pig peripheral 
parenchyma of the lungs and observed feasibly and clearly, and then we performed 
NPe6-PDT safely. We measured the blood-flow at the irradiated area by COF during 
PDT, and we observed gradually disappearance of the blood-flow. The mean diameter of 
necrosis in normal peripheral lung caused by NPe6-PDT was 16 mm. Conclusion: The 
1.0 mm COF was a very useful device of NPe6-PDT for peripheral parenchyma of the 
lung. In the future, for non-invasive adenocarcinoma such as AIS, NPe6-PDT using 
COF will become one option of standard treatment and play a important role for the 
treatment of syncronous or metachronous multiple primary lung cancer lesions. 
Keywords: photodynamic therapy, interventional technique, composite-type optical 
fiberscope, lung cancer
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P1.02-014 Predictive Factors of Postoperative Acute Exacerbation of 
Interstitial Pneumonia for Patients with Lung Cancer Haruhiro Yukiue, Hiroshi 
Niwa, Masayuki Tanahashi, Eriko Suzuki, Naoko Yoshii, Masayuki Shitara, Toshio Fujino 
Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, 
Hamamatsu, Shizuoka/Japan
Background: Currently, postoperative acute exacerbation (AE) of idiopathic interstitial 
pneumonia (IIP) accounts for the most common cause of death after pulmonary resection 
for lung cancer. Preoperative risk assessment and prevention of postoperative AE is 
essential for the operative performance improvement. Methods: From 2000 through 
2013, a total of 1730 patients underwent pulmonary resections for primary lung cancer. 
One hundred and two patients (5.9%) were diagnosed the lung cancer combined with 
IIP based on the postoperative pathological findings. Postoperative AE was defined 
as acute exacerbation within 30 days after the operation. Results: Postoperative AE 
was observed in 9 patients (8.8%), of which 6 patients (66.7%) died of respiratory 
failure. Although three patients had improved and discharged, two patients of which 
finally died with re-exacerbation. All of the postoperative AE patients were men having 
all cases smoking history, and many of them were advanced stage. The AE patients 
were significantly worse than non-AE patients in following clinicopathological factors. 
Preoperative serum LDH（248±52IU/l vs 206±45）、CRP（1.6±1.8mg/dl vs 0.9±1.8
）、PaO2（78.1±7.8mmHg vs 84.9±10.5）and ％VC（78.9±14.3% vs 94.4±15.1）. 
Moreover, for the postoperative AE patients, the changes of these factors and X-ray or CT 
findings before operation were analyzed. An exacerbation before operation observed for 
serum LDH in five patients, CRP in three patients, and increased lung opacity on imaging 
findings observed in four patients. Conclusion: To see the exacerbation of laboratory 
values (LDH, CRP) and imaging findings (increasing lung opacity) during preoperative 
time, there is a possibility of selecting high-risk patients of postoperative AE. 
Keywords: Interstitial pneumonia, lung cancer, acute exacerbation
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P1.02-015 Pathological Variables in Resected NSCLC Tumours: Predictors of 
Survival? Matthew Evison, Stuart Britton, Haider Al-Najjar, Rajesh Shah, Philip Crosbie, 
Richard Booton Manchester Thoracic Oncology Centre, University Hospital of South 
Manchester, Manchester/United Kingdom
Background: Lung cancer recurrence following treatment with radical intent remains 
a significant problem for thoracic oncology specialists. Identifying novel predictors of 
recurrence may inform future management strategies including indications for adjuvant 
chemotherapy and the intensity of surveillance programs. This study used survival 
analysis, as a surrogate marker of disease recurrence, to assess if pathological variables 
in resected NSCLC could predict survival. Methods: We retrospectively reviewed 
all pathological reports for patients undergoing surgical resection for NSCLC at the 
University Hospital South Manchester from 01/01/2011 to 31/12/2013. The following 
variables were analysed in univariate and multivariate (cox regression) analysis: extra-
capsular nodal disease, lymphovascular invasion, pleural invasion (PL0-3), residual 
disease (R0 vs R1), grade of differentiation, pT-stage and pN-stage. Survival was provided 
by national death registry data. Results: Extra-capsular nodal disease (p=<0.001, Figure 
1), Lymphovascular invasion (p=<0.001), pleural invasion (PL3, p=<0.001), residual 
disease (R1, p=<0.001), pT-stage (pT4, pT3, pT2b, p=<0.001) and pN-stage (pN2, 
p<0.001) were all associated with significantly lower survival on univariate analysis. A 
multivariate cox regrerssion model was run with all significant univariate variables. The 
least significant variable was removed and this was repeated until only those significant 
at the 0.05 level remained (Table 1). 
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P1.02-018 Needlescopic Lobectomy and Segmentectomy for Primary Lung 
Cancer: Less Invasive Surgery Using Fine Scope and Forceps Michihiko Tajiri, 
Hiromasa Arai, Kohei Ando General Thoracic Surgery, Kanagawa Cardiovascular and 
Respiratory Center, Yokohama/Japan
Background: If we can maintain a satisfactory technical level, safeness and prognosis 
equal to conventional surgery, a less invasive procedure will bring more benefits to 
patients. We have performed thoracoscopic anatomical lobectomy and segmentectomy 
for primary lung cancer for twenty years. At first we used and slid 10mm-diameter 
scope and forceps through three or four ports. Later we changed to 5mm-diameter 
scope and forceps, and presently we start performing the needlescopic surgery（1 
port+3 punctures method）using a 3mm-diameter scope and forceps, which we have 
used since September 2012. Now we would like to explain this operative procedure and 
effectiveness. Methods: 【Patients】One hundred and eleven patients underwent the 
needlescopic anatomical lobectomy and segmentectomy of the lung between September 
2012 to March 2015. They had clinical stage IA or IB lung cancer. We compared the 
operation time, blood loss volume, post-operative creatinine phosphokinase (CK) and 
other peri-operative parameters of this method with those of the conventional method 
using a 5mm-diameter scope which were performed on 73 patients from January 2012 
to August 2012. 【Operative procedure】1. We make a 2 to 3 cm length skin incision 
on the 4th or 6th intercostal space of the chest trunk and set the polyurethane-made 
retractor. We use it as the main port. 2. We puncture the skin with three 3mm-diameter 
trocars. Then we insert and slide a 3mm-diameter scope and forceps through them. We 
observe thoracic lumen and perform various manipulations using them. 3. Endostaplers, 
energy devices and electric cautery of which diameters are larger than 3mm go into 
the thoracic lumen through the main port. 4. Finally we remove specimens and set the 
chest tube within the main port incision at the end of surgery. Results: We performed 15 
segmentectomies and 96 lobectomies of the lung using this method for the lung cancer. 
We dissected mediastinal nodes in all cases. We had one case that was converted to the 
conventional method, and one case that was converted to the open method. However 
we elongated the incision of one puncture from 3 mm to 10 mm in four cases in order 
to insert endostaplers for dissecting pulmonary veins and arteries. Mean operation time 
was 220±63 minutes. It was not significantly different from that of the conventional 
method. Mean blood loss volume was 16.6±22.3 ml. It was significantly less than that 
of the conventional method. Post-operative peak titers of CK and CRP of this method 
were significantly lower than that of the conventional method. We had no severe 
intraoperative accidents or postoperative complications. All patients were smoothly 
discharged. Conclusion: This one plus three method is less invasive than a conventional 
procedure. We were able to successfully perform the needlescopic lobectomy and 
segmentectomy for lung cancer as well as conventional thoracoscopic surgery. This 
method would be the optimal and optional method if and when we appropriately select cases. 
Keywords: lung cancer, Surgery, Thoracoscopy, Needlescope
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P1.02-019 Effectiveness of Touch Cytology on the Staple Line in the 
Assessment of Resection Margins for Pulmonary Malignant Tumors 
Rie Nakahara1, Ikuma Wakamatsu1, Seiji Igarashi2, Haruhisa Matsuguma1 1Division of 
Thoracic Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi/Japan, 2Division of Pathology, 
Tochigi Cancer Center, Utsunomiya, Tochigi/Japan
Background: Assessing the presence of cancer cells in resected margins following 
partial or segmental resection of malignant lung tumors is an important step when 
planning complete resection. When the tumor is deemed proximal to the resection 
margin, the policy at our hospital is to swiftly conduct touch cytology on the staple line 
of the resected tissue sample and, when positive, to perform additional resection. In the 
present study, we evaluated whether or not this strategy is appropriate. Methods: From 
among 161 patients who had a partial or segmental lung resection at our hospital 
between April 2009 and December 2013, forty-two patients who underwent touch 
cytology of resection margins were evaluated. Variables investigated were cytodiagnostic 
findings, tumor size and distance from margin, and subsequent occurrence of local 
relapse. Results: Resection of lung metastasis was performed on 16 of the 42 patients, 
intentional limited resection for primary lung carcinoma was performed in 13 patients, 
and conservative limited resection was performed on 13 patients due to issues with 
their respiratory function and systemic condition. Two patients tested positive on 
cytodiagnosis of the resected margin; hence, the surgical procedure was modified from 
partial to segmental resection and from lung lobe and partial resection to resection 
of both lobes, respectively. Moreover, both of these patients underwent conservative 
procedures, and both tumors were adenocarcinoma. Mean tumor size (mm) in the 
metastasis group, intentional limited resection group and conservative limited resection 
group was 14 mm, 15 mm and 24 mm respectively, and distance to resection margin 
was 9.3 mm, 11.2 mm and 8.6 mm respectively. None of the 42 patients, including the 
2 patients who tested positive, exhibited subsequent local relapse. Conclusion: Both 
the patients who tested positive on cytodiagnosis belonged to the conservative limited 
resection group and tended to have a larger tumor size than patients in the other 
groups. Inadequate distance from the resected margin with respect to tumor size 
increases the risk of a positive result at the resected margin. Of the 42 patients in the 
present study who underwent touch cytology of resected margins, none experienced 
subsequent local relapse, which implies the appropriateness of our evaluation method. 
Keywords: touch cytology, limited resection, assessment of resection margins
enhanced computed tomographic scan (CT) for PTE. Results: Of all patients, only 1 
failed to undergo preoperative measurement of D-dimer because of emergency surgery. 
Among the remaining 275 patients, a total of 113 patients ( 95 with elevated D-dimer, 15 
with varicose veins in their lower extremities, one with swelling in his extremities, one 
with paralyzed inferior limbs, and one with previously diagnosed PTE ) were examined 
with venous ultrasonography of lower extremities. Of them, 34 patients (12.6%) were 
diagnosed DVT (Figure 1) Proximal and distal DVT were diagnosed in ten patients ( three 
with isolated DVT, three with multiple DVT, and four with a wide range of huge clots ) and 
24 patients ( 15 with isolated DVT and nine with multiple DVT ) , respectively. Of them, 
none was diagnosed preoperative PTE. For a peri-operative management, all the patients 
received unfractionated heparin. In addition, of four patients with a wide range of huge 
clots, three had prophylactic inferior vena cava filter placed. Of 34 patients, one was 
diagnosed asymptomatic exacerbation of DVT by ultrasonography one week after 
surgery, but none developed symptomatic PTE. 
Conclusion: This study showed an DVT prevalence of 12.6% in patients undergoing 
thoracic surgery in Japan. However, none developed symptomatic PTE in the peri-operative 
period.  
Keywords: deep vein thrombosis, Thoracic Surgery
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P1.02-017 Complications after Lobectomy or Segmentectomy for 
cT1aN0M0 Non-Small Cell Lung Cancer Takashi Ohtsuka, Yasoo Sugiura, Ikuo 
Kamiyama, Hisao Asamura Department of Surgery, Division of Thoracic Surgery, Keio 
University, Tokyo/Japan
Background: Although lobectomy is considered the standard surgical approach for 
clinical T1aN0M0 non-small cell lung cancer (NSCLC), several recent studies have shown 
segmentectomy could be a substitute for lobectomy for early stage NSCLC. However, 
the differences of perioperative complications between lobectomy and segmentectomy 
have not yet been fully evaluated. The aim of this study is to investigate the postoperative 
complications which occurred after lobectomy or segmentectomy using propensity-
matched analysis. Methods: Between February 2006 and February 2013, 100 patients 
underwent lobectomy and 111 patients underwent segmentectomy for clinical T1aN0M0 
NSCLC. A retrospective comparison with each group was performed in perioperative 
mortality, morbidity, operative time, blood loss, length of hospital stay, chest tube 
duration and clinical parameters including age, gender, preoperative forced expiratory 
volume in 1 second percentage predicted (preop FEV1%), and Charlson Comorbidity 
Index (CCI). Data was analyzed for all patients and their propensity score matched 
pairs. Results: The rate of postoperative complications in the segmentectomy group 
(n = 21, 19%) was significantly higher than that in the lobectomy group (n = 7, 7%) (p < 
0.01). The majority of complications were prolonged air leak. There was no significant 
difference in postoperative length of hopital stay and chest tube duration.The average 
operative time of 263 ± 64 minutes and estimated blood loss of 133 ± 125 ml for 
segmentectomy were significantly more than those of lobectomy (201 ± 61 minutes 
and 88 ± 101ml, respectively). In propensity score matched analysis (61 patients each), 
the average operative time of 270 ± 70 minutes for segmentectomy was longer than 
that of lobectomy (202 ± 67 minutes). Postoperative complications were more frequent 
in the segmentectomy group than those in lobectomy group (19.6% and 6.5%, p = 
0.03). Conclusion: Although segmentectomy could offer preservation of pulmonary 
function, significantly more postoperative complications occurred in the segmentectomy 
group compared with lobectomy group. The majority of complications were prolonged air 
leaks in all patients and propensity matched pairs. The operation time was also longer in 
the segmentectomy group. Surgeons should bear in mind that complications can happen 
more frequently after segmentectomy than after lobectomy for cT1aN0M0 NSCLC. 
Keywords: lung segmentectomy, complications, surgery
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Results:
ICG-fluorescent imaging was observed 10 out of the 11 patient. 1 squamous cell 
carcinoma was not detected fluorescent. 2 false – positive nodules (necrotic 
inflammation) were identified among the 10 fluorescent specimens. Fluorescence signal 
of nodules (Signal to Background Ratio (SBR)) was 4.3 ± 2.5. There was no significant 
difference depending on histology, size and tumor grade. However, Fluorescence signal 
of 2 false – positive nodules was 9.5 ± 0.7 was higher than nodules. Conclusion: This 
study demonstrated that fluorescence imaging using a low dosage of ICG can be useful 
to identify and locate pulmonary nodules during surgery. However, our results (2 false 
positive) also show limitation of present fluorescence image guide surgery which 
used only ICG for passive cancer targeting. Base on this result, we thought that for 
ideal fluorescence guided surgery, we will need a further study about active targeting 
by using biomarker as well as passive targeting. We hope that this data will give us 
some clue to develop fluorescence guided surgery technique in lung cancer surgery. 
Keywords: Fluorescence, Indocyanine green, pulmonary nodule
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P1.02-022 Sleeve Lobectomy Is a Safe and Effective Oncologic Procedure: A 
Single Center Experience over Three Decades Luis Carlos Silva Corten1, Johnny 
Moons1, James Villeneuve2, Alessia Stanzi1, Lieven Depypere1, Hans Van Veer1, Philippe 
Nafteux1, Willy Coosemans1, Herbert Decaluwé1, Dirk Van Raemdonck1, Paul De Leyn1 
1Thoracic Surgery, University Hospitals Leuven, Leuven/Belgium, 2Thoracic Surgery, Ottawa 
General Hospital, Ottawa/ON/Canada
Background: Sleeve lobectomy is a parenchyma-sparing technique suitable for 
treating central tumors, avoiding pneumonectomy. The aim of this study was 
to assess perioperative and long-term survival outcomes in patients treated by 
sleeve lobectomy. Methods: Data were analysed from a prospectively collected 
database. All consecutive cases of sleeve lobectomy/bilobectomy (1985 - 
2013) were included. Cox-Regression was used to analyse survival outcomes. 
There were 300 patients available for analysis. Sleeve lobectomy was performed in 272 
patients (RUL:153; RML:5; RLL:1; LUL:83; LLL:30), sleeve bilobectomy in 28 (RUM:17; 
RLM:11). In most patients a sleeve of the bronchus (n=219) or a reversed sleeve of 
the bronchus (n=19) was performed. Arterial (n=35) or combined arterial and bronchial 
sleeve (n=27) resections were less common. The most common operative indication was 
non-small cell lung cancer (254 cases, 85%), less commonly for carcinoid (n=27), small 
cell lung cancer (n=6) , pulmonary metastasis (n=9) and 4 others. Results: Patients 
were predominantly male (85%) with a mean age of 62.7 years (range 20.1-84.6). 
Postoperative course was uneventful (Dindo-grade 0/1) in 60%; with minor complications 
(Dindo-grade 2/3a) in 30% and major complications (Dindo-grade 3b/4) in 7.3%. In 
hospital mortality (Dindo-grade 5) was 2.7%. Overall median survival was 68 months, 
with a 5- and 10-year survival of 52.3% and 35.8%. A Cox-Regression model showed five 
independent prognosticators for survival: asymptomatic at presentation, age, pT, pN 
and neoadjuvant treatment (see table). Although neoadjuvant treatment showed to be a 
negative prognosticator for survival, complete responders (n=8 or 14.5% of neoadjuvant 
treated patients) showed a mean survival of 132 months and a 5-year survival of 80%.
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P1.02-020 Physiological Assessment in Thoracic Surgery for High Risk Patients 
with Lung Cancer; How Do International Guidelines Compare? Haider Al-Najjar, 
Matthew Evison, Nigel Clayton, Stuart Britton, Rajesh Shah, Philip Crosbie, Richard 
Booton Manchester Thoracic Oncology Centre, University Hospital of South Manchester, 
Manchester/United Kingdom
Background: Surgical resection is the best curative option in patients with 
appropriately staged lung cancer. Physiological assessment is vital in selecting patients 
for surgical resection with particular attention to risk of mortality and morbidity with 
the planned surgery. This is most crucial in patients deemed high-risk. Physiological 
parameters employed include spirometry (FEV1%), diffusion (DLCO%), Shuttle walks, 
Cardiopulmonary Exercise Testing (VO2Max absolute value and %) as well as post-
operative predicted values for all of these tests using segment counting to discriminate 
depending on the planned surgery. However, three major international guidelines 
exist which advocate different approaches to assessing this patient group (BTS, ERS, 
ACCP). We aim to assess how these guidelines compare to one another and our local 
practice in informing decision-making. Methods: Patients with operable thoracic 
malignancy who were candidates for surgery and had CPET were eligible for inclusion. 
We retrospectively analysed all patients who underwent CPET at the University Hospital 
of South Manchester, a tertiary Thoracic Oncology Centre, between 01/01/2013 and 
31/12/2013. Physiology reports, clinical correspondence and survival databases 
were analysed. Results: 96 patients fulfilled the inclusion criteria. 3 were excluded 
due to no available pulmonary function data. A further 17 were excluded as they were 
denied surgery for non-physiology reasons (patient declined surgery, metastatic 
disease discovered before, small cell histology, adequate resection margin impossible, 
severe comorbidities). The remaining 74 patients were included in the final analysis. 
62/74(84%) underwent surgery (12 pneumonectomy, 3 bilobectomy, 33 lobectomy, 4 
segmentectomy, 6 wedge resection, 4 futile thoracotomy due to finding unexpected 
advanced disease) The overall breakdown of risk classification of patients using the 3 
guidelines was as follows. BTS: low-risk 27/74 (36%), medium-risk 31/74 (42%), high-
risk 16/74 (22%). ACCP: low-risk 19/74 (26%), medium-risk 52/74 (70%), high-risk 3/74 
(4%). ERS: low-risk 47/74 (63%), medium-risk 16/74 (22%), high-risk 11/74 (15%). Of 
the patients BTS guidelines classed high-risk, we operated on 8/16 (1 pneumonectomy, 
3 lobectomy, 1 segmentectomy, 2 wedge resection, 1 futile thoracotomy) with 100% 
survival at 90 days. We did not operate on any of the 3 patients classed high-risk by 
ACCP guidelines. Of the patients ERS guidelines classed high-risk, we operated on 5/11 
(1 pneumonectomy, 1 bilobectomy, 2 lobectomy, 1 segmentectomy) with 100% survival 
at 90 days. Of those classed high-risk by ACCP 2/3 would be high-risk by BTS guidelines 
and of those classed high risk by BTS 2/16 would be high-risk by ACCP guidelines. Of 
those classed high-risk by ERS 8/11 would be high-risk by BTS guidelines and of those 
classed high-risk by BTS 2/16 would be high-risk by ERS guidelines. Conclusion: From 
our results a lack of concordance between the three guidelines in classification of high-
risk is evident. Also, with the exception of the ACCP guidelines, our local practice has 
shown that patients deemed high-risk for surgery were operated on (upto and including 
pneumonectomy) with no cases of 90-day mortality. With this in mind an appraisal of 
current guidelines is indicated as well as a more consistent approach worldwide to 
ensure that no potentially fit patients are excluded from surgical resection of lung cancer. 
Keywords: Pulmonary function tests, Thoracic Surgery, Respiratory Physiology, 
Cardiopulmonary Exercise Test
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P1.02-021 The Feasibility of Fluorescence Image-Guided Surgery for 
Pulmonary Nodules Hyun Koo Kim1, Yu Hua Quan2, Byeong Hyun Choi2, Kook Nam 
Han2, Young Ho Choi2 1Thoracic and Cardiovascular Surgery, Korea University Guro Hospital, 
Seoul/Korea, 2Korea University Guro Hospital, Seoul/Korea
Background: Recently, fluorescence imaging using indocyanine green (ICG) has 
been applied to cancer, not only to visualize the sentinel lymph node, but also to 
identify mass during surgery. We hypothesized that this fluorescence imaging will also 
be useful to identify and locate pulmonary nodules during surgery. We try to detect 
pulmonary nodules and measure fluorescence intensity by using reasonable dosage of 
ICG. Methods: We enrolled 11 patients who were diagnosed with a pulmonary nodule. 
ICG is administered intravenously at a dose of 1 mg/kg prior to operation. Surgical 
specimens were investigated using a near-infrared light camera system (SPY Elite) at 20 
hours after injection. And we examined the histologic characteristics of the specimens.
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P1.02-024 Conditional Survival after Surgical Treatment of Non-Small Cell 
Lung Cancer Takayuki Fukui, Toshiki Okasaka, Koji Kawaguchi, Koichi Fukumoto, Shota 
Nakamura, Kohei Yokoi Thoracic Surgery, Nagoya University, Nagoya/Japan
Background: Conditional survival (CS) is an estimate of survival probability for patients 
who have already survived at least 1 year after diagnosis or treatment. This study was 
intended to find some useful informations in postoperative follow-up plan by CS analyses 
of resected non-small lung cancer patients. Methods: We retrospectively analyzed data 
on the clinicopathological features and survival outcomes of 925 patients with non-small 
cell lung cancer who had undergone complete resection at Nagoya University Hospital 
between 2005 and 2012. CS is the probability of surviving additional time (y) after 
already surviving time (x), and can be calculated from the following formula: CS(y|x) 
= S(x+y)/S(x), where S(t) is the overall survival at time (t). In this study, two methods 
of CS analyses were performed. Briefly, CS(5|x), which meant 5-year conditional 
survival (5Y-CS(x)), and CS(5-x|x), which was the probability of surviving when five 
years has passed from surgery (CS5(x)), were calculated in the various setting or 
subgroups. Results: The cohort consisted of 624 males and 301 females, ranging in 
age 26 to 89. The 5-year overall survival rate of all patients was 76%. 5Y-CS(1,2,3,4) 
was 74, 76, 77, 80%, respecively, showing gradually improvement. This meant that the 
given treatment for NSCLC including surgery contributed the survival of the patients to 
some degree. However, the 5Y-CS did not approach 100%, which indicated a certain 
number of patients coninued to die during the follow-up period. The CS5(1, 2, 3, 4) in all 
patients were 79%, 84%, 90% and 96%, respectively, which meant the 90% of patients 
who were alive at 3 years after surgery would survive for next 2 years. The patients with 
younger female (≤ 70 years), no or light smoker, adenocarcinoma histology, pathologocal 
stage I and normal serum carcinoembryonal antigen level showed the CS5(3) higher than 
90%. Both CS5(3) and 5Y-CS(3) of the patients with all the six favorable factors reached 
98%. Conclusion: Postoperative follow-up visit after 3 years from surgery might be 
minimum for the patients with younger female, no or light smoker, adenocarcinoma 
histology, pathological stage I, and normal serum carcinoembryonic antigen level. 
Keywords: conditional survival, non-small cell lung cancer, postoperative follow-up
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P1.02-025 Complete VATS Resection and Reconstruction of Carina and 
Trachea for Malignant or Benign Disease Jianxing He, Jingpei Li, Hanzhang 
Chen, Weiqiang Yin, Jun Liu, Xin Xu, Xin Zhang, Wei Wang Department of Thoracic 
Surgery, Guangzhou Medical University First Affiliated Hospital, Guangzhou 510120, China, 
Guangzhou/China
Background: General thoracic surgery involving carinal and/or tracheal reconstruction 
is technically demanding. The aim of this study is to discuss the feasibility of complete 
video assisted thoracoscopic surgery (VATS) in the surgical treatment of disease involving 
the carina and/or trachea. Methods: Between May 2012 and April 2015, seven cases of 
malignant or benign disease involving carina and/or trachea were treated via complete 
VATS resection and reconstruction of carina and trachea in our hospital. Among the 
seven patients (median age, 47 years; range, 43-60 years), two patients suffered from a 
malignant tracheal tumor, one from a main bronchial malignant tumor invading the carina, 
two from right upper lobe malignant tumor invading the carina, and two from benign 
bronchial stenosis due to endobronchial tuberculosis. A prospective analysis of clinical 
characteristics, operative data, and postoperative events was performed.
 
 
Conclusion: Sleeve lobectomy can be safely performed as treatment for 
centrally-located lung tumours. A single-institution experience over 3 decades 
demonstrates acceptable morbidity and mortality rates. Overall survival 
seems to be mainly determined by oncologic variables (TNM-staging factors). 
Keywords: sleeve lobectomy, broncho-plastic resection, long term, lung cancer
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P1.02-023 The Role of Selective EBUS-TBNA Mediastinal Sampling in Early 
Lung Cancer Rajaram Burrah1, Phillip Antippa1, Daniel P. Steinfort2, Louis B. Irving2 
1Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne/ACT/Australia, 2Respiratory 
Medicine, Royal Melbourne Hospital, Melbourne/ACT/Australia
Background: Accurate pre-operative staging of the mediastinum in lung 
cancer is essential to determine the type of treatment. The commonly 
used investigations are CT scan, PET scan, EBUS-TBNA (Endobronchial 
ultrasound-guided transbronchial needle aspiration) and mediastinoscopy, and often 
these tests complement each other to increase the accuracy of staging. With advances in 
technology and increased experience, EBUS has the potential to replace mediastinoscopy 
to stage the mediastinum. Surgical mediastinal dissection, though commonly performed, 
has not been convincingly proven to have a therapeutic value. We postulate that if the 
mediastinum can be staged accurately with EBUS-TBNA (a low morbid procedure) then 
a surgical staging of the mediastinum (mediastinoscopy and / or dissection) can be 
avoided and therefore, avoid the morbidity associated with these procedures. We 
have studied the use of selective EBUS-TBNA which is sampling abnormal nodes on 
imaging (CT, PET scan) and compared it with the mediastinal dissection done surgically. 
Methods: This is a retrospective study of patients who underwent surgery (lobectomy/
pneumonectomy + mediastinal lymphnode dissection) for early stage lung cancer (stage 
I/II).Patients who had negative N2 lymph nodes on EBUS-TBNA evaluation were included in 
the study. All patients had CT and PET scans which assisted the EBUS study. The results of 
EBUS-TBNA were compared with that of the surgical mediastinal lymph node dissection. 
Results: A total of 86 patients were included in the study. EBUS-TBNA correctly staged 
the mediastinum in 78 patients (90.7%, negative predictive value (NPV) = 0.90). Eight 
patients had false negative (FN) evaluation by EBUS-TBNA. On review, two of these patients 
had a sampling error. Three patients had incomplete evaluation of the mediastinum. All 
these 3 patients had left lung cancer whose level 5 lymph nodes could not be sampled, 
and surgical sampling displayed these nodes to be involved with extracapsular spread. 
There were three other patients with FN results, and they had mediastinal nodes biopsied 
by EBUS which with surgical removal showed metastasis. Two of these patients had 
metastatic deposits < 3mm in size. We feel that diligent and systematic EBUS would 
have avoided the FN result in most of the above patients except for sampling of level 5 
nodes which may not be technically accessible by EBUS. The NPV for right lung cancers, 
especially right upper lobe (NPV=0.96) was higher as compared to left sided cancers. 
Conclusion: This study shows that selective EBUS-TBNA mediastinal staging 
in early lung cancer is feasible, has an acceptable NPV and provides evidence 
to facilitate studies on systematic EBUS. This study draws attention thorough 
the identified 8 FNs to the real and potentially avoidable limitations of selective 
EBUS mediastinal lymphnode sampling. The accuracy of systematic EBUS 
evaluation should be superior to a selective study and can therefore potentially 
avoid a surgical staging of the mediastinum and its associated complications. 
Keywords: Staging, EBUS, lung cancer
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in focusing on T3 central non-small cell lung cancer (NSCLC). Methods: Patients who 
underwent sleeve lobectomy (n = 58) or pneumonectomy (n = 42) were retrospectively 
analyzed. For bias reduction, these 100 patients had been selected according to the 
following criteria: (1) tumor located in the main bronchus less than 2 cm distal to the 
carina, (2) there was no N2 disease, (3) no induction therapy was applied, (4) a complete 
resection was achieved. Results: Sleeve lobectomy and pneumonectomy patients have 
had comparable mean ages, gender distribution, mean forced expiratory volume in 1 
second, stage and tumor grade. Postoperative mortality (3.4% vs 4.8%, p = 1.0) and 
morbidity (41% vs 38%, p = 0.74) were similar between the two groups. Recurrences 
occurred in 48% of patients after sleeve lobectomy and in 31% of those after 
pneumonectomy (p = 0.08). The 5-year survival after sleeve lobectomy (64.8%) and 
pneumonectomy (61.4%) was not significantly different (p = 0.20). Multivariable survival 
analysis showed that there were no independent prognostic factors. Conclusion: Sleeve 
lobectomy does not compromise survival for NSCLC with T3 central disease 
compared with pneumonectomy. It is an adequate oncologic resection and should be 
treated as the first line intervention whenever complete resection can be achieved. 
Keywords: sleeve lobectomy, pneumonectomy, lung neoplasm
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P1.02-027 Thoracoscopic Segmentectomy of Pulmonary Nodules after 
Computed Tomography-Assisted Bronchoscopic Metallic Coil Marking 
Takanori Miyoshi, Masayuki Sumitomo, Mariko Aoyama, Naoki Hino Department of 
Thoracic Surgery, Tokushima Municipal Hospital, Tokushima City/Japan
Background: With advances in computed tomography (CT), small pulmonary lesions 
previously unseen on chest radiographs are being increasingly detected. Among lesions 
less than 10 mm in size, a considerable number of malignancies have been reported. 
To localize small and deeply situated pulmonary nodules during thoracoscopy with 
roentgenographic fluoroscopy, we developed a marking procedure that uses a metallic 
coil and a coin for thoracoscopic segmentectomy. Methods:Thirteen patients underwent 
video-assisted thoracoscopic surgery for removal of 14 pulmonary lesions. Fluoroscopy-
assisted thoracoscopic surgery after CT-assisted bronchoscopic metallic coil marking 
was performed using an ultrathin bronchoscope under fluoroscopy viewing a coin on a 
patient’s chest wall. The coin was simulated a pulmonary lesion by the CT findings, and it was 
put on the patient’s chest wall. During thoracoscopy, a C-arm-shaped roentgenographic 
fluoroscope was used to detect the radiopaque nodules. The nodule with coil markings 
was grasped with forceps and resected in segmentectomy under fluoroscopic and 
thoracoscopic guidance. Results: The marking procedure took 10 to 50 minutes 
from insertion to removal of the bronchoscope. There were no complications from the 
marking, and all 14 nodules were easily localized by means of thoracoscopy. The metallic 
coil showed the nodules on the fluoroscopic monitor, which aided in nodule manipulation. 
Nodules were completely resected under thoracoscopic guidance in segmentectomy. 
The pathologic diagnosis was primary adenocarcinoma in 7 patients, a primary 
adenosquamous carcinoma in 1 patient, pulmonary metastases in 3 patients, an atypical 
adenomatous hyperplasia in 1 patient, a hamartoma in 1 patient and a nontuberculous 
mycobacteriosis in 1 patient. One case of a bronchiolo-alveolar adenocarcinoma with 
an extensive two segments was performed a curative segmentectomy. Conclusion: In 
this study, CT-guided transbronchial metallic coil marking with an ultrathin bronchoscope 
with a coin on a patient’s chest wall after CT-assisted stimulation was found to be 
feasible and safe. In our previous report, CT had been needed at least three times, 
but this method needed only twice CT scan. It might be a useful method not only for 
making a diagnosis but also for therapeutic resection in selected early lung cancers. 
Keywords: VATS, coil marking, CT assisted bronchoscopy, segmentectomy
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P1.02-028 Surgical Resection for Sarcomatoid Carcinoma of the Lung 
Tarek Kilani1, Sarra Zairi1, Sadok Boudaya1, Hazem Zribi1, Mouna Mlika2, Adel 
Marghli1, Aida Ayadi2, Hammouda Boussen3, Faouzi Mezni2, Tahar Mestiri1 1Thoracic 
and Cardiovascular Surgery, Abderrahmane Mami Hospital, Ariana/Tunisia, 2Pathology, 
Abderrahmane Mami Hospital, Ariana/Tunisia, 3Medical Oncolog, Abderrahmane Mami 
Hospital, Ariana/Tunisia
Background: Sarcomatoid carcinoma of the lung is not very common. It consists 
of poorly differentiated non-small cell carcinomas with sarcoma or sarcoma-
like differentiation component. The World Health Organization lists five subtypes 
representing an overall continuum of epithelial and mesenchymal differentiation: 
pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, 
and pulmonary blastoma. The diagnosis is pathological and requires a good sampling 
of the tumor. The purpose of this study was to assess the surgical management 
of primary sarcomatoid carcinomas of the lung which could benefit from surgery 
with curative intent. Methods: We retrospectively reviewed the 38 cases of primary 
sarcomatoid carcinoma, which were managed between 2000 and 2012, in the 
thoracic surgery department of our Hospital. All the included patients had surgical 
resection. Results: There were 33 males and 5 females with a mean age of 59.7 years 
(42-81). The main symptoms were respiratory. Imaging features showed a pulmonary 
mass invading pleura or the thoracic wall in 14 cases. The diagnosis was confirmed in all 
cases on histological examination of the resected tumor. According to the pathological 
results there were 23 pleomorphic carcinomas, 7 giant cell carcinomas, 1 spindle cell 
carcinoma, 5 carcinosarcomas and 2 blastomas. Associated treatments were split as 
follows: neoadjuvant (four cases) or adjuvant (six cases) chemotherapy, and radiotherapy 
(ten cases). Lobectomy (26 cases) or bilobectomy (2 cases) was performed in 28 
patients and pneumonectomy in 9 patients. Chest wall enlargement with costal resection 
 
Results: There were five different types of VATS airway reconstruction in our group, 
including left main bronchus resection and carinal reconstruction, right main bronchus 
resection and carinal reconstruction, right upper lobectomy and carinal reconstruction, 
right upper lobectomy and half carinal reconstruction, and tracheal resection and 
reconstruction. Median data of surgical outcome are as follows: operative time-200 
minutes (range, 50-300 minutes); time of airway reconstruction-50 minutes (range, 
19-130 minutes); blood loss-100 mL (range, 30-1000 mL). One patient suffered from 
endobronchial tuberculosis; during the thoracic procedure we observed complete pleural 
adhesions which led to large volume of blood loss during pleuropneumonolysis. No 
conversions to thoracotomy were performed. There was no 30-day mortality. Median data 
of perioperative outcomes are as follows: postoperative hospital stay-12 days (range, 
7-15 days); ICU stay -1 day (range, 0-6 days) and duration of thoracic drainage- 2 days 
(range, 1-5 days). No patient required postoperative mechanical ventilation. One patient 
had to be assisted with bronchoscopy as a result of insufficient sputum excretion. Median 
duration of follow-up was 6 months (range, 0-37 months). Minor anastomotic stenosis(less 
than 1/4 diameter) was found in two patients during follow-up, but no complaints of 
significant impact on activity were noted. Conclusion: Complete VATS for carina and 
trachea resection and reconstruction is a technically challenging, but feasible procedure 
for both benign and malignant disease and should be restricted to skilled VATS surgeons. 
Keywords: VATS, carinal reconstruction, trachea reconstruction
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P1.02-026 For NSCLC with T3 (Central) Disease, Sleeve Lobectomy or 
Pneumonectomy? Qianli Ma, Deruo Liu, Yongqing Guo Thoracic Surgery, China-Japan 
Friendship Hospital, Beijing/China
Background: Pneumonectomy has traditionally been the treatment of choice for central 
lung tumors for which the alternative is sleeve lobectomy. The aim of this study was 
to compare early and long-term results after sleeve lobectomy and pneumonectomy 
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data were compared according to the p stage. Results: Overall 5-year survival rate in 
the 289 patients of left lung primary was 64.6%. Operative mortality in 289 patients 
was 3.0%,1.2% from January 2001 till December 2014. Lymph node metastasis to the 
mediastinum was confirmed in 98 (33.9%) patients (pN2 was 50 patients,pN3α was 
29 patients, pN3β was 2 patients, pN3γ was 17 patients). According to pathological 
stages, five-year survival rate was was 88.7% in stage IA, 75.3% in stage IB, 60.6% in 
stage IIA, 71.4% in stageIIB, 47.5% in stageIIIA, 39.6% in stageIIIB. Five-year survival 
rate was 48% in pN2 cases, and 48.8% in pN3α cases. Compere with previouse our 
reports, this result is more safety and better prognosis. Conclusion: Our result suggest 
that ND3 operation would provide better prognosis in the patients with pN2 and pN3α 
Lt.NSCLC. And better local tumor control by ND3 operation than conventional lung 
cancer operation does not increase mortality.Lung cancer surgery should be denied 
due to clinical N status because patient with N2,N3 disease NSCLC can be operated 
for curative intent by our ND3 with acceptable surgical risk and long term survival. 
Keywords: Lymph node dissection, mediastinal lymph node, median sternotomy, non 
small cell lung cancer
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P1.02-031 Wedge Resection for NSCLC: Does Minimally Invasive Surgery 
Warrant the Maximum Advantage? Pietro Bertoglio, Marco Lucchi, Carmelina C. 
Zirafa, Federico Davini, Alfredo Mussi Department of Surgical Medical Molecular Pathology 
and Critical Care, Divison of Thoracic Surgery, University Hospital of Pisa, Pisa/Italy
Background: Anatomic resections of the lung are firmly considered the gold standard 
treatment for early stage Non Small Cell Lung Cancer (NSCLC). The role of non-anatomic 
surgery is still not clear and it is generally used for very selected patients, who cannot 
undergo an anatomical resection of lung parenchyma for functional reasons. The aim of 
this study is to analyze whether surgical approach (VATS or open) might have an influence 
on the long term outcome of NSCLC patients treated by wedge resection. Methods: From 
December 2006 till 2010, 1695 patients underwent surgery for primary NSCLC at our 
Institution. Among them, 97 patients received a wedge resection either by open or 
thoracoscopic apprach due to coexisting morbidities or low pulmonary function; 54 were 
selected for our study. We excluded from our analysis all patients with a previous lung 
cancer, with suspected (on the basis of CT or PET CT images) or confirmed N2 disease, 
nodules greater than 5 cm or with involvement of the chest wall or mediastinal structures. 
Follow-up was carried out at December 2013. Results: Out of the 54 wedge resections, 
30 were performed through a thoracothomy, while 24 cases by means of a VATS 
procedures. There were no statistically significant difference among clinical features of 
the two groups. Mean tumor diameter were 2,1 cm in the open group (OG) and 1,7 cm in 
the VATS group (VG); mean distance from visceral pleura was significantly higher in the 
OG (2,1 cm vs 0,8 cm; p=0,02) and so were the stapler edge (2,4 cm vs 1,2 cm; p<0,03). 
Mean follow-up was 42 months. In the open surgery group 2 patients (6,7%) had a local 
recurrence and in 10 patients (33,3%) we noticed systemic metasthasis. In the VATS 
group we had 4 cases (16,7%) of local recurrences and 7 (29,2%) of distant metasthasis. 
Local recurrence rate was significantly different between the two groups (p=0,048), 
while no significant correlation was found regarding the distant methastasis rate. Three 
patients died during the follow up period (two in the group treated with thoracotomy, 1 
with VATS). Conclusion: Although different deepness of nodule between the two groups 
may represent a bias, we noticed a significant lower recurrence rate when surgery was 
performed by thoracotomy. Tumors larger than 1,5 cm are more likely to develop a 
recurrence, regardless to the kind of surgical approach. Wedge resection may be considered 
a feasible procedure for highly selected patients affected by NSCLC: open approach 
may be related to a better long term outcome in patients with small and deep nodules. 
Keywords: Non-small-cell lung cancer, wedge resection, VATS, limited resection
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P1.02-032 Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy 
in Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701) 
Norihito Okumura1, Junichi Soh2, Masao Nakata3, Hiroshige Nakamura4, Minoru Fukuda5, 
Masafumi Kataoka6, Shinsuke Kajiwara7, Yoshifumi Sano8, Motoi Aoe9, Kazuhiko 
Kataoka10, Katsuyuki Hotta2, Keitaro Matsuo11, Shinichi Toyooka2, Hiroshi Date12 
1Kurashiki Central Hospital, Kurashiki/Japan, 2Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Okayama/Japan, 3Kawasaki Medical 
School, Kurashiki/Japan, 4Tottori University Faculty of Medicine, Yonago/Japan, 5Japanese 
Red Cross Nagasaki Genbaku Hospital, Nagasaki/Japan, 6Okayama Saiseikai General 
Hospital, Okayama/Japan, 7Uwajima City Hospital, Uwajima/Japan, 8Ehime University 
Hospital, Touon/Japan, 9Kagawa Prefectural Central Hospital, Takamatsu/Japan, 10Iwakuni 
Clinical Center, Iwakuni/Japan, 11Kyushu University Faculty of Medical Sciences, Fukuoka/
Japan, 12Kyoto University Graduate School of Medicine, Kyoto/Japan
Background: The aim of this multicenter study (the Setouchi Lung Cancer Group Study 
0701) was to determine the feasible administration schedule of S-1, an oral fluoropyrimidine, 
for adjuvant chemotherapy in patients with completely-resected pathological stage IA 
(tumor diameter, 2 to 3 cm) non-small-cell lung cancer (NSCLC). Methods: Patients 
were randomly assigned to receive an adjuvant chemotherapy of either 4-week oral 
administration of S-1 (80 mg/m2/day) followed by 2-week rest (group A), or 2-week oral 
administration of S-1 (80 mg/m2/day) followed by one week rest (Group B). The duration 
of adjuvant chemotherapy was one year in both arms. The primary endpoint was feasibility. 
was associated in 5 cases. One patient had a conservative resection (segmentectomy) 
because of a history of contralateral adenocarcinoma for which he had a lobectomy (2 
years earlier). The tumors were classified as: T1 in 2 cases, T2 in 16, T3 in 16 and T4 in 
4. The different stages were: Ia (n=2), Ib (n=8), IIa (n=1), IIb (n=13), IIIa (n=8), IIIb (n=2) 
and IV (n=4). The margins of the resected parenchyma showed tumoral involvement 
in 1 case. The median survival of our patients was 9 months. Two patients died in the 
early postoperative course. Conclusion: Sarcomatoid carcinomas are rare, aggressive 
tumors which require early diagnosis and management. Surgery whenever performed 
can be beneficial for these tumors which are of bad prognosis compared to other NSCLC. 
Keywords: Surgery, Sarcomatoid Carcinoma, NSCLC
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P1.02-029 Long and Short-Term Predictors of Outcome in Elderly Patients 
(≥ 75 Years) Undergoing Lobectomy for Stage I Non-Small Cell Lung Cancer 
Takashi Eguchi1, Daniel H. Buitrago1, Marissa Mayor2, Kyuichi Kadota3, Nabil P. Rizk1, 
Bernard J. Park1, David R. Jones4, Prasad S. Adusumilli2 1Thoracic Service, Department 
of Surgery, Memorial Sloan Kettering Cancer Center, New York/NY/United States of 
America, 2Thoracic Service and Center for Cell Engineering, Memorial Sloan Kettering Cancer 
Center, New York/NY/United States of America, 3Department of Diagnostic Pathology, 
Kagawa University, Kagawa/Japan, 4Thoracic Service, Memorial Sloan Kettering Cancer 
Center, New York/NY/United States of America
Background: More than 65% of patients diagnosed with non-small cell lung cancer 
(NSCLC) are above the age of 65 years. Half of this cohort are ≥75 years who are at higher 
risk following surgical resection, which is the mainstay of treatment for early-stage NSCLC. 
The purpose of this study is to determine the factors influencing the outcomes in patients 
≥75 years who underwent lobectomy for stage I NSCLC: postoperative complications, 
short-term (30- and 90-day mortality) and long-term (overall survival (OS) and cancer-
specific survival (CSS)). In addition to the routinely used clinical factors, we investigated 
the utility of lung age, the tool commonly used for smoking cessation. Methods: Patients 
with pathological stage I NSCLC who underwent lobectomy between 2000 and 2011, 
age ≥75 years at surgery with no induction therapy, and no previous lung resection 
were included in the study (n =435). We investigated the influence of smoking history, 
preoperative history of cardiovascular disease (CVD) and chronic obstructive pulmonary 
disease (COPD), Carlson comorbidity index (CCI), serum creatinine level, lung age 
(calculated by height and forced expiratory volume in one second), percent predicted 
diffusing capacity of the lung for carbon monoxide (%DLCO), and p-stage. Outcomes 
studied were postoperative in-hospital complication (CTCAE grade ≥3), 30- and 90-
day mortality, OS, and CSS. Complications and mortality were analyzed by chi-square 
tests for univariate analysis. OS and CSS were analyzed by Kaplan-Meier methods with 
log-rank tests for univariate analysis, and Cox proportional analysis for multivariate 
analysis. Results: Median chronological age was 79 years, whereas median lung age 
was 89 years (female gender n = 334, positive smoking history n = 391, p-stage IA/
IB were 282/153). In univariate analysis, low %DLCO and CVD history were significantly 
associated with postoperative complications (p = 0.032 and 0.018, respectively), 
and only high serum creatinine level was significantly associated with 30- and 90-day 
mortality (p = 0.02 and 0.027, respectively). P-stage, lung age, %DLCO, and COPD 
history were significantly associated with poor OS (p <0.001, p <0.001, p = 0.009 and 
0.008, respectively). P-stage, lung age, and COPD history were significantly associated 
with poor CSS (p =0.003, 0.004, and 0.046, respectively). In multivariate analysis, 
both p-stage and lung age were independently associated with poor OS (p <0.001 and 
<0.001, respectively) and poor CSS (p = 0.006 and 0.01, respectively). Conclusion: In 
elderly patients with stage I NSCLC undergoing lobectomy, p-stage and lung age were 
independent risk predictor for long-term prognosis (OS and CSS); serum creatinine 
level was associated with short-term mortality; and %DLCO and CVD history were 
associated with postoperative complications. Our observations from this large cohort 
are useful for treatment decision making in elderly patients with stage I NSCLC. 
Keywords: lung age, elderly, postoperative prognosis, non-small cell lung cancer
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P1.02-030 Effectiveness of Extended Bilateral Superior Mediastinal Lymph 
Node Dissection Through a Median Sternotomy in Patients with Left NSCLC 
Toshiya Yokota, Shingo Ikeda Thoracic Surgery, Misui Memorial Hospiral, Tokyo/Japan
Background: Lymph node dissection plays important role in oncologic surgery. The 
removal of the whole regional lymphatic system together with primary tumor is one of the 
fundamental rules in oncological surgery. But, the role of surgical treatment in non-small-
cell lung cancer (NSCLC) with clinically manifested mediastinal lymph node metastasis 
is controversial. Bilateral paratracheal lymphnodes for left side tumors are considered 
inaccessible through a standard thoracotomy. It is difficult to perform complete 
dissection of superior mediastinal lymph nodes through the left thoracotomy in the left 
lung cancer. We had devised Systemic extended bilateral superior mediastinal dissection 
and lung resection through a median sternotomy (ND3 operation, Hata’s method), 
and reported that ND3 operation can allow for complete dissection of all stations of 
mediastinal lymph nodes. The aim of this study was to evaluate the surgical outcomes 
and long term survival in patients of survival of the patient with non-small lung cancer 
(NSCLC) who underwent our ND3 operation. Methods: We retrospectively studied 289 
patients ( 202 male and 87 female, mean ages 59.7 years (range, 38-75)) , underwent 
ND3 operation due to Left NSCLC, from January 1988 till December 2014. The patients 
with NSCLC of left side primary who are estimated to be able to conventional radical 
operation and aged 75 years old or less becomes the adaptation of our ND3 operation. 
Postoperative survival rates calculated with Kaplan-Meier method. Clinicopathological 
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NHS Foundation Trust, Manchester/United Kingdom, 2Clinical Oncology, Belfast Health 
and Social Care Trust, Belfast/United Kingdom, 3Univ. of Manchester, Manchester/United 
Kingdom
Background: Intensity Modulated Radiotherapy (IMRT) facilitates superior dose 
conformity, due to sculpting of the high dose volume and reduction of dose to normal 
tissues. However, the use of IMRT for lung cancer in the U.K. remains low, as a result of 
the paucity of clinical data and concerns about the impact of the low dose bath on toxicity. 
Our institution has treated 738 lung cancer patients with IMRT since 2008. Here we 
report the results of 227 patients, focusing on toxicity. Survival will be reported at a later 
date. Methods: A retrospective review of the first 227 patients receiving 6MV inversely 
planned (6-8 field) step and shoot IMRT for lung cancer from 2008-2013 was carried 
out. A database was interrogated to correlate planning parameters with toxicity. Toxicity 
was collected using Common Terminology Criteria for Adverse Events (CTCAE) version 
3.0. Results: 227 patients with a median age of 66 (36-87) were included. Patients 
received a dose of 50-68 Gy in 20-33 fractions. One hundred and sixty (70%) had non-
small cell lung cancer, 47 (21%) small cell lung cancer, 8 (4%) mixed histology and 12 
(5%) no histology. At presentation, 6 (3%), 27 (12%), 184 (81%) and 9 patients (4%) had 
stage I, II, III and IV disease respectively. Treatment modalities were split evenly between 
concurrent (37%), sequential (31%) chemo-radiotherapy and radiotherapy alone (32%). 
Median PTV volume was 502.7 cc (67.3-1297.2). Median lung V20, V10 and V5 were 
27.7% (6.8-35.3), 50.4% (9.8-83.1) and 64.3% (12.9-98.9). Mean dose to the oesophagus 
was 23.8 Gy (3.1-51.0); oesophageal V55 and V35 were 2.9% (0-70.8) and 36.8% (0-
79.8). Heart V30 and V5 were 23.6% (0-60.6) and 57.6% (0-100) respectively. Despite 
104 patients (46%) with V5 values > 65%, acute G3 pneumonitis was observed in only 7 
(3.1%) patients. Acute G3 oesophagitis was observed in 31 (13.7%) patients. Late toxicity 
was not available in all patients. 6/154 (4%) developed late G3 pneumonitis, 8/154 
(5.3%) had late G3 dyspnoea and late G2 cough was reported in 12/154 (8.1%). Grades 
1, 2 and 3 pulmonary fibrosis occurred in 68/178 (30%), 13/178 (6%) and 1/178 (0.4%) 
patients respectively. Oesophageal stricture was evident in 7/173 (3%) and 4 patients 
developed an oesophageal fistula. There was no significant correlation between lung V5 
and acute or late lung toxicity, using >65% as a cut off. Similar results were found with 
lung V10. There was also no relationship between mean oesophageal dose/V35/V55 and 
fistula or oesophageal stricture. Conclusion: From our experience, IMRT to the thorax 
is well tolerated, with minimal grade 3 toxicity. Contrary to reports, we did not observe 
a correlation between lung V5 and acute/late lung toxicity. However the heterogeneous 
population, retrospective nature of this study and small number of grade 3+ events limit 
the scope for multivariate analysis of toxicity. The data needs to be confirmed with a 
larger number of patients and integrated within predictive models of radiation-induced 
toxicity using patient reported outcome tools to facilitate collection of prospective 
toxicity data in the routine clinical setting. Data will be updated prior to the meeting. 
Keywords: lung cancer, intensity modulated radiotherapy, toxicity
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P1.02-035 Radiographic Changes in Lung of Patients Treated with Stereotactic 
Ablative Body Radiation Therapy and the Dosimetric Correlations Fen Wang1, 
John Park2, Bruce F. Kimler1, Rajeev Badkul1, Parvesh Kumar1 1University of Kansas 
Medical Center, Kansas City/KS/United States of America, 2Kansas City Va Hospital, Kansas 
City/MO/United States of America
Background: To describe radiographic evidence of radiation 
pneumonitis (rRP) and fibrosis (rRF) and determine what dosimetric parameters 
correlate with rRP and rRF after stereotactic ablative radiation therapy 
(SABR) to the lung. Methods: 98 follow up CT scans from 32 patients treated 
by SABR were retrospectively reviewed for CT appearance of rRP and rRF 
determined by the Ikezoe (≤ 6 months) and Koenig (≥ 7 months) systems. The correlation 
of dosimetric parameters such as planning target volume (PTV) and the volume of 
lung receiving dose of radiation (V2.5, V5, V7, V10, V15, V20, V25, and V30) to rRP, 
rRF, and fibrotic volume (Vfibrosis) were analyzed using Spearman’s rho. Results: The 
median follow up was 10 months (range 2 – 24 months). There was a 55% incidence 
of rRP and 59% incidence of rRF. The low dose parameters of V2.5, V5, V7, and V10 (the 
volume of lung receiving more than 2.5, 5, 7, and 10 Gy of radiation, respectively) 
were correlated to the development of rRP (p < 0.05). There was only V10 correlated 
statistic significantly to the incidence of rRF, with V5, V7, and V10 trended towards 
significance. The median Vfibrosis was 119 cm
3 with a range of 49 – 829 cm3. The 
medians of the PTV and ITV were 52.6 cm3 and 12.6 cm3,respectively. The absolute 
fibrotic volume was correlated with the planning target volume (PTV), V7 and V10 (p < 
0.05). Conclusion: The development of rRP and rRF was associated with the volume 
of lung that received lower dose of radiation. The absolute fibrotic volume from SABR 
was correlated with PTV and the volume of lung receiving lower dose of radiation. 
This finding needs to be validated with more patients’ data and longer follow up. 
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P1.02-036 Peripheral Blood Immunophenotype Changes Following Thoracic 
Stereotactic Ablative Radiotherapy Megan E. Daly1, Karen Kelly2, Abhinav Reddy3, 
Gail D. Sckisel3, Renee N. Donahue4, William J. Murphy3, Arta M. Monjazeb1 1Radiation 
Oncology, University of California Davis Comprehensive Cancer Center, Sacramento/CA/
United States of America, 2Hematology Oncology, Uc Davis Comprehensive Cancer Center, 
Sacramento/CA/United States of America,3Dermatology, University of California Davis, 
Sacramento/United States of America, 4Laboratory of Tumor Immunology and Biology, 
Center for Cancer Research, National Cancer Institute, National Institutes of Health, 
Bethesda/MD/United States of America
Results:
 
Eighty patients were enrolled, of whom 76 were received S-1 treatment. The treatment 
completion rates were 49.4% [95% confidential interval (CI), 32.8 to 65.9%] in group A 
and 52.1 % (95%CI, 35.5 to 68.6%) in group B (P = 0.4). The relative dose intensities were 
40.4% (95%CI, 20.3 to 60.5%) in group A and 53.5% (95%CI, 37.7 to 69.3%) in group B (P 
= 0.4). There were no treatment-related deaths. Patients with grade 3/4 toxicities were 
significantly more frequent in group A (40.5%) than group B (15.4%, P = 0.02). The 2-year 
relapse-free survival rates were 97.5% in group A and 92.5% in group B, and the 2-year 
overall survival rates were 100% in both groups. Conclusion: Two-week oral administration 
of S-1 followed by one week rest for one year may be more feasible for adjuvant 
chemotherapy in patients with completely-resected stage IA (T diameter, 2 to 3 cm) NSCLC. 
Keywords: adjuvant chemotherapy, Non-small-cell lung cancer
POSTER SESSION/ TREATMENT OF LOCALIZED DISEASE – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.02-033 Pemetrexed plus Platinum as Adjuvant Therapy in Patients with 
Resected Lung Adenocarcinoma and Exploratory Biomarkers Analysis 
Bing Wang1, Weiyu Shen2, Hong Jiang3, Kan Wu1, Ruping Zhao1, Xiao Xu1, Shirong 
Zhang3, Bing Xia1, Shenglin Ma1 1Hangzhou First People’S Hospital, Hangzhou Cancer 
Hospital, Hangzhou/China, 2Ningbo Medical Treatment Center Lihuili Hospital, Ningbo/
China, 3Hangzhou First People’S Hospital, Hangzhou/China
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-
related death around the world. Currently, adjuvant platinum-based chemotherapy is 
recommended as the standard treatment for patients with completely resected stage 
IB-IIIA NSCLC. Pemetrexed, a multitargeted antifolate agent, has been shown to have 
definite activity in non-squamous NSCLC and has proven to be efficacious in the first-line 
metastatic NSCLC. Hence, the aim of this study was to evaluate the efficacy and toxicity 
of pemetrexed/ platinum in patients with completely resected lung adenocarcinoma 
and identify prognostic factors in this setting. Methods: A retrospective study was 
performed in patients with completely resected stage IB-IIIA lung adenocarcinoma 
who received pemetrexed and a platinum as adjuvant therapy. Generally, pemetrexed 
500mg/m2 d1 and cisplatin 30mg/ m2 day1-3 were administrated every 21-28 
days for 4 cycles. Study endpoints included overall survival (OS), progression-free 
survival (PFS) and treated-related toxicities. Immunohistochemical (IHC) was used 
to examine the protein expression of p53, thymidylate synthase (TS), dihydrofolate 
reductase (DHFR), Lipocalin 2 and nm23-H1 in surgical resection specimens of 23 
patients. The associations between protein expression level and clinical outcome were 
evaluated using cox proportional hazards model. Results: Between Feb. 2012 and 
Jan.2014, 49 patients were treated with pemetrexed-based chemotherapy. Median 
age 57(range35-79, years), males 47%; stage IB 41%, II 18%, IIIA 41%; ever smokers 
35%; lobectomy 92%, wedge resection 8%. The completion of 4-cycle chemotherapy 
was 67.3%. Grade 3+ hematologic and gastrointestinal toxicities were observed in 5 
(10%) patients and 4 (8%) patients, respectively. The median PFS was 39.63 months 
(95%CI 26.55-52.71 months), and the median OS was unreachable. 1-, 2- and 3-year 
survival rates were 95.9%, 93.6%, 83.2%, respectively. 1-, 2- and 3-year PFS rates 
were 93.9%, 75.3% and 56.8%, respectively. Of 23 patients measured by IHC, 19 
expressed TS, 9 expressed p53, 10 expressed DHFR, and none expressed Lipocalin 
2 or nm23-H1. No significant correlations of these protein expression and clinical 
outcome were observed. Conclusion: The regimen of pemetrexed/platinum showed 
lower incidence rates of toxicities and promising treatment outcomes in patients 
with completely resected stage IB-IIIA lung adenocarcinoma. However,no prognostic 
biomarker was identified in our study, which may be related to the small sample size. 
Keywords: lung adenocarcinoma, Biomarkers, pemetrexed, adjuvant chemotherapy
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P1.02-034 Lung v5 Does Not Predict for Lung Toxicity after Fixed-Beam 
Intensity Modulated Radiotherapy (IMRT) Clara Chan1, Paula Mccloskey2, Linda 
Ashcroft1, Philip Whitehurst1, Jason Kennedy1, Annalie Shears1, Michelle Bewley1, 
Rhiannon Goldstraw1, Neil Bayman1, Corinne Faivre-Finn3 1Clinical Oncology, The Christie 
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73.2%, 81.0%, 50.7%, 66.8% and 27.8%, respectively. The median follow-up duration 
was 14.6 (range, 0.7-80.8) months. Of 51 patients (24.9%) who developed RIPE, 
40 had symptomatic RIPE including chest pain (47.1%), cough (23.5%) and short of 
breath or dyspnea (35.3%). The median (range) RIPE interval from end of TRT was 
3.7 (0.6-18.0) months. The RIPE rates of the two institutions were 20.2% and 32.1% 
with a borderline signifi cance (p = 0.053). Caucasian race (HR = 2.930, 95% CI: 1.197-
7.172, p = 0.019) and histology of squamous cell lung cancer (HR = 0.645, 95% CI: 
0.425-0.980, p = 0.04) were signifi cantly associated with the low risk of RIPE, while 
age (p = 0.378), gender (p = 0.071), stage (p = 0.148), radiation dose (p = 0.782) and 
concurrent chemotherapy (p = 0.173) were not. The whole lung V5, V10, V15, V20, V25, 
V30, V35, V40, V45, V50 and MLD were signifi cantly higher in patients with RIPE than 
in those without RIPE (p = 0.007, 0.022, 0.044, 0.048, 0.034, 0.016, 0.010, 0.026, 
0.040 and 0.014), and only V5 was the signifi cant predictive factor for both RIPE and 
symptomatic RIPE (p = 0.007 and 0.021) with the largest areas under ROC curve (AUC 
= 0.779). Using a cutpoint of 41.5% for V5, the sensitivity and specifi city were 100% 
and 61.5%, respectively. Conclusion: Radiation induced pleural effusion is notable. 
Caucasian race and squamous cell tumor histology may be associated with lower risk 
of RIPE. The whole lung V5 seems to be a signifi cant risk factor for symptomatic RIPE. 
Keywords: Thoracic radiation induced pleural effusion, risk factors, lung cancer
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P1.02-038 A Comparison of Stereotactic Body Radiation Therapy vs. No 
Treatment for Patients with Early-Stage Non-Small Cell Lung Cancer
Stefan S. Jeppesen1, Tine Schytte2, Carsten Brink3, Niels Christian G. Hansen4, 
Olfred Hansen5 1Institute of Clinical Research, University of Southern Denmark, 
Odense C/Denmark, 2Department of Oncology, Odense University Hospital, Odense 
C/Denmark, 3Laboratory of Radiation Physics, Odense University Hospital, Odense/
Denmark,4Center of Thoracic Oncology, Odense University Hospital, Odense C/
Denmark, 5Department of Oncology, Odense University Hospital, Odense/Denmark
Background: Scarce information is available concerning the natural history of untreated 
patients with early-stage Non-Small Cell Lung Cancer (NSCLC). No randomized studies 
have been conducted comparing Stereotactic Body Radiation Therapy (SBRT) with no 
treatment for patients with early-stage NSCLC. Previously, it has been suggested that 
SBRT increases overall survival for patients with NSCLC T1-2N0M0. In this study a national 
group of untreated patients with early-stage NSCLC was identifi ed in order to compare 
the effect of SBRT with the natural history in a retrospective setting. Methods: From 
2007 to 2013, 136 patients diagnosed NSCLC T1-2N0M0 with a tumor diameter up to 5 
cm were treated with SBRT at Odense University Hospital. The thoracic RT consisted of 
45-66 Gy/3 F delivered in 9 days. For the same period, a national group of 121 untreated 
patients with early-stage NSCLC was extracted from the Danish Lung Cancer Registry. 
Of these, 85 patients survived more than one month after the diagnosis was established 
and might have been candiates to SBRT. Twenty-four patients with unrecorded tumor 
diameter were excluded from the present analysis thus, 61 patients remained in the 
untreated group. Pathoanatomical diagnosis was known for all patients. Kaplan-Meier and 
Cox proportional hazard analyses were used for uni- and multivariable survival analyses, 
respectively. Overall survival (OS) was calculated from the date of diagnosis. Results: The 
mean age was 72 vs. 78 years in the SBRT and untreated group, respectively. Statistically 
signifi cant (p<0.05) inter-group differences in patient characteristics were observed for 
pathological type and FEV1 (%predicted). No difference in gender, tumor size, ECOG 
performance status, or pack years was observed. The potential median follow-up time 
was 38 months in the SBRT group vs. 57 months among untreated. A log rank test 
showed a signifi cant difference of overall survival (OS) between groups e.g. resulting in 
an OS at 5-year of 44% vs. 10% respectively and a median OS of 47.8 vs. 12.2 months 
for SBRT and untreated group, respectively (p < 0.01). Multivariate analysis indicated 
that age, tumor size, pack years, gender, adenocarcinoma and FEV1 (%predicted) had no 
signifi cant infl uence on survival, while SBRT and ECOG performance status had (Table 1).
Conclusion: In this study SBRT was associated with signifi cantly longer OS compared to 
no treatment, suggesting that SBRT is a convenient treatment that increases survival for 
patients with early-stage NSCLC. Keywords: Natural history, Early-stage, NSCLC, SBRT
Background: Stereotactic ablative radiotherapy (SAR) is a standard therapy for early 
stage, medically inoperable non-small cell lung cancer (NSCLC) and select metastatic 
tumors. Strategies combining SAR and immune checkpoint inhibitors are of great interest 
in potentially augmenting anti-tumor immune response, and prospective trials evaluating 
SAR/immunotherapy combinations are underway. However, the systemic immune 
response profi le following SAR is poorly defi ned. Better understanding of the systemic 
immune response following SAR should allow optimization of SAR/immunotherapy 
protocols. We performed pre and 1 week post-SAR immune profi ling on patients 
undergoing lung SAR, focusing on central memory T-cells which have been implicated as 
important mediators of systemic anti-tumor immune responses. Methods: Patients are 
actively accruing to an IRB approved protocol examining systemic immunophenotype 
changes following SAR for early stage (T1-2N0) NSCLC or metastatic lesions to the lung. 
Patients underwent collection of 30 cc blood by venipuncture immediately prior to and at 
1 week post-SAR to a median dose of 50 Gy (range: 50-54 Gy) over 5 fractions (range: 
3-5 fractions). Immunophenotyping of peripheral blood mononuclear cells (pbmc’s) was 
performed using fl ow cytometric analysis. Central Memory T-cells were defi ned as 
CD62L+ and CD45RA- subsets of CD4+ or CD8+ T-cells. Changes pre-treatment to post-
treatment were compared across the cohort using a paired T-test. Results: To date 
eleven NSCLC patients have accrued, and evaluable pre- and post-SAR specimens are 
available for six, all with early stage NSCLC (T1=4, T2=2, synchronous primaries =1). At 
one week post-SAR increases in systemic central memory CD4+ T-cells were observed 
in 4/6 patients and increases in systemic central memory CD8+ T-cells were observed in 
3/6 patients with substantial (up to 10-fold) increases observed in some patients. Across 
the cohort the percent of circulating memory CD4+ T-cells increased from 1.9% pre-SAR 
to 3.1% post-SAR (p=0.06, Figure 1) and the percent of circulating memory CD8+ T-cells 
increased from 0.3% pre-SAR to 0.5% post-SAR (p=0.34, Figure 1). Conclusion: Our 
preliminary data in a limited patient cohort suggest lung SAR may induce systemic 
upregulation of circulating central memory T-cells which may be important mediators of 
the anti-tumor immune response. As more patients accrue, additional post-treatment 
time points are evaluated, and further analyses including cytokine/chemokine signatures 
are performed, we aim to better defi ne systemic immunophenotype changes induced by 
lung SAR, assess how these changes relate to treatment toxicity and effi cacy, and 
whether they can predict which patients will most likely benefi t from the addition of 
immunotherapy to SAR.
 
Keywords: SBRT, Immunophenotype, biomarker
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P1.02-037 Thoracic Radiation-Induced Pleural Effusion and Risk Factors in 
Patients with Lung Cancer Jing Zhao1, Matthew Stenmark2, Jianyue Jin3, Catherine 
Ferguson3, Hadyn Williams4, Leslie Quint5, Shulian Wang6, Martha Mastuzak2, Randy 
Ten Haken2, Regina M. Day7, Feng-Ming (Spring) Kong3 1Georgia Regents University;Tongji 
Hospital, Tongji Medical College, Huazhong University of Science and Technology, Augusta/
GA/United States of America, 2Department of Radiation Oncology, University of Michigan 
Health System, Ann Arbor/United States of America, 3Department of Radiation Oncology, 
Gru Cancer Center/Medical College of Georgia, Georgia Regents University, Augusta/
United States of America, 4Department of Radiology, Gru Cancer Center/Medical College of 
Georgia, Georgia Regents University, Augusta/GA/United States of America, 5Department 
of Radiology, University of Michigan Health System, Ann Arbor/United States of 
America, 6Department of Radiation Oncology, Georgia Regents University, Cancer Hospital 
and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 
Augusta/GA/United States of America, 7Department of Pharmacology, Uniformed Services 
University of the Health Sciences, Bethesda/MD/United States of America
Background: Pleural effusion is regarded as a frequent late toxicity after thoracic 
radiotherapy (TRT). However, recent literature is lacking on this toxicity. This study 
aimed to examine the patient and dosimetric risk factors associated with radiation 
induced pleural effusion (RIPE) in lung cancer patients treated with TRT. Methods: Lung 
cancer patients treated with TRT having follow-up imaging, CT or PET/CT, were eligible. 
Pleural effusion of increased volume after TRT without evidence of tumor progression 
was considered to be RIPE. Parameters of lung dose-volume histogram including 
percent volumes irradiated with 5 to 55 Gy (V5-V55) and mean lung dose (MLD) were 
analyzed. Optimal dosimetric thresholds for RIPE were calculated by receiver operating 
characteristic (ROC) analysis. Associating clinical and treatment-related risk factors for 
RIPE were detected by univariate and multivariate analyses with SPSS 18.0. Data were 
considered statistically signifi cant at value of p < 0.05. Results: Of 806 consecutive 
patients who received TRT at two institutions, 205 had post-treatment imaging available 
and were included in this study. The median (range) age was 63 (34-85) years; Male, 
Caucasian race, current smokers, stage III and squamous cell cancer accounted for 
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was administered 25 and chemoradiation to 7 patients. No differences were observed 
between patient groups in age or Charlson Co-morbidity Index. A total of 47 operated 
patients were downstaged to pathological N0 or N1 disease and pathological N2 disease 
was observed in 27 patients, of 11 patients had multi-level N2 involvement. Median 
survival for pN0/1 was 47 months, pN2 15 months and definitive chemoradiation 19 
months. Survival for pathological N-stage is presented in Figure 1, and for preoperative 
therapy in Figure 2.
 
 
Conclusion: Operative treatment for clinically suspected N2 disease is feasible option 
if patients are downstaged to pathological N0 or N1 with means of chemoradiation 
therapy or pre- or intraoperative frozen sections. Surgery for pathological N2 disease 
has no survival advantage over definitive chemoradiation and should be discouraged. 
Keywords: Staging, non-small cell lung cancer, Logoregional disease
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P1.03-002 Surgery in Subclassified Stage IIIA-N2 Lung Cancer Improves 
Survival Hans-Stefan Hofmann1, Jan Braess2, Susanne Krause2, Michael Allgäuer3, 
Tamas Szöke1, Michael Ried4 1Department of Thoracic Surgery, Hospital Barmherzige 
Brüder Regensburg, Regensburg/Germany, 2Department of Oncology, Hospital Barmherzige 
Brüder Regensburg, Regensburg/Germany, 3Department of Radiotherapy, Hospital 
Barmherzige Brüder Regensburg, Regensburg/Germany, 4Department of Thoracic Surgery, 
University Medical Center Regensburg, Regensburg/Germany
Background: Lung cancer with mediastinal lymph node involvement (N2) is a heterogeneous 
entity. The Robinson-classification subdivided these N2-patients in four groups (IIIA1-IIIA4). 
Objective of this analysis was to investigate the result of strict treatment strategies for 
N2-patients determined by the interdisciplinary tumorboard. Methods: Retrospective 
study and survival analysis of 118 consecutive patients with stage IIIA-N2 lung cancer 
classified according to the Robinson-classification and treated within a multimodality 
treatment regime between January 2009 and June 2014. All patients were evaluated 
and discussed in an interdisciplinary lung tumorboard and a therapy recommendation 
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P1.02-039 Stereotactic Radiotherapy as Salvage Treatment after Stereotactic 
Radiotherapy or after Operated Non-Small-Cell Lung Cancer 
Charlotte Kristiansen1, Tine Schytte1, Stefan S. Jeppesen2, Olfred Hansen1 1Department 
of Clinical Oncology, Odense University Hospital, Odense C/Denmark, 2Institute of Clinical 
Research, University of Southern Denmark, Odense C/Denmark
Background: Lobectomy is regarded as the standard of care for early stage non-small-
cell lung cancer (NSCLC), but stereotactic radiotherapy (SBRT) is an option for patients 
who are not candidates for surgery. Although the curative intention treatments, a 
significant proportion of patients with NSCLC will develop recurrent disease. For patients 
previously treated with SBRT little is known of retreatment with SBRT in the recurrent 
setting. Methods: All patients with lung cancer treated at our center with SBRT have 
been registered prospectively. We identified the patients who had salvage SBRT after 
prior pulmonary surgery or SBRT. Overall survival was calculated from the day of salvage 
SBRT. Results: Between November 2008 and February 2015, 198 patients were treated 
with SBRT. We identified 24 patients that had received SBRT as salvage treatment for 
their first recurrence in the lung. Surgery was the initial treatment for 13 of the patients 
(OP-group) and SBRT was the initial treatment for the remaining 11 patients (RT-group). 
By the end of follow up, 5 patients in the OP-group had died and 3 in the RT-group. In 
the OP-group all the salvage SBRT was given as 66 Gy in 3 fractions. In the SB-group, 5 
was treated with 56 Gy in 8 fractions, 1 with 45 Gy in 3 fraction and 1 with 45 Gy in 10 
fractions when given salvage SBRT.
Primary 
surgery Primary SBRT All
Number of patients 13 11 24
Age mean (range) 75 (62-88) 69 (53-87) 72 (53-88)
Histology Plano/Adeno/NOS 3/8/2 4/5/2 7/13/4
Time in months from pri-
mary treatment to salvage 
SBRT median (range)
65 (4-236) 17 (5-44) 21 (4-236)
Survival time from SBRT 1 
year (%) 85 89 87
2 year (%) 62 61 60
Median follow-up months 
(range) 
27.6 (14.3-
62.8) 15.9 (1.4-32.9) 21 (1.4-62.9)
Lung function FEV1, median 
(range 1.4 (0.6-2.7) 1.4 (0.4-2.8) 1.4 (0.4-2.8)
ECOG Performance Status 0 4 1 5
1 5 2 7
2 3 7 10
3 1 1 2
Conclusion: Although the time from primary treatment to salvage SBRT 
was longer if surgery was the primary treatment than if the primary 
treatment was SBRT, the overall survival was equal for the two groups. 
Keywords: Operation, recurrence, SBRT, NSCLC
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P1.03-001 Survival of the NSCLC Patients with Clinical Stage IIIA Disease with 
N2 Involvement: Case-Control Study with Emphasis on Treatment Modality 
Saana Andersson, Ilkka Ilonen, Jarmo A. Salo Department of General Thoracic Surgery, 
Heart and Lung Center, Helsinki University Central Hospital, Helsinki/Finland
Background: The aim of this study was to determine the survival rate of patients with 
non-small cell lung cancer (NSCLC) who were preoperatively diagnosed with positive 
N2 lymph node and compare survival with chemo- or chemoradiotherapy treated 
patients to surgically operated patients, with or without preoperative chemoradiation 
therapy. Methods: Study included two patient groups. Operative patient group consisted 
of 74 clinical Stage IIIA patients with cN2 lymph node involment, from a 1105 patient 
cohort, who were operated between January 2000 and December 2014. Definitive 
chemoradiation group consisted of 49 Stage IIIA NSCLC patients that were treated 
between September 2008 and October 2014. Institutional tumour board was used 
to evaluate operative treatment. Routine positron emission tomography (PET) was 
established in 2006 at our institution. Results: 37 had preoperative mediastinoscopy, 
66 PET-CT and 24 received both. In the operative patient group, adjuvant chemotherapy 
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little is known about the treatment outcomes. As such, we reviewed our institutional 
experience to determine if subsequent development of lung tumors is common and 
whether prognosis is comparable to stage III NSCLC in general. Methods: This study 
was an IRB-approved retrospective review of an institutional NSCLC database. Twenty-six 
patients with biopsy-proven NSCLC involving mediastinal lymph nodes with no identifiable 
lung primary lesion and no evidence of distant metastases treated with curative intent 
between 1995-2013 were identified. PET-CT staging was performed in 25 of 26 patients. 
All followup was calculated from date of diagnosis. Results: The median followup was 44 
months. The median age at diagnosis was 60 years (range 51-81) among the 18 males 
(69%) and 8 females (31%). N2 and N3 disease were each present in 13 (50%) patients, 
respectively. Histologies included adenocarcinoma in 12 (46%), squamous cell carcinoma 
in 10 (38%), NSCLC not otherwise specified in 3 (12%), and large cell lung carcinoma in 
1 (4%). Eleven patients underwent EGFR mutation analysis, with no sensitizing mutations 
identified. All patients had a smoking history (median 35 pack-years). Four (15%) patients 
underwent complete surgical resection, of whom 3 underwent induction chemotherapy 
and 1 was treated with surgery alone. One of the four patients underwent post-operative 
radiation therapy to 54 Gy. Twenty-two (85%) patients were treated with definitive 
radiation therapy including sequential chemotherapy and radiation in 8 (mean RT dose 
= 70 Gy), concurrent chemoradiation in 10 (mean RT dose = 60 Gy), neoadjuvant 
chemotherapy followed by concurrent chemoradiation in 3 (mean RT dose = 66 Gy), 
and radiation alone in 1 (treated to 60 Gy). The median overall survival was 78.1 months 
with actuarial 2- and 5-year survival rates of 78% and 67%, respectively. Five patients 
developed intrathoracic failure at a median of 19.8 months. One patient had an isolated 
lung failure at 13.6 years, but this likely represents a secondary primary and not tumor 
recurrence. Two patients had isolated mediastinal lymph node failures at 18.1 and 19.8 
months and 2 patients initially had a mediastinal lymph node recurrence at 0.2 and 3.4 
years, but subsequently failed in the lung at 8.5 and 3.6 years respectively. The actuarial 
2- and 5-year intrathoracic control rates were 85.7% and 78.6%. Nine patients developed 
metastatic disease at a median of 16.5 months. The 2- and 5-year actuarial freedom 
from distant metastases was 70.9% and 59.1%. Among patients receiving definitive 
radiation, there was no difference between those receiving concurrent chemotherapy 
and those who did not. Conclusion: To our knowledge, this is the largest reported 
series of occult primary NSCLC involving mediastinal nodes. Definitive local therapy, 
including radiotherapy and surgery, was associated with very favorable locoregional 
control and survival, particularly compared with expected outcomes for stage III NSCLC. 
Keywords: non-small cell lung cancer, occult primary, chemoradiation, locally advanced 
disease
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P1.03-005 Bilobectomy for Lung Cancer: Postoperative Results, and Long-
Term Outcomes M Rahouma, Galal Ghaly, Mohamed Kamel, Brendon Stiles, Subroto 
Paul, Jeffery Port, Paul Lee, Abu Nasar, Nasser Altorki Cardiothoracic Surgery, Weill 
Cornell Medical Center-Ny Presbyterian Hospital, Ny/United States of America
Background: Bilobectomy for treatment of lung cancer is considered a high-risk 
procedure as it is associated with increased postoperative complication rate and the 
negative impact on survival. We analyzed the safety and the oncologic results of this 
procedure. Methods: We retrospectively reviewed a prospectively collected database to 
retrieve patients who underwent bilobectomy for lung cancer between 1991 and 2015. 
Age, gender, neoadjuvant treatment, bilobectomy type and indication, complications, 
pathology, stage, and survival were analyzed using Cox regression in univariate and 
multivariate analysis. Kaplan–Meier survival curves were obtained and compared 
by log–rank. Results: From our 4144 resected lung cancer cases, bilobectomy was 
performed on 106(2.5%) patients (55 men; mean age, 65.5 years). There were 51 upper-
middle and 55 middle-lower bilobectomies (adenocarcinoma,67 (63.3%); squamous cell 
carcinoma,35(33%); carcinoid tumor,4(3.8%)). Indications were tumor invasion of the 
bronchus intermedius in 58 (54.7%), vascular invasion in 26 (24.5%), and tumor crossing 
the fissure in 22 (20.8%) patients. Induction therapy was performed in 24 patients 
(24.5%). Thirty-day mortality was 1.89% (n = 2). Overall major morbidity occurred 
in 13 patients ( 12.3%) among them 9 patients(69.2%) had pulmonary complications 
. Overall 3 and 5-year survivals were 64.5% and 56.2% respectively. Disease free 3 
and 5-year survivals were 47.4% and 43.8% respectively. Significant decrease in 5 year 
survival was observed among smoker (p=0.046), higher tumor grades (Grade3 versus 
1or2 (p=<0.005)), higher stages (stage I, 66.6%; stage II, 51.5%; stage III, 31.2%; p= 
0.012)(see Figure) and the nodal(N) disease s (N0, 58.2%; N1and 2, 38.1%; p = 0.054) 
adversely influenced survival. Multivariate analysis demonstrated that a higher tumor 
grade (p = 0.005), a larger tumor (p=0.019), advanced N status (p=0.085) and smoking 
(p=0.056) adversely affecting prognosis. 
was made based on the Interdisciplinary Guideline of the German Respiratory Society 
and German Cancer Society. Results: Robinson subgroups were: IIIA1 (n= 28; mean age 
60.4 years), IIIA3 (n= 70; mean age 63 years) and IIIA4 (n= 20; mean age 64.4 years). 
We have no stage IIIA2, because we did not perform an intraoperative frozen section 
of mediastinal lymph nodes. Surgical resection with systematic lymph node dissection 
was performed in all patients with stage IIIA1 (n= 28). After induction chemotherapy or 
chemo-/radiotherapy, 47% of patients in IIIA3 (n= 33) and 10% of patients in IIIA4 (n= 2) 
could be operated with curative intention. Complete tumor resection (R0) was achieved 
in 93% (n= 26) in stage IIIA1, in 94% (n= 31) in stage IIIA3 and in 100% (n= 2) in stage 
IIIA4. Operative mortality within 30 days was 3.17%. Overall median survival was 29.8 
months. The 3- and 5-year survivals were 44.9% and 28.5%, respectively, in all patients 
with stage IIIA-N2 disease. There were no significant differences (p= 0.477) in survival 
regarding the Robinson subgroups. Patients who underwent surgical tumor resection 
had a significant better median survival (43.6 vs. 22.8 months; p= 0.013) compared to 
patients treated conservatively. In addition, patients in stage IIIA3 who were considered 
for surgery after induction therapy had a significant better median survival according 
to non-surgically treated patients (45.4 vs. 22.8 months; p= 0.014) and they had the 
good overall survival of IIIA1 patients (3- and 5-year survival rates of 59.4% and 40.8%). 
Deviation of the interdisciplinary recommended therapy (n= 15) lead to a significant 
reduced median survival (12.9 vs. 31.9 months; p= 0.011) compared to implementation 
of the suggested treatment approach (n= 100). Conclusion: Stage IIIA-N2-patients 
should be classified according to the Robinson-classification and discussed in the 
tumorboard. The treatment recommendation should be respected, because enforcement 
of the interdisciplinary recommended therapy significantly impacts survival. Surgical 
resection did lead to significant better survival rates. All stage IIIA3 and IIIA4 patients 
should be reevaluated for surgery depending on their response to induction therapy. 
Keywords: lung cancer, Robinson-classification, surgery, multimodality therapy
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P1.03-003 A Clinicopathological Study of Resected Small-Sized Non-Small 
Cell Lung Cancer 2 cm or Less in Diameter with N2 Lymph Node Metastasis 
Yasufumi Kato, Junichiro Ohsawa, Yoshihisa Shimada, Junichi Maeda, Koichi Yoshida, 
Masaru Hagiwara, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda 
Thoracic Surgery, Tokyo Medical University Hospital, Tokyo/Japan
Background: The detection of small-sized (≤ 2 cm) non-small cell lung cancer (NSCLC) 
has increased with the development of high-resolution computed tomography. The 
reported 5-year survival rate of T1a (≤ 2 cm) N0M0 patients is more than 80%, and 
that of p-T (≤ 2 cm) N2M0 patients has also steadily improved. Methods: Between 
January 1991 and December 2011, a total of 917 patients with small-sized NSCLC 
underwent curative pulmonary resection with systematic lymph node dissection by 
open thoracotomy or video-assisted thoracic surgery at our hospital. We retrospectively 
evaluated their postoperative clinical outcomes and survival rates. Survival was analyzed 
using the Kaplan-Meier method and log-rank test. Results: There were 57 (6.2%) 
patients with mediastinal lymph node metastasis (pN2 disease). The distributions of the 
histological types were adenocarcinoma 41 cases, squamous cell carcinoma 11, large 
cell carcinoma 4, and carcinoid 1. The procedures included lobectomy in 48 cases, 
segmentectomy in 6, and pneumonectomy in 3. The respectively status of lymph node 
metastasis was single station in 36 cases and multiple station in 21. Skip lymph node 
metastasis (no hilum lymph node metastasis) was observed in 13 cases. In 44 cases, 
there was both hilum lymph node and mediastinal lymph node metastases. There were 34 
cases (59.6%) that were upstaged from preoperative clinical diagnosis (cN0 or N1). The 
median overall survival period and 5 year survival of the 57 patients with pN2 was 43.5 
months and 41%. The recurrence rate was 70% (40/57) and the median disease-free 
interval was 41.3 months. Of the 18 patients without recurrence, 14 (77.8%) had single 
station mediastinal metastasis. The 5-year overall survival rates with multiple station or 
single station mediastinal metastases were 34.5% and 48.9%, respectively (NS). The 
5-year overall survival rates with multiple (hilum and mediastinal) station lymph node 
metastases and only mediastinal station lymph node metastasis were 37.7% and 64.8%, 
respectively. Conclusion: This study showed that 6.2% of small-sized NSCLC had N2 
disease. Moreover, 59.6% of small-sized NSCLC was upstaged from clinical diagnosis 
to pathological diagnosis. Single station mediastinal metastases showed a longer 
overall survival rate (64.8%) than multiple station mediastinal lymph node metastases. 
Therefore, we recommend systematic lymph node dissection for local treatment 
as well as accurate diagnosis. As multiple mediastinal node metastases showed an 
unfavorable prognosis, surgery combined with systematic treatment is recommended. 
Keywords: recurrrence, non-small cell lung cancer, lymph node, mediastinal
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P1.03-004 Occult Primary Non-Small Cell Lung Cancer with Mediastinal 
Lymph Node Involvement Paul B. Romesser1, Andreas Rimner2, Amanda Foster2, 
Jamie E. Chaft3, James Huang4, David R. Jones5, Abraham J. Wu3 1Radiation Oncology, 
Memorial Sloan Kettering Cancer Center, New York/AL/United States of America, 2Radiation 
Oncology, Memorial Sloan Kettering Cancer Center, New York/NY/United States of 
America, 3Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York/United 
States of America, 4Surgery, Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America, 5Surgery, Memorial Sloan Kettering Cancer Center, New York/United 
States of America
Background: Non-small cell lung cancer (NSCLC) involving mediastinal lymph nodes 
without an identifiable primary tumor is a rare presentation. While definitive surgery 
or radiotherapy with or without concurrent chemotherapy is typically recommended, 
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disease, and they were divided into three groups according to the site of residual disease. 
The “bronchus group” included 9 patients: 5 with cancer cells at the bronchial stump, 3 
with carcinoma in situ change at the bronchial stump, and 1 with a clump of tumor cells 
in the parabronchial tissues (1 patient). The “lymph node group” included 5 patients with 
residual cancer cells in the lymph node. The “chest wall and lung tissue group” included 
14 patients with cancer cells present at the following locations: the margin of chest wall 
invasion (9 patients), vertebral bodies (2 patients), the pericardium (1 patient) and lung 
tissue (2 patients). Actuarial survival curves were estimated by the Kaplan-Meier method. 
Statistical comparisons between survival distributions were performed using the log-
rank test. A multivariate analysis was performed using the Cox proportional hazards 
model for overall survival analysis. A probability value of less than 0.05 was considered 
to be statistically significant. Results: This study included 24 men and 4 women with an 
age range of 49 to 80 years (median, 64 years). Six (21%), 18 (64%), and 4 (15%) patients 
had undergone pneumonectomy, lobectomy, and the other procedures, respectively. 
One (4%), 5 (18%), 19 (68%), and 3 (10%) patients had stage I, II, III, and IV disease, 
respectively. All 28 patients had non-small cell lung carcinoma. Eleven (39%), 12 (43%), 
and 5 (18%) patients had adenocarcinoma, squamous carcinoma, and other forms of 
carcinoma, respectively. The 5-year survival rate and median survival period were 30.3% 
and 37 months, respectively. The median recurrence-free survival time was 14.8 months. 
Regarding recurrence patterns, 11 (39%) patients did not experience recurrence, 4 (14%) 
developed only local recurrence, 5 (18%) developed only distant metastasis, 7 (25%) 
developed both local recurrence and distant metastasis, and 1 was lost to follow up. Sixteen 
patients received adjuvant therapy: 11 received radiotherapy, 3 received chemotherapy, 
and 2 received chemo-radiotherapy. Six patients (66%) in the bronchus group received 
radiotherapy. Six of the 11 patients with no recurrence were in the bronchus group. The 
univariate survival analysis identified the following factors that significantly influenced the 
5-year overall survival rate: R1 anatomical sites (other sites vs the bronchus, p=0.0467, 
HR 2.775) and adjuvant therapy (no adjuvant therapy vs adjuvant therapy, p=0.0084, 
HR 3.509). The multivariate survival analysis identified only one factor that influenced 
survival: adjuvant therapy (adjuvant therapy vs no adjuvant therapy, p=0.0056, 
HR7.284). Conclusion: Patients with R1 disease generally had a poor prognosis, but this 
study suggested that adjuvant therapy improves the prognosis of these patients. In terms 
of sites of R1 disease, the bronchus group had a better prognosis than the other groups. 
Keywords: residual tumor, lung cancer
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P1.03-008 Weekly Carboplatin/Gemcitabine + Concurrent Thoracic RT 
Followed by Consolidation Carboplatin/Gemcitabine for Inoperable Stage 
III NSCLC Manuel Domine, Cristina Carames, Francisco Lobo, Tatiana Hernandez 
Guerrero, Ana Leon, Victoria Casado, Gustavo Rubio, Irene Moreno, Jose Ignacio Martin 
Valades, Yann Izarzugaza, Juan Luis Arranz, Victor Moreno, Andrea Correa, Victor 
Zenzola, Susana Casado, Ana Ruperez, Roberto Hernandez, Jesus Garcia-Foncillas 
Oncology, Hospital Universitario- Fundacion Jimenez Diaz, Madrid/Spain
Background: Concurrent chemo and radiotherapy (CT- RT) is standard of care 
for inoperable stage IIIA/B non-small cell lung cancer (NSCLC). Optimal regimen 
and schedule of concurrent CT- RT remain undefined. This phase II trial evaluated 
carboplatin –gemcitabine + concurrent RT followed by consolidation carboplatin – 
gemcitabine Methods: Treatment schedule during CT-RT phase: weekly carboplatin 
(AUC 2) + gemcitabine (200mg/m2) for 6 weeks + concurrent RT (60 Gy). CT 
consolidation phase: carboplatin (AUC 3) gemcitabine (2500 mg/m2) every two weeks 
for 3 cycles. Primary endpoint was security and secondary response rate, time to 
progression (TTP) and overall survival (OS) Results: 24 patients were enrolled: Sex 
18 male, 6 female. Histology: 12 adenocarcinoma, 8 squamous, 4 undifferentiated 
large cell carcinoma. Stage: IIIB: 20, IIIA: 4. ECOG 0-1: 23, ECOG 2: 1. All the patients 
completed concurrent CT-RT and 22 consolidation CT. Toxicity:CT- RT phase: No grade 
4 toxicity was observed. Grade 3: Neutropenia 0, anemia 4.1%, thrombocytopenia 
12.5%, esophagitis 16.6%. CT consolidation phase: Grade 3-4 toxicity: Neutropenia 
16.6%, Anemia 21%, Thrombocytopenia 16.6% of the patients. 3 patients required 
red blood cell transfusion and 1 patient died for febrile neutropenia grade 4 during 
consolidation. Efficacy: Response Rate: 75% (Partial: 50% Complete: 22%), Stable 
disease 21% Progression 4%. Median TTP: 11 months (95% CI 7-17) and median OS: 
18 months (95% CI 16.2- 20.5) Conclusion: Concurrent carboplatin – gemcitabine with 
thoracic RT is feasible with a favorable profile showing less hematologic toxicity and 
esophagitis than other CT-RT regimens. CT consolidation showed severe hematological 
toxicity. This regimen is active and could be a good option to combine with concurrent RT. 
Keywords: Locally advanced NSCLC, Chemo-radiotherapy
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P1.03-009 Integration of Chemoradiotherapy in a Single Facility: Impact on 
Outcomes for Locally Advanced Non-Small Cell Lung Cancer Henry S.-M. Park1, 
Sanjay Aneja1, Christopher D. Corso1, Charles E. Rutter1, Nataniel H. Lester-Coll1, Roy 
H. Decker1, Lynn D. Wilson1, Anthony W. Kim2, Cary P. Gross3, James B. Yu1 1Therapeutic 
Radiology, Yale School of Medicine, New Haven/CT/United States of America, 2Surgery, Yale 
School of Medicine, New Haven/CT/United States of America, 3Internal Medicine, Yale School 
of Medicine, New Haven/United States of America
Background: One of the major challenges to delivering coordinated oncologic care is 
multimodality management. While it has been hypothesized that providing all treatment 
in a single institution (“integrated”) may improve access and outcomes, it is unclear 
whether outcomes are affected by receiving treatment at more than one facility 
(“nonintegrated”). Our aim was to determine whether integration of concurrent 
 
Conclusion: Bilobectomy is associated with a low mortality and an acceptable 
morbidity. Survival relates to disease stage and N factor. Optimal prognosis 
is obtained in patients with early stage, low grade tumors and nonsmoker. 
Keywords: Bilobectomy, lung cancer, postoperative results, long-term survival
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P1.03-006 Survival Analysis of 121 Cases of Stage III A (N2) Non-Small Cell 
Lung Cancer Treated with Surgery Resection Liang Dai, Hao Fu, Ying M. Fan, Pu W. 
Yan, Zheng X. Kang Thoracic Surgery, Beijing Cancer Hospital, Beijing/China
Background: Lung cancer is the leading cause of both morbidity and mortality related 
to cancer worldwide. The most controversial academic strategies for the treatment of 
lung cancer is ⅢA-N2 non-small cell lung cancer.This study was a retrospective analysis 
of the clinical features of stage ⅢA-N2 patients, in order to find the factors that affecting 
long-term survival in the postoperative patients of stage ⅢA-N2 NSCLC. Methods: One 
thousand two houndred and ningtyLung cancer patients from a prospectively maintained 
database, treated by a single surgeon group between January 2000 and Jun 2013, at 
Beijing Cancer Hospital, Peking University, were reviewed.121 patients of stage ⅢA-
N2 NSCLCs were analyzed, comparing gender, age, smoking index, perioperative 
chemotherapy, surgical approach, histological type, intravascular cancer emboli, pT 
stage and N2 lymph node status with long-term survival. Results: The postoperative 
pathological findings in this group showed that 79 patients(65.3%) were single-station 
N2, 42 patients (34.7%, 30 patients had 2 stations N2, 8 patients had 3 stations N2, 4 
patients had 4 stations N2) were multi-stations N2; 42 patients’ (34.7%) N2 status were 
ⅢA1/A2, and 79 patients (65.3%) N2 status were ⅢA3/A4; 54 patients (44.6%) had 
subcarinal lymph node metastasis. The overall 1,3,5-year survival rates of 121 patients 
was 91.7%, 62.2%, 43.6%, respectively, and the median survival time was 50.3 months. 
Univariate analysis showed that the 1,3,5-year survival rates between single-station 
N2 and multi-station N2 metastasis was 94.9% vs. 85.5%, 70.3% vs. 46.7%, 58.3% 
vs. 25.5% respectively, with a significant difference (p= 0.001); the 1,3,5-year survival 
rates between ⅢA1/A2 and ⅢA3/A4 was 97.6% vs. 88.5%, 78.3% vs. 53.5%, 52.7% 
vs. 38.4% respectively, with a significant difference (p=0.020); subcarinal lymph node 
metastasis was not a prognostic factor, the 1,3,5-year survival rates between metastesis 
and no metastasis was 92.6% vs. 91.0%, 56.0% vs. 68.4%, 37.4 vs. 49.5% respectively, 
with no significant difference (p=0.276). Gender, age, smoking index, perioperative 
chemotherapy, T stage, histological type, intravascular cancer emboli and other factors 
are not prognostic factors in this group. COX regression analysis showed that only single 
station N2 metastasis（HR=0.326，95%CI：0.186～0.572）and IIIA1/A2（HR=0.494
，95%CI：0.259～0.941）were the independence factors. Conclusion: 1. After a rigorous 
selection of stage ⅢA-N2 NSCLC, patients obtain good prognosis by surgery combined 
with multidisciplinary treatment. 2. Single-station N2 metastasis had a better survial 
comparing to multi-station N2 metastasis. 3. The dicovery of pathology of N2 metastasis 
in intraoperative or postoperative pathological findings (ⅢA1/A2) had a better survival 
comparing to pretreatment fingdings(ⅢA3/A4). 4. Subcarinal lymph node metastasis 
was not ⅢA-N2 indicator of poor prognosis in NSCLC. 5. Gender, age, surgical approach, 
histological type, pT staging does not affect the stage ⅢA-N2 NSCLC prognosis. 
Keywords: Non-small-cell lung cancer, N2 lymph node metastasis, survival analysis
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P1.03-007 Prognosis of Microscopic Residual Disease (R1) at Different 
Resection Margins and Efficacy of Adjuvant Therapy Masato Chiba Division of 
Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama/Japan
Background: The aims of this study were to assess the prognosis of microscopic 
residual (R1) disease at different resection margins and to evaluate the prognostic 
impact of adjuvant therapy for R1 disease at different sites. Methods: We retrospectively 
reviewed the clinical records of 1,667 patients who underwent lung resection at the Aichi 
Cancer Center from 1998 to 2007. Twenty-eight patients (1.7%) were found to have R1 
S446 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ TREATMENT OF LOCOREGIONAL DISEASE – NSCLC 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:3
P1.03-011 Standard Pre-Hydration May Compromise Treatment Outcome of 
CRT with Low-Dose Cisplatin Else Aalbersberg1, Linda De Wit - Van Der Veen1, Erik 
Vegt1, Maarten Smeekens2, Michel Van Den Heuvel2, Jose Belderbos3, Wouter Vogel1 
1Nuclear Medicine, NKI-AVL, Amsterdam/Netherlands, 2Thoracic Oncology, NKI-AVL, 
Amsterdam/Netherlands, 3Radiotherapy, NKI-AVL, Amsterdam/Netherlands
Background: Cisplatin-based chemoradiation is the standard treatment for many types 
of cancer, including NSCLC. A main drawback of cisplatin is the high nephrotoxicity 
rate, that can be reduced by a stringent hydration regimen before, during, and/or 
after cisplatin administration. Standard pre-hydration with all cisplatin administrations 
is mandatory for high-dose cisplatin, and can be considered for low-dose cisplatin. 
However, it has recently been shown that pre-hydration not only reduces nephrotoxicity, 
but also reduces esophageal toxicity in lung cancer patients treated with concurrent daily 
low-dose cisplatin. This suggested that pre-hydration might systemically lower cisplatin 
dose in tissues, including in the tumor, and may therefore adversely affect treatment 
outcome. Aim: The aim of this study was to determine (1) if pre-hydration lowers cisplatin 
concentrations in tumor tissue in a mouse model, and (2) if the introduction of standard pre-
hydration for low-dose cisplatin has adversely affected treatment outcome in lung cancer 
patients. Methods: Tumor-bearing Balb/c nude mice with cisplatin sensitive tumors were 
either pre-hydrated with saline, dehydrated, or had no intervention (control) before a 
single administration of cisplatin 6mg/kg or 3mg/kg. Renal function was assessed with 
MAG3 scintigraphy at 1, 24, 72, or 168h after treatment, and mice were subsequently 
sacrificed to determine tumor platinum concentrations. For the patient study, all stage 
III NSCLC patients who received daily concurrent low-dose cisplatin and radiotherapy in 
the NKI-AVL between 01-2007 and 06-2014 were evaluated for PFS. Patients treated in 
2007-2010 (n=224) started pre-hydration with 1L saline only after renal function loss was 
detected, while patients treated in 2011-2014 (n=216) received standard pre-hydration 
from treatment day 1. Results: Pre-hydration protected mice from nephrotoxicity caused 
by cisplatin and dehydration worsened nephrotoxicity, confirming the validity of the 
mouse model. Pre-hydration significantly reduced tumor platinum concentrations (down 
to 50% of control mice at 1h after treatment, and comparable to mice treated with only 
half the dose of cisplatin), and dehydration increased tumor platinum concentrations. 
In patients the pre-hydration cohort demonstrated a shorter PFS (median 14 vs. 11 
months, log-rank p=0.06), against the trend of gradually improving treatment outcome 
over the past decades. Conclusion: Pre-hydration reduces tumor platinum levels in 
mice, comparable to giving only half a dose of cisplatin. Patients treated with standard 
pre-hydration show a tendency to a lower PFS compared to patients with pre-hydration 
on indication. Further research is needed to elucidate this phenomenon. Meanwhile the 
application of standard pre-hydration in low-dose cisplatin regimens may be reconsidered. 
Keywords: NSCLC, Cisplatin, Prehydration
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P1.03-012 Combined Effects of SAHA and Cisplatin on Radiation Sensitivity 
and Cancer Cell Invasion in NSCLC Shirong Zhang1, Kan Wu2, Jianguo Feng3, Jeffrey 
Y. Wong4, Bing Wang2, Hong Jiang1, Rujun Xu1, Lisha Ying3, Xufeng Chen5, Shenglin Ma6 
1Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou/China, 2Affiliated 
Hangzhou First People’S Hospital of Zhejiang Chinese Medical University, Hangzhou/
China, 3Zhejiang Cancer Hospital, Hangzhou/China, 4Department of Radiation Oncology, City 
of Hope Cancer Center, Duarte/CA/United States of America, 5Department of Pathology and 
Laboratory Medicine, University of California at Los Angeles, Los Angeles/CA/United States 
of America, 6Department of Radiation Oncology, The First People′S Hospital of Hangzhou 
Medical Group, Hangzhou/China
Background: Lung cancer is a leading cause of cancer mortality worldwide. In an 
effort to improve local control of the disease and to increase survival, concurrent 
chemoradiotherapy has been explored as a therapeutic option. Of them, cisplatin-
based chemoradiotherapy is currently used as first line therapy for non-small-cell lung 
cancer (NSCLC). However, the chemotherapeutic agents cannot be administered 
for most patients at full doses safely with radical doses of thoracic radiation, and 
thus further optimizations of chemotherapy regimen to be given with radiation are 
needed. Methods: We examined the effects of suberoylanilide hydroxamic acid (SAHA) 
and cisplatin on DNA damage repairs using U2OS reporter cells and in vivo end-joining 
assay, and determined the combination effects of SAHA and cisplatin on various cell 
lines, primary tumor tissues and in vivo xenograft in response to irradiation. We also 
investigated the potential differentiation effect of SAHA and its consequent effect on 
cancer cell invasion in cisplatin-treated cancer cells. Results: Our data demonstrated 
that SAHA and cisplatin compromised distinct DNA damage repair pathways. Treatment 
with SAHA enhanced synergistic radiosensitization effects of cisplatin in NSCLC cells, and 
induced prolonged persistence of γ-H2A.X nuclear foci in irradiated primary NSCLC tumor 
tissues treated with cisplatin. SAHA combined with cisplatin also significantly increased 
inhibitory effect of ionizing radiation on tumor growth in mouse xenograft model. In 
addition, we showed here that SAHA could induce differentiation in stem cell-like cancer 
cell population, reduce tumorogenesity and decrease the invasion/migration capabilities 
of human lung cancer H460 cells. Conclusion: Our results suggest a potential clinical 
impact for SAHA as a radiosensitizer and as a part of chemoradiotherapy regimen for 
NSCLC. The strategy may also benefit those patients with high risk of cancer metastasis. 
Keywords: SAHA, radiosensitivity, HDAC inhibitor, lung cancer
chemoradiation therapy (CCRT) at a single center impacts outcomes for patients with 
locally advanced non-small cell lung cancer (NSCLC). Methods: Using the National 
Cancer Data Base, we identified adult patients with stage III NSCLC diagnosed in 2010-
2011. We included non-surgical patients who underwent CCRT with thoracic radiotherapy 
to 59.4-74.0 Gy delivered at the reporting facility. Demographic, clinicopathologic, and 
healthcare system characteristics were compared among patients receiving integrated 
vs. nonintegrated therapy using hierarchical mixed-effects logistic regression analysis 
with clustering by reporting facility and bootstrapping. Overall survival was compared 
using Kaplan-Meier analysis, the log-rank test, and Cox proportional hazards regression 
analysis. Time from diagnosis to radiotherapy initiation was compared using the Wilcoxon 
rank-sum test given a non-normal distribution. Results: A total of 2,794 patients were 
included, among whom 1,695 (61%) received integrated therapy and 1,099 (39%) 
received nonintegrated therapy. Patients receiving integrated therapy were significantly 
more likely to have a Charlson-Deyo comorbidity score ≥1 (OR 1.67, 95% CI 1.24-2.24, 
p=0.001) and receive treatment at an academic center (OR 3.26, 95% CI 2.13-5.15, 
p<0.001) compared to those receiving nonintegrated therapy. In both unadjusted and 
adjusted analyses, there was no difference in overall survival among patients receiving 
integrated vs. nonintegrated therapy (HR 0.95, 95% CI 0.85-1.06, p=0.33). Time to 
radiotherapy initiation was also not significantly different among patients receiving 
integrated vs. nonintegrated therapy (median 35 vs. 36 days, p=0.06).
 
Conclusion: Our results demonstrate that administering CCRT at more than 
one facility may not adversely affect survival outcomes for patients with stage 
III NSCLC, suggesting that this approach may be reasonable based on individual 
patient preference and specialist availability. Further research is needed to 
determine the impact of integrated CCRT on tumor control and complication rates. 
Keywords: coordination, chemoradiation, survival, integration
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P1.03-010 Adjuvant Chemotherapy plus Radiotherapy is Superior to 
Chemotherapy in Surgically Treated IIIA N2 Non-Small-Cell Lung Cancer 
Xiao-Ling Xu1, Wei Chen1, Weimin Mao2, Weimin Mao2 1Zhejiang Cancer Research Institute, 
Hangzhou/China, 2Zhejiang Cancer Hospital, Hangzhou/China
Background: The role of addition radiotherapy for resected stage IIIA (N2) non-small 
cell lung cancer (NSCLC) in the setting of standard adjuvant chemotherapy remains 
controversial. Methods: A comprehensive search of PubMed, Embase, Medline database 
(last search updated in March 2015) for relevant studies comparing patients with stage 
IIIA (N2) NSCLC undergoing resection after treatment with adjuvant chemotherapy alone 
(POCT) or adjuvant chemoradiotherapy (POCRT) was conducted. Hazard ratios (HR) were 
extracted from these studies to give pooled estimates of the effect of POCRT on overall 
survival (OS) and disease free survival (DFS). Results: A total of six studies including 
two randomized controlled trials (RCTs) and four retrospective studies were enrolled 
in this meta-analysis. There were 6 studies that met criteria for analysis, including 2 
RCTs and 4 retrospective reviews. The meta-analysis enrolling all studies (5172 cases) 
demonstrated an OS benefit to POCRT versus POCT (HR 0.87, 95% confidence interval 
[CI] 0.79 to 0.96, p = 0.006). DFS was investigated in four studies including 2 RCTs 
and 2 retrospective reviews. Unfortunately, there was no significant difference in DFS 
of two groups for the combined HR for PFS was 0.86 (95% CI: 0.70-1.06; p = 0.158). 
The sub-group analysis performed on two RCTs (n = 172 patients) demonstrated no 
benefit from adding radiation in neither OS (HR 0.72, 95% CI 0.49 to 1.06, p = 0.094) 
nor DFS (HR 1.45, 95% CI 1.00 to 2.09, p = 0.047). Conclusion: Compared with 
POCT, POCRT had a benefit for OS but not DFS in the patients with IIIA-pN2 NSCLC. 
Considering the relatively small sample size of most studies and only included two 
RCTs, caution should be taken when adopting the conclusions. Future RCT to investigate 
the role of POCRT after surgical resection of stage IIIA (N2) NSCLC is warranted. 
Keywords: NSCLC, N2-stage, therapy, surgery
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performed. Conclusion: Although concomitant chemoradiotherapy is the standard of 
care in patients with stage IIIA/B NSCLC, more than 50% of the patients were treated 
otherwise. Only 17% of the patients were eligible for concomitant chemoradiotherapy. 
Most frequent reasons to refrain from concomitant chemoradiotherapy were 
the size of the radiation field and performance status of the patients (87%). 
Keywords: Chemoradiotherapy, Concomitant, Sequential, Non-small cell lungcancer
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P1.03-015 Safety and Effectiveness of Chemo-Radiotherapy with Weekly Nab 
Paclitaxel plus Carboplatin in Locally Advanced Non-Small Cell Lung Cancer 
Toshiyuki Sawa1, Takaaki Hasegawa2, Tsutomu Yoshida1, Takashi Ishiguro1, Akane 
Horiba3, Yohei Futamura4, Yasushi Ohno5, Tatsuo Katoh6, Shinya Hayashi7 1Respiratory 
Medicine and Oncology, Gifu Municipal Hospital, Gifu/Japan, 2Gifu Municipa Hospital, 
Ggifu/Japan, 3Gifu Municipal Hopsital, Gifu/Japan, 4Gifu Municipal Hospital, Gifu/
Japan, 5Respiratory Medicine, Gifu University, Gifu/Japan,6Nagara Medical Center, Gifu/
Japan, 7Gifu University, Gifu/Japan
Background: Combination therapy of carboplatin (CBDCA) and nab-PTX is a useful 
choice for first-line therapy of patients with advanced non-small cell lung cancer (NSCLC). 
The efficacy and safety of weekly albumin-bound paclitaxel (nab-PTX) and carboplatin 
(CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small cell 
lung cancer was evaluated as a multicenter phase II study of Gifu thoracic oncology 
group. Methods: Patients with stage III NSCLC and an Eastern Cooperative Oncology 
Group performance status of 0 or 1 were eligible. Concurrent chemoradiotherapy 
consisted of weekly administration of nab-PTX (40 mg/m2) plus CBDCA (area under the 
plasma concentration time curve (AUC) 2) and thoracic radiotherapy (60 Gy/30 fractions) 
for a total of 6 weeks. The primary tumor and involved nodal disease received 60 Gy in 
2-Gy fractions over 6 weeks. A three dimensional treatment planning system was used 
in every institute. After concurrent chemoradiotherapy, patients received an additional 
two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-
PTX (100 mg/m2 on days 1, 8, and 15)/CBDCA (AUC 5 mg/ml/min on day 1). Response 
was evaluated in accordance with the RECIST. Progression-free and overall survival were 
estimated using the Kaplan Meier method. Toxicity was graded using the National Cancer 
Institute Common Terminology Criteria for Adverse Events. Results:The study became 
way canceled for serious adverse events, when the 10 cases were enrolled in this trial 
between September 2013 and January 2014 from 3 institutes. Patient characteristics 
are summarized as follow. The median age was 73 years. The ECOG performance status 
was 0 for 30% of patients and 1 for 70% of patients. Of these patients, 5 cases had 
squamous cell carcinoma and 5 cases had adenocarcinoma. The overall response rate 
was 40.0% and the median progression-free survival was 6.7 months. total of 7 patients 
were unable to complete the consolidation phase chemotherapy because of toxicities 
(pneumonitis, lung infection, or heart failure), poor PS, or patient preference. The most 
common grade 3/4 hematological toxicity was leukopenia (8 patients, 80%). Other 
grade 3/4 hematological toxicities were neutropenia (5 patients, 50%) and anemia (1 
patient, 10%). Other grade 3 or worse severe toxicities were anorexia (3 patients, 30%), 
nausea (2 patients, 20%), diarrhea (1 patient, 10%), pneumonitis (2 patients, 20%), heart 
failure (2 patients, 20%), and lung infection (1 patient, 10%). Treatment-related death 
occurred in two patients. Grade 2 or worse severe pneumonitis was observed in all 3 
patients that had volume of lung receiving at least 20 Gy (V20) >30%. Conclusion: The 
results of this study indicate that no further investigation is warranted into nab-PTX 
and CBDCA with concurrent thoracic radiation using three dimensional treatment 
planning system for stage III NSCLC with V20 >30% due to severe toxicity. 
Keywords: thoracic radiation, carboplatin, non-small cell lung cancer, nab-paclitaxel
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P1.03-016 Clinical Outcome of Hybrid-Volumetric Arc Therapy (H-VMAT) for 
Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC) Oscar S.H. Chan, 
Albert W.M. Hung, Amy T.Y. Chang, Lucy L.K. Chan, Connie C.C. Chan, R M W Yeung 
Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong/
Hong Kong
Background: H-VMAT is a mix of rotational arcs and static beams. Our previous published 
planning study indicates that H-VMAT is superior in dosimetric outcomes: improved 
conformity with better sparing of lung and spinal cord, compared to VMAT alone or 
conformal radiotherapy (CRT). While there are many planning studies, reports on clinical 
outcomes in IMRT especially VMAT for NSCLC are relatively sparse. Methods: This 
retrospective study included inoperable stage IIA-IIIB NSCLC patients treated with H-VMAT 
or IMRT between late 2009 and 2013. Patients underwent simulation using 4D-CT. PET-CT 
data were fused with simulation images to enhance target delineation. H-VMAT composing 
of 2 hemi-arcs plus 2 static fields or 5-9 fields IMRT technique was used. Precision of 
treatment delivery was ensured by on-board kilovoltage imaging, mainly cone-beam CT. 
Survival outcomes, dosimetric data, patient characteristics and complication profiles 
were analysed. Results: A total of 71 patients were included. Patients characteristics 
and dosimetric parameters were tabulated in table one. The median follow-up was 2.5 
years for alive subjects. The median prescribed dose was 60Gy. Three patients did not 
complete the planned treatment. The estimated 5-year overall survival (OS) was 19.2% 
(Figure 1a). Patients receiving sequential chemotherapy or chemo-radiotherapy fared 
much better than RT alone (Figure 1b). The 3-year disease-free survival was 12.7% in 
RT alone group and 17.0% in chemo-radiotherapy group. Two grade 3 esophagitis and 
three ≥grade 3 radiation pneumonitis were noted. Two treatment death were considered 
related to radiation pneumonitis, with superimposed chest infection. Compared to an 
unmatched historic cohort treated in 2004-08 using CRT, a trend of improvement in OS 
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P1.03-013 Clinical Characteristics and Survival in Stage IIIA NSCLC Patients 
Treated with Neoadjuvant Chemotherapy and Surgery Narjust Duma1, Claudia 
Miranda1, Chad Glisch1, Harry D. Harper2, Martin Gutierrez2 1Internal Medicine, Rutgers-
New Jersey Medical School, Newark/NJ/United States of America, 2Medical Oncology, 
Hackensack University Medical Center, Hackensack/NJ/United States of America
Background: The role of surgery in the management of stage IIIA non-small cell lung 
cancer (NSCLC) is controversial, with several studies reporting mixed results regarding 
the benefit of surgery in this group of patients. This study aimed to analyze the clinical 
characteristics and prognostic factors in stage IIIA patients treated with neoadjuvant 
chemotherapy followed by surgery. Methods: We reviewed the medical records of 
all patients diagnosed with stage IIIA NSCLC at our institution from 2000 to 2012. 
Tissue diagnosis and PET-Scan at our institution were required. Median follow up was 
36 months. Cox regression model was used for multivariate analysis. Results: A total 
of 275 stage IIIA patients were identified, and 84 of those patients were treated with 
induction chemotherapy followed by surgery. Median age at diagnosis was 65 years 
(range: 42-82). There were more males than females (68% vs. 32%). 64% of the tumors 
were located in the upper, 24% lower and 12% middle lobe. Adenocarcinoma was the 
most prevalent histologic subtype (69%) followed by squamous cell (24%). 57% were 
poorly differentiated tumors. All patients received cisplatin based chemotherapy; 
response to induction therapy was: CR 0%, PR 55%, and SD 44%. Median time from 
induction chemotherapy to surgery was 80 days (range: 15-126). About surgery: 69% 
were lobectomies, 26% pneumonectomies and 5% wedge resections. Post-operatively, 
microscopic residual tumor was found in 8% of the patients. Pneumonectomies had a 
higher post-operatively mortality when compared with lobectomies (5% vs 2%). 50% of 
the patients received post-surgical radiation. Median overall survival was 19.5 months 
(95%CI: 14.5-26.7) and when comparing these patients with stage IIIA patients that 
received chemoradiation alone, a survival benefit was observed (19.5 months vs. 15.8 
months). Recurrence was observed in 26% of the patients (64% had local and 36% distal 
recurrence). Patients that did not receive radiation had a higher risk of recurrence. Male 
gender (OR: 0.33, p<0.002), age>65 (OR: 2.61, p<0.03) tumor size >4cm (OR: 3.10, 
p<0.01) and partial response with induction therapy (OR. 0.69, p<0.005) were significant 
predictors of survival in this group of patients. Conclusion: In our cohort, we observed 
that patients who underwent induction chemotherapy followed by surgery had a higher 
overall median survival than patients treated with chemoradiation alone. Gender, age, 
tumor size and response to induction therapy were independent and significant predictors 
of survival in these patients. Adding radiation therapy to the regimen was associated with 
a lower recurrence rate. Further research is needed to identify the optimal management 
of stage IIIA NSCLC as well as the effect of other clinical characteristics on survival. 
Keywords: Stage IIIA, Predictors of Survival, Multimodality treatment
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P1.03-014 Is Concomitant Chemoradiotherapy Feasible for Patients with 
NSCLC Stage III A/B? Femke S. Van Der Meer1, Franz Schramel1, Sherif El Sharouni2, 
Marco Van Vulpen2 1Department of Pulmonology, St. Antonius Hospital, Nieuwegein/
Netherlands, 2Radiotherapy, University Medical Center Utrecht, Utrecht/Netherlands
Background: In patients with NSCLC approximately 25% has locally advanced disease. 
For the group of patients with mediastinal lymph node metastasis the standard treatment 
consists of concomitant chemoradiotherapy. Concomitant chemoradiotherapy improves 
survival compared to sequential chemoradiotherapy in patients with locally advanced 
NSCLC, but has a higher toxicity. Methods: This is a retrospective cohort analysis of all 
patients with NSCLC stage IIIA/B treated in our hospital from 2008-2011. We reviewed 
primary treatment plans in all patients and evaluated patients primarily treated with 
sequential and concomitant chemoradiotherapy. Reasons to choose sequential treatment 
instead of concomitant treatment were reviewed. In both treatment groups completing 
of treatment and causes to discontinue treatment were explored. Results: 180 patients 
with NSCLC stage IIIA/B (103 stage IIIA, 77 stage IIIB) were treated in our hospital 
between 2008 and 2011. Surgery was the primary treatment in 28 patients (16%), 
chemotherapy in 22 patients (12%), radiotherapy in 16 patients (8%), best supportive 
care was agreed on in 32 patients (18%). In 78 (43%) patients the primary treatment 
was chemoradiotherapy, of who 31 were planned to receive concomitant treatment 
and 47 were planned to receive sequential treatment. Most frequent reasons to choose 
sequential instead of concomitant chemoradiotherapy were: radiation field too large 
(N=24) and physical condition (co-morbidity, age, poor performance score or poor lung 
function; N=17). Other reasons to start sequential therapy were: planning to evaluate 
the possibility of resection after chemotherapy (N=1), no pathological diagnosis (N=1), 
suspicion of second tumor (N=1) or unknown (N=3). In 20 of the 31 patients planned for 
concomitant chemoradiotherapy, total treatment was completed. Two patients deceased 
before start of therapy, five patients switched to sequential planning before start of therapy 
because of patients wish (N=1), radiation field too large at CT planning at radiotherapy 
(N=3), suspicion of cerebral tumor: (N=1) or decrease of performance score (N=1). In 
two patients treatment was disturbed by toxicity: one patient developed a pulmonary 
cavitating infection, radiotherapy was discontinued after 20Gy, the other patient switched 
to sequential schedule after a pulmonary infection during the first treatment cycle. In 32 
of 47 patients planned for sequential therapy treatment was completed. One patient 
deceased before start of therapy. In one patient the radiation field was still too large after 
chemotherapy. Three patients developed hemoptysis and were treated primary with 
radiotherapy. Three patients discontinued treatment because of disease progression. 
Three patients discontinued during chemotherapy because of kidney failure(N=1) or 
other toxicity (N=2). Of one patient cause of discontinuation was not documented. 
One patient showed mediastinal downstaging after chemotherapy and a resection was 
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P1.03-018 International Patterns of Radiotherapy Practice for Non-Small Cell 
Lung Cancer Shalini K. Vinod Cancer Therapy Centre, Liverpool Hospital, Liverpool/NSW/
Australia
Background: Radiotherapy is an important treatment modality for Non-Small Cell 
Lung Cancer (NSCLC). Models of radiotherapy utilization which evaluate the proportion 
on NSCLC patients who have an evidence-based indication for radiotherapy estimate 
a utilization of 46% -68% at diagnosis and 64%-75% during the overall course of the 
disease. The aim of this review was to document the actual use of radiotherapy for 
NSCLC patients and examine reasons for any discrepancies identified. Methods: A 
literature search was conducted using Medline and Pubmed databases to identify 
population-based studies, published in English, which reported the use of radiotherapy 
between 1990 and 2014. Reference lists of the identified studies were also scrutinised 
for further relevant publications. Results: Ten studies were identified from regions 
including North America, Europe, United Kingdom and Australasia. Actual radiotherapy 
utilization varied across these regions ranging from 20%-53%. In North America, actual 
utilization approached model estimates, but in the other regions actual utilization was 
lower than model estimates. The largest differences between actual and estimated 
radiotherapy utilization was seen in stage III NSCLC. Some of this discrepancy is 
attributable to the assumptions in the models which are based on broad factors such as 
stage and performance status. Characteristics of the underlying lung cancer population 
who often have comorbidities or compromised respiratory function also impact on 
the ability to deliver radiotherapy safely. Sociodemographic factors such as race and 
income have been found to affect access to radiotherapy in certain jurisdictions. The 
type of clinician or medical setting the patient presents to initially has also been found to 
influence radiotherapy use in NSCLC. Conclusion: Radiotherapy utilization for NSCLC is 
lower than that predicted by model estimates throughout much of the world. This is partly 
due to characteristics of the underlying lung cancer population which may preclude 
guideline-based treatment including radiotherapy. Physician characteristics and referral 
patterns can have a significant impact on the use of radiotherapy in NSCLC. Potential 
solutions to overcome this include restructuring models of care to ensure all lung cancer 
patients are managed within a multidisciplinary team including a radiation oncologist. 
Keywords: non-small cell lung cancer, Radiotherapy, patterns of care, treatment 
utilization
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P1.03-019 NTCP-Models for Esophagitis with Dose-Differentiated-Radiotherapy 
(DART-Bid) Franz Zehentmayr1, Matthias Söhn2, Ann-Katrin Exeli1, Karl Wurstbauer1, 
Almut Tröller2, Heinz Deutschmann1, Gerd Fastner1, Christoph Fussl1, Philipp Steininger3, 
Manfred Kranzinger1, Claus Belka2, Michael Studnicak4, Felix Sedlmayer1 1Dept. of 
Radiation Oncology, Paracelsus Medical University, Salzburg/Austria, 2Dept. of Radiation 
Oncology, Ludwig-Maximilians-Universität, Munich/Germany, 3Institute for Research and 
Development of Advanced Radiation Technologies, Paracelsus Medical University, Salzburg/
Austria, 4Dept. of Pneumology, Paracelsus Medical University, Salzburg/Austria
Background: The primary dose-limiting toxicity during thoracic irradiation is acute 
esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors 
for AE grade ≥ 2 in patients treated with accelerated radiotherapy. Methods: 66 patients 
were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB. All 
patients received induction chemotherapy followed by dose differentiated accelerated 
radiotherapy (DART-bid). Depending on size (mean of three perpendicular diameters) 
tumors were binned in four groups: <2.5 cm 73.8 Gy, 2.5–4.5 cm 79.2 Gy, 4.5–6 cm 
84.6 Gy, >6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to 
estimate the normal tissue complication probability (NTCP), two Lyman models and the 
cutoff-logistic regression model were fitted to the data with AE ≥ grade 2 as statistical 
endpoint. Toxicity was documented prospectively according to RTOG. Results: The 
median follow up was 686 days (range 84–2921 days), 23/66 patients (35%) 
experienced AE ≥ grade 2. The Lyman-MED model (D50=32.8 Gy, m=0.48) and the 
cutoff dose model (Dc=38 Gy) provide the most efficient fit to the current dataset. 
On multivariate analysis V38 was the most significant predictor of AE ≥ grade 2 
(HR=1.05, CI 1.01–1.09, p=0.009). Conclusion: Following high-dose accelerated 
radiotherapy the rate of AE ≥ grade 2 is lower than reported for concomitant radio-
chemotherapy with the additional benefit of markedly increased loco-regional tumor 
control. In the current patient cohort the most significant predictor of AE was found 
to be V38 (volume of the esophagus that receives 38 Gy or above, CI 28.2 – 57.3). 
Keywords: NTCP-modeling, Accelerated Radiotherapy, NSCLC
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P1.03-020 IMRT Improves Survival in Locally Advanced NSCLC (LA-NSCLC) 
Receiving Definitive Radiotherapy: A Population Based Time-Trend Analysis 
Jingbo Wang1, Jianzhong Cao2, Zhe Ji2, Lipin Liu2, Wei Jiang2, Yu Men2, Cai Xu2, Luhua 
(Jingbo) Wang1 1Radiation Oncology, Cancer Hospital, Chinese Academy of Medical 
Sciences, Beijing/China, 2Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/
China
Background: Currently intensity-modulated radiotherapy (IMRT) is regarded as a 
promising but unproven therapy for locally advanced non-small cell lung cancer (LA-
NSCLC). This study aimed to evaluate the impact of introducing IMRT in LA-NSCLC based 
on patients receiving definitive radiotherapy (RT) throughout an 11-year span from an 
academic cancer center. Methods: Patients treated with definitive RT (≥ 50Gy) between 
was observed (Figure 1c). Multivariate analysis demonstrated that GTV-volume and use 
of chemotherapy were important predictors in OS (both p <0.01).
Patient demographics and dosimetric data (n=71)
Age median (range) 68 (34-89)
Gender male: female 52: 19
Histology Adenocarcinoma 29
Squamous cell carcinoma 22
Not otherwise specified 15
Others 5
PET-CT Staging 65(91.5%)
Group Stage (7th Ed.) IIA 3 (4.2%)
IIB 9 (12.7%)
IIIA 46 (64.8%)
IIIB 13 (18.3%)
RT Technique H-VMAT/ IMRT 60/ 11
Chemotherapy With vs. Without 43: 28
PTV Dmean median/ Gray (range) 62.2 (61.2-77.3)
GTV volume median/ cc (range) 91.3 (12.6-312.2)
PTV volume median/ cc (range) 359.6 (99.5-1070.5)
V20 (Lung-CTV) median/ % (range) 22.8 (3.7-34.9)
Max Cord Dose median/ Gray (range) 41.3 (14.8-44.8)
 
Conclusion: H-VMAT/ IMRT together with chemotherapy resulted in 
favourable OS and low incidence of esophageal and pulmonary toxicities. 
Keywords: Volumetric Arc Therapy, intensity modulated radiotherapy, advanced NSCLC, 
survival
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P1.03-017 Radiation Dose-Related Lymphopenia as an Outcome Predictor 
in Stage III NSCLC Patients Treated with Chemoradiation Nooshin Hashemi 
Sadraei1, Mahender Yellu1, Farhad Fakhrejahani2, Arun Sendilnathan1, Nagla Abdel-
Karim1, John Morris1, Tahir Latif1, Michelle Mierzwa1, Brdaley Huth1, Kevin Redmond1, 
William Barrett1, Patrick Ma3, Nathan Pennell4, Jun Ying5, Gregory M.M. Videtic3 
1University of Cincinnati, Cincinnati/OH/United States of America, 2Nci, Bethesda/MD/
United States of America, 3Radiation Oncology, Cleveland Clinic, Cleveland/United States 
of America, 4University of Cincinnati, Cincinnati/AL/United States of America, 5University of 
Cincinnati, Cincinnati/United States of America
Background: RTOG 0617 failed to show survival advantage from increased radiation 
dose in stage III concurrent chemo radiation-treated patients. While toxicity was not 
significantly different between standard and high dose radiation groups, local-regional 
control and survival were inferior in high dose, experimental arm. These findings have 
largely remained unexplained. There is increased evidence in literature suggesting 
survival disadvantage associated with lymphopenia in certain malignancies. We 
hypothesize radiation-induced lymphopenia may be dose-dependent and may carry 
a survival disadvantage. Methods: Stage III NSCLC patients treated with curative 
chemoradiation were retrospectively studied. Patients were categorized into those 
receiving standard dose and those receieiving high dose ( > 66Gy). Hematologic values 
including absolute lymphocyte count (ALC) was evaluated at diagnosis and at regular 
intervals during and after treatnent. Numerical variables were summarized using median 
(range) and compared between groups using non parametric Wilcoxon rank sum tests. 
Overall survival (OS) and other time to event endpoints were assessed using Kaplan-
Meier (K-M) survival curves and compared between standard and high dose groups using 
log rank tests. Results: 182 patients with stage III NSCLC were identified. 77 % male, 
52% adenocarcinoma, and 41% squamous cell carcinoma. 155 patients received SD RT 
and 27 received HD RT. Pre-treatment ALC were not different between Standard and High 
dose groups [ 1730 /ul vs. 2065/ul (p=0.4955) ]. The High dose group showed lower 
Nadir ALC ( 279/ul vs 324/ul and shorter time to Nadir ( 29 d vs 35 d) than the Standar 
group ( two sided p’s =0.11and 0.06, and one sided p’s=0.05, 0.03 respectively). The 
K–M survival curves showed that Standard dose group has better OS than the High 
dose group (31.3 m vs 11.4 m , p<0.001). For patients whose Nadir ALC >600 (about 
80% percentile level of Nadir ALC), median survival was 37.8 month as compared to 
18.2 month among those Nadir ALC≤600 (p=0.192). Conclusion: Our study showed 
sutrvival among patients treated with higher dose radiation was significantly worse. 
Although baseline absulte lymphocyte counts were not different between the two groups, 
patient treated with high dose radiation reached their nadir counts more quickly and 
also developed a lower absolute lymphocyte count compared to patients treated with 
standard dose. Regardless of treatment group, there was a trend towards a worse survival 
among patients who developed lower lymphocyte counts subsequent to traetment. 
Keywords: lymphopenia, stage III
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measure D50 as second covariate resulted in models with 0.73 and 0.83 respectively. The 
advantage of incorporating D50 was significant in the second fit (p=0.05). Conclusion: A 
significant improvement of predictive models for radiation-induced lung toxicity was 
achieved using patient-specific lung damage measured on CT scans. An early detection 
of the patient-specific D50 through dedicated per-treatment imaging optimized for 
the detection of lung tissue changes is crucial for the clinical implementation of the 
model. Future work analysing more CT features could also improve the model. 
Keywords: radiation-induced lung toxicity, lung damage, CT, radiosensitivity
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P1.03-022 The Effect of Adaptive Planning on Target and Critical Structures 
During Radiation Treatment for Locally Advanced Lung Cancer Hale B. Caglar, 
Esra Kucukmorkoc, Ayse Altinok, Nadir Kucuk, Mine Doyuran, Hilal Acar 
Radiation Oncology, Medipol University Hospital, Istanbul/Turkey
Background: Many patients with lung cancer have tumor changes like shrinkage, 
improvement in atelectasis or mediastinal replacement during radiotherapy. The aim of 
this study is to determine the dosimetric effects of repeated CT scanning and adaptive 
planning during intensity modulated radiotherapy (IMRT) on both target volumes and 
critical structures. Methods: Patients treated with concurrent chemoradiation were 
included within the study. The initial IMRT planning (IMRTinitial) was done on the primary CT 
and 4DCT scan using the ITV technique. The dose was prescribed to 66 Gy in 33 fractions. 
After the initiation of the study weekly cone beam CT (CBCT) images were obtained 
before treatment. The volumes were evaluated by the treating physician in terms of 
target volume changes or mediastinal replacement. When adequate change was 
distinguished on the CBCT images an adaptive CT (CTadapt) was obtained and the volumes 
were recontoured by the same physician and replanned by the same physicist (IMRTadapt). 
The calculated multileaf collimator (MLC) motion on IMRTinitial was transferred on CTadapt and 
a recalculation was performed. The plan obtained was renamed as IMRTtransfer. The 
changes occurred in critical organs such as lung, spinal cord, heart, esophagus and the 
target volumes were obtained and compared with IMRTinitial using paired samples 
t-test. Results: A total of 15 patients were included in the analysis. The mean PTV 
volumes on initial and adaptive planning CT scans were significantly different (791 vs 498 
cc; p<0.001). Significant changes were observed in lung doses between IMRTinitial vs 
IMRTtransfer and IMRTadapt vs IMRTtransfer (mean V5, 50% vs 54%, p=0.001 and 40% vs 54%, 
p=0.003; mean V20, 24% vs 28% p<0.001 and 20% vs 28%, p<0.001). Spinal cord 
dosed also significantly changed on these 3 plans (mean Dmax on IMRTinitial vs 
IMRTtransfer and IMRTadapt vs IMRTtransfer41.4Gy vs 45.5Gy, p=0.042 and 37.8Gy vs 45.5Gy, 
p=0.005). The PTV coverage significantly changed in 3 patients because of replacement.
 
Conclusion:Repeat CT imaging and replanning during the course of IMRT for selected 
patients with lung cancer may help to identify dosimetric changes and to ensure safe 
doses to critical structures such as lung and spinal cord. With the implementation of 
adaptive treatments dose escalation may be possible in the future for improvements 
in clinical outcome without significant increase in toxicity. The anatomic changes seen 
throughout the treatment may increase the lung doses when replanning is not performed. 
Keywords: adaptive, Radiotherapy planning, lung cancer
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P1.03-023 Changes in Pulmonary Function after Stereotactic Body 
Radiotherapy and after Surgery for Stage I and II Non-Small-Cell Lung Cancer  
Leonie Alberts1, Sherif Y. El Sharouni2, Frederik N. Hofman3, Bart P. Van 
Putte3, Ellen Tromp4, Marco Van Vulpen2, Robbert C. Van Heemst5, Elisabeth 
A. Kastelijn1, Franz M.N.H. Schramel1 1Pulmonology, St. Antonius Hospital, 
Nieuwegein/Netherlands, 2Radiotherapy, University Medical Center Utrecht, 
Utrecht/Netherlands, 3Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein/
Netherlands, 4Epidemiology and Statistics, St. Antonius Hospital, Nieuwegein/
Netherlands, 5Pulmonology, Deventer Ziekenhuis, Deventer/Netherlands
Background: Although surgical resection is the standard treatment for stage I and II 
non-small-cell lung cancer (NSCLC), approximately 20% of these patients are not eligible 
for surgery. Stereotactic body radiotherapy (SBRT) is a good alternative treatment for 
these patients. Lung resection will lead to a decrease in pulmonary function. However, 
previous studies have shown that pulmonary function after SBRT remains either stable or 
shows a small decline post-SBRT. In this study changes in pulmonary function tests (PFTs) 
were evaluated at different follow-up durations, up to more than 2 years after treatment 
2000 and 2010 were divided into three eras according to availability of IMRT: 2000 to 
2003 (period A, no IMRT, IMRT rate 0%), 2004 to 2006 (period B, introduction of IMRT, 
IMRT rate 3.5%) and 2007 to 2010 (period C, full access to IMRT, IMRT rate 85.6%). 
Patients’ characteristics, treatment modality, survival and treatment related toxicities 
were compared between 3 periods. Results: A total of 946 patients were analyzed. Less 
smokers, more stage IIIA diseases and more patients receiving concurrent chemo-
radiotherapy (CRT) were observed in period C. The median overall survival (OS), local-
regional progression free survival (LRPFS), distant metastasis free survival (DMFS) and 
progression free survival (PFS) for the whole population, period A, B and C were 19.8 vs. 
16.6 vs. 18.2 vs. 23.3 moths, 22.1 vs. 16.2 vs. 18.7 vs. 40.5 months, 20.7 vs. 17.1 vs. 
17.0 vs. 33.1 months and 11.4 vs. 10.8 vs. 11.3 vs. 11.9 months, respectively. 
Accordingly, the 5-y OS, LRPFS, DMFS and PFS were 14.3% vs. 9.8% vs. 12.0% vs. 
18.3%, 34.3% vs. 22.9% vs. 28.4% vs. 43.6%, 32.2% vs. 25.2% vs. 23.6% vs. 40.5% and 
14.2% vs. 10.7% vs. 11.1% vs. 18.0%, respectively. All survival indexes significantly 
increased in period C (Figure 1). Multivariate analyses identified IMRT as the independently 
favorable indicators for all survival indexes. The incidence of radiation induced lung 
toxicity (RILT) significantly decreased in period C (32.2% vs. 24.9% vs. 12.8%, p < 0.001) 
whereas that of radiation induced esophagus toxicity (RIET) remained stable (29.4% vs. 
39.0% vs. 33.1%, p = 0.064) throughout the overall study period.
 
 
Conclusion: IMRT was associated with improved tumor control, prolonged survival 
and decreased RILT, independent of treatment modality and radiation dose. 
Keywords: intensity modulated radiotherapy, time-trend analysis, survival, non small cell 
lung cancer
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P1.03-021 Lung Damage Quantification on CT Scans Strengthens Radiation-
Induced Lung Toxicity Prediction Models Gilles Defraene1, Wouter Van Elmpt2, 
Wouter Crijns1, Pieter Slagmolen3, Dirk De Ruysscher1 1Experimental Radiation Oncology, 
Ku Leuven, Leuven/Belgium, 2Department of Radiation Oncology (Maastro), Grow-School 
for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht/
Netherlands, 3Esat/Psi – Uz Leuven, Mirc – Iminds, Medical It Dept., Ku Leuven, Leuven/
Belgium
Background: Predictive models for radiation-induced lung toxicity have shown a lack of 
validation and low values of area under the curve (AUC) below 0.7, for various reasons. 
Radiation-induced lung tissue damage scored as density changes on CT scans proved 
to be a less multifactorial endpoint compared to dyspnea. Its continuous variation 
in the patient population is an indication that it could be an expression of patient-
specific radiosensitivity variation. This study explores the advantage of incorporating 
patient-specific lung damage measures in the classical predictive models based 
on mean lung dose (MLD). Methods: 61 stage I-IV lung cancer patients treated with 
chemoradiotherapy were retrieved from two hospitals. Prescribed dose was 66 Gy in 
fractions of 2 Gy (concurrent) or 2.75 Gy (sequential). Baseline and follow-up dyspnea 
scores were retrospectively assessed according to CTCAE 4.0. Image analysis of the 
radiation-induced lung damage was performed by comparison of the baseline planning 
CT0 and the non-rigidly registered follow-up CTfup. The median Hounsfield Unit increase 
(∆HU=HUfup-HU0) was calculated per dose bin of 5 Gy. The local dose-∆HU response 
curve was described using a sigmoidal model. This resulted in a sigmoidal parameter 
D50 (corresponding to 50% of the saturation level of ∆HU) for each patient, as an 
expression of the patient-specific lung tissue radiosensitivity. Logistic models predicting 
dyspnea increase with respect to the baseline score were then built using MLD and 
D50 as covariates. The likelihood-ratio identified significant differences between nested 
models. Results: Dyspnea score increase by 2 grades was observed in 9 patients (14,8%), 
while an increase by 1 grade was observed in 29 patients (47.5%). The average timepoint 
of CTfup was 2.3 months after end of radiotherapy. For 51 patients the sigmoidal dose-∆HU 
fits were acceptable (sum of squared residuals below 10 HU per datapoint on average). 
10 of these patients did not show any dose response in the analysed dose range. The 41 
reacting patients showed large variation in D50 (median: 34.8 Gy, range: 12.1 Gy-70.0 Gy) 
and were further analysed. Predictive models based on MLD alone had AUCs of 0.71 and 
0.65 for dyspnea increase by 1 and 2 grades respectively. Incorporating the CT damage 
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Results: Visceral pleura invasion (PL1 and PL2) was detected in 56 of 174 surgically 
treated patients (32.1%). In this group, PL1 was found in 43 patients (24.7%) and 
PL2 was found in 13 patients (7.4%). Mean follow-up was 48.68±27.47 months (4-
106). We found that visceral pleura invasion statistically significantly reduce survival 
independently from hilar/mediastinal lymph node involvement (N1-N2) and tumor 
size (mean survival 53.78±28.91 vs 37.95±20.54 months, p=0.001). Also we found 
that the ratio of the presence of hilar lymph node involvement with visceral pleura 
invasion is statistically higher than the group without visceral pleura invasion (30.9% 
vs 18.1% p=0.03). There were no statistically significance in terms of survival 
between the groups PL1 and PL2 (mean survival 39.23±20.01 vs 33.69±22.49 
p=0.39). Conclusion: We should consider adjuvant treatment independently from 
tumor size and lymph node involvement for patients with visceral pleura invasion. 
Keywords: visceral pleura invasion, survival, lung cancer
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P1.03-026 Prognostic Value of Pre-Treatment Neutrophil:Lymphocyte Ratio 
and Platelet:Lymphocyte Ratio in Stage III NSCLC Kylie H. Kang1, Neelesh 
Sharma2, Mitchell Machtay3, Tithi Biswas3 1Radiation Oncology, Sideman Cancer Center, 
Case Medical Center, Cleveland/United States of America, 2Medical Oncology, Sideman 
Cancer Center, Case Medical Center, Cleveland/United States of America, 3Radiation 
Oncology, Sideman Cancer Center, Case Medical Center, Cleveland/OH/United States of 
America
Background: Stage III locally advanced NSCLC is a challenging disease with poor 
outcome. The currently accepted treatment consideration is definitive chemo-radiation 
with the addition of surgery for selected patients. There are few if any reliable predictors 
for treatment outcome in these patients. Recent studies have suggested that the pre-
treatment presence of systemic inflammatory response, as indicated by the neutrophil/
lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR), may be useful prognostic 
factors. Thus, we undertook this retrospective analysis of stage III NSCLC to examine 
the role of pre-treatment NLR and PLR as a predictor of outcome and also to compare 
the value of surgery in addition to chemo and radiotherapy. Methods: A total of 107 
patients with stage III disease were identified from our institutional lung cancer database. 
Patients were staged as per AJCC system, 7th edition. Patients with N0 or N1 status 
were excluded. The following information was collected from their electronic medical 
records as available: age, gender, substage, histology, grade, baseline blood work, 
and treatment type. NLR was defined as the ratio between neutrophil and lymphocyte 
count and PLR was defined as ratio between platelet and lymphocyte count, measured 
prior to any cytotoxic therapy. We studied both median value and NLR ≥5 in order to 
categorize patients as high- or low-NLR group. Median PLR was used to categorize as 
high- or low-PLR group. The recurrence-free (RFS) and overall (OS) cumulative probability 
of survival was calculated by the Kaplan-Meier method, and the difference was assessed 
by the log-rank test. Results: The median age at diagnosis was 62 years (range: 44 - 87) 
and 50% (n=53) were male. The median follow-up was 25 months. The most common 
histology was adenocarcinoma (60%, n=64) followed by squamous cell cancer (19%, 
n=20), large cell carcinoma (4%, n=4) while rest had NSCLC not specified. Most (54%) 
were of poor grade and 17% were grade 2. Only 3% had grade 1 tumor while it was not 
reported in 26% cases. The T stage distribution was T1 (20%, n=21), T2 (35%, n=38), 
T3 (17%, n=18), T4 (26%, n=28). 66 (62%) patients underwent concurrent CRT while 41 
(38%) patients had surgery as a part of their treatment, with 17 (42%) underwent surgery 
following neoadjuvant therapy while 23 (56%) patients had upfront surgery. Surgery in 
any form was associated with improved RFS (p=0.013, log-rank) but not OS (p=0.074, 
log-rank). A higher baseline PLR ratio was associated with inferior OS (p=0.044, log-
rank), but there was no significant association between NLR for either RFS or OS. 
Conclusion: This is a retrospective series of advanced NSCLC suggesting benefit in RFS 
but not in OS with addition of surgery as the third modality in the definitive treatment. 
A higher baseline PLR was associated with inferior survival, suggesting potential 
prognostic value but not NLR. Further analysis is underway for a multivariate model. 
Keywords: NSCLC, stage III, chemo-radiation
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P1.03-027 Factors Predicting Lymph Node Metastasis in Resected Lung 
Adenocarcinoma of 2cm or Smaller Jung-Jyh Hung1, Yu-Chung Wu2, Teh-Ying Chou1, 
Wen-Hu Hsu2 1Taipei Veterans General Hospital and National Yang-Ming University, Taipei/
Taiwan, 2Taipei Veterans General Hospital, Taipei/Taiwan
Background: The predictive value of the new International Association for the Study 
of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/
ATS/ERS) classification of lung adenocarcinoma predicting lymph node metastasis 
in lung adenocarcinoma has not been well demonstrated. The aim of the study is 
to demonstrate factors associated with lymph node metastasis in patients with 
resected lung adenocarcinoma of 2 cm or smaller. Methods: The clinicopathological 
characteristics of 246 patients with completely resected lung adenocarcinoma of 
2cm or smaller at Taipei Veterans General Hospital between 2004 and 2012 were 
retrospectively reviewed. The association between clinicopathological variables 
and lymph node metastasis was analyzed by univariate and multivariate logistic 
regression. Results: Among the 246 patients, there were 215 (87.4%) patients with 
N0 status, 13 (5.3%) with N1 status, and 18 (7.3%) with N2 status. Greater tumor size 
(P < 0.001) and predominant pattern group (micropapillary/solid predominant) (P = 
0.001) were significantly associated with higher percentage of N1 or N2 lymph node 
metastasis. In multivariate analysis, greater tumor size (P < 0.001), and micropapillary/
solid predominant pattern (P = 0.029) were significant predictors of N1 or N2 lymph 
in both groups. Methods: All patients diagnosed with stage I and II NSCLC and treated 
with SBRT or surgery between 2008 and 2011 at St. Antonius Hospital Nieuwegein, 
The Netherlands were included. There was no routine protocol for assessment of 
post-treatment PFTs. Therefore, follow-up durations were categorized in early (0-9 
months), middle (10-21 months) and late (≥ 22 months). We assessed forced expiratory 
volume in 1 second (FEV1) and diffusion capacity to carbon monoxide corrected for 
the actual hemoglobin level (DLCOc) absolute and percentage of predicted values. 
Wilcoxon signed-rank test for paired samples was used to analyze statistical differences 
between baseline- and follow-up PFTs. Results: Among 230 patients, 123 patients had 
both pre- and a minimum of one post-treatment PFT. Of the 123 patients, 30 patients 
were treated with SBRT and 93 patients with surgery. Mean pre-treatment FEV1 and 
DLCOc values were respectively 1.27 liter (54.90% of predicted) and 4.25 mL/min/
mmHg (56.11% of predicted) in the SBRT group and 2.44 liter (88.38% of predicted) and 
6.10 mL/min/mmHg (71.96% of predicted) in the surgery group. There were significant 
changes in FEV1 and DLCOc after surgery for all follow-up durations. After SBRT, absolute 
FEV1 values remained stable up to 22 months. After 22 months a statistical significant 
change was observed (from 1.27 liter pre-treatment to 1.11 liter (p=0.008). DLCOc 
was not significantly impaired after SBRT (from 4.25 mL/min/mmHg pre-treatment 
to 3.47 mL/min/mmHg (p=0.061)), and showed a small, non-significant, increase 
for the middle-follow-up term (to 5.22 mL/min/mmHg) compared to pre-treatment 
values. Conclusion: Surgery results in a decline of pulmonary function short after resection 
and on long-term, for stage I and II non-small-cell lungcancer. Pulmonary function after 
SBRT showed a non-significant decline, except for absolute FEV1 values at long-term follow-
up. Further analysis of these data must reveal if these changes are clinically significant. 
Keywords: Stereotactic body radiation, Pulmonary Function, Surgery, stage I and II non-
small-cell lung cancer
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P1.03-024 Comparison of Prognosis Between Patients with Solitary Lung 
Adenocarcinoma and With Multiple Primary Cancers Including Lung 
Adenocarcinoma Eunjue Yi1, Hyun Hwak Shin1, Hyo-Jun Jang1, Mi Kyung Bae2, Sukki 
Cho1, Kwhanmien Kim1, Sanghoon Jheon1 1Seoul National University Bundang Hospital, 
Seongnam-Si/Korea, 2National Health Insurance Service Ilsan Hospital, Goyang-Si/Korea
Background: As advances in diagnostic tools and treatment methods, patients with 
multiple primary cancers are expected to increase. We investigated the prognosis 
of multiple primary cancer patients who underwent surgical management for lung 
adenocarcinoma, and compared it with that of patients who suffered from lung 
adenocarcinoma only. Methods: Medical records of lung adenocarcinoma patients 
who underwent surgical management in our institute between 2003 and 2012 were 
reviewed retrospectively. Patients with multiple primary lung cancer, either synchronous 
or metachronous, and patients underwent neoadjuvant therapy were excluded. 
We categorized enrolled patients into 2 categories; (1) Group 1; patients with lung 
adenocarcinoma only, (2) Group 2; patients with lung adenocarcinoma and other primary 
cancers. Clinicopathologic characteristics were compared between two groups, and 
survival analysis was done. Results: A total of 964 patents were enrolled in this study, 
and 17.7% have primary cancers other than lung adenocarcinoma (Group 1; 793, and 
Group 2; 171). Mean follow-up periods were 55.1 months (± 29.00, ranged from 0.0 
to 139.2 months), and mean age at the time of surgery were 62.0 (± 10.51, ranged 
from 20 to 91). There were no significant differences in gender between two groups 
(p=0.400), however, the mean age of Group 2 was higher in Group 2 (p=0.005). 
The SUVmax value and tumor sizes were higher in Group 1 (p<0.000 and p<0.000 
respectively). The presence of visceral pleural invasion, EGFR mutations and p53 showed 
no significance between two groups (p=0.322, p=0.728 and p=0.966 respectively). 
N stages were higher in Group 1 than group 2 (p=0.026). Overall 3-year and 5-year 
survival rates in Group 1 (87.0% and 80.6%) and Group 2 (89.1% and 80.6%) showed no 
statistically significant differences (p=0.926), Likewise, those of disease-free survival 
rates in two groups (71.1% and 66.5% in Group 1, 78.0% and 74.4% in Group 2) revealed 
no significant differences (p=0.054). Conclusion: Patients of lung adenocarcinoma 
with multiple primary cancers showed no prognostic inferiority, and the stages of 
lung cancers tended to be lower. Careful inspections for finding other malignancies 
in multiple primary cancer patients can contribute to reduce lung cancer mortality. 
Keywords: lung adenocarcinoma, multiple primary cancers, Prognosis
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P1.03-025 Relation of Visceral Pleura Invasion with Hilar Lymph 
Node Involvement and Survival in Primary Lung Cancer Serhan Tanju1, Suat 
Erus2, Yusuf Bayrak3, Nil Molinas Mandel4, Şükrü Dilege1 1Thoracic Surgery, Koç University 
School of Medicine, Istanbul/Turkey, 2Thoracic Surgery, Koç University Hospital, Istanbul/
Turkey, 3Thoracic Surgery, Vkf American Hospital, Istanbul/Turkey, 4Medical Oncology, Koç 
University School of Medicine, Istanbul/Turkey
Background: The aim of this study is to investigate the role of visceral pleura invasion 
on hilar lymph node involvement and survival in surgically treated primary lung cancer 
patients. Methods: We examined pathological data of 219 surgically treated primary non-
small cell lung cancer patients operated between january 2006 & March 2012. Patients 
were divided into three groups. Group 1: Patients with a tumor entrapped within the thick 
elastic layer (PL0), Group 2: Patients with tumor crossed the elastic layer of visceral 
pleura (PL1), Group 3: patients with a tumor crossed the elastic layer and reached 
the surface of visceral pleura (PL2). Patients with parietal pleura invasion (PL3) and 
operative mortality (45 patients) were excluded from the study. Groups were examined 
in terms of tumor size, mediastinal involvement, lymphovasculary invasionand survival. 
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Table 1: Baseline Characteristics of Study Cohort
  
 
Conclusion: In this retrospective study of definitively treated LA-NSCLC patients, 
obese pts had significantly improved survival relative to normal weight pts. This 
favorable prognostic effect was independent of stage and was significantly more 
durable than previously reported in advanced NSCLC patients. Additionally, the putative 
relationship between BMI and smoking history was not observed in this cohort. These 
new findings suggest that the protective effect of obesity in NSCLC is not solely due to 
short-term treatment effects or decreased smoking exposure. We plan to investigate 
additional parameters such as histology, chemoradiation course, subsequent surgery, 
and metformin use to further clarify the role of obesity in survival of NSCLC pts. 
Keywords: obesity BMI NSCLC
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P1.03-030 Marital Status Is Strongly Prognostic and Associated with More 
Favorable Nutritional Status in Locally Advanced Non-Small Cell Lung Cancer 
Josephine L. Feliciano, Søren M. Bentzen, Vincent K. Lam, Katherine A. Schrenk, 
Pranshu Mohindra, Elizabeth M. Nichols, Melissa Vyfthius, Neha Bhooshan, Steven 
J. Feigenberg, Martin Edelman Greenebaum Cancer Center, University of Maryland, 
Baltimore/MD/United States of America
Background: We updated our previous analysis demonstrating marital status is 
prognostic in stage III NSCLC. We hypothesized that married patients have more favorable 
nutritional or immunologic status than unmarried patients as a potential mechanism for 
this survival advantage. Methods: Between January 2000 and December 2010, 268 
patients with stage III NSCLC received definitive chemotherapy and radiation therapy, 
with or without surgery at our institution. All had complete demographic, diagnosis, 
treatment, lab, and survival data. A Kaplan-Meier method estimated overall survival 
and we applied the log-rank test to compare mortality between groups. Multivariable 
analysis of prognostic factors was conducted using the Cox proportional hazards model. 
We tested the interaction between marital status and pre-treatment body mass index 
(BMI), albumin, white blood count, absolute neutrophil count, absolute lymphocyte 
count and calculated neutrophil-lymphocyte ratio (NLR). Results: More married patients 
presented with stage IIIA (rather than IIIB) disease (58% vs. 46%, P=0.03), had a PS 0 
(57% vs. 36%, P<0.001), were white (69% vs. 43% (P<0.001) and lived in higher median 
income areas ($45,646 vs. $38,331, P<0.001) than non-married patients. There was no 
difference in tobacco history or diagnosis age between married and unmarried patients. 
After adjusting for stage, PS, race, and median household income, the hazard ratio for 
any-cause mortality in married patients was 0.59, 95% CI (0.45, 0.78), P<0.001. Median 
OS for married vs. unmarried patients was 28 (23, 34) vs. 16 (13, 19) months (P<0.001). 
Contrary to other reports, the reduction in mortality associated with being married was 
similar in males, 45%,and females 43%, with the test for interaction in a multivariable Cox 
model being non-significant (P=0.38).
 
node metastasis in tumors of 2cm or smaller. Micropapillary/solid predominant pattern 
(P = 0.031) was also a significant predictor of N2 lymph node metastasis in multivariate 
analysis. Conclusion: Tumor size and histological subtypes were significantly associated 
with lymph node metastasis in lung adenocarcinoma of 2cm or smaller. Micropapillary/
solid predominant pattern is a significant predictor of lymph node metastasis. 
Keywords: Adenocarcinoma, lymph node metastasis, histology, predictor
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P1.03-028 Multicenter Study of the Usefulness of FDG-PET as a Predictor of 
the Clinicopathological Characteristics and Prognosis of Lung Cancer 
Norihiko Ikeda1, Yasufumi Kato1, Tatsuo Ohira1, Haruhiko Nakayama2, Morihito Okada3 
1Thoracic Surgery, Tokyo Medical University Hospital, Tokyo/Japan, 2Thoracic Surgery, 
Kanagawa Cancer Center, Kanagawa/Japan, 3Surgical Oncology, Hiroshima University, 
Hiroshima/Japan
Background: This multicenter study aimed to investigate the performance of 
standardized uptake value (SUV) on [18F]-fluoro-2-deoxy-d-glucose positron emission 
tomography (FDG-PET) as a predictor of the clinicopathological characteristics and 
prognosis of resected lung cancers. Methods: A total of 721 patients underwent 
curative resection with systematic lymph node dissection. The relationship among 
histological characteristics, pathological staging, prognosis, and SUV on FDG-PET was 
retrospectively examined. Results: There were 107 squamous cell carcinomas and 614 
adenocarcinomas. The pathological stages of the cases were IA 408, IB 162, IIA 57, 
IIB 23, IIIA 65, IIIB 1, and IV 5. The SUVmax on FDG-PET/CT was significantly higher 
in squamous cell carcinoma than in adenocarcinoma (11.98 ± 6.81 vs 4.03 ± 4.99; p 
< 0.001) and this tendency was similar in all stages. Pathological N1 (n = 19), N2 (n 
= 9) cases showed a significantly higher SUVmax than N0 (n = 79) in squamous cell 
carcinoma (15.00 ± 5.42, 17.24 ± 8.10 vs 10.65 ± 6.50). This was also the case with 
adenocarcinoma N2 (n = 48) 8.58 ± 6.14, N1 (n = 40) 9.15 ± 7.13 vs N0 (n = 526) 3.23 ± 
4.16. Cases with pathological tumor invasiveness such as lymphatic, vascular or pleural 
infiltration showed a significantly higher SUVmax than cases with no invasiveness in 
squamous cell carcinoma (13.75 ± 6.75 vs 7.21 ± 4.22; p < 0.001) and adenocarcinoma 
(7.39 ± 6.12 vs 1.94 ± 2.37; p < 0.001). The areas under the receiver operating 
characteristic curves for SUVmax used to predict the relapse-free survival were 12.3 (p 
= 0.058) in squamous cell carcinoma and 2.6 (p < 0.001) in adenocarcinoma. The 2-year 
relapse-free survival was 93%/68% (SUVmax lower/higher than 12.3) in squamous 
cell carcinoma and 99%/78% (SUVmax lower/higher than 2.6) in adenocarcinoma. 
Following multivariate analysis, pathological nodal status and SUVmax were found to 
be independent predictive factors for relapse-free survival. Conclusion: SUVmax of 
the primary tumor reflected the biological malignancy of lung cancers. As SUVmax 
tended to be higher in squamous cell carcinoma than in adenocarcinoma, this should 
be clinically used separately according to histology. SUVmax is also useful for 
predicting survival, and multimodality treatment might be indicated if the value is high. 
Keywords: Prognosis, lung cancer, FDG-PET, stage
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P1.03-029 Obesity Is Associated with Long-Term Improved Survival in 
Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (LA-
NSCLC) Vincent K. Lam, Søren M. Bentzen, Pranshu Mohindra, Elizabeth M. Nichols, 
Neha Bhooshan, Melissa Vyfhuis, Steven J. Feigenberg, Martin Edelman, Josephine L. 
Feliciano Greenebaum Cancer Center, University of Maryland, Baltimore/MD/United States 
of America
Background: Limited studies suggest that obese patients (pts) with NSCLC paradoxically 
have improved survival. However, characterization of factors influencing Body Mass 
Index (BMI) at disease presentation and the impact that it may have on outcomes in 
NSCLC patients remains incomplete. We evaluated the prognostic effect of BMI in a 
retrospective cohort treated for LA-NSCLC (AJCC 7th edition stage III). Methods: From 
January 2000 to December 2010, 311 consecutive LA-NSCLC pts were definitively 
treated at our institution with chemotherapy and radiotherapy ± surgery. Radiation was 
most commonly administered with concurrent chemotherapy. After excluding pts for 
whom pre-treatment BMI was not available, we evaluated 291 pts who were stratified 
into four BMI groups based on World Health Organization criteria: underweight (< 18.5 
kg/m2), normal weight (18.5 to < 25 kg/m2), overweight (25 to < 30 kg/m2), and 
obese (>= 30 kg/m2). Kaplan-Meier survival analysis was performed with log-rank test-
for-trend. Cox proportional hazards modeling was used for univariate and multivariate 
analyses. Results: Baseline characteristics were similar between obese and normal 
weight pts (Table 1). Median survival was 17 months (mo), 19 mo, 23 mo, and 29 mo 
for each BMI group respectively. A trend for improved survival with increasing BMI was 
highly significant (P=0.009) and persisted even when underweight cases were excluded, 
suggesting that the survival benefit is not driven by unfavorable prognostic factors in the 
underweight cases. There was a sustained 31% to 58% reduction in mortality of obese 
relative to normal weight pts (HR 0.68±0.21, 0.61±0.19, and 0.42±0.19, for each year 
post-treatment respectively). Additionally, there was no correlation between BMI and 
smoking pack-years, even when underweight pts were excluded. (correlation coefficient 
0.033 [95% CI 0.09 – 0.15, P=0.59]).
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Conclusion: Concurrent chemoradiotherapy using advanced radiotherapeutic 
technologies and docetaxel-cisplatin followed by adjuvant chemotherapy for inoperable 
stage III non-small-cell lung cancer demonstrated good response rates, overall 
survival and progression free survival. The treatment protocol was generally safe 
and well tolerated. Adverse events are less common than reported in the literature. 
Keywords: lung cancer, Chemoradiotherapy, SPECT-CT, radiotherapy technologies
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P1.04-001 MET/RON Inhibition in KRAS Mutated Non Small Cell Lung 
Cancer Sravya Tumuluru1, Rifat Hasina2, Juan Alban1, Aliya Husain3, Mark Ferguson3, 
Everett E. Vokes4, Ravi Salgia5 1Bsd, Hem/Onc, University of Chicago, Chicago/IL/
United States of America, 2Bsd, Hem/Onc, University of Chicago, Chicago/United States 
of America, 3University of Chicago, Chicago/AL/United States of America, 4Medicine, The 
University of Chicago, Chicago/United States of America, 5Medicine, Section of Hematology/
Oncology, University of Chicago, Chicago/IL/United States of America
Background: Molecular genetics have allowed us to categorize non-small cell lung 
cancer (NSCLC) based on their genetic profile. KRAS mutations occur in 25-30% 
of NSCLCs. KRAS regulates cellular function in response to growth factors and their 
receptors. When mutated, KRAS is constitutively active and is responsible for driving 
tumor oncogenesis. Direct inhibition of KRAS has not been a successful clinical strategy. 
The strategy of synthetic lethality (targeting a non-lethal defect in cancer cells combined 
with a second defect, that together make the cancer cell more susceptible to treatment) 
has gained traction in recent years. Several synthetic lethal targets have been identified 
with KRAS. We have previously shown that MET plays an important role in the oncogenic 
addiction observed in KRAS mutated NSCLC and contributes to both tumor growth and 
metastasis. However, the development of resistance in MET targeting due to upregulation 
of RON, a related receptor tyrosine kinase, is also evident. Our hypothesis is that dual 
targeting of MET and RON may be synthetic lethal to KRAS mutated NSCLC and studies 
to investigate this as a potential therapeutic strategy are warranted. Methods: MET- 
and RON-specific siRNAs (small molecule inhibitors), crizotinib, and the ligand for MET 
(hepatocyte growth factor), were used in in vitro assays. Immunoblotting, cell viability, 
and cell migration assays were carried out in a panel of KRAS mutated as well as KRAS 
wild type NSCLC cells. In addition, human bronchial epithelial cells (HBECs) that were 
rendered tumorigenic with sequential mutations in CDk4, hTERT, p53, and KRAS genes 
were also used. Results: Our analysis of a panel of NSCLC cells showed that most KRAS 
mutant cell lines express both MET and RON, and stimulation with HGF activated KRAS 
effector pathways such as MAPK, AKT and S6RP. When we silenced MET expression with 
siRNA, it led to upregulation of RON, indicating the interaction between MET and RON. 
Cell viability assays using crizotinib showed that KRAS mutant cell lines (A549 and H460) 
are three-fold more sensitive than KRAS wild type cells (H1975 and H1437), and cells with 
MET amplification (H1993) showed the highest response. Preliminary data with the KRAS-
transformed HBECs also showed that they are more sensitive to crizotinib inhibition than 
the non-transformed control HBECs. Wound healing assays with these same cells showed 
a similar trend in MET specific inhibition of cell migration in KRAS-mutated cells compared 
to wild type cells. Conclusion: These data highlight the potential therapeutic benefit 
of targeting MET and RON simultaneously in a subpopulation of KRAS mutated NSCLC 
We also found married status was associated with higher median, 25th, and 75th percentile 
BMI (26.3 vs. 23.8; 23.3 vs. 20.6, and 30.8 vs. 28.4, respectively; P=0.014) and albumin 
(3.7 vs. 3.6; 3.4 vs. 3.1; and 4.0 vs. 3.8, respectively; P=0.001). Conclusion: Marital 
status is an important predictor of survival in stage III NSCLC and appears to offset 
the disadvantage of higher stage disease. Our results suggest one mechanism for 
this may be married patients have more favorable nutritional status evidenced by 
higher BMI and albumin. We did not find an association between marital status and 
immunologic status in our analysis. Future studies that evaluate how social support 
impacts nutritional status prior to therapy may lead to interventions to target vulnerable 
populations. Marital status may be an important stratification factor in clinical trials. 
Keywords: marital, lung, nutrition, locally advanced
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P1.03-031 Concurrent Chemoradiotherapy Using Advanced Radiotherapy 
Technologies for Inoperable Stage III Non-Small-Cell Lung Cancer 
Joseph S K Au1, S H Chan2, K T Yuen3, F Lee1, R M W Yeung2, C C Yau3, Y C. Li1, C K Law1 
1Queen Elizabeth Hospital, Hong Kong/China, 2Pamela Youde Nethersole Eastern Hospital, 
Hong Kong/China, 3Princess Margaret Hospital, Hong Kong/China
Background: Concurrent chemoradiotherapy with the standard regimen of docetaxel 
plus cisplatin/carboplatin for inoperable stage III non-small-cell lung cancer (NSCLC) 
demonstrates good synergistic activity and radiosensitizing properties but toxicities are 
of major concerns. This phase II noncomparative trial was conducted to determine the 
use of newer radiotherapy technologies including IMRT planning with PET-CT to ensure 
dose conformity and SPECT-CT to define functional lung volume for avoidance in reducing 
radiation-induced toxicity and in improving treatment outcome in patients with NSCLC. 
Methods: Patients with locally advanced, inoperable stage III NSCLC received weekly 
docetaxel (20mg/m2) and cisplatin/carboplatin (20mg/m2) for 6 weeks with concurrent 
IMRT (66Gy/6.5 weeks over 33 fraction) followed by a resting period of two weeks before 
administration of 2 cycles of every 3 week adjuvant chemotherapy with docetaxel 
(35mg/m2) and cisplatin/carboplatin (35mg/m2) at Day 1 & 8. Results: A total of thirty-
four patients were recruited in the study as intent-to-treat (ITT) population. Of the twenty-
seven patients (as per-protocol population, PPP) evaluable for treatment response, the 
overall response rate was 77.8%. Median overall survival was 35.5 months (95% CI: 21.3 
– 49.7 months) (Figure 1) and progression free survival was 20.8 months (95% CI: 15.3 
– 26.2 months) (Figure 2). Tolerability was evaluated in the ITT population with the 
majority of adverse events to be predominantly grade 1 or 2. Three (8.8%) deaths 
occurred, two due to fulminant chest infection and one due to disease progression. 
Fifteen (44.1%) had emergent severe adverse events (SAE). The incidence rates of severe 
oesophagitis and pneumonitis were 8.8% and 5.9% respectively.
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pleural dissemination and liver metastasis were associated with decreased KRAS 
mutation prevalence (25.4% and 24.1%, respectively; p=0.007). We found no difference 
in the median OS between KRAS-mutant and WT cases in any metastatic site-specific 
analysis. Conclusion: Lung adenocarcinoma patients with KRAS-mutant tumors more 
often present with intrapulmonary metastases. KRAS mutation prevalence, however, 
lacks to provide prognostic information. Further studies are required to determine if 
KRAS status can be used to risk stratify patients for the onset of pulmonary metastasis. 
Keywords: lung adenocarcinoma, KRAS, metastasis
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-004 Inhibition of Telomerase Activity Suppresses Kras Mutation-Induced 
Lung Carcinogenesis and Chemoresistance Bin Zhang, Yuesong Yin, Hua Zhang, 
Bowen Shi, Jinfang Zhu, Changli Wang Department of Lung Cancer, Tianjin Medical 
University Cancer Institute and Hospital, Tianjin/China
Background: Kras mutations are one of the most common driver mutations in NSCLC, 
which promote lung tumorigenesis. And many patients harboring Kras mutation fail to benefit 
from chemotherapy. Treatment of Kras-mutant lung cancer is still a challenge. It is reported 
that telomere shorting inhibits tumor formation and prolongs life span in a KrasG12D 
mouse lung cancer model. Telomerase inhibitors show a trend toward improving survival 
of patients with advanced NSCLC with short telomere. However, the roles of telomerase 
inhibition have not been defined in Kras-mutant NSCLC. Methods: KrasG12D was lentivirally 
transduced into normal human lung cell line (BEAS-2B) and lung cancer cell lines (Calu-3 
and H1299) for stable expression. The cells were transfected with TERTshRNA or treated 
with the telomerase inhibitor BIBR1532 to suppress the telomerase activity. Telomerase 
activity and telomere length were examined by the telomeric repeat amplification protocol 
(TRAP) assay and the Southern blot analysis of terminal restriction fragment lengths. Cell 
proliferation, colony formation and migration were analyzed by cell growth curves, soft 
agar assay and transwell migration assay. Calu-3- KrasG12D xenograft mice models were 
used to validate the effects of telomerase inhibition on cell growth and chemosensitivity 
in vivo. Results: We found that continuing inhibition of telomerase shorted telomere 
length and inhibited mutant KrasG12D-induced cell migration, colony formation, long-term 
proliferative capability and activation of Kras signaling pathway in both normal human lung 
and lung cancer cells. In addition, decreasing telomerase activity increased cells sensitivity 
to chemotherapeutic agents in Calu-3 and H1299 cells with KrasG12D overexpression. 
Notably, the effects of telomerase inhibition on Kras-mutant cells were P53 independent. In 
vivo experiments also confirmed treatment with telomerase inhibitor significantly enhanced 
tumor growth inhibition and the antitumor efficacy of chemotherapy in Calu-3-KrasG12D 
tumor-bearing mice. Conclusion: Our data suggest that Kras mutation-induced lung 
carcinogenesis and chemoresistance are attenuated by telomerase inhibition. Targeting 
telomerase/telomere may be a promising therapeutic strategy for Kras mutant NSCLC. 
Keywords: non-small cell lung cancer(NSCLC), chemoresistance, telomerase, kras 
mutation
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P1.04-005 Concurrent EGFR and ALK Mutations in KRAS-Mutant Lung 
Adenocarcinomas and Their Clinical Behavior Kevin C. Wood, Thomas Hensing, 
Brian Won, Everett Vokes, Ravi Salgia Medicine, Section of Hematology/Oncology, 
University of Chicago, Chicago/IL/United States of America
Background: KRAS represents the most commonly mutated oncogene in non-small cell 
lung cancer (20-30%). Multiple studies have suggested mutations of KRAS, epidermal 
growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) to be mutually 
exclusive[i], though there are few case studies showing coexisting EGFR and KRAS 
mutations[ii]. Methods: We reviewed clinical genotyping data from 118 patients with 
stage I – IV KRAS mutated NSCLC. We investigated prevalence of concomitant EGFR and 
ALK mutations and evaluated clinical behavior in regards to overall survival (OS) and 
response to tyrosine kinase inhibitor therapy. Results: Among these 118 samples with 
KRAS alterations (codon 12 =98, 13 = 8, 61 = 3, 146 = 2, 189 =1, amplification = 6), 
median OS was 61.97 months (Graph 1). Concomitant EGFR mutations were noted in 6 
subjects (5.0%) and ALK mutations were noted in 2 subjects (1.7%). One patient was 
found to have mutations of KRAS, EGFR, and ALK. These patients’ stage at diagnosis, 
response to TKI therapy (if utilized), and OS is documented in Table 1. 
patients who may have MET overexpression or amplification. Based on KRAS oncogenic 
addiction to MET, we propose that NSCLC cells that are MET amplified and KRAS 
mutated are potentially synthetic lethal and will benefit from dual MET/RON treatment 
Keywords: NSCLC, KRAS
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P1.04-002 Protein Signaling Analysis of KRAS Mutant Lung Adenocarcionomas 
Reveals Variable MAPK and mTOR Pathway Activation Elisa Baldelli1, Eric Haura2, 
Lucio Crinò3, W Douglas Cress2, Vienna Ludovini3, Matthew B. Schabath4, Guido 
Bellezza5, Jacopo Vannucci6, Jianghong Deng1, Lorenza Pistola3, Francesca Romana 
Tofanetti3, Annamaria Siggillino3, Lance A Liotta1, Emanuel F. Petricoin1, Mariaelena 
Pierobon1 1Center for Applied Proteomics and Molecular Medicine, George Mason University, 
Manassas/United States of America, 2Dept of Thoracic Oncology, Moffitt Cancer Center and 
Research Institute, Tampa/FL/United States of America, 3Medical Oncology, S. Maria Della 
Misericordia Hospital, Perugia/Italy, 4Cancer Epidemiology, H. Lee Moffitt Cancer Center and 
Research Institute, Tampa/AL/United States of America, 5Institute of Pathological Anatomy 
and Histology, University of Perugia, Perugia/Italy, 6Department of Thoracic Surgery, 
University of Perugia, Perugia/Italy
Background: Despite the numerous efforts made to target KRAS directly, this protein is 
still undruggable. A number of therapeutics that target linked KRAS pathway members have 
been tested, but their efficacy in KRAS mutant lung adenocarcinoma is still controversial. 
Understanding the biochemically linked protein signaling network associated with a KRAS 
mutation may lead to the identification of therapeutic targets to identify patients that may 
benefit from a therapeutic agent targeting KRAS downstream substrates. Methods: Thirty-
four archived samples from surgically-treated KRAS mutant adenocarcinomas were included 
in this study. Samples were collected at the H.Lee Moffitt Cancer Center & Research Institute 
(Tampa, FL) and at the Santa Maria della Misericordia Hospital (Perugia, Italy). Pure cancer 
epithelial cell subpopulations were isolated using Laser Capture Microdissection. The 
expression/activation level of 155 proteins was then measured by Reverse Phase Protein 
Microarray, a high-throughput semi-quantitative platform. Results: The protein activation 
level of ERK (as measured by phosphorylation of T202/Y204), a direct downstream 
substrate of KRAS activity, was highly variable across KRAS mutant samples. While a 
subgroup of patients showed, as expected, high activation of ERK, approximately 2/3 of 
the patients had a comparable ERK activation level to the wild-type counterpart previously 
analyzed. The activation level of the remaining protein signaling analytes was then compared 
between samples with high and low ERK activation. Tumors with high levels of ERK activation 
showed a significant increase in the signaling network of: 1) the MAPK proliferative pathway 
including Ras-GRF1 S916, Mek 1/2 S217/221, MSK1 S360, p38MAPKinase T180/Y182 
(p=0.03, p<0.01, p=0.04, p<0.01 respectively), 2) the AKT-mTOR pathway including Akt 
S473, AMPKα1 S485, ATP Citrate Lyase S454, LKB1 S428, mTOR S2448, p70S6K T389, 
p70S6K T412, 4E-BP1 S65 (p<0.01, p<0.01, p<0.01, p<0.01, p<0.01, p<0.01, p=0.02, 
p=0.03 respectively). Conclusion: This analysis suggests that the signaling network of 
KRAS mutant lung adenocarcinomas, while manifesting expected ERK activation as a group, 
is highly variable. In fact a majority of KRAS mutant tumors had the same range of MEK-
ERK activation as KRAS WT tumors. Analysis of high and low ERK activation in the KRAS 
mutant tumors revealed druggable protein signaling activation of a number of important 
targets. If validated in a larger study set, these data may have important clinical implication 
for the allocation of patients toward more effective and specific targeted treatments. 
Keywords: Signaling pathway analysis, KRAS mutant adenocarcinoma, Reverse phase 
protein microarray
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P1.04-003 Metastatic Site-Specific Variation of KRAS Status in Lung 
Adenocarcinoma Zoltan Lohinai1, Judit Moldvay1, Katalin Fabian2, Mihaly Cserepes1, 
Anita Rozsas3, Gyula Ostoros4, Erzsebet Raso2, Ilona Kovalszky2, Gayane Badalian-
Very2, Jozsef Timar2, Walter Klepetko3, Balazs Dome3, Balazs Hegedus5 1Tumor Biology, 
National Koranyi Institute of Pulmonology, Budapest/Hungary, 2Semmelweis University, 
Budapest/Hungary, 3Division of Thoracic Surgery, Medical University Vienna, Vienna/
Austria, 48Th Dept. of Pulmonology, Koranyi National Institute of Tbc and Pulmonology, 
Budapest/Hungary, 5Molecular Oncology Research Group, Mta-Se, Budapest/Hungary
Background: While KRAS mutation is a negative predictive marker for EGFR tyrosine 
kinase inhibitor therapy, there is limited data available regarding the influence of KRAS 
mutation on the organ specificity of lung adenocarcinoma metastases. Methods: In 
our retrospective, single center study, 820 lung adenocarcinoma patients with KRAS 
mutation analyses were included. At the time of diagnosis, 462 patients had metastatic 
disease. These cases were analyzed for the potential association between KRAS 
status and metastatic site and clinical outcome. Patients with known EGFR mutations 
were excluded from the study. Results: 534 (65.3%) KRAS wild-type and 284 (34.7%) 
KRAS-mutant cases were identified. There was no difference in the KRAS mutation 
prevalence between the metastatic (35.7%) and non-metastatic cases (33.4%). The 
most frequent metastatic sites included bone (29%), contralateral lung (24.8%), 
ipsilateral lung (19.7%), brain (17.3%), adrenal gland (15.6%), pleura (12.8%) and liver 
(11.7%). Patients with multiple metastases tended to have inferior median overall 
survival (OS) compared to those with single-organ metastasis (6.3 vs. 8.2 months, 
respectively; p=0.09) and, moreover, showed a slight but non-significant increase in 
the prevalence of KRAS mutations (38.5%, p=0.35). Importantly, patients with brain 
(35.8%), bone (33.1%) or adrenal gland (35.2%) metastases demonstrated similar 
KRAS mutation frequencies. However, both ipsilateral and contralateral intrapulmonary 
metastatic cases demonstrated increased KRAS mutation frequency when compared 
to those with extrapulmonary metastases (42.2% and 42.5%, p=0.014). In contrast, 
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G12C (41.8%) and G12V (26.1%). There was a statistically significant association between 
KRAS mutations and non-squamous histology (93.5% in KRAS mutated patients vs. 74.1% 
in KRAS wild-type patients, p=0.020) and a history of past or current smoking (93.4% 
vs. 78.4%, p=0.032). No statistical differences were found regarding age, gender, 
performance status or cancer stage at diagnosis. With respect to patients staged IIIB 
or IV at diagnosis, overall survival tended to be inferior in patients with KRAS mutations 
(median survival: 5 vs. 9 months, p=0.127). There was no statistical difference between 
groups regarding response to first-line chemotherapy and time to progression after first-
line chemotherapy. Conclusion: The prevalence of KRAS mutation in this Portuguese 
cohort is consistent with results of similar studies in other countries (20-25%). KRAS 
mutations were associated to adenocarcinoma histology and smoking habits. Despite 
overall survival tending to be half in KRAS mutated IIIB/IV patients, this study showed 
little relevance as a prognostic marker. Thus, it is important to pursue the search for 
other molecular biomarkers that could be used in prognosis and even as therapy targets. 
Keywords: non-small cell lung cancer, KRAS mutations, Prognosis
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P1.04-008 Tissue Hyaluronan and Its Relationship with Angiogenesis Are 
Indicators of Lung Cancer Malignancy Maristela P. Rangel1, Tabatha Prieto2, 
Eloisa R. Olivieri3, Dirce M. Carraro3, Vera L. Capelozzi2 1Pathology, Faculty of Medicine; 
University of Sao Paulo, São Paulo/Brazil, 2Pathology, Faculty of Medicine, University of Sao 
Paulo, São Paulo/Brazil, 3Pathology, Ac Camargo Cancer Center, São Paulo/Brazil
Background: Cell-extracellular matrix interactions participate in several steps required 
for tumor cell invasion and because of that, a group of glycosaminoglycans have been 
targeted as potentially useful tumor markers. Hyaluronan has shown promise, but still there 
is uncertainty about its localization in tumor tissue and its relationship with histological 
types and angiogenesis. Regarding that, we evaluated the association between HA and 
degree of malignancy through its expression in lung tumor tissue and association with 
angiogenesis. Methods: Forty-six lung specimens were evaluated. Hyaluronan and 
microvessel (CD34) quantification in situ was done in FFPE sections of nonneoplastic 
cells, lung cancer cells, and tumor stroma. Colocation was evaluated in tumor stroma 
using confocal microscopy. Cox proportional hazards model, MantelHaenszel test and 
Pearson’s x2 were used to evaluate the hyaluronan and microvessel staining inferences 
and the relationship between them. Results: Squamous cell carcinoma showed abundant 
hyaluronan on the cancer cell-stroma interface coincident with prominent microvessel 
staining and identical colocalization at confocal microscopy. Strong hyaluronan staining 
associated with cancer cells was significant in 32.1% of squamous cell carcinoma 
compared to 17.9% of adenocarcinoma and 0.0% in large cell carcinoma (P<0.001). 
Adenocarcinomas revealed strong stromal hyaluronan staining in contrast with the 
hyaluronan-poor tumor cells. The foci of hyaluronan stromal staining was coincident with 
foci of microvessel and colocalization. Furthermore, adenocarcinoma more often showed 
a lower percentage of hyaluronan-positive cancer cells (35.7% of cases) than large cell 
carcinoma (14.3% of cases) or squamous cell carcinoma (0% of cases; P<0.001). For 
large cell carcinoma, the hyaluronan signal in tumor cells was very poor and contrasted 
with the foci of staining in stroma, coincident with focal microvessel density and 
colocalization. All these results are shown in Figure 1. A significant direct association was 
found between tumors with a high percentage of HA and MVD in tumor stroma (R=0.6; 
P=0.02). Similarly significant was the direct association between tumors at the N1 stage 
and high levels of hyaluronan in cancer cells (R=0.31; P=0.05). In addition, tumors in the 
T4 stage presented positive association with a high percentage of hyaluronan-positive 
cancer cells (R=0.80; P=0.01).
 
Conclusion: This analysis demonstrates it is possible for KRAS mutations to occur 
concurrently with EGFR and ALK missense mutations (not translocation) and emphasizes 
that a complete molecular analysis should be performed on all NSCLC patients. Further 
data is needed to more firmly elucidate how these concurrent mutations affect clinical 
behavior. Citations [I] Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually 
exclusive with mutations in EGFR and KRAS in non-small cell lung cancer. Clin Cancer Res. 
2013 Aug 1; 19(15): 4273-81. [II] Zhu CQ, Sants GC, Ding K, et al. Role of KRAS and EGFR 
as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical 
Trials Group study BR.21. Journal of Clinical Oncology. 2008 Sep 10; 26(26): 4268-4275. 
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P1.04-006 Prognostic and Predictive Role of KRAS-Mutations in Patients with 
Advanced Non-Squmous Non-Small-Cell Lung Cancer (NS-NSCLC) Mario A. 
Sanchez-Salinas1, Javier Garde-Noguera2, Jose Garcia Sanchez1, Marisol Valera1, Sara 
Marin1, Julia Hidalgo1, Rene Arturo Albino1, Jose Ferrando Marco1, Antonio Llombart 
Cussac1 1Hospital Arnau de Vilanova, Valencia/Spain, 2Medical Oncology, Hospital Arnau de 
Vilanova, Valencia/Spain
Background: KRAS is the most frequently mutated oncogene in lung adenocarcinoma 
patients. The prognostic rolo of mutatn-KRAS in lung adenocarcinoma is controversial, 
especially in non-asian populations. Studies also suggest the potencial predictive role 
of mutant-KRAS in the context of chemosensitivity of NSCLC. The aim of our study is 
to analyze the role of KRAS mutations as prognostic factor in advanced NSCLC, and 
their value as predictive biomarker of chemotherapy efficacy. Methods: Retrospective 
study of patients with advanced NS-NSCLC in our institution between january-2013 and 
december-2014. Mutation analysis for KRAS was performed an the relation with overall 
survival was assessed. Secondary endpoints were its relation with progression-free 
survival and response to chemotherapy. Results: A total of 42 patients met inclusion 
criteria. Median age was 61.5 years. Thirty-three male (78.6%), 27 ECOG-PS 0-1 (64.3%), 
and 40 (95.2%) adenocarcinoma. Twenty-six patients (61.9%) received chemotherapy as 
first line treatment, 4 (9.5%) anti-EGFR treatment and 12 supportive care. Nine patients 
(21.4%) harboured KRAS mutations, all of them at exon 12. There were no differences 
in age, performance status or smoking history between patients with KRAS mutants vs 
those with wild-type tumours; instead KRASmut patients presented a higher rate of brain 
metastases (55.5 vs 20%; p=0.05) and higher number of methastatic locations at diagnosis 
(77.7 vs 41.3% of patients with more than one site of metastases). Median Overall Survival 
was superior for patients with wild type tumours (19 vs 10 months, p =0.22). There were 
no differences in response rate in patients treated with platinum doblet chemotherapy 
(Wild-type vs KRAS mut: 44.4 vs 33.3%, p=0.5), but progression free survival and overall 
survival were superior for wild-type tumour patients (PFS: 3 vs 15 months, p=0.001; 
OS: 10 vs NR, p=0.06). Conclusion: With the limitation of small numbers, our data 
suggest that KRASmut patients are a subgroup with poorer prognostic. Moreover, 
they seem to benefit less from standard chemotherapy based in platinum doublets. 
Keywords: KRAS mutations, lung cancer, prognostic factor, predictive factor
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P1.04-007 KRAS Mutations in Lung Cancer: Prevalence and Outcomes 
Margarida Dias1, Rita Linhas1, José Carlos Machado2, Luís Cirnes2, Ana Gonçalves1, 
Sérgio Campainha1, Sara Conde1, Ana Barroso1 1Pulmonology, Centro Hospitalar Vila Nova 
de Gaia Espinho, Vila Nova de Gaia/Portugal, 2Ipatimup, Porto/Portugal
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death 
worldwide. The most commonly mutated oncogene in NSCLC encodes for KRAS and 
its mutations are usually associated to a poor prognosis. The aim of this study was to 
evaluate the prevalence and the prognosis of these mutations in a Portuguese cohort of 
patients with NSCLC, EGFR wild-type. Methods: We included 201 patients diagnosed 
with NSCLC, EGFR wild-type, followed in a Lung Cancer Unit. KRAS mutations in exon 12 
and 13 were screened. Demographic and clinical data were analyzed. Overall survival, 
objective response to first-line chemotherapy and time to progression was evaluated in 
patients staged IIIB or IV at diagnosis. Results: 173 (81.1%) were male, mean age 67±12 
years, 40.1% smokers and 42.6% ex-smokers. At diagnosis, 9.1% were stage IA, 4.6% IB, 
3% IIA, 2.5% IIB, 13.7% IIIA, 11.7% IIIB, 54.8% IV. 68.2% were adenocarcinoma and 21.4% 
squamous tumors. 79.5% was performance status 0-1. KRAS mutations were found in 46 
(22.9%) patients and in 4.5% results were not valid. The most common mutations were 
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(12.5%), 39 (16.9), 111 (48.1%) respectively. Positive lymphatic invasion and, or vascular 
invasion and, or pleural invasion in Group A, Group B, Group C were 0 (0%), 4 (1.2%), 24 
(21.6%) respectively. There are significant difference in 5-year recurrence free survival 
(5y-RFS) between Group A and B (5y-RFS rate 100% versus 88.1%; p = 0.022), and 
Group A and C (5y-RFS rate 100% versus 88.1%: p = 0.046). Conclusion: Max collapse 
and fibrosis below 5 cm correlated with the prognosis of pT1 lepidic predominant 
adenocarcinoma. Max collapse and fibrosis below 5cm is more simpl and easy method 
to measure invasive component than the new IASLC/ATS/ERS classification. This 
method may have potential to diagnose MIA instead of the IASLC/ATS/ERS classification. 
Keywords: minimal invasive adenocarcinoma, collapse and fibrosis, lepidic predominant 
adenocarcinoma, Prognosis
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P1.04-010 Pilot Internet Survey of Interobserver Variability in Pathology 
Diagnoses of Multiple Tumor Nodules Wilbur A. Franklin1, Andrew G. Nicholson2, 
Kathleen Torkko3, William D. Travis4, Frank Detterbeck5 1Pathology, University of Colorado 
Health Sciences Center, Aurora/CO/United States of America, 2Pathology, Royal Brompton 
and Harefield NHS Foundation Trust and National Heart and Lung Institute, London/United 
Kingdom, 3Pathology, University of Colorado Health Sciences Center, Aurora/United States of 
America, 4Dept of Pathology, Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America, 5Surgery, Yale U, New Haven/CT/United States of America
Background: The distinction between separate primary lung cancers (SPLC) or 
intrapulmonary metastases (IM) is of great clinical importance because of the substantial 
staging and prognostic implications. With the broad implementation of CT screening for 
lung cancer, the recognition of multiple tumor nodules is increasingly common. Currently, 
similarities and differences in histology between two tumors provide the most definitive 
distinction between SPT and IM. However, the level of agreement among pathologists 
regarding this question has not been tested. The IASLC Pathology Committee and the 
Multidisciplinary SPT Working Group has addressed this issue through a pilot online 
survey. This study assesses the feasibility and reports preliminary results of a web-based 
survey to determine interobserver variation in distinguishing SPT and IM. Methods: A 
pilot study was conducted to test whether multiple observers could assess a collection 
 
Conclusion: Our findings showed that an elevated hyaluronan signal in tumor cells 
was associated with poor prognosis and its localization relationship with histological 
types and angiogenesis was related to malignancy of lung cancer. To realize 
these findings a greater larger scale study in a randomized trial will be required. 
Keywords: extracellular matrix, hyaluronan, lung cancer, angiogenesis
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P1.04-009 Max Collapse and Fibrosis below 5 cm Predict the Prognosis of pT1 
Lepidic Predominant Adenocarcinoma Masahito Naito1, Masahiro Tsuboi2, Keiju 
Aokage3, Tomoyuki Hishida4, Genichio Ishii5, Junji Yoshida6 1Thoracic Surgery, National 
Cancer Center Hospital East, Kashiwa-Shi, Chiba/Japan, 2Thoracic Surgery, National Cancer 
Center Hospital East, Kashiwa, Chiba/Japan, 3Thoracic Oncology, National Cancer Center 
Hospital East, Kashiwa, Chiba/Japan, 4Division of Thoracic Surgery, Department of Thoracic 
Oncology, National Cancer Center Hospital East, Kashiwa/Japan, 5Pathology, Resarch 
Center of Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba/
Japan, 6Thoracic Surgery, National Cancer Center Hospital East, Kashiwa/Japan
Background: According to the International Association for the Study of Lung Cancer 
, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) 
classification, lepidic predominant pattern in pT1 lung adenocarcinoma is divided into 
adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and lepidic 
predominant invasive adenocarcinoma (LPIA) by using new diagnostic criteria. However 
the new criteria have many item to diagnose MIA. So we simply classified the pT1 lepidic 
predominant adenocarcinoma by using only collapse and fibrosis below 5cm as invasive 
component, and we evaluated prognosis of MIA. Methods: A total of 231 patients treated 
for pT1 lepidic predominant lung adenocarcinoma by complete resection at National 
cancer center hospital east, Chiba, Japan from January 2003 to December 2010 were 
assessed. We excluded multiple tumor and mucinous invasive adenocarcinoma from the 
analysis. We classified 187 patients into AIS, MIA, LPIA, according to the IASLC/ATS/ERS 
classification. The MIA was defined as group A. In the LPIA, we defined invasive component 
as collapse and fibrosis 5 cm below, and reclassified into MIA and LPIA. Reclassified MIA 
and LPIA were defined as Group B and C respectively. We analyzed the prognosis of these 
patients retrospectively. Results: AIS, Group A, Group B, Group C were 52 (22.5%), 29 
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America, 5Section of Hematology/Oncology, University of Chicago, Chicago/IL/United States 
of America, 6Surgery, University of Chicago, Chicago/United States of America
Background: The purpose of this study is to assess the histology of malignant pleural 
mesothelioma using computed tomography (CT) based imaging. Methods: 28 patients 
with malignant pleural mesothelioma were used (histologies: 17 epithelioid, 11 biphasic). 
A CT scan was acquired for each patient prior to surgical resection of the tumor. A 
radiologist identified and outlined the tumor boundary on each CT section that 
demonstrated tumor. These outlines were analyzed to determine the total volume of 
disease present, the mean volume of disease per outlined section, and the distribution of 
Hounsfield Unit (HU) values throughout the outlined tumor. These parameters were used 
to differentiate tumors of epithelioid and biphasic histologies. For each parameter, 
cutoffs were determined to maximize the extraction of biphasic cases from the entire 
cohort, while minimizing the extraction of epithelioid cases. Results: Discernable 
differences were extracted from the images of the two different histologies of the 
disease. Figure 1 shows the mean HU value, the standard deviation and skew in the 
distribution in the HU values, and the volume of tumor represented on each CT section 
demonstrating disease. With regard to HU distribution, the biphasic cases generally had 
a higher mean HU value. For example, 73% of the biphasic cases had a mean value 
greater than 30, compared to only 29% of the epithelioid cases. Biphasic cases also tend 
to have a more negative skew in their HU distribution; 73% of biphasic cases had a skew 
value less than -1, compared to 35% of epithelioid cases. It was also seen that biphasic 
cases also tended to have a higher volume of tumor present throughout their disease 
presenting CT sections. There were promising results from extracting the biphasic cases 
by using optimized cutoffs from gathered data. The criteria used were as follows: Cases 
that exhibited more than 9 mL of tumor per outlined CT section, or exhibited a mean HU 
value greater than 10 as well as a skew in HU values less than -1 were extracted from the 
cohort and identified as biphasic. Of the cases that match these criteria, 10 were actually 
biphasic while 6 were actually epithelioid. These results are 91% specific, missing only 
one biphasic case, and 65% specific, correctly excluding 11 of the 17 epithelioid cases.
 
Figure 1 – Comparison of Epithlioid and Biphasic cell types. Conclusion: This 
study demonstrates that CT-based imaging may be a useful tool 
for the assessment of tumor histology through image analysis. 
Keywords: imaging, Mesothelioma
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P1.04-013 Clinicopathological Characteristics of Lung Cancer with Combined 
Pulmonary Fibrosis and Emphysema Akihiko Yoshizawa1, Meng Zhang2, Shiho 
Asaka3, Takayuki Shiina4, Kazuo Yoshida5 1Department of Diagnostic Pathology, Kyoto 
University Hospital, Kyoto/Japan, 2Dept. of Surgery 2, Shinshu University Hospital, 
Matsumoto/Japan, 3Dept. of Laboratory Medicine, Shinshu University Hospital, Matsumoto/
Japan, 4Thoracic Surgery, Shinshu University Hospital, Matsumoto/Japan, 5Department of 
Thoracic Surgery, Shinshu University School of Medicine, Matsumoto/Japan
Background: Combined pulmonary fibrosis and emphysema (CPFE) is a clinical 
syndrome that is diagnosed with computed tomography (CT), sometimes in conjunction 
with histopathology. Mostly all patients with CPFE are smokers, and thus, they are at 
high risk of developing lung cancer (LC). The histological and clinical characteristics 
of coexisting LC and CPFE syndrome remain unclear. Therefore, we conducted a 
retrospective study to explore the clinicopathological characteristics of LC along with 
CPFE (LC-CPFE). Methods: We retrospectively reviewed the data of 1647 patients 
who underwent lung resection for pulmonary masses at Shinshu University Hospital 
between December 1995 and December 2013. After excluding patients without CT 
images, patients with metastatic tumors, and patients without sufficient clinical and 
histological information, the remaining patients were divided into four groups based 
of 50 cases of multiple tumors through a digital web-based system. Five pairs of 
resected nodules were assembled from the University of Colorado and scanned into 
an image database using an Aperio AT2 slide scanner (Leica Biosystems) with a 40X 
objective. Reviewers were asked to review slide images, to provide a histological 
diagnosis according to WHO criteria, to answer questions regarding specific histological 
details related to each nodule and to determine whether the multiple nodules were 
SPT and IM. Combined results were evaluated for level of concordance on the central 
question of primary or metastatic status. Results were also correlated with EGFR, KRAS, 
ALK and TP53 mutational status. Results: A total 21 pulmonary pathology subspecialists 
completed the survey, evaluating 10 nodules from 5 patients. Ten of the reviewers 
were from the US, 3 from Japan, 2 from the UK, and one each from Canada, France, 
Germany, the Netherlands, Korea and Sweden. On the question of SPLC vs IM, 10 
reviewers agreed on all cases and these determinations were regarded the histological 
consensus. There was 85% overall concordance with the consensus diagnosis. Most 
of dissenting opinions related to a single case. In all but one instance, tumors from 
the same individual with different histological diagnoses were designated SPLC. 
However, in 30% of the cases, tumors from the same individual with identical histological 
diagnoses were determined to be SPLC. The histological attributes regardless of WHO 
diagnostic category that significantly (each p>0.0001) contributed to this conclusion 
included lepidic growth, cell size, nuclear pleomorphism and nucleolar prominence. 
The mutational status of these cases was in complete agreement with the histological 
consensus. Mutations that distinguished SPT included KRAS, EGFR or TP53 mutation 
in only one member of a tumor pair or different EGFR mutations in each member 
of a pair. In IM, identical KRAS mutation was found in both members of a tumor 
pair. Conclusion: In this pilot study a high level of consensus was achieved in separating 
SPLC vs or IM. A large minority (30%) of tumor pairs with identical histological 
diagnoses were determined to be SPLC suggesting that histological features beyond 
those used for WHO classification are taken into account when determining SPT status. 
Keywords: Second Primary, Pathology, Internet Survey, intrapulmonary metastasis
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P1.04-011 Intraoperative Diagnosis of Lymph Node Metastasis Using a Rapid-
Immunohistochemical (R-IHC) Staining Method in Non-Small Cell Lung Cancer 
Hayato Konno1, Yoshihiro Minamiya1, Hajime Saito1, Kazuhiro Imai2, Yoshitaro Saito1, 
Hiroshi Nanjo3 1Thoracic Surgery, Akita University Graduate School of Medicine, Akita/
Japan, 2Sarantopoulos Lab, Duke University Medical Center, Durham/AL/United States of 
America, 3Pathology, Akita University Graduate School of Medicine, Akita/Japan
Background: Nodal micrometastasis in non-small cell lung cancer (NSCLC) is 
associated with a poorer survival rate than node-negative disease. Furthermore, 
lymph node micrometastasis often cannot be detected using conventional hematoxylin 
and eosin staining of frozen sections; detection requires additional time-consuming 
immunohistochemical (IHC) analysis of paraffin-embedded tissue. We developed a novel 
ultrarapid immunohistochemical staining method in which an AC electric field is used 
to facilitate detection of tumor cells. This method allows detection of tumor cells in 
frozen sections in less than 20 min, and could be a useful tool for frozen diagnosis. We 
previously reported IHC analysis for NSCLC in detection of lymph node micrometastasis 
without misdiagnosis using the rapid-IHC protocol developed at our institute. This 
technology, which has been patented, was released in May 2014 as “Histotech-R-IHCR”. 
The purpose of rapid-IHC analysis during surgery for NSCLC is the utility of intraoperative 
diagnosis of lymph node metastasis. Methods: Thirty-four patients with NSCLC were 
enrolled in the study between June 2014 and March 2015 after obtaining signed 
informed consent. Surgery was performed at Akita University School of Medicine and 
University Hospital. The patients were taken to an operating room, and the standard 
preparations were made for a thoracotomy and lung resection such as lobectomy with 
systematic/selective nodal dissection or segmentectomy. Dissected lymph nodes from 
each patient were used in this study. Intraoperative samples from dissected lymph 
nodes were sectioned, conventionally stained with HE, and immunohistochemically 
labeled with anti-CK (AE1/AE3) antibody using the rapid-IHC procedures, after which 
they were examined by a pathologist. Results: IHC analyses were completed within 20 
min, and the diagnosis was made by the pathologist within about 30 min. Two patients 
were diagnosed as positive on the basis of conventional histological examination, and 
the same two patients were deemed positive on the basis of CK detection using rapid-
IHC. There were no micrometastases in this study. All patients diagnosed as negative 
based on CK detection using rapid-IHC were pathologically N0. Twenty-one patients 
underwent lobectomy, and 13 patients received segmentectomy. Twenty-eight patients 
underwent lymph node dissection of hilar and mediastinal (ND2a) nodes, and six patients 
underwent lymph node dissection of hilar nodes only (ND1). Conclusion: The rapid-IHC 
device is useful for intraoperative diagnosis of lymph node metastasis in lung cancer 
surgery. We want to apply this method to the minimally invasive surgery selection 
such as segmentectomy and selective mediastinal lymph node dissection. Further 
investigation in multicenter studies will be needed to confirm the utility of this method. 
Keywords: immunohistochemical staining, Intraoperative diagnosis, lymph node 
metastasis, micrometastasis
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P1.04-012 Using Computed Tomography Scans to Assess the Histology 
of Malignant Pleural Mesothelioma Samuel Armato1, Fawwaz Qayyum2, Aliya 
Husain3, Christopher Straus4, Hedy Lee Kindler5, Wickii T. Vigneswaran6 1Department 
of Radiology, University of Chicago, Chicago/IL/United States of America, 2University of 
Chicago, Chicago/United States of America, 3Pathology, University of Chicago, Chicago/
United States of America, 4Radiology, University of Chicago, Chicago/United States of 
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P1.04-015 Pleomorphic Carcinoma of the Lung: A Clinicopathologic Study 
of 23 Resected Cases Dai Sonoda, Mototugu Ono, Yasuto Kondo, Shoko Hayashi, 
Masashi Mikubo, Hiroyasu Nakashima, Yoshio Matsui, Masaaki Ichinoe, Kazu Shiomi, 
Shi-Xu Jiang, Yoshiki Murakumo, Yukitoshi Satoh Kitasato University School of Medicine, 
Sagamihara/Japan
Background: Pleomorphic carcinoma (PC) of the lung is rare, and it is classified as a 
subtype of sarcomatoid carcinoma of the lung in the WHO histologic classification of 
lung tumors. We here demonstrated the clinicopathologic characteristics of PC surgically 
resected in our hospital. Methods: In this study, 23cases (2.3%) of PC among 968 of 
non-small cell lung cancer surgically resected at the Kitasato University Hospital between 
January 2004 and January 2015 were reviewed. The registry data of the patients with PC 
were analyzed, and the clinicopathologic profiles and surgical outcomes of the patients 
were evaluated. Results: There were 19 men and 4 women, and their mean age was 64 
years (range: 39 to 81 y). All but two patients were smoker, and their mean smoking 
index was 41 pack year. In this study, the mean diameter of the tumor was 48.8 mm; 
tumors over 50 mm in diameter comprised 45% of all cases. The TNM pathological 
stages of PC were classified as: 2 (9%) cases with stage IA, 5 (22%) with stage IB, 2 
(9%) with stage IIA, 8 (35%) with stage IIB, 5 (22%) with stage IIIA, and 1 (4%) with stage 
IIIB carcinoma. Ten tumors contained identifiable epithelial components, and the other 
12 consisted of spindle cells and giant cells alone: an adenocarcinoma component was 
found in 11 cases, and 4 of the 11 cases had a coexisting squamous cell carcinoma 
component. In all the 23 patients, lymphatic infiltration and/or venous infiltration were 
evident. Overall follow-up ranged from 60 to 2605 days, with a median (for patients still 
alive) of 896 days. The overall survival rate and disease-free survival rate were 65% and 
57%, respectively. Furthermore, 58% of the clinical stage I patients with PC demonstrated 
advance in the pathological stage. Cancer recurrence was identified in 6 patients; 
local or local with distant recurrence in one each and distant in 4. Conclusion: We 
concluded that PC should be considered as an aggressive disease and vascular 
infiltration should be usually reported and used as a factor in clinical assessments. 
Keywords: clinicopathologic study, aggressive disease, Pleomorphic carcinoma
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P1.04-016 Assessment of the Adequacy of Tissue Diagnosis by EBUS in 
Relation to the PET Scan and the Operator’s Experience Ahmed Mostafa1, Nagla 
Abdel Karim2, Michelle Kirshner3, Mahmoud Mahmoud4, Changchun Xie5, Sadia 
Benzaquin3 1Pulmonary and Critical Care, The University of Cincinnati, Ohio/AL/United 
States of America, 2Internal Medicine/Division of Hematology/Oncology, The University of 
Cincinnati, Ohio/OH/United States of America, 3Pulmonary and Critical Care, The University 
of Cincinnati, Ohio/OH/United States of America, 4Internal Medicine-Division of Hematology/
Oncology, The University of Cincinnati, Cincinnati/United States of America, 5Biostatistics, 
The University of Cincinnati, Ohio/OH/United States of America
Background: Lung cancer remains the leading cause of cancer related death in USA and 
around the world. Multiple modalities are available for sampling lung neoplasms, mediastinal 
and hilar lymph nodes . Endobronchial ultrasound –guided transbronchial needle aspiration 
(EBUS-TBNA) has become an important diagnostic tool . Although the samples obtained 
by EBUS-TBNA are smaller than specimens collected by other surgical methods, the 
procedure has shown excellent specificity and sensitivity for the diagnosis of neoplastic 
diseases, is cost-effective compared to mediastinoscopy , and has become the procedure 
of choice for initial evaluation of patients with mediastinal and hilar lymphadenopathy . 
EBUS is currently performed by both interventional and general pulmonologists. Aim of 
the study: To assess the adequacy of tissue for diagnosis in relevance to PET scan, the 
diagnostic yield of the various lymph node (LN) stations and the level of experience of 
the operator. Methods: We reviewed the chart of 171 patients who underwent EBUS 
between the years of 2011-2013. We reviewed the pathological diagnosis, the LN 
stations, the PET scan results and the operator who performed the EBUS. Results: We 
included 171 patients where adequacy of tissue diagnosis was achieved by majority of 
patients in whom EBUS was performed (p<.0001). More tissue seemed to be positive 
in LN station 4 compared to the other LN stations but with no statistical significance. 
There was no correlation between the positivity of the PET scan and the 
tissue adequacy for diagnosis by EBUS (p=0.6410). PET scan showed 
a trend to increase in positive uptake in LN station 2 (p=0.0705). 
The adequacy of tissue diagnosis was achieved most significantly by Interventional 
Pulmonary (IP) trained operator, followed by an operator of more than 5 years’ 
experience followed by an operator of less than 5 years’ experience with 100% ‚ 93.33% 
‚ 88.89% subsequently for tissue diagnosis accuracy (p=0.0019). The diagnostic tissue 
adequacy had a positive correlation with the PET scan when analyzed by operator, where 
the operator with more than five years’ experience had a closer correlation with the 
PET scan positive uptake. The percentage of tissue adequacy in relation to the PET 
scan positive uptake was of 54.64% ‚ 76.67% and 35.56% subsequently (p=0.0009). 
Conclusion: The adequacy of tissue diagnosis was achieved by majority of patients 
in whom EBUS was performed. There was no correlation between the positivity 
of the PET scan and the tissue adequacy for diagnosis by EBUS therefore PET 
scan and EBUS should be used complementary to each other for the appropriate 
diagnosis and staging of patients. The adequacy of tissue diagnosis was achieved 
most significantly by (IP) trained operator, followed by an operator of more than 
5 years’ experience followed by an operator of less than 5 years’ experience. 
Keywords: Tissue diagnosis, EBUS, IP, Adequacy
on chest CT findings: LC-CPFE, LC along with pulmonary fibrosis (LC-PF), LC along 
with emphysema (LC-Emp), and LC in normal lungs (LC-Norm). The clinicopathological 
characteristics of patients with LC-CPFE were compared to those of the patients in the 
other groups. Results: After excluding patients for the reasons described above, 985 
patients were enrolled in this study. Of these 985 patients, there were 72, 28, 84, and 
801 cases of LC-CPFE, LC-PF, LC-Emp, and LC-Norm, respectively. Patients with LC-CPFE 
were all smokers, with a mean Brinkman index of 1158. Compared with the other groups, 
patients with LC-CPFE were predominantly men (n = 67, 93.0%) and were older (a mean 
age of 70.5); LC-CPFE was also associated with a larger tumor size (a mean tumor size 
of 29.5 mm), the presence of multiple tumors (n = 13, 18.0%), higher stage, squamous 
cell carcinoma-predominant histology (n = 46, 63.9%), and higher tumor grade (n = 45, 
62.5%). Patients with LC-CPFE showed a significantly worse outcome than did patients 
with LC-Emp and LC-Norm, with a 5-year disease-free survival (DFS) rate of 63.5% 
and a 5-year overall survival (OS) rate of 53.5%. The OS rate of patients with LC-CPFE 
was worse than that of patients with LC-PF, although the statistical difference was not 
significant (p = 0.06), whereas the DFS rates between the LC-CPFE group and the LC-PF 
group were not significantly different (p = 0.664). In the LC-CPFE group, the tumors were 
mostly found in associated fibrotic areas (n = 56, 77.7%), followed by emphysematous 
areas (n = 9) and normal lung areas (n = 7). The pattern of the fibrotic area was as 
follows: 31 unclassified, 19 UIP, and 6 NSIP. In situ carcinomatous lesions were found in 
fibrotic areas of more than half of the LC-CPFE cases (n = 30, 53.5%). Conclusion: This 
study indicates that LCs in patients with CPFE syndrome developed in heterogeneous 
tumorigenic backgrounds. However, because patients with LC-CPFE showed significantly 
poorer outcomes compared with the other groups, CPFE should be considered 
an important background disease for patients after resection of lung cancer. 
Keywords: Combined pulmonary fibrosis and emphysema, lung cancer
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P1.04-014 Clinicopathologic Significance of Epithelio-Mesenchymal Transition 
in Human Lung Adenocarcinoma Toshi Menju1, Terumasa Sowa1, Shinya Neri1, 
Takao Nakanishi1, Hiroyuki Cho1, Kei Shikuma1, Kyoko Hijiya1, Hideki Motoyama1, Akihiro 
Aoyama1, Fengshi Chen1, Makoto Sonobe1, Toshihiko Sato1, Mitsugu Oomasa1, Akihiko 
Yoshizawa2, Hironori Haga2, Hiroshi Date1 1Thoracic Surgery, Kyoto University, Graduate 
School of Medicine, Kyoto/Japan, 2Diagnostic Pathology, Kyoto University Hospital, Kyoto/
Japan
Background: Activation of Epithelial-Mesenchymal Transition (EMT) mechanisms in tumor 
cells is known to be associated with its invasive and metastatic properties. However, this 
hypothesis has not been fully elucidated from the point of detailed clinicopathological 
view using surgically resected clinical samples. We, hereby, examined the expression 
levels of EMT marker and analyzed the integrated data of clinicopathlogical information 
including background genetic alterations. Methods:Clinical samples were obtained from 
the 256 cases of resected lung adenocarcinoma which were consecutively operated 
from January 2001 to December 2007 in Kyoto University Hospital. Pathological stage 
distribution of the cases by TNM classification (WHO, 7th edition) was below: 1A: 132, 
1B: 56, 2A: 22, 2B: 4, 3A: 26, 3B: 2, 4:14. Mean survival time of all the cases was 62 
months, and 5-year survival rate was 75.3%. The distribution of predominant histlogical 
subtype by IASLC/ATS/ERS classification was AIS (9, 3.5 %), MIA (13, 5.1 %), lepidic (18, 
7.0 %), acinar （32, 12.5 %）, papillary (122, 47.6%), solid (44, 17.2 %), micropapillary 
(9, 3.5 %), mucinous (8, 3.1 %), others (1, 0.4 %). We performed immunohistochemical 
staining for the expression of E-cadherin and Vimentin on tissue microarrays of resected 
samples to assess the activation level of EMT. Then, we classified the cases with positive 
E-cadherin expression and negative for Vimentin as “null” activation of EMT mechanisms, 
called ‘Group N’, whereas loss of E-cadherin and positive for Vimentin as “full” activation, 
‘Group F’, and, further, either loss of E-cadherin or positive Vimentin as “partial” activation, 
‘Group P’. DNA samples were extracted from frozen surgical samples and the mutations 
for the hot-spot exons of EGFR, ALK, K-ras, and p53 were detected by SSCP or direct 
sequencing methods. Statistical analyses for survival were performed by Kaplan-Meirer 
curve and log-rank test. Categorical data were analyzed by Pearson’s test. P-values 
< 0.05 were considered to be statistically significant. Results: Histological subtypes 
were significantly associated with EMT activation level. Poorly differentiated tumors 
mainly comprising solid, micropapillary, and mucinous adenocarcinoma possessed 
highly activated EMT level, and vice versa. Group F showed the highest positivity both 
in local lymphatic/vascular invasion and lymph-node metastasis (35.7%/ 42.9%/ 46.3%, 
respectively), followed by group P and group N in order. Significant difference was found 
in 5-year disease-free/ overall survival rate among these 3 groups: group F, 46.9%/ 
50.6%; group P, 64.9%/ 73.4%; group N, 74.9%/ 85.4%. Tumors harboring wild type 
EGFR or mutant p53 had tendency to acquire higher EMT activation level. Interestingly, 
p53 mutation rate significantly correlated with EMT activation level especially in mutant 
EGFR tumors, whereas no correlation in wild type EGFR ones. No significant correlation 
was shown between EMT activation level and the proportion of K-ras mutation or ALK 
fusion gene. Conclusion: Our results revealed that the activation of EMT mechanisms 
in human lung adenocarcinoma is significantly associated with histological subtypes 
and plays important roles in the tumor progression through its lymph-vascular local 
involvement leading to the node-metastasis. Among human lung adenocarcinomas 
harboring EGFR mutation, p53 alteration deeply correlates with EMT activation. 
Keywords: lung cancer, EMT, invasion and metastasis, DNA mutation
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studied, but the diagnostic yield have been marginally investigated in a larger cohort of 
patients. Methods: We review tertiary hospital experience with EBUS-FNA and EUS-B-FNA in 
obtaining tissue diagnosis for lung cancer and evaluate, if the cell block processing method 
increases diagnostic accuracy in pathological lung cancer subtyping. The pathological 
examination was based on smear cytology (SC) and cell block preparation (CBP) routinely 
obtained during EBUS (EUS-B) -FNA. After cell block embedding in paraffin and sectioning 
at 3 micrometer hematoxylin and eosin staining and if required immunostaining was 
available for microscopical histopathological examination. Results: From January 2011 
to December 2013, 608 patients, including 208 lung cancer patients with mediastinal and 
hilar lymphnodes pathology, underwent EBUS-FNA or simultaneous EUS-B-FNA in North 
Estonia Medical Center. In lung cancer patients cytological assessment was performed 
in all 208 cases. Formalin fixed paraffin-embedded cell block for histopathological 
examination was available in 196 (94.2%) cases. The overall morphological verification 
rate in CBP group was 85.6% (n=178) and in SC group 79.3% (n=165). The pathological 
diagnosis of undifferentiated type of lung cancer was provided in 43.7% (n=91) of CBP 
cases and in 35.6% (n=74) of SC cases. Diagnostic yield in pathological subtyping of 
lung cancer was significantly higher in CPB compare to SC: 81.2 % (n=169) vs. 43.7% 
(n=91), respectively (p<0.005). Adding CBP to SC provided an accurate subtyping of 
lung cancer in 102 more patients and the diagnostic efficacy was increased by 49.0% 
(n=102/208) (p<0.005). Conclusion: Cell block processing method combined with 
smear cytology obtained from intrathoracic lymphnodes applying EBUS (EUS-B) -FNA 
significantly increases diagnostic yield in pathologic lung cancer subtyping. Both tissue 
processing techniques should be routinely applied simultaneously whenever possible 
with aim to facilitate clinical decision and make impact on lung cancer patients outcome. 
Keywords: cell clock, endobronchial ultrasound, ultrasound guided fine-needle 
aspiration, lymphnodes
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P1.04-019 A Comparative Study of Micropapillary Pattern and Computed 
Tomographic Findings in the Patients with Small Lung Adenocarcinoma (≤ 
2cm) Jun-Ichi Nitadori1, Yukihiro Yoshida1, Aya Shinozaki-Ushiku2, Hideki Kuwano1, 
Kazuhiro Nagayama1, Masaki Anraku1, Masaaki Sato1, Masashi Fukayama2, Jun 
Nakajima1 1Department of Thoracic Surgery, The University of Tokyo Hospital, Tokyo/
Japan, 2Department of Pathology, University of Tokyo Hospital, Tokyo/Japan
Background: We have recently demonstrated that presence of the micropapillary 
pattern increases the risk of local recurrence after limited resection for ≤2 cm lung 
adenocarcinoma (ADC). Currently, limited resection for small lung ADC has been done 
based on the definition of radiological non-invasive lung cancer, until histological subtype 
have not been examination. The purpose of this study is to investigate whether the 
presence of micropapillary pattern correlates with radiological non-invasive lung cancer 
in small lung ADC. Methods: All available tumor slides from patients with clinical stage 
IA, therapy-naive, surgically resected solitary lung ADC ≤2 cm in size (2001-2012) were 
reviewed. Comprehensive histologic subtyping was performed according to the IASLC/
ATS/ERS classification. Tumor diameter and solid component diameter were measured 
at the maximum cut surface of the tumor using high-resolution CT (HRCT). HRCT findings 
were classified as three groups as pure ground glass nodule (GGN), part-solid, solid 
based on the IASLC/ATS/ERS classification. Recurrence-free probability (RFP) was 
estimated using the Kaplan-Meier method. Results: 233 patients met inclusion criteria 
(50% women; median age: 67yrs; 48% never-smokers; median tumor size: 1.2cm; 
68 pure GGN/ 76 part-solid/ 89 solid; 157 lobectomy; 43 AIS/ 77 MIA/113 IAD; 13 
lymph node metastasis). Presence of the micropapillary pattern (≧5%) (MPP≧5) was 
identified in 21 cases (9%). MPP≧5 was significantly associated with tumor size, lymph 
node recurrence, lymphatic invasion, vascular invasion (P = .001, .003, .0017, .014, 
respectively) and was associated with increased risk of recurrence as compared to 
MMP<5% (5-year RFP: MIP≧5%:74.3%; MIP<5%:87.6%; P = .046). Twenty-one patients 
with MPP≧5 included 1 pure GGN / 5 part-solid / 15 solid in HRCT. The patient with 
pure GGN and MPP≧5 showed recurrence in lymph nodes in 10 months after surgery. In 
pure GGN group, MPP≧5 was associated with increased risk of recurrence as compared 
to MMP<5% (P=0.0001). Conclusion: The patient with radiological non-invasive 
lung cancer may be included in micropapillary pattern. It is necessary to consider 
lung adenocarcinoma histological subtypes for the patient with limited resection. 
Keywords: radiological non-invasive lung cancer, small lung adenocarcinoma, 
micropapillary, IASLC/ATS/ERS classification
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P1.04-020 Adenocarcinoma Metastatic Gastrointestinal Origin and Lung 
Squamous Carcinoma Associated with HIV Disease: Case Report 
Liliana Fernandez1, Lina Garcia2, Carlos A. Muñoz3, Luz F. Sua4 1Interventional 
Pulmonology, Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia, 2Internal Medicine 
Resident, Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia, 3Medical Research, 
Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia, 4Department of Pathology and 
Laboratory Medicine. Phd Biomedical Sciences, Fundacion Valle Del Lili, Universidad ICESI, 
Cali/Colombia
Background: Individuals infected with HIV have a higher predisposition to develop 
malignancies. The spectrum of neoplastic diseases in HIV-infected patients has changed 
after the introduction of antiretroviral therapy which decreased the AIDS defining 
malignancies such as Kaposi’s sarcoma (KS) and non-Hodgkin lymphoma (NHL), but 
augmented other tumor types contributing to increased mortality of patients on chronic 
treatment. We report a patient with HIV on more than 10 years of antiretroviral treatment 
in whom diagnosis of a metastatic adenocarcinoma of gastrointestinal origin and a 
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P1.04-017 Pulmonary Lymphoepithelial-Like Carcinoma: A Surveillance, 
Epidemiology, and End Results Database Analysis Jiaxi He, Jianfei Shen, Hui Pan, 
Chenglin Yang, Long Jiang, Wenhua Liang, Jianxing He Thoracic Surgery, Guangzhou 
Medical University First Affiliated Hospital, Guangzhou/China
Background: Pulmonary lymphoepithelial-like carcinoma (LELC) is one of the rare 
histological non-small cell lung cancers. Only a few case reports have been published. 
The knowledge of its characteristics and prognosis is limited. Based on the data of 
the Surveillance, Epidemiology, and End Results Database (SEER), an analysis was 
performed to fill the gap of our knowledge Methods: Characteristics, treatment and 
outcomes of all pulmonary LELC patients was extracted both from the SEER database 
with 18 registered center from 1973-2011 using SEER*Stat 8.1.5 Statistical analysis was 
performed using SPSS 16.0 and GraphPad Prism 5. Results: A total of 62 patients with 
pulmonary LELC are identified and recorded. Among them, Caucasian patients account 
for the largest proportion (64.4%). The medium age at diagnosis is 65. The 1, 3 and 5 
years survival rates of LELC are 85.6%, 74.5% and 55.2%. The median survival time of all 
LELC patients is 34 months. Comparing to other types of lung cancer, LELC has a better 
survival. 14 patients have received radiation, while most of the early stage LELC patients 
(30/34, 88.2%) have received surgical resection as the first treatment.
Conclusion: Pulmonary LELC is a rare pathological type of lung cancer . In this cohort, male 
and Caucasian patients account for a large proportion of LELC patients. The mean age of 
pulmonary LELC patients in this study is older than the patients in Asian studies. A large 
amount of patients are in the early stages (localized and regional) when they are diagnosed 
as LELC. LELC has a better prognosis than adenocarcinoma, most early stage patients 
have received surgical resection. However, no prognosis factor has been identified in our 
study. In order to understand pulmonary LELC more thoroughly, more cases are required. 
Keywords: NSCLC, lymphoepithelial-like carcinoma, SEER, Outcomes
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P1.04-018 The Value of Histopathological Examination for Bronchoscopic 
Ultrasound Guided Fine-Needle Aspiration in Diagnosis of Lung Cancer 
Subtypes Tõnu Vanakesa1, Ingemar Almre1, Sirje Marran2 1Center of Cardiothoracic 
Surgery, North Estonia Medical Center, Tallinn/Estonia, 2Department of Endoscopy, North 
Estonia Medical Center, Tallinn/Estonia
Background: The role of endobronchial ultrasound (EBUS) and transesophageal 
bronchoscopic ultrasound (EUS-B) -guided fine-needle aspiration (FNA) of intrathoracic 
lymphnodes has acquired paramount importance in obtaining definitive diagnosis in 
malignant diseases. Recently, the diagnostic value of cell block processing of EBUS-
FNA samples to obtain accurate distinction between lung cancer subtypes has been 
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P1.04-021 No MAML2 Gene Alteration Found in Ciliated Muconodular Papillary 
Tumor of Lung; Genetic Difference from Mucoepidermoid Carcinoma
Noriko Motoi1, Hiroko Nagano1, Hironori Ninomiya1, Sakae Okumura2, Yuichi Ishikawa1
1Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 
Tokyo/Japan, 2Thoracic Surgery, The Cancer Institute Hospital of Jfcr, Tokyo/Japan
Background: MAML2 (mastermind-like 2 (Drosophila)) gene, a transcriptional 
coactivator for NOTCH proteins, is known to be involved as a part of fusion gene (MECT1-
MAML2) which is found in mucoepidermoid carcinoma (MEC) both of salivary gland and 
pulmonary origin. Ciliated muconodular papillary tumor (CMPT) is sharing morphologic 
features with mucoepidermoid carcinoma, at least in part, i.e. consist of mixture of 
mucinous and squamous epithelium. To determine whether these morphological mimics 
can share the molecular alterations, we evaluated MAML2 rearrangement of CMPT by 
FISH. Methods: Five cases of CMPT was recruited from pathologic diagnostic records 
between 2005 to 2014. Morphological assessment was done on routine HE stained 
slides of whole tumor specimen. Representative area was selected and submitted to 
FISH analysis. Fluorescence in situ hybridization (FISH) using break apart type MAML2 
gene probes was performed on FFPE specimen. The break apart signal percentages 
on separated tumor nuclei was counted on the captured images of digital fl uorescence 
microscope. 100 nuclei was counted in each cases. More than 30% of break apart signal 
is considered as positive result. Results: All fi ve CMPTs were reviewed and confi rmed 
the diagnosis on HE stained slides. These cases included 4 male, 1 female, were mean 
age of 71 years-old (range 60-83). There were three incidental cases which were patients 
with one primary lung adenosquamous carcinoma and two metastatic cancer (one colon 
cancer, one liposarcoma). All of fi ve CMPT resulted negative for MAML2 break-apart 
FISH. Conclusion: These results indicated that CMPTs do not share the molecular 
alteration of MAML2, which is commonly detected in mucoepidermoid carcinoma of lung. 
In conclusion, CMPT is a distinct tumor or tumor-like lesion, does not related to MEC. 
Although, it is still uncertain whether CMPT is a true neoplastic lesion with multi-lineage 
differentiation potential or a reactive process with extensive epithelial proliferation. 
Keywords: ciliated muconodular papillary tumor of lung, MAML2 (mastermind-like 2 
(Drosophila), mucoepidermoid carcinoma
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P1.04-022 Prognostic Signifi cance of Solid or Micropapillary Component in 
Pulmonary Invasive Adenocarcinoma Measuring ≦ 3cm Yuki Matsuoka1, Makoto 
Wakahara1, Yohei Yurugi1, Yuzo Takagi1, Tomohiro Haruki1, Ken Miwa1, Kunio Araki1, Yuji 
Taniguchi1, Kanae Nosaka2, Tatsushi Shiomi2, Yoshihisa Umekita2, Hiroshige Nakamura1
1Department of Surgery, Division of General Thoracic Surgery, Tottori University, Faculty of 
Medicine, Tottori/Japan, 2Department of Pathology, Tottori University, Faculty of Medicine, 
Tottori/Japan
Background: According to the International Association for the Study of Lung 
Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) 
classifi cation, both solid- and micropapillary-predominant pulmonary adenocarcinoma 
have been reported to have a poor prognosis. Although pulmonary adenocarcinoma 
with some solid or micropapillary component have also been reported to have a 
poor prognosis, the ratio of these component to be chosen as the cutoff value for 
a prognostic factor remains controversial. Methods: A total of 115 patients with 
pulmonary invasive adenocarcinoma measuring ≦ 3 cm who underwent curative surgery 
at Tottori University Hospital between January 2005 and December 2008 were included. 
Patients with variants of invasive adenocarcinoma were excluded from this study. The 
median follow-up time was 78.0 months. A total of 84, 9, and 22 patients underwent 
lobectomy, segmentectomy, and wedge resection, respectively, and 100, 5, and 10 
patients had stages I, II, and III, respectively. The tumors were divided into subtypes 
according to the IASLC/ATS/ERS classifi cation. Cases with solid component occupying 
≧ 5% of the entire tumor were defi ned as S-positive (S+), and cases with micropapillary 
component occupying ≧ 1% of the entire tumor were defi ned as MP-positive (MP+). 
Of the 115 adenocarcinoma, 30 and 85 were S+ and S-, and 27 and 88 were MP+ 
and MP-. The clinical characteristics and pathologic data of all 115 adenocarcinoma 
were retrospectively evaluated. The Kaplan-Meier method was used to estimate the 
recurrence-free survival (RFS) and overall survival (OS) rates, and the log-rank test was 
used to compare the RFS and OS among the subgroups. Results: The 5-year OS rate of 
cases that were S＋ and S- was 92.5% and 62.1%, respectively (log rank P < 0.001). The 
5-year RFS rate of cases that were MP＋ and MP- was 77.3% and 51.9%, respectively 
(log rank P = 0.001). On multivariate survival analysis, the presence of solid component 
proved to be an independent prognostic factor, and the presence of micropapillary 
component proved to be an independent recurrence factor. Conclusion: The presence 
of solid component occupying ≧ 5% of the entire tumor was an independent predictor 
of a poor prognosis in pulmonary invasive adenocarcinoma measuring ≦ 3cm. The 
presence of any micropapillary component, even if only in 1% of the entire tumor, 
was a risk factor for post-operative recurrence and it affected the prognostic value. 
Keywords: pulmonary adenocarcinoma, solid, micropapillary, component
concomitant primary lung squamous carcinoma was made. Methods: Clinical History 
Revission Results: A 68-year-old man with a history of HIV on antiretroviral treatment 
(ART) since 2004, ex-smoker with COPD, osteoporosis and chronic malnutrition, who 
presents with cough, dyspnea and hemoptysis. On the chest CT-scan a right paravertebral 
mass associated with atelectasis, a parahilar mass extending to the left upper lobe, and 
a mass in the pancreatic head is observed. A bronchoscopy with biopsies is performed. 
The morphological and inmunophenotypic expression patterns of the right lower lobe 
show metastatic adenocarcinoma of gastrointestinal origin while the left lower lobe 
biopsy shows primary squamous cell lung carcinoma and the presences of Aspergillus. 
The patient continued with hemoptysis, developed refractory respiratory failure and died. 
Conclusion: With the widespread use of potent ART there was a dramatic decrease in 
the incidence of KS and NHL and a signifi cant increase in the incidence of several other 
malignancies. Although the biology of malignancy in HIV-infected people is often more 
aggressive than in those without HIV infection, standard treatment is generally indicated 
and can be associated with a favorable outcome, depending upon the tumor type, stage, 
and comorbidity. In this case two advanced stage tumor lesions associated with 
hemoptysis were documented, which fi nally led to the death of the patient.
 
Keywords: HIV, Antiretroviral treatment, lung cancer
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P1.04-025 Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and 
Socioeconomic Status Manali I. Patel1, Meg Mckinley2, Iona Cheng2, Heather A. 
Wakelee1, Scarlett Gomez2 1Stanford University, Stanford/United States of America, 2Cpic, 
Fremont/United States of America
Background: The incidence trends of lung cancer (LC) by histology, gender, race/
ethnicity and neighborhood socioeconomic status (nSES, derived from US Census 
data) have not been reported. To examine these trends, we conducted a population-
based study, using data from the California Cancer Registry across three discrete 
time periods to correspond with Census data on nSES: 1988-1992; 1998-2002; 2008-
2011. Methods: Incidence data for invasive LC were abstracted for the three time periods. 
In each time period, male and female age adjusted incidence rates of LC and incidence 
rate ratios were calculated by histologic cell type and stratified by nSES. Results: A total 
of 240,307 LC cases were identified across the three time periods. Histology incidence 
trends by race/ethnicity are shown in Figure 1 and by nSES in Table 1 for males and 
females. Larger declines in incidence were seen over the 3 time periods among males 
than females. Among males, incidence rate declines over time were seen in all race/
ethnic and nSES groups, but were largest among Blacks and Hispanics. Across all 
races/ethnicities among males, there was a slight increase over time in the incidence 
of adenocarcinoma histology. Among females, incidence rate declines were seen among 
Hispanics regardless of nSES, mid- and high-nSES Whites, and low- and mid-nSES Blacks; 
incidence trends among Asian/Pacific Islander females did not change significantly over 
time, regardless of nSES. Among females, there were variations in incidence trends by 
histology with a slight increase in the adenocarcinoma histology.
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P1.04-023 Primary Adenocarcinoma in the Lung Reclassified - Histological 
Subtypes and Outcome Gudrun N. Oskarsdottir1, Tomas Gudbjartsson2, Steinn 
Jonsson1, Johannes Bjornsson3, Helgi J. Isaksson4 1Department of Internal Medicine, 
Landspitali University Hospital, Reykjavik/Iceland, 2Department of Thoracic Surgery, 
Landspitali University Hospital, Reykjavik/Iceland, 3Department of Pathology, Akureyri 
Hospital, Akureyri/Iceland, 4Department of Pathology, Landspitali University Hospital, 
Reykjavik/Iceland
Background: Non-small cell lung cancer (NSCLC) comprises 85% of primary lung cancer, 
where adenocarcinoma, squamous cell and large cell carcinoma are the most common 
histological types. Recently a new classification of primary adenocarcinomas of the lung 
was published. The aim of this study was to review the histology of all primary lung 
adenocarcinomas operated on in Iceland during a 20 year period, 1991-2010, using the 
new criteria and assess the impact of histology on survival. Methods: This nationwide 
study included 301 patients with primary lung adenocarcinoma (mean age 65.5 yrs., 56% 
female) that underwent resection in Iceland between 1991-2010. Tumors were reclassified 
according to the current IASLC/ATS/ERS pulmonary adenocarcinoma classification 
system. Overall survival was estimated by the Kaplan-Meier method and multivariate Cox 
regression analysis used to evaluate prognostic factors of survival, including histological 
subtype Results: Acinar predominant adenocarcinoma was the most common 
histological subtype (45%). Solid predominant with mucin production comprised 24% 
of the cases, lepidic predominant 19% and papillary predominant 8%. There was one in 
situ adenocarcinoma, three minimally invasive adenocarcinomas and seven invasive 
mucinous adenocarcinomas. Overall survival at 1 year for all histological subtypes of 
adenocarcinoma was 81.1% and 42.6% at 5 years. A statistically significant difference in 
survival between the histological subtypes was not seen (log-rank test, p=0.43). Using 
multivariate analysis advanced stage and age predicted a worse outcome. Histologic 
subtyping did neither predict survival in uni- or multivariate analysis. Conclusion: Acinar 
and solid predominant adenocarcinoma are the most common histological subtypes for 
primary lung adenocarcinoma in Iceland. There was not a statistical difference in survival 
according to histological subtypes and the subtyping was not a prognostic factor of survival. 
Keywords: survival, lung adenocarcinoma, outcome, adenocarcinoma subtypes
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P1.04-024 When Bone Starts Growing in the Lung: A Case Series of Pulmonary 
Ossifications Jan F. Gielis1, Vassiliki Siozopoulou2, Patrick Lauwers1, Jeroen 
Hendriks1, Paul Van Schil1 1Vascular & Thoracic Surgery, Antwerp University, Edegem/
Belgium, 2Pathology, Antwerp University, Edegem/Belgium
Background: Pulmonary ossifications are heterotopic bone formations in the lung, 
previously thought to be a post-mortem finding only. Two types are described: nodular 
ossifications, smoothly edged, which are found in the alveoli themselves, and dendriform 
ossifications, branching through the alveolar septa. In this study the incidence of 
pulmonary ossifications was studied in a consecutive series of patients undergoing 
pulmonary surgery. Methods: From January 2008 to February 2015 19 patients with 
pulmonary ossifications were identified in patients undergoing thoracic surgery at 
Antwerp University Hospital. Diagnosis was made by the pathologist team. Neither PET 
nor CT was able to differentiate these ossifications from solid tumors. Results: 15 
patients (79%) were male. 8 received lung surgery for tumoral pathology. Most 
ossifications (58%) were found in the lower lung lobes without predilection for either 
chest side. 3 patients (16%) died during follow-up due to oncologic pathology unrelated 
to the ossifications. Most ossifications were nodular-type (12 or 63%), 6 or 32% were 
dendriform and one case contained both types.
 
Conclusion: Pulmonary ossifications are not as seldom as previously thought. These 
benign lesions are not simply a post-mortem finding and could be mistaken for a malignant 
space-occupying process. There appears to be a predilection for the lower lung lobes in 
male patients, without a clear association with other pathologies. Therefore, pulmonary 
ossifications deserve a place in the differential diagnosis of solitary pulmonary nodules. 
Keywords: Pathology, ossification, solitary pulmonary nodule
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P1.04-027 The Expression of Fibroblast Activation Protein (FAP) in Human 
Lung Cancer Tissues and Its Clinical Significance Xue Pan, Hua Shi 
Department of Respiration, The Second Affiliated Hospital of Soochow University, Suzhou, 
China, Suzhou/China
Background: To study the expression of fibroblast activation protein (FAP) in human 
lung cancer tissues and its clinical significance． Methods: Western-blot analysis was 
used to explore the expression of FAP in lung cancer tissues, paraneoplatic tissues 
(2cm beyond the cancer margin) and distal normal lung tissues(surgical resected 
specimens of lung tissue near the cut end) and also the lung cancer cell lines(A549, 
H1299, SPCA-1). Immunohistochemistry was performed to study the expression of FAP 
at protein level in tissues from 41 cases of lung cancer and 6 cases of benign pulmonary 
lesion． Results: Western blot analysis showed the expression of FAP was higher than in 
paraneoplatic tissues as well as normal lung tissues (P<0.05). It was also be positive in lung 
cancer cell lines (P<0.05). Immunohisto-chemistry showed that the positive rate of FAP 
staining was in fibroblast cells were 75.6%(31/41), the positive rate of FAP staining was in 
lung cancer cells were also 90.2%(37/41), whereas the expression in benign pulmonary 
lesion tissues was poor plus (1/6)．FAP expression was found to be significantly correlated 
with smoking status (x2=5.4085,P=0.02). However, there were no significant correlations 
between FAP and age, sex and TNM stage(P>0.05)． Conclusion: FAP could be over-
expressed in lung cancer cells, which signifies that FAP also plays a role in the development 
of lung cancer and may serve as a potential biomarker in the treatment of lung cancer. 
Keywords: PD-1/PD-L1 fap
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P1.04-028 High Vimentin Expression in Micropapillary Component of Lung 
Adenocarcinomas Hiroyasu Nakashima, Shi-Xu Jiang, Yuichi Sato, Keika Hoshi, 
Toshihide Matsumoto, Ryo Nagashio, Makoto Kobayashi, Yukiko Matsuo, Kazu Shiomi, 
Kazushige Hayakawa, Makoto Saegusa, Yukitoshi Satoh 
Kitasato University, Sagamihara City/Japan
Background: It is increasingly being recognized that adenocarcinomas (AC) of various 
organs with tumor cells arranged in a micropapillary pattern are more malignant than those 
without such a micropapillary component (MPC). However, the factors and mechanisms 
conferring the increased malignancy on MPC remain to be elucidated, so the exploration 
of such factors was the main purpose of the present study. Methods: We histologically 
reviewed the 629 radically resected lung adenocarcinomas at Kitasato University Hospital, 
Japan, from January 2002 to December 2012. MPC was defined as a small papillary 
tumor cell tuft without an obvious fibrovascular core. Tumors with ≥ 1% of their tumor 
cells arranged in a micropapillary pattern were diagnosed as AC with MPC (AC-MPC), 
while the remainder were diagnosed as conventional AC (CAC). The histological subtypes 
and differentiation grade of CAC as well as the background non-MPC of the AC-MPE were 
determined according to the 4th WHO classification. The clinicopathological features of 
AC-MPC and CAC were comparatively studied. The specific proteins expressed in AC-MPC 
were also analyzed using proteomic study based on 2-dimensional gel electrophoresis 
(2-DE), and the results were confirmed in vivo with imunohistochemistry. Results: One 
hundred and one (16.1%) of the 629 histologically reviewed lung adenocarcinomas met 
the criteria defined above and were thus diagnosed as AC-MPC. Compared with the 
CAC, the AC-MPC had worse statuses for tumor size, vascular invasion, pleural invasion, 
node metastasis, disease stage, postoperative up-staging, and overall survival (OS) and 
disease-free survival (DFS) (p<0.0001, respectively). On 2-DE, 19 proteins differentially 
expressed more than 1.5-fold in amount between lung CAC and AC-MPC; in particular, 
vimentin, one of the identified proteins, was most up-regulated (3.5-fold) in AC-MPC 
cases. Vimentin expression was detected in MPC of 95 (94.1%) AC-MPC, and when 
compared with the 119 control CAC, the expression scores in MPC were higher than 
those of well- and moderately differentiated CAC, as well as the background non-MPC of 
the AC-MPC (p<0.0001), but not significantly different from those of poorly differentiated 
CAC (p=0.561). Within the AC-MPC entity, higher vimentin expression was correlated 
with more frequent vascular invasion and more advanced node metastasis, and 
multivariate analysis showed that high vimentin expression was an independent indicator 
of worse prognosis (OS: p=0.012, DFS: p=0.047). Conclusion: Vimentin expression is 
prevalent and markedly up-regulated in MPC, which might reflect the biological essence 
of poorer differentiation or dedifferentiation of MPC, and this might have a role in the 
acquisition and increase of invasiveness and consequent more malignant nature of MPC. 
Keywords: micropapillary adenocarcinoma, vimentin, Immunohistochemistry, 
2-dimensional gel electrophoresis
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P1.04-029 Detection of Sputum Cofilin-1 Protein for Diagnosis of Human Non-
Small Cell Lung Carcinomas Maristela P. Rangel1, Milena M.P. Acencio2, Caroline S. 
Faria3, Vera L. Capelozzi1, Cecilia A.V. Farhat1, Leila Antonangelo3 1Pathology Department 
of University of Sao Paulo Medical School, Sao Paulo/Brazil, 2Cardiopneumology, Pleura 
Laboratory, Pulmonary Division, Heart Institute (Incor) of University of Sao Paulo Medical 
School, Sao Paulo/Brazil, 3Lim 03, Pathology Department of University of Sao Paulo Medical 
School, Sao Paulo/Brazil
Background: The high incidence and mortality rates of lung cancer reflect the need for new 
diagnostic and prognostic markers capable to early detect the disease and also predict 
its recurrence. The ideal biomarker should be evaluated in biological samples obtained by 
minimally invasive procedures. In this context, sputum is an attractive biological sample 
 
 
Conclusion: Our findings demonstrate differences in LC incidence over 
time by histology, gender, race/ethnicity and SES. While incidence rates 
consistently declined for males, there were greater declines in incidence for the 
high SES patient populations. For females, there were variations in trends by 
histology, race/ethnicity, and SES. These findings warrant further investigation. 
Keywords: incidence trends, race/ethnicity, histology, socioeconomic status
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P1.04-026 Lung Cancer Patients Who ‘Relapse’ After Primary Treatment May 
Have Different Pathology or No Malignancy Noelle O’Rourke1, Fiona Roberts2, 
Aqilah Othman1 1Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow/
United Kingdom, 2Pathology, Southern General Hospital, Glasgow/United Kingdom
Background: In the evolving era of genetic sequencing of lung tumours and targeted 
agents, there is impetus to repeat biopsies of previously treated lung cancers when 
there is clinical and radiological evidence of relapse, justified on the basis that genetic 
status of the tumour may change over time. In our centre, even prior to genetic subtyping 
of lung cancers we have operated a policy of confirming relapse histologically and we 
present here the value of this strategy. This audit describes the outcome of repeat 
biopsies in the lung cancer population of Greater Glasgow over a five year period. 
Methods: The regional pathology database was interrogated for all patients with 
previous diagnosis of lung cancer who had repeat biopsy between February 2009 
and March 2014. Inclusion criteria were those whose initial diagnostic biopsy was six 
months or more previously and included were CT guided biopsies, bronchoscopic 
brushings or washings, transbronchial or endobronchial guided biopsies, 
mediastinoscopies, surgical resections and cytology of pleural fluid. We excluded 
from our analysis those who were having lung biopsy due to metastasis from extra 
thoracic primary sites. We collated data on patient demographics, time between 
initial diagnosis and second biopsy, first and second pathology, stage and treatment 
at first presentation and again at second, whether second biopsy was a different site, 
and whether pathology was identical on second biopsy/similar (more or less well 
differentiated but same subtype of lung cancer)/ not malignant or different pathology. 
Results: 103 patients fulfilled our inclusion criteria: 41 men, 62 women; age range 
35-85y with initial stage of disease: 55 I, 18 II, 25 III, 4 IV and 1 small cell. 91 had 
primary treatment with curative intent: 66 surgery, 25 radical radiotherapy +/- chemo. 
11 had chemo alone, 1 observation only as first treatment. Time to second biopsy 
ranged 6-52 months (median 17). 70 patients (70%) had identical or similar pathology 
at second presentation. 13 had different pathology: 2 patients with initial NSCLC 
developed a second tumour which was SCLC, 1 previously treated SCLC developed 
a second tumour which was NSCLC, 1 resected carcinoid developed subsequent 
adenocarcinoma and one adenocarcinoma developed subsequent carcinoid. 8 patients 
had change of NSCLC subtype at second presentation. The remaining 20 patients 
had no malignancy on second biopsy: these had had prior radiotherapy or surgery all 
with radiological/clinical suspicion of recurrence. Of the 103 patients 42 are still alive. 
Conclusion: Although lung cancer carries a high risk of relapse following 
primary therapy our results demonstrate that clinical or radiological 
suspicion of recurrence cannot justify treatment without confirmatory biopsy. 
One third of our cohort either had no malignancy or a second pathology. 
Keywords: relapse, biopsy, second pathology
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Background: Traditionally, squamous cell carcinoma of the lung (SqCC) is 
conceptualized as more of a central rather than a peripheral form of lung cancer. While 
there is some variability with respect to the definition in the literature of what constitutes 
the ‘peripheral’ portions of the lung, historically, rates of squamous cell carcinoma in the 
lung periphery are typically sited in the 15% to 30% range. More recently, and especially 
in light of the historical data, we increasingly observed that a significant portion of newly 
diagnosed peripheral lung lesions – perhaps even a majority, appeared to be squamous 
cell carcinomas. Therefore, a comprehensive review of the tumor data at our facility, a 
busy teaching hospital with a large cohort of cancer patients, was undertaken to assess 
whether there had been a substantive change in the traditional epidemiologic distributions 
of the lung cancer, specifically with respect to squamous cell carcinoma. Given the 
differences in cell biology and carcinogenesis of different types of cancer, a potential 
epidemiologic shift might suggest a change in tumor biology, etc. Methods: From May 
12th, 2012 through May 13th of 2013, all histopathologicallly confirmed diagnoses of 
squamous cell carcinoma of the lung at our facility were reviewed. Again, while there 
is some dissonance in the literature with respect to the definition of the ‘periphery’, a 
reasonable approach given the existing data is to define the lung periphery as the lateral 
or outer half of the lung with respect to the position of the lesion on the axial cuts of the 
computed tomography scans of the chest. Each patient’s lesion was then classified as 
peripheral or central using that definition. Furthermore, various demographic data points 
for each patient such as age, race, sex, smoking history, use of inhaled corticosteroids, 
and concomitant use of proton pump inhibitors were also collected and analyzed. In 
addition, a cohort of patients without a prior history of malignancy was also analyzed as 
a “de novo” subset. Results: During the evaluation period, a total of fifty-six patients were 
diagnosed with SqCC. Of these, 55% (31/56) had SqCC located in the lung periphery 
with the remaining 45% (25/56) being found in a central location. Of the 56 patients 
diagnosed with SqCC, 27 had a prior history of malignancy. These 27 patients were 
then removed from the analysis in an effort to assess whether this distribution would 
persist in the remaining 29 patients. This “de novo” SqCC subset was then analyzed. Of 
this subset of patients, 62% (18/29) had SqCC that were located in the lung periphery 
and 38% (11/29) had lesions that were located centrally. Other epidemiological features 
correlated with typical trends seen in patients with SqCC. Conclusion: Our findings 
appear to confirm our initial observation that, within our institution, there has been a 
substantive shift in the traditional distribution of Squamous Cell Carcinoma with the 
majority of these cancers now being diagnosed in the lung periphery as opposed 
to the more central locations. Further work will be needed to confirm these results. 
Keywords: peripheral lung lesions, Squamous cell carcinoma of the lung, Distribution 
of SqCC
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P1.04-032 Clinical and Pathological Characterization of Long-Term Survivors 
with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in 
Madrid María Sereno Moyano1, Rosa Álvarez2, Maria Eugenia Olmedo3, Javier Puente4, 
Xabier Mielgo5, Fátima Navarro6, Francisco Zambrana1, Juan Moreno-Rubio1, Sagrario 
García1, Enrique Casado1, Ana Sánchez7, Santiago Ponce8 1Medical Oncology, Infanta 
Sofía University Hospital, Ss de Los Reyes/Spain, 2Gergorio Marañón University Hospital, 
Madrid/Spain, 3Ramón Y Cajal Hospital, Madrid/Spain, 4Hospital Clínico San Carlos, Madrid/
Spain, 5Fundación Alcorcón, Madrid/Spain, 6Principe de Asturias University Hospital, Madrid/
Spain, 7Getafe University Hospital, Madrid/Spain, 8Hospital 12 de Octubre, Madrid/Spain
Background: Long-time survival is an important goal in NSCLC treatment. However, in 
patients (pts) with wild type EGFR and non translocated ALK (EGFRwt/ALKnt) advanced 
disease, median survival at diagnosis is around 9-14 months and long time survivors 
(LTS) constitute a very small proportion of these patients. The aim of our research was 
to explore the clinical-pathological characteristics of a population of EGFRwt/ALKnt 
LTS with an overall survival (OS) of at least 36 months, with the purpose to identify 
which clinical-pathological features could help to identify a better outcome in advanced 
NSCLC. Methods: We analyzed retrospectively data from patients diagnosed of EGFRwt/
ALKnt advanced NSCLC with an OS of at least 36 months and treated in 8 institutions 
from Madrid (Spain). All these patients were selected in a period of 10 years (January 
2002 to 2012). We analyzed clinical-pathological characteristics (age, sex, ECOG, 
stage IIIB vs IV, histology, smoking status, diabetes and vascular disease, weight loss 
>10%, symptoms at diagnosis and sites of metastasis), laboratory parameters (LDH 
and haemoglobin levels) and type of treatment administered (platinum based treatment, 
metasectomies, number of chemotherapy lines, maintenance, grade 4 toxicity as well as 
metformine intake). Finally, data from PFS and OS were also collected. Results: Among 
all patients diagnosed with EGFRwt/ALKnt NSCLC and treated in 8 institutions in 10 years, 
we identified 93 pts with an OS of at least 36 months. 55 pts (60%) were older 65 years, 
67 pts (71%) male and 85 pts (91 %) were smokers/former smokers. Comorbidities 
(diabetes and vascular disease) were infrequent: 7pts (7%) and 13 pts (14%), respectively. 
Adenocarcinoma was most common pathological subgroup (60 pts, 65%) followed by 
squamous (21 pts, 22%), large cell carcinoma (7, 7%) and “other histologies” (6 pts, 
6%). The majority of them, had a good PS; ECOG 0 32 pts (34%) and 1 57 pts (61%). 
A minority of patients had weight loss greater than 10% at presentation (12 pts, 14%). 
Most frequent symptoms were cough (41 pts, 44%), followed by pain (34 pts, 36%), 
dyspnea (25 pts, 27%) and haemoptysis (9 pts, 9%). LDH and haemoglobin leves were 
normal in the majority (65 pts, 70% and 72 pts, 77%, respectively). On the other hand, 
metformin intake was uncommon (16 pts, 17%). One or two metastatic sites at diagnosis 
were described in 44 pts, 47% and 29 pts, 31%, respectively and only 13 pts (14%) had 
for these tests since it may represent the field of injury. Because cell–extracellular matrix 
interactions participate in several steps required for tumor cell invasion and formation of 
metastases, cofilin-1, hyaluronic acid (HA) and CD44 have been targeted as potential useful 
tumor markers. To our knowledge, cofilin-1 has never been evaluated in sputum from lung 
cancer patients. Objective: To evaluate the diagnostic and prognostic role of sputum 
cofilin-1 and to the relationship between this biomarker with HA and its receptor (CD44) 
in patients with non small cell lung cancer (NSCLC). Methods: Cofilin-1 and CD44 were 
analyzed by Elisa immunoassay and HA by “Elisa-like” fluorometric assay in the sputum of 
74 NSCLC patients, 13 cancer-free patients with obstructive lung disease and 8 healthy 
individuals. Statistical analyses included ANOVA, ROC curves, Spearman correlation, and 
logistic regression. Results: Sputum cofilin-1 levels were increased in patients with lung 
cancer (1475.83 pg/ml ±145.35) when compared to cancer-free patients (662.63 pg/
ml ±5.74) and volunteers (415.25 ±3.68 pg/ml). A significant association was found 
between cancer patients with high levels of cofilin-1 and CD44 (R=0.21; P=0.04) as 
well as between HA and CD44 (R=0.46; P<0.01). Cofilin-1 did not correlate with HA 
(P>0.4). Univariate analysis demonstrated that high expression of sputum cofilin-1 
significantly correlated to T4 (P=0.01) and M stage (P=0.03), tobacco history (P=0.01) 
and squamous cell carcinoma histologic type (P=0.04). Logistic regression analysis 
controlled for tobacco history, histologic types, stage, HA and CD44 expression showed 
that cancer cell–associated cofilin-1 was an independent predictor of metastases 
[OR=5.77 (0.78-42.74)]. Patients with sputum cofilin-1 >1475.83pg/ml had a high risk 
for metastasis. In relating to diagnosis, sputum Cofilin-1, at a cut off value of 248.9pg/mL 
presented sensitivity and specificity of 0.80 and 0.67 respectively, in distinguish healthy 
volunteers from NSCLC patients with AUC of 0.787. Cofilin-1 was also able to distinguish 
cancer-free patients from cancer patients at a cut off of 802.5pg/mL with AUC of 
0.693 and respective sensitivity and specificity of 0.60 and 0.54. Conclusion: Cofilin-1 
presented moderate sensitivity as diagnostic biomarker for lung cancer in sputum. 
Cofilin-1 was associated with metastases, but its prognostic value was dependent on 
the histological type and tobacco history. The association between sputum cofilin-1 and 
CD44 in cancer patients suggests that during tumor development, high levels of cofilin-1 
facilitate tumors growth and the penetration of capillaries into the tissue milieu. Thus, 
increased tumor expression of cofilin-1 seems to be more associated to primary events, 
while increased angiogenesis seems to be related to a secondary event. Regardless of 
the involved mechanism, detection of sputum cofilin-1 provides important prognostic 
information on cancer patients. Larger series of NSCLC patients still needs to be studied 
to confirm the usefulness of sputum cofilin-1 as diagnostic and/or prognostic biomarker. 
Keywords: Cofilin, CD44, NSCLC
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P1.04-030 Intra-Operative Pleural Lavage Cytology after Thoracotomy for 
Lung Cancer Masatoshi Kakihana, Kimitoshi Nawa, Yasufumi Kato, Masaru Hagiwara, 
Junichi Maeda, Koichi Yoshida, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda 
General Thoracic Surgery, Tokyo Medical University, Tokyo/Japan
Background: Pleural lavage cytology (PLC) is the microscopic study of cells obtained from 
saline instilled into and retrieved from the chest cavity (in patients without preoperative 
pleural effusion) during surgery for non–small-cell lung cancer. The solution is aspirated, 
and cytologic analysis is performed to screen for malignant cells. Results from this 
procedure have been published from Japan as early as 1989,1 and internationally, an 
increasing number of centers have adopted this practice. Methods: Between 1995 and 
2013, 2616 patients underwent surgical pulmonary resection for primary lung cancer 
without disseminated disease at our institute. Cytology of pleural lavage immediately 
after thoracotomy before any manipulation of the lung was examined in 1563consecutive 
patients with lung cancer with no pleural effusion. The macroscopic status of the pleural 
cavity was evaluated before any manipulation, and when no malignant findings were noted, 
the pleural cavity was washed with 100 ml of physiologic saline solution. Results: The 
results of the cytologic examination were divided into two categories, positive and 
negative PLC group. Papanicolaou classes I to IIIa were regarded as negative, classes 
IIIb, IV and V as positive. Of the 83 patients (6.8%) whose specimens were positive for 
PLC. Of the 83 patients in the positive PLC group, 74 (4.7%) had adenocarcinoma, with 
a significantly higher ratio of adenocarcinoma compared with the negative PLC group. 
Survival in the positive PLC group was significantly worse than in the negative PLC 
group (p = 0.001), especially in pathologic stage II (p = 0.001). We assume that the PLC 
positive cases have a T4 status. All PLC positive cases are reassigned Stage III. The 
result showed almost similar curves was shown between PLC negative Stage III and the 
adjusted PLC positive Stage III. We propose that positive PLC positive disease should 
be classified to pathologic T4 and managed similarly to dissemination. Conclusion: A 
positive PLC result was a strong unfavorable prognostic factor, and almost all patients 
with positive PLC relapsed within 5 years. PLC should be considered in all patients 
with early stage lung cancer suitable for resection ,especially, done when assessing 
the final stage in patients with adenocarcinoma of the lung. A positive result is an 
independent predictor of adverse survival and carries a prognosis. That suggests it 
may be appropriate to upstage patients by 1 T category or consider as T4 disease. 
Keywords: pleural lavage cytology, NSCLC
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P1.04-031 The Changing Anatomic Position of Squamous Cell Carcinoma 
of the Lung - A New Conundrum William S. Krimsky1, Manasa Vulchi2, Daniel P. 
Harley3, Pujan Patel4, Suman B. Rao5, Sarkar Saiyad1, Ruth Evans6, Joel Hammer7 
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the epithelial cells were positive for cytokeratin, EMA, and TTF-1. The interstitial cells 
were diffusely positive for vimentin and smooth muscle actin, and negative for desmin. 
Not nuclear but cytoplasmic staining of beta-catenin was observed in the epithelial 
cells. The tumor cells were immunohistochemically negative for ALK. The differential 
diagnoses of the tumor included pleulopulnmonary blastoma (PPB), and congenital 
cystic adenomatoid malformation/congenital pulmonary airway malformation (CCAM/
CPAM) type 3. PPB is characterized by rhabdoid or blastemal cells and/or anaplastic 
features and CCAM/CPAM type 3 generally shows a diffuse lesion without a capsule.
These histological features were not observed in the present tumor, and it was diagnosed 
as FLIT. Yoshida M, et al. noticed the nuclear stainig of beta-catenin in the epitheliaｌ cells 
of FLIT. Its nulcear staining is also observed in the epithelai cells in fetal lung at pseudo-
glandular stage, and they discussed the resembrance between FLIT and fetal lung at 
pseudo-glandular stage. In the present case, beta-catenin expression was observed in 
the cytoplasm of epithelial cells, which rahter resembled to the lung in alveolar stage. 
In 2014, Onoda T, et al. reported a novel chromosomal rearrangement resulting in α-2-
macroglobulin (A2M) and anaplastic lymphoma kinase (ALK) gene fusion in a case of 
FLIT. However, the present case was negative for ALK by immunohistochemistry. 
Immunohistochemical findings of beta-catenin and ALK of the present case suggested 
the pathogenic heterogeneity of FLIT. Conclusion: A case of FLIT in a neonate 
is presented with typical histopathological findings. Pathogenic heterogeneity of 
FLIT was suggested by beta-catenin and ALK immunohistochemistry of the case. 
Keywords: Fetal Lung Interstitial Tumor (FLIT), Congenital lung lesions
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P1.04-035 Clinicopathologic and Biological Characteristics of Young Age Non-
Small Cell Lung Cancer Tatsuo Ohira, Keishi Ohtani, Hiroaki Kataba, Sachio Maehara, 
Yoshihisa Shimada, Junichi Maeda, Koichi Yoshida, Yasufumi Kato, Masaru Hagiwara, 
Masatoshi Kakihana, Naohiro Kajiwara, Norihiko Ikeda Surgery, Tokyo Medical University, 
Tokyo/Japan
Background: The Japan Lung Cancer Society, Japanese Association for Chest 
Surgery, and Japanese Respiratory Society jointly established the Japanese Joint 
Committee for Lung Cancer Registration. The Japanese Joint Committee reported 
that number of resected lung cancer patients under 40 years of age in Japan was 
101 cases of 11663 registered patients in 2004. Apparently there are many people 
on their 50s to 70s who was resected for treatment of lung cancer. Lung cancer in 
patients under 40 years old is rare. Young lung cancer patients should have specific 
characteristics. Methods: We performed 2835 operations for lung cancer for 15years 
from 2000 through 2014 in our hospital. Among 2835 patients with lung cancer, 47 
patients were younger than 40. Among 47 patients 26 patients were male and 21 
patients were female. We examined characteristics of young lung cancer patients by 
clinicopathologic and molecular biologic characteristics. Results:Among patients 
with operation, pathological stage IA, IB, IIA, IIB, IIIA, IIIB were 24, 6, 3, 2, 6, 5 cases, 
respectively. 36 cases were diagnosed as adenocarcinoma. Squamous cell carcinoma 
was only one case. 3 cases were diagnosed as large cell carcinoma. Most of young 
lung cancer cases were diagnosed as adenocarcinoma. 5-year survival of resected 
lung cancer patients was 74%. 5-year survival of inoperable cases was 23.8%. We 
will show the biological characteristics of young age lung cancer patients. 9cases 
showed EGFR sensitive mutation. 4 cases showed the transforming EML4-ALK fusion 
gene. Conclusion: Young lung cancer patients showed specific clinicopathologic 
and molecular biologic characteristics compared with the older age patients. 
Keywords: Adenocarcinoma, biomarker, lung cancer
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P1.04-036 Primary Pulmonary Melanoma: A Report of Two Cases Mototsugu 
Watanabe, Hiromasa Yamamoto, Hiroki Sato, Hidejiro Torigoe, Ken Suzawa, Shinsuke 
Hashida, Yuho Maki, Junichi Soh, Shinichi Toyooka, Shinichiro Miyoshi Departments of 
Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of 
Medicine, Okayama/Japan
Background: Malignant melanoma is a refractory malignancy with a dismal prognosis. It 
generally arises from the skin in most cases, and cases of primary pulmonary malignant 
melanoma are rare and often behave aggressively. We have treated two cases of localized 
primary pulmonary malignant melanoma by surgical resection. Although cutaneous 
melanomas often carry activating mutations in the BRAF gene (V600E) and express 
programmed death ligand 1 (PD-L1), little is known about primary pulmonary malignant 
melanoma. Methods: We determined the BRAF mutational status (exons 11 and 15) by 
direct sequencing in the two tumors. Next, we performed a target sequencing analysis using 
the Human Lung Cancer Panel (Qiagen, Hilden, Germany), which targets 20 lung cancer-
related genes including most of the exons in BRAF, using the same samples. We evaluated 
the expression of PD-L1 on the surface of the tumor cells by immunohistochemical testing 
in formalin-fixed, paraffin-embedded tumor specimens with the use of a rabbit monoclonal 
antihuman PD-L1 antibody. Results: No BRAF mutations and PD-L1 expression were 
detected in both of two cases. We detected a p53 mutation, which was thought to be a 
potential somatic mutation, in one of the two cases using a sequencing panel targeting 
20 lung cancer-related genes. Conclusion: We encountered two cases of malignant 
melanoma of the lung that did not carry activating mutations in the BRAF gene. Further 
molecular analyses may uncover the characteristics of primary malignant melanoma. 
Keywords: primary pulmonary malignant melanoma, target sequencing
brain metastasis (mts) and 5 (5%) adrenal mts. First-line chemotherapy based in platinum 
was administrated in 92 pts (98%), however, maintenance therapy only in 41 pts (44%). 
Local treatment (metasectomies +/-RT), was done in 35 pts (38 %). Grade 4 toxicity was 
detected in 7 pts (7%). Finally, we estimated a median PFS of 13.4 months and median 
OS of 40.5 months Conclusion: To our knowledge, this is the largest multicenter serie 
reported of very long-term survivors (OS >36 months) with with EGFRwt/ALKnt advanced 
NSCLC. This study includes an exhaustive clinical and pathological analysis of this specific 
population. In this moment, we are carrying out a comprehensive molecular analysis 
Keywords: long-term survival, non small cell lung cancer, advanced disease
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P1.04-033 Case of a Patient Who Underwent Right Middle Lobectomy of 
Lung Adenocarcinoma with Histological Characteristics Similar to Papillary 
Adenoma Masato Watanabe1, Shozo Fujino1, Takehiro Okumura1, Masasi Kawamoto2, 
Mikiko Takahashi2 1Thoracic Surgery, Teikyo University School of Medicine Mizonokuchi 
Hospital, Kawasaki City/Japan, 2Pathology, Teikyo University School of Medicine Mizonokuchi 
Hospital, Kawasaki City/Japan
Background: Pulmonary papillary adenoma is a rare benign tumor of the lung, characterized 
by a histological appearance in which low-grade cuboid or single columnar cells proliferate, 
centering on the fibrovascular interstitium. Since diagnosis is made morphologically, genetic 
analysis is not used for its diagnosis in common practice. Methods: [Case presentation] 
A 60-year-old woman with no history of smoking or asbestos exposure was referred 
to our hospital with lung cancer suspected due to an abnormal shadow detected on a 
plain chest radiograph for screening. A mass lesion 3.5 cm in diameter was detected in 
the right middle lobe on chest computed tomography (CT). Although positron emission 
tomography (PET)/CT revealed fluorodeoxyglucose accumulation in the mass (SUV 
max 3.4), there was no other clear accumulation and there were no findings indicating 
lymph node metastasis or distant metastasis on enhanced CT and magnetic resonance 
imaging (MRI) scans. Therefore, the clinical stage was estimated as cT2aN0M0, stage 
IB. As a treatment strategy, we decided to use surgical biopsy because a definitive 
diagnosis could not be made from bronchoscopy. Thoracoscopy showed no apparent 
pleural dissemination or pleural effusion. Since the tumor in the middle lobe was 
difficult to resect, we resected the middle lobe and submitted it for intraoperative 
pathological examination. As a result, it was diagnosed as pulmonary papillary adenoma. 
Consequently, in surgery, systematic lymph node excision was not performed and 
samples were obtained from lymph nodes #11s and #11i. The permanent preparation 
showed the appearance of cuboid and low columnar-shaped cells proliferating on the 
fibrovascular interstitium, which was consistent with papillary adenoma. However, it 
also indicated a marginal region of lepidic pattern with focal low papillary projection. In 
immunohistological examination, both the marginal region and the body of tumor were 
stained with epidermal growth factor receptor (EGFR) mutation specific antibodies. 
Furthermore, genetic mutation was found in EGFR genetic analysis. Thus, this patient 
was diagnosed with invasive adenocarcinoma in papillary pattern predominant. The 
final pathological stage was estimated as T2aN0M0. However, adjuvant postoperative 
treatment was not performed. The patient was followed up in the outpatient 
department, and no recurrence has been observed eight months. Results: [Discussion] 
Pulmonary papillary adenoma is commonly diagnosed based on the histological forms and 
genetic examination is not usually used. Thus, we cannot deny the possibility that lesions 
with gene mutations have been present in the patients diagnosed with papillary adenoma 
in the past. In addition, in patients with a large primary tumor with a morphologically 
low grade, it is difficult to judge whether postoperative treatment should be provided 
and it is considered necessary to judge it by taking the clinical course into account. 
Conclusion: Pulmonary papillary adenoma is a rare tumor. To obtain 
the definite diagnosis with the exclusion of malignancy, it has been 
suggested that complete resection and genetic analysis is necessary . 
Keywords: papillary adenoma, Adenocarcinoma, EGFR mutation, lung cancer
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P1.04-034 A Case of Fetal Lung Interstitial Tumor (FLIT) in a Neonate Akiteru 
Goto1, Toshikaki Yoshioka2, Tomoo Ito3, Michihiro Yano3, Taku Hebiguchi4, Hiroaki 
Yoshino4 1Department of Cellular and Organ Pathology, Akita University, Akita/Japan, 
2Course of Occupational Therapy, Akita University, Akita/Japan, 3Pediatrics, Akita University 
Hospital, Akita/Japan, 4Pediatric Surgery, Akita University, Akita/Japan
Background: Fetal lung interstitial tumor (FLIT) is a newly recognized and a rare lung 
lesion of neonates. The entity was firstly proposed by Dishop MK, et al. in 2010. FLIT 
is histologically charized by unique mixture of immature interstitial mesenchyme with 
irregular airspace-like structures, which mimicks abnormal and incompletely developed 
lung.To date, only 13 cases of FLIT have been reported including 2 cases from Japan. 
We herein present another case of FLIT in a neonate with histopathological and 
immunohistochemical analyses to discuss its pathogenesis. Methods: not applicable 
Results: A 3 day-old boy was referred to our hospital with respiratory distress. He was 
born at 36 weeks of gestation, weighing 2070 g. Chest X-ray and computed tomography 
findings depicted a mediastinal tumor containing viscous fluid. However, the operation 
revealed that the tumor was developed in the left lung, and the tumor was resected. The 
postoperative course was uneventful and no recurrent disease was detected at his latest 
follow-up at 2 years after the resection. The tumor was 30x25x20mm-sized and its cut 
section showed a well-circumscribed solid and cystic mass. Histological examination 
revealed a well-circumscribed lesion with a fibrous capsule. The lesion consisted of 
immature airspace-like structures with widened septa containing immature mesenchymal 
cells, also, overlaying low cuboidal epithelium was observed. Immunohistochemically, 
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P1.04-038 Endobronchial Ultrasound Guided Transbronchial Fine Needle 
Aspiration Cytology (EBUS-TBNA) for Peribronchial Mediastinal Tumor 
Mitsutoshi Shiba, Taiki Fujiwara, Takahide Toyoda, Tomohiko Iida Thoracic Surgery, 
Kimitsu General Hospital, Kisarazu/Japan
Background: Recently endobronchial ultrasound guided transbronchial needle 
aspiration system (EBUS-TBNA) was developed in Japan and probed to be an 
effective method to diagnose peribronchial tree lesions especially for lymphnode 
metastasis of lung cancer. In this time, we present our experience of EBUS-TBNA 
for peritracheal mediastinal tumors and discuss current advances of EBUS-TBNA for 
lung peri-tracheobronchial lesions. Methods: Between 2008 and 2014, EBUS-TBNA 
was performed in nine patients with peritracheal mediastinal mass to diagnose them 
morphologically. Results: Final histological type of these nine cases were, 6 malignant 
tumors (two malignant lymphomas, one multiple myeloma, one thyroid carcinoma, one 
squamous cell carcinoma, one large cell carcinoma) and 3 benign tumors (one neurogenic 
schwanoma, one bronchogenic cyst and one thymic cyst). Of the detected 6 malignant 
tumors, cytology diagnoses were positive in three cases, suspicious in two cases and 
inadequate in one case. Of the detected three benign tumors, cytology diagnoses were 
benign in two cases and inadequate in one case. Among 7 solid mediastinal tumors, 
histological evaluation was capable in 3 cases and insuffi cient in 4 cases. Combined 
with cytological and histological examination, morphological diagnoses were useful in 6 
cases (67%) with EBUS-TBNA for peritracheal mediastinal tumors. Conclusion: Although 
histological type of peri-trachal mediastinal tumor was various, morphological diagnosis 
with EBUS-TBNA was useful in 67% of the lesions in this series. Analysis of atypical cells 
in the cytology specimen was effective to estimate the histological fi gures of the lesions. 
Keywords: bronchoscopy, EBUS-TBNA, Mediastinal Tumor, diagnosis
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P1.04-039 Ex-Vivo Artifacts and Histopathological Pitfalls in the Lung Erik 
Thunnissen1, Hans J. Blaauwgeers2, Douglas Flieder3 1Department of Pathology, VU 
University Medical Center,, Amsterdam/Netherlands, 2Pathology, Olvg, Amsterdam/
Netherlands, 3Pathology, Fox Chase Cancer Center, Philadelphia/United States of America
Background: Surgical and pathological handling of lung physically affects lung 
tissue. This leads to artifacts that alter the morphological appearance of pulmonary 
parenchyma. Methods: In this study four mechanisms of ex-vivo artifacts and 
corresponding diagnostic pitfalls are described and illustrated. Results: The four 
patterns of artifacts are: 1) Surgical collapse, due to the removal of air and blood 
from pulmonary resections; 2) Ex-vivo contraction of bronchial and bronchiolar 
smooth muscle; 3) Clamping edema of open lung biopsies, and 4) Spreading of 
tissue fragments and individual cells through a knife surface. Morphologic pitfalls 
include diagnostic patterns of adenocarcinoma, asthma, constrictive bronchiolitis, 
and lymphedema. Conclusion: Four patterns of pulmonary ex-vivo artifacts 
are important to recognize, in order to avoid morphologic misinterpretations, 
possibly improving reproducibility in histopathological diagnosis of lung cancer 
Keywords: lung*adenocarcinoma*diagnosis*artifact
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-040 Stage I Adenocarcinoma According to the 2011 IASLC/ ATS/ ERS: 
Case Series from Brazil André Luiz C. Trajano1, Juliana P. Franceschini2, Túlio Geraldo 
D.S. Souza3, Tadeu L.F. Pereira4, Mário C. Ghefter2, Rodrigo P.C. Sapucaia5, Ricardo S. 
Santos2 1Instituto Tórax, Salvador/Brazil, 2Instituto Tórax, São Paulo/Brazil, 3Laboratório 
de Anatomia Patológica E Citopatologia, Hospital Aliança, Salvador/Brazil, 4Cirtorax Bahia, 
Salvador/Brazil, 5Escola Bahiana de Medicina, Salvador/Brazil
Background: Lung cancer is the deadliest cancer worldwide and it is of particular concern 
in Brazil as the second cause of cancer death in both genders. The new classifi cation 
proposed by International Association for the Study of Lung Cancer/American Thoracic 
Society/European Respiratory Society Classifi cation has proven its prognostic value with 
also a better clinical understanding of lung adenocarcinoma. Prior to this classifi cation all 
patients diagnosed with early stage adenocarcinoma were considered to have practically 
the same disease. In our country, however, medical literature is still incipient on this topic. 
We reviewed the histopathology of a consecutive series of patients diagnosed with stage 
I adenocarcinoma. Methods: Cross-sectional study including 50 patients diagnosed with 
stages IA or IB adenocarcinoma undergoing surgical resection of non-small cell lung 
cancer. The variables: histological subtype, sex, age and tumour size. We have divided 
patients in two groups based on the presence of lepidic features. Statistical analysis was 
performed by Anova and Bonferroni multiple comparison test, to correlate tumour size 
among histological subtype groups. Results: The mean age was 63.7 (11.5) years, 50% 
were men. The average size of resected tumours was 1.4 (0.7) mm; 45 cases (90%) were 
stage IA. The predominant subtypes were histologically lepidic (n=24, 48%); the acinar 
subtype was found in 20 (40%) cases. Patients and tumour characteristics according 
to histological subtype are showed in table 1. There was statistical difference in size 
(p<0.05) when comparing lepidic tumors with acinar tumors (1.3mm versus 2.3mm 
respectively). Table 1: Patients and tumour characteristics according to histological 
subtype.
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P1.04-037 Lung and Hypopharyngeal Angiosarcoma (AS) in a Renal Transplant 
Patient: Case Report Liliana Fernandez1, Fernando Sanabria2, William Martinez2, 
Carlos A. Muñoz3, Luz F. Sua4 1Interventional Pulmonology, Fundacion Valle Del Lili, 
Universidad ICESI, Cali/Colombia, 2Clinic Pulmonology, Fundacion Valle Del Lili, Universidad 
ICESI, Cali/Colombia, 3Medical Research, Fundacion Valle Del Lili, Universidad ICESI, Cali/
Colombia, 4Department of Pathology and Laboratory Medicine. Phd Biomedical Sciences, 
Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia
Background: (AS) are rare malignant soft tissue tumors of endothelial cell origin 
representing 2% of all sarcomas. Most AS develops in the absence of precursor lesions. 
To date, only 20 cases of (AS) have been described after renal transplantation, occurring 
mostly on the skin or in a dialysis fi stula, their pulmonary location is very rare. We report 
the case of a patient with a renal transplant who presents a hypo pharyngeal and a right 
lower lobe (RLL) lesion where a Angiosarcoma was documented. Methods: Clinical History 
Revision Results: A 78 years-old patient, ex-smoker, with end-stage renal failure received 
a cadaveric donor renal transplant in 2000. Immunosuppressed with relatively low doses 
of tacrolimus and steroids, graft function remained stable with a serum creatinine in 
1,2 until January 2015 when he consults with dysphonia, dysphagia, cough, and mild 
hemoptysis. The patient had bilateral neck lymphadenopathy, bilateral basal crackles and 
the rest of the physical examination within normal parameters. Pulmonology evaluated 
the patient fi nding a hypopharyngeal mass and another with round morphology in RLL that 
were metabolically active in PET-CT. A hypopharyngeal biopsy is taken and a CT-guided 
transthoracic puncture, fi nding a high grade undifferentiated tumor of mesenchymal origin, 
expressing Vimenin and CD10, with vascular marker CD31 and gene C-Myc. Gene p53 and 
Ki-67 in 90% of the tumor. No lymphoid or epithelial line markers are expressed. The 
patient is currently in chemotherapy and immunotherapy. Conclusion: The use of potent 
immunosuppressive agents has signifi cantly reduced the rates of acute rejection after 
renal transplantation. However, increased cancer incidence after renal transplantation 
has become an important problem. Skin tumors, post-transplant lymphoproliferative 
diseases and organ cancers are the most common malignant tumors seen in these 
patients. Angiosarcoma is rarely seen in this group of patients, and location in lung and 
hypopharynx without evidence elsewhere of commitment affectation is very rare.
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P1.04-043 Pulmonary Lepidic Adenocarcinoma in a Patient with Prior 
Diagnosis of Breast Cancer: Case Report Liliana Fernandez1, Lina Garcia2, Mauricio 
Velasquez3, Carlos A. Muñoz4, Luz F. Sua5 1Interventional Pulmonology, Fundacion Valle Del 
Lili, Universidad ICESI, Cali/Colombia, 2Internal Medicine Resident, Fundacion Valle Del Lili, 
Universidad ICESI, Cali/Colombia, 3Thoracic Surgery, Fundacion Valle Del Lili, Universidad 
ICESI, Cali/Colombia, 4Medical Research, Fundacion Valle Del Lili, Universidad ICESI, Cali/
Colombia, 5Department of Pathology and Laboratory Medicine. Phd Biomedical Sciences, 
Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia
Background: The combined effect of improved cancer diagnosis and management has 
led to a marked increase in cancer survivors. Consequently, an appreciable proportion 
of cancer diagnoses are registered among patients who had already received a cancer 
diagnosis in the past, and more accurate diagnostic procedures lead to the identifi cation 
of more than one cancer in a subset of patients. We present the case of a patient with 
breast cancer in whom a lepidic primary lung adenocarcinoma was discovered during 
a follow-up. Methods: Medical History Revission Results: A 68-years-old female with 
breast cancer EC EIII diagnosed in March / 2010, handled with lumpectomy and lymph 
node removal, solid mucinous ductal carcinoma Ki67 expression: 35% RH: E (+) 100%, 
P (-), HER 2 NEU negative, negative margins with angiolymphatic invasion 3/15. She 
received radiotherapy, tamoxifen and later anastrozole. In Dec / 2010 she presents tumor 
recurrence managed with radical mastectomy, received chemotherapy with Adriamycin 
and Cyclophosphamide. In April / 2013 she consults with two months of dry cough and 
dyspnea, normal physical examination, an unremarkable mammography, chest CT-scan 
with irregular right basal nodular lesion and mediastinal nodes. The patient underwent 
resection through thoracoscopy, pathology shows lepidic adenocarcinoma pattern with 
mutated EGFR exon 19 and exon 21 negative, with metastatic nodal involvement by the 
primary lung tumor and previous breast carcinoma. Conclusion: Patients that have 
been diagnosed with a cancer, have an increased lifetime risk for developing another 
de novo malignancy depending on various inherited, environmental and iatrogenic risk 
factors. Cancer patients could survive longer due to settling treatment modalities, and 
then would likely develop a new malignancy. The monitoring and evaluation procedures 
are especially useful for early detection of tumors associated when there’s a known 
tumor lesion. 
 
Keywords: Breast cancer, Pulmonary lepidic adenocarcinoma
Subtypes Variables Lepidid Acinar Others p
n (%) 24 (48) 20 (40) 6 (12)
Men n (%) 11 (45.8) 9 (45) 6 (100)
Age mean (SD) 63 (11.6) 66.3 (10.8) 62.7 (7.7)
Tumor size mean (SD) 1.3 (0.6) 2.3 (1.4) 1.6 (0.6) 0.02*
*Anova with Bonferroni multiple comparison test. Conclusion: In our brief series of 
lung adenocarcinoma patients, the most common subtypes were acinar and lepidic; 
the latter being larger in this sample. The long-term follow-up will give us important 
information about the prognosis of these patients treated exclusively with surgery. 
Keywords: Adenocarcinoma, Histological type, lung cancer
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P1.04-041 Synchronous Lung Cancers, Squamous Cell and Adenocarcinoma 
Coexistence, Case Report Nesrin Ocal1, Deniz Dogan1, Omer Deniz1, Ali F. Cicek2, 
Hayati Bilgic1 1Chest Diseases, Gulhane Military Medical Faculty, Ankara/Turkey, 2Pathology, 
Gulhane Military Medical Faculty, Ankara/Turkey
Background: Synchronous lung cancers are simultaneously diagnosed, physically 
distinct and separate lung cancers which have no common lymphatics with the primary 
tumor and may have same or different histology with the primary neoplasms. Although 
radiological imaging techniques guide in terms of initial diagnosis, histopathological 
evidence is required for defi nitive diagnosis of synchronous multiplee primary lung 
cancers. Early diagnosis represents the only chance to obtain a surgical cure in these 
patients. Methods: not applicable Results: Here, we present a case with synchronous 
multiplee primary lung cancers in whom both tumors are diagnosed simultaneously. A 
69 year-old male patient with cough and left-sided chest pain complaints and 90 pack / 
year history of active smoking admitted to our clinic. Thoracic CT of the patient revealed 
a pleural-based mass in the right lower lobe and another mass on the left lung which 
is associated with the hilum and caused atelectasis in the distal airways. Diagnostic 
bronchoscopy was performed to the patient and separate biopsies were taken from the 
both lesions. Histological sections obtained from the bronchoscopic biopsy specimens 
revealed that there was an infi ltrative tumor in both right and left lung. In right lung, 
the tumor composed of abortive glandular structures and single cell infi ltrations within 
the desmoplastic stroma. The second tumor (left lung) was consist of solid islands 
composed of atypical squamous cells with eosinophilic cytoplasm and darkly basophilic 
nuclei. Histochemically, in the fi rst tumor, neoplastic cells had intracytoplasmic vacuoles 
stained by mucicarmin indicating a feature of adenocarcinoma whereas there were 
no cells containing mucin vacuoles in the second tumor. Immunohistochemical study 
has supported the histological and histochemical fi ndings. The tumor on the right 
side showed a diffuse immunoreactivity by CK7 which is a highly spesifi c marker for 
adenocarcinomas whereas the tumor on the left side was stained by the basal cell 
markers such as CK5/6 and p63 which are highly specifi c markers for squamous cell 
carcinoma. Briefl y, histopathologic examination of the biopsies from left upper lobe 
and right lower lobe revealed squamous cell lung carcinoma and adenocarcinoma, 
respectively. Thereupon oncologic PET examination was performed for screening and 
evaluating if there is another primary tumor site for adenocarcinoma. In PET examination, 
FDG uptakes of extrapulmonary tissues were considered to be normal. Thus both 
lesions thought to be primary lung tumors. Conclusion: Our case is a good example of 
simultaneously detected synchronous primary tumors of the lung and we reported this 
case in order to emphasize the possibility of another primary tumor in the cases which 
are initially thought to be metastatic lesions and for sure the need of biopsies separately. 
Keywords: synchronous tumors, lung cancer, squamous, Adenocarcinoma
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P1.04-042 Diagnostic Role of Immunocytochemistry in Malignant Pleural 
Mesothelioma Nguyen S. Lam Pathology Department, Pham Ngoc Thach Hospital, Ho Chi 
Minh City/Viet Nam
Background: Malignant pleural mesothelioma is a diffi cult diagnosis, more severe 
cases may not perform by pleural biopsy. With these cases, the technique of 
immunocytochemistry was performed proposals. Methods: A prospective, cross-
sectional descriptive statistics with clinical series cases. Results: § Implementing 
58 cases of malignant pleural mesothelioma by immunocytochemistry. § Technical 
Cytospin method has helped for immunocytochemistry have high results. § Should be 
done more staining with markers for the other diagnostic diseases: lung cancer and 
non-lung cancers that metastatic to pleura. § The results of the data: - Sensitivity: 
84.06 % - Specifi city: 100 % - Positive Prognostic Value: 100 % - Negative Prognostic 
Value: 92.25 % - Accuracy: 94.12 % Conclusion: The diagnosis of malignant pleural 
mesothelioma is always a diffi cult diagnosis. Needing the differential diagnosis with 
other types of diseases, such as lung cancer and non-lung cancers that to pleural 
pulmonary metastases. Staining with immunocytochemistry in cases of pleural 
effusion showed relatively high value. This suggests that the ability to diagnose 
initially screening properties of this technique is very good, especially valuable in the 
diagnosis of severe disease progression can not perform other diagnostic techniques. 
Keywords: Immunocytochemistry, Malignant Pleural Mesothelioma
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P1.04-044 Local Diagnostic Practices for Advanced Non-Small-Cell Lung 
Cancer in Asia-Pacific and Russia: IGNITE Study Sergei Tjulandin1, Baohui Han2, 
Koichi Hagiwara3, Nicola Normanno4, Laksmi Wulandari5, Konstantin Laktionov6, 
Achmad Hudoyo7, Yong He8, Yi P. Zhang9, Meng-Zhao Wang10, Chien Ying Liu11, Marianne 
Ratcliffe12, Rose Mccormack12,Martin Reck13 1Department of Clinical Pharmacology and 
Chemotherapy, Russian Cancer Research Center, Moscow/Russian Federation, 2Department 
of Respiratory Medicine, Shanghai Chest Hospital, Jiao Tong University, Shanghai/
China, 3Jichi Medical University, Saitama Medical Center, Saitama-Ken/Japan, 4Cell Biology 
and Biotherapy Unit, Istituto Nazionale Tumori ‘Fondazione Giovanni Pascale’, Irccs, 
Naples/Italy, 5Department of Pulmonology, Dr Soetomo General Hospital, Surabaya/
Indonesia, 6Department of Clinical Biotechnology, Russian Cancer Research Center, 
Moscow/Russian Federation, 7Department of Pulmonology and Respiratory Medicine, Faculty 
of Medicine, University of Indonesia - Persahabatan, Jakarta/Indonesia, 8Department of 
Respiratory Medicine, Daping Hospital, the Third Military Medical University, Chongqing/
China, 9Department of Chemotherapy, Zhejiang Cancer Hospital and Key Laboratory 
Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Province Hangzhou/
China, 10Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking 
Union Medical College and Chinese Academy of Medical Sciences, Beijing/China,11Division 
of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taipei/
Taiwan, 12Personalised Healthcare and Biomarkers, Astrazeneca, Macclesfield/United 
Kingdom, 13Department of Thoracic Oncology, Lungen Clinic Grosshansdorf, Airway Research 
Center North (Arcn), Member of the German Center for Lung Research (Dzl), Grosshansdorf/
Germany
Background: IGNITE (a large, multicentre, interventional, non-comparative diagnostic 
study; NCT01788163) evaluated local diagnostic practices for patients with advanced 
non-small-cell lung cancer (aNSCLC) in Asia-Pacific/Russia. Methods:Eligible patients: 
local/metastatic aNSCLC; chemotherapy-naïve, newly diagnosed/recurrent disease 
after resection; ineligible for curative treatment. We report diagnostic assessments and 
epidermal growth factor receptor (EGFR ) mutation test turnaround times (secondary 
endpoints) associated with tissue/cytology samples from patients in Asia-Pacific/
Russia. Results: 3382 patients enrolled (972 Russia). Immunohistochemistry (IHC) 
analysis was used to confirm diagnosis in 989/2093 (47%) and 165/949 (17%) patients 
in Asia-Pacific and Russia, respectively (where data were available). Where IHC was 
used, the markers assessed were: TTF-1 (Asia-Pacific 95% and Russia 90%); p65 (3% 
and 5%); and p40 (17% and 4%).EGFR mutation tests were not performed on samples 
from 262 patients and tested samples from 23 patients did not yield results. The most 
common reason for not testing was insufficient material provided to test (Asia-Pacific 
93% [100/108 responses], Russia 67% [24/36]). The percentages of neoplastic cells in 
samples (data available: Asia-Pacific n=1042; Russia n=187) were: <20% tumour cells: 
Asia-Pacific 33% vs Russia 6%; 20–50% tumour cells: 28% vs 33%; and >50% tumour 
cells: 40% vs 61%. Considering sampling methodologies (data available: Asia-Pacific 
n=2410; Russia n=972), the most common sampling sites were the lungs (Asia-Pacific 
68%; Russia 80%) or lymph nodes (Asia-Pacific 14%; Russia 10%); the most common 
sample collection method was bronchoscopy (Asia-Pacific 22%; Russia 45%; Table 1). 
Median EGFR mutation test turnaround time was within 2 weeks for all countries except 
Thailand (70 days; Table 2). Mutation test success rates were high for Asia-Pacific (99.5%) 
and Russia (98.7%). Conclusion: Diagnostic assessments, sampling methodologies and 
EGFR mutation testing practices vary between and within Asia-Pacific and Russia; further 
understanding of local practices will drive improvements and enable more patients to 
receive appropriate personalised treatment.
S467Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
 
 
Results: We were able to combine histological and radiological information into a software 
solution which provids an integrated and improved research opportunity for pathologists, 
radiologists and biologists. It allows correlation of findings on molecular and cell level 
with findings from in-vivo functional imaging. Conclusion: We demonstrated that a 
combined evaluation of functional MRI and pathology can be facilitated. New studies 
will show the usage in more common lung cancers and larger numbers of patients. 
Keywords: Pathology, 3D reconstruction, tumor board, functional MRI
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P1.04-046 MFN2 Regulates Lung Adenocarcinoma Cell Proliferation and 
Invasion Yuqing Lou1, Rong Li1, Jielin Liu2, Yanwei Zhang1, Wei Zhang1, Xueyan Zhang1, 
Hua Zhong1, Liyan Jiang1, Shaojun Wen2, Baohui Han1 1Department of Pulmonary, 
Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/China, 2Department of 
Hypertension Research, Beijing Anzhen Hospital, Capital Medical University and Beijing 
Institute of Heart Lung and Blood Vessel Diseases, Beijing/China
Background: Mitofusin-2 gene (MFN2) encodes a mitochondrial protein which is critical 
for mitochondrial fusion process. MFN2 was initially identified as a hypertension-
associated gene and implicated in the pathogenesis of multiple cancer types. However, 
roles and underlying mechanisms of MFN2 in lung adenocarcinoma development remain 
to be determined. Methods: MFN2 expression at protein level was examined in 30 pair 
lung adenocarcinoma/adjacent normal lung samples with immunohistochemistry 
staining. Then MFN2 knockdown was performed in human lung adenocarcinoma cells 
A549 with lentiviral-mediated shRNA strategy. The effects of MFN2 knockdown on cell 
proliferation, cell cycle process, cell migration and invasion was investigated in A549 
cells. Then MFN2-knockdown induced gene expression changes in A549 cells was 
analyzed by microarray assay and then functional pathway enrichment analysis was 
performed to identify critical pathways involved in MFN2-mediated lung adenocarcinoma 
development. The expression changes of downstream factors were further determined 
in A549 cells by western blot. Results: As compared to adjacent normal lung tissues, 
MFN2 expression was significantly higher in lung adenocarcinoma tissues with positive 
MFN2 signals in 90% (27/30) lung adenocarcinoma tissues and only in 26.7% (8/30) 
adjacent normal tissues (Fig. 1A, B). Furthermore, MFN2 knockdown inhibited cell 
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P1.04-045 Software Support for Combined Staging of Lung Cancer in CT, 
Functional MRI and Pathology Hendrik O.A. Laue1, Peter Kohlmann2, Johannes Lotz3, 
Oliver Sedlaczek4, Benedikt Müller5, Kai Breuhahn5, Niels Grabe6, Arne Warth5, Horst 
Hahn1 1Fraunhofer Mevis, Bremen/Germany, 2Fraunhofer Mevis, Berlin/Germany, 3Project 
Group Image Registration, Fraunhofer Mevis, Bremen/Germany, 4Diagnostic and 
Interventional Radiology, Radiological Clinic, Heidelberg/Germany, 5Institute of Pathology, 
University of Heidelberg, Heidelberg/Germany, 6Tissue Imaging & Analysis Center, University 
Heidelberg, Heidelberg/Germany
Background: Treatment and diagnosis of lung cancer is an interdisciplinary challenge. 
New treatment options can benefit from refined information on biological processes in 
the tumor. Two diagnostic disciplines, pathology and radiology, can provide oncology 
with valuable information allowing to select of the most appropriate treatment. Linking 
radiology and pathology on the imaging level requires sophisticated software. Therefore, 
we developed a computer tool combining quantitative functional MRI and CT with state-of-
the-art whole-slide and 3D reconstructed histology. Methods: We selected a model lung 
cancer patient to investigate the requirements and possibilities for a combined software. 
The patient had a squamous cell carcinoma. Prior to excision, functional imaging using 
MRI as well as highly resolved CT and MRI volumes were acquired. These included a 
dynamic contrast-enhanced (DCE) - and a diffusion-weighted imaging (DWI) - MR scan. 
After imaging, the tumor was resected and a macroscopic slice of 5 mm thickness 
was resected from the center region of the tumor. This slice was further divided into 
11 blocks, which were then cut into microscopic (~ 2 µm) slices. Staining was applied 
to these slices according to the requirements of the pathologist and then scanned by 
a whole-slide histological scanner (Hamamatsu, Japan). The obtained images of the 
microscopic slices were automatically reconstructed into histological 3D volumes by 
means of registration. Functional MRI and morphological CT data was imported into the 
software prototype. The tumor volume was determined in the CT image by a two-click 
automatic segmentation method. Quantitative parametric maps of the extended general 
kinetic model (eGKM) for vascular information and the apparent diffusion coefficient 
(ADC) for cell density were calculated. Afterwards, the histological blocks were aligned 
such that the blocks were located correctly on a photo of the macroscopic slice. They 
were then manually aligned to the morphologic contrast enhanced T1 image showing 
the best contrast for structures visible in the macroscopic slice. Finally, the pathological 
data were imported into the software for direct comparison of pathology and functional 
imaging in human lung tumors.
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P1.04-047 The Inhibitory Effects of CDK4 and MDM2 on Migration and 
Invasion in Human Non-Small Cell Lung Cancer Cells Soojeong Kang1, Sachiko 
Takikawa1, Alain C. Borczuk2, Pierre P. Massion3, Charles A. Powell4 1Icahn School of 
Medicine at Mount Sinai, New York/NY/United States of America, 2Department of Pathology 
and Laboratory Medicine, Weill Cornell Medical College, New York/NY/United States of 
America, 3Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram 
Cancer Center, Nashville/TN/United States of America, 4Division of Pulmonary, Critical Care, 
and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York/United States of 
America
Background: Cyclin-dependent kinase 4 (CDK4)/RB and mouse double minute 2 
(MDM2)/p53 are the two main regulators of the tumor-suppressor pathways that control 
cellular responses to potentially oncogenic stimuli. CDK4 inhibits RB by triggering its 
phosphorylation, leading to releasing the G1-S restriction point. MDM2 inhibits the 
transcription activity of p53 by blocking the transfer of p53 from cytoplasm to nucleus and 
by accelerating ubiquitination of p53. Our preliminary SNP microarray analysis using lung 
specimens from non-invasive tumor (adenocarcinoma in situ) and invasive tumor (lepidic 
predominant adenocarcinoma) showed the amplification of chromosome 12q13–15, 
including CDK4 and MDM2 gene regions. The aim of the present study was to determine 
the mechanistic implications of CDK4 and MDM2 in lung adenocarcinoma migration 
and invasion. Methods: Using siRNAs specific for CDK4 and MDM2, the expressions 
of CDK4 and MDM2 were knocked down in the human non-small cell lung cancer cell 
lines A549, H460, H1299, SK-Lu-1 and H23, which harbor wild-type RB yet contain other 
aberrations in p53 (wild-type in A549, H460, absent in H1299, and mutated in SK-Lu-1, 
H23). Cell proliferation (AlamarBlue staining), mobility (scratch assay), and invasion 
(transwell-matrigel chamber system) were investigated. Results: The knockdown of 
CDK4 (5.5, 18.5, 2.2, 22.8 and 8.3% compared to scrambled siRNA in A549, H460, 
H1299, SK-Lu-1 and H23, respectively) significantly inhibited cell proliferation in H23 
and SK-Lu-1, and decreased cell migration in SK-Lu-1 and H460. It also repressed cell 
invasion in H460, SK-Lu-1 and A549. The decreased expression of MDM2 (43.4, 69.6, 
6.4, 27.3, 8.7% compared to scrambled siRNA in A549, H460, H1299, SK-Lu-1 and 
H23, respectively) dramatically inhibited cell proliferation in H1299, SK-Lu-1 and H23, 
and diminished cell migration in H23, A549 and SK-Lu-1. It also hindered cell invasion 
in H460 and H23. Conclusion: These findings suggest CDK4 and/or MDM2 pathways 
may play critical roles in cell proliferation, mobility and invasion, and furthermore, the 
targeting CDK4 and/or MDM2 may provide therapeutic benefit to lung cancer patients. 
Keywords: CDK4, MDM2, siRNA, NSCLC
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P1.04-048 DNA Demethylation Related Hypoxia-Induced Stem-Like Properties 
in Lung Cancer Hyon Soo Joo, Seung Joon Kim, Chankwon Park Department of Internal 
Medicine, The Catholic University of Korea, Seoul/Korea
Background: Tumors exhibiting extensive hypoxia have been shown to be more 
aggressive than corresponding tumors that are better oxygenized, which suggests that 
hypoxic condition induces stem-like properties. The purpose of the present study was to 
investigate whether hypoxic stress induces acquisition of stem-like properties, and the 
mechanism is involved with DNA demethylation in lung cancer. Methods: Normal epithelial 
cell line (BEAS-2B) and human lung cancer cell lines (A549, H292, H226 and H460) were 
incubated either in normoxic or in hypoxic (below 1% O2) condition. The cell lines were 
treated with a DNA methyltransferase inhibitor (5-azacytidine, AZA) to determine whether 
the expression of stem cell markers (CD44, CD133, CXCR4, ABCG2, CD117, ALDH1A1, 
EpCAM, CD90, Oct4, Nanog, SOX2, SSEA4 and CD166) was reactivated. Methylation-
specific PCR and bisulfite sequencing were used to analyze the methylation status, and 
real-time RT-PCR and western blotting were performed to analyze the expression of 
the stem cell markers. Cell migration and Matrigel invasion assay were performed for 
functional analysis Results: Among the 13 stem cell markers, CXCR4, Oct4 and Nanog 
were increased at least one lung cancer cell line in hypoxic condition compared with 
in normoxic condition. These three stem cell markers were reactivated by treatment 
with AZA. Methylation-specific PCR showed decreased promoter methylation of these 
three stem cell markers in hypoxic condition compared with in normoxic condition, which 
was further validated by bisulfite sequencing. Migration and invasion were increase in 
hypoxic condition compared with in normoxic condition Conclusion: These results 
suggest that under the hypoxic condition, reactivation of stem-like properties was 
related with promoter demethylation of stem cell markers. Further studies are needed 
to assess its value as a prognostic factor and potential therapeutic applications. 
Keywords: lung cancer, DNA demethylation, hypoxic stress
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P1.04-049 The MRE11/RAD50/NBS1 Complex Was Impaired in Lung Cancer 
from Chromate-Exposed Workers Kazuya Kondo1, Tomoko Kawanishi1, Mariko 
Shiraishi1, Chikako Takai1, Yuki Morimoto1, Tamaki Otani1, Mitsuhiro Tsuboi2, Koichiro 
Kajiura2, Hiromitsu Takizawa2, Gokei Kawakami2, Hiroaki Toba2, Shoji Sakiyama2, Akira 
Tangoku2 1University Tokushima, Tokushima/Japan, 2Department of Thoraci,Endocrine 
Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate 
School, Tokushima City/Japan
Background: Our previous studies demonstrated that one third of lung cancers 
of chromate-exposed workers (chromate LC) showed high-degree microsatellite 
instability (MSI), most of which repressed DNA mismatch repair (MMR) hMLH1protein. 
proliferation (Fig. 1C), induced cell cycle arrest (Fig. 1E) and blocked invasion behavior 
(Fig. 1D) in A549 lung adenocarcinoma cells. Microarray analysis revealed that a lot of 
genes were deregulated in A549 cells with MFN2 knockdown (Fig. 1F). Then functional 
pathway enrichment revealed six pathways were enriched in deregulated genes including 
Cell cycle, DNA replication, ECM-receptor interaction, Focal adhesion, MAPK signaling 
pathway and Chemokine signaling pathway (Fig. 1G). Furthermore, the downregulation of 
RAP1A and upregulation of RALB and ITGA2 identified in MFN2-knockdown cells by 
microarray analysis were confirmed by western blot (Fig. 1H).
 
Conclusion: Our results confirmed the involvement of MFN2 in the pathogenesis of lung 
adenocarcinoma and revealed that MFN2 was critical for cell proliferation and invasion 
in lung adenocarcinoma cell line A549. Furthermore, microarray analysis identified 
multiple pathways deregulated in MFN2-knockdown cells, providing valuable insights 
about the mechanisms underlying MFN2-associated lung adenocarcinoma development. 
Keywords: cell proliferation, cell invasion, MFN2, lung adenocarcinoma
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c-Cbl mutant. Heat map analysis of gene expression profiling data clearly revealed that 
the various kinases and phosphatases in C. elegans that are marginally expressed in N2 
worms were significantly enhanced upon chronic nicotine exposure. The expression of 
these genes was already elevated in SD551 and that was further increased in response to 
nicotine. Conclusion: Taken together, chronic nicotine exposure adversely affects various 
biological functions of C. elegans and these effects are exaggerated in the mutants. 
Interestingly, nicotine treatment also upregulates the expression of various kinases and 
phosphatases thereby strengthening our contention that the initial screening studies for 
the oncogenic mutants detected in humans can be rapidly carried out in C. elegans. 
Keywords: C. elegans, nicotine, vab-1, SD551
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P1.04-052 TGF-β Induced EMT and Stem-Like Characteristics in Lung Cancer 
Seung Joon Kim1, Su Yeon Choi2, Nahyeon Kang2, Young Kyoon Kim2 1Department of 
Internal Medicine, The Catholic University of Korea, Seoul/Korea, 2The Catholic University of 
Korea, Seoul/Korea
Background: TGF-β promotes tumor invasion and metastasis by inducing an epithelial-
mesenchymal transition (EMT). EMT is often associated with acquisition of stem-like 
characteristics. In the present study, we investigated whether EMT induced by TGF-β 
could acquire stem-like characteristics in lung cancer. Methods: Normal epithelial cell 
line (BEAS-2B) and lung cancer cell lines (A549, H292, H226 and H460) were used in 
the study. These cell lines were incubated with 10 ng/ml of TGF-β for 3 days. Western 
blot was performed to analyze the expression of epithelial marker (E-cadherin) and 
mesenchymal markers (N-cadherin, vimentin, fibronectin and alpha-smooth muscle 
actin). Real-time RT-PCR and western blot were performed to analyze the expression 
of stem cell markers (CD44, CD133, CXCR4, ABCG2, CD117, ALDH1A1, EpCAM, CD90, 
Oct4, Nanog, SOX2, SSEA4, and CD166). Wound-healing assay, Matrigel invasion 
assay and sphere formation assay were used to assess functional characteristics of 
EMT and stemness acquisition. Results: TGF-β induced EMT and stem cell markers 
with variable degrees according to lung cancer cell lines. Most of the stem cell markers 
were increased by treatment with TGF-β except H460 cell line. Increased expression 
of mesenchymal markers was associated with the acquisition of stem cell makers. 
Migration, invasion and sphere formation were increased according to the expression of 
stem cell markers. Conclusion: TGF-β induced EMT was associated with acquisition of 
stem-like characteristics which was different according to lung cancer cell lines. Further 
studies are needed to investigate the signal mechanism of EMT and stemness acquisition. 
Keywords: TGF-β, EMT, Cancer stem cell, lung cancer
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P1.04-053 Characterization of Invasive Cancer Cells and Potential Therapeutic 
Effect of Suberoylanilide Hydroxamic Acid on Human Lung Cancer Metastasis 
Shirong Zhang1, Kan Wu2, Jianguo Feng3, Lucheng Zhu4, Bing Wang2, Hong Jiang5, 
Zhibing Wu4, Xufeng Chen6, Shenglin Ma2 1Hangzhou First People’S Hospital, Hangzhou/
China, 2Affiliated Hangzhou First People’S Hospital of Zhejiang Chinese Medical 
University, Hangzhou/China, 3Zhejiang Cancer Hospital, Hangzhou/China, 4Department 
of Radiation Oncology, Affiliated Hangzhou Hospital of Nanjing Medical University, 
Hangzhou/China, 5Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou/
China, 6Department of Pathology and Laboratory Medicine, University of California at Los 
Angeles, California/AL/United States of America
Background: Lung cancer is a worldwide problem andthe leading cause of death among 
all malignancies. Despite tremendous progresses in diagnosis and treatment, the overall 
treatment outcomes for lung cancer patients remain poor, and metastatic lung cancer 
is responsible for more than ninety percent of lung cancer related deaths. However, the 
details for lung cancer invasion and thereafter metastasis remain unclear. In this study, we 
characterized the biological features of invasive human lung cancer cells, and investigated 
the potential therapeutic effects of Suberoylanilide Hydroxamic Acid (SAHA) on invasive 
cancer cell subpopulation. Methods: Boyden-type cell invasion chambers were used 
for isolation of cancer cell subpopulations with high invasiveness (H-INV) and low 
invasiveness (L-INV) from human lung cancer H460 cells. The potential enrichment of stem 
cell-like cancer cells in H-INV cells and the resistances of H-INV cells to chemotherapy 
and radiation treatment were investigated. We also tested the effects of SAHA on the 
differentiation of cancer stem cell and its consequences on cancer cell invasion and the 
sensitivities to radio/chemotherapies in H-INV cells. Furthermore, microarray for message 
RNA was performed for identification of gene expression profiling for invasive cancer 
cells. Results: Comparing to L-INV cells, H-INV cells are with enrichments of stem cell-
like cancer cells, with increased positive staining of putative stem cell markers such as 
CD24low/CD44+ and OCT3/4, and more tumorigenic. H-INV cells are also more resistant 
to treatments of chemotherapeutic agents and ionizing radiation. Treatment with SAHA 
can induce differentiation of stem cell-like cell in H-INV cells, causing reduced cancer cell 
invasion and increased sensitivity to chemo/radiotherapy in cells. With mRNA microarray 
assay, we identified 453 genes differentially expressed in H-INV versus L-INV, and five of 
these genes have been further tested for their significances in paired primary and metastatic 
lung tumors. Conclusion: Our study suggested putative roles of cancer stem cell in lung 
cancer invasion and migration. Study also showed that invasive lung cancer cells are 
resistant to most of first-line and second-line chemotherapeutic agents and radiotherapy, 
indicating novel therapeutic strategies are needed for the treatment of metastatic lung 
cancer. Of this setting, SAHA may serve as a chemotherapeutic agent for benefiting lung 
cancer patients. The candidate genes identified in this study may also have clinic impact 
as potential metastatic predictors for diagnosis and prognosis for human lung cancer. 
Keywords: lung cancer, invasion, Cancer stem cell, SAHA
MMR-deficient tumors are characterized by widespread changes in the number of 
microsatellites accumulating in both coding and non-coding sequences of many human 
genes. The MRE11–RAD50–NBS1 complex is essential for DNA double-strand break 
(DSB) repair performing by homologous recombination (HR) or non-homologous end 
joining (NHEJ). In gastric and colorectal cancers with MSI, the mono- or biallelic deletions 
in the poly(T)11 within MRE11 intron 4 and the frameshift mutations in the (A)9 repeat 
in RAD50 exon 13 were detected and the significant reduction of both proteins were 
identified. Methods: We used formalin-fixed paraffin-embedded materials from 36 
chromate LC (28 cases; all male, mean age 56.8, squamous cell ca (SQ) 35, stage I 27, 
BI=488, mean chromate exposure 24 years) and 28 non-chromate LC (all male, mean 
age 61, SQ 28, stage I 8, BI=674). DNA was extracted and amplified using nested-PCR. 
The fragment analysis was performed using a capillary electrophoresis and GeneScan 
Analysis software (Applied Biosystem, USA). Results: In the poly(T)11 within MRE11 
intron 4, 8 (29%) of 28 non-chromate LC showed 1bp deletion or insertion and 14 (52%) 
of 33 chromate LC showed 1bp deletion or insertion. In the (A)9 repeat in RAD50 exon 13, 
none of 27 non-chromate LC showed deletion or insertion and 4 (16%) of 25 chromate LC 
showed deletion. 67% of chromate LC with more than 3 MSI had abnormality of MRE11 
gene, and 60% of chromate LC with 2 MSI had it. While, 27% of chromate LC with less 
than one MSI and 28% of non-chromate LC had it. 17% of chromate LC with more than 
3 MSI had abnormality of MRE11 gene, and 10% of chromate LC with 2 MSI had it. 
While, 25% of chromate LC with less than one MSI had it and none of non-chromate LC 
had it. Conclusion: Half of chromate LC had the abnormality of the poly(T)11 within 
MRE11, which was associated with the degree of MSI. Sixteen percentage of chromate 
LC had the abnormality of the (A)9 repeat in RAD50. The carcinogenesis of chromate 
LC may be involved in the abnormality of DNA repair MRE11–RAD50–NBS1 complex. 
Keywords: MRE11–RAD50–NBS1 complex, chromate-exposed workers, lung cancer, 
microsatellite instability
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P1.04-050 COX-2 Genetic Variants Influence Intratumoral Infiltration of Foxp-3-
Positive Regulatory T Cells in Non-Small Cell Lung Cancer Masao Nakata, Takuro 
Yukawa, Katsuhiko Shimizu, Ai Maeda, Yuji Nojima, Sinsuke Saisho, Riki Okita 
General Thoracic Surgery, Kawasaki Medical School, Kurashiki/Japan
Background: The immune microenvironment of primary tumors has been reported to 
be a prognostic factor. We previously reported that the tumor-infiltrating regulatory T 
sell (Treg) count was positively correlted with the intratumoral cyclooxygenase-2 (COX-2) 
expession level and was associated with a poor survival among patients with non-small 
cell lung cancer (NSCLC). Recently, numerous single nucleotide polymorphisms (SNPs) in 
the COX-2 gene have been identified, and those SNPs may contribute to differential gene 
expression and enzyme activity levels. However, whether COX-2 genetic variants influence 
the functions of COX-2 in NSCLC remains unclear. Methods: Eighty NSCLC patients who 
underwent a complete recection at our institute ware enrolled. We extracted DNA from 
the peripheral blood and identified five different COX-2 SNPs. The correlations between 
the COX-2 SNPs and the expression levels of COX-2, Tregs and Ki-67 were studied. 
The prognostic significance of the COX-2 SNPs was also evaluated. Results: COX-
2 SNPs were not correlated with the expression of COX-2. However, for the COX-
2 -1195G/A polymorphism, the AA genotype group had a significantly higher Treg 
score. Furthermore, the AA group had a significantly higher Treg score regardless 
of the COX-2 expression level. The COX-2 -1195AA genotype group tended to have a 
shorter disease-free survival period than the GA/GG group. Conclusion: In conclusion, 
the COX-2 -1195G/A polymorphism influences the infiltration of Tregs into NSCLC, and 
the COX-2 SNP factor may be a prognostic factor reflecting Treg infiltration in NSCLC. 
Keywords: non-small cell lung cancer, COX-2, SNP, Treg
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P1.04-051 C. Elegans, an in Vivo Model for Lung Cancer: Effect of Chronic 
Exposure of Nicotine on Specific Mutants Relevant to Lung Cancer Jacob J. 
Riehm1, Rajani Kanteti2, Ravi Salgia3 1Hem/Onc, University of Chicago, Chicago/IL/United 
States of America, 2University of Chicago, Chicago/IL/United States of America, 3Medicine, 
Section of Hematology/Oncology, University of Chicago, Chicago/IL/United States of 
America
Background: There are a number of genetic abnormalities that can occur in lung 
cancer. We, and others, have shown that receptor tyrosine kinases (RTKs), such as 
EGFR, c-MET, RON, and Eph, frequently harbor gain-of-function mutations in addition 
to being overexpressed in lung cancer. We also have shown that the soil nematode C. 
elegans overexpressing a c-Met mutant revealed an abnormal vulval phenotype with 
hyperplasia. Interestingly, exposure to nicotine significantly aggravated the phenotype 
suggesting that C. elegans can be used as an in vivo model for rapid screening of RTK 
mutants as well as carcinogens. Methods: C. elegans strains vab-1 (Eph receptor), 
RB2088 (MET receptor), SD551 (temperature sensitive strain expressing constitutively 
active form of KRAS), and three sli-1 mutants PS2728, PS1258, and MT13032 (inactive, 
c-CBL) were compared to wild-type N2 worms for survival, fertility, egg-laying capacity, 
locomotion, and phenotypic changes in the absence or presence of nicotine. Gene 
expression analysis was also performed on each of the strains in the absence or presence 
of nicotine. Results: Nicotine treatment reduced the lifespan of worms for all strains 
(p=.0034). Nicotine treatment adversely affected egg-laying capacity of all strains, 
including N2 control, reducing egg production by 13% at 50µM nicotine and 31% at 500 
µM nicotine. Furthermore, the fertility (the number of eggs laid/worm) was significantly 
reduced in SD551 mutant worms compared to N2 worms (p=.003). Overall locomotion 
velocity did not change with increasing concentration of nicotine except in MT13032, a 
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P1.04-056 Use of Pooled shRNA Synthetic Lethal Screens within an In Vivo 
Murine Model to Identify Microenvironment-Dependent Lung Cancer Genes 
Nathaniel R. Little1, Joanna M. Poczobutt2, Hannah A. Scarborough3, Howard Li1, 
Raphael Nemenoff2, James V. Degregori3 1Division of Pulmonary Sciences and Critical 
Care, University of Colorado, Aurora/CO/United States of America, 2Department of Medicine, 
University of Colorado, Aurora/CO/United States of America, 3Biochemistry and Molecular 
Biology, University of Colorado Denver, Denver/CO/United States of America
Background: Lung cancer remains the leading cause of cancer-related deaths worldwide. 
While significant knowledge has been gained regarding the characterization of mutational 
drivers in NSCLC, much less is known regarding interactions between tumor cells and 
the surrounding microenvironment that are critical for tumor progression. Additionally, 
a significant limitation in current understanding is the lack of knowledge regarding 
which tumor gene products are necessary for promoting cell survival in the context of 
the tumor microenvironment. We hypothesize that the use of pooled shRNA synthetic 
lethal screens within an in vivo murine model will allow for the elucidation of targetable 
microenvironment-dependent genes. Methods: We generated a custom murine shRNA 
lentiviral library targeting 250 genes implicated in the communication between cancer 
cells and the microenvironment, which was used to transduce two murine cell lines: 
Lewis Lung carcinoma (LLC) and CMT167 cells. Following puromycin selection of cells 
harboring incorporated shRNA’s of interest, populations were expanded and designated 
for in vitro versus in vivo replication and growth. Selected cells were allocated to either in 
vitro passage vs direct in vivo injection into the lungs of 18 week-old syngeneic C57BL6 
mice. After 4 weeks, cells were harvested and gDNA was isolated. Sequencing and 
quantitation of shRNA was performed using an Illumina deep-sequencing platform. Both 
raw and normalized read counts were assessed and analyzed to determine the relative 
representation of a particular shRNA within an in vitro or in vivo sample. Following quality 
control assessments which demonstrated adequate read count numbers per sample, and 
appropriate correlation of sample similarity per groups, direct comparisons between in 
vitro and in vivo samples were performed. Results: Multiple gene candidates were identified 
and largely reproducible via either rank analysis, mean, or t-test analyses. Candidate 
genes included multiple chemokines, and their receptors, matrix proteases, complement 
factors, and growth factor receptors. Conclusion: These results suggest a list of genes 
that are both intriguing and diverse, pointing toward gene products that would not have 
been previously predicted to influence cancer cell survival and growth through a lung 
cancer cell-autonomous fashion. Furthermore, these genes appear to potentially interact 
with multiple compartments of the tumor microenvironment including the extracellular 
matrix, cytokine milieu, vascular structures (complement factors), and the adaptive 
immune system. Validation of specific gene targets are ongoing through assessment 
of tumor growth comparing murine cell lines transfected with individual shRNA’s of 
interest vs control tumor cells. Furthermore, parallel pooled shRNA synthetic lethal 
screens within selectively adaptive immune-deficient models are currently in progress. 
Keywords: tumor microenvironment, in vivo, synthetic lethal, murine
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P1.04-057 Wnt Signaling Regulates Cancer Stem Cell in Lung Cancer SPC-A1 
Cells Xueyan Zhang1, Yuqing Lou1, Huiming Wang1, Xiaoxuan Zheng1, Qianggang Dong2, 
Jiayuan Sun1, Baohui Han1 1Shanghai Jiaotong Univ. Affiliated Shanghai Chest Hospital, 
Shanghai/China, 2Shanghaijiaotong University, Shanghai/China
Background: Wnt signaling is invovled in driving cancer stem cells (CSCs) activity in 
a variety of cancers. The aim of this study was to explore the role of Wnt signaling 
in the lung cancer stem cells (LCSCs). Methods: Sphere culture was processed by 
treating human lung adenocarcinoma cell line SPC-A1 with IGF, EGF and FGF-10 to 
obtain the LCSCs. After confirming the stemness by immunoflurescence, functional 
genome screening and RT-PCR were employed to perform pathway analysis. The 
relationship between the identified signaling pathway and stemness gene expression 
was explored by agnoist/antagonist assay. Moreover, the effects on sphere formation, 
cell viability and colony formation by different signaling molecule inhibitors were also 
analyzed. Results: The results showed that LCSCs were successfully generated and 
the phenotype characterization was confirmed by expressing pluripotent stem cell 
markers Nanog and Oct 4, and lung distal epithelial markers CCSP and SP-C. The 
involvement of Wnt pathway in LCSCs was confirmed by functional genome screening 
and verified by RT-PCR. The expression of Wnt signaling components were related with 
the expression of the Nanog and Oct 4. Anti-cancer effects could be exerted by using 
different signaling molecule inhibitors targeting Wnt signaling pathway. Conclusion: In 
conclusion, Wnt signaling pathway is involved in the stemness regulation of LCSCs 
and could be considered as a potential therapeutic target in the lung adenocarcinoma. 
Keywords: Lung cancer stem cells, Wnt signaling pathway, sphere culture, Functional 
genome screening
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P1.04-058 Inhibition of ERK1/2 Down-Regulates the Hippo/YAP Signaling 
Pathway in Human NSCLC Cells Bin You1, Yi-Lin Yang2, Zhidong Xu2, Yuyuan Dai2, Shu 
Liu2, Jian-Hua Mao2, Osamu Testu3, Hui Li1, David Jablons2, Liang You2 1Thoracic Surgery, 
Beijing Chao-Yang Hospital, Beijing/China, 2Surgery, UCSF, San Francisco/CA/United States 
of America, 3UCSF, San Francisco/CA/United States of America
Background: Alterations of the EGFR/ERK and Hippo/YAP pathway have been found 
in non-small cell lung cancer (NSCLC). Methods: Luciferase reporter and downstream 
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P1.04-054 Mitochondrial Status in Peripheral Blood Mononuclear Cells in 
Relation to Cognitive Impairment in Lung Cancer Patients Rodryg Ramlau1, 
Slawomir Michalak2, Joanna Rybacka-Mossakowska2, Joanna Gazdulska3, Iwona 
Golda-Gocka4 1Department of Oncology, Poznan University of Medical Sciences, Poznan/
Poland, 2Department of Neurochemistry and Neuropathology, Poznan University of Medical 
Sciences, Poznan/Poland, 3Oncology Center, Poznan University of Medical Sciences, 
Poznan/Poland, 4Lung Diseases Center, Poznan University of Medical Sciences, Poznan/
Poland
Background: Mitochondrial dysfunction is observed not only in lung cancer cel, but 
can develop in peripheral tissues. Peripheral blood mononuclear cells (PBMC) represent 
an available population of cells that can be used for the studies on remote effects of 
lung cancer. NADH dehydrogenase (ubiquinone) Fe-S protein 1 (Ndufs1) is located at 
the inner mitochondrial and transfers electrons from NADH to the respiratory system. 
Mitochondrially encoded cytochrome c oxidase I (MT-CO1) is involved in the coupling 
between O2 reduction and proton pumping. The changes in both key components of 
respiratory system reflect mitochodrial status. On the other hand the impairment of 
mitochondrial function may be crucial among pathomechanisms leading to neurological 
deficits. The aim of the study was evaluate mitochondrial status in PBMC in relation 
to the cognition in lung cancer patients. Methods: The study included 80 (24 females 
and 56 males, aged 61.5±6.7 years) consecutive lung cancer patients (5 small-cell 
lung cancer, 75 non-small cell lung cancer) hospitalized in Clinical Oncology with The 
Sub-department of Diurnal Chemotherapy Wielkopolska Center of Pulmonology and 
Thoracosurgery of Eugenia and Janusz Zeyland and Chair and Clinic of Oncology. PBMC 
were isolated by density gradient centrifugation. The expression Ndufs1 a marker of 
mitochondrial complex I and MTCO1 a marker of complex IV in PBMC was evaluated 
by means of ELISA and expressed in pg per mg of protein. Neurological examination, 
MiniMental State Examination (MMSE), Trail Making Test (TMT) A and B, and Hamilton 
scale were performed at baseline (time of lung cancer diagnosis) and after 6 months. 
Patients serum was tested for the presence of onconeuronal antibodies with indirect 
immunofluorescence as a screening and Line blot as confirmation test. Results: Ndufs 
1 expression in PBMC was lower in patient with peripheral nervous system involvement 
(0.00; 0.0-3.6218 ; median; minimum-maximum) than in subjects without neurological 
deficit (0.0; 0.0-8.61; median; minimum-maximum; P= 0,024). Up-regulated expression 
of Ndufs 1 in PBMC is associated with worse TMT- A (13.61±3.13s) than in patients 
with down-regulated complex I marker (8.60±4.51s; P=0.003). Similarly TMT- B 
results were worse in patients with higher Ndufs 1 expression (162.48±46.40s) than 
in cases with inhibited Ndufs1 (124.78±51.77s; P<0,05). Ndufs1 expression correlated 
negatively with MMSE 6 months after lung cancer diagnosis (Kendall tau =-0.310; 
P=0.0236), and positively with Hamilton scale score after 6 months (Kendall tau=0.288; 
P=0.0428), TMT-A (Kendall tau=0.301; P=0.0001) and TMT-B (Kendall tau=0.199; 
P=0.0120) at baseline. Up-regulated expression of MTCO1 was associated with worse 
TMT-A results (11.05±5.81s) compared to down-regulated marker of mitochondrial 
complex IV (8.52±4.14s; P=0.048). MTCO1 expression correlated positively with 
TMT-A results (Kendall tau=0.167; P=0.0344) at baseline. In 12 patients onconeuronal 
antibodies were identified (Ma/Ta, Yo, Ri). No differences in Ndufs1 and MTCO1 
expression were found between patients with onconeronal antibodies and seronegative 
subjects. Conclusion: Up-regulation of mitochondrial complex I and IV in PBMC of 
lung cancer patients is associated with cognitive decline. Stimulation of mitochondria 
status in PBMC may indicate cytotoxic response leading to cognitive impairement. 
Keywords: peripheral blood mononuclear cells, mitochondria, cognition, lung cancer
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P1.04-055 Fibroblast-Dependent Cancer Cell Invasion: Analysis of Cancer-
Associated Fibroblasts That Remodel the Extracellular Matrix Shinya Neri1, 
Genichio Ishii2, Hiroshi Date1, Atsushi Ochiai2 1Thoracic Surgery, Kyoto University, Graduate 
School of Medicine, Kyoto/Japan, 2Pathology, Resarch Center of Innovative Oncology, 
National Cancer Center Hospital East, Kashiwa, Chiba/Japan
Background: Cancer-associated fibroblasts (CAFs) communicate with cancer cells and play 
important roles in cancer invasion. We previously reported that local invasion of cancer cells was 
frequently observed in lung adenocarcinoma patients with podoplanin(PDPN)-expressing CAFs. 
However, the underlying mechanisms of this phenomenon have remained unclear. Methods: We 
established a novel collagen invasion assay model in which cancer cells and CAFs were co-
cultured; we analyzed the mechanisms governing how cancer cell invasion was promoted by 
PDPN(+)CAFs. Results: By observing the dynamic movement of both CAFs and cancer cells in 
the collagen matrix, we found that PDPN(+)CAFs invaded the matrix to a greater extent, with 
more cancer cells invading within the “tracks” created by the CAFs, compared with control 
CAFs. The knockdown of PDPN in CAFs decreased the invasion of both the CAFs and the cancer 
cells. PDPN(+)CAFs displayed a higher RhoA activity, and treatment with a ROCK inhibitor 
cancelled the increased invasion ability of PDPN(+)CAFs and subsequently decreased the 
number of invaded cancer cells. After intravenous injection in the mouse tail vein, PDPN(+)CAFs 
invaded and promoted cancer cell invasion into the lung parenchyma, compared with control 
CAFs. Among the patients with lung adenocarcinoma, we observed some cases with PDPN(+)
CAFs at the invasive front of the tumor. These cases predominantly exhibited pleural invasion 
of cancer cells, known as pathological invasiveness. Conclusion: Our results indicated that 
PDPN(+)CAFs were tumor-promoting CAFs that lead and enhance the local invasion of cancer 
cells, suggesting that the invasion activity of CAFs themselves could be rate-determining for 
cancer cell invasion. For analysis of fibroblast-dependent cancer cell invasion, we established 
single-cell derived clones from primarily cultured CAFs and conduct further investigation. 
Keywords: tumor microenvironment, cancer-associated fibroblasts, lung cancer, cancer 
invasion
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presence of druggable driver mutations. In order to search for new putative targets of 
therapy, we seek to identify pathways involved different subgroups of patients and in 
patients with early relapse. Methods: A total of 190 patients undergoing surgery for lung 
cancer were included in the study (154 EGFR positive, 23 EGFR negative, 170 smokers 
and 20 non-smokers). Lung cancer tissue and clinical information was available for all 
patients and normal lung tissue was available for 30 of the patients. Whole genome 
expression array analysis (Agilent) was performed using mRNA isolated from all samples 
and DNA-methylation was analysed for 168 tumours and 21 matched normal lung tissue 
samples. R was used for statistical analyses; annHeatmap (from Heatplus) for hierarchical 
clustering, limma to identify differentially expressed genes, SPIA for pathway analysis 
and canonical correlation of methylation and mRNA-expression was performed with 
the CCA function from the PMA package. Pathways with an FDR<0.1 were considered 
significant. DAVID was used for gene ontology analysis. Results: Based on correlation 
of mRNA and methylation, different pathways were identified as predominant in specific 
subgroups of lung adenocarcinomas. Preliminary results indicate that genes involved in 
the KEGG-pathways cell cycle are more highly expressed in EGFR positive than in EGFR 
negative tumours in smokers. In the EGFR-negative tumours, several pathways are up-
regulated: Oocyte meiosis, progesterone-mediated oocyte maturation, HTLV-1 infection, p53 
signalling pathway and small cell lung cancer. For non-smoking patients, four pathways 
were up-regulated in EGFR-positive tumours: ECM-receptor interaction, TGF-beta signalling 
pathway, bile secretion and cocaine addiction. There were no pathways up-regulated in 
EGFR-negative compared with EGFR-positive never-smokers. This may partly be due to 
small numbers. Similarly, pathways dominating the tumours of patients with early relapse 
will be identified. Genes whose expression and methylation status were correlated 
were identified within smokers and non-smokers separately. Conclusion: Based 
on correlation between mRNA and methylation, specific pathways were identified 
activated in subgroups of lung adenocarcinomas. There are significant differences 
between ever-smokers and never-smokers. Survival analyses are ongoing. 
Keywords: methylation, Adenocarcinoma, Pathway analysis, Gene Expression
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P1.04-061 Comparison of MET Expression in Primary and Corresponding 
Nodal and Distant Metastases in Non-Small Cell Lung Cancer (NSCLC) 
Babak Tamjid1, Paul Mitchell2, Thomas John3, Simon Knight4, Adrienne Morey5, 
Carmel Murone6, Khashayar Asadi7 1Medical Oncology, Austin Health, Heidelberg/
VIC/Australia, 2Austin Health, Melbourne/ACT/Australia, 3Olivia Newton-John Cancer 
Centre, Austin Health, Melbourne/VIC/Australia, 4Surgery, Austin Health, Heidelberg/
Australia, 5Pathology, St Vincents Pathology, Sydney/ACT/Australia, 6Olivia Newton-John, 
Austin Health, Heidelberg/VIC/Australia, 7Pathology, Austin Health, Heidelberg/Australia
Background: Hepatocyte Growth Factor and its corresponding receptor MET are potential 
therapeutic targets for NSCLC. In NSCLC MET is over expressed, activated and mutated 
and is involved in resistance to tyrosine kinase inhibitors. A high proportion of primary 
NSCLC cases show elevated MET expression on immunohistochemistry (IHC), however, it 
is not clear whether expression changes during the metastatic process. We investigated 
paired NSCLC tumour samples to determine whether MET receptor expression differs in 
the primary and its corresponding lymph node and distant metastases. Methods: Tissue 
Microarrays (TMAs) were constructed using 1mm cores of primary and metastatic 
matched NSCLC archival paraffin tissues in triplicate. For IHC, TMAs were stained with 
the SP44 clone (Ventana) and an H-score calculated based on the percentage of cells 
stained and their intensity with a minimum of 0 and maximum of 300. The mean of 
values from multiple cores was calculated. Two independent scorers assessed the 
tissues. Discordance was defined as an H-score difference of greater than 100 between 
the primary tumour and its metastasis. Results: 61 patients with primary and matched 
distant metastasis were included in the main analysis with 38 (62%) male and brain the 
most common site of metastasis (27/61, 44%). The histology was adenocarcinoma in 26 
patients, squamous cell in 21 and large cell, undifferentiated or mixed in 14. The median 
H-score was 100 in primary tissue and 120 in metastatic tissue. Brain secondaries showed 
the highest median H-score (140) compared with other metastatic sites (105). MET 
concordance was present in 50/61 cases (82%). MET discordance was found in 11/61 
tumours including 6/26 (23%) of adenocarcinomas, 2/21 (10%) of squamous carcinomas 
and 3/14 (21%) of mixed or large cell tumours. Discordant elevation in metastases was 
present in 6/61 (10 %) and reduction in 5/61 (8%). MET FISH data was available for 
54/61 of primary tissues and 60/61 of metastasis. MET was amplified only in 2/61(3%) 
cases, seen in both primary and secondary tissues, associated with strong positivity on 
IHC. An additional 75 patients had matched primary and lymph node metastasis MET IHC 
and FISH data available. High rate of concordance, 66/75 (88%) also was present in this 
nodal cohort. The median H-score was 100 in primary tissue and 117 in nodal metastatic, 
similar to the main primary and distant metastatic group. MET discordance between 
primary and nodal secondary was found only in 9/75 (12%) with discordant elevation in 
4/75 (5%) and discordant reduction in 5/75 (7%). MET FISH true amplification was seen in 
2 paired specimens and one primary with clonal amplification which was non-amplified in 
the lymph node metastasis. Conclusion: In this cohort of paired biopsies, increased MET 
expression in the primary was retained in a high proportion of distant and lymph node 
metastases. These data indicate that MET expression in metastases can be predicted by 
expression in the primary and further suggests that treatment decisions in the metastatic 
setting can be based on MET IHC results of archival primary or lymph node tumour. 
Keywords: NSCLC, MET expression, Lymph node and distant metastasis, Concordance
gene expression assays were used to test hippo pathway activity. Results: Herein, we 
show that ERK1 and ERK2 have an effect on the Hippo/YAP pathway in human NSCLC 
cells. Firstly, inhibition of ERK1/2 by siRNA or small-molecular inhibitors decreased the 
YAP protein level, the reporter activity of the Hippo pathway, and the mRNA levels of 
the Hippo downstream genes, CTGF, Gli2, and BIRC5. Secondly, degradation of YAP 
protein was accelerated after ERK1/2 depletion in NSCLC cell lines, in which YAP mRNA 
level was not decreased. Thirdly, forced over-expression of the ERK2 gene rescued the 
YAP protein level and Hippo reporter activity after siRNA knockdown targeting 3’UTR 
of the ERK2 gene in NSCLC cells. Fourthly, depletion of ERK1/2 reduced the migration 
and invasion of NSCLC cells. Combined depletion of ERK1/2 had a greater effect on 
cell migration than depletion of either one separately. Finally, the MEK1/2 inhibitor 
Trametinib decreased YAP protein level and transcriptional activity of the Hippo pathway 
in NSCLC cell lines. Conclusion: Our results suggest that ERK1/2 inhibition participates 
in reducing YAP protein level, which in turn down-regulates expression of the downstream 
genes of the Hippo pathway to suppress migration and invasion of NSCLC cells. 
Keywords: yes-associated protein, non-small cell lung cancer, extracellular signal 
regulated kinases, Hippo pathway
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P1.04-059 The Role of Histone Methyltransferases G9a/Glp in Mouse Lung 
Tumor Propagating Cells and Lung Stem Cells Samuel Rowbotham1, Carla Kim2 
1Hematolgy/Oncology, Boston Children’S Hospital, Boston/United States of 
America, 2Hematolgy/Oncology, Boston Children’S Hospital, Boston/MA/United States of 
America
Background: Proper epigenetic control of transcription is essential for stem 
cell homeostasis and is frequently disrupted in cancer, but this has not been well 
investigated in lung biology or lung disease. We have previously demonstrated that the 
stem cell marker Sca-1 enriches for mouse bronchioalveolar stem cells (BASCs) and 
lung adenocarcinoma cells with enhanced metastatic and tumor propagation abilities 
(TPCs). Methods: I performed a small chemical library screen using a Kras; p53-flox 
driven mouse lung adenocarcinoma cell line, CK1750 with high expression of the stem 
cell markers Sca-1 and CD24. Chemically treated cels were seperated and screened 
by FACS analysis for changes in the surface antigens Sca-1 and CD24. I treated Sca-1 
low expressing mouse lung adenocarcinoma cell lines TM1 and TnM2 with either 1 uM 
UNC0638 or DMSO for 4 days. 100,000 cells per mouse were injected intravenously. 
After 3-4 Weeks mice were sacrificed and lungs and other organs were analyzed for 
tumor formation. Treated cells were also plated in 3D organoid culture and grown for 
14 days. After this matrigel plugs were fixed and counted for organoid formation. I 
isolated BASCs and AT2 cells from 6 week old mice by FACS and plated cells in 3D 
organoid co-culture. Cells were grown with either 250 nM UNC0638 or DMSO for 21 
days. At this point plugs were fixed, sectioned and organoids were stained for lung 
lineage markers SPC and CC10 and organoids expressing each were scored. Results: A 
FACS screen of adenocarcinoma cell lines revealed that UNC0638, an inhibitor of 
H3K9me1/2 methyltransferases G9a and Glp enriches for high Sca-1 expressing, TPC-
like cells. Gene expression analysis of primary adenocarcinomas shows that G9a/Glp are 
down-regulated in Sca-1+ metastatic TPCs. Furthermore, analysis of 400+ early stage 
patient lung adenocarcinomas reveals that low G9a expression and high expression 
of KDM3A, an H3K9me1/2 demethylase, significantly correlate with worse survival 
(P=0.008, P=0.002). This implies that dysregulation of H3K9me1/2 is also a significant 
factor in human disease. Interestingly, G9a/Glp inhibition of adenocarcinoma cells prior 
to transplantation increases Sca-1+ cells but does not increase recipient lung tumor 
burden. Instead, significantly more tumors are found in non-lung locations (58% vs. 13%, 
P=0.02). Whilst inhibition does not affect cell proliferation or migration, colony forming 
efficiency in 3D organoid culture is significantly increased (1.1% vs 0.3%, P=0.04). 
This suggests that altered stem-like properties such as tumor initiation may underlie 
the more tumorigenic phenotypes of H3K9me1/2 low, Sca-1+ TPCs. H3K9me1/2 
also regulates the behavior of lung stem cells. G9a/Glp inhibition of BASCs or alveolar 
type 2 cells in 3D co-culture assays increases both Sca-1+ cells and undifferentiated 
organoids, and significantly decreases alveolar-lineage organoids (P<0.0005). 
BASC cultures also show increases in bronchiolar-lineage organoids (P<0.0005), 
implying that cell fate decisions may regulated by H3K9me1/2. Conclusion: These 
findings suggest that common mechanisms of epigenetic regulation exist between 
mouse lung stem cells and lung TPCs. Determining the precise mechanisms of this 
regulation will be important for our understanding of lung biology and disease, with 
potential implications for the diagnosis and treatment of human adenocarcinoma. 
Keywords: stem cells, epigenetics
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P1.04-060 Pathways Involved in Lung Adenocarcinomas, - Integrated Analyses 
on Methylation and mRNA Data Vilde D. Haakensen1, Maria M. Bjaanæs1, Liliana 
Gregers2, Ann R. Halvorsen1, Lars Jørgensen3, Steinar Solberg3, Alvis Brazma2, Odd 
Terje Brustugun4, Åslaug Helland5 1Institute for Cancer Research, Oslo University Hospital, 
Oslo/Norway, 2Embl-Ebi, Hinxton/United Kingdom, 3Department of Cardiothoracic Surgery, 
Oslo University Hospital-Rikshospitalet, Oslo/Norway, 4Oncology, Oslo University Hosital,The 
Norwegian Radium Hospital, Oslo/Norwa, Oslo/Norway, 5Department of Oncology, The 
Norwegian Radium Hospital, Oslo/Norwa, Oslo/Norway
Background: Lung cancer is one of the biggest cancer killers in the world. Despite 
certain recent advances, mortality is still high. Targeted therapy has increased the 
time to death for metastastic lung cancer, but such therapy is not available for all lung 
cancer patients. Targeted therapy is more often available for never smokers, due to 
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inflammatory stimulus as EMT “memory.” Further studies showed that fra-1 is only 
required to establish but not to maintain EMT memory. Chemical inhibition of a variety of 
enzymes involved in histone modifications and DNA methylation indicates the repression 
of E-cadherin is mediated by different mechanisms depending on the duration of IL-1β 
exposure. H3K27Me3 and histone acetylation mediate E-cadherin repression during 
acute EMT but DNA methylation is responsible for the downregulation of E-cadherin in 
EMT memory. In fact, we have found increased CpG island methylation in the E-cadherin 
promoter region in EMT memory. In vitro functional studies further showed that EMT 
memory enables cancer cells to enhance their motility but gradually regain proliferative 
advantage. Conclusion: We conclude that lung cancer cells utilize distinct mechanisms 
for EMT in response to acute and chronic inflammation. We also demonstrate that dynamic 
alteration of histone modification and DNA methylation can lead to prolonged but reversible 
EMT, subsequently creating a time window for cancer cells to migrate to distant organs 
and eventually undergo mesenchymal-epithelial transition to form macro-metastases. 
Keywords: EMT memory, epigenetics, IL-1 beta, Acute and Chronic inflammation
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P1.04-064 2’-Hydroxyflavanone Inhibits Lung Cancer Growth by Inhibiting 
Tumor Cell Proliferation and Angiogenesis David Berz1, Sharad Singhal2, Jotsana 
Singhal3, Sushma Yadav3, Sanjay Awasthi1 1Research/Oncology, City of Hope, Duarte/
CA/United States of America, 2Research, City of Hope, Duarte/AL/United States of 
America, 3Research/Oncology, City of Hope, Duarte/United States of America
Background: Epidemiologic studies suggest that citrus fruit consumption reduces 
cancer risk. We have previously shown that 2-hydroxyflavanone (2HF), a naturally 
occurring compound in citrus fruits, exerts antineoplastic effects in-vitro and in-vivo 
against renal cell carcinoma in a manner dependent on VHL function and expression 
of glutathione S-transferase p (GSTP). GSTP is a stress- and xenobiotic-defense 
protein that catalyzes the first step committed step of the mercapturic acid pathway 
(MPy). Methods: We performed mining of molecular databases, including the TCGA. 
Then, we conducted cytotoxicity assays, followed by signaling studies. Finally xenograft 
experiments, using nu/nu athymic nude mice were performed. Results: 2HF inhibited 
non-small and small cell lung cancer cell line growth in-vitro. Reduced CDK4 and cyclin 
B1 levels were correlated with G2/M arrest. Apoptosis was accompanied by Bcl2 down-
regulation and Bax upregulation. Inhibition of PI3K signaling was evident from reduction 
in AKT and p70S6K phosphorylation. Reduction of vimentin and fibronectin and increase 
in E-cadherin indicated inhibition of epithelial-mesenchymal transition. Remarkably, 
2HF reduced the expression of RLIP76/RALBP1, a rate-limiting glutathione-conjugate/
multidrug transporter of the MPy. 2HF also inhibited the transport activity of RLIP76. 
Dose-dependent 2HF cytotoxicity was enhanced by antibodies to RLIP76. Oral dosing of 
2HF resulted in 3-5 mM serum concentrations and inhibited the growth of H1618 and H358 
NSCLC cell line xenografts in nu/nu athymic nude mice. Residual tumors had reduced 
Ki67 and CD31 staining, indicating inhibited proliferation and angiogenesis. Higher MPy 
expression in lung cancer was evident from increased RLIP expression in human lung 
cancer tissues, and analyses of the TCGA database showed that RLIP76 expression was 
inversely correlated with survival in lung adenocarcinoma. Conclusion: Taken together, 
these studies demonstrate antineoplastic activity of 2HF against lung cancer cell 
lines in-vitro and in-vivo through a novel mechanism that simultaneously causes down-
regulation of MaP, stress-signaling, EMT and angiogenesis. Excellent oral absorption 
of 2HF indicates its suitability for therapy and possibly prevention of lung cancer. 
Keywords: stress signaling, Rlip-76, lung cancer, 2-HF
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P1.04-065 Cyclin-Dependent kinase11 (CDK11) Is Crucial for Growth of Lung 
Cancer Cells Tomohiko Kakumu1, Mitsuo Sato1, Toshio Kato1, Naoyuki Yogo1, Tetsunari 
Hase1, Masahiro Morise1, Masashi Kondo1, Yoshitaka Sekido2, Yoshinori Hasegawa1 
1Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya/
Japan, 2Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya/Japan
Background: Cyclin dependent kinases (CDKs) are protein kinases that regulate cell 
growth and proliferation in cells. CDK11 belongs to transcriptional subfamilies of CDKs 
and has been reported to be crucial for survival of sarcoma and breast cancer cells. To 
examine its roles in lung cancer cells, we investigated the effect of CDK11 knockdown 
on non-small cell lung cancer (NSCLC) cell lines. Methods: 17 NSCLC cell lines were 
used for expression analysis of CDK11. Among them, we used three lung cancer cell 
lines, H460, H1299 and H358 for functional analysis. Synthetic siRNAs were utilized 
to knockdown CDK11. mRNA and protein levels of CDK11 were evaluated by real-time 
PCR and western blotting, respectively. Changes in growth were examined by WST-1 
proliferation assay and liquid and soft agar colony formation assays. Cell cycle and 
apoptosis were analyzed by FACS with propidium iodide staining. Results: Western blot 
analysis revealed that all of the 17 lung cancer cell lines expressed CDK11 mRNA and 
protein and that compared to a normal cell line, H460 expressed CDK11 at lower levels 
but H1299 and H358 expressed CDK11 at higher levels. CDK11 knockdown suppressed 
proliferation and anchorage-dependent and independent clonal growth in H460 and 
H1299 cell lines but not in H358. Induction of apoptosis was seen in H460 but not in 
the others. Conclusion: CDK11 knockdown suppressed proliferation and clonogenic 
growth in H460 and H1299 cells, and induced apoptosis in H460. These results 
suggest that inhibiting CDK11 may be an attractive target for the treatment of NSCLC. 
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P1.04-062 Phagocytic Behaviour in Lung Adenocarcinoma Cells: Clinical 
Implications and Cellular Mechanisms Hannah Mackay1, David Moore2, Patricia 
Muller3, John Le Quesne3 1Leicester University, Leicester/United Kingdom, 2University 
Hospitals Leicester NHS Trust, Leicester/United Kingdom, 3Hodgkin Building, Mrc Toxicology 
Unit, Leicester/United Kingdom
Background: Pulmonary adenocarcinoma is the commonest and the most histologically 
diverse form of lung cancer. ‘Cell-in-cell’ structures are frequently seen as incidental 
findings when making diagnoses of lung cancer. These structures arise when one viable 
tumour cell is enveloped within a vacuole within another viable tumour cell. They have been 
identified in a number of solid tumours including breast, lung, endometrial, pancreatic, 
melanoma and squamous cell carcinomas. The repeated occurrence of the phenomenon 
in such a range of tumour types suggests that it may represent a process that confers a 
selective advantage to the malignant clone (or subclone). Possible mechanisms for this 
include the acquisition of nutrition by the host cell, horizontal gene transfer, or simple 
clonal extinction of neighbouring subclones. The biological significance and mechanisms 
of action still all remain largely unknown. We set out to investigate these. Methods: 100 
recent consecutive cases of lung adenocarcinoma from our surgical centre were de-
archived and examined. For each, high-resolution digital images of 10 high-power field 
(hpf) equivalents were examined. A scoring scheme for both cell-in-cell appearances and 
multinucleated cells was formulated and used to score the tumours. Independently from 
this they were classified by histological pattern and graded for numerous architectural 
and cytological characteristics. Results were collated and statistical tests carried out. In 
vitro experiments using cocultures of H1299 lung cancer cells transfected to express 
either GFP (Green Fluorescent Protein) or RFP (Red Fluorescent Protein) were also 
conducted. These cells were seeded on a selection of coated surfaces including gelatin, 
fibronectin and collagen to mimic the extracellular matrix proteins. Results: Cell-in-cell 
structures are frequently observed in primary lung adenocarcinomas. 15% of cases have 
frequent occurrences (≥0.8/hpf). Cell-in-cell structure frequently is strongly associated 
with multinucleation (P<0.0001). In addition, there is a strong association with cytological 
measures of tumour grade such as mitoses (P<0.0001), necrosis (P 0.015) and solid 
pattern (P=0.002). In cell co-culture experiments we are able to reproduce the same 
appearances, and to visualize cultured lung adenocarcinoma cells engulfing one another. 
The process is greatly enhanced by the presence of extracellular fibronectin or collagen, 
but gelatin has a negative effect. This suggests integrins may be involved in the process, 
as collagen and fibronectin are integrin activators, while gelatin is known for its lack 
of integrin activation. Conclusion: Lung adenocarcinomas frequently contain numerous 
cell-in-cell structures. This is related to the solid phenotype; this implies that engulfment 
requires full three-dimensional movement which is impossible in two-dimensional lepidic/
acinar/papillary conformations. It is associated with high cytological grade, and may be a 
useful component of future grading systems. The association with multinuclearity implies 
that cell engulfment may be the mechanism that leads to the formation of multinucleated 
giant cells. The same appearances can be reproduced in cell culture systems, where they 
appear to be dependent upon the presence of signaling from the extracellular matrix. 
Keywords: Cell-in-cell, Adenocarcinoma
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P1.04-063 Exposure to IL-1β Leads to EMT via Distinct Mechanisms in Acute 
and Chronic Inflammation in NSCLC Rui Li1, Stephanie L. Ong2, Kostyantyn Krysan3, 
Tonya Walser3, Zhe Jing3, Steven M. Dubinett3 1Molecular and Medical Pharmacology, 
UCLA, Los Angeles/CA/United States of America, 2Ecology and Evolutionary Biology, UCLA, 
Los Angeles/CA/United States of America, 3Medicine, David Geffen School of Medicine at 
UCLA, Los Angeles/CA/United States of America
Background: Dysregulated inflammation is associated with the development 
and progression of lung cancer. Pulmonary diseases characterized by increased 
inflammation, including emphysema and pulmonary fibrosis, are strongly related to 
heightened risk of lung cancer. Moreover, lung cancer patients with increased levels of 
inflammatory mediators or inflammatory cells have poor outcomes. It has been shown 
that dysregulated inflammatory cytokines in the tumor microenvironment can promote 
cancer metastasis. However, the mechanisms of this effect in lung cancer have not been 
fully understood. Interleukin 1β (IL-1β), a key pro-inflammatory cytokine, is associated 
with tumor aggressiveness and poor patient outcomes in NSCLC. Herein, we report 
that treatment of IL-1β leads to epithelial-to-mesenchymal transition (EMT) in NSCLC 
cell lines. Delineation of the underlying molecular pathway(s) may potentiate novel 
therapeutic strategies. Methods: We treated NSCLC cell lines with IL-1β acutely (3 days) 
and chronically (21 days) in vitro and identified EMT mediators using RNA interference 
and chemical inhibitors. Histone modifications and DNA methylation were analyzed with 
chemical inhibitors, ChIPassays and methylation-specific PCR. We utilized transwell 
migration, cell proliferation and anchorage-independent cell growth assays to evaluate 
the functional phenotypes Results: We found that following acute IL-1β exposure (within 
7 days), the activator protein 1 (AP-1) transcription factor components, including Fra-1 
and c-jun, mediate EMT. AP-1 functions downstream of ERK1/2 and JNK signaling and 
resides upstream of the transcription factors Slug and Zeb2. Importantly, inhibition of 
slug, zeb2, fra-1 or ERK1/2 and JNK signaling by RNA interference or chemical inhibitor 
is sufficient to abolish IL-1β-induced E-cadherin repression. This occurs concomitantly 
with decreased cell migration and invasion. Surprisingly, following prolonged IL-1β 
exposure (21 days), cells do not revert back to the epithelial state despite inhibition of 
these acute EMT mediators. We also found that following withdrawal of IL-1β after twenty 
one-day exposure, the treated cells are able to maintain their mesenchymal phenotype 
for more than 30 days before reverting back to an epithelial phenotype. We refer to 
this prolonged but reversible EMT program that persists in the absence of the original 
S473Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
 
Conclusion: Cells with high mitochondrial capacity may tolerate 
glucose starvation/ blockade, while a limited mitochondrial reserve 
exposes the cells to higher sensitivity to glycolysis stress. This might 
suggest a potential therapeutic avenue with a companion predictive test. 
Keywords: mitochondria, lung cancer, glycolysis
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-068 Protein Tyrosine Kinase 7 Plays a Tumor Suppressor Role by 
Inhibiting ERK and Akt Phosphorylation in Lung Cancer Haewon Lee1, Junhye 
Kwon2, Moonchul Kang1, Hyungjun Yoo3, Jae Soo Koh4 1Thoracic Surgery, Korea Cancer 
Center Hospital, Seoul/Korea, 2Translational Research, Korea Cancer Center Hospital, Seoul/
Korea, 3Radio-Oncology, Korea Cancer Center Hospital, Seoul/Korea, 4Pathology, Korea 
Cancer Center Hospital, Seoul/Korea
Background: Protein tyrosine kinase 7 (PTK7) is a catalytically inactive receptor 
tyrosine kinase that is also known as colon carcinoma kinase-4 (CCK-4). Recent reports 
have shown that PTK7 plays an important role in carcinogenesis, and it is known to 
be up-regulated in gastric cancer, colon cancer, esophageal cancer, and liposarcoma. 
However, we found that PTK7 expression was down-regulated at the mRNA as well as 
protein levels in human lung squamous cell carcinoma (SCC), unlike in other tumors. 
In this study, we attempted to explore the role of PTK7 in lung cancer Methods: We 
analyzed expression of PTK7 by RT-PCR and western blot analysis using tumor and 
normal lung tissue from 10 SCC patients. To explore the functional role of PTK7, the 
expression of PTK7 in SCC cells was examined using empty vector and PTK7 gene 
inserted vector. Results: We found that PTK7 expression was down-regulated at the 
mRNA as well as protein levels in human lung squamous cell carcinoma (SCC). Upon 
investigating the functional role of PTK7 in SCC, we found that overexpression of PTK7 
in SCC cells resulted in inhibition of cell proliferation, invasion, and migration. Further, 
we confi rmed that these phenotypic changes are associated with the activation of 
Akt and ERK. Conclusion: These observations may indicate a role for PTK7 in cell 
proliferation, wound healing and invasion via regulating Akt and Erk activation. Our 
fi ndings suggest that PTK7 has different oncogenic roles in organs and target tumors. 
Keywords: biomarker, PTK7, lung cancer, Squamous cell carcinoma
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P1.04-069 LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small 
Cell Lung Cancer Plasticity and Therapeutic Response Fuming Li1, Xiangkun Han1, 
Fei Li1, Rui Wang2, Yuan Li2, Kowk-Kin Wong3, Haiquan Chen2, Hongbin Ji1 1Shanghai 
Institutes for Biological Sciences, Shanghai/China, 2Department of Thoracic Surgery, Fudan 
University Shanghai Cancer Center, Shanghai/China, 3Department of Medicine, Harvard 
Medical School, Boston, Boston/AL/United States of America
Background: LKB1 regulates both cell growth and energy metabolism. It remains 
unclear how LKB1 inactivation coordinates tumor progression with metabolic adaptation 
in non-small cell lung cancer (NSCLC). Methods: Mouse Colony, Mouse Treatment 
and Tumor Analyses Statistical Analysis Hematoxylin and Eosin (HE) Staining and 
Immunohistochemistry (IHC) Bioinformatics Analysis Cell Lines and In vitro Assays ShRNA, 
Plasmids, Lentivirus Production and Infection Analysis of Human Lung ADC and Ad-SCC 
Specimens Western Blotting Enzymatic Activity Assays and Liquid Chromatography-
tandem Mass Spectrometry (LC-MS) Analysis Oil red O Staining Reverse Transcription 
and Quantitative PCR Analysis Results:Here in KRAS/LKB1 (KL) mouse model, we 
reveal differential reactive oxygen species (ROS) levels in lung adenocarcinoma (ADC) 
and squamous cell carcinoma (SCC). ROS can modulate ADC-to-SCC transdifferentiation 
(AST). Further, pentose phosphate pathway deregulation and impaired fatty acid 
oxidation collectively contribute to the redox imbalance and functionally affect AST. 
Similar tumor and redox heterogeneity also exist in human NSCLC with LKB1 inactivation. 
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-066 Site-Selected Chromatin-Immunoprecipitation (ChIP) Analysis by 
Laser Captured Microdissection Shingo Sakashita1, Masafumi Muratani2, Masato 
Sugano3, Tomoki Nakagawa1, Yoshihiko Murata1, Yoko Yano4, Noriyuki Nakano4, Ryota 
Matsuoka4, Taiki Sato4, Akiko Sakata4, Yuko Minami3, Yukio Sato5, Masayuki Noguchi3
1Department of Pathology, Univerysity of Tsukuba Hospital, Tsukuba/Japan, 2Faculty of 
Medicine, Department of Genome Biology, Univerysity of Tsukuba, Tsukuba/Japan, 3Faculty 
of Medicine, Department of Pathology, Univerysity of Tsukuba, Tsukuba/Japan, 4Graduate 
School of Comprehensive Human Science, Department of Pathology, University of Tsukuba, 
Tsukuba/Japan, 5Faculty of Medicine, Department of Thracic Surgery, Univerysity of Tsukuba, 
Tsukuba/Japan
Background: High throughput sequencing methods such as exome sequencing, RNA 
sequencing, Chromatin–immunoprecipitation (ChIP) sequencing are essential tools for 
cancer research. However, these fi ne and delicate analyses contain several methodological 
problems. For example, although tumor mass may be suitable for mutation analysis, 
histological heterogeneity of the tumor tissue causes insuffi cient results especially for 
epigenetic or RNA analyses. Besides, the cancer-associated stromal cells and immune 
cells in the tumor will also affect the results. In this study, we tried ChIP for tiny but pure 
tumor samples which were selected by laser captured microdissection and verifi ed its 
availability for ChIP sequence analysis. Methods: We used a lung adenocarcinoma frozen 
tissue harboring EGFR L858R mutation. After formalin fi xation (1%, 10min), tumor cells, 
stroma cells and immune cells were microdissected separately by LMD4000 (Leica) 
and ChIP was performed to using H3K4me3 anti-body. Then, the quality was confi rmed 
by real-time PCR for CCR7 which is one of the tumor specifi c markers and CD3 which 
is representative T lymphocyte marker. Sanger sequence for EGFR L858R mutation 
was also analyzed for confi rmation that each sample was dissected and extracted 
correctly. Results: Only from the sample of tumor cells, we detected EGFR L858R 
mutation by Sanger sequence but from stromal cells and immune cells, we did not detect 
EGFR mutation. The result showed that we extracted samples correctly. And H3K4me3 
mark at CCR7 gene was detected only from tumor cells and was not detected from the 
other samples. Moreover, H3K4me3 mark at CD3 gene was detected from stroma cells 
and immune cells but not tumor cells. These results indicated that microdissection method 
is useful and necessary method for ChIP analysis. Conclusion: Microdissection can be 
applied for epigenetic analysis like ChIP method. Our results indicated that microdissection 
method is useful for tumor-cell-specifi c epigenome profi ling by ChIP sequencing. 
Keywords: Chromatin–immunoprecipitation, laser micro dissection, Epigenetic
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-067 Mitochondrial Respiration Capacity and Sensitivity to Glycolysis 
Blockade in Lung Cancer Tali Feinberg1, Guy Lass2, Fernanada Cerqueira2, Dovi 
Shlomo2, Maya Ilouze3, Ronen Shavit4, Nir Peled5 1Physiology and Pharmacology, Tel 
Aviv University, Tel-Aviv/Israel, 2Clinical Biochemistry, Ben Gurion University, Beer Sheva/
Israel, 3Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Petach 
Tiqwa/Israel, 4Thoracic Cancer Reasearch and Detection Center, Sheba Medical Center Tel 
Hashomer, Ramat Gan/Israel, 5Rabin Medical Center, Tel Aviv/Israel
Background: One of the metabolic perturbations in cancer cells is the Warburg effect; 
glycolysis is preferred over oxidative phosphorylation (OXPHOS), even in the presence 
of oxygen. The precise mitochondrial alterations that underlie the increased dependence 
of cancer cells on aerobic glycolysis for energy generation may serve as an escape 
mechanism from apoptosis. Here, we aimed to profi le the mitochondrial activity 
in different lung cancer cell lines in reference to their glycolytic activity and to their 
sensitivity to metabolic modifi cations. Methods: The metabolic profi le of A549 and 
H358 cell lines were tested before and after glycolysis blockade (glucose starvation, 
2DG) and mitochondrial induction (FCCP). Glycolysis inhibition and mitochondrial activity 
were assessed by western-blot quantifi cation of key enzymes involved in the glycolysis 
pathway (e.g. Hexokinase I/II, glyceraldehyde-3-phosphate dehydrogenase, pyruvate 
kinase 2) and of mitochondrial coded proteins (e.g. ND1, ATP6 synthase). The oxygen 
consumption rates (OCR) and extra cellular acidifi cation rate (ECAR) were measured 
by XFe24 extracellular fl ux analyzer. Further, mitochondrial index was compared to the 
cells’ sensitivity to glycolysis inhibition. Results: A549 cells were highly affected by 
glucose inhibition/starvation accompanied by ineffective mitochondrial compensation. 
On the other hand, H358 cells recovered completely from glucose starvation through 
mitochondrial hyper-activation (Fig 1); At the basal level (when no material was applied), 
A549 cells that were starved had a decrease of 68% in the ECAR, as compared to 
non-treated cells. Their recovery was limited after glucose injection (23 vs.41 mpH/
min). In comparison, H358 cells had a 43% decrease in their glycolysis rate with a full 
recovery after glucose injection (44-46 mpH/min; pre & post respectively). Mitochondrial 
respiration was very low for A549 cells under starvation, while signifi cantly increased 
in H358 cells (223 vs.143 pmol/min, *Pv<0.0001). Respectively, the expression level 
of mitochondrial coded proteins was higher in the cells that demonstrated higher 
mitochondrial capacity (Fig 2).
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encoding the SWI/SNF complex antagonist with prostate cancer 1, non protein coding, 
gene and the gene UBE2E3 on chromosome 2. At this locus there was no gene-smoking 
correlation in the controls and no evidence for heterogeneity in strength of association 
among the 7 contributing studies. Conclusion: UBE2E3 is the ubiquitin conjugating 
enzyme E3. This gene is overexpressed in a substantial number of lung cancers. 
Further studies to characterize the impact of this variant on lung cancer risk according 
to further variation in smoking behavior and also impacts on function are warranted. 
Keywords: genetic epidemiology, gene environment interaction, smoking behavior, 
population genetics
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P1.04-073 The Role of the Stress-Response to a Lung Cancer Diagnosis in 
Disease Progression Hronn Hardardottir1, Steinn Jonsson2, Tomas Gudbjartsson3, 
Arna Hauksdottir4, Kristbjorn Reynisson5, Heiddis Valdimarsdottir6, Magnus K. 
Magnusson7, Unnur Valdimarsdottir8 1Center of Public Health Sciences, Faculty of 
Medicine, Reykjavík/Iceland, 2Department of Internal Medicine, Landspitali University 
Hospital, Reykjavik/Iceland, 3Department of Cardiothoracic Surgery, Landspítali University 
Hospital, Reykjavik/Iceland, 4Center of Public Health Sciences, Faculty of Medicine, 
University of Iceland, Reykjavík/Iceland, 5Department of Radiology, Landspitali University 
Hospital, Reykjavik/Iceland, 6Department of Psychology, Reykjavik University, Reykjavik/
Iceland, 7Faculty of Medicine, University of Iceland, Reykjavik/Iceland, 8Center of Public 
Health, Faculty of Medicine, University of Iceland, Reykjavik/Iceland
Background: Receiving a cancer diagnosis, particularly of lung cancer, has been 
shown to increase psychological and biological stress responses and the immediate 
risks of extreme adverse health outcomes, such as suicide and cardiovascular deaths. 
Data are scarce on the potential influence of this diagnosis on tumor progression. 
Prior studies lend suggestive evidence for an association of psychobiological 
stress-responses on lung cancer progression. The aim of this study is to improve 
understanding of determinants of the stress-response to a lung cancer diagnosis 
and explore potential role of this response in disease progression and survival. 
Methods: We have initiated a nationwide prospective cohort study of Icelandic lung 
cancer patients with a comprehensive questionnaire and biomarker measures of 
stress, as well as detailed documentation of clinical parameters and disease course. 
Eligible are all individuals diagnosed with lung cancer at Landspitali University Hospital 
in Iceland. The aim is to recruit 300 patients over a three year period between 2015 
and 2017. Patients with clinical or radigraphic changes suggestive of lung cancer are 
referred to our hospital. They go through a diagnostic work-up, leading to a definite lung 
cancer diagnosis and staging during a 24 hour diagnostic course or within few days 
thereafter. Assessment of psychological stress and relevant biomarkers are integrated 
with clinical assessments at two time points, i.e. during the diagnostic work-up and 
at follow-up visit 1-3 weeks later (before treatment). The study participation involves 
questionnaire assessment of symptoms of anxiety, depression, posttraumatic stress, 
sleep disturbances and quality of life. Biomarker repositories include overnight urine 
collection, diurnal saliva and hair sampling for analysis of cortisol and catecholamines 
along with ECG to determine heart rate variability. Bronchoscopic and core needle 
biopsies as well as surgical tumor samples will be used for assessment of apoptosis, 
proliferation, microvascular density and adrenoreceptors expression. Radiographic 
progression will be assessed at baseline and every 6 months from diagnosis along with 
complete documentation of clinical parameters, disease course and survival. Results: In 
4 weeks we have recruited 8 patients (80% acceptance rate). We will characterize 
determinants of a severe psychological-, neuro-endocrine- and cardiovascular stress-
response to a cancer diagnosis, as well as the potential relevance of these responses 
on tumor characteristics, radiographic progression and disease-specific survival. We 
expect to present preliminary results from approximately 30 patients at the conference. 
Conclusion: Significance: This research program is the first comprehensive attempt to 
evaluate determinants of psychobiological-induced responses to a lung cancer diagnosis and 
their potential impact on cancer progression. The findings might guide intervention strategies 
to improve quality of life, reduce morbidity and prolong survival in lung cancer patients. 
Keywords: lung cancer, Stress-response, psychobiological
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P1.04-074 ITPKA Expression in Lung and Other Cancers, Regulated via 
Gene Body Methylation, Functions as an Oncogene Yi-Wei Wang1, Xiaotu 
Ma2, Yu-An Zhang3, Mei-Jung Wang1, Yasushi Yatabe4, Stephen Lam5, Luc Girard6, 
Jeou-Yuan Chen1, Adi F. Gazdar3 1Institute of Biomedical Sciences, Academia Sinica, 
Taipei/Taiwan, 2Department of Molecular and Cell Biology, University of Texas at Dallas, 
Richardson/TX/United States of America, 3Hamon Center for Therapeutic Oncology 
Research, University of Texas Southwestern Medical Center, Dallas/TX/United States 
of America, 4Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, 
Nagoya/Japan, 5British Columbia Cancer Agency, Vancouver/Canada, 6Hamon Center for 
Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas/
United States of America
Background: Lung cancer is the leading cause of cancer mortality and accounts for 1.6 
million deaths annually in the world. Lung cancers may be classified into non-small cell 
(NSCLC) and small cell (SCLC) lung cancers, which individually account for approximately 
85% and 15%, respectively, of lung cancer cases. Despite recent advances in cancer therapy, 
the overall 5-year survival rate of lung cancer remains low. There remains an urgent need 
for discovery of novel approaches for early diagnosis and therapy. Inositol-trisphosphate 
3-kinase A (ITPKA) regulates inositol phosphate metabolism and calcium signaling by 
phosphorylation of the second messenger inositol 1,4,5-trisphosphate (Ins-1,4,5-P3) 
In preclinical trials towards metabolic stress, certain KL ADC can develop drug 
resistance through squamous transdifferentiation. Conclusion: This study uncovers 
critical redox control of tumor plasticity that may affect therapeutic response in NSCLC. 
Keywords: Therapeutic response, LKB1, Plasticity, Metabolism
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P1.04-070 Silencing of Rac3 Inhibits Proliferation and Induces Apoptosis of 
Human Lung Cancer Cells Hongxu Liu, Tieqin Liu, Gebang Wang Department of 
Thoracic Surgery, First Affiliated Hospital, China Medical University, Shenyang/China
Background: Rac3 is a member of the Rac family of small guanosine triphosphatases 
(GTPases), regulates a variety of cell functions, including the organization of the 
cytoskeleton, cell migration, and invasion. The overexpression of Rac3 has been 
reported in several human cancers. However, the role of Rac3 in Lung cancer 
(LC) has not been determined yet. The purpose of this study is to investigate the 
effect of silence on Rac3 expression in human LC cells and the consequence of cell 
survival. Methods: Lentivirus small hairpin RNA (shRNA) interference techniques were 
utilized to knock down Rac3 gene. Gene and protein expression was quantified by 
quantitative Real-time polymerase chain reaction (qRT-PCR) and Western Blot. LC cell 
apoptosis was examined by Annexin V-APC /propidium iodide staining. Results: Efficient 
silence of of Rac3 strongly inhibited A549 cells proliferation and colony formation 
ability, and significantly decreased tumor growth. Moreover, flow cytometry 
analysis showed that knockdown of Rac3 led to G2/M phase cell cycle arrest as 
well as an excess accumulation of cells in the G1and S phase. Conclusion: Thus, 
functional analysis using shRNAs reveals a critical role for Rac3 in the tumor growth 
of LC cells. shRNAs silencing of Rac3 could provide an effective strategy to treat LC. 
Keywords: lung cancer, Rac3, proliferation, shRNAs
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P1.04-071 Inhibition of EGFR Lysosomal Degradation in Lung Adenocarcinoma 
by Ubiquitin-Specific Protease 8 and Stratifin Yun-Jung Kim, Aya Shiba, Masayuki 
Noguchi Pathology, Tsukuba University, Tsukuba/Japan
Background: The epidermal growth factor receptor (EGFR) is one of the best-known 
targets of therapy for non-small cell lung cancer (NSCLC). Our purpose was to investigate 
whether ubiquitin-specific protease 8 (USP8) and stratifin (14-3-3σ or SFN) inhibit or 
stimulate lysosomal degradation of EGFR in lung adenocarcinoma. Methods: Using 
Western blotting and immunofluorescence analysis, we examined the effect of USP8 
or SFN knockdown by siRNA and overexpression of USP8. Expressions of USP8 and 
SFN in normal and tumorous lung tissue were examined by Western blotting and 
immunohistochemistry. Results: USP8 or SFN knockdown led to downregulation of 
cellular proliferation, receptor tyrosine kinases such as EGFR and proto-oncogenes 
(c-Met), and downstream signaling pathways such as the AKT, ERK, and STAT3 pathways, 
whereas it upregulated the accumulation of EGFR at lysosomes for degradation. However, 
overexpression of USP8 led to an increase of EGFR and downstream signaling after EGF 
stimulation. Moreover, USP8 and SFN expressions were increased in the tumorous lung 
tissue in comparison with normal lung tissue from the same patient. Conclusion: USP8 
and SFN inhibit ubiquitination of EGFR for lysosomal degradation in lung adenocarcinoma 
cells, suggesting that USP8 and SFN could be potential therapeutic targets for NSCLC. 
Keywords: Epidermal growth factor receptor, ubiquitin-specific protease, stratifin, lung 
adenocarcinoma
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P1.04-072 Gene-Smoking Interactions in Lung Cancer Etiology Christopher I. 
Amos1, Summer Han2, Younghun Han1, Iona Cheng3 1Biomedical Data Science, Dartmouth, 
Hanover/NH/United States of America, 2Radiology, Stanford, Stanford/CA/United States of 
America, 3Public Health, Cancer Prevention Institute of California, Oakland/CA/United States 
of America
Background: Even among heavy smokers, the lifetime risk for developing lung cancer 
is between 15 and 20% which raises a question about whether there are protective 
factors that mitigate risk from toxic exposures in tobacco smoke. Previously we have 
shown significant gene-environment interaction effects between smoking and genetic 
loci on chromosome 15q25.1 near the nicotinic acetylcholine receptor locus contrasting 
minimal increases in risk for never smokers from SNPs in this region versus substantial 
impact on risk for smokers. Studies contrasting risk in heavy versus light smokers have 
not been conducted and little is known about protective factors that may reduce risk 
for some smokers. Methods: In order to identify genetic factors that might reduce 
lung cancer risk, we performed a genome-wide case only analysis of lung cancer risk, 
comparing heavy to light smokers. This approach to analysis is powerful for identifying 
gene-environment interactions provided there is no correlation between the genetic 
factor and the environment exposure. We performed a genome-wide association of 
heavy smokers who had a 30 packyear or more background of smoking versus 1824 
lung cancer cases with less than 30 packyears of smoking exposure using data derived 
from studies conducted by 7 sites within the Transdisciplinary Research in Cancer of 
the Lung (TRICL) consortium. To improve our ability to identify genetic variants, we 
used imputation based on the March 2012 release of the 1000 Genomes to impute and 
analyze data from more than 9 million genetic variants. Results: This analysis identified 
one region showing many highly significant associations with the most significant 
being rs62180069 (p=5x10-8, OR = 0.76). This SNP lies between the SCHLAP1 gene 
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kDa (TSPO), which reflects microglia activation, G Protein-coupled Receptor (GPR35), 
a KYNA receptor and kynurenine aminotransferase II (KAT) in PBMC and serum L-KYN 
concentration in relations to cognitive functions in lung cancer patients. Methods: We 
included in the study 80 consecutive lung cancer patients (5 small-cell lung cancer, 75 
non-small cel lung cancer, 24 females and 56 males, aged 61.5±6.7 years) hospitalized 
in Clinical Oncology with The Sub-department of Diurnal Chemotherapy Wielkopolska 
Center of Pulmonology and Thoracosurgery of Eugenia and Janusz Zeyland and Chair 
and Clinic of Oncology. PBMC were isolated by density gradient centrifugation. The 
expression of TSPO, GPR35 KAT in PBMC was evaluated with ELISA. Serum L-KYN 
concentration was measured by means of spectrofotometric method. Neurological 
examination, MiniMental State Examination (MMSE), Trail Making Test (TMT) A and B, 
and Hamilton scale were performed at baseline (time of lung cancer diagnosis) and after 
6 months. Results: Decreased TSPO expression in PBMC was associated with better 
results of MMSE evaluation (29.00; 28.0–29.0; median, interquartile range) than in lung 
cancer patients with up-regulated TPSO (28.0; 26.0–28.7; P=0.016). Also, TMT-A results 
were better in lung cancer patients with down-regulated TPSO (8.41±3.68s) compared 
to the subject with stimulated TPSO (12.92±7.30s; P=0.002). TSPO expression in PBMC 
negatively correlated with MMSE score (Kendall’s tau = -0.182; P=0.0178) and positively 
with TMT-A (Kendall’s tau = 0.168; P=0.0309) evaluated at baseline. The up-regulation of 
KAT expression in PBMC was associated with better cognitive functions measured with 
MMSE 6 months after baseline (28.4±0.7) comparing to lung cancer patients with inhibited 
KAT (27.1±1.8). KAT correlated positively with MMSE scoring 6 months after baseline 
(Kendall’s tau= 0.308; P=0.0234).The expression of GPR35 in PBMC did not correlated 
with cognitive measures. Serum L-KYN concentration correlated negatively with TMT-A 
evaluated 6 months after baseline (Kendall’s tau= -0.586; P=0.0141). Moreover, TPSO 
expression correlated positively with KAT (Kendall’s tau= 0.253, P=0.0009) and negatively 
with GPR35 (Kendall’s tau= -0.173, P=0.0491), but no correlation with L-KYN was 
found. Conclusion: Stimulation of kynurenine pathway in PBMC seems to be protective 
against cognitive decline during the course of lung cancer. Microglial activation can be 
independent pathomechanism leading to cognitive impairement in lung cancer patients. 
Keywords: kynurenine pathway, cognition, lung cancer
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-076 CDCA3 Is a Novel Cell Cycle Regulator in Lung Cancer Mark N. 
Adams1, Kenneth J. O’Byrne2, Derek Richard3 1Translational Research Institute, Institute 
of Health and Biomedical Innovation, Woolloongabba/QLD/Australia, 2Cancer and Ageing 
Research Program, Queensland University of Technology, Brisbane/Australia, 3Cancer and 
Ageing Research Program, Queensland University of Technology, Brisbane/QLD/Australia
Background: Progression through the mammalian cell cycle relies upon coordination of 
a complex network of proteins. Following genomic insult, checkpoints during each stage 
of the cell cycle are engaged to halt cell cycle progression to allow faithful DNA repair. 
Failure to arrest cell cycle may lead to genomic instability and cancer development. 
However, the molecular basis for the loss of genome integrity during cancer development 
remains to be determined. Cell division cycle associated 3 (CDCA3) is a key regulator of 
the normal cell cycle. CDCA3 modulates this process by enabling cell entry into mitosis 
through degradation of the mitosis-inhibitory factor WEE1. CDCA3 itself is also degraded 
in G1 yet re-expressed in G2/M phase, to allow successful progression through the cell 
cycle. Here we describe for the first time a novel function for CDCA3 in maintaining 
effective cell cycle progression in lung cancer. Methods: To examine the role of 
CDCA3 in modulating the cell cycle of lung cancer cells, CDCA3 was depleted using an 
siRNA approach in A549, SKMES and H460 cell lines. CDCA3 depletion was assessed 
using Western blot analysis. Cell proliferation assays were performed on control and 
CDCA3 knockdown cells over a period of 96 h using the Promega CellTitre-Glo cell 
viability assay. Cell cycle progression was assessed on propidium iodide stained cells 
using a Beckman Coulter Gallios flow cytometer. To determine if CDCA3 expression is 
associated with lung cancer progression, a tissue microarray (TMA) with cores from 
600 patients was stained with an anti-CDCA3 antibody. Correlation of CDCA3 staining 
with clinical data and patient prognosis is ongoing. Results: As a cell cycle related 
protein, we tested if CDCA3 is required for effective proliferation of a range of lung 
cancer cell lines. CDCA3 depletion reduced the proliferation of U2OS (osteosarcoma), 
A549, MOR (lung adenomcarcenoma) and SKMES cancer cells (squamous lung cancer). 
Interestingly, depletion of CDCA3 did not affect proliferation of H460 cells (large 
neuroendocrine lung cancer). We next tested the cell cycle progression and noted that 
knockdown of CDCA3 induced an increase of all cell lines in G1 arrest with the exception 
of H460 cells. To observe if CDCA3 expression is linked with disease progression, TMA 
staining of lung cancer biopsies was performed. Accordingly, elevated expression of 
CDCA3 was identified specifically in tumour cells. These data highlight the potential 
prognostic value of CDCA3 expression. Conclusion: Our data point to a potential 
role for CDCA3 in the progression of lung cancer. While the precise mechanism for 
CDCA3-dependent cell cycle regulation remains unknown, it is possible that elevated 
CDCA3 levels modulate tumour cell proliferation. Identifying the molecular basis may 
yield novel therapeutic avenues worth targeting during aberrant cell cycle in cancer. 
Keywords: Genome instability, proliferation, Cell cycle
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P1.04-077 KIF5B-RET Fusion Kinase Promotes Cell Invasion and Migration 
Which Can Be Suppressed by RET Inhibitors Jianhua Chang, Shanshan Wang, 
Weiwei Xie Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
Shanghai/China
Background: Non-small cell lung cancer has become the leading cause of cancer-
to inositol-1,3,4,5-tetrakisphosphate (Ins-1,3,4,5-P4) (1). ITPKA has a very limited tissue 
expression, mainly in brain and testis. ITPKA, previously known as a neuron-specific F-actin 
bundling protein, has recently been shown to be overexpressed in lung adenocarcinoma 
and associated with increased metastatic potential (2). However, our understanding of 
the role and regulation of ITPKA in cancers is limited. Reference: 1. Shears SB. How 
versatile are inositol phosphate kinases? The Biochemical journal. 2004; 377:265-80. 
2. Windhorst S, Kalinina T, Schmid K, Blechner C, Kriebitzsch N, Hinsch R, et al. Functional 
role of inositol-1,4,5-trisphosphate-3-kinase-A for motility of malignant transformed 
cells. International journal of cancer Journal international du cancer. 2011;129:1300-
9. Methods: To identify potential oncogenes that are involved in the pathogenesis of 
lung cancer, cDNA microarray analysis was performed to search for up-regulated genes 
in primary lung adenocarcinomas. Inositol-trisphosphate 3-kinase A (ITPKA) was found 
to be overexpressed in lung ADC. Results: Using gain-of-function and loss-of-function 
approaches, we demonstrated that ITPKA contributes to cancer development. We also 
showed that methylation level in the ITPKA gene body is highly tumor-specific, and is 
positively correlated with its expression. Furthermore, DNMT3B-mediated methylation of 
the CpG island in ITPKA gene body regulates its expression via modulation of the binding 
of transcription activator SP1 to the ITPKA promoter. ITPKA gene body methylation 
first appeared at the in situ carcinoma stage and progressively increased during the 
multistage pathogenesis of lung carcinoma.
 
Conclusion: Altogether, deregulation of ITPKA may promote oncogenic transformation and 
function as a universal or near universal hallmark of malignancy. A novel regulatory mechanism 
of oncogene expression was demonstrated via gene body methylation which manipulates 
the binding of transcriptional factor(s) to its promoter and controls gene expression. 
Keywords: SP1, biomarker, ITPKA, DNA methylation
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P1.04-075 Kynurenine Pathway Activity in Peripheral Blood Mononuclear Cells 
and Cognitive Functions in Lung Cancer Patients Rodryg Ramlau1, Slawomir 
Michalak2, Joanna Rybacka-Mossakowska2, Iwona Golda-Gocka3, Joanna Gazdulska4 
1Department of Oncology, Poznan University of Medical Sciences, Poznan/Poland, 2Department 
of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan/
Poland, 3Lung Diseases Center, Poznan University of Medical Sciences, Poznan/
Poland, 4Oncology Center, Poznan University of Medical Sciences, Poznan/Poland
Background: The kynurenine pathway is crucial for tryptophan metabolism, which has 
been shown to be active both in macrophages and microglial cells. L-Kynurenine (L-KYN) is 
transported across the blood-brain barrier and serves as a source for the synthesis of all 
the other metabolites of the kynurenine pathway. Glial cells have the enzymatic capability 
for the biosynthesis of brain kynurenines as kynurenine aminotransferase (KAT). KAT 
converts L-KYN to kynurenic acid, which is an inhibitor of glutamate neurotransmission. 
The lowered KAT activity was observed in the plasma and brains of patients with 
neurodegenerative disorders followed by a tendency to a decrease KYNA in plasma and 
brains. Peripheral blood mononuclear cells (PBMC) can be considered as representative 
for metabolic changes in peripheral tisues during the course of lung cancer. With this 
background in mind we have undertaken the evaluation of translocator protein 18 
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Results: Real time RT-PCR data for ASCL1 in the distal airway brushing samples of the 8 
subjects suggested a trend toward higher ASCL1 mRNA titers (p = 0.26) in current 
smokers (mean = 33 pack-years) compared to former smokers (mean = 51 pack-years), 
whose ASCL1 mRNA expression levels were higher than that of a never-smoker [Figure 
1A]. A549 cells exposed to 10 mcg/mL of CSC for 4 hours had 4.1 fold (p = 0.023) and 
2.0 fold (p = 0.017) increases in ASCL1 expression compared to those exposed to 1% 
DMSO and serum-free media (SF) only, respectively [Figure 1B]. No statistically significant 
change in ASCL1 expression was noted in the other CSC exposure groups. Conclusion: 
CSC induced ASCL1 expression in A549 cells, and the stimulatory effect of CSC was no 
longer observed at the higher concentration and the longer exposure times. This in vitro 
finding is in agreement with the RT-PCR data, which also suggest a trend toward increased 
ASCL1 expression with more recent smoking history in the distal airways of cancer-free 
human subjects.
Keywords: Achaete-Scute Homologue 1 (ASCL1), Cigarette Smoke Condensate, A549
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P1.04-079 RBM5-Wnt/β-Catenin Signaling in Cigarette Smoke PM 2.5 Induced 
Alveolar Epithelial Injury and Its Molecular Mechanism Zhang Jie, Hao Y. Qiu, Lv 
X. Jiao, Li J. Yao, Su Z. Zhong, Wang Chen, Bai Yue Department of Respiratory Medicine, 
The Second Clinical Medical College of Jilin University, Chang Chun/China
Background: Tobacco related death has become the first cause of death worldwide and 
it is estimated that approximately 1 millions patients each year died from tobacco related 
diseases in China ,the most common diseases from which are COPD and lung cancer.
Recently,the effects of long-term exposure to PM2.5(particulate matter) on human 
health have drawn much attention from clinicians and researches.Cigarette smoke 
is one of the main sources of indoor PM2.5. At the same time, cigarette smoke also 
includes nearly six thousand kinds of chemical substances, most of which are harmful 
to the body, especially benzopyrene.It is proved that benzopyrene is a class of organic 
compounds with significant carcinogenic effect. However, the underlying mechanisms 
remain unclear. The aims of this study were to determine the involvement of RNA-binding 
motif protein 5 (RBM5) and Wnt/β-catenin signaling in cigarette smoke PM2.5 induced 
alveolar epithelial injury, as well as the interaction between both. Methods: A549 cells 
were treated with cigarette smoke extract (CSE). The MTT assay was used to assess 
the effects of CSE on cell viability. The levels of RBM5 and Wnt/β-catenin/GSK3β were 
detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) 
and western blots. A luciferase assay was used to assess the activity of β-catenin/
TCF signaling Results: CSE inhibits the proliferation of A549 cells, with increasing CSE 
concentration and action time, the growth inhibition rate of A549 cells is more big, has 
the time and dose dependence; Cytosolic and nuclear β-catenin levels significantly 
increased following CSE treatment, compared with those in control cells (P < 0.05); 
The luciferase activity in CSE-exposed cells transfected with the TCF luciferase reporter 
wild-type plasmid (pGL3-OT) was significantly greater than that in cells without CSE 
exposure (33,167 ± 3085 vs. 19,978 ± 1916, respectively, P < 0.05);given CSE 
A549 cells, RBM5 mRNA increased with the increase of CSE concentration and action 
time prolonged expression gradually decreased, with time and dose dependence; 
with increasing concentrations of cigarette smoke extract, reduce the expression of 
RBM5 protein expression, with dose dependent(all P < 0.05);after pcDNA3.1-RBM5 
transfection, Wnt/β-catenin signaling pathway inhibition; siRBM5 after transfection, 
Wnt/β-catenin signaling enhanced; give the Wnt signal pathway blocker ICG-001 blocked 
Wnt/β-catenin signaling pathway, the expression of RBM5 and the difference was not 
statistically significant. Conclusion: Down regulation of RBM5 and activation of Wnt/β-
catenin signaling are involved in CSE PM 2.5 induced alveolar epithelial injury. RBM5 acts 
as an upstream molecule that negatively regulates the activity of Wnt/β-catenin signaling 
This study was supported by grants from the National Natural 
Science Foundation of China (No.81472169 and No.81241069) 
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P1.04-080 miR-326 Is Down-Regulated in Non-Small Cell Lung Cancer and 
Targets NFIB, a Lung Developmental Gene: A Pilot Study Deepali Jain1, Bijay 
Pattnaik2, Anurag Agrawal2, Sunil Kumar3, Durgatosh Pandey3, Palaniappan Ramanathan3 
1Pathology, All India Institute of Medical Sciences, New Delhi/India, 2Csir-Institute of 
Genomics and Integrative Biology, Delhi/India, 3Surgical Oncology, All India Institute of 
Medical Sciences, New Delhi/India
Background: Lung cancer is the leading cause of cancer mortality worldwide. Non-small 
cell lung cancer (NSCLC) is the most common subtype, accounting for about 80% of all 
lung cancers. miRNAs are small RNAs of 21-24 nucleotides in length, which play major 
role in cell proliferation and differentiation and their differential expression is known to 
be associated with various cancers including lung cancer. Role of miR-326 has been 
previously studied as a marker of bone metastasis in lung cancer. Moreover, we have 
previously shown that miR-326 plays a critical role in the epithelial to mesenchymal 
transition (EMT) by targeting transforming growth factor (TGF) -β1 and other members 
of TGF-β signaling pathway. The aim of present study is to check the expression and 
correlation of miR-326 and lung epithelial developmental gene nuclear factor IB (NFIB) 
in non-small cell lung cancer tissue samples as cancer metastasis is accompanied by 
EMT. Methods: We have examined eight pathologically confirmed non-small cell lung 
cancer cases. All patients were men and smokers with age ranged from 29 to 74 years 
(mean 54.6 years). Surgical resection was performed in all the cases which were either 
stage II or III. Histopathologically, 4 cases were squamous cell carcinomas, 3 were 
related deaths worldwide. The subset of NSCLC can be further defined at molecular level 
by driver mutations that occur in multiple oncogenes, such as EGFR, KRAS and EML4/
ALK alterations. The KIF5B-RET fusion gene has been established as a new oncogenic 
driver in NSCLC. Several studies have demonstrated that KIF5B-RET promote cell growth 
and tumorigenicity, however, few progress has been made further. Our study aims to 
investigate other characters of KIF5B-RET fusion gene and tries to explore the potential 
signaling pathways involved in the gene functions. Methods: Lentivirus（encoding KIF5B-
RET）was used to transfect the lung epithelial cell line BEAS-2B and lung cancer cell 
line A549 to generate stable transfectant and the protein expression was analysed 
using western blot . To verify the oncogenic features of KIF5B-RET in vitro, we detected 
its expression genetically followed by CCK8 assay, colony formation assay, transwell 
and Annexin V-FITC/PI double staining to explore proliferation, invasion, migration and 
apoptosis. The mechanism by which KIF5B-RET kinase induced invasion and migration was 
investigated by western blot, and administration of RET and SRC inhibitions. Results: The 
stable transfected cell line expressed phosphorylation RET, examined by western blot, 
suggesting that KIF5B-RET could automatically activate RET protein in the absence of 
ligand. Firstly we detected the basic characters of KIF5B-RET, but found no significant 
difference in proliferation as it’s reported in previous studies. To further detect the 
function of KIF5B-RET fusion gene, we focused on characters of invasion, migration, and 
apoptosis. We demonstrated that KIF5B-RET showed a significantly increased ability of 
invasion and migration compared with control group, suggesting that KIF5B-RET fusion 
gene could promote cell invasion and migration. However, no change was observed after 
treating the transfected cells with Cisplatin, indicating the gene may have no influence 
on apoptosis. As we all know, RET tyrosine kinase can activate ERK which belongs to the 
downstream signaling system. Our restult showed that KIF5B-RET fusion kinase can also 
induced activation of ERK and even SRC kinase. Finally, we found that stable cells became 
sensitive to the RET tyrosine kinase inhibitors Sunitinib and Apatinib. The invasion and 
migration could be suppressed by RET or SRC inhibitors significantly. Conclusion: Out 
data showed that KIF5B-RET fusion gene can activate ERK and SRC kinase through 
activating RET tyrosine kinase, and promote migration and invasion in vitro ，but did not 
have an effort on proliferation and apoptosis. RET inhibitor Apatinib and Sunitinib and SRC 
inhibitor could suppress the phenomenon of invasion and migration, suggesting that KIF5B-
RET promotes invasion and migration through activation of SRC kinase. Our preclinical 
data demonstrated the antitumor activities of Apatinib and Sunitinib against KIF5B-
RET gene fusion-driven cells and indicated the therapeutic potential of tyrosine kinase 
inhibitors targeting RET, which may benefit this certain subpopulation of NSCLC patients. 
Keywords: KIF5B-RET fusion gene, invasion, RET inhibitor, Migration
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P1.04-078 Induction of Achaete-Scute Homologue 1 (ASCL1) by Cigarette 
Smoke Condensate in A549 Cells Michael H. Lee, Ting-An Yie, John S. Munger, 
Jun-Chieh J. Tsay, William N. Rom New York University School of Medicine, New York/NY/
United States of America
Background: About 10% of lung adenocarcinomas express neuroendocrine features, 
which are thought to denote a subset of adenocarcinomas with poor prognosis. Achaete-
scute homologue 1 (ASCL1) is a transcription factor implicated in the neuroendocrine 
differentiation of lung tissue. Recently, ASCL1 was identified as a neuroendocrine marker 
in lung adenocarcinomas, and its expression was upregulated in lung adenocarcinomas 
of smokers when compared to adenocarcinomas of non-smokers and other types of lung 
cancers. ASCL1 expression in the peripheral airways of cancer-free smokers has not 
been studied. Moreover, the effect of cigarette smoke exposure on the neuroendocrine 
differentiation of lung cancer cells has not been examined in vitro. Methods: Distal airway 
brushings for epithelial cells were obtained in 8 subjects who participated in CT scan 
lung cancer screening at the NYU Lung Cancer Biomarker Center (part of the NCI Early 
Detection Research Network); never (n=1), former (n=4) and current (n=3) smokers. 
ASCL1 mRNA expression was measured using real time reverse transcription polymerase 
chain reaction (RT-PCR). A549 cell line was incubated with cigarette smoke condensate 
(CSC; extracted to DMSO) at 10 or 40 mcg/mL for 4, 24 or 48 hours. Following the 
incubation periods, ASCL1 expression levels were measured via western blot with lamin 
B1 as the nuclear protein loading control. Three individual experiments were performed. 
Statistical analyses were performed with Kruskal-Wallis test (RT-PCR) and Student’s t-test 
(western blot).
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to restore these two enzymes to generate endogenous 13(S) -HODE and 15(S) -HETE 
before the cell function was assessed. Results: The application of exogenous 13(S) -
HODE and 15(S) -HETE significantly enhanced the activity of peroxisome proliferator-
activated receptor-γ(PPARγ), inhibited cell proliferation, induced apoptosis, and 
activated caspase-9 and caspase-3. The overexpression of 15-LOX-1 and 15-LOX-2 
could obviously promote the endogenous levels of 13(S) -HODE and 15(S) -HETE, which 
were demonstrated to be more effective in the inhibition of NSCLC. Conclusion: We 
have demonstrated that exogenous or endogenous 13(S) -HODE and 15(S) -HETE can 
functionally inhibit NSCLC likely by activating PPARγ. The restoration of 15-LOXs 
activities to increase the production of endogenous 15(S) -HETE and 13(S) -HODE may 
offer a novel research direction for the molecular targeting treatment of NSCLC and 
avoid potential side-effects associated with the application of synthetic PPARγ ligands. 
Keywords: lung cancer, 13S-HODE, 15S-HETE, 15-lipoxygenase
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P1.04-083 The Metastasis-Related Noncoding RNA Expression Profile and 
LncRNA LOC101448202 Induces 95D Cell Migration and Tumor Growth Hou 
Yanli, Shuanying Yang, Wang Guoen The Second Affiliated Hospital, Xi’An Jiaotong 
University, Xi’An/China
Background: Metastasis of non-small cell lung cancer shortens the survival time of 
patients and decreases their quality of life. This unfortunate situation could be improved 
if the functions of long noncoding RNAs (lncRNAs) were identified in depth. Methods: not 
applicable Results: In the present study, a large number of lncRNAs and mRNAs with 
different expression patterns were verified in 95D and 95C lung cancer cell lines. The 
lncRNA, LOC101448202, was highly expressed in 95D cells, and lentivirus-mediated 
RNA interference was able to silence its expression with a silencing efficiency of 
92%. LOC101448202 gene silencing led to a decrease in cell proliferation, adhesion, 
migration, and invasion and the number of pseudopods and microvillion the cell surface 
was also reduced. At the mRNA level, her-2 expression was inhibited and the expression 
of nm23-H1 and E-cadherin was increased. At the protein level, β-catenin and ezrin 
levels were decreased bothin vitro and in vivo. In clinical specimens and mouse models, 
LOC101448202 expression was positively related to tumor growth. Conclusion: These 
data indicate that LOC101448202 expression levels are associated with 95D 
cell metastasis, demonstrating the tumor-promoting function of this lncRNA. 
Keywords: lncRNA, LOC101448202, 95D cells, metastasis
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P1.04-084 Ubiquitin Protein Ligase E3C Promotes Growth and Metastasis of 
Non-Small Cell Lung Cancer Jie Gu, Di Ge Department of Thoracic Surgery, Zhongshan 
Hospital Fudan University, Shanghai/China
Background: Ubiquitin protein ligase E3C (UBE3C) has been recently proposed as a potential 
oncogene in hepatocellular carcinoma. However, its role and mechanism in non-small cell lung 
cancer remains unknown. Methods: Eight cases of NSCLC and matched nontumorous samples 
were used to analyze UBE3C expression at the level of protein. Then, we down-regulated the 
expression of UBE3C in NSCLC cells and assessed the biological role of UBE3C in NSCLC cell 
line. Finally, the prognostic role of UBE3C was examined by Immunohistochemistry (IHC) in 
tissue microarray (TMA) consisting of 208 cases of NSCLC. Results: The expression of UBE3C 
in NSCLC tissues was much higher than that in nontumorous samples. Downregulation of UBE3C 
expression suppressed the proliferation and invasion of lung cancer cells. Further analysis 
showed that downregulation of UBE3C expression mainly promoted cell apoptosis but without 
an effect on cell cycle. High levels of UBE3C expression were associated with higher tumor stage 
in NSCLC patients. The 5-year overall survival rate in the UBE3Chigh group was significantly 
lower than that in the UBE3Clow group. In multivariate analysis, UBE3C was identified as an 
independent prognostic factor for overall survival. Conclusion: Our findings indicated that 
UBE3C may represent a candidate therapeutic target and a novel prognostic marker of NSCLC. 
Keywords: NSCLC, Ubiquitin protein ligase E3C, invasion, Prognosis
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P1.04-085 The Role and Potential Mechanisms of LncRNA-TATDN1 in the 
Metastasis and Invasion of 95D Cell Shuanying Yang, N Zequn Department of 
Respiratory Medicine,, The Second Affiliated Hospital, Xi’An/China
Background: The invasion and metastasis of malignant cell is generally considered as 
a major reason why it is always failed in the therapy of lung cancer. The mechanism 
in metastasis is complicated and uncertain as well. The scientific research proves 
that Long non-coding RNA (LncRNA) is bound up with the occurrence, development 
and prognoses of lung cancer. Methods: Application of high throughput LncRNA 
chip to investigate the differentially expressed LncRNA between 95D and 95C 
cell lines. RNA interference (RNAi) approaches were used for the analysis of the 
biological functions and metastasis of TATDN1. Tumor growth was studied in nude 
mice. Results: TATDN1-1 was highly expressed in 95D cells lines and NSCLC tissues. 
In 95D cells knockdown of TATDN1 by using small interfering RNA (siRNA) resulted in 
significant reduction in proliferation, adhesion, migration and invasion of these cells 
in vitro. 95D cells xenografts with decreased TATDN1 expression were impaired 
in tumor formation and growth. On genetic level, MALAT-1displays the strongest 
association with genes involved in cancer like cellular growth, movement, proliferation, 
signaling. Conclusion: These data indicate that TATDN1expression levels are 
associated with 95D cells metastasis and identify tumor-promoting functions of TATDN1. 
adenocarcinomas including one case of invasive mucinous carcinoma and one case was 
low grade mucoepidermoid carcinoma. RNA was isolated from fresh frozen tissue to 
check for miR-326 and NFIB levels by real time PCR. Protein expression was checked by 
immunohistochemistry (NFIB; 1:200; Abcam)) and in-situ hybridization (miR-326; Exiqon). 
Adjoining lung tissue served as normal control in each case. Results: Expression of both 
miR-326 and NFIB was found to be down regulated in non-small cell lung cancer tissue 
at both RNA and protein level (Fig 1A-C). Our in silico experiments identified a target site 
of miR-326 at the 3’UTR of NFIB gene; presumably it stabilizes the transcripts of NFIB 
(Fig 1D).
  
Conclusion:Our preliminary data suggests that miR-326 stabilizes the transcripts of 
NFIB in normal epithelial cells and maintain epithelial cell integrity. Dysregulation of 
miR-326 and NFIB in non-small cell lung cancer indicate that miR-326 and NFIB work 
synergistically and may contribute to the development of non-small cell lung cancer. 
Keywords: miR-326, NFIB, NSCLC, epithelial to mesenchymal transition
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P1.04-081 Expression of PPAR-γ Ligand in Lung Cancer and Its Effect on the 
Apoptosis of Lung Cancer Qiuping Luo Department of Pulmonary Medicine, The First 
Affiliated Hospital, Zhejiang University, Hangzhou/China
Background: To explore the expression of PPAR-γ ligand in lung cancer and its effect 
on the apoptosis of lung cancer. Methods: The expression of PPAR-γ in 80 patients 
with lung cancer was detected using cell-culture method and its expression in the 
lung cancer cell lines was also determined by RT-PCR and Western blot. Additionally, 
TUNEL method was used to detect the apoptosis. Results: PPAR-γ was expressed in 
the lung cancer tissue and the tissue of lung benign lesions. Its optical density was 
the highest in the lung cancer tissue (0.1832±0.0407), then the tissue of lung benign 
lesions (0.1201±0.0308), and the lowest in the normal tissue (0.1185±0.0296). The 
total expression of PPAR-γ showed significant difference in the patients with different 
pathological types and differentiated degrees (P<0.05), and there was also statistical 
significance regarding the total expression of PPAR-γ in small cell lung cancer and 
non-small cell lung cancer (P<0.01). The expression of squamous cell carcinoma is 
the highest in non-small cell lung cancer. Significant difference was presented by 
comparison to the expression of PPAR-γ in poorly-differentiated and moderately, highly-
differentiated lung cancer tissues (P<0.05). Conclusion: The expression of PPAR-γ is 
closely related to the pathological features of patients with lung cancer, and hence, to 
research PPAR-γ ligand can provide new evidences for the treatment of lung cancer. 
Keywords: apoptosis, PPAR-γ ligand; lung cancer; expression; differentiation and 
proliferation
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P1.04-082 Anti-Neoplastic Effects of 15(S)-HETE and 13(S)-HODE in Lung 
Cancer George G. Chen, Ming-Yue Li, Hl Yuan, Calvin S. Ng, Innes Y. Wan, Malcolm 
J. Underwood Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong 
Kong/China
Background: Previous studies have shown that the levels of 15-lipoxygenase-1(15-LOX-
1),15-lipoxygenase-2(15-LOX-2) and their metabolites 13(S) -HODE and 15(S) -HETE are 
significantly reduced in human non-small cell lung carcinoma (NSCLC). Furthermore, 
animal model experiments indicate that the reduction of these molecules occurs before 
the establishment of lung tumor, suggesting their roles in lung tumorigenesis. However, 
the functions of these molecules remain unknown in NSCLC. Methods: We treated 
NSCLC cells with exogenous 13(S) -HODE and 15(S) -HETE and then examined how they 
affected cell functions. We also over-expressed 15-LOX-1 and 15-LOX-2 in tumor cells 
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P1.04-088 Lung Cancer Cells Can Alter the Behaviour of Normal Bronchial 
Epithelial Cells Through Multiple Mechanisms Anne-Marie Baird1, Martin P. Barr2, 
Aaron Urquhart1, Sarah-Louise Ryan3, Steven G. Gray2, Anthony Davies3, Derek Richard1, 
Kathy Gately2, Kenneth J. O’Byrne4 1Cancer and Ageing Research Program, Queensland 
University of Technology, Brisbane/QLD/Australia, 2Thoracic Oncology Research Group, 
Trinity College Dublin/St. James’S Hospital, Dublin/Ireland, 3Translational Cell Imaging 
Queensland, Queensland University of Technology, Brisbane/QLD/Australia, 4Cancer and 
Ageing Research Program, Princess Alexandra Hospital and Queensland University of 
Technology, Brisbane/Australia
Background: Lung cancer is one of the most heterogeneous of all solid cancers. This may 
in part be due to hi-jacking and additional bystander affects that are exerted on the normal 
lung cell population by the cancer cells. A number of pathways may be stimulated through 
soluble factors or effector filled vesicles such as exosomes secreted by cancer cells. The 
aim of this project was to evaluate the effects of non-small cell lung cancer (NSCLC) cells 
on an immortalised normal bronchial epithelial cell line. Methods: A normal bronchial 
epithelial cell line (HBEC4) was exposed to adenocarcinoma, large cell and squamous 
NSCLC cell lines and a number of phenotypic and genotypic characterisations were 
undertaken. These included cellular proliferation (BrdU ELISA), gene (RT-PCR) and miRNA 
expression screening (Nanostring). The effect of cancer exosome fractions was also 
determined. Results: Exposure to various subtypes of NSCLC significantly increased the 
cellular proliferation rate of the immortalised cell line in a number of models. Expression of 
a number of miRNAs were altered in the normal cells pre- and post exposure to the cancer 
cells. Various stem cell factor markers (KLF4, Oct, c-myc) were also significantly changed 
at the mRNA level. In addition, exosome fractions altered the behaviour of the normal cell 
line, likewise stimulating cell proliferation. Conclusion: Lung cancer cells may influence 
normal cell behaviour in both a direct and indirect manner using multiple mechanisms. 
Normal bronchial epithelial cells with stem like features may be induced to proliferate 
and behave in a malignant manner. This, akin to Hodgkin’s lymphoma, may contribute 
significantly to the composition of the tumour. Furthermore this observation may 
contribute to the heterogeneity of lung cancer tumours and affect treatment response. 
Ongoing studies are evaluating these effects in novel 2D and 3D culture systems. 
Keywords: Stem cell markers, NSCLC, miRNA, exosomes
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P1.04-089 MicroRNA miR-615-3p and let-7b Targets Multiple Key Pathways 
Overexpressed in Lung Adenocarcinoma Kostas Kerkentzes1, Robin Mjelle2, Oluf 
D. Røe2 1Dept. of Computer Science, University of Crete, Heraklion/Greece, 2Dept. of 
Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, 
Trondheim/Norway
Background: Lung adenocarcinoma gene expression is highly aberrant and 
heterogeneous and not due to mutations in all these protein-coding genes. Epigenetic 
regulation by microRNAs has been shown to explain some of this dysregulation. We 
aimed at identifying whether few microRNAs could explain multiple overexpressed 
genes in key pathways of lung adenocarcinoma. Methods: Publicly available gene 
expression profiling data from three different publications were included in this in 
silico analysis. In the lung adenocarcinomas (n=139/49/45) and normal lung tissue 
(n=17/9/65) among the common 8543 genes (based on the EntrezID), the differentially 
expressed and diagnostic genes were investigated. The genes with q-value under 0.01 
and with concordant regulation among all three datasets were regarded as significantly 
differentially expressed. Diagnostic genes were identified through the performance 
of each differentially expressed gene as a classifier. Finally, the miRNAs with highly 
probable predicted (PCT>0.9 in TargetScan), miRNA targeting interactions (MTI) and/
or with experimentally validated MTIs were assessed, the number of gene targets in the 
down- or up-regulated genes measured for each miRNA and an enrichment analysis was 
performed. Results: The common overexpressed and down-regulated genes among the 
three datasets were 534 and 638 respectively. Among the diagnostic genes with AUC 
over 0.8 were the known genes encoding recently discovered diagnostic proteins but 
also new unknown genes. Among the pathways in KEGG, genes of the Cell Cycle, Carbon-
pool by Folate and Base Excision and Mismatch Repair were significantly overexpressed. 
Importantly, we identified few microRNAs (q‹ 0.01) that could target most of these genes 
and that are all previously shown to be down-regulated and validated in lung and/or other 
cancer. Among the top microRNA were the following; Mir-615-3p targets 86 highly over-
expressed genes in all three datasets. This microRNA was recently shown to act as a tumor 
suppressor through inhibition of the AKT2 in pancreatic cancer cell lines. Let-7b targets 83 
highly over-expressed genes in all three datasets. Let-7b is controlling genomic balance 
and is down-regulated in aggressive breast cancer and significantly reduced in serum is 
correlated to poor survival in resectable NSCLC. Mir-16 targets 75 of the up-regulated 
genes in adenocarcinoma and was verified down-regulated in NSCLC versus adjacent 
normal lung tissue. Mir-193b targets 65 genes and was identified as a tumor suppressor 
in NSCLC and hepatocellular carcinoma. Mir-320a targets 50 genes and was identified as 
a crucial miRNA regulating glycolysis and was verified down-regulated in NSCLC. Mir-34a 
targets 46 of the overexpressed genes and is a crucial miRNA down-regulated in lung 
cancer and already proposed as a treatment with cisplatin. Conclusion: By combined in-
silico analysis of three large datasets on adenocarcinoma versus normal adjacent lung 
tissue we detected novel candidate diagnostic genes and important pathways that 
recapitulate the phenotype of this cancer. Importantly, we found microRNAs that could 
target and thus explain a large portion of the pathway dysregulation. One of these identified 
microRNAs, miR-34a, has already demonstrated a therapeutic potential in lung cancer. 
Keywords: Gene Expression, microRNA, Adenocarcinoma, multiple pathways
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P1.04-086 Dopamine D2 Receptor Agonists Inhibit Lung Cancer Progression 
by Reducing Angiogenesis and Tumor Infiltrating Myeloid Derived Suppressor 
Cells Luke H. Hoeppner1, Ying Wang2, Anil Sharma1, Naureen Javeed2, Virginia P. Van 
Keulen3, Enfeng Wang2, Ping Yang4, Anja C. Roden5, Tobias Peikert3, Julian Molina6, 
Debabrata Mukhopadhyay1 1Biochemistry and Molecular Biology, Mayo Clinic, Rochester/
MN/United States of America, 2Biochemistry and Molecular Biology, Mayo Clinic, Rochester/
United States of America, 3Immunology, Mayo Clinic, Rochester/MN/United States 
of America, 4Health Sciences Research, Mayo Clinic, Rochester/MN/United States of 
America, 5Laboratory Medicine and Pathology, Mayo Clinic, Rochester/MN/United States of 
America, 6Oncology, Mayo Clinic in Rochester, Rochester/MN/United States of America
Background: Lung cancer remains the leading cancer related cause of death in the 
United States and worldwide. Non-small cell lung cancer (NSCLC), the most common 
subtype (85%) of lung cancer, continues to be associated with a very poor 5-year survival 
rate of less than 15%. Despite the recent advances in systemic lung cancer treatment 
due to the introduction new therapies targeting angiogenesis, epidermal growth factor 
receptor (EGFR), and activin receptor-like kinase-1 (ALK1) in selected patient subgroups, 
the overall mortality of patients with advanced stage disease remains high. The 
development of new biomarkers and individualized therapies is needed to overcome 
these challenges and make significant strides towards improving the care of lung cancer 
patients. Dopamine (DA) has long been used in the treatment of Parkinson’s disease and 
acute cardiac dysfunction. Given that DA is produced by the sympathetic nerves ending 
in blood vessels, we originally postulated and later revealed that DA and its dopamine D2 
receptor (D2R) agonists inhibit VEGF-mediated angiogenesis and also completely block 
accumulation of tumor ascites and tumor growth in mice. Specifically, we demonstrated 
that DA stimulates endocytosis of VEGFR-2 via D2R thereby preventing angiogenesis 
by inhibiting VEGF binding, receptor phosphorylation and subsequent downstream 
signaling. These observations define a possible link between DA and vascular biology. 
Subsequent studies by numerous investigators clearly demonstrate that this strategy 
can be successfully applied to various diseases including cancer . Correspondingly, we 
observed significantly more angiogenesis, tumor growth, and VEGFR-2 phosphorylation 
in D2R knockout mice. We documented D2R colocalization with VEGFR-2 and described 
the molecular mechanism through which D2R/VEGFR-2 crosstalk can mediate the 
dephosphorylation of VEGFR-2. D2R agonists have been shown to increase the efficacy of 
anti-cancer drugs in preclinical models of breast and colon cancer. Here we show that D2R 
agonists inhibit tumor growth in orthotopic murine lung cancer models through inhibition 
of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor 
cells. Methods: We utilize syngeneic (LLC1) and human xenograft (A549) orthotopic 
murine lung cancer models as well as pathological examination of human lung cancer tissue 
to describe D2R agonist-mediated inhibition of lung tumor growth. Results: We sought to 
determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression 
and identify subpopulations of lung cancer patients that benefit most from D2R agonist 
therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic 
(LLC1) and human xenograft (A549) orthotopic murine models through inhibition of 
tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. 
Pathological examination of human lung cancer tissue revealed a positive correlation 
between endothelial D2R expression and tumor stage. Lung cancer patients with a 
smoking history exhibited greater levels of D2R in lung endothelium. Conclusion: Our 
results suggest D2R agonists may represent a promising individualized therapy for lung 
cancer patients with high levels of endothelial D2R expression and a smoking history. 
Keywords: dopamine; myeloid derived suppressor cells; VEGF, cabergoline
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P1.04-087 The Role and Mechanism of Twist1 in Non-Small Cell Lung Cancer 
Pathogenesis Tang F. Lv1, Yong Song2, Weimin Gao3 1Respiratory Medicine, Jinling 
Hospital, Nanjing/China, 2Department of Respiratory Medicine, Jinling Hospital, Nanjing 
University School of Medicine, Nanjing/China, 3Texas Tech University, Lubbock/United States 
of America
Background: Metastasis is a multistep process and the main cause of disease failure 
and mortality in lung cancer patients. Twist1 is a highly conserved developmental 
gene involved in embryogenesis that could be reactivated in cancers promoting both 
malignant conversion and cancer progression through epithelial-mesenchymal transition 
(EMT). The aim of this study was to investigate the role and mechanism of Twist1 in the 
pathogenesis of lung cancer. Methods: We examined a series of surgical lung cancer 
samples from Chinese patients (n=75) and showed that Twist1 expression was linked 
to lymph node status (P<0.05). To validate that Twist1 is a driver of EMT in non-small 
cell lung cancer (NSCLC), we used two human lung cancer cell lines (H1650 and H1975, 
EGFR mutation) and demonstrated that Twist1 was associated with cell growth and 
mobility. Results: Overexpression of Twist1 increased cell growth, mobility, and a decrease 
of Twist1 by shRNA technology reversed the phenomenon. Twist1 promoted the tumor 
growth in vivo and induced the expression changes of many genes by tumor gene RNA array. 
Twist1 significantly down-regulated p4EBP1 expression in H1650 cells and up-regulated 
p4EBP1 in H1975 cells by qRT-PCR and western blot assay. Conclusion: Collectively, 
both our in vivo and in vitro findings support that Twist1 in promoting lung cancer by 
upregulation p4EBP1, which are needed to further study the role of Twist1in NSCLC 
Keywords: Twist1, p4EBP1, Metastasis,Invasion, epithelial-mesenchymal transition
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P1.04-091 Biological Significance of CHK2 Gene Expression in Lung 
Adenocarcinoma Tatsuro Okamoto, Tetsuzo Tagawa, Fumihiro Shoji, Yosuke 
Morodomi, Mikihiro Kohno, Kensaku Ito, Yuzo Suzuki, Takatoshi Fujishita, Masakazu 
Katsura, Yoshihiko Maehara Department of Surgery and Science, Kyushu University, 
Graduate School of Medical Sciences, Fukuoka/Japan
Background: CHK2 is a transducer protein that is involved in DNA damage response 
(DDR). CHK2 phosphorylates effector proteins that play roles in DNA repair, cell cycle 
regulation and apoptosis. Recently, CHK2 have been found to have a critical role in 
the mitosis, and disruption of CHK2-BRCA pathway caused chromosomal instability 
in colon cancer cell lines (Stolz et al. Nat Cell Biol 2010:12; 492). The purpose 
of this study was to investigate the biological role of CHK2 and related factors 
in lung adenocarcinoma. Methods: We investigated 60 surgically resected lung 
adenocarcinomas. CHK2 and BRCA1 mRNA expression levels were evaluated by qRT-PCR. 
Relative mRNA expression levels of each sample were standardized to those of β-actin. 
EGFR mutation (exon 19 deletion and 21 point mutation) was detected by PNA-LNA PCR 
clamp method. KRAS mutation (exon 2, codon 12, 13) and p53 mutation (exon 5-9) were 
examined by direct sequencing. p27 and p21 protein expression levels were assessed by 
immunohistochemistry. Chromosomal aberration (CA) was examined in 20 samples with 
single-nucleotide polymorphism–CGH (SNP–CGH). Results: CHK2 mRNA levels were 
significantly increased in the tumor tissues compared to the normal tissues (p=0.012). 
CHK2 mRNA level was not correlated with patients’ clinicopathological factors, EGFR 
mutation status or p53 mutation status. CHK2 mRNA levels were significantly correlated 
with BRCA1 mRNA levels (ρ = 0.569, p < 0.0001). High CHK2 mRNA expression and 
high p27 protein expression levels were associated with poor prognosis for recurrence 
free survival (P = 0.028, P = 0.048), although both expression levels were not correlated 
with each other. 7 samples were determined to be high CA, while 13 samples to be low 
CA according to SNP-CGH. CHK2 mRNA level was higher in high CA (7 samples) than 
in low CA samples (13 samples) (Ave. 0.326 vs. 0.185; p=0.0129). Conclusion: CHK2 
mRNA expression level was increased in lung adenocarcinoma and was related to 
poor prognostic outcomes. CHK2 pathway may be important for the proliferation 
of lung adenocarcinoma, especially in tumors with chromosomal instability. 
Keywords: chromosomal instability, lung adenocarcinoma, DNA damage response, 
Prognosis
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P1.04-092 LKB1 Inactivation Confers Human Lung Adenocarcinoma with 
Strong Plasticity for Squamous Transdifferentiation Xiangkun Han1, Yingjiao Xue1, 
Yanzhen Nie1, Liao Kan1, Haiquan Chen2, Hongbin Ji1 1Shanghai Institutes for Biological 
Sciences, Shanghai/China, 2Department of Thoracic Surgery, Fudan University Shanghai 
Cancer Center, Shanghai/China
Background: Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are 
considered as two distinct subtypes of lung cancer and derived from different types of 
lung epithelial cells and featured with different biomarker expression. Interestingly, there 
exist certain lung tumors so called adenosquamous cell carcinoma (Ad-SCC) containing 
mixed both adenomatous and squamous pathologies; more importantly, these two 
different pathologies within a single tumor are consistently shown to have identical gene 
mutations. In consideration the fact that most tumors are derived from a single epithelial 
cell, it’s reasonable to hypothesize that there must exist lineage transition between ADC 
and SCC subtypes. However, this fundamental question remains unanswered due to the 
difficulty of study of human clinical samples. Indeed, most studies of clinical samples 
can only provide indirect evidences to support this hypothesis. Taking advantage of 
mouse models mimicking human lung cancer, we have recently successfully shown that 
inactivation of a tumor suppressor LKB1 confers mouse lung ADC with strong plasticity 
and makes them transdifferentiate into SCC through mixed Ad-SCC as intermediates (Han 
XK, et al. Nat Commun, 2014). However, whether there exists a phenotypic transition from 
ADC to SCC in human lung cancer remains unknown. Methods: Immunohistochemical 
analyses Integrative genomic analyses Establishement of patient-derived tumor 
xenograft model Statistic Analyses Results: not applicable. Conclusion: We 
pathologically analyzed a large cohort of human NSCLC samples and carefully evaluate 
the prevalence of mixed pathologies in context with LKB1 genetic inactivation. Moreover, 
we took advantage of the established lung ADC PDX mouse models to perform serial 
transplantation w/o the interfere of essential signaling pathways identified from de 
novo animal model study and test if possible that human ADC with LKB1 inactivation can 
progress and transdifferentiate into SCC. Based on our current understanding of this 
type of phenotypic transition in mice as well as the resources and systems established 
in the lab, we here succeed in proving the transdifferentiation of human ADC to SCC. 
Keywords: LKB1, Plasticity, patient-derived xenograft mouse model, lung cancer
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P1.04-093 CCNY2 Promotes Lung Cancer Cell Migration and Invasion via 
Regulating F-Actin Expression Wentao Yue1, Xiaoting Zhao1, Mei Jiang1, Weiying 
Li1, Yu Teng2, Jinjing Tan1, Lina Zhang1, Li Ma2 1Beijing Chest Hospital, Capital Medical 
University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijng/China, 2Beijing 
Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research 
Institute, Beijing/China
Background: Cyclin Y (CCNY) is a novel cyclin and is highly conserved in metazoan species. 
Cyclin Y mRNA has several transcripts and only ccny1 and ccny2 has been documented. 
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P1.04-090 Roles of MLF1IP in the Proliferation of Lung Adenocarcinoma Cells 
Yuqing Lou1, Rong Li1, Jielin Liu2, Yanwei Zhang1, Wei Zhang1, Xueyan Zhang1, Hua 
Zhong1, Liyan Jiang1, Shaojun Wen2, Baohui Han1 1Department of Pulmonary, Shanghai 
Chest Hospital, Shanghai Jiaotong University, Shanghai/China, 2Department of Hypertension 
Research, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart 
Lung and Blood Vessel Diseases, Beijing/China
Background: MLF1IP was initially identified as a MLF1 interacting protein, which encodes 
a centromere protein essential for cell cycle and mitosis. It has been reported that MLF1IP 
depletion impaired the interaction between centromere and microtubules, finally inducing 
defects in cell mitosis. However, the involvement of MLF1IP in lung adenocarcinoma 
development and related mechanisms remain to be elucidated. Methods: MLF1IP 
expression at mRNA level in 15 pair lung adenocarcinoma/adjacent normal lung samples 
was examined with real-time PCR assay. Then the expression of MLF1IP in human lung 
adenocarcinoma cells A549 was inhibited with lentiviral-mediated shRNA strategy. 
Effects of MLF1IP knockdown on cell proliferation was analyzed by Cellomics cell counting 
method and MTT assay. Then the impact of MLF1IP knockdown on colony formation, cell 
cycle process and cell survival was determined in A549 cells by colonogenesis assay, 
PI staining and Annexin V-APC staining respectively. Results: MLF1IP expression was 
significantly increased in lung adenocarcinomas as compared to adjacent normal lung 
tissues (fold change=2.50, P<0.05), with higher MLF1IP expression observed in 66.7% 
(10/15) samples while lower expression observed in only 20% (3/15) samples (Fig. 1A). 
Furthermore, MLF1IP knockdown impaired cell proliferation (Fig. 1B, C), inhibited colony 
formation ability (Fig. 1D), induced cell cycle arrest (Fig. 1E) and promoted cell apoptosis 
(Fig. 1F) in A549 lung adenocarcinoma cells.
 
 
Conclusion: Our study showed that MLF1IP expression is correlated with 
lung adenocarcinoma development and MLF1IP expression is critical for 
cell proliferation and survival in lung adenocarcinoma cell line A549. MLF1IP 
represents a novel potential target for lung adenocarcinoma therapy. 
Keywords: MLF1IP, lung adenocarcinoma, Cell cycle, cell proliferation
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Results: CD73 was upregulated in 52.38% of the lung tumor tissues and its expression 
was significantly related to histology and differentiation (P < 0.05). Reduced CD73 
expression suppressed NSCLC cell growth in vitro. miR-30a-5p was significantly 
downregulated in 4 paired lung cancer tissues(with > 2.0-fold change and FDR < 0.05) 
and was validated in the 38 independent paired tissues (63.16%, P < 0.05), CD73 was a 
novel target of miR-30a-5p predicted by TargetScan, miRanda, PicTar, MirTarget2, PITA 
and detected by luciferase report assay, then ectopic miR-30a-5p expression in cancer 
cells reduced CD73 expression. Conclusion: CD73 play a very important role in NSCLC, 
and regulated by miR-30a-5p. CD73 may provide a potential target for diagnosis and 
treatment for lung cancer. 
Keywords: MicroRNAs, NSCLC, CD73, miR-30a-5p
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P1.04-095 Integrin a11b1 Regulates Cancer Stromal Stiffness and Promotes 
Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer Roya Navab1, 
Elena Pasko2, Kris S. Kim3, Gilbert C. Walker3, Donald Gullberg4, Ming S. Tsao2 
1Research, Princess Margaret Hospital, Mg L/ON/Canada, 2Research, Princess Margaret 
Hospital and Ontario Cancer Institute, Mg L/ON/Canada, 3Chemistry, University of Toronto, 
Ms H/ON/Canada, 4Biomedicine, University of Bergen, Bergen/Norway
Background: Integrin α11β1 is a stromal cell-specific receptor for fibrillar collagens 
and is over-expressed in carcinoma-associated fibroblasts (CAFs) in non- small cell 
lung cancer (NSCLC). We have studied the direct role of stromal integrin a11 on the 
growth and metastasis of NSCLC cells using novel immune-compromised a11 deficient 
mice. Methods: We developed α11 non-expressing immune-deficient mice by back-
crossing for at least 10 times the α11-deficient heterozygous C57BL/6J mice (+/-) to 
obtain a homogenous C57BL/6 background. These were subsequently bred with the 
BALB/c SCID mice for 7 generations, producing α11-deficient heterozygous (+/-) in 
SCID background. In vivo studies were done using subcutaneous tumorigenicity assay 
and orthotopic model to evaluate metastatic potential of integrin α11. Immunostaining 
were carried out using integrin α11, α-SMA, and cytokeratin. PisroSirius red staining 
was used to visualize the collagen fibers. Images were taken by polarized-light 
microscopy using parallel and perpendicular polarizer orientations on an Olympus 
BX51 microscope. Second Harmonic Generation (SHG) was used to visualize fibrillar 
collagen and atomic force microscopy was applied to measure the stiffness in tumor 
stroma. Results: The tumor growth of both primary human lung cancer (PHLC) and 
established NSCLC cells in α11 knockout (α11-/-) mice was significantly impeded 
compared to wild type (α11+/+). Orthotopic implantation of a spontaneously metastatic 
NCI-H460SM cell line into the lungs of α11-/- and α11+/+ mice showed significant 
reduction in the metastatic potential of these cells in the α11-/- mice. Using mouse 
WG-6v2 Illumina Bead Chips, we identified that alpha11 expression correlates with that 
of a fibrillar collagen cross-linking enzyme, LOXL1, in the xenograft stroma. Fibrillar 
collagen was highly disorganized and had a significantly lower elastic modulus in the 
alpha11 knockout xenografts compared to wildtype. The results suggest a role for 
α11 in promoting tumor growth and metastatic progression by affecting the collagen 
stiffness of the tumor stroma. Conclusion: The integrin a11β1 signaling pathway in 
CAFs promotes tumor growth and metastasis of NSCLC cells. This appears closely linked 
to collagen cross-linking, the organization, and stiffness of fibrillar collagen matrices. 
Keywords: metastasis, non-small cell lung cancer, integrin, stroma stiffness
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P1.04-096 Second Tumors in Lung Cancer (LC) Patients. Should We Think 
About This Issue in Long Term Survival Setting? Martin Pitzzu1, Norberto Olguin1, 
Karina O´leary1, Maria V. Colica1, Ivana Fajreldine1, Nestor Spizzamiglio2, Miguel 
Galmes2, Gustavo Jankilevich1 1Oncology Unit, Hospital Carlos Durand, Buenos Aires/
Argentina, 2Thoracic Surgery, Hospital Carlos Durand, Buenos Aires/Argentina
Background: Lung cancer (LC) is the first cause of cancer death in men and the third in 
women in Argentina. Multiple studies have shown that patients with LC treatment prolong 
their survival and thus increases the risk of second tumors. The prevalence of second 
tumors after lung cancer ranges from 2% to 15%, which further increases after ten years 
since the diagnosis was made. Reports from latinoamerica are scarce. Methods: We 
evaluated retrospectively the medical record of pts with LC from 2005 to 2014. We 
recorded the presence of second tumor in the follow-up. Results: Two hundred twelve 
patients were registered. Ten patients (4.56%) were recorded with second tumors. 
Median age was 68 years old (r. 59-80),most of them were men (80%) and smokers 
A potential CDK partner of Cyclin Y is PFTAIRE kinase (PFTK1). In hepatocellular 
carcinoma, cell motility and invasion was enhanced by PFTK1 expression. But the 
function of CCNY1 and CCNY2 on cell migration and invasiveness has not been reported 
yet. Methods: Recombined plasmids carrying CCNY1 and CCNY2 were constructed and 
transfected to H1299 cells to obtain CCNY up-regulation cells. A lentivirus-based RNAi 
delivery system was used to inhibit CCNY mRNA expression. The role of CCNY in cell 
motility and invasion was investigated using wound healing and transwell assay. The 
protein levels in lung cancer cells were determined by western-blot, immunofluorescence 
technique and high-content cell analysis. Mouse xenograft experiments were carried 
out to study the metastasis ability of CCNY1 and CCNY2 in vivo. Immunohistochemistry 
was used to detect the CCNY protein level of lung cancer tissues. Results: cell motility 
and invasion activity were inhibited and MET (Mesenchymal - Epithelial Transition) was 
caused by down-regulating of CCNY in 95D and H1299 cells. CCNY2 could enhance cell 
migration and invasion activity in vivo and vitro. The F-actin level was regulated by CCNY2 
expression. In non-small cell lung cancer tissues, CCNY2 was highly expressed and the 
CCNY2 expression was associated with histological grade. Conclusion: CCNY2 was 
firstly detected in lung cancer cells and non-small cell lung cancer tissues. Our findings 
demonstrated CCNY2 not CCNY1 promoted cell motility and invasion by regulating 
the expression of F-actin and modulating intracellular cytoskeletal components. 
Keywords: CCNY, cell migration, cell invasion, actin cytoskeleton
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P1.04-094 NT5E(CD73) Is a Target of miR-30a-5p and Plays a Critical Role in 
Non-Small Lung Cancer Zeyi Liu1, Jianjie Zhu1, Yuanyuan Zeng1, Hualong Qin2, Jian-
An Huang1 1Department of Respiratory Medicine, the First Affiliated Hospital of Soochow 
University, Institute of Respiratory Diseases, Suzhou/China, 2Department of Cardiothoracic 
Surgery, the First Affiliated Hospital of Soochow University, Suzhou/China
Background: CD73, is a glycosylphosphatidylinositol (GPI) -linked 70-kDa cell surface 
enzyme that catalyzes the dephosphorylation of extracellular AMP to adenosine, its 
dysregulation contributes to tumorigenesis and progression of a variety of malignancies, 
and it was suggested as a therapeutic target of cancers. But the functional relevance of 
CD73 and the mechanism underlying its dysregulation in lung tumorigenesis remained 
unclear. Here, we mainly focus on if CD73 has important functions in non-small-cell lung 
cancer (NSCLC) by: 1.evaluating the clinicopathologic significance of CD73 through 
analysing its expression in 38 human NSCLCs tissues using quantitative PCR, Western 
Blot; 2. determining its role in NSCLC using in vitro assays; 3. investigating the regulatory 
mechanism of CD73 dysregulation in NSCLS cell lines. Methods: Western blot analysis, 
real-time quantitative reverse transcriptase PCR, RNA interference microarray analysis 
and trans well were performed on human NSCLC tissues and cell lines. Thirty-one paired 
NSCLC tissues and adjacent noncancerous lung tissues were collected.
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P1.04-098 Mithramycin Is a Potential Therapeutic Agent for Elimination of 
Stem-Like Cells in Lung Cancer Haobin Chen, Mary Zhang, Sichuan Xi, Yin Xiong, 
Julie A Hong, David S. Schrump Thoracic and Gi Oncology Branch, Nci, Bethesda/United 
States of America
Background: There have been several studies demonstrating existence of cancer stem-
like cells in lung cancers, and resistance of such cells to conventional chemotherapy 
or targeted agents. As such, targeting cancer stem-like cells is a potential strategy to 
prevent development of drug resistance and tumor recurrence. Previously our group 
has demonstrated that mithramycin, a specific inhibitor of transcription factor SP1, 
attenuates induction of side population (a phenotype of cancer stem-like cells) by 
cigarette smoke condensate, and modulates expression of multiple genes regulating 
stem-cell related pathways in lung cancer cells. The present study was performed 
to further examine the effects of mithramycin on stem cell signaling pathways, 
and ascertain if mithramycin can eliminate stem-like cells in lung cancer following 
exposure to conventional chemotherapeutic or targeted agents. Methods: Stem-
like cell populations in cultured H358 and H2228 lung adenocarcinoma cells were 
identified based on expression of stem cell markers, ALDH1 and CD133 using 
ALDEFLUORTM assay and flow cytometry, respectively. Sphere-formation assays were 
used to examine clonogenic growth of stem-like cells. qRT-PCR techniques were used 
to evaluate expression levels of stemness-related genes. Western blot techniques 
were utilized to assess activation of stemness-related (WNT/β-catenin and NOTCH) 
signaling pathways. Results: Small CD133+ or ALDH1+fractions were detected in 
untreated H2228 and H358 cells, respectively. Consistent with notion that stem-like 
cells are present in these two lines, H2228 and H358 cells formed pulmospheroids 
when cultured in stem cell media in low attachment plates; these phenotypic changes 
were accompanied by increased expression of stemness-related genes including Oct4, 
Sox2 and Nanog. Cisplatin treatment enriched CD133+ fraction in H2228 cells and 
ALDH+ fraction in H358 cells. Mithramycin abolished this enrichment, and mediated 
dose-dependent decreases in Oct4, Sox2 and Nanog expression in a dose-dependent 
manner. Preliminary analysis demonstrated that mithramycin decreased total as well 
as active forms of β-catenin, but did not affect levels of cleaved NOTCH1, suggesting 
that mithramycin eliminates lung cancer stem-like cells partially through suppression 
of WNT/β-catenin signaling. The effects of mithramycin on lung cancer stem-like cells 
induced by targeted agents are currently under investigation. Conclusion: Mithramycin 
suppresses stemness-related signaling, and is a potential therapeutic agent for 
elimination of stem-like cells emerging in lung cancers after cisplatin therapy. 
Keywords: Stem-like cell, WNT/beta-catenin, Cisplatin, Mithramycin
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P1.04-099 Wnt Blockers Inhibit the Proliferation of Lung Cancer Stem Cells 
Xueyan Zhang1, Yuqing Lou1, Xiaoxuan Zheng1, Huiming Wang1, Jiayuan Sun1, Qianggang 
Dong2, Baohui Han1 1Shanghai Jiaotong Univ. Affiliated Shanghai Chest Hospital, Shanghai/
China, 2Shanghaijiaotong University, Shanghai/China
Background: Previous study has confirmed that the occurrence of Wnt pathway 
activation is associated with risk of non-small-cell lung cancer recurrence. However, 
whether the pharmacologic blocking of the Wnt signaling pathway could provide 
therapeutic possibility remains unknown. The aim of the present study was to evaluate 
the therapeutic functions of the Wnt signaling pathway inhibitor pyrvinium pamoate 
(PP) on lung cancer stem cells (LCSCs) in vitro. Methods: Colony formation and 
sphere culture were performed to enrich LCSCs from three lung cancer cell lines: 
PC9, SPC-A1, and A549. After confirming stemness by immunofluorescence, PP was 
employed for cell viability assay by comparison with three other kinds of Wnt signaling 
inhibitor: salinomycin, ICG-001, and silibinin. The effect of PP on LCSCs was further 
verified by colony formation assay and gene expression analysis. Results: LCSCs were 
successfully generated by sphere culture from SPC-A1 and PC9 cells, but not A549 
cells. Immunofluorescence assay showed that LCSCs could express pluripotent stem 
cell markers, including NANOG, Oct4, KLF5, and SOX2, and Wnt signaling pathway 
molecules β-catenin and MYC. Half-maximal inhibitory concentrations of PP on SPC-A1, 
PC9, and A549 were 10 nM, 0.44 nM, and 0.21 nM, respectively, which are much lower 
than those of salinomycin, ICG-001, and silibinin. Moreover, significantly decreased 
colony formation and downregulation of pluripotent stem cell signaling pathway were 
observed in lung cancer cells after treatment with PP. Conclusion: Wnt signaling 
inhibitor PP can inhibit proliferation of LCSCs, and the Wnt signaling pathway could be 
considered a promising therapeutic or interventional target in lung adenocarcinoma. 
Keywords: pyrvinium pamoate, Wnt signaling pathway, sphere culture, colony formation
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P1.04-100 Combination of Pitavastatin and Erlotinib Induces Apoptosis and 
Growth Arrest in Non-Small Cell Lung Cancer (NSCLC)-Celllines Christoph 
Minichsdorfer, Duygu Aydemr Oncology, Medical University of Vienna, Vienna/Austria
Background: Primary resistance against epithelial growth factor receptor (EGFR) 
targetet therapy is often caused by K-Ras mutations or amplification of the MET-oncogene. 
HMG-CoA reductase inhibitors (statins) are well tolerated drug mainly prescribed for the 
the primary and secondary prophylaxis of coronary artery disease. However, the majority 
of statins are metabolized in the liver by Cyp3A4, which may lead to interactions with 
Erlotinib a tyrosin kinase inhibitor (TKI) which targets the EGFR. Therefore we tested the 
efficacy of Erlotinib in combination with Pitavastatin, which is metabolized by Cyp3A4, 
(90%). Regarding primary tumor, 90% (9 pts) were non small lung cancer (NSCLC) versus 
10% SCLC. The most frequent histological type was squamous carcinoma 60% (6 pts) and 
adenocarcinoma 30% (3 pts). The most frequent second tumor site was: lung 40% (4 pts) 
followed by larynx , bladder, kidney, ovary, breast and NHL. Median survival was 22 months 
(r. 1-160) in pts without second tumors versus 65 months (r. 22-165) in pts with second 
tumors (p: 0,005 – Fisher Test). The median of diagnosis time of second tumor was 22.5 
months. Conclusion: These results show the paramount importance of a correct follow-
up in these patients. In our series, one each twenty patients with lung cáncer had a second 
cancer during their follow-up. The most frequent site were respiratory and genitourinary 
tracts. There was a significant difference in the survival in pts with second tumors. 
Keywords: lung cancer, second tumors, long term survival, second tumors in lung 
cancer
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P1.04-097 Genome-Wide Methylome Alterations in Lung Cancer 
Nandita Mullapudi1, Bin Ye2, Masako Suzuki3, Melissa Fazzari3, Weiguo Han1, Miao Shi1, 
Gabrielle Marquardt1, Juan Lin4, Tao Wang4, Steven Keller5, Changcheng Zhu6, Joseph 
Locker6, Simon D. Spivack1 1Medicine/Pulmonary, Albert Einstein College of Medicine, 
Bronx/NY/United States of America, 2Bioinformatics, Albert Einstein College of Medicine, 
Bronx/NY/United States of America, 3Genetics, Albert Einstein College of Medicine, Bronx/
NY/United States of America, 4Biostatistics, Albert Einstein College of Medicine, Bronx/NY/
United States of America, 5Thoracic Surgery, Albert Einstein College of Medicine, Bronx/NY/
United States of America, 6Pathology, Albert Einstein College of Medicine, Bronx/NY/United 
States of America
Background: DNA cytosine methylation profiles are important features of malignancy. 
This study was designed to identify 5-methyl cytosines on a genome-wide scale in non-
small cell lung cancers (NSCLC) relative to paired non-tumor lung which, analyzed alone 
or coupled to transcriptome data, could suggest methylome-deregulated loci. Methods: 
Twenty-four NSCLC tumor (T) – non-tumor (NT) pairs were interrogated for 1.2 million 
CCGG-bounded fragments across all genomic compartments, using a methylation-
sensitive restriction enzyme based HELP-microarray assay. Expression microarrays 
were also employed, from specimens from the same lung resections. Results: We found: 
(i) Good correlation (r2 =0.52, p=0.0006) between HELP and the reference quantitative 
methylation assay MassArray ®; (ii) Wide distribution of differential methylation (DM) 
among 32,037 promoters (PR, 26% of array-represented loci), 248,721 gene bodies (GB, 
39 %), and 171,996 intergenic (IG, 48%) loci; (iii) In PR CpG island (CGI) hypermethylation 
exceeded CGI hypomethylation; (iv) DM hypermethylation in adenocarcinoma specifically 
was observed in many unexpected PR [e.g., RASL12; SPTAN1, mir-26a,] and GB [e.g., 
AKAP13, ANK family, PRKCE, ROS1] regions; (v) Overlay of DMxDE (differential expression) 
for adenocarcinoma yielded loci with canonical DM:DE patterns (e.g. PR hyper/hypo-
methylation:mRNA down/up-regulated n=80; GB hyper/hypo-methylated:mRNA up/down-
regulated GB n=3,136). (vi) Examples in adenocarcinoma hypermethylated PR loci with 
reduced expression included: HBEGF, DPT, AGER, SPARCL1, PTPRM; GB hypermethylated 
loci with upregulated expression included FERMT1, SLC7A5, FAP, TFAP2a genes. (vii) IPA 
analyses showed adenocarcinoma-specific promoter DMxDE overlay identifying familiar 
lung cancer nodes [tP53, Akt] and less familiar nodes [HBEGF, NQO1, GRK5, VWF, HPGD, 
CDH5, CTNNAL1, PTPN13, DACH1, SMAD6, LAMA3, AR ].
 
Conclusion: Methylome sampling, alone and combined with transcriptome data, yields 
new loci, as well as previously recognized ones, distributed throughout the genome that 
are deregulated in NSCLC. 
Keywords: DNA methylation, genome-wide, lung cancer
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compared the cell cycle of 2D cells and CTCs using propidium iodide. Next, we tested 
the CTCs and 2D cells with 5 µM vinorelbine, 50 µM gemcitabine, 0.1 µM paclitaxel, or 
10 µg/ml etoposide and measured total live cells after 2 days of culture. All analysis 
was performed using PRISM software and Student’s t-test was used to compare the 
significance of variance. Results: Cell cycle analysis of CTCs from a 4D model seeded 
with H1299 cells showed a significantly higher population of cells in G0/G1, resting cell 
cycle phase, than in respective 2D cells (65% vs 49%, p<0.01). Furthermore, our results 
showed a significant decrease in 2D cells upon treatment with all chemotherapeutic 
drugs. There was a significantly smaller number of 2D cells in the treatment group when 
treated with gemcitabine (p<0.0001), paclitaxel (p=0.01) and etoposide (p<0.0001) 
and vinorelbine (p=0.006) than in the control group. On the other hand, there was no 
significant effect of drugs on the total live CTCs from the 4D model with H1299 that were 
treated with all four drugs on a 96-well plate as compared to the untreated control group. 
For H1299 CTCs, there was no significant difference in the number of cells when treated 
with gemcitabine (p=0.38), paclitaxel (p=0.828), and etoposide (p=0.162), while there 
were significantly more CTCs with the vinorelbine treatment (p=0.04) compared to the 
control group. Conclusion: Overall, our results show that CTCs from the 4D model are 
different from parental 2D cells that were placed in the 4D model. These CTCs enter 
the G0/G1 phase, which may confer resistance to chemotherapeutic agents that are 
cell-cycle-dependent in efficacy. Further characterization of the CTCs from the model 
may provide the mechanism of the cell cycle arrest and chemotherapy resistance. 
Keywords: 4D model, Circulating tumor cells, Chemotherapy resistance, Cell cycle
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P1.04-103 Oncolytic Virus Therapy for Lung Cancers Using a Genetically 
Engineered Oncolytic Herpes Simplex Virus Type 1 G47Δ Yoshinori Sakata1, 
Yasushi Ino2, Tomoki Todo2, Norihiko Ikeda3 1Thoracic Surgery, Tokyo Medical University, 
Tokyo/Japan, 21Division of Innovative Cancer Therapy, The Institute of Medical Science, the 
University of Tokyo, Tokyo/Japan, 3Tokyo Medical University Hospital, Tokyo/Japan
Background: Lung cancer is the leading cause of cancer deaths in Japan and worldwide. 
Despite recent advances in targeted therapy, long-term survival of patients with lung 
cancer remains poor. Novel treatment approaches are needed to extend survival of 
these patients and improve control of this disease. Oncolytic virus therapy is a promising 
therapy for various tumor types. A third generation oncolytic herpes simplex virus type 
1 (HSV-1), G47Δ, has been tested in clinical trials in Japan for glioma, prostate cancer, 
and olfactory neuroblastoma. In this study, we investigated the potential of G47∆ as a 
new therapeutic modality for human lung cancer. Methods: Human lung cancer cell lines 
A549 (adenocarcinoma), EBC-1 (squamous cell carcinoma), LU99 (large cell carcinoma) 
and SBC-3 (small cell carcinoma) were used. Infectivity and cytopathic effects of G47Δ on 
lung cancer cell lines were assayed in vitro. Viral replication was determined by standard 
viral plaque assay. For in vivo studies, athymic mice harboring established subcutaneous 
tumors and lung tumors generated with A549 or EBC-1 were used. Results: All cell lines 
were susceptible and sensitive to G47Δ irrespective of histological types. Viral replication 
assay resulted in approximately a 200-fold increase in virus titer by 48 h. In subcutaneous 
xenograft models, intraneoplastic inoculations with G47Δ significantly inhibited 
the tumor growth compared with those with mock. In orthotopic xenograft models, 
intrapleural inoculations with G47Δ prolonged the survival time. Conclusion: Oncolytic 
HSV-1 G47Δ was effective in human lung cancer cell lines. Direct intratumoral 
inoculation of G47Δ induced an obvious therapeutic effect on lung cancer, suggesting 
G47Δ may be a potent therapeutic modality for all histological types of lung cancer. 
Keywords: herpes simplex virus, Oncolytic virus therapy
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P1.04-104 Lung Cancer Patients Derived Xenografts: Prospective Molecular 
Profiling and Potential Evaluation of Drug Resistance Teresa Mele1, Silvia Novello1, 
Francesca Cottino2, Marco Busso1, Diego Sardo1, Francesco Guerrera3, Enrico Ruffini3, 
Elena Asteggiano4, Luisa Delsedime5, Luisella Righi1, Andrea Bertotti6, Giorgio V.V. 
Scagliotti1, Livio Trusolino6 1Department of Oncology, University of Turin, Orbassano/
Italy, 2Candiolo Cancer Institute – Fpo Irccs, Candiolo/Italy, 3Department of Surgery, Section 
of Thoracic Surgery, University of Turin, Turin/Italy, 4Department of Thoracic Surgery, 
University of Turin, Orbassano/Italy, 5Department of Medical Sciences, University of Turin, 
Turin/Italy, 6Department of Oncology, University of Turin, Candiolo/Italy
Background: The discovery of “driver mutations” such as the Epidermal Growth Factor 
Receptor (EGFR) and the Anaplastic Lymphoma Kinase (ALK) has led to a remarkable 
improvement in the outcomes of lung adenocarcinoma, which accounts 50% of the non-
small cell lung cancer (NSCLC) diagnoses. Up today, no druggable molecular targets 
have been identified for squamous carcinoma or small cell lung cancer, which are still 
treated with the “one-fits-all” therapeutic approach, as it is for a relevant percentage 
of adenocarcinomas too. The precise definition of molecular profile and, possibly, the 
description of predictive factors are research priority in the thoracic oncology field. The 
vast majority of preclinical data are based on in vitro studies, but cell lines models do 
not entirely reflect tumour characteristics and are hampered by genetic divergence from 
primary tumours. Patient derived tumour xenografts (PDTX) are a valuable alternative to 
closely reproduce tumour biology and to prospectively characterize in vivo mechanisms 
of cancer growth and therapeutic response. Through the generation of a cohort of lung 
cancer xenopatients, the project aims to confirm the reliability of such models in this 
disease and to prospectively characterize its biomolecular features. Methods: Metastatic 
and early stages lung cancer cases are considered for the enrolment. Written informed 
consent is requested from each patient. Fresh tumour tissue from lung biopsies or lung 
resections is collected and kept in serum free medium (4° C), embedded in 20% matrigel 
for the treatment of primary Erlotinib-resistant NSCLC celllines. Methods: Experiments 
were carried out with human NSCLC celllines A549 (K-RAS mutation), Calu-6 (K-RAS 
mutation, P53 mutation), HCC 827 (EGFR mutation, Erlotinib sensitive) and H1993 (MET 
amplification). Apoptosis was measured by the activity of caspase 3 by cleavage of 
specific fluorescent caspase substrates, by binding of AnnexinV by FACS analysis or by 
the cleavage of PARP by Western blot. Inhibition of growth was assessed by MTS assays. 
The effect of either drug alone or in combination on phosphorylation of AKT and ERK1/2 
was evaluated by Western blot. Results: Inhibition of growth by erlotinib was seen in 
the sensitive cell line HCC 827 but not in A549, Calu6 and H1993. Pitavastatin led to 
growth inhibition in all 4 cell lines investigated in a dose dependant manner. However, 
the combination of Pitavastatin and Erlotinib was significantly more effective than either 
drug alone. Erlotinib and Pitavastatin did not induce apoptosis when used as single 
agents in A549, Calu6 or H1993. When a combination of TKI and Pitavastatin was used 
we observed significantly increased caspase 3 activity and a higher rate of annexin V 
positive cells. Moreover an increased cleavage of PARP was shown in the combination 
treatment. Taken together we could show increased rate of apoptosis when Erlotinib and 
Pitavastatin where used in combination. Importantly the activation of survival pathways 
mediated by phosphorylation of AKT was markedly decreased, by the combined 
treatment in A549, Calu6 and H1993 cells. ERK 1/2 phosphorylation was reduced in 
H1993 and Calu6 cells upon combined treatment. Conclusion: Our data indicate, that 
the treatment of primary EGFR-TKI resistant cells (A549, Calu6 and H1993) with Erlotinib 
in combination with Pitavastatin leads to growth arrest and an induced rate of apoptosis. 
Keywords: NSCLC, TKI, Statins, Erlotinib
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P1.04-101 Utility of Patient-Derived Cell Line Models Using Conditional 
Reprogramming for in Vitro Pharmacogenomics Platform Hyun Chang1, Hye 
Ryun Kim2, Yong-Wha Moon2, Su Jin Heo2, Sun Min Lim2, Joo-Hang Kim2, Soonmyung 
Paik3, Byoung Chul Cho2 1Hematology and Medical Oncology, Catholic Kwandong University 
International St. Mary’S Hospital, Incheon/Korea, 2Division of Medical Oncology, Yonsei 
Cancer Center, Yonsei University College of Medicine, Seoul/Korea, 3Severance Biomedical 
Science Institute, Yonsei University College of Medicine, Seoul/Korea
Background: To evaluate the potential of conditional reprogrammed cells (CRCs) 
established from biopsy or effusion samples of advanced non-small cell lung cancer 
(NSCLC) for in vitro pharmacologic screen and identification of drug resistance 
mechanisms. Methods: A total of 48 tumor specimens obtained from 46 patients with 
NSCLC were cultured with irradiated fibroblast feeder cells and Rho kinase inhibitor 
(Y-27632) to induce tumor cells to proliferate indefinitely. The cell lines established 
from patients harboring EGFR mutation or other druggable oncogenes were subjected 
to genetic analyses and pharmacologic screen. Corresponding tumor cells were 
injected into nude mice to test for tumorigenicity and efficacy of targeted agents in 
vivo. Results: Twenty one male patients and twenty five female patients were assessed 
for establishment of CRC. Adenocarcinoma was the most frequent histologic type 
(84.7%). There were 21 patients (46%) who harbored an active EGFR mutation. There 
were four patients with ALK fusion and five with ROS1 fusion. Twenty-six patients 
experienced disease progressed while on treatment with EGFR (20), ALK (2) or ROS1 
(4) tyrosine kinase inhibitors. Tumor cells came from primary or distant metastases in 
48% and 52%, respectively. Thirty one (65%) samples were obtained by tumor biopsy 
and 17 from malignant pleural effusion. Nine CRC model were successfully established 
(18.7%, 9/48). The successful growth was not dependent on the clinicopathologic 
characteristics. Both cells from pleural effusion (4 of 17) and biopsy (5 of 31) and 
adenocarcinoma (8 of 41) and squamous cell carcinoma (1 of 3) were successfully 
cultured. For biopsy samples, the success rate of cells obtained from primary lung lesion 
was 21.7% (5 of 23) and cells from metastatic site outside lung was 0% (0 of 8) (P = 0.3). 
For effusion samples, volume of effusion required for CRC was not significant factors for 
establishment (success vs. failure cases: mean volume 500 ml vs. 267 ml). The genetic 
characteristics of patients with non-squamous cell carcinoma did not affect the success 
rate of CRC (EGFR mutation, 4 of 21; ALK translocation, 0 of 4; ROS1 translocation, 
2 of 5; wild or unknown, 2 of 15). Two xenograft models with CRC were successfully 
established and passaged to maintain tumor in vivo. Conclusion: The CRC models 
derived from NSCLC patients provide useful in vitro platforms of preclinical studies 
evaluating novel targeted therapies and uncovering the drug resistance mechanisms. 
Keywords: Reprogrammed Cell, Lung cancer,
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P1.04-102 Ex Vivo 4D Lung Cancer Model CTCs Show Resistance to 
Chemotherapeutic Drugs Dhruva K. Mishra1, Min P. Kim2 1Surgery, Houston Methodist 
Research Institute, Houston/TX/United States of America, 2Surgery, Houston Methodist 
Hospital, Houston/United States of America
Background: Metastasis is the main cause of cancer-associated mortality. We recently 
developed an ex vivo 4D lung cancer model that mimics metastasis. One of the unique 
features of the model is its ability to isolate tumor cells in three different phases of 
cancer progression: primary tumors, circulating tumor cells (CTCs), and metastatic 
lesions. In this study, we want to further characterize the CTCs from the model and 
determine whether they enter a resting cell cycle phase, and conferring them to 
be resistant to chemotherapeutic drugs. Methods: We harvested rat lung and heart 
block and decellularized them using 0.1% sodium dodecyl sulfate and 1% Triton-X100. 
Acellular lung scaffolds were set up in a customized bioreactor and seeded with 50 
million cells of human lung cancer cell line H1299 that were cultured on a petri dish 
(2D). Culture media was replenished and CTCs were collected daily. We measured and 
S483Copyright © 2015 by the International Association for the Study of Lung Cancer
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into the C57BL/6 mice in the proximal dorsa midline. The mice were randomized into 
4 groups, group 1) saline control, 2) G-CSF alone, 3) CDDP alone and 4) CDDP plus 
G-CSF group. The mice were injected 5 mg/kg CDDP intraperitoneally 2 hours after 
tumor cell transplantation and then, were given 5 mg/kg CDDP intraperitoneally each 
week. Two hours after CDDP or saline injection, the mice were given 30 mµg/kg G-CSF 
or the same volume of saline intraperitoneally each day, and 21 days after tumor cell 
transplantation they were sacrificed and the tumors were removed. Results: We found 
that LL-2 and KLN-205 cell proliferation was unchanged significantly in the presence of 
various concentrations of G-CSF. To ensure that the results were due to the absence of 
the G-CSF receptor,we investigated the G-CSF receptor mRNA in these two cell lines by 
RT-PCR.Groups of mice were intraperiotoneally given 5mg/kg CDDP or saline per week 
starting 2 hours after tumor cell transplantation. Then, 2 hours after CDDP or saline 
injection the mice were intraperitoneally given 30m µg/kg G-CSF or saline per day. Tumor 
growth was markedly inhibited in the CDDP and CDDP+G-CSF treatment group compared 
with the saline control group. Concurrent administration of G-CSF significantly enhanced 
the tumor suppressing effect of CDDP in early stage tumor growth. 7 days after tumor 
cells transplantation, the tumor volume were 6.84±9.07 for CDDP plus G-CSF treatment 
VS 16.34±10.29 mm3 for CDDP alone (p=0.047). Conclusion: In summary, our 
results provide evidence that G-CSF as a growth factor does not promote tumor cell 
proliferation. Concurrent (Combination) administration of G-CSF significantly enhances 
the tumor suppressing effect of CDDP in early stage tumor growth. Thus, concurrent 
(combination) administration of G-CSF with anticancer agents is a safe and effective 
method for reducing chemotherapeutic agent-induced myelosuppression. In spite of 
further studies are required to determine whether this effect of G-CSF is a common 
feature against lung cancer and the solid tumors of the other organs, in this time, 
our study suggested a novel importance of G-CSF treatment against cancer therapy. 
Keywords: G-CSF, lung cancer, CDDP, proliferation
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P1.04-107 Prediction of Molecular Tageting Drugs’ Sensitivity Enabled by 
In-Vitro Drug Sensitivity Tests for Surgically Resected Lung Cancer Ryohei 
Miyazaki, Takashi Anayama, Kentaro Hirohashi, Hironobu Okada, Motohiko Kume, 
Nobutaka Kawamoto, Kazumasa Orihashi Thoracic Surgery, Kochi Medical School, Kochi 
University, Kochi/Japan
Background: The molecular target anticancer drugs such as EGFR-TKI and ALK inhibitor 
have dramatically changed the strategy of medical treatment for lung cancer. The 
investigation of each driver mutation is recommended to pick up the responder to the 
corresponding molecular targeting drugs. In-vitro anticancer drug sensitivity tests such 
as succinate dehydrogenase inhibition test (SDI) and the collagen gel-droplet embedded 
culture drug sensitivity test (CD-DST) are able to examine the sensitivities of the surgically 
resected fresh cancer tissue to multiple cytotoxic chemotherapeutic drugs at one time. 
We develop the method to predict the effect for multiple molecular targeting 
drugs for individual lung cancer patient by applying CD-DST or SDI. 
Methods: Firstly, we titrated the growth inhibitory effect of the molecular targeting drugs 
on cultured lung cancer cell lines (H460, A549, HCC827, H1975, H3122) using SDI and 
CD-DST. Secondly, we evaluated sensitivity of surgically resected cancer tissues obtained 
from 33 lung cancer patients to Erlotinib by using SDI or CD-DST. Finally, we compared 
the drug sensitivity and EGFR mutation profile. Results: Both Erlotinib and Crizotinib 
exhibited significantly stronger growth inhibitory effects on lung cancer cell lines with 
target gene alterations than the others without driver mutation or with T790M-mediated 
resistance to EGFR-TKI. In clinical study using SDI (n=21), 20µM of Erlotinib inhibited 
cell growth more in EGFR mutant cases (60.0 ± 9.8(%)), than in wild type EGFR cases 
(86.8 ± 13.9 (%)) (p = 0.0004). The area under the curve (AUC) of receiver operating 
characteristic (ROC) curve was 0.958 for cell viability. The ratio showed best combination 
of sensitivity and specificity for prediction of drug sensitivity at values >72.7 (93.3% 
sensitivity and 100% specificity). By using CD-DST method (n=12), the cell viabilities 
were 33.5 ± 21.2(%) in EGFR mutants, and 79.0 ± 18.6(%) in wild type EGFR cases (p = 
0.026). The AUC of ROC was 0.963 for cell viability. The ratio showed best combination 
of sensitivity and specificity for prediction of drug sensitivity at values >55.9 (88.9% 
sensitivity and 100% specificity) Conclusion: The growth inhibitory effects of Erlotinib 
evaluated by both SDI and CD-DST were correlated with EGFR mutation profile. In-vitro drug 
sentivity tests may be able to predict the clinical effect of molecular targeted drugs. 
Keywords: molecular tageting drug, CD-DST, SDI, lung cancer
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P1.04-108 Non-Invasive Assessment of Cisplatin and Erlotinib Efficacy in 
Lung Cancer by Monitoring an Orthotopic SCID Mouse Model with Computed 
Tomography Tamaki Otani1, Kazuya Kondo2, Hiromitsu Takizawa2, Koichiro Kajiura2, 
Haruhiko Fujino2, Hideki Otsuka1 1Tokushima University, Tokushima/Japan, 2University 
Tokushima, Tokushima/Japan
Background: Orthotopic models are likely to provide more relevant pharmacokinetic 
and pharmacodynamic information than subcutaneous models. We established an 
orthotopically implanted SCID mouse model of lung cancer without thoracotomy. This 
model is simple and reproducible and many transplanted mice can be produced at once. 
The main disadvantage of the orthotopic model is that tumor size and volume changes 
are difficult to continuously monitor reproducibly and can only be assessed at necropsy. 
In this study, we evaluated the usefulness of small-animal computed tomography (CT) to 
non-invasively and repeatedly monitored the inhibitory effect of cisplatin and erlotinib on 
lung cancer in an orthotopic SCID mouse model. Our goal was to establish a standard 
model to evaluate efficacy of novel treatment regimens in lung cancer. Methods: We 
and subcutaneously engrafted into NSG and NOD SCID mice, within 24 hours from 
sample collection. The exponentially growing tumours are passaged subcutaneously to 
other mice for a second passage after which they are archived for subsequent analyses 
(formalin fixed, snap frozen and RNA later). Each sample from surgical resection is also 
stored to create a DNA lung cancer bank. Results:Fourteen samples from TC-guided 
lung biopsies and sixty-six from radically resected NSCLC were engrafted in NSG and 
NOD SCID mice lineage in a 1:1 ratio. Due to the low engraftment rate and high morbidity 
observed in NGS mice in the first 73 samples, subsequent engraftments and expansions 
were performed in NOD SCID mice only. The overall engraftment rate in biopsy samples 
was 0 % in NGS and 7.14 % in NOD SCID mice as opposed to 0 % in NGS and 27,27 % in 
NOD SCID for surgical samples (50% adenocarcinomas, 44,45% squamous carcinomas 
and 5,55% sarcomatoid carcinomas). Nineteen samples underwent the second passage: 
of those, 10 samples have been archived after the second successful passage and will 
be used for further analyses. Conclusion: The trial is still ongoing and a longer follow-up 
is needed. In biopsy-derived samples, engraftment is deeply limited by the paucity of 
tissue. The results of this study will possibly confirm the reliability of PDTX in lung cancer 
and provide prospective biomolecular characterization for different histological types. 
Keywords: lung cancer mouse models, lung cancer, patient derived tumour xenografts
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P1.04-105 The Development and Assessment of Advanced Cellular Models for 
the Study of Non-Small Cell Lung Cancer Sarah-Louise Ryan1, Anne-Marie Baird2, 
Anthony Davies1, Kenneth J. O’Byrne3 1Translational Cell Imaging Queensland, Queensland 
University of Technology, Brisbane/QLD/Australia, 2Cancer Ageing and Research Program, 
Queensland University of Technology, Brisbane/Australia, 3Cancer and Ageing Research 
Program, Princess Alexandra Hospital and Queensland University of Technology, Brisbane/
Australia
Background: The key mechanisms that underlie drug resistance in lung cancer have 
yet to be fully elucidated. A significant limiting factor is the lack of biologically relevant 
cellular models for basic laboratory research. To address these issues, many are now 
turning to three-dimensional (3D) based cellular assay systems that permit the formation 
of multicellular structures such as tumour spheroids. Depending on their size the internal 
microenvironment of these structures mimics closely that of those in vivo. In the majority 
of cases, spheroids with a diameter greater than 100µm exhibit an asymmetry in cellular 
proliferation and viability - proliferating tumour cells at the periphery; cell-cycle arrested 
cells at larger distances from the surface. Regions of necrosis associated with reduced 
oxygen tension and hypoxia have often been reported. This study compared drug 
resistant models of non-small cell lung cancer (NSCLC) in 3D culture with those in grown 
in two-dimensional (2D) culture. The behaviour of cells grown in these distinct geometric 
configurations was monitored and compared by measuring viability, proliferation and 
oxygen tensions. Methods: Happy Cell Advanced Suspension Medium™ (ASM) was 
chosen to culture our 3D spheroids. This polymer-based formulation was selected for 
its ease of use, as well as its compliance with liquid handling, high content imaging and 
analysis (HCSA) and high throughput screening (HTS) systems. Isogenic NSCLC cell line 
models of cisplatin resistance were cultured in 2D and 3D cell culture systems. Cisplatin 
sensitive (Pt) and isogenic cisplatin resistant (CisR) NSCLC sub-types were studied. IC50 
values were calculated and a positive control was selected. All cultures were grown in 
a range of cisplatin concentrations for 72 hours. Subsequently, viability and hypoxia 
assays were conducted in order to compare the response of Pt and CisR cells in both 2D 
and 3D culture systems. Morphological analysis was performed via high content analysis 
(HCA) and confocal microscopy. Results: At equivalent cisplatin concentrations 3D 
spheroids exhibit greater resistance compared with monolayers. Imaging experiments 
have shown that these 3D structures have a central necrotic core, a feature of the 
asymmetric growth patterns associated with 3D structures. Conclusion: Happy Cell 
ASM is a novel 3D culture medium for generating multicellular tumour spheroids and 
has potential for HTS and HCSA. When treated with cisplatin our spheroids exhibited 
resistance to therapy compared to 2D monolayer cultures. These results suggest that 
spheroids may provide a more accurate in vitro model to elucidate mechanisms of drug 
resistance and may aid the identification of novel targets to re-sensitise patient therapy. 
Keywords: 3D Cell Culture, drug resistance, Multicellular tumour spheroids, non-small 
cell lung cancer
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P1.04-106 Granulocyte Colony-Stimulating Factor Enhances the Anticancer 
Effects of Cisplatin Against Lung Cancer by Promoting Angiogenesis Yasushi 
Ohno1, Toshiyuki Sawa2, Sayaka Toyoshi1, Daizou Kaito1, Koumei Yanase1, Fumitaka Ito1, 
Junki Endo1, Megumi Morishita1, Masahiro Asano1, Hidenori Mori1, Shinya Minatoguchi1 
1Respirology, Gifu University, -/Japan, 2Respirology, Gifu Municipal Hospital, -/Japan
Background: G-CSF is a hematopoietic growth factor which enhances the proliferation 
and differentiation of neutrophil precursor cells. However the results of studies on G-CSF-
induced tumor growth are controversial. Recently, some studies reported that G-CSF 
stimulates the growth of tumor cells such as colon cancer cells, small lung cancer cells 
, skin carcinoma cells and astrocytoma cells, In contrast, Brandstetter et al. reported 
that G-CSF does not exhibit any effect on the proliferation of ovarian carcinoma cell 
lines or tumor samples despite presence of the G-CSF receptor in the tested cell 
lines and biopsies. Methods: In vitro effects of G-CSF on tumor cell proliferation. 
Two mouse non-small lung cancer cell lines, Lewis lung cancer cell line (LL-2) and KLN-205 were 
grown in DMEM medium with FBS. In vivo evaluation of the effects of G-CSF on tumor growth. 
Seven week-old male C57BL/6 mice were purchased from CLEA Japan . LL-2 cancer 
cells were grown in culture, harvested and subcutaneously injected as a suspension 
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antiserum were tested in vitro. A/J mice intravenously injected with LM2 non-small 
cell lung cancer cells were treated with PBS, VSV-IFNβ or VSV-IFNβ-infected BOECs 
(3 sequential treatments 3 weeks after tumor cell injection). Tumor growth, intratumor 
viral titer and survival were tested. Results: We demonstrated that VSV-IFNβ-infected 
BOECs can effectively transfer VSV-IFNβ to co-cultured human lung cancer cells 
and result in viral oncolysis even in the presence of VSV antiserum. In mice bearing 
metastatic lung cancer, BOECs injected via tail vein preferentially accumulated in 
lung tumor tissues, and were absent in either normal lung or liver tissues. Moreover, 
treatment with VSV-IFNβ-BOECs had higher and more sustained intra-tumoral viral titers 
comparing with those treated with either PBS or naked VSV-IFNβ. Furthermore, there 
was a trend (p=0.09) towards reduced tumor burden in the VSV-IFNβ-BOEC treated 
mice (n=5). Currently, we are testing the survival benefit of VSV virus in metastatic 
lung cancer model. Conclusion: In summary, the pre-clinical data showed promise to 
support developing a clinical protocol in the near future to assess the safety, response 
and efficacy of VSV-IFNβ-infected BOECs in treatment of metastatic lung cancer. 
Keywords: blood outgrowth endothelial cells, non-small cell lung cancer, vesicular 
stomatitis virus
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P1.04-111 Establishing a Mouse Model for Radiation-Induced Esophagitis 
Kyung Su Kim1, Sanghyuk Song1, Young-Eun Kim2, Seong-Uk Jeon2, Seoyeon Bok2, 
Beom-Ju Hong2, Chan-Ju Lee2, Moon-June Cho3, Hong-Gyun Wu1, G-One Ahn2, Hak Jae 
Kim1 1Department of Radiation Oncology, Seoul National University College of Medicine, 
Seoul/Korea, 2Division of Integrative Biosciences and Biotechnology, Pohang University of 
Science and Technology (Postech), Pohang,Gyeongbuk/Korea,3Department of Radiation 
Oncology, Chungnam National University Hospital & Cancer Research Institute, Daejeon/
Korea
Background: To establish mouse models of radiation-induced esophagitis with 
fractionated irradiation using BALB/c or C57Bl/6 mice Methods: Thoracic irradiation at 
0, 8, 12, or 15 Gy was given daily for 5 days by 320 kV X-ray irradiator to anesthetized, 6 
week-old male BALB/c (n = 4~5 per group) or C57Bl/6 mice (n = 4 per group). Changes 
in the body weight and daily food intake were assessed for both strains of mice. At 
day 11, BALB/c esophagus was harvested and examined for the following assays: 
(i) histology by H&E staining; (ii) Cytokine array (R & D Systems); (iii) fluorescence-
activated cell sorting (FACS) analysis by using Annexin V and propidium iodide (PI); (iv) 
quantitative real time-PCR (qRT-PCR) (Life Technologies) analysis. Results: We observed 
that fractionated irradiation produced a significant body weight reduction in Balb/c mice 
(20% by 12Gy X 5 and 30% by 15 Gy X 5). In contrast, C57Bl/6 mice seemed to be more 
resistant to fractionation irradiation as they exhibited little change in the body weight. As 
food intake in Balb/c mice was also significantly decreased at these doses compared 
to the control mice (p<0.05 for 12 Gy X 5 and P<0.01 for 15 Gy X 5), dose of 12Gy x 5 
were selected for all assays. Histopathology of irradiated Balb/c mice showed erosive 
epithelium, mucosal detachment, and leukocyte infiltration. FACS analysis confirmed 
that irradiated esophagus had increased number of apoptotic cells, as evidenced by 
Annexin V and PI double positivity. We found that cytokines for C5/C5a, Timp-1 (tissue-
inhibitor of metalloproteinases-1), Ccl2/Mcp-1 (monocyte chemoattractant protein-1), 
and Il-16 (interleukin-16) were increased in the irradiated esophagus compared to non-
irradiated esophagus. qRT-PCR analyses revealed that Timp-1 as well as other genes 
involved in extracellular matrix remodeling including Pai-1 (plasminogen activator 
inhibitor-1), Gm-csf (granulocyte macrophage-colony stimulating factor), Vegf (vascular 
endothelial growth factor), and Sdf-1 (stromal-derived factor-1) were increased 
whereas Egf (epidermal growth factor), a potent mitogen for epithelial cells, was 
significantly decreased in the esophagus of irradiated mice. Conclusion: We established 
that BALB/c mice were more sensitive to fractionated irradiation than C57Bl/6 mice 
for developing symptoms reflecting radiation-induced esophagitis. In BALB/c mice, 12 
Gy X 5 regimen seem to be the best schedule producing a significant reduction in the 
body weight and food intake, and histopathologic features similar to human esophagitis. 
Increased RNA transcripts for extracellular remodeling and cytokines indicate an active 
dynamics of tissue remodeling in the irradiated esophagus. Decreased Egf expression 
in the irradiated esophagus suggests that EGF may be a potential therapeutic strategy 
to treat radiation-induced esophagitis and we are currently investigating this strategy. 
Keywords: Mouse model, EGF, Radiation esophagitis, Fractionated radiation
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P1.04-112 Rapamycin Attenuated Epithelial-Mesenchymal Transition in Lung 
Cancer Cells Lianjun Lin1, Xinmin Liu1, Nanping Wang2 1The Geriatrics Department, 
Peking University First Hospital, Beijing/China, 2Key Laboratory of Molecular Cardiovascular 
Science of Ministry of Education, Peking University Health Science Center, Beijing/China
Background: Mammalian target of rapamycin (mTOR) plays an important role in the 
physiological regulation of cell growth and development. Dysregulation of mTOR 
signaling frequently occurs in malignancies, including lung cancer. Inhibition of mTOR 
is a promising therapeutic strategy against lung cancer shown by clinical trials. But its 
mechanism remains unclear. Epithelial–mesenchymal transition (EMT) is critical in the 
pathogenesis of lung carcinoma. This study aimed to examine the effect of rapamycin 
on TGF-β1-induced EMT in lung carcinoma cells. Methods: Lung carcinoma cells (A549 
cells) were pre-incubated with rapamycin and stimulated with TGF-β1. Morphological 
changes were observed under microscope. Cell phenotype markers were analyzed 
by western blotting and immunocytochemistry. F-actin cytoskeleton rearrangement 
was examined by phalloidin staining. Cell migration ability was measured by cell 
scratch test. The phosphorylated Smad2/3 and mTOR were measured by western 
created an orthotopic lung cancer transplantation model in mice. Suspensions of 2.0 × 
104 cancer cells were injected into the left lung of SCID mice. We tested several non-small 
cell lung cancer cell lines, A549, FT821 and PC9 cells—only PC9 cells have an epidermal 
growth factor receptor (EGFR) mutation. We treated mice with cisplatin or erlotinib. 
When tumor volume had reached 1–3 mm3, mice were divided into three groups: control, 
cisplatin and erlotinib. After treatment had begun, tumor volumes were evaluated by 
CT measurement every 3 days. All mice were sacrificed for histopathological analysis 
on day 18 after treatment began. Results: Mice implanted with A549, FT821 and PC9 
cells were treated beginning on day 21, 50 and 35, respectively, after implantation. In 
mice transplanted with PC9 cells, tumor volume in the cisplatin group measured by CT 
was lower than in the control group, though not achieving statistical significance. In mice 
with A549 cells, tumor volume in the cisplatin group was similar to that in the control 
group. In mice with FT821 cells, tumor volume in the cisplatin group was significantly 
lower than in the control group. The mice in the cisplatin group showed temporarily 
decreased body weights. Histopathological analysis on day 18 after treatment 
showed necrotic lesions in lungs of mice transplanted with PC9 and FT821 cells but 
not in those with A549 cells. In mice with PC9 cells, which have a deletion of exon 19 
in the EGFR gene, tumor volume in the erlotinib group was significantly lower than in 
the control group. In mice with A549 and FT821 cells, tumor volume in the erlotinib 
group was similar to that in the control group. There were no body weight changes 
in the erlotinib group. Histopathological analysis on day 18 after treatment showed 
necrotic lesions in lungs of mice implanted with PC9 cells but not in those with A549 and 
FT821 cells. Conclusion: This study supports using CT to monitor, non-invasively and 
repeatedly, tumor progression and therapeutic response of lung cancer in an orthotopic 
mouse model. This model is more analogous to the clinical condition than subcutaneously 
transplanted tumor models. Therefore, orthotopic tumor models have potential value as 
fundamental tools for the design and development of new therapies for cancer treatment. 
Keywords: orthotopic mouse model, Cisplatin, Erlotinib, computed tomography
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.04-109 Antitumor Efficacy of Histone Deacetylase Inhibitor or in 
Combination with EGFR-TKI in Non-Small Cell Lung Cancer Cell Lines Xiaohong 
Han, Ningning Zhang, Jiarui Yao, Yuankai Shi Department of Medical Oncology, Cancer 
Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 
College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, 
Beijing/China
Background: To investigate the antitumor efficacy of histone deacetylase inhibitor 
(HDACi) or in combination with epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) in non-small cell lung cancer (NSCLC) cell lines. Methods:Ten NSCLC cell 
lines with varying mutation status were treated with chidamide (HDACi) and icotinib 
(TKI) alone or in combination. MTS assay was performed to determine IC50 of each drug 
or in combination. Cell cycle was analyzed by flow cytometry. Markers of epithelial-to-
mesenchymal transition (E-cadherin), apoptosis (caspase-3, PARP) were determined 
by western blot. Results: The results demonstrated that A549 (TKI-resistant, KRAS-
mutated), HCC827 (TKI-sensitive, EGFR-mutated), HCC827IR (TKI-resistant, EGFR-
mutated) was sensitive to chidamide, the IC50 of these three cell lines was less than 
0.5nM and the IC50 of the other seven cell lines was more than 5µM. Chidamide increased 
the sensitivity of icotinib synergistically in EGFR and KRAS wild type cells (H292, Calu-3), 
KRAS mutant cells (A549, H460), and TKI resistant EGFR mutant cells (H1650, H1650GR, 
HCC827IR, H1975), but the synergistic effect was most meaningful in H1975 (EGFR 
L858R and T790M mutation). We also found that H460 and Calu-3 had no E-cadherin 
expression, H1975 had low level of E-cadherin expression, and the other seven cell 
lines had relatively high levels of E-cadherin expression. Moreover, with the increasing 
dosage of chidamide, E-cadherin expression was significantly increased in H1975 cell 
line, but was not changed in chidamide sensitive cell lines. In addition, chidamide alone 
or in combination with icotinib could induce H1975 cell cycle arrest at G1/S phase, and 
reduce the expression of casepase-3 and PARP. Conclusion: These results suggest 
that chidamide as a single agent exhibits antiproliferative effectives in NSCLC cells 
with EGFR and KRAS mutations. The combination of chidamide and icotinib may be a 
beneficial treatment strategy for NSCLC with EGFR-T790M mutation. But the role of 
chidamide in the antiproliferative or synergistic mechanisms should be further explored 
Keywords: Epidermal growth factor receptor tyrosine kinase inhibitor, non-small cell 
lung cancer, histone deacetylase inhibitor, antitumor efficacy
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P1.04-110 Use of Blood Outgrowth Endothelial Cells as a Carrier of Oncolytic 
Vesicular Stomatitis Virus-Interferon Beta in Treating Metastatic NSCLC Yan Ji1, 
Blake Jacobson1, Manish Patel1, Andrea Kratzke1, Stephen Russell2, Robert Kratzke1 
1Hematology/Oncology/Transplant, University of Minnesota, Minneapolis/MN/United States 
of America, 2Molecular Medicine, Mayo Clinic, Rochester/AL/United States of America
Background: Oncolytic viruses have been extensively studies in the past two decades 
and are promising for cancer treatment. We have shown previously that vesicular 
stomatitis virus expressing interferon β (VSV-IFNβ) has oncolytic activity in vitro and 
in vivo in an immune competent mouse model of NSCLC. However, for treatment of 
metastatic NSCLC, intravenous delivery of VSV-IFNβ still faces several challenges, such 
as rapid clearance from bloodstream due to serum complement as well as sequestration 
in lymphoid tissue. In order to overcome these problems, we are exploring the potential 
role of blood outgrowth endothelial cells (BOECs) as carrier cells to deliver VSV-IFNβ 
to lung tumor sites. Methods: Efficacy of VSV-IFNβ-infected BOECs in transferring 
VSV-IFNβ to co-cultured human lung cancer cell lines in presence or absence of VSV 
S485Copyright © 2015 by the International Association for the Study of Lung Cancer
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P1.04-115 Chemoterapy and Targeted Therapy Sensitivity Testing in Malignant 
Pleural Effusions Safiye Aktas1, Pınar Ercetin1, Banu Demir1, Ayca Pamukoglu1, Begum 
Gorgulu1, Zekiye Altun1, Atila Akkoclu2 1Dokuz Eylul University Faculty of Medicine, Izmir/
Turkey, 2Dokuz Eylul University Medical Faculty, Izmir/Turkey
Background: Clinical management of malignant pleural effusions (MPE) is a major 
problem in oncology with short survival. MPE is caused by various types of malignancies, 
especially lung, breast carcinomas, lymphomas besides ovarian carcinoma, malignant 
melanoma. Intrapleural chemotherapy might be a helpful treatment strategy in MPE cases. 
Intrapleural chemotherapy also enters systemic circulation and affects the primary tumor 
as well. The aim of this study is to evaluate ex vivo chemoterapy and targeted therapy 
sensitivity in MPE cases to project which drug might be effective. Methods: Effusion fluids 
from patients with MPE were fresh obtained. After centrifugation, the pellet was diluted in 
PBS and cell isolation was performed by Ficoll gradient to separate cells from erytrocytes. 
Cells were incubated in HITES supplemented complete RPMI medium at 37C with 5%CO2. 
After primary cell culture was obtained, cells were incubated to 96 well plates and agents 
( Bevacuzimab, Cetuximab, Rituximab, Bortozemib, Gemsitabin, Vinblastin, Bleomycin, 
Docetaxel, 5 Florourasil, Cisplatin, Cyclophosphamide, Doxorubicine) in different dose 
ranges for 24 hours. WST-1 was performed to check cell viability. Results: The primary 
tumors of nine cases in this study with MPEs are breast carcinomas, lung adenocarcinoma, 
small cell carcinoma and mantle cell lymphoma. Resistance were observed in most 
drugs. Breast carcinoma cells and lung adenocarcinoma cells were sensitive to cisplatin 
and/or vinsblastin. Small cell carcinoma cells were sensitive to docetaxel and/ or 
bleomycin. Sensitivity was not observed to targeted therapy agents at single dose 
during 24 hours incubation. Conclusion: Our results indicate that ex vivo cancer cell 
culture and testing cell death results of various chemotherapoetic and new targeted 
drugs might help managing highly agressive disease of patients with MPE. Intrapleural 
chemotherapy application that is found sensitive by ex vivo tests might help patients. 
Keywords: Malignant pleural effusions, Intrapleural chemoterapy and targeted therapy, 
ex vivo sensitivity testing
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P1.04-116 The Role of JAK/STAT3 Signaling Pathway on Apoptosis of Lung 
Adenocarcinoma Cell Line PC-9 Induced by Icotinib Yuping Zhang1, Xia Meng1, 
Hongyang Shi1, Wei Li1, Zongjuan Ming1, Yujie Zhong1, Wenjing Deng1, Qiuhong Zhang1, 
Na Fan1, Zequn Niu1, Guo’An Chen2, Shuanying Yang1 1Department of Respiratory 
Diseases, the Second Affiliated Hospital, Medical College, Xi’An Jiaotong University, Xi’An/
China, Xi’An/China, 2Toracic Surgery Section, Department of Surgery,University of Michigan, 
Ann Arbor, Michigan/American Samoa
Background: The aim of the study is to estimate the role of JAK/STAT3 signaling pathway 
on apoptosis of lung adenocarcinoma induced by icotinib. Methods: EGFR mutation was 
detected in lung adenocarcinoma cell line PC-9 by ARMS assay; The inhibitory rates of 
cell proliferation, at different concentrations (0 ~ 100 umol/L) of icofinib and continued 
incubating for 24，48 and 72 h respectively, were evaluated by MTT assay; Apoptosis 
of PC-9 cells exposured to different concentrations of icotinib(0, 0.1, 1 and 10 umol/L) 
for 48 h were evaluated by TUNEL assay; JAK2, STAT3, Bcl-2, Bax mRNA expressions 
were evaluated by Real-time PCR assay; The protein levels of P-STAT3 and IL-6 were 
evaluated by Western-blot assay. Results: Human lung adenocarcinoma cell line PC-9 
had an exon 19 deletion mutation in EGFR gene; Followed by treatment of icotinib，the 
proliferation of PC-9 cells were all inhibited significantly, especially in 48 and 72 h 
(P<0.01) in all concentrations; The inhibitory rates of cell proliferation in different treating 
time had statistical significance (P<0.01); Cell apoptosis at different concentrations 
were increased significantly (P<0.05); Along with the increasing concentrations, gen 
expression levels of JAK2, STAT3 and Bcl-2 decreased significantly (P<0.05), Bax 
increased significantly (P<0.05), JAK2/STAT3 ratios increased significantly (P<0.01), 
and Bcl-2/bax ratios decreased significantly (P<0.01); P-STAT3 and IL-6 protein levels 
were inhibited significantly at by higher concentration. Conclusion: JAK/STAT3 signaling 
pathway take a participate in apoptosis of PC-9 cells induced by icotinib. The most likely 
mechanism is icotinib inhibited the gen expression levels of JAK2, STAT3 and Bcl-2, 
so with the P-STAT3 and IL-6 protein levels, and mediated gene Bax overexpression. 
Keywords: icotinib, JAK/STAT3 signaling pathway, apoptosis, lung adenocarcinoma
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P1.05-001 Rural Tobacco Smoke Pollution: Preliminary Results of a 
Longitudinal Study Kelly Buettner-Schmidt1, Blake Boursaw2, Marie L. Lobo2 
1Department of Nursing, North Dakota State University, Fargo/United States of 
America, 2University of New Mexico, Albuquerque/NM/United States of America
Background: In 2012, North Dakota enacted a comprehensive smoke-
free law. In 2014, the 3rd phase of a stratified random sample longitudinal 
study of tobacco smoke pollution in restaurants and bars was conducted (n 
= 107). Phase 1 was conducted prior to passage of the law, Phases 2 and 
3 were conducted 3 and 21 months post-implementation respectively. 
blotting. Results: Firstly, TGF-β1 induced EMT in lung carcinoma cells confirmed by the 
morphological changes, as well as the down-regulation of epithelial marker (E-cadherin) 
and the up-regulation of mesenchymal marker (fibronectin) and the F-actin cytoskeleton 
rearrangement during which the mTOR pathway was activated. Secondly, rapamycin 
decreased the degree of TGF-β1 induced morphological changes, attenuated the 
down-regulation of E-cadherin and up-regulation of fibronectin, and inhibited the F-actin 
cytoskeleton rearrangement. Moreover, rapamycin inhibited the migration ability of 
lung carcinoma cells. Further research on mechanism showed that the attenuation 
TGF-β1-induced-EMT by rapamycin was associated with the down-regulation of the 
phosphorylation of Smad2/3. Conclusion: Rapamycin attenuated TGF-β1- induced EMT 
and migration in lung carcinoma cells which was mediated, at least in part, by decrease 
of Smad2/3 phosphorylation.
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P1.04-113 Nonclinical Development of PF-06439535, a Potential Biosimilar to 
Bevacizumab Karen Rule1, Marjorie Peraza1, Michael Shiue2, Gregory Finch3, Stéphane 
Thibault2, Julie A. Rosenberg3, Michael W. Leach1 1Pfizer Inc, Andover/MA/United States 
of America, 2Pfizer Inc, San Diego/CA/United States of America, 3Pfizer Inc, Groton/CT/
United States of America
Background: Bevacizumab is a recombinant, humanized, IgG1 monoclonal antibody 
that binds to and inhibits the activity of vascular endothelial growth factor (VEGF), 
and is approved to treat a variety of advanced solid tumors. PF06439535 is under 
development as a potential biosimilar to bevacizumab. Methods: Amino acid 
sequences of PF06439535 and EU and USsourced bevacizumab (bevacizumabEU and 
bevacizumabUS, respectively) were compared by peptide mapping; post-translational 
modifications and biochemical properties were analyzed by N-linked oligosaccharide 
profiling and imaged capillary electrophoresis. Functional analysis of PF06439535, 
bevacizumabEU, and bevacizumabUS included an enzyme-linked immunosorbent assay 
to detect binding to the 4 major VEGF isoforms (VEGF121, VEGF165, VEGF189, VEGF206), 
and a cell growth inhibition assay in human umbilical vein endothelial cells (HUVEC). 
Toxicokinetics and potential toxicity of PF06439535 and bevacizumabEU were evaluated 
following intravenous (IV) administration (10 mg/kg twice weekly for 1 month, 9 doses 
total) in sexually- and skeletally-immature male cynomolgus monkeys; control animals 
received vehicle. Results: PF06439535, bevacizumabEU, and bevacizumabUS had 
identical primary amino acid sequences and similar levels of N-linked oligosaccharides. 
Predominant charge isoforms were similar; charge heterogeneity was due to variations 
between PF06439535 and reference products in relative proportions of species with 
C-terminal lysines. Target binding to each VEGF isoform showed similar dose responses 
between PF06439535, bevacizumabEU, and bevacizumabUS; comparable biological 
activity was observed by inhibition of VEGF-induced HUVEC proliferation. In cynomolgus 
monkeys, PF06439535 and bevacizumabEU (n=4 each) were well tolerated, with no 
PF06439535- or bevacizumabEU–related clinical, laboratory, or histopathology findings, 
except physeal dysplasia of the distal femur with similar incidence and severity for both 
molecules. Induction of antidrug antibodies was not observed in the PF06439535- or 
bevacizumabEU–dosed groups. Systemic exposure (mean area under the serum 
drug concentration–time curve from 0 to 72 hr ± standard deviation) was similar for 
PF06439535 and bevacizumabEU on Day 1 (12100 ± 876 vs 14700 ± 2260 µg·hr/
mL) and Day 25 (45500 ± 5420 vs 45100 ± 3670 µg·hr/mL). Conclusion: Results 
from the analytical similarity assessments and nonclinical studies have supported the 
clinical development of PF06439535 as a potential biosimilar to bevacizumab. These 
data supported a randomized, double-blind phase I study (NCT02031991) in healthy 
human male volunteers in the United States, which assessed pharmacokinetics, safety, 
and immunogenicity of a single 5 mg/kg IV dose of PF06439535, bevacizumabEU, 
or bevacizumabUS. A global, randomized phase III trial (NCT02364999) comparing 
PF06439535 and bevacizumabEU, plus paclitaxel/carboplatin, for first-line 
treatment of advanced non-squamous nonsmall cell lung cancer is enrolling patients. 
Keywords: PF-06439535, bevacizumab, biosimilar, NSCLC
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P1.04-114 Effect of Interleukin-2 Treatment Combined with Magnetic Fluid 
Hyperthermia on Lewis Lung Cancer-Bearing Mice Runlei Hu1, Shenglin Ma2 
1Department of Thoracic Surgery, Hangzhou First People’S Hospital, Hangzhou/
China, 2Department of Radiation Oncology, Hangzhou First People’S Hospital, Hangzhou/
China
Background: The study aimed to investigate the therapeutic effect of interleukin-2 (IL-
2) treatment combined with magnetic fluid hyperthermia (MFH) on Lewis lung cancer-
bearing mice. Methods: Magnetic fluids were prepared in vitro and directly injected 
into the tumors in the mice, which were subjected to an alternating magnetic field. The 
temperature in the tumor reached 43°C and was maintained by controlling the strength 
of magnetic field for 30 minutes. Twenty-four hours later, IL-2 was injected directly into 
the tumors. Mice were divided into four groups: group I (control), group II (MFH), group 
III (IL-2), and group IV (IL-2+MFH). Results: The tumor grew gradually in group II and 
group IV (both P<0.05) compared to the control group. Histological analysis showed 
that the tumor cells underwent apoptosis and necrosis. Immunohistochemistry results 
demonstrated that heat shock protein 70 (HSP70) and CD8-positive T cells were 
strongly expressed. Conclusion: The results have provided evidence that IL-2 treatment 
combined with MFH could improve the therapeutic effect on lung cancer-bearing mice 
Keywords: lung cancer, magnetic fluid, hyperthermia, interleukin-2
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P1.05-003 Dutch Government Taken to Court by 2 Chest Physicians Because 
of Violation WHO FCTC 5.3 Wanda D. Kanter Chest Oncology, Netherlands Cancer 
Institute, Amsterdam/Netherlands
Background: The Youth Smoking Prevention Foundation is taking the Kingdom of 
the Netherlands to court to end the structural and excessive influence exerted by 
the tobacco lobby on government anti-smoking policies. The Foundation is calling 
on the Dutch government to comply fully with the anti-smoking convention (WHO FCTC), 
which it signed and which is therefore legally binding. One of the most important articles 
in the convention states that every form of influence by the tobacco industry on policies 
to deter smoking must be avoided. In the court summons issued, the Foundation offers 
dozens of examples that show how the government has systematically violated this 
provision, and even invites the tobacco industry to clarify its position on matters of policy 
development. 19,000 tobacco-related deaths More than 19,000 Dutch people, half 
of them younger than 65, die each year as a result of smoking. In addition, an average 
of 120 children under the age of 18 start smoking every day. Some 60 of them will 
continue to smoke for the rest of their lives, and 30 of them will die prematurely from 
the effects of smoking. Smoking is by far the biggest cause of death that could be 
avoided through prevention. However, the marketing techniques deployed by the tobacco 
industry are so refined that many youths cannot resist the temptation to start smoking. 
Moreover, cigarettes are designed to be highly addictive. Children who start smoking end 
up addicted within weeks. For many of them, the question of ‘free will’ no longer applies: 
they are unable to stop smoking without help. Numerous national and international laws 
and conventions make it a duty of the Dutch government to protect the health of its 
citizens from a serious cause of illness like tobacco. With as many as 19,000 tobacco 
deaths every year, the government has an obligation to do all in its power to combat the 
massive scale of premature fatalities. And it should certainly prevent minors from starting 
to smoke, because almost nobody starts after they turn 18. Despite all this, the Dutch 
government has failed to implement measures that could be very effective in achieving 
results: imposing much higher taxes on tobacco and greatly reducing the current number 
of over 60,000 points of sale. Instead, the government listens to the tobacco industry, 
whose effective lobbying continues to successfully obstruct measures to discourage 
tobacco use. Methods: not applicable Results: ongoing lawsuit. Conclusion: The 
lawsuit is ongoing. Our foundation has had a lot publicity in all national media (television 
,newspapers) As a chest physician working in an oncology center mainly treating patients 
with lungcancer it is very powerfull to start a lawsuit against the state to prevent lung 
cancer. We are making progress: we are at the table of several Ministries (finance, 
health department) to discuss the firewall protocol against the lobby of big tobacco. 
We use social media and patients advocates to make our message even stronger 
Keywords: WHO FCTC 5.3 bigtobacco lobby
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P1.05-004 Smoking Prevention Intervention with School Classes at a University 
Hospital by Thoracic Surgeon and Pulmonologist Macé Schuurmans1, Sandra 
Tomaszek2, Didier Schneiter2, Walter Weder2, Sven Hillinger2 1Pulmonology, University 
Hospital Zürich, Zürich/Switzerland, 2Thoracic Surgery, University Hospital Zürich, Zürich/
Switzerland
Background: Smoking prevention in schoolchildren with the aim to inform and prevent 
smoking initiation has been widely studied and has shown variable results. Interventions 
provided by physicians in a hospital setting have been rarely reported. Here we show 
the feasibility and gain of knowledge of our smoking prevention project in a hospital 
setting. Methods: Interventions performed from November 2009 - December 2014 
were evaluated. Overall 790 children participated in our preventive intervention. A 
7-item questionnaire was provided to the school classes (Grades 6 to 10) before 
and after a two-hour smoking prevention intervention consisting of anatomical 
models, oral presentations, videos, patient interviews and hands-on lung function 
tests. The goal was to show the anatomical and physiological basics as well as age-
based information about the harms of smoking. During the intervention the children 
have been motivated to be actively involved. Class selection has been performed 
for groups of children in a highly vulnerable phase of age before smoking initiation. 
Results: The baseline questionnaire was completed by 768 children, the one after 
intervention by 719. The knowledge about which organs are affected by smoking 
increased from 7.1-99.3% to 64.5-99.5% (p<0.01). While only 58.9% knew that only a 
minority of people is able to quit smoking successfully, 96.3% answered the question 
correctly after intervention (p<0.001). Prior to the intervention only 75.6% believed 
that minor tobacco consumption is not damaging which increased to 87.8% after the 
teaching session (p<0.05). Smoking hookah was believed to be less harmful than 
cigarettes by 32.2% of children decreasing to 8.3% after the intervention (p<0.001). 
Conclusion: Information on health effects provided by lung specialists in the hospital 
leads to a statistically significant increase in knowledge as assessed by a short 
questionnaire. The intervention is feasible and well received. This kind of interventions 
might help to prevent schoolchildren from smoking in a highly vulnerable phase of age. 
Keywords: smoking prevention, Tobacco Control, school children
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P1.05-005 Italian Multicentric Survey on Smoking Cessation in Lung Disease 
Patients and the Role of Healthcare Workers in This Contest Sara Demichelis1, 
Simonetta G. Rapetti1, Domenico Galetta2, Arianna Bruno3, Emilio Bria4, Sara Pilotto4, 
Methods: Tobacco smoke pollution levels were assessed by collection of particulate 
matter 2.5 microns aerodynamic in diameter or smaller using SidePak TM AM510 Personal 
Aerosol Monitors. Results: The geometric mean PM2.5 was 6.9 microns/m
3. Statistically 
significant reduction in mean PM2.5 occurred from Phases 1 to 3 but not from Phases 2 
to 3 in all venues and for bars alone. A significant increase in indoor PM2.5 occurred when 
there was outdoor smoking or ashtrays within 20 feet of the venue entrance, exit, or 
windows and when smoking was observed within designated outdoor smoking shelters. 
Multi-level linear models found that the presence of a local ordinance and venue type 
were predictors of PM2.5 in Phase 1 but not in Phases 2 or 3. Significant decreases in 
mean PM2.5 by rurality occurred between Phases 1 and Phase 3. In contrast with the 
Phase 1 study, there were no significant differences in PM2.5 by rurality in only Phase 3. 
Conclusion: This longitudinal study is the largest rural pre and post-law 
rural study known globally. Passage of the comprehensive statewide smoke-
free law effectively reduced PM2.5 levels in restaurants and bars statewide. 
Keywords: compliance, pollution, Policy
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P1.05-002 Comparative Study regarding Perception of Japanese Tobacco-
Related Disease Risk Warning Package Message Tomoyasu Uno Health Care 
Center, Fukushima University, Fukushima-City/Japan
Background: There are two types of tobacco warning messages in Japan, category A 
is Direct disease for smoker-themselves, category B is for other person (e.g. Nuisance 
around, The risk in pregnancy). Previously, we had reported that awareness of COPD 
is low in who visited to a certain hospital. Recognition rate is slowly increasing, 
however, still been not satisfactory. Assessment studies and discussions for the 
impact of health warnings knowledge about tobacco risks are ongoing in worldwide. 
However, it is insufficient since 2005. So, in this survey aimed at improvement of 
present condition, especially, we evaluated about the recognition of tobacco package 
warning messages for the smokers themselves. Methods: The questionnaire for our 
university employees[n=132, 44.6±11.6 yrs, Male(M)/Female(F)= 60.6/39.4] (Group B) 
and students[n=641, 20.4±1.6 yrs, M/F=53.4/46.6] (Group C) was performed. As the 
control subject was our previous report cases [n=335, 62.2±12.2yrs, M/F=55.6/44.0] 
(Group A). In particular, we evaluated about the recognition of the smokers themselves 
(Category A), I: Cause of lung cancer, II: Risk of cerebral stroke, III: Risk of myocardial 
infarction, IV: Risk of deteriorating pulmonary emphysema. Results:
Characteristics and Knowledge of Warning Risk Massage (*Multiple answers act)
A B C
N 335 132 641
Age(yrs±SD) 62.2±12.2 44.6±11.6 20.4±1.6
Sex[M/F］(%) 55.6/44.0 60.6/39.4 53.4/46.6
Smoking history(%)
  Current 24.3 8.3 8.4
  Ex 34.3 25.0 5.6
  Never 41.4 66.7 80.6
Knowledge of Warning(%)*
I 49.2 60.3 70.5
II 17.3 27.5 41.3
III 25.6 32.1 38.4
IV 28.9 25.2 43.7
 
Imbalance in the warning messages recognition was observed in all groups and “Risk 
of Lung cancer” knowledge was significantly higher than other diseases risk warning. 
Knowledge of Warning(%) [Multiple answers act, I /II /III /IV] was A: 49.2/17.3/25.6/28.9, B: 
60.3/27.5/32.1/25.2, C: 70.5/41.3/38.4/43.7, respectively. And also the ratio is almost 
same between smoker and non-smoker. Especially, disparity in identical respiratory-
related emphysema (≒ COPD) risk was conspicuous. On the other hand Category B 
messages is almost same recognition. Conclusion: These results were considered that 
source of the text size of tobacco package warning is small and mild. In addition, smoking 
is harm to health, nevertheless the knowledge of package warning ratio was not unified. 
Furthermore it was speculated that the elderly from the young adolescents who were not 
exposed to anti-tobacco msg and/or were not taught about the harmful effects. Therefore 
we should do more educate about the risk of warning the awareness of Smoking and COPD. 
Awareness of tobacco risk was poor, therefore the necessity of further 
education about stop-smoking was indicated. Last year, the agenda debate 
regarding risk of pulmonary emphysema msg will be change to COPD was 
started in Japan. We hope the change will be widespread and raise aware COPD. 
Keywords: Education, Imbalance recognition of tobacco, Risk Warning, lung cancer
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www.quitgate.com. 
After visitors ordered a product or called the Quitline, a questionaire was emailed to them. 
Questions asked included year of smoking initiation, number of cigarettes smoked per day 
and number of quit attempts and through what means. Results:Interestingly, 37% of the 
participants reported that they were motivated to quit because when they called the 
Quitline and received counselling from the Tobacco Treatment Specialist, they were 
immediately provided without obligation, the option of getting a smoking cessation product 
on same platform with either some of the product free or highly discounted. Another group, 
11% said they prefered the platform to quit because it was social, friendly, professional, 
non-judgemental and yet non-clinical. Overall, most of the participants said it was a great 
idea to have a one-stop platform which provided free professional counselling, smoking 
cessation products, tools/apps like smoking calculator, DNA (Dependence on Nicotine 
Assessment) low prices, free shipping and premium customer service to highly motivate 
smokers quit for good. Conclusion: It is great to note that while Quitlines are provided by 
several institutions to help in smoking cessation, an important area of also making smoking 
cessation products availble either for free or a little amount will go a long way to motivate 
smokers. The Centers for Disease Control and Prevention-CDC cites evidence-based 
counseling, behavioral cessation therapies, medication, and social support as treatments 
that increase the chances of tobacco cessation 
Keywords: Smoking Cessation, tobacco, one-stop platform, non clinical
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P1.05-008 Big Tobacco and the Creation of an Epidemic of Smoking-Related 
Adenocarcinoma of the Lung: SEER-Based Analysis, 1973-2011 Gary Strauss1, 
Alejandro Moreno-Koehler2, Matthew Finkelman3 1Hematology/Oncology, Tufts Medical 
Center, Boston/MA/United States of America, 2Tufts Medical Center, Boston/MA/United 
States of America, 3Tufts University School of Dental Medicine, Boston/MA/United States of 
America
Background: When epidemiologic research first demonstrated an association between 
cigarette smoking and lung cancer in the early 1950s, adenocarcinoma comprised about 
5% of lung cancers and appeared to be unrelated to smoking. In the 1960s and 1970s, 
adenocarcinoma increased sharply, and became strongly related to cigarette smoking. 
At the 2007 IASLC-sponsored 12th World Conference in Lung Cancer in Seoul, Korea, our 
group reported that by 2003, adenocarcinoma of the lung had risen to comprise 47% 
of all lung cancers in the US. The objective of this presentation is to update and expand 
upon our previous analysis. Methods: We analyzed time trends in lung cancer histology 
with changes in cigarette design and Tobacco Industry actions over six decades. We 
utilized Surveillance-Epidemiology and End Results (SEER) data on 419,941 lung cancers 
diagnosed between 1973 and 2011 to analyze time trends of age-standardized incidence 
rates of five histologic subtypes: adenocarcinoma, squamous cell, small cell, large cell, 
and adenosquamous carcinoma. Results: Over time, the percentage of lung cancers 
that were adenocarcinomas increased from 29% (in 1973-1974) to 55% (in 2010-2011). 
During this 38-year period, the percentage of lung cancers that were squamous cell 
carcinomas decreased from 41% to 26%. Among all patients, adenocarcinoma incidence 
surpassed squamous carcinoma by 1985-1989 to become the most common histologic 
subtype. Adenocarcinoma surpassed squamous cell in 1990-1994 in men, while 
it was already most common in women by 1973-1974. Adenocarcinoma rose 77% in 
men from 1973-1974 to 1990-1994, while it rose 197% in women between 1973-1974 
and 2005-2006. Among whites, adenocarcinoma surpassed squamous carcinoma 
by 1985-1989, while this occurred among blacks by 1990-1994. It was already most 
common among other race individuals in 1973-1974. Adenocarcinoma was already 
most common among patients <50 years of age by 1973-1974, while adenocarcinoma 
rapidly increased and surpassed squamous carcinoma in all other age groups by 1990-
1994. Conclusion: Incidence of adenocarcinoma of the lung has continued to increase 
to such an extent that it comprises a clear majority of all lung cancers in the US. Indeed, 
our analysis demonstrated that lung adenocarcinoma currently represents 55% of US 
lung cancers. It is the most common histology in men and women, in whites, blacks, and 
other-races, and in all age groups. The question of how the actions of Big Tobacco helped 
to create this epidemic will be addressed in a separate presentation at this meeting. 
Keywords: Big Tobacco, Adenocarcinoma, Epidemic
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P1.05-009 EGCG Regulated Ku70 Acetylation for Apoptosis in Human Lung 
Giuseppe Valmadre5, Annamaria Catino2, Martina Gianetta1, Stefania Vallone6, Maria 
Vittoria Pacchiana1, Silvia Novello1 1Department of Oncology, University of Turin, Turin/
Italy, 2Clinical Cancer Center “Giovanni Paolo Ii”,, Bari/Italy, 3Pulmonology Division, Hospital 
of Putignano, Putignano (Ba)/Italy, 4Medical Oncology, University of Verona, Verona/
Italy, 5Eugenio Morelli Hospital Aovv, Sondalo/Italy, 6Walce, Orbassano (To)/Italy
Background: Smoking is a risk factor for several lung diseases. Quitting smoking 
provides positive outcomes and gives the best chance for the treatment in patients 
with pulmonary diseases, including lung cancer diagnoses. Currently few centers in 
Italy offer counseling for smoking cessation in cancer patients (and for patients with 
other lung diseases), despite the demonstrated efficacy of it. Methods: 408 patients 
with pulmonary diseases (72% with lung cancer) were prospectively and sequentially 
evaluated from January 2013 to February 2015. An anonymous survey was developed 
with the aim to understand if current or former smoker patients received information by 
healthcare workers about smoking cessation before or after the diagnosis, their reaction 
and the actions adopted for quitting smoking. The survey included the Fagerström test 
for assessing the intensity of addiction to nicotine and it was conducted in several Italian 
Thoracic Oncology Units and Pulmonology Divisions. Results: After a pulmonary disease 
diagnosis, 72% of patients state to quit smoking, 20% to smoke less or not feel the same 
pleasure as before and only 8% confirms to continue to smoke or smoking even more. 
Among former smokers (298 people), 150 patients state how long they quitted smoking 
and in 45% of the cases was at the time of diagnosis or even later, about 35% 10 years 
before the diagnosis and 8% between 5 and 10 years earlier, while 12% more recently. 
Most of current smokers state that they continue because smoking helps them to control 
the stress, others because they like it or are not able to quit and very few because 
is a repetitive gesture. Data show that 39% of patients did not receive information 
about smoking cessation by health professionals, 26% received it before the diagnosis, 
12% after it and 23% received it both before and after the diagnosis. Concerning the 
reaction to the counseling, 53% considers positively the health care provider action, 
even if 28% hoped they could have helped them more quit smoking and 19% reports a 
warning and paternalistic attitude of them. Only 23% of patients who attempted to quit 
smoking considers the gradual termination as the most effective measure, more than 
the sudden interruption. Regarding the smoking-cessation method or specific therapy 
adopted, 65% disclosed they simply quitted smoking overnight and 80% confirmed 
it as the most effective technique, while only 16% used electronic cigarettes, 8% a 
nicotine replacement treatment, 7% books and 4% attending a dedicated clinic. The 
Fagerström Test confirms that 50% has a low to moderate dependence to nicotine, 
while 50% has a high dependence. Conclusion: The survey was distributed to 293 
lung cancer patients and 115 with pulmonary disease (mainly COPD patients). The 
result analysis underlines that the vast majority quitted smoking after having received 
their diagnosis. No main differences were seen evaluating the group with malignant 
and non-malignant diseases. Although many of them got advice by healthcare workers, 
the recourse to the use of techniques, drugs or access to specific clinic is still very 
low, especially considering that 50% of patients result highly dependent to nicotine. 
Keywords: Smoking Cessation, counseling, lung disease, pulmonary disease
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P1.05-006 One Cigarette Takes 12.6 Minutes of Your Life Erik Thunnissen 
Department of Pathology, VU University Medical Center, Amsterdam/Netherlands
Background: Smoking is the largest cause of premature mortality. Smoking cessation 
is important, but is difficult to reach. A general underestimation of personal risk in 
smokers or a degree of misunderstanding around key risk factors for disease may 
be substantial. 1The aim of this abstract is to calculate the reduction in average life 
expectancy per cigarette. Methods: Men born in 1900-1930 who smoked only cigarettes 
and continued smoking died on average about 10 years younger than lifelong non-
smokers. Cessation at age 60, 50, 40, or 30 years gained, respectively, about 3, 6, 9, or 
10 years of life expectancy.2Assuming that these men started at age 15 years and died 
at age of 72 this results on average in 57 years of smoking. Also assumed is that each 
day one pack of 20 cigarettes is smoked. Results: Smoking for 57 years 20 cigarettes 
per day results in a total of 416,100 cigarettes. The total number of minutes in 10 years 
is 5,256,000. The average decrease in life expectancy is 12.6 minutes/ cigarette or 
4.2 hours /pack, equals more than a day/week. Discussion: If a smoker is aware of the 
reduced life expectancy then smoking of one cigarette may be looked-upon as a mini-
suicide attempt. Taken also into account the passive smoking effect, the smoker may be 
seen as a mini-suicide-nano-terrorist. Conclusion: Conclusion The reduction in average 
life expectancy is 12.6 minutes per cigarette or 4 hours per pack. This knowledge may 
be of help to raise more awareness for the dangers of smoking. 1. Bethea J, Murtagh B, 
Wallace SE. “ I don ’ t mind damaging my own body ” A qualitative study of the factors 
that motivate smokers to quit. 2015;1–9. 2. Doll R, Peto R, Hall E, Wheatley K, Gray R. 
Mortality in relation to consumption of alcohol: 13 years’ observations on male British 
doctors. BMJ. 1994;309(6959):911–8.
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P1.05-007 One-Stop Counselling, Social Support & Stop Smoking Aids Helps 
Smokers Quit Emmanuel Odiase Epidemiology, University of Ibadan, Abuja/Nigeria
Background: It has been a normal practice for governments, not-for-profits and other 
platforms to provide Quitlines to help smokers quit. There has been positive results, 
however a recent study shows that a one-stop platform can offer more desirable 
outcomes. Methods: We conducted a 6-month study through an online survey involving 
1,200 smokers who visited a revolutionary one-stop smoking cessation online platform, 
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Background: In December 2013, the United States Preventive Services Task Force 
(USPSTF) provided a level B recommendation for the use of low-dose computed 
tomography (LDCT) to screen high-risk patients for lung cancer. Most recently, in 
February 2015, the Centers for Medicare and Medicaid Services (CMS) likewise approved 
coverage for at-risk patients, defined as those 55 years of age or older with a strong (30 
pack-year) smoking history. The current USPSTF and CMS specified eligibility criteria for 
lung cancer screening are similar to those implemented by the National Lung Screening 
Trial and other studies which provided the evidence base that precipitated the decision 
to screen high risk patients, however these criteria may not adequately capture all sub-
groups that comprise the complete population at risk for developing lung cancer. For 
example, younger patients (50+ years) who have a moderate (20 pack-year) smoking 
history and at least one other known lung cancer-related risk factor are considered to 
be at high risk by the National Comprehensive Cancer Network (NCCN). The purpose 
of this investigation is to investigate the prevalence of lung cancer among younger and 
older age groups of screening patients nationwide and to begin to provide important 
data that may assist with evaluating the adequacy of the eligibility criteria currently being 
used to define the population at-risk for developing lung cancer. Methods: The Center 
for Lung Cancer Screening and Prevention at the Stony Brook Cancer Center, recently 
conducted an electronic survey of all Lung Cancer Alliance Centers of Excellence 
for Lung Cancer Screening nationwide. The survey collected information regarding 
numbers and age groups of patients screened, numbers and stages of lung cancers 
detected, smoking history and other demographic variables. Lung cancer status (cancer 
detected vs. no cancer detected), stratified by age group (50-54 years vs 55-80 years) 
are presented here. A total of 24 Centers (among 240) provided data for the survey. 
Many Centers did not have available data for the younger subgroup of patients likely 
due to the implementation of the USPSTF criteria rather than the NCCN guidelines that 
recommend screening this younger, at-risk subgroup. Results: The survey data were 
cumulated over all 24 participating Centers of Excellence nationwide and included 
7,252 patients. Of these, n= 697 patients were 50-54 years of age and n=6,555 were 
55 years or older. Among the younger cohort, 16 patients (2.3%) were found to have 
lung cancer. In the older age category, lung cancer was detected in 130 patients or 
2.0%. Conclusion: These findings suggest that this younger subgroup of at-risk patients 
warrant further consideration for lung cancer screening. Additionally the data suggest 
that this well-defined subgroup of 50-54 year old patients who have a moderate smoking 
history and at least one other known lung cancer-related risk factor may be at even 
higher risk for developing the disease than those 55+ years with a 30 pack-year smoking 
history. These nationwide data highlight the urgent need to re-evaluate the eligibility 
criteria currently being used to define the population at risk for developing lung cancer. 
Keywords: Screening, high risk, eligibility criteria, prevention
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P1.06-003 Low-Dose CT Lung Cancer Screening in the Community: A 
Prospective Cohort Study Incorporating a Gene-Based Lung Cancer Risk Test 
Robert Young1, Raewyn J. Hopkins1, Vincent K. Lam2, Elwyn Cabebe2, Mary Miller2, Greg 
D. Gamble1 1University of Auckland, Auckland/New Zealand, 2Genomic Institute, El Camino 
Hospital, Mountain View/CA/United States of America
Background: Following the publication of the National Lung Screening Trial (NLST) 
results in 2011, CT screening for lung cancer is now widely recommended in the US. 
However concerns remain with regards to patient selection according to risk level 
and overdiagnosis.Moreover adherence outside screening trials is typically about 50-
60% and has been shown to be highly dependent on an individual’s risk perception. 
This feasibility study explores the relevance of gene-based data on lung cancer risk 
assessment and adherence to screening, in a pilot screening program. Methods: This 
feasibility study was initiated in 2010 prior to NLST results being published. Following 
local media-based advertising, 157 current or former smokers (>50 years old with ≥20 
pack year history), volunteered for lung cancer risk assessment and CT screening (using 
the IELCAP protocol). Participants were followed up for a mean of 2.4 years.At baseline 
CT screening, participants were assigned their lung cancer risk category according 
to a published and prospectively validated gene-based risk algorithm. This algorithm 
combines clinical risk variables with risk genotypes, derived from analysis of 20 risk 
single nucleotide polymorphisms (SNPS), to derive a composite lung cancer risk score 
categorised as moderate, high or very high. Results: SNP genotype results contributed 
to overall lung cancer risk in 88% of participants compared to the contribution from 
age = 68%, family history of lung cancer = 29% and self reported chronic obstructive 
pulmonary disease =15%. The SNP genotype results were the sole basis of risk in 18% of 
participants and contributed to risk in a further 70% of participants (total 88%). Adding 
SNP scores to the clinical risk score re-assigned screening participants into different 
risk categories in 28% (44/157) of participants (Figure 1). Importantly, timely adherence 
to the CT screening protocol was two-fold greater in those with a very high risk score 
compared to the high and moderate risk categories (71% vs 52% vs 52% respectively, 
OR =2.3, P<0.05).
  
Cancer A549 Cells Min Li, Jing J. Li, Qi H. Gu, Li M. Cao, Hua P. Yang, Cheng P. Hu 
Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha/
China
Background: Lung cancer is one of the malignant tumors whose global incidence and 
mortality are very high. The chemoprevention has become an important prevention 
and control means of lung cancer except for giving up smoking and early detection. 
Research has showed the main component in green tea (-) -epigallocatechin-3-gallate 
(EGCG) is a potential chemopreventive agent for various tumors, especially lung 
cancer. Methods: The cells in each group were treated with different concentrations 
of EGCG for a certain time in the experiment. Two gene point mutation plasmid were 
constructed and transfected in A549 cells. Induction of apoptosis was examined 
using AnnexinV/Pl double staining flow cytometry. Western Blot detected the protein 
expressions of Bax, Bcl-xl and Caspase-3. Co-immunoprecipitation was used to detect the 
interaction of Ku70-Bax and acetylation status of Ku70. P<0.05 showed the difference had 
statistical significance. Results: Treatment of A549 cells with EGCG induced apoptosis 
with increasing expression of Bax and Caspase-3, but decreasing expression of Bcl-xl. 
EGCG could up-regulate K70 acetylation status of A549 cells，then down-regulate the 
interaction of Bax-Ku70 in the manner of concentration and time dependent. The apoptosis-
promoting effect of EGCG on A549 cells was obviously weakened with the interaction of 
Bax-Ku70 strengthened and Caspase-3 (17KDa) expression declining after pCDNA3.1(+) -
Ku70 plasmid and pCDNA3.1(+) -Ku70539/542R plasmid transfection. Conclusion: The 
authors induced apoptosis in human lung adenocarcinoma A549 cells after treatment 
with EGCG, and it was realized by interfering the interaction between Ku70 and 
Bax through regulating K70 acetylation. It verified that two loci K539 and K542 of 
Ku70 acetylation might play a crucial role in EGCG inducing apoptosis of A549 cells. 
Keywords: apoptosis, Ku70 acetylation, EGCG, lung cancer
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P1.06-001 Ultra-Low Dose-CT Accurately Detects Significant Lung Nodules 
with a Fraction of the Radiation of Conventional Low Dose-CT Alistair Miller1, 
Dana Jackson2, Sheetal Deshpande1, Cathryn Hui2, Garun Hamilton1, Ken Lau2 1Monash 
Lung and Sleep, Monash Medical Centre, Clayton/VIC/Australia, 2Monash Imaging, Monash 
Medical Centre, Clayton/VIC/Australia
Background: Indeterminate lung nodules are a common and increasing incidental 
finding on CT imaging and there are widely accepted surveillance protocols. However, 
even when using Low Dose (LD) -CT with a total effective dose of ~1mSv, concerns exist 
regarding the cumulative radiation exposure of subjects under surveillance, particularly 
in individuals not at high risk of lung cancer. By utilizing the Model Based Iterative 
Reconstruction (MBIR) technique, CT images can be obtained with a radiation dose 
comparable to chest x-ray (0.06-0.1 mSv). At this Ultra-Low Dose (ULD), MBIR images 
have generally less signal to noise ratio which may prevent small nodule detection. 
The aim of this prospective study was to assess the efficacy of ULD-CT in detecting 
clinically significant lung nodules (≥4mm) as compared to LD-CT. Methods: Following 
approval from the local Human Research Ethics Committee, adult subjects undergoing 
CT surveillance for incidental lung nodules were recruited from a tertiary hospital. Once 
informed consent was obtained, both standard LD- and a ULD-CT chest were performed. 
Scans were performed on the GE750HD Discovery scanner. Demographic information 
including lung cancer risk factor evaluation was obtained by questionnaire. Patients 
who withdrew consent or whose images were degraded by gross movement or metallic 
artefacts were excluded. Images from the ULD-CT were reconstructed with MBIR prior 
to reading. Each of LD/ULD-CT image sets was read blindly, randomly and independently 
by two experienced thoracic radiologists. The number, size and location of nodules was 
reported and subsequently compared. Results: 100 subjects were recruited with a mean 
age of 65 years (range 32-87). Around 62% were ever smokers, with 30% smoking ≥30 
pack years. Around 30% had risk factors other than smoking, but only α of these (9%) did 
not have a significant smoking history. Only a small proportion were high risk as evidenced 
by only 8 meeting Lung Cancer screening criteria (NLST criteria). A total of 200 nodules 
≥4mm were detected, with all seen on both LD and ULD-CTs. In addition, there were 244 
nodules <4mm seen on the LD-CT, with greater than 80% sensitivity for the ULD-CT, 
with minor variation between lobes. There were no false positive findings. There was 
a 10 fold reduction in effective radiation when comparing ULD-CT (0.09mSv) imaging 
with the standard LD-CT (1.11mSv). Lung nodules were subjectively better seen on the 
ULD-CT. Conclusion: ULD-CT with the advanced MBIR allows detection of all clinically 
significant lung nodules while achieving a radiation dose comparable to that of plain 
chest radiography. Particularly in low-risk populations, the use of ULD-CT for surveillance 
of lung nodules has the potential to significantly reduce cumulative radiation exposure. 
Keywords: Surveillance, Indeterminate nodule, Screening
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P1.06-002 Lung Cancer Screening Guidelines May Not Capture the Complete 
Population At-Risk April Plank1, William Moore1, Barbara Nemesure2 1Radiology, Stony 
Brook Medicine, Stony Brook/NY/United States of America, 2Preventive Medicine, Stony 
Brook Medicine, Stony Brook/NY/United States of America
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P1.06-005 The Correlation between Visceral Pleural Invasion in T1a Non-
Small Lung Cancer and Lymph Node Metastasis Mitsuhiro Tsuboi, Hiromitsu 
Takizawa, Daisuke Matsumoto, Naoya Kawakita, Koichiro Kajiura, Hiroaki Toba, 
Yukikiyo Kawakami, Syoji Sakiyama, Kazuya Kondo, Akira Tangoku Department of 
Thoraci,Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima 
University Graduate School, Tokushima City/Japan
Background: Visceral pleural invasion (VPI) of non-small cell lung cancer (NSCLC) has 
been recognized as a poor prognostic factor. Peripheral lung cancers often invade visceral 
pleura, and positive VPI upstages the T category of tumors from T1a to T2a. In addition, it 
is possible that peripheral lung cancers with positive VPI causes lymph nodes metastasis 
because of subpleural lymphovascular invasion. In this study, we statistically analyzed the 
correlation between VPI and lymph node metastasis. Methods: 129 patients with NSCLC 
and a tumor diameter of ≤ 2cm underwent lobectomy or segmentectomy with systematic 
lymph node dissection in Tokushima University Hospital between January 2008 to 
December 2013. Excluding 11 patients who were not examined by FDG-PET before the 
surgery, we reviewed the medical records of 118 patients to obtain information on age, sex, 
CEA, SUVmax, CT findings, pathological VPI and lymph node metastasis. Results: Patient 
characteristics were as follows: median age of 66.5 (range: 41-86); male/female: 52/66; 
histologic type adenocarcinoma/squamous cell carcinoma/other: 103/12/3. 13(36.1%) 
of 36 patients who were suspected to be with visceral pleural invasion by preoperative CT 
findings were diagnosed with pathological visceral pleural invasion. The mean SUVmax 
on FDG-PET in patients with VPI was significantly higher than that of patients without 
VPI(p=0.01). Pathological visceral pleural invasion was identified in 19(16.1%) of 118 
patients and associated with high incidence of lymph node metastasis significantly on 
multivariable analyses (p=0.00). Conclusion: VPI is important factors of lymph node 
involvement in small peripheral lung cancers. It is difficult to identify VPI of peripheral 
lung cancers by preoperative CT findings. FDG-PET may be useful for diagnose VPI. 
Keywords: visceral pleural invasion, lymph nodes metastasis, FDG-PET
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P1.06-006 Metabolomics by NMR Facilitates the Non-Invasive Diagnosis 
and Staging of NSCLC Clara Pérez-Rambla1, Leonor Puchades-Carrasco1, Eloisa 
Jantus-Lewintre2, Francisco García-García3, Rut Lucas2, Silvia Calabuig2, Ana Blasco4, 
J Dopazo3, Carlos Camps4, Antonio Pineda-Lucena1 1Structural Biochemistry Laboratory, 
Centro Investigación Príncipe Felipe, Valencia/Spain, 2Molecular Oncology Laboratory, 
Fundación Investigación Hospital General Universitario, Valencia/Spain, 3Computational 
Genomics Department, Centro Investigación Príncipe Felipe, Valencia/Spain, 4Department of 
Medical Oncology, Consorcio Hospital General Universitario, Valencia/Spain
Background: Lung cancer (LC) is the most common cause of cancer death worldwide. 
At present, the diagnosis is primarily based on symptoms and detection occurs at late 
stages, thus resulting in a very poor prognosis. If the diagnosis could be shifted to 
early stages, then the overall morbidity for this disease could be dramatically altered. 
Metabolomics, an analytical platform used in combination with statistical techniques, 
has been shown to be a very powerful approach for the understanding of biological 
pathways involved in the onset and progression of diseases. The objective of this study 
was to identify, using metabolomics by NMR, a set of specific metabolites that could be 
used for LC screening in the clinical context. Methods: Metabolic profiles corresponding 
to a training set of serum samples from early-stage (n = 66) and advanced-stage (n 
= 69) NSCLC patients were obtained using 1H-NMR spectroscopy. A matched control 
set of 71 serum samples from healthy subjects was also included. Furthermore, NMR 
experiments were also performed for an external validation set consisting of 20 early-
stage and 20 advanced-stage NSCLC patients, 13 healthy individuals, and 27 benign 
pulmonary disease patients (BPD). Results: Multivariate statistical modeling of the data 
revealed that the serum of NSCLC patients, when compared with healthy individuals, 
exhibit a specific serum metabolic profile (R2 = 0.931; Q2 = 0.873) characterized by 
statistically significant differences in the concentrations of a number of lipids, organic 
acids and amino acids. The metabolic profiles obtained for NSCLC patients and healthy 
individuals were also different to that obtained for BPD patients. A similar analysis 
performed to compare the serum metabolomic profile of NSCLC patients at early 
and advanced stages of the disease (R2 = 0.779; Q2 = 0.592) showed that disease 
evolution has also a reflection in the metabolic profile of patients. Furthermore, a 
logistic regression analysis allowed the identification of a specific combination of five 
metabolites (threonine, glutamine, lactate, choline and methanol) that enables the 
discrimination between healthy individuals and NSCLC patients with a 77,5% sensitivity 
and a 76,9% specificity (70% for all non-cancer samples). Conclusion: Our results 
highlight the potential of metabolomics by 1H-NMR for identifying biological pathways 
involved in the onset and progression of NSCLC, thus providing a sensitive, specific, 
minimally invasive and easily implementable method in clinical practice for the early 
diagnosis of NSCLC and for the optimization of risk profile models. Acknowledgements: 
Spanish Ministerio de Economía y Competitividad (MINECO, SAF2011-28350), Centro 
de Investigación Príncipe Felipe and Fundación Mutua Madrileña for their economic 
support and Red de Biobancos de Valencia and Bruker BioSpin for technical 
contributions. This study was also supported by the ISCIII (RTICC, RD12/0036/0025). 
Keywords: Lung cancer, early detection, NMR, metabolomics, biomarker.
 
Conclusion: In this feasibility study of a pilot community-based CT screening program 
we found gene-based risk assessment was of interest to all screening volunteers. As 
part of risk assessment, personalised SNP data made the greatest contribution to 
overall assignment of lung cancer risk in association with established clinical variables 
and significantly improved screening adherence. We conclude that gene-based risk 
stratification helps assign lung cancer risk and appears to improve adherence to screening. 
Keywords: Lung cancer, risk prediction, single nucleotide polymorphism, adherence to 
CT screening
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P1.06-004 Common Misconceptions About Lung Cancer Screening: A 
Nationwide Survey Alexis Cortot1, Laurent Greillier2, Chantal Touboul3, François 
Eisinger4, Xavier Pivot5, Jérôme Viguier6, Jean-Yves Blay7, Christine Lhomel8, Sébastien 
Couraud9, Jean-François Morere10 1Hôpital Calmette, Lille/France, 2Hôpital Nord, Marseille/
France, 3Kantarhealth, Montrouge/France, 4Institut Poali Calmette, Marseille/France, 5CHU 
de Besançon, Besançon/France, 6Hôpital Bretonneau, Tours/France, 7Centre Léon Bérard, 
Lyon/France, 8Roche, Boulogne-Billancourt/France, 9Hospices Civils de Lyon, Lyon/
France, 10Hôpital Paul Brousse, Villejuif/France
Background: The National Lung Cancer Screening Trial has demonstrated the efficacy 
of lung cancer screening based on annual low-dose computed tomography (CT) scanning 
in both former and current smokers. Nationwide lung cancer screening programs are 
therefore expected to be implemented. Adhesion to these programs will depend largely 
on public information regarding lung cancer screening. Here, we report on widespread 
beliefs regarding lung cancer screening in the general population prior to any information 
campaigns on lung cancer screening. Methods: The EDIFICE French nationwide 
observational surveys, conducted every 3 years since 2005, set out to characterize 
behaviors related to cancer screening. The 4th edition, EDIFICE 4, was conducted 
by phone interviews of a representative sample of 1602 subjects aged between 40 
and 75 years, using the quota method, from June 12 to July 10, 2014. Attitudes and 
opinions regarding colorectal, prostate, breast, cervical and lung cancer screening were 
assessed. Results: For 43% of the French population, lung cancer screening is more 
reassuring than distressing. This figure is lower than those reported for perceptions 
of other screening programs, including colorectal cancer screening (51%) and breast 
cancer screening (63% vs. 46.7% for lung cancer screening in the female population). 
Eleven percent of the respondents (N=162) declared having already undergone a lung 
cancer screening test. For the vast majority (87%, N=140), this comprised a chest 
X-ray and for 63%, (N=101) the chest X-ray was not associated with another type of 
examination. Respondent-declared reasons for not undergoing screening included 
absence of risk factors (36%), absence of respiratory symptoms (34%), absence of 
physician recommendations for screening (29%) and futility (11%). Seven percent of 
current smokers and 32% of former smokers did not undergo screening because they 
did not consider themselves at risk for lung cancer. Fear of the results pushed 9% of 
current smokers to avoid lung cancer screening. However, 22% of all respondents and 
38% of current smokers declared their intention to undergo a lung cancer screening 
test in the future. Conclusion: The general population has many misconceptions 
of lung cancer screening. Implementation of nationwide lung cancer screening 
programs should include information for the general public regarding selection criteria, 
techniques used and the benefits of lung cancer screening using low-dose CT scanning. 
Keywords: lung cancer screeening, chest X-ray, risk factors
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Conclusion: Our research is a first study investigating the plasma expression 
of miR-944 and miR-3662 in patients with neoplasms and in healthy individuals. 
Moreover, this is a first study that described a miR-3662 expression. We have shown 
that examination of these two miRNAs may be considered as a tool for NSCLC 
early diagnosis as well as for non-invasive diagnosis of lung cancer late stages. 
Studied miRNAs have also shown high utility in detection of histological type-
specific NSCLC subtypes, such as adenocarcinoma and squamous-cell carcinoma. 
Keywords: microRNA, lung cancer, biomarkers, early detection
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P1.06-008 Functional Polymorphisms in PD-L1 Gene Are Associated with the 
Prognosis of Patients with Early Stage Non-Small Cell Lung Cancer Deuk Kju 
Jung, Cheng Cheng Jin, Mi Jeong Hong, Sook Kyung Do, Jae Yong Park Biochemistry and 
Cell Biology, Kyungpook National University, Daegu/Korea
Background: This study was conducted to investigate whether polymorphisms of genes 
involved in immune checkpoints can predict the prognosis of patients with early stage 
non-small cell lung cancer (NSCLC) after surgical resection. Methods:Twelve single 
nucleotide polymorphisms (SNPs) of PD-1, PD-L1, and CTLA-4 genes were selected and 
genotyped. A total of 354 patients with early stage NSCLC who underwent curative 
surgical resection were enrolled. The association of the SNPs with overall survival (OS) 
was analyzed.Twelve single nucleotide polymorphisms (SNPs) of PD-1, PD-L1, and CTLA-
4 genes were selected and genotyped. A total of 354 patients with early stage NSCLC 
who underwent curative surgical resection were enrolled. The association of the SNPs 
with overall survival (OS) was analyzed. Results: Among the 12 SNPs investigated, PD-
L1 SNP1C>G, SNP2G>C, and SNP3T>A were significantly associated with worse 
survival outcomes in multivariate analyses. When the three SNPs were combined, OS 
decreased in a dose-dependent manner as the number of bad genotypes increased 
(Ptrend = 0.0003). A higher expression of the reporter gene for the SNP2G- SNP3T 
haplotype was observed compared with the SNP2C- SNP3A haplotype by luciferase 
assay (P = 0.004). Patients with higher expression of PD-L1 mRNA had a better 
survival compared with lower expression (P = 0.03). Conclusion: PD-L1 SNP1C>G, 
SNP2G>C, and SNP3T>A polymorphisms may be useful for the prediction of 
prognosis in patients with surgically resected NSCLC. Further studies are needed to 
confirm our findings and to understand the role of PD-L1 in the antitumor immunity. 
Keywords: polymorphism, lung cancer, immune checkpoint, PD-L1
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P1.06-009 Volatolomic Signatures to Assess Sensitivity to FGFR Tyrosine 
Kinase Inhibitors Regina Kwon1, Orna Barash2, Haneen Kayal2, Leslie Rozeboom1, 
Giulia Courthod3, Ashley A. Kowalewski1, Christopher J. Rivard1, Brad Rikke1, Nir Peled4, 
Hossam Haick2, Fred R. Hirsch1 1Medical Oncology, University of Colorado Denver, Aurora/
United States of America, 2Technion-Israel Institute of Technology, Haifa/Israel, 3Medical 
Oncology, University of Torino, Torino/Italy, 4Rabin Medical Center, Tel Aviv/Israel
Background: Targeted therapy is transforming the treatment of lung cancer. Such 
therapies are critically dependent on companion diagnostics that can predict the 
response to therapy. An ideal test is one that is quick, inexpensive, and non-invasive. 
In this regard, artificial intelligence nanosensor-based devices that profile volatolomic 
signatures (through volatile organic compounds (VOCs) analysis) have shown exciting 
potential. Numerous studies have shown cancer cells produce characteristic patterns 
of VOCs as a byproduct of their metabolism. These patterns can be used to diagnose 
patients with cancer using exhaled-breath samples. Here we asked whether the VOC 
patterns emanating from cancer cells could also be used to guide targeted therapy. In 
particular, we investigated whether lung cancer cell lines known to be sensitive to FGFR 
tyrosine kinase inhibitors (TKIs) can be distinguished from cell lines known to be resistant 
using an array of cross reactive, highly sensitive chemiresistors composed of gold 
nanoparticles (GNP) and carbon nanotubes (CNTs) coated with various recognition layers 
previously shown to be highly effective at profiling VOCs. Methods: Fourteen sensitive 
cell lines having an IC50 ≤ 50 nM for Ponatinib and AZD4547 (nonspecific and specific 
FGFR TKIs, respectively) and 21 resistant cell lines representing small cell and non-small 
cell lung cancers were cultured in complete media (RPMI 1640, 10% fetal bovine serum, 
and penicillin/streptomycin) under standard conditions to 50% to 75% confluency. SKC 
Tenax® TA Adsorbent resin was used to collect the VOCs from the head space of each 
cell line over a period of 60 to 72 hours. Triplicate measures were collected on each 
sample along with biological replicates. VOCs were also collected at the same time 
from control plates containing media only. After thermal desorption, the VOC pattern 
of each sample was characterized using a chemiresistor array of 36 sensors and 4 
features per sensor. A statistical pattern recognition analysis was then conducted using 
a discriminant function analysis (DFA) algorithm to identify the most informative sensors 
and features. Results: We found that sensitive cell lines could be distinguished from 
resistant cell lines using only 4 sensors and one feature from each (GNP+dodecanethiol, 
CNT+PAH, GNP+thiol and CNT+β dextrin). Leave-one-out cross validation indicated a 
sensitivity of 88% for the FGFR TKI-sensitive cell lines with 100% specificity and 92% 
accuracy. The area under the receiver-operating characteristic curve was 70% and 
Wilcoxon p-value of 0.06. Conclusion: Profiling the VOCs emanating from lung cancer 
cells shows excellent diagnostic potential as a means of gauging initial sensitivity to 
FGFR1 TKIs. Consequently, this study suggests that the electronic nose devices 
currently being developed to profile exhaled breath for cancer detection could also play 
an important role in predicting responses to targeted therapies. Although cell lines are 
useful for identifying the VOC pattern that predicts the cancer cell response to therapy, 
they do not necessarily reflect the complexity that occurs in vivo due to interactions 
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P1.06-007 Plasma Circulating MicroRNA-944 and MicroRNA-3662 as 
Novel Histologic Type-Specific Lung Cancer Biomarkers Tomasz Powrózek1, 
Pawel Krawczyk2, Dariusz Kowalski3, Kinga Winiarczyk3, Marta Olszyna-Serementa3, 
Marcin Nicoś1, Maciej Krzakowski3, Janusz Milanowski1 1Pneumonology, Oncology and 
Allergology, Medical University of Lublin, Lublin/Poland, 2Laboratory of Immunology and 
Genetics, Department of Pneumonology, Oncology and Allergology, Medical University of 
Lublin, Lublin/Poland, 3Lung and Chest Tumors, Oncology Centre - Institute M. Sklodowska- 
Curie in Warsaw, Warsaw/Poland
Background: Altered expression of microRNAs is associated with development and 
invasion of cancers by regulating post-transcriptionally gene function. Possibility of 
detection of circulating miRNAs expression in patients’ plasma or serum make them 
valuable biomarkers of different neoplasms, such as lung cancer. Methods: We 
investigated potential role of miR-944 and miR-3662 expression analysis as a novel lung 
cancer biomarkers and their lung tumor specificity in plasma samples of 90 lung cancer 
patients (40 NSCLC patients in stage IA-IIIA and 20 NSCLC patients in stage IIIB-IV; 8 
SCLC patients with limited and 22 SCLC patients with extensive disease) and 85 healthy 
individuals using qRT-PCR analysis. Results:Expression of miR-944 and miR-3662 was 
significantly upregulated in lung cancer patients in comparison to healthy individuals. 
Higher stage of lung cancer correlated with higher miRNAs expression (Figure 1). 
Receiver operating curves (ROC) analysis have presented diagnostic power of analysis 
of both miRNAs expression for detection of patients with I and II stage of NSCLC with 
area under curve (AUC) of 0.881. Moreover, miR-944 has shown diagnostic accuracy 
for operable squamous cell carcinoma detection (AUC=0.982) whereas miR-3662 - for 
operable adenocarcinoma (AUC=0.926) (Figure 2).
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chain reaction (qRT-PCR) with eight sample pairs. miRNAs potentially associated with 
a malignant phenotype were selected for further qRT-PCR analysis in an independent 
validation cohort (16 sample pairs). Results: All patients underwent BMS without 
complications. miRNA profiling by qRT-PCR could be reliably applied to EELF samples 
and resulted in potential miRNA markers for malignant pulmonary nodules. In particular, 
the miRNA pair miR-126/miR-126* significantly differentiated between EELF close to the 
indeterminate pulmonary nodules and the sample taken from the healthy contralateral 
lung (p<0.0001). Conclusion: Our study suggests that the analysis of miR-126/miR-
126* in EELF collected by BMS could be a potentially useful adjunct to other diagnostic 
techniques aiming at the preoperative diagnosis of indeterminate pulmonary nodules. 
Keywords: pulmonary nodules, Biomarkers, bronchoscopic microsampling
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P1.06-012 Components of Serum Peptidome Can Differentiate between 
Healthy Controls and Patients with Early Stage Lung Cancer Piotr Widlak1, 
Monika Pietrowska1, Joanna Polanska2, Michal Marczyk2, Rafal Dziadziuszko3, 
Witold Rzyman3 1Maria Sklodowska-Curie Memorial Cancer Center and Institute of 
Oncology, Gliwice Branch, Gliwice/Poland, 2Silesian University of Technologies, Gliwice/
Poland, 3Medical University of Gdansk, Gdansk/Poland
Background: Screening with low-dose computed tomography of high-risk group for lung 
cancer development allows for early detection of malignancy in a minor proportion of 
subjects and leads to improved outcomes. Implementation of complementary minimally-
invasive molecular markers for more efficient pre-selection of candidates for imaging 
tests or help to further define detected changes is a rational way to further improve 
efficacy of such screening. Here we aimed to identify features of serum peptidome 
that could be used for differentiation of individuals with early lung cancer from other 
participants of lung cancer screening program. Methods: Blood samples were collected 
during lung cancer screening program performed in Pomerania district (Poland). MALDI-
ToF mass spectrometry was used to characterize the low-molecular-weight fraction of 
serum proteome in the 800-14,000 Da range (i.e. endogenous serum peptidome). The 
analysis was performed in a group of 100 lung cancer patients (with early stage lung 
cancer diagnosed without clinical symptoms during the screening program or through 
routine diagnostic procedures) and a matched group of 300 controls (participants 
of the screening without malignancy). Results: Components of mass spectra were 
detected and specific features allowing differentiation of cancer cases were identified. 
The first group of 50 cancer cases and 150 matched controls was used to built and 
test multi-component peptide signature for cancer classification; obtained classifier 
showed about 70% specificity and sensitivity. The signature was validated in the second 
group of independently analyzed samples (50 cancer cases and 150 matched controls); 
the classifier performed well and the total number of misclassifications was below 
25%. Conclusion: MALDI-based profiling of serum peptidome allowed identification of 
components differentiating patients with early stage lung cancer from healthy individuals. 
Hence, biomarker based on serum peptide signature has a potential applicability for early 
detection of lung cancer.
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P1.06-013 Delays of Diagnosis and Treatment of Lung Cancer in a Populous 
Region of Brazil Fernando C. Abrão1, Igor R.L.B.D. Abreu1, Alessandra R. Silva2, João 
H.G. Rodrigues2, Larissa T.C. Correa2 1Thoracic Surgery, Hospital Santa Marcelina, São 
Paulo/Brazil, 2Medicine, Faculdade Santa Marcelina, São Paulo/Brazil
Background: This study was undertaken to measure delays of diagnosis and treatment 
of lung cancer in a poor region of São Paulo, Brazil, where there are four million 
people. In addition, the relation of delay times and survival was analyzedMethods: We 
retrospectively reviewed 509 patients with lung cancer between July 2008 and December 
2014. All patients admitted with lung cancer in our institution, which is the only reference 
for patients with cancer in this region, were considered eligible for this study once they 
had not undergone any previous oncology treatment. Dates for symptoms, visits to 
doctors, treatment and death were recorded. The delays in the diagnosis and treatment 
of lung cancer were arranged in the following time intervals: -Time (months) from the first 
symptoms experienced by the patient (history patients - HP) to the date on which the 
patient was diagnosed with cancer (DX); -Time (months) from initial presentation to the 
first appointment (first app) with a specialist in our institution to the date on which the 
patient was diagnosed with cancer (DX); -Time (months) from date on which the patient was 
diagnosed with cancer (DX) to the starting date of treatment (TTO). Descriptive analysis of 
data was carried out using measures of central tendency (median). Kaplan-Meier survival 
estimates were used to determine 5-year lung cancer specific survival for all patient and 
Log-rank (Mantel-cox) and Breslow (Generalized Wilcoxon) analyses were used to compare 
differences between factors. Survival was calculated from the date of patient admission 
at our institution to the date of last follow-up or until death from any cause. Statistical 
analyses were performed using SPSS v 17.0 for Windows. Results: Demographic 
characteristics of the 509 lung cancer patients were analyzed. The median age of 
these patients was 62 years (range 26 -96 years) and more than 75 percent of these 
patients were smokers. For all patients, median overall survival was 7 months (95% CI: 
5.7 to 8.2) with 34.5% of these patients surviving one year and 8.1% surviving five years. 
Patients have spent a relevant time waiting in each interval period. For instance, the 
median time from the history patient (HP) to the diagnosis (DX) was 3 months. From the 
first appointment (first app) to diagnosis (DX) was 1 month, however, 79% of patients 
were diagnosed up to 2 months. Finally, the median time from the diagnosis (DX) to 
the starting date of treatment (TTO) was 1 month, but the majority of patients (82.5%) 
started the treatment up to 2 months. There was no statistical relationship between 
with the microenvironment. Therefore, future studies are needed to confirm if these 
results can be extended to project efficacy in patients assigned to FGFR TKI therapy. 
Keywords: FGFR, VOCs, inhibitor, cancer cell lines
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P1.06-010 Allelic Heterogeneity and Its Role in Identifying Non-Small Cell 
Lung Cancer Phenotypes Lisa M. Alley1, Rosalind B. Penney2, Konstantinos 
Arnaoutakis3, Matthew Steliga3, Susanne K. Jeffus4, Mohammed S. Orloff1 1Department 
of Epidemiology, University of Arkansas for Medical Sciences, Little Rock/AR/United 
States of America, 2Environmental and Occupational Health, University of Arkansas for 
Medical Sciences, Little Rock/AR/United States of America,3Winthrop P. Rockefeller Cancer 
Institute, University of Arkansas for Medical Sciences, Little Rock/AR/United States of 
America, 4Department of Pathology, University of Arkansas for Medical Sciences, Little 
Rock/AR/United States of America
Background: More people die of lung cancer (LC) annually than of prostate, colon, and 
breast cancers combined, making it the leading cause of cancer-related mortality in 
the United States. LC can be divided into two main categories: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). NSCLC is the predominant LC category 
accounting for roughly 85% to 90% of all diagnosed LCs. NSCLC can be further 
subdivided into three main histological subtypes including adenocarcinoma, squamous 
cell carcinoma, and large cell carcinoma. Phenotypic characterization (i.e. histological 
features and LC subtypes) for NSCLC tissues remains a difficult task. Many studies have 
revealed certain genes that are associated with NSCLC; however, these genes cannot 
completely decipher between its varying phenotypes. CD36 is a biologically plausible 
candidate gene that is significantly under-expressed in NSCLC tissues compared to 
normal tissues. This differential expression is not observed in NSCLC tissue subtypes; 
however, significant differences in CD36 expression have been observed in NSCLC 
subtype-derived cell lines. Based on this previous expression data, we hypothesized 
that allelic heterogeneity within CD36 exons could disparately contribute to the 
development of NSCLC subtypes. Methods: To test this hypothesis, we obtained fresh-
frozen LC tissues from the UAMS tissue bank and performed mutation screenings 
using Sanger sequencing methods and Mutation Surveyor software. Quantitative 
RT-PCR was performed on tissue mRNA and CD36 mRNA expression was normalized 
to HPRT1 (a housekeeping gene that is more stable in lung tissues) expression in the 
same samples. Genotype-specific CD36 expressions profiles were then identified and 
analyzed. Results: Several previously undiscovered variants were identified in Exon 4 of 
the CD36 gene. Two of these variants are associated with mRNA expression differences 
between the variant and wild-type genotypes that identify phenotypic heterogeneity. 
Adenocarcinoma samples with transcript harboring the first variant genotype 
overexpressed CD36 mRNA as compared to adenocarcinoma samples containing the 
wild-type genotype (p=0.013; N=37). In squamous cell carcinoma samples, there was 
no significant difference between samples with the first variant and wild-type (p=0.74; 
N=26). Squamous cell carcinoma samples withCD36 transcript harboring the second 
variant genotype was relatively under-expressed when compared to the squamous cell 
carcinoma samples with the wild-type genotype, though the comparison only approached 
significance at p=0.053 (N=37). A similar comparison in adenocarcinoma samples 
yielded non-significant results (p=0.59; N=25). Conclusion: Identification of NSCLC 
phenotypes is critical to treatment, but remains difficult with current histopathological 
methods. Our analysis of publicly available expression data has shown that probes 
used in global expression microarrays cannot completely and reliably distinguish 
between NSCLC phenotypes at the CD36 locus. We propose that allelic heterogeneity 
at theCD36 locus may alter array probe binding properties leading to inconsistent 
expression results. Our data has identified two previously undiscovered CD36 variants 
that may uniquely lead to altered CD36 mRNA expressions correlating to specific 
NSCLC subtypes. Hence, these results suggest that we may be able to accurately 
quantify transcripts associated with NSCLC subtypes using allele-specific probes. 
Keywords: histologic phenotypes, expression, non-small cell lung cancer (NSCLC), 
allelic heterogeneity
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P1.06-011 miR-126 Is a Potential Diagnostic Marker for Malignant Pulmonary 
Nodules in Endobronchial Epithelial Lining Fluid Nicolas Kahn1, Sajo Kaduthanam2, 
Uwe Schirmer2, Thomas Muley3, Ruprecht Kuner2, Felix Herth1, Michael Meister3, 
Holger Sültmann2 1Department of Pneumology and Critical Care Medicine, Thoraxklinik at 
University of Heidelberg and TLRC, Heidelberg/Germany, 2Cancer Genome Research Group, 
German Cancer Research Center and National Center of Tumor Diseases, Heidelberg/
Germany, 3Translational Research Unit, Thoraxklinik at University of Heidelberg and 
Translational Lung Research Center (TLRC), Heidelberg/Germany
Background: Early detection and diagnostic clarification of indeterminate pulmonary 
nodules by less invasive methods could contribute to better intervention strategies and 
to the reduction of the high mortality in lung cancer patients. Endobronchial epithelial 
lining fluid (EELF) might contains molecular markers with diagnostic potential. With the 
bronchoscopic microsampling (BMS) technique, it is possible to collect EELF in close 
proximity to the suspected lesion without the risk of biopsy-associated complications. We 
investigated whether microRNA (miRNA) in EELF collected by BMS may be useful to facilitate 
preoperative diagnosis of indeterminate pulmonary nodules. Methods: The study included 
24 non–small-cell lung cancer patients with 48 EELF samples. From each patient, EELF 
was collected from subsegmental bronchi close to the indeterminate pulmonary nodule, 
which was detected by computed tomography, and from the contralateral healthy lung. 
Diagnosis was confirmed by transbronchial biopsy or surgery. Global miRNA expression 
profile analysis (754 miRNAs) was performed using quantitative real-time polymerase 
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P1.06-015 A Population Based Study on Pulmonary Carcinoids in Iceland: 
Epidemiology, Diagnosis and Survival Over Sixty Years Astridur Petursdottir1, 
Bjorn M. Fridriksson1, Johanna Sigurdardottir2, Helgi Isaksson3, Steinn Jonsson4, Tomas 
Gudbjartsson5 1Faculty of Medicine, University of Iceland, Reykjavik/Iceland, 2Department 
of Surgery, Vasteras Hospital, Vasteras/Sweden, 3Department of Pathology, Landspítali 
University Hospital, Reykjavik/Iceland, 4Department of Pneumology, Landspítali University 
Hospital, Reykjavik/Iceland, 5Department of Cardiothoracic Surgery, Landspítali University 
Hospital, Reykjavik/Iceland
Background: Pulmonary carcinoids are usually localized to the lungs but can also 
metastasize to mediastinal lymph nodes or to other organs. We studied the incidence 
and patient outcome in a well-defined population over a 60 year period. Methods: A 
nationwide study, including all pulmonary carcinoids diagnosed in Iceland from 1955 to 
2014. Histologic specimens were re-evaluated and information retrieved from medical 
records. The tumors were staged according to the TNM staging system (6th edition). 
Survival was estimated using the Kaplan-Meier method, with end of follow-up on January 
1st 2015. Mean follow-up was 186 months. Results: 93 patients (62 females, average 
age of 52 years) were diagnosed during the 60 year period. Incidence increased from 
0,2/100.000/year between 1955-1964 to 0,7 2005-2014. A total of 26 out of 85 
patients (31%) were asymptomatic upon diagnosis and the rate of incidental detection 
increased from 17% in the first 30 years to 33% in the later 30 years. The most common 
symptoms were cough (56%), pneumonia (28%) and chest pain (11%). Mean tumor 
diameter was 2,7 cm (range: 0,3-6,3), 71 (84%) patients were diagnosed with typical 
carcinoid tumors and 14(16%) with atypical carcinoid tumors. Out of 77(91%) patients 
who had surgery, 65(84%) underwent a lobectomy. One patient died within 30 days 
of surgery. Most patients(n=67, 79%) were on stage I upon diagnosis and 4(5%) on 
stage II. Another 4 patients were on stage III with mediastinal lymph node metastases, 
all with typical histology. Out of six patients(7%) with distal metastases (stage IV), two 
had typical histology. Five patients(6%) had died from pulmonary carcinoids upon follow-
up, but total 5-year survival was 92% for all patients and 87% for patients with typical 
carcinoids. Conclusion: The incidence of pulmonary carcinoids in Iceland has tripled 
over the last 6 decades, mostly due to steep increase in incidental detection on chest 
imaging. Most patients (>84%) are diagnosed with a localized disease, where long-term 
outcome is excellent.
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P1.06-016 A Novel Functional Polymorphism in CIR1 Gene Is Associated with 
the Risk of Lung Cancer Chengcheng Jin, Deuk Kju Jung, Jae Yong Park Kyungpook 
National University, Daegu/Korea
Background: We evaluated the associations between potentially functional variants in 
cancer-related genes and the risk of lung cancer to identify genetic factors responsible 
for lung cancer susceptibility in a Korean population. Methods: A total of 1,969 
potentially functional single nucleotide polymorphisms (SNPs) of 1,151 genes involved in 
carcinogenesis were evaluated using the Affymetrix custom-made GeneChip in 610 NSCLC 
patients and 610 healthy controls. A replication study was performed on an independent 
set of 490 cases and 486 controls. Results: Eighty two SNPs with P < 0.05 for genotype 
distribution in the discovery set were tested in the replication study. Among the 82 SNPs, 
three SNPs (corepressor interacting with RBPJ 1 [CIR1] SNP1T>C, solute carrier family 
38, member 4 [SLC38A4] SNP2C>T, ribonucleotide reductase M1 [RRM1] SNP3T>C) 
constantly showed significant associations with lung cancer (adjusted odds ratio [aOR] = 
0.68, 95% CI = 0.59-0.84, P < 0.0001; aOR = 0.74, 95% CI = 0.63-0.88, P = 0.001; aOR = 
0.72, 95% CI = 0.56-0.93, P = 0.01, respectively, under dominant model). Promoter assay 
demonstrated a decreased reporter gene expression for CIR1 SNP1 C allele was observed 
compared with T allele (P = 0.02). Conclusion: Our results suggest that the three SNPs, 
particularly CIR1 SNP1T>C, may contribute to lung cancer susceptibility in Koreans. 
Keywords: CIR1, lung cancer, polymorphism
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P1.06-017 Small Cell Lung Cancer in Lung Cancer Screening: Frequency 
and Outcome Mario Silva1, Carlotta Galeone2, Alfonso Marchianò3, Giuseppina 
Calareso3, Stefano Sestini4, Carlo La Vecchia2, Gabriella Sozzi5, Nicola Sverzellati1, 
Giuseppe Pelosi6, Ugo Pastorino4 1Radiology, University Hospital of Parma, Parma/
Italy, 2Clinical Sciences and Community Health, University of Milan, Milan/Italy, 3Radiology, 
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan/Italy, 4Thoracic Surgery, Fondazione 
Irccs Istituto Nazionale Dei Tumori, Milan/Italy, 5Tumor Genomics, Fondazione Irccs Istituto 
Nazionale Dei Tumori, Milan/Italy, 6Pathology and Laboratory Medicine, Fondazione Irccs 
Istituto Nazionale Dei Tumori, Milan/Italy
Background: Only 30% of small cell lung cancers (SCLC) are diagnosed as limited stage 
(LS-SCLC), whereas the majority of cases show extensive stage disease (ES-SCLC). 
Specific frequency and outcome of SCLC within lung cancer screening trials have not 
been described. The purpose of this study was to describe the frequency and outcome of 
SCLC in lung cancer screening trials with annual or biennial LDCT controls. Methods: The 
population was selected from two lung cancer screening trials (one pilot study and one 
randomized controlled study) based on serial low-dose computed tomography (LDCT). 
Subjects with diagnosis of SCLC were selected and the stage of the disease was 
assessed at the time of diagnosis, as follows: a) TNM staging system; b) 2-stage staging 
system (e.g. LS-SCLC or ES-SCLC). Survival curves were estimated using Kaplan-Meier 
method and were compared by log-rank test. Results: 5,134 subjects were recruited 
the delays and the mortality of patients. The time gap between the development of the 
first symptoms and the beginning of treatment was not relevant to the mortality rate of 
lung cancer, as shown in the survival data of the Kaplan-Meier graph. Conclusion: We 
have a relatively long time for confirmation of lung cancer and also to start treatment. 
Despite these data were not an independent significant factor for survival, this type 
of study is important to alert medical societies and government health agencies. 
Keywords: lung, Delays, Cancer, treatment
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P1.06-014 Impact of Surgery for Stage I Non-Small Cell Lung Cancer on 
Quality of Life Rebecca Schwartz1, Rowena Yip2, Ingram Olkin3, Emanuela Taioli1, 
Claudia I. Henschke2 1Occupational Medicine, Epidemiology and Prevention, Hofstra North 
Shore-Lij School of Medicine, Great Neck/NY/United States of America, 2Radiology, Icahn 
School of Medicine at Mount Sinai, New York/United States of America, 3Stanford University, 
Stanford/United States of America
Background: The literature is mixed regarding the impact of lung cancer surgery 
on physical and mental health quality of life (QoL)1-4. Some studies have found an 
improvement in QoL post surgery1 while others have indicated a decrease in various 
aspects of QoL2,3. Further, the impact on QoL is often dependent on numerous factors 
such as type of surgery. The current study aims to assess the impact of surgery on 
both physical and mental health QoL in screening-diagnosed patients with early stage 
lung cancer, an under-studied population. Methods: SF-12 QoL indicators were collected 
from 86 participants (40 women, 46 men) at baseline CT screening and one-year follow 
up post-surgery for clinical stage IA non-small cell lung cancer. 69 had lobectomy and 
17 had sublobar resection. Average time of follow up was 12 months since surgery (SD: 
1.5 months; range: 9-15 months post surgery). Univariate and multivariate analyses 
were performed to examine the difference in physical (PHC) and mental (MHC) health 
component scores of the SF-12 before and after surgery using the Wilcoxon signed rank 
and Mann Whitney tests. 
SF-12 Quality of Life Scores Pre and Post Surgery
ALL 
M(SD)
MALE 
M(SD)
FEMALE 
M(SD)
LIMITED 
RESEC-
TION 
M(SD)
LOBECTO-
MY M(SD)
PHC
Baseline 
(Pre-Sur-
gery)
49.4(6.8) 49.8(5.8) 49.0(7.8) 47.8 (7.8) 49.8(6.5)
Post-Sur-
gery 48.7(7.1) 48.5(7.7) 49.0(6.4) 50.3(6.3) 48.3(7.2)
Differ-
ence 
(Post-Pre)
-0.7(7.6) -1.3(7.5) 0.0(7.6) 2.5*(6.0) -1.5(7.7)
MHC
Baseline 
(Pre-Sur-
gery)
53.7(8.6) 55.5(7.6) 51.7(9.3) 52.3(13.4) 54.0(7.1)
Post-Sur-
gerY 55.8(8.2) 57.3(8.1) 54.1(8.2) 55.7(6.3) 55.8(8.7)
Differ-
ence 
(Post-Pre)
2.0*(9.6) 1.7*(8.5) 2.4*(10.9) 2.9(10.7) 1.8(9.4)
*p<.05
 
 
Results: There was no significant change in PHC post-surgery (Wilcoxon signed rank 
test, S=-216, p=0.32), but MHC significantly improved from baseline to post-surgery 
(S=527, P=0.01). Mean MHC was significantly higher among males as compared to 
females at both baseline (Chi-square=3.95, p=.047) and post-surgery (Chi-square=4.23, 
p=.039) and after controlling for age, ethnicity, and education, while no differences in 
PHC was observed. Further, there was an improvement in PCS score post-surgery among 
participants who underwent limited resection while a decrease in PCS score was observed 
among those who underwent lobectomy. The change in PCS score was significantly 
different between type of surgery (t=-2.01, p=0.048). After controlling for demographics, 
the difference was borderline significant (F=3.62, p=0.06). Conclusion: Surgery for 
early stage lung cancer was associated with an increase in mental health QoL one 
year after surgery, however, physical health QoL was not affected by surgery overall, 
but it did marginally improve among participants who underwent limited resection as 
compared to lobectomy. Further, although mental health QoL improved for both males 
and females, females had lower mental health QoL as compared to males at both time 
points. Current study findings have implications for lung cancer health professionals 
regarding how to most effectively present the possible impacts of surgery on the 
QoL of this subset of patients in which disease has not yet significantly progressed. 
Keywords: early stage, epidemiology, mental health
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P1.06-019 A Comparison of Demographic Risk Variables for Lung Cancer in 
New Zealand Europeans and Maori: Are Maori More Susceptible to the Effects 
of Smoking? Raewyn J. Hopkins1, Cameron Kendall2, Greg D. Gamble1, Robert Young1
1University of Auckland, Auckland/New Zealand, 2University of Otago, Dunedin/New Zealand
Background: Lung Cancer is the leading cause of cancer death among New Zealand 
(NZ) Maori. Over the past twenty years lung cancer incidence has decreased in New 
Zealand for non-Maori but has increased for Maori, and is recognised to be the highest 
in the world of any ethnic group. Nationally, the incidence of lung cancer in Maori is 3.5 
times higher than that in New Zealand Europeans, and lung cancer mortality in Maori 
males and females respectively, is 2.4 and 4.2 times higher than NZ Europeans. Maori 
have a higher incidence of lung cancer than countries with similar smoking rates. This 
suggests that there are additional factors other than smoking that predispose Maori 
to this disease. In the current study demographic and the well-established clinical risk 
variables for lung cancer were compared between New Zealand Maori and Europeans 
residing in the greater Auckland region and who were diagnosed between January 
2004-January 2015. Methods: A retrospective review of patient clinical notes for 
those identifi ed as being of NZ Maori ethnicity who were diagnosed with lung cancer 
(n=473) between January 2004 and January 2015 and treated within the greater 
Auckland region. Data extracted included histological type, smoking history, spirometry 
and basic demographics. This data was then compared with an established cohort of 
NZ European patients n= 417, with similar recruitment criteria over the period 2004-
2008. Results:Despite comparable smoking exposure histories, NZ Maori patients 
were diagnosed on average 6 years younger than NZ European lung cancer patients 
(P<0.0001). At diagnosis, current smoking rate was 2 fold greater in NZ Maori compared 
to NZ Europeans (69% vs 36%, P<0.0001). Although NZ Maori patients had similar rates 
of COPD (≈64%), they had a trend towards less GOLD 1 (mild stage disease, P=0.08) 
and signifi cantly greater airfl ow obstruction (worse COPD, FEV1%predicted 64% vs 73% 
in NZ Europeans, P<0.001). At lower smoking exposure (≤10 pk yrs), COPD rates in Maori 
with lung cancer were 2 fold greater than in NZ Europeans (64% vs 32% respectively, 
P<0.05). NZ Maori lung cancer patients had a lower prevalence of adenocarcinoma than 
in NZ Europeans (32% vs 43%, P=0.002) and a higher proportion of more aggressive 
lung cancer subtypes (squamous, non-small cell and small cell cancers) than NZ 
Europeans (61% vs 52%, P<0.0007). Conclusion: These results show that lung cancer 
in NZ Maori is associated with younger age at diagnosis, worse lung function and more 
aggressive histological subtypes compared to NZ Europeans. These results suggest 
that NZ Maori may have a greater inherent susceptibility to lung cancer compared to 
NZ Europeans. This greater susceptibility to lung cancer in Maori, along with socio-
cultural factors, may contribute to their considerably greater mortality. These results 
suggest that for the future management of lung cancer, prevention measures (such 
as smoking cessation and tobacco control), risk assessment (such as lung function 
testing) and early diagnostic approaches (such as computed tomography screening) 
should be prioritised in high risk groups, particularly those with NZ Maori ancestry. 
Keywords: lung cancer, Maori, susceptibility, ethnicity
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P1.06-020 Detection of Aberrant ALK Expression from Circulating Tumor 
Cells for Accurate Monitoring of ALK Driven NSCLC Kasey D. Lawrence1, Pavel 
Tsinberg2, Brock L. Schweitzer1, Leslie W. Abad1, Lyle Arnold2, David Hout1 1Insight 
Genetics, Inc., Nashville/TN/United States of America, 2Biocept, Inc., San Diego/CA/United 
States of America
Background: Insight Genetics Inc. and Biocept, Inc. have established a collaboration 
to develop a non-invasive work fl ow to enhance detection of the oncogenic Anaplastic 
Lymphoma Kinase (ALK) status in NSCLC patients. A barrier to detection of oncogenic 
transcripts in circulating tumor cells (CTCs) has been purifi cation methods that are 
incompatible with downstream qPCR detection technologies. In contrast, Biocept’s 
proprietary CTC capture technology has been shown to be benign for follow up qPCR 
detection using Insight Genetics proprietary qPCR-based oncogenic ALK detection 
assay. Methods: Initial studies were conducted to demonstrate cell capture on the 
Biocept platform with spiked ALK fusion positive H3122 cells. These studies show this to 
be a feasible option for non-invasive detection of ALK mRNA. A pre-amplifi cation allele-
specifi c approach including reference controls was incorporated. H3122 cells spiked 
into peripheral blood also demonstrated feasibility of the accurate detection of aberrant 
ALK expression using the Biocept CTC extraction methodology and Insight Genetics’ 
qPCR detection strategy. Results: from these studies and the detection of aberrant ALK 
expression from a cohort of ALK positive patients will be presented along with the potential 
to use CTCs to monitor ALK inhibitor resistant mutation profi les. Conclusion: Together, 
Biocept’s proprietary CTC capture technology coupled to Insight Genetics qPCR ALK 
detection assay appears to be a viable strategy to accurately monitor ALK status in 
NSCLC patient populations using a liquid biopsy.
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P1.06-021 Is Safe to Follow High-Risk Patients with Suspicious Lung Nodules 
without Invasive Tests? Ricardo S. Santos1, Juliana P. Franceschini1, Mário C. Ghefter2, 
André Luiz C. Trajano3, Rodrigo C. Chate1, Vinicius M. Boaventura1, Roberto Saad 
and, thereafter, followed up for a median time of 8.3 years, with 45,141 person-year of 
clinical follow up. Ten SCLC were reported with incidence of SCLC 22/100,000 person-
year, notably, 8 in the LDCT arms with incidence of 24/100,000. SCLC was diagnosed 
in 3/1643 women and 7/3385 men, age at diagnosis 65 years (range 53-73), and 
cumulative tobacco consumption of 82 pack-years (range 30-113). The proportion of 
SCLC among all lung cancers diagnosed in the screening was 10/164. Six out of the 8 
SCLC reported in LDCT arms were screen-detected, whereas 2 SCLC were non-screen-
detected. Median standard uptake value (SUV) by 18F-Fluorodeoxyglucose Positron 
Emission Tomography was 10 (range 5.5-14.4). According to TNM classifi cation, all but 
1 SCLC were advanced stage at the time of diagnosis, whereas according to the 2-stage 
system 5 LS-SCLC and 5 ES-SCLC were observed. The prevalence of LS-SCLC was 62.5% 
in LDCT arm, in particular, 66.7% among screen-detected and 50% non-screen-detected. 
The 2 SCLC reported in control group were both ES-SCLC. Six of the 10 subjects died 
from SCLC, with median overall survival of 21.2 months (95% CI 7.4 – nc months; Figure). 
Median overall survival was 12-month longer for LS-SCLC (p = 0.02). Survival at 5 years 
was 0%.
Conclusion: SCLC was diagnosed with higher proportion of LS-SCLC in LDCT-based 
screening trials, as compared to data from the literature. Median overall survival of LS-
SCLC was slightly longer than ES-SCLC, allegedly related to diagnosis anticipation. None 
of these patients was alive at 5 years. 
Keywords: small cell lung cancer, Lung Cancer Screening Trial, Early Detection, survival
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P1.06-018 Can 30-Mortality after Lung Cancer Resection Be Used as an 
Individual Surgeon Quality Outcome Internationally? National Data from the UK 
Chiara Proli, Maria Elena Cufari, Hilgardt Raubenheimer, May Al Sahaf, Lynn Shedden, 
Giulia Luciano, Periklis Perikleous, Nizar Asadi, Hemangi Chavan, Miguel Meza Guzman, 
Michael Dusmet, Eric Lim Department of Thoracic Surgery, Royal Brompton and Harefi eld 
NHS Trust, London/United Kingdom
Background: Internationally, one of the most commonly reported quality outcome in 
surgery for lung cancer is 30 day mortality. However, is diffi cult to know what constitutes 
unacceptably high mortality or unacceptable variation between surgeons. In October 
2014 national data was released from the Society for Cardiothoracic Surgery (SCTS) 
in the United Kingdom (UK) on hospital and individual surgeon volume performance 
for lung cancer resection in the UK. The implicit assumption is benchmarking of the 
performance. The aim of this study is to report on the impact of individual surgeon 
volume in relation to each death associated with the an average 30-day mortality rate 
of 2.2% using national data driven performance control limits (i.e. funnel plots), and 
determine the applicability on surgeon performance internationally. Methods: Data 
released by the SCTS were downloaded, complied and analysed. Each step change for 
individual mortality was calculated, and alert limits modelled using current UK national 
standard of the upper 99% binomial confi dence limit. Results: Data from 29 units were 
published with the annual volume of 125 surgeons for 2012. Data from 6 surgeons 
were excluded for no lung resections performed. In the remaining 118 surgeons, the 
mean (SD) annual lung resection volume for cancer was 42 (27). A total of 25% of 
surgeons performed 18 resections (or less) per year. For 50% of surgeons undertaking 
40 resections (or less) each death represents at least 2.5% (0 to 13%) of their annual 
work load. Using a 99% binomial confi dence limit at 50 cases, the upper alert is 16%. 
Therefore for the majority of surgeons, a mortality rate of 15% which is 7.5 fold higher 
than average would not trigger the conventional national alert limits. Conclusion: Based 
on UK national data, lung cancer resection volumes for individual surgeons are low 
and for the majority even a single death (which could be due to chance), affects the 
overall mortality rate much more, carries a disproportionately high weighting and 
may encourage risk adverse behaviour whilst simultaneously failing to detect 7.5 fold 
increased mortality rates using conventional national limits. Such data driven limits would 
also not be applicable on an international level basis unless individual surgeon volume is 
higher than 100 resections per year, a level that was not achieved by most UK surgeons. 
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P1.06-023 Addition of Low Dose Computed Tomography Image-Features 
Improves Diagnostic Accuracy for Indeterminate Pulmonary Nodules 
Roshni Bhagalia1, Xiaojie Huang2, Keyur Desai3, Ronald Walker4, Pierre P. Massion4 
1Biomedical Image Analysis, General Electric Global Research, Niskyauna/United States 
of America, 2Image & Visual Analytics Lab, General Electric Global Research, Niskyauna/
United States of America, 3Computational Biology & Biostatistics Lab, General Electric Global 
Research, Niskyauna/United States of America, 4Vanderbilt University, Nashville/TN/United 
States of America
Background: Lung cancer is the leading cause of cancer related deaths world-wide. 
While low dose computed tomography (LDCT) screening of the high risk patient population 
was recently shown to decrease deaths from lung cancer by 20%, LDCT also resulted 
in 18% over-diagnosis [c.f. Patz-E.-F.-JAMA-2003] with a positive predictive value of only 
52.9% when a suspicious LDCT finding led to a biopsy [c.f. Church-T.-NEJM-368-2003]. 
We tested whether combining novel image-features (IF) with routinely collected baseline-
features (BF) can improve the accuracy of diagnosing suspicious findings on baseline 
LDCT. Methods: This exploratory case-control study included N=123 (66-cancer, 
57-no-cancer) high risk subjects with at least one suspicious finding (nodule >= 8mm 
[c.f. Lung-RADS-ACR-2014]) on baseline LDCT screening at Vanderbilt University on 
a VCT Discovery (GE-Healthcare, UK) or a Brilliance iCT 128 SP (Philips, Amsterdam) 
system. The cohort was randomly divided into a separate training-set (N=55, 32-cancer, 
23-no-cancer) and a test-set (N=68, 34-cancer, 34-no-cancer). All model training and 
leave-one-out cross-validation were strictly restricted to the training-set. Performance 
was evaluated on the unseen test-set. Definitive lung cancer or no-cancer diagnosis, 
smoking history and at least 6 baseline-features (BF6) viz. age, family-history, pack-
smoking-years, body-mass-index, nodule-location, nodule-size were recorded for all 
subjects. Baseline lung cancer predictions were generated by (a) using the Gould-model 
[c.f. Gould,M.-Chest-2007] and (b) fitting an Elastic-Net Regularized Generalized Linear 
Model (GLMnet [c.f. Zou-H.-Journ-Royal-Stats-Soc-B-2005]) to BF6. The final baseline 
model (“GLMnet:BF”) effectively utilized 4 baseline-features with the coefficients for age 
and body-mass-index shrunk to zero. New LDCT specific information was extracted by 
computing 589 intensity, shape, surface and texture features (IF589) [c.f. Aerts-H.-Nat-
Comm-S2014, Way-T.-Med-Phys-2009] from a 3D volume-of-interest (VOI) encompassing 
a rough Graph-cuts [c.f. Li-K.-IEEE-PAMI-2006] segmentation for each suspicious nodule. 
A GLMnet was fit to all 595 features (BF6 and IF589) yielding a final enhanced model 
(“GLMnet:BF+IF”), which contained 12 features after GLMnet shrinkage: 10 IF related 
to VOI energy, nodule shape and surface statistics and image intensity variability and 2 
BF (family-history, nodule-location). Results: Baseline AUC increase by 7.4% from 0.81 
(Gould-model) and 0.80 (GLMnet:BF) to 0.87 (GLMnet:BF+IF). At 88% sensitivity, false 
positive rate reduced by 60% from 56% (Gould-model) and 44% (GLMnet:BF) to 18% 
(GLMnet:BF+IF); accuracy improved from 65% (Gould-model) and 71% (GLMnet:BF) to 
84% (GLMnet:BF+IF). Fig.1 below shows more details:
Junior4 1Hospital Israelita Albert Einstein, São Paulo/Brazil, 2Instituto Tórax, São Paulo/Brazil, 
3Instituto Tórax, Salvador/Brazil, 4Faculdade de Ciências Médicas Da Santa Casa de São 
Paulo, São Paulo/Brazil
Background: Low dose computed tomography (LDCT) screening for lung cancer (LC) 
provides reduction in mortality rates among individuals at high risk. Pre-Test Probability 
of Malignancy (PTPM) is a common tool used during the decision process: when the 
probability of malignancy is moderate or high, patients should be referred for further 
testing or tissue sampling. However, in some cases, these statistic models may give 
an overestimated value, especially in countries with a high incidence of granulomatous 
diseases. We have calculated the PTPM in our LDCT screening program and this work 
explores its main results. Methods: Prospective cohort of current or former smokers, with 
a heavy smoking history. Data of the first LDCT were analyzed to calculate the PTPM. The 
inclusion criteria were similar to NLST. LDCT scans with indeterminate pulmonary nodules 
above 4mm in size were considered positive and were evaluated by a multidisciplinary 
team. The PTPM model used in this study was designed by Swensen et al and included 
patient’s age, smoking history, diameter of the nodule, spiculation and upper lobe location. 
A PTPM > 60% was considered high and between 6 and 60% was considered moderate. 
 
Results: From January 2013 to July 2014, 790 were included in the protocol. We 
found 310 positive LDCT at baseline (39%), 34 (11%) with high PTPM. Among them, 
16 were followed with LDCT in 3 (56.2%), 6 (37.5%) or 12 (6.3%) months and the 
remaining were investigated with PET-CT and/or lung biopsy. From the patients followed 
by LDCT, one case showed an increase in nodule size and was investigated with lung 
biopsy; all others were stable in one-year follow up. LC was diagnosed in 7 patients 
and benign diseases in 5 patients with high PTPM, including 1 case of tuberculosis. 
Other 4 cases of NSCLC were found in the moderate PTPM group (n=272). Therefore, 
malignancy rate was 20.6% for high PTPM and 1.5% for moderate PTPM nodules. 
Conclusion: The Swensen’s PTPM model overestimates the prevalence 
of LC in both groups of moderate and high-calculated values of PTPM. The 
decision making process should include other variables discussed in a 
multidisciplinary board, been safe to follow patients with further image tests. 
Keywords: lung cancer, Screening, Low dose computed tomography
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P1.06-022 The British Thoracic Society Guideline on the Investigation and 
Management of Pulmonary Nodules (2015) David R. Baldwin1, Matthew C. Callister2 
1Respiratory Medicine, Nottingham University Hospitals, Nottingham/United 
Kingdom, 2Respiratory Medicine, Leeds Teaching Hospitals, Leeds/United Kingdom
Background: British Thoracic Society (BTS) Guidelines are aimed primarily at practitioners 
within the UK. They are National Health Service Evidence accredited which means they 
must adhere to robust guideline development methodology. The evidence base for this 
guideline comes mostly from countries outside the UK so the recommendations will have 
relevance to other countries healthcare systems. Methods: The recommendations are 
based on a comprehensive review of the literature on pulmonary nodules and expert 
opinion. A third of the 360 references cited were from 2012 onwards, reflecting the rapid 
expansion of the evidence base. The new evidence has resulted in important differences 
from guidelines previously published by the American College of Chest Physicians and the 
Fleischner Society. Results: There are four algorithms: initial approach to solid nodules; 
surveillance of solid nodules; management of sub-sold nodules; and pulmonary nodule 
treatment. Two malignancy prediction calculators are recommended to assess the risk 
of malignancy; one (the Brock University model) that performs best for smaller nodules 
and one that has the better accuracy for larger nodules following PET-CT (the Herder 
model). There are recommendations based on recent evidence from screening studies, 
for a higher nodule size threshold for follow up (≥5mm or ≥80mm3). This will reduce the 
number of follow up CTs which, in the UK at least, are not cost effective. Surveillance 
recommendations are also different from previous guidelines: people can be discharged 
after 1 year of stability if measured by semi-automated volumetry. Management is also 
dependent on the volume doubling time (VDT) with immediate further assessment for 
nodules that show a VDT of ≤400 days and either biopsy or further observation for 
nodules with VDTs of >400 to ≤600 days. People with nodules with a VDT >600 days 
have the option of discharge, if VDT is measured by volumetry. As in previous guidelines, 
a 3 month repaet CT is recommended for sub-solid nodules.After that, management is 
governed by risk assessment by the Brock tool (with the proviso that it may underestimate 
risk after the initial CT) and according to specific features that predict malignancy. 
Acknowledging the good prognosis of sub-solid nodules, there are recommendations 
for less aggressive options in their management. The guidelines provide more clarity 
in the use of further imaging, with ordinal scale reporting for PET-CT recommended to 
facilitate incorporation into the Herder risk model and more clarity about the place of 
biopsy and its influence on pre-test probability. Segmentectomy can be considered for 
primary diagnosis and treatment for nodules smaller than 2cm, and sub-lobar resection 
is recommended for pure ground glass nodules. Where fitness levels preclude surgery, 
non-surgical treatment with stereotactic ablative radiotherapy or radiofrequency 
ablation is recommended, even where biopsy is not possible, provided the probability 
of malignancy is high. Finally, there are evidence based recommendations about the 
information that people need that should be provided for them. Conclusion: The BTS 
guideline is intended to be used both as a summary in the day to day management 
of the person with a pulmonary nodule as well as a comprehensive reference text. 
Keywords: Guideline, pulmonary nodule
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(solid-part diameter <4.55mm). There is higher correlation in the solid-part diameter 
and SUV-max. We should keep in mind the limitation of PET/CT for GGN diagnosis. 
Keywords: PET/CT, GGN
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P1.06-026 18F-FDG PET/CT Evaluation of Non-Small Cell Lung Cancer - 
Initial Experience from Johannesburg Osayande Evbuomwan, Olusegun A. Ayeni, 
Khushica Purbhoo, Mboyo D.T. Vangu Department of Nuclear Medicine and Molecular 
Imaging, Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand, 
Johannesburg/South Africa
Background: Lung cancer is the most common cause of cancer-related mortality, with 
an overall five year survival of 16.6%. It is most likely to recur in the first four years after 
therapy. The overall five year survival for newly diagnosed lung cancer is poor in both 
developed and developing countries. In South Africa, statistics show that lung cancer 
caused 52,217 deaths between 1995 and 2006. The 2009 data from South Africa 
showed that the number of male and female cases of lung cancer was 1440 and 685, 
respectively. 18F-FDG PET/CT allows non-invasive imaging of non-small cell lung cancer 
(NSCLC) based on the increased glucose metabolism by the cancer cells. 18F-FDG PET/CT 
imaging of NSCLC has been found to be useful in staging, early detection of recurrence, 
detection of residual disease and monitoring of treatment response. Our study was 
carried out to evaluate its role in histologically proven NSCLC in our center. Methods: We 
retrospectively reviewed data of 34 patients with histologically confirmed NSCLC. A total 
of 51 scans were reviewed, of which 17 were follow-up PET/CT scans. Eleven patients 
had 1 follow up (FU) scan, 5 patients had 2 FU scans and one patient had 3 FU scans. 
FDG-PET/CT findings were reported as positive or negative for disease. Sites for distant 
and nodal metastases were noted. Follow up scans were also compared with previous 
or base line scans to assess for treatment response, early detection of recurrence and 
detection of residual disease. Of the total number of patients, only 24 patients have 
had follow up to see how PET/CT influenced their management. Results: Data were 
analysed from 20 males (59%) and 14 females (41%) of which majority (83%) were aged 
between 61 to 80 years old. A total of 51 scans were done, 37 (72.5%) were positive and 
14 (27.5%) were negative. Almost a quarter of PET/CT scans were referred for staging 
(25.3%), about half for detection of residual disease (47.1%) and the remaining for the 
detection of recurrence (13.8%) and assessment of treatment response (13.8%). At initial 
imaging, metastases were visualized in 44% of patients; two-thirds of the metastases 
being in the adrenal, bone and contralateral lung. Nodal disease on the initial scans was 
noted in 56% of patients. We compared the findings in patients with FU studies. The 
changes from the initial studies and the first FU showed a tendency towards a significant 
difference (p=0.05; Pearson Chi-square). When the rest of FU scans were compared, 
there was no significant difference (p=0.66 for FU1 Vs FU2) and (p=0.71 for FU2 Vs FU3). 
PET/CT correctly up staged 29.4% and down stage 5.9% of patients and at the same 
time falsely down staged 5.9% and upstaged 2.9% of patients. Conclusion: 18F-FDG 
PET/CT is useful in staging, early detection of recurrence, detection of residual disease 
and monitoring of treatment response in patients with non-small cell cancer. The 
tendency noted in comparing the initial and FU scans is due to lower power of this study. 
Keywords: 18F-FDG PET/CT, non-small cell lung cancer, Detection of residual disease, 
Staging
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P1.06-027 Role of Brain MRI and PET-CT in Follow-Up after Lung Cancer 
Surgery Akira Sakurada, Chiaki Endo, Hirotsugu Notsuda, Ken Onodera, Yoshinori 
Okada Tohoku University Hospital, Miyagi/Japan
Background: Standard follow-up method after pulmonary resection for lung cancer 
is not determined. While chest computed tomography (CT) is widely utilized, brain 
magnetic resonance imaging (MRI) and positron emission tomography (PET) are also 
used as follow-up examination to detect cancer recurrence recently. Object of this study 
is to clarify the ability of MRI and PET to detect recurrence as follow-up examination 
setting. Methods: Medical records of 281 patients with lung cancer who underwent 
complete pulmonary resection for lung cancer from 2009 to 2012 were retrospectively 
reviewed. Information regarding recurrence, such as site of recurrence, time after 
surgery, tumor markers, and survival, were collected. Pathological stage according 
to 7th version of TNM staging was IA/IB/IIA/IIB/IIIA for 143/75/23/16/24 patients, 
respectively. Number of the patients with adenocarcinoma/squamous cell carcinoma/
large cell carcinoma/small cell carcinoma/pleomorphic carcinoma/others was 
190/71/2/2/7/9, respectively. All PET images were combined with simultaneously 
performed CT scan. Statistical analysis was performed using Mann-Whitney test for 
comparing groups and log-rank test for survival analysis. P-values less than 0.05 were 
regarded as significance. Results: CT was utilized for 255(90.7%), brain MRI for 130 
(46.3%), and PET for 102 (36.3%). Recurrence of lung cancer was observed in 58 
patients (20.6%).  Pathological stage was IA/IB/IIA/IIB/IIIA for 11/14/12/7/14 patients, 
respectively. Initial recurrent site was intrathorax/bone/brain/adrenal gland/liver for 
34/15/5/3/1 patients, respectively. Motive to detect initial recurrence was patients’ 
symptom/CT/MRI/PET for 16/24/3/15 patients, respectively. Brain MRI detected 3 
out of 5 (60%) of brain metastasis as an initial recurrence in asymptomatic status. PET 
detected 8 out of 15(53.3%) of bone metastasis as an initial recurrence in asymptomatic 
status. In 19 of 48 (39.6%) patients, elevation of tumor markers beyond normal range 
was observed before detection of metastasis by diagnostic imaging examination. Time 
after surgery to initial recurrence was shorter in symptom-detected group than in 
examination-detected group (median 233 versus 404 days, p<0.001). Similarly, survival 
after initial recurrence was shorter in symptom-detected group than in examination-
Conclusion: This initial exploratory analysis showed that image-features 
extracted from suspicious LDCT findings may help reduce the number 
of unnecessary biopsies. Additional validation studies are warranted 
to determine the value of this structural imaging-based approach. 
Keywords: CT image features, Elastic-net Regularized GLM, diagnostic accuracy for 
indeterminate pulmonary nodules, Low dose CT lung cancer screening
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P1.06-024 Patterns of 18F FDG-PET/CT Studies in Patients with Suspected or 
Confirmed Lung Cancer - A Johannesburg Academic Hospital Perspective 
Olusegun A. Ayeni1, Osayande Evbuomwan1, Khushica Purbhoo2, Mboyo.Di.Tamba 
Vangu1 1Department of Nuclear Medicine and Molecular Imaging, Charlotte Maxeke 
Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg/South 
Africa, 2Department of Nuclear Medicine and Molecular Imaging, Chris Hani Baragwanath 
Academic Hospital, University of the Witwatersrand, Johannesburg/South Africa
Background: Lung cancer incidence has increased rapidly in developing countries over 
the last few decades. It is estimated to account for nearly one-fifth of cancer-related deaths 
in South Africa. Imaging plays an integral role in the evaluation of patients with lung cancer. 
2-[18F] fluoro-2-deoxy-d- positron emission tomography (18F FDG-PET) is now an accepted 
part of the imaging assessment. Integrated FDG-PET/ CT imaging is recognised as being 
superior to PET alone and CT alone in the imaging of lung cancer especially for staging 
of untreated non-small cell lung cancer (NSCLC). An audit was conducted to describe the 
patterns of disease in our centre. Methods: Retrospective audit which included 89 studies 
performed for patients with suspected or histologically confirmed lung cancer referred 
to us for PET/CT from September 2008 to March 2015. PET/CT reports of the patients 
were retrieved together with relevant clinical information from the case files whenever 
necessary. Over two-third (71%) of patients were referred for diagnosis/staging, others 
for re-staging (19%) and response to therapy (10%). All of the studies were reported by 
qualified and experienced Nuclear Medicine Physicians and the CT components of these 
studies were also read in conjunction with qualified Radiologists. Results: There were 
89 scans from 87 patients. Majority of the patients were males (60%) and the mean 
age was 61.0 ± 9.4 years. About 42% (n=37) of the studies were performed on patients 
with histologically confirmed lung cancer; of the remaining indications, 15% (n=13) were 
referred for solitary pulmonary nodule and 43% (n=39) for multiple pulmonary nodules 
and masses. More than two-thirds (71%) were referred for staging, about one fifth (19%) 
for re-staging and 10% to assess response to treatment. The vast majority (94%) of 
known lung cancer were NSCLC that included adenocarcinoma (40%), squamous cancer 
(29%) and NSCLC not otherwise specified [NOS] (26%). F-18 FDG PET/CT showed almost 
an equal number in the presence (37%) or absence of metastases (36%). No significant 
differences were noted on FDG PET uptake between the three subtypes mentioned above 
(p > 0.05, Chi square). However, there was a tendency for a difference between these 
histological subtypes [squamous, adenocarcinoma and NSCLC NOS] for the presence of 
metastases (p<0.09) and the sites of metastatic predilection (p<0.08). Just more than 
half (53%) of patients showed evidence of positive regional nodal involvement on PET. 
All SPN were visualised on PET (sensitivity 100%) with about 57% with high FDG uptake 
(mean SUV=7.71) and about 43% with low FDG uptake (mean SUV=1.05). Correlation 
with histology was available for 38% of all SPNs and FDG PET correctly identified all of 
them as malignant or benign (100% specificity). Conclusion: 18F FDG-PET/CT is useful 
in characterising solitary pulmonary nodules (SPNs) and staging as well as monitoring 
treatment response in lung cancer. Although it cannot replace histological confirmation 
of nodal and metastatic involvement, it serves as a roadmap to identify areas for tissue 
diagnosis. The detection of metastases may alter the therapeutic decision of NSCLC. 
Keywords: Lung Cancer, NSCLC, SPN, PET/CT
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P1.06-025 Statistical Analysis of 18F-FDG-PET/CT Findings of Ground Glass 
Nodule (GGN) Kazuya Nishii1, Akihiro Bessho1, Nobuaki Fukamatsu1, Yoshiko Ogata1, 
Shinobu Hosokawa1, Makoto Sakugawa1, Mitsumasa Kaji2 1Respiratory Medicine, 
Japanese Red Cross Okayama Hospital, Okayama/Japan, 2Department of Radiology, 
Okayama Diagnostic Imaging Center, Okayama/Japan
Background: 18F-FDG-PET/CT (PET/CT) is one of the most important image inspections 
for the diagnosis of lung cancer. However, there are often false negatives caused by 
small lesions such as Ground Glass Nodule (GGN). Whether PET/CT is useful for the 
diagnosis of GGN is unknown. Therefore, we analyzed the relationship of computed 
tomography (CT) findings (size, properties) and maximum standardized up-take values 
(SUV-max) of GGN. Methods: We had 69 patients with pathological-Stage IA-IB lung 
adenocarcinoma who underwent surgical resection and PET/CT from January 2010 to 
December 2014. We retrospectively examined their clinical characteristics, CT findings, 
and PET/CT findings. Results:Characteristics of 69 patients were as follows, 47 - 86 
years old (median 70 years old), female/male: 39/30, pathological-Stage IA/IB: 59/10. 
GGN diameter: 1.1 - 41.13mm (median 19.43mm), Solid-part diameter: 0.0 - 23.23mm 
(median 4.55mm), Solid-part-ratio (solid-part diameter / GGN diameter): 0 - 77% (median 
20%). SUV-max was insignificant to 6.8 (median 1.0). Correlation coefficient of each 
factor and SUV-max were as follows, GGN diameter: 0.49, Solid-part diameter: 0.54, 
Solid-part-ratio: 0.41 (Pearson’s product-moment correlation). All pure-GGN show 
no significant SUV-max (<2.5), even though there are some large GGN included (max 
40.0mm). GGN diameter >20mm or solid-part diameter >5mm were significant factor of 
FDG-uptake (Fisher’s exact test). In this study, SUV-max was lower than significant level 
with solid-part diameter <4.55mm. Conclusion: There was no significant SUV-max with 
diagnostic value in pure-GGN. PET/CT is not useful for pure-GGN or small part-solid nodule 
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P1.07-001 Preoperative Serum proGRP as a Predictor for Lung Tumor 
Histology Marius Lund-Iversen1, Odd Terje Brustugun2, Marianne N. Broughton3, Junbai 
Wang1, Nils Bolstad3, David Warren3, Zhenhe Sou1 1Pathology, Oslo University Hospital, 
Radiumhospitalet, Oslo/Norway, 2Oncology, Oslo University Hospital, Radiumhospitalet, 
Oslo/Norway, 3Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo/
Norway
Background: Progastrin-releasing peptide (proGRP) is the stable precursor of gastrin-
releasing peptide, a hormone secreted by neuroendocrine cells. Serum measurements 
of proGRP are helpful to detect relapses of small cell carcinoma during follow up, but 
its usefulness as a preoperative marker to distinguish between different lung tumors 
is unclear. Methods: Preoperative serum proGRP was determined in 116 patients 
with primary pulmonary tumors. 31% of the tumors displayed endocrine features (19 
carcinoids, 8 small cell carcinoma, 9 large cell carcinomas) whilst the remainder were 
non-small cell carcinomas (40 adenocarcinomas and 40 squamous cell carcinomas). 
The presence of proGRP in tumors with possible endocrine features was evaluated by 
immunohistochemistry using two in-house anti-proGRP monoclonal antibodies (mAb 
M16 and mAb E149]. Tumors with less than 2 % positive cells were considered negative 
for proGRP expression. Serum levels of proGRP above 70 ng/L were considered 
elevated. Results: Mean serum proGRP (s-proGRP) was 267 ng/L (median: 96.5 ng/L, 
[range 25 – 2080 ng/L] for the neuroendocrine tumors, while adenocarcinomas and 
squamous cell carcinomas had mean values of 50 and 60 ng/L respectively [19,137] and 
median values 53.5 ng/L and 59.6 ng/L respectively (table 1). Among the tumors with 
possible endocrine features, serum levels of proGRP reflected the IHC score (Wilcoxon 
rank-sum test, p<0.0005). We did not find any relationship between tumor size and 
s-proGRP levels, but values >70 ng/L were predictive of either carcinoid tumor or small 
cell carcinoma. Table 1: Tumor characteristics
Histology
ProGRP IHC 
positives 
(n/total)
S-proGRP 
(median)
S-proGRP 
(mean)
Mean tumor 
size (mm)
Carcinoid 9/19 127 424 26.1
Small cell carcinoma 5/8 75.5 145 30.2
Large cell carcinoma 3/9 46 72.8 42.2
Squamous cell 
carcinoma NA 59.6 60 NA
Adenocarcinma NA 53.5 50 NA
 
Conclusion: The correlation between s-proGRP and IHC scores suggest that the elevated 
s-proGRP results from proGRP produced by the tumor. The lack of correlation between 
s-proGRP and tumor size might be explained by variations in number of proGRP producing 
cells within the different tumors and/or to the amount proGRP secreted by different 
tumors. For lung tumors with unclear preoperative histology or cytology, s-proGRP-levels 
can be helpful as an adjuvant diagnostic marker to differentiate between tumors with and 
without endocrine features, but the test is not robust enough for final decision making. 
Keywords: serum proGRP, immunohistochemistry proGRP, small cell carcinoma, 
carcinoid tumors
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P1.07-002 FAK Inhibition by PF228 Has Anti-Tumoral Effects Associated with 
Inhibition of Histone 3 and Aurora Kinases A/B Phosphorylation in SCLC 
Frank Aboubakar Nana1, Marylene Lecocq1, Ladjemi Maha1, Sebastien Dupasquier1, 
Bruno Detry1, Pierre P. Massion2, Charles Pilette3, Charles Pilette1, Yves Sibille1, Yves 
Sibille4, Sebahat Ocak4, Sebahat Ocak1 1Institut de Recherche Expérimentale Et Clinique 
(Irec), Pôle de Pneumologie, Orl Et Dermatologie,, Université Catholique de Louvain, 
Bruxelles/Belgium, 2Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-
Ingram Cancer Center, Vanderbilt University Medical Center, Nashville/TN/United States 
of America, 3Division of Pneumology, Cliniques Universitaires St-Luc, UCL, Bruxelles/
Belgium, 4Division of Pneumology, Cliniques Universitaires UCL Mont-Godinne, Yvoir/Belgium
Background: Lung cancer is the most common cancer and the leading cause of 
cancer-related death worldwide. Small cell lung cancer (SCLC) accounts for 15% 
of all lung cancer cases and is the most aggressive histologic type, with a five-year 
overall survival as low as 5%. Focal Adhesion Kinase (FAK) is a non-receptor tyrosine 
kinase, which regulates integrin and growth factor signaling pathways involved in cell 
proliferation, survival, migration, and invasion. FAK is overexpressed and/or activated 
in many cancers,including SCLC. We hypothesized that FAK may represent a good 
target for therapeutic intervention in SCLC and tested the changes of cell phenotype 
and signaling events following FAK inhibition, by using PF-573,228 (PF-228) in SCLC cell 
lines. Methods: Two SCLC cell lines growing in suspension (NCI-H82 and NCI-H146), an 
adherent SCLC cell line (NCI-H196), and a mixed morphology SCLC cell line (NCI-H446) 
were treated with increasing concentrations of PF-228. Cell proliferation was evaluated 
by WST-1 assay, cell cycle by flow cytometry following propidium iodide (PI) and 
detected group (median 149 versus 916 days, p<0.001). Conclusion: Follow up after 
lung cancer surgery utilizing brain MRI and PET effectively detect ansymptomatic 
metastasis to brain and bone. Survival benefit need be concluded by different 
setting. Furthermore, economic efficiency are also warranted to be analyzed. 
Keywords: Surgery, follow up, PET, MRI
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P1.06-028 Distribution of Stage, Surgical Methods and Prognosis of Lung 
Adenocarcinoma According to the Initial Diagnostic Patterns Eunjue Yi1, Hyun 
Hwak Shin1, Hyo-Jun Jang1, Mi Kyung Bae2, Sukki Cho1, Kwhanmien Kim1, Sanghoon 
Jheon1 1Seoul National University Bundang Hospital, Seongnam-Si/Korea, 2National Health 
Insurance Service Ilsan Hospital, Goyang-Si/Korea
Background: Early detection of lung adenocarcinoma is important for reducing cancer 
mortality. We investigated how lung adenocarcinoma has been diagnosed in our institute, 
and evaluate the effects on the treatment and prognosis. Methods:Medical records 
of 1065 patients who had undergone lung cancer treatment including surgery in our 
institute between 2003 and 2012 were reviewed retrospectively. We excluded patients 
who lacked data for diagnostic process (3 patients) and underwent neoadjuvant therapy 
(38 patients). Patients were categorized into 3 groups, (1) group1; patients who were 
diagnosed during routine medical examination, (2) group2; patients with symptoms, 
and (3) group3; patients who were diagnosed during the treatment of other diseases. 
Surgical methods, stages and diagnostic tools were compared and survival analysis 
was done. Results: A total of 1024 patients were included. The mean follow-up periods 
were 55.8 months (± 29.00, range from 0.00 to 139.20). The number of sublobal 
resection (wedge resection and segmentectomy) in group1, 2, and 3were 85, 37 and 
89 respectively. Group1 and group3 underwent significantly more limited resection than 
group 2 (p<0.000). The number of VATS approaches were 341 (80.6%), 148 (52.7%) and 
231 (70.3%) in group1, 2, and 3 respectively. Group2 and group3 had significantly more 
open thoracotomy than group1 (p<0.000 for group2 and p=0.042 for group3). Early stage 
lung adenocarcinoma (including 0, IA and IB) was found more in group1 (318 patients, 
75.2%) and in group3 (251, 78.4%) than in group 2 (150, 53.4%). Overall and disease-free 
survival periods of group1 (57.0 ± 27.60 and 50.4 ± 30.89) and group3 (54.6 ± 27.67 
and 46.9 ± 29.57) were significantly higher (p <0.000 and p=0.002 for overall survival, 
P<0.000 for disease-free survival) respectively than those of group2 (55.5 ± 32.38 and 
42.6 ± 34.92). Group 1 and group3 has no significant differences both in overall and 
disease free survival periods. Chest computed tomography was most commonly used 
diagnostic tool in group2 and group3 (48.4% and 35.6% respectively), on the contrary, 
chest roentogram in group1. Conclusion: Incidentally found lung adenocarcinoma during 
treatment for other diseases has no differences with those in regular health examinations 
in stages, surgical extent and prognosis. Careful inspection for those patients could 
contribute equally for early detection of lung adenocarcinoma as routine screening. 
Keywords: lung adenocarcinoma, diagnosis, Prognosis
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P1.06-029 Serum Glutathione Peroxidase 3 as a Biomarker of Postoperative 
Relapse in Patients with Lung Cancer In-Jae Oh1, Hyun-Ju Cho1, Chul-Kyu Park1, 
Young-Chul Kim1, Ju-Sik Yun1, Sang-Yun Song1, Kook-Joo Na1, Mee Sun Yoon1, Sung-Ja 
Ahn1, Hyun-Ju Seon1, Yoo-Duk Choi1, Seung-Won Lee2 1Lung and Esophageal Cancer Clinic, 
Chonnam National University Hwasun Hospital, Jeonnam/Korea, 2Department of Anatomy, 
Chonnam National University Medical School, Gwangju/Korea
Background: Glutathione peroxidase 3 (GPx3) which is an extracellular secretory 
protein is down regulated in patients with early stage lung cancer. We examined 
the usefulness of serum GPx3 as a biomarker for monitoring of relapse after 
surgery. Methods: We prospectively collected serial serum samples at baseline, 3 
months (3m), 6 months (6m), and 12 months (12m) after operation from the patients 
who underwent surgery during the year 2013. GPx3 levels were measured three times 
per sample using the enzyme-linked immunosorbent assay, and the mean values 
were analyzed by repeated measure analysis of variance. Results: A total of 126 (73 
adenocarcinoma, 31 squamous cell carcinoma, 22 others) patients were analyzed in 
this study. Median age of patients was 66 years old (range, 39-80) and 19 (15.4%) out 
of 123 lung cancer patients were confirmed relapse during the follow-up period of 2 
years. In squamous cell carcinoma, the changes of mean serum GPx3 were significantly 
different between relapse (baseline: 13.3 ± 1.1 µg/mL, 3m: 17.1 ± 4.6 µg/mL, 6m: 14.8 
± 2.7 µg/mL, 12m: 17.9 ± 1.7 µg/mL) and control group (baseline: 10.8 ± 2.3 µg/mL, 
3m: 13.4 ± 3.4 µg/mL, 6m: 12.4 ± 2.6 µg/mL, 12m: 13.5 ± 4.7 µg/mL, p=0.043). 
The changes of mean serum GPx3 levels were not different between two groups in 
all histology (p=0.258) and adenocarcinoma (p=0.701). Conclusion: Postoperative 
serum GPx3 levels were significantly elevated only in relapsed squamous cell 
histology, not in adenocarcinoma. More large scaled validation studies are warranted. 
Keywords: Squamous cell carcinoma, serum, biomarker, Glutathione peroxidase 3
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• Correlation when stratified by stage:
• In LS-SCLC, no correlation between OS of LS-SCLC and number TiLs’s found 
(Spearman’s rho=0.19, p=0.45 for total of 18 patients).
• In ES-SCLC, no correlation between OS of ES-SCLC and TiLs (Spearman’s rho=-
0.02, p=0.91).
Conclusion: Recent data in breast cancer (1) and melanoma indicate the presence 
of TiLs is a positive prognostic marker. However, we were not able to find a positive 
or negative correlation of TiLs to SCLC outcomes. It is possible that small sample 
size failed to show a correlation. However, the known prognostic markers for SCLC 
i.e. female sex, PS, and stage of disease showed correlation with OS in our sample 
size (data not shown). This indicates that a) our sample size is a good representation 
of previously studied larger samples, and b) a likely accurate assessment of this 
correlation. Previously, Wang et al (3) has described FOXP3+ T cell lymphocytes 
as negative prognostic maskers for SCLC. However, our clinical data fails to provide 
additional support. Taken together, these studies advocate for larger sample size 
evaluation. References: 1)Loi et al. Prognostic and Predictive Value of Tumor-Infiltrating 
Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive 
Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-
Based Chemotherapy: BIG 02-98. JCO September 20, 2014;32;2935-2937 2)Thomas 
et al. Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently 
Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment 
and Melanoma Study. JCO November 20, 2013;31:4252-4259 3)Wang et al. Small cell 
lung cancer tumor cells induce regulatory T lymphocytes, and patient survival correlates 
negatively with FOXP31 cells in tumor infiltrate. IJC April 24, 2012; 131:E928–E937 
Keywords: TiL, SCLC
POSTER SESSION/ SMALL CELL LUNG CANCER 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.07-004 Efficacy of Endostar Combined with Chemotherapy and Endostar 
Maintenance Treatment for Patients with Extensive Small-Cell Lung Cancer 
Li Chen, Yongxin Wu Department of Oncology, The First Hospital of Nanchang University, 
Nanchang/China
Background: EP scheme is a standard regimen ad the first-line treatment for small 
cell lung cancer, with the complete remission of 10～25% and overall survival up to 
10 months. However, almost all patients reoccur or progress within 1 year after first-
line treatment. Endostar combined with chemotherapy had synergistic effect and 
slight toxic effect. Methods: Patient, female, was admitted in the hospital in March, 
2010 because of cough and hemoptysis and diagnosed as small cell lung cancer by 
bronchoscopic biopsy. Patient was finally diagnosed as extensive small-cell lung cancer 
by pathology and imaging (CT, MRI), who was treated by EP scheme (etoposide and 
cisplatin) and endostar for 6 months from July, 2010—Jan. 2011. Patient was remitted 
completely after treated by EP scheme (etoposide and cisplatin) and endostar. 
However, patients had brain metastases in Jan., 2011 and received radiotherapy and 
endostar maintenance treatment for 4 cycles. And patient was partially remitted. The 
reoccurrence of lung was considered in Nov., 2011 and treated by EP plus endostar 
for 2 cycles and patients was remitted completely until Feb., 2012. Results: During the 
course of treatment, patient was well tolerated to chemotherapy and had no intolerant 
toxic effects. Performance status of patients scored 0 point. Extra-cerebral progress 
Free Survival (PFS) reached 13 months and the follow up on overall survival is up to 33 
months. Conclusion:Endostar combined with chemotherapy and endostar maintenance 
treatment is effective and safe for the treatment of extensive small-cell lung cancer. 
Keywords: small cell lung cancer; endostar; chemotherapy; endostar maintenance 
treatment
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P1.07-005 Paclitaxel and Irinotecan in Platinum Refractory/Resistant Small 
Cell Lung Cancer: Final Analisis of One Galician Lung Cancer Group Experience 
Francisco J. Afonso-Afonso1, Natalia F. Núñez2, María J. Villanueva Silva3, José L. Fírvida 
Pérez4, Margarita Amenedo5, Urbano Anido Herránz6, Laura M. De Paz Arias1, Marta 
Covela Rúa2, Gerardo Huidobro Vence3, Maria C. Areses4, Lorena Cadavid Vieitez2, 
Nohelia Garcia Cid3, Sergio Vzsquez-Estevez7 1Oncología Médica, Complejo Hospitalario 
Universitario de Ferrol, Ferrol, A Coruña/Spain, 2Oncología Médica, Hospital Universitario 
Lucus Augusti, Lugo/Spain, 3Oncología Médica, Complexo Hospitalario Universitario de 
Vigo, Vigo/Spain,4Complezo Hospitalario Universitario de Ourense, Ourense/Spain, 5Centro 
Oncolóxico de Galicia, A Coruña/Spain, 6Complexo Hospitalario Universitario de Santiago, 
Santiago de Compostela/Spain, 7Oncology, Hospital Universitario Lucus Augusti, Lugo/Spain
Background: Patients with Small Cell Lung Cancer (SCLC) whose disease progresses 
during or shortly after treatment with platinum, have a poor prognosis. Paclitaxel (P) 
and irinotecan(I) have demonstrated activity both as monotherapy as in combination 
regimen for this neoplasm. We have previously presented data from our experience 
with this agents in patients with SCLC . Here, we present a final analysis of survival and 
security. Methods: We included patients with measurable disease that had progressed 
during or within six months of first-line chemotherapy based on platinum, with an 
Eastern Cooperative Oncology Group (ECOG) performance status <2, adequate liver, 
renal and bone marrow function. They were treated with (P): 75 mg/m2 and (I): 50 
mg/m2, both drugs administered on days 1 and 8 of a 21 day cycle. Treatment was 
maintained until disease progression and/or unacceptable toxicity. Results: We included 
50 patients with a mean age of 65 years (43-77) and with metastases in two or more 
locations in 39 of them (78%). A median of 4 cycles of treatment was administered and 
eight patients (16%) received six or more cycles. The main reason for discontinuation 
bromodeoxyuridine (BrdU) staining, and apoptosis by flow cytometry after intracellular 
caspase 3 staining. FAK expression/activity and signaling events downstream of FAK 
were evaluated by Western blotting (WB). Results: While PF-228 did not modify total 
FAK expression, it decreased the phosphorylation of FAK (Tyr 397) in a dose dependent 
manner in all tested SCLC cell lines. Inhibition of FAK activity by PF-228 significantly 
decreased cell proliferation, induced cell cycle arrest in G2/M phases,decrease DNA 
replication and increased apoptosis in all tested cell lines proportionally to the dose. 
Regarding signaling events, we observed that inhibition of FAK activity induced the 
inhibition of phosphorylation of histone-3 (Ser 10) and Aurora Kinase A (Thr288) and B 
(Thr232). 
 
 
Conclusion: These results show that FAK activity is required for proliferation, cell cycle 
progression, and survival in SCLC cell lines, suggesting that this pathway is central to SCLC 
biology. The antitumoral effects of PF-228 may occur through (1) the inhibition of histone-3 
phosphorylation mediated by the inhibition of Aurora kinase B and leading to cell cycle arrest 
in G2/M phase and (2) the inhibition of Aurora kinase A leading to decreased DNA replication. 
Keywords: SCLC, lung cancer, FAK, PF-573,228 (PF-228), AURK
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P1.07-003 Role of Tumor Infiltrating Lymphocytes in Small Cell Lung Cancer 
Inderjit Mehmi1, Indira Bhavsar2, Doreen Griswald2, Todd Gress3, Yehuda Lebowicz4 
1Department of Medicine, Section of Hematology/Oncology, West Virginia University School 
of Medicine, Morgantown/WV/United States of America, 2Marshall University Jce Som, 
Huntington/WV/United States of America, 3Dept of Medicine, Marshall University Jce Som, 
Huntington/WV/United States of America, 4Dept of Medicine, Edwards Comprehensive 
Cancer Center/Chh/Jcesom/Mu, Huntington/WV/United States of America
Background: Small-cell lung cancer (SCLC), a histological subtype of lung cancers, 
carries a very poor prognosis. Female sex, performance status (PS), and stage are 
known prognostic markers for SCLC. Lymphocytes have been observed and described 
in SCLC biopsies from the lung. However, no information is available that defines the 
correlation of these lymphocytes to SCLC outcomes. To identify this correlation of TiLs 
to overall survival (OS) and progression free survival (PFS) in SCLC, we carried out a 
retrospective analysis of SCLC cases diagnosed at our hospital 2008-2013. Methods: 53 
patients’ biopsies of SCLC stained with hematoxylin and eosin were examined with light 
microscopy at 40X by in-house hematopathologist . Lymphocytes that were interspersed 
among the tumor cells were counted, and then obtained the pertinent data. Spearman 
rank correlation analysis was used to assess correlation. Results: Among the 53 patients 
30 (57%) females and 23 (43%) male, age mean 62.87 years (35-89), average PS 1.53 
(0-4), 99% of the patients Caucasian, TiLs mean 70 (10-400), 18 (34%) had LS-SCLC, 
and 35 (66%) had EX-SCLC
• Progression free survival (data available for total of 36 patient, of which 16 LS-
SCLC, 20 ES-SCLC): LS-SCLC 20.84 months (95% CI; 13.76-27.92), ES-SCLC 5.7 
months (95% CI; 4.17-7.23)
• OS: LS-SCLC 22.97 months (95% CI; 16.16-29.78), ES-SCLC 8.21 months (95% CI; 
5.30-11.13)
• Correlation between TiLs and OS
• Spearman’s rho was calculated at 0.15, p=0.28; indicating no correlation between 
TiLs and OS.
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progression to chemotherapy. On multivariate analysis, the only statistically significant 
predictors of overall survival were initial performance status and use of PCI. Using t-test, 
only partial vs. complete response to chemotherapy was found to be significantly different 
between the PCI and no PCI groups. There was a statistically significant difference in 
survival (p= 0.0021) and time to brain metastasis curves (p = 0.00029). Median survival 
for PCI and non-PCI groups was 14.0 and 8.2 months respectively. Median time to brain 
metastasis was 18.0 and 9.0 months respectively. There was no significant difference in 
incidence of brain metastases (40.6% vs. 43.8%) in either group. With regards to uptake 
of PCI for ES-SCLC at The Ottawa Hospital, 24.2% (16/66) of patients before Jan. 1, 2008 
were treated with PCI compared to 57.6% (53/92) after 2008. 
Conclusion: PCI in the setting of at least partial response to chemotherapy was found to 
have a survival benefit and prolongation of time to brain metastasis. This has 
corresponded with an increased uptake of PCI at The Ottawa Hospital since publication 
of the EORTC 22993-08993 in 2007. 
Keywords: extensive stage small cell lung cancer, prophylactic cranial irradiation, Brain 
metastasis, PCI
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P1.07-008 Preliminary Results from a Phase Ib/II Trial of Belotecan plus 
Ifosfamide in Patients with Extensive-Stage Small-Cell Lung Cancer Young Saing 
Kim1, Eun Kyung Cho1, Min Young Baek1, Eun Young Kim2, Hee Kyung Ahn1 1Division of 
Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
Center, Incheon/Korea, 2Radiology, Gachon University Gil Medical Center, Incheon/Korea
Background: Belotecan is a novel camptothecin analogue, topoisomerase I inhibitor. 
Belotecan, alone or in combination with cisplatin, has shown activity in small cell lung 
cancer. The objective of the phase Ib part was to determine the maximum tolerated dose 
(MTD) and safety of belotecan plus ifosfamide in patients with extensive-stage small-
cell lung cancer. Methods: Patients with age ≥ 18 years, no previous chemotherapy, 
measurable disease, ECOG PS 0-2, and adequate organ function were eligible. The phase 
Ib portion of the trial is a conventional 3+3 dose-escalation design. The following dose 
levels (belotecan/ifosfamide, mg/m2) were explored: 0.5 x 4d/1200 x 2d (level 1), 0.5 x 
4d/1000 x 3d (level 2, starting dose), 0.5 x 4d/1000 x 4d (level 3), 0.5 x 5d/1000 x 4d 
(level 4), and 0.5 x 5d/1000 x 5d (level 5) every 21 days. Results: Here we report the phase 
Ib portion of the trial. Thirteen patients were enrolled and completed at least one cycle. 
The median age is 68 years (range, 48-77). ECOG PS was 0/1/2:1/6/6, respectively. 
A total of 53 cycles (median, 5; range, 1-6) of chemotherapy were administered. The 
MTD was belotecan 0.5 mg/m2 on days 1-4 in combination with ifosfamide 1000 mg/
m2 on days 1-4 (level 3). Three patients experienced dose-limiting toxicities; death 
from neutropenic sepsis and grade 3 fatigue at dose level 4, and febrile neutropenia at 
dose level 3. The most frequent grade 3-4 toxicities were myelosuppression, including 
neutropenia (54%), anemia (23%), and febrile neutropenia (23%). Eleven patients were 
evaluable for response and 9 (82%) had partial responses. Conclusion: The combination 
of bleotecan and ifosfamide is feasible and active. The recommended phase II dose is 
belotecan 0.5 mg/m2 on days 1-4 and ifosfamide 1000 mg/m2 on days 1-4 of a 21-
day cycle. The phase II trial is currently ongoing. Clinical trial information:NCT01784107. 
Keywords: phase Ib, small-cell lung cancer, belotecan, ifosfamide
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P1.07-009 Effect of Accurate Heart Outlining on Cardiac Dose - the CONVERT 
Trial Experience Nichola Groom1, Elena Wilson2, Corinne Faivre-Finn3, Sally Falk4 
1Radiotherapy Physics, Mount Vernon Hospital, London/United Kingdom, 2Radiotherapy 
Department, University College London Hospitals NHS Foundation Trust, London/United 
Kingdom, 3Department of Clinical Oncology, Univ. of Manchester and the Christie NHS 
Foundation Trust, Manchester/United Kingdom, 4Clinical Trials Unit, University of Manchester 
of chemotherapy was disease progression, observed in 22 patients (44%). Partial 
response was documented in 18 patients (36%), stable disease in 20 (40%) and 
disease progression in 7 (14%). There were five patients in whom it was not possible 
to evaluate response. The median progression free survival was 4.09 months (CI 95%: 
2.13-6.05) and the median overall survival was 5.092 months (CI 95% 4.22 – 5.96). 
No treatment-related deaths were described. The clinical and hematologic toxicities 
most frequently observed were grade 1 and 2: asthenia (n:20; 40%), diarrhea (n:14; 
28%), anorexia (n:12; 24%), alopecia (n:11; 22%), neutropenia (n:5; 10%) and anemia 
(n:4; 8%). There was one (2%) grade 4 and four (8%) grade 3 neutropenia. There 
were no cases of grade 4 clinical toxicity and there were 16 (32%) grade 3: nine of 
diarrhea (18%), three of asthenia (6%), one of vomiting (2%), one of hiponatremia (2%), 
one hepatic (2%) and one hyperglycemia (2%). Conclusion: This (P) and (I) regimen 
is an effective and well tolerated option for this subgroup of very poor prognosis 
patients with SCLC.Future explorations using this therapeutic regimen are warranted. 
Keywords: small cell lung cancer, refractory, resistant, second-line
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P1.07-006 Final Results of Randomized Phase II Study of Carboplatin plus 
Irinotecan vs. Carboplatin plus Amrubicin for ED-SCLC  
Yuka Fujita1, Naoto Morikawa2, Shunichi Sugawara3, Makoto Maemondo4, Toshiyuki 
Harada5, Masao Harada6, Akira Inoue7, Terufumi Katoh8, Hiroshi Yokouchi9, Toshihiro 
Nukiwa10 1Asahikawa Medical Center, Asahikawa/Japan, 2Iwate Medical University School 
of Medicine, Morioka/Japan, 3Sendai Kousei Hospital, Sendai/Japan, 4Miyagi Cancer 
Center, Natori/Japan, 5Jcho Hokkaido Hospital, Sapporo/Japan, 6Hokkaido Cancer Center, 
Sapporo/Japan, 7Tohoku University Hospital, Sendai/Japan, 8Kanagawa Cardiovascular 
and Respiratory Center, Yokohama/Japan, 9Fukushima Medical University, Fukushima/
Japan, 10Japan Anti-Tuberculosis Assiciation, Tokyo/Japan
Background: Carboplatin-based regimens, such as carboplatin plus etoposide 
(CE), are among the standard regimens for the management of extended disease 
small-cell lung cancer (ED-SCLC). However, the efficacy of carboplatin-based 
regimens is unsatisfactory. Carboplatin plus irinotecan (CI) and carboplatin plus 
amrubicin (CA) are promising new carboplatin-based regimens identified in our 
previous studies. Accordingly, we conducted this randomized phase II study to 
identify the appropriate regimen for comparison with CE in future phase III trials. 
Methods: Chemotherapy-naïve patients with ED-SCLC were randomly assigned to 
receive 4–6 cycles of carboplatin (area under the curve [AUC] 5.0, day 1) plus irinotecan 
(70 mg/m2, days 1 and 8) every 3 weeks (CI arm) or carboplatin (AUC 4.0, day 1) plus 
amrubicin (35 mg/m2, days 1–3) every 3 weeks (CA arm). The primary endpoint was 
the overall response rate (ORR). Secondary endpoints were progression-free survival 
(PFS), overall survival (OS), and toxicity. Results: Between December 2009 and March 
2013, 71 patients were enrolled. One patient in each arm did not receive any protocol 
treatment owing to rapid disease progression. The characteristics of the treated patients 
were as follows: median age, 70 years (range 51–84 years) and proportion of males, 
84%. Delivered mean dose intensities (mean actual dose/mean planned dose) were 
similar for both arms: carboplatin 98% and irinotecan 94% for CI arm, and carboplatin 
97% and amrubicin 94% for CA arm. The ORRs were 79% and 89%, median PFS was 
5.1 and 6.2 months (CA; hazard ratio [HR] = 0.59, 95% CI: 0.35–0.98, P = 0.042), 
and median OS was 12.2 and 15.9 months in the CI and CA arms, respectively (CA; 
HR, 0.77; 95% CI: 0.49–1.29; P =.318). Grade 3 or higher neutropenia (CI, 53% and 
CA, 89%), anemia (CI, 26% and CA, 20%), thrombocytopenia (CI, 18% and CA, 14%), 
and febrile neutropenia (CI, 12% and CA, 29%) were observed. No treatment-related 
deaths were observed. Overall, 25 patients (74%) in the CI arm and 28 patients 
(80%) in the CA arm received post-discontinuation therapies. Conclusion: CA was 
numerically effective than CI in chemotherapy-naïve patients with ED-SCLC, with 
acceptable toxicity. Therefore, CA could be selected for future phase III trials. 
Keywords: ED-SCLC, carboplatin, Amrubicin, irinotecan
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P1.07-007 Prophylactic Cranial Irradiation in Extensive Stage Small Cell 
Lung Cancer: The Ottawa Hospital Experience Andrew Bang1, Wayne Kendal2, 
Graham Cook2, Robert M. Macrae2 1Radiation Oncology, The Ottawa Hospital, Ottawa/ON/
Canada, 2Radiation Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa/ON/
Canada
Background: The role of radiation has been investigated in extensive stage small cell 
lung cancer (ES-SCLC) in two-fold: prophylactic cranial irradiation (PCI) and consolidative 
radiotherapy. A randomized control trial was published in 2007 (Slotman) which showed 
benefits for PCI in median survival and decreased cumulative risk of symptomatic brain 
metastases. We conducted a retrospective study to evaluate the uptake of PCI at The 
Ottawa Hospital (TOH) for ES-SCLC and its impact on time to brain metastasis and survival. 
TOH is the sole provider of cancer services for a population of 1.3 million. Methods: The 
medical records of 605 patients (206 limited stage, 399 extensive stage) with small cell 
lung cancer between Jan. 1, 2005 and Dec. 31, 2011 were reviewed. The cumulative 
incidence of brain metastases and cumulative proportion surviving was estimated 
using the Kaplan–Meier method comparing patients receiving PCI or not. Differences 
between the groups with covariates including age, gender, smoking status, ECOG 
score, extrathoracic involvement, and response to chemotherapy were analyzed using 
t-test. Results: 158 out of 399 ES-SCLC patients (39.6%) had no brain metastases at 
diagnosis, received chemotherapy, and had a partial or complete response. Of the 158 
patients with these criteria, 69 patients received PCI and 89 did not. 90 patients had 
brain metastasis on diagnosis, and 151 patients were not eligible or had no response/
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Conclusion: This study indicated that the use of hypofractionated radiotherapy 
failed to significantly improve the local regional control rate and overall survival 
time compared with hyperfractionated radiotherapy. However, the incidence 
of grade 2 and 3 acute radiation induced esophagitis was significantly 
more common in the hyperfractionated arm than in hypofractionated arm. 
Keywords: limited-stage, thoracic radiotherapy, radiation dose, small cell lung cancer
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P1.07-011 ‘Peripheral Limited’ Small Cell Lung Cancer (SCLC). Does Surgical 
Resection Have a Role in Primary Management? Lana Y. Schumacher1, Mathew 
A. Vandeusen1, Ali H. Zaidi1, Samantha A. Martin1, Emily J. Lloyd1, Gene G. Finley2, 
Athanasios Colonias1, Blair A. Jobe1, Rodney J. Landreneau1 1Esophageal and Lung 
Institute, Allegheny Health Network, Pittsburgh/United States of America, 2Medical Oncology, 
Allegheny Health Network Cancer Institute, Pittsburgh/PA/United States of America
Background: Limited stage SCLC, even peripheral completely resectable disease, is 
considered by many thoracic oncologic specialists to be a systemic process with a limited 
role of surgery beyond diagnosis. We hypothesized that surgical resection may improve 
local control, and potentially enhance survival for the small subset of SCLC patients (pts) 
with peripheral, resectable disease. Methods: Retrospective review of outcomes of all 
pts (n=127) with “limited stage” SCLC treated at our Institution from 2004-2014. Local 
disease progression and distant recurrence among pts undergoing primary systemic 
therapy +/- radiation therapy (n=106, 83%) were compared to pts with peripheral SCLC 
(n=21, 17%) undergoing surgical resection as first line therapy + adjuvant therapy. Patient 
demographics, surgical mortality, disease-free and overall survival outcomes were 
compared between the non-surgical and surgical groups. Systemic therapy was Platinum 
agent based. Survival was estimated using Kaplan-Meier survival analysis. Groups were 
and the Christie NHS Foundation Trust, Manchester/United Kingdom
Background: RTOG 0617 showed greater one year overall survival of 81% in the 60Gy 
group versus 70.4% in the 74Gy group, supporting the hypothesis that cardio pulmonary 
effects of radiotherapy can contribute to death. It has demonstrated that the percentage 
of heart receiving ≥5 and ≥30Gy is correlated with survival. Hence there is a need to 
improve planning and delivery of radiotherapy to avoid irradiating normal lung and 
heart wherever possible. This current study investigates the effect on cardiac dose of 
inaccurate cardiac outlining (non compliant to protocol) for a selection of plans submitted 
as part of the CONVERT Trial quality assurance programme. Methods: The CONVERT 
Trial is a multicentre phase III study which recruited 547 patients with limited-stage 
small cell lung cancer from April 2008 to November 2013. Patients were randomised to 
receive once daily (66Gy in 33 fractions) or twice daily (45Gy in 30 fractions) radiotherapy 
concurrently with chemotherapy. The primary endpoint was overall survival. The spinal 
canal, lungs, oesophagus and heart were contoured as organs at risk for dose-volume 
histograms. The trial protocol specified that the heart and pericardial sac should be 
contoured. Outlining should extend superiorly to the inferior aspect of the aortic arch and 
inferiorly to the apex of the heart. An atlas was provided to each centre which included 
example organ at risk contours. In this current study, heart outline volumes (in cm3) 
provided by participating centres have been compared to gold standard heart outlines 
(in cm3) drawn according to the trial protocol for 50 patients. The impact of the change 
in heart volume on heart dose (V30) is also presented. The CT and structure set for each 
case was imported into Eclipse (Version 11), and the heart was re-outlined according 
to the trial protocol. The plan data were then imported into Vodca along with the dose 
cube provided by the centre so that DVH data could be extracted. Results: The mean 
difference in cardiac volume between the gold standard and that provided by the centre 
was 80.0cm3 (range: 1.9cm3 to 248.2cm3). In the experimental trial arm (66Gy), an 
increase in calculated cardiac dose (V30/%) was seen in 22/28 cases (78.6%) by using 
the gold standard cardiac outline rather than that provided by the centre. The mean 
increase in V30 was 5.7% (range: 0.92% to 15.29%). In the control dose arm (45Gy), 
an increase in calculated cardiac dose (V30/%) was seen in 17/22 cases (77.3%). The 
mean increase in V30 was 6.9% (range: 0.93% to 14.1%). Conclusion: In this study we 
have shown that in 86% of cases reviewed the heart was not delineated according to 
protocol. As a result the mean heart dose was underestimated by an average of 2.3Gy. In 
conclusion, this study highlights the importance of collecting radiotherapy plans to check 
heart contours as part of a QA programme and to feedback deviations to investigators. 
Keywords: heart, outlining, cardiac, Dose
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P1.07-010 Hyperfractionated Versus Hypofractionated Radiotherapy for 
Limited-Stage SCLC: A Retrospective Comparison of Two Prospective Studies  
Xiao Hu1, Bing Xia2, Yong Bao3, Yu-Jin Xu1, Xiaolong Fu4, Ming Chen1 1Department 
of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation 
Oncology, Hangzhou/China, 2Department of Radiation Oncology, Hangzhou Cancer Hospital, 
Hangzhou/China, 3Department of Radiation Oncology, Sun Yat-Sen University, Cancer 
Center, Guangzhou/China, 4Department of Radiation Oncology, Shanghai Jiaotong University, 
Shanghai Chest Hospital, Shanghai/China
Background: The optimal thoracic radiation dose/fraction for limited-stage small cell lung 
cancer (SCLC) is not yet established at present. This study mainly aims to retrospectively 
compare the impact on local/regional control of different thoracic radiation dose/
fraction schedules from two prospective trials. Methods: Patients received thoracic 
radiotherapy consisted of 1.5 Gy twice a day in 30 fractions over a 19-day period to a 
total of 45 Gy (hyperfractionated arm, BED=53.3 Gy) or 2.5 Gy daily in 22 fractions over 
a 30-day period to a total of 55 Gy (hypofractionated arm, BED=62.6 Gy) combined with 
concurrent chemotherapy were included into this study. A statistical software package 
SPSS 13.0 was applied, and Kaplan-Meier method was used to estimate survival data. 
Fisher’s exact test was used for comparisons of categorical data. Results: From 2005 
to 2014, nighty-two patients were accrued into to the hyperfractionated arm. From 
2005 to 2012, nighty-one patients were accrued into the hypofractionated arm. The 
1-year, 2-year local/regional progression free survival rates of hyperfractionated arm 
and hypofractionated arm were 82.1%, 60.7% and 83.8%, 67.9%, respectively (P=0.33). 
The median survival time (months) of hyperfractionated arm and hypofractionated arm 
were 27.9 (95% CI: 15.7-40.1) and 22.0 (95% CI: 16.4-27.5) respectively, while 1-year, 
3-year, 5-year overall survival rates of the two arms were 85.2%, 39.4%, 26% and 77.1%, 
34.4%, 26.9% respectively (P=0.48). Grade 2 and 3 acute radiation esophagitis were 
observed in 28.3%, 8.7% and 15.5%, 2.1% of patients in hyperfractionated arm and 
hypofractionated arm (P=0.009).
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cohort (p=0.221). The 2-year OS for the ConvTRT and the HypoTRT cohort were 56.0% 
and 62.8%, respectively. The median PFS was 19.3 months for patients received HypoTRT, 
which was similar to that of the ConvTRT group (13.7 months, p=0.375). Sixty-three 
patients(62.4％) experienced disease progression in ConvTRT cohort, compared with 
41 patients(59.4%) in HypoTRT cohort. The patterns of failure (stratified by local-regional 
recurrence, distant metastasis or both as first relapse) were also similar between the two 
dose cohorts (p=0.219, p=0.466, p=0.724). The 2-year local-regional progression free 
survival rates for the ConvTRT and HypoTRT cohorts were 59.7% and 70.6% (p=0.128), 
respectively. PCI reduced the incidence of brain metastasis by 31% at 20 months. 
Patients who received PCI had a significant longer survival with a 2-year OS rate of 69.8%, 
as comparing 44.4% of those who did not (p=0.000). Concurrent chemoradiotherapy 
was another predictor for favorable survival. However, patients who were treated with 
concurrent approach tended to be younger, receive early thoracic radiotherapy, more 
cycles of chemotherapy and PCI. No differences in treatment-related toxicity rates 
were demonstrated between the two dose-prescription cohorts (p=0.815). Grade ≥3 
esophagitis and pneumonitis occurred in 9.9% and 9.9% in ConvTRT cohort, whereas 
11.6% and 8.6% in HypoTRT cohort, respectively. Conclusion: In this retrospective 
analysis, HypoTRT or ConvTRT combined with etoposide/platinum chemotherapy 
yielded statistically similar survival, treatment failure outcomes, and toxicity profiles. 
Keywords: survival, Limited-stage small cell lung cancer, Hypofractionated radiotherapy, 
Conventionally fractionated radiotherapy
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P1.07-013 Real-Life 2-Year Therapeutic Strategies in the Management of 525 
Small-Cell Lung Cancers: The ESCAP Study Preliminary Results 
Didier Debieuvre1, François Goupil2, Philippe Brun3, Adrien Dixmier4, Geoffroy De 
Faverges5, Cécilia Nocent-Ejnaini6, Jacky Crequit7, Sylvie Vuillermoz-Blas8, Christophe 
Perrin9, Olivier Leleu10, Michel Carbonnelle11, Frédéric Goutorbe12, Bernard Asselain13, 
François Blanchon14, Françis Martin15, Michel Grivaux14 1Emile Muller General Hospital, 
Mulhouse/France, 2Centre Hospitalier Du Mans, Le Mans/France, 3Centre Hospitalier Général 
de Valence, Valence/France, 4Centre Hospitalier D’Orléans, Orléans/France, 5Hopital Pierre 
Beregovoy, Nevers/France, 6Centre Hospitalier de La Cote Basque, Bayonne/France, 7Centre 
Hôspitalier Laënnec, Creil/France, 8Centre Hospitalier St Joseph St Luc, Lyon/
France, 9Centre Hospitalier de Cannes, Cannes/France, 10Centre Hospitalier D’Abbeville, 
Abbeville/France, 11Hôpital Auban Moet, Epernay/France, 12Centre Hospitalier Général 
de Béziers, Béziers/France, 13Institut Curie, Paris/France, 14Centre Hospitalier de Meaux, 
Meaux/France, 15Centre Hospitalier Général de Compiègne, Compiegne/France
Background: In the last years, new drugs and strategies have emerged in the 
management of lung cancer (LC). The French College of General Hospital Respiratory 
Physicians therefore promoted a prospective multicenter epidemiological study: the 
ESCAP study. This study was aimed to describe the therapeutic strategies implemented 
during the first 2-year after diagnosis in patients with LC followed in French General 
Hospital chest departments. We report below descriptive results for small-cell lung 
cancer (SCLC). Methods: For each patient with a LC diagnosed in 2010, a standardized 
form was completed at diagnosis and following each change in treatment strategy up to 
at least 2 years after diagnosis. Results: 53 centers participated in the ESCAP study, 
and included 3,943 LC patients. Of these, 525 patients had a SCLC. Characteristics of 
SCLC patients at diagnosis were: mean age +/- standard deviation (SD), 65.6 +/- 10.8 
years; male, 77%; never-smokers, 4.8%. The mean follow-up in SCLC patients was 10.5 
months (SD: 8.8) and median number of strategies was 2 (Interquartile range: 1-3). Main 
strategy characteristics are summarized in the following table.
First strategy 
(N=525)
Second strategy 
(N=309)
Third strategy 
(N=153)
Duration (months): mean+/-
SD 5.4 +/- 4.5 3.6 +/- 3.5 2.7 +/- 2.4
Curative surgery 2% 1% -
Radiotherapy 10% 47% 20%
Radiochemotherapy 15% - -
Chemotherapy 75% 55% 61%
Exclusive supportive care 8% 14% 27%
Patients died during the 
strategy 195 (37%) 134 (43%) 90 (59%)
Patients with a new strategy 309 (59%) 153 (50%) 54 (35%)
 
 
As regards first strategy, cisplatin (46%) and carboplatin (42%) were the most frequent used 
drugs associated with etoposide. As regards second strategy, the most frequently used 
drugs were topotecan (22%), etoposide (21%), or carboplatin (20%). Few patients received 
targeted therapy (< 1% in strategies 1 and 2). Conclusion: The ESCAP study describes 
the 2-year management of SCLC on real-life settings in France. Its preliminary results 
showed that 3 or 4 strategies were not uncommon in the management of SCLC patients. 
Keywords: therapeutic strategies, small-cell lung cancers
compared using a log-rank test. Results: Pts demographics were similar between non- 
surgical and surgically treated SCLC pts. Systemic therapy / radiation was utilized for 
88 (83%) non-surgical pts. Systemic therapy alone was utilized for 18 (16.9%) pts, and 2 
(1.8%) patients received radiotherapy alone. Local disease progression represented first 
site of treatment failure in 19 (17.9%), while distant metastases was first noted in 65 pts 
(61.3%). Of the 65 distant metastasis first site of progression, 27 (41.5%) were cerebral. 
First site of progression was unable to be verified 16 (26.2%) medically treated pts. 
Among the 21 pts having “surgical resection” of peripheral, limited SCLC, there was no 
perioperative (30 day) mortality. Local recurrence was noted first in 7 (33.3%) of surgical 
pts. Distant metastases was discovered first in 3 (14.3%), and cerebral metastasis was 
found in 2 of these 3 pts. Nine (42.9%) surgical pts were recurrence free (mean 43 
months), while only 7 (5.7%) medically treated pts were free of recurrence (mean 31 
months). The 5 year survival among medially treated pts was 8% compared to 21% 
among patients undergoing surgical resection of peripheral SCLC (p= 0.008).
(See figure 1. below)
  
 
Conclusion: Survival for all SCLC patients is affected by the common presence of 
systemic disease, despite an apparently limited, peripheral disease presentation. 
Surgical resection as “First line” therapy combined with adjuvant systemic + radiation 
therapy for peripheral, limited small cell lung cancer may be beneficial. Cerebral 
metastases are important sites of first distant recurrence for all limited stage SCLC. 
Keywords: Survival, SCLC, Recurrence, Surgery
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P1.07-012 Hypo- or Conventionally Fractionated Radiotherapy in Patients with 
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Retrospective Analysis  
Jing Zhang, Min Fan, Di Liu, Yu Xin Shen, Kuai Le Zhao, Kai Liang Wu, Wei Xin Zhao, 
Ling Li, Xiao Long Fu, Zheng Fei Zhu Department of Radiation Oncology, Fudan University 
Shanghai Cancer Center, Shanghai/China
Background: Previous data from our institution showed that hypofractionated thoracic 
radiotherapy (HypoTRT) concurrently with etoposide/platinum chemotherapy yielded 
favorable survival in patients with LS-SCLC. The aim of the present study was to compare 
the survival outcomes, failure patterns and toxicities between groups of LS-SCLC patients 
treated with conventionally fractionated radiotherapy (ConvTRT) or HypoTRT combined 
with etoposide/platinum chemotherapy. Methods: Medical records of LS-SCLC patients 
between January 2010 and December 2013 at Fudan University Shanghai Cancer Center 
were retrospectively reviewed. All patients treated with chemotherapy and ConvTRT (2.0 
Gy per faction daily, DT≥56Gy) or HypoTRT (2.5 Gy per faction daily, DT= 55Gy) were 
eligible for analysis. The progression-free survival (PFS) and overall survival (OS) were 
generated for different populations using the Kaplan-Meier method and compared by 
log-rank test. The comparison of failure patterns and toxicity were analyzed with the 
χ2 test. Results: One hundred and seventy-nine patients were indentified. All patients 
received 1-6 cycles of Etoposide/Platinum chemotherapy. Except for nine patients who 
received hyperfractionated regimen, 170 of 179 patients treated with were eligible for 
analysis (median age 58 years; male 85.3%). Sixty-nine patients received HypoTRT and 
101 patients received ConvTRT (median 60Gy/30Fx). PCI (25Gy/10Fx) was given to 
patients with partial or complete remission in chest tumor. PCI was administered to 46 
(66.7%) and 48 (47.5%) patients in HypoTRT and ConvTRT cohorts (p=0.014), respectively. 
Except for PCI, the patient- or treatment-related variables were similar between the two 
cohorts. With a median follow-up of 23 months, the median OS was 26.7 months (95%CI: 
23.2-30.2) in the ConvTRT cohort and 30.4 months (95%CI: 25.6-35.2) in the HypoTRT 
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was seen in 36 (45%) patients. Overall, median absolute neutrophil count was 6.15 K/
uL and absolute lymphocyte count was 1.6 K/uL. Both groups were comparable for age, 
gender, body mass index and ECOG functional score. We found 31/36 (86.11%) patients 
with NLR ≥4 who had extensive stage disease. In contrast, only 24/44 (54.55%) patients 
with NLR <4 had extensive stage disease (P= 0.0024). All 25/25 (100%) patients with 
limited stage disease received chemoradiation, while 44/55 (80%) of patients with 
extensive stage disease received chemotherapy. The median overall survival was 8.7 
versus 11.2 months for patients with NLR ≥4 versus NLR <4 (log-rank P=0.014) (Figure 
1). Multivariate Cox regression detected a strong interaction (P=0.0024) between NLR 
and the combined status of chemotherapy and stage. In the limited stage group, NLR 
≥4 patients had slightly worse OS (HR=2.13, 95% CI: 0.66-6.86; P=0.20), whereas in 
the extensive stage group which received chemotherapy, NLR ≥4 patients had slightly 
better OS (HR=0.80, 95% CI: 0.42-1.53; P=0.50). In the extensive-stage group which 
did not receive chemotherapy, NLR ≥4 patients had significantly worse OS (HR=12.7, 
95% CI: 2.94-55.2; P=0.0007). Conclusion: Similar to the other studies in solid 
tumors, we found a prognostic value of NLR in all patients with SCLC. However, NLR 
was prognostically significant only among patients with extensive-stage disease who 
did not receive chemotherapy. Among patients of both stage groups who received 
chemotherapy, NLR had little prognostic value. NLR ≥4 appears to be more prevalent in 
patients with extensive stage disease probably reflecting an impaired immune system. 
Further research exploring the role of immune system and associated immune surrogate 
markers in SCLC is needed.
 
Keywords: Neutrophil lymphocyte ratio, small cell lung cancer, Prognosis
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P1.07-016 Comparison of PET/CT, 99mTc-MDP Bone Scan and Serum Alkaline 
Phosphatase for Detecting Bony Metastasis in Patients with Small Cell Lung 
Cancer Jing Zhang, Min Fan, Di Liu, Yu Xin Shen, Xiao Long Fu, Kuai Le Zhao, Kai 
Liang Wu, Wei Xin Zhao, Ling Li, Zheng Fei Zhu Department of Radiation Oncology, Fudan 
University Shanghai Cancer Center, Shanghai/China
Background: The data on the diagnostic ability of 18F-FDG positron emission 
tomography/computed tomography (PET/CT) compared that of 99mTc-MDP bone 
scan (BS) or serum alkaline phosphatase (ALP) for the detection of bone metastasis 
in patients with small cell lung cancer (SCLC) was sparse. The aimed of this study was 
to compare the diagnostic accuracy and agreement among PET/CT, BS and serum 
ALP for detecting bone metastasis in SCLC patients. Methods: The database at 
Fudan University Shanghai Cancer Center was retrospectively reviewed to identify all 
patients with SCLC who underwent both integrated whole-body PET/CT and BS between 
January 2010 and December 2013. In addition, serum ALP concentration of all eligible 
patients was recorded. The interval between PET/CT and BS was less than two weeks. 
Bone metastasis was confirmed if any of the following criteria were met: histology or 
pathology, concordance between PET/CT and BS, results of supplemental examinations 
(magnetic resonance imaging) or progression of bony lesions seen on follow-up studies. 
The sensitivity, specificity and accuracy of each modality were calculated. The overall 
differences were analyzed using the McNemar’s paired-sample test. The comparison 
of sensitivity, specificity and accuracy were analyzed with the χ2 test or Fisher exact 
test. Agreement between PET/CT, BS and ALP was assessed by kappa statistic. The 
κ-value was categorized as follows: poor (< 0.30), good (0.31–0.60), and excellent 
(0.61–1.0). Results: Of 368 patients with SCLC, a total of 30 patients were enrolled 
in this retrospective analysis. Six (20%) of thirty eligible patients were confirmed with 
bone metastasis, while 24 patients (80%) were found free from bone metastasis. The 
corresponding sensitivity, specificity, accuracy, positive and negative predictive value 
of PET/CT in detecting bone metastasis were 66.7%, 100%, 93.3%, 100% and 96.2% 
as compared to those of BS which were 100.0%, 70.8%, 76.7%, 46.2% and 100%, 
respectively. PET/CT had much higher specificity than BS (p=0.009). No statistically 
significant differences in sensitivity and accuracy were demonstrated between PET/CT 
and BS (p=0.455; p=0.145). Elevated serum ALP alone has the lowest sensitivity in 
detecting bone metastasis (16.7%), with the specificity of 87.5% and the accuracy of 73.3%, 
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P1.07-014 Predictors of Survival in Small Cell Lung Cancer (SCLC) Patients 
(pts) < 50 Years of Age: Results from the California Cancer Registry (CCR) 
Joshua D. Lara1, Ann Brunson2, Jonathan W. Riess3, Karen Kelly3, Primo Lara Jr.1, 
David R. Gandara1 1Uc Davis Comprehensive Cancer Center, Sacramento/CA/United 
States of America, 2Uc Davis Comprehensive Cancer Center, Sacramento/United States of 
America, 3University of California Davis Comprehensive Cancer Center, Sacramento/CA/
United States of America
Background: SCLC is an often lethal disease that commonly occurs in older individuals 
with a history of heavy tobacco use. Limited epidemiologic and outcomes data are 
available for young SCLC pts (< 50 years of age). We analyzed the CCR to explore the 
clinical variables related to cause specific survival (CSS) of young pts. Methods: SCLC 
pts diagnosed between 1998-2012 were included. Primary outcome was CSS. Hazard 
ratios (HR) for CSS were calculated using Cox Proportional Hazards (PH) models for 
all ages & for pts <50 years, adjusted for baseline variables: age, gender, stage, 
race, year of diagnosis, treatment, socioeconomic status (SES), and location (urban 
vs. rural). Results: We identified 22,863 SCLC pts, of which 975 were <50 years of 
age (4.2%). Demographics for pts <50 years: Males-51%; White-71%; Stage IV-60%; 
Chemotherapy-79%; Urban location-92%; high SES-28%. Fewer pts < 50 years were 
diagnosed in later years: from 40% in ‘98-’02 to 24% in ‘08-‘12. Results of multivariate 
Cox PH models are shown. (HR=Hazard Ratio).
Select Variables
All pts Pts<50 years of age
HR P-value HR P-value
Age at diagnosis (vs. ≥50yrs) 0.82 <0.0001 N/A N/A
Female sex (vs.Male) 0.91 <0.0001 0.81 0.0045
Race (vs.White)
Asian 0.84 <0.0001 0.57 0.0075
Year of Dx (vs.’88-’02)
2003-’07 0.96 0.0096 0.95 0.5562
2008-’11 0.94 0.0017 0.89 0.2796
Stage (vs.I)
Stage II 1.22 0.0111 1.20 0.7255
Stage III 1.80 <0.0001 1.81 0.0282
Stage IV 2.93 <0.0001 3.81 <0.0001
Treatment (vs.None)
Surgery 0.43 <0.0001 0.37 0.004
Chemotherapy 0.44 <0.0001 0.49 <0.0001
Radiation 0.66 <0.0001 0.71 <0.0001
Rural (vs.Urban) 0.97 0.3042 0.75 0.0419
Low SES {vs.High SES(4,5)} 1.05 0.0011 1.04 0.6306
 
Conclusion: Age < 50 years was an independent predictor of improved CSS (HR 0.82, 
p<0.0001). In younger pts, female sex (HR 0.81, p=0.0045), Asian race (HR 0.57, 
p=0.0075), and rural residence (HR 0.75, p=0.042) were associated with better CSS, 
among other variables. Analyses for relevant interactions within subgroups will be presented. 
Keywords: small cell lung cancer, epidemiology, young patients
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P1.07-015 The Prognostic Value of the Neutrophil Lymphocyte Ratio in Patients 
with Small Cell Lung Cancer Harjot Kaur1, Konstantinos Arnaoutakis2, Andrew L. 
Dunn3, Eric R. Siegel4, Francisco A. Socola2 1Department of Internal Medicine, University 
of Arkansas for Medical Sciences, Little Rock/AR/United States of America, 2Division of 
Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock/AR/
United States of America,3Department of Pathology, University of Arkansas for Medical 
Sciences, Little Rock/AR/United States of America, 4Department of Biostatistics, University 
of Arkansas for Medical Sciences, Little Rock/AR/United States of America
Background: A high neutrophil to lymphocyte ratio (NLR) is reported to be a poor 
prognostic indicator in several malignancies and is associated with inferior survival. 
There is limited data exploring the prognostic role of NLR in small cell lung cancer 
(SCLC). The aim of the study was to evaluate the prognostic role of the NLR at the 
time of diagnosis in patients with SCLC. Methods: We retrospectively analyzed data 
from July 2010 to June 2013 of patients diagnosed with SCLC at a single tertiary care 
center. NLR ≥4 at the time of diagnosis was correlated with other prognostic variables 
to estimate its effect on the overall survival (OS). Results: There were a total of 80 
eligible patients, including 33 males and 47 females. At the time of diagnosis, NLR ≥4 
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of all MPM cell lines in a dose-dependent manner. IC50 values ranged from 3.3–106.0 
µM. p-Stat3 levels decreased by 50% with 1 µM Stattic treatment in H226 cells. H226 
cells were treated with 0.01 to 10 µM Stattic. Vimentin expression was stable; however, 
E-cadherin expression increased with 0.1, 1, and 10 µM Stattic treatment. In untreated 
H226 cells, p-Stat3 was observed in the cytoplasm and localized in the nucleus. In 
contrast, in Stattic-treated cells, decreased p-Stat3 was observed in the cytoplasm 
only, and it did not localize to the nucleus. Caspase 3/7 cleavage increased with 
Stattic treatment after 12 h and decreased after 48 h. In vivo mouse xenograft model, 
Stattic suppressed tumor growth (vehicle control vs.Stattic, P < 0.05). Conclusion: In 
this study, we have shown that Stattic inhibits proliferation of all MPM cell lines and 
suppresses tumor growth in a mouse model. In addition, we have demonstrated that 
Stattic inhibits Stat3 phosphorylation and blocks nuclear translocation. Furthermore, 
Stattic inhibits EMT. Thus, the STAT3 inhibitor is a promising candidate in MPM therapy. 
Keywords: Mesothelioma, STAT3
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P1.08-003 Minimal Asbestos Exposure in Germline BAP1 Heterozygous Mice Is 
Associated with Deregulated Inflammatory Response and Increased Risk of MM 
Andrea Napolitano1, Laura Pellegrini1, Anwesha Dey2, David Larson1, Mika Tanji1, Amy 
Powers1, Shreya Kanodia1, Sandra Pastorino1, Harvey I. Pass3, Vishva Dixit2, Haining 
Yang1, Michele Carbone1 1Cancer Center, University of Hawaii, Honolulu/HI/United States 
of America, 2Department of Molecular Biology, Genentech, San Francisco/United States 
of America, 3Department of Cardiothoracic Surgery, New York University Langone Medical 
Center, New York/NY/United States of America
Background: Germline BAP1 mutations predispose to several cancers, in particular 
malignant mesothelioma. Mesothelioma is an aggressive malignancy generally 
associated to professional exposure to asbestos. However, to date we found 
that none of the mesothelioma patients carrying germline BAP1 mutations were 
professionally exposed to asbestos. We hypothesized that germline BAP1 mutations 
might influence the asbestos-induced inflammatory response that is linked to asbestos 
carcinogenesis, thereby increasing the risk of developing mesothelioma after even 
minimal exposure. Methods: We experimentally tested in a BAP1+/- murine model 
whether germline BAP1 heterozygosity would result in alterations of the asbestos-
induced inflammatory response, and whether low doses of asbestos might be sufficient 
to cause MM. Results: Germline BAP1 heterozygosity is associated with a significantly 
altered peritoneal inflammatory response upon exposure to asbestos fibers and to an 
increased risk of MM following exposure to even minimal amounts of asbestos that rarely 
cause MM in wild type animals. Conclusion: Our findings support our hypothesis that 
germline BAP1 heterozygosity increases susceptibility to the carcinogenic effects of low 
doses of asbestos. Based on these results, we suggest that prevention programs of 
MM in individuals carrying germline BAP1 mutations should focus on reducing exposure 
to even minimal indoor and/or naturally occurring outdoor sources of carcinogenic 
fibers, levels that are within the acceptable “safe” limits for the population at large. 
Keywords: macrophages, Mesothelioma, BAP1, asbestos
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P1.08-004 Aki1 as a Potential Therapeutics Target in CREB1 Signaling 
in Malignant Mesothelioma Tadaaki Yamada1, Seiji Yano2, Joseph M. Amann1, 
Konstantin Shilo1, David P. Carbone1 1The Ohio State Wexner Medical Center, Columbus/
United States of America, 2Cancer Research Institute, Kanazawa University, Kanazawa/Japan
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor arising 
from the mesothelial cells of serosal membranes. Since current treatment options are 
largely ineffective, novel therapeutic strategies based on molecular mechanisms and 
the disease characteristics are needed to improve its prognosis. Akt kinase-interacting 
protein 1 (Aki1)/Freud-1/CC2D1A known as a scaffold protein of PI3K/PDK1/Akt that 
determines receptor signal selectivity for EGFR has been suggested as a therapeutic 
target in lung cancer. The aim of this study was to elucidate the role of Aki1 and its potential 
for treatment of MPM. Methods: We tested the effects of the treatment with Aki1 or 
CREB1 siRNAs on cell viability by MTT assay, cell cycle by FACS analysis, cell signaling by 
WB, and CREB transcriptional activity in 7 MPM cells and 1 mesothelial cells using in vitro 
experiments. We investigated the efficacy of Aki1 siRNA against growth of 211H cells in an 
orthotropic implantation model using SCID mice. We further examined Aki1 and p-CREB1 
expressions in MPM tumors from 35 patients by TMA specimens and from 33 patients by 
the tissues. Results: Cell based assay showed that silencing of Aki1 inhibited cell viability 
and caused cell arrest of some of MPM cells but not mesothelial cells. Importantly, we 
identified that the efficacy of Aki1 is regulated by CREB1 signaling which is involved 
in cell viability, cell cycle, and transcriptional activity. Aki1 and phosphorylated CREB1 
were frequently expressed in MPM patients (65/68 cases) (30/35 cases), respectively. 
Furthermore, the expression of Aki1 correlated with phosphorylation of CREB1 (Spearman 
rank correlations = 0.521; p = 0.002). Furthermore, direct application of Aki1 siRNA 
into the pleural cavity significantly inhibited growth of 211H cells compared with that of 
control siRNA in an orthotropic implantation model using SCID mice. Conclusion: Our 
data suggest an important role of Aki1/CREB axis in pathogenesis of MPM and provide 
a rationale for targeting Aki1 by intrathoracic therapy in locally advanced tumors. 
Keywords: molecular target, malignant pleural mesothelioma, short interfering RNA, 
Aki1
respectively. Combining the results of ALP and BS will significantly improve the specificity 
as compare to BS alone (100% vs 70.8%, p=0.009), while the sensitivity remains low 
(16.7%) and the accuracy remain unchanged (83.3% vs 76.7%, p=0.519). The κ-values 
were 0.276 between PET/CT and BS, 0.092 between PET/CT and serum ALP, and 0.099 
between BS and serum ALP, indicating poor agreement among the three modalities in 
detecting bony metastasis. Conclusion: PET/CT had statistically higher specificity and 
numerically higher accuracy than BS in detecting bone metastasis in this group of patients 
with SCLC. The addition of serum ALP to BS improved the detection specificity comparing 
BS alone. There was still controversy involving in the use of PET/CT in SCLC. The 
diagnostic value of PET/CT needed to be validated in prospective and larger clinical trials. 
Keywords: small cell lung cancer, bone metastasis, PET/CT, BS
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P1.08-001 Rituximab for Treatment of Lymphoma Induced Marked Regression 
of Malignant Mesothelioma with Dynamic Changes of Serum Cytokine Profiles 
Keisuke Aoe1, Shoichi Kuyama2, Yusuke Mimura3, Yuka Mimura-Kimura3, Tomoyuki 
Murakami4, Tsuneo Matsumoto1, Hiroshi Ueoka1 1National Hospital Organization 
Yamaguchi-Ube Medical Center, Ube/Japan, 25. Department of Respiratory Medicine, NHO 
Iwakuni Medical Center, Iwakuni/Japan, 3Department of Clinical Research, National Hospital 
Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi/Japan, 4Department of 
Pathology, National Hospital Organization Manmon Medical Center, Shimonoseki/Japan
Background: Malignant mesothelioma (MM) is a highly aggressive tumor with poor 
prognosis. As an effective therapy remains to be established, increased attention 
has been given to immunotherapy in MM. Methods: We experienced a patient with 
malignant lymphoma and MM who showed marked regression of MM after the anti-CD20 
monoclonal antibody rituximab therapy. Here we investigated the mechanism underlying 
this response by immunohistochemical staining and serum cytokine assay. Results: A 
78-year-old man with diffuse large B-cell lymphoma and epithelioid MM was treated with 
rituximab for malignant lymphoma. The lymphoma responded well to rituximab, and the 
pleural thickening of MM regressed markedly after this treatment without therapy for 
mesothelioma. Immunohistochemical stainings revealed negative expression of CD20 on 
mesothelioma cells, indicating that rituximab did not directly attack the mesothelioma 
cells. The serum levels of 27 cytokines were measured 12 days before and 16, 45 and 
54 days after this treatment to compare with those in 24 untreated MPM patients. The 
serum levels of cytokines of this patient including IL-12, INF-g, TNF-a, VEGF and IP-10 
were higher than those of other mesothelioma patients before the rituximab treatment. 
Notably, during the treatment the level of IL-12 increased approximately 10-fold, 
relative to its baseline level. In addition, the levels of IL-2, Eotaxin, G-CSF, and TNF-a 
transiently increased several fold as compared with their baseline levels. In contrast, 
the levels of VEGF, PDGF, IP-10, and IL-8 which are associated with mesothelioma 
proliferation, decreased after the treatment. These results suggest that the mechanism 
of mesothelioma regression in this case involves antitumor immunity enhanced 
with high baseline levels of IL-12 and other Th1 cytokines and B-cell depletion by the 
rituximab treatment. Conclusion: The relationship between these cytokine profiles 
and the clinical outcome might provide a potential immunotherapeutic strategy for MM. 
Keywords: Mesothelioma, cytokine, Immunotherapy, rituximab
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P1.08-002 Stat3 Is a Potential Target for Malignant Pleural Mesothelioma 
(MPM) Treatment Seiji Matsumoto, Tohoru Nakamichi, Ayumi Kuroda, Masaki 
Hashimoto, Teruhisa Takuwa, Nobuyuki Kondo, Seiki Hasegawa Thoracic Surgery, Hyogo 
College of Medicine, Nishinomiya/Japan
Background: The prognosis of malignant pleural mesothelioma (MPM) is very poor; thus, 
a new drug treatment is necessary. Serum IL-6 is high in patients with MPM because of 
the activation of IL-6/Stat3 pathway. Thus, we investigated Stat3 as a potential target for 
the treatment of MPM. Methods: Cell viability was examined using the Cell Counting Kit-
8 (CCK-8: WST-8 Dojindo). MPM cell lines (NCI-H28, NCI-H226, NCI-H2052, NCI-H2452, 
and MSTO-211H) were seeded onto 96-well plates. After treatment with Stattic, a 
Stat3 inhibitor, CCK-8 solution was added to each well and absorbance was measured 
using a microplate reader. Phosphorylated Stat3 levels (p-Stat3) were measured in cell 
lysates using the InstantOne ELISA assay (eBioscience). The expression of p-Stat3, 
E-cadherin, and vimentin was determined by western blot analysis. Translocated p-Stat3 
was analyzed by confocal immunofluorescence microscopy. Cells were plated onto 
chamber slides containing medium. After the Stattic treatment, cells were fixed and cell 
membranes permeabilized. p-Stat3 antibody was added to chamber slides and incubated 
overnight at 4°C. Images were captured using a Zeiss LSM780 confocal microscopy 
system. Apotosis induced by Stat3 inhibitor was measured using the Caspase-
GloR 3/7 assay (Promega). Cells were seeded onto 96-well plates. After the Stattic 
treatment, Caspase-GloR 3/7 reagent was added to each well, and the luminescence 
of each sample was measured in a plate-reading luminometer. For our in vivo study, 
H226 cells were subcutaneously injected into the flank region of nude mice. Mice were 
randomly assigned into two groups, with 5 mice in each group: vehicle control and 
Stattic (treated with10 mg/kg po 5 days per week). Results: Stattic inhibited viability 
S503Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
should be applied when radiotherapy is administered in multimodality treatment. 
Keywords: malignant pleural mesothelioma, non-small cell lung cancer, extra-pleural 
pneumonectomy, lung toxicity
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P1.08-007 Programmed Cell Death 1 Ligand 1 (PD-L1) Expression in Thymoma 
Shintaro Yokoyama1, Hiroaki Miyoshi2, Tatsuya Nishi1, Ryouichi Matsumoto1, Toshihiro 
Hashiguchi1, Daigo Murakami1, Masaki Kashihara1, Shinzo Takamori1, Yoshito Akagi1, 
Koichi Ohshima2 1Department of Surgery, Kurume University, School of Medicine, Kurume/
Japan, 2Department of Pathology, Kurume University, School of Medicine, Kurume/Japan
Background: Programmed cell death 1 ligand-1 (PD-L1) has been reported to be 
expressed in various malignancies, and is considered to be a prognostic factor and an 
immunotherapeutic target. The aim of this study was to characterize PD-L1 expression in 
thymoma and statistical associations between this expression and clinical 
features. Methods: We reviewed formalin-fixed paraffin-embedded tissue specimens from 
82 thymoma cases at Kurume University. PD-L1 expression was evaluated by 
immunohistochemistry (IHC). Statistical associations between PD-L1 expression and 
clinicopathological features were evaluated by using chi-square test and Fisher’s exact test. 
Disease-free survival (DFS) analysis, the end event of which is recurrence, was performed 
by the Kaplan-Meier method. Results: A total of 44 thymoma cases (54%) revealed high 
PD-L1 expression by IHC. No significant differences were observed between high and low 
PD-L1 expression with respect to sex (P = 0.938), age (P = 1.000), symptomatic myasthenia 
gravis (P = 0.471), anti-acetylcholine receptor antibody titer (P = 0.513), primary tumor size 
(P = 0.527), or curability (P = 0.620). However, high PD-L1 expression was statistically 
associated with Masaoka’s stage III/IV disease (P = 0.043) and WHO type B2 or B3 thymoma 
(P = 0.044). DFS after complete resection in high PD-L1 expression cases was significantly 
worse than that in low PD-L1 expression cases (P = 0.021).
Conclusion: Characterization of PD-L1 expression in thymoma should 
enable more effective clinical approaches, including prognostic 
stratification of patients and use of anti-PD-L1 antibody immunotherapy. 
Keywords: Thymoma, programmed cell death 1 ligand 1, immune checkpoint, cancer 
immunotherapy
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P1.08-005 Met and PI3K/mTOR as a Potential Combinatorial Therapeutic 
Target in Malignant Pleural Mesothelioma Rajani Kanteti1, Jacob J. Riehm2, Frances 
Lennon2, Wickii T. Vigneswaran2, Rifat Hasina2, Hedy Lee Kindler3, Ravi Salgia2 1University 
of Chicago, Chicago/IL/United States of America, 2University of Chicago, Chicago/United 
States of America, 3University of Chicago, Chicago/AL/United States of America
Background: There are a number of genetic alterations such as BAP1 and NF2 that 
can occur in malignant pleural mesothelioma (MPM). Various studies have shown that 
both MET and its downstream key intracellular signaling partners PI3K and mTOR are 
known to be overexpressed and frequently mutated in MPM. Here we have examined 
the therapeutic efficacy of a new generation small molecule inhibitor of MET receptor 
tyrosine kinase ARQ 197 and phosphatidylinositol 3-kinase and mTOR (PI3K/mTOR) 
inhibitors BEZ-235 and GDC-0980 in MPM. Methods: The mesothelioma cells were 
treated with ARQ 197, NVP-BEZ235, or GDC-0980 alone or in combination for 72 hours 
and cell proliferation was measured by using Alamar Blue assay. Synergistic efficacy 
was determined by isobologram and combination-index methods of Chou and Talalay. 
Signaling was assessed by immunoblotting. The mechanism of inhibition was further 
studied by using apoptosis assays and cell cycle analysis. Cell motility was studied by 
using scratch assays. We also examined efficacy of the combination of ARQ 197 and 
GDC-0980 on in vivo tumor growth by using mouse xenograft models. Results: MPM 
cell lines over-express MET and its active form p-MET, PI3K, and p-AKT and total AKT. 
ARQ 197, NVP-BEZ235, and GDC-0980, when used alone, significantly inhibited the 
cell proliferation of mesothelioma cells in a dose dependent manner. The combination 
of MET and PI3K/mTOR inhibitors was synergistic in suppressing MPM cell growth as 
compared to any single drug alone. Treatment of ARQ 197, NVP-BEZ235, and GDC-
0980 alone or in combination inhibited the phosphorylation of AKT and S6 kinase in 
mesothelioma cells. MET and PI3K/mTOR inhibitors affect cell growth of mesothelioma 
cells by cell cycle inhibition (cyclin D1) and induction of apoptosis (presence of cleaved 
PARP, by IF/ confocal microscopy). MET inhibitor ARQ 197 alone inhibits the cell motility 
of mesothelioma cells in scratch assay. The combination of ARQ 197/ GDC-0980 was 
much more effective than each single agent alone in inhibiting the tumor growth of 
mesothelioma xenografts in nude mice. Compared to the control mice (2946±403 
mm3), the tumors of mice treated with ARQ 197(2262±317 mm3) and GDC-0980 
(1631±229.57mm3) alone had a significant decrease in the tumor volume. The tumor 
volume of mice treated with the combination of ARQ 197 and GDC-0980 further decreased 
it to six fold (475±97.43 mm3) compared to the control mice. Conclusion: Our results 
suggest that the combined use of ARQ 197/NVP-BEZ235 and ARQ 197/GDC-0980 is 
far more effective than single drug use in suppressing MPM cell motility and growth 
in vitro and tumor growth in vivo and therefore merits further translational studies. 
Keywords: BKM-120, GDC-0980, Mesothelioma,, ARQ 197
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P1.08-006 Lung Toxicity after Post-Operative Radiotherapy after EPP for 
Mesothelioma and Pneumonectomy for Non-Small Cell Lung Cancer 
Angela Botticella1, Cedric Draulans1, Gilles Defraene1, Kristiaan Nackaerts2, Christophe 
Deroose3, Johan Coolen4, Philippe Nafteux5, Stéphanie Peeters6, Dirk De Ruysscher6 
1Department of Oncology, Laboratory of Experimental Radiotherapy, Ku Leuven, Leuven/
Belgium, 2Department of Respiratory Diseases, Respiratory Oncology Unit, Ku Leuven-
University of Leuven, University Hospitals Leuven, Leuven/Belgium,3Department Imaging 
and Pathology, Nuclear Medicine and Molecular Imaging, Ku Leuven - University of Leuven, 
University Hospitals Leuven, Leuven/Belgium, 4Department of Radiology, University 
Hospitals Leuven, Leuven/Belgium, 5Thoracic Surgery, University Hospitals Leuven, Leuven/
Belgium, 6Department of Radiation Oncology, Ku Leuven - University of Leuven, University 
Hospitals Leuven, Leuven/Belgium
Background: Our hypothesis is that MPM patients treated with post-operative RT after 
EPP are more prone to develop lung toxicity compared to non-small cell lung cancer 
(NCSLC) patients treated with post-operative RT after pneumonectomy, since their 
higher baseline inflammation status. Methods: We retrospectively reviewed the records 
of 39 consecutive patients with MPM who received post-operative RT after extrapleural 
pneumonectomy (EPP), and of 10 consecutive patients with non-small cell lung cancer 
who received post-operative RT after pneumonectomy between March 2003 and March 
2012 at the University Hospitals of Leuven. For MPM patients, the planning target volume 
was defined as the entire hemi-thorax, chest wall incisions, drain sites, and involved nodal 
stations. Prescription dose was 54 Gy in 2-Gy fractions delivered to the planning target 
volume (PTV). For NSCLC patients, the planning target volume was defined as mediastinal 
nodal stations according to the pathologic nodal involvement. Prescription dose was 54-
66 Gy in 2-Gy fractions delivered to the PTV. Both cohorts received induction systemic 
chemotherapy before surgery. Primary endpoint was lung toxicity. Dyspnea was graded 
using the Common Toxicity Criteria (CTC) v. 4.03 and was recorded before RT, 45 days 
after the completion of RT and every 3 months thereafter until the completion of the 
follow up. Dosimetric dose-volume parameters (lung V5, lung V20, mean lung dose [MLD], 
mean heart dose, heart V45) were retrieved for both cohorts. The correlation between 
the dosimetric parameters and the toxicity (dyspnea score) was investigated. Results: In 
MPM patients, the dyspnea score was 0-1 in 24/39 patients (61.5%), 2 in 11/39 patients 
(28.2%), 3 in 3/39 patients (7.7%) and 4 in 1/39 patients (2.5%). No grade 5 toxicity 
was recorded. In NSCLC patients, only grade 0-1 dyspnea was registered (grade 0: 
4/10 patients; grade 1: 6/10 patients). Mean MLD was 7.56 Gy (range: 1.60-14.80; SD: 
3.65) for the MPM group and 5.96 Gy (range: 3.2-14.5; SD: 3.57) for the NSCLC group. 
Univariate analysis showed a significant correlation between grade > 2 dyspnea and 
MLD, lung V5 and lung V20. Conclusion: Post-operative radiotherapy after EPP is well-
tolerated, with 10% of patients experiencing grade > 3 dyspnea. Strict dose-constraints 
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observed. The automated and manual in situ hybridization methods showed concordant 
results. Conclusion: Non-isotopic bDNA assay can be used to reliably detect HGF 
mRNA in mesothelioma tissue sections. A range of HGF expression levels can be seen 
with a subset of cases showing moderate to strong (18%) expression. Intratumoral 
heterogeneity is present and both paracrine and autocrine sources of HGF can be 
identified. The majority of c-met positive (2+ and 3+) tumors exhibit weak or no HGF 
expression with only 1 of 3 HGF strongly positive tumor showing positive (2+) c-met 
staining. Further studies are needed to determine if HGF expression can be used as 
a predictive marker for c-met/HGF targeted therapy in malignant mesothelioma. 
Keywords: mesothelioma, c-met, HGF, therapy
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P1.08-010 Understanding the Genetic Landscape of Malignant Mesothelioma - 
A Comparison of Human and Murine Mesothelioma Cell Lines Jenette Creaney1, 
Sophie Sneddon1, Nicola Waddell2, John Pearson2, Sean Grimmond3, Bruce W.S. 
Robinson1 1National Centre for Asbestos Related Disease, Perth/WA/Australia, 2Qimr 
Berghofer Medical Research Institute, Brisbane/QLD/Australia, 3University of Glasgow, 
Glasgow/United Kingdom
Background: Malignant mesothelioma (MM) is predominantly caused by exposure to 
asbestos. Next generation sequencing is being used in MM to understand the nature of 
the genetic lesions that underlie the disease and to identify potential new therapeutic 
targets. MM has the unusual distinction of having a mouse homologue that largely 
replicates the human cancer. This provides an opportunity to use murine tumor 
sequence data to understand mesothelioma pathogenesis, examine asbestos mutational 
signatures and test potential treatment strategies predicted by the genetic landscape. 
We have undertaken exome sequencing of asbestos induced murine MM, and compared 
our findings with human MM. Methods: Whole exome sequencing (WES) was performed 
on the Ion Torrent Proton platform on 15 early passage MM cell lines developed from 
ascites induced following asbestos exposure and tumour development in three wild-type 
mouse strains (BALB/c, CBA and C57BL/6 strains). Wild type germline murine normal 
samples were sequenced concurrently. Somatic single nucleotide variants (SNVs) were 
identified using publicly available algorithms with a subset being validated using Sanger 
sequencing. Copy number variation was analysed using GISTIC. Mutation signatures were 
identified using the Somatic Signatures algorithm in R. Results: There were on average 
760 SNV identified in mouse MM cell lines (range 212-2234) equivalent to a median 
of approximately 9 mutations per Mb. There were significantly more SNV detected in 
the BALB/c strain than the CBA and C57Bl/6 strains. As previously observed there 
was a tendency for chromosome deletion rather than amplification in MM. Deletions in 
chromosome 4 in the region of p16 were common. Non-synonymous mutations accounted 
for 60-80% of all exonic mutations. C>T and G>A transitions were more prevalent than 
other mutation types across all tumours. Mutation signature analysis showed a higher rate 
of C>A, C>G and C>T mutations in specific dinucleotide contexts, which was mirrored in 
the human MM tumours. Conclusion: Genetic analysis of murine models of MM enables 
the identification of candidate mutational changes that can help inform about changes 
in human tumors. These models also provide excellent opportunities for pre-clinical 
proof-of-principle therapeutic studies of the use of sequence information in clinical trials. 
Keywords: mouse models, Mesothelioma, sequencing
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P1.08-011 Clinical Outcome and Prognostic Factors for Advanced Malignant 
Mesothelioma (MM) Patients (pts) Treated on Phase I Trials Dionysis Papadatos-
Pastos, Desamparados Roda, Maria Jose De Miguel Luken, Vasiliki Michalarea, Joao 
Lima, Nikolaos Diamantis, Marta Capelan, Awais Jalil, Shankar Bodla, Jaishree Bhosle, 
Rhoda Molife, Mary O’Brien, Udai Banerji, Sanjay Popat, Timothy A. Yap Royal Marsden 
NHS Foundation Trust, London/United Kingdom
Background: Relapse after approved anticancer treatments is inevitable in MM pts. 
Novel agents in phase I trials may benefit such pts and the development of a prognostic 
score can help identify those who are likely to benefit most. We review the outcome of 
pts with relapsed MM who have participated in phase I trials in the drug development unit 
(DDU) of the Royal Marsden Hospital (RMH). Methods: The RMH prognostic score (RPS) 
(albumin < 35 g/L, lactate dehydrogenase [LDH] > upper limit of normal [ULN], and > 
2 sites of metastases) is an objective tool used to select pts for phase I trials. In view of 
the pattern of disease spread in MM, we sought to define a MM-specific RPS (m-RPS), 
by assessing baseline patient factors. Data from consecutive patients who participated 
in 33 phase I trials between 09/2003 and 12/2014 were included in this analysis. The 
endpoints were time to progression (TTP) overall survival (OS) and safety. Kaplan-Meier 
analysis using a log rank test was used to determine survival outcomes. Results: Data 
from 54 pts, M:F (36:18), median age 62 years (range, 25-76) were studied. All pts 
had ECOG PS 0-1. TTP was 2.5 (95% CI 1.7-3) months, OS was 7.6 (95% CI 5.3-8.4) 
months and the clinical benefit rate was 15%; Three (6%) pts had RECIST confirmed 
partial response (to PI3K pathway inhibitors [n=2] and immunotherapy [n=1]); 5 (9%) pts 
had RECIST stable disease ³6 months. Male gender was highlighted as a factor of poor 
prognosis (p=0.004) in a multivariate analysis and therefore, we propose m-RPS for MM 
pts that now incorporates gender instead of the number of metastatic sites (Table). The 
good prognosis group [A] (m-RPS 0-1; n=23) had a median OS of 13.7 (95% CI 7.9-24) 
months and the poor prognosis group [B] (m-RPS 2-3; n=28) had a median OS of 4 (95% 
CI 2.8-7.5) months, p<0.001. 13 pts (24%) had an OS < 12 weeks: 3 (11%) pts from 
Group [A] and 10 (36%) pts from Group [B]. 39 (72%) pts experienced G1-G2 toxicities, 
³G3 toxicities were seen in 8 (15%) pts and 7 (13%) pts discontinued trial due to toxicity.
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P1.08-008 Efficacy of Palliative Chemotherapy in Malignant Pleural 
Mesothelioma from Spanish BEMME Database. The Spanish Lung Cancer 
Group (SLCG) Jordi Remon1, Noemi Reguart2, Ernest Nadal3, Rafael López-Caastro4, 
Paloma Martin Martorell5, Eugenia Olmedo6, José Luis González-Larriba7, Santiago 
Ponce8, Laureano Molins2, Margarita Majem9, Bartomeu Massuti10, Ruth Porta11, 
Maria Angeles Sala12, Lourdes Calera13, Pilar Diz14, Julia Calzas15, Belen Rubio16, Javier 
Garde17, Ana Laura Ortega18, Elisa Galvez19, Rafael Rosell20 1Hospital de Mataró, Mataró/
Spain, 2Medical Oncology, Hospital Clinic, Barcelona/Spain, 3Institut Catala D’Oncologia, 
L’Hospitalet, Barcelona/Spain, 4Hospital Clinico Universitario de Valladolid, Valladolid/
Spain, 5Hospital Clínico Universitario Valencia, Valencia/Spain, 6Hospital Ramon Y Cajal, 
Madrid/Spain, 7Hospital Clínico San Carlos, Madrid/Spain, 8Hospital Universitario 12 de 
Octubre, Madrid/Spain, 9Hopital de La Santa Creu I Sant Pau, Barcelona/Spain, 10Hospital 
General Universitario de Alicante, Alicante/Spain, 11Institut Català D’Oncologia Girona –Ico, 
Girona/Spain, 12Hospital de Basurto, Basurto/Spain, 13Hospital Universitario Miguel Servet, 
Zaragoza, Zaragoza/Spain, 14Hospital de Leon, Leon/Spain,15Hospital Universitario de 
Fuenlabrada, Madrid/Spain, 16Hopital Quirón de Madrid, Madrid/Spain, 17Hospital Universitari 
Arnau de Vilanova de Lleida, Lleida/Spain, 18Complejo Hospitalario de Jaén, Jaen/
Spain, 19Hospital General de Elda-Virgen de La Salud, Elda/Spain, 20Hospital Germans Trias I 
Pujol, Catalan Institute of Oncology, Barcelona/Spain
Background: Palliative chemotherapy with cisplatin and antifolate (pemetrexed or 
raltitrexed) conferred a median overall survival of 12 months with a response rate of 24% 
to 43% in malignant pleural mesothelioma (MPM) patients. BEMME (Base Epidemiológica 
Mesotelioma Maligno en España) is an observational and retrospective study sponsored 
by the Spanish Lung Cancer Group that aimed to characterize the patient’s and tumor’s 
features as well as the treatment modalities outcomes of patients diagnosed with 
mesothelioma in Spain. Methods: Clinical records of patients with malignant pleural 
mesothelioma were retrospectively reviewed to collect epidemiological and survival data 
into an electronic and anonymous database. Thirty-five Spanish hospitals participated 
in the project and 538 MPM patients were included in the BEMME database. Here we 
present a descriptive analysis of MPM patients (stage III and IV) treated with palliative 
chemotherapy. Results: From January 2008 to December 2013, 297 of 538 patients 
(p) (55%) with MPM were treated with palliative chemotherapy. Most patients were males 
(79%), aged between 60-70y (40%), and 60% had a performance status 1 at diagnosis. 
No exposure to asbestos was reported in 54% of patients. Epithelioid was the most 
frequent histological subtype (66%), followed by sarcomatoide (12%), biphasic (9%) and 
not specified (14%). In stage IV, the most frequent metastatic site was lung (35%). Among 
patients who received chemotherapy, 55% were treated with palliative intent and reached 
a disease control rate (CR+PR+SD) of 62%. Platinum plus pemetrexed was the most 
common schedule used as a palliative treatment, without differences in ORR according 
to platinum-based agent used (Cisplatin: 36% vs. Carboplatin: 32%). A total of 61 of the 
297p (21%) received maintenance treatment with an ORR of 10% and stable disease 
in 50% of p. The median overall survival (OS) for all patients was 12.6 months (95% CI 
10.8 – 14.3). There were statistically significant differences in OS according histological 
subtype. The median OS for epithelioid was significantly longer (15 months, 95% CI 13.8-
18) as compared with non-epithelioid (7 months 95% CI 4.3-9, p<0.001). There were no 
statistically significant differences in OS according to gender, asbestos exposure or type 
of platinum chemotherapy (Cisplatin 15.2 months 95% CI: 13.7-18.75; vs.Carboplatin 18 
months 95% 12-25.3, p=0.32). Conclusion: In Spain, OS of MPM patients treated with 
platinum palliative chemotherapy exceeded the median OS reported in phase III trials. 
Keywords: Mesothelioma,, chemotherapy, Spain
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P1.08-009 Hepatocyte Growth Factor (HGF) Expression in Malignant 
Mesothelioma: A Potential Predictive Marker for met/HGF-Targeted Therapy? 
Morgan L. Cowan1, Murat Yaylaoglu2, Jocelyn Bailey2, Susan Sa2, Peter B. Illei1 
1Pathology, Johns Hopkins University School of Medicine, Baltimore/MD/United States of 
America, 2Pathology, Genentech, San Francisco/CA/United States of America
Background: Malignant mesothelioma (MM) is an aggressive neoplasm predominantly 
involving the pleura with less than 2 years median patient survival time and limited 
systemic therapeutic options. The HGF-MET axis is important in cell proliferation and 
homeostasis. Dysregulation of the pathway has been linked to tumorigenesis. Met 
overexpression has been used as a predictor of response to Met-targeted therapy 
with limited success. HGF is the only known ligand for Met, but intratumoral HGF levels 
have not been studied in MM. In a preclinical glioblastoma model autocrine signaling by 
HGF was predictive for Met-Targeted therapy. Our aim was to evaluate HGF expression 
patterns and to assess the feasibility of non-isotopic bDNA in situ hybridization to reliably 
detect HGF expression in MM. Methods: We analyzed HGF expression using non-isotopic 
branched-DNA in situ hybridization on an automated platform in 39 samples of MM. In a 
subset of cases manual in situ hybridization was also performed. Immunohistochemistry 
for c-met using a rabbit monoclonal antibody and semiquantitative scoring system 
proposed for NSCLC was also available for 33 tumors. The cohort included 10 peritoneal 
(3 male and 7 female, age range 15-77; median 64.5) and 29 pleural tumors (24 male 
and 5 female, age range 24-88; median 67.4). There were 28 epithelioid, 10 biphasic and 
1 sarcomatoid tumors. HGF expression was scored as none, weak, moderate or strong 
(normal placenta and surrounding benign tissue served as controls). Results: Moderate 
to strong HGF expression was seen in 7 cases (6 strong, 1 moderate), weak expression 
was noted in 10 tumors while 22 were negative. Met IHC was only available for 3 of 
the 6 strong HGF expressing tumors. Of the 16 met positive tumors only 1 showed 
strong HGF expression while the majority were HGF negative (10) or weak positive (5). 
Intratumoral heterogeneity and both paracrine and autocrine HGF expression were also 
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expression of the various lncRNAs was detectable across our panel of cell lines. In primary 
tumours the expression of these lncRNAs were significantly elevated in malignant MPM 
compared to benign pleura (p<0.05), and significant differences were also observed 
when samples were analysed across different histological subtypes. Conclusion: The 
expression of these lncRNAs are significantly altered in MPM. We have cloned KDM4A-
AS1 and PCAT6 into overexpression constructs and future studies will assess the 
effects of these lncRNAs overexpression on mesothelioma proliferation, cellular 
health and gene expression to determine their potential role in mesothelioma. 
Keywords: lncRNA, Lysine Demethylase, Mesothelioma
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P1.08-014 The Small Molecule Inhibitor, LCRF004, Is Effective in Targeting 
the RON/MST1R Pathway in Malignant Pleural Mesothelioma Anne-Marie Baird1, 
Kenneth J. O’Byrne2, David Easty3, Liam Shiels4, Annette Byrne4, Stéphane Raeppel5, 
Bryan Stanfill6, Alex Soltermann7, Daisuke Nonaka8, Dean A. Fennell9, Luciano Mutti10, 
Harvey I. Pass11, Isabelle Opitz12, Steven G. Gray3 1Cancer and Ageing Research Program, 
Queensland University of Technology, Brisbane/QLD/Australia, 2Cancer and Ageing Research 
Program, Princess Alexandra Hospital and Queensland University of Technology, Brisbane/
QLD/Australia,3Thoracic Oncology Research Group, Trinity College Dublin/St. James’S 
Hospital, Dublin/Ireland, 4Royal College of Surgeons in Ireland, Dublin/Ireland, 5Chemrf 
Laboratories Inc, Montreal/QC/Canada, 6Commonwealth Scientific and Industrial Research 
Organisation, Brisbane/QLD/Australia, 7Institute of Surgical Pathology, University Hospital 
Zurich, Zurich/Switzerland, 8Christie Hospital NHS Foundation Trust, Manchester/United 
Kingdom, 9Mrc Toxicology Unit, University of Leicester & Leicester University Hospitals, 
Leicester/United Kingdom, 10Environment and Life Sciences, University of Salford, 
Manchester/United Kingdom, 11Department of Cardiothoracic Surgery, NYU Langone Medical 
Center, New York/NY/United States of America, 12Division of Thoracic Surgery, University 
Hospital Zurich, Zurich/Switzerland
Background: Malignant pleural mesothelioma (MPM) is an aggressive inflammatory 
cancer. We have previously identified RON as frequently activated in MPM patient 
samples and cell lines. RON is a member of the MET proto-oncogene family and is bound 
by macrophage stimulating protein (MSP). High positivity for total RON by IHC was an 
independent predictor of favourable prognosis. Additionally, elevated expression levels 
of MSP correlated with better survival. The aim of this study was to further examine 
the MSP-RON signalling axis in MPM using a RON inhibitor, LCRF004. Methods: MPM 
cell lines and a normal mesothelial cell line were screened for the expression of RON 
and MSP at the protein (Western) and mRNA (RT-PCR) level. Downstream mediators 
affected by MSP stimulation and LCRF004 were identified using a proteome profiler 
array. The effect of LCRF004 and MSP were examined using proliferation (BrdU ELISA), 
viability (High Content Analysis), migration (xCELLigence), apoptosis and cell cycle 
(HCA) assays. A xenograft study was also completed. Results: Treatment with LCRF004 
resulted in a significant decrease in proliferation, viability and migration in vitro and 
reduced tumour growth in vivo (p<0.05, compared with vehicle control). In addition, 
LCRF004 significantly increased apoptosis. In terms of cell cycle, drug treatment 
decreased cells in 2n, whilst increasing cells in the G0/G1 phase. Experiments are on 
going to further characterise the mechanism of action of LCRF004. Conclusion: The in 
vivo and in vitro data generated in this study, indicates that the MSP-RON signalling 
axis is a potential target in MPM. Targeting the RTK domain of the RON receptor 
with a small molecule inhibitor is an effective interventional strategy in MPM. 
Keywords: LCRF004, MSP, malignant pleural mesothelioma, RON
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P1.08-015 Malignant Pleural Mesothelioma: Observational and Retrospective 
Analysis of Spanish Database (BEMME). The Spanish Lung Cancer Group 
(SLCG) Noemi Reguart1, Jordi Remon2, Felipe Cardenal3, Ernest Nadal3, Yolanda 
Garcia4, M. Rosario Garcia-Campelo5, Óscar Juan Vidal6, J.R. Jarabo7, Manuel Domine8, 
Carlos Martinez-Barenys9, David Cumplido10, Sergio Bolufer11, Delvis Rodríguez12, Mireia 
Martinez-Barenys13, Sergio Peralta14, Isidoro Barneto15, Pilar Lianes2, M.P Lopez16, 
Natividad Martinez17, Ignacio Gil-Bazo18, Nieves Martinez-Lago19, Mariano Provencio20 
1Medical Oncology, Hospital Clinic, Translational Genomics and Targeted Therapeutics in 
Solid Tumors, Institut D’Investigacions Biomèdiques August Pi I Sunyer (Idibaps), Barcelona/
Spain, 2Hospital de Mataró, Mataró/Spain, 3Department of Medical Oncology, Catalan 
Institute of Oncology, L’Hospitalet/Spain, 4Hospital de Sabadell, Sabadell/Spain, 5Complejo 
Hospitalario Universitario A Coruña, A Coruña/Spain, 6Medical Oncology, Hospital Universitari 
I Politècnic La Fe, Valencia/Spain, 7Hospital Clínico San Carlos, Madrid/Spain, 8Oncology, 
Hospital Universitario- Fundacion Jimenez Diaz, Madrid/Spain, 9Hospital Universitari Germans 
Trias I Pujol, Badalona/Spain, 10Hospital de Torrevieja, Alicante/Spain,11Hospital General 
Universitario Alicante, Alicante/Spain, 12Hospital Universitario Insular de Gran Canaria, Gran 
Canaria/Spain, 13Hospital Universitario Araba-Sede Txagorritxu, Vitoria/Spain, 14Hospital 
Universitari Sant Joan de Reus, Reus/Spain, 15Hospital Reina Sofia, Cordoba/Spain, 16Centro 
Oncologico MD Anderson Internacional España, Madrid/Spain, 17Hospital General de Elche, 
Elche/Spain, 18Clinica Universitaria de Navarra, Pamplona/Spain, 19Complexo Hospitalario 
Universitario de Santiago, Santiago de Compostela/Spain, 20Hospital Puerta de Hierro, 
Madrid/Spain
Background: Malignant Pleural Mesothelioma (MPM) is a rare but aggressive 
malignancy of the pleura, with a strong causal link to asbestos exposure. Although 
in Spain asbestos was banned in 2002, it is estimated that occupationally related 
deaths due to MPM will continue to occur until 2040. BEMME (Base Epidemiológica 
Mesotelioma Maligno en España) is an observational and retrospective study sponsored 
by the Spanish Lung Cancer Group that aimed to characterize the patient’s and tumour’s 
Variable Score
LDH
≤Upper limit of normal (ULN) 0
>ULN 1
Albumin
³35g/L 0
<35g/L 1
Gender
Female 0
Male 1
Table. modified RMH prognostic score (m-RPS)
 
Conclusion: Experimental agents in the phase 1 setting appeared to be well tolerated 
with preliminary signals of benefit in selected advanced MM pts. The m-RPS should be 
prospectively validated as a screening tool for MM pts considered for phase I studies 
Keywords: mesothelioma, phase 1, prognostic, RMH score
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P1.08-012 Immunohistochemistry as Prognostic Markers for Malignant Pleural 
Mesothelioma Taiichiro Otsuki1, Nobuko Maehashi2, Yuki Kataoka2, Takayuki Terada1, 
Kozo Kuribayashi1, Masataka Hirabayashi2, Ryuji Ieki1, Takashi Nakano1 1Department of 
Respiratory Medicine, Hyogo College of Medicine, Nishinomiya,Hyogo/Japan, 2Respiratory 
Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki Hyogo/Japan
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive 
malignancy of the mesothelium. Several previous studies reported the prognostic 
ability of immunohistochemistry markers. But there are few reports adjusted for 
confounding appropriately. Methods: A retrospective cohort study was performed 
using epithelial and biphasic MPM patients treated in two tertiary hospitals in Japan 
between 2007 and 2014. Candidate prognostic factors were as follows: age; gender; 
performance status; stage; treatment modality; NLR (neutrophil lymphocyte ratio); 
calretinin expression; D2-40 expression; WT1 (Willms’ tumor 1). The primary outcome 
was overall survival (OS). The log-rank test and the Cox proportional hazards model 
were used for analyses to detect prognostic factors. We defined p<0.05 was statistically 
significant. Results: Total 371 patients comprised 309 epithelioid, 62 biphasic subtype 
of MPM. Median OS was 12.9 months. On univariate analysis all variables except for 
WT1 were associated with OS. On multivariate Cox proportional regression analysis 
PS (1<), Stage (II<), treatment modality, NLR (3<=), D2-40 negative expression were 
associated with shorter OS. Conclusion:Positive expression of D2-40 were associated 
with longer OS of epithelial and biphasic MPM. Further studies are warranted. 
Keywords: Mesothelioma
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P1.08-013 Long Non-Coding RNAs Associated with Lysine Demethylases 
Are Overexpressed and Epigenetically Regulated in Malignant Pleural 
Mesothelioma Anand S. Singh1, Leah Quinn1, Stephen P. Finn2, Sinead Cuffe3, Steven 
G. Gray1 1Thoracic Oncology Research Group, Trinity College Dublin/St. James’S Hospital, 
Dublin/Ireland, 2Department of Pathology, University of Dublin, Trinity College and St. 
James’S Hospital, Dublin/Ireland, 3Hope Department, St.James’S Hospital, Dublin/Ireland
Background: Malignant pleural mesothelioma (MPM) is an aggressive rare cancer 
affecting the pleura and is predominatly associated with prior exposure to asbestos. 
Treatment options are limited, and most patients die within 24 months of diagnosis. The 
current standard of care for MPM patients is a combination of cisplatin and pemetrexed 
(or alternatively cisplatin and raltitrexed), yet most patients die within 24 months 
of diagnosis. Lysine Demethylases (KDMs) containing a JmjC domain regulate gene 
expression by “erasing or removing” methylation on histones in chromatin. Members 
of this family are frequently found to have aberrant expression in cancer and currently 
are actively pursued as candidate pharmaceutical therapeutic targets. We have shown 
that various members of the JmjC family of KDMs have significantly altered expression 
in MPM. Long non-coding RNAs (lncRNAs) belong to a group of RNAs that are usually 
more than 200 nucleotides long and play important roles in different regulatory 
processes, including regulation of gene expression. Several lncRNAs have also been 
shown to play a role as oncogenic molecules in different cancer cells (one example being 
HOTAIR). Altered expression of lncRNAS therefore make them candidate biomarkers 
with diagnostic and therapeutic potential in cancer. Several such lncRNAs have now 
been shown to locate to the same chromosomal region as various KDMs. These are 
KDM4A/KDM4A-AS1, KDM5B/KDM5B-AS1 (also known as PCAT6), KDM5C/ AY927613.1 
and JARID2/JARID2-AS1. We therefore examined the expression of these lncRNAs in 
MPM. Methods: A panel of MPM cell lines were screened for expression of KDM4A-
AS1, KDM5B-AS1, AY927613.1 and JARID2-AS1 by RT-PCR. lncRNA transcript levels were 
subsequently examined by RT-PCR in a cohort of snap-frozen patient samples isolated 
at surgery comprising benign, epithelial, biphasic, and sarcomatoid histologies. The 
effects of KDM and HDAC inhibitors on their expression was also examined. Results: The 
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17 (p<0.0001), miR-21 (p=0.004), miR-126 (p=0.0016) and miR-486 (p=0.003) was 
significantly lower in patients with asbestosis compared with subjects with benign 
pulmonary disease. In MPM plasma samples, VEGF expression was negatively correlated 
to miR-126 (p=0.004). Conclusion: The expression of miR-16, miR-17 and miR-126 was 
able to distinguish patients with MPM compared with patients with benign pulmonary 
diseases. miR-17 and miR-486 were significantly higher in patients with epithelial 
mesothelioma. An immunohistochemistry analysis evaluating the expression of VEGF in 
MPM tissue samples is ongoing. The available data support the role of miRNAs in the 
aetiology of MPM, suggesting their possible use as diagnostic markers of the disease. 
Keywords: miRNA, Asbestosis, malignant pleural mesothelioma
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P1.08-018 Spontaneous Regression of Mesothelioma Gunnar N. Hillerdal, Ocar 
Grundberg Pulmonary Diseases, Karolinska Hospital, Stockholm/Sweden
Background: Malignant pleural mesothelioma is a progressive disease with a poor 
prognosis. However, a few cases of spontanous regression has been reported in the 
literature. We here report another case. Methods: Not applicable Results: A 68-year old 
woman was referred to the clnic because of increasing dyspnoea and changes on her chest 
roentgenogram. She had never smoked and had worked in an office all life and denied 
all exposure to asbestos or other dangerous substances. CT scan revealed an irregular 
pleural thickening all around the right lung, in the interlobar fissure, and some enlarged 
mediastinal lymph nodes on the right side. Bronchsocpy, ultrasound biopsy of the pleura, 
and mediastinosccopy yielded no diagnosis, and therfore the thoracic surgeons made 
a pleural biopsy. This showed an epitheloid tumor , and the immune staining onfirmed 
that it was a malignant mesothelioma. The patient was offered cytostatic treatment but 
refused; she wanted to try with cost changes. She excluded meat in her diet, ate broccoli, 
nuts etc, and at check-up 3 months later the chest X-ray and the CT scan were normal. 
At follow-up, however, 18 months later there was a recurrence, ans she has now been 
started on chemotherapy. Conclusion: We have in the literature managed to find only 
three case reports similar to this one. An immunological reaction has been postulated 
to be the cause. In at least two of the cases, as in this one, there was none or only slight 
exposure to asbestos. In one case, there was no recurrence after 7 years, in another a 
single local recurrence after 6 years which was surgically removed. Odd patients which 
have lived for many years, even decades, without any treatment have also been described. 
In our own experience, the longest survivor survived 20 years with minimal symptoms. It 
is important to realize that good otcomes not always are due to the actions of doctors. 
Keywords: Mesothelioma, survival
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P1.08-019 Pure Bronchoplasty without Lung Parenchyma Resection for 
Central Carcinoid Oleg Pikin1, Andrey Ryabov2, Victor Sokolov3, Vladimir Glushko1, 
Konstantin Kolbanov1, Larisa Telegina3, Ali Amiraliev1, Vitaliy Barmin1 1Thoracic Surgery, 
Hertzen Research Institute of Oncology, Moscow/Russian Federation, 2Thoraco-Abdominal 
Surgery, Hertzen Research Institute of Oncology, Moscow/Russian Federation, 3Endoscopic 
Department, Hertzen Research Institute of Oncology, Moscow/Russian Federation
Background: The aim of the study is to evaluate the efficacy of combined approach 
(endoscopic resection followed by pure bronchoplasty without any pulmonary resection) 
in patients with endobronchial carcinoids. Methods: We applied two-staged technique 
(endoscopic resection first followed by pure bronchoplasty) to 25 patients (males – 10) 
with endobronchial carcinoid. The median age was 32,4 years with a range from 19 to 
64 years. The indications to this technique were pure endobronchial carcinoid without 
lymph node involvement. Tumour was located on the right side in 18 (72%), on the left – in 
7(28%) patients. Endoscopic resection/desobliteraton of central airway was performed 
to all patients as the first stage procedure to resolve the obstructive pneumonia and to 
localize the pedicle of the tumour for proper planning of further bronchoplasty followed 
by endobronchial ultrasound to detect the peribronchial component. Different types 
of pure bronchoplasty were performed as the second stage surgery with systematic 
mediastinal lymph node dissection (table 1). Table 1.Types of bronchial sleeve resections 
in our series
type of resection right side left side
main stem bronchus 7 5
bronchus intermedius 7 -
main stem bronchus+upper lobe bronchus 2 2
bronchus intermedius+middle lobe bronchus 1 -
bronchus intermedius+lower lobe bronchus 1 -
Total 18(5)* 7(2)*
* polybronchial anastomosis was performed
 
 
Results: The resection was complete (R0) in all cases. No lymph node metastases 
were observed, and tumours were pathologically staged as pT1aN0 in 18, pT2N0 – 
in 5, pT3N0 – in 2 patients and that all cases had invasive components limited to the 
bronchial wall. Twenty three tumours were typical and only two - atypical carcinoids. 
Morbidity was 33,3% (only minor complications) with no mortality. The stenosis 
features as well as the treatment modalities of patients diagnosed with mesothelioma 
in Spain. Methods: Clinical records of patients with malignant pleural and peritoneal 
mesothelioma were retrospectively reviewed to collect epidemiological data, diagnostic 
tests, treatment modalities and survival data into an electronic and anonymous 
database. Thirty-five Spanish hospitals participated in the project and 570 mesothelioma 
patients were included in the BEMME database. Here we present a descriptive analysis 
of MPM patients based upon these data. Results: From January 2008 to December 
2013, 538 patients (p) had MPM. Most patients were males (77%) and 74% of patients 
were ≥ 60 years (60-70y: 33%, >70y: 41%). Most patients (49%) had a performance 
status 1 at diagnosis. Only 32% of patients were recorded as positive for asbestos 
exposure and 77% of patients were never-smokers. Dyspnoea (35%) and thoracic pain 
(26%) were reported as the most frequent symptoms at diagnosis. Epithelioid was the 
most frequent histological subtype (63%), followed by sarcomatoid (12%), biphasic 
(8%) and not specified (17%). Disease stages at diagnosis were: stage I, 7%; stage II, 
9%; stage III, 17%; stage IV, 45%; not specified, 22%. Surgery was performed in 41p: 
extrapleural neumonectomy 16p, extended pleurectomy 15p and partial pleurectomy 
10p. Palliative pleurodesis was performed in 22% of patients. A total of 70% of patients 
received chemotherapy (55% palliative, 11 neoadjuvant and 6% adjuvant). The median 
overall survival (OS) for all patients was 13.2 months (95% CI 12.2 – 15.2). There were no 
statistically significant differences in OS according to age, gender and asbestos exposure. 
In the univariate analysis, higher stage (III-IV vs. I-II, p=0.0003) and non-epithelioid 
subtype (non-epithelioid vs. epithelioid, p=0.00001) were significantly associated with 
shorter OS. Conclusion: In Spain, most MPM patients are diagnosed at advanced 
stages and are treated with palliative modalities: mainly chemotherapy and pleurodesis. 
Stage and histologic subtype were prognostic factors for survival. BEMME database is 
a helpful tool to describe the therapeutic strategies employed in MPM patients in Spain. 
Keywords: Epidemiology, Mesothelioma, Spain
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P1.08-016 Ponatinib Shows Promise in Malignant Pleural Mesothelioma Cells 
with Abl Pathway Dysregulation Yi-Wei Yang, Gavitt Woodard, Jillian Chase, Angelica 
Marrufo, David Jablons, Hassan Lemjabbar-Alaoui Surgery, University of California San 
Francisco, San Francisco/CA/United States of America
Background: Malignant pleural mesothelioma (MPM) remains a lethal cancer with 
limited treatment options. Various tyrosine kinases including c-Abl/Arg, FGFR1, Src and 
PDGFRa/b have been implicated in driving the growth of MPM. Ponatinib is an FDA approved 
potent multi-target inhibitor of cAbl/Arg, PDGFRα, VEGFR2, FGFR1, and Src. The aim of 
this study was to investigate the effects of ponatinib on MPM cells. Methods: The in 
vitro effect of ponatinib on different MPM cell lines (H2052, MSTO211H, H2452, H28) 
were evaluated by MTS assay and the effect on cell migration was determined using a 
“scratch wound” assay. Levels of phosphorylated-Crkl (pCrkl) were evaluated by western 
blot and double-strand DNA breaks (DSDBs) measured via the surrogate marker γ-H2AX 
in an ELISA assay. A xenograft MPM model was used to examine the effects of ponatinib 
on tumor grown in vivo. Results: High levels of pCrkl were expressed in all MPM cell 
lines studied indicating c-Abl/Arg pathway activation. In vitro, ponatinib was effective 
against all MPM cell lines by cytotoxicity assay, led to dramatic cell migration inhibition, 
significantly reduced pCrkl expression, and increased DSDBs. In vivo, ponatinib blunted 
tumor growth in a xenograft model. Reduced pCrkl levels were observed in xenograft 
tumor specimens following ponatinib treatment. Conclusion: Inhibition of Abl kinase 
activity with ponatinib is a potential therapeutic approach in MPM patients with Abl 
pathway dysregulation. pCrkl shows promise as a biomarker of increased Abl kinase 
activity and may be useful in identifying MPM patients most likely to benefit from ponatinib. 
Keywords: Abl, Ponatinib, DNA damage, Mesothelioma
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P1.08-017 microRNAs Expression in Malignant Pleural Mesothelioma, 
Asbestosis and Benign Pulmonary Disease Luca Ampollini1, Paola Mozzoni2, 
Letizia Gnetti3, Marcello Tiseo4, Luigi Rolli1, Michela Solinas1, Luigi Ventura1, Enrico 
Maria Silini3, Matteo Goldoni2, Rossella Alinovi2, Michele Rusca1, Massimo Corradi2, 
Paolo Carbognani1, Antonio Mutti2 1Thoracic Surgery, University of Parma, Parma/
Italy, 2Department of Clinical and Experimental Medicine, University of Parma, Parma/
Italy, 3Pathology, University of Parma, Parma/Italy, 4Medical Oncology, University Hospital of 
Parma, Parma/Italy
Background: To evaluate the diagnostic potential of a panel of microRNAs in plasma 
samples of patients with malignant pleural mesothelioma (MPM). Methods: A group 
of patients with pathological diagnosis of MPM were randomly selected from a 
prospective mesothelioma database. Similarly, a group of patients with asbestosis 
and one with benign pulmonary disease, were chosen for comparison. A panel of 
miRNA including miR-16, miR-17, miR-21, miR-126 and miR-486 were evaluated. VEGF 
(vascular endothelial growth factor) was evaluated in plasma samples of patients with 
mesothelioma. Analysis of covariance (ANCOVA) followed by Bonferroni post-hoc test 
were used for multiple comparisons. P<0.05 was considered significant. Results: 14 
patients with malignant pleural mesothelioma, 14 patients with asbestosis and 21 
patients with benign pulmonary disease were studied. The expression of miR-16 
(p=0.018), miR-17 (p=0.024) and miR-126 (p=0.019) was significantly lower in patients 
with MPM compared with patients with benign pulmonary disease. Interestingly, miR-
486 was able to discriminate patients with MPM compared to patients with asbestosis 
(p=0.004). Considering patients with MPM, miR-17 (p=0.023) and miR-486 (p=0.015) 
were significantly more expressed in patients with epithelial type than in patients with 
sarcomatoid and biphasic type. Moreover, the expression of miR-16 (p<0.0001), miR-
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and 120/28, respectively. The main clinical, surgical and pathological features of the 
population are summarized in Table 1. Thirty-six pts (24.3%) had pathologic stage-I 
disease and 70 pts (47.3%) presented with mixed histological tumor (SaLC combined 
with NSCLC). The overall median and 5-year (LTS) survivals were 17 months and 11.3%, 
respectively. During follow-up, 101 patients (68.2%) experienced a relapse of disease (84 
pts (57%) at distance). Log-rank analysis identified the administration of pre-op PET/CT 
scan (LTS: yes=17.9% vs no=5.5%; p=0.040), the surgical radicality (LTS: R0=13.2% 
vs R+=0%, p<0.001), the pStage (LTS: p-I=13.2%, p-II=10.6%, p-III=6.3%, p-IV=0%; 
p<0.001) as prognostic factors in SaLC patients. Finally, Cox regression analysis 
confirmed the administration of pre-op PET/CT scan (p=0.021), the surgical radicality 
(p<0.001) and the p-Stage (p=0.022) as independent prognostic factors in such cohort of 
patients. Conclusion: Primary SaLC presented a poor prognosis after surgical treatment 
(overall 5-yr survival=11.3%), even in early stages (LTS: 13.2% in pStage-I). Such results 
imply that the role of surgery for primary SaLC is questionable and eventually limited 
(after an accurate preoperative staging) to “early-stage” tumors only. In this framework, 
stronger efforts should be made for target therapies development for such rare entity.
 
 
Keywords: Sarcomatoid tumors, long-term survival
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.08-022 Intraoperative Brachytherapy for Thoracic Malignancies Resected 
with Close or Positive Margins Christopher Fleming1, Andreas Rimner1, Gilad N. 
Cohen1, Kenneth Rosenzweig2, Kaled M. Alektiar1, Michael J. Zelefsky1, Manjit S. Bains1, 
Abraham J. Wu1 1Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York/
United States of America, 2Radiation Oncology, Mount Sinai, New York/NY/United States of 
America
Background: Local recurrence is a significant problem after surgical resection of 
of bronchial anastomosis was observed in one patient treated by endoscopic 
intervention. Overall 5- and 10-years survival was 100,0% and 96,0% (one patient 
died from myocardial infarction 8 years after surgery). No recurrence of the primary 
tumour was observed in any case. Conclusion: Two-staged surgery (endoscopic 
resection+pure bronchoplasty without lung parenchyma resection) is an effective 
technique for treatment of endobronchial carcinoids with excellent oncologic outcome. 
Keywords: carcinoid, bronchoplasty, endoscopic resection
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.08-020 Survival Impact of Adjuvant Radiation and Chemotherapy in 
Patients with Typical and Atypical Pulmonary Carcinoids Lindsay M. Hannan1, 
Jeffrey Switchenko2, Yuan Liu2, Madhusmita Behera2, Kristin A. Higgins3, Felix 
Fernandez4, Rathi N. Pillai5, Fadlo Khuri5, Suresh S. Ramalingam5, Theresa W. Gillespie2, 
Taofeek K. Owonikoko5 1Emory University School of Medicine, Atlanta/United States of 
America, 2Biostatistics and Bioinformatics, Emory University Winship Cancer Institute, 
Atlanta/United States of America, 3Radiation Oncology, Emory University Winship Cancer 
Institute, Atlanta/United States of America, 4Thoracic Surgery, Emory University Winship 
Cancer Institute, Atlanta/United States of America, 5Medical Oncology, Emory University 
Winship Cancer Institute, Atlanta/United States of America
Background: Adjuvant chemotherapy or radiation is commonly employed after 
resection of primary pulmonary carcinoid especially for patients with advanced stage 
disease with expectation of survival benefit. The indication for adjuvant therapy is poorly 
defined and there are limited data in support of this clinical practice. We therefore 
evaluated predictors and potential benefit of adjuvant chemotherapy and radiation using 
the National Cancer Database (NCDB), an oncology outcomes database administered 
by the American College of Surgeons and the American Cancer Society Methods: The 
NCDB was queried for patients who had undergone surgical resection of pulmonary 
carcinoid tumors between 2003 and 2006. Patients younger than 18 years and 
those with incomplete survival data were excluded from this analysis. Overall survival 
was defined as time from date of definitive surgery to date of death or last follow-
up. Univariate and multivariable models were employed to assess for association 
between patient survival and variables of interest. Gender, age, and race were fit in a 
multivariable Cox model with treatment, and backward selection criteria (alpha = 0.1) 
were used to determine whether education, urban/rural, tumor size, income, laterality, 
insurance, or comorbidity score were included in the model. The proportional hazards 
assumption was checked for all models. Results: We included 4984 eligible patients 
diagnosed between 2003 and 2006 in the analysis. Post resection adjuvant radiation 
was administered to 4.2% of the patients; 1.9% received chemotherapy while the 
remaining patients did not receive any adjuvant therapy. Patients treated with adjuvant 
chemotherapy or radiation had worse survival at 2 years post surgery (75.7% and 
70.8%% respectively) in comparison to patients managed with surgical resection only 
(94.2%). This survival difference was still significant in multivariable Cox models after 
adjusting for relevant patient and prognostic factors including gender, age, race, stage, 
lymph node involvement, tumor size, education level and co-morbidity score (HR: 2.35, 
95% CI: 1.43 - 3.85, p<0.001 and HR: 1.97, 95% CI:1.48 - 2.61, p<0.001 for adjuvant 
chemotherapy and radiation, respectively). Decreased survival persisted in analyses 
restricted to patients with lymph node involvement (HR 1.58, p 0.084 and 3.21, p<0.001 
for chemotherapy and radiation, respectively), and with advanced stage cancer (HR 
4.10, p <0.001 and 2.04, p=0.036 and for radiation and chemotherapy, respectively) 
. Results did not differ by histology Conclusion: We observed worse outcomes in 
patients with typical and atypical carcinoid treated with adjuvant chemotherapy and 
radiation post surgery. The poor outcome associated with adjuvant therapy may be 
explained in part by the fact that patients considered for adjuvant therapy are more 
likely to have advanced stage disease and adverse tumor characteristics. However, 
contribution from potential toxicities of chemotherapy and radiation cannot be entirely 
excluded pending additional analysis in propensity-matched cohorts of patients. 
Keywords: Adjuvant therapy, Pulmonary carcinoid
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P1.08-021 Role of Surgery in Sarcomatoid Tumors of the Lung: A Multicentre 
Analysis Filippo Lococo1, Cristian Rapicetta2, Giuseppe Cardillo3, Alessandro Stefani4, 
Stefano Margaritora5, Giovanni Leuzzi6, Leonardo Petracca5, Giulio Rossi7, Uliano 
Morandi4, Francesco Facciolo6, Tommaso Ricchetti2, Massimiliano Paci2, Giorgio 
Sgarbi2 1Unit of Thoracic Surgery, Irccs_Arcispedale Santa Maria Nuova, Reggio Emilia/
Italy, 2Unit of Thoracic Surgery, Irccs-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 
Reggio Emilia/Italy, 3Unit of Thoracic Surgery, San Camillo-Forlanini Hospital, Rome, Italy, 
Rome/Italy, 4Unit of Thoracic Surgery, University of Modena and Reggio Emilia, Modena, 
Italy, Modena/Italy, 5Department of General Thoracic Surgery, Catholic University, Rome, 
Italy, Rome/Italy, 65Department of Surgical Oncology, Thoracic Surgery Unit, Regina Elena 
National Cancer Institute - Ifo, Rome, Italy, Rome/Italy, 7Unit of Pathology, University of 
Modena and Reggio Emilia, Modena, Italy, Modena/Italy
Background: Sarcomatoid lung carcinoma (SaLC) is a very rare and aggressive 
subtype of non-small cell lung cancer (NSCLC). To better understand the long-term 
results after surgical treatment and the main prognostic factors of such rare entities, 
we have revisited the clinical records of patients affected by SaLC in a large multicentre 
surgical series. Methods: Among 6569 patients who underwent curative resection for 
NSCLC from 01/2003 to 12/2013 in 5 Institutions, 148 patients (2.2%) had sarcomatoid 
carcinoma. Clinical and pathological data were retrospectively reviewed. Kaplan-
Meier method, log-rank test and Cox-regression analysis were used for the statistical 
analysis when indicated. Results: Mean age and male/female ratio were 66.6±9.9 yrs 
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cell neuroendocrine carcinoma (LCNEC) is established on presence of neuroendocrine 
morphology (i.e. organoid nesting/trabecular pattern, palisading cells and/or rosette 
formation) and neuroendocrine staining by immunohistochemical (IHC) markers. 
Furthermore, large cells should be present. However, diagnosis of LCNEC is restrained 
by the need of a resection or large biopsy specimen. Nonetheless, lung cancer is 
often diagnosed on small biopsies and therefore application of these WHO criteria in 
daily practice can be difficult. In this nationwide study we investigate on what tissue 
the diagnosis of LCNEC was established and to what extend the WHO 2004 criteria 
are reported in pathology reports established in the daily pathology practice in the 
Netherlands. Methods: Written conclusions (diagnoses) of pathology reports (2003-
2012) were retrieved from the Dutch Pathology Registry (PALGA). Conclusions describing 
LCNEC were selected by queries on anatomic location, diagnosis and keywords (e.g. 
large cell + endocrine) and screened in accordance with a pathologist (JLD & RJS). 
Histologically diagnosed LCNEC cases were then selected and pathology centers were 
requested to send the report. After screening (JLD), consultation reports were excluded 
and the following data were extracted and compared: 1) mitotic index, 2) necrosis, 3) 
growth pattern (reported ≥1 feature(s) according to WHO or mentioning neuroendocrine 
morphology) and 4) neuroendocrine IHC marker staining. Additionally, the sampling method 
was recorded and retrieved diagnoses were clustered. Results:N=892 (72%) of 1235 
requested reports were received (43 centers, mean 20 (range 1-67) reports). In N=869 
pathology reports the conclusion was LCNEC including 759 original and 110 consultation 
reports. Most diagnoses were established on resection specimens (N=404, 53%) followed 
by needle (N=195, 26%) and small biopsies (N=160, 20%). Retrieved diagnoses could be 
clustered into LCNEC (N=658, 87%), combined LCNEC (N=41, 5%) and carcinoma favor 
LCNEC (N=60, 8%) respectively. Presence of mitoses was reported in N=541 (71%) yet 
only N=121 (16%) mentioned the mitotic index (≥10 mitoses 2mm2 N=107). Necrosis 
was described in N=466 (61%) reports, most had central/abundant necrosis N=317 
(68%) but in N=84 (11%) necrosis was undefined. Neuroendocrine morphology or a 
feature of neuroendocrine morphology was described in N=452 (60%) reports and in 
all except N=13 reports a neuroendocrine IHC marker was positive. When combining the 
WHO criteria, only N=66 (9%) of reports described all criteria, this increased to N=253 
(33%) when mitosis without description of an index was included and N=403 (53%) if 
the report described either mitosis or necrosis. Lowest reported rates were observed 
in reports of needle biopsy (8-27%) and biopsy (4-15%) specimens. Conclusion: In 91% 
of retrieved pathology reports the WHO criteria for the diagnosis LCNEC could not be 
retrieved. Although 53% of reports included descriptions of neuroendocrine growth 
pattern and mitosis or necrosis, these regularly were incomplete or not quantifiable. 
Most commonly this was observed in reports from (needle) biopsy specimens. Whether 
the WHO criteria could not be established or if it is due to preference of the pathologist 
remains unclear and requires further investigation. Nevertheless, implementation 
of structured pathology reporting protocols for LCNEC should be considered. 
Keywords: LCNEC, diagnosis, classification, large cell neuroendocrine carcinoma
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P1.08-025 Tumor Control of Advanced Pulmonary Neuroendocrine Tumors 
(Carcinoids) with Somatostatin Analogs: Experience at Gustave Roussy 
Ivana Sullivan1, Eric Baudin2, Joël Guigay1, Jean-Yves Scoazec3, Sophie Leboulleux2, 
Amandine Berdelou2, Caroline Caramella4, Michel Ducreux1, Benjamin Besse1, David 
Planchard1 1Medical Oncology, Gustave Roussy, Villejuif/France, 2Nuclear Medicine and 
Endocrine Oncology, Gustave Roussy, Villejuif/France, 3Pathology, Gustave Roussy, Villejuif/
France, 4Radiology, Gustave Roussy, Villejuif/France
Background: Pulmonary carcinoids are rare neuroendocrine tumors (puNETs) of the 
lung with no standard therapeutic option. Antitumor control benefit of somatostatin 
analogs (SSAs) has been demonstrated in gastroeneropancreatic (GEP) -NETs, but only 
a few data have been published in puNETs. Methods: Data from advanced puNETs 
patients treated with SSAs in monotherapy between 1986 and 2014 at Gustave Roussy 
were retrospectively collected. Demographical, clinical and tumor-related features were 
recorded. Patients had a tumor evaluation by CT-scan and/or MRI every 3 months. 
Progression-free survival (PFS) and Overall survival (OS) were estimated using Kaplan-
Meier. Response rate and toxicity were assessed according to RECIST (v1.0 until 2008 
and v1.1 since 2009) and NCI.CTC v4.03 criteria respectively. Results: Sixty-one 
metastatic patients with a median follow-up of 5.8 yrs (0.4-13.0 yrs) were included, with 
a median age of 55 yrs (13-84 yrs), 55.7% were male, 29% current or former smokers, 
and 95% had PS ≤1. At diagnosis, 20 patients were classified as typical carcinoids (TCs) 
and 41 as atypical carcinoids (ACs) according to 2004 WHO classification. Before SSAs 
initiation, 49 patients (80%) showed uptake at somatostatin receptor scintigraphy (SRS) 
(grade ≥2) and 29 (52%) showed hormone-related symptoms. The majority of patients 
(75.4%) presented at least two metastatic sites, liver being the most frequent one 
(80.3%). Forty-six (75%) patients received SSAs as first-line therapy: 32 patients (70%) 
for disease progression and 14 patients (30%) for symptomatic carcinoid syndrome. 
The median duration of SSAs was 13.7 months (3.0-155.1). Overall, median PFS (mPFS) 
and OS (mOS) were 17.4 [95% CI=8.7-26.0] and 58.4 months [44.2-102.7], respectively. 
Best response was stable disease (SD) for 43 patients (70.5%) and progression disease 
(PD) for 14 patients (23%). All PD were ACs. The number of events and deaths was 46 
(75%) and 29 (48%), respectively. mPFS was 24.8 months [10.1-36.3] for the TCs and 
12.8 months [6.2-26.0] for the ACs patients (p=0.32). mPFS was significantly longer in 
functional puNETs with a mPFS of 28.7 months [13.2-55.6] vs. 8.7 months [5.8-21.2] in 
non-functional tumors (p=0.01). The most common adverse event was grade 1 diarrhea 
in 43% of patients. Only one grade 3 (abdominal pain) was reported with a consequent 
withdrawal of treatment. Conclusion: In the real-world setting, SSAs are safe and 
potentially effective for the antitumor control of puNETs. Our results suggest that patients 
with typical carcinoids and functional puNETs seem to benefit most from SSAs therapy. 
Keywords: Pulmonary carcinoids tumors, advanced disease, somatostatin analogs
thoracic tumors, particularly when close or positive margins are anticipated. As 
intraoperative radiotherapy (IORT) can deliver radiation directly to the threatened margin, 
we used this technique in an attempt to reduce local recurrence, particularly for patients 
who had already received external beam radiation. We updated our experience with 
thoracic IORT to assess disease control and toxicity outcomes. Methods: We performed 
a retrospective review of patients undergoing permanent I-125 mesh placement or 
temporary Ir-192 afterloading therapy during surgical resection of primary or metastatic 
thoracic tumors between 2001 and 2013. In general, for I-125 brachytherapy, iodine 
seeds were sutured into a mesh at 1cm intervals to form a planar implant delivering 85-
250Gy to the MPD, which was then sutured onto the at-risk site. For Ir-192 brachytherapy, 
a HAM applicator was apposed to the at-risk site, then connected to the afterloader to 
deliver 7.5-16Gy to a depth of 0.5cm from the applicator surface. Kaplan-Meier method 
was used to estimate local control and overall survival, and logrank test was used to 
assess the impact of various clinical or treatment factors on local control. Results: Fifty-
nine procedures (41 permanent, 18 temporary) were performed on fifty-eight patients 
(median 56 years old, range 19-77). Most common tumor histologies were NSCLC 
(n=23), sarcoma (n=18), thymic carcinoma (n=10), and mesothelioma (n=3). Treated 
sites were chest wall/paraspinal (n=31), lung (n=16), and mediastinum (n=12). Thirty-
four procedures were performed on patients who had previously received external beam 
RT (EBRT) to the area (median 53.1 Gy). Final margins were microscopically negative 
in 25 cases (42.4%) and positive or not assessed in the remainder. The median size 
of the treated area was 27cm2 (range: 4-152cm2). Median followup was 28.5 months. 
Actuarial local control at 1 and 2 years was 68.1% and 63.4% respectively. Median 
survival was 46.2 months. Overall survival at 1 and 2 years was 80.2% and 70.4% 
respectively. No perioperative deaths occurred. There was no significant difference in 
local control according to margin status, brachytherapy technique, use of adjuvant EBRT, 
or metastatic vs. primary tumor. Two patients (3.4%) experienced grade 3+ toxicities 
possibly related to IORT: one patient who also received preoperative EBRT developed 
pneumonitis; a second patient with prior EBRT for lymphoma died from complications 
of SVC syndrome likely induced by radiation fibrosis. An additional 8 patients had 
grade 3+ postsurgical complications (such as empyema, chylothorax, and pulmonary 
emboli) unlikely related to IORT. Four patients had grade 2 nerve injury also unlikely 
related to IORT. Conclusion: Intraoperative brachytherapy is associated with good local 
control after resection of thoracic tumors felt to be at very high risk for recurrence 
due to close or positive margins. There is a very low incidence of severe toxicity 
attributable to brachytherapy. Intraoperative brachytherapy should be considered in 
situations where the oncologic completeness of thoracic tumor resection is in doubt. 
Keywords: Thoracic, brachytherapy, Intraoperative, Radiotherapy
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P1.08-023 Induction Chemotherapy Increases the Survival of Patients with 
Primary Neuroectodermal Tumors of the Thorax Adalet Demir1, Akif Turna2, Elvin 
Hekimoglu2, Alper Toker1, Nil Molinas Mandel3, Zeynep Hande Turna4, Kamil Kaynak4 
1Department of Thoracic Surgery, Istanbul University Istanbul Medical Faculty, Istanbul/
Turkey, 2Department of Thoracic Surgery, Istanbul University Cerrahpasa Medical School, 
Istanbul/Turkey, 3Medical Oncology, Koç University School of Medicine, Istanbul/
Turkey, 4Department of Medical Oncology, Istanbul University Cerrahpasa Medical School, 
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Background: Primary neuroectodermal tumors (PNETs) of the thorax are rare, small-
round cell tumors with a poor prognosis despite multimodal therapy, including surgery 
and chemoradiotherapy. The ideal treatment was unknown since no comparative clinical 
series with surgical therapy had been reported. We evaluated the results of multimodal 
treatment in patients with PNETs located in the thoracic region. Methods: Between 2000 
and 2013, 27 patients with PNETs in the thoracic region were treated in 3 tertiary-care 
hospitals. There were 15 males and 10 females with a mean age of 26.3 years (range, 
6 – 60). The tumor was located in the chest wall in 21 (involving the costovertebral 
junction in 7), the lung in 6 patients. Thirteen patients had induction chemotherapy, 
whereas 22 patients underwent resectional surgery. All the patients received adjuvant 
chemo/radiotherapy. Results: There was no hospital mortality. The overall 5-year 
survival rate was 42% and median survival was 36±14 months in all patients. Five year 
survival in patients who had induction chemotherapy was 56%, whereas it was 36% 
in cases who did not receive induction chemotherapy (p=0.045). The 5-year survival 
rate of patients with and without costovertebral junction involvement was 21% and 
64%respectively(p=0.076). The 5-year survival in the patients who had pulmonary 
involvement without vertebral or chest wall invasion had 50%. Conclusion: Primary 
thoracic PNET is an aggressive entity that often requires multimodal therapy. Induction 
chemotherapy seems to lead a greater complete resection rate and better survival, 
while involvement of the costovertebral junction indicates a slightly worse prognosis. 
Keywords: Pnet, thoracic wall, resection, neoadjuvant
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P1.08-024 Large Cell Neuroendocrine Carcinoma: How Accurate Are 
the WHO 2004 Classification Criteria Applied? Jules L. Derks1, Ernst-Jan M. 
Speel2, Robert Jan Van Suylen3, Anne-Marie Dingemans1 1Department of Respiratory 
Diseases, Grow School for Oncology & Developmental Biology, Maastricht University 
Medical Center, Maastricht/Netherlands, 2Department of Pathology, Grow School for 
Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht/
Netherlands, 3Department of Pathology, Jeroen Bosch Hospital, ‘S Hertogenbosch/
Netherlands
Background: According to the WHO 2004 (and 2015) classification, the diagnosis large 
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T790M mutation, 17 of 32 patients had KRAS positive staining and no BRAF mutation 
was found. Interestingly, we found 3 ALK rearrangement which accounted for 7.5% of 
all tested patients. Conclusion: TNM staging is an independent prognostic factor for 
bronchial MEC patients. Mediastinoscopy should be performed on patients who are 
clinically N2 stage to get precise stage and treatment decision. Early diagnosis and 
early surgery may improve patients’ survival. For advanced MEC patients, ALK fusion 
gene may be routinely tested so as to provide patients with more therapy options. 
Keywords: Prognostic factors, Bronchial mucoepidermoid carcinoma, ALK 
rearrangement
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P1.08-028 PD-L1 Expression in Neuroendocrine Tumors of the Lung 
Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, 
Hiroshi Nokihara, Noboru Yamamoto, Shun-Ichi Watanabe, Koji Tsuta, Yuichiro Ohe 
Thoracic Oncology, National Cancer Center Hospital, Tokyo/Japan
Background: The World Health Organization (WHO) classification recognizes four major 
types of neuroendocrine tumors of the lung: typical carcinoid, atypical carcinoid, small cell 
lung cancer (SCLC), and large-cell neuroendocrine carcinoma (LCNEC). These diagnostic 
categories have different prognostic implications and require distinct treatment 
strategies. The PD-1/PD-L1 pathway is a major target of anti-tumor immunotherapy. PD-
L1 expression has been reported to cause local immune suppression and is considered 
as a predictive marker of immune checkpoint therapeutics. In order to clarify any 
differences in the expression of PD-L1 according to the type of neuroendocrine tumor 
in the lung, we investigated the expression levels of PD-L1 by immunohistochemistry in 
neuroendocrine tumors of the lung. Methods: The subjects of this study were patients 
who were diagnosed as having lung neuroendocrine tumors and were treated at the 
National Cancer Center Hospital from 1982 to 2010. A tissue microarray (TMA) made 
from the surgical specimens was analyzed. After the rabbit monoclonal PD-L1 antibody 
was validated (clone E1L3N, Cell Signaling Technology, Danvers, MA), the TMA was 
stained and the tumor PD-L1 expression score was calculated by a semiquantitative 
method (by multiplying the intensity [0–3] by the staining area [0–100%]). To determine 
the PD-L1 expression, 3 (1%) was used as the cutoff score. Results: A total of 227 
patients were included in this study. The characteristics of the entire patient population 
were as follows; median age, 65 years (range: 19-84 years); gender, male 168 (74.0%) 
/ female 59 (26.0%); smoking status, smokers 191 (84.1%)/non-smokers 36 (15.9%); 
pStage: IA 79 (34.8%)/IB 36 (15.9%)/IIA 25 (11.0%)/IIB 29 (12.8%)/IIIA 47 (20.7%)/
IIIB 6 (2.6%)/IV 5 (2.2%); histology, typical carcinoid 46 (20.3%)/atypical carcinoid 
6 (2.6%)/SCLC 69 (30.4%)/LCNEC 106 (46.7%). Of the 227, samples from 15 (6.6%) 
showed positive staining for PD-L1. The characteristics of the patients showing positive 
staining for PD-L1 were as follows; median age, 71 years (range: 37-84 years); gender, 
males 12 (7.1%)/females 3 (5.1%); smoking status, smokers 13 (6.8%)/non-smokers 
2 (5.6%); pStage, IA 3 (3.8%)/IB 2 (5.6%)/IIA 2 (8.0%)/IIB 5 (17.2%)/IIIA 2 (4.3%)/IIIB 
0 (0%)/IV 1 (20.0%); histology, typical carcinoid 0 (0%)/atypical carcinoid 0 (0%)/
SCLC 4 (5.8%)/LCNEC 11 (10.4%). In 31 of the 69 cases of SCLC who were treated by 
surgery, the disease recurred; of these 31 patients who developed disease recurrence, 
positive expression for PD-L1 was noted in 2 patients (6.5%). Furthermore, the disease 
recurred in 33 of the 106 cases of LCNEC treated by surgery; of the 33, 2 (6.1%) showed 
expression of PD-L1. Conclusion: None of the tumors in the patients with typical 
or atypical carcinoid in our study showed expression of PD-L1. Only the tumors in 4 
of the 69 patients (5.8%) with SCLC and 11 of the 106 patients (10.4%) with LCNEC 
showed positive staining results for PD-L1. The data suggest that drugs directed against 
PD-1/PD-L1 might be potentially useful in the immunotherapy of SCLC and LCNEC. 
Keywords: carcinoid, small cell lung cancer, large-cell neuroendocrine carcinoma, PD-L1
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P1.08-029 Combination Treatment of Intrathoracic Esofageal Cancer 
Olga Lebedieva, Yurii Kondratsky, Roman Fridel Tumors of Thoracic Cavity, National 
Cancer Institute, Ukraine, Kyiv, Kyiv/Ukraine
Background: Introduction. Esophageal cancer (EC) is the sixth most common cause of 
death in cancer patients in the world. EC is classified into squamous cell carcinoma (80%) 
and adenocarcinoma (20%). Squamous EC is more sensitive to chemoradiotherapy (CRT) 
than adenocarcinoma, but long-term results of their treatment are similar. Combination 
therapy is used for EC treatment due to poor overall survival performance in patients 
who received only surgical treatment. Neoadjuvant CRT followed by surgical treatment 
is the most common treatment paradigm in patients with resectable EC. According 
to results of meta-analyses, neoadjuvant CRT in combination with surgical treatment 
significantly improves 3-year survival and reduces the incidence of local recurrence in 
comparison with surgery alone. Objective. To study and compare short-term results 
of treatment in patients with EC using intravenous and intra-arterial neoadjuvant 
CRT. Methods: using intravenous and intra-arterial neoadjuvant CRT. Materials and 
methods: 54 patients with verified squamous EC of intrathoracic esophagus (T2-3N0-
1M0) were enrolled into the study and randomized into two groups. Group I patients (n = 
26) received neoadjuvant CRT with intra-arterial injection, while group II patients (n = 28) - 
intravenous CRT. In accordance with standards, chemotherapy, radiotherapy and surgery 
were performed. Operation was performed 2-3 weeks after CRT. Results: Therapeutic 
pathomorphism was detected in 75% of group I patients and in 81% of group II patients. 
Complete tumour regression occurred in 4% and 11%, partial regression - in 73% and 
68%, stabilization process - in 4% and 7%, and progression of the disease was observed 
in 19% and 14% of patients in groups I and II, respectively. Conclusion: Tumour response 
to neoadjuvant treatment is evident in both groups. Short-term results of treatment 
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P1.08-026 First Case of SMARCB1(INI1)- Deficient Squamous Cell Carcinoma 
of the Pleura Kazushi Yoshida1, Yutaka Fujiwara1, Hideaki Shiraishi1, Keiko Goto1, 
Kenjiro Tsuruoka1, Kota Itahashi1, Yasushi Goto1, Hidehito Horinouchi1, Shintaro Kanda1, 
Hiroshi Nokihara1, Noboru Yamamoto1, Koji Tsuta2, Yuichiro Ohe1 1Thoracic Oncology, 
National Cancer Center Hospital, Tokyo/Japan, 2Pathology, National Cancer Center Hospital, 
Tokyo/Japan
Background: SMARCB1(INI1) is a tumor-suppressor gene located at 22q11.2. It is 
considered an integral component of the chromatin remodeling complex SW1/SNF. 
Loss of SMARCB1 expression has been reported to be associated with atypical teratoid/
rhabdoid tumors and malignant rhabdoid tumors of the kidney and extrarenal tissues. In 
addition, sinonasal basaloid carcinomas and neoplasms arising from the gastrointestinal 
tract, pancreas and uterus with SMARCB1 deficiency have been reported.To date, however, 
SMARCB1-deficient carcinoma of the pleura has not been reported. Methods: We report 
the first case of SMARCB1-deficient squamous cell carcinoma of the pleura in a patient, 
and describe the clinical course from initial presentation to diagnosis with pathological 
findings. Results: The case was a 33-year-old female never smoker with no previous 
medical or family history of malignant disease. She visited a previous hospital with a one-
month history of worsening cough and dyspnea. Chest X-ray and computed tomography 
(CT) showed left pleural tumors with a large amount of pleural effusion. She underwent 
the diagnostic thoracoscopy to obtain sufficient tumor tissue from the parietal pleura. 
Systemic work-up including CT identified no other lesions apart from those in the left 
thoracic cavity. Pathological diagnosis in the previous hospital was squamous cell 
carcinoma of the pleura. She received six cycles of cisplatin plus gemcitabine therapy 
and achieved stable disease an overall best response. After progression, she transferred 
to our institution for expected further treatment. Although she received TS-1 therapy as 
second-line treatment, her disease progressed rapidly with worsening chest pain and 
dyspnea, and she died at 10 months after diagnosis. On pathological review of formalin-
fixed, paraffin-embedded tissues of parietal pleura obtained in the previous hospital, 
primary tumors were composed of morphologically poorly differentiated cancer cells 
with characteristics of squamous cell carcinoma. Tumor cells were completely negative 
for INI1 protein expression by immunohistochemistry. Malignant pleural mesothelioma, 
thymic carcinoma and NUT midline carcinoma were ruled out. Claudin4 and MOC31 
were positive, and C-kit and NUT were negative by immunohistochemistry suggesting 
that the tumor was primary squamous cell carcinoma of the pleura with SMARCB1 
deficiency. Genome analysis using next-generation sequence data revealed no oncogene 
mutations, such as EGFR mutation, ALK, RET or ROS1 rearrangement. Conclusion: To 
our knowledge, this is the first report of SMARCB1-deficient squamous cell carcinoma 
of pleura. The tumor was highly aggressive and carried a poor prognosis with short 
survival. The existence of other SMARCB1- deficient tumors is likely, such as atypical 
teratoid/rhabdoid tumors and malignant rhabdoid tumors of the kidney and extrarenal 
tissues. The clinical features and treatments of this tumor are not clear, and additional 
cases wiii assist the establishment of treatments and improve the poor prognosis. 
Keywords: chemotherapy, SMARCB1(INI1), carcinoma of pleura
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P1.08-027 Clinicopathologic Study and Prognostic Analysis of Bronchial 
Mucoepidermoid Carcinoma Jian Ni1, Zhaoying Sheng2, Chunyan Wu3, Likun 
Hou4, Jianfang Xu1 1Department of Oncology, Shanghai Pulmonary Hospital,Tongji 
University School of Medicine, Shanghai/China, 2Department of Radiotherapy, Shanghai 
Pulmonary Hospital, Shanghai/China, 3Pathology, Shanghai Pulmonary Hospital, Shanghai/
China, 4Department of Pathology Shanghai Pulmonary Hospital, Tongji University Shcool of 
Medicine, Shanghai, China, Shanghai/China
Background: Bronchial mucoepidermoid carcinoma (MEC) is a rare type of lung cancer. 
The present study tried to establish the clinicopathologic characteristics and prognostic 
factors of patients with this cancer who were treated in Shanghai Pulmonary Hospital. 
In addition, the common genetic changes were analyzed here. Methods: Sixty-four 
cases of bronchial MEC treated in Shanghai Pulmonary Hospital between 1995 and 2013 
were collected for our study. Retrospective cohort study was performed to analyze 
the relationship between clinical characteristics and prognosis. The common genetic 
changes of non-small cell lung cancer, such as EGFR, ALK ,ROS1,BRAF, KRAS status were 
tested. Results: All 64 MECs were reconfirmed by pathologists and tumor staging of all 
patients were reevaluated according to AJCC 7th edition system. There were 35male 
patients and 29 females with median age of 40.5 years old. Cough and hemoptysis were 
the most common clinical manifestations. The mean time between symptom appearance 
and going to see doctors was 8.7months. Fibre optic bronchoscopy confirmed the 
presence of bronchial tumor in 48 of 64 patients, but only half of them were diagnostic 
of MEC by endobronchial biopsies. The pathological findings were cellular mixture 
consisting of mucus-secreting cells, squamous cells and mesenchymal cells. There were 
52 and 4 patients who were in an early stage (stage I-II) and stage IIIA at the time of 
diagnosis. All those patients underwent surgical resection with lymph node sampling 
and dissection and 10 patients received adjuvant chemotherapy, 2 patients adjuvant 
radiocherapy. There were 5 and 3 patients in stage IIIB and IV. Among them, 4 were 
treated by chemotherapy. The median survival time for patients with stage I-II ,IIIA and 
IIIB-IV were 71months (10-223months), 35 months (5.3-126months) and 4 months 
(1-51months) respectively. Single factor analysis showed that the early TNM staging 
(p=0.000), no mediastinal lymph node involvement or N1 involvement (p=0.000) and 
surgery (p=0.001) were the positive prognostic factors for MEC patients. There was 
a trend that shorter disease course might benefit for survival (p=0.09). Multi-factor 
analysis showed that TNM staging was an independent prognostic factor for the patients 
suffering from bronchial MEC. Genetic testing showed that 1of 38 patient presented 
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Narjust Duma1, Chad Glisch1, Laysa Sanchez1, Tatyana Feldman2, Andre Goy2, Martin 
Gutierrez2 1Internal Medicine, Rutgers-New Jersey Medical School, Newark/NJ/United States 
of America, 2Medical Oncology, Hackensack University Medical Center, Hackensack/NJ/
United States of America
Background: Primary pulmonary lymphoma (PPL) accounts for only 0.5% of all 
primary lung cancers and 10% of all extranodal lymphomas. Though the majority are 
non-Hodgkin lymphomas (NHL), PPL can easily be misdiagnosed or missed due to their 
nonspecific clinical features and imaging findings. Our goal was to investigate the clinical 
characteristics, treatment and prognosis of PPL. Methods: We reviewed the clinical 
data of 34 patients diagnosed with PPL at our cancer center from 2005 to 2013. Initial 
diagnosis at our institution and minimum 24 month follow up were required. Kaplan-Meier 
method was used for survival analysis. Results: A total of 34 patients were identified. 
Median age at diagnosis was 55 years (range: 35-84), 53% were males and 47% females. 
61% were current or former smokers. 14 patients (41%) had an autoimmune disorder 
(8 patients had Hashimoto’s hypothyroidism, 4 rheumatoid arthritis and 1 DM type 1). 
32% had family history of cancer and 27% of autoimmune disorders. The major clinical 
manifestations were: cough (53%), weight loss (41%), incidental finding on chest x-ray 
(29%) and only 11% presented with B symptoms. Regarding tumor characteristics, 
41% of the patients were stage I, 18% stage II, 6% stage III and 35% stage IV. Marginal 
zone B-cell lymphoma and mucosa-associated lymphoid tissue lymphoma were the 
most prevalent subtypes, representing 97% of the cases. Patients were more likely to 
have upper lobe lesions (50%) vs. middle (29%) or lower lobe (21%) lesions. Regarding 
treatment, 15 patients (44%) were treated with surgery, 79% with chemotherapy (44% 
CHOP vs. 35% Rituximab monotherapy) and 24% with radiation (+/- chemotherapy or 
surgery). Overall median survival was 67.5 months (95%CI: 48.0-87.2) Factors associated 
with poor prognosis were: bilateral lung disease, presence of B symptoms and pleural 
involvement. Conclusion: PPL is a rare type of primary lung malignancy with an equal 
gender distribution. It is usually seen in middle-aged patients with history of autoimmune 
disorders and carries a good overall survival. The high incidence of misdiagnosis in PPL is 
associated with the lack of specific clinical features, making preoperative diagnosis difficult 
with most of the patients requiring lung tissue biopsy and immunohistochemistry studies. 
Keywords: Primary pulmonary lymphoma, Non-Hodgkin lymphomas, lung cancer
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P1.08-033 pRb and p16INK4 in Human Thymic Epithelial Tumors in Relation 
to Human Polyomavirus 7 Marlies Keijzers1, Dorit Rennspiess2, Sreedhar Pujari2, 
Myrurgia Abdul Hamid2, Anne-Marie Dingemans3, Monique Hochstenbag3, Anke Haugg2, 
Marc De Baets4, Anna Kordelia Kurz5, Jos Maessen1, Axel Zur Hausen2 1Cardiothoracic 
Surgery, Maastricht University Medical Center, Maastricht/Netherlands, 2Pathology, 
Maastricht University Medical Center, Maastricht/Netherlands, 3Pulmonology, Maastricht 
University Medical Center, Maastricht/Netherlands,4Neuroscience, Maastricht University, 
Maastricht/Netherlands, 5University Hospital Aachen, Aachen/Germany
Background: We have recently reported the presence of the Human polyomavirus 
7 (HPyV7) in human thymic epithelial tumors as assessed by diverse molecular 
techniques. Here we report on the co-expression of p16, retinoblastoma protein (pRb) 
and phosphoralized retinoblastoma protein (phospho-Rb) in human thymic epithelial 
tumors in relation to HPyV7. Methods: PRB, phospho-RB and p16 expression was 
assessed by immunohistochemistry in 37 thymomas and 2 thymic carcinomas. 17 
thymomas (46%) and 1 thymic carcinoma (50%) were recently tested positive for HPyV7. 
In addition, 20 follicular hyperplasias were tested. Results: Expression of pRb was 
observed in 35 thymomas (94.6%), in 16 thymomas (43.2%) the expression was strong. 
Phospho-Rb was observed in 31 thymomas (83.8%). 19 thymomas (51.4%) showed 
immunoreactivity for p16 of which 8 thymomas revealed very strong p16 expression. 
No p16 expression was detected in thymic carcinomas. In addition, no significant 
correlation between the presence of HPyV7 and pRb-, phospho-Rb- and p16-expression 
could be established. No correlation between pRb, phospho-Rb, p16 and WHO staging, 
Masaoka-Koga staging or the presence of MG was found. All 20 follicular hyperplasias 
showed expression of pRb and less expression of phospho-Rb. Conclusion: Although 
polyomaviruses have been shown to interact with cell cycle proteins no correlation 
between the presence of HPyV7 and the expression of pRb, phospho-Rb and p16 in 
human thymic epithelial tumors was observed. In as much HPyV7 contributes to human 
thymomagenesis remains to be established. Our data indicate pRb, phospho-Rb and 
p16 expression are rather unlikely to be involved in HPyV7 related thymomagenesis. 
Keywords: Thymic epithelial tumors, human polyomavirus 7, viral tumorigenesis
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P1.08-034 The Clinicopathological Significance of PD-L1 Expression in 
Thymoma Yohei Takumi, Atsushi Osoegawa, Takafumi Hashimoto, Miyuki Abe, Shuji 
Suehiro, Michiyo Miyawaki, Kenji Sugio Department of Thoracic and Breast Surgery, Oita 
University Faculty of Medicine, Yufu/Japan
Background: Programmed Death Ligand 1 (PD-L1) is an immune checkpoint molecule 
that binds to the PD-1 receptor, thereby suppressing the activity of tumor infiltrating 
cytotoxic T cells. On the other hand, the immune checkpoint inhibitors (PD-L1, PD-1, 
CTLA-4) are notorious for causing autoimmune disorders. Ipilimab, an anti-CTLA-4 
antibody, and nivolumab, an anti-PD-1 antibody, have been shown to induce myasthenia 
gravis (MG) in clinical trials. Although it has been hypothesized that the binding of 
PD-L1 to PD-1 is essential for T cell maturation, the role of PD-L1 in thymoma and 
autoimmune disorders remains unclear. Methods: We studied 52 consecutive patients 
who underwent resection for thymoma in our institution from 1995 to 2013. The median 
demonstrate no advantages of intra-arterial chemotherapy, which is economically 
unjustified compared to intravenous chemotherapy. The ultimate conclusions regarding 
the advisability of intra-arterial neoadjuvant CRT injection of drugs in patients with 
intrathoracic esophageal cancer may be drawn after studying of the long-term results. 
Keywords: Chemoradiotherapy, esophageal cancer
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P1.08-030 Increasing the Interval between Neoadjuvant Chemoradiotherapy 
and Surgery in Esophageal Cancer. A Meta-Analysis of Published Studies 
Gang Lin, Shuiyun Han, Maohui Yan, Yaping Xu, Xiaojiang Shun, Weimin Mao Zhejiang 
Cancer Hospital, Hangzhou/China
Background: Neoadjuvant chemordiotherapy followed by surgery was the most common 
approach for patients with resectable esophageal cancer. Operation was performed 
within 2 to 8 weeks after nCRT were completed. The aim of this meta-analysis was to 
clarify whether a longer interval between the end of neoadjuvant chemoradiotherapy 
(nCRT) and surgery was associated with a better overall survival in esophageal 
cancer. Methods: We performed a systematic literature search in MEDLINE, EMBASE, 
Cochrane Central Register of Contralled Trials (CENTRAL/CCTR), Clinical Trials from 
January 2000 to December 2014. Eligible studies were prospective or retrospective 
studies of esophageal cancer that assessed the effects of intervals longer or shorter 
than 7 to 8 weeks between the end of nCRT and surgery. The primary endpoint was 
the overall survival (OS) and pathologic complete response (pCR). Secondary endpoints 
were anastomotic leak, R0 resection and postoperative mortality rate. A meta-analysis 
was performed to estimate odds ratios (ORs) , using the fixed- or random-effects model, 
with review manager 5.2. Results: Five studies met the eligibility requirements, including 
1016 patients, with 520 in the shorter interval group (≦7~8 weeks) and 496 in the longer 
interval group (＞7～8 weeks). The results of our meta-analysis showed that the longer 
interval between nCRT and surgery may be at a disadvantage in 2-year overall survival 
(OR =1.40 ,95% CI: 1.09–1.80, P=0.010) and R0 resection rate (OR =1.71, 95%CI:1.14-
2.22, P=0.009 ). The pCR, anastomotic leak rate and postoperative morbidity were 
similar in the two groups. Conclusion: A longer waiting interval (more than the classical 
6–8 weeks) from the end of preoperative CRT is not an increases the rate of pCR in 
esophageal cancer, with similar anastomotic leak rate and postoperative mortality rates. 
However, the longer interval between nCRT and surgery may be at a disadvantage in 
the long-term overall survival, thus it may be reasonable to perform surgery for patients 
at the esrliest opportunity after adequate recovery form nCRT, especially, who have 
clinical pCR. These results should be validated prospectively in a randomized trial. 
Keywords: interval, neoadjuvant therapy, esophageal cancer, Surgery
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P1.08-031 Induction of Protein Citrullination and Auto-Antibodies Production 
in Murine Exposed to Nickel Nanomaterials Bashir M. Mohamed1, Adriele 
Prina-Mello2, Noreen T. Boyle3, Anja Schinwald4, Bruno Murer5, Tatsiana Rakovich1, 
Kieran Crosbie-Staunton1, Omar K Mahfoud1, Steven G. Gray6, Yuri Volkov2 
1Clinical Medicine Department, Trinity College Dublin and St James`S Hospital, Dublin/
Ireland, 2Clinical Medicine Department, Trinity College Dublin and Crann Institute, Dublin/
Ireland, 3Physiology Department, Trinity College Dublin and St James`S Hospital, Dublin/
Ireland, 4Centre for Inflammation Research,, Mrc/University of Edinburgh, Edinburgh/United 
Kingdom, 5Department of Clinical Pathology, Ospedale Dell’Angelo, Venice/Italy, 6Thoracic 
Oncology, St James’S Hospital & Trinity College Dublin, Dublin/Ireland
Background: Citrullination, or the post-translational deimination of polypeptide-bound 
arginine, is involved in several pathological processes in the body, including autoimmunity 
and tumorigenesis. This enzymatic conversion is governed by the family of Ca2+-dependent 
peptidylarginine deiminases (PAD). Citrullinated proteins are recognised as non-self-
proteins, and subsequently can induce an autoimmune response. Recent studies have 
shown that nanomaterials of diverse origin can trigger protein citrullination, which might 
constitute a common pathogenic link to disease development. Methods: Engineered 
nickel nanomaterials, which can mimic environmental filamentous materials were 
hypothesised to trigger similar pathophysiological responses. Mice were injected 
intraperitoneally with either nickel nanomaterials or phosphate buffered saline. Murine 
sera samples for anti-CCP3 detection and tissue samples for immunohistochemical 
analysis were collected at day 1 and day 14. Results: Auto-antibody production was 
detected in serum of nickel nanomaterials-treated mice. Citrullination-associated 
phenomena and PAD levels were found to be elevated in nanomaterials -treated cell 
lines as well as in the spleen, kidneys and lymph nodes of mice, suggesting a systemic 
response to nickel nanomaterials injection, and validated in human pleural and pericardial 
malignant mesothelioma (MM) samples. Conclusion: The observed systemic responses 
in mice exposed to nickel nanomaterials support the evidence linking exposure to 
environmental factors with the development of autoimmunity responses and reinforces 
the need for comprehensive safety screening of nanomaterials. Furthermore, 
these nanomaterials induce pathological processes that mimic those observed in 
Pleural MM, and therefore require further investigations into their carcinogenicity. 
Keywords: Nanomaterials, nickel nanowires, protein citrullination, malignant pleural 
mesothelioma
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Epidem iology and End Results database in the United States, the European Society of 
Thoracic Surgeons, and the Japanese multicenter database. This paper retrospectively 
analyzes survival data from a large-sample multicenter database in China. Methods: The 
Chinese Alliance for Research of Thymoma (ChART), established in June 2012 in China, 
constructed a retrospective database of patients with thymic epithelial tumors. This 
database enrolled 1,930 patients, including 369 with thymic carcinoma. In this study, 
we analyzed clinical, pathologic and treatment imformation, measured long-term survival 
rates, and identified relevant prognostic factors. Results: Among 369 thymic carcinoma 
underwented radical intended surgery, 211 underwent R0 resection; 34, R1 resection; 
and 84, R2 resection. The 3-, 5-, and 10-year survival rates were 78.3%, 67.1%, and 
47.9%, respectively. The survival rates of the patients at different Masaoka-Koga stages 
were significantly different (P ＜ 0.001). The survival rate of the patients who underwent 
complete resection (R0) was significantly higher than that with incomplete resection (R1/
R2)（P < 0.001）. Postoperative chemotherapy did not significantly affect patient survival 
(P = 0.873). Postoperative radiotherapy significantly improved the overall survival not 
only of the patients with R1/R2 resection but also of those with stage III/IV disease 
who underwent R0 resection. Multivariate analyses showed that R0 resection, Masaoka-
Koga stage and postoperative radiotherapy were major prognostic factors of overall and 
disease-free survival.
 
Conclusion: Surgery remains the primary treatment for thymic carcinoma. 
R0 resection was the main factor of prognosis. For patients with stage III/
IV disease who had undergone R0 resection and all the patients who had 
undergone R1+R2 resection, postoperative radiotherapy should be administered. 
Keywords: Thymic carcinoma, Staging, Prognostic factors, Thymic tumors
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P1.08-037 PD-L1 Expression in Surgically Resected Thymic Epithelial Tumor 
Su Jin Lee1, Sang Yun Ha2, Ingu Do2, Joungho Han2, Mikyong Kwak1, Mijung Han1, 
Jong-Mu Sun1, Jin Seok Ahn1, Jhingook Kim3, Young Mog Shim3, Keunchil Park1, Myung-
Ju Ahn1 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul/Korea, 2Department of 
Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/
Korea, 3Thoracic & Cardiovascular Surgery, Samsung Medical Center, Seoul/Korea
Background: Blockade of the immune checkpoint programmed death receptor ligand-1 
(PD-L1)/PD-1 pathway has recently shown clinical activity across many tumor types. 
PD-L1 protein expression by immunohistochemistry (IHC) is emerging as a predictive 
biomarker of response to these therapies. Hence, we studied PD-L1 expression in a 
thymic epithelial tumor (TET). Methods: Of the patients who previously underwent 
resection of TET at Samsung Medical Center between January 2000 and January 2013, 
220 patients who had available tissue block for immunohistochemistry were included. 
Formalin-fixed paraffin embedded tumor samples were stained with murine monoclonal 
antibody (clone h5H1) to human PD-L1. PD-L1 staining was classified based on intensity 
and moderate or strong intensity in 5% or more of tumor tissues was considered as 
positive PD-L1 expression. Results: The median age was 52 years (range, 18-81), and 
57.7% of patients were male. WHO histologic type was mostly B2 (N=96, 43.6%), followed 
by C (N=48, 21.8%), B3 (N=47, 21.4%) and neuroendocrine tumor (N=17, 7.7%). R0 
resection was possible in 193 patients (87.7%). Positive PD-L1 expression was observed 
in 83 samples (37.7%). PD-L1 expression and histologic type was significantly correlated, 
with high PD-L1 expression in histologic type B2/B3/C (7.1% vs. 42.4% in type A/AB/
neuroendocrine tumor vs. type B2/B3/C; P<0.001). PD-L1 expression did not affect 
overall survival both in univariate and multivariate survival analysis. Conclusion: In TET, 
PD-L1 expression was positive in 37.7% and it was more frequently observed in aggressive 
histology (B2/B3/C). PD-1/PD-L1 targeting agents could be a promising therapy for TET. 
Keywords: Immunohistochemistry, Thymic epithelial tumor (TET), PD-1/PD-L1
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P1.08-038 The Effect of the WHO Histologic Classification on Thymic Specific 
age of the 52 patients was 59 years (range: 21-77), 46% were male, and 31%, 52% 
and 15% corresponded to the WHO types of A or AB, B1 or B2, and B3, respectively. 
Thirty-five percent of the patients had MG, and 23% had advanced disease (Masaoka 
stage IV). Formalin-fixed paraffin embedded tissue sections were stained with PD-L1 
rabbit monoclonal antibody (Cell Signaling Technology). The PD-L1 staining scores 
were calculated by multiplying the staining intensity (0: negative to 3: strong) of the 
membrane / cytoplasm in the tumor cell by the proportion of stained tumor cells. The 
staining score, WHO classification, Masaoka stage and the coexistence of MG were 
compared using the Mann-Whitney U -test. Results: The mean PD-L1 score was 45 
(range: 0-300). The PD-L1 scores were higher in patients with more advanced disease 
(Masaoka stage IV; median 60, range 10-300) than in those with localized disease 
(Masaoka stage I-III; median, 20; range 0-160; p=0.047). Furthermore, the score was 
also related with the WHO classification; it was high in WHO type B3 patients (median, 
60; range, 10-300), despite the fact that it remained low among types A, AB, B1 and B2 
(median 20, range 0-160, p=0.033). There was no statistically significant association 
between the presence of MG and a high PD-L1 score. Conclusion: PD-L1 was highly 
expressed in more aggressive and advanced stages of thymoma. No prior studies 
have so far reported the significance of the PD-L1 expression on thymoma. Further 
studies are warranted to utilize immune checkpoint targeting therapies for thymoma. 
Keywords: immune checkpoint, PD-L1, Thymoma
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P1.08-035 Pan-European Survey on Thymic Malignancies: A Collaboration 
of the EORTC Lung Cancer Group (LCG) with the RYTHMIC Network Jessica 
Menis1, Nicolas Girard2, Baktiar Hasan1, Benjamin Besse3 1Medical Department, Eortc 
Headquarters, Brussels/Belgium, 2Respiratory Medicine, Thoracic Oncology, Louis Pradel 
Hospital, Hospices Civils de Lyon, Lyon/France, 3Gustave Roussy Cancer Campus, Villejuif/
France
Background: Thymic malignancies are rare tumors with an incidence of over 0.15 
cases per 100.000 persons/year. Because of the indolent course and sporadic 
occurrence, the management of this disease has been mainly based on single-institution 
retrospective, observational studies. Clinical trials have been run in the recent years 
but no uniformly accepted guidelines are available so far. For advanced disease at 
diagnosis or with relapse/ progression treatment options are limited in first line and 
there is no standard treatment for second line treatment. The EORTC Lung Cancer Group 
(LCG) and French RYTHMIC network developed a survey with the aim of assessing the 
current treatment strategies and respective outcomes, thus providing an overview on 
the management of these tumors in advanced stage. Methods: We conducted a 25-item 
survey disseminated as dedicated mailing in the EORTC LCG and RYTHMIC network. 
Descriptive statistical analysis was applied to assess and present the preliminary 
replies. Results: At the time of the analysis, a total of 45 physicians from 11 countries 
participated in the study, the majority of participants were EORTC members (60.8%) 
and 11.1% were both EORTC and RYTHMIC members. About half of the institutions have 
a dedicate team for thymic malignancies (46.7%) but almost all of them have in place 
multidisciplinary meeting to discuss new diagnosed patients (91.1%).Diagnosis is made 
on surgical sample in 53.4% of the cases flowed by core needle biopsy (33.6%) and 
open biopsy (13%). For both thymoma and thymic carcinoma, the preferred choice 
for induction chemotherapy is CAP (cisplatin, doxorubicin and cyclophosphamide) 
(42.2% and 31.1% respectively) followed by cisplatin and etoposide (13.3% and 13.3% 
respectively). Also for first line chemotherapy, for both thymoma and thymic carcinoma, 
the preferred choice is CAP (35.6% and 28.9% respectively). For first line treatment the 
reported Overall Response Rate (ORR) is about 40% for thymoma and 31% for thymic 
carcinoma, the median Progression Free Survival (PFS) is 8 months for thymoma and 
3 months for thymic carcinoma and the reported median Overall Survival (OS) is 28 
months for thymoma and 18 months for thymic carcinoma. For both thymoma and thymic 
carcinoma, the preferred first choice for second line chemotherapy is carboplatin and 
paclitaxel (35.6% and 31.1% respectively) and the prefered second choice is cisplatin and 
etoposide (13.3 and 17.8% respectively). For second line treatment the reported ORR is 
about 36% for thymoma and 23% for thymic carcinoma, the median reported PFS is 8 
months for thymoma and 4 months for thymic carcinoma; the median OS is 15 months 
for thymoma and 9 months for thymic carcinoma. No testing for c-kit or EGFR mutations 
is routinely performed. Conclusion: The survey provides a large, multi-institutional 
overview of the clinical practice in the management of thymic tumors in Europe, and 
provides relevant and updated background for the development of future collaborative 
trials. The survey is still ongoing and final results will be presented at the conference. 
Keywords: Thymic tumors, treatment, Survey
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P1.08-036 Long-Term Survival after Surgical Treatment for Thymic Carcinoma 
Hao Fu1, Zhi-Tao Gu2, Wen-Tao Fang2, Jian-Hua Fu3, Yi Shen4, Yong-Tao Han5, Yin Li6, 
Zhen-Tao Yu7, Lie-Wen Pang8, Li-Jie Tan9, Ke-Neng Chen1 1Beijing Cancer Hospital, Beijing/
China, 2Shanghai Chest Hospital, Shanghai/China, 3Sun Yat-Sen University Cancer Center, 
Guangzhou/China, 4The Affiliated Hospital of Qingdao University, Qingdao/China, 5Sichuan 
Cancer Hospital, Chengdu/China, 6Henan Cancer Hospital, Zhengzhou/China, 7Tianjin Medical 
University Cancer Institute and Hospital, Tianjin/China, 8Huashan Hospital Affiliated To Fudan 
University, Shanghai/China, 9Zhongshan Hospital, Shangha, Shanghai/China
Background: Thymic carcinoma is a type of highly malignant tumor that originates from 
the thymic epithelium. It is rare and distinct from thymoma. Treatment methods and 
prognosis of thymic carcinoma remain controversial. To date, three studies with relatively 
large sample populations have been conducted based respectively on the Surveillance, 
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program sponsored by a pharmaceutical company in Brazil, tumor samples of patients 
with stage IIIb/IV NSCLC were submitted, at the discretion of the attending physicians, 
for EGFR mutation testing. All analyses were performed at 02 reference laboratories, as 
follows: after microdissection, DNA was isolated from serial sections of formalin-fixed, 
paraffin-embedded tumor tissue to obtain at least 70% tumor cells. Exons 18, 19, 20 
and 21 of the EGFR gene were analysed using Sanger sequencing. EGFR mutation rate 
was calculated and its frequency compared between clinical subgroups using chi-square 
test. Data about smoking status was incomplete and thus not included in this analysis. 
Furthermore, a commercial database with 3,296 patients treated in Brazil in 2014 was 
evaluated for mutation testing patterns. Results: 3,364 tests out of 3,771 samples 
analyzed (1,799 male; 1,942 female) yielded informative results. EGFR mutation was 
present in 25.5% (857/3364) of informative samples. Deletions in exon 19 were the most 
frequent alteration detected (54%), followed by point mutations in exon 21 (28%) and 
exon 20 (9.7%). The most important predictors for the presence of EGFR mutations were 
adenocarcinoma histology (p<0.001), 89% of positive tests occurred in this histology; 
and female gender (p<0.001), for which 30.2% of the patients tested were positive. No 
differences in EGFR mutation frequency were found between age groups or regions within 
the country. In the commercial database of patients with NSCLC treated in the country in 
2014, 1,792 patients had adenocarcinomas, 930 had squamous cancer, 71 had large cell 
cancer and 99 had other histologies. Overall, 34% of patients were tested for mutations 
(47% in the private sector and 20% in public centers); the corresponding number was 
50% for patients with adenocarcinoma (62% of cases in the private and 33% in the public 
settings, respectively) and 10% for patients with squamous cancer. Of note fewer than 
5% of patients overall were tested for ALK alterations. Conclusion: To the best of our 
knowledge, this is the largest study to assess EGFR mutation status in Latin America 
and in Brazil. Our findings suggest that the frequency of EGFR mutation in this cohort 
was lower than that found in Asia, but higher than in Caucasian populations, confirming 
findings seen in other Latin American countries. Despite this high prevalence, a significant 
number of patients, especially in the public sector, are not currently tested for mutations 
in the country, and further advocacy efforts are necessary to improve this situation. 
Keywords: testing pattern, EGFR, non small cell lung cancer
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P1.10-002 Lung Cancer Patients’ Perspectives on Multi-Disciplinary Care in 
a Community Setting Orion Osborne1, Kenneth D. Ward2, Satish Kedia2, Fedoria E. 
Rugless1, Bianca Jackson2, Kristi S. Roark1, Laura Mchugh1, Courtney Foust1, Michael 
Sheean1, Raymond U. Osarogiagbon1 1Thoracic Oncology Research Group, Multidisciplinary 
Thoracic Oncology Program, Baptist Cancer Center, Memphis/TN/United States of 
America, 2School of Public Health, University of Memphis, Memphis/TN/United States of 
America
Background: Lung cancer causes 27% of all cancer deaths in the United States, 
with very modest improvement in patient survival in the past 30 years. In addition to 
cancer biology, adverse patient factors such as cumulative age- and tobacco-related 
co-morbidities, and care-delivery factors such as the need for multiple physician 
involvement, contribute to the paucity of progress. The standard serial model of care, 
involving sequential referrals to specific care providers, if not carefully coordinated, 
may delay care and enable discordance between patient needs and provider priorities. 
The multidisciplinary model, widely touted as potentially superior, has never been 
rigorously evaluated. Leading up to a comparative effectiveness study of the serial 
and multidisciplinary care models, we closely examined patient experiences with lung 
cancer care delivery. Methods: We conducted a qualitative study, in 5 focus groups of 
22 patients (10 males/12 females; 15 White/7 Black) receiving care within the previous 
6 months for confirmed or suspected lung cancer at a community-based hospital, the 
Baptist Memorial Health Care System. Stage distribution was: 6 stage I lung cancer, 
2 stage II, 3 stage III, 3 stage IV, 5 undetermined; 3 patients had a non-lung primary 
malignant lung lesion. A standardized script was used to ensure consistency of questions 
across all focus groups. Saturation of emergent themes determined the number of 
focus groups conducted. We used verbatim transcripts and field notes to analyze the 
content of each focus group, and Dedoose Software to identify recurring themes and 
variants. Results: Patients perceived that the multidisciplinary care approach enabled 
more timely care-delivery, better physical collaboration, improved patient-physician 
communication, and reduced redundant testing. Use of a nurse navigator in this model 
also helped decrease confusion, stress, and anxiety associated with care-coordination. 
There was a perception of the multidisciplinary model as providing a ‘one-stop shop’, 
a central point of contact that reduces the amount of travel and coordination required 
between multiple specialists. Among those patients who had prior encounters with 
serial care, some had experienced insensitive disclosure of diagnosis, poor physician 
communication, redundant testing, delays in diagnosis and treatment, misdiagnosis, and 
mistreatment. Patients involved in serial care were also more likely to seek a second 
opinion after initial diagnosis. The multidisciplinary care model was believed to provide 
multiple opinions in one visit. Conclusion: Lung cancer patients strongly preferred the 
multidisciplinary model of care, perceiving it to be more patient-centered and efficient 
than serial care. These data provide useful information on important patient-centered 
benchmarks that should be incorporated into rigorous comparisons of the effectiveness of 
these two care delivery models. Additional work is needed to examine barriers to program 
development through meaningful input from other key stakeholders, such as healthcare 
providers, institutional administrators, third party payers, and healthcare policymakers. 
Keywords: Multidisciplinary Care, One-stop shop, Lung Cancer Care, Patients’ 
Perspectives
Survival and Overall Survival Karl Uy1, John M. Varlotto1, Malcolm Decamp2, Dani 
Zander3, Suhail Ali4, Yousif Yonan5, Geoffrey Graeber1, Deborah Maddox1, Syed Quadri6, 
Cameron Stock1, Fei Gu1, James Liebmann1, Vijay Kasturi1, William Walsh1, John 
Flickinger7, Jonathan Glanzman1, Aaron Yao8 1University of Massachusetts, Worcester/
MA/United States of America, 2Northwestern University, Chicago/IL/United States of 
America, 3Penn State Hershey Medical Center, Hershey/AL/United States of America, 4Penn 
State Hershey Medical Center, Hershey/PA/United States of America, 5Penn State College of 
Medicine, Hershey/PA/United States of America, 6University of Massachusetts, Worcester/
United States of America, 7University of Pittsburgh, Pittsburgh/AL/United States of 
America, 8Virginia Commonwealth University, Richmond/United States of America
Background: In 1999 the World Health Organization published a histologic classification 
system for thymoma that divided it into 5 categories (A, AB, B1-B3). We investigated the 
effect that this classification has on outcomes and determined if there was a role for 
radiotherapy in patients undergoing resection. Methods: The SEER database was used 
to retrospectively analyze thymomas from 2000-2011. Only those patients having first 
primary thymic neoplasia and undergoing resection were included in the analysis. Overall 
survival (OS) and thymic-specific survival(TSS) were evaluated by Kaplan-Meier Methods. 
Propensity Score was used to determine the role of radiotherapy. Results: 1047 
patients had median follow-up of 53 months. In patients not receiving radiation 
(N=428), multivariate analysis found that worse OS was associated with older age, 
unmarried status, advanced stage, and partial resection. Better TSS was associated 
with white race and early stage. Histologic classification did not have any effect on OS 
or TSS. In patients with stage I and II disease (N=541), the 5-year OS and cumulative 
incidence rates of thymic death were 87.5% and 3.0%. In 483 stage III/IVA patients, 
propensity match of 153 patients treated with or without radiation demonstrated 
that radiation was associated with a significantly better OS (HR=0.400, p= 0.001) 
and TSS (HR=0.473, p=0.034), and that the effect of radiation did not depend upon 
histologic subtype. Selection factors for radiation included younger age and tumor size. 
Radiation was not associated with an increase in cardiopulmonary deaths or deaths 
due to second malignancies. Only 36.6% of patients had any lymph nodes explored, 
and 12.0% were positive. WHO Histology B3 was most likely to have involved lymph 
nodes (20%), while histology A (0%) and B2 (2%) were least likely. 125 (11.9%) patients 
have developed secondary malignancies. Conclusion: Radiation may be beneficial for 
surgically-resected advanced-stage thymoma. Neither OS or TSS was affected nodal 
involvement or histology. The lack of correlation of histology with outcomes may 
demonstrate that the current histologic system is not predictive of outcomes or that 
it does not translate to the broad spectrum of pathologists in SEER registry areas. 
Keywords: Thymoma, Histologic classification, radiation
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P1.08-039 Adjuvant Treatment of Thymic Carcinoma Yen-Han Tseng1, Yuh-Min 
Chen1, Yu-Chin Lee2, Yu-Chung Wu3, Wen-Hu Hsu2, Sang -Hue Yen2 1Chest, Taipei Veterans 
General Hospital, Taipei/Taiwan, 2Taipei Veterans General Hospital, Taipei/Taiwan, 3Thoracic 
Surgery, Taipei Veterans General Hospital, Taipei/Taiwan
Background: Thymic carcinomas are rare tumors. Surgical resection is first 
considered. However, data for adjuvant treatment after surgery is limited Methods: We 
retrospectively reviewed records of our thymic carcinoma patients who were 
treated between 2004 and 2014. Data on age, smoking or not, performance status 
of each patient, TNM staging, surgical margin, type of adjuvant therapy, and type of 
chemotherapy were collected. Results: Thirty-two patients received surgical resection 
and 49 patients did not. Both PFS and OS were significantly longer among patients who 
received surgical resection (26.0 months vs 7.2 months, p<0.001; 37.8 months vs 
14.8 months, p<0.001). Patients with stage III thymic carcinoma had a longer overall 
survival when they received surgical resection. (70.1 months vs 23.9 months, p=0.017). 
Among stage IV patients, those received extended thymothymectomy had a longer PFS 
than did not received surgery (10.6 months vs 7.0 months,p=0.003). Among all 32 
patients (stage I-IV) who received surgery, twenty-one patients were R0 resection, 6 
patients were R1 resection, and 5 patients were R2 resection. Among 21 patients who 
were R0 resection, 10 received adjuvant radiotherapy and had better PFS than those 
received adjuvant chemotherapy (n=2) or concurrent chemo-radiotherapy after surgery 
(n=4) (50.3 months vs 5.9 months vs 7.5 months, p=0.001). Conclusion: Surgical 
resection should always be considered first whenever possible in thymic 
carcinoma patients. Adjuvant radiotherapy had better PFS after R0 resection. 
Keywords: Thymic carcinoma
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P1.10-001 EGFR Mutation Testing Patterns and Results in Brazil and the 
Need for Greater Public Health Awareness of Molecular Testing Gilberto De 
Lima Lopes1, Edna Prado2 1Grupo Oncoclinicas Do Brasil, São Paulo/Brazil, 2Close Up 
International, São Paulo/Brazil
Background: Epidermal growth factor receptor (EGFR) mutation testing allows for 
optimal selection of therapy with tyrosine kinase inhibitors in patients with non-small-cell 
lung cancer (NSCLC). Previous studies have shown a variation in EGRF genotype according 
to ethnic background, with scarce data about EGFR mutation status and testing patterns 
among Brazilian patients with NSCLC. Methods: Between 2011 and 2013, as part of a 
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shortcomings and optimise patient experience. Keywords: Challenges, Patients, Carers, 
lung cancer
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P1.10-005 Immunotherapy, What Lung Cancer and Melanoma Patients ..and 
Physicians, Know Enrica Capelletto1, Silvia Novello1, Paolo A. Ascierto2, Maria 
Michiara3, Federica Hauber2, Raffaella Furia2, Martina Gianetta1, Stefania Vallone4, 
Carmine Pinto3 1Department of Oncology, University of Turin, Aou San Luigi, Orbassano/
Italy, 2Melanoma and Cancer Immunherapy Unit, Istituto Nazionale Tumori Fondazione 
Pascale, Napoli/Italy, 3Medical Oncolgy Unit, University Hospital of Parma, Parma/
Italy, 4Women Against Lung Cancer in Europe (Walce Onlus), Orbassano/Italy
Background: Advances in the understanding of the role of the immune system in tumor 
immune-surveillance have led in the last few years to the development of a series of new 
drugs rapidly affirmed as new paradigm of treatment for certain cancers, like advanced 
melanoma. The recent re-evaluation of the immunogenicity of Non-small Cell Lung Cancer 
(NSCLC) has opened a new field of research, with a new attempt to apply immunotherapy 
also to this disease. Methods: A 9 question-anonymous survey has been carried out by 
AIOM (Associazione Italiana di Oncologia Medica) and supported by WALCE (Women 
Against Lung Cancer in Europe) with the purpose to investigate patients’ knowledge 
about the immunotherapy, their expectations in terms of toxicity and efficacy, but also to 
evaluate how much physicians are becoming confident about the immunotherapy and 
their expected impact on daily clinical practice. The survey has been distributed, between 
10th of November 2014 and 19th of March 2015, to 77 NSCLC patients (prevalently men 
and over 60 years old) and 89 melanoma patients (equally distributed for gender and 
age) within various Italian Oncologic Units. A similar electronic survey has been filled out 
by 128 and 68 physicians dealing with NSCLC and Melanoma, respectively, who reported 
to employ immunotherapy in their clinical practice in 55% and 74% of cases, respectively, 
and to have participated into clinical trials with immunotherapy in 39% and 41% of 
cases. Results: Patients’ knowledge and expectations about immunotherapy resulted to 
be extremely heterogeneous. Only 19% of NSCLC patients, compared to 73% of 
melanoma patients, declared to have performed immunotherapy in their clinical history. 
Main results about patients’ perception about immunotherapy are shown in Table 1. 
NSCLC and melanoma physicians globally reported a positive attitude for this new kind of 
treatment, postulating a general improving of their clinical practice in the next future 
(88% and 99% of cases, respectively). They have speculated a non-limiting toxicity profile 
of this drugs in 77% and 76% of cases, respectively.
 
Conclusion: Although the role of immunotherapy for NSCLC treatment, as already 
happened for melanoma in the past few years, still need a confirmation by the results of 
the ongoing clinical trials, patients and physicians widely express great expectation on 
this kind of treatment, waiting for a large anti-cancer efficacy together with a low toxicity. 
Keywords: Immunotherapy, non-small cell lung cancer, Melanoma
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P1.10-006 Defining a Standard Set of Patient-Centered Outcomes for Patients 
with Lung Cancer Jan P. Van Meerbeeck1, Kimberley S. Mak2, Annelotte C. Van 
Bommel3, Caleb Stowell4, Michael D. Peake5, International C. Ichom6 1Thoracic Oncology, 
Antwerp University Hospital, Edegem/Belgium, 2Radiation Oncology Program, Harvard 
University, Boston/MA/United States of America, 3. International Consortium for Health 
Outcomes Measurement, Boston/MA/United States of America, 4Business School, Harvard 
University, Boston/United States of America, 5Pulmonology, University Hospital Leicester, 
Leicester/United Kingdom, 6Lung Cancer Working Group, International Consortium for Health 
Outcomes Measurement, Boston/AL/United States of America
Background: Value-based healthcare improves outcomes while controlling costs. 
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P1.10-003 Lung Cancer in Ireland 2010 - 2015 - Are We Making Progress?  
Aoife Mcnamara Information Development, Irish Cancer Society, Dublin/Ireland
Background: The burden of lung cancer: According to the National Cancer 
Registry in Ireland (NCRI) lung cancer was the single most common cause of 
cancer death during 2010-2012, with approximately 1,780 deaths annually, 
just over one-fifth of all cancer deaths. The lung cancer mortality rate in Ireland 
decreased significantly, by almost 2% annually, in males but increased by 0.5% 
annually in females during 1994-2012. These trends reflect smoking prevalence 
from decades earlier, but the contrast between males and females is striking (1). Since 
2010, lung cancer detection and awareness has changed considerably in Ireland. Health 
Services: In 2010, the National Cancer Control Programme (NCCP) and Health Service 
Executive (HSE) distributed General Practitioner (GP) Guidelines on the management 
of suspected lung cancers. At the same time, rapid access clinics were established 
in the eight National designated cancer centres. National Awareness: In 2011 the 
Irish Cancer Society (the Society) launched a five year advertising and PR campaign to 
raise awareness of lung cancer in a novel and engaging way. The aim of the campaign 
was to avoid adding to the stigmatisation of lung cancer, but instead encourage people 
concerned about lung cancer and those already affected by it to contact the Society’s 
National Cancer Helpline. Methods: Since 2010, substantial changes have been put in 
place to manage the burden of lung cancer in Ireland. An audit was performed in 2015 to 
measure the impact of these changes and ask if we are making progress. Results: Health 
Services: In 2013; a total of 869 primary cancers were detected by the eight 
NCCP rapid access lung cancer clinics. This represents a 30% detection rate (2). 
National Awareness: Behaviour & Attitudes undertook market research (commissioned 
by the Society) in 2011 and 2013 to evaluate the impact of the advertising and PR 
campaign and found just under three million adults recall some media attention on 
the issue of lung cancer in February (2013). This was up considerably on 2011 levels 
(2.1 million Vs. 2.8 million). Conclusion: The NCRI state that lung cancer incidence is 
rising and by 2040 the rate is projected to increase by 136% in females and 52% in 
males (3). While the burden of lung cancer increases in Ireland, the changes in health 
services has ensured that anyone concerned about lung cancer can go to their GP 
and be referred to a rapid access clinic if necessary. A dedicated pathway to allow for 
suspect cases to be fast tracked and diagnosed on an urgent basis is now in place 
(2). At the same time, awareness is on the increase; by removing the link between 
lung cancer and grim tobacco messaging and instead communicating a message 
of empowerment, more people engaged with the Society’s campaign and it was 
deemed a success. The Society continues to utilise a variety of mediums in future 
campaigns to support people concerned about lung cancer without stigmatising them. 
Keywords: awareness, Ireland, lung cancer, progress
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P1.10-004 Novel Survey to Identify Single Greatest Challenge for Lung 
Cancer Patients and Carers Aoife Mcnamara1, Winfield Boerckel2, Albert Van Eijk3 
1Information Development, Irish Cancer Society, Dublin/Ireland, 2Programs Division, Cancer 
Care, New York/NY/United States of America, 3Boehringer Ingelheim Gmbh, Ingelheim/
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Background: People living with lung cancer (LC), LC survivors and carers are impacted 
by LC in different ways. The Global Lung Cancer Coalition (GLCC) recognises lung cancer 
patients’ and carers’ isolation and the challenges they face (GLCC, 2015). However for 
those affected by LC, limited data exists on the priority of their challenges, their ability to 
cope with these challenges and if enough relevant information and support is available. 
Identifiable variances between patient and carer experience and how challenges differ 
based on gender, age and nationality are also unknown. In 2013, The GLCC and Boehringer 
Ingelheim collaborated to create a global survey to identify these priorities and variances. 
Methods: A unique web-based survey was designed to isolate the single greatest 
challenge faced by individuals affected by LC. 200 specific and globally relevant 
challenges related to medical and psychosocial topics were identified by LC experts 
from the GLCC, grouped into categories and illustrated, with a small text descriptor. 
Each illustration was designed to represent a specific challenge, to be culturally sensitive 
and to overcome potential language barriers. At survey entry, respondents identified 
their greatest challenge as relevant to either daily life or medical care. Via an associated 
illustration, respondents chose subsequent sub-categories of challenges until one 
specific challenge was identified as being the most significant. Respondents answered 3 
questions in relation to that challenge regarding: 1) availability of information 2) 
ability to cope 3) level of support required. Screening was conducted for age, 
gender, treatment and nationality. Respondents were asked whether they were living 
with LC, a LC survivor or a carer. The survey was available in 11 languages and 
promoted through the GLCC, LC clinicians, charities and associated support groups. 
Results: 2871 individuals visited the survey site. 725 (25%) completed the survey. 
17% were from North America, 38% Europe, 31% Asia/Pacific, 7% Central/ South 
America, 7% Middle East / Africa. 52% were carers, 18% were LC survivors and 
30% were living with LC. 64% of LC patients chose a daily life challenge as their 
most significant, compared to a medical care challenge (36%); 55% of carers 
also chose a daily life challenge, compared to a medical care challenge (45%). 
Conclusion: A unique survey to effectively isolate the single greatest challenge 
for individuals affected by LC and to identify current gaps in care, support 
and information. Bespoke illustrations, combined with a simple and 
easy-to-complete method, created a globally relevant tool that could produce 
specific, action-orientated results in order to shape global and local 
approaches to LC patient care and carer support; alleviate potential 
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using a four-point Likert-type scale ranging from 1 (strongly disagree) to 4 (strongly 
agree). Cronbach alpha for the scale was 0.96. Patients gave informed consent after 
the purpose of the study was thoroughly explained. Of the 45 patients approached, 
four refused to participate and two questionnaires were incomplete. Results: Stigma 
in the sample was not associated with age or gender. Contrary to expectations it 
was not It was not associated with current smoking status. Conclusion: Stigma in 
lung cancer patients is significant problem, but in our sample it was not associated 
with age gender or current smoking status. This issue needs further research. 
Keywords: stigma, lung cancer
SESSION: POSTER SESSION/ PALLIATIVE 
AND SUPPORTIVE CARE 
MONDAY, SEPTEMBER 7, 2015
POSTER SESSION/ PALLIATIVE AND SUPPORTIVE CARE 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.11-001 Short Form Chronic Respiratory Questionnaire Validation in a 
Lung Cancer Population Andreas Charalambous1, Alex Molasiotis2 1Nnursing, Cyprus 
University of Technology, Limassol/Cyprus, 2Nursing, The Hong Kong Polytechnic University, 
Hong Kong, Hong Kong/Hong Kong
Background: The Chronic Respiratory Questionnaire short form (SF-CRQ) is frequently 
used in patients with obstructive pulmonary disease and it has demonstrated excellent 
psychometric properties. The CRQ (both in its original or short form) has not been 
previously used in the assessment of lung cancer patients’ HRQL. Therefore this study, 
being part of a larger therapeutic trial, aims to evaluate the psychometric properties 
of the SF-CRQ in patients diagnosed with thoracic malignancies. Methods: Forty-six 
patients were assessed at two time points (with a four-week interval) using the SF-CRQ, 
the modified Borg Scale, five numerical rating scales related to perceived severity of 
breathlessness, and the Hospital Anxiety & Depression Scale. Internal consistency 
reliability was investigated by Cronbach’s α reliability coefficient, test-retest reliability 
by Spearman-Brown reliability coefficient (p) and convergent validity by Pearson’s 
correlation coefficient between the SF-CRQ, and the conceptual similar scales mentioned 
above and content validity was also explored. A principal component factor analysis was 
performed. Results: The internal consistency was high, indicated by an α=0.88 (baseline) 
and 0.91 (after one month). The SF-CRQ had good stability with test-retest reliability 
ranging from r=0.64 to r=0.78, p<0.001. Factor analysis suggests a single construct in 
this population showing that the items of the SF-CRQ scale are strongly correlated and 
represent the conceptual meaning of the underlying construct, which is the quality of life 
of lung cancer patients as related to breathlessness. Conclusion: The data analyses 
supported the convergent, content, and construct validity of the SF-CRQ indicating this is a 
valid and reliable instrument for the assessment of quality of life related to breathlessness 
in lung cancer patients. This study is the first study that provides initial data of the 
psychometric properties of the SF-CRQ in lung cancer patients, and further validation 
with larger sample sizes and across different settings and dyspnea severity is needed. 
Keywords: breathlessness, quality of life, lung cancer patients, Chronic Respiratory 
Questionnaire
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P1.11-002 The Impact of Gastric Acid Suppressive Therapy on Treatment 
Outcomes of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer 
Nesaretnam B. Kumarakulasinghe1, Yu Y. Soon1, Huili Zheng2, En Y. Loy2, Brendan 
Pang3, Ross Soo1 1National University Cancer Institute Singapore, Singapore/
Singapore, 2National Registry of Diseases Office,Health Promotion Board, Singapore, 
Singapore/Singapore, 3Cancer Science Institute, Singapore/Singapore
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
such as gefitinib and erlotinib are dependent on gastric pH for absorption which may 
be affected by concomitant gastric acid suppressive therapy (AS) with proton pump 
inhibitors and histamine 2 antagonists. We sought to determine the effect of gastric 
acid suppressive therapy on overall survival (OS) in patients treated with EGFR 
tyrosine kinase inhibitors. Methods: Patients with advanced stage non-small cell 
lung cancer harboring EGFR mutations treated with EGFR tyrosine kinase inhibitors 
were retrospectively identified. Medical records in our single institution were 
reviewed from 1st January 2008 to 30th December 2013. Patient clinico-pathological 
characteristics,use of gastric acid suppressive therapy and the overall survival were 
obtained. Statistical analysis was performed using chi2, log rank test and cox regression 
where indicated Results: We identified 191 patients. The median age of patients was 
64 years (range: 30-89) ,109 (57.1%) were female, 117(61.3%) were never smokers, 91 
(47.6%) harbored EGFR exon 19 deletion and 144 (75.4%) received EGFR tyrosine kinase 
inhibitors as first line treatment. 55 (28.8%) patients received gastric acid suppressive 
therapy The groups of patients who received gastric acid suppressive therapy and 
those who did not receive gastric acid suppressive therapy were similar with regards 
to gender, smoking status, and type of EGFR mutations, Charlson co-morbidity score 
and Kanorfsky performance status. Brain metastasis at the time of diagnosis was more 
frequent in the group who received gastric acid suppressive therapy compared with the 
group who did not receive gastric acid suppressive therapy (61.8% v 35.3% respectively, 
p= 0.001). The median overall survival in the total patient population was 13.1 months 
(95%CI 11.7-15.2 months). On multivariate analysis, presence of visceral metastasis 
at diagnosis was associated with a worse overall survival (HR: 1.53, 95% CI:1.10-2.13 
p value: 0.012). However a Karnofsky performance score of 90-100 was associated 
Registries and clinical trials frequently capture survival outcomes for lung cancer, but a 
unifying set of outcomes that matter to patients is lacking. Our objective was to define 
a Standard Set of multi-dimensional patient-centered health outcomes for measuring, 
comparing, and improving lung cancer treatment quality. This Set applies to all patients 
with newly diagnosed lung cancer, including non-small cell and small-cell lung cancer, 
treated with either curative or palliative intent. Methods: The International Consortium 
for Health Outcomes Measurement (ICHOM) convened an international, multi-disciplinary 
working group of medical oncologists, surgeons, radiation oncologists, pulmonologists, 
palliative care specialists, registry experts, patient representatives, and specialist 
nurses to review existing data and practices. Using a modified Delphi method, the group 
developed a consensus Set of important outcomes and case-mix variables for risk 
adjustment to enable meaningful benchmarking. Results: The outcome variables included 
in the Standard Set are overall survival, disease-specific mortality, cause of death, and 
treatment-related mortality. We recommend that complications during or within six 
months of treatment be collected. Patient reported outcomes should be tracked regularly 
using the EORTC QLQ-C30 core quality of life questionnaire and lung-cancer specific 
module (EORTC QLQ-LC13). Baseline demographic, clinical, and tumor information is also 
included in the Standard Set to improve interpretability of comparisons. Conclusion: We 
defined a Standard Set of outcomes that we believe should be measured in all patients 
with lung cancer. The Set provides a universal rubric for outcome comparisons, with 
the ultimate goal of improving the value of care. The Lung Cancer Standard Set is made 
possible through the generous support of the Alliance of Dedicated Cancer Centers 
Keywords: outcome indicator, lung cancer, quality performance indicator
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P1.10-007 Impact of Intensive Interprofessional Perioperative Management on 
Clinical Outcome in the Elderly Patients with Lung Cancer Surgery 
Hidejiro Torigoe1, Junichi Soh1, Takako Ashiwa2, Takeshi Kurosaki1, Shinji Ohtani1, Yuho 
Maki1, Kentaro Miyoshi1, Hiromasa Yamamoto1, Seiichiro Sugimoto1, Masaomi Yamane1, 
Shinichi Toyooka1, Takahiro Oto1, Shinichiro Miyoshi1 1Thoracic Surgery, Okayama 
University Hospital, Okayama/Japan, 2Perioperative Management Center, Okayama University 
Hospital, Okayama/Japan
Background: Perioperative assessment and care, such as enhanced recovery after 
surgery(ERAS), are important to improve clinical outcome in the patient who receive 
surgery. Standard therapy for the patients with clinical stage I non-small-cell lung 
carcinoma (NSCLC) is radical surgery. However, the elderly patients often suffer from 
several comorbidities, poor performance status (PS) and/or poor respitary/motor 
function, causing high incidence of postoperative complication and resulting in a limited 
resection or other alternative therapy. In September 2008, our hospital launched a 
perioperative management center (PERIO) to improve perioperative management and 
clinical outcome of patient receiving surgery, which was organized with dedicated 
nurses, anesthesiologists, dentists, physiotherapists, pharmacist and nutritionist. 
All patients, not only elderly patients, who are scheduled to receive thoracic surgery 
present to PERIO center which perform intensive perioperative assessment and care 
with interprofessional collaboration consistently from before hospitalization until 
discharge after surgery. In this study, we investigated the impact of introduction of 
PERIO on clinical outcome in the elderly patients who received thoracic surgery due 
to clinical stage I NSCLC. Methods: Ninety-one elderly patients (over 80 years old) 
who received pulmonary resection were enrolled in this study. We excluded patients 
harboring ground glass opacity-dominant tumor in the diameter less than 2cm because 
of high curative rate even if it is treated with limited resection. We categorized those 
patients into non-PERIO group among January 2000 to August 2008 (n = 42) and PERIO 
group among September 2008 to November 2014 (n = 49). We compared perioperative 
factors between the two groups. Results: The median age, PS (0-1 / 2-4) and median 
FEV1.0 were 81.5 vs 82.0 years old, 38/4 vs 42/7, 1.9L vs 1.8L in non-PERIO and PERIO 
groups, respectively. The patient with comorbidity were significantly more frequent in 
PERIO group (75.5%) than non-PERIO group (52.4%, P =0.025 ). Although the radical 
surgery (lobectomy or segmentectomy with systemic lymph node dissection) were more 
frequently performed in PERIO group (75.5%) than non-PERIO group (52.4%, P =0.022 ), 
there was no significant difference in the incidence of postoperative complication ( 24.4% 
and 28.6% in non-PERIO and PERIO groups, respectively) and post-operative hospital 
days (median 15 days in both group) in both groups. Conclusion: Radical surgery was 
more frequently performed after introduction of PERIO without increase of postoperative 
complication rate and hospital days, suggesting that PERIO may play an important role to 
improve perioperative clinical outcome in elderly patients treated with thoracic surgery. 
Keywords: elderly, lung cancer, perioperative management, interprofessional
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P1.10-008 Stigma in Lung Cancer Patients Suzana Kukulj1, Branka Aukst Margetic2, 
Kristina Galic3, Marko Jakopovic4 1Department for Mediastinal Tumors, University Hospital 
Center Zagreb, Zagreb/Croatia, 2Department for Psychiatry, University Center Zagreb, 
Zagreb/Croatia, 3Department for Pulmonary Diseases, University Hospital Mostar, Mostar/
Bosnia and Herzegovina, 4Department for Pulmonary Diseases, University Center Zagreb, 
Zagreb/Croatia
Background: The burden of stigma in cancer patients is a significant problem, but 
it is especially emphasised problem in lung cancer patients due to their tendency to 
believe that their behaviour was the cause of the cancer. Methods: We included 
consecutively 39 newly hospitalised patients (58%male) with the diagnosis of lung 
cancer (mean age 59.3 SD 6.9 years). Stigma was assessed with 31-item Cataldo Lung 
Cancer Stigma Scale ( mean value 45.4 SD 11.05). Each stigma item was measured 
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thermometer for psychological distress, family version of QOL scale in four domains 
(physical, psychological, social, and spiritual well being), and Caregiver Burden Scale. 
Patients were assessed using distress thermometer and FACT-L for QOL 
domains. Results: QOL data were available for 41 pairs of patients and FCGs (10 usual 
care and 31 intervention). Psychological distress levels were highest for patients (3.8/10) 
and FCGs (5.1/10) before surgery, then decreased six weeks after surgery for both 
groups respectively (2.9/10 and 4.2/10). Patients’ distress continued to decrease at 12 
weeks (2.2/10, p = .001), but FCGs did not (4.4/10, p = .0.157). Although patients had 
improvements in all domains between 6 and 12 weeks, FCGs did not experience similar 
improvements in most domains (Figure 1). Likewise, there was no significant decrease in 
caregiver objective burden over the 12 weeks (21.1 vs. 21.3, p = 0.942). Patients in the 
intervention group had improved total QOL at 12 weeks compared to usual care (Total 
FACT-L 116 vs. 94, p <.001). In contrast, there were no significant differences between 
the usual care and intervention groups in QOL of FCGs. Conclusion: FCGs of lung cancer 
patients experience significant psychological distress. FCGs continue to have decreased 
QOL 3 months after lung cancer surgery. The trajectory of QOL for FCGs does not mirror 
that of patients. FCGs play an important role in patient recovery and greater research is 
needed to understand how they are impacted by thoracic surgery.
 
Keywords: Surgery, family caregivers, quality of life, psychological distress
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P1.11-005 Enhancing Evaluation of Cancer Cachexia in Patients with NSCLC by 
Assessing Change in Skeletal Muscle Mass at the L1 Level on Routine Chest CT 
Jose N. Galeas1, Alejandro Recio Boiles1, Louise M.-W. Man2, Ryan D. Gentzler2, 
Patricia Hollen2, Richard J. Gralla1 1Department of Medicine, Jacobi Medical Center - Albert 
Einstein College of Medicine, Bronx/NY/United States of America, 2University of Virginia, 
Charlottesville/VA/United States of America
Background: Cancer cachexia (CC) and sarcopenia occur in up to 60% of patients with 
lung cancer. With better knowledge of the pathophysiology leading to cancer cachexia, 
multiple recent therapeutic trials have been directed at these mechanisms. Additionally, 
it is clear that cancer cachexia is associated with several negative outcomes. Inherent 
in all studies for this problem, is the ability to measure components of cancer cachexia, 
such as skeletal muscle mass (SMM). SMM assessment by CT scanning (SD <1.2kgs) is 
more accurate than either Dual X ray absorptiometry (DXA, SD 3kgs) or than bioelectrical 
impedance (SD 9.3kgs). A single slice on CT at the third lumbar vertebra (L3) correlates 
highly (r=0.924) with total body SMM in healthy individuals. While CT measurement at L3 
is often used in cancer cachexia trials, the problem exists that routine chest CT scans 
rarely extend to L3; thus routine chest CTs will not allow inclusion of most patients. 
Importantly, prior studies in normal subjects demonstrated high correlation (r = 0.903) of 
SMM measurement at L1 with L3; however, the utility and feasibility of L1 measurement 
of SMM has not been assessed in patients with cancer. Methods: We enlisted patients 
with NSCLC and performed SMM measurements at L1 using Slice-O-Matic software for 
muscle mass in the Hounsfield unit range of -29 to +150. Patients were assessed for 
accuracy of using the L1 level for imaging quality and the ability to use the software 
properly. Results: 56 patients with NSCLC (99 CT assessments) were enlisted at three 
institutions. Characteristics: 45% female; medians: age 60, KPS 80%; BMI 24.96, weight 
72.38 kg, SMM index 58.89. Sarcopenia was detected in 29% of patients (58% of males 
<55.5 cm2/M2; 6% of females <38.5cm2/M2) with all having normal or overweight 
BMI. Overall, of the 99 CT images, 92.9% (95% CI = 88%-98%) included L1. 5 additional 
images (5%) were difficult to evaluate for SMM due to ascites or effusions; also, 1 patient 
was too obese for proper imaging; 2 had poor quality scans. Importantly, inclusion 
of L1 differed among the 3 institutions ranging from 80.6% to 97.2%. Also noted, as 
previously reported with assessment at L3 (r = 0.35), the correlation of BMI with SMM in 
this study at L1 was low (r = 0.36) as well. Conclusion: This study indicates that: 1) SMM 
assessment at L1 is achievable on routine chest CT in patients with lung cancer, with 
93% of patients having images at this level, and 93% have acceptable quality for SMM 
evaluation; 2) although L1 is included in the majority of patients at all 3 institutions, this 
may vary by different radiologic protocols; 3) the low correlation and poor sensitivity of 
BMI to identify muscle mass loss is equally demonstrated at both L3 and L1, and 4) use 
of L1 enhances patient evaluation for SMM without needing additional testing or radiation 
exposure, and allows many more patients with NSCLC to have assessment of SMM in 
clinical trials and patient management. Funding in part: NIH/NCI 1 R01 CA157409-01A1 
Keywords: skeletal muscle mass, NSCLC, sarcopenia, cancer cachexia
with an improved overall survival (HR: 0.69, 95% CI; 0.49-0.97 p value: 0.031). The 
median overall survival OS in patients with gastric acid suppressive therapy was 11.9 
months (95%CI: 9.90-16.94 months) and 14.5 months (95%CI: 11.74-15.95 months) 
in the group not receiving gastric acid suppressive therapy. (HR: 0.98, 95% CI: 0.69-
1.40 p value: 0.934) Conclusion: Although the group of patients who were treated with 
gastric acid suppressive therapy had a numerically poorer overall survival compared to 
the group who did not receive gastric acid suppressive therapy, this difference was not 
statistically significant. Based on the our analysis, the use of gastric acid suppressive 
therapy concurrent with EGFR tyrosine kinase inhibitors in patients with advanced 
non-small cell lung cancer harboring EGFR mutations did not affect overall survival. 
Keywords: EGFR TKI, NSCLC, GASTRIC ACID SUPRESSION
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P1.11-003 New Clinical and Biologic Insight Into Lung Cancer-Associated 
Cachexia From a Large Cohort Study Bhavani S. Gannavarapu1, Kristen Carter1, 
Chul Ahn1, Nathan Cannon2, Jeffrey Meyer2, Puneeth Iyengar2 1UT Southwestern Medical 
Center, Dallas/TX/United States of America, 2Radiation Oncology, UT Southwestern, Dallas/
TX/United States of America
Background: Cancer cachexia (CC) is a wasting syndrome without durable palliative 
intervention observed in 50% of all solid tumors and responsible for 20-30% of all cancer-
related deaths. Knowledge of prevalence and survival outcomes for lung CC patients by 
clinical and pathologic parameters is scarce due to limited series. We provide the largest, 
most detailed evaluation of lung cancer patients for cachexia, enabling new clinical and 
biologic insight. Methods: A retrospective review of 1627 patients with non-small cell 
lung cancer (NSCLC) or small cell lung cancer (SCLC) treated at UT Southwestern Medical 
Center between 1/1/2006 and 12/31/2013 was performed. Patient demographics and 
tumor characteristics including histology, stage, grade, and size were collected. Each 
patient was assessed for CC at diagnosis, retrospectively identified by the presence 
of significant weight loss (>5% loss over 6 months in patients with BMI >= 20; >2% in 
patients with BMI <20). Overall Survival (OS) was evaluated, and clinicopathologic factors 
predicting for cachexia development were identified with stepwise logistic regression 
(SLR). Results: Overall, CC independently predicted reduced OS on stepwise Cox 
regression (1.21 OR). 419/1468 (28.5%) of all NSCLC and 57/159 (35.8%) of all SCLC 
patients had CC. Within NSCLC, CC was documented in 107/350 (30.6%) of squamous 
carcinomas and 208/761 (27.3%) of adenocarcinomas. CC significantly reduced NSCLC 
OS across all stages: 21.0 vs. 9.9 months (log-rank P<0.0001). However, CC did not 
significantly affect SCLC OS: 10.5 vs. 9.9 months (log-rank P=0.46). Prevalence of CC in 
NSCLC for stages 1, 2, 3, and 4 was 48/309 (15.5%), 16/124 (12.9%), 118/377 (31.3%), 
and 237/658 (36.0%), respectively. OS for NSCLC -/+ CC for stages 1, 2, 3, and 4 were 
67.1 vs. 45.0, 35.4 vs. 37.2, 20.9 vs. 14.3, and 11.4 vs. 6.6 months, respectively (log-
rank P=0.0427, =0.5803, =0.0155, <0.0001). OS for squamous histologies -/+ CC for 
stages 1, 2, 3, and 4 were 56.9 vs. 22.7, 19.3 vs. 19.5, 18.6 vs. 14.3, and 7.8 vs. 5.8 
months, respectively. OS for adenocarcinoma histologies -/+ CC for stages 1, 2, 3, and 
4 were 86.4 vs. 51.1, 43.9 vs. 23.3, 28.6 vs. 19.2, and 13.0 vs. 8.2 months, respectively. 
On univariate analysis, grade, stage, tumor size, and tobacco use were significant factors 
in the development of CC in adenocarcinomas, while stage alone was significant in 
squamous carcinomas. On SLR, stages 3+4 were associated with increased odds of CC 
development as compared to stages 1+2 (OR 2.6, P=0.0004) in squamous histologies. 
On SLR, tumor size >50mm was associated with increased odds of CC development when 
compared to 0-20 mm (OR 4.3, P<0.0001) in adenocarcinomas. Conclusion: Cachexia 
significantly impacts OS in lung cancer, primarily for NSCLC. Fundamental differences 
of CC prevalence and associated OS were observed for the first time between different 
histologies and stages. Though CC can manifest in all stages, increased stage and tumor 
size were independent, significant predictors for CC in squamous and adenocarcinoma 
populations, respectively. Understanding which clinicopathologic characteristics impact 
CC prevalence and OS may offer insight into the syndrome’s clinical and biologic 
underpinnings, providing impetus for novel therapeutics and prediction methods. 
Keywords: Cachexia, non-small cell lung cancer, Weight Loss, Survival outcomes
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P1.11-004 Impact of Lung Cancer Surgery on Quality of Life of Family 
Caregivers Jae Y. Kim1, Virginia Sun2, Dan J. Raz1, Anna Cathy Williams2, Rebecca 
Fujinami2, Karen Reckamp3, Marianna Koczywas3, Mihaela Cristea3, Arti Hurria3, Betty 
Ferrell2 1Division of Thoracic Surgery, Department of Surgery, City of Hope, Duarte/CA/
United States of America, 2Division of Nursing Research & Education, Department of 
Population Sciences, City of Hope, Duarte/CA/United States of America, 3Medical Oncology 
and Therapeutics Research, City of Hope, Duarte/CA/United States of America
Background: Family caregivers (FCGs) of lung cancer patients experience decreased 
quality of life (QOL) and psychological distress related to their caregiving role. Although 
there is extensive data about the significant impact of lung cancer surgery on patient 
QOL, little is known about the impact on FCGs. We describe QOL, psychological distress, 
and perceived caregiver burden outcomes among FCGs of patients undergoing lung 
cancer surgery. Methods: As part of a National Cancer Institute-supported Program 
Project (P01) testing the effect of a palliative care intervention in patients with non-small 
cell lung cancer, patients and their FCGs were sequentially enrolled into a usual care 
group or an intervention group, which received interdisciplinary care planning as well as 
a comprehensive assessment and education by an advanced practice nurse. For this 
subset analysis, we included only those patients who underwent surgery and their FCGs. 
Outcomes were assessed at baseline (pre-operatively), at 6-7 weeks, and 12 weeks after 
surgery. FCGs were assessed using the following validated measures: distress 
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52% (adjusted R2) of the variation in depression scores. Stigma became insignificant 
in the multivariable model Conclusion: Psychosocial factors are important predictors 
of depression. Emotional support and organized religious activities may represent 
protective factors against depression, whereas collectivism may increase their risk 
Implications for Management: Care providers need to be particularly aware of the 
potential psychological strain for patients with collectivist values, experienced stigma, 
disruptions in church attendance, and lack of emotional support. In addition, the 
treatment plans for these patients should ensure that family members are knowledgeable 
about cancer, its treatment, and side effects so they are empowered to meet support 
needs. Knowledge Translation: Among Indian Lung Cancer Patients patients with 
cancer, emotional support and reassurance from family and friends that they will not 
abandon them decreases the likelihood of depressive symptoms and minimizes the 
impact of stigmatizing responses, but the perception that the illness is placing a strain 
on the family increases the likelihood of such symptoms. Emotional support likely is 
a stronger predictor of depressive symptoms than religious service attendance 
Keywords: Psychological factors; Depression; Indian Lung Cancer Patients
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P1.11-008 What Happens to the Pleural Space Affected by Malignant Effusion 
after Bedside Pleurodesis? Ricardo M. Terra1, Pedro N. Araujo2, Thiago S. Santos1, 
Rdrigo C. Chate3, Antonio L. Paiva3, Paulo M. Pêgo-Fernandes1 1Thoracic Surgery, Heart 
Institute Incor-Hcfmusp, São Paulo/Brazil, 2Thoracic Surgery, Heart Institute, Incor-Hcfmusp, 
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P1.11-006 Association between Nutritional Status Variables and Fatigue 
Diagnosis in Patients with Non Small Cells Lung Cancer Julissa L. Morales, 
Jenny T. Chaparro, Martha De La Torre-Vallejo, Luis Fernando O. Ocaña, Oscar Arrieta 
Rodriguez Thoracic Oncology Clinic, Instituto Nacional de Cancerología, Mexico City/Mexico
Background: Cancer-related fatigue (CRF) is a common and persistent symptom 
experienced by patients with Non Small Cells Lung Cancer (NSCLC). It is produced by 
multifactorial factors including those associated to the disease itself, comorbidities, life 
style and/or treatment. Malnutrition is found in up to 80% of patients with advanced 
cancer and could be associated with the presence of CRF. Both, malnutrition and 
fatigue have a negative impact on many aspects of patients’ Health-related quality 
of life, treatment compliance and prognosis. The aim of this study was to associate 
nutritional status variables with the occurrence of CRF in patients with advanced 
NSCLC. Methods: Patients with advance stage NSCLC under different lines of treatment 
were prospectively evaluated. Fatigue was assessed by the FA-13 (EORTC) test; 
malnutrition and anorexia were diagnosed using Subjective Global Assessment (SGA) and 
(S/AC-12) FAACT, respectively. Weight loss in the last six months was calculated, albumin 
and hemoglobin levels were used as biochemical parameters of nutrition. Results: 129 
patients were included, 75 were female (58%), the mean age was 61.9±13.8 years, 
Adenocarcinoma histology was present in 92 patients (71.4%) and the rest were classified 
as other histology, 90 patients (69.8%) were in ≤2nd line of treatment, 106 patients 
(83.5%) had a functional status between 0-1 and the rest between 2-3, according to SGA 
79 patients (64.8%) had any grade of malnutrition, 94 patients (75.8%) had a weight 
loss ≥10kg in six months, 25 patients (19.4%) were diagnosed with anorexia, albumin 
mean was 3.8mg/dl and 55 patients (32%) had less than that, as well as Hemoglobin 
level mean was 12.7 mg/dl and 61 patients (35.5%) had a valor less than it. Nutritional 
variables associated with CRF are shown in Table 2. Nutritional variables as Malnutrition, 
weight loss ≥10% and albumin were related with higher presence of physical, emotional, 
cognitive and daily-life fatigue. Clinical variables as histology, line of treatment and 
functional status were analyzed and just poor functional status was associated with 
higher presence of physical, emotional, cognitive and daily-life fatigue (p≤0.01).
Table 2.- Nutritional status variables related fatigue
n=129 Physic-FS p Emotion-al-FS p Cognitive-FS p Daily-life-FS p Social-FS p
Nutritional-Status Malnourished Wellnourished 42 25 <0.01 42 25 <0.01 42 25 0.001 33 33 0.001 0 0.224
Weight-loss (≥10% 6 
months) ≥10 <10 50 33 0.003 50 33 0.001 42 25 0.002 67 33 0.006 0 0.273
Anorexia Yes No 67 33 <0.01 58 33 <0.01 58 25 <0.01 67 33 <0.01 33 0 0.02
Albumin-(gr/dL) <3.8 ≥3.8 42 33 0.004 42 25 0.003 42 25 0.004 33 33 0.002 0 0.212
Hemoglobin-(gr/dL) <12.7 ≥12.7 42 33 0.077 42 25 0.04 42 25 0.012 33 33 0.227 0 0.023
 
FS: fatigue score Conclusion: Malnutrition, weight loss, anorexia, hypoalbuminemia and 
low hemoglobin are associated with CRF. Hence, timely nutritional evaluation should be 
considered in NSCLC patients. Early nutritional treatment could help to reduce treatment and 
disease related fatigue. Nutritional and psychological support might confer beneficial effects. 
Keywords: compliance, Prognosis, nutrition, Cancer-related fatigue
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P1.11-007 To Determine Whether Psychosocial Factors Predict Depression 
among Older Indian Lung Cancer Patients Gouri Shankar Bhattacharyya1, 
Purvish M. Parikh2, Ghanashyam Biswas3, Raja Dhar4, Shailesh A. Bondarde5, Hemant 
Malhotra6, Amish Vora7, K Govindbabu8, Anantbhushan A.B. Ranade9 1Medical Oncology, 
Fortis Hospital, Kolkata/India, 2Icon-Aro, Mumbai/India, 3Sparsh Hospital and Critical 
Care, Bhubaneshwar/India, 4Fortis Hospital, Kolkata/India, 5Shatabdi Super Specialty 
Hospital, Nashik/India, 6Medical Oncology, Sms Medical College Hospital, Jaipur/
India, 7Max Healthcare, Gurgaon/India, 8Kidwai Memorial Institute of Oncology, Bangalore/
India, 9Deenanath Mangeshkar Hospital, Pune/India
Background: Depression is extremely common in elderly lung cancer patients. 
However, it is extremely difficult to predict or develop predicting tools. There is some 
early studies suggesting using psychosocial factors. Unfortunately there appears to be 
no data from developing countries, more so from India. This is an attempt to initiate 
the process. Methods: Design: A descriptive correlational study. Setting: Multispeciality 
Hospitao Oncology OPD Sample: Indian Lung Cancer Patients with cancer aged 50–
88 years. Methods: Fisher’s exact and Wilcoxon rank-sum tests were used to evaluate 
differences between patients who were possibly depressed (Geriatric Depression Scale) 
or not.Multivariate linear regression statistics were used to identify the psychosocial 
factors that predicted higher depression scores. Education and gender were included 
as covariates. Main Research Variables: Religiosity, emotional support, collectivism, 
perceived stigma, and depression. Results: Participants (N = 67) had a mean age of 
65 years (SD = 8.4), and a majority were well-educated, insured, religiously affiliated, 
and currently in treatment. Participants who were in the lowest income category, not 
married, or male had higher depression scores. The multivariable model consisting of 
organized religion, emotional support, collectivism, education, and gender explained 
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therapies during their lung cancer treatment regimens. The various measures of 
outcomes, disease progression, treatments, quality of life, and side effects and their 
management were stratified according to lung cancer stage at diagnosis and other 
patient factors. Results: Responses from 106 lung cancer (non-small cell and small cell) 
patients were collected and analyzed. The study population had a significantly better 
5-year survival rate compared to the national average for lung cancer patients. Only 2% 
of patients reported financial difficulties as a result of lung cancer. The patient population 
was quite homogenous (89.3% females and 90.4% white). Eighty percent of patients 
reported experiencing side effects from chemotherapy and of those, 86% reported 
that taking chemotherapy was difficult because of the side effects. Patients diagnosed 
at Stage II and III experienced the most side effects and received the highest average 
number of treatment modalities. Patients who agreed/strongly agreed that side effects 
affected ability to take chemotherapy experienced a significantly higher number of side 
effects than those patients who reported that side effects were not as bothersome. The 
same was seen with patients who agreed/ strongly agreed that side effects caused 
lifestyle disturbance. A subset of side effects negatively affected quality of life to a 
greater extent than other (nausea, vomiting, diarrhea, loss of appetite, and fatigue). 
Neuropathy and loss of appetite were the most poorly managed side effects. When 
asked what changes to chemotherapy administration they would like, the most common 
responses were oral agents or no changes. Conclusion: Even with excellent therapeutic 
outcomes, there continue to be unmet needs that can improve patient experience and 
quality of life. Side effects continue to be troublesome and common in cancer therapy. 
Side effects had negative impact on lifestyle and ability to take chemotherapy. Certain 
side effects are poorly managed. Better supportive care for chemotherapy-related 
issues can enhance patient quality of life and may further improve quality of life. 
Keywords: supportive care, quality of life, drug development, side effects
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P1.11-011 Taste Disorder in Patients with Thoracic Malignancy Who Received 
Chemotherapy Keisuke Azuma, Hiroshi Yokouchi, Ryuichi Togawa, Yasuhito Suzuki, 
Yuki Sato, Kenichiro Hirai, Manabu Uematsu, Kenichi Misa, Hiroyuki Minemura, Kenya 
Kanazawa, Yoshinori Tanino, Mitsuru Munakata Department of Pulmonary Medicine, 
Fukushima Medical University, Fukushima/Japan
Background: Recent development of novel cancer treatments have enabled patients 
to have prolonged survival; however, some patients cannot receive benefits from those 
effective therapies because of severe adverse effects. One of the major adverse effects 
that are recognized by medical staff in patients who undergo chemotherapy is taste 
disorder, although little is known about how to treat it. To overcome this problem, 
accumulating fundamental data, such as incidence rate and timing of taste disorder in 
cancer patients who have undergone chemotherapy, is necessary. With this in mind, 
we attempted to collect the data regarding taste disorder in patients with thoracic 
malignancy after initiation of chemotherapy as a pilot study, in order to determine the 
primary endpoint for subsequent intervention studies. Methods: All eligible patients 
had treatment-naive non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) 
or malignant pleural mesothelioma (MPM) with ECOG performance status (PS) 0-2, and 
underwent chemotherapy. Written informed consent was obtained from all participants. 
We prospectively investigated the incidence rate and timing of taste disorder in these 
patients using the following two methods: i) analysis of gustatory threshold for salty taste 
using a sodium-impregnated test strip (SALSAVE, Advantec Toyo Co. Ltd., Tokyo, Japan); 
and ii) analysis of responses of a questionnaire which asked about the patient’s appetite, 
the timing of each taste change (sweet, salty, sour, and bitter taste), the presence of 
a taste in the mouth without eating any food, changes in sense of smell, tolerability 
against taste disorder, and the condition of the mouth and stomach after each cycle (1-4 
cycles) of chemotherapy. This study was registered with the University Hospital Medical 
Information Network Clinical Trials Registry, identification number UMIN00007879, 
and approved by the Institutional Review Board of our institution. Results:From June 
2012 to August 2014, 36 pts were enrolled. The average age was 64.5 years (range: 
37-83); male/female=29/7 (81/19%); ECOG PS 0/1/2=20/12/1 (56/33/3%); 
NSCLC/SCLC/MPM=25/8/3 (69/22/8%), clinical stage IIIA/IIIB/IV/adjuvant of lung 
cancer =2/6/23/2 (6/18/70/6%), and IMIG stage III/IV of MPM=2/1. Chemotherapy 
regimens were as follows; cisplatin/carboplatin/pemetrexed/etoposide/ paclitaxel/
others=18/14/16/8/3/7. There was a trend of increased threshold for salty taste 
detected by a test strip after one or two cycles of chemotherapy (p=0.10, each). 
Questionnaire analysis demonstrated that patients felt changes in taste after two or three 
cycles of chemotherapy (p=0.04, 0.005, respectively), felt changes in their sense of 
smell after one to three cycles (p=0.04, 0.002, 0.001, respectively), and had a reduced 
sensitivity to salty tastes after three cycles (p=0.02). Conclusion: These results 
suggest that using a salt test strip may detect salty taste disorder earlier than analysis 
of the patient’s subjective symptoms as answered in a questionnaire. The questionnaire 
evidently demonstrated taste disorder from various aspects in patients with thoracic 
malignancy receiving chemotherapy, and thus intervention using novel drugs is 
necessary. Further accumulation of such data is definitely warranted for further studies. 
Keywords: Adverse effects, taste disorder, chemotherapy, thoracic malignancy
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P1.11-012 Process for Developing a Rapid Tissue Donation Program in 
a Thoracic Program: Ethical and Logistical Considerations Gwendolyn 
Quinn1, Matthew B. Schabath1, Teresita M. Anotnia2, Christie Pratt2, Ivana Sehovic3, Eric 
Haura2 1Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa/
FL/United States of America, 2Immunology, Moffitt Cancer Center and Research Institute, 
Tampa/United States of America, 3Cancer Epidemiology, H. Lee Moffitt Cancer Center and 
Background: The treatment of recurrent malignant pleural effusion (RMPE) has a 
palliative purpose. Pleurodesis is the most used method. However, not all the procedures 
are effective, in part because of the lung entrapment by the visceral pleura, preventing 
the contact between the pleural surfaces. The behavior of the pleural cavities submitted 
to pleurodesis has not been studied more objectively to date. Moreover, how evolve cases 
with good initial lung expansion and those with poor expansion? Methods: Prospective 
study including 131 patients with recurrent malignant pleural effusion candidates for 
treatment with bedside pleurodesis with silver nitrate or mineral talc. Each patient 
underwent two chest CT scans, one right after the drainage (CT1) and another 30 days 
after pleurodesis (CT30). A thoracic radiologist has calculated pleural volume using the 
software Aquarius Intuition Viewer® (Terarecon). The evaluation of lung expansion was 
based on residual pleural volume on CT1 and the radiological evolution on the difference 
between the pleural volumes on CT30 and CT1 (Delta volume). The pleural volumes on 
CT1 were arbitrarily classified into small cavity after the drainage (volume <500mL) 
and large cavity after the drainage (volume ≥500 mL). After that, the Delta volume 
was classified in unchanged (≥-268.77 and ≤254,49 mL), negative (<-268.77 mL) and 
positive (> 254.49 mL). For such we used the average of the numerical variable and 
half of the standard deviation upwards and downwards. The clinical effectiveness was 
evaluated as the need for additional procedures to control symptoms. Results: We 
evaluated 87 patients of a total of 131 recruited. The median pleural volume on CT1 
was 377 (IR: 171-722) mL and 386 (IR: 164-726) mL on CT30, and has no significant 
difference between them (p= 0.753). The clinical effectiveness was observed in 86.2% 
of patients. We found 54 patients (62.06%) in the small cavity after the drainage group 
and 33 (37.93%) in the large cavity group. Clinical effectiveness was 92.6% and 75.8% 
respectively. There was significant difference (p= 0.051), with an odds ratio of 4.00 
(CI: 1.098 to 14.570) in favor of the small cavity. Among patients with small pleural 
cavity, 27.77% progress with a significant accumulation of fluid, 66.66% did not show 
significant changes and 5.55% have decreased pleural volume. Clinical effectiveness was 
86.7%, 94.4% and 100% respectively with no significant difference (p= 0.552). Among 
patients with large pleural cavity, 21.21% progress with an even greater volume of pleural 
cavity, 27.27% did not show significant changes and the majority (51.51%) evolves with 
a decrease in the pleural volume. Clinical effectiveness was 57.1%, 77.8% and 82.4% 
respectively with no significant difference (p= 0.418). Conclusion: Almost two third of 
the patients with RMPE treated with pleurodesis had good lung expansion, while just 
over one-third had a bad one. Those with good expansion had 4 times higher chances 
of clinical success. Among poor lung expansion patients, more than half had significant 
reduction of pleural volume in 30 days, while a fifth had a significant accumulation. 
Keywords: malignant, tomography, pleural effusion, pleurodesis
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P1.11-009 Predictors of Hospital Discharge in Cancer Patients with Pericardial 
Effusion Who Undergo Surgical Pericardial Drainage Thamara Kazantzis, Ricardo 
M. Terra, Benoit J. Bibas, Leticia L. Lauricella, Pedro N. Araujo, Alberto J.M. Dela-Vega, 
Paulo M. Pêgo-Fernandes Thoracic Surgery, University of São Paulo, São Paulo/Brazil
Background: Pericardial effusion (PE) is a complication of late-stage cancer and operative 
pericardial drainage is its standard treatment. However, in many patients PE is an end-of-
life event and some never leave the hospital despite the procedure. The main objective 
of this study was to identify predictors of hospital discharge in patients with cancer 
who coursed pericardial effusion and underwent operative pericardial drainage. We also 
looked at predictors of ICU discharge and overall survival and also factors that might 
be associated with paradoxical hemodynamic instability (PHI). Methods: Retrospective 
study carried out in a tertiary cancer center. We included all patients with known 
malignancy who coursed with PE and underwent surgical pericardial drainage from 
2011 to 2014. Patients who underwent previous pericardial drainage or only needle 
pericardiocentesis were excluded from the study. Results: Out of the 90 patients included 
in this study, fifty one were discharged from hospital (56%). Renal failure and pulmonary 
embolism negatively influenced the chances of hospital discharge [OR 0,247; p=0,039 
and OR 0,293; p=0.089, respectively]. On the other hand, patients who received recent 
chemotherapy were more likely to leave the hospital (OR 3,9; p=0,009). 55 patients 
(61%) were discharged from ICU. Renal failure was the main determinant of that (OR 0,284 
(p=0,047)). Mean survival was 138.2 days (95% CI 84,48-189,90), influenced only by 
ECOG status (OR 1,258; p=0,047). PHI occurred in 6 patients and all of them died within 30 
days after surgery. In our series, we could not identify predictors for PHI. Conclusion: In 
this study we demonstrated that almost half of cancer patients admitted with PE requiring 
drainage never leave the hospital. Renal failure and pulmonary embolism are strong 
predictors of in-hospital death. PHI remains a serious condition with causes unknown. 
Keywords: pericardial effusion, hospital discharge, survival
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P1.11-010 Therapeutic and Supportive Care Unmet Needs in Lung Cancer 
Patients Ronak Savla, Cornell Stamoran Catalent Applied Drug Delivery Institute, 
Somerset/United States of America
Background: The current drug evaluation model is designed at primarily optimizing 
therapeutic outcomes. Measures of quality of life and patient reported outcomes are 
often relegated as secondary endpoints. Even with excellent outcome results, there 
are many aspects of the patient journey that need to be addressed and improved. It is 
possible to improve therapeutic outcomes by addressing these other aspects of patient 
care. This study was concerned with elucidating these areas of unmet therapeutic and 
supportive needs. Methods: An online survey tool was used to collect lung cancer 
patient responses to questions about treatments, quality of life, and supportive 
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P1.12-001 Trends in Accuracy and Comprehensiveness of Pathology Reports 
of Resected Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Area 
of the US Matthew P. Smeltzer1, Fedoria E. Rugless2, Nicholas Faris2, Xinhua Yu1, 
Ransome Eke1, George Relyea1, Carrie Fehnel2, Nibedita Chakraborty2, Cheryl Houston-
Harris2, Fujin Lu2, David Spencer3, Allen Berry4, Elizabeth Sales5, Clara Finch Cruz6, 
Raymond U. Osarogiagbon2 1Epidemiology and Biostatistics, University of Memphis School 
of Public Health, Memphis/TN/United States of America, 2Thoracic Oncology Research 
Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis/TN/
United States of America, 3Trumbull Labs, Memphis/United States of America, 4St. Francis 
Hospital Pathology, Memphis/TN/United States of America, 5Doctors Anatomic Pathology, 
Jonesboro/AR/United States of America, 6Va Medical Center, Memphis/United States of 
America
Background: Pathologic examination of NSCLC resection specimens is vital to optimal 
treatment. In 2004, the College of American Pathologists (CAP) issued guidelines for NSCLC 
reporting, which were most recently updated in 2013. We evaluated the adoption of CAP 
reporting elements in a regional database. Methods: The Mid-South Quality of Surgical 
Resection (MS-QSR) database includes detailed information on 2,593 NSCLC resections 
in 11 institutions in 5 Dartmouth Hospital Referral Regions in Eastern Arkansas, North 
Mississippi and Western Tennessee from 2009-2014. In 2009, we started a multifaceted 
educational intervention: 1. Analyzed 2004-2008 pathology reports demonstrating the 
quality deficit in pathology reporting. 2. Recommended adoption of synoptic reporting of 
CAP checklist items. 3. Embedded a surgical intervention to improve mediastinal lymph 
node examination at some institutions. To allow for comparisons between eras and across 
the post-intervention era by intervention and type of hospital, we evaluated 4 groups: 
pre-intervention (pre-int), post-intervention participating hospital with surgical intervention 
(post-int/surg), post-intervention participating hospital without surgical intervention (post-
int/non-surg), and non-participating non-surgical intervention hospital (post-int/non-part). 
We evaluated the inclusion of each CAP checklist item and the percent of cases with 
all items and 6 key items reported. We also evaluated the accuracy of T and N-stage 
categorization. Proportions reporting each item were compared between groups using 
Fisher’s Exact test. Results: Details of the completeness of pathology reporting are 
shown in Table 1 by group. The percent reporting the 6 key checklist items improved 
significantly from 63% pre-int to 76% post-int/non-part, 86% post-int/non-surg, and 95% 
post-int/surg (p-value<0.0001). A similar pattern of improvement was observed for 
N-stage (p-value<0.0001) and T-stage (p-value<0.0001) reporting. However, we observed 
significant decreases in the reporting of M-stage, and therefore all key items, post-
intervention (p-value<0.0001). The accuracy of N-stage reporting improved significantly 
from 66% pre-int to 72% post-int/non-part, 86% post-int/non-surg, and 97% post-int/surg 
(p-value<0.0001). A similar trend was observed for T-stage accuracy (p-Value<0.0001).
Research Institute, Tampa/United States of America
Background: Rapid tissue donation (RTD), also known as “warm autopsy,” is a novel 
method of tissue procurement for research purposes where tissues from the primary 
tumor and metastatic sites are collected within 24 hours of patient death. These 
tissues provide tremendous research possibilities and hope for new cancer treatments. 
However, recruiting for RTD has ethical challenges such as diminishing patients’ hope and 
causing distress to Next of Kin (NoK). Presently there is limited RTD education, training, 
or protocols for biomedical researchers and healthcare professionals (HCPs) to address 
the psychosocial and ethical aspects of the request for postmortem tissue donation. 
The purpose of this study was to: i) identify barriers and facilitators to RTD recruitment 
and tissue collection from key stakeholders; ii) identify the RTD processes used in 
other organizations and programs; and iii) establish a standardized process for RTD 
in a Thoracic Oncology Program at a Comprehensive Cancer Center. Methods: Mixed 
methods were used for each of the 3 purposes of the study: i) formative research (surveys 
and focus groups) was conducted to explore knowledge, perceptions, and barriers and 
facilitators to patient recruitment to RTD across key stakeholders including HCPs (n= 
91), cancer patients/survivors and advocates, caregivers, physicians and clinic staff 
(n=42); ii) semi-structured interviews with hospice staff, morgue pathologists, funeral 
home directors, national organ/tissue donation programs (n= 27); and iii) conducted 
an extensive review of the literature regarding existing models of RTD. Results: Results 
from part 1 of the study identified several barriers including use of the word “autopsy”; 
discussing RTD during an initial appointment; approaching patients who attended visits 
alone; having staff discuss RTD with patients; and expecting all physicians would want 
to assist with recruitment. Facilitators included identifying enthusiastic physicians; 
establishing that the treating physician should identify who would be a good candidate 
(interest and willingness); use of the word “donation”; only approaching patients who 
have expressed interest and are coping well with their diagnosis; engaging family 
members in the consenting process; developing written educational materials about 
RTD; and allowing family members the authority to revoke consent after patient death. 
Results from part 2 identified the need to use a body map to indicate metastatic sites, 
developing a standardized operation procedure (SOP); restricting the geographic area 
where patients reside to facilitate quick retrieval; enlisting the help of Hospice, providing 
training to staff and physicians and developing a mechanism to provide study results 
to NoK and recognition for donors. Results from part 3 revealed that despite more 
than 300 publications using tissue collected via RTD, only 1 study actually described 
the process for obtaining the tissues and consent. Based on these results, a 12-step 
RTD SOP was developed. Conclusion: Ethical guidelines, an SOP, and training for 
HCPs is needed prior to initiation of an RTD program. A verbatim script is necessary 
for physicians’ comfort level and to ensure consistent messaging. Our study provides 
important information about knowledge, attitudes, and logistics related to RTD from all 
stakeholders and guided the development of a RTD at a Comprehensive Cancer Center. 
Keywords: Hospice, Rapid Tissue Donation, Ethics
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P1.11-013 Place and Cause of Death in Patients with Lung Cancer in the United 
Kingdom Emma L. O’Dowd1, Tricia Mckeever1, David R. Baldwin2, Sadia Anwar2, Richard 
B. Hubbard1 1Epidemiology and Public Health, University of Nottingham, Nottingham/United 
Kingdom, 2Respiratory Medicine, Nottingham University Hospitals, Nottingham/United 
Kingdom
Background: Many patients with cancer die in an acute hospital bed, which has been 
frequently identified as the least preferred location, with psychological and financial 
implications. This study aims to look at place and cause of death in patients with lung 
cancer to identify which factors are associated with dying in an acute hospital bed versus 
at home. Methods: We used data from the National Lung Cancer Audit (NLCA) linked 
to Hospital Episode Statistics (HES) and Office of National Statistics (ONS) records 
to determine cause and place of death in those with lung cancer overall. England was 
divided into 28 cancer Networks at the time these data were collected so we used 
these to assess geographical variation in place of death. We used multivariate logistic 
regression to compare demographic, co-morbid and tumour-related factors between 
those who died in an acute hospital versus those who died at home. Results: Of 143627 
patients identified 40% (57678) died in an acute hospital, 29% (41957) died at home and 
17% (24108) died in a hospice. Individual factors strongly associated with death in an 
acute hospital bed compared to home were male sex, increasing age, poor performance 
status, social deprivation and diagnosis via an emergency route (table 1). There was 
marked variation between cancer Networks in place of death. The proportion of patients 
dying in an acute hospital ranged from 28% to 48%, with variation most notable in 
provision of hospice care (9% versus 33%). Cause of death in the majority was lung 
cancer (86%), with other malignancies, chronic obstructive pulmonary disease (COPD) 
and ischaemic heart disease (IHD) comprising 9% collectively. Conclusion: A substantial 
proportion of patients with lung cancer die in acute hospital beds and this is more likely 
with increasing age, male sex, social deprivation and in those with poor performance 
status. There is marked variation between Networks, suggesting a need to improve end-
of-life planning in those at greatest risk, and to review the allocation of resources to 
provide more hospice beds, enhanced community support and ensure equal access.
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5.5% disagreed with expert recommendations and 8% indicated barriers to implementing 
the recommendations. In comparing overall results from V1.0 (2012) to V2.0 (2014), 
more oncologist users were likely to select TKIs in both EGFR mutation (49% vs 67%) and 
ALK translocation (35% vs 61%), with a corresponding decrease in use of chemotherapy. 
A detailed analysis of expert vs user data will be presented, comparing V1.0 (2012) and 
V2.0 (2014). Conclusion: Expert opinions were largely unchanged between V1.0 and 
V2.0, while oncologist users increased use of TKIs. Most oncologist users of V2.0 either 
confirmed or changed treatment choices based on expert recommendations. This online 
tool can aid decision making, serve an educational purpose, and capture practice trends. 
Keywords: online tool, first-line therapy, practice trends
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P1.12-003 Acquistion of and Early Clinical Results of Electromagnetic 
Navigational Bronchoscopy for Diagnosis of Lung Cancer in a Community 
Setting Alexandra Reichman1, Jessica Parkyn2, Jerry Birk3, Laura De La Cruz1, Royce 
Calhoun2 1Pathology, Rideout Regional Medical Center, Marysville/CA/United States of 
America, 2Thoracic Surgical Oncology, Rideout Health, Marysville/CA/United States of 
America, 3Administration, Rideout Regional Medical Center, Marysville/CA/United States of 
America
Background: Electromagnetic Navigational Bronchoscopy (ENB) is an emerging 
technology to assist in obtaining a tissue diagnosis from suspicious lung nodules or 
masses. Despite the recognized advantages of having access to ENB technology, 
there are barriers to procure such expensive technology and effectively implement 
it. Acquiring and leveraging ENB technology is dependent on diverse considerations 
for community need, financial feasibility, patient / referral work flow and synergy 
with complimentary diagnostics and programs, proper coding and revenue cycle 
management and associated service development and marketing. There are many 
elements to implementing and achieving acceptable results which include the initial 
capital planning and service optimization, maximizing utilization, learning the techniques 
with enhanced competency and the handling and management of the specimens once 
obtained. Herein, we describe our approach to procuring the technology and early 
clinical results. Methods: ENB technology was purchased after partnering with the 
parent company (Covidien) and our health system’s business development department, 
to perform a market analysis as well as a return on investment that integrated multiple 
service lines and hospital costs centers. From these data, a business plan was created 
and ultimately approved by the Foundation Board. All ENBs (SuperDimension®) were 
performed under general anesthesia by a single thoracic surgeon in the operating room, 
using a therapeutic bronchoscope inserted through a 9 endotracheal tube. Almost 
all procedures utilized fine needle aspiration, brushings, biopsies and washings. The 
biopsy phase of the procedure was done under fluoroscopy. Cytologic slide review via 
Rapid Onsite Evaluation (ROSE) was performed by a pathologist in the operating room 
in 100% of the cases. Results were obtained by retrospective review of a prospective 
database. Time period of study was 12/11/13-03/30/14. Results: 72 total ENB 
cases were performed in the time period of which 52 were for suspected malignancy. 
There were no pneumothoraces or bleeding complications. Two patients had to be 
admitted for 23 hours secondary to poor respiratory function following procedure. Of 
the 52 suspected malignancies, 33 (64%) were found to be a primary lung cancer, 7 
were atypical and 12 benign or non-diagnostic. 5 of the patients with atypia went on 
to surgical resection and were found to have lung adenocarcinoma. Conclusion: ENB 
is an emerging technology with promising results for tissue diagnosis of lung nodules 
suspected of being malignant. Implementing new and costly technologies in smaller 
healthcare systems, such as a regional hospital, can be challenging. Some of the barriers 
to implementation are finding the capital and justification for procuring the technology, 
perfecting the technique and securing support from pathology, anesthesiology and 
operating room time. By partnering with industry and our business department, we 
were able to justify procurement of ENB technology. In our first 72 cases, 52 were for 
suspected malignancy. A diagnosis of lung cancer was achieved in 64% of lung lesions, 
with a low complication rate (2/72). Our results compare favorably to published results 
of trans thoracic needle biopsies as well as within our own health system. Initiating and 
implementing an ENB program in a community setting is feasible with acceptable results. 
Keywords: Community Setting, Electromagnetic Navigational Bronchoscopy, lung 
cancer, Thoracic Surgeon
POSTER SESSION/ COMMUNITY PRACTICE 
MONDAY, SEPTEMBER 7, 2015 - 09:30-16:30
P1.12-004 Early Results of Endobronchial Ultrasound for Lung Cancer 
Mediastinal Nodal Staging in a Community Setting Alexandra Reichman1, Jessica 
Parkyn2, Laura De La Cruz1, Royce Calhoun2 1Pathology, Rideout Regional Medical Center, 
Marysville/CA/United States of America, 2Thoracic Surgical Oncology, Rideout Health, 
Marysville/CA/United States of America
Background: Endobronchial Ultrasound (EBUS) has become an established modality 
for pathological mediastinal staging for lung cancer and in some centers, is used at the 
exclusion of mediastinoscopy, the traditional gold standard. Herein, we describe our 
early results of EBUS, in a community setting, for mediastinal pathologic staging for lung 
cancer and compare it to concomitant mediastinoscopy. Methods: All EBUS procedures 
were performed in the operating room under general anesthesia, with a Pentax scope 
introduced through a 9 endotracheal tube, by a single thoracic surgeon. The Pentax 
needle was used early in the series and the Cook needle later. Rapid Onsite Evaluation 
(ROSE) for immediate cytologic evaluation of specimens was performed in 100% of the 
cases. For lung cancer staging patients, mediastinoscopy was performed immediately 
after the EBUS under the same anesthetic. This was an outpatient procedure. Study 
%Reporting Pre-Int (N=1390)
Post-Int/ 
Non-Part 
(N=271)
Post-Int/ 
No-Surg 
(N=645)
Post-Int/ 
With-Surg 
(N=310)
P-Value
Specimen* 98.4 100 100 100 <0.0001
TumorSize* 97.2 99.6 98.1 99.4 0.0094
Histology* 99.8 99.6 99.5 99.7 0.59
MarginStatus* 97.1 98.5 92.6 98.7 <0.0001
T-Stage* 67.8 76.4 92.1 97.1 <0.0001
N-Stage* 66.3 76.8 89.8 97.7 <0.0001
*All Key-Items 62.7 75.7 85.7 94.8 <0.0001
Laterality 99.8 100 99.5 100 0.56
HistologicGrade 99.9 100 99.5 100 0.18
M-Stage 75.8 31.4 25 21.6 <0.0001
VascularInvasion 28.6 10.7 25 11.9 <0.0001
All Items 10.7 4.1 6.2 3.2 <0.0001
%Accurate
N-Stage 66.2 71.6 86.2 96.8 <0.0001
T-Stage 55.3 61.6 83 84.8 <0.0001
 
Conclusion: There was significant improvement in reporting of CAP checklist items and 
the accuracy of pT- and pN-categorization. After the introduction of synoptic reporting, 
we observed a secular trend of improvement, shown by our post-int/non-part external 
control. Direct educational intervention in 2009-2010 further improved the completeness 
and accuracy of reports in participating hospitals. The surgical intervention provided 
additional benefit. Interventions to improve the quality of reporting for NSCLC are impactful 
on accuracy and thoroughness of reporting, thereby improving the quality of care. 
Keywords: Pathology Reporting, non-small cell lung cancer, Accuracy, 
Comprehensiveness
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P1.12-002 International Online Tool for Therapeutic Decision Making in NSCLC 
(V2.0) Timothy A. Quill1, David R. Gandara2, Wilfried E.E. Eberhardt3, Tony Mok4, 
Nagahiro Saijo5, Yi-Long Wu6, Kevin Obholz1, Andrew Bowser1, Helen Chow7, Giorgio 
V.V. Scagliotti8 1Clinical Care Options, Virginia/United States of America, 2University of 
California Davis Cancer Center, Sacramento/CA/United States of America, 3University 
Hospital Essen, West German Cancer Centre, Ruhrlandklinik, University Duisburg-Essen, 
Essen/Germany, 4Princess of Wales Hospital, The Chinese University of Hong Kong, 
Hong Kong/Hong Kong, 5Administration, Japanese Society Medical Oncology, Tokyo/
Japan, 6Guangdong General Hospital & Guangdong Academy of Medical Sciences, 
Guangzhgou/China, 7University of California Davis Cancer Center, Sacramento/United States 
of America, 8Thoracic Oncology Unit, University of Turin, Turin/Italy
Background: Practice guidelines in non-small-cell lung cancer (NSCLC) list multiple 
therapy choices based on levels of evidence but cannot account for variability in patient 
(pt) -tumor characteristics between individual patient cases. To provide oncologists with 
expert guidance and feedback on choice of treatment (Tx) for specific pt scenarios, we 
previously implemented an interactive Web-based decision support tool in 2012, in which 
oncologist users input specific pt characteristics and selected among treatment options, 
then compared their selection with that of an NSCLC expert panel for that scenario. 
(Chow JTO 2015). Here we report data from version 2.0 of this tool, capturing current Tx 
trends for advanced NSCLC and investigating the impact of this online tool on oncology 
practitioners. Methods: V2.0 was developed based on input from 6 international NSCLC 
experts who provided Tx recommendations for 1st-line treatment in 96 pt case variations 
based on histology (nonsquamous vs squamous), EGFR mutational status (positive [+] vs 
negative [-]), ALK rearrangement (+ vs -), age (< 70 vs ≥ 70 years), performance status (0, 
1 vs 2), smoking history (never/former light vs former heavy/current), and pt primary Tx 
goal (response and survival vs quality of life and low adverse events). As in V1.0, oncologist 
users input specific pt scenarios, then were prompted for their treatment choice. 
Once completed, recommendations for that scenario from each of the experts were 
displayed, and users were prompted to indicate whether the expert recommendations 
changed their treatment choice. Statistical methods: as previously described (Chow JTO 
2015). Results: V2.0 oncologist users (N = 218 unique users) contributing 314 unique 
cases were 87% non-USA, 13% USA. As in V1.0, experts agreed on selection of targeted 
therapies (TKIs) for cases with actionable EGFR mutations and ALK translocations. Choice 
of a specific EGFR inhibitor by experts varied depending on region and clinical factors. By 
comparison, among online users of V2.0, an EGFR inhibitor was selected for 67% of EGFR-
mutated cases (n = 78), while an ALK inhibitor was selected for 61% of ALK cases (n = 
31). For nonsquamous histology cases without actionable mutations, use of pemetrexed 
was more common among experts compared with oncologist users (91% vs 48% of 
case scenarios). In 182 cases entered by users who reported on the impact of expert 
recommendations, treatment choice was affected in 86% of cases (confirmed in 71%); 
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P1.12-006 Factors That Influence Tobacco Consumption Among Portuguese 
Adolescents Diana Silva1, Julia A. Fernandes2, Ana Valente3, Claudia Dias4, Altamiro 
Pereira4, Henrique Queiroga5, Alberto Caldas Afonso1, António Guerra1 1Paediatric 
Service, Hospital São João, Porto/Portugal, 2Faculty of Nutrition and Food Sciences, 
University of Porto², Porto/Portugal, 3Faculty of Nutrition and Food Sciences, University 
of Porto, Porto/Portugal, 4Department of Bioestatistics and Medical Informatics, Porto/
Portugal, 5Pulmonology Unit, Hospital São João, Porto/Portugal
Background: The majority of smokers start smoking at a very early age. Many teenagers, 
who start smoking at school age, are at increased risk of becoming adult smokers. The 
purpose of this study was to evaluate family and social factors that might contribute to 
the acquisition of smoking in Portuguese adolescents. Methods: A cross-sectional study 
was conducted in 285 healthy adolescents (15–19 years old) of both sex attending 3 high 
schools (public and private) from northern Portugal. The smoking habits of teenagers 
were evaluated according to a protocol adapted from the Global Youth Survey (GYTS), 
Center of Disease Control and Prevention (2001). The questionnaire consisted of 34 
questions related to tobacco consumption, knowledge and attitudes towards smoking, 
smoking cessation, school regulation and the family role in preventing smoking. 
Participants were classified as: 1 - never having tried smoking; 2 - have just tried smoking 
(not smoked in the previous month); 3 - occasional smokers (smoked at least 1 day 
during the previous month); 4 - current smokers (smoked at least 20 days in the previous 
month). The protocol was approved by the School Direction and statistical analysis was 
performed with SPSS ® for the entire sample and by gender. Results: Of the total sample 
(n=285), 46% were males and 54% females with an average age of 16.6±1.2 years 
(minimum:15; maximum:19). About 59.6% of adolescents have experienced smoking at 
least once, 54% of whom were female. Although the average age of tobacco onset was 
between 12-15 years (64%), we found that 21% of subjects experienced smoking before 
11 years of age. Regarding parents tobacco use, there is a higher percentage of smoking 
fathers (30.2%) versus 15.2% of mothers. 38% (n=170) of smoking adolescents do it 
in public places, mainly in social events (65%) and with friends (91%). It is noteworthy 
that the major causes referred by the adolescents to smoke were: have many smoking 
friends [girls: OR=44,0 (9,932- 194,92)] (p<0,001); boys: OR=33,21 (6,14-179,65)] 
(p<0,001) and a smoking mother [girls: OR=4,39 (1,417-13,637)] (p=0,010); boys: 
OR=2,627 (0,824-8,378)] (p=0,103). Conclusion: It should be noted that in addition to 
early initiation, a high percentage of adolescents smoke regularly. Having parents and/or 
friends who smoke are the highest prediction factors for adolescent smoking. This study 
highlights the importance for an effective intervention in respect to tobacco harmful 
effects, with strong family involvement, in order to reduce consumption and prevent 
its negative health consequences, as well as the morbidity and mortality associated. 
Keywords: family, tobacco, adolescents
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P1.12-007 Thoracic Surgery Information on the Internet: Multilingual Quality 
Assessment Myles T. Davaris1, Stephen Barnett2, Nathan Lawrentschuk3, Robert 
Abouassaly4 1University of Melbourne; Austin Hospital, Melbourne/VIC/Australia, 2Austin 
Hospital; Peter Maccallum Cancer Institute, Melbourne/Australia, 3Ludwig Institute for Cancer 
Research, Austin Hospital; Department of Surgery, Austin Hospital; University of Melbourne, 
Melbourne/VIC/Australia, 4Urological Institute, University Hospitals Case Medical Centre, 
Case Western Reserve University, Cleveland/OH/United States of America
Background: Previous data suggests quality of Internet information regarding surgical 
conditions and their treatments is variable. However, no comprehensive analysis exists 
for Thoracic surgery. Methods: World Health Organization Health on the NET (HON) 
principles may be applied to websites using an automated toolbar function. We used the 
English, French, Spanish and German Google search engines to identify 12,000 websites 
using keywords related to Thoracic conditions and procedures. The first 150 websites 
returned by each keyword in each language had HON principles examined. We compared 
website quality to assess for tertile (thirds) and language differences. A further evaluation 
of the English site types was undertaken, with a comparative analysis of website provider 
types. Results: ‘Lung Cancer’ returned over 150 million websites, whereas ‘Ravitch 
Procedure’ returned less than 250 thousand. Less than 10% of websites are HON 
accredited with differences by search term (p<0.05) and tertiles (p<0.05) of the first 
150 websites but, in contrast to earlier work in other tumour streams, not between 
languages. Oncological keywords regarding conditions and procedures were found 
to return a higher percentage of HON-accreditation than cosmetic search terms. The 
percentage of HON-accredited sites was similar across all four languages (p<0.05). In 
general, the first tertile contained a higher percentage of HON-accredited sites for every 
keyword.
period was 04/21/14-04/13/15. Data was collected from a retrospective review of a 
prospective database. Results: There were 40 EBUS cases performed during the study 
period. There were no complications. 36 were performed for cancer diagnosis/staging 
and 21 for lung cancer staging specifically. 27 cases had EBUS and mediastinoscopy 
performed concomitantly under one anesthetic and thus could be directly compared. 
46 total # of lymph node stations were evaulated with EBUS and 16 (35%) resulted in 
no lymphocytes or diagnosis. Regarding the 21 lung cancer patients who were being 
evaluated for pre-treatment pathologic mediastinal staging, the average # of lymph 
node stations was 1.1 for EBUS vs. 3.4 for mediastinoscopy. Using mediastinoscopy 
as the reference for pathologic staging, the sensitivity of EBUS was 80% and specificity 
100%. If the EBUS stations that yielded no lymphocytes or diagnosis were eliminated 
from the analysis, the sensitivity was 89% and specificity 100%. Conclusion: EBUS 
has become an established technique to pathologically stage mediastinal nodes for 
lung cancer. In some centers, it is used at the exclusion of mediastinoscopy (the gold 
standard) and in others, selectively. Our early results with the adoption of this technique 
and comparing it to mediastinoscopy performed concommitantly, has an acceptable 
sensitivity and specificity. However, we experienced a relatively high rate of absence 
of lymphocytes/non-diagnostic (35%), compared to mediastinoscopy (0%), and fewer 
nodal stations biopsied per procedure (avg. 1.1) compared to mediastinoscopy (avg. 
3.4). This does represent an early experience and likely not beyond the learning curve. 
We will continue to utilize EBUS for lung cancer staging but will be liberal to employ 
concomitant mediastinoscopy until we can approach the results of our mediastinoscopy 
with respect to yield of lymphocytes/diagnosis and # of stations biopsied per procedure. 
Keywords: Community Setting, Thoracic Surgeon, endobronchial ultrasound
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P1.12-005 Concomitant Electromagnetic Navigational Bronchoscopy and 
Endobronchial Ultrasound to Diagnose and Stage Lung Cancer in a Community 
Setting Jessica Parkyn1, Alexandra Reichman2, Laura De La Cruz2, Royce Calhoun1 
1Thoracic Surgical Oncology, Rideout Health, Marysville/CA/United States of 
America, 2Pathology, Rideout Regional Medical Center, Marysville/CA/United States of 
America
Background: Delays in lung cancer diagnosis and adequate staging can both delay 
and affect appropriate care. It is not uncommon to take months from the time of the 
first suspicion of lung cancer on imaging to diagnosis, staging and treatment. We 
have recently adopted both electromagnetic navigational bronchoscopy (ENB) and 
endobronchial ultrasound (EBUS) technologies as part of our comprehensive lung cancer 
program. By cultivating an early referral system, within the primary care network, of 
suspected lung cancer and with the understanding of which patients should have 
pathologic mediastinal staging, we are able to both diagnose a primary lung cancer and 
pathologically stage the mediastinal nodes in one setting under the same anesthetic. This 
combined approach by a lung cancer expert, saves many potential delays of separate 
serial procedures often ordered by those not as familiar with lung cancer evaluation 
and staging. Herein, we describe our early results with this approach. Methods: Criteria 
for patient selection was a lung nodule/mass suspicious for lung cancer and either 
clinically positive hilar or mediastinal lymph nodes (>1cm on short axis or > 2.5 SUV 
on PET) or central primary, >4 cm primary or >10 SUV of suspected primary lung 
cancer. All procedures were performed by a single thoracic surgeon, in the operating 
room with the patient under general anesthesia. The Superdimension® ENB system was 
utilized and the Pentax® EBUS system. Rapid Onsite Evaluation (ROSE) for immediate 
cytologic evaluation of specimens was performed in 100% of the cases. The study 
period was 04/21/14-04/13/15. Data was evaluated retrospectively from a prospective 
collected database. Results: 21 patients had a combination of ENB and EBUS and/
or mediastinoscopy or both. 19 patients had lung cancer and constitute this analysis. 
A diagnosis of lung cancer was achieved in 16 patients (84%). EBUS/Mediastinoscopy 
was negative for cancer in 11 (59%) patients and positive for cancer in 8. (41%). There 
were no complications and all procedures were outpatient. The subsequent treatment 
of the patients were as follows: 5 definitive chemoradiation, 3 lobectomy followed by 
chemotherapy, 1 lobectomy followed by radiation to chest wall, 1 lobectomy, 2 clinical 
trials, 1 neoadjuvant chemotherapy followed by lobectomy (intent), 2 chemoradiation 
followed by lobectomy (intent), 1 radiation, 2 chemotherapy, 1 hospice. Conclusion: The 
ability to both diagnose lung cancer and pathologically stage the mediastinum under one 
anesthetic with utilization of ROSE, has several potential advantages. It allows an efficient 
and expeditious diagnosis and staging in select patients so they move expeditiously 
to the appropriate treatment and potentially skip several serial appointments and 
tests. Like most centers, we selectively pathologically stage the mediastinum for lung 
cancer patients and this is likely why in this series there is a relatively high percentage 
of pathologic N2 nodes (41%) found on pre-treatment pathologic staging and relatively 
high percentage of patients having adjuvant treatment after lobectomy. We believe this 
is an efficient approach for patients with a suspected lung cancer and meet criteria 
for pathologic mediastinal staging. Future studies will focus on quantifying the time 
savings differential between this approach and the more traditional approaches. 
Keywords: Electromagnetic Navigational Bronchoscopy, endobronchial ultrasound, 
Community Setting, Thoracic Surgeon
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work and a rotation of surgeons, pulmonologists and primary care physicians. 5. The 
procurement and implementation of Electromagnetic Navigational Bronchoscopy to the 
community to obtain tissue diagnosis of suspected lung lesions. 6. The procurement 
and implementation of Endobronchial Ultrasound for the minimally invasive pathologic 
staging of appropriate lung cancer patients. 7. The procurement and participation in the 
Society of Thoracic Surgery (STS) General Thoracic Surgery Database for registration 
of patient outcomes and national comparison. 8. The introduction of VATS lobectomies 
and complex open resections. 9 400 new thoracic surgical cases to the Regional Medical 
Center. 10. 54 cases of multimodallity therapy for lung cancer patients compared 
with 4 the previous two years. 11. The establishment of stereotactic body radiation 
therapy (SBRT) as a treatment alternative to surgery for medically inoperable stage I 
lung cancer patients. Conclusion: It is possible to create a de novo comprehensive 
lung cancer program in a community setting with the appropriate expertise and 
leadership. General thoracic surgeons with expertise in current lung cancer diagnostics, 
staging and treatment options are uniquely positioned to provide the expertise and 
leadership to create a comprehensive lung cancer program as they are integrally 
part of assessing pulmonary nodules, establishing diagnosis, rigorously staging lung 
cancer and treatments including surgery, radiation chemotherapy and multimodality 
regimens. This approach could serve as a paradigm for similar communities to bring 
current, evidence based lung cancer diagnostics and treatment to their region. 
Keywords: Comprehensive Lung Cancer Program, endobronchial ultrasound, 
Electromagnetic Navigational Bronchoscopy, Thoracic Surgeon
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P1.12-009 Lung Cancer in Octogenarians Nuria Cárdenas Quesada1, Ana Laura 
Ortega Granados1, Carmen Rosa-Garrido2, Yéssica Plata Fernández1, Tamara Díaz 
Redondo1, Irene González Cebrián1, Francisco José García Verdejo1, Natalia Luque 
Caro1, Pedro López Leiva1, Pedro Sánchez Rovira1 1Medical Oncology, Complejo 
Hospitalario de Jaén, Jaen/Spain, 2Fibao, Complejo Hospitalario de Jaén, Jaen/Spain
Background: Octogenarian patients with lung cancer are underestimated in the 
scientifi c literature. Since in our institution, the median age of patients with lung cancer 
is 71 years old, we decide to conduct a study to get specifi c data of our population 
over 80 years Methods: Retrospective observational cohort study of patients with 
lung cancer referred to Medical Oncology at our institution, during 4 years (2010-2013) 
and follow-up until April 2015. Inclusion criteria were age (80 years or older) and lung 
cancer diagnosis. The cohort was 41 patients Results: Our octogenarian patients were 
a 6.1% of our 672 patients seen in 2010-2013 interval. Of our 41 patients, 78% were 
male, and the median age is 81 years (80-87). Histologies are 88% NSCLC and 12% 
SCLC; in the NSCLC group, squamous carcinomas are most common (50%), followed 
by adenocarcinoma (26.8%). 51% patients were diagnosed in stages I-III, but only 3 
patients were under radical treatment (2 surgery, 1 radiation therapy). 34% patients 
did not receive any oncologic treatment, only palliative care. Of the patients with active 
cancer treatment, 92% received fi rst-line therapy. In the fi rst-line group, 68% were 
under chemotherapy, 48% platinum doublet (more used schedules were carboplatin-
vinorelbine, carboplatin-pemetrexed and carboplatin-paclitaxel), and 20% monotherapy 
(vinorelbine, pemetrexed and carboplatin) and 24% TKi (all EGFR mutated, with gefi tinib 
and erlotinib). 26.8% (11) of patients received second-line treatment (10 erlotinib and 1 
pemetrexed), and only 2 patients received 3 or more lines (1 patient up to 7 lines). 39 
of 41 patients died (95%), and most patients die at home (95%). The median survival 
time is 11.19 months (CI 95% 7.84-14.53) and median overall survival is 8 months (CI 
95% 4.51-11.48). In male patients, median survival time expected is 9.97 months, 
and in female patients, 14.88 months. Depending on the stage, stage IV patients had 
a expected survival of 9.94 months and stage I-III patients, 11.40 months, with no 
statistically signifi cant diference. Depending on smoking status, survival is 8.95 months 
for ever-smokers, and 18.44 months for never-smokers (p-value: 0.035). Depending on 
therapy, survival in active cancer treatment group is 14.56 months, and in palliative 
care only group is 5.28 months (p-value: 0.001) Conclusion: In our cohort of elderly 
patients, with a small number of patients (a 6% of all the patients, maybe underreferred), 
we found some differences with our global lung cancer patients group. The ratio SCLC-
NSCLC is quite similar (12-88% in elderly vs 14-86% in all our patients), but there is 
a different pattern according histological subtypes, with more squamous carcinomas 
in this cohort (44% vs 29.6%), and more EGFR mutations (24% vs 18%). We see that 
survival was better in patients receiving active cancer treatment plus best supportive 
care vs only palliative care. Factors infl uencing survival are smoking status (ever vs 
never-smokers) and sex. Although is essential a joint management with Palliative Care, in 
this particular group of patients, that are believed that cancer treatment is less useful, 
active cancer treatment is benefi cial, if we always individualize decisions in each patient. 
Keywords: elderly, octogenarians, TKI, chemotherapy
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P1.12-010 Bench to Bedside Detection of Actionable Genotypes by SNaPshot 
for Lung Cancer Panel Anuradha Choughule1, Vaishakhi Trivedi1, Pratik Chandrani2, 
Amit Dutt3, Kumar Prabhash4 1Medical Oncology-Molecular Laboratory, Tata Memorial 
Centre, Mumbai/India, 2Dutt Lab, Actrec, Mumbai/India, 3Dutt Laboratory, Actrec, 
Navimumbai/India, 4Tata Memorial Centre, Mumbai/India
Background: Conventional therapeutic solutions in NSCLC are not effective to treat 
the disease. Despite of all developments in understanding of the disease, mortality 
of lung cancer patients remains high. Recent developments of personalized therapy 
have given promising results in terms of improved survival of NSCLC patients. Thus, 
we were keen to develop a cost effective and sensitive diagnostic lung cancer panel 
Conclusion: Clinicians should appreciate the lack of validation of the majority of 
thoracic websites, with discrepancies in quality and number of websites across 
conditions and procedures. These differences appear similar regardless of language. 
An opportunity exists for clinicians to participate in the development of informative, 
ethical and reliable health websites on the Internet and direct patients to them. 
Keywords: Internet, Thoracic, Tertile, Language
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P1.12-008 Components of Creating and Implementing a Comprehensive 
Lung Cancer Program in a Community Setting Jessica Parkyn1, Alexandra 
Reichman2, Laura De La Cruz2, Jerry Birk3, Hoa Nguyen4, Charles M. Wilkinson4, Russell 
Suey5, Royce Calhoun1 1Thoracic Surgical Oncology, Rideout Health, Marysville/CA/United 
States of America, 2Pathology, Rideout Regional Medical Center, Marysville/CA/United States 
of America, 3Administration, Rideout Regional Medical Center, Marysville/CA/United States 
of America, 4Medical Oncology, Rideout Cancer Center, Marysville/CA/United States of 
America, 5Imaging Services, Rideout Cancer Center, Marysville/CA/United States of America
Background: Many communities do not have a comprehensive, evidence based 
approach to lung cancer diagnosis, staging and treatment. This is often secondary to 
lack of providers in the area with expertise in lung cancer as well as lack of appropriate 
diagnostic and treatment modalities. Herein we describe the creation and implementation 
of a comprehensive lung cancer program in a community setting. Methods: A regional 
health system that serves a population with a relatively high incidence of lung cancer, 
recruited an experienced general thoracic surgeon, with expertise in the diagnosis, 
staging and treatment of lung cancer. The community had a pre-existing cardiac surgery 
program, a cancer center that provided chemotherapy and traditional radiation, a PET 
scanner and 2 CT scanners. Results: The study period was 9/1-2012 to 4/1/2015 
which spans the time after the introduction of the general thoracic surgeon in the 
community to present. Under the leadership of the thoracic surgeon, the following was 
accomplished: 1. An extensive outreach campaign to primary care physicians as well as 
directly to the community regarding lung cancer awareness, modern diagnostic, staging 
and treatment modalities. 2. Establishment of a pulmonary nodule clinic to provide 
expertise and continuity in the evaluation of pulmonary nodules. 3. The establishment 
of a lung cancer CT screening program, 4. Evolution of the tumor board from a once 
a month meeting, reviewing an average of 3.1 patients retrospectively and an average 
attendance of 3.6 attendees to currently meeting weekly, prospectively reviewing an 
average of 8.6 cases per meeting (>90% lung cancer) and an average attendance of 9.3 
attendees including thoracic surgery, medical and radiation oncology, pathology, social 
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P2.01-001 Dendritic Cells: Cytokine-Induced Killer Cells Therapy in Advanced 
Non-Small Cell Lung Cancer: A Case Report of an Aggressive Tumor Relapse 
Francisco Iii M. Heralde1, Maria Teresa A. Barzaga2, Gloria R. Cristal-Luna3, Ana Karina 
De Jesus3, Ramoncito S. Habaluyas4, Victoria C. Idolor5, Jose Luis J. Danguilan6, Nelia 
S. Tan-Liu2 1Biochemistry and Molecular Biology, University of the Philippines - Manila, 
Manila/Philippines, 2Pathology, Lung Center of the Philippines, Quezon/Philippines, 3National 
Kidney and Transplant Institute, Quezon/Philippines, 4Cardiology, Lung Center of the 
Philippines, Quezon/Philippines, 5Anesthesiology, Lung Center of the Philippines, Quezon/
Philippines, 6Thoracic Surgery, Lung Center of the Philippines, Quezon/Philippines
Background: Cancer has been associated with immuno-surveillance dysfunction 
resulting to failure in identification and removal of malignant cells, followed by 
subsequent proliferation. Immune cell therapy aims to restore this immuno-surveillance 
function and manages micro-metastasis. DC/CIK (dendritic cell/cytokine-induced killer 
cells) an immune-based-maintenance therapy for advanced non-small cell lung cancer 
has been reported to improve progression free survival in several studies. Our early 
study suggested limited advantage of autologous DC vaccination in advanced NSCLC, 
hence, we proceeded to evaluate the response of a patient with Stage IV NSCLC to 
DC/CIK. Methods: The patient, 43-year-old nonsmoker male with family history of 
maternal breast cancer signed an informed consent to undergo the cell therapy protocol 
institutionally approved by Ethics Review Board of Lung Center of the Philippines. 
The patient earlier diagnosed with Stage IV NSCLC in November 2013, underwent 
chemotherapy of two cycles of Paclitaxel and Carboplatin and subsequently Erlotinib 
following partial remission. Patient had no severe existing medical condition that affected 
protocol compliance. The patient enrolled in November 17, 2014, and underwent 
hematology clearance, hematopoietic stem cell (HSC) mobilization with GCSF injection 
and leukapheresis. HSC’s recovered from the buffy coat were propagated in-vitro using 
standard procedures to produce dendritic cells and cytokine induced killer cells. Three 
DC/CIK treatments were given at three-week intervals consisting of 25-28x106 DC 
primed with mixed peptide antigens based on personalized circulating tumor cell (CTC) 
RT-PCR profile and 10-20x106 CIK. The blood IFN-Y level, CTC count, RT-PCR profile and 
PET-CT data were obtained. Results: DC/CIK treatment resulted to initial decline in IFN-Y 
levels relative to baseline which recovered in levels on the second and third treatment. 
The CTC count showed reduction in number (i.e., from 229 to 699 and down to one 
cell/ml) while the RT-PCR profile indicated downregulated expression of three tumor 
markers (MUC1, Recoverin and p53), obliteration of one marker (KRT19) and emergence 
of four markers (Brachury, NFYC, S100A14 and MAGE-A3). Meanwhile, the PET-CT 
results indicated significant regression of bilateral pulmonary nodules and masses; 
interval resolution of some hypermetabolic lymph nodes and interval increase in others 
consistent with metastatic lymphadenopathy; osseous metastasis with interval decrease 
in metabolic activity of bone lesions; and occurrence of patchy reticular and ground 
glass opacities in right upper and lower lobe with possible infectious or inflammatory 
nature; and right atrium and pulmonary artery thrombosis. Few days post-PET-CT, 
patient manifested difficulty of breathing, cough and back pain; initially managed for 
pneumonia and pulmonary embolism, but showed progressive deterioration. Repeat CT-
scan imaging of chest with angiography revealed drastic size increase of right lung mass 
relative to previous PET-CT scan; while sample biopsy revealed poorly differentiated 
carcinoma of lung primary. In 28 days post-PET-CT, patient yielded to Acute Respiratory 
Distress secondary to aggressive tumor in right lung of primary origin. Conclusion: DC/
CIK treatment can be a promising immunobiological maintenance therapy for advanced 
NSCLC with recognizable molecular and clinical benefit to patients. Optimization of 
protocol towards anticipative strategies addressing aggressive primary tumor relapse 
may have to be considered in order to realize its complimentary therapeutic potential.
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P2.01-002 Immunotherapy as an Effective Treatment Option in the Metastatic 
NSCLC in Spite of PD-1 or PDL-1 Inhibition and Line of Therapy Jesús Corral, 
Carlos Robles, Miriam Alonso, Maria Dolores Mediano, Maria José Flor, Marta Amérigo, 
Inmaculada Sánchez, María Iglesias University Hospital Virgen Del Rocio, Seville/Spain
Background: Lung cancer is the leading cause of cancer death globally. Important 
survival benefit has been recently obtained with targeted therapies against driver 
mutations. Immunotherapy approach under development will probably represent 
a new standard option of care in pretreated patients: clinical and/or pathological 
prognostic factors will further be needed to select the maximum benefit treated 
population. Methods: We reviewed retrospectively clinical, pathological and efficacy 
data from 28 patients with metastatic NSCLC treated with anti-PD1 (programmed 
cell death 1) and anti-PDL1 (programmed cell death-ligand 1) check-point inhibitors in 
our Institution between 2013 and 2015. Results: 28 metastatic NSCLC patients were 
treated: 2 (7,14%) in first line, 14 (50%) in second line and 12 (40%) patients beyond 
third line. 82% were males, median age was 61 years old, and 71,4% adenocarcinomas. 
Mutation profile was defined as 1 patient (3,5%) EGFR positive and 1 patient ROS-
1 positive (3,5%). PDL-1 resulted positive by immunohistochemistry on 43% of total 
population. 75% of patients received anti-PDL-1 therapy versus 25% anti-PD1 check 
point inhibitors. With a median follow up time of 22 months, overall response rate (ORR) 
was 10,7% and disease control rate (DCR) was 64,3%: no differences were seen by 
assay for targetable mutation detection by using SNaPShot PCR technique on FFPE 
samples. Methods: Method: Multiplexed (SNaPShot) PCR was optimized to amplify 
hotspot regions from 9 targetable genes followed by single base extension reaction 
using fragment analysis on ABI 3500 Sequencer. Gene Mapper software was used for 
analysis Results: The successfully developed mutation profiling assay was divided into 3 
multiplexed reactions, covering 23 actionable genotypes of EGFR, KRAS, BRAF, PIK3CA, 
Her2, AKT1, NRAS, MEK1 andPTEN genes. The assay was standardized and validated on 
20 blood samples, 10 cell lines and 20 FFPE samples expressing good sensitivity and 
specificity for wild type and mutant genotypes. Conclusion: This In house developed 
SNaPShot PCR technology is robust, economical, specific and sensitive to detect 
actionable mutations in FFPE Adeno as well as in Squamous Carcinoma samples. Because 
these variants have differing genetic, biological, and clinical properties, including response 
to treatment, this Bench to Bedside research will lead us to correct classification of lung 
cancer cases and will assure that lung cancer patients receive optimum management. 
Keywords: actionable genotypes, Multiplexing by SNapshot assay
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P1.12-011 Treatment Patterns and Overall Survival for Advanced NSCLC 
Following Platinum-Based Chemotherapy in US Community Oncology Clinical 
Practice Caroline Mckay1, Tom Burke2, Xiting Cao3, Amy Abernethy4, David P. Carbone5 
1Center for Observational & Real World Evidence (Core), Merck & Co., Inc., North Wales/PA/
United States of America, 2Center for Observational & Real World Evidence (Core), Merck & 
Co., Inc., Cokesbury/NJ/United States of America, 3Center for Observational & Real World 
Evidence (Core), Merck & Co., Inc., Cokesbury/United States of America, 4Flatiron Health, 
Inc., New York/NY/United States of America, 5Medical Oncology, The Ohio State University - 
James Thoracic Center, Columbus/OH/United States of America
Background: While clinical guidelines provide clinical decision support for selection 
of agent, combination, and order of administration, there are few studies that provide 
a comprehensive description of contemporary advanced NSCLC treatment patterns 
in patients following platinum therapy over time; there are limited recent US data on 
practice patterns and outcomes for advanced NSCLC patients following chemotherapy. 
The purpose of this study is (1) to describe patient flow from advanced NSCLC 
diagnosis to anti-cancer treatment following completion of a platinum regimen, and 
if EGFR mutation or ALK translocation positive, an appropriate TKI; (2) to describe 
the characteristics of advanced NSCLC patients treated with anti-cancer therapy 
following platinum therapy and, if EGFR mutation or ALK translocation positive, an 
appropriate TKI; to describe anti-cancer treatment patterns following completion of 
platinum therapy and, if EGFR mutation or ALK translocation positive, an appropriate 
TKI. Methods: Retrospective EMR database cohort study using data from a cloud-
based Oncology Electronic Medical Record (EMR) system with 220 cancer clinics, 700 
community-based cancer treatment clinics, 1750 clinicians, and 725,000 active cancer 
patients, representing 17% of incident cases in the United States. The data represents 
lab values and physician notes from both structured and unstructured data. Variables 
of interest include demographic, disease-related, biomarker testing-related, anti-cancer 
treatment. Treatment patterns include regimens by line of therapy, agents and number 
of doses administered or prescribed, and distribution of dosage strengths. Analyses will 
be conducted by histology and EGFR/ALK status (among non-squamous cell carcinoma 
patients). Data will be analyzed descriptively. Overall survival, if data are available, will 
be estimated using a series of Kaplan Meier curves, with median OS (95% confidence 
interval) reported. Results: Approximately 1598 patients with advanced NSCLC initiating 
a line of therapy after completing a platinum regimen and, if EGFR mutation or ALK 
translocation positive, an appropriate TKI between January 1, 2013 and October 31, 
2014 will be followed until April 30, 2015. Preliminary results identified 6536 patients 
with advanced NSCLC; of these, 5048 (77.2%) received any 1L treatment after advanced 
NSCLC diagnosis with 3786 (57.9%) receiving platinum-based chemotherapy as 1L 
treatment. Among the final cohort of patients (n=1598), the majority were men (54.0%) 
initially diagnosed with stage IV disease (68.5%) at age 66. The distribution of histological 
subtypes in the sample included non-squamous (74.4%), squamous (21.0%), and NOS 
(4.6%). Treatment patterns will be described according to histology and biomarker status 
at index date. Patient characteristics and overall survival will be reported by histology, 
biomarker status at index date, and regimen type. Conclusion: Results from this study 
will describe treatment patterns in the second-line setting, prior to the introduction 
of newer therapies, such as anti-PD1/PD-L1 inhibitors and angiogenesis inhibitors. 
Additionally, it will advance current understanding of the specific patterns of 2L care for 
patients being treated with anti-cancer therapy in the real world of community settings.
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range 7-41) considering the advanced stage and the poor prognosis of these heavily 
pretreated patients. All patients had received from 1 to 3 previous chemo lines. Evaluation 
of CTL responses to 5 epitopes of OSE-2101 in 5 patients shows that each patient had a 
CTL response to at least one and up to 5 epitopes. Surprisingly patients with positive HTL 
response (patient 108, 150, 169) achieve the longest OS when compared with negative HTL 
patients (132 and 133). Conclusion: Long OS has been documented in NSCLC patients with 
BM treated with T-specific immunotherapy following RT and 1 to 3 previous chemo lines. 
Keywords: Non-small-cell lung cancer, brain metastases, T specific immunotherapy
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P2.01-004 Oncologists’ Comprehension and Beliefs Surrounding Cancer 
Immunotherapy in Advanced NSCLC Tara Herrmann1, Haleh Kadkhoda2, Sheryl 
L. Konrad3, Ramaswamy Govindan4, Daniel Morgensztern5 1Medscape Education, 
Fort Sam Houston/United States of America, 2Medscape Education, New York/United 
States of America, 3Society for Immunotherapy of Cancer, Milwaukee/WI/United States 
of America, 4Washington University School of Medicine, St. Louis/United States of 
America, 5Oncology, Washington Univresity School of Medicine in St. Louis, St. Louis/MO/
United States of America
Background: Advanced NSCLC is now recognized as an immune-modifiable disease, 
and with the approval of the first PD-1 inhibitor, immune checkpoint inhibitors represent 
a new standard of care for patients with previously treated squamous cell lung 
cancer. The objective of this study was to evaluate oncologists’ familiarity with cancer 
immunotherapy in the context of advanced NSCLC and the impact of an educational 
curriculum on narrowing gaps in clinical practices. Methods: An expert panel of 
oncologists identified educational gaps in the area of cancer immunotherapy. A series 
of 9 CME online activities were developed, 2 of which centered on advanced NSCLC and 
are the focus of this study. Interactivity questions allowed learners to self-report their 
familiarity with immunotherapy concepts in the management of advanced NSCLC, while 
case vignette and knowledge-based questions were constructed around evidence-based 
medicine. Confidentiality of survey respondents was maintained and responses were de-
identified and aggregated prior to all analyses. Results: 1368 oncologists participated 
in the 2 activities on advanced NSCLC. As seen in the table below participation in the 
education activities resulted in numerous improvements in knowledge and competence 
as seen in the table below. Despite improvements, several important gaps remained. 
Only70% of oncologists comprehend that a tumor may increase in size or new lesions 
appear during initial therapy with an immune checkpoint inhibitor. In addition, about half 
of oncologists still had difficulty grasping how immune checkpoints downregulate T cell 
responses. Finally, oncologists still had difficulty identifying the unique side effect profile 
associated with immune checkpoint inhibitors. In addition, 55% of oncologists reported 
they were not comfortable with managing side effects associated with these agents.
Table
% answered 
correctly
% answered 
correctly
Pre-Activity Post-Activity
Comprehension of Basic Immunology
Interaction of TCR with MHC-peptide complex 
and co-stimulatory receptors CD28/CD80 and 
CD86
52% 69%
Which does not represent a role of an immune 
checkpoint in the adaptive immune response: 
CTLA-4 binds to CD28, augmenting T-cell 
activation
50% 57%
Knowledge of Immune System’s Role in Re-
sponse to Cancer
T cell infiltration and decreased risk of recur-
rence 69% 76%
Disease progression on an immune checkpoint 
inhibitor 65% 71%
Efficacy, Safety, Limitations of Immune Check-
point Inhibitors
Limitations PD-L1 as a biomarker 26% 70%
Durability of response 5% 30%
Unique side effect profile 41% 59%
 
Conclusion: The study evaluated oncologists’ familiarity with cancer immunotherapy 
in advanced NSCLC and demonstrated the necessity of developing targeted 
educational interventions for improving the knowledge and practice patterns of 
oncologists. Additional education is needed to continue to improve clinicians’ 
competence in the use of cancer immunotherapies in the management of NSCLC. 
Keywords: Education, NSCLC, Immunotherapy
immunotherapy strategy. ORR, DCR, and median time for treatment (MTT) were analysed 
according to the line of therapy and type of immunotherapy. ORR 0%, DCR 100% and 
MTT 104 days at first line setting; ORR 7,14%, DCR 64,28% and MTT 98 days at second 
line; and finally, ORR 18,18%, DCR 63,63% and MTT 67 days at third line or beyond. Most 
of patients remain on treatment so survival data were not reached. The most common 
grade III-IV adverse events related with treatment were pneumonitis (14,3%), fatigue 
(3,6%), hyperamylasemia (3,6%), hypertransaminasemia (3,6%) and neurologic disorders 
(7%). Conclusion: Our retrospective and local analysis confirmed immunotherapy 
as a safe and effective therapy option with high rate of DCR and longer MTT than 
standard chemotherapy, independently PD-1 or PDL-1 inhibition or line of therapy used. 
Keywords: Immunotherapy, PD-1, PD-L1, line
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P2.01-003 T-Cytotoxic Specific Immunotherapy in NSCLC with Brain 
Metastases NCT00104780 John Nemunaitis1, David Mccune2, F A. Greco3, Francis 
Nugent4, Joe Stephenson5, Dominique Costantini6, Alessandro Sette7, John D. Fikes8 
1Mary Crowley Cancer Research Centers, Dallas/TX/United States of America, 2Madigan 
Army Medical Center, Tacoma/WA/United States of America, 3Sarah Cannon Cancer Center 
and Research Institute, Tennessee Oncology, Nashville/United States of America, 4New York 
Hematology/Oncology, Albany/NY/United States of America, 5Greenville Health System, 
Greenville/SC/United States of America, 6Ose Pharma, Paris/France, 7La Jolla Institute of 
Allergy and Immunology, La Jolla/CA/United States of America, 8Former Epimune Inc, San 
Diego/CA/United States of America
Background: Brain metastases (BM) come with poor prognosis (median survival 
3 to 6 months) and data are lacking as patients are often excluded from clinical 
trials. Methods: We present the results of a subgroup of NSCLC patients with BM treated 
with OSE-2101 (T-cytotoxic specific immunotherapy combining 9 epitopes targeting 5 
tumor associated antigens and 1 pan-DR epitope) during a phase IIb study of OSE-2101 
(1 injection per 3 week for 6 injections followed by 1 injection every 2 to 3 months) in 
advanced stage IIIB and IV NSCLC (Barve et al. 2008. J Clin Oncol 26:4418-4425). Patients 
were eligible whatever the number of prior chemotherapy (chemo) lines (65.5% entering 
3rd line) and patients with stable BM for 2 months could be included. Six out of 64 treated 
patients had BM prior to inclusion and are reviewed. Results:
Table 1: NSCLC patients included with BM
Patient 108 150 169 132 133 135
Gender F M M M M M
Ethnic 
origin CAU CAU CAU CAU AA CAU
Age 
(years) 46 61 58 79 46 57
ECOG 
perfor-
mance 
status
1 1 1 1 1 1
Previous 
treatment
RT 30 Gy 
Chemo 2 
lines
WBRT 
30 Gy 
Chemo 2 
lines
RT 30 Gy 
Chemo 2 
lines
WBRT 
30 Gy 
Chemo 3 
lines
RT 30 Gy 
Chemo 1 
line
WBRT 
30 Gy 
Chemo 3 
lines
 
AA: African-American, CAU: Caucasian, Chemo: chemotherapy, 
F: female, Gy: Gray, M: male, RT: radiotherapy, WBRT: whole brain radiotherapy
 
Table 2: Response to therapy
Patient 108 150 169 132 133 135
OS 30.16 mo 41 mo* 16.5 mo 9.6 mo 11 mo 7 mo**
Time 
without 
progres-
sion
11.57 mo 24.39 mo 11.9 mo 4.53 mo 6.2 mo 2 mo*2
CTL 
response 
(positive 
epitopes 
out of 5 
tested)
3 2 5 2 1 Not tested
HTL 
response + + + - -
Not 
tested
 
* Patient still alive at the time of the last follow up, ** treatment stopped after 2 injections 
for progressive disease. CTL: cytotoxic T lymphocytes, HTL: helper T lymphocytes, mo: 
months, OS: Overall survival, The 6 BM patients present long survival (median 13 mo, 
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P2.01-007 Prognostic Factors including EGFR Status in Advanced Lung 
Adenocarcinoma Patients Shunsaku Hayai, Hiroyuki Taniguchi, Yasuhiro Kondoh, 
Tomoki Kimura, Kensuke Kataoka, Toshiaki Matsuda, Toshiki Yokoyama Respiratory 
Medicine and Allergy, Tosei General Hospital, Seto, Achi/Japan
Background: Disease stage and performance status (PS) are the most widely 
accepted prognostic factors of non-small cell lung carcinoma. Several other features 
such as sex, age, histology, and health related quality of life (HRQOL) have also been 
reported as prognostic factors. Adenocarcinoma, especially EGFR mutation status, 
influences therapeutic strategy and prognosis. However, there have been few studies 
evaluating prognostic factors including activating EGFR mutation status focused on 
lung adenocarcinoma. This study aimed to clarify prognostic factors including EGFR 
status in advanced lung adenocarcinoma. Methods: From April 2010 to December 
2014, patients diagnosed with lung adenocarcinoma were identified retrospectively. 
Stage ⅢB, StageⅣ and recurrent post-operative patients were included. A total of 95 
patients with adenocarcinoma who was measured EGFR mutation status and completed 
the overall health related quality of life (HRQOL) item before receiving initial cytotoxic 
chemotherapy were included in the analysis. We evaluated HRQOL using EORTC QOL-C30 
and LC-13 (European Organisation for the Research and Treatment of Cancer Quality 
of Life Questionnaire). The activating EGFR mutations consist of a deletion in exon 
19 and a point mutation involving the replacement of leucine with arginine at codon 
858 (L858R) in exon 21. EGFR mutation status, HRQOL scales, PS, age, sex, stage, 
data on Charlson comorbidity index, pulmonary function testing, and serum levels of 
white blood cells, haemoglobin, fibrinogen, calcium, alkaline phosphatases, lactate 
dehydrogenase were included in univariate and multivariate Cox proportional hazard 
analyses. Results: The median age was 67 years. Sixty one patients were men. Five 
patients had stage ⅢB , 76 had stage Ⅳand 14 were recurrent post-operative cases. 
Thirty two patients had activating EGFR mutation. Median survival time was 556 days. 
Global health status, Physical functioning, Role functioning, Social functioning, Fatigue 
scales of EORTC QOL-C30, Coughing scales of LC-13, EGFR mutation status, PS, 
Stage and serum levels of white blood cells, fibrinogen and albumin were associated 
with poor prognosis in univariate analyses. On multivariate analysis, Role functioning 
(HR: 0.988, 95% CI: 0.979-0.997), activating EGFR mutation (HR: 2.621, 95% CI: 
1.401-4.906), female sex (HR: 2.158, 95% CI: 1.118-4.163) and stage (HR: 0.213, 
95% CI: 0.090-0.501) were significantly predictors of survival. Conclusion: EGFR 
mutation status, Role functioning, sex and stage are significant and independent 
prognostic factors for survival in patients with advanced lung adenocarcinoma. 
Keywords: advanced lung adenocarcinoma, EGFR mutation, QOL, Prognostic factors
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P2.01-008 Efficacy and Tolerability Analysis of Icotinib in EGFR Mutation-
Positive and Unknown Advanced NSCLC Patients from Eastern Coastal China 
Chuantao Zhang, Xiaomei Xu, Xiaofei Wang, Helei Hou, Chun Yan, Wenjun Yu, Airong Tan, 
Congmin Liu, Xiaofeng Cheng, Zijun Yu, Junshuai Liu, Xin Liu, Xiaochun Zhang Medical 
Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao/China
Background: The phase III clinical study (ICOGEN) showed that Icotinib has a similar 
efficacy and tolerability in Asian patients with advanced non-small cell lung cancer 
(NSCLC) compared with Gefitinib. This retrospective study aims to evaluate the 
efficacy and tolerability of the EGFR-TKI Icotinib in first-month effective (unknown EGFR 
mutation type) and EGFR mutation positive (exon 19 deletion or exon 21 L858R point 
mutation) advanced non-small-cell lung cancer patients group from Eastern Coastal 
China. Methods: In this retrospective, observational, and multicentric study, 342 
Eastern Coastal Chinese patients from 5 centers in China with histologically confirmed 
stage IIIB/IV non-small-cell lung cancer were treated in Qingdao, China. The patients with 
performance status from 0 to 3 wrote informed consent, and then received the standard 
dose of Icotinib (125 mg three times daily) until disease progression or unacceptable 
toxicity between Aug, 2012 and Dec, 2013. The patients were divided into EGFR mutation 
positive group and First-month effective group. First-month effective group refers to 
those patients whose tissue sample was difficult to obtain for EGFR measure and were 
responsive to Icotinib for one month trial. The primary outcome was progression-free 
survival among patients who received at least first dose of study treatment and the 
patients are still in follow-up. Results: The disease control rate (DCR) at 4th month was 
81.6% in first-month effective group (n=170) and 89.41% in EGFR mutation positive group 
(n=174). The median progression-free survival (PFS) is 13.0 months (95% CI 1.0-22.8m) 
in first-month effective group (n=170) and 13.9 months (95% CI 1.8-24.6m) in EGFR 
mutation positive group (n=174), respectively (P>0.05). The 1-year survival rate of overall 
patients is 65.5%, 54.70% in these groups. It is impressive that PFS from first-month 
effective group is similar with from EGFR mutation positive group. The characteristics of 
non-smoker, female gender, performance status 0 or 1 are associated with a significantly 
better prognosis in terms of disease control rate.The median overall survival (OS) was 
not reached in EGFR mutation positive patients and the first-month effective group 
patients. The most common treatment-related adverse events are rash (n=154[45.0%]), 
diarrhea (n=78[22.8%]) and increase in AST and ALT (n=61[18.12%]). Most of the 
drug-related adverse events are mild (grade I or II) and reversible with no grade IV 
toxicity. Conclusion: Icotinib is effective and well tolerated in advanced NSCLC patients. For 
those patients with unknown EGFR mutation status, Icotinib first-month effective regimen 
may be an optical treatment rather than standard first-line chemotherapy in the future. 
Keywords: EGFR, icotinib, non-small cell lung cancer
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P2.01-005 Relationship between Icotinib Exposure and Clinical Outcome in 
Chinese ANSCLC Jun Ni1, Li Zhang2 1Peking Union Medical College Hosptial, Peking 
Union Medical College&Chinese Academy of Medical Sciences, Department of Respiratory 
Medicine, Beijing/China, 2Department of Respiratory Medicine, Peking Union Medical College 
Hosptial, Peking Union Medical College&Chinese Academy of Medical Sciences, Beijing/
China
Background: The icotinib hydrochloride tablets (Conmana) is a novel orally administered 
EGFR-TKI agent, which is the first homegrown anticancer drug designed, synthesizedand 
screened by Betapharma (Zhejiang, China) . The preclinical animal experiments showed 
that the agent had an anticancer activity in vitro and in vivo whose mechanism is that 
icotinib can inhibit EGFR activity specifically and competitively through binding to 
the tyrosine of the EGFR. A head-to-head Phase III clinical trial (ICOGEN) comparing 
the roles of icotinib and gefitinib in treating NSCLC in China has suggested that 
icotinib has similar (and even better) efficacy with gefitinib in treating Chinese NSCLC 
patients, with much better safety profiles; furthermore, it is superior to gefitinib in 
terms of treatment cost. Recently, a retrospective study demostrated that icotinib 
is active in the treatment of patients with NSCLC both in first or second/third line. 
Up to date, Icotinib has completed phase I、 II and III trials, Pharmacokinetic study in 
Phase I clinical trial data displayde that non-linear character with saturated absorption 
and first-order elimination. But whether the exposure of icotinib would influence the 
therapeutic effects is cofused us.So Beta Pharma (China) and Peking Union Medical 
College Hospital (PUMCH) jointly conducted this single-center open-label Phase I clinical 
trial, from August 2007 to April 2009, to explore the relationship between icotinib 
exposure and clinical outcomes of a single dose or administration for 31 consecutive 
days among Chinese NSCLC patients. In this article, by analysing the clinical efficacies 
and pharmacokinetic characteristics of iconitib in 30 subjects, we tried to elucidate the 
relationship between the iconitib exposure and therapeutic effects. Methods: In this 
single-center open-label phase I clinical trial, a dose-escalation method was applied until 
disease progression or unacceptable toxicities. Different doses of icotinib were orally 
administered for 31 consecutive days in different groups until disease progression or 
unacceptable toxicities. Blood samples were collected in the first treatment cycle (day 
1 - day 28) for the pharmacokinetic analysis. Tumor responses were assessed by using 
the Response Evaluation Criteria in Solid Tumors(RECIST). The plasma concentrations 
of icotinib were assessed by liquid chromatography–mass spectrometry (LC-MS). 
Results: Univariate analysis showed that the time to maximum (Tmax) after a single dose 
of icotinib was significantly correlated with the overall survival (OS) (Spearman correlation 
coefficient=0.441, P=0.021). Patients with higher Clast were independently associated 
with PFS (p=0.012). Multivariate analysis showed that the AUC0-last and AUC0-∞ after 
a single dose of icotinib were significantly correlated with OS (P=0.037, P=0.042, 
respectively). Stratification of these subjects according to smoking status indicated 
significant correlation between OS and AUC0-last (Spearman correlation coefficient 
= -0.709, P=0.015). Conclusion: Iconitib is a novel EGFR TKI developed by Chinese 
scientists. For advanced NSCLC patients who have failed prior treatment(s), the exposure 
of a single dose of iconitib was significantly correlated with the treatment efficacy. This 
finding may provide a simple and feasible clinical indicator for predicting the survivals. 
Keywords: icotinib hydrochloride, non-small cell lung cancer, pharmacokinetics, clinical 
outcomes
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P2.01-006 Continuing EGFR-TKI in Combination with Regional Chemotherapy 
Beyond RECIST PD for Patients with Advanced EGFR(+) Non-Small Cell Lung 
Cancer Jie Zhang, Huiwei Qi, Sen Jiang, Juan H. Ni, Caicun Zhou Shanghai Pulmonary 
Hospital, Shanghai/China
Background: Local therapy showed promising results for the patient who had an oligo-
metastasis after acquired resistance of epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs).Our study is to evaluate the efficacy and safety of continuing 
EGFR-TKI treatment in combination with regional chemotherapy beyond RECIST 
progression disease (PD) of EGFR-TKI in advanced patients with EGFR mutation-positive 
NSCLC. Methods: Advanced NSCLC patients with EGFR mutation who got a locally 
progressed in central lung lesion after the treatment of EGFR-TKI were included.Patients 
received EGFR-TKI continually in combination with super-selectedsystemicarterial 
infusionwith docetaxel (75 mg/m2) every 21 days until disease progression again or 
unacceptable side effect.Response to treatment, progression-free survival (PFS) 1 
(time to RECIST PD), PFS 2(time to PD if EGFR-TKI was extended beyond RECIST PD) 
andtreatment-related adverse effects (AEs)were analyzed. Patient-reported outcomes 
were evaluated inall patients who had completed a baselineassessment and at least 
one post-baseline assessment based on the QLQ-LC13 scales. Results: A total of 6 
patientswere recruited. Patients had the median age of 54.17 years (range, 40-68 
years).Two patients achieved partial responses and four had stable disease. Median 
PFS1was 11.70±8.97 months. Median PFS2 was 5.36±1.47 months.There was one 
death (none treatment related). OS data are immature. No unexpected side effects 
were found in our study.Patients reported significantly greater reductions from 
baseline in the symptoms of cough, hemoptysis, chest pain and dyspnea (P<0.05 
for all comparisons). Conclusion: Continuing EGFR-TKI in combination with super-
selected systemic arterial infusion chemotherapybeyond progression for advanced 
NSCLC patients with EGFR mutation is feasible and warrent further investigation. 
Keywords: regional chemotherapy, EGFR positive mutation, EGFR-TKI, non-small cell 
lung cancer
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Table 1: The clinic-pathologic characteristics
VARIABLES NUMBER %
Patients 40 100
Gender Male Female 19 21 47.5 52.5
Age (years) Median (range) 62 (40-85)
Race European Others 38 2 95 5
Smoking Yes No Former smokers 9 22 9 22.5 55 22.5
Packs-year Median (range) 35.5 (5-185)
PS 0 1 >2 14 22 4 35 55 10
Pathology diagnosis Adenocarcinoma Squamous 
Others 37 2 1 82.5 5 2.5
Stage IIIB IV 2 38 5 95
Number of prior chemotherapies 0 1-2 >2 17 20 3 42.5 50 7.5
TKI Erlotinib Gefitinib Afatinib 30 8 2 75 20 5
 
Conclusion: The ERR to TKI could be a predictive factor of PFS and OS in 
NSCLC with activating EGFR mutation. Patients with SD at the first evaluation 
should be followed closely because of the risk of early progression. 
Keywords: TKI, NSCLC, EGFR mutation, Early Radiographic Response.
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P2.01-011 Relationship between EGFR Mutation Status and Response to 
Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell 
Lung Cancer Vinicius Ernani, Monica S. Chatwal, Mukesh Kumar, Chao Zhang, 
Zhengjia Chen, Taofeek K. Owonikoko, Suresh S. Ramalingam Emory University, Atlanta/
GA/United States of America
Background: The purpose of this study was to investigate whether outcomes with 
various chemotherapy regimens were affected by the specific epidermal growth 
factor receptor (EGFR) mutations in patients with stage IV non-small cell lung cancer 
(NSCLC). Methods: We retrospectively analyzed the association between the different 
EGFR mutations (exon 19 deletion, exon 21, and 18 mutations) and their response to 
chemotherapy. A total of 17 patients with stage IV NSCLC treated at Winship Cancer 
Institute of Emory University between January 2007 and February 2015 who received 
chemotherapy were investigated retrospectively, and their clinical date were assessed 
according to EFGR mutation. Results: 14 (82.4%) females and 3 (17.6%) males were 
identified harboring EGFR mutations. Median age at the time of diagnosis was 66 years 
(SD 14.08). 12 patients (70.6%) were never smokers, and 5 (29.4%) were former or 
current smokers. EGFR exon 19 deletion was present in 7 patients (41.2%), exon 21 
mutation in 8 (47.1%), and exon 18 in 2 (11.8%). 15 (88.2%) received chemotherapy, and 
11 (64.7%) received pemetrexed-based treatment. Four patients had partial response (PR) 
as the best response to pemetrexed-based chemotherapy, and all of them harbored exon 
21 mutation. Among patients that received other types of chemotherapies (paclitaxel, 
gemcitabine, navelbine and platinum), 6 with exon 21 mutation, and 2 with exon 19 deletion 
experienced PR. Progression-free survival (PFS) was not significantly different among 
the groups of mutation (p=0.3645) that received paclitaxel, gemcitabine, navelbine and 
platinum as chemotherapies, and PFS was also not different for pemetrexed-based regimen 
(p=0.4569). Conclusion: We did not find differential sensitivity to various chemotherapy 
agents based on mutation type in advanced NSCLC patients harboring an EGFR mutation. 
Keywords: stage IV, NSCLC, EGFR mutation, Chemotherapy response
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P2.01-012 Clinical Implications of Isolated Bone Failure without Systemic 
Disease Progression During EGFR-TKI Treatment Ji An Hwang1, Eun Young Kim1, 
Chang-Min Choi2, Dae Ho Lee3, Sang-We Kim3, Jung-Shin Lee3, Woo Sung Kim2, Joon 
Seon Song4, Jae Cheol Lee3 1Department of Pulmonology, Severance Hospital, Yonsei 
University College of Medicine, Seoul/Korea, 2Department of Pulmonary and Critical 
Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul/
Korea,3Department of Oncology, Asan Medical Center, University of Ulsan College of 
Medicine, Seoul/Korea, 4Department of Pathology, Asan Medical Center, University of Ulsan 
College of Medicine, Seoul/Korea
Background: Bone metastasis and skeletal-related events (SREs) such as pathologic 
fracture and spinal cord compression are common in advanced lung cancer. This study 
was aimed to investigate the characteristics of disease progression focused on SREs 
during EGFR-TKI treatment. Methods: We retrospectively reviewed the medical records 
of 3,085 Korean patients with advanced non-small cell lung cancer who were treated with 
gefitinib or erlotinib between 2004 and 2014. SRE associated with aggravation of bone 
metastasis was termed ‘bone failure (BF)’. BFs were classified into 2 categories according 
to the presence of accompanying disease progression of preexisting cancer lesions in 
extra-skeletal organs; isolated bone failure (IBF) versus non-IBF. Results: The incidence 
of SREs during EGFR-TKI treatment was 4.7% (146/3085). Among them, 60 patients 
experienced IBF without aggravation of disease in extra-skeletal organs. IBF was more 
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P2.01-009 EGFR Mutation and Brain Metastasis in Patients with Non Small 
Cell Lung Cancer Eun Kyung Cho, Min Young Baek, Hee Kyung Ahn, Shin Myung 
Kang, Inkeun Park, Young Saing Kim, Junshik Hong, Sun Jin Sym, Jinny Park, Jae Hoon 
Lee, Dong Bok Shin Hematology and Oncology, Department of Internal Medicine, Gachon 
University Gil Medical Center, Incheon/Korea
Background: It has been demonstrated that lung cancer is the most common 
cause of brain metastases(BM). This study was designed to analyse the association 
of timing and survival of BM according to histology and epidermal growth factor 
receptor (EGFR) mutation status in patients with metastatic nonsmall cell lung cancer 
(NSLCL). Methods: We retrospectively analysed the medical records of 268 patients 
with NSCLC in single center in Incheon, Korea who were tested for EGFR mutation analysis 
from January 2010 to August 2013. We analysed the cumulative incidence of BM regard 
to EGFR mutation status, the time from the diagnosis to the development of BM, the 
time from BM to death and median survival. Survival was estimated by the Kaplan-Meier 
method and compared with the log-rank test. Results: Out of 268 patients, 74 (28%) 
had BM, 54(73%) patients already at the time of diagnosis. Synchronous BM was more 
frequent in patient with EGFR mutation than WT EGFR patient (79% vs. 69%). But patients 
with metachronous BM, time to BM diagnosis was not significantly different according 
to EGFR status. (p=0.298) Among the 67 patients with BM, 25(37%) had mutations in 
EGFR, including 13 exon 19 deletions and 12 L858R mutations and 40 had WT (60%). The 
time from diagnosis of first brain metastases to death(BM-OS) was significantly longer 
in patient with EGFR mutation than WT (22.28 vs. 7.55 month, p<0.005). The BM-OS in 
EGFR mutated patients with synchronous BM was longer than in EGFR WT patients (25.42 
vs. 8.86 month, p<0.005). But the BM-OS in EGFR mutated patients with metachronous 
BM was not significant different from WT EGFR patients. (p=0.16). Conclusion: NSCLC 
patients with EGFR mutations were more prevalent with synchronous BM than those with 
EGFR WT patients. EGFR mutation was associated with significantly longer survival from 
BM diagnosis, especially in those with synchronous BM.
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P2.01-010 Early Radiographic Response to TKI in Non Small Cell Lung Cancer 
with EGFR Mutations Carmen Salvador Coloma, Óscar Niño Gómez, Encarnación 
Reche Santos, Dilara Akhoundova, José Gómez Codina, Sarai Palanca, Joaquin 
Montalar, Óscar Juan Vidal Medical Oncology, Hospital Universitari I Politècnic La Fe, 
Valencia/Spain
Background: EGFR mutations have become an important target to choose a treatment 
for non-small cell lung cancer (NSCLC) patients. The response to chemotherapy is 
evaluated after the patient completes the second-third course of treatment. The response 
to tyrosine Kinase Inhibitor (TKI) could be observed in few days, the time for response 
evaluation is not well-defined. Methods: From January 2009 to November 2014, EGFR 
mutation status was analysed in 360 NSCLC patients’ samples. 55 patients (15,3%) were 
EGFR mutation positive. Among the 55 patients, 40 patients who were stage IIIB-IV and 
had received treatment with either gefitinib 250 mg, erlotinib 150 mg or afatinib 40 mg 
once daily were included in this analysis. The principal aim was to correlate the early 
radiological response (ERR) to TKI by computed tomography (TC) with progressionfree 
survival (PFS) and overall survival (OS) in NSCLC patients with EGFR mutations and stage 
IIIB-IV disease. Secondary objectives were to correlate the TKI response with different 
EGFR mutations and to evaluate the safety and efficacy of TKI treatment. The PFS and 
OS were estimated by the Kaplan–Meier method with (SPSSv.19). The logrank test was 
used to assess significant differences betweengroups (p<0.05). Results: The clinic-
pathologic characteristics of the 40 eligible patients are listed in table 1. The EGFR 
mutations identified were mainly exon 19 deletions (12 patients) and L858R point 
mutations (16 patients). Twentysix patients (65%) had ERR. Four patients with a partial 
response (PR) on early CT achieved a complete response (CR). The median followup time 
was 17 months (range 2-66 months). Among the 26 patients with ERR the median PFS 
was 11.8 months. The median PFS for patients with stable disease (SD) and progressive 
disease (PD) was 7.5 months. The overall logrank test for PFS, when comparing the 
groups of patients (ERR vs SD and PD) showed a significant difference (p<0.034). For 
patients with ERR the median OS was 20.1 months. The median OS for patients with SD 
and PD was 11.9 months. The overall logrank test for OS, when comparing the groups 
showed a significant difference (p<0.017).
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advanced NSCLC, EGFR-TKI after first-line chemotherapy may improve survival than 
frontline EGFR-TKI. These findings need to be validated in further randomized trials. 
Keywords: EGFR mutation, EGFR-TKI, chemotherapy, NSCLC
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P2.01-015 The Management of Brain Metastases in Patients with EGFR 
Mutated Advanced Non-Small Cell Lung Cancer Noelle O’Rourke1, Christine M.N. 
Gray2, Aishah Coyte3, Carolyn Featherstone2 1Clinical Oncology, Beatson Cancer Centre, 
Glasgow/United Kingdom, 2Beatson Cancer Centre, Glasgow/United Kingdom, 3Glasgow 
Royal Infirmary, Glasgow/United Kingdom
Background: Brain metastases (BM) are common in non-small cell lung cancer 
(NSCLC). They are often associated with significant impairment of quality of life and a 
poor prognosis. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
have proven superior to chemotherapy in patients with advanced NSCLC that harbour 
an EGFR mutation. They are now standard of care as first line treatment. Many studies, 
however, have excluded patients with BM. Therefore the best treatment modality for 
these patients remains unknown. Different treatment options include: surgery, whole 
brain radiotherapy (WBRT), radiosurgery, chemotherapy and TKIs. This report looks at 
the outcomes of patients with EGFR mutated lung cancer and BM who have undergone 
different treatment modalities. Methods: The West of Scotland Network for Lung Cancer 
supports over 2,000 lung cancer patients per year. We collected data on patients 
diagnosed with EGFR mutated lung cancer between 2012 and 2014. Patients had to 
have radiological evidence of BM either at time of diagnosis or subsequently. Patient 
demographics were recorded alongside response to different treatment modalities. 
Outcomes included progression free survival and overall survival. Results: Between 
2012 and 2014, 117 patients were diagnosed with EGFR mutated lung cancer. Eleven 
patients had confirmed BM: 10 women, 1 man, ages 48-83 years (median 62). Nine 
patients had BM at presentation, one developed BM while on erlotinib and another had 
BM on relapse post lobectomy. The median overall survival was 28 weeks (range 10-96). 
Three patients remain alive at 55, 64 and 139 weeks post diagnosis. Three patients 
were treated with erlotinib alone. Two remain alive 64 and 55 weeks from diagnosis. 
The first has controlled intra and extra cranial disease, whilst the other had extracranial 
progression at 49 weeks. The third patient only survived 22 weeks. Three patients had 
WBRT, two with erlotinib. Overall survival was 19 weeks without erlotinib and 34 and 42 
weeks with erlotinib. A separate patient developed BM while on erlotinib and underwent 
WBRT. She survived a further 13 weeks from diagnosis of BM and had an overall survival 
of 96 weeks. One patient achieved stable extracranial disease for 81 weeks with 
erlotinib. At 16 weeks, however, there was progression of an isolated BM. She underwent 
radiosurgery with a single 20Gy fraction and on subsequent scans has stable intracranial 
disease 67 weeks post radiosurgery. She remains alive 139 weeks post diagnosis. 
Finally, two patients received no active treatment and died at 10 and 18 weeks post 
diagnosis. Conclusion: There is currently little trial data to guide our treatment decisions 
in patients with EGFR mutated lung cancer and BM. In our group only 9% of patients 
with EGFR mutated NSCLC had BM. They underwent a variety of treatment modalities, 
however, numbers are too small to draw firm conclusions. Without treatment, or with 
WBRT alone, survival is similar to patients with advanced non EGFR mutated NSCLC. The 
use of a TKI either with or without radiotherapy appears to have a prolonged survival and 
is probably the treatment of choice. Of note, no patient in this group had a change in TKI. 
Keywords: EGFR mutation, brain metastases, Tyrosine kinase inhibitors, non small cell 
lung cancer
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P2.01-016 BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the 
Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations 
Victoria L. Wilde, Don X. Zhang, Jirong Peng, Michael N. Greco, Michael A. Green, 
Michael J. Costanzo Research & Development, Beta Pharma Usa, Inc., Princeton/NJ/United 
States of America
Background: First generation EGFR TKIs, erlotinib, gefitinib and icotinib, have shown 
excellent clinical efficacy in non-small-cell lung cancer (NSCLC) patients with activating 
EGFR mutations. However, patients eventually progress due to acquired resistance in 
the form of a T790M point mutation. This mutation occurs in about 50-60% of EGFR TKI 
treated patients. Second generation, irreversible EGFR TKIs, afatinib and dacomitinib, 
express even higher kinase potency in the activating mutation as well as potency 
against the acquired resistance mutation. Clinical efficacy of these TKIs is reduced 
due to the dose limiting toxicities of the drugs, attributed to wild type EGFR potency of 
the compounds. In order to improve clinical efficacy against the activating and double 
mutant EGFR tumor cells, it is important to build in selectivity against wild type EGFR to 
avoid dose-limiting toxicities. Here, we present BPI-7701, a novel EGFR inhibitor with high 
potency against the activating mutant EGFR and the T790M resistance mutation with 
good selectivity over wild type EGFR. Methods: BPI-7701 was evaluated in biochemical 
and in vitro assays against mutant EGFR (L858R, del ex19, del ex19/T790M) and WT 
EGFR.In vivo anti-tumor activity was evaluated in xenografts of HCC827 (del ex19) and 
H1975 (del ex19/T790M) NSCLC cells. Results: Biochemical assays showed that BPI-
7701 inhibited del ex19 and L858R mutant EGFR, as well as the T790M resistance 
mutation of EGFR at IC50 values lower than that of WT EGFR, showing an ~100-fold 
difference in activity. BPI-7701 showed growth inhibition of PC-9 (del ex19), HCC827 
(L858R) and H1975 (del ex19/T790M) cells in vitro, with IC50values of 11-160 nM. BPI-
7701 showed an IC50 value of 1.25 µM against A431, wild type EGFR epithelial cells. In 
vivo, BPI-7701 showed greater than 90% inhibition of pEGFR at tested doses as low as 
6.25 mpk in nude mice. pEGFR inhibition was dose-dependent and was maintained over 
frequent in clinical benefit group (responders and stable ≥ 6 months) than in non-clinical 
benefit group (53.5% vs 13.3%; P < 0.001). Adenocarcinoma histology and clinical benefit 
from EGFR-TKI were independent risk factors for IBF (adenocarcinoma: adjusted hazard 
ratio [HR] 10.283; 95% confidence interval [CI] 1.148 – 92.121; P= 0.037, clinical benefit 
from TKI: adjusted HR 9.463; 95% CI 3.027 – 29.584; P < 0.001). The time from the start 
of EGFR-TKI to the occurrence of SRE was significantly longer in IBF than that in non-IBF 
(9.8 vs 5.2 months; P= 0.054). Moreover, patients with IBF exhibited longer survival time 
from the initiation of TKI (20.1 vs 7.7 months; P = 0.008) and from the occurrence of 
SRE (9.2 vs 1.9 months; P = 0.006). Multivariate analysis showed that IBF was one of 
independent prognostic factors for better survival although the statistical significance 
was marginal (adjusted HR 0.492; 95% CI 0.237 – 1.021; P = 0.057). Conclusion: IBF 
without systemic disease progression frequently occurs in patients with clinical benefits 
from EGFR-TKI treatment and shows the better survival requiring more active treatment. 
Keywords: skeletal-related event, Epidermal growth factor receptor, tyrosine kinase 
inhibitor, non-small cell lung cancer
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P2.01-013 Association of PK/PG with Toxicity of Gefitinib in Patients with 
Advanced NSCLC Takashi Hirose1, Ken-Ichi Fujita2, Sojiro Kusumoto3, Yasunari 
Oki3, Yasunori Murata3, Tomohide Sugiyama3, Hiroo Ishida3, Takao Shirai3, Masanao 
Nakashima3, Toshimitsu Yamaoka2, Kentaro Okuda3, Tohru Ohmori2, Yasutsuna Sasaki2, 
Atsuhisa Tamura1, Ken Ohta1 1Department of Respirology, NHO Tokyo National Hospital, 
Tokyo/Japan, 2Inst Molecular Oncology, Showa University, Tokyo/Japan, 3Division of 
Respiratory & Allergology, Showa University School of Medicine, Tokyo/Japan
Background: Gefitinib is a potent epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) and is a key drug for patients with advanced non-small cell lung 
cancer (NSCLC) harboring EGFR mutation. The orally administered gefitinib showed 
large interindividual variability in its pharmacokinetics. Some phase I studies have 
suggested there is a relationship between gefitinib plasma concentration and skin 
toxicity, diarrhea, and liver toxicity. The aim of this study was to evaluate the association 
of pharmacokinetics or pharmacogenomics with toxicity or effectiveness of gefitinib 
in patients with advanced NSCLC. Methods: The evaluation of pharmacokinetics 
was performed using sample obtained on day 1 at 0, 1, 3, 5, 8, 24 hour and day 8 
and day 15 after start of gefitinib 250mg administration. Plasma concentration of 
gefitinib was analyzed by high-performance liquid chromatography. The genotypes 
of ABCG2, ABCB1, ABCC2, CYP3A4, CYP3A5, CYP2D6 were analyzed by direct 
sequencing. Results: Thirty-five patients with advanced NSCLC (14 men and 21 women; 
median age, 72 years; range, 53 to 90 years) were enrolled. All patients were stage 
IV adenocarcinoma harboring EGFR mutation: 18 had exon 19 deletions, 16 had exon 
21 L858R, and 1 had exon 18 G719A. The overall response rate was 82.9% (95% 
confidence interval 66.4-93.4%). The median survival time was 21.2 months, and the 
median progression-free survival time was 10 months. The common adverse events were 
rash or acne (68%), diarrhea (46%), and liver injury (63%). One patient died of drug 
induced interstitial lung disease (ILD). The median area under the plasma concentration-
time curve of gefitinib estimated from 0 to 24 hour (AUC0-24) was 10.9 (1.5-31.3) µM·h. 
The peak plasma concentrations (Cmax) was achieved 5 hour after dosing, and the 
median was 0.84 (0.38-1.74) µM. There were no statistically significant association of 
pharmacokinetics or pharmacogenomics with response rate, survival, and toxicity, such 
as skin toxicity, diarrhea, liver injury, and ILD of gefitinib. However, one patient died of 
drug induced ILD showed the highest AUC and Cmax. Conclusion: The elevated gefitinib 
exposure could be associated with drug-induced ILD. Further studies of the association 
of pharmacokinetics or pharmacogenomics with toxicity of EGFR-TKI are needed. 
Keywords: gefitinib, pharmacokinetics, pharmacogenomics
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P2.01-014 EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR 
Mutation-Positive Non-Small Cell Lung Cancer Kazumi Nishino1, Madoka 
Kimura2, Takako Inoue2, Junji Uchida1, Toru Kumagai1, Fumio Imamura1 1Department of 
Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka/
Japan, 2Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseses, 
Osaka/Japan
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
are recommended in the first-line setting for patients with EGFR mutation-positive 
non-small cell lung cancer (NSCLC). However, it remains unclear whether frontline 
EGFR TKIs are better strategy than first-line chemotherapy in EGFR-mutant patients. 
Generally, EGFR-TKIs had no significant benefits in overall survival (OS) compared 
with chemotherapy in both first-line and second-line setting. This retrospective study 
compared survival benefits in patients treated with post-TKI chemotherapy and first-line 
chemotherapy controls. Methods: This retrospective study included 442 EGFR-mutant 
patients in our institute. We examined EGFR gene status from 2007 to 2015. The patients 
treated from 1999 to 2015. The study group contained 173 patients treated with first-
line EGFR-TKI and the control group contained 109 patients who received EGFR-TKI after 
first-line chemotherapy. The overall survival (OS) was assessed. Results: There was no 
significant difference between first-line chemotherapy and EGFR-TKI in OS for patients 
with mutation-positive NSCLC (median OS; 43 vs. 38 months, P = 1.645). There was 
substantial difference in OS between patients with postoperative recurrence and those 
with III/IV stage disease. Among patients with III/IV stage NSCLC, median OS was 40.8 
months in first-line chemotherapy group, 30.5 months in chemotherapy after frontline 
EGFR-TKI group and 21.1 months in only EGFR-TKI group. Conclusion: In EGFR-mutant 
patients, both EGFR-TKI and chemotherapy improve the survival. Among patients with 
S527Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
 
Conclusion:Our results suggest baseline LMR is a prognostic marker 
for EGFR mutant NSCLC patients receiving fi rst line EGFR-TKIs. 
Keywords: Lymphocye to monocyte ratio, prognostic factor, Non-small-cell lung cancer, 
EGFR mutation
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P2.01-019 Effect of EGFR Mutation Status on Graded Prognostic Assessment 
for Non-Small Cell Lung Cancer and Brain Metastases Yu Yang Soon1, Huili 
Zheng2, Nesaretnam B. Kumarakulasinghe3, Wee Yao Koh1, Cheng Nang Leong1, 
Brandon Pang4, Atasha Asmat5, Ross Soo3, Ivan Tham1 1Radiation Oncology, National 
University Cancer Institute Singapore, Singapore/Singapore, 2Health Promotion 
Board, Singapore/Singapore, 3Medical Oncology, National University Cancer Institute 
Singapore, Singapore/Singapore, 4Pathology, National University Hospital, Singapore/
Singapore, 5Cardiothoracic Surgery, Tan Tock Seng Hospital, Singapore/Singapore
Background: The aim of this study is to refi ne the existing lung cancer graded 
prognostic assessment (GPA) index by analysing a cohort of patients with non-small cell 
lung cancer (NSCLC) tested for epidermal growth factor receptor (EGFR) mutation status 
and newly diagnosed brain metastases. Methods: We used the pathology registries 
of two institutions to identify 259 eligible patients diagnosed with brain metastases 
secondary to NSCLC between 2006 and 2014. We linked the electronic medical records 
of these patients to the National Death Registry. Survival is defi ned as from date of fi rst 
treatment for brain metastases or date of brain metastases diagnosis for patients on best 
supportive care till death. We analysed the prognostic factors signifi cant for survival by 
multivariate Cox regression and recursive partitioning analysis (RPA). Results: Signifi cant 
prognostic factors identifi ed by multivariate Cox regression and RPA were age, Karnofsky 
performance status (KPS), presence of extra-cranial metastases (ECM), number of brain 
metastases (BM) and presence of sensitizing EGFR mutations. Patients who were age 
70 years old and above (Hazard ratio (HR) 1.47, 95% confi dence interval (CI) 1.07-2.01, 
reference (ref) age < 70 years old); with KPS score 70-80 (HR 2.37, 95%CI 1.69-3.34, 
ref KPS 90-100); with KPS score < 70 (HR 4.34, 95%CI 2.90-6.51, ref KPS 90-100); ECM 
present (HR 1.82, 95%CI 1.27-2.62, ref no ECM); having two or more BM (HR 1.40, 95%CI 
1.01-1.95, ref less than two BM) and absence of sensitizing EGFR mutations (HR 1.97, 
95%CI 1.49-2.61, ref sensitizing EGFR mutations present) were poor prognostic factors. 
There was a robust separation of survival curves between GPA score 0-1.0 (median 
survival (MS) 2.1 months), GPA score 1.5-2.0 (MS 6.3 months) and GPA score 2.5-3.0 
(MS 14.1 months). The proposed modifi ed GPA index is shown in below table.
Proposed modifi ed GPA index
Prognostic factors 
/ score 0 0.5 1.0
Age Group ≥70 years old <70 years old -
KPS <70 70-80 90-100
ECM Present - Absent
No. of BM ≥2 0-1
Sensitising EGFR 
mutations Absent - Present
Conclusion: EGFR mutation status is a signifi cant prognostic factor and 
should be considered in the design of lung-cancer GPA index. The proposed 
modifi ed GPA index need to be validated with an independent dataset. 
Keywords: non-small cell lung cancer, EGFR mutation, brain metastases
the course of 24 hours. In mouse xenograft studies, BPI-7701 induced complete tumor 
regression in H1975 (del ex19/T790M) and HCC827 (L858R) NSCLC cell lines after 14-
day repeat dose treatment. In an H1975 xenograft model, complete tumor regression 
occurred after 6 days of BPI-7701 treatment (14-day regimen), with 80% of mice 
remaining tumor-free 35 days after the completion of BPI-7701 dosing. Conclusion: BPI-
7701 inhibits the growth of NSCLC cells with EGFR mutations and T790M resistance 
mutation, both in vitro and in vivo. BPI-7701 may be an excellent option for NSCLC patients 
with activating EGFR mutations. Clinical trials are planned to begin Q2 2016 in Asia. 
Keywords: NSCLC, EGFR, T790M
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P2.01-017 Genetic Variations in the EGFR Gene Predicts Outcome in Advanced 
NSCLC Patients Treated with Erlotinib Anne Winther Larsen1, Peter H. Nissen1, 
Kristine R. Jakobsen1, Christina Demuth1, Boe S. Sorensen1, Peter Meldgaard2
1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus C/
Denmark, 2Department of Oncology, Aarhus University Hospital, Aarhus/Denmark
Background: Genetic variations in the epidermal growth factor receptor (EGFR) gene may 
alter protein expression or function and infl uence response to tyrosine kinase inhibitors. 
This study evaluates the role of genetic polymorphisms in the EGFR gene in advanced 
non-small cell lung cancer (NSCLC) patients treated with erlotinib. EGFR mutation status 
was known for all patients. Methods: Genotypes for -216G>T, -191C>A and 181946C>T 
in the EGFR gene were retrospectively evaluated by DNA sequencing and polymerase 
chain reaction in 354 Caucasian patients with advanced NSCLC. Hundred and seven of 
the patients had a somatic EGFR mutation, and all patients had been treated with erlotinib. 
Genotypes were correlated with clinical characteristics and outcome. A multivariate 
analysis was conducted adjusting for clinical relevant factors, including EGFR mutation 
status, using Cox proportional hazards model. A subgroup analysis was performed based 
on the EGFR mutation status. Results: Patients harboring at least one variant T allele (CT 
or TT) at position 181946 had a signifi cantly longer median progression-free survival (PFS) 
(5.6 versus (vs.) 2.9 months; p =0.032) and overall survival (OS) (8.3 vs. 6.7 months; 
p=0.032) compared to patients with the CC genotype. The result remained signifi cant 
in a multivariate analysis; PFS, adjusted hazard ratio (AHR)=0.73 (95% confi dence 
interval (CI): 0.55-0.98); OS, AHR=0.72 (95%CI: 0.54-0.97). Patients carrying -216GT or 
TT genotypes showed a trend to a better clinical outcome compared to those with the 
GG genotype. The -216GT or TT and 181946CT or TT combined genotypes showed an 
even more pronounced association with clinical outcome compared to patients with the 
-216GG and 181946CC genotype (PFS, AHR=0.66 (95%CI: 0.44-0.98); OS, AHR=0.58 
(95%CI: 0.38-0.87)). A subgroup analysis demonstrated that the association might be 
most relevant in EGFR mutation-positive patients; PFS, AHR=0.27 (95% CI: 0.11-0.68); 
OS, AHR=0.33 (95% CI: 0.13-0.83). Conclusion: A combination of 181946C>T and 
-216G>T polymorphisms in the EGFR gene seems to be a potential predictor of longer PFS 
and OS in advanced NSCLC patients treated with erlotinib; especially in EGFR mutation-
positive patients. A prospective randomized study is wanted to confi rm our data. 
Keywords: EGFR, TKI, genetic polymorphisms, survival
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P2.01-018 Baseline Lymphocyte-Monocyte Ratio Is a Prognostic Marker in 
EGFR Mutant NSCLC Patients Receiving First Line EGFR TKIs Yu-Mu Chen, Meng-
Chih Lin, Wen-Feng Fang, Chien-Hao Lie, Huang-Chih Chang, Chin-Chou Wang Pulmonary 
and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City/
Taiwan
Background: Patients with higher lymphocyte to monocyte ratio (LMR) has shown 
to have favorable prognostic in early stage lung cancer, non-metastatic renal cell 
carcinoma, gastric cancer, colon cancer, pancreatic cancer and breast cancer. 
However, prognostic signifi cance of LMR in patients with advanced stage, epidermal 
growth factor receptor (EGFR) mutant non-small cell lung cancer receiving fi rst line EGFR 
tyrosine kinase inhibitors is not well known. We conducted a retrospective analysis to 
investigate the infl uence of baseline LMR on clinical outcomes including progression free 
survival (PFS) and overall survival (OS) in EGFR mutant NSCLC patients. Methods: This 
retrospective study evaluated 253 patients harboring EGFR mutation received TKIs as 
fi rst line therapy for advanced NSCLC between January 2011 and October 2013. The 
cut- off value determined by Receiver operating characteristic (ROC) curves for LMR was 
3.29. Patients were divided into high and low LMR ratio based on above cut-off level. 
Kaplan–Meier analysis was used for PFS and OS estimation; and the log-rank test was 
utilized to examine the signifi cance of the differences of survival distributions between 
groups. Results: Among 253 patients mean age was 65.2 years, 41% were male, 
medium PFS was 10.3 months, medium OS was 22 months. Low baseline LMR patients 
had shorter PFS (low vs. high: 8.2 vs 11.6m, HR: 1.508, p=0.003), and OS (low vs. high: 
14.3m vs. 32.1m HR: 2.23, p<0.001) 
S528 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Background: Many randomized clinical trials have demonstrated that epidermal growth 
factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard 
chemotherapy either as front-line treatment or as further management of patients 
with EGFR mutation-positive non-small-cell lung cancer (NSCLC). But which subgroup 
of patients with EGFR mutation-positive advanced NSCLC could benefi t more from 
EGFR-TKIs needs to be further explored. In the present study, we attempted to explore 
predictive factors in such cohorts of patients who received gefi tinib by classifi cation and 
regression tree (CART) analysis. Methods: Included in this study were 95 patients with 
EGFR mutation-positive advanced NSCLC who received gefi tinib treatment at the Cancer 
Institute (Hospital) of the Chinese Academy of Medical Sciences between February 2010 
and October 2013. Multivariate analysis of progression-free survival (PFS) was performed 
using recursive partitioning referred to as CART analysis to assess the effect of specifi c 
variables on PFS in subgroups of patients with similar clinical features. Results: The 
median PFS in patients with EGFR mutation-positive advanced NSCLC who received 
gefi tinib treatment was 13.3 months (95% CI 9.4-17.2). CART analysis showed an initial 
split on body mass index (BMI), based on which three terminal subgroups were formed. 
The median PFS in the three subsets ranged from 8.2 months to 15.2 months, in which 
the subgroup with a BMI less than or equal to 20.768Kg/m2 had the longest PFS (15.2 
months). In addition, PFS in EGFR exon 19 mutation group was better than that in other 
mutation site group (10.3 vs. 8.2 months). Conclusion:BMI and exon 19 mutation are 
predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who received 
gefi tinib treatment. Both active EGFR mutation and patient’s own factors could be used 
to predict the therapeutic effi cacy of EGFR-TKIs. 
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P2.01-020 Clinical Differences of EGFR Mutations in Exon 19 and 21 in Clinical 
Course of Non-Small Cell Lung Cancer Patients Tae Won Jang, Maanhong Jung, 
Chul H. Oak, Sung J. Nam Kosin University Medical College, Pusan/Korea
Background: In patients with non -small cell lung cancer (NSCLC), mutations in the
epidermal growth factor receptor (EGFR) have been associated with sensitivity to EGRF-
tyrosin kinase inhibitors (TKIs). However, clinical course of EGFR mutation subtypes are 
still controvertial. The aim of this study was to analyze clinical features between EGFR 
mutation exon 19 and 21, including treatment with EGFR-TKIs Methods: In patients 
with NSCLC, EGFR exon 19 deletion mutations and EGFR L858R point mutations were 
analyzed by DNA sequencing method or pyrosequencing method from paraffi n blocks 
of tissue obtained before treatment. We reviewed clinical characteristics of the patients,
retrospectively. Results: One hundred and sixty seven patients displayed EGFR mutations 
in exon 19 and exon 21 from October 2002 to December 2013. 63.6% (n=100) had 
EGFR 19 deletion, whereas 36.3 % (n=67) had an EGFR L858R mutation. There were no 
differences in sex, smoking, ECOG status, stages, blood chemistry, tumor marker, and 
overall survivals (OS) between two groups. Overall survival was similar in both groups. 
However, OS was longer in non-smoker (p=0.000), female (p=0.007), and age ≥ 65 
(p=0.031) only in 19 deletion group. After treatment with gefi tinib (n=74), erlotinib 
(n=31), and afatinib (n=2), patients with EGFR mutations had a median overall survival of 
47 month. Among the patients treated with gefi tinib or erlotinib, gefi tinib treated patients 
had signifi cantly longer progression free survival (PFS) than erlotinib treated patients in 
EGFR exon 19 deletions (10.3 versus 5.1 months; p=0.002), but not in exon 21 mutation. 
The median PFS of the patients with higher body surface area (BSA, ≥1.5 m2) was worse 
than that of those with lower BSA (3.9 vs. 8.9 month; p=0.063) in exon 21 mutation 
group. Conclusion: There are different clinical course between types of EGFR exon 19 and 
21 mutations. We need confi rmation in a prospective study and have to more elucidation 
of the biological mechanisms of the differences between the two major EGFR mutations. 
Keywords: lung cancer, Prognostic factors, Epidermal growth factor receptor
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P2.01-021 Non-Inferior Progression Free Survival in NSCLC Patients Sensitive 
to EGFR TKI Receiving Low Dose versus Regular Dose of Gefi tinib or Erlotinib 
Hsing-Chun Chen, Shu-Lan Hsu, Kuo-Sheng Fan, Chun-Liang Lai
Buddhist Dalin Tzu Chi Hospital, Chia-Yi/Taiwan
Background: Preclinical data demonstrate that the T790M clone is associated with a 
growth disadvantage in the absence of TKI selection. With selection stress of standard 
dose of TKI, T790M cells may become a dominant population. In a mathematical model, 
high pulse dose combined with continuous low-dose of TKI could delay the emergence 
of resistant clone of T790M. Clinically, some patients use lower dose of EGFR TKI due to 
various reasons such as toxicity. The treatment outcome in terms of PFS in this group 
of patients has not been reported. Whether the PFS would be impaired due to dose 
adjustment or unaffected and even better to support above theory may need further 
clarifi cation. Methods: A retrospective cohort study was conducted to recruit patients 
with advanced NSCLC from 1997/1 to 2014/12 in a regional teaching hospital. Inclusion 
criteria were patients whose tumors were either tested to have sensitizing mutations of 
EGFR using highly sensitive methods or clinically responsive to EGFR TKI using Jackman’s 
criteria. Patients having titrated dose of TKI to two-thirds or less for more than 6 months 
were assigned to low-dose (LD) group. The standard-dose (control) group includes 
patients receiving daily 250 mg of Gefi tinib or 150 mg of Erlotinib during whole course 
of treatment, matched with sex and age to LD group. The primary outcome was PFS. 
Secondary outcome was overall survival (OS). Results: LD group includes 20 patients 
and control group 80 patients. Patients using LD treatment were mostly due to intolerable 
side effects with standard dose (n=18, 90%). The median PFS was 15.4 months in the LD 
group and 9.3 months in control (hazard ratio 0.45, 95% CI of 0.29-0.71; p=0.018). The 
median OS was 31.5 months in LD and 31.4 months in control (hazard ratio 0.99, 95% 
CI 0.49-1.98; p=0.98). In the subgroup of Gefi tinib treatment, the median PFS was 17.9 
months in LD and 8.1 months in control (hazard ratio 0.35, 95% CI 0.19-0.62; p=0.0037). 
In patients receiving Erlotinib, median PFS was 15.3 months in LD and 12.1 months in 
control (hazard ratio 0.67, 95% CI 0.33-1.37; p=0.2652). Median OS was similar in LD and 
control in either subgroup of Gefi tinib or Erlotinib. Conclusion: This study showed that 
lower dose of EGFR-TKI treatment is a non-inferior strategy for patients sensitive to EGFR 
TKI. Better PFS in the LD group of Gefi tinib-treated patients support the theory of delayed 
emergence of resistant clone. Since 150 mg of Erlotinib is at its maximum tolerated 
dose, a dose choice of no more than optimum biologic dose may be needed to gain 
such benefi t as Gefi tinib. Larger-scale studies would be needed to confi rm this fi nding. 
Keywords: gefi tinib, Erlotinib, low dose, optimum biologic dose
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P2.01-022 BMI as Factor Predicting the Effi cacy of Gefi tinib in NSCLC with 
EGFR Mutation Sun Hongyan1, Sun Xiaoteng2, Zhai Xiaoyu3, Guo Jingfeng4, Liu Yutao3, 
Ying Jianming5, Wang Ziping3 1General Internal Department, Ling Nan Hospital, the Third 
Affi liated Hospital, Sun Yat-Sen University,, Guangzhou/China, 2Department of Pathology, 
Rushan County People’S Hospital, Shandong/China, 3Department of Medical Oncology, 
Cancer Institute (Hospital), Chinese Academy of Medical Sciences & Peking Union Medical 
College, Beijing/China, 4Hexian Affi liated Memorial Hospital of Southern Medical University, 
Guangzhou/China, 5Department of Pathology, Cancer Institute (Hospital), Chinese Academy 
of Medical Sciences & Peking Union Medical College, Beijing/China
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of Third Military Medical University, Chongqing/China,11Fujian Cancer Hospital, Fuzhou/
China, 12Third Affiliated Hospital of Third Military Medical University, Chongqing/China
Background: ENSURE study shows that 1st line treatment with erlotinib provides 
longer PFS over gemcitabine/cisplatin (GP) for stage IIIB/IV NSCLC patients with EGFR 
mutations. Cross-over treatments after progression of disease (PD) was allowed in 
ENSURE study. However, post-study treatments might have significant impact on patient 
survival or other clinical benefits, which is insufficiently investigated. This trial in an 
extension of the ENSURE study, intended to evaluate PFS in 2nd line progression after 
cross-over treatments in ENSURE. Methods: Chinese patients who had PD after 1st line 
treatment in ENSURE were enrolled. Enrolled patients received cross-over treatment as 
2nd line treatment after 1st line PD. The primary endpoint was PFS, defined as the time 
of randomization in ENSURE to disease progression or death while on 2nd line treatment. 
For patients who had already progressed after 2nd line therapy prior to entering this 
extension study, relevant information would be collected retrospectively. PFS from 
1st line PD to 2nd line PD was also calculated. The study was approved by IRB and 
all patients signed informed consent. This study was registered in clinicalgrials.gov 
(NCT02000531). We also retrospectively analyzed the time to 2nd line treatment failure 
(TTF) defined as the time from randomization to discontinuation of 2nd line treatment 
for any reason. Results: Forty-five patients (21 from erlotinib arm and 24 from GP arm) 
were enrolled in the final analysis in this ENSURE extension study. Limited recruitment 
was mainly due to later initiation of this study (from January to December of 2014), many 
deaths at the beginning of this study, or unwillingness to sign informed consent by some 
patients. Age, sex, and ECOG at baseline in erlotinib group and GP group were balanced. 
Among 45 enrolled subjects, 33 (73.3%) subjects completed the study. There was no 
significant difference in median PFS from the date of randomization in ENSURE study to 
2nd line PD for both arms 26.3 (95%CI: 19.8 , 34.0 ) months vs 23.4 (95%CI: 17.8, 39.0 
) months, HR=1.26 (95%CI: 0.61, 2.62), p=0.529). For 2nd line cross-over treatment, 
ORR in erlotinib and GP arms was 33.3% (7PR/21) and 66.7% (16PR/24) respectively 
(p=0.0377). In a retrospective analysis of 175 patients from the whole ENSURE study, 
63.2% patients in erlotinib arm (n=87) received 2nd line chemotherapy and 86.4% 
patients in GP arm (n=88) received 2nd line targeted therapy. The median TTF in 
erlotinib and GP arm were 29.4 (95%CI: 24.7, 34.2) and 24.7 (95%CI: 21.9, 28.4) months 
respectively (HR=0.74(95%CI: 0.47, 1.17), p=0.192).The subgroup analysis (mutation 
type, ECOG performance status, gender) for TTF between erlotinib and GP arm showed 
similar trend to the primary analysis. Conclusion: Despite limitations, both median PFS 
(in prospective analysis) and TTF (in retrospective analysis) for erlotinib patients were 
numerically larger than that in GP arm. This first cross-over treatment ENSURE extension 
study further confirms benefits of erlotinib as standard 1st line treatment for EGFR 
mutant NSCLC. It also supports the importance of 1st and 2nd line treatment sequence 
of erlotinib and platinum-based chemotherapy for the treatment of EGFR mutant NSCLC. 
Keywords: cross-over treatment, ENSURE study, EGFR TKI, NSCLC
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P2.01-025 Crizotinib in Advanced ALK-Positive NSCLC - A Retrospective 
Multicenter Study in the Slovak Republic Peter Kasan1, Peter Berzinec2, Lukas 
Plank3, Igor Andrasina4, Robert Godal5, Juraj Mazal6, Andrea Cipkova4, Maria Cerna7, 
Lucia Denkova1, Gabriela Chowaniecova2, Iveta Kuliskova3, Helena Kuzmova2, Marian 
Martak1, Zuzana Pribulova4, Marian Reckova8, Milada Vesela1 
1University Hospital, Bratislava/Slovak Republic, 2Specialised Hospital of St Zoerardus 
Zobor, Nitra/Slovak Republic, 3University Hospital, Martin/Slovak Republic, 4East Slovakian 
Cancer Institute, Kosice/Slovak Republic, 5National Cancer Institute, Bratislava/Slovak 
Republic, 6Faculty Hospital, Banska Bystrica/Slovak Republic, 7Slovak Medical University, 
Bratislava/Slovak Republic, 8Adus Polyclinic, Poprad/Slovak Republic
Background: Crizotinib has been available in Slovakia since October 2012 for the 
treatment of adults with previously treated ALK-positive advanced non-small cell lung 
cancer (NSCLC), based on the therapeutic indication approved by the European Medicines 
Agency. Purpose of this study was to assess the results achieved with crizotinib in 
the treatment of advanced NSCLC in clinical practice in Slovakia. Methods: In this 
multicenter retrospective study, approved by the Ethical Committee of the Specialized 
Hospital of St Zoerardus Zobor, the data of 30 ALK-positive patients were reviewed. FISH 
with break-apart probes was used for the confirmation of ALK rearrangement in all cases. 
MedCalc® was used for the statistical analyses. Results: Between October 2012 and 
August 2014, 20 out of 30 ALK-positive patients were treated with crizotinib. Ten patients 
did not receive crizotinib: five due to on-going first-line chemotherapy, five due to other 
reasons. Characteristics of the treated patients: M/W: 6/14, age (years) median 56, range 
23-77, PS (ECOG/WHO): 0/1/2/3: 1/10/4/5, Histology: 19 patients adenocarcinoma, 1 
NSCLC, NOS. Treatment results: RR was evaluated in 20 patients: PR + CR: 13 (12+1), 
65% (95% CI: 41-85), SD: 3, 15% (95% CI: 3-38), PD: 3, 15% (95% CI: 3-38), NS: 1, 5%, 
DCR: 16, 80% (95% CI: 56-94), PFS: Kaplan-Meier estimate: 13 months (95% CI: 7 -18), 0S 
(with 60% of patients censored): 19 months (95%CI: 12 - NR), PS: significant improvement 
within 2 months (mean dif. –0.95, P=0.0021), toxicities grade 3/4 occurred in 11 of 20 
patients (55%), hematologic: 0, non-hematologic: hepatotoxicity 3/1, pneumonitis: 1/0, 
diarrhea 1/0, nausea: 3/0, vomiting: 1/1, vision disorder: 1/0, peripheral edema: 1/0, 
QT-interval prolongation: 1/0. Crizotinib was permanently discontinued due to toxicity 
in only two patients. Conclusion: Treatment results seen in this retrospective study 
are encouraging and consistent with the published data from the prospective trials. 
Keywords: NSCLC, crizotinib, ALK
Keywords: classification and regression tree (CART), non-small-cell lung cancer 
(NSCLC), EGFR active mutation, body mass index (BMI)
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P2.01-023 Intercalated Therapy with Gemcitabine, Cisplatin and Erlotinib May 
Be Superior to TKI Alone for Patients with Advanced EGFR Mutated NSCLC 
Matjaz Zwitter1, Karmen Stanic1, Mirjana Rajer1, Nina Turnsek Hitij2, Martina Vrankar1, 
Izidor Kern2, Viljem Kovac1 1Institute of Oncology, Ljubljana/Slovenia, 2University Clinic of 
Respiratory and Allergic Diseases Golnik, Golnik/Slovenia
Background: The biological rationale for intercalated therapy in EGFR mutated NSCLC 
is to derive benefit both from cytotoxic and from targeted therapy, avoid their mutual 
antagonism, and prevent tumor repopulation during intervals of cytotoxic treatment. 
After a promising report from a single-arm trial of intercalated treatment (Zwitter et 
al, Radiol Oncol 2014;48:361), we here present a comparison to treatment with TKI 
alone on a similar population of patients. Methods: All patients were treatment-naive 
with metastatic EGFR mutated NSCLC, were in fair general condition and fulfilled the 
standard criteria for platin-based chemotherapy. Patients in the intercalated group 
joined a prospective clinical trial and signed informed consent. Treatment consisted of 
gemcitabine at 1250 mg/m2 on days 1 and 4, cisplatin at 75 mg/m2 on day 2 and 
erlotinib 150 mg on days 5 – 15 of a 3-weekly cycle for 4 to 6 cycles, followed by 
continuous erlotinib as maintenance. Due to reluctance of their physicians to join the 
intercalated trial, patients in the TKI alone group were treated with erlotinib or gefitinib as 
the standard treatment. Results: Regarding demographics and main prognostic factors, 
there was a slight disbalance in favor of the TKI alone group (Table). The intercalated trial 
recruited 38 patients. Treatment was well tolerated, with 6 cases of grade 4 toxicity. 
Complete or partial response was seen in 16 and 17 patients, respectively, for response 
rate of 87%. For 21 patients on TKI alone as standard treatment, precise evaluation of 
response was not feasible. Median time to progression was 24.3 months and 9.6 months 
(p < 0.05), and median survival was 34.9 and 25.8 months for the intercalated and TKI 
alone group, respectively.
TKI alone 21 patients Intercalated schedule 38 patients
Gender, Female/Male 13/8 21/17
Age, median 63 61
Age, range 42 – 70 37 – 74
Performance status, 0 - 1 18 30
Performance status, 2 – 3 3 8
Brain metastases at 
diagnosis 5 13
 
 
Conclusion: In advanced EGFR mutated NSCLC, intercalated schedule appears 
superior to TKI alone. These observations should be confirmed in a randomized trial. 
Keywords: chemotherapy, NSCLC, EGFR, TKI
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P2.01-024 An ENSURE Extension Study to Evaluate 2nd Line Erlotinib and 
Gemcitabine/Cisplatin Cross-Over Treatment for EGFR-Mutant Chinese NSCLC 
Patients Yi-Long Wu1, Lei Chen2, Caicun Zhou3, Shun Lu4, Yunzhong Zhu5, Shukui Qin6, 
Gang Wu7, Ying Cheng8, Baohui Han9, Houjie Liang10, Cheng Huang11, Zhaoyang Zhong12 
1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy 
of Medical Sciences, Guangzhou/China, 2Medical College, Cancer Hospital of Shantou 
University, Shantou/China, 3Department of Medical Oncology, Shanghai Pulmonary Hospital, 
Tongji University; Tongji University Medical School Pulmonary Cancer Institute, Shanghai/
China, 4Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 
Shanghai/China, 5Oncology Department, Beijing Chest Hospital, Beijing/China, 6The 81St 
Hospital of PLA, Nanjing/China, 7Cancer Center, Union Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan/China, 8Thoracic Oncology, Jilin 
Provincial Cancer Hospital, Changchun/China, 9Department of Pulmonary Medicine, Shanghai 
Chest Hospital, Shanghai Jiao Tong University, Shanghai/China, 1010. Affiliated Xinan Hospital 
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P2.01-026 Proactive Management of Potential Gastrointestinal Adverse 
Reactions with Ceritinib in Patients with Advanced ALK+ NSCLC Eric Schaefer1, 
Margaret Power1, Christina Baik2 1Highlands Oncology Group, Fayetteville/AR/United States 
of America, 2Medical Oncology Division, University of Washington, Seattle/WA/United States 
of America
Background: Anaplastic lymphoma kinase (ALK) gene fusions are implicated in the 
pathogenesis of non-small cell lung cancer (NSCLC), occurring in 3–7% of cases. 
Crizotinib, a first-in-class ALK inhibitor, was granted US FDA approval in 2011 to treat 
metastatic ALK-positive (ALK+) NSCLC. However, intrinsic and acquired resistance 
limits its duration of use. Ceritinib, an ALK inhibitor with activity against crizotinib-
resistant NSCLC and brain metastases, was granted accelerated approval by the 
US FDA in 2014 for treating crizotinib-resistant ALK+ NSCLC. Adverse events (AEs), 
particularly gastrointestinal (GI) AEs, are commonly experienced at the recommended 
dose of 750 mg/day (Shaw A et al. NEJM 2014;370:1189–1197) and around 60% of 
patients require dose interruption or reduction. This report details our experience with 
the use of proactive GI AE management regimens with ceritinib. Methods: Proactive 
regimens A and B were implemented in patients with metastatic ALK+ NSCLC treated 
with ceritinib to manage drug-related GI AEs. Regimen A comprised ondansetron and 
diphenoxylate/atropine or loperamide, taken 30 minutes prior to dosage. Regimen B 
included dicyclomine, taken with the first ceritinib dose, ondansetron, taken 30 minutes 
prior to dosage for the first 7 doses, and loperamide, taken as needed with the onset of 
diarrhea. The proactive medications were tapered off depending on patient tolerability 
to ceritinib. We report a case series comprising 9 patients treated at two sites with 
ceritinib (750 mg/day) for whom these proactive GI AE management programs were 
successfully implemented. Results: The 9 patients presented had discontinued crizotinib 
due to disease progression or intolerance, and received ceritinib as their 2nd–5th line 
of treatment (Table). Rapidly starting regimens A or B before the first dose of ceritinib, 
or as soon as GI symptoms were encountered, prevented the need for dose reduction 
due to GI toxicity in 8/9 patients. One patient discontinued therapy due to GI toxicities 
despite prophylaxis. One patient required dose reduction to 600 mg/day due to Grade 
3 transaminitis. Using these regimens, 78% of patients were able to remain on 750 mg/
day fasting. Two patients have completed 16 and 12 months of therapy, and remain on 
ceritinib 750 and 600 mg/day, respectively.
 
Conclusion: Although not currently recommended or implemented 
in clinical studies, based on the patients evaluated here, upfront or 
proactive treatment plans that address AEs early on can allow the 
majority of patients to remain on the approved 750-mg/day ceritinib dose. 
Keywords: Ceritinib, ALK+ NSCLC, AE Management, Gastrointestinal
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treatment for advanced lung adenocarcinoma with anaplastic lymphoma kinase gene 
rearrangement. First-line therapy with crizotinib prolonged progression-free survival and 
improved qulity of life among selected patients. The possibility of using crizotinib as 
neoadjuvant therapy is interesting because of low toxicity of tyrosine kinase inhibitors. 
Here we report two cases affected by locally advanced lung adenocarcinoma, in 
whom one-month crizotinib treatment rendered the tumors reduction to surgical 
removal. Results: These two patients with ALK-positive stage IIIA received oral crizotinib 
250mg twice daily in thirty days, and crizotinib was well tolerated with rapid, prominent 
responses following by surgery in a week. The sequential therapy of case 1 showed 
the less adverse events in crizotinib than chemotherapy, while case 2 revealed more 
obvious responses. Conclusion: For pulmonary adenocarcinoma patients with ALK 
rearrangement, crizotinib could achieve a higher remission rate and less adverse 
events as compared with the chemotherapy, suggesting that crizotinib may be better 
option for neoadjuvant therapy. A propositional clinical trial exploring the ability of 
preoperative crizotinib to achieve better results than can be obtained with chemotherapy 
in patients selected on the basis of ALK gene rearrangement is urgently needed. 
Keywords: neoadjuvant therapy, Surgery, lung cancer, crizotinib
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P2.01-029 Physician Decision-Making on Modifying or Discontinuing Crizotinib 
in ALK+ NSCLC: A Survey of US Physicians Annie Guerin1, Medha Sasane2, Jie 
Zhang2, Elyse Swallow3, Alexander R. Macalalad3, Karen Stein2, Andrew Kageleiry3, Philip 
Galebach3, Jacquelyn Kercheval3, Dony Patel4, Edmond Bendaly5 1Analysis Group, Inc., 
Montreal/QC/Canada, 2Novartis Pharmaceuticals Corporation, East Hanover/United States of 
America, 3Analysis Group, Inc., Boston/United States of America, 4Navigant Consulting, Inc., 
London/United Kingdom, 5Marion General Hospital, Marion/IN/United States of America
Background: Crizotinib has been commercially available since August 2011 for the 
treatment of locally-advanced or metastatic ALK+ non-small cell lung cancer (NSCLC). 
In April 2014, a second-generation ALK inhibitor, ceritinib, was approved in the US for 
use after intolerance to or progression on crizotinib. Tumor progression, which varies 
by anatomical site and extent, is complex and evolves over time, often with insidious 
onset. Considering this heterogeneity, it is currently unclear at which point physicians 
may decide to change therapy. The objective of this study was to evaluate physicians’ 
decision-making with regard to determining progression during crizotinib treatment 
of locally-advanced or metastatic ALK+ NSCLC. This research question is particularly 
relevant with the introduction of new, effective treatment options available to patients 
who progress on first-line ALK inhibitor therapy. Methods: In July-November 2014, 
US oncologists were invited to respond to a survey regarding their decision-making 
with regard to treatment changes following progression on crizotinib for patients with 
locally-advanced or metastatic ALK+ NSCLC. Information was also collected on the 
characteristics of their practice. Results: Of the 34 oncologists who responded to the 
survey, 59% were from private practice, 26% were from an academic practice, and 15% 
were from an institutional practice. In terms of practice size, 53% were from small/
intermediate practices of 2-9 oncologists, and the rest were from larger practices. Half 
(50%) of physicians had their practice in an urban setting; 35% were in a suburban and 
15% were in a rural setting. Responding physicians had been in practice for an average 
of 12 years. When asked to indicate all of the clinical scenarios for which they would 
modify or discontinue crizotinib therapy, 62% of the physicians indicated that they would 
do so following disease progression detected on scan; 53% following either new or 
worsening symptoms; 29% following the development of new metastases in the brain; 
35% following the development of new metastases elsewhere; 29% following onset 
of a paraneoplastic neurological disorder; and 26% following lack of improvement of 
patient’s symptoms. Conclusion: The study suggests there is substantial heterogeneity 
in the clinical scenarios physicians would consider for modifying or discontinuing 
therapy after progression on crizotinib. These findings highlight the need for further 
clinical guidance with regard to the early identification of progression on crizotinib, 
and in particular, for a better understanding of the optimal point to switch from 
crizotinib when patients present with different manifestations of disease progression. 
Keywords: Locally-advanced or metastatic ALK+ NSCLC, crizotinib, Physician treatment 
preferences, progression
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P2.01-030 Challenging Diagnosis of Adenocarcinoma of the Lung Confirmed by 
Molecular Analysis: A Clinical Case Robert El-Maraghi Royal Victoria Regional Health 
Centre, Barrie/ON/Canada
Background: Lung cancer is the leading cause of cancer related deaths worldwide, 
with approximately 1.8 million new cases diagnosed in 2012 resulting in an estimated 
1.6 million deaths (Torre 2015). The basic tools of diagnosis include the assessment of 
clinical status (Rivera 2013), imaging to determine the size and location of tumors as well 
as the presence of metastases (Liam 2015), and tissue biopsies for establishing tumor 
histology and molecular subtype (Ofiara 2012). Correct characterization of the primary 
tumor can be particularly challenging when presentation includes confounding elements 
such as multiple lesions and/or no definite mass at the primary site. The accuracy and 
timing of molecular testing can play a vital role in compressing the diagnostic window 
for adenocarcinoma of the lung, allowing for timely treatment and a broader range of 
therapeutic options. Methods: Local research ethics board approval was obtained for 
this study. A standard diagnostic work up was undertaken, then supplemented by both 
internal and external pathological review of the available tissue sample, including EGFR 
and ALK mutation testing to clarify the diagnosis. Results: The patient, a 49 year old male 
smoker, initially presented with nausea, vomiting, weight loss and shortness of breath. 
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P2.01-027 Responses to Crizotinib in Six Lung Adenocarcinoma Patients of 
ALK IHC-Positive and FISH-Negative Di Ma1, Zheng Wang2, Lin Yang3, Xinlin Mu4, 
Yan Wang1, Xinming Zhao1, Junling Li1, Dongmei Lin5 1Medical Oncology, Cancer Institute 
and Hospital Chinese Academy of Medical Sciences Peking Union Medical College, Beijing/
China, 2Pathology, Beijing Hospital, Beijing/China, 3Pathology, Cancer Hospital, Chinese 
Academy of Medical Sciences, Beijing/China, 4Respiratory Disease and Critical Care 
Medicine, Peking University People’S Hospital, Beijing/China, 5Pathology, Key Laboratory of 
Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer 
Hospital and Institute, Beijing/China
Background: The anaplastic large cell kinase gene (ALK) -positive is a special type of 
non-small cell lung carcinomas (NSCLC). Although Ventana IHC (D5F3) and FISH showed 
high coincidence for detecting ALK rearrangement, discordant results exist in some 
cases. Treatment strategy as well as efficacy of crizotinib in these cases is such an 
issue. We studied and reported the efficacy of crizotinib in six lung adenocarcinomas 
patients with ALK IHC positive and FISH negative. Methods: All histologic and cytologic 
specimens were stained by IHC with an anti-ALK monoclonal antibody (D5F3, Roche) 
with the OptiView DAB IHC Detection Kit (Roche) and OptiView Amplification kit (Ventana 
Medical Systems, Inc., Tucson, AZ). All histologic and cytologic samples were also tested 
by FISH, which was carried out using the Vysis ALK Break Apart FISH probe kit. Three 
samples [one histologic (patient 1) and two cytologic samples (patients 2 and 6), patients’ 
numbers were listed in Table 1] were still enough to further perform for EML4-ALK fusion 
by qRT-PCR. Two samples [one histologic(patient 1) and one cytologic sample(patient 
6)] were still enough to further perform for next generation sequencing (NGS) analysis 
(using modified circulating single molecule amplification and resequencing technology, 
cSMART). The follow up data from 6 lung adenocarcinoma patients with ALK IHC-positive 
and FISH-negative who received crizotinib treatment were collected. Results: Table 1 
showed the clinicopathological characteristics and the therapeutic efficacy of crozitinib 
for 6 patients in the study. The patients have achieved a response rate of 66.7% (4/6). 
Pathologically, for patient 1, the 3 unique DNA templates with EML4->EXOC6B->ALK 
fusion were identified in 710 DNA copies in tumor tissue. The fusion ratio is only 0.42%. 
For patient 6, we detected 75 unique DNA templates in total 495 DNA copies with 15.15% 
fusion ration in cytologic specimen. The fusion types of patient 1 and 6 were confirmed 
by sanger sequencing. Some unknown mechanisms caused the 3 gene fragments fusion 
of patient 1, the complex fusion type and low fusion ratio cause FISH negative.
Table 1: Patient Characteristics, pathologic characteristics and molecular tests in 6 
cases
Patient 
NO.
Gen-
der Age
Smok-
ing 
history
ALK 
IHC
ALK 
FISH
NGS-
ALK
PFS 
(month)
Assess-
ment
P1 Fe-male 31
Never 
smoked + 6%
E13:EXO-
C6B:A20 7.46+
Partial 
response
P2 Male 48 Ever smoker + 10% - 11.96+
Stable 
disease
P3 Fe-male 49
Never 
smoked + 6% - 19.94+
Partial 
response
P4 Male 59 Ever smoker + 6% - 6.60+
Partial 
response
P5 Male 69 Ever smoker + 10% - 15.08+
Partial 
response
P6 Fe-male 65
Never 
smoked + 12% E13:A2 3.58
Stable 
disease
 
ALK FISH: % of split signals by FISH; NGS: Next generation sequencing; +: No progressive 
disease was observed at the time of analyse. Conclusion: Lung adenocarcinoma patients 
with ALK IHC-positive and FISH-negative may also response to crizotinib. Ventana IHC is 
another candidate method for detecting ALK. One new fusion type EML4->EXOC6B->ALK 
fusion was verified and the patient with this fusion type showed partial response to crozitinib. 
Keywords: Anaplastic lymphoma kinase, lung adenocarcinoma, fluorescence in situ 
hybridization, Immunohistochemistry
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P2.01-028 Neoadjuvant Crizotinib and Surgical Resection of Two Stage 
IIIA Lung Adenocarcinomas with Anaplastic Lymphoma Kinase Gene 
Rearrangement Shaolei Li1, Yue Yang2 1Department of Thoracic Surgery Ⅱ, Peking 
University Cancer Hospital & Institute, Beijing/China, 2Department of Thoracic Surgery 
Ii, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and 
Translational Research (Ministry of Education), Beijing/China
Background: Neoadjuvant therapy is also known as induction therapy or preoperative 
therapy. For lung cancer, the neoadjuvant medication includes chemotherapy and 
targeted medication. Neoadjuvant chemotherapy is widely used in clinical practices, 
but targeted therapy is still rare in the preoperative applications. To our knowledge, 
this is the first report of neoadjuvant crizotinib and following surgery of pulmonary 
adenocarcinoma. Methods: Crizotinib had already been recommend as the standard 
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available- Stage III & IV comprise 160 patients of these 30 patients survived more 
than 3 years. The analysis shows Male: Female ratio 5:4, mean age 55 years (range 
36 to 90 yrs) stage III is 18(60%) stage IV 12(40%). Histologically, Squamous cell Ca. 
60% Adeno ca. 24% and small cell 12% and rest others. KPS range from 60% to 90%. 
Treatment given: 80% received intent to cure with Chemo ± RT. And 20% palliative 
care only. Long survivors (>3years) 24 patients (16F + 8M) who received intent to 
treat chemo or chemo+ RT compared to none in supportive care only Conclusion: The 
result shows that females with Histo type adenocarcinoma who received therapy with 
Chemo + RT +/- targeted therapy with intent to treat are the long survivors according 
to this study. The study indicates that treatment should be given in a sub set of 
patients with advanced disease who are responders for increasing meaningful survival. 
Keywords: NSCLC long survivors, pattern of care
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P2.01-033 Patients with Advanced NSCLC Requiring Inpatient Oncology 
Consultation Joanna Gotfrit1, Tinghua Zhang2, Sylvia Zanon-Heacock3, Paul Wheatley-
Price4 1Department of Internal Medicine, University of Ottawa, Ottawa/ON/Canada, 2Ottawa 
Hospital Research Institute, Ottawa/Canada, 3The Ottawa Hospital Cancer Centre, Ottawa/
ON/Canada, 4Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa/ON/
Canada
Background: Most newly diagnosed advanced lung cancer patients have an initial 
medical oncology consult as an outpatient. However, occasionally the initial referral 
occurs as an inpatient. We explored the characteristics of advanced NSCLC patients 
whose first medical oncology consultation occurred while hospitalized. Methods: With 
ethics approval, we performed a retrospective analysis of all advanced NSCLC 
patients at our institution whose initial consult occurred while hospitalized, from 2007 
to 2012. Demographics, treatment and survival data were collected. This was an 
exploratory analysis. Multivariate survival analysis was performed using Cox regression 
models. Results: In total, 223 patients were included (baseline characteristics in 
Table 1). Overall, only 24% received chemotherapy while 72% received some palliative 
radiotherapy. Median time from diagnosis to chemotherapy was 43 days. Reasons for 
not receiving chemotherapy included poor performance status (PS) (72%), patient choice 
(9%), clinical deterioration (6%) or co-morbidities (4%). Factors associated with receiving 
chemotherapy were good PS (OR 11.11 [95% CI 5.56-25.00], p<0.001), no constitutional 
symptoms (OR 2.86 [95% CI 1.41-5.88], p=0.004), no leukocytosis (OR 2.38 [95% CI 
1.23-4.55], p=0.01), fewer co-morbidities (OR 1.54 [95% CI 1.27-1.89], p<0.001) and 
younger age (OR 1.09 [95% CI 1.05-1.12], p<0.001). Median OS was shorter in those not 
receiving chemotherapy (1.7 v 7.1 months, HR 2.76 [95% CI 1.72-4.41], p-value<0.001). 
Figure 1 shows Kaplan-Meier survival curves. In multivariate analysis, in addition to not 
receiving chemotherapy, factors associated with shorter OS were PS 3-4, (HR 1.55 
[CI 1.03-2.33, p=0.04]), leukocytosis (HR 2.23 [95% CI 1.51-3.28], p-value <0.001) 
and thrombocytosis (HR 1.52 [1.06-2.18], p=0.02). Conclusion: Patients whose first 
consultation with medical oncologists occurs while hospitalized are an inherently sick 
population and only a minority receive chemotherapy. The lung cancer community must 
advocate for earlier diagnosis and referral, so more patients have access to treatment 
options before a terminal functional decline.
Table 1: Baseline Characteristics
Demographic (N=223) %
Age in years, median (range) 65 (23-89)
Gender
Male 48
Female 52
Charlson Comorbidity Index total score, median (range) 10 (6-18)
Performance status
0-2 24
3-4 69
Unknown 7
Smoking status
Current 49
Ex 34
Never 9
Unknown 8
Stage at diagnosis
IIIB 10
IV 89
Unknown 1
NSCLC subtype
Imaging revealed an anterior mediastinal mass with hilar, mediastinal, bilateral neck and 
left supraclavicular region lymphadenopathy. Ultrasound confirmed bilateral adrenal 
lesions and a solid lesion in the right testicle, but no definitive lung mass was identified. 
Presentation characteristics were initially thought to indicate a lymphoma or germ 
cell tumour, however, additional analysis of tissue from a biopsy of the supraclavicular 
node was more consistent with a poorly differentiated carcinoma suggestive of lung 
adenocarcinoma, with positive staining for TTF-1 and EMA and negative staining for 
CK20, CK45, CK30, melanoma markers and thyroglobulin. Molecular testing for EGFR 
and ALK mutations was then requested, along with external pathology review. Findings 
from external review confirmed the aforementioned molecular profile and revealed 
that the tumour was also negative for CDX2, CK5, P63, PAX8, OCT3/4, SALL4 and 
synaptophysin expression, suggestive of thymic cancer, a teratoma, a germ cell tumour, 
or metastases from upper gastrointestinal origin. Molecular testing results identified 
an EGFR exon 21 point mutation, confirming the diagnosis of primary lung cancer. 
Treatment with afatinib was considered; however, due to the protracted diagnostic 
window, the patient was ultimately too debilitated to receive therapy. Conclusion: The 
absence of a definite lung mass and the unusual clinical and molecular presentation 
of this case made primary tumour site identification very challenging. The differential 
diagnosis was ultimately achieved through molecular testing. It is now well-
established that early (reflexive testing) knowledge of EGFR and ALK mutation status, 
accomplished through molecular profiling, is essential for the appropriate management 
of patients with adenocarcinoma of the lung. However, this case also highlights the 
importance of this type molecular characterization in achieving a timely diagnosis. 
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P2.01-031 Characteristics of Squamous Cellular Carcinoma Patients In 
‘Colombian Coffee Zone’ Jaime A. Echeverri F1, Gustavo Rojas2, Marco Kimmel2, 
Paula Londno2, Jose W. Martinez2, German A. Moreno2 1Pulmonary Medicine, Oncologos 
Del Occidente, Pereira/Colombia, 2Oncologos Del Occidente S.A., Pereira/Colombia
Background: During 1998 and 2013 the “Colombian Coffee Zone” (conformed by Caldas, 
Quindio, and Risaralda states) had an increase of 105 mortality cases of Bronchi and lung 
malignant tumors, as reported in death certificates. Methods:This is an observational 
and descriptive study that was made in patients at Clinica Oncologos del Occidente in 
the year 2014 and the Information was taken from the Clinical History Administration 
System (SAHICO). Thereafter, pending data was collected, by phone calls to patients 
or patient’s family, according to every case. Patients were interviewed to know their 
actual performance status and, in case of death, date and basic cause of death was 
asked. Results: SAHICO reported 178 patients with lung cancer. From these patients, 
33 did not have a correct diagnosis. Basically they did not have histology report. There 
were 130 patients with Non-Small Cell Lung Cancer and Small Cell Lung Cancer. The 
frequency of lung cancer was slightly more common in men; most of the patients were 
from Risaralda, followed by Caldas. 50% of the patients were 60.7 to 74 years old. The 
median age for men was 69.1 years old, and 64.1 years old for women. These median 
ages differences were statistically significant (F=9,121 p value=0,003). And 90.8% of 
the patients were from urban areas. 85.3% of tumors treated in 2014 correspond to 
NSCLC, meanwhile 10% were Small Cell lung cancer. Patients who received radiation 
therapy had a longer survival than patients without any radiations treatment. The survival 
media in the radiotherapy group was 180.4 days, and 113.2 days for the group without 
radiation therapy. This difference was significant (Log Rank test: 4.74, p value 0.029). 
Only 2 patients had both surgery and radiotherapy and had the major survival time, with a 
media of 331 days. The mean age of the squamous cellular carcinoma patients was 69.8 
years old in 64 patients. It was reported a median survival of 120 days with a confidence 
interval between 78 and 162 days. Only 8 patients with squamous cellular carcinoma had 
surgery and reported an increase in their survival time. The time median of survival for the 
surgical patients was 270 days. Meanwhile, this indicator decreased in the non-surgical 
patients to 109.9 days. Conclusion: In general, characteristics of lung squamous cellular 
carcinoma patients in the Coffee area of Colombia are similar than other regions of 
the world; incidence in men is only slightly greater than in women, presumably by the 
early age to start of smoke of the female population and the expose since childhood to 
others risk factors like biomass combustion smoke. Is clear that patients are detected 
in an advance stage of disease which has strong influence in prognosis and outcome. 
Highlights the importance of an integral treatment including all management alternatives 
and a multidisciplinary equipment of attention for modification of prognosis and survival. 
Keywords: Lung Neoplasms, Surveillance, Survival, Carcinoma Bronchogenic
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P2.01-032 Patterns of Care in Long Term Survivors (> 3 Years) in Advanced 
NSCLC- Retrospective Analysis of 30 Patients from a Single Institute 
Indibor S. Yengkhom Rcc, Radiation Onccology, Regional Institute of Medical Sciences, 
Imphal/India
Background: Long term survivors ( >3years) in advanced NSCLC is steadily increasing 
from 5 - 10% to 15 - 20%. It is related with the more effective and better treatment given 
in an individualised manner along with better understanding of the tumour biology. Many 
factors are also associated with the improved outcome. Our Institute’s 3 years data is 
analysed in an attempt to find out the favourable factors. Methods: Data mining of Stage 
III & IV non small cell lung cancers treated at RCC, RIMS during 2010 to 2012 are carried 
out from the patient’s departmental records. Only patients diagnosed and treated at 
RIMS who survive more than 3 years are included for analysis. Patient characteristics, 
disease profile & treatment pattern are analysed. Results: Out of 196 patients records 
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P2.01-034 Predictive Factors of Brain Metastases Development in Non-Small 
Cells Lung Cancer Eduardo A. Richardet, Maria E. Pacher, Matias Molina, Matias 
Cortes, Luciana P. Acosta, Aldo A. Riso, Pablo Companys, Eduardo Cuestas, Martin E. 
Richardet Capital, Ionc (Instituto Oncologico de Cordoba), Cordoba/Argentina
Background: Brain metastases are evidenced in 10 to 30 % of NSCLC patients sometime 
during the disease. The purpose of our research is to identify the clinical pathological 
characteristics in patients with stage IIIB-IV in relation to the development of brain 
metastases. Methods: 590 patients with lung cancer at our institution were analyzed 
between 2000 and 2013, of which 190 (32,3%) were stage EIIIB and 400 (67,7%) EIV. 
76 (12.8%) had brain metastases. The variables included in the analysis of patients with 
and without brain metastases were: gender, age, histology, smoking status and ECOG. 
The multivariate logistic regression model was used to identify factors related to brain 
metastases. Results: 64 patients out of the total 76 had brain metastases at initial 
diagnosis and 11 EIIIB developed brain metastasis in relapses. The development of brain 
metastasis was higher in men compared to women (77.7% vs 22.2%). Over 80% of patients 
presented ECOG of 0-1. Regarding histology, 60.32% were adenocarcinomas; 30% 
squamous, and 9.5% undifferentiated. 65% of patients were under 65 years old. 66.6% 
of patients were former smokers. Patients under 65 years old were at increased risk of 
developing brain metastases than older patients (HR=0,5-IC95%= 0,6-1,16- p=0,045). 
Adenocarcinoma histology was associated with an increased number of brain metastases 
development (OR = 2.42 - 95% CI = 1.84 to 3.00 - p= 0.003). Conclusion: Patients 
who were younger than 65 years old and adenocarcinoma histology, had a statistically 
significant higher risk of developing brain metastases. Regarding gender, we observed 
an increased risk in men; however, the differences were not statistically significant. 
Keywords: brain metastases nonsmall lung
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P2.01-035 The Survival Effect of Resection of Cranial Metastatic Lesions in 
Patients with Lung Cancer Adem Deligonul1, Ozgur Taskapilioglu2, Huseyin Melek3, 
Ahmet Bekar2, Gamze Cetinkaya3, Sureyya Sarıhan4, Ahmet Sami Bayram3, Cengiz 
Gebitekin3, Türkkan Evrensel1 1Oncology, Uludag University, Bursa/Turkey, 2Uludag 
University, Bursa/Turkey, 3Thoracic Surgery, Uludag University, Bursa/Turkey, 4Radiation 
Oncology, Uludag University, Bursa/Turkey
Background: The brain is one of the organs where lung cancer often metastasizes. At the 
time of diagnosis, the central nervous system metastases are present in approximately 
Table 1: Baseline Characteristics
Demographic (N=223) %
Adenocarcinoma 45
Squamous cell 23
Large cell 8
Other 23
Dominant presenting symptom
Dyspnea 34
Pain 23
Constitutional symptoms 9
Pneumonia 7
Cough 5
Hemoptysis 3
Other 18
Weight loss
<5% 22
>5% 52
Unknown 25
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P2.01-037 Genomic Alterations of KRAS, EGFR, and ALK in Patients with 
Non-Small Cell Lung Cancer, Single Institution Experience Yi-Hung Carol Tan1, 
Janani Vigneswaran2, Septimiu D. Murgu1, Brian Won1, Victoria M. Villaflor1, Everett 
E. Vokes1, Ravi Salgia1 1Medicine, The University of Chicago, Chicago/United States of 
America, 2Aalpert Medical School, Brown University, Providence/RI/United States of America
Background: This study reviews the results of extensive genetic analysis in non-small 
cell lung cancer (NSCLC) patients from a University of Chicago database in order to: 
describe how actionable mutation genes interrelate with the genes identified as variants 
of unknown significance; assess the percentage of patients with a potentially actionable 
genetic alterations; evaluate the percentage of patients who had concurrent alterations, 
previously considered to be mutually exclusive; and characterize the molecular subset 
of KRAS. This study reviews the results of extensive genetic analysis in non-small cell lung 
cancer (NSCLC) patients from a University of Chicago database in order to: describe 
how actionable mutation genes interrelate with the genes identified as variants of 
unknown significance; assess the percentage of patients with a potentially actionable 
genetic alterations; evaluate the percentage of patients who had concurrent alterations, 
previously considered to be mutually exclusive; and characterize the molecular subset 
of KRAS. Methods: Thoracic Oncology Research Program (TORP) Databases at the 
University of Chicago provided patient demographics, pathology, and results of genetic 
testing. Three hundred and sixty four patients included in this analysis had advanced 
NSCLC and underwent genotype testing by FoundationOne, Caris Molecular Intelligence, 
and Response Genetics. Results: 99.4% (159/160) of patients, whose samples were 
analyzed by next-generation sequencing (NGS), had genetic alterations identified with an 
10% of lung cancer cases. 80-85% of them are located supratentorially, and 10-15% of 
supratentorial lesions are located on cerebellar regions. Median survival is 1-2 months 
from the time of diagnosis without treatment. A general consensus about standard 
treatment could not be provided in lung cancer with a single brain metastasis; but distant 
metastases should necessarily be controlled with surgery or stereotactic radiation 
therapy. Methods: 74 patients (65 men and 9 women) were included in the study and 
evaluated retrospectively. They were followed in the department of medical oncology, 
school of medicine, Uludag University. All the patients had cranial operations for cranial 
metastases between 2004 and 2012. The ages and the first symptoms of the patients 
at the time of diagnosis, tumor localizations, surgical procedures, chemotherapy and 
radiotherapy protocols and histologic subtypes of lung cancer were analyzed. Time from 
diagnosis of cranial metastases to death was estimated as overall survival. Results:The 
symptoms of the patients at the time of diagnosis were as follows: 21 (28%) headache, 
17 (23%) hemiparesis, 18 (24%) more than one neurologic symptoms, 8 (10%) seizure, 
and 8 (10%) imbalance. The distrıbution of histologic subtypes of patients was as follows: 
42 (56%) adenocarcinoma, 17 (23%) squamous cell carcinoma, 14 (14%) small cell 
carcinoma, and 1 (1%) large cell carcinoma. According to surgical procedures, patients 
are distributed as follows: 68 (92%) total resection, 4 (5%) subtotal resection, and 2 (3%) 
stereotactic biopsy. 55 (74%) patients received cranial radiotherapy postoperatively. 
15 (20%) patients received radiotherapy for both cranium and lung. 3 (4%) patients 
did not received radiotherapy. 1 patient’s information about radiotherapy could not be 
reached. 70 (95%) patients received platinum-based chemotherapy. 4 ()patients did 
not receive any chemotherapy regimens. Median overall survival was 12 months (1-110 
months) in patients with cranial metastases. Conclusion: In an article examining brain 
metastases that were developed postoperatively, 65 patients were evaluated. 5-year 
survival in this group of patients was 15%. In that study, factors that affect survival 
positively, were listed as: female gender, adenocarcinoma histologic subtype, presence 
of limited number of metastases (1-2), no other extra thoracic metastases except 
brain metastases, stereotactic, radiologic and/or surgical treatment for metastases. 
However, in the literature it was reported that three cases, whose brain metastases 
appeared after surgical resection of lung cancer, had overall survival over 12 years with 
stereotactic radiotherapy. On the other hand, it is obvious that systemic therapy is so 
important for metastatic patients. The benefits of the combined treatment with surgery 
were studied by many groups. Although the studies have not identified the prognostic 
factors for survival exactly and either responded which group of patients could see 
more benefit from aggressive treatment yet; good results have been taken by adding 
surgical resection of metastases to combined treatment in especially selected patients. 
Keywords: lung cancer, metastases, survival
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P2.01-036 Long Term Survival of Patients with Metastatic Adenocarcinoma 
of the Lung in the Era of Targeted Agents Doru Paul1, Cristina Ghiuzeli1, Nina 
Kohn2, Dennis Timony3, Rosemarie Buro-Cavasinni4, Mohammed Aziz5, Haralambos 
Raftopoulos1, Lawrence Glassman6 1Hematology-Oncology, North Shore LIJ Cancer 
Institute Monter Cancer Center, Lake Success/NY/United States of America, 2Biostatistics, 
Feinstein Institute for Medical Research, Manhasset/NY/United States of America, 3Cancer 
Registry, North Shore Hospital, Manhasset/NY/United States of America, 4Cancer Registry, 
Long Island Hospital, New Hyde Park/NY/United States of America, 5Pathology, North 
Shore LIJ Cancer Institute Monter Cancer Center, New Hyde Park/NY/United States of 
America, 6Thoracic Surgery, North Shore Hospital, Manhasset/NY/United States of America
Background: Several studies have shown that tyrosine kinase inhibitors and 
chemotherapy improve the short term and median survival of patients with metastatic 
adenocarcinoma of the lung (MAL), but the long term survival (LTS) of these patients has 
not been thoroughly investigated. Methods: We performed a univariate retrospective 
analysis on 174 patients with MAL diagnosed at our institution between 2009 and 2011, 
and with up to a 5-year follow-up. Most patients received multiple treatment modalities. 
Overall survival was estimated using the product-limit method and compared using the 
log-rank test (significant results listed in Table 1); patients alive at last follow-up were 
censored. Results: In our series, 19% (33) of all patients (174) received erlotinib as 
part of their treatment, and 39%(13) of those receiving erlotinib had epidermal growth 
factor receptor (EGFR) mutations. Although the 2-year and median survival were superior 
in patients receiving erlotinib and chemotherapy, neither improved the 5-year survival 
rate (LTS). Surprinsingly, the 60-months survival rate was higher in the no erlotinib arm 
(Figure 1). The only treatment modality that significantly improved LTS was surgery. For 
the patients treated with erlotinib and chemotherapy, regardless of EGFR mutations, 
all observed deaths occurred within 4 years. Factors associated with LTS were: sex, 
surgery, and presence of metastatic disease confined to the the lungs. Conclusion: In 
our univariate retrospective analysis, MAL patients who were treated with erlotinib and 
chemotherapy had improved 2-year and median survival rates compared to patients 
treated with chemotherapy alone, but had no improvement in LTS. Factors such as: 
surgery, metastases limited to the lungs only, female sex were associated with LTS in 
MAL patients, but larger prospective studies are needed to confirm our findings. Our 
study puts into question the long term survival benefit of tyrosine kinase inhibitors in MAL 
and suggests a prominent role of surgery in this clinical context.
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the presence of bisphosphonate therapy. The association of histopathological subtypes 
and bone metastases was not detected. Patients with multiple bone metastasis had 
significantly increased SRE when compared to patients with single bone metastasis 
(p=0.002). Patients with single bone metastasis had a better median SRE-free survival 
compared with patients multiple bone metastasis (7 vs. 2 months, respectively, 
p<0.0001). Univariate analysis revealed that performance status (PS), the presence 
of bone metastasis at diagnosis, number of bone metastasis, SRE, the presence of 
palliative radiotherapy and bisphosphonate therapy were significant prognostic factors 
for overall survival (OS). Patients with bone metastasis at diagnosis had a shorter median 
OS compared with patients developed bone metastasis after diagnosis (8 vs. 18 months, 
respectively, p<0.0001). The presence of bone metastasis at diagnosis and number of 
bone metastasis were found to be an independent factors for predicting the occurrence 
of SRE (p<0.001 and p<0.001, respectively). Conclusion: Our results showed that the 
presence of multiple bone metastases was significantly associated with the development 
of SRE for NSCLC patients with bone metastases. In addition, bone metastasis at diagnosis 
is related with poor OS. The determining of additional factors affecting the occurrence 
of SREs may guide to best treatment for NSCLC patients with bone metastases. 
Keywords: Non-small cell lung cancer, Bone metastases, Skeletal-free events, Survival,
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P2.01-040 Survival Gains From Systemic Therapy in Advanced Non-Small 
Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities Joshua 
A. Roth1, Bernardo H.L. Goulart1, Arliene Ravelo2, Holli Dickson2, Scott D. Ramsey1 
1Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research 
Center, Seattle/WA/United States of America, 2Genentech, Inc., South San Francisco/CA/
United States of America
Background: Approximately 180,000 Americans are diagnosed with non-small cell lung 
cancer (NSCLC) annually, and more than half have advanced (Stage IIIB/IV) disease. 
Historically, survival for these patients has been poor. Moreover, even though standard 
systemic therapies (e.g. platinum-doublet chemotherapy) provide a modest survival 
advantage, a substantial proportion(~60%) of patients do not initiate or complete 
treatment. The advent of newer systemic therapies with more favorable effectiveness 
and toxicity profiles affords opportunities to improve NSCLC outcomes. The objectives of 
this study were: 1)to quantify survival gains from 1990-2015, ranging from a period when 
best supportive care(BSC) only was standard, to the present, where multiple cytotoxic 
and targeted therapies are available, and 2)to project the potential impact of increasing 
use of modern systemic therapies in clinically appropriate patients. Methods: We 
developed a simulation model to estimate observed and potential survival gains for 
patients diagnosed with advanced NSCLC in 1990 and 2015. Survival inputs were derived 
from Phase III clinical trials referenced in National Comprehensive Cancer Network 
guidelines, and extrapolated to a lifetime horizon by fitting Weibull curves. Proportions of 
patients receiving available therapies were derived from SEER (for % receiving BSC only) 
and a commercial treatment registry. Outcomes included one-year survival proportion, 
mean expected overall survival(OS), expected OS if the proportion receiving systemic 
therapy is increased by 10% (“Scenario 1”) and 30% (“Scenario 2”) relative to current 
use, and population-level estimates of total life years. Results were calibrated with SEER 
overall survival curves. Annual incidence of advanced NSCLC was assumed to be 92,000 
in both years. Results: In the expected survival analysis, from 1990 to 2015, one-year 
survival proportion increased by 15.8% and mean per-patient survival improved by 4.3 
months (33,412 population life years)(Table 1). In scenarios 1 and 2, the improvement in 
survival increased to 4.6 months (35,684 population life years) and 5.2 months (40,279 
population life years), respectively. Considering the proportion receiving each treatment, 
and the size of overall survival treatment effects, the majority of the survival gains were 
attributable to the advent of platinum-doublet chemotherapy (49%), followed by EGFR 
(35%), VEGF (10%), and ALK (6%) targeted therapies.
Table 1: Advanced non-small cell lung cancer outcomes by year of diagnosis.
Diagnosis 
Year
Expected: 
One-Year 
Survival (%)
Expected: 
Mean 
Per-Patient 
Survival 
(Months)
Expected: 
Population 
Life Years
Scenario 1: 
Population 
Life Years 
with 10% 
Relative 
Increase in 
Proportion 
Treated
Scenario 2: 
Population 
Life Years 
with 30% 
Relative 
Increase in 
Proportion 
Treated
2015 29.3% 11.4 87,287 89,559 95,154
1990 13.5% 7.1 53,875 53,875 53,875
Difference +15.8% +4.3 +33,412 +35,684 +40,279
 
Conclusion: Though survival remains poor in advanced NSCLC relative to 
other common cancers, meaningful progress in per-patient and population-level 
outcomes has been realized over the past 25 years. These advances can be 
improved even further by increasing use of systemic therapies in the substantial 
proportion of patients who are suitable for treatment, yet currently receive BSC only. 
Keywords: Non-small cell lung cancer, Advanced, Survival, Systemic Therapy
average of 10.8 alterations/tumor throughout different tumor types. However, mutations 
were not mutually exclusive. For the entire cohort 28% of patients were African Americans; 
adenocarcinoma was the most commonly tested tumor subtype; 91% of KRAS mutations 
were detected in smokers; 46% of EGFR alterations and 50% of ALK translocations 
were detected in never smokers. The majority of ALK translocations were detected in 
adenocarcinomas. Conclusion: Personalized medicine is a significant step forward in the 
realm of lung cancer treatment. In conjunction with NGS to identify and characterize tumor 
specific molecular abnormalities, biomarker-driven therapies have improved patients’ 
overall survival. NGS in this study identified potentially actionable genetic alterations 
across various tumor histology subtypes, races and smoking status. NGS also provided 
additional information by uncovering targetable concurrent alterations or alterations 
of unknown significance at this point in time, but potentially targetable in the future. 
Keywords: next generation sequencing, gene alteration, database, non-small cell lung 
caancer
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P2.01-038 Prognostic Factors for Brain Metastasis in Non-Small Cell Lung 
Cancer Narjust Duma1, Laysa Sanchez1, Claudia Miranda1, Chad Glisch1, Khaleb Abu-
Ihweij1, Shijia Zhang1, Carlos Osorio1, Matthew Listo1, Harry D. Harper2, Martin Gutierrez2 
1Internal Medicine, Rutgers-New Jersey Medical School, Newark/NJ/United States of 
America, 2Medical Oncology, Hackensack University Medical Center, Hackensack/NJ/United 
States of America
Background: Non-Small Cell Lung Cancer (NSCLC) patients tend to develop brain 
metastasis (BM) early in the course of the disease, usually within 2 years of diagnosis. 
BM are an important cause of morbidity and mortality, the study of prognostic factors 
for its development are invaluable in implementing measures to prevent or decrease the 
incidence of BM. The aim of this study was to evaluate the prognostic value of certain 
clinical characteristics in the development of BM in NSCLC patients. Methods: We 
retrospectively analyzed all patients diagnosed with NSCLC at our institution between 
2000 and 2013. Demographics, tumor characteristics and metastatic patterns were 
studied. Median follow up was 45 months. Cox regression was used for multivariate 
analysis. Results: A total of 1062 patients were studied. Of these, 172 (16%) had BM 
at the time of analysis, with 61 (35%) patients having BM at diagnosis. Median age was 
68 years (range, 18-91); median time from diagnosis to BM was 259 days. There were 
more females than males (64% vs. 36%, p < 0.0001). About NSCLC characteristics, 
patients with BM were more likely to have upper lobe tumors than all other tumor 
locations combined (63% vs. 37%, p < 0.0001). 32% of the lung tumors were 5-7cm 
in diameter and adenocarcinoma represented 68% of all the histologic subtypes. 
In regards to other distant metastases: 34% of the patients had bone metastasis, 
23% adrenal and 17% hepatic. BM were most commonly located in the frontal (41%), 
parietal (17%) and occipital (14%) lobes. There was a significant survival difference 
between Stage IV patients with and without BM; patients with BM survived 6.1 months 
compared with 11.9 months in those without BM (p < 0.0001). In univariate analysis, 
female sex, histologic grade, upper lobe tumors and high LDH levels were associated 
with BM. Age < 65 years (HR: 0.60, 95%CI: 0.37-0.95, p < 0.03), T3-4 tumors (HR: 
3.4, 95%CI: 2.04-5.64, p < 0.0001), adrenal metastasis (HR: 5.2 95%CI: 2.5-10.7, p < 
0.0001) and liver metastasis (HR: 8.6, 95%CI: 4.3-17.2, p < 0.0001) were independent 
risk factors for the development BM. Conclusion: The results of this study pose 
female sex, tumor histologic grade, tumor location, and LDH levels as important 
prognosticators of future BM. In addition, younger age, T3-4 tumors, and the presence 
of adrenal/liver metastases are noted as independent risk factors for BM development. 
With this information, criteria for the selection of patients as suitable candidates for 
intra-cranial irradiation, periodic brain imaging studies, and close outpatient follow-
up may aid in further prevention of BM, early identification, and timely management. 
Keywords: Brain metastasis, non-small cell lung cancer, Prognostic factors, Early 
Detection
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P2.01-039 Clinicopathological Factors in Non-Small Cell Lung Cancer Patients 
with Bone Metastases Arife Ulas1, Ahmet Bilici2, Ayse Durnali3, Saadet Tokluoglu3, 
Sema Akinci4, Kamile Silay5, Berna Oksuzoglu3, Necati Alkis3 1Department of Medical 
Oncology, Ankara Ataturk Training and Research Hospital, Ankara/Turkey, 2Department of 
Medical Oncology, Istanbul Medipol University, Medical Faculty, Istanbul/Turkey, 3Department 
of Medical Oncology, Ankara Oncology Teaching and Research Hospital, Ankara/
Turkey, 4Department of Hematology, Ankara Ataturk Training and Research Hospital, Ankara/
Turkey, 5Department of Internal Medicine, Yildirim Beyazit University, Faculty of Medicine, 
Ataturk Research and Training Hospital, Ankara/Turkey
Background: The bone is one of the most frequent sites for metastases from non-small 
cell lung cancer (NSCLC) and bone metastases are diagnosed in 30-40% of patients. They 
are resulted in skeletal-related events (SREs) that associate with an important morbidity 
and poor survival. In the current study, clinicopathological factors and SRE-free survival 
were evaluated for patients with NSCLC with bone metastases. Methods: Three-hundred 
and thirty-five NCSLC patients with bone metastases were retrospectively analyzed, 
between 2010 and 2013. The effect of clinicopathological factors on SRE and survival 
were evaluated for all patients with or without SREs. Results: Totally, 244 (72.8%) 
patients developed SREs at the diagnosis or during treatment of disease. Of these, 
145 required radiotherapy to the bone or pathological fracture, 59 developed malignant 
hypercalcemia, 21 developed compression fracture of the vertebrae and 5 required 
surgical treatment of the bone. There were significant differences between the patients 
with respect to number of bone metastasis, the presence of palliative radiotherapy and 
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free”, “progressive disease”, and “death” health states. Patients entered the model in the 
progression-free state and advanced to progressive disease and death based on the 
progression-free survival and overall survival curves. The survival curves for afatinib were 
estimated by fitting parametric models to the empirical data from the LUX-Lung 3 clinical 
trial. For erlotinib the survival curves were estimated based on hazard ratios that were 
applied to the afatinib curves. The hazard ratios were derived via a network meta-analysis. 
Patients incurred treatment-specific drug costs for afatinib and erlotinib until disease 
progression. Costs to treat grade 3/4 adverse events were applied to each treatment. 
Resource use from the LUX-Lung 3 trial data and unit costs from published literature 
and from standard U.S. sources were used to derive the additional, monthly costs of 
being progression free. Monthly continuing care costs and one-time, end-of-life costs for 
patients with progressive disease were obtained from published literature. The utility of 
progression-free disease was obtained from LUX-Lung 3, and the disutility of progressive 
disease was obtained from the published literature. Disutilities associated with adverse 
events were also obtained from the literature. The model calculated patient survival (life 
years) and quality of life adjusted years (QALYs), and total costs per patient. Incremental 
cost-effectiveness ratios (ICERs) were calculated as the ratio of the difference in cost 
to the difference in LYs and QALYs. Costs and outcomes were calculated over a 20-year 
time horizon and discounted at an annual rate of 3%. Results: Based on the model, 
the patients taking afatinib accrued more life years (3.09 vs. 2.46) and QALYs (2.17 vs. 
1.72) than patients taking erlotinib. Although the wholesale acquisition cost (WAC) of 
afatinib was lower than that of erlotinib, the incremental per patient cost was higher with 
afatinib ($ 32,961) owing to patients spending more time in “progression-free”, and “post-
progression” health states in the afatinib group. At an accepted US ICER threshold of 
$100,000/QALY, afatinib vs. erlotinib had an ICER/QALY gained of $74,345 and cost per 
LY gained was $52,401. Conclusion: Afatinib as a 1st-line therapy for locally advanced 
or metastatic NSCLC with EGFR exon 19 deletion mutations is a cost-effective alternative 
to erlotinib according to the commonly accepted cost-effectiveness threshold in the US. 
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P2.01-043 Lung Cancer Radiotherapy - Current Patterns of Practice in 
Australia and New Zealand Syed M. Islam1, Jeremy D. Ruben2, Helen M. Lehman3, 
Shankar Siva4, Tomas Kron5, Patrick M. Dwyer6, Lois Holloway7, Shalini K. Vinod8 
1William Buckland Radiotherapy Centre, Melbourne/Australia, 2Radiation Oncology, William 
Buckland Radiotherapy Centre and Monash University, Melbourne/Australia, 3Radiation 
Oncology, Princess Alexandra Hospital, Brisbane/Australia,4Radiation Oncology, Peter 
Maccallum Cancer Centre, East Melbourne/Australia, 5Medical Physics, Peter Maccallum 
Cancer Centre, Melbourne/VIC/Australia, 6North Coast Cancer Institute, Lismore/NSW/
Australia, 7Medical Physics, Liverpool Hospital, Liverpool BC/Australia, 8Cancer Therapy 
Centre, Liverpool Hospital, Liverpool BC/NSW/Australia
Background: The RANZCR Faculty of Radiation Oncology Lung Interest Cooperative 
(FROLIC) surveyed patterns of lung cancer radiotherapy practice in Australasia for both 
non-small cell (NSCLC)and small cell lung (SCLC) cancer to evaluate current patterns 
of care and define gaps in optimal care requiring improvement. Methods: Radiation 
Oncologists were surveyed at all 62 departments in Australasia using a web-based 
survey targeting those treating lung cancer. Questions covered current radiotherapy 
practice as well as measures of quality Results: Of 62 responses received, 57 did treat 
lung cancer and were eligible for analysis. All Australian states and New Zealand were 
represented. Sixty-two percent of respondents worked at metropolitan centres, 58% 
were subspecialists in lung cancer and 60% participate in lung cancer trials. Ninety-four 
percent discuss lung cancer patients at a tumour board, 74% peer review contours for 
conventional fractionation and 50% for SABR. Fifty percent used a department protocol 
for contouring and/or prescription, 39%, an external protocol and 11% had no protocol. 
For radical conventional radiotherapy, 58% use 4DCT to assess tumour motion, 44% 
utilise breath hold or respiratory gating, 44% use PET Fusion, 35%, free-breathing CT 
and 23% PET-CT simulation. In palliative settings, free-breathing CT was most common 
(81%). For conventional treatment, 98% use 3DCRT, 34% IMRT and 18% VMAT. Image 
verification was primarily with cone beam CT (86%), KV imaging (72%) and MV imaging 
(30%). The commonest dose fractionation regime in NSCLC was 60Gy in 30 fractions 
used in 95% of node-positive and 82% of node-negative disease. 66Gy in 33 fractions 
and 50-55Gy in 20 had been used by 32% and 30%of respondents respectively. 30Gy/10 
fractions was the most frequent palliative regime that had been used (by 76%), followed 
by 36Gy/12 (72%) . For limited stage SCLC, the majority (61%) treated with 45-50.4Gy 
in 25-28 fractions while 45Gy/30 twice daily had been used by 48%. In extensive stage 
SCLC, consolidation chest radiotherapy was used by 63% in complete response, 48% 
for partial response and 24% would not treat. 46% of departments provided SABR but 
only half treated central tumours. For peripheral tumours, 80% used 54Gy in 3 fractions 
and if close to chest wall, 70% used 48Gy in 4 fractions. In fit patients with synchronous 
solitary brain metastasis and controlled extra-thoracic disease, 37% of respondents 
would treat both chest and brain definitively, 43% would do so only if chest disease was 
equivalent to Stage I/II, and 9% would never treat radically. If three brain metastases 
were present, just 46% would treat definitively. In the setting of an isolated systemic 
metastasis only, 35% would treat definitively while 61% do not offer definitive treatment 
in the setting of systemic oligo-metastases. Conclusion: A significant proportion of 
radiation oncologists did not have access to 4DCT for simulation. The majority used 
3D image verification and consistently prescribed evidence-based doses. Although 
protocols were widely used, a significant number did not participate in peer review 
of contours. The treatment of synchronous oligo-metastatic disease was variable, 
likely due to a lack of high quality evidence and should be an area of future research. 
Keywords: patterns of practice, non small cell lung cancer, small cell lung cancer, 
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P2.01-041 MD Anderson Oncology Expert Advisor™ System (OEA™): A 
Cognitive Computing Recommendations Application (App) for Lung Cancer 
George R. Simon1, Daniel Gomez2, Mara B. Antonoff3, Quynh-Nhu Nguyen2, Emily 
Roarty4, Kathryn A. Gold5, Sunil Patel6, Renata Ferrarotto1, Joshua Allen7, Rick Stevens8, 
Fernando S. Siaz9, Mitchell Berger10, Garrett Walsh11, Mark Mynier12, Rob High13, 
Andy Futreal14, Stephen Hahn15, Stephen Swisher16, John V. Heymach17, Oea System 
Development Team14, Lynda Chin18 1Thoracic Medical Oncology, MD Anderson Cancer 
Center, Houston/TX/United States of America, 2Dept of Radiation Oncology, MD Anderson 
Cancer Center, Houston/TX/United States of America, 3Thoracic and Cardiovascular Surgery, 
UT MD Anderson Cancer Center, Houston/TX/United States of America, 4Thoracic, Head & 
Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston/
TX/United States of America, 5University of Texas MD Anderson Cancer Center, Houston/
TX/United States of America, 61400 Holcombe Blvd, Unit#432, MD Anderson Cancer 
Center, Houston/TX/United States of America, 7Watson Solutions, Ibm, Durham/NC/United 
States of America, 8Ibm, Burlington/VT/United States of America, 9Ibm, Houston/AL/
United States of America, 10Pwc, Atlanta/AL/United States of America, 11Thoracic Surgery, 
MD Anderson Cancer Center, Houston/TX/United States of America, 12Pwc, Atlanta/United 
States of America, 13Ibm Watson, Austin/AL/United States of America, 14MD Anderson 
Cancer Center, Houston/AL/United States of America, 15Radiation Oncology, The University 
of Texas MD Anderson Cancer Center, Houston/TX/United States of America, 16Thoracic and 
Cardiovascular Surgery, MD Anderson, Houston/AL/United States of America, 17Thoracic/
Head and Neck Medical Oncology, MD Anderson, Houston/TX/United States of 
America, 18Instituteof Applied Cancer Sciences, MD Anderson Cancer Center, Houston/TX/
United States of America
Background: The OEATM is a clinical support system with a continuous improvement 
capability. Its objectives are to enable/empower evidence-based decisions/care 
by disseminating knowledge and expertise to physicians/users tailored to meet the 
clinical needs of individual patients as if consulting with an expert. Cognitive computing 
platforms have the potential to disseminate expert knowledge and tertiary level care to 
patients. This objective is made possible by making available to physicians/providers 
cognitive computing generated expert recommendations in diagnosis, staging and 
treatment. The cognitive computing software was trained by MD Anderson experts using 
currently available consensus guidelines and an iterative feedback process. Here we test 
the capability of this cognitive computing software program developed at MD Anderson 
to generate expert recommendations when patients with advanced-stage NSCLC have 
a targetable molecular aberration. Methods: We developed a web based prototype of 
MD Anderson’s Oncology Expert Advisor (OEATM), a cognitive clinical decision support 
tool powered by IBM Watson. The Watson technology is IBM’s third generation cognitive 
computing system based on its unique capabilities in natural language processing 
and deep QA (question-answer). We trained OEATM by loading historical patient cases 
and assessed the accuracy of targeted treatment suggestions using MD Anderson’s 
physicians’ decisions as benchmark. A false positive result was defined as a treatment 
recommendation rendered with high confidence that was non-correct (less optimal), 
whereas false negative was defined as a correct or more optimal treatment suggestion 
listed as a low confidence recommendation. Results: In our preliminary analyses, 
OEATM demonstrated four core capabilities: 1) Patient Evaluation through interpretation 
of structured and unstructured clinical data to create a dynamic case summary with 
longitudinal view of the pertinent events 2) Treatment and management suggestions 
based on patient profile weighed against consensus guidelines, relevant literature, and 
MD Anderson expertise, which included approved therapies, genomic based therapies 
as well as automated matching to appropriate clinical trials at MD Anderson, 3) Care 
pathway advisory that alerts the user for anticipated toxicities and its early identification 
and proactive management, and 4) Patient-oriented research functionalities for 
identification of patient cohorts and hypothesis generation for future potential clinical 
investigations. Detailed testing continues and the accuracy of standard-of-care (SOC) 
treatment recommendations of OEATM, as well as false positivity and negativity rates will 
be presented in detail at the meeting. Conclusion: OEATM is able to generate dynamic 
patient case summary by interpreting structured and unstructured clinical data and 
suggest personalized treatment options. Live system evaluation of OEATM is ongoing and 
the application of OEATM in clinical practice is expected to be piloted at our institution. 
Keywords: Cognitive Computing, lung cancer, Targeted therapy, Oncology Expert 
Advisor
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P2.01-042 Cost-Effectiveness of Afatinib vs. Erlotinib in the 1st-Line Treatment 
of Metastatic NSCLC Patients with EGFR Exon 19 Deletion Mutations Jonathan 
Graham1, Rakesh Luthra2, Stephanie Earnshaw1, Rohit Borker2 1RTI Health Solutions, 
Research Triangle Park/NC/United States of America, 2Boehringer Ingelheim, Ridgefield/CT/
United States of America
Background: EGFR mutation-positive (EGFR M+) NSCLC is a specific lung cancer subtype 
characterized by presence of EGFR mutations and sensitivity to treatment with EGFR 
tyrosine kinase inhibitors (TKIs). Common activating mutations (Del19, L858R) account 
for ~90% of EGFR M+ NSCLC cases. Afatinib, an oral, irreversible ErbB family blocker, 
improved progression-free survival (PFS) versus standard platinum-based chemotherapy 
in 1st-line EGFR M+ NSCLC. Afatinib also significantly prolonged overall survival (OS) in 
the EGFR Del19 mutation subgroup. Erlotinib, a reversible EGFR TKI licensed in the US 
has also improved PFS in EGFR Del19 mutation subgroup, but not OS. The objective of 
this study was to assess the cost-effectiveness of afatinib versus erlotinib in the 1st-
line treatment of patients with metastatic EGFR Del19 M+ NSCLC in the US healthcare 
setting. Methods: A partitioned survival model was developed consisting of “progression-
S537Copyright © 2015 by the International Association for the Study of Lung Cancer
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resection. Nine patients received adjuvant chemotherapy, which were not relapsed in 
6 months after finishing last cycle. The common regimens of first-line treatment were 
gemcitabine plus platinum (n=36) and pemetrexed plus platinum (n=32). Eleven patients 
received EGFR-TKIs as first-line treatment. Other drugs included docetaxel, paclitaxel, 
novelbine and etc. The commonest second-line treatment was oral EGFR-TKIs (n=44). 
Fifty patients received third-line treatment and 19 received fourth-line treatment. At 
the end of follow-up (2015-3-30), 91 patients were dead and 22 patients were alive 
or lost follow up. The median survival of this whole cohort was 20.0m (16.1m-24.0m, 
95%CI). The overall survival was not associated with sex (p=0.441), performance status 
(p=0.809) and smoking (p=0.677). Those patients (29.9m, 95%CI; 18.6m-41.1m) who 
received surgical resection lived longer than the patients (17.8m, 95%CI; 13.8m-21.8m) 
who were advanced stage when diagnosed (p=0.01). The overall survival was also not 
associated with the chemotherapy drugs used in the first-line treatment. The patients 
(19.0m, 95%CI; 11.4m-26.5m) used pemetrexed plus platinum lived no longer than 
other regimens (20.5m, 95%CI; 13.4m-27.4m) (p=0.272). In the gemcitabine plus 
platinum group, the median survival was 19.9m (95%CI; 9.2m-30.6m), which was not 
longer than other regimens (20.0m, 95%CI; 15.4m-27.4m). The p value was 0.404. 
We also analyzed the influence of oral EGFR-TKIs on overall survival. Those who had 
a chance taken EGFR-TKIs lived numerically longer than never; the median survival 
was 24.8m (19.1m-30.5m, 95%CI) and 16.3m (12.7m-19.9m, 95%CI), respectively. 
However, the overall difference was not significant (p=0.184). Conclusion: The 
median survival of patients with advanced lung adenocarcinoma with UN-EGFR-
GS was 20m. Oral EGFR-TKIs appear to be useful for this group of patients. 
Keywords: Adenocarcinoma, treatment, EGFR-TKI, non-small cell lung cancer
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P2.01-046 Making the Diagnosis of Cardiac Tamponade in Lung Cancer 
Patients Pooja Ghatalia1, Christopher Wang2, Stefan C. Grant3 1Internal Medicine, 
University of Alabama at Birmingham, Birmingham/AL/United States of America, 2Medical 
Oncology, University of Alabama at Birmingham, Birmingham/United States of 
America, 3Medical Oncology, Wake Forest University, Winston-Salem/AL/United States of 
America
Background: Malignant pericardial effusions are common in lung cancer (LC) and 
can produce cardiac tamponade (CT). This oncologic emergency requires a high index 
of suspicion for accurate, prompt diagnosis. To study how CT is diagnosed in LC, we 
reviewed symptoms, signs and differential diagnoses recorded, and tests obtained, at 
a tertiary teaching hospital. Methods: Records of patients hospitalized with a diagnosis 
of CT between April 1999 and September 2011 were reviewed, focusing on LC related 
CT. Extent of disease, treatment history and response, symptoms, vital signs, physical 
exam and EKG findings recorded by the initial and admitting physicians were recorded, 
together with differential diagnoses mentioned in the physician notes before radiologic 
testing. Finally, the radiologic tests used to make or confirm the diagnosis were 
recorded. Results: Of 770 patients with a diagnosis of CT, 57 had malignant CT and 26 
had LC. Of these, 7 (27%) were newly diagnosed with cancer at the time of diagnosis of 
CT. The most common symptom, shortness of breath, was present in 24 (92%) cases. 
Physical exam findings recorded by physicians are listed in Table 1. EKG findings of low 
QRS voltage/electrical alternans were present in 3, absent in 3 and were not documented 
in 20 patients. In only 8 cases (31%) CT was included in the differential diagnosis based 
on the signs, symptoms and EKG findings at initial presentation. Of these, 3 had a known 
prior history of pericardial effusion and 3 were newly diagnosed with LC at the time 
of presentation. Two of these diagnoses were made by oncologists and the other 6 
were made by Emergency physicians (ED)/internists. In the remaining 18 cases, the 
diagnosis was made serendipitously with imaging studies obtained for other reasons. Of 
these, 5 patients had a known history of malignant pericardial disease and 6 were newly 
diagnosed with LC. The physician seeing the patient initially was an oncologist in 5 cases 
and an ED /internist in 13 cases.
Jugular 
venous 
distention
Distant 
heart 
sounds
Pulsus 
paradoxus Tachycardia Hypotension
Present 7 (27%) 5 (19.2%) 3 (11.5%) 22 (84.6%) 6 (23%)
Absent 10 (38.4%) - 4 (15.3%) 4 (15.3%) 20 (77%)
Not 
recorded 9 (34.6%) 21 (80.7%) 19 (73%) - -
 
Conclusion: Not including CT in the differential diagnosis of LC patients presenting with 
dyspnea is common among physicians of all types, including oncologists, internists, and 
ED. Physicians should include CT in the differential diagnosis of LC patients presenting 
with dyspnea and tachycardia, especially those with advanced disease, and a careful 
physical examination will elicit the classic signs in a substantial proportion of patients. 
Without a high index of clinical suspicion the diagnosis may be delayed or missed. 
Keywords: lung cancer, diagnosis, physical examination, cardiac tamponade
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P2.01-044 EGFR-TKIs as Second-Line Treatment of Patients with NSCLC with 
or without Activating EGFR Mutation as Assessed by Sensitive PNA Clamping 
Method Young-Chul Kim, Hayoung Choi, Cheol-Kyu Park, In-Jae Oh, Sung-Ja Ahn, Kook-
Joo Na, Sang-Yun Song, Yoo-Duk Choi, Mee Sun Yoon, Ju-Sik Yun, Hyun-Ju Seon Lung 
and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Jeonnam/
Korea
Background: Although TAILOR phase 3 trial showed superiority of docetaxel versus 
erlotinib as second line treatment in NSCLC with wild type EGFR as assessed by direct 
sequencing, second-line treatment of patients with wild-type status is controversial and 
EGFR-TKIs are still used as second line treatment. Methods: We retrospectively analyzed 
the results of 2nd line treatment with EGFR-TKIs in 25 patients with activating EGFR 
mutations and 68 patients with wild-type EGFR as assessed by PNA clamping 
(Panagene®, South Korea), which is more sensitive than direct sequencing. Results: There 
was no significant difference in age, sex, smoking history and histologic subtypes of 
NSCLC between the two groups. Erlotinib was more frequently used in EGFR wild group 
(48/68, 71%), while use of gefitinib was significantly higher in EGFR mutation group 
(15/25, 60%, p=0.003). Progression-free survival (PFS) was significantly longer in EGFR 
mutation group than EGFR wild group: median PFS was 11.6 months (95% CI 6.2~17.1) in 
mutation group versus 1.8 months (1.5~2.1) in wild group (log rank p<0.001). PFS was 
numerically shorter than the 2.4 months (2.1~2.6) of TAILOR trial.
 
 
Conclusion: This results show that possibility of survival benefit using second-line EGFR-
TKI is very low in patients with NSCLC with wild-type EGFR status, when tested with 
sensitive EGFR mutation detection technique. Thus chemotherapy should be favored 
for the second line treatment of patients with NSCLC with wild-type EGFR status. 
Keywords: EGFR, PNA clamping, EGFR-TKI
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.01-045 Clinical Experience on Treatment of Advanced Lung 
Adenocarcinoma With Unknown EGFR Gene Status From a Tertiary Care Center 
in China Long Y. Zheng1, Chen X. Zhang1, Li L. Chen2, Yu C. Mao1, Jiong Qian1, Ping H. 
Jiang1, Jing Deng1, Ming G. Shi1, Nong Xu1 1Medical Oncology, The First Affiliated Hospital 
of Zhejiang University, Hangzhou/China, 2Taizhou First Hospital, Taizhou/China
Background: Limited data are available on treatment experience in patients with 
advanced lung adenocarcinoma with unknown EGFR gene status (UN-EGFR-GS). We 
studied the demographic profile and treatment outcomes of advanced NSCLC patients 
with adenocarcinoma, which the EGFR gene status was unknown. Methods: Retrospective 
study of patients with UN-EGFR-GS advanced lung adenocarcinoma over a 4-year period 
at a tertiary care institute in China. Patients diagnosed with stage IIIb or IV were included 
for analysis during 2009 and 2012. Results: In total, 113 patients were included, 
females and males constituted 46.9% (n=53) and 53.1% (n=60), respectively. Among 
the 113 patients, 53 were non-smokers and 60 were smokers. The median age was 
57.5y(35y-85y). The performance score was 2 in only 12 patients, otherwise was 0 or 1. 
Majority of patients had stage IV disease (95.6%). Seventy-five patients were advanced 
stage when diagnosed, and 38 patients were relapsed disease once received surgical 
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The most frequent chemotherapy during the first strategy was platinum salts doublet 
with pemetrexed (39%), followed by platinum salts doublet with paclitaxel (15%). 
Chemotherapy during the second strategy was second line chemotherapy (67%) or 
maintenance therapy (25%). EGFR-TKi (34%) and docetaxel (26%) alone were the most 
frequently prescribed drugs for second line chemotherapy, and pemetrexed (44%) and 
EGFR-TKi (26%) alone for maintenance therapy. Conclusion: The ESCAP study describes 
the 2-year management of metastatic NSCLC on real-life settings in France. Its preliminary 
results are consistent with the guidelines of the French National Cancer Institute. 
Keywords: therapeutic strategies, Metastatic NSCLC, New drugs
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P2.01-049 Surgical Treatment Results of T4 Lung Cancer Invading 
Mediastinum Masayuki Tanahashi, Hiroshi Niwa, Haruhiro Yukiue, Eriko Suzuki, Naoko 
Yoshii, Masayuki Shitara, Toshio Fujino Division of Thoracic Surgery, Respiratory Disease 
Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka/Japan
Background: Inoperable cases are common in T4 lung cancer patients, and their 
prognoses are mostly poor. Nevertheless, among those who undergo resection, some 
can achieve long-term survival. We reviewed the validity of surgical treatment for T4 
lung cancer at our department. Methods: Fifty-six cases of pathologically confirmed 
T4 lung cancer resection between January 1989 and December 2013 were selected 
for this study. Cases of nodules in different lobes of the same lung were ineligible. The 
relationships among the number of infiltrated organs, pN factor, presence or absence of 
preoperative treatment, histological effect (Ef), and surgical curative rate and prognosis 
were assessed using statistical techniques. Results:The subjects consisted of 53 males 
and 3 females with an average age of 62.2 years. Depending on the histological types, 
they were classified as squamous cell cancer (29 cases), adenocarcinoma (16 cases), 
adenosquamous cancer (7 cases), large cell cancer (1 case), and other cancers (2 
cases). Also, there were 37 single and 19 multiple organ infiltration cases, which were 
classified by infiltrated organ as 16 in the trachea and tracheal bifurcation, 11 in the 
vertebral body, 10 in the aorta, 10 in the superior vena cava, 9 in the mediastinum, 6 in 
the left atrium, 6 in the pulmonary artery, 5 in the esophagus, and 2 in the subclavian 
artery, including duplicated cases. Preoperative treatment was carried out in 22 cases 
(chemoradiotherapy, 14; chemotherapy, 8), whose histological effect was Ef0-1 in 13 
and Ef2-3 in 9. The surgical curative rate was complete resection in 27 and incomplete 
resection in 29; complete resection was common in those receiving preoperative 
treatment. There were no death cases within 30 days after the surgery. In all cases, 
the five-year survival rate was 21.7% and median survival time (MST) was 16.5 months. 
The five-year survival rate was 27.5% in single organ infiltration compared with 15.8% 
in multiple organ infiltration (P = 0.08), 27.5% in n0-1 versus 13.8% in n2-3 (P = 0.30), 
36.8% with preoperative treatment in contrast to 11.2% without preoperative treatment 
(P = 0.06), 9.4% in Ef0-1 as opposed to 76.2% in Ef2-3 (P = 0.05), and 37.7% in complete 
resection in comparison with 7.8% in incomplete resection (P = 0.003). Long-term 
survival over 5 years was noted in 7 cases (12.5%), 4 of which involved single organ 
infiltration, n0-1, preoperative treatment, and Ef2-3. Conclusion: Single organ infiltration 
and n0-1 are good surgical indications for T4 lung cancer, and a favorable prognosis 
can be expected if preoperative treatment and complete resection are performed. 
Keywords: T4 NSCLC, Surgical treatment, Induction treatment
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P2.01-050 Influence of Maintenance Therapy on Incidence of 2nd Line Therapy 
and OS in NSCLC IV Anne C. Lueers1, Nicole Neemann2, Regina Prenzel1, Douglas 
Scriba1, Michael Hoheisel1, Katrin Wedeken1, Kay Wilborn1, Frank Griesinger1 
1Pius-Hospital, Oldenburg/Germany, 2University of Oldenburg, Oldenburg/Germany
Background: One of the strongest rationale for maintenance therapy in NSCLC is the fact 
that exposure to 2nd line therapy is only 40-60% in clinical trials in specialized treatment 
centers. Even with follow-up intervals of 6 weeks, the 2nd line treatment rate does not 
seem to increase. We analyzed the exposure of 2nd line therapy as well as OS and PFS in 
patients with stage IV NSCLC in the subgroups no 2nd line, 2nd line after maintenance and 
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P2.01-047 Fibrobronchoscopic Cryorecanalization for Unresectable Secondary 
Malignant Tumors of the Trachea and Main Bronchi Qianli Ma1, Bin Shi2, Yanchu 
Tian2, Deruo Liu1 1Thoracic Surgery, China-Japan Friendship Hospital, Beijing/China, 2China-
Japan Friendship Hospital, Beijing/China
Background: Most patients with secondary malignant tracheobronchial tumors have 
distressing symptoms due to major airway obstruction. However, they are always too 
frail for curative surgical resection. We choose fibrobronchoscopic cryorecanalization to 
improve their life quality and analyzed the long time survival outcome.Most patients with 
secondary malignant tracheobronchial tumors have distressing symptoms due to major 
airway obstruction. However, they are always too frail for curative surgical resection. 
We choose fibrobronchoscopic cryorecanalization to improve their life quality and 
analyzed the long time survival outcome. file://localhost/Users/app/Documents/2014
下半年/11122014%20JTO/冷冻/Figures/Figure%202.tif file://localhost/Users/app/
Documents/2014下半年/11122014%20JTO/冷冻/Figures/Figure%201.tif file://
localhost/Users/app/Documents/2014下半年/11122014%20JTO/冷冻/Figures/
Figure%203.tif Methods: Clinical records of 14 patients were reviewed retrospectively 
from December 2005 to January 2013. A temperature from -50℃ to -70℃ was delivered 
to the central part of the tumor by cryo-probe for 4 to 6 minutes causing destruction of 
the tumor mass (Cryo-melt method). Subsequently, the edge of tumor was froze for 0.5 
to 2 minutes and then tore the lesion piece by piece immediately with the advantage of 
concretion between the frozen probe tip and the tumor tissue (Cryo-resection method). 
file://localhost/Users/app/Documents/2014下半年/11122014%20JTO/冷冻/Figures/
Figure%204.tif Results: The rates of dramatic and partial symptomatic alleviation were 
57.1% and 28.6% respectively. There were no intraoperative deaths. The median survival 
was 16.0 months. Overall survival was 64.3% at half year, and 50.0% at 2 years. 2-year 
survival was significantly correlated to age (less than 60 years 22.2% versus more than 60 
years 100%, p=0.011), tumor location (main bronchi 0% versus trachea 77.8%, p=0.003), 
and cryorecanalization times (one time 33.3% versus two or more times 80.0%, p=0.037). 
file://localhost/Users/app/Documents/2014下半年/11122014%20JTO/冷冻/Figures/
Figure%205.tif file://localhost/Users/app/Documents/2014下半年/11122014%20
JTO/冷冻/Figures/Figure%206.tif file://localhost/Users/app/Documents/2014下半
年/11122014%20JTO/冷冻/Figures/Figure%207.tif Conclusion: Fibrobronchoscopic 
cryorecanalization is a safe, easily repeatable and effective minimally invasive choice 
for releasing the airway obstructive symptoms. In addition to high local-regional 
control rates, a rewarding result of prolonged survive time can also be obtained. 
Keywords: secondary tracheobronchial tumors, Airway obstruction, cryosurgery, 
bronchoscopy
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P2.01-048 Real-Life 2-Year Therapeutic Strategies in the Management of 
Metastatic Non-Small-Cell Lung Cancers: The ESCAP Study Didier Debieuvre1, 
François Goupil2, Bertrand Lemaire3, Dominique Herman4, Lionel Falchero5, Patrick-Aldo 
Renault6, Antoine Lévy7, Patrick Dumont8, Nadine Paillot9, Philippe Masson10, Jean-
Renaud Barrière11, Yannick Duval12, Bernard Asselain13, François Blanchon14, Françis 
Martin15, Michel Grivaux14 1Emile Muller General Hospital, Mulhouse/France, 2Centre 
Hospitalier Du Mans, Le Mans/France, 3Centre Hospitalier D’Orléans, Orléans/
France, 4Hopital Pierre Beregovoy, Nevers/France, 5Centre Hospitalier de Villefranche-
Sur-Saône, Villefranche-Sur-Saône/France, 6Centre Hospitalier Général de Pau, Pau/
France, 7Centre Hospitalier Jacques Coeur, Bourges/France, 8Centre Hospitalier de Chauny, 
Chauny/France, 9Hôpital Notre Dame de Bon Secours, Metz/France, 10Centre Hospitalier de 
Cholet, Cholet/France, 11Centre Hospitalier Général Draguignan, Draguignan/France, 12Centre 
Hospitalier Cannes, Cannes/France, 13Institut Curie, Paris/France, 14Centre Hospitalier de 
Meaux, Meaux/France, 15Centre Hospitalier Général de Compiègne, Compiegne/France
Background: In the last years, new drugs and strategies have emerged in the 
management of lung cancer (LC). The French College of General Hospital Respiratory 
Physicians therefore promoted a prospective multicenter epidemiological study: the 
ESCAP study. This study was aimed to describe the therapeutic strategies implemented 
during the first 2-year after diagnosis in patients with LC followed in French General 
Hospital chest departments. We report below descriptive results for metastatic non-
small-cell lung cancer (mNSCLC). Methods: For each patient with a LC diagnosed in 2010, 
a standardized form was completed at diagnosis and following each change in treatment 
strategy up to at least 2 years after diagnosis. Results: 53 centers participated in the 
ESCAP study and included 3,943 patients. Among them, 3,418 patients had a NSCLC. 
NSCLC was metastatic in 2,003 patients. In patients with mNSCLC, the first therapeutic 
strategy was chemotherapy alone (56%) followed by palliative chemotherapy plus 
incidental radiotherapy (35%); 4% of patients died without any implemented therapeutic 
strategy (see figure). 29% of patients with chemotherapy alone as first strategy 
died without undergoing any other strategy and 70% had a second strategy (72% 
chemotherapy alone). 35% of patients with radiochemotherapy died without undergoing 
any other strategy and 64% had a 2nd strategy (73% chemotherapy alone).
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P2.01-052 Augmentation of NAD+ by NQO1 Activation Attenuates Cisplatin-
Mediated Hearing Impairment Seihoon Yang1, Sun-Rock Moon2, Kang-Beom Kwon2, 
Hong-Seob So2, Sam-Youn Lee2 1Internal Medicine, Wonkwang University Hospital, Iksan/
Korea, 2Wonkwang Universit Hospital, Iksan/Korea
Background: Cisplatin [cis-diaminedichloroplatinum-II] is an extensively used 
chemotherapeutic agent, and one of its most adverse effects is ototoxicity. A number 
of studies have demonstrated that these effects are related to oxidative stress and 
DNA damage. However, the precise mechanism underlying cisplatin-associated 
ototoxicity is still unclear. The cofactor nicotinamide adenine dinucleotide (NAD+) 
has emerged as a key regulator of cellular energy metabolism and homeostasis. 
Although a link between NAD+-dependent molecular events and cellular metabolism 
is evident, it remains unclear whether modulation of NAD+ levels has an impact on 
cisplatin-induced hearing impairment. Methods: To investigate whether augmentation 
of NAD+ by NQO1 activation using b-Lapachone (b-Lap) attenuates cisplatin-mediated 
hearing impairment, male C57BL/6 mice and NQO1 knockout mice on a C57BL/6 
background were used. For analysis of the auditory threshold, auditory brainstem 
response (ABR) was recorded. For biochemical analysis, we measured the enzymatic 
activity of SIRT1, PARP1, ROS production, NAD+/NADH ratio, mRNA levels of miR-34a 
and pro-inflammatory cytokines. Immunohistochemistry and western blot analysis 
were also performed. Results: We have demonstrated for the first time that both the 
protein expression level and the activity of SIRT1 were suppressed by the reduction 
of intracellular NAD+ levels in cisplatin-treated cochlear tissue. We also found that the 
decrease in SIRT1 protein expression and its activity after cisplatin exposure were 
mediated by the increase in transcriptional activity of p53 for miR-34a expression 
and PARP-1 activation causing NAD+-depletion, respectively. However, the increase 
in cellular NAD+ levels by NQO1 activation using b-Lap prevented mice from cisplatin-
induced cochlear damage and hearing impairment through the modulation of PARP-1, 
SIRT1, p53, and NF-kB. Conclusion: Considering that b-Lap itself did not attenuate 
the tumoricidal effect of cisplatin, these results suggest that the direct modulation of 
the cellular NAD+ level by pharmacological agents could be a promising therapeutic 
strategy for enhancing the efficacy of cisplatin chemotherapy without its adverse effects. 
Keywords: cisplatin, ototoxicity, Lapachone, NAD+
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P2.01-053 The Role of Systemic Therapy in Sarcomatoid Carcinoma of the 
Lung Nagla Abdel Karim, Jiang Wang, Tariq Namad, Ehsan Malek, Changchun Xie, John 
Morris The University of Cincinnati, Ohio/OH/United States of America
Background: Primary sarcomatoid carcinoma (PSC) accounts for 2% to 3% of all 
lung cancers. Stage-for-stage, PSC carries a poorer prognosis compared to the more 
common types of lung cancer. It typically occurs in older heavy smoking men and 
has a predilection for upper lobe involvement. PSC of the lung was initially described 
by Virchow in 1865 as a “biphasic” lesion of adenocarcinomatous or squamous cell 
components along with spindle cell or giant cell elements forming at least 10% of 
the tumor mass. This description fulfills the current WHO criteria for the diagnosis 
of PSC. Mutational analysis has revealed a common origin of both elements and it 
is thought that epithelial-mesenchymal transition (EMT) is the mechanism of that 
gives rise to this tumor, with the epithelial elements (adenocarcinoma or squamous 
component) that has undergone a transition to a poorly-differentiated mesenchymal 
type (sarcomatoid) with the expression of mesenchymal proteins such as vimentin. 
Efforts to study PSC has been hindered by the rarity of this variant. Aim of the study: 
To assess the impact of surgery and various systemic therapies on patients with 
PSC of the lung at the University of Cincinnati Medical Center (UCMC). Methods: This 
retrospective study included all patients identified with a pathologically confirmed 
diagnosis of PSC of the lung treated at UCMC between the years 2000-2014. Death was 
considered as the study endpoint. Kaplan-Meier analysis was used to calculate median 
overall survival (OS) and 95% confidence intervals (CI). Cox model was used to test the 
chemotherapy effect adjusted for age, sex and surgery, and determine hazard ratios 
(HR). Data was analyzed using SAS® Version 9.4. Results: We identified 21 patients 
with a diagnosis of PSC of the lung that were eligible for chart review and analysis. 
The 14 men and 7 women had a median age of 59 (range, 31-84 years). Treatment 
with systemic chemotherapy showed a trend in improvement in outcome among all 
stages of disease (p=0.08 and HR 0.04) but chemotherapy was most often used in 
advanced stages. Female gender demonstrated a trend for improved OS (p=0.1), and 
older patients demonstrated a better OS (HR=0.849; p=0.041) by a one-year increase 
in age. The median OS of the patients with PSC treated with systemic chemotherapy 
was 375 days (95% CI 114-600 days). Patients with early stage disease who were 
eligible for surgical resection, with or without the addition of systemic chemotherapy 
had a median survival of 457.5 days (95% CI 206.-1187 days), only slightly different 
from patients with advanced disease that received systemic chemotherapy. Patients 
who did not receive systemic chemotherapy had a lower median OS of 256 days (95% 
CI 98-999 days). Two patients demonstrated EML-4/ALK translocations. The patient 
with the longest OS of about three years was treated with systemic therapies including 
cisplatin, gemcitabine, docetaxel and crizotinib. Conclusion: Patients with PSC of the 
lung may benefit from systemic therapy. Larger prospective studies are needed to 
confirm this benefit especially if used as an adjuvant therapy in early stage disease. 
Keywords: Sarcomatoid Carcinoma of the lung, Systemic therapy, chemotherapy, 
Primary Sarcomatoid Carcinoma
2nd line without maintenance therapy. Methods: All primary lung cancer cases stage IV 
in the lung cancer center were analyzed based on the documentation files between 2009 
and 2013. Patients were followed-up between 1st and 2nd line therapy every 6-8 weeks 
according to S3 guidelines. Patients with EGFR+, ALK+ or ROS1+ were excluded from the 
analysis. Results: 221 patients were diagnosed with NSCLC IV (UICC7), or had systemic 
relapse of localized disease and were treated with 1st line therapy for metastatic disease. 
Of these, 160 (72%) received 1st line combination therapy with Carboplatin, 50 (23%) 
with Cisplatin and 11 (5%) with platin-free single agent therapy. 45 (19%) of all patients 
received maintenance therapy, most of them with bevacizumab. Of 221 patients, 203 
(92%) progressed after 1st line therapy or 1st line and maintenance therapy. 106/163 
(65%) of non-maintenance therapy patients received 2nd line therapy, 57 patients (36%) 
did not. Of 40 patients receiving maintenance therapy and requiring 2nd line therapy, 
31 (78%) received 2nd line therapy. Reasons for not obtaining 2nd line therapy were 
captured and were manifold. Survival analyses showed significant differences regarding 
overall survival (median survival 21 (maintenance and 2nd line) vs. 13 (1st and 2nd line) 
months) but no relevant differences regarding progression free survival on 2nd line 
(median 2 months). Conclusion: In a certified lung cancer center and stringent follow-up 
every 6 to 8 weeks, 1/3 of patients do not receive 2nd line therapy because of various 
reasons. The application of maintenance therapy raises the chances of receiving 2nd line 
therapy and increases overall survival whereas progression free survival is not affected. 
Keywords: second line therapy, maintenance therapy
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P2.01-051 Determinants of Sequential versus Concurrent Chemoradiotherapy 
in Stage III Non-Small Cell Lung Cancer Patients Iris Walraven1, M Ten Berge2, 
Ronald Damhuis3, C. Tissing-Tan4, E. Troost5, B. Reymen5, J. Widder6, F. Koppe7, 
A. Van Der Wel8, E. Vonk9, I. Coremans10, J. Bussink11, K. De Jaeger12, N. Van Der 
Voort Van Zyp13, Sherif El Sharouni14, H. Knol15, D. Woutersen16, Jose Belderbos1 
1Department of Radiation Oncology, The Netherlands Cancer Institute – Antoni Van 
Leeuwenhoek Hospital, Amsterdam/Netherlands, 2Leiden University Medical Center, 
Leiden/Netherlands, 3Comprehensive Cancer Center the Netherlands, Rotterdam/
Netherlands, 4Institute for Radiation Oncology Arnhem, Arnhem/Netherlands, 5Department 
of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, Maastricht/
Netherlands, 6Department of Radiation Oncology, University Medical Center Groningen, 
Groningen/Netherlands, 7Department of Radiation Oncology, Verbeeten Institute, Tilburg/
Netherlands, 8Department of Radiation Oncology, Radiotherapy Institute Friesland, 
Leeuwarden/Netherlands,9Department of Radiation Oncology, Radiotherapeutisch 
Instituut Stedendriehoek En Omstreken (Riso), Deventer/Netherlands, 10Department of 
Radiation Oncology, Leiden University Medical Center, Leiden/Netherlands, 11Department 
of Radiation Oncology, Radboud University Nijmegen Medical Center, Nijmegen/
Netherlands, 12Department of Radiation Oncology, Catharina Hospital, Eindhoven/
Netherlands, 13Department of Radiation Oncology, Medical Center Haaglanden, The Hague/
Netherlands, 14Department of Radiotherapy, University Medical Centre Utrecht, Utrecht/
Netherlands, 15Department of Radiation Oncology, Medical Center Alkmaar, Alkmaar/
Netherlands, 16Department of Radiation Oncology, Medical Spectrum Twente, Enschede/
Netherlands
Background: Concurrent chemoradiotherapy (CCRT) is considered the standard 
treatment regimen in patients with inoperable stage III non-small cell lung cancer (NSCLC). 
Sequential chemoradiotherapy (SCRT) is recommended in patients who are deemed unfit 
to receive CCRT. As this selection criterion is not very explicit, the ‘personalized’ choice 
for either CCRT or SCRT is mainly dependent on the multidisciplinary team and treating 
physician’s judgment. Consequently, this may result in a variation of treatment policies 
across hospitals/radiotherapy (RT) departments. In this study, we investigated the ratio 
CCRT/SCRT in eight RT departments in the Netherlands. Furthermore, we explored 
which patient and disease characteristics determined the choice for SCRT compared to 
CCRT. Methods: Data were derived from the Dutch Lung Radiotherapy Audit (DLRA). Within 
the DLRA, lung cancer patients undergoing a curative intent treatment are prospectively 
registered with respect to patient and disease characteristics, diagnostics and treatment. 
For this study, from eight out of 21 Dutch RT departments, patients with stage III NSCLC 
undergoing chemoradiotherapy in 2014 were selected. CCRT was defined as ≤ 50 
days between the start of chemotherapy and the start of radiotherapy. Furthermore, 
RT had to start before the end of the last chemotherapy in CCRT. Patients with < 150 
days between treatments were scored as undergoing SCRT. Differences in patient and 
disease characteristics between CCRT and SCRT were tested with independent samples 
t-tests (for continuous variables) and with chi-square tests (for categorical variables). 
A multivariate logistic regression model was constructed to determine patient and 
disease characteristics associated with the choice for SCRT, using a backward selection 
procedure. Odds ratios (OR) with 95% confidence intervals (CI) are reported. Results: In 
total, 453 stage III NSCLC patients (mean age 65.4 years, 56.5% male) were registered. 
Of those, 351 (77.5%) patients underwent CCRT and 102 (22.5%) patients received 
SCRT. The proportion of patients treated with CCRT ranged from 51% to 89% across RT 
departments. Gender, smoking, gross target volume (GTV), performance score (PS), lung 
function, Charlson comorbidity index and tumor location were not significantly associated 
with SCRT in the multivariate model. Conversely, older age (OR 1.05 [95%CI 1.03-1.09]), 
histology (large cell carcinoma vs adenocarcinoma [OR 0.42 CI 0.19 to 0.97]) and cN-
stage (N3 vs N0-1 [OR 5.71 {95%CI 2.10-15.50}]) were significantly associated with 
SCRT. Conclusion: In this selected group of registered NSCLC patients, a large variation 
was observed in the proportion of stage III NSCLC patients treated with CCRT, ranging from 
51% to 89% across RT departments. Surprisingly, PS and comorbidity index (as indicators 
of a patients’ physical fitness) were not significantly different in CCRT or SCRT patients 
while age and cN-stage were. Based on the analyzed patient and disease characteristics, 
it is currently unclear why patients treated with SCRT were not eligible for CCRT. 
Keywords: sequential chemoradiotherapy, non-small cell lung cancer, concurrent 
chemoradiotherapy
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P2.01-056 Thyroid Transcription Factor 1 (TTF1) as a Possible Predictive 
Biomarker for Pemetrexed-Based Chemotherapy in Non-Squamous NSCLC 
Xabier Mielgo Rubio1, Alejandro Velastegui1, Ruth Martínez Cabañes2, Adriana Rosero1, 
Leticia Ruiz-Giménez1, Maria Garcia Ferron1, Jorge Silva1, Cristina Aguayo1, Clara Olier1, 
Carlos Jara1 1Medical Oncology, Hospital Universitario Fundación Alcorcón, Alcorcón/
Spain, 2Medical Oncology Research Unit, Hospital Universitario Fundación Alcorcón, 
Alcorcón/Spain
Background: There are no demonstrated predictive molecular markers for pemetrexed. 
The aim of this study is to explore and evaluate whether thyroid transcription factor 
1 (TTF1) protein expression can be a predictive biomarker of clinical activity for 
pemetrexed-based chemotherapy in patients with nonsquamous non-small cell lung 
cancer (NSCLC). Methods: 123 patients with advanced nonsquamous NSCLC treated 
with pemetrexed-based chemotherapy as first-line, maintenance, second or later-line 
therapy were retrospectively reviewed. Then we chosen patients who had undergone 
assay of immunohistochemical expression of TTF1 in their tumor tissue sample, and we 
analyzed for their clinicopathological features, expression of TTF1 and clinical outcomes. 
Analysis of TTF1 expression was done according to the routine clinical practice of our 
center. Results: Immunohistochemical analysis of TTF1 expression was only performed 
in 51 of the 123 patients reviewed. Of these 51 patients, 36 were men and 15 women, 7 
(13,7%) had never smoked and 44 (86,3%) were former or current smokers. Median age 
was 65 (range 39-79). Performance status (PS) distribution: 0 (25,4%), 1 (62,7%), 2 (7,8%), 
3 (3,9%). Predominant histology type was adenocarcinoma (78,4%), followed by large 
cell carcinoma (13,7%) and not otherwhise specified-NOS (7,8%). 36 patientes had TTF1-
positive tumors (70,5%), and 15 TTF1-negative ones (29,5%). The types of tumor tissue 
sample in which TTF1 assay was undergone were the following: endobronquial biopsy 
(43,1%), percutaneous biopsy (33,3%), fine needle aspiration puncture (17,6%), citology 
(0,5%). TTF1 positive tumors shown a higher disease control rate (DCR) for pemetrexed-
based chemotherapy (60,5% vs 39,5%, p=0,05). Median progresión free survival (PFS) 
and overall survival (OS) in the whole group was 5,55 and 23,95 months respectively. 
TTF1-positive tumors had significant longer PFS (6,96 vs 3,64 months; p=0,0156) and 
a nonsignificant trend of longer OS (24,27 vs 13,66 months; p=0,581) to pemetrexed-
based chemotherapy than patients with TTF1-negative tumors. Conclusion: TTF1 
protein expression was associated with better clinical outcomes. TTF1 positive tumors 
shown a significant association with better PFS and a nonsignificant trend of better 
DCR and OS in nonsquamous NSCLC patients who were treated with pemetrexed-
based chemotherapy. The predictive role of TTF1 expression should be further studied. 
Keywords: pemetrexed, TTF1, biomarker, NSCLC
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P2.01-057 Serum Mass-Spectrometry Test in First-Line Advanced Non-Small 
Cell Lung Cancer Patients Treated with Standard Chemotherapy Regimens 
Francesco Grossi1, Carlo Genova1, Erika Rijavec1, Maria Giovanna Dal Bello1, Giulia 
Barletta1, Federica Biello1, Claudia Maggioni1, Julia Grigorieva2, Krista Meyer2, Heinrich 
Roder3 1Lung Cancer Unit, Irccs Aou San Martino - Ist, Genova/Italy, 2Biodesix Inc., Boulder/
CO/United States of America, 3Biodesix Inc., Boulder/United States of America
Background: The mass-spectrometry based serum test VeriStrat® (VS) was developed 
using samples from non-small cell lung cancer (NSCLC) patients (pts) treated with 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs); VS was shown 
to be prognostic in several tumors and predictive of differential overall survival (OS) 
benefit for erlotinib vs. chemotherapy (CT) in 2nd line for NSCLC. We investigated the 
role of VS in pts receiving Cisplatin (CDDP) or Carboplatin (CBDCA) plus Pemetrexed (P) 
as 1st line for advanced, non-squamous NSCLC. Methods: VeriStrat classification was 
available for 55 eligible pts, who were classified as VS Good (VSG) or VS Poor (VSP); VS 
testing was done blinded to clinical data. Progression-free survival (PFS) and OS were 
analyzed by Kaplan-Meier method and compared using log-rank p-values; Cox models 
were used in multivariate analysis. Association with categorical variables was analyzed 
by Fisher’s exact test. Results: 36 (65%) pts were classified as VSG and 19 (35%) as 
VSP. In the overall population, median PFS was 6.1 months (mo) for VSG vs.1.3 mo for 
VSP (hazard ratio (HR) 0.39 [0.21-0.70], p=0.001 ); adjusted HR (AHR) 0.43 [0.21-0.91], 
p=0.026). Median OS was 10.6 mo for VSG vs. 3.1 mo for VSP (HR 0.26 [0.14-0.50], 
p<0.001; AHR 0.20 [0.09-0.47], p<0.001). A similar relationship was found in both 
treatments: In CBDCA-P median PFS in VSG and VSP was 3.9 mo and 1.6 mo respectively 
(HR 0.34 [0.14-0.81], p=0.011); median OS was 10.0 mo in VSG and 2.0 mo in VSP (HR 
0.26 [0.11-0.61], p=0.001). In CDDP-P median PFS was 6.6 mo in VSG and 1.2 mo in 
VSP (HR 0.52 [0.20-1.33], p=0.161), median OS was 12.3 mo in VSG, 3.5 mo in VSP (HR 
0.25 [0.09-0.70], p=0.005).When compared within VS groups, no statistically significant 
differences between CBDCA-P and CDDP-P was found either for PFS (VSG: p=0.471, 
VSP: p=0.493) or OS (VSG: p=0.319, VSP: p=0.429). VS was significantly associated 
with disease control rate (p=0.003) and objective response (p=0.021).
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P2.01-054 Continuation Maintenance Therapy of Pemetrexed and Renal 
Toxicities Teppei Yamaguchi, Kazuyoshi Imaizumi, Toru Nakanishi, Masamichi Hayashi, 
Yasuhiro Goto, Sumito Isogai, Atsushi Kato Department of Respiratory Medicine, Fujita 
Health University, Toyoake/Japan
Background: Pemetrexed is a multitargeted antifolate agent approved for use in the 
treatment of pleural mesothelioma and non-small cell lung cancer. A recent phase III 
PARAMOUNT trial has shown that pemetrexed continuation maintenance therapy reduced 
the risk of disease progression and death compared with a placebo. However, renal 
toxicities of maintenance therapy of pemetrexed has not been clarified. Methods: We 
retrospectively evaluated a total of 30 patients who had received 4 cycles of induction 
therapy with pemetrexed with platinum (cisplatin or carboplatin) regimens with or 
without bevacizumab followed by more than 4 cycles of pemetrexed (± bevacizumab) 
maintenance therapy. Estimated creatinine clearance at three different time points (before 
the induction therapy, after the induction therapy, and after the 4 cycles of maintenance 
therapy) were analyzed. We also investigated factors significantly associated with 
deterioration in renal function during pemetrexed maintenance therapy using univariate 
and multivariate logistic regression analyses. Results: Significant decrease in the mean 
value of eCcr could be observed during pemetrexed maintenance therapy in both cisplatin 
and carboplatin groups. Multivariate analysis revealed that cisplatin administration and 
poor performance status (PS ≥1) were risk factors significantly associated with eCcr 
decrease. Conclusion: Continuance maintenance therapy of pemetrexed generally 
could cause renal dysfunction. More attention should be paid to the patients receiving 
a cisplatin based induction therapy and patients with poor performance status. 
Keywords: non-small cell lung cancer, pemetrexed, maintenance therapy, renal toxicity
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P2.01-055 Prospective Study of UGT1A1*27 Gene Polymorphism for Irinotecan 
Therapy: Result of Lung Oncology Group in Kyushu (LOGiK1004B) Minoru 
Fukuda1, Takayuki Suetsugu2, Midori Shimada3, Takeshi Kitazaki3, Kohji Hashiguchi3, 
Junji Kishimoto4, Noriyuki Ebi5, Koichi Takayama6, Kenji Sugio7, Hiroshi Semba8, Yoichi 
Nakanishi4, Yukito Ichinose9 1Clinical Oncology Center, Nagasaki University Hospital, 
Nagasaki/Japan, 2Respiratory Medicine, Sendai Medical Association Hospital, Kagoshima/
Japan, 3Department of Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki/
Japan, 4Center for Clinical and Translational Research (Ccrt), Kyusyu University Hospital, 
Fukuoka/Japan, 5Department of Respiratory Oncology Medicine, Iizuka Hospital, Fukuoka/
Japan, 6Research Institute for Disease of the Chest, Graduate School of Medical Sciences, 
Kyusyu University, Fukuoka/Japan, 7Department of Thoracic and Breast Surgery, Oita 
University Faculty of Medicine, Oita/Japan, 8Department of Respiratory Medicine, Kumamoto 
Regional Medical Center, Kumamoto/Japan, 9Department of Thoracic Oncology, National 
Hospital Organization Kyusyu Cancer Center, Fukuoka/Japan
Background: UGT1A1*27 is known that exist together with UGT1A1*28 as linkage 
disequilibrium and impair the effect of UDP-glucuronosyltransferase (UGT) in basic 
research, however, poor clinical investigation because of the rare frequency. The aim 
of this study is to evaluate the effect of UGT1A1*27 gene polymorphism for safety 
and efficacy in irinotecan therapy. Methods: Eligibility criteria were: lung cancer 
patients; scheduled the dose of irinotecan therapy as single ≥ 80 mg/m2, combination 
≥ 50 mg/m2, radiation with single ≥ 50 mg/m2, radiation with combination ≥ 40 mg/
m2; age ≥ 20 years; performance status 0-2. After informed consents, patients were 
enrolled and collected the blood to examine UGT1A1*28 andUGT1A1*6 polymorphism 
and received irinotecan therapy. Examination of UGT1A1*27 were added when 
founding UGT1A1*28 polymorphism. We planned 111 enrollment for an accrual of 10 
patients with UGT1A1*27 gene polymorphism. Results: Fifty patients were enrolled in this 
trial between October 2011 and December 2013. Two patients judged protocol violation. 
Remaining 48 were evaluated. UGT1A1 gene polymorphisms *28/*28, *6/*6, *28/*6, 
*28/-, *6/-, -/- observed 0, 1, 1, 7, 17 and 22, respectively. UGT1A1*27 were analyzed in 
9 patients including ineligible one patients with *28/*28, however, no UGT1A1*27 gene 
polymorphism was found and the study was stopped. A total of 153 times of irinotecan 
therapy were administered with a median of 3 times per one patient: 1 time in 7 
patients (15%), 2 times in 9 (19%), 3 in 19 (40%), 4 in 3 (6%), 5 in 1 (2%), and 6 in 9 
(19%). Irinotecan were used as combination chemotherapy in 32 (67%) patients, with 
cisplatin in 12 (25%), carboplatin in 10 (21%), gemcitabine in 9 (19%), paclitaxel in 1 
(2%). In remaining 16 patients (33%), only irinotecan single therapy were administered. 
Radiotherapies were administered concurrently in 23 (48%) patients with median 60 
(range 40-61.4) Gy. Febrile neutropenia were observed higher tendency in patients 
with UGT1A1*6 (32%) and UGT1A1*28 (25%) gene polymorphism compare with wild type 
(14%) but had no significant difference. Grade 3/ 4 leukopenia and neutropenia were 
observed in 6 out of 8 patients with UGT1A1*28 gene polymorphism and significant higher 
compare with wild type (75% vs. 32%, p=0.049; 75% vs. 36%, p=0.039, respectively). 
The other toxicities have no difference betweenUGT1A1 gene polymorphism and wild 
type. There was no pneumonitis and treatment-related death. Tumor response was not 
evaluated because not included endpoints. Median PFS of 48 patients was 6.8 months 
and the 1- and 2-year survival rates were 20.8%. Median PFS separated by UGT1A1 
gene polymorphisms were 10.1 months in UGT1A1*28 heterozygous, 8.5 months 
in UGT1A1*6 heterozygous, and 6.8 months in both wild type, respectively. Median OS of 
48 patients was 15.7 months and the 1- and 2-year survival rates were 57.7% and 40.3%, 
respectively. Median OS separated by UGT1A1 gene polymorphisms were not reached in 
in UGT1A1*28 heterozygous, 16.4 months in UGT1A1*6 heterozygous, and 12.3 months in 
wild type, respectively. Conclusion: UGT1A1*27 gene polymorphism was not found in our 
methods. Further investigation might be warranted in patients with UGT1A1*28 wild type. 
Keywords: irinotecan, UGT1A1, gene polymorphism, lung cancer
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nine records were reviewed. The median age was 62 (28-79), 60% were male, 40% 
were never smoker, 89% had an ECOG PS0-1 and 11% had a PS 2-3. The median value 
of CEA and CYFRA were 10.5 ng/ml and 3.0 ng/ml, respectively. 93% were diagnosed 
as adenocarcinoma and 7% were diagnosed as other subtypes (large, adenosquamous, 
sarcomatoid and not otherwise specified). 79% (81/102) had a positive TTF1 staining. 
26% had EGFR mutation, 7% had ALK fusion and 11% had KRAS mutation. 36% of patients 
were received bevacizumab with pemetrexed/platinum. 35% of patients were treated 
with cisplatin. The response rate of pemetrexed/platinum was 34.8%. Median overall 
survival was 537days. 65% of patients were treated with taxane and the response rate 
was 15.0%. In multivariate analysis, poor PS(HR 1.33; p=0.027), others in histological 
subtypes (HR2.00; p=0.047) and K-RAS mutation(HR 2.74; p=0.021) correlated 
significantly with a shorter overall survival and low CYFRA(≤3.0ng/ml, HR 0.55; p=0.002) 
correlated significantly with a longer overall survival. Conclusion: High CYFRA, KRAS 
mutation and others in histological subtypes may be associated with shorter overall 
survival treated with pemetrexed/platinum in non-squamous NSCLC. The development 
of effective treatment regimens for such patients is needed to improve their outcomes. 
Keywords: pemetrexed, NSCLC, CYFRA, histology
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P2.01-060 Biweekly Irinotecan/Bevacizumab in Heavily Treated Advanced 
NSCLC and Survival According to TIMP1 and EGFR Expression Andrés F. 
Cardona1, Leonardo Rojas2, Carlos A. Vargas1, Hernan Carranza1, Jorge M. Otero1, 
Claudio Martin3, Luis Corrales4, Mauricio Cuello5, Guillermo Bramuglia6, Pilar Archila1, 
Oscar Arrieta Rodriguez7 1Clinical and Translational Oncology Group, Foundation for Clinical 
and Applied Cancer Research - Ficmac, Bogotá/Colombia, 2Centro Javeriano de Oncología, 
Hospital Universitario San Ignacio, Bogotá/Colombia, 3Clinical Oncology, Instituto Fleming, 
Buenos Aires/Argentina, 4Clinical Oncology, Hospital San Juan de Dios, San José/Costa 
Rica, 5Clinical Oncology, Hospital de Clínicas - Udelar, Montevideo/Uruguay, 6Argenomics, 
Buenos Aires/Argentina, 7Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina 
Personalizada, National Cancer Institute, Mexico City/Mexico
Background: Irinotecan and bevacizumab are effective against non-small cell lung 
cancer (NSCLC) and synergism with non-cross-resistance has been demonstrated in 
preclinical studies. Tissue inhibitor of metalloproteinases 1 (TIMP1) and EGFR regulates 
extracellular matrix catabolism and promotion of cell growth and anti-apoptotic activity 
in NSCLC. Methods: Forty nine patients with heavily treated metastatic NSCLC were 
enrolled from March 2011 to November 2014. Thirty-three (67%) had never been 
exposed to bevacizumab and 16 had received antiangiogenic therapy as part of their 
first-line (all had achieved a previous response for more than 6 months). Treatment 
consisted of a 90-min intravenous infusion of 125 mg/m2 irinotecan on day 1 and 8 
plus 7.5 mg/kg bevacizumab on day 1 (treatment was repeated every 3 weeks). In all 
patients the mutational status of KRAS and EGFR, as well as TIMP1 and EGFR expression 
was evaluated. Results: The median age was 60 years (range, 44-78 years), 57% was 
male and 75% had ECOG 0-1. The median follow-up was 13.2 months and twenty-three 
patients had received >3 prior lines. The ORR was 32% (95%CI 22% to 39%) and thirteen 
patients (26%) achieve stable disease. Median progression-free survival (PFS) rate was 
4.4 months (95%CI 2.8-8.3) and median overall survival (OS) rate was 18.0 months 
(95%CI 16.2-30.7). Nine patients harbouring EGFR mutations had a long-lasting, partial 
response (>5 months after at least 4 prior lines). Major toxicity was myelosuppression 
(grade 3 neutropenia occurred in 32% of patients and thrombocytopenia in 8.3%). Three 
patients experienced febrile neutropenia, one patient suffered grade 4 diarrhoea, and 
non-haematological toxicity was usually mild. Shorter OS was found in patients with a 
higher expression of TIMP1 mRNA (P=0.0001) but not according to the expression of 
EGFR (P=0.14). Conclusion: Irinotecan plus bevacizumab resulted in favourable activity 
and manageable toxicity profiles as third or fourth line for patients with advanced NSCLC. 
Our results suggested that such regimen can represent a reasonable chemotherapeutic 
option, especially for subjects having EGFR mutations and low expression of TIMP1. 
Keywords: irinotecan, TIMP1, Heavily treated, NSCLC
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P2.01-061 COX-2 Expression Does Not Predict Outcome of Celecoxib in 
Addition to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer 
Miklós Gulyás1, Johanna S.M. Mattsson2, Andrea Lindgren3, Christer Sederholm4, 
Lars Ek5, Kristina Lamberg6, Annelie Behndig7, Erik Holmberg8, Patrick Micke2, Bengt 
Bergman9 1Academic Hospital, Clinical Pathology, Uppsala/Sweden, 2Department of 
Immunology, Genetics and Pathology, Uppsala University, Uppsala/Sweden, 3Inst for 
Medicine and Health, Linkoping University, Linkoping/Sweden, 4Pulmonary Medicin, 
Linkoping University Hospital, Linkoping/Sweden, 5Pulmonary Medicine, Skane 
University Hospital, Lund/Sweden, 6Pulmonary Medicine, Akademiska Hospital, Uppsala/
Sweden, 7Pulmonary Medicine, Norrland University Hospital, Umeå/Sweden, 8Dept of 
Oncology, Inst of Clinical Sciences, Sahlgrensk Academy at University of Gothenburg, 
Gothenburg/Sweden, 9Dept of Pulmonary Medicine, Sahlgrenska University Hospital, 
Gothenburg/Sweden
Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small 
cell lung cancer (NSCLC), and is therefore a potential target for treatment. However, 
phase III trials have failed to demonstrate beneficial survival effects of adding COX-2 
inhibitors to standard chemotherapy. We investigated whether COX-2 expression in tumor 
and stromal cells had any predictive impact on the effects of celecoxib, a selective COX-2 
inhibitor. Methods: In a previously published multicenter phase III trial, 316 patients with 
NSCLC stage IIIB or IV and WHO performance status 0-2 were randomized to receive 
celecoxib 400 mg b.i.d. or placebo up to one year in addition to a two-drug platinum-
Population 
(N°)
Median PFS 
(months) Hazard ratio, p
Median OS 
(months) Hazard ratio, p
VSG VSP VSG VSP
Overall (55) 6.1 1.3 0.39 [0.21-0.70] p=0.001 10.6 3.1
0.26 [0.14-0.50] 
p<0.001
CBDCA-P 
(30) 3.9 1.6
0.34 [0.14-0.84] 
p=0.011 10.0 2.0
0.26 [0.11-0.61] 
p=0.001
CDDP-P (25) 6.6 1.2 0.52 [0.20-1.33] p=0.161 12.3 3.5
0.25 [0.09-0.70] 
p=0.005
 
 
Conclusion: VeriStrat has prognostic significance in platinum-based CT: overall, VSP 
pts have significantly shorter PFS and OS than VSG pts. In each VS group, CDDP-P 
and CBDCA-P showed similar behavior. Further research is needed to find alternative 
treatments to improve outcomes for VSP pts. ClinicalTrials.gov Identifier: NCT02055144. 
Keywords: prognostic factor, non-small cell lung cancer, VeriStrat, chemotherapy
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P2.01-058 Factors Predicting Long Duration of Pemetrexed Maintenance 
Therapy: A Retrospective Cohort of 65 Patients Clara Fontaine-Delaruelle1, Virginie 
Avrillon2, Jérôme Fayette2, Maurice Pérol2 1Service de Pneumologie, Centre Hospitaliser 
Lyon Sud, Pierre Bénite/France, 2Groupe Thoracique Et Orl, Centre Léon Bérard, Lyon/France
Background: BACKGROUND: The Paramount trial demonstrated a significant survival 
benefit with pemetrexed continuation maintenance therapy for non-squamous NSCLC. 
This retrospective work aims to study predictive factors for a long duration of 
maintenance therapy and its toxicities. Methods: METHOD: All patients who received 
pemetrexed maintenance between 1st January 2009 and 1st July 2013 in Centre 
Léon Bérard (France) were included. Patients were classified in two groups: “long 
maintenance” if they received ≥ 5 cycles of maintenance with pemetrexed and “short 
maintenance” if they received ≤ 4 cycles. We retrospectively collected data about 
patients (age, gender, smoking status, PS), histological subtype, number of metastatic 
sites, number of induction and maintenance cycles, response to induction chemotherapy, 
bevacizumab use, reason for discontinuation, and toxicities. Proportions of patients or 
disease characteristics in each group were compared with univariate test (Fisher exact 
and Wilcoxon). Results: RESULTS: 65 patients were included, 33 in “short maintenance” 
group and 32 in “long maintenance” group, with 60% male and a mean age of 61.13 
(±7,78). 55% of patients had ≥ 2 metastatic sites with PS 0, 1 or 2 in 21%, 67%, and 
13% out of patients, respectively. Induction cycles were initiated with cisplatin in 71% 
and carboplatin in 29% of patients; median number of induction cycles was 4 [3-6]. 
39% of patients achieved partial response to induction chemotherapy and 61% stable 
disease. Median number of maintenance cycles was 4 [1-28]. 19 patients (29%) received 
bevacizumab in combination to pemetrexed during induction and maintenance therapy. 
Maintenance discontinuation was due to progressive disease in 61%, toxicity in 19% 
and local treatment in 16% of patients, respectively. Significant predictive factors of 
a long duration of maintenance therapy were female gender (27% vs 53%; p=0.044) 
and ≥ 2 metastatic sites (42% vs 70%; p=0,046). Age, smoking status, histological 
subtype, response to induction therapy, bevacizumab use, and PS were not significantly 
related to maintenance duration. Grade 3-5 adverse events occurred in 20 patients (31%) 
including 5 treatment-related deaths (8%) (including 4 infectious-related deaths). There 
was a similar rate of grade 3-5 toxicities in both groups. Toxicities were mainly infectious 
(n= 13; 65%) including 4 febrile neutropenia. Predictive factors of grade 3-5 toxicities 
were age > 70 years (35% vs 9%; p=0.026) and carboplatin use (50% vs 20%; p=0,020). 
At the end of the study, maintenance therapy was ongoing in 3 patients. Among the 62 
other patients, 81% received subsequent systemic therapy with a similar duration of 
treatment between “short” and “long” maintenance groups. Conclusion: CONCLUSION: 
Univariate analysis identified female gender and ≥2 metastatic sites as only predictive 
factors for a long duration of pemetrexed maintenance therapy. Patients with single 
metastasis frequently stopped maintenance treatment for administration of local 
therapy. Predictive factors for severe toxicities were age > 70 years and carboplatin use 
whereas addition of bevacizumab to pemetrexed did not result in an increase of toxicity. 
Keywords: pemetrexed, maintenance therapy, lung cancer
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P2.01-059 Does Pemetrexed/Platinum Fit All Patients with Non-Squamous 
Non-Small Cell Lung Cancer? A Retrospective Study of Clinical Factors and 
Outcomes Junichi Shimizu1, Yuko Oya1, Kosuke Tanaka1, Tatsuya Yoshida1, Yoshitsugu 
Horio1, Yasushi Yatabe2, Toyoaki Hida1 1Thoracic Oncology, Aichi Cancer Center, Nagoya/
Japan, 2Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya/Japan
Background: Pemetrexed/platinum is one of the standard treatment regimens for 
patients with advanced non-squamous non-small cell lung cancer(NSCLC). The aim of 
this study was to examine the association between survival of lung cancer patients 
treated with pemetrexed/platinum and clinical factors. Methods: The medical records 
of advanced or relapsed non-squamous NSCLC patients treated with pemetrexed/
platinum at our hospital between January 2010 and December 2013 were reviewed. 
Basic characteristics, histological subtypes of NSCLC, driver mutation status, TTF1 
staining status and status of treatment with taxane were evaluated for association with 
the survival from pemetrexed/platinum started day to deaths. Results: Two hundreds 
S542 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
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trial. Methods: This analysis was performed in the overall safety population (N=656) 
and the EA subgroup safety population (N=152) mainly from China, Taiwan, and Korea 
including squamous and non-squamous NSCLC patients. The Common Terminology 
Criteria for Adverse Events (version 3.0) was used for summary of the AE incidence 
rates by cycle and AE severity reported by investigator. The Lung Cancer Symptom 
Scale (LCSS) was used to evaluate patients’ QoL. Worsening of fatigue was defined as 
an increase of 15 mm or more from baseline on a 100 mm scale in LCSS reported by 
the patients. The percentage of patients with worsening fatigue was also summarized 
by cycle. The time to worsening of fatigue symptom was analyzed using Kaplan-Meier 
method and Cox proportional model. Results: In the EA population drug-related fatigue 
(grade 1-4) occurred more frequently in pemetrexed arm compared with placebo 
arm (30.4% vs 16.0%, p=0.075). The grade 3/4 drug-related fatigue was rare in both 
arms (1 event reported in each arm). For both overall and EA populations, the fatigue 
incidence by cycle during the maintenance treatment with pemetrexed did not increase 
during subsequent cycles (Figure 1A, B). The percentage of patients who experienced 
worsening of fatigue based on the patients-reported LCSS scores was also comparable 
between the two arms in the overall and EA populations (Figure 1C, D). EA Patients in the 
pemetrexed arm experienced a numerically longer median time to worsening of fatigue 
compared to EA patients in the placebo arm, although the difference is not statistically 
significant (5.95 months vs. 3.91 months, HR= 0.84, 95% confidence interval [CI]: 0.51-
1.37, p= 0.471).
(See next page for figure.)
based chemotherapy regimen. In a subset of 122 patients, archive tumor tissue was 
available for further analyses. Immune stainings for COX-2 expression were undertaken. 
Intensity and extent of positively stained cells in tumor and stroma cells were scored on a 
0 to 3 scale, and the product of these scores was used as a co-variable in the predictive 
analysis. Results: An updated analysis of all 316 patients included in the original trial, 
and of the 122 patients with available tumor tissue showed no survival differences 
between the celecoxib or placebo arms (HR 0.99; 95% CI 0.79-1.24 and HR 0.89; 95% 
CI 0.62-1.28, respectively). Similarly, in patients with high COX-2 expression in tumor 
cells (n=71) or stroma cells (n=55), survival did not differ significantly between patients 
who received celecoxib or placebo (HR 0.96; 95% CI 0.60-1.54 and HR 0.66; 95% CI 
0.38-1.16). The p-value for interaction effect between COX-2 score in tumor or stroma 
cells and celecoxib effect on survival was 0.48 and 0.25, respectively. Conclusion: In 
this subgroup analysis of patients with advanced NSCLC treated in a randomized trial, 
we could not detect any significant interaction between COX-2 expression in tumor or 
stroma cells and outcome of celecoxib treatment in addition to standard chemotherapy. 
Keywords: non-small cell lung cancer, COX-2 expression, chemotherapy, celecoxib
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P2.01-062 Efficacy and Safety of Weekly Albumin-Bound Paclitaxel for Non-
Small-Cell Lung Cancer Patients Who Have Failed ≥ 2 Prior Systemic Regimens 
Jie Wang1, Jianchun Duan2, Yueqin Hao2, Jun Zhao2, Zhijie Wang2, Tongtong An2, Meina 
Wu2 1Department of Thoracic Medical Oncology, Peking University, School of Oncology, 
Beijing Cancer Hospital and Institute, Beijing/China, 2Peking University Cancer Hospital and 
Institute, Beijing/China
Background: To evaluate the efficacy and safety of weekly intravenous Nanoparticle 
albumin-bound paclitaxel (NAB-paclitaxel) for the patients with advanced non-small-cell 
lung cancer (NSCLC) who have failed prior multilines treatments, and to investigate the 
association of status of secreted protein, acidic and rich in cysteine (SPARC) expression 
and clinipathological factors with clinical outcome. Methods: We retrospectively 
analyzed the efficacy and toxicities of NAB-paclitaxel monotherapy in treating 84 patients 
who had progression disease after at least two lines standard chemotherapy from May 
1, 2011 to June 31, 2014. All patients were treated with NAB-paclitaxel 130mg/m2 on 
days 1 and 8 of a 21-day cycle. Radiologic tumor assessment was performed every 6 
weeks or when the patient’s symptoms deteriorated obviously. We also detected the 
SPARC status expression (by immunohistochemistry) in 35 patients who had tumor 
tissue available. 76 of 84 patients had EGFR mutation status. The date of last follow-
up was March 31, 2015. Results: Of these 84 patients, 76 patients had complete 
follow-up data, 5 patients lost of follow-up for overall survival, and 3 patients couldn’t 
tolerate the continuous NAB-paclitaxel therapy due to serious adverse events and had 
only the evaluation of safety data. EGFR mutation were found in 22 of 76 patients and 
their median PFS and OS were 4.4 months and 11.5months. The median treatment 
line of weekly NAB-paclitaxel therapy was 4 line (range: 2~7 line). The median follow-
up interval time was 11.2 months. The objective response rate (ORR) and disease 
control rate (DCR) (N=81) were 14.8% (12/81) and 67.9% (55/81), respectively. The 
median progression-free survival (PFS) and overall survival (OS) were 3.9 months 
(95% CI: 2.8~5.0 months) and 11.0 months (95%CI: 7.6~14.4 months), respectively. 
Pearson’s correlation analysis showed that previous treatment with Solvent-based 
Paclitaxel or Docetaxel didn’t affect the response to NAB-paclitaxel. However, the 
patients who reached disease control after previous Solvent-based Paclitaxel or 
Docetaxel presented better DCR than the patients who failed to previous Solvent-based 
Paclitaxel or Docetaxel (DCR: 77.1% vs 47.6%, p=0.040) (by Fisher’s Exact Test). Cox 
regression analysis showed that ORR was related with both PFS and OS. The common 
adverse events (N=84) included leukopenia (36.1%), neutropenia (29.2%), peripheral 
neurotoxicity (23.6%), et al. The main grade 3/4 toxicities included neutropenia (9.7%) 
and leukopenia (6.9%). 3 patients had discontinued chemotherapy due to drug induced 
lung injury, serious fatigue and serious anorexia, separately. In this study, no association 
between SPARC expression and efficacy was observed. Conclusion: Advanced NSCLC 
patients who have experienced multiline chemotherapy with disease progression could 
benefit from weekly NAB-paclitaxel therapy with good safety and clinical outcome. 
It seemed that SPARC expression could not predict efficacy to NAB-paclitaxel. 
Keywords: nab-paclitaxel, Advanced Non-Small Cell Lung Cancer, SPARC
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P2.01-063 Dynamic Change of Fatigue for East-Asian Patients in the JMEN 
Trial Li Zhang1, Chandra P. Belani2, Pinghai Zhang3, Xin Wang4, Mauro Orlando5, Yi-Long 
Wu6 1Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/
China, 2Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute, 
Hershey/PA/United States of America, 3Oncology, Lilly China Drug Development and 
Medical Affairs Center, Shanghai/China, 4Asia Pacific Statistical Sciences, Lilly China Drug 
Development and Medical Affairs Center, Shanghai/China, 5Oncology Emerging Markets, 
Eli Lilly Interamérica Inc., Buenos Aires/Argentina, 6Guangdong Lung Cancer Institute, 
Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/
China
Background: In the JMEN trial (Ciuleanu et al., Lancet 374:1432-1440, 2009), 
patients with advanced non-squamous non-small cell lung cancer (NSCLC) derived a 
benefit from pemetrexed maintenance therapy after platinum-based initial therapy by 
extending survival, delaying disease progression, and maintaining overall quality of life 
(QoL). However, fatigue was the most common physician-reported toxic effect in the 
pemetrexed treated group. We conducted a post-hoc analysis to investigate the dynamic 
change of fatigue in overall population and East-Asian (EA) patients treated on the JMEN 
S543Copyright © 2015 by the International Association for the Study of Lung Cancer
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Conclusion: These analyses suggest that despite a higher incidence of grade 1/2 
drug-related fatigue compared with placebo, pemetrexed maintenance treatment 
for EA patients with advanced NSCLC will not impair patient-reported QoL. 
Keywords: Dynamic change, fatigue, Quality of life, NSCLC
S544 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
 
Keywords: nab-paclitaxel, carboplatin, NSCLC, renal function
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.01-066 A Prospective, Randomized, Multicenter, Phase III Study, Comparing 
rhTPO with rhIL-11 Treating CIT - An Interim Analysis (NCT02344979) Shun 
Lu1, Xia Song2, Fang M. Du3, Li Liu4, Yun H. Xu1, Zhi Y. Ma5, Qiong Zhao6, Yi P. Zhang7, 
Hai Y. Liu8 1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong 
University, Shanghai/China, 2Respiratory Medicine, Shanxi Cancer Hospital, Taiyuan/
China, 3Medical Oncology, Dongyang People’S Hospital, Dongyang/China,4Cancer 
Center, Wuhan Union Hospital, Wuhan/China, 5Medical Oncology, Henan Cancer Hospital, 
Zhengzhou/China, 6Medical Oncology, The First Hospital of Zhejiang Province, Hangzhou/
China, 7Thoracic Medical Oncology, Zhejiiang Cancer Hospital, Hangzhou/China, 8Medical 
Oncology and Hematology, Jilin Oil Field General Hospital, Songyuan/China
Background: Chemotherapy-induced thrombocytopenia (CIT) has seriously hindered 
the application of anti-cancer drugs. Thrombopoietic factors such as recombinant 
human interleukin-11(rhIL-11), thrombopoietin and its derivative(recombinant human 
thrombopoietin, rhTPO) are routinely administrated for CIT. But there is no randomized 
study to compare rhTPO with rhIL-11 on efficacy and safety of thrombocytopenia 
prophylactic treatment before. This is the first randomized, open-label, multicenter, phase 
Ⅲ study to compare them in China. We tried to investigate the efficacy and safety of 
prophylactic administration with rhTPO or rhIL-11 to prevent CIT in advanced non-small-cell 
lung cancer(NSCLC) patients. Methods: From June 2009 to February 2015, 71 patients 
with advanced NSCLC who were receiving the first-line platinum-based chemotherapy 
suffered severe thrombocytopenia(the nadir of platelet counts＜50×109/L, confirmed by 
two times of blood routine in different days) during prior chemotherapy cycle. They were 
randomized to rhTPO arm or rhIL-11 arm in the following chemotherapy cycle, and the 
chemotherapy regimens and drug doses were consistent in the prior and following cycle 
(GC Gemcitabine 1000-1250 mg/m2, D1 and D8; Carboplatin dosing by AUC value=5, D1; 
Q3W) or GP (Gemcitabine 1000-1250 mg/m2, D1 and D8; Cisplatin 75 mg/m2, D1; Q3W). 
49 patients (34 males, 15 females) were enrolled rhTPO arm and 22 patients (14 males, 
8 females) were enrolled rhIL-11 arm. There were no statistical difference between two 
arms in terms of gender[34 males(69.4%) vs.14 males(63.6%),P＞0.05], age(58.5±9.3 
yrs vs. 60.3±7.5 yrs, P＞0.05), and the nadir of platelet counts during prior chemotherapy 
cycle(31.4±13.1×109/L vs. 28.6±12.8×109/L, P＞0.05). rhTPO (15000U/d) was injected 
subcutaneously on the 2nd, 4th, 6th, 9th Day after the initiation of chemotherapy, and 
IL-11(3mg/d) was injected subcutaneously per day from Day 9 to Day15 after the initiation 
of chemotherapy. Blood routines were conducted to test before chemotherapy initiation 
and the 3th, 5th, 7th, 9th, 11th, 13th, 15th, 17th, and 21th day after chemotherapy. 
Toxicity and efficacy were monitored. Results: In the following chemotherapy cycle 
there were no statistical difference between rhTPO arm and rhIL-11 arm on the following 
indexes: the nadir of platelet counts(66.6±43.1×109/L vs. 53.8±40.6×109/L, P＞0.05) , 
the maximum platelet counts (219±132×109/L vs. 240±151×109/L, P＞0.05) , duration 
of platelet counts less than 50×109/L[Median (95%CI): 4.0(3.0-5.0) days vs. 4.5(3.0-
6.0) days, P＞0.05], time of platelet count recovered to 75×109/L [Median(95%CI): 
2(2-3) days vs. 3(0-4) days, P＞0.05] and to 100×109/L[median(95%CI): 4(3-6) 
days vs. 4.5(3-8) days, P＞0.05]. Drug-related adverse events in rhTPO arm were 
less than that of rhIL-11 arm (5 cases(10.2%) in rhTPO arm, 7 cases(31.8%) in rhIL-11 
arm, P<0.05). Conclusion: Although there is no statistical difference on efficacies, 
prophylactic administration of rhTPO is safer and more convenient than that of rhIL-
11 in advanced NSCLC patients. This is an interim analysis. More data is still waiting. 
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P2.01-064 A Randomized Phase II Trial of ERCC1 and RRM1 Expression-Based 
Chemotherapy versus Docetaxel/Carboplatin in Advanced Non-Small Cell Lung 
Cancer Su Jin Heo1, Hye Ryun Kim1, Inkyung Jung2, Jaeheon Jeong3, Sun Min Lim1, 
Yong Wha Moon1, Joo-Hang Kim1, Byoung Chul Cho1 1Medical Oncology, Yonsei University 
College of Medicine, Seoul/Korea, 2Biostatistics and Informatics, Yonsei University College of 
Medicine, Seoul/Korea, 3Kyung Hee University, Seoul/Korea
Background: Platinum-based doublet chemotherapy is still mainstay in treatment of 
advanced non-small-cell lung cancer (NSCLC). There was no molecular determinant for 
guiding platinum-based chemotherapy. Excision repair cross-complementing group 1 
gene (ERCC1) is important for platinum-induced DNA adduct repair and ribonucleotide 
reductase subunit 1 (RRM1) is crucial for nucleotide metabolism and has been known 
for the dominant molecular determinant of gemcitabine efficacy. We assessed whether 
selection of first-line chemotherapy based on ERCC1 and RRM1 mRNA expression levels 
would improve clinical outcomes in patients with advanced NSCLC. Methods: Eligible 
patients were randomly assigned 1:1 to experimental arm and control arm. The 
experimental arm consisted of gemcitabine/carboplatin (GC) if ERCC1 and RRM1 were 
low, gemcitabine/vinorelbine (GV) if ERCC1 was high and RRM1 was low, docetaxel/
carboplatin (DC) if ERCC1 was low and RRM1 was high, and docetaxel/vinorelbine (DV) 
if both were high. In the control arm, patients received docetaxel/carboplatin (DC). All 
chemotherapy regimens were to be continued for maximum 4 cycles every 3 weeks or 
unacceptable toxicity. ERCC1 and RRM1 mRNA expression were measured by quantitative 
real-time PCR in formalin-fixed paraffin-embedded (FFPE) tissue. The trial was powered 
for an 80% improvement in overall response rate (ORR, P0=0.25, P1=0.45, α=0.1). 
Secondary endpoints included progression-free survival (PFS), overall survival (OS), and 
safety. The study was prematurely terminated after the futility analysis of 42 PFS events, 
which showed a low conditional probability (conditional power=0.14) of a statistically 
significant outcome. Results: A total of 56 patients (n=26 in experimental arm, n=30 
in control arm) were evaluable for efficacy and toxicity. Patient characteristics were well 
balanced in both groups. Majority of patients had adenocarcinoma histology (64.3%) and 
ECOG performance status 0 to 1 (96.4%). EGFR mutation was documented in 8 patients 
(4 in experimental arm, 4 in control arm). Among 26 patients in the experimental arm, 
mRNA expression of ERCC1 and RRM1 ranged from 0.18 to 2.81 (median, 0.69) and 0.22 
to 16.65 (median, 0.66), respectively. Based on mRNA expression levels, 19 (73.1%) 
patients were assigned to GC, 0 (0.0%) to GV, 4 (15.4%) to DC, and 3 (11.5%) to VD. The 
median number of chemotherapy cycles delivered was 3.7 in experimental arm and 3.5 in 
control arm. The ORRs were 26.9% in experimental arm and 40.0% in control arm, which 
were not statistically significant (P=0.58). With a median follow-up of 30.1 months, median 
PFS was 4.6 months in experimental arm and 5.1 months in control arm (hazard ratio [HR] 
1.27; 95% CI 0.69-2.31; P=0.43). Median OS was 18.2 months in experimental arm and 
was 12.6 months in control arm (HR 0.71; 95% CI 0.32-1.53; P=0.38). The occurrence of 
grade 3 or higher neutropenia (69.2% vs. 93.4%, P=0.02) and febrile neutropenia (3.8% vs. 
23.3%, P=0.04) was significantly more common in control arm. There was no treatment-
related death. Conclusion: ERCC1 and RRM1 expression-based chemotherapy did 
not improve clinical outcomes in advanced NSCLC (NCT01648517). Keywords: advanced 
NSCLC, ERCC1, RRM1, chemotherapy
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P2.01-065 nab-Paclitaxel + Carboplatin in Advanced NSCLC: Analysis of Age 
and Renal Function Eric Bernicker1, Corey J. Langer2, Amy Ko3, Teng Jin Ong3, Mark 
A. Socinski4, Mary E.R. O’Brien5 1Houston Methodist Cancer Center, Houston/United States 
of America, 2Abramson Cancer Center, University of Pennsylvania, Philadelphia/PA/United 
States of America, 3Celgene Corporation, Summit/NJ/United States of America, 4University 
of Pittsburgh, Pittsburgh/PA/United States of America, 5Royal Marsden Hospital, London/
United Kingdom
Background: Renal impairment increases with age and can impact treatment decisions. 
In a phase III trial, first-line treatment with nab -paclitaxel plus carboplatin (nab -P/C) 
significantly improved the overall response rate (ORR; primary endpoint) compared 
with solvent-based paclitaxel plus C (sb-P/C) in patients with advanced NSCLC (Socinski 
et al. J Clin Oncol. 2012;30:2055-2062). In a subgroup analysis of this phase III 
trial, nab -P/C demonstrated promising efficacy and was well tolerated in patients with 
or without renal impairment (Langer et al. Clin Lung Cancer. 2015;16:112-120). This 
analysis examined outcomes of patients in the phase III trial stratified by age and renal 
function. Methods: Patients with histologically or cytologically confirmed stage IIIB/IV 
NSCLC and no prior chemotherapy for metastatic disease received either nab -P 100 mg/
m2 on days 1, 8, and 15 or sb-P 200 mg/m2 on day 1 in combination with C AUC 6 on day 1 
every 21 days (randomized 1:1). Treatment continued until disease progression. Baseline 
renal function (creatinine clearance [CrCl]) was assessed in a central lab. ORR and 
progression-free survival (PFS) were assessed by blinded, centralized review. P values 
for ORR were based on the chi-square test, and those for overall survival (OS) and PFS 
were based on the log-rank test. Results: Treatment with nab -P/C resulted in improved 
outcomes compared with sb-P/C in patients with mild renal impairment, regardless of 
age (Table). nab -P/C also consistently demonstrated greater treatment effect compared 
with sb-P/C for ORR and similar or better PFS and OS in patients ≥ 60 years, regardless 
of renal function. In patients with either mild renal impairment or normal renal function, 
the toxicity profiles in each treatment arm were similar to those of the intent-to-treat 
population. Conclusion: These results suggest that, in general, clinical outcomes in 
patients with advanced NSCLC and mild renal impairment are better with nab -P/C vs 
sb-P/C, regardless of age. It should be noted that these were small subset analyses and 
results should be interpreted with caution.
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P2.01-069 Design and Stratification for Phase III Trials in First-Line Non-Small 
Cell Lung Cancer Takefumi Komiya1, Raymond P. Perez1, Kirsten D. Erickson2, Chao H. 
Huang3 1Division of Hematology/Oncology, University of Kansas Medical Center, Fairway/KS/
United States of America, 2Clinical Trial Office, University of Kansas Medical Center, Fairway/
United States of America, 3Division of Hematology/Oncology, University of Kansas Medical 
Center, Westwood/KS/United States of America
Background: Metastatic non-small cell lung cancer (NSCLC) remains an incurable 
disease. Sacher et al reviewed phase III studies in first-line advanced/metastatic NSCLC 
conducted from 1981 to 2010. Although trends in study outcomes were assessed, 
design and stratification factors have never been analyzed. Methods: The recently 
published list of phase III trials by Sacher et al (JCO 2014;32:1407-11) was reviewed 
thoroughly. Eligible trials for this study must have been published in the English literature 
between 1981 and 2010. Trials that included a substantial number of previously treated 
NSCLC patients were excluded. Maintenance studies after first-line chemotherapy 
were also excluded. Characteristics in each decade were determined for sample size, 
number of trials, region, rate of meeting accrual goal, primary endpoint, type of phase 
III, interim analysis, allocation method, and stratification factors (SFs). Any p-value of 
less than 0.05 was considered significant for statistical analysis. Results: A total of 162 
studies were considered to meet the criteria. The number of studies and median sample 
size increased from 29 and 133 in 1980s to 46 and 181 in 1990s to 87 and 407 in 
2000s, respectively. Primary endpoint was reported more frequently in recent decades; 
24% of studies in 1980s, 83% in 1990s, 99% in 2000s. Non-overall survival endpoints 
were frequently chosen in European and Asian studies. Interim analysis was planned 
for 3% in 1980s, 20% in 1990s, 33% in 2000s. Allocation method was rarely reported 
throughout the three decades (0% in 1980s, 22% in 1990s, 28% in 2000s). The median 
number of SFs increased significantly from one in 1980s to three in 2000s (see Table). 
Performance status (PS), stage, and institution have been most frequently selected, 
and at least one of the three factors was used in most of the studies (84%) in 2000s. 
There are many other SFs that were used infrequently. More details will be presented. 
Table: SFs in first-line phase III NSCLC trials. All others; stratification factors other than 
PS, stage, and institution. The median number of SFs increased significantly (one way 
ANOVA, p=0.003).
1981-1990 1991-2000 2001-2010 Total
No. of studies 29 46 87 162
Median no. of SFs 1 2 3 2
PS 14(48%) 21(46) 48(55) 83(51)
Stage 2(7) 22(48) 63(72) 86(53)
Institution 2(7) 17(37) 37(43) 56(35)
PS or Stage 15(52) 29(63) 6(7) 113(70)
PS, Stage, or Institution 16(55) 32(70) 73(84) 121(75)
Not reported or None 12(41) 13(28) 13(15) 38(23)
All others 1(3) 1(2) 1(1) 3(2)
 
 
Conclusion: This study reports extensive details in design of phase III trials 
for first-line NSCLC that have been published over three decades. We found 
increases in sample size and reporting primary endpoint, whereas allocation 
method remains underreported. Although PS, stage, and institution are the 
most frequently selected, choice of SFs remains inconsistent across studies. 
Our report provides researchers with valuable information for future studies. 
Keywords: meta-analysis, phase III, non-small cell lung cancer, first-line
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P2.01-070 Serum Albumin in Patients with Advanced-Stage NSCLC Treated 
with Erlotinib Ondrej Fiala1, Milos Pesek2, Jindrich Finek1, Jaroslav Racek3, 
Marek Minarik4, Lucie Benesova5, Ondrej Topolcan6 1Department of Oncology and 
Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen/
Czech Republic, 2Department of Pneumology, Medical School and Teaching Hospital in 
Pilsen, Charles University, Pilsen/Czech Republic, 3Istitute of Clinical Biochemistry and 
Hematology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen/
Czech Republic, 4Center for Applied Genomics of Solid Tumours, Genomac Research 
Institute, Prague, Czech Republic, Pilsen/Czech Republic, 5Center for Applied Genomics 
of Solid Tumours, Genomac Research Institute, Prague/Czech Republic, 6Department of 
Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen/
Czech Republic
Background: Molecular targeted therapy based on tyrozine kinase inhibitors (TKI), 
directed at epidermal growth factor receptor (EGFR) is one of the novel effective agents 
in management of advanced-stage NSCLC. However several candidate predictors 
have been extensively studied, apart from activating EGFR gene mutations, no reliable 
biochemical or molecular predictors of response to erlotinib have been validated. 
The aim of our retrospective study was to evaluate the association of baseline serum 
albumin with outcomes in a large cohort of patients with advanced-stage NSCLC treated 
with erlotinib. Methods: Clinical data of 457 patients with locally-advanced (IIIB) or 
Keywords: recombinant human thrombopoietin, prophylactic use, Non-small-cell lung 
cancer, chemotherapy-induced thrombocytopenia
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P2.01-067 Quality in Lung Cancer Care: The Victorian Lung Cancer Registry 
Pilot Initial Report Rob Stirling1, Sue Evans1, Meera Senthuren1, Peta Mclaughlin1, 
Sara Mclaughlin-Barrett2, Jeremy Millar3, Julian Gooi3, Jennifer Phillip4, Louis Irving5, 
Paul Mitchell6, Andrew Haydon3, Jeremy Ruben3, Matthew Conron4, Neil Watkins7, 
John Mcneil1 1Epidemiology and Preventative Medicine, Monash University, Melbourne/
VIC/Australia, 2Epworth Healthcare, Richmond/VIC/Australia, 3Alfred Health, Melbourne/
Australia, 4St Vincents Hospital, Fitzroy/VIC/Australia, 5Royal Melbourne Hospital, Melbourne/
ACT/Australia, 6Austin Health, Melbourne/ACT/Australia, 7Garvan Institute, Sydney/NSW/
Australia
Background: The Victorian Lung Cancer Registry is a clinical quality registry designed 
with the aim of improving the quality of care delivered to Victorians with lung cancer by 
collecting and assessing management, treatment and outcome data on all new cases 
of lung cancer. Methods: The establishment of the Victorian Lung Cancer Registry Pilot 
Project commenced with the appointment of a Steering Committee to provide project 
governance. Review of current literature and evidence-based national and international 
clinical practice guidelines was undertaken by an expert working group. Included data 
items were epidemiologically sound, reproducible and valid. The data set enables the 
capture of identified quality indicators designed to describe the structural quality, process 
quality and indicators of outcome in lung cancer management. Case ascertainment is 
derived from institutional ICD-10 coding and participant consent occurs via an “opt-off” 
system. Follow up and outcome measures are collected at baseline, 6 and 12 months 
after diagnosis capturing survival, treatment and quality of life. Institutional recruitment 
was designed to sample from metropolitan public, metropolitan private and regional 
hospitals. Results: Data was collected on 690 patients from 1 July 2012 to 31 June 2013 
from 8 Victorian Hospitals (3 public and 3 private metropolitan and 2 regional). Evidence 
of distress screening was available for 27% of subjects. Diagnosis was confirmed < 28 
days from referral in 66% of cases across institutions. A statement of ECOG status was 
available in 45% of cases and clinical TNM staging in 49% prior to treatment. A record 
of multidisciplinary team meeting presentation was available in 59% of cases. First 
treatment was initiated < 42 days from diagnosis in 76% of cases. Curative surgery was 
provided for 28% of subjects, curative chemotherapy <5% and curative radiotherapy < 
5%. Conclusion: The evaluation of registry outcomes at governance, administrative and 
clinical levels may identify targets for quality and service improvement and further define 
safety measures. The comparison of performance outcomes across institutions and 
sectors may drive competitive recruitment to improve measures on a longitudinal basis.
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P2.01-068 Androgen Deprivation Therapy for Prostate Cancer Associated with 
Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis 
Mukesh Kumar1, Camille Ragin2, Chao Zhang3, Zhengjia Chen3, Erica J. Han3, Vinicius 
Ernani3, Madhusmita Behera3, Conor Steuer3, Nabil Saba3, Dong Shin3, Chandra P. 
Belani2, Fadlo Khuri3, Suresh S. Ramalingam3, Taofeek K. Owonikoko1 1Hematology/
Oncology, Emory University, Atlanta/GA/United States of America, 2Penn State Milton S. 
Hershey Medical Center, Hershey/PA/United States of America, 3Hematology/Oncology, 
Emory University, Atlanta/United States of America
Background: Cancer of the prostate and lung are most commonly diagnosed in the 
elderly. Aberrant female sex hormone signaling has been well-described in NSCLC. 
The impact of androgen deprivation therapy (ADT) on non-small cell lung cancer 
(NSCLC) outcome has, however, not been well studied. Methods: We employed the 
linked SEER-MEDICARE database to assess the potential impact of ADT on NSCLC. 
We analyzed data from patients diagnosed with NSCLC between 1985 and 2005 
and registered in the SEER-MEDICARE database. Patients were categorized into 
three groups: prostate cancer diagnosis followed by NSCLC (PL), NSCLC followed by 
prostate cancer (LP) and NSCLC only (L). Demographic and survival outcomes were 
compared between these groups. The impact of sequence of cancer diagnosis and 
ADT on survival post NSCLC diagnosis was assessed within the PL group using logistic 
regression model. Cox proportional hazards models were employed to estimate the 
effect of ADT and stage of prostate cancer on survival with adjustment for significant 
prognostic factors. Results: A total of 417630 patients were included in this analysis; 
male/female (56.4%/43.6%); Race: White (84.0%), Black (9.0%), Asian (2.1%), Hispanic 
(1.0%), others (3.0%); Stage: I (17.4%), II (2.9%), III (33.6%) and IV (46.1%). The majority 
of the patients were in the L group (96.3%), followed by PL (2.9%) and LP (0.8%). Patients 
in the LP group had the best 12-month survival rates (84.5%), followed by L (44.4%) 
and PL (40.1%). Analysis within the PL group showed an inverse correlation between 
stage of prostate cancer diagnosis and interval of time to NSCLC diagnosis: 54.8, 54.1, 
62.1 and 59.3 months for stage I, II, III and IV prostate cancer, respectively. Prostate 
cancer patients exposed to ADT had a shorter interval to lung cancer diagnosis (48.3 
vs. 52.7 months; p < 0.001). On multivariate analysis, patients exposed to ADT had 
a higher median survival (10 months vs. 9 months; p < 0.001) and reduced risk of 
death (HR:1.11; 95%CI:1.05-1.18), p <0.001). Conclusion: ADT therapy for prostate 
cancer was associated with improved survival for subsequent NSCLC diagnosis. Our 
result supports systematic exploration of ADT as a treatment strategy for NSCLC. 
Keywords: Androgen Deprivation Therapy (ADT), NSCLC, Androgen Receptor
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P2.01-072 A Phase II Study of Carboplatin/Pemetrexed/Bevacizumab Followed 
by Bevacizumab/Erlotinib Maintenance for NonSq-NSCLC with Wild-Type 
EGFR Hiroshi Yokouchi1, Taichi Takashina2, Hajime Asahina2, Noriyuki Yamada3, Masao 
Harada4, Kosuke Nakano4, Kenya Kanazawa1, Kei Takamura5, Takahiro Ogi5, Toshiyuki 
Harada6, Osamu Honjo7, Naoto Morikawa8, Ichiro Kinoshita9, Ryoichi Honda10, Toraji 
Amano11, Hirotoshi Dosaka-Akita9, Hiroshi Isobe12, Masaharu Nishimura2 
1Department of Pulmonary Medicine, Fukushima Medical University, Fukushima/
Japan, 2First Department of Medicine, Hokkaido University School of Medicine, Sapporo/
Japan, 3Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, 
Iwamizawa/Japan, 4Department of Respiratory Medicine, Hokkaido Cancer Center, 
Sapporo/Japan, 5First Department of Medicine, Obihiro-Kosei General Hospital, Obihiro/
Japan, 6Department of Respiratory Medicine, Jcho Hokkaido Hospital, Sapporo/
Japan, 7Department of Respiratory Medicine, Sapporo-Kosei Hospital, Sapporo/
Japan, 8Division of Pulmonary Medicine, Allergy, and Rheumatology, Iwate Medical University 
School of Medicine, Morioka/Japan, 9Department of Medical Oncology, Hokkaido University 
Graduate School of Medicine, Sapporo/Japan, 10Department of Respiratory Medicine, 
Sapporo Higashi Tokushukai Hospital, Sapporo/Japan, 11Clinical Research and Medical 
Innovation Center, Hokkaido University Hospital, Sapporo/Japan, 12Department of Medical 
Oncology, Kkr Sapporo Medical Center, Sapporo/Japan
Background: Maintenance therapy (MT) after platinum doublet chemotherapy has 
been shown to improve progression-free survival (PFS) and overall survival (OS) in 
advanced non-small-cell lung cancer (NSCLC), whereas optimal strategies for MT, such 
as continuation or switch maintenance, have yet to be determined. ATLAS trial adopted 
a combination maintenance strategy design in which both EGFR-positive and -negative 
NSCLC patients received platinum doublet chemotherapy at the choice of investigators 
plus bevacizumab (Bev) followed by Bev with either erlotinib (Erl) or a placebo as a 
maintenance therapy. The trial demonstrated that Erl plus Bev was favorable for PFS, but 
not for either OS or toxicity, when compared with placebo plus Bev. The aim of this phase 
II study was to clarify the effects and safety of a fixed induction regimen: carboplatin 
(Cb)/pemetrexed (PEM)/Bev followed by Bev plus Erl as a maintenance therapy in non-
squamous (nonSq) -NSCLC patients with wild-type (WT) EGFR. Methods: All eligible 
patients (pts) had treatment-naive nonSq-NSCLC (stage IIIB, IV, or postoperative recurrent) 
with WT EGFR. Cb (AUC 5), PEM (500 mg/m2) and Bev (15mg/kg) were administered on 
Day 1 every three weeks for four-to-six cycles and maintenance therapy with Bev (15mg/
kg) once every three weeks plus continuous Erl (150mg/body) was administered until 
occurrence of either disease progression or unacceptable toxicity. The primary endpoint 
was PFS at 6 months (mo). The secondary endpoints included OS, tumor response, 
toxicity, and quality of life (QOL). Results: From September 2011 to June 2014, 51 pts 
were enrolled. Fifty pts were evaluated for the efficacy and safety of the treatment. The 
median follow-up duration was 14.3 months (range: 1.1-30.7). The median age was 64 
years (range: 36-74); male/female=27/23 (54/46%); ECOG PS 0/1=28/22 (56/44%); 
Stage IIIB/IV/recurrent=5/41/4 (10/82/8%); adenocarcinoma/NSCLC=48/2 (96/4%). 
The median cycles of the induction/maintenance therapy were 4 (range: 1-6)/4 (range: 
1-20). Twenty-nine pts (58%) received the MT. Overall response rate was 48.0% (95% 
CI: 34.8-61.5%), and disease control rate was 86% (95% CI: 73.8-93.0%). Six-month 
PFS rate was 59.5% (95% CI: 45.0-72.6%). Median OS and PFS were 18.4 mo (95% 
CI: 11.9-24.9 mo) and 6.5 mo (95% CI: 5.8-7.2 mo), respectively. CTCAE Grade (Gr) 
3/4 hematological toxicities were neutropenia (48%/3.4%), anemia (18%/3.4%) and 
thrombocytopenia (22%/0%). The most frequent Gr 3/4 non-hematological toxicities 
were anorexia (14%/3.4%), hypertension (10%/3.4%), malaise (6%/3.4%), nausea 
(6%/0%) and rash (0%/10%). There were two interstitial lung diseases (Gr1), one 
gastrointestinal perforation (Gr4), and one treatment-related death due to ventricular 
fibrillation. QOL results are still under analysis. Conclusion: Cb/PEM/Bev followed by 
maintenance Bev/Erl was effective and well tolerated in NS-NSCLC pts with WT EGFR. 
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P2.01-073 Impact of Prophylactic Doxycycline (Doxy) on Maintaining Planned 
Dosing of Dacomitinib (D) an Irreversible panHER Inhibitor Mario E. Lacouture1, 
Dorothy Keefe2, Stephen T. Sonis3, Nagdeep Giri4, Tao Wang5, Arlene Reisman6, Eric 
Sbar7, Diana Gernhardt5, Aminah Jatoi8 1Department of Medicine, Memorial Sloan-Kettering 
Cancer Center, New York/NY/United States of America, 2Royal Adelaide Hospital, Adelaide/
ACT/Australia, 3Brigham and Women’S Hospital, Dana-Farber Cancer Institute, Boston/
United States of America, 4Pfizer Oncology, La Jolla/CA/United States of America, 5Pfizer 
Oncology, Groton/CT/United States of America, 6Pfizer Oncology, New York/NY/United 
States of America, 7Pfizer Oncology, Collegeville/PA/United States of America,8Mayo Clinic, 
Rochester/MN/United States of America
Background: ARCHER 1042 (NCT01465802) was a randomized patient (pt) blinded trial 
that explored prophylactic interventions to minimize select dermatologic adverse events 
of interest (SDAEI) and diarrhea associated with D, an irreversible small molecule PanHER 
inhibitor. Methods: In Cohorts I (CI) and II (CII) pts with advanced NSCLC, ≥1 prior chemo, 
ECOG 0–2, were randomized (pt blinded) in CI to (a) D 45 mg daily (QD) plus placebo 
(pbo) (D+pbo) or (b) D 45 mg QD plus doxy 100 mg twice daily x 4 wks (D+doxy) and 
in CII assigned to D 45 mg QD plus probiotic (prob) and topical alclometasone (alclo) 
(D+prob+alclo). Primary endpoints in first 8 wks included: all grade (G) and G≥2 SDAEI 
and PRO (Skindex-16) (CI, CII) and CII G and G≥2 diarrhea and PRO (modified Mucositis 
Daily Questionnaire). Plasma samples were collected to confirm that exposure of D is 
not altered with doxy treatment. Results: As of August 25, 2014, 112 pts randomized 
to Cohort I D+pbo vs. D+doxy (median age 66 years, 53% male) and 59 pts to CII 
D+prob+alclo (median age 66 years, 66% male) were evaluable (>6 wks treatment). 
metastatic stage (IV) NSCLC treated with erlotinib were analysed. Serum samples were 
collected and the measurement was performed one day before the initiation of erlotinib 
treatment. Results: Before the treatment initiation, low albumin was (<35 g/l) measured 
in 37 (8.1%) patients and normal albumin (≥ 35 g/l) was measured in 420 (91.9%). The 
median PFS and OS for patients with low serum albumin was 0.9 and 1.9 months compared 
to 1.9 and 11.4 months for patients with normal serum albumin (p=0.001 and p<0.001). 
The multivariate Cox proportional hazards model revealed that EGFR mutation status 
(HR=2.50; CI: 1.59-3.92; p<0.001) and pretreatment serum albumin (HR=1.73; 
CI: 1.21-2.47; p=0.003) were significant independent predictive factors for PFS, 
whereas EGFR mutation status (HR=3.14; CI: 1.70-5.81; p<0.001), stage (HR=1.48; CI: 
1.09-2.02; p=0.013), ECOG PS (HR=1.77; CI: 1.37-2.29; p<0.001) and pretreatment 
serum albumin (HR=4.60; CI: 2.98-7.10; p<0.001) were significant independent 
predictive factors for OS. Conclusion: The results of the present retrospective study 
indicate that pretreatment hypoalbuminemia is associated with poor outcome of NSCLC 
patients treated with erlotinib. Based on the present study results, measuement of serum 
albumin is an objective laboratory method feasible for estimation of prognosis of patients 
with advanced-stage NSCLC. This study is supported by Ministry of Health, Czech Republic - 
conceptual development of research organization Faculty Hospital in Pilsen - FNPl, 00669806 
and by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund. 
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P2.01-071 TULUNG REGISTRY: Data Analysis of Patients with Non-Squamous 
NSCLC Treated with Bevacizumab in the Czech Republic Libor Havel1, Jana 
Krejci1, Karel Hejduk2, Jana Skrickova3, Marcela Tomiskova4, Helena Coupkova5, 
František Salajka6, Michal Hrnciarik6, Vitezslav Kolek7, Ivona Grygarkova8, Jaromir 
Roubec9, Milos Pesek10, Milada Zemanova11, Leona Koubkova12, Marketa Cernovska13 
1Pneumology and Thoracic Oncology, Municipal Hospital, Prague/Czech Republic, 2Biostatistics, 
Iba Institute, Brno/Czech Republic, 3Pulmonary Medicine, University Hospital, Brno/Czech 
Republic, 4Department of Respiratory Diseases and TB, University Hospital and Medical Faculty 
Brno, Brno/Czech Republic, 5Departmen of Oncology, Masaryk Memorila Institute, Brno/Czech 
Republic, 6Dept.Of Pneumology, Hradec Kralove/Czech Republic, 7Dept of Klinika Plicnich 
Nemoci A Tuberkulozy, Fakultni Nemocnice Olomouc, Olomouc/Czech Republic, 8Respiratory 
Medicine, University Hospital, Olomouc/Czech Republic, 9Pulmonary Medicine, University 
Hospital, Ostrava/Czech Republic, 10Department of Pneumology, University Hospital Pilsen, 
Plzen/Czech Republic, 11Clinical Oncology, General University Hospital Prague, Prague/Czech 
Republic, 12Pulmonary Medicine, University Hospital,, Praha/Czech Republic, 13Pulmonary 
Medicine, Thomayer Memorial Hospital, Prague/Czech Republic
Background: We conducted a systematic review of data from patients reported in 
the TULUNG registry (data cut-off 26-Jan-15). The TULUNG registry is Czech national 
oncology registry which prospectively collects data from all NSCLC patients treated with 
new targeted therapies in Czech Republic since 2008. Methods: Analysis was performed 
on a group of patients with non-squamous NSCLC with good performance status (PS 
0-2), treated with bevacizumab. Since 2008 bevacizumab has been used for treatment 
in 193 patients (full record criteria met). 10 patients with incomplete records were not 
included to the review Results: In this group of patients 35.8% were female; the median 
age at bevacizumab treatment initiation was 60 years (range 29-83). The majority of 
patients were smokers and ex-smokers (37.8% and 34.7% respectively) and 91.7% of 
tumors were adenocarcinomas by histology. 91.7% patients were at the metastatic stage 
at the initiation of bevacizumab treatment, 6.2% of patients were in stage IIIb and only 
2.1% of patients in stage IIIa (UICC6). The performance status was distributed between 
ECOG PS0 and PS1 mainly (40.9% PS0 and 58% PS1)at the initiation of the bevacizumab 
treatment. Majority of patients received bevacizumab treatment in the first line (96.4%). 
Two main chemotherapy regimens were used; carboplatin+paclitaxel (68.4%) and 
cisplatin+gemcitabine (9.8%). In this group of 193 patients analyzed, bevacizumab 
therapy was terminated in 152 (78.8%) patients at data cut-off. The most frequent 
reasons for termination were disease progression, in 55.9%, termination of treatment 
according to plan in 8.6% and death, in 7.9% of patients. Treatment with bevacizumab is 
ongoing in 41 (21.2%) patients. In 152 of patients with terminated treatment, the median 
duration of treatment was 15.6 weeks (95% CI 0.3 – 51.3). Response assessment 
showed CR in 0.7%, PR in 40.8% and SD in 35.5% of patients. Median progression free 
survival was 6.9 months (95% CI 5.8 – 8.1), median overall survival 16.7 months (95% CI 
11.7 – 21.7). 1-year survival from bevacizumab treatment initiation was 67.9%. Adverse 
events were reported in 9.8% of patients, the most frequently reported adverse events 
were thromboembolic events (5.2%) and neutropenia (1.6%). Tromboembolic events 
were observed in 10 patients, none of these was fatal. We didn´t observe any severe 
episode of bleeding event. Conclusion: Therapy with bevacizumab in non-squamous 
NSCLC was active and very well tolerated. In eligible patients, only 7 patients (4.6%) had 
to discontinue bevacizumab therapy due to safety reasons. In patients with completed 
bevacizumab therapy 77.0% disease control rate was reached with a median survival 
of approximately 16.7 months from initiation of first line therapy with bevacizumab. 
Keywords: non-squamous, bevacizumab, advanced NSCLC
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of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto/Japan, 7Department of Respiratory 
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Background: This multicenter, randomized phase II trial investigated the efficacy 
and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-
line treatment of non-squamous (non-Sq) non-small-cell lung cancer (NSCLC). 
Methods: Patients with non-Sq NSCLC who experienced disease progression after prior 
platinum-based chemotherapy with or without bevacizumab were randomly assigned (1:1) 
to receive docetaxel 60 mg/m2 plus bevacizumab 15 mg/kg (DB) once every 3 weeks 
or S-1 40 mg/m2 orally twice daily on days 1–14 plus bevacizumab 15 mg/kg (SB) on 
day 1 every 3 weeks until disease progression. The primary endpoint was progression-
free survival (PFS). Results: Ninety patients were randomized. The median PFS was 3.9 
months (95% confidence interval [CI] = 3.0–6.5) in the DB arm and 3.5 months (95% CI = 
2.9–5.9) in the SB arm. The objective response rate was significantly higher in the DB arm 
than in the SB arm (22.2%vs. 2.2%; P = 0.004), whereas the disease control rates of the 
arms were identical (62.2% vs. 62.2%; P = 1.00). Patients receiving DB were more likely 
to have ≥grade 3 neutropenia (93.4% vs. 4.4%) and febrile neutropenia (33.3% vs. 0%) 
than SB-treated patients. In the DB arm, PFS and overall survival were significantly 
longer among bevacizumab-naïve patients than among bevacizumab-experienced 
patients (median PFS: 7.4 months vs. 2.8 months; P < 0.001; and median OS: 27.4 
months vs. 11.7 months; P = 0.002). Conclusion: DB and SB produced modest PFS 
benefits in the second-line treatment of patients with advanced non-Sq NSCLC. Because 
of the toxicity of DB and the low response rate of SB, neither regimen warrants further 
investigation, excluding DB in bevacizumab-naïve patients with advanced non-Sq NSCLC. 
Keywords: Non-squamous non-small-cell lung cancer, bevacizumab, docetaxel, S-1
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P2.01-076 Clinical Study of Anti-Angiogenesis Therapy Combined with Neo-
Adjuvant Chemotherapy on NSCLC Patients in Phase IIIa (N2) Xiao-Liang Zhao 
Tianjin Medical University Cancer Institute & Hospital, Tianjin/China
Background: This study aimed to explore the safety and effectiveness of anti-
angiogenesis agent Endostar combined with neo-adjuvant chemotherapeutic therapy 
in the treatment of non-small cell lung cancer (NSCLC) patients in phase ⅢA (N2). 
Methods: From April, 2011 to December, 2013, a total of 30 patients diagnosed as 
NSCLC in phase ⅢA (N2) by pathology or assistant examinations were selected in the 
randomized, control and open clinical study treated with NP combined with Endostar 
or single NP neo-adjuvant chemotherapeutic therapy. Control group was treated with 
neo-adjuvant NP chemotherapy for 2 weeks, on which basis trial group was added 
with Endostar for 2 weeks. Clinical efficacy was evaluated 3 weeks and surgery was 
performed within 4 weeks after 2-cycle treatment. The primary end points were 
response rate (RR), clinical benefit rate (CBR) and tumor regression rate (TRR) as 
well as peri-operative clinical indexes and safety. The secondary end points included 
disease-free survival time (DFS) and overall survival time (OS). Results: In the 26 
patients with evaluable efficacy, trial group and control group were 50.0% and 40.0% 
in RR (P＝1.0), 87.5% and 64.0% in CBR (P＝0.76), 19.7% and 7.1% in TRR (P＝0.036), 
12.0 months and 10.0 months in total DFS (P＝0.44) and 16.0 months and 14.0 months 
in OS (P＝0.39), respectively. however, there was no significant difference between 
two groups in all clinical indexes and hematological and non-hematological toxicities 
in all degrees (P＞0.05). Conclusion: Endostar combined with NP chemotherapy are 
markedly higher than single NP neo-adjuvant chemotherapy in RR, CBR, TRR, DFS and OS 
without increasing the therapeutic toxicities. In addition, there is no significant difference 
between two groups in peri-operative clinical indexes, indicating that Endostar combined 
with NP chemotherapy are safe and effective in treating patients with NSCLC in ⅢA (N2). 
Keywords: Recombinant human endostatin; NP protocol; Randomized; Control; Non-
small cell lung cancer
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P2.01-077 A Phase 1b Trial of the Combination of Capecitabine and Erlotinib 
in Advanced Lung Cancer Rajiv Kumar1, Karl Lo1, Anna R. Minchom1, Adam Sharp1, 
Michael Davidson1, Ranga Gunapala1, Timothy Yap2, Jaishree Bhosle1, Sanjay Popat1, 
Mary E.R. O’Brien1 1Department of Medicine - Lung, Royal Marsden NHS Foundation Trust, 
Surrey/United Kingdom, 2Department of Medicine - Lung, The Institute of Cancer Research 
and the Royal Marsden NHS Foundation Trust, Surrey/United Kingdom
Background: Erlotinib is active in tumors with an EGFR mutation. Capecitabine, a 
thymidylate synthetase inhibitor, has shown some activity in advanced lung cancer (ALC). 
The combination of erlotinib and capecitabine has not been studied in ALC. Methods: We 
conducted a phase 1b trial, using a standard 3+3 dose escalation design to define 
the maximum tolerated dose (MTD) and safety of the combination of erlotinib and 
capecitabine, given on a 3-weekly cycle in 2nd line patients unselected for EGFR status. 
DLT was any grade≥2 toxicity. After MTD was defined in the 2nd line patients, we planned 
expansion of the trial to 1st line patients for further dose escalation. Dosing levels are 
listed in Table 1. Toxicity was assessed using CTCAE v3.0, response rate was assessed 
using RECIST 1.1, and survival assessed using Kaplan-Meier method. Results: We 
recruited 40 patients with adenocarcinoma. 55% were male, with median age of 67 years 
(range 38-84). 65% were ex-smokers and 28% were current smokers. Performance status 
was ECOG 1 in 65% and 2 in 35% of patients. 85% of patients had received platinum-
Median relative dose intensity (RDI) of D in the first 8 wks was 82.74% for D+doxy 
compared with 79.76% for D+pbo and 75.00% for D+prob+alclo.
  
PRO Skindex scores improved with prophylactic doxy, but not alclo; prophylactic 
probiotic was not associated with improved CTCAE or PRO. Plasma exposure of 
D was similar when administered either with pbo or doxy. Conclusion: These 
preliminary data suggest prophylactic doxy improves ≥G2 Select Dermatologic 
AEs with improved D RDI and less need for dose discontinuations. The prophylactic 
effect observed with doxy cannot be attributed to altered exposure of D. In 
contrast, prophylactic topical corticosteroids had no effect on rash or diarrhea. 
Keywords: Dacomitinib, dermatologic toxicity, doxycycline prophylaxis
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P2.01-074 Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly 
Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer 
Hiroyuki Minemura1, Hiroshi Yokouchi1, Keisuke Azuma1, Kenichiro Hirai1, Satoko 
Sekine1, Kengo Oshima1, Kenya Kanazawa1, Yoshinori Tanino1, Yayoi Inokoshi2, Taeko 
Ishii2, Yutaka Katsuura2, Akio Oishi3, Takashi Ishida1, Mitsuru Munakata1 1Department 
of Pulmonary Medicine, Fukushima Medical University, Fukushima/Japan, 2Department of 
Pulmonary Medicine, Saiseikai Fukushima General Hospital, Fukushima/Japan, 3Department 
of Thoracic Surgery, Fukushima Red Cross Hospital, Fukushima/Japan
Background: In industrialized countries, the age of approximately 50% of patients 
at diagnosis of non-small cell lung cancer (NSCLC) is >70 years old. Exploration of 
an optimal treatment strategy for elderly patients with NSCLC as either a first-line or 
second-line therapy is required. Erlotinib is an epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor that is an effective treatment for patients with NSCLC, especially 
those harboring activating EGFR mutations. A previous phase III trial suggested 
that patients with EGFR wild-type (EGFR-wt) NSCLC or elderly patients with disease 
progression after cytotoxic chemotherapy might benefit from erlotinib monotherapy. 
However, few studies have prospectively evaluated the efficacy and safety of second or 
third-line erlotinib monotherapy in elderly patients with EGFR-wt advanced or recurrent 
NSCLC. Methods: Eligibility criteria included: patients aged ≥70 years with pathologically 
or cytologically proven NSCLC; measurable tumor sites according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1; an Eastern Cooperative 
Oncology Group performance status of 0–2; no activating EGFR gene mutations (exon 
18, 19, 20 and 21); history of 1–2 regimens of systemic chemotherapy; stage IIIB or 
IV NSCLC, or postoperative recurrence; treatment naïve to EGFR-TKI; and appropriate 
organ function. EGFR gene mutation analysis was performed by using invasive signal 
amplification reaction with a structure-specific 5’ nuclease and a polymerase chain 
reaction (PCR) product (PCR-invader). Patients received oral erlotinib at a dose of 150 mg/
day until disease progression. Primary outcome was the objective response rate (ORR). 
Secondary end points included the disease control rate (DCR), progression-free survival 
(PFS), overall survival (OS), and toxicity profile. Results: This study was terminated early 
because of the results from a Japanese phase III trial (DELTA trial). Sixteen patients 
were enrolled between April 2010 and May 2013. The median age was 78 years (range, 
70–84 years), and six patients were female. Five patients had an Eastern Cooperative 
Oncology Group performance status of 0, and 11 (69%) patients had adenocarcinoma. 
Fifteen (94%) patients were treated with erlotinib as a second-line therapy. The ORR was 
0% (95% confidence interval [CI]: 0–17.1) and DCR was 56.3% (95% CI: 33.2–76.9). The 
median PFS and OS were 1.7 months (95% CI: 1.3–2.2) and 7.2 months (95% CI: 5.6-8.7), 
respectively. The most commonly occurring adverse events included acneiform eruption 
(31.3%) and skin rash (25.0%). One patient developed grade 3 interstitial lung disease, 
which was improved by following steroid therapy. Conclusion: In pretreated elderly 
patients with advanced or recurrent EGFR-wt NSCLC, daily oral erlotinib was well tolerated; 
however, administration of the drug should not be considered as a second-line therapy. 
Keywords: elderly, Non-small-cell lung cancer, Erlotinib, EGFR wild-type
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P2.01-075 Bevacizumab with Docetaxel or S-1 in Non-Squamous NSCLC 
(HANSHIN 0110) Motoko Tachihara1, Kazumi Nishino2, Daisuke Tamura1, Toru 
Kumagai2, Fumio Imamura2, Chiyuki Okuda3, Akito Hata3, Nobuyuki Katakami3, Yoshiko 
Urata4, Yoshihiro Hattori4, Miyako Satouchi4, Tsutomu Yoneda5, Soichiro Yokota5, 
Takashi Nishimura6, Toshihiko Kaneda7, Yoshihiro Nishimura1, Satoshi Morita8, Shunichi 
Negoro4 1Division of Respiratory Medicine, Department of Internal Medicine,, Kobe University 
Graduate School of Medicine, Kobe/Japan, 2Department of Thoracic Oncology, Osaka 
Medical Center for Cancer and Cardiovascular Diseases, Osaka/Japan,3Division of Integrated 
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days, with extended safety and immunogenicity assessments up to 100 days postdose. 
PK similarity was achieved if 90% confidence intervals (CIs) for the test-to-reference ratios 
of the maximum concentration (Cmax), the area under the concentration-time curve (AUC) 
from time 0 to the last quantifiable time point (AUCT), and AUC from time 0 extrapolated 
to infinity (AUC0-∞) were within 80.00%–125.00%. Results: Ninety-seven subjects were 
eligible and included in the PK analysis. The demographics of the PK eligible subjects 
were comparable among the 3 treatment groups. The 3 study drugs exhibited similar 
PK parameters (Table 1). For the comparisons of PF-06439535 to bevacizumab-EU 
or bevacizumab-US, and of bevacizumab-EU to bevacizumab-US, the 90% CIs for the 
ratios of Cmax, AUCT, and AUC0-∞ were all within 80.00%–125.00% (Table 2). Treatment-
related adverse events were reported in 15.2%, 25.7%, and 18.2% of subjects in the PF-
06439535, bevacizumab-EU, and bevacizumab-US treatment arms, respectively. Table 
1: Mean (±SD) PK Parameter Estimates
Parameters (units) PF-06439535 Bevacizumab-EU Bevacizumab-US
N 32 33 32
Cmax (µg/mL) 142.9 ± 20.3 137.0 ± 20.5 130.0 ± 18.2
AUCT (µg•hr/mL)a 40840 ± 6411 41010 ± 6711 38920 ± 4566
AUC0-∞ (µg•hr/mL) 43080 ± 7103 43830 ± 8326 41450 ± 5350
 
aAUCT was ≥80% of the corresponding AUC0-∞ in all 97 PK eligible subjects. Table 
2: Comparisons of Pharmacokinetic Exposure Parameters between Test and 
Reference Products
Compari-
son (Test to 
Reference)
Parameters, 
units Testa Referencea
Test/Refer-
ence Ratio 
(%)
90% CI 
for Ratio
PF-06439535 
to bevacizum-
ab-EU
Cmax, µg/mL 141.5 135.5 104.42
98.36–
110.84
AUCT, µg•hr/
mL 40330 40490 99.62
93.69–
105.93
AUC0-∞, 
µg•hr/mL 42490 43100 98.58
92.16–
105.44
PF-06439535 
to bevacizum-
ab-US
Cmax, µg/mL 141.5 128.9 109.79
103.38–
116.60
AUCT, µg•hr/
mL 40330 38660 104.32
98.06–
110.97
AUC0-∞, 
µg•hr/mL 42490 41120 103.33
96.55–
110.58
Bevacizum-
ab-EU to 
bevacizum-
ab-US
Cmax, µg/mL 135.5 128.9 105.15
99.05–
111.62
AUCT, µg•hr/
mL 40490 38660 104.71
98.48–
111.34
AUC0-∞, 
µg•hr/mL 43100 41120 104.82
98.00–
112.12
 
aAdjusted geometric means Conclusion: This study demonstrates PK 
similarity of PF-06439535 to both bevacizumab-US and bevacizumab-EU, 
and of bevacizumab-EU to bevacizumab-US. The safety profile was similar 
in the 3 treatment groups with no significant safety findings reported. 
Keywords: biosimilar, NSCLC, PF-06439535, bevacizumab
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P2.01-080 Pemetrexed, Carboplatin and Bevacizumab in Patients 
with Non-Squamous NSCLC without or with Activating EGFR Mutation 
(CJLSG0909/0910) Tomoki Kimura1, Hiroyuki Taniguchi1, Tomohiko Ogasawara2, 
Masashi Kondo3, Yoshihiro Takeyama4, Masashi Yamamoto5, Joe Shindoh6, Osamu 
Hataji7, Norio Yoshida8, Eiji Kojima9, Kazuyoshi Imaizumi10, Yoshimasa Tanikawa11, 
Yoshiyuki Yamada12, Takuya Ikeda13, Motoshi Ichikawa14, Yoshinori Hasegawa3, Hiroshi 
Saito15 1Tosei General Hospital, Seto/Japan, 2Japanese Red Cross Nagoya Daini Hospital, 
Nagiya/Japan, 3Nagoya University Graduate School of Medicine, Nagoya/Japan, 4Toyohashi 
Municipal Hospital, Toyohashi/Japan, 5Nagoya Ekisaikai Hospital, Nagoya/Japan, 6Ogaki 
Municipal Hospital, Ogaki/Japan, 7Matsusaka Municipal Hospital, Matsusaka/Japan, 8Kariya 
Toyota General Hospital, Kariya/Japan, 9Komaki Municipal Hospital, Komaki/Japan, 10Fujita 
Health University, Toyoake/Japan,11Toyota Kosei Hospital, Toyota/Japan, 12Konan Kosei 
Hospital, Konan/Japan, 13Yokkaichi Municipal Hospital, Yokkaichi/Japan, 14Gifu Prefectural 
Tajimi Hospital, Tajimi/Japan, 15Aichi Cancer Center Aichi Hospital, Okazaki/Japan
Background: Treatment strategies for advanced non-squamous (sq) non-small cell lung 
doublet chemotherapy for 1st line ALC, with 10% having maintenance pemetrexed. One 
patient had an EGFR mutation. Dose escalation stopped at level 3 in 2nd line patients with 
expansion to 6 patients due to dose limiting toxicities (DLTs) of grade (G) 2 creatinine 
rise, G2 anemia, G3 atrial fibrillation, and G3 pneumonia in 2/6 patients. The MTD was 
thus at level 2 that was also expanded to 6 patients, confirming safety. First line patients 
were then recruited at MTD but resulted in DLTs in 3/4 patients with G3 troponin rise, 
G2 rash, and G2 bilirubin rise in 2 patients. Hence the 1st line approach was abandoned. 
The MTD in 2nd line patients was further expanded for toxicity and activity. The overall 
response rate was 3% with a disease control rate of 34%. A partial response was seen 
in 1 patient with EGFR mutation of 11.3 months duration. The median progressive free 
survival was 1.6 months (95%CI 1.4 – 3.5) and the median overall survival was 6.1 
months (95%CI 5.1 – 12.5). Conclusion: The MTD for capecitabine is 750mg/m2 bd days 
1–14 and erlotinib 100mg od on a 3-weekly cycle. The addition of capecitabine does not 
improve the efficacy of erlotinib in unselected ALC. This combination could be explored 
further in ALC selected for EGFR mutation. Table 1: Patient disposition.
Dose escalation No. of pts No. of pts with DLTs
Level 1 - Erlotinib 100mg od, Capecitabine 500mg/
m2, bd, days 1-14 3
Level 2 - Erlotinib 100mg od, Capecitabine 750mg/m2, 
bd, days 1-14 3 + 3
Level 3 - Erlotinib 100mg, od, Capecitabine 1000mg/
m2 bd, days 1-14 3 + 3 2
1st line ALC at level 2 4 3
Dose Expansion
2nd line ALC 21
 
Keywords: Erlotinib, Capecitabine, Non-small-cell lung cancer, Phase 1
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P2.01-078 Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors 
for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer 
Zhi S. Zheng1, Bing Xia2, Rui F. Xie1, Xia D. Li1, Jue Zhu3, Shi X. Wu1 1Radiotherapy, 
Hangzhou Cancer Hospital, Hangzhou/China, 2Department of Radiation Oncology, Hangzhou 
Cancer Hospital, Hangzhou/China, 3First Clinical College, Nanjing Medical University, 
Nanjing/China
Background: Concurrent chemoradiotheray is the standard of care for patients with 
locally advanced non-small cell lung cancer (NSCLC), but often accompanying with high 
toxicities and poor tolerability. Radiosensitization of EGFR tyrosine kinase inhibitors (TKI) 
has been proved in preclinical studies, and the safety of TKI combined with thoracic 
radiotherapy has also been evaluated in several phase II trials. Methods: Patients 
with previously untreated, non-metastasis NSCLC, EGFR wild-type, Easter Cooperative 
Oncology Group performance status of 0-2 and acceptable organ function were eligible. 
The prescribed radiation dose was 60-70Gy, and both three dimensional conformal and 
intensity-modulated radiation therapies were allowed. TKI was administrated concurrently 
with thoracic radiotherapy. The primary endpoint was local-regional control; second 
endpoints included progression-free survival, overall survival and treatment-related 
toxicities. Results: Between 2012.1 and 2015.3, 12 eligible patients were recruited 
into this study, with an median age of 65 years (range 47 ~ 82 years)， 1 female and 
11 males. One of them was stage Ⅳ, two of them were stage Ⅱ and nine of them 
were stage Ⅲ. During the process of treatment, 2 (16.7%) of patients developed grade 
Ⅱ radiation pneumonitis and 9 (75.0%) developed level Ⅰ~Ⅱ hematological toxicity. 
Patients were followed up with a median follow-up time of 13 months (6~35months) 
and the last follow-up time was 2015.3. The results showed that 1-year and 2-year 
overall survival rates were 76.2% and 57.1%, respectively. 1-year and 2-year local 
recurrence-free survival rates (LRFS) were 62.2% and 62.2%, respectively. 1-year and 
2-years PFS rates were 55.0% and 55.0% (see table), respectively. Conclusion: The 
preliminary results showed that concurrent thoracic radiotherapy and EGFR-TKI 
were safe and effective in NSCLC patients with wild-type EGFR. This trial is on going. 
Keywords: EGFR-TKI, NSCLC, Concurrent thoracic radiotherapy
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P2.01-079 A Phase I Study Comparing PF-06439535 (A Potential Biosimilar) 
with Bevacizumab Beverly Knight1, Danielle Rassam1, Shanmei Liao2, Xu Meng1, 
Reginald Ewesuedo3 1Pfizer Inc, San Diego/CA/United States of America, 2Pfizer China, 
Shanghai/China, 3Pfizer Inc, Cambridge/MA/United States of America
Background: PF-06439535, a potential biosimilar to bevacizumab, is a humanized 
monoclonal IgG1 antibody that targets the vascular endothelial growth factor. This study 
(B7391001) compared the pharmacokinetics (PK) of PF-06439535 to bevacizumab 
sourced from the US (bevacizumab-US) and EU (bevacizumab–EU), and the PK of 
bevacizumab-EU to bevacizumab–US in healthy male volunteers. Methods: In this double-
blind study, 102 healthy males, aged 21-55 years, were randomized 1:1:1 to receive a 
single 5 mg/kg intravenous dose of PF-06439535, bevacizumab-US, or bevacizumab-
EU. One subject discontinued before dosing. Assessments for PK were conducted for 71 
S549Copyright © 2015 by the International Association for the Study of Lung Cancer
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has progressed on previous therapies. Our results are consistent with the study by 
Mazières et al. Vinorelbine was dosed as 25 mg/m2 and trastuzumab as 2 mg/kg every 
1 week (with 4mg/kg first loading dose) or 6 mg/kg every 3 weeks. All three patients 
were able to tolerate therapies well with no significant toxicities nor cardiac toxicity. 
Keywords: trastuzumab, NSCLC, HER2
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.01-082 Pathological Response with Angiotensin Converting Enzyme 
Inhibitor/Angiotensin Receptor Blocker Use in Advanced Non-Small Cell Lung 
Cancer Jalal Hyder1, Neha Bhooshan1, Josephine L. Feliciano2, Melissa Vyfhuis1, Vincent 
K. Lam2, Mohan Suntharalingam1, Whitney Burrows3, Elizabeth M. Nichols1, Martin 
Edelman2, Steven J. Feigenberg1, Eric P. Cohen4, Zeljko Vujaskovic1,Pranshu Mohindra1 
1Radiation Oncology, Univeristy of Maryland, Baltimore/United States of America, 2Department 
of Medicine, University of Maryland, Baltimore/United States of America, 3Department of 
Surgery, University of Maryland, Baltimore/MD/United States of America, 4Medical College of 
Wisconsin, Milwaukee/WI/United States of America
Background: Angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor 
blocker (ARB) are among the most common medications in the treatment of hypertension 
and diabetes. These drugs are under evaluation as a means to mitigate radiation 
pneumonitis/fibrosis likely mediated by anti-inflammatory and endothelial effects. Their 
collateral impact on oncological outcomes is unknown. We retrospectively evaluate the 
effect of ACEi and ARB usage on pathological response during preoperative platinum-
based concurrent chemoradiotherapy (CCRT) with high-dose radiotherapy (≥59.4 Gy) in a 
cohort of patients with stage III non-small cell lung cancer (NSCLC). Methods: Between 
June 2000 and December 2009, 79 patients with stage III NSCLC (AJCC 7th ed.) were 
treated with preoperative CCRT at our institution. Data on ACEi/ARB usage during CCRT 
and pathological response was available for 72 patients. The primary end-point was 
pathological complete response (pCR), in both the primary site and involved lymph nodes. 
X2 analysis was to assess distribution of categorical variables, Kaplan-Meier survival 
analysis with log rank test for univariate and Cox regression multivariate (age, gender, 
race, stage, RT dose and chemotherapy regimen) analysis of overall survival (OS) and 
freedom-from recurrence (FFR) was performed. Results: The median age at diagnosis 
was 56 years (range, 38-78) with 56% males, 74% Caucasians and 96% smokers. Stage 
distribution was IIIA (72%), IIIB (28%), T1/2 (54%), T3/4 (46%), N0/1 (14%) and N2/3 
(86%). The median radiation dose was 66.6 Gy (range 59.4-69.6 Gy) with the most 
common CCRT regimen being carboplatin-paclitaxel (54%). At a median follow up of 3.8 
years for all patients and 6.8 years for surviving patients, the median OS and FFR of the 
entire cohort were 4.9 years (95% Confidence Interval (CI): 3.5-6.5) and 3.1 years (95% 
CI: 1.3-4.9), respectively with overall pCR rate of 44%. During CCRT, 11 patients (15%) 
were taking ACEi/ARB and 61 patients (85%) were not taking ACEi/ARB. No statistical 
differences were seen in the distribution of baseline variables between the two cohorts. 
None of the patients developed acute radiation pneumonitis in the time interval between 
radiotherapy completion and surgery (median 55 days; range, 33-105 days). The pCR 
rate without and with ACEi/ARB was 46% vs 36% (p=0.56). The median FFR without 
and with concurrent ACEi/ARB use was 3.1 years vs. not reached, p = 0.35, while the 
corresponding median OS values were 4.8 years and 5.5 years, p = 0.59, respectively. 
On multivariate analysis, an improved OS was associated with younger age (HR: 0.39, 
95%CI: 0.2-0.8, p<0.01), an improved FFR was associated with lower stage (HR: 0.3, 
95%CI: 0.15-0.76, p<0.01) and Caucasian race (HR=0.37, 95% CI: 0.15-0.88, p=0.02), 
with no impact of ACEi/ARB use on either outcome. Conclusion: The use of ACEi/ARB 
did not have any apparent influence the rates of pCR in this small cohort of advanced 
stage NSCLC patients treated with trimodality therapy following preoperative platinum-
based CCRT with high-dose radiotherapy. As the role of these drugs in mitigating radiation 
pneumonitis continues to be evaluated, simultaneous assessment of lack of a negative 
impact on disease outcomes needs to be validated in larger, prospective analyses. 
Keywords: Angiotensin converting enzyme inhibitor, radiation toxicities mitigators, 
trimodality therapy, locally advanced NSCLS
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P2.01-083 Prognostic Significance of CK19mRNA Positive Cells in the 
Peripheral Blood of Patients with Advanced Non Small Cell Lung Cancer 
(NSCLC) Ippokratis Messaritakis1, Stella Apostolaki1, Georgia Milaki2, Filippos Koinis3, 
Lefteris Manouras1, Maria Perraki1, Vassilis Georgoulias1, Athanasios Kotsakis3 
1University of Crete,Laboratory Tumor Cell Biology, Heraklion/Greece, 2Venizeleio Hospital, 
Heraklion/Greece, 3Medical Oncology, University Hospital of Heraklion, Heraklion/Greece
Background: Circulating Tumor Cells (CTCs) have been shown to be a useful prognostic 
tool in several cancers. Non-small-cell-lung cancer (NSCLC) lacks validated prognostic 
biomarkers and, thus, this study aimed to explore the sensitivity and clinical significance 
of the detection of CK19mRNA (+) CTCs in NSCLC patients. Methods: Peripheral 
blood was obtained from 642 patients with previously untreated stage IIIB/IV NSCLC 
and from 455 patients after the completion of 1st line chemotherapy. RNA extracted 
from the Calu-3 and ARH-77 cell lines was used as positive and negative controls, 
respectively. The detection of CK19mRNA-positive cells was performed using an RT-qPCR 
assay. Results: The analytical detection limit of the method was found to correspond to 
0.42 Calu-3 cell equivalents/5µg RNA. One hundred and sixty seven (26.0%) patients had 
detectable CK19mRNA (+) CTCs at baseline; the detection of CK19mRNA (+) CTCs post 
chemotherapy was associated with significantly decreased PFS and OS (PFS: 2.6 vs 3.8 
months, p=0.008; OS: 5.7 vs 10.0 months, p=0.006). Multivariate analysis revealed that 
gender, performance status and the detection of CK19mRNA (+) CTCs post chemotherapy 
emerged as independent factors associated with reduced PFS (HR=1.350, p=0.010) and 
cancer (NSCLC) are divided by EGFR mutations. However, there has been no previous 
report about efficacy of cytotoxic agents separated by EGFR mutations. In addition, the 
influence of the EGFR mutations on the maintenance therapy with pemetrexed (Pem) 
or bevacizumab (Bev) has not been elucidated. We planned two studies designed to 
evaluate the efficacy and safety of combination therapy with Pem, carboplatin (Cb) and 
Bev followed by Pem and Bev maintenance therapy for non-sq NSCLC patients without 
or with activating EGFR mutation. Methods: We undertook two multicenter, open-
label, single-arm, phase II studies. Patients with wild type EGFR or with EGFR 
mutation (exon 19 deletions or exon 21 point mutation) entered CJLSG0909 or 
0910, respectively. Patients received Pem 500mg/m2, Cb AUC 6, and Bev 15mg/
kg day1, every 3 weeks, 4 to 6 cycles (induction therapy). Patients who had 
achieved disease control received Pem+Bev maintenance therapy until progressive 
disease or unacceptable adverse event. Key inclusion criteria were stage IIIB, IV, or 
recurrent disease after surgery, no prior chemotherapy, age 20 to 74. The primary 
endpoint was the objective response rate (ORR), and the secondary endpoints were 
the disease control rate (DCR), progression free survival (PFS), overall survival (OS) 
and safety. (Unique trial Number; UMIN000003736/UMIN000003737) Results: In 
CJLSG0909, 50 patients received induction treatment. They had a median age of 64 
years and were predominantly men (40 [80%]) with adenocarcinoma (47 [94%]), stage 
IV (40 [80%]), and a performance status (PS) of 1 (40 [80%]). The median of induction 
therapy was 5 cycles. Thirty-five (70%) patients received maintenance therapy, and the 
median of maintenance therapy was 5 cycles. Partial response was observed in 25 
patients with a ORR of 50.0% (95% confidence interval, 33.7–62.6%). Stable disease was 
observed in 21 patients and the DCR was 92%. Median PFS was 6.8 months and median 
OS was 19.4 months. Grade 3/4 toxicities during induction therapy included neutropenia 
(40 [80%]), thrombocytopenia (12 [24%]), anemia (8 [16%]), nausea (4 [8%]), anorexia (3 
[6%]), ALT elevation (3 [6%]), AST elevation (2 [4%]), vomiting, periodontal, hemoptysis, 
thrombosis and proteinuria (1 [2%]) respectively. In CJLSG0910, 30 patients received 
induction treatment. They had a median age of 65.5 years and were predominantly 
women (17 [57%]) with adenocarcinoma (29 [97%]), stage IV (27 [90%]), and a PS of 
0 (23 [77%]). The median of induction therapy was 6 cycles. Twenty-five (83%) patients 
received maintenance therapy, and the median of maintenance therapy was 8.5 cycles. 
Partial response was observed in 15 patients with a ORR of 50.0% (95% confidence 
interval, 33.9–66.1%). Stable disease was observed in 15 patients and the DCR was 
100%. Median PFS was 10.0 months and median OS was 41.4 months. Grade 3/4 
toxicities during induction therapy included neutropenia (14 [47%]), thrombocytopenia 
(6 [20%]), anemia (6 [20%]), diarrhea (2 [7%]), nausea, anorexia, amylase elevation 
(1 [3%]) respectively. Conclusion: These studies suggested that chemotherapy 
with Pem+Cb+Bev, including Pem+Bev maintenance therapy is candidate for first 
line therapy in non-sq NSCLC patients regardless of the activating EGFR mutations. 
Keywords: non-squamous NSCLC, activating EGFR mutation, pemetrexed, bevacizumab
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P2.01-081 Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and 
Response to HER2 Targeted Therapies Jody Chuang1, Joel W. Neal2, Heather A. 
Wakelee3 1Hematology and Oncology, Stanford Hospial & Clinics, Stanford/AL/United States 
of America, 2Medicine (Oncology), Stanford Cancer Intitute/Stanford University, Stanford/
CA/United States of America, 3Stanford University, Stanford/United States of America
Background: HER2 has long been recognized as an oncogenic driver in some breast 
and gastro-esophageal cancers. More recently, somatic mutations in HER2 have been 
reported in 1-2% of patients with lung adenocarcinoma, and the promise of HER2 as a 
treatment target in lung cancer has been suggested using anti-HER2 small molecules and 
antibodies. Methods: Here we report the outcomes of three patients with metastatic 
lung adenocarcinoma with HER2 mutations being treated with HER2 targeted therapies 
at a single institution. Results: The first patient is a 65yo Caucasian woman, minimal 
smoking history, with stage IIIA lung adenocarcinoma who then developed recurrent 
metastatic disease mainly in the liver after completing definitive chemoradiotherapy. 
She progressed through three lines of chemotherapies, with near replacement of 
liver with tumor. At that time she was found to have HER2 exon 20 insertion mutation 
(A775_G776 insSVMA) and was started on vinorelbine and trastuzumab. The main side 
effect was fatigue, which was tolerable. She achieved radiographic stable disease 
with 13% reduction of her liver metastasis as her best response by RECIST v1.1 for 6 
months and significant clinical improvement before progression of disease in all sites. 
The second patient is a 60yo Caucasian woman, former smoker, diagnosed with 
stage IV lung adenocarcinoma with HER2 exon 20 insertion mutation (unknown 
exact sequence) with extensive bony disease. She was treated with carboplatin, 
paclitaxel, bevacizumab, and an investigational anti-Met therapy with initial mild 
decrease in lung mass and nodules after one month, then mild progression 
for 14 months. She was taken off trial then and started on vinorelbine and 
trastuzumab, and so far shows no measurable growth after 5 months on therapy. 
The third patient is a 35yo Asian woman, non-smoker, diagnosed with stage IV lung 
adenocarcinoma with HER2 exon 20 insertion mutation (unknown exact sequence) with 
malignant pleural effusions, bilateral lung and brain lesions, and extensive lymph node 
involvement. She was treated with carboplatin, pemetrexed, and bevacizumab first 
followed by pemetrexed and bevacizumab maintenance, with initial mild improvement 
then progression after 4.5 months. She was then treated with erlotinib with rapid 
progression within 1 month. She was then treated with afatinib 40mg daily based on the 
HER2 mutation, improved disease after 2 months with best response 21% reduction, 
then progression after 3 more months (5 months total of clinical benefit). She was 
then started on vinorelbine and trastuzumab. Treatment was interrupted due to one 
new brain lesion requiring stereotactic radiation treatment. She has shown partial 
response with best response of 31% on the latest imaging done 4 months after starting 
therapy. Conclusion: From our single institution experience, HER2 targeted therapy 
can provide disease control for patients with metastatic HER-2 mutated NSCLC that 
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patients (Parts A-C) received ≥1 dose; 15 patients at 150 mg and 55 patients (including 
all 39 patients in expansion) at 200 mg Q12H abemaciclib. The MTD was established at 
200 mg Q12H abemaciclib for Parts A-C. See Table 1 for treatment-emergent adverse 
events (TEAEs). Stable disease was observed in 13/23 patients in Part A; 7 unknown, 
4/24 patients in Part B; 10 unknown, and 7/23 patients in Part C; 12 unknown. In Parts 
A-C, 18/70 (26%) patients started ≥4 cycles (Part A=9, Part B=3, Part C=6). Three 
confirmed PRs were observed: Part B, 1 patient with squamous histology (unknown 
mutation status), Part C, 1 patient with nonsquamous histology (KRAS mutation positive; 
EGFR mutation negative), and 1 patient with squamous histology (unknown mutation 
status). Updated analyses will be presented including Part D and longer term follow-up 
for Parts A-C through approximately June 2015. Table 1. TEAEs related to treatment 
(≥20% in ≥1 part)
% All grades (% Gr3/4) Part A (n=23) Part B (n=24) Part C (n=23)
Diarrhea 65 (4) 50 (17) 52 (9)
Fatigue 57 (9) 63 (8) 17 (4)
Nausea 35 (0) 50 (4) 48 (9)
Neutropenia 61 (61) 50 (33) 17 (4)
Anemia 57 (26) 33 (17) 9 (0)
Thrombocytopenia 39 (9) 38 (8) 17 (13)
Decreased appetite 30 (0) 25 (0) 22 (0)
Vomiting 9 (0) 21 (0) 35 (0)
Blood creatinine increased 30 (0) 8 (0) 17 (4)
Leukopenia 30 (22) 17 (8) 9 (4)
 
 
Conclusion: Abemaciclib combined with single-agents with acceptable toxicity. 
Safety findings observed in Parts A and B are consistent with AEs expected 
when combining myelosuppressive compounds with abemaciclib, resulting in 
an increased myelosuppressive effect. In Part C, safety findings are consistent 
with those of single-agents. Tumor responses were observed in Parts B and C. 
Keywords: NSCLC, CDK4, CDK6, Cell cycle
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P2.01-086 Ceritinib in ALK+ NSCLC Metastatic to Brain and/or Leptomeninges: 
The ASCEND-7 Study Laura Q. Chow1, Fabrice Barlesi2, Erin M. Bertino3, Dong-Wan 
Kim4, Martin J. Van Den Bent5, Heather A. Wakelee6, Patrick Y. Wen7, Pilar Cazorla 
Arratia8, Junwu Shen8, Fabrice Branle9 1Department of Medicine, Division of Medical 
Oncology, University of Washington, Seattle/WA/United States of America, 2Aix Marseille 
University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and 
Therapeutic Innovations, Marseille/France, 3The Ohio State University, Columbus/OH/
United States of America, 4Seoul National University Hospital, Seoul/Korea, 5Erasmus Mc, 
Rotterdam/Netherlands, 6Department of Medicine, Division of Oncology, Stanford University, 
Stanford/CA/United States of America, 7Center for Neuro-Oncology, Department of Medical 
Oncology, Dana Farber Cancer Institute, Boston/MA/United States of America, 8Novartis 
Pharma, East Hanover/NJ/United States of America, 9Novartis Pharma Ag, Basel/Switzerland
Background: Although the anaplastic lymphoma kinase inhibitor (ALKi), crizotinib 
achieves high responses in patients with ALK-rearranged (ALK+) non–small cell lung 
cancer (NSCLC), disease progression within 1 year can occur, with the brain/central 
nervous system (CNS) as a common site of progression and relapse. Ceritinib is a novel 
oral ALKi with 20-fold greater potency than crizotinib in enzymatic assays and crosses 
the blood-brain barrier with good CNS penetration in preclinical studies. In the pivotal 
phase 1 study (NCT01283516), ceritinib was highly active in ALK+ NSCLC patients 
(regardless of prior crizotinib exposure) and achieved intracranial responses in 7 of 14 
patients with measurable baseline brain lesions. The adverse events profile in these 
patients was similar to that of the full study population. Methods: This international, 
prospective, phase 2, open-label study is designed to evaluate the antitumor activity 
of ceritinib in patients with ALK+ NSCLC metastatic to the brain or leptomeninges 
(ASCEND-7; CLDK378A2205). Eligible patients must have ALK+ (centrally assessed) 
NSCLC metastatic to the brain and ≥ 1 extracranial measurable lesion using Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients must be neurologically 
stable ≥ 1 week prior to study drug administration and will be allocated to 1 of 5 arms 
depending on prior treatment:
OS (HR=1.608; p=0.001). Conclusion: Detection of peripheral blood CK19mRNA (+) 
CTCs post chemotherapy is an adverse prognostic factor correlated with poor clinical 
outcome in patients with stage IIIB/IV NSCLC.
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P2.01-084 Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment 
of Relapsed or Refractory Non-Small Cell Lung Cancer Anne Steino1, Guangan 
He2, Jeffrey A. Bacha1, Sarath Kanekal1, Dennis M. Brown1, Nancy D. Santos3, 
Ming Chen4, Zahid Siddik2, Lu Shun5 1Delmar Pharmaceuticals, Vancouver/BC/
Canada, 2University of Texas MD Anderson Cancer Center, Houston/AL/United States of 
America, 3BC Cancer Agency, Vancouver/BC/Canada, 4Guangxi Wuzhou Pharmaceutical 
(Group) Co. Ltd., Guangxi/China, 5Shanghai Lung Cancer Center, Shanghai/China
Background: The median overall survival time for patients with stage IV non-small 
cell lung cancer (NSCLC) is 4 months, and 1- and 5-year survival is less than 16% and 
2%, respectively. NSCLC is usually treated with surgery followed by radiation and 
treatment with platinum-based regimens or in some cases Tyrosine Kinase Inhibitors 
(TKIs). Unfortunately, long-term prognosis with platinum-based therapies is poor, and 
TKI resistance has emerged as a significant unmet medical need. Dianhydrogalactitol 
(VAL-083) is a structurally unique bi-functional alkylating agent mediating interstrand DNA 
crosslinks at N7 of guanine. It has previously demonstrated activity against NSCLC in 
NCI-sponsored preclinical and clinical trials and is approved for treatment of lung cancer 
in China (Approval No. Guoyao Zhunzi H45021133); however, it is currently not widely 
known or used for the treatment of NSCLC. Methods: not applicable Results: Recent 
preclinical data suggest that VAL-083 may be a therapeutic option for drug-resistant 
NSCLC. VAL-083 has superior activity to cisplatin in both in vitro and in vivo models 
of NSCLC, including TKI-resistant NSCLC. When combined with either cisplatin or 
oxaliplatin in vitro, VAL-083 demonstrates significant superadditivity (p<0.05) and 
synergism (CI < 1) for both combinations in NSCLC cell lines A549, H1975 and H460. 
When tested in a standard syngeneic mouse fibrosarcoma model (RIF-1 cell-line in C3H 
mice), VAL-083 (10 mg/kg) was superior to cisplatin (4 mg/kg) in tumor growth delay. 
Mice were treated with a single IP injection of either cisplatin, VAL-083 or VAL-083 
followed immediately by cisplatin. Combination treatment of with cisplatin produced 
a more than additive effect by delaying growth 8.65 days. In another in vivo model 
using NSCLC cell-line A549 in Rag2mice, VAL-083 was given as part of a combination 
treatment with cisplatin. Tumour growth delays of 11, 18 and 25 days were observed 
for 2 mg/kg cisplatin in combination with 2, 2.5 or 3 mg/kg VAL-083, respectively, 
while no significant tumour growth delay was observed between untreated and Cisplatin 
(2 mg/kg). The median survival time was increased by 2 days for cisplatin alone, while 
the combination of VAL-083 (2 mg/kg, 2.5 mg/kg and 3 mg/kg) with cisplatin (2 mg/
kg) increased survival by 17 days, 17 days, and 14 days, respectively. Conclusion: The 
preclinical data strongly suggest VAL-083 as a potential treatment for drug-resistant 
NSCLC. A planned open-label phase IV (post market) clinical trial will investigate the 
activity of VAL-083 in relapsed or refractory NSCLC assessed by objective response 
rates, complete and partial response rates and stable disease. VAL-083 will be dosed in 
accordance with the approved label (40 mg/day) and the results will provide guidance 
to treating physicians under the context of VAL-083’s current approval in China, as 
well as serve as proof of concept for expanded development in the rest of the world. 
Keywords: VAL-083, NSCLC, Cisplatin, combination-treatment
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P2.01-085 Abemaciclib in Combination with Single Agent Options in Stage IV 
NSCLC, a Phase 1b Study Karen Kelly1, Jonathan W. Goldman2, Pilar Garrido3, Shadia 
Jalal4, Daruka Mahadevan5, Martin Gutierrez6, Luis Paz-Ares7, Mariano Provencio8, Eric 
Schaefer9, Monte Shaheen10, Erica L. Johnston11, Na Cai11, William J. John11, Edward 
S. Kim12 1University of California Davis Comprehensive Cancer Center, Sacramento/CA/
United States of America, 2University of California at Los Angeles, Santa Monica/CA/
United States of America, 3Hospital Universitario Ramón Y Cajal, Madrid/Spain,4Indiana 
University School of Medicine, Indianapolis/IN/United States of America, 5West Cancer 
Center, Memphis/TN/United States of America, 6Medical Oncology, Hackensack University 
Medical Center, Hackensack/NJ/United States of America,77Servicio de Oncología Médica, 
University Hospital Virgen Del Rocio, Seville/Spain, 8Servicio de Oncología Médica, Hospital 
Puerta de Hierro, Madrid/Spain, 9Highlands Oncology Group, Fayetteville/AR/United States 
of America, 10Division of Hematology-Oncology, Dept of Internal Medicine, and the Cancer 
Center, University of New Mexico, Albuquerque/NM/United States of America, 11Eli Lilly and 
Company, Indianapolis/IN/United States of America, 12Levine Cancer Institute, Carolinas 
Healthcare System, Charlotte/NC/United States of America
Background: Abemaciclib, a cell cycle inhibitor selective for CDK4/6, demonstrated 
acceptable safety and early clinical activity in metastatic NSCLC, given orally as 
monotherapy on a continuous schedule. Combinations of abemaciclib showed 
greater activity compared with monotherapy in KRAS-mutant NSCLC preclinical 
models. Primary aim of study NCT02079636 was safety/tolerability of combination 
therapy with abemaciclib; secondary aims included pharmacokinetics and antitumor 
activity. Methods: In this open-label 3+3 dose-escalation study with expansion cohorts, 
eligibility included stage IV NSCLC, measurable or nonmeasurable disease (RECISTv1.1), 
ECOG PS ≤1, and 1-3 prior therapies. Abemaciclib was combined with pemetrexed (Part 
A, nonsquamous, 500 mg/m2 IV day 1), gemcitabine (Part B, 1250 mg/m2 IV days 1 and 
8), ramucirumab (Part C, 10 mg/kg IV day 1, or 8 or 10 mg/kg IV days 1 and 8) (Q21), or 
LY3023414 (dual PI3K-mTOR inhibitor) (Part D, 100 mg, 150 mg or 200 mg orally Q12H). 
In escalation, patients were dosed continuously until progression with abemaciclib at 
100 mg (Part D), 150 mg or 200 mg orally Q12H. Results: As of February 27, 2015, 70 
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with nab -paclitaxel plus carboplatin (nab -P/C) significantly increased median overall 
survival (OS) vs solvent-based paclitaxel plus C in a subset of patients ≥ 70 years of age 
with advanced NSCLC (19.9 vs 10.4 months; HR 0.583; P = 0.009; Socinski et al. Ann 
Oncol. 2013;24:314-321). However, 55% of elderly patients treated with nab -P/C required 
dose reductions and 84% had dose delays, primarily due to adverse events, including 
myelosuppression. In the open-label, multicenter phase IV ABOUND.70+ trial, the safety 
and efficacy of 2 different schedules of first-line nab -P/C treatment will be evaluated 
prospectively in elderly patients with advanced NSCLC. Methods: Approximately 284 
patients with NSCLC ≥ 70 years of age who are not candidates for curative surgery or 
radiation therapy will be randomized 1:1 to nab -P 100 mg/m2 intravenously (IV; 30-minute 
infusion) on days 1, 8, and 15 plus C AUC 6 on day 1 every 21 days or the same nab -
P/C dose every 21 days followed by a 1-week break. Key eligibility criteria include 
histologically/cytologically confirmed locally advanced or metastatic NSCLC, no prior 
chemotherapy for metastatic disease, ECOG performance status ≤ 1, adequate organ 
function, no active brain metastases, and absence of preexisting peripheral neuropathy 
(PN) grade > 2. Patients will be stratified by ECOG performance status (0 vs 1) and 
histology (squamous vs nonsquamous). ClinicalTrials.gov identifier NCT02151149.
Key Endpoints
Primary • Percentage of patients developing either PN grade ≥ 2 or myelosuppression grade ≥ 3
Secondary
• Safety
• Progression-free survival
• OS
• Overall response rate
Exploratorya
• Healthcare resource utilization throughout the study
• Changes in quality of life
 
a Additional exploratory endpoints may be defined in the statistical analysis plan if 
applicable. Results: TPS Abstract Section NA Conclusion: TPS Abstract Section NA 
Keywords: elderly, nab-Paclitaxel,, carboplatin, NSCLC
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P2.01-089 A Phase 1b/2 Randomized Study of PEGPH20 in Combination 
with Docetaxel in Hyaluronan High NSCLC Patients Treated with Platinum 
Chemotherapy Chandra P. Belani1, Steve Shuey2, Deborah Carson2, Xionghua Wu2, 
Athena Countouriotis2 1Penn State Milton S. Hershey Medical Center, Hershey/PA/United 
States of America, 2Halozyme Therapeutics, San Diego/CA/United States of America
Background: Patients with advanced non-small cell lung cancer (NSCLC) progressing 
after 1st line platinum containing doublet chemotherapy +/- targeted therapy for EGFR 
mutations and EML4-ALK fusion genes have limited therapeutic options. Extracellular 
components such as hyaluronan (HA) make up the tumor microenvironment (TME) and 
may limit access of chemotherapeutic agents to the cell as a result of increased interstitial 
pressure and decreased blood flow. PEGPH20 (PEG) decreases HA and restores blood 
flow. In animal models of NSCLC, PEG + docetaxel (Doc) significantly prolonged survival 
compared to Doc alone. These results are consistent with results in previous studies 
in pancreatic adenocarcinoma (PDA). In a Phase 1b trial of the combination of PEG + 
gemcitabine in Stage IV pts with PDA whose tumors were HA-high pts had higher ORR, PFS 
and OS compared to pts with HA-low tumors. Methods: This is an ongoing Phase 1b/2 
open-label, randomized study of the addition of PEG to docetaxel (PDoc) compared to 
docetaxel (Doc) in pts with Stage IIIB/IV NSCLC having been treated with at least 1st line 
platinum containing chemotherapy. The Phase 1b portion of the study will determine the 
maximum tolerated dose (MTD), dose limiting toxicity and recommended Phase 2 dose 
for two schedules of PEG; one given every 21 days with Doc and the second dosed 2X 
per week with Doc. Up to 40 subjects are expected to be enrolled in the Phase 1b dose 
escalation. Once MTDs are determined the second portion of the Phase 1b will accrue 
approximately 10 patients whose tumors are HA-high to determine which schedule will go 
forward in Phase 2. The Phase 2 will randomize 188 patients in a 1:1 fashion to receive 
PDoc or Doc stratified by histology and prior targeted therapy. The primary endpoint of 
the Phase 2 portion is PFS. This is the first clinical trial evaluating PEGPH20 in NSCLC. 
The trial is currently accruing to the dose finding portion of the Phase 1b. ClinicalTrials.
gov Identifier: NCT02346370 Results: not applicable Conclusion: not applicable 
Keywords: NSCLC, PEGPH20, hyaluronan, TME
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P2.01-090 A Phase 2, Single Arm Study of Lucitanib in Patients with Advanced/
Metastatic Lung Cancer and FGF, VEGF, or PDGF-Related Genetic Changes 
David R. Spigel1, Enriqueta Felip2, Silvia Novello3, Marina C. Garassino4, Melanie Collins5, 
Jason B. Litten5, Andrew R. Allen5, Roberta Cereda6, Taofeek K. Owonikoko7, Mark A. 
Socinski8, Ross Camidge9, Benjamin Besse10 1Sarah Cannon Research Institute/Tennessee 
Oncology, Pllc, Nashville/TN/United States of America, 2Vall D’Hebron University Hospital 
and Vall D’Hebron Institute of Oncology (Vhio), Barcelona/Spain, 3Department of Oncology, 
University of Turin, Aou San Luigi, Orbassano/Italy, 4Fondazione Irccs Istituto Nazionale Dei 
Tumori, Milano/Italy, 5Clovis Oncology, San Francisco/CA/United States of America, 6Clovis 
Oncology, Milano/Italy, 7Winship Cancer Institute of Emory University, Atlanta/United 
States of America, 8University of Pittsburgh Cancer Insitute, Pittsburgh/PA/United States 
Arms 1-4 
(patients with active* brain me-
tastases, without leptomeningeal 
carcinomatosis [LC])
Prior ALKi treatment No prior ALKi treatment
Prior whole brain radiotherapy 
(WBRT) Arm 1 Arm 3
No prior WBRT Arm 2 Arm 4
Arm 5: patients with LC with or 
without evidence of active lesion 
at baseline
*Lesion free of local treatment (stereotactic or WBRT) or lesions in unequivocal 
progression after radiotherapy. Oral ceritinib 750 mg/d will be dosed on a continuous 
schedule and study assessments are consistent across arms. The primary and key 
secondary objectives are to evaluate overall response rate and disease control rate, 
respectively. Other secondary objectives include assessment of intracranial and 
extracranial responses for all patients and for each of arms 1–4; overall survival and safety 
for all patients and for each of arms 1–5; and ceritinib pharmacokinetics in all patients. 
Enrollment is ongoing. Results: This study is in the activation phase. Conclusion:This 
study will demonstrate the efficacy of ceritinib in ALK+ NSCLC brain metastases and 
leptomeningeal metastases, in both WBRT-naive patients and prior irradiated patients. 
Keywords: Ceritinib, ALK, NSCLC, brain metastases
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P2.01-087 A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic 
Squamous NSCLC Shihfan Yeh1, Lyudmila Bazhenova1, Gloria Lee2, Lan Huang2 
1University of California, San Diego, San Diego/CA/United States of America, 2Beyondspring 
Pharmaceuticals, Inc, New York/NY/United States of America
Background: Plinabulin (P) is a microtubule-depolymerizing agent that inhibits tumor 
growth by targeting both angiogenesis and tumor vasculature as well as directly by 
inducing apoptosis via the Ras-JNK pathway. It also could activate anti-tumor immunity 
via inducing maturation of dendritic cells. Pinabulin at 30 mg/m2 given on days 1 and 8 
was studied in a randomized phase 2 study in combination with docetaxel 75 mg/m2. 
Despite the fact that ITT overall survival (OS) was not statistically different between both 
arms, duration of response was notably longer in DP compared to D, 12.7 months vs 1.5 
month in the 30 cohort ( p=0.049). Nivolumab (Nivo) is the first PD-1 inhibitor approved 
by the FDA in metastatic squamous NSCLC, based on results of a phase III trial showing 
that patients receiving Nivo lived, on average, 3.2 months longer than patients receiving 
standard ChRx. Microtubule-depolymerizing agents are known to induce dendritic cell 
maturation and synergize with immune checkpoint inhibitors in immune competent cancer 
models. Therefore we hypothesize that combining plinabulin with nivolumab will enhance 
the immune response which will in turn lead to a higher response rate (RR) and longer 
OS in patients with metastatic squamous NSCLC. Methods: This is a phase I open-label, 
dose escalation study of plinabulin in combination with nivolumab (PNivo) in patients 
with metastatic squamous NSCLC that have progressed through one line of platinum-
containing ChRx. The primary objectives are safety and tolerability of combination 
therapy to define the maximum tolerated dose (MTD), dose limiting toxicities (DLT) and/
or RP2D for PNivo. The secondary objective is the efficacy of PNivo in terms of RR, 
progression free survival and OS in the expanded cohort. Plinabulin will be escalated from 
the biologically active dose of 13.5 mg/m2 using a “3+3” design. At the MTD or highest 
dose level in this study, the cohort will be expanded as applicable to ensure a total of 9 
subjects are treated at the RP2D. Correlative studies to investigate pharmacodynamical 
effects will be performed. Main inclusion criteria are histologically documented 
metastatic squamous NSCLC with measurable disease, EGFR/ALK and ROS-1 negativity, 
ECOG status 0 to 2, preserved organ and marrow function. Main exclusion criteria are 
untreated brain metastases, concurrent radiation and systemic therapy within 21 days 
of the first dose of study drug. Results: not applicable Conclusion: not applicable 
Keywords: plinabulin, Nivolumab, squamous NSCLC
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P2.01-088 nab-Paclitaxel + Carboplatin for Elderly Patients with Advanced 
NSCLC (ABOUND.70+) Corey J. Langer1, Katayoun I. Amiri2, Morton Coleman3, Daniel 
Haggstrom4, Katrik Konduri5, Alexandra Sanford2, William Skinner6, David Smith7, Matei 
Socoteanu5, Nataliya Trunova2, Jared Weiss8, Edgardo Santos9 1Abramson Cancer 
Center, University of Pennsylvania, Philadelphia/PA/United States of America, 2Celgene 
Corporation, Summit/NJ/United States of America, 3New York Presbyterian, Weill Cornell, 
New York City/NY/United States of America,4Levine Cancer Institute; Carolinas Healthcare 
System, Charlotte/NC/United States of America, 5Usoncology Research, Houston/TX/
United States of America, 6Paducah Cancer and Blood Center, Paducah/KY/United States 
of America, 7Compass Oncology, Vancouver/WA/United States of America, 8Lineberger 
Comprehensive Cancer Center, University of North Carolina, Chapel Hill/NC/United States 
of America, 9Thoracic and Head and Neck Cancer Programs, Eugene M. & Christine E. Lynn 
Cancer Institute, Florida Atlantic University, Boca Raton, Fl, Boca Raton/FL/United States of 
America
Background: Treatment of elderly patients with non-small cell lung cancer (NSCLC) is 
challenging due to comorbidities and reduced tolerability; as a result, these patients 
often receive suboptimal treatment. In addition, 5-year survival rates are lower in elderly 
than in younger patients with NSCLC. In a multicenter phase III trial, first-line treatment 
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counterparts. AUY922 potently inhibits HSP90, showing preclinical activity in a wide range 
of cancer cell lines, including NSCLC (1). Phase I clinical trials established 70 mg/m2 as 
the dose for further development (2). A single agent phase II trial demonstrated clinical 
activity of AUY922 in NSCLC, particularly molecular subsets with driver mutations in the 
known HSP90 client proteins, epidermal growth factor receptor (EGFR) and anaplastic 
lymphoma kinase (ALK) (3). Pemetrexed is a folate antimetabolite chemotherapeutic 
approved for use in advanced non-squamous, NSCLC. In pre-clinical models, mRNA for 
dihydrofolate reductase (DHFR), a target of pemetrexed, reliably decreased in response 
to AUY922 exposure (1). These findings suggest that the combination of AUY922 and 
premetrexed in NSCLC is worthy of investigation. Methods: Adult patients with previously 
treated stage IV non-squamous, NSCLC, measureable disease per RECIST 1.1, ECOG 
performance status < 2, and life expectancy > 3 months are eligible for this open label 
phase Ib clinical trial (NCT01784640). A standard 3 x 3 design will evaluate 3 cohorts, 
all with pemetrexed at the standard 500 mg/m2 dose, plus: AUY922 40 mg/m2, 55 mg/
m2, and 70 mg/m2 qwk. Enrollment of the 70 mg/m2 qwk cohort has been open since 
November 2014 and is currently ongoing. After the optimal dose for further evaluation 
is determined, an additional 20 patients will be enrolled at that dose. This expansion 
phase will focus on patients with EGFR mutations and ALK gene rearrangements. The 
primary endpoint is safety and tolerability of AUY922 combined with pemetrexed 
in patients with previously treated non-squamous NSCLC. [Funding by Novartis, 
K23CA149079, Wolfen Family, One Ball Matt Memorial Golf Tournament]. References 1) 
Garon EB et. al. Mol Cancer Ther. 2013 2) Sessa C et. al. Clin Cancer Res. 2013 3) 
Garon EB et. al. ASCO 2012 Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, AUY922, HSP90, pemetrexed
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P2.01-093 A Phase III Study of Radiosurgery with TTFields for 1-10 Brain 
Metastases from NSCLC Minesh P. Mehta1, Vinai Gondi2, Paul D. Brown3 1University of 
Maryland Medical Center, Baltimore/MD/United States of America, 2Cadence Health Brain 
Tumor Center and Cadence Health Proton Center, Chicago/United States of America, 3MD 
Anderson Cancer Center, Huston/TX/United States of America
Background: Tumor Treating Fields (TTFields) are a novel, non-invasive regional anti-
mitotic treatment modality, based on low intensity alternating electric fields. Efficacy 
of TTFields in non-small cell lung cancer (NSCLC) has been demonstrated in multiple in 
vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain 
was shown to be safe and effective in glioblastoma patients. Local treatment options 
for patient with brain metastases (BM) are limited to neuro-surgery (NS), stereotactic 
radiosurgery (SRS) or whole brain radiotherapy (WBRT) or a combination thereof. In 
patients treated with NS or SRS, intracranial recurrence remains high, since the rest 
of the brain is not treated. The addition of WBRT, can improve intracranial control 
either alone or when added to SRS but at the risk of severe neurocognitive and other 
complications. Thus, new therapeutic options are needed, particularly ones that allow 
for greater intracranial control while minimizing the risk of neurocognitive and other 
adverse events. Methods: The METIS Clinical Trial 240 patients with 1-10 BM from 
NSCLC will be randomized in a ratio of 1:1 to receive SRS followed by either TTFields 
or supportive care alone. Patients are followed-up bimonthly until 2nd intracerebral 
progression. Patients in the control arm may cross over to receive TTFields at the time of 
1st intracerebral progression. Objectives To test the efficacy, safety and neurocognitive 
outcomes of TTFields in this patient population. Endpoints Time to intracerebral 
progression (primary); time to first/second intracerebral progression for patients with 
1-4 and 5-10 BM; 2, 4, 6, 8, 10, 12-month first/second intracerebral progression rate; 
intracerebral progression free survival; overall survival; time to neurocognitive failure; 
rate of decline in cognitive function; neurocognitive failure-free survival; radiological 
response; safety (secondary). Treatment Continuous TTFields at 150 kHz will be 
applied to the brain using the NovoTTF-100M System within 7 days of SRS. The System 
is a portable medical device allowing normal daily life activities. The device delivers 
alternating electric fields to the brain using 4 Transducer Arrays, which may be covered 
by a wig or a hat for cosmetic reasons. Patients will receive the best standard of care for 
their systemic disease. Statistical Considerations This is a prospective, randomized, 
multicenter study for 240 patients. The trial is designed to detect an increase in the time 
to intracerebral progression from 7.7 to 13.4 months (hazard ratio 0.57). This sample 
size assessment takes into consideration a competing risk (death prior to intracerebral 
progression) of 0.08252 per month in both treatment arms. The competing risk is based 
on a predicted median overall survival of 8.4 months mainly due to systemic disease 
progression. The trial has 80% power at a two sided alpha of 0.05. The sample size was 
calculated using a log-rank test (based on Lakatos 1988 and 2002) with the competing 
risk taken as loss to follow up (patients will be censored at time of death if it occurs 
prior to intracerebral progression). Results: not applicable Conclusion: not applicable 
Keywords: Tumor Treating Fields, brain metastases, Stereotactic Radiosurgery, NSCLC
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P2.01-094 Phase II Trial of Tepotinib/Gefitinib vs Cisplatin/Pemetrexed in 
T790M-/c-Met+ NSCLC Yi-Long Wu1, Keunchil Park2, Dong-Wan Kim3, Ross Soo4, 
Uz Stammberger5, Huiiling Xiong6, Christian Ihling5, James Chih-Hsin Yang7 1Guangdong 
Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical 
Sciences, Guangzhou/China, 2Innovative Cancer Medicine Institute, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul/Korea, 3Department of Internal 
Medicine, Seoul National University Hospital, Seoul/Korea, 4National University Cancer 
Institute Singapore, National University Health System, Singapore/Singapore, 5Merck Kgaa, 
Darmstadt/Germany,6Merck Serono Pharmaceutical R&D Co., Ltd, Beijing/China, 7National 
Taiwan University, Graduate Institute of Oncology, Taipei/Taiwan
of America, 9Medical Oncology, University of Colorado, Denver/CO/United States of 
America, 10Institut Gustave Roussy, Villejuif/France
Background: Lucitanib is a potent, oral inhibitor of the tyrosine kinase activity of Fibroblast 
Growth Factor Receptors 1-3 (FGFR1-3), Vascular Endothelial Growth Factor Receptors 
1-3 (VEGFR1-3) and Platelet-Derived Growth Factor Receptors A/B (PDGFRA/B). Clinical 
activity was observed in a phase 1/2 study of lucitanib monotherapy in cancer patients 
with tumor amplification of FGF-related genes or in tumors with predicted sensitivity to 
VEGF inhibitors. Genomic evidence of FGF, VEGF or PDGF axis aberrancy is seen in up to 
15% of patients with lung cancer, which provides a strong rationale to assess lucitanib in 
this setting. Methods: The current study evaluates daily oral lucitanib monotherapy in 40 
patients with amplification or activating mutations in FGF, VEGF or PDGF-related genes. 
This is an international, multicenter, open-label, single-arm study. The primary endpoint 
is objective response rate (ORR; RECIST 1.1) with secondary endpoints of response 
duration, clinical benefit rate, progression-free survival, and safety. Exploratory objectives 
include volumetric assessment of tumor growth kinetics, serial circulating tumor DNA 
measurement, and identification of additional biomarkers of lucitanib activity. Key 
inclusion criteria include: patients with advanced/metastatic non-small cell lung cancer 
(NSCLC), small cell lung cancer (SCLC) or large cell lung cancer and tumor tissue evidence 
of relevant genomic aberrancies. Patients must have measurable disease and at least 
one previous treatment for advanced disease. Key exclusion criteria include: carcinoid 
histology, symptomatic CNS metastases, anti-cancer treatment for lung cancer within 
28 days or 5 half-lives before first dose of lucitanib. This study is enrolling patients in the 
United States and Europe at centers skilled in the identification of patients with relatively 
uncommon genetic tumor alterations. Results: not applicable Conclusion: not applicable 
Keywords: SCLC, FGFR1, VEGF, NSCLC
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P2.01-091 Multicenter, Randomized, Double-Blind Study of Erlotinib plus 
Ramucirumab or Placebo in Patients with EGFR Mutation-Positive Metastatic 
NSCLC Edward B. Garon1, Martin Reck2, Oscar J. Vidal3, Ernest Nadal4, Pablo Lee5, 
Rita Dalal5, Jingyi Liu6, Shuang He6, Joseph Treat6, Kazuhiko Nakagawa7 1UCLA Medical 
Center, Santa Monica/CA/United States of America, 2Lungen Clinic Grosshansdorf, 
Grosshansdorf/Germany, 3Hospital Universitario La Fe, Valencia/Spain, 4Institut Catala 
D’Oncologia, L’Hospitalet, Barcelona/Spain, 5Eli Lilly and Company, Bridgewater/NJ/United 
States of America, 6Eli Lilly and Company, Indianapolis/IN/United States of America, 7Kinki 
University School of Medicine, Osaka/Japan
Background: Ramucirumab, a human IgG1 monoclonal antibody, binds to Vascular 
Endothelial Growth Factor (VEGF) Receptor 2, preventing binding of VEGF-A, C and 
D. Ramucirumab in combination with docetaxel has demonstrated improvement in 
overall survival, progression free survival (PFS), objective response rate and disease 
control rate in 2nd line treatment of NSCLC patients in the phase III REVEL study, 
which included non-squamous and squamous cell carcinoma patients. Although 
erlotinib is recognized as one of the standard of care options in the frontline 
treatment of patients whose tumors harbor an Epidermal Growth Factor Receptor 
(EGFR) mutation, it is hypothesized that the duration of disease control would be 
greater when an antiangiogenic agent such as ramucirumab is added to erlotinib. 
This global phase Ib/III trial will assess safety, tolerability and efficacy (phase III) of the 
combination of ramucirumab with erlotinib in previously untreated stage IV NSCLC patients 
harboring activating EGFR mutations. The trial is planned to be conducted in ~120 sites in the 
Americas, Europe, and Asia and is currently open for enrollment. (RELAY, NCT02411448) 
Methods: In part A (phase Ib) approximately 12 patients (6 Japan + 6 US/EU) will 
receive ramucirumab (10mg/kg on day 1) every two weeks + erlotinib (150 mg/
day). DLT assessment will be performed after patients complete four weeks of 
treatment. In part B (phase III), approximately 450 patients will be randomized in 
a 1:1 ratio to receive ramucirumab or placebo every two weeks with erlotinib until 
disease progression, unacceptable toxicity, or other withdrawal criteria are met. 
The primary endpoint is PFS. There are 3 planned interim analyses that will evaluate 
safety, futility and efficacy, respectively. Other secondary endpoints include overall 
survival, objective response rate, disease control rate, duration of response, 
safety and quality of life. Results: Not applicable Conclusion: Not applicable 
Keywords: treatment, EGFR, antiangiogenic, NSCLC
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P2.01-092 A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in 
Previously Treated Metastatic Non-Squamous, Non-Small Cell Lung Cancer 
Edward B. Garon1, James Sanchez2, Brian A. Dicarlo3, John L. Barstis1, Mark Hancock4, 
Eddie H.-L. Hu1, Fairooz F. Kabbinavar1, Brad Adams1, Diego A. Martinez1, Naeimeh 
Kamranpour1, Kevin Chau1, Phillip Abarca1, Mary Han1, Marshall L. Spiegel1, Brian Wolf1, 
Isett Laux1, Meghan B. Brennan1, Jonathan W. Goldman5 1David Geffen School of Medicine 
at University of California, Los Angeles/Translational Research in Oncology-Us Network, 
Santa Monica/CA/United States of America, 2Comp Cancer Ctrs of Nevada, Las Vegas/
NV/United States of America,3Coastal Integrative Cancer Care, San Luis Obispo/CA/United 
States of America, 4St. Mary’S Hospital & Regional Medical Center, Grand Junction/CO/
United States of America, 5School of Medicine of California, Los Angeles/AL/United States 
of America
Background: Despite advances in targeted therapy, treatment options for metastatic 
NSCLC progressing after initial therapy remains limited. HSP90 is an ATP-dependent 
molecular chaperone that plays a vital role in protein stabilization. Some HSP90 client 
proteins are key regulators in cell proliferation and survival. Many mutant oncoproteins 
are more dependent on HSP90 for proper folding and stability compared to their wildtype 
S553Copyright © 2015 by the International Association for the Study of Lung Cancer
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Key Endpoints
Primary • The percentage of patients who discontinue treatment during the induction part due to treatment-emergent adverse events
Secondary
• Safety
• Progression-free survival
• Disease control rate
• Overall survival
• ORR
Exploratory
• Healthcare resource utilization throughout the study
• Changes in physician-reported ECOG PS and patient-reported 
quality of life
• Summary of Charlson Co-Morbidity Index at baseline
• Correlation between patient- and physician-reported ECOG PS 
during treatment
• Correlation between patient- and physician-reported Karnofsky 
PS at baseline
Results: This is a TPS abstract Results = NA Conclusion: This is a TPS abstract Results = NA 
Keywords: PS2, nab-paclitaxel, NSCLC, carboplatin
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P2.01-096 Randomized, Double-Blind, Placebo-Controlled Trial of 
Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced ns-
NSCLC Jonathan W. Goldman1, Charles Bennett2, Corey Carter3, Tudor Ciuleanu4, 
Morton Coleman5, Tibor Csoszi6, Filippo De Marinis7, Ramon Garcia Gomez8, Maciej 
Krakowski9, Julian Molina10, Silvia Novello11, Sergei Orlov12, Gyula Ostoros13, Robert 
Palmer2, Francisco Robert14, Philip Stella15, Joachim Von Pawel16, Tillman Pearce17, Stew 
Kroll17, Chandra P. Belani18 1Oncology, UCLA Hematology/Oncology-Santa Monica, Santa 
Monica/CA/United States of America, 2Oncology, Wm Jennings Bryan Dorn Va Med Ctr, 
Columbia/SC/United States of America, 3Oncology, Walter Reed National Military Med Ctr, 
Bethesda/MD/United States of America, 4Radiotherapy, “Prof. Dr. Ion Chiricuta” Institute of 
Oncology, Cluj-Napoca/Romania, 5Oncology, Clinical Research Alliance, Inc., New York/AL/
United States of America, 6Department of Oncology, Hetenyi G Korhaz, Onkologiai Kozpont, 
Szolnok/Hungary, 7European Institute of Oncology, Milan/Italy, 8Department of Oncology, 
General University Hospital Gregorio Maranon, Madrid/Spain, 9Oncology, Maria Sklodowska-
Curie Institute of Oncology, Warsaw/Poland, 10Oncology, Mayo Clinic in Rochester, 
Rochester/MN/United States of America, 11Department of Oncology, University of Turin, 
Aou San Luigi (Orbassano), Italy, Orbassano/Italy, 12Oncology, First Pavlov State Medical 
University of St. Peterburg, St. Petersburg/Russian Federation, 138Th Dept. of Pulmonology, 
Koranyi National Institute of Tbc and Pulmonology, Budapest/Hungary, 14Oncology, U. 
Alabama-Birmingham, Birmingham/AL/United States of America, 15Oncology, St. Joseph 
Mercy Ann Arbor Hospital, Ann Arbor/MI/United States of America, 16Asklepios Fachkliniken 
München-Gauting, Gauting/Germany, 17Clinical, Threshold Pharmaceutical, Inc., South San 
Francisco/CA/United States of America, 18Penn State Hershey Cancer Institute, Hershey/PA/
United States of America
Background: Tumor hypoxia is associated with chemo- and radioresistance and is a 
prevalent characteristic in tumors of patients with non-small cell lung cancer (NSCLC). 
Evofosfamide (previously known as TH-302) is a hypoxia-activated prodrug designed to 
release the bis-alkylating DNA crosslinker bromo-isophosphoramide mustard (Br-IPM) 
when reduced in severe hypoxia. In a Phase 1/2 study (NCT00743379) that included a 
single arm evofosfamide in combination with pemetrexed in 18 patients with relapsed/
refractory non-squamous NSCLC, median PFS was 7.0 months and median OS was 14.9 
months. Response in 15 evaluable patients: 6 partial responses (4 confirmed), 6 stable 
disease and 3 progressive disease. The most common adverse events were fatigue, 
anemia, stomatitis and nausea. Methods: An international, multicenter, randomized, 
double-blind, placebo-controlled trial was initiated to evaluate evofosfamide in 
combination with pemetrexed versus placebo and pemetrexed as a potential second-
line treatment for patients with non-squamous NSCLC (NCT02093962). Approximately 
440 patients will be enrolled with histologically confirmed stage IIIB or IV NSCLC with 
non-squamous histology, measurable disease according to RECIST 1.1, and ECOG 
performance status 0-1. Eligible patients have recurrent or progressive disease after 
one prior platinum-based non-pemetrexed chemotherapy treatment for advanced 
disease with or without maintenance. EGFR-activating and ALK rearrangements status 
must be known, and if identified, patients must have received a targeted kinase inhibitor. 
Evofosfamide (400 mg/m2) or matched placebo is administered by IV infusion over 30 - 60 
minutes on Day 1 and Day 8 of a 21-day cycle. Pemetrexed (500 mg/m2) is administered 
by IV infusion 2 to 4 hours after evofosfamide administration on Day 1. Overall survival 
(OS) is the primary endpoint; secondary endpoints include safety, progression-free 
survival and RECIST response rate. The study design has 85% power to detect a 40% 
improvement in OS with a one-sided alpha of 0.025. The first patient was enrolled in 
June 2014; recruitment is ongoing. Results: not applicable Conclusion: not applicable 
Keywords: Phase 2/3, Hypoxia, microenvironment
Background: The recommended phase II dose of the highly selective c-Met inhibitor 
tepotinib (MSC2156119J) for use in combination with gefitinib was confirmed as 500 
mg/day in the phase Ib part of the current trial, in which patients with gefitinib-resistant 
locally advanced/metastatic c-Met-positive NSCLC were treated with tepotinib plus 
gefitinib. This trial demonstrated that the combination regimen is well tolerated and has 
evidence of antitumor activity that may be associated with c-Met-positive tumor status. 
These observations suggest that c-Met inhibition may have a role in EGFR tyrosine kinase 
inhibitor-resistant NSCLC and that a phase II trial is warranted. Methods: The design 
of the phase II part of a phase Ib/II trial (NCT01982955) is described. Asian adults with 
histologically or cytologically confirmed, gefitinib-resistant locally advanced/metastatic 
NSCLC other than predominantly squamous histology and ECOG PS 0/1 are eligible. 
Patients must have tumors with documented activating mutations of EGFR. Tumor tissue 
obtained between documentation of acquired resistance to gefitinib and enrollment must 
be available. Tumors must be confirmed as being c-Met positive (2+/3+ c-Met protein 
overexpression by immunohistochemistry using CONFIRM anti-total c-MET [SP44] rabbit 
MAb [Ventana] or c-Met gene amplification on IQ FISH [Dako] [c-Met:CEP7 ratio ≥2 or 
<2.0 with >15 c-Met signals/cell in >10% of cells or clusters in >10% of tumor cell 
nuclei]). EGFR mutation status will be assessed centrally using the therascreen® EGFR 
RGQ PCR Kit (QIAGEN). Patients will be enrolled into different parts of the trial based 
on tumor T790M status. Patients with c-Met-positive, T790M-negative NSCLC (n=136) 
will be randomized to tepotinib 500 mg/day p.o. + gefitinib 250 mg/day q3w or 
cisplatin 75 mg/m2 + pemetrexed 500 mg/m2 q3w for up to 6 cycles. Patients with 
c-Met-positive, T790M-positive NSCLC (n=15) will be treated with tepotinib 500 mg/
day p.o. + gefitinib 250 mg/day q3w. The primary objective is to determine whether 
progression-free survival (PFS) in patients treated with second-line tepotinib combined 
with gefitinib is superior to that of pemetrexed + cisplatin in patients with c-Met-positive, 
T790M-negative advanced NSCLC and acquired resistance to first-line gefitinib. The two 
T790M subgroups will be analyzed separately. An interim analysis of the randomized part 
of the study is planned when 50% of PFS events have occurred in both arms. Secondary 
objectives are to evaluate: the safety and tolerability tepotinib combined with gefitinib; 
the efficacy of tepotinib combined with gefitinib; the antitumor activity of tepotinib 
combined with gefitinib in patients with c-Met-positive, T790M-positive tumors; and 
patient-reported outcomes. Results: not applicable Conclusion: This randomized phase 
II trial will provide the first evidence regarding whether tepotinib has a role in the treatment 
of Asian patients with gefitinib-resistant, c-Met-positive, T790M-negative NSCLC. 
Keywords: MSC2156119J, phase II, c-Met, tepotinib
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P2.01-095 nab-Paclitaxel/Carboplatin Followed By nab-Paclitaxel for NSCLC 
PS 2 (ABOUND.PS2) Ajeet Gajra1, Mark A. Socinski2, Haythem Ali3, Katayoun I. Amiri4, 
Nagla Abdel Karim5, Eric Kim6, Marc R. Matrana7, Alexandra Sanford4, Nataliya Trunova4, 
David R. Spigel8 1Upstate Medical University, Upstate Cancer Center, Syracuse/NY/United 
States of America, 2University of Pittsburgh, Pittsburgh/PA/United States of America, 3Henry 
Ford Health System, Detroit/MI/United States of America, 4Celgene Corporation, Summit/
NJ/United States of America, 5Medicine-Division of Hematology/Oncology, The University 
of Cincinnati, Oh/OH/United States of America, 6University of Rochester Medical Center, 
Wilmott Cancer Institute, Rochester/NY/United States of America, 7Ochsner Medical Center, 
New Orleans/NY/United States of America, 8Sarah Cannon Research Institute/Tennessee 
Oncology, Pllc, Nashville/TN/United States of America
Background: Many patients with advanced non-small cell lung cancer (NSCLC) often 
present with poor performance status (PS), and there is no clear consensus on how 
best to treat these patients. Despite an increased risk of toxicity resulting from standard 
chemotherapy, patients with NSCLC and a poor PS can clinically benefit from platinum-
doublet therapy. In a multicenter phase III trial, first-line treatment with nab -paclitaxel plus 
carboplatin (nab -P/C) in patients with NSCLC and an ECOG PS 0-1 significantly improved 
the overall response rate (ORR) compared with solvent-based paclitaxel plus C (33% vs 
25%; P = 0.005; Socinski et al. J Clin Oncol. 2012;30:2055-2062). In the single-arm, 
open-label, multicenter phase II ABOUND.PS2 study, the safety and efficacy of first-
line nab -P/C followed by nab -P monotherapy will be evaluated in patients with locally 
advanced/metastatic NSCLC and an ECOG PS of 2. Methods: During the induction part 
of the study, approximately 50 patients will be treated with 4 cycles of nab -P 100 mg/
m2 intravenously (IV; 30-minute infusion) on days 1 and 8 plus C AUC 5 IV on day 1 
every 21 days. Patients without disease progression may proceed to the monotherapy 
part of the study in which they will continue to receive nab -P 100 mg/m2 IV (30-minute 
infusion) on days 1 and 8 every 21 days until progression or unacceptable toxicity. Key 
eligibility criteria include histologically/cytologically confirmed stage IIIB/IV NSCLC, no 
prior chemotherapy for metastatic disease, ECOG PS of 2, adequate organ function, no 
active brain metastases, and preexisting peripheral neuropathy grade < 2. ClinicalTrials.
gov number NCT02289456.
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P2.01-099 nab-Paclitaxel as Maintenance Therapy in Patients with Squamous 
Cell NSCLC (ABOUND.sqm) David R. Spigel1, Cesare Gridelli2, Robert Jotte3, Edward 
S. Kim4, Amy Ko5, Teng Jin Ong5, Robert Pirker6, Michael Thomas7, Nataliya Trunova5, 
Howard West8, Craig H. Reynolds9 1Sarah Cannon Research Institute, Nashville/TN/
United States of America, 2S.G. Moscati Hospital, Avellino/Italy, 3Rocky Mountain Cancer 
Centers, Denver/CO/United States of America, 4Levine Cancer Institute--Morehead, Carolinas 
Healthcare System, Charlotte/NC/United States of America, 5Celgene Corporation, Summit/
NJ/United States of America, 6Department of Medicine I, Medical University of Vienna, 
Vienna/Austria, 7Thoraxklinik at Heidelberg University, Heidelberg/Germany,8Swedish Cancer 
Institute, Seattle/WA/United States of America, 9Ocala Oncology Center, Ocala/FL/United 
States of America
Background: Patients with squamous cell (SCC) non-small cell lung cancer (NSCLC) 
may be at risk of poorer outcomes and have fewer treatment options than those with 
other histologies. Furthermore, no randomized studies have demonstrated the benefit 
of maintenance therapy in these patients. In a phase III trial, first-line treatment with nab -
paclitaxel plus carboplatin (nab -P/C) demonstrated a 68% improvement in the overall 
response rate (ORR; 41% vs 24%; P < 0.001) and a trend toward improved overall 
survival (OS; median, 10.7 vs 9.5 months; HR 0.890; P = 0.310) compared with solvent-
based paclitaxel plus C in a subset of patients with advanced SCC NSCLC (Socinski 
et al. Ann Oncol. 2013;24:2390-2396). An exploratory analysis of the phase III trial 
demonstrated that therapy with nab-P/C beyond 4 cycles of first-line treatment was 
effective in the subset of patients with SCC NSCLC who did not progress (from the time 
of randomization, median progression-free survival [PFS] and OS were 6.8 and 13.8 
months, respectively), and no new safety signals were noted (Socinski et al. IASLC 
2013 [abstract 3438]). In the open-label, multicenter phase III ABOUND.sqm trial, the 
efficacy and safety of nab -P maintenance therapy after nab -P/C induction therapy will 
be evaluated in patients with advanced SCC NSCLC. Methods: During the induction part 
of the study, approximately 540 patients will be treated with 4 cycles of nab -P 100 mg/
m2intravenously (IV; 30-minute infusion) on days 1, 8, and 15 plus IV C AUC 6 on day 
1 every 21 days. Patients with a complete response (CR), a partial response (PR), or 
stable disease (SD) will be eligible for maintenance. In the maintenance part of the study, 
approximately 260 patients will be randomized 2:1 to nab -P 100 mg/m2 on days 1 and 8 
every 21 days plus best supportive care (BSC) or BSC alone until disease progression. 
Patients will be stratified by disease stage (IIIB vs IV), response to induction therapy (CR/
PR vs SD), and ECOG performance status at the end of induction (0 vs 1). Key eligibility 
criteria include histologically or cytologically confirmed stage IIIB/IV SCC NSCLC, no 
prior chemotherapy for metastatic disease, ECOG performance status ≤ 1, adequate 
organ function, no active brain metastases, and preexisting peripheral neuropathy grade 
< 2. ClinicalTrials.gov identifier NCT02027428.
Key Endpoints
Primary • PFS from randomization into the maintenance part of the study
Secondary
• Safety
• OS from randomization into the maintenance part of the study
• ORR during the induction and maintenance parts of the study
Exploratory
• Correlation between pretreatment tumor characteristics and 
response to treatment
• Association between changes in tumor characteristics and 
acquisition of resistance to therapy at the time of treatment 
failure during maintenance
• Correlation between genetic polymorphisms and treatment 
efficacy and/or toxicity
• Healthcare resource utilization during the maintenance part of 
the study
• Changes in quality of life
 
Results: Not applicable. Conclusion: Not applicable. Keywords: nab-paclitaxel, 
maintenance, squamous cell, NSCLC
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P2.01-100 Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell 
Lung Cancer (NSCLC) Keunchil Park1, Chia-Chi Lin2, Dennis Chin-Lun Huang3, Heather 
Hye-Jung Shin4, Thomas Bogenrieder5, Daniel S.-W. Tan6 1Division of Hematology-
Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul/Korea, 2Department of Oncology, National Taiwan University 
Hospital, Taipei/Taiwan, 3Boehringer Ingelheim Taiwan Limited, Taipei/Taiwan, 4Boehringer 
Ingelheim Korea, Seoul/Korea, 5Boehringer Ingelheim Rcv, Vienna/Austria, 6Department of 
Medical Oncology, National Cancer Center, Singapore/Singapore
Background: Patients harboring epidermal growth factor receptor (EGFR ) -mutated 
NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) invariably develop acquired 
resistance (AR). The mechanisms of AR are unknown in 30–40% of patients. In pre-clinical 
studies, insulin-like growth factor (IGF) signaling has been implicated in AR to EGFR TKIs 
in the absence of other known mechanisms including T790M mutation. It is hypothesized 
that an EGFR TKI combined with an IGF inhibitor can overcome this resistance. BI 836845 
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P2.01-097 Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy 
for PD-L1+ NSCLC Tony Mok1, Yi-Long Wu2, Sara Sadowski3, Jin Zhang3, Reshma 
Rangwala3, Gilberto De Lima Lopes4 1Department of Clinical Oncology, The Chinese 
University of Hong Kong, Hong Kong/Hong Kong, 2Guangdong Lung Cancer Institute, 
Guangdong General Hospital, Guagnzhou/China, 3Merck & Co., Inc., Kenilworth/NJ/United 
States of America,4Centro Paulista de Oncologia E Hcor Onco, Members of the Oncoclínicas 
Do Brasil Group, São Paulo/Brazil
Background: Platinum-based chemotherapy with or without maintenance therapy is 
the standard of care for treatment-naive non-small cell lung carcinoma (NSCLC) that 
lacks EGFR sensitizing mutations and ALK translocations. The PD-1 pathway is frequently 
used by tumors to evade an immune response. Pembrolizumab (MK-3475), an anti–PD-1 
monoclonal antibody, has demonstrated manageable toxicity and promising antitumor 
activity in patients with treatment-naive NSCLC enrolled in the phase 1b KEYNOTE-001 
study. In this study, a relationship between increased tumor PD-L1 expression and 
improved pembrolizumab antitumor activity was observed. KEYNOTE-042 (ClinicalTrials.
gov identifier NCT02220894) is a randomized, open-label, international, phase 3 
study designed to compare the efficacy and safety of pembrolizumab with those of 
platinum-doublet chemotherapy as first-line therapy for PD-L1–positive advanced 
NSCLC. Methods: Eligibility criteria include age ≥18 years, advanced NSCLC 
without EGFR sensitizing mutations or ALK translocation, no prior systemic chemotherapy, 
PD-L1 expression in ≥1% of tumor cells, and Eastern Cooperative Oncology Group 
performance status (ECOG PS) 0-1. Patients are randomly assigned in a 1:1 ratio to a 
200-mg fixed dose of pembrolizumab every 3 weeks (Q3W) or investigator’s choice of 
carboplatin AUC 5 or 6 plus paclitaxel 200 mg/m2 Q3W or carboplatin AUC 5 or 6 plus 
pemetrexed 500 mg/m2 Q3W. Randomization is stratified by ECOG PS (0 vs 1), histology 
(squamous vs nonsquamous), region (East Asia vs non-East Asia), and PD-L1 expression 
(strong [staining in ≥50% of tumor cells] vs weak [staining in 1%-49% of tumor cells], 
as assessed by immunohistochemistry at a central laboratory). Pembrolizumab will be 
continued for 35 cycles or until disease progression, intolerable toxicity, or investigator 
decision; treatment may be continued beyond initial radiographic disease progression 
in eligible patients. Discontinuation of pembrolizumab is permitted for patients who 
experience a complete response confirmed on a follow-up scan performed ≥4 weeks 
after initial observation. Chemotherapy will be given for a maximum of 6 cycles and may 
be followed by optional pemetrexed 500 mg/m2 Q3W maintenance therapy in patients 
with nonsquamous histology. Adverse events will be collected throughout the study and 
for 30 days (90 days for serious adverse events) thereafter and graded per NCI CTCAE 
v4.0. Response will be assessed every 9 weeks per RECIST v1.1 by independent central 
review. Patients will be followed for survival every 2 months. Primary end point is overall 
survival in the PD-L1–strong-positive stratum; secondary end points are progression-free 
survival in the strong-positive stratum and progression-free and overall survival in all 
patients. Enrollment is ongoing and will continue until approximately 1240 patients have 
been allocated to study treatment. Results: Not applicable. Conclusion: Not applicable. 
Keywords: pembrolizumab
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P2.01-098 Addition of Custirsen, a Clusterin Inhibitor, to Docetaxel in Stage IV 
Non-Small Cell Lung Cancer (NSCLC): The ENSPIRIT™ Phase 3 Trial Joachim 
Von Pawel1, Kirsten Anderson2, Cindy Jacobs3 1Pneumology, Asklepios Fachkliniken, 
Gauting/Germany, 2Clinical Operations, Oncogenex Pharmaceuticals, Inc., Bothell/WA/United 
States of America, 3Clinical Development, Oncogenex Pharmaceuticals, Inc., Bothell/WA/
United States of America
Background: Treatments that improve overall survival (OS) in advanced NSCLC are 
urgently needed. Docetaxel (DOC) is recommended as 2nd-line chemotherapy for 
advanced NSCLC, with a median OS of 7-8 months. The chaperone protein clusterin (CLU) 
is upregulated in NSCLC and other cancers in response to anticancer therapies. Custirsen 
(OGX-011) is a second-generation antisense oligonucleotide that inhibits CLU expression, 
enhances chemotherapeutic activity, and in vivo has reversed DOC resistance. In early 
phase studies in metastatic castration resistant prostate cancer (mCRPC), custirsen 
plus DOC was well tolerated and showed encouraging results. In a phase 3 mCRPC study 
(SYNERGY), 50% of patients defined as poor prognosis had survival benefit from custirsen 
when added to 1st-line DOC. Methods: ENSPIRIT was initiated September 2012. Eligible 
patients in this phase 3, multinational, open-label trial have failed 1 prior line of platinum 
(PT) -based therapy, have an ECOG of 0-1, and adequate bone marrow, renal, and liver 
function. Randomization is 1:1, with stratification by gender, NSCLC histology, best 
response to 1st-line PT therapy (response/stable disease vs progression), and ECOG 
score. Patients receive 21-day cycles of DOC (75 mg/m2 IV day 1) or DOC plus custirsen 
(640 mg IV/wk, preceded by 3 doses during a 9-day loading period) until progressive 
disease, unacceptable toxicity, or withdrawal. The primary efficacy measure is OS. Two 
interim analyses are planned for stopping the trial based on inadequate evidence of 
clinical benefit or futility; the first futility analysis was completed in August 2014. A recent 
amendment changed the hypothesized hazard ratio for the primary analysis from 0.80 to 
0.75 (power remains at 90%), resulting in a required sample size of 700 patients (instead 
of original 1100). In addition, the second futility has a more rigorous criterion for stopping 
due to survival futility and is to occur earlier than originally planned. The study will not be 
stopped early for efficacy. The aim of the ENSPIRIT amendment is to assess for a more 
clinically relevant survival benefit when adding custirsen to 2nd-line DOC or terminate 
the trial early for survival futility. Results: Not applicable. Conclusion: Not applicable. 
Keywords: custirsen, clusterin, docetaxel, survival
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cancer. These results suggest that inhaled Aza could inhibit lung cancer initiation and 
progression in subjects with chronic airborne carcinogen exposure. Thus, we designed the 
first phase I study of aerosolized Aza to determine the minimum effective dose of inhaled 
Aza required to induce relevant TSG re-expression in the bronchial epithelium of patients 
with advanced NSCLC. Methods: This is a phase I study following a 6+6 dose escalation 
and de-escalation design. Patients with advanced NSCLC, who have received at least 
one prior standard chemotherapy or targeted therapy, with ECOG PS 0-1, and adequate 
baseline bone marrow reserve, pulmonary reserve, and organ function are eligible. This 
study has received IRB and FDA approval as of 01/2015. Patients will be treated with 
inhaled Aza daily (20-minute inhalation) x 5 days per week once every 2 weeks. Based 
on our toxicity studies in mice, the recommended starting dose is 15 mg/m2 . Dose 
escalation will proceed if <33% subjects in a given cohort experience pre-defined dose 
limiting toxicity (DLT) defined as grade 2 or higher pulmonary toxicity, grade 4 anemia, 
neutropenia, thrombocytopenia or any grade 3 or higher non-hematologic toxicity. The 
primary objective of the study is to determine the minimum effective dose of inhaled Aza 
required to induce re-expression of 5 relevant candidate TSGs (p16, H-Cad, OPCML, SFRP-
1, and RASSF1A) that are silenced in the bronchial tissue of 20-50% heavy smokers with 
lung cancer. This will be determined in the bronchial epithelium of patients with advanced 
NSCLC in pre and post treatment biopsies. Secondary objectives include determining 
changes in global methylation patterns in the bronchial epithelium, and changes in 
methylation patterns in the exhaled breath. Clinical trial information: NCT02009436. 
Supported by NIH CA154755 Results: not applicable Conclusion: not applicable 
Keywords: lung cancer, 5-azacytidine
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P2.02-001 Predictors of Occult Nodal Metastasis in Clinical Stage I NSCLC 
Staged by FDG-PET/CT Kaoru Kaseda1, Ken-Ichi Watanabe1, Keisuke Asakura1, Akio 
Kazama2 1Department of Thoracic Surgery, Sagamihara Kyodo Hospital, Kanagawa/Japan, 
2Department of Pathology, Sagamihara Kyodo Hospital, Kanagawa/Japan
Background: Integrated 18F-fluorodeoxyglucose positron emission tomography/
computed tomography (FDG-PET/CT) is widely used for lymph node staging in patients 
with non-small cell lung cancer (NSCLC). However, FDG-PET/CT has certain limitations. If 
N0 cases staged by FDG-PET/CT were reliable, anatomy resection and systematic lymph 
node dissection might be avoided. And prediction of occult nodal metastasis could allow 
selection of candidates for preoperative cervical mediastinoscopy or endobronchial 
ultrasound-guided transbronchial needle aspiration. This study defined risk factors for 
occult nodal metastasis in patients with NSCLC patients who were diagnosed as clinical 
stage I by preoperative integrated FDG-PET/CT. Methods: We retrospectively reviewed 
the records of 423 NSCLC patients who underwent surgical resection from April 2007 
to March 2015 at the department of Thoracic Surgery, Sagamihara Kyodo Hospital. No 
preoperative mediastinoscopy was carried out in this group and all underwent curative 
intent surgical resection. The following patients were excluded from the present study: 
those who were diagnosed as clinical stage IIA/IIB/IIIA by preoperative integrated FDG-
PET/CT (n = 101), patients who underwent limited resection (wide-wedge resection 
or segmentectomy; n = 62), patients who received neo-adjuvant chemotherapy or 
radiotherapy (n = 1), and patients with preoperative integrated FDG-PET/CT was not 
performed (n = 20). The remaining 239 patients who were diagnosed as clinical stage I 
NSCLC were identified. They underwent surgical resection with systematic lymph node 
dissection. The prevalence of occult nodal metastasis in patients as clinical stage I 
was analyzed according to clinicopathological factors such as gender, age, smoking 
status, history of lung disease, serum carcinoembryonic antigen (CEA) level, concurrent 
diabetes, histopathological type, grade, tumor side, tumor localization, primary tumor 
location (central, non-central), tumor size (cm), pleural invasion, standardized uptake 
value (SUV) max of primary tumor. Risk factors for occult nodal metastasis were defined 
by univariate and multivariate analysis. Results: Occult nodal metastasis was detected 
in 12.5% (30/239) of the patients. N1 involvement was identified in 5.0% (12/239) of 
the patients and N2 disease was identified in 7.5% (18/239). An optimal cut-off value of 
primary tumor SUVmax for occult nodal metastasis was identified as 3.0 by the receiver 
operator characteristic (ROC) curve, the sensitivity and specificity were 90.0% and 42.1% 
respectively. In univariate analysis, the following were significant predictors of occult nodal 
metastasis: adenocarcinoma (P = 0.023), tumor size >3cm (P = 0.002), pleural invasion 
(P = 0.034) and SUVmax of primary tumor >3.0 (P = 0.018). In multivariate analysis, the 
following were independent predictors of occult nodal metastasis: adenocarcinoma (P = 
0.006), tumor size >3cm (P = 0.013), and SUVmax of primary tumor >3.0 (P = 0.033). 
Conclusion: The present study demonstrated that adenocarcinoma, tumor size >3 cm, 
and SUVmax of primary tumor > 3.0 are risk factors for occult nodal metastasis in patients 
with NSCLC who were diagnosed as clinical stage I by preoperative integrated FDG-PET/
CT.This study may provide some aids to pre-therapy evaluation and decision-making. 
Keywords: Positron emission tomography / computed tomography, lymph node staging, 
occult nodal metastasis
is a fully human, affinity-optimized, IGF ligand-neutralizing antibody. BI 836845 binds 
to IGF-1 and IGF-2 and neutralizes growth-promoting signaling. Preliminary results from 
two Phase I studies have shown a tolerable safety profile. This trial was designed to 
evaluate the safety and anti-tumor activity of BI 836845 combined with afatinib in 
patients with EGFR-mutated NSCLC progressing following prior treatment with reversible 
or irreversible EGFR TKIs. Methods: This is an open-label, dose-escalation trial in Korea, 
Taiwan and Singapore (NCT02191891; Study 1280.16) consisting of a dose confirmation 
part (Part A) followed by an expansion part (Part B). Eligible patients are aged ≥18 years 
with advanced and/or metastatic NSCLC progressing during continuous treatment with 
single-agent EGFR TKI ≤30 days immediately prior to study treatment, with documented 
presence of an activating EGFR mutation and lacking an EGFR T790M mutation (confirmed 
by central testing in Part B). Patients with prior afatinib treatment at a dose below the 
assigned dose level (Part A only) or <30 mg/day (Parts A and B), or disease progression 
on an insufficient dose of EGFR TKI immediately prior to study in the investigator’s 
opinion, or >2 (Part A) or >1 (Part B) prior EGFR TKI treatment regimens for relapsed or 
metastatic NSCLC are excluded. Part A follows a 3+3 design to determine the MTD and/
or recommended Phase 2 dose (RP2D) of BI 836845 combined with afatinib (starting 
dose: BI 836845 1000 mg/week intravenous infusion over 60 minutes plus oral afatinib 
30 mg/day administered in 4-week courses). Patients receive continuous treatment 
until disease progression, intolerable adverse events (AEs), consent withdrawal or non-
compliance with the study protocol. Patients are entered sequentially into escalating/
de-escalating dose tiers to determine the MTD based on the occurrence of dose-
limiting toxicities (DLTs) during Course 1 (3–6 patients per cohort); 6 additional patients 
will be enrolled in an extension cohort at the R2PD. Part B consists of two separate 
expansion cohorts of patients previously treated with irreversible EGFR TKIs (e.g. 
afatinib, dacomitinib; Cohort 1) and those previously treated with reversible EGFR TKIs 
(gefitinib or erlotinib; Cohort 2). In each cohort, 18 patients will be treated with the RP2D 
determined in Part A. Primary endpoints are the MTD and DLTs during Course 1 (Part A) 
and the objective response assessed using Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1 (Part B). Secondary endpoints include disease control, time to objective 
response, duration of objective response, and pharmacokinetic parameters. AEs are 
evaluated according to Common Terminology Criteria for AEs (CTCAE) v4.03. All analyses 
will be descriptive and exploratory. Results: Not applicable. Conclusion: Not applicable. 
Keywords: Monoclonal antibody, IGF, Phase 1, NSCLC
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P2.01-101 Randomized Phase 3 Trial of Docetaxel+Plinabulin Compared to 
Docetaxel in Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung 
Lesion Lyudmila Bazhenova1, Gloria Lee2, William Mikrut3, Lan Huang2 1Moores Cancer 
Center, University of California San Diego, La Jolla/United States of America, 2Beyondspring 
Pharmaceuticals, New York/United States of America, 3Currently Vantage Data Designs, San 
Diego/CA/United States of America
Background: Plinabulin (BPI-2358) is a marine derived tubulin binding agent, which 
inhibits existing tumor vasculature and directly induces cancer cell apoptosis via the 
Ras-JNK pathway. Additional effect of inducing dendritic cell maturation is also observed. 
Phase 1/2 randomized clinical trial of Docetaxel + Plinabulin (DP) compared to Docetaxel 
(D) alone failed to show improvement in OS in an ITT analysis. The median OS was 8.6 
months in DP, and 7.5 months in D arm. (HR 0.97, P=0.90). However, post hoc subset 
analysis showed improvement in OS in patient with pulmonary tumors >3 cm regardless 
of number of prior therapy for metastatic disease. In this population, OS was 11.47 
(7.13, 16.73) months vs. 7.10 (4.06, 10.60) in DP vs D arm (HR 0.76 and P=0.36). 
Mechanistically it is postulated that those patients are more dependent on angiogenesis. 
This phase 3 protocol is designed to test the hypothesis generated from the subset 
analysis. Methods: This is a randomized phase 3, open label clinical trial comparing 
DP at 75 mg/m2 of D on day1 and 30 mg/m2 of P on days 1 and 8 to D alone at 
75 mg/m2 on day 1 in a 21-day cycle. Randomization stratified by ECOG performance 
status and region. Study population: patients with metastatic with non small cell lung 
cancer ( NSCLC), who has failed one line of chemotherapy and have at least one lung 
lesion larger than 3 cm. Primary endpoint of the study is to compare overall survival (OS) 
between two arms. Secondary endpoints are Progression free survival (PFS), overall 
response rate (ORR), duration of response (DOR), and adverse event profile. Planned 
number of subjects 550 (440 from China and 110 from the US). Primary outcome 
analysis is planned after 434 death events which will provide a 0.85 power to detect a 
statistically significant treatment effect using a two-sided log-rank test at a significance 
level of α = 0.05. Results: Not applicable, trial in progress. Conclusion:not applicable 
Keywords: metastatic, lung cancer, trial in progress
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P2.01-102 Phase I Study of Inhaled 5-Azacytidine in Patients with Advanced 
NSCLC Emrullah Yilmaz1, Haiying Cheng1, Bilal Piperdi2, Chirag D. Shah3, Simon D. 
Spivack3, Rasim A. Gucalp1, Steven M. Keller4, Roman Perez-Soler1 1Oncology, Montefiore 
Medical Center, Bronx/NY/United States of America, 2Merck Research Laboratories, Rahway/
NJ/United States of America, 3Pulmonary Medicine, Montefiore Medical Center, Bronx/NY/
United States of America,4Cardiovascular and Thoracic Surgery, Montefiore Medical Center, 
Bronx/NY/United States of America
Background: Epigenetic changes due to promoter hypermethylation have been shown 
to cause loss of tumor suppressor gene (TSG) function in NSCLC. Significant toxicity 
and lack of tumor selectivity have been the main limitations of systemic demethylating 
agents. We previously showed that aerosolized 5-Azacytidine (Aza) was superior to 
systemic administration in prolonging the survival of mice with carcinogen-induced lung 
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P2.02-004 Clinicopathological Features and Outcomes of AAH, AIS and MIA 
in Resected Lung Adenocarcinoma Hironori Ishida1, Hirozo Sakaguchi1, Nobuhiro 
Yamazaki1, Hiroyuki Nitanda1, Ryo Taguchi1, Soichiro Suzuki1, Akitoshi Yanagihara1, 
Koichi Kaneko1, Masanori Yasuda2, Yoshihiko Shimizu3 1General Thoracic Surgery, Saitama 
Medical University International Medical Center, Saitama/Japan, 2Pathology, Saitama Medical 
University International Medical Center, Saitama/Japan, 3Pathology, Saitama Cardiovascular 
and Respiratory Center, Saitama/Japan
Background: After proposal of a new histologic classification of lung adenocarcinoma 
from the IASLC/ATS/ERS in 2011, the 2015 WHO classification of lung cancer new defines 
the new subtypes of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma 
(MIA). The former shows a lepidic growth pattern without invasion (BAC) and the latter a 
lepidic growth pattern with <= 5mm invasion. Atypical adenomatous hyperplasia (AAH) and 
AIS（previously, bronchioloalveolar carcinoma）are categorized as preinvasive lesions of 
adenocarcinoma. Recent studies have shown that patients with AIS and MIA had nearly 100% 
disease-free survival (DFS), if complete resection was achieved, though the details of the 
surgical procedures were not mentioned. Methods: We reviewed 93 patients with AAH, AIS 
or MIA, enrolled from among 629 lung adenocarcinoma patients who underwent resection 
at our hospital from 2007 to 2014. We retrospectively investigated clinical features, 
pathological findings and the presence of epidermal growth factor (EGFR) mutations, 
as well as the surgical procedures of wedge resection, segmentectomy and lobectomy. 
The results were compared with clinical outcomes. Results: The patients ranged in age 
from 40 to 82 years (median 66) and included 40 males and 53 females. Synchronous or 
metachronous multiple primary lung carcinomas were documented in 15 (16%) patients, 
who had undergone resections of one to four lesions. Seven of 15 patients had combined 
lesions of AAH, AIS and MIA, and 8 of 15 had invasive adenocarcinoma combined with AIS 
or MIA. The total numbers of resected lesions were 7 AAHs, 28 AISs, and 70 MIAs. The 
diameters of the AAH, AIS and MIA were 4 to 10 mm (median 7), 5 to 20 mm (median 8) and 
4 to 23 mm (median 11), respectively. In gene analysis for each lesion, the EGFR mutations 
were detected in one of five AAH lesions (20%), in eight of 28 AIS lesions (28%) and in 34 
of 67 MIA lesions (50%). It was confirmed that both tumor size and the frequency of EGFR 
mutations gradually increased in the direction from AAH to MIA. As for surgical procedures, 
we performed 1) wedge resection for 5 AAH lesions, 12 AIS lesions and 22 MIA lesions, 2) 
segmentectomy with N1 lymph node sampling for 1 AAH, 6 AIS and 15 MIA and 3) lobectomy 
with N2 lymph node dissection for 1 AAH, 10 AIS and 33 MIA. None of the cases had lymph 
node metastasis pathologically and all were p-Stage IA. The median follow-up duration from 
the date of surgery was 31 months (1.7-86 months). Two patients with MIA died 22 and 
29 months after surgery due to other malignancies, but none of the patients experienced 
recurrence and the 5-year DFS rate was 100%. Of 70 MIA lesions, 37 (53%) were removed 
by wedge resection or segmentectomy. Conclusion: AAH/AIS/MIA lesions were related 
to multiple primary lung carcinomas. Gradual malignant progression from AAH to AIS to 
MIA was verified. Although accumulation of further cases and long-term follow-up are 
needed, a subset of these lesions might be treated by wedge resection or segmentectomy. 
Keywords: adenocarcinoma in situ, minimally invasive adenocarcinoma, segmentectomy, 
wedge resection
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P2.02-005 Precise Prediction of 5-Year Survival of Lung Cancer Patients after 
Radical Surgery Oleg Kshivets Surgery, Kaluga Cancer Clinical Center, Kaluga/Russian 
Federation
Background: This study aimed to determine homeostasis and tumor factors for 5-year 
survival (5YS) of non-small cell lung cancer (LC) patients (LCP) (T1-4N0-2M0) after complete 
en block (R0) lobectomies/pneumonectomies (LP). Methods: We analyzed data of 665 
consecutive LCP (age=57.5±8.3 years; tumor size=4.4±2.4 cm) radically operated and 
monitored in 1985-2015 (m=575, f=90; lobectomies=423, pneumonectomies=242, 
combined LP with resection of trachea, carina, atrium, aorta, VCS, vena azygos, 
pericardium, liver, diaphragm, ribs, esophagus=180; only surgery-S=524, adjuvant 
chemoimmunoradiotherapy-AT=141: CAV/gemzar + cisplatin + thymalin/taktivin + 
radiotherapy 45-50Gy; T1=237, T2=248, T3=125, T4=55; N0=419, N1=130, N2=116, 
M0=665; G1=163, G2=199, G3=303; squamous=377, adenocarcinoma=243, large 
cell=45; early LC=132, invasive LC=533. Multivariate Cox modeling, clustering, 
SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine 
any significant dependence. Results: Overall life span (LS) was 2114.8±1685 days and 
cumulative 5YS reached 69.6%, 10 years – 61.2%, 20 years – 43.1%. 415 LCP lived more 
than 5 years without cancer (LS=3041.4±1472.5 days). 194 LCP died because of LC 
(LS=559.6±373.5 days). AT significantly improved 5YS (65.1% vs. 34.3%) (P=0.00001 
by log-rank test) only for LCP with N1-2. Cox modeling displayed (Chi2=290.78, df=13, 
P=0.000) that 5YS of LCP significantly depended on: phase transition (PT)“early-invasive 
LC” in terms of synergetics, PT N0-N12, histology, G, blood cell subpopulations, cell ratio 
factors (ratio between blood cells subpopulations and cancer cells-CC), prothrombin 
index, heparin tolerance, recalcification time, glucose, AT (P=0.000-0.035). Neural 
networks, genetic algorithm selection and bootstrap simulation revealed relationships 
between 5YS and PT N0-N12 (rank=1), PT “early-invasive LC” (rank=2), lymphocytes 
(3), segmented neutrophils (4), tumor size (5), AT (6), T1-4 (7), ESS (8), prothrombin 
index (9), glucose (10), thrombocytes/CC (11), healthy cells/CC (12), lymphocytes/CC 
(13), erythrocytes/CC (14). Correct prediction of 5YS was 100% by neural networks 
computing (error=0.000; area under ROC curve=1.0). Conclusion: 5YS of LCP after 
radical procedures significantly depended on: tumor characteristics, blood cell circuit, 
cell ratio factors, hemostasis system and AT.
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P2.02-002 Impact of Multiple Cancer Treatment History on Outcome in 
Patients with Surgically Resected Non-Small Cell Lung Cancer Masaki Anraku1, 
Kazuhiro Nagayama1, Jun-Ichi Nitadori1, Tomohiro Murakawa2, Jun Nakajima1 1General 
Thoracic Surgery, The University of Tokyo, Tokyo/Japan, 2Kansai Medical University, 
Hirakata, Osaka/Japan
Background: It has been common that patients with previous cancer treatment history 
undergo curative resection of non-small cell lung cancer (NSCLC); however, the impact 
of multiple cancer history on outcome after surgery remains unclear. Methods: We 
conducted a retrospective study by using data from patients who underwent curative 
surgical resection for NSCLC between 1998 and 2011 at our institution. Data recorded 
for analyses were: age, gender, clinical and pathological stages of NSCLC, mode of 
surgical resection, comorbidities, pre-treatment serum CEA level, smoking history, and 
previous cancer history (organ, histologic type, number of cancer treated). The chi-
square test and Wilcoxon test were used to analyze the factors between groups (ie, cases 
with previous cancer history versus those without cancer history). The Kaplan-Meier 
method was used to estimate survival rates. The log-rank test was applied to compare 
the survival rates between the groups. A p value less than 0.05 was considered as 
statistically significant. Results: In the study, 229 out of 923 cases (24.8%) had previous 
cancer treatment history. In the 229 cases, 194 had single cancer treatment history, 30 
had double cancer treatment history, and 5 had triple cancer treatment history. Types 
of cancer treated were: colorectal cancer (n=51), lung cancer (n=30), hepatocellular 
carcinoma (n=25), breast cancer (n=16), esophageal cancer (n=15), renal cell cancer 
(n=12), cancers of head and neck (n=11), and others (n=56). There were significantly 
increased rate of having cancer treatment history in the later study period (2005-2011) 
compared to a rate in the earlier study period (1998-2004)(30% versus 15%, p<0.01). 
When comparing to patients without previous cancer history, those with previous 
cancer history were significantly older (69.1 versus 66.4 years, p<0.01), and had higher 
smoking history rate (75.1% versus 64.7%, p<0.01). On the other hand, the proportion 
of stage I NSCLC was significantly higher in cases with previous cancer history than 
those without previous cancer history (95.2% versus 74.4%, p<0.01). All cases with 
triple cancer treatment history had clinical and pathological stage I NSCLCs. The survival 
outcome after surgical resection was significantly better in cases without previous 
cancer treatment history than those with cancer treatment history (5-year survival rates; 
79% versus 75%). In those with cancer treatment history, cases with 2 or more cancers 
treated had worse outcome than those with only one cancer treated before lung cancer 
resection (5-year survival rates; 69% versus 76%). Conclusion: Although the previous 
cancer treatment history and the number of cancers treated affected the outcome of 
patients who underwent curative lung cancer resection, the 5-year survival rate of 75% was 
achieved in the population. In those with previous cancer history, lung cancer tends to be 
found in early stage because of the periodical check-up for previous cancers. Therefore, 
surgical resection of newly detected NSCLC can be a viable option, if the previously 
treated cancer(s) are well controlled and the new lung cancer is deemed resectable. 
Keywords: cancer history, Surgery, NCSLC
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P2.02-003 Blood Loss Volume During Surgery Is a Significant Adverse 
Prognostic Factor in Patients with Stage I to IIIA Resected NSCLC 
Wenhua Liang1, Gening Jiang2, Qun Wang3, Lunxu Liu4, Deruo Liu5, Zheng Wang6, Zhihua 
Zhu7, Jianxing He1 1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou/
China, 2Shanghai Pulmonary Hospital of Tongji University, Shanghai/China, 3Shanghai 
Zhongshan Hospital of Fudan University, Shanghai/China, 4West China Hospital, Chengdu/
China, 5China and Japan Friendship Hospital, Beijing/China, 6Shenzhen People’S Hospital, 
Shenzhen/China, 7Cancer Center of Sun Yat-Sen University, Guangzhou/China
Background: There is little evidence reagrding the impact of blood loss volume during 
operation on long term survival. Using a large-scale multicenter database for NSCLC, 
we sought to investigate the prognostic value of blood loss volume. Methods: We 
collected a cohort of resected NSCLC patients from a multi-institutional registry in 
China (7 centers, 2001-2008) to examine the relationship between blood loss volume 
and overall survival (OS). According to clinical significance and expertise, blood loss 
volume was divided into two groups, <200 or ≥200. OS was calculated with the 
Kaplan-Meier method and univariate comparison between groups was performed 
using the log-rank test. Cox regression served as a multivariate technique. Results: A 
total of 5,762 cases were available. The mean blood loss volume was 218.4±197.2 
mL, median value was 200 mL (0-5000mL). Patients who had less than 200mL blood 
loss during the operation had more favorable prognosis than those with blood loss 
of 200mL or more (median OS, 98.8 vs. 76.0 months; HR 0.756, 95% CI 0.691 to 
0.829). After adjusting for sex, age, histology, T stage, N stage and operation type 
(complete VATS, assisted VATS and thoracotomy), blood loss volume remained an 
independent prognostic factor (HR 0.791, 95% CI 0.716 to 0.874). The volume of blood 
loss directly correlated with operation time (r=0.21, P<0.001), drainage days (r=0.17, 
P<0.001), days of ICU stay (r=0.11, P<0.001), drainage volume (r=0.05, P=0.04), 
and potentially the number of stations examined (r=0.03, P=0.06). Conclusion: We 
revealed that blood loss volume during surgery is a significant adverse prognostic factor 
for long-term survival. Patients with blood loss volume greater than 200mL require 
more attention on the recovery strategy. In addition, blood loss volume might be a 
comprehensive reflection of surgical trauma, and might serve as a marker for evaluating 
the adequacy of patient’s physical condition for receiving adjuvant chemotherapy. 
Keywords: survival, NSCLC, Surgery, Blood Loss Volume
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n (%)
Total number of patients 264
Number with lung cancer 73 (28%)
PET-CT 67 (25%)
Bronchoscopy 45 (17%)
Diagnostic EBUS 29 (15%)
Staging EBUS 29 (15%)
Mediastinoscopy 0 (0%)
Percutaneous CT-guided lung biopsy 25 (9%)
Neck USS & biopsy 6 (2%)
Liver biopsy 1 (1%)
MR (brain, spine, adrenal, liver) 10 (4%)
Bone biopsy 1 (1%)
Bone scan 2 (1%)
Spirometry 109 (41%)
Diffusion studies 69 (26%)
Differential perfusion scan 6 (2%)
Shuttle walk 41 (16%)
CPET 17 (6%)
Echocardiogram 29 ( 11%)
Conclusion: Approximately one-third of new referrals to this lung cancer clinic 
are subsequently diagnosed with lung cancer. Reliable and rapid access to PET-
CT, specialist bronchoscopy services and cardiorespiratory physiology testing 
is paramount for streamlining patient pathways. To realise our aspirations of an 
“investigation day” we estimate a need for 4 PET-CT slots, 4 lung function slots (with 
capability of spirometry, diffusion studies and shuttle walk), 8 bronchoscopy / EBUS 
slots and 2 CT-guided biopsy slots per week to serve our lung cancer population. 
Keywords: Lung Cancer diagnosis and staging
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P2.02-009 Expected Variability of C-Reactive Protein after Pulmonary 
Resections: Which Factors Are Associated with Their Normal Variation? Diogo 
G. Augusto, Hugo V. Sampaio-Fonseca, Ricardo M. Terra, Benoit J. Bibas, Leandro R. 
Iuamoto, Pedro N. Araujo, Alessandro W. Mariani, Paulo M. Pêgo-Fernandes Thoracic 
Surgery, University of São Paulo, São Paulo/Brazil
Background: In patients undergoing lung resection, infectious complications are 
diagnosed when clinical and radiological evidences are observed. Therefore, early 
detection of complications may benefit patients and could lead cost reduction. C-reactive 
protein (CRP) measurements persistently high may indicate complications after surgical 
resection. Our aim is to define the expected variability of CRP after pulmonary resections 
which have not progressed to clinical or surgical complications. Methods: Retrospective 
Cohort of patients with neoplastic lung disease treated by anatomic pulmonary 
resection, between January-2010 and June-2014, which had not developed postoperative 
complications. A CRP curve was built with data until the fifth postoperative day (POD). 
Surgical and clinical data was collected to look for predictors of CRP values. Statistical 
analysis was made with median and confidence interval, T-test for median comparison 
and logistic regression for predictors. Results: We analyzed 220 medical records, 100 
patients were excluded because lack of data and 50 due to complication development. 
Seventy patients were included. The median age was 65 years (from 14 to 89). Forty-
one were male (58%). Ten patients (14,8%) had Diabetes, 1 (1,42%) hepatopathy and 
1 (1,42%) renal failure. Sixty-one patients (87,14%) underwent lobectomy, 8 (11,42%) 
pneumonectomy and 1 (1,42%) segmentectomy. There were 48 (68,57%) open 
thoracotomy and 22 (31,42%) video assisted thoracotomy. The histologic type of 
tumor was 33 (47,14%) adenocarcinoma, 14 (20%) spinocellular carcinoma, 3 (4,28%) 
benign diseases and 20 (28,57%) others. The median CRP were 12,85 mg/dl (CI-5,44) 
preoperative; 76,82 mg/dl (CI-8,49) first day, 156,36 mg/dl (CI-17,91) second , 132,35 
mg/dl (CI-17,62) third, 103,24 mg/dl (CI-16,29) forth and 94,11 mg/dl (CI-14,32) fifth. 
Logistic regression pointed that patients operated by videothoracoscopy (VATS) approach 
are associated with are associated with lower increase of CRP levels (p=0,002). Other 
studied factors as age, sex, type of surgery, comorbidities and histology fail to predict 
CRP level. Conclusion: It was observed that CRP peak occurs in the second POD. From 
the third to the fifth POD, there was a drop of CRP levels, however, it does not returne 
to the preoperative baseline. The VATS approach induces smaller increases in CRP 
Keywords: C-reactive protein, lobectomy, complications
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P2.02-006 Development of the New Photodynamic Therapy for Peripheral 
Type Lung Cancer Keishi Ohtani, Sachio Maehara, Yujin Kudo, Shotaro Ono, Junichiro 
Osawa, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda Department 
of Surgery, Tokyo Medical University, Tokyo/Japan
Background: In Japan, photodynamic therapy (PDT) has been recommended for the 
treatment of centrally located early lung cancers (CLELC). With recent advances in the 
diagnosis lung cancer, we continually attempt to expand the indications of PDT, not only 
for CLELC but also for peripheral type lung cancer. PDT for peripheral lung cancer could 
be one of the desirable treatment options for patients without surgical indication such 
as poor pulmonary function. To perform PDT for peripheral lung nodules, it is necessary 
to use a thin and flexible laser fiber that can sufficiently reach the peripheral lung 
parenchyma. In this study, we evaluated the feasibility and efficacy of a plastic laser 
fiber for peripheral PDT. Methods: A plastic fiber (cylindrical light diffuser Model RD 
[Medlight, Switzerland]) was used as a laser fiber for peripheral PDT. The laser output 
and the light irradiation distribution of the RD cylindrical light diffuser were measured 
and compared with those of the Panasonic cylindrical probe currently used for PDT. 
NPe6-PDT was performed for peripheral pig lung. One week after PDT, the pigs were 
dissected and the lung was removed. The efficacy of NPe6-PDT was evaluated by 
the pathological findings. Results: The mean difference in laser output and the laser 
source output was 17.7±1.6% for the Panasonic cylindrical fiber and 11.6±3.1% for the 
RD cylindrical light diffuser. For the light irradiation distribution, the RD cylindrical light 
diffuser was able to produce more uniform irradiation than the Panasonic cylindrical 
fiber. The pathological findings showed necrotic tissue and infiltration of lymphoid cells 
at the laser irradiation area. Around the necrotic tissue, thickening of the alveolar walls 
and obstruction of the vessels due to thickening of the vascular endothelium were 
observed. Conclusion: The cylindrical light diffuser Model RD showed comparable 
laser irradiation to the Panasonic cylindrical fiber. The animal experiment showed the 
effect of PDT in peripheral lung. We conclude that PDT for peripheral lung using the 
new fiber is feasible and could become one treatment option for peripheral lung cancer. 
Keywords: Photodynamic therapy, peripheral lung cancer
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P2.02-007 Correlation Between Histological Invasiveness and CT Value in Pure 
GGNs Akihiko Kitami, Fumitoshi Sano, Shoko Hayashi, Kosuke Suzuki, Shugo Uematsu, 
Takashi Suzuki Respiratory Disease Center, Showa University Northern Yokohama Hospital, 
Yokohama/Japan
Background: The purpose of this study is to evaluate the correlation between 
histological invasiveness and computed tomography (CT) value and size in pure ground 
glass nodules (GGNs) to determine optimal “follow-up or resection” strategies. Methods: 
Between 2001 and 2014, 78 resected pure GGNs were evaluated retrospectively. 
Maximum diameter and CT value of pure GGNs were measured using a computer 
graphics support system. Results: All GGN with a maximum diameter ≦10mm and CT 
value ≦-600 Hounsfield units (HU) were noninvasive lesions, while 21 of 26 (81%) with a 
maximum diameter >10 mm and CT value >-600 HU were invasive lesions. With respect 
to a correlation between each histological type and pure GGN with a maximum diameter 
≦10 mm and CT value ≦-600 HU, the specificity was 90% and the sensitivity and negative 
predictive value were both 100% in atypical adenomatous hyperplasia (AAH), while the 
specificity was 58% and the sensitivity and positive predictive value were 0% in minimally 
invasive and invasive adenocarcinoma. Conclusion: In establishing follow-up criteria for 
pure GGNs at a maximum diameter of ≦10mm and CT value of ≦-600HU, unnecessary 
surgery for AAH and therapeutic delay for invasive adenocarcinoma can be avoided. 
Keywords: lung cancer, diagnosis, Surgery, computed tomography
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P2.02-008 Planning the Optimal Patient Pathway in the Diagnosis and Staging 
of Suspected Lung Cancer; What Infrastructure Is Needed? Matthew Evison, 
Stuart Britton, Haider Al-Najjar, Philip Crosbie, Richard Booton Manchester Thoracic 
Oncology Centre, University Hospital of South Manchester, Manchester/United Kingdom
Background: Lung cancer is the commonest cause of cancer death in the world. Recent 
research has suggested reducing the length of the diagnostic and staging pathway from 
30 to 14 days may improve survival. University Hospital of South Manchester (UHSM) is a 
regional cancer centre in Manchester Cancer, a large cancer network in the North of the 
United Kingdom. Manchester Cancer diagnoses over 2000 lung cancers every year and 
UHSM is responsible for the diagnostic and staging pathways for over 200 lung cancer 
patients per year locally. We anticipate that an efficient patient journey will involve an 
“investigation day” where patients undergo the majority of the necessary investigations 
in a single visit/overnight stay. The results of this work may assist in planning the 
infrastructure required. Methods: Prospective data was collected on all patients referred 
to the rapid access chest clinic (suspected lung cancer) at UHSM from November 2014 to 
February 2015. Specifically, the investigations each patient underwent in their pathway, 
both for diagnosis/staging and physiological tests to determine appropriate treatment 
were recorded. Results: Results are presented in table 1.
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Conclusion: Beta-blockers and Flecainide are effective in reducing the incidence of 
postoperative AF in patients after pulmonary resections which is not the case with digoxin; 
data on remaining treatments are sparse and preclude drawing definite conclusions. 
Keywords: non-small cell lung cancer, meta-analysis, postoperative atrial fibrillation, 
pulmonary resection
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P2.02-012 Prediction of Postoperative Pulmonary Function Using CT Volumetry 
Masayuki Hashimoto1, Jun Hanaoka1, Koji Teramoto2, Tomoyuki Igarashi3 
1Division of General Thoracic Surgery, Department of Surgery, Shiga University of Medical 
Science, Seta-Tsukinowa, Otsu, Shiga/Japan, 2Department of Medical Oncology, Shiga 
University of Medical Science, Otsu/Japan, 3Department of Surgery, Shiga University of 
Medical Science, Otsu/Japan
Background: According to some guidelines, prediction of postoperative pulmonary 
function is important in preoperative assessment for the lung cancer resection. 
Generally, it used to be calculated the function by Segmental method (S method) or 
Subsegmental method (SS method). But, the volume of pulmonary (sub) segments 
varies between individuals. The purpose of this study is to evaluate the efficacy of the 
prediction of postoperative pulmonary function using CT volumetry. Methods:This study 
included 29 cases who were performed segmentectomy or (bi) lobectomy for primary 
lung cancer from August 2013 to June 2014. Actual pulmonary function obtained at 6 
months postoperation (VC, %VC, FVC, %FVC, FEV1.0, %FEV1.0, DLco’, % DLco’, DLco’/
Na’, %DLco’/Na’) was compared with the predicted pulmonary function calculated by 
S method, SS method and CT volumetry method (CTV method), respectively. CTV 
method was calculated by Image analysis software (Synapse Vincent; Fuji Film, Japan) 
which used the preoperative chest CT scan data (mediastinum conditions, 0.5mm 
thickness). Results: The median age of patient was 69 years old, ranging 47 to 83 years 
old. Seven patients underwent thoracotomy and 22 underwent VATS. Upper lobectomy 
or upper and middle bilobectomy / upper segmentectomy / middle or lower lobectomy / 
lower segmentectomy were 12/3/10/4 cases, respectively. These 3 methods were found 
to have a good correlation with actual pulmonary function. In particular, the CTV method’s 
function was better correlated with actual VC, %VC, FVC, %FVC, FEV1.0, %FEV1.0(r = 
0.909, 0.839, 0.913, 0.849, 0.935, 0.875, respectively). On the other hand, SS method’s 
function has better correlated with actual DLco’, DLco’/Na’, %DLco’/Na’ (r=0.916, 0.817, 
0.789, respectively). The cases of upper lobectomy or upper segmentectomy (U group) 
were found to overestimate on DLco’/Na’, %DLco’/Na’ (t =4.714, 4.634). The other 
cases (non-U group) were found to overestimate on FVC, FEV1.0, %FEV1.0 (t=2.446, 
3.797, 5.657) . Conclusion: CTV method may be better correlated evaluation of the 
ventilation ability than conventional methods, but the evaluation of the diffusion ability 
is not. Therefore, in the poor pulmonary function case, it is necessary to selectively use 
these methods in order to make more accurate predictions. And, you should take care 
that there is pulmonary function to be overestimated or underestimated by the location. 
Keywords: CT volumetry, Pulmonary Function, lung cancer
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P2.02-013 Strategy of Management for Synchronous Pure GGOs Detected in 
Patients Undergoing Resection for Primary NSCLC Chenyang Dai1, Yijiu Ren1, 
Huikang Xie2, Sen Jiang3, Ke Fei1, Gening Jiang1, Chang Chen1 1Department of Thoracic 
Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/
China, 2Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of 
Medicine, Shanghai/China,3Department of Radiology, Shanghai Pulmonary Hospital, Tongji 
University School of Medicine, Shanghai/China
Background: It is quite common to discover some synchronous pure ground-glass 
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P2.02-010 Pathological Examination of Primary Lung Adenocarcinoma Cases 
That Were Positive for Intraoperative Pleural Effusion (E1(+), M1a) Shunta Ishihara1, 
Masanori Shimomura2 1General of Thoracic Surgery, Ayabe City Hospital, Ayabe, Kyoto/
Japan, 2Department of General Thoracic Surgery, Ayabe City Hospital, Ayabe, Kyoto/Japan
Background: Malignant pleural effusion or dissemination is not an indication for surgery 
or poor prognosis. However, cases that are positive for intraoperative pleural effusion 
may have better prognosis. We retrospectively examined cases that were positive for 
intraoperative pleural effusion. Methods: We retrospectively investigated the data of 96 
patients with primary lung adenocarcinoma who underwent surgery between 2010 and 
2013 at the Department of Thoracic Surgery of the Ayabe City Hospital. A total of 11 
patients (11.5%) were positive for intraoperative pleural effusion. We compared the data 
between these patients and the patients who were negative for intraoperative pleural 
effusion. Results: The mean patient age was 72 years (range, 57–83 years); 4 patients 
were men and 7 were women. The median time from diagnosis to surgery was 89 days 
(range, 39–1610 days). The median tumor size was 42 mm (range, 15–90 mm). All 
cases were clinical N0 tumors. Regarding the surgical technique, 2 patients underwent 
exploratory thoracotomy, 4 underwent wedge resection, and 5 underwent lobectomy. 
The following pathological findings were obtained. Pleural invasion was pl1 in 1 patient, 
pl2 in 6, and pl3 in 2. Five patients showed lymphatic vessel invasion (Ly+), 4 patients 
showed vascular invasion (V+), and 3 patients showed the presence of micropapillary 
patterns (MPPs). One patient was positive for an EGFR mutation. Five patients had 
received adjuvant chemotherapy. The overall 4-year survival rate was 72.7%. The 
patients with E(+) showed a significantly higher extent of Ly+, pleural invasion (pl2), and 
MPPs (P < 0.05 for all). Conclusion: Primary lung adenocarcinoma with intraoperative 
findings of malignant pleural effusion tend to show Ly+, vascular invasion, and MPPs. 
Keywords: intraoperative pleural effusion, lung cancer, lung adenocarcinoma
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P2.02-011 Optimal Strategy to Prevent Atrial Fibrillation in Patients 
Undergoing Pulmonary Resection for Lung Cancer. Network Meta-Analysis 
Mariusz Kowalewski1, Marzena A. Lewandowska2, Lukasz Zolna1, Aleksandra Chrzastek1, 
Paweł Wnuk1, Maciej Dancewicz1, Mariusz Bella1, Przemysław Bławat1, Tomasz 
Szczαsny1, Janusz Kowalewski3 1Department of Thoracic Surgery and Tumours, Oncology 
Centre – Prof. Lukaszczyk Memorial Hospital in Bydgoszcz, Department of Thoracic Surgery 
and Tumours, Bydgoszcz, Poland;, Bydgoszcz/Poland, 2Molecular Oncology and Genetics 
Departament, The Inovative Medical Forum, the Franciszek Lukaszczyk Oncology Center, 
Bydgoszcz/Poland, 3Department of Thoracic Surgery and Tumors, Collegium Medicum, 
Nicoalus Copernicus University in Torun, Bydgoszcz/Poland
Background: Atrial fibrillation (AF) after pulmonary resections for lung cancer, 
although transient in most cases, occurs in up to 30% following lobectomy and 
up to 65% after pneumonectomy and might, in turn, lead to serious adverse events 
including stroke, myocardial infarction and death. Different preventive measures have 
been investigated, however because of paucity of evidence from randomized studies, 
straightforward recommendations are still uncertain. We aimed to perform a Bayesian-
framework mixed treatments comparison (network) meta-analysis of both randomized 
controlled- (RCTs) and observational studies, to investigate the net-relative benefit of 
diverse drugs in prevention of atrial fibrillation following pulmonary resections for lung 
cancer. Methods: We screened Medline, Google Scholar, EMBASE and Cochrane 
CENTRAL registries for randomized and observational studies comparing drugs to each 
other and/or to placebo. Studies with post-operative AF as prespecified end-point were 
retrieved for detailed abstraction. Primary outcome was assessed at longest available 
follow-up. Results: Overall 15 studies (13 RCTs) were identified, enrolling N=1753 
patients. Beta-blockers, Atrial Natriuretic Peptide and Flecainide were associated with 
significant relative reduction in odds of postoperative AF, OR (2.5-97.5% CrI) of 0.34 
(0.02-0.92); 0.35 (0.00-0.94) and 0.11 (0.00-0.46) respectively; Digoxin was found 
to increase these odds. Addition of observational data allowed for identification of 
Amiodarone as another potentially preventive treatment OR (2.5-97.5% CrI) 0.28 (0.03-
0.69). Bayesian posterior probability curves revealed the ranking among treatments 
with Flecainide, beta-blockers, ANP and Amiodarone being associated with the highest 
probability to reduce the odds of AF, magnesium and calcium blockers with virtually no 
effect and digoxin found inferior to placebo.
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P2.02-014 Cross-Sectional Study on Surgical Treatment Patterns of 1927 
Stage I-IIIa NSCLC Patients from 11 Medical Centers in China in 2013 Jian Zhou, 
Fan Yang, Xun Wang, Tian Guan, Jun Wang Thoracic Surgery, Peking University People’S 
Hospital, Beijing/China
Background: Video- assisted thoracoscopic surgery (VATS) was introduced into China in 
1992. Over the past two decades, VATS has experienced dramatic development in China. 
However, the development is imbalanced. This cross-sectional study aimed to assess 
the ulitility of VATS in lung cancer patients in China Methods: Data of non-small cell lung 
cancer (NSCLC) patients who received curative-intent resections during the year 2013 
were obtained from the national lung cancer registry , which included 1927 patients from 
11 tertiary hospitals nationwide. Surgery patterns, stations of lymph nodes dissected, 
operation time were analyzed. Results: Among the 1927 patients, the mean age was 
60.0 years old, and 1228 were male. The numbers of patients in final pathologic stages 0, 
Ia, Ib, IIa, IIb, IIIa were 13, 571,414,243,171,495. Sublobar resection/ lobectomy/ sleeve 
lobectomy/ pneumonectomy number was 112/1643/57/111. The overall VATS rate is 
45.0%, 71.9%, 52.2%,19.3%,6.3% in lobectomies，wedge resection, segmentectomy, 
sleeve lobectomy, pneumonectomy respectively . In different centers, the median 
number of lymph nodes stations dissected in VATS single lobectomy is 6 (ranging from 0 
to 11) in different centers, while 6.5 (ranging from 0 to 11) in thoracotomy . The average 
VATS lobectomy surgery time is 184.0 minutes. VATS rates of lobectomy in different 
centers ranged from 4.4% to 90.2% respectively . VATS rates of Ia,Ib,IIa,IIb,IIIa lobectomy 
is 65.4%, 41.7%, 31.3%, 24.2%, 38.5% respectively. Conclusion: The difference of VATS 
rate is quite significant between different centers in China . Some centers perform 90-
100% VATS in early stage patients and more VATS than thoracotomy in II and III patients. 
While some centers still perform over 80% thoracotomy surgeries even in stage I patients. 
Keywords: cross-sectional study, lung cancer, registry, VATS
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P2.02-015 Prognostic Significance of Histologic Subtype in Stage I Non-Small 
Cell Lung Cancer Youngkyu Moon, Jae Kil Park, Sook Whan Sung Thoracic and 
Cardiovascular Surgery, Seoul St. Mary’S Hospital, Seoul/Korea
Background: Non-small cell lung cancer consist of several histologic types. Among 
them, pulmonary adenocarcinoma has histologic heterogeneity. Current staging system 
relied on anatomical involvement of lung cancer. Histologic subtype has not been 
reflected in the TNM stage of lung cancer although there is some positive reports on 
prognostic factor. This study aimed to evaluate histologic difference as prognostic factor 
in stage I lung cancer. Methods: We retrospectively reviewed 269 patients with stage 
I adenocarcinoma and squamous cell carcinoma after curative pulmonary resection at 
single institute in Korea from August 2010 to December 2013. Adenocarcinoma was 
divided into 3 groups according to lepidic component; group 1(lepidic component 
≥50%), group 2(lepidic component <50%), and group 3(no lepidic component). We 
compared these three groups with squamous cell carcinoma. Results: Mean tumor 
size of squamous cell carcinoma was larger than other three groups(2.8cm vs 1.9cm, 
2.3cm, 1.9cm, p<0.001). There was no difference between group 3 and squamous cell 
carcinoma in the presence of pleural invasion(p=0.386) or vascular invasion(p=0.930), 
but lymphatic invasion was more frequent in squamous cell carcinoma(p=0.018)(Table 
1). Three-year recurrence free survival of group 1, group 2, group 3 and squamous 
cell carcinoma were 98.5%, 86.8%, 74.3%, and 66.3%, respectively. (group 1 vs group 
2, p=0.077; group 2 vs group 3, p=0.023; group 3 vs squamous cell carcinoma, 
p=0.907)(figure). Multivariate analysis showed that these 4 grouping was the statistically 
significant risk factor for the recurrence (HR 1.719, 95% confidence interval 1.051-2.811, 
p=0.031) Table 1. Clinicopathologic characteristics
Group 
1(n=74)
Group 
2(n=119)
Group 
3(n=36)
Sqc-
c(n=40) p value
Age 61.2(±9.2) 65.0(±10.0) 65.3(±10.0) 67.3(±1.7) 0.009
Female 45.9% 69.7% 25.0% 12.5% <0.001
Smoking 
history(pack 
years)
7.8(±14.7) 5.2 (±11.8) 20.8 (±22.9) 35.4 (±26.2) <0.001
Procedures 
Standard 
resection 
Limited 
resection
86.5% 
13.5% 86.6% 13.4% 83.3% 16.7%
75.0% 
25.0% 0.337
SUVmax 1.9 (±1.7) 3.8 (±3.3) 4.7 (±3.8) 10.0(±5.8) <0.001
Tumor size 1.9 (±0.8) 2.3 (±0.9) 1.9 (±0.6) 2.8(±1.0) <0.001
Number of 
dissected 
lymph 
nodes
12.7 (±7.6) 14.6 (±9.9) 11.1 (±8.1) 14.0 (±10.1) 0.181
Pleural 
invasion 6.8% 27.7% 25.7% 15.4% 0.003
Lymphatic 
invasion 13.5% 32.8% 25.7% 53.8% <0.001
Vascular 
invasion 1.4% 10.9% 14.3% 15.0% 0.037
opacity (GGO) nodules in other lobes beside the operable primary tumor on initial 
CT scans, while the appropriate surgical strategy for these pure GGOs remains 
controversial. Methods: We included patients with primary tumor lesion and pure GGOs in 
different lobes between June 2010 and December 2013. The radiographic manifestations 
of all GGOs, pathologic features of resected GGOs and follow-up outcomes of unresected 
GGOs were analyzed to make clear which GGOs should be resected concomitantly with 
the primary tumor. Results: A total of 59 patients with 72 pure GGOs were included, of 
which, 29 were resected at the primary surgery and 43 were left behind and followed 
up. In the resection group, 8 (27.6%) were invasive or minimally invasive lesions, 12 
(41.4%) were preinvasive lesions and 9 (31%) were benign lesions. In the follow-up 
group, 7 nodules grew, and the growth rate was 16.3% (7 of 43) on a per-nodule basis, 
and 19.4% (7 of 36) on per-person basis. In all, concomitant resection at the primary 
surgery was considered for 15 of 72 GGOs (8 malignant lesions and 7 growth lesions). 
Multivariate analysis showed that the initial size was an independent risk factor for these 
GGOs (P=0.011), and a cut-off value was calculated as 9.9 mm by receiver operating 
curve (ROC) curve analysis. Tabel Predictors for synchronous GGO nodules which need 
concomitant resection
Univariate analysis Multivariate analysis
P value OR P value OR
Age at operation 0.056 1.075 0.872 1.01
Sex 0.279 0.527
Smoking 0.136 2.667
Size <0.001 18.733 0.011 10.922
Location
LUL Reference
LLL 0.345 0.333
RUL 0.217 0.381
RML 0.577 1.778
RLL 0.886 0.889
Location of primary lesion
Ipsilateral Reference
Contralateral 0.334 1.8
Shape
Round Reference
Oral 0.584 1.625
Irregular 0.349 2.275
Margin
Smooth Reference
Lobulated 0.629 1.4
Spiculated 0.125 3.111
Air bronchogram 0.001 8 0.355 2.199
Bubble lucency 0.024 6.545 0.274 3.356
Pleural tag 0.006 6.933 0.175 3.724
  
Conclusion: About 20% of synchronous pure GGO nodules should need surgical treatment at 
the time of primary operation, and a lesion size of more than 9.9 mm is an effective discriminator 
of these GGOs. As to the unresected GGOs, a close follow-up is always indispensible. 
Keywords: lung adenocarcinoma, follow-up,, ground-glass opacity, limited surgery
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adapted for the management of not only perioperative care but also long-term survival 
of COPD patients after surgery, and the hypothesis should be examined in the future. 
Keywords: morbidity, LABA, lung cancer, copd
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P2.02-017 Video-Assisted Mediastinoscopic Lymphadenectomy Decreases the 
Need for Lymph Node Dissection during Lobectomy in Lung Cancer Patients 
Akif Turna1, Elvin Hekimoglu2, Ezel Ersen1, Kamil Kaynak3 1Department of Thoracic 
Surgery, Istanbul University, Cerrahpasa Medical Faculty, Istanbul/Turkey, 2Department 
of Thoracic Surgery, Istanbul University Cerrahpasa Medical School, Istanbul/
Turkey, 3Department of Medical Oncology, Istanbul University Cerrahpasa Medical School, 
Istanbul/Turkey
Background: Mediastinoscopy has been accepted as a gold standard in preoperative 
staging of patients with cT1-3N1-3M0 non-small cell lung cancer. However, video-
assisted mediastinoscopic lymphadenectomy (VAMLA) has been shown to provide 
higher negative predictive value. We aimed to investigate the role of VAMLA on the 
need and time for lymph node dissection following anatomical resection in these 
patients. Methods: Between May 2005 and March 2014, 299 patients who have 
undergone lobectomy following mediastinoscopy or VAMLA were analyzed.One-hundred-
four patients (34.8%) underwent VAMLA, wehereas 195 patients (65.2%) had standard 
mediastinoscopy. 245 patients (81.9%) underwent open lobectomy while 54 (8.1%) 
had videothoracoscopic lobectomy. The median and mean numbers of resected lymph 
node stations were 5 and 4.9 in the VAMLA group and 4 and 4.2 in the mediastinoscopy 
group. Results: The mean number of lymph nodes per biopsy specimen using standard 
mediastinoscopy was 11.0 (ranging 2 to 33), whereas it was 29.7(Ranging 16-110) using 
VAMLA (p<0.001). ,The negative predictive value, sensitivity, false-negative value, and 
accuracy of VAMLA were statistically higher in the VAMLA groups compared with those 
of standard mediastinoscopy. In the VAMLA group, lymph node dissection of stations 2R, 
2L, 4R, 4L, 7, and 8 was achieved in 90 (86.5%), 61 (59.6%), 90 (86.5%), 88 (84.6%), 101 
(97.1%), and 30 (28.8%) of the patients, respectively. In the standard mediastinoscopy 
group, 2R, 2L, 4R, 4L, 7, and 8 underwent biopsy in 101 (52.0%), 46 (23.7%), 145 
(74.7%), 91 (46.9%), 157 (80.9%), and 0 of the patients, respectively. The difference was 
statistically significant (p < 0.001). The mean number of dissected mediastinal lymph 
nodes following pulmonary resection was 9.4 (ranging 0 to 32) or 4.4 (ranging, 0-11) in 
patients who underwent standard mediastinoscopy or VAMLA, respectively (p<0.001). A 
statistical difference was found when analyzing the VATS lobectomy patients (mean 8.6 
vs 3.1 lymph nodes )(p<0.001). The time for lymph node dissection was also found to be 
shorter(p=0.02). Conclusion: VAMLA provides bilateral lymph node dissection before 
resectional surgery and it decreases the necessity of lymph node dissection and alleviates 
it during VATS and open lobectomies performed in non-small cell lung cancer patients. 
Keywords: VAMLA, mediastinoscopy, resection, lymph node dissection
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P2.02-018 Evaluation of Invasiveness among 3 Methods of Thoracoscopic 
Lobectomy in Patients with NSCLC: A Favorable Result for Uniportal VATS 
Qihang Zhu, Haiping Xiao, Ming Liao, Yong Tang, Yiwen Xuan, Kai Su, Zhe He, Xiufan 
Peng, Zhuohua Zhang, Yan Liu, Guibin Qiao Department of Thoracic Surgery, General 
Hospital of Guangzhou Military Command of P.L.A, Guangzhou/China
Background: Video-assisted thoracoscopic surgery (VATS) lobectomy includes 3 main 
methods: assisted VATS (a-VATS), multiport complete VATS (m-VATS), and uniportal 
VATS (u-VATS). However, the comparison of invasiveness among 3 methods remains 
unclear. Methods: 74 consecutive patients with early stage NSCLC undertaken VATS 
lobectomies at a single unit during Jan 2014 to Aug 2014 were analyzed. According 
to the surgical approach, patients were divided into a-VATS group (n=31), m-VATS 
group (n=21), and u-VATS group (n=22). Certain perioperative parameters, VAS 
scores, WBC and CRP levels were analyzed. Results: Age, gender, pathological 
type, TNM stage, operative time, postoperative drainage time, volume of drain, 
postoperative hospital stays and hospitalization cost were no statistical difference 
among 3 groups. Intraoperative blood loss of u-VATS was less than c-VATS, and c-VATS 
was less than a-VATS (Kruskal-Wallis test, p<0.01).VAS scores on the postoperative 
3rd day and 1 month of a-VATS were higher than u-VATS (p<0.05). WBC level on 
postoperative 5th day of a-VATS was higher than u-VATS (p<0.05). CRP levels of u-VATS 
on the postoperative 1st, 3rd and 5th day (p<0.01) were all significantly difference 
compared to a-VATS. Conclusion: Uniportal VATS lobectomy causes less surgical 
damage than assisted VATS method. Further researches are needed to clarify whether 
uniportal VATS lobectomy is better than multiport complete VATS in surgical damage. 
Keywords: Thoracic Surgery, Video-assisted thoracic surgery, non-small cell lung 
cancer, Thoracoscopy
POSTER SESSION/ TREATMENT OF LOCALIZED DISEASE – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.02-019 Role of Sentinel Node Biopsy in Stage IA NSCLC Surgery Nenad 
Ilic1, Josko Juricic2, Vinko Markovic2, Dragan Krnic2, Nives Frleta Ilic2, Duje Orsulic2, 
Darko Ilic2, Ivan Simundza2 1Thoracic Surgery Dept., University Surgical Hospital, Split/
Croatia, 2Thoracic Surhery Dept., University Surgical Hospital, Split/Croatia
Background: Systematic mediastinal lymphadenectomy is still essential for an 
adequate intraoperative staging and adjuvant therapy of NSCLC. We tried to investigate 
still controversial role of sentinel node biopsy (SNB) in early stage non small cell 
Conclusion: Among stage I adenocarcinoma, the prognosis of non lepidic 
component adenocarcinoma was poorer than lepidic adenocarcinoma. 
Although the malignant potential of squamous cell carcinoma was higher than 
adenocarcinoma in this study, the prognosis was not different between non 
lepidic component adenocarcinoma and squamous cell carcinoma. We expect 
these histologic prognosis factor will be considered in the new staging system. 
Keywords: Prognosis, histologic component, Squamous cell carcinoma, Adenocarcinoma
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P2.02-016 A New Strategy for Preoperative-Management of Patients with Lung 
Cancer with Chronic Obstructive Pulmonary Disease (COPD) Jitsuo Usuda 
Nippon Medical School, Tokyo/Japan
Background: Recently, it has been reported that the prognosis for patients with lung 
cancer with Chronic obstructive lung disease (COPD) was worse than that of patients 
with lung cancer without COPD. Therefore, long-term respiratory management not 
only perioperative care is also important. For lung cancer patients with COPD, the 
frequency of the postoperative complications should be reduced. Methods: In lung 
cancer patients with COPD, it was examined whether it is possible to reduce the 
frequency of post-operative complications after surgical resection of the lungs by 
smoking cessation not only the introduction of inhaled long-acting anticholinergic 
(LAMA) or long-acting β2-agonists (LABA). Patients who quit smoking more than 6 
months before the operation were defined as former smokers and those who were 
smoking at the time of the operation or quit within 6 months before the operation 
were defined as current smokers. COPD was defined as FEV1/FVC< 0.7 (FEV1; 
forced expiratory volume in one second, FVC, forced vital capacity) with a smoking 
history. Among 260 patients who underwent surgical resection for lung cancer from 
January 2013 to February 2015 in our hospital, COPD patients 77, non-COPD 183. 
We analyzed retrospectively the relationship between the introduction of inhaled 
LABA or LAMA and the frequency of the postoperative complications in lung cancer 
patients with COPD. Results: In COPD patients 77 cases, male 62 cases, female 15 
cases, age 60-85 years old (mean: 74). Smoking history 15~150 pack-years (mean 57), 
current smokers were 39 cases, and former-smokers were 38 cases. The average 
of FEV1/FVC is 59.6% (26.6~69.5%). Lung resection, partial resection 11 cases, 
segmental resection 1 case, lobectomy 64 cases, pneumonectomy 1 case. There was 
no mortality. There were 17 postoperative complications in COPD (22.1%), prolonged air 
leak (more than 7 days) 9 cases, pneumonia 3 cases, arrhythmia 2 
cases, chylothorax 2 cases, wound infection 1 case. In particular, 
the frequency of postoperative pulmonary complications such 
as prolonged air leakage and pneumonia, showed a significant high in COPD (12 cases, 
15.6%) compared with non COPD (9 cases, 4.9%).Inhaled bronchodilators such as 
LAMA or LABA were prescribed to 22 cases in COPD, not to 50 cases. The pulmonary 
complications were significant lower in LAMA or LABA users (2 cases, 9.1%) than 
in no users (10 cases, 18.2%). Among current smoker 38 cases, which were preoperatively 
treated with smoking cessation and chest physiotherapy for more than one month, the 
inhalants with LABA or LAMA were prescribed before pulmonary resection in 18 cases, not 
prescribed in 20 cases. The frequency of the pulmonary complications was 2 cases (11.1%) 
in the inhalant users, respectively 4 cases (20%) in the inhalant-no-users. Conclusion: For 
lung cancer patients with COPD, preoperative management using the inhalants with LABA 
or LAMA, and smoking cessation can reduce the frequency of the postoperative pulmonary 
complications after surgical lung resection. The inhalants with LAMA or LABA may be 
S561Copyright © 2015 by the International Association for the Study of Lung Cancer
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P2.02-022 Short and Long-Term Outcomes of Pneumonectomy for Lung 
Cancer: 15-Years Experience Syed S.A. Qadri1, Mubarak Chaudhry2, Alex Cale1, 
Michael Cowen1, Mahmoud Loubani1 1Cardiothoracic Surgery, Castle Hill Hospitall, Hull/
United Kingdom, 2Castle Hill Hospital, Hull/United Kingdom
Background: Surgery is the most important therapeutic modality for the treatment of 
lung cancer. Surgical outcomes are normally reported as 30-day or 90-day mortality 
or 5-year survival. However, 10-years survival is rarely mentioned in the national data 
or international studies. Methods: Patients included who underwent penumonectomy 
from January1998 to February2013, and analysed their short and long-term 
outcome till september2014. Thoracoscore was used to calculate the risk of hospital 
mortality Results: 306-patients underwent pneumonectomy mainly for lung cancer. 79% 
were male, median age was 64-years(22-82years) and 24% were ≥ 70-years. Operative 
mortality was 4.5% while predicted mortality was 8%. However, operative mortality for 
cancer patients was 3.3% while reported national mortality for lung cancer is 6.5%. Only 
2-patients died in hospital after pneumonectomy in the last 5 years. Half of the patients, 
who died in hospital, were ≥70-years while 29%(4-patients) died after urgent operation 
for non-malignant-disease. Overall 5 and 10-year survival rates were 32% and 20%. 
Median and mean survival was 26 and 57-months respectively. Long-term survival was 
better in female, patients with age <70 years, in left pneumonectomy and for squamous-
cell-lung-cancer patients. Conclusion: This retrospective single institutional review have 
shown that our mortality for pneumonectomy is 50% less than national mortality and 
significantly lower than that predicted by Thoracoscore for lung cancer. This confirms 
that pneumonectomy is still an effective modality in the treatment of lung cancer with low 
operative mortality and good long-term survival especially in younger patients. It can be 
done safely with good short and long-term outcome by trained experienced surgeons. 
Keywords: Pneumonectomy, Lung Cancer, survival, mortality
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P2.02-023 Robotic Thoracic Surgery for Elderly Patients with Non-Small Cell 
Lung Cancer Ryan T. Hughes1, Vanessa M. Dipasquale1, Stefan C. Grant2, Brian E. 
Lally3, William J. Petty2, Alfred Proto4, Leonard J. Wudel4 1Wake Forest School of Medicine, 
Winston-Salem/NC/United States of America, 2Medical Oncology, Wake Forest Baptist 
Medical Center, Winston-Salem/NC/United States of America, 3Radiation Oncology, Wake 
Forest Baptist Medical Center, Winston-Salem/NC/United States of America, 4Cardiothoracic 
Surgery, Wake Forest Baptist Medical Center, Winston-Salem/NC/United States of America
Background: The evidence supporting robotic pulmonary resection for the 
management of early stage NSCLC continues to grow. Limited data exist describing the 
results of elderly patients undergoing these procedures. We compared the outcomes 
of patients >70 years old versus patients <70 years old undergoing robotic-assisted 
thoracic surgery. Methods: We retrospectively reviewed the medical records of 
patients treated with robotic-assisted pulmonary resection with lymph node dissection 
for NSCLC at our institution from March 2013 to the present. Clinical, pathologic, and 
treatment-related factors were analyzed with regard to perioperative complication rates, 
hospitalization duration, and clinical outcomes in patients ≥70 versus <70 years old. 
Categorical and continuous data were compared between age groups using the Chi-
square and t-test, respectively. Survival data were described using the Kaplan-Meier 
method and compared between age groups using the log-rank test. Results: This 
analysis included 101 consecutively treated patients, 40 of whom were over the age of 
70 at diagnosis. The cohort was predominantly female (64%), clinical stage I (80%), with 
an ECOG performance status of 0-1 (97%). Lobectomy (92.5%), wedge resection (13%) 
and bilobectomy (3%) were performed involving the upper (48.5%), middle (16.8%) and 
lower (47.5%) lobes. The majority (80%) were right sided due to institutional policies. 
Open conversion was required in only 3 (3%) patients. The above data did not differ 
significantly between the two age cohorts. The median chest tube duration (4 days) 
and length of stay (5 days) were equal in both groups. The median length of epidural 
anesthesia was 3 days in patients <70 and 2 days in the patients ≥70 years of age. 
The most common complications for younger vs. older patients included persistent 
air leak (18% v. 12.5%), atrial fibrillation (8.2% v. 17.5%), urinary retention (3.3% v. 
12.5%), and pneumonia (3.3% v. 10%); none of these differences reached statistical 
significance. Major perioperative complications included one non-fatal myocardial 
infarction and 2 inpatient deaths secondary to septic shock (one in each age group). 
The 1-month readmission rate was 4.9% vs. 2.5% for patients younger vs. older than 
70 years (p=0.54). The 1-year overall survival was 90% and 89% for younger and older 
patients, respectively (p=0.35). Conclusion: Robotic-assisted thoracic surgery is an 
appropriate surgical approach for patients older than 70 years of age with early stage 
NSCLC. Although some complication rates were increased in older patients, these 
differences did not reach statistical significance and do not appear to be related to 
the particular surgical procedure performed. Elderly patients with good performance 
status tolerate minimally-invasive robotic pulmonary resection extremely well and 
should be considered candidates for this surgical procedure when clinically appropriate. 
Keywords: Robotic surgery, NSCLC, elderly
lung cancer (NSCLC) surgery. Methods: A total of 72 patients with clinical T1N0MO 
NSCLC underwent SN navigation lobectomy using Tc-99 labeled tin colloid followed 
by systematic mediastinal lymphadenectomy (SML) in three years time period (2010-
2013). Mapping of the mediastinal lymph nodes by their number and station followed 
by hystopathological evaluation was performed. Patients data were statistically 
analyzed. Results: Intraoperative SN was identified in 62 (87%) of these patients with 
92% of accuracy. We found lobe specific skip nodal metastases in 7 (10%) patients 
resulting in upstaging. The incidence of ML metastases seemed to be more often 
in adenocarcinoma patients (p<0.05), but skip nodal metastases showed higher 
rate in squamous cell carcinoma patients. Intraoperative frozen section was not 
confirmed accurate for detecting micrometastases in two (4%) patients. Operative 
time was prolonged for 10 (8-25) minutes showing no difference in complication 
rate. Conclusion: Procedure showed absolute safety and high accuracy. Our results 
indicated that SN identification could replace mediastinal lymph node dissection in 
early stage NSCLC. Further clinical studies should be carried out in order to prove that 
minimally invasive mediastinal surgical procedures could be curative for T1N0MO NSCLC. 
Keywords: Surgery, Sentinel node biopsy, Mediastinal lymphadenectomy, NSCLC
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P2.02-020 Determining the Location of Early-Stage Lung Cancer Using an 
Endoscopic Ultrasound Device during VATS Procedure Takashi Inoue, Ikuo 
Wakamatsu, Osamu Araki, Yoko Karube, Norio Seki, Satoru Kobayashi, Tetsu Sado, 
Takeshi Oyaidu, Masayuki Chida Department of General Thoracic Surgery, Dokkyo Medical 
University, Mibu Tochigi/Japan
Background: Recently, it is possible to detect early-stage lung adenocarcinoma by 
using computed tomography. However, during video-assisted thoracic surgery (VATS), 
it is difficult to determine the location of early-stage lung adenocarcinoma without 
pleural indentation. In this study, we used an endoscopic ultrasound device to identify 
the location of early stage lung adenocarcinoma during VATS. Methods: We enrolled 
patients with a pure ground-glass-opacity (GGO) lesion (considered adenocarcinoma in 
situ) of less than 2 cm, which was considered undetectable during VATS because it was 
located inside the lungs, and was not adjacent to the visceral pleura. After single lung 
ventilation, we inserted the endoscopic ultrasound device (UST-5536-7.5, Hitachi Aloka 
Medical, Tokyo, Japan) through a 12-mm thoracoport . Results: Three patients (age 
range: 49–69 years) were enrolled. The diameter of the three lesions was 7 mm, 10 mm, 
and 12 mm, respectively. These lesions could not be observed through the visceral pleura 
and could not be palpated. The endoscopic ultrasound device detected each lesions as 
an area with high-signal intensity. The location of each lesion was determined on the 
basis of the intersection of the device when inserted from two different thoracoports;,the 
tumors were then resected. Pathological examination revealed adenocarcinomas 
in situ in 2 patients and an atypical adenomatous hyperplasia in 1. Local recurrence 
after surgery was not observed in any of the patients. Conclusion: Detecting a GGO 
lesion by using an endoscopic ultrasound device is an easy and effective method during 
the VATS procedure to determine the location of early-stage lung adenocarcinoma. 
Keywords: Early-stage lung cancer, Ultrasound, video-assisted thoracic surgery (VATS), 
Endoscopy
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P2.02-021 Robotic Pulmonary Resection for Lung Cancer: Analysis of the 
Learning Curve in a Novel Surgical Program Wael C. Hanna1, Christine Fahim2, 
Priya Patel3, Yaron Shargall1, Thomas K. Waddell3, Kazuhiro Yasufuku3 1Division of 
Thoracic Surgery, St. Joseph’S Healthcare Hamilton, Hamilton/ON/Canada, 2St. Joseph’S 
Healthcare Hamilton, Hamilton/Canada, 3University Health Network, Toronto/ON/Canada
Background: We present the first Canadian series of robotic pulmonary resection for 
lung cancer, examining the effects of learning curves associated with new technology 
on perioperative outcomes. Methods: Prospective databases at two institutions 
were queried for patients who underwent robotic pulmonary resection for lung cancer 
between October 2011 and February 2015. Data was collected on demographics, 
comorbidities, perioperative variables and complications. Results are presented as 
median (range). The learning curve effect was evaluated in temporal tertiles, stratified 
by surgeon. Differences in perioperative outcomes were evaluated using the Mantel-Cox 
Log-Rank test. Results: Of 116 patients included, 48% were males and median age was 
67 (28-88). The majority (88%, 102/116) underwent a robotic lobectomy, 9% (11/116) a 
segmentectomy, and 3% (3/116) a wedge resection. Five patients (4%) were converted 
to thoracotomy. Median operative time was 281 minutes (134-650) and length of stay 
was 4 days (1-19). Total operative time decreased significantly (p<0.01) over the learning 
curve; tertile 1 (326 min (290-362)), tertile 2 (275 min (261-289)) and tertile 3 (235 
min (210-260)). Median time spent on the robotic console also decreased significantly 
(p<0.01) over tertiles- 195 (144-246), 148 (136-160), and 116 (100-132) minutes, 
respectively. Across tertiles, there were no differences in the median number of lymph 
node stations harvested (6, 5, 6; p=0.33), length of stay (4, 4, 4; p=0.25, or the rate 
of major complications (Clavien-Dindo Class >= III; 5, 1, 4, respectively; p=0.26). There 
were no mortalities. Conclusion: The early Canadian experience with robotic lung cancer 
resection demonstrates excellent results that are comparable to those of experienced 
centers in operative times, length of stay and conversion rates. Further improvement 
was demonstrated by the learning curve effect. A prospective study to examine the 
outcomes and cost of robotic pulmonary resection compared to video-assisted 
thoracoscopic surgery should be done in the context of the Canadian healthcare system. 
Keywords: robotic pulmonary resection, Robotic surgery, Canadian, case series
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Mediastinal lymph nodes metastasis occurred 34 cases in absence of N1 metastasis. 
Among the 48 cases with aortic nodes metastasis, 45.8%(22 cases) had Upper Zone 
(superior mediastinal nodes) metastasis. The next common metastatic station was #4L 
nodes (24 cases(35.8%)). Metastasis to the Upper Zone lymph nodes occurred in 32 
cases of the 202 cases (15.8%), representing 47.8% rate of occurrence (32/67) among 
those with mediastinal nodal involvement. Furthermore, Upper Zone metastasis was rare 
5.0% in the absence of aortic node metastasis. Conclusion: The aortic lymph node is 
the most common site of metastasis from left upper lobe cancer. Based upon the rates of 
metastasis in our study, dissection of aortic nodes and left tracheobronchial nodes may 
be important for patients with left upper lobe cancer. We conclude our procedure (Hata’s 
method, ND3 operation) improve pTNM staging in left upper lobe lung cancer,whether 
Upper Zone dissection has a beneficial effect on prognosis remains controversial. 
Keywords: non small cell lung cancer, Hata’s operation, lymph node disseciton, ND3 
opration
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P2.02-027 A Study of Segmentectomy for Primary Lung Cancer Kotaro Mizuno, 
Risa Oda, Takuya Matsui, Takeshi Yamada Kariya Toyota General Hospital, Kariya/Japan
Background: Lung segmentectomy has been developed to reduce the invasion for 
patients. We have performed segmentectomy for primary lung cancer as much as 
possible. We have analyzed the usefulness of segmentectomy, especially by focusing 
on the recurrent cases. Methods: A total of 639 patients underwent operation for 
primary lung cancer in the period of January 2006 to August 2014 in our hospital. 
We performed an analysis of 144 patients (22.5%) who accepted segmentectomy. To 
compare the clinical data, we divided 144 patients into four groups depending on the 
size. Group A means ≤1.0cm, B means >1.0cm and ≤2.0cm, C means >2.0 cm and 
≤3.0cm, D means >3.0cm. The overall survival rates were calculated using Kaplan-Meier 
test. Results: Group A are 40 (27.8%), B are 72 (50.0%), C are 20 (13.9%), D are 12 
(8.3%). The pathological stage was 0/1=3/37 in Group A, 0/1A/1B(pl1)/2A(n1)/2B(
pl3)=1/63/5/2/1 in B, 1A/1B/2A/3A/4=11/6/1/1/1 in C, 1A/1B/2A/3A=1/8/1/2 in 
D. The 5-year survival rate was 89.6% in 144, 100% in A, 90.1% in B, 68.1% in C, 83.3% 
in D, respectively. There were 8 recurrent cases (5.6%) for all 144 cases, pulmonary 
metastasis (same lobe) = 1 in A, carcinomatous pleuritis / pulmonary metastasis (same 
lobe) / pulmonary and liver metastasis = 2/1/1 in B, brain metastasis = 1 in C, pulmonary 
metastasis (contralateral) / chest wall metastasis = 1/1 in D. Conclusion: This study 
revealed segmentectomy could contribute to long-term survival for group A and 
B. In recurrent cases of A and B, two of carcinomatous pleuritis and pulmonary and 
liver metastasis were showed pl1 or pl3. These cases would not be able to prevent 
recurrence even if they were performed lobectomy. However, two cases of pulmonary 
metastasis possibly could not occur recurrence if they were enforced lobectomy. 
Keywords: primary lung cancer, survival, lung segmentectomy
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P2.02-028 Diagnostic and Therapeutic Benefits of Thoracoscopic Surgery 
in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Hirohisa Kato, 
Hiroyuki Oizumi, Makoto Endoh, Jun Suzuki, Hikaru Watarai, Mitsuaki Sadahiro Second 
Department of Surgery, Yamagata University Faculty of Medicine, Yamagata/Japan
Background: Only a few reports have been published on pulmonary mucosa-associated 
lymphoid tissue lymphoma, a relatively rare disease. However, diagnostic and therapeutic 
surgery for this disease has increased recently due to the greater number of cases with 
indeterminate tumors detected by CT. We elucidated the characteristics of pulmonary 
mucosa-associated lymphoid tissue lymphoma and evaluated the role of thoracoscopic 
surgery. Methods: From March 2005 to March 2015, 13 patients underwent surgery for 
pulmonary mucosa-associated lymphoid tissue lymphoma diagnosed post-operatively. 
Three-dimensional CT simulation provides useful information for thoracoscopic 
surgery. We performed thoracoscopic lobectomy, anatomic segmentectomy, and 
subsegmentectomy for almost of these patients using the three-dimensional CT 
simulation. We evaluated patient characteristics, CT and FDG-PET findings, diagnostic 
methods, surgical procedures, operative time and bleeding, and prognosis. Results: The 
median age of the patients at surgery was 64 yr (range, 38–78 yr). All the tumors were 
solid nodules, with 11 patients having a single tumor and 2 patients multiple tumours. 
Median tumor size was 2.5 cm (range, 1.5-10 cm). FDG-PET showed SUV was 3.89-
5.54 (range, 1.86-18.02). Only two patients were diagnosed preoperatively with mucosa-
associated lymphoid tissue lymphoma by trans-bronchoscopic biopsies, while 11 
patients were assumed preoperatively to have lung cancer and were diagnosed finally 
with the frozen section using a surgical approach. Ten of the 13 patients underwent 
resections with thoracoscopic surgery and 3 patients underwent resection with 
thoracotomy. The procedures were 6 lobectomies, 5 segmentectomies, and 2 wedge 
resections. The most recent case had a thoracoscopic lobectomy combined with a 
segmentectomy and subsegmentectomy. The mean surgical time and median bleed 
were 194 min and 9 mL and 215 min and 200 mL in the thoracoscopic and thoracotomy 
groups, respectively. These operative parameters were showing a tendency to 
reduce in the thoracoscopic group. No complications or recurrences occurred 
during the follow-up period (range 4- 120 mth, mean, 45.8 mth). Conclusion: Three-
dimensional CT simulation was very useful and safely enabled reliable thoracoscopic 
segmentecomy and subsegmentectomy. Thoracoscopic surgery for pulmonary 
mucosa-associated lymphoid tissue lymphoma in which preoperative diagnosis is 
difficult can be performed safely and is beneficial for diagnosis and curative treatment. 
Keywords: Thoracoscopic surgery, MALT lymphoma
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P2.02-024 Simplified Comorbidity Score for Elderly Patients with Primary Lung 
Cancer Treated by Video-Assisted Thoracoscopic Surgery Yohei Yurugi, Tomohiro 
Haruki, Yuki Matsuoka, Ken Miwa, Kunio Araki, Yuji Taniguchi, Hiroshige Nakamura 
General Thoracic Surgery, Tottori University Hospital, Yonago/Japan
Background: Especially for elderly lung cancer patients, it would be important to 
evaluate the risks for postoperative complication and prognostic implication accurately. 
The aim of this study is to investigate whether Simplified Comorbidity Score (SCS) is 
useful for prediction of postoperative complication and prognosis. Methods: We reviewed 
216 elderly lung cancer patients aged 75 years and older who underwent pulmonary 
resection by video-assisted thoracoscopic surgery (VATS) between January 2005 and 
December 2012. The SCS, which is one of the weighting and scoring system for patients’ 
comorbidities, summarized the following variables: tabacco consumption, diabetes 
mellitus and renal insufficiency (respective weightings = 7, 5 and 4), respiratory, neoplastic 
and cardiovascular comorbidities and alcoholism (weighting = 1 for each item). Patients 
were divided into high and low groups according to calculated SCS (cut-off valued = 9), 
and we analyzed the differences of perioperative factors and prognosis between these 
groups. Results: There were 154 patients with low SCS and 62 with high SCS. Limited 
resection was performed more frequently in high SCS group than in low SCS group (58% 
and 40%, respectively; p = 0.02). Postoperative complications were occurred more 
frequently in high SCS group than in low SCS group (15% and 45%, respectively; p < 0.01). 
High SCS was a significant predictive factor of postoperative complications by logistic 
regression analysis (Odds ratio: 2.7; p = 0.02). The five year overall survival was 74% for 
low SCS group and 49% for high SCS group, respectively, with a significant difference 
(p < 0.01). Conclusion: SCS could provide useful information about postoperative 
complications and prognosis in elderly lung cancer patients with VATS treatment. 
Keywords: non-small cell lung cancer, Elderly patients, Video-assisted thoracoscopic 
surgery, Simplified comorbidity score
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P2.02-025 The Equivalent Efficacy of Multiple Operations for MPLC and a 
Single Operation for SPLC Keneng Chen1, Liang Dai1, Hao Fu2 1Thoracic Surgery, 
Peking University Cancer Hospital, Peking/China, 2Beijing Cancer Hospital, Beijing/China
Background: The incidence of synchronous and metachronous multiple primary lung 
cancers (MPLCs) has been increasing recently. The new multidisciplinary classification 
of lung adenocarcinoma and TNM Classification of Lung Cancer (7thedition, 2009), have 
improved the understanding of MPLC. Most researchers recommend that surgical therapy 
be actively pursued if the patient’s physical condition and lung function permit it and if 
a complete cure can be achieved. However, few studies have reported the long-term 
efficacy of surgical treatment for MPLC, which we explored in this study. Methods: One 
thousand two houndred and ningty Lung cancer patients from a prospectively maintained 
database, treated by a single surgeon group between January 2000 and July 2013, at 
Beijing Cancer Hospital, Peking University, were reviewed. We retrospectively analyzed 
the clinical data of 31 patients diagnosed with MPLC out of 1290 lung cancer patients, 
focusing on long-term survival. Results: MPLC patients accounted for 2.4% (31/1290) 
of the patient cohort: 27 had synchronous MPLC (87.1%) and 4 had metachronous 
MPLC (12.9%). The 1- and 3-year postoperative survival rates were 100% and 73.5%, 
respectively. On stratification according to TNM stage, the 1- and 3-year survival rates 
of patients with stage I cancer (20 patients) were 100% and 77.8%, respectively, not 
statistically significant with those for the entire cohort (1290 patients; 95.4% and 80.5%, 
respectively, p=0.876). Conclusion: When the patient’s physical condition and tumor-
related factors permit it, surgery should be the first choice of treatment for MPLC; it is 
associated with an equivalent efficacy to that of surgery for single primary lung cancer. 
Keywords: multiple primary lung cancer, Surgery, survival
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P2.02-026 Mediastainal Lymph Node Metasatsis Pattern from Left Upper Lobe 
Cancer: Results of Bilateral Superior Mediastinal Nodal Dissection 
Toshiya Yokota, Shingo Ikeda Thoracic Surgery, Misui Memorial Hospiral, Tokyo/Japan
Background: The accurate assessment of lymph node involvement is an important part 
of the management of lung cancer. However, due to anatomical limitations imposed by 
arch of aorta, it is difficult to perform complete dissection of superior mediastinal lymph 
nodes through the left thoracotomy in the left lung cancer. The aim of this study is to 
evaluate the location, frequency of metastatic lymph nodes in the mediastinum among 
patients with left upper lung cancer who underwent complete dissection of the bilateral 
superior mediastinal lymph node through a median sternotomy (Hata’s method, ND3 
operation). Methods: 202 patients with left upper lobe cancer underwent extended radical 
mediastinal lymph node dissection. We retrospectively studied clinical data of these 
patients [202 male and 87 female, mean ages 60.2 years (range, 38-75)], underwent ND3 
operation due to NSCLC, from January 1988 till December 2014. Mediastinal nodal status 
was assessed according to the systems of IASLC lymph node map 2009. The superior 
mediastinal lymph nodes which cannot be dissected through a left thoracotomy (bilateral 
#1,#2 and #4, right #3a according to IASLC lymph node map 2009 were defined as 
extra-superior mediastinal nodes for left lung cancer . Results: N1 disease was identified 
in 28 patients,N2 was in 39 patients, N3α disease was in 18, N3γ disease was in 10. 
67 patients (33.2%) had one or more metastases to mediastinal lymph nodes . Among 
them the most common metastatic station was the aortic nodes (AP Zone). 34 cases 
(50.7%) had metastasis to #5 or #6 (19 cases(29.2%) to #5 and 15 cases (22.4%) to #6). 
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other lung malignancies; however atypical carcinoids are more aggressive. Surgery 
remains the gold standard with the same requirements as other malignancies, although 
conservative techniques with broncho-plastic surgery for typical carcinoids are well 
established. However, their management has to be multidisciplinary, The purpose 
of this study was to assess the surgical management of primary broncho-pulmonary 
carcinoid tumors. Methods: We reviewed retrospectively 137 cases managed in our 
thoracic surgery department for bronchial carcinoid tumors during a twenty-three-year 
period, between 1992 and 2014. Results: There were 64 men and 73 women (sex-
ratio: 0.87), with a mean age of 44.2 years. One hundred and twenty-one patients 
had typical carcinoids and 16 patients had atypical carcinoids. Respiratory symptoms 
were the chief complaint in 98.42%. CT showed a proximal obstructive mass in 52% 
of the cases, with lung consolidation or atelectasis in 77.2%. Bronchoscopy showed 
an endo-bronchial tumor in 82.67% of the cases. Anatomical resection had been 
achieved among 119 patients (86.9%) (Pneumonectomy: 24 cases, bilobectomy: 
27 cases, lobectomy: 68), with extended resection to the left atrium in 2 cases and 
to the adjacent upper lobe in 1 case. Conservative resection was performed in 18 
patients (13.1%) with typical carcinoid tumor (bronchotomy and resection of the tumor: 
3 cases, anatomical segmentectomy: 3 cases, sleeve lobectomy: 12 cases). Lymph 
node metastases were present in 12.6% of the cases. The postoperative course was 
uneventful in 89.05% of the cases and complicated in 10.94%, with atelectasis being 
the most reported in 5 cases. One patient was readmitted and reoperated two months 
after surgery for post operative empyema. 2 patients deceased in the post operative 
course (1.4%). Follow-up revealed recurrence in one patient with a typical carcinoid 
and distant metastasis in 4 others (2 atypical and 2 typical carcinoids). The 5-year 
survival rate was 45% for atypical carcinoid vs 95% for typical carcinoid. Reported 
prognostic factors for typical carcinoids were sex (male), the size of the tumor and 
lymph nodes involvement. Conclusion: Carcinoids are rare malignant tumors, almost 
with a favorable outcome after surgery, given that their resection is complete, with 
a thorough lymph node dissection. However, local recurrence and metastases can 
occur with both typical and atypical carcinoid tumors, justifying the need for early 
diagnosis and long-term follow-up. Survival rates in our series were largely influenced 
by the pathological type, distant metastasis and mediastinal lymph node involvement. 
Keywords: Surgery, Typical carcinoid tumor, Atypical carcinoids, Prognosis
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P2.02-032 Phase II Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) 
in Surgically Operable Stage I Non-Small Cell Lung Cancer (STARS) Joe Y. 
Chang1, Reza Mehran2, Peter Balter1, Stephen Mcrae3, Lei Feng4, Donald Berry4, Ritsuko 
U. Komaki1, Jack Roth2 1Radiation Oncology, MD Anderson Cancer Center, Houston/United 
States of America, 2Thoracic Surgery, MD Anderson Cancer Center, Houston/AL/United 
States of America, 3Radiology, MD Anderson Cancer Center, Houston/AL/United States of 
America, 4Biostatistics, MD Anderson Cancer Center, Houston/AL/United States of America
Background: Standard therapy for operable clinical stage I non-small cell lung 
cancer (NSCLC) is lobectomy with sampling or dissection of mediastinal lymph nodes. 
Stereotactic ablative radiotherapy (SABR) has produced local control rates in excess of 
95% and has become standard care for medically inoperable stage I NSCLC. However, 
the role of SABR in operable stage I NSCLC remains controversial due to concerns about 
the risk of local or nodal recurrence after SABR, either of which could lead to worse OS 
than that after standard surgery. We report here the preliminary outcome using SABR 
in clinically operable stage I NSCLC. Methods: Patients with clinical T1A(<3 cm)N0M0 
biopsy proven operable NSCLC who meet criteria for lobectomy are being enrolled. All 
patients are staged with chest CT, PET/CT imaging, and EBUS. 54 Gy in 3 fractions was 
used for peripheral lesions and 50 Gy in 4 fractions for central lesions, respecting critical 
normal tissue dose volume constraints. SABR plans are typically optimized by using 6 to 
12 coplanar or non-coplanar 6-MV photon beams (3-D CRT or IMRT) or Cyberknife or one 
to three arcs (VMAT). Daily CT-on-rail or a cone-beam CT scans or tumor tracking was 
used during each radiotherapy fraction. Results: Enrollment was started in September 
2009, temporally closed in 2013 with 20 patients and re-opened in 2014. The study is 
ongoing and 58 patients have been enrolled up to date. The median follow-up time for the 
first 20 patients was 40 months; for all patients, median follow up was 7 months (range 
0.8-49.6 months, interquartile 4.7, 22.8 months). No deaths have occurred to date. There 
was one local failure in the treated lobe that was salvaged with lobectomy. There were 5 
cases of regional mediastinal lymph node progression treated with concurrent chemo/
radiotherapy. Three of these cases had suspicious lymph nodes by CT and PET before 
SABR but were enrolled because EBUS was negative. One patient developed distant 
metastasis and was treated with chemotherapy. No one had grade 3-5 toxicity. Six patients 
had grade 2 chest wall pain (10.3%) and three patients developed grade 2 pulmonary 
toxicity (5%). Conclusion: SABR is well tolerated with minimal toxicity and promising local 
control and survival. More stringent mediastinal staging is recommended in the future. 
Keywords: operable Stage I lung cancer, stereotactic radiotherapy, SBRT, SABR
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P2.02-033 Actual Situation of Adjuvant Chemotherapy for NSCLC in Japan 
Ryu Nakajima, Hidetoshi Inoue, Michitaka Kimura, Takuma Tsukioka, Makoto Takahama, 
Ryoji Yamamoto General Thoracic Surgery, Osaka City General Hospital, -- Miyakojima-
Hondori Miyakojimaku Osaka/Japan
Background: Several Clinical Trials were revealed survival advantage of adjuvant 
chemotherapy (AC) for completely resected NSCLC (increased 5 year survival rate 
by 4% to 15%), and AC has been standard of care for completely resected stage II to 
IIIA NSCLC. Further more, on JLCSG study has been revealed survival advantage of 
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P2.02-029 Pre-Operative Pulmonary Function Tests (PFT) and Outcomes from 
Stage I and II Non-Small Cell Lung Cancer (NSCLC) Treated with Surgery 
Nabin Khanal1, Daniel Almquist2, Lynette Smith3, Apar K. Ganti4 1Internal Medicine, 
Creighton University Medical Center, Omaha/NE/United States of America, 2Internal 
Medicine, University of Nebraska Medical Center, Omaha/NE/United States of 
America, 3University of Nebraska Medical Center, Omaha/NE/United States of 
America, 4Internal Medicine/Oncology-Hematology, Veteran’S Affairs Nebraska-Western Iowa 
Health Care System, University of Nebraska Medical Center, Omaha/NE/United States of 
America
Background: Pre-operative PFTs predict operative morbidity and mortality after 
resection in lung cancer. However, the impact of pre-operative PFT on overall survival 
(OS) in surgically resected stage I and II NSCLC is relatively less studied. Methods: This 
is a retrospective study of 149 patients who underwent surgical resection as first-line 
treatment for stage I and II NSCLC at a single center between 2003 and 2014. PFTs 
(FEV1, DLCO, both absolute values and percentage of predicted values were categorized 
into quartiles The Kaplan-Meier method and Cox regression analysis were used to 
determine whether PFTs predicted for OS. The t-test was used to compare the risk of 
post-op complications and length of stay greater than 10 days based on the results of 
PFTs and multivariate logistic regression was used for predictive modeling. P-value<0.05 
was considered statistically significant. Results: The median age of the cohort was 
68 years. The cohort was predominantly male (98.6%), current or ex-smokers (98%), 
with stage I NSCLC (82.76%). The majority of patients underwent a lobectomy (n=121, 
81.21%). The predominant tumor histology was adenocarcinoma (n=70, 47%) followed 
by squamous cell carcinoma (n=61, 41%). The median follow-up of surviving patients 
was 53.2 months. Although DLCO was found to be a significant predictor of OS (HR: 
0.93, 95% CI, 0.87-0.99; p=0.03), this was no longer significant on multivariate analysis. 
While PFTs did not predict for post-operative complications, worse PFTS were significant 
predictors of length of stay >10 days. Table 1. PFTs and Outcome:
Multivariate model for of LOS > 10 days Odds Ratio(95% CI, p-value)
FEV1 0.34(0.16-0.76,p=0.0087)
FEV1 (percentage predicted) 0.96(0.94-0.99,p=0.0033)
DLCO 0.78(0.68-0.90,p=0.0004)
DLCO (percentage predicted) 0.96(0.94-0.99,p=0.0060)
 
OS=Overall Survival, LOS= Length of stay, ULN= Upper Limit of Normal *PFT as 
continuous variables Conclusion: Preoperative PFTs did not predict for survival from 
resected early stage NSCLC, but did predict for longer hospital stays following surgery. 
Keywords: NSCLC, Surgical treatment, Pulmonary Function test, Survival
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P2.02-030 Bronchoscopic Therapy for Centrally-Located Early Lung Cancers 
Taichiro Ishizumi, Jitsuo Usuda, Tatsuya Inoue, Takayuki Ibi, Akira Sato Thoracic Surgery, 
Nippon Medical School Hospital, Tokyo/Japan
Background: Photodynamic therapy (PDT) is recommended as a treatment option for 
centrally-located early lung cancers (CLELCs). Although PDT using Photofrin has not been 
recommended for large tumors or deeply invasive tumors, in the past, if their mass is 
reduced by electrocautery, PDT with the NPe6 second-generation photosensitizer has 
been found to be capable of destroying the residual cancer lesion. NPe6 is a second-
generation photosensitizer, and since it has a longer absorption band (664 nm) than 
Photofrin (630 nm), we hypothesized that NPe6-PDT would exert a strong antitumor effect 
against cancer lesions greater than > 1.0 cm in diameter. Methods: Between June 2004 
and October 2013, 128 patients (151 lesions) with CLELC underwent NPe6-PDT after the 
extent of their tumors had been assessed by fluorescence bronchoscopy for photodynamic 
diagnosis and tumor depth had been assessed by OCT. Results: Ninety-four cancer 
lesions ≦1.0 cm in diameter and 57 lesions >1.0 cm in diameter were identified, and 
the CR rate was 93.6% (88/94) and 96.5% (55/57), respectively. After the mass of large 
tumors and deeply invasive tumors, had been reduced by electrocautery, NPe6-PDT was 
capable of destroying the residual cancer lesions. Conclusion: NPe6-PDT has a strong 
antitumor effect against CLELCs >1.0 cm in diameter, thereby enabling the destruction 
of residual cancer lesions after mass reduction of large nodular or polypoid type-lung 
cancers by electrocautery. The PDT guidelines for lung cancers should therefore be 
revised, because use of NPe6-PDT will enable expansion of the clinical indications for PDT. 
Keywords: centrally-located early lung cancers, photodynamic therapy
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P2.02-031 Surgical Management of Bronchial Carcinoid Tumors: A 
Monocentric Tunisian Experience Tarek Kilani1, Adel Marghli1, Hazem Zribi1, Sadok 
Boudaya1, Sarra Zairi1, Aida Ayadi2, Mouna Mlika2, Tahar Mestiri1, Faouzi Mezni2, 
Hammouda Boussen3 1Thoracic and Cardiovascular Surgery, Abderrahmane Mami Hospital, 
Ariana/Tunisia, 2Pathology, Abderrahmane Mami Hospital, Ariana/Tunisia, 3Medical Oncolog, 
Abderrahmane Mami Hospital, Ariana/Tunisia
Background: Bronchial carcinoids are rare and account among well differentiated 
neuroendocrine tumors, with low-grade malignancy. They are divided in two different 
groups: typical and atypical carcinoids. They have almost a better prognosis than 
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day(Figure 2). According to the cutoff value of 50, patients were divided into 2 groups, 
group1 (≤50days, n=183) and group2 (>50 days, n=25). Figure 1 shows the baseline 
characteristics of the two groups of patients before and after PSM .There was significant 
difference in DFS between the two groups (mDFS: 737days vs. 369days, P=0.005)(Figure 
2), and the TTAC was found to be a significant predictive factor for DFS in multivariable 
analysis (P =0.035).Unfortunately, DFS was not continually significant difference in 22 
PSM pairs (mDFS:576days vs. 369days,P=0.122) (Figure 2).
Conclusion: TTAC does not appear to be associated with DFS in NSCLC. The conclusion 
was limited by the small sample size; therefore the number of patients between 
the groups was not close. Larger sample of cases should be warranted in future. 
Keywords: non-small cell lung cancer, adjuvant chemotherapy, time to adjuvant 
chemotherapy, disease free survival
adjuvant UFT treatment for Japanese stage I (size>2cm) patients. To investigate the 
practical situation of Adjuvant chemotherapy (AC) for completely resected NSCLC in 
our institution. Methods: We retrospectively reviewed completely resected NSCLC 
patients who were p-stage IA (Size > 2cm) to IIIA at our institution between 2005 and 
2010. Enforcement status of AC, regimen and survival were analyzed. Results: Of the 
648 had oncological indication of AC, but only 123 patients (19%) were received AC. 
Poor postoperative physical condition (25%), age (24%) and doctor’s decision (Tumor 
size nearly 2cm, AIS) (22%) were popular reasons for avoid to AC. Ten presents of 
patients refuse AC by their intention. Forty-nine percent of patients were received AC 
by platinum doublet regimen and 33% were UFT regimen. Treatment related death 
and severe adverse event were not observed in all AC treatment. Conclusion: AC 
is standard of care for completely resected stage II to IIIA NSCLC and safety 
performed in practical situation. But majority of patients could not receive it. 
Keywords: NSCLC, adjuvant chemotherapy
POSTER SESSION/ TREATMENT OF LOCALIZED DISEASE – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.02-034 Induction Therapy with Intercalated TKI and Chemotherapy in 
NSCLC with Activating EGFR Mutation in Stages II-IIIB: NeoIntercal 
Frank Griesinger1, Martin Sebastian2, Monika H. Serke3, Christian Grohé4, Lars Hillejan5, 
Bernward Passlick6, Nils Reinmuth7, Ullrich Graeven8, Anne C. Lueers9, Susanne M. 
Radke10, Aysun Karatas11, Markus Tiemann12, Lukas Heukamp12, Tobias Overbeck13 
1Pius-Hospital, Oldenburg/Germany, 2Department of Medicine, Hematology/Oncology, 
Goethe University, Frankfurt/Germany, 3Lungenklinik Hemer, Hemer/Germany, 4Evangelische 
Lungenklinik Berlin, Berlin/Germany, 5Niels-Stensen-Kliniken, Ostercappeln/
Germany, 6Thoracic Surgery, University Hospital Freiburg, Freiburg/Germany, 7Lungenclinic 
Grosshansdorf, Grosshansdorf/Germany, 8Kliniken Maria Hilf Gmbh, Moenchengladbach/
Germany, 9Oncology, Pius-Hospital, Oldenburg/Germany, 10Medical Affairs, Astrazeneca, 
Wedel/Germany, 11Aio-Studien-Ggmbh, Berlin/Germany, 12Hematopathology Hamburg, 
Hamburg/Germany, 13University of Goettingen, Goettingen/Germany
Background: EGFR TKI treatment is standard of care in patients with metastasized 
NSCLC carrying an activating EGFR mutation. 1st and 2nd generation agents lead to 
response rates of up to 70% in metastatic EGFRM+ NSCLC. Recently, new light has been 
shed on intercalated regimens of chemotherapy and TKI have shown improved PFS as 
well as OS in the metastatic setting in an unselected Asian population (Wu et al. 2013 The 
Lancet Oncology 14 (8): 777-86). Response is a predictor of PFS and OS in limited and 
locally advanced NSCLC. Chemotherapy induction alone leads to pCR rates of no more 
than 15%. No data have been generated for induction therapy including EGFR TKI in 
EGFRM+ NSCLC. Four cases treated in one center have demonstrated the feasibility 
and tolerability of an intercalated induction therapy concept (Lüers et al. 2013 Abstract 
WCLC). Methods: Therefore, NeoIntercal a single arm phase II study has been initiated in 
9 centers in Germany. In a first step, patients with stage II to IIIB staged according to local 
standards will be screened for EGFR mutations by a ring certified pathologist. EGFRM+ 
patients will receive gefitinib 250 mg / die p.o. on d-12 to -1 (d1 = first day of first cycle of 
chemotherapy) followed by 3 cycles of taxane and platinum containing chemotherapy with 
intercalated gefitinib on d4-d20 of each cycle. After 2 cycles, restaging CT is performed 
and patients are scheduled to undergo surgery during the 4th or 5th week of the last cycle 
of CTx-gefitinib. Pathologic response rate is the primary endpoint. If more than 30% of 
patients achieve pCR (regression grades IIB and III according to Junker) in the mediastinal 
lymph nodes, it is planned to additionally enroll 28 patients in the 2nd part of the study. 
Secondary endpoints include OS, PFS, relapse rate and pattern, toxicity and feasibility. 
A liquid biopsy project is included in the study to correlate EGFR mutation status from 
tumor biopsy results with ctDNA plasma analysis. Furthermore, therapy effects will be 
monitored by liquid biopsy. Results: Study preparation and recruitment of clinical trial 
centers is nearly completed and the enrollment of the first patient is planned for 3Q2015. 
An interim analysis will be performed approximately 12 months after enrollment initiation 
with data from 21 patients. Should the interim analysis be positive and an additional 28 
patients are included, the study is scheduled to end in approximately 2019 after a follow 
up period of 24 months. Conclusion: According to our knowledge, NeoIntercal is the first 
study in the neoadjuvant setting with curative intent applying an intercalating combination 
of chemotherapy and targeted therapy. The NeoIntercal study group believes that 
this study will potentially contribute to the improvement of EGFRM+ NSCLC therapy. 
Keywords: EGFR TKI, activating mutation, gefitinib, neoadjuvant therapy
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P2.02-035 Is There an Optimal Time to Initiate Adjuvant Chemotherapy in 
Order to Predict the Benefit of Survival in Non-Small Cell Lung Cancer? 
Xiaoyu Zhai, Ziping Wang Department of Medical Oncology, Cancer Institute and Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/China
Background: Adjuvant chemotherapy (ACT) improves the survival for completely 
resected non-small cell lung cancer (NSCLC) patients. However, there are very few 
reports to explore the correlation between time of initiation of adjuvant chemotherapy 
(TTAC) and survival. Methods: 208 completely resected NSCLC patients received 
adjuvant chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences from 
2001-2010 were analyzed. TTAC was measured from the date of surgery to initiation of 
ACT. Disease-free survival (DFS) was defined as the duration from the surgery to the 
time of relapse or last follow-up. Optimal cutoff value of the TTAC was determined by 
maximally selected log-rank statistics. Survival analysis was performed using Kaplan–
Meier estimates, log-rank tests and Cox’s proportional hazards regression analysis. 
Propensity score matching (PSM) was used, and a survival analysis of the match data 
was carried out. Results: The best discriminating cutoff value of TTAC was the 50th 
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P2.02-038 Clinical Evaluations of Odd/Even Respiratory Phases Based 
Approach for Determining Internal Target Volume in NSCLC Treated with 4D 
SABR Xia D. Li1, Qing-Hua Deng1, Li-Dan Zhang1, Yao Ren1, Jiale Gu1, Sheng-Lin Ma1, Zhi-
Bing Wu1, Jia-Hao Wang1, Gang Li2 1Radiotherapy, Hangzhou Cancer Hospital, Hangzhou/
China, 2Radiotherapy, Xiaoshan Hospital of Zhejiang, Hangzhou/China
Background: Appropriate definition of the target volume with an efficient approach 
remains a major challenge for early stage NSCLS treated with SBRT technique; one 
of crucial disturbed factors in delineation of target volume is the tumors movement 
due to irregular respiration patterns(3), to account for tumor motion, the ICRU Report 
62 introduced the concept of an internal target volume (ITV), defined as the clinical 
target volume (CTV), plus an additional margin to account for geometric uncertainties 
due to variable tumor motion (4), Conventionally, a free-breathing three-dimensional 
(3D) -CT scan was adopted to acquire the patient’s anatomic information which leads 
to geometric distortions (5). To account for these geometric uncertainties, large 
target volumes are needed, thereby limiting the effectiveness of the radiotherapy (6).
To reduce geometric uncertainties in 3D-CT images, time related four-dimensional 
CT (4D-CT) scanning techniques have been developed in radiation therapy to obtain 
information about volumetric organ motion associated with respiration. And various 
methods for definition of the target volume using 4D-CT scans in treatment planning 
have been reported recently(7,8,9,10), the most accurate method of determining ITV 
is combined by contouring in each phase of the 4DCT dataset (typically 10 phases). 
Although this method is widely accepted as a golden standard for delineation of ITV , 
it poses more efforts and time consuming due to the increased workload for radiation 
oncologists. To Improve work efficiency many efforts has been done to reduce the 
workload meanwhile maintain a reasonable ITV, the maximal intensity projection (MIP) 
dataset has been widely applied in the clinic to define ITV in the early stage; some other 
researchers investigated ITV from 4D-CT such as ITV2ep(including two extreme phases 
) and ITV4phase= ITV2ep+ two phases (20% and 70%) , The matching index (MI) was 
adopted to evaluate the marching degree between different determining approaches,in 
this research, we will proposed a new approach to definite an ITV with the best marching 
index meanwhile with the least time and human resource. Methods:December 2013 and 
March 2014, 46 patients who underwent SABR were included in this retrospective study. 
All patients underwent imaging with 4DCT scans, The MI and DI index were evaluated 
ITV10,ITVYeo,ITVEI+EE,And combining GTV from five odd phasesITVodd, Accordingly the 
ITVEVEN , and ITVAVG ,ITVMIP were Contoured from two reconstructed 4D-CT Sequences, 
finally, a method which was not sensitive to the tumor volume and motion Characteristic 
was selected for clinical use. Results: The mean tumor motion (RLR, RAP, RCC, and 
R3D) were 3.5mm(1.4mm~8.4mm)，4.5mm(1.1mm~8.6mm)，9.5mm(0mm~10mm), 
12.3mm (2.5-55.3 mm) respectively. IGTVx volume were Underestimated by25.7%
、35.6%、17.9%、12.8%、3.6%、4.8% (P=0.000) respectively. MI index comparisons 
between six ITV generation methods and ITV10 showed statistical significance: 
0.69、0.62、0.80、0.86、0.93、0.91（P=0.006）, DI index showed no statistical 
significance: 0.98、0.98、0.97、0.97、0.99、0.98（P=0.13）, the tumor size and motion 
amplitude were certified not the independent factors for the MI index of ITVodd and 
ITVEVEN Conclusion: IGTVODD/EVEN based on odd or even 4D-CT phases was not sensitive 
to tumor size or motion characteristic and was proved to have a good marching with 
ITV10 meanwhile Maintaining a reasonable contouring efficiency, it can be recommend 
to the institutions which not equipped with the deformable registration systems. 
Keywords: non-small cell lung cancer, Stereotactic ablative radiotherapy, internal target 
volume, 4DCT
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P2.02-039 Patterns-Of-Care Study of Stereotactic Ablative Radiotherapy for 
Lung Cancer in Korea Sanghyuk Song1, Hak Jae Kim2, Jin Hee Kim3, Jae-Sung Kim4, 
Yong Chan Ahn1, Yeon Sil Kim5, Si Yeol Song6, Sung Ho Moon7, Moon June Cho8, Seon 
Min Youn9, Won Il Jang10 1Samsung Medical Center, Seoul/Korea, 2Seoul National University 
Hospital, Seoul/Korea, 3Keimyung University, School of Medicine, Taegu/Korea, 4Seoul 
National University Bundang Hospital, Seongnam/Korea, 5Seoul St. Mary’S Hospital, 
Seoul/Korea, 6Asan Medical Center, Seoul/Korea, 7National Cancer Center, Goyang/
Korea, 8Chungnam National University Hospital, Daejeon/Korea, 9Eulji University Hospital, 
Daejeon/Korea, 10Korea Institute of Radiological & Medical Sciences, Seoul/Korea
Background: Stereotactic ablative radiotherapy (SABR) is an emerging effective technique 
for early stage lung cancer. We investigated the current practice patterns for stereotactic 
ablative radiotherapy (SABR) for lung cancer in Korea. Methods: A nationwide survey 
about experience with SABR for lung cancer was sent by e-mail to the radiation oncologists 
of 85 institutions in May 2014. SABR was defined as hypofractionated radiotherapy (1–8 
fractions). The survey contained 23 questions, and those regarding technical details 
allowed multiple choices. Results: Of the 59 institutions that responded to the survey, 
33 (56%) had used SABR for lung cancer. Thirty-seven radiation oncologists from these 
33 institutions responded to the survey. Seventy-five percent of the oncologists had 
been treating lung cancer with SABR for less than 5 years, while 89% treat less than 20 
cases annually. The most common planning method was rotational intensity-modulated 
technique (59%), followed by static intensity-modulated technique (49%). A wing board 
(54%) was most frequently used for immobilization, followed by the vacuum lock system 
(51%). Respiratory motion was managed by gating (54%) or abdominal compression 
(51%), and 86% of the planning scans were obtained with 4-dimensional computed 
tomography. More than half of the respondents (62%) treated daily if a multi-fraction 
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P2.02-036 Radiation Therapy Alone in cT1-3N0 Lung Cancer Patients Who 
Are Unfit for Surgery or Stereotactic Ablative Radiation Therapy Yong Chan 
Ahn, Wonkyung Cho, Jae Myung Noh, Dongryul Oh, Hongryull Pyo Radiation Oncology, 
Samsung Medical Center, Seoul/Korea
Background: High dose radiation therapy (RT) alone is recommended to cT1-3N0 
lung cancer patients, who are unfit for surgical resection or stereotactic RT based 
on medical comorbidity, tumor size and location. This study is to evaluate clinical 
outcomes and costs following definitive RT alone using 2 modest hypo-fractionated dose 
schemes. Methods: Retrospective review on 116 patients who received high dose RT 
alone from January 2001 till December 2013 was done. Median age was 74 years and 
91 patients (78.4%) were male. All had cT1-3N0 disease and 65 patients (56.0%) had 
squamous cell carcinoma, followed by adenocarcinoma in 35 (30.2%). Dose-fractionation 
scheme of 60 Gy in 20 fractions over 4 weeks was applied to 79 patients from 2001 
till 2010 (68.1%, Group I). Meanwhile, 2 dose-fractionation schemes were used from 
2011 till 2013: 60 Gy in 20 fractions to 17 patients (14.7%, Group II); and more hypo-
fractionated scheme of 60 Gy in 15 fractions over 3 weeks to 20 patients (17.2%, Group 
III). 60 Gy in 15 fractions was chosen on individual basis if RT-related acute side effects 
(bronchitis, esophagitis) could be avoided based on tumor location and geometry. 
Group I/II patients had central tumors (defined as within 2 cm from lobar bronchi) more 
frequently (78.5% vs. 64.7% vs. 35.0%, p<0.0001), and larger mean tumor size (4.2 cm 
vs. 5.0 cm vs. 3.8 cm, p=0.0725) than Group III. Elective nodal irradiation to regional 
lymphatics (median 30 Gy/10 fractions) was delivered to 30 patients: 23 in Group I 
(29.1%); seven in Group II (41.2%); and none in Group III (0%), respectively (p=0.0341). 
Local control (LC), progression free survival (PFS), overall survival (OS), and RT-related 
toxicity profile were estimated and compared. Results: After median 19.3 (1.2-119.5) 
months’ follow-up, 68 patients (58.6%) experienced disease progression, and 66 (56.9%) 
died. 2-year LC and PFS rates of all patients were 62.0% and 39.3%, respectively, which 
were not different between Groups (59.3% and 36.1% vs. 52.1% and 26.9% vs. 78.8% and 
61.6%, p=0.3010 and 0.1620, respectively). 2-year OS rate of all patients was 57.5%, 
and was significantly better in Group III (51.3% vs. 69.1% vs. 83.0%, p=0.0232). Grade 
≥2 pneumonitis developed in 27 patients (23.3%), and was not different between Groups 
(19.0% vs. 35.3% vs. 30.0%, p=0.1908), while Grade ≥2 esophagitis developed in 22 
patients (19.0%), however, none in Group III (22.8% vs. 23.5% vs. 0%, p=0.0373). Good 
performance status (ECOG 0-1 vs. 2-3) and low cT-stage (T1-2 vs. T3) were significantly 
favorable factors affecting LC, PFS, and OS, however, central location of tumor was 
not. Costs incurred by RT under Korean Health Insurance Policy were 6,080,000 KW 
in Groups I and II and 4,707,500 KW in Group III, respectively. Conclusion: Hypo-
fractionated RT delivering 60 Gy in either 15 or 20 fractions could lead to reasonably 
favorable and comparable clinical outcomes in cT1-3N0 lung cancer. 60 Gy in 15 fractions 
in selective cases as in Group III, however, seems more cost-effective and attractive 
by virtue of shorter RT duration, lower cost, and increased patients’ convenience. 
Keywords: non-small cell lung cancer, hypofractionated radiation therapy
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P2.02-037 Evaluation of the Dosimetric Characteristics of Salvage Lung SBRT 
with Image Deformable Registration Technique Kaile Li1, Eward Jung2 1Radiation 
Oncology, John R Marsh Cancer Center, Hagerstown/United States of America, 2Radiation 
Oncology, John R Marsh Cancer Center, Hagerstown/AL/United States of America
Background: Treatment planning for salvage radiation therapy after failing initial 
treatment is challenging. Many factors can contribute to local failure, including inherent 
aggressiveness of the tumor, target motion localization accuracy, and dose delivery 
variation. Especially when a patient is re-treated for local failure with repeat lung SBRT 
at a different institution, or using a different radiation treatment platform or software, 
treatment planning becomes very complex. In particular, it is crucial to create a reliable 
composite plan to determine the dose delivered to critical structures to prevent serious 
complications with repeat lung SBRT. Another factor which has not been well studied 
is a method to compare temporal changes in dose delivered to the target volume after 
initial treatment, which can surely affect local control. We present a method to compare 
lung SBRT treatments and analyze the dosimetric characteristics of salvage lung SBRT 
by applying image deformation registration techniques with dose distributions, and 
incorporating temporal changes in dose over time. Methods: A patient treated with repeat 
lung SBRT to a region of local failure involving the left upper lobe was used for analysis. 
The target volume was initially treated on a CyberKnife radiosurgery unit, and then re-
treated with lung SBRT on a Varian Trilogy machine (LINAC). Dosimetric characteristics 
were compared for these two platforms. Indexes used for analysis include target volume 
dose coverage, and dose target dose conformity, which is quantified by conformity index 
(CI), integrated conformity index (ICI), dose spillage level outside of treatment target, and 
dose to the critical structure. The spillage is defined to be the ratio of maximum dose 
ouside of the target to the maximum plan dose.Treatment dose effect was described 
by Biologically Effective Dose (BED) with dose conversion by considering changes in 
BED over time. CyberKnife SBRT dose distribution was converted for treatment with 
salvage SBRT with deformable registration by MIM software. Results: Parameters were 
compared for initial CyberKnife SBRT treatment alone, salvage LINAC SBRT treatment 
alone, and composite sum SBRT with deformable registration. Assuming α/β=10 for the 
tumor, the calculated BEDs were 100, 138, and 127, respectively. The corresponding CIs 
were 1.03, 1.18, and 1.28. The ICIs were 0.894, 0.807, and 0.881. Dose spillages were 
0.81, 0 .78, and 0.56. V20 was 4.9%, 7.2%, and 5.4% for each plan. Conclusion: This 
study provides a method to estimate the dosimetric characteristics of lung SBRT from 
different treatment platforms with incorporation of temporal loss of dose between 
initial and salvage treatments. Deformable registration accuracy and the appropriate 
parameters affecting local control of lung tumor need further investigation and validation. 
Keywords: Biologically Effective Dose (BED), Deformable Registration, Stereotactic 
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P2.03-001 Perioperative Cardiac Events in Patients with Coronary Artery 
Stent Undergoing Lung Resection for Lung Cancer Takayuki Ibi, Taichiro Ishizumi, 
Tatsuya Inoue, Akira Sato, Kyoshiro Takegahara, Toriyama Sayuko, Jitsuo Usuda 
Thoracic Surgery, Nippon Medical School Hospital, Tokyo/Japan
Background: Many patients with coronary artery disease (CAD) receive coronary artery 
stents. Some of them require major lung resection for non-small cell lung cancer (NSCLC). 
Patients with coronary artery stent have problems with antiplatelet therapy. After coronary 
artery stent, patients need dual antiplatelet therapy for a while to decrease the risk of stent 
thrombosis. The ACC/AHA Guidelines recommended continuation of dual antiplatelet 
therapy for 4 to 6 weeks after bare-metal stent (BMS) placement and 12 months for a 
drug-eluting stent (DES). Lung resection with discontinuation of antiplatelet therapy may 
increase a risk of perioperative coronary event in patients with CAD. Many patients with 
coronary artery disease (CAD) receive coronary artery stents. Some of them require major 
lung resection for non-small cell lung cancer (NSCLC). Patients with coronary artery stent 
have problems with antiplatelet therapy. After coronary artery stent, patients need dual 
antiplatelet therapy for a while to decrease the risk of stent thrombosis. The ACC/AHA 
Guidelines recommended continuation of dual antiplatelet therapy for 4 to 6 weeks after 
bare-metal stent (BMS) placement and 12 months for a drug-eluting stent (DES). Lung 
resection with discontinuation of antiplatelet therapy may increase a risk of perioperative 
coronary event in patients with CAD. Methods: This retrospective analysis is based on 
all patients with coronary artery stent requiring major lung resection for NSCLC between 
January 2011 and December 2013 at Nippon Medical School Hospital, Tokyo, Japan．We 
retrospectively examined major adverse cardiac events (MACE) and perioperative 
management of the patients with coronary artery stent requiring major lung resection 
for NSCLC. Results: There were thirteen patients (5.8%) with coronary artery stent in 
two hundred twenty six patients who underwent radical lung cancer resection. The stent 
group had more males (p = 0.020). There were no differences in age, histological type, 
operative procedure, intraoperative blood loss, pathological stage and perioperative 
complication. Thirty-day MACE occurred one patient in the no-stent group (0.4%). There 
was no patient of MACE in the stent group. Overall 3-year survival rates were 93.2% and 
92.3% in the no-stent group and the stent group, respectively (p = 0.545). In the stent 
group, all patients were managed by cardiologists to estimate the coronary risk and 
preoperatively discontinued aspirin and clopidogrel. Eight patients had taken cilostazol 
by three days before operation day, instead of aspirin. Conclusion: In this retrospective 
study, patients with coronary stent undergoing surgical therapy for NSCLC were not 
at risk of for perioperative MACE. Larger prospective studies are required to conclude 
the risk of in-stent thrombosis in patients with coronary stent required lung resection. 
Keywords: lung cancer, ischemic heart disease, coronary, stent
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P2.03-002 Surgery for Locally Advanced Lung Cancer after Induction 
Concurrent Chemo-Radiation Therapy Kazunori Okabe1, Hiroyuki Tao2, Toshiki 
Tanaka2, Tatsuro Hayashi2, Kouichi Yoshiyama2, Masashi Furukawa2, Kumiko Yoshida2, 
Hiroshi Ueoka2, Tsuneo Matsumoto2 1Thoracic Surgery, Yamaguchi Ube Medical Center, 
Ube/Japan, 2Yamaguchi Ube Medical Center, Ube/Japan
Background: The prognosis of locally advanced non-small-cell lung cancer is very 
poor. According to the American Cancer Society website, 5-year observed survival 
rate of Stage IIIA is 14%, and that of IIIB is 5%. A highly effective treatment strategy is 
needed to improve it. Surgery after induction concurrent chemo-radiation therapy for 
locally advanced non-small-cell lung cancer in our hospital over the last 8 years was 
retrospectively reviewed. Methods: Our standard induction chemo-radiation therapy 
consisted of cisplatin 40 mg/m2 and docetaxel hydrate 40 mg/m2 given on days 1, 8, 
29, and 36 plus concurrent irradiation of 46 Gy (2 Gy/day) to the tumor, hilum, and 
mediastinum. Surgery was performed between 4 and 6 weeks after completion of the 
radiotherapy. 37 consecutive patients with 21 cases of lobectomy and 16 cases of 
pneumonectomy were reviewed. The median age at surgery was 62 (41 – 74) years old. 
There were 6 females and 31 males. Adenocarcinoma was present in 18, squamous 
cell carcinoma in 13, large cell neuroendocrine carcinoma in 2, adenosquamous cell 
carcinoma in 1, giant cell carcinoma in 1, NSCLC in 1, and atypical carcinoid which was 
preoperatively diagnosed as squamous cell carcinoma in 1. The pretreatment stage was 
IIIB in 11, IIIA in 20, IIB in 3, IIA in 1, and IB in 2. The pretreatment very high tumor 
marker levels in blood were as follows: CEA 367, 337, 266, 180, 154, 151, 105 ng/
ml, CYFRA 47, 23, 20 ng/ml, and SCC 15, 10 ng/ml. Survival was calculated using 
the Kaplan-Meier method, and analyzed by the Log-Lank test. Results: Toxicity was 
manageable, and no serious complication was noted. All 37 cases were R0 resection. 
The median operation time of 21 cases of lobectomy and 16 cases of pneumonectomy 
were 5 hr 4 min and 4 hr 35 min, respectively. The median bleeding time of 21 cases of 
lobectomy and 16 cases of pneumonectomy were 200 ml and 175 ml, respectively. A 
pathologically complete response was obtained in 11 (30%) patients. The pathological 
stage was complete response in 11, IIIB in 3, IIIA in 6, IIB in 5, IIA in 4, IB in 2, and IA in 
6. All abnormal blood tumor marker levels went down to normal. At a median follow-up 
period of 3 years 4 months (5 months - 8 years 8 month), 5-year survival rate of all 37 
patients was 80%, and that of 21 lobectomy patients was 63%. Although 2 patients 
regimen was used. Conclusion: The results of our survey indicated that SABR for lung 
cancer is being used increasingly in Korea, and that the majority of radiation oncologists 
using this therapy have limited experience in its use. There was wide variation among 
institutions with regard to the technical protocols, which indicates that standardization is 
necessary prior to the initiation of further nationwide multi-center, randomized studies. 
Keywords: lung cancer, Stereotactic ablative radiotherapy, Patterns-of-care, Survey
POSTER SESSION/ TREATMENT OF LOCALIZED DISEASE – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.02-040 Clinical Outcome of Fiducial-Less CyberKnife Stereotactic Ablative 
Body Radiotherapy for Stage I Non-Small Cell Lung Cancer Inhye Jung, Si Yeol 
Song, Jinhong Jung, Byungchul Cho, Jungwon Kwak, Hyoung Uk Je, Wonsik Choi, Nuri 
H. Jung, Eun Kyung Cho Radiation Oncology, Asan Medical Center, Seoul/Korea
Background: CyberKnifeTM is a dedicated system for radiosurgery, with a capability 
of real-time tumor tracking; Synchrony® Respiratory tracking system. Xsight® lung 
tracking system with Synchrony® Respiratory tracking system make possible direct lung 
tumor tracking without fiducial markers. However, there was no establised indication 
of fiducial-less Cyberknife Radiosurgery (CKRS). So, to ascertain whether indication of 
fiducial-less CKRS can be extended or not , we had evaluated treatment outcome of 
fiducial-less CKRS using Xsight® lung tracking system at AMC and tested accuracy of 
CyberKnife Xsight® lung tracking system without fiducial marker by phantom experiment. 
Here are the results of fiducial-less CKRS using Xsight® lung tracking system for 
stage I NSCLC. Methods: From June 2011 to November 2013, 58 patients received 
Cyberknife Radiosurgery to lung at Asan medical center. We retrospectively reviewed 
records of 44 patients of stage I lung cancer exclude 14 patients (6 with Advanced 
NSCLC, 6 with Rec. lung cancer within 5 years, 2 with lung metastasis from other 
primary cancer). All analyses were performed using SPSS, version 21. Results: Median 
age at diagnosis was 75 years. Man was 37 (84.1%). Most of patients were inoperable 
primary lung cancer with poor PFT (mean FEV1: 63.0 % (range 24-138%), mean DLCo: 
50.8 % (range 43- 96 %)) or comorbidity or old age. Clinical stage was IA in 30 (68.2 
%), IB in 14 (31.8 %) patients. Mean tumor size was 2.6 cm. (1.2 cm-4.8cm, smaller 
than 2 cm was 12 (27.3%)) Radiation dose were 48 – 60 Gy per 3 - 4 fx. With median 
follow-up of 23.1 months, there were LR in 3 patients ( 1Y LRFSR: 94.9%, 2Y LRFSR: 
90.4% ) and DM in 13 patients (DM only, n= 7). All patients tolerated the radiosurgery 
well, only 2 patients had grade 3 dyspnea (1 of 2 suffered from ILD aggravation). Most 
common complication was RT-induced fibrosis & pneumonitis. Eight patients have 
died due to cancer progression.(1Y OSR: 86%, 2Y OSR: 80.3%) Conclusion: Fiducial-
less cyberknife radiosurgery showed good local tumor control and survival in 
medically inoperable stage I NSCLC, which was comparable with that of linac-based 
stereotactic body radiosurgery or CKRS with fiducial marker. Even though there were 
some limitations to apply Xsight ® lung tracking system without fiducial marker, but 
it could be used safely in relatively small tumor located in not recommended site. 
Keywords: lung cancer, cyberknife radiosurgery (CKRS), fiducial marker
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P2.02-041 Stereotactic Body Radiotherapy (SBRT) or Surgery in Early Stage 
(I & II) Non Small Cell Lung Cancer (NSCLC) Hirsh Koyi1, Gunnar Hillerdal2, 
Signe Friesland3, Karl Gustav Kölbeck2, Olov Andersson2, Per Bergman4, Lotta Orre4, 
Per Liv5, Eva Brandén1 1Department of Respiratory Medicine, Gävle Hospital, Gävle/
Sweden, 2Deartment of Respiratory Medicine, Karolinska University Hospital, Stockholm/
Sweden, 3Dept of Oncology, Karolinska University Hospital, Stockholm/Sweden, 4Deprtment 
of Thoracic Surgery, Karolinska University Hopsital, Stockholm/Sweden, 5Centre for 
Research and Development, Uppsala University/County Council of Gävleborg, Gävle/Sweden
Background: For patients with NSCLC clinical stages I and II disease with no medical 
contraindications, surgery is treatment of choice showing 5-year survival rates of about 
60–80% for stage I and 40–50% for stage II, respectively. However, for patients who 
are medically or technically unfit for surgery and for patients refusing surgery, SBRT) 
is an alternative with local control rates >90% at 3 years. Methods: Medical journals 
in all patients with stage I or II NSCLC who were underwent surgery and treated with 
SBRT at the Department of oncology or thoracic surgery, Karolinska University Hospital, 
Sweden from 2003 to 2009 were retrospectively reviewed. Results: In all, 186 (78.2%) 
underwent surgery and 52 (21.8%) were treated with SBRT. Mean, median and range 
of age among the surgery group was 69.29, 70.52 and 45-85 years, while in the SBRT 
group, these figures were 78.04, 80.03 and 61-89 years. The difference in age between 
the groups was significant (p=0.03).There were significantly more comorbidites in the 
SBRT group. Among the surgery group, 91.3% were smokers or former smokers. The 
figures for SBRT group was 94.1%. There was a significant difference in performance 
status (PS) between the groups (p<0.001) with with PS 0-1 in 98.9% in the surgery 
group compared with 69.2% in the SBRT group. There was a significant difference in 
lung function with mean FEV1 2.15 liter in surgery group compared to 1.45 in the SBRT 
group. The figures for mean FEV1% was 83% respectively 57.5%. The median overall 
survival was 97 months for the surgery group and 61.8 months for the SBRT group 
(p<0.001). Conclusion: The much worse median overall survival in the SBRT group can be 
explained by the selection of patients, but still, a survival of more than 5 years in an elderly 
group with so many comorbidities and a bad PS indicates that SBRT has been of value. 
Keywords: early stage, Surgery, stereotactic body radiotherapy
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Conclusion: Surgical resection of locally advanced lung cancer involving 
great vessels or heart showed an important role with affordable outcomes. 
Keywords: non-small cell lung cancer, locally advanced lung cancer, great vessel, 
Surgery
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P2.03-005 Surgical Resection after Definitive Chemoradiotherapy Laura 
Romero Vielva, José A. Maestre, Santiago Viteri, Maria Gonzalez Cao, Daniela Morales, 
Rafael Rosell Thoracic Surgery, Dr. Rosell Oncology Institute, Quiron Dexeus University 
Hospital, Barcelona/Spain
Background: Approximately, 30% of non-small-cell lung cancer (NSCLC) patients 
are diagnosed with locally advanced disease (IIIA-B). Treatment of these patients is 
controversial, with recommendations including definitive chemoradiotherapy, induction 
chemotherapy followed by surgery or induction chemoradiotherapy followed by surgical 
resection. Salvage surgery is defined as resection after high doses of radiation (>50Gy), 
planned as a primary curative intent, and usually more than 12 weeks after radiotherapy. 
Lung resection after high-dose radiotherapy has traditionally been avoided due to 
high rates of morbidity and mortality. Methods: The aim of this review is to analyze 
the outcome of patients referred to our institution for surgical resection after definitive 
chemoradiation. We reviewed 23 NSCLC patients who underwent surgical treatment 
after definitive chemoradiation between 2003 and 2014. Results: There were 15 
men and eight women with a median age of 54.64 years (range 33-69 years). Fifteen 
patients were diagnosed with adenocarcinoma (65.2%), and the most frequent cTNM 
stage was T3N2M0 (34.8%) followed by T2N2M0 and T4N2M0. The type of surgical 
resection included five lobectomies, six bilobectomies and 12 pneumonectomies (seven 
right and five left pneumonectomies). Four patients showed a complete pathological 
response after treatment (pT0N0M0 17.4%). There was only one postoperative death 
due to a bronchopleural fistula. All patients received platinum-based chemotherapy and 
definitive radiotherapy, with a median dose of 65Gy (range 45-70Gy). Median time from 
radiotherapy to surgical resection was 8.28 months (0.9-35.47 months). Six patients 
suffered recurrence after surgery, three to a distant site and three local recurrences. 
Median disease free survival for the group of patients who relapsed after surgery was 7.7 
months (3.9-17.5 months).
had recurrent tumors, 16 pneumonectomy patients were all alive without oxygen 
therapy. The prognosis of pneumonectomy was significantly better than lobectomy (p 
< 0.05). Conclusion: Surgery after induction concurrent chemo-radiation therapy for 
locally advanced non-small-cell lung cancer is feasible and highly effective. This treatment 
strategy has greatly improved the prognosis of locally advanced non-small-cell lung cancer. 
Keywords: lung cancer, multimodality treatment, surgery, induction chemo-radiation
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P2.03-003 Video Assisted Thoracoscopic Anatomical Resection for Non Small 
Cell Lung Cancer (NSCLC) Is Increasingly Safe Diego M. Avella1, Ujala Bokhary2, 
Brittany Lapin2, Ki W. Kim2, John Howington2 1Surgery, University of Chicago, Chicago/IL/
United States of America, 2Thoracic Surgery, Northshore University Healthsystem, Evanston/
IL/United States of America
Background: We analyze our institutional clinical data of patients that underwent 
video assisted thoracoscopic (VATS) anatomical lung resection for Non-small cell lung 
carcinoma (NSCLC). Methods: This is a retrospective analysis from January 1st of 2009 
to December 31st of 2013. We extracted the data through standard queries and by 
manual extraction from the Electronic Data Warehouse of the NorthShore University 
Health System. The patients were selected based on surgical description of anatomical 
resection defined as lobectomy, bilobectomy or segmentectomy for proven NSCLC. 
Patients with more than one procedure performed, diagnosis of carcinoid tumor or 
incomplete data were excluded. The variables evaluated included demographics, 
preoperative workup and clinical evaluation, pathology reports, intra-operative data and 
post-operative outcomes. Results: A total of 224 patients were included. The mean age 
at the time of diagnosis was 70.9 years, 63% were females, 81.5% were Caucasian 
with a 37 pack-year smoking history. The most common comorbidities encountered 
were hypertension, COPD and coronary artery disease. Sixty four percent of patients 
were diagnosed with pathologic stage I, 20.5% with stage II and 13.2% with stage III 
disease. Eighty nine percent of patients had FEV1 whereas DLCO was available in 
83.6% of the patients. VATS lobectomy was performed in 84% of the patients and VATS 
segmentectomy in 14% of the patients. The mean procedure time was 157 minutes, 
the median length of chest drainage with tube thoracostomy was 2 days. Twenty three 
percent of the patients required admission to the Intensive Care Unit (ICU) with a median 
length of stay in the ICU of 1.1 days. The length of stay in the hospital was 3 days. The 
overall rate of complications was 30% with atrial fibrillation (17.9%), prolonged air leak 
(>5 days) (9.8%) and atrial arrhythmia (3.8%) being the most frequent complications. 
Atrial Fibrillation had a postoperative onset in 50% of the patients whereas 50% of the 
patients with history of atrial fibrillation did not have atrial fibrillation perioperatively. 
The median follow-up was 26 months. There were only two in-hospital deaths (0.9%). 
Recurrences occurred in 18.2% of the patients with a mean time of 1.5(±1.0) years after 
surgery (local: 62.7%/1.7 years; distant: 37.3% 1.3 years). The overall mortality rate 
was 12% with 90 day mortality of only 1% (unrelated to the procedure). The 1 and 3-year 
overall survival was 96.6% and 93.8% for stage I, 93.7% and 73.9% for stage II and 97.1% 
and 52.2% for stage III. The 1 and 3-year disease-free survival was 96.3% and 89.8% for 
stage I, 93.4% and 68.8% for stage II and 96.7% and 52.7% for stage III. Conclusion: Our 
data suggests that over the last several years the rate of complications, need for ICU 
admission, length of hospital stay and overall mortality associated with the VATS 
anatomical resection for all stages of NSCLC has decreased in comparison with 
reported analysis from national data. In our series the 1-year and 3-years survival of 
VATS anatomical resection are similar to the reported data for open thoracotomy. 
Keywords: Long term survival NSCLC
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P2.03-004 Surgical Outcomes of Locally Advanced Non-Small Cell Lung 
Cancer Invading Great Vessels and Heart Byungjoon Park1, Hong Kwan Kim2, Yong 
Soo Choi3, Jae Ill Zo3, Young Mog Shim3, Jhingook Kim2 1Thoracic and Cardiovascular 
Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea, Seoul/Korea, 2Thoracic & Cardiovascular Surgery, Samsung Medical Center, Seoul/
Korea, 3Department Thoracic & Cardiovascular Surgery, Sungkyunkwan University School of 
Medicine, Samsung Medical Center, Seoul/Korea
Background: The role of surgery has been debated in locally advanced lung cancer, 
especially in cases with great vessel or cardiac invasion. The aim of this study was to 
evaluate predictive factors and clarify whether surgical resection is beneficial in lung 
cancer with great vessels and heart involvement. Methods: Patients who were surgically 
treated and pathologically diagnosed as T4N0/1 non-small cell lung cancer (NSCLC) with 
great vessel or heart invasion were enrolled and evaluated for surgical outcomes. 
Patients with other structural invasion to trachea, carina, esophagus, and vertebrae were 
excluded. Patients with previous history of other malignant disease or double primary 
cancer were also excluded. Results:We included 50 patients and mean age was 63 9 
years old. The structural involvement included main pulmonary artery (54%), pulmonary 
vein (38%), aorta (12%), superior vena cava (10%) and heart (10%). Complete resection 
was achieved in 45 patients (90%) and 5 patients underwent tumor resection under 
cardio-pulmonary bypass. In-hospital mortality was 12% and 5-year overall and disease-
free survival rate was 44% and 40%, respectively. Multivariate analysis demonstrated 
that right sided cancer (p = 0.023), grossly incomplete resection (R2; p = 0.032), 
pneumonectomy (p = 0.029), and large cell neuroendocrine cancer (p < 0.001) were 
significant unfavorable prognostic factors for overall survival. NSCLC with heart invasion 
showed worse 5-year overall survival than NSCLC with great vessel involvement (53% vs. 
20%), but did not show statistical significance (p = 0.143) due to small number of patients 
(Figure).
S568 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
morbidity and mortality. Patients with pre-existing medical comorbidities experience an 
increased frequency of post-operative complications. This is of increased importance in 
this patient population, compared to patients undergoing lesser anatomic resections, 
as it is associated with a decrease in overall survival. Methods: A retrospective review 
of all patients undergoing pneumonectomy for non small cell lung cancer from 2004 
to 2014 was undertaken. IRB approval was obtained. Demographics and pre-existing 
medical comorbidities, including the utilization of neoadjuvant therapy, were evaluated. 
Major morbidities occurring in the post-operative period were evaluated. Stage specific 
survival was evaluated and compared to published survival data following anatomic 
lobectomy. Results: From 2004 to 2014, 84 pneumonectomies were performed for 
resectable non small cell lung carcinoma. Complete STS data and staging information 
was available for 81 patients. Demographics and pre-existing medical comorbidities are 
reported in Table 1. Post-operative major morbidities are reported in Table 2. Mean stage 
specific survival was 32, 28 and 26 months for Stage I, II and III respectively.
 
Conclusion: Overall survival is decreased in patients undergoing pneumonectomy for 
NSCLC compared with patients undergoing lesser anatomic resections. Pre-existing 
medical conditions may contribute to the increased frequency of post-operative morbidity, 
resulting in decreased overall survival in these patients. Further evaluation of the severity 
of pre-existent medical comorbidities and the impact on post-operative morbidity on long 
term survival following pneumonectomy for non small cell lung carcinoma is warranted. 
Keywords: complications, Comorbidities, NSCLC, pneumonectomy
Median overall survival was 88.3 months (CI 95% 57.6–118.9), with 1, 3 and 5 year 
survival rates of 87%, 74.5% and 66.3% respectively.
 
Conclusion: Salvage surgery after definitive chemoradiotherapy is feasible, 
with low postoperative complication rates and encouraging survival. 
Keywords: salvage surgery, definitive chemoradiotherapy, outcome
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P2.03-006 Survival Rates after Surgery for Stage-3A (N2) Non-Small Cell Lung 
Cancer with Induction versus Adjuvant Chemotherapy+/-Radiation Therapy 
Eric M. Toloza1, Tawee Tanvetyanon1, Dung-Tsa Chen2, Alberto Chiappori1, Benjamin 
Creelan1, Thomas Dilling1, Jacques Fontaine1, Jhanelle Gray3, Eric Haura1, Mary Pinder-
Schenck1, Lary A. Robinson1, Craig Stevens1, Charles Williams1, Scott J. Antonia1 
1Thoracic Oncology, Moffitt Cancer Center, Tampa/FL/United States of 
America, 2Immunology, Moffitt Cancer Center, Tampa/FL/United States of America, 3Thoracic 
Oncology, Moffitt Cancer Center, Tampa/United States of America
Background: We compared survival of stage-3A non-small cell lung cancer (NSCLC) patients 
(pts) after surgery without or with induction versus adjuvant chemotherapy + radiation 
therapy (chemo+XRT). Methods: We retrospectively analyzed pts with clinical stage-
3A (cStage3A) NSCLC and who had surgery without or with induction chemo+XRT or 
who were pathologic stage-3A (pStage3A) and had adjuvant chemo+XRT. Kaplan-Meier 
survival curves were compared for these 3 groups, with significant differences at p<0.05 
by Chi Square test, with Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon), and 
Tarone-Ware pairwise comparisons. Results: From 1/1986 to 12/2010, there were 300 
NSCLC pts who were cStage3A at surgery. Another 52 pts were not cStage3A at surgery, 
but were then pStage3A. Of these 352 pts, 192 had curative resection, with 56 pts 
having surgery alone (SURG), 43 pts having surgery after induction therapy (NEOADJ), 
and 93 pts having surgery then adjuvant therapy (ADJ). Kaplan-Meier survival for SURG 
was worse than that for either NEOADJ (p=0.03) or ADJ (p=0.005), while NEOADJ and 
ADJ had similar survival (p=0.90). Median survival was 18+3 mon (95%CI: 12-24 mon) for 
SURG, 37+6 mon (95%CI: 25-50 mon) for NEOADJ, and 41+5 mon (95%CI: 31- 51 mon) 
for ADJ. Survival for NEOADJ chemo-alone pts was better than for SURG pts (p=0.031), 
while that of NEOADJ chemo+XRT pts was similar to SURG survival (p=0.488). Survival 
for ADJ chemo-alone pts was better than for SURG pts (p=0.007), while that of ADJ 
chemo+XRT pts was similar to SURG survival (p=0.163). Conclusion: Stage-3A 
NSCLC pts have improved survival with either induction or adjuvant therapy compared 
to surgery alone. Patients with induction or adjuvant chemo alone, but not those with 
induction or adjuvant chemo+XRT, have improved survival compared to surgery alone. 
Keywords: non-small cell lung cancer, stage-3A, induction therapy, Adjuvant therapy
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P2.03-007 Pneumonectomy for Non Small Cell Lung Carcinoma: Pre-Operative 
Comorbidities and Post-Operative Morbidity Affect Long Term Survival Mathew 
A. Vandeusen1, Lana Y. Schumacher2, Ali H. Zaidi2, Samantha A. Martin1, Emily J. 
Lloyd2, Athanasios Colonias2, Gene G. Finley3, Blair A. Jobe2, Rodney J. Landreneau2 
1Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh/PA/United States 
of America, 2Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh/United 
States of America, 3Medical Oncology and Esophageal and Lung Institute, Allegheny Health 
Network, Pittsburgh/PA/United States of America
Background: Pneumonectomy for NSCLC is commonly associated with significant 
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P2.03-010 Sleeve, Semsleeve Lobectomy, Segment Pyramidobasalectomy 
in Patients with Preoperative Contraindication for Pneumonectomy Fadil 
Gradica1, Lutfi Lisha1, Dhimitraq Argjiri2, Alma Cani3, Fahri Kokici3, Ylber Vata4, Leon 
Shpataraku4, Sali Gradica5, Perlat Kapisyzi2, Zef Perduka2 1Thorax Surgery, University 
Hospital”Shefqet Ndroqi”, Al/Albania, 2Pnemology, University Hospital”Shefqet Ndroqi”, 
Al/Albania, 3Anestesiology Reanimacion, University Hospital”Shefqet Ndroqi”, Al/
Albania, 4Visceral Surgery, University Hospital”Shefqet Ndroqi”, Al/Albania, 5Farmacy, 
Gradica Farmacy, Al/Albania
Background: Sleeve and semisleeve lobectomy and segment pyramydobasalectomy is 
a parenchyma-sparing procedure that is particularly valuable in patients with cardiac or 
pulmonary contraindications to pneumonectomy. The purpose of this study is to report 
our experience with sleeve lobectomy for bronchogenic cancer and carcinoid , and 
to investigate factors associated with long-term survival. Methods: Between January 
2006 and Novembre 2014,19 patients were treated by saving lung parencima. Patients 
underwent sleeve lobectomy for non-small-cell lung cancer (n = 3) one patient underwent 
double sleeve lobectomy or carcinoid tumor (n = 15), including 5 patients underwent 
sleeve lobectomy (atipic carcinoid) and 10 patients underwent semisleeve lobectomy 
(tipic carcinois) with a preoperative contraindication to pneumonectomy. Mean age was 
52 ± 14 years (range, 19 to 79 years). Vascular sleeve resection was performed in 1 
patient and segmentbasalectomy on the right lung. Results: Major bronchial anastomotic 
complications occurred in 2 (13%) patient: One was fatal postoperatively(double sleeve 
bronchial and vasculare) two weeks after intervent ,because was massive hemoptisia , 
and one after pyramidbazalectomy 6-th day after intervent because nosocomial difusse 
pneumonia in the rest lung(shock septic). In the non-small-cell lung cancer group, operative 
mortality was 13% (2 of 15), and overall 5-year and 10-year survival rates were 60% . 
By multivariate analysis, two factors significantly and independently influenced survival: 
nodal status (N0 or N1 versus N2; p = 0.01) and microscopic invasion of the bronchial 
stump (p = 0.02). In the carcinoid tumor group, there were no operative deaths, and overall 
5-year and 10-year survival rates were 100% and 95%, respectively. Conclusion: Sleeve 
lobectomy achieves local tumor control and is associated with low mortality and 
bronchial anastomotic complication rates. Long-term survival is excellent for carcinoid 
tumors. For patients with non-small-cell lung cancer, N2 disease or incomplete 
resection is associated with a worse prognosis; outcome is not affected by presence 
of a preoperative contraindication to pneumonectomy.Sleeve lobectomy facilitated 
the maintenance of residual lung function without serious perioperative complications. 
This finding suggests that patients with direct tumor invasion to the bronchus might 
be good candidates for a sleeve lobectomy, but not those with extra-nodal invasion. 
Keywords: sleeve lobectomy ,semisleve,carcinoid ,pyramidbasal segmentectomy
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P2.03-011 A Phase II Trial of Concurrent Chemoradiation with Consolidation 
Pembrolizumab in Unresectable Stage III Non-Small Cell Lung Cancer 
Greg Durm, Nasser Hanna Simon Cancer Center, Indiana University School of Medicine, 
Indianapolis/IN/United States of America
Background: Outcomes for patients with locally advanced non-small cell lung cancer 
(NSCLC) are poor, and the landscape of treatment in this disease has not changed 
considerably over the last several years. In those patients with unresectable stage 
IIIA/IIIB tumors, concurrent chemoradiation has become the standard of care in fit 
patients, and no alternative approach including induction, consolidation, or maintenance 
chemotherapy, has been shown to improve overall survival (OS). New treatment 
paradigms are desperately needed in this setting. Pembrolizumab is a humanized 
monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on regulatory 
T-cells (T-reg) and inhibits its interaction with its ligands, PD-L1 and PD-L2. PD-1 exerts an 
inhibitory effect on T-regs, and blocking this pathway allows for enhanced T-reg activity 
and an improved anti-tumor immune response. In a phase I trial of previously treated 
NSCLC patients, Pembrolizumab was well tolerated and demonstrated a 21% response 
rate by RECIST criteria. Furthermore, preclinical data suggests that the combination of 
radiation therapy and immunotherapy may have additive or even synergistic effects. 
Based on these findings, we proposed a phase II trial of consolidation Pembrolizumab 
following concurrent chemoradiation for patients with inoperable or unresectable stage 
IIIA or IIIB NSCLC. Methods: This study is a multi-institutional phase II trial investigating 
the PD-1 inhibitor Pembrolizumab as consolidation therapy following initial concurrent 
chemoradiation in patients with unresectable or inoperable stage IIIA/IIIB NSCLC. 
Concurrent chemoradiation is defined as platinum-based chemotherapy (Cisplatin/
Etoposide or Carboplatin/Paclitaxel) that overlaps with radiotherapy (total dose of 
59.4-66Gy). Patients must demonstrate stable disease or disease response following 
chemoradiation and must have no evidence of metastatic disease. Patients who 
qualify will receive Pembrolizumab at a dose of 200mg IV every 3 weeks starting a 
minimum of 4 weeks and a maximum of 8 weeks after completion of chemoradiation. 
The primary endpoint will be time to distant metastatic disease, defined as disease 
recurrence outside of the radiated field. Secondary endpoints will include progression 
free survival (PFS), OS, and toxicity. An exploratory objective will involve assessing 
PD-L1 expression levels in the tumor samples of participating subjects and correlating 
that with time to metastatic disease, PFS, OS, and treatment toxicity. Approximately 93 
patients will be enrolled. The sample size was calculated based on the hypothesis that 
consolidation Pembrolizumab will improve time to metastatic disease to 18 months from 
a historical control of approximately 12 months with a power of 0.80 and a type I error of 
0.05. Results: Accrual for this trial has begun, and the first patient was enrolled in March 
2015. Conclusion: This study will determine whether immunotherapeutic consolidation 
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P2.03-008 Surgery for Primary Lung Tumors with Histology Other than Non-
Small Cell Lung Cancer: A Single Center Experience Durgatosh Pandey1, Bharat 
B. Khurse1, Rambha Pandey2, Sunil Kumar1, Karan Madan3, Randeep Guleria3 1Surgical 
Oncology, All India Institute of Medical Sciences, New Delhi/India, 2Radiation Oncology, All 
India Institute of Medical Sciences, New Delhi/India, 3Pulmonary Medicine, All India Institute 
of Medical Sciences, New Delhi/India
Background: Primary lung tumors with histology other than small cell and non-small 
cell carcinoma are uncommon, and generally have a better prognosis and differing 
criteria of resectability. We present our experience of surgery in such tumors over the 
last three years at a tertiary cancer center in north India. Methods: This is an analysis 
of a prospective database of patients with primary lung tumors undergoing surgery in 
a three-year period between May 2012 and April 2015 at the Department of Surgical 
Oncology, All India Institute of Medical Sciences, New Delhi. We included the group of 
patients with histology other than non-small cell lung cancer (NSCLC). Details concerning 
the clinical presentation, preoperative therapy, operative procedure, postoperative 
complications and outcome were retrieved from the database. Results: Between May 
2012 and April 2015, out of the 101 patients who underwent surgery for primary lung 
neoplasm, twenty eight (28) patients had histology other than NSCLC. There were 
19 males and 9 females, with a median age of 36 (range 6 to 64). They included 18 
patients with carcinoid tumor, 3 with mucoepidermoid tumor, 4 with adenoid cystic 
carcinomas, 2 with myofibroblastic tumor, and 1 with clear cell tumor. Four patients 
had been previously treated presumptively for pulmonary tuberculosis, and two had 
received chemotherapy elsewhere before presenting to us. Two patients had prior 
bronchoscopic debulking. The surgical procedures included lobectomy in 8, bilobectomy 
in 8, pneumonectomy in 10, and pneumonectomy with carinal resection in 2 patients. 
Bronchoplastic procedures or sleeve resections were performed in 5 patients. All these 
surgeries were performed using muscle-sparing thoracotomy approach, except in two 
patients who underwent left pneumonectomy with carinal resection and reconstruction 
using median sternotomy approach and cardiopulmonary bypass. Postoperative 
morbidity was observed in 5 patients (prolonged air leak in 2patients, postoperative lung 
collapse, pneumonia, and empyema in one patient each). There was one postoperative 
mortality; this patient had mucoepidermoid carcinoma of the left main bronchus for 
which he underwent left pneumonectomy with carinal resection under cardiopulmonary 
bypass through median sternotomy approach. He was re-explored for a pericardial 
bleed on the first postoperative day, subsequently developed postoperative pneumonia 
of the solitary lung, and succumbed on 9thpostoperative day. Although the follow-up 
period is short, there has been no recurrence so far; and all patients are surviving 
without evidence of disease, except the one patient who died due to postoperative 
complications. Conclusion: Patients with carcinoid tumor, minor salivary gland neoplasm, 
or other unusual histologies of the lung usually have a better prognosis than those with 
non-small cell carcinoma. Aggressive surgical approaches should be pursued in such 
tumors, even in face of advanced local disease that would preclude resection in NSCLC. 
Keywords: carcinoid tumor, minor salivary gland tumor, primary lung neoplasm, Surgery
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P2.03-009 Single Institutional Experience of the Surgical Treatment of Second 
Primary Lung Cancer Hisashi Saji, Hideki Marushima, Rie Tagaya, Hiroyuki Kimura, 
Noriaki Kurimoto, Haruhiko Nakamura Chest Surgery, St. Marianna University School of 
Medicine, Kanagawa/Japan
Background: Surgical strategies for second primary lung cancer is still a controversial 
issue. We sought to assess postoperative and survival outcome of surgical resection 
in the treatment of patients with a second primary lung cancer. Methods:From 
January 2010 to August 2014, 439 patients with lung cancer were underwent 
surgical resection at our institution. Among them, 18 (4.1%) patients with second 
primary lung cancer, classified by the criteria proposed by Martini and Melamed, 
were treated. We retrospectively reviewed these cases for assessment of treatment 
outcome. Results: There are 12 males and 6 females with mean (range) age of 72 (58-
85). We had 9 (50%) patients with a synchronous tumor and 9 (50%) with metachronous. 
Median interval time (range) between metachronous tumors was 42 months (1-194). 
These second primary located with 9 (50%) cases in right and 9 (50%) cases in left side. 
Mean (range) tumor size was 20 (7-45) mm with ground glass opacity in 9 (50%) cases. 
Histology was adenocarcinoma in 15 (83%), large cells in 2 (11%), and small cells in 1 
(6%). Pathological stage was IA in 11 (61%), IB in 4 (22%), and IIA in 3 (17%). Mean VC 
and FEV1.0 were 2.48L and 1.8L, respectively. As second treatment, we performed 3 
(17%) lobectomies, 4 (22%) segmentectomies and 11 (61%) wedge resections. Mean 
operation time and blood loss was 133 min and 47 ml, respectively. Major postoperative 
complications at second treatment were prolonged air leakage in 2 (11%) cases and 
interstitial pneumonitis in 1 (5%) case. Operative morbidity and mortality were 16% and 
5%, respectively. There years overall survival were 94% with 13 months of median follow 
up time. Loco-regional and distant recurrence were occurred in 2 (12%) and 1 (5%) cases, 
respectively. Conclusion: From our experience, surgical treatment of second primary 
lung cancer is feasible. Surgical strategies including lobectomy, segmentectomy, and 
wedge resection should be selected with considering in the balance with oncological and 
pulmonary functional status. Furthermore cases need to be collected for detail analysis. 
Keywords: Surgery, second primary lung cancer
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constitutes 80-85% of all lung cancers. One third of NSCLC is diagnosed at locally 
advanced. Stage III involves heterogeneous group of patients. Therefore, it is the group 
of patients with most controversial for treatment. Currently there is no standardized 
approach to defi nitive treatment. In this study, we aimed to determine the response 
to neoadjuvant chemotherapy in patients with stage III NSCLC who had received 
neoadjuvant therapy. We also aimed to determine the relationship with prognosis and 
treatment response of the expression of ERCC1 and RRM1. Methods: 27 pts with stage 
III NSCLC were included in this study who received neoadjuvant chemotherapy at the 
Dept of M. Oncology and had been operated by the at Baskent University 2003 and 
2013. Lung tissue biopsies were evaluated by IHC methods for ERCC1 protein expression 
in patients who received neoadjuvant cisplatin and for RRM1 protein expression in 
patients who received neoadjuvant gemcitabine. OS and DFS durations were calculated 
for patients who received neoadjuvant chemotherapy. In addition, the relationship 
between pathological response and survival of the expression of ERCC1 and of RRM1 
were evaluated. Results: One (3.7%) women and 26 (96.3%) male pts were enrolled in 
the study. Median age 59. 14 (51.9%) underwent lobectomy and 13 pts (48.1%) were 
performed pneumonectomy. According to the TNM staging system; 19 pts (70.4%) 
were at stage 3A and eight pts (29.6 %) were at stage 3B. All of the patients received 
neoadjuvant cisplatin-based chemotherapy. 15 patients (55.6%) were identifi ed of relapse 
during follow-up. The median f/u was 36 mos. In follow-up, 14 pts have died. The average 
DFS was 26.6 months. The average OS was 48 mos. From the perspective of stage 3A 
and 3B; DFS (p = 0.379) and OS (p = 0.69) did not differ signifi cantly in terms. 16 pts 
(59.3%) after receiving neoadjuvant chemotherapy was found viable tumor ratio equal 
and under 10% in the surgical pathology materials. 11 pts (40%) was found viable tumor 
above the rate of 10% . When considered from this point of view DFS and OS showed no 
difference. More patients survived in the group with low ERCC1 expression. Between pts 
with low ERCC1 expression and pts with high ERCC1 expression showed no difference in 
terms of survival . (both DFS and OS). Pts with high RRM1 expression showing resistance 
to gemcitabine and with low RRM1 expression had similar survival rates. Conclusion: In 
patients with stage III NSCLC who received neoadjuvant chemotherapy found longer OS 
and DFS durations than from literature. Published studies and the results of our study 
albeit small scale, suggests that in the near future especially for patients with stage IIIA 
and stage IIIB NSCLC will be suitable for neoadjuvant chemotherapy as standard approach 
applied. ERCC1 and RRM1 expressions that were predictive markers of response of the 
treatment for cisplatin and gemcitabine was not correlated to therapy and survival . This 
may be associated with less number of and is a lack of full-refractory patient population. 
Keywords: RRM1, neoadjuvant, locally advanced, ERCC1
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P2.03-015 A Phase II Trial of Individual Trimodality Treatment in Patients with 
Stage IIIA (N2) Non-Small Cell Lung Cancer: The ZTOG 1202 Study Yaping Xu, 
Qixun Chen, Xinmin Yu, Jinshi Liu, Qiang Zhao, Youhua Jiang, Xinming Zhou, Weimin Mao
Zhejiang Cancer Hospital, Zhejiang/China
Background: Currently, optimal management of clinical stage IIIA (N2) non-small cell 
lung cancer (NSCLC) is still controversial. We investigated the effi cacy and toxicity of 
individual trimodality treatment using concurrent chemoradiotherapy as a neoadjuvant 
treatment followed by surgery in patients with stage IIIA (N2) NSCLC. This study is 
registered with ClinicalTrials.gov, number NCT01926483). Methods: Patients with 
potentially resectable locally advanced stage IIIA (N2) NSCLC received surgery and 
individual concurrent induction chemotherapy Docetaxel/Cisplatin or Pemetrexed/
Cisplatin (Patients received individual chemotherapy regimens depending on the different 
pathological types: squamous cell carcinoma: Docetaxel 60mg/m2 d1, Cisplatines 
75mg/m2 d1, repeated every 3 weeks for 2 cycles; non-squamous cell carcinoma: 
Pemetrexed 500mg/m2 d1, Cisplatin 75mg/m2 d1, repeated every 3 weeks for 2 cycles.) 
plus radiotherapy (46 Gy/23 fractions, 5 days per week) (Fig.1). Primary endpoint was 
pathological complete remission rate in the mediastinal lymph nodes and we aimed at a 
rate >47%. Secondary endpoint was a near pathologic complete response (pnCR) (Near 
pCR: near pathological complete response means only original site exist a small amount 
of cancer cells, without lymph node metastasis) rate and we aimed for >33%.
Results: Twenty two patients were included in analyses (12 patients with squamous 
cell carcinoma treated with Docetaxel/Cisplatin, 10 patients with non-squamous cell 
carcinoma treated with Pemetrexed/Cisplatin ). Pathological complete remission rate 
in the mediastinal lymph nodes was achieved in 11 patients (50%) exceeded the goal 
per study design. The postinduction pathological fi ndings by T and N category were 
recorded. The categories were 3 T 0N0 (13.6% patients) and 6 Tnear 0N0 (27.3% patients). 
In our study, the prevalence of postoperative complications was low, which was probably 
with Pembrolizumab will increase the time to metastatic disease in patients with stage 
IIIA/IIIB NSCLC following concurrent chemoradiation. It will also answer questions about 
the safety and tolerability of this combination of therapies in this patient population. 
Keywords: Immunotherapy, PD-1 inhibitor, NSCLC, pembrolizumab
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P2.03-012 Neoadjuvant Chemoradiotherapy or Chemotherapy Followed by 
Surgery Is Superior to That Defi nitive Chemoradiation in Stage IIIA (N2) NSCLC
Xiao-Ling Xu1, Wei Chen2, Ya-Ping Xu2, Weimin Mao1 1Zhejiang Cancer Hospital, Hangzhou/
China, 2Zhejiang Cancer Research Institute, Hangzhou/China
Background: Whether neoadjuvant chemoradiotherapy or chemotherapysurgery 
followed by surgery is superior to that followed by defi nitive radiotherapy in Stage IIIA 
(N2) NSCLC remains controversial. Methods: A literature search was performed in 
the Pubmed, Embase, Medline database (last search updated in March 2015) and a 
systematic review and meta-analysis of available data was conducted. Results: A total 
of nine studies including fi ve randomized controlled trials and four retrospective studies 
were enrolled in this meta-analysis. A signifi cant homogeneity (χ2=49.62 ,p=0.000
，I2=81.9% ) between the four studies with a total of 11948 selected cases was detected 
between the nine studied investigated overall survival (OS), the random effects model 
was used to conduct meta-analysis. The combined hazard ratio (HR) of for was 0.65 
(95% confi dence interval [CI]: 0.60-0.71; p=0.000). Subgroup analysis was investigated 
according to study design and extent of resection. We observed a statistically 
signifi cantly better outcome after lobectomy (combined HR: 0.52; 95% CI: 0.47-0.58; 
p =0.000) than after pneumonectomy (combined HR: 0.82; 95% CI: 0.69–0.98; p=0. 
028). Unfortunately, there was no signifi cant difference in randomized controlled studies 
for the combined HR was 0.94 (95% CI: 0.81-1.09; p = 0. 440). Conclusion: Neoadjuvant 
chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by 
defi nitive radiotherapy, particularly in patients with lobectomy. Further study to investigate 
randomized trial be performed comparing chemoradiation followed by lobectomy 
vs. defi nitive chemoradiation in patients with stage IIIA disease is urgently needed. 
Keywords: NSCLC, N2-stage, therapy, surgery
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P2.03-013 A Phase II Study of S-1 and Thoracic Irradiation for Elderly Pts with 
Locally Advanced Non-Small Cell Lung Cancer: Okayama Lung Cancer Study 
Group Hiroshi Ueoka1, Katsuyuki Hotta2, Nagio Takigawa3, Tadashi Maeda1, Keisuke 
Aoe1, Kenichi Chikamori1, Daizo Kishino1, Naoyuki Nogami4, Shingo Harita5, Shinobu 
Hosokawa6, Kenichi Gemba7, Keiichi Fujiwara8, Yoshiro Fujiwara9, Masahiro Tabata2, 
Mitsune Tanimoto2, Katsuyuki Kiura2 1Medicine, National Hospital Organization, Yamaguchi-
Ube Medical Center, Ube, Yamaguchi Prefecture/Japan, 2Okayama University Hospital, 
Okayama/Japan, 3General Internal Medicine, Kawasaki Medical School, Okayama/Japan, 
4Pulmonary Medicine, National Hospital Organaization, Shikoku Cancer Center, Matsuyama/
Japan, 5Medicine, Chugoku Central Hospital, Fukuyama/Japan, 6Red Cross Okayama 
Hospital, Okayama/Japan, 7National Hospital Organaization, Fukuyama Medical Center, 
Fukuyama/Japan, 8National Hospital Organaization, Okayama Medical Center, Okayama/
Japan, 9Tsuyama Central Hospital, Tsuyama/Japan
Background: Although thoracic irradiation (TRT) is one of the standarad therapies in 
elderly pts with locally advanced non-small cell lung cancer (LA-NSCLC), its treatment 
outcome is still poor. We previously reported safety profi les of S-1, an oral fl uoropyrimidine 
possesing a radio-sensitizing effect, and concurrent TRT in such population [Lung 
Cancer 2011]. Here, we investigated the effi cacy and safety of S-1 with concurrent TRT 
for elderly pts with LA-NSCLC. Methods: Pts with stage III, aged >75 years and PS 
0-1, and without any prior chemotherapy were eligible for this study. Pts were treated 
with S-1 (40 mg/m2/dose b.i.d on days 1-14 and 29-42) and TRT (60 Gy/30 fr over 
6 weeks starting on day 1). Primary endpoint was response rate (RR), and required 
sample siza was 30 pts. Results: Between 2007 and 2012, 30 pts were enrolled (24 
men; median age, 79 years; PS 1, 15; IIIa, 20; Sq, 12). Median Charlson score was 1 
(range; 0-3). The proportion of actual dose schedule relative to the planned one of S-1 
and TRT was 95 and 98%, respectively. Partial response was observed in 19 pts (63%; 
95% confi dence interval: 45-82%), which did not meet the endpoint. At the time of the 
analysis, 24 (80%) of the 30 had experienced recurrences; 13 (43%) were locoregional, 
6(20%) distant, and 5 (17%) both locoregional and distant. At a median follow-up of 23.7 
months, median progression-free survival and MST were 13.0 months and 27.9 months, 
respectively. Toxicities were generally mild, including G3/4 neutropenia (17%), G3 febrile 
neutropenia (7%) and G3 pneumonitis (10%). No toxic deaths occurred. Conclusion: 
This study did not meet the primary endpoint. However, concurrent S-1 and TRT 
yielded favorable survival data. Also, it was well-tolerated in elderly pts with LA-NSCLC 
Keywords: locally advanced non-small cell lung cancer, Elderly patients, concurrent 
chemoradiotherapy, S-1
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P2.03-014 Correlation of Response and Prognostic Markers with Survival 
in Locally Advanced NSCLC Patients Who Have Treated with Neoadjuvant 
Chemotherapy Ozden Altundag1, Nadire Kucukoztas2, Samed Rahatli1, Gul 
Sema Yildiran Keskin1, Arzu Oguz1 1Medical Oncology, Baskent University, Ankara/
Turkey, 2Medical Oncology, Izzet Baysal University, Bolu/Turkey
Background: Lung cancer is the most common cause of death from cancer.. NSCLC 
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P2.03-017 Pre-Operative Chemotherapy Followed by Surgery for N2 Non-Small 
Cell Lung Cancer: A 15-Year Experience Jonathan D. Spicer1, Jitesh Shewale1, 
Arlene M. Correa1, John V. Heymach2, Mara B. Antonoff1, Wayne Hofstetter1, Reza 
Mehran1, Jack Roth1, David Rice1, Boris Sepesi1, Ara A. Vaporciyan1, William William2, 
Garrett Walsh1, Stephen Swisher1 1Thoracic and Cardiovascular Surgery, MD Anderson 
Cancer Center, Houston/TX/United States of America, 2Medical Oncology, MD Anderson 
Cancer Center, Houston/United States of America
Background: The ideal approach to patients with N2 non-small cell lung cancer (NSCLC) 
remains controversial. While pathological confirmation of nodal status is advocated, 
in clinical practice patients with suspicious radiographic evidence of N2 disease are 
frequently assigned to pre-operative therapy without pathological confirmation. Herein, 
we review our experience with pre-operative chemotherapy followed by surgery in 
patients with N2 NSCLC and compare outcomes of biopsy proven N2 disease and those 
patients who were diagnosed based on PET/CT alone. Methods: A prospectively entered 
institutional database was accessed to identify all patients with N2 NSCLC treated by 
pre-operative chemotherapy followed by surgery from 1999 to 2014. Data were verified 
by chart review. Patients without biopsy or PET-based evidence of N2 disease were 
excluded. Results: We identified 113 patients of whom 57 had biopsy proof of cN2 
and 56 were cN2 based on PET-positivity. See Table 1 for patient demographic and 
clinico-pathologic variables. Median survival for the cohort was 53.3 months and there 
was only 1 (0.88%) peri-operative death at 90 days. Three and 5-year survival rates 
were 63.8% and 39.7%, respectively. Locoregional recurrences occurred in 16.8% of 
patients. Induction chemotherapy resulted in a significant PET response (SUV reduction 
> 6) in 38.5% of cases (15/39) where pre- and post-treatment imaging was available. 
Only 8.77% of patients remained pN2 after pre-operative chemotherapy in those patients 
who had pre-treatment pathological confirmation. No survival differences were noted 
between patients with biopsy proven N2 and those with PET-positive N2 nodes (Figure 1).
Demographic and clinico-pathologic variables.
Variables
Biopsy 
proven 
N2(N=57)
PET positive 
N2(N=56) P value
Totalco-
hort(N=113)
Median age 
(range) 64(38-80) 62(43-77) 0.763 63(38-80)
Male gender 25(46.3) 28(54.90) 0.378 53(50.48)
Mean FEV1 
(%pred) 85.78 86.54 0.798 86.16
Mean DLCO 
(%pred) 81.89 82.28 0.916 82.08
Type of surgery 0.743
Wedge/Segmen-
tectomy 3(5.26) 4(7.14) 7(6.19)
Lobectomy 48(84.21) 44(78.57) 92(81.42)
Pneumonectomy 6(10.53) 8(14.29) 14(12.39)
Post-operative 
treatment 0.094
None 24(42.11) 27(48.21) 51(45.13)
Chemo 1(1.75) 15(26.79) 6(5.31)
Radiation 6(5.31) 9(16.07) 41(36.28)
Chemoradiation 6(10.53) 9(16.07) 9(16.07)
Pathological N 
stage 0.090
N0 20(35.09) 22(39.29) 42(37.17)
N1 32(56.14) 22(39.29) 54(47.79)
N2 5(8.77) 12(21.43) 17(15.04)
 
due to the thoracoscopic approach that was employed. No treatment-related deaths 
were reported. Toxicities associated with induction chemoradiotherapy were similar 
in both regimens. Neutropenia and esophagitis were the main grade 3 or 4 toxicities 
(9 [40.9%] and 2 [9.1%], respectively). Other grade 2 or higher toxicities occurring in 
about 50% of patients included nausea, vomiting, and fatigue. Most side effects were 
grade 2 and well tolerated by supportive care. Conclusion: Individual concurrent 
chemoradiotherapy based on the pathological type as a neoadjuvant treatment (two 
cycles of Docetaxel/Cisplatin or Pemetrexed/Cisplatin with 46 Gy/23f of concurrent 
radiotherapy) followed by resection was safe and well tolerated in patients with stage 
IIIa (N2) NSCLC. It could improve the pathological complete remission rate in the 
mediastinal lymph nodes to the preset criterion of 50% and a pnCR rate of 40.9%. 
Keywords: N2 non-small-cell lung cancer, Mediastinal nodal involvement, induction 
chemoradiotherapy, Individual treatment
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P2.03-016 Comparing Outcomes of Neoadjuvant and Adjuvant Chemotherapy 
in Non-Small Cell Lung Cancer Sandhya Sharma1, Amir Bista1, Abhash Joshi2, Kevin 
Charles1, Bradley Lash3 1Internal Medicine, Guthrie-Robert Packer Hospital, Sayre/PA/
United States of America, 2Hospitalist, Guthrie-Robert Packer Hospital, Sayre/PA/United 
States of America, 3Hematology/Oncology, Guthrie-Robert Packer Hospital, Sayre/PA/United 
States of America
Background: Lung Cancer is the most common cancer in the US, and the leading cause 
of cancer deaths. Patient with Non-Small Cell lung cancer (NSCLC) are at substantial 
risk for recurrence and death even after complete surgical resection, and hence there is 
rationale for the use of chemotherapy and/or radiation therapy. Cisplatin based regimen 
is recommended. Adjuvant chemotherapy is most preferred treatment in patients with 
resectable disease. However, the role of neoadjuvant therapy is unclear. The purpose of 
this study was to compare the outcome of neoadjuvant and adjuvant chemotherapy in 
resectable NSCLC. The primary objective was to compare the observed and progression 
free survival. Secondary objective was to analyze the factors associated with better 
outcomes in both groups. Methods: This is a retrospective study conducted at a 
community based teaching hospital after IRB approval. A total of 117 patients diagnosed 
with NSCLC Stage 2 and 3, treated with either adjuvant or neoadjuvant chemotherapy, 
in addition to surgery, from 2001 to 2013 were included in the study. Chemotherapy 
consisted of cisplatin based regimen. The patients were followed to a maximum of 5 
years. Median follow up period was 31 months. Overall survival and progression free 
survival was calculated using Kaplan Meyer Curve and compared using Log rank 
test. Results: Median age of diagnosis was 66 years. 26.4% of the patients were in 
neoadjuvant group. Mean 5 year overall survival was found to be better in neoadjuvant 
group (80.3%) when compared to adjuvant group (54.7%) with p value of 0.314. Mean 5 
year progression free survival was better in neoadjuvant group (63.5%) when compared 
to adjuvant group (33.6%) with p value of 0.234. As the demographic profile for the 
patients were not comparable, five year overall survival after adjusting for age, sex and 
stage at diagnosis was compared using COX proportionate hazard model. This was found 
to be significantly better for neoadjuvant group compared to adjuvant group with HR of 
0.374, 95% CI of 0.152 to 0.919; p value of 0.032.
Conclusion: Overall survival and progression free survival was found to be 
better in neoadjuvant group, but it was not statistically significant. However, when 
adjusted for age, sex and stage at diagnosis survival was statistically significant 
in neoadjuvant group. This study suggests a trend in overall and progression free 
survival benefit in neoadjuvant group. Further large population randomized trials 
would be needed to confirm the survival benefit seen in this small retrospective study. 
Keywords: NSCLC, Neoadjuvant, Adjuvant, Overall Survival,
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once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 
fractions/week) followed by consolidation chemotherapy (IV cisplatin 100 mg/m2 once 
every 28 days and vinorelbine 25 mg/m2 once per week for 3 weeks out of 4) as first 
line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR 
status. Results: Due to a low recruitment rate in this study, the sample size (n=50) was 
not reached. Sixteen patients were included in four centers between 2004 and 2006, 
50% had adenocarcinoma and 75% were male. Molecular analysis (n=10) revealed that 
2, 2, and 4 patients had positive biopsies for pERK, pAKT, and EGFR, respectively. EGFR 
mutation status was not explored at this time. Four weeks after radiotherapy, 3 patients 
(19%) had a PR, 6 (38%) had a SD, and 9 had PD (56%).Median OS was 11 months 
and median TTP was 5 months. At the time of the last contact, 5 patients (31%) were 
still alive. Compliance was good and all patients completed the combination of gefitinib 
and radiotherapy. Main toxicities were gastrointestinal (81%), cutaneous (81%), General 
(56%), and respiratory (50%). Seven (47%) patients had at least one grade 3-4 related 
adverse event. Conclusion: Gefitinib (250 mg daily) in combination with RT is feasible but 
its impact on outcomes remains to be determined, especially in EGFR mutated patients. 
Keywords: Chemo-radiotherapy, NSCLC, gefitinib, phase II
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P2.03-020 Radical Lung Resection after Curative Chemoradiotherapy for 
Locally Advanced Lung Cancer Motohiro Yamashita1, Tsuyashi Ueno1, Hiroshi 
Suehisa1, Sihigeki Sawada1, Hiromoto Kitajima2, Daijiro Harada2, Toshiyuki Kohzuki2, 
Naoyuki Nogami2 1General Thoracic Surgery, Shikoku Cancer Center, Matsuyama/
Japan, 2Thoracic Oncology, Shikoku Cancer Center, Matsuyama/Japan
Background: The safety and perioperative complications of radical pulmonary resection 
after concurrent chemoradiotherapy (CRT) for locally advanced lung cancer (LALC) have 
been problematic. Methods: We retrospectively evaluated 16 patients who received CRT 
and radical surgical resection for locally advanced lung cancer from May 2008 to April 
2015. The treatment for LALC consisted of cisplatin and drugs (Docetaxel, Vinorelbine, 
or TS-1) with curative concurrent thoracic radiotherapy (60Gy.).
Results: 
 
The mean age at the surgery was 61 years (range 46- 71 years), one woman and 15 men. 
The mean interval from CRT to the surgery was 19 months (range 3-96 months). All 
patients except one case underwent complete surgical resection with mediastinal nodal 
dissection including lobectomy in 11 cases, lobectomy with bronchoplasty in 2 cases, 
pneumonectomy in, 2 cases, and segmentectomy in one case. The bronchial stump was 
covered with pericardial fat tissue or intercostal muscle. Histological type was 
adenocarcinoma in 9 cases, squamous carcinoma in 4 cases, large-cell-carcinoma in 2 
cases, and combined cell type small-cell carcinoma in one case. The mean operation 
time was 301 minutes (range 163-649 minutes), and mean blood loss was 842g (range 
90-6000g). There was no operative mortality and three cases post-operative morbidity 
such as arrhythmia in 2 cases, atelectasis in 2 cases, pneumonia and heart failure in 
each. There was no broncho-pleural fistula or bronchial dehiscence. The 3 and 5 years 
survival after surgical resection was 70 % and 70 % with 39 months median follow-up 
period. Conclusion: Radical pulmonary resection after curative concurrent 
chemoradiotherapy for LALC is feasible in careful patient selection, operative procedure 
and meticulous perioperative care. Keywords: Radical pulmonary resection, Salvage 
resection, Trimodality, Chemoradiotherapy
Conclusion: Pre-operative chemotherapy followed by surgery for N2 NSCLC in a well-
selected cohort results in good short and long-term outcomes. When pathological 
confirmation of N2 disease requires invasive staging, it may be acceptable to forgo 
such tests without compromising patient outcomes. Further prospective studies 
are needed to determine the ideal treatment regimen for these complex patients. 
Keywords: lung cancer, Surgery, chemotherapy, N2
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P2.03-018 Tolerability of Re-Irradiation for Locally Recurrent Lung Cancer 
Veronica Finnegan1, Tyler Underriner2, Paul Aridgides3, Seung Hahn3, Anna Shaprio1, 
Mary Kilpatrick1, Russell Kincaid1, Weidong Li1, Jeff A. Bogart4 1Radiation Oncology, Suny 
Upstate Medical University, Syracuse/NY/United States of America, 2Suny Upstate Medical 
University, Syracuse/United States of America, 3Radiation Oncology, Suny Upstate Medical 
University, Syracuse/United States of America, 4Radiation Oncology, Suny Upstate Medical 
Center, Syracuse/NY/United States of America
Background: Treatment of locally recurrent of lung cancer in the setting of prior 
radiotherapy is a therapeutic challenge, particularly when treating with curative 
intent. Methods: Retrospective review of lung cancer patients treated with 2+ 
courses of modern radiotherapy, which included image guidance (IGRT). Repeat 
irradiation was defined as an overlap of the gross tumor volume (GTV) in all treatment 
courses. Results: Thirty-three patients, 25 non-small cell and 8 small cell, received 
re-irradiation including one patient treated thrice. Thirteen patients initially had early 
disease (6 stage I, 7 II), and 20 patients had locally advanced or advanced disease. 
Median interval between treatments was 15 months (range 5 months – 13 years 3 
months). 16 patients received concurrent chemotherapy with both courses. 13 additional 
patients received chemotherapy concurrently during one of the courses of treatment. 
Seven patients were treated with stereotactic body radiation therapy for one of the 
courses. 24 patients were treated to the mediastinum twice and 9 additional patients 
received mediastinal treatment during one of the courses. Cumulative prescribed doses 
ranged up to 14,000 cGy and 18 patients received > 10,000 cGy. Maximum absolute 
dose to the lung was 14,000 cGy and to the mediastinum was 14,500 cGy. Ten patients 
remain alive with a median follow up of 20 months (range 9 months – 36 months). 
Treatment was generally well tolerated with esophagitis <= grade 3 common during 
the first or second course of therapy (16% and 24% respectively). Fatigue was noted 
in 18% of patients following the 2nd course of radiotherapy and only 3% during the 
initial course but this may be related to concurrent chemotherapy. One patient developed 
grade 4 dyspnea possibly related to repeat irradiation, though it was the 5th overall 
course of radiotherapy to the chest. Grade 5 toxicity was not observed and severe 
late effects were also not reported. Conclusion: Re-irradiation, even when concurrent 
chemotherapy is utilized, appears to be well tolerated with modern treatment planning 
including the use of IGRT. Further follow-up is necessary to better define local control, 
overall survival, and potential late toxicity. Additional studies are warranted to further 
investigate the long-term impact of patients treated more than once to the same region. 
Keywords: Retreatment, recurrent, Re-Irradiation
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P2.03-019 A Phase II Multicentre Study of Gefitinib in Combination with 
Irradiation Followed by Chemotherapy in Patients with Inoperable Stage III 
NSCLC Antonin Levy1, Etienne Bardet2, Xavier Artignan3, Pierre Verrelle4, Cecile Le 
Pechoux1 1Radiotherapy, Gustave Roussy, Villejuif/France, 2Centre René Gauducheau, 
Nantes/France, 3Chp St Gégoire, Saint-Grégoire/France, 4Centre Jean Perrin, Clermont-
Ferrand/France
Background: Gefitinib is an oral EGFR TKI approved in first-line treatment for 
metastatic NSCLC patients with activating mutations of EGFR that may act as a 
radiosensitizer. Methods: This phase II study evaluated the efficacy of gefitinib 250 mg 
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P2.03-022 Is the Radiosensitivity of the Tumour Related to That of the Lung? 
A CT-Based Response Analysis of Both Gilles Defraene, Dirk De Ruysscher 
Experimental Radiation Oncology, Ku Leuven, Leuven/Belgium
Background: Lung tissue damage after radiotherapy scored as density changes on CT 
scans proved to be a less multifactorial endpoint compared to dyspnea. Its continuous 
variation in the patient population is an indication that it could be an expression of patient-
specifi c radiosensitivity variation. This study linked patients’ lung damage measures 
defi ned on CT with tumour shrinkage. Methods: 32 stage I-IV lung cancer patients 
treated with chemoradiotherapy were studied. Prescribed dose was 66 Gy in fractions of 
2 Gy (concurrent) or 2.75 Gy (sequential). Image analysis of the radiation-induced lung 
damage was performed by comparison of the baseline planning CT0 and the non-rigidly 
registered follow-up CTfup. The median Hounsfi eld Unit increase (∆HU=HUfup-HU0) was 
calculated per dose bin of 5 Gy. The local dose-∆HU response curve was described using 
a sigmoidal model. This resulted in a sigmoidal parameter D50 (corresponding to 50% of 
the saturation level of ∆HU) for each patient, as an expression of the patient-specifi c lung 
tissue radiosensitivity. On both the CT0 and CTfup scans, an experienced radiation 
oncologist delineated the tumour gross target volume (GTV). Volumetric (volume and 
equivalent diameter) and intensity-based (median, maximal and minimal HU) features 
were collected for all GTVs. Results: The average timepoint of CTfup was 2.3 months after 
end of radiotherapy. For 25 patients the sigmoidal dose-∆HU fi ts were acceptable (sum 
of squared residuals below 10 HU per datapoint on average). 8 of these patients did not 
show any dose response in the analysed dose range. The 17 reacting patients showed 
large variation in D50 (median: 30.9 Gy, range: 15,8 Gy-70,0 Gy) and were further analysed. 
Their median GTV volumes were 25.9cc (range 1.3cc-275.9cc) and 5.2cc (range 0.4cc-
42.4cc) on CT0 and CTfup respectively. No correlation of tumour intensity-based features 
with lung D50 was observed. The relative diameter change of tumour however showed 
moderate correlation (R2=0.21) with lung radiosensitivity (see Figure). Patients with 
D50 below the population’s median showed a mean reduction of tumour diameter of 
46.8%, while this was 30.0% in the group with high D50 (p=0.03).
Conclusion: The patient-specifi c D50 for lung damage shows correlation with tumour 
shrinkage. This corroborates the hypothesis that it is a measure of intrinsic radiosensitivity. 
This study shows that imaging characteristics can provide independent and reproducible 
measures of radiosensitivity and can play a crucial role in defi ning patient-specifi c 
therapeutic ratio and thus treatment selection. Future radiogenomics studies could also 
benefi t from the input of imaging. 
Keywords: radiosensitivity, density change, CT, lung tissue damage
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P2.03-023 In-Field Nodal Relapse after Irradiation for Locally Advanced 
Non-Small-Cell Lung Cancer: Is There a Dose-Effect Relationship? Lisa Van Den 
Bosch1, Gilles Defraene1, Stéphanie Peeters2, Christophe Dooms3, Walter De Wever4, 
Christophe Deroose5, Dirk De Ruysscher1 1Radiation Oncology, University Hospitals Uz 
Leuven, Leuven/Belgium, 2Department of Radiation Oncology, Ku Leuven - University of 
Leuven, University Hospitals Leuven, Leuven/Belgium, 3Respiratory Oncology, University 
Hospital Ku Leuven, Leuven/Belgium, 4Radiology, University Hospitals Uz Leuven, Leuven/
Belgium, 5Department Imaging and Pathology, Nuclear Medicine and Molecular Imaging, Ku 
Leuven - University of Leuven, University Hospitals Leuven, Leuven/Belgium
Background: We investigated whether prescribed radiation dose is related to in-fi eld nodal 
relapse. Since in-fi eld nodal relapse is rare according to current literature, the infl uence of 
radiation dose on the incidence could be questioned. Methods:A retrospective analysis 
of prospective data was performed. Pathologic lymph nodes were registered based on 
RECIST 1.1 criteria. An in-fi eld nodal relapse is defi ned as an increase of at least 20% of 
the short axis diameter and a minimum absolute increase of 2 mm, taking as reference 
the short axis diameter measured 3 months (+/-2 months) after radiation therapy. Three 
subgroups were defi ned based on EQD2,T (group A: EQD2,T < 50 Gy, group B: EQD2,T 
50-55 Gy, group C: EQD2,T > 55 Gy). An actuarial Kaplan-Meier analysis was performed 
to evaluate the cumulative proportion of in-fi eld nodal relapse per subgroup. A Cox 
proportional hazards regression analysis was performed to take initial nodal diameter 
into account. Results: A total of 75 patients were reviewed. Sixty-two patients (83%) had 
stadium IIIA/IIIB disease. Twelve patients (16%) had stadium IV NSCLC who were treated 
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P2.03-021 Impact of Radiation on Recurrence Patterns and Survival for 
Patients Undergoing Lobectomy for Stage IIIA-pN2 Non-Small Cell Lung Cancer 
Chi-Fu J. Yang1, Syed M. Adil1, Robert R. Meyerhoff1, Kevin L. Anderson1, Sameer A. 
Hirji1, David Harpole1, Betty C. Tong1, Mark W. Onaitis1, Matthew G. Hartwig1, Thomas 
A. D’Amico1, Mark F. Berry2 1Surgery, Duke University, Durham/NC/United States of 
America, 2Surgery, Stanford University, Stanford/CA/United States of America
Background: There is controversy regarding the optimal multimodality treatment 
strategy for stage IIIA-pN2 non-small cell lung cancer (NSCLC). This study evaluated 
the impact of induction and adjuvant radiation on locoregional and distant recurrence 
and survival when induction chemotherapy and surgery is used. Methods: Cancer 
recurrence and survival of 113 consecutive patients who were treated with lobectomy 
after induction chemotherapy ± radiation for pathologically staged IIIA-N2 NSCLC 
between 1995 and 2012 at a single institution were evaluated using Kaplan-Meier, 
logistic regression, and Cox proportional hazard analysis. Results: Induction radiation 
was used in 58 (51%) patients and adjuvant radiation was used in 29 (26%) patients 
(Table 1). For the entire cohort (n=113), median survival was 30.1 months (95% CI, 22.0 
to 56.4). Five-year overall and recurrence-free survivals were 39.0% (95% CI, 29.1 to 
48.7) and 28.2% (95% CI, 18.0 to 39.2), respectively. Recurrent disease occurred in 62 
(55%) patients after a median (IQR) time of 11.5 months (4.3, 18.7) after surgery. First 
recurrence site was locoregional only (n=19), distant only (n=34), and locoregional and 
distant (n=9) (Table 1). In multivariable analysis, induction radiation was associated with 
decreased likelihood of developing locoregional recurrence (odds ratio (OR), 0.17; 95% 
CI: 0.04-0.90; p=0.04) but not improved survival (hazard ratio [HR], 1.47; 95% CI: 0.71-
3.03; p=0.04) while adjuvant radiation was not associated with decreased likelihood 
of developing locoregional recurrence (OR, 0.48; 95% CI: 0.07-3.37; p=0.46) but was 
associated with improved survival (HR, 0.20; 95% CI: 0.04-0.91; p=0.04) (Table 2).
  
Conclusion: A signifi cant number of recurrences in stage IIIA-pN2 NSCLC patients who 
undergo induction therapy followed by lobectomy are locoregional recurrences. Use of 
radiation was associated with improved local control only in the induction setting and 
may be optimal in terms of survival when given in the adjuvant rather than induction 
setting.
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Histology was adenocarcinoma in 66%. Clinical N stage was N0 (51%), N1 (4%), or N2 
(45%). Baseline positron emission tomography staging was performed in 91%. Pre-
operative chemotherapy was administered to 21%. Surgery was pneumonectomy in 
16%. Median (range) number of positive pN2 nodes was 1 (0-15). Seven patients with 
biopsy-proven cN2 had negative pN2 nodes after induction chemotherapy. Extranodal 
extension occurred in 9%. Surgical margins were positive in 4%. Chemotherapy 
(preoperative and/or postoperative) was administered to 83%. PORT was administered 
to 41 patients (54%) with a median (range) dose of 50 (41.4 – 60) Gy. Factors associated 
with increased likelihood of receiving PORT were increasing age (p=0.006) and no 
receipt of chemotherapy (p=0.0001). Median follow-up time for living patients was 4.5 
(range 0.2 – 15.4) years. For all patients, OS at 5 years was 65%. OS at 5 years for 
patients receiving PORT vs. no PORT was 71% vs. 58% (p=0.19). For all patients, LC 
at 5 years was 84%. LC at 5 years for patients receiving PORT vs. no PORT was 89% 
vs. 77% (p=0.16). Factors associated with decreased LC were male gender (p=0.004), 
pT3/4 (vs. pT1/2, p=0.008). For all patients, MFS at 5 years was 61%. MFS at 5 years 
for patients receiving PORT vs. no PORT was 62% vs. 61% (p=0.89). Conclusion: In this 
modern series of patients with surgically resected stage III (N2) NSCLC, patients who 
received PORT (vs. no PORT) had numerically higher rates of OS and LC, although these 
differences were not statistically significant, potentially related to limited statistical power. 
Keywords: Post-operative Radiation Therapy, non-small cell lung cancer, Adjuvant 
therapy
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P2.03-026 Assessing the Risk of Cardiac Toxicity with Esophageal-Sparing 
Intensity Modulated Radiotherapy for Locally Advanced Lung Cancers 
Katrina Woodford, Sashendra Senthi, Vanessa Panettieri, Jeremy Ruben William 
Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne/VIC/Australia
Background: Intensity-modulated radiotherapy (IMRT) can be used to reduce high doses 
to the esophagus for locally advanced non-small cell lung cancer (NSCLC), at the cost 
of increasing low to intermediate doses to adjacent healthy organs. Care is generally 
taken to ensure dose to healthy lung is minimized, resulting in IMRT not increasing lung 
toxicity. Such measures are not normally taken for the heart. Recently, a trial evaluating 
dose-escalated radiotherapy (RTOG 0617) found that overall survival was impacted by 
increased low (5Gy) and intermediate (30Gy) cardiac doses. We evaluated the impact 
of esophageal-sparing IMRT on cardiac doses and predicted toxicity compared to 
conventional radiotherapy (CRT). Methods: Ten consecutive patients with N2 Stage III 
NSCLC treated to 60Gy in 30 fractions, between February 2012 and September 2014, 
were evaluated. For each patient, CRT and esophageal-sparing IMRT plans were generated 
(Eclipse, Anisotropic Analytical Algorithm v11.0.31). For IMRT, treatments were planned 
such that no radiotherapy beams entered the contralateral lung or heart whenever 
possible. To compare CRT and IMRT plans, the dose delivered to more than 95% of the 
target (D95%) was compared. Doses to the esophagus, lung and heart were compared 
by determining the volume receiving X dose (VXGy) and the normal tissue complication 
probability (NTCP). Results: Seven patients had Stage IIIA disease, while three had Stage 
IIIB. The median PTV size was 435.5cc (range 175.0-1309.5). CRT treatment plans used 
3-4 fields. IMRT plans had the same (30%), one additional (50%) or two additional fields 
(20%). Dosimetric and NTCP results are summarized in the table below. IMRT resulted 
in satisfactory target coverage in 90% of patients. In the one patient with unsatisfactory 
coverage, the target was adjacent to the spinal cord and IMRT improved the D95% from 
42.6Gy to 54.3Gy. Esophageal-sparing was achieved in every patient at all dose levels. 
There were statistically significant reductions in V40Gy and V50Gy and the NTCP for grade 
2 or higher toxicity. IMRT decreased low and intermediate heart doses significantly 
compared to CRT. This translated into a significantly lower NTCP for cardiac mortality. 
The cost of this was increased low dose (5Gy) lung exposure, however this did not reach 
statistical significance, nor did it worsen NTCP for grade 2 pneumonitis.
CRT IMRT p-value
Mean Dose (Gy)
Target D95% 55.9 57.5 0.20
Esophagus V60Gy 3.5 0 0.17
Esophagus V50Gy 32 22.9 <0.01
Esophagus V40Gy 36.4 27.4 <0.01
Heart V30Gy 21.2 15.8 0.03
Heart V5Gy 45.7 39.1 0.01
Lung V20Gy 22 21.9 0.95
Lung V5Gy 45.5 48 0.28
NTCP (%)
Esophagus 15.4 9.9 <0.01
Heart 5.7 2.8 0.01
Lung 10.0 8.5 0.02
 
Conclusion: Esophageal-sparing IMRT for locally advanced NSCLC can 
additionally achieve cardiac-sparing and reduce the theoretical risk of 
with a radical oligometastatic approach. One patient (1%) had stadium IIB disease. 
Sixteen patients (21%) were treated with radiotherapy alone (38% group A, 25% group 
B, 38% group C). Sequential chemoradiotherapy was given in 47 patients (63%) (32% 
group A, 45% group B and 23% group C). Twelve patients (16%) received concurrent 
chemoradiotherapy (33% group A, 66% group B). Group A consisted of 25 patients 
(median age: 65 years (range 45-88), median follow-up: 6 months (range 1-54)). Thirty-
three patients were included in group B (median age: 59 years (range 45-80), median 
follow-up: 8 months (range 1-86)). Group C consisted of seventeen patients (median age: 
67 years (range 54-83), median follow-up: 9 months (range 2-45)). In all three groups 
median number of follow-up CT scans is 2 (range of 1-11 for group A and C, range of 1-13 
for group B). Any relapse occurred in fifty-eight patients (77,3%). Nineteen patients (33%) 
had a locoregional failure only. Twenty-two patients (38%) had distant failure only, either 
by progression of a known metastasis or occurrence of a new distant lesion. Seventeen 
patients (29%) had a locoregional and distant failure at once. A total of 142 lymph nodes 
were taken into account (55 (39%) in group A, 52 (37%) in group B and 35 (25%) in group 
C). The average baseline short axis diameter per group was 16,3 mm, 15,8 mm and 14,6 
mm for group A, B and C respectively. An actuarial Kaplan-Meier analysis performed 
on all lymph nodes (n=142) showed no significant difference between subgroups 
(p=0,24). A Cox proportional hazards regression analysis didn’t show a significant effect 
of baseline nodal diameter on in-field nodal relapse (p=0,82). Conclusion: Prescribed 
radiation dose is not related to the occurrence of in-field nodal relapse. There 
was no relation between initial lymph node diameter and in-field nodal relapse. 
Keywords: NSCLC, in-field nodal relapse
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P2.03-024 PORT-First Strategy After Surgery in Patients with IIIA-N2 Non-
Small Cell Lung Cancer Hyun Woo Lee1, O Kyu Noh2, Young-Taek Oh2, Jin-Hyuk Choi1, 
Mison Chun2, Hwanik Kim2, Jaesung Heo2, Mi Sun Ahn1, Oyeon Cho2 1Department of 
Hematology-Oncology, Ajou University School of Medicine, Suwon/Korea, 2Department of 
Radiation Oncology, Ajou University School of Medicine, Suwon/Korea
Background: Postoperative radiotherapy (PORT) and postoperative chemotherapy 
(POCT) can be administered as adjuvant therapies in patients with non-small cell lung 
cancer (NSCLC). The purpose of this study was to investigate the clinical outcomes of 
the patients treated with PORT-first and following with/without POCT in stage IIIA-N2 
NSCLC. Methods: From March 1997 to October 2012, 97 patients with stage IIIA-N2 
NSCLC who received PORT-first and following with/without POCT were analysed. PORT 
began within 4-6 weeks after surgical resection, and was delivered using conventional 
fractionation (1.8 – 2.0 Gy / day) with total dose of 50.4 – 66 Gy. According to the patient’s 
comorbidity, platinum-based POCT was administered 3 – 4 weeks after completion of 
PORT. We analysed the outcomes and clinical factors affecting survivals. Results: Of 97 
patients, 32 (33.0%) received POCT with median of 4 cycles (range, 2 – 6). The follow-up 
time ranged from 3 to 110 months (median, 24) and 5-year locoregional recurrence-
free survival (LRRFS), distant metastasis-free survival (DMFS) and overall survival 
(OS) were 50.6%, 42.2% and 36.6%. Five-year OS of patients treated with PORT and 
POCT was significantly higher than that of patients with PORT only (62.9% vs. 28.1%, 
p = 0.005), and no significant differences in LRRFS (58.9% vs. 47.5%, p = 0.935) and 
DMFS (52.3% vs. 38.8%, p = 0.541). In multivariate analysis, the significant prognostic 
factors affecting OS were the use of POCT (HR = 0.44, CI, 0.20 – 0.96, p = 0.039), 
type of surgery (pneumonectomy/lobectomy, HR = 1.83, CI, 1.01 – 3.35, p = 0.047) 
and the status of resection margin (positive/negative, HR = 3.20, CI, 1.14 – 8.99, p 
= 0.027). Conclusion: PORT-first strategy after surgery appears not to compromise 
the clinical outcomes in the treatment of stage IIIA-N2 NSCLC. The additional use 
of POCT showed improving effect on overall survival even in PORT-first setting. 
Keywords: adjuvant chemotherapy, sequence of therapy, non-small cell lung cancer, 
postoperative radiotherapy
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P2.03-025 Predictors of Relapse and Evaluation of Post-Operative 
Radiotherapy in Patients with Resected Stage III (N2) Non-Small Cell Lung 
Cancer William Breen1, Kenneth Merrell2, Aaron Mansfield3, Dennis Wigle4, Yolanda 
Garces2, Kenneth Olivier5, Christopher Hallemeier2 1Mayo Medical School, Mayo Clinic, 
Rochester/MN/United States of America, 2Radiation Oncology, Mayo Clinic, Rochester/
United States of America, 3Medical Oncology, Mayo Clinic, Rochester/United States of 
America, 4Thoracic Surgery, Mayo Clinic, Rochester/AL/United States of America, 5Radiation 
Oncology, Mayo Clinic, Rochester/MN/United States of America
Background: For patients with stage III (N2) NSCLC treated with surgical resection, 
chemotherapy improves survival, whereas the role of PORT is controversial. The purpose 
of this study was to evaluate risk factors for recurrence and the role of PORT in a modern 
series of patients with surgically resected stage III (N2) NSCLC. Methods: A retrospective 
review was performed of patients with Stage III (N2) NSCLC who underwent curative 
intent surgical resection at our institution between February 1999 and January 2012. 
Patients who received neoadjuvant RT were excluded. Chi-Square or Fisher’s exact tests 
assessed associations between patient/disease characteristics and receipt of PORT. 
Local control was defined as lack of disease recurrence within the radiation field for PORT 
patients, or in the mediastinum or resection area for chemotherapy patients. Overall 
survival (OS), local control (LC), and metastasis-free survival (MFS) were estimated from 
the date of surgery using the Kaplan Meier method, with between-group comparisons 
(PORT vs. no PORT) made with the Log-rank test. Univariate Cox proportional hazards 
models were used to assess association of patient/disease characteristics and 
outcomes. Results: A total of 76 patients were included. Median age was 62.5 years. 
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significantly higher in G2+ PNM patients following independent testing, particularly mean 
lung dose (MLD 23 vs. 9 Gy RBE EQD2α/β=3, p=0.03) and V20Gy (33% vs. 9%, p=0.03). 
Perfused lung dose was also higher in patients with G2+ PNM (DPERF70% 18 vs. 3 Gy, 
p=0.04). Using a cutoff value of MLD>20 Gy, 3/4 patients had G2+ PNM. The addition 
of mean perfused lung dose DPERF70%>17.5 Gy to MLD>20Gy improved specificity, with all 
3/3 patients who received high MLD and DPERF70% developing G2+ PNM (See Figure 1). 
Anatomic and perfused lung metrics were statistically correlated (Spearman R2=0.6, 
p=0.03). Figure 1. Mean dose to perfused lung vs. anatomic lung for patients with(black 
circle)/without(gray circle) G2+PNM. Adding perfused lung dose to anatomic lung dose 
increases specificity for pneumonitis. Radiotherapy plan is highlighted for one false 
positive case, in which dose to perfused lung is low(white arrow) while dose to anatomic 
lung is high.
 
 
Conclusion: Our data suggests that incorporating perfused lung metrics into radiotherapy 
planning objectives may improve our ability to predict and mitigate the risk of pneumonitis. 
Given the limited sample size, further investigation is warranted in a larger population. 
Keywords: Radiation pneumonitis, functional imaging, perfusion SPECT/CT
POSTER SESSION/ TREATMENT OF LOCOREGIONAL DISEASE – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.03-029 SBRT for Localized Central NSCLC Conventional Radiation 
Failures; Recurrent Laryngeal Nerve Paralysis Is a Novel Toxicity Ryan Malik1, 
Nima Aghdam1, Richa Bhasin1, Shaan Kataria1, Simeng Suy1, Sean Collins1, Eric 
Anderson2, Brian Collins1 1Department of Radiation Medicine, Georgetown University 
Hospital, Washington Dc/United States of America, 2Division of Pulmonary, Critical Care 
and Sleep Medicine, Georgetown University Hospital, Washington Dc/DC/United States of 
America
Background: To report local control, overall survival and toxicity following robotic 
SBRT for localized central NSCLC conventional radiation failures. Methods: Patients 
presenting with localized central recurrent NSCLC within previously treated radical 
conventional radiation fields (> 60 Gy) salvaged using robotic SBRT in 5 fractions were 
retrospectively reviewed. Recurrences were considered central if they involved the hilum 
or mediastinum. Results: Twenty patients were treated over a 10-year period and followed 
for a minimum of 2 years or until death. Eight presented with hilar recurrence and twelve 
recurrences involved the mediastinum. Seventeen patients had gold fiducials placed for 
tumor tracking via bronchoscopy; three mediastinal tumors were tracked using the spine 
as a reference structure. A cumulative dose of 25 to 45 Gy (median, 35 Gy) was delivered 
to the gross tumor volume (GTV) in 5 fractions. The median GTV was 84 cc (range, 6 to 
300). At median potential follow-up of 32 months, the 1-year Kaplan-Meier local control and 
overall survival estimates were poor at 34% and 40%. However, 1-year Kaplan-Meier local 
control and overall survival were improved at 67% and 67% when doses greater than 35 
Gy were delivered. Two patients with hilar tumors developed acute radiation pneumonitis 
(Grade III) following 35 Gy and 40 Gy. Two patients with recurrent superior mediastinal 
tumors unexpectedly developed permanent recurrent laryngeal nerve paralysis (Grade II) 
12 months following 40 Gy. One patient with recurrent hilar tumor experienced transient 
hemoptysis (Grade III) and benign pleural effusion (Grade II) 32 months following 45 
Gy. Conclusion: Robotic SBRT is a novel salvage treatment option for localized NSCLC 
central recurrence following radical conventional irradiation. Dose escalation beyond 
35 Gy resulted in improved local control and survival. However, doses > 35 Gy also 
resulted in significant toxicity including acute radiation pneumonitis, pleural effusion, 
hemoptysis and newly described permanent recurrent laryngeal nerve paralysis. 
Keywords: Treatment Toxicity, NSCLC, Stereotactic body radiation therapy, Re-
Irradiation
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P2.03-030 Adjuvant Radiation Therapy Improves Survival in Pathological 
Stage IIIA N2 Non-Small Cell Lung Cancer Patients Staged with PET Mo Mo Tin1, 
Catherine Kennedy2, Daniel Wong3, Regina Tse1, Michael Boyer4, Brian Mccaughan2 
1Radiation Oncology, Royal Prince Alfred Hospital, Camperdown/NSW/Australia, 2University 
of Sydney, Sydney/NSW/Australia, 3University of Malaya, Kuala Lumpur/Malaysia, 4Medical 
Oncology, Chris O’Brien Lifehouse, Camperdown/NSW/Australia
Background: Recent studies suggest a possible survival benefit associated with 
adjuvant radiation therapy (ART) following curative surgery for patients with pathological 
stage IIIA N2 (pN2) Non Small-cell Lung cancer (NSCLC) but there is no randomized 
cardiac death. With careful consideration this can be achieved without 
compromising target coverage or increasing the risk of radiation pneumonitis. 
Keywords: intensity modulated radiotherapy, Cardiac toxicity, non-small cell lung 
cancer, esophageal-sparing
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P2.03-027 Predicting the Effect of 7-Days-A-Week Radiotherapy for Locally 
Advanced Non-Small Cell Lung Cancer Based on Clinicopathological Features 
Rafal Suwinski, Katarzyna Galwas, Bogna Klusek, Monika Giglok, Urszula Dworzecka, 
Bozena Jochymek, Grzegorz Plewicki, Barbara Maslyk M. Sklodowska-Curie Memorial 
Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice/Poland
Background: Concurrent radiochemotherapy is currently considered as standard 
treatment for locally advanced non-small cell lung cancer. Some clinical studies 
suggest, however, that an acceptable treatment outcome can be also obtained 
with induction chemotherapy followed by accelerated radiotherapy. We explored 
this direction, considering that not all of the patients are candidates for concurrent 
treatment. The aim of the present report is to identify clinicopathological features that 
may help to predict the effect of combined induction chemotherapy and 7-days-a-week 
radiotherapy. Methods: For the purpose of the present report we selected 113 patients 
from the institutional database that included individuals treated within prospective 
studies on combined induction chemotherapy and 7-days-a-week radiotherapy . The 
patients had pathologically confirmed non-small cell lung cancer (74 squamous, 15 
adenocarcinoma, 24 NOS), stage IIIA N2 or IIIB. All patients had cisplatin based induction 
chemotherapy (1-6 courses, median 4) and curative radiotherapy (66-70 Gy, median 69.2 
Gy) in 1.8-2.0 Gy per fraction. Fifty seven patients (50.4%) were treated conventionally 
, 5- days-a- week (CF), while 56 (49.6%) had 7- days-a- week radiotherapy (CAIR). The 
median dose-intensity of radiotherapy in CF was 9.5 Gy per week compared to 13,4 Gy 
per week in CAIR. Several clinicopathological features were considered including age, 
sex, general performance status, gross tumor volume, pathology, Hb concentration, 
response to chemotherapy and SUV from PET/CT scans. Kaplan-Meier method was used 
to estimate the overall survival, Cox proportional hazard model was used to assess 
impact of fractionation in subgroups uniform with respect to the clinicopathological 
features. Results: After median follow-up of 2.8 years the actuarial 3-year survival was 
37% in CAIR, compared to 28% in CF, the difference was not statistically significant 
(HR=0.75, p=0.23). Patients with gross tumor volume smaller than the median of 
60 cm3 tended to benefit from CAIR (3 years survival of 49% vs 21% for CAIR and CF 
respectively, HR=0.54, p=0.11) unlike the patients with gross tumor volume above the 
median (3 years survival of 30% vs 28% for CAIR and CF respectively, HR=0.93, p=0.83). 
Likewise, patients with age of 60 years or less tended to have higher 3 years survival in 
CAIR vs. CF (42% vs. 8%, HR=0.60, p=0.15) unlike the patients with age over 60 years 
(3 year survival of 34% in both CAIR and CF, HR=1.01, p=0.97). Some other variables 
studied (pathology, Hb concentration, SUV) had strong prognostic, but not predictive 
significance (adenocarcinoma, high Hb concentration and low SUV were prognosticators 
of favorable overall survival). Conclusion: The present data suggest that an improvement 
in overall survival from 7-days-a-week radiotherapy as compared to conventionally 
fractionated treatment is relatively small in unselected group of patients with locally 
advanced non-small cell lung cancer treated in sequential fashion. Patients with small 
gross tumor volume and those with age of 60 years or less tended, however, to benefit 
from accelerated radiotherapy, unlike those with large tumor volume or with advanced 
age. Interestingly, the overall survival was satisfactory both in CAIR and CF, that might 
be attributed to relatively high total radiation doses given sequentially to chemotherapy. 
Keywords: Accelerated Radiotherapy, predictive factors, overall survival, sequential 
treatment
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P2.03-028 Functional Lung Imaging with Perfusion SPECT/CT Improves 
Prediction of Radiation Pneumonitis Jing Zeng1, Gurleen Dhami1, Shilpen A. Patel1, 
Paul E. Kinahan2, Robert S. Miyaoka2, Hubert J. Vesselle2, Ramesh Rengan1, Stephen 
R. Bowen1 1Radiation Oncology, University of Washington, Seattle/WA/United States of 
America, 2Radiology, University of Washington, Seattle/United States of America
Background: Current standard of care relies on CT-based lung dose-volume parameters 
to predict risk of pulmonary toxicity from radiotherapy. However, this approach remains 
imperfect as patients treated with radiotherapy for lung cancer still experience up to 
20% clinically significant pneumonitis despite efforts to avoid it. We propose to improve 
prediction accuracy for radiation pneumonitis through incorporation of functional lung 
radiation dose parameters defined on ventilation/perfusion SPECT/CT. Methods: Pre-
treatment 99mTc-MAA perfusion and 99mTc-DTPA ventilation SPECT/CT scans were co-
registered to planning CT scans in 12 patients who received thoracic radiotherapy: 11 with 
lung cancer and 1 with lung metastasis. Five patients were treated with IMRT/3DCRT, 3 
SBRT, and 4 proton RT. Two patients had clinical grade 2 and one patient had grade 
3 pneumonitis (G2+ PNM) defined by CTCAE v4. Total lung minus GTV (TL-GTV) mean 
dose, V5Gy, V20Gy, and V30Gy were calculated. Threshold percentages of maximum 
ventilation and perfusion (10-90%) within TL-GTV defined functional dose-volume regions, 
from which the mean dose (DPERF10-90%, DVENT10-90%) and volume fraction of TL-GTV (VPERF10-90%, 
VVENT10-90%) were extracted. Mann-Whitney tests were conducted between patients 
with and without G2+ PNM. Receiver operating characteristic (ROC) curves identified 
functional dose-volume thresholds that could predict for G2+ PNM status. Logistic 
regression of G2+ PNM incidence from anatomic and functional dose-volume parameters 
was modeled. Spearman rank correlation between predictive anatomic and functional 
dose-volume parameters was calculated. Results: Anatomic TL-GTV parameters were 
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P2.03-032 Prognostic Impact of EGFR and KRAS Mutations in Patients with 
Lung Adenocarcinoma Treated with Definitive Radiation Therapy Federica Oro1, 
Mark Sonnick1, Hongyun Wang1, Maureen Zakowski1, Abraham J. Wu1, Jamie E. Chaft1, 
Paul Paik1, Mazie Tsang1, Meier Hsu1, Kenneth Rosenzweig2, Zhigang Zhang1, Andreas 
Rimner1 1Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York/United 
States of America, 2Radiation Oncology, Mount Sinai, New York/NY/United States of America
Background: An association of EGFR and KRAS mutations with radiation sensitivity 
has been postulated in preclinical studies. Recent clinical studies reported longer 
local control and survival in patients (pts) harboring EGFR mutations treated with 
definitive radiotherapy (RT). Here, we sought to evaluate the prognostic impact of 
EGFR and KRAS mutations in 223 adenocarcinoma pts treated with definitive RT at our 
institution. Methods: Between 2004 and 2013, 466 inoperable pts with non-squamous 
lung cancer were treated with definitive RT ± chemotherapy. Mutational testing was 
performed in 223 pts. 44% were male, 56% female. 65% were former, 13% never, and 
22% current smokers. Clinical stage was II in 5%, IIIA in 37% and IIIB in 58%. Median size 
of tumor was 3.8 cm (range 0.5-12.2 cm). 60% received concurrent, 31% sequential 
chemo-RT and 9% RT alone. The median RT dose was 63Gy (range 50-80Gy). OS was 
estimated by the Kaplan-Meier method. Cumulative incidence functions were used 
to estimate local failure (LF) and distal failure (DF), using death without failure as a 
competing risk. Association of factors with OS was analyzed by Cox regression and 
association with LF and DF by competing risk regression. Results: EGFR status was wild-
type in 205 pts (92%) and mutated in 18 (8%). The most common EGFR mutations were 
exon 19 deletion (8 pts), followed by exon 21 L858R (7 pts), and exon 20 insertion (3 pts). 
KRAS status was wild- type in 142 pts (64%), mutated in 63 (28%), and not performed 
in 18 (8%). The most common mutations were G12C (13%), followed by G12V (5%) and 
G12A and G12D (3% each). With a median follow-up among survivors of 32.7 months 
(range 0.6-114), the median OS was 38 months for pts with EGFR mutation versus 26 
months for pts without (p=0.96); 21 months for patients with KRAS mutation versus 31 
months for pts without (p=0.24). 2-year LF was 37% and 46% for pts with and without 
EGFR mutation, and 48% and 46% for pts with and without KRAS mutation, respectively. 
2-year DF was 80% and 64% for pts with and without EGFR mutation, and 62% and 64% 
for pts with and without KRAS mutation, respectively. On univariate analysis, factors 
significantly associated with improved OS included KPS ≥ 80 (p=0.01), increasing RT 
dose (p=0.04) and use of concurrent chemotherapy compared to RT alone (p=0.001). 
Factors associated with higher risk of LF included stage IIIB (p=0.04) and sequential 
rather than concurrent chemotherapy (p=0.05). Factors associated with a higher risk 
of DM included stage IIIB (p=0.03) and lower RT dose (p=0.003). Association of EGFR 
and KRAS mutations did not reach statistical significance on univariate analysis, thus we 
did not further investigate their effects by multivariable analysis. Conclusion: Despite 
analyzing the largest patient population to date, we did not identify a significant 
prognostic impact by EGFR or KRAS mutational status. The lack of an observed 
association could be related to the low rate of EGFR mutations identified. RT dose and 
use of concurrent chemotherapy were significantly associated with overall survival. 
Keywords: EGFR mutation, kras mutation, lung adenocarcinoma, radiation therapy
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P2.03-033 18FDG-PET/CT Improves Lung Cancer Staging and Treatment 
Selection Accuracy Margarita Majem1, Nuria Dueñas2, Nuria Farre2, Cinta Pallarès2, 
Alejandro Fernandez2, Valle Camacho2, Alfons Torrego2, Elisabeth Martinez2, Anna 
Virgili2, Andrea Vethencourt2, Agustí Barnadas2 1Hopital de La Santa Creu I Sant Pau, 
Barcelona/Spain, 2Hospital de La Santa Creu I Sant Pau, Barcelona/Spain
Background: Integrated [18]F-fluorodeoxyglucose Positron-Emission Tomography 
- Computed tomography (18FDG-PET/CT) has emerged as the new standard in staging 
and treatment planning for patients with lung cancer, not only improving the diagnostic 
accuracy of mediastinal nodal involvement but also the detection of metastases. The aim 
of this study is to analyse this data in our centre and to evaluate the treatment variations 
derived from the results of this technique. Methods: We included patients with proven 
or suspected lung cancer diagnosed between September 2010 and February 2014. 
A computed tomography (CT) and 18FDG-PET/CT were performed in all patients, both 
explorations were evaluated separately, and a tumour-node-metastasis (TNM) stage and 
a specific treatment based on its results was established for each technique. We used 
the 7th TNM edition, and nodal stations were identified according to mapping system of 
the American Thoracic Society. Results: We included 249 patients, the median age was 
65 years (23-88), the 78.7% were males and the 21.2% were females. Non-small cell lung 
cancer (NSCLC) represented an 86.3% and small-cell-lung cancer (SCLC) a 8%. In 14 
patients (5.6%) no pathologic diagnosis was established. In 137 of 249 (55%) patients no 
change in staging between CT and 18FDG-PET/CT was observed: 65 (47.4%) were stage I, 
10 (7.2%) stage II, 22 (16%) stage IIIA, 22 (16%) stage IIIB and 18 (7.2%) stage IV. Compared 
with CT, 18FDG-PET/CT provided additional information in 112 of 249 patients (45 %): 36 
patients (14,4%) had downstaging, and a curative treatment was feasible in 13 patients 
(5.2%) (1 SCLC, 12 NSCLC). Seventy six patients (30.5%) had upstaging, and a palliative 
treatment was proposed to 49 of them (19.67%) (10 SCLC, 37 NSCLC, 2 without histology). 
**Of-line: occult metastases were detected in 49 of 249 patients, which represent a 
19.67%. Conclusion: The study confirms that in our institution, integrated 18FDG-PET/CT 
improves both lung cancer staging in all histologies and the treatment selection accuracy. 
Keywords: 18FDG-PET/CT, Staging, lung cancer
data. Lack of survival benefit observed in some of the studies could be due to some of 
these patients harbouring unexpected distant metastases. 18-FDG Positron Emission 
Tomography (PET) scanning has been shown to upstage 24% of patients with stage 
III NSCLC. We hypothesized that survival benefit may become apparent by excluding 
patients with unexpected distant metastases who would not benefit from ART with the 
use of PET staging. The objective of this study is to evaluate whether ART improves 
overall survival in pN2 NSCLC patients staged with PET. Methods: Patients with stage 
IIIA pN2 NSCLC who underwent pre-operative PET staging and curative surgery in a 
tertiary thoracic oncology facility between January 1995 and June 2014 were identified 
from a prospectively collected database. 388 patients fit the selection criteria of which 
219 patients (57%) received ART (≥ 45Gy). The impact of ART on survival was analysed 
using the Kaplan-Meier method. Results: Median follow up duration was 24 months. 
29% of the patients had pneumonectomies. 30 day post-operative mortality was 1.8%. 
Conformal radiotherapy was used in all patients. 195 patients (51%) received systemic 
chemotherapy (33% induction, 67% adjuvant). The use of chemotherapy was uncommon 
in the earlier part of the study. Median age was 65 years (range 29-85 years). The most 
common histopathology was adenocarcinoma (55%). Patient characteristics, type of 
resection, complete resection rate, and histopathology subtypes were similar between 
the group which received ART (219 patients) and the group which did not receive ART 
(162 patients) but more patients in the ART group received chemotherapy (60% vs.38%). 
ART group did significantly better in terms of median, 2-year and 5-year Overall Survival 
(OS) compared to No ART group (median survival 29 months vs. 20 months respectively, 
2-year OS 57% vs. 44% respectively, 5-year OS 30% vs.16% respectively, Hazard 
Ratio 0.62 95% Confidence Interval 0.49 – 0.79; p <0.0001) Conclusion: Adjuvant 
Radiation Therapy improved overall survival in pathological stage IIIA N2 NSCLC 
patients staged with PET in this series. This is consistent with the growing evidence 
supporting the use of ART in the modern era. Tri-modality therapy in a large 
number of patients may have contributed to the superior result in the ART group. 
Keywords: non small cell lung cancer, PET staging, Adjuvant Radiation Therapy,, 
Pathological Stage IIIA N2
POSTER SESSION/ TREATMENT OF LOCOREGIONAL DISEASE – NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.03-031 Subgroup Analysis of East Asian Patients in the Phase III PROCLAIM 
Trial Luhua (Jingbo) Wang1, Yi-Long Wu2, Shun Lu3, Lei Deng1, Myung-Ju Ahn4, Feng-
Ming Hsu5, Neill Iscoe6, Anwar Hossain7, Tarun Puri8, Pinghai Zhang9, Mauro Orlando10 
1Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 
Beijing/China, 2Guangdong Lung Cancer Institute, Guangdong General Hospital and 
Guangdong Academy of Medical Sciences, Guangzhou/China, 3Lung Cancer Center, 
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China, 4Samsung Medical 
Center, Gangnam-Gu, Seoul/Korea, Democratic People’s Republic of, 5Division of Radiation 
Oncology, Department of Oncology, National Taiwan University Hospital, Taipei City/
Taiwan, 6Eli Lilly and Company, Toronto/ON/Canada, 7Eli Lilly and Company, Indianapolis/
IN/United States of America, 8Eli Lilly and Company, Gurgaon/India, 9Eli Lilly and Company, 
Shanghai/China, 10Eli Lilly and Company, Buenos Aires/Argentina
Background: PROCLAIM is a phase III trial comparing overall survival (OS) in patients 
with stage III, unresectable, nonsquamous non-small cell lung cancer (NSCLC) receiving 
pemetrexed (Pem) plus cisplatin (Cis) and concurrent thoracic radiation therapy 
(TRT) for 3 cycles followed by 4 cycles of Pem consolidation (Pem+Cis arm) versus 
etoposide (Etop) plus Cis and concurrent TRT for 2 cycles followed by up to 2 cycles of 
consolidation with a platinum-based doublet of choice (Etop+Cis arm). Overall efficacy 
and safety results for the intent-to-treat (ITT) population (N=598) will be presented 
in a separate disclosure. Efficacy and safety results from an East Asia (EA) subgroup 
analysis are presented here. Methods: A subgroup analysis was performed using the EA 
randomized population (N=97), which consisted of all patients who were randomized to 
the study from China (n=61), Taiwan (n=25), and The Republic of Korea (n=11). OS and 
progression-free survival (PFS) were evaluated by the Kaplan-Meier method and hazard 
ratios (HRs) were calculated using a Cox regression model. The log-rank test was used 
to compare treatment arms. Objective response rates (ORRs) were compared using an 
unadjusted, normal distribution approximation for the difference in rates. ClinicalTrials.
gov number NCT00686959. Results: Baseline characteristics were balanced between 
treatment arms for EA patients. In the 97 randomized EA patients (n=44 in the Pem+Cis 
arm; n=53 in the Etop+Cis arm), median PFS was 10.0 months for the Pem+Cis arm 
and 7.6 months for the Etop+Cis arm (HR: 0.97, 95% confidence interval [CI]: 0.61–
1.54, p=0.890). The censoring rate was high for OS (Pem+Cis arm: 43.2%; Etop+Cis 
arm: 52.8%), and there was no significant difference in OS between the Pem+Cis arm 
and the Etop+Cis arm (HR: 1.23, 95% CI: 0.70–2.14, p=0.469). The interaction test 
for region and treatment effect for OS was not significant (p=0.374). The ORRs were 
47.7% (95% CI: 32.46–63.31) in the Pem+Cis arm and 34.0% (95% CI: 21.52–48.27) 
in the Etop+Cis arm. In the 90 treated EA patients (n=44 in the Pem+Cis arm; n=46 
in the Etop+Cis arm), the overall incidence of drug-related grade 3/4 treatment-
emergent adverse events (TEAEs) was significantly lower in the Pem+Cis arm versus 
the Etop+Cis arm (61.4% vs. 91.3%; p=0.001). All drug-related grade 3/4 TEAEs 
occurring in ≥5% of patients had a numerically lower incidence in the Pem+Cis arm than 
in the Etop+Cis arm except lymphopenia (17 [38.6%] vs. 17 [37.0%]). Conclusion: For 
EA patients with nonsquamous NSCLC, Pem+Cis did not improve OS, but did have a 
good safety profile and numerically improved PFS and ORR compared to Etop+Cis. 
Keywords: pemetrexed, nonsquamous non-small cell lung cancer, phase III, East Asian 
patients
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be incorporated into the staging system for N0-1 SqCC patients This information might 
prompt the design of clinical trials on additional therapy for these patients.
 
Keywords: Lymph node involvement, N2, N1, Squamous cell carcinoma
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P2.03-036 Primary Pulmonary Large Cell Carcinoma with 
Syncytiotrophoblastic Aspect: Report of a Case Luigi Ventura1, Letizia Gnetti2, 
Luigi Rolli1, Michela Solinas1, Valeria Balestra1, Livia Ruffini3, Paolo Carbognani1, Enrico 
Maria Silini2, Michele Rusca1, Luca Ampollini1 1Thoracic Surgery, University Hospital 
of Parma, Parma/Italy, 2Pathology, University of Parma, Parma/Italy, 3Nuclear Medicine, 
University Hospital of Parma, Parma/Italy
Background: To present the case of a primary large cell lung carcinoma with 
syncytiotrophoblastic aspect. Methods: A 54-year-old smoking man (60 pack/years), 
with no significant past medical history, presented for incidental radiological finding of a 
5cm mass in the right middle lobe with partial invasion of the lower lobe (Fig.1). A PET/
CT-scan showed a unique intense FDG-uptake of the pulmonary mass. A trans-thoracic 
fine-needle aspiration led to the diagnosis of non-small-cell lung cancer with sarcomatoid 
features. Preoperative cardiac and pulmonary function tests were normal.
 
Results: The patient underwent a right middle lobectomy and wedge resection of 
the lower lobe and radical lymphadenectomy through a posterolateral thoracotomy. 
The postoperative course was uneventful; the patient was discharged on the 
seventh postoperative day. After 52 months the patient is alive and disease-free. 
Macroscopically, the mass measured 5.5cm, had a greyish colour with lobulated 
margins. Microscopically, a poor differentiated tumor characterized by giant and medium 
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P2.03-034 Association of EGFR Mutation Status with Treatment Outcome 
in Stage III Non-small Cell Lung Cancer Patients Treated with Concurrent 
Chemoradiotherapy Shi Feng Nyaw1, Ka Chai Lee1, Willian Goggins2, Sing Hung Lo1, 
Wing Yan Tin1, Yuk Tung1 1Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong/
Hong Kong, 2Division of Biostatistics, the Jockey Club School of Public Health and Primary 
Care, The Chinese University of Hong Kong, Hong Kong/Hong Kong
Background: Epidermal growth factor receptor (EGFR) mutation is a biomarker 
predictive of favorable response to EGFR tyrosine kinase inhibitor in advanced non-small 
cell lung cancer (NSCLC). Its prognostic value in stage III NSCLC is unclear. The objective 
of this study is to analyze the association of EGFR mutation with clinical outcome in 
stage III NSCLC patients treated with concurrent chemoradiotherapy. Methods: 91 
consecutive patients with stage III non-small cell lung cancer who received concurrent 
chemoradiotherapy from January 2008 to January 2015 were retrospectively identified. 
EGFR mutation status was analyzed in 61 patients. Activated EGFR mutations were 
detected in 17 (28%) patients. Kaplan-Meier method was used to conduct the progression-
free survival (PFS) and overall survival (OS) analyses. Univariate and multivariable 
analyses were performed to investigate the effects of predictor variables including age, 
disease stage, performance status, histology, EGFR mutation status, radiation dose 
and surgery after neoadjuvant chemoradiotherapy. Results: 51 (56%) patients had 
stage IIIA and 40 (44%) patients had stage IIIB disease. All patients received at least 2 
cycles of platinum-based chemotherapy. Majority (77%) of patients received radiation 
dose of 60Gy (range 50-66Gy). Among the 17 patients with activated EGFR mutation, 
13(76%) of them had disease progression. 12 of them subsequently received EGFR TKI. 
The median progression-free survival (PFS) was 13.3 months. The median PFS was 
12.3 months in patients with mutated EGFR compared with 15 months in patients with 
wild-type EGFR (log-rank p=0.33). However, in the subgroup analysis of non-squamous 
histology, there was no significance difference in PFS between patients with or without 
activated EGFR mutation (Median PFS 12.3 vs. 12.4 months; log-rank p=0.96). 
In the multivariable analysis with the Cox proportional hazard model, significant 
predictors of longer PFS include squamous cell histology (HR 0.3; 95% C.I. 0.09, 
0.99; p=0.05) and surgery after chemoradiotherapy (HR 0.36; 95% C.I. 0.13, 0.95; 
p= 0.04). EGFR mutation status was not a significant predictor of PFS (P=0.45) 
The median overall survival (OS) was 28.6 months. The median OS in patients with 
mutated EGFR was 33 months while the median OS in patients with wild-type EGFR 
was 36.7 months (log-rank p=0.24). In the subgroup analysis of non-squamous 
histology, there was no significance difference in OS between patients with or 
without activated EGFR mutation (Median OS 33 vs. 31 months; log-rank p=0.65). 
In the multivariable analysis, significant predictors of longer OS include surgery after 
chemoradiotherapy (HR 0.16; 95% C.I. 0.04, 0.61; p=0.01), N-stage (p=0.04) and 
ECOG performance status (p=0.01). A trend of inferior OS was shown in patients 
with activated EGFR mutation compared with wild-type EGFR (HR 2.6; 95% C.I. 0.9, 
7.64; p=0.08). Conclusion: In patients with stage III non-small cell lung cancer who 
received concurrent chemoradiotherapy, EGFR mutation status does not affect the 
progression-free survival. A trend of shorter overall survival was shown in patients 
with activated EGFR mutation, which was not statistically significant. This could 
be due to higher risks of distant metastasis in patients with EGFR mutation. The 
role of adjuvant EGFR TKI after chemoradiotherapy should be further investigated. 
Keywords: Chemoradiotherapy, Prognosis, locally advanced non-small cell lung cancer, 
Epidermal growth factor receptor
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P2.03-035 Impact of Lymph Node Involvement on Survival in Patients with 
Completely Resected Pulmonary Squamous Cell Carcinoma Yujin Kudo1, 
Yoshihisa Shimada1, Ryosuke Amemiya1, Junichi Maeda1, Koichi Yoshida1, Yasufumi 
Kato1, Masaru Hagiwara1, Jun Matsubayashi2, Masatoshi Kakihana1, Naohiro Kajiwara1, 
Tatsuo Ohira1, Norihiko Ikeda1 1Thoracic Surgery, Tokyo Medical University, Tokyo/
Japan, 2Anatomic Pathology, Tokyo Medical University, Tokyo/Japan
Background: Lymph node involvement is an important prognostic factor in non-small 
cell lung cancer (NSCLC) patients. However, the prognostic impact varies among the 
histological types of NSCLC because of the lymph node spread pattern or other factors. 
We re-evaluated the impact of lymph node involvement and other clinicopathologic factors 
on survival in patients with pulmonary squamous cell carcinoma (SqCC) and identified 
high-risk patients who may benefit from additional therapy. Methods: Between 1990 
and 2010, 530 consecutive T1-4N0-2M0 SqCC patients underwent complete resection 
with systematic lymph node dissection at our hospital. We statistically analyzed the 
association between lymph node involvement and clinicopathologic factors, as well as 
clinical outcomes. Results: The 5-year overall survival (5y-OS) rates of the patients with 
stages I, II, and III were 66.5%, 57.6%, and 30.0%, respectively (stage I vs stage II, NS). 
Multivariate survival analysis showed that patients with N2 had significant associations 
with unfavorable prognosis (HR = 2.58, p < 0.0001). The 5y-OS rate for N2 tumors 
(32.1%) was significantly worse than those for N0 and N1 tumors (63.0% and 56.6%, 
respectively). In stages I and II, tumor size > 5 cm, pleural invasion (PL), and age over 
70 years were found to be significant independent prognostic factors by multivariate 
survival analysis, but lymph node status (N0 or N1) was not. Thus, tumors ≤ 5 cm without 
PL and tumors ≤ 3 cm with PL were classified as the new stage I (5y-OS, 69.8%) in the 
patients with N0 or N1, and tumors > 5 cm without PL and tumors > 3 cm with PL were 
classified as the new stage II (5y-OS, 45.7%). In contrast, tumors with N2 were classified 
as the new stage III (5y-OS, 32.1%). There was a statistically significant difference among 
these groups. Conclusion: N2 status was strongly associated with poor outcome in 
SqCC patients, but not N1 status. Our results indicate that lymph node status should not 
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Results:
Mean follow up duration was 41 months and 5 year survival rate was 50% for the study 
population. As postoperative stage, majority of the study group was IIIA (84%). Patients’ 
clinical stage and clinical T stage did not make difference in survival and recurrence. 
However clinical N0 group showed superior result in survival (p<0.001) and recurrence 
(p=0.46) even in same stage. In metastatic mediastinal LN extent analysis, extended N2 
disease made worse survival than regional N2 disease (p=0.04). Total number of 
metastatic LN did not make any difference in prognosis. Conclusion: Owing to 
heterogeneity, even in same stage group, pathologic N2 patients have showed different 
prognosis. In this study, we confirmed that clinical N0 was relatively good prognostic 
factor and extended N2 disease was bad prognostic factor. Deciding postoperative 
treatment plan, we should take account of these factors. Also, the survival difference 
between regional and extended N2 disease might be considered in staging revision of 
NSCLC.  
Keywords: lung cancer, mediastinal lymph node
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P2.03-038 Whole Tumor Perfusion CT in Patients with NSCLC Treated with 
Endostar Combined with Concurrent Radiotherapy Lei Shi1, Ming Chen2, Guo-Liang 
Shao1, Yu-Jin Xu2, Jing-Jing Sun1, Xu Wang1, Jie-Hui Huang1, Bo Liu3, Hong-Lian Ma2, Dan 
Long1 1Department of Radiology, Zhejiang Cancer Hospital, Hang Zhou/China, 2Department 
of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation 
Oncology, Hangzhou/China, 3Siemens Ltd.China, Healthcare Sector, Shanghai/China
Background: Endostar was reported as an anti-angiogenic agent, which could inhibit new 
vessel formation in tumor. This study is to investigate the NSCLC response to Endostar 
combined with concurrent radiotherapy using volumetric perfusion CT. Methods: This 
study was performed with the approval of the local Medical Ethics Committee, and all the 
enrolled patients gave their written informed consent before the inclusion in the study. 
Six patients with NSCLC were involved in the current study. The histological subtype for 
each patient was confirmed by biopsy. All patients were treated with Endostar combined 
with concurrent radiotherapy for 7 weeks. Whole tumor perfusion CT was performed for 
all patients before treatment (baseline) and 4weeks after combined therapy on a dual-
source CT. All images were reviewed in consensus by 2 radiologists. Blood flow (BF), 
blood volume (BV) and permeability (PMB) values for the whole tumor were calculated by 
an alternative deconvolution algorithm and then quantitatively assessed. These perfusion 
parameters before and after therapy were compared to investigate the therapy response 
of NSCLC. Results: Histology revealed adenocarcinoma (AC) in 3 patients and squamous 
cell carcinoma (SCC) in 3 patients. In SCC group, BF, BV and PMB at baseline were 
116.2±34.57, 11.53±3.14 and 21.87±4.86. Four weeks after treatment, those perfusion 
values were 50.59±16.09, 4.58±1.26 and 10.70±1.05 respectively, which showed 
obvious decreasing trends compared with baseline data. In AC group, BF, BV and PMB at 
baseline were 66.58±5.82, 6.66±0.14 and 16.50±1.29, respectively. The parameters 
were 49.94±5.07, 5.45±1.34 and 13.2±1.67 respectively, which did not show obvious 
changes compared with baseline data. However, the tendency of perfusion parameters 
might vary considerably. Of 3 patients with AC, 1 case also showed decreasing trend of 
BF, BV and PMB after treatment compared with baseline data. On the basis of RECIST 
criteria, all the four cases (3 cases with SCC and 1 case with AC) that perfusion parameters 
showed obvious decreasing trend were classified as having a partial response (PR) to 
therapy, the remaining 2 cases with AC as having stable disease. Conclusion: The AC 
and SCC might respond differently to treatment with endostar combined with concurrent 
pleomorphic cells sometimes with syncytial-trophoblastic features were observed 
(Fig.2a). Immunohistochemically, tumor cells were positive for beta-human-chorionic-
gonadotrophin (Beta-HCG) (Fig.2b), anti-endomisium antibody (EMA), placental alkaline 
phosphatase (PLAP) e cytokeratin 7 (CK 7); the cells resulted negative for octamer-
binding transcription factor-4 (OCT-4) (Fig.2c), spalt like transcription factor 4 (SALL4) 
(Fig.2d) and glypican-3.A subsequent genital examination and testicular ultrasonography 
excluded the presence of a primary gonadal choriocarcinoma. Beta-HCG serum levels 
were undetectable after surgery. Based on the above findings, a diagnosis of primary 
large cell lung carcinoma with syncytiotrophoblastic aspect was made. Final pathological 
stage was pT2aN0M0. No adjuvant therapy was proposed.
 
 
Conclusion: Large cell lung carcinoma with syncytiotrophoblastic aspect is an extremely 
rare finding. The prognosis is usually poor irrespective of the treatment; a few long-term 
survivors have been reported. Keywords: Surgery, large cell lung cancer
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P2.03-037 Prognostic Factors in Pathologic N2 Non-Small Cell Lung Cancer 
Hye-Seon Kim1, Sukki Cho2, Kwhanmien Kim2, Sanghoon Jheon2 1Department of Thoracic 
and Cardiovascular Surgery, Hanyang University Seoul Hospital, Seoul/Korea, 2Department 
of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital,Seoul 
National University College of Medicine, Seongnam-Si/Korea
Background: Mediastinal lymph node metastasis is one of the strong prognostic factors 
in non-small cell lung cancer (NSCLC). Pathologic N2 patients group is heterogenous 
group consists of stage IIIA to stage IV. Moreover owing to difficulty in preoperative 
prediction of N2 disease, pathologic N2 patients group shows more variable in 
clinical stage. We tried to figure out which factors make difference in prognosis of 
N2 patients. Methods: Between May 2003 and December 2013, total 1994 patients 
underwent pulmonary resection surgery due to lung cancer. Only pathologically proven 
N2 patients were included in the study. Among them, patients with small cell lung cancer, 
double primary lung cancer and other malignant disease were excluded. Therefore, 
195 N2 patients were analyzed for the study. The patients’ clinical information was 
collected from prospectively recorded database and analyzed retrospectively. Regional 
N2 disease was defined as upper mediastinal LN involvement for upper lobar disease 
and lower mediastinal LN involvement for lower lobar disease. Extended N2 disease was 
defined as involvement of non-regional N2 station. 
S579Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Table 1. EGFR mutational profile of non-small cell lung carcinoma patients.
Variable No. of patients (%)
Exon 18
G719X 2 (1.2%)
T725T polymorphism 6 (3.7%)
Exon 19 (deletion) 15 (9.2%)
Exon 20
Insertion 2 (1.2%)
Q787Q polymorphism 39 (23.9%)
Exon 21 (L858R) 19 (11.7%)
Complex mutation
Exon 18(T725T)+ Exon 19 (deletion) 1 (0.6%)
Exon 19 (deletion)+ Exon 20 (Q787Q) 4 (2.4 %)
Exon 21 (L858R)+ Exon 20 (Q787Q) 4 (2.4 %)
Table 2. Multivariate analyses of overall survival according to clinicopathologic 
variables
Variables Hazard ratio Pvalue
Age <60 vs. ≥60 1.836 0.021
Sex female vs. male 2.071 0.121
Histologic subtype Adenocarcinoma vs. Squa-mous cell carcinoma 0.754 0.275
pN stage 0 vs. 1-3 1.552 0.078
Adjuvant radiotherapy (-) vs. (+) 1.175 0.491
Smoking grade Non-smoker refer-ence
Ex-smoker 1.907 0.144
Light-smoker 1.378 0.452
Heavy-smoker 1.799 0.197
Q787Q EGFR polymorphism (-) vs. (+) 1.874 0.013
 
Conclusion: The Q787Q EGFR polymorphism enables the stratification of 
pulmonary squamous cell carcinoma patients, particularly among those in stage I/II. 
Keywords: Prognosis, Lung Squamous cell carcinoma, EGFR, polymorphism
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-003 Two Methods for Developing in Vitro Erlotinib-Resistant Cell Lines 
Lead to Distinct RTK Shifts, but Both Result in EMT Kristine R. Jakobsen1, Anne T. 
Madsen1, Christina Demuth1, Dianna Hussmann2, Peter Meldgaard3, Anders L. Nielsen2, 
Boe S. Sørensen1 1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus 
C/Denmark, 2Department of Biomedicine, Aarhus University, Aarhus/Denmark, 3Department 
of Oncology, Aarhus University Hospital, Aarhus/Denmark
Background: Several studies have investigated resistance mechanisms underlying 
acquired erlotinib-resistance in vitro. To mimic the in vivo distribution of the drugs, 
different approaches such as applying gradually increasing doses of erlotinib to the 
cells or exposing them to a high fixed concentration of the drug have been used. We 
demonstrate that two different approaches of developing erlotinib-resistant HCC827 
cells results in activation of two distinct RTK bypass-signalling pathways. However, 
despite these differences both cell lines undergo EMT. Our finding suggests that EMT is 
a common marker of erlotinib-resistance. Methods: Two HCC827 erlotinib-resistant cell 
lines were established using either gradually increasing doses of erlotinib (0.01 µM – 5 
µM) resulting in erlotinib-resistant HCC827ER cells. Alternatively a fixed concentration of 
5 µM generated HCC827HD with erlotinib resistance. Growth of the resistant cell lines 
was investigated using MTS assay in combination with erlotinib, linsitinib and crizotinib. 
Phospho-RTK arrays (R&D Systems), qPCR and immunofluorescence were used to 
characterize the cells. Results: Phospho-RTK array analysis revealed that the erlotinib-
resistant HCC827ER cells had an increased activation of MET, and copy number analysis 
demonstrated the activation to be caused by a MET amplification. Furthermore, HCC827ER 
showed growth inhibition when treated with the MET-inhibitor crizotinib. The other type of 
erlotinib-resistant cells, HCC827HD, had increased activation of IGF1R and also responded 
to the IGF1R-inhibitor linsitinib. However, a common feature is that both HCC827ER and 
HCC827HD gained EMT features. HCC827ER showed increased expression SLUG, 
SNAIL and ZEB1, whereas HCC827HD showed increased SLUG and TWIST expression. 
radiotherapy. The obvious decreasing trend of perfusion parameters after therapy 
might predict a better response to endostar combined with concurrent radiotherapy. 
Keywords: perfusion CT, Endostar, non-small cell lung cancer
SESSION: POSTER SESSION/ BIOLOGY, PATHOLOGY, 
AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-001 EGFR Activating and T790M Resistance Mutation in Plasma 
exoRNA and cfDNA, Detected with Single-Step Isolation Columns and Targeted 
Resequencing Daniel Enderle1, Kay Brinkmann1, Tina Koestler1, Alexandra Spiel1, Anne 
K. Krug1, Jennifer Emenegger1, Romy Mueller1, Stefan Bentink1, Johan Skog2, Mikkel 
Noerholm1, Vince O’Neill1 1Exosome Diagnostics Gmbh, Martinsried/Germany, 2Exosome 
Diagnostics Inc., Ma/MA/United States of America
Background: After initial responses to tyrosine kinase inhibitors (TKIs), NSCLC patients 
harboring EGFR activating mutations inevitably show progression, a consequence of 
acquired resistance (AR). Secondary mutations in the EGFR domains,e.g. the gatekeeper 
mutation T790M, are thought to play a role in clinical resistance of approximately half 
the patients that experience disease progression during treatment with TKIs, and novel 
therapeutic agents are in development to circumvent this resistance mechanism. Tissue 
based assays, requiring repeat biopsy, are fundamentally unattractive, and detection 
of AR mutations in circulation would be an appealing alternative. Here we present data 
demonstrating the feasibility of detection of activating and AR EGFR mutations with a 
targeted resequencing panel, using a combined single-step exosomal RNA (exoRNA) 
and cell-free DNA (cfDNA) isolation to maximize sensitivity. Methods: Plasma from 
more than 40 lung cancer patients was collected at the time of clinical resistance to 
EGFR TKI therapy. The plasma samples are complemented by EGFR-genotyping on 
time-matched tissue from a repeat biopsy. We applied our proprietary column-based 
method to co-isolate both exoRNA and cfDNA from patient plasma, and analyzed 
the mutations with a custom procedure for next generation sequencing (NGS). 
The targeted resequencing panel covers the most important mutation hotspots in 
NSCLC relevant genes including EGFR mutations on exon 19, 20 and 21. A custom 
library preparation method and bioinformatics pipeline is used to efficiently call rare 
mutations in a qualitative and quantitative manner. Results: Our data demonstrate the 
ability to detect low copy numbers of activating and AR mutations in plasma of lung 
cancer patients by combining the mutation signal from exoRNA and cfDNA and using 
a focused NGS gene panel. The mutation signal in plasma is highly concordant with 
data obtained from repeat biopsies, showing the feasibility of the approach. Moreover, 
EGFR mutations of patients with intrathoracic disease (M0/M1a) are readily detected 
in the combined exoRNA/cfDNA isolation, in contrast to methods relying only on the 
isolation of cfDNA. Conclusion: Detection of both activating and AR mutations to EGFR 
therapy in plasma is a feasible alternate to repeat biopsy and the combined isolation 
of exoRNA and cfDNA offers superior sensitivity. Especially in challenging cases, 
e.g. with intrathoracic disease, the advantage of combined plasma exoRNA/cfDNA 
isolation substantially improves the sensitivity over approaches that utilize only cfDNA. 
Keywords: exosomal RNA, cell-free DNA, next generation sequencing, T790M
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P2.04-002 Q787Q EGFR Polymorphism as a Prognostic Factor for Lung 
Squamous Cell Carcinoma Young Wha Koh1, Jae-Ho Han2, Changjin Kim3 
1Pathology, Ajou University School of Medicine, Suwon/Korea, 2Ajou University School 
of Medicine, Suwon/Korea, 3Pathology, College of Medicine, Soonchunhyang University, 
Chonan/Korea
Background: EGFR (epidermal growth factor receptor) mutations have been frequently 
reported in the early stages of non-small cell lung cancer (NSCLC) and have shown 
survival benefits in advanced lung adenocarcinoma. However, testing for EGFR mutations 
have rarely been recommended for lung squamous cell carcinoma patients. Previous 
studies have revealed that the Q787Q polymorphism in exon 20 of the EGFR gene is 
associated with a poor prognosis in patients treated with gefitinib (an EGFR tyrosine-
kinase inhibitor) and is frequently detected in non-adenocarcinoma lung cancer patients. 
There is no result for an association between Q787Q EGFR polymorphism and EGFR 
common mutations. The prognostic data of Q787Q EGFR polymorphism was limited to 
patients treated with gefitinib; therefore, prognostic information for patients without 
gefitinib treatment is also needed. Methods: To determine the presence of Q787Q 
polymorphism in patients with lung cancer, we performed direct sequencing analyses 
of four exons for 83 squamous cell carcinomas and 80 adenocarcinomas untreated with 
EGFR tyrosine-kinase inhibitors. Results: When complex mutations were excluded, the 
Q787Q EGFR polymorphism was more frequently detected in squamous cell carcinoma 
patients than adenocarcinoma patients (24% and 15.9%, respectively). The group of 
patients with Q787Q EGFR polymorphism included more males and heavy-smokers 
compared with other patient groups. The presence of the Q787Q EGFR polymorphism 
significantly and negatively affected the overall survival (OS) rate in patients with NSCLC 
(P = 0.024), particularly those with squamous cell carcinoma (P = 0.044). For stage I 
and II squamous cell carcinoma patients, those with the Q787Q EGFR polymorphism had 
lower OS rates than those with other mutations or those with a wild type phenotype (P = 
0.04).
S580 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
combination of BEV plus ERL demonstrated promising efficacy in the B901L xenograft 
model of EGFR Mut+ NSCLC. The observed continuous inhibition of ERK phosphorylation 
may contribute to the antitumor activity of BEV plus ERL treatment. Re-induction of 
VEGF and subsequent VEGF-dependent tumor growth, either directly or indirectly, was 
suggested as one of the major mechanism of acquired resistance to ERL leading to 
remarkably prolonged antitumor activity of BEV in combination with ERL in this model. 
These encouraging preclinical results warrant further investigation in a clinical setting. 
Keywords: NSCLC, bevacizumab, Erlotinib, VEGF
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-006 MiRNA Signature to Assess Sensitivity to FGFR Tyrosine Kinase 
Inhibitors Christopher J. Rivard1, Brad Rikke2, Murry Wynes3, Leslie Rozeboom2, Xian 
Lu4, Dexiang Gao4, Trista Hinz5, Lynn Heasley5, Paul A. Bunn, Jr2, Fred R. Hirsch2 
1Medical Oncology, University of Colorado Denver, Aurora/CO/United States of 
America, 2Medical Oncology, University of Colorado Denver, Aurora/United States of 
America, 3Iaslc, Aurora/CO/United States of America, 4Biostatistics and Informatics, 
University of Colorado School of Public Health, Denver/CO/United States of 
America, 5Craniofacial Biology, University of Colorado Denver, Aurora/CO/United States of 
America
Background: Increased signaling through the FGF/FGFR signaling pathway has been 
implicated as a driver in a number of different malignancies including lymphomas, 
prostate cancer, breast cancer, and lung cancer. This pathway also appears to play a 
role in conferring de novo and acquired resistance to cancers driven by EGFR mutations. 
Consequently, drugs that inhibit FGFRs are being investigated as potential therapeutics 
for cancer. Here we screened a large panel of miRNAs as potential predictors of sensitivity 
to FGFR tyrosine kinase inhibitors (TKIs). Methods: A panel of 377 miRNAs (Megaplex 
Card A, Life Technologies) was screened for expression level differences between four 
lung cancer cell lines that are sensitive (IC50< 50 nM) and four lines that are resistant 
(IC50 > 100 nM) to ponatinib (non-specific FGFR TKI) and AZD4547 (FGFR-specific TKI). 
Expression levels were assayed by RT-qPCR and analyzed using the Statistical Analysis of 
Microarrays (SAM) method. Thirty-nine miRNAs having an estimated false discover rate 
(FDR) of zero and large median fold differences (> 8) between the sensitive and resistant 
lines were selected for signature development. RT-qPCR assays were incorporated 
into a custom microfluidics card (Life Technologies), which was used to profile the 
original 8 cell lines and 10 additional sensitive lines and 16 additional resistant lines (34 
lines total). Logistic regression was then used to identify the best signature panel for 
distinguishing sensitive cell lines from resistant. Results: Univariate analysis indicated 
three miRNAs (let-7c, miR-338, and miR-218) that differed between the sensitive and 
resistant lines at p < .05. The best signature panel consisted of let-7c, miR-200a and 
miR-200b, which gave an area under the receiver operator characteristic (AUROC) curve 
of 0.90 (95% CI = 0.8 to 1). This performance was nearly as good as using FGFR1 
mRNA alone (AUROC = 0.94). The predominant miRNA in our 3-miRNA signature was 
let-7c, which also exhibited a suggestive additive effect to using FGFR1 as a biomarker 
(p = 0.09). We also tested whether cell lines with high sensitivity to ponatinib can be 
made resistant by reducing the high level of let-7c in these lines. We have found that 
transient transfection of let-7c silencing RNA (Life Technologies) produces a decrease in 
FGFR1 mRNA levels for some cell lines but not others. Conclusion: It appears possible 
to predict sensitivity to an FGFR1 inhibitor using miRNA expression signatures. More 
studies, however, are needed to confirm the 3-marker signature developed in this study. 
Modulating let-7c, the predominant predictor within the signature, appears to modulate 
FGFR1 levels in a manner consistent with altering ponatinib sensitivity. This effect is most 
likely indirect as the mRNA of FGFR1 does not contain predicted binding sites for let-7c. 
Keywords: miRNA signature, FGFR, inhibitor, Let-7c
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P2.04-007 In Vitro and in Vivo Efficacy of AZD9291 Is Enhanced by 
Combination with AZD4547 in EGFR Mutant Lung Cancer Cells Daniel C. Chan1, 
Trista K. Hinz2, Lindsay A. Marek2, Zhiyong Zhang1, Teresa T. Nguyen2, Paul A. Bunn, Jr1, 
Lynn Heasley2 1Medical Oncology, University of Colorado Denver, Aurora/CO/United States 
of America, 2University of Colorado Anschutz Medical Campus, Aurora/CO/United States of 
America
Background: EGFR-specific tyrosine kinase inhibitors (TKIs) provide marked clinical 
responses in patients bearing EGFR mutated lung tumors, although acquired resistance 
limits the durability of the response. In light of the frequent emergence of erlotinib and 
gefitinib-resistant EGFR T790M mutations upon tumor progression, 3rd generation 
EGFR-specific TKIs have been developed that specifically inhibit gain-of-function EGFR 
mutants irrespective of T790M status. Recently, we reported a distinct mechanism of 
acquired resistance whereby specific EGFR mutant lung cancer cell lines including H1650 
and HCC4006 cells, but not PC9 cells, undergo an epithelial-mesenchymal transition 
(EMT) upon chronic in vitro treatment with gefitinib. As a result, the adapted cells acquire 
vulnerability to FGFR inhibitors by virtue of EMT-mediated FGF2 and FGFR1 induction. 
Herein, we have tested the hypothesis that combination of the FGFR inhibitor, AZD4547, 
with the 3rd generation EGFR TKI, AZD9291 will yield superior anti-tumor activity relative 
to AZD9291 alone. Methods: Lung cancer cell lines bearing gain-of-function EGFR 
mutations (HCC4006, H1650 and PC9) were submitted to in vitro clonogenic growth 
assays in the presence of AZD9291 and/or AZD4547 over concentration ranges for 
1 to 300 nM for each drug. For in vivo measurement of the activity of these drugs, 
flank xenografts were established in Nu/Nu mice with the 3 lung cancer cell lines and 
treated by daily oral gavage (5 days on, 2 days off) with diluent, AZD9291 (5 mg/
kg), AZD4547 (12.5 mg/kg) and the combination of the two drugs at these doses. 
To detect the relevance of MET and IGF1R signalling in accordance to EMT in the two 
cell lines, we treated the HCC827ER cells with the tyrosine kinase inhibitor crizotinib 
(MET) and the HCC827HD cells with linsitinib (IGF1R). In both cases, we saw a 
decrease in EMT-marker transcription after the treatment. Conclusion: Our study 
demonstrates that different approaches to developing erlotinib-resistant cell lines 
can lead to distinct activation of bypass receptor tyrosine kinase signalling pathways. 
EMT, however, is induced in both types of erlotinib-resistance. This finding indicates 
that EMT is a common trait of the phenotype of erlotinib-resistant cells. More research 
needs to be done to establish the functional role of EMT in erlotinib resistance. 
Keywords: NSCLC, EGFR TKI-resistance, EMT
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P2.04-004 The BIM Deletion Polymorphism in Patients with EGFR-Mutant Non-
Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Ji Yun Lee1, Bo Mi Ku2, Sung Hee Lim1, Haesu Kim1, Kwai Han Yoo1, Ki Sun Jung1, 
Haa-Na Song1, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Myung-Ju 
Ahn1 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul/Korea, 2Samsung Biomedical Research 
Institute, Samsung Cancer Research Institute, Samsung Medical Center, Sungkyunkwan 
University School of Medicine, Seoul/Korea
Background: A germline BIM deletion polymorphism has been proposed to predict 
poor treatment response to certain kinase inhibitors. The purpose of this study was 
to explore whether the BIM deletion polymorphism predicts treatment efficacy of 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in Korean 
patients with EGFR-mutant NSCLC. Methods: Peripheral blood samples from a total of 
205 patients with EGFR-mutant NSCLC who were treated with EGFR TKIs between July 
2008 and April 2013 were included. The incidence of BIM deletions in these samples 
was detected by polymerase chain reaction. We compared the clinical outcomes in 
patients with and without the polymorphism after treatment with EGFR TKIs (gefitinib 
or erlotinib). Results: The BIM deletion polymorphism was present in 15.6% (32/205) 
of patients. One patient was homozygous for the deletion, and the remaining 31 had 
heterozygous deletions. The majority of patients were < 65 years old (74%), female 
(68%), never smokers (76%), and had stage IV NSCLC (67%). There were no associations 
between the BIM deletion polymorphism and clinicopathological features including 
gender, age, smoking status, histology, stage, and number of metastasis sites. Patients 
with and without the BIM deletion polymorphism had similar ORRs (91% vs. 84%, P = 
0.585). Progression-free survival (PFS) and overall survival (OS) did not differ significantly 
between patients with and without the BIM deletion polymorphism (median PFS 12 vs. 11 
months, P = 0.160; median OS 31 vs. 30 months, P = 0.452). Multivariate analysis 
identified significantly predictive markers for clinical outcomes of EGFR TKIs including 
ECOG PS 0-1, adenocarcinoma histology, recurrent disease, and EGFR mutation type. The 
results were validated in an independent cohort of 69 NSCLC patients. Conclusion: It 
remains to be determined whether the BIM deletion polymorphism provides intrinsic 
resistance or decreased sensitivity to EGFR TKIs in EGFR-mutant NSCLC patients. 
Keywords: non-small cell lung cancer, Epidermal growth factor receptor, Tyrosine kinase 
inhibitors, BIM Deletion Polymorphism
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P2.04-005 Bevacizumab plus Erlotinib in B901L Xenograft Model of EGFR 
Mut+ NSCLC Chinami Masuda, Nobuyuki Ishikura, Toshiki Iwai, Keigo Yorozu, Mtsue 
Kurasawa, Koh Furugaki, Kaname Yamamoto Product Research, Chugai Pharmaceutical 
Co., Ltd., Kanagawa/Japan
Background: Erlotinib (ERL), an epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor, has shown clinical efficacy in EGFR mutation-positive (EGFR Mut+) 
non-small-cell lung cancer (NSCLC). However, almost all tumors recur and eventually 
develop resistance to ERL. Bevacizumab (BEV), a humanized anti-vascular endothelial 
growth factor (anti-VEGF) monoclonal antibody, in combination with standard first-line 
chemotherapies, has improved clinical outcomes in advanced NSCLC. Recently, the 
phase II JO25567 study reported that the combination of BEV plus ERL significantly 
prolonged progression-free survival compared with ERL alone in EGFR Mut+ NSCLC 
(Seto, et al. Lancet Oncol 2014; 15:1236–44). However, the mechanism by which this 
combination confers efficacy remains unknown. In the present study, we examined the 
antitumor activity of BEV in combination with ERL and analyzed the mechanism of action 
in a human EGFR Mut+ NSCLC xenograft model. Methods: Mice (BALB-nu/nu) were 
subcutaneously inoculated with the human NSCLC cell line B901L harboring EGFR exon 
19 deletion. BEV (5 mg/kg) was intraperitoneally administered once a week and 
oral ERL (60 mg/kg; maximum tolerated dose) was given daily, starting from Day 1. 
Antitumor activity was evaluated by measuring tumor volume (TV; mm3) twice a week. 
Human VEGF protein was quantified by ELISA, and EGFR signaling in tumor tissues was 
examined by immunoblot analysis. Statistical analysis was performed using the Wilcoxon 
test. Results: In the initial phase, ERL showed remarkable tumor growth inhibition in 
the B901L xenograft model. However, tumor regrowth was observed in the ERL-treated 
group during further treatment. In contrast, no significant tumor regrowth was observed 
in the BEV plus ERL-treated group (WCLC 2013; P2.05-004). In the ERL-treated group, 
tumor VEGF protein was significantly increased (p<0.05) on Day 68 (ERL-refractory 
phase) compared with Day 4 (ERL-sensitive phase) and the levels of phosphorylation 
of extracellular signal-regulated kinase (ERK), AKT and signal transducer and activator 
of transcription 3 were markedly increased on Day 75 compared with Day 5, although 
phosphorylation of EGFR was still inhibited. In contrast, the combination of BEV plus ERL 
inhibited phosphorylation of ERK on Day 75, although BEV alone did not. Conclusion: The 
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had PD. Seven of eight patients who showed greater than 1.5-fold elevation of HGF 
before re-challenge with EGFR-TKI suffered PD. Elevation of HGF ratio to above 1.5 
was significantly associated with poor response to EGFR-TKI re-challenge (p = 0.005). 
Having no history of T790M and an HGF ratio less than 1.5 was significantly associated 
with a good response to EGFR-TKI re-challenge (p<0.001). Afatinib demonstrated one 
PR and four SD, and one had PD. T790M was detected in four of six patients before 
afatinib treatment. Three of four patients with a history of T790M positivity had PR or 
SD. Elevation of HGF ratio to above 1.5 was not detected in six patients who treated 
with afatinib. Conclusion:Combination of T790M detection and HGF quantification using 
plasma is a potentially useful assay system for predicting the effect of EGFR-TKI re-
challenge with not only first generations but also afatinib. Eventually, we strive to develop 
more effective treatment strategies for NSCLC patients with EGFR activating mutations 
depending on the status of T790M and HGF level in plasma, for example the second or 
the third generation EGFR-TKI for detection of T790M, MET inhibitor for elevation of HGF 
level, and EGFR-TKI re-challenge without detection of T790M and elevation of HGF level. 
Keywords: plasma DNA, predictive marker, EGFR-TKI
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P2.04-010 18F-FDG Uptake and CEA between Different EGFR Mutations in 
Patients with Non-Small Cell Lung Cancer Xiaorong Dong, Xican Gao, Qian Cai, 
Ruiguang Zhang, Gang Wu Cancer Center, Union Hospital, Wuhan/China
Background: Many studies have demonstrated the clinical efficacy of the epidermal 
growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib 
compared with chemotherapy against non–small-cell lung cancer (NSCLC) when used 
as first-line treatment for patients whose tumors harbor activating EGFR mutations. But 
sometimes the acquisition of adequate tissues for EGFR mutation analysis is not feasible. 
The aim of this study is to evaluate the relationship between EGFR mutation status, serum 
carcinoembryonic antigen (CEA) levels, and the SUVmax of [18F]-fluorodeoxyglucose 
positron emission tomography (FDG-PET) in primary disease and metastatic lymph nodes, 
and in Chinese non-small cell lung cancer patients. Methods: From January 2009 and 
October 2010, 167 patients with definite pathological diagnosis of NSCLC who underwent 
[18F]-FDG-PET, EGFR mutation analysis by amplification refractory mutation system 
(ARMOS) method, and CEA value by Elecsys chemiluminescence immunoassay system 
were eligible to participate in this study. The associations of EGFR mutation status with 
patient characteristics, maximal standard uptake value (SUVmax) of primary tumors and 
metastatic lymph nodes, serum CEA level at diagnosis were analyzed. Receiver-operating 
characteristic (ROC) curve analysis was performed to quantify the predictive value of 
these factors. Multivariate logistic regression analysis was used to analyze predictors 
of EGFR mutations. Results: EGFR mutations were identified in 167 patients (73 EGFR-
mutant and 94 wild-type). The [18F]-FDG uptake was significantly lower in EGFR-mutant 
(mean SUVmax=9.3) than wild-type (10.2) NSCLC patients (P=0.045). The CEA value 
was significantly higher in EGFR-mutant (mean CEA=12.5) than wild-type (5.8) NSCLC 
patients (P=0.030). The ROC analysis concluded that high FDG uptake (SUV≥9.6) may be 
predictive of the wild-type EGFR genotype, whereas a low normalized SUVmax may predict 
the presence of EGFR mutations less robustly. We also demonstrated that high CEA levels 
(CEA≥9.25) were positively correlated with histological EGFR gene mutations by ROC 
analysis. On multivariate analysis, non-smoker, the low SUVmax of the primary tumor and 
the high CEA value were significantly associated with EGFR mutation status. In addition, we 
also showed that the exon 19 mutation (mean SUVmax=10.6) is strongly correlated with 
higher SUVmax than exon 21 mutation (mean SUVmax=8.7) (P=0.017). The metastatic 
lymph nodes in EGFR-mutant patients had lower SUVmax than EGFR wild-type patients 
(SUVmax 7.3 vs 6.65, P < 0.001). Conclusion: The combined evaluation of SUVmax FDG 
uptake in primary tumor and metastatic lymph nodes, CEA level, and smoking status may 
be helpful in predicting EGFR mutation status in patients with NSCLC, especially when 
the tumor sample is inadequate for genetic analysis or genetic testing is not available. 
Keywords: Positron emission tomography, Epidermal growth factor receptor, 
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P2.04-011 Whole-Genome Copy Number Analyses of NSCLC Tumors Reveal 
Aberrations Associated With EGFR Mutations and May Have Prognostic 
Impact Maria M. Bjaanæs1, Gro Nilsen2, Steinar Solberg3, Odd Terje Brustugun4, 
Ole C. Lingjærde2, Åslaug Helland5 1Department of Genetics, Institute for Cancer 
Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway, Oslo/
Norway, 2Department of Computer Science, University of Oslo, Oslo/Norway, 3Department 
of Cardiothoracic Surgery, Oslo University Hospital-Rikshospitalet, Oslo/Norway, 4Dept 
of Oncology, Oslo University Hosital,The Norwegian Radium Hospital, Oslo/Norwa, Oslo/
Norway, 5Department of Oncology, The Norwegian Radium Hospital, Oslo/Norwa, Oslo/
Norway
Background: Knowledge about genetic alterations in Non-Small Cell Lung Cancer 
(NSCLC) has given us a significant insight in the biology of these tumors. It is of great 
clinical importance with consequences for the patients, and DNA mutations and 
translocations are currently targets for therapy. Aberrations in DNA copy number are 
frequent events in NSCLC tumors and important in tumorogenesis. In this present 
study we want to investigate how the copy number changes varies between different 
subgroups of NSCLC tumors based on the patients’ smoking status, histology or EGFR-
, KRAS - and TP53 mutations. The DNA copy number data will be integrated with global 
mRNA expression to study the cis-associated mRNA expression changes. Last, we 
want to investigate whether genomic events, like specific copy number changes or 
the complex arm-wise aberration index (CAAI), have prognostic impact in patients with 
Tumor size was measured with calipers and volume was calculated using the formula, 
Volume=3.14(short diameter)2(long diameter)/6. Results: HCC4006, H1650 and PC9 
cells were highly sensitive to ZD9291 in vitro with IC50 values of 1.6, 7.4 and 3.3 nM, 
respectively. In a 2 week clonogenic growth assay, AZD9291 reduced growth of all cell 
lines by >95%, although viable drug resistant persisters clearly remained. While none 
of these cell lines exhibited significant growth inhibition in response to AZD4547 alone, 
combination of AZD9291 and AZD4547 further reduced clonogenic growth of HCC4006 
and H1650 cells, but not PC9 cells. In flank xenograft studies, AZD9291 monotherapy 
induced marked tumor shrinkage (H1650, ~80% at day 10; HCC4006, ~90% at day 30; 
PC9, 89% at day 25), although regrowth of the tumors occurred with all three xenografts. 
AZD4547 yielded little or no growth inhibition as a monotherapy, but significantly 
enhanced the degree of tumor shrinkage and delayed the time to tumor progression 
in H1650 and HCC4006 tumors, but not PC9 tumors. Conclusion: Combination of the 
FGFR inhibitor AZD4547 with AZD9291 affords greater growth suppression relative to 
AZD9291 alone in HCC4006 and H1650 cells that undergo EMT and induction of an 
FGF2-FGFR1 pathway. Predictably, this combination was not more effective compared 
to AZD9291 alone in PC9 cells that fail to undergo EMT in response to EGFR TKI 
treatment. The studies support the efficacy of combined AZD9291 and AZD4547 
treatment of a subset of lung tumors driven by mutated EGFR, although the features 
of these particular lung tumors that predict this response is unknown at this time. 
Keywords: AZD9291 and AZD4547, Drug combination, EMT as a resistant mechanism, 
EGFR mutant lung cancer cells
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P2.04-008 IGF1R Expression Is Predictive of Poor Prognosis in EGFR-Mutant 
Lung Adenocarcinoma Eunhyang Park1, Hyojin Kim1, Ping-Li Sun2, Yan Jin2, Jin-Haeng 
Chung2 1Seoul National University College of Medicine, Seoul/Korea, 2Seoul National 
University Bundang Hospital, Seoul National University College of Medicine, Seoul/Korea
Background: Insulin-like growth factor-1 receptor (IGF1R) is a membrane receptor-type 
tyrosine kinase that has attracted considerable attention as a potential therapeutic target, 
although its clinical significance in non-small cell lung cancer (NSCLC) is controversial. 
This study aimed to clarify the clinical significance of IGF1R expression in human 
NSCLC. Methods: IGFIR protein expression was evaluated by immunohistochemistry 
in 386 patients with NSCLC who underwent surgical resection (150 squamous cell 
carcinomas [SqCCs] and 236 adenocarcinomas [ADCs]). Correlations of the expression 
of IGF1R with clinicopathological and molecular features, and prognostic significance 
were analyzed. Results: Membranous and cytoplasmic IGFIR expression was significantly 
higher in SqCCs than in ADCs. In patients with SqCC, membranous IGFIR expression was 
associated with lower cancer stage, and better progression-free survival (PFS) (hazard 
ratio [HR] = 0.60, 95% confidence interval [CI]: 0.36–0.99, p = 0.045). In patients 
with ADC, IGFIR expression had no significant prognostic value, but in the subgroup 
of epidermal growth factor receptor (EGFR) -mutant ADC, membranous IGF1R expression was 
associated with vascular, lymphatic and perineural invasion, solid predominant histology, 
higher cancer stage, and was significantly associated with worse PFS (HR = 2.27, 95% 
CI: 1.30–5.48, p = 0.008). Conclusion: Lung ADC and SqCC showed distinct IGF1R 
expression profiles that demonstrated prognostic significance. High membranous IGF1R 
expression was predictive of poor PFS in EGFR-mutant lung ADC, while was predictive of 
better PFS in SqCC. These findings may serve to improve study design for subsequent 
investigations into IGF1R and NSCLC, and to select patients for future anti-IGF1R therapy. 
Keywords: non-small cell lung cancer, Insulin-like growth factor-1 receptor, Prognosis, 
Epidermal growth factor receptor
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P2.04-009 Potential Predictive Markers with Plasma for Re-Challenge with 
EGFR-TKIs Tomomi Nakamura1, Akemi Sato2, Naomi Kobayashi2, Hitomi Umeguchi2, 
Kazutishi Komiya2, Shinya Kimura2, Naoko Sueoka-Aragane2 1Internal Medicine, Saga 
University, Saga/Japan, 2Saga University, Saga/Japan
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKI) have produced dramatic anti-cancer effects in non-small cell lung cancer 
patients carrying EGFR activating mutations. However, patients eventually acquire 
resistance resulting from various mechanisms such as secondary EGFR mutation, 
T790M, MET amplification, and hepatocyte growth factor (HGF) overexpression. Recently, 
the second generation EGFR-TKI, afatinib which was expected for anti-cancer efficacy in 
T790M positive lung cancer patients has been developed. However, it has not evidenced 
acceptable anti-cancer efficacy in lung cancer patients who acquired resistance 
to first generation EGFR-TKI because of difficulty to identify mechanisms of acquired 
resistance by re-biopsy. The purpose of this study is to investigate whether T790M and 
HGF in plasma are useful as predictive markers for determination efficacious treatment 
including re-challenge of the first generation of EGFR-TKI and treatment with the second 
generation, afatinib after acquired resistance. Methods: We analyzed retrospectively 
16 re-challenges with first generation EGFR-TKI, and 6 treatments with afatinib after 
acquired resistance with first generation EGFR-TKI undertaken by investigating T790M 
and HGF in plasma coupled with clinical characteristics. EGFR mutations in plasma DNA 
were detected using the wild inhibiting PCR and quenched probe (WIP-QP) system for 
exon 19 deletions, and T790M and L858R were detected using the mutation-biased PCR 
and quenched probe (MBP-QP) system. HGF level in plasma was measured by enzyme-
linked immunosorbent assay; ratio of HGF level before re-challenge or afatinib to that 
prior to the previous EGFR-TKI treatment was calculated. Results: Two re-challenges 
demonstrated partial response (PR), six remained as stable disease (SD), and eight 
had progressive disease (PD). Four of five patients with a history of T790M positivity 
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expression in 3D. So we assumed that TraiL is one of the possible mechanisms of more 
apoptosis to Erlotinib in EGFR-mutant lung cancer 3D spheroids. After silencing the TraiL 
by siRNA, we found that there was no difference in the degree of apoptosis between 3D 
spheroids and 2D monolayer. Conclusion: Adding to increased BIM, we can suggest that 
elevated TraiL expression can be one of the possible mechanisms of the more prominent 
apoptosis in 3D spheroids of EGFR-mutant lung cancer cell lines. So potential therapies 
that upregulate BIM and/or TraiL expression can improved the efficacy of TKI treatment. 
Keywords: 3D spheroids, BIM, TRAIL, EGFR-mutant lung cancer
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P2.04-014 High Resolution Metabolomics to Discover the Potential 
Biomarkers in EGFR Mutated Lung Cancer Joon Woo Lee1, Sung Yong Lee2, 
Jeong Eun Lee3, Youngja Hwang Park1 1College of Pharmacy, Korea University, Sejong 
City/Korea, 2Department of Internal Medicine, Korea University Medical Center, Seoul/
Korea, 3Chungnam National University, Daejeon/Korea
Background: Lung cancer is the most common cause of cancer death in the world. 
The epidermal growth factor receptor (EGFR) is a key target in the treatment of 
advanced non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (EGFR 
TKIs) have shown good clinical efficacies in EGFR mutation positive patients. For the 
determination of lung cancer, biopsy has been the method of choice. However, this 
method is invasive and not safe. Therefore, non-invasive test for the detection of EGFR 
mutation is required for the safety of the patients. This study aims to discover novel 
biomarkers which could be utilized in clinical use in the non-invasive diagnosis of EGFR 
mutation among NSCLC patients. Methods: Plasma samples from 15 patients were 
analyzed to detect biomarkers of EGFR-activating mutations. All patients had histological 
confirmation of advanced NSCLC. EGFR mutations in tumor tissue were detected using 
the peptide nucleic acid (PNA) -mediated polymerase chain reaction (PCR) clamping 
method. Ten (66.7%) of the patients had EGFR mutations in tumor tissue. The mutation 
groups were divided into exon 21 deletion group (G2) (n=6), and exon 19 deletion group 
(G3) (n=4). Differences in metabolic profiles of EGFR mutation lung cancer populations 
and no mutation lung cancer patients (G1) (n=5) were examined through the use of 
high-throughput mass spectrometry. Results: A total of 216 significant metabolites 
were found to be different between non-mutated and mutated samples. It was found 
that patients with EGFR mutated NSCLC have a significantly lower levels of leucine. 
Comparison between G1 and G2 showed that L-proline levels of G2 patients were 
decreased. Lastly, the comparison between G1 and G3 showed that Butyryl-L-carnitine 
concentrations of G3 were decreased as compared to G1 patients. Conclusion: These 
findings may not only open a door to a thorough non-invasive diagnosis of an EGFR 
mutation but also a possibility to classify the type of mutation present. Our results 
show that changes in metabolite pattern are useful for in diagnosing EGFR mutation. 
One of the potential biomarkers, leucine discriminates EGFR-mutated lung cancer from 
that of non-mutated ones. Therefore, high resolution metabolomics can be the potential 
non-invasive tool to utilize clinically to detect the EGFR mutations in NSCLC patients. 
Keywords: metabolomics, NSCLC, EGFR mutation
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P2.04-015 Screening EGFR Mutations in NSCLC by Immunohistochemistry 
Rania Gaber1, Iris Watermann2, Ekkehard Vollmer2, Torsten Goldmann2 1Pathology, 
Faculty of Medicine, University of Alexandria, Egypt, Alexandria/Egypt, 2Clinical and 
Experimental Pathology, Research Center Borstel, Borstel/Germany
Background: EGFR mutations are important targets for therapy in NSCLC. EGFR 
mutations, receptor overexpression and increase gene copy number are main 
factors inducing EGFR tumorigenic activity. The aim of the present study was to 
detect EGFR mutations in NSCLC by immunohistochemistry (IHC) and investigate its 
relation to mutations detected by DNA sequencing, level of wild type EGFR protein 
overexpression, gene copy number gain and clinicopathological data. Methods: The 
study was performed in a cohort of 216 tumor tissues of primary chemotherapeutic 
naïve NSCLC. Expression of EGFR mutations was identified by immunohistochemistry 
(IHC), using the specific antibodies 6B6 and 43B2 (Cell Signaling Technology) followed 
by DNA sequencing of positive cases for NSCLC-associated EGFR mutations (Applied 
Biosystems). IHC was scored by two systems: (a) a modified H-score ranging from 0 to 
300 (% cancer cells with membranous/cytoplasmic EGFR protein staining multiplied by 
the staining intensity rank from 0 to 3+) with score 100 as the positive threshold and (b) 
a qualitative score with cut off for positivity as ≥10% cells with 1+ to 3+ membranous or 
cytoplasmic staining for the mutation specific antibodies and 2+ and 3+ membranous 
staining for the wild form of EGFR. Wild EGFR protein expression determined by the 
31G7 antibody (Zymed laboratories, CA). Gene copy number was investigated by 
Fluorescence In Situ Hybridization (FISH) using the SPEC EGFR/CEN7 dual color probe 
(ZytoLight) and specimens were scored according to the Colorado scoring system with 
high copy number defined as high polysomy (HP), low amplification (EGFR/CEN7=2.1-3) 
or high amplification (EGFR/CEN7=3). Results: Forty-one cases (19.9%) were positive to 
mutated EGFR by IHC, and 8 of them showed EGFR specific mutations on exons 18-21 
by DNA sequencing. All the mutation confirmed cases had membranous or cytoplasmic 
staining intensity 2+ and 3+ with the different positive cut-off points of the two scoring 
systems. 6/10 (60%) of the genotyped NSCLC- associated mutations cases were positive 
to 43B2 and 4/10 (40%) were positive to 6B6 antibody. 7/10 (70%) of these cases showed 
3+ membranous staining in ≥10% of tumor cells, 3/10(30%) showed 2+ cytoplasmic 
staining in ≥ 10% of tumor cells. All 8 cases (100%) positive for mutations by sequencing 
had adenocarcinoma histology. Positive correlations were found between EGFR 
mutations, by IHC and sequencing, and both overexpression of wild EGFR and increase 
NSCLC. Methods: In this study we have included 200 patients with operable NSCLC 
tumors. Copy number data were obtained by using the Affimetrix Genome-wide human 
SNP array 6.0. Histopathological information, EGFR-, KRAS - and TP53 mutation status 
were determined and clinical information and follow-up data was obtained for all patients. 
The mRNA expression was determined by the Agilent 60K mRNA expression array on a 
subset of 117 patients. The data was analyzed by using bioinformatic tools like ASCAT and 
integration of the mRNA data and the survival analyses are on-going. Results: Preliminary 
results have shown that copy number aberrations are frequent events in NSCLC tumors, 
consistent with previous reports. We have identified that the copy number patterns differ 
between adenocarcinomas and squamous cell carcinomas, and between tumors from 
patients with different smoking history. However, the largest differences were found 
between the EGFR-mutated adenocarcinomas compared with EGFR wildtype tumors, 
where we identified a specific pattern of copy number changes in the tumors that 
harbour EGFR mutation. These changes were mainly located at chromosome arm 1p, 
2p, 3q, 5q, 7, 12 and 13. Preliminary analyses have also identified specific copy number 
aberrations with prognostic significance. Conclusion: Copy number aberrations are 
frequent in NSCLC tumors and may have great impact on gene expression and give us 
valuable prognostic information. EGFR-mutated adenocarcinomas have a specific pattern 
of copy number changes, which provides new insight of the biology of these tumors. 
Keywords: Copy number aberrations, mRNA expression, Prognosis, EGFR
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P2.04-012 The Development of EGFR Mutation Diagnostic Program for 
NSCLC Patients in Poland (2011-2014) Joanna Chorostowska-Wynimko1, Pawel 
Krawczyk2, Bartosz Wasag3, Iwona K. Rzepecka4, Piotr Wojcik5, Karolina Tecza6, 
Paulina Jagus1, Tomasz Powrozek2, Bozena Konopka4, Agata Gizycka1, Kamila 
Wojas-Krawczyk2, Janusz Limon3, Barbara Pienkowska-Grela4, Piotr Pierzchalski5, 
Marzena A. Lewandowska7, Liliana Pieciak8, Artur Kowalik8, Piotr Widlak6 1Department 
of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 
Warsaw/Poland, 2Laboratory of Immunology and Genetics, Department of Pneumonology, 
Oncology and Allergology, Medical University of Lublin, Lublin/Poland, 3Department 
of Biology and Genetics, Gdansk Medical University, Gdansk/Poland, 4Department of 
Pathology and Laboratory Diagnostics, Cancer Center and Institute of Oncology, Warsaw/
Poland, 5Oncogene Diagnostics Inc., Cracow/Poland, 6Center for Translational Research and 
Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Center and Institute 
of Oncology, Gliwice/Poland, 7Molecular Oncology and Genetics Departament, The Inovative 
Medical Forum, the Franciszek Lukaszczyk Oncology Center, Bydgoszcz/Poland, 8Department 
of Molecular Diagnostics, Holycross Cancer Center, Kielce/Poland
Background: Targeted therapy of non-small cell lung cancer necessitates fast and 
reliable molecular evaluation of tissue/cytologic samples within the routine diagnostic 
process. Here we present the dynamic development of the EGFR mutation screening 
program for NSCLC patients in Poland within the previous 4 years. Methods: In 
total, 287 samples were analysed for EGFR mutations in 2011 (13.3% positive, 3% 
unsuitable for diagnostics), 1249 (9.2%, 1.5%) in 2012, 2104 (10.1%, 1.9%) in 2013, 
4307 (10.2%, 2.7%) in 2014. Adenocarcinomas were 85.9% in 2012, 93.2% in 2014. 
The percentage of NSCLC NOS materials decreased continuously (10% down to 5.3%). 
72% of samples contained >50% of cancer cells, 15% - 20-50%, 5.5% - 10-20%, 7.5% - 
below 10%. Results: Between 2011-2014, 727 activating EGFR mutations were identified, 
including 5.8% in exon 18, 58.5% in exon 19, 35.7% in exon 21, and 83 in exon 20 
(10%). Currently, all laboratories employ CE-IVD real-time PCR tests as diagnostic method 
of choice. Additionally, 3 labs use alternative diagnostic methods as well. Results are 
available within 48 hrs (1 lab), 3-5 days (3 labs), 6-7 days (2), >8 days (2). All centres 
participate in the external quality schemes. Conclusion: The diagnostic program 
provides fast and reliable diagnostics of EGFR mutation in NSCLC patients in Poland. 
Keywords: non-small cell lung cancer (NSCLC), EGFR Tyrosine-kinase inhibitor (EGFR 
TKI), EGFR gene mutation detection, molecular diagnostics
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P2.04-013 TraiL Mediates Erlotinib-Induced Apoptosis in EGFR-Mutant 
Lung Cancer 3D Spheroids Hyun-Kyung Lee1, Yunock Choi2, Dario Barbone3, 
V. C. Broaddus3, Dae Young Hur2 1Division of Pulmonary and Critical Care Medicine, 
INJE University Busan Paik Hospital, Busan/Korea, 2Department of Anatomy and Tumor 
Immunology, INJE University, Busan/Korea, 3Lung Biology Center, San Francisco General 
Hospital, Uc San Francisco, San Francisco/CA/United States of America
Background: Three-dimentional (3D) spheroid culture model were known to be a good 
model to study of the multicellular apoptotic resistance in most cancer cell lines. Contrary 
to the result with other cancer cell lines, we found that 3D spheroids of EGFR-mutant lung 
cancer cell lines showed more prominent apoptosis to tyrosine-kinase inhibitor (TKI), 
erlotinib than 2D monolayers in our previous experiments. BIM (the proapoptotic BH3-only 
BCL-2 family protein) expressions before and/or after treatment of TKI were more prominent 
in 3D than 2D in several EGFR-mutant lung cancer cell lines. But the other mechanisms 
of 3D sensitivity to TKI treatment are not studied yet. Methods: We used EGFR-mutant 
cell line, HCC4006 and A549 without EGFR mutation and generated 3D spheroids using 
poly-HEMA-coated 96-well plates. 2D monolayers and 3D spheroids were treatment with 
erlotinib. The degree of apoptosis were compared between 2D and 3D. Also the BIM and 
TNF-related apoptosis-inducing ligand (TraiL) expression were compared. After finding 
of relatively elevated TraiL expression in 3D, we silenced TraiL by siRNA and compared 
the degree of apoptosis between 2D and 3D. Results: We found that only HCC4006 
not A549 showed apoptosis and elevated BIM expression after Erlotinib treatment. In 
line with our previous results, 3D spheroids showed more apoptosis and elevated BIM 
expression after Erlotinib treatment compared to 2D. Also we found more elevated TraiL 
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total of 91 NSCLC samples with available results of molecular-based EGFR mutational 
status were collected. The common TKI-sensitive EGFR mutation was detected in 38/91 
cases (42%) which included Exon19 del in 18/91 cases (20%), Exon 21 (L858R) point 
mutations in 20/91 cases (22%). The others 4 cases were found with uncommon EGFR 
mutations included Exon 20 (T790M), Exon18 (G719X), Exon 20 S768I and Exon 20 ins. 
There was 1 case with EGFR mutations at both Exon18 (G719X) and 20 ins. No mutation 
detected (wild-type, WT) were found in 48/91 patients. Of all 91 tissue samples were 
available for TTF-1 IHC testing, 80 of 91 patients were positive for TTF-1 (88%). For 80 
patients with adenocarcinoma histology and 10 patients with squamous cell carcinoma 
history, TTF-1 was positive in 93% and 60 % respectively (P<0.05). The expression of 
TTF-1 in EGFR 19 del and 21 exon (L858R) mutation groups were significantly higher 
than the WT group (95% vs 81%, P < 0.05). In only 1 of 38 specimens positive for 
EGFR mutations was TTF-1 negative. The sensitivity was 97 % and specificity was 
17%. Estimated negative predictive values (NPV) of TTF-1 expression for common TKI-
sensitive EGFR mutation prevalence rates of 42% was 90%. Conclusion: These results 
indicated that positive TTF-1 expression has a significant positive correlation with 
common TKI-sensitive EGFR mutation at exon 19 and 21. In high prevalence area of EGFR 
mutation positive in Thailand, TTF-1 could be a valuable marker of EGFR mutation status. 
Keywords: EGFR Tyrosine Kinase Inhibitors, non-small cell lung cancer, TTF-1, EGFR 
mutations
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P2.04-018 Whole Transcriptome Analysis of EGFR Wildtype Non-Small Cell 
Lung Cancer Patients with Clinical Benefit from Erlotinib Michael F. Sharpnack1, 
Luiz H. Araujo1, Tadaaki Yamada1, Leora Horn2, Kun Huang1, David P. Carbone1 
1The Ohio State University Wexner Medical Center, Columbus/OH/United States of 
America, 2Vanderbilt-Ingram Cancer Center, Nashville/TN/United States of America
Background: Despite the success of targeted assays of EGFR mutations in defining 
the non-small cell lung cancer patients who benefit from EGFR-tyrosine kinase inhibition, 
there still remains a significant portion of patients whose tumors do not harbor EGFR 
mutations, yet achieve clinical benefit (progression-free survival > 6 months) from 
erlotinib treatment. We apply whole transcriptome sequencing (RNAseq) to discover 
expression and mutation changes associated with erlotinib response. Methods: We 
report the results of 108 stage IV non-small cell lung cancer patients treated with first line 
erlotinib. The primary endpoint assessed was progression-free survival (PFS), to which 
erlotinib has already shown to be beneficial when compared to placebo. Furthermore, 
RNAseq was performed on 73 tumors from 29 (40%) males and 44 (60%) females. The 
RNAseq samples were processed to obtain mutation and expression data. Results: 108 
patients were followed for PFS, 7 of which declined to be followed, 2 came off erlotinib 
due to toxicity, 3 died before completion of the first cycle of erlotinib, 5 were ineligible, 
and 2 have not had tumor recurrence to date. The remaining 92 patients had a mean PFS 
of 4.71 months (±1.03 months, 95% CI). No patients experienced a complete response, 
and 14 of 92 (15%) patients had a partial response. Of the tumors analyzed via RNAseq, 
7 harbored EGFR mutations, including a complex exon 18 deletion in a patient with a 
partial response to erlotinib. 14 of 64 (22%) patients without EGFR mutations showed 
clinical benefit from erlotinib, none of which harbored other known actionable mutations. 
These EGFR wildtype tumors did not exhibit mutations in other known oncogenes in lung 
cancer. We hypothesize that they are addicted to EGFR signaling through other means 
than overactive kinase activity caused by activating mutations.
gene copy number (p=0.002 and p<0.001, respectively). Also, positive correlation was 
detected between EGFR mutations and high tumor grade and clinical stage (p<0.001 for 
both). Conclusion: IHC staining using mutation specific antibodies was demonstrated 
as a useful sensitive screening test before DNA sequencing. EGFR mutations play 
synergistic role with EGFR overexpression and increased gene copy number in NSCLC 
poor prognosis. Follow up of the cases with further evaluation of expression of EGFR 
wild and mutated forms after chemotherapy and targeted therapy will be performed. 
Keywords: EGFR mutations, DNA sequencing, NSCLC, Immunohistochemistry
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P2.04-016 Minority Exon 19 Deletions Also Have Major Response of EGFR 
Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Eiji Nakajima1, Michio 
Sugita2, Kinya Furukawa3, Hiroyuki Miura1, Hidenobu Takahashi1, Norihiko Ikeda4, 
Fred R. Hirsch5, Wilbur A. Franklin2 1Thoracic Surgery, Tokyo Medical University Hachioji 
Medical Center, Tokyo/Japan, 2Pathology, University of Colorado Health Sciences Center, 
Aurora/CO/United States of America, 3Thoracic Surgery, Tokyo Medical University Ibaraki 
Medical Center, Ibaraki/Japan, 4Thoracic Surgery, Tokyo Medical University Hospital, Tokyo/
Japan, 5Medical Oncology, University of Colorado Health Sciences Center, Aurora/CO/United 
States of America
Background: This study points out an issue of PCR methods to detect exon 19 
deletions. Exon 19 deletions are most important among exon 18 to 21 EGFR mutations to 
dictate EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy in non-small cell lung cancer 
(NSCLC), and exon 19 deletions and insertions have over 170 species by catalog of 
somatic mutation in cancer (COSMIC). PCR methods are used for clinical examination, 
because they are useful, rapid and cost-effective to detectEGFR mutations. Some PCR 
methods could detect all of exon 19 deletions and insertions, while others could not. 
We investigated the clinical significance of minority exon 19 deletions, which could not 
be detected according to the PCR methods, selected majority deletions. Methods: The 
study included a series of 73 NSCLC patients, which were treated with EGFR-TKI for 
recurrent disease after they had undergone surgery from 1992 to 2004. EGFR mutations 
were detected in 34 (47%) in 73 patients. Sixty patients were evaluable for response, and 
remaining 13 patients who had taken EGFR-TKI for less than one month. In 60 assessable 
patients, exon 19 deletions and exon 21 point mutation were detected from 19 patients and 
10 patients, respectively. Patients with EGFR mutations had significantly higher response 
rates to EGFR-TKI than those with wild-type (p=.047), and exon 19 deletions had still rates 
(p=.024). In 51 samples, including 17 exon 19 deletions and 6 exon 21 mutations, four 
PCR methods are commonly used in Japan, were performed and compared. PCR-based 
methods were (1) PCR-Invader for the selected common mutations of exons 18, 19, 20 and 
21, and micro capillary electrophoresis for the exhaustive detection of exon 19 deletions 
and insertions, (2) Peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp for the 
selected common mutations of exons 18, 19, 20 and 21, and direct sequence for the 
other mutations, (3) Cycleave PCR for the selected common mutations of exons 18, 20 
and 21, and fragment analysis with micro capillary electrophoresis for the exhaustive 
detection of exon 19 deletions and insertions, (4) Scorpion Amplification Refractory 
Mutation System (ARMS) for the selected 29 mutations including 19 species of exons 
19 deletions and insertions. Results: All four methods detected 6 exon 21 mutations as 
L858R point mutation. However, in exon 19 deletions and insertions including over 170 
species, only micro capillary electrophoresis detected all 17 exon 19 deletions. PNA-LNA 
PCR clamp and direct sequence missed one 9 bp short deletion “L747-E749 del”, which 
had complete response on EGFR-TKI therapy. Scorpion ARMS missed one 24 bp deletion 
and insertion “T751-I759 del ins S”, which had stable disease for over 3 years on EGFR-TKI 
therapy. Conclusion: This study suggests micro capillary electrophoresis is necessary 
for the exhaustive detection of exon 19 deletions and insertions, and may identify tumors 
responsive to EGFR-TKIs therapy, especially those with small or unusual deletions. 
Keywords: Exon 19 deletions, PCR methods, non-small cell lung cancer, EGFR Tyrosine 
Kinase Inhibitors
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P2.04-017 The Study of a Relationship between Thyroid Transcription Factor-1 
Expression and EGFR Mutations in Unselected Thai Patients with NSCLC 
Chaiyut Charoentum1, Nirush Lertprasertsuke2, Chumut Phanthunane2, Theerakorn 
Theerakittikul2, Atikun Limsukon2, Somcharoen Saeteng2, Apichart Tantraworasin2, 
Juntima Euathrongchit2, Yutthaphan Wannasopha2, Thatthan Suksombooncharoen2, 
Busyamas Chewaskulyong2 1Internal Medicine, Chiang Mai University, Chiang Mai/
Thailand, 2Chiang Mai University, Chiang Mai/Thailand
Background: Epidermal growth factor receptor (EGFR) mutation status is a important 
test to guide treatment with EGFR tyrosine kinase inhibitors (EGFR TKI) effectively. 
However mutation detection by DNA direct sequencing remains expensive and is not 
readily available for routine practice in advanced NSCLC in Thailand. Thus a simple 
alternative method of EGFR mutation detection is required in NSCLC treatment. Recent 
studies have demonstrated a good association of Thyroid Transcription Factor-1 (TTF-1) 
with common TKI-sensitive EGFR mutations in NSCLC. We investigated the possibility of 
the routine test of TTF-1 expression by a simple immunohistochemistry (IHC) method 
as a potential indicator of common TKI-sensitive EGFR status in unselected Thai 
patients with non-small cell lung cancer. Methods: We collected tissue sample from 
91 patients with NSCLC whose EGFR mutation status had previously been detected by 
DNA direct sequencing from January 2010 to January 2015. TTF-1 was detected by 
immunohistochemistry method. Results of expression of TTF-1 staining were scored as 
two categories were negative (no immunostaining or <5% stained cells) and positive 
(more than 5% positive cells with unequivocal nuclear immunostaining). Results: A 
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P2.04-020 Epidermal Growth Factor Receptor (EGFR) Testing among Veterans 
Diagnosed with Lung Cancer Julie Lynch1, Brygida Berse2, Andrew Freedman3, Kelly 
Filipski3, Scott Duvall4, Scott Kulich5, Michael Kelley6 1Veterans Health Administration, 
Utah/United States of America, 2Boston University Medical School, Ma/United States of 
America, 3National Cancer Institute, Dc/DC/United States of America, 4Veterans Health 
Administration, Utah/UT/United States of America, 5Veterans Healthcare Administration, 
Pa/PA/United States of America, 6Veterans Health Administration, Nc/NC/United States of 
America
Background: Molecular profi ling has resulted in new, targeted therapies that may 
improve survival for non-small cell lung cancer patients (NSCLC). Erlotinib is used in 
stage-IV patients and requires testing patients’ tumors for EGFR mutations. In 2010, 
guidelines recommended screening for EGFR gene mutations in non-squamous, stage IV 
NSCLC patients. Current guidelines recommend testing for all patients diagnosed with 
adenocarcinoma. Data on population-level implementation of molecular tests are sparse, 
yet are crucial to evaluate differences in access and outcomes. Methods: Patient-level test 
orders and results from January 2011 until December 2013 were provided by reference 
laboratories that conduct molecular testing for VA medical centers (VAMCs). The VA 
Central Cancer Registry (VACCR) reported clinical characteristics of lung cancer patients 
diagnosed in 2011 and 2012. We analyzed rate of testing, prevalence of EGFR mutations, 
clinicians’ perspectives regarding testing, and characteristics that predicted likelihood 
to undergo testing. Results: Our previous data showed that in 2010, 15 VAMCs ordered 
93 assays. Lab data from 2011 to 2013 identifi ed 986 tests ordered by 70 VAMCs, of 
which 352 were newly diagnosed patients included in the VACCR for 2011/2012. Patient 
characteristics of those tested were: 95% male, age (M=67, range 23 to 93). VACCR 
data (95% male, age (M=68, range 28 to 97) showed that 2,889 (19.64%) of Veterans 
diagnosed in 2011/2012 were eligible for EGFR testing. Clinicians reported an expected 
low rate of EGFR mutations among the Veteran clinical phenotype (histology, smoking 
status, gender). Lab and VACCR data confi rmed this. Activating EGFR mutations were 
detected in 5.6% of cases. The 2361G>A polymorphism, missense mutations expected 
to be clinically insignifi cant, and variants of unknown signifi cance were detected in 16.7%, 
Conclusion: We present results from a clinical trial of fi rst line erlotinib in stage IV non-small 
cell lung cancer. We show that there is a signifi cant cohort of EGFR wildtype patients who 
receive clinical benefi t from erlotinib and present preliminary data of their mutation status. 
Keywords: Erlotinib, RNAseq, EGFR, targeted treatment
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P2.04-019 PD 0332991 Inhibits the Growth of Gefi tinib-Resistant Human Lung 
Cancer Cells in Vitro and in Vivo, When Combined with Gefi tinib Hongyu Liu, 
Ying Li, Minghui Liu, Yongwen Li, Yuli Wang, Jun Chen Tianjin Medical University General 
Hospital, Tianjin/China
Background: Tyrosine kinase inhibitors (TKIs), such as gefi tinib and erlotinib, which 
target the EGFR pathway, have a dramatic effect in the treatment of NSCLC patients, 
especially for patients with EGFR mutations, which is the leading cause of cancer-related 
mortality. Unfortunately, despite the success of these drugs, almost all cases progress, 
and eventually become resistant to such treatment, known as acquired resistance, and 
current targeted therapeutic strategies for patients with acquired resistance are limited. 
PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases CDK4 
and CDK6, with the ability to block retinoblastoma (Rb) phosphorylation. Methods: In 
this study, we evaluated, both in vitro and in vivo, the therapeutic approach of targeting 
the CDK4/6 and Rb pathway in PC-9/AB2 cells, which is an EGFR-TKIs acquired resistant 
lung adenocarcinoma cells. Results: PD 0332991 inhibits the growth and proliferation 
of both gefi tinib-sensitive and gefi tinib-resistant lung adenocarcinoma cells. In addition, 
PD 0332991 inhibits Rb phosphorylation in sensitive and resistant cell lines, as well as 
enhancing apoptosis in lung adenocarcinoma cells, when combined with gefi tinib. The 
combination of PD 0332991 plus gefi tinib induced G1 phase arrest for both gefi tinib-
sensitive and gefi tinib-resistant lung cancer cells. This combination treatment also 
inhibited the growth and relapse of tumors in human PC-9/AB2 tumor xenograft mice, 
as well as inhibiting proliferation, and induced apoptosis in human PC-9/AB2 tumor 
xenograft mice. Treatment with PD 0332991 and gefi tinib also inhibited angiogenesis 
in human PC-9/AB2 tumor xenograft mice. Conclusion: These fi ndings provide the 
rationale for evaluating PD 0332991 combined with gefi tinib for a novel therapeutic 
approach for overcoming acquired resistance to gefi tinib in lung cancer. 
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lysed in 200µl of lysis buffer. Results: First, we performed a pilot study by using cell 
lysates of 3 lung cancer lines expressing wild-type (H358) or E746_A750del mutant 
(HCC827) or L858R mutant (H3255) EGFR. Using our newly developed diagnostic device, 
we were able to specifically distinguish EGFR mutant proteins from that of wild-type 
EGFR in all of these cell lines. Next, we tested the device for detecting EGFR mutations 
in cytological samples of MPEs. Results of the mutation testing of the lysates using 
this device were consistent with those obtained by commercially available techniques 
in Japan although the number of samples assessed in this experiment was limited. 
The cost was less than a few dollars per assay. Conclusion: These results suggest 
that our device may be possible candidates for the next generation companion 
diagnostics devices for EGFR-TKI. Further investigation will be needed to elucidate the 
most appropriate detection method of EGFR mutation as a companion diagnostics. 
Keywords: EGFR mutation testing
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P2.04-023 Global Epidemiology of EGFR Mutation in Advanced Non-Small 
Cell Lung Cancer Gustavo Werutsky1, Marcio Debiasi2, Fernanda H.D. Sampaio2, 
Paulo Ricardo S. Nunes Filho2, Gilberto D.L. Lopes Júnior3 1Latin American Cooperative 
Oncology Group, Porto Alegre/Brazil, 2Medical Oncology, Pontificia Universidade Catolica Do 
Rio Grande Do Sul, Porto Alegre/Brazil, 3Oncoclinicas Do Brasil Group, São Paulo/Brazil
Background: Lung cancer is a leading cause of cancer-related mortality worldwide. 
Subsets of patients with driver oncogenes can be treated with targeted therapies 
achieving longer survival than the general population of patients with advanced non-
small cell lung cancer. Epidermal growth factor receptor (EGFR) mutations represent an 
important predictive factor for responses to EGFR inhibitors. This study aims to describe 
the prevalence of EGFR mutations throughout the world. Methods: We used MEDLINE 
to searched for articles describing the prevalence of EGFR mutations in countries 
around the world. Key search terms included “lung cancer”, “NSCLC” and “non-small 
cell lung cancer” in combination with the following terms: “EGFR”, “EGFR mutation” and 
“epidermal growth factor receptor”. The search was limited to human studies published 
in English, Portuguese or Spanish. No date limits were included. All studies describing 
the prevalence of EGFR mutations were included, provided they used any of the validated 
testing methods.We excluded the following types of studies: (i) animal xenograft 
experiments using human cancer cell lines, and (ii) abstracts, letters and posters for 
which the full study was not published. Results: Our search retrieved 2,369 articles 
dated from 1989 to 2015, of which 324 were selected based on the criteria described 
above. 213 of these studies (65.8%) were published between 2011 and 2015; 15 (4.7%) 
were clinical trials and 306 (98%) were cohort studies, case series or epidemiological 
series. We found articles from 37 different countries throughout the world, accounting 
for 121,109 patients. The global prevalence of EGFR mutation was 14.62% (CI 95%; 7.64-
21.60%). In an exploratory subgroup analysis by region of the world, gender, smoking 
status and histology, we found higher prevalence of EGFR mutation in South/East Asia 
(41.67%; 95%CI: 37.99-45.35%; p<0.001), women (39.68%; 95%CI: 31.49-47-87; 
p<0.001), non-smokers (54.61%; 95%CI: 45.91-63.31; p<0.001) and adenocarcinoma 
(35.28%; CI 95%: 28.68-41.90%; p<0.001). 
2.3% and 0.8% of patients, respectively. 70.1% of patients were negative for EGFR 
mutations. 4.4% of tests were not processed for technical reasons. Conclusion: Veterans 
have a much lower rate clinically actionable EGFR mutations than the reported average 
of 15%. Among Veterans diagnosed with lung cancer, 52% are current smokers, 
40% are former smokers, which may explain the low rate of EGFR mutations. 
Keywords: Cancer Registry, reporting actionable mutations, Veterans prevalence of 
EGFR mutations
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P2.04-021 Predictive Value of Initial Maximal Standardized Uptake Value of 
18F-FDG PET/CT in Patients with Lung Adenocarcinoma Treated with Erlotinib 
Tulay Kus1, Alper Sevinc1, Gokmen Aktas2, Serdar Oztuzcu2, Mehmet E. Kalender2, 
Celaletdin Camci2 1Medical Oncology Dept., Gaziantep University Onkoloji Hastanesi, 
Gaziantep/Turkey, 2Gaziantep University Onkoloji Hastanesi, Gaziantep/Turkey
Background: Targeted therapies like erlotinib, afatinib, gefitinib, crizotinib and ceritinib 
were suggested to be used in the first line treatment of non-small cell lung cancer (NSCLC) 
according to EGFR mutation and EML-4/ALK fusion gene analysis. EGFR mutation rate 
is about 10% in NSCLC and Exon 9 deletion and Exon 21 L858R are indicators of a 
longer progression free survival (PFS). According to guidelines thyrosine kinase inhibitors 
can also be used as switch or maintenance therapy after progression first-line therapy 
independent of EGFR mutation. This retrospective analysis indicates the predictive 
value of initial PET-CT SUVmax. in patients treated with erlotinib. Methods: This 
retrospective study about erlotinib was performed on patients with diagnosis of lung 
adenocarcinoma, treated with erlotinib as first-line, switch or maintenance therapy and 
after progression of first line chemotherapy in Gaziantep University Hospital Department 
of Medical Oncology, between 2008 and 2014. Preatreatment PET-CT imagings in last 
six months were scanned and peak SUVmax values of primary mass or metastasis 
were noted. Mean SUVmax values was 10,8. Thus, patients stratified as SUVmax above 
10,8 and SUV max below 10,8. Also patients were grouped as EGFR muation positive 
(+), negative(-), and unknown. PET-CT and CT were used for follow-up and 3 months 
PFS and 6 months PFS ratios were enlisted according to RECIST criteria. Results:50 
patient enrolled to this study. 27 of patients had SUV max. value below 10.8. Three 
months PFS rate of these patient was 77.8% (p:0.020), while it was 43.5% in patients 
who have SUV max. above 10.8. Also these rates were 66.7% and 21.7% for 6 months 
PFS (p:0.020). Subgroup analysis according to EGFR mutation status showed that 3 
months PFS rates were %75.0, 54.5%, 52.6% in EGFR (+), EGFR (-) and EGFR unknown 
group respectively (p:0,301). These rates were %50, 45.5%, 42.1% for 6 months PFS (p: 
0,884). In subgroup analysis of EGFR (+) patients, 3 months PFS rate was %100 in patients 
who have SUVmax below 10,8 and %66,7 in patients who have SUVmax above 10,8. 
These rates were %100 and %33,3 for 6-months PFS. Conclusion: Erlotinib showed 
better PFS ratios in EGFR positive patients who have low SUVmax values. Also erlotinib 
is an available drug for EGFR negative and unknown patients in consequent treatment of 
lung adenocarcinoma. SUVmax could be a predictive value for response. Predictive value 
of SUVmax could effect treatment decisions with multicenter studies proving this effect. 
Keywords: Erlotinib, PET-CT, Lung cancer,
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P2.04-022 Development of Microfluidic Devices for Rapid, Low-Cost Detection 
of EGFR Mutations in Cytological Samples from Patients with Lung Cancer 
Tetsunari Hase1, Toshihiro Kasama2, Nanako Nishiwaki3, Naoyuki Yogo1, Mitsuo 
Sato1, Noritada Kaji2, Masashi Kondo1, Manabu Tokeshi4, Yoshinobu Baba2, Yoshinori 
Hasegawa1 1Department of Respiratory Medicine, Nagoya University Graduate School of 
Medicine, Nagoya/Japan, 2Department of Applied Chemistry, Nagoya University Graduate 
School of Engineering, Nagoya/Japan, 3Hokkaido University Graduate School of Chemical 
Science and Engineering, Sapporo/Japan, 4Division of Biotechnology and Macromolecular 
Chemistry, Hokkaido University Faculty of Engineering, Sapporo/Japan
Background: Epidermal Growth Factor Receptor (EGFR) mutation testing plays an important 
role in selecting patients for targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs). 
However, a currently available PCR-based sequencing is time-consuming and expensive. 
In order to overcome these problems, we have developed microfluidic devices which 
enable rapid and specific detection of mutant EGFR proteins at low-cost in cytological 
samples from patients with non-small cell lung cancer (NSCLC). Methods: The diagnostic 
device consisted of the capture antibody against EGFR and photo-reactive polymer. The 
antibody-immobilized photo-reactive polymer wall (40 µm width, 40 µm height and 4 mm 
length) was constructed at the center of a microchannel (1 mm width, 40 µm height and 
8.5 mm length) by ultraviolet light irradiation. The substrate was made of cyclic olefin 
polymer by using injection molding. The inner wall of the microchannel was blocked with 
bovine serum albumin. By using the diagnosis devices, the sandwich-type fluorescence 
immunoassay procedure was conducted. The sample, detection antibody reagent 
(mutation specific monoclonal antibody against EGFR with the E746_A750 deletion in exon 
19 or the L858R point mutation and control EGFR antibody), and fluorescence-labeled 
anti-IgG antibody reagent were injected in turn. Between each injection, we performed 
a washing procedure, in which the microchannel was filled with the washing buffer for 
1 minute followed by flushing with 5 µL of the same washing buffer. The amount of the 
sample and reagents to fill the microchannel was 1 µL. Incubation times were 15 minutes, 
30 seconds, and 30 seconds for capture antibody-antigen reaction, antigen-detection 
antibody reaction, and detection antibody-fluorescence-labeled antibody reaction, 
respectively. After the immunoassay, fluorescence images were captured by using a 
digital CCD camera. Malignant pleural effusions (MPEs) were obtained from patients with 
NSCLC with written informed consent. After centrifugation, the cell pellets of MPEs were 
S586 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
had a preexisting T790M mutation, suggesting that tumors acquired T790M mutations 
during progression or after the acquisition of resistance to EGFR-TKI. Statistical analysis 
confirmed that T790M (-) patients group had significant enrichment of mutated genes 
belonging to the angiogenesis (P=0.003394) and extracellular matrix (P=0.00905) 
pathways before treatment of EGFR-TKI compared to T790M (+) patients. One patient 
with poor response (PFS = 3.6 months) lost EGFR activating mutation (allele frequencies 
from 20.8% to 0%) without detectable T790M mutation after EGFR-TKI treatment. We 
identified a novel missense mutation (T263P) of the extracellular domain (subdomain II) 
of EGFR, concurrently with an activating EGFR G719A mutation in pre- and post-EGFR-TKI 
samples of a lung adenocarcinoma showing poor response to erlotinib. Transfection 
of T263P vectors conferred resistance to erlotinib in PC-9 cells. Conclusion: NGS of 
pre-EGFR-TKI and post-progression tumor samples provides insight into the complex 
molecular mechanisms of acquired resistance to EGFR-TKIs in EGFR-mutant NSCLC. 
Keywords: non-small cell lung cancer, Epidermal growth factor receptor, tyrosine kinase 
inhibitor resistance mechanism, next-generation sequencing
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-025 Frequency of EGFR Mutation in Nsclc and Its Relationship with 
Clinicopathological Features: A Multicenter Asmo Trial Sinemis Yuksel1, Hilmi 
Kodaz2, Ibrahim Yildiz3, Hatice Odabas1, Ayse Ocak4, Ibrahim V. Bayoglu3, Ilhan 
Hacibekiroglu2, Ozlem Ercelep1, Ahmet S. Ekinci5, Bulent Erdogan2, Aslihan G. Mert1, 
Halit Karaca4, Tarik Salman3, Serkan Menekse6, Ozge Gumusay7, Basak O. Ustaalioglu8, 
Mehmet N. Aldemir9, Caglayan Geredeli10, Meltem Baykara11, Mukremin Uysal12, Alper 
Sevinc13, Asude Aksoy14, Arife Ulas15, Mevlude Inanc4, Ozgur Tanriverdi16, Nilufer Avci17, 
Nedim Turan18, Mehmet Aliustaoglu1, Mahmut Gumus19 1Medical Oncology, Kartal Dr.Lutfi 
Kirdar Research and Training Hospital, Istanbul/Turkey, 2Medical Oncology, Trakya University 
Medical School, Istanbul/Turkey, 3Medical Oncology, Katip Celebi University Medical School, 
Izmir/Turkey, 4Medical Oncology, Erciyes University Medical School, Kayseri/Turkey, 5Medical 
Oncology, Abdurrahman Yurtaslan Oncology Research and Training Hospital, Ankara/
Turkey, 6Medical Oncology, Celal Bayar University Medical School, Manisa/Turkey,7Medical 
Oncology, Gazi University Medical School, Ankara/Turkey, 8Medical Oncology, Haydarpasa 
Numne Research and Training Hospital, Istanbul/Turkey, 9Medical Oncology, Erzurum 
Research and Training Hospital, Erzurum/Turkey,10Medical Oncology, Necmettin Erbakan 
University Medical School, Konya/Turkey, 11Medical Oncology, Sakarya Research and 
Training Hospital, Sakarya/Turkey, 12Medical Oncology, Kocatepe University Medical 
School, Afyon/Turkey,13Medical Oncology, Gaziantep University Medical School, Gaziantep/
Turkey, 14Medical Oncology, Firat University Medical School, Elazıg/Turkey, 15Medical 
Oncology, Bursa Oncology Hospital, Bursa/Turkey, 16Medical Oncology, Mugla University 
Medical School, Mugla/Turkey, 17Medical Oncology, Balikesir State Hospital, Balikesir/
Turkey, 18Medical Oncology, Malatya State Hospital, Malatya/Turkey, 19Medical Oncology, 
Bezmialem Vakif University, Istanbul/Turkey
Background: There has been important developments in NSCLC since the understanding 
of molecular pathways and the initiation of targeted treatments. The aim of the study is to 
find the EGFR mutation frequency and its correlation to survival and clinicopathological 
features. Methods: In this multicenter study, 827 NSCLC patients were included 
retrospectively to find out the EGFR mutation status with age, sex, performance status, 
histopathological diagnosis, smoking status and stage. Survival correlates were 
determined. The primary aim was to find out the EGFR mutation status with all of the features 
in the database. The secondary aim was to find out the effects of EGFR mutation status 
on survival with multivariate analysis. Results: The median age was 59 (24-87) years. 
Median follow-up period was 14 (2-117) months. 29,7% were female. 85,2% were stage 
IIIB-IV and 94% was adenocarcinoma. EGFR mutation frequency was 21,6% including exon 
19 (62,3%). There was no correlation between mutational status and age, performance 
status and stage at diagnosis (p>0,05). However, there was a correlation between sex, 
smoking, and the metastatic area (p= 0.000, 0,000 ve 0.04 relatively). The frequency of 
mutation in female subjects was more pronounced in non-smokers/ex-smokers and less 
metastatic sites. Median progression-free survival was 9 months and overall survival was 
20 months. The overall survival was 27 (SE:5; 95% CI 17-36) months in EGFR positive 
cases whereas 19 (SE:1; 95% CI 16-21) months in EGFR negative cases (p=0,008). 
The multivariate analysis showed good performance status, ealy stage diseaase and 
presence of EGFR mutation as a prognostic factor (p<0,05). Conclusion: Presence 
of EGFR mutation seems to be correlated with survival. The determination of EGFR 
mutation will lead the pathway for a better treatment outcome and individualised therapy. 
Keywords: EGFR mutation, non small cell lung cancer, molecular testing, survival
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P2.04-026 Second Generation EGFR TKIs Inhibit Tumor Growth in a Chemo-
Resistant Squamous Cell Lung Cancer Patient Derived Xenograft Model Céline 
Mascaux1, Ludovic Dhont2, Erin Stewart2, Naoki Yanagawa2, Nhu-An Pham2, Ming 
Li2, Yuhui Wang2, Frances Shepherd1, Ming S. Tsao2 1Division of Medical Oncology and 
Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto/ON/
Canada, 2Departments of Laboratory Medicine and Pathobiology, University of Toronto, 
University Health Network, Toronto/ON/Canada
Background: In clinical trials testing the efficacy of first generation epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), occasional responses were 
observed in patients with lung squamous cell carcinomas (LSCC) (Shepherd FA, et 
al. New Engl J Med 2005) and survival benefit was confirmed for erlotinib in a subset 
analysis of male, ever-smokers with LSCC (Clark GM, et al. Clin Lung Cancer 2006). 
Currently, the LUX-Lung 8 phase III clinical trial is comparing afatinib versus erlotinib 
in the second-line setting for LSCC after cisplatin-based chemotherapy (Goss GD, et 
Table 1 summarizes the results.
 
Conclusion: To our knowledge this is the most comprehensive study of EGFR mutation 
prevalence in NSCLC worldwide. Our finds corroborate the estimate that EGFR mutations 
occur in around 20% of patients and the higher incidence among southeastern populations 
in Asia, females, non-smokers and adenocarcinoma. Policy makers can use this information 
to supporting testing of all non-smokers and of patients with adenocarcinoma worldwide. 
Keywords: EGFR, non-small cell lung cancer, epidemiology, PREVALENCE
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P2.04-024 NGS reveals potential druggable targets and molecular 
heterogeneity in EGFR mutant NSCLC with acquired resistance to EGFR TKIs 
Choong-Kun Lee1, Sora Kim2, Jae Seok Lee3, Hye Ryun Kim1, Joo-Hang Kim1, Sang 
Woo Kim2, Byoung Chul Cho1 1Division of Medical Oncology, Yonsei Cancer Center, Yonsei 
University College of Medicine, Seoul/Korea, 2Severance Biomedical Science Institute, 
Yonsei University College of Medicine, Seoul/Korea, 3Department of Pathology, Yonsei 
University College of Medicine, Seoul/Korea
Background: Although patients with non-small cell lung cancer (NSCLC) harboring 
epidermal growth factor receptor (EGFR) mutations respond to EGFR tyrosine kinase 
inhibitors (EGFR-TKIs), acquired resistance to these agents eventually occurs. To date, 
there has been no study on the comprehensive genome-wide alterations using next-
generation sequencing (NGS). Methods: At pre-EGFR-TKI and post-progression, we 
collected formalin-fixed paraffin-embedded tumor/normal pairs form 19 NSCLC patients. 
Ion AmpliSeqTM Comprehensive Cancer Panel was used to identify alterations across all 
exons of 409 target genes. The predicted mutated gene associated with resistance to 
EGFR-TKIs was subjected to in vitrofunctional assay. Results: All patients satisfied the 
clinical definition of acquired resistance to the EGFR-TKIs. The patients characteristics 
were as follows; median age of 58 years, male/female (n=7/12), pretreatment with 
erlotinib/gefitinib (n=2/17), and exon 19 deletion/L858R/others (n=14/3/2). Median 
progression-free survival (mPFS) of all patients on EGFR-TKIs was 6.7 months (2.4 to 27.8) 
and best overall response was partial responses in 10 patients and stable diseases in 8 
patients. Tumors were sequenced to a median coverage of 607x. Cancer genomes are 
characterized by 1,398 somatic single-nucleotide variants (788 missense, 74 nonsense, 
and 20 splice-site) and 1,774 frameshift and in frame insertions/deletions, with a median 
of 93.42 mutations per Mb (18.03 to 692.03 mutations per Mb). Overall, there was no 
significant difference in number and type of somatic mutation between pre-EGFR-TKI and 
post-progression tumors. In post-progression samples, patients with T790M mutation 
(n=12, 63.2%) had significant better mPFS and median overall survival (mOS) compared 
to patients who maintained EGFR activating mutation without evidence of acquired T790M 
(n=5) or without T790M nor EGFR activating mutation (n=2) (12.4 vs. 3.9 months for 
mPFS, P=<0.0001; 28.9 vs. 11.7 months for mOS, P=0.0306). No pre-EGFR-TKI tumor 
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P2.04-028 BIM Deletion Polymorphisms in Hispanic Patients with Non-Small 
Cell Lung Cancer Who Carriers EGFR Mutations (CLICaP) Andrés F. Cardona1, 
Oscar Arrieta Rodriguez2, Claudio Martin3, Hernan Carranza1, Carlos A. Vargas1, 
Jorge M. Otero1, Leonardo Rojas4, Mauricio Cuello5, Rafael Rosell6 1Clinical and 
Translational Oncology Group, Foundation for Clinical and Applied Cancer Research - Ficmac, 
Bogotá/Colombia, 2Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina 
Personalizada, National Cancer Institute, Mexico City/Mexico, 3Clinical Oncology, Instituto 
Fleming, Buenos Aires/Argentina, 4Centro Javeriano de Oncologia, Hospital Universitario San 
Ignacio, Bogota/Colombia, 5Clinical Oncology, Hospital de Clínicas - Udelar, Montevideo/
Uruguay, 6Hospital Germans Trias I Pujol, Catalan Institute of Oncology, Barcelona/Spain
Background: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can 
have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM 
deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-small-cell 
lung cancer (NSCLC), we examined outcomes of patients (pts) with and without BIM 
alterations Methods: We studied 89 NSCLC pts with EGFR mutation who were treated 
with erlotinib between January 2009 and November 2014. BIM deletion was analyzed 
by PCR in formalin-fixed paraffin-embedded (FFPE) tissues of tumor biopsies. We 
retrospectively analyzed clinical characteristics, response rate, toxicity, and outcomes 
among patients with and without BIM deletion (del)Results: BIM deletion was present 
in 14 pts (15.7%). There were no significant differences between pts with and without 
BIM del in clinical characteristics or type of EGFR mutation; however, pts with BIM del 
had a worse overall response rate to erlotinib (42.9% vs. 73.3% for pts without BIM del; 
p=0.024) as well as a significantly shorter progression-free survival (PFS) (10.8 del+ 
vs. 21.7 months for pts without BIM del; p=0.029) and overall survival (OS) (15.5 del+ 
vs. 34.0 months for pts without BIM del; p=0.035). Multivariate Cox regression analysis 
showed that BIM deletion was an independent indicator of shorter PFS (HR 3.0; 95%CI 
1.2-7.6; p=0.01) and OS (HR 3.4; 95%CI 1.4-8.3; p=0.006) Conclusion: The incidence 
of BIM del found in pts from Colombia is similar to that previously described in Asia; 
this alteration is associated with a poor clinical response to erlotinib and represents 
an independent prognostic factor for pts who had NSCLC with EGFR mutations 
Keywords: EGFR mutations, non-small cell lung cancer, BIM DELETION
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P2.04-029 Could EGFR Gene Mutations Provide a Selective Advantage to 
Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma 
Biology Tindara Franchina, Alessandro Russo, Veronica Franchina, Antonio Picone, 
Giuseppina R.R. Ricciardi, Giuseppa Ferraro, Maria Picciotto, Giuseppe Toscano, 
Vincenzo Adamo Department of Human Pathology, University of Messina & Medical 
Oncology Unit, A.O.O.R. Papardo-Piemonte, Messina/Italy
Background: There is growing evidence about differences in metastatic spread among 
distinct subsets of nonsmall cell lung cancer (NSCLC) characterized by activation of different 
driver oncogenes at the time of diagnosis. It is hypothesized that the dominant oncogenes 
in NSCLC would be associated with distinct patterns of metastatic spread. Aim of this study 
was to analyze the pattern of metastasization in lung adenocarcinomas according to EGFR 
mutational status. Methods: A total of 104 consecutive patients (60 M/44 F) with stage 
al. ESMO 2014). Preclinical data indicate that high EGFR protein expression may be 
predictive of response to erlotinib in EGFR wild type LSCC (Cranston et al, AACR 2013). 
Herein we assessed and compared the anti-tumor efficacy of different EGFR inhibitors 
in chemo-resistant squamous cell lung cancer patient derived xenograft (PDX) models 
with high EGFR expression and EGFRamplification. Methods: The cryopreserved PDX 
model established from a resected early stage LSCC was revived in non-obese diabetic 
severe combined immunodeficient mice (NOD SCID), expanded and subsequently treated 
with chemotherapy (cisplatin 3 mg/kg and vinorelbine 7 mg/kg intraperitoneally [IP]), 
cetuximab 20 mg/kg IP, and daily oral schedules were followed for erlotinib 50 mg/
kg, afatinib 20 mg/kg, dacomitinib 3 mg/kg. For each model, 6 mice were used in 
each of the different treatment and the control arms. Treatment was initiated in the 
PDXs at a tumor average volume of 150 mm3. Results: The PDX was derived from a 
57 year old male, smoker, following right pneumonectomy for a stage IIIB (T4N1M0) 
LSCC. This patient received adjuvant cisplatin/vinorelbine, but relapsed three weeks 
after the end of cycle 4 and died a week later. The tumor had a high EGFR expression by 
immunohistochemistry (H score = 300) and EGFRamplification (clusters) by fluorescent 
in situ hybridization. The PDX was EGFR wild type by Illumina exome sequencing and 
OncoCartaTM MassArray mutation screen (Sequenom), also was refractory to cisplatin/
vinorelbine. Reduced growth rate (stable disease, SD) was obtained with erlotinib 
and cetuximab. Treatment with afatinib and dacomitinib resulted in tumor growth 
inhibition (partial response, PR). The PDX developed resistance to dacomitinib after 
100 days of treatment, but continued to be inhibited by afatinib after 215 days of 
treatment. Conclusion: This study shows the efficacy of second generation especially 
afatinib irreversible EGFR TKIs in a chemoresistant LSCC PDX, with high wild type 
EGFR expression andEGFR amplification. Our results lend further support to the LUX-
Lung 8 trial, and also the use of PDX to model therapeutic responses in lung cancer. 
Keywords: Patient derived xenograft model, EGFR TKI, Squamous cell lung carcinoma
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P2.04-027 Erlotinib Induce miRNA Alterations in T790M EGFR Mutated 
NSCLC: Preclinical Study Jorge Chacartegui1, Marco Giallombardo2, Nele Van Der 
Steen3, Patrick Pauwels4, Christian Rolfo1 1Phase I-Early Clinical Trials Unit&Centre for 
Oncological Research (Core), Antwerp University Hospital & Antwerp University, Edegem/
Belgium, 2Phase I- Early Clinical Trials Unit, Antwerp University Hospital & Palermo University, 
Edegem/Belgium, 3Center for Oncological Research (Core), Antwerp University, Edegem/
Belgium, 4Molecular Pathology Unit & Core, Antwerp University Hospital & Antwerp 
University, Edegem/Belgium
Background: Lung cancer is one of the leading causes of cancer-related deaths 
worldwide. In the most common type, non-small cell lung cancer (NSCLC), an array of 
oncogenic driver mutations affecting growth factor receptors and signaling pathways, 
such as EGFR, KRAS, c-Met or ALK translocation has driven the development of 
directed-drug therapies with tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. 
Nevertheless, the appearance of resistance mechanisms, such as c-Met amplification 
or de novo mutations in EGFR, decreases the effectiveness of these therapies. 
Therefore, we analyzed the levels of miRNA which have proved to be involved in disease 
progression (miR-30b-5p,195-5p,221-3p) in NSCLC cells that are resistant (H1975) or 
sensitive (HCC827) against first generation TKI (erlotinib) treatment, to assess whether 
they are markers of response to the treatment. Methods: The H1975 cell line (EGFR 
mutations T790M/L858R) was cultured in RPMI 1640 medium, supplied with 10% FBS, 
2 mM L-glutamine and 1% penicillin/streptomycin (Gibco). The sulforhodamine B assay 
was performed to assess cell proliferation. The cells were treated during 72h with 
10µM erlotinib (SelleckChem) or DMSO. After collection, cells were lysed and RNA was 
extracted through commercial kit (RNA Mini Spin, GE Healthcare). The miRNAs profile 
analysis was performed through TaqMan Real-Time PCR and miRNA RNU-48 was used 
as endogenous control. Data was processed according to the formula 2-ΔΔct. Control 
values (H1975 + vehicle) are used as baseline and results are shown in logarithmic scale 
(Image). Results: Cells treated with 10µM erlotinib show an increased expression of 
miR-30b-5p, miR-195-5p compared to control values. On the other hand, we detected 
that the expression of the miR-221-3p was strongly down-regulated in respect the 
control values. Conclusion: H1975 carries the T790M mutation in EGFR, associated in 
NSCLC with appearance of resistance to TKIs treatment. However, we observed after 
treatment an increase of onco-suppressor miR-30b-5p and decrease of the oncogenic 
mir-221-3p, which are reported to correlate with good prognosis (Garofalo 2013, Zhong 
2014). Moreover, mir-195-5p, another miRNA related with onco-suppression, is also 
upregulated, which has been reported to correlate with good response (Liu, 2015). 
Overall, our data suggests that erlotinib treatment alters miRNA in an EGFR mutated 
cell line. Further analysis of miRNA in exosomes produced by H1975, and comparison 
with HCC827 exosomal and cellular miRNA levels is currently undergoing in our group to 
confirm their value as response to treatment biomarkers.
S588 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
was found to be tended with EGFR mutation (RR=1.37, 95%CI=1.08-1.74, p=0.011). 
On the contrary, the solid predominant subtype has a low EGFR mutation frequency 
(RR=0.74, 95%CI=0.59-0.93, p=0.009). Obvious correlation with EGFR mutation states 
is not found among other histologic subtypes. Conclusion: Taken together, the new 
IASLC/ATS/ERS lung adenocarcinoma classification is a very useful predictor of EGFR 
mutation frequency, the micropapillary predominant subtype has higher EGFR mutation 
frequency, on the contrary, the solid predominant subtype with lower frequency. 
Keywords: NSCLC, IASLC/ATS/ERS adenocarcinoma classification, EGFR mutation
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P2.04-032 Epidemiology and Clinical Outcomes of Epidermal Growth Factor 
Receptor (EGFR) Mutant Patients at the Brazilian National Cancer Institute 
(INCA) Pedro M. Domingues, Tatiane Montella, Mauro Zukin, Clarissa Baldotto, Carlos 
Ferreira Department of Thoracic Oncology, Brazilian National Cancer Institute, Rio de 
Janeiro/Brazil
Background: It is largely recognized the relationship between ethnicity and frequency 
of EGFR mutation. In Eastern Asia EGFR mutation prevalence in unselected lung 
adenocarcinoma reaches 52% as reported by large molecular studies. In withe 
populations, such as in European and North-American data, the EGFR mutation frequency 
decreases to 13-24%. Latin-America is a large and heterogeneous region with an elevated 
frequency of non-small-cell lung cancer (NSCLC) tumors. However, with the hurdles to 
access a high quality molecular test and targeted drugs, data regarding EGFR epidemiology 
in this region are lacking. For instance, in Brazil is estimated that less than 15% of 
advanced non-squamous cell lung cancer are tested. In this study, we describe the 
epidemiology and clinical outcomes of EGFR-mutant patients with advanced NSCLC after 
the implementation of EGFR reflex testing at a Brazilian public hospital. Methods: From 
May-2011 to Dec-2014 we retrospectively collected data from EGFR reflex test at INCA. 
The test was recommended for all advanced non-squamous NSCLC patients treated at 
the institution. EGFR exons 18, 19, 20 and 21 were examined using either Cobas® 
platform or Sanger sequencing. Results: From May 2011 to Dec 2014, 288 samples 
were screened for EGFR mutations and 40 (13.9%) harbored common EGFR mutations 
(del19-L858R). Of all tested patients, 21% had >70 years-old, 56% were women and 26% 
were never-smokers. Most patients had adenocarcinoma (95%). Results were obtained 
from cytological specimen in 65 cases (23%). Sanger sequencing was performed in the 
majority of patients (73%). EGFR mutation frequency was significantly higher in females 
than in males (19%[13.4–25.4] vs 8%[4.4–13.9]), and in never-smokers (29%[20.2–40.4] 
vs 8%[5.1–12.6] in ever-smokers)[Table 1]. The median Overall Survival (OS) of the entire 
cohort was 15.1 months. EGFRmutation was associated with better OS, as compared 
with EGFR-WT (26.4 vs 13.7 months [HR-0.37;p<0.001], respectively). Other prognostic 
factors identified were age>70y (p=0.01) and stage IV (p=0.008). In the 40 EGFR-mutant 
patients, 32 received EGFR-TKI. The exposure to EGFR-TKI was associated with better 
survival as compared with no TKI treatment (62.9 vs 9.8 months [HR-0.25;p<0.01], 
respectively).
 
Conclusion: Our results have demonstrated that the epidemiology and clinical 
outcomes of EGFR-mutant patients in a Brazilian cohort are in line with previous 
western studies. Further data with a higher number of patients and a wider extension 
are needed to confirm this results and point out possible intraregional differences. 
Keywords: epidermal growth factor receptor (EGFR), epidemiology, lung cancer
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P2.04-033 Patterns of EGFR Mutations in a Cohort of 395 Patients from a Single 
Institution in Brazil Augusto O. Saito, Vladmir C.C. Lima, Aldo L.A. Dettino, Mariana P. 
Macedo, Izabela W. Cunha, Graziela Z. Dal Molin, Helano C. Freitas 
Oncologia Clínica, A C Camargo Cancer Center, Sao Paulo/Brazil
Background: Lung cancer is among the most common malignancies in Brazil. 
Nevertheless, so far, there are no official data on EGFR mutation frequency in the 
country, the test is not routinely offered in the public system and there seems to 
exist great disparities in patient access to EGFR testing across regions. In this study 
we describe the frequency and patterns of EGFR mutations from a single brazilian 
IV adenocarcinoma and an EGFR mutation (25.9%), or wild-type (74.1%) were included. 
We compared the incidence rates of metastatic spread at a given site between EGFR 
mutated and wild type. Descriptive analysis was performed on the two molecularly 
defined groups and associated clinical data. Results: 37% of pts with EGFR activating 
mutations had bone metastases and 44% lung metastases. Moreover, BM were 
reported in 18%. Lung metastases were more common among pts harboring exon 
19 deletions (10/12 pts). In the subgroups of EGFR wild type pts BM were present 
in 15%, while bone and lung metastases in 17% and 22% of pts, respectively.The 
difference between the incidence of metastases in the different sites according to 
EGFR mutational status was not statistically significant. An interesting trend toward 
significance was observed in the evaluation of the incidence of lung metastases in 
EGFR mutated pts (p=0.1). Conclusion: The biomolecular characteristics and the 
pathways involved in the different lung cancer subtypes may directly influence the 
metastases formation and evolution. This report underline the need to better define 
the clinical and molecular characteristics in adenocarcinoma subtype related to EGFR 
mutational status, to improve therapeutic choices and obtain relevant clinical results. 
Keywords: Metastatic spread, Adenocarcinoma, EGFR mutational status
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P2.04-030 Activating and Resistance Mutations of EGFR in Peruvian Patients 
with Metastatic NSCLC Juan C. Gomez De La Torre1, Claudia Barletta1, Angelo M. 
Storace2, Christian Piscocha1, Jose Landa1, Carlos Roe1, Eduardo Roe1, Manuel Leiva1, 
Luis Mas3, Sandro Casavilca4, Carlos Barrionuevo4 1Laboratorio Roe, Lima/Peru, 2Roche 
Farma Peru, Lima/Peru, 3Oncosalud-Auna, Lima/Peru, 4Instituto Nacional de Enfermedades 
Neoplásicas (Inen), Lima/Peru
Background: The evaluation of EGFR mutational status of the EGFR in non-small cell 
lung cancer (NSCLC) is crucial to select the adequate targeted therapy and to know the 
prognostic of patients. Our aim was describe to determine the frequency of activating 
and resistance mutations of EGFR in a large cohort of Peruvian patients. Methods: We 
tested metastatic tumor samples from 436 NSCLC patients for known EGFR mutations 
involving exon 18 (G719X), exon 19 (deletions), exon 20 (T790M, S768I and insertions) 
and exon 21 (L858R). Samples were from a mutational testing program sponsored by a 
pharmaceutical company. All samples were processed at a central reference laboratory 
(Roe laboratory, Lima-Peru) under protocolized laboratory procedures. Results: A 
total of 398 out of 436 samples were evaluable for determination of EGFR mutational 
status. Fifty five percent of patients were male. EGFR mutations was present in 36.7% 
of cases (n = 146). In regard to specific mutations, G719X (in exon 18) was present 
in 1% (n = 4); deletions in exon 19 had a frequency of 19.6% (n = 78). Mutations in 
exon 20 were present in 3.5% (n = 14). In patients with exon 20 mutated, 8 cases 
had insertions, 5 cases had the mutation T790M and 1 case had the mutation S768I. 
Mutation L858R (exon 21) in 14.1% (n = 56) of cases. Coexistence of two mutations 
were present in exon 19/exon 20 (n = 3) and exon 20/ exon 21 (n = 3). Female patients 
were more likely to have any EGFR mutation with a Relative Risk = 1.92 and a P < 
0.001, in the Chi-square test. In tumors with EGFR mutated. The sensible profile for 
EGFR tyrosine kinase inhibitors (TKI´s) was present in 94.5% of cases (n=138) while 
8 cases (5.5%) had mutations associated with resistance to TKI´s. Conclusion: Most 
patients with metastatic NSCLC and EGFR mutations will benefit from anti-EGFR 
targeted therapy. Our frequency of EGFR activating or resistance mutation was similar 
to other Latin American countries where mutations in exon 19 are the most frequent. 
Keywords: lung cancer, Adenocarcinoma, EGFR, Targeted therapy
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P2.04-031 EGFR Mutation Associated with Histologic Subtype According to the 
IASLC/ATS/ERS Adenocarcinoma Classification: A Meta-Analysis Chen H. Ma1, 
Qian Li1, Ya F. Liu2, Yan W. Yao3, Yong Song3 1Department of Respiratory Medicine, Nanjing 
University School of Medicine, Nanjing/China, 2Department of Respiratory Medicine, Nanfang 
Medical University, Nanjing/China, 3Department of Respiratory Medicine, Jinling Hospital, 
Nanjing University School of Medicine, Nanjing/China
Background: In 2011, the International Association for the Study of Lung Cancer, 
American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS) 
proposed the new lung adenocarcinoma histologic classification. The purpose of this 
meta-analysis is to determine the relationship between EGFR mutation states and 
different predominant histologic subtypes. Methods: We carried out a comprehensive 
search for published articles from 2011 to February, 2015, using the PubMed, EMBASE 
databases and Cochrane Library. The main key words used for search were: IASLC/
ATS/ERS, new lung adenocarcinoma classification, EGFR. By searching the databases 
and further checking the reference lists of the publications, we obtained the initial 
articles. Next, we performed the preliminary screening through reading the titles and 
abstracts and excluded the obviously irrelevant articles. Then, we downloaded the 
full texts and read these articles intensively, excluding articles not giving the detailed 
data for meta-analysis. We extracted information from all eligible studies as follows: 
author, publish year, region, total cases, mean age, number of a certain histologic 
subtype, number of EGFR mutation in certain histologic subtype, total number of other 
histologic subtypes, total number of EGFR mutation in other histologic subtypes. This 
meta-analysis was completed using the Stata software (version 11.0; StataCorp LP, 
College Station, TX, USA). Detailed numbers in each included study were pooled to 
evaluate the association between EGFR mutation and histologic subtype. A random-
effect model was used to calculate the pooled relative risks (RRs), 95% confidence 
interval (95%CI), and P values. Two-sided P values less than 0.05(P<0.05) were 
considered statistically significant. Results: The micropapillary predominant subtype 
S589Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
33 non-responders as responders. Looking at early progression (16 in total) , visual 
evaluation identified 6 correctly, The SULpeak method identified 4 correctly, the TLG 
method identified 2 early progressions correctly
.  
Table 1: Response groups by patient, ordered by PFS (in months) as found by the 
three methods. 1 partial response, 2 stable disease and 3 progression. “true” 
progression and response values are highlighted in bold. Division lines in bold 
separates response and early progression from the middle group as according 
to PFS and CT. * Not Available, ** treatment stopped early because of side effects 
. Conclusion: Visual evaluation identified more responders and patients with early 
progression during treatment with erlotinib. The more objective method based on 
calculation of SUV calculations identified less responders as well as less patients with early 
progression, suggesting a lower sensibility for this method. This suggests that the 40% cut 
off in % change used in this study (as suggested by Wahl et al in the PERCIST criteria), and 
perhaps the 30% cut off used for SULpeak change are too high for very early evaluation. 
Keywords: FDG-PET/CT, Adenocarcinoma, Erlotinib, response evaluation
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P2.04-036 The Association of EGFR Mutations with Stage at Diagnosis in Lung 
Adenocarcinomas Jaeyoung Cho1, Sun Mi Choi1, Jinwoo Lee1, Chang-Hoon Lee1, Sang-
Min Lee1, Jae-Joon Yim1, Chul-Gyu Yoo1, Young Whan Kim1, Sung Koo Han1, Doo Hyun 
Chung2, Young Sik Park1 1Internal Medicine, Seoul National University Hospital, Seoul/
Korea, 2Pathology, Seoul National University Hospital, Seoul/Korea
Background: The prognostic role of epidermal growth factor receptor (EGFR ) 
mutations in patients with lung adenocarcinomas remains controversial and the 
association between EGFR mutations and stage at the time of the initial diagnosis is 
debatable. Here we evaluated the association of EGFR mutations with initial stage 
in lung adenocarcinomas. Methods: From June 2011 to December 2014, 1004 
institution. Methods: DNA samples were obtained either by slide scraping or by 
laser microdissection of tumoral cells from paraffin embedded tissue blocks. Exons 
18, 19, 20 and 21 of EGFR gene were tested for mutation by direct sequencing or by 
pyrosequencing using standard protocols. We used chi-square statistics, or Fisher’s 
exact test when appropriate, to compare proportions among groups. Results: From 
Aug/2010 to Jun/2014, 395 patients were tested for EGFR mutation at AC Camargo 
Cancer Center, Sao Paulo. Among tested patients, median age was 64y, 51% were 
female, 91% had adenocarcinoma, 27% were smokers/former smokers with median 
12 pack year smoking history. The presence of EGFR mutations was associated with 
non-smoking status (p=0.023). Twenty six percent of patients (105/395) had EGFR 
mutations, 28.6% (30/105) of them were L858R, 42.9% (45/105) were exon 19 
deletions and 28.6% (30/105) were composed of rare or complex mutations. Among 
patients with rare mutations, 56.6% (17/30) had more than one mutation detected. Rare/
complex mutations were more frequently associated with non-adenocarcinoma histology 
(p=0.014), smoking history (p=0.03) and smoking intensity (p=0.02). Conclusion: In 
this cohort, the mutation frequency was higher than that reported in other western 
countries series. The high proportion of rare and complex mutations is also worthnoting 
and was more frequently seen in heavy smokers with non-adenocarcinoma histology. 
Keywords: EGFR testing, NSCLC, Rare EGFR mutations, EGFR mutation frequence
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P2.04-034 The Study of EGFR Mutation Specific-Antibody for Detection 
of EGFR Status in Non-Small Cell Lung Cancer Chaiyut Charoentum, Chumut 
Phanthunane, Nirush Lertprasertsuke, Theerakorn Theerakittikul, Atikun Limsukon, 
Somcharoen Saeteng, Apichart Tantraworasin, Juntima Euathrongchit, Yutthaphan 
Wannasopha, Thatthan Suksombooncharoen, Busyamas Chewaskulyong, Sumitra 
Thongprasert Internal Medicine, Faculty of Medicine, Chiangmai University, Chiangmai/
Thailand
Background: Specific somatic mutations of the epidermal growth factor receptor (EGFR) 
associate with increasing response to EGFR tyrosine kinase inhibitors (TKIs) treatment in 
NSCLC. Assessment of EGFR mutation status by gene-based assay remains expensive 
and is not routinely reimbursed in Thailand. The objective of this study is to test a simple 
immunohistochemical (IHC) method using EGFR mutation-specific antibodies for detection 
of EGFR status. Methods: Specimen from 76 NSCLC patients whose EGFR mutation 
status had been detected by DNA direct sequencing were collected from January 2010 to 
July 2014 as the reference standard. We performed IHC analyses using 2 EGFR mutation-
specific antibodies to E746-A750 del in exon 19 and the other to L858R in axon 21 for 
all samples. IHC staining were score as 0 (no, or faint staining intensity in <10% tumor 
cells), 1+ (faint, staining >10%), 2+ (moderate) and 3+ (strong). Results: The reference 
DNA sequencing showed exon 21 L858R EGFR mutations in 17 (22.4%) patients, exon 19 
deletions in 12 (15.8%) patients, G719X mutation in 1 (1.3%) patients, exon 20 insertion 
in 1 (1.3%) patients, multiple sites mutation in 1 (1.3%) patients and no mutation detected 
in 46 (52.9%) patients. With the DNA sequencing results were set as the reference 
standard, the prevalence of mutation detected by IHC-based analyses was 25.8% (8/31), 
44.4% (8/18), 100% (7/7) and 66.7% (8/12) respectively, for samples with scores 0, 1+, 
2+ and 3+. At IHC cut point value 2+, sensitivity and specificity for antibodies L858R 
were 52.9% wand 98.3 respectively. Likewise for antibodies E746-A750, cut point value 
2+ showed sensitivity and specificity as 50.0% and 95.3% E746-A750 respectively. 
Additional, indicate similar cut point as score 2 ,PPV and NPV were 66.7% and 91.0% for 
antibodies E746-A750 and 90.0% and 88% for L858R antibodies. Conclusion: A simple 
IHC-based analysis using EGFR mutation-specific antibodies in this study have good 
correlation with gene-based for EGFR mutation analysis. In Thailand, these simple IHC 
cost less for five times, have shorter turn around time than gene-based for EGFR mutation 
analysis and could be useful where molecular-based assay is not readily accessible. 
Keywords: lungcancer, EGFR, Immunohistochemistry, thailand
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P2.04-035 Methods for Evaluating Early Response to Erlotinib Treatment Using 
FDG-PET/CT Joan Fledelius1, Anne W. Larsen2, Azza Ahmed Khalil2, Jørgen Frøkiær3, 
Peter Meldgaard4 1Nuclear Medicine, Herning Hospital, Herning/Denmark, 2Department of 
Oncology, Århus University Hospital, Århus/Denmark, 3Department of Nuclear Medicine and 
Pet Centre, Århus University Hospital, Århus/Denmark, 4Department of Oncology, Aarhus 
University Hospital, Aarhus/Denmark
Background: Early evaluation of response to treatment with Fluoro-deoxy-glucose-
Positron-Emission-Tomograpy-CT (FDG-PET/CT ) is increasing rapidly, but which method 
is the ideal to use is not clear. In this study early response (1-2 weeks) evaluation was 
performed using three different methods and compared to clinical response at three 
months. Methods: Forty-three patients with metastatic pulmonary adenocarcinoma 
had FDG-PET/CT scans performed prior to erlotinib treatment and after 1-2 weeks of 
treatment. The scans were evaluated by one experienced nuclear medicine specialist. 
The scans were evaluated by three different methods using Siemens Syngovia software: 
Visual evaluation, as according to Hicks et al, % change in SULpeak as according 
to PERCIST 1.0 , and finally calculating the % change in total tumor glycolysis (TLG) 
proposed in PERCIST 1.0. The early response was compared to response on CT at 12 
weeks and to progression free survival (PFS) Results: The results are shown in figure 1. 
Defining response as “not progression” on CT at 12 weeks (10 in total), visual evaluation 
identifies 6 correctly, and 5 of 33 non-responders as responders. One patient classified 
as a responder who had a PFS of 0.9 months, had stopped treatment because of side 
effects. The SULpeak method identifies the same 6 responders correctly, and 3 of 33 
non-responders as responders. TLG change identifies 4 responders correctly and 3 of 
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mutated. From all patients tested, 15 patients (18.98%) were positive for exon 19, three 
patients for exon 21 (3.79%), two patients (2.53%) for exon 20 (T790M), two patients 
(2.53%) for exon 20 (T790M) and exon 21 (L858R) and one patient (1.26%) for exons 20 
(R776C) and 21 (L858R). No patients were positive for exon 18. Therefore, percentage of 
patients with T790M was 5.06% of all patients tested for EGFR mutation. Among patients 
with positive EGFR, 56.21% was female, 95.65% had adenocarcinoma and 4.34% large 
cell. About 69.56% was brown, 21.73% white and 8.69% black; 73.91% never smoked, 
17.39% former smokers, while 8.69% was current smoker. The mean age was 55.95 and 
median of 57 years. Approximately 47.82% of patients had one metastatic site, 39.13% 
2 metastatic sites and 13.04% 3 metastatic sites. As for first-line therapy, 52.17% 
of patients used TKIs (Afatinib or Gefitinib or Erlotinib), while 43.47% used platinum-
based chemotherapy, 4.34% used only Pemetrexed. Conclusion: The percentage of 
patients who tested EGFR mutation was high and presence of T790M was also quite 
significant. Other study found that 81% of patients with stage IIIb/IV NSCLC were tested 
for EGFR before first-line therapy administration. In a multicenter study, about 90.7% 
of newly diagnosed NSCLC patients were tested for EGFR mutation and mutation rate 
was 11.6% for exons 19 and 21. Some of our patients have not been tested for EGFR 
mutation because they were supportive patients or because the sample was insufficient/
inadequate. The profile of patients with positive EGFR was similar to that found in literature. 
Some patients did not use TKI as first-line treatment because the result of mutation 
delayed to arrive. Molecular study in NSCLC patients is essential for the best treatment 
choice and TKIs should be started as soon as there is positive result of mutation. 
Keywords: EGFR mutation, T790 EGFR mutation, non small cell lung cancer
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P2.04-039 A World of EGFR Screening Test Mélodie Carbonnaux, Pierre Jean 
Souquet, Sébastien Couraud Service de Pneumologie Aiguë Spécialisée & Cancérologie 
Thoracique, Institut Du Cancer Des Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 
Pierre Bénite/France
Background: EGFR mutation status has emerged as a crucial issue in the management 
of lung cancer. In France, the national cancer institute has launched a network of EGFR 
screening test facilities for daily practice. There is however very little information about 
EGFR screening test and TKI drugs availability in routine at a worldwide level. We also 
hypothesized that inequalities might occur in the EGFR test availability regarding country 
development. Thus, the aim of this study was to edit a map of routine EGFR test and drugs 
availability and cost subsequently associated to development indicators. Methods: We 
conducted a prospective expert opinion survey. An electronic questionnaire, edited 
in French or English, was addressed to experts in thoracic oncology in each country 
of the world. Experts were selected by three different ways: (i) email lists of partner 
institutions (the European Respiratory Society, the Asian Pacific Society of Respiratory, the 
Asociacion Latinoamericana del Torax, the Thoracic society of Australia and New Zealand ), 
(ii) manual research on the internet, and (iii) the IASLC member. Interpretation of multiple 
answers was performed according to an a priori determined algorithm. Questionnaire 
contained 10 multiple-choice questions on availability, and cost of EGFR screening test 
and EGFR tyrosine kinases inhibitors (TKI). Country development was estimated by the 
human development index (HDI) provided by UN development program. Results: We 
obtained answer from 74 countries, covering 78% of world population according to UN 
data. Experts (n=100) were mainly clinicians and worked in hospitals or cancer centers. 
Non-responding countries were mainly from Africa and Asia, and had a significantly lower 
HDI than responding countries. EGFR screening test was routinely available in whole 
the country or only in some region for 57 countries (70% of the world population; figure 
1). The remaining-cost of the test was less than 500 US$ in 49 countries (42.5% of 
the population). Availability and cost of the test were both significantly linked to HDI. 
The delay to obtain test result was less than 30 working-days in 71% of the population. 
Erlotinib, Gefitinib, Afatinib and Icotinib were routinely available in 75%, 66%, 31% and 
23% of the world population respectively. Availability and cost of erlotinib, gefitinib and 
afatinib were also associated to HDI.
consecutive patients who were diagnosed with lung adenocarcinomas and tested 
for EGFR mutations were retrospectively analyzed. As screening detects lung 
cancer at early stage, screening was incorporated as a confounder in multivariable 
analysis. Results: Among 1004 patients with lung adenocarcinomas, EGFRmutations 
were detected in 49.2% (494 of 1004). In multivariable analysis, EGFR mutations were 
significantly associated with early stage (stage I to II) at diagnosis (OR, 0.65; 95% CI, 
0.49 to 0.87; P = 0.003). When adjusted for age, sex, smoking status, and screening, 
adjusted proportion of EGFR mutations significantly decreased according to stage. 
Adjusted proportion of EGFR was 57.6% (95% CI, 51.7% to 63.3%) in stage I, 47.9% 
(95% CI, 36.9% to 59.0%) in stage II, 47.5% (95% CI, 39.6% to 55.5%) in stage III, and 
43.4% (95% CI, 38.3% to 48.6%) in stage IV (P = 0.0082). Conclusion: The presence 
of EGFR mutations is significantly associated with early stage at initial diagnosis in lung 
adenocarcinomas after adjusting for age, sex, smoking status, and screening. This 
finding implies that EGFR mutations may play a role as a positive prognostic marker. 
Keywords: lung cancer, Adenocarcinoma, EGFR, stage
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P2.04-037 Frequency of EGFR Mutations in NSCLC Patients of the Lung 
Center of the Philippines Maria Teresa A. Barzaga1, Francisco Iii M. Heralde2, Jose 
Luis J. Danguilan3, Nelia S. Tan-Liu1 1Pathology, Lung Center of the Philippines, Quezon/
Philippines, 2Biochemistry and Molecular Biology, University of the Philippines - Manila, 
Manila/Philippines, 3Thoracic Surgery, Lung Center of the Philippines, Quezon/Philippines
Background: In 2014, the Lung Center of the Philippines embarked on a program to offer 
Epidermal Growth Factor Receptor (EGFR) mutation testing to its Non-Small Cell Lung 
Carcinoma (NSCLC) patients to support the diagnostic and decision-making capability 
of its allied oncologists towards anti-EGFR targeted therapy. As previous clinical studies 
indicated significant benefit from Tyrosine Kinase Inhibitor (TKI) therapies among Asian 
patients, enrolling patients on a TKI program based on anti-EGFR profile would realize 
the Lung Center of the Philippines’ objective of providing better chemotherapy to its 
patients. Meanwhile, early reports showed variable frequency of EGFR mutations among 
NSCLC patients from two private Philippine hospitals (i.e. San Juan De Dios, 52.3% EGFR 
positive in 2012 and Saint Luke’s Medical Center, 38.9% EGFR positive in 2015). This 
study will report the profile of EGFR mutation among NSCLC patients from a government 
tertiary hospital catering to the general Philippine population. Methods: Tissue samples 
from 80 patients clinically diagnosed with NSCLC at stages II to IV via histopathologic 
sections of biopsy derived specimens, were subjected to EGFR mutation analysis 
following the Roche EGFR protocol using the Roche EGFR mutation detection kit and 
the Cobas Quantitative Real Time PCR. The patients’ background data were obtained 
via a survey questionnaire at the time of sample submission and followed up through 
telephone interview. The patients were made to execute informed consents following 
the guidelines of the Institutional Ethics Review Committee of the Hospital. Results: Out 
of the 80 NSCLC samples analyzed, 55% (44/80) were from males and 45% (36/80) 
were from females with a mean age of 61.3 (SD: 11.5) years old. There were 47.5% 
(38/80) specimens that were positive for EGFR mutations of which 39.5% (15/38) 
were from males and 60.5% (23/38) were from females. Majority of the EGFR positive 
patients were non-smokers with only 13.8% (11/80) confirmed to be smokers and 
only 18.2% (2/11) of the smokers showing positive EGFR mutation. For patients 
showing positive EGFR mutations, 73.7% (28/38) were Exon 19 deletions, 23.7% 
(9/38) were Exon 21 L858R, and 2.6% (1/38) was a double mutation comprising Exon 
19 deletion and Exon 20 insertion, and is a non-smoker. Conclusion: EGFR mutation 
frequency in LCP’s NSCLC patients were midway between the reported values in two 
Philippine private hospitals and consistent with the reported preponderance among 
females. Smoking appears not to be a driver for EGFR mutation. Majority of the EGFR 
mutations detected were on Exon 19 deletion. How these mutation patterns correlate 
with the chemotherapeutic response would be an important area for future follow-up. 
Keywords: Non-small-cell lung cancer, EGFR testing, Lung Center of the Philippines, 
Exon 19 deletion
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P2.04-038 EGFR Mutation Prevalence and Epidemiological Profile of Patients 
with Metastatic Nonsquamous Non Small Cell Lung Cancer Maria Fernanda E. 
Simões, Eldsamira Mascarenhas, Tercia V. Reis, Clarissa Mathias Núcleo de Oncologia 
Da Bahia, Bahia/Brazil
Background: Presence of epidermal growth factor receptor (EGFR) mutation in patients 
with non small cell lung cancer (NSCLC) is very important for therapeutic choice, 
since these patients benefit from the use of targeted therapies, such as EGFR tyrosine 
kinase inhibitors (TKIs). There are different types of EGFR mutation causing deletions 
in exons 18, 19, 20 and 21. Presence of this mutation is commonly found in female, 
Asian ethnicity, never smokers and adenocarcinoma histology. Patients with EGFR 
mutations have benefit of use TKIs because these drugs inhibit tyrosine kinase activity, 
enabling apoptosis of tumor cells. However, there are cases of TKI resistance due to 
mutations at EGFR second site, resulting in T790 mutation (T790M), which prevents 
TKI connection to tyrosine kinase. This study aimed to determine the percentage of 
patients with metastatic nonsquamous NSCLC which realized molecular analysis for 
EGFR mutation, especially T790M, and to describe epidemiological profile of these 
patients. Methods: Observational, retrospective, single-institutional study in metastatic 
nonsquamous NSCLC patients, in attendance during January 2012 and December 
2014. Variables analyzed: age, sex, race, smoking, number of metastatic sites, first-
line therapy, presence of EGFR mutation and T790M. Results: There were 93 eligible 
patients, 79 (84,94%) of them were tested for EGFR and 23 patients (29.11%) of 79 were 
S591Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-041 Characterization of EGFR Activating Mutations in Brazilian Patients 
with Pulmonary Adenocarcinoma Cheng T. Yen1, Rafael C. Bitton1, Luiz G.C.A. De 
Lima1, Alex V. Amadio2, Tiago K. Takahashi1, Andrea M. Marini1, Tereza Y. Takagaki1, 
Ricardo M. Terra1, Evandro S. Mello1, Gilberto De Castro Jr1 1Medical Oncology, Instituto 
Do Cancer Do Estado de Sao Paulo - Icesp, Sao Paulo/Brazil, 2Usp, Sao Paulo/Brazil
Background: The presence of EGFR activating mutations in pulmonary adenocarcinoma 
is predictive of exquisite response to EGFR-tyrosine kinase inhibitors. Here we studied 
the frequency of EGFR activating mutations in pts consecutively treated in our 
institution. Methods: It is a retrospective, uniinstitutional study of all consecutively 
tested samples from pts diagnosed with pulmonary adenocarcinoma and treated in our 
Institute. All samples were formalin-fixed and paraffin-embedded. Tumor areas were 
selected and macrodissected, followed by whole DNA extraction and amplification by 
PCR. EGFR genotyping was performed through DNA sequencing (exons 18, 19, 20 and 
21) by Sanger´s methodology. Results:417 pts had tumor samples genotyped between 
Aug/2011 and Sep/2015. Median age was 62 y (17-91), 237 (57%) female. According to 
ethnicity, 357 pts were Caucasian (86%), 37 African-American (9%) and 21 Asian (5%); 
140 pts were classified as never-smokers (34%), 37 (9%) as light-smokers (≤ 10 p.y.) and 
238 (57%) as current smokers/> 10 p.y. EGFR activating mutations could be identified 
in 103 out of 417 samples (24.7%): 78 were exon 19 deletions (76%), 23 were L858R 
mutation in exon 21 (22%), and two were rare mutations (G719S in exon 18, and V774M 
and S768I in exon 20). These mutations were found to be more frequent in females 
than in males (32% vs. 15%, p=0.0001), and in never-smokers and light-smokers than 
in current smokers/> 10 p.y. (65% vs. 16%, p<0.0001). It is noteworthy to mention that 
EGFR mutations were detected in 31 current smokers/> 10 p.y. pts. With the exception of 
2 cases, all tumors harboring EGFR activating mutations presented TTF-1 expression by 
immunohistochemistry, and among those TTF-1-negative adenocarcinomas, no mutation 
was detected in 36/38 samples (p=0.0011). In a median follow-up of 12 months, the 
median overall survival was 16.3 months among those pts with stage IV and ECOG-PS 0-1, 
whose tumors presented EGFR-activating mutations. Conclusion: In this Brazilian pts, the 
frequency of EGFR activating mutations was 28%, being more frequent in females, and 
never-smokers or light smokers. These results reinforce the importance of diagnosing 
EGFR activating mutations in all pts with TTF-1-positive, pulmonary adenocarcinoma. 
Keywords: EGFR activating mutations, pulmonary adenocarcinoma
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P2.04-042 Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients 
with Non-Small Cell Lung Cancer (NSCLC) in a University Hospital in Latin 
America Luz F. Sua1, Lisa X. Rodriguez2, Liliana Fernandez3, Carlos A. Muñoz4, Juan G. 
Restrepo5 1Department of Pathology and Laboratory Medicine and Phd Biomedical Sciences, 
Fundacion Valle Del Lili, Universidad ICESI, Cali/Colombia, 2Department of Pathology 
and Laboratory Medicine and Phd Human Genetics, Fundacion Valle Del Lili, Universidad 
ICESI, Cali/Colombia, 3Interventional Pulmonology, Fundacion Valle Del Lili, Universidad 
ICESI, Cali/Colombia, 4Medical Research, Fundacion Valle Del Lili, Universidad ICESI, Cali/
Colombia, 5Hemato-Oncology Clinic, Fundacion Valle Del Lili, Universidad ICESI, Cali/
Colombia
Background: The presence of activating gene mutations in the epidermal growth factor 
receptor of non-small cell lung cancer patients is predictive. It improved progression-free 
survival and improved response rate when treated with small molecule tyrosine kinase 
inhibitors. Together, exon 19 deletion and exon 21 L858R gene substitution are present in 
about 10% of Caucasian patients and in 20–40% of Asian patients. Moreover, guidelines 
now suggest EGFR gene mutation testing should be conducted in all patients with lung 
adenocarcinoma or mixed lung cancers with an adenocarcinoma component, regardless 
of characteristics such as smoking status, gender or race. The success of targeted 
therapies in non-small cell lung cancer patients has changed the treatment paradigm in 
metastatic non-small cell lung cancer. We describe the frequency of mutations in exons 
19 and 21 of the EGFR gene in (NSCLC) in our hospital Methods: Between June 2013 
and March 2015, 73 samples of lung tissue of patients with NSCLC were obtained in 
Fundacion Valle del Lili Cali-Colombia. Microdissection cuts on paraffin-embedded lung 
tissue was performed with the objective of increasing the amount of tumor DNA. DNA 
was extracted with DNA FFPE Tissue Kit QIAamo Kit (Qiagen), then amplified with PCR 
and exons 19 and 20 of EGFR mutations studied for amplification. Visualization was 
performed using microfluidic electrophoresis in the Agilent Bioanalyzer. Results: We 
analyzed tumor samples from 73 patients with NSCLC by PCR and RFLP. Good quantity 
and quality of DNA in 96% (70) cases was obtained. The average age was 65.6 years 
± SD, 69% (48) women and 31% (22) men. EGFR mutations were observed in 21% (15) 
of the samples with 80% (12) in females. 47% of mutations were in exon 19 and 53% 
in exon 21. 80% of cases with mutations were adenocarcinomas. 53% of patients with 
mutations were in stage IV disease and 33% of patients received the tyrosine kinase 
inhibitor. Conclusion: In patients who are properly selected for EGFR-positive gene 
mutations, EGFR-TKIs have been shown to improve symptom control and quality of 
life, especially in frail elderly patients who desire to avoid the systemic side effects of 
cytotoxic chemotherapy while achieving a certain level of clinical efficacy. As more clinical 
trials for novel third-generation EGFR TKIs and other alternative therapies mature, better 
understanding may be gained through the use of these agents in improving treatment 
efficacy in adenocarcinoma or even squamous cell histology of metastatic NSCLC.
 
Conclusion: EGFR screening test and EGFR TKI are widely accessible in 
routine worldwide. However, there are large discrepancies in the access 
and the cost of this innovative process regarding development index. 
Keywords: EGFR mutation, EGFR Tyrosine Kinase Inhibitors, worldwide mapping
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P2.04-040 Impact of Ethnicity on Incidence of Brain Metastasis in Patients 
with EGFR-Mutant Lung Cancer Jiexia Zhang1, Huiyu Wen2, Di Cai1, Hahn La2, David 
R. Gandara2, Jianxin He1, Lihong Qi3, Tianhong Li2 1Guangzhou Institute of Respiratory 
Disease, Guangzhou/China, 2Division of Hematology & Oncology, Uc Davis Comprehensive 
Cancer Center, Sacramento/CA/United States of America, 3Department of Public Health 
Sciences, University of California, Davis, Davis/CA/United States of America
Background: Better systemic control and longer survival have been cited as the reason 
for the higher incidence of brain metastasis observed in patients with EGFR-mutant lung 
cancer compared to patients with EGFR wild-type lung cancer. The prevalence of EGFR 
mutation is particularly dependent on patient’s ethnicity: 30-40% and 10-16% in East 
Asian and Caucasian patients, respectively. However, the incidence of brain metastasis in 
EGFR mutant lung cancer at initial diagnosis in these ethnic groups is less well defined. The 
objective of this study was to investigate the incidence of brain metastasis at diagnosis 
in East Asian and Caucasian patients with EGFR-mutant lung cancer. Methods: This 
retrospective study included 163 consecutive patients with EGFR-mutant metastatic 
NSCLC from a Chinese (N=72) and a US academic (N=91) institution. The EGFR 
mutation status was determined by the institutional laboratory in China and CLIA-certified 
laboratory in the US. East Asians in Northern California and Chinese patients in China had 
a similar incidence of brain metastasis at diagnosis (10/23=43.5% and 30/72=41.7%, 
respectively), and were combined as East Asians in the analysis. Descriptive statistics 
were generated for demographics, smoking habits, histology, and EGFR mutation 
subtypes, stratified by status of brain metastasis at diagnosis. Chi-squared tests and 
t-tests were used for testing associations of categorical variables and continuous 
variables with brain metastasis at diagnosis, respectively. Logistic regression models 
were used to study the association between race and brain metastasis at diagnosis, with 
and without adjusting for age at initial diagnosis, gender, EGFR mutation type, smoking 
status, and histology. Odds ratio (OR) and corresponding 95% confidence intervals 
(CI) were obtained. All analyses were two sided and a p value <0.05 were considered 
significant. Results: Three patients who were neither East Asian nor Caucasian were 
ineligible for analysis. Among the remaining 160 patients, 44.2% were Caucasians and 
55.8% East Asians. Higher incidence of brain metastasis at diagnosis was detected in 
East Asian patients than Caucasian patients (42.1% vs 13.8%, p= 0.0001). There is no 
significant difference in the mean age (62 and 59 years old), smoking history (34.2% 
vs 26.5%), histology (93.8% adenocarcinoma in both groups), type of EGFR mutation 
(Exon 19 Deletion: 47.8% vs 48.0%; L858R: 35.4% vs 38.0%) between patients without 
brain metastasis and with brain metastasis at diagnosis. Comparing to Caucasians, 
East Asians had significantly higher incidence of brain metastasis at diagnosis (OR = 
4.53, 95% CI: 2.01–10.20, p= 0.0003). The result remained significant after adjusting 
for other factors (aOR = 4.24, 95% CI: 1.76–10.18, p= 0.001). Conclusion: Regardless 
of place of residence (Northern California or China), East Asians were more likely to 
have brain metastasis at initial diagnosis than Caucasian patients, suggesting ethnicity-
related genomic and pharmacogenomic differences and less impact of environmental 
factors on tumorigenesis and clinical course of EGFR-mutant lung cancer. Further 
study is indicated to understand the impact of ethnicity and population-related 
genomics and pharmacogenomics on tumor biology of EGFR-mutant lung cancer. 
Keywords: EGFR-mutant lung cancer, Ethnicity, Brain metastasis
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Results: All 3 lesions were successfully navigated and tissue samples were all adequate 
for molecular testing. NSCLC favoring adenocarcinoma was diagnosed for all 3 sites. 
However, the admixture of cell types (bronchial epithelial, infl ammatory cells, etc) meant 
that only the smallest 6mm peripheral right middle lobe lesion tissue sample biopsy 
could be used for this specifi c trial. Based on these pathology results this patient was 
enrolled. Conclusion: Newer minimally invasive biopsy technologies such as ENB™ 
guidance can facilitate biopsies of multiple pulmonary sites in one procedure; such 
procedures are safe and feasible in a community based setting. Moreover, these procedures 
are increasingly important to meet the expanding needs for advanced histological and 
molecular testing in oncology. This procedure enabled us to enroll this patient in a Phase 
I National Trial that may potentially address his acquired resistance to Erlotinib treatment. 
Keywords: bronchoscopy, EGFR, navigation, molecular testing
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P2.04-044 Analysis of the Intra-Tumor Heterogeneity and Consistency 
between FGFR1 Gene Amplifi cation and Protein Expression in Squamous 
Cell Lung Cancer Monika M. Skupinska1, Paulina Jagus2, Paulina Grygielewicz1, 
Agata Mikolajczyk1, Ewa Szczepulska3, Adriana Rozy2, Renata Langfort3, Joanna 
Chorostowska-Wynimko2, Maciej Wieczorek1, Aleksandra Stanczak1 1Innovative 
Drugs R&D Department, Celon Pharma S.A., Lomianki/Poland, 2Department of Genetics 
and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw/
Poland, 3Department of Pathomorphology, National Institute of Tuberculosis and Lung 
Diseases, Warsaw/Poland
Background: Preclinical data have shown that inhibition of fi broblast growth factor 
receptor 1 (FGFR1) could be a promising therapy for lung tumors with FGFR1 amplifi cation 
or expression. The candidate predictive biomarkers FGFR1 amplifi cation and protein 
overexpression has been reported respectively in 10-20% or 10-41% patients (pts) with 
squamous cell lung carcinoma (SqCLC). Therefore, there is an urgent need to assess 
relationship between both, as well as the heterogeneity of their intratumoral distribution 
as the potential confounding factors for testing reliability. Methods: 3 to 5 FFPE 
sections from different regions of each of 20 SqCLC tumors were analyzed. FGFR1 gene 
copy number was assessed by FISH method using probes specifi c for the 8p12 locus 
and the chromosome 8 centromere (CEN8). Criteria of FGFR1 amplifi cation were 
as follows: FGFR1/CEN8 >2.0 or the average number of FGFR1 signals per cell >6 or 
>10% of tumor cells containing >15FGFR1 signals. FGFR1 protein expression was 
determined by immunohistochemistry (IHC). Expression was defi ned as staining intensity 
2+ or 3+ (graded from 0 to 3+) in >1% of the cancer cells. For the heterogeneity 
analysis only patients with >4 slides per tumor were taken into account (15/20 pts). 
Different defi nition of heterogeneity was considered. Finally, tumor was classifi ed as 
heterogeneous, when >25% of slides showed different results of FISH or IHC. Statistical 
calculation of correlation between FISH and IHC results (19/20 pts) was performed using 
the GraphPad Prism software using Spearman test. Results: FGFR1 amplifi cation was 
observed in 6/20 (30%) SqCLC tumors. The average FGFR1 gene copy number per cell 
ranged from 1.9 to 10.9 (mean: 4.6) and the mean FGFR1/CEN8 ratio was 2.3 (range: 
0.7–3.7). The mean content of tumor cells with >15 FGFR1 copies was 2.2%. In IHC(+) 
tumors (5/20, 25%) the percentage of stained cancer cells with intensity >2 was low 
- only 10/78 samples contained more than 10% of them. In total, 62 FFPE samples 
from 15 SqCLC patients were analyzed for tumor heterogeneity. FGFR1 amplifi cation 
was homogeneous in all pts (15/15), in contrast to expression, as 1/15 tumor was 
confi rmed heterogeneous. The FISH and IHC results were consistent in 52% SqCC 
patients (n=19), including 1/19 (5.2%) double-positive and 9/19 (47.3%) double-negative 
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POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-043 A Successful Case in Which Electromagnetic Navigation 
Bronchoscopy Identifi ed an EGFR Mutation in Small Peripheral Lung Lesions
Jaspal Singh1, John W. Longshore2, Daniel Haggstrom1 1Thoracic Oncology, Levine 
Cancer Institute, Charlotte/United States of America, 2Carolinas Pathology Group, Carolinas 
Healthcare System, Charlotte/NC/United States of America
Background: Our institution participated in a Phase I National Trial that treats patients 
with advanced NSCLC. Clinical enrollment not only required repeat biopsy of tissue for 
histopathological analysis and molecular testing, but the target lesions were technically 
challenging due to size, number of lesions, risk, and and time constraints. Utilization of 
electromagnetic navigation bronchoscopy (ENB) was used to enroll a patient in a clinical 
trial in which multiple target lesions were identifi ed, but the only viable target lesion was 
a mere 6mm in diameter in the periphery of the lung. Methods: A 54 year old Asian 
male showed disease progression in a follow-up chest CT after 9 months of treatment 
with Erlotinib, suggesting that an acquired resistance to Erlotinib had developed after 
an initial successful response. Additional tissue specimens were needed to determine if 
the patient was eligible to participate in a Phase I National Clinical Trial that is attempting 
to prevent EGFR mutations from acquiring resistance mechanisms. An electromagnetic 
navigational bronchoscopy (ENB™) guided forceps biopsy tool was utilized to obtain 
tissue samples from 3 separately identifi ed lesions.
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essential and potentially transformative kinases to connect them to drugs. One of the 
top kinase inhibitors connected by K-Map was sunitinib. From published papers, we 
found that H1703 has been validated to be sensitive to sunitinib, supporting the K-Map 
prediction of inhibitors on the essential kinases. Further validation will be performed 
and presented in the conference. Conclusion: Functional genetic screens have the 
potential to identify genes essential for cancer cell survival and proliferation, providing 
a “functional” map in “driver negative” NSCLC. Using a series of novel bioinformatics 
analyses, specifically connecting the essential kinases with small molecules based 
on inhibition activities, we have identified that candidate drugs effectively inhibits the 
essential kinases in “driver negative” NSCLC cell lines resulting in cell death. Further 
investigation of these candidate drugs and the functional role of these essential kinases 
could provide personalized treatment for the “driver negative” lung cancer patients. 
Keywords: RNAi screen, kinases, NSCLC, Bioinformatics
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P2.04-047 Mitochondrial Activation- A Potential Therapy in Lung Cancer Ronen 
Shavit1, Maya Ilouze2, Tali Feinberg3, Yaacov Richard Lawrence1, Nir Peled2, Yossi Tzur1 
1Thoracic Cancer Reasearch and Detection Center, Sheba Medical Center Tel Hashomer, 
Ramat Gan/Israel, 2Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa/
Israel, 3Physiology and Pharmacology, Tel Aviv University, Tel-Aviv/Israel
Background: Lung cancer is the leading cause of cancer related deaths in the United 
States with an overall 5- year survival rate of all stages of~ 17%. Radiation therapy plays 
a key role in lung cancer treatment. However, many lung cancer patients show resistance 
to radiation. There is a growing body of evidence indicating that mitochondria may be the 
primary targets for cancer therapeutics: The unique metabolism of most solid tumors, 
including lung cancer, stems from remodeling mitochondrial functions to produce a 
glycolytic phenotype and a strong resistance to apoptosis (Warburg effect). Cancer 
specific remodeling can be reversed by a small molecule named dichloroacetate (DCA) 
which promote mitochondrial activation by increasing the influx of pyruvate. Sodium 
oxamate- another molecule that interferes with cells metabolism, inhibits the formation 
of the lactate-the end product of glycolysis. Here, we tested whether mitochondrial 
induction (using DCA and sodium oxamate) may increase the sensitivity of non-small 
cell lung cancer (NSCLC) cells to radiation through this mechanism. Moreover we tested 
whether sodium oxamate, increases the effect of DCA on radiation. Methods: Two 
representative NSCLC cell lines (A549 and H1299) were tested for their sensitivity to 
radiation with and without pre-exposure to DCA and sodium oxamate. The treatment 
efficacy was evaluated using a clonogenic survival assay. An extracellular flux analyzer 
was used to assess the effect of DCA on cellular oxygen consumption as a surrogate 
marker for mitochondrial activity. Results: We found that DCA increases the oxygen 
consumption rate in both A549 and H1299 cells by 60 % (p = 0.0037) and 20 % 
(p = 0.0039), respectively. Pre-exposure to DCA one hour before radiation increased the 
cytotoxic death rate 4-fold in A549 cells (55 to 13 %, p = 0.004) and 2-fold in H1299 
cells (35 to 17 %, p = 0.28) respectively, compared to radiation alone. Sodium Oxamate 
radisosensitized H1299 cells as well. Double treatment with DCA and Sodium Oxamate 
enhances the radiosensitivity of H1299 cells. Conclusion: Mitochondrial activation may 
serve as a radio-sensitizer in the treatment of non-small cell lung cancer. Inhibition of 
the end stage of glycolysis increases the effect of mitochondrial activation on radiation. 
Keywords: DCA, Radiation, Warburg effect, Non small cell lung cancer, radiosensitization
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P2.04-048 Analysis of Gene Expression in the Re-Replication Pathway and 
Selective Blockade with Checkpoint Inhibitors as a Therapeutic Option in 
NSCLC Daniela Morales-Espinosa1, Miguel A. Molina-Vila2, Ana Gimenez-Capitan2, Silvia 
García-Román2, Jordi Bertrán-Alamillo2, Pedro Méndez-Romero3, José L. Ramírez-
Serrano4, Santiago Viteri5, Niki Karachaliou6, Rafael Rosell7 1Translational Lung Cancer 
Research Laboratory, Germans Trias I Pujol Health Sciences Institute and Hospital, Catalan 
Institute of Oncology, Badalona/Spain, 2Laboratorio de Oncología/Pangaea Biotech. Hospital 
Universitario Quirón Dexeus. Barcelona, Barcelona/Spain, 3Thoracic Oncology Laboratory, 
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco/CA/United States of 
America, 4Hospital Germans Trias I Pujol, Catalan Institute of Oncology, Badalona/Spain,5Dr 
Rosell Oncology Institute, Quirón Dexeus University Institute,, Barcelona/Spain, 6Translational 
Research Unit, Dr Rosell Oncology Institute, Barcelona/Spain, 7Hospital Germans Trias I 
Pujol, Catalan Institute of Oncology, Barcelona/Spain
Background: Targeted lung cancer therapy has undoubtedly made a difference to 
the treatment of EGFR mutation and ALK translocation carriers. However, targeted 
therapies for other subgroups like squamous cell carcinoma are still scarce. Re-
replication of the genome could initiate gene amplification and cause chromosomal 
translocation and loss, contributing to tumor progression. It has been shown that cell 
cycle checkpoints and DNA damage response are activated when re-replication is 
induced. Cell cycle checkpoints, mediated by CHK1 and 2, are essential to prevent re-
replication and maintain genomic integrity. Specific CHK1 inhibitors such as LY2603618 
have been shown to delay tumor growth when given in combination with pemetrexed in 
NSCLC xenograft models. Methods: We selected a panel of NSCLC adenocarcinoma 
and squamous cell carcinoma cell lines representing different genetic backgrounds 
with TP53, KRAS and EGFR mutations. In addition, six PC9-derived, TKI resistant cell 
lines were included (PC9-ER, PC9-GR1 to GR5). Expression of genes involved in the 
re-replication pathway (MDC1, ATR, ATM, CHEK2, Rap80, Cdc1, Cdc6, MYC, SLX4, CHEK1, 
BRCA1, BRCA2, p53, ORC4, ORC5, ORC6 and GMNN ) was analyzed by RT-PCR. All cell lines 
were treated with CHK1 and a CHK1/2 inhibitors, and the IC50 was determined by the 
MTT assay Results: We observed different expression levels of key genes involved in 
tumors. In 9/19 pts results were discordant: 5/19 (26.3%) IHC(-) FISH(+), while in 4 
(21%) pts IHC(+) FISH(-). FGFR1 amplification did not correlate with protein expression 
(P=0.543; r=-0.149) for 19 SqCLC tumors . Conclusion: Our study demonstrated 
relative SqCLC tumor homogeneity in terms of FGFR1 amplification and expression. 
However, FGFR1 amplification did not relate to protein expression. Therefore, further 
more detailed evaluation of both biomarkers FGFR1 amplification and protein expression 
regarding their predictive diagnostic value towards anti-FGFR therapy is needed. 
Keywords: Squamous cell lung cancer, biomarker, FGFR1 expression, FGFR1 
amplification
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P2.04-045 Targeting eIF4A1 and eIF4A2 mRNA Helicases in Pulmonary 
Adenocarcinoma Farheen Raza1, Junichi Tanaka2, John Le Quesne1 1Medical Research 
Council Toxicology Unit, Leicester/United Kingdom, 2University of the Ryukyus, Okinawa/
Japan
Background: Neoplasia is frequently associated with dysregulated mRNA translation. 
This dysregulation facilitates tumour growth by promoting proliferation, survival 
and angiogenesis. Translation is mostly regulated at the initiation stage during which 
translation initiation factors facilitate positioning of the translation-competent ribosome 
at the start codon of mRNA. Eukaryotic initiation factors 4A1 and 4A2 are ATP-dependent 
DEAD-box helicases that unwind 5’ UTR as a subunit of the eIF4F complex. eIF4A2 shares 
91% amino-acid sequence identity with eIF4A1 and has been implicated in mRNA-
mediated silencing. Studies have suggested separate roles for the two eIF4A isoforms. 
High-level expression of eIF4A1 in early stage non-small cell lung cancer (NSCLC) primary 
tumours was shown to be associated with poor survival, and, recently, downregulation 
of eIF4A2 was shown to promote NSCLC progression. Small molecule inhibitors of eIF4A 
have been shown to have anticancer effects in cell culture and xenograft models. Thus, 
eIF4A1 and eIf4A2 hold promise as important mediators in lung cancer. This study aims 
to elucidate the role of eIF4A1 and eIF4A2 in the development of malignant phenotype 
in pulmonary adenocarcinoma. Methods: This study employed two human cancer cell 
lines as a model for pulmonary adenocarcinoma: HCC364 and H2228. eIF4A activity 
was modified by using hippuristanol, a non-specific allosteric small molecule inhibitor 
of both eIF4A isoforms, and siRNA-mediated knockdown of eIFA1 or eIF4A2. Cell cycle 
analysis was performed using EdU labelling and flow cytometry and cell proliferation was 
measured by cell counting, xCELLigence and WST metabolic assays. Effects of eIf4A 
inhibition on protein translation were studied through polysome profiling. Results: Both 
adenocarcinoma cell lines showed significant reduction in S-phase cell population and 
metabolic activity when treated with hippuristanol. Polysome profiling of HCC364 
cells treated with hippuristanol revealed a substantial decrease in polysomal fractions 
accompanied with the liberation of ribosomal units. Although siRNA-mediated silencing 
of eIF4A1 markedly suppressed cell proliferation in HCC364 cells, the H2228 cells 
were unaffected. Interestingly, silencing of eIF4A2 in H2228 cells sometimes results in 
marked hyperproliferation. Conclusion: Our data suggest very different roles of eIF4A 
isoforms in lung cancer, which have major implications for possible anti-eIF4A therapies. 
In particular, it suggests that inhibition of eIF4A2 may have a growth-promoting effect 
in some tumours. As current small molecule inhibitors are non-specific between the two 
isoforms, this has major implications for the use of similar compounds in a clinical setting. 
Keywords: eif4a, Adenocarcinoma, helicase
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P2.04-046 Kinome RNAi Screens Identify Essential Genes and Therapeutics In 
‘Driver Negative’ Non-Small Cell Lung Cancer Jihye Kim1, Daniel Foster2, Rangnath 
Mishra2, Jeffrey Kern2, Aik-Choon Tan1, James H. Finigan2 1Division of Medical Oncology, 
University of Colorado Som, Aurora/CO/United States of America, 2Oncology, National 
Jewish Health, Denver,Co/CO/United States of America
Background: Lung adenocarcinoma is a leading cause of cancer-related death worldwide. 
The discovery of “driver” mutations in genes such as the epidermal growth factor 
receptor (EGFR) which are required for malignant transformation have revolutionized lung 
cancer care as chemotherapy directed against these proteins has resulted in dramatic 
improvements in survival. Approximately 75% of the non-small cell lung cancer (NSCLC) 
patients harbor a driver gene (KRAS, EGFR, ALK, ROS etc) from the recent molecular 
characterization of lung adenocarcinomas by The Cancer Genome Atlas. Unfortunately, 
~25% of the patients are “driver negative”. Therefore, identifying genes essential for 
malignant pathogenesis in these “driver negative” NSCLC may serve as new therapeutic 
targets for these patients. Methods: Four “driver negative” NSCLC cell lines – H292, 
H1703, H228, and H322C – were used in the kinome RNAi essential screen. Cells were 
transduced with a short-hairpin loop lentiviral kinome library (~3700 shRNAs targeting 
~600 kinases) developed by The RNAi Consortium (TRC 1.0/1.5). Cells were cultured 
and harvested after 2, 7, and 14 days of transduction. ShRNAs from surviving cells were 
extracted, reverse transcribed and barcoded for individual replicates. These samples 
were sequenced on the Illumina HiSEQ 2000. BiNGS! software was used for analyzing 
and interpreting the essential screen. Kinases were considered essential if were present 
at day 2 but they were lost (i.e. knocked out causing cell death) at both day 7 and day 
14. We then queried these essential kinases to K-Map, a bioinformatics platform that 
systematically connects a kinase profile with a reference kinase inhibitor database and 
predicts the most effective inhibitor for a queried kinase profile. Results: All samples 
from four cell lines had on average 85% of mapping rates (70% - 92%) with 5 to 24 
million mapped reads per sample. In total, twenty kinases were identified as essential 
kinases for these “driver negative” cell lines. For example, MAPK4 for H292; ERBB3 
for H322C; ATR for H228; and KDR for H1703. We queried the K-Map using the twenty 
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P2.04-050 Basaloid Squamous Cell Cancers Arising from the Lung: Next 
Generation Sequencing Reveals PTCH1 Mutations in the Hedgehog Pathway 
Bob T. Li1, Natasha Rekhtman2, Helen Won2, Maria E. Arcila2, Charles M. Rudin1, Mark 
G. Kris1, Michael Berger2, Paul Paik1 1Department of Medicine, Memorial Sloan Kettering 
Cancer Center, New York/NY/United States of America, 2Department of Pathology, Memorial 
Sloan Kettering Cancer Center, New York/NY/United States of America
Background: Basaloid squamous cell lung cancers are a defined variant of non-small 
cell lung cancers associated with a high mitotic count and rapid clinical progression. 
Due to its morphologic similarities with basal cell carcinoma of the skin, distinguishing 
between the two can be difficult. We sought to define the molecular characteristics of 
basaloid squamous cell cancers that were clinically defined as possible lung primaries 
in an effort to aid in the diagnosis of this disease. Methods:We reviewed a total of 179 
patients who were diagnosed with squamous cell lung cancers and had undergone tumor 
next generation sequencing at Memorial Sloan Kettering. Through the MSK-Integrated 
Mutation Profiling for Actionable Cancer Targets (MSK-IMPACT), the illumina HiSeq 
platform was used to detect 341 potentially actionable genetic alterations, including 
single base substitutions, indels, copy number alterations and selected gene fusions. 
Data on clinicopathologic characteristics, smoking history were reviewed, and their 
mutational profile described. Results: A total of 6 of 179 (2%) patients with squamous 
cell lung cancers were found to have basaloid features. Of the 6 patients with basaloid 
features, 5 (83%) were men, 2 (33%) were never-smokers, 6 (100%) were white 
Caucasians, 3 (50%) had resected lung specimens, and 2 (33%) presented with stage 
IV disease. Three cases (50%) had protein patched homolog 1 (PTCH1) mutations in the 
hedgehog pathway (H652Y, V1057splice, V579fs), identical to those found in basal cell 
carcinoma of the skin. Two of these patients had a history of basal cell carcinoma of 
the skin, raising the possibility of metachronous metastatic basal cell carcinoma of the 
skin. One patient had no such history of basal cell skin cancer. Conclusion: Basaloid 
squamous cell cancers that appear to arise from the lung frequently harbor PTCH1 
mutations. Metachronous metastatic basal cell carcinoma of the skin needs to be 
considered as a possibility in patients with a history of superficial skin lesions. Patients 
diagnosed with these basaloid cancers that harbor PTCH1 mutations, whether from 
skin or lung origin, may benefit from hedgehog pathway inhibitors such as vismodegib. 
Keywords: Squamous cell carcinoma, Basaloid features, hedgehog pathway, PTCH1 
mutation
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P2.04-051 The Pluripotency Factor Musashi-2 Is a Potential Target for Lung 
Cancer Therapy Mary Zhang, Sichuan Xi, Yin Xiong, Shakirat Oyetunji1, Julie A Hong, 
David Straughan, Saïd Azoury, Emily Reardon, Haobin Chen, David S. Schrump 
Tgib, Nci/Ccr/Nih, Bethesda/MD/United States of America
Background: Recent studies have demonstrated that mithramycin represses multiple 
pathways critical for stem cell signaling and pluripotency in lung cancer cells. This 
phenomenon coincides with decreased side population (SP) fraction, and dramatic 
dose-dependent growth arrest of lung cancer cells in-vitro and in-vivo. The present study 
was performed to further examine the effects of mithramycin on stem cell signaling 
in an attempt to identify novel targets for lung cancer therapy. Methods: Microarray, 
quantitative RT-PCR (qRT-PCR) and immunoblot techniques were used to examine 
stem cell gene expression and proliferation of human lung cancer cells and normal/
immortalized human respiratory epithelial cells (SAEC/NHBE/HBEC) cultured in 
the presence or absence of mithramycin, or lung cancer cells following stem cell 
gene knockdown. Micro-array and qRT-PCR techniques were used to assess effects 
of systemic mithramycin exposure on stem cell gene expression in subcutaneous 
lung cancer xenografts in athymic nude mice. qRT-PCR and immunoblot techniques 
were used to examine endogenous levels of selected stem cell genes in induced 
pluripotent stem cells (iPSC) derived from SAEC, as well as primary lung cancers and 
paired normal respiratory tissues. siRNA techniques were used to knockdown Msi-2 to 
confirm potential mechanisms of action of mithramycin-mediated cytotoxicity in lung 
cancer cells. Results:Preliminary microarray analysis of cultured lung cancer cells 
and xenografts demonstrated that mithramycin decreased expression of musashi-2 
(Msi-2), a RNA binding protein which mediates self-renewal in normal stem cells and 
aggressive phenotype of several human cancers. Subsequent qRT-PCR and immunoblot 
experiments confirmed that mithramycin depletes Msi-2 in lung cancer cells in a time and 
dose-dependent manner. Expression levels of Msi-2 were significantly elevated in non-
small cell as well as small-cell lung cancer lines relative to normal/immortalized human 
respiratory epithelial cells (p < 0.001). Consistent with these findings, Msi-2 mRNA 
levels in primary lung cancers were significantly higher than those detected in adjacent 
paired normal lung parenchyma (p< 0.0003). Msi-2 expression was enriched in SP 
fractions of cultured lung cancer cells, and was significantly increased in SAEC following 
reprogramming to pluripotency. si-RNA-mediated knock-down of Msi-2 decreased 
expression of Oct4, Nanog and Myc, and transiently inhibited proliferation of lung cancer 
cells. Attempts to permanently knockdown Msi-2 by shRNA techniques thus far have been 
unsuccessful, suggesting a strong selective pressure to maintain Msi-2 expression in 
these cells. Conclusion: Mithramycin depletes Msi-2 in lung cancer cells. Pharmacologic 
depletion of this pluripotency factor may be a novel strategy for lung cancer therapy. 
Keywords: NSCLC, SCLC, stem cell signaling, Mithramycin
the re-replication pathway. Interestingly, a p53 mutated squamous cell line (SK MES1), 
which has high expression levels of CHK1 and CHK2 (22.31 and 18.66, respectively), 
showed the lowest IC50 in our study (IC50= 0.024 mM) with a CHK1selective inhibitor 
(LY2603618). Also, two EGFR-resistant cell lines, one harbouring the T790M mutation, 
were highly sensitive to CHK1 inhibition (IC50 of 0.19µM for PC-GR5; 0.40 µM for PC9-
GR4). Interestingly, when using a dual CHK1-CHK2, the IC50 is significantly higher 
in the SK MES1 cell line (84.62 µM vs 0.024 µM) when compared to single CHK1 
inhibiton
Half maximal inhibitory concentrations (IC50s) of CHK1 and CHK1-2 inhibitors
Cell line CHK1 (IC50 µM, mean) CHK1-2 (IC50 µM, mean)
SK-MES1 0.027 84.62
A549 0.8 15
HCC78 1.2 33.4
H2228 2 0.5
H3255 8.1 12.6
H1975 22.6 9.6
 
Conclusion: A great advance has been made in targeted therapy for NSCLC during 
the last 10 years. Nevertheless, few specific therapeutic options exist for squamous 
cell carcinoma of the lung nowadays. Different expression of genes involved in the re-
replication pathway, and the sensitivity of some NSCLC cell lines (such as SK-MES1, 
a squamous carcinoma cell line) to selective CHK-1 and dual CHK1-CHK2 inhibitors 
identify this pathway as a possible therapeutic target worthy of further investigation. 
Keywords: NSCLC, Targeted therapy, Re-replication pathway, CHK1 inhibition
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P2.04-049 Efficacy of Focal Adhesion Kinase (FAK) Inhibition in RAS Mutant 
and EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Hao Zhang1, Shao 
Huanjie1, Hongbin Chen1, Vita Golubovskaya2, William Cance2, Alex Adjei1, Grace Dy1 
1Medicine, Roswell Park Cancer Institute, Buffalo/NY/United States of America, 2Surgery, 
Roswell Park Cancer Institute, Buffalo/NY/United States of America
Background: Focal Adhesion Kinase (FAK) is overexpressed in many types of tumors, 
including lung cancer. We sought to determine the antitumor activity of various FAK 
inhibitors in NSCLC cell lines with RAS mutations as well as in epidermal growth factor 
receptor (EGFR) mutant cell lines with known resistance to EGFR tyrosine kinase 
inhibitors (TKIs). Methods: The effects of FAK inhibitors (NVP-TAE226, PF-562271, 
PF-573228, Y15) were tested against a variety of lung cancer cell lines (H157, H358, 
H460, H727, H1299, A549, H1650, H1975). Cell viability and clonogenic assays were 
performed to determine the IC50 of each agent. Western blot analysis was performed to 
determine alterations in relevant signaling proteins. RNA interference studies were done 
to elucidate mechanisms of action. Xenograft experiments were conducted to evaluate 
the efficacy of Y15 in vivo. Results: Y15 is more potent compared to the most selective 
FAK inhibitor PF-574228, with comparable to slightly more potent activity compared to 
PF-573228 and TAE-226 (Table 1). Y15 blocked autophosphorylation of FAK in a time- and 
dose-dependent manner. It caused dose-dependent decrease of lung cancer cell viability 
and clonogenicity. Apoptosis through Bcl-2 and Bcl-xL downregulation induced by Y15 
occurs in an Akt-independent manner via JNK activation. Moreover, knockdown of Bcl-2 
or Bcl-xL potentiated the effects of Y15. The combination of various inhibitors of the Bcl-2 
family of proteins with FAK inhibitors demonstrated synergy in multiple lung cancer cell 
lines in vitro. Y15 blocked tumor growth of RAS mutant (A549 with KRAS mutation and 
H1299 with NRAS mutation) as well as EGFR mutant cell lines with known resistance to 
EGFR TKIs (H1650 and H1975) in xenograft experiments.
Table 1. The IC50 values of FAK inhibitors in lung cancer cell lines as determined by MTS 
assay.
H157 H358 H460 H727 H1299 A549 H1650 H1975
TAE226 IC50 (uM) 7.46 3.18 4.32 0.30 2.98 2.59 2.30 2.88
PF-
562271
IC50 
(uM) 5.76 6.38 4,26 2.26 3.94 5.41 5.31 5.47
PF-
573228
IC50 
(uM) 11.39 27.49 6.17 2.80 9.18 9.08 20.70 13.20
Y15 IC50 (uM) 2.1 2.72 3.16 1.30 3.88 3.49 1.9 1.56
 
Conclusion: FAK inhibition using Y15 demonstrated efficacy both in vitro and in 
vivo in lung cancers with either oncogenic RAS or EGFR mutations. The combination 
of FAK inhibitors with inhibitors of the Bcl-2-family of anti-apoptotic proteins 
has synergistic activity in these RAS and EGFR mutant NSCLC cell line models. 
Keywords: focal adhesion kinase, RAS mutation, bcl-2, EGFR mutation
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(DNMT3a-CD) was reported in a chromatin context for the tumor suppressor gene 
MASPIN, and the oncogene SOX2, and showed definite but modest activity, but require 
that a new protein be re-engineered for every new target site. Cas9 directed constructs 
can potentially be retargeted by simply changing the identity of the guide RNA (gRNA) 
sequence. Methods: We synthesized a Cas9x-DNMT3a-P2A-EGFP fusion in which the 
catalytic domain of DNMT3a (DNMT3a-CD) is fused to the carboxy terminus of Cas9 
D10A-H840A mutant (Cas9x) along with a fluorescent reporter (EGFP) for targeting to the 
SOX2 promoter. The constructs was transfected into 293T cells and the transfected cells 
were sorted by flow cytometry. DNA methylation was analyzed by bisulfite sequencing and 
SOX2 expression was determined by real-time RT-PCR. Results: We sorted transfected 
293T cells with flow cytometry and found ~50% of the GFP positive cells were methylated 
with an average methylation level of ~17% (~4 of 21 CpG sites with the target region, 
but vaired from clone-to-clone); the Cas9x-only expressing vector (as control) showed no 
methylation. SOX2 mRNA expression was reduced 31% compared to the Cas9x control. 
Cell adhesion was disrupted, as was growth in culture, compared to empty vector Cas9x 
controls. Replication studies in A549 lung cancer and other cells are ongoing, as are 
optimization refinements.
  
 
Figure. The methylation state of SOX2 promoter targeted by Cas9x-DNMT3a-CD. 
The Cas9x-DNMT3a-2A-GFP expression vector was transfected into 293Tcells with 
LipoFectamin 2000. The sgRNA-targeted site is depicted in yellow. GFP expressing cells 
were sorted with flow cytometry. Genomic DNA was extracted. After bisulfite treatment, 
the 400 bp promoter region was amplified and cloned into sequencing vector. Four out 
of eight colonies (50%) showed some degree of targeted methylation (red marks) 
adjacent to the Cas9x binding site. Conclusion: These results suggest that one can use 
de-activated Cas9 to direct methyltransferases to specific sites within the genome and 
regulate gene expression. This has not previously been reported, and may represent a 
significant advance in the ability to methylate and regulate specific target sites in the 
cancer genome on a heritable basis.
Keywords: Cas9, DNA methylation, targeting
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P2.04-055 Anti-Glut-1 Antibody as a Novel Therapeutic Modality against 
Breast and Lung Cancers Viral Vaghani1, Patrick Nassarre2, Harry A. Drabkin3, 
Robert M. Gemmill4, George R. Simon5 1University of Texas, Houston/TX/United States of 
America, 2Hematology/Oncology Division, Medical University of South Carolina, Charleston/
SC/United States of America, 3Medicine, Medical Univ. of South Carolina, Charleston/United 
States of America, 4Medicine, Medical Univ. of South Carolina, Charleston/SC/United States 
of America, 5Thoracic Medical Oncology, MD Anderson Cancer Center, Houston/TX/United 
States of America
Background: The growth and survival of many tumors are dependent upon high glucose 
uptake to meets it energy needs. A family of glucose transporters proteins (GLUTs) 
facilitate glucose uptake by cancer cells. There are at least 12 known isoforms of glucose 
transporter proteins. These transporter proteins differ in their kinetics and its expression 
is tailored to the requirement of the individual cell type. Although more than one Glut 
transporter protein may be expressed by a particular tumor cell type, tumors frequently 
over express Glut-1 which is a high affinity glucose transporter protein allowing the tumor 
to internalized a relatively large amount of glucose. Indeed tumoral Glut-1 expression 
correlates with the intensity of glucose uptake seen in a PET scan. We have previously 
demonstrated that anti-Glut-1 monoclonal antibody inhibited proliferation and induced 
apoptosis in breast cancer and lung cancer cell lines in vitro. Here we report the results 
of our in vivo studies where we investigated the ability of anti-Glut-1 monoclonal antibody 
to retard tumor growth in orthotopically implanted MDAMB-231 cell line in female 
athymic nude mice. We also examined the ability of the Glut-1 antibody to augment the 
retardation of tumor growth induced by cisplatin, paclitaxel, tamoxifen, and trastuzumab 
in the study. Methods: MDA-MB-231 breast cancer cells were orthotopically implanted 
in female thymic nude mice. Cohorts of tumor bearing mice were treated with control 
solution (PBS) or different dose levels of anti-Glut 1 antibody through tail vein injections. 
The Glut-1 monoclonal antibody used in the studies detailed here was generated from 
the clone SPM498. Once an optimal dose of Glu-1 antibody was selected we tested its 
ability to augment the growth retardation induced by cisplatin, paclitaxel, tamoxifen and 
trastuzumab. Tumors were measured as treatments continued. At the sign of earliest 
distress the animals were sacrificed and the organs were harvested and examined for 
evidence of toxicity and metastases. The harvested tumors were then subjected to 
Western blot and immunohistochemical analysis to look for markers of apoptosis and 
proliferation. All the organs and peripheral blood were examined to look for evidence 
of organ toxicity as a consequence of treatment by the Glut-1 antibody. Results: Anti-
Glut 1 antibody can be administered safely in high doses to mice. No consistent organ 
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P2.04-052 Targeting Oncogenic Eukaryotic Protein Translation in Thoracic 
Malignancies with Small-Molecule Inhibitors Zeeshan Ahmad1, Blake Jacobson1, 
Aniekan M. Okon2, Manish Patel1, Ezzideen B. Al Rawi1, Gabe Vattendahl Vidal3, Carston 
R. Wagner2, Robert Kratzke1 1Hematology/Oncology/Transplant, University of Minnesota, 
Minneapolis/MN/United States of America, 2Dept. Medicinal Chemistry, University of 
Minnesota, Minneapolis/MN/United States of America, 3Department of Medicine, University 
of Minnesota, Minneapolis/MN/United States of America
Background: Hyperactivation of cap-mediated translation can induce oncogenic 
transformation by enhancing the translation of a subset of mRNAs involved in the genesis, 
maintenance and progression of cancer.In this investigation, disabling the eIF4F complex 
by disrupting the eIF4E-mRNA-cap interaction is evaluated as a therapy for mesothelioma 
and non-small cell lung cancer (NSCLC). Methods: Cell lines and culture. H513 and 
H2373 were from American Type Culture Collection (ATCC) and cultured in either RPMI 
1640 containing 10% calf serum supplemented with 10% calf serum and maintained at 
37oC. Cell proliferation assay. 5000 cells were seeded into wells of 96 well plates. 
Following overnight incubation cells were treated with varying doses of cpd 267, 272 
or pemetrexed for 72 h. Viable cells were counted employing Cell Counting Kit 8 
(Dojindo). Cap-affinity assay. Cell lysate was mixed with 50 mL of a 50% mixture of 
m7GTP-Sepharose resin with and without 400 mM of cpd 267 for 2 h at 4oC to capture 
eIF4E and eIF4G. The captured bound proteins were eluted and prepared for immunoblot 
analysis. Immunoblot analysis. Protein samples were separated by SDS-PAGE and 
transferred to Hybond PVDF membrane. Blots were probed for eIF4E and eIF4G (both 
from Cell Signaling and diluted 1:1000). Detection was carried out using ECL Plus Western 
Blotting System (Amersham) to visualize the bands of interest. Results:Mesothelioma 
and NSCLC cells were treated with small-molecule inhibitors [compounds 267 and 272] 
that mimic the cap structure that displace capped mRNAs from the eIF4F complex 
resulting in suppression of cap-dependent translation of malignancy-related proteins. 
Treatment with the compounds resulted in a dose dependent decrease in cell viability. 
Combination therapy of the compounds with cytotoxic agents further decreased cell 
survival. Binding to a synthetic cap-analogue was employed to assess the strength of 
eIF4F complex activation in lysates exposed to the compounds. Conclusion: These 
novel compounds reduce cancer cell proliferation,reduce eIF4F complex 
formation and sensitizes mesothelioma and NSCLC cells to cytotoxic agents. 
Keywords: Small molecule inhibitors, non-small cell lung cancer, Mesothelioma, Cap-
dependent translation
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P2.04-053 Patient-Derived Xenograft Studies Suggest FGFR1 Amplification 
Is Insufficient to Predict Response to FGFR Inhibitors in Lung SqCC Shingo 
Sakashita1, Nhu-An Pham1, Philipp Alberts2, Olga Ludkovski1, Ming Li1, Christine Ng1, 
Dennis Wang1, Ghassan Allo1, Lucia Kim1, Naoki Yanagawa1, Chang-Qi Zhu1, Ming S. 
Tsao1 1Departments of Laboratory Medicine and Pathobiology, University of Toronto, 
University Health Network, Toronto/ON/Canada, 2University of Toronto, Toronto/Canada
Background: FGFR1 amplification has been reported in 16%-20% of lung squamous cell 
carcinoma (SqCC). Early phase clinical trials with anti-FGFR small molecule inhibitors are 
in progress. It remains unclear whether genomic changes involving FGFR1 is associated 
with a dependency in FGFR-driven oncogenic activity that could be inhibited with 
pharmacologic agents. We evaluated a pan-FGFR inhibitor (BGJ398) in four SqCC patient-
derived xenograft (PDX) models with amplification of the FGFR1 gene.  Methods: FGFR1 
gene copy changes were assessed by fluorescence in-situ hybridization. PDX models 
were established by implanting surgical resected tumor fragments into the subcutaneous 
tissue of non-obese diabetic severe combined immune deficient (NOD-SCID) mice. 
Protein and mRNA expression levels were assessed by immunohistochemistry/western 
blot and RT-qPCR, respectively. Results: FGFR1 amplification was observed in 13 of 60 
(22%) SqCC patient tumors, with all amplified tumors forming PDX. PDX models with 
FGFR1 gene amplification displayed higher levels of mRNA and protein compared to non-
amplified tumor, excluding polysomy cases. One model demonstrated an average of 
50% decrease in tumor volume in the BGJ398 treated group compared to control group, 
21 days post-treatment. This model also expressed high FGFR1 and high cMYC protein. 
BGJ398-resistant PDX models included one model with high FGFR1 but low cMYC protein 
levels, and two models with low FGFR1 and high cMYC protein levels. Conclusion: The 
lack of growth arrest to a pan-FGFR small molecule inhibitor in the 4 PDX models 
evaluated suggests that FGFR1 amplification alone was not a sufficient predictive marker 
for pan-FGFR1 inhibitor activity. FGFR1 protein and MYC protein are putative markers. 
Keywords: FGFR1 amplified Squamous cell lung cancer, Patient derived Xenograft, FGFR 
inhibitor
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P2.04-054 Targeting DNA Methylation in Chromatin Weiguo Han1, Amos Yan2, 
Miao Shi1, Matthew Levy2, Simon D. Spivack1 1Medicine/Pulmonary, Albert Einstein 
College of Medicine, Bronx/NY/United States of America, 2Bichemistry, Albert Einstein 
College of Medicine, Bronx/NY/United States of America
Background: DNA methylation is heritable during mitosis, and has been reported 
to serve as a strong molecular mark for gene silencing memory. Therefore, to more 
permanently down-regulate a gene’s expression than by siRNA or other means, target-
directed DNA methyltransferases are desirable. Recently, the first gene-specific targeted 
DNA methylation using a zinc finger protein fused to the catalytic domain of DNMT3a 
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P2.04-057 Targeting PIM Kinase in NSCLC Kathy Gately1, Susan Heavey1, 
Stephen P. Finn1, Sinead Cuffe1, Niamh Leonard2, Siobhan Nicholson2, Ronan Ryan3, 
Vincent Young3, Kenneth J. O’Byrne4, Martin Page5, Michael O’Neill5, Martin P. Barr6 
1Clinical Medicine, Trinity College Dublin, Dublin/Ireland, 2Department of Histopathology, 
St. James’S Hospital, Dublin/Ireland, 3Department of Cardiothoracic Surgery, St. James’S 
Hospital, Dublin/Ireland, 4Institute of Health and Biomedical Innovation, Queensland 
University of Technology, Brisbane/Australia, 5Inflection Bioscience Ltd, London/United 
Kingdom, 6Thoracic Oncology Research Group, Trinity College Dublin/St. James’S Hospital, 
Dublin/Ireland
Background: PIM proteins belong to a family of serine/threonine kinases composed 
of 3 isoforms, PIM1, PIM2 and PIM3, that play a key role in cell cycle regulation, have 
potent anti-apoptotic activity and play a role in the homing and migration of metastatic 
cells. Furthermore, PIM kinases have also been shown to be activated in response to Akt 
pathway inhibition, indicating a role in adaptive responses to inhibition of this pathway 
potentially leading to treatment resistance. Thus, there is a strong rationale for combining 
PIM kinase inhibition with inhibition of the Akt pathway (i.e., inhibitors of EGFR, PI3K, 
Akt and mTOR). PIM kinase has been recognised as a therapeutic target particularly in 
haematological malignancies however the role of PIM kinases in solid tumours and NSCLC 
in particular are less well characterised. This study is the first to elucidate the expression 
of all 3 PIM isoforms in NSCLC cell lines and patient tumours as well as to examine the 
effect of Inflection Bioscience Ltd novel dual PI3K/PIM kinase (IBL-202) and triple PI3K/
mTOR/PIM kinase (IBL-301) targeted therapies in-vitro and in-vivo. Methods: PIM 1/2/3 
protein expression was quantified by western blot analysis in a panel of NSCLC cell lines 
and 40 matched normal/tumour tissues from NSCLC patients (20 adenocarcinoma 
and 20 squamous cell carcinoma). PIM kinase expression was correlated to patient 
clinicopathological characteristics and survival data. The effectiveness of IBL-202 and 
IBL-301 on proliferation and apoptosis in NSCLC cell lines were examined by BrdU and 
Annexin V/PI FACS analysis, respectively. A head-to-head in-vivo study of IBL-202 vs. 
IBL-301 in xenograft nude mice formed using H1975 cells is ongoing. Results: All 3 
isoforms of PIM kinase are highly expressed across a panel of NSCLC cell lines. PIM 
kinase is expressed in ~ 90% of NSCLC tumour tissues across all stages of the disease. 
IBL-202 and IBL-301 induced apoptosis and decreased cell proliferation in NSCLC cell 
lines at micromolar concentrations in-vitro. The in-vivo study is ongoing and results will 
be presented. Conclusion: PIM kinase is a promising new therapeutic target for the 
treatment of NSCLC patients. Dual PI3K/PIM kinase (IBL-202) and triple PI3K/mTOR/PIM 
kinase (IBL-301) targeted therapies have demonstrated pro-apoptotic and anti-proliferative 
activity in-vitro and in-vivo and should be considered in the treatment of NSCLC patients. 
Keywords: PIM kinase, PI3K, IBL-202, IBL-301
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P2.04-058 Neutrophil-Lymphocyte Ratio (NLR) as a Prognostic Marker in 
Locally Advanced Non-Small Cell Lung Cancer (LANSCLC) Katherine A. Schrenk, 
Søren M. Bentzen, Vincent K. Lam, Pranshu Mohindra, Elizabeth M. Nichols, Melissa 
Vyfhuis, Neha Bhooshan, Steven J. Feigenberg, Martin Edelman, Josephine L. Feliciano 
Greenebaum Cancer Center, University of Maryland, Baltimore/MD/United States of America
Background: NLR is a measure of systemic inflammation which appears prognostic 
in localized and advanced NSCLC. Increased systemic inflammation portends 
a poorer prognosis in cancer patients. We hypothesize that low NLR measured 
at diagnosis is associated with improved overall survival (OS) in patients with 
LANSCLC. Methods: Records from 276 patients with stage IIIA and IIIB NSCLC treated 
with definitive chemoradiation with or without surgery at our institution between 
2000 and 2010 with adequate data were retrospectively reviewed. Baseline patient 
demographic data and pre-treatment absolute neutrophil and lymphocyte counts were 
collected. Patients were grouped into quartiles based on NLR. OS was estimated using 
the Kaplan-Meier method and the logrank test was used to compare mortality between 
groups. A linear test-for-trend was used for the NLR quartile groups. The Cox proportional 
hazards model was used to adjust for other prognostic factors in a multivariable analysis. 
Distributions of NLR in subgroups were compared using the Mann-Whitney U test. All 
P-values are 2-tailed. Results: NLR was a highly prognostic factor for overall survival 
(p<0.0001). Median survival [95% CI] for the first, second, third and fourth quartile 
groups of the population distribution of NLR were 27 months [19-36], 28 months [22-34], 
22 months [12-31] and 10 months [8-12], respectively. NLR correlated with race, gender, 
stage and performance status. Even after adjusting for stage (IIIA vs. IIIB), NLR remained 
predictive of overall survival (p=0.001). 
toxicities associated with Glut-1 treatment were observed. Specifically, there was no 
central nervous system side effects noted in the mice given that the brain accounts 
for approximately 30% of the total glucose consumption. Treatment with Anti-Glut-1 
antibody did not demonstrate significant single agent activity; however an increase in 
survival was observed in mice treated with the combination of tamoxifen and the anti-
Glut-1 antibody compared with tamoxifen alone. The results of the detailed analyses 
will be presented at the meeting. Conclusion: Our studies demonstrate that anti-Glut1 
antibody can be safely administered to mice without major organ toxicity including CNS 
toxicity. It demonstrated limited anti-tumor efficacy as a single agent, but it shows an 
increased anti-tumor effect when combined with tamoxifen. Further studies evaluating 
the combination of anti-Glut-1 antibody with targeted and hormonal agents are warranted. 
Keywords: Breast cancer, Anti-Glut-1 Antibody, Glut-1, lung cancer
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P2.04-056 Analysis of EGFRvIII, PIK3CA, and DDR2 Mutations in Chinese Lung 
Squamous Cell Carcinoma Patients Min Li, Jian An, Jun Tan, Qi H. Gu, Cheng P. Hu 
Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha/
China
Background: As the role of targeted therapy of lung adenocarcinoma affirming, people 
pay more attention to targeted therapy of squamous cell lung cancer . EGFRvIII , PIK3CA 
and DDR2 genes become research hotspots as targeted therapy of potential squamous 
cell lung cancer. However there are few reports on the state of these genes in Chinese 
patients. Therefore, this study intends to conduct PIK3CA, DDR2 and EGFRvⅢ genetic 
testing on the surgical specimens from Chinese lung squamous cell carcinoma patients, 
in order to understand the gene status of Chinese lung squamous cell carcinoma 
patients and its relationship with clinical factors. Methods: This study collected 100 
surgical tissue samples of lung squamouscarcinoma patients from Xiangya Hospital of 
Central South University. All patients had not received preoperative radiotherapy and 
chemotherapy. EGFRvIII gene was detected by Immunofluorescence，PIK3CA and DDR2 
was detected by direct sequencing. X2 test was applied to analyze the relationship of 
each gene mutation, expression and clinical characteristics (age, gender, smoking 
status, tumor stage, tumor differentiation), and two-sided test P <0.05 is considered 
statistically significant. Results: Patient Enrollment A total of 100 cases met eligibility 
for this study. Clinicopathologic characteristics of 100 patients are shown in Table 1.
Table 1 Detailed Clinicopathologic Characteristics of 100 Lung Squamous Cell 
Carcinomas
Variable No. (%)
Total patients 100
Age
α60y 59(59)
≥60y 41(41)
Sex
Male 92(92)
Female 8(8)
Smoking
Smoker 82(82)
Never Smoker 18(18)
TNM stage
Stage I 20(20)
Stage II 23(23)
Stage IIIa 57(57)
Stage IIIb 0(0)
Stage IV 0(0)
Differentiation
Poor 26(26)
Moderate 65(65)
Well 9(9)
 
EGFRvIII expression and mutational spectrum of PIK3CA, DDR2 In the 100 cases 
of lung squamous cell carcinoma specimens, 15 cases were positive of EGFRvIII gene 
staining (15%); 5 cases of PIK3CA mutation (5%), of which all occurred on 9th exon 
E545K; among all tested specimens, no DDR2 mutation was found. Correlation 
between clinicopathologic characteristics and status of EGFRvIII expression, and 
PIK3CA mutantion The EGFRvIII gene expression and PIK3CA gene mutation in the 
patients’ age, gender, smoking, TNM stage and tumor differentiation had no statistically 
significant difference. Conclusion: This study found out that the PIK3CA mutation 
rate in Chinese lung squamous cell carcinoma patients was higher than in Westerners. 
Keywords: Lung Squamous cell carcinoma, EGFRvIII, PIK3CA, DDR2
S597Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
(T) and spared distal (Dist) lung from 30 patients affected by NSCLC (21 Adeno and 
9 Squamous) and 9 Neuroendocrine tumors were processed for immunohistochemical 
analysis and cell isolation. Control healthy lung (CTRL) was represented by 12 samples 
collected at autopsy from patients who died in the absence of respiratory diseases and 
6 surgical specimens of pneumothorax. Immunofluorescence and confocal microscopy 
were employed using specific antibodies to detect blood (CD31, vWF, a-SMA) and 
lymphatic (Podoplanin Pdn, Lyve-1 and Prox-1) vessels. Moreover, the distribution of cells 
expressing stem/progenitor cell associated antigens (c-kit, CD133, CD34 and PDGFR) 
was assessed. Phenotypical and functional characterization on immunomagnetically 
sorted hematic (CD31pos) and lymphatic (CD31pos/Pdnpos) endothelial cells was 
performed on cells isolated from Dist and T lung samples. Results: Results indicated 
that, compared to CTRL capillary density increased by 77% and 74% in Dist and T 
portions of the lung, respectively. Conversely, the numerical incidence of venules did not 
show significant difference. These parameters were similarly represented in the three 
different tumor histotypes. A significant increase in arteriolar density was observed in 
all tumor types compared to CTRL. Moreover, the number of arterioles within T was 
increased by 3-fold compared to Dist portion. The quantitative analysis of lymphatic 
vessels showed similar values in all types of cancer specimens although rarefaction of 
these vascular structures was observed compared to CTRL. Moreover, lymphatic vessels 
density was 10-fold higher in Dist lung than in T. Immunofluorescence confocal analysis 
documented a positive gradient of c-kitpos, CD34pos and PDGFRpos progenitor cells 
from Dist towards T in all cancer samples. However, compared to CTRL, cells expressing 
c-kit and CD34 were more numerous both in the Dist and T portion of the lung, while 
the increase in PDGFRpos cells was present only in T. Blood (BEC) and lymphatic (LEC) 
endothelial cells isolated from Dist and T samples of the lung, showed different growth 
properties and variable expression of Tumor Endothelial Marker (TEM) and receptor 
tyrosine kinases as VEGFR 2 and 3, PDGFRbeta, EGFR, IGF-1R, and c-met. Functional 
assays indicated that T derived LEC possess higher tube forming ability on matrigel 
than Dist LEC while this phenomenon was not observed in BEC. Moreover, wound healing 
assay showed a VEGF-C independent reduced migratory capacity of LEC isolated 
from T samples compared to the Dist counterpart. Conclusion: Specific changes 
in the composition and function of the tumor hemolymphangiogenic environment 
occur in lung cancer providing innovative pathogenetic and therapeutic approaches. 
Keywords: tumor lymphangiogenesis, cancer initiating cells, vascular niche, tumor 
microenvironment
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P2.04-060 Analysis of Lung Microbiome From Patients Undergoing 
Bronchoscopy Glen J. Weiss1, Mark Linhart2, Daniel A. Nader3, J. F. Turner4, J. B. Ross1, 
J. G. Caporaso2, Paul Keim2, Brandy Harmon1, Heather Barilla1, Talima Pearson2 
1Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear/
AZ/United States of America, 2Northern Arizona University, Flagstaff/United States of 
America, 3Southwestern Regional Medical Center, Cancer Treatment Centers of America, 
Tulsa/AL/United States of America, 4University of Tennessee Graduate School of Medicine, 
Knoxville/AL/United States of America
Background: Recent studies have demonstrated diversity in the lung microbiomes 
of chronic obstructive pulmonary disease and healthy individuals. Lung microbial 
communities may not just serve as a predictor of cancer development, but also as a target 
of pharmacological cancer prevention strategies. We sought to characterize the lung 
microbiome diversity within patients with lung cancer for comparison to those without 
lung cancer. Methods: Signed informed consent was obtained from patients ages 18 
years and older that underwent a bronchoscopy during the course of clinical evaluation at 
one of two cancer centers. A bronchial lavage was collected for research purposes after 
routine bronchoscopic procedures were completed. The lavage sample was collected 
in a sterile collection container and immediately placed on dry ice. Subsequently, 
samples were diluted 1:1, incubated with dithiothreitol to aid in mucus dissolution, and 
then mechanically homogenized. DNA was extracted and 515F/806R 16S rRNA primers 
used to amplify Variable Region 4. Amplicons were sequenced using the Illumina MiSeq. 
Sequences were clustered into operational taxonomic units (OTUs) using QIIME’s open 
reference OTU picking workflow, and taxonomy was assigned to OTUs by classification 
against the Greengenes database using the RDP Classifier. Microbial communities were 
compared using phylogenetic beta diversity metrics based on 16S rRNA reads. Statistical 
significance of diversity between samples was determined by comparing the UniFrac 
distances between pairs of samples using parametric and non-parametric Monte Carlo-
based t-tests. Differences in alpha diversity were tested using a t-test comparing the 
distributions of diversity values across the sample types. Results: None of the patients 
undergoing a research-related bronchial lavage experienced a significant adverse event 
from the procedure. There were seven lung cancer patients with a median age of 56.0 
years (range 45-75). Of these, six were current/former smokers with an average of 32.5 
pack-years. All seven lung cancer patients were Caucasian with five using prescription 
inhalers and none on recent antibiotics. Five patients had adenocarcinoma and one each 
of squamous cell carcinoma and small cell lung cancer. There were six non-lung cancer 
patients with a median age of 57.5 years (range 39-68). Of these, three were current/
former smokers with an average of 40 pack-years. All six non-lung cancer patients were 
Caucasian with three using prescription inhalers and one recently taking antibiotics. 
Analyses of the microbiota present in lung samples show the presence of multiple bacterial 
taxonomic groups in each sample, however, the phylogenetic diversity of the bacterial 
community is low compared to other body sites. Fusobacteria represented a significant 
portion of the bacterial community of lavage samples. Not surprisingly, the community 
composition of these samples is most similar to human oral communities, however, a 
portion of these communities is unlike communities from other characterized human body 
sites and we are still actively investigating these differences. Conclusion: Microbiota 
associated with lung cancer have not been well-characterized or associated with 
treatment and outcome. Our analyses suggest that bacterial communities may play an 
 
Conclusion: To our knowledge, this is the first large series evaluating NLR as a 
prognostic indicator in LANSCLC. Pre-treatment NLR is strongly associated with 
OS in LANSCLC. NLR is an inexpensive biomarker which is significantly prognostic 
even after adjusting for race, gender and stage. It can be easily utilized at the time 
of LANSCLC diagnosis to help predict life expectancy. As an indicator of inflammatory 
response, it should be explored in the context of immunomodulatory therapy. 
Keywords: inflammation, neutrophil-lymphocyte ratio, non-small cell lung cancer, 
Prognosis
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P2.04-059 Structural and Functional Characterization of the 
Hemolymphangiogenic Microenvironment in Lung Cancer Federico Quaini1, 
Denise Madeddu1, Bruno Lorusso1, Angela Falco1, Andrea Gervasi1, Costanzaannamaria 
Lagrasta2, Gallia Graiani1, Paolo Carbognani3, Luca Ampollini3, Eugenio Quaini4, Konrad 
Urbanek5 1Clinical and Experimental Medicine, University of Parma, Parma/Italy, 2Pathology, 
University of Parma, Parma/Italy, 3Thoracic Surgery, University of Parma, Parma/
Italy, 4Cardiac Surgery, University of Milan, Milan/Italy, 5Pharmacology, Univesity of Naples, 
Naples/Italy
Background: The hypothesis of the existence of a Lung Cancer Initiating Cell (LCIC) offers 
new pathogenetic and therapeutic options. CICs express vascular-related molecules in 
order to induce neoangiogenesis and establish an aberrant vascular niche. Conversely, 
tumor angiogenesis and formation of a cancer vascular niche contribute to the maintenance 
of CIC. The limited success of anti-angiogenic strategies in lung cancer imposes a better 
knowledge of the biology and architecture of the tumor vascular microenvironment. The 
aim of our study was to characterize the structural and functional changes of blood and 
lymphatic vasculature in human lung cancer. Methods: Fresh samples of the neoplastic 
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lesions at times similar to those in continuous exposure groups. Alveolar macrophage 
numbers also increase as a function of time in the short term/high dose model whereas 
there is less reproducibility of this increase in the continuous dosing model. Changes 
in alveolar macrophage programming occur during dysplastic lesion development, but 
not to the same extent as that seen in progression of adenomas and adenocarcinomas. 
Keywords: squamous dysplasia, mouse models, macrophage programming
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P2.04-063 Secretome of BM Mesenchymal Stem Cells: An Emerging 
Player in NSCLC Progression Oshrat Attar-Schneider1, Victoria Zismanov1, Liat 
Drucker2, Maya Gottfried3 1Lung Cancer Research Lab, Meir Medical Center, Kfar-Saba/
Israel, 2Oncogenetic Lab, Meir Medical Center, Kfar-Saba/Israel, 3Oncology Department, 
Lung Cancer Unit & Lung Cancer Research Lab, Meir Medical Center, Kfar-Saba/Israel
Background: Non-small cell lung cancer (NSCLC) remains the most common cause of 
cancer-related death worldwide. Patients presenting with advanced stage NSCLC have 
poor prognosis while metastatic spread accounts for >70% of patients deaths. The major 
advances in treatment of lung cancer have brought only minor improvements in survival; 
therefore novel strategic treatment approaches are urgently needed. Accumulating data 
allocate a central role for the cancer microenvironment including mesenchymal stem 
cells (MSCs) in acquisition of drug resistance and disease relapse. Several studies that 
investigate MSCs in the lung cancer microenvironment revealed that they exhibit genetic 
and functional abnormalities compared to their normal counterparts. Furthermore, 
studies indicate that translation initiation factors are over expressed in NSCLC and 
negatively impact its prognosis. Importantly, translation initiation is highly modulated 
by microenvironmental cues. Therefore, we decided to examine the effect of BM-MSCs 
from normal donors on NSCLC cell lines with special emphasis on the role of translation 
initiation in the crosstalk. Methods: BM samples were obtained from femur head BM 
samples of normal donors. NSCLC cell lines (H1299, H460) were treated with BM-MSCs’ 
conditioned medium (i.e secretome) for 72 hours after which NSCLC cells were harvested 
and assesed for changes in the cells’ viability, proliferation/ death, and migration. The 
cells’ were immunoblotted for the levels of translation initiation factors (eIF4E, eIF4GI), 
their targets, and regulators. Results: Our results demonstarted deleterious effects on 
the cells’ proliferation, viability, death and migration. We also demonstrated reduced 
levels of translation initiation factors implicated in cancer progression eIF4E and 
eIF4GI, their targets, and regulators. Finally, we outlined a mechanism by which BM-
MSCs’ secretome affected NSCLC’s MAPK signaling pathway, downredulated the cells’ 
migration and diminshed translation initiation factors’ levles. Conclusion: Our study 
investigates the effects of microenvironmental cues on NSCLC cells’ fate and critical 
translation factors that regulate the cells’ tumorigenesis. We showed that there is direct 
dialogue between the BM-MSCs’ secretome and NSCLC cells that manipulates translation 
initiation and critically affects cell fate. We showed inhibitory effect on the lung cancer 
cells’ migration that is regulated both by MAPK signaling pathways and by translation 
initiation mechanism. Understanding the molecular events which promote metastasis 
and improving the means of foretelling their development is a major goal of current 
clinical research. We suggest that theraputic approach that will sabotage this dialoge, 
espacially in the BM microenviornment, may diminish lung cancer metastatic spread and 
morbidity and improve the patients life quality.
 
Keywords: NSCLC, Translation initiation, Mesenchymal stem cells, Migration
important role in cancer development and present an opportunity to better characterize 
these communities and their components. Updated results will be presented at WCLC. 
Keywords: microbiota, bronchial lavage, lung cancer, non-lung cancer
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P2.04-061 Tumor-Associated Fibroblasts Increased Density in Non-Small Cell 
Lung Cancer Is Mediated by Microenvironment Through β1/FAK Signaling 
Noemi Reguart1, Marta Gabasa2, Marta Puig2, Jose Ramirez3, Oscar Busnadiego4, 
Fernando Rodríguez-Pascual4, Aleix Prat1, Pere Gascon5, Jordi Alcaraz2 1Medical 
Oncology, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid 
Tumors, Institut D’Investigacions Biomèdiques August Pi I Sunyer (Idibaps), Barcelona/
Spain, 2Unitat de Biofísica I Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, 
Barcelona/Spain, 3Pathology, Hospital Clinic, Barcelona/Spain, 4Centro de Biología 
Molecular Severo Ochoa, Csic, Madrid, Spain., Madrid/Spain, 5Medical Oncology, Hospital 
Clinic, Centre de Recerca Biomèdica Cellex, Barcelona/Spain
Background: The current paradigm assumes that the abundance of tumor-associated 
fibroblasts (TAFs) is largely driven by soluble growth factors as in generic repair 
responses irrespective of the tumor type or subtype. We recently challenged this 
assumption by showing that the increased population of lung cancer squamous (SQC)-
TAFs in culture was largely driven by matrix stiffening rather than by soluble growth 
factors (i.e. serum), whereas lung adenocarcinoma (ADC)-TAFs were poorly responsive 
to exogenous mechanical cues (i.e. matrix rigidity). Moreover, we described that the 
differential mechano-responses observed in SQC- and ADC-TAFs were associated with 
increased FAK and a β1 integrin expression. Methods: To check whether β1 integrin 
was necessary for the larger TAF density observed, we treated CCD-19Lu fibroblasts 
with increasing concentrations of the β1 integrin-inhibitory monoclonal antibody AIIB2 
and the monoclonal b1 integrin–activating antibody TS2/16. To further confirm the 
requirement of β1 integrin through FAK we either depleted or overexpressed FAK in 
mouse embryonic fibroblasts (MEFs) by transducing with adenoviral infection with FAK 
(Adv-FAK). Results: We observed a dose-dependent decrease in cell density in cells 
cultured in stiff (30 kPa) gels treated with AIIB2. Moreover, activating β1 integrin with 
TS2/16 antibody was sufficient to increase both cell density and FAKpY397 expression 
of CCD-19Lu fibroblasts in soft (1 kPa) gels. As in CCD-19 Lu fibroblasts, matrix stiffening 
enhanced cell density and FAK expression in wild-type MEFs (FAK+/+), whereas such 
increases were not observed in FAK null fibroblasts (FAK-/-). Conversely, overexpressing 
FAK in wild-type MEFs (FAK+/+) was sufficient to markedly increase both cell density 
and FAK expression in 1 kPa gels compared with control MEFs. Conclusion: Abnormally 
high intrinsic mechano-sensing through β1 integrins and FAK can bypass the inhibitory 
(protective) role of an extrinsic soft microenvironment. Inhibition of either β1 integrin 
or FAK signaling may be a suitable approach to target tumor-supporting TAFs in SQC-
NSCLC.
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P2.04-062 Temporal Programming of Murine Pulmonary Macrophages in 
N-Nitroso-Tris-(2-Chloroethyl) Urea (NTCU)-Induced Squamous Dysplasia 
Lori D. Dwyer-Nield1, Meredith Tennis2, Kevin S. Choo3, Robert L. Keith3, Elizabeth F. 
Redente4 1Pharmaceutical Sciences, University of Colorado Denver, Aurora/CO/United 
States of America, 2Pulmonary, University of Colorado Denver Anschutz, Aurora/CO/United 
States of America, 3Pulmonary Medicine, Denver Veteran Affairs Medical Center, Denver/CO/
United States of America, 4National Jewish Health, Denver/CO/United States of America
Background: Continuous topical application of N-Nitroso-tris- (2-chloroethyl)urea 
(NTCU) twice per week for 32 weeks causes the development of squamous dysplasia 
and lung carcinoma (SCC) in certain strains of inbred mice including A/J and FVB mice. 
In A/J mice, short term/high dose topical application of NTCU induces higher grade 
squamous lung lesions at earlier times with less toxicity than the 32 week, continuous 
dosing model. In lung adenocarcinoma, alveolar macrophages become alternatively 
programmed shortly after carcinogen exposure, before lung lesions are detected 
indicating that inflammation may be important in lesion development. Herein we examine 
whether short term/high dose NTCU exposure produces squamous dysplastic lesions 
in FVB mice. In addition, we characterize macrophage programming as a function of 
time during lesion development. Methods: FVB/N mice were treated with 20mM NTCU 
twice/week for 2, 4, 8, or 32 weeks and lungs were harvested at 16, 20, 24, 28, and 32 
weeks after the initial application. The appearance of squamous lesions was monitored 
by stereology at the later time point and by the appearance of cytokeratin 5-positive 
bronchial cells at the earlier time points. Inflammatory cell content was determined by 
flow cytometry at the 16, 20, 24, and 32 week time in the mice continuously exposed 
to NTCU and compared to vehicle control. Macrophage programming was assessed 
by immunofluorescent detection iNOS or arginase I expression . Results: Squamous 
dysplasia appeared in the tracheas of NTCU-treated mice after 16 continual weeks 
of NTCU exposure, but lung dysplasia was not evident until 8-10 weeks later. The 
appearance of cytokeratin 5 positive cells in the airways preceded the appearance 
of these lesions. In mice treated with 8 weeks of NTCU, cytokeratin 5 positive cells in 
the airways appeared at 24 weeks and dysplastic lesions were also detected. Alveolar 
macrophage numbers also increased at the 24 week time point in these mice. Data 
from 28 and 32 week time points is currently being analyzed. Alveolar macrophages 
displayed little change in iNOS or arginase I staining through 20 weeks, however there 
were isolated iNOS+ and arginase I+ macrophages at 24 weeks. There were also weakly 
activated macrophages present in mice treated with NTCU continuously for 32 weeks 
although alveolar macrophage numbers did not increase significantly. Conclusion: The 
short term/high dose NTCU treatment regimen is less toxic and produces dysplastic 
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bystander effect through immune system stimulation in immunocompetent mice model. 
Our findings suggest that Ad-REIC therapy is a promising treatment for MM and lung cancer 
Keywords: REIC/Dkk-3, gene therapy, lung cancer, malignant pleural mesothelioma
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-066 Programmed Cell Death Ligand 1 (PD-L1) Overexpression and Low 
Immune Infiltrate Score Correlate with Poor Outcome in Lung Adenocarcinoma  
Edwin R. Parra Cuentas1, Carmen Behrens2, Jaime Rodriguez-Canales2, Heather Lin3, 
Barbara Mino2, Jorge Blando4, Don L. Gibbons5, John V. Heymach5, Stephen Swisher6, 
Annikka Weissferdt7, Neda Kahlor7, Julie Izzo2, Jack Lee8, Humam Kadara2, Cesar 
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Background: PD-L1 is a key immunoregulatory checkpoint which suppresses cytotoxic 
immune response in a variety of physiologic and pathologic conditions. Thus, inhibition 
of PD-L1 can lead to reactivating tumor immunity and assist to cancer therapy. PD-L1 
overexpression in the tumor cells has been correlated to a lessened immune response 
and consequent worse prognosis in a variety of cancers. To better understand the 
immune profiling of PD-L1 expression and its interplay with immune cells, we analyzed the 
correlation between image analysis-based immunohistochemical (IHC) expression of PD-
L1 and tumor infiltrating immune cells density in surgically resected non-small cell lung 
carcinomas (NSCLC), and the correlation with clinical and pathological features, including 
patient outcome. Methods: IHC for PD-L1, PD-1, CD3, CD4, CD8, CD45RO, CD57, CD68, 
Granzyme B and FOXP3 were performed in 254 surgical resected stages I-III NSCLC, 
Adenocarcinoma (ADC=146) and Squamous cell Carcinoma (SqCC=108) from formalin-
fixed and paraffin-embedded tissues. PD-L1 membrane expression on tumor cells and 
density of inflammatory cells were quantified using image analysis in intra-tumoral (IT) 
and peri-tumoral (PT) compartments. H-score > 5 was used as a cut-off for positive 
PD-L1 expression and an immune-score (IMS) using CD8/CD4/CD68 was devised. PD-L1 
expression and inflammatory cells were correlated with clinico-pathologic features and 
patient outcomes. Results: Positive PD-L1 expression was seen in 26.84% (n=69) of 
the entire cohort, 23.29% (n=34) of 146 ADC and 23.40% (n=35) of 115 SqCC. In ADC, 
higher levels of PD-L1 expression were detected in tumors with solid histology pattern 
compared with other histology patterns (P=0.034), and in lifetime smokers compared 
with non-smokers (P<0.0001). In SqCC PD-L1 expression was positive correlation with 
tumor size (Rho=0.19471,P=0.0435). In overall, PD-L1 expression correlated positively 
with inflammatory cell density in both IT and PT compartments in ADC and SqCC. Patients 
with KRAS mutation (P=0.00058), solid tumor (P<0.0001) or smoker (P = 0.0446) were 
more likely to have positive PD-L1 expression tumor cells in ADC. No correlation was 
detected between EGFR mutation and immune markers. Using PD-L1 and CD8/CD4/
CD68 IMS expression levels, in ADC and SqCC, we identified 4 groups of tumors (Table 
1). Multivariate Cox proportional hazard regression analysis demonstrated that tumors 
with high PD-L1 expression and low IMS in ADC exhibited significantly poor recurrence-
free (HR=4.299; P=0.0101) and overall survival (HR=5.632;P=0.0010).
Table 1. Summary of the correlation between PD-L1 expression levels and im-
mune-score (IMS=CD8/CD4/CD68) in adenocarcinoma (ADC) and squamous cells 
carcinoma (SQCC).
PDL-1 H-score 
(ADC) IMS (Low) IMS (High) Total
<5 61 (41.78%) 51 (34.93%) 112 (76.71%)
≥5 8 (5.48%) 26 (17.81%) 34 (23.29%)
Total 69 (47.26%) 77 (52.74%) 146 (100.0%)
PDL-1 H-score 
(SqCC)
<5 37 (34.30%) 36 (33.30%) 73 (67.60%)
≥5 17 (15.70%) 18 (16.70%) 35 (32.40%)
Total 54 (50.00%) 54 (50.00%) 108 (100.0%)
 
Conclusion: Higher PD-L1 expression is associated with solid pattern in adenocarcinoma 
and higher level of tumoral immune infiltrate. We developed an immune score which when 
combined with PD-L1 expression significantly correlates with patient outcome in surgically 
resected ADCs. (Supported by grants UT-Lung SPORE P50CA70907 and CPRIT RP120713). 
Keywords: Non-small cell lung carcinomas, Programmed cell death ligand 1, Immune-
score, Survival outcomes
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P2.04-064 Microenvironmental Factor of Primary Lung Adenocarcinoma 
Which Predicts the Effectiveness of Chemotherapy in Patients with 
Recurrences Haruki Koriyama1, Kiyotaka Yoh1, Keisuke Kirita1, Shigeki Umemura1, 
Shingo Matsumoto1, Seiji Niho1, Hironobu Ohmatsu1, Masahiro Tsuboi2, Koichi Goto1, 
Genichio Ishii3 1Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 
Chiba/Japan, 2Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba/
Japan, 3Pathology, Resarch Center of Innovative Oncology, National Cancer Center Hospital 
East, Kashiwa, Chiba/Japan
Background: The influence of microenvironmental factors on the effectiveness of 
chemotherapy is being increasingly recognized. Stromal cells in cancer tissue, such as 
tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), have 
been shown to influence tumor progression. The associations of CD204-positive cells, 
which represent an M2 phenotype of TAMs, and podoplanin-positive CAFs, which represent 
a subpopulation of CAFs with a tumor-promoting phenotype, with a poor prognosis have 
been identified in patients with lung adenocarcinoma, but whether these associations are 
involved in the response to chemotherapy remains unknown. The purpose of this study 
was to investigate the relationships between cancer cell and stromal cell phenotypes in 
primary tumors and the progression-free survival (PFS) of recurrent lung cancer patients 
who received platinum-based chemotherapy. Methods: We retrospectively analyzed 
87 postoperative recurrent lung adenocarcinoma patients treated with platinum-based 
chemotherapy. The expressions of drug resistance-related proteins including BCRP, Ezrin 
and ALDH1 in cancer cells, the number of CD204-positive TAMs, and the presence of 
podoplanin-positive CAFs in the primary tumor were examined. The relationships between 
the immunohistochemical staining results of primary tumors and the PFS after receiving 
chemotherapy were also analyzed. Results:Among the clinicopathological factors of 
primary tumors, only an advanced pathological stage was significantly associated with a 
shorter PFS. As for immunohistochemical staining, no significant relationships were found 
between the PFS and the expression of BCRP, Ezrin, or ALDH1. The number of CD204-
positive TAMs was not associated with the PFS. The presence of podoplanin-positive 
CAFs, identified in thirty (34%) of 87 samples, was significantly associated with a shorter 
PFS (median PFS: 5.1 vs. 7.8 months, P=0.028), but was not significantly associated 
with a shorter overall survival (median survival time: 18.1 vs. 23.7 months, P=0.156). A 
multivariate analysis revealed a tendency of podoplanin-positive CAFs to be correlated 
with a shorter PFS (P=0.087). Conclusion: The presence of podoplanin-positive CAFs in 
the primary tumor could be a predictor of a shorter PFS in recurrent lung adenocarcinoma 
patients who received chemotherapy. These findings suggest that stromal-cell derived 
factors should be incorporated into predictions of the effectiveness of chemotherapy. 
Keywords: Adenocarcinoma, platinum-based chemotherapy, cancer-associated 
fibroblasts, podoplanin
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P2.04-065 Distant Bystander Effect of REIC/Dkk-3 Gene Therapy through 
Immune System Stimulation in a Murine Model of Thoracic Malignancies 
Ken Suzawa1, Kazuhiko Shien1, Peng Huang2, Masakiyo Sakaguchi3, Masami Watanabe4, 
Shinsuke Hashida1, Junichi Soh1, Hiromasa Yamamoto1, Yuho Maki1, Hiroaki Asano1, 
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School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama/Japan, 2Innovation 
Center Okayama Fo Nanobio-Targeted Therapy, Okayama University Graduate School of 
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Background: We previously identified the tumor suppressor gene REIC/Dkk-3 whose 
expression is reduced in many human cancers, and overexpression of REIC/Dkk-3 by an 
adenovirus (Ad-REIC) exhibited a dramatic therapeutic effect on several human cancers 
through a mechanism triggered by endoplasmic reticulum (ER) stress. In addition to the 
direct anti-tumor effect, we also have shown that Ad-REIC has a host-mediated bystander 
effect on human prostate cancer and scirrhous gastric cancer through REIC-mediated 
cancer vaccination and production of IL-7. In this study, we examined possible direct 
and indirect distant bystander effects of Ad-REIC via activation of systemic anti-tumor 
immunity on thoracic malignancies. Methods: We examined anti-tumor effect of Ad-
REIC gene therapy on lung cancer and malignant mesothelioma (MM) cell lines in vitro. In 
addition, we examined the direct and distant bystander effect of Ad-REIC in bilateral flank 
allograft tumor model using immunocompetent BALB/c mice. Mice received intratumoral 
injection of Ad-REIC into the right-flank tumors, and the effect in bilateral-flank tumors 
were examined. Dissected bilateral flank tumors after sacrifice were also subjected to 
immunohistochemical analysis. Results: Ad-REIC treatment showed anti-tumor effect in 
many of lung cancer and MM cell lines in vitro due to the activation of c-Jun N-terminal 
kinase (JNK). REIC/Dkk-3 was highly expressed after Ad-SGE-REIC treatment in Ad-
SGE-REIC sensitive cell lines, while it was not or weakly expressed in some cells, which 
were resist to Ad-SGE-REIC treatment. In an in vivo model, Ad-REIC treatment inhibited 
the tumorigenic growth of not only direct injected tumor but also distant non-injected 
tumor. In immunohistochemical examination, infiltration of CD49b positive NK cells and 
expression of MHC Class-I molecules H60 and Rae-1 were revealed in bilateral tumors, 
suggesting that Ad-REIC treatment showed bystander anti-tumor effect through immune 
system-mediated apoptosis, and protein expression of MHC class-I molecules induces 
NK cell infiltration to the tumor. Conclusion: We newly revealed that Ad-REIC treatment 
induced MHC Class-I expression both in primary and distant tumor sites, which lead NK cell 
infiltration. Ad-REIC treatment showed not only direct anti-tumor effect but also indirect 
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Tregs and association between them. Also, we analyzed the correlation between Tregs 
and clinical indicators of lung cancer and between PD-1,PD-L1 expressed by Treg 
and clinical indicators, thereby preliminary revealed the expression characteristics 
of PD-1,PD-L1 on Treg and its significant, and providing valuable indicators to 
clinical diagnosis. Methods: The phenotypic characteristics and PD-1 expression of 
CD4+CD25+CD127lowTreg were studied by flow cytometry. Twenty- two primarily lung 
cancer patients,ten patients with benign lung disease,twenty-five healthy volunteers 
were included.The datas were analyzed by SPSS 14.0 software. Results: 1.The levels 
of CD4+CD25+CD127lowTreg in the peripheral blood of patients with lung cancer,with 
benign lung disease and healthy volunteers were (7.66土2.25%)、(5.73土1.43%)、(3.76
土1.06%)respectively.The level of patients with lung cancer was significant higher than 
those of patients with benign lung disease and healthy volunteers.In the present study, 
PD-1 and PD-L1 expressions were detected in CD4+CD25+CD127lowTreg in both patients 
and health controls.The levels of PD-1 expression of CD4+CD25+CD127lowTreg were 
(46.01土11.33%)、(33.34土13.54%)respectively and the levels of PD-L1 expression of 
CD4+CD25+CD127low Treg were （73.39土11.64%）、（72.16土12.95%）respectively. 
Of note, higher level of PD-1 expression was found on tregs in patients with lung cancer. 
2.The level of CD4+CD25+CD127lowTreg was not related to pathologic subtype and 
lymphatic metastasis, but clinical stage(stage Ⅲ6.29土1.18%，stage Ⅳ10.06土
1.58%，P＜0.01). 3.The level of PD-1 expression of CD4+CD25+CD127lowTreg was 
not related to pathologic subtype,lymphatic metastasis ,but clinical stage(stage 
Ⅲ41.85土6.1%，stage Ⅳ56.57土12.52%，P＜0.05) .Moreover,the level of PD-L1 
expression of CD4+CD25+CD127lowTreg was not associated with pathologic subtype 
and lymphatic metastasis, but clinical stage(stage Ⅲ48.51土18.17%，stage Ⅳ77.48
土8.33%，P＜0.05). Conclusion: Costimulatory molecule receptor interacting with 
corresponding ligand mediate positive or negative costimulatory signal and regulate the 
proliferation of T cells, the production of cytokine, cell toxicity as well as cell apoptosis 
and existence, which control T cell activation. PD-1 (programmed cell death-1) belongs 
to the CD28 family and is expressed on activated T, B, and myeloid cells. PD-1 and 
its ligand PD-L1 deliver inhibitory signals that regulate the balance between effector 
T cell activation and immune-mediated tissue damage.The proliferation and immune 
inhibitory function of Treg is related to the costimulatory molecules expressed on its 
own surface.Our study showed that:1.The level of CD4+CD25+CD127lowTreg cells 
in the patients with lung cancer increased.The abnormal level of this negative immue 
cell may play an important role in the development,progression of lung cancer.2.Our 
study indicated that distinctive characteristics of PD-1 and PD-L1 expression on 
Tregs in lung cancer suggests associated with impaired adaptive immunity. The 
cross talk between Treg cells and PD-1/PD-L1 induced inhibition in lung cancer 
deserved further exploration for lung cancer associated immune pathogenesis. 
Keywords: PD-1/PD-L1 Treg
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-070 Immunological Characterization of PD-L1-Positive Non-Small Cell 
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Background: The expression of programmed cell death-ligand 1 (PD-L1) on tumor 
cells plays an essential role in the suppression of anti-tumor immune responses, thus 
resulting in tumor progression. However, pathological features of PD-L1-positive cancer 
cells in non-small cell lung cancer (NSCLC) remain unclear.To clarify the characteristics 
of NSCLCs that are eligible for the-PD-L1-targeted immunotherapy, we examined 
the immunological feature of PD-L1-positive tumor cells by immunohistochemical 
analysis. Methods: We stained serial sections of formalin-fixed paraffin-embedded 
NSCLC tissues from 34 patients who had undergone surgery using antibodies to PD-L1 
or major histocompatibility complex (MHC) class I. We also identified tumor infiltrated 
lymphocytes (TIL) in the section, and analyzed the association between PD-L1 expression 
and MHC class I expression on tumor cells or TIL around tumor cells. Results: The 
patients with median age of 68 years (range, 49-79 years) consisted of 25 males and 9 
females. Histological types included 23 adenocarcinomas, 8 squamous cell carcinomas, 
2 adeno-squamous cell carcinomas and 1 pleomorphic carcinoma. PD-L1 and MHC class 
I were expressed on tumor cells in 28 (82.3%) and 29 (85.3%) of 34 cases, respectively. 
In 18 of 34 cases (52.9%), MHC class I-positive tumor cells were dominant in the tumor; 
whereas MHC class I-negative tumor cells were dominant in 16 of 34 cases (47.1%). PD-
L1 expression was observed in 14 of 18 (77.7%) NSCLCs that are dominant with MHC 
class I-positive tumor cells, whereas it was detected in 4 of 16 (25.0%) those mainly 
containing MHC class I-negative tumor cells. There was a significant association between 
PD-L1 and MHC class I expressions on NSCLC cells (p=0.0045). We next examined the 
association between the co-expression of PD-L1 and MHC class I on tumor cells and the 
number of TIL, and found that the incidence of PD-L1+ MHC class I+ tumor cells was 
likely to associate with the large number of TIL (r=0.42). The frequency of PD-L1-positive 
cells in MHC class I-positive tumor cells was also associated with the large number of TIL 
(r=0.33). Conclusion: MHC class I expression on tumor cells may be required for their 
expression of PD-L1, probably through the cell-to-cell interaction with TIL. Further study is 
warranted, however, the patient with the co-expression of PD-L1 and MHC class I on larger 
number of tumor cells is likely to be a suitable candidate for PD-L1-targeted immunotherapy. 
Keywords: Immunohistochemistry, PD-L1, MHC class I, non-small cell lung cancer
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Background: Multiple different PD1 and PDL1 targeting antibodies have been 
developed for the treatment of NSCLC. Identifying the population most likely to 
benefit from PD1/PDL1 direct therapy has focused on PDL1 immunohistochemistry 
(IHC) of the tumor cells. However, each therapeutic agent has a different companion 
diagnostic test therefore it is difficult to consistently ascertain the PDL1 status of an 
individual patient. We proposed to evaluate clinical predictors of PDL1 positive status 
based on consensus PDL1 immunohistochemistry. Methods: Patients with resected 
Stage II lung adenocarcinoma who underwent adjuvant chemotherapy at the BC 
Cancer Agency were selected for this study. A tissue microarray (TMA) with matched 
primary and lymph node was constructed. IHC directed towards PD-L1 was performed 
with 2 different primary antibody clones: E1L3N (Cell Signaling Technology) and 
SP142 (Spring Bioscience). PDL1 consensus score was considered positive if there 
was concordance with both antibodies. Clinical characteristics were abstracted by 
retrospective chart review. Results: Eighty cases of NSCLC were identified and used in 
TMA construction. 19 primary tumors (24%) were PD-L1 positive by consensus scoring. 
Lymph node metastases showed a concordant PD-L1 score in 92% cases. Patients 
were categorized as PDL1 positive based on consensus score of the primary tumor. 
Baseline characteristics based on PDL1 primary tumor status negative/positive: female 
64%/47%, median age 61/65 (NS). Current smoker at the time of diagnosis 34%/58% 
(p=0.07). The 7 EGFR mutation positive and 2 ALK positive patients were PDL1 negative. 
PDL1 positivity was examined by pack years of smoking: >10 pk yrs 69%/90% (p=0.13), 
>20 pk yrs 62%/79% (p=0.26), >30 pk yrs 39/63% (p=0.11) and tumor differentiation: 
well 13%/5%, moderate 48%/21%, poorly 39%/74% (p=0.03). Conclusion: PDL1 
positive status is associated with poorly differentiated tumors and demonstrates 
a trend towards current smokers. This is consistent with the concept that smoking 
related malignancies and poorly differentiated tumors are more antigenic and therefore 
require immunosuppression via PDL1 to remain undetected by the immune system. 
Keywords: PDL1, Immunohistochemistry, Adenocarcinoma, clinical characteristics
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P2.04-068 PD-L1 Expression in Tumor Infiltrating Immune Cells Determined 
by Digital Imaging Is Associated with Poor Survival in NSCLC Patients 
Bernadette G. Reyna Asuncion1, Zul Fazreen1, Mohd Feroz Mohd Omar2, Nur Lina Mohd 
Salleh1, Michelle Ann Rozario3, Min-En Nga4, Yin Huei Pang4, Brendan Pang4, Marie 
Loh5, Byoung Chul Cho6, Barry Iacopetta7, Richie Soong1, Ross Soo3 1Cancer Science 
Institute, Natl Univ of Singapore, Singapore/Singapore, 2Dept of Pathology, Nus, Singapore/
Singapore, 3Dept of Hema-Onco, Nuhs, Singapore/Singapore, 4Dept of Pathology, Nuh-
Singapore, Singapore/Singapore, 5Translational Laboratory in Genetic Medicine, Agency 
for Science Tech and Research, Singapore/Singapore, 6Medical Oncology, Yonsei Cancer 
Center, Seoul/Korea, 7School of Surgery, University of Western Australia, Perth/ACT/Australia
Background: Programmed Death-Ligand 1 (PD-L1) has emerged as a potential 
prognostic marker and as an effective target for therapeutic inhibition in cancer. Using 
digital slide imaging, we evaluated the clinical, molecular and survival associations of 
PD-L1 expression in non-small cell lung cancer (NSCLC) according to cell type (tumor 
and immune cell) and tissue localization (tumor and stroma). Methods: Tumor samples 
from 199 NSCLC patients were stained for PD-L1 by immunohistochemistry (IHC) and 
quantitatively assessed using the Vectra slide imaging system for PD-L1 tumor membrane 
expression (TME), PD-L1 positive (+) tumor immune cell density (TICD) and PD-L1+ stroma 
immune cell density (SICD). Assessment of gene mutation and anaplastic lymphoma 
kinase rearrangement were performed using the AmpliSeq Cancer Hotspot V2 assay and 
IHC, respectively. Results: High PD-L1 TME correlated with larger tumor size, squamous 
cell histology and poor differentiation. PD-L1+ TICD was associated with male gender and 
wild-type EGFR. Univariate analysis revealed that stage (p=0.001), PD-L1 TME (p=0.007) 
and PD-L1+ TICD (p=0.006) were associated with worse survival. Iterative p-value analysis 
indicated the optimal thresholds for PD-L1 TME were 30 (p=0.003, 73% of cases) or 160 
(p<0.001, 7%), while for PD-L1+ TICD they were 6.9% (p=0.022, 33%) or 20% (p=0.001, 
5%). In multivariate analysis, stage (p=0.018), PD-L1 TME≥160 (p=0.040) and PD-L1+ 
TICD≥6.9% (p=0.015) were independently associated with survival. Conclusion: PD-
L1 Tumor Membrane Expression (TME) and PD-L1+ Tumor Immune Cell Density 
(TICD) expression determined by digital analysis have prognostic value in NSCLC. 
Keywords: NSCLC, PD-L1, immune cells, digital slide imaging
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P2.04-069 Characteristics and PD-1/PD-L1 Expression of Periphera 
CD4+CD25+CD127low Treg Cells in Lung Cancer Xue Pan, Yuan An, Hua Shi 
Department of Respiration, The Second Affiliated Hospital of Soochow University, Suzhou, 
China, Suzhou/China
Background: Both regulatory T cells (Tregs) and PD-1/PD-L1 pathway were critically 
involved in lung cancer. However, the association between them was not well investigated. 
Herein, we aimed to investigate the characteristics of PD-1 and PD-L1 expression on 
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criteria; including primary lung cancer, excluding pathological incomplete resection, 
limited resection, in-situ carcinoma, small-sized carcinoma, large cell neuroendocrine 
carcinoma, pleomorphic carcinoma, synchronous or metachronous multiple cancer 
and metastatic cancer. Tissue microarrays (TMA) were constructed using formalin-
fixed paraffin embedded (FFPE) tumor specimen of each representative histologic 
area. Patients’ characteristics and outcomes were collected from medical chart. The 
PDL1 expression was evaluated by immunohistochemistry (IHC) using anti-CD274 
(PDL1) antibody (Clone ERP1161 (2), Abcam) as primary antibody on 4-micrometer-
thick TMA specimen by an auto-staining machine. The results of IHC were evaluated by 
microscopy and scored with a combination of intensity and proportion. The intensity was 
defined as negative: 0, weakly positive: 1+, strongly positive: 2+), the proportion was 
defined positive cell percentage with 10% increments. Based on PDL1 score defined 
as ∑ [intensity (0, 1, 2) x proportion of each intensity], the tumors were divided as 
PDL1 positive group (score >50) and PDL1 negative group (score ≤50). We compared 
between two groups in clinicopathological characteristics and prognosis. Results: 541 
NSCLCs were classified into PDL1 positive (n = 171, 32%) and negative group (n = 370, 
68%). The PDL1 positive group was significantly less differentiated (p < 0.001), higher 
rate of lymphatic (p = 0.010), vascular invasion (p = 0.036), lymph node metastasis 
(pN1-3) (p = 0.012), and advanced pStage (p = 0.002) compared to negative group. 
There were no significant differences in sex, age, smoking habit, tumor size, pT factor, 
and distribution of histological types between two groups. Although the prognostic 
analysis showed no difference between PDL1 positive vs negative groups (p = 0.861), 
the histology-based stratification analysis revealed that PDL1 positive squamous 
cell carcinoma (SqCC, n=28) showed better overall survival rate compared to PDL1-
negative SqCC (n=53) (p = 0.018). Conclusion: Our data indicated that the PDL1 
positive NSCLCs had worse pathological factors, including tumor differentiation, 
lymphovascular invasion, pN, and pStage, but did not show a statistically significant 
difference in terms of overall survival rate compared to PDL1-negative group. It is of 
interest that PDL1 positive SqCC showed a better prognosis than PDL1 negative SqCC. 
Keywords: NSCLC, PDL1, Immune-checkpoint, Immunohistochemistry
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P2.04-073 PD-L1 Expression Is Induced by MET in an Erlotinib-Resistant Cell 
Line with MET Amplification Christina Demuth, Morten Nørgaard Andersen, Anne 
Tranberg Madsen, Kristine R. Jakobsen, Peter Meldgaard, Boe S. Sorensen 
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus C/Denmark
Background: The programmed cell death receptor 1 (PD-1) and its ligand PD-L1 have 
proved to be of significant importance in lung cancer. Production of PD-L1 helps the 
cancer cells evade the immune system by inactivating T-cells. Clinical trials investigating 
the effect of treating lung cancer patients with monoclonal antibodies targeting the PD-
L1 and PD-1 shows promising results. Expression of PD-L1 is associated with epidermal 
growth factor receptor (EGFR) mutational status. Further, expression can be significantly 
decreased by targeting EGFR with tyrosine kinase inhibitors (TKIs). In vitro studies 
suggest that this initial regulation of PD-L1 expression by EGFR occurs through the Erk 
pathway. Though, currently not much is known about expression of PD-L1 when TKI-
resistance develops. We have developed erlotinib-resistant cell lines. The resistant cell 
line gained a MET amplification. We demonstrate that PD-L1 is increases in the resistant 
cells and that this increment is induced by MET signalling. Methods: The lung cancer cell 
line HCC827 with a deletion in exon 19 in the EGFR gene, was treated with increasing 
concentrations of erlotinib over 5 months until resistance developed. MET gene 
amplification in the resistant cells was confirmed by PCR. The resistant cell line was used 
for studying the effect of EGFR and MET inhibitors on PD-L1 expression. Results: The 
HCC827 erlotinib-resistant (ER) cell line gained a MET gene amplification, as seen in 
previous studies. In the initial phase of erlotinib treatment the expression of PD-L1 
decreases. As the dose increases and resistance starts to develop the expression of 
PD-L1 increases. Activation of Erk is intact in HCC827ER as compared to the parental 
HCC827 cell line; most likely due to the activation of MET. When HCC827ER cells are 
treated with the MET inhibitor crizotinib, expression of PD-L1 decreases. When erlotinib 
is combined with crizotinib an additional effect on PD-L1 expression is observed. 
These results indicate that increased PD-L1 expression in erlotinib-resistant cell lines 
may be caused by activation of Erk through MET signalling. Conclusion: Our data 
demonstrates that Erk-dependent PD-L1 expression is increased in cells with erlotinib 
resistance caused by MET gene amplification. This mechanism might even be general 
and include several by-pass resistance mechanisms. Our findings suggest that the 
role of the PD-L1/PD-1 system should also be studied in erlotinib resistant tumors. 
Keywords: Resistance, EGFR TKI, PD-L1, MET
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P2.04-074 PD-L1 Gene Expression and Total Cell-Free RNA Measured in Blood 
Positively Differentiate Healthy Individuals from Metastatic NSCLC Patients  
Kathleen Danenberg1, Andreas-Claudius Hoffmann2, Peter V. Danenberg3, Joshua 
Usher4, Jin Li1, Yahya Elshimali1, Xu Huang1, Mai Dang1, Todd Sturdevant5, Yolanda 
Jaimes1, Robert Findlater1, Mary Grino1 1Liquid Genomics, Inc., Torrance/CA/United States 
of America, 2Medical Oncology, West German Cancer Center, Essen/Germany, 3Biochemisty 
& Molecular Biology, University of Southern California, Los Angeles/CA/United States of 
America,4Applied Biostatistics, University of Southern California, Los Angeles/CA/United 
States of America, 5Research & Development, Liquid Genomics, Inc., Torrance/CA/United 
States of America
Background: Cell-free DNA (cfDNA) released into the bloodstream by tumors allows non-
invasive identification of tumor-specific mutations. However, not all molecular changes in 
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P2.04-071 PD-L1 Expression Is Not Associated with Disease-Free Survival 
in NSCLC Patients Who Underwent Radical Resection Wenhua Liang, Qihua He, 
Jianrong Zhang, Jianxing He The First Affiliated Hospital of Guangzhou Medical University, 
Guangzhou/China
Background: The expression of Programmed Cell Death Ligand 1 (PD-L1), as a major 
mechanism of immune escape, has been observed in various malignancies. However, its 
prognostic impact on non-small cell lung cancer (NSCLC) patients remains controversial, 
especially those in early stage when theoretically all tumors have been removed. We 
sought to examine the correlation between PD-L1 expression and prognosis of NSCLC 
patients after radical resection. Methods: A consecutive cohort of 681 patients who 
underwent radical resection for stage I to III NSCLC in our center between Sep 2009 
and Dec 2011 was collected. All available cancerous tissues were collected and were 
made into tissue arrays. Immunohistochemistry staining using PD-L1 (E1L3N ®) XP ® 
Rabbit mAb was performed to detect the PD-L1 expression. PD-L1 positive expression 
was denoted as more than 10% tumor cells with PD-L1 staining, while PD-L1 high 
expression was denoted as H score≥100. The primary endpoint was disease-free survival 
(DFS). Results: Tissues of 670 patients were available and all of them were eligible for 
PD-L1 staining. There were 222 events (recurrence/death) and the median follow-up 
was 3.1 year (range, 0.1 to 5.6). Neither positive expression (HR 0.93, 95%CI 0.69 to 
1.25; P=0.61) nor high expression of PD-L1 (HR 0.88, 95% CI 0.59 to 1.31; P=0.54) was 
associated with DFS (Figure 1). The absence of discrepancies in prognosis did not differ 
in each stage and histology (Table 1)
.  
Figure 1. Kaplan-Meier curve. Table 1. Subgroup analyses
Subgroup No. HR 95% CI Sig.
Stage
I 340 0.754 0.299 1.897 0.548
II 139 0.827 0.406 1.683 0.600
III 162 0.669 0.355 1.259 0.213
Histology
Non-squamous without neuro-
endocrine differentiation 473 0.840 0.483 1.461 0.537
Squamous 146 0.867 0.445 1.690 0.675
Other or mix 49 0.763 0.225 2.585 0.664
 
Conclusion: This large scale study showed that PD-L1 is not a prognostic factor in early 
stage NSCLC after radical resection. These results encourage us to investigate whether the 
nature of the disease especially regarding immune escape will change after radical resection. 
Keywords: NSCLC, PD-L1, survival, Surgery
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P2.04-072 Immunohistochemical PDL1 Expression and Clinicopathological 
Characteristics in 541 Surgically Resected Non-Small Cell Lung Cancers Shohei 
Mori1, Noriko Motoi1, Yosuke Matsuura2, Hironori Ninomiya1, Sakae Okumura2, Makoto 
Nishio3, Yuichi Ishikawa1 1Division of Pathology, The Cancer Institute, Japanese Foundation 
for Cancer Research, Tokyo/Japan, 2Thoracic Surgery, The Cancer Institute Hospital of Jfcr, 
Tokyo/Japan, 3Thoracic Medical Oncology, The Cancer Institute Hospital of Jfcr, Tokyo/Japan
Background: Immune-checkpoint therapy targeting programmed cell death protein 
1 (PD1) and programmed cell death protein ligand1 (PD-L1, PDL1, CD274) has been 
emerging as a new therapeutic strategy for patients with cancer. PDL1 binding to PD1 
expressing on the surface of T-cell suppresses activation and proliferation of T-cell. 
Many types of cancer frequently overexpress PDL1 and escape the immune system. 
PDL1 expression of tumors may be a useful marker of responsibility for the immune-
checkpoint therapy targeting for PDL1. However, the incidence of PDL1 positive cases 
and related patients’ characteristics among NSCLC is still unclear. The aim of this study 
is to clarify these unsolved questions. Methods: The 541 surgically resected non-
small cell lung cancers (NSCLC) between 1994 and 2014 were recruited as following 
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the cure rate from 10% for anti-CTLA-4 alone to 60-80% as combination therapy. 
These repurposed drugs are normally used in completely unrelated conditions such as 
cardiovascular or skin diseases. Conclusion: Together, our results show that using network 
analysis of gene expression data from immunotherapy-responsive tumours generates 
testable hypotheses for the identifi cation of novel synergistic drug combinations. 
Keywords: immune checkpoint, systems biology, combination therapy, drug discovery
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P2.04-076 Dynamics of Soluble PD-1 during Treatment with EGFR-TKI in 
Advanced NSCLC Patients Steffen F. Sorensen1, Christina Demuth2, Boe S. 
Sorensen2, Peter Meldgaard1 1Department of Oncology, Aarhus University Hospital, Aarhus 
C/Denmark, 2Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus C/
Denmark
Background: The programmed cell death receptor-ligand pathway (PD-1/PD-L1) 
is hijacked by tumors in order to evade immune response. Therapy with monoclonal 
antibodies against PD-1 or PD-L1 in patients with advanced NSCLC has shown promising 
results in recent clinical trials. Preclinical studies indicate that the PD-L1 expression 
on tumor cells, and subsequently the PD-L1/PD-1 interaction, is increased when 
resistance to EGFR-TKI treatment in EGFR mutated NSCLC tumors occur. A soluble 
form of PD-1 receptor is present in the blood plasma, and can be detected in healthy 
individuals and in increased amounts in patients with autoimmune diseases and cancer. 
The dynamics of soluble PD-1 (sPD-1) during treatment and at the point of resistance 
to EGFR-TKI treatment is unknown. The aim of the present study is to assess the 
dynamics in plasma of EGFR mutated circulating tumor DNA and sPD-1 longitudinally 
during treatment with EGFR-TKI, and to study if the level of sPD-1 will increase at the 
time of resistance to EGFR-TKI treatment. Methods: Consecutive blood samples taken 
before initiation of treatment with erlotinib, during treatment, and at disease progression 
while on erlotinib from 20 patients with EGFR wildtype and 20 patients with EGFR 
mutated advanced NSCLC, has been collected, and will be analyzed. The amount of 
EGFR mutated circulating tumor DNA (in the EGFR mutated patients) and sPD-1 (all 
patients) will be detected by use of the Cobas® instrument (RMD) and ELISA (R&D 
systems), respectively. These results will be described and correlated to the clinico-
pathological characteristics of the patients. Results: Preliminary results show that 
sPD-1 can be detected in plasma from lung cancer patients. The fi nal results of the 
analysis will be presented at the conference. Conclusion: The present study is to our 
knowledge the fi rst to describe the dynamics of soluble PD-1 during EGFR-TKI therapy 
in both EGFR mutated and EGFR wildtype patients treated with erlotinib. The results 
will elucidate on the role of sPD-1 as a potential biomarker of resistance to EGFR-TKI 
therapy. The clinical time point of increased sPD-1 in plasma could indicate a “window of 
opportunity”, in which these patients could be highly responsive to anti-PD-1 or anti-PD-L1 
immunotherapy. Such fi ndings have to be further investigated in prospective clinical trials. 
Keywords: PD-1, Circulating Tumor DNA, Erlotinib, EGFR mutation
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P2.04-077 PDL1 Expression in Metastatic Non-Small Cell Lung Cancer 
Patients from Colombia (CLICaP) Andrés F. Cardona1, Leonardo Rojas2, Carlos A. 
Vargas1, Hernan Carranza1, Jorge M. Otero1, Oscar Arrieta Rodriguez3, Claudio Martin4, 
Luis Corrales5, Mauricio Cuello6, Rafael Rosell7 1Clinical and Translational Oncology Group, 
Foundation for Clinical and Applied Cancer Research - Ficmac, Bogotá/Colombia, 2Centro 
Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá/Colombia, 3Unidad 
Funcional de Oncología Torácica Y Laboratorio de Medicina Personalizada, National 
Cancer Institute, Mexico City/Mexico, 4Clinical Oncology, Instituto Fleming, Buenos Aires/
Argentina, 5Clinical Oncology, Hospital San Juan de Dios, San José/Costa Rica,6Clinical 
Oncology, Hospital de Clínicas - Udelar, Montevideo/Uruguay, 7Hospital Germans Trias I 
Pujol, Catalan Institute of Oncology, Barcelona/Spain
Background: Programmed cell death-1-ligand 1 (PD-L1) is involved in the ability of tumor 
cells to escape the host’s immune system. PD-L1 is selectively expressed in a number 
of tumors. The blockade of interactions between PD-1 and PD-L1 enhances the immune 
function in vitro and mediates antitumor activity in preclinical models. Recent studies have 
suggested that antibody-mediated blockade of PD-L1 induced durable tumor regression 
and prolonged stabilization of the disease in certain cancers including NSCLC. A recent 
study demonstrated that immunohistochemical (IHC) analysis detected no objective 
response in PD-L1-negative patients. However, 36% of the patients with PD-L1-positive 
tumors had a positive response. Methods: PD-L1 was assessed by IHC (Dako MAb) in 
115 NSCLC patients, considering as positive a staining intensity ≥ 2 in more than 5% of 
cells. The driver mutation epidermal growth factor receptor (EGFR) was examined by 
direct sequencing and allele specifi c PCR. ALK FISH was performed using the Vysis ALK 
Break-Apart Probe. The correlations of PD-L1 expression with major clinicopathologic 
parameters and outcomes were analyzed. Results: Mean age was 64.3 years (SD+/-10.7), 
66% were females, 83% had adenocarcinoma and 58% were former/current smokers. 
Fourteen patients (18%) had mutations in the EGFR and 19 (25%) were PD-L1+. PD-L1 was 
positive in fi fty-nine patients (51%) and this condition was more frequent in the light or 
never smokers (p=0.05). In the same way PD-L1 positivity was signifi cantly associated 
with presence of EGFR mutations (p=0.03), in tumors with a higher grade of differentiation 
(p=0.023) and in presence of vascular invasion (p=0.038). Patients with positive PD-L1 
expresion had a longer progression free survival (PFS) (6.4 months vs. 3.0 months, p= 
0.001) and overall survival (OS) (28.2 vs. 12.4 months; p=0.001). Conclusion: Although 
the study sample is small, PD-L1 positivity correlates with PFS and OS. This results 
supports that PD-L1 might be a critical factor in the use of NSCLC immunotherapy. 
Keywords: Immunotherapy, PD-L1, NSCLC, survival
tumors involve DNA mutations; in many cases it is also the quantity of a particular gene 
(i.e., gene expression) that is important. In this study, we investigated the use of cell-free 
RNA (cfRNA) released into the blood in order to monitor PD-L1 gene expression in NSCLC 
patients. The PD-1/PD-L1 pathway is a promising therapeutic target and anti-PD-L1 
agents have shown encouraging activity in a variety of tumor types. Methods: Blood 
samples were collected from NSCLC patients at various times during therapy. 
Additionally, non-cancer bearing blood samples were obtained from healthy volunteers 
(“control group”). Plasma was fractionated from blood samples and nucleic acids were 
extracted. RNA was reverse-transcribed into cDNA using random primers, and then 
analyzed by quantitative RT-PCR using appropriate gene-specifi c primers. The cDNA of 
PD-L1 was quantitated in both cancer patients and the control group. ERCC1 expression 
was also quantitated as an example of a non-tumor-specifi c gene. β-actin expression 
was used as the denominator gene representing total RNA. Results: PD-L1 expression 
was detected in the cfRNA of 60% (3/5 plasma samples) from the NSCLC patients, but 
was not detected in any samples from the control group (0/9), (p = 0.0005, Fisher’s 
Exact Test). ERCC1 expression was detected in 100% (5/5) of NSCLC patients and 67% 
(6/9) of the control group but its median expression value was about 8-fold higher in the 
plasma of cancer patients (p = 0.0045, Pearson’s chi-square). Median relative β-actin 
expressions in cancer patients and the control group were 19.3 (7.9-68.9) and 0.41 (0-
0.75), respectively (p < 0.0062, Pearson chi-square) (Fig. 1)
.  
Conclusion: These data demonstrate the potential value of using cfRNA from blood 
to measure gene expressions for detection of cancer and its recurrence, and in 
selecting and monitoring therapies. The presence of PD-L1 cfRNA in blood may be 
a specifi c indicator of cancer, although its sensitivity of tumor detection is less than 
100% because it is not expressed in all cancer patients. ERCC1 expression, while 
not specifi c for tumors, nevertheless shows considerably higher overall levels in 
cancer patients. The surprisingly large (about 50-fold) difference in median total 
cfRNA between cancer patients and healthy individuals without any overlap in 
the ranges of expression suggests that total cfRNA may be useful as a sensitive 
preliminary indicator of the presence of cancer and for recurrence monitoring. 
Keywords: Cell-free RNA, NSCLC, Gene Expression, PD-L1
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P2.04-075 Network Analysis of Anti-CTLA4-Induced Regressing Tumours 
Identifi es Novel Synergistic Drug Combinations Willem Joost Lesterhuis1, Anna 
K. Nowak1, Catherine Rinaldi1, Anya Jones2, Ian Dick1, Bruce W.S. Robinson1, Anthony 
Bosco2, Richard A. Lake1 1School of Medicine and Pharmacology, University of Western 
Australia, Perth/WA/Australia, 2Telethon Kids Institute, University of Western Australia, Perth/
Australia
Background: Antibodies blocking immune checkpoint molecules such as CTLA-4 have 
been shown to be effective in several cancer types, with some patients displaying 
durable complete regression. However, many patients do not respond to treatment. 
It is not known what molecular events control the response nor which co-treatments 
are likely to combine effectively with checkpoint blockade. Current strategies involve 
empirically testing different combinations of checkpoint blocking antibodies with other 
immunotherapeutic strategies or conventional anti-cancer drugs. We provide an alternative 
approach. Methods: Through performing network analysis of gene expression data from 
responding versus non-responding AB1-HA mesothelioma tumours from mice treated 
with anti-CTLA-4, we identifi ed genetic modules and hub genes within these modules 
that were associated with responsiveness. We subsequently identifi ed synergistic anti-
CTLA-4/drug combinations using two different approaches: fi rst, by pinpointing drugs 
that modulated hub genes within these response-associated modules, and second, by 
interrogating overlaps in the modular response patterns and drug-perturbation signatures 
in drug repurposing databases. The approaches were validated by testing the identifi ed 
drugs in vivo, in combination with anti-CTLA-4 in murine cancer models. Results: We 
identifi ed and validated several drugs that increased the response rate to anti-CTLA-4 in 
a highly synergistic manner. We identifi ed four drug classes with the capacity to increase 
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in both sera and tissue of patients with NSCLC.
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P2.04-081 The Role of B7-H4–Expressing Macrophage in Malignant Pleural 
Effusion Jian An Huang1, Chen Cheng1, Xiao Hui Zhang2 1Respiratory Medicine, The First 
Affiliated Hospital of Soochow University, Suzhou/China, 2The First Affiliated Hospital of 
Soochow University, Suzhou/China
Background: B7-H4 is a novel protein of the B7 family which regulated tumor immune 
escape through inhibition of T-cell activation and cytokine secretion. Tumor-associated 
macrophages (TAM) are a major component of cancer-related inflammation and play 
a central role in tumor promotion. Previously, some study have shown that B7-H4–
expressing macrophage in peripheral blood from lung cancer patients was significantly 
higher than that from healthy donors and tuberculosis patients. However, the role of B7-
H4–expressing macrophage in malignant pleural effusion is unknown. Methods: Pleural 
effusion mononuclear cells (PEMC) were isolated using Histopaque gradient 
centrifugation. The percentages of B7-H4–expressing CD68+cells were estimated by 
comparing the proportions of labeled cells with respect to total number of CD68+cells 
from the subjects studied. Intracellular staining was performed with FITC-TGF-beta1 mAb 
through the Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit. The detection of 
EMT related proteins by Western blotting and Flow cytometry. Using ROC curve to evaluate 
the diagnostic values of B7-H4+cell percentage in total macrophages in malignant pleural 
effusion caused by lung cancer. Results: In this study, we found that malignant pleural 
effusion caused by lung cancer have higher level of B7-H4–expressing macrophage than 
tuberculous pleural effusion, which have diagnostic value for malignant pleural effusion 
（CD68+B7-H4+ 16.97±10.32%vs 7.17±5.52%，P＜0.01）Further studies indicated that 
B7-H4–expressing macrophage is a source of TGF-β1, which is the most important factors 
of epithelial-mesenchymal transition (EMT). As supported, we proved malignant pleural 
effusion of lung cancer and TGF-β1 can both induce the EMT of A549 cells, accompanying 
with enhancement of A549 cell migration and invasion ability. Conclusion: Taken 
together, it is suggested that B7-H4–expressing macrophage may promote pleural 
metastasis of lung cancer though regulate the process of EMT by secreting TGF-β1. 
Keywords: B7-H4, macrophage, malignant pleural effusion
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P2.04-082 Diagnostic Value of Survivin-Expressing Circulating Tumor Cells 
in Patients with Non-Small Cell Lung Cancer Mi-Hyun Kim1, Jung Seop Eom2, Min 
Ke Lee1 1School of Medicine, Pusan National University, Busan/Korea, 2Pusan National 
University Hospital, Busan/Korea
Background: The most widely used circulating tumor cell (CTC) isolation techniques 
rely on antibody-based capture of CTCs, which express epithelial cell surface markers 
that are absent from normal leucocytes. Among these, epithelial cell adhesion molecule 
(EpCAM) is most commonly used. Although this platform is the most standardized of 
any current technology, it suffers from relatively low sensitivity. Survivin is a member of 
the inhibitor of apoptosis protein gene family that is highly expressed in most cancers. 
Several studies have shown the prognostic value of survivin in various malignancies, 
including lung cancer. But the diagnostic significance of survivin for non-small cell 
lung cancer (NSCLC) remains controversial. The purpose of this prospective study 
was to evaluate the diagnostic value of survivin-expressing CTCs in peripheral blood 
of patients with NSCLC. Methods: Blood samples were collected from patients with 
NSCLC before treatment and healthy volunteers. The EpCAM- and survivin- expressing 
CTCs were detected by real-time quantitative PCR. Results: To date, 43 patients 
with NSCLC stages I-IV and 15 healthy controls, all aged 52-79 years were enrolled in 
the study. Survivin mRNA was detected in the CTCs. Survivin- expressing CTCs were 
upregulated with more than 2-fold difference as compared with controls (p=0.004). 
EpCAM was not significantly different between NSCLC patients and controls (p=0.409). 
No correlation between the survivin-expressing CTCs levels and the stage of disease 
and histology can be made at this point. Conclusion: We demonstrated the significant 
difference in the levels of survivin-expressing CTCs between NSCLC patients and 
controls. These results suggest that survivin might be useful molecular marker for CTCs. 
Keywords: survivin, non-small cell lung cancer, Circulating tumor cell
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P2.04-083 Influence of Surgery on EGFR Mutation Abundance among Patients 
with Early-Stage Non–Small-Cell Lung Cancer Chengliang Yang1, Yi Ren1, Ye Gang 
Ma1, Dan Yang2, Bo Dong2, Wen Yuan Shang2, Xue Qiao2, Yang Zhou2, Yongyu Liu1 
1Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Shenyang/
China, 2Lab of Lung Cancer, Liaoning Cancer Hospital & Institute, Shenyang/China
Background: Detecting circulating plasma cell-free DNA (cfDNA) in patients with 
early-stage cancer has the potential to change how oncologists recommend systemic 
therapies for solid tumors after surgery. However, it remains unclear whether surgery 
affects epidermal growth factor receptor (EGFR) mutation abundance in early-
stage non–small-cell lung cancer (NSCLC). We investigated the influence of surgery 
on EGFR mutations in plasma and tumor tissues from patients with early-stage 
NSCLC. Methods: In this prospective study, primary lung tumors and matched pre- and 
postsurgery blood samples were collected from patients with early-stage NSCLC (n=96). 
We detected EGFR mutations (exon19 deletions, T790M and L858R) in 96 early-stage 
lung cancer samples using droplet digital PCR (ddPCR) and amplification refractory 
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P2.04-078 Functional Characterization of NK Cells in Non-Small Cell Lung 
Cancer Oscar Arrieta Rodriguez1, Ángel Gómez-Gallegos2, Renato Morales-Flores3, 
Angeles Garcia-Vicente2, Edgar Montes-Servín3, Fernanda Salinas-Parra3, Lourdes 
Barrera4 1Laboratory of Experimental Oncology and Thoracic Oncology Unit, National 
Institute of Cancer, Mexico City/Mexico, 2Laboratory of Integrative Immunology, National 
Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City/Mexico,3Laboratory 
of Experimental Oncology, National Institute of Cancer, Mexico City/Mexico, 4Business 
Oncology Unit, Astrazeneca, Mexico City/Mexico
Background: Lung cancer is the leading cause of cancer death worldwide and most of 
the patients are diagnosed with advanced disease. Lung cancer is the leading cause of 
cancer death worldwide. Natural killer (NK) cells are important effector cells in control 
of infected, malignant, and tumor cells. The aim of this study was to investigate the 
activation state and cytotoxic potential of NK peripheral cells in patients with Non-
Small Cell Lung Cancer (NSCLC). Methods: We investigated the relationship between 
NK cells apoptosis and Fas expression. NK cell apoptosis, Fas and Fas-L, NKG2D, 
CD69, KIR, CD244, CD122 and CD161 receptors were evaluated with multiparametric 
flow cytometry. We further evaluated the cytotoxic activity of NK cells and IFN-gamma 
expression. For this purpose, we simultaneously analyzed the loss of intracellular 
perforin and the surface expression of CD107a/b as well as the intracellular IFN-gamma 
expression with multiparametric flow cytometry. Results: Our results showed that Fas-
positive NK cells in lung cancer patients were higher than healthy controls (P<0.001). 
These results also showed that up-regulation of Fas expression is related to increased 
apoptosis of circulating NK cells. Regarding the cytotoxic capacity, our results showed 
that upon PMA stimulation, the expression of surface CD107a/b and loss of intracellular 
perforin of NK cells from patients with NSCLC were not correlated indicating an impaired 
functional cytotoxic activity. Interestingly, we also found that, IFN-gamma (P<0.005) and 
NKG2D expression were also impaired significantly (P<0.001). Conclusion: The results 
from this study suggest a possible NK cells anergy state. Our description will help to 
provide a mechanistic insight into tumor immune escape via negative regulation of NK 
cell innate function; however, the underlying mechanisms remained to be addressed. 
Keywords: NK cells, NSCLC, Tumor escape, biomarker
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P2.04-079 Targeting Antigen Presentation by Tumor Infiltrating B Cells to CD4 
T Cells in Non-Small Cell Lung Cancer Patient Tumors Tullia C. Bruno1, Brandon 
Moore1, Peggy Ebner1, Daniel Munson1, Jeffrey Kern2, Jill E. Slansky1 1Immunology 
and Microbiology, University of Colorado School of Medicine, Aurora/CO/United States of 
America, 2Oncology, National Jewish Health, Denver,Co/CO/United States of America
Background: B cells in tumors (TIL-Bs) are detected in non-small cell lung cancer (NSCLC) 
and their frequency correlates with improved survival, however, the functional mechanism 
of TIL-Bs in solid tumors is not well understood. We hypothesize that TIL-Bs help generate 
potent, long-term immune responses against cancer by presenting tumor antigens to 
CD4 tumor infiltrating lymphocytes (TILs) in primary human lung tumors. Methods: not 
applicable Results: Using un-manipulated, primary human B cells from fresh tumor, 
tumor-adjacent, and normal (cancer-free) lung tissue we observed that the total number 
of B cells at the site of the tumor versus the tumor-adjacent tissue was increased 
compared to other immune subsets. Further, in analyzing B cell markers of activation 
and exhaustion, we observed a spectrum of activation of TIL-Bs. Finally, we showed that 
TIL-Bs present autologous tumor antigens to CD4 TILs in a subset of NSCLC patients, 
and that depending on the activation or exhaustion profile of the TIL-Bs, differentiate 
CD4 TILs to T regulatory cells (Treg). These data suggest that some patients with TIL-Bs 
have differential function that is influenced by their activation or exhaustion phenotype. 
Conclusion: In conclusion, the anti-tumor functon of TIL-Bs can be stimulated in some 
NSCLC patients, and TIL-Bs that cannot be stimulated have increased immune exhaustion 
and promote Treg differentiation. Ultimately, results from this study will help predict which 
TIL-B functions to target in future TIL-B-specific immunotherapies or in combination with 
current immunotherapies for NSCLC patients like blockade of the inhibitory receptor, PD-1. 
Keywords: non-small cell lung cancer, Immunology, B cell, T cell
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P2.04-080 Novel Biomarkers for Non Small Cell Lung Cancer (NSCLC) Lukman 
Tijani, Cynthia Jumper, Leonardo Mirandola, Hassan Kaleem, Mohamed Shanshal, 
Maurizio Chiriva-Internati Internal Medicine, Texas Tech Health Sciences Center, Lubbock/
TX/United States of America
Background: Abstract Cancer testis antigens (CTA) are a class of tumor associated 
antigens, showing a restricted expression in cancer, strong immunogenicity, and 
weak expression in normal tissues. Sp17/AKAP4/PTTG1 have been previously 
investigated, showing promising results as a target. Our aim was to investigate 
the expression of Sp17/AKAP4/PTTG1 in lung cancer patients. Methods: 
We analyzed 2 lung cancer cell lines, one normal bronchus cell line, a panel of normal 
tissues and patients cells by RT-PCR, flow-cytometry, immunocytochemistry (ICC), 
and immunofluorescence (IF). CTA immunogenicity was investigated by measuring 
circulating specific antibodies in the sera of lung cancer patients. Results: ELISA 
analyses show the presence of circulating CTA-specific antibodies in the sera 
of lung cancer patients, indicating the immunogenicity of Sp17, AKAP-4 and 
PTTG-1. Sp17/AKAP4/PTTG1 were detected only in the cells of lung cancer 
patients. Conclusion: We showed that CTA, Sp17, AKAP-4 and PTTG-1 can be detected 
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kits (QIAamp DNA Micro kit, QIAamp DNA blood mini kit and QIAamp FFPE tissue kit, 
respectively). The 90 (30 matched triplicates) DNA samples were sequenced by Illumina 
HiSeq using Z3 cancer panel (Illumina, San Diego). Agreements of variant calls were 
compared between the three DNA substrates and a kappa statistic was reported using 
Stata 13. Results: Between 2011 and 2013, samples from 30 consenting patients 
were obtained. In total, 10 had primary lung cancer, 19 had secondary lung cancer, 
and 1 (intentionally included) had no evidence of cancer. From the 90 samples, a total 
of 18,821 variant calls were identified after the removal of known 1,048 germline 
variants. Within the hotspot panel alone, the mean (SD) number of variant calls per 
patient was 151 (44) on FFPE samples, 136 (49) on CTC samples and 463(108) on 
ctDNA samples. There was good agreement between CTCs and FFPE of 79.8% with 
a Kappa statistic of 0.42 (P<0.001). Agreement between ctDNA and FFPE was much 
poorer at 12.7% with a Kappa statistic of -0.40 (P=1.000). The results also suggested 
poor agreement between CTC and ctDNA of 16.1% with a Kappa statistic of -0.32 
(P=1.000). Focusing on single gene comparisons on the multiplex platform, agreement 
was considerably better for KRAS and EGFR for CTCs compared to ctDNA at 44% versus 
11% for KRAS and 92% versus 9% for EGFR respectively. Discordances were largely due 
to an increased number of variants that were identified in ctDNA and not in CTC or FFPE 
tissue. Conclusion: Our results suggest on a next generation sequencing platform that 
the global genetic variant profile between DNA extracted from CTC had good agreement 
with FFPE primary tumour tissue, and the agreement for ctDNA and FFPE was much 
poorer. This was observed to be an increase in the number of variants detected on single 
gene analysis and may be due to processing, sample or analytic difficulties with ctDNA. 
Keywords: next generation sequencing, ctDNA, Circulating Tumour Cells, Mutation 
profile
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P2.04-086 An Effective In Vivo Liquid Biopsy Tool for High-Yield Isolation of 
Circulating Tumor Cells Klaus Luecke1, Dave Hoon2, Christopher Booth3, Lucasz 
Gasiorowski4, Wojciech Wojciech4 1Gilupi, Potsdam/Germany, 2Molecular Diagnostic, John 
Wayne Cancer Institute, Santa Monica/AL/United States of America, 3Ekf, Cardiff/United 
Kingdom, 4Medical University Poznan, Poznan/Poland
Background: Analysis of tumor biopsy material represents only assessable tumor 
and represents the state at the time of diagnosis. This approach neglects tumoral 
heterogeneity changes occurring during disease progression. However, during 
systemic therapies tumors undergo molecular changes and usually develop resistance 
mechanisms. Reevaluation of tumors after therapy, at disease progression and before 
new treatment initiation would be informative for the selection of appropriate next steps. 
However, re-biopsies are not often feasible and can cause morbidity. . Liquid biopsy, i.e. 
isolating and analyzing circulating tumor cells (CTCs), can be an additional source of 
diagnosis, prognosis, evaluation of treatment efficacy, and molecular tumor evolution 
and metastatic sites. Commonly, CTCs are isolated from small blood volumes (5-10 
ml) in in vitro approaches. This approach has limited sampling volume particularly in 
detecting low frequency CTC. To overcome this limitation, the GILUPI CellCollectorâ, an 
intravascularly in-dwelling device, screens a large volume (>1 liter) of blood for CTCs 
directly in the vein of the cancer patient. The device has specific monoclonal antibodies 
attached to pull down epithelial derived CTCs. We demonstrate the application of the 
CellCollector in the assessment of CTC in non-small cell lung cancer (NSCLC) patients. 
The novel study demonstrates a novel in vivo approach of assessing CTC in different 
stages of NSCLC. Methods: : In this study a total of 25 non-small cell lung cancer 
(NSCLC) patients stage IA to IIIB, were applied for CTC isolation before (n=50) time and 
after surgery how long after (n=25). CTC validation and enumeration was conducted by 
immunofluorescence (IF) microscopy. Following this, isolated CTCs were analysed for 
mutations in KRAS and EGFR genes commonly found in NSCLC using the PointMan DNA 
mutation enrichment assay. Primary tumor tissue was analysed for the same mutations 
to investigate concordance. Results: In a previous studies have shown a significantly 
higher isolation efficacy compared to the FDA-cleared CellSearchâ System. In the current 
study we focused on the comparison of the status of driver mutations in KRAS and EGFR 
in CTCs compared to the primary tumor tissue. Overall, successful isolation of CTCs with 
the CellCollectorâ was detectable in 77% of the samples. The pre-surgical isolation rate 
was 79%, slightly higher than the post-operative rate of 72%. In this cohort of patients, 
EGFR and KRAS mutations could be detected in all patients? Frequency level need to given 
and were compared by analysis of the respective primary tumor sgive concordance. 
Conclusion: The GILUPI CellCollectorâ overcomes blood volume limitations of other CTC 
extraction approaches and thereby increases the diagnostic sensitivity of CTC isolation. 
It allows CTC enumeration, molecular characterization, and biomarker expression 
analysis, which could help guide treatment strategies and monitoring therapy efficacy. 
Keywords: molecular diagnostic, NSCLC, Oncology, CTC
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P2.04-087 Detection of Mutations from Peripheral Blood in Patients with 
Non-Small Cell Lung Cancer with Fast Turn-Around Kathleen Danenberg1, Joshua 
Usher2, Todd Sturdevant3, Yolanda Jaimes4, Robert Findlater1, Jinliang Li1, Mai Dang1, 
Xu Huang1, Yahya Elshimali1, Annette Parr5, Peter V. Danenberg6, Andreas-Claudius 
Hoffmann5 1Liquid Genomics, Inc., Torrance/CA/United States of America, 2Applied 
Biostatistics, University of Southern California, Los Angeles/CA/United States of 
America, 3Research & Development, Liquid Genomics, Inc., Torrance/CA/United States of 
America, 4Liquid Genomics, Inc., Torrance/United States of America, 5Medical Oncology, 
West German Cancer Center, Essen/Germany, 6Biochemisty & Molecular Biology, University 
of Southern California, Los Angeles/CA/United States of America
mutation system (ARMS). EGFR mutation abundance was determined and analyzed 
to reveal potential impact of surgery. Results:Presurgery plasma samples (n=96) 
matched tumor tissue samples (n=96) were analyzed for EGFR mutations using ddPCR 
and ARMS respectively. Of the 56 EGFR mutations detected in tumor tissues by ARMS, 
48 of the corresponding mutations were detected in presurgical cfDNA, whereas no 
mutations were found in plasma from patients with EGFR wild-type tumors (sensitivity 
85.71%, specificity 100%). Forty patients with mutation-positive cfDNA presurgery had 
ddPCR analysis of postsurgery plasma, with twenty-four patients having detectable 
cfDNA postsurgery. The decrease in EGFR mutation abundance was statistically 
significant (0.22 vs 0.04, P <0.05). Conclusion: This study demonstrates accurate 
mutation detection in plasma using ddPCR, and that cfDNA can be detected in blood 
before and after surgery in patients with early-stage lung cancer. Our results suggest 
that surgery may reduce EGFR mutation abundance in early-stage NSCLC patients 
with mutation-positive cfDNA presurgery. Future studies can now address whether 
monitoring the change of EGFR mutation abundance after surgery identifies patients at 
risk forrecurrence, which could guide therapy decisions for individual NSCLC patients. 
Keywords: EGFR Mutation Abundance, Early-stage NSCLC, droplet digital PCR, Surgery
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P2.04-084 Next-Generation Sequencing with Digital Droplet PCR for 
Circulating Tumor DNA Quantification in Non-Small-Cell Lung Cancer Patients 
Nicolas P. Pécuchet1, Eleonora Zonta2, Audrey Didelot2, Pierre Combe3, Laure Gibault4, 
Nadege Rice5, Pierre Laurent-Puig6, Valerie Taly2, Helene Blons6, Elizabeth Fabre1 
1Department of Medical Oncology, Inserm Umr-S1147, Hôpital Européen Georges Pompidou 
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France, 2Umr-S1147, Inserm, Paris Descartes University, Paris/France, 3Medical Oncology, 
Hôpital Européen Georges Pompidou (Hegp), Assistance Publique Hôpitaux de Paris (Ap-
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Assistance Publique Hôpitaux de Paris (Ap-Hp), Paris, France, Paris/France, 5Biochemistry 
Department - Unit of Pharmacogenetic and Molecular Oncology, Hôpital Européen Georges 
Pompidou (Hegp), Assistance Publique Hôpitaux de Paris (Ap-Hp), Paris, France, Paris/
France, 6Department of Biochemistry, Inserm Umr-S1147, Hôpital Européen Georges 
Pompidou (Hegp), Assistance Publique - Hôpitaux de Paris, Paris Sorbonne Cité Université, 
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Background: We aimed to compare different methods to assess the dynamics of 
circulating tumor DNA (ctDNA) in metastatic NSCLC pts. Methods: A cohort of advanced 
NSCLC pts was followed by serial plasma blood samples and RECIST assessments every 
2 months. Plasmatic cell-free DNA was extracted with the QIAsymphony DSP Virus/
Pathogen kit (Qiagen). EGFR and KRAS mutations were assessed in plasmatic DNA using 
Q-PCR and picoliter droplet based digital PCR (ddPCR, Raindance) with CAST probes. 
Nexte-Generation Sequencing (NGS) was performed using the Lung and Colon Cancer 
Panel v2 (Iontorrent, AmpliSeq, Lifetechnologies) with a target of 10,000X (Proton). 
For NGS and dPCR, the limit of blank was determined for each mutation. Results: We 
included 37 pts treated by TKI (n=21) or chemotherapy (n=16), in 1rst (n=31) or 2nd line 
(n=6). Median follow-up, progression-free survival (PFS) and overall survival were 12, 6 
and 31 months, respectively. Tumor mutations were: EGFR [L858R (n=9), Del19 (n=9), 
L861Q (n=1), Ins20 (n=2)], KRAS (n=2), TP53 (n=4). No mutation was found in 8 pts. 
At baseline, ctDNA was positive by one of the 3 technics in 22/29 (76%) pts, with 2 pts 
being positive by dPCR only. ctDNA quantification was highly correlated between NGS 
and ddPCR r2=0.74), but not with Q-PCR. The fraction of ctDNA (‰) was associated 
with radiological outcome (ROC AUC 0.87 and 0.81 for NGS and dPCR). The relative 
change of ctDNA between 2 consecutive samples did not improve the prediction of tumor 
evolution (AUC 0.74 and 0.76). RECIST tumor progression was best predicted by pDNA 
>1.1‰ in NGS (sensitivity 0.85, specificity 0.80), and >1.4‰ in dPCR (sensitivity 0.82, 
specificity 0.74). Persistence of >1‰ ctDNA under treatment was associated with a 
short PFS (2.2 months vs. 8 months, log-rank P = .0002). Conclusion: In this cohort, 
the persistence of plasmatic tumor DNA using NGS (10,000 X) or dPCR was associated 
with treatment failure in NSCLC patients. A threshold of 1/1000 mutation ratio was 
clinically meaningful using both technics. Plasmatic tumor DNA normalization could be 
evaluated in addition to standard RECIST criteria as clinical endpoints for clinical trials. 
Keywords: digital droplet PCR, circulating DNA, next generation sequencing
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P2.04-085 A Comparative Analysis of Cancer Hotspot Mutation Profiles in 
Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary 
Lung Tumour Maria Leung1, Maxim Freidin2, Dasha Freidina2, Sanjay Popat3, Andrew 
Nicholson4, Alexandra Rice4, Angeles M. Fernandez4, Eric Lim1 1Thoracic Surgery, Royal 
Brompton Hospital, London/United Kingdom, 2National Heart and Lung Institute, Imperial 
College, London/United Kingdom, 3Medical Oncology, Royal Marsden Hospital, London/
United Kingdom, 4Histopathology, Royal Brompton Hospital, London/United Kingdom
Background: Blood based mutation profile analyses are becoming an increasingly 
important non-invasive form of mutation screening in cancer. Many have reported on 
single mutation comparisons between blood based and primary tumour tissue, but 
limited information is available on multiplex comparisons between the DNA extracted 
from circulating tumour cells (CTC), circulating free tumour DNA in the plasma (ctDNA) 
against the current standard of FFPE analysis of primary tumour. Methods: Pre-
operative whole blood samples were collected from 30 patients who underwent thoracic 
surgery. CTCs were isolated using ScreenCell MB devices from 6ml of whole blood, 
and 1ml aliquots of plasma were removed from 9ml of EDTA samples. Matching FFPE 
samples were retrieved from post-resection primary tumour tissue in three 10µm PCR 
rolls. DNA was extracted from the CTCs, ctDNA and matched FFPE tissues using Qiagen 
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mutation detection techniques between tumor tissue and peripheral blood sample in 
patients with EGFR-TKI treatment. Methods: We collected plasma and serum sample 
before EGFR-TKI and after acquired resistance in 11 patients with EGFR mutations (5 
cases of 19 deletion and 5 cases of L858R) from paraffin-embedded tissues using 
PNAClampTMEGFR Mutation Detection kit. DNA extraction from plasma and serum was 
performed using the QIAamp MinElute virus spin kit. EGFR mutation analysis for blood 
was done by pyrosequencing and PANAMutyperTMR EGFR kit. The degree of agreement 
was evaluated by Cohen’s kappa value. Results: The median EGFR-TKI duration of total 
11 (7 male, 4 female) cases was 6 months (range 4-24). The sensitivity of plasma EGFR 
mutations were 33.3% in pyrosequencing. The sensitivities of PANAMutyperTMR were 
72.7% in plasma and 45.5% in serum sample. The degree of agreements between 
tissue and blood sample were better in plasma PANAMutyperTMR (k=0.429, p=0.033) 
and serum PANAMutyperTMR (k=0.290, p=0.026) than plasma pyrosequencing 
(k=0.194, p=0.087). After the development of acquired resistance, plasma EGFR 
mutations were still detected in 4 cases by PANAMutyperTMR. One of them showed 
19 deletion and T790M mutation at the same time. Conclusion: The sensitivity and 
the strength of agreement of PANAMutyperTMR test were better than pyrosequencing. 
So this technique can be useful to detect EGFR mutation in peripheral blood. 
Keywords: Circulating tumor cell, Epidermal growth factor receptor mutations, 
Sensitivity
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P2.04-090 Changes in Circulating Epidermal Growth Factor Receptor (EGFR) 
during Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Ping Ye1, 
Jing Zhao2, Nita Maihle2, Shulian Wang2, Jianyue Jin2, Feng-Ming (Spring) Kong1 
1Gru-Cancer Center, Georgia Regents University, Augusta/GA/United States of America, 2Gru-
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Background: Epidermal growth factor receptor (EGFR) is overexpressed in a variety of 
malignant tumors including lung cancer. A circulating isoform of EGFR has been detected 
in the blood of lung cancer patients. Previous reports suggest that low baseline plasma 
EGFR concentrations are associated with reduced survival in patients with stage IV 
non-small cell lung cancer (NSCLC) post-chemotherapy. The goal of the present study 
was to determine whether: 1) plasma EGFR concentrations change during- and/or after 
radiotherapy, 2) the changes are associated with overall survival (OS) in stage I-III NSCLC 
following radiation treatment. Methods: Patients enrolled in prospective studies in which 
platelet poor plasma samples had been collected were eligible. All patients received 
radiation-based treatment. Patient age, gender, ECOG score, clinical stage, pathology, 
smoking history, chemotherapy and radiotherapy were all included in this analysis. Blood 
samples were collected pre-radiotherapy (pre-), during radiotherapy (2 weeks) (2w), 
during radiotherapy (4 weeks) (4w) and post-radiotherapy (more than 4 weeks post-
radiotherapy). Plasma EGFR concentrations were measured using a commercial enzyme-
linked immunoassay kit (BosterBio Inc., Pleasanton, CA) that detects the extracellular 
domain of EGFR. The primary endpoint was OS. Results: 183 patients with median age of 
66, 143 male and 40 female, were included in this study. The median OS was 15.5 months 
(95% confidence interval [CI]: 20.8-27.3). The mean plasma concentration of EGFR was 
35.6 ng/ml for pre- (n=116, 95% CI: 33.9-37.4); 22.4 ng/ml for 2w (n=114, 95% CI: 
20.8-24.0); 34.5 ng/ml for 4w (n=114, 95% CI: 31.4-37.7); and 45.0 ng/ml for post 
(n=114, 95% CI: 40.1-49.9). The plasma level at 2w was significantly lower than pre-levels 
(p < 0.01). The plasma EGFR level at 4w was significantly higher than at 2w (p < 0.01), 
though it was not significantly different from that of pre-RT levels. There is a significant 
increase in EGFR levels in post-RT treated patients (p < 0.01). Post-treatment levels are 
above all other points observed in cancer patients, including at baseline and during-RT. 
However, no significant correlation between the levels of EGFR and OS, or between the 
ratio 2w/pre or post/pre and OS were observed. Kaplan-Meier survival analysis showed 
pre- EGFR concentrations [22.2 months (95% CI: 6.8-37.7) versus 23.5 months (95% CI: 
14.1-32.9) (p = 0.527)] and fold changes of 2w/pre- [24.5 months (95% CI: 11.2-35.9) 
versus 23.7 months (95% CI: 12.2-42.3) (p=0.928)] respectively. Conclusion: In parallel 
with previous reports for the treatment of NSCLC patients with gefitinib, RT results in a 
decrease in EGFR plasma concentrations shortly after therapy (2 weeks), but an increase 
relative to baseline levels by 4 weeks, followed by a further increase (to above baseline 
levels) by 3 months post-treatment. In patients treated with gefitinib, this increase 
correlated with worse response to therapy. Here there does not appear to be a correlation 
between increased plasma EGFR levels and OS following RT. The biologic mechanism(s) 
underlying these observations, and their clinical implications warrant further study. 
Keywords: NSCLC, Radiotherapy, EGFR
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P2.04-091 Digital PCR Analysis of Plasma Cell-Free DNA as a Noninvasive 
Detection of the Drug Resistance Mechanisms in EGFR Mutant NSCLC Hidenobu 
Ishii1, Koichi Azuma1, Kazuko Sakai2, Takaaki Tokito1, Kazuhiko Yamada1, Kazuto Nishio2, 
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Background: Although the epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKI) have shown dramatic effects against EGFR mutant non-small-cell lung 
cancer (NSCLC), patients demonstrate resistant by various mechanisms, such as second-
site point mutation that substitutes methionine for threonine at position 790 (T790M) 
in EGFR, and amplification of mesenchymal-epithelial transition (MET) proto-oncogene 
and human epidermal growth factor receptor 2 (HER2). With the development of 
overcoming resistance to EGFR-TKIs, identification of the mechanisms of drug resistance 
Background: In non-small cell lung cancer (NSCLC) several genetic changes that have 
clinical consequences for targeted treatment approaches have been identified. As for 
EGFR Mutations there are already options for more than one line of treatment. For those 
patients with secondary changes like the T790M-mediated resistance to EGFR inhibitors 
irreversible tyrosine kinase inhibitors (TKI) seem to be a promising alternative. These 
options may however be limited to missing proof of such changes as with progressing 
tumor burden patients may be susceptible to higher mortality with necessary invasive 
procedures. The so called “Liquid Biopsy” – using peripheral blood to obtain timely 
information on genetic information in solid malignancies – seems to be the urgently 
needed solution to this problem. Methods are needed that hold the promise of fast-
turn around and broad availability. Methods: Serum was tested from 130 patients with 
adenocarcinoma or squamous cell cancer of the lung. All patients received at least one 
line of systemic therapy. Frequencies of EGFR ex19dels, EGFR L848R and EGFR T790M 
were tested as well as KRAS G12C, D and V. The detected frequencies were correlated 
with expected frequencies obtained from published data (mycancergenome.com). 
Furthermore the results from serum were correlated to results obtained from the available 
tumor tissue. Additional samples of fresh blood were tested. Results: Correlation of 
mutation detection results from serum correlated significantly with measurement of the 
available tumor specimen. Furthermore expected frequencies were in line with published 
occurrence of genetic changes. There was however a potential bias as T790M mutations 
were higher than expected which may be due to cancer center specific patient selection. 
These results were in line with the fresh blood samples tested. Turn-Around of fresh 
samples was three (3) days. Conclusion: Mutation detection is feasible from peripheral 
blood with fast turn-around and high sensitivity and specificity. In addition samples can be 
used either fresh or as stored serum probes. This will allow faster treatment decisions and 
higher patient satisfaction due to shorter intervals until start of therapy. The Liquid Biopsy 
is a clear and medically needed alternative to analyzing tissue samples. Especially in cases 
of secondary changes to tumors during systemic therapy this method will be crucial. 
Keywords: liquid biopsy, cell-free DNA, EGFR, KRAS
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
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University of California San Diego, La Jolla/United States of America, 3Biocept Incorporated, 
San Diego/CA/United States of America
Background: Identification of molecular drivers such as EGFR in non-small cell lung 
cancer (NSCLC) has increased our capability to deliver personalized cancer therapy. 
EGFR tyrosine kinase inhibitors (TKI) are very effective in patients with EGFR sensitive 
mutations, but resistance ultimately develops. Determining mechanisms of secondary 
resistance requires post progression biopsies which carry non-trivial complication risks 
for patients and thus are not suitable means for serial monitoring. Cell free circulating 
DNA (cfcDNA) could represent an alternative method to detect molecular mechanisms of 
secondary resistance. Methods: Single institution observational study of 13 patients with 
EGFR mutant Stage IV lung adenocarcinoma. Two 8-10 ml tubes of blood were collected 
from patients who progressed on erlotinib. Patient samples were tested for T790M 
mutations using the Biocept Selector assay as well as MET using FISH amplification. 
Results from these “liquid-biopsies” were then compared to results obtained on standard 
tissue biopsy. Results: 13 patients with secondary resistance were enrolled, all 13 had 
adenocarcinoma. Median age was 61 with an age range 52-76, male to female ratio 7:6, 
8/13 (62%) had deletion 19, 5/13 (38%) had an L858R mutation. Median duration of EGFR 
TKI therapy prior to cfcDNA sample collection was 16 months, range 5.2-64.4 months. 
9/13 patients underwent a post-progression tissue biopsy with 8/13 found to have the 
T790M mutation, 1/13 with c-MET amplification, and 1/13 with both. 11/13 patients were 
found to have T790M in cfcDNA. Average concentration of T790M clone in cfcDNA was 
4% with a range from .004-27.6% (from 3mL of blood). Average copy number of T790M in 
cfcDNA was 2310 with a range from 7-20507 (from 3mL of blood). Average copy number 
of the EGFR gene in cfcDNA was 39404 with a range from 4308-169628 (from 3mL 
of blood). Among the 10 patient thus far whose post-progression biopsies and cfcDNA 
sampling was completed, the sensitivity and positive predictive value (PPV) of Selector 
was 88% and 88% respectively. Concordance was 80% between cfcDNA and tissue. 7/9 
patients with tissue confirmed T790M were switched to third generation TKI with 6/7 
currently with stable disease after an average of 7 months (5-9). 1/7 passed away after 
one month on the next generation TKI due to disease progression. Conclusion: Biocept’s 
blood based assay detecting T790M and MET amplifications from cfcDNA is highly 
concordant with mutations present in tumor tissue and therefore a non-invasive 
surrogate for determining mutational status of patients’ who progress on TKI therapy. 
Keywords: Advanced Stage NSCLC, EGFR sensitizing mutation, T790M, Cell Free 
Circulating DNA
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P2.04-089 Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in 
Circulating Tumor DNA During EGFR-Tyrosine Kinase Inhibitor Treatment 
In-Jae Oh, Hyun-Ju Cho, Chul-Kyu Park, Young-Chul Kim, Ju-Sik Yun, Sang-Yun Song, 
Kook-Joo Na, Mee-Sun Yun, Sung-Ja Ahn, Hyun-Ju Seon, Yoo-Duk Choi Lung and 
Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Jeonnam/Korea
Background: Epidermal growth factor receptor (EGFR) mutations are predictive marker 
of EGFR-tyrosine kinase inhibitor (TKI) therapy. We compared the sensitivity of EGFR 
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P2.04-093 Assessment of Clinical Applications of Circulating Tumor DNA 
in Lung Cancer Using an Enhanced TAm-Seq Platform Davina Gale1, Andrew 
Lawson1, Jordi Remon2, Vincent Plagnol1, Sarah Smalley1, Espereanza Perez2, Karen 
Howarth1, Michelle Pugh1, Tim Forshew1, Abdelaziz Fahem1, Amanda Bettison1, John 
Beeler1, Ludovic Lacroix2, Emma Green1, Michael Stocum1, Benjamin Besse2, Nitzan 
Rosenfeld1 1Inivata Ltd, Cambridge/United Kingdom, 2Institut Gustave-Roussy, Villejuif/
France
Background: Novel biomarkers are required to assess tumor burden and response in 
lung cancer as conventional biopsies are invasive, costly and only provide a snapshot 
of the mutational profile at a given time and location. A promising biomarker is the 
detection of genomic material released from tumors into the blood plasma of patients, 
known as circulating tumor DNA (ctDNA). ctDNA has been detected in plasma for a 
wide range of solid tumors and can be distinguished from other (germline) cell-free 
DNA by the presence of tumor-specific DNA alterations or known hotspot mutations. 
However, the potential of ctDNA as a biomarker in lung cancer has not yet been fully 
realized due to technical challenges associated with its detection and analysis, including 
the short fragment sizes (140-170 bp), small number of amplifiable copies and low/
variable allele fractions of ctDNA. To further develop applications of ctDNA in lung 
cancer, we have developed a process to analyse ctDNA and utilise it in a range of clinical 
studies. Methods: We have developed an enhanced platform for tagged-amplicon 
deep sequencing (TAm-Seq). Using a combination of improved library preparation and 
bespoke data analysis methods, this platform can be used to sequence established 
cancer hotspots and the entire coding regions of selected genes, while preserving high 
levels of specificity and sensitivity. Results: Using this approach, we have developed 
an assay that analyzes ~20 kb of the genome (including regions of interest in more 
than 30 genes) with sensitivity down to a few mutant copies. Performance of this 
assay has been demonstrated using spike-in experiments, dilution series and clinical 
sample cohorts from lung cancer patients. Conclusion: Our proof of concept studies 
show the potential of ctDNA to be used to assess tumor mutation status, monitor 
tumor dynamics, assess response to treatment and identify mutations associated 
with acquired drug resistance and disease progression. This non-invasive approach - 
a “liquid biopsy” - offers a revolution in how cancer can be detected, monitored and 
treated. Further studies in lung cancer are being developed and will be presented. 
Keywords: Circulating tumour DNA, personalised medicine, liquid biopsy
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P2.04-094 Exosomal MiRNA Analysis of Non-Small Cell Lung Cancer (NSCLC) 
Liquid Biopsies. Mirror of the Disease Status?: Proof of Concept Study 
Marco Giallombardo1, Jorge Chacartegui2, Laure Sober3, Jan P. Van Meerbeeck4, 
Sofie Goethals5, Riccardo Alessandro6, Patrick Pauwels3, Christian Rolfo7 1Phase 
I- Early Clinical Trials Unit, Antwerp University Hospital & Palermo University, Edegem/
Belgium, 2Phase I- Early Clinical Trials Unit, Antwerp University Hospital, Edegem/
Belgium, 3Molecular Pathology Unit & Core, Antwerp University Hospital & Antwerp 
University, Edegem/Belgium, 4Thoracic Oncology, Antwerp University Hospital, 
Edegem/Belgium, 5Molecular Pathology Unit, Antwerp University Hospital, Edegem/
Belgium, 6Department of Medical Biotechnology - Dibimed, University of Palermo, Palermo/
Italy, 7Phase I-Early Clinical Trials Unit, Department of Medical Oncology & Core, Antwerp 
University Hospital & Antwerp University, Edegem/Belgium
Background: The discovery of the alterations in EGFR, c-Met or ALK in NSCLC has 
driven the development of targeted-drug therapy using tyrosine kinase inhibitors (TKIs). 
To optimize the use of these TKIs, the discovery of new biomarkers for early detection 
and disease progression is needed. The exosomes extracted from blood samples could 
be non-invasive and regularly updated biomarkers. Here we analyze selected exosomal 
miRNAs to evaluate its biomarker potential in NSCLC. Methods: 1 ml of serum/plasma 
sample from 11 NSCLC patients, with different mutations and treatments (and 6 healthy 
donors as controls), were used as exosome sources. Exosome were isolated through 
commercial-kit or D2O/sucrose density-gradient ultracentrifugation. After exosome 
characterization (Western-Blot, Transmission Electron Microscopy) a panel of miRNAs 
(30b-5p, 30c-5p, 103,195,221-3p,222-3p), correlated with NSCLC disease (Garofalo et 
al, 2013), was analyzed. The miRNAs profile analysis was performed through TaqMan 
Real-Time PCR and mir-1228-3p was used as endogenous control. The data was 
processed according to the formula 2-ΔΔct. Control values are used as baseline and 
results are shown in logarithmic scale (figure). Results: Patients without molecular 
alterations (WMA): The levels of miR-30b-5p/30c-5p/103/221-3p/222-3p were down-
regulated relative to the healthy controls. The patient with docetaxel treatment (P2) has 
an increased down-regulation of these miRNAs compared to the non-treated patient 
(P1). Patient with BRAF G464V: We observed an increased up-regulation of miR-30b-
5p/30c-5p/103/221-3p/222-3p just after stopping Erlotinib treatment (P4a) compared 
with one month after the treatment (P4b). Patients with C-Met 3+ over-expression: We 
detected an increase of expression of miR-30b-5p/30c-5p and a decrease of expression 
of mir221-3p/222-3p in a patient treated with Crizotinib (P6) compared to a non-treated 
patient (P5). Patients with EGFR (exon 19 del): We observed a decrease of expression of 
mir221-3p/222-3p in a patient treated with Afatinib beyond progression (P8) compared 
to a non-treated patient (P7). Patients with ALK t(2p23): We detected a decrease of 
expression of miR-30b-5p/30c-5p/103 compared to healthy controls. No differences 
between treated (P9-P11) and non-treated (P3) patients were observed. Nevertheless, 
mir221-3p/222-3p differs significantly between patients treated with Ceritinib one week 
(P10) and one month (P11) after the treatment was started. Conclusion: This panel of 
exosomal miRNAs derived from patients with varying mutations is responsive to different 
treatments. The down-regulation of miR-30b-5p/30c-5p in exosomes of patients with 
is urgently needed. However, tumor samples for detecting the resistant mechanisms 
were not easily available in patients with EGFRmutation-positive NSCLC relapsed 
after EGFR-TKIs treatment. Here, we examined the correlation of T790M mutation, 
activating EGFR mutations, HER2 amplification, and MET amplification in relapsed NSCLC 
patients between plasma and tumor samples using digital PCR assay as an alternative 
and noninvasive method. Methods: A total of 18 patients obtained pairs of tumor and 
blood samples after resistance to EGFR-TKI treatment were enrolled in this study. 
T790M mutation, activatingEGFR mutations, MET amplification, and HER2 amplification 
in relapsed NSCLC patients after EGFR-TKIs treatment were analyzed by digital 
PCR. Results: Digital PCR analysis of T790M mutation in plasma had a sensitivity of 
81.8% and specificity of 85.7%, with the overall concordance between plasma and tissue 
samples 83.3%. Analysis of primary active mutation in plasma showed inconsistent 
results with lower sensitivity of 66.7% and concordance of 70.6% compared to those of 
T790M mutation. MET gene copy number gain of tumor DNA by digital PCR was observed 
in three patients. Of these patients, one patient exhibited positive for MET amplification 
by FISH, whereas no patient demonstrated MET and HER2 copy number gain in plasma 
DNA. Conclusion: Digital PCR analysis in plasma is feasible and accurate method 
for detecting the T790M mutation in NSCLC resistance to EGFR-TKIs treatment. 
Keywords: digital PCR, EGFR, T790M, plasma
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P2.04-092 Sequencing of Actionable EGFR Mutations from PtDNA in NSCLC: 
A Feasibility Study of Non-Invasive Analysis of Sensitivity to TKI Svitlana 
Tarasevych1, Marta Castiglia1, Birgitta I. Hiddinga1, Patrick Pauwels1, Christian Rolfo2, 
Jan P. Van Meerbeeck1 1Thoracic Oncology, Multidisciplinary Oncology Centre Antwerp, 
Antwerp University Hospital, Edegem/Belgium, 2Phase I-Early Clinical Trials Unit&Centre for 
Oncological Research (Core), Antwerp University Hospital, Edegem/Belgium
Background: In ~10 % of Caucasian patients with non-small cell lung cancer (NSCLC), 
the presence of an activating epidermal growth factor receptor (EGFR) -mutation 
has resulted in a more favourable prognosis by its exquisite sensitivity to a targeted 
treatment with tyrosine kinase inhibitors (TKI’s). However, in up to 20% of those patients, 
the presence of “driver” alterations cannot reliably be established due to an inadequate 
diagnostic sample and/or impossibility to re-biopsy a patient. Activating EGFR-mutations 
can be accurately detected in plasma with a high concordance to matched tumour tissue 
with allele-specific PCR assays of plasma tumor DNA (ptDNA). This ‘liquid biopsy’ can 
replace response to treatment, allow detection of early relapse in the follow-up and 
estimate prognosis. The aim of this study is to assess the feasibility of detecting ptDNA 
in patients with EGFR mutations, to assess the concordance of ptDNA levels to mutations 
in matched tissue samples and to correlate ptDNA levels with clinical response or relapse 
after start of TKI-treatment. Methods: Tumour tissue samples of 20 patients (10 with/10 
without activating EGFR-mutations), was assessed for the presence of the respective 
mutation in matched ptDNA, obtained either at presentation or during follow up. DNA was 
extracted from aliquots (1ml) of plasma with the use of QIamp circulating nucleic acid kit 
(Qiagen). The target DNA is amplified and detected on the cobas z 480 analyzer using the 
amplification and detection reagents provided in the cobas EGFR Mutation Test kit. The 
concordance was estimated with Bayesian variables. Results: 26 tissue and 34 plasma 
samples were collected from 20 Caucasian patients with median age of 67 years (54 
to 84), 60% female, 30% non-smokers, 100% adenocarcinomas and 95% histologically 
or cytologically confirmed stage IV NSCLC. The median number of samples per patient 
was 3 (2 - 5). In the tissue samples 6 patients had an exon 19 deletion, 1 had exon 18 
mutation, 2 had exon 20 mutation and in 1 patient a simultaneous exon 19 deletion and 
T790M mutation. The Bayesian characteristics of ptDNA determination are as follows:
A: at sample level ( n 
= 34)
B: at study population 
level (n = 20)
1. Prevalence of mutation 8.8% 10%
2. Sensitivity 12.5% 20%
3. Specificity 100% 100%
4. PPV 100% 100%
5. NPV 32.2% 55%
6. Accuracy 38% 60%
7. Concordance 11.5% 7.7%
 
Conclusion: Detection of ptDNA in EGFR-positive patients is feasible. However, 
ptDNA mutation testing by cobasR 4800_Blood Test was not reliable due to the low 
analytical sensitivity and the heterogeneity of the patient population. Further studies 
with other methods as next-generation sequencing or digital droplet PCR are warranted. 
Keywords: plasma tumor DNA, tyrosine kinase inhibitor, non-small cell lung cancer, 
Epidermal growth factor receptor
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device. No studies have been conducted examining whether the blood test can be 
used to monitor patients who undergo curative treatment. Methods: Six patients with 
EGFR mutated tumors were monitored with continuous blood samples from the time of 
diagnosis until relapse, death or present date. The blood samples were tested for the 
level of EGFR mutations using the Cobas® EGFR Mutation Test developed for plasma 
DNA (Roche Molecular Systems, Inc.). Results were compared to the clinical course of 
the disease. Results: Operated without adjuvant chemotherapy (n=3, all patients 
with T1N0M0 disease). In two patients there were no measurable mutations in the blood 
samples at any point. One patient is at present date without sign of relapse after 3 years 
and attends follow up. The other patient died of non-cancer related causes. The third 
patient had declining level of mutations the first two years after the operation but the 
mutated DNA has never reached zero. Operated with adjuvant chemotherapy (n=1, 
T2N2M0). Mutations were measurable before operation and declined to zero after. 
One year after the operation, metastatic disease (CNS) was discovered along with a 
rise in mutation level, which again declined after local irradiation and initiation of 
erlotinib treatment. Chemoradiotherapy (n=2, T2N2-3M0). One of these patients had 
measurable levels of mutations initially, which declined to zero during the course of 
treatment with chemoradiotherapy and a supplement of erlotinib. Metastatic disease 
(CNS) was found during the treatment, and the patient proceeded with erlotinib 
treatment and cerebral irradiation. The patient died due to disease progression 9 
months later, no measurable mutated DNA was identified. In contrast, another patient 
had no measurable mutations until after relapse was detected. Conclusion: Our 
results suggest that in some cases monitoring the level of EGFR mutations in the blood 
might be a valuable tool in the detection of relapse in patients who have undergone 
curative treatment for their lung cancer. Further investigations are warranted to 
elucidate the subject. We have initiated a project, where we prospectively follow all 
patients with EGFR mutated NSCLC regardless of stage and treatment modality and 
we examine their blood for EGFR mutations every time a blood sample is drawn. 
Keywords: liquid biopsies, Curative treatment, NSCLC, EGFR mutations
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P2.04-097 Vinorelbine Resistance in Lung Cancer; Role of Focal Adhesion 
Signaling Pathways Takao Nakanishi, Toshi Menju, Kei Shikuma, Terumasa Sowa, 
Hiroyuki Cho, Shinya Neri, Makoto Sonobe, Hideki Motoyama, Kyoko Hijiya, Toshihiko 
Sato, Akihiro Aoyama, Fengshi Chen, Hiroshi Date Thoracic Surgery, Kyoto University, 
Graduate School of Medicine, Kyoto/Japan
Background: Vinorelbine (VRB) combined with cisplatin is a widely used regimen for 
the treatment of non-small cell lung cancer, but their curative effect is unsatisfactory. 
The resistance to these drugs is the main cause of chemotherapeutic failure. Several 
factors are reported to be related with VRB resistance, however their validity remains 
controversial. In the present study, we compared the gene expression and protein 
phosphorylation between parental (P) and induced VRB resistant (VR) cell lines to 
elucidate candidate mechanisms for VRB resistance. Methods: First we established VR 
lung cancer cells (H1299) with the exposure to the graded increase in VRB concentration. 
Then, transcriptional changes were measured with DNA microarray and pathway 
analysis by comparing VR line to the parental. Protein expression and its activation in 
the candidate pathway were examined by western blot analysis. Cell viability about VRB 
and Src / ABCB1 inhibitors was assessed by ‘WST-8 assays’. Results: Half-maximum 
inhibitory concentration (IC50) of VR cells to VRB were 190 times higher than that 
of parental cells. VR cells had cross resistance to docetaxel and etoposide, but they 
did not have cross resistance to cisplatin. VR cells highly expressed ABC transporter 
(ABCB1: fold change = 13.4) and focal adhesion (FA) related genes, such as integrins and 
underlining molecules (ITGB3: fold change = 3.7, Src: fold change = 1.1). Western blot 
analysis confirmed the high expression of intergrin β1, β3 and the activation of the FA 
pathways including Src, and Akt in VR cells. VRB sensitivity in VR cells was recovered with 
ABCB1 inhibitor (tariquidar: TQD). Although single usage of Src inhibitor (dasatinib: DAS) 
did not show any effectiveness, TQD and DAS had synergistic effect on VRB sensitivity. 
VRB IC50 concomitant use with DMSO, DAS 50 nM, TQD 15 nM, and DAS 50 nM + TQD 15 
nM were 1261 nM, 1125 nM, 466.5 nM, and 75.58 nM, respectively. Saracatinib (SAR), a 
dual inhibitor of Src and ABCB1, recovered VRB sensitivity (Fig.).
 
WMA and ALK t(2p23) mutations, mirrored the reported low levels of these miRNAs in 
NSCLC tissue (Zhong et al.,2014). Follow-up analysis to correlate clinical progression and 
exosome miRNAs profile is currently ongoing.
 
 
Keywords: liquid biopsies, exosomes, miRNA analysis, molecular profile
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P2.04-095 Detection of Mutations in Tumor and Blood Samples from Lung 
Adenocarcinoma Patients Using Two Different Techniques Jose M. Clavero1, 
Claudia Hurtado2, Mauricio Moreno2, Tania Quiroz2, Marcela Figueroa2, David Lazo1, 
Patricio Rodriguez1, Alvaro Ibarra3, Manuel Alvarez4 1Thoracic Surgery, Clínica Las 
Condes, Santiago/Chile, 2Laboratorio de Oncología Y Biología Molecular, Clínica Las Condes, 
Santiago/Chile, 3Department of Pathology, Clínica Las Condes, Santiago/Chile, 4Clinic 
Cancer Center, Clínica Las Condes, Santiago/Chile
Background: Adenocarcinoma is currently the most common type of lung cancer in 
which genetic alterations with prognostic and predictive value have been identified. EGFR 
mutations are predictive of response to TKI and mutually exclusive with KRAS mutation. 
Molecular analyses from tissue biopsies are nowadays mandatory in initial pathology 
studies and recommended if TKI resistance develop. Molecular analysis in circulating 
cell-free DNA (cfDNA) appeared as an easier method to perform these studies. cfDNA 
analysis from plasma or serum in lung cancer have identified mutations in EGFR, KRAS, 
ALK and HER-2, that correlated with those observed in the primary tumor. This study 
compared two different techniques to determine KRAS and EGFR mutations in tissue 
and blood samples from patients with lung adenocarcinoma. Methods: Patients 
with suspected lung cancer admitted to Clinica Las Condes between October 2012 
and March 2014, were offered to enter the Study. Previous to biopsy, 20ml of blood 
was drawn and samples of plasma and serum stored. When an adenocarcinoma was 
diagnosed EGFR and KRAS mutations of the biopsy were analyzed by COBAS® KRAS/
EGFR Mutation Tests and by SSCP (Single Stranded Conformational Polymorphism) 
and confirmed by Sanger sequencing. Blind analysis of stored plasma and serum was 
performed, isolating cfDNA using QIAamp® Circulating Nucleic Acid kit, and tumor DNA 
by QIAamp® DNA FFPE Tissue kit. Clínica Las Condes Ethics Board approved the study, 
and informed consent obtained in all patients. Results: Twenty-one patients entered the 
study; two were excluded because final pathology showed Atypic Hyperplasia. Of the 
reminding 19 patients: 14 had invasive Adenocarcinoma, 3 in situ Adenocarcinoma and 
2 Adenosquamous carcinoma. Tissue biopsies were obtained from the primary tumor 
in 14 cases, pleural metastases in 2, lymphnode metastases in 2 and brain metastases 
in one. Two patients had Adenocarcinoma in situ, 10 stage I, 1 stage II, 2 stage III and 
4 stage IV. Seven patients have mutations detected by COBAS® and SSCP in tissue 
biopsies: 3 EGFR and 4 KRAS mutations. EGFR mutations were detected in 2 stage 
I, and one stage IV patients. KRAS in 1 ACAis, 2 stage I and one stage IV. In these 
patient´s plasma only 1 mutation was detected in cfDNA (KRAS mutation in one stage 
IV patient), correlation between tissue biopsy and cfDNA 1 out of 7 (14%). No mutations 
were detected in cfDNA from serum samples. Conclusion: In our study EGFR and KRAS 
mutations rates were lower than expected for Chilean population, but it could be due 
to the small sample size. We had poor general correlation between mutations in tissue 
biopsies compared with those detected in cfDNA (14%). In stage IV correlation was better 
(50%). No EGFR mutations were detected in cfDNA, but again could be due to the sample 
size. COBAS® technique was useful to determine KRAS mutations in plasma cfDNA. 
Both SSCP and COBAS techniques allow determining mutations in tumor samples. 
cfDNA analysis could be used to determine KRAS mutations in patients with advanced 
disease. Its use to determine EGFR mutations need to be investigated in larger studies. 
Keywords: KRAS, EGFR, lung cancer, cell free DNA
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P2.04-096 Liquid Biopsies in Patients with EGFR Mutated Non-Small Cell Lung 
Cancer Undergoing Curative Treatment Eva B. Hansen1, Boe S. Sorensen2, Peter 
Meldgaard3 1Oncology, Aarhus University Hospital, Aarhus/Denmark, 2Dept. of Clinical 
Biochemistry, Aarhus University Hospital, Aarhus C/Denmark, 3Dept. of Oncology, Aarhus 
University Hospital, Aarhus C/Denmark
Background: A blood based test for detection of EGFR mutations has been developed. 
Studies have shown a correlation between level of mutations in the blood and course of 
the disease in stage IV patients, suggesting that the test could be used as a monitoring 
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the clinical setting are warranted. The identification of alterations in specific proteins 
and pathways that contribute to these unique DNA repair pathways in cisplatin 
resistant cancer cells may potentially lead to a renewed interest in the development 
of rational novel therapies for cisplatin resistant cancers, in particular, lung cancer. 
Keywords: DNA repair, cisplatin, resistance, p53, NSCLC
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-100 Platin-Induced ATM Activation in Non-Small Cell Lung Cancer 
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Background: Platinum based antineoplastic therapies (platins) are a first line treatment 
prescribed for non-small cell lung cancer (NSCLC), but unfortunately have many 
adverse side effects. Cytotoxicity is caused by the generation of DNA adducts, which 
create single and double stranded DNA breaks and stimulate DNA damage response 
pathways. A key mediator of this response is ataxia telangiectasia mutated (ATM), which 
is responsible for the activation of several downstream targets involved in DNA repair, 
cell cycle arrest, and apoptosis. Of great interest are platin sensitivity markers that help 
identify patients more susceptible to these treatments. Previous research on predictive 
markers of platin sensitivity has focused on ERCC1 and RRM1 with varying levels of 
success. Our lab has shown that cells lacking ATM have increased sensitivity to some 
platin therapies. We hypothesize that ATM signaling may be invoked by platin exposure 
and that tumours deficient in ATM may have innate sensitivity to platin therapies. Here we 
assess the molecular action of ATM in response to different platin therapies to determine 
whether low activity in ATM-deficient cells is predictive of platin sensitivity. Methods: Six 
NSCLC cell lines were assessed for the presence of ATM by western blot. Those cell 
lines for which ATM was not found were deemed ATM-deficient. Cell lines were treated 
with varying concentrations of platinum based therapies (cisplatin, carboplatin and 
oxaloplatin) for two hours or overnight. ATM activation was determined by assessment 
of phosphorylated-ATM protein levels using western blots. Additionally, downstream 
targets of ATM were probed to determine ATM pathway activation. Results:NSCLC cell 
lines H226, H460 and H522 were found to be ATM-proficient whereas cell lines H23, 
H1373 and H1395 were found to be ATM-deficient. ATM-proficient cell lines demonstrated 
an increased level of phosphorylated-ATM in response to treatments with cisplatin, 
carboplatin, and oxaliplatin. In addition, downstream targets of ATM also showed 
increased levels of activation when compared to non-treated controls. ATM-deficient 
cell lines showed no increased levels of phosphorylated-ATM however, downstream 
targets of ATM showed some activation in ATM-deficient cell lines. Conclusion: We have 
shown that cisplatin, carboplatin and oxaliplatin treatments induce the phosphorylation 
of ATM, a prominent regulator of the DNA damage response. In addition, the ATM-
deficient cell lines showed reduced activation of ATM to platin treatments. It is clear that 
platin exposure induced an ATM mediated signalling response, however its predictive 
capabilities of platin sensitivity is still unclear. Activation of DNA repair by platins may 
leave ATM-deficient tumours at a disadvantage when mounting repair responses to 
these treatments. This data suggests that individuals with low or non-functioning 
ATM may be candidates for precision low-dose therapies that exploit this deficiency. 
Keywords: ATM, NSCLC, DNA damage, Cisplatin
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P2.04-101 Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated 
through Reactivation of the RAF/MEK/ERK and PI3K/MTOR Pathways Suman 
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Background: One third of all malignancies and approximately 25% of non-small cell 
lung cancer (NSCLC) patients have KRAS mutations which leads to the activation of 
several growth regulatory signaling pathways including RAF/MEK/ERK and PI3K/AKT/
MTOR. Unfortunately, there are no current therapies targeting this critical oncogene. 
Heat shock protein 90 (HSP90) is a molecular chaperone required for the stability of 
‘client’ oncoproteins, many of which are effectors of KRAS. Unfortunately, limited 
efficacy was observed in early clinical studies of single agent HSP90 inhibitors (HSP90i) 
in KRAS mutant NSCLC. Here, we examined the mechanism(s) of acquired resistance to 
ganetespib, a Phase 3 HSP90i, in KRASmutant NSCLC to develop rationale combinations 
with ganetespib. Methods: Growth inhibition was determined through the colony 
formation and MTS assays. Ganetespib resistant (GR) -KRAS mutant NSCLC cell lines 
were derived to identify resistance mechanism(s). Flow-cytometry was performed to 
generate cell-cycle profiles. Genetic (shRNA) and pharmacologic inhibition of candidate 
mediators of resistance was performed. Results: Ganetespib was cytotoxic in a panel 
of KRASmutant NSCLC cell lines and decreased expression and activity of both RAF/
MEK/ERK and PI3K/AKT/MTOR pathways. In order to identify the mechanisms of 
ganetespib resistance in KRAS mutant NSCLC, we derived three KRAS mutant NSCLC 
ganetespib resistant (GR) cell lines. GR cells were cross-resistant to a first generation 
HSP90i, 17-AAG, suggesting that altered metabolism of ganetespib is unlikely to explain 
this resistance. Moreover, the ganetespib-induced G2/M checkpoint arrest observed in 
A549 parental cells was significantly diminished in A549-GR cells. These results suggest 
that bypass of this checkpoint may contribute to the observed ganetespib resistance. 
Furthermore, we demonstrated that GR cells were cross-resistant to docetaxel, an anti-
microtubule agent. In addition, expression and activity of the PI3K/AKT/MTOR pathway 
members as well as the RAF/MEK/ERK pathway members were significantly increased 
suggesting that reactivation of these pathways may be responsible for the observed 
resistance. To test this hypothesis, we treated parental and GR cells with inhibitors of 
Conclusion: Indeed, ABCB1 is the main cause of VRB resistance and multi-drug 
resistance in lung cancer. Genome-wide gene expression analyses revealed another 
candidate, focal adhesion pathways, except for drug efflux in VRB resistance. Our 
results show the potential of Src inhibitor to overcome these drug resistance. 
Keywords: Chemotherapeutic resistance, vinorelbine, Focal Adhesion Signaling 
Pathways, Src
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-17:00
P2.04-098 Acquired Resistance to Anti-VEGF Therapy in Non-Small Cell Lung 
Cancer Is Not Associated with Angiogenic Compensation Robin E. Frink, Laura 
A. Sullivan, Wenting Du, Ashley Barraza, Rolf A. Brekken Hamon Center for Therapeutic 
Oncology Res, UT Southwestern, Dallas/TX/United States of America
Background: The vascular system provides nutrients and oxygen to cells and tissues 
via the circulation of blood. Tissues require an efficient vascular network to maintain 
homeostasis. Angiogenesis, the process of expansion and remodeling of the vascular 
network, is driven by the expression and secretion of angiogenic growth factors that 
stimulate endothelial cell migration, proliferation and survival. Induction of angiogenesis 
is an early event in the progression of tumors, including non-small cell lung cancer 
(NSCLC). Vascular endothelial growth factor-A (VEGF) is a principal angiogenic growth 
factor in NSCLC and as a result is an attractive therapeutic target. Despite promising 
preclinical results, therapies targeting VEGF have shown only modest improvements 
in progression free survival and overall survival in NSCLC patients. Many NSCLC 
patients that initially respond to anti-VEGF therapy develop resistance with continued 
use. We sought to determine factors associated with acquired resistance to anti-VEGF 
monoclonal antibodies (mAbs). r84 is a fully human anti-VEGF mAb that inhibits human 
and mouse VEGF binding to VEGF receptor 2 (VEGFR2) but not VEGFR1 and is currently 
in Phase I clinical trials. Bevacizumab is a humanized mAb specific for human VEGF that 
blocks VEGF from binding VEGFR1 and VEGFR2 and is currently approved for treatment 
of NSCLC. Methods: Acquired resistance to anti-VEGF therapy was driven in NSCLC cell 
lines (H1975, H1993, and H2073) by prolonged in vivo therapy with r84 or bevacizumab. 
Over 20 cell lines (e.g., H1975-81) were generated by ex vivo culture from tumors that 
displayed acquired resistance to therapy. In addition, tumor cell lines were generated from 
tumor-bearing mice treated with saline (e.g. H1975-713). A subset of control and resistant 
cell lines were implanted in vivo and evaluated for response to anti-VEGF therapy. Tumor 
microvessel density was determined by immunohistochemistry. Results: Two of five 
acquired resistance cell lines were verified as resistant upon reimplantation and treatment 
with r84 and bevacizumab demonstrating that the changes induced by prolonged 
anti-VEGF therapy in these cell lines are heritable. Conversely, tumor xenografts from 
saline control tumors remained sensitive to anti-VEGF therapy. Anti-VEGF therapy with 
r84 or bevacizumab reduced microvessel density in each tumor regardless of whether 
therapy reduced tumor growth or not. Conclusion: Anti-VEGF therapy significantly 
reduces angiogenesis even in tumors that show resistance to therapy, suggesting that 
compensation by other angiogenic growth factors is not a significant contributor to 
tumor response to anti-VEGF therapy. Further, prolonged treatment with anti-VEGF can 
induce heritable changes in NSCLC cells that confer resistance to anti-VEGF therapy. 
Keywords: angiogenesis, NSCLC, bevacizumab
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P2.04-099 Differential Regulation of DNA Repair Genes in Cisplatin Resistant 
Non-Small Cell Lung Cancer Cells Yuexi He1, Sinead Cuffe1, Stephen Finn2, Kenneth 
J. O’Byrne3, Martin P. Barr1 1Thoracic Oncology, St James’S Hospital & Trinity College 
Dublin, Dublin/Ireland, 2Histopathology, St James’S Hospital & Trinity College Dublin, Dublin/
Ireland, 3Cancer and Ageing Research Program, Princess Alexandra Hospital and Queensland 
University of Technology, Brisbane/Australia
Background: In the absence of specific treatable mutations, cisplatin-based doublet 
chemotherapy remains the gold standard treatment for NSCLC patients. However, its 
clinical efficacy is hindered in many patients due to both intrinsic and acquired resistance 
to this drug. Alterations in the DNA repair capacity of damaged cells is now recognised 
as an important factor in mediating this phenomenon. DNA repair is therefore a vital 
target to improving cancer therapy and overcoming resistance of tumour cells to DNA 
damaging agents currently used in the treatment of NSCLC patients. Methods: DNA 
Repair Pathway RT2 Profiler Arrays were used to elucidate the key DNA repair genes 
implicated in cisplatin resistant NSCLC cells using cisplatin resistant (CisR) and 
corresponding parental (PT) H460 NSCLC cells previously established in our laboratory. 
The regulation of the trans-activation of p53 in response to DNA damage was studied 
by examining protein accumulation, post-translational modifications (p53Ser15) and 
whether depletion of the novel DNA repair protein, hSSB1, affects the regulation 
of p53 in response to cisplatin. The repair of cisplatin-induced double strand breaks 
(DSBs) was examined by immunofluorescence imaging of γH2AX foci. Expression of 
p53Ser15 (phosphorylated & total) in addition to hSSB1 was also assessed by HCA and 
Western blot analysis. Results: We identified a number of critical DNA repair genes that 
were differentially regulated between parental and cisplatin resistant NSCLC cells, some 
of which are known to be implicated in the nucleotide and mismatch repair pathways. H2AX 
was shown to be a reliable and specific marker of DNA double strand DNA breaks induced 
by platinum agents such as cisplatin. Cisplatin induced the translocation of p53 from the 
cytoplasmic compartment of H460 PT cells to the nuclear compartment, while significant 
levels of p53 were retained within the cytoplasmic compartment of CisR cells. Using 
both HCS and Western blot analysis, hSSB1 protein was undetectable. Conclusion: To 
date, despite reports that differential expression of components of the various DNA 
repair pathways correlate with response to cisplatin, translation of such findings in 
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human lung cancer cells with a predominant epithelial phenotype. Conversely, the 
latter responded to T12 when combined with doxorubicin, an inducer of the epithelial-
to-mesenchymal transition (EMT). Consequently, we suggest that the GPBP kinase 
activity and concomitant type IV collagen expression stabilize the privileged niche 
of the mesenchymal drug-resistant CSC in human lung cancer. Accordingly, down-
regulation of either GPBP kinase activity or type IV collagen expression using siRNA or 
T12 treatment, compromised human lung cancer cell viability only after EMT induction. 
Moreover, the pivotal role of GPBP in stabilizing the tumor invasive phenotype was further 
demonstrated by exhibiting reduced tumor implantation and metastasis formation in 
GPBP -/- mice. Finally, confirmation that T12 inhibition of GPBP kinase was responsible 
for anti-tumor activity in mice was accomplished by showing analogous therapeutic 
effects following administering of N26, a GPBP-specific monoclonal antibody that inhibits 
GPBP binding to type IV collagen. Conclusion: The general mechanism for multidrug-
resistance and poor prognosis associated with COL4A3BP expression depends by 
and large on its affiliated kinase activity. Thus, T12 emerges as a First-in-Class drug 
candidate to specifically treat drug-resistant and metastatic non-small cell lung cancer. 
Keywords: GPBP, CERT, collagen IV, COL4A3BP
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P2.04-104 Regulating the Response to Cisplatin in Lung Cancer Cells through 
the Transcription Factor TCF4: A New Potential Role for Wnt Signaling 
Javier De Castro1, Olga Vera2, Olga Pernia2, Ana Sastre Perona3, Rocío Rosas2, Pilar 
Santisteban3, María Palomares-Bralo4, Inmaculada Ibáñez De Cáceres2 1Medical 
Oncology. Laboratorio de Epigenética, Ingemm. Terapias Experimentales Y Biomarcadores 
En Cáncer N33 Idipaz., Hospital Universitario La Paz, Idipaz, Madrid/Spain, 2Laboratorio de 
Epigenética, Ingemm. Terapias Experimentales Y Biomarcadores En Cáncer N33 Idipaz., 
Hospital Universitario La Paz, Idipaz, Madrid/Spain, 3Instituto de Investigaciones Biomedicas 
Csic/Uam, Madrid/Spain, 4Laboratorio de Genómica Estructural Y Funcional, Ingemm. N29. 
Idipaz. Ciber de Enfermedades Raras (Ciberer), Hospital Universitario La Paz, Idipaz, Madrid/
Spain
Background: The standard treatment for non-small cell lung cancer (NSCLC) is Platinum-
based chemotherapy, although the main clinical problem associated is the progression of 
the disease to a platinum-resistant state. This fact has limited its efficacy in these tumor 
types, which is one of the first causes of cancer deaths in developed countries. Thus, it is 
of great interest to identify predictive molecular biomarkers that could help in the patient 
treatment selection. Methods: In this study we used array-CGH to analyze the cytogenetic 
alterations that arise in NSCLC and ovarian cancer cells after cisplatin treatment, by using 
four paired sensitive(S) and resistant(R) cell lines: H23S/R, H460S/R, A2780S/R and 
OVCAR3S/R. Results: Our experimental approach revealed the presence of a common 
deletion of the gene TCF4 in a mosaic manner in at least 50% of the resistant cells in both 
tumor types, while a decrease in TCF4 expression was confirmed through qRT-PCR in the 
same cells. As TCF4 is a downstream transcription factor of Wnt signaling, we analyzed 
its potential role regulating the CDDP response in resistant cells through its action 
in the Wnt pathway. Combination of Top-Fop vectors and TCF4-cDNA overexpression 
plasmids showed firstly, that resistant cells responded easily to the activation of Wnt 
pathway, an effect in part mediated by the decrease in TCF4 expression; secondly the 
overexpression of TCF4 induced an increase in the Cisplatin sensitivity. These results 
indicate that TCF4 could be acting as a Wnt transcriptional repressor, maintaining the 
sensitivity to Cisplatin in A2780-S cells. Conclusion: Our translational approach in a 
total of 40 ovarian and lung primary tumors and in 14 normal tissues confirmed that 
TCF4 expression is frequently downregulated in these tumor types. Altogether we 
present a novel role for Wnt signaling pathway, regulating the response to CDDP, which 
could be a potential target for cancer treatment. Supported by ISCIII PI12/00386, ISCIII 
PI12/01463 and the Miguel Servet II program (CP08/00068) to I. Ibáñez de Cáceres 
Keywords: Biomarkers, Wnt signalling, non-small cell lung cancer, Cisplatin resistance
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P2.04-105 PARP Inhibition Sensitises ATM Deficient NSCLC Cells to Cisplatin 
Treatment Anifat A. Elegbede1, Lars Petersen2, D. G. Bebb2 1Oncology, Tbcc 
Translational Labs, University of Calgary, Calgary/AB/Canada, 2Oncology, Tbcc Translational 
Labs, University of Calgary, Calgary/Canada
Background: We have previously demonstrated that non-small cell lung cancer (NSCLC) 
cells with low or undetectable ATM are sensitive to synthetic lethality with PARP inhibitor 
as a single agent. In contrast, lack of ATM alone does not seem to predict sensitivity 
of these cells to other agents such as cisplatin, a part of standard chemotherapy 
often used in NSCLC with limited efficacy. Because Cisplatin can induce some DNA 
damage that can activate ATM, we sought to determine whether PARP inhibition will 
improve cisplatin efficacy in NSCLC cells that are ATM deficient. Methods: A panel of 
NSCLC cell lines (NCI-H23, NCI-H460, NC1-H522, NCI-H1373) were assessed for ATM 
status by western blot in terms of a) ATM protein levels and b) ATM functionality by 
examining active phosphorylated ATM and downstream targets of ATM e.g. p53 and 
KRAB-associated protein 1 (KAP1) in irradiated cells. The biological effects of PARP-1 
inhibition and cisplatin on viability of these cells were examined using the clonogenic 
survival assay. Results: Two NSCLC cell lines H23 and H1373 were found to be ATM 
deficient and they show increased sensitivity to the combination of cisplatin with PARP 
inhibition using olaparib, (Table 1).
the PI3K/AKT/MTOR pathway (dual PI3K/mTOR inhibitor, BEZ235 and PI3K inhibitor 
PX866) or the RAF/MEK/ERF pathway (ERK inhibitor, SCH772984). Remarkably, GR 
cells were more sensitive to these inhibitors compared to the parental ones suggesting 
that the acquired ganetespib resistance lead to increased dependence on the both RAF/
MEK/ERK and PI3K/MTOR pathways. Interestingly, the expression/activity of the key 
ERK and PDK1 substrate and activator of the PI3K/MTOR pathway, p90 ribosomal S6 
kinase (RSK) was strikingly increased in the GR cells. Since RSK has been implicated as 
a key mediator of crosstalk between these two pathways, as well as in promoting G2/M 
progression, we examine the effect of genetic (shRNA) or pharmacologic (BI-D1870 and 
SL0101) inhibition of RSK in two GR cell lines. Remarkably, the GR cells showed increased 
dependency on RSK activity compared to the parental cell lines. Conclusion: These data 
suggests that the combination of inhibitors for HSP90 and PI3K/mTOR or a RSK inhibitor 
may prevent ganetespib resistance and/or help overcome the resistance after single 
agent treatment, providing the preclinical rationale for our planned Phase I/II trial of 
the combination of ganetespib and a dual PI3K/MTOR inhibitor in KRAS mutant NSCLC. 
Keywords: KRAS, HSP90 inhibitor, p90RSK, Acquired resistance
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P2.04-102 Targeting Inflammatory Mediators to Overcome Intrinsic and 
Acquired Cisplatin Resistance in Non-Small Cell Lung Cancer Anne-Marie Baird1, 
Peter Godwin2, Susan Heavey2, Kazuo Umezawa3, Martin P. Barr2, Anthony Davies4, 
Derek Richard1, Kathy Gately2, Kenneth J. O’Byrne5 1Cancer and Ageing Research 
Program, Queensland University of Technology, Brisbane/QLD/Australia, 2Thoracic Oncology 
Research Group, Trinity College Dublin/St. James’S Hospital, Dublin/Ireland, 3Dept. of 
Molecular Target Medicine Screening, Aichi Medical University, Aichi/Japan, 4Translational 
Cell Imaging Queensland, Queensland University of Technology, Brisbane/QLD/
Australia, 5Cancer and Ageing Research Program, Princess Alexandra Hospital and 
Queensland University of Technology, Brisbane/Australia
Background: Cisplatin based doublet-chemotherapy is commonly used in non-small 
cell lung cancer (NSCLC) treatment with an initial objective response rate of 40-
50%. However, intrinsic and acquired chemo-resistance constitutes a major clinical 
obstacle. The mechanisms of resistance have yet to be fully understood. We have 
previously demonstrated that NF-κB levels are elevated in cisplatin resistant cells 
(CisR) and that the use of an NF-κB inhibitor, DHMEQ, resulted in greater CisR cell 
death. The goal of this project is to elucidate the mechanistic links between NF-κB 
regulated pathways and the development of cisplatin resistant NSCLC. Methods: The 
expression of NF-κB mediators and immune regulators were assessed in an isogenic 
NSCLC cell line model of cisplatin resistance using qPCR arrays (252 genes). A number 
of targets were identified and validated using PCR. The effect of drug combinations 
(Cisplatin and DHMEQ) was also determined. Comet assays (DNA damage) were also 
performed to determine the effect of DHMEQ alone or in combination with irradiation 
(6 Gy). Results: Various chemokines and their receptors were elevated in cisplatin 
resistant (CisR) cells compared with cisplatin sensitive (PT). In addition, a number of 
key TLRs and regulators of the innate immune pathway were altered. DHMEQ enhanced 
cellular sensitivity to cisplatin in both PT and CisR cell lines (p<0.05). This drug also 
overcame the chemo-protective effect of a number of chemokines and enhanced 
irradiation induced DNA damage. An animal study will commence shortly using 
DHMEQ alone and in combination with cisplatin. Conclusion: Immune-modulators 
such as DHMEQ may be a novel viable option in addressing inflammatory mediated 
acquired and intrinsic NSCLC chemo-resistance. In addition, immune regulators 
identified in this project may provide innovative targets for immuno-oncology therapy. 
Keywords: inflammation, Cisplatin resistance, Chemokines, NSCLC
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P2.04-103 A Goodpasture Antigen-Binding Protein Kinase Inhibitor to Treat 
Drug-Resistant Metastatic Lung Cancer Juan Saus1, Fernando Revert2, Aida 
Artigot2, Raül Blasco2, Juan F. Sanz-Cervera3, Enrique Pérez-Paya4, Ernesto López-
Pascual2, Alejandra Pérez-Sastre2, Roberto Gozalbo-Rovira2, Francisco Revert-Ros2 
1Biochemistry and Molecular Biology, University of Valencia Medical School, Valencia/
Spain, 2Research & Development, Fibrostatin Sl, Paterna - Valencia/Spain, 3Organic 
Chemistry, University of Valencia, Burjassot-Valencia/Spain,4Biochemistry and Molecular 
Biology, University of Valencia, Burjassot-Valencia/Spain
Background: Goodpasture antigen-binding protein (GPBP) is a secretable Ser/
Thr kinase which regulates the organization of the type IV collagen network in the 
extracellular matrix. Current evidence suggests that this network interacts directly with 
Cancer Stem Cells (CSC) and forms a protective shield against anti-tumor therapies. CSC 
are recognized as responsible for tumor’s drug resistance and invasiveness. Remarkably, 
expression of COL4A3BP, the gene coding for both GPBP kinase and cytosolic ceramide 
transporter CERT, has been associated with multidrug resistance and poor prognosis in 
breast and lung cancer patients. Here, we have developed T12, a highly specific small 
molecule inhibitor of GPBP kinase and demonstrated its potential to treat drug-resistant 
and metastatic non-small cell lung cancer. Methods: The yeast two-hybrid system was 
used to identify a five-residue motif responsible for GPBP multimerization and enhanced 
kinase activity. We then generated a series of peptidomimetic compounds featuring a 
terphenyl structure. The compound 3-[4’’-methoxy-3,2’-dimethyl- (1,1’;4’,1’’)terphenyl-
2’’-yl] propionic acid, referred to as T12, exhibited a suitable kinase inhibitory activity 
and toxicokinetics, and as a result was selected for additional testing using relevant ex 
vivo and in vivo models of human non-small cell lung cancer (A549 and patient-derived 
primary cultures). Results: T12 treatment reduced the viability of human lung cancer 
cells exhibiting a prevalent mesenchymal-invasive phenotype, but had no effect on 
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established. A network graphic determining the association of CFL1 expression and 
cisplatin drug resistance was drawn applying a spring model algorithm. Using the 
STRING database all proteins directly interacting with CFL1 were retrieved and crossed 
with gene expression data of cisplatin-resistant cells. Results: CFL1 levels in biopsies 
are able to discriminate between good and bad prognosis at early tumor stages, 
where high CFL1 levels are correlated with lower overall survival rate (P < 0.0001). In 
vitro evidences suggest that CFL1 is a biological predictor of cisplatin resistance. Cell 
lines with high CFL1 expression are resistant to 21 of 30 alkylating drugs (including 
cisplatin and carboplatin). Intrinsically cisplatin resistant (ICR) -A549 cells presented a 
six-fold increase in cisplatin GI50 value and an increased in CFL1 protein levels (P < 0.01). 
Also, a high activity of the CFL1 gene network was found in cisplatin-resistant cells (P < 
0.01) and in response to acute cisplatin treatment.
  
 
Conclusion: CFL1 emerges as a biomarker of a more aggressive cancer phenotype. 
The potential of CFL1 in screening patients less sensitive to alkylating agents 
represents a major impact with regard to the therapeutic strategy and should 
be explored further. Using a retrospective clinical cohort of NSCLC we intend to 
confirm the laboratory results in clinical patients. Also, we aim to establish a cutoff 
value of CFL1, and test it for predicting treatment response and patient survival. 
Keywords: Non-small cell long cancer, Chemotherapy resistance, biomarker, Cofilin-1
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P2.04-108 The Role of miR-30c-2* in Clinical Outcome and Drug Resistance 
in HPV-Infected Non-Small Cell Lung Cancer Ya-Wen Cheng Graduate Institute of 
Cancer Biology and Drug Discovery, Taipei Medical University, Taipei/Taiwan
Background: Lung cancer is leading cause of cancer death in Taiwanese women who 
are mostly to be life-time never smokers. Majority of drugs and combinations are used 
to treat with smoking lung cancer patients, not for nonsmokers. However, the 5-year 
survival rate in lung cancer patients remains ~15% during the past three decades. 
Therefore, dissolving tumor recurrence and drug resistance is urgent needed for 
improving outcome in lung cancer, especially in nonsmokers. Mir-30c-2* has been 
considered to be tumor suppressor gene in various cancers. MiR-30c-2* levels were 
associated with in gemcitabine sensitivity of lung cancer cells. Down-regulation of 
miR-30c promotes tumor invasion via an increased in MTA1 expression. Methods: We 
examined whether miR-30c and HPV oncoprotein expression could be associated with 
patients’ outcome by collecting 150 lung tumors from patients with NSCLC to determine 
miR-30c, MTA gene expression,HPV 16/18 infection, and HPV 16/18 E6 and p53 protein 
expression by PCR-RFLP, nested-PCR, and immunohistochemical analysis. Results: Our 
previous reports have indicated that HPV16/18 infection may be involved in Taiwanese 
lung tumorigenesis. Preliminary data showed that miR-30C-2* levels were elevated 
45-fold in E6-knockdown TL-1 cells as compared with parental cells with non-specific 
RNAi tranfection. More interestingly, MTA-1 expression was negatively correlated with 
miR-30C-2* in lung tumors from lung cancer patients. Expression levels of MTA-1 were 
positive correlated with tumor stage and nodal metastasis in tumor tissues of lung 
cancer patients. Our cell model studies also found that miR-30C-2* suppressed by E6 
could contribute to tumor metastasis and drug resistance via an increased in MTA-1 
expression. Conclusion: These results were showed that miR-30C-2* levels in patients’ 
tumor tissues could be useful to predict outcome and therapeutic response and to select 
useful therapy drugs for lung cancer patients, especially in patients with HPV-infection. 
Keywords: HPV, tumor metastasis, poor prognosis, miR-30c
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P2.04-109 Epithelial-To-Mesenchymal Transition (EMT) and Acquired 
Resistance to PI3K-mTOR Inhibition in NSCLC Kathy Gately1, Paul Dowling2, 
Martin P. Barr1, Niamh Kelly1, Sinead Cuffe1, Stephen P. Finn1, Bryan Hennessy3, 
Sinead Toomey4, Kenneth J. O’Byrne5, Susan Heavey1 1Thoracic Oncology Research 
Group, Trinity College Dublin/St. James’S Hospital, Dublin/Ireland, 2Biology, Nui Maynooth, 
Kildare/Ireland, 3Beaumont Hospital, Dublin/Ireland, 4Royal College of Surgoens, Dublin/
Ireland, 5Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Brisbane/Australia
Background: The PI3K-Akt-mTOR pathway regulates cell growth and proliferation and is 
often dysregulated in NSCLC, making it an attractive therapeutic target in this setting. 
GDC-0980 is a selective dual inhibitor of PI3K and mTOR, which is currently in Phase II 
clinical trials for solid tumours. As with all targeted therapies, acquired resistance to 
GDC-0980 is anticipated to be a major hurdle in the success of this drug. The aims of 
this project are to (i) elucidate the frequency of PIK3CA mutations in an Irish cohort of 
  
Conclusion: Here, we show that PARP inhibitor sensitized ATM deficient NSCLC cells 
to cisplatin. These results suggest that a significant treatment response could be 
achieved in ATM deficient NSCLC cells with low dose cisplatin and PARP inhibition. 
We have evidence to suggest that ATM deficiency may be present in as much as 20 
- 25% of NSCLC patients. This cohort may be able to benefit from modified therapy 
using lower dose chemotherapy, producing milder side effects and better quality of life. 
Keywords: Cisplatin, PARP inhibitor, ATM, Lung cancer
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P2.04-106 Expression of AEG-1 Associated with Increase of TS Contributes 
to Chemoresistance of Pemetrexed in Lung Adenocarcinoma Chung-Yu Chen1, 
Ying-Yin Chen1, Kuan-Yu Chen2, Jin-Yuan Shih2, Yih-Leong Chang2, Chong-Jen Yu2 1National 
Taiwan University Hospital Yunlin Branch, Douliou/Taiwan, 2National Taiwan University 
Hospital, Taipei/Taiwan
Background: Previous studies have suggested that astrocyte-elevated gene-1 (AEG1) 
contributes to a broad spectrum of resistance to various chemotherapeutics. Expression 
of thymidylate synthase (TS) has implication for effectiveness of pemetrexed in treatment 
of lung cancer. In this study, we investigated the AEG-1 activity to determine whether its 
expression is correlated with TS increasing resulted in chemoresistance of pemetrexed 
in patients with advanced lung adenocarcinoma. Methods: Patients with advanced lung 
adenocarcinoma treated with pemetrexed plus cisplatin as first-line chemotherapy were 
enrolled. Re-biopsy was performed until disease progression. Immunohistochemical 
stain of AEG-1 and TS were studied in all patients’ tissue before chemotherapy and after 
disease progression. The primary antibodies used were anti-AEG-1 (1:1,000; chicken 
polyclonal), anti-actin (1:1,000; rabbit polyclonal; Santa Cruz), and anti-TS (1:1,000; 
mouse monoclonal; Abcam). The expression of TS and AEG-1 were calculated by H-score. 
The medical records were reviewed and analyzed, including data on age, gender, smoking 
status, epidermal growth factor receptor (EGFR) mutation status, treatment responses, 
and survival. Results: A total of six patients (3 male and 3 female) received first-line 
chemotherapy as pemetrexed/cisplatin for 6 cycles and continuation maintenance 
therapy with pemetrexed. The mean age was 57.2 years old. Overall best treatment 
response were partial response. The median of progression-free survival was 5.8 months. 
Re-biopsy was performed in all of them after disease progression. The expression of 
AEG-1 level increased from baseline to disease progression (mean, AEG-1, 133.3 to 
175.0, p = 0.001), associated with elevation of TS level (mean, TS, 57.9 to 116,1, p = 
0.01). Conclusion: Expression of AEG-1 associated with increase of TS contributes 
to chemoresistance of pemetrexed in lung adenocarcinoma. TS expression might be 
regulated by AEG-1 associated with development of chemoresistance to pemetrexed. 
Keywords: astrocyte-elevated gene-1, Thymidylate Synthase, pemetrexed, 
chemoresistance
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P2.04-107 Cofilin-1 as a Biomarker for Non-Small Cell Lung Cancer and a 
Potential Predictor to Platinum-Based Chemotherapy Resistance 
Juliano Cé Coelho1, Carolina Beatriz Muller2, Marco Antônio De Bastiani2, Matheus 
Becker2, Mariane Araújo Branco3, Cristiano Feijó Andrades4, Mauro Antônio Alves 
Castro5, Fábio Klamt2 1Medical Oncology, Hospital de Clínicas de Porto Alegre, Porto 
Alegre/Brazil, 2Department of Biochemistry, Universidade Federal Do Rio Grande Do 
Sul, Porto Alegre/Brazil, 3Universidade Federal Do Rio Grande Do Sul, Porto Alegre/
Brazil,4Hospital de Clínicas de Porto Alegre, Porto Alegre/Brazil, 5Universidade Federal Do 
Paraná, Curitiba/Brazil
Background: Non-small cell Lung cancer (NSCLC) is a highly lethal disease, whose 
symptoms are not common in the early stages, making detection difficult in this scenario. 
Biomarkers may be important for prognosis and prediction of therapy, resulting in more 
effective treatments and lower mortality rates. The expression of several genes have 
been tested for its potential as a biomarker for lung cancer, but none was positive as a 
prognostic factor. Cofilin-1 (CFL1) was first described in breast and ovarian cancer and 
emerges as a potencial biomarker for NSCLC. Methods: To identify and validate CFL1 as 
a prognostic biomarker for NSCLC, independets cohorts obtained from published 
NSCLC microarray data (GSE3141/GSE42127/GSE13213) were used and the results 
were validated in a retrospective cohort. A semi-quantitative immunohistochemistry 
method was established measuring the intensity of IHC reaction using images software. 
The CFL1potential in predicting drug resistance was also explored. A panel of 120 
anticancer compound and the CFL1 levels in human NSCLC cell lines were analysed 
and an in vitro model for intrinsic and acquired cisplatin resistance protocols was 
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P2.05-002 The Risk of Lung Cancer among Women Who Start Smoking as 
Teenagers Malcolm O. Tagbarha Public Health, University of Abuja, Abuja/Nigeria
Background: To examine the effect of smoking on lung cancer risk in a large population-
based cohort of women, many of whom started smoking as teenagers Methods: We 
followed 102,098 women, ages 30 to 50 years, completing a mailed questionnaire at 
recruitment to the Nigerian-Ethiopian Cohort Study in 2011/2012, through December 
2013. We used Cox proportional hazard regression models to estimate relative risk 
(RR) of lung cancer associated with different measures of smoking initiation, duration, 
and intensity adjusting for confounding variables. We conducted analyses on the entire 
study population, among women who had smoked for at least 20 years, among non 
drinkers, and separately for each countryResults: Altogether, 1,240 women were 
diagnosed with incident, invasive lung cancer. Compared with never smokers, women 
who smoked for at least 20 years and who smoked 10 cigarettes or more daily had 
a RR of 1.34 (95% CI, 1.06-1.70). Likewise, those who initiated smoking prior to their 
first birth (1.27, 1.00-1.62), before menarche (1.39, 1.03-1.87), or before age 15 
(1.48, 1.03-2.13) had an increased risk. The increased RR associated with smoking 
was observed among nondrinkers of alcohol, women with and without a family 
history of lung cancer, pre-menopausal and post-menopausal women, and in both 
countries Conclusion: Our results support the notion that women who start smoking as 
teenagers and continue to smoke for at least 20 years have increased lung cancer risk 
Keywords: lung cancer, smoking, teenagers, cancer risk
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P2.05-003 Poor & Heavy Smokers in Nigeria Face Higher Risk of Lung Cancer 
DNA Damage Emmanuel Odiase Epidemiology, University of Ibadan, Abuja/Nigeria
Background: Many poor smokers in Northen Nigeria who started smoking at teenage, 
smoked for at least 15 years, have the least access to medical attention and who probably 
smoke more sticks and/or packets because of the cheap price of cigarettes may face a 
higher risk of entire DNA damage from lung cancer Methods: There were 98,500 men, 
ages 30 to 55 years involved in a community-based tobacco control/smoking cessation 
study through questionnaires in English and the local languages for two Nigerian geo-
political zones which are the North western and North eastern with the most smoking 
prevalence in the country. The Nigerian Cohort Study was from 2007 through December 
2013. Relative Risk (RR) of tobacco-related lung cancer associated with different 
measures of smoking initiation, duration, and intensity adjusting for confounding 
variables were estimated. There were also analyses conducted on the entire study 
population, among men who had smoked for at least 15 years, most of whom started 
smoking at youth. Study was separately for each geo-political zone. Results: From the 
entire number participating in the study, 19,200 men or about 20% were diagnosed 
with tobacco-specific lung cancer. Compared with never smokers, men who smoked 
for at least 15 years and who smoked 10 cigarettes or more daily had a higher Relative 
Risk (RR). On the other side, men who had smoked for at least 15 years, but were 
priviledged to periodic hospital visits or started smoking after teenage, had their lung 
cancer risk reduced and/or averted. The increased RR of DNA damage from lung cancer 
associated with smoking was higher amongst “I dont care” smokers in both geo-political 
zones in Northern Nigeria. Conclusion: Results here show that young initiation, poverty, 
high tobacco consumption, duration of smoking and inacesability to regular medical 
check up very well increases the risk of lung cancer leading to entire DNA damage. 
Keywords: lung cancer, DNA damage, tobacco, nigerian
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P2.05-004 ETS Exposure Presents a High Risk of Lung Cancer to Restuarant/
Bar Workers in Nigeria Emmanuel Odiase Epidemiology, University of Ibadan, Abuja/
Nigeria
Background: Several studies have proved that over ninety percent of lung cancer 
cases are caused by tobacco. Smoking causes numerous cancers but surely has 
lung cancer on the highest. The alarming issue at the hand is that exposure to 
Environmental Tobacco Smoke-ETS may result to lung cancer among innocent non 
smoking employees in work places or elsewhere. Methods: Further from an earlier 
study where about 200 restuarant and bar non-smoking staff in four states in Nigeria-
Lagos, Kano, Port-Harcourt and Abuja from were examined, we scaled up to conduct 
a similar expanded study among 450 non-smoking bar employees and regular non 
smoking bar users to reteirate our claims in 4 additional states. Level of ETS exposure 
was compared with survey results from participants. Duration of employment and 
level of exposure(number of hours daily) to Environmental Tobacco Smoke (ETS) for 
each person was also taken into account. Results: We discovered that participants 
exposed to workplace second-hand smoke were more likely to have any detectable 
level of NNAL (P=.005) and higher mean levels of NNAL (P < .001) compared with non-
exposed participants. Increased levels of NNAL were also associated with hours of a 
single workplace exposure. Furthermore, some risks were noticed from non smoking 
daily bar users. Conclusion: Non-smoking employees left unprotected from workplace 
secondhand smoke exposure had elevated levels of a tobacco-specific carcinogen in 
their bodies. All workers—including bar and restaurant workers—should be protected 
from indoor workplace exposure to cancer-causing secondhand smoke. This calls for 
countries without a comprehensive National Tobacco Control Law to pass one as soon 
as possible in line with the WHO Framework Convention on Tobacco Control- FCTC. 
Keywords: tobacco, lung cancer, non smokers, ETS
NSCLC patients and (ii) develop and characterise three cell line models of resistance 
to GDC-0980, each representing a different molecular subtype of NSCLC, in order to 
identify biomarkers of response/resistance to the drug that may dictate beneficial 
treatment strategies. Methods: DNA was extracted from 250 NSCLC patient tissue 
samples, and screened for 547 clinically relevant mutations in 46 genes using the 
Sequenom platform. H460, A549, and H1975 cells were cultured in GDC-0980 at IC50 
concentrations over a period of several months, along with matched ‘parent’ cell lines. 
Development of resistance was assessed by monthly BrdU proliferation assays. Cell 
growth patterns were compared across the sensitive and resistant cell lines in real time 
using the xCELLigence platform. Cell lines were then interrogated for alterations in DNA 
(Sequenom), mRNA (SABiosciences arrays profiling expression of >150 genes), miRNA 
(Exiqon expression profiling of 2100 miRNAs) and protein (R&D Phospho Kinase array 
expression profiling of 43 kinases and 2 associated total proteins, PTMScan® Ubiquitin 
Remnant Motif (K-ε-GG) Kit from CST and Western blot analysis). Results: PIK3CA 
mutations occur in ~5% adenocarcinomas & 12% squamous cell carcinomas. H1975 
cells (PIK3CA mutant and activated pAkt (Ser473/Thr308), pmTOR, pS6R) were most 
sensitive to GDC-0980, however they were the first to develop resistance to the drug. 
Results obtained from xCELLigence studies identified H1975 resistant (H1975R) cells as 
having the highest cell index out of all parent and resistant cell lines after 100 hours of 
cell growth, suggesting that these are the most aggressive cells. Initially a 33 miRNA 
signature was identified contrasting H1975P and H1975R. qPCR validation of miR-205 (a 
regulator of EMT) identified expression in H1975P cells but miR-205 was undetectable 
in H1975R cells. mRNA expression of Zeb1 & Zeb2 (direct targets of miR-205) were 
increased in H1975R cells compared to H1975P cells. 1,200 proteins were found to 
be differentially expressed between H1975P and H1975R cells. Increased expression 
of EMT proteins vimentin, desmin and filamin was detected in H1975R cells (p < 0.05, 
fold change >2). Vimentin overexpression in H1975R cells was confirmed by western 
blot analyis. Activation of EMT was identified as one potential mechanism of resistance 
to GDC-0980 in H1975R cells. Conclusion: The PI3K-mTOR pathway is frequently 
mutated in NSCLC, in particular squamous cell carcinoma, making it an ideal therapeutic 
target. Acquired resistance to GDC-0980 developed rapidly in NSCLC cell lines, (4-6 
months) and correlates to the induction of EMT. Further elucidation of EMT regulation 
is under investigation and is crucial to the design of improved treatment protocols. 
Keywords: EMT, PIK3CA, PI3K-mTOR, Resistance
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P2.05-001 Assessment of Faculty and Staff Smoking Behavior at Total Ban 
on Smoking in Campus Tomoyasu Uno Health Care Center, Fukushima University, 
Fukushima-City/Japan
Background: Recently, tobacco was positioned “the essence of smoking is nicotine 
addiction” and conjunction with advanced of scientific research. However, not only 
the social situation and also tobacco-free (TF) campus has not been fulfilled in 
Japan. Therefore, we investigated the current state about smoking and analyzed for 
improvement the recognition and for change behavior in non-medical TF campus since 
2010. Methods: The questionnaire for all faculty members(employees) in our campus 
was performed. Subjects in this survey conducted in 2012-13 who enrolled over 20 
years of age was examined in 132 cases that consent were obtained. Results: Base 
of analyzed subjects’ characteristics were male/female(%)=60.6/39.4, 44.6±11.6 yrs 
(mean±SD), respectively. Current smoking prevalence was 8.3% and Ex was 25.0%. 
The starting smoking age was 17.9±3.2 (Mean±SD, [Range 6;32]),opportunity(%) 
was “Out of interest/Incidentally/Because neighboring smoke”:11.7/10.2/8.6 were 
accounted for a large number (*multiple answers act). Tobacco products(connect 
with the Japanese government) sold in domestic market are required to have health 
warnings in Japanese, however, low level of recognition. This may be due to text size of 
tobacco package warning documents (Risk of Lung cancer, Secondhand smoke, etc.) 
are small, mild message and include educational problems. Currently, the people of quit 
smoking several decades has led to resmoking has been occasionally observed. After 
the Great East Japan Earthquake, resmoking rate was turned out to be themselves/
blood relationship persons 1.9%/3.3%. Surprisingly found that awareness of TF within 
the campus, 10.8% was unknown and continuing smoke. Conclusion: The results 
revealed that stood out that lack of information on the status of tobacco and TF 
campus, and be considered sharing the critical issue. Road to TF campuses is difficult 
now in Japan, however, we should be make as the realization. Awareness of TF was 
poor, therefor the necessity of further education about stop smoking was indicated. 
Alongside we need a certain degree of understanding about resmoking status according 
to psychological damage factors of post-disaster, however, faculty members should be 
effort to critical that leads to a complete TF campus for youth-adult student in low-dose 
radiation exposure risk area. We would like to further advance a this research. For this 
purpose, the achieving completely TF campus, not only our university, we think need 
initiatives of the entire university in Japan. In addition, by resolving the current college 
students and faculty/staff problems, the younger generation, it aims to contribute 
to that improvement will be prevention and cessation education to (e.g. elementary 
and junior high schools), smoking current situation that is later than other countries. 
Keywords: Smoke-Free Campus, Health Care Education
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show the level of CO through their indicator lights. CO Analyser parts , it consists of D 
piece and instrument body. 1st step- ask the patient to take deep breath and hold it for 
15 seconds then patient will blow the air slowly in D piece which is attached to anlyser , 
aiming to empty the lungs completely. The instrument will then display the level of Carbon 
monoxide by the relevant indicatror lights. CO is calculated in PPM. Normal Range - a) 
0-6ppm- Normal (green light - less then 1 cigarette): b) 7-10ppm- Orange light (light 
smoker- 2-5 cigarette ) ; c) 11-15ppm- regular smoker (red light) ; d) 16-25ppm- red light 
with beep sound( chronic smoker). After this, we can do nicotine urine test by centrifugal 
method and prescibing the NRT products depending upon the investigation result. NRT is 
of differnt types- Gums, Patch, Nicotine nasal spray, Lozenges,Inhaler, etc. Results: CO 
anlyser can be helpful in knowing “SWOT” analysis of the patient. It will be a beneficial 
tool in counselling and helping the smokers to quit the habit. “SWOT - Strength, 
Weakness,Opportunity, Threatning analysis. Conclusion: By using CO analyser & NRT, 
we can help tobacco user to quit the habit by eliminating the exposure to 2nd hand smoke, 
prevent quiting among young and adults. Prevent initiation among youths at Dental clinics. 
Keywords: CO analyser, NRT products, Dentist as Tobacco therapist
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P2.05-008 The Role of Haplotype in 15q25.1 Locus in Lung Cancer Risk: 
Results of Scanning Chromosome 15 Xuemei Ji1, Jiang Gui1, Younghun Han1, 
Paul Brennan2, Yafang Li1, James Mckay2, Neil Caporaso3, Pier A. Bertazzi4, Maria T. 
Landi5, Christopher I. Amos1 1Biomedical Data Science, Dartmouth College, Hanover/
NH/United States of America, 2International Agency for Research on Cancer, Lyon/
France, 3National Institutes of Health, Bethesda/MD/United States of America, 4University of 
Milan, Milan/Italy, 5National Cancer Institute, Bethesda/NH/United States of America
Background: The role of haplotypes and the interaction of haplotypes and smoking 
exposure in the etiology of lung cancer have not been well characterized. Methods: We 
analyzed data from an Italian population-based case-control study among 1815 lung cancer 
cases and 1959 healthy controls in discovery phase and performed a validation using a 
case-control study comprising 2983 lung cancer cases and 3553 healthy controls of 
European ancestry for replication. Haplotype analyses and logistic regression were used 
to explore the casual haplotype and its association with lung cancer risk. Results: Sliding 
window haplotype analysis within chromosome 15, evaluating 4,722,250 haplotypes, 
and pair-wise haplotype analysis identified that rs16969968-rs588765 was the most 
significant haplotype associated with lung cancer risk (omnibus p = 8.35 × 10−15 in 
discovery and 7.26× 10−14 in replication), and improved the prediction of case status 
over that provided by the individual SNPs rs16969968 or rs588765 (likelihood ratio 
test p = 0.006 for rs16969968 and 3.83 × 10−14 for rs588765 in discovery, 0.009 for 
rs16969968 and 4.62 × 10−13 for rs588765 in replication, compared with rs16969968-
rs588765). Compared to the wild type homozygous diplotype, the CA/CA homozygote 
exhibited an approximately 2-fold increase risk for lung cancer (OR = 2.12; 95% CI, 1.46 
- 3.07 in discovery, and OR = 2.01; 95% CI, 1.51 - 2.67 in replication). Even among 
never-smokers, individuals with CA/CA homozygous diplotype had an increased risk of 
lung cancer with borderline significance in the discovery (adjusted OR = 1.75, 95% CI, 
0.96 – 3.19) and statistical significance in the replication (adjusted OR = 2.10, 95% 
CI, 1.12 – 3.96), compared to those with combined genotypes (CG/CG + CG/TG). 
We also found that smokers with the CA/CA homozygous diplotype had a more than 
13-fold increased risk for lung cancer in the discovery (adjusted OR = 13.42, 95% CI, 
8.21 – 21.95) and 15-fold increased risk in the replication (adjusted OR = 15.52, 95% 
CI, 9.85 – 24.45), compared to nonsmokers with the combined genotypes (CG/CG + 
CG/TG). Conclusion: The rs16969968-rs588765 haplotype modifies lung cancer 
risk more than effects from individual variations at rs16969968 or rs588765, may 
be a marker of genetic susceptibility to lung cancer even among never-smokers, and 
has a joint effect with smoking exposure on lung risk.This knowledge may facilitate 
our understanding of lung cancer etiology and identifies a particularly high risk. 
Keywords: genetic factor, lung cancer, haplotype, smoking
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P2.05-009 Tobacco Addiction and Perception of Risk of Lung Cancer in 
Vulnerable Populations Jean-François Morere1, Laurent Greillier2, Chantal Touboul3, 
Xavier Pivot4, Jérôme Viguier5, François Eisinger6, Jean-Yves Blay7, Christine Lhomel8, 
Alexis Cortot9, Sébastien Couraud10 1Hôpital Paul Brousse, Villejuif/France, 2Hôpital 
Nord, Marseille/France, 3Kantarhealth, Montrouge/France, 4CHU de Besançon, Besançon/
France, 5Hôpital Bretonneau, Tours/France, 6Institut Poali Calmette, Marseille/France, 7Centre 
Léon Bérard, Lyon/France, 8Roche, Boulogne-Billancourt/France, 9Hôpital Calmette, Lille/
France, 10Hospices Civils de Lyon, Lyon/France
Background: Social indicators of vulnerable populations are associated with increased 
rates of comorbidities and risk factors for cancer but not with screening attendance, as 
previously shown by the French EDIFICE surveys. The present work sought to determine 
whether living in poor economic social conditions is associated with specific behavior 
or beliefs that increase exposure to the risk factors for lung cancer. Methods: The 4th 
French nationwide observational survey, EDIFICE 4, was conducted by phone from June 
12 to July 10, 2014 among a representative sample of 1602 individuals aged between 40 
and 75 years, using the quota method. Individuals were questioned about their smoking 
habits. Tobacco addiction was evaluated in current smokers using the Fagerström Test 
for Cigarette Dependence (FTCD) score, which ranks participants into one of four groups: 
no dependence, low, moderate, and high dependence. Risk perception compared to 
the average-risk population was self-assessed. Data were analyzed according to the 
validated EPICES vulnerability score. Results: Vulnerable individuals (N=455) were more 
frequently current smokers than non-vulnerable individuals (N=941) (34.1% vs 19.9%; 
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P2.05-005 Radon Exposure Prevention of Lung Cancer Policies in Brazil 
Carina M. Abrahão, Aline D.R. Lino, Marcus Paulo F. Amarante, Marcelo R. De Sousa 
Cruz Medical Oncology, Beneficencia Portuguesa de Sao Paulo, Sao Paulo/Brazil
Background: Lung cancer is the leading cause of cancer death in the United States 
and other industrialized countries. The most important risk factor is still smoking. 
However, given the increased incidence of lung cancer in non-smokers, it is necessary 
to increase knowledge of the other risk factors. The Radon (Rn) is a noble gas and is 
the most important natural source of human exposure to ionizing radiation. Exposure 
to high levels of this radioactive gas are related to increased risk of developing lung 
cancer. Methods: We have conducted a survey on the website of the Brazilian National 
Health Surveillance Agency (ANVISA), LAMIN (Mineral Analysis Laboratory), CPRM 
(Geological Survey of Brazil), Ministry of Health and Pubmed The objective was to 
highlight the importance of measuring the concentration of this gas indoors and identify 
which steps should be taken for radiological protection. Results: We emphasize that 
lung cancer is a major public health problem and the exposure to Rn indoors should be 
considered as a risk factor in patients with non-smokers lung cancer. Buildings or houses 
with high concentrations of radon should be identified. However, currently, there is not in 
Brazil, a country with great potential of mineral extraction, any regulated recommendation 
for control of exposure to Rn. Conclusion: Exposure to indoor Rn should be considered 
as the main risk factor in patients with non-smokers lung cancer and second risk 
factor in smokers. Buildings or houses with high concentrations of radon should be 
identified. It is essential that regular reviews of radon levels are carried out at these sites 
Keywords: lung, Cancer, Radon
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P2.05-006 Meta-Analysis of Radon Indoor Concentrations and Risk of Lung 
Cancer Yula L. Merola1, Luiz E. Mendes2, Nize Yamaguchi3 1Medical Pathophysiology, 
University of Campinas, Campinas/Brazil, 2Production Engineering, Puc Minas, Poços de 
Caldas/Brazil, 3Instituto Avanços Em Medicina, São Paulo/Brazil
Background: Our ongoing research is assessing stem cells alterations in cancer due 
to indoor radon exposure. Therefore, we performed a meta-analysis of previous studies 
on radon exposure and lung cancer to evaluate the strength of the statistical and radon-
detection methods for determining exposure-response risk levels. Methods: Literature 
search used PubMed. Inclusion criteria: a), original case-control studies; b), use of alpha 
track detectors; c), report weighted average values of radon concentrations over time 
and/or cumulative exposure rates; d), include only lung cancer diagnosis by pathology 
and/or imaging; e), frequency-matched controls by age, gender and smoking status; 
f), enough samples and data for odds ratio estimation and variations; g), published in 
English. Data Extraction: Statistical data extracted from the selected studies. Studies 
selected were stratified by level of exposure to evaluate the dose-response relationships. 
Adjusted odds ratios (CI 95%) extracted for radon concentrations expressed in Bq/m-
3). All data was later adjusted to WHO’s categories 0-99, 100-199, 200-299 and >300 
Bq/m-3. Meta-analysis: For each study, analysis of the weighted linear regression of 
log-adjusted odds ratio was performed according to the average radon concentrations. 
Coefficients and 95% confidence intervals were calculated according to the various levels 
of radon concentration. Sensitivity analyzes: Separate meta-analysis was performed 
by grouping studies with similar characteristics Results: The log-OR for lung cancer risk 
was 1.22 higher at radon indoor levels >Bq/100-3, being such levels more frequent in the 
homes of lung cancer cases. As for smokers, the 1.14 metanalytical measure indicates a 
log-OR of 3.19 (CI: 95%). Conclusion: This meta-analysis suggests a statistical significant 
higher risk of lung cancer in individuals exposed to indoor radon levels >Bq/100-3. 
Keywords: lung cancer risk, environmental factors, indoor radon gas, alpha particles 
detectors
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P2.05-007 Role of Carbon Monoxide Analyser and NRT in Smoking Cessation 
Sachin Sinha1, Anshu Gupta2, Khushboo Rani3 1Tobacco de Addiction Specialist, Narain 
Sewa Sansthan, Bangalore/India, 2General Pathology, Ibhas, New Delhi/India, 3Tobacco 
Control, Narain Sewa Sansthan, Bangalore/India
Background: Tobacco consumption is increasing day by day world wide. In developed 
countries, the pattern of using tobacco is in the form of smoke where as in developing 
or underdeveloped countries both form (smoke & smokeless) of tobacco is in use. In 
developing countries like India, more than 2200 people are dying daily because of 
consuming tobacco in various forms, data issued by WHO & GATS. Dentist can play an 
important role in tobacco cessation , as they closely deal the patient of any gender and 
of any age groups. Smoking is very common among age of 20-45 years. Most of the 
dental problems arises during this age group and may be because of smoking. Dentist 
can counsel and motivate the patient by taking case history of the patient on Dental 
chair to quit this habit. He can use Carbon Monoxide analyser as a helping tool to tell 
the amount of carbon monoxide in patients lungs. CO analyser can be used as threating 
tool for smokers and later we can advice Nicotine replacement therapy according to the 
dependency on nicotine. Methods: Carbon monoxide analyser is a device which is used 
to measure the amount of carbon monoxide in smokers lung. It is of various types:- a) CO 
analyser with USB port which can be attached to Computer and printer ,b) Baby Carbon 
monoxide analyser. Benefit of CO analyser with USB port- it can be used in clinic and we 
can save data as clinic record and can give print out to the patient as their motivational 
agent. where as Baby CO analyser can be used for masses in camps. It immedidiately 
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and lung cancer (even after adjustment for asbestos exposure) is well established [Reid et 
al, OEM 2005], the link between lung cancer and the presence of pleural plaque remains 
controversial. Methods: We followed 2,218 subjects exposed to crocidolite asbestos 
as miners (n=1286) or mine township residents, monitored with annual review, chest 
radiography (CXR) and outcome linkage to national cancer and mortality registry data 
over a 25-year period. Subjects were followed up from the date of their latest x-ray taken 
a year or more before the date of death, cancer incidence, or end of follow-up. Hazard 
ratios for lung cancer were estimated by Cox regression, with age as the underlying 
matching time variable, for sex, tobacco smoking, asbestos exposure estimates (time 
since first exposure and fibre/ml years), International Labour Organisation CXR readings 
for asbestosis (defined as profusion score > 1/0) and presence (and extent) of pleural 
plaques. Results: Mean age at follow up was 60.6 years, 1,575 (71%) were male, 328 
(14.8%) had any pleural plaque and 359 (16.2%) had asbestosis. 103 (4.64%) lung 
cancers were recorded. 1568 (70.7%) were ever-smokers with a mean tobacco exposure 
of 39.3 pack years.
HR Lower 95% CI
Upper 
95% CI p-value
Log (yrs) SFE 1.77 .60 5.22 0.298
Ever smoker 18.1 2.5 132 0.004
Pack years 1.009 1.005 1.01 <0.0005
Female 0.75 .38 1.48 0.408
Profusion: 0/1 1.88 1.14 3.10 0.013
1/0 1.64 0.87 3.07 0.124
1/1 3.64 1.83 7.24 <0.0005
1/2 6.10 2.03 18.3 0.001
> 2/1 2.18 0.64 7.49 0.215
Log f/ml yrs 1.223 1.076 1.390 0.002
Any PP 1.048 0.601 1.826 0.869
SFE = since first exposure; 
f/ml = fibres / ml; PP = 
pleural plaque; HR = hazard 
ratio; CI = confidence 
interval
 
Table 1. Hazard ratios for diagnosis of lung cancer Conclusion: In our population, 
the presence of pleural plaque is not associated with an increased risk of 
subsequent lung cancer. This is contrary to a recent report that had smaller 
numbers of lung cancer and used death certificates [Pairon, AJRCCM, 2014]. As 
we have demonstrated previously, the presence of asbestosis and cumulative 
asbestos exposure both contribute to increased subsequent lung cancer risk, 
although previous tobacco smoke exposure remains the strongest risk factor. 
Keywords: lung cancer, asbestos, pleural plaque, epidemiology
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P2.06-001 Community-Based Low-Dose Computed Tomography (LDCT) Lung 
Cancer Screening in the Histoplasmosis Belt of the United States Emilia A. 
Porubcin, Judith A. Howell, Steven A. Cremer Unity Point Medical Center, Moline/IL/United 
States of America
Background: LDCT lung cancer screening has been incorporated into most major 
American medical societies’ screening guidelines and has recently been approved 
for reimbursement by the Centers for Medicare and Medicaid Services. However, its 
performance in a non-tertiary care community setting with a high prevalence of fungal 
infections has not been sufficiently studied. Methods: Beginning in April 2013, high-risk 
adults ages 55-80 with at least a 30 pack-year smoking history, including former smokers 
who had quit within the previous 15 years, were prospectively evaluated with an LDCT 
scan performed at our community hospital (Unity Point Health Medical Center in Quad 
Cities, Illinois). Standard National Lung Screening Trial exclusion criteria were followed 
with the exception of previous chest CTs being allowed up to 12 months rather than 18 
months prior to study entry and extension of age of the studied population to 80 years. 
An oncology nurse navigator contacted and monitored all participants. The CTs were 
interpreted by a local radiology group with two radiologists spearheading the program 
and ensuring consistent interpretations. Results: As of April 2015, we have evaluated 
176 participants, 86 of whom were men (49%). Median age of the studied population was 
64 years (range 55 - 80). Screening adherence was 97% with a total of 36 participants 
(20%) having at least one follow-up LDCT. 40 participants (23%) had a positive baseline 
screening test. 1 patient had a baseline screening test positive for pneumonia and was 
subsequently diagnosed with stage IV non-small cell lung cancer (NSCLC). 135 patients 
P≤0.01) and less frequently former smokers (25.9% vs. 35.8%; P≤0.01). Compared to 
the non-vulnerable population, current and former cigarette smokers in the vulnerable 
population were more likely to have started smoking before the age of 15 (33.8% vs. 
25.5%, P≤0.05), and had a higher average consumption (16.6 pack-years [SD 16.25] vs. 
13.59 pack-years [SD 16.44]; P≤0.01). Vulnerable individuals were also more likely to stop 
smoking for periods of less than 1 year or for 1-9 years (18.6% vs. 10.4% and 29.2% vs. 
19.4%, respectively; P≤0.05) but were less likely to quit for longer periods (10-19 years, 
17.6% vs. 27.1%, P≤0.05; 20-29 years, 17.2% vs. 22.5% and ≥30 years, 17.5% vs. 20.3%, 
not statistically different). Likewise, vulnerable individuals had higher average FTCD 
scores (3.24 [SD 2.38] vs. 2.55 [SD 2.16], P≤0.01) and were more frequently ranked as 
moderately or highly dependent on cigarettes (32.0% vs. 21.5%, P≤0.05). Respondents 
were asked about the number of cigarettes per day they considered to be associated with 
no risk of lung cancer; average replies were 3.01 (SD 5.40) in the vulnerable population 
vs. 1.93 (SD 3.90, P≤0.01) in the non-vulnerable population. The former were also less 
likely to spontaneously cite a number of lung cancer risk factors (unhealthy life-style 
93.8% vs. 97.5%, active smoking 91.3% vs. 95.5%; passive smoking 60.4% vs. 72.0%; 
P≤0.01). But they were more likely to rank their own risk of lung cancer as higher than 
that of the average population (22.6% vs. 16.6%, P≤0.01) and to consider screening as 
more distressing than reassuring (25.9% vs 18.3%, P≤0.01). Conclusion: Because they 
develop a heavy, long-lasting consumption of tobacco and are less likely to quit smoking 
permanently, vulnerable individuals are more exposed to the tobacco-consumption-
related risks of lung cancer. Paradoxically, they also appeared both less concerned and 
more anxious about the risks of lung cancer than non-vulnerable populations. These results 
highlight the urgency of implementing information campaigns, prevention messages, 
and smoking cessation support specifically targeting this vulnerable population. 
Keywords: tobacco addiction, lung cancer risk, vulnerable population
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P2.05-010 The Chronic Respiratory Infection as a Background of the Lung 
Cancers Tsutomu Yoshida, Takayuki Nakagawa, Kiyomi Shimoda, Miyako Hiramatsu, 
Yuji Shiraishi Chest Surgery Division, Respiratory Disease Center, Fukujuji Hospital, Japan 
Anti-Tuberculosis Association, Tokyo/Japan
Background: It had been pointed out about the respiratory infectious disease that 
the tuberculosis patients had increased risk of lung cancers, and the lung cancer 
patients had increased risk of tuberculous infection. In recent years, primary lung 
cancer cases are increased, despite of decreasing of tuberculosis infection and, on 
the other hand, of increasing of chronic respiratory infectious diseases such as the 
pulmonary non-tuberculous mycobacteriosis or mycosis. A purpose of this study is to 
research the chronic respiratory infectious diseases as a background of the lung cancer 
treatment. Methods: From January, 2010 to December, 2014, 431 cases of radical 
operations for primary lung cancers were performed in our institute. A bacteriological 
search by the expectoration and bronchus absorption sputum was examined in 389 
cases preoperatively. Among these cases, we retrospectively researched about 
the fungal infections and mycobacterial infections. Results: Among the 431 primary 
lung cancer cases, 19 cases of fungal infections were detected, 12 cases of non-
tuberculous mycobacterium infections were detected, four were co-existing and none 
was tuberculosis. In the patient background of mycosis, gender was 15 cases of male 
and four of female, the mean age was 69.7±8.1 years old (53-88 years old), and 
mean smoking index was 1073 (0-2640). The histological types of the lung cancers 
were eight cases of squamous cell carcinoma, seven of adenocarcinoma, each one of 
small cell lung cancer, pleomorphic carcinoma and LCNEC. The pathological stages 
of the lung cancers were nine cases of stage I, five of stage II, four of stage III and 
two of stage IV. The detected species of bacteria were nine cases of Candida spp., 
eight of Candida albicans, two of Aspergillus fumigatus and one of Aspergillus niger. The 
patients had past history of tuberculosis in three cases, cancer in four, diabetes in 6 and 
continuous treatment by steroid in two. In the patient background of non-tuberculous 
mycobacteriosis, gender was 7 cases of male and 5 of female, the mean age was 
71.7±10.2 years old (50-88 years old), and mean smoking index was 556 (0-1800). 
The histological types of the lung cancers were six cases of adenocarcinoma, three of 
LCNEC, two of squamous cell carcinoma, one of small cell lung cancer. The pathological 
stages of the lung cancers were eight cases of stage I, one of stage II, two of stage III 
and one of stage IV. The detected species of bacteria were 11 cases of Mycobacterium 
avium complex and one of Mycobacterium mucogenicum. The patients had past history of 
cancer in two cases and continuous treatment by steroid in two, but none of tuberculosis 
and diabetes. The five year survival rate of the lung cancer cases with the chronic 
respiratory infections was 63.0% and that without the chronic respiratory infections 
was 76.6%. The lung cancer cases with chronic respiratory infections showed tendency 
of poor prognosis, although there was no significant difference between two groups 
(p=0.087). Conclusion: The lung cancer cases with chronic respiratory infections 
had past history of coexisting disease, and showed tendency of poor prognosis. 
Keywords: mycosis, mycobacteriosis, lung cancer
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P2.05-011 Presence of Pleural Plaques and/or Asbestosis and the Risk of Lung 
Cancer in a Crocidolite Asbestos Exposed Population from Western Australia 
Fraser Brims1, Bill Musk1, Alison Reid2, S C Pang1, Peter Franklin3, Susan Peters3, Nick 
De Klerk3 1Respiratory Department, Sir Charles Gairdner Hospital, Perth/Australia, 2Curtin 
University, Perth/WA/Australia, 3University of Western Australia, Perth/WA/Australia
Background: Asbestos exposure is associated with dose-dependent risk of benign 
pleural disease, lung cancer and mesothelioma. While an association between asbestosis 
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developed a comprehensive lung cancer screening program open to patients aged 55-80 
with either a 30 pack-year smoking history (USPSTF criteria) or a 20 pack-year smoking 
history plus a risk factor (NCCN criteria) who continue to smoke or have quit within the 
past 15 years. At the time of patient enrollment, a nurse coordinator was supposed to 
complete an electronic intake form that assessed patient screening eligibility, smoking 
history, symptoms, and environmental carcinogen exposure. Radiographic reporting 
and nodule evaluation were standardized. Results: From September 4, 2013 to October 
1, 2014, 258 patients were referred to the lung cancer-screening program. Thirty-four 
patients were ineligible for screening based on the aforementioned guidelines while 17 
patients declined screening. Of the 207 patients who met USPSTF or NCCN criteria, 
forty-five were not processed by the coordinator primarily due to physician office 
staff calling radiology directly. Of the 162 properly processed patients the mean age 
was 65.7 +/- 5.5 years, 50.6% (82) were active smokers, 45.7 %(74) had additional 
environmental exposures and 61.1% (74) reported symptoms at the time of intake. 
Of the 74 patients with symptoms 66 (89%) reported cough. Of the total of 207 who 
were screened 48.3%(100) had no nodules, 30.4% (63) had a nodule >6mm requiring 
follow up studies, 6.8% (14) had a nodule suspected of being cancer and 14.5% (30) had 
significant incidental findings. Eight of the 14 patients with suspicious lesions had been 
evaluated at the time of review. Three were found to have lung cancer (stages 1A, 2A 
and 4) and 2 others had a non-lung malignancy (renal, lymphoma). Three patients had 
benign lesions (2 hamartomas and 1 fibrosis). Conclusion: Despite vigorous attempts to 
standardize the process and broad discussion of the indications with physician groups, 
numerous patients who were ineligible were referred and several underwent screening 
when physician’s office staffs were able to bypass the coordinator step. Cough as a 
symptom needs further clarification as a significant majority of patients present with 
cough. The CMS recommendation for physician counseling is likely to have little impact as 
most physicians are not knowledgeable about the nuances of screening for lung cancer. 
For lung screening to realize its true potential these technical issues must be resolved. 
Keywords: lung cancer screening, lung nodule
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P2.06-004 Lung Cancer Screening Perceptions in Vermont Edmund Folefac 
Medicine, Unversity of Vermont, Burlington/VT/United States of America
Background: In 2014 the University of Vermont Cancer Center obtained accreditation 
for the new Lung Cancer Screening Program from the American College of Radiology. 
During the first 6 months of the LDCT screening program, there were 100 participants 
in the program. Patient understanding of lung cancer screening did not seem to be 
clear. Methods: We conducted a preliminary survey to define the perceptions of the 
first 76 participants enrolled in the program. A 30 question questionnaire was done 
by telephone survey. Descriptive statistics were used. Results: Thirty-six participants 
(47%) responded to the survey. Referral of the majority of participants was done by less 
than primary care providers. 32Participants did not know about the program before they 
were told by their doctor. Although 92% of respondents knew they had a “lung X-Ray” 
done, 14% did not know why the test was done and only 28% knew they had undergone 
a LDCT of the lungs. All 36 patients knew they had received the results of the test and 
26 (72%) had a follow-up appointment with their provider. Fourteen percent had further 
testing and 3 were diagnosed with early stage lung cancer. Only 25% received education 
material on lung cancer screening program. Eleven participants (30%) would have liked 
more information. Interestingly, 45% were not interested. Twenty-two percent incurred 
additional expenditure from $10 to $1200. Over 90% of the participants would agree to 
refer a family member to the program if this was an option. Most patients (75%) reported 
that the test did not affect their mood. The highest level of anxiety was in those who were 
diagnosed with cancer. Of the current smokers (N=20), only 17 (85%) were counseled 
to quit smoking. Of the 17 participants who received counseling, 9 followed the advice 
and sought help to quit, 2 did decrease smoking, and 7 did not follow the advice. Over 
97% of patients (35/36) wanted to know what other anomalies were diagnosed on 
the LDCT. Interestingly, these 35 patients thought they would be more likely to quit if 
they had a better understanding of the damage done by tobacco. Conclusion: LDCT 
scan is an effective tool to diagnose early stage lung cancer and does not affect the 
mood of the majority of the participant, but it is still much underutilized mainly because 
of the knowledge gap among providers responsible for educating and referring at-
risk patients. Most of the participants were satisfied with the program but there is 
a need to better educate the public and primary providers about the purpose of the 
study and the importance of smoking cessation. Finally showing participants the 
LDCT images of their lungs and counseling them about tobacco related changes 
in their lungs found during screening can be a power tool to help them quit smoking. 
Keywords: lung cancer screening
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P2.06-005 Lung Cancer Risk Perception: Findings from the PAIRS-COPD Study 
Stephen P. Brummell1, Angela M. Tod2, Trevor Rogers3, Dawn Bowen4, Mark Boon4 
1Health and Wellbeing, Sheffield Hallam University, Sheffield/United Kingdom, 2University 
of Manchester, Manchester/United Kingdom, 3Doncaster Royal Infirmary and Hon. Senior 
Lecturer, University of Sheffield, Doncaster/United Kingdom,4Conisbrough Group Practice,, 
Doncaster/United Kingdom
Background: Detecting new or early lung cancer symptoms in people who have COPD 
is especially difficult as early signs of disease may be masked by existing chronic 
respiratory symptoms. Public awareness of lung cancer symptoms remains low despite 
recent media campaigns. A lack of knowledge and understanding of their condition and 
associated risks may account for patient symptom reporting delay. Over 60% of UK 
(77%) had a negative baseline screening test. Benign appearing calcified granulomas 
were detected in 60 participants (34%) with a nearly identical relative distribution 
between those with negative and positive screening tests. Only seven follow-up PET-CT 
scans were necessary. One was performed for staging purposes after a histologically 
proven cancer diagnosis. Six were performed for evaluation of lesions felt to be highly 
suspicious on LDCT. Four of the six PET-CTs were positive and led to a diagnosis of 
malignancy. A total of five malignancies (2.8%) were detected as a direct result of the 
screening. Four were NSCLC, of which three were stage I and one was stage IV. One 
participant was diagnosed with Marginal Zone Non-Hodgkin Lymphoma of the lung. All 
biopsies that were performed were positive for malignancy. No unnecessary biopsies 
were performed. No biopsy-related complications occurred. Four out of five patients with 
detected malignancies are still alive and doing well. Two patients (1%) died during the 
follow-up. One patient died secondary to an advanced NSCLC detected by the screening 
program; the other death was due to an unrelated cause, pneumonia. Conclusion: To our 
knowledge, this is the first community hospital-based study evaluating the results of LDCT 
lung cancer screening in an area of the United States endemic for both Histoplasmosis 
and Blastomycosis. LDCT cancer screening in such a setting can be done effectively 
without significant false positive results due to fungal infections. A significant number 
of early stage lung cancers were detected without excessive testing or complications. 
Keywords: community-setting, Screening, lung cancer, histoplasmosis
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P2.06-002 Preliminary Results of Early Stage Lung Cancer Detection Using 
Low-Dose Computed Tomographic Screening Huimin Wang1, Jiajun Teng1, Yanwei 
Zhang1, Qunhui Chen2, Jianding Ye2, Jiatao Lou3, Rong Shi4, Bo Jin1, Xueyan Zhang1, 
Jianlin Xu1, Xue Dong1, Yuqing Lou1, Baohui Han1 1Department of Pulmonary, Shanghai 
Chest Hospital, Shanghai Jiaotong University, Shanghai/China, 2Department of Radiology, 
Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/China, 3Department of 
Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/
China, 4Department of Public Health, Shanghai Jiaotong University, Shanghai/China
Background: The overall 5 years survival for lung cancer patients is approximately 
16%, a survival advantage is noted for early stage lung cancer, with 5-year survivals 
up to 65%. However, only 10% patients are diagnosed when the primary tumor is 
resectable. Our trial was conducted to improving the early stage lung cancer detection 
rate using low-dose CT. Methods: Eligible participants enrolled in our trial were local 
residents in 6 communities located in Xuhui District, Shanghai, China, aged from 45 to 
70 years and with either of the following risk factors: 1) history of cigarette smoking 
≥ 20 pack-years, and, if former smokers, had quit within the previous 15 years; 2) 
malignant tumors history in immediate family members; 3) personal cancer history; 4) 
professional exposure to carcinogens; 5) long term exposure to second-hand smoke; 
6) long term exposure to cooking oil fumes. From November 2013 to November 2014, 
the high risk residents received free chest low-dose CT (LDCT) scans at Shanghai 
Jiao Tong University Affiliated Shanghai Chest Hospital. The findings of CT scan were 
identified by three experts. The shadows on the lungs were grouped accordingly. 
If imaging was highly suggestive of malignancy, the expert group would have further 
discussion. The residents would be assigned to undergo biopsy or surgical resection 
directly. Results: Up to January 2015, 2933 participants were received LDCT screening. 
According to the inclusion criteria, 2892 persons at high risk for lung cancer were 
included in our trail, and 41cases were finally excluded. Of the 2892 aged 45 -70 years 
old cases, the median age was 61years old. Of the included participants, 1151 cases 
were male, and 1741 cases were female. Pulmonary small nodules were found in 742 
cases; small nodules detection rate was 25.66% (742/2892). 69 cases were suspected 
of lung cancer. Accounting for pulmonary small nodules was 9.30% (69/742), and 
was 2.39% (69/2892) of the total number of screening high risk population. 23 cases 
underwent surgery, with 22 lung cancer (10 males and 12 females) and 1 hamartoma, 
representing a positive lung cancer detection rate with low-dose CT screening of 0.76% 
(22/2892). 21 of the 22 cases resected lung cancers were stage I (95.45%) and 1 
was stage II (4.55%), with 21 adenocarcinomas (95.45%) and 1 squamous lung cancer 
(4.55%). Conclusion: The application of low-dose CT screening prompted an increase 
detection rate of early stage lung cancers (stage I and II) in the high risk population. 
Keywords: high risk population, lung cancer, Screening, low-dose CT
POSTER SESSION/ SCREENING AND EARLY DETECTION 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.06-003 A System-Wide Lung Cancer Screening Program: First Year 
Experiences John C. Ruckdeschel1, Andrew T. Miller2, Patricia Kruger3, Braden 
Row;Ey3, Teresa J. Robertson4, William T. Sause5, Karen Connor6, Denitza P. Blagev7 
1Thoracic Oncology, Synergy Cancer Center, Las Vegas/NV/United States of 
America, 2Internal Medicine, Intermountain Healthcare, Murray/UT/United States 
of America, 3Oncology, Intermountain Healthcare, Murray/UT/United States of 
America,4Clinical Information Systems, Intermountain Healthcare, Murray/UT/United States 
of America, 5Radiation Oncology, Intermountain Healthcare, Murray/UT/United States of 
America, 6Diagnostic Radiology, Intermountain Healthcare, Murray/UT/United States of 
America, 7Division Ofpulmonary Medicine, University of Utah, Salt Lake City/UT/United States 
of America
Background: The United States Preventive Services Task Force (USPSTF) and 
National Comprehensive Cancer Network (NCCN) recommend screening with Low-
Dose Computed Tomography (LDCT) for asymptomatic patients at high risk of lung 
cancer. It remains unknown, however, how well these recommendations will translate 
to the medical community at large. Here, we report on the initial year of a statewide 
lung cancer-screening program implemented at Intermountain Healthcare. Methods: We 
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highest median area-under the receiver operating curve (AUC) obtained from 1000 
bootstrap replicates. A second, independent set of 68 tumor-normal samples (half 
adenocarcinoma, half squamous) was used as a test set, and bootstrapping was used 
to determine the 95% confidence interval for the AUC. Results: The median AUC for the 
top-performing panel of 4 miRNAs in our training set was 0.96. Several other miRNA 
combinations exhibited AUCs > 0.95 as well. In our test set, the top-performing panel 
(and only panel tested) exhibited an AUC of 0.97 (0.93, 0.99). This panel consisted of 
miRs 26a, 145, 183 and 486. miRs 145 and183 have previously been shown, when used 
individually, to be significant lung tumor biomarkers in at least 4 previous studies; miR-
486 has been replicated 8 times.
 
 
Conclusion: Consistent with previous studies, we’ve identified a panel of 4 miRNAs that 
shows excellent potential for diagnosing lung tumors. Each of these miRNAs has been 
replicated as a biomarker of lung cancer in at least two previous studies, suggesting 
a high likelihood of achieving clinical validation. Several previous studies have also 
shown that these four miRNAs are potentially useful as biomarkers for diagnosing lung 
cancer using blood samples, and we are currently pursuing such validation studies. 
Keywords: Biomarkers, miRNA signature, NSCLC
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P2.06-008 Diagnostic Yield of Autoantibody Panel for Patients with Ground-
Glass Nodules (GGNs) or Solid Nodules in Chinese Population Caicun Zhou, 
Shengxiang Ren, Yayi He Shanghai Pulmonary Hospital, Tongji University School of 
Medicine, Shanghai/China
Background: Autoantibodies is an attractive diagnostic approach for early 
detection of malignant tumors. Our previous studies found a panel of 7 TAAs(p53
，PGP9.5，SOX2，GAGE7，GBU4-5，MAGE A1，CAGE) was associated with lung 
cancer. We performed this large-scale clinical trial to validate their ability to aid early 
diagnosis of lung adenocarcinoma presenting with GGNs or solid nodules in Chinese 
population. Methods: The 7 TAAs were selected from 43 candidate TAAs from our 
previous studies. These samples including lung adenocarcinoma presenting with GGNs 
(n = 170) or solid nodules (n = 100) and healthy volunteers (n = 200). The sensitivity and 
specificity from 7 TAAs and the traditional cancer biomarkers CEA, NSE, and CYFRA21-1 
were compared. Results: The sensitivity and specificity of autoantibody assay were 53% 
and 91% respectively, which were similar in different subgroups such as age, gender, 
smoker status and histological type. The sensitivity of autoantibody assay was 50% 
in lung adenocarcinoma presenting with GGNs. The sensitivity of autoantibody assay 
was 58% in lung adenocarcinoma presenting with nodules. The results were significantly 
higher than 27% when using the combination of CEA, NSE, and CYFRA21-1 to detect 
patients with lung cancer. Conclusion: Our study suggested that the 7 TAAs autoantibody 
panel might be helpful to aid diagnosis of lung cancer with GGNs or solid nodule. Large 
scale trial to validate our finding of patients with GGNs is ongoing in our institute. 
Keywords: ground-glass nodules (GGNs), solid nodules, autoantibody panel, lung 
adenocarcinoma
lung cancer patients are diagnosed at a stage where curative treatment is no longer 
an option. Early reporting and diagnosis can provide curative treatment options and 
improved outcomes. New, cost effective interventions that promote timely detection and 
diagnosis and that are acceptable to patients are required. Prospective Assessment of 
Incident Respiratory Symptoms (PAIRS-COPD) is a feasibility study that evaluated four-
monthly telephone reviews of COPD patient’s respiratory symptoms, by a primary care 
nurse. This abstract presents findings that identify the intervention’s effectiveness in 
prompting symptom reporting and referral and explores participant’s perceptions of their 
chest condition and lung cancer risk. Methods: Mixed methods were used. Quantitative 
analysis of frequency of identification of indications for a chest X-ray was undertaken 
with COPD patients on a primary care register (n=77). A purposive sample (n=12) were 
selected for semi-structured telephone interviews (7 women and 5 men) to evaluate 
patient perceptions and experiences and acceptability of the intervention. Interviews 
were audio taped and transcribed. Thematic analysis was used. Results: Interviewees 
revealed that living with respiratory symptoms for protracted periods resulted in a 
high level of symptom tolerance. New symptoms were assumed to be an inevitable 
and expected part of their normal illness trajectory or of aging more generally. 
Awareness of prognostic implications and lung cancer risk was low. The interviewees 
reported the belief that decline was inevitable. This, combined with their worsening 
respiratory condition and high symptom tolerance, had made delay in reporting new 
or deteriorating symptoms inevitable. However, as a consequence of the intervention, 
symptoms recommended to prompt a chest X-ray by the National Institute of Clinical 
Excellence (NICE) were identified in 27% of the 77 volunteers over the 12-month study 
period. In 5%, criteria for an urgent lung cancer referral were met. Importantly, the 
interviewees described how the intervention was acceptable and accessible as it did 
not require additional travel and visits to the doctor. It successfully provided them with 
a more nuanced understanding of their chest condition, increased knowledge of early 
indicators of acute exacerbation and enhanced their self-management skills. The calls 
also heightened interviewees’ appreciation of their increased risk of lung cancer and 
awareness of the associated symptoms. They reported adopting more proactive help 
seeking behaviours. Conclusion: This study reveals how the PAIRS-COPD intervention can 
help COPD patients identify and report new symptoms that may otherwise be accepted 
or missed. In the study symptoms requiring further investigation and referral were 
uncovered surprisingly frequently. For a client group with a significant symptom burden, 
the lack of disruption was a primary reason for the acceptability of the intervention. 
Keywords: lung cancer detection, COPD patients, Telephone based intervention, 
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P2.06-006 Diagnostic Accuracy of CT-Guided Transthoracic Needle Biopsy 
for Solitary Pulmonary Nodules Yong Song, Wen Yang, Wenkui Sun Jinling Hospital, 
Nanjing/China
Background: To evaluate the diagnostic accuracy of computed tomography (CT) -guided 
percutaneous lung biopsy for solitary pulmonary nodules. Methods: Three hundred and 
eleven patients (211 males and 100 females), with a mean age of 59.6 years (range, 
19–87 years), who were diagnosed with solitary pulmonary nodules and underwent CT-
guided percutaneous transthoracic needle biopsy between January 2008 and January 
2014 were reviewed. Results: All patients were confirmed by surgery or the clinical 
course. The overall diagnostic accuracy and incidence of complications were calculated, 
and the factors influencing these were statistically evaluated and compared. Specimens 
were successfully obtained from all 311 patients. A total of 217 and 94 cases were 
found to be malignant and benign lesions, respectively, by biopsy. Two hundred and 
twenty-five (72.3%) carcinomas, 78 (25.1%) benign lesions, and 8 (2.6%) inconclusive 
lesions were confirmed by surgery and the clinical course. The diagnostic accuracy, 
sensitivity, and specificity of CT-guided percutaneous transthoracic needle biopsy were 
92.9%, 95.3%, and 95.7%, respectively. The incidences of pneumothorax and self-
limiting bleeding were 17.7% and 11.6%, respectively. Conclusion: Taking account of 
all evidence, CT-guided percutaneous lung biopsy for solitary pulmonary nodules is an 
irreplaceable, efficient, and safe diagnostic method associated with few complications. 
Keywords: specificity, Percutaneous lung biopsy, solitary pulmonary nodules, Sensitivity
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P2.06-007 A miRNA Signature Derived From Independently Replicated 
Biomarkers of Non-Small Cell Lung Cancer Christopher J. Rivard1, Brad Rikke1, 
Leslie Rozeboom1, Ashley A. Kowalewski1, William J. Feser2, Anna E. Barón2, York E. 
Miller3, Paul A. Bunn, Jr1, Fred R. Hirsch1 1Medical Oncology, University of Colorado Denver, 
Aurora/CO/United States of America, 2Biostatistics and Informatics, Colorado School of 
Public Health, University of Colorado Anschutz Medical Campus, Aurora/CO/United States 
of America,3Pulmonary and Critical Care Medicine, University of Colorado Anschutz Medical 
Campus, Aurora/United States of America
Background: miRNAs have shown exceptional promise as biomarkers of lung cancer; 
however, no miRNA signatures have yet reached the clinic. Towards developing a 
signature with a high likelihood of being validated externally for clinical use, we screened 
a panel of 50 miRNAs shown to be effective biomarkers in at least two previous studies 
for distinguishing human lung cancer samples from non-cancer samples. Methods: Sixty 
tumor-normal pairs (33 adenocarcinoma, 27 squamous cell carcinoma) were used to 
identify the best-performing combination of 4 miRNAs for distinguishing tumor samples 
from normal. The miRNA levels were measured by RT-qPCR using Taqman custom-made 
microfluidics cards and primer pools purchased from Life Technologies. All possible 
combinations of 4 miRNAs were tested, and best performance was defined as the 
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Conclusion: These exciting preliminary results suggest that exhaled 
breath collected from subjects attending respiratory clinic may serve as 
screening test to aid the physician in the identification of patients with 
lung cancer and pulmonary tuberculosis from other respiratory diseases. 
Keywords: lung cancer tuberculosis exhaled breath
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P2.06-011 Periostin Investigational Use Only Automated Immunoassay for 
Abbott ARCHITECT® Philip M. Hemken1, Nicolette Jeanblanc1, Maria Datwyler1, 
Susan Brophy1, Scott Manetz2, Roxanne Lee2, Meina Liang2, Partha Choudhury2, 
Reena Varkey2, Ethan Grant2, Katie Streicher2, Lydia Greenlees2, Koustubh Ranade2, 
Gerard Davis1 1Research and Development, Abbott, Abbott Park/IL/United States of 
America, 2Medimmune, Gaithersburg/MD/United States of America
Background: Periostin is an 836 amino acid, 93314 Da, protein secreted by airway 
epithelial cells that induces cell attachment and spreading and plays a role in cell 
adhesion. Specifically, it functions to enhance incorporation of BMP1 in the fibronectin 
matrix of connective tissues, and subsequent proteolytic activation of lysyl oxidase. 
Its expression is induced by the Th2 cytokine IL-13. Periostin serum levels have shown 
to be elevated in some asthmatic patients. Therefore, it is hypothesized that periostin 
may be useful as a surrogate marker for IL-13 up-regulation and to identify asthmatics 
more likely to benefit from IL-13 targeted therapy. The clinical utility of the assay is being 
explored in patients with uncontrolled severe asthma in Phase III trials of tralokinumab, an 
investigational anti-IL13 monoclonal antibody. An analytically robust investigational use 
only (IUO) immunoassay was developed to quantitate serum periostin on the ARCHITECT® 
immunoassayiSystem. Methods: The ARCHITECT® Periostin assay is a monoclonal 
antibody (mAb) sandwich twostep immunoassay for the quantitative determination 
of periostin in human serum using Chemiluminescent Magnetic Immunoassay (CMIA) 
technology. Periostin is captured by microparticles coated with an anti-periostin 
mAb and detected with a mAb conjugated with acridinium. Chemiluminesence is 
triggered, and signal is measured as relative light units (RLUs), which directly reflect 
to the quantitative amount of periostin. ARCHITECT® iSystem has throughput of 200 
tests per hour. The analytical performance of the assay was assessed for sensitivity, 
linearity, precision, endogenous and drug interfering substances, specimen handling/
preanalytics, and periostin isoform reactivity. The assay was standardized using 
gravimetrically prepared periostin isoform 1 with protein concentration determined 
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P2.06-009 Oral Glucose Tolerance Test as a Diagnostic Tool in Lung Cancer 
Layah Alkoby1, Tali Feinberg2, Manal Abud Hawa3, John Cancilla4, Jair Bar2, Naomi 
Gaimor2, Maya Ilouze5, Amir Onn2, Jose Torrecilla4, Jens Herbing6, Hiack Hossam3, Nir 
Peled5 1Tel Aviv University, Tel Aviv/Israel, 2Sheba Medical Center, Ramat Gan/
Israel, 3Technion, Haifa/Israel, 4Complutense University of Madrid, Madrid/Spain, 5Rabin 
Medical Center, Petach Tikvah/Israel, 6Ionicon Analytic, Austria/Austria
Background: Previous studies have demonstrated that volatile organic compounds 
(VOCs) in exhaled breath can distinguish between healthy and affected individuals, and 
can even discern between SCLC and NSCLC and within the subtypes of lung cancer 
(LC) and its mutations status. The current study assessed the differences in glucose 
metabolism on the volatile signature in LC through an oral glucose tolerance test 
(OGTT). Methods: This cohort included forty participants (22 control participants whom 
are at high risk for LC, 18 study participants whom have active, naïve lung cancer). Pre-
OGTT and Post-OGTT blood glucose levels and exhaled breath samples were measured 
with a lay period of 90 minutes. A proton transfer reaction mass spectrometer (PTR MS) 
detected and measured the VOCs. The data was then analyzed using a series of feature 
selection methods to identify relevant inputs for multilayer perceptron (MLP) models to 
distinguish LC patients from controls, with and without the consideration of the glucose 
effect. Results: The feature selection method “infogain” revealed a combination of 
14 masses (m/e) that were different between the two groups without considering the 
glucose effect. All the average values of these masses were higher in the LC group 
except for m/e 52, which was higher in the high-risk group. These 14 masses enable 
us to distinguish between the two groups with an average accuracy of 91.67% for three 
internal validation tests of a MLP (threshold set at 0.45). The analysis of the effect 
of glucose revealed that several m/e increased more for the control group whereas 
others increased more for the LC group. Moreover, three feature selections, each with 
a different combination of 4 masses, allowed the design of three MLPs that yielded 90% 
for K-fold cross-validation accuracy.  Conclusion: This study showed that breath analysis 
could discriminate between the high-risk and LC group. Furthermore, it demonstrated 
that glucose metabolism leaves a unique VOC pattern in the LC group. These findings 
may assist in the development of a non-invasive screening method for lung cancer. 
Keywords: warburg effect, volatile organic compounds, oral glucose tolerance test, 
lung cancer screening
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P2.06-010 Exhaled Biomarkers for Lung Cancer Screening Pyng Lee1, Zou Li2, 
Yvette Jee3, Choon Nam Ong2 1Respiratory and Critical Care Medicine, National University 
Hospital, Singapore/Singapore, 2Public Health, National University of Singapore, Singapore/
Singapore, 3Medicine, National University of Singapore, Singapore/Singapore
Background: Lung cancer is the leading cause of global cancer death in both males 
and females. Figures on disease outcome are disappointing despite advances in 
treatment since 86% lung cancer patients die within 5 yrs of diagnosis. However with 
early detection and treatment, 5-year survival improves from 20% stage III to 70% stage I 
disease. Breath chemical tests have been applied in respiratory disorders and we sought 
to determine if exhaled breath volatile compounds (VOC) could discriminate patients with 
lung cancer from pulmonary tuberculosis (TB) by comparing them against age matched 
controls. Methods: Subjects seen at outpatient respiratory clinics with CXR suspicious 
of lung cancer were recruited. Diagnosis of lung cancer or TB was established via 
bronchoscopic, CT lung biopsy or sputum cultures and exhaled breath was collected. 
Patients with other lung diseases but gender and age matched were recruited as controls. 
Analysis of VOC was performed by Thermal Desorption-Gas Chromatography mass 
spectrometry (TD-GC/MS) using Unity Series 2 Thermal Desorber (Markes International 
Limited) and 6890 GC system (Agilent Technologies), interfaced with 5973 MSD (Agilent 
Technologies). Data were analyzed by MZmine 2.11 for peak alignment and normalization, 
and OPLS for statistical clustering analysis. Additional univariate and receiver operating 
characteristic analysis were performed with SPSS. Results: Statistical clustering 
analysis OPLS Fig1 showed breath profile differences between lung cancer (n=17) and 
those with other lung diseases (CON, n=19). Fig2 indicated that breath profile of lung 
cancer patients was also different from those with Tuberculosis (TB). Specific VOC that 
contribute to these breath differences will be identified by TD-GC/MS. Individual breath 
VOC was reproducible in triplicates.
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processed plasma samples. A peptide banking system equipped with a local spectral 
library of synthetic peptides was used to facilitate automatic generation of LC-SRM 
methods. Multiplexed LC-SRM assays for >100 potential markers for NSCLC were 
generated to screen the plasma samples. Results: In the first set of screening for 190 
peptides, a total of 60 peptides corresponding to 44 proteins were detectable by LC-
SRM in the plasma. Among them, 17 proteins exhibited higher expression levels in the 
NSCLC patients compared to the control. For those proteins, additional peptides were 
prepared in order to increase the coverage of the protein sequence, and the number 
of samples were expanded (72 NSCLC and 30 controls). After differential analysis of 
the SRM results, 17 proteins were finally verified as potential diagnostic markers. The 
verified targets include ACTN1, ALDOA, ENO1, FLNA, G6PD, GPI, HSP90B1, ICAM1, ILK, 
LDHB, MSN, PGK1, PKM2, SPP1, TALDO1, THBS1, and ZYX. The expression levels were 
cross-validated by ELISAs if available. A novel plasma-based biomarker, ZYX, showed a 
potential of early diagnostics as its plasma level increases from the early stages (stages I 
and II). The overall pattern of the plasma levels of four ZYX peptides and the ELISA results 
were correlated. The role of ZYX in cancer has been recently discussed as a key player 
in epithelial-mesenchymal transition mechanism, and the association to lung cancer was 
reported in several studies. To the best of our knowledge, the potential use of ZYX protein 
as a tumor biomarker in plasma for lung cancer has been verified for the first time in this 
study. Conclusion: A targeted proteomics-based, analytical pipeline was designed for a 
large-scale biomarker verification and successfully applied to verifying a set of potential 
biomarkers for NSCLC. The robust workflow is critical to the early-stage screening where 
the attrition rate tends to be high (68% in this study). Several novel targets were verified 
as plasma-based NSCLC biomarkers, and ZYX showed a potential of early diagnostics. 
Keywords: biomarker, NSCLC, targeted proteomics, plasma
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P2.06-014 A Czech Page in the Lung Cancer Multiplicity Teodor Horvath1, 
Radek Vesely2, Jan Savolt2, Martin Sobotka2, Ilona Kocakova3, Ivo Kocak3, Stanislav 
Spelda3, Edvard Geryk4, Radim Stampach5, Petr Kubicek5, Helena Bartonkova3, Milan 
Prasek3, Drahomira Chasakova2, Sylva Rybnickova3, Ivo Capak3, Jan Dolezel3, Daniel 
Macik3, Richard Feranec3, Renata Kalabova3, Ilona Kantorova2, Barbora Garajova1, 
Tomas Racek2, Marie Horvathova6 1Faculty Hospital, Dept. of Surgery, Faculty of Medicine, 
Masaryk University, Brno/Czech Republic, 2Department of Traumatology at the Medical 
Faculty, Masaryk University, Trauma Hospital Brno, Brno/Czech Republic, 3Masaryk Memorial 
Cancer Institute, Brno/Czech Republic, 4Department of Preventive Medicine, Masaryk 
University, Brno/Czech Republic, 5Department of Geography, Masaryk University, Faculty of 
Science, Brno/Czech Republic, 6Early Diagnosis, Cbc Vznik S.R.O., Brno/Czech Republic
Background: There are estimated in the National Czech Cancer Registry since 1976 to 
2010 among 203, 858 cancers a total of 16 622 lung cancers (LCs) in males associated 
with other neoplasms, presented 10 % of 166 239 (81,5%) newly registered LCs in males. 
They were 4,395 (2.6 %) primary and 12,227 (7.4 %) subsequent LCs; A total of 5,322 LCs 
in females, presented 14.1 % of 37,619 (18,5%) newly registered LCs in females, of which 
were 1,022 (2.7 %) primary and 4,300 (11.4 %) subsequent LCs. Their representation at 
the early clinical stages decreased gradually from 53% to 22 %, at the advanced stages 
increased from 20 % to 64 %; One third of subsequent neoplasms in early stage and 
one fifth in advanced stage evaluated replenish 51,2% of unknown stage in men and 
47,4% in women. High proportion of LCs at unknown stages limited detailed analysis. 
Dichotomous question of early diagnosis is inquired. Methods: Miscellaneous group of 
548 individuals (260 females and 288 males) with high risk of lung cancer was formed 
predominantly from South Moravia region of the Czech Republic, EU. They were enrolled 
since 2001 to 2010. Approximately one third (n=185) from the group had undergone 
surgery due to cancer of head and neck, gastrointestinal, gynecological including breast, 
urological and skin location (n=86) and due to pulmonary malignancy (n=99) . The follow 
up scheme for this subgroup represents four time yearly careful clinical investigation with 
monitoring of appropriate TM levels during first three years, then three time in the year 
during fourth and fifth years, and two time yearly follow up investigation during sixth to 
tenth year in connection with yearly paraclinical set of CT of thorax and USG of abdominal 
spaces on even-numbered, and X-rays of thorax and CT of abdomen on odd-numbered 
years, two-year period bone scan, endoscopy, and yearly laboratory screening tests – 
serology, hematology, and basic urine investigation. Another parts of the risk group are 
represented by persons (n=203) with high risk of lung cancer (uranium miners with long 
term professional exposure to Rn222, heavy smokers minimally 20 yrs with 1 to 2 packs 
cigarettes per day (n=60), pts with hemoptysis (n=15) and persons with other kind of risk 
(n=85). These were screened one time yearly by clinical, laboratory, and bronchoscopy 
examination and imaging alternately yearly X rays / thoracic CT scan and abdominal USG. 
Classification of malignant tumours TNM-7 and Program Microsoft Excel® were used 
to data analysis. Results: Among 548 persons from the risk group followed during ten 
years period they were found in 29 individuals (5,3%) counting 11 females and 18 males a 
total of 40 lung cancers. They were 14 primaries and 26 subsequent LC with two cases of 
triplicity. The early diagnosis in the stage (I, II) was established 32-times (i.e. 4/5) versus 
8-times diagnosed advanced stage (III, IV) of disease (i.e. 1/5). Appropriate treatment 
was organized and follow up continues to evaluate survival. Conclusion: Early diagnosis 
in patients with lung cancer multiplicity seems attainable despite of certain limitation. 
Keywords: early diagnosis, lung cancer, Primary and Subsequent Neoplasms
using an extinction coefficient established by amino acid analysis. Results: Prototyping 
was performed on ARCHITECT® iSR2000. Numerous antibody formats were evaluated 
for key analytical performance prior to final pair selection and completion of extensive 
analytical performance testing. Limit of quantitation is </= 4 ng/mL. Specimen dilution 
analysis yielded linear results across the dynamic range of the assay (4-100 ng/mL). 
Five-day total precision results ranged from 3.4 to 6.4 %CV across 3 controls and 3 
serum based panels. No endogenous sample and drug interferences were observed. 
Drugs assessed for interference were selected as representatives from drug classes 
that are commonly used to treat asthma. Periostin in serum separator tubes (SST) was 
stable at room temperature or refrigerated for up to 24 hours. Serum samples are stable 
for up to 2 freeze/thaw cycles. Beyond 24 hours of collection, freezing (-10oC or colder) 
for long term storage is recommended. All known periostin isoforms expressed in the 
lung (2-4, 7, 8) are detected with the ARCHITECT® Periostin assay. Using this newly 
developed IUO assay, periostin levels were measured in over 1000 serum samples from 
patients with severe asthma. The periostin levels ranged from 5.2-73.3 ng/mL with a 
median level of 16.4 ng/mL. Conclusion: The IUO ARCHITECT® Periostin immunoassay 
is a robust and reliable test for the measurement of serum periostin. Periostin testing 
is in progress in Phase III trials for tralokinumab, an anti-IL-13 human IgG4 mAb. 
Keywords: periostin, Abbott ARCHITECT®, tralokinumab, companion diagnostic
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P2.06-012 A Model Incorporating Clinical, Radiographic, and Biomarker 
Characteristics Predicts Malignancy in Indeterminate Pulmonary Nodules 
Christopher W. Seder1, Maria D. Martin2, Palmi N. Shah3, Xuanji Wang4, Ravi Pithadia5, 
Sanjib Basu6, Cristina L. Fhied7, Gary W. Chmielewski1, William H. Warren1, Michael J. 
Liptay1, Jeffrey A. Borgia7 1Thoracic Surgery, Rush University Medical Center, Chicago/IL/
United States of America, 2Diagnostic Radiology, Rush University Medical Center, Chicago/
IL/United States of America, 3Diagnostic Radiology, Rush University Medical Center, 
Chicago/United States of America, 4Rush University Medical Center, Chicago/IL/United 
States of America, 5Pathology, Rush University Medical Center, Chicago/IL/United States of 
America, 6Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago/
United States of America, 7Pathology, Rush University Medical Center, Chicago/United States 
of America
Background: The high false-positive rate associated with low-dose computed 
tomography (CT) lung cancer screening results in unnecessary testing, cost, and 
patient anxiety. We hypothesized that an algorithm incorporating clinical, radiographic, 
and serum biomarker data would be capable of differentiating benign from malignant 
pulmonary nodules. Methods: An institutional biorepository was used to identify 84 
patients with ≤ 2 cm indeterminate pulmonary nodules identified on CT scan, including 50 
patients with biopsy-proven, node-negative, non-small cell lung cancer (NSCLC) and 34 
patients with benign, non-calcified, solitary pulmonary nodules. Clinical and radiographic 
data were collected from patient charts and imaging studies. Serum specimens were 
evaluated in a blinded manner for 55 biomarkers using multiplex immunoassays. Random 
forest analyses were used to generate a multivariate cross-validation prediction model 
incorporating clinical, radiographic, and serum biomarker data. Results: A total of 84 
patients were identified with a median nodule size of 5 mm for benign nodules and 15 mm 
for NSCLC. Median smoking histories were 21 and 28 pack-years and patient age was 62 
and 70 years, respectively. An algorithm incorporating serum biomarker profile (IGFBP-4, 
IGFBP-5, IL-10, IL-1ra, IL-6, SDF-1alpha, IGF-2), age, sex, BMI, COPD, smoking history, 
hemoptysis, previous cancer, nodule size, nodule location, spiculation, nodule type, 
and nodule count provided the optimal performance with a sensitivity 92%, specificity 
65%, NPV 85%, and PPV 79%. This model performed with an overall accuracy of 81% 
with a cross-validated AUC=0.904. Conclusion: An algorithm incorporating clinical, 
radiographic, and serum biomarker characteristics may help differentiate benign from 
malignant pulmonary nodules. This model is currently being externally validated in a 
second-site patient cohort.
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P2.06-013 Verification of the Biomarker Candidates for Non-Small-Cell Lung 
Cancer Using a Targeted Proteomics Approach Yeoun Jin Kim1, Katriina Sertamo1, 
Marie-Aline Pierrad1, Marc Schlesser2, Guy Berchem3, Bruno Domon1 1Luxembourg 
Clinical Proteomics Center, Luxembourg Institute of Health, Strassen/Luxembourg, 2Service 
de Pneumologie, Centre Hospitalier de Luxembourg, Luxembourg/Luxembourg, 3Service 
D’Hémato-Cancérologie, Centre Hospitalier de Luxembourg, Luxembourg/Luxembourg
Background: Lung cancer, with its high metastatic potential and high mortality rate, is 
the worldwide leading cause of cancer-related deaths. High-throughput “omics”-based 
platforms have accelerated the discovery of biomarkers for lung cancer, and the resulting 
candidates are to be evaluated for their diagnostic potential as non-invasive biomarkers. 
The evaluation of the biomarker candidates involves the quantitative measurement 
of large numbers of proteins in bodily fluids using advanced mass spectrometric 
techniques. In this study, a robust method based on targeted proteomics was developed 
for biomarker verification in plasma samples and applied to verifying lung cancer 
biomarker candidates. Methods: Sample acquisition: Blood samples were obtained 
from 72 patients diagnosed with non-small-cell lung cancer (NSCLC) (stages I-IV), and 
30 healthy volunteers with the approval of the National Research Ethics Committee. 
Sample processing and Liquid Chromatography-Selected Reaction Monitoring (LC-SRM): 
Two most-abundant plasma proteins were depleted from each sample. Proteins were 
digested by trypsin to generate peptide mixtures. Peptides representing the potential 
biomarker proteins were selected. Stable isotope-labeled (SIL) peptides of the selected 
target peptides were synthesized to be used as internal standards, and spiked-in the 
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of 520 cases were analyzed retrospectively who were referred to our clinic between 
January 2014-January 2015. Results: Through them, 6 (1.2%) patients (4 men, 2 women) 
with mass and/or nodule images in their chest radiographs, were histopathologicaly 
diagnosed with lung cancer. 3 of these cases were planned for inguinal herniorrhaphy, 
and other 3 cases for knee replacement surgery. The common points of these cases 
were being asymptomatic and included into ASA 1 - grade II group. The mean age of 
the patients was 71.1 (65- 87). Lung cancer diagnosis was proven by transthoracic 
needle biopsy in 3 cases, bronchoscopy in 1 case and thoracentesis + pleural biopsy 
in 1 case with pleural effusion. All of the cases are non-small cell lung cancer; 3 
adenocarcinoma and 3 squamous cell lung carcinoma. 4 cases were found to be in 
stage IIIB and over, while the other 2 patients who were underwent lobectomy were in 
stage IB. Chemoradiotherapy was performed to the inoperable cases. Conclusion: Pre-
operative tests conducted according to current ASA classification are still useful in 
terms of determining the possible complications and risks. However, in some cases, 
as in ours, examinations broader than recommended may be necessary. According to 
ASA classification; ASA group 1describes healthy person with no systemic problem 
accept for current surgical pathology, and grade 2 describes short timed operations 
(30 minutes - 1 hour) in which vital organs are affected minimum (inguinal herniorrhaphy, 
tonsillectomy, arthroscopy, cystoscopy, etc.). ASA recommends preoperatively 
complete blood count, serum electrolytes, blood glucose, blood urea nitrogen, creatinine 
tests for ASA group 1- grade II patients aged 61 years and older. Chest radiography 
is not routinely recommended in these patients with no obvious symptoms or signs. 
However, in our own clinical approach for pre-operative evaluation of patients aged over 
65 years, chest radiograph is a preferred test. Considering that 6 asymptomatic lung 
cancer patients were determined by this approach, the benefits of pre-operative chest 
radiograph which is a cheap, fast and easy examination are remarkable in pre-operative 
pulmonary evaluation. We presented this case series in order to emphasize this subject. 
Keywords: ASA, lung cancer, pre-operative, chest radiograph
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P2.06-018 Health Disparities Assessment in a Newly Established Lung Cancer 
Screening Program Mary Pasquinelli1, Kevin Kovitz1, Arkadiusz Z. Dudek2, Matthew 
Koshy1, Martha Menchaca1, Lawrence E. Feldman1 1The University of Illinois Hospital and 
Health Sciences System, Chicago/United States of America, 2Medicine, University of Illinois, 
Chicago/IL/United States of America
Background: Lung cancer incidence and mortality rates differ depending on race, 
ethnicity, and gender. African American (AA) men have significant higher incidence and 
mortality from lung cancer compared to white men (incidence 87.3 vs. 72.5; mortality 
70.1 vs. 57.8 per 100,000). Lung cancer screening is an effective lifesaving tool. The 
National Lung Screening Trial (NLST) showed a 20 percent reduction in lung cancer 
mortality with low-dose computerized tomography (LDCT) versus chest X-ray screening, 
but the study population was 91% white and only 4.5% AA. Could the reduction in lung 
cancer mortality be even greater if the NLST population included a larger minority 
population? UI Health has a large community outreach that serves minority populations in 
Chicago (48% AA, 24% classified as “other”, 16% White, 7% Hispanic). In March 2015, UI 
Health began a comprehensive lung cancer-screening program. Methods: The program 
coverage and eligibility is broadly advertised to patients and primary practitioners in 
our community. Previously, low cost lung cancer screening was available but coverage 
was a concern for patients and practitioners. Lung cancer screening eligibility criteria 
used is set by the CMS (age 55-77, current smoker or one that have quit within the past 
15 years, smoking history of > 30 pack-years) and the U.S. Preventive Services Task 
Force (including ages up to 80 for non-Medicare patient). American College of Radiology 
LungRADS system is used for standardized image reporting, and recommended 
management for positive screens. Data elements include age, gender, race/ethnicity, 
insurance type, LDCT findings, and treatment modalities for diagnosed lung cancer 
is collected in a secure registry. Results: In our first month, 13 patients have been 
screened between the ages of 56-76, 7 females/6 males. Race/ethnicity make-up: 54% 
AA, 31% White, 15% Hispanic. Estimated volume of LDCT screens is 200 per year. As 
yet, there are no significant findings requiring intervention. Of note, in the greater than 
2 years that screening was an option but coverage was not clarified by CMS, fewer 
than 10 patients participated, suggesting that lack of coverage by CMS or commercial 
carriers was a barrier for our patients. Conclusion: Coverage by CMS and commercial 
carriers for LDCT screening has a significant impact on our patient population. Analysis 
from this study will assess if we can reach a large underserved group with a screening 
program and whether it will result in decrease of lung cancer mortality in this population. 
Keywords: Screening Program, low-dose computerized tomography (LDCT), high-risk 
population, health disparities
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P2.06-019 Prognosis of Lung Cancer Patients Diagnosed with National Health 
Surveillance Chun Sung Byun1, Il Hwan Park1, Myoung Kyu Lee2, Won Yeon Lee2 
1Department of Thoracic and Cardiovascular Surgery, Yonsei University Wonju College of 
Medicine, Wonju/Korea, 2Department of Internal Medicine, Yonsei University Wonju College of 
Medicine, Wonju/Korea
Background: National health surveillance with chest X-ray is performing in our country 
every two years. The present study was performed to evaluate the differences in clinical 
characteristics and survival outcomes of patients with non-small cell lung cancer 
(NSCLC) according to detecting the disease by health surveillance with chest X-ray (CXR) 
or presenting symptoms (SX). Methods: We identified 294 patients (male/female ratio: 
226/68; mean age: 68.7 years old) in tertiary university hospital between Jan 2010 
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P2.06-015 Detecting Obstructive Lung Diseases with Aerosol Breath Test: A 
Non-Invasive Diagnostic Method Using Fractal Analysis and SVM Classification 
Jinxiang Xi1, Jiayao E. Yuan2, Xiuhua A. Si3 1School of Engineering and Technology, 
Central Michigan University, Mt Pleasant/MI/United States of America, 2School of 
Engineering and Technology, Central Michigan Univresity, Mt Pleasant/MI/United States of 
America, 3Mechanical Engineering, California Baptist University, Riverside/CA/United States 
of America
Background: Each lung structure has a unique pattern of exhaled aerosols 
(aerosol fingerprint), whose deviation from the normal pattern may indicate an anomaly 
inside the airway. Therefore, an exhaled aerosol test can be used to detect and monitor 
lung diseases non-invasively. The key challenge is accurately interpreting the exhaled 
aerosol fingerprints and quantitatively correlating them to lung diseases. Methods: In 
this study, a novel integrated algorithm was developed to evaluate the feasibility of the 
exhaled aerosol tests. This algorithm has four steps: data generation via physiology-
based modeling, image feature extraction using sub-regional fractal analysis, data 
classification using a support vector machine (SVM), and data quality assessment using 
principle component analysis. Results: By employing the 10-fold cross-validation method, 
we achieved 100% classification accuracy among four asthmatic models using an ideal 
108-sample dataset and 99.1% accuracy using a more realistic 324-sample dataset. The 
fractal-SVM classifier has been shown to be robust, highly sensitive to structural variations, 
and inherently suitable for investigating aerosol-disease correlations. Conclusion: For the 
first time, this study quantitatively links the exhaled aerosol patterns with their underlying 
diseases and sets the stage for the development of a computer-aided diagnostic system 
for non-invasive detection of obstructive respiratory diseases. The proposed aerosol 
breath test is especially suitable for the use of screening to detect lung tumors at early 
stages, and to monitor tumor growth or therapeutic outcome of medical interventions. 
Keywords: Obstructive respiratory diseases, aerosol breath test, computer-aided 
diagnostic system, lung tumor early detection
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P2.06-016 An Epidemiological Study on Detection of Chronic Obstructive 
Pulmonary Diseases and Lung Cancer by Regional Lung Cancer Mass 
Screening Takehiko Fujisawa1, Yasuo Sekine1, Ryoko Yanagibori1, Kiminori Suzuki1, 
Haruko Yamaji1, Atsuko Tokuda1, Sonomi Sugiyama2 1Respiratory Medicine, Chiba 
Foundation for Health Promotion and Disease Prevention, Chiba/Japan, 2Diagnostic 
Radiology, Chiba Foundation for Health Promotion and Disease Prevention, Chiba/Japan
Background: Lung cancer is a major cause of death in the world and chronic obstructive 
pulmonary disease(COPD) are at risk for lung cancer. Both the diseases have common 
etiologies, including cigarette smoking. We aimed to clarify the effectiveness of lung 
cancer screening by chest X-ray and by low-dose computed tomography（LDCT）among 
patients with COPD tested by pulmonary function test(PFT) by using regional lung 
cancer mass screening. Methods: A total of 7,067 residents including 2,720 males and 
4,347 females of Togane City, Chiba, Japan received lung cancer screening between 
May and July, 2011. All residents underwent chest X-ray and answered questionnaire, 
including smoking history , chronic respiratory symptoms and lifestyle-related disease 
for selecting COPD. We hypothesized that individuals with a positive smoking history 
with chronic respiratory symptoms or lifestyle-related disease considered COPD 
candidates and advised to undergo PFT. COPD candidates whose forced-expiratory 
volume in 1 second/ forced vital capacity less than 70 % were considered COPD who 
underwent LDCT. They were followed additional two years by high resolution CT for 
detecting lung cancer. Results: Chest X-ray showed normal in 6,749 and abnormal in 
318(4.5%). Among participants with normal chest x-ray, positive COPD candidates were 
1,686(23.9%) and negative COPD candidates were 5,381(76.1%), according to the 
questionnaire. 1,500 of 1,686 underwent PFT and diagnosed COPD in 171(2.4%). 
151(2.1%) of them received LDCT. Six of 318(1.9%) cases with abnormal chest X-ray 
were finally diagnosed lung cancer (86/100,000). One case at initial time and three 
cases during follow-up periods were diagnosed lung cancer by LDCT in COPD patients 
(0.88 % per year). Conclusion: Chest X-ray and LDCT for COPD patients may be 
effective for lung cancer surveillance in community-based lung cancer screening. 
Keywords: lung cancer,COPD, screening, LDCT
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P2.06-017 Incidental Detection of Lung Cancer by Pre-Operative Evaluation, 
a Series of 6 Cases Deniz Dogan1, Nesrin Ocal1, Gurhan Taskin2, Ergun Ucar1 1Chest 
Diseases, Gulhane Military Medical Faculty, Ankara/Turkey, 2Intensive Care Unit, Gulhane 
Military Medical Faculty, Ankara/Turkey
Background: American Society of Anesthesiologists (ASA) classification is an useful pre-
operative evaluation system which helps clinicians in prediction of possible complications 
and risks due to surgery. In ASA classification, surgical candidates are divided into six 
groups according to their risk status. Following ASA classification, grading is done 
according to the severity of the operation. Grades are determined due to the severity 
and the duration of the operation. After determining ASA classes and grades, necessary 
tests are performed according to age groups to complete the pre-operative assessment. 
However, in this evaluation, randomly determined pathologies can dramatically change 
the assessment results in those cases without any symptoms. For this purpose, we 
retrospectively analyzed the results of the patients received pre-operative pulmonary 
evaluation during the last one year. Methods: Pre-operative pulmonary evaluation results 
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P2.06-020 Comparison of Cytological Diagnosis Between Solitary and Semi-
Solitary Lung Nodules in Biopsy Samples: Experience from a Single Academic 
Center Gary Gong1, Haiyan Wang1, Russell Hales1, Derek B. Allison2, Susan Geddes2, 
Edward Gabrielson3, Frederic Askin2, Qing Kay K. Li2 1Radiology, Johns Hopkins Medical 
Institutions, Baltimore/United States of America, 2Pathology, Johns Hopkins Medical 
Institutions, Baltimore/MD/United States of America, 3Pathology, Johns Hopkins Medical 
Institutions, Baltimore/United States of America
Background: The recent large scale National Lung Cancer Screening Trial in the 
United States (NLST) demonstrated an increased detection of stage I lung cancers. 
This approach was associated with a 20% reduction of lung cancer-related deaths in 
the screening population. However, the current clinical guideline for the management 
of lung nodule is primarily based on studies of non-calcified solitary pulmonary nodules 
(SPN). Although several recent studies have addressed the issue of the management 
of semi-solitary and/or partially calcified lung nodules, the evidence-based study is still 
necessary. Clinically, the diagnosis of small pulmonary nodules involves the combination 
of radiological surveillance and the morphological examination of pulmonary cells, 
such as bronchoscopic sampling of the lesion, including bronchial brushing and/or 
transbronchial fine needle aspiration biopsy (TBNA) with or without ultrasound guidance. 
In this study, we correlated cytomorphological diagnoses of lung nodules with radiological 
characteristics, and compared them with findings of mediastinal lymph nodes (LN) fine 
needle aspiration (FNA) biopsy. Methods: A total of 300 lung and mediastinal LN cases 
over a one-year period were identified by a computer search, including 117 lung and 
183 lymph nodes biopsies. All cases were divided into three categories: solitary, semi-
solitary and partially calcified nodules/lesions according to radiographic image. The 
cytological diagnoses of all cases were correlated with radiographic findings. Results: In 
lung biopsies, the average sizes of the solitary, semi-solitary and calcified lesions were 
1.952+/-2.225, 1.333+/-1.827, and 1.152+/-1.984 cm, whereas, in lymph nodes the 
average sizes of the solitary, semi-solitary and calcified lesions were 1.696+/-2.225, 
0.909+/-1.041, and 2.788+/-3.371 cm. The cytological diagnosis was summarized in 
the table.
Lesions Lung (n=117)
Lymph 
node 
(n=183)
Malig-
nant Benign
Suspi-
cious
Malig-
nant Benign
Suspi-
cious
Solitary (lung 
n=88) (LN 
n=156)
58 
(65.9%)
23 
(26.1%)
7  
8.0%)
136 
(87.2%)
20 
(12.8%) 0
Semi-soli-
tary (Lung 
n=23) (LN 
n=23)
8 
(34.8%)
12 
(52.2%)
3  
(13.4%)
21 
(91.3%)
2 
(8.7%) 0
Calcified (Lung 
n=6) (LN n=4)
2 
(33.3%)
3 
(50%)
1 
(16.7%)
4 
(100%) 0 0
Total 68 (58.1%)
38 
(32.5%)
11 
(9.4%)
161 
(88%)
22 
(12%) 0
 
Conclusion: In suspicious solitary and semi-solitary lung nodules, the malignancy was 
diagnosed as 65.9% and 34.8%, respectively. In suspicious solitary and semi-solitary 
lymph nodes, the malignancy was diagnosed as 87.2% and 91.3%, respectively. In lung 
lesions with partial calcifications (we only had very limited number of cases), approximately 
50% were malignant lesions. In addition to radiological evaluation, the cytomorphological 
evaluation of semi-solitary and partially calcified nodules is still crucial for the 
accurate diagnosis and the appropriate clinical management of lung nodules patients. 
Keywords: cytological diagnosis, Lung nodule FNA, semi-solid lung nodule, partial 
calcified lung nodule
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P2.06-021 Analysis of Autofluorescence Bronchoscopy Used for 
Characterisation and Identification of Bronchopulmonary Cancer 
Xiaoxuan Zheng1, Baohui Han2, Hongkai Xiong3, Yong Li3, Jiayuan Sun1 1Department 
of Endoscopy, Shanghai Jiaotong Univ. Affiliated Shanghai Chest Hospital, Shanghai/
China, 2Department of Pulmonary Medicine, Shanghai Jiaotong Univ. Affiliated Shanghai 
Chest Hospital, Shanghai/China, 3Department of Electronic Engineering, Shanghaijiaotong 
University, Shanghai/China
Background: The aim of the study is to introduce a more effective quantitative 
method(optimal identification index and reference value) for characterizing the AFB 
images within the region of interest and to explore the value of AFB in diagnosis 
of different types of lung cancer. Methods: Patients with one or more preinvasive 
bronchial lesions were entolled, followed-up by white light bronchoscope(WLB) and 
AFB. A quantitative analysis based on color space(red-to-green value, R/G value) 
was conducted and the result was compared with the final diagnosis obtained by the 
pathology of biopsy and/or by surgical pathology. Results: A retrospective analysis 
was conducted on 218 cases with 1,208 biopsies. 173 cases were diagnosed as 
positive by WLB associated with AFB, which included 151 true positive cases and 22 
and Dec 2012. The patients were divided into two categories according to method of 
detection. The clinical characteristics and treatment outcomes were estimated according 
to CXR group and SX group. Results: CXR group was 102 patients and SX group was 
192 patients. There were significant shift to early TNM stage distribution, cancer cell 
type, initial treatment modality and type of surgery in the CXR group compared with 
SX group (table 1). Median survival times were 35.2 months (95% confidence interval 
(CI): 24.1–46.3) in CXR group, and 14.2 months (95% CI: 12.1–16.3) in SX group. There 
were statistically significant differences in overall survival between CXR and SX groups 
(P=0.001) (figure1).
 
Conclusion: Lung cancer screening by national health surveillance with 
chest X-ray contributed to better clinical outcome in patients with NSCLC. 
Keywords: lung cancer, Screening, symptom, survival
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P2.06-023 A Complete Thoracic Navigation System to Allow for Nodal and 
Parenchymal Molecular Assessment in NSCLC: A Prospective Human Study 
Lonny Yarmus1, David Feller-Kopman1, Jason Akulian2, Hans Lee3 1Johns Hopkins 
University, Baltimore/United States of America, 2University of North Carolina, Chapel Hill/
NC/United States of America, 3Johns Hopkins University, Baltimore/MD/United States of 
America
Background: Peripheral pulmonary nodules (PPN) remain a diagnostic challenge 
for physicians. Minimally invasive biopsy methods for molecular analysis include 
endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), navigational 
bronchoscopy (NB) and transthoracic needle aspiration under computer tomography 
(CT) guidance. Recently, a combined thoracic navigation system (TNS) allowing for NB 
and electromagnetic navigational trans-thoracic needle aspiration (N-TTNA) has become 
available allowing for all necessary procedures to obtain diagnostic and molecular 
analysis for NSCLC to be performed during a single procedural session. Methods: This 
study was a prospective single arm study examining the success in obtaining molecular 
tissue in NSCLC cases from the lymph nodes and/or PPN using a novel combined 
diagnostic approach with TNS (EBUS, NB and N-TTNA) in a single procedural setting. 
Consecutive patients who consented with a PPN undergoing bronchoscopy were 
enrolled. All patients underwent convex EBUS for full lymph node staging followed by 
NB and N-TTNA. All non-diagnostic biopsies were followed with radiographic interval 
imaging revealing a decrease in size or resolution or a surgical biopsy was performed. 
The primary outcome was successful acquisition and testing of tissue for molecular 
analysis. Results: Twenty-four subjects with PPN were enrolled in this study (9 male and 
15 female) with a median age of 70 years (range 52-85). An EBUS with NB and/or N-TTNA 
was completed in 24/24 (100%) of the patients. In this cohort, there were seven cases 
of Adenocarcinoma in which adequate tissue for molecular analysis was obtained in all 
(100%) of the cases. PPN diagnostic tissue that was adequate for molecular testing was 
achieved in six out of seven patients (85%). Four patients had evidence of nodal disease 
on EBUS and all four (100%) nodal samples were adequate for molecular analysis. When 
a complete TNS is performed combining convex EBUS with the combined TNS procedure 
for complete staging, the overall diagnostic yield was 92%. No bleeding or hemoptysis 
events were encountered during the study. There were two (8%) subjects required 
small bore pigtail catheter placement secondary to pneumothorax. Conclusion: This 
is the first human study demonstrating the sampling adequacy for both nodal and 
parenchymal tissue sampling for NSCLC molecular analysis in a single procedural 
setting. Multicentered prospective studies are needed to confirm the utility of these 
findings in an era of expanding need for tissue acquisition in a minimally invasive setting. 
Keywords: molecular testing, bronchoscopy, TTNA
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P2.06-024 Study on the Clinical Application of CT-Guided Percutaneous Lung 
Biopsy Peng Zhang, Feng Long, Youzhi Zhang, Haihua Yang Department of Respiratory 
Medicine, Huashan Hospital North, Fudan University, Shanghai/China
Background: To research the clinical value and complications of CT-guided 
percutaneous lung biopsy Methods: 116 patients with pulmonary lesion were applied 
percutaneous lung biopsy, using the BRAND 18 G automatic puncturing pistol, under 
64-slice spiral CT guiding. Results: 114 patients succeed to get the biopsy of lung,2 
cases failed due to sever pneumothorax,the achievement rate was 98.3%. Among them, 
95 were diagnosed as malignant,91 cases being lung cancer (including 18 squamous 
cell carcinoma, 54 adenocarcinoma,2 small cell lung carcinoma,3 large cell lung 
carcinoma, and 4 are unclassified).The others contained 2 pleural mesothelioma,2 non-
Hodgkin lymphoma,19 non-cancerous lesions (all of these cases,9 with tuberculosis,5 
with organized pneumonia,2 with sarcoidosis, 2 with Vasculitis, 2 with inflammatory 
pseudo tumor).There were 26 patients presenting side effects or complications, the 
total incidence was 22.4%. Among these, 18 patients had pneumothorax (2 serious, 
ending puncture), 11 patients had lung bleeding, 2 patients with both pneumothorax 
and lung bleeding, 8 patients also had chest pain, nausea or other discomfort 
reactions. Conclusion: CTguided percutaneous lung biopsy has the advantages 
of security and accuracy ,was important method to identify pulmonary lesion. 
Keywords: Lung biopsy, CT-guided
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P2.06-025 New PET/CT Criterion for Nodal Staging in Lung Cancer: Area of 
SUV ≥ 2.5 / Lymph Node Area Kazuhiro Imai, Yoshitaro Saito, Hajime Saito, Satoru 
Motoyama, Yusuke Sato, Hayato Konno, Satoshi Kudo, Shinogu Takashima, Maiko Atari, 
Yoshihiro Minamiya Thoracic Surgery, Akita University Graduate School of Medicine, Akita/
Japan
Background: Surgical resection is the accepted standard of care for patients with non-
small cell lung cancer (NSCLC) at an early stage, patients have a favorable prognosis. 
Unfortunately, however, only about 25% of NSCLC patients are eligible for surgery, and 
once the surgical candidates are selected, mediastinal staging is mandatory because 
up to 50% of these patients have regional metastasis. Accurate nodal staging is crucial 
for determining optimal treatment strategies and optimizing prognoses. The aim of the 
present study was to use surgical and histological results to develop a simple noninvasive 
technique for improving nodal staging using routine preoperative PET/CT in patients 
presenting with localized and clinically resectable NSCLC. Methods: The institutional 
review board approved this retrospective study, and written informed consent to perform 
false positive cases. There were 45 cases in 151 true postive cases which included 
13 false negative cases and 32 true negative cases. WLB associated with AFB was 
able to differentiate between benign and malignant lesion lymph nodes with a high 
sensitivity, specificity, positive predictive value and negative predictive value(92.1%, 
59.3%, 87.3% and 71.1%, respectively). The quantitative method of R/G value allowed 
an more excellent discrimination and yielded a high sensitivity and specificity(82.3% 
and 80.5%), based on a cut-off level of 1.485. Conclusion: AFB associated with 
WLB is a promising method which allows characterisation and differentiation of 
benign and malignant lesions with a high sensitivity, specificity based on R/G value. 
Keywords: medical image processing, autofluorescence bronchoscopy, white light 
bronchoscopy, lung cancer
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P2.06-022 Multiple Primary Malignancies - A Retrospective Analysis 
Anna Romaszko1, Paweł Szpruch1, Joanna Luks1, Emilia Świetlik2, Barbara 
Poszewiecka3, Anna Doboszyńska3 1Student Science Club for Cardiopulmonary 
Diseases and Rare Respiratory Diseases, University of Warmia and Mazury, Olsztyn/
Poland, 2Pulmonary Vascular Disease Unit Gb, Papworth Hospital NHS Foundation Trust, 
Cambridge/United Kingdom, 3Department of Pulmonology, University of Warmia and Mazury, 
Olsztyn/Poland
Background: With the increase in survival of cancer patients over the past three decades, 
both as a result of improved treatments and earlier diagnosis, the likelihood of developing 
a second cancer has increased. The aim of our study was to assess the frequency of 
multiple malignancies in patients hospitalised at the Centre for Pulmonary Diseases in 
Olsztyn, Poland. Methods: We performed a retrospective review of medical records of 
1112 patients hospitalised at our Centre between January 2013 and September 2014. 
We selected cases with at least two malignancies. We recorded the number and locations 
of the tumours in the patients and their relatives, risk factors and co-morbidities. The 
inclusion criteria were met by 56 patients (18 women and 38 men). Results: Among 
the patients with multiple primary neoplasms we identified 52 cases where at least 
one of the primary cancers was lung cancer and 4 cases where none of the primary 
cancers was lung cancer. The mean age at diagnosis of the first and the second cancer 
was 62,16 (SD 12,04) years an 67,20 (SD 9,68) years, respectively. The mean interval 
between the diagnosis of the first and the second cancer was 3,84 (SD 13,03) years. We 
identified 4 cases of triple primaries and 1 case of quadruple primaries. Regarding the 
sequence of diagnosis, lung cancer was the first malignancy in 11 cases (1 - non-small-
cell carcinoma, 4 - adenocarcinoma and 5 - squamous cell carcinoma, 1 - undiagnosed), 
the second malignancy in 39 cases (4 - non-small-cell carcinoma, 12 - adenocarcinoma, 
10 - squamous cell carcinoma, 7 - small-cell carcinoma and 6 - undiagnosed) and the 
third malignancy in 2 cases (1 - squamous cell carcinoma, 1- undiagnosed). The other 
malignancies diagnosed as the first ones and the second ones were:
First Second
Prostate cancer 6 4
Breast cancer 5 2
Vocal cord cancer 1 1
Renal cel carcinoma 4 1
Uterine cancer 4 0
Colorectal cancer 8 0
Skin cancer 3 0
Bladder cancer 2 3
Adrenal cancer 2 1
Lymphoma 1 3
Laryngeal cancer 3 0
Gastric cancer 1 1
Brain cancer 2 0
Tongue cancer 1 0
Salivary gland cancer 1 0
Ovarian cancer 1 0
Thyroid cancer 0 1
 
We identified the following co-morbidities: hypertension (28), COPD (17), coronary artery 
disease (8), atrial fibrillation (6), myocardial infarction (3) type 2 diabetes mellitus (4), 
thyroid diseases (4), chronic renal failure (2), peripheral artery disease (1), stroke (1) and 
connective tissue disease (1). Conclusion: · Lung cancer occur more frequently as the 
second malignancy. · Patients with multiple neoplasms make up 5,04% of all patients with 
lung cancer and the number seems to increase. · Generally synchronous neoplasms occur 
later (medium age; 67,31; SD 11,64), while metachronous neoplasms occur earlier (medium 
age of the first cancer: 60,12; SD 11,55 and the second one 67,17; SD 9,15), p=0,0014. 
Keywords: frequency, multiple neoplasms, retrospective analysis
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articles. Eligible studies should study any of the new techniques with histopathology as a 
golden standard, and should have suffi cient data to construct 2×2 contingency tables. 
We used random-effects bivariate models to pool sensitivity, specifi city, diagnostic odds 
ratio (DOR) and the area under the receiver operating curve (AUC) with 95% confi dence 
interval. Results:Fifty-three studies involving a total of 6543 patients and 18458 biopsy 
specimens were included. Single arm synthesis of the new techniques showed that the 
overall sensitivity of AFB, AFB+WLB, NBI and WLB was 87% (82%-90%), 88% (82%-93%), 
96% (78%-99%) and 54% (46%-61%); overall specifi city was 65% (58%-72%), 59% (48%-
68%), 84% (70%-92%) and 79% (73%-84%); and AUC was 85% (81%-87%), 82% (78%-
85%), 94% (91%-96%) and 72% (68%-76%) respectively. In direct comparison, AFB, 
AFB+WLB and NBI had higher overall sensitivity, DOR and AUC, but lower specifi city than 
WLB alone, regardless of precancerous or cancerous lesions (see in Table 1). In 
exploratory subgroup analysis, the sensitivities of all techniques were relatively higher in 
studies with higher proportion of elder patients, or in those with higher proportion of ‘high 
risk’ patients who had prior/suspected lung cancer or head & neck cancer.
 
Conclusion: Based on this pooled analysis, the performance of AFB, 
AFB+WLB or NBI is superior to WLB alone for diagnosing both lung 
precancerous and cancerous lesions. Its application might be preferably 
encouraged in populations with higher risk for non-benign lesions. 
Keywords: autofl uorescence bronchoscopy combine with white light bronchoscopy, 
autofl uorescence bronchoscopy, Lung cancerous and precancerous lesions, narrow-
band imaging bronchoscopy
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P2.06-027 Pleural Fluid Reactive Oxygen Species Modulator 1 (Romo1) as 
a Diagnostic and Prognostic Marker in Lung Cancer Patients with Malignant 
Effusion Seung Hyeun Lee1, Eun Joo Lee2, Kyung Hoon Min2, Gyu Young Hur2, Seung 
Heon Lee2, Sung Yong Lee2, Je Hyeong Kim2, Sang Yeub Lee2, Chol Shin2, Jae Jeong 
Shim2, Kyung Ho Kang2, Kwang Ho In2 1Department of Internal Medicine, Kepco Medical 
Center, Seoul/Korea, 2Division of Respiratory and Critical Care Medicine, Department of 
Internal Medicine, College of Medicine, Korea University, Seoul/Korea
Background: Reactive oxygen species modulator 1 (Romo1) is a novel protein that is 
critical in mitochondrial reactive oxygen species (ROS) generation. It is increased in most 
cancer cell lines and is associated with resistance to chemotherapy in vitro. Recently, 
serum Romo1 has been suggested as a potential diagnostic marker for non-small cell 
lung cancer (NSCLC), and increased tissue Romo1 protein expression has been related 
with poor prognosis in patients following surgical resection for NSCLC. The clinical 
signifi cance of pleural fl uid Romo1 is unknown. We evaluated the clinical usefulness of 
pleural fl uid Romo1 as a potential diagnostic and prognostic marker in patients with lung 
cancer-associated malignant effusion. Methods: Romo1 level was measured in pleural 
fl uid using enzyme-linked immunosorbent assay in four groups: lung cancer-associated 
malignant effusion (n =24; 15 adenocarcinomas, 7 squamous cell carcinomas and 2 
small cell lung cancers), tuberculous pleurisy (n = 14), parapneumonic effusion (n =15) 
and transudative effusion (n = 16). The discriminative power in lung cancer-associated 
malignant effusion and the association with survival of Romo1 was determined using 
receiver operating characteristic (ROC) curve and Kaplan-Meier survival analysis, 
respectively. Results: Pleural fl uid Romo1 level was signifi cantly higher in lung cancer-
associated malignant effusion compared with other groups (all p < 0.001). In the ROC 
curve analysis, the optimal cutoff value for lung cancer-associated malignant effusion was 
451.5 pg/mL with a sensitivity of 81.9% and specifi city of 84.8%, with an area under the 
curve of 0.838 (95% confi dence interval: 0.789 - 0892, p < 0.01). In addition, at the cutoff 
determined by median Romo1 level, high Romo1 expression was related with reduced 
overall survival in patients with NSCLC (p = 0.03). For all patients, pleural fl uid Romo1 
level was not related with age, gender, smoking status, tumor differentiation, histological 
type, glucose, protein, albumin and lactate dehydrogenase level. Conclusion: Romo1 
discriminated lung cancer-associated malignant effusion from non-malignant effusions 
with considerable sensitivity and specifi city. Also, high Romo1 level was associated with 
poor prognosis in lung cancer patients. Pleural fl uid Romo1 could be a potential diagnostic 
and prognostic marker in patients with lung cancer-associated malignant effusion. 
Keywords: pleural effusion, biomarker, reactive oxygen species, non-small cell lung 
cancer
the initial and follow-up CT studies was obtained from all patients. Preoperative PET/
CT fi ndings (n=163 patients with resectable NSCLC) and pathological diagnoses after 
surgical resection were evaluated. Using PET/CT images, lymph node surface area (SA), 
the maximum standardized uptake value (SUVmax), SA of SUV ≥2.5 (Figure) and ≥3.0 were 
drawn freehand and measured using caliper software. Receiver operating characteristic 
(ROC) curves were then used to analyze those data.
 
Results: Based on ROC analyses, the cut-off values for SA of SUV ≥2.5, SA of SUV ≥3.0, 
SUV ≥2.5 SA / node SA ratio and SUV ≥3.0 SA / node SA ratio for diagnosis of lymph node 
metastasis were 200 mm2, 30 mm2, 1.0 and 0.4. When the conventional SUVmax ≥2.5 
was used for diagnosis, the sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), accuracy of nodal staging were 61.1%, 62.2%, 28.9%, 
86.4%, 62.0% , respectively. SUV ≥2.5 SA / node SA ≥1.0 had the highest negative 
predictive value, and when a cut-off value of SUV ≥2.5 SA / node SA ≥1.0 was used for 
diagnosis, the sensitivity, specificity, PPV, NPV and accuracy were 61.1%, 73.4%, 36.7%, 
88.2% and 70.9%, respectively. Conclusion: When diagnosing nodal staging based a 
lymph node SUV ≥2.5 SA / node SA ratio of ≥1.0, we achieved a higher performance 
level than was achieved using the conventional of SUVmax criterion. Furthermore, 
determination of this ratio from PET/CT images is a simple noninvasive procedure. 
Keywords: lymph node, metastasis, PET CT, lung cancer
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P2.06-026 Advanced Bronchoscopies for Diagnosing Precancerous or 
Cancerous Lesions: A Meta-Analysis Jianrong Zhang1, Jieyu Wu2, Yujing Yang3, Hua 
Liao4, Long Jiang1, Zhiheng Xu5, Ziyan Liang6, Jun Huang7, Huishan Wei8, Xiaoru Deng9, 
Gongle Zhong10, Minzhang Guo1, Xuewei Chen1, Yi Zhang11, Qihua He1, Shengyi Zhong1, 
Liqi Yang12, Miao Chen12, Minyi Yang13, Yonghong Chen11, Jingyi Chen1, Xusen Zou1, Ying 
Chen1, Wenhua Liang1, Jianxing He1 1Department of Thoracic Surgery, The First Affi liated 
Hospital of Guangzhou Medical University, Guangzhou/China, 2Department of Pathology, The 
First Affi liated Hospital of Guangzhou Medical University, Guangzhou/China, 3Department 
of Clinical Laboratory, Guangdong General Hospital, Guangzhou/China, 4Department of 
Cadre Health Care, The First Affi liated Hospital of Guangdong Pharmaceutical University, 
Guangzhou/China, 5Department of Cadre Health Care, The First Affi liated Hospital of 
Guangzhou Medical University, Guangzhou/China, 6Department of Neonatology, The Third 
Affi liated Hospital of Guangzhou Medical University, Guangzhou/China, 7Medical Equipment 
Section, The Third Affi liated Hospital of Sun Yat-Sen University, Guangzhou/China, 8The 
Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese 
University of Hong Kong, Hong Kong/China, 9Library, Guangzhou Medical University, 
Guangzhou/China,10Department of Gynaecology, Dongguan Kanghua Hospital, Dongguan/
China, 11Guangzhou Medical University, Guangzhou/China, 12Department of Pulmonary 
Medicine, The First Affi liated Hospital of Guangzhou Medical University, Guangzhou/
China, 13Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou/
China
Background: Conventional white light bronchoscopy (WLB) has been used for decades. 
Some technical advances in bronchoscopies are available for detecting lung precancerous 
and cancerous lesions currently. Our aim was to investigate the performance of 
autofl uorescence bronchoscopy (AFB), AFB combined with white light bronchoscopy 
(AFB+WLB), narrow-band imaging bronchoscopy (NBI) and, additionally, to directly 
compare these new techniques with WLB alone. Methods:Pubmed, Embase, Web of 
Science, Ovid, ProQuest, Scopus and the Cochrane Library were searched for relevant 
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Conclusion: In patients with completely resected stage IIIA (N2) NSCLC, 
adenocarcinomas and multiple N2 stations were independent risk factors of 
BM as the initial failure in 3 years. Patients with the tumor budding >5 had a 
tendency to experience more BM. Patients with adenocarcinomas and multiple 
N2 stations are at the highest risk of BM, and are most likely to benefit from PCI. 
Keywords: stage IIIA(N2), NSCLC, risk factor, brain metastases
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P2.07-001 CK2α Is Highly Expressed and Could Represent a Suitable 
Therapeutic Target in Small Cell Lung Cancer Zhilong Zhao1, Hongsheng Xue1, Haili 
Qian2 1Thoracic Department, Zhongshan Hospital, Dalian University, Dalian/China, 2State 
Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of 
Medical Sciences, Beijing/China
Background: Protein kinase CK2 has long been associated with increased cell growth 
and proliferation in both normal and malignant cells. CK2α (a catalytic subunit) is highly 
expressed and pivotal for survival and proliferation in multiple malignancies; however, 
whether CK2α functions in small cell lung cancer (SCLC) malignant behavior and whether 
it is feasible to be used as a therapeutic target have not been evaluated. Methods: The 
expression levels of CK2α were analyzed in SCLC tissue microarray and cell line 
(NCI-H446) by immunohistochemistry and immunofluorescence. After knocking down 
the CK 2α level by specific siRNA sequence, biological consequences on proliferation, 
migration, invasion and apoptosis were evaluated. Results: CK2α was detected in 
66.7% of cases with a trend towards a stronger CK2α immunostain in SCLC tissues 
compared to normal lung tissues. CK2α silencing had potent suppressive effects 
on SCLC proliferation, migration and invasion, resulted in abrogation of tumor-cell 
pseudopod formation, however, did not lead to cell arrest and apoptosis. Western-blot 
analysis confirmed elevated PML/Bcl-2 protein levels as well as reduced E-Cadherin 
protein level in the CK2α-silenced SCLC cells.
Patient Characteristics No. of Cases %
Gender (F/M) 9/31 22.5/77.5
Stage
Ⅰ 10 25
Ⅱ 21 52.5
Ⅲ 9 22.5
Tumor
T1/T2 36 90
T3/T4 4 10
N0 12 30
N1/N2 28 70
Normal Lung Tissue 10  
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P2.06-028 Accumulation of 18F-FDG Might Predict the Survival of Early-Stage 
Lung Cancer Patients Masashi Yanada, Katsuhiko Nishiyama, Hiroshi Okazaki General 
Thoracic Surgery, Japanese Red Cross Kyoto Daini Hospital, Kyoto/Japan
Background: In recent years, the outcome of surgically treated early lung cancer 
patients have improved steadily. However postoperative recurrence following early 
stage lung cancer surgery can occur: 10-20% possibility of recurrence presents within 5 
years after the initial operation. Numerous reports of various malignancies have revealed 
that 18-Fluoro-2-deoxy-D-glucose (18F-FDG) accumulation, evaluated by positron 
emission tomography, can be used to predict the prognosis of patients. Our purpose 
in this retrospective study was to determine if the maximum standardized uptake value 
(SUVmax) of a primary tumor predicts survival for patients of surgically treated early 
lung cancer. Methods: A total of 170 patients (99 males and 71 females) with curatively 
operated early lung cancer (p-stage I/II) were enrolled in this study between April 2010 
and February 2015 at Japanese Red Cross Kyoto Daini Hospital. Lobectomy 160 cases, 
segmentectomy 20 cases, and wedge resection 4 cases. The FDG uptake of all primary 
lung tumor lesions diagnosed by conventional CT was evaluated by 18F-FDG PET/CT. 
The relation between SUVmax and patient survival was analyzed retrospectively. The 
postoperative survival rate was analyzed by Kaplan-Meier method, and the differences in 
survival rates were assessed by log-rank test. A probability value of <0.05 was considered 
significant. The optimal cut-off value of SUVmax for postoperative recurrences was 
determined using a receiver operating characteristic (ROC) curve. Results: The SUVmax 
of 170 patients ranged between 0 and 23.7. The median SUVmax was 3.5 for all cases, 
3.5 for stage IA, 7.2 for stage IB, 8.2 for stage IIA, and 12.8 for stage IIB (P<0.01). Tumor 
recurrence occurred in 26 cases (15.3%). According to a survey by the ROC curve, the 
optimal cut-off value of SUVmax for postoperative recurrences was set at 3.75 with 81% 
sensitivity, 63% specificity. The survival between patients with SUVmax cut-off value 3.75 
or more and patients with SUVmax less than 3.75 were statistically different. The 5-year 
survival for patients with SUVmax more than 3.75 was 76.6% and the 5-year survival for 
patients with SUVmax less than 3.75 was 90.6% (P=0.0196). However, the number of 
patients and the follow-up period were still not extensive enough to settle this important 
problem conclusively. Conclusion: The survival of patients with surgically treated early 
lung cancer might be predicted by evaluating their SUVmax using 18F-FDG -PET/CT. 
Among early lung cancer patients, there are potentially advanced lung cancer. The present 
findings suggested that SUVmax of more than 3.75 in lung cancer patients is predictive 
of a higher likelihood of recurrence. We recommended close clinical follow-up of the early 
lung cancer patients with SUVmax more than 3.75 for early diagnosis of recurrence. 
Keywords: early lung cancer, 18F-FDG -PET/CT, maximum standardized uptake value
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P2.06-029 Risk Factors of Brain Metastases in Completely Resected Stage 
IIIA(N2) Non-Small Cell Lung Cancer Qin Zhang Radiation Oncology, Hanghai Chest 
Hospital, Shanghai Jiao Tong University, Shanghai/China
Background: As the first failure, the rate of distant failure was much higher than local 
failure in patients with completely resected stage IIIA(N2) NSCLC . Brain was the most 
common site of distant failure as the first failure, and more than 90% Brain metastases 
(BM) developed in 3 years.We aimed to identify the risk factors of BM as the initial site of 
failure in 3 years and to define the highest-risk patients who are most likely to benefit from 
prophylactic cranial irradiation (PCI). Methods: The medical records of 301 consecutive 
patients with pathological stage IIIA (N2) NSCLC who underwent complete surgery were 
reviewed between January 2005 and July 2012. We observed the correlation between 
clinical, pathological, microenvironmental factors and BM to find out the risk factors of 
BM. Main outcome measure was BM as the first site of failure in 3 years. The cumulative 
incidence of BM as the first site of failure were determined using the Kaplan–Meier 
analyiss. To assess the risk factors of BM as the first site of failure in 3 years, the log-
rank test was used for univariate analysis, and Cox regression was used for multivariate 
analysis. Results: The 1-, 2-, and 3-year risks for patients developing BM as the initial 
site of failure were 9.3%，17.7% and 25.8%, respectively. Univariate analysis showed 
that adenocarcinomas (P = 0.000), multiple N2 stations (P = 0.025), multiple regions 
of mediastinal lymph node (MLN) involvement (P = 0.023), and highest MLN metastasis 
(P=0.023) were significantly associated with an increased risk of developing BM as the 
first site of failure in 3 years. Patients with the tumor budding >5 experienced increased 
BM in 3 years versus patients with the tumor budding ≤5 (P=0.068) Multivariate analysis 
showed that adenocarcinomas and multiple N2 stations were significantly associated with 
the high risk of BM as the initial site of failure in 3 years. In patients with adenocarcinomas 
and multiple N2 stations, the 3-year actuarial risk of BM as the initial failure was 43.5%.
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P2.07-003 Attempt to Validate Drug Repositioning for Metastatic Small Cell 
Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit 
Zoltan Lohinai1, Peter Dome2, Zsuzsa Szilagyi1, Gyula Ostoros3, Judit Moldvay1, Balazs 
Hegedus4, Balazs Dome1, Glen J. Weiss5 1Department of Tumor Biology, National Koranyi 
Institute of Pulmonology, Budapest/Hungary, 2Department of Clinical and Theoretical Mental 
Health, Kútvölgyi Clinical Center,, Semelweis University, Budapest/Hungary, 38Th Dept. of 
Pulmonology, National Koranyi Institute of Pulmonology, Budapest/Hungary, 4Translational 
Thoracic Oncology Laboratory, Department of Thoracic Surgery, Comprehensive Cancer 
Center, Medical University Vienna, Vienna/Austria, 5Medical Oncology, Cancer Treatment 
Centers of America, Goodyear/AZ/United States of America
Background: SCLC is an aggressive malignancy with limited treatment options. Based on 
in vitro data and results of a recent drug repositioning study, some medications approved 
by the FDA for the treatment of various non-malignant disorders were demonstrated to 
have anti-SCLC activity in preclinical models. Drug dose levels that demonstrated anti-
cancer activity were similar to those used in the clinics. The aim of our study is to confirm 
whether use of these medications is associated with survival benefit in a large cohort of 
SCLC patients from a single institution. Methods: Consecutive patients with cytologically 
or histologically confirmed, metastatic SCLC evaluated between 2000-2013 at the 
National Koranyi Institute of Pulmonology were analyzed in this retrospective analysis. 
Patients that were prescribed statins, aspirin, clomipramine (a tricyclic antidepressant 
[TCA]), selective serotonin re-uptake inhibitors (SSRIs), doxazosin, and prazosin were 
identified. Next, we evaluated the associations amongst these various medications, 
clinicopathological characteristics (including gender, age, and Eastern Cooperative 
Oncology Group performance status [ECOG PS]), and overall survival (OS) in univariate 
and multivariate analyses with Bonferroni correction applied. Results: There were a 
total of 876 patients (508 men and 368 women) with a median age of 61 years (range, 
33-86). 75% of the chemotherapy administered in the first line setting was platinum-
based. Aspirin, statin, SSRIs, doxazosin, prazosin, and TCA were administered in 138, 
72, 20, 14, 14, and 5 cases; respectively. Univariate analysis identified age, ECOG PS, 
and statin treatment as significant prognostic factors (p<0.001; p<0.001; and p=0.002; 
respectively). A statistically significant increase in OS was observed only in statin-treated 
patients when compared to those not receiving any of the aforementioned medications 
(median OS, 8.4 vs. 6.1 months; respectively). The administration of SSRIs, TCA, aspirin, 
prazosin, or doxazosin did not result in a statistically significant OS benefit (median OS, 
8.5, 7.2, 6.8, 6.8, and 4.6 months; respectively). The multivariate Cox model showed that 
besides age and ECOG PS, statin treatment was an independent survival predictor (Hazard 
Ratio, 1.41; 95% confidence interval, 1.1–1.8; p=0.007). Conclusion: Statins appear 
to provide a statistically significant survival benefit in metastatic SCLC. Other classes 
of medications analyzed in this study did not validate the preclinical drug repositioning 
studies previously reported. Drug repositioning studies using only preclinical data or 
small numbers of patients should be treated with caution before application in the clinic. 
Keywords: small cell lung cancer, Drug repositioning, statins
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P2.07-004 The Relationship between UGT1A1 Gene Polymorphism and 
Irinotecan Effect on ED-SCLC Xiao Xiaoguang, Xia Shu, Mei Qi, Yuan Chen 
Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of 
Science and Technology, Wuhan/China
Background: NCCN recommends IP program as a first-line chemotherapy of ED-SCLC.
Several clinical study conducted in colorectal cancer showed that the polymorphism of 
UGT1A1*28 gene can evaluate the risk of severe neutropenia and diarrhea occurred in 
patients receiving irinotecan chemotherapy. The purpose of this research is to analyze 
the distribution of UGT1A1 gene polymorphisms in Chinese Han patients with ED-
SCLC，and to evaluate correlations between UGT1A1 gene polymorphisms and toxicity 
and efficacy of irinotecan in patients with ED-SCLC. Methods: Analysis of UGT1A1*28 
and UGT1A1*6 gene polymorphisms were performed by peripheral blood gene 
sequencing. From June 2011 to Nov 2013, 67 cases admitted to hospital with ED-SCLC 
treated by irinotecan(CPT-11) based regimen were enrolled in this study. We observe the 
relationship of PFS , OS and AEs between different genotypes.
Conclusion: The results suggest that CK2α negative regulation of the 
protein levels of tumor suppressor PML/Bcl-2 and activation of the E-Cadherin 
pathway could be involved in SCLC malignant behavior. Depleting CK2α 
level may serve as a promising therapeutic strategy for human SCLC. 
Keywords: Protein Kinase, CK2α, Small cell, Lung cancer
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P2.07-002 Effects of Eribulin and Radiation on a Panel of Small Cell Lung 
Cancer (SCLC) Cell Lines Barbara Helfrich1, David Raben2, Dexiang Gao3, Paul 
A. Bunn, Jr4 1Medicine, University of Colorado Denver-Amc, Aurora/United States of 
America, 2Radiation Oncology, University of Colorado Denver-Amc, Aurora/United States of 
America, 3Biostatistics & Informatics, University of Colorado, Aurora/CO/United States of 
America, 4Medicine, University of Colorado, Aurora/United States of America
Background: Background: Chemotherapy produces high response rates in extensive 
stage SCLC and a modest improvement in 5-year survival rates when combined with 
chest radiation in limited stage SCLC. Chemotherapeutic agents for SCLC have not 
changed in 20 years. Eribulin is a microtubule inhibitor that arrests cells in the G2/M 
fraction of the cell cycle with established activity in breast cancer. Radiobiological 
studies demonstrated that cells in the G2/M phase of the cell cycle are less efficient at 
repairing radiation induced DNA damage. Thus, we investigated the effects of eribulin, 
radiation and the combination on growth and cell cycle distribution in a panel of SCLC 
cell lines. Methods: Methods: Growth inhibition (GI) by varying concentrations of eribulin 
alone, radiation alone and the combination was assessed by MTS assay at 5 days post-
treatment. Growth inhibition or fraction affected (FA) was determined by 1- (x/y) where x 
is the MTS signal for the experimental condition and y is the MTS signal for the untreated 
control cells. Our goal was to use a dose of radiation that alone induced a FA of about 
0.5 allowing determination of the combination effects with eribulin. Changes in the G2/M 
distribution of cells treated with eribulin alone, radiation alone and the combination 
were evaluated at 24 and 48 hours post treatment by propidium iodine staining and 
analysis by FACS. Results: Results: Four of the eight SCLC cell lines were very sensitive 
to eribulin with half maximal growth inhibitory concentration (FA<0.5) of < 2nM. Four 
lines had 0.5 FA values > 2nM. 2 Gy radiation produced 32% to 58% growth inhibition in 
all 8 lines irrespective of their eribulin sensitivity. Low eribulin concentrations (≤ 1.25nM) 
and 2Gy radiation produced >70% growth inhibition in the 4 sensitive lines, which was 
significantly more growth inhibition than either alone. Eribulin concentrations of >2.5nM 
were required to increase growth inhibition over either alone in the 4 more resistant lines 
and the maximal GI was less in these lines (48%-70%) even at higher concentrations. 
With respect to G2/M, in the 4 most sensitive eribulin lines, there was a significant 
increase in the G2/M fraction following eribulin alone (0.625-1.25nM), radiation alone (2 
or 3Gy) and a further increase occurred with the combination treatment. In these eribulin 
sensitive lines, 59% to 93% of the cells were in the G2/M phase by 48 hours. In 3 of the 
4 less sensitive eribulin lines, higher concentrations of eribulin (>2.5nM) were required to 
increase the G2/M fraction to >50% and 2 or 3 Gy irradiation increased the G2/M fraction 
to 59% to 64%. The combination produced maximal G2/M fractions of 64%-79%. The 
one most eribulin resistance line never had more than 50% GI or > 40% of cells in G2/M 
at any concentration or radiation dose up to 4 Gy. Conclusion: Conclusions: SCLC cell 
lines are sensitive to eribulin and radiation and the combination produced significantly 
more growth inhibition and cell cycle arrest then either alone. The combination warrants 
further evaluation in in vivo models and potentially clinical trial study in patients with SCLC. 
Keywords: SCLC eribulin radiation
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age 60 years, 19 pts received two or more previous lines of CT. Seven pts did not 
receive any CT leaving 51 pts assessable for the primary endpoint. Objective response 
rate was 19.6% (95% CI 8.7%-30.5%). Median PFS was 2.75 months (95% CI, 2.46 to 
3.61) and 6-months PFS was 6%. Median survival time was 5.9 months (95% CI, 4.7 
to 7.5) with 6 and 12-months survival rates of 50% and 6%. As expected, toxicity was 
mainly haematological with 88% and 26% grade 3-4 neutropenia and thrombopenia, 
respectively. Conclusion: Despite an interesting response rate, the addition of 
valproic acid to AVE did not translate into adequate PFS in relapsing/refractory SCLC 
to platinum/etoposide. This regimen cannot be recommended for further investigation. 
Keywords: small cell lung cancer, epigenetics, valproic acid
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P2.07-006 Study on Feasibility of Hippocampal Avoidance Prophylactic Cranial 
Irradiation Mao Zhang, Tao Sun, Mingwei Bu, Xiao Guo, Jin Zhang Departement of 
Radiation Oncology, Jilin Province Cancer Hospital, Changchun, Jilin/China
Background: To investigate the dosimetric characteristics, feasibility and risk of 
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI), in intensity-modulated 
radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT). Methods:Sixteen 
patients with limited-stage small-cell lung cancer (LS-SCLC) achieved complete remission 
after chemoradiotherapy accepted HA-PCI. After image evaluation by fusing CT and MRI, 
hippocampal avoidance regions were created in the hippocampus. A 5 mm area around 
the hippocampus was plotted as radiation dose deduction area. Patients were randomly 
assigned to accept intensity-modulated radiotherapy (IMRT) or volumetric modulated arc 
therapy (VMAT). The prescription dose was DT25Gy per 10 fractions.The dose distribution 
of whole brain, hippocampus and hippocampal plus 5mm were calculated. Results: The 
mean value of Hippocampal volume in the sixteen patients was 2.76 cm3(range 2.56cm3-
3.01cm3). Using IMRT and VMAT, the mean value of radiation dosein hippocampus was 
9.04Gy (range 8.92Gy-9.39Gy)and 10.32Gy (range 10.13Gy-10.82Gy), respectively, 
reduced by 66.03% and 61.17% compared with whole-brainirradiation.The mean dose 
in the avoidance regions for IMRT and VMAT was 13.57Gy (range 13.47Gy-13.67Gy),and 
14.86Gy (range 14.33Gy-15.89Gy), respectively, reduced by 49.00% and 44.29% 
compare with whole-brain radiation. Conclusion: HA-PCI in IMRT and VMAT is feasible 
in clinical practice and can achieve adequate whole brain coverage, as well as reduce 
exposure dose in hippocampus. HS-PCI can protect patient’s neurocognitive function. 
Keywords: Lung neoplasms, prophylactic cranial irradiation, hippocampal avoidance, 
radiotherapy technique
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P2.07-007 Prophylactic Cranial Irradiation for Extensive Stage Small Cell 
Lung Cancer Yu Yang Soon1, Huili Zheng2, Shaun Z. Ho3, Wee Yao Koh1, Su Woon 
Kim3, Cheng Nang Leong1, En Yun Loy2, Jeremy Tey1, Balamurugan Vellayappan1, Swee 
Peng Yap3, Kam Weng Fong3, Ivan Tham1 1National University Cancer Institute Singapore, 
Singapore/Singapore, 2Health Promotion Board, Singapore/Singapore, 3National Cancer 
Centre Singapore, Singapore/Singapore
Background: The survival benefit of prophylactic cranial irradiation (PCI) in extensive 
stage small-cell lung cancer (ES-SCLC) reported by an EORTC randomized trial in 2007 
has been questioned recently, as a Japanese study with similar trial design failed to show 
similar results. This retrospective cohort study aims to evaluate the uptake of PCI and its 
impact on the survival of ES-SCLC before and after publication of the EORTC randomized 
trial. Methods: All patients diagnosed with ES-SCLC without brain metastases and had 
stable disease or better after first line chemotherapy in the only two Singapore national 
cancer centers from 2003 to 2010 were identified using the institutions’ pathology 
registries. We linked the treatment records to the national death registry. We described 
the utilization of PCI and compared survival of patients diagnosed from 2003 to 2006 
(pre-adoption cohort) with patients diagnosed from 2007 to 2010 (post-adoption cohort). 
Characteristics between pre and post-adoption cohorts were analyzed using chi-square 
test. Survival was determined from date of diagnosis to death using Kaplan-Meier 
method. Predictors for improved survival were determined using multivariate analysis. 
Results: 71 patients were identified. The demographic and clinical characteristics were 
similar between the two cohorts save for more patients in the post-adoption cohort having 
second line therapy (49% versus (vs) 16%, P = 0.01) and receiving PCI (32% vs 10%, P 
= 0.04). There was no difference in overall survival between the two cohorts (Hazard 
ratio [HR] 0.70; 95% Confidence Interval [CI] 0.43 to 1.13, P = 0.148). Multivariate 
analysis showed that PCI (HR 0.47; 95% CI 0.24 to 0.91, P = 0.024) and thoracic 
radiotherapy (HR 0.49; 95% CI 0.28 to 0.86, P = 0.013) was associated with lower risk of 
death. Conclusion: There was an increase in the uptake of PCI for ES-SCLC since 2007. 
The use of PCI and thoracic radiotherapy has been shown to be predictors for improved 
survival in ES-SCLC who had stable disease or better after first line chemotherapy. A 
larger population based outcome study is warranted to confirm these observations. 
Keywords: prophylactic cranial irradiation, small cell lung cancer
Results:
 
figure 1 the PFS and different gene type 
 
figure 2 the OS and different gene type
The median PFS of wild type UGT1A1*28 (TA6/6) and mutant (TA6/7) was 9.9 months 
and 10 months respectively; the median PFS of wild type UGT1A1*6 (G/G) and 
UGT1A1*6 mutant (G/A) was 9.7 months and 9.9 months respectively. The median 
OS of wild type UGT1A1*28 (TA6/6) and mutant (TA6/7) was 13.9 months and 14.5 
months respectively; the median OS of wild type UGT1A1*6 (G/G) and UGT1A1*6 
mutant (G/A) was 13.8 months and 14.1 months respectively. No significant 
difference of PFS and OS was observed between different genotypes(p>0.05). 
The incidence of grade 3 and 4 delayed diarrhea and neutropenia in patients carrying 
UGT1A1*6 G/A was higher than that in the WT genotype(36.4% vs. 6.6% p<0.05; 
27.2% vs. 4.4% p<0.05 respectively); The patients simultaneously carrying UGT1A1*28 
TA6/7 and UGT1A1*6 G/A were prone to suffering 3 and 4 delayed diarrhea and 
neutropenia. Conclusion: Although UGT1A1 polymorphisms failed to predict the 
efficacy of CPT-11 in ED-SCLC, the prediction of adverse effect may worth attention. 
Keywords: gene polymorphism, irinotecan, adverse effect, small cell lung cancer
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P2.07-005 AVE plus Valproate for Refractory/Relapsing SCLC: A Phase II Study 
by the ELCWP Thierry Berghmans1, Jean-Jacques Lafitte2, Arnaud Scherpereel2, 
Marianne Paesmans3, Lieveke Ameye3, Anne-Pascale Meert1, Luc Willems4, Nathalie 
Leclercq1, Jean-Paul Sculier1 1Intensive Care and Thoracic Oncology, Institut Jules Bordet, 
Brussels/Belgium, 2Pneumology, CHU Lille, Lille/France, 3Data Centre, Institut Jules Bordet, 
Brussels/Belgium, 4Gembloux Agro-Bio Tech and Interdisciplinary Cluster for Applied 
Genoproteomics, University of Liège, Liège/Belgium
Background: Salvage chemotherapy (CT) for relapsing or refractory small cell lung 
cancer (SCLC) to platinum-etoposide remains disappointing. In vitro experiments are 
suggesting that valproic acid, by inhibiting histone deacetylases (HDAC), could increase 
apoptosis of SCLC cell lines exposed to doxorubicin, vindesine and bis(2-chloroethyl)
amine. The primary objective of this phase II study is to determine if epigenetic 
modulation with valproic acid in addition to a doxorubicin, vindesine, cyclophosphamide 
(AVE) regimen may allow adequate improved 6-months progression-free survival (PFS) 
in refractory/relapsing SCLC. Methods: Patients (pts) with previously pathologically 
proven SCLC, either primary or secondary refractory to prior chemotherapy regimen 
including platinum derivatives and etoposide, Karnofsky performance status ≥ 60, 
adequate haematological, hepatic, renal, lung and cardiac functions were eligible. After 
central registration, pts received AVE (doxorubicin 45 mg/m², vindesine 3 mg/m², 
cyclophosphamide 1 g/m² every 3 weeks) plus daily oral valproic acid to obtain serum 
concentration in the range of the recommended values for the treatment of epilepsy 
(50-100 µg/ml). Response was assessed after 3 courses and responders continued 
treatment until best response, unacceptable toxicity or cumulative dose of doxorubicin 
> 500 mg/m². The trial was designed to show that 6-months PFS was > 18%, powering 
the trial to detect an increase to at least 39%. With this assumption, at least 43 pts 
assessable for PFS had to be registered (a 10%, b 10%). Results: From 11/2008 to 
12/2013, 64 pts were registered of whom 6 were ineligible. The main characteristics of 
the 58 eligible pts were: male/female 38/20 pts, PS 60-70/80-100 17/41 pts, median 
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Conclusion: The efficacy of IP regimen was similar to EP regimen 
for untreated ES-SCLC. UGT1A1 polymorphisms was associated 
with late-onset diarrhea, however it has no influence on efficacy. 
Keywords: irinotecan, extensive-stage small cell lung cancer, etoposide, UGT1A1
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P2.07-010 Alisertib (MLN8237)+Paclitaxel versus Placebo+Paclitaxel for 
Relapsed SCLC Taofeek K. Owonikoko1, Tibor Csoszi2, Kristiaan Nackaerts3, Edgardo 
Santos4, Christina S. Baik5, Erzesbet Juhasz6, Vitezslav Kolek7, Gyula Ostoros8, Jaromir 
Roubec9, Hossein Borghaei10, Alberto Chiappori11, Christos Chouaid12, Margarita 
Majem13, E Jane Leonard14, Jungah Jung15, Claudio Dansky Ullmann14, David Spigel16 
1Hematology & Medical Oncology, Emory University School of Medicine, Atlanta/GA/
United States of America, 2Department of Oncology, Hetenyi G Korhaz, Onkologiai Kozpont, 
Szolnok/Hungary, 3Department of Respiratory Diseases, Respiratory Oncology Unit, Ku 
Leuven-University of Leuven, University Hospitals Leuven, Leuven/Belgium, 4Department 
of Oncology, Lynn Cancer Institute/Florida Atlantic University, Boca Raton/FL/United 
States of America, 5Division of Medical Oncology, Thoracic, Head, and Neck Program, 
University of Washington, Seattle Cancer Care Alliance, Seattle/WA/United States of 
America, 6Orszagos Koranyi Tbc Es Pulmonologiai Intezet, Budapest/Hungary, 7Department 
of Klinika Plicnich Nemoci A Tuberkulozy, Fakultni Nemocnice Olomouc, Olomouc/Czech 
Republic, 8Viii. Tudobelosztaly, Orszagos Koranyi Tbc Es Pulmonologiai Intezet, Budapest/
Hungary, 9Klinika Plicních Nemocí A Tbc, Fakultní Nemocnice Ostrava-Poruba, Ostrava/Czech 
Republic, 10Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia/PA/
United States of America, 11Department of Thoracic Oncology, H. Lee Moffitt Cancer Center 
and Research Institute, Inc, Tampa/FL/United States of America,12Service de Pneumologie, 
Centre Hospitalier Intercommunal de Créteil, Créteil/France, 13Department of Oncology, 
Hospital de La Santa Creu I Sant Pau, Barcelona/Spain, 14Oncology Clinical Research, 
Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical 
Company Limited, Cambridge/MA/United States of America, 15Statistics, Millennium 
Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company 
Limited, Cambridge/MA/United States of America, 16Sarah Cannon Research Institute/
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P2.07-008 CTC 11-001: PhI Study of Carfilzomib (C) + Irinotecan (I) in 
Relapsed, Irinotecan Sensitive Solid Tumors Susanne M. Arnold1, Kari Chansky2, 
Markos Leggas3, Michael Thompson4, John Hamm5, Rachel E. Sanborn6, Glen J. Weiss7, 
Kamal Chatta8, Maria Q. Baggstrom9 1Medical Oncology, University of Kentucky, Lexington/
KY/United States of America, 2Biostatistics, Cancer Research and Biostatistics, Seattle/
United States of America, 3College of Pharmacy, University of Kentucky, Lexington/KY/
United States of America, 4Cancer Center, Aurora Research Institute, Wauwatosa/WI/United 
States of America, 5Medical Oncology, Norton Cancer Institute, Louisville/KY/United States 
of America, 6Medical Oncology, Providence Portland Medical Center, Portland/OR/United 
States of America, 7Medical Oncology, Cancer Treatment Centers of America, Goodyear/AZ/
United States of America, 8Medical Oncology, Virginia Mason Cancer Institute, Seattle/WA/
United States of America, 9Division of Oncology, Washington University School of Medicine, 
St. Louis/MO/United States of America
Background: Inactivation of proteasome function allows for increased apoptosis and the 
potential for enhanced antitumor effect by chemotherapy. Carfilzomib (C) and Irinotecan (I) 
potentially synergize by increasing camptothecin-induced apoptosis and interfering with 
topoisomerase-I degradation, preventing DNA damage repair. This report describes the 
initial phase I study of C + I in adults with relapsed, irinotecan-sensitive cancers including 
small cell lung cancer (SCLC). Methods: The primary endpoint was determination of the 
MTD of 28-day cycle 1 of I (D1,8,15) and C (D1,2,8,9,15,16) using a standard 3+3 Ph1 
design. Toxicity and response were evaluated using NCI CTCAE (v4) and RECIST (v1.1). 
Pharmacodynamics endpoints (proteasome activity, topo-1 expression, and gamma-
H2AX protein expression in PBMC) were assessed on C1D1 and C1D2. Results: 16 
patients were enrolled at 3 dose levels of C (mg/m2/d) using stepped-up dosing: 20 mg 
given C1D1 & C1D2 then increased to the dose indicated: 20/27 (N=4), 20/36 (N=9), 
20/45 (N=3) and I dosed at 125 mg/m2d. Median age: 64 (range 56-78), 8 M/8F. Tumor 
types included: SCLC (N=13), non-small cell lung cancer (NSCLC) (N=2) and ovarian 
(N=1). 6 subjects completed 2 or more cycles of therapy, 4 subjects were not evaluable 
for dose-limiting toxicity (DLT) secondary to rapid progressive disease (PD) or withdrawal 
and were replaced. 2 DLTs were observed in cohort 3, Grade (Gr)4 thrombocytopenia 
lasting ≥ 7 days and Gr3 diarrhea lasting ≥ 7 days) and 1 DLT in cohort 2 (Gr3 diarrhea 
lasting > 7 days). Serious adverse events (SAEs) by dose level: 20/27: Gr3 Dysphagia and 
recurrent laryngeal nerve palsy, (unrelated); Gr3 peripheral motor neuropathy and Gr3 
urinary incontinence, (unrelated); 20/36: Gr3 fatigue, multiple occurrences; Gr3 diarrhea 
with dehydration; Gr3 cholelithiasis with dehydration (unrelated); 20/45: Gr3 dehydration, 
Gr3 anemia, Gr2 anemia and Gr3 acute on chronic kidney disease. Common Gr3/4 AEs 
were: fatigue (19%), thrombocytopenia (19%), diarrhea (13%), anemia (6%), neutropenia 
(6%), and leukopenia (6%). One patient (25%), five patients (55%), and two patients (67%) 
experienced Gr3/4 AEs in cohorts 1, 2, and 3, respectively. The maximum tolerated 
dose was exceeded at 20/45. Antitumor activity (stable disease or better) was observed 
in 3 SCLC subjects to date, with updated follow-up to be reported. Conclusion: C and 
I is a well-tolerated combination with anti-tumor activity in heavily pretreated patients. 
The recommended phase 2 dose of Carfilzomib is 20/36 mg/m2/d in combination 
with Irinotecan 125 mg/m2/d. A phase 2 study in SCLC is ongoing through the Lung 
Cancer Research Team (LCRT). This study was supported by Onyx Pharmaceuticals, 
a subsidiary of Amgen Corporation. Clinical trial information: NCT01941316. 
Keywords: camptothecins, phase I clinical trial, pharmacokinetics
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P2.07-009 Cisplatin Combined with Irinotecan or Etoposide for Untreated 
Extensive-Stage Small Cell Lung Cancer Yuankai Shi1, Xingsheng Hu1, Yi Hu2, 
Xiaohong Han1, Xue Li3, Lin Lin1 1Department of Medical Oncology, Cancer Institute 
and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing/
China,2Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing/China, 3China-
Japan Friendship Hospital, China-Japan Friendship Hospital, Beijing/China
Background: This study aims to evaluate the efficacy and safety of irinotecan/cisplatin 
(IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and 
the distribution of UGT1A1. Simultaneously, the relationship between UGT1A1 genotypes 
and patient outcomes were assessed. Methods: Patients with untreated ES-SCLC were 
randomly assigned to receive either IP or EP, and blood specimens were collected 
to test the genotypes of UGT1A1*28 and UGT1A1*6. The association of efficacy and 
toxicity of IP regimen with UGT1A1 genotype was analyzed. Results: Of the 62 patients 
enrolled from three institutions, 30 patients were in the IP and 32 patients were in the EP 
arms, respectively. Disease control rates (DCR) with IP and EP were 83.3% and 71.9%, 
respectively (P=0.043). Median progression-free survival (PFS) for IP and EP were both 6 
months. Median overall survival (OS) for IP and EP was 18.1 and 15.8 months respectively, 
without significant difference. Grade 3-4 thrombocytopenia was more common with EP 
(18.8% versus 6.7%, P=0.035), while the incidence of diarrhea was higher with IP (70% 
versus 15.6%, P=0.008). The incidence of grade1-4 late-onset diarrhea of wild-type, 
heterozygous and homozygous UGT1A1*28 were 65.0%，85.7% and 66.7% respectively 
(P=0.037). UGT1A1*28 polymorphisms, Eastern Cooperative Oncology Group (ECOG) 
performance status, chemotherapy cycles were the essential factors affecting grade1-4 
late-onset diarrhea in a logistic regression analysis.
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patients experienced PD (41.38%), and 16 are still on study (55.17%); among 24 patients 
randomized to Arm B, 2 deaths occurred (8.33%), while 11 patients experienced PD 
(45.83%) and 11 are still on study (45.83%). In Arm A, no significant adverse events were 
reported. Conclusion: This study will determine whether maintenance with lanreotide 
could prolong PFS of patients with SCLC expressing SST receptors and responsive to 
upfront CHT or CHT/RT. Moreover, the final results of this study might establish if this 
treatment could result in an improved overall survival rate after two years. To date, 
lanreotide has demonstrated an excellent safety profile in all the treated patients. On behalf 
of FONICAP (Forza Operativa Nazionale Interdisciplinare contro il Cancro del Polmone) 
Keywords: SCLC, maintenance, SST analogue
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P2.07-012 Accelerated Hypofractionated Radiotherapy and Concurrent 
Etoposide / Cisplatin in Patients with Limited-Disease SCLC (LD-SCLC) 
Sherif Abdelwahab, Wesam Elghamry, Ali Azmy, Iman Fouad, Zeinab Elsayed Clinical 
Oncology, Ain Shams University, Cairo/Egypt
Background: The optimal TRT dose/fraction for LS-SCLC remains debatable, and due 
to increasing number of population in Egypt and number of patients as well, so reducing 
the duration of radiation therapy is favored. This study was conducted using etoposide 
and cisplatin (EP) concurrently with accelerated hypofractionated thoracic radiation 
therapy to evaluate the response and toxicity of this protocol in the treatment of patients 
with limited-disease small cell lung cancer (LD-SCLC). Methods: Thirty patients with 
previously untreated LD-SCLC were enrolled into this study between June 2012 and 
February 2015. All patients received etoposide 100 mg/m2 days 1 to 3 and cisplatin 25 
mg/m2 days 1 to 3 with start of accelerated hypofractionated thoracic radiation therapy 
on first day of the second cycle of chemotherapy of 55 Gy,2.5 Gy/ fraction over 30 days. 
Chemotherapy was given 4-6 cycles. Prophylactic cranial irradiation 25 Gy in 10 daily 
fractions was given for patient who achieved complete remission. Results: The median 
age was 61 years; 28 patients (93%) were men. ECOG PS was 0 in 6 (20%) patients , 1 
in 20 (67%) patients and 2 in 4(13%) patients. Five (17%) patients achieved a complete 
response (CR), 22 (73%) patients achieved a partial response (PR), while 2 patients (7%) 
had progressive disease (PD) and 1(3 %) patients achieved stable disease; therefore, the 
overall response rate was 90%. The median survival time was 26.4 months and 1- and 
2-year survival rates were 78% and 58.3%, respectively. The median progression-free 
survival (PFS) was 16.7 months, and 1- and 2-year PFS times were 60% and 41.4%, 
respectively. Among the hematologic toxicities neutropenia was the most prevalent 
toxicity and it was evident as grade 3-4 in 12 patients (40%). Grade 3-4 Asthenia was the 
most prevalent nonhematological toxicity, in 12 patients (40%); esophagitis occurred in 
7 patients (23%). No treatment-related deaths (due to sepsis or bleeding) were reported 
in the study. Conclusion: Using etoposide and cisplatin concurrently with accelerated 
hypofractionated thoracic radiation therapy for the treatment of patients with LD-SCLC 
showed an encouraging outcomes and acceptable toxicity and warrants further research. 
Keywords: LD-SCLC, Elderly, Accelerated Hypofractionated Radiotherapy
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P2.07-013 Medically Inoperable Early Stage Small Cell Lung Cancer: Patterns 
of Failure after SBRT Gregory M.M. Videtic1, Chandana Reddy2, Neil Woody2, 
Kevin Stephans2 1Radiation Oncology, Cleveland Clinic, Cleveland/OH/United States of 
America, 2Cleveland Clinic, Cleveland/United States of America
Background: To report on the patterns of failure for medically inoperable early stage 
small cell lung cancer (SCLC) when stereotactic body radiotherapy (SBRT) manages the 
primary lung tumor. Methods: We queried our institutional IRB-approved SBRT registry 
for the period 2004-2014 for any early stage SCLC patients with a minimum of 6 months 
follow up. All patients had biopsy proven disease and were deemed medically inoperable 
after multi-disciplinary review. Routine staging consisted of PET/CT and MRI brain scans 
only. The treatment model consisted of SBRT to the primary followed by adjuvant platinum-
based chemotherapy (CHT) and then prophylactic cranial irradiation (PCI). SBRT was 
delivered employing a stereotactic-specific LINAC with vacuum-bag based immobilization, 
and infrared-based X-ray positioning system+/- CBCT for image-guidance. Results: Of 
747 definitively treated cancers over 10 years , 16 (2%) were SCLCs meeting study 
criteria. Patient characteristics revealed: median KPS was 80 (range 50-90), median age 
was 69 years (range 45-87), 50% of patients were female, median BMI was 28.2 (range 
17.4-41.2). Tumor characteristics revealed: median tumor size was 3.25cm (range1.4-7.2 
), 4 (25%) tumors were “central” (per RTOG 0813 criteria), median PET-SUVmax was 10.3 
(range 2.8-21.1). Median time to SBRT from diagnosis was 2.1 months (range 0.6-6.7). 
SBRT schedules were: 60 Gy/3 fractions in 25%, 50 Gy/5 fractions in 68.75%, 30 Gy/1 
fraction in 6.25% of cases. Mean follow up was 15 months. Fifteen (94%) received at 
least 2 cycles CHT, of which 2 (12.5%) received CHT before SBRT. Nine patients (56%) 
received PCI and of the 7 (44%) that did not, 1 developed brain metastases prior, 1 
refused, and 5 died of non-cancer issues before PCI . There was no grade 3 or higher 
toxicity; rate of grade 2 or less toxicity was 12.5%. Seven patients (43.75%) were alive at 
analysis and of the 9 deaths, 2 (22%)were cancer, 5 were non-cancer (56%), 2 unknown 
cause(22%). Local control was 100% with 13 patients (81.25%) without any failure. 
Crude rates of failure were one (6.3%) distant and regional nodal and two (12.5%) distant. 
Median survival was 39 months. Three-year actuarial overall and progression-free 
survivals were 50.5% and 76%, respectively. Conclusion: SBRT for stage I medically 
inoperable SCLC yields excellent local control. The absence of regional nodal failure 
lends support to PET for mediastinal staging. The primary pattern of failure is distant. 
Keywords: small cell lung cancer, early stage, SBRT, patterns of failure
Tennessee Oncology, Nashville/TN/United States of America
Background: Small cell lung cancer (SCLC) is an aggressive malignant disease 
comprising approximately 14% of all lung cancers, with approximately 31,000 new 
diagnoses each year in the USA. SCLC has a very poor prognosis, particularly in patients 
presenting with extensive stage disease. Platinum-based combinations are standard 
first-line therapy for SCLC; however, relapse is almost universal (≥85%) and patients 
require further treatment in subsequent lines. Effective new targeted therapies are 
needed to improve the poor outcomes observed in SCLC. Alisertib is an investigational, 
orally available, selective inhibitor of Aurora A kinase. Alisertib has shown single-agent 
antitumor activity in preclinical in vivo models of SCLC and has demonstrated synergism 
with paclitaxel in this setting. Single-agent alisertib has demonstrated promising 
efficacy in patients with relapsed/refractory SCLC (Melichar B, et al. Lancet Oncol 
2015;16[4]:395–405). Further, phase 1 and 2 evaluation of alisertib+paclitaxel in 
patients with relapsed ovarian cancer and breast cancer has suggested the antitumor 
activity of this combination (Falchook G, et al. Int J Gynecol Cancer 2013;23[8] 
Suppl_1:abstract; Coleman R, et al. Ann Oncol 2014;25[Suppl_4]:abstract 876O). Here 
we describe the design and objectives of an ongoing phase 2, randomized, double-
blind, placebo-controlled study of alisertib+paclitaxel versus placebo+paclitaxel in 
patients with relapsed SCLC and previously treated with only one line of platinum-based 
therapy (NCT02038647). Methods: Approximately 166 adult patients with relapsed 
SCLC after standard first-line platinum-based therapy, measurable disease by RECIST 
v1.1, and Eastern Cooperative Oncology Group performance status 0 or 1 will be 
enrolled at approximately 80 sites in the USA and Europe. Patients will be randomized 
1:1 (stratified by type of relapse [sensitive vs resistant/refractory] and presence 
of brain metastases) to receive 28-day cycles of either alisertib 40 mg or matched 
placebo PO twice daily on days 1−3, 8−10, and 15−17, plus paclitaxel 60 or 80 mg/
m2 IV, respectively, on days 1, 8, and 15, until disease progression or unacceptable 
toxicity. The primary endpoint of the trial is progression-free survival (PFS). Assuming a 
hazard ratio of 0.6 for PFS, a total of 138 progression/death events will be required to 
provide 85% power (two-sided alpha=0.05). Secondary endpoints include: overall and 
complete response rates; disease control rate; duration of response; overall survival; 
safety (NCI-CTCAE v4.03); alisertib pharmacokinetics; and symptom-related endpoints 
(symptom score, time to symptom relief, time to symptom progression). Evaluation of 
candidate biomarkers in tumor tissue specimens and in circulating tumor cells (CTC)/
circulating tumor DNA, change from baseline in CTC numbers, and health-related quality 
of life (EORTC QLQ-C30/QLQ-LC13 instruments) are exploratory endpoints. As of 10 
April 2015, there are 60 sites open in 6 countries with 90 patients randomized. The 
study continues to enroll patients. Results: not applicable Conclusion: not applicable 
Keywords: small cell lung cancer, alisertib, paclitaxel, relapsed
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P2.07-011 Maintenance with Lanreotide in SCLC Patients, Expressing 
Somatostatine Receptors, after Response to First Line Therapy Antonio Santo1, 
Elisa Roca2, Francesca La Russa3, Francesco Grossi4, Carlo Genova5, Adolfo G. 
Favaretto6, Angela Sibau7, Alessandro Follador7, Alessandra Bearz8, Giampiero Romano9, 
Maximilian Papi10, Alberto Caprioli2, Annamaria Catino11, Domenico Galetta12 
1Givop (Gruppo Interdisciplinare Veronese Oncologia Polmonare), Azienda Ospedaliera 
Universitaria Integrata Di Verona, Verona/Italy, 2Pneumologia E Fisiopatologia Respiratoria, 
Azienda Ospedaliera Spedali Civili Di Brescia, Brescia/Italy,3Oncologia Do, Azienda 
Ospedaliera Universitaria Integrata Di Verona, Verona/Italy, 4Medical Oncology, Irccs Aou 
San Martino - Ist, Genova/Italy, 5Lung Cancer Unit, Irccs Aou San Martino - Ist, Genova/
Italy, 6Medical Oncology 2, Istituto Oncologico Veneto, Padova/Italy, 7Dipartimento Di 
Oncologia, Azienda Ospedaliera Universitaria Santa Maria Della Misericordia Di Udine, Udine/
Italy, 8Medical Oncology, CRO-IRCCS, Aviano/Italy, 9Oncologia Do, Presidio Ospedaliero Vito 
Fazzi, Lecce/Italy, 10Medical Oncology, Infermi Hospital, Rimini/Italy, 11Clinical Cancer Center 
“Giovanni Paolo Ii”,, Bari/Italy, 12Medical Oncology Unit, Clinical Cancer Center “Giovanni 
Paolo Ii”, Bari/Italy
Background: Small cell lung cancer (SCLC) is a rapidly progressive disease, 
characterized by rapid progression in spite of initial responsiveness to first-line 
chemotherapy. In this setting, an effective and safe maintenance therapy might result 
in improved disease control; to date, no maintenance strategy has been registered 
for SCLC yet. Since SCLC cells express a neuroendocrine phenotype, some tumors 
may express significant levels of somatostatin (SST) receptors; this feature might be 
exploited for new therapeutic approaches. The aim of our study is to investigate the 
activity of lanreotide, a SST analogue, as maintenance for patients with SCLC who have 
achieved a complete response (CR) or partial response (PR) to standard platinum-based 
chemotherapy (CHT) alone or combined with radiation therapy (RT) , in order to improve 
progression-free survival (PFS). Methods: In this prospective, open-label, multicenter, 
randomized phase III trial, patients with confirmed diagnosis of SCLC (limited or extended 
disease) expressing SST receptors (assessed by SST receptor scintigraphy) and with 
objective response (CR or PR) after CHT or CHT/RT are randomized (1:1) to one of the 
following arms: maintenance therapy/consolidation with 120 mg lanreotide, by deep 
subcutaneous injection, every 28 days up to progressive disease (PD) or one year 
(Arm A); or observation (Arm B). The patients were re-assessed every two months until 
documented PD during the first year after randomization, and then every three months. 
The planned enrollment period is 24 months, followed by a period of maintenance of 12 
months and further 6 months for the completion of follow-up; the planned global period 
of the study is 3 years and a half. Results: This study is still ongoing; therefore, it is not 
possible to show its final results yet. However, relevant preliminary data can be described. 
Currently, out of 76 expected patients, 53 were enrolled; of these, 11 patients (37.96%) 
in Arm A had limited disease and 18 (62.06%) extended disease. In Arm B, 11 patients 
had limited disease (45.83%) and 13 (54.17%) had extended disease. After one year of 
follow-up, among 29 patients randomized to Arm A, 1 patient died (3.45%), while 12 
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Conclusion: In this study the locoregional control and overall survival was not signifi cantly 
better in the bi-daily regimen with 45 Gy/30 F compared to once-daily treatment with 45 
Gy/25 F. This was unexpected, because the two groups differed signifi cantly in PS, PCI and 
age in favour of the bi-daily regimen. But the size sample was small and follow-up time short. 
Keywords: SCLC, defi nitive radiotherapy, pattern of failure
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P2.07-016 Prognostic Impact of Bone Metastases in Small Cell Lung 
Carcinoma Konstantinos Syrigos, Dimitris Vassos, Paraskevi Boura, Sotirios 
Tsimpoukis, Alexandra Kopitopoulou, Andriani Charpidou, Ioannis Gkiozos
University of Athens, Athens/Greece Background: Metastatic bone disease is associated 
with increased morbidity as it may cause disabling pain and lead to other skeletal-
related events (SREs), such as pathologic fractures, spinal cord compression or 
hypercalcemia of malignancy, with signifi cant consequences on quality of life and 
overall functioning of patients, potentially affecting survival as well. The aim of the 
present study was to further explore the potential impact of bone metastases (BMs) 
and their therapeutic management on the overall prognosis of patients with small cell 
lung carcinoma (SCLC). Methods: A retrospective analysis of medical records of 363 
patients with SCLC was performed. Clinicopathological features and survival data were 
correlated with the presence of BMs, their time point of development (early versus late 
onset) and their treatment modality (radiotherapy, bisphosphonates or both), in the 
entire study population and in the subgroups of patients with limited or extensive-stage 
disease (LD or ED-SCLC, respectively) at diagnosis. Results: Overall, 35.8% of our 
patients were diagnosed with BMs, either at diagnosis (early onset BMs, 26.7%) or at a 
subsequent time point (late onset BMs, 9.1%). Patients with early onset BMs had a 
worse survival time compared to those with late-onset BMs or those without BMs (log 
rank test, p=0.020; fi gure 1). No statistically signifi cant associations were observed 
between OS and the presence of BMs in the ED and LD subgroups of patients (p=0.926 
and p=0.144, respectively). Treatment modality of BMs had no impact on OS either 
(p>0.05). Multiple Cox regression analysis showed that increased age, poor 
performance status, presence of BMs and early onset BMs were independently 
associated with reduced OS. 
 
Conclusion: The presence of early-onset BMs may represent an independent prognostic 
factor in patients with SCLC. In contrast, the type of modality employed for treatment 
of BMs had no statistically signifi cant impact on survival in our study population. 
Keywords: bone metastases, overall survival, Prognosis, small cell lung carcinoma
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P2.07-014 Does Prophylactic Cranial Irradiation Improve Overall Survival of 
Elderly Patients with Limited-Stage Small Cell Lung Cancer? Ritsuko U. Komaki, 
Xiong Wei, Pamela K. Allen, Emma B. Holliday, Ahsan Farooqi, Steven H. Lin, James W. 
Welsh, James D. Cox Radiation Oncology, MD Anderson Cancer Center, Houston/TX/United 
States of America
Background: Prophylactic cranial irradiation (PCI) has led to improved overall survival 
(OS) for patients with small cell lung cancer (SCLC) that has responded completely to 
chemotherapy and thoracic radiotherapy. However, whether PCI is indicated for elderly 
patients remains unclear. Methods: We reviewed 658 patients with limited-stage SCLC 
treated in 1986-2009 at a single institution with defi nitive concurrent chemoradiation to 
a total radiation dose of 45-70 Gy. Variables investigated for possible association with 
OS included patient sex, age, ethnicity, Karnofsky performance status (KPS) score, year 
of diagnosis and treatment period (1986-1999 vs. 2000-2009), tumor size, radiation 
dose, cycles of induction chemotherapy, use of intensity-modulated-radiation-therapy 
(IMRT), and fractionation. Groups were compared with chi-square tests for categorical 
variables or medians tests for continuous variables. Kaplan-Meier estimates were 
constructed for overall survival (OS), disease-free survival (DFS), local-recurrence-free 
survival (LRFS), distant metastasis-free survival (DMFS). Results: Among 658 patients, 
507 patients were <70 years old (Group A) and 151 patients were ≥70 years old (Group 
B). Median survival time was signifi cantly longer in the younger group (25.6 months vs. 
20.3 months, P=0.007), but no differences were found in DFS, LRFS, or DMFS time by 
age. Of the 151 patients aged ≥70 years (54 of whom received PCI and 89 did not), 
those treated in 2000-2009 (vs. 1986-1999) had better brain MFS than those treated in 
1986-1999 (P=0.048); those who received PCI had better brain MFS than those who did 
not (P=0.033). Multivariate analysis showed that among patients aged ≥70, receiving 
PCI, not receiving induction chemotherapy, and local-regional control were associated 
with fewer brain metastases (for PCI, subdistribution hazard ratio [SHR]=0.40, 95% 
confi dence interval [CI] 0.17-0.95, P=0.037; for induction chemotherapy, SHR=0.43, 
95% CI=0.19-0.96, P=0.039; and for local-regional failure, SHR=0.996, 95% CI=0.993-
0.998, P=0.001). Among patients ≥70, receipt of PCI seemed to have been associated with 
better OS for those with small-volume disease (primary+nodal disease <5 cm, P=0.0545) 
but not for those with larger-volume disease (P=0.7387). Conclusion: Patients aged 
≥70 years with small-volume limited-stage SCLC seemed to show a benefi t in OS from 
the use of PCI, but those with larger-volume disease did not. Improved brain MFS was 
associated with use of PCI, no induction chemotherapy, and locoregional control. 
Keywords: prophylactic cranial irradiation, Elderly patients, Limited-stage small cell lung 
cancer
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P2.07-015 Pattern of Failure after Defi nitive Radiotherapy for Small Cell Lung 
Cancer Siri S. Rasmussen1, Olfred Hansen2, Karin H. Hansen2, Tine Schytte3
1Department of Oncology, Odense University Hospital, Odense/Denmark, 2Department 
of Clinical Oncology, Odense University Hospital, Odense C/Denmark, 3Department of 
Oncology, Odense University Hospital, Odense C/Denmark
Background: The standard of care for limited disease SCLC is chemo-radiotherapy. 
The recommended radiotherapy schedule is 45 Gy/30 F bi-daily (BD-RT) for patients in 
good performance status according to various guidelines. However, a large proportion 
of these patients are not able to fulfi ll the bi-daily schedule due to frailty. For these 
patients 45 Gy/25 F, once-daily (OD-RT) has been the standard of care at our institution. 
The aim of this study was to investigate the pattern of failure and survival after chemo-
radiotherapy with the 2 different radiotherapy schedules. Methods: Records of 106 
patients with limited disease SCLC treated from 2007 to 2013 with defi nitive chemo-
radiotherapy in our institution were reviewed. The chemotherapy regimen was a platinum 
doublet with etoposide. The radiotherapy schedule for 69 patients was treatment OD-RT 
(45 Gy/25 F), whereas 37 patients were treated BD-RT (45 Gy/30 F). Log rank tests 
were used to compare overall survival (OS) and local failure free survival (LFS) between 
the groups. Results: In the OD-RT 23 patients (33%) were either alive or dead without 
evidence of recurrence, and 15 patients (41%) in the BD-RT. In the OD-RT 21 patients 
(30%) had locoregional recurrence only, 12 patients (17%) had locoregional and distant 
relapse, and 13 patients (19%) had distant metastasis only. In the BD-RT 8 patients 
(22%) had locoregional recurrence only, 8 patients (22%) had locoregional and distant 
failure, and 6 patients (16%) had distant relapse only. Statistically signifi cant (p<0,05) 
differences in patient characteristics between the two groups were observed: fraction 
of Performance Status 0-1 93% vs 67%, fraction treated with PCI 78% vs 54% and mean 
age of 62 vs 67 years for the groups BD-RT and OD-RT respectively. No differences 
were observed in S-sodium, LDH or gender. The mean follow-up was 24 months. Median 
overall survival was 18 months in OD-RT and 24 months in BD-RT, and 2 year OS was 
45% vs 43% respectively (p=0.23). Median local-failure free survival was 13 months in 
OD-RT vs 33 months in BD-RT, and 2 year LFS was 57% vs 40% respectively (p=0.19) 
Local failure free survival:
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(MPM) will receive P/C and are randomized 1:1 to receive weekly amatuximab, 5 mg/
kg or saline placebo IV in this global study. The primary endpoint of the study is to 
demonstrate whether amatuximab in combination with P/C has superior OS compared 
with P/C in subjects with MPM. The secondary endpoints are to compare amatuximab 
versus placebo with regard to PFS, ORR, duration of response, health-related QOL 
(LCSS-Meso), and the safety of amatuximab when administered with P/C. Clinical 
trial information: NCT02357147. Results: Not applicable Conclusion: Not applicable 
Keywords: Maligant Pleural Mesothelioma
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P2.08-002 Germline BAP1 Mutation Is Associated with a Signifi cant Increased 
Survival and Multiple Cancer in Mesothelioma Patients Francine Baumann1, 
Erin Flores1, Andrea Napolitano1, Emanuela Taioli2, Harvey I. Pass3, Haining Yang1, 
Michele Carbone4 1Cancer Center, University of Hawaii, Honolulu/HI/United States of 
America, 2Department of Population Health, Hofstra-North Shore LIJ School of Medicine, 
Great Neck/NY/United States of America, 3Department of Cardiothoracic Surgery, New York 
University Langone Medical Center, New York/NY/United States of America, 4Cancer Center, 
University of Hawaii, Honolulu/United States of America
Background: Because the diagnosis is often made at a late stage, malignant 
mesothelioma (MM) prognosis is very poor, with a median survival of 6-12 months and 
a fi ve-year survival of less than 5%. We found that germline BAP1 mutation is associated 
with a new cancer syndrome, including rare malignancies such as MM and uveal 
carcinoma (UV), and other cancers. We noted that some MM cases that we followed 
from BAP1 mutated families had prolonged survival. We carried out a pooled analysis 
of BAP1 mutated MM patients to test the hypothesis that they had a better survival 
compared to sporadic MM. Methods: : We included all published BAP1 germline mutated 
MMs with available data on BAP1 status, site of MM, age at diagnosis, gender, and age 
at death or status at end of follow-up, in addition to the BAP1 mutated MM cases from 
families that we are following. Twenty-three BAP1 MM patients were included. Using the 
Kaplan-Meier method and Wilcoxon test, we compared survival among BAP1 mutated MM 
patients with that of all MMs (N = 10 556) recorded in the US SEER data from 1973 to 
2010. Results: In our BAP1 cohort, ten patients had peritoneal MM, ten pleural MM, and 
three MM in both locations. Thirteen patients had one or more malignancies in addition 
to MM. Actuarial median survival for the MM patients with germline BAP1 mutations 
was fi ve years, as compared with less than one year in the SEER MM control group. 
Five-year survival was 47%, 95%CI [24-67%], as compared with 6.7% [6.2-7.3%] in the 
SEER MM control group. The small size of our BAP1 cohort did not allow for signifi cant 
statistical comparisons. However, patients with peritoneal MM (median survival of 10 
years, P=0.0571), or with a second malignancy in addition to MM (median survival of 10 
years, P=0.0716), survived for a longer time compared to patients who only had pleural 
MM, or MM patients without a second malignancy, respectively.
 
Conclusion: MM patients with germline BAP1 mutations have an overall seven-fold 
increased survival, independently of sex and age. This better prognosis was associated 
with multiple cancer and/or peritoneal MM. Appropriate genetic counseling and clinical 
management should be considered for MM patients who are also BAP1 mutation carriers. 
Keywords: Mesothelioma, survival, BAP1 germline mutation, Multiple cancer
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P2.08-003 MDM2 Inhibitor plus rhAPO2L/TRAIL: A Promising Strategy for 
Malignant Pleural Mesothelioma Treatment Loredana Urso1, Micol Silic-Benussi1, 
Vincenzo Ciminale1, Federico Rea2, Pierfranco Conte1, Adolfo Favaretto3, Giulia Pasello3
1Surgical Oncologic and Gastroenterological Sciences Department, University of Padova, 
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P2.07-017 Body Composition Analysis Using Computed Tomography in Patients 
with Small Cell Lung Cancer Eun Young Kim1, Young Saing Kim2, Inkeun Park2, Hee 
Kyung Ahn2, Eun Kyung Cho2 1Department of Radiology, Gachon University Gil Medical 
Center, Incheon/Korea, 2Division of Hematology and Oncology, Department of Internal 
Medicine, Gachon University Gil Medical Center, Incheon/Korea
Background: Although the clinical signifi cance of body composition has been 
recognized as associated with performance status and prognoses for solid tumors, no 
study has specifi cally evaluated baseline body composition in detail using computed 
tomography (CT) images for patients with small cell lung cancer (SCLC). Methods: We 
analyzed skeletal muscle mass and fat mass in 150 patients with pathologically proven 
SCLC between January 2010 and November 2014 in our institution. Cross-sectional 
areas of skeletal muscle (Hounsfi eld unit, HU ranges -29 to 150) and fat tissue (HU, 
-190 to -30) were measured on the level of 3rd lumbar vertebra using the baseline CT 
images. Data on clinical characteristics were retrospectively collected. Results: Mean 
age was 69 ± 9 years (85.3% were male). At the time of diagnosis, mean body mass 
index (BMI) was 22.1, with 40.7% of patients being overweight or obese (BMI ≥ 23). 
Only 16.7% overall were underweight as conventionally understood (BMI < 18.5). The 
overall prevalence of severe muscle depletion (sarcopenia) was 53.3% and was present 
in patients in all BMI categories (84.0% in underweight patients, 45.2% in overweight 
and obese patients). A much higher proportion of men (60.2%) than women (13.6%) 
met the criteria of sarcopenia. Conclusion: Wasting of skeletal muscle is a prominent 
feature of patients with small cell lung cancer, despite normal or heavy body weights. 
Keywords: body composition, sarcopenia, tomography, X-ray computed, small cell lung 
cancer
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P2.07-018 The Association of Hyponatremia with the Prognosis of Patients with 
SCLC Kong Yue Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang 
Province/China
Background: Lung cancer is still one of the leading causes of cancer patients,which has 
a high incidence and poor prognosis. Hyponatremia is found in about 15% patients with 
small cell lung cancer(SCLC) at different disease stages. This study aims to analyze the 
association of hyponatremia with the prognosis of patients with SCLC. Methods: The 
clinical materials of 489 patients with SCLC treated in ZheJiang cancer hospital between 
January 2010 and December 2012 were retrospectively analyzed. Kaplan- Meier 
and Log-Rank test were used to analyze the data. Prognostic factors were analyzed 
by multivariate Cox proportional hazards model. Results: Hyponatremia occurred 
in 17.9%、13.3%、12.5% and 18.9% patients at 4 different clinical stages(before 
treatment, after 2 cycles of chemotheropy, after radiotheropy and after all the 
treatments). The serum sodium level was not signifi cantly different among patients 
of different gender, age, BMI, KPS, hypertension and diabetes mellitus history, tumor 
stage, smoking history and tumor metastasis (P>0.05). Univariate analysis showed 
that hyponatremia signifi cantly affected the survival of patients. Multivariate analysis 
showed that hyponatremia was the independent prognostic factor for SCLC. The 
relative risk of death of patients with hyponatremia was elevated by 1.297 times 
(95%CI:1.160~1.449，P<0.001), 1.366 times (95%CI:1.023~1.825,P=0.035), 
1.77 times (95%CI:1.168~2.682,P=0.007) and 1.507 times 
(95%CI:1.167~1.944,P=0.002). Conclusion: Hyponatremia is an independent prognostic 
indicator for the survival of initially treated patients with small cell lung cancer(SCLC). 
Keywords: Prognosis, small cell lung cancer, Hyponatremia
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P2.08-001 A Randomized, Placebo-Controlled Study of Amatuximab in 
Combination with Pemetrexed and Cisplatin (P/C) in Subjects with Pleural 
Mesothelioma Bruce A. Wallin1, Julis D. Maltzman1, Alex Dmietrienko2, Kimberly 
Hoffman1, Megan Mclaughlin1, Raffi t Hassan3 1Clinical Development, Morphotek, Exton/PA/
United States of America, 2Quintiles, Overland Park/KS/United States of America, 3Thoracic 
and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda/MD/United States 
of America
Background: Amatuximab is a chimeric monoclonal antibody that binds to mesothelin, 
which is highly expressed in malignant mesothelioma and largely absent from normal 
tissue. In vitro studies indicate that amatuximab potentially has anti-tumor activity 
via antibody-dependent cellular cytotoxicity. Amatuximab was studied in a Phase 2 
malignant pleural mesothelioma (MPM) trial which demonstrated that the safety profi le 
of amatuximab in combination with P/C was consistent with that seen previously for 
the P/C regimen. Although PFS was not signifi cantly different from historical results of 
P/C alone, the median OS was 14.8 months (as compared to 13.3 months for P/C). The 
post-hoc PK/PD analysis demonstrated that amatuximab trough concentrations were a 
signifi cant predictor of both OS and PFS where higher concentrations were associated 
with longer OS (583 days; p=0.0202 ) and PFS (238 days; p<0.001). Methods: 560 
subjects with previously untreated, unresectable malignant pleural mesothelioma 
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during or after pemetrexed/platinum-based chemotherapy (PBC). Single agent 
chemotherapy is often administered in everyday practice, although its use is poorly 
supported by clinical trials. The aim of this retrospective study (NCI01865045) was to 
analyze the efficacy and toxicity of second (2nd) and third (3rd) line vinorelbine (VNR) in 
a large cohort of PBC-pretreated MPM patients. Methods: The clinical records of MPM 
pts consecutively treated in 8 Italian Centers with intravenous (iv) or oral (po) VNR as 2nd 
or 3rd line treatment following PBC were reviewed. Radiological response was assessed 
by modified RECIST criteria. Toxicity was reported according to CTCAEv4 criteria. 
Relative dose-intensity (DI) of VNR was calculated. Progression-free survival (PFS) and 
overall survival (OS) were estimated and correlated to clinical variables: age, gender, 
histological subtype, ECOG performance status (PS), line of VNR therapy (2nd vs 3rd) and 
outcome of first-line treatment. Results: From August 2001 to September 2014, 161 pts 
(M/F 120/41) were treated, 128 with iv and 33 with po VNR. Most of the cases included 
(92%) were treated after 2007. Histological subtype was epithelioid in 134, biphasic in 
15, sarcomatoid in 8 and unspecified in 4 pts. Median age was 67 years (range 41-82). 
VNR was administered as 2nd or 3rd line treatment in 94 and 67 pts, respectively. Median 
number of VNR cycles was 3 (range 1-26), median relative DI was 88%. Main grade 3-4 
toxicities were neutropenia in 9%, fatigue in 4% and constipation in 5% of pts. No toxic 
death occurred. A partial response was observed in 10 pts (6%), stable disease in 57 (35%), 
for an overall disease control rate of 41%. Median PFS and OS were 2.5 and 6.7 months, 
respectively. In multivariate analysis, only ECOG PS (0 vs 1-2) was significantly associated 
with improved PFS and OS. An analysis of molecular predictors of VNR response is 
ongoing. Conclusion: In this large retrospective patient cohort, 2nd and 3rd line VNR had 
modest but definite activity in PBC-pretreated MPM patients, with an excellent toxicity 
profile. Although inclusion in prospective clinical trials of new agents should be always 
considered in this setting, single agent VNR remains a reasonable option for palliation. 
Keywords: Mesothelioma, chemotherapy, Second-line, vinorelbine
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P2.08-006 The JmjC Family of Lysine Demethylases Are Overexpressed 
and Potential Therapeutic Targets in Malignant Pleural Mesothelioma Maeve 
Breslin1, Sian Cregan1, Leah Quinn1, Sigrid Wennstedt1, Gerard Roche1, Yun Gao2, Kim 
Griggs3, Michaela B. Kirschner4, Kenneth J. O’Byrne5, Stephen P. Finn6, Sinead Cuffe7, 
Sonja Klebe3, Glen Reid4, Steven G. Gray1 1Thoracic Oncology Research Group, Trinity 
College Dublin/St. James’S Hospital, Dublin/Ireland, 2Department of Oncology, Aerospace 
Central Clinical Medical College of Peking University, Beijing/China, 3Anatomical Pathology, 
Flinders University, Adelaide/SA/Australia, 4Asbestos Diseases Research Institute, Sydney/
NSW/Australia, 5Cancer and Ageing Research Program, Princess Alexandra Hospital and 
Queensland University of Technology, Brisbane/QLD/Australia,6Department of Pathology, 
University of Dublin, Trinity College and St. James’S Hospital, Dublin/Ireland, 7Hope 
Department, St.James’S Hospital, Dublin/Ireland
Background: Malignant pleural mesothelioma (MPM) is an aggressive rare cancer 
affecting the pleura and is predominatly associated with prior exposure to asbestos. 
Treatment options are limited, and most patients die within 24 months of diagnosis. 
The current standard of care for MPM patients is a combination of cisplatin and 
pemetrexed (or alternatively cisplatin and raltitrexed), yet most patients die within 24 
months of diagnosis. There is therefore an urgent unmet need to identify new therapeutic 
options for the treatment of MPM. Asbestos fibres contain of transition metals and their 
ability to both adsorb and accumulate these metals was one of the first mechanisms 
suggested for explaining the toxic and particularly carcinogenic effects of asbestos. 
One of the transition metals in asbestos fibres is iron, and therefore asbestos fibres 
may cause an alteration of iron homeostasis in the tissue. In addition, asbestos fibres 
have also been shown to have high affinity for histones, and therefore may result in high 
accumulation of iron around chromatin. Lysine Demethylases (KDMs) containing a JmjC 
domain require both Fe2+ and 2-oxoglutarate as co-factors to regulate gene expression 
by “erasing or removing” methylation on histones in chromatin. Members of this family 
are frequently found to have aberrant expression in cancer and currently are actively 
pursued as candidate pharmaceutical therapeutic targets. Given that asbestos increases 
iron levels, this may result in aberrant KDM activity, and these KDMs could therefore 
be novel candidate targets in mesothelioma. We therefore examined the expression 
of several JmjC containing KDMs in MPM and assessed their potential for therapeutic 
intervention in mesothelioma using existing small molecule inhibitors. Methods: A panel 
of MPM cell lines were screened for expression of KDM4A-D, KDM5A/B and KDM6A/B 
by RT-PCR. mRNA levels were subsequently examined by RT-PCR in a cohort of snap-
frozen patient samples isolated at surgery comprising benign, epithelial, biphasic, and 
sarcomatoid histologies. IHC was performed for KDM4A on a cohort of FFPE specimens. 
The effects of treatments with small molecule inhibitors targeting these proteins on 
both cellular health and gene expression were assessed. Results: The expression of 
the various KDMs was detectable across our panel of cell lines. In primary tumours the 
expression of these KDMs were significantly elevated in malignant MPM compared to 
benign pleura (p<0.05), and significant differences were also observed when samples 
were analysed across different histological subtypes. Treatment of mesothelioma 
cell lines with various small molecule inhibitors caused significant effects on cellular 
health and on the expression of a panel of genes. Conclusion: The expression of 
KDMs are significantly altered in MPM. Small molecule inhibitors directed against these 
KDMs show potential therapeutic efficacy with significant anti-proliferative effects. We 
continue to assess the effects of these compounds on gene expression and cellular 
health to confirm their potential utility as novel therapies for the treatment of MPM. 
Keywords: JumonjiC, Mesothelioma, epigenetics, therapeutic target
Background: Malignant Pleural Mesothelioma (MPM) is an aggressive tumor 
characterized by chemoresistance. Most MPM tumor specimens have wild type p53 
but show a deletion of INK4A/ARF locus (70-80%) which contains p14/ARF gene. The 
p14 lack increases MDM2 activity and subsequently down-regulates p53. The role 
of MDM2 is not only related to p53 control but it is also involved in regulation of cell 
proliferation, apoptosis and angiogenesis in p53 independent manner. Tumor necrosis 
factor (TNF) -Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) is a promising agent 
for antitumor treatment because its ability to selectively kill cancer cells through the 
extrinsic apoptotic pathway. The aim of our study is to investigate, the anticancer effect 
of the MDM2 inhibitor, Nutlin 3a, in association with rhAPO2L/TRAIL in MPM in vitro and in 
vivo. Methods: In vitro apoptosis assay was performed using PI staining, positive cells 
were detected by flow cytometry. Cycle analysis was performed by PI staining and 
flow cytometry detection, DNA content was analyzed by MODFIT software. p53, p21 
and survivin protein expression levels were detected by western blot analysis. TRAIL 
receptors levels were assessed by flow cytometry analysis. mRNA expression levels 
were evaluated by real-time PCR. In vivo experiments were performed in 32 SCID male 
mice, intraperitoneally injected with sarcomatoid MPM cells trasduced with lentiviral 
Luciferase vector and treated with Nutlin and/or rhAPO2L/TRAIL. Results: Nutlin 3a 
treatment provoked p21 induction and cell cycle arrest in p53 wild type cells (M14K 
epithelioid, MSTO-211H biphasic and ZL34 sarcomatoid) but had no effect in p53 
mutated cells (ZL55 epithelioid). Interesting, apoptosis assay showed a synergistic cell 
death induction of Nutlin3a plus rhAPO2L/TRAIL in both p53 wild type and p53 mutated 
MPM cells with a greater effect in ZL34 cell lines that expressed higher mRNA and protein 
levels of MDM2. Nutlin 3a increased the expression of DR4/DR5 TRAIL death receptors 
and inhibition of survivin only in p53 wild type cells. As a consequence, western blot 
analysis of Caspase 8 activation showed that the MDM2 inhibitor induced an increase 
of extrinsic apoptosis signal only when p53 was functional. Finally, antitumor activity 
tested in ZL34 in vivo mouse model showed a strong inhibition of tumor growth in mice 
treated with Nutlin 3a plus Apo2L/TRAIL compared to Nutlin 3a or Apo2L/TRAIL used 
as single agents. Conclusion: The results demonstrate that the combination of Nutlin 
3a plus Apo2L/TRAIL may be a promising strategy for MPM treatment independently 
to p53 status. Further esperiments are needed in order to clarify the role of p53 status 
as selection criterium for treatment and to explore p53-independent MDM2 functions.
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.08-004 Healthcare Professional Perceptions of Chemotherapy in Treatment 
of Malignant Pleural Mesothelioma (MPM) Steven Kao1, Haryana Dhillon2, 
Anne Warby3, Janette Vardy4 1Medical Oncology, Chris O’Brien Lifehouse, Sydney/
Australia, 2University of Sydney, Sydney/Australia, 3Asbestos Diseases Research Institute, 
University of Sydney, Sydney/ACT/Australia, 4Concord Cancer Centre, University of Sydney, 
Sydney/ACT/Australia
Background: Background: An evidence-based chemotherapy utilisation model for 
MPM suggests rates of use should be around 65%. Actual Australian rates are about 
54%. Aim: To examine healthcare professional perceptions of chemotherapy use and 
barriers to it in MPM patients. Methods: Methods: Healthcare professionals caring for 
people with MPM were invited via email from professional groups, to complete a purpose 
designed online survey. Data were collected from January-July 2014. Descriptive data 
are presented. Results: Results: Surveys were completed by 102 doctors (Respiratory 
Physicians=53, Medical Oncologists (MO)=35, Other=15) and 19 nurses. Doctors mean 
age 47 (31-75) years, 74% male, 49% worked only in public system, 57% did not have 
lung cancer nurse specialist, and saw mean of 7 new patients with MPM annually. Nurses 
mean age 45 (29-68) years, all female, 53% worked only in public system, and saw 
mean of 12 (1-40) new patients with MPM annually. 74% of doctors and 53% of nurses 
believed >11% of MPM patients potentially eligible for chemotherapy do not receive it. 
Clinician barriers most commonly endorsed include: clinician nihilism 70%, 37%; non-
referral to MO 47%, 63%; lack of cancer services 43%, 53%; no MDT review 40%, 
32% for doctor, nurse respectively. 74% of nurses also indicated delayed diagnosis 
and 58% lack of clinician knowledge about treatment. Conclusion: Conclusions: 
Healthcare professionals’ estimates of potentially eligible patients with MPM who 
do not receive chemotherapy are consistent with or higher than evidence-based 
estimates. Barriers to chemotherapy access endorsed suggest strategies to increase 
knowledge of evidence-based treatment and address clinical nihilism are required. 
Keywords: Mesothelioma, chemotherapy treatment, decision-making, healthcare 
professionals
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P2.08-005 Vinorelbine as Second or Third-Line Therapy in Pemetrexed-
Pretreated Malignant Pleural Mesothelioma (MPM) Patients Giovanni L. Ceresoli1, 
Paolo A. Zucali2, Federica Grosso3, Manlio Mencoboni4, Philip Bonomi1, Hector J.M. 
Soto Parra5, Giulia Pasello6, Diego Cortinovis7, Matteo Perrino2, Alberto Muzio8, Andrea 
Bruzzone4, Fabio De Vincenzo2, Daniela Degiovanni9, Matteo Simonelli2, Giordano D. 
Beretta1, Laura Giordano10, Armando Santoro2 1Oncology, Cliniche Humanitas Gavazzeni, 
Bergamo/Italy, 2Oncology, Humanitas Cancer Center, Rozzano, Milan/Italy, 3Oncology, 
Ospedale Ss Antonio E Biagio, Alessandria/Italy, 4Oncology Unit, Villa Scassi Hospital, Asl 
3 Genovese, Genova/Italy, 5Oncology, Policlinico Universitario Vittorio Emanuele, Catania/
Italy, 6Medical Oncology 2, Istituto Oncologico Veneto, Padova/Italy, 7Medical Oncology 
Unit, San Gerardo Hospital, Monza/Italy, 8Oncology, Ospedale Santo Spirito, Casale 
Monferrato (Al)/Italy, 9Palliative Care Unit, Ospedale Santo Spirito, Casale Monferrato (Al)/
Italy, 10Biostatistic Unit, Humanitas Cancer Center, Rozzano, Milan/Italy
Background: There is no standard treatment for patients (pts) with MPM progressing 
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the clinico-epidemiological data and different treatment modalities offered for (MPM) 
patients and to evaluate their impact on survival Methods: Data was retrospectively 
collected from the medical files of 103 cases presented as MPM to Department 
of Clinical Oncology and Nuclear Medicine, Ain Shams University Hospitals from 
January 2011 to December 2013. Demographics, risk factors, morphological status 
and treatment received were described using frequencies. Survival outcome was 
described using Kaplan Meier curves stratified according to morphology and treatment 
received. Results: A steady increase in the number of cases was detected, from 30 in 
2011 and 40 cases in 2013. Male/female ratio was 0.98 (p = 0.989). The median age was 
58 years (range 28-85). About 60 patients (58.3 %) came from endemic areas. Only one 
patient underwent decortication surgery. About 70.9 %, 21.4 % and 5.8% of the patients 
received chemotherapy (CT) in 1st line, 2nd line and 3rd line respectively and median 
OS was 5 months (Range 1-48). Only 5.5%, 21.7% and 33.3% of the patients received 
Pemetrexed in 1st line, 2nd line and 3rd line CT respectively.Kaplan-Meier survival for 
sex, age, residence and the pathological types was insignificant. The median survival for 
epithelial versus non-epithelial pathological types was 6 and 5 months respectively (P= 
0.165).The median survival for the patients who received 1st line, 2nd line and 3rd line CT 
versus best supportive care (BSC) was 3 and 8 months (P = 0.001), 12 and 5 months (P < 
0.001) and 12 and 5 months (P =0.417) respectively.There was a significant difference 
(P = 0.001) between the median survival for patients who received CT (8 months, 95% 
CI 5.422-10.578) and those who were offered BSC ( 3 months, 95% CI 1.715-4.285). 
Another factor that affected the survival negatively was non-platinum based CT in the 
1st line (2 months versus 9 months P =0.001). Cox regression analysis revealed that 
the factors that predicted better OS were patients being offered CT rather than BSC 
especially patients who received 1st and 2nd line of CT (P =0.004). Conclusion: MPM 
is a growing health burden in Egypt which is underestimated and need more support 
to offer new treatment modalities. The CT prolongs survival compared to BSC in 
patients with MPM. Moreover, using platinum based CT provides survival advantages. 
Keywords: Chemotherapy; epidemiology; malignant pleural mesothelioma.
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P2.08-010 Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients 
with Malignant Mesothelioma Hedy Lee Kindler1, Theodore Karrison2, Arun Khattri1, 
Zhixiang Zuo1, Nanna Sulai1, Buerkley Rose1, Mehwish I. Ahmad1, Samuel Armato3, 
Ravi Salgia1, Tanguy Seiwert1 1Section of Hematology/Oncology, University of Chicago, 
Chicago/IL/United States of America, 2Department of Public Health Sciences, University 
of Chicago, Chicago/IL/United States of America, 3Department of Radiology, University of 
Chicago, Chicago/IL/United States of America
Background: Mesothelioma is a frequently “inflamed” tumor. We previously identified 
PD-L1 expression, a CD8 infiltrative pattern, and the presence of PD-1/PD-L1 immune 
checkpoints in about 1/3 of mesothelioma tumors, similar to the phenotype found in 
malignancies such as melanoma that benefit from immune checkpoint blockade (Kindler 
and Seiwert, ASCO 2014). Based on these data, we have initiated a single-center phase 
II trial (NCT02399371) of the anti-PD-1 antibody pembrolizumab in previously-treated 
mesothelioma patients. The rationale for this study is further supported by recent data 
from a phase IB multi-cohort study of pembrolizumab in PD-L1 positive solid tumors, in 
which an objective response rate of 28% and a disease control rate of 76% was observed 
in 25 pleural mesothelioma patients, who received 10 mg/kg pembrolizumab every 
2 weeks (Alley, AACR 2015). Methods: Eligible patients have histologically-confirmed 
pleural or peritoneal mesothelioma, measurable disease, PS 0-1, disease progression 
on or after treatment with pemetrexed plus cis- or carboplatin, no more than 2 prior 
lines of cytotoxic therapy, normal organ function, and tissue available for correlative 
studies. Patients receive a flat dose of 200 mg pembrolizumab intravenously every 
3 weeks. CT scans are obtained every 9 weeks. The primary objectives are: 1) to 
determine the objective response rate in A] an unselected population and in B] a PD-
L1 positive population, and 2) to determine the optimal threshold for PD-L1 expression 
using the 22C3 antibody-based IHC assay. Secondary objectives include progression-
free and overall survival, disease control rate, and toxicity. Correlative studies are 
intended to characterize the T-cell inflamed phenotype in mesothelioma via CD8, 
CD4, and PD-L1 staining, immune related gene expression signatures (Nanostring), 
and determination of other immune escape mechanisms including T-regulatory cells 
(FOXP3 expression), IDO expression, MDSCs, and other checkpoints/co-stimulatory 
signals by immunohistochemistry and/or flow cytometry. A single-stage binomial 
design will be used. Part A requires ≥ 3 responses in 35 patients. Part B, which uses 
PD-L1 pre-selection (optimal expression pattern and threshold determined in cohort A), 
requires ≥ 6 responses in 30 patients. Funded in part by a grant from the Mesothelioma 
Applied Research Foundation. Results:Not applicable. Conclusion: Not applicable. 
Keywords: phase II trial, Mesothelioma, PD-1, pembrolizumab
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P2.08-011 Surgical Cytoreduction and HITHOC for Malignant Pleural Tumors 
Michael Ried1, Reiner Neu1, Berthold Schalke2, Hans-Stefan Hofmann1 
1Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg/
Germany, 2Department of Neurology, University of Regensburg at the District Medical Center, 
Regensburg/Germany
Background: Combination of surgical cytoreduction and hyperthermic intrathoracic 
chemotherapy (HITHOC) is performed for therapy of pleural malignancies within a 
multimodality treatment concept. We describe the perioperative management and our 
clinical experience. Methods: Between September 2008 and January 2015 a total of 
23 patients with malignant pleural mesothelioma (MPM) and 27 patients with thymoma/
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P2.08-007 The Efficacy and Safety of Re-Challenge Platinum plus Pemetrexed 
Combination Therapy for Recurrent Malignant Pleural Mesothelioma Mariko 
Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori 
Hasegawa Department of Intgrated Medicine, Nagoya University Graduate School of 
Medicine, Nagoya/Japan
Background: Malignant pleural mesothelioma (MPM) is associated with poor prognosis 
and 5-year survival rate was only 23.1%.Tri-modality therapy (induction chemotherapy 
followed by pleural pneumonectomy and adjuvant radiation), bimodality therapy 
(induction chemotherapy followed by pleural decortication) and chemotherapy alone 
viable treatment option for MPM. These initial therapies are selected according to IMIG 
staging, performance status, and the severity of comorbidity. These treatment options 
all include platinum plus pemetrexed combination therapy, which is regarded as the 
standard regimen for advanced MPM. However, the majority of patients showed disease 
relapse even when treated with multimodality strategy and the treatment options for 
recurrent MPM are limited. Under these findings, the current study investigated the 
efficacy and safety of re-challenge platinum plus pemetrexed combination therapy 
for recurrent MPM. Methods:We retrospectively reviewed 36 patients pathologically 
diagnosed as MPM between April 2007 and April 2015. The patients who received re-
challenge platinum plus pemetrexed combination therapy as second line therapy for 
recurrent MPM were eligible for this study. Results: Of these 36 patients, 15 showed 
disease relapse after receiving the first treatment. 7 patients received monotherapy 
or best supportive care after the relapse. After all, 8 patients received re-challenge 
platinum plus pemetrexed combination therapy. The characteristics of the 8 patients 
were as follows, male/female:6/2, median age:58 years (range 49-69), performance 
status 0/1:2/6, epithelioid/sarcomatoid/biphasic/unknown: 6/0/1/1. Prior therapy 
tri-modality/bimodality/chemotherapy alone:5/0/3, treatment free interval from the 
completion of initial therapy <90days/≧90days; 0:8. 1 partial response and 6 stable 
disease were observed in 8 patients, respectively. Median progression free survival 
and median overall survival was 8.3 and 17.3 months, respectively. In terms of toxicity, 
grade 3 leukopenia was observed in one patient. No grade 3-4 thrombocytopenia 
was observed. In addition, grade 2 erythema was observed in one patient. Over all, 
the combination therapy was well tolerated. Conclusion: The re-challenge platinum 
plus pemetrexed combination was active and well tolerable for recurrent MPM. 
Keywords: malignant pleural mesothelioma, recurrent, Platinum, pemetrexed
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P2.08-008 A Phase 1 Dose Escalation Study of VS-5584, a PI3K/MTOR 
Inhibitor, Administered with VS-6063, a Focal Adhesion Kinase Inhibitor, 
in Mesothelioma Udai Banerji1, Dean A. Fennell2, Hedy Lee Kindler3, Marjorie G. 
Zauderer4, Mitchell Keegan5, Joanna Horobin6 1Royal Marsden NHS Foundation Trust, 
London/United Kingdom, 2University of Leicester & Leicester University Hospitals, Leicester/
United Kingdom, 3Section of Hematology/Oncology, University of Chicago, Chicago/IL/
United States of America,4Medicine/Thoracic Oncology, Mskcc, New York/NY/United States 
of America, 5Verastem, Boston/AL/United States of America, 6Verastem, Boston/United 
States of America
Background: Malignant mesothelioma is a rare, but aggressive pleural or peritoneal 
tumor which is highly invasive and progresses rapidly. The median survival of patients 
with mesothelioma is between 9 and 13 months, and survival has not been significantly 
affected by most currently available therapeutic interventions. There are no approved 
therapies following first line treatment. VS-6063 is an oral inhibitor of focal adhesion 
kinase (FAK) currently being evaluated in a randomized phase 2 study in patients with 
malignant pleural mesothelioma who have stable disease or better after front line 
chemotherapy. VS-5584 is an oral dual inhibitor of PI3K/mTOR currently undergoing 
phase I testing in solid tumors. Previously reported literature has shown that dual PI3K/
mTOR inhibitors have activity in patients with relapsed mesothelioma. In preclinical 
models, the combination of VS-6063 and VS-5584 have demonstrated synergy in 
tumor models of malignant mesothelioma supporting the potential exploration of this 
combination clinically. Methods: This is a multi-center, open-label, phase 1 trial in 
subjects with relapsed malignant mesothelioma. The study is comprised of two sequential 
parts: Part 1 (Dose Escalation of VS-5584 with a fixed dose of VS-6063) and Part 2 
(Expansion). Patients receive VS-5584 orally on an intermittent dosing schedule and VS-
6063 400 mg orally BID. Primary endpoints are to determine the maximum tolerated 
dose, recommended Phase 2 dose/schedule and to assess safety and tolerability of 
the combination in this patient population. Secondary endpoints include assessing 
the pharmacokinetics of VS-5584 and VS-6063 when co-administered. Exploratory 
endpoints include response rate and biomarker correlation with response and PD. The 
study is currently enrolling across 4 sites in the United States and United Kingdom. 
Clinical trial: NCT02372227. Results: Not applicable Conclusion: Not applicable 
Keywords: Mesothelioma, PI3K, mTOR
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P2.08-009 Malignant Pleural Mesothelioma: A Retrospective Analysis 
of Clinicopathological and Survival Data in Egyptian Patients Mona K. 
Jomaa, Ahmed Nagy, Nesreen Mosalam, Mostafa Mohamed, Marwa Ezzat Clinical 
Oncology and Nuclear Medicine, Ain Shams University, Cairo/Egypt
Background: The incidence of Malignant pleural mesothelioma ( MPM) in Egypt showing 
a steady increase which mandate more intension. This study was conducted to study 
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6 weeks) until disease progression. Objectives To test the efficacy and safety of TTFields 
combined with standard chemotherapy in this patient population. Endpoints The primary 
endpoint is overall survival (OS) and secondary endpoints are response rate, progression 
free survival and treatment-emergent toxicity. Statistical Considerations This is a 
prospective phase II, single arm, multicenter study for 80 patients. The sample size 
(71 + 12% loss to follow up) is based upon the asymptotic distribution provided by 
Lachin (2000) using the log of the hazard rate. The historical control is assumed to 
have an exponential distribution with a constant hazard rate of 0.03938 calculated 
from the median survival of 12.1 Months reported by Vogelzang et al. The sample size 
provides 80% power with a two sided alpha of 0.05 to detect an increase of 5.5 months 
in OS which is equivalent to a Hazard Ratio of 0.67 compared to the historical control 
data for OS. Major Eligibility Criteria Patients are 18 years of age or older with good 
performance status (ECOG 0-1). The patients must have pathological or histological 
evidence of MPM with at least one measurable or evaluable lesion according to modified 
RECIST criteria. The disease should be previously untreated and not amendable 
for curative treatment (surgery or radiotherapy). Untreated brain metastases and 
contraindications to any of the study treatments are exclusionary. Treatment Continuous 
TTFields at 150 kHz is applied to the thorax using the NovoTTF-100L System. The 
System is a portable medical device allowing normal daily life activities. The device 
delivers alternating electric fields to the thorax using 4 Transducer Arrays. The 
experimental treatment is administered on top of the standard of care chemotherapy 
– pemetrexed/platinum doublet. Results: not applicable Conclusion: not applicable 
Keywords: Tumor Treating Fields, TTFields, malignant pleural mesothelioma, 
Unresectable
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P2.08-014 Therapeutic Effectiveness of MET/RON Small Molecule Inhibitor 
BMS-777607 on Cell Viability of Human Malignant Pleural Mesothelioma 
Cell Lines Bashir M. Mohamed1, Melad A. Aswisi1, Steven G. Gray2 1Clinical Medicine 
Department, Trinity College Dublin and St James`S Hospital, Dublin/Ireland, 2Thoracic 
Oncology, St James’S Hospital & Trinity College Dublin, Dublin/Ireland
Background: Overexpression of c-Met receptor tyrosine kinase has been highly 
associated with oncogenic progression of non-neoplastic mesothelial progenitor cells to 
malignant pleural mesothelioma (MPM). Moreover, activated c-Met receptor tyrosine kinase 
transduces signals that regulate tumorigenic activities including cell growth, migration, 
survival, and invasion of extracellular matrixes. A small molecule MET kinase inhibitor 
(BMS-777607) is an inhibitor of tyrosine receptor currently under clinical trials. Previous 
studies reported the effect of this inhibitor on cancer cells such as breast, hepatic and 
prostate cancer. However, its inhibitory effect on malignant pleural mesothelioma (MPM) 
cells has not yet been evaluated. In our study, we aimed to investigate the therapeutic 
usefulness of this small molecule on MPM. Methods: Human MPM cell lines such as REN 
and NCl-H2373 and a human lung carcinoma cell line (NCl-H226) were used. LP-9 cell 
line, which resembles normal human mesothelial cells, was used as control. These cells 
were cultured and exposed to BMS-777607 at concentrations 1uM, 5uM and 10uM. Cell 
cycle, cell viability, lysosomal mass/pH changes and mitochondrial membrane potential 
were examined using immunofluorescent staining methods and data were collected and 
analysed with high content screening systems such as Cytell and IN Cell Investigator 
software. Results: Both MPM cell lines and the lung cell line showed cell cycle arrest as 
examined by Cytell in significant dose-dependent manner with maximum effects seen at 
the highest dose (10 µM) of BMS-777607. Cell viability and other biological cellular markers 
were also altered upon exposure to this small molecule. Our results showed that BMS-
777607 induces negligible changes of these markers examined in the normal mesothelial 
cells line (LP-9). Conclusion: Taken together, these findings indicate that inhibition of MET/
RON signalling using a small molecule inhibitor such as BMS-777607 could significantly 
interrupt the cell cycle stages and alter other cellular compartments (i.e; lysosomal mass/
pH, mitochondrial membrane potential) which lead to suppression of MPM cell viability, 
suggesting that such a targeting strategy may hold promise for the treatment of MPM. 
Keywords: MET/RON kinase inhibitor, BMS-777607, malignant pleural mesothelioma, 
lysosomal mass/pH
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P2.08-015 The Relationship between the Cost of Treatment and Prognosis in 
Malignant Mesothelioma in Turkey Guntulu Ak1, Selma Metintas2, Tunc Kose3, Filiz 
Bogar4, Nuray Girginer3, Hasan F. Batirel5, Nurullah Uckun3, Muzaffer Metintas1 1Lung 
and Pleural Cancers Research and Clinical Center; Medical Faculty Department of Chest 
Diseases, Esogu, Eskisehir/Turkey, 2Lung and Pleural Cancers Research and Clinical Center; 
Medical Faculty Department of Public Health, Esogu, Eskisehir/Turkey, 3Faculty of Economics 
and Administrative Sciences, Esogu, Eskisehir/Turkey, 4Lung and Pleural Cancers Research 
and Clinical Center, Esogu, Eskisehir/Turkey, 5Medical Faculty General Thoracic Surgery, 
Marmara University, Istanbul/Turkey
Background: Malignant mesothelioma (MM) is endemic in the population exposed 
to asbestos and has high healthcare cost with a limited life expectancy. The aim of 
this study is to evaluate the relationship between cost according to treatment type 
and prognosis in MM patients followed up from diagnosis to death. Methods: The 
demographics and healthcare costs of 239 patients with MM were obtained from 
hospital records in the tertiary university hospital between 2005 and 2014. Variance 
analysis and t-test were performed to compare the groups. The survival rates were 
estimated using the Kaplan-Meier method. To clarify health care cost in Turkey, the 
following information was given according to the national reimbursement price in April 
2015. This study was supported by General Directorate of Health Researches, Republic 
thymic carcinoma with pleural involvement (Masaoka-stage IVa) were prospectively 
enrolled. Perioperative management, postoperative morbidity and mortality were 
analyzed. Results: Included were 17 female and 33 male patients with a mean age of 54.6 
years (25 to 72 years). All patients received multimodality therapy depending on tumor 
stage, histology and their overall condition. Histologic subtype of patients with MPM was 
epitheloid (n= 19; 83%) or biphasic (n= 4; 17%). WHO-classification of thymoma patients 
was: B1 n= 2, B2 n= 10, B2/B3 n= 6, B3 n= 4 and C n= 5. All patients underwent 
radical surgical cytoreduction with pleurectomy/decortication (P/D; n= 25), extended 
P/D (P/D + resection of pericardium and/or diaphragm; n= 19) or extrapleural pleuro-
pneumonectomy (EPP; n= 6) followed by HITHOC perfusion at 42°C for one hour. HITHOC 
was performed with an increasing concentration of cisplatin (100 mg/m2 n= 14; 150 mg/
m2 n= 18; 175 mg/m2 n= 2) or combination of cisplatin/doxorubicin (175 mg/m2 / 65 
mg n= 16). Macroscopic complete resection (R0/R1) was achieved in 46 patients (92%). 
Severe chemotherapy-related complications were not observed. Operative revision was 
necessary in seven patients (14%). Postoperative renal insufficiency was observed in 
six patients (12%) with two patients requiring temporary postoperative dialysis (4%). 
Prolonged bronchopleural fistula was documented in five patients (11%) after lungsparing 
P/D or extended P/D. 30-day mortality was 4%, both after EPP. Conclusion: Surgical 
cytoreduction in combination with HITHOC can be performed with acceptable morbidity 
and mortality rates in selected patients. Patients should be evaluated interdisciplinary 
to determine their eligibility for this multimodality approach. Early clinical results 
may encourage the use of additional HITHOC to provide better local tumor control. 
Keywords: Pleural mesothelioma, thymoma, surgical cytoreduction, hyperthermic 
intrathoracic chemotherapy
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.08-012 Differentiation of Mesothelioma from Lung Cancer and Healthy 
Individuals Using Human Serum by ATR-FTIR Spectroscopy Coupled with 
Chemometrics Salih A. Emri1, Dilek Yonar2, Abdulsamet Sandal3, Ulku Yılmaz4, Feride 
Severcan2 1Hacettepe University, Mesothelioma and Medical Geology Research and 
Application Center, Ankara/Turkey, 2Biological Sciences, Middle East Technical University, 
Ankara/Turkey, 3Chest Disases, Hacettepe University, School of Medicine, Ankara/
Turkey, 4Chest Diseases, Atatürk Chest Diseases and Chest Surgery Training Hospital, 
Ankara/Turkey
Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer that 
progresses in the thin layer of pleura. The inhalation of microscopic asbestos fibers 
primarily the main reason of the disease. Early symptoms of pleural mesothelioma 
often are confused with other respiratory ailments. Therefore, MPM can only be 
diagnosed in the advanced stage. Consequently, it is important to develop a new 
approach with high specificity and sensitivity for the differential diagnosis of MPM. 
Fourier Transform Infrared (FTIR) spectroscopy is a novel and non-invasive method 
that has potential to diagnose cancer with high specificity and sensitivity. Hence, we 
used ATR-FTIR spectroscopy coupled with chemometric methods to differentiate 
MPM from healthy individuals and lung cancer patients. Methods: FTIR spectra of 
the samples collected from patients diagnosed with malignant pleural mesothelioma 
(MPM), lung cancer (LC), and healthy control (C) were recorded in the 4000-650 cm-
1spectral region. Recording the spectra and analysis of the spectral data were obtained 
with Perkin Elmer Spectrum One Program. Both unsupervised Principal Component 
Analysis (PCA) (The Unscrambler X 10.3, CAMO Software) and Hierarchical Cluster 
Analysis (HCA) (OPUS 5.5, BRUKER) were applied for differentiation MPM from other 
groups. Results: Cluster analysis of the samples demonstrated that MPM and lung 
cancer successfully differentiated from healthy controls at whole spectral region (4000-
650 cm-1). Moreover, successful clusters of these three groups were obtained in the 
fingerprint (1800-650 cm-1) and 1500-800 cm-1 regions. In addition, some special bands 
such as DNA band at 832 cm-1 gave very successful differentiation by PCA from serum 
samples. Conclusion: These findings indicate that FTIR spectroscopic analysis of serum 
coupled with chemometric analyses enabled differential diagnosis of mesothelioma from 
lung cancer patients and healthy individuals. *This work was supported by the Scientific 
and Technical Research Council of Turkey (TUBITAK), SBAG-113S294 Research Fund. 
Keywords: ATR-FTIR Spectroscopy, Mesothelioma, Diagnosis, Chemometric Analysis
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P2.08-013 A Phase II Trial of TTFields with Chemotherapy for First Line 
Treatment of Malignant Mesothelioma Uri Weinberg1, Ori Farber2 1Novocure Gmbh, 
Lucerne/Switzerland, 2Novocure Ltd., Haifa/Israel
Background: Tumor Treating Fields (TTFields) are an anti-mitotic, regional treatment 
modality, which is based on low intensity alternating electric fields delivered non-invasively 
using a portable, home use, medical device (NovoTTF-100L, Novocure Ltd.). In-vitro, 
human mesothelioma cells were found to be highly susceptible to TTFields. When applied 
to the thorax, TTFields were found to be safe and efficacious in a clinical trial of 42 patients 
with advanced non-small cell lung cancer, where the only common device-related adverse 
event was mild to moderate skin reaction. Malignant pleural mesothelioma (MPM) is always 
fatal when unresectable, and existing therapies provide very limited clinical benefit. Since 
MPM normally progresses regionally within the thorax, the addition of a regional therapy 
to systemic chemotherapy is an appealing treatment approach. However, the use of 
radiation therapy as a loco-regional treatment is limited, due to significant pulmonary 
toxicity. TTFields may therefore serve as a potential non-toxic regional therapy in 
MPM. Methods: The STELLAR Clinical Trial Eighty (80) patients with unresectable and 
previously untreated MPM will be treated with pemetrexed and cisplatin or carboplatin in 
combination with TTFields. The patients will be followed up every 3 weeks (CT scan every 
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surgery alone and 104 surgery + RT) showed significant 1-, 3- and 5-year overall survival 
difference (p = 0.034) in surgery + RT compared to surgery alone. Conclusion: In a 
matched large population cohort, adjuvant radiation therapy appears to improve overall 
survival following surgical resection of chest wall soft tissue sarcomas. Further trials are 
required to determine the efficacy of adjuvant radiation therapy in this population.
 
Keywords: Thoracic Surgery, Chest wall soft tissue sarcoma, radiation therapy
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P2.08-018 The Impact of the Resection Margin on Recurrence and Survival in 
Bronchopulmonary Carcinoids Severin Schmid1, Michael Aicher1, Agnes Csanadi2, 
Bernward Passlick1, Jussuf T. Kaifi1 1Thoracic Surgery, University Hospital Freiburg, 
Freiburg/Germany, 2Pathology, University Hospital Freiburg, Freiburg/Germany
Background: Complete surgical resection is the treatment of choice in 
bronchopulmonary carcinoids. Previously published data showed no inferiority of 
sublobar versus lobar resection. Data on the extent of resection margins are lacking, 
thus we aimed to analyze resection margins in pulmonary carcinoids and correlated them 
with survival and recurrence. Methods: We retrospectively analyzed 85 patients that 
underwent surgery for atypical (AC) or typical (TC) pulmonary carcinoids. Patient charts 
were reviewed and clinicopathologic and survival data was collected. Pathology reports 
were reviewed for length of resection margins. Results: The median follow-up period 
was 42.3 months (range 0.3 - 172.2). There was no statistically significant difference 
in disease-free survival (DS) when comparing resection margins ≤2 mm to >2 mm 
(p=0.93, Hazard Ratio (HR)=1.7). When looking at AC alone, a worse DS can be seen 
if the resection margin was smaller than 2 mm (p=0.06, HR=15.8). In AC likelihood of 
recurrence was higher when the resection margin was ≤1 cm (Odds ratio=5.1, p=0.28). 
In TC this tendency was not present (Odds ratio=1.2, p=1). Conclusion: There is a trend 
towards a worse prognosis and higher likelihood of recurrence in smaller resection 
margins in AC in contrast to TC. Due to low sample size no definitive statements can 
be made based on this study, however respective data on these rare tumors cannot 
be drawn from tumor databases. The resection margin is the most critical issue for the 
treating surgeon and any information on this topic is of highest importance to the field. 
Keywords: Resection margin, Surgical treatment, recurrence, bronchopulmonary 
carcinoids
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P2.08-019 Accuracy of Percutaneous Closed Pleural Biopsy in Thoracic 
Malignancies Renata Báez-Saldaña, Uriel Rumbo-Nava, Patricia Castillo-González, 
Teresa Aguirre-Pérez, María Eugenia Vázquez-Manríquez Respiratory Oncology, Instituto 
Nacional de Enfermedades Respiratorias, Distrito Federal/Mexico
Background: Recently there has been some controversy about the value of percutaneous 
closed pleural biopsy (PCPB) as a diagnostic procedure for establishing the etiology 
of pleural effusion. Our objective was to assess the accuracy of percutaneous closed 
pleural biopsy as a diagnostic procedure for lung cancer and mesothelioma in patients 
with pleural effusion. Methods: We performed a prospective study of all individuals 
who underwent percutaneous closed pleural biopsy, using Cope needle or Abram’s 
needle in order to establish the etiology of pleural effusion, during a 8/year period in 
a refering hospital of respiratory diseases in Mexico City. The identification of patients 
who underwent closed pleural biopsy was obtained from the anatomopathological 
registries. The information of each patient was obtained by medical record review. In 
this study, when the pleural biopsy did not establish the definite diagnostic, we used 
as a gold standard other procedures such as thoracoscopy, open lung/pleural biopsy, 
fiberoptic bronchoscopy, adenosine deaminase and/or microbiological tests. All cases 
of Turkey, Ministry of Health. Results: The mean age of the patients were 62.9±11.3 
years and 125 (52.3%) of them were male. The median survival time was 9.0±0.8 months 
(95% CI: 7.3–10.7). Patients’ numbers according to treatment schema: 52 (21.8%) 
best supportive care (BSC); 3 (1.3%) BSC+palliative radiotherapy (pRT); 117 (49.0%) 
chemotherapy; 39 (16.3%) chemotherapy+pRT, 16 (6.7%) pleurectomy/decortication 
(P/D)+chemotherapy+RT; 4 (1.7%) P/D+chemotherapy; 8 (3.3%) extrapleural 
pneumonectomy (EPP)+chemotherapy+RT. BSC group had the lowest average cost 
with $1,355 (r:258-4,909) per patient. The average cost was $6,595 (r:1,621-21,371) 
for patients received only chemotherapy. When pRT added to chemotherapy, cost was 
increasing to $8,962 per patient. The average cost was $11,691 (r:6,567-19,064) per 
patient for P/D+chemotherapy+RT group. It decreased to $10,676 without RT. The 
highest average cost was seen in the group of EPP+chemotherapy+RT with $13,788 
(r:6,168-19,577) per patient. The median survival times were 6 months (95%CI:5.3-6.7), 
12 months (95%CI:9.8-14.2), 18 months (95%CI:11.5-24.5), 27 months (95%CI:7.6-
46.4) for BSC, chemotherapy, P/D+chemotherapy+RT and EPP+chemotherapy+RT 
group, respectively. The median survival time was significantly different between BSC 
and chemotherapy groups (Log-Rank:10.607; p=0.001). The average cost of 6 months 
prolongation of lifetime was $5,239 in chemotherapy group and incremental cost was 
$873 per month gained. The median survival time was not different between chemotherapy 
and P/D+chemotherapy+RT groups (Log-Rank: 1.263; p=0.261). However, there was 
6 months survival difference between the two groups. The average cost of 6 months 
prolongation of lifetime was $5,097 and incremental cost was $850 per month gained 
in EPP+chemotherapy+RT. The median survival time was significantly different between 
chemotherapy and EPP+chemotherapy+RT groups (Log-Rank: 8.082; p=0.004). The 
average cost of 15 months prolongation of lifetime was $7,194 and incremental cost 
was $480 per month gained in EPP+chemotherapy+RT group. There was a difference 
between surgical groups in terms of median survival (Log-Rank:4.421; p=0.036). The 
average cost for prolongation of lifetime was $2,097 and incremental cost was $233 per 
month gained. Conclusion: MM has a limited survival time despite antitumor treatment 
and treatment cost is relatively high by prolongation of lifetime. Treatment should be 
given to selected patients and EPP should be preferred to P/D as much as possible. It 
is clear that there is need well designed prospective studies for cost analysis of MM. 
Keywords: mesothelioma, cost analysis
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
TUESDAY, SEPTEMBER 8, 2015 - 09:30-16:30
P2.08-016 Pleural Mesothelioma Incidence in Sweden: No Cecrease in Sight 
Gunnar N. Hillerdal Pulmonary Diseases, Karolinska Hospital, Stockholm/Sweden
Background: Sweden was one of the first countries in the world to ban asbestos, which 
happened in the early mid-seventies. The use of asbestos in Sweden was thus mainly 
in the 1960ies. The incidence of mesothelioma started rising from around 1975 and 
reached a little more tha 100 cases a year in 1985, in parallell to asbestos use 30 
years earlier. It has been postulated that it should start sinking in the first decade of the 
2000s. Methods: The incidence of pleural mesothelioma for both sexes have been taken 
from the ofiicial Swedish pulblication “Cancer Incidence in Sweden”, the latest avialable 
figures of which is 2012. Results: Since 1984, a plateau has been reached, with around 
100 cases of new pleural mesotheliomas occurring in Sweden every year, sometimes a 
little less, more often a little more. No tendency to declining figures can be seen so far. 
The median age st diagnosis has remained the same since the 1960ies, 54-70 years. 
Furthermore, the percentage of women is the same, 15-20 % of the total. Conclusion: The 
heaviest exposure took place in Sweden around 1965; after this date, in most working 
places people became more aware and the exposure was diminished, but continued 
until early 1970ies. It has been postulated that 40 years after exposure, the risk should 
decline, and if so those who were 20 years old in 1970 should by now have a decreasing 
risk, but there are no signs of this. Since the relative risk for men and women is about 
the same, it is unlikely that general environmental exposure to asbestos explains the 
lack of decline of the curve. Interestingly, the median age at diagnosis has remained 
the same though most of those exposed should by now have a fairly advanced age. 
Keywords: Mesothelioma, Incidence, Sweden
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P2.08-017 Chest Wall Soft Tissue Sarcomas: Impact of Adjuvant Radiation 
Therapy Following Surgical Resection Adnan M. Al-Ayoubi, Sadiq S. Rehmani, 
Andrea Wolf, Andrew Kaumfan, Raja Flores, Faiz Y. Bhora Thoracic Surgery, Icahn School 
of Medicine at Mount Sinai, New York/NY/United States of America
Background: Primary chest wall soft tissue sarcomas are rare tumors of the thoracic 
wall. The objective of this study is to evaluate the impact of adjuvant radiation therapy on 
survival following surgical resection using the Surveillance, Epidemiology, and End 
Results (SEER) database. Methods: We queried the SEER database for all surgically 
resected histologically proven primary chest wall soft tissue sarcomas between 1998 
and 2010. Exclusion criteria included pediatric sarcomas, multiple malignancies and 
unknown grade, stage or radiation therapy status. Chi-square tests were performed to 
identify covariates associated with receiving adjuvant radiation therapy. Coarsened-
exact matching was used to generate a matched cohort of patients who received 
adjuvant radiation following surgery and patients who underwent surgery alone. Cox 
regression and Kaplan-Meier analyses were performed to determine covariates 
associated with overall survival. Results: A total of 570 patients were included in the 
cohort prior to matching based on the selection criteria. Histological type (p = 0.003) 
and tumor grade (p < 0.001) were independently associated with receiving radiation 
therapy. Cox-regression did not demonstrate reduced hazards of death for adjuvant RT. 
After coarsened-exact matching, Kaplan-Meier survival analysis of matched groups (105 
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pulmonary carcinoid tumor and who underwent MIBG treatment at our institution were 
included. Tumor characteristics, demographic information, response rate and survival 
was captured. Patients without adequate records were excluded. All patients required 
MIBG avid disease on MIBG scintigraphy. MIBG treatment consisted on 200 mCi of 131I 
MIBG delivered over one hour at 30 cc/hour. Follow up CT scans were used to determine 
response by RECIST 1.1. Results: Six pulmonary carcinoid patients were identified who 
had undergone MIBG treatment. The mean age at initial MIBG treatment was 66 (range 
44-89) Females represented 83% of patients. There were five typical and one atypical 
carcinoid patient included. Two patients achieved a partial response, one patient had 
stable disease and three patients had progression following MIBG treatment. Overall 
survival for the entire cohort from the date of MIBG therapy is shown. 
 
Conclusion: In our small cohort, MIBG treatment seemed to be beneficial in 
50% of patients with MIBG avid disease with a partial response observed in 
33% of patients. This treatment was well tolerated and offered an increased 
survival in an already heavily pretreated cohort. MIBG may offer some pulmonary 
carcinoid patients an additional treatment option. Further research should be 
directed at examining radionuclide therapy in pulmonary carcinoid patients. 
Keywords: carcinoid, radionuclide, neuroendocrine, MIBG
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P2.08-022 Pulmonary Resection of Metastatic Renal Cell Carcinoma 
Olga Lebedieva, Yurii Kondratsky, Andrii Ganul, Leonid Bororov Tumors of Thoracic 
Cavity, National Cancer Institute, Ukraine, Kyiv, Kyiv/Ukraine
Background: Pulmonary resection for metastases from renal cell carcinoma (mRCC) is a 
treatment option that can provide long-term disease-free survival. Larger number and size 
of metastatic nodules, increasing number of lymph node metastases, shorter disease-
free interval, and decreased preoperative forced vital capacity are negative prognostic 
factors in this setting. The potential role of surgery is illustrated by the results from a 
series of 278 patients with mRCC in which 51 percent underwent removal of all of their 
metastatic disease with curative intent, 25 percent underwent partial resection of their 
metastatic disease, and 24 percent were treated without surgery. Metastases were most 
frequently resected from the lung, brain, bone and soft tissue. Methods: Between 1989 
and 2014, 73 patients (44 men, 29 women) underwent pulmonary resection of mRCC. 
Only patients who met the criteria for potentially curative operation, that means, control 
of primary tumor, ability to resect metastatic diseas were included. All patients received 
immunotherapy after surgical treatment. Results: Pulmonary metastases were bilateral 
in 15 patients and unilateral in 58 patients. 15 bilateral (9 staged) and 58 unilateral 
thoracotomies were performed. Wedge resection was performed in 68 and lobectomy in 
5 patients. The overall 5-year survival was 72.8 % 10-year survival was 43,9% and 15-year 
survival was 20,9% among the patients, who had no other extrapulmonary metastases. 
The 5-year survival of curative resected patients with metachronous metastases was 
better then patiens with synchronous metastases. The overall 5-year survival was 31,3 
% among the patients, who had extrapulmonary metastases. Conclusion: Surgical 
resection of isolated lung metastases in carefully selected patients is safe and 
effective. Metastasectomy nowadays is the best treatment option in cases with 
technical resectable metastases with as much as possible good prognostic factors. 
Keywords: pulmonary resection, renal cell carcinoma, metastasis
were followed up at least three months through medical record review and direct contact 
with the patient. With 2x2 table we determined the accuracy of PCPB. Results: A total 
of 1034 pleural biopsies were performed. Malignancy was identified in 466 (45.07%) 
of whom 252 (24.37%) had adenocarcinoma,105 (10.16%) mesothelioma, cancer not 
differentiated 28 (2.71%), epidermoid 5 (0.48%) small cells cancer 19 (1.84%), giant 
cells cancer 6 (0.58%), limphomas 11 (1.06%) and others malignancies 40 (3.87%). 116 
(%) cases of pleural tuberculosis and 2 (0.19%) parapneumonicos. 378 (36.56%) biopsies 
were non/specific inflammatory. 171 (19.81%) were excluded to the analysis due to 72 
(6.96%) obtaining no pleural tissue and in 99 (9.57%) we can not obtain case information. 
A total of 863 biopsies were analysed to asses the accuracy.
Indicator Lung cancer and other malignancies Mesothelioma
Sensitivity % (CI 95%) 77 (74-79) 81 (78-83)
Specificity % (CI 95%) 98 (97-99) 100
Positive predictive value % (CI 95%) 99 (98-100) 100
Negative predictive value % (CI 95%) 66 (63-70) 97 (96-98)
Likelihood ratio positive 38.5 81
Likelihood ratio negative 0.23 0.19
Prevalence % (CI 95%) 68 (65-71.3) 15 (13-17)
 
Conclusion: This is a valid, available, accurate and precise diagnostic test which 
can be applied in patients with pleural effusion to establish cancer or tuberculosis 
diagnostic. The percutaneous closed pleural biopsy in this setting is useful in 
our practice due to produces big change from pre-test to post-test probability. 
Keywords: percutaneous closed pleural biopsy, lung cancer, diagnostic test
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P2.08-020 Percutaneous Cryoablation for Pulmonary Metastasis of Soft 
Tissue and Bone Sarcomas Keisuke Asakura1, Yoshikane Yamauchi1, Masafumi 
Kawamura2, Seishi Nakatsuka3, Hideaki Yashiro3, Masanori Inoue3, Ikuo Kamiyama1, 
Takashi Ohtsuka1, Mitsutomo Kohno1, Hisao Asamura1 1Department of Thoracic Surgery, 
Keio University, School of Medicine, Tokyo/Japan, 2Department of Surgery, Teikyo University 
School of Medicine, Tokyo/Japan, 3Department of Diagnostic Radiology, Keio University, 
School of Medicine, Tokyo/Japan
Background: The treatment of pulmonary metastases of soft-tissue and bone sarcomas 
is challenging, as they are highly resistant to both chemotherapy and radiotherapy. 
Hence, while surgery is the treatment of choice, the treatment options are currently very 
limited for non-surgical patients. Therefore, the purpose of this study was to evaluate the 
safety and efficacy of percutaneous computed tomography (CT) -guided cryoablation for 
pulmonary metastases of soft tissue and bone sarcomas. Methods: Hospital records of 
patients who underwent cryoablation for metastatic lung tumors of soft-tissue and bone 
sarcomas were reviewed. Percutaneous cryoablation was performed using the Cryocare 
system (Endocare, Irvine, CA) and multi-slice CT fluoroscopy. CT scans were obtained 
immediately after the procedure; follow-up CT was performed on days 1, 7, 30, and 90, 
and subsequently at 6-month intervals. The procedural safety, local progression-free 
survival, and overall survival were assessed retrospectively. Results: Between 2002 and 
2011, percutaneous cryoablation was performed on 20 patients (12 men and 8 women; 
median age, 46 years; age range, 17-83 years) for 56 metastatic lung tumors of soft 
tissue and bone sarcomas, during a total of 36 sessions. Of the 20 patients, 2 (10%) 
refused surgery and 18 (90%) were considered inoperable due to multiple tumors or 
insufficient pulmonary function. Of the 36 sessions, pneumothorax occurred in 12 (33%), 
transient hemoptysis in 11 (31%), and hemothorax in 1 session (3%). Of the 12 sessions 
with pneumothorax, 1 (8%) required chest tube insertion. No surgical intervention was 
required for any of these complications. With a median follow-up of 27 months, 2 tumors 
(4%) showed disease progression at the original cryoablation site. The local progression-
free survival rates at 1 and 3 years after cryoablation were 95% each, and the 1- and 3- 
year overall survival rates were 77% and 49%, respectively. Four patients were alive over 5 
years after cryoablation. Conclusion: Percutaneous cryoablation is a feasible and efficient 
treatment option for inoperable metastatic lung tumors of soft tissue and bone sarcomas. 
Keywords: cryoablation, soft tissue and bone sarcomas, metastatic lung tumor
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P2.08-021 Radionuclide Therapy with Meta-Iodo-Benzyl-Guanidine (MIBG) for 
Patients with MIBG Avid Pulmonary Carcinoid Tumors Robert A. Ramirez, David 
T. Beyer, Richard J. Campeau Neuroendocrine Tumor Program, Ochsner Medical Center - 
Kenner, Kenner/United States of America
Background: Pulmonary carcinoid tumors represent only 2% of all lung tumors. 
Treatment generally involves surgery which many times is curative, however, once 
metastasis develops there are no standard treatment options. Radionuclide therapy with 
MIBG has been shown to be beneficial for gastroenteropancreatic neuroendocrine 
tumors. We sought to determine the efficacy of MIBG treatment for metastatic pulmonary 
carcinoid tumors at the Ochsner/Louisiana State University Neuroendocrine 
Program. Methods: All patients who had a diagnosis of a metastatic typical or atypical 
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irregularity in 72%/54%, high-level irregularity in 5%/23% and mass formation in 0%/14% 
of BAPE and e-MPM group patients, respectively. • As for localization (including overlap) 
of pleural irregularity, irregularity in mediastinal pleura was observed in 30%/74%, basal 
pleura in 91%/77% and interlobar pleura in 0%/55% of BAPE and e-MPM group patients, 
respectively. The mediastinal pleural thickening was minimal in BAPE group and found 
regressed in the follow-up CT scans. Conclusion: • In BAPE group the occurrence 
rate of asbestos-related lesions was higher than in e-MPM group. • Because the 5% 
of BAPE cases presented irregular pleural thickening, the differentiation with MPM was 
difficult in such case. • The mediastinal pleural thickening, which is considered to be a 
characteristic of MPM, was also observed in 30% of BAPE cases. However, the finding 
disappeared during observation. And no BAPE case with interlobar pleural irregularity 
was found. These findings can be useful for differentiation BAPE and e-MPM cases. 
Keywords: Mesothelioma, benign asbestos-related pleural effusion, CT, asbestos
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P2.08-025 Contributing Factors to the Outcome of Primary Malignant Chest 
Wall Tumors Abdelrahman M. Abdelrahman1, Rabab Gaafar2, Mohamed Rahoma2, 
Hoda Baki2 1Suregry, National Cancer Institute, Cairo/Egypt, 2National Cancer Institute, 
Cairo/Egypt
Background: Primary malignant chest wall tumors are a heterogeneous group of tumors. 
They require special experience in designing resection and reconstruction. They account 
for less than 1% of all primary malignant tumors. This study is designed to clarify different 
factors contributing to the outcome of patients with primary malignant chest wall tumors 
in our institution. Methods: A retrospective study included 97 patients with pathology 
proven primary malignant chest wall tumors, treated at the national cancer institute, 
Cairo University, Egypt, during the period from 2002 to 2012. Computed tomography 
scan of the chest and upper abdomen was considered the primary staging tool for all 
patients. Magnetic resonance imaging was requested whenever indicated. Surgical 
resection and reconstruction was designed according to the site and extent of the lesion. 
resected. Adjuvant and neo-adjuvant therapy was given according to thoracic oncology 
committee decision. This study was approved by the ethical committee of our institution 
and informed patient consent was taken. Results: Primary malignant chest wall tumors 
represented 10.5% of all thoracic malignanciesin our institution. There were 46 males and 
51 females, the median age was 41 years. Chondrosarcoma was the commonest tumor 
histology (20.6%). The mean tumor size was 9.3x6.2cm. Tumor multiplicity was found in 
15.4% of patients. Bone resection was performed in 76 patients (78.3%), ribs resection 
was performed in 62 patients and the average number of resected ribs per patient was 
2.57 ribs. Sternal resection was done in 9 patients. R0 resection was achieved in 73% 
of patients. There was one operative related mortality and 23% of patients suffered 
procedure related complications. Local recurrence developed in 45.3% of patients. The 
overall survival for the whole group at 1, 3 and 5 years was 67.1%, 37.2% and 26.1 % 
respectively and the median survival time was 26 months. Different prognostic variables 
were used to assess better survival including: age , sex, site , size pathologic subtype , 
tumor grade,, safety margin Good prognostic factors include female sex, age ≤ 40years, 
no rib resection, safety margin ≥ 1cm, when the least safety margin involve the soft 
tissue and not the bone, tumor size ≤ 6cm in diameter. Conclusion: rimary malignant 
chest wall tumors should be treated with highly qualified thoracic surgeon and achieving 
wide resection margins is of great importance to minimize local tumor recurrence that 
will have an impact on long-term survival.
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P2.08-026 Molecular Markers of Resected Esophageal Squamous Cell Cancer 
and Its Correlation with Clinical Outcome Gang Lin, Shuiyun Han, Maohui Yan, 
Xiaojiang Sun, Yaping Xu, Weimin Mao Zhejiang Cancer Hospital, Hangzhou/China
Background: The tumor related molecular markers in esophageal squamous cell 
cancer(ESCC) remains unknown and requires further investigation in order to promote 
effiicient and rapid development of therapeutic methods. The aim of our study was 
to evaluate if molecular markers of ESCC correlates with patients’ prognosis and the 
outcome. Methods: Protein expressions of EGFR, C-MET, HER2 were detected by 
immunohistochemistry (IHC) in 180 paraffin-embedded tissue samples from stage IIB-
IIIC ESCC patients with esophagectomy at the Zhejiang Cancer Hospital between January 
2007 and December 2012. Log-rank test was used for univariate analysis, and Cox’s 
proportional hazards model was used for multivariate analysis. Assessed factors were 
age, gender, somking, alcohol use , tumor location, stage, differentiation, venous or nerve 
invasion, radiation, chemotherapy and expressions of EGFR, C-MET, HER2. Results: The 
median survival of all patients was 46 months. Of the all 180 patients, the positive rates 
of EGFR, C-MET, HER2 were 94.4%, 87.2% and 11.1%, respectively. The high expression 
rates of EGFR and MET were 47.8% and 46.7%, respectively. On univariate analysis ( 
Tabel 1 ), stage and high expression MET were the statistically significant unfavorable 
factors for overall survival, meanwhile, a nonsignificant trend toward dcreased overall 
survival was found with non chemotherapy patients. The multivariate analysis indicated 
that independent prognostic risk factors included MET ( P=0.029 ) , chemotherapy 
(P=0.046) and late stage ( p=0.000 ) with very high statistical significance. In subgroub 
of the patients with MET high expression, tumor location ( p=0.029 ), non chemotherapy 
( p=0.043 ) and late stage (p=0.014) had been the statistically significant unfavorable 
factors, analyzed by Cox proportional hazards model. In subgroub of the patients with 
C-MET low or negative expression, non chemotherapy ( p=0.043 ) and late stage ( 
p=0.014 ) had been the statistically significant unfavorable factors.
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P2.08-023 Aberrant Neuroendocrine Lung Tumor Nomenclature in Daily 
Practice, How Common Is It? Jules L. Derks1, Ernst-Jan M. Speel2, Robert Jan Van 
Suylen3, Erik Thunnissen4, Michael Den Bakker5, Anne-Marie Dingemans1 1Department 
of Respiratory Diseases, Grow School for Oncology & Developmental Biology, Maastricht 
University Medical Center, Maastricht/Netherlands, 2Department of Pathology, Grow School 
for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht/
Netherlands, 3Department of Pathology, Jeroen Bosch Hospital, ‘S Hertogenbosch/
Netherlands, 4Department of Pathology, VU University Medical Center,, Amsterdam/
Netherlands, 5Department of Pathology, Maasstad Hospital, Rotterdam/Netherlands
Background: The WHO 2015 classification for pulmonary carcinoids (PC) and high-grade 
neuroendocrine carcinomas (NEC) has in essence, not been changed compared to the 
previous one, despite known limitations in the diagnostic process such as 1) the need for 
resection material or large biopsies 2) reported inter-observer variability and 3) sporadic 
exposure in daily practice. Furthermore, nomenclature used in previous or different 
classification systems for neuroendocrine tumors may result in an aberrantly applied 
description of the WHO 2004 diagnoses. Here we evaluate if nomenclature established in 
daily pathology practice in the Netherlands is according to that advised by the WHO 2004 
for PC, NEC and non-small cell lung cancer (NSCLC) with neuroendocrine differentiation 
established by immunohistochemistry (IHC). Methods: Written conclusions (diagnoses) 
of pathology reports (2003-2012) were retrieved from the Dutch Pathology Registry. 
Conclusions describing PC, NEC and carcinomas with neuroendocrine features/
differentiation were selected by multiple queries on anatomic location, diagnosis and 
keywords (e.g. carcinoma + endocrine). All conclusions were screened in concordance 
with an experienced pathologist (JLD & RJS) and data on sampling method, diagnoses 
and origin of primary tumor were collected. Conclusions were excluded if established 
on autopsy cases or if it reported differential diagnoses, diagnoses of non-pulmonary/
unknown primary, non-neuroendocrine or small cell lung cancer. We compared the 
retrieved diagnoses with the advised WHO 2004 nomenclature after which all diagnoses 
were clustered (e.g. typical/well differentiated/grade I carcinoid into “PC”). For statistical 
analysis the X2 test was used. Results: 4612 conclusions were eligible for analysis of 
which N=698 (15%) described a diagnoses that did not match the WHO nomenclature. 
Foremost non-WHO diagnoses were: (poorly differentiated) neuroendocrine carcinoma; 
high-grade neuroendocrine carcinoma/tumor; NSCLC neuroendocrine carcinoma; 
neuroendocrine tumor and low grade (well differentiated) neuroendocrine carcinoma/
tumor (carcinoids). After discussion, we clustered N=2005 (43%) diagnoses into 
PC, N=1788 (39%) in high-grade NEC, N=763 (17%) in carcinoma with neuroendocrine 
features/differentiation and N=56 (1%) in neuroendocrine tumor n.o.s., respectively. 
Deviations from the WHO nomenclature occurred in 8% (N=157) of PC and 21% (N=377) of 
high-grade NEC and this occurred mainly on biopsy/cytology specimens (75% (N=399)). 
In (NSCLC) carcinomas with neuroendocrine features/differentiation diagnoses deviated 
from the WHO in 14% (N=108). Additionally, both the terms neuroendocrine “features” and 
“differentiation” were used to address positive neuroendocrine IHC staining (16% vs 25%) 
though differentiation was used slightly more often(p=0.001). Finally, 52% (N=1045) of 
PC diagnoses were established on biopsy/cytology specimens and a strong increase 
in diagnoses of large cell neuroendocrine carcinoma (LCNEC) on biopsy/cytology 
specimens was observed (<2008 N=174 vs. ≥2008 N=464, p<0.001). Conclusion: In 
daily practice 8% of PC, 21% of high-grade NEC and 14% of (NSCLC) carcinomas with 
neuroendocrine features/differentiation diagnoses deviated from the WHO 2004 
nomenclature. This occurred mainly on biopsy/cytology specimens. Also, the diagnosis 
(NSCLC) carcinoma with neuroendocrine ‘differentiation/features’ was unclear and 
should be specified (i.e. IHC or morphologically based (or both)). Finally, often the 
diagnosis LCNEC was established on biopsy/cytology specimens whereas this is 
not advised by the WHO. Whether these findings are due to personal preferences or 
difficulties applying current classification to limited samples, require further investigation. 
Keywords: neuroendocrine, Nomenclature, carcinoid, diagnosis
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P2.08-024 CT Findings of Early Pleural Mesothelioma and Benign Asbestos 
Pleural Effusion Katsuya Kato1, Takumi Kishimoto2, Nobukazu Fujimoto2, Kenichi 
Gemba3, Keisuke Aoe4, Yukio Takeshima5, Kouki Inai6 1Diganostic Radiolgy 2, Kawasaki 
Medical School, Okayama/Japan, 2Asbestos Study Center, Okayama Rosai Hospital, 
Okayama/Japan, 3National Hospital Organization Fukuyama Medical Center, Fukuyama/Japan, 
4National Hospital Organization Yamaguchi-Ube Medical Center, Ube/Japan, 5Hiroshima 
University, Hiroshima/Japan, 6Pathological Diagnostic Center, Hiroshima/Japan
Background: • Malignant pleural mesothelioma is known as disease of the poor 
prognoses. • Our purpose is to find useful CT findings for correct differentiation between 
Malignant Pleural Mesothelioma in the early stage (e-MPM) and Benign Asbestos Pleural 
Effusion (BAPE) to improve prognosis of MPM. Methods: • The BAPE group consisted of 
36 patients diagnosed at Okayama Rosai Hospital since Jan 2000. In all BAPE patients 
thoracoscopic biopsies were conducted to exclude malignant diseases including MPM. 
• In e-MPM group, 66 patients who were diagnosed mesotheliomas with T1 or T2 (IMIG 
system) by the CT evaluation were studied. The e-MPM patients were selected from 2,742 
mesothelioma death cases of Japanese vital statistics of 2003-05. • We evaluated CT 
scans taken at the time of diagnosis for each group. The evaluating items were presence 
of asbestosis, pleural plaque (PQ), rounded atelectasis (RA) and diffuse pleural thickening 
(DPT), as well as the grade and localization of pleural irregularities. Results: • In BAPE 
group (36 cases), the occurrence rate of asbestos-related lesions was significantly 
higher than in e-MPM group (66 cases) as follows; prevalence of asbestosis 17%/2% 
(*), PQ 92%/35% (**), RA 44%/0% (**) and DPT 25%/2% (**). (*P=0.0038 **P<0.001) 
• As for grade of pleural irregularity, no irregularity was found in 22%/9%, low-level 
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Medicine, Kurume/Japan, 33Toyama Prefectual Central Hospital, Tpyama/Japan,34University 
of Tsukuba Hospital, Tsukuba/Japan, 35Department of Thoracic and Cardiovascular Surgery, 
Mie University School of Medicine, Mie/Japan, 36Department of Thoracic Surgery, Kanagawa 
Cancer Center, Kanagawa/Japan,37Department of General Thoracic Surgery, Tokai University 
Hachioji Hospital, Tokyo/Japan, 38Department of Thoracic and Visceral Organ Surgery, 
Gunma University Graduate School of Medicine, Gunma/Japan, 39Department of Surgery, 
Okayama Saiseikai General Hospital, Okayama/Japan, 40Department of Chest Surgery, St. 
Marianna University School of Medicine, Kanagawa/Japan, 41Division of Chest Surgery, 
Nishi-Niigata Chuo National Hospital, Niigata/Japan,42Department of Regenerative Surgery, 
Fukushima Medical University, Fukushima/Japan, 43Department of Chest Surgery, Oita 
Prefectural Hospital, Ooita/Japan, 44Department of General Thoracic Surgery, Ishikawa 
Prefectural Central Hospital, Ishikawa/Japan, 45Department of General Thoracic Surgery, 
Kawasaki Medical School, Kurashiki/Japan, 46Division of Chest Surgery, Department of 
Surgery, Showa University School of Medicine., Tokyo/Japan, 47Division of Gastroenterology 
Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba/Japan, 48Clinical 
Research Support Center, Shizuoka Cancer Center, Shizuoka/Japan, 49General Thoracic 
Surgery, School of Medicine, Kyorin University, Tokyo/Japan
Background: Surgery is still standard modality for the patients with pulmonary metastases 
from colorectal cancer in spite of recent remarkable development of chemotherapy. The 
aim of this multi-institutional retrospective study was to determine which pathological 
size is the best suited to pulmonary resection, and to evaluate the prognostic 
factors in the patients with small colorectal solitary metastasis. Methods: Patients 
and Methods Patients with pathologically solitary metastasis were recruited. The 
retrospective examined sample size was finally 561 who underwent complete resection 
at 46 facilities in Japan from 2004 to 2009. Results: No statistically significant 
difference was detected between with adjuvant chemotherapy and without in disease 
free survival (DFS) and overall survival (OS) (p=0.09 and p=0.79). Disease free survival 
(DFS) and overall survival (OS) calculated after initial pulmonary resection at 5 years were 
71.0% and 41.7%, respectively. Tumors from 8-15mm in diameter showed the lowest 
incidence of recurrence in this series. Especially, relapse was occurred in all patients with 
pathological size 5mm (7/7, 100%) among the smallest group in the course of a median 
279 days. Although significant difference was not found, a tendency was recognized 
with 15mm as the border by the recurrence proportion and the receiver operating 
characteristic curves for DFS. CEA abnormality, pathological size (more than 20 mm), and 
Disease free interval (more than 2 years) were the prognostic factors for DFS, whereas 
age (more than 70 years old), CEA abnormality, DFI (more than 2 years), and previous 
extrapulmonary treatment were the prognostic factors for OS in both univariate and 
multivariate analyses. Conclusion: Our multi-institutional retrospective study proposed 
that the optimum pathological size up to 15 mm was suitable to pulmonary resection 
in the patients with solitary metastasis from colorectal cancers, but the smallest 
nodules (less than 7 mm) had a possibility of re-recurrence within a median one year. 
Keywords: pulmonary metastasis , colorectal cancer, solitary metastasis
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P2.08-028 Mediastinal Primary Malignant Germ Cell Tumor - Analysis of 
Prognostic Factors for Patients’ Survival. Single Institution Experience 
Elzbieta Nowara, Katarzyna Drosik-Rutowicz, Jaroslaw Nieckula, Joanna Huszno 
Clinical and Experimental Chemotherapy Department, Cancer Center and Institute of 
Oncology, Gliwice/Poland
Background: Primary mediastinal malignant germ cell tumours (MGCT) are a rare 
entity as typical localization of MGCT are gonads. As there is no concept of how to 
encode diagnosis of primary mediastinal MGCT (PMMGCT), they are usually reported 
as mediastinal tumor. The primary aim of the study was to evaluate the prognostic 
factors for survival of patients with PMMGCT. Methods: We analyzed data from patients’ 
medical records who had been diagnosed with a mediastinal tumor and encoded as 
C38 according to ICD-10. All of them had been diagnosed, treated and followed up 
in Cancer Center and Institute of Oncology in Gliwice Poland (COI). Patients’ medical 
records were analysed according to the national low regulation. We found 509 patients 
(pts) with mediastinal tumor diagnosis and reported as C38 according to ICD-10. The 
most frequently diagnosed tumors were mesothelioma - 32% of pts, and thymoma - 11% 
of pts. PMMGCT accounted for approximately 4% (19pts). 47% of them had seminoma 
and 53% non-seminoma diagnosed (the most frequent was tumor mixed). Median age 
was 28 years (range 19-41). Only 2 pts did not have any disease symptoms and the 
mediastinal mass has been discovered accidentally during periodic testing. The most 
frequent symptoms of disease were mediastinal pain and cough, in 79 and 74% of pts, 
respectively. The impact of the clinicopathological features was analyzed using the chi-
squared test with Yates’ correction. Survival evaluation was performed using the Kaplan 
Meier estimate with log rank test. Results: Median tumor size was 15cm (range 6,5-
20cm). All of pts received cisplatin based chemotherapy. In 53% of pts surgery was the 
primary treatment and the remaining pts started therapy with chemotherapy. 53% of pts 
experienced mediastinal radiotherapy. Total median dose was 40Gy (range 12-59,5Gy). 
All pts with seminoma achieved partial or complete response, disease progression was 
observed only in pts with non-seminoma tumors. 47% of pts had disease recurrence, 
including only one pts with seminoma. One pts had two high-dose chemotherapies 
followed by bone marrow transplant. 53% of the pts died due to disease progression or 
treatment complication, including one pts with seminoma. Median overall survival was 
27,5 months with 5-OS of 53%. Pts with seminoma had smaller tumor size than pts with 
non-seminoma tumors, p=0.03. Pts with a smallers tumor lived longer, p=0.09, however, 
neither surgery nor radiotherapy had an impact on survival, p=0.5 and 0.2, respectively. 
Pts with no general disease symptoms lived significantly longer than those who had 
any disease symptoms, p=0.03. Pts with mediastinal pain at the time at diagnosis lived 
significantly shorter, p=0.02. Pts with seminoma lived significantly longer than pts with 
non-seminoma tumors, p<0.001. Conclusion: Primary mediastinal germ cell tumours 
Table.1 Prognostic factors for overall survival in univariate analyses
Factors Category P-value
Age ≤65 (vs.＞65) 0.130
Gender Male (vs. Female) 0.486
Smoking Nonsmokers (vs. Smokers) 0.148
Alcohol use Non use (vs. Use) 0.977
Tumor location Upper and middle (vs. Lower) 0.193
Stage IIA-IIIA (vs. IIIB-IIIC) 0.000
Differentiation Well (vs. moderate and poor) 0.265
Venous or nerve in 
invasion Non invasion (vs. Invasion) 0.613
Radiation Non radiation (vs. Radiation) 0.957
Chemotherapy Non chemotherapy (vs. Chemother-apy) 0.090
EGFR >median (vs. ≦median) 0.347
C-MET >median (vs. ≦median) 0.018
HER2 Positive (vs. Negative) 0.142
 
Conclusion: In the Chinese population, HER2 expression rate was very low. The high 
expressions of HER2 and EGFR was not correlated with prognosis. High expression of 
C-MET may be prognostic factors for IIB-IIIC ESCC patients who underwent esophagectomy. 
ESCC with high expression of C-MET might be a poorer prognosis than those with C-MET 
low expression. In conclusion, C-MET is a important molecular marker in esophageal 
squamous cell cancer(ESCC) and further studies are necessary to explore the role of C-MET. 
Keywords: Esophageal squamous cell carcinoma, c-Met, EGFR, HER2
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P2.08-027 Investigation for the Optimum Resectable Pathological Size of 
Small Solitary Metastasis from Colorectal Cancers Yukinori Sakao1, Hiroaki 
Kuroda1, Takehiro Okumura2, Narikazu Boku3, Tomoyuki Hishida4, Yasuhisa Ohde5, 
Katsuo Yoshiya6, Masahiko Higashiyama7, Hirofumi Adachi8, Yukitoshi Satoh9, Kotaro 
Kameyama10, Masato Kanzaki11, Masahiro Yoshimura12, Yoshinobu Hata13, Motoki 
Matsuura14, Fengshi Chen15, Kazuo Yoshida16, Hidefumi Sasaki17, Hirotoshi Horio18, 
Mitsuhiro Takenoyama19, Motohiro Yamashita20, Takehisa Hashimoto21, Atsushi Fujita22, 
Meinoshin Okumura23, Kazuhito Funai24, Satoshi Shiono25, Hisatoshi Asano26, Makoto 
Suzuki27, Eishin Hoshi28, Yuji Shiraishi29, Mitsuo Nakayama30, Nobuhiro Yamazaki31, 
Toshihiro Matsuo32, Hideki Miyazawa33, Yukio Sato34, Motoshi Takao35, Haruhiko 
Nakayama36, Shunsuke Yamada37, Kimihiro Shimizu38, Masafumi Kataoka39, Haruhiko 
Nakamura40, Takehiro Watanabe41, Hiroyuki Suzuki42, Shinji Akamine43, Yoshio 
Tsunezuka44, Masao Nakata45, Mitsutaka Kadokura46, Ichinosuke Hyodo47, Keita Mori48, 
Haruhiko Kondo49 1Thoracic Surgery, Aichi Cancer Center Hospital, -/Japan, 2Department of 
Surgery, University Hospital Mizonokuchi, Teikyo University School of Medicine, Kanagawa/
Japan, 3Division of Gastrointesitnal Medical Onclogy, National Cancer Center Hospital, Tokyo/
Japan, 4Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba/
Japan, 5Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka/Japan, 6Department 
of Chest Surgery, Niigata Cancer Center Hospital, Niigata/Japan, 7Department of General 
Thoracic Surgery, Osaka Medical Center for Cancer & Cardiovascular Diseases, Osaka/
Japan, 8Department of Thoracic Surgery National Hospital Organization, Hokkaido 
Cancer Center, Sapporo/Japan, 9Department of Thoracic Surgery, Kitasato University 
School of Medicine, Sagamihara/Japan, 10Department of Thoracic Surgery,A Kurashiki 
Central Hospital, Kurashiki/Japan, 11Department of Surgery I, Tokyo Women’S Medical 
University, Tokyo/Japan, 12Department of Thoracic Surgery, Hyogo Cancer Center, Akashi/
Japan, 13Division of Chest Surgery, Department of Surgery, Toho University School of 
Medicine, Tokyo/Japan, 14Department of Chest Surgery, Hiroshima City Hospital, Hiroshima/
Japan, 15Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, 
Kyoto/Japan, 16Division of Thoracic Surgery, Department of Surgery Shinshu University 
School of Medicine, Matsumoto/Japan,17Department of Immunology, Oncology and Surgery, 
Nagoya City University Graduate School of Medical Sciences, Nagoya/Japan, 18Department 
of Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome 
Hospital, Tokyo/Japan, 19Department of Thoracic Oncology, National Kyushu Cancer Center, 
Fukuoka/Japan, 20General Thoracic Surgery, Shikoku Cancer Center, Ehime/Japan, 21Division 
of Thoracic and Cardiovascular Surgery, Niigata University Graduate School of Medical 
and Dental Sciences, Niigata/Japan, 22Department of Thoracic Surgery, Gunma Prefectural 
Cancer Center, Gumma/Japan, 23Graduate School of Medicine, Faculty of Medicine, 
Osaka University, Oosaka/Japan, 24First Department of Surgery, Hamamatsu University 
School of Medicine, Hamamatsu/Japan, 25Department of Thoracic Surgery, Yamagata 
Prefectural Central Hospital, Yamagata/Japan, 26Department of Surgery, University Hospital, 
Jikei University School of Medicine, Tokyo/Japan, 27Department of Thoracic Surgery 
Kumamoto University Hospital, Kumamoto/Japan, 28Department of Thoracic Surgery, 
Saitama Cardiovascular and Respiratory Center, Saitama/Japan,29Chest Surgery Division, 
Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo/
Japan, 30Department of General Thoracic Surgery, Saitama Medical Center, Saitama Medical 
University, Saitama/Japan,31Department of Surgery,Saitama Medical University International 
Medical Center, Saitama/Japan, 32Department of Surgery, Kurume University School of 
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P2.08-031 Usefullness of Positron Emission Tomography in Thymic Lesions’ 
Surgery Sotirios D. Moraitis1, Ioannis Gkiozos2, Konstantinos Kanakakis1, Dimitros S. 
Moraitis1, Dimitrios Angouras3, Konstantinos Syrigos2, Theodore Liakakos4 
1Cardiothoracic Surgery, Naval and Veterans Hospital of Athens, Athens/Greece, 2Oncology 
Unit, 3Rd Internal Medicine Dpt, University of Athens, Medical School, Athens/
Greece, 3Cardiothooracic Surgery Dpt., University of Athens, Medical School, Athens/
Greece, 41St General Surgery Dpt., University of Athens, Medical School, Athens/Greece
Background: To evaluate the utilization of positron emission tomography (PET) scan 
with fluorine-18 fluorodeoxyglucose (FDG) in the selection of the surgical approach 
for thymic lesions. Methods: Twenty-two consecutive patients with thymic pathology, 
underwent PET-FDG after being evaluated by computed tomography (CT), since 
2011. The Standard Uptake Value (SUV) max of the lesion, as well as the SUV of the 
mediastinum, were estimated. The ratio SUVmax Lesion/Mediastinum was the caliber for 
selecting thoracoscopic thymectomy (TT) or thymectomy via median sternotomy (TMS), 
as the therapeutic procedure. If the ratio SUVmax L/M < 1, thoracocscopic thymectomy 
was preferable. If the ratio was, 1 < SUVmax L/M < 2, the selection was depended on 
the lesion’s dimensions (TT was preferred for lesions < 4 cm). If the ratio was SUVmax 
L/M > 2, a median sternotomy was the approach of choice. Results: There were 14 
male and 8 female patients, with a mean age of 41.1 y.o. In 13 patients the ratio SUVmax 
L/M showed up > 1, while in 4 patients was higher than 2. The histopathology revealed 
7 thymomas, 2 thymolipomas, 8 true thymic hyperplasias, 1 non seminomatous tumour, 
1 silicone indused lemphadenopathy while 1 patient is waiting for TT and another one 
(type C thymoma by fine needle biopsy), for TMS. The mean SUVmax for thymomas 
was 3.02+-1.67, for thymolipomas was 1.48+-0.26, for true thymic hyperplasias was 
1.82+-0.42, while the non seminomatous’ tumour SUVmax was 12.4. There have been 
performed 7 TTs, 1 Transcervical approach and 13 TMSs. R0 resection was achieved 
in all 21 patients, have undergone operation, so far. All patients had an uneventful 
postoperative course and the mean duration of hospital stay was 4 days for TTs and 7 
days for TMSs. Conclusion: There is no imaging modality sufficient by itself to identify 
the nature of thymic lesions. The intensity of FDG uptake is useful for predicting the grade 
of malignancy, and high FDG uptake may reflect the invasiveness of the malignant nature 
in thymic epithelial tumors. The creation of a scale of “metabolic biopsy” with the use of 
the ratio SUVmax L/M, will allow the use of TT to a larger patient population, following of 
course, the surgical oncology guidelines for the removal of thymic lesions.
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P2.08-032 Multimodality Treatment for Advanced Thymoma 
Ikuo Kamiyama, Takashi Ohtsuka, Takao Shigenobu, Yasoo Sugiura, Hisao 
Asamura Department of Surgery, Division of Thoracic Surgery, Keio University, School of 
Medicine, Tokyo/Japan
Background: Surgery remains the center of treatment of resectable thymoma. Radiation 
and chemotherapy have been applied widely as adjuvant treatment. However, the optimal 
treatment strategy for advanced thymoma remains controversial. This study aimed to 
evaluate the efficacy of multimodal treatment for patients with advanced stage III, IV 
thymoma. Methods: A total 250 consecutive patients with thymoma were treated in our 
hospital from January 1985 to December 2013. Among these, 70 patients were staged 
as Ⅲ and Ⅳ. The overall survival (OS) was analyzed according to clinicopathological 
factors and types of treatment. Results: There were 32 patients with stage III (46%), 35 
patients with IVa (50%), and 3 patients with IVb (4%). The 10-year OS rates of patients 
with III+IV, III, IVa were 76%, 89%, and 64%, respectively. Types of treatment were as 
follows: surgery alone in 23 patients (33%), surgery followed by radiation in 31 (44%), 
surgery followed by chemotherapy in 2 (3%), surgery followed by chemo-radio therapy 
in 8 (11%), chemo-radio therapy alone in 6 (9%). There was no significant difference in 
OS among the treatment groups. Twenty-eight (40%) patients coexisted with myasthenia 
gravis (MG). There were no differences in OS between those with and without MG. 
Significant difference in OS was observed between 49 patients who underwent R0/
R1 resection and 21 patients who underwent R2 resection (P = 0.004). The disease-
free survival was worse in patients with combined full-dose mediastinal and low-dose, 
entire thoracic radiation than in those with full-dose mediastinal radiation alone (P = 
0.04). Conclusion: In this retrospective study, it was shown that the surgical resection 
should always try to leave no gross tumor behind to ensure better prognosis. Although 
the future comparative, prospective study seems difficult because of the limited number 
of new cases, the multimodal approach with maximal treatment intensity looks promising. 
Keywords: radiation, advanced thymoma, Multimodality treatment, sugery
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P2.08-033 DNA Methylation on Promotor Region of RASSF1 Gene in Thymic 
Neuroendocrine Tumor Is Higher than B3 Thymoma and Thymic Squamous 
Cell Carcinoma Koichiro Kajiura1, Kazuya Kondo2, Seiji Masuda3, Issei Imoto3, Yuki 
Morimoto4, Daisuke Matsumoto1, Naoya Kawakita1, Mitsuhiro Tsuboi1, Hiroaki Toba1, 
Yukikiyo Kawakami1, Hiromitsu Takizawa1, Shoji Sakiyama1, Akira Tangoku1 1Department 
of Thoraci,Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima 
University Graduate School, Tokushima City/Japan, 2Department of Oncological Medical 
Services, Tokushima University, Tokushima/Japan,3Department of Human Genetics, 
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 
occur mostly in males. Pts with mediastinal MGCT had poor prognosis, nonetheless. Pts 
with seminoma lived significantly longer than pts with non-seminoma tumors, p<0.001. 
Tumor size and general disease symptoms were the most important prognostic 
factors. The results of this study have many limitations, mostly due to the group of pts 
being small. That is why the results should be taken into consideration with caution. 
Keywords: primary mediastinal gern cell tumor, chemotherapy, Prognostic factors
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P2.08-029 Stereotactic Ablative Radiotherapy (SABR) for Pulmonary 
Oligometastases and Oligoprogression Joelle Helou1, Isabelle Thibault1, Latifa 
Yeung L2, Ian Poon1, Michael Tjong2, Andrew Chiang1, Suneil Jain1, Hany Soliman1, 
Patrick Cheung1 1Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto/Canada, 
2University of Toronto, Toronto/ON/Canada
Background: Use of SABR to treat pulmonary oligometastases, and more recently, 
oligoprogression to delay the need to change systemic therapy, is increasing despite 
no randomized evidence. This project reviews the outcomes of treating pulmonary 
metastases from a large single institution. Methods: From a prospective SABR database, 
180 pulmonary metastases in 120 patients were treated between 11/2008 and 12/2013. 
Indications for SABR were: 1) oligometastases, where the goal was to irradiate all sites of 
disease, 2) oligoprogression, where the goal was to irradiate only those tumours which 
were progressing while a systemic therapy strategy was controlling all other tumours, 
and 3) dominant areas of progression, where the goal was to irradiate dominant tumours, 
even if other tumours were progressing, usually in patients with indolent disease not on 
systemic therapy. Doses of 48-52 Gy in 4-5 fractions were delivered as per institutional 
policy depending on tumour location and histology. Since 2010 the dose for peripheral 
colorectal cancer (CRC) metastases was increased to 60 Gy in 4 fractions after 
a preliminary analysis revealed a higher local failure rate in those tumours. Results: 
Median age of patients was 66.5 years. Median duration of follow-up was 21.1 months. 
Median biological effective dose (BED) was 120 Gy10. We observed 1 (<1%) grade 5, 1 
(<1%) grade 3 and 8 (7%) grade 2 radiation pneumonitis. 2 year local control (LC) of 
irradiated tumours was 81%. Non-CRC metastases had higher 2 year LC compared to 
CRC tumours (94% vs 70%, p=0.002). In 18 patients with non small cell lung cancer 
(NSCLC) pulmonary metastases, 2 year LC was 95%. In the subgroup of 59 patients with 
CRC metastases, delivering 60 Gy was associated with significantly higher 2 year LC 
compared to lower doses (88% vs 61%, p=0.011). In 79 patients with oligometastases 
treated with SABR, the 2 year progression free probability (PFP), progression free 
survival (PFS) and overall survival (OS) were 63%, 42%, and 73%, respectively. In 27 
patients with oligoprogression treated with SABR, the 2 year PFP, PFS, and OS were 42%, 
24%, and 70%, respectively. At 2 years, no change in systemic therapy was seen in 56% 
of the patients irradiated for oligoprogression, with a median time to changing systemic 
therapy of 30.8 months. In the 12 oligoprogression patients where a change of systemic 
therapy strategy occurred after SABR, the median time to systemic therapy change was 
8.3 months. Conclusion: CRC metastases require higher SABR doses to optimize their 
LC. Outcomes for patients with oligometastases and oligoprogression treated with SABR 
seem favourable, but prospective clinical trials are needed to confirm these benefits. 
Keywords: lung metastases, SABR, Oligometastases, oligoprogression
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P2.08-030 Sunitinib in Patients with Advanced Thymoma and Thymic 
Carcinoma. Retrospective Analysis from RYTHMIC Database Jordi Remon1, 
Nicolas Girard2, Julien Mazières3, Eric Dansin4, Eric Pichon5, Julie Biemar6, Catherine 
Dubos7, Benjamin Besse8 1Gustave Roussy Cancer Campus,, Villejuif/France, 22Louis Pradel 
Hospital, Hospices Civils de Lyon, Lyon/France, 3University Hospital of Toulouse, University 
of Toulouse Iii (Paul Sabatier),, Toulouse/France, 4Clcc Oscar-Lambret, Lille/France,5Chru de 
Tours – Hospital Bretonneau, Tours/France, 6Aix Marseille University - Assistance Publique 
Hopitaux de Marseille,, Marseille/France, 7Centre de Lutte Contre Le Cancer François 
Baclesse, Caen/France, 8Gustave Roussy Cancer Campus, Villejuif/France
Background: Sunitinib is a potent oral tyrosine kinase inhibitor of VEGFR, KIT and 
PDGFR. In a single arm phase 2 study of sunitinib after at least one previous line of 
chemotherapy, a 26% of partial response rate (PR) was reported in thymic carcinoma 
(TC) and 6% in thymoma (T), with a median progression free survival (mPFS) of 7.2 
months and 8.5 months, respectively. We investigated if off-labelled prescription of 
sunitinib in this population induced the same efficacy signal. Methods: We investigated 
the database of the French thymic malignancies network. We reviewed advanced 
T and TC patients (p) who were treated with sunitinib in order to evaluate patient’s 
outcome. Results: From October 2011 to January 2015, 28 patients of 7 institutions 
were identified (20 TC and 8 T). 32% of patients were females and median age was 
49.7 y. Fifteen patients (54%) received sunitinib in ≥ 4th line of treatment. Two patients 
received sunitinib in 1st line treatment (1 T and 1 TC). The 37.5 mg was the initial dose 
of sunitinib in 16p. In the whole population, the PR rate was 21% (of 20p with TC, 4 (20%) 
had a PR; and of 8p with T, 2 (25%) had partial responses). Of note, PR to sunitinib was 
independent of treatment line (1p at 1st lines, 1p at 3rd line, 2 p at 4th line and 2p at ≥ 
5th line). 3 TC p were c-KIT positive, without a clear relationship with response rate (1 
PR, 2 PD). The mPFS in whole population was 103 days. For TC the mPFS was 87 days 
and 139 days for T. Sunitinib adverse events were manageable and tolerable. 8p stopped 
sunitinib due to toxicity. The median overall survival (OS) in the whole population was 
175 days, with prolonged OS in T vs. TC (403 days vs. 166 days)Conclusion: Sunitinib 
is an active treatment in thymic epithelial malignancies irrespective of histological 
subtype, even in a heavy pre-treated population, and treatment line, supporting 
antiangiogenic therapies as an alternative treatment option for these patients. 
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P2.08-035 Thymoma in Persahabatan Hospital Jakarta, Indonesia 2007 - 
2012: An Observational Study Elisna Syahruddin Faculty of Medicine, Universitas 
Indonesia, Persahabatan Hospital, Department of Pulmonology and Respiratory Medicine, Dki 
Jakarta/Indonesia
Background: In general Indonesian population, mediastinal tumors are rare. However 
In Persahabatan Hospital Jakarta as National Refferal Hospital in Respiratory Diseases, 
mediastinal tumors are ranked second in thoracic malignancy after lung cancer, and 
thymomas are common type. Methods: An observational study was done in patients 
diagnosed as thymoma in Persahabatan Hospital between 2007-2012. Clinical stages, 
histological types, treatment modalities and survival were analyzed. Histological 
classification were done based on World Health Organization criteria, and stage of the 
diseases was determined by Mosaoka Staging System. Results: We found that the 
trend of thymoma cases was increased annually since 2007 to 2012 in Persahabatan 
hospital Jakarta Indonesia. Among 67 cases diagnosed with thymoma, 43 cases has 
a complete data and follow up, of which 30 cases were male (69.8%) and 13 female 
(30.2%) with median age 50 years old ( range 16 years old to 79 years old). Myastenia 
gravis were found in 23 of 43 cases (53.5%). During follow up, 1-year survival rate 
was 72.1% and 3-year survival rate was 58,1 % respectively. There was no significant 
difference in survival rate of thymoma based on age, gender and the presence of 
myasthenia gravis, but Masaoka Staging and histological type were corellated with 
the survival. Using the Log-Rank test comparisons, We found statistically significant 
differences between type A-B2 (p 0.009), type A-C (p 0.001), type AB-C (p 0.032) and 
type B1-C (p 0.018). Masaoka staging has significant differences between stage I - IV 
A (p 0.012), the I - IV B (p 0.007), II-IV A (p 0.002) and II-IV B (p 0.002). Multivariate 
analysis showed that the most influential factor on the survival rate in these series 
was staging,-based on Masaoka Staging system. Conclusion: The Masaoka staging 
system is the most important determinant of survival in surgically cases of thymoma. 
Keywords: survival, Thymoma, Persahabatan Hospital, Indonesia
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P2.09-001 Triage Nurse Navigator Implementation: Improvements in NSCLC 
Resource Utilization Kelly Zibrik, Janessa Laskin, Cheryl Ho Medical Oncology, BC 
Cancer Agency, Vancouver/BC/Canada
Background: Involvement of nurse navigators (NN) in oncology care is becoming 
increasingly common to facilitate more timely access to diagnostic services and 
treatment for patients. A lung cancer NN was implemented at the British Columbia 
Cancer Agency (BCCA) and this role involved developing pathways for triage and staging 
investigations, initiating molecular tests and coordinating new patient referrals. In the 
BC publicly funded health care model, reflex molecular testing is not available. The 
purpose was to evaluate referral practice, timelines and molecular testing for advanced 
NSCLC patients in cohorts with and without a triage nurse navigator. Methods: The study 
included all advanced NSCLC patients referred to the BCCA – Vancouver Centre in two 
separate 1 year cohorts for comparison; 2011 and 2014. Timelines between referral and 
systemic therapy/radiotherapy (XRT) treatments, availability of molecular testing and 
data on referral patterns were collected. Results: A total of 408 patients were included: 
212 in 2011, 196 in 2014. Endpoints for medical oncology (MO) comparing 2011 to 
2014: overall referral rates remained the same and the proportion of patients receiving 
systemic treatment increased, 57% vs 69% (p=0.05). Referral to MO consult 18 d vs 15.5 
d (p=0.11), referral to systemic therapy initiation was reduced 48 d vs 38 d (p=0.016). 
Molecular testing: time from referral to EGFR result was reduced 34 d vs 20 d (p<0.001), 
EGFR results available at MO consult increased 6% vs 37% (p<0.001), rate of molecular 
testing increased 62% vs 91% (p<0.001), EGFR mutation positive (19% vs 26% p=0.26). 
For radiation oncology (RO) endpoints: RO consults 87% vs 80% (p=0.05), the same 
proportion of patients received XRT (91% vs 87%). Time from referral to RO consult 10 d 
vs 8 d (p=0.005), referral to XRT 18 d vs 11.5 d (p<0.001). Conclusion: Implementation 
of a NN at triage reduced the time period between referral and treatment for MO and RO. 
The proportion of patients provided with molecular testing increased and the rate of EGFR 
positive results remained the same, an indication that more patients received appropriate 
first line targeted therapy. Nurse navigator participation during triage activities suggests 
that physician, diagnostic and clinical resources are more appropriately allocated. 
Keywords: nurse navigator, NSCLC, triage, wait times
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P2.09-002 Development of ‘Living Well’ - A Health and Wellbeing Programme 
for Thoracic Cancer Patients Paula Tindale-Paul, Tom Fynmore, Pippa Labuc, Olivera 
Kegey, Emma North Oncology, Guy’S & St Thomas’ NHS Foundation Trust, London/United 
Kingdom
Background: In 2013 the Holistic needs assessment (HNA) for newly diagnosed 
cancer patient, which highlights patient concerns and symptoms, was introduced in 
the UK. The use of the tool, in a leading cancer centre, identified a need for a multi-
disciplinary education and support group to better address the management of patient 
City/Japan, 4Department of Pathology and Laboratory Medicine, Tokushima University, 
Tokushima/Japan
Background: RASSF1 gene, located in 3p21.3, has eight exons and two promotor 
regions. RASSF1 is very famous tumor suppressor gene in various cancers. It was 
reported that DNA methylation on promotor region of RASSF1 in lung cancer, bladder 
cancer, and breast cancer and so on was higher, additionally low expression of 
RASSF1 was possible to cause to be poor prognosis. It is few reports about epigenome 
status in thymic epitherial tumors. We planned to explore DNA methylation in thymic 
epitherial tumors cyclopedically. Methods: ①DNA and RNA were extracted from 
frozen specimen of B3 thymomas (8cases), thymic cancers (8cases), and thymic 
neuroendocrine tumors(NET)(3cases). ②DNA was treated by bisulfite conversion. 
③DNA methylation level in 470000 CpG sites were measured by infinium methylation 
assay (Human methylation 450K; ILLMINA) exhaustively. ④DNA methylation on promotor 
regions of RASSF1 was measured by pyrosequencing（PyroMARKTMsystem;QIAGEN）. 
⑤Expression level of mRNA was measured by Real time RT-PCR(Thermal Cycler Dice® 
Real Time System Single; Takara), using TaqMan Gene Expression Assays (Hs00200394_
m1；Applied Biosystems). Internal reference gene is GAPDH（Hs02758991_g1；Applied 
Biosystems). ⑥Expression level of protein was analysed by immunostaining. Anti-
RASSF1a antibody（Anti-RASSF1a antibody [3F3] ab23950, Mouse monoclonal, 
abcam）was used by CSAⅡmethod（DAKO CSA II, Biotin-Free Catalyzed Amplification 
System）. Results: Significant difference of DNA methylation was recognized by analysis 
of infinium methylation assay. All 11 CpG sites were configured on 1α promotor region 
of RASSF1 in this assay. This assay showed DNA methylation level was highest in NET 
group. DNA methylation level were 70.9±4.9% in NET, 22.2±20.0% in thymic cancer, 
14.3±12.3% in B3 thymoma. ( NET vs Cancer/B3 t-test：P<0.00001). Pyrosequencing 
showed DNA methylation level were 24.0±13.1% in NET, 3.0±0.5% in thymic cancer, 
3.0±0.9% in B3 thymoma. Real time RT-PCR showed that relative expression level (/
normal thymus) were 0.48±0.31 in NET, 1.02±0.82 in carcinoma, 2.13±2.93 in 
B3 thymoma ( NET vs Carcinoma/B3 t-test：P=0.16). Immunostaining of RASSF1 
was scored by stain intensity and stain extend. Immunostaining scoring of RASSF1 
showed expression inhibition rate were 66% in NET, 50% in thymic cancer, 14% in B3 
thymoma. Conclusion: The infinium methylation assay showed that DNA methylation on 
promotor region of RASSF1 in NET is higher than B3 thymoma and thymic cancer. The 
pyrosequencing validated this result. It was tendency to suppress the mRNA or protein 
expression of RASSF1 in NET, compared to other tumors. It is possible that aberrant 
DNA methylation on promotor region of RASSF1 may be specific change in NET among 
thymic epitherial tumors. Now we collected 8 formalin-fixed paraffin-embedded samples 
of thymic NETs to perform pyrosequencing and immunostaining of RASSF1 gene. 
Keywords: thymic epitherial tumor, RASSF1, DNA methylation
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P2.08-034 ‘Nerve Sparing’ Surgery for Invasive Thymomas Stylianos 
Korasidis1, Pietro Bertoglio1, Marco Lucchi1, Gabriella Fontanini2, Alfredo Mussi1 
1Department of Surgical Medical Molecular Pathology and Critical Care, Divison of Thoracic 
Surgery, University Hospital of Pisa, Pisa/Italy, 2Department of Surgical Medical Molecular 
Pathology and Critical Care, Divison of Pathological Anatomy, University Hospital of Pisa, 
Pisa/Italy
Background: Masaoka-Koga stage and the radicality of the surgical resection are 
the most important prognostic factors for thymomas. Infiltration of the phrenic nerve 
interests 10-40 % of invasive thymomas (stage III and IVA). We report the clinical and 
oncological outcome of patients operated on for invasive thymoma by a intention-to-
treat “nerve sparing” technique. Methods: In the period 1992-2012 we have applied the 
“nerve sparing” surgery in all patients with invasive thymoma, and without pre-operative 
evidence of phrenic nerve paralysis. In that period we have operated on 72 stage III e 
33 stage IVA thymomas. Thirteen out of them had a preoperative radiological evidence 
of phrenic paralysis (5 stage III and 8 IVA) and they were preliminary excluded. In 30 
patients phrenic nerve was partially or completely surrounded by the thymoma and they 
underwent an attempt of ‘’nerve sparing’’ surgery. In twenty six cases the resection of 
the thymoma with a phrenic sparing procedure was possible. All patients underwent 
subsequent adjuvant radiation (45-60 Gy). Results: Twelve male and 14 female have 
been treated, with a mean age of 56 years (range 26-83). At the hystological analysis 
there were: 1 Type A, 5 Type AB, 10 Type B1, 5 Type B2, 5 Type B3. Myasthenia gravis 
and red cell aplasia were associated in fifteen and one case, respectively. Despite the 
attempt of preserving the phrenic nerve, in five patients phrenic palsy was observed in 
the immediate postoperative period. Three of them showed a complete phrenic nerve 
recovery, while in the other 2 cases nerve paralysis was irreversible. Mean follow up 
was 96 months (DS ±73) with an mean overall survival of 89 months (DS ±68). The 
mean disease free interval was 81 months (DS ±71). Three patients (11,5%) had a pleural 
recurrence (2 stage IVA, 1 stage III) requiring further surgical resection. Two patients 
(7,7 %) died (1 of systemic metastases and 1 for other cause). Conclusion: Preserving 
the phrenic nerve in case of invasive thymomas is feasible and if associated to adjuvant 
radiotherapy may also allow to achieve good long term disease-free results. In reason 
of the excellent local control of disease it should be proposed mainly to patients 
with invasive thymoma and myasthenia gravis or with a poor pulmonary function. 
Keywords: Thymoma, phrenic nerve, Pulmonary Function, disease free survival
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recurrence after lung cancer surgery? · Are there strategies or interventions aimed 
at managing uncertainty in this group that could have wider application for patients? 
Keywords: Recurrence-risk, Communication, Information
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P2.09-004 Prospective Audit of Lung Cancer Nurse Specialists Telephone 
Link Line Call to Surgical Patients 30 Days Post Hospital Discharge Maureen 
King, Lavinia Magee Thoracic Oncology, Papworth Hospital, Cambridge/United Kingdom
Background: The Lung Cancer Nurse Specialists (LCNS) at Papworth Hospital provide 
support and information throughout the surgical patient’s pathway. The Thoracic 
Enhanced Recovery Program has shortened post-operative length-of-stay from 9 days 
(2010) to 5 days (2013). The aim of this audit was to evaluate the role of a follow up 
telephone link line call 30 days post-surgery. There is evidence in the literature that 
telephone contact is beneficial for patients. Patients receive a telephone call from a 
LCNS within the first week of their discharge and this is considered to be a good means of 
providing health education and advice, managing symptoms, recognizing complications 
early and giving reassurance to patients after discharge. However, in order to gain a 
more detailed account of a patient’s recovery / rehabilitation (particularly visits to A&E, 
readmissions and complications) it was proposed that a second phone call be made 
by the LCNS at 30 days post discharge. Methods: A data collection spreadsheet was 
designed. From 01/01/2013 to 31/08/2013 patients following a lung cancer resection 
received a telephone call from a LCNS, 30 days post-surgical discharge. A holistic 
assessment of the patient’s needs, and their progress was explored and actioned. 
Information regarding advice sought, recovery perception and readmission rates were 
gained. Results: 101 patients underwent surgery, 93 received a 30 day call (61M/32F). 
91 (98%) were aware of whom to contact following discharge and were able to name 
their LCNS. 73 felt ready for discharge, 11 unsure, 9 not ready (8 unanswered). 37 
recovered better than expected, 35 as expected, 15 slower and 6 worse than 
expected. Post-operative pain was more persistent / severe in thoracotomy patients 
48/57 (84%) compared to a video assisted thoracoscopy approach 24/36 (66%). 26 
patients required advice for constipation, 7 diarrhoea. 60 breathlessness on exertion, 
1 discharged home on oxygen. 10 felt low in mood since discharge. 7 were readmitted 
within 30days. Conclusion: The 30 day post discharge link line call has revealed some 
areas of self-care needs which appear not to have been fully understood or addressed. 
Patients were perhaps not able to retain the information. The introduction of a structured 
pre-operative education program may assist with addressing these issues. Also, active 
telephone follow ups, initiated by the LCNS, appeared relevant to the problems patients 
face after discharge. With telephone follow-up information can be reinforced, thereby 
increasing compliance, and ensuring the physical and emotional comfort of the patient. 
Limitations to this audit include the use of no nationally recognised quality of life tools / 
scales. A review of the timing and number of calls to a patient with focus given to pain, 
constipation and psychological support will help deliver a more comprehensive service. 
Keywords: post operative, surgical, Lung cancer nurse specialists, telephone
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P2.09-005 Living With Lung Cancer - Preferred Sources of Patient Support and 
Information: The Papworth Experience Georgina Howell, Lavinia Magee 
Thoracic Oncology, Papworth Hospital, Cambridge/United Kingdom
Background: Support groups can help to improve patients’ coping and mental 
adjustment to a cancer diagnosis and treatment. They have also been shown to have a 
positive impact on psychological wellbeing and reduce anxiety and depression. However, 
at Papworth Hospital (a regional cardio-thoracic centre), it became increasingly difficult 
to recruit patients to the lung cancer support group. Consequently, before starting any 
new initiative, the decision was made to disband the group in December 2013 and to 
identify alternative and beneficial ways of supporting patients. Methods: With patient 
user involvement, a questionnaire was designed Living with lung cancer - how can we 
help you? From 12/05/2014 to 30/05/2014, 100 questionnaires were distributed to all 
patients with a confirmed diagnosis of lung cancer who attended a thoracic oncology 
outpatient clinic. Responses were anonymous and returned to a secure box for review in 
the audit department. Results:81% of the questionnaires were returned. Patients were 
referred to Papworth from 8 different hospitals in the region. 79% were over 60 years old 
at diagnosis. 84% recorded a diagnosis within the last 4 years, the remaining recording 
diagnosis back to 2001. Since diagnosis, the most useful sources of information are 
listed below as recorded by the patients (please note more than one answer could be 
selected):
Family/ friends 38
Hospital doctor 62
LCNS / key worker 60
GP 32
District nurses 9
Macmillan nurses 9
Hospice 3
Cancer Centre 3
symptoms and supportive care needs. The most common physical symptoms reported 
were; Fatigue/tiredness (74%), sleep (64%), walking/stairs (58%), breathing (56%), 
appetite/weight changes (46%), and pain (40%). The most common psychosocial 
concerns were; Fear/anxieties (48%), and sadness (48%). With increasing national 
focus on cancer survivorship and rehabilitation initiatives for cancer patients there 
is growing evidence that support programmes can increase quality of life and 
psychological functioning. A multi-disciplinary team (MDT) was established to develop 
a health and wellbeing programme for thoracic cancer patients treated at Guy’s and 
St Thomas’ NHS Foundation Trust (GSTT). Methods: Working as a MDT, consisting of 
Cancer Nurse Specialists, Physiotherapists, Occupational Therapists and Dietetics, 
a programme of physical, psychosocial and educational components was devised 
to address the key symptoms, including the following; 1. Managing your energy 2. 
Keeping active 3. Eating Well 4. Managing breathlessness 5. Keeping on top of things 
6. Time to relax - Qigong Inclusion criteria; Medically stable thoracic cancer patients 
under GSTT, at any point along their pathway plus carer/family member Exclusion 
criteria; Anaemia, Hb <80g/L, untreated brain mets/cognitive issues restricting ability 
to participate in group sessions. Each session was paced to optimise patient care 
allowing interventions to be tailored to individual’s situations, stage of disease, and their 
wishes. Patient experience questionnaires, which were standardised across all sessions, 
are handed out and following the end of the programme the CSQ-8 is completed by 
the patients, allowing for continuous quality control of our service from the patient’s 
perspective. Results: Data to February 2015 showed the following; -94% of patients 
reported an improvement in their ability to self-manage their symptoms -100% of patients 
reported increased confidence in managing their symptoms -100% of patients reported 
that anxiety was reduced -Mean CSQ-8 evaluation score = 9.6/10 Patient attendance; 
-6 week programme format: 9 patients started the programme, 3 completed. -3 week 
programme format: 21 patients started the programme, 12 completed. -1 week 
programme format (only 1 programme completed at time of abstract submission): 
9 attended and completed entire day Conclusion: A programme of this nature 
represents a valuable intervention output following HNA across the cancer pathway. It 
supports local and national cancer strategies around survivourship and rehabilitation. 
With progression free survival in thoracic cancer improving the self-management of 
physical and psychosocial symptoms, longer term, becomes increasingly relevant. The 
numbers have been limited, indicative of the symptom and treatment burden for this 
patient group, however overall results are impressive. This indicates the requirement 
of a flexible approach. In adapting the format over time patient reported experience 
remained very positive, moreover attendance improved. Thus making it more accessible 
for our patient group, as well as enabling, equiping and empowering them to self-
manage symptoms and live well with cancer. This model can be adapted and translated 
into other health care settings and tumor types, both nationally and internationally. 
Keywords: multidisciplinary, survivorship, Wellbeing, Self-management
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P2.09-003 Identifying Research Questions in Disclosure of Risk of Recurrence 
following Lung Cancer Surgery Using a Critical Synthesis of the Literature 
Matthew Johnson1, Karen Collins2, Stephen Brummell2, Angela M. Tod3 1Cancer Nursing, 
Royal Brompton and Harefield NHS Foundation Trust, London/United Kingdom, 2Centre 
for Health and Social Care Research, Sheffield Hallam University, Sheffield/United 
Kingdom, 3University of Manchester, Manchester/United Kingdom
Background: Although surgery for lung cancer is often a successful treatment, very 
little is known about how patients cope and live with the possibility of recurrence of 
cancer in the future. Two published literature reviews on prognosis disclosure in cancer 
care have identified no papers focused specifically on risk of recurrence in post-surgical 
lung cancer patients. Aims were to develop a synthesis of the current literature around 
prognostic disclosure in cancer care in order to: · Identify a thematic framework that can 
be used to provide a model for the factors present in prognostic disclosure in cancer care. 
· Identify research questions that will inform future study into disclosure of recurrence 
risk in lung cancer patients following potentially curative surgery. Methods: A review of 
published studies on prognostic disclosure in cancer care up until the end of 2003 was 
used as a starting point. An updated review was undertaken and a systematic approach 
was taken to searching the literature from 2004 – June 2014. Data were extracted from 
the identified papers using a comprehensive data extraction form. Codes were assigned 
to key elements of data within the results and conclusion sections of the papers. Critical 
interpretive synthesis was used to explore themes by constructing an integrative grid to 
examine findings between studies and to identify similarities and contradictions. Themes 
from the original review were identified and compared to the updated findings. A further 
framework grid was constructed to investigate between-theme relationships and to help 
identify “synthetic constructs” and a thematic framework. Results: Twenty papers were 
identified in the updated review and were diverse in their objectives and patient groups. 
Themes were identified in these studies and in the original review covering the nature of 
prognostic information, patient need for prognostic information, patient need to maintain 
hope, balancing hope and realism, patient factors, disease factors and clinician factors. 
A thematic framework was developed. Future research questions were framed around 
disclosure of risk of recurrence following lung cancer surgery. Conclusion: There are 
no studies looking at prognostic information-giving in post-surgical lung cancer patients. 
Patients generally want prognostic information, but also want information that supports 
hope. Patients appear to struggle to fully understand complex prognostic information and 
value help making sense of information. Working with patients to understand and manage 
the uncertainty of their situation may be particularly valuable. Future research questions 
include: · How do patients and their clinical teams manage information disclosure about 
possible cancer recurrence following lung cancer surgery? · What is the emotional impact 
on patients of the uncertainty of potential recurrence following lung cancer surgery? 
· What information do patients want regarding recurrence risk? · What strategies do 
patients and professionals currently use to help manage the uncertainty of potential 
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“Functional Assessment of Chronic Illness Therapy-Fatigue” (FACIT-F). Results: The total 
carnitine concentration in the plasma samples was the highest after 48 hours (day3) of 
administration and showed significant increase compared to before the administration 
of CDDP (day1)(65.3±17.6 µmol/L vs. 95.2±28.9 µmol/L, p=0.001). Total urine 
carnitine concentration was the highest after 24 hours (day2) of administration and 
showed significant increase compared to day1 (122.3±108.7 µmol/L vs. 632.9±376.6 
µmol/L, p=0.003). Fatigue levels were the most severe on day 4 and did not improve 
thereafter. Conclusion: The study suggests an increase of the amount of carnitine 
excretion within urine is a possible predictive factor for the appearance of fatigue related 
to chemotherapy. Future studies will be planned to investigate the protective effects of 
carnitine administration for fatigue in patients treated with CDDP-containing chemotherapy. 
Keywords: Cisplatin, chemotherapy, fatigue, Carnitine
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P2.11-002 Identifying Relationship between Symptom Burden and Overall 
Survival in Patients with Advanced Nonsmall Cell Lung Cancer: A Prospective 
Study Fatma Özbaki, Ülkü Yılmaz, Yurdanur Erdoğan, Derya Özaydın Kızılgöz Atatürk 
Chest Diseases and Chest Surgery Education and Training Hospital, Ankara/Turkey
Background: Prognostic factors in nonsmall cell lung carsinoma (NSCLC) has been 
described in many studies in medical literature. It is unclear the relationship between 
overall survival and symptom burden. The aim of our study is defining the prognostic 
factors in advanced NSCLC and to describe relationship between symptoms and overall 
survival. Methods: In this study, the patients newly diagnosed stage 3b and 4 with 
NSCLC and Eastern Cooperative Oncology Group Performans Status (ECOG PS) of 
0 to 2, from August 2011 to May 2013 in Ataturk Chest Diseases and Chest Surgery 
Education and Training Hospital were included. We obtained the demographic, diseases 
related and laboratory data for all patients. Symptoms were analyzed with The Edmonton 
Symptom Assessment Scale (ESAS) before and after chemotherapy. The study was 
designed prospectively and the patients were followed up to 826 days. Cox model 
proportional risk analysis was performed at the end of the the followed-up period to 
assess the beginning symptoms, symptoms differences after chemotheraphy and the 
relationship between the general characteristics and the survival. Results: We conducted 
a multivariate analysis and it is found that as one of the general characteristics; the 
stage of the diseases (p= 0,004 HR: 2,373 95% CI: 1,317-4,274) and the histopathologic 
subtypes (p=0,006 HR: 2,311 95% CI:1,271-4,202) were prognostically significant. The 
patients with fatigue as the beginning symptoms (p=0,001 HR:2,389 %95 % CI: 1,460-
3,908) and the sadness score 4 and over (p= 0,032 HR:2,311 95% CI: 1,271-4,202) 
had lower survival, it is also found that patients with cough intensity increasing after 
chemotheraphy (p=0,006 HR: 1,933 95% CI: 1,128-3,314) had lower survival and high 
mortality risk as well in multivariate analysis. Conclusion: During the treatment process, 
together with performance scores of patients with symptom score monitoring will be 
meaningful. Further prospective studies including a larger group of patients are required 
in order to describe better the relationship between the symptoms and the prognosis. 
Keywords: advanced NSCLC, ESAS, Prognostic factors, survival
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P2.11-003 Changes in Quality of Life Through the Early Intervention by a 
Palliative Care Team for Patients with Advanced Lung Cancer Taro Yokoyama1, 
Hiroshi Kunikane1, Hiroaki Okamoto2, Tsuneo Shimokawa2, Yukiko Nakamura2, Youko 
Agemi2, Akira Sato2, Yuki Misumi2, Kazuhito Miyazaki2, Naoto Aiko2, Mari Ishii3, Rie Oishi4 
1Department of Palliative Medicine, Yokohama Municipal Citizen’S Hospital, Yokohama-
Shi/Japan, 2Department of Respiratory Medicine, Yokohama Municipal Citizen’S Hospital, 
Yokohama/Japan, 3Department of Medical Oncology, Yokohama Municipal Citizen’S Hospital, 
Yokohama/Japan, 4Research Support Center, Yokohama Municipal Citizen’S Hospital, 
Yokohama/Japan
Background: The change in quality of life (QOL) through the early intervention by a 
palliative care team was analyzed in patients with advanced lung cancer. The contrast 
between patients’ own evaluation on their QOL and their QOL estimated by their 
attending physicians was examined as well. Methods: The eligibility criteria were 
newly-diagnosed Japanese patients with stage IV lung cancer, whose ages were over 
20- years old, whose Eastern Cooperative Oncology Group Performance Status were 
from 0 to 3, and those who had written informed consent. For the patients and attending 
physicians, QOL questionnaires, which were in line European Organization for Research 
and treatment of Cancer Quality of Life Questionnaire-Core15 （EORTC QLQ c-15）, were 
conducted at the time of the enrollment and twelve weeks later. The primary endpoint 
was a change in global QOL score, which ranged from 0 (worst) to 100 (best), after the 
twelve-week intervention. Results: 58 patients out of 96 who were newly diagnosed as 
stage IV lung cancer were enrolled in this study. 43 patients had the QOL evaluation after 
twelve weeks. One patient withdrew consent, one patient moved to another hospital 
and other thirteen patients died during the intervention period. The primary endpoint 
improved by more than 25% that was originally anticipated (50 points at the enrollment, 
64.7 points after the intervention.). All of the following factors including emotional state, 
nausea, vomiting, pain, constipation improved by more than 25% similarly to the primary 
endpoints, although other QOL factors showed a slight improvement or no change. 
While the difference between the QOL score by the patients and the physicians was 
apparent at the beginning the intervention, it became smaller by every measurement 
after twelve weeks. In Japan, Palliative care units (PCUs) have a role of hospices as well, 
and there are not enough number of them, to meet the entire needs for the end-of-life 
care. Some patients end up dying while on the waiting lists of PCU. Less percentage 
of patients who had early palliative care (EPC) died while waiting PCU admission, as 
Of those diagnosed within the last 12 months the Lung Cancer Nurse Specialist (LCNS) 
was the most useful source of information. The questionnaire proposed a number of topics 
that might be included in some form of additional support of which 34% were interested. 
The most common request was for information on symptom control (breathlessness 
and fatigue), relaxation techniques and treatment options. The questionnaire suggested 
a number of different formats for providing additional support. Of the 27 respondents, 
15 (55%) preferred telephone support from a LCNS. Conclusion: The LCNS plays a 
pivotal role in providing relevant information and support. The challenge is to find new 
and innovative ways that will help to optimize patients’ psychosocial as well as physical 
wellbeing. Consideration will be given to increasing telephone support to signpost 
patients to appropriate information on treatment options and symptom control. We 
plan to audit the effectiveness of LCNS telephone consultations to ascertain the impact 
on patient wellbeing. Different types of relaxaion techniques such as yoga classes will 
be explored. Co-ordination of information management within a large geographical 
area, incorporating many hospitals and local community facilities, is essential. 
Keywords: Patient information, support, wellbeing, telephone
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P2.09-006 A Breathlessness Booklet Carol A. Davies1, Nuala Galligan2, Larissa 
Cowpe3 1Macmillan Lung Cancer Clinical Nurse Specialist, Aneurin Bevan Univesity Health 
Board, Monmouthshire/United Kingdom, 2Palliative Care, Aneurin Bevan University Health 
Board, Newport/United Kingdom, 3Palliative Care Team, Aneurin Bevan University Health 
Board, Monmouthshire/United Kingdom
Background: Breathlessness is common amongst lung cancer patients. It leads to 
inactivity, helplessness and loss of self esteem. As the experience of breathlessness 
has physical and non-physical aspects, management of the symptom of breathlessness 
is challenging. It is recognised that non pharmacological intervention for breathlessness 
is beneficial. In 2012 lung cancer patients expressed the need for an easy to use 
breathlessness aid. A breathlessness booklet was subsequently developed. Patients 
were asked to assess the usefulness, understanding and easiness of each entry. The 
booklet evaluated well with patients and users. The appointment of a Macmillan specialist 
occupational therapist to the palliative care team was an ideal opportunity to re-examine 
the breathlessness aid and introduce a multi disciplinary approach. Methods: The 
booklet was reviewed with the layout redesigned and an additional section added on 
activities of daily living. Information includes anatomy and physiology, breathing control, 
anxiety management including relaxation techniques, activity pacing and positional 
aids. Results: The revised A5 booklet has since been used by patients and a number 
of the multi-disciplinary team have had sight of it. Information remains, as intended 
simplistic but is comprehensive. The booklet is being distributed by the Macmillan lung 
cancer CNS and palliative care team which includes consultant, CNS’s Macmillan OT 
and healthcare support workers. Patient feedback remains very positive. It suggests 
patients feel more equipped to cope with their breathlessness. They report it has helped 
them cope with pacing themselves and controlling breathing when using the stairs. 
Others enjoy the choice of breathing techniques and tips for managing activities of daily 
living in and out of the home. Conclusion: Interest in this breathlessness aid has been 
expressed from a variety of specialities and hospitals within Aneurin Bevan Health Board. 
Requests have been made for the breathlessness leaflet to be available on intranet so 
that all personnel within ABHB can access information. An additional booklet has been 
produced on Fatigue. Both booklets have subsequently been presented at The All Wales 
Lung Cancer Forum 2014 Annual Conference. Delegate feedback was very positive. 
Keywords: breathlessness, Coping techniques, Multi-disciplinary working
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P2.11-001 The Relationship between Carnitine Pharmacokinetics and Fatigue 
in Thoracic Cancer Patients Treated with Cisplatin-Containing Chemotherapy 
Tatsuhiko Kashii1, Toshiro Miwa1, Kensuke Suzuki1, Seisuke Okazawa1, Kenta Kambara1, 
Minehiko Inomata1, Tomoaki Ikezaki1, Kouichi Tanabe2, Hatsuna Yasuda1, Shinya Kajiura1 
1Toyama University Hospital, Toyama/Japan, 2Meijo University, Nagoya/Japan
Background: A large majority of patients who receive chemotherapy suffer from fatigue, 
which lowers their QOL and activities and also has a negative influence on therapeutic 
efficacy. Although supportive care for those undergoing chemotherapy has steadily 
progressed, the pathogenesis and treatment of fatigue during chemotherapy is still 
unknown. Carnitine is an amino acid with a molecular weight of 161, and it plays a critical 
role in energy production. A decreased level of plasma carnitine has been reported in 
the case of cancer patients who developed cachexia. It has been reported that carnitine 
is excreted in the urine after the administration of platinum-type anticancer drugs. We 
examined the relationship between carnitine pharmacokinetics in patients who received 
chemotherapy including cisplatin (CDDP) and fatigue. Methods: Ten patients (7 male/3 
female, median age 66.5 yrs (46-73), 3 SCLC/4 NSCLC/3 malignant mesothelioma, 
6 PS0/4 PS1) who received standard chemotherapy including CDDP were examined. 
We performed 24-hour urine collection and took blood samples on day 1 (before the 
administration of chemotherapy), day 2, 3, 4, and 8 to measure free carnitine concentration, 
total carnitine concentration, and acylcarnitine concentration in the plasma and urine. We 
simultaneously evaluated fatigue levels using the CTCAE, STAT Japanese version, and 
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P2.11-006 Impact of Different Comorbidities in Clinical and Molecular 
Characteristics in a Cohort of Non-Small Cell Lung Cancer (NSCLC) Patients 
(P) Enric Carcereny, Teresa Morán, Laia Vila, Ana Estival, Maria De Los Llanos Gil, 
Iris Teruel, Max Hardy-Weber Medical Oncology, Catalan Institute of Oncology-Hospital 
Germans Trias I Pujol, Badalona/Spain
Background: The most common comorbid conditions related to Lung Cancer are age- and 
tobacco-related illnesses, such us cardiovascular disease, chronic obstructive pulmonary 
disease(COPD) and other malignancies. Different studies have demonstrated and impact 
in clinical outcome. We retrospectively review the clinical and molecular characteristics, 
and the outcome related to comorbidities of an homogeneus cohort of advanced 
NSCLC. Methods: The study included data from all consecutive p who were diagnosed 
as having advanced NSCLC at our hospital between January 2008 and December 2013. 
Overall survival (OS) and progression free survival (PFS) were evaluated with Kaplan-Meier 
curves and groups are compared using the Log-rank test. Variables analyzed included 
patient characteristics (age, gender, smoking history, Performance Status by ECOG), 
tumor characteristics (histology, stage, molecular profile, site of metastasis), treatment 
characteristics (chemotherapy regimen, total cicles per line, total chemotherapy lines, 
objective response(ORR) according to the RECIST criteria). Comorbidities analyzed 
were: COPD, Cardiovascular diseases, Other Cancers and Others. Results:A total of 
580 p were included, 163 p no had comorbidities and 417(71.8%) had at least one. Table 
1 summarized patient’s characteristics. Any comorbidity were more frequent in female 
sex (79.6% vs 64.4%; p0.0002), older patients(mean age 64.3 vs 56.7 yo; p<0.0001), 
less never-smokers(16.1% vs 25.2; p0.033), less molecular alterations (14.2% vs 22.1%; 
p0.025) and more squamous histology (25.7% vs 12.9; p0.0043). No differences is 
ORR, PFS and OS were seen globally. For each comorbidity, COPD was associated to 
worse ORR (65.9% vs 75.6%; p0.023) and OS (8.1 months vs 14 months; p0.018), and 
cardiovascular diseases were associated to worse OS (9.1 monthsvs 15.5 months; 
p<0.0015). In univariate and multivariate analysis COPD, Cardiovascular comorbidity, 
male sex, age more than 65 yo, and non molecular alteration were related to worse 
OS. Table 1. Baseline characteristics (N of patients treated with at least one line: 
486).
No comorbidities 
(N=163) Any comorbididy (N=417) p-value
Median age 
Gender 
(Female) 
Smoking 
history (%) 
-never -former 
-current -not 
reported 
EGFR 
mut/ ALK 
translocation 
Histology 
-NOS -Ade-
nocarcinoma 
-Squamous 
-Adenosqua-
mous -LCC 
-LCC-NE Site 
of metastasis 
-Lung -Brain 
-Bone -Liver 
-Adrenal gland
56.7(11.0) 105(64.4) 
41(25.2) 63(38.7) 
58(35.6) 1(0.6) 
36(22.1) 22(13.5) 
109(66.9) 21(12.9) 
1(0.6) 9(5.5) 1(0.6) 
59(36.2) 35 (21.5) 
59(36.2) 23(14.1) 
25(15.3)
64.3(9.8) 332(79.6) 
67(16.1) 209(50.1) 
138(33.1) 3(0.7) 59(14.2) 
60(14.4) 228(54.7) 107 
(25.7) 7(1.7) 8(1.9) 6(1.4) 
159(38.1) 96(23.0) 
131(31.4) 50(12.0) 
53(12.7)
<0.0001 
<0.0001 
0.033 
0.025 
0.0043 
0.70 0.74 
0.28 0.49 
0.99
 
Conclusion: Comorbidities are frequent in patients with advanced NSCLC p, and 
are age and tobacco related. Patients with COPD have a worse ORR and OS, and 
patients with Cardiovascular comorbidities have worse OS. In our knowledge, 
is the first study that relates comorbidities in NSCLC to molecular alterations. 
Keywords: NSCLC, comorbidities
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P2.11-007 Geriatric Oncology and Lung Cancer: Comprehensive Geriatric 
Assessment (CGA) Aspects Related to Outcomes and Important End-Points 
Aldo L.A. Dettino1, Marcello F. Fanelli1, Ludmilla T.D. Chinen2, Graziela Z. Dal Molin3, 
Geraldine E.D. Lima3, Solange M. Sanches1, Barbara Figueroa1, Ana M.M. Leite4, Marcilei 
E.C. Buim2, Helano C. Freitas1 1Oncologia Clínica, A C Camargo Cancer Center, Sao Paulo/
Brazil, 2Oncologia Clínica & Centro Internacional de Ensino E Pesquisa, A C Camargo Cancer 
Center, Sao Paulo/Brazil, 3Oncologia Clínica - Residency To 2014, A C Camargo Cancer 
Center, Sao Paulo/Brazil, 4Oncologia Clínica - Geriatric Oncology Unit, A C Camargo Cancer 
Center, Sao Paulo/Brazil
Background: Interdisciplinary oncology approach for geriatric patients (pts) is 
essential to improve health care, in the global era of populational aging. A possible 
way to implement that is to use CGA and interventions directed by its findings. Lung 
cancer (LC) treatment is a good scenario to present the importance of CGA, since its 
pts are usually old and with multiple comorbidities. Methods: LC pts with 70+ years 
compared with other cancer patients who applied for PCU during the same period as 
the present study. (12.5 % vs 30.4 %) In addition, duration of best supportive care in 
patients were extended approximately one month, as compared with past patients with 
stage IV lung cancer in undergoing EPC.(108.7day vs 78day) Conclusion: QOL improved 
in studied Japanese patients after the early interventions by the palliative care team. 
This result may indicate that discrepancy of QOL evaluation between the patients and 
physicians was lessened due to the early intervention by the palliative care team, which 
is considered to have fostered the improvement of the overall QOL. It was suggested 
that such intervention might support the patients in decision making for end-of-life-care. 
Keywords: palliative care team, early palliative care, advance care planning, lung cancer
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P2.11-004 Assessment of Pain Management in Cancer Outpatients Who 
Receive Chemotherapy Akiko Fujii1, Yu Yamada2, Koichi Takayama1, Takako Nakano1, 
Tatsuya Morita3, Junji Kishimoto4, Yoichi Nakanishi1 1Research Institute for Diseases of the 
Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka/Japan, 2Saitama 
Cancer Center, Saitama/Japan, 3Seirei Mikatahara Hospital, Hamamatsu/Japan, 4Research 
and Development of Next Generation Medicine Faculty of Medical Sciences, Kyushu 
University, Fukuoka/Japan
Background: Pain is one of the most frequent and burdensome symptoms in cancer 
patients. In addition, inadequate pain management may limit anti-cancer active treatment 
in these patients and impair their quality of life. Chemotherapy in the outpatient settings 
has become common in Japan in the last decade. However, the adequacy of pain 
management in patients who receive outpatient chemotherapy is not yet well-known. 
The primary objective of this study was to assess pain prevalence and intensity in these 
patients. The secondary objective was to assess the pain management status using the 
pain management index (PMI). Methods: Cancer patients with solid tumors or hematologic 
malignancies who received chemotherapy in the outpatient setting were enrolled. The 
PMI scores were calculated using the patient-rated pain score and the analgesic score. 
The PMI was evaluated twice in each patient on the first day and 3 to 5 weeks later 
when patients received chemotherapy at Outpatient Chemotherapy Administration Unit, 
Kyushu University Hospital, Japan. Patients were required to complete questionnaires 
including Japanese Brief Pain Inventory and the Distress Thermometer and Impact 
Thermometer. Results: Of 740 patients enrolled, 524 patients (71%) who completed 
the questionnaires at both baseline and follow-up were applied to the statistical analysis. 
54% patients experienced any pain and 14% patients had moderate or severe pain. 286 
patients (55%) received adequate pain management at both baseline and follow-up, while 
238 patients (45%) received inadequate pain management at baseline and/or follow-up. 
Multivariable analysis revealed that major depression had the most impact on adequacy 
of pain management. Conclusion: Patients who receive outpatient chemotherapy 
have a high prevalence of pain. The PMI is available to evaluate the pain management 
status of cancer patients in outpatient setting. Pain management for cancer patients 
needs to be assessed regularly even though their initial pain management is adequate. 
Keywords: pain management index, Cancer, Pain, outpatient chemotherapy
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P2.11-005 The Use of Duloxetine in Chemotherapy-Induced Peripheral 
Neuropathy Martin E. Richardet, Aldo A. Riso, Matias Molina, Matias Cortes, Patricia A. 
Hernandez, Luciana P. Acosta, Maria E. Pacher, Eduardo A. Richardet, Pablo Companys 
Capital, Ionc (Instituto Oncologico de Cordoba), Cordoba/Argentina
Background: Approximately 50% to 70% of patients with cancer who receive 
neurotoxic chemotherapy with taxanes and platinums will develop painful chemotherapy-
induced peripheral neuropathy. Duloxetine is a balanced serotonin and noradrenaline 
reuptake inhibitor licensed for the treatment of major depressive disorders and the 
management of neuropathic pain associated with peripheral neuropathy. Our objective 
is to assess the efficacy, compliance and toxicity of duloxetine for treating painful 
neuropathy. Methods: We analyzed data from 79 patients of the Instituto Oncológico de 
Córdoba (IONC) with breast, lung, colorectal, cervix and endometrium cancer. Eligibility 
required that patients have grade 2 (G2) or higher sensory neuropathy according to the 
NCI Common Terminology Criteria for Adverse Events, after paclitaxel, other taxane, or 
platinum treatment. The initial treatment consisted of taking 1 capsule daily of 30 mg of 
duloxetine for the first week and 2 capsules of 30 mg of duloxetine daily for 4 additional 
weeks. Results: We enrolled 79 patients with a median age of 63.25 years. Of these, 
67% were female and 33% male; 40.5% received adjuvant treatment, 55.6% advanced 
treatment and 3.7% neoadjuvant treatment. Chemotherapies used were Oxaliplatin 
(35.4%), paclitaxel (36.5%) carboplatin + paclitaxel (25.3%), and cisplatin (2.5%). At 
the time of starting treatment with duloxetine, 78.5% of patients had neuropathy G3 
and 21.5% G4. 91.5% of them have at least one decrease of neuropathy grade after 
30 days of treatment (p = 0.001). 12.6% of patients discontinued treatment due to 
somnolence (10.8%), vomiting or abdominal pain. 6.3% refused to receive treatment 
for being a psychotropic drug. Conclusion: In our study, treatment with duloxetine 
showed a response rate, statistically significant, of 91.5% (p: 0,001). Adherence to 
treatment was 81.1%, with somnolence and vomiting as the primary adverse events. 
Keywords: PERIPHERAL NEUROPATHY LUNG DULOXETINE
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primary tumor from lung, 70% stage III or IV, 50% current or former smokers, 67% having 
no coexisting lung or heart disease before, 42% also receiving chemotherapy. For the 
overall group, there were no statistically significant differences between the pre-RT value 
(QOL score 80.6) and any of the post-RT time points (QOL scores 79.9, 79.9 and 76.3 at 
1.5, 3 and 6 months post-RT, respectively). On a per-patient basis, there were no significant 
associations between any of the lung or heart dosimetric parameters and subsequent 
declines in QOL, though there was a non-significant trend towards greater declines in QOL 
with larger lung doses (e.g. mean, V20 and 30). There were no similar trends seen with 
the heart-based dosimetric parameters. When limiting the analysis to patients whose QOL 
score declined post-RT, there was a positive correlation between the degree of decline 
and the V30 and V40 of heart (p＜0.05). Among patients with lung cancer, the degree of 
decline in QOL was associated with the heart V20, V30, V40 (p＜0.05). Conclusion: There 
are no significant associations seen between lung and heart dosimetric parameters and 
subsequent declines in QOL. Additional analyses involving a larger number of patients are 
needed to better define predictors of RT-associated declines in QOL. (Supported in part by 
National Institutes of Health Grant CA69579 , a grant from the Lance Armstrong Foundation) 
Keywords: Cardiopulmonary function, quality of life, thoracic radiotherapy, 3D-planned RT
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P2.11-009 Depression and Disability in Lung Cancer Patients in a Nigerian 
Teaching Hospital Victor Lasebikan1, Ousoji M. Ige2, Babalola Faseru3 1Psychiatry, 
College of Medicine, University of Ibadan, Ibadan/Nigeria, 2Department of Medicine, Chest 
Unit, Ibadan/Nigeria, 3Department of Preventive Medicine and Public Health | Department of 
Family Medicine (Secondary), University of Kansas Medical Center, Kansas/United States of 
America
Background: Introduction: Research evidences show that depression and 
disability are important comorbid conditions in patients with Malignancies. However, 
little is known regarding the relationship between depression, disability and lung 
cancer in Nigeria. Objectives: The objectives of this study were to determine the 
prevalence of depression and disability in patients with lung cancer in a teaching 
hospital. Methods: Eighty patients diagnosed with lung cancer aged 35 to 80 years, 
were matched by age and gender with 80 patients without lung cancer from the Out-
Patient Department of the study centre. Depression was assessed using the Mini 
International Neuropsychiatry Interview (MINI) while the World Health Organization 
Disability Assessment Schedule 2.0 (WHODAS 2.0), was used to assess disability. 
All analyses were carried out using SPSS version 16.0. Results: Fifty one percent of 
patients with lung cancer had depression compared to 6.4% in the matched control. 
Among patients with lung cancer, disability was significantly associated with depression 
after controlling for smoking OR = 9.1, 95% CI (2.5-28.5), and stage of lung cancer OR 
= 2.1, 95% CI (1-13-9.42). Conclusion: There is a critical need to screen and manage 
depression in lung cancer patients in other to reduce disability and improve quality of life. 
Keywords: Depression, Disability, Lung Cancer, Early Detection
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P2.11-010 Predictors of Thromboembolic Events in Patients with Lung Cancer  
Bohdan Kadlec, Jana Skrickova Department of Respiratory Diseases and TB, University 
Hospital and Masaryk University Brno, Brno/Czech Republic
Background: Patients with lung cancer experience elevated risk of venous 
thromboembolism Prothrombotic factors in lung cancer include the ability of tumour 
cells to produce and secrete procoagulant substances and inflammatory cytokines, and 
the physical interaction between tumour cell and blood. Other mechanisms of thrombus 
promotion in malignancy include surgery, metastatic disease and use of chemotherapeutic 
drugs in combination with novel targeted drugs, such as antiangiogenic agents. Cancer 
patients with thrombosis have a shorter life expectancy than cancer patients without 
this complication. The occurrence of VTE worsens the quality of life and may delay, 
interrupt, or completely halt the cancer therapy. Methods: Patients diagnosed with 
primary lung cancer were followed up between 2006-2010. We recorded demographic 
data, histology and clinical stage, basic laboratory values of blood and coagulation, 
frequent and significant comorbidities, and details of initial cancer treatment. In 
patients with advanced, unresectable or metastatic lung cancer, these parameters were 
evaluated before the first cycle of chemotherapy or targeted therapy. Thromboembolic 
events were being detected by standard diagnostic procedure; if detected, the risk of 
VTE was automatically considered to be high. Statistical analysis included standard 
descriptive statistics; absolute and relative frequency of each category for categorical 
variables, median and 5% -95% percentile in the case of continuous variables. Analysis of 
categorical variables was supplemented with an analysis of frequency tables. Results: A 
total of 950 patients were enrolled, of whom 600 were men and 350 women. The median 
age of all patients was 64 years. Squamous cell carcinoma was the most frequent 
histological subtype (27.3%), followed by adenocarcinoma (23.8%), small cell carcinoma 
(18.4%) and non-small cell NOS. Hypertension was the most frequent comorbidity 
(39.6%),followed by COPD (38.2%), diabetes mellitus (19.4%), cerebrovascular disease 
9.6%, and heart failure (7.7%). Ninety-one thromboembolic events were registered in 
the entire group (9.6%), of which 80 (87.9%) were severe and 11(12.1%) less severe. In 
the group of patients with thromboembolic disease, platelet counts were significantly 
increased at the time of diagnosis of lung cancer – 368 x109 (191.0 to 540.0). Among 
comorbidites, heart failure was associated with an increased risk of VTE – OR 13.48 
(7.80 to 23.28), followed by cerebrovascular disease – OR 3.17 (1.78 to 5.64), atrial 
fibrillation – OR 2.96 (1.50 to 5.83), and obesity – OR 2.40 (1.26 to 4.58). Among 
laboratory parameters, platelet counts above 330,5x109 were associated with the 
occurrence of severe VTE – OR 3.66 (2.25 to 5.96). Conclusion: The incidence of 
old were found in our cohort of more than 600 pts, evaluated from Jan/12-Dez/12, the 
period of implementation of CGA in the Geriatric Oncology Unit of A. C. Camargo Cancer 
Center, a tertiary cancer care institution in Sao Paulo-SP, Brazil. Important geriatric data 
were extracted to evaluate those pts, to exemplify the importance of a coordinated 
interdisciplinary treatment plan with better chances of improving favorable clinical end-
points. CGA assessments included scales of: activities of daily living/ADL (basic: Katz; 
instrumental: Lawton), mini-nutritional assessment, depression (geriatric depression 
scale/GDS), comorbidities and polypharmacy. Fit pts received mainly full treatment; 
frail/borderline pts, mainly modified tx and/or specific supportive care. Results: Eighty 
pts with LC were part of a subgroup of the major cohort. Most relevant data at first visit 
are show in the table below. All pts were assessed with CGA by at least one nurse, before 
medical oncology evaluation - sometimes, by a psychologist as well. Table 1. Relevant 
CGA data and elderly with lung cancer (n=80).
Variable Categories or values
Age Median (range) 75 (70-88)
n (%)*
Sex Male/Female 44/36 55/45
ECOG/PS 0-1/2-3 53/23 63/29
Histology Adeno/SCC/Small cel 42/17/8 53/21/10
BADL KATZ = A 60 75
Altered KATZ 20 25
IADL Lawton = 27 27 34
Altered Lawton 53 60
GDS Normal (0-4) 43 54
Altered (≥4) 17 21
Not available (na) 20 25
Nutrition Undernourished ( < 8) 15 19
Under risk (8-11) 24 30
Normal (12-14) 24 30
na 17 21
 
* Some subjects may have variable not available. In addition, selected comorbidity 
count ranged 0-5 (median 2); polipharmacy 0-6 (median 5). Seventeen pts were in 
follow-up only (21%); 48 (60%) pts were under chemotherapy (isolated or combined 
with other therapies). Even though CGA domains were altered in around 60% of 
them, the planned treatment could be offered to 57 (71%) pts. Longer survival 
probability, in the series, was predicted by performance status (ECOG), BADL 
(Katz) and mini-nutritional assessment. Conclusion: CGA is gaining increasing 
importance in geriatric oncology. In the present LC subgroup cohort, even though 
in a small case series, it shows that many pts are vulnerable or even frail; however, 
interdisciplinary evaluation and multimodal treatment could be offered, without major 
complications. Limitations include missing data in any domain of CGA, for example. 
All efforts to better study and define CGA and help to implement interdisciplinary 
interventions may be utile to improve elderly quality of life and survival in LC care. 
Keywords: Geriatric Oncology, lung cancer, Geriatric assessment
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P2.11-008 Association between Heart/Lung Dosimetric Parameters and 
Subsequent Changes in Quality of Life in Patients Receiving Thoracic 
Radiotherapy Jing Chen1, Shiva K. Das2, Becky Green2, Stravers Lori2, Timothy Zagar2, 
Toni M. Roth2, Patricia Rivera3, Arif Sheikh4, William Mccartney4, Lawrence B. Marks2 
1Department of Radiation and Medical Oncology, Wuhan University, Wuhan City/
China, 2Departments of Radiation Oncology, Medicine and Radiology, University of North 
Carolina, Chapel Hill/United States of America, 3Department of Medicine-Pulmonary, 
University of North Carolina, Chapel Hill/NC/United States of America, 4Department of 
Radiology-Nuclear Medicine, University of North Carolina, Chapel Hill/NC/United States of 
America
Background: Thoracic radiotherapy can negatively affect cardiopulmonary function. 
We herein report on a prospective assessment of the association between heart/lung 
dosimetric parameters and subsequent changes in the quality of life (QOL) in patients 
receiving thoracic radiotherapy. Methods: Patients about to initiate a course of 3D-planned 
external beam RT for tumors in/around the thorax were prospectively studied as part 
of an IRB-approved clinical study. Written informed consent was obtained. Patients had 
assessments of cardiopulmonary QOL pre-RT and serially post-RT (e.g. 1.5, 3, 6, 12.. months 
post-RT) using the Functional Assessment of cancer Therapy-Lung (FACT-L) questionnaire. 
An association between a variety of dosimetric parameters for the heart and lungs (e.g. 
mean dose, Vx) and changes in pulmonary QOL (e.g. declines in QOL; pre-RT minus post-
RT values) were assessed using univariate and multivariate techniques. Results: The data 
from 24 patients treated between 2009-2013 and with evaluable QOL were studied. Their 
demographics are as follows: median age 68 (range 48-87), 46% male, 92% white, 98% 
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detected. The underlying death cause defines the disorder which initiated the events 
leading to death.The immediate death cause defines the final disorder or condition 
resulting in death.Some definitions were used in classifying the cause of death. When 
the amount of tumor in the lungs was the most important factor in fatal respiratory 
failure, this death cause was defined as tumor burden. Malfunction of the organs due 
to widespread metastases was defined as metastatic organ failure. Results: 56 cases 
were primary lung cancer patients. 11 cases were female and 45 cases were male. 
Mean age of the cases was 71.81 (46-88) in females and 68.91(50-84) in males. 5 of 
female cases were adenocancer, 4 were squamous cell lung cancer and 2 were small cell 
lung cancer. 20 of male cases were squamous cell lung cancer, 14 were adenocancer, 
11 were small cell lung cancer. Diagnostic methods were bronchoscopy in 33 patients, 
transthoracic lung biopsy in 12 patients, thoracentesis in 7 patients, metastatic organ 
biopsy in 4 patients. Mean survival periods were 3.1 months for small cell lung cancer, 
6.7 months for squamous cell lung cancer and 8.2 months for adenocancer. All of the 
small cell lung cancer cases had metastasis at diagnosis time. Pneumonia and MODS-
sepsis were the most common death causes in all cases. Conclusion: We think that 
our results would be helpful clinicians about lung cancer and follow up these patients. 
Keywords: lung cancer, mortality, survival, intensive care
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P2.11-013 Prognostic Factors Associated with Overall Survival in Croatian 
Patients with Advanced Lung Cancer Dragan Trivanovic, Lidija Kocic, Marina 
Dembic, Nika Spasic, Anuska Budisavljevic Oncology, General Hospital Pula, Pula/Croatia
Background: In Croatian population Lung cancer (LC) is the most common cancer in 
male and third most common in women. The age-adjusted incidence rates are 63.5 per 
100,000 populations per year. The aim of this study was to investigate the prognostic 
factors associated with overall survival in patients with cytological and/or histological 
confirmed advanced (IIIA-IV stage) LC. Methods: In this single institution prospective 
study, 164 consecutive patients were included between September 2008 and January 
2013 from Istrian County, Croatia.The prognostic factors evaluated for 2-year overall 
survival including gender, age, performance status, histology, blood group type, location 
od tumor, metastatic sites, anemia, elevated WBC, platelets, and diabetes mellitus. All 
factors with a P value < 0.05 at univariate analysis were entered into a multivariate 
analysis using Cox proportional-hazards models. Results: The median age of patients 
was 64.0 years (range 36 – 85 years) with males predominance (115 males vs. 49 
females). The histological types included: adenocarcinoma 56 (34%), squamous cell 
carcinoma 50 (30%), small cell carcinoma 33 (20%) other or not-otherwise specified 25 
(16%). The median follow-up time was 14.1 months. The 2-year overall survival rate of 
164 patients was 27.0%. Female gender and non liver metastatic disease are significantly 
associated with better overall survival. Data were shown in Table 1. Cox Regression 
analysis adjusted to tumor stage and age demonstrated that patients with 0 type blood 
group in adenocarcinoma subpopulation present a worst overall survival when compared 
to other blood type groups. Not elevated serum platelets in squamous NSCLC and 
elevated WBC, and female gender are independent prognostic factors in SCLC. Table 1 
Significant prognostic factors for overall survival in NSCLC
Baseline prognostic factor Univariate analysis
Multivariate 
analysis
2-year 
survival 
rate %
P-value HR (95% CI) P-value
Female* vs Male 0.020 0.62 (0,41-0.93) 0.022 38.0
Non-liver metastasis 0.024 0.60 (0.39-0.95) 0.028 28.8
0 blood group in adenocar-
cinoma NSCLC 0.008
6.64 (1.38-
32.14) 0.019 18.7
Normal serum platelets 
level 0.013
1.27 (0,45-
3.59) 0.654 23
Female* vs Male gender 
in SCLC 0.01
0.30 (0.11-
0.82) 0.019 44
Non-liver metastasis in 
SCLC 0.027
0.43 (0.18-
1.01) 0.055 20
Elevated serum WBC 0.015 0.39 (0.17-0.90) 0.026 19
 
 
Abbrevations: *referent, NSCL=Non Small Cell Lung Cancer, SCLC= Small Cell 
Lung Cancer, WBC= White Blood Cells Conclusion: Our results indicated that 
female gender is powerfull favorable prognostic factor in NSCLC and SCLC. 
0-type blood group is significant prognostic factor for short term survival 
following diagnosis of advanced lung adenocarcinoma and elevated WBC is 
associated with longer survival in SCLC subpopulation of advanced disease. 
Keywords: Lung Cancer, O-type blood group, Survival
serious thromboembolic events (8.4%) in our group of lung cancer patients was high, 
especially in patients with adenocarcinoma, advanced-stage disease, and in patiens 
on cancer treatment. In patients with thromboembolic disease, significantly higher 
median platelet counts were observed at the time of cancer diagnosis. In patients 
treated with chemotherapy, most thromboembolic events were observed shortly after 
the treatment starts and the majority of thromboembolic events occurred within 6 
months after the initiation of chemotherapy. These results justify prophylactic treatment 
in most patients with advanced or metastatic disease, adenocarcinoma, patients 
receiving radiotherapy or chemotherapy, and in presence of some associated disorders. 
Keywords: VTE, lung cancer, thrombosis, incidence, predictors
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P2.11-011 Utility of Tolvaptan and Demeclocycline in Addition to Systemic 
Chemotherapy for the Management of Hyponatraemia in Small Cell Lung 
Cancer Robert L. Metcalf1, Rachael Mccarthy2, Claire Higham3, Raffeale Califano1, 
Yvonne Summers1 1Department of Medical Oncology, The Christie NHS Foundation Trust, 
Manchester/United Kingdom, 2The University of Manchester Medical School, Manchester/
United Kingdom, 3Department of Endocrinology, The Christie NHS Foundation Trust, 
Manchester/United Kingdom
Background: Hyponatraemia due to the syndrome of inappropriate anti-diuretic hormone 
(SIADH) occurs in 10-25% of small cell lung cancer (SCLC) patients. Management of 
SIADH includes review of medications, fluid restriction and increased solute intake in 
addition to commencing chemotherapy. The risk/benefit of the tetracycline derivative 
demeclocycline and the vasopressin receptor antagonist tolvaptan were recently 
questioned in a clinical practice guideline for hyponatraemia management (Spasovski, 
2014). We sought to evaluate how demeclocycline and tolvaptan were used in addition to 
chemotherapy in the management of hyponatraemia in patients with SCLC and their effect 
on serum sodium prior to the publication of this guideline. Methods: A retrospective 
case-note review of 132 patients with SCLC treated at The Christie NHS Foundation 
Trust between 2009 and 2013 was undertaken to identify patients with serum sodium 
≤132 mmol/L at diagnosis. Clinical and laboratory data were collected and change in 
sodium from nadir to peak values at day 7-14 and day 20-40 was calculated. Patients 
were divided in three groups: treated with chemotherapy alone, and chemotherapy plus 
demeclocycline or tolvaptan. Patients with complete data were included in the statistical 
analysis. Mean values were compared using an unpaired Students t-test. Results: Twenty 
seven patients (20%) had sodium ≤132mmol/L at diagnosis (mean 128 mmol/L, SD 
3.9). Measurement of urine and plasma osmolality and urine sodium were performed 
in 6/27 (22%); thyroid function was measured in 6/27 patients and adrenal function 
in 4/27. Remaining patients were treated empirically. Patients receiving platinum 
based chemotherapy alone (12/27 patients receiving 1 to 6 cycles) had the highest 
mean sodium nadir of 128 mmol/L. Those receiving demeclocycline (13/27 patients) 
had a mean sodium nadir of 126 mmol/L. Patients receiving tolvaptan (6/27, 4 after 
prior demeclocycline) had the lowest mean sodium nadir of 121 mmol/L (p=0.0132 
comparing with chemotherapy only group). Chemotherapy alone increased mean sodium 
from 128 mmol/L to 134 mmol/L by day 7-14 (p=0.0062) and 135 mmol/L by day 
20-40 (p=0.0007). The addition of demeclocycline increased mean sodium from 126 
mmol/L to 130 mmol/L (p=0.0527) and 132 mmol/L (p=0.0102) at the same time-
points. The addition of tolvaptan increased mean sodium from a nadir of 121 mmol/L 
to 135 mmol/L at 7-14 days (p=0.0126) and 133 mmol/L at 20-40 days (p=0.0080). 
No significant toxicity of demeclocycline or tolvaptan were reported. Conclusion: Most 
cases of hyponatraemia were treated empirically as SIADH using demeclocycline 
and/or tolvaptan in over half of patients in addition to chemotherapy. Tolvaptan was 
used to treat patients with the lowest mean sodium most often following failure of 
demeclocycline. Despite this, these patients had peak sodium levels post treatment 
equivalent to those in other patients in this study. Clinician choice to treat patients with 
tolvaptan and/or demeclocycline in adition to chemotherapy was associated with a 
statistically and clinically meaningful improvement in serum sodium levels in all groups 
studied. Although this study is limited by the retrospective nature of the analysis, our 
group is using these data to produce guidelines on the management of hyponatraemia 
in SCLC to standardise patient management which will be prospectively evaluated. 
Keywords: small cell lung cancer, SIADH, Hyponatraemia, Tolvaptan
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P2.11-012 A Retrospective Assessment of Mortality of Patients Who Died in the 
Respiratory Intensive Care Unit with a Diagnosis of Lung Cancer Nesrin Ocal1, 
Deniz Dogan1, Gurhan Taskin2 1Chest Diseases, Gulhane Military Medical Faculty, Ankara/
Turkey, 2Intensive Care Medicine, Gulhane Military Medical Faculty, Ankara/Turkey
Background: According to 2015 data of WHO, lung cancer is still the most common 
causes of cancer death (1.59 million deaths in 2012) which is more than the combination 
of next three most common cancers (colon, breast and pancreatic). The number of deaths 
due to lung cancer has increased approximately 3.5 percent between 1999 and 2012. 
The number of deaths among men has reached a plateau but the number is still rising 
among women perhaps related with changesinsmoking habits. The age-adjusted death 
rate for lung cancer is higher for men than for women. Methods: In this study, firstly we 
retrospectively reviewed the data of 123 patients who died in respiratory intensive care 
unit of our hospital within last two years. We determined that 63 of them died because of 
lung malignancies and associated pathologies. Ages, genders, smoking habits, survival 
times, diagnosis methods, histopathological types of lung cancer, stages, metastatic 
states of the patients were compiled. In addition; clinical findings just before the death, 
indications of intensive care unit intake, underlying and immediate death causes were 
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P3.01-001 Imprime PGG, a Novel Innate Immune Modulator, Combined with 
Carboplatin, Paclitaxel and Bevacizumab for 1st Line Advanced Nonsquamous 
NSCLC Walburga Engel-Reidel1, Folker Schneller2, Martin Wolf3, Wolfgang Schuette4, 
Jamie Lowe5, Paulette Mattson5, Michele A. Gargano5, Myra Patchen5, Richard D. 
Huhn5, B. Ma5, A Braun5 1Kliniken Der Stadt Köln Ggmbh, Koln/Germany, 2Klinikum 
Rechts Der Isar, Technical University, Munich/Germany, 3Klinikum Kassel Gmbh, Kassel/
Germany, 4Krankenhaus Martha-Maria Halle Dölau, Halle (Saale)/Germany, 5Biothera, Eagan/
MN/United States of America
Background: Imprime PGG (PGG) in combination with carboplatin/paclitaxel 
chemotherapy (C/P) and bevacizumab (Bev) increased objective response rates 
(ORR) and overall survival (OS) of patients (pts) with previously untreated stage IV 
non-squamous NSCLC in comparison to C/P + Bev alone in a randomized, controlled, 
multicenter phase 2 trial (Engel-Riedel W et al, Ann Oncol 25 [Suppl 5], 2014, LBA32). 
Herein, we report landmark survival analyses at the 1- and 2-year time points. The trial 
was sponsored by Biothera, ClinicalTrials.gov NCT 00874107, EudraCT 2008-006780-
37. Methods: 92 pts with stage IV nonsquamous NSCLC were randomized 2:1 to receive 
PGG (4 mg/kg IV days 1, 8, 15 of each 3-week cycle) + C/P + Bev (PGG group) vs C/P 
+ Bev alone (Ctrl group). C/P was administered for 4 to 6 cycles; Bev +/- PGG were 
administered until disease progression or intolerable toxicity. The primary endpoint was 
ORR based on modified RECIST v1.0 and was assessed centrally. Secondary endpoints 
included overall survival (OS), progression-free survival (PFS), duration of response (DoR) 
and safety. Imaging assessments (CT of chest and abdomen) were reviewed every 6 
weeks. The primary analysis occurred after all pts had either progressed or had the 
opportunity to complete at least 18 treatment cycles (54 weeks). Results: An objective 
response was achieved by 29 out of 48 evaluable pts (60.4%; 1 CR, 28 PR) in the PGG 
group and 10 out of 23 (43.5%; 0 CR, 10 PR) in the Ctrl group (p=0.21). Median (m) 
OS was 16.1 mos with PGG compared to 11.6 mos (HR=0.66; p=0.13) with Ctrl. The 
mPFS was 11.9 mos vs 10.2 mos (HR=0.86; p=0.59), and mDoR was 10.3 mos vs 5.6 
mos (HR=0.92; p=0.90) among subjects receiving PGG vs Ctrl, respectively. Survival 
rates of pts (95% CI) in the PGG vs Ctrl groups were 62.8% (48.8, 74.0) vs 42.7% (22.7, 
61.4) at 12 mos, and 37.0% (22.5, 51.5) vs 24.4% (7.9, 45.7) at 24 mos. Overall, the 
incidence of adverse events (AEs) was similar across treatment groups. The most 
common AEs (occurring in ≥ 5 pts) deemed possibly or probably related to PGG by the 
investigator were chills (13.6%); dyspnea, fatigue (10.2% each); nausea, pyrexia, and 
infusion-related reactions (8.5% each). Overall, 37.3% of pts receiving PGG and 43.3% 
receiving Ctrl discontinued the study due to AEs. Conclusion: The addition of PGG to 
C/P + Bev therapy was well tolerated and resulted in clinically meaningful increases in 
ORR, DoR, and OS. Results did not reach statistical significance in this phase 2 study. 
Further investigation is warranted to confirm the efficacy and safety of this combination. 
Keywords: Nonsquamous, Immunotherapy, non-small cell lung cancer, Imprime PGG
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P3.01-002 PD-L1 Expression and FGFR1 Amplification in Chinese Stage III/IV 
Lung Squamous Carcinoma Jie Wang, Hua Bai, Sifan Yu, Qinxiang Guo, Minglei Zhuo 
Peking University Cancer Hospital and Institute, Beijing/China
Background: This study aims to explore status of PD-L1 expression and FGFR1 
amplification in stage IIIB/IV SQC, further to analyze their correlation with clinicpothological 
characteristics, efficacy of gemcitabine based chemotherapy and prognosis of SQC 
patients. Methods: 128 stage III/IV SQC patients were enrolled into this study from 
May 1st 2009 to May 31st 2014, all of which had complete clinical profile. 78 patients 
received gemcitabine-based chemotherapy. Immunohistochemistry (IHC) was used to 
detect PD-L1 expression, fluorescence in situ hybridization was applied to detect FGFR1 
amplification. SPSS17.0 was used for statistical analysis. Results: 80 (62.5%) SQC 
had IHC positive PD-L1 expression. PD-L1expression was significantly higher in male 
and smoker population than female and non-smoker, respectively. (gender: 65.5% VS. 
22.2%, P=0.011; smoke histology 67.0% VS. 44.0%, P=0.039). PD-L1 expression had no 
significant relationship with objective response rate (ORR) and disease control rate(DCR) 
for gemcitabine-based chemotherapy(54.8% VS.59.7%, P =0.434 and P=0.840). 
However, the overall survival (OS) of PD-L1 negative SQC was significantly longer than PD-
L1 positive group (29.8 vs. 20.1 months, P=0.001). 32 cases showed FGFR1 FISH positive 
(32/128, 25.0%), and stage III patients presented lower rate compared with stage IV SQC 
(17.1% vs. 36.5%, P=0.013). FGFR1 amplification had no relationship with ORR and DCR 
in patients treated with gemcitabine-base chemotherapy(32.3% VS.30.6%. P=0.663 and 
P=0.659). No correlation between PD-L1 expression and FGFR1 amplification was found 
(P=0.916). Conclusion: PD-L1 expression could act as a prognosis factor in Chinese 
stage III/IV SQC patients. PD-L1 expression and FGFR1 amplification might be irrelevant. 
Keywords: PD-L1 expression, FGFR1 amplification, squamous lung carcinoma
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P2.11-014 Tunneled Pleural Catheters Are Safe in the Setting of Chemotherapy 
and Immune Suppression Candice L. Wilshire1, Brian E. Louie2, Ralph W. Aye2, 
Alexander S. Farivar2, Eric Vallieres2, Jed A. Gorden3 1Interventional Pulmonolgy and 
Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle/WA/United States 
of America, 2Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle/WA/
United States of America,3Interventional Pulmonolgy, Swedish Medical Center and Cancer 
Institute, Seattle/WA/United States of America
Background: The reported rate of tunneled pleural catheter (TPC) -related infections 
in patients on chemotherapy ranges from 4-20%. Thus, infection is often cited as 
a contraindication to placement of a TPC in patients with recurrent symptomatic 
malignant/para-malignant pleural effusions (MPE/PMPE) receiving chemotherapy. Delay 
in the definitive management of such pleural effusions can result in an increased number 
of procedures, progressive symptoms and decreased independence in patients with 
advanced disease. Current data does not directly associate TPC-related infections to a 
patient’s immune status on chemotherapy. We aim to correlate catheter-related infections 
to immune system competency around the time of chemotherapy. Methods: A review 
of patients with MPE/PMPEs managed with a TPC from 2009-2014 was conducted. We 
identified 182 patients, of which 109 had chemotherapy within 1 month of TPC insertion 
or at any time during TPC drainage. An immunocompromised state was defined as 
the presence of leukopenia [white blood cells (WBC) <4 th/mm3] when a differential 
count was unavailable; or lymphopenia [lymphocytes <1 th/mm3], and/or neutropenia 
[absolute neutrophil count (ANC) <1.5 th/mm3]. A pleural infection was defined as the 
presence of a positive gram stain/culture of pleural fluid. Results: Seventy-three (67%) 
of the 109 patients were identified to be immunocompromised. Only 5 (7%) of the 73 
developed a pleural infection. All 5 (100%) received antibiotic treatment. Two of the 
5 (40%) pleurodesed and underwent catheter removal, 2 (40%) maintained effective 
catheter drainage, while 1 (20%) underwent TPC removal and replacement with a pigtail 
catheter. Of the 5 patients, 4 (80%) demised at a median of 5 months (IQR, 3-8) following 
the pleural infection. All deaths were considered related to progression of malignant 
disease and not a consequence of infection. One patient is alive and still undergoing 
drainage. Conclusion: These preliminary results suggest that chemotherapy and 
immune suppression do not significantly increase the risk of TPC-related infections as 
the rate is low and comparable to immunocompetent patients. Chemotherapy should 
not delay the decision to definitely palliate patients with TPCs in the setting MPE/PMPEs. 
Keywords: Infection, immunosuppression, Tunneled pleural catheter, chemotherapy
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P2.11-015 Factors Related with Reluctance to Treatment in Lung Cancer Jung 
Hyun Chang Respiratory and Critical Care Medicine, Ewha Womans University, Seoul/Korea
Background: Lung cancer is one of increasing cancer in incidence with longer survival 
of life in Korea. Some patients do not have a condition to receive cancer therapy by the 
decision of patients themselves and/or family as well as doctors. Refusal or avoidance 
of active treatment is prone to suffer from cancer symptoms and causes to shorten life 
survival. The purpose of this study is to define factors related to avoid or refuse active 
therapy in lung cancer. Methods: The population was retrospectively collected from 
patients’ record in one tertiary university hospital from 2010 to 2012. Total 306 subjects 
were enrolled as lung cancer and 18 subjects were excluded due to incomplete data 
or follow-up loss. Among 288 subjects, 66 subjects, avoiding cancer treatment were 
allocated to nontreatment group (NTG), whereas remaining 222 subjects to treatment 
group (TG). Results: Mean age of NTG was older than TG. Previous operation history, low 
BMI, high ECOG score and Charlson comorbidity index (CCI) score were significant in NTG. 
Factors of sex, smoking behavior, drinking, offspring number, degree of scholarship, 
familial history of cancer, pathologic type, TNM stage, presence of chest symptoms or 
systemic symptoms, and absence of occupation, religion and partner were insignificant. 
In univariate and multivariate analysis, high ECOG (2-3 vs 0-1; odds ratio [OR]: 6.0; 95% 
confidence interval [CI]:1.5-23.4) and high CCI score (OR: 1.3; 95% CI; 1.02-1.7) were 
the significant determinants to the avoidance of treatment. Conclusion: Nontreatment 
decision in lung cancer was associated with performance status and comorbidities, 
which are considered prior to the guidance of cancer treatment. Patient’s 
personal factors give little influence to the decision of cancer treatment. 
Keywords: lung cancer, avoidance of treatment
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ARMS PCR or Sanger sequencing. The patients received first line Icotinib of 125mg 
three times a day after giving informed consent and they would continue to take Icotinib 
unless disease progressed or other reasons. No concurrent brain radiotherapy was 
given during this process. Results: Out of the 28 patients treated, 12 achieve partial 
response, 11 experienced stable disease and 5 experienced progressive disease. 
The response rate and disease control rate of Icotinib for brain metastasis was 42.8% 
and 82.1% respectively. After a median follow-up of 15.1 months (range 5-27 months), 
the median progression-free time was 7.5 months. Rash and diarrhea were the most 
common adverse events. Conclusion: Icotinib might be an alterative treatment for 
brain metastasis in Chinese NSCLC patients harboring an activating EGFR mutation. 
Keywords: non-small cell lung cancer, Brain metastasis, EGFR, icotinib
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P3.01-006 Propensity Score Matched Comparison of EGFR TKI for EGFR 
Mutation 19del vs 21L858R Zhen Zhou, Shun Lu, Xiaoming Niu, Mailing Liao, 
Chuanjia Li Lung Cancer Center, Shanghai Chest Hospital, Shanghai/China
Background: Previously, data of Lux-lung 3 and Lux-lung 6 showed overall survival 
was improved with the afatinib for patients with 19del EGFR mutations and the 
absence of an effect in patients with L858R EGFR mutations suggests that EGFR 
19del-positive disease might be distinct from L858R-positive disease. We aimed 
to assess the effect of first-generation reverse EGFR TKI (Gefitinib and Elotinib) on 
overall survival of patients with EGFR mutation-positive lung adenocarcinoma through 
an analysis of data from real world practice. Methods: This is a retrospective study, 
134 patients with EGFRm 19del or 21L858R with reverse EGFR TKI gefitinib or elotinib 
in clinical practice from Jun.2012 to April.2014 in Shanghai Chest Hospital , follow-
up to April.1,2015. To control for selection bias, matched groups of patients were 
selected using a propensity score matching method. Overall survival and PFS were 
estimated using the Kaplan-Meier method with log-rank test. The Wilcoxon rank sum 
test was used for variables not normally distributed. Categorical data are displayed as 
frequencies and comparisons were made with Chi-square tests (Fisher exact tests if 
appropriate). Results: After1:1 the propensity score matching, matching was based on 
a one-to-two nearest neighbor matching method with a tolerance level on the maximum 
propensity score distance (calipers of width 0.2 standard deviation of the logit of the 
PS). 70 patients were enrolled, the baseline variables (eg, age, sex, smoking , PS, line of 
EGFR TKI treatment ) were comparable between the matched cohorts (P > 0.05 for all). 
Follow-up time: 19del (median 16.2 months, range 1.0-49.2) , 21L858R (median 16.4 
months, range 0.4-41.1). m PFS in 19 del and 21L858R was 16.3months, 16.8months, 
respectively, m OS in 19 del and 21L858R was28.4 months, 32.2 months, respectively, 
There are no significant difference between EGFR mutation 19del and 21L858R 
patients with the reversible first-generation inhibitors. Conclusion: CONCLUSION: 
There are no significant difference between EGFR mutation 19del and 21L858R 
patients with the reversible first-generation inhibitors either PFS or OS. The 
results maybe related to the sample size, waiting for the results of meta-analysis. 
Keywords: Propensity score match, EGFR mutation, First-generation inhibitor, overall 
survival
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P3.01-007 Evaluation of Gefitinib Efficacy According to Body Surface Area, 
Body Weight, and Body Mass Index in Patients with NSCLC Harboring EGFR 
Mutations Reiko Sakurai1, Hisao Imai2, Tomohito Kuwako3, Mai Tomizawa1, Tomomi 
Masuda3, Yosuke Miura3, Kyoichi Kaira4, Mitsuyoshi Utsugi5, Akihiro Yoshii1, Kimihiro 
Shimizu6, Noriaki Sunaga3, Yoshio Tomizawa1, Shinichi Ishihara7, Takao Ishizuka8, 
Akira Mogi9, Satoru Watanabe1, Takeshi Hisada3, Koichi Minato2, Atsushi Takise10, 
Ryusei Saito1, Masanobu Yamada3 1Department of Respiratory Medicine, National 
Hospital Organization Nishigunma Hospital, Shibukawa/Japan, 2Department of Respiratory 
Medicine, Gunma Prefectural Cancer Center, Ota/Japan, 3Department of Medicine 
and Molecular Science, Gunma University Graduate School of Medicine, Maebashi/
Japan, 4Oncology Clinical Development, Gunma University Graduate School of Medicine, 
Maebashi/Japan, 5Division of Internal Medicine, Kiryu Kosei General Hospital, Kiryu/
Japan,6Department of Thoracic Visceral Organ Surgery, Gunma University Graduate School 
of Medicine, Maebashi/Japan, 7Division of Internal Medicine, Isesaki Municipal Hospital, 
Isesaki/Japan, 8Division of Internal Medicine, Public Tomioka General Hospital, Tomioka/
Japan, 9Department of General Surgical Science, Gunma University Graduate School of 
Medicine, Maebashi/Japan, 10Division of Respiratory Medicine, Maebashi Red Cross Hospital, 
Maebashi/Japan
Background: Gefitinib is effective as first-line chemotherapy for advanced non-small 
cell lung cancer (NSCLC) patients harboring sensitive epidermal growth factor receptor 
(EGFR ) mutations. Exon 19 deletions and the L858R point mutation are the most commonly 
encountered sensitive EGFR mutations in NSCLC, and have been shown to predict greater 
efficacy of gefitinib therapy. The objective of this study was to evaluate whether body 
surface area (BSA), body weight (BW), and body mass index (BMI) affect the efficacy 
of gefitinib in patients with NSCLC harboring sensitive EGFR mutations. Methods: We 
reviewed the medical charts of consecutive patients with advanced NSCLC harboring 
sensitive EGFR mutations who received gefitinib. The median values were used as the 
cutoffs to evaluate the impact of BSA and BW on the efficacy of gefitinib. BMI was 
categorized as underweight (BMI < 18.5 kg/m2), normal weight (BMI 18.5 to < 25 kg/m2), 
and overweight (BMI ≥ 25 kg/m2). Results: The median BSA and BW of the 138 NSCLC 
patients harboring sensitive EGFR mutations were 1.48 m2 and 53 kg, respectively. The 
overall response rate, progression-free survival (PFS), and overall survival (OS) were 
65.2%, 12.2 months, and 24.2 months, respectively. There were no significant differences 
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P3.01-003 Patterns of Disease Progression for Stage IV NSCLC While on PD-1 
Directed Therapy as Compared to Standard Chemotherapy Monica S. Chatwal1, 
Vinicius Ernani2, Taofeek K. Owonikoko3, Suresh S. Ramalingam4, Rathi N. Pillai5 
1Emory University, Atlanta/GA/United States of America, 2Hematology and Medical 
Oncology, Emory University, Atlanta/GA/United States of America, 3Hematology & 
Medical Oncology, Emory University School of Medicine, Atlanta/GA/United States of 
America, 4Medical Oncology, Emory University Winship Cancer Institute, Atlanta/United 
States of America, 5Winship Cancer Institute, Emory University, Atlanta/GA/United States 
of America Background: Programmed Cell Death 1 (PD-1) inhibitor therapy is now an 
established therapeutic modality in certain solid malignancies, including non-small 
cell lung cancer (NSCLC). The purpose of this study is to determine whether disease 
progression patterns are different between PD-1 inhibitor therapy or chemotherapy 
in patients with advanced NSCLC. Methods: We performed a retrospective analysis 
of patients who received PD-1 targeted therapies and systemic chemotherapy for 
advanced NSCLC treated at the Winship Cancer Institute at Emory University. We 
reviewed demographic data and treatment history of these patients. RECIST criteria 
were used to evaluate the patients’ baseline tumor burden and their subsequent 
disease progression from imaging studies (CT, PET/CT, MRI). Results: The total cohort 
included 37 patients with a mean age of 67 years. The PD-1 therapy group included 
19 patients (14 males, 5 females), with 9 on MK-3475, 3 on MDPL3280A, and 7 on 
nivolumab. This group included 3 African Americans and 16 Caucasians. The median 
number of lines of prior chemotherapy was 3. A comparator group of 18 patients on 
standard chemotherapy was identified (14 males, 4 females). This group included 8 
African Americans and 10 Caucasians. In the PD-1 therapy group, 5 patients had no 
progression and 14 had disease progression. Of these, 5 progressed at their sites 
of known cancer (36%), 4 progressed at new sites (28.5%), and 5 progressed at 
both old and new sites (36%). In the chemotherapy group, 4 patients had no disease 
progression and 14 had progression. Of those 14, 2 were at old sites only (14%), 4 
were at new sites only (29%), and 8 were at both old and new sites (57%). The median 
time to progression was 3.5 months with PD-1 targeted therapy (range 2-13 months) 
and 6 months with chemotherapy (range 2-21 months). Conclusion: Our data suggests 
no difference between the progression patterns between PD-1 inhibitor therapy and 
standard chemotherapy patients. Patients on PD-1 therapy appear to have a shorter 
time to progression than those on traditional chemotherapy.  
Keywords: NSCLC, PD-1 Therapy
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P3.01-004 Paxillin Confers Resistance to TKI via Modulating BIM and Mcl-1 
Protein Stability Huei Lee1, De-Wei Wu1, Chih-Yi Chen2 1Graduate Institute of Cancer 
Biology and Drug Discovery, Taipei Medical University, Taipei/Taiwan, 2Chung Shan Medical 
University Hospital, Taichung/Taiwan
Background: Tyrosine kinase inhibitors (TKIs) have been documented to have substantial 
clinical benefits to non-small cell lung cancer (NSCLC) with epidermal growth factor 
receptor (EGFR) mutation. TKI resistance occurs in nearly all patients who receive TKI 
targeting therapy, resulting in a modest overall survival benefit. Therefore, establishing a 
biomarker for early prediction and exploring the mechanism of primary TKI resistance is 
essential for improving the therapeutic efficacy in NSCLC patients. Methods: In this study, 
we provide evidence indicating that paxillin (PXN) overexpression may confer gefitinib 
resistance in EGFR-mutant lung cancer cells. Results: Mechanistically, PXN-mediated 
ERK activation is responsible for gefitinib resistance via decreased BIM and increased 
Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at 
Serine 69 and Mcl-1 at Threonine 163. The mechanistic action in the cell model was further 
confirmed by the observation of xenograft tumors in nude mice, revealing that the PXN-
mediated gefitinib resistance was conquered by ERK inhibitor (AZD6244) and Bcl-2 family 
inhibitor (obatoclax), but the gefitinib resistance overcome by AZD6244 is more effective 
than that of obatoclax. Conclusion: Therefore, we suggest that PXN expression may be 
useful in predicting primary TKI resistance, and combining TKI with ERK inhibitors may 
clinically benefit EGFR-mutant NSCLC patients whose tumors exhibit high PXN expression. 
Keywords: Tyrosine kinase inhibitors, Paxillin, EGFR-Mutant
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P3.01-005 Clinical Effects of Icotinib for Brain Metastasis in Chinese Non-Small 
Cell Lung Cancer Patients Harboring an EGFR Mutation Helei Hou, Xiaomei Xu, 
Xiaofei Wang, Lihua Deng, Airong Tan, Congmin Liu, Wenjun Yu, Chuantao Zhang, Chun 
Yan, Xiaofeng Cheng, Xiaochun Zhang Medical Oncology, Qingdao Municipal Hospital, 
Qingdao University, Qingdao/China
Background: Icotinib hydrochloride, an oral EGFR tyrosine kinase inhibitor, was proved 
to be non-inferior to gefitinib in patients with non-small-cell lung cancer (NSCLC). Brain 
metastasis is a serious factor associated with poor outcomes of NSCLC because 
systemic chemotherapy usually showed little effects due to the blood-brain barrier. 
Besides, other treatments such as whole brain or stereotatic radiotherapy may cause 
neurological complications. There have been some studies showing that gefitinib or 
erlotinib plus concurrent brain radiotherapy or not was effective in controlling brain 
metastasis in NSCLC. Herein, we observed the function of Icotinib on brain metastasis 
in Chinese NSCLC patients harboring an EGFR mutation. Methods: The clinical data 
of 28 NSCLC patients with brain metastasis referred to Qingdao Municipal Hospital 
from May 2012 to December 2014 were retrospectively analyzed. All the patients had 
pathological diagnosis of adenocarcinoma. EGFR mutation state was confirmed by 
S645Copyright © 2015 by the International Association for the Study of Lung Cancer
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P3.01-009 Impact of EGRR Mutation on Brain Metastasis and Disease-Free 
Survival in Patients with Surgically Resected Lung Adenocarcinoma Takefumi 
Akita, Taisuke Akamatsu, Yuichiro Shishido, Satoru Morita, Kazuhiro Asada, Toshihiro 
Shirai, Takashi Etou, Syunnsuke Eba, Masahide Hirose, Shinichiro Otha Shizuoka General 
Hospital, Shizuoka-City/Japan
Background: Central nervous system (CNS) invasion is a common occurrence in patients 
with non-small-cell lung cancer (NSCLC) and is associated with poor outcome. For patients 
who develop CNS invasion, epidermal growth factor receptor (EGFR) mutation derives 
clinical benefits from EGFR tyrosine kinase inhibitors (TKIs). The clinical manifestation of 
CNS invasion, EGFR mutation, and prognosis are unclear in patients with resected stage 
I to III lung adenocarcinoma. Methods: The records of 261 patients with completely 
resected stage I to III lung adenocarcinoma who were hospitalized between March 2002 
and January 2013 were reviewed retrospectively. Their pathological records indicated 
that EGFR mutation testing had been performed. Data on basic patient demographics, 
EGFR mutation, disease-free survival (DFS), and postoperative recurrence were collected. 
Kaplan Meier curves were used for survival analysis. Results: Of the 261 patients 
(median age: 68, range: 31-90) identified, 49% were male and 53% were EGFR mutant. 
Tumor stages were I, II, and III in 153, 47, and 61 patients, respectively.DFS after surgery 
for stage I, II, and III EGFR-mutant patients were 62 mo, 40 mo, and 29 mo, respectively, 
and 71 mo, 30 mo, and 74 mo, respectively, for patients with wild-type EGFR, showing 
no significant difference (p=0.19). Recurrence after surgery occurred in 124 patients 
(36 with CNS, 23 with bone metastasis, and 87 with other organ metastasis).In patients 
with CNS relapse, the incidence of CNS relapse as first metastasis was significantly high 
at 13.3% for EGFR-mutant patients, compared with 4.3% for wild-type EGFR patients 
(HR 2.5, p=0.046). As for second CNS metastasis, there was no significant difference 
between EGFR-mutant patients (8.1%) and wild-type EGFR patients (4.2%) (p=0.44).In 
patients whose first relapse was CNS metastasis, DFS after surgery was significantly 
longer at 22 months for EGFR-mutant patients, compared with 8 months for wild-type 
EGFR patients (p=0.012). Patients with recurrence in other organs showed no significant 
differences in terms of DFS regardless of being EGFR mutant or not. Conclusion: The 
EGFR-mutant patients showed a higher incidence of brain metastasis as the first relapse, 
and significantly longer DFS than the wild-type EGFR patients. In the present study, the 
brain metastasis of postoperative lung adenocarcinoma as the first relapse was limited 
to early in the wild-type EGFR patients, but occurred in later in the EGFR-mutant patients. 
Keywords: EGFR, CNS Metastasis, resected, DFS
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P3.01-010 Multivariate Survival Analysis of China IRESSA Charitable Aid 
Project in Shanghai Hong Jian1, Baohui Han2, Qiang Li3, Shun Lu1, Xiaolong Fu4, 
Chunxue Bai5, Liang Xue6, Beili Gao7, Meilin Liao1 1Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China, 2Department of 
Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/
China, 3Department of Respiratory Medicine, Changhai Hospital Affiliated To Shanghai 
Second Military Medical University, Shanghai/China, 4Department of Radiotherapy, Shanghai 
Cancer Hospital, Fudan University, Shanghai/China, 5Department of Respiratory Medicine, 
Zhongshan Hospital, Fudan University, Shanghai/China, 6Department of Thoracic Surgery, 
Zhongshan Hospital, Fudan University, Shanghai/China, 7Department of Respiratory 
Medicine, Ruijin Hospital Affiliated To Shanghai Jiao Tong University, Shanghai/China
Background: Since Jan 2007, China Charity Federation launched IRESSA Charitable Aid 
Project for advanced non small cell lung cancer which oral IRESSA was effective for 6 
months and have failed previous chemotherapy or received first line IRESSA for EGFR 
mutation positive. This study investigated the survival and correlation influencing factor 
of China Charitable Aid Project in shanghai by COX multivariate analysis . Methods: A 
retrospective investigation enrolled advanced non small cell lung cancer patient of 
IRESSA Charitable Aid Project from Jan 2007 to 30 Jun 2013 at 7 centre in Shanghai . The 
patients oral IRESSA was effective for 6 months who have failed previous chemotherapy 
or received first line IRESSA for EGFR mutation positive. IRESSA 250mg QD was taken 
and prescribed monthly. Tumor assessment was performed every 8 weeks, patients 
continued to receive IRESSA until disease progression (timely withdraw) or unacceptable 
toxicity or no benefit from this project which was considered as slower progression(late 
withdraw). The patient were Followed up until 30 Aug 2014. The primary end point was 
OS and correlation influencing factor. Using the Kaplan-Meier and COX proportional 
hazards model analyze the correlation between survival and age, gender, smoking 
status, pathology, indications and timely withdraw of IRESSA. Results: A total of 1066 
patients were enrolled, the median age was 64, including 339 cases of greater than 
or equal to 70. Most patients were female (845,79.3%) and no-smokers (992,93.1%), 
and 94.1% was adenocarcinoma. Indication for second and multiple line patients were 
96.1%(1024). The midian PFS was 33 months (95%CI:29.8-36.2），and the MST was 37 
months (95%CI:32.5-41.5). COX multivariate analysis revealed timely withdraw group 
was significantly longer OS ( hazard ration 1.627; 95%CI:1.378-1.922, p=0.000) , more 
than 70 years old, smoking and indication for second line patient was significantly 
worse OS (hazard ration 0.692; 95%CI:0.587-0.816, p=0.000; 0.714; 95%CI: 0.531-
0.960, p=0.026; 0.498 ;95%CI: 0.265-0.935,p=0.03 respectively. Conclusion: 96.1% 
of the patient in Iressa charitable aid projects were second or multiple line treatment 
due to chemotherapy failure, PFS and OS still reached 33 and 37 months, significantly 
better than the historical reports. The possible reason was enrolled patients with IRESSA 
effective for 6 months , It could be EGFR mutation positive, of which no-smoking patients 
ratio were as high as 93.1%, they maybe have a better prognosis. Multivariate analysis 
showed OS was significantly prolonged in timely withdraw group after disease deteriorate. 
Keywords: non small cell lung cancer, IRESSA, Prognosis
in clinical outcomes between the high-BSA (BSA ≥ 1.43 m2) and low-BSA groups (BSA < 
1.43 m2), with response rates of 68.5% and 72.0% (p = 0.92), median PFS of 12.2 and 
11.5 months (p = 0.73), and median OS of 25.0 and 21.9 months, respectively (p = 0.28). 
Moreover, there were no significant differences in clinical outcomes between the high-BW 
(BW ≥ 53 kg) and low-BW groups (BW < 53 kg), with response rates of 63.3% and 67.1% 
(p = 0.72), median PFS of 12.2 and 10.8 months (p = 0.46), and median OS of 28.9 and 
21.9 months, respectively (p = 0.22). For BMI, the median PFS and OS estimated among 
underweight, normal weight, and overweight patients were 10.6 and 19.2 months, 12.0 
and 23.3 months, and 13.1 and 33.1 months, respectively. There were no statistically 
significant differences in PFS and OS among underweight, normal weight, and overweight 
patients (p = 0.52 and p = 0.30, respectively). Finally, to substantiate possible differences 
in the efficacy in patients who are young (<75 years) vs. elderly (≥ 75 years) and who have 
exon 19 deletions vs. L858R, we also evaluated these subgroups separately regarding 
BSA, BW, and BMI. However, there were no significant differences in the PFS and OS 
between these groups. Conclusion: The efficacy of gefitinib in patients with NSCLC 
harboring sensitive EGFR mutations does not differ according to their BSA, BW, and BMI. 
Keywords: non-small cell lung cancer, gefitinib, EGFR mutations, body surface area, 
body weight, and body mass index
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P3.01-008 Gefitinib in Front-Line Treatment of 161 Caucasian Patients with 
NSCLC of the Czech Republic Jana Skrickova1, Zbynek Bortlicek2, Karel Hejduk2, 
Milos Pesek3, Vitezslav Kolek4, Leona Koubkova5, Marketa Cernovska6, Marcela 
Tomiskova1, Jaromir Roubec7, Libor Havel8, Frantisek Salajka9, Helena Coupkova10, 
Michal Hrnciarik9, Milada Zemanova11, Dimka Sixtova12, Minika Satankova1, Bohdan 
Kadlec1, Miloslav Marel5 1Department of Respiratory Diseases and TB, University Hospital 
and Medical Faculty Brno, Brno/Czech Republic, 2Biostatistics, Iba Institute, Brno/Czech 
Republic, 3Pulmonary Medicine, University Hospital, Plzen/Czech Republic, 4Respiratory 
Medicine, University Hospital, Olomouc/Czech Republic, 5Pulmonary Medicine, University 
Hospital,, Praha/Czech Republic, 6Pulmonary Medicine, Thomayer Memorial Hospital, 
Prague/Czech Republic, 7Pulmonary Medicine, University Hospital, Ostrava/Czech 
Republic, 8P Neumology and Thoracic Oncology, Municipal Hospital, Prague/Czech 
Republic, 9University Hospital, Hradev Kralove/Czech Republic, 10Departmen of Oncology, 
Masaryk Memorila Institute, Brno/Czech Republic,11Clinical Oncology, General University 
Hospital Prague, Prague/Czech Republic, 12Respiratory Medicine, General University Hospital 
Prague, Prague/Czech Republic
Background: Gefitinib is a potent oral non-cytotoxic, active and selective epidermal 
growth factor receptor tyrosine kinase inhibitor. This study evaluates treatment outcomes 
in 161 NSCLC patients from Czech Republic according to activated mutations located in 
exons 19 and 21. Methods: Data treated patients with gefitinib are collected in the 
TULUNG registry, which is a common project of the Czech Pneumological Society, Czech 
Oncological Society, and Institute Biostatistics and Analyses Masaryk University Brno. 
NSCLC patients with EGFR activated mutations were treated in first line between 02/2010 
and 12/2014 in 10 institutions. Retrospective analyses were carried out to assess the 
effectiveness and safety of gefitinib treatment according to activated mutations located 
in exons 19 and 21. The analysed outcomes include following: treatment response rate, 
median Overall Survival (mOS), median Progression Free Survival (mPFS) and occurrence 
of types adverse events. Results: Out of 161 treated patients, 105 (70 female, 35 male) 
had EGFR mutations in exon 19, and 56 (39 female, 17 male) had EGFR mutations in exon 
21. Median age was 66 years in the group with mutations in exon 19 and 69 years in the 
group with mutations in exon 21. There was no statistically significant difference in sex 
(p=0.727) and in age (p=0.204). No statistically significant difference was observed in 
the representation in smoking (p=0.354). There was statistically borderline significant 
difference in adenocarcinoma proportion (p=0.045). In the group with mutations in exon 
19 were 96% patients with adenocarcinoma and in the group with mutations in exon 
21 were 85% patients with adenocarcinoma. Between these two groups, there was 
no statistically significant difference according to performance status (p=0.547); no 
statistically significant difference according to disease control (CR+PR+SD) (p=0.479); 
no statistically significant difference according the response to the treatment (CR + 
PR) (p=0.052). There was no statistically significant difference in mOS (p=0.390). In 
the group of patients with mutations located in exon 19, the overall survival was 22.7 
months (CI 95%: 17.7; 27.8), in the group with mutations in exon 21, overall survival 
was 16.3 months (CI 95%: 10.8; 21.8). There was no statistically significant difference 
(p=0.202) in mPFS; in the group of patients with mutations in exon 19 it was 11,0 months 
(CI 95%:9.1; 12.8) and in the group with mutations in exon 21 it was 9.4 months (CI 95% 
6.6; 12.2). SimiIar numbers of adverse effects were observed in either group (35.2% and 
35.7%). Almost 70% of patients with mutations in exon 19 and almost 60% of patients with 
mutations in exon 21 are still alive or were lost to follow up. These patients are censored 
to the date of last update. Conclusion: In both groups of patients, the treatment was 
very safe. Median PFS and median OS were satisfactory without statistically significant 
differences between the two groups; however, a better trend was observed in the 
group of patients with mutations in exon 19. Consequently survival estimates shows 
great variability and longer potential follow up is needed to confirm these results. 
Keywords: advanced NSCLC, Targeted therapy, EGFR activated mutations, gefitinib
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the clinical effects of second-line platinum combination chemotherapy after first-line 
gefitinib treatment in NSCLC patients harboring sensitive EGFRmutations (exon 19 
deletion or exon 21 L858R mutation) at 5 institutions. All patients were initially treated 
with gefitinib (250 mg/day) followed by platinum combination chemotherapy as second-
line chemotherapy. Results: Between January 2006 and December 2012, 42 patients 
(8 men, 34 women; median age, 63 years [range, 39–75 years]) were enrolled. The 
overall response rate, disease control rate, and median progression-free survival (PFS) 
were 26.2%, 61.9%, and 5.1 months, respectively, after the second-line treatment. 
The corresponding values for first-line gefitinib treatment were 69.0%, 95.2%, and 
11.1 months, respectively. Moreover, second-line platinum combination chemotherapy 
with pemetrexed or bevacizumab-containing regimens was indpendently associated 
with improved PFS. Conclusion: Second-line platinum combination chemotherapy 
after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations 
was effective and showed equivalent outcomes to first-line platinum combination 
chemotherapy. After failure of first-line gefitinib therapy, second-line platinum combination 
chemotherapy with pemetrexed or bevacizumab might result in improved PFS. 
Keywords: Advanced Non-Small Cell Lung Cancer, EGFR mutations, gefitinib, second-line 
platinum-based chemotherapy
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P3.01-013 Combination of Chemotherapy and Gefitinib as First-Line Treatment 
of Patients with Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations 
Bo Jin, Yanjie Niu, Yanwei Zhang, Tianqing Chu, Aiqin Gu, Jun Pei, Baohui Han Shanghai 
Jiaotong Univ. Affiliated Shanghai Chest Hospital, Shanghai/China
Background: The results of fastact2 show that chemotherapy plus erlotinib significantly 
prolonged PFS and OS of patients with NSCLC. However, outcome of the combination 
therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which 
is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? 
We need a head-to-head study to reply. Methods: 77 untreated patients with advanced 
lung adenocarcinoma who harbored sensitive EGFR mutations, and with ECOG PS 0-1, 
were randomly assigned to 3 groups. 25 patients were allocated to the combination 
therapy group (group A), received pemetrexed (500 mg/m(2) on day 1) plus carboplatin 
(AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated 
every 4 weeks for up to six cycles, then continued to receive pemetrexed combined 
with gefitinib every 4 weeks. 26 patients allocated to the chemotherapy group (group 
B), received the same chemotherapy regimen alone every 4 weeks for up to six cycles, 
then continued to receive pemetrexed alone every 4 weeks. 26 patients allocated to the 
gefitinib group (group C), and received gefitinib alone. All therapies of 3 groups were 
continued until progression or unacceptable toxicity or death. The primary endpoint was 
Median PFS. Analyses were done on an ITT basis. Results: Median PFS for patients in 
group A was 19.1months, 95% CI (17.1, 21.1), Median PFS for patients in group B was 
5.5months, 95% CI (4.4, 6.8), Median PFS for patients in group C was 9.9months, 95% 
CI (7.0, 12.7). 6-month PFS was96.0% (24 of 25) in the group A, 38.5% (10 of 26) in the 
group B, and 73.1% (19 of 26) in the group C. ORR was 80.0% in the group A, 34.6% in 
the group B, and 61.5% in the group C. The most common grade 3-4 adverse events were 
neutropenia (3 [12.0%] of patients in the group A vs 4 [15.4%] in the group B vs 0 [0.0%] 
in the group C ), fatigue (2 [8.0%] of patients in the group A vs 2 [7.7%] in the group B vs 
0 [0.0%] in the group C ), and liver dysfunction (3 [12.0%] of patients in the group A vs 
0 [0.0%] in the group B vs 1 [3.8%] in the group C ), skin allergy (0 [0.0%] of patients in 
the group A vs 1 [3.8%] in the group B vs 0 [0.0%] in the group C ) Conclusion: Patients 
with lung adenocarcinoma who harbored a sensitive EGFR mutation have longer 
PFS if they are treated with pemetrexed plus carboplatin combined with gefitinib. 
Keywords: gefitinib, lung adenocarcinoma, EGFR mutation, chemotherapy
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P3.01-014 Interleukin-6 Is a Valuable Predictive Marker for Therapeutic Effect 
of Gefitinib in Patients with Advanced NSCLC Harboring EGFR Mutations Yuka 
Kato1, Katsuyuki Hotta2, Tomoki Tamura2, Takehiro Tanaka3, Koichi Ichimura3, Kadoaki 
Ohashi2, Toshio Kubo2, Eiki Ichihara2, Mitsune Tanimoto4, Katsuyuki Kiura2 1Center for 
Innovative Clinical Medicine, Okayama University Hospital, Okayama/Japan, 2Respiratory 
Medicine, Okayama University Hospital, Okayama/Japan, 3Department of Pathology, 
Okayama University Hospital, Okayama/Japan, 4Okayama University Hospital, Okayama/
Japan
Background: Although epidermal growth factor receptor (EGFR) -tyrosine kinase 
inhibitors (TKIs) are the key drug in patients with EGFR-mutant Non-small-cell Lung Cancer 
(NSCLC), some of them can not respond well to its therapy. An overexpression of 
Interleukin (IL) -6 in tumor cells is postulated as a potential mechanism for such resistance 
or low sensitivity to EGFR-TKI in the preclinical models (PNAS 2010). Here, we evaluated 
clinically if tumor IL-6 level can be predictive for the effect of EGFR-TKI therapy. Methods: A 
total of 52 patients with advanced EGFR-mutation NSCLC who had received gefitinib were 
retrospectively assessed. The protein expression of IL-6 in the tumor cells was 
immunostained. Each specimen was assessed independently by 2 physicians (YK and TT) 
and 2 pathologists (KI and TT), and judged as positive if ≥ 50% of 100 tumor cells were 
stained positively (BJC 1999). Serum IL-6 level was measured by CLEIA in 11 (21%) of 52 
patients. Results: Patients demographics were as follows: 24 men; median age, 66 yrs; 
PS 0-1, 48; stage IV, 22; Ad, 49; exon19, 29). Of these, 24 (46%) and 28 (54%) were 
defined as IL-6-postitive (group P) and IL-6-negative (group N), respectively. Group P had 
worse PFS (75% v 92% at 6m; p < 0.05), which was retained in the multivariate analysis 
(HR: 2.38; 95%CI: 1.00-5.68; p=0.05) (Fig1). In contrast, PFS in the platinum-based 
chemotherapy did not differ in groups P and N (p=0.47). The serum IL-6 level ranged from 
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P3.01-011 Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with 
Met+ EGFRm+ NSCLC Dong-Wan Kim1, Ross Soo2, James Chih-Hsin Yang3, Keunchil 
Park4, Uz Stammberger5, Huiiling Xiong6, Christian Ihling5, Yi-Long Wu7 1Department 
of Internal Medicine, Seoul National University Hospital, Seoul/Korea, 2Medical Oncology, 
National University Cancer Institute Singapore, Singapore/Singapore, 3Department of 
Oncology, National Taiwan University Hospital, Graduate Institute of Oncology & Cancer 
Research Center, National Taiwan University, Taipei/Taiwan, 4Innovative Cancer Medicine 
Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/
Korea, 5Merck Kgaa, Darmstadt/Germany, 6Merck Serono Pharmaceutical R&D Co., 
Ltd, Beijing/China, 7Guangdong Lung Cancer Institute, Guangdong General Hospital and 
Guangdong Academy of Medical Sciences, Guangzhou/China
Background: c-Met abnormalities are key in resistance to EGFR TKIs in EGFRm+ 
NSCLC patients (pts). The highly selective c-Met inhibitor tepotinib (MSC2156119J) 
had promising activity in a phase I trial in pts with advanced solid tumors. We report 
phase Ib data from a trial evaluating tepotinib + gefitinib in pts with Met+ NSCLC 
(NCT01982955). Methods: Asian adults with locally advanced/metastatic NSCLC, Met+ 
status (2+/3+ c-Met protein overexpression by immunohistochemistry using CONFIRM 
anti-total c-MET [SP44] rabbit MAb [Ventana] or c-Met gene amplification on IQ FISH 
[Dako] [c-Met:CEP7 ratio ≥2 or <2.0 with >15 c-Met signals/cell in >10% of cells or 
clusters in >10% of tumor cell nuclei]) and ECOG PS 0/1 were eligible. EGFR mutation 
status was assessed using the therascreen® EGFR RGQ PCR Kit (QIAGEN). A 3+3 
design was used for the phase Ib part; planned recruitment was 15-18 pts, who received 
tepotinib 300 or 500 mg p.o. + gefitinib 250 mg/d q3w. Primary objective: determine 
the RP2D of tepotinib for use in combination; secondary objectives: pharmacokinetics, 
safety, antitumor activity. Results: 14 pts have been enrolled (median age 65 years; male 
43%; ECOG PS 0/1 2/12; median prior therapy regimens including an EGFR TKI 3.5). 3 
pts received tepotinib 300 mg + gefitinib and 11 tepotinib 500 mg + gefitinib. No DLTs 
were observed; 4 pts had grade 3/4 treatment-related adverse events (amylase increase 
[n=3], lipase increase [2], decreased neutrophil count [1]). Best overall response by 
c-Met status (cut-off Jan 20, 2015) for the 12 evaluable pts is shown in the table. EGFR 
mutation status for these 12 pts was T790M and L858R mutation (n=2), L858R mutation 
alone (4), exon 19 deletion (4), no mutation detected using the therascreen® kit (2).
Best overall response (n)
n=12 Partial response Stable disease Progression
IHC
2+ 0 5 2
3+ 4 0 1
FISH
c-Met:CEP7 ratio >2 1 0 0
≥5 copies in >50% of cells 3 1 1
Negative 0 3 2
Not valid 0 1 0
 
Conclusion: The RP2D of tepotinib in combination with gefitinib has been 
confirmed as 500 mg/d in pts with advanced NSCLC. The data show evidence 
of antitumor activity and that response may be associated with c-Met status. 
The phase II trial will randomize ≈136 pts with T790M-/c-Met+ tumors who have 
failed first-line gefitinib to tepotinib 500 mg/d + gefitinib or cisplatin/pemetrexed. 
Keywords: MSC2156119J, EGFR mutation, c-Met, tepotinib
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P3.01-012 Efficacy of Chemotherapy after First-Line Gefitinib for EGFR-Mutant 
NSCLC Patients Tomohito Kuwako1, Hisao Imai1, Tomomi Masuda1, Yosuke Miura2, 
Reiko Yoshino3, Kyoichi Kaira4, Kimihiro Shimizu5, Noriaki Sunaga1, Yoshio Tomizawa3, 
Shinichi Ishihara6, Akira Mogi7, Takeshi Hisada1, Koichi Minato2, Atsushi Takise8, 
Ryusei Saito3, Masanobu Yamada1 1Department of Medicine and Molecular Science, 
Gunma University Graduate School of Medicine, Maebashi/Japan, 2Division of Respiratory 
Medicine, Gunma Prefectural Cancer Center, Ohta/Japan, 3Division of Respiratory Medicine, 
National Hospital Organization Nishigunma Hospital, Shibukawa/Japan, 4Department of 
Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi/
Japan, 5Department of Thoracic Visceral Organ Surgery, Gunma University Graduate School 
of Medicine, Maebashi/Japan, 6Division of Internal Medicine, Isesaki Municipal Hospital, 
Isesaki/Japan, 7Department of Surgical Science, Gunma University Graduate School of 
Medicine, Maebashi/Japan, 8Division of Respiratory Medicine, Maebashi Red Cross Hospital, 
Maebashi/Japan
Background: Gefitinib is an effective first-line chemotherapy for advanced non-small 
cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. However, 
whether second-line platinum combination chemotherapy after first-line gefitinib 
treatment shows similar effects to first-line platinum combination chemotherapy in 
these patients remains unclear. Therefore, we here aimed to investigate the efficacy 
of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC 
patients harboring sensitive EGFR mutations. Methods: We retrospectively evaluated 
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cases. Patients were grouped by final dosage of afatinib (50mg in 25 cases, 40/30mg 
in 35 cases). The PFS and OS were significantly longer for patients whose dosage of 
afatinib were reduced to 40 or 30 mg, compared to patients without dosage reduction 
(7.5 vs 3.1m and 18.0 vs 9.1m, respectively, p<0.05).
 
 
Conclusion: Afatinib showed PFS of 5.2 months and OS of 13.4 months in selected 
patients after failure of prior EGFR-TKIs. Aggressive dosage reduction should be 
considered in the course of treatment with afatinib. Keywords: Dose, afatinib, EGFR-TKI, 
EGFR
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P3.01-016 Does Sequence of Cranial Radiotherapy Matter in EGFR Mutant Non-
Small Cell Lung Cancer Patients with Brain Metastasis? Seonggyu Byeon, Jun 
Soo Ham, Se-Hoon Lee, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn 
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul/
Korea
Background: The incidence of brain metastasis in EGFR mutant advanced non-small 
cell lung cancer (NSCLC) is higher than EGFR wild type at the time of diagnosis. Although 
cranial radiotherapy is considered standard treatment for brain metastasis, EGFR 
tyrosine kinase inhibitors (TKIs) alone have shown promising activity with up to 80% of 
response in EGFR mutant NSCLC patients with brain metastasis. However, the role of 
sequential cranial radiotherapy in EGFR mutant NSCLC treated with EGFR TKIs remains 
to be determined. Methods: Advanced NSCLC patients harboring EGFR mutation (exon 
19 deletion or L858R) with brain metastasis who were treated with EGFR TKIs were 
retrospectively reviewed. To investigate the role of cranial radiotherapy, we analyzed 
the clinical outcomes between patients treated with EGFR TKIs alone and those treated 
with cranial radiotherapy (WBRT or SRS) followed by EGFR TKIs (combination therapy). 
The primary end point was overall survival (OS) and secondary end points included 
intracranial and extracranial progression free survival (PFS). Results: A total of 573 
patients who identified EGFR mutation and received EGFR TKIs treatment for NSCLC 
with brain metastasis from Jan 2007 to Dec 2013 at Samsung Medical Center were 
enrolled for analysis. Of all 573 patients, 121 patients had brain metastasis in initial 
work up. There were 38 males and 83 female, a median age was 59.5 years (range 
30 – 80). All 121 patients were received gefitinib (n=103) or erlotinib (n=18) as EGFR 
TKI treatment for 1st line chemotherapy. 74 patients were treated with combination 
therapy (34 patients were taken SRS, 28 patients WBRT, 12 patients both), and 47 
patients were treated with EGFR TKI alone. In combination therapy group, 32 patients had 
brain metastasis related symptoms.The median OS was 38.7 months [95% Confidence 
Interval 35.0 to 42.5] in combination therapy group and 28.6 months [95% CI 24.3 
to 32.8] in EGFR TKI alone group (p=0.295). There were no significant differences in 
intracrainal PFS (18.6 vs 19.7 months, p=0.343) and extracranial PFS (15.7 vs 15.3 
months, p=0.574) between two groups. Conclusion: In this retrospective analysis, 
the combination therapy with cranial radiotherapy followed EGFR TKI did not improve 
OS and intracranial PFS compared with EGFR TKI alone therapy in EGFR mutant NSCLC 
patients with brain metastases. Further prospective studies are needed to refine the 
role of sequential cranial radiotherapy in EGFR mutant NSCLC treated with EGFR TKIs. 
Keywords: EGFT TKI, intracranial radiotherapy, NSCLC, Brain metastasis
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P3.01-017 P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR 
M+ NSCLC Treated with TKIEfficacy and Safety of Gefitinib for Elderly Patients 
with EGFR Mutation Positive NSCLC Kei Kusaka, Takashi Hirose, Atsuhisa Tamura, 
Satoshi Ide, Minako Saito, Masahiro Ogiya, Eri Inoue, Hiroyuki Tashimo, Akira Yamane, 
Hirotoshi Matsui, Ken Ohta The Center for Pulmonary Diseases, National Hospital 
Organization Tokyo National Hospital, Kiyose City, Tokyo/Japan
Background: Elderly patients with lung cancer have been increasing. Of all cases of 
lung cancer 47% were 70 years or older and 14% were 80 years or older. Epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is a key drug for patients 
with EGFR mutation positive advanced non-small cell lung cancer (NSCLC). Although 
treatment of gefitinib is known to have fewer myelosuppression and gastrointestinal 
adverse events than cytotoxic chemotherapy, treatment of gefitinib frequently has skin 
rash and liver dysfunction. Until now, there have been few reports of the efficacy and 
0.75 to 23.80 pg/ml (median: 2.90 pg/ml), which correlated neither to that in the tumor 
cells (regression coefficient: 1.69, p = 0.29) nor PFS in gefitinib therapy (p = 0.44).
 
 
Conclusion: Patients in group P benefited less from gefitinib therapy. This 
might suggest the inhibition of IL-6 expression can improve the low sensitivity 
to EGFR-TKI especially in EGFR-mutation tumors with high IL-6 expression. 
Keywords: EGFR-TKI, NSCLC, IL-6, EGFR mutation
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P3.01-015 Efficacy, Safety and Dosage of Afatinib in Patients with NSCLC after 
Failure of Prior EGFR-TKI Young-Chul Kim, Hayoung Choi, Cheol-Kyu Park, In-Jae Oh, 
Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Sung-Ja Ahn, Mee Sun Yoon, Yoo-Duk Choi, 
Hyun-Ju Seon Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun 
Hospital, Jeonnam/Korea
Background: Afatinib is an irreversible ErbB family blocker that inhibits EGFR with 
activating mutations as well as the T790M resistance mutations. In Non-Small Cell lung 
cancer (NSCLC), afatinib has been evaluated in the LUX-Lung trials, with improvement in 
progression-free survival (PFS) in patients with acquired resistance to prior EGFR tyrosine 
kinase inhibitor (EGFR-TKI) treatment. This study investigated efficacy, safety and dosage 
of afatinib under a Named Patient Use (NPU) program in a single institution. Methods: We 
analyzed 60 patients with stage IV NSCLC that had been treated with ≥ 1 platinum based 
chemotherapy, and with activating EGFR mutation or disease control for ≥ 6 months with 
prior EGFR-TKIs (gefitinib or erlotinib). The daily dose of afatinib was started with 50mg, 
which was decreased to 40mg and 30mg according to adverse events and tolerability 
of patients. Of 60 analyzed patients, 2 received afatinib as 3rd line treatment, 27 as 4th 
line, 19 as 5th line and 12 as ≥ 6th line. Activating EGFR mutations were detected in 11 
(exon 19 deletion) and 7 (L858R) cases. No activating mutation was found in 19 cases, 
and EGFR status was not studied in 23 cases. Results: Thirteen patients achieved partial 
remission, 33 stable disease, and 12 progression, and 2 not-evaluable resulting in a 
response rate of 21.7% and a disease control rate of 76.7%. Median PFS was 5.2 months 
(95% CI, 4.1 to 6.4 months) and median OS was 13.4m (95% CI, 12.6 to 14.2) since the 
commencement of afatinib. Toxicities leading to drug discontinuation were experienced 
by 4 patients (6.7%). Grade 3 diarrhea occurred in 10 patients (16.7%), and dosage 
reductions of afatinib were required in 35 patients, to 40mg in 25 and to 30mg in 10 
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deletions as compared to L858R mutantions (22.9m vs 13.4m, respectively; p=0.42). 
There was no difference in overal survival (OS) between patients treated with TKI in 
first or second line. Median OS for patients receiving first line TKI was 36.3m and was 
not reached for patients that received TKI in second line (p=0.61). Conclusion: OS 
survival was not different for patients bearing EGFR mutated NSCLC tumors treated 
in first or second line, despite a longer PFS for TKI given as first line therapy. 
Keywords: EGFR testing, EGFR mutation frequence, Rare EGFR mutations
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P3.01-020 Updated Data from JP28927 Study of Alectinib in ALK+ NSCLC 
Patients with or without History of ALK Inhibitor Treatment Katsuyuki Hotta1, 
Toyoaki Hida2, Kazuhiko Nakagawa3, Takashi Seto4, Miyako Satouchi5, Makoto Nishio6, 
Haruyasu Murakami7, Yuichiro Ohe8, Koji Takeda9, Takuya Yoshimoto10, Tomohiro 
Tanaka10, Tomohide Tamura11 1Okayama University Hospital, Okayama/Japan, 2Aichi Cancer 
Center, Nagoya/Japan, 3Kinki University Faculty of Medicine, Osaka-Sayama/Japan, 4National 
Kyusyu Cancer Center, Fukuoka City/Japan, 5Hyogo Cancer Center, Akashi/Japan,6The 
Cancer Institute Hospital of Jfcr, Tokyo/Japan, 7Shizuoka Cancer Center, Shizuoka/
Japan, 8National Cancer Center Hospital, Tokyo/Japan, 9Osaka City General Hospital, Osaka/
Japan, 10Chugai Pharmaceutical Co., Ltd, Tokyo/Japan,11St.Luke’S International Hospital, 
Tokyo/Japan
Background: Alectinib, a next generation ALK inhibitor, was granted approval in Japan 
2014, since it showed good efficacy and tolerability in ALK+ NSCLC patients without 
previous ALK inhibitor treatment in Phase I/II study (AF-001JP). We also reported its 
promising response and good tolerability for crizotinib pre-treated patients in JP28927 
study (ESMO 2014). This report describes the update of efficacy and safety result 
in JP28927 study. Methods: Patients (with/without prior ALK inhibitor treatment) 
who had ALK+ NSCLC were enrolled in JP28927. Patients received alectinib (300mg) 
twice daily; treatment was continued until the investigator determined lack of clinical 
benefit. Results: Thirty-five patients were enrolled into JP28927 study. Median follow-
up duration was 400 days (35-457 days). The median progression free survival (PFS) 
of 35 patients was 13.9 months (95%CI: 11.1- NR). Among 30 patients with the target 
lesions at base line, the overall response rate (ORR) was 70% (95%CI: 50.6-85.3) 
with rapid response (the median time to response was 1.2 months [95%CI: 1.1-2.1]). 
Twenty-three out of 35 patients had been confirmed the progressive disease with 
crizotinib treatment. Their median PFS was 12.9 months (95%CI: 3.9-NR). Twenty out 
of 23 patients had the target lesions at base line. ORR was 65% (95%CI: 40.8-84.6) and 
the median time to response was 1.2 months (95%CI: 1.1-1.3). The treatment-related 
adverse events (AEs) observed in more than 10% of the patients were constipation 
(31.4%), dysgeusia (25.7%), WBC count decreased (22.9%), neutrophil count 
decreased (22.9%), vomiting (14.3%), rash (14.3%), blood bilirubin increased (14.3%) 
and AST increase (14.3%). Treatment-related Grade 3 AEs, i.e. pulmonary thrombosis, 
lymphocyte count decrease, hypophosphatemia, were observed in 3 patients. No 
treatment-related Grade 4 or 5 AEs were observed. Conclusion: The updated results in 
JP28927 study once again endorsed our previous reports which had indicated alectinib’s 
promising response even for ALK+NSCLC patients who failed to crizotinib treatment. 
Keywords: Alectinib, ALK+ NSCLC, ALK Inhibitor
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P3.01-021 New Perspectives for the Patients with ALK Positive Lung 
Adenocarcinomas, after Failure of Crizotinib Therapy. A Single Institution 
Experience Milos Pesek1, Petr Grossman2, Marek Minarik3, Gabriela Krakorova1, 
Ondrej Fiala4 1Department of Pneumology, University Hospital Pilsen, Plzen/Czech 
Republic, 2Deratment of Pathology, Medical School and Teaching Hospital in Pilsen, Charles 
University, Pilsen/Czech Republic, 3Center for Applied Genomics of Solid Tumours, Genomac 
Research Institute, Prague, Czech Republic, Prague/Czech Republic, 4Department of 
Oncology and Radiotherapy, University Hospital Pilsen, Pilsen/Czech Republic
Background: Patients suffering from ALK-rearranged non-small cell lung cancer 
(NSCLC) should have significant benefit of ALK inhibitor targeted therapy by crizotinib. 
Even if high frequency of response rate to this therapy is documented, wast majority 
of those tumors become resistent due to overgrow of secondary resistent mutations 
bearing tumour cells. Such resistence should be overcome with the help of an alternative 
second generation ALK inhibitors. Methods: We present our diagnostic and therapeutic 
single institution experience in patients having ALK-rearranged NSCLC, as examined by 
FISH. We also present two case reports of patients treated by a second generation ALK 
inhibitor (ceritinib) after failure of the initial crizotinib therapy. Results: Between January 
2011 and January 2015, a total of 595 tumour tissue samples were prospectively 
analysed for a presence of ALK rearrangements. A conclusive FISH result was obtained 
from a subset of 483. ALK rearranement was found in 15 patients (3.1%). The group 
consisted of 9 males and 6 females, with a median age of 65. 13 of the tumours were 
adenocarcinomas, 2 adenosquamous carcinomas. 8 patients were nonsmokers, seven 
were smokers. Consequently, 6 patients were treated by crizotinib while the rest did 
show a rapidly progressing tumours. 3 of the 6 crisotinib patients had a documented 
benefit from the therapy lasting for 22, 15 and 6 months.Finally, after failure of 
crizotinib, 2 patients reached a second partial remission on ceritinib,lasting 9 and 6 
months. Conclusion: Targeted therapy of ALK-positive tumours is capable to prolong 
survival of patients quite significantly. In crizotinib - resistent tumours, second generation 
ALK inhibitors (such as ceritinib in this case), maybring further benefits to patients. 
Keywords: Ceritinib, NSCLC, ALK, crisotinib
safety of gefitinib in elderly patients with advanced NSCLC. Therefore, the efficacy and 
safety of treatment of gefitinib in elderly patients with EGFR mutation positive advanced 
NSCLC have yet to be confirmed. Methods: We retrospectively assessed the efficacy 
and safety of gefitinib in 52 patients with EGFR mutation positive advanced NSCLC 
who were 70 years older and were treated with gefitinib. In addition, we compared the 
frequency and severity of adverse effects between patients 70 to 79 years and patients 
80 years or older. Results: Of 52 patients, 35 (67%) were female and 13 (25%) were 
performance status of 2 or more, and the median age was 75 (range, 70-89 years). 
Fifteen patients (29%) were 80 years or older. All patients were adenocarcinoma. The 
type of EGFR mutation was as follows: 28 patients (54%) had exon 19 deletion, 23 (44%) 
had exon 21 L858R, and 1 (2%) had exon 18 G719A. The response rate was 73.1% 
(95% CI, 59.0% to 84.4%) and the disease control rate was 90.4% (95% CI, 79.0 to 
96.8%). The median time to progression was 10.7 months (range, 0 to 36.2 months). 
The median survival time was 23.8 months (range, 0.2 to 65.6 months). The common 
adverse events were skin rash (52%), liver dysfunction (29%), diarrhea (25%), and 
interstitial lung disease (4%). Doses of gefitinib were reduced in 12 patients (23%) and 
discontinued in 11 patients (21%) due to toxicity, mainly skin rash and liver dysfunction. 
There were no differences in response rates, disease control rates, survivals, adverse 
events, and dose reduction rates between patients 70 to 79 years and patients 80 years 
or older. Conclusion: Treatment of gefitinib is highly effective for elderly patients with 
EGFR mutation positive advanced NSCLC, although dose reduction rates were more 
frequent in elderly patients than those in recently published trials in younger patients. 
Keywords: EGFR-TKI, elderly
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P3.01-018 Icotinib for Control of Leptomeningeal Carcinomatosis in Non-
Small Cell Lung Cancer with Sensitive EGFR Mutations Yun Fan1, Lei Gong2, Zhiyu 
Huang2, Lulu Miao2, Yanjun Xu2 1Zhejiang Cancer Hospital,Key Laboratory Diagnosis and 
Treatment Technology on Thoracic Oncology , Hangzhou, China, Hangzhou/China, 2Zhejiang 
Cancer Hospital, Hangzhou/China
Background: The incidence rate of leptomeningeal carcinomatosis (LC) has been 
increased in advanced non-small cell lung cancer (NSCLC) patients, especially 
with EGFR mutations. The purpose of this study was to evaluate the efficacy of icotinib 
for the control of LC in NSCLC with sensitive EGFR mutations. Methods: Twenty-
one NSCLC patients with sensitive EGFR mutations and cytologically proven LC 
diagnoses between 2011 and 2014 at Zhejiang Cancer Hospital were retrospectively 
reviewed. Results: Ten patients had exon 21 point mutations and eleven patients had 
exon 19 deletional mutations. Sixteen of 21 patients received standard dose of icotinib 
(125 mg/day, three times a day) after LC diagnoses. The other five patients had already 
used icotinib and switched to double dose of icotinib (250 mg/day, three times a day) 
after LC occurrence. Eight patients received intrathecal chemotherapy, and nine of 
them were treated with combined whole-brain radiotherapy. Eighteen of 20 patients 
(90.0%) showed improvement of dizziness and headache. Seventeen of 21 patients 
(80.9%) had an improved Eastern Cooperative Oncology Group performance status 
(ECOG PS) score after icotinib treatment. The median overall survival was 10.1 months 
(95% CI: 8.4–12.0). Univariate analysis showed that the poor ECOG PS score (PS > 
2), coexisting parenchymal brain metastasis, and the taken of icotinib were unfavorable 
prognostic factors for patient survival.The ECOG PS scare was an only independently 
predictor for survival in the multivariable analysis. Conclusion: This study suggested 
that icotinib had efficacy for the control of LC in NSCLC with sensitive EGFR mutations 
and was well tolerated. The Further prospective study is warranted. 
Keywords: icotinib, non-small cell lung cancer, EGFR mutation, leptomeningeal 
carcinomatosis
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P3.01-019 Treatment and Clinical Evolution of a Cohort of 105 EGFR Mutant 
Patients from a Single Institution Helano C. Freitas, Augusto O. Saito, Fabio N. 
Santos, Izabela W. Cunha, Aldo L.A. Dettino, Mariana P. Macedo, Graziela Z. Dal Molin, 
Vladmir C.C. Lima Oncologia Clínica, A C Camargo Cancer Center, Sao Paulo/Brazil
Background: Lung cancer is among the most common malignancies in Brazil. The use 
of tyrosine-kinase inhibitors (TKI) is nowadays a solidIy stablished treatment strategy 
for EGFR mutaion bearing NSCLC metastatic tumors. In this study we describe the 
clinical evolution of a cohort of 115 EGFR-mutant NSCLC patients from a single brazilian 
institution. Methods: We describe a retrospective cohort of 115 consecutive patients 
bearing metastatic EGFR mutated NSCLC, treated at A.C. Camargo Cancer Center, 
Sao Paulo, from August/2010 to December/2014. Patients were older than 18y and 
had to have a histologically confirmed NSCLC dianosis. Clinical and pathological data 
was extracted from their eletronical medical charts. Chi-square statistics, or Fisher’s 
exact test when appropriate, was used to compare proportions among groups, 
Kaplan-Meier method was used for survival analysis and log-rank’s test was performed 
to compare survival curves. Results:Median age was 64y, 62% of patients were 
female, 94% had adenocarcinoma and 22% were smokers/former smokers. Data 
about treatment and survival was available for 85/115 patients. Eighty eight percent 
(75/85) of them were metastatic at diagnosis, of whom 52% (39/75) received a TKI 
in first line, 24% (18/75) in second line, 5% (4/75) in third/later lines and 16% were 
never treated with a TKI. Median progression free survival (PFS) was 13.9 months (m) 
for first line TKI and 11.4m for TKI treatment in second line (p=0.028). Median PFS 
for first line platin-based chemotherapy was 9.6m as compared to 3.1m for platin-
based chemotherapy in second line (p=0.001). PFS with TKI treatment was numerically 
superior but not statistically significant for patients bearing tumors with exon 19 
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FISH. Participants were treated with AUY922 at a dose of 70 mg/m2 IV once weekly 
until disease progression, unacceptable toxicity, or death. The primary endpoint was 
objective response rate (ORR) according to RECIST version 1.1. Key secondary endpoints 
included safety, progression-free survival (PFS), and disease control rate (DCR). The 
planned sample size was 20 patients. Results: Between December 2012 and December 
2014, 6 patients were enrolled. Median age was 52.5 years (range 42-54 years). A 
majority of patients (83%) were female. The median number of prior lines of therapy 
was 3 (range 2-4). All patients had previously received at least 1 ALK TKI (crizotinib n=5, 
alectinib n=1), and 2 patients had received a second ALK inhibitor (ceritinib n=2). Most 
patients (n=4) had received an ALK inhibitor as the last line of therapy prior to enrollment. 
Among the 6 patients enrolled, no objective responses were observed (ORR 0%). Three 
patients (50%) had a best response of stable disease (SD), but none remained on therapy 
beyond 3 months from the time of enrollment (Table). The median PFS was 1.43 months 
(95% CI 1.3-2.8 months). Common adverse events (AEs) included grade 1-2 diarrhea 
(83%), vision disorders (50%), fatigue (50%), and constipation (33%). The only treatment-
related grade 3 AE was alkaline phosphatase elevation in 1 patient. The study was closed 
due to poor accrual in December 2012.
Table 1
Patient Best Response RECIST v1.1.
Progression-Free Survival 
(months)
1 -4.9% 2.80
2 36.5 0.73
3 5.1 1.03*
4 121.9 1.43
5 11 2.60
6 69.5 1.30
* Censored (Discontinued 
due to toxicity)
 
Conclusion: Although limited by a small sample size and premature closure, this study 
suggests that AUY922 is associated with minimal anti-tumor activity in ALK-positive 
patients previously treated with ALK inhibitors. Combinations of ALK TKIs and HSP90 
inhibitors may represent an alternative strategy, and several such studies are now ongoing. 
Keywords: ALK, Heat shock protein 90, HSP90
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P3.01-024 The Effect of Pemetrexed as First Line Chemotherapy in Advanced 
Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene 
Rearrangements Di Ma, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang Medical 
Oncology, Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union 
Medical College, Beijing/China
Background: The efficacy of pemetrexed-based first-line chemotherapy in ALK-positive 
NSCLC has been documented in several studies. More data for Chinese population 
are still needed. Methods: We retrospectively reviewed the chart of 34 patients with 
ALK-positive advanced NSCLC. All of them had received pemetrexed as the first-line 
chemotherapy in our hospital from May 2011 to October 2014. We analyzed the clinical 
characteristics and treatment outcomes of these patients.The primary end points 
were response rate and progression-free survival. Results: The median age was 52 
years (range from 34 to 76) and 58.8% (20/34) of the patients were never smokers. 
All tumors were adenocarcinoma. There were two cases harboring ALK translocation 
and EGFR mutation. Pemetrexed combined with platinum was administered in the 
first-line setting and the median treatment cycle was 4.5. The median progression-
free survival (PFS) of ALK-positive patients was 8.8 months (95%CI 7.397-10.213). At 
the time of analysis, 7 with PR (20.6%)，23 with SD (67.6%)，4 with PD (11.8%) and no 
CR achieved. The objective response rate was 20.6% (7/34)，and the disease control 
rate was 88.2% (30/34). Common adverse events with pemetrexed were neutropenia 
(52.9%)，nausea (58.8%)，transaminase elevation (29.4%) and fatigue (9.3%)，mainly 
in grade 1 or 2. Conclusion: Pemetrexed is efficient and well tolerated as first-line 
treatment for ALK-positive NSCLC in Chinese population. Thus, pemetrexed might 
provide an alternative option for the treatment of ALK-positive lung adenocarcinoma. 
Keywords: Anaplastic lymphoma kinase, lung cancer, pemetrexed, Progression-free 
survival
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P3.01-025 Real-Life Experience and Clinical Characterization in Patients with 
ALK Positive NSCLC: A Multicentre Study of the Austrian Lung Cancer Group 
Maximilian J. Hochmair1, Sophia Holzer1, Andrea Mohn-Staudner1, Klaus Kirchbacher2, 
Ulrike Setinek1, Irene Kapfhammer1, Madeleine Arns3, Arschang Valipour1, Georg 
Christian Funk1, Andreas Fazekas1, Otto Chris Burghuber1 1Department of Respiratory and 
Critical Care Medicine, Otto Wagner Hospital, Vienna/Austria, 2Wilhelminenspital, Vienna/
Austria, 3Landeskrankenhaus Hochegg, Hochegg/Austria
Background: ALK translocations, occuring in 3-5% of patients with NSCLC (non-small 
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P3.01-022 A Prospective Multicenter Study for ALK IHC+ Metastasized NSCLC 
Erik Thunnissen1, Bg Skov2, Jens Sorensen3, Anders Mellemgaard4, H.J.M. Groen5, Ed 
Schuuring6, Wim Timens6, Michel V.D. Heuvel7, J. De Jong8, Kim Monkhorst8, Joop De 
Langen9, Miep Van Der Drift10, Monika Looijen-Salamon11, Anne-Marie Dingemans12, 
Ernst-Jan M. Speel13, Suzy Samii14, F Duplaquet15, Birgit Weynand16, X Durando17, 
Frederique Penault-Llorca18, Patrick Pauwels19, Keith Kerr20, Marianne Nicolson21, 
Stephen P. Finn22, O Schildgen23, Lukas Bubendorf24, S Rohtschild25, Annemieke 
Hiemstra1, Birgit Witte26, Egbert Smit27 1Department of Pathology, VU University Medical 
Center, Amsterdam/Netherlands, 2Department of Pathology, Copenhagen University 
Hospital, Rigshospitalet, Copenhagen/Denmark, 3Department of Oncology, Copenhagen 
University Hospital, Rigshospitalet, Copenhagen/Denmark, 4Department of Oncology, Herlev 
University Hospital, Copenhagen/Denmark, 5Department of Pulmonary Diseases, University 
of Groningen and University Medical Center Groningen, Groningen/Netherlands, 6Department 
of Pathology and Medical Biology, University of Groningen and University Medical Center 
Groningen, Groningen/Netherlands, 7Department of Thoracic Oncology, The Netherlands 
Cancer Institute – Antoni Van Leeuwenhoek Hospital, Amsterdam/Netherlands, 8Department 
of Pathology, The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, 
Amsterdam/Netherlands, 9Department of Pulmonary Diseases, VU University Medical 
Center, Amsterdam/Netherlands, 10Department of Pulmonary Diseases, Radboud University 
Medical Center, Nijmegen/Netherlands, 11Department of Pathology, Radboud University 
Medical Center, Nijmegen/Netherlands, 12Department of Pulmonary Diseases, Maastricht 
University Medical Center, Maastricht/Netherlands, 13Department of Pathology, Maastricht 
University Medical Centre, Maastricht/Netherlands, 14Department of Pulmonary Diseases, 
Deventer Hospital, Deventer/Netherlands, 15Department of Pneumology, CHU Mont-
Godinne, Catholic University of Louvain (Ucl), Yvoir/Belgium, 16Department of Pathology, 
CHU Mont-Godinne, Catholic University of Louvain (Ucl), Yvoir/Belgium, 17Department 
of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand/France, 18Department of 
Pathology, Centre Jean Perrin, Clermont-Ferrand/France, 19Department of Pathology, 
Antwerp University Hospital, Edegem/Belgium, 20Department of Pathology, Aberdeen Royal 
Infirmary, Aberdeen/United Kingdom, 21Department of Oncology, Aberdeen Royal Infirmary, 
Aberdeen/United Kingdom, 22Department of Pathology, University of Dublin, Trinity College 
and St. James’S Hospital, Dublin/Ireland,23Institute of Pathology, University Medical Center 
Witten/Herdecke, Cologne/Germany, 24Insitute of Pathology, University Hospital Basel, 
Basel/Switzerland, 25Department of Medical Oncology, University Hospital Basel, Basel/
Switzerland,26Department of Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam/Netherlands, 27Departments of Pulmonary Diseases and Thoracic Oncology, VU 
University Medical Center and the Netherlands Cancer Institute - Antoni Van Leeuwenhoek, 
Amsterdam/Netherlands
Background: Pulmonary adenocarcinomas may harbor driver mutations, that sensitize 
tumors to drugs that specifically target the genetic alteration. Metastasized NSCLC with 
an EML4-ALK translocation are sensitive to a range of tyrosine kinase inhibitors, of which 
crizotinib is most extensively studied. ALK-positive NSCLC was determined in a phase 
III trial with fluorescence in situ hybridisation (ALK FISH+). ALK immunohistochemistry 
(IHC) seems to run parallel with ALK FISH positivity. However discrepant cases occur, 
which include ALK IHC+ FISH-. The aim of this study is to collect cases with ALK IHC+ 
and compare within this group response to crizotinib treatment of ALK FISH+ cases with 
ALK FISH- cases. Methods: A prospective multicenter investigator initiated research 
study was started in Europe. This study is supported by Pfizer. Cases diagnosed with 
ALK IHC+ lung cancer (5A4 or D5F3) treated with crizotinib are collected centrally. Slides 
are submitted centrally for validation of ALK IHC (with ETOP and Ventana protocol), 
ALK FISH (with Vysis probes) and DNA analysis. Results: The study started on April 
1 2014 and is still open. Currently 10 centers are actively participating. 1443 cases 
have been examined with ALK IHC of which 39 (2.7%) recorded positive. 24 cases have 
been submitted to the database. The validation process is still ongoing. The fraction 
of ALK IHC+ FISH- cases is low. Two cases with ALK IHC+ FISH- metastastatic NSCLC 
responded to crizotinib treatment. In two cases ALK positivity could not be confirmed 
(ALK IHC- and ALK FISH-). These patients had progressive disease following crizotinib 
treatment. Conclusion: A clinically relevant question what the effect of ALK inhibitor 
treatment is on metastatic NSCLC ALK IHC+ FISH- compared to ALK IHC+ FISH+ is 
examined. Other centers with interested collaborating physicians are invited to participate. 
Keywords: ALK* immunohistochemistry*NSCLC* treatment
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P3.01-023 A Phase II Trial of AUY922, a Heat Shock Protein 90 (HSP90) 
Inhibitor, in ALK-Positive Lung Cancer Patients Previously Treated with ALK 
Inhibitors Justin F. Gainor1, J. P. Marcoux2, Michael Rabin2, Leena Gandhi2, Daniel 
B. Costa3, Jennifer Logan1, David M. Jackman2, Alice Shaw1 1Massachusetts General 
Hospital, Boston/MA/United States of America, 2Dana Farber Cancer Institute, Boston/MA/
United States of America, 3Beth Israel Deaconess Medical Center, Boston/MA/United States 
of America
Background: Anaplastic lymphoma kinase (ALK) fusions are key oncogenic drivers in 
non-small cell lung cancer (NSCLC) that confer sensitivity to treatment with ALK tyrosine 
kinase inhibitors (TKIs), such as crizotinib. Despite this activity, ALK-positive patients 
ultimately develop resistance to ALK TKIs. In preclinical models, ALK fusion proteins are 
HSP90 clients and remain sensitive to HSP90 inhibition despite acquired resistance to 
ALK TKIs. We therefore designed a phase II trial of the HSP90 inhibitor AUY922 in patients 
with previously treated, ALK-positive NSCLC. Methods: In this single-arm, multicenter, 
open-label study, we enrolled patients with advanced, ALK-positive NSCLC who had failed 
at least one prior ALK inhibitor. Key eligibility criteria included ECOG PS 0-2, measurable 
disease based upon RECIST version 1.1, and presence of an ALK rearrangement by 
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for confidence interval of 95% (CI95% 67.3 to 267.9) Conclusion: Of the population 
evaluated, proportion of lung adenocarcinoma (ratio of tumors), is different than other 
reports of the world. Outcome is like patients with another tumors, because they consult 
to late, in advance stage of disease, then mortality is higher and shorter survival. 
Implementation in diagnosis of detection of epidermic growth factor receptor mutation 
(EGFR) in the institution has been of great value to reorient pharmacological treatment.  
Keywords: Lung Neoplasms, Survival, Carcinoma Bronchogenic
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P3.01-028 Serum Levels of C-Reactive Protein Predict Poor Outcome of 
Patients with Advanced-Stage NSCLC Treated with Erlotinib Ondrej Fiala1, 
Milos Pesek2, Jindrich Finek1, Ondrej Topolcan3, Jaroslav Racek4, Marek Minarik5, 
Lucie Benesova6, Zbynek Bortlicek7, Tomas Buchler8 1Department of Oncology and 
Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen/
Czech Republic, 2Department of Pneumology, Medical School and Teaching Hospital in 
Pilsen, Charles University, Pilsen/Czech Republic, 3Department of Nuclear Medicine, Medical 
School and Teaching Hospital in Pilsen, Charles University, Pilsen/Czech Republic, 4Istitute 
of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, 
Charles University, Pilsen/Czech Republic, 5Center for Applied Genomics of Solid Tumours, 
Genomac Research Institute, Prague, Czech Republic, Pilsen/Czech Republic, 6Center 
for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague/Czech 
Republic, 7Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, 
Brno/Czech Republic, 8Department of Oncology and First Faculty of Medicine, Charles 
University and Thomayer Hospital, Prague/Czech Republic
Background: Erlotinib is a low-molecular weight tyrosine kinase inhibitor (TKI) directed at 
epidermal growth factor receptor (EGFR), widely used in the treatment of locally-advanced 
or metastatic stage NSCLC. Although introduction of EGFR-TKIs have significantly 
extended survival of advanced-stage NSCLC patients, their efficacy in the entire patient 
population is relatively low, especially in Caucasians. Aside from activating EGFR gene 
mutations, no reliable biochemical or molecular predictors of response to erlotinib have 
been established. The aim of our retrospective study was to evaluate the association 
of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with 
advanced-stage NSCLC treated with erlotinib. Methods: We retrospectively analysed 
clinical data of 595 patients with advanced-stage NSCLC (IIIB or IV) treated with erlotinib. 
Serum CRP was measured using immunoturbidimetric method. Results: Before the 
treatment initiation, high baseline levels of CRP (≥ 10 mg/l) were measured in 387 
(65%) patients and normal levels (< 10 mg/l) were measured in 208 (35%) patients. 
The median PFS and OS for patients with high CRP was 1.8 and 7.7 compared to 2.8 
and 14.4 months for patients with low CRP (p<0.001 and p<0.001). The multivariate 
Cox proportional hazards model revealed that CRP (HR=1.57, p<0.001), EGFR status 
(HR=2.22, p<0.001), stage (HR=1.31, p=0.013) and ECOG PS (HR=1.22, p=0.024) 
were significantly associated with PFS and also with OS (HR=1.63, p<0.001; HR= 1.97, 
p=0.011; HR=1.44; p=0.007 and HR=1.72, p<0.001, respectively). Conclusion: The 
results of the conducted retrospective study suggest that the baseline level of CRP 
was independently associated with PFS and also with OS. CRP is commonly used 
biomarker which is simple and easy to detect and thus it is feasible for the use in the 
routine clinical practice. This study is supported by Ministry of Health, Czech Republic - 
conceptual development of research organization Faculty Hospital in Pilsen - FNPl, 00669806 
and by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund. 
Keywords: Erlotinib, NSCLC, C-reactive protein, biomarker
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P3.01-029 Factors Impacting Delay in Timely Care for Patients Diagnosed 
with Lung Cancer in Victoria Sue Evans, Arul Earnest, Meera Senthuren, Peta 
Mclaughlin, Rob Stirling Epidemiology and Preventative Medicine, Monash University, 
Melbourne/VIC/Australia
Background: Delay in patient management timelines in lung cancer may exceed 
recommended timeframes, potentially adversely impacting quality of life, curative 
resection rates, disease progression and survival. The aim of this study was to evaluate 
the contribution of health service variables to delay between referral (T0), diagnosis (T1) 
and treatment (T2) for lung cancer patients. Methods: Demographic, clinical and health 
service data from the Victorian Lung Cancer Registry (VLCR) was analysed to identify 
variables predictive of extended critical time intervals. Explanatory variables were 
included in multivariate models. Sub-group analysis of the magnitude of delay of each 
interval was also performed. Results: Among 1417 subjects, median T0-T1 interval was 
15 days (IQR 5-38), T1-T2 was 12 days (IQR 0-34) and diagnosis to palliative care 19 days 
(IQR 5-48). Significant T0-T1 delay was associated with country of birth, whether English 
is the first language, treatment first received and health status at diagnosis (ECOG score). 
Significant T1-T2 delay was associated with country of birth, the type of hospital where 
treatment was provided, presence of major comorbidities and initial treatment type. 
Factors associated with T2-T3 delay included age at diagnosis, the type of hospital where 
treatment was provided, health status at diagnosis and initial treatment type. Multivariate 
analysis demonstrated that type of hospital, stage of disease at diagnosis, ethnicity and 
type of initial treatment were all associated with significant delay at various stages of the 
patient journey to initial treatment (T0, T1 and T2). Conclusion: Understanding factors 
associated with delay in patients with lung cancer receiving effective management is 
crucial to developing interventions to address gaps. This research has identified priority 
areas for action in Victoria
cell lung cancer), has improved the treatment for these patients. We examined the 
clinical characteristics, diagnosis modalities and treatment outcomes of these ALK + 
NSCLC patients. Methods: Data from patients with adenocarcinoma and NSCLC/NOS 
(Not Otherwise Specified) whose tumors were routinely analyzed for EML4-ALK were 
reviewed. Patient characteristics including age, sex, race, smoking history, localization 
of biopsy, response to ALK inhibitors and presence/absence of brain metastasis 
were collected. All data were obtained from 4 hospitals in Austria with high expertise 
in the management of lung cancer from August 2011 till October 2014. EML4-ALK 
was identified by a two-step procedure. First an immunhistochemical staining was 
done with the Ventana anti ALK (D5F3), Opti View DAB IHC DetectionKit and Opti View 
Amplifikation Kit®. Further, all positive cases (weak to strong) were tested by ALK FISH 
(dual colour breakapart FISH/Abbott Vysis®). Results: 1754 consecutive patients 
were tested for EML4-ALK mutation. EML4-ALK positive immunohistochemical staining 
was found in 226 patients (12.9 %). 37 of these patients (2.1 %) showed positive ALK 
FISH analysis. However 2 patients with strong immunohistochemical staining showed 
no rearrangement in FISH analysis. These 2 patients were also treated with an ALK 
Inhibitor and showed tumour shrinkage. From these EML4-ALK translocation positive 
39 patients, 23 patients were women and 16 men. 24 patients (61%) were Never-
Smoker, 9 were former smokers (23 %) and 6 smokers (15 %). Biopsies were taken 
in 24 patients from the primary tumor and in 8 patients from the lymph nodes; in 6 
patients the analysis was performed by drainage of pleura effusions and in 1 patient by 
drainage of a pericardial effusion. 24 patients received an ALK inhibitor. 5 patients had 
a complete response, 18 patients a partial response, 0 patients a stable disease and 
1 patient showed a progressive disease. 15 patients did not receive an ALK Inhibitor, 
because they were in an operable stage. Before therapy with an ALK inhibitor, 5 patients 
had initial brain metastasis and additional 8 patients developed brain metastasis during 
treatment. Conclusion: ALK rearrangements are observed in 2.2 % of Adenocarcinoma 
and NSCLC/NOS. It can be detected in all patients independent of any clinical 
characterization and/or smoking behavior. Therefore, reflex testing is recommended, 
since patients treated with an ALK inhibitor had a clear benefit from treatment. 
Keywords: EML4-ALK, Real-life experience , targeted therapy, NSCLC
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P3.01-026 Short-Term Efficacy of Helical Tomotherapy in the Treatment of 
Intracranial Multiple Brain Metastases of Lung Cancer Feng Wang, Rongqing Li, 
Yong Zhang Radiotherapy, First Affiliated Hospital of Kunming Medical University, Kunming/
China
Background: To explore the dosimetry advantages, adverse reactions and efficacy of 
helical tomotherapy in the treatment of intracranial multiple brain metastases of lung 
cancer. Methods: Seven patients with intracranial multiple brain metastases from Feb., 
2012 to May 2014 were treated with helical tomotherapy. Whole-brain radiotherapy: 
the clinical target volume (CTV) was 45 Gy/25 times and gross tumor volume (GTV) 
was 50～58 Gy/25 times, 5 times in a week. Results: Both the homogeneity and 
shape-adaptability of radiation in 7 patients were better. The response rate came 
up to 78%, and the adverse reactions could be tolerated. Conclusion: Helical 
tomotherapy in the treatment of intracranial multiple brain metastases of lung 
cancer has better dose distribution and short-term efficacy. It provides a new 
therapeutic platform for the treatment of multiple brain metastases of lung cancer. 
Keywords: multiple brain metastases; helical tomotherapy; radiotherapy
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P3.01-027 Lung Adenocarcinoma in Patients from the Colombian Coffee 
Zone Gustavo Rojas1, Jaime A. Echeverri F2, Marco Kimmel1, Jose W. Martinez1, Paula 
Londno1 1Oncologos Del Occidente S.A., Pereira/Colombia, 2Pulmonary Medicine, 
Oncologos Del Occidente, Pereira/Colombia
Background: During 1998 and 2013 the “Colombian Coffee Zone” (conformed 
by Caldas, Quindio, and Risaralda states) had an increase of 105 mortality cases of 
Bronchi and lung malignant tumors, as reported in death certificates. Methods:This is 
an observational and descriptive study that was made in patients at Clinica Oncologos 
del Occidente in the year 2014 and the Information was taken from the Clinical History 
Administration System (SAHICO). Thereafter, pending data was collected, by phone calls 
to patients or patient’s family, according to every case. Patients were interviewed to 
know their actual performance status and, in case of death, date and basic cause of 
death was asked. Results: SAHICO reported 178 patients with lung cancer. From these 
patients, 33 did not have a correct diagnosis. Basically, they did not have a histology 
report. This happens in patients that consulted with a clinical presentation compatible 
with a pulmonary origin neoplasia and radiology reports concluding in thorax tumors, 
which had a lung dependency. But such patients had a very low performance status, 
because they did not assist to the second consult, they never started treatment, and 
finally because they died. Among these 178 patients 3 had other diagnoses, which 
initially were unclear: one had Gastric Cancer, the second had prostate carcinoma 
and the last one had breast cancer. Also, 12 Patients came with the diagnosis of 
Adenocarcinoma or Squamous cellular lung cancer, they only went to radiation 
treatment with us and the rest of the clinical treatment was taken in another clinic, or 
they died before treatment initiates, this group was called without following. There were 
38 patients with adenocarcinoma. The proportion between Squamous Cellular and 
Adenocarcinoma was 1.7 patients with squamous cellular carcinoma for every patient 
with Adenocarcinoma. 28 patients were tested for the EGFR mutation analysis, from 
these, 5 had the EGFR mutation. The average age of the patients with adenocarcinoma 
was 64.2 years old. The median survival time found was 167.6 days and the calculation 
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cell lung cancer (NSCLC) model. Methods: In vitro and in vivo experiments were conducted 
with a HER2, luciferase and GFP expressing NSCLC cell line (Calu3-luc-GFP). An antibody-
photosensitizer conjugate (APC) consisting of trastuzumab and a phthalocyanine 
dye, IRDye-700DX, was synthesized. In vitro NIR-PIT cytotoxicity was assessed with 
dead staining, luciferase activity, and GFP fluorescence intensity. In vivo NIR-PIT was 
performed in mice with tumors implanted within the intrathoracic cavity or in the flank, 
and assessed by tumor volume and/or bioluminescence and fluorescence thoracoscopy. 
Body weight was measured as an index of systemic toxicity. Results: In vitro NIR-PIT-
induced cytotoxicity was light dose dependent. In vivo NIR-PIT led to significant reductions 
in both tumor volume (p = 0.002 vs. APC) and luciferase activity (p = 0.0004 vs. APC) in a 
flank model, and prolonged survival (p < 0.0001). Bioluminescence indicated that NIR-PIT 
lead to a significant reduction in the volume of pleural metastases 1 day after PIT (p = 
0.0180)(Figure). Fluorescence thoracoscopy confirmed this result (Figure). Body weight 
ratio showed no significant reduction in NIR-PIT treated mice.
 
 
Conclusion: NIR-PIT has the ability to effectively treat pleural metastases caused by 
NSCLC. We foresee NIR-PIT as an adjuvant to surgery with an initial conventional debulking 
procedure followed by NIR-PIT to “mop up” residual disease. Moreover, it would be 
feasible to deliver light via thoracoscopy, bronchoscopy or even during open-surgery. 
Thus, although this particular animal model is not typical of NSCLC, the feasibility of 
treating thoracic malignancies with light therapy is demonstrated. NIR-PIT is a promising 
therapy for disseminated pleural tumors. 
Keywords: photoimmunotherapy, NSCLC, pleural disseminated metastases, 
fluorescence thoracoscopy
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P3.01-033 Comparison of Symptom Score and Bronchoscopy Based 
Assessment with Conventional CT Based Assessment of Response to 
Chemotherapy in Lung Cancer Digambar Behera, Yenge L. Baburao, Ashutosh N. 
Aggarwal, Navneet Singh Pulmonary Medicine, Postgraduate Institute of Medical Education 
and Research (Pgimer), Chandigarh/India
Background: Computed tomographic (CT) measurements of primary tumor and/
or metastatic sites are commonly used for assessment of objective responses to 
chemotherapy by RECIST and/or WHO criteria. Decisions regarding continuation/
stopping chemotherapy are often also based upon changes in clinical symptoms. There 
is paucity of published literature on symptom plus bronchoscopy based decision making 
in routine clinical practice. This study aimed to compare reliability of response evaluation 
of lung cancer patients undergoing chemotherapy by symptoms, chest radiograph 
(CXR) and fibreoptic bronchoscopy (FOB) based assessment with conventional CT based 
assessment. Methods: Prospective, non-interventional, comparative analysis study. 
Treatment naïve patients with lung cancer having atleast one evaluable lesion on FOB and 
planned for chemotherapy were enrolled over a 1-year period. All assessments were done 
at baseline and after 3rd cycle of chemotherapy. Six symptoms (dyspnea, cough, chest 
pain, hemoptysis, anorexia and weight loss) on visual analogue scale [VAS] were noted. 
Respiratory symptom burden (RSB) and Total symptom burden (TSB) were calculated 
from first four and all six symptoms respectively. CXR responses were assessed as 
per WHO criteria. Bronchoscopic findings were recorded in a proforma adapted and 
modified from European Respiratory Society (ERS) classification for tracheobronchial 
stenosis. Video-recording of all bronchoscopies was preserved for objective review. CT 
response as per RECIST 1.1 was taken as reference standard and agreements tested 
using Cohen’s kappa (k) statistic. Results: Of 87 patients enrolled, 53 completed ≥3 
cycles and were included for final analysis. Mean age was 55 years, majority (81.1%) 
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P3.01-030 Multimodality Treatment for Non-Small Cell Lung Cancer with 
Ipsilateral Pleural Dessimination Aleksey Kurchenkov, Vyacheslav Kurchin Thoracic 
Oncopathology, N.N. Alexandrov National Cancer Centre of Belarus, P. Lesnoy-/Belarus
Background: Patients with non-small cell lung cancer (NSCLC) with ipsilateral pleural 
dissemination previously treated without surgery. There are few reports about sucsessful 
surgical treatment of these patients. Using intrapleural hyperthermochemotherapy cans 
improve survival patients NSCLC with pleural dissemination. The aim of our research 
is increasing the efficiency of the treatment of these patients. Methods: From january 
2006 to decemder 2012 in N.N. Alexandrov National Cancer Centre of Belarus twenty one 
patients with non-small cell lung cancer with ipsilateral pleural dissemination was included 
of the study under histological examination. All patients was shared in two groups: 1) 
control group – 10 patients was done chemotherapy (2-6 courses: cisplatin 75-90 mg/
m2 in 1 day, vinorelbine 30 mg/m2 in 1 and 8 days); 2) study group – 11 patients was treated 
by multimodality care: pleuropneumonectomy, intrapleural hyperthermochemotherapy 
(IHTC) and adjuvant chemotherapy. The regimen of IHTC (ThermoChem HT-1000) 
was 420C in 1 hour with cisplatin 120 mg/m2 and vinorelbine 30 mg/m2. Adjuvant 
chemotherapy was done 4 courses: cisplatin 90 mg/m2 in 1 day, and vinorelbine 30 mg/
m2 in 1 and 8 days. Results: 4 patients was done intrapleural hyperthermochemotherapy 
before surgery, because of pleural dissemination was diagnosed by thoracoscopy. 
Radical surgery was done through 2-4 weeks after IHTC. The rest of patients intrapleural 
hyperthermochemotherapy was spent with surgery jointly, because pleural dissemination 
was seen and verified by thoracotomy. All patients of the control group was died during 
24 months, while overall 3-years survival patients of the study group was 61.4±15.3% 
(p=0.05). Conclusion: Multimodality treatment is including: surgery, intrapleural 
hyperthermochemotherapy and adjuvant chemotherapy for non-small cell lung cancer 
with ipsilateral pleural dissemination, allowing to increase level of 3-years overall survival 
for patients from 0.0% till 61.4±15.3% (p<0.05) as compared with chemotherapy. 
Keywords: itrapleural hyperthermochemotherapy, adjuvant chemotherapy
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P3.01-031 Prognosis Factors in Stage IV Lung Adenocarcinoma with Single 
Brain Metastasis Lucian Miron1, Marius Paduraru2, Adela Calancea2, Ingrith Crenguta 
Miron1, Teodora Alexa1 1Medical Oncology, University of Medicine and Pharmacy Gr. T. 
Popa, Iasi/Romania, 2Medical Oncology, Regional Institute of Oncology, Iasi/Romania
Background: With the change of lung cancer epidemiology, the frequency of lung 
adenocarcinoma is steadily increasing. This histological subtype is often associated 
with brain metastasis, which negatively impact survival. Standard treatment for single-
brain metastasis includes surgery, radiotherapy and platinum-based chemotherapy. 
However, this approach is often associated with acute and chronic toxicity and may 
negatively impact quality of life in these patients. We need simple prognosis factors to 
better determine which patients will benefit from this combined therapy. Methods: We 
performed a retrospective analysis of all lung cancer patients treated in the Oncology 
department of the Regional Oncology Institute, Iaşi, Romania between January 2012 and 
January 2014. Inclusion criteria: ECOG 1-2, stage IV lung adenocarcinoma with single-
brain metastasis that underwent surgery and radiotherapy for the brain metastasis, 
followed by systemic treatment with a platinum-based regimen. Data were collected for 
each patient: age, sex, metastasis size and localization, neurological symptoms, the 
presence of other secondary lesions at diagnosis, concurrent illnesses, hemoglobin 
levels, white blood cells, platelets and lactate dehydrogenase (at the time of diagnosis). 
Data were analyzed by means of SPSS v.20 software - Cox regression. Continuous 
variables are expressed as mean±SE. Statistical significance was set at .05. Results: 31 
patients met the inclusion criteria. Mean age was 58.6±1.55 years. Overall survival (OS) 
was 266±28.32 days. Cox regression analysis indicated that a high white blood cell 
count, extra-cerebral metastatic sites, age and pre-existing illnessesnegatively 
impact OS (p<0.05). In contrast, symptoms, localization and size of the brain metastasis, 
as well as hemoglobin, lactate dehydrogenase and platelets had no impact on OS in 
this analysis. Patients with a high white blood cell count (n=13) had an average OS of 
168.3±35.3 days as compared with 336±33.2 days in patients with normal white blood 
cell count at diagnosis (n=18). Conclusion: As more and more aggressive therapeutic 
strategies emerge, we need simple and effective parameters that can predict survival 
in order to select the best approach for each individual patient. High white blood cell 
count, extra-cerebral metastatic sites, age and pre-existing illnesses were associated 
with decreased OS. A future prospective study is warranted to confirm our results. 
Keywords: Brain metastasis, Prognosis, Adenocarcinoma
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P3.01-032 Near Infrared Photoimmunotherapy for Pleural Metastases: 
Preclinical Experience Kazuhide Sato, Peter L. Choyke, Hisataka Kobayashi 
Molecular Imaging Program, Ccr, National Cancer Institute/ National Institutes of Health, 
Bethesda/MD/United States of America
Background: Pleural metastases are common in patients with advanced thoracic 
cancers and are a cause of considerable morbidity and mortality yet they are difficult to 
treat. Near Infrared Photoimmunotherapy (NIR-PIT) is a new cancer treatment that utilizes 
the specificity of intravenously injected antibodies to target photosensitizers to specific 
cancers (Figure). Since one interesting property of the lung is that it transmits light better 
than any other organ, light therapy is a viable alternative therapy. Herein, we evaluate the 
efficacy of NIR-PIT in a mouse model of disseminated pleural metastases in a non-small 
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and identify practice patterns. Assessments were repeated following the 1-hour CME 
certified activity. Long-term assessment was conducted electronically 6-weeks following 
the educational initiative. Results: The overall program educated 847 practitioners, 
including 477 physicians. Three patient scenarios were profiled during the activity: 1) non-
squamous NSCLC, non-smoker, no targetable mutation, 2) non-squamous NSCLC, EGFR 
del19 mutation, and 3) non-squamous NSCLC, ALK rearranged. Participant responses 
at baseline indicated a need for further education about molecular testing, maintenance 
therapies, and front-line therapies. All three cases also addressed treatment options 
at disease progression following initial treatment. For all cases, education resulted in 
responses better aligned to current practice guidelines and clinical data. With respect 
to molecular testing there was a 28% increase in the number of participants who would 
recommend testing and a 17% increase in participants who would recommend sufficient 
biopsy specimen for testing prior to treatment. There was a large gap in knowledge about 
the need for a repeat biopsy after progression on EGFR TKI therapy to confirm the nature 
of the lesion and select the optimal targeted therapy. Education closed this gap with 
a 53% increase in respondents understanding this need. With respect to maintenance 
therapies in the different scenarios, there was 22% change in the use of pemetrexed 
for non-targeted NSCLC and 21% for radiotherapy after progression on crizotinib. Self-
reported levels of competence to integrate biomarkers, clinical characteristics and 
tumor histology to provide an individualized treatment for patients increased after 
education. At 6-week follow-up the majority of participants reported that they were 
more likely to order molecular testing (80%), and were better able to select first-line 
(93%) and second-line therapies (93%). Participants also report increased familiarity with 
therapeutic options after education. Barriers to implementation included the newness of 
treatment data and lack of reimbursement. Conclusion: The results highlight baseline 
gaps in clinical practice. Several gaps are closed both in the short-term and the long-
term through continuing education. Educational benefits appear to endure to the 6-week 
time point. Longer term follow-up would benefit CME educational providers and in turn 
drive more relevant activities that would benefit clinicians and ultimately, their patients. 
Keywords: Education, CME, educational outcomes
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P3.01-036 The Safety and Efficacy of Thoracic Reirradiation Michael W. Straza1, 
Adam Currey1, Selim Firat1, Rafael Santana-Davila2, Smitha Menon3, Elizabeth Gore4 
1Medical College of Wisconsin, Milwaukee/WI/United States of America, 2University of 
Washington, Seattle/United States of America, 3Hematology/Oncology, Medical College 
of Wisconsin, Milwaukee/WI/United States of America, 4Medical College of Wisconsin, 
Milwaukee/AL/United States of America
Background: Intrathoracic malignancies including lung, esophageal, and pulmonary 
metastases frequently recur locally or regionally after initial therapy. The existing 
literature on the safety and efficacy of multiple courses of thoracic irradiation is limited. 
The purpose of this study was to evaluate local regional control and toxicity in patients 
who received up to three courses of thoracic radiation. Methods: We conducted a 
retrospective review of 51 patients who had undergone at least two courses of thoracic 
radiation. Two patients were found to have only a previous course of whole breast 
irradiation and were thus excluded for a total of 49 patients. Patient age, diagnosis, 
courses and doses of radiation therapy, chemotherapy and surgery were extracted from 
the record. Time to recurrence was determined by time from last radiation treatment to 
pathological confirmation or radiographic progression. Six potential treatment related 
grade 4 or 5 toxicities were identified (5 deaths). Results: The median age at diagnosis 
was 64. Median follow up was 3 years (range 0.76-12). 43 of the patients were with 
primary lung malignancy, 2 with esophageal, 3 with metastases and 1 unknown. 49 
patients received at least two courses of intrathoracic radiation, 5 received 3 courses. 
38 patients had died at time of last follow up, 10 were alive and one lost to follow up. 
46% had local-regional recurrence at time of last follow up while 24% were disease free. 
The median cumulative dose was 111Gy for all patients, 113 Gy in those with Grade 4 or 
higher toxicity (NS). Median survival after completion of the first radiation treatment was 
3.2 years. Median survival after completion of the last course of radiation was 1.25 years 
versus 0.58 years for those without and with Grade 4-5 toxicity respectively. The median 
time between the first and last course of radiation was 1.7 years. Five of the six patients 
with severe toxicity were disease free at time of death or last follow up. Grade 5 toxicities 
included massive hemoptysis, tracheal erosion, cardiac arrest, and respiratory failure. 
Dosimetric evaluation of these patients is underway. 50% of patients with severe toxicity 
had previous or subsequent thoracic surgery versus 23% in those without. Median time 
from end of first treatment to end of last treatment was 634 days (range: 0.39 -7.5 years) 
versus 465 days (range: 0.6-2.3 years) for patients without and with Grade 4-5 toxicity, 
respectively. None of the 5 patients who received 3 courses of radiation exhibited severe 
toxicity. Conclusion: Repeat courses of thoracic irradiation appear to be generally safe 
and effective with a median survival of 1.26 years following the last radiation treatment 
with 10% Gr4-5 toxicity in this population with cancer specific mortality of 78%. Future 
studies will identify clinical and dosimetric parameters that predict for severe toxicity. 
Keywords: Retreatment, recurrence, radiation
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P3.01-037 Impact of Endobronchial Stents on Patients with NSCLC and Central 
Airway Obstruction (CAO) Nagla Abdel Karim1, Mahmoud Shehata1, Ahmed Mostafa2, 
Shuchi Gulati3, Michelle Kirshner4, Changchun Xie5, John Morris6, Sadia Benzaquin7 
1Internal Medicine/Division of Hematology/Oncology, The University of Cincinnati, Ohio/OH/
United States of America, 2Pulmonary Medicine, The University of Cincinnati, Ohio/United 
States of America, 3Internal Medicine, The University of Cincinnati, Ohio/OH/United States 
of America, 4The University of Cincinnati, Ohio/OH/United States of America, 5Biostatistics, 
were males, had advanced/metastatic disease [stage IV 56.6%; IIIB 37.7%] and ECOG 
performance status of 0-1 (52.8%) or 2 (32.1%). Squamous cell carcinoma (50.9%) 
and small cell (35.8%) were the commonest histological types. Mean scores of all 
six individual symptoms, RSB and TSB showed statistically significant improvement 
after chemotherapy. Mean number as well as distribution of FOB lesions decreased 
significantly after chemotherapy. CXR response had poor agreement with both FOB 
based and CT based responses. Changes in RSB and TSB categories had no/minimal 
agreement with CT based responses. RECIST and WHO criteria had strong agreement 
(k=0.872) with each other for overall response assessment. Bronchoscopic assessment 
had minimal agreement with both RECIST (k=0.324) and WHO (k=0.349) criteria based 
assessment. For differentiating responders (CR+PR) from non-responders (SD+PD), 
FOB based assessment had weak agreement with both RECIST (k=0.462) and WHO 
(k=0.501) criteria based assessment. For differentiating disease control (CR+PR+SD) 
from disease progression (PD), WHO criteria based CT response had perfect agreement 
(k=1.000) while FOB based assessment had moderate agreement (k=0.629) in 
comparison to RECIST. Variable combinations of FOB based assessment with symptom 
based assessment and/or CXR response continued to show only moderate agreement 
(k=0.600-0.799) with CT based assessment for detecting PD. Conclusion: Majority 
of patients have symptomatic improvement after chemotherapy. However, changes 
in symptom scores and CXR responses correlate poorly with CT responses. CT scan 
based assessment by RECIST/WHO criteria remains the reference standard for objective 
evaluation of response to chemotherapy in lung cancer. Bronchoscopic progression 
may be used as a surrogate for disease progression if CT assessment is not feasible. 
Keywords: RECIST, Response assessment, Symptom score, bronchoscopy
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P3.01-034 Long-Term Survival in Metastatic Non-Small Cell Lung Cancer: 
Predictive Clinical Factors Leonardo A. Boente, Alexandre A.B.A. Da Costa, Augusto 
A.R. Pereira, Talita Gonzaga, Aline F. Fares, Daniel V. Araújo, Daniel Garcia, Daniela 
Lacerda, Marcello F. Fanelli, Jose A. Rinck Cinical Oncology, Ac Camargo Cancer Center, 
Sao Paulo/Brazil
Background: While most patients with non-small cell lung cancer (NSCLC) stage IV, 
presents an unfavorable prognosis, a small proportion presents median overall survival 
beyond 2 years. The aim of this study is to identify clinical factors associated with long-
term survival (LTS) in patients metastatic NSCLC. Methods: Single-center, retrospective 
study performed from the selection of patients in electronic medical records with a 
diagnosis of NSCLC, metastatic at diagnosis, and treated at AC Camargo Cancer Center 
in Brazil, from January / 2007 to June / 2014. We compared the group of patients 
who survived more than two years, the long-term survivors (LTS), to that survived less 
than two years, the short-term survival (STS), regarding the clinical characteristics 
and treatments performed. Using the chi-square test (categorical variable), and T test 
(continuous variables), for univariate analysis and by binary logistic regression model 
for multivariate analyzes, adopting the significance level P < 0.05 Results: From 292 
patients with stage IV NSCLC, there were 46 (15.7%) patients who survived beyond 2 
years, and the remaining 246 patients who survived less than two years, we selected 
a control group of 46 patients. In the LTS group, the median overall survival (OS) was 
39.7 months, and five-year-survival was 10.8%, while in the control group median 
OS was 9.2 months. In the univariate analysis related to clinical factors, the LTS was 
associated with female gender (P: 0.03); not smoking (P: 0.013); ≤ 2 metastatic sites 
(P: 0.02); ECOG of 0-1 (P: 0.01); absence of extra-thoracic metastasis (P: 0.001); 
absence of liver metastasis (P: 0.004) absence of bone metastasis (P: 0.001); absence 
of weight loss (P: 0.03); absence of decreased appetite (P: 0.001); and the presence of 
activating mutation in the EGFR gene (0.024). In univariate analysis regarding factors 
related to treatment, the LTS was associated with: two or more systemic treatment 
lines (P: 0.001); partial or complete response in first-line chemotherapy (p = 0.0001); 
use of tyrosine-kinase inhibitor (p = 0.0001); and maintenance chemotherapy 
(P: 0.012). In multivariate analysis of clinical factors, were considered long predictors 
of survival: two or fewer metastatic sites (OR: 7.1; P: 0.008) and ECOG 0-1 (OR: 
12.2 P: 0.024). There was a trend for female gender (OR: 3.1 P: 0.057). Conclusion: We 
conclude that, in our sample, patients with stage IV NSCLC who have ECOG 0-1 
and oligometastatic disease (≤ 2 sites) are more likely to long-term survival. 
Keywords: Long-term survivor, metastatic non-small cell lung cancer, prognostic fators, 
retrospective study
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P3.01-035 Treatment of NSCLC Patients by Community Health Practitioners: 
Practice Pattern and Competence Assessments Marie N. Becker, Alison Heintz, 
Jason Everly Educational Concepts Group, Llc, Atlanta/GA/United States of America
Background: The complexity of current treatment and management for patients 
with metastatic non-small cell lung cancer (NSCLC) continues to rise. The volume and 
pace of scientific advances make it challenging for the community practitioner to stay 
abreast of optimal patient care. Education is vital in disseminating critical information 
to practitioners and allows professional reflection of appropriate therapeutic decision 
making and peer discussion. Understanding the base knowledge, competence, and 
current practice patterns of practitioners is essential to identifying community needs 
and implementation of education that impacts patient care. Methods: From May 
through December 2014, educational outcomes assessments were gathered from 42 
live independent continuing medical education (CME) activities held within community 
practices across the United States. Participants were asked a series of case-based 
questions via an audience response system to assess baseline knowledge, competence, 
S653Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-039 Patient Characteristics and Treatment Outcome of Advanced Non-
Squamous NSCLC with over 6-Month Disease Control from Icotinib Sheng Yang, 
Xingsheng Hu, Junling Li, Ziping Wang, Yan Wang, Xuezhi Hao, Hongyu Wang, Jianping 
Xu, Bin Wang, Lin Lin, Xin Zhang, Shengyu Zhou, Peng Liu, Haiyan Wang, Puyuan Xing, 
Yutao Liu, Shanshan Chen, Hua Lin, Xiangru Zhang, Yan Sun, Yuankai Shi Department 
of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences 
and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer 
Molecular Targeted Drugs, Beijing/China
Background: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) 
has an established role in the treatment of advanced non-squamous non-small cell lung 
cancer (NSCLC). Icotinib is an EGFR-TKI with non-inferior efficacy but milder toxicities 
compared with gefitinib. Disease control for over 6 months suggests that the case is not 
primary resistant to the drug. The present study investigated the patient characteristics 
and treatment outcome of advanced non-squamous NSCLC with at least 6-month disease 
control from icotinib. Methods: Non-squamous NSCLC patients with disease control 
after 6-month icotinib treatment were enrolled and retrospectively analyzed. Clinical 
characteristics were collected from the medical records. Efficacy and outcome data 
were analyzed. Results: A total of 87 patients were enrolled onto this study in which 56 
were female, 18 with brain metastasis, and 32 patients harbored known EGFR mutation. 
For the overall population, 42(48.3%) patients achieved partial response. Response 
rate were 65.6%（21/32）and 38.2%（21/55）in patients with EGFR mutation and those 
with unknown mutation status, respectively(P=0.014). Patients with brain metastasis 
appeared to have lower response rate (26.7% vs 56.9%, p=0.033).The median 
progression-free survival (PFS) after 6 months’ icotinib treatment was 9.7 months (95% 
CI 4.1-15.4 months) for the overall population, and 5.0 months (95% CI 0.6-3.9 months) 
and 12.9 months (95% CI 3.4-6.2 months) for those with and without brain metastasis, 
respectively. Median progression-free survival in patients with PR or SD showed no 
statistically significant difference (15.5 months vs 9.3 months, P=0.477). Conclusion: The 
present study provided evidence from a relatively large single institutional study of 
icotinib in clinical practice. Patients with disease control for over 6 months showed 
similar clinical features to those with EGFR mutation. Those patients will have prolonged 
clinical benefits with continuous icotinib therapy after 6 months, regardless of PR or SD. 
Brain metastasis is a potential unfavorable predictive factor for PFS for those patients 
Keywords: Epidermal growth factor receptor tyrosine kinase inhibitor, icotinib, Brain 
metastasis
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P3.01-040 Prospective Evaluation of Changes in Cancer Cachexia in NSCLC 
in Patients given Chemotherapy by Correlating Skeletal Muscle Mass with 
PRO Results Ryan D. Gentzler1, Alejandro R. Boiles2, Jose N. Galeas2, Louise M.-W. 
Man1, Richard D. Hall1, Patricia Hollen3, Richard J. Gralla2 1Hematology/Oncology, 
University of Virginia, Charlottesville/VA/United States of America, 2Department of Medicine, 
Jacobi Medical Center - Albert Einstein College of Medicine, Bronx/NY/United States of 
America, 3School of Nursing, University of Virginia, Charlottesville/VA/United States of 
America
Background: Cancer cachexia and sarcopenia are common in lung cancer, and are 
associated with poor outcomes. Several recent interventional trials in cancer cachexia in 
patients with lung cancer have endeavored to improve skeletal muscle mass (measured 
by skeletal muscle mass index – SMI - using DXA or CT) and to correlate changes with 
functional outcomes of benefit to the patient. While functional tests such as stair climb 
power and hand grip strength have been used, these measures are neither sufficiently 
sensitive in patients with cancer, nor do they evaluate outcomes demonstrated to be 
valuable to patients. Patient Reported Outcomes (PROs) such as EORTC, FACT and 
others, have been collected, but specific components useful to patients have not been 
identified as ones correlating highly with SMI. Recent large studies at baseline using the 
3-Item Global Index (3IGI) of the Lung Cancer Symptoms Scale (LCSS) quality of life and 
functional measure found strong correlations predicting survival in non-small cell lung 
cancer (N = 602) and in mesothelioma (N = 444); thus the 3IGI appears to be a good 
factor for associating PROs with SMI changes (Symanowski ASCO 2014; Gralla ASCO 
2014). Additionally, over 90% of patients with NSCLC have expressed that parameters 
such as activity level and quality of life (included in the 3IGI) are of great importance to 
them. Methods: The LCSS was measured every 3 weeks in patients with a minimum KPS 
= 60 who were receiving chemotherapy. Correlations of SMI changes with 3IGI scores 
were made at baseline (at the time of initiation of chemotherapy) and at a median of 14 
weeks in patients with Stage IIIB or IV NSCLC. SMI was measured by CT (Slice-O-Matic 
software) at the L1 vertebral level. A change in SMI by ± 4% was considered a threshold 
change of importance. Results: We have analyzed 24 patients to date (50% female; 
medians: age 57, KPS 80%; baseline: BMI 24.3, SMI 59.9, with 38% of males < 55.4 SMI). 
19 patients are evaluable at this time. 42% of patients had a change in SMI by ± 4%; of 
these 75% had either improvement or worsening of the 3IGI in the direction expected 
from the change in SMI (improved 3IGI with increased SMI; worsened 3IGI with decreased 
SMI). No clear relationship in SMI was observed with response to chemotherapy thus 
far in the analysis. Conclusion: These results suggest: 1) the 3IGI may be useful in 
identifying both positive and negative changes in SMI, when using a 4% threshold change; 
2) while we continue to enlist patients in this study, a confirmatory larger evaluation 
should be conducted; and 3) no measure should be used in practice or clinical trials of 
cancer cachexia or sarcopenia unless it has demonstrated validity in patients with cancer. 
Keywords: sarcopenia, patient reported outcomes, lung cancer
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Background: Approximately 30% of lung cancer patients develop central airway 
obstruction (CAO) increasing the risk of post-obstructive pneumonia and respiratory 
failure. Therapeutic interventional bronchoscopy including airway stenting (AS) can provide 
immediate and effective palliation to improve patient quality of life (QoL). Unfortunately, 
there is little data about the impact on OS or the risk of hospitalization in patients with 
CAO mandating stent placement versus patients with CAO lesions that did not require stent 
placement. Methods: Between 2011-2014, twenty five patients with advanced lung cancer 
were evaluated by the Interventional Pulmonary (IP) Service at the University of Cincinnati 
for endobronchial stent placement for CAO. We retrospectively reviewed the OS and the risk 
of hospitalization in patients with lung cancer with CAO mandating stent placements versus 
patients who did not have lesions requiring stent placement. Death was considered as the 
endpoint. Kaplan-Meier method was used to calculate median overall survival and 95% CI. 
Cox model was used to test the overall survival difference between the patients who need 
stent and patients who do not need stent adjusted for age and sex. Logistic regression was 
used to test the hospitalization rate difference between the patients who need stent and 
patients who do not need stent adjusted for age and sex. Data were analyzed using the SAS 
® Version 9.4. Results: Between 2011-2014, twenty five patients with advanced lung cancer 
were evaluated by the Interventional Pulmonary (IP) Service at the University of Cincinnati 
for endobronchial stent placement for CAO. Eight patients did not require placement of a 
stent and 17 patients had obstructive lesions that required stenting. Age and gender did 
not have any impact on the risk of hospitalization or OS of both of these groups of patients. 
The eight patients whose lesions did not mandate stent placement had a significantly lower 
risk of hospitalization compared to the 17 patients with CAO requiring a stent (OR 15.9, 
95%CI 1.2, 209.1; p =0.035). Patients with advanced NSCLC and CAO that required IP stent 
placement had a median OS of 424 days (95%CI, 119-606 days) compared to a median OS of 
729 days (95%CI, 426-. days) for patients with CAO not requiring a stent. Even with a lower 
survival in patients with stent placement, their OS of 424 days was slightly longer than the 
reported one-year survival for patients with stage IV NSCLC suggestive of improved outcome 
of patients with advanced stage NSCLC supported by IP. Conclusion: Lung cancer patients 
with less severe CAO have a lower risk of hospitalization and have better OS compared to 
patients with CAO mandating stent placement; however, CAO patients with IP evaluation 
and management in addition, may have improved OS suggesting that IP consultation 
may offer both improvements in QoL and OS to patients with advanced NSCLC and CAO. 
Keywords: endobronchial, stents, central airway obstruction, NSCLC
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P3.01-038 Comparing Next-Generation Sequencing (NGS) Platforms in 
Patients with Thoracic Tumors: Tumor Tissue vs. Circulating Cell-Free DNA 
from Blood Melissa L. Johnson1, Rebecca Nagy2, Holli H. Dilks3, Richard B. Lanman2, 
Amir A. Talasaz2, Kimberly Banks2, Charles Swanton3, Howard Burris1, David R. Spigel1 
1Sarah Cannon Research Institute/Tennessee Oncology, Pllc, Nashville/TN/United States 
of America, 2Guardant Health, Inc, Redwood City/United States of America, 3Sarah Cannon 
Research Institute, Nashville/TN/United States of America
Background: Next-generation sequencing (NGS) from tumor tissue is used to acquire 
comprehensive genomic information to aid clinical decision-making for cancer patients. 
In order to obtain sufficient tissue for tumor-based NGS, patients must often undergo 
repeat biopsies after diagnosis which are invasive, associated with risk and expense, 
and sometimes unsuccessful because of tumor size or location. Genomic information 
may also be obtained by analyzing cell-free DNA (cfDNA) from plasma samples, which 
affords the potential for NGS testing to a greater number of patients, and offers a wide 
variety of cancer diagnostic and surveillance applications. We sought to compare the 
results of tumor based-NGS with an analysis of circulating tumor cfDNA from matched 
plasma samples in patients with thoracic tumors (non-small cell lung cancer, small 
cell lung cancer and thymic malignancies) to determine concordance between the 
tests. Methods: We compared NGS results obtained from tumor tissue analyzed by 
Foundation One with plasma-based analysis of cfDNA using Guardant360, a 54-gene panel 
covering 80,000 base pairs with high sensitivity (75-85% in most solid tumors) and ultra-
high specificity (>99.9999%). Guardant360 detects single nucleotide variants (SNVs), 
including synonymous alterations, variants of uncertain significance, and somatic point 
mutations, gene amplifications (CNVs), select insertions/deletions (indels) and genomic 
rearrangements. Because Foundation One is a 316-gene panel, concordance was defined 
based on the genes covered by both panels. Only patients with cancers originating in 
the chest were included. Results: Of 56 patients with Guardant360 testing performed 
between 6/2014 and 2/2015, 100% were successfully assayed. Eleven had matched NGS 
from tumor and concordance was noted in 5/11 (45%) of patients. TP53 and KRAS were 
commonly found in both tumor tissue and plasma cfDNA. A total of 34 patients (61%) 
with successful plasma-based cfDNA analysis were unable to undergo tissue-based NGS 
for various reasons; fourteen patients had tumor tissue sent for NGS analysis that was 
deemed “insufficient”, 16 had exhausted prior tumor biopsy specimen, and 4 patients were 
too ill to undergo a repeat biopsy. In 19 of these 34 cases where tissue NGS results 
were not available (56%), a genomic alternation was identified by plasma cfDNA analysis, 
which corresponded to targeted therapies available on clinical trials that otherwise would 
not have been known. Conclusion: Plasma-based NGS testing identified actionable 
genomic alternations in 23 of 56 (41%) patients tested. In most cases, this information 
was supplementary to that obtained from tumor-based NGS and partially concordant in 
matched cases. These findings support continued efforts to establish the value of cfDNA 
in those cases where repeat tissue biopsy is contraindicated or may pose undesirable 
risk of complications, or when tissue-biopsy based NGS is inadequate or uninformative. 
Keywords: cell-free DNA, next-generation sequencing, blood-based biomarkers, re-biopsy
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population, only limited data about treatment strategies and results are available, as 
those patients are usually not eligible for clinical trials; meanwhile, previously reported 
cohorts mostly focused on early-stage tumors. Our objective was then to provide a global 
picture of the treatment strategies for lung cancer in octogenerians, and to parallel those 
with available standards. Methods: Retrospective observational study of all consecutive 
patients aged 80 or more, with pathologically-confirmed lung cancer, and diagnosed at 
the Hospices Civils de Lyon between January 2005 and April 2014. Results: 337 patients 
were included, 298 (88%) with non-small cell lung cancer (NSCLC), and 39 (12%) with 
small-cell lung cancer. For NSCLC, tumor was stage I, II, III, and IV in 10%, 9%, 25% et 
57% of cases, respectively. Overall survival was 8.4 months. Geriatric assessment had 
been done only for 11% of patients. Overall, a standard treatment strategy - i.e. based 
on available recommendations and guidelines - was conducted for 42% of patients, 
while 24% received non-standard treatment, and 34% best supportive care only. At 
multivariate analysis, favorable prognostic factors on overall survival were performance 
status 0-1 (p<0.001), stage I/II (p<0.001), adenocarcinoma histology (p=0.026), and 
a standard treatment strategy (p<0.001). In the setting of metastatic NSCLC, 35% 
of patients received chemotherapy, the most frequent regimen being carboplatine 
and paclitaxel. Conclusion: Octogenarians with lung cancer are eligible for antitumor 
treatment in nearly 70% of cases, consisting of standard, recommended therapy in about 
half of the cases. Our data provide a unique overview of the management of octogenarians 
with lung cancer, to foster future prospective studies dedicated to this subset of patients. 
Keywords: Surgery, chemotherapy, NSCLC, elderly
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P3.01-044 FDG-PET/CT Based Response Prediction of Stage IV NSCLC Treated 
with Paclitaxel-Carboplatin-Bevacizumab with or without Nitroglycerin Evelyn 
E.C. De Jong1, Wouter Van Elmpt1, Otto S. Hoekstra2, Harry J.M. Groen3, Egbert Smit4, 
Ronald Boellaard2, Esther G.C. Troost1, Philippe Lambin1, Anne-Marie C. Dingemans5 
1Department of Radiation Oncology (Maastro), Grow-School for Oncology and Developmental 
Biology, Maastricht University Medical Centre, Maastricht/Netherlands, 2Department 
of Nuclear Medicine & Pet Research, VU University Medical Center, Amsterdam/
Netherlands, 3Department of Pulmonary Diseases, University Medical Center Groningen, 
Groningen/Netherlands, 4Department of Pulmonary Diseases, VU University Medical Center, 
Amsterdam/Netherlands, 5Department of Pulmonology, Grow-School for Oncology and 
Developmental Biology, Maastricht University Medical Centre, Maastricht/Netherlands
Background: A prospective study in stage IV non-small cell lung cancer (NSCLC) 
patients was performed to assess the predictive value of early response of the primary 
tumor evaluated by [18F]FDG-PET/CT to bevacizumab containing combination therapy 
with or without nitroglycerin (NTG) patches as first line treatment. NTG is a vasodilator 
which is hypothesized to increase tumor blood flow thereby decrease hypoxia, and 1) 
leading to a decrease in [18F]FDG uptake, and 2) facilitating early response assessment 
using [18F]FDG to predict treatment outcome. Methods: In total, 223 patients were 
randomized between carboplatin-paclitaxel-bevacizumab (PCB) with or without NTG (day 
-2 to +3; NVALT12 trial, NCT01171170). 78 patients were available for image analysis 
having undergone an [18F]FDG-PET/CT scan prior to the first cycle of chemotherapy and 
a second (optional) [18F]FDG-PET/CT scan at day 1-2 after start of the second cycle. The 
primary gross tumor volume (GTV) was delineated on both PET/CT scans. On the [18F]
FDG-PET scan, the maximum standardized uptake value (SUV), mean SUV, peak SUV 
and total lesion glycolysis (TLG defined as SUVmean*CTvolume) were calculated and 
correlated with progression-free survival (PFS) and overall survival (OS). Early response 
assessment was quantified using relative changes in [18F]FDG-PET uptake parameters of 
the GTV expressed as delta. The median of the parameter of interest was used as cut-off 
value for both study arms for analysis using cox regression. Furthermore response was 
assessed according to PERCIST and RECIST. Results:
Hazard ratio os SUV parameters > versus < the median for PFS and OS
SUV pa-
rameter median PFS OS
HR (p-val-
ue) 95% CI
HR 
(p-val-
ue)
95% CI
Delta PC-
B+NTG 
(%)
SUVmax 40.4 1.026 (0.408)
0.966-
1.090
1.006 
(0.844) 0.945-1.071
SU-
Vmean 39.9
1.048 
(0.127)
0.987-
1.113
1.034 
(0.279) 0.973-1.099
SUVpeak 42.3 1.035 (0.258)
0.975-
1.100
1.016 
(0.615) 0.955-1.082
TLG 64.5 1.064 (0.043)
1.002-
1.131
1.039 
(0.221) 0.977-1.106
Delta 
PCB (%) SUVmax 53.2
1.027 
(0.454)
0.957-
1.103
1.009 
(0.810) 0.939-1.084
SU-
Vmean 51.6
1.027 
(0.465)
0.957-
1.102
1.011 
(0.766) 0.941-1.086
SUVpeak 53.9 1.040 (0.281)
0.969-
1.116
1.018 
(0.623) 0.947-1.094
TLG 75.9 0.994 (0.873)
0.927-
1.066
0.998 
(0.951) 0.928-1.072
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P3.01-041 Treatment Beyond Second Line Chemotherapy Outside of a Clinical 
Trial Is Appropriate for Selected NSCLC Patients Ahmed A. Badawy1, Sejong 
Bae2, Stefan C. Grant3 1Alexandria University, Alexandria/Egypt, 2University of Alabama 
at Birmingham, Birmingham/AL/United States of America, 3Medical Oncology, Wake Forest 
Baptist Medical Center, Winston-Salem/NC/United States of America
Background: Guidelines generally recommend entry into a clinical trial or best 
supportive care for patients with NSCLC who progress after second line chemotherapy. 
We sought to explore whether this strategy remains valid with newer drugs and regimens 
and to evaluate the benefit of additional treatment beyond second line in advanced 
NSCLC. Methods: A retrospective analysis of stage IV NSCLC patients treated at a 
tertiary teaching hospital from 2002-2012 was undertaken. Demographics, details of 
treatment and overall survival was recorded for each patient. Patients who originally 
received adjuvant therapy and no further treatment upon recurrence and those 
receiving first line treatment on a clinical trial with no further therapy were excluded 
from analysis. Statistical analyses was performed using SPSS software and calculated 
using log-rank testing. Results: 409 cases of NSCLC were included in this analysis. 239 
(58.4%) patients received second line chemotherapy, 102 (24.9%) received third line 
treatment, 36 (8.8%) received fourth line treatment and 11 patients (2.7%) received fifth 
line therapy. The addition of second line treatment was associated with a statistically 
significant improvement in overall survival, with median survival for patients received 
second line treatment of 18.7 vs 9.1 months (p<0.001) for patients not receiving 
second line treatment. The most commonly used second line regimens were single 
agent docetaxel, single agent pemetrexed, tyrosine kinase inhibitors or combined 
chemotherapy doublets and there was no significant difference in overall survival based 
on what regimen was used as second line therapy. The addition of third line treatment 
also was associated with a statistically significant improvement in overall survival, with a 
median survival for patients receiving third line therapy of 26.1 vs 11.3 months (p<0.001) 
for patients not receiving third line treatment. The most common therapeutics regimens 
for third line treatment were single agent docetaxel, single agent pemetrexed, single 
agent gemcitabine, single agent vinorelbine, tyrosine kinase inhibitors or combined 
chemotherapy doublet, and there is no significant difference between these regimens 
regarding overall survival. The addition of fourth and fifth line treatment also resulted in 
statistically significant improvements in overall survival with median survival compared 
to patients not receiving this treatment of 32.7 vs 13 months (p<0.001) and 40.3 vs 
13.4 months (p=0.003) respectively. Conclusion: Although the present analysis is 
limited by its retrospective nature, our data suggest that continuing treatment after 
progression in patients who previously responded to chemotherapy is appropriate and 
is likely to prolong survival, provided their performance status and functional reserve 
are adequate to tolerate further treatment. In addition, the sequence of chemotherapy 
regimens did not appear to have a major impact on survival. Analysis is ongoing. 
Keywords: chemotherapy, NSCLC, third line
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P3.01-042 Neutrophilia and Lymphopenia Can Be Prognostic Factors in Non-
Small Cell Lung Cancer with Adenocarcinoma Histology Jaeheon Jeong, Jae Joon 
Han, Chi Hoon Maeng, Sun Kyung Baek, Hwijoong Yoon, Si-Young Kim Internal Medicine, 
Kyung Hee University, Seoul/Korea
Background: Neutrophil count is associated with prognosis in some cancers. Direct 
cell-cell interactions between neutrophils and tumor cells enhance tumor growth 
in Non-small cell lung cancer (NSCLC). We planned to identify clinical and laboratory 
factors including neutrophil and lymphocyte counts that can be used to estimate the 
overall survival. Methods: We retrospectively reviewed 60 patients with advanced or 
recurrent NSCLC with adenocarcinoma histology diagnosed between 2009 and 2013. 
We performed univariate and multivariate stepwise Cox regression analyses to identify 
survival prognostic factors. Results: Median survival time was 18.0 months (95% CI; 
13.8 – 22.2 months). Median age was 64.5 years old. Sixteen patients (26.7%) were 
current smoker, sixteen patients (26.6%) were past smokers and 28 patients (46.7%) 
were non-smokers. Forty three patients’ ECOG PS was 0 or 1 and remaining seventeen 
patients’ ECOG PS was 2. Number of metastatic sites was less than four in the forty 
four patients and remaining sixteen patients have more than four metastatic sites. In 
univariate analysis, seven factors were identified: Loss of appetite (HR, 0.344), brain 
metastasis (HR, 0.444), metastasis in other organs (HR, 2.886), WBC count (HR, 3), 
neutrophil count (HR, 2.322), lymphocyte count (HR, 0.431), neutrophil lymphocyte ratio 
(HR, 2.322). In multivariate analysis, two independent prognostic factors were identified: 
neutrophil count (HR, 2.418), lymphocyte count (HR, 0.414). Conclusion: Increase of 
neutrophil count and decrease of lymphocyte count can be used to predict survival in 
advanced or recurrent non-small cell lung cancer patients with adenocarcinoma histology. 
Keywords: NEUTROPHIL, prognostic factor, LYMPHOCYTE, lung cancer
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P3.01-043 Assessing Treatment Strategies for Lung Cancer in Octogenarians: 
Insights From a Cohort of 337 Patients Virginie Zarza1, Bénédicte Mastroïanni1, Lize 
Kiakouama2, François Tronc1, Maurice Perol3, Pierre Jean Souquet4, Nicolas Girard1 
1Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon/France, 2Hôpital de La Croix-Rousse, 
Hospices Civils de Lyon, Lyon/France, 3Léon Bérard Cancer Center, Lyon/France, 4Centre 
Hospitalier Lyon Sud, Pierre Bénite/France
Background: Aging increases the incidence of lung cancer in octogenarians. In this 
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Background: Combination of weekly paclitaxel and bevacizumab showed synergistic 
effect, anti-tumor efficacy and a good toxicity profile in patients with non small cell 
lung cancer (NSCLC). We retrospectively reviewed safety and efficacy of this regimen 
in metastatic non-squamous NSCLC as fourth-line therapy or beyond. Methods: Thirty 
nine patients were included between November 2011 and December 2014; those were 
bevacizumab eligible and received weekly paclitaxel (80 mg/m2, days 1, 8 and 15 every 
21 days) plus bevacizumab (7.5 mg/kg at day 1) after three prior lines of chemotherapy. 
Efficacy was evaluated by CT-scan every 10 to 12 weeks and treatment was continued 
until progression or unacceptable toxicity. Main outcomes were overall response rate 
(ORR), progression free survival (PFS) and overall survival (OS). Results: Median age 
61 (44-78), female 51.3%, never smokers 53.8%, ECOG >2 25.6% and more than four 
previous lines 53.8%. All patients were treated with a first-line platinum-based doublet 
with (38.5%) or without bevacizumab (61.5%) and all of them received docetaxel 
as second-line (ORR 33.4/SLP 4.6 months, CI95% 2-6.7). With weekly paclitaxel/
bevacizumab the ORR was 36% and 28.2% achieved stable disease for at least 3 months. 
Median PFS was 5.8 months (CI95% 4.6-7.1) and OS was 18.0 months (CI95% 15.2-
34.2). Grade 3-4 adverse events included neutropenia (10%), onycholysis (7.6%) and 
infection (5%). One patient died from a massive hemoptysis and prolonged responses 
were observed in two patients who had received bevacizumab as part of first-line 
chemotherapy and in another one who harbored an ALK rearrangement. Conclusion: In 
this retrospective series, our results suggest that weekly paclitaxel/bevacizumab 
had a good safety and efficacy profile in heavily pre-treated metastatic NSCLC. 
Keywords: paclitaxel, bevacizumab, non-small cell lung cancer
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P3.01-048 Predictors of Subsequent Lines of Therapy (LOTs) in Non-Small 
Cell Lung Cancer (NSCLC) Eric Nadler1, John R. Penrod2, Janet L. Espirito3, Thomas 
Wilson3, Debra A. Patt4, Beata Korytowsky2 1Texas Oncology, Dallas/TX/United States 
of America, 2Bristol-Myers Squibb, Princeton/NJ/United States of America, 3Mckesson 
Specialty Health, The Woodlands/TX/United States of America, 4Texas Oncology, Austin/TX/
United States of America
Background: In recent years, the number of NSCLC treatment options has increased. 
The majority of patients receiving first-line therapy (1L) for locally advanced or metastatic 
NSCLC progress; however, fewer than half receive subsequent treatment. This analysis 
investigated which factors might be predictive of patients receiving subsequent LOTs 
within a US community network. Methods: A retrospective data analysis was conducted 
using electronic health records in the US Oncology Network for adult patients with 
advanced NSCLC receiving second-line therapy from 3/1/10 to 12/31/12, with 
follow-up through 10/31/14. Patients receiving 1L tyrosine kinase inhibitors (EGFR/
ALK+), with concurrent cancer diagnoses, or in a clinical trial were excluded. Data on 
monotherapy/combination treatments, LOT, staging, histology, ECOG performance 
status (PS), metastases, comorbidities, age, gender, geography and practice size were 
collected. Chi-square tests examined patient and disease factors related to the receipt of 
subsequent treatments (2L–3L and 3L–4L). Logistic regression was used to predict the 
likelihood of receiving a subsequent LOT in multivariate models. Overall survival (OS) was 
estimated from diagnosis and from the initiation of each LOT. Results: Of 2,122 patients 
receiving 2L treatment, 963 (45%) advanced to receive 3L and 319 (15%) advanced to 
receive ≥4L treatment. Median age at 2L was 67 years (range, 34–94); 58% were male. 
PS at 2L was available for 80% of patients; 8%, 68%, and 24% were PS 0, 1, or 2+, 
respectively. The histology breakdown was 54% non-squamous, 25% squamous, and 
21% not-specified. In univariate analysis, significance (P<0.05) for receiving a 3L/4L+ 
therapy was found for age, PS, histology, and treatment type. Multivariate analysis 
results are presented (Table).
 
Of patients receiving 2+ LOTs, median OS from advanced NSCLC diagnosis was 
22 months (95% CI: 20, 23). Median OS from the start of 2L, 3L, and 4L was 8.9, 
7.0, and 7.2 months, respectively. In 2L, median OS for patients who received a 3L 
compared to those who did not was 13.4 vs 5.0 months (P<0.0001); median OS in 3L 
for patients who received a 4L compared to those who did not was 12.9 vs 4.9 months 
(P<0.0001). Conclusion: Receiving subsequent LOTs is associated with improved OS 
in advanced NSCLC. Whether this represents the efficacy of therapeutic agents or an 
enrichment for patients capable of receiving additional therapy is unclear. Nonetheless, 
these data on patient and treatment predictive factors may assist in understanding how 
future treatments might allow more patients to advance to later LOTs.
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P3.01-049 Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus 
Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer Yesim 
Eralp1, Fatma Sen1, Makbule Tambas2, Kubra Ozkaya2, Berker Ozkan3, Ethem N. Oral2, 
Esra K. Saglam2, Pinar Firat4, Pinar Saip1, Alper Toker3, Ahmet Kizir2, Adnan Aydiner1 
1Istanbul University, Institute of Oncology, Department of Medical Oncology, Istanbul/
Turkey, 2Istanbul University, Institute of Oncology, Department of Radiation Oncology, 
1) On average no decrease in [18F]FDG-PET uptake was observed for the experimental 
NTG group. However, patients in the experimental group showed a significantly 
larger variation in most SUV parameters of the second PET/CT scan compared to 
control group without NTG.2) In table 1 the hazard ratios are shown for the relative 
delta SUVmax, SUVmean, SUVpeak and TLG for both study arms. In the experimental 
group, patients with a small delta TLG (<64%) had a shorter PFS than patients with a 
larger change in TLG (HR:1.064; 95% CI 1.002-1.131; p=0.043). Response assessed 
by PERCIST and RECIST did not predict for a longer PFS or OS. Conclusion: Adding 
NTG did not result in a decrease in [18F]FDG-PET uptake compared to patients 
without NTG although NTG increased variability of the measured SUV parameters. 
Patients in the experimental NTG arm without an early response on [18F]FDG-PET/
CT imaging had a worse PFS than patients with a response. For the group without 
NTG no difference was observed. Also, RECIST and PERCIST were not predictive. 
Keywords: response assesment, FDG-PET, NSCLC, nitroglycerine
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P3.01-045 Short-Term Outcomes of Stage IV Non-Small Cell Lung Cancer with 
Brain Metastasis Su Kyung Hwang, Seung Il Park, Dong Kwan Kim, Yong-Hee Kim, Se 
Hoon Choi, Hyeong Ryul Kim Department of Thoracic and Cardiovascular Surgery, Asan 
Medical Center, University of Ulsan College of Medicine, Seoul/Korea
Background: Patients who had non-small cell lung cancer with brain metastasis at 
the initial diagnosis had poor prognosis and quality of life. We reviewed patients who 
had undergone lung resection and brain surgery. We also analyzed the characteristics 
of the patients and the factors affecting survival and recurrence. Methods: Between 
2007 and 2012, 25 consecutive patients who had undergone lung resection and 
brain surgery because of non-small cell lung cancer with brain metastasis were 
retrospectively evaluated in a single-center. The non-small cell lung cancer subtype 
was adenocarcinoma in 23 patients, squamous cell carcinoma in 1 patient, and 
adenosquamous cell carcinoma in 1 patient. Twenty patients underwent Gamma 
Knife radiosurgery. Nodal stage was stage 0 in 9 patients, stage 1 in 9 patients, and 
stage 2 in 7 patients. Results: The median survival time after lung resection was 36.8 
months. The 1-, 2-, and 3-year survival rates after lung resection were 95.8%, 79.2%, 
and 54.2%, respectively, and the 1-, 2-, and 3-year disease-free survival rates were 
95.8%, 82.9%, and 64.2%, respectively. There were no local recurrences. Brain surgery 
methods did not affect disease-free survival (p=0.201) or overall survival (p=0.567). 
Nodal stage also did not affect disease-free survival (p=0.519) or overall survival 
(p=0.645). Conclusion: Even in cases of stage IV non-small cell lung cancer with brain 
metastasis, assertive lung resection and brain surgery bring improvements of survival 
and recurrence to patients. Brain surgery methods do not affect survival or recurrence. 
Therefore, Gamma Knife radiosurgery is a good choice for quality of life for patients. 
Keywords: Short-term outcomes, Brain metastasis, non-small cell lung cancer
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P3.01-046 Pleural Photodynamic Therapy in Pleural Metastasis by Lung 
Cancer Ke-Cheng Chen, Yi-Shan Hsieh, Ming-Jium Shieh, Jang-Ming Lee Institute of 
Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan 
University, Taipei/Taiwan
Background: Pleural metastasis is difficult to treat in malignancies, especially in 
lung cancer. Currently, the options of management of pleural metastasis include 
chemotherapy, operation with pleurectomy, or/and photodynamic therapy. Photodynamic 
therapy is a method utilizing photosensitizer to locate the site of tumor, and the tumor is 
exposed to the light after performing pleurectomy. Literature had reported successfully 
treatment of malignant mesothelioma by photodynamic therapy, a new approach for 
pleural malignancy dissemination. However, little was known about the result when in 
lung cancer. Methods: Between 2005 and 2015, we retrospectively reviewed the clinical 
characteristics, operative methods, and treatment outcomes of 25 patients with lung 
cancer with pleural seeding. Results: The mean patient age was 51.6 ± 10.7 years. 
There is no procedure-related mortality. Using Kaplan-Meier survival analysis, 3-year 
survival rate and 5-year survival rate was reached 71.8% and 59.3%, respectively. 
We compared the PDT lung cancer patients with those receiving chemotherapy or 
target therapy (n=51) and found that the PDT group had better survival than non-PDT 
patients (mean survival time: 42.8 versus 17.6 months; P=.041). Conclusion: With 
proper patient selection, photodynamic therapy of pleural dissemination in 
patients with lung cancer is feasible and associated with a good survival rate 
Keywords: pleural dissemination, non-small cell lung cancer, photodynamic therapy
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P3.01-047 Weekly Paclitaxel plus Bevacizumab in Heavily Pre-Treated Non-
Small-Cell Lung Cancer (NSCLC) Patients Andrés F. Cardona1, Leonardo Rojas2, 
Hernan Carranza1, Carlos A. Vargas1, Jorge M. Otero1, Mauricio Cuello3, Luis Corrales4, 
Claudio Martin5, Oscar Arrieta Rodriguez6 1Clinical and Translational Oncology Group, 
Foundation for Clinical and Applied Cancer Research - Ficmac, Bogotá/Colombia, 2Centro 
Javeriano de Oncologia, Hospital Universitario San Ignacio, Bogota/Colombia, 3Clinical 
Oncology, Hospital de Clínicas - Udelar, Montevideo/Uruguay, 4Clinical Oncology, Hospital 
San Juan de Dios, San José/Costa Rica, 5Clinical Oncology, Instituto Fleming, Buenos 
Aires/Argentina, 6Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina 
Personalizada, National Cancer Institute, Mexico City/Mexico
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P3.01-051 Biomarker Analyses from a Phase II Trial of Nab-Paclitaxel/
Carboplatin vs Emcitabine/Carboplatin in Advanced Squamous Cell Lung 
Cancer Jin-Ji Yang1, Xiao-Song Ben1, Cheng Huang2, Yong Song3, Ying Cheng4, Gongyan 
Chen5, Hong -Hong Yan1, Qing Zhou1, Hua-Jun Chen1, Xu-Chao Zhang1, Yi-Long Wu1 
1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy 
of Medical Sciences, Guangzhou/China, 2Fujian Cancer Hospital, Fuzhou/China, 3Department 
of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing/
China, 4Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/China, 5Harbin 
Medical University Cancer Hospital, Harbin/China
Background: The administration of nab -paclitaxel/carboplatin (nab -PC) as first-line 
therapy in patients with advanced non-small-cell lung cancer (NSCLC) was efficacious and 
resulted in a significantly improved objective overall response rate (ORR) versus solvent-
based PC in a phase Ⅲ trial. However, our phase Ⅱ trial (NCT01236716; CTONG1002), 
which compared the efficacy and safety of first-line nab -PC with gemcitabine/carboplatin 
(GC) in advanced squamous cell carcinoma of the lung, only showed a marginally 
improved ORR caused by first-line nab-PC. Meanwhile, the matricellular glycoprotein 
SPARC (secreted protein acidic and rich in cysteine) and caveolin-1 are potential 
biomarkers for advanced NSCLC patients receiving nab-PC. Therefore, we retrospectively 
aimed to explore their predictive and prognostic value using immunohistochemistry 
(IHC). Methods: From November 2010 to June 2013, 127 untreated patients with locally 
advanced and metastatic squamous cell carcinoma of the lung were randomly assigned 
1:1 to receive first-line nab -PC (nab -P, 135 mg/m2, d1, d8, q3w; C, AUC = 5, d1, q3w ) 
or GC (G, 1,250 mg/m2, d1, d8, q3w; C, AUC = 5, d1, q3w). There were 110 patients 
evaluable for ORR (nab-PC, 54; GC, 56), 119 evaluable for survival (nab-PC, 57; GC, 
62) respectively. However, there were 72 patients with sufficient tissue for IHC of both 
SPARC and caveolin-1 proteins. Different cut-off values of IHC scoring systems were 
used to explore predictive and prognostic role of both biomarkers. Results: The last 
follow-up was on January 16, 2015. Considering treatment, when the maximum rank 
method was used for cut-off values, median progression-free survival (PFS) was 7.5 
(95%CI: 2.4~12.6) months in higher SPARC-expression arm and 4.3 (95%CI: 2.2~6.3) 
months in lower SPARC-expression arm for patients treated with GC, HR=0.43 (95%CI: 
0.19~0.94), p = 0.030; Median overall survival (OS) was 20.0 (95%CI: 14.7~25.3) months 
in lower SPARC-expression arm and 10.1 (95%CI: 6.2~14.0) months in higher SPARC-
expression arm for patients treated with nab-PC, HR=2.41 (95%CI: 1.08~5.40), p = 
0.027. When average method was used for cut-off values, median OS was 18.2 (95%CI: 
9.6~26.8) months in lower SPARC-expression arm and 8.4 (95%CI: 5.1~11.7) months 
in higher SPARC-expression arm for patients treated with nab-PC, HR=2.46 (95%CI: 
1.07~5.65), p = 0.029. Regardless of treatment, when the maximum rank method was 
used for cut-off values, median OS was 14.5 (95%CI: 6.8~22.1) months in lower SPARC-
expression arm and 8.4 (95%CI: 5.3~11.5) months in higher SPARC-expression arm, 
HR=0.47 (95%CI: 0.27~0.83), p = 0.007. When average method was used for cut-off 
values, median OS was 14.4 (95%CI: 9.2~19.5) months in lower SPARC-expression arm 
and 8.4 (95%CI: 5.4~11.4) months in higher SPARC-expression arm, HR=0.48 (95%CI: 
0.27~0.87), p = 0.013. ORR was not correlated with expression of SPARC, p＞0.05. 
However, there were no significant differences in ORR, PFS and OS between higher and 
lower caveolin-1 expression arms, p＞0.05. Conclusion: SPARC expression could be a 
negative prognostic factor for OS of patients with advanced squamous cell carcinoma 
of the lung, but was not a predictive factor for ORR and PFS, except for patients treated 
with GC. However, caveolin-1 expression had neither predictive nor prognostic value. 
Keywords: Gemcitabine, Squamous cell carcinoma of the lung, biomarker, nab-paclitaxel
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P3.01-052 Randomized Phase II Individualized Chemotherapy Study Based 
on BRCA1 and RRM1 Message RNA Level for Advanced NSCLC (BRAVO Study) 
Guanghui Gao1, Shengxiang Ren1, Aiwu Li1, Xuefei Li2, Chao Zhao2, Wei Li1, Yayi He1, 
Chunxia Su1, Xiaoxia Chen1, Yan Wang1, Jie Zhang2, Caicun Zhou1 1Oncology, Shanghai 
Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, 
Shanghai/China, 2Tongji University Cancer Institute, Shanghai Pulmonary Hospital, Tongji 
University School of Medicine, Shanghai/China
Background: We assessed whether BRCA1 and RRM1 message RNA(mRNA) levels 
could help to select chemotherapy regimen to improve objective response rate in 
patients with advanced NSCLC. Methods: Eligible patients were randomly assigned 
2:1 according to stratification factors of smoking, gender and histological type. In 
experimental arm, gemcitabine/cisplatin(GP) were selected if both RRM1 and ERCC1 
mRNA levels were low, irinotecan/cisplatin(IP) if RRM1 high and BRCA1 low, gemcitabine/
vinorelbine(GN) if RRM1 low and BRCA1 high, and docetaxel(T) if both high. GP was 
chose in the control arm. The primary end point was objective response rate (ORR). 
(Registered No. NCT01424709). Results: 121 patients were enrolled and 120 received 
at least one dose of therapy. The median number of cycles given was four in both arms. In 
experimental arm, 36 patients treated with GP, 14 with IP, 13 with GN and 17 with T. The 
ORR and DCR were 33.3% and 79.5% in the experimental arm, which were not significant 
different from 32.5% (p=0.12) and 87.5%(p=0.18) in the control arm. When patients 
with both low mRNA levels of RRM1 and ERCC1 were removed, the sub-analysis showed 
the ORR in the experimental arm was marginally significantly higher than in the control 
arm (42% vs. 36.3%, p=0.06)). Survival analysis showed similar PFS in the two arms 
(5.1 vs. 5.3m, p=0.11), while sub-analysis revealed that PFS was marginally significantly 
longer in the experimental arm (5.7 vs. 5.3m p=0.09). No unexpected side effect 
happened in both arms. Conclusion: BRCA1 and RRM1 mRNA levels were potentially 
used for therapeutic decision making in newly diagnosed patients with advanced NSCLC. 
Keywords: NSCLC; mRNA;BRCA1;RRM1
Istanbul/Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Department of Thoracic 
Surgery, Istanbul/Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of 
Pathology, Istanbul/Turkey
Background: There is currently no consensus regarding which chemotherapy regimen 
is best to administer with radiotherapy in patients with locally advanced non–small-cell 
lung cancer. Here, our aim was to compare the outcome of patients treated with either 
etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting. Methods: The 
patients treated with concurrent radiotherapy with either EP or DP with from 2004 to 
2012 were identified. Patients whose medical records and follow up information obtained 
in details were included to this retrospective study. Survival rates were compared 
using Cox proportional hazards regression models with adjustments for confounding 
provided by propensity score methods. Results: A total of 105 patients were treated 
with concurrent chemoradiotherapy for locally advanced (IIB-IIIA-IIIB) non-small cell 
lung cancer in Istanbul University, Institute of Oncology between 2004 and 2012. 
Totally 50 patients (median age 54 yr; 32-70 yr) given concurrent EP and 55 patients 
(median age 55 yr; 37-73) given concurrent DP were enrolled to analyses. There was 
no statistically significant difference in baseline clinicopathological features including 
age, gender, performance status, and weight loss, histological subtype, primary lung 
side, clinical T, N and TNM stages between 2 groups. In univariate analysis, median 
overall survival of patients treated with EP was found to be higher than that of patients 
treated with DP (41 months versus 20 months, p= 0.003). Multivariate analysis further 
revealed survival advantage with EP as compared to DP (hazard ratio [HR], 0.46; 95% 
CI, 0.25 to 0.83) (p=0.009). Toxicity profile of 2 treatment groups were found to be 
similar except that pulmonary toxicity was higher in DP group compared to EP (grade 
3-4: 0 versus 6%, p= 0.024). Conclusion: Concurrent chemoradiotherapy with EP 
may provide more favorable outcome than that of DP with acceptable safety profile. 
Keywords: locally advanced non-small cell lung cancer, concomitant chemoradiotherapy, 
etoposide plus cisplatin, docetaxel plus cisplatin
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P3.01-050 A Interim Analysis of Randomized Phase III Trial of Nedaplatin or 
Cisplatin Combined with Docetaxel as First-Line Treatment for Advanced ASQC 
Shun Lu1, Cheng P. Hu2, Yuan Chen3, Zhiwei Chen4, Xinling Ren5, Yong Song6, Zhiyong 
Ma7, Yun Fan8, Gang Wu9, Xiangqun Song10, Qiong Zhao11, Fang Jian12, Zhe Liu13 
1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 
Shanghai/China, 2Department of Respiratory Medicine, Xiangya Hospital, Central South 
University, Changsha/China, 3Department of Oncology, Tongji Hospital, Tongji Medical 
College of Huazhong University of Science and Technology, Wuhan/China, 4Lung Cancer 
Center, Shanghai Chest Hospital, Shanghai/China, 5Xijing Hospital, Xi‘An/China, 6Nanjing 
Military General Hospital, Nanjing/China, 7Henan Cancer Hospital, Zhengzhou/China, 8Cancer 
Hospital of Zhejiang Province, Hangzhou/China, 9Cancer Center, Union Hospital, Tongji 
Medical College, Huazhong University of Science and Technology, Wuhan/China,10Medical 
Oncology, Cancer Hospital of Guangxi Medical University, Nanning/China, 11Medical 
Oncology, The First Hospital of Zhejiang Province, Hangzhou/China, 12Medical Oncology, 
Beijing Cancer Hospital, Beijing/China, 13Oncology, Beijing Chest Hospital，Capital Medical 
University, Beijing/China
Background: Cisplatin combined with docetaxel is one of the stand treatment in 
advanced squamous cell carcinoma(ASQC) of the lung. Nedaplatin combined with 
docetaxel has demonstrated potent activity in ASQC in phase II study. But until now 
there is no randomized phase III study comparing these 2 chemotherapy regimens. 
The aim of this study was to evaluate and compare the efficacy and safety between 
the combination chemotherapy of nedaplatin or cisplatin plus docetaxel in patients 
with ASQC. Methods: This is a multicentre, open-label, randomized, phase III study 
in China (NCT02088515). Chemo-naive stage IIIB/IV squamous NSCLC with Eastern 
Cooperative Oncology Group performance status 0/1 were randomized (1:1) to 
four cycles of nedaplatin (80 mg/m2) plus docetaxel(75 mg/m2) or cisplatin(75 mg/
m2) plus docetaxel (75 mg/m2) . The primary endpoint was progression-free survival 
(PFS). Secondary end points were overall survival (OS), overall response rate (ORR), 
disease control rate (DCR) and quality of life. Results: From December 2013 to January 
2015, 117 patients were accrued: nedaplatin plus docetaxel (n = 57) and cisplatin plus 
docetaxel (n = 60). The objective response rates were 27% and 31% and the disease 
control rate were 78.92 % and 82.67% in nedaplatin and cisplatin groups, respectively. 
There is no significance difference in nausea / vomiting(21% vs 30%) , diarrhea(3% vs 
5%), liver dysfunction(12% vs 15%), neutropenia(60% vs 65%), thrombocytopenia(10% 
vs 12%), anemia(8% vs 7%) between the 2 arms. The renal dysfunction incidence 
is higher in the cisplatin group(3% vs 0%). Although there is no 3/4 grade toxicities 
difference between 2 arms including nausea / vomiting(0% vs 0%) , diarrhea(0% vs 
1%), liver dysfunction(0% vs 0%), renal dysfunction(0% vs 0%) , neutropenia(4% vs 
3%), thrombocytopenia(0% vs 0%), anemia(0% vs 0%) . This is an interim analysis 
and we haven’t got the data of survival and quality of life. Conclusion: There is no 
ORR difference between the group of nedaplatin plus docetaxel and cisplatin plus 
docetaxel. But the toxicity of nedaplatin regiment is less toxicities, especially in 
renal toxicity,as first-line treatment for patients with advanced squamous NSCLC 
Keywords: squamous cell carcinoma, chemotherapy
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P3.01-054 Etirinotecan Pegol (NKTR-102) in the Treatment of Patients with 
Metastatic NSCLC after Failure of 2nd Line Treatment: A Phase II Study Charu 
Aggarwal, Roger B. Cohen, Tracey Evans, Evan Alley, Joshua Bauml, Arati Desai, 
Kristine Mykulowycz, Hope Kushner, Mona Jacobs-Small, Corey J. Langer University of 
Pennsylvania, Philadelphia/PA/United States of America
Background: 3rd line treatment options are limited for patient (pts) with metastatic 
NSCLC. NKTR-102 is a long-acting topoisomerase-I inhibitor designed to concentrate 
in tumors and provide continuous exposure throughout the chemotherapy cycle. Based 
on clinical activity of irinotecan in NSCLC, we conducted a Phase II single arm trial to 
evaluate efficacy of NKTR-102. Methods: Pts >18 yrs with histologically proven NSCLC 
who received 2 prior systemic therapy regimens were eligible. Measurable disease, 
ECOG PS ≤1 and adequate end organ function were required. NKTR-102, 145mg/m2 
was administered IV q3 weeks till progression. Response was assessed q6 weeks by 
RECIST 1.1. Primary endpoint was overall response rate. Secondary endpoints were 
progression free survival (PFS), overall survival (OS) and safety. Simon two-stage design 
was implemented; if 0/12 responses were observed in the 1st stage, the study would be 
terminated for futility. If there was at least 1 objective response in the 1st stage, the study 
would continue to stage 2, enrolling an additional 25 pts, for a total of 37. Results: Between 
01/2013 and 01/2015, 37 pts have been enrolled. Median age 63 yrs (18-82), 45% 
female, ECOG PS 0=8 pts, 92% current/former smokers, 9 pts with squamous cell, 28 
had adenocarcinoma. Median time from diagnosis to initiation of NKTR-102 was 18 mos 
(6-72). Pts received a median of 3 cycles (1-13). All pts were evaluable for response rate 
and toxicity. One pt in Stage I (adenocarcinoma) had a partial response. Fifteen pts had 
stable disease, 7 pts are still on treatment. 3 pts had Grade 3 GI toxicity attributable to 
NKTR-102. 6 pts required a dose reduction to 120 mg/m2 due to diarrhea. There was 
no hematological toxicity. Median PFS was 2.3 mos. For pts with >1 yr follow up (n=20), 
median OS was 5.5 mos. Complete PFS and OS data will be presented. Conclusion: NKTR-
102 is well tolerated and leads to stabilization of disease in third line treatment of 
metastatic NSCLC. These clinical data combined with a favorable safety profile warrant 
further clinical investigation of this agent. Clinical trial information: NCT01773109. 
Keywords: pegylated irinotecan, 3rd line therapy
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P3.01-055 Carboplatin-Pemetrexed Combination in Elderly Patients with 
Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC) Sergio 
Vazquez1, Maria Carmen Areses2, Natalia F. Núñez3, Ana Alonso Herrero4, Marta 
Covela Rúa3, María J. Villanueva Silva4, Francisco J. Afonso-Afonso5, Gaspar Esquerdo 
Galiana6, Martin Lazaro Quintela4, Jesus Garcia Mata2, Urbano Anido Herránz7, 
Joaquin Casal Rubio4, José L. Fírvida Pérez2 1Hospital Universitario Lucus Augusti, Lugo/
Spain, 2Complejo Hospitalario Universitario de Ourense, Ourense/Spain, 3Oncología Médica, 
Hospital Universitario Lucus Augusti, Lugo/Spain, 4Oncología Médica, Complexo Hospitalario 
Universitario de Vigo, Vigo/Spain, 5Oncología Médica, Complejo Hospitalario Universitario 
de Ferrol, Ferrol, A Coruña/Spain, 6Oncología Medica, Hospital de Benidorm, Benidorm/
Spain, 7Complexo Hospitalario Universitario de Santiago, Santiago de Compostela/Spain
Background: The standard treatment for elderly patients in advanced NS-NSCLC is 
not defined. The aim of this study was to evaluate the efficacy and safety profile of 
the combination of carboplatin and pemetrexed in this population. Methods:Elegibility 
criteria included, histologically or citologically confirmed NS-NSCLC clinical stage IIIB 
vs IV, evaluable disease, no prior cytotoxic chemotherapy, an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1, an adequate organ function 
and ³ 70 years old. Patients received carboplatin at an area under the concentration 
time curve (AUC) of 5 and pemetrexed 500 mg/m2 for four cycles on day 1 every 3 
weeks. In non-progressing patients, maintenance therapy with pemetrexed every 3 
weeks was optional to continue at the discretion of the investigator, until either disease 
progression or unacceptable toxicity. The primary endpoint was progression-free 
survival (PFS). The secundary endpoints were the response rate (RR), disease control 
rate (DCR), overall survival (OS) and the rates of adverse events. Results: A total of 
thirty-six patients were included in a phase II clinical trial from 6 different centers. 
The patients demographics were: median age 76 years (range 70-82), 8 female 
and 28 male; 33 patients adenocarcinoma and 3 large-cell lung carcinoma; tumor 
EGFR status wild type in all patients. 51% went to manteinance. Among 32 patients 
evaluated, the RR was 31,3%, disease stabilization 31,3%, disease progression 28,1% 
and non-evaluable 9,3%. The DCR was 62.5%. In non-manteinance group the PFS was 
4.1 months and OS 8.6 months. In the manteinance group instead, the PFS was 9.5 
months and OS 11.9 months. Most common attributable adverse events were fatigue 
and anemia. Each of the toxicities were controllable and there were no treatment-
related deaths. Conclusion: These data provided that Carboplatin and pemetrexed 
combination is effective and well tolerated in elderly patients with advanced NS-NSCLC 
Keywords: Carboplatin and pemetrexed; NS-NSCLC; elderly; effective; well tolerated
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P3.01-056 Phase II Study of Carboplatin plus Weekly Nab-Paclitaxel in Elderly 
Patients with NSCLC: North Japan Lung Cancer Study Group Trial 1301 Osamu 
Ishimoto1, Kazuhiro Usui2, Makoto Maemondo3, Eisaku Miyauchi4, Heisuke Saito5, Yuka 
Fujita6, Terufumi Kato7, Toshiro Suzuki8, Taku Nakagawa9, Toshiyuki Harada10, Hiroyuki 
Miura11, Hiroshi Watanabe12, Akira Inoue4, Masakazu Ichinose4 1Respiratory Medicine, 
Sendai Kousei Hospital, Sendai/Japan, 2Respirology, Ntt Medical Center Tokyo, Tokyo/
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P3.01-053 Efficacy and Safety of Extended Therapy with Endostar Combined 
with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Study 
Weiheng Hu, Fang Jian, Jun Nie, Ling Dai Department of Thoracic Oncology Ii, Beijing 
Cancer Hospital, Beijing/China
Background: It is known that the addition of endostar (recombinant human endostatin, 
a novel broad-spectrum inhibitor of tumor angiogenesis) to chemotherapy resulted in 
a significant effective benefit in the treatment of patients with advanced non–small 
cell lung cancer (NSCLC). Previous research showed that multicycle application of 
angiogenetic drug combined with chemotherapy might prolong overall survival of 
NSCLC. However, the optimal treatment duration of endostar and chemotherapy remains 
uncertain. Methods: A retrospective analysis of ≥ 4 cycles versus < 4 cycles of endostar 
combined with platinum-based doublet chemotherapy(PBDC) was performed in patients 
with advanced NSCLC. For efficacy assessments, patients received ≥ 4 cycles of therapy 
(extended group) were compared with those who received less than 4 cycles but not 
because of tumor progression (control group). Toxicity analyses were performed for 
all patients. Results: A total of 232 patients were enrolled, of whom 128 patients 
completed at least four cycles of the therapy (extended group), 64 patients ceased 
their therapy before 4 cycles not because of progression(control group). The median 
progress free survival(PFS) was 8.2 months versus 5.4 months in extended group and 
control group (p=0.027), and the median overall survival(OS) was 22.5 months versus 
13.6 months (p=0.000), respectively. Subgroup analysis showed that, among the 
EGFR mutation-positive patients, the control group seemed to result in a trend toward 
survival benefit according to the Kaplan-Meier curves, although the differences are not 
statistically significant. Hematological toxicity and fatigue occurred more frequently in 
patients received 4 or more cycles (p<0.05), but no statistically significant difference 
was detected in all grade ≥3 adverse events.
 
Conclusion:Extended treatment of endostar combined with chemotherapy 
exhibited increased survival and acceptable toxicity in previously untreated 
patients with NSCLC, supporting further evaluation in larger prospective studies. 
Keywords: NSCLC, Extended Therapy, chemotherapy, Endostar
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Table 1: Exploratory Analysis of Overall Survival by Tumor Size
Patients Tumor size
Median 
OS Months 
(95% CI)
Hazard 
Ratio P-value
DN (30mg/m2) D
ITT 1 and 2 prior 
chemo-therapy All
8.68 (6.33, 
12.63) 
N=50
7.47 (6.17, 
10.60) 
N=55
0.972 0.8993
≤ 3 cm
6.45 (3.73, 
NA) 
N=16
6.47 (5.6, 
22.43) 
N=19
0.934 0.8687
> 3 cm
8.98 (6.60, 
12.63) 
N=34
7.47 (4.77, 
11.60) 
N=36
0.967 0.8990
> 5 cm
8.98 (4.57, 
19.23) N= 
20
6.70 (4.07, 
12.93) 
N=21
0.750 0.4176
> 7 cm
7.32 (4.57, 
19.23) 
N= 8
5.03 (2.93, 
6.70) N= 
10
0.507 0.1936
 
CI = confidence interval; D = docetaxel; DN, docetaxel + plinabulin; ITT = intent-to-treat; 
OS = overall survival (Months). Conclusion: Mechanism-based exploratory analyses of 
Phase 2 results have identified advanced NSCLC patients with lung lesion size >3 cm 
to have benefited from plinabulin. A Phase 3 to confirm this observation is on-going. 
Keywords: metastatic, chemotherapy, lung cancer
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P3.01-058 nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung 
Cancer NSCLC: Dose Modification Analysis Pieter E. Postmus1, Mary E.R. O’Brien2, 
Mark A. Socinski3, Li Li4, Teng Jin Ong4, Cesare Gridelli5 1Clatterbridge Cancer Center, 
Liverpool/United Kingdom, 2Royal Marsden Hospital, London/United Kingdom, 3Upmc 
Cancer Pavilion, University of Pittsburgh, Pittsburgh/PA/United States of America, 4Celgene 
Corporation, Summit/United States of America, 5S.G. Moscati Hospital, Avellino/Italy
Background: Chemotherapy dose modifications may impact clinical outcomes in 
patients with cancer. In a phase III trial, first-line treatment of patients with advanced 
NSCLC with nab -paclitaxel plus carboplatin (nab -P/C) significantly improved the 
overall response rate (ORR; primary endpoint) compared with solvent-based paclitaxel 
plus C (sb-P/C; 33% vs 25%; P = 0.005; Socinski et al. J Clin Oncol. 2012;30:2055-
2062). This exploratory analysis examined the correlation between patients 
receiving protocol-specified dose modifications and clinical outcomes in the phase III 
trial. Methods: Patients with histologically or cytologically confirmed stage IIIB/IV 
NSCLC and no prior chemotherapy for metastatic disease received either nab -P 100 
mg/m2 on days 1, 8, and 15 or sb-P 200 mg/m2 on day 1, both in combination with C 
AUC 6 on day 1, every 21 days (randomized 1:1). ORR and progression-free survival 
(PFS) were assessed by blinded, centralized review. P values for ORR were based on the 
chi-square test, and those for overall survival (OS) and PFS were based on the log-rank 
test. Patients who discontinued treatment before cycle 3 or remained on treatment after 
6 months were excluded from this analysis unless otherwise specified. Results: Dose 
modification and clinical outcomes for patients treated for ≥ 3 cycles but ≤ 6 months are 
shown in the Table. In the nab -P/C arm, 268 of 310 patients (86%) who were treated for 
≥ 3 cycles and ≤ 6 months had a dose modification compared with 200 of 319 (63%) in 
the sb-P/C arm. In the nab -P/C cohort, ORR and PFS were significantly higher in patients 
who received a dose modification vs those who did not (Table), possibly due to better 
tolerability and longer treatment duration. In the sb-P/C arm, there were no differences 
in efficacy outcomes between either group. As predicted, patients with a lower numerical 
incidence of toxicity were those that did not require dose modifications. Conclusion:This 
exploratory analysis suggested that, in this patient subset, protocol-specified dose 
modifications did not negatively impact the primary endpoint of ORR and in fact resulted 
in a greater ORR for those receiving nab -P/C.
 
Keywords: nab-paclitaxel, carboplatin, NSCLC, dose modification
Japan, 3Respiratory Medicine, Miyagi Cancer Center, Natori/Japan, 4Respiratory Medicine, 
Tohoku University Hospital, Sendai/Japan,5Pulmonary Medicine, Allergy, and Rheumatology, 
Iwate Medical University School of Medicine, Morioka/Japan, 6Respiratory Medicine, National 
Hospital Organization Asahikawa Medical Center, Asahikawa/Japan, 7Respiratory Medicine, 
Kanagawa Cardiovascular and Respiratory Center, Yokohama/Japan, 8Respiratory Medicine, 
Iwate Prefectural Isawa Hospital, Oushu/Japan, 9Thoracic Surgery, Omagari-Kousei Medical 
Center, Daisen/Japan, 10Center for Respiratory Disease, Jcho Hokkaido Hospital, Sapporo/
Japan, 11Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo/
Japan, 12Respiratory Medicine, Saka General Hospital, Shiogama/Japan
Background: Recent IFCT-0501 trial demonstrated that carboplatin (CBDCA) combined 
with weekly paclitaxel (PTX) would be advantageous compared with monotherapy. 
Subsequently, CA031 trial suggested that weekly nab-paclitaxel (nab-PTX) was superior 
in efficacy and safety compared with 3-weekly PTX when combined with CBDCA. Since 
the subgroup analysis for elderly patients (pts) in CA031 showed very promising data 
(34% of overall response rate (ORR) and 8.0 months of progression-free survival (PFS)), 
we conducted this multicenter, non-randomized, open label, phase II trial to evaluate the 
efficacy and tolerability of CBDCA plus weekly nab-PTX regimen for elderly patients with 
advanced non-small cell lung cancer (NSCLC) prospectively. Methods: Eligible pts were 
aged 75 years or older with newly diagnosed clinical stage IIIB, IV, and postoperative 
recurrence NSCLC; ECOG performance status (PS) of 0-1; adequate organ function; 
written informed consent. Pts received CBDCA (AUC 6) on day 1 and nab-PTX (75mg/
m2) on day1, 8, and 15, every 4 weeks. The primary endpoint was ORR and secondary 
endpoints were PFS, overall survival (OS), and toxicity profile. Assuming that ORR 
of 40% would be potential usefulness while ORR of 20% would be the lower limit of 
interest, 32 pts were required. Results: Between March 2013 and May 2014, 35 pts 
were enrolled and 32 pts were eligible. Median age was 78 years (range, 75-86), 84% 
(27/32) were male and 56% (18/32) were stage IV. 56% (18/32) had squamous cell 
carcinoma and 44% (14/32) had adenocarcinoma. Median treatment cycle was 4 (range, 
1-6). ORR and DCR were 50% (95%CI: 33-67) and 94% (95%CI: 85-100), respectively. 
With a median follow-up of 9.1 months, median PFS was 6.4 months (95%CI: 4.8-8.0). 
Median OS had not been reached at the data cutoff point. Grade 3 or severer toxicities 
were as follows: neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia 
(25%), and anorexia (9%). No febrile neutropenia and treatment-related deaths were 
observed. Conclusion: The combination of CBDCA and weekly nab-PTX demonstrated 
significant efficacy with acceptable toxicities in elderly patients with advanced NSCLC. 
Keywords: NSCLC, elderly, nab-paclitaxel, carboplatin
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P3.01-057 Randomized Phase 2 Study of Plinabulin and Docetaxel in Patients 
with Advanced Non-Small Cell Lung Cancer - Mechanism-Based Efficacy 
Analyses Lyudmila Bazhenova1, Osvaldo Arén Frontera2, Alain Mita3, Jonathan Polikoff4, 
Steven Reich5, Gloria Lee6, William Mikrut7, Lan Huang6 1Moores Cancer Center, University 
of California San Diego, La Jolla/United States of America, 2Centro Internacional de Estudios 
Clinicos, Santiago/Chile, 3Cedars Sinai Medical Center, Los Angeles/CA/United States 
of America, 4Kaiser Permanente, San Diego/CA/United States of America, 5Na, Del Mar/
CA/United States of America, 6Beyondspring Pharmaceuticals, New York/United States of 
America, 7Currently Vantage Data Designs, San Diego/AL/United States of America
Background: Plinabulin (N), a tubulin binding agent, which depolarizes microtubules, 
resulting in tumor vasculature obliteration, apoptosis via JNK pathway and maturation 
of dendritic cells. A multicenter randomized phase 2 study was performed to compare 
overall survival (OS) between plinabulin/docetaxel (DN) and docetaxel (D). Results of 
Intent-to-treat (ITT) analyses have been presented at ASCO 2014. The primary objective 
of OS prolongation was not met, however, exploratory mechanism based analysis 
revealed improvement in outcomes in patients with large tumors. Methods: From 
November 2008 to July 2011 172 patients with advanced NSCLC who progressed after 
at least one chemotherapy were enrolled. Patients were treated with D 75mg/m2 on day 
1 and N 30 mg/2 on days 1 and 8. A second cohort of N 20 mg/m2 was also enrolled. 
This exploratory analysis is based on 105 patients (50 DN arm and 55 D arm) receiving 
30 mg/m2 dose, which was selected for an ongoing Phase 3 study and explains the 
population chosen for future investigation. Results: Median OS was 8.7 months (m) (CI 
6.6-12.6) in DN arm and 7.5 m (6.3-10.5) in D arm (p=0.899, HR=0.97). PFS was 2.8 m 
and 3.5 m and ORR was 14.0% vs 14.5% respectively. Among clinical parameters, lesion 
size (Table 1) and presence of pulmonary disease were identified to impact OS. The OS 
in patients with pulmonary disease was 11.3 m (6.7-15.1) in DN and 6.7 m (6-9.8) in D, 
respectively (p=0.29, HR=0.76) regardless of lesion size.
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group, respectively. Treatment efficacy of patients’ overall survival (OS), progression-
free survival (PFS) and response rate (RR), as well as treatment-related toxicity, 
were compared among the four groups. A prognosis score system was established 
by Cox proportional hazard model. Results: All patients had Eastern Cooperative 
Oncology Group performance status (ECOG PS) of 0-1. As part of the platinum-doublet 
regimen,145(39.8%) patients received taxol, 81(22.3%) received gemcitabine, 99(27.2%) 
received pemetrexed, 32(8.8%) received vinorelbine, 4(1.1%) received etoposide, and 
3(0.8%) received irinotecan. The most frequent grade 3/4 toxicity was neutropenia 
(20.1%) and nausea/vomiting (3.3%).The median follow-up time was 11.0 months. Patients 
with TTP> 12 months had significant longer survival than the rest of the group after 
second-line platinum-rechallenge (HR, 0.809; 95% CI: 0.703-0.931;P=0.003).Prognostic 
score (TAF score) was calculated by adding 1 point each for any of the following: TTP>12 
months, age≤60 years, and female, all of which were independent prognostic factors 
for patient survival (P=0.015, P=0.002, P=0.012, respectively). Median OS were equal 
to 25.0, 16.0 and 11.0 months for best (2-3 points), intermediate (1 point) and worst 
(0 point) category, respectively (P<0.0001, Figure 1). Figure 1 Kaplan–Meier curves 
of overall survival according to patients’ TAF Score. After second-line platinum-based 
chemotherapy, patients with a TAF Score of 2-3 had significant better survival than those 
scored 0 or 1 (P<0.0001).
 
Conclusion: A TAF score of 2 or 3 points indicates a good prognosis if advanced 
NSCLC patients received platinum-rechallenge after disease progression. 
Keywords: Non-small-cell lung cancer, platinum rechallenge, second-line chemotherapy, 
prognostic model
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P3.01-062 Impact of Gender on Survival Outcome in Saudi Patients with 
Advanced Non-Small Cell Lung Cancer Hani Eltaani1, Shereef Elsamany2, Turki 
Al-Fayea3 1King Abdullah Medical City, Makkah/Saudi Arabia, 2Oncology Center, Mansoura 
University, Mansoura/Egypt, 3King Abdulaziz Medical City(Kamc) - Jeddah Princess Nourah 
Oncology Centre, Jeddah/Saudi Arabia
Background: Different prognostic variables have been proposed in non-small cell lung 
cancer (NSCLC). The present study aims to evaluate the prognostic value of patients’ 
gender in Saudi patients with advanced non-squamous NSCLC. Methods: In this 
retrospective study, patients with stage IIIB-IV non-squamous NSCLC, from 3 institutes 
in Saudi Arabia, were included. We examined the distribution of patients and treatment 
characteristics at diagnosis according to the gender.These categorical variables were 
compared using Chi-square test. Overall survival (OS) was assessed according to the 
gender in addition to age categories (≤ 60 vs. > 60 years), ECOG performance status 
(PS) (0-2 vs. 3-4), type of 1st line chemotherapy (pemetrexed containing vs. others) 
and EGFR status. Differences in survival distributions were evaluated via Log Rank 
test. Multivariate analysis by Cox proportional hazard model has been used to check 
for independent prognostic factors associated with OS. Results: One hundred and 
twenty patients were included (100 stage IV, 20 stage IIIB, 92 males, 28 females). Eighty 
patients had available results of EGFR testing and 26.2% of them were mutant. EGFR 
mutations were more common among female patients (45.4% vs.18.9%, p=0.023). Only 
half of EGFR-mutant patients received 1st line erlotinib, while the other half received 
erlotinib as a maintenance or 2nd line therapy due to delayed EGFR testing results. No 
difference in the distribution of other parameters according to the gender including 
age, PS, site (bone vs. others) and number of metastasis (single vs. multiple), type of 
1st line therapy and number of cycles of chemotherapy. After a median follow up of 
22 months (range 15-31 months), greater proportion of females were alive compared 
to males (60.7% vs. 23.9% respectively, p<0.0001). In univariate analysis, OS was 
improved in female patients (female; 23.0 months, 95% CI= 17.03-28.97 vs. male; 
8.7 months, 95% CI= 5.16-12.24, p < 0.0001), PS 0-2 (PS 0-2;14.4 months, 95% CI= 
10.66-18.14 vs. PS 3-4; 2.0 months, 95% CI= 0.50-4.99, p < 0.0001), those with 
pemetrexed-containing chemotherapy (pemetrexed-containing; 17.0 months, 95% 
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P3.01-059 Treatment Intensity and Duration in Patients Receiving First-
Line Nab-paclitaxel or Paclitaxel (Weekly or Every 3 weeks) for Stage IV 
Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis Utilizing 
Electronic Medical Records Jared Weiss1, Rex W. Force2, Brooke A. Pugmire2, 
Teri Peterson2, Claudio Faria3, Sandra Margunato-Debay3, Manish Patel4 1Lineberger 
Comprehensive Cancer Center, University of North Carolina, Chapel Hill/NC/United States of 
America, 2Improverx, Pocatello/United States of America, 3Celgene Corporation, Summit/
NJ/United States of America, 4Health Economics, Celgene Corporation, Summit/NJ/United 
States of America
Background: In a phase III trial, weekly nab -paclitaxel (nab -P) plus carboplatin 
demonstrated a significantly higher response rate than paclitaxel (P) plus carboplatin 
every 3 weeks, with less grade ≥ 3 neuropathy, neutropenia, arthralgia, and myalgia 
but more thrombocytopenia and anemia in patients with advanced NSCLC (Socinski 
et al. J Clin Oncol. 2012;30:2055-2062). We hypothesized that these differences 
might lead to differences in the cumulative dose received and regimen duration in 
clinical practice. Methods: Fully de-identified electronic medical records (EMRs) from 
October 1, 2012, to September 30, 2014, from a national EMR (OncoEMR; Altos 
Solutions, Inc) were analyzed. Patients receiving first-line therapy with P every week 
(P7), P every 3 weeks (P21), or nab -P every week for stage IV NSCLC were identified. 
The majority of patients also received carboplatin. The total cumulative dose (mg/
m2), treatment duration, and database persistence (a surrogate for overall survival) 
for the taxane regimens were determined. Regression and Cox proportional hazards 
models were used to assess the 3 groups, with the inclusion of age, sex, race, platin 
use, bevacizumab use, histology, prior adjuvant taxane use, and comorbidities (a 
total of 11 degrees of freedom) to control for the potentially confounding effects of 
these variables. Results: A total of 475 patients had complete data. 208 patients with 
NSCLC received P7, 153 received P21, and 114 received nab -P. The total cumulative 
dose was significantly greater for nab -P (932 mg vs 487 mg for P7 and 695 mg for 
P21; P < 0.001 for both). The median treatment duration was 104.5 days for nab -P, 
69.5 days for P7, and 84.0 days for P21 (P < 0.05 for both). The median database 
persistence after taxane initiation was significantly longer for nab -P (378 days vs 214 
days for P7 and 196 days for P21; P < 0.001 for both). Conclusion: Patients with NSCLC 
treated with nab -P had a longer treatment duration, received a greater cumulative 
dose, and had longer database persistence than patients treated with P7 or P21. 
Keywords: NSCLC, treatment intensity, duration
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P3.01-060 Prognostic Value of Serum Proteomic Test and of Comorbidity 
Index in Diversified Population with Lung Cancer Arkadiusz Z. Dudek1, Mani 
Keshgtarpur2, Jack Zwanziger3 1Medicine, University of Illinois, Chicago/IL/United States 
of America, 2Medicine, University of Illinois, Chicago/United States of America, 3School of 
Public Health, University of Illinois, Chicago/AL/United States of America
Background: Proteomic (VeriStrat®) serum test has prognostic and predictive 
value in response to erlotinib; but the relation between comorbidity index and test 
performance and usefulness of this test in different races has not been adequately 
studied yet. Patients and Methods: We have reviewed electronic records of lung 
cancer patients from 09/2009 till 07/2014who had proteomic test performed to help 
with therapy choice. Extracted data was analyzed for survival using SAS software 
9.4. Results: Among 49 qualified patients, 31 had VeriStrat® test done before and 
18 after the first line treatment for metastatic disease. Nineteen cases with good 
VeriStrat® (VSG) test received erlotinib, and 12 received chemotherapy; 4 cases with 
VeriStrat® poor (VSP) results received erlotinib and 12 received chemotherapy. When 
stratified for test results “VSG vs. VSP” overall survival did not differ between white 
race and other races (HR=1.005; 95%CI=0.43-2.35; p=0.99). There was a trend of 
better survival for combined effect of VeriStrat® good test (VSG) and African American 
(AA) race. Patients with VSG test had better survival than patients with VSP test in 
each Charlson comorbidity index (CCI) stratum. Conclusion: Our study shows that 
there is no significant impact of race on prognostic and predictive values of VeriStrat® 
test. Prognostic value of this test is independent of comorbidities and older age. 
Keywords: comorbidity ndex, non-smal cell lung cancer, epidermal growth factor 
inhibitor therapy, proteomic serum test
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P3.01-061 A Prognostic Model for Platinum-Doublet Regimens as Second-Line 
Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients 
Yuankai Shi, Hongnan Mo, Xuezhi Hao, Yutao Liu, Lin Wang, Xingsheng Hu, Jianping Xu, 
Sheng Yang, Puyuan Xing, Youwu Shi, Bo Jia, Yan Wang, Junling Li, Hongyu Wang, Ziping 
Wang, Yan Sun Department of Medical Oncology, Cancer Institute and Hospital, Chinese 
Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of 
Clinical Study on Anticancer Molecular Targeted Drugs, Beijing/China
Background: Poor prognosis of advanced non-small-cell lung cancer (NSCLC) patients 
and the promising therapeutic effect of platinum urge the oncologists to evaluate the 
role of platinum-doublet as second-line chemotherapy and establish the definition of 
platinum sensitivity in NSCLC. Methods: We retrospectively analyzed 364 advanced 
NSCLC patients who received platinum-doublet regimens as second-line chemotherapy 
after platinum-based first-line treatment. Patients were divided into four groups by their 
time-to-progression (TTP) after first-line chemotherapy: 0-3, 4-6, 7-12, and >12months 
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questionnaires completed by 69% of p are shown in Table 1. 
Table 1: Results from patient-reported questionnaires (N=69)
Before the biopsy procedure, you thought that it would be N (%)
Not uncomfortable 13 (18.84)
Uncomfortable 31 (44.93)
Painful 22 (31.88)
Insufferable 3 (4.35)
The punctures of each lesion have been N(%)
Not uncomfortable 23 (33.33)
Uncomfortable 34 (49.28)
Painful 9 (13.04)
Insufferable 3 (4.35)
Overall, you consider the procedure N(%)
Not uncomfortable 20 (28.99)
Uncomfortable 37 (53.62)
Painful 9 (13.04)
Insufferable 3 (4.35)
If you would have to repeat another biopsy N(%)
I will do it 52 (75.36)
I will not repeat it again 4 (5.80)
I would need anesthesia 13 (18.84)
Conclusion: Rebiopsy is considered feasible for physicians in clinical practice and 
the majority of p would undergo a second biopsy. No new safety data have seen so 
far and efficacy results in terms of responses match with previously reported data. 
Keywords: Erlotinib, EGFR, rebiopsy, NSCLC
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P3.01-065 PET Tumor Response by PERCIST Predicts Local-Regional Control in 
Locally Advanced NSCLC after Concurrent Chemoradiotherapy with Erlotinib 
Xiong Wei1, Pamela K. Allen1, Jeremy Erasmus Jr2, George Blumenschein, Jr.3, Myrna 
Godoy2, Jack Lee4, Michael S. O’Reilly1, James W. Welsh1, James D. Cox1, Waun Ki 
Hong5, Ritsuko U. Komaki1 1Radiation Oncology, The University of Texas MD Anderson 
Cancer Center, Houston/TX/United States of America, 2Diagnostic Radiology, The University 
of Texas MD Anderson Cancer Center, Houston/TX/United States of America, 3The University 
of Texas MD Anderson Cancer Center, Houston/United States of America, 4Biostatistics, 
The University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 5Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 
Houston/United States of America
Background: Assessing response of locally advanced non-small cell lung cancer 
(NSCLC) after concurrent chemoradiotherapy by computed tomography (CT) can 
be complicated by treatment-related pneumonitis or fibrosis. Hypothesizing that 
measurements of tumor response by 18F-fluorodeoxyglucose standardized uptake 
values (SUVs) on positron emission tomography (PET) are more reliably associated with 
treatment outcomes than those by CT, we compared outcomes and responses according 
to PET SUV vs. CT among patients in a phase II study of erlotinib+chemoradiation for 
stage III NSCLC. Methods: Trial 2005-1023 enrolled 46 patients in 2007–2010; patients 
received 63 Gy in 35 fractions over 7 weeks with daily erlotinib and weekly paclitaxel-
carboplatin. Tumor response was assessed on diagnostic CT scans with contrast or CT 
from PET-CT and scored according to RECIST 1.1. Tumor response was also assessed 
by PERCIST 1.0 (based on SUV) as follows: complete response (CR), disappearance of 
all measurable tumors; partial response (PR), ≥30% reduction in the sum of SUVs of 
target lesions; progressive disease (PD), ≥30% increase in the sum of SUVs of target 
lesions; and stable disease (SD), insufficient change in SUV to qualify for PR or PD. The 
longest diameter of measurable primary lesions and the short axis of measurable lymph 
CI=12.87-21.13 vs. others; 11.0 months, 95% CI=5.90-16.10, p= 0.019) and EGFR- 
mutant patients (mutant; 23.0 months, 95% CI=16.41-27.39 vs. wild;11.7 months, 95% 
CI=8.24-15.16, p=0.006). In multivariate analysis, mutant EGFR status (HR=2.49, 95% 
CI=1.19-5.19, p=0.015) and female gender (HR=2.78, 95% CI= 1.30-5.95, p=0.008) 
were independent predictors of improved OS. Conclusion: Female Saudi patients with 
advanced non-squamous NSCLC have better survival outcome irrespective of their EGFR 
status. Low frequency of smoking habit among Saudi females may explain this outcome. 
Keywords: gender, prognosis, advanced, lung cancer
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P3.01-063 Development of a Patient-Reported Outcome (pro) Assessment of 
Core Non-Small Cell Lung Cancer (NSCLC) Symptoms Kendra Debusk1, Nathan 
Johnson2, Christopher Evans3, Adrian Jubb4, Alan Sandler5, Suresh S. Ramalingam6, 
Alicyn K. Campbell1 1Patient Centered Outcomes Research, Genentech, South San 
Francisco/CA/United States of America, 2Endpoint Outcomes, Boston/MA/United States 
of America, 3Endpoint Outcomes, Boston/United States of America, 4Achaogen, South San 
Francisco/AL/United States of America, 5Genentech, South San Francisco/United States of 
America, 6Emory University, Atlanta/United States of America
Background: Early stage lung cancer is largely asymptomatic; however, as the disease 
progresses, patients experience significant distress from their lung cancer symptoms. The 
assessment and monitoring of changes in NSCLC symptoms is increasingly important in 
clinical trials when making treatment comparisons between new therapies. The objective 
of this study was to capture the patient perspective on core symptoms of NSCLC in order 
to develop a new symptom measure for use in clinical trials. Methods: This was a non-
interventional, cross-sectional qualitative study that consisted of conducting individual 
interviews with patients with a diagnosis of NSCLC who were either treatment-naïve or had 
already received surgery, chemotherapy, radiation, or targeted therapy. Patients aged 
≥18 years with stage IIB-IV NSCLC took part in concept elicitation interviews to provide 
descriptions of NSCLC symptoms, including severity, frequency and development over 
time. Data were used to develop the items constituting the Symptoms in Lung Cancer 
(SILC) Questionnaire. Results: A total of 28 patients were recruited (17 treatment-naïve, 
11 post-treatment) for concept elicitation interviews. In the treatment-naïve population, 
the most common spontaneously reported symptoms of NSCLC were cough (58.8%), 
shortness of breath (47.1%), chest pain (47.1%) and fatigue (29.4%). These symptoms 
were included in the initial 12-item version of the SILC. An additional 10 patients 
participated in cognitive interviews to ensure that the items were correctly interpreted, 
relevant, and disease-related (i.e., not treatment-related). Following cognitive interviews 
and analysis of data from treatment-naïve and post-treatment patients, the fatigue 
items were dropped after patients indicated that attributing a specific symptom to the 
underlying condition or treatment was challenging. The final draft of the 9-item SILC uses 
a 5-point verbal response scale (higher scores indicating greater severity/frequency), a 
7-day recall period, and assesses 3 core symptom concepts: chest pain (severity and 
frequency), cough (severity and frequency), dyspnea (while lying down/sitting, standing, 
walking, carrying a light load and when walking up an incline). Conclusion: SILC 
is an easy-to-use and concise tool to assess the core symptoms of disease in 
NSCLC patients, and is in compliance with the FDA PRO Guidance (2009) document. 
Keywords: Patient-reported outcomes, PRO, Patient-centered outcomes research, 
symptoms
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P3.01-064 Erlotinib in EGFR-Positive NSCLC: Efficacy, Safety and Feasibility 
for Rebiopsy Manuel Trigo1, Juana Oramas2, David Aguilar3, Javier De Castro4, 
An Laura Ortega5, Margarita Majem6, Emilio Esteban7, Beatriz Esteban8, Cristina 
García-Bernáldez9, Rocio Gordo9 1Hospital Universitario Virgen de La Victoria, Málaga/
Spain, 2Hospital Universitario de Canarias, Tenerife/Spain, 3Hospital Universitario de 
Gran Canaria Doctor Negrín, Gran Canaria/Spain, 4Hospital Universitario La Paz, Madrid/
Spain,5Complejo Hospitalario Ciudad de Jaén, Jaén/Spain, 6Hospital de La Santa Creu I Sant 
Pau, Barcelona/Spain, 7Hospital Universitario Central de Asturias, Asturias/Spain, 8Hospital 
General de Segovia, Segovia/Spain, 9Roche Farma S.A., Madrid/Spain
Background: First-line Erlotinib (E) delays progression in 10-14 months in patients (p) 
harboring EGFR mutations (EGFRm+). Understanding the resistance mechanisms in order 
to personalize treatment justify the need for rebiopsy. However, undergoing this procedure 
could be not feasible on a daily basis. Due to different clinical courses and progression 
patterns, NCCN guidelines recommend strategies according to symptomatology, 
extent and site of metastasis in recurrent setting. Nowadays, identifying tumour 
recurrence patterns and evaluating the potential limitations of rebiopsy are relevant 
in clinical practice. Methods: ASPET is an ongoing, multicentre, observational study. 
Eligible p are chemonaïve with EGFRm+ advanced NSCLC treated with E (150mg/d, 
until unacceptable toxicity or progressive disease). Primary endpoint is to correlate 
PFS and tumour localization/characteristics at progression. The evaluation of potential 
feasibility of rebiopsy (questionnaires completed by physicians and p at diagnosis) is 
one of the secondary endpoints. Results: Baseline characteristics of 100 p included 
in this preliminary analysis: mean age 66 yrs; 65% female; 89% adenocarcinoma; 91% 
stage IV; 69% PS-ECOG 0-1; 60% never smokers; 31% central tumours; 57% Del19, 35% 
L858R, 8% other mutations. Different metastatic locations according to type of mutation 
have been reported (Figure 1). Objective Response Rate of 63.33% and Disease Control 
Rate of 90% (60 p evaluable). Main related grade≥3 toxicities were skin disorders (7%) 
and diarrhoea (2%). Questionnaires completed by 80 physicians: 81.2% considered 
technically feasible repeat biopsy, 66.25% believe that p would be willing to undergo 
rebiopsy and 72.5% would direct changes in therapy with rebiopsy results. Results from 
S661Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Keywords: First line therapy, Manteinance, bevacizumab, Adenocarcinoma
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-068 Phase II Study of S-1 plus Bevacizumab for Pretreated Patients 
with Non-Squamous NSCLC Kazuhiko Yamada1, Masao Ichiki2, Kazuhisa 
Takahashi3, Yasushi Hisamatsu4, Koichi Azuma1, Takaaki Tokito1, Hidenobu Ishii1, 
Hiroaki Takeoka2, Takehito Shukuya3, Kazuo Nishikawa4, Tomoaki Hoshino1 1Division of 
Respirology, Department of Internal Medicine, Kurume University School of Medicine, Kurume 
Japan, 2Kyushu Medical Center, Fukuoka/Japan, 3Division of Respiratory Medicine, Juntendo 
University Faculty of Medicine & Graduate School of Medicine, Tokyo/Japan, 4Department 
Ofmedical Oncology and Hematology, Oita University Faculty of Medicine, Oita/Japan
Background: The additional effects of bevacizumab (B) as first-line chemotherapy 
for non-squamous non-small cell lung cancer (Non-sq NSCLC) have been established. 
However, the efficacy of B in a second-line setting or further has not been clarified. 
It has recently become clear that S-1 (S), an oral fluoropyrimidine, is effective for 
advanced NSCLC, and S is now used with platinum as one of the standard forms of 
first-line chemotherapy. Furthermore, preclinical findings have suggested that the 
combination of S plus B is a promising treatment option. Methods: Non-sq NSCLC 
patients with an ECOG performance status of 0-2, and who had undergone prior 
platinum-based chemotherapy regardless of the use of B, were eligible for the study. 
S (80 mg/m2) was administered orally twice daily for 14 days, and B (15 mg/kg) on 
day 1 every 3 weeks until disease progression or unacceptable toxicity occurred. The 
primary endpoint was progression-free survival (PFS), and the planned sample size was 
28 patients. Results: Between March 2012 and June 2014, 28 patients (14 males and 
14 females; median age 62 years; PS 0/1/2: 21/7/0; Ad/Other: 26/2, EGFR mutation 
positive/wild type 12/16) were accrued from 4 centers in Japan. All 28 patients were 
included in analysis of efficacy and toxicity. With a median follow-up of 9.3 months, 
the median PFS was 3.2 months (95% CI: 2.2-4.0 months). Patients who had not 
received prior pemetrexed or who had shown a good response to prior chemotherapy 
tended to have a longer PFS (5.3 and 5.0 months, respectively), although this was 
not statistically significant. An objective response was observed in 4 patients (PR; 4, 
SD; 20, PD 4), the response rate and disease control rate being 14.3% and 85.7%, 
respectively. The treatment was well tolerated, the most common treatment-related 
side effects being anorexia (75%) and fatigue (68%). Conclusion: This is the first report 
to evaluate the efficacy and safety of SB. Although SB seems to have a higher tumor 
reduction effect than S alone for previously treated Non-sq NSCLC, this study failed to 
meet its primary endpoint. SB is well tolerated and no new toxicities were observed. 
Keywords: NSCLC, S-1, bevacizumab, non-squamous
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P3.01-069 Phase II Trial of Paclitaxel, Irinotecan, and Bevacizumab for 
Patients with Untreated NSCLC Overexpressed ERCC1 MRNA; Evaluated by 
EBUS-GS Yoichi Nakamaura1, Ken Kitazaki2, Takaya Ikeda3, Hirofumi Nakano4, Shinya 
Tomari5, Seiji Nagashima6, Shuntaro Sato7, Katsumi Nakatomi1, Shinnosuke Takemoto1, 
Hiroyuki Yamaguchi1, Minoru Fukuda8 1Nagasaki University Hospital, Nagasaki/Japan, 2The 
Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki/Japan, 3Sasebo General Hospital, 
Sasebo/Japan, 4Uresino Medical Center, Uresino/Japan, 5Isahaya General Hospital, Isahaya/
Japan, 6Nagasaki Medical Center, Omura/Japan, 7Nagasaki University Hospital Clinical 
Research Center, Nagasaki/Japan, 8Clinical Oncology Center, Nagasaki University Hospital, 
Nagasaki/Japan
Background: We prospectively evaluated the efficacy and toxicity of non-platinum 
triplet regimen, which consist of paclitaxel, irinotecan, and bevacizumab for 
patients with advanced non-small cell lung cancer (NSCLC) expected to be platinum 
resistant. Methods: All patients were diagnosed with NSCLC using endobronchial 
ultrasonography with a guide sheath (EBUS-GS) system. We defined the EBUS-GS as 
a core biopsy. RNA was immediately isolated from this unfixed biopsy specimens, and 
quantitative real-time reverse transcriptase PCR assays were performed to determine 
the excision repair cross-complementing 1 (ERCC1) mRNA expression. Patients with 
advanced, untreated NSCLC showing high ERCC1 levels (ΔCt≧6.5) were entered the 
phase II trial of the non-platinum triplet regimen. Paclitaxel of 180mg/m2 on day 1, 
irinotecan of 50mg/m2 on day 1 and 8, and bevacizumab of 15mg/kg on day 1 were 
administered every 4 weeks. Primary end point was the objective response rate (ORR), 
assuming 30% for a standard therapy and 60% for a target therapy (alpha=0.05 and 
beta=0.1), and the estimated required total number of patients was 28 by Simon’s Optimal 
Two-stage Design. Results: Total 141 untreated patients received EBUS-GS and were 
evaluated the expression of ERCC1, and 30 patients were entered in this trial. The ORR 
was 66.7%(95% confidence interval [CI]: 47.2-82.7). Median progression-free survival 
was 174 days. Grade 4 thrombosis occurred one patient, but other toxicities were mild 
and controllable. Fifty-three patients were treated with platinum-containing regimens 
and 22 patients were responded (ORR was 41.5% [95% CI: 28.1-55.9]). Twenty-three of 
these patients were high ERCC1 levels and 6 patients were responded, and 30 patients 
were low ERCC1 levels and 16 patients were responded (p=0.0053, by Fisher’s exact 
test). Conclusion: The triplet combination of paclitaxel, irinotecan and bevacizumab 
might be effective for patients with advanced, untreated NSCLC overexpressing 
ERCC1. ERCC1 mRNA levels extracted from unfixed lung biopsy specimens obtained 
by EBUS-GS also might be a predictive factor for platinum-containing regimens. 
Keywords: non-small cell lung cancer, EBUS-GS, ERCC1, non-platinum regimen
nodes were measured. All non-target lesions were also measured. Two-sided Pearson’s 
chi-square tests were used to assess frequency associations. Overall survival (OS) and 
local-regional control (LRC) rates were assessed from treatment start by Kaplan-Meier 
analysis and log-rank tests; P≤0.05 indicated significance. Results: One patient did not 
have CT and PET after treatment. For the 45 evaluable patients, best response by PET-
CT at 6 months after treatment was CR for 15 patients (33%), PR for 19 (42%), SD for 0, 
PD for 4 (9%), and not available due to did not have baseline or post treatment PET for 
7 (16%). Best response by CT at 6 months was CR for 11 (24%), PR for 27 (60), SD for 3 
(7%), and PD for 4 (9%) (P<0.001). The 3 patients with SD by CT all died within 7 months 
after treatment; the 4 patients with PD had new distant metastases. Four-year OS was 
associated with best overall response on both PET and CT at 6 months (P<0.05) and at 1 
year (P<0.05). LRC was associated with best overall response on PET (P<0.01) and best 
primary tumor response on PET (P<0.05) at 6 and 12 months. Lymph node response was 
not associated with OS or LRC by PET or CT. Conclusion: The CR rate was higher with PET 
than with CT. Tumor response at 6 months by PET or CT predicted treatment outcomes 
after chemoradiotherapy for stage III NSCLC. The best overall and primary tumor response 
by PET within 6 months after treatment was more reliably associated with LRC than was 
response on CT because of difficulty to assess response due to pneumonitis/lung fibrosis. 
Keywords: NSCLC, Tumor response, PERCIST, RECIST
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P3.01-066 Bevacizumab Combined with Docetaxel: A Real Active Second Line 
Regimen in Elderly Patients with Advanced Non-Small Cell Cancer (NSCLC)
Sherif Abdelwahab, Wesam Elghamry, Mohamed Kelany, Mai Ezzdin Clinical Oncology, 
Ain Shams University, Cairo/Egypt
Background: Majority of patients with non-small cell lung cancer (NSCLC) are 
elderly, and age is known to be an important factor for management and treatment. 
Elderly are underpresented in cancer research. Therefore, we conducted this 
phase II study aiming at assessing the efficacy and safety of adding bevacizumab to 
docetaxel as a second line treatment of elderly patients with advanced non squamous 
NSCLC Methods: Twenty five previously treated elderly patients with advanced non 
squamous NSCLC (stage III, IV) were enrolled into this study between May 2011 and 
May 2014. All patients received docetaxel 60 mg/m2 followed by bevacizumab 15mg/
kg, both agents were given via I.V infusion on day 1 and the cycle was repeated every 
21 days until disease progression or unacceptable toxicity developed. Results: The 
median age was 70 years old (range 65-79 years); 19 (76%) patients were men; ECOC 
PS was 0 in 6 (24%) patients, 1 in 12 (48%) patients and 2 in 7 (28%) patients. The 
objective response rate was 60%, while disease control rate was 84%.The median 
progression-free survival time was 7 months, while the median overall survival time 
was 19.8 months. Grade 3/4 neutropenia had been recorded in 18(72%) patients, and 
grade 3/4 fatigue had occurred in 5(20%) patients. No cases of severe bleeding nor 
treatment-related deaths had been reported in this study. Conclusion: Bevacizumab 
added to docetaxel showed a real activity as a second line treatment in previously 
treated elderly patients with advanced NSCLC and has an acceptable toxicity. 
Keywords: Bevacizumab,docetaxel,elderly,NSCLC
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-067 Pemetrexed (P)/Carboplatin/Bevacizumab (B) Followed by 
Maintenance P/B in Hispanic Patients with Non-Squamous NSCLC Leonardo 
Rojas1, Andrés F. Cardona2, Hernan Carranza2, Carlos A. Vargas2, Jorge M. Otero2, 
Mauricio Cuello3, Luis Corrales4, Claudio Martin5, Oscar Arrieta Rodriguez6 
1Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá/
Colombia, 2Clinical and Translational Oncology Group, Foundation for Clinical and Applied 
Cancer Research - Ficmac, Bogotá/Colombia, 3Clinical Oncology, Hospital de Clínicas - 
Udelar, Montevideo/Uruguay, 4Clinical Oncology, Hospital San Juan de Dios, San José/
Costa Rica, 5Clinical Oncology, Instituto Fleming, Buenos Aires/Argentina, 6Laboratory of 
Experimental Oncology and Thoracic Oncology Unit, National Institute of Cancer, Mexico 
City/Mexico
Background: The present study evaluated the efficacy and safety of pemetrexed, 
carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, 
in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer 
(NSCLC). Methods: The patients were administered pemetrexed (500 mg/m2), 
carboplatin (AUC 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every 
three weeks for up to four cycles. Patients who did not experience tumor progression 
remained on maintenance pemetrexed and bevacizumab until disease progression or 
unacceptable toxicity. Primary endpoints were overall response rate (ORR), progression 
free survival (PFS) and overall survival (OS). Results: Hundred forty-four Colombian 
patients were included and received treatment. The median age was 64 years (range, 
32-86 years), 61% was female and 55% had some history of tobacco exposure. The 
median follow-up was 13.8 months, and the median number of manteinance cycles was 
8 (range, 1- 32). Among patients assessable for response, the ORR was 66% (95%CI, 
47% to 79%). Median progression-free and overall survival rates were 7.9 months (95%CI 
5.9-10.0 months) and 21.4 months (95%CI 18.3 to 24.4 months), respectively. Grade 3/4 
hematologic toxicity was anemia (14%), neutropenia (8%), and thrombocytopenia (16%). 
Grade 3/4 nonhematologic toxicities were proteinuria (2%), venous thrombosis (4%), 
fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). There was 
no grade 3 or greater hemorrhagic events or hypertension cases. Conclusion: Overall, 
pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed 
and bevacizumab, was effective and tolerable in hispanic patients with non-squamous 
NSCLC. This regimen was associated with acceptable toxicity and prolonged OS. 
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P3.01-072 Final Efficacy and Safety Results of ECOG Performance Status 
(PS) Subgroup Analyses From the SQUIRE Phase III Study Mark A. Socinski1, 
Alexander V. Luft2, Aleksandra Szczesna3, Wojciech Szafrański4, Rinat K. Galiulin5, 
Beatrix Bálint6, Keunchil Park7, Martin Reck8, Henrik Depenbrock9, Shivani Nanda10, 
Nadia Chouaki11, Nick Thatcher12 1University of Pittsburgh, Pittsburgh/PA/United States of 
America, 2Leningrad Regional Clinical Hospital, St. Petersburg/Russian Federation, 3Regional 
Lung Disease Hospital, Otwock/Poland, 4Voivodeship Specialist Hospital, Radom/
Poland,5Omsk Regional Oncology Center, Omsk/Russian Federation, 6Csongrád County 
Hospital of Chest Diseases, Deszk/Hungary, 7Division of Hematology-Oncology, Department 
of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/
Korea, 8Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research 
Center North (Arcn), Member of the German Center for Lung Research (Dzl), Grosshansdorf/
Germany, 9Lilly Deutschland Gmbh, Bad Homburg/Germany, 10Eli Lilly and Company, 
Bridgewater/NJ/United States of America, 11Eli Lilly and Company, Neuilly-Sur-Seine/
France, 12The Christie Hospital, Manchester/United Kingdom
Background: As previously reported, the SQUIRE study demonstrated that the addition 
of necitumumab (N) to gemcitabine-cisplatin (GC) chemotherapy significantly improved 
survival in patients with stage IV squamous NSCLC. Overall survival (OS), progression-
free survival (PFS), and safety results are presented for Eastern Cooperative Oncology 
Group (ECOG) PS 0–1/2 subgroups. Methods: Patients with stage IV squamous NSCLC 
were randomized 1:1 to N (800 mg iv, days 1 and 8) plus GC (G=1250 mg/m² iv, days 
1 and 8; C=75 mg/m² iv, day 1) or GC alone every 21 days for up to six cycles in this 
multicenter, open-label study. N+GC patients without progression continued on N alone 
until progressive disease or intolerable toxicity. The study was powered for OS and PFS 
(previously reported). Preplanned subgroup analyses were performed for ECOG PS 0–1 
and 2. Results: Subgroups PS 0–1/2 (n=996 [91%]/n=96 [9%]) were well balanced 
regarding baseline characteristics (males, 83% vs 86%; median age, 62 vs 65 yrs; 
smoking/ex-light smoker/nonsmoker, 91/4/5% vs 89/6/5%). GC median relative dose 
intensity was similar between PS 0–1/2 subgroups; N (overall) was higher for the PS 
0–1 than for PS 2 subgroup (94.8% and 90.0%). Post-study therapy use was generally 
higher in the PS 0–1 than in the PS 2 subgroup, but was balanced between both arms. 
The OS hazard ratio (HR) for N+GC vs. GC was 0.85 (95% CI: 0.74, 0.98; p=0.026) for 
PS 0–1 and 0.78 (95% CI: 0.51, 1.21; p=0.275) for PS 2. The PFS HR (N+GC vs. GC) was 
0.86 (95% CI: 0.75, 0.99; p=0.035) for PS 0–1 and 0.79 (95% CI: 0.50, 1.24; p=0.292) 
for PS 2. Select Grade ≥3 treatment-emergent adverse events (TEAEs) are shown in the 
table. The percentage of patients with adverse events leading to discontinuation of any 
study drug was lower in the PS 0–1 subgroup (N+GC=30%; GC=23%) than the PS 2 
subgroup (N+GC=42%; GC=41%). The percentage of patients hospitalized was higher 
in the PS 0–1 subgroup (N+GC=43%; GC=34%) than the PS2 subgroup (N+GC=25%; 
GC=30%). Table. Select TEAEs
Grade ≥3 Event*
PS 0-1 
N+GC 
(%) N=490
PS 0-1 
GC 
(%) N=495
PS 2 
N+GC 
(%) N=48
PS 2 
GC 
(%) N=46
Neutropenia 25.5 28.1 12.5 21.7
Febrile neutropenia 0.6 1.4 2.1 0
Anemia 11.2 10.3 4.2 17.4
Thrombocytopenia 10.4 10.5 8.3 13.0
Fatigue 7.1 7.1 8.3 6.5
Hypomagnesemia 9.8 1.0 4.2 2.2
Rash 7.8 0.4 0 0
Arterial thromboembolic 
events 3.7 1.8 6.3 4.3
Venous thromboembolic 
events 5.5 2.6 0 2.2
 
*Adverse events of possible relevance to treatment, according to either composite 
categories or preferred terms (febrile neutropenia only) Conclusion: OS and PFS 
treatment results for N+GC were consistent and considered favorable across 
subgroups including ECOG PS 2 patients. Administration of N+GC was well tolerated 
in PS 2 patients, with no evidence of an increased safety risk in this subgroup. 
Keywords: necitumumab, ECOG PS, efficacy, safety
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P3.01-073 Nimotuzumab in Advanced Squamous Cell Lung Cancer: A 2 Year 
Comparative Indian Clinical Experience Govind Babu Medical Oncology, Kidwai 
Memorial Institute of Oncology, Karnataka/India
Background: Lung cancer is mainly a disease of modern era and probably one of the 
most important health problems today. Approximately 63,000 new lung cancer cases are 
reported each year (Ganesh et al., 2011) in India. In the series from west as well as from 
India, it is reported that 30% of lung cancers are of squamous cell histology (SQCLC) 
and 50-70% cases usually present in advanced stage (Becket, 1993; Govindan et al., 
2006; Grivaux et al., 2011; Malik et al., 2013). The median overall survival observed 
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P3.01-070 Experience with Docetaxel plus Nintedanib with Previously Treated 
NSCLC Patients: Compassionate Use Program Single Institution in Mexico Saul 
Campos-Gomez, Karen A. Campos-Gomez Dep of Medical Oncology, Centro Oncologico 
Estatal Issemym, Toluca/Mexico
Background: Nintedanib is an oral, potent, tyrosine kinase inhibitor that simultaneously 
targets vascular endothelial growth factor receptors 1-3, platelet-derived growth factor 
receptors α and β, and fibroblast growth factor receptors 1-3, as well as FLT3 and Src. 
Currently, the molecule has proved benefit for second-line in non-small cell lung cancer 
patients. We report the results of a cohort of NSCLC patients receiving nintedanib within a 
compassionate-use program (CUP) in México. Methods: Patients with advanced NSCLC 
progressing after one line of chemotherapy were enrolled. Eligible patients received 
docetaxel 75 mg/m(2) (day 1) plus nintedanib 200 mg twice daily; days 2-21) in 21-day 
cycles. Data collection was monitored. Treatment continued until disease progression 
or unacceptable drug-related AEs. The intention of this CUP was to provide controlled 
access to nintedanib. Results: From February 2014 to April 2015, 17 patients (63% male; 
median age: 61 years [range: 29-83 years]) were enrolled. Patients received nintedanib 
200 mg BID (n=16). The primary analysis was done after a median follow-up of 7 months; 
the median overall survival was 42 months (33-52 weeks). Grade 3 or worse febrile 
neutropenia developed in eight patients (31 %) and neutropenia in four patients (15 %). 
The most frequent drug-related adverse events (all grades) were diarrhea (30%), asthenia 
(61.9%), nausea (23%), hand-foot syndrome (15%), and vomiting (7.6%). Drug-related 
adverse events all grades included neutropenia (12.5%), fatigue (18.7%), decreased 
appetite (18.7%), and elevations in alanine aminotransferase (37.5%) and aspartate 
aminotransferase (31.2%). Dose-limiting toxicities (all grade 3 hepatic enzyme elevations) 
occurred only in 2/16 patients (12.5%). All hepatic enzyme elevations were reversible and 
manageable with dose reduction. Among 16 evaluable patients, 13 (81.25%) had a partial 
response and 3 (18.75%) had stable disease by Response Evaluation Criteria In Solid 
Tumours criteria. Three of all patients died of events unrelated to disease progression; the 
most common of these events were sepsis and pneumonia. Conclusion: Based on cohort 
result, treatment with second-line nintedanib combined with docetaxel was well tolerated 
and showed efficacy in Mexican patients with advanced non-small-cell lung cancer. 
Keywords: advanced lung cancer, Secod line, nintedanib, Safety
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P3.01-071 RAS Inhibitor Prevent Proteinuria of NSCLC Patients Who Received 
Bevasizumab Chemotherapy: NJLCG 1303 Shoichi Kuyama1, Satoru Nihei2, 
Toshiyuki Harada3, Toshiro Suzuki4, Yoshitaka Saito5, Satoshi Oizumi6, Shigeki Kisara7, 
Akira Inoue8, Atsuko Yokota9, Hiroshi Yokouchi10, Koji Okada11, Yoshiaki Mori12, Masami 
Tsuchiya13, Makoto Maemondo14, Kazufumi Terui15, Kageaki Taima16, Yumiko Tadokoro17, 
Hiroshi Watanabe18, Junya Sato2, Naoto Morikawa19 1Department of Respiratory 
Medicine, NHO Iwakuni Medical Center, Iwakuni/Japan, 2Department of Pharmacy, Iwate 
Medical University Hospital, Iwate/Japan, 3Center for Respiratory Disease, Jcho Hokkaido 
Hospital, Sapporo/Japan, 4Respiratory Medicine, Iwate Prefectural Isawa Hospital, Oushu/
Japan, 5Department of Pharmacy, Hokkaido University Hospital, Sapporo/Japan, 61St 
Dept of Medicine, Hokkaido University School of Medicine, Sapporo/Japan, 7Department 
of Pharmacy, Tohoku University Hospital, Sendai/Japan, 8Respiratory Medicine, Tohoku 
University Hospital, Sendai/Japan, 9Department of Pharmacy, Fukushima Medical University 
Hospital, Fukushima/Japan, 10Department of Pulmonary Medicine, Fukushima Medical 
University, Fukushima/Japan, 11Department of Pharmacy, Iwate Prefectural Central Hospital, 
Iwate/Japan, 12Iwate Prefectural Central Hospital, Iwate/Japan, 13Department of Pharmacy, 
Miyagi Cancer Center, Sendai/Japan, 14Respiratory Medicine, Miyagi Cancer Center, Natori/
Japan, 15Department of Pharmacy, Hirosaki University Hospital, Hirosaki/Japan, 16Hirosaki 
University Hospital, Hirosaki/Japan, 17Saka General Hospital, Shiogama/Japan, 18Respiratory 
Medicine, Saka General Hospital, Shiogama/Japan, 19Iwate Medical University School of 
Medicine, Morioka/Japan
Background: Proteinuria caused by bevacizumab (BV) often becomes an obstacle to 
continuation of the treatment. Renin-angiotensin system inhibitor (RASI), angiotensin 
receptor blocker and angiotensin converting enzyme inhibitor, has demonstrated 
anti-proteinuria effect in diabetic nephropathy and nondiabetic kidney disease. This 
retrospective observational study was conducted to evaluate the anti-proteinuria 
effect of RASI for NSCLC patients (pts) who received BV chemotherapy. Methods: We 
reviewed the medical records of NSCLC pts between 2008 and 2014 at 11 hospitals. 
Eligible pts had a treatment of BV chemotherapy, no proteinuria, and no diabetes 
mellitus. Clinical characteristics, use of the antihypertensive drugs, change of the 
blood pressure, and proteinuria generation were investigated during first 6 courses 
of BV chemotherapy. Results: A total of 211 pts were enrolled. Pts characteristics 
were: male/female 121/90; median age 63 (range 35-88); ECOG performance 
status 0-1/2-3 199/12; stage Ⅳ/recurrent 189/22; dose of BV(/kg) 7.5mg/15mg 
21/190; BV cycle 1-2/3-4/5-6 18/55/138; antihypertensive drugs RASI/non-RASI/
none 59/44/108. Proteinuria was observed in 49 pts (23%) as grade 1/2/3 33/14/2. 
The rate of proteinuria generation was significantly lower in the RASI group than 
non-RASI group (17% vs. 41%, P=0.025). Multivariate analysis revealed that RASI 
significantly reduced proteinuria (HR=0.43, 95% CI=0.17-0.91, P=0.043). Conclusion: 
RASI demonstrated anti-proteinuria effect for NSCLC pts who received BV therapy. 
Keywords: Renin-angiotensin system inhibitor, Anti-proteinuria effect, bevacizumab
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Background: KRAS mutations are the most common oncogenic drivers in lung 
cancers without any approved targeted therapy. Preclinical evidence suggests that 
KRAS mutations are highly dependent on the NF-kB pathway. Bortezomib, a small 
molecule proteasome inhibitor, has been shown to downregulate the NF-kB pathway 
and lead to objective responses in patients with KRAS G12D in early phase clinical 
trials. In this single-institution, open label, phase II study we assessed the efficacy and 
safety of subcutaneous bortezomib in KRAS mutant lung cancers. Methods: Patients 
with advanced KRAS G12D mutant lung cancers were eligible. Bortezomib was 
administered at 1.3mg/m2/dose subcutaneously on days 1, 4, 8, and 11 of a 21 
day cycle until disease progression or unacceptable toxicity. The primary objective 
was radiographic response rate (RECIST version 1.1). The secondary endpoints were 
progression free survival (PFS) and overall survival (OS) determined from the time of 
first bortezomib treatment. Simon two-stage minimax design was used (H0=10%, 
H1=30%, power=90%). Results: Sixteen patients with KRAS G12D mutant lung 
adenocarcinomas were treated on study: 44% women, 38% never smokers, 31% former 
smokers ≤15 pack years, and 69% with invasive mucinous adenocarcinomas. Patients 
received treatment for a median of 2 months (range 1-12months). One patient had a 
partial response with a 66% reduction in disease burden (6% observed rate, 95% CI 
0.2 to 30.2%). Of the 6 patients (40%) with stable disease, 2 remained on study for 
over 5 months. The median PFS was 1 month (95% CI 1-6). The median OS was 13 
months (95% CI 6-NA). The median OS from date of diagnosis of metastatic disease 
was 39 months (95% CI 35-NA). The most common treatment-related toxicities of any 
grade were fatigue (50%), diarrhea (38%), nausea (31%), and papulopustular rash (31%). 
Treatment-related peripheral neuropathy occurred in 25% of patients (3 patients with 
grade 1, 1 patient with grade 2). Conclusion: In patients with G12D KRAS mutant lung 
cancers, bortezomib was well tolerated and associated with modest anti-tumor activity 
and durable disease control in a small subset of patients. Further investigation into 
predictive biomarkers for the efficacy of bortezomib should be pursued. Without a clear 
biomarker, no further study of bortezomib in KRAS- mutant lung cancers is warranted. 
Keywords: KRAS, synthetic lethal
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P3.01-076 Efficacy and Safety of Recombinant Human Tumor Necrosis Factor 
Application for the Treatment of Malignant Pleural Effusion Caused by Lung 
Cancer Qian Li1, Wenkui Sun1, Dongmei Yuan1, Tangfeng Lv1, Jie Yin1, Ehong Cao1, 
Xinwu Xiao1, Yong Song2 1Department of Respiratory Medicine, Jinling Hospital, School of 
Medicine, Nanjing University, Nanjing/China, 2Department of Respiratory Medicine, Jinling 
Hospital, Nanjing University School of Medicine, Nanjing/China
Background: Malignant pleural effusion (MPE) is mainly caused by metastatic pleural 
cancer and defines malignant tumors with a poor prognosis. To achieve sufficient 
control of MPE and to minimize invasive interventions are the primary goals of the 
treating physicians. Recombinant human mutant tumor necrosis factor-alpha (rhu-
TNF) has been used in the treatment of MPE. The aim of our research study, which 
included a total of 102 patients with MPE caused by lung cancer, was retrospectively 
to evaluate efficacy and safety of rhu-TNF application via ultrasound-guided chest 
tube for the treatment of MPE. Malignant pleural effusion (MPE) is mainly caused by 
metastatic pleural cancer and defines malignant tumors with a poor prognosis. To 
achieve sufficient control of MPE and to minimize invasive interventions are the primary 
goals of the treating physicians. Recombinant human mutant tumor necrosis factor-alpha 
(rhu-TNF) has been used in the treatment of MPE. The aim of our research study, which 
included a total of 102 patients with MPE caused by lung cancer, was retrospectively 
to evaluate efficacy and safety of rhu-TNF application via ultrasound-guided chest 
tube for the treatment of MPE. Methods:Rhu-TNF was administered as a single dose 
to 102 patients, and dexamethasone (Dmx, 5 mg) was administered 30 min before 
rhu-TNF in 35 patients in order to prevent side effects. The primary endpoint was the 
efficacy of the Rhu-TNF treatment (disease response rate) and side effects (pain, fever 
and flu-like symptoms) evaluated four weeks after instillation. Results: The disease 
response rate of Rhu-TNF treatment in 102 patients was 81.37%. Side effects included 
13 (12.75%) patients complaining about flu-like symptoms, 15 (14.71%) with fever/
chill, and 14 (13.73%) with chest pain. A significantly higher efficacy was observed for 
the treatment with three versus two million units rhu-TNF (= 0.036), while the adverse 
effects were similar. Although application of Dmx before the intra-pleural instillation 
of rhu-TNF reduced the incidence of adverse events, no significant differences were 
found. Conclusion: In conclusion, our study shows that intra-pleural instillation of rhu-TNF 
in MPE patients achieves sufficient control of MPE and minimizes invasive interventions. 
Keywords: lung cancer, malignant pleural effusion, Rhu-TNF, Intra-pleural instillation
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-077 A Randomized, Phase II Study of Nimotuzumab Plus Gefitinib vs 
Gefitinib in Advanced Non-Small Cell Lung Cancer After Platinum- Based 
Chemotherapy Hye Ryun Kim1, Joung Soon Jang2, Jong-Mu Sun3, Myung-Ju Ahn4, 
Dong-Wan Kim5, Inkyung Jung6, Yong-Wha Moon7, Sun Min Lim8, Jae Heon Jeong9, Ki 
Hyeong Lee10, Joo-Hang Kim1, Dae Ho Lee11, Sang-We Kim12, Byoung Chul Cho1 1Medical 
Oncology, Yonsei Cancer Center, Seoul/Korea, 2Department of Internal Medicine,, Chung-Ang 
University, College of Medicine, Seoul/Korea, 3Division of Hematology-Oncology, Department 
of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/
Korea, 4Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/
Korea, 5Seoul National University Hospital, Seoul/Korea, 6Biostatistics and Informatics, 
Yonsei University College of Medicine, Seoul/Korea, 7Yonsei Cancer Center, Seoul/
with the current standard of care is 9-11 months and highlights the need for targeted 
agents that will add to the survival and quality of life of these patients. EGFR is the most 
evaluated target in lung cancer. EGFR overexpression is recorded in about 75-80% of 
the patients and associated with a worser clinical outcome. Nimotuzumab is humanized 
EGFR antagonist and is being actively evaluated in the management of advanced 
lung cancer. This study is done to observe the safety and efficacy of nimotuzumab in 
combination with chemotherapy (docetaxel and carboplatin) versus chemotherapy alone 
in patients with stage IIIB/IV SQCLC with recorded EGFR overexpression. Methods: This 
single-center, open-label, study evaluating 20 patients to receive nimotuzumab plus 
chemotherapy (nimo group, n=10) or chemotherapy alone (control group, n=10), and 
comprised concomitant, maintenance, and follow-up phases. Nimotuzumab 200 mg was 
administered once weekly for 13 weeks during the first two phases with four cycles of 
chemotherapy and docetaxel 75 mg/m2 and carboplatin (area under the curve 5 mg/
mL*min) every 3 weeks for a maximum of four cycles during the concomitant phase. The 
primary endpoint was objective response rate (sum of complete response and partial 
response). Secondary endpoints, ie, overall survival and progression-free survival, were 
estimated using the Kaplan–Meier method. Efficacy was evaluated on the intent-to-
treat and efficacy-evaluable sets. Safety was assessed from adverse event and serious 
adverse event data. Results: The objective response rate was significantly higher in the 
nimotuzumab group than in the control group in the intent-to-treat population (66% versus 
34.5%; P=0.04). A complete response and partial response were achieved in 15% and 
50% of patients, respectively, in the nimotuzumab group, and in 4% and 30.9% of patients, 
respectively, in the control group. Median progression-free survival and median overall 
survival in nimo group and control groups were 5.9 vs 3.7 months and 12.2 vs 9.8 months 
respectively, both being significant for Nimotuzumab. Safety profiles were comparable 
between the two groups. Conclusion: Nimotuzumab plus chemotherapy significantly 
improved the tumor response, PFS and mOS as compared with chemotherapy alone. 
The combination was safe and well tolerated in patients with stage IIIB/IV lung cancer. 
Keywords: nimotuzumab, Targeted therapy, Advanced squmous cell lung cancer, 
Epidermal growth factor receptor
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P3.01-074 Phase I-II Trial of Combined PKC Iota and mTOR Inhibition for 
Patients with Advanced or Recurrent Lung Cancer - A Trial in Progress 
Helen J. Ross1, Harshita Paripati2, Verline Justilien3, Alan Fields3 1Mayo Clinic, Scottsdale/
AZ/United States of America, 2Mayo Clinic, Scottsdale/United States of America, 3Mayo 
Clinic, Jacksonville/FL/United States of America
Background: Cancer stem cells may be responsible for initiation, maintenance, 
progression and metastatic spread of lung cancers and native or acquired drug 
resistance can allow cancers to escape from conventional therapy. Eradicating 
cancer stem cells may improve clinical outcomes. We (APF, VJ) showed that PKCi is 
an oncogene for NSCLC and is amplified in most squamous lung cancer cells (LSCC). 
PKCι is required for LSCC cell proliferation in vitro and tumorigenicity in vivo and for 
maintenance of the lung cancer tumor initiating cell (TIC) phenotype. LSCC oncospheres 
have cancer stem cell characteristics, express stem genes, and exhibit clonal expansion, 
enhanced transformed growth and the ability to maintain lung tumors and metastases 
in vivo. The PKCi-Rac1-Ect2-MMP10 signaling axis is activated in LSCC TICs and PKCι 
knock down, impairs soft agar growth, clonal expansion and tumorigenicity. The gold 
salt auranofin (ANF) reproduces the effects of PKCι knock down on the PKCi-Rac1-Ect2-
MMP10 signaling pathway and on clonal expansion and tumorigenicity. ANF potently and 
selectively inhibits oncogenic PKCι signaling and combined PKCι and mTOR inhibition 
synergistically reduces lung cancer cell proliferation and tumor growth in vivo and in 
vitro (Ross H, Justilien V, Hill K, Walsh M, Fields AP. Protein kinase C iota is required 
for maintenance of a tumor initiating cell phenotype in lung squamous cell carcinoma. 
Abstract 2644 WCLC 2013). A phase I/II clinical trial of oral ANF + the mTOR inhibitor 
sirolimus in patients with advanced or recurrent lung cancer is ongoing. Methods: A 
phase I/II clinical trial is accruing patients to test the hypothesis that combined inhibition 
of PKCι and mTOR is safe and effective in lung cancer patients. NCT01737502 NCI 
sponsored clinical trial R21 CA153000 Eligible participants are adults with confirmed 
diagnosis of lung cancer (squamous, RAS-mutated adenocarcinoma or small cell lung 
cancer), PS 0-2, adequate organ function, no significant comorbidities and who have 
completed at least one prior course of platinum doublet chemotherapy. Patients receive 
ANF + sirolimus orally daily in 28 day continuous cycles. Tumor biopsies are collected for 
biomarker assessment focused on the PKCi-Rac1-Ect2-MMP10 pathway. Study endpoints 
are safety, survival and biomarker development. Results: The trial has completed the 
phase I portion with six patients without dose limiting toxicity. The phase II portion of the 
trial is now accruing with doses of ANF 6 mg daily and sirolimus 5 mg daily continuously 
in 28 day cycles. Biomarker assessment is ongoing. Conclusion: The phase I portion of 
this trial demonstrated preliminary safety of the combination of auranofin and sirolimus at 
doses that were effective against NSCLC in preclinical models. Phase II accrual is ongoing. 
Keywords: Protein kinase C iota, mTOR, Phase I/II clinical trial, Cancer Stem Cells
POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-075 Phase 2 Trial of Bortezomib in KRAS G12D Mutant Lung Cancers 
Gregory J. Riely1, Anya Litvak2, Natasha Rekhtman2, M Catherine Pietanza2, Jamie 
E. Chaft2, Kaitlin Woo3, Paul Paik1, Vincent Miller4, Mark G. Kris5, K Rodriguez1, 
Alexander Drilon2 1Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America, 2Memorial Sloan Kettering Cancer Center, New York/United States of 
America, 3Epidemiolgy and Biostatistics, Memorial Sloan Kettering Cancer Center, New York/
NY/United States of America, 4Clinical Development, Foundation Medicine, Inc, Cambridge/
MA/United States of America, 5Thoracic Oncology, Memorial Sloan Kettering Cancer Center, 
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v4.03. Patients receiving avelumab who have achieved a complete response (CR) will be 
treated for a minimum of 6 months and a maximum of 12 months after confirmation. In 
the case of relapse following a CR, treatment with avelumab may be re-initiated once at 
the discretion of the investigator and in the absence of treatment-related toxicity. For 
patients whose disease progresses with avelumab, treatment may continue past the 
initial determination of disease progression per RECIST 1.1 if the patient’s performance 
status has remained stable, other criteria are fulfilled, and the investigator’s opinion 
supports a possible benefit of continued treatment with avelumab. Patients treated 
with docetaxel may not crossover to the avelumab arm as long as the primary endpoint 
has not been met in the planned interim or final analyses. Enrollment in this trial began 
in April 2015. *Proposed INN. Results: not applicable Conclusion: not applicable 
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P3.01-079 Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/
Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar™ 
Trial Peter Schmid1, Dakshinamoorthy Muthukumar2, Fiona Blackhall3, Jason Lester4, 
Sarah Khan5, Marianne C. Illsley6, Joss Adams7, Shobhit Baijal8, Angel Garcia9, Carey 
Macdonald Smith9, Siow-Ming Lee10, Cindy Jacobs11, Gary Middleton12, Christine 
James13, Kelly Mousa13, Shah-Jalal Sarker13, Louise Lim1 1Barts Cancer Institute, London/
United Kingdom, 2Essex County Hospital NHS Trust, Colchester/United Kingdom, 3The 
Christie NHS Foundation Trust, Manchester/United Kingdom, 4Velindre Cancer Centre, 
Cardiff/United Kingdom, 5Nottingham University Hospitals NHS Trust, Nottingham/
United Kingdom, 6Royal Surrey County Hospital NHS Foundation Trust, Guildford/United 
Kingdom, 7Royal Berkshire NHS Foundation Trust, Reading/United Kingdom, 8Heart of 
England NHS Foundation Trust, Birmingham/United Kingdom, 9Betsi Cadwaladr University 
Health Board, Rhyl/United Kingdom, 10University College Hospitals NHS Foundation Trust, 
London/United Kingdom, 11Suite 201, Oncogenex Pharmaceuticals, Inc., Bothell/United 
States of America, 12University Hospital Birmingham NHS Foundation Trust, Birmingham/
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Background: Outcomes remain poor in patients with non-small cell lung cancer (NSCLC) 
of squamous origin. There are few established therapeutic targets, and benefits of 
chemotherapy are frequently short-lived, with rapid development of treatment resistance. 
More effective therapies are urgently required. Substantial preclinical data demonstrate 
that heat shock protein 27 (Hsp27) affects numerous pathways implicated in cancer 
progression and treatment resistance. Approximately 70-98% of squamous-cell tumours 
express Hsp27. Apatorsen (OGX-427) is a second generation antisense oligonucleotide 
that effectively down-regulates Hsp27 in vitro and in vivo; clinical studies are evaluating 
apatorsen in lung, bladder, prostate, and pancreatic cancers. Methods: The phase 
2, UK, investigator led, randomized, open-label trial Cedar trial was initiated in July 
2014. Eligible patients have confirmed Stage IIIB/IV squamous cell lung cancer and 
no prior chemotherapy for advanced disease, with ECOG score of 0-2 and adequate 
bone marrow, renal, and liver function; patients with known EGFR mutation or ALK 
rearrangements are excluded. Planned enrollment is 140 patients; randomization 
(1:1) is stratified by stage and performance status. Patients receive 21-day cycles of 
gemcitabine (1250 mg/m2) and carboplatin (AUC5) or gemcitabine/carboplatin plus 
apatorsen (600 mg IV/wk, preceded by 3 doses during a 9-day loading period) for up to 6 
cycles. Tumor evaluation occurs q6 wks. Patients randomized to apatorsen may continue 
weekly single agent maintenance until progressive disease (PD), unacceptable toxicity, 
or withdrawal of consent. The primary efficacy measure is progression-free survival. 
Secondary efficacy measures include objective response (OR), change in tumour size 
at 12 wks, clinical benefit rate, duration of OR/clinical benefit, overall survival, and 
proportion without PD at 12 and 24 wks. Efficacy analyses are intent-to-treat. Adverse 
events and laboratory results are assessed, and interim safety analyses are planned. 
Pre-specified subset analyses will characterize the relevance of Hsp27 expression in 
tumour and blood samples. Results: Not applicable. Conclusion: Not applicable. 
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POSTER SESSION/ TREATMENT OF ADVANCED DISEASES – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.01-080 An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate 
Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line 
Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell 
Lung Cancer (NSCLC) Tomohide Tamura1, Makoto Nishio2, Nobuyuki Yamamoto3, 
Yuichiro Ohe1, Katharina Wolff4, Mika Tsujimoto5, Sotaro Enatsu4, Kazuhiko Nakagawa6 
1Thoracic Oncology, National Cancer Center Hospital, Tokyo/Japan, 2Thoracic Medical 
Oncology, The Cancer Institute Hospital of Jfcr, Tokyo/Japan, 3Medical Oncology, Wakayama 
Medical University Hospital, Wakayama/Japan, 4Medical Science, Eli Lilly Japan, Kobe/
Japan, 5Statistical Science, Eli Lilly Japan, Kobe/Japan, 6Medical Oncology, Kinki University 
Faculty of Medicine, Osaka-Sayama/Japan
Background: Necitumumab (N) is a human IgG1 anti-epidermal growth factor 
receptor (EGFR) monoclonal antibody. Squamous (SQ) histology accounts for 25-30% 
of non-small cell lung cancer (NSCLC) and gemcitabine combined with cisplatin (GC) 
is a standard of care for advanced or metastatic SQ-NSCLC. In the previous global 
randomized, open-label, Phase 3 trial (SQUIRE), compared with GC, the addition of N 
to GC (GC+N) significantly improved overall survival (OS) (HR=0.84,p=0.012; median 
11.5 vs 9.9 months) and progression-free survival (PFS) (HR=0.85, p=0.020; median 
5.7 vs 5.5 months). The objective response rate (ORR) was 31% vs 29% (p=0.400), and 
the disease control rate (DCR) was 82% vs 77% (p=0.043), respectively. The SQUIRE 
results were an important advance in the search for a new treatment for patients with 
metastatic SQ-NSCLC, where limited progress has been made over the last two decades. 
Korea, 8Department of Internal Medicine, Yonsei Cancer Center, Seoul/Korea, 9College of 
Medicine, Kyung Hee University, Seoul/Korea, 10Department of Internal Medicine, Chungbuk 
National University, College of Medicine,, Cheongju,/Korea, 11Department of Oncology, 
University of Ulsan College of Medicine, Asan Medical Center, Seoul/Korea, 12Department of 
Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/Korea
Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor 
(EGFR) monoclonal antibody. We aim to evaluate the efficacy of dual inhibition of 
EGFR with nimotuzumab plus gefitinib in advanced non-small cell lung cancer (NSCLC) 
previously treated with platinum-based chemotherapy. Methods: An open label, 
randomized, phase II trial was conducted in 6 centers; 160 patients were randomized 
(1:1) to either nimotuzumab (200mg, IV weekly) plus gefitinib (250mg p.o. daily) or 
gefitinib alone until disease progression or intolerable toxicities. The primary endpoint 
was progression free survival (PFS) rate at 3 months. Secondary endpoints included 
PFS, overall survival (OS), overall response rate (ORR) and safety. Results: A total of 155 
patients (78 in nimotuzumab plus gefitinib, 77 in gefitinib) were evaluable for efficacy and 
toxicity. Patient characteristics were well balanced in both groups. Majority of patients 
had adenocarcinoma histology (65.2%) and ECOG performance status 0 to 1 (83.5%). 
Among 102 patients with EGFR mutation results available, activating EGFR mutation was 
documented in 27 patients (12/50 in nimotuzumab plus gefitinib, 15/52 in gefitinib). With 
a median follow-up of 12.1 months, PFS rate at 3 months was 37.2% in nimotuzumab 
plus gefitinib and 48.1% in gefitinib [HR 1.03; 95% CI, 0.71–1.40; P=0.98]. Median 
PFS and OS were 2.0 months and 14.0 months in nimotuzumab plus gefitinib and 2.8 
months and 13.2 months in gefitinib [HR 1.03, 95% CI 0.71-1.41, P=0.98 for PFS; HR 
0.86, 95% CI 0.57–1.30, P=0.47 for OS]. The ORRs were 14.1% in nimotuzumab plus 
gefitinib and 22.1% in gefitinib, which was not statistically significant (P=0.76). As 
expected, patients with EGFR mutation showed significantly longer survival than those 
with wild-type EGFR or unknown EGFR mutation status (10.3 vs. 1.2 vs. 2.7 months, P < 
0.001 for PFS; 23.5 vs. 13.5 vs. 10.5 months, P= 0.001 for OS). Combined treatment 
of nimotuzumab plus gefitinib did not show superior PFS compared to gefitinib alone 
in patients with EGFR mutation (13.5 vs. 10.2 months in gefitinib alone, P=0.30) and 
patients with wild-type EGFR (0.9 vs. 2.0 months in gefitinib alone, P=0.90). The 
median PFS was not significantly different between two treatment arms according to 
histology (2.8 vs. 2.9 months in gefitinib alone for adenocarcinoma, P=0.64; 1.2 vs. 2.8 
months in gefitinib alone for non-adenocarcinoma, P=0.35). Adverse events (AEs) in 
both treatment arms were mostly grade 1 to 2 and easily manageable. Importantly, 
combined EGFR inhibition with nimotuzumab and gefitinib did not increase EGFR 
inhibition-related AEs, such as acneiform rash (32.4 vs. 30.3% in gefitinib alone, P=0.38), 
diarrhea (30.7 vs. 35.7% in gefitinib alone, P=0.32), and stomatitis (11.5 vs. 13.4% in 
gefitinib alone, P=0.19). There was no treatment-related death. Conclusion: The 
dual inhibition of EGFR with nimotuzumab plus gefitinib did not show superiority 
over gefitinib alone for second-line treatment of advanced NSCLC (NCT01498562). 
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P3.01-078 Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in 
a Phase III Trial versus Docetaxel in Patients with Relapsing NSCLC Keunchil 
Park1, Johan Vansteenkiste2, Marcis Bajars3, Christoph Helwig4, Fabrice Barlesi5 
1Division of Hematology/Oncology, Innovative Cancer Medicine Institute, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul/Korea, 2Respiratory Oncology, 
University Hospital Ku Leuven, Leuven/Belgium, 3Global Research and Early Development 
- Immunooncology, Emd Serono, Inc., Billerica/MA/United States of America, 4R&D Global 
Biostatistics, Merck Kgaa, Darmstadt/Germany, 5Multidisciplinary Oncology and Therapeutic 
Innovations, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille/
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Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key 
therapeutic targets in the reactivation of the immune response against multiple cancers. 
Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently being 
investigated in clinical trials. The phase III study (NCT02395172) is an open-label, 
multicenter trial of avelumab compared with docetaxel in patients with non-small-cell 
lung cancer (NSCLC) that has progressed after treatment with a platinum-containing 
doublet. Methods: The primary objective of this head-to-head phase III study is to 
demonstrate superiority defined by overall survival (OS) of avelumab versus docetaxel 
in patients with locally advanced unresectable, metastatic, or recurrent NSCLC whose 
tumors express PD-L1 and whose disease has progressed following treatment with a 
platinum-containing doublet. Approximately 650 eligible patients (ECOG performance 
status 0-1 at trial entry, tumor archival material or fresh biopsy suitable for PD-L1 
expression assessment, histologically confirmed NSCLC, and known-negative ALK 
mutation status, among other inclusion and exclusion criteria), including 522 patients 
with PD-L1—positive tumors, will be randomized 1:1 to receive either avelumab at a dose 
of 10 mg/kg as a 1h intravenous (IV) infusion Q2W or docetaxel at a starting dose of 75 
mg/m2 (per label) by IV infusion Q3W. Patients will be stratified according to PD-L1 status. 
NSCLC histology and EGFR mutation status will be used to define 3 stratified levels for 
randomization: squamous cell, non-squamous cell/EGFR wildtype, and non-squamous 
cell/EGFR-activating mutations. Treatment will continue until disease progression, 
unacceptable toxicity, or any criterion for withdrawal occurs. Responses will be evaluated 
according to RECIST 1.1 and adjudicated by a blinded independent review committee. 
In addition to the primary endpoint of OS, secondary endpoints include progression-free 
survival, best overall response, quality of life assessments, and safety profile. Exploratory 
endpoints include duration of response, tumor shrinkage in target lesions per timepoint, 
immunogenicity, PK profile, and evaluation of molecular, cellular, and soluble markers 
in peripheral blood or tumor tissue that may be relevant to the mechanism of action of, 
or response/resistance to, avelumab. Safety profiling of trial drugs includes incidence 
of adverse events (AEs), serious AEs, and other assessments according to NCI-CTCAE 
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Background: In clinical practice, approximately one third of patients with advanced 
non-small cell lung cancer (NSCLC) is candidate at third-line treatment. Currently, only 
erlotinib is licensed with this indication. Recent studies (TAILOR and DELTA trials) have 
questioned the role of erlotinib in second-line therapy of patients with advanced EGFR 
wild-type NSCLC, suggesting an inferiority in survival compared to chemotherapy 
with docetaxel. For this reason, the use of erlotinib is gradually shifting to the third-
line. However, in this setting, chemotherapy drugs, such as gemcitabine or vinorelbine, 
could achieve similar survival results, with limited toxicity and lower costs than erlotinib. 
Therefore, the objective of this study is to evaluate the efficacy of chemotherapy 
(gemcitabine or vinorelbine) vs. erlotinib in the treatment of patients with advanced EGFR 
wild-type or unknown NSCLC progressing after two lines of chemotherapy in terms of 
overall survival (primary end-point). The treatments will be also compared in terms of 
activity, quality of life, toxicity and costs (secondary end-points). Methods: 538 patients 
will be enrolled from 40 clinical Italian centers and assigned by randomization to one 
of 2 treatment arms (chemotherapy vs. erlotinib) with a ratio of 1:1. As stratification 
factors will be considered: the center, histology (squamous vs. non-squamous), EGFR 
(wild type vs. unknown) and PS (0-1 vs. 2). Patients will be randomized to receive 
treatment with erlotinib 150 mg/day (control arm) or chemotherapy with gemcitabine 
1000 mg/m2 or vinorelbine 25 mg/m2 on days 1, 8 every 21 days (experimental arm), 
according to investigator choice and previous treatment received. Treatments will be 
administered until disease progression, patient refusal, unacceptable toxicity, patient 
clinical deterioration or investigator decision. It was estimated that with 440 deaths 
from any cause the study would have 85% power to detect a hazard ratio of 0.75 at 
a two-sided significance level of 5%. If the superiority comparison will fail to detect a 
significant difference between treatments, the non-inferiority of the chemotherapy 
arm will be tested with a power equal to 65% against a prospectively defined margin 
for non-inferiority of the HR equal to 1.25. Results: not applicable Conclusion: If 
this study should be positive, it will follow a change in clinical practice with an 
improvement in life expectancy of patients with advanced NSCLC and savings in 
terms of economic resources for the NHS. This study (CONFERMER trial) is supported 
by NHS, Regione Emila Romagna. As to 14 April 2015, 44 patients were randomized. 
Keywords: NSCLC, Third-line, Erlotinib, chemotherapy
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P3.01-083 Phase III Trial of PF-06439535 or Bevacizumab-EU plus Paclitaxel/
Carboplatin in NSCLC Bhardwaj Desai1, Danielle Rassam1, Patrick Ezeh2, Leah 
Isakov2, Ira Jacobs3, Julie A. Rosenberg4 1Pfizer Inc, San Diego/CA/United States of 
America, 2Pfizer Inc, Cambridge/MA/United States of America, 3Pfizer Inc, New York/NY/
United States of America, 4Pfizer Inc, Groton/CT/United States of America
Background: The recombinant, humanized, monoclonal antibody bevacizumab targets 
vascular endothelial growth factor (VEGF) and is approved globally, including in the United 
States (US) and European Union (EU), for the treatment of select solid tumors, including 
as a first-line therapy, in combination with platinum-based chemotherapy, for advanced 
non-squamous non-small cell lung cancer (NSCLC). PF06439535 is being developed as a 
potential biosimilar to bevacizumab and has the same primary amino acid sequence as EU- 
and US-sourced bevacizumab (bevacizumabEU and bevacizumabUS, respectively), with 
sufficiently equivalent physiochemical properties and comparable inhibition of VEGF/VEGF-
receptor binding in vitro. In a nonclinical model using sexually- and skeletally-immature 
male cynomolgus monkeys, PF06439535 showed similar toxicokinetic parameters to 
bevacizumabEU and no induction of anti-drug antibodies. In a phase I trial in healthy 
male volunteers, PF06439535 showed pharmacokinetic similarity to bevacizumabEU 
and bevacizumabUS and had a comparable safety profile. These strong foundational 
data supported implementation of a phase III study. This phase III, multinational, double-
blind, randomized, parallel-group clinical trial (NCT02364999) is evaluating the efficacy, 
safety, pharmacokinetics, and immunogenicity of PF06439535 versus bevacizumabEU, 
in combination with paclitaxel and carboplatin, in previously untreated patients with 
advanced non-squamous NSCLC. Methods: A total of 798 patients (399 per treatment 
arm) will be enrolled. Eligible patients are aged ≥18 years (or ≥ age of consent in the 
region), and have newly diagnosed stage IIIB/IV NSCLC or recurrent NSCLC with no 
prior chemotherapy for metastatic disease; predominantly non-squamous disease; ≥1 
measureable lesion per RECIST 1.1; Eastern Cooperative Oncology Group performance 
status 0/1; and adequate hematologic, renal, and hepatic organ function. Patients with 
known sensitizing mutations in epidermal growth factor receptor (EGFR ) or translocation 
positive mutations in echinoderm microtubule-associated protein-like 4-anaplastic 
lymphoma kinase (EML4-ALK) are excluded. Patients will be stratified by region, gender, 
and smoking status, and randomized 1:1 to receive PF06439535 or bevacizumabEU 
(15 mg/kg intravenously [IV]) plus paclitaxel (200 mg/m2 IV) and carboplatin (area 
under the curve 6 mg·min/mL IV) on Day 1 of 21-day cycles. Following 4–6 cycles of 
chemotherapy, patients will continue to receive PF06439535 or bevacizumabEU as 
blinded monotherapy every 3 weeks until disease progression or unacceptable toxicity. 
Tumors will be radiographically assessed every 6 weeks according to RECIST v1.1 until 
Week 25, after which tumor assessments will be performed every 9 weeks. The primary 
objective of the study is to compare objective response rate (ORR) achieved by Week 19 
between treatment arms; objective responses will be subsequently confirmed by 6 weeks 
thereafter. Secondary objectives include evaluation of safety, additional measures of 
tumor control (eg, duration of response and 1-year progression-free survival and overall 
survival rates), population pharmacokinetics, and immunogenicity. The main hypothesis 
to be tested is that the 90% confidence interval of the relative risk of ORR of PF06439535 
versus that of bevacizumabEU by Week 19 is within a pre-specified margin of 76%–132%. 
The study is open for enrollment. Results: Not applicable Conclusion: Not applicable 
Keywords: PF-06439535, bevacizumab, biosimilar, NSCLC
However, only 8% of patients in SQUIRE Trial were Asian and no Japanese institutions 
participated. We have therefore conducted this Phase 1b/2 trial to evaluate the efficacy 
and safety of GC+N in Japanese patients with advanced SQ-NSCLC. Methods: This 
trial consists of a Phase 1b and Phase 2 part. Patients with advanced (Stage IV) SQ-
NSCLC are eligible for enrollment if they are aged³20 years with an Eastern Cooperative 
Oncology Group performance status (ECOG PS) 0 or 1; measurable or nonmeasurable 
disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 
1.0; adequate organ function. GC+N or GC may continue for a maximum of 4 cycles; 
patients with at least stable disease in GC+N may continue to receive N until disease 
progression or emerging non-acceptable toxicity. The purpose of Phase 1b part is to 
determine the recommended dose of the combination of GC (G=1000 or 1250 mg/
m2 iv, Days 1 and 8; C=75 mg/m2 iv, Day 1; 3-week cycle) and N (800 mg iv, Days 
1 and 8; 3-week cycle). Patients are enrolled in 2 cohorts using a conventional 3+3 
study design, with dose-escalation of gemcitabine permitted according to the incidence 
of dose-limiting toxicity (DLT). The Phase 2 part is an open-label, randomized trial to 
evaluate the efficacy and safety of addition of N to GC. Patients are randomly assigned 
on a 1:1 basis (Stratification factors: ECOG PS and gender) to GC+N (Arm A) or GC (Arm 
B). The primary endpoint is OS for which the final analysis will be performed when at least 
137 events are observed. The sample size of 180 patients (137 events) has 68% power 
for a log-rank test at 0.2 one-sided alpha. The secondary endpoints include PFS, ORR, 
time to treatment failure, Pharmacokinetics, safety and patient-reported outcomes. The 
relationship between EGFR protein expression level by immunohistochemistry (IHC) and 
each of several efficacy measures will also be assessed. Translational research analyses 
will be performed to analyze relevant biomarkers for clinical outcomes. ClinicalTrial.
gov Identifier: NCT01763788. Results: Not applicable Conclusion: Not applicable 
Keywords: gemcitabine-cisplatin, necitumumab, squamous non-small cell lung cancer, 
trial in progress
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P3.01-081 Navotrial 3: Oral Vinorelbine + Cisplatin (P) vs Gemcitabine + P in 
1st Line Advanced Squamous Non-Small-Cell Lung Cancer Piotr Jaskiewicz1, 
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Background: Gemcitabine – cisplatin is one of the most frequent treatment used in 
patients with advanced S-NSCLC without any direct comparison with other active 
doublets and with superiority reported only versus pemetrexed-cisplatin (Scagliotti 
G., 2008). Oral vinorelbine-cisplatin is also one main standard doublet but no trial 
has been specifically conducted in S-NSCLC. The aim of the current study is to 
assess efficacy and safety of oral vinorelbine-cisplatin and gemcitabine-cisplatin 
in S-NSCLC patients (NAVoTRIAL 3). Methods: This is a phase II, international 
multicentre, randomised study (1:1). At baseline, patients must have stage IIIB 
or IV, squamous histologically or cytologically proven NSCLC, Karnofsky PS ≥70 
and must not have received prior systemic CT or immunotherapy for NSCLC. 
Patients in arm A will receive oral vinorelbine at the dose of 60 mg/m² in 
combination with cisplatin at the dose of 80 mg/m² on day 1, followed by oral 
vinorelbine, 60 mg/m² on day 8 at the first cycle; the dose is increased at the 
second cycle to 80 mg/m² in absence of haematological tolerance. Both agents are 
repeated every 3 weeks, followed by maintenance after four cycles for patients 
with OR/SD: oral vinorelbine at the same dose as cycle 4, day 1, 8 every 3 weeks. 
Patients in arm B will receive gemcitabine at the dose of 1250 mg/m² in combination 
with cisplatin 75 mg/m² on day 1, followed by gemcitabine, 1250 mg/m² on day 8. 
Both agents are repeated every 3 weeks, followed by maintenance after four cycles for 
patients with OR/SD: Gemcitabine at the same dose as cycle 4, day 1, 8 every 3 weeks. 
The primary endpoint is the disease control rate (NC, CR, PR, 
RECIST 1.1). Enrolment began in March 2013 and 110 patients will 
be recruited. Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, Oral Vinorelbine, Cisplatin, Gemcitabine
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P3.01-082 Multicenter Randomized Trial Comparing Erlotinib vs. Gemcitabine 
or Vinorelbine as Third-Line in Advanced EGFR-Wild-Type or Unknown NSCLC 
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years or older, have histologically or cytologically documented stage IIIb, IV or recurrent 
non-squamous NSCLC for which they had no received chemotherapy, ECOG performance 
status 0 or 1, and adequate organ function. Patients are randomly assigned to PB and DB 
arm (1:1). Bevacizumab is administered 15 mg/kg, pemetrexed is 500 mg/m2 and 
docetaxel is 50 mg/m2 every 3 weeks until disease progression or unacceptable toxicity. 
Selection design is adopted for this study. The planned sample size is 120 patients to 
yield 80 % power to select an optimal regimen correctly. Enrollment time is 2 years 8 
months and follow-up time is 1 year. The first patient on this clinical trial was enrolled in 
April 2014. Further details can be found on UMIN Clinical Trials Registry (UMIN000012786).
 
Results: not applicable Conclusion: not applicable 
Keywords: elderly, Clinical Trial in Progress, NSCLC, bevacizumab
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Varela4 1Department of Graduate Medical Education, University of South Florida, Moffitt 
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Background: Approximately 1.6 million people are diagnosed with lung cancer annually, of 
which 85% of cases are NSCLC. Due to limited efficacy of current conventional chemotherapy, 
the majority of patients face poor prognosis; thus, combining chemotherapy with agents 
targeting the tumor microenvironment may be a novel approach to improving survival 
outcomes. Pirfenidone (5-methyl-1-phenyl-1H-pyridine-one), an agent demonstrating 
activity against fibroblasts and growth-promoting cytokines (TGF-β1, fibroblast growth 
factor [FGF], epidermal growth factor [EGF], and platelet-derived growth factor [PDGF]), 
has demonstrated clinical efficacy in IPF but has not yet been studied in lung cancer. We 
propose a proof-of-concept trial testing a novel combination of pirfenidone plus standard 
first-line chemotherapy in the treatment of advanced-stage NSCLC. Pirfenidone 
Pirfenidone has demonstrated activity against growth-promoting cytokines such 
as TGF-β1, FGF, EGF, and PDGF. A recent Phase III clinical trial of pirfenidone 
compared to placebo in patients with IPF demonstrated improved lung function, 
exercise tolerance, and progression-free survival (PFS) with an acceptable side-
effect profile. To date, pirfenidone has not been studied in cancer, but its anti-
fibroblast properties may play an important role in the tumor microenvironment. 
Our hypothesis is that pirfenidone (by targeting CAFs) in combination with standard 
chemotherapy will act synergistically and proffer a more potent strategy for NSCLC 
treatment. Data Generated in Dr Antonia’s Lab at Moffitt Cancer Center 
Using low doses of pirfenidone (0.5 mg/ml), we observed a small decrease in cell 
proliferation (20%), also noted with low doses of cisplatin (10%). When both drugs were 
used, we observed a synergistic decline in proliferation (60%). An in vivo model was 
performed to verify this data: nude mice were inoculated with a combination of A549 
cells and CAF cells at a 1:1 ratio. Treatment with pirfenidone and cisplatin began as 
soon as tumors were palpable. Cisplatin- or pirfenidone-treated mice had a larger tumor 
size than mice treated with the combination, and on the final day (43 days after start of 
treatment), the combination showed statistically significant improvement compared to 
controls. This led to our hypothesis that similar tumor regression may occur in NSCLC 
patients.
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P3.01-084 Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in 
a Phase Ib Trial as a First-Line Treatment for Patients with Metastatic NSCLC 
Claire Verschraegen1, Sanjay Goel2, Franklin Chen3, David R. Spigel4, Nicholas Iannotti5, 
Marcis Bajars6, Anja Von Heydebreck7, Karen Kelly8 1Division of Hematology/Oncology, 
University of Vermont Cancer Center, Burlington/VT/United States of America, 2Montefiore 
Medical Center, Bronx/NY/United States of America, 3Novant Health Oncology Specialists, 
Forsyth Regional Cancer Center, Winston-Salem/NC/United States of America, 4Sarah 
Cannon Research Institute, Tennessee Oncology, Llc, North Nashville/TN/United States 
of America, 5Hematology Oncology Associates of the Treasure Coast, Port St. Lucie/FL/
United States of America, 6Global Research and Early Development - Immunooncology, 
Emd Serono, Inc., Billerica/MA/United States of America, 7R&D Global Biostatistics, Merck 
Kgaa, Darmstadt/Germany, 8University of California Davis Comprehensive Cancer Center, 
Sacramento/CA/United States of America
Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key 
therapeutic targets in the reactivation of the immune response against multiple cancers. 
Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently being 
investigated in clinical trials. The phase Ib study (NCT01772004) is an open-label, 
parallel group expansion trial in patients with metastatic or locally advanced solid tumors 
that includes a cohort of patients with non-small-cell lung cancer (NSCLC) who have 
not been previously treated for metastatic or recurrent disease. Prior to adding this 
first-line cohort, this study had enrolled a separate cohort of patients with NSCLC who 
had received a prior platinum-containing doublet regimen. Methods: This trial cohort is 
enrolling patients with histologically confirmed stage IV (according to IASLC) or recurrent 
NSCLC who have not previously received treatment for metastatic or recurrent disease. In 
addition, this cohort is restricted to patients without an activating EGFR mutation or ALK 
rearrangement. Patients with unknown EGFR or ALK status will be tested during screening 
and are required to have negative status for inclusion. Eligible patients also must have 
tumor archival material or fresh biopsy, an ECOG performance status of 0 or 1 at the 
time of trial entry, and disease with at least 1 measurable lesion according to RECIST 1.1. 
Exclusion criteria include prior therapy with immune checkpoint drugs or a known history 
of autoimmune disease. Up to 150 eligible patients will receive avelumab at 10 mg/kg as 
an infusion Q2W. Treatment will continue until disease progression, unacceptable toxicity, 
or any criterion for withdrawal occurs. Treatment may be continued despite progression 
according to RECIST 1.1 if the patient’s clinical status is stable and, according to 
investigator opinion, there is no need to start salvage therapy. The primary objective 
of the trial is to assess the safety and tolerability of avelumab as a first-line therapy. 
Select secondary objectives include: assessment of best overall response (BOR) and 
progression-free survival (PFS) according to RECIST 1.1; assessment of immune-related 
BOR and immune-related PFS (using modified Immune-Related Response Criteria); and 
assessment of overall survival. Association between tumor PD-L1 expression and efficacy 
will be evaluated. Immunomonitoring of cellular and soluble markers and intratumoral 
cellular surveillance will also be carried out. At each visit during the treatment phase, 
adverse events will be assessed and graded according to NCI-CTCAE v4.0. Tumor 
evaluation will be performed every 6 weeks until progression. Enrollment in this cohort 
began in March 2015. *Proposed INN. Results: not applicable Conclusion: not applicable 
Keywords: avelumab, NSCLC, PD-L1, MSB0010718C
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P3.01-085 Randomized Phase II Study of Docetaxel plus Bevacizumab or 
Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323) 
Toshiyuki Kozuki1, Naoyuki Nogami1, Natsumi Yamashita2, Tetsu Shinkai3, Takehito 
Shukuya4, Nobuhiko Seki5, Terufumi Kato6, Miyako Satouchi7, Noriyuki Masuda8, Koshiro 
Watanabe9 1Dept. of Thoracic Oncology and Medicine, National Hospital Organization, 
Shikoku Cancer Center, Matsuyama/Japan, 2Clinical Research Center, National Hospital 
Organization, Shikoku Cancer Center, Matsuyama/Japan, 3Dept. of Internal Medicine, 
Shonan East General Hospital, Chigasaki/Japan, 4Division of Respiratory Medicine, Juntendo 
University Faculty of Medicine & Graduate School of Medicine, Tokyo/Japan, 5Dept. of 
Medical Oncology, Teikyo University School of Medicine, Tokyo/Japan, 6Respiratory 
Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama/Japan, 7Department 
of Thoracic Oncology, Hyogo Cancer Center, Akashi/Japan, 8Dept. of Respiratory Medicine, 
Kitasato University School of Medicine, Kanagawa/Japan, 9Thoracic Oncology Research 
Group, Yokohama/Japan
Background: A randomized study comparing carboplatin plus weekly paclitaxel versus 
single-agent chemotherapy in elderly patients with non-small cell lung cancer (NSCLC) 
demonstrated a survival advantage for combination therapy, however, increased toxicity 
and treatment-related deaths were also observed. Thus, single agent approaches remain 
the standard of care and the improvement of treatment remains a challenge in elderly 
patients. The combination of bevacizumab and other platinum-based chemotherapies is 
the standard of care in non-elderly patients with non-squamous NSCLC. Additionally, a 
randomized phase II study suggested the improvement of efficacy for the combination of 
B plus single-agent pemetrexed or docetaxel compared with single-agent alone. Even in 
elderly patients, two prospective studies which we conducted demonstrated the 
feasibility of the combination of bevacizumab and single agent pemetrexed or docetaxel. 
Thus we plan this randomized phase II study (TORG1323) to select the optimal regimen 
for experimental arm of the future phase III study in elderly patients. Methods: TORG1323 
is an open label multicenter randomized phase II study to compare docetaxel plus 
bevacizumab (DB) with pemetrexed plus bevacizumab (PB). The primary endpoint is 
progression free survival (PFS, assessed by independent review committee). The 
secondary endpoints are safety, PFS (assessed by investigators), objective response 
rate, overall survival, time to treatment failure and quality of life. Eligible patients are 75 
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chemotherapy and there are limited data regarding the effect of afatinib in chemotherapy 
pre-treated EGFR mutation-positive patients. This study was designed to evaluate the 
effi cacy and safety of 40 mg/day afatinib in the second-line setting. Methods: Across 
centers in Europe, Asia and North Africa, 60 patients with locally advanced or metastatic 
NSCLC (stage IIIB/IV) harboring common EGFR mutations (Del19 and/or L858R) who 
have failed fi rst-line platinum-based chemotherapy will be recruited to this ongoing, 
single-arm, open-label, Phase IV trial. Patients will be treated with oral afatinib 40 
mg/day until the development of progressive disease or study discontinuation due to 
intolerable adverse events (AEs). Inclusion criteria include age ≥18 years, ECOG PS 0 or 
1, documented EGFR Del19 and/or L858R mutation with no other known EGFR mutation, 
and adequate organ function with a life expectancy of ≥3 months. Patients are excluded 
from enrolling if they have received >1 line of prior therapy for disease (radiotherapy and 
radiosensitizers and/or intrapleural administration of anti-cancer agents is not counted as 
a line of therapy), or received <3 cycles of platinum-based chemotherapy due to toxicity 
and/or intolerance of treatment, or received previous treatment with an EGFR-targeted 
tyrosine kinase inhibitor or antibody. The primary endpoint is objective tumor response 
(complete response [CR], partial response [PR]) according to RECIST v1.1. Secondary 
endpoints include PFS, disease control (CR, PR, stable disease) and assessment of safety. 
All patients who received at least one dose of afatinib will be included in the analysis of 
safety, with AEs graded according to CTCAE v3.0. Effi cacy and safety will be evaluated in 
a descriptive manner; there are no formal statistical hypotheses. This trial was initiated in 
October 2014 and is open for accrual. Study locations include 22 trial sites in 7 countries. 
Trial sites are currently open to enrollment in Egypt, Romania, and Serbia. Enrollment will 
soon be open in Malaysia, the Philippines, Poland, and Thailand. The estimated completion 
date for the primary outcome is December 2016; further details are available at 
ClinicalTrials.gov (NCT02208843). Results: Not applicable. Conclusion: Not applicable. 
Keywords: afatinib, NSCLC, EGFR mutated, Second-line
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P3.01-089 Nab-Paclitaxel with or without CC-486 as Second-Line Therapy 
for NSCLC (ABOUND.2L) Ramaswamy Govindan1, Andrea Ardizzoni2, Wilfried E.E. 
Eberhardt3, Pilar Garrido4, Amy Ko5, Daniel Morgensztern6, Petros Nikolinakos7, Teng 
Jin Ong8, Marianne Wolfsteiner8, Martin Reck9 1Washington University School of Medicine, 
St. Louis/MO/United States of America, 2Medical Oncology, S. Orsola-Malpighi University 
Hospital, Bologna/Italy, 3Department of Medical Oncology, University Hospital Essen, West 
German Cancer Centre, Ruhrlandklinik, University Duisburg-Essen, Essen/Germany, 4Irycis, 
Hospital Universitario Ramón Y Cajal, Madrid/Spain, 5Celgene Corporation, Summit/
NJ/United States of America, 6Oncology, Washington Univresity School of Medicine in 
St. Louis, St. Louis/MO/United States of America, 7University Cancer and Blood Center, 
Athens/GA/United States of America, 8Celgene Corporation, Summit/United States of 
America, 9Department of Thoracic Oncology, Lungen Clinic Grosshansdorf, Airway Research 
Center North (Arcn), Member of the German Center for Lung Research (Dzl), Grosshansdorf/
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Background: Many patients with advanced non-small cell lung cancer (NSCLC) will 
experience disease progression during fi rst-line chemotherapy. Effective and well-
tolerated second-line treatment options for this patient population are limited. In 
a multicenter phase III trial, fi rst-line treatment with nab -paclitaxel plus carboplatin 
(nab -P/C) signifi cantly improved the primary endpoint of overall response rate (ORR) 
compared with solvent-based paclitaxel plus C in patients with advanced NSCLC (33% 
vs 25%; P = 0.005; Socinski et al. J Clin Oncol. 2012;30:2055-2062). nab -P combined 
with CC-486, an oral formulation of azacitidine, resulted in promising outcomes in a 
phase I trial of patients with relapsed/refractory solid tumors (LoRusso et al. Mol 
Cancer Ther. 2013;12(11 Suppl):Abstract A120). In the open-label, multicenter phase 
II ABOUND.2L trial, the safety and effi cacy of nab -P with or without CC-486 will be 
evaluated in the second-line treatment of patients with advanced nonsquamous 
NSCLC. Methods: Approximately 160 patients who have received 1 platinum-containing 
chemotherapy regimen for treatment of advanced disease will be randomized 1:1 to CC-
486 200 mg/day on days 1 to 14 every 21 days plus nab -P 100 mg/m2 intravenously (IV; 
30-minute infusion) on days 8 and 15 every 21 days or nab -P 100 mg/m2 IV (30-minute 
infusion) on days 1 and 8 every 21 days. Key eligibility criteria include histologically or 
cytologically confi rmed advanced nonsquamous NSCLC, ECOG performance status ≤ 
1, adequate organ function, no active brain metastases, no prior taxane therapy, no 
known EGFR mutation or EML4-ALK translocation, and peripheral neuropathy grade < 2. 
Randomization will be stratifi ed by ECOG performance status (0 vs 1), sex, and smoking 
status (yes vs no). ClinicalTrials.gov identifi er NCT02250326.
Key Endpoints
Primary • Progression-free Survival
Secondary • Disease control rate -Overall Survival -ORR -Safety
Exploratory
• Changes in quality of life -Healthcare resource utilization 
throughout the study -Correlation between pretreatment tumor 
characteristics and response to treatment
Results: Not applicable Conclusion: Not applicable Keywords: nab, CC486, NSCLC, 
2nd line
Methods: Phase I, single-center, dose-escalation study. Phase I trial, followed by an 
expansion of 20 pts with non-squamous and 10 pts with squamous cell lung 
cancer. Primary Objectives: Determine safety, tolerability, and MTD of pirfenidone plus 
chemotherapy in pts with advanced NSCLC, and obtain the preliminary ORR. Secondary 
Objectives: Determine OS and PFS of pts treated with pirfenidone plus standard fi rst-line 
chemotherapy. Results: Not applicable Conclusion: Not applicable Keywords: non-
small cell lung cancer (NSCLC), tumor microenvironment, Cancer-associated fi broblasts 
(CAFs)
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P3.01-087 A Phase I Study of Exemestane with Carboplatin and Pemetrexed in 
Postmenopausal Women with Metastatic, Non-Squamous Non-Small Cell Lung 
Cancer Richard Pietras, Jonathan W. Goldman, Diana C. Marquez-Garban, Deborah 
J.L. Wong, Steven Applebaum, Melody Mendenhall, Blanca A. Ledezma, Brian Wolf, 
Carlos R. Adame, Sarah Rosales, Jill Paroly, Sebastian Paiz, Danielle Nameth, Marshall 
L. Spiegel, Naomi Hecht, Meghan Brennan, Steven M. Dubinett, Edward B. Garon David 
Geffen School of Medicine at University of California, Los Angeles/Translational Research in 
Oncology-Us Network, Santa Monica/United States of America
Background: Lung cancer is the most common cause of cancer-related deaths in the 
US, with adenocarcinoma being the most common histologic subtype. Aromatase, a 
critical rate-limiting enzyme in estrogen biosynthesis, is notably expressed in NSCLC 
cells. Retrospective studies show that high NSCLC aromatase levels are associated with 
worse clinical outcome, particularly in postmenopausal women (Weinberg et al., Cancer 
Res, 2005; Mah et al., Cancer Res, 2007; Garon et al., J Thoracic Oncol, 2013). Estrogens 
are known survival factors in lung and promote expression of nucleotide excision repair 
enzyme ERCC1 that is implicated in resistance to platinum-therapy. In NSCLC cells, ERCC1 
transcript expression is blocked by exemestane, an aromatase inhibitor (AI), enhancing 
cisplatin-induced apoptosis. In preclinical NSCLC xenograft models, exemestane exerts 
synergistic antitumor activity combined with cisplatin and results in prolonged tumor 
suppression (Marquez-Garban et al., Ann NY Acad Sci, 2009). These data provide a 
rationale to assess an AI in the clinic. Methods: Based on our preclinical studies, we are 
conducting a phase IB, open-label, single-center study in postmenopausal, treatment-
naïve (except prior single-agent tyrosine kinase inhibitor use) women with metastatic, 
non-squamous NSCLC (NCT 01664754). We plan to enroll 12-15 participants divided 
into two dose-escalation cohorts of exemestane. All participants receive standard 
chemotherapy with pemetrexed (500 mg/m2) and carboplatin (AUC 6), both given 
intravenously every 3 weeks. Cohort 1, which added exemestane 25 mg orally daily, has 
completed enrollment without any dose-limiting toxicities. Cohort 2, for which enrollment 
started in December of 2013, evaluates exemestane at 50 mg orally daily. Our primary 
aim is to evaluate safety and tolerability of the indicated regimen. Secondary objectives 
are tumor response rate, quality of life, pharmacokinetics/pharmacodynamics, and 
correlative studies of biomarkers (such as blood estrogens, tumor ERs, aromatase, and 
apoptosis) with tumor response. Results: Not applicable Conclusion: Not applicable 
Keywords: Estrogen, NSCLC, Post-menopausal women, Exemestane
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P3.01-088 Phase IV Study of Afatinib in Locally Advanced or Metastatic 
Non-Small Cell Lung Cancer Sumitra Thongprasert1, Cosmin Boldeanu2, Davorin 
Radosavljević3, Marina Petrović4, Hilary Jones5, Agnieszka Cseh6, Rabab Gaafar7
1Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai/
Thailand, 2Brăila County Emergency Hospital,, Brăila/Romania, 3Institute for Oncology 
and Radiology of Serbia, Belgrade/Serbia, 4Clinical Center Kragujevac, Kragujevac/
Serbia, 5Oncology Department, Boehringer Ingelheim Ltd., Bracknell/United 
Kingdom, 6Oncology Department, Boehringer Ingelheim Rcv Gmbh & Co. Kg, Vienna/
Austria, 7National Cancer Institute, Cairo University, Cairo/Egypt
Background: First-line afatinib, an oral, irreversible ErbB family blocker, improved 
progression-free survival (PFS), objective response rate and symptom control in patients 
with epidermal growth factor receptor (EGFR ) mutation-positive locally advanced or 
metastatic non-small cell lung cancer (NSCLC), when compared with standard platinum-
doublet chemotherapy. Afatinib also signifi cantly prolonged overall survival in patients 
with Del19 mutations. Some EGFR mutation-positive patients still receive fi rst-line 
S668 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
the thorax using the NovoTTF-100L System. The System is a portable medical device 
allowing normal daily life activities. The device delivers alternating electric fields 
to the thorax using 4 Transducer Arrays. Chemotherapy options include a taxane or 
gemcitabine platinum-based doublet. Results: not applicable Conclusion: not applicable 
Keywords: Tumor Treating Fields, First Line, advanced NSCLC, TTFields
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P3.02-001 Factors Affecting Tumor Recurrence in Early Stage Non-Small Cell 
Lung Cancer Narjust Duma1, Yulanka Castro1, Harry D. Harper2, Martin Gutierrez2 
1Internal Medicine, Rutgers-New Jersey Medical School, Newark/NJ/United States of 
America, 2Medical Oncology, Hackensack University Medical Center, Hackensack/NJ/United 
States of America
Background: For early stage non-small cell lung cancer (NSCLC) surgery is potentially 
the only curative treatment. However, a proportion of lung cancer patients develop 
recurrence, even after complete resection. The factors affecting recurrence in these 
patients are largely unknown. This study aimed to identify the predictive factors for 
recurrence in patients with stage I/II NSCLC. Methods: We retrospectively reviewed 
all patients diagnosed with stage I/II NSCLC at our institution from 2000 to 2013. Initial 
diagnosis at our institution and a minimum follow up of 36 months were required. Cox 
regression model was used for multivariate analysis. Results: A total of 673 patients with 
stage I/II were identified, of those 175 (26%) developed local or distant recurrence, with a 
median time to recurrence of 18 months. Median age was 74 (range: 44-96 years), 56% 
were current or former smokers. Patients were more likely to have upper lobe tumors 
than all other tumor locations combined (58% vs 42%), adenocarcinoma was the most 
prevalent histologic subtype (53%) and 47% had poorly differentiated or anaplastic 
tumors. 152 patients (87%) received surgery with lobectomy being the most common 
procedure followed by wedge resection. 24% received chemotherapy and 7% radiation. 
Median overall survival was 26 months (95%CI: 17.2-34.5). Patients with squamous cell 
carcinoma had a shorter median time to recurrence when compared with adenocarcinomas 
(13.2 months vs. 19.7 months) (p<0.02). Smoking history (HR: 1.98, 95%CI: 1.62-2.82, 
p<0.007), central tumor location (HR: 1.24, 95%CI: 1.09-1.56, p<0.01), squamous 
subtype (HR: 1.46, 95%CI: 1.22-1.84, p<0.002) , high histologic grade (HR: 2.76, 95%CI: 
1.34-5.97, p<0.01) and lymphovascular invasion (HR: 4.3, 95%CI: 3.32-5.00, p<0.001) 
were independent predictors of recurrence by multivariate analysis. Poorly differentiated 
tumors were associated with a higher frequency of distant recurrence when compared 
with well differentiated tumors (OR: 2.7 vs. 1.2). In 43% of the patients with recurrence 
lung cancer was the primary cause of death. Conclusion: In our cohort, we observed 
that patients with lymphovascular invasion have the highest recurrence risk followed 
by high histologic grade tumors with the former having a direct correlation with distant 
metastasis. Patients with these risk factors may benefit from close surveillance after 
surgical resection, adjuvant therapy and aggressive management of local recurrence. 
Keywords: recurrence, early stage non-small cell lung cancer, Risk factors for 
recurrence, patients follow up
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P3.02-002 Long-Term Survival of Patients Undergoing Video Assisted 
Thoracoscopic Anatomical Resection for Stage I NSCLC Is Equivalent 
to Open Thoracotomy Diego M. Avella1, Ujala Bokhary2, Brittany Lapin3, Ki W. 
Kim2, John Howington2 1Surgery, University of Chicago, Chicago/IL/United States of 
America, 2Thoracic Surgery, Northshore University Healthsystem, Evanston/IL/United States 
of America, 3Thoracic Surgery, Northshore University Healthsystem, Evanston/United States 
of America
Background: We analyze the long-term survival of patients that underwent video assisted 
thoracoscopic (VATS) anatomical lung resection for Stage I Non-small cell carcinoma 
(NSCLC) of the lung before at the Northshore University Health System Methods: This 
is a retrospective analysis of data from patients that underwent VATS lung anatomical 
resection before December 31st of 2010.We extracted the data through standard 
queries and by manual extraction from the Electronic Data Warehouse of the Northshore 
University Health System. The patients were selected based on surgical description 
of anatomical resection defined as lobectomy, bilobectomy or segmentectomy for 
proven NSCLC. Patients with more than one procedure performed, diagnosis of 
carcinoid tumor or incomplete data were excluded. The variables evaluated included 
demographics, preoperative workup and clinical evaluation, pathology reports, intra-
operative data and post-operative outcomes and 3 and 5 years overall and disease free 
survival. Results: A total of 265 patients were included. The mean age at the time of 
diagnosis was 70.9 (±9.9) years, 68.5% were female, 84.3% were Caucasian with a 
39.6 (±26.3) pack year smoking history. The most common comorbidities encountered 
were hypertension (66.3%), COPD (34.8%) and coronary artery disease (28.1%). VATS 
lobectomy was performed in 90% of the patients. FEV1 data was available in 91.1% of the 
patients whereas DLCO data was available in 84.3% of the patients that underwent VATS 
anatomical resection. The mean procedure time was 151 (±59) minutes; the median 
length of chest drainage with tube thoracostomy was 3 days. Eighteen (20.2%) patients 
required admission to the Intensive Care Unit (ICU) with a median length of stay in the 
ICU of 2.2 days. The median length of stay in the hospital was 3.6 days. There were 
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P3.01-090 Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After 
Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC) 
Byoung Chul Cho1, Joo-Hang Kim1, Augusto Villegas2, Nicolas Frusch3, Shuji Murakami4, 
Kelvin Shi5, Ramy Ibrahim5, Marc Ballas5, Scott J. Antonia6 1Yonsei Cancer Center, 
Severance Hospital, Yonsei University Health System, Seoul/Korea, 2Cancer Specialists of 
North Florida, Jacksonville/FL/United States of America, 3Centre Hospitalier de L’Ardenne, 
Libramont/Belgium, 4Kanagawa Cancer Center, Yokohama, Kanagawa/Japan, 5Astrazeneca, 
Gaithersburg/MD/United States of America, 6H. Lee Moffitt Cancer Center and Research 
Institute, Tampa/FL/United States of America
Background: Non-small cell lung cancer (NSCLC) accounts for 85–90% of all lung cancer 
cases. Approximately 35% of patients with NSCLC have Stage III disease at the time of 
diagnosis. Platinum-based, concurrent chemoradiation therapy is the standard treatment 
for patients with locally advanced, unresectable NSCLC. However, most patients 
progress despite treatment, and 5-year overall survival (OS) is only ~15%. Therefore, 
there is a significant unmet need for novel, effective therapeutic approaches to prolong 
survival. Immunotherapies that block checkpoints used by tumor cells to dampen 
immune responses are a promising new treatment option. Encouraging clinical activity 
against several tumor types has been seen for anti-PD-L1/PD-1 monoclonal antibodies 
(mAbs). MEDI4736 is a human IgG1 mAb that blocks programmed cell death ligand-1 
(PD-L1) binding to programmed cell death-1 and CD-80 with high affinity and selectivity, 
preventing PD-L1-mediated inhibition of T-cell activation. It has been engineered to 
harbor a triple mutation in the fragment crystallizable domain, which removes antibody-
dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Evidence 
of clinical activity for MEDI4736 in NSCLC has been observed in a Phase 1 study (Study 
1108, NCT01693562), with initial data indicating that PD-L1 expression is associated with 
a higher objective response rate (ORR). Chemotherapy and radiotherapy upregulate the 
expression of tumor PD-L1, which could increase sensitivity to PD-L1-directed therapy. 
Based on this rationale, the PACIFIC study (NCT02125461) will evaluate the efficacy and 
safety of MEDI4736 in patients with locally advanced, unresectable NSCLC (Stage III) 
whose disease has not progressed following platinum-based, concurrent chemoradiation 
therapy. Methods: In this Phase 3, randomized, double-blind, multicenter, international 
study, ~700 patients will be randomized 2:1 to receive MEDI4736 (10 mg/kg IV) or 
placebo every 2 weeks for up to 12 months. Eligible patients must have previously 
received ≥2 cycles of platinum-based concurrent chemoradiation with no subsequent 
disease progression, have received a total dose of radiation of ≥60 Gy, and have archival 
tissue available. Patients treated with sequential chemoradiation therapy for locally 
advanced disease and those with metastatic disease are excluded. Randomization must 
occur within 42 days of radiation. Co-primary endpoints are OS and progression-free 
survival (PFS) (RECIST v1.1). Secondary endpoints include OS at 24 months, proportion 
of patients alive and progression-free at 12 and 18 months, time to second progression, 
objective response rate, duration of response, health-related quality of life, safety/
tolerability, pharmacokinetics and immunogenicity of MEDI4736. Patients who achieve 
and maintain disease control up to 12 months will enter follow-up. Patients will be recruited 
at approximately 300 sites across Australia, Asia, Europe, North and South America and 
South Africa. Recruitment is ongoing. Results: Not applicable Conclusion: Not applicable 
Keywords: NSCLC, MEDI4736, PD-L1, Immunotherapy
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P3.01-091 Phase III Study of Front-Line Chemotherapy with TTFields for 
Advanced Squamous NSCLC Ori Farber1, Uri Weinberg2 1Novocure Ltd., Haifa/
Israel, 2Novocure Gmbh, Lucerne/Switzerland
Background: Tumor Treating Fields (TTFields) are a novel, non-invasive, anti-mitotic 
treatment modality, based on low intensity alternating electric fields. TTFields 
predominantly affect two phases of mitosis: metaphase – by disrupting the formation 
of the mitotic spindle, and cytokinesis – by dielectrophoretic dislocation of intracellular 
constituents. Efficacy of TTFields in non-small cell lung cancer (NSCLC) of all histologies 
has been demonstrated in multiple in vitro and in vivo models, as well as in a phase I/II pilot 
study, in combination with pemetrexed. At the time of this study, squamous histology 
patients were still treated with pemetrexed, and those enrolled in the trial surprisingly 
demonstrated a high median overall survival of 13.8 months. The promising preclinical 
data, high safety profile and initial clinical data in squamous histology patients have led 
to the design of the current study. Methods: The LUNAR Clinical Trial 300 patients 
with advanced NSCLC of squamous histology will be randomized in a ratio of 1:1 to 
receive either standard doublet chemotherapy alone or chemotherapy combined with 
TTFields. Patients will be followed-up every 6 weeks clinically and radiographically until 
intra-thoracic progression, then continue a follow up for vital status. Objectives To test 
the efficacy and safety of TTFields in combination with chemotherapy in this patient 
population. Endpoints Overall survival (primary), radiological response, progression 
free survival, in field vs. out of field time to progression, quality of life and safety 
(secondary). Statistical Considerations This is prospective, randomized, multicenter 
study for 300 patients. The total sample size of 300 patients (272 + 10% loss to follow 
up), will achieve a 80% power with an alpha of 0.05 using a two-sided log rank test 
to detect a hazard ratio of 0.69 for OS. Patients will be stratified based on presence 
of extra-thoracic disease (intra-thoracic disease only versus extra-thoracic disease), 
gender (male vs. female) and region. Key Eligibility Criteria Age > 18 years; Intra-
thoracic advanced (stage IV) NSCLC with squamous histology; No prior chemotherapy 
or biological therapy for advanced disease; No prior intra-thoracic radiotherapy for 
advanced disease; ECOG performance status of 0-1; No serious co-morbidities; 
No contraindication for chemotherapy or TTFields; Adequate bone marrow, liver and 
renal functions. Treatment Continuous, daily TTFields Therapy at 150 kHz, applied to 
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mutation. Among the mutations,15 are happened on exome 19 and 33 are on exome 21. 
PD-L1 positively expression imply a longer survival time compared with PD-L1negatively 
expression. Conclusion: Our results suggest a prognostic value of PD-L1 expression 
evaluation, which can also be a potentiall immuno-target therapy for lung cancer 
Keywords: lung cancer, PD-L1, Immunotherapy
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P3.02-005 Third Primary Lung Cancers: Incidence and Benefits of Surgical 
Therapy Dong-Seok Lee, Emanuela Taioli, Andrew Kaufman, Andrea Wolf, Daniel 
Nicastri, Faiz Y. Bhora, Fouad Lajam, Suresh Ramanathan, Raja Flores Thoracic Surgery, 
Mount Sinai Health System, New York/NY/United States of America
Background: Continued surveillance of lung cancer patients after curative surgery allows 
for the diagnosis of new disease. However, there is a relative paucity of data in regards to 
the development of third primary lung cancers. The goals of this study were to examine the 
incidence of third primary cancers and the results of surgical therapy. Methods: Surgically 
resected Stage 1 second primary lung cancers with complete data were identified in The 
Survival Epidemiology and End Results (SEER) database between 2004 and 2010. Among 
these 238 cases, those which developed a third primary lung cancer 6 or more months 
after the diagnosis of the second primary were analyzed. Statistical methods were 
performed using Kaplan-Meier and multivariate analysis. A p value < 0.05 was considered 
statistically considered significant. Results: Twenty-four patients (10.1%) experienced a 
third primary lung cancer; sixteen cases (66.7%) were diagnosed in stage I. Twelve patients 
(50% of cases) underwent cancer surgery. Nine patients (37.5%) were treated with beam 
radiation – alone (8 cases, 89%) or in combination with surgery (1 case, 11%). Surgery was 
performed more frequently in early stages (75% of surgical cases were stage I versus 58% 
of non-surgical cases). There was no difference in age between patients who underwent 
any treatment and those who did not. Length of follow-up in third primary cancers was 18 
months if surgically treated and 8 months if not surgically treated (p < 0.02). At multivariate 
analysis, the only independent predictor of improved survival was treatment (Hazard ratio 
(HR) 0.21, 95% CI: 0.07-0.66; p=0.007). Both surgery (HR=0.02; 95% CI: 0.002-0.29) and 
radiation (HR= 0.04; 95% CI: 0.002-0.54) significantly improved survival. 
 
Conclusion: The overall incidence of third primary lung cancers after a second primary 
is 10.1%. Surveillance and intervention at early stage results in improved survival. 
Keywords: lung cancer, Third primary, Surgery, radiation
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P3.02-006 How Should We Handle Elderly Patients of the Non-Small Cell Lung 
Cancer? Junichi Okamoto1, Hirotoshi Kubokura1, Jitsuo Usuda2 1Thoracic Surgery, 
Nippon Medical School Musashikosugi Hospital, Kanagawa/Japan, 2Thoracic Surgery, Nippon 
Medical School, Bunkyo-Ku/Japan
Background: In Japan, the ratio of lung cancer patients of octogenarian was still increasing 
in 2012. Elderly patients used to have comorbidities. Thus it is more difficult to select the 
surgical treatment of the elderly person in the lung cancer. Therefore, we aimed to clarify 
the preferred surgical management in this patient group. Methods: A retrospective 
study was conducted between April 2008 and March 2015 that included patients with 
non-small cell lung cancer (NSCLC) aged ≥75 years. Patients were divided into those who 
underwent partial resection and those who underwent lobectomy. Results: This study 
included 44 patients: 28 men and 16 women. We divided into two groups; one is partial 
resection (P-group) and another is lobectomy group (L-group). In patient’s characteristics, 
there were mostly no significant differences between two groups, without preoperative 
diabetes mellitus (p = 0.0271), tumor size on CT (p = 0.0002), operation time (p < 
0.0001), post-operative hospital days (p = 0.0003), or pathological tumor size (p < 
0.0001). In survival analysis, there were significant differences in overall survival (OS) 
between P-group and L-group (p = 0.0335). However, there was no significant difference 
in disease-free survival (DFS) rate among the two categories (p = 0.41), and in OS among 
stage I patients (p = 0.16). Postoperative complication caused poor prognosis (p = 
no deaths within 90 days post-surgery. The overall rate of complications was 25.8% 
with prolonged air leak (>5 days) (11.2%) and atrial fibrillation (9.0%) being the most 
frequent complications. The rate of adverse events decreased over time from 27.8% in 
2008 to 20% in 2010. Only one patient required a second intervention within 30 days 
of the first surgery for a persistent chylothorax. The median follow-up was 57 months. 
Recurrences occurred in 10.2% of the patients with a mean time of 1.7 (±1.0) years 
after surgery. Local recurrence occurred in 68.4% of the times 1.9(±1.09) years after 
surgery whereas distant recurrences occurred in 31.6% of the times 1.4(±0.89) years 
after surgery. Overall mortality was 16%. The 3- and 5-years overall survival was 86% and 
76.2%. The 3 and 5-years disease-free survival was 86.8% and 82.2% Conclusion: VATS 
anatomical lung resection does not seem to affect the long-term survival in comparison 
with reported analysis for open thoracotomy for patients with stage I NSCLC. Our data 
demonstrated a decreasing rate of complications with a high rate of cure for this group 
of patients, which might be utilized to compare with nonsurgical therapy for NSCLC 
Keywords: VATS, Stage I NSCLC
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P3.02-003 Availability of the Serum CYFRA 21-1 Level with Resected Non-
Small Cell Lung Cancer: The Detectability of Recurrence and the Prognostic 
Impact Mikiko Suzuki, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki Department of General 
Thoracic Surgery, Juntendo University School of Medicine, Tokyo/Japan
Background: The appropriate protocol of postoperative surveillance for patients 
with non-small cell lung cancer (NSCLC) is still controversial. The aim of this study is 
to evaluate the detectability of recurrence and the prognostic impact of the serum 
CYFRA 21-1 levels. Methods: We retrospectively reviewed 1076 patients who underwent 
surgical resection for NSCLC at Juntendo University Hospital, between January 2008 
and May 2013. Patients with renal dysfunction were excluded. Results: Recurrence 
developed in 47 patients (30.5%) in high preoperative serum CYFRA 21-1 group, 
and 147 patients (16.0%) in normal preoperative serum CYFRA 21-1 group. High 
preoperative serum CYFRA 21-1 was related to the high recurrence rate (p<.0001) 
and the poor prognosis (p<.0001). In high preoperative serum CYFRA 21-1 group, 111 
patients measured the serum CYFRA 21-1 level within the 1-3 months after surgery. 
Among them, 31 patients (27.9%) had an elevated serum CYFRA 21-1 level, and the 
poor prognosis (p<.0001) (Fig.). In 94 patients who measured the serum CYFRA 21-1 
level during the follow-up period, 35 patients (37.2%) could detect recurrence by an 
elevated serum CYFRA 21-1 level before recurrence. Only for high preoperative serum 
CYFRA 21-1 group, 23 patients (67.6%) could detect recurrence. Conclusion: High 
preoperative serum CYFRA 21-1 was related to the high recurrence rate and the poor 
prognosis. In addition, high early-postoperative (1-3 months after surgery) serum 
CYFRA 21-1 was related to the poor prognosis. Measuring the serum CYFRA 21-1 level 
during the follow-up period is useful in the detection of recurrence, but that rate is low. 
Keywords: NSCLC, CYFRA 21-1
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P3.02-004 PD-L1 Overexpression in NSCLC Inversely Correlated with Survival 
of NSCLC Patients Hua Zhong, Yan Zhou, Baohui Han, Xianxun Liu Pulmonary 
Department, Shanghai Chest Hospital, Shanghai/China
Background: Programmed cell death protein 1, also known as PD1, is a 288 amino 
acids cell surface protein in the immunoglobulin superfamily. [1] PD-1 is expressed 
on T-cells and pro-B cells, plays a pivotal role in their differentiation. [2] PD-1 has two 
ligands, PD-L1 and PD-L2, which are the members of a peripheral membrane protein 
family called B7. [3][4] PD-L1 can suppress immune system in some special events such 
as pregnancy and auto immune disease. Binding of PD-L1 with its receptor PD-1 on T 
cells delivers a signal that inhibits TCR-mediated activation of IL-2 production and T cell 
proliferation. [5] PD-L2’s expression is more restricted compare to PD-L1 and mainly 
in antigen-presenting cells like Dendritic Cells and microphages. [4] Here we report a 
study of 139 NSCLC patients diagnosed and undergone primary surgery in Shanghai 
Chest Hospital. The expression of PD-L1 was exanimated by immunohistochemistry, 
and has a positive correlation with the stage of NSCLC. We also observed a significant 
correlation between PD-L1 over expression and EGFR mutation, which has the potential 
to be an favorable prognostic factor. High PD-L1 expression and EGFR mutation also 
correlated with a significant longer survival time of patients Methods: One pathologist 
examined the H&E- and IHC-stained slides and evaluated the results. The evaluation were 
done blinded as to the clinical pathologic characteristics and patient outcome. A series 
of 139 patients diagnosed with NSCLC and undergone primary surgery at Shanghai 
Chest Hospital (Shanghai, China) from January to December of 2008 were selected in 
this study. All the patients received lobectomy standard with systematic lymph node 
dissection. Immunohistochemistry staining for PD-L1 were performed both for tumor 
and tissue surrounding the tumor.PD-L1 positivity (PDL1+) was defined as 5% tumor cell 
membrane staining at any intensity.One pathologist examined the H&E- and IHC-stained 
slides and evaluated the results. The evaluation were done blinded as to the clinical 
pathologic characteristics and patient outcome. Overall survival data were obtained for 
each patient by following up visit performed on 2014. Results: A total of 139 tumors 
were examined after exclusion of uninformative slides. There were 72 patients (54.1 
%) with stage II, and 61 (45.9 %) with stage III disease. For histological subtypes, there 
were 90 with adenocarcinoma, 43 with square carcinoma, and 6 with others. Of these, 
positive evaluation of PD-L1 staining was present in 81 (61.8 %) specimens, while 50 ( 
38.2 %) specimens showed negtive/low PD-L1 staining, while the tumor adjacent tissue 
showed also negtive/low PD-L1 expression .We also did genotyping for the specimens 
and found about one third of them (50 in a total 133 specimens, 33.3%) carry EGFR 
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P3.02-008 Clinical Characteristics of EML4-ALK Positive and Surgically 
Resected NSCLC Patients Hong Tao1, Yiran Cai2, Zhe Liu1, Liang Shi1, Junfang Tang1 
1Oncology, Beijing Chest Hospital，Capital Medical University, Beijing/China, 2Pathology, 
Beijing Chest Hospital，Capital Medical University, Beijing/China
Background: Along with the research progress of lung cancer-related driver genes, 
echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinas(EML4-
ALK) positive non-small cell lung cancer(NSCLC), which is a distinctive molecular 
subtype, has been concerned. In this study we evaluate the clinical features of 
EML4-ALK positive and postoperative NSCLC patients. Methods: Clinical data of 42 
patients with EML4-ALK positive, postsurgical NSCLC were retrospectively analyized. 
The organs of distant metastasis were observed. Log-rank test were used to analyse 
the relationship between clinical characteristics and disease free survival(DFS), 
overall survival(OS). Results: EML4-ALK positive patients are raletive young, most 
of them are never-smokers, peripheral type. The tumors were either moderately 
or poorly differentiated. The most common organ of distant metastasis was brain. 
Much more brain metastasis occurred in center type patients than in peripheral 
type patients(70.0% vs 30.0%，P=0.004).The median time from operation to brain 
metastasis was 17.2 months. The median post brain metastasis OS was 9.4 months. 
The DFS of earlier stage, peripheral type, moderately differentiated, without lymph 
node metastasis and with adjuvant treatment patients were significant longer than 
those of later stage(30.3months vs 12.8 months, P=0.016), center type(27.4months 
vs 7.3months, P=0.000), poorly differentiated(27.0 months vs 11.9months, P=0.048), 
with lymph node metastasis(30.0months vs 12.8months, P=0.027) and without adjuvant 
treatment(19.1months vs 1.8months, P=0.000) patients. Earlier stage, peripheral type, 
with adjuvant treatment patients obtained longer OS than later stage, center type, without 
adjuvant treatment counterparts（respectively 55.5months vs 26.2months，P=0.025; 
39.2months vs 20.9 months， P=0.003; 33.4months vs 15.7months，P=0.001）. Tab 1 
Clinical characteristics of paients
Characteristics No. of patients Percent(%)
Gender
Male 23 54.8
Female 19 45.2
Age(yr)
≤55 26 61.9
＞55 Median(range) 16 52(23-71) 38.1
Smoking history
Yes 13 31.0
No 29 69.0
Stage
Ⅰ stage 10 23.8
Ⅱ stage 3 7.1
Ⅲ stage 24 57.1
Ⅳ stage 5 11.9
Tumor location
Center type 12 28.6
Peripheral type 30 71.4
Histology
Adenocarcinoma 39 92.9
Squamous cell carcinoma 0 0
Adenosquamous carcinoma 1 2.4
Others 2 4.8
Differentiation degree
Well differentiated 0 0
Moderately differentiated 26 61.9
Poorly differentiated 16 38.1
0.0004). However, operation procedure did not correlate with postoperative morbidity. 
Cox regression analysis revealed statistical significance for the Brinkman Index(BI) (p 
= 0.0318), the ratio of the pulmonary artery diameter to the ascending aorta diameter 
(PA:A) (p = 0.0182), and the alveolar–arterial oxygen gradient (A-aDO2) (p = 0.0300). 
Only the PA:A ratio remained significant after multivariate analysis, with a higher ratio 
associated with better survival. Only the PA:A ratio remained significant after multivariate 
analysis, with a higher ratio associated with better survival, by Wilcoxon’s test (p = 
0.0376). Conclusion: In elder patients with NSCLC, surgical resection should not be denied 
by only age. However, operation procedure should select Partial resection, compare to 
Lobectomy, as much as possible, especially, with the higher patients of PA: A ratio. 
Keywords: Elderly patient, NSCLC, Operation, PA: A ratio
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P3.02-007 Survival and Prognostic Factor in Pathological N1 Non-Small-Cell 
Lung Cancer Taketsugu Yamamoto1, Takamitsu Maehara1, Munetaka Masuda2 
1Thoracic Surgery, Yokohama Rosai Hospital, Yokohama/Japan, 2Department of Surgery, 
Yokohama City University Graduate School of Medicine, Yokohama/Japan
Background: The 5-year survival rates of N1 non-small-cell lung cancer (NSCLC) were 
reported to be between 27% and 67%. The aim of the study was to identify common 
prognostic factors in NSCLC with N1 nodal involvement. Methods: The medical records 
and the follow-up data of the patients operated for NSCLC(p-N1) between January 1991 
and December 2013 in Yokohama Rosai Hospital were analyzed retrospectively. Fifty-
four patients with NSCLC (p-N1) who underwent lung resections with negative surgical 
margins were included in this study. Results: The subjects were 45 men and 9 women 
with a mean age of 67 years (range, 45-81 years). Among them 24 had adenocarcinoma, 
16 had squamous cell carcinoma, 6 had large cell carcinoma, and 8 had the other 
histologies. T-factor of the primary tumor was T1 in 12 patients, T2 in 34, T3 in 7, and 
T4 in 1. Among N1 disease, peripheral zone lymph node (#12,13,14) metastasis was 
18 cases, while hilar zone node(#10,11) metastasis was 30 cases, and both zone in 
6 cases. The overall 5-year survival rates were 54.7 % in N1 disease. In a univariate 
analysis, survival was worse in case of higher T factor (T3,4) (p<0.01), multiple-N1-
node involvement(p<0.01), and multiple-N1-zone involvement(p<0.01). Among patients 
with single-N1-zone involvement, overall survival was lower in patients with hilar zone 
metastasis than in those with peripheral zone metastasis, although this difference was 
not statistically significant (p=0.272).
 
Conclusion: In pN1 NSCLC patients, higher T-factor, multiple-N1-node 
involvement, and multiple-N1-zone involvement were worse prognostic factors. 
Keywords: NSCLC, N1 disease
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albumin level (4.0±0.7 vs 4.3±0.3 g/dl; p=0.003), and a long operative time (230±84 
vs 184±53 min; p=0.045). A tendency toward a longer stapler length used for the 
interlober fissure division was also shown in the patient with PAL (109±61 vs 77±68 mm; 
p=0.064). PAL was not influenced by age, BMI, preoperative serum total protein level, 
preoperative hemoglobin, preoperative total lymphocyte count, %VC, FEV1.0%, resected 
lobe, and pleural adhesions. Conclusion: We report that a male, a long smoking history, 
a preoperative low albumin level, and a long operative time increased the risk of air 
leak lasting more than 7 days following lobectomy for primary lung cancer. Pleural 
adhesion, which had been reported to be a risk factor of PAL, was not related with PAL. 
Our analysis suggests that, for the sake of preventing PAL, we should pay attention 
to the preoperative nutritional status as well as well as surgical techniques, such as 
interlober fissure division in the cases that need multiple stapling to complete fissures. 
Keywords: pulmonary air leak, lung cancer, Surgery, complication
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P3.02-010 Tumor Recurrence of the Chest Wall after Percutaneous Hook Wire 
Localization Hee Jong Baek1, Jongheon Park2, Du Hwan Choe2, Hyungjun Yoo2, Jae 
Soo Koh2, Cheol Hyeon Kim2, Im Il Na2, Sung Hyun Yang2 1Thoracic Surgery, Korea Cancer 
Center Hospital, Seoul/Korea, 2Korea Cancer Center Hospital, Seoul/Korea
Background: Increasingly, localization of small lung nodule (solid or ground glass) is 
needed for thoracoscopic resection of accurate diagnostic and/or curative intent. Hook 
wire implantation is one of important localization techniques. Meanwhile, tumor 
recurrence in the chest wall of the percutaneous FNA tract is well known in thoracic 
malignancy, particularly lung cancer. Methods: We report the case of a 64-year-old-man 
with tumor recurrence of the chest wall. Eight months earlier, he underwent hook wire-
guided thoracoscopic resection of RUL nodule and further anterior segmentectomy 
because of intraoperative diagnosis of NSCLC (squamous cell carcinoma, pT1aN0M0 
IA). Results: Location of the chest wall tumor was coincident with the hook wire tract. 
The tumor was resected en-bloc, and reported as a metastatic squamous cell carcinoma. 
Tab 2 Relationship between clinical characteristics and DFS, OS
Group DFS(month) P OS(month) P
Gender
Male 14.7 0.117 26.2 0.630
Female 18.8 32.8
Age(yr)
≤55 19.1 0.257 32.0 0.652
＞55 17.4 30.0
Stage
Ⅰ+Ⅱ stage 30.3 0.016 55.5 0.025
Ⅲ+Ⅳ stage 12.8 26.2
Tumor location
Center type 7.3 0.000 20.9 0.003
Peripheral type 27.4 39.2
Smoking history
Yes 7.0 0.167 22.9 0.524
No 17.4 32.8
Differentiation degree
Moderately differentiated 27.0 0.048 39.2 0.055
Poorly differentiated 11.9 26.2
Tumor diameter
>3cm 12.8 0.200 32.0 0.502
≤3cm 27.0 33.4
Lymph node metastasis
Yes 12.8 0.027 27.8 0.071
No 30.0 45.0
adjuvant treatment
Yes 19.1 0.000 33.4 0.001
No 1.8 15.7
 
Conclusion: EML4-ALK positive, postoperative NSCLC patients have distinctive clinical 
characteristics. The most common location of extrapulmonary metastasis was brain. DFS was 
associated with TNM stage, tumor location, differentiation degree, lymph node metastasis 
and adjuvant therapy. OS was related to TNM stage, tumor location and adjuvant therapy. 
Keywords: postoperative, brain metastases, Lung neoplasms, EML4-ALK positive
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P3.02-009 Predictors of Prolonged Air Leak after Pulmonary Lobectomy Satoru 
Okada, Junichi Shimada, Daishiro Kato, Hiroaki Tsunezuka, Kaori Abe, Tatsuo Furuya, 
Narumi Ishikawa Division of Chest Surgery, Department of Surgery, Kyoto Prefectural 
University of Medicine, Kyoto/Japan
Background: Prolonged air leak (PAL) is a common complication, which occurs 
in 3% to 25% of patients undergoing pulmonary resection. PAL may cause severe 
morbidity such as pneumonia and empyema, and prolong the need for chest 
tube drainage and hospitalization. Thus, a careful perioperative management to 
decrease the risk of PAL is needed. The purpose of this study is to analyze the 
significance of various risk factors for postoperative PAL (air leak longer lasting 
more than 7 days) in patients undergoing pulmonary lobectomy for lung cancer. 
Methods: This study includes 134 patients who underwent pulmonary lobectomy 
for lung cancer between September 2009 and December 2014 at Kyoto Prefectural 
University of Medicine. We usually approached through video assisted thoracoscopic 
surgery that used a mini-thoracotomy and two ports. The divided interlober fissures 
and the small pleural defects causing minor air leak were covered with bioabsorbable 
sheet and/or fibrin glue. The patients with pulmonary air leak lasting until postoperative 
day 7 underwent pleurodesis. We retrospectively analyzed the perioperative variables 
in the two groups of the patients with PAL or without PAL. All results were expressed as 
mean ± standard error (patients with PAL vs patients without PAL). P-value <0.05 was 
considered statistically significant. Results: PAL occurred in 17 patients (12.7%), lasting 
an average of 8.9 days. The patients were 16 men and 1 woman with a mean age of 70.3 
years old (58-79 years old). All patients underwent pleurodesis with successful closure 
of air leak and no patients required re-thoracotomy. Univariate analysis demonstrated 
significant independent predictors of PAL; a male predominance (94 vs 57% ;p=0.004), 
a high Brinkman index (960±580 vs 490±590; p=0.003), a preoperative low serum 
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sex, tumor size, histology, differentiation, lymphatic permeation, vessel invasion, 
pathological N2 location, pathological N2 number, and adjuvant chemotherapy, and 
classified them as the local recurrence group (recurrences limited to lymph nodes up 
to N3 or adjacent to the surgical margin), the distant recurrence group (in whom distant 
recurrence occurred within 6 months after local recurrence) and the no-recurrence 
group. Relationships between these clinical parameters and recurrence patterns (local 
or distant) were statistically assessed by Fisher’s exact test. Results: All 21 patients 
underwent lobectomies and systematic mediastinal nodal dissections that included 
upper mediastinal nodes and subcarinal nodes. Postoperatively, 17 patients underwent 
chemotherapy and none underwent radiotherapy. Recurrence was seen in 15 patients: 5 
local and 10 distant recurrences. Histologically, squamous cell carcinomas (SCC) were 
significantly more common in the local recurrence group (P=0.0358) at 3 SCC and 2 
adenocarcinomas (AD), compared with the distant recurrence group: 0 SCC and 10 AD; 
and the no-recurrence group: 2 SCC and 4 AD. No other clinical factors were significantly 
associated with recurrence. Notably, vessel invasion was seen in 80% of the local 
recurrence group, 90% of the distant recurrence group, and 17% of the no-recurrence 
group. Conclusion: Among patients with clinical N0 or N1 and pathological N2 NSCLC, 
postoperative radiotherapy was most suited to those whose pathology showed SCC. 
Keywords: pN2, postoperative radiotherapy, recurrence
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P3.02-013 Preoperative CT-Guided Percutaneous Localization of GGO with PA 
Injection Hu Mu Thoracic Surgery Department, Xuanwu Hospital Capital Mediacl University, 
Beijing/China
Background: Localization of ground glass nodule is a difficult challenge for thoracic 
surgeons, especially for those GGOs less than 10 mm in diameter. In this study we 
implant a new method for Preoperative localization of ground glass pulmonary opacity 
(GGO). Methods: From October 2013 to December 2014, CT-guided percutaneous 
Polylactic acid injection localizations were performed for 5 pulmonary nodules in 5 
patients (2 men and 3 women; mean age, 59.8 years; range, 54-65 years). 
 
Results: The injection was feasible in all patients and the localization effect was excellent, 
with total procedure duration 12.6 minutes (range; 10-15), Volume of Polylactic acid injected 
0.38ml (Table 2). The wedge resections were easily and successfully performed in 5 cases, 
the cutting margin was no less than 2cm from lesion. Conclusion: This technique will 
be promising for GGO location in facilitating thoracoscopic surgery for wedge resection. 
Keywords: percutaneous localization, glass pulmonary opacity, Preoperative, Polylactic 
acid injection
Conclusion: To reduce the risk of the tumor recurrence related with localization 
techniques, thoracic surgeons had better know very well the topographical anatomy of 
lung and avoid an unnecessary localization technique, and the wire is recommended 
to be withdrawn through the VATS port rather than percutaneously. This is the first 
report of tumor recurrence related with hook wire localization in the PubMed search. 
Keywords: lung cancer, tumor recurrence, hook wire localization
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P3.02-011 Evaluation of a New Chest Tube Management Using Digital Air Leak 
Monitoring after Lung Resection Koichi Yoshida, Yasufumi Kato, Yoshihisa Shimada, 
Keishi Otani, Junichi Maeda, Masaru Hagiwara, Masatoshi Kakihana, Naohiro Kajiwara, 
Tatsuo Ohira, Norihiko Ikeda Thoracic Surgery, Tokyo Medical University Hospital, Tokyo/
Japan
Background: The use of digital drainage systems after thoracic surgery is becoming 
accepted as a safe method. The aim of this study was to assess the effectiveness of 
the digital drainage system versus traditional devices on chest tube removal and air leak 
duration after lung resection. We report the management of a digital drainage system 
in patients undergoing lung resection. Methods: This study is retrospective study of 
patients undergoing anatomical lung resection (segmentectomy, lobectomy, sleeve 
lobectomy, or bilobectomy).145 patients who underwent lung resections for lung cancer 
were evaluated. Chest tubes were removed when an air leak was not evident anymore 
and the drained fluid was less than 200 mL/day. Results: These series includes 140 
lobectomies, 2 sleeve lobectomies, 1 bilobectomy and 2 anatomical segmentectomies. 
Patients who use digital drainage system had a significantly shorter air leak duration 
(0.9 versus 1.7 days; p=0.037), no significance of duration of chest tube placement 
(4.4 versus 5.5 days; p=0.112) and no significance of chest tube placement after 
the air leakage disappearance (3.5 versus 3.8 days; p=0.71). Conclusion: Patients 
managed with digital drainage system experienced a shorter duration of air leak 
compared with those managed with traditional devices. Digital devices appear to be safe 
and effective and may prove to be a useful tool in the management of lung resection. 
Keywords: digital drainage system, lung resection, Surgery, lung cancer
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P3.02-012 Post-Surgical Recurrence of cN0-1 and pN2 Non-Small-Cell Lung 
Cancer in Postoperative Radiotherapy Candidates Haruchika Yamamoto1, Yuji 
Hirami1, Kanmei Rai2, Ken Sato2, Keiichi Fujiwara2, Takuo Shibayama2, Toshirou Yonei2, 
Toshio Sato2, Tomohiro Toji3, Yoko Shinnou3, Akio Andou1 1Thoracic Surgery, National 
Hospital Organaization Okayama Medical Center, Okayama/Japan, 2Respiratory Medicine, 
National Hospital Organaization Okayama Medical Center, Okayama/Japan, 3Pathology, 
National Hospital Organaization Okayama Medical Center, Okayama/Japan
Background: Radiotherapy after initial surgery significantly improves outcomes in 
patients with pathological N2 non-small–cell lung cancer (NSCLC). Here, we aimed 
to identify best candidates for postoperative radiotherapy among patients with local 
recurrence. Methods: Among patients who underwent complete resections for NSCLC 
between August 2007 and December 2011 in our hospital, we enrolled all 21 patients 
with clinical N0–1 and pathological N2 NSCLC in this study. We assessed their age, 
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Hemostatic procedures with angiorrhaphy and/or using the sealant were defined as 
intraoperative unexpected bleeding in this study. The location, cause, management of 
injured vessels, and perioperative outcome, including blood loss, hospital stay, the rate 
of morbidity and mortality were investigated to compare those without vessel injured. 
Results: From 2007 to 2014, a total of 241 thoracoscopic anatomical pulmonary resection 
was performed. 20 (8.3%) cases were required hemostatic procedures with angiorrhaphy 
and/or using the sealant. 15 (75%) cases of 20 were converted to thoracotomy. Injured 
vessels were pulmonary artery (n=13), vein (n=3), azygous vein (n=3), and superior vena 
cava (n=1), respectively. In pulmonary artery, the injury was seen in first branch (n=5) and 
small branches to right upper lobe (n=5). The main causes of injured vessels were related 
to the technical problems of energy devices and staplers. 16 (80%) cases were direct 
suture, ligation or division of injured vessels, and 3 cases were successfully controlled 
by TachoSil without converted to thoracotomy. Blood loss of 20 cases ranged from 150-
2160 (median, 500) ml. 6 (30%) were administered with blood transfusion. Perioperative 
5 comorbidities were identified in 4 patients, consisted of prolonged air leak in 2 patients 
and atrial fibrillation, transient recurrent laryngeal nerve palsy, and chylothorax in each 
patient. No mortality was identified in this study. The difference between vessel injured and 
non-injured patients in operation time (285 vs 235 minutes, average, p=0.003) and blood 
loss (804 vs 121 ml, average, p<0.001) were significant, but perioperative comorbidities 
including respiratory and cardiovascular complications and the duration of chest tube 
insertion (4.5 vs 3.5 days, average, p=0.20) and postoperative hospital stay (12.7 
days vs 11.0 days, average, p=0.08) were not significant. Conclusion: The frequency 
of unexpected bleeding in this study was relatively high, but the management and the 
outcome of patients in this study were feasible in terms of safety. TachoSil is a useful 
sealant to be used next step for bleeding. For surgeons, it should be establish algorithms for 
this catastrophic intraoperative complication during thoracoscopic pulmonary resection. 
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P3.02-017 Preoperative Bronchoscopy in Patients with Persistent Ground-
Glass Nodule Byung Woo Jhun, Sang-Won Um, Hojoong Kim, Jhingook Kim, Kyung Soo 
Lee, Joungho Han Samsung Medical Center, Seoul/Korea
Background: There are no accurate data on the diagnostic value of preoperative 
flexible bronchoscopy (FB) for persistent ground-glass nodule (GGN) of the lung. 
We evaluated the value of preoperative FB in patients with suspected GGN-type lung 
cancer. Methods: We retrospectively searched a database for subjects who had 
‘ground-glass opacity’, ‘non-solid nodule’, ‘part-solid nodule’, or ‘sub-solid nodule’ on 
chest computed tomography reports between February 2004 and March 2012. Patients 
who had infiltrative ground-glass opacity lesions, mediastinal lymphadenopathy, or 
pleural effusion, focal ground-glass opacity lesions >3 cm, and were lost to follow-up 
were excluded. We assessed the diagnostic value of preoperative FB in patients with 
persistent GGNs who underwent surgical resection. Results: In total, 296 GGNs were 
evaluated by FB in 264 patients with persistent GGNs who underwent preoperative FB 
and surgical resection. The median size of the GGNs was 18 mm; 135 (46%) were pure 
GGN and 161 (54%) were part-solid GGN. No visible tumor or unsuspected endobronchial 
metastasis was identified by preoperative FB. Only 3 (1%, 3/208) GGNs were identified 
preoperatively as malignant by bronchial washing cytology; all were part-solid GGNs. No 
other etiology was identified by FB. Of the GGNs, 271 (91%) were subsequently confirmed 
as malignant and 25 (9%) were confirmed as benign at surgical resection. Consequently, 
the overall diagnostic sensitivity and negative predictive value of preoperative FB on a 
per-nodule basis was 1% (3/271) and 8% (25/293), respectively. The preoperative FB 
did not change the surgical strategy. Conclusion:Preoperative FB did not add much to 
the evaluation of persistent GGNs of the lung. Routine preoperative FB may have limited 
value in surgical candidates, especially in patients with small persistent pure GGNs. 
Keywords: lung cancer, ground-glass, nodule, bronchoscopy
POSTER SESSION/ TREATMENT OF LOCALIZED DISEASE – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.02-018 Factors Associated with Preserved Pulmonary Function in Non-
Small Cell Lung Cancer Patients after Video-Assisted Thoracic Surgery Choon-
Taek Lee, Se Joong Kim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jae 
Ho Lee Internal Medicine, Seoul National University Bundang Hospital, Seongnam/Korea
Background: Some non-small cell lung cancer (NSCLC) patients showed preserved 
pulmonary function after surgery. Video-assisted thoracic surgery (VATS) is currently 
widely performed and well known to preserve pulmonary function compared to open 
thoracotomy. However, it is unknown which factors are associated with the preservation 
of pulmonary function after VATS in NSCLC patients. Methods: Three hundred and 
fifty one patients with NSCLC who underwent VATS were enrolled. Pulmonary function 
tests were performed preoperatively and at 12 months postoperatively. Patients who 
showed preserved forced expiratory volume in 1 second (FEV1) and diffusing capacity of 
carbon monoxide (DLCO) were compared with patients who did not. Results: FEV1 was 
preserved after VATS in 65 (18.5 %) patients. They were significantly related to 
undertake VATS sublobar resection (P<0.001) and resect at right upper lobe (RUL) or 
right middle lobe (RML) (P<0.05) in multivariable analysis. DLCO showed preservation 
in 95 (27.1%) patients. VATS sublobar resection (P=0.005), lower baseline DLCO 
(P<0.001) and RUL or RML resection (P<0.05) were significantly associated with 
DLCO preservation in multivariable analysis. Conclusion: For the preservation of 
pulmonary function after NSCLC surgery, VATS sublobar resection was superior to 
VATS lobectomy and the surgical location of RUL or RML was superior to other sites. 
Keywords: VATS, Pulmonary Function, non-small cell lung cancer
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P3.02-014 COPD Being Misdiagnosed in Lung Cancer Patients with Thoracic 
Operation Guifang Wang1, Pang Shuai2 1Department of Pulmonary Diseases, Huashan 
Hospital, Shanghai/China, 2Department of Pulmonary Diseases, Changzheng Hospital, 
Shanghai/China
Background: Chronic obstructive pulmonary disease (COPD) is a risk factor and 
important coexisting disease for lung cancer; at the same time, coexisting COPD owes 
unfavorable effect on management of lung cancer. However, the current status of 
management of COPD in lung cancer patients with operable sites is not fully described. 
This study addressed this issue in a general teaching hospital in China. Methods: All 
patients with lung cancer underwent surgery were collected retrospectively from 
Jan. 2002 to Dec. 2008. Medical records were reviewed about clinical information, 
pathological records, lung functions, etc., so as to analysis comorbidity rate about COPD 
and characters. The definition of COPD was according the spirometric criteria of the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) document. The diagnostic 
rate (COPD recorded as a discharge diagnosis/spirometry-defined percentage) and 
conformity to GOLD treatment guidelines were investigated. The factors influencing 
diagnosis were analyzed. Results: Among all 437 undergone surgery patients aged 
older than 40 years old, 94 patients were diagnosed COPD, the prevalence of COPD was 
21.36%(41 as GOLD 1, 52 as GOLD 2, and 1 as GOLD 3)。Among them, 89.36% was male, 
with average age being 63.3 years old. Only 9 patients were diagnosed as COPD, the 
rate of misdiagnosis was 90.4% and all of them did not receive pulmonary function test. 
71.3% of those patients with COPD had smoke history; average smoke intensity was 26.7 
pack-year. All surgery of pathological staging were classified as followed according to 
the standards of the Union International Contre le Cancer (UICC):Ⅰstage (A+B：38+119); 
Ⅱ(A+B：14+83); Ⅲ(A+B：100+32); IV: 31; No specific: 20 cases. And patients 
complicated with COPD presented stages as followed:Ⅰstages (A+B：6+23)、Ⅱ(B：21); 
Ⅲ(A+B：33+7); IV: 1; No specific: 3 cases. The rate of lung cancer complicated with 
COPD was 24.8%, 21.6%, 30.3% respectively. Conclusion: Patients of lung cancer 
undergone surgery have high risk morbidity of COPD. To improve the result of peri-
operation period management, COPD should be pay attention to treat for these patients. 
Keywords: lung cancer, complication, copd
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P3.02-015 Impact of a Lung Multidisciplinary Team Meeting Casey Lo, Sean 
Galvin, Prakash Balakrishnan Cardiothoracic Surgery, Wellington Regional Hospital, 
Wellington/New Zealand
Background: Multidisciplinary team meetings (MDM) have become the standard of 
practice across a variety of medical disciplines. In particular, MDMs have found utility 
in the management of complex diseases requiring multi-modal treatment such as 
cancer. Advancements in information sharing technology have extended the reach 
of MDMs to improve care in previously remote and underserved areas. Lung cancer 
management is now largely directed through MDMs. However, MDMs are, by their very 
nature, resource intensive. In a world of increasing accountability for the distribution of 
limited resources, a review of the evidence for benefit of MDMs, as well as the different 
strategies employed in running a successful MDM, is necessary to ensure efficient 
provision of this care. Methods: A review of the existing peer-reviewed literature on 
MDM was conducted on Pubmed, using the broad search term of “multidisciplinary team 
meeting.” Existing reviews and original research were included, while non-English studies 
and letters were excluded. Results: Introduction of MDMs have been attributed to a 
variety of positive outcomes in the management of multiple oncological diseases. While 
there are a handful of studies questioning the cost-benefit of MDM without adequate 
patient selection in colorectal cancers, the evidence for improving management in 
most cancers (including lung cancer) is strong. An additional benefit is the increased 
reach of clinical trials, with MDMs being demonstrated to improve subscription rates. 
However, while lung MDMs have been demonstrated to make significant improvements 
to the overall care of a lung cancer patient, the evidence for improved survival remains 
limited. The limited impact of lung MDM to overall survival may be at least partially 
attributable to the late-presenting nature of the disease. This may be exacerbated by 
geographical limitations of some healthcare networks. However, with improvements in 
health informatics and telemedicine, standardising early care across a vast region has 
been shown to be possible and improve outcomes in other cancers. Conclusion: While 
it is clear that disease management is improved with the introduction of lung MDM, 
further study is needed to optimise its efficacy and define its impact on survival. 
Keywords: MDM, multidisciplinary, outcomes, survival
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P3.02-016 How to Manage for Unexpected Bleeding During Thoracoscopic 
Anatomical Pulmonary Resection Takuro Miyazaki, Naoya Yamasaki, Tomoshi 
Tsuchiya, Keitaro Matsumoto, Takeshi Nagayasu Surgical Oncology, Nagasaki Graduate 
School of Medicine, Nagasaki/Japan
Background: The number of thoracoscopic pulmonary resection has been increasing due 
to the less invasiveness and development of endoscopic instruments and perioperative 
management of the patients. However, the intraoperative unexpected bleeding cases 
which required emergent conversion to thoracotomy were gradually reported. The aim of 
this retrospective study was to review our experience, management, and the outcome of 
unexpected bleeding during thoracoscopic surgery. Methods: All patients who underwent 
thoracoscopic anatomical pulmonary resection for primary lung cancer were analysed. 
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P3.02-021 Lung Cancer Surgery: A 30 Years Monocentric Experience in 
Tunisia Tarek Kilani1, Sadok Boudaya1, Adel Marghli1, Hazem Zribi1, Sarra Zairi1, Tahar 
Mestiri1, Faouzi Mezni2, Hammouda Boussen3 1Thoracic and Cardiovascular Surgery, 
Abderrahmane Mami Hospital, Ariana/Tunisia, 2Pathology, Abderrahmane Mami Hospital, 
Ariana/Tunisia, 3Medical Oncolog, Abderrahmane Mami Hospital, Ariana/Tunisia
Background: The results of lung cancer surgical treatment depend on several factors 
inherent to the tumour, the patient and the socio-economic context in which the disease 
is managed. Few studies have described the results of surgery for lung cancer in 
emerging countries, particularly in Africa. The objective of this study was to report a 
large monocentric experience of a North African country. Methods: The results of lung 
cancer surgical treatment depend on several factors inherent to the tumour, the patient 
and the socio-economic context in which the disease is managed. Few studies have 
described the results of surgery for lung cancer in emerging countries, particularly in 
Africa. The objective of this study was to report a large monocentric experience of a 
North African country. Results: There were 1485 males and 196 females (sex ratio 
7.57) with a mean age of 58 (range 10-91). Clinical findings were dominated by thoracic 
symptoms and 176 (10.4%) were asymptomatic. Imaging findings showed a peripheral 
mass in 883 cases (52.5%). The mean tumour size was 5.3 cm (range, 1 – 20 cm). 48 
patients received induction therapy (this treatment was not prescribed before 2009). 
Lobectomy or bilobectomy was performed in 1036 patients (61.6%) and pneumonectomy 
in 448 patients (26.6%), thoracotomy was exploratory in 153 cases (9.1%), the rate of 
exploratory thoracotomy has fallen at 4.5% in the last 10 years (2003 to 2012). The 
histology diagnoses were: squamous cell carcinoma (n=693), adenocarcinoma (n=622), 
carcinoid tumour (n=135). Different stages were: IA (n=167), IB (n=523), IIA (n=56), IIB 
(n=393), IIIA (n=244), IIIB (n=188) and IV (n=109). There were 4 operative deaths. 69 died 
within 1 month of surgical complications. Post operative course was uneventful in 1203 
patients (71.5%) and the most frequent post operative complication was persistent air 
leak. Post operative mortality was 4.3% (within 30 days PO), 3.47% for lobectomies and 
6.25% for pneumonectomy. Adjuvant therapy was performed in 157 patients. The median 
survival time was 45 months with a maximum of 276 months. The overall 5-year survival 
rate was at 30% and it was at 67%, 41%, 44%, 24%, 17%, 3% and 13% respectively for 
stages IA, IB, IIA, IIB, IIIA, IIIB and IV. Survival was influenced by sex; age over 70 years, 
tumour size, nodal status, tumour stage and surgical procedure. By cons, post operative 
radiotherapy and neoadjuvant chemotherapy did not significantly improve the prognosis 
of our patients. Conclusion: Our 30 years experience initiated in 1985 of surgery for 
lung cancer demonstrated that major thoracic surgery is feasible with good early results 
and low mortality and morbidity rates. Survival rates are lower than those of the world 
literature; this may be related to the more advanced stages of our series and the lack 
to a complete assessment of the patients: number of patients did not have CTscan in 
the beginning of the series, and nowadays we don’t yet have PET scan in our country. 
Keywords: survival, lung cancer surgery, emerging country, results
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P3.02-022 The Digital Monitoring of Postoperative Air Leak Patterns and 
Air Leak Flow Is Useful for Predicting Prolonged Air Leak after Pulmonary 
Resection Kazuya Takamochi1, Kota Imashimizu1, Tatsuo Maeyashiki2, Mikiko Suzuki2, 
Takuya Ueda2, Kenji Suzuki1, Shiaki Oh1 1Juntendo University School of Medicine, Tokyo/
Japan, 2General Thoracic Surgery, Juntendo University School of Medicine, Tokyo/Japan
Background: The presence of prolonged air leak (PAL) after pulmonary resection 
sometimes results in serious complications, such as empyema. Therefore, early 
prediction and intervention for PAL should be performed. ThopazTM is a digital 
monitoring thoracic drainage system which enables the objective evaluation of air 
leak. This study aimed to establish the diagnostic criteria for the early prediction of 
PAL using the ThopazTM system. Methods: The postoperative data of 150 patients 
who underwent pulmonary resection and for whom the digital monitoring of thoracic 
drainage was performed using ThopazTM between December 2013 and January 2015 
were prospectively collected. When the air flow level was < 20 mL/min for > 12 hours, 
the chest tube was removed. We examined the postoperative data, including the chest 
X-ray findings, the presence of postoperative complications, the duration of air leak, the 
duration of chest tube placement, the patterns of air leak until 72 hours after operation 
and the level of peak air flow until 24 hours after operation as determined by ThopazTM. 
The patterns of air leak were defined as Types A-E (A: No air leak was observed until 
the removal of the chest tube; B: Air leak flow gradually decreased; C: Although no 
air leak was observed immediately after operation, air leak occurred postoperatively; 
D: The repeated exacerbation and remission of air leak was observed; E: Air leak was 
observed without a trend toward improvement). Results: There were 100 men and 50 
women; 99 smokers and 51 never-smokers; and 119 cases of lung cancer and 31 cases 
of other diseases. Their surgeries included 23 wedge resections, 24 segmentectomies 
and 103 lobectomies. Air leak at the time of the sealing test during the operation was 
observed in 82 (55%) patients. Air leak was observed in 31 (21%) patients, in whom 
the mean (± SD) duration of air leak was 3.9 (± 3.7) days. The mean (± SD) duration 
of chest tube placement was 3.2 (± 1.9) days in the whole study population (n = 150) 
and 5.2 (± 2.7) days in the 31patients with postoperative air leak. On chest X-ray films, 
12 cases of subcutaneous emphysema and 4 cases of atelectasis were observed 
postoperatively. No complications associated with ThopazTM developed. PAL > 4 days 
was observed in 10 (6.7%) patients. The frequencies of PAL according to the air leak 
patterns were 0% (0/119) in type A, 23% (3/13) in type B, 20% (2/10) in type C, 50% 
(2/4) in type D and 75% (3/4) in type E. The frequencies of PAL according to the peak 
air flow were 11% (2/18) in < 100 ml/min, 62% (8/13) in ≥ 100 ml/min, 60% (6/10) in ≥ 
200 ml/min, 83% (5/6) in ≥ 400 ml/min and 80% (4/5) in ≥ 500ml/min. Conclusion: The 
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P3.02-019 Surgery in Elderly Patients ( > 70 Years or Older) with Non-Small 
Lung Cancer (NSCLC). Impact of Adjuvant Chemotherapy Hirsh Koyi1, Gunnar 
Hillerdal2, Karl Gustav Kölbeck2, Olov Andersson2, Per Bergman3, Lotta Orre3, 
Per Liv4, Eva Brandén1 1Department of Respiratory Medicine, Gävle Hospital, Gävle/
Sweden, 2Deartment of Respiratory Medicine, Karolinska University Hospital, Stockholm/
Sweden, 3Deprtment of Thoracic Surgery, Karolinska University Hopsital, Stockholm/
Sweden,4Centre for Research and Development, Uppsala University/County Council of 
Gävleborg, Gävle/Sweden
Background: Surgery remains the cornerstone of therapy for medically operable 
patients with early stage NSCLC. Differences in the frequency of surgery for patients 
with respect to their age, sex and socioeconomic deprivation have been described. Older 
patients have been found to be less likely to undergo surgery compared with younger 
patients even when they have similar performance status. Several randomized trials 
and meta-analyses have shown that adjuvant chemotherapy after resection of stages 
II–IIIA NSCLC improves survival. Methods: The medical records of all 164 patients ≥70 
years, who underwent surgery for NSCLC from 2003 to 2009 at our department, were 
reviewed retrospectively. Results: One-hundred twenty-six given no adjuvant therapy. 
Eigthy-seven (52.4%) were male. Median mean and range of age male patients was 75.0, 
74.8 and 70-85 years, while in females, these figures were 74.0, 75.5 and 70-84 years. 
Eighty-one (94.2%) of the males and 65 (82.3%) of the females were smoker/former-
smoker. In both sexes 99% had performance status 0-1. Eighty-one (93.1%) of male 
patients and 71 (89.9%) of the females were stage I-II. Adenocarcinoma was the common 
histology in both sexes (55% of the males and 67.1% of the females). Squamous cell 
carcinoma came in second place, 31% respectively 20%. Lobectomi performed in 61 
(84.1%) of the male patients and 62 (86.2%) female patients, left pneumonectomy in 6 
(7.3%) male patients and 5 (6.9%) in female patients, right pneumonectomy in 1(1.4%) 
female patient. One-hundred twenty-six (77%) did not receive adjuvant therapy, mainly 
because of age. Median overall survival among all was 7.2 years, in the non-adjuvant 
group was 6.7 years and 7.6 years in the adjuvant group (p=0.5712). Conclusion: This 
single-institution series demonstrates that surgical intervention for appropriately 
selected elderly patients with NSCLC results in improved overall survival. Surgery 
should, therefore, be strongly considered for select patients ≥ 70 years of age with 
stage I/II and select stage IIIA NSCLC who have adequate pulmonary reserve. 
Keywords: lung cancer, elderly, Surgery, adjuvant chemotherapy
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P3.02-020 What Factors Affect Postoperative Respiratory Function in the 
Patients Performed Sleeve Lobectomy Shunki Hirayama, Kazuya Takamochi, Shiaki 
Oh, Kenji Suzuki Department of General Thoracic Surgery, Juntendo University School of 
Medicine, Tokyo/Japan
Background: Prediction of postoperative forced expiratory volume in 1 second (FEV1.0) 
is known as the basis for surgical indications of lung resection. The 0.8L or less estimated 
postoperative FEV1.0 has been reported an increase in surgery related deaths. In fact, 
there are some cases that the postoperative FEV1.0 is less than prediction of postoperative 
FEV1.0. The postoperative respiratory function have been reported in segmentectomy 
and lobectomy, but little is known in sleeve lobectomy. Methods: Between January 2008 
and October 2014, 37 patients underwent sleeve lobectomy and evaluated respiratory 
function tests of preoperative and passing more than six months after surgery at the 
Juntendo university, Tokyo, Japan. We defined postoperative FEV1.0 / prediction of 
postoperative FEV1.0 ratio as postoperative FEV1.0 ratio. The patients were divided 
by postoperative FEV1.0 ratio into the 16 patients who evaluated postoperative FEV1.0 
ratio < 1 and the 21 patients who postoperative FEV1.0 ratio ≧ 1. We investigated 
clinic-pathological features, postoperative complications and predictive factors in 
postoperative reduction of FEV1.0. Results: In the group of postoperative FEV1.0 
ratio < 1, the median age was 63 years old (range, 35-77 years), 14 cases (88%) 
were male, the median postoperative FEV1.0 was 2.05L (range, 0.99-2.54) and the 
median prediction of postoperative FEV1.0 was 1.82L (range, 0.97-2.23). The group of 
postoperative FEV1.0 ratio < 1 had marginally more phrenic nerve resection (19%) and 
blood transfusion (50%) than the group of postoperative FEV1.0 ratio ≧ 1 (p=0.077 and 
p=0.072). There was no difference in the incidence of morbidity between both groups. 
The phrenic nerve resection was marginally risk factors of postoperative reduction of 
FEV1.0 in univariate analysis (p =0.053). The phrenic nerve resection and right side 
were risk factors of postoperative reduction of FEV1.0 in multivariate analysis (p =0.026 
and p =0.048). Conclusion: Right side and phrenic nerve resection were independent 
factors to predict the postoperative FEV1.0 falls below postoperative prediction FEV1.0. 
Keywords: FEV1.0, sleeve lobectomy, phrenic nerve resection
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RT Surg Total p^
n=88 (%) n=94 (%) n=182(%)
Gender
Male 70(79.5) 61(64.9) 131(72.0) 0.032
Female 18(20.5) 33(35.1) 51(28.0)
Age (median)
<72 26(29.5) 67(71.3) 93(51.1) 0.0001
>72 62(70.5) 27(28.7) 89(48.9)
Hystology
Adenocarcinoma 36(59.0) 69(73.4) 105(67.7) 0.14
SCC 23(37.7) 24(25.5) 47(30.4)
Large Cell Carcinoma 2(3.3) 1(1.1) 33(18.1)
Performance Status
0 13(14.8) 62(66.0) 75(41.2) 0.0001
1 45(51.1) 29(30.9) 74(40.7)
2 30(34.1) 3(3.1) 33(18.1)
FEV1
<1.5 35(43.8) 7(17.5) 42(35.0) 0.005
>1.5 45(56.2) 33(82.5) 78(65.0)
 
Results: Median follow-up time was 25 months (range: 6-110). Three local relapses 
(LR) were observed in L and 18 in SABRT group (p=0,0001). No difference in distant 
metastases was observed (19 in L vs 18 in SABRT group) (p=1-data not shown). Results 
of univariate survival analysis are shown in table II. Multivariate analysis confirmed the 
protective effect of L on OS and of good FEV1 (>1,5L) on DFS. A subgroup comparison 
of SABRT patients treated with BED>100Gy vs surgical patients showed no difference in 
local control (LC) (p=0,60) while OS and tumor-specific survival (TSS) remain in favor of 
L (p=0,001 and 0,049 respectively). Moreover, comparing surgical patients with SABRT 
with known histology and BED>100 Gy no difference was seen in TSS (p=0.10) nor in LC 
(p=0,36). No grade 3-5 toxicity was observed in both group.
Died % OS p^ LR % DFS p^
Age (median) <72 26 56.1 0.001 10 84.3 0.50
>72 50 10 11 79.9
Hystology Adenocar-
cinoma 34 37.9 0.66 9 87 0.81
SCC 22 35 3 91.2
Large Cell Carcinoma 1 66.7 0 100
Performance Status 0 17 59.8 0.001 7 87.3 0.52
1 29 19 9 79.5
2 3 18.3 5 81
FEV1 <1.5 27 20.4 0.14 11 86.2 0.005
>1.5 37 14 7 80.9
Treatment Radiotherapy 62 4.4 0.0001 18 67.4 0.0001
Surgery 14 72.9 3 95.1
Total 76 12.2 21 82.4
 
Conclusion: SABRT with adequate doses vs L in operable patients 
shows promising results in terms of LC and TSS with few toxicitiy. OS is 
mainly influenced by the selection of patients addressed to L vs SABRT. 
Keywords: biological equivalent dose (BED), lobectomy, Stereotactic ablative radiotherapy
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P3.02-025 Therapeutic Lung Resection in Biliopancreatic Cancer Patients 
Lary A. Robinson1, Gregory Springett2, Tawee Tanvetyanon1, Jacques Fontaine1, Eric 
M. Toloza1, Pamela Hodul2, Mokege Malafa2 1Thoracic Oncology, Moffitt Cancer Center, 
Tampa/FL/United States of America, 2Gastrointestinal Oncology, Moffitt Cancer Center, 
Tampa/FL/United States of America
Background: Of the major malignancies, carcinoma of the pancreas and the distal 
risk of PAL was higher in patients showing type D and E air leak patterns, and a peak 
air flow of ≥ 400 ml/min. The results indicate that PAL after pulmonary resection 
may be predicted by air leak patterns and peak air flow using the ThopazTM system. 
Keywords: pulmonary resection, chest drainage, air leak, lung cancer
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P3.02-023 Surgical Outcomes of Lung Cancer Combined With Interstitial 
Pneumonia. - Single Institutional Report - Daisuke Taniguchi1, Naoya Yamasaki2, 
Tomoshi Tsuchiya2, Keitaro Matsumoto2, Takuro Miyazaki2, Takeshi Nagayasu3 
1Department of Surgical Oncology, Nagasaki University Graduate School of Medicine, 
Sakamoto/Japan, 2Surgical Oncology, Nagasaki Graduate School of Medicine, Nagasaki/
Japan, 3Division of Surgical Oncology, Department of Translational Medical Sciences, 
Nagasaki University Graduate School of Biomedical Science, Nagasaki, Nagasaki/Japan
Background: Several studies have reported that acute exacervation (AE) of idiopathic 
interstitial pneumonia (IIP) can occur after lung resection for patients with non-small 
cell lung cancer (NSCLC), though the strategy of the perioperative management is 
controversial. Methods: We examined our institutional data about the lung cancer patients 
from June 1994 through October 2013 at Nagasaki University Hospital in a retrospective 
manner. Results: A total of patients who underwent lung resection for NSCLC(1701 
cases) was investigated, 58 had IIP, for an incidence rate of 3.8%. The majority of 
patients were men (52 cases, 89.6%) and ex- or current smokers (53 cases, 91.3%), and 
the average of Packs per year was 54.1 (range 30-150). Squamous cell carcinoma was 
the most common type of lung cancer (23 cases, 39.6%), and the second common type 
was adenocarcinoma (22 cases, 37.9%). Surgical procedure was wedge resection in 12 
cases, segmentectomy in 6 cases, lobectomy in 39 cases, pneumonectomy in 1 case, 
respectively. 6 cases(10.3%) had AE of IIP following lung resection, 3 cases(50%) of 
those patient died in the hospital. The univariate analysis and multivariate analysis were 
carried out to identify possible risk factors for AE. The univariate analysis identified LDH 
and bleeding amount. Multivariate analysis further identified only LDH. As a treatment 
for AE, we performed steroid pulse therapy and administration of Neutrophil elastase 
inhibitor. In some cases that no effect was given by such treatments, we performed 
direct hemoperfusion with a polymyxin B immobilized fiber column and administered 
immunosuppressant. Conclusion: Patients with lung cancer combined with IIP increases 
the risk of chest surgery, and the prognosis of them is poor. Because the prediction of AE 
is often difficult, surgery and perioperative management should be done very carefully. 
Keywords: non-small cell lung cancer, Interstitial pneumonia, lung resection, acute 
exacervation
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P3.02-024 Lobectomy versus Stereotactic Ablative Radiotherapy (SABR) 
for Stage I Non Small Cell Lung Cancer (NSCLC) in 182 Patients Vieri Scotti1, 
Gabriele Simontacchi1, Ilaria Francesca Furfaro1, Daniele Scartoni1, Alessandro 
Gonfiotti2, Domenico Viggiano2, Carla De Luca Cardillo1, Katia Ferrari3, Benedetta 
Agresti1, Giacomo Zei1, Marco Perna1, Paolo Bastiani4, Alessio Bruni5, Luca Voltolini2, 
Lorenzo Livi1 1Oncology, Radiation Oncology Unit, Florence/Italy, 2Thoracic Surgery Unit, 
Cardiovascular Department, Florence/Italy, 32Nd Pneumology Unit, Geriatric Department, 
Florence/Italy, 4Radiotherapy Unit Azienda Sanitaria Firenze, Oncology Department, 
Florence/Italy, 5Radiotherapy Unit Aou Policlinico of Modena, Oncology and Respiratory 
Disease Department, Modena/Italy
Background: Data from prospective randomized clinical trials are lacking in the 
comparison between lobectomy (L) and SABRT in operable patients and ongoing trials 
have troubles in recruiting. In inoperable patients a local control of 64-95% in retrospective 
and 92-98% in prospective trial is reported when BED is over 100 Gy. Methods: From 
2003 to 2013, 182 I-IIA NSCLC patients were treated at our Institution. Clinical 
characteristics are summarized in table I; cyto-histological prove of NSCLC was available 
in all surgical patients and in 61/88 (69%) SABRT patients. Spirometry was available 
in 120/182 (66%). Response was evaluated according to RECIST criteria after primary 
treatment. Toxicity was graduated according to CTCAE version 4 criteria.
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IA; 71.4/100 for IB; 0/0 for IIB; and 50/50 for IIIB. There were 9 cases of death due to 
other diseases. There were 6 cases of death due to lung cancer recurrence. Among the 
patients with c-stage I tumours, 7 died of other disease, while only 2 died of lung cancer 
distant metastasis recurrence (Table). Table
Death due to lung cancer 6 Death due to other diseases 9
1st recurrence site Other malignancy 4
bone 3 Cardiovascular disease 2
pleura 2 Cerebral disease 1
brain 1 Liver failure 1
Hemorrhagic enteritis 1
 
 
Conclusion: Wedge resection is positively indicated in PW cases. Negative wedge 
resection should be positively indicated in NW cases of c-stage I disease because 
treatment for other diseases must start as quickly as possible to maximize quality of life. 
Keywords: wedge resection, limitted resection, non-small cell lung cancer
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P3.02-027 Surgical Salvage Resection for Local Recurrence after Stereotactic 
Body Radiotherapy for Primary and Metastatic Lung Tumors Therezia 
Bokor-Billmann1, Sonja Adebahr2, Severin Schmid1, Agnes Csanadi3, Ursula Nestle4, 
Bernward Passlick1, Jussuf T. Kaifi1 1Thoracic Surgery, University of Freiburg, Freiburg/
Germany, 2Radiation Oncology, University of Freiburg, Freiburg/Germany, 3Pathology, 
University of Freiburg, Freiburg/Germany, 4Radiation Therapy, University Medical Center 
Freiburg, Freiburg/Germany
Background: Stereotactic body radiation therapy (SBRT) is an alternative to 
surgery for the treatment of early stage lung cancer or solitary metastasis in high-
risk individuals. The aim of the study was to identify patients that underwent surgical 
resection as a salvage therapy for local recurrences following SBRT. Methods: In a 
single institution prospective database patients that underwent SBRT for early-stage 
NSCLC or pulmonary metastatic tumors were identified over 5 years. Patients that 
underwent surgical salvage resection for local recurrences after SBRT were analyzed 
for clinicopathological data and outcome. Results: In 4/188 (2.1%) patients salvage 
surgery was performed for local recurrences after SBRT within a median period of 
14.5 months. SBRT was performed with a total dosage of 35 Gy in 3 and 37.5 Gy in 
1 patient. No perioperative mortality occurred after salvage resection, and complete 
resection was achieved in all cases. Histopathology demonstrated viable tumor cells 
accompanied by fibrosis and necrosis in all resected specimens. Conclusion: Salvage 
surgery should be considered in operable patients after lung SBRT for primary and 
metastatic tumors as viable tumor can be expected. It can be performed safely in 
appropriate candidates that need to be identified in a multidisciplinary setting. Further 
analysis of larger series could further clarify true incidence of local recurrences after 
SBRT and selection criteria for salvage surgery in this challenging group of patients. 
Keywords: local recurrence, non small cell lung cancer, Lung metastasis, Stereotactic 
body radiation
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P3.02-028 miMRST Wedge Resection Cured Aged, Cardiopulmonary 
Dysfunction Patients with Small Lung Cancer (≤2cm) Jun Zhang1, Ning Chen2, 
Xueshan Qiu1 1China Medical University Lung Cancer Center, The First Hospital of China 
Medical University, Shenyang/China, 2Department of Logistic Management, College of 
Economics and Management, Liaoning University of Traditional Chinese Medicine, Shenyang/
China
Background: In China, lung cancer is increasing rapidly. There are more and more 
aged, cardiopulmonary dysfunction patients were found with peripheral small lung 
cancer (≤2cm); chemotherapy and radiation are usually denied because of age, 
cardiopulmonary dysfunction, and fear of the serious side effects of chemo-radiation; 
surgery was denied because they could not tolerate traditional “large-incision” 
posterolateral thoracotomy. Video-assisted thoracoscopic surgery (VATS) is good for 
them; however, most Chinese patients refuse VATS because of the high cost not covered 
by medical insurance. “miMRST”, minimally invasive small incision, muscle- and rib-
sparing thoracotomy, minimally invasive lung cancer radical surgery, was developed to 
help resolve these problems: helps resect the tumor, minimally invasive, not cost too 
much, with good prognosis, widely accepted by Chinese patients. We discussed typical 
cases here. Methods: Case1: Man, aged 80 in Nov 2007, right upper lobe suspected 
peripheral lung cancer 2.0cm; smoking 57 years, with years’ serious chronic bronchitis, 
pulmonary bullae, emphysema, and diabetes mellitus, encephalatrophy; chemotherapy 
and radiation was denied; surgery was denied; VATS was not available then. Case2: Man, 
aged 68 in Oct 2007, right lower lobe suspected peripheral lung cancer or metastatic 
cancer 1.5cm; gastric cancer resection in 2002, lung cancer left lower lobe resection in 
2006, followed by chemo-radiation; chemotherapy and radiation was denied because of 
sickly status, age, cardiopulmonary dysfunction, possible resistance to chemotherapy; 
surgery was denied because of suspected potential multi metastasis, and the heavy risk 
and difficulties may meet in operation, fear of single one left upper lobe could not ensure 
the safety of operation and anesthesia, and further resection of the lung will obviously 
biliary duct are the most lethal, primarily because the diagnosis is usually made at an 
advanced stage and the cancer is relatively resistant to therapy. Occasionally, pancreatic 
cancer presents as a relatively indolent disease and localized blood-borne lung 
metastases may be solitary and potentially resectable for therapy. As well, some lung 
lesions that develop may represent another disease unrelated to the pancreatic cancer 
and may be treated with surgical resection. Therefore we reviewed our experience with 
therapeutic lung resections in pancreatic cancer patients. Methods: We performed a 
retrospective, case-control study of treated pancreatic cancer patients who underwent 
subsequent therapeutic lung resections from 1998-2015. All clinical and pathologic data 
were gathered for comparison in patients undergoing pancreatic pulmonary 
metastasectomy and those undergoing lung resection for other diseases. Kaplan-Meier 
(KM) analyses of survivals were calculated. Results: 25 patients with treated 
biliopancreatic cancer underwent lung resections with curative intent. 13 patients (mean 
age 60.2 ± 10.7 years) had resection of isolated biliopancreatic cancer metastases. 11 
patients had 12 resections of primary lung cancers (all Stage I) and 1 patient had 
resection of active Cryptococcus granulomas (mean age 70.8 ± 7.0 years). A smoking 
history was present in 77% of metastasecomy patients and 67% of lung cancer resection 
patients. All never-smokers with lung cancer were females. There were no surgical 
complications or operative mortalities. The median times from pancreatectomy to 
pulmonary metastasectomy was 29 months (range 0-64), and 12.5 months (range 
0-108) for the lung cancer resection group. During the study period, 11/25 (44%) 
patients died, although only 64% of the deaths were related to pancreatic cancer 
recurrence. The KM median survivals after lung resection in the pulmonary 
metastasectomy group was 28 months (range 3-76) and 78 months (range 2-81) in the 
lung cancer resection group (see Figure). 
 
Conclusion: Although biliopancreatic cancers have an overall dismal prognosis with just 
a 12.7 month median survival, 40% present with potentially resectable disease. The lung 
is the primary site of recurrence after resection of the primary biliopancreatic cancer. 
Based on our experience, we recommend considering pulmonary metastasectomy 
in highly selected patients who present with no evidence of disease elsewhere. 
Pulmonary resection can be done safely in this patient population. Additionally, not all 
new lung masses in pancreatic cancer patients are metastases, and resection should 
be considered, whenever feasible, for often we find a second primary lung cancer. 
Keywords: non-small cell lung cancer, biliopancreatic cancer, pulmonary metastasectomy
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P3.02-026 Positive or Negative Indications for Wedge Resection of Non-Small 
Cell Lung Cancer Masafumi Kataoka1, Haruyuki Kawai2, Kazuhiko Watanabe2, Koukichi 
Miyamoto2, Izumi Togami3, Tsuneharu Morito3, Kotaro Yasui3, Souichi Kojima3, Toshinori 
Ohara1 1Surgery, Okayama Saiseikai General Hospital, Okyayama/Japan, 2Internal Medicine, 
Okayama Saiseikai General Hospital, Okayama/Japan, 3Radiology, Okayama Saiseikai 
General Hospital, Okyayama/Japan
Background: Limited resection for non-small cell lung cancer is gaining popularity 
because of early detection and the increase of elderly patients. To reveal the relevant 
indications for wedge resection, we retrospectively investigated patients who underwent 
wedge resection by dividing them into positive (PW) and negative (NW) indication 
groups. Methods: Clinical N0M0 cases with tumours <1 cm or predicted lepidic pattern 
adenocarcinoma were labelled PW, while other wedge resection cases were labelled NW. 
We investigated 35 PW and 32 NW cases surgically treated at our hospital between 2002 
and 2009. The mean age was 66 years in the PW group and 77 years in the NW group. 
All PW cases were c-stage IA, while the NW group included 21, 7, 2, and 4 cases of IA, IB, 
IIB, and IIIB, respectively. Results: The overall 5-year survival rates (OS) of the PW and 
NW groups were 100% and 59.4%, while the disease-specific 5-year survival rates (DS) 
were 100% and 82.6%, respectively. The indications for (number of) limited resections in 
the NW group were low respiratory function (15), other malignancies (4), cardiac disease 
(4), cerebral disease (3), and other (5). The OS/DS of the NW group were 57.1/85.7 for 
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management of lung cancer in elderly patients. Here we report the case of a 97 year 
old man with NSCLC successfully treated with anatomical pulmonary resection. To the 
best of our knowledge this is the oldest individual reported to have undergone this lung 
cancer surgery. Methods: A 97 year old gentleman presented with a cough and was 
found to have an abnormal chest x-ray. CT scan demonstrated a lesion within the apex 
of the left upper lobe, which was confirmed as a squamous cell carcinoma on CT guided 
biopsy. Further staging was carried out with a PET scan showing a T2b N0 M0 disease. 
At review the patient appeared to be a fit and active gentleman with a good exercise 
tolerance of a half mile without any shortness of breath and at least one flight of stairs. 
He had a past history of stroke four years ago with no significant residual neurology. 
He also had a history of hypertension, diabetes, raised cholesterol and chronic renal 
impairment. Pulmonary function tests were reasonable with an FEV1 of 1.75L (75% 
predicted) and an FVC of 2.5L (96% predicted). Results: Following counselling regarding 
management options and risk the patient opted for surgical resection. A left lingular-
sparing upper lobectomy was performed via posterolateral thoracotomy. Lymph nodes 
were taken from stations 5, 7 and 10. Postoperative airleak was prolonged with drain 
removal on day 10. In addition, the patient developed a pseudomonas urinary tract 
infection which required a course of antibiotics. The postoperative course was otherwise 
unremarkable and he was discharged home on day 14. At follow-up in the outpatient 
clinic 6 weeks following surgery the patient had returned to his pre-operative exercise 
tolerance. Conclusion: Lung cancer is the leading cause of cancer death in both men and 
women in the UK. In the past there has been a trend towards a less aggressive approach 
in elderly patients. Here we present successful anatomical pulmonary resection for 
NSCLC in a 97 year old. A significant number of studies have demonstrated the feasibility 
of anatomic lung resection in carefully selected octogenarians with acceptable morbidity 
and mortality. Although there are only a few case reports of surgical management in 
patients over ninety years old it is fair to assume that similar criteria could be used 
for patient selection. Surgical resection remains the gold-standard of care for 
curative intent in early lung cancers and should not be precluded based on age alone. 
Keywords: lung cancer surgery, Nonagenarian
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P3.02-031 Patient Outcomes following Curative-Intent Lung Resection among 
Non-Small Cell Lung Cancer (NSCLC) Patients in China Jian Zhou1, Eric Q. Wu2, 
Fan Yang1, Jipan Xie3, Simeng Han4, Xun Wang1, Huaying Song4, Jun Wang1 1Thoracic 
Surgery, Peking University People’S Hospital, Beijing/China, 2Analysis Group, Inc., Boston/
MA/United States of America, 3Analysis Group, Inc., New York/NY/United States of 
America, 4Analysis Group, Inc., Beijing/China
Background: Lung resection is a common treatment for patients with non-small cell 
lung cancer (NSCLC), particularly those with early stage disease. This study aimed to 
assess patient short-term outcomes following curative-intent lung resection among 
patients with NSCLC. Methods: Data were obtained from an NSCLC surgical outcome 
registry, which included patients from 13 tertiary hospitals in 11 provinces in 2013 and 
2014. The surgery types include thoracotomy, video-assisted thoracic surgery (VATS), 
conversion from thoracotomy to VATS and mini-thoracotomy under VATS. Among all 
patients, 1,071 were followed up for at least 6 months. Post-surgery treatment pattern 
and patient outcomes (surgical complication rate and rates of survival, new metastasis 
and recurrent at the 6-month follow-up) were described; patient outcomes were 
compared among different tumor stages using Fisher’s exact test. Results: Among the 
1,071 patients with ≥ 6-month follow up, the median age was 60 (range 26 to 84) years 
old and 68.3% were male. The most common types of cancer were adenocarcinoma 
(56.1%) and squamous cell carcinoma (38.3%). Based on the pathologic staging, 
42.3% patients had stage I tumor; and stage II, III and IV tumor accounted for 27.5%, 
27.8% and 2.4% of the patients, respectively. After surgery, 57.9% patients received 
further treatment: most of them received chemotherapy (78.3%), 1.2% received 
targeted therapy, 1.2% received radiation, 0.3% received re-operation, 7.2% received 
alternative medicine treatment. The overall post-surgery complication rate following 
surgeries was 6.0% and it did not vary significantly by stage (5.1%, 5.4%, 9.4% and 
9.5% for stage I-IV, respectively; p=0.122). The overall survival rate at 6 months was 
96.2% and it decreased substantially with increasing stage (98.3%, 95.4%, 92.2% 
and 85.7% for stage I-IV, respectively; p=0.0005). Recurrence rate was 1.5% for all 
patients and it was substantially higher among patients with stage IV cancer (2.2 %, 
1.7%, 0.4% and 10.0% for stage I-IV, respectively; p=0.032). New metastasis occurred 
in 6.4% patients. Again, the rate varied significantly across different stages (4.9%, 4.2%, 
10.0% and 25.0% for stage I-IV, respectively; p=0.001). Conclusion: Chemotherapy 
was the most commonly used treatment after surgery for NSCLC patients. Additionally, 
the NSCLC patients who underwent curative-intent lung resection surgeries had 
relatively high survival rate, low rates of recurrence and new metastasis at the 6-month 
follow up. As expected, prognosis became worse with increasing tumor stage. 
Keywords: outcome, follow up, Surgical resection, NSCLC registry
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P3.02-032 Effect of Age on Adjuvant Chemotherapy after Resection of Non-
Small Cell Lung Cancer Xiaoyu Zhai, Ziping Wang Department of Medical Oncology, 
Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union 
Medical College, Beijing/China
Background: Adjuvant chemotherapy (ACT) improves the survival for completely 
resected non-small cell lung cancer (NSCLC) patients. However, there are few reports 
to explore the effect of age on the efficacy of adjuvant chemotherapy of NSCLC after 
surgery. Methods: Patients received adjuvant chemotherapy after surgery in Cancer 
aggravate postoperative pulmonary dysfunction. Both patients were transferred to CMU 
Lung Cancer Center. “miMRST” wedge resection became the best choice for these aged, 
cardiopulmonary dysfunction patients with suspected peripheral small lung cancer 
(≤2cm). Results: About 10cm lateral chest incision was enough for most lung cancer 
resection and mediastinal lymph node dissection, with the latissimus dorsi and serratus 
anterior muscles were protected, no rib cut needed. Wedge resection was performed 
for both patients, and cutting edges of the lung were more than 2-3cm away from 
the tumors. No swelling lymph node was found and no dissection done. The patients 
recovered much better and quickly than other patients who underwent traditional “large-
incision” posterolateral thoracotomy. Regular follow-up: Case 1 now alive healthily 
for his 8th year postoperatively, no sign of recurrence and metastasis; Case 2 lived 
healthily for more than 4 years, no sign of recurrence and metastasis, but died at the 
5th year postoperatively due to other reason not lung cancer. Conclusion: miMRST, 
neither causes serious damage as traditional “large-incision” posterolateral thoracotomy 
does, nor costs too much as VATS does. miMRST wedge resection is a good choice for 
aged cardiopulmonary dysfunction patients with peripheral small lung cancer (≤2cm), 
with a good acceptable prognosis, even cure lung cancer, very suitable for lung cancer 
surgery in developing countries. (This study was partly supported by the Fund for 
Scientific Research of The First Hospital of China Medical University, No.FSFH1210). 
Keywords: lung cancer, muscle-sparing rib-sparing thoracotomy, minimally invasive lung 
cancer radical surgery, minimally invasive small incision
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P3.02-029 Micro- Small Lung Cancer (≤1cm) Needs Lobectomy with 
Systematic Lymph Node Dissection or Sublobular Limited Resection Only? Jun 
Zhang1, Ning Chen2, Xueshan Qiu1 1China Medical University Lung Cancer Center, The First 
Hospital of China Medical University, Shenyang/China, 2Department of Logistic Management, 
College of Economics and Management, Liaoning University of Traditional Chinese Medicine, 
Shenyang/China
Background: Lung cancer is increasing rapidly in China. More and more pulmonary 
ground-glass opacity (GGO) were detected, most are not malignant, but some are 
indeed early stage lung cancer, micro- small lung cancer (≤1cm) (mi-SLC), either 
adenocarcinoma in situ (AIS), or minimally invasive adenocarcinoma (MIA). Surgical 
resection could cure most of them, but the resection extent for mi-SLC is a dilemma. 
Typical cases will be discussed. Methods: Case 1: Woman, aged 67 in Mar 2013, left 
upper lobe GGO 0.8cm, not peripheral; hypertension and coronary heart disease 10 
years; anti-inflammatory strategy used, GGO size increased a little one month later. Her 
mental stress increased greatly. Case 2: Woman, aged 59 in Nov 2013, right middle 
lobe pure GGO 1.0cm, peripheral; sickly status for years; anti-inflammatory strategy 
used, GGO size no change. Both patients were referral to China Medical University 
Lung Cancer Center for surgical resection, “miMRST”, minimally invasive small incision, 
muscle- and rib-sparing thoracotomy, minimally invasive lung cancer radical surgery, was 
scheduled. Results: About 10cm lateral chest incision was enough for most lung cancer 
resection and mediastinal lymph node dissection, with the latissimus dorsi and serratus 
anterior muscles were protected, no rib cut needed. For Case 1, the lesion could not 
be located, left upper lobe resection was undergone as expected; frozen pathological 
diagnosis was AIS; swollen lymph node 3a,5,6,10,11,12 and surrounding adipose tissue 
were systematicly dissected. No lymph node in subcarinal and pulmonary ligament region 
was found. Postoperative pathology confirmed AIS, no lymph node metastasis. For Case 
2, wedge resection was performed as expected; cutting edges of the lung were more than 
2cm away from the tumor. The frozen pathological diagnosis was atypical adenomatous 
hyperplasia (AAH), cancer to be excluded by wax slide pathology. No swollen lymph 
node was found and no dissection done. Postoperative pathology was minimally invasive 
adenocarcinoma (MIA). The patients recovered much better and quickly than other 
patients who underwent traditional “large-incision” posterolateral thoracotomy. Regular 
follow-up: both patients are alive healthily, in her 3rd year postoperatively for Case 1, 
in her 2nd year postoperatively for Case 2; no sign of recurrence and metastasis. No 
adjuvant treatment used. Conclusion: For these micro- small lung cancer (≤1cm), wedge 
resection is the first choice for frozn pathological diagnosis; if the diagnosis is AAH, 
wedge resection should be enough; if is AIS, lobular resection, at least segment resection 
is to be performed; if the diagnosis is MIA or just lung cancer, thus standard lobectomy 
plus systematic lymph node dissection is essential. For AIS, lymph node dissection is 
a dilemma. For GGO not in peripheral part, if segment resection is difficult, loectomy 
become dilemma. But for wedge resection of AAH, it would become a bigger dilemma 
when the postoperative pathology become MIA. Prospective observation of more patients 
with long follow-up will be more helpful. (This study was partly supported by the Fund 
for Scientific Research of The First Hospital of China Medical University, No.FSFH1210). 
Keywords: micro- small lung cancer, GGO, AIS, MIA
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P3.02-030 Linguar-Sparing Left Upper Lobectomy for Lung Cancer in a 97 
Year Old Man Henrietta Wilson, Michael Ghosh-Dastidar, Karen Harrison-Phipps 
Thoracic Surgery, Guy’S Hospital, London/United Kingdom
Background: Current trends in increased life-expectancy and lung cancer incidence 
have led to a growing number of elderly patients with non-small cell lung cancer. 
Advances in surgical techniques and perioperative care have led to improved outcomes in 
octogenarians undergoing pulmonary resection. There have been few reports, however, 
of surgical management in patients over the age of ninety years. Between 2009 and 
2011 a total of 5133 new cases of lung cancer were reported in people over the age of 
85 years in the UK. In view of this, clinicians will face more difficult decisions as to the 
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University of Technology, Gliwice/Poland
Background: Surgery is the only potentially curative treatment in early stage non-small 
cell lung cancer (NSCLC). Even though relapse occurred in the majority of operated 
patients. Adjuvant chemotherapy is a standard management of an operable IIA –IV NSCLC, 
in order to reduce cancer recurrence and prolong overall survival. The aim of the study 
was to define the factors that reduce delivery of adjuvant chemotherapy. Methods: We 
performed a retrospective analysis of prospectively collected data of 498 IIA-IV 
NSCLC patients operated with radical intent between 2007 and 2013. Age, type and 
extension of surgery, presence of surgical complications, Charlson Comorbidity 
Index, forced vital capacity (FVC), forced expiratory volume in one second (FEV1), 
6-minutes walk test (6MWT), marital status, distance between home to the hospital, 
duration of smoking habit, number of cigarettes smoked daily, number of packyears 
were considered in uni- and multivariate analysis for identification of factors that have 
potential influence the application adjuvant chemotherapy. Results: In univariate 
analysis age (p<0.001), 6MWT distance (p=0.007), FEV1 [dm3] (p<0.001), FEV1 (%) 
(p=0.006), FVC [dm3] (p<0.001), FVC (%) (p<0.001), complications after surgery 
(p=0.005), and type of surgery (p=0.036) were identified as factors that have impact 
on delivery of adjuvant chemotherapy. In the multivariate analysis, FVC [dm3] (p=0.043) 
and FEV1 [dm3] (p=0.013) were found as independent factors. Conclusion: Low 
pulmonary function tests limits delivery of complete adjuvant chemotherapy while 
age, comorbidity, type and extension of surgery has no impact in this regard. 
Keywords: non-small cell lung cancer, adjuvant chemotherapy
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P3.02-034 Utilization of Adjuvant Therapy Among Completely Resected Non-
Small Cell Lung Cancer (NSCLC) Patients at Charleston Area Medical Center 
Steven J. Jubelirer1, Seth B. Larson2, Christine A. Welch3, Zelia R. Budhan1 
1Hematology Oncology, Charleston Area Medical Center/ West Virginia University, Charleston 
Division, Charleston/WV/United States of America, 2Hematology Oncology, Charleston Area 
Medical Center, Charleston/WV/United States of America,3Outcomes Research, Charleston 
Area Medical Center, Charleston/WV/United States of America
Background: Recently, adjuvant chemotherapy has become the standard of care for 
completely resected (R0) stage II and IIIA NSCLC patients; up for debate is the use of 
adjuvant therapy for stage IB. This retrospective study examined the therapies used in 
completely resected NSCLC patients. Methods: Information was initially gathered from 
the CAMC Cancer Registry which recorded nearly 2,500 occurrences of lung cancer 
during the study period (2005-2012). Those with completely resected (R0) stage IB 
(tumor size ≥ 4 cm) through IIIA (R0) NSCLC were selected for further review. Patients who 
did not receive preoperative therapy were included. Results: Meeting inclusion criteria 
were 171 patients, 96% Caucasian, with an average age of 66 ± 10 years (range 40-86). 
The majority were male (66%), 63% were married, and 55% had Medicare/Medicaid and 
most underwent a lobectomy (82%) Stages included IB (26%), IIA (23%), IIB (35%), and 
IIIA (16%), with 46% adenocarcinoma and 42% squamous cell. Adjuvant treatment type 
by stage is presented in Table 1. The majority of those not receiving treatment refused 
or elected observation (52%), while 16% were not treated due to comorbidities and 12% 
expired within 2 months of surgery. Logistic regression revealed that those who were 
treated were age < 65 years (odds ratio 3.3, CI 1.6-7.1, p = .002), stage IIIA (odd ratio 
2.0, CI 1.3-2.9, p < .0005) and stage IIB (odd ratio 1.3, CI 1.0-1.7, p < .03).
Treatment by stage for completely resected NSCLC
Stage
IB IIA IIB IIIA
n(%)
Treatment
No Treatment 33(73.3) 24(60) 31(52.5) 6(22.2)
Chemotherapy
Cisplatin-based 7(15) 9(22.5) 12(20.3) 9(33.3)
Carboplatin-based 4(8.9) 6(15) 9(15.3) 2(7.4)
Sequential chemo/RT 0(0) 1(2.5) 1(1.7) 0(0)
Concurrent chemo/RT 0(0) 0(0) 6(10.2) 7(25.9)
RT alone 1(2.2) 0(0) 0(0) 3(11.1)
 
 
Conclusion: Adjuvant therapy was seen more in stages IIB and IIIA. Stage IIIA received 
the highest rate of radiation. Of the patients who underwent treatment the majority 
received treatment that is compliant with NCCN guidelines. Unfortunately only 2 of 
the patients who received treatment were part of a clinical trial. The proportion of 
patients treated, was similar to the NCCN Outcomes Data Project of Zornosa C, et al. 
Keywords: non-small cell lung cancer, Adjuvant therapy
Hospital, Chinese Academy of Medical Sciences from 2001-2010 were analyzed. Disease 
Free Survival (DFS) of the two groups of patients was compared in terms of their age. 
Survival analysis was performed using Kaplan–Meier estimates, log-rank tests and Cox’s 
proportional hazards regression analysis. Propensity score matching (PSM) was used, and 
a survival analysis of the match data was carried out. Results: The data of 256 patients 
with stage I to stage Ⅲ NSCLC who underwent completely resection was analyzed. 
Those two groups,patients aged≤65 years (27~65, n=206) and patients aged＞65 years 
(66~72, n=50) ,were compared. Figure 1 shows the baseline characteristics of the two 
groups of patients before and after PSM. There was no significant difference in DFS 
between the two groups (mDFS: 594 days vs. 554 days, P=0.951) (Figure 2), and the age 
was not associated with DFS in multivariable analysis (P =0.602). DFS was continually 
not significant difference in 40 PSM pairs (mDFS: 600 days vs. 554 days, P=0.731) 
(Figure 2).
 
 
Conclusion: The results suggest that older patients do not appear a shorter DFS than 
younger. Thus, elderly patients should not be denied adjuvant chemotherapy based merely 
on age. The conclusion was limited by the small sample size; moreover, the number of patients 
between the groups was not close. Larger sample of cases should be warranted in future. 
Keywords: non-small cell lung cancer, adjuvant chemotherapy, disease free survival
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P3.02-033 Analysis of Factors That Have Impact on Adjuvant Chemotherapy 
Application in Operated Stage IIA-IV Non-Small Cell Lung Cancer Patients 
Krzysztof Lesniewski-Kmak1, Tomasz Marjanski2, Wojciech Zurek2, Michal Marczyk3, 
Joanna Polanska3, Witold Rzyman2 1Oncology Propedeutics, Gdansk Medical University, 
Gdynia/Poland, 2Thoracic Surgery, Gdansk Medical University, Gdansk/Poland, 3Silesian 
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used to assess clinical and dosimetric variables under univariate and multivariate 
analyses. Results: We identified 26 patients and 27 lesions that met inclusion criteria. On 
UVA, increasing PTV volume, V20, and intermediate dose spillage (maximum total dose 
to any point 2 cm from PTV divided by dose prescribed) were significantly associated 
with increasing fibrosis (p<0.05). Non-significant predictors of fibrosis included patient 
age, pack years of smoking, COPD GOLD stage, use of ACE-I, and radiation dose to 
the PTV. On MVA accounting for factors significant for fibrosis (PTV volume, V20, 
intermediate dose spillage), only PTV volume remained significantly correlated with 
fibrosis volume (0.43 cm3 increase in fibrosis for every 1 cm3 increase in PTV, 95% CI, 
0.08-0.77, p=0.02). Conclusion: In this analysis of predictors of fibrosis after SBRT, 
only increasing PTV volume was associated with increased fibrosis. We plan to utilize 
these results for future studies using pharmacologic strategies to decrease lung fibrosis. 
Keywords: fibrosis, PTV, SBRT
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P3.02-037 Robotic SBRT with Fiducial Tracking for Inoperable Peripheral 
Stage I NSCLC: Mature Survival and Toxicity Outcomes Nima Aghdam1, Richa 
Bhasin1, Ryan Malik1, Shaan Kataria1, Simeng Suy1, Sean Collins1, Thomas Chang2, Filip 
Benovac2, Eric Anderson3, Brian Collins1 1Department of Radiation Medicine, Georgetown 
University Hospital, Washington Dc/United States of America, 2Department of Radiology, 
Georgetown University Hospital, Washington Dc/United States of America, 3Division of 
Pulmonary, Critical Care and Sleep Medicine, Georgetown University Hospital, Washington/
DC/United States of America
Background: Surgery is not an option for many patients with stage I non-small-cell lung 
cancer (NSCLC). Here we report mature robotic stereotactic body radiation therapy 
(SBRT) with fiducial tracking outcomes for inoperable patients with peripheral clinical 
stage I NSCLC. Methods: Inoperable patients with biopsy-proven peripheral clinical 
stage I NSCLC were treated. PET/CT imaging was completed for staging. Three-to-five 
gold fiducial markers were implanted in or near tumors to serve as targeting references. 
Gross tumor volumes (GTVs) were contoured using lung windows. The margins were 
expanded by 5 mm circumferentially to establish the planning treatment volume (PTV). 
Doses delivered to the PTV ranged from 45 to 60 Gy in 3 or 5 fractions (BED Gy10 >100 
Gy). Results: Forty patients ranging in age from 62-94 years (median age 76 years) with 
a median percent predicted FEV1 of 61% (range, 21-107%) were treated over a 6-year 
period extending from August 2005 to August 2011 and followed for a minimum of 40 
months or until death. The median maximum tumor diameter was 2.6 cm (range, 1.4-5.0 
cm). A median dose of 50 Gy was delivered over a 3 to 13 day period (median, 7 days). 
At a median potential follow-up of 56 months, the 5-year Kaplan-Meier locoregional and 
distant control estimates were 95% and 82%. The 5-year cancer-specific and overall 
survival estimates were 75% and 40%. There was no change in percent predicted 
FEV1 one year following robotic SBRT; there was a small but statistically significant 
8% decline in percent predicted DLCO at one year. Radiation induced rib fracture (RIRF) 
was identified on surveillance CT imaging in 17 patients. The estimated cumulative 
incidence of RIRF at 3 years was 40%. The median time to rib fracture was 24 months 
(range, 7-38 months). Conclusion: Robotic SBRT with fiducial tracking outcomes for 
inoperable peripheral stage I NSCLC are comparable to conventional SBRT outcomes. 
Additional research will be required to determine the optimal SBRT technique. 
Keywords: Rib Fracture, Robotic SBRT, NSCLC, Inoperable
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P3.02-038 Survival outcomes of Stereotactic body radiotherapy for early-
staged non-small cell lung cancer: a comparison between different doses 
Yin Kwan Chik, Ka Man Cheung, Ho Ching Lam, Chung Kong Kwan, Joseph S K Au 
Clinical Oncology, Queen Elizabeth Hospital, Hong Kong/Hong Kong
Background: Stereotactic body radiotherapy (SBRT) is a definitive local treatment option 
for patients with early stage non-small cell lung cancer (NSCLC) who are considered unfit 
for surgical treatment either due to poor lung function or medical comorbidities. The 
purpose of this work is to report on the outcomes of stage I and II non-small cell lung 
cancers treated with SBRT in a tertiary oncology centre in Hong Kong. Methods: One 
hundred and five patients diagnosed with Stage I-II NSCLC underwent treatment with 
SBRT between January 2006 and December 2014. Data were collected and analyzed 
retrospectively. Overall survival (OS) and local control (LC) were calculated using the 
Kaplan-Meier method. Results: Median follow-up was 28 months (range 5-100 months) 
with a median age of 77 years. The median size of treated lesion was 2.7cm (range 
1.2-7cm). The median SBRT dose was 50Gy (range 40-60 Gy) delievered in a median 
of 4 fractions (range 4-10). The median biological equivalent dose (BED10) was 105.6 
Gy (range 39 -180Gy). The overall median OS was 28 months. The overall LC was 
86.5% and 43.7% at 1 and 3 years, the overall OS was 91% and 51.3% at 1 and 3 
years, respectively. Patients with stage T1 (n=60) disease had better LC and OS 
when compared with T2 (n=42). Median OS was 30.5 months (T1) and 18 months (T2; 
P=0.006). 1-year LC was 89% (T1) and 83% (T2; p=0.45), 1-year OS was 96.3% (T1) 
and 83.8% (T2; p=0.006), 3-year LC was 57.8% (T1) and 37.5% (T2; p=0.045), 3-year 
OS was 60.4% (T1) and 38.7% (T2; p=0.006). A higher BED10 of more than 105Gy was 
associated with improvement in OS and LC. For tumors treated with BED10<105 Gy 
and BED10>=105 Gy, overall LC at 2 year was 71.8% and 86% (p= 0.017), 2-year OS 
was 69.4% and 79%, respectively (p=0.026). T2, but not T1 tumors was associated 
with improved LC with higher BED10. 2-year LC at 2 years for T2 tumors treated with 
BED10<105 Gy and BED10>=105 Gy were 40 % and 75% respectively (p=0.002). 
Median OS for T2 tumors treated with BED10<105 Gy and BED10>=105 Gy were 28 
months and 31 months respectively (p=0.14). Toxicity was graded based on Common 
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P3.02-035 A Case of Synchronous Quintuple Lung Cancers Treated with 
Salvage Surgery after Treatment with Erlotinib Kaori Abe, Junichi Shimada, 
Daishiro Kato, Hiroaki Tsunezuka, Satoru Okada, Tatsuo Huruya, Narumi Ishikwa 
Division of Chest Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 
Kyoto/Japan
Background: The detection of multiple ground glass nodules(GGNs) is increasing 
with improvement in the computed tomography (CT) technique. Indelible GGNs are 
very often indicative of atypical adenomatous hyperplasia or relatively early stage lung 
adenocarcinoma, so its detection and accurate diagnosis are required for appropriate 
treatment. Methods:
A 64-year-old woman with no significant medical history was referred to our hospital after 
an abnormal shadow was detected on chest radiograph. CT showed two part-solid GGNs 
in the right upper lobe(diameter: S2,9mm;S3, 5mm), two solid nodules surrounded 
slightly part of GGN in the right middle lobe (S4, 27mm;S5, 38mm), and one part-solid 
GGN in the right lower lobe(S8, 8mm).Fluorine-18-fluorodeoxyglucose positron emission 
tomography showed abnormal uptake in the two nodules in the middle lobe. Biopsy of the 
nodule in S4 was performed using a bronchoscope, and the results indicated 
adenocarcinoma with an EGFR exon21 (L858R) substitution mutation. The two solid 
nodules in the middle lobe were diagnosed as intrapulmonary metastasis in the same 
lobe(cT3N0M0,stageIIB). Because the patient refused surgery, two courses of 
combination chemotherapy with cisplatin, pemetrexed, and bevacizumab were 
administered, which was discontinued because of the adverse effects. Therefore, oral 
administration of erlotinib was started, and she showed a partial response. Fourteen 
months after initiation of treatment with erlotinib, salvage surgery was performed. 
Salvage surgery involved right middle lobe resection with preoperative lipiodol marking 
for GGNs, upper lobe wedge resection, and lower lobe wedge resection. Results: The 
five nodules could be resected completely with adequate resection margin. 
Histopathologically, all nodules were diagnosed as adenocarcinoma of the lung, with a 
lepidic pattern and no vascular invasion. Since the histopathological features differed 
slightly between nodules, the lung cancers were not diagnosed as intrapulmonary 
metastases but synchronous quintuple lung cancers. The final histopathological 
diagnosis was pT2aN0M0, stage IB lung cancer. Conclusion: Our findings indicate that 
synchronous lung cancers as well as lung intrapulmonary metastasis need to be 
considered in patients presenting with multiple lung nodules with even a minor GGN 
component, and that complete resection after treatment with erlotinib could be the 
appropriate treatment in such cases. EGFR tyrosine kinase inhibitor (TKI) often leads lung 
cancers with EGFR mutations to good response, but most tumors acquire resistance to 
EGFR-TKI after less than 12 months treatment. There is a possibility that salvage 
operation is useful after treatment of EGFR-TKI. 
Keywords: synchronous multiple lung cancers, salvage operation, Erlotinib, ground 
glass nodule
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P3.02-036 Predictors of Lung Fibrosis after Stereotactic Body Radiation 
Therapy (SBRT) for Stage I-II Non-Small Cell Lung Cancer (NSCLC) Norman Yeh1, 
Quentin Diot1, Basel Altoos1, Brian Kavanagh2, Laurie Gaspar1 1University of Colorado-
Denver, Aurora/CO/United States of America, 2University of Colorado-Denver, Aurora/United 
States of America
Background: Radiographic lung injury, fibrosis, occurs in over 50% of patients after 
SBRT. The purpose of this study was to evaluate clinical and dosimetric predictors of 
lung fibrosis after SBRT for stage I-II NSCLC Methods: A retrospective single institution 
database was examined for patients with Stage I-II NSCLC, T1-2N0, and lesions less than 
5 cm treated with SBRT to 45-54 Gy in 3-5 fractions from 2010 to 2013. 4D CT imaging 
was used to assist with target localization and CT scans with at least 9 months of followup 
were rigidly registered to the planning CT scan based on common anatomical landmarks. 
Fibrosis volume was manually contoured. Simple and multiple linear regression were 
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P3.02-041 Stereotactic Body Radiation Therapy Associated with Erlotinib 
for Localized Clonal Progression of Metastatic Non Small Cell Lung Cancer 
Lisa K. Morikawa1, Guilherme M. Gondin2, Ernani Anderson1, Helio A. Salmon1, 
Clarissa Baldotto3, Juliana Panichella1, Carlos G. Ferreira4 1Radiation Oncology, Clinicas 
Oncologicas Integradas (Coi), Rio de Janeiro/Brazil, 2Radiation Oncology, Ac Camargo 
Hospital, Sao Paulo/Brazil, 3Medical Oncology, Clinicas Oncologicas Integradas (Coi), Rio de 
Janeiro/Brazil, 4Medical Oncology, Oncologistas Associados, Rio de Janeiro/Brazil
Background: Stereotactic Body Radiation Therapy (SBRT) has been widely used in 
early stage Non-Small-Cell Lung Cancer (NSCLC) with low toxicity and local control rates 
above 90%. Experience with this technique in the treatment of metastatic tumors is 
limited. EGFR receptor antagonist Erlotinib acts as a radiosensitizer and increases the 
overall survival of patients with metastatic NSCLC harboring mutations of this receptor. 
Temporary suspension of this drug may cause a quick progression of the disease known 
as “disease flare.” Reports about the combination of this drug with SBRT are rare and 
the toxicity of this treatment is practically unknown. Methods: We present an 80 years-
old, female patient with metastatic NSCLC who was treated with Erlotinib and had her 
disease controlled for 3 years. The patient underwent SBRT in a small lung lesion of 
22mm representing the isolated progression of the disease. Treatment with Erlotinib was 
briefly suspended for the SBRT to avoid “disease flare.” The patient was treated with a 
dose of 5000 cGy in 5 fractions delivered by Volumetric Modulated Arc Therapy (VMAT) 
without using an accessory for rigid immobilization. Treatment was performed by a linear 
accelerator with 6 MV photon beam and a 2.5mm micro-multileaf collimator. Margins of 
5mm from Internal Target Volume (ITV) were applied, which included the tumor and its 
movements during the breathing cycle, without safety margin for microscopic disease. 
IGRT was performed daily with Cone Beam kV computed tomography. Results: Before 
undergoing SBRT, the patient had a Carcinoembryonic Antigen (CEA) level of 8 ng/mL. 
This tumor marker dropped to 3.5 ng/mL immediately and 1.7 ng/mL three months after 
the procedure. PET-CT 6 months after SBRT showed a reduction from 9.0 to 3.6 in the 
SUVmax of the lung lesion. Approximately 60 days after SBRT, the patient developed 
cough and was diagnosed with actinic pneumonitis. Prednisone was started and kept 
for about a month with complete resolution of the condition. It has been more than 1 
year after she underwent SBRT and more than 3 years since she started chemotherapy 
with Erlotinib. The patient still shows no evidence of new metastatic lesions and 
remains with good tolerance to chemotherapy. Conclusion: Actinic pneumonitis is 
uncommon after SBRT of lesions with these small dimensions. A dose of 5000 cGy 
in 5 fractions is considered a conservative approach and all normal tissue constraints 
were respected in the present case. We believe this side effect to be a result of the 
radiosensitizer action of Erlotinib when associated with SBRT. We recommend caution 
when applying SBRT after a recent suspension of chemotherapy with this drug. 
Keywords: NSCLC, SBRT, Erlotinib, pneumonitis
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P3.03-001 Comparison of Adjuvant Therapy Modes Following Resection in 
Lung Cancer Patients with Clinically (-) but Pathologically (+) N2 Disease 
Hyojung Park1, Dongryul Oh1, Yong Chan Ahn1, Hongryull Pyo1, Jong-Mu Sun2, Jin Seok 
Ahn2, Myung-Ju Ahn2, Keunchil Park2, Yong Soo Choi3, Hong Kwan Kim3, Jhingook 
Kim3, Jae Ill Zo3, Young Mog Shim3 1Radiation Oncology, Samsung Medical Center, Seoul/
Korea, 2Medicine, Samsung Medical Center, Seoul/Korea, 3Thoracic & Cardiovascular 
Surgery, Samsung Medical Center, Seoul/Korea
Background: Mediastinal nodal staging is very important before recommending surgical 
resection in newly diagnosed non-small cell lung cancer patients. Following curative 
resection for having apparently clinically uninvolved mediastinal node (cN0-1), some 
proportion of patients, however, turns out to have pathologically involved mediastinal 
node (pN2). There have been controversies on optimal adjuvant therapy during past 2 
decades in this clinical setting. Systemic chemotherapy, either followed by or concurrent 
with radiation therapy, has remained most important modality. This study is to evaluate 
clinical outcomes following similar, but different, 3 adjuvant therapy modalities, in all 
of which included systemic chemotherapy, at authors’ institute. Methods: Between 
2006 and 2012, authors identified 240 cN0-1/pN2 patients who received adjuvant 
systemic chemotherapy following curative resection: chemotherapy alone in 85 
patients (Group A); chemotherapy concurrent with thoracic radiation therapy (CCRT) 
in 68 (Group B); and CCRT followed by consolidation chemotherapy in 87 (Group C), 
respectively. Chemotherapy dose intensity was lower in CCRT setting than in upfront or 
consolidation chemotherapy settings, while thoracic radiation therapy dose schedule 
was the same (50 Gy/25 fractions). Clinical outcomes of loco-regional control (LRC), 
distant-metastasis free survival (DMFS) and overall survival (OS) were compared among 
Groups. Results: Median follow-up duration was 30 (5~93) months. Median age of 
all patients was 60 years and 149 patients (62.1%) were male. Majority of patients 
(224 patients, 93.3%) underwent lobectomy, while 16 (6.7%) did pneumonectomy. 
Adenocarcinoma was most common in 165 patients (68.8%) followed by squamous 
cell carcinoma in 53 (22.1%), and others in 22 (9.2%). There was no difference among 
Groups with respects to pretreatment and treatment characteristics except median 
age (Group A was older: 63 years vs. 58 years vs. 58 years, p=0.022). LRC, DMFS 
and OS rates at 5 years in all patients were 75.1%, 38.0% and 76.2%, respectively. 
Terminology Criteria for Adverse Events (CTCAE v4.02). Two patients (1.9%) developed 
grade 3 toxicity of esophagus. There were no grade 4 or above toxicity. Eight patients 
developed asymptomatic rib fracture, all of these patients had peripheral lesions 
( defined as < 2.5cm from chest wall), of which three patients had lesions touching 
chest wall, median time to development of rib fracture was 19 months (range 9-40 
months). Conclusion: SBRT is an effective treatment option for early-stage-non-small 
cell lung cancer with limited toxicity. Overall survival and local control were greater for 
patients with T1 tumors compared to T2 tumors. Higher doses (BED10>105 Gy) were 
associated with improvement in local control and overall survival. Significant improvement 
in local control was observed in patients with T2 tumors treated with BED10>105 Gy. 
Keywords: lung cancer, non-small cell lung cancer, stereotactic body radiotherapy, 
Biologically effective dose
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P3.02-039 Is Volumetric Rapid Arc Irradiation Superior in the Treatment 
of Non Small Cell Lung Cancer? Evy Bossuyt1, Christel M. De Pooter2, Katrien 
Erven1, Yasmine Geussens1, Rita Reymen1, Philippe Huget1 1Az St Augustinus, Wilrijk/
Belgium, 2Radiotherapy, Az St Augustinus, Wilrijk/Belgium
Background: To make an irradiation plan for a patient with non small cell lung cancer 
without compromising myelum and healthy lung tissue, is often a challenging task. The 
purpose of this study was to investigate if Volumetric Rapid Arc irradiation would be 
superior in doing so. Methods: Patients were simulated with regular breathing on a lung 
support. The target alignation and definitions were standard. Dose optimalisation and 
calculation were performed in Eclipse using AAA version 10.0.28. 82 Different approaches 
in planning were made for different patients: conventional beams, and rapid arc plans with 
half arcs, full arcs, arcs with avoidance sectors and hybrid solutions. Calculations were 
made for a dose of 33 x 2Gy , with 98% coverage of PTV (planning target volume) with 
95% of the dose , taking into account the mean lung dose, V20 and V5. Results: There is 
no class solution for the best treatment approach. The best technique depents on tumor 
size, lung size, tumor localisation and patient anatomy. Especially for small tumors, the 
conventional beams often give the best results in terms of lung dose, especially when 
myelum can be avoided without irradiating the contralateral lung. Half arcs were mostly 
not interesting, probably because both sides of oblique posterior fields are often needed 
for good PTV coverage. Using avoidance sectors was a better approach to spare more 
healthy lung tissue. Choosing the angles of the avoidance sectors is important, like 
choosing angles for conventional fields. Making a simple conventional plan first, gives 
a good idea of feasible lung and PTV dose and about angles for the avoidance sectors. 
The use of avoidance sectors generally gives a better solution in terms of lung dose, 
but if PTV is not fully covered and a lot of overdosage appears, one has to use smaller 
avoidance sectors or even work without. If the proposed constraints are not reached 
with these tools, it is possible to work with a hybrid solution. This is in practice more 
complicated, therefore we did not introduce this as a standard planning technique in our 
clinic. Conclusion: For small tumors, conventional beams are often better than rapid 
arc. If the tumorvolume is larger (> 300cc) and reaching different sides of the body (from 
left to right or from cranial to caudal), rapid arc gives better results. Avoidance sectors 
have to be chosen wisely to optain the constraints without turning to hybrid techniques. 
Keywords: hybrid irradiation, Radiotherapy, rapid arc irradiation, NSCLC
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P3.02-040 PEARL: Pathologic Effect of NeoAdjuvant Stereotactic Ablative 
Body Radiotherapy (SABR) in Operable Early Stage Lung Cancer Jan P. Van 
Meerbeeck1, Katrien Vandecasteele2, Kurt Tournoy3, Karim Y. Vermaelen4, Frederic 
De Ryck5, Veerle F. Surmont4 1Thoracic Oncology, University Hospital, Edegem/
Belgium, 2Radiation Oncology, University Hospital, Gent/Belgium, 3Pulmonology, Onze 
Lieve Vrouwe Ziekenhuis, Aalst/Belgium, 4Pulmonology, University Hospital, Gent/
Belgium, 5Thoracic Surgery, University Hospital, Gent/Belgium
Background: SABR is considered a valid alternative to surgical resection in stage 
IA NSCLC (Senan, TLO 2013). However, doubts persists regarding the risk of local 
recurrence as lymph node staging is suboptimal and the completeness of pathological 
response is not verified (Van Schil, TLO 2013). Methods: We conducted a prospective 
phase 2 trial in functionally operable patients with NSCLC, staged cIA after PET/CT 
and endosonographic staging, who provided informed consent for neoadjuvant SABR, 
followed by VATS resection of primary tumour and draining lymph nodes. Results: We 
report on 1 patient, after which the trial was prematurely closed. This 57 year old 
smoker was incidentally diagnosed with a cT1bN0M0 adenocarcinoma in the middle 
lobe (2.9 x 2.1 cm) and EBUS-confirmed tumour-free ipsilateral hilar and mediastinal 
lymphnodes. 3 weeks after receiving 20 Gray on the tumour bed on days 1/4/7 
each, he underwent a VATS middle lobectomy with systematic lymph node sampling. 
The resection specimen showed a completely resected 2.5 cm vital adenocarcinoma 
with invasion of 1/3 hilar lymph nodes (ypT1bpN1M0R0Pl0). 4 cycles of adjuvant 
cisplatin-based chemotherapy were uneventfully administered and patient remains 
in complete remission 4 years after resection. Conclusion: This prospective case 
report challenges the completeness of pathological response and of lymph node 
staging with SABR. Comprehensive bio-imaging will be presented at the meeting. 
Keywords: lymph node staging, SABR, stage IA NSCLC, lobectomy
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P3.03-003 Pilot introduction of the IASLC nodal classification system across 
EBUS-TBNA, CT and PET in staging of Non Small Cell Lung Cancer 
Lorena F. Zhang1, Louise Emmett2, Brad Milner2, Natalia Belousova3, Liam Clifford4, 
Adrian Havryk2, Emily Stone2 1The Kinghorn Cancer Centre, Sydney/NSW/Australia, 2St 
Vincent’S Hospital, Sydney/NSW/Australia, 3Port Macquarie Hospital, Port Macquarie/NSW/
Australia, 4The University of New South Wales, Sydney/NSW/Australia
Background: The accurate reporting of lymph node status is important in the staging 
and subsequent management of primary non small cell (NSCLC) lung cancer. However, 
lymph node nomenclature varies widely across staging modalities and between 
operators. Nodal stage may therefore be lost in translation when interpreting reports, 
compromising accuracy and possibly patient care. The International Association 
for the Study of Lung Cancer (IASLC) system of lymph node classification facilitates 
standardized, accurate identification of mediastinal lymph node groups. Preliminary 
work at our institution indicates a low uptake of this classification system in staging 
modalities, particularly CT and PET/CT. Application of this classification system 
across staging modalities may improve consistency of staging in primary NSCLC. 
 
Aim 
To determine the feasibility and impact of prospectively introducing the IASLC nodal 
classification system in a retrospectively identified series of NSCLC cases Methods: A 
series of cases of NSCLC (n=54) with IASLC classification at EBUS-TBNA identified in 
preliminary work will be reviewed. A sub-group will be selected that have had both other 
key staging modalities (CT and PET/CT) at our institution. IASLC classification will be 
applied retrospectively to two other key staging modalities, CT and PET/CT, by study 
investigators. Results: The primary endpoint for analysis is change in final nodal stage 
before and after the application of IASLC classification. Secondary endpoints include 
(i) change in IASLC classification between PET/CT and EBUS-TBNA, (ii) change in IASLC 
classification between CT and PET/CT, (iii) change in IASLC classification between CT 
and EBUS-TBNA. Conclusion: The effect of introducing IASLC lymph node classification 
across three staging modalities in NSLC (CT, PET/CT and EBUS-TBNA) will be presented. 
Keywords: Nodal classification, EBUS-TBNA, Mountain-Dresler, NSCLC
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P3.03-004 Clinicopathological Factors Associated With Postoperative Survival 
in Patients With Pathological Stage IB Non-Small-Cell Lung Cancer 
Masanori Shimomura, Shunta Ishihara Department of General Thoracic Surgery, Ayabe 
City Hospital, Ayabe, Kyoto/Japan
Background: The treatment outcomes of patients with non-small-cell lung cancer have 
improved because of advances in diagnostic imaging and multidisciplinary therapies. 
However, the reported 5-year survival rate of patients with pathological stage IB non-
small-cell lung cancer is approximately only 60%. We evaluated the clinicopathological 
factors associated with postoperative survival in patients with pathological stage IB 
non-small-cell lung cancer. Methods: From July 2006 through July 2014, 56 patients 
with pathological stage IB non-small-cell lung cancer underwent lung resection. We 
retrospectively evaluated the factors of age, sex, preoperative carcinoembryonic 
antigen level, pathological classification, tumor diameter,EGFR mutation, and pleural, 
lymph duct, and venous invasion. Results: The 5-year survival rates of the overall 
cohort and of patient subsets with squamous and non-squamous cell carcinoma 
were 60.8%, 22.7%, and 83.2%, respectively. A survival analysis revealed that 
both squamous cell carcinoma and v1 venous invasion were associated with poor 
prognosis. Further analysis revealed that the 5-year survival rates of patients with 
v1 and v0 invasion were 24.6% and 73.9%, respectively. Conclusion: Patients 
with pathological stage IB non-small-cell lung cancer classified as squamous 
cell carcinoma and those with v1 invasion have a higher risk of recurrence. 
Keywords: Non-small-cell lung cancer, Surgery, stage IB, Prognosis
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P3.03-005 Review of the Impact of Robotic Surgery on Pulmonary Resections 
Performed at a Comprehensive Cancer Center Patrick Ross1, Patsy Skabla2, Priyal 
Shah1, Thomas Williams2 1The Ohio State University Wexner Medical Center, Columbus/
OH/United States of America, 2The Ohio State University Wexner Medical Center, Columbus/
United States of America
Background: Minimally invasive surgical techniques have emerged as potential 
platforms for improving surgical outcomes. Thoracoscopic pulmonary resection 
was developed in the mid 1990’s but has yet to achieved dominance as the resection 
approach of choice. Robotic-assisted pulmonary resection has been developed in a 
number of institutions. In this report we will review the impact of the robotic platform 
on pulmonary resections at a comprehensive cancer center. Methods: All robotic cases 
were entered prospectively into an IRB outcomes database. Comparable data for open 
and thoracoscopic procedures was retrieved from our STS database submissions. We 
limited the review to the procedures performed by a single surgeon to eliminate the 
impact of multiple learning curves on the robotic resections. We reviewed 330 robotic 
pulmonary resections culled from the total robotic experience of 503 between 2010 
through March, 2015. Single-surgeon data for open cases was retrieved for the same 
time frame through the STS database. We evaluated percentage of minimally invasive 
cases annually, length of stay, length of procedure, complications, duration of air 
leak, readmissions and mortality. Results:Between 2010 and 2015 the percentage 
Though no significant difference in OS at 5 years among Groups (76.8% vs. 68.4% vs. 
82.5%, p=0.096), LRC rate at 5 years was significantly improved by addition of thoracic 
radiation therapy (62.9% vs. 78.9% vs. 82.9%, p=0.011), while DMFS rate at 5 years was 
significantly improved by delivering full dose chemotherapy (40.6% vs. 19.4% vs. 28.6%, 
p=0.018). Conclusion: Although in retrospective nature having potential selection bias, 
current observations support that maximal benefit could be achieved by thoracic radiation 
therapy concurrent with chemotherapy and consolidation full dose chemotherapy 
with respects to LRC and DMFS. Further prospective clinical trial would be desired. 
Keywords: Stage IIIA, non-small cell lung cancer, concurrent chemoradiotherapy
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P3.03-002 Risk Factors and Outcomes of Pneumonectomy in Patients with 
Lung Cancer Manuel Wong Jaen, Joan Solé Montserrat, Laura Romero Vielva, María 
Deu Martin, Alberto Jauregui Abularach, Irene Bello Rodriguez, Mercedes Canela 
Cardona Thoracic Surgery, Vall D’Hebron University Hospital, Barcelona/Spain
Background: Pneumonectomy has been associated with high morbidity and mortality. 
The aim of this study is to evaluate complications, risk factors of mortality and overall 
survival of patients undergoing pneumonectomy for lung cancer. Methods:Retrospective 
study of 380 consecutive patients operated between January 2004 and December 2014. 
The majority were male (87, 4%), with a mean age of 60.7 years (r: 29-81) and a mean 
follow-up of 31.7 months. Results: Right pneumonectomy was the most frequent 
procedure (58.2%). Most of the patients were diagnosed with squamous cell carcinoma 
(56.1%). Half of the patients received neoadjuvant chemotherapy (50.5%) and 18 (4.7%) 
concomitant radiotherapy. N2 disease was present in 125 patients (32.9%). 
 
The most frequent complication was atrial fibrillation (14%). Twenty-seven patients (7.1%) 
required reoperation for postoperative bleeding. Bronchopleural fistula appeared in 54 
patients (14.21%). Twenty-five patients (6.6%) died within 30-days after surgery. Overall 
survival was 36.6% months with rates at 1, 3 and 5 years of 73.2%, 42.5% and 31,2% 
respectively.
 
Survival according to tumor size showed significant differences (T1: 33.1 months, T2: 
21.1 months, T3: 11.4 months and T4:10.3 months). Survival was lower in patients with N2 
disease (10.8 vs 30 months, p=0.0000). Overall survival was higher for left pneumonectomy 
(17.6 vs 24.8 months).There were significant differences in survival when analyzing lung 
function parameters, histological type, cancer stage, neoadjuvant treatment, pulmonary 
or cardiac complications, and reoperation for postoperative bleeding. Conclusion: In our 
series, age, side of resection, lung capacity, tumor extension, extent of surgical resection, 
comorbidities and postoperative complications are associated with decreased survival. 
Keywords: overall survival, pneumonectomy, risk factors, morbidity
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local failure. Results: Case1: A woman was underwent cryoablation treatment for second 
primary T1aN0M0 lung adenocarcinoma in left lower lobe after 6 years of right lower 
lobectomy for lung adenocarcinoma. 4 years after the cryoablation, CT scan showed a 
tumor increasing in size in the area of treatment and local recurrence was suspected. 
Recurrence of adenocarcinoma was confirmed by CT guided biopsy. Segmentectomy of 
posterior segment of left lower lobe was performed. Operation time was 155minutes and 
blood loss was 72 ml. This patient is alive without any sign of recurrence after 8 years 
from surgery. Case2: A woman was underwent cryoablation for clinical stage T1aN0M0 
lung adenocarcinoma in right lower lobe after 20 years of right upper lobectomy for lung 
cancer. 3 years after the cryoablation, CT scan showed a tumor growing in size in the area 
of treatment and local recurrence was suspected. Local recurrence of adenocarcinoma 
was proved by CT guided biopsy. Segmentectomy of superior segment of right lower lobe 
was performed. Operation time was 291minues and blood loss was 230 ml. This patient is 
alive without any sign of recurrence after 22 months from surgery. In both cases, salvage 
surgeries were performed without any difficulties. Pathological examinations showed 
viable cancer cells with necrotic tissue and fibrosis around which was consistent with 
the local recurrence after cryoablation. Conclusion: The salvage surgery for the local 
failures after non-surgical treatment modalities might be indicated in selected cases. The 
difficulties in diagnosis of local recurrence might cause the optimal timing of surgery. 
Keywords: salvage surgery, lung cancer, local recurrence, cryoablation
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P3.03-008 Lung Resections: Limited Resection for Operable Lung Cancer 
Swamyvelu Krishnamurthy, Durgesh Kumar Surgical Oncology, Kidwai Memorial Institute 
of Oncology, Bangalore/India
Background: Lung cancer is the commonest cancer worldwide and the leading cause 
of cancer related deaths. Most common etiology is smoking which includes both active 
and passive. Surgery ,chemotherapy and radiation therapy ,are treatment options 
available . In india presentation of the lung cancer is usually in advanced stages because 
of various socioeconomic conditions. Methods: It is a retrospective study. Data were 
collected from the hospital database which includes no of patients who underwent lung 
resection for carcinoma lung between a period of January 2011 to December 2014. 
Data was analysed regarding number of patients who underwent surgery, surgery related 
complications, adjuvant treatment , and survival Results: Total number of cases seen 
in this time period was 360 with a sex ratio of 2:1 out of which 45 underwent surgery 
{12.5 %},rest underwent palliative chemotherapy due to advance disease .Out of 45 
cases 28 were diagnosed as adenocarcinoma, 16 squamous cell and 1 case of limited 
stage small cell lung cancer .Most cases were stage IIA {17/45} followed by {IB 9/45}, 
6 cases were diagnosed as stage IIB , 4 cases stage IA and 9 out of 45 cases were 
stage IIIA .39 out of 45 underwent lung resection and rest 6 cases were found locally 
advanced on exploration ,biopsy taken and closed .Lobectomy done in 23 patients (60 
%) followed by bilobectomy (30.7 %) pneumonectomy in 3 cases only and 1 patient 
underwent bilobectomy with excision of the ribs with chest wall reconstruction .Post 
operative pneumonia was the most common complication found in 3 patients ,followed 
by wound infection (1/39) , prolonged air leak(2/39) and chest wall recurrence (1/39).All 
patients with stage IB and above underwent cisplatin based adjuvant chemotherapy and 
six patients underwent adjuvant radiotherapy . Average survival in our study was 2 years 
for stage IA – IIB and 6 months for stage IIIA . Conclusion: The incidence of lung cancer 
is rising dramatically and it is now the most common cause of cancer related mortality 
and morbidity not only in industrialised nations,but also in developing countries like India 
as well.In our study we found only 13 % operable lung cancer despite of huge incidence 
and we were able to do less than pnemonectomy in majority of the patients .The survival 
is moderate for the lung cancer patients in view of our inability to detect early lung cancer 
patients.The ideal screening tools for early detection of the lung cancerhas still not found 
so drastic measures amied at discouraging people from smoking and early encouraging 
high risk population to undergo regular screening to reduce the morbidity and mortality.
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P3.03-009 A Case of Completion Pneumonectomy Performed Through Mid-
Sternal Incision and Posterolateral Incision Masato Watanabe, Shozo Fujino, 
Takehiro Okumura Department of Surgery, University Hospital Mizonokuchi, Teikyo 
University School of Medicine, Kawasaki, Kanagawa/Japan
Background: We report a case of completion pneumonectomy (CP) for recurrent 
lung cancer in which we resected the residual left lower lobe through posterolateral 
incision following confirmation of resectability of residual lung and no mediastinal lymph 
node metastasis through mid-sternal incision. Methods: [Case] A 71 year-old-man 
who underwent left upper sleeve lobectomy 2 years ago (squamous cell carcinoma, 
pT2bN1M0 2B) complained chronic coughing and sputum. Bronchofibroscope and chest 
computed tomography (CT) revealed a local recurrence at the left main bronchus and 
surrounding tissue of left pulmonary artery. No distant metastasis was pointed out 
by CT and other examinations. The patient’s pulmonary function was good (VC 3.29L, 
FEV1 .0 2.05L) and the predictive FEV1 .0 was 1.94L by the ventilation-perfusion 
scintigraphy. [Surgery] We added a mid-sternal incision in the supine position and 
confirmed no mediastinal lymph node metastasis and the resectability of left main 
pulmonary artery, then we cut the left main pulmonary artery in the pericardial cavity 
with exposing trachea, tracheal bifurcation and left main bronchus. After closing mid-
sternal incision, the patient was converted into the right decubitus position and added 
posterolateral incision. After having separated the lower pulmonary vein and the stump 
of upper pulmonary vein in a pericardium, we exfoliated and cut left main bronchus and 
removed the residual left lower lobe. The operation time was 13 hours and 7 minutes 
of minimally invasive lobectomies performed annually increased from 23 % to 94%. 
Conversions from robotic approach to open decreased from 8% in the first 100 cases 
to 4% in the last 100 cases. Mortality for robotic lobectomy was 0.8% compared to 
open lobectomy 2.0%. Readmission rate for robotic resections was 9.7 % compared to 
16% for open cases. Only a single robotic case was readmitted for pain management. 
There was a trend to lower post-operative pneumonia incidence in the minimally 
invasive group. Conclusion: In our single institution, single surgeon experience, adding 
the robotic platform quadrupled the percentage of lobectomies accomplished with a 
minimally invasive approach. There was a continued decrease in length of procedure 
as team experience accumulated. The outcomes measures of mortality, readmission, 
length of stay and pneumonia demonstrated advantage to the robotic platform. 
Robotic pulmonary resection may be the platform for increasing minimally invasive 
resections. Throughput metrics of operating time, length of stay and readmission 
are favored in the robotically performed procedures with an experienced team. 
Keywords: Thoracic Surgery, Robot, lobectomy, lung cancer
POSTER SESSION/ TREATMENT OF LOCOREGIONAL DISEASE – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.03-006 Wide Wedge Resection with Adequate Surgical Margin for Pure GGO 
Lesion after Marking the Position near the Tumor with Lipiodol under a CT Scan 
Guide Katsuo Kojima1, Ken Takahashi1, Yasunori Arai2 1Thoracic Surgery, Musashino Red-
Cross Hospital, Musashino-Shi, Tokyo/Japan, 2Division of Radiology, Musashino Red-Cross 
Hospital, Musashino-Shi, Tokyo/Japan
Background: It is said that wide wedge resection of lung is suitable for the surgical 
method for adenocarcinoma in situ (=AIS) in lung cancer in case that surgical margin 
is gotten enough. If the tumor shadow in high resolution CT scan is pure ground glass 
opacity (=pure GGO), we can suppose the tumor to be AIS. But pure GGO lesion is often 
too difficult for us to recognize the localization and the border of a tumor at surgery. 
We had once undergone segmentectomy or lobectomy after the pure GGO lesion had 
progressed so as to include consolidation in the tumor as a result of several follow-up CT 
examinations. The technique of the lipiodol marking to lung under a CT scan guide was 
developed and a small lesion of lung came to be able to be marked safely. Therefore we 
have undergone wide wedge resection in which the surgical margin was gotten enough 
for expected AIS with the following modified technique of the marking. Methods: We 
have performed this technique for the pure GGO lesions which is increasing in size or in 
concentrations but do not have occurrence of consolidations in periodic high resolution 
CT scan examination. Marking technique is following. Marking is performed under local 
anesthesia in a CT room one day before surgery. We stab the skin at slightly remote 
diagonal position from right above tumor with 22G needle and push forward needlepoint 
to the central near side of tumor while confirming it by real-time CT scan before we 
inject 0.3ml of lipiodol at the central near side of tumor. The operation of marking is 
finished after confirming whether pneumothorax exists. Surgical technique is following. 
We perform this surgery by three port thoracoscopic surgery. We grasp the marked 
position of the lung with ring forceps under thoracoscope while confirming the lesion 
marked by lipiodol is located in the center of the ring by real time fluoroscopy (Mobile 
C-arms). Then we cut the lung along ring circumference of the forceps with automatic 
suture instruments. After taking out a specimen outside the body, we confirmed 
that the surgical margin was gotten enough by measuring the distance between 
the resection stump and the position of marking under fluoroscopy. Results: We 
performed wide wedge resection to 19 cases (22 lesions) with this technique between 
2011 and 2014. Tumor diameter was an average of 9mm (6-13mm). Surgical margin 
was an average of 17mm (11-28mm). Pathological diagnosis was AIS in 19 lesions, 
minimally invasive adenocarcinoma in 1 lesion, atypical adenomatous hyperplasia in 1 
lesion and mucinous adenocarcinoma in 1 lesion. There was one complication before 
surgery (pneumothorax which needed drainage after marking). We underwent left S9 
segmental resection with lymph node dissection in addition for a case of mucinous 
adenocarcinoma. Conclusion: This technique is an extremely useful method when we 
perform the most minimally invasive surgery such as wide wedge resection for very 
early lung cancer before progressing because it is easy to get surgical margin enough. 
Keywords: pure GGO, lipiodol marking under a CT scan guide, wide wedge resection, 
surgical margin
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P3.03-007 Salvage Surgery for Local Recurrence after Cryoablation for 
Non-Small Cell Lung Cancer: Importance of Diagnosis of Recurrence without 
Delay Shinsaksu Matsuda1, Takashi Ohtsuka1, Hideaki Yashiro2, Seishi Nakatsuka2, 
Keisuke Asakura1, Tai Hato1, Ikuo Kamiyama1, Katsura Emoto3, Yuichiro Hayashi3, 
Hisao Asamura1 1Division of General Thoracic Surgery, Department of Surgery,, School of 
Medicine, Keio University, Shinjuku-Ku, Tokyo/Japan, 2Department of Diagnostic Radiology, 
Keio University, School of Medicine, Tokyo/Japan, 3Division of Pathology, School of Medicine, 
Keio University, Shinjuku-Ku, Tokyo/Japan
Background: Non-surgical treatment for lung cancer, such as stereotactic body 
radiation therapy (SBRT), radiofrequency ablation (RFA), and percutaneous cryoablation 
have been performed as alternatives to surgery for lung cancer in patients with 
comorbidities, limited pulmonary reserve, or early diseases. Not many, but the significant 
portion of patients with such local modalities experience the local failures. The salvage 
surgery for such recurrence might have been attempted with considerable technical 
and oncological difficulties. Two cases with salvage resection for local failure after 
cryoablation are described. Methods: We reviewed two patients who had previously 
undergone cryoablation, in whom local recurrences were treated with salvage surgery. 
We evaluated perioperative parameters and histological findings, which indicated the 
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cardiac chest pain in a patient receiving GA, and two episodes of desaturation in the 
MS group that resolved with temporary interruption of the procedure. Conclusion: As 
payor scrutiny and emphasis on quality, cost-effective health care increases, convex 
probe EBUS-guided biopsy utilizing moderate sedation remains an effective, accurate 
method of diagnosing malignant and non-malignant disease in the mediastinum without 
the added cost of general anesthesia and without compromising patient safety. Certainly 
general anesthesia can be an invaluable resource for bronchoscopic procedures in 
high-risk patients with morbid obesity, sleep apnea, heavy home narcotic or sedative 
use and other complex comorbidities, but healthcare facilities without anesthesia 
services can acquire and effectively employ convex EBUS technology with confidence. 
Keywords: TBNA, EBUS, general anesthesia
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P3.03-012 Prediction of Occult Lymph Node Metastasis Using Metabolic PET 
Parameters in Small Size Peripheral Non-Small Cell Lung Cancer Joonho Jung1, 
Seong Yong Park1, Su Jin Lee2 1Department of Thoracic and Cardiovascular Surgery, Ajou 
University School of Medicine, Suwon/Korea, 2Department of Nuclear Medicine & Molecular 
Imaging, Ajou University School of Medicine, Suwon/Korea
Background: Small size peripheral non-small cell lung cancer (NSCLC) patients without 
lymph node metastasis may be the optimal candidates for sublobar resection. We aimed 
to identify the predictors of occult lymph node metastasis using F-18 fluorodeoxyglucose 
positron emission positron emission tomography/computer tomography (PET/CT) in 
small size NSCLC patients who were clinically node negative. Methods: One hundred 
fifty three patients with small size NSCLC (less than 3cm in diameter) who underwent 
surgical resection with mediastinal lymph node dissection were evaluated. The 
maximum standardized uptake value (SUVmax), metabolic total volume (MTV), and 
total lesion glycolysis (TLG) of primary tumor were measured on pretreatment PET/CT. 
These metabolic parameters and pathological variables were analyzed for lymph node 
metastasis. Results: The mean tumor size was 2.11 ± 0.55 cm and the mean numbers of 
dissected lymph nodes were 16.33 ± 9.81. The adenocarcinoma was 103 (67.3%). Thirty 
patients (19.6%) had lymph node metastasis. The mean SUVmax, MTV and TLG were 4.85 
± 4.02 (0.5 ~ 16.4), 3.39 ± 5.54 (0 ~27.2) and 14.99 ± 27.78 (0 ~155.9), respectively. 
On receiver operating characteristic curve analysis, area under the curve (AUC) of 
SUVmax, MTV, TLG for node metastasis were 0.744, 0.750 and 0.745, respectively. On 
multivariate analysis, SUVmax (Odds ratio [OR] = 1.172, p=0.006), MTV (OR = 1.153, 
p=0.002) and TLG (OR=1.024, p=0.08) were risk factors for node metastasis after 
adjusting the tumor size and cell type. The concordance index of MTV was 0.722, which 
was slightly higher than those of SUVmax and TLG.
 
Figure. ROC curve of each volume parameters of positron emission tomography/
computer tomography for predicting the node metastasis Conclusion: SUVmax 
and volume-dependent parameters of primary lesion were significant risk factors 
for node metastasis in small peripheral NSCLC. MTV showed better predictive 
performance than other PET parameters, therefore MTV may be the possible 
indicator for sublobar resection in clinically node-negative small size NSCLC. 
Keywords: NSCLC, lymph node metastasis, PET/CT
and total blood loss was 2.23L. Postoperative course was almost uneventful and he 
left our hospital on the 30th postoperative day. He has no recurrence or metastasis 
12-months after surgery. Results: [Discussion] It is said that the incidence of serious 
complications after CP extends to 18.4~40.7% and the incidence of bronchial fistula is 
over 10 percent. Because the survival rate is reported with 38.9~48.3% at 3-year and 
16.9~48% at 5-year, careful adaptation decision is necessary. Conclusion: [Concluding 
remarks] Our approach to confirm the resectability and no mediastinal lymph node 
metastasis through mid-sternal incision is useful to make final decision of indication 
for CP. In addition, there is an advantage that intrathoracic operation is easy to 
perform because hilar region is handled beforehand through mid-sternal incision. 
Keywords: completion pneumonectomy, mid-sternal incision, posterolateral incision
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P3.03-010 Usefulness of Vessel Sealing Devices in Thoracoscopic Lobectomy 
for Lung Cancer Masayuki Toishi, Kazuo Yoshida, Hiroyuki Agatsuma, Takao 
Sakaizawa, Takashi Eguchi, Gaku Saito, Akira Hyogotani, Kazutoshi Hamanaka, Takayuki 
Shiina Department of Thoracic Surgery, Shinshu University School of Medicine, Matsumoto/
Japan
Background: Vessel sealing devices (VSD) are widely used for various surgical 
procedures. They are regarded as useful in thoracoscopic surgery, but few reports have 
substantiated this belief by comparison with non-use of VSD in human thoracoscopic 
lobectomy. Aiming to establish a simpler and safer thoracoscopic lobectomy, we 
examined the usefulness of VSDs. Methods: Primary lung cancer patients for whom a 
thoracoscopic lobectomy involving mediastinal lymph node dissection was planned in 
our department from April 2011 to June 2013 were recruited for the study. Patients were 
randomly allocated to a control group (n=15) or a VSD group (n=46), which constituted 
of three subgroups, namely, EnSeal (n=17), LigaSure (n=15), and Harmonic (n=14). 
The control group comprised of patients undergoing surgery solely with ligation and 
conventional electrocautery. EnSeal, LigaSure, and Harmonic were chosen because they 
are the 3 most popular disposable VSDs used in Japan. Primary endpoints were burst 
pressure of the pulmonary artery stump (measured using resected specimens), operative 
time, intraoperative blood loss, instances of endostapler use, intraoperative surgeon 
stress (assessed by visual analog scale), and postoperative drainage volume and duration. 
As a secondary objective, the individual VSD groups were also compared with each 
other. Results: The burst pressure of ligation-treated pulmonary artery stumps was higher 
than that of VSD-treated stumps (P<0.0001). The burst pressure of < 5-mm wide VSD-
treated stumps was higher than that of ≥ 5 mm wide stumps (P=0.0359). However, burst 
pressure for all groups and all vessel diameters was sufficient to withstand physiological 
pulmonary artery pressure. The VSD group demonstrated reduced intraoperative blood 
loss (P=0.0174), surgeon stress (P=0.0001), postoperative drainage volume (P=0.0270), 
and shortened postoperative drainage duration (P=0.0330). Operative time and the 
instances of endostapler use did not significantly differ. Comparison between each of 
the VSD groups revealed no significant differences. None of the patients experienced 
serious perioperative complications or died because of surgery. Conclusion: VSD 
is simple and safe to use in thoracoscopic lobectomy involving mediastinal lymph 
node dissection for primary lung cancer. Further, none of the VSDs used in this study 
presented any observable differences in quality that could lead to clinical problems. 
Keywords: vessel sealing, burst pressure, mediastinal lymph node dissection, 
thoracoscopic lobectomy
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P3.03-011 General Anesthesia Is Not Required for Safe, Accurate Endoscopic 
Diagnosis of Malignant and Non-Malignant Disease in the Mediastinum 
John D. Doty1, Jaspal Singh2, H J. Norton3 1Thoracic Oncology, Levine Cancer Institute, 
Charlotte/NC/United States of America, 2Thoracic Oncology, Levine Cancer Institute, 
Charlotte/United States of America, 3Department of Biostatistics, Carolinasheathcare 
System, Charlotte/NC/United States of America
Background: Since its introduction in the early to mid 2000’s, endobronchial ultrasound 
(EBUS)-guided transbronchial needle aspiration (TBNA) of mediastinal lymph nodes 
has been shown to be superior to “blind” TBNA for the diagnosis of malignancy and 
sarcoidosis in multiple studies. There is no consensus, however, regarding the 
optimal method of procedural sedation for EBUS. The purpose of this retrospective 
study was to determine differences in sampling accuracy and safety between a 
group of patients undergoing EBUS with moderate sedation and a group with general 
anesthesia. Methods: A retrospective chart review was performed of 51 consecutive 
patients undergoing convex probe EBUS-guided TBNA over a six-month period at a large, 
community-based referral hospital. Fifteen procedures were performed under general 
anesthesia and 36 with moderate sedation using midazolam and fentanyl after topical 
preparation of the upper airway with lidocaine. Twenty nodal biopsies were performed 
on the 15 general anesthesia patients, and 47 biopsies were performed on the 36 
patients from the moderate sedation group. Rapid on-site cytologic evaluation (ROSE) 
was used for most cases. Results: No statistically significant difference was found in 
any measured variable between the two groups, specifically sample adequacy (85% in 
the general anesthesia [GA] group vs. 83% in the moderate sedation [MS] group; p = 
1.0; 95% confidence interval (CI), -17.0 to 21.0%) or frequency of adverse events (6.7% 
GA vs. 5.6% MS; p = 1.0; 95% confidence interval (CI), -13.6 to 15.8%). There was no 
significant difference in the mean size of lymph nodes biopsied (16.4 mm GA vs. 18.3 
mm MS; p = 0.28). Additionally, there was no difference in the proportion of biopsies 
taken from individual nodal stations or in the numbers and types of diagnoses made 
between the two groups. Adverse events were mild and included self-limited, non-
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with locally advanced non-small cell lung cancer (IIIA or IIIB) treated with etoposide/
cisplatin (EP) with concurrent radiotherapy at an University Hospital in South of 
Brazil were identified from electronic database. Medical records were revised and 
demographic data, tumor and treatment characteristics were collected. Overall survival 
and progression freen survival were estimated by Kaplan-Meier curves. Multivariate 
analysis (Log-Rank tests) was performed to identify factors associated with survival. 
Statistical analysis was performed with SPSS 22.0. Results: Seventy-three patients were 
identified and included in analysis. Patients characteristics revealed a mean age of 59.2 
± 10,7 years, male sex in 63%, Caucasian ethnicity in 90%, smoking history in 86%, 
good performance status (0-1) 89% and stage IIIA and IIIB in 52% and 48%, respectively. 
Thirty-eight (52%) patients had adenocarcinoma, 24 (34%) squamous cell and 10 (13%) 
other histologies. All patients were treated with EP concurrent to radiation and 20% 
received two consolidation cycles of chemotherapy. Fifty-three (72%) completed all the 
treatment and 34 (45%) achieved complete or partial response. In the observational 
period 64 patients (88%) had died, with progression free survival of 10,1 months 
(95% IC, 6.97 to 13.17) and overall survival of 15.9 months (95% IC, 9.83 to 22.10). In 
multivariable analysis, clinical stage (IIIA vs IIIB) and performance status (0-1 vs ≥ 2) were 
independently associated with survival, HR 2.23 (95% IC, 1.16 to 4.29) and HR 6.39 (95% 
IC, 2.09 to 19.54), respectively. Conclusion: To our knowledge, this is the first Brazilian 
report of concurrent chemoradiation of locally advanced non small cell lung patients. Our 
outcomes are similar to previously reported clinical trials of concurrent treatment. Stage 
IIIB and performance status > 2 were predictors of worst outcomes in our population. 
Keywords: non-small cell lung cancer, chemoradiation, EP
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P3.03-016 Randomized ph II Trial of Cyclophosphamide with Allogeneic DPV-
001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III 
NSCLC Rachel E. Sanborn1, Brian Boulmay2, Rui Li1, Kyle T. Happel2, Helen J. Ross3, 
Sachin Puri1, Christopher Paustian1, Christopher Dubay1, Helena Hoen1, Sandra Aung4, 
Brenda Fisher1, Carlo Bifulco1, Keith Bahjat1, Augusto C. Ochoa2, Hong-Ming Hu1, Traci 
L. Hilton4, Bernard A. Fox1, Walter J. Urba1 1Providence Cancer Center, Earle A. Chiles 
Research Institute, Portland/OR/United States of America, 2School of Medicine, Louisiana 
State University Health Science Center, Stanley S. Scott Cancer Center, New Orleans/United 
States of America,3Mayo Clinic Arizona, Phoenix/AZ/United States of America, 4Ubivac, 
Portland/OR/United States of America
Background: Tumor-derived autophagosomes (DRibbles) are a novel dendritic cell-
targeted cancer immunotherapy that preclinically provides cross-protection against 
related tumors and efficacy against established tumors. We hypothesize DRibbles’ 
efficacy is due to presentation of stabilized tumor-derived short-lived proteins (SLiPs) and 
defective ribosomal products (DRiPs) normally not processed or presented by antigen 
presenting cells (APCs). SLiPs and DRiPs provide a potential pool of tumor antigen to 
which the host may not be not tolerant. This DRibble DPV-001 vaccine packages several 
hundred putative cancer antigens, including 13 antigens from the NCI list of priority 
antigens and agonist activity for TLR 2, 3, 4, 7 and 9 into stable double membrane 
microvesicles which have surface molecules targeting DRibbles to CLEC9A+ APCs (the 
most effective APC at cross-priming immunity). DPV-001 contains an average of 176 
proteins from genes overexpressed in NSCLC patient tumors. Many of these putative 
cancer antigens have single amino acid variants that may serve as mimetopes, or altered 
peptide ligands, and thereby increase immunogenicity. Methods: Pts are eligible after 
completion of standard curative-intent therapy for stage III NSCLC. Pts receive induction 
cyclophosphamide, then 7 DPV-001 vaccines at 3-week intervals. The first vaccine is 
given intranodally; subsequent vaccines intradermally. Pts are randomized to receive 
DRibble alone, or with adjuvant imiquimod or GM-CSF. Peripheral blood mononuclear 
cells and serum are collected at baseline and at each vaccination. Serum from baseline 
and week 12 is analyzed for antibody response to >9000 human proteins (ProtoArray). 
When available, multispectral Immunoprofiling is performed on tumor to evaluate pre-
existing immunity and Human Exome Capture and Next Generation Sequencing is 
done on tumor (100x coverage) and matched normal tissue. Tumor somatic mutations 
are compared to DPV-001 to identify shared non-synonymous single nucleotide 
variations (nsSNVs) with the vaccine, including mutations with potential increased 
immunogenicity. Pts will be analyzed comparatively for strong antibody responses (>15 
fold increase in titer). 11 pts will be randomized to each arm, with 15 more enrolled 
on the arm with greatest number of strong antibody response. 8 pts have been 
enrolled, and accrual is ongoing. Results: Not applicable Conclusion: Not applicable 
Keywords: non-small cell lung cancer, Vaccine, Immunotherapy
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P3.03-017 Interim Overall Survival of Neoadjuvant Erlotinib Intercalated with 
Gemcitabine/Cisplatin for IIIA N2 NSCLC Patients: A Phase II Study Zhiwei 
Chen1, Gening Jiang2, Xin Wang3, Qingquan Luo1, Shun Lu1 1Lung Cancer Center, Shanghai 
Chest Hospital, Shanghai/China, 2Department of Thoracic Surgery, Shanghai Pulmonary 
Hospital, Tongji University School of Medicine, Shanghai/China, 3Sun Yat-Sen University 
Cancer Center, Guangzhou/China
Background: The optimal treatment for locally advanced stage IIIA non-small cell lung 
cancer (NSCLC) disease is not well established although neoadjuvant chemotherapy 
showed active results in stage IIIA N2 pts. A few case reports also indicate the 
advantages of neoadjuvant erlotinib. FASTACT II study showed that the regimen of 
erlotinib intercalated with chemotherapy improved PFS and OS in an unselected 
advanced NSCLC population of east Asian patients. Here we report the interim overall 
survival (OS) results of a phase II study which was to assess the efficacy and safety 
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P3.03-013 Predictive Factors for Survival in Stage IIIA (N2) NSCLC Patients 
Treated with Neoadjuvant Chemotherapy Followed by Surgery Yaping Xu, Jinshi 
Liu, Xinmin Yu, Qiang Zhao, Youhua Jiang, Qixun Chen, Xinming Zhou, Weimin Mao 
Zhejiang Cancer Hospital, Zhejiang/China
Background: For locally advanced non-small cell lung cancer (NSCLC) patients, although 
the evidence level for induction chemo (chemoradio) therapy is low, the incorporation 
of chemotherapy, radiotherapy, and surgery will greatly impact the strategy of future 
treatment. The objective of this study was to evaluate the risks of recurrence and 
overall survival (OS) in stage IIIA (N2) NSCLC patients undergoing definitive resection 
after neoadjuvant chemotherapy. Methods: A retrospective analysis of 106 consecutive 
patients with stage IIIA (N2) NSCLC who received neoadjuvant chemotherapy followed 
by surgery between January 2008 and October 2013. While reviewing the clinical and 
surgical data, we also assessed histopathologic and imaging (chest CT scan) factors. 
Disease-free survival (DFS) and OS were estimated with predictors for recurrence and 
survival. The Kaplan–Meier method was used to evaluate patient DFS and OS. Univariate 
analysis of patient clinical characteristics and treatment response were conducted using 
the Chi-square and Fisher’s exact test. Results: Median age was 60, 96 (90.5%) patients 
were male, 85 (80.2%) patients were squamous cell carcinoma and 21 (19.8%) patients 
were non-squamous cell carcinoma, 93 (87.7%) patients had a lobectomy. The 3-year OS 
for patients with and without recurrence was 33.1 and 56.7 %, respectively (p < 0.001). 
Size decrease of target lesion(s) ≥30 % on post-neoadjuvant chemotherapy chest CT 
scan (p = 0.040), primary tumor size on surgical specimen <10 mm (p = 0.047), and 
pathological complete remission in the mediastinal lymph nodes were related to longer 
OS. Larger tumor size on post-neoadjuvant chemotherapy chest CT scan (p = 0.038), 
male gender (p = 0.043), squamous cell carcinoma (p = 0.048), larger primary tumor size 
on surgical specimen (p = 0.041), pathological non-complete remission in the mediastinal 
lymph nodes (p = 0.031 ) were related to shorter DFS significantly. Conclusion: OS is 
prolonged with greater extent of size decrease of target lesion(s) on post-neoadjuvant 
chemotherapy chest CT scan, smaller tumor size on surgical specimen and pathological 
complete remission in the mediastinal lymph nodes. Larger tumor size on post-
neoadjuvant chemotherapy chest CT scan, male gender, squamous cell carcinoma, 
larger primary tumor size on surgical specimen, pathological non-complete remission 
in the mediastinal lymph nodes may prone to the higher probability of recurrence. 
Keywords: Mediastinal nodal involvement, N2 non-small-cell lung cancer, predictive 
factors, neoadjuvant therapy
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P3.03-014 The Impact of Post-Operative Adjuvant Chemotherapy for Resected 
NSCLC in the Real-World Setting: Single Center Experience Wenhua Liang1, Qihua 
He2, Jianrong Zhang1, Jianxing He1 1The First Affiliated Hospital of Guangzhou Medical 
University, Guangzhou/China, 2Department of Thoracic Surgery, The First Affiliated Hospital 
of Guangzhou Medical University, Guangzhou/China
Background: Recent evidence argues against the benefits from adjuvant chemotherapy 
(ad-chemo) for resected NSCLC in the real world setting. We sought to examine the 
impact of ad-chemo based on the data from our center. Methods: A consecutive 
cohort of 681 patients who underwent radical resection for stage I to III NSCLC in our 
center between Sep 2009 and Dec 2011 was collected. Patients who received adjuvant 
EGFR-TKIs were excluded. Patients lost follow-up upon discharge (uncertain history of 
ad-chemo) were included in sensitivity analyses. The primary endpoint was disease-
free survival (DFS). Results: 372 patients received ad-chemo whereas 224 did not, 
and the remaining 85 had no certain record of ad-chemo. There were 222 events (175 
recurrence and 47 deaths). Univariate analysis showed that patients who received ad-
chemo had shorter DFS than those who did not (HR 1.94, 95%CI 1.40 to 2.67; P<0.001). 
Incorporation of those without certain record of ad-chemo (HR 1.88; P<0.001) or 
excluding patients with stage I disease (HR 1.36; P=0.17) did not alter the trend. After 
adjusting for some important prognostic factors, such as stage, histology, visceral-
pleural invasion, the inferiority of ad-chemo remained. In ad-chemo arm, we observed 
potentially better DFS in patients receiving platinum-based regimen (HR 0.64, 95% CI 
0.38 to 1.07; P=0.09) and patients complete 4 or more cycles of ad-chemo (HR 0.73, 
95% CI 0.52 to 1.01; P=0.05). Conclusion: Current results suggested that applying 
adjuvant chemotherapy should be based on strict patient selection. Establishment of 
selection criteria regarding recurrence risk and physical status is highly encouraged. 
Keywords: NSCLC, adjuvant chemotherapy, Real world
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P3.03-015 Outcomes of Chemoradiotherapy for Stage III Non-Small Cell Lung 
Cancer in South of Brazil Juliano Cé Coelho1, Mariane Araújo Branco2, Rafaela Pirolli2, 
Carolina Beatriz Muller3, Luis Felipe Carissimi Schmidt1, Fábio Klamt3, Guilherme Geib1, 
Gilberto Schwartsmann1 1Medical Oncology, Hospital de Clínicas de Porto Alegre, Porto 
Alegre/Brazil, 2Universidade Federal Do Rio Grande Do Sul, Porto Alegre/Brazil, 3Department 
of Biochemistry, Universidade Federal Do Rio Grande Do Sul, Porto Alegre/Brazil
Background: Patient with stage III lung cancer are commonly treated with chemotherapy 
and radiation. The concurrent treatment improves local control and overall survival, 
but also increase toxicity. A meta-analysis study with more than 1800 patients found 
a 30% reduction in 2-years mortality in who received a platinum-based chemotherapy. 
Trials populations are selected and usually are not representative of Brazil lung cancer 
population. Methods: From January 2005 to December 2013, all patients diagnosed 
S685Copyright © 2015 by the International Association for the Study of Lung Cancer
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P3.03-019 Salvage Surgery after Definitive Chemoradiotherapy in NSCLC 
Patients Oleg Pikin1, Andrey Ryabov2, Vladimir Glushko1, Konstantin Kolbanov1, Ali 
Amiraliev1, Dmitriy Vursol1, Vladimir Bagrov1, Vitaliy Barmin1, Roman Rudakov1 1Thoracic 
Surgery, Hertzen Research Institute of Oncology, Moscow/Russian Federation, 2Thoraco-
Abdominal Surgery, Hertzen Research Institute of Oncology, Moscow/Russian Federation
Background: The benefits of salvage resection for lung cancer recurrence following high-
dose curative-intent chemoradiation therapy are unclear. The study was aimed to assess 
postoperative morbidity and survival after salvage lung resection following definitive 
chemoradiation. Methods: In this retrospective study, medical records of 14 patients 
undergoing lung cancer resections at our institution following definitive chemoradiation 
therapy were reviewed from June 2008 to December 2013. There were 10 (71,4%) males 
and 4 (28,6%) females, median age - 52,6 years. The most common histologic type of 
lung cancer was squamous cell carcinoma (64,3%). Pretreatment lung cancer stage was 
IIB - in 2, IIIA - in 11 and IIIB - in one patient. Definitive radiation treatment varied from 45 
to 70 Gy (median - 58Gy). Mean number of chemotherapy cycles was 3,8 per patient. 
Surgery included pneumonectomy in all patients, except one, whom left-lower lobectomy 
was performed. In all cases bronchial stump was reinforced with a pedicled muscle flap. 
Postoperative complications were registered according to the Thoracic Morbidity and 
Mortality System (TMM). Results: Postoperative complications were registered in 7 
(50,0%) patients: grade II complications were detected in 2, grade IIIA – in 1, grade IVA – 
in 3 and grade V (mortality) – in one patient (7,1%). Pathologic stage was IB – in 2, IIA – in 
1, IIB – in 5, IIIA – in 4 and IIIB – in 2 patients. Overall 1, 2 and 3-year survival was 89,1%, 
82,0% and 48,0% with median survival 35 months. Disease-free 1, 2 and 3-year survival 
was 84,2%, 72,0% and 24,8% respectively, median – 28 months. Overall and recurrence-
free 5-year survival was 10,8%. Recurrence in the chest was diagnosed in one patient, 
distant relapse – in 6. No variables were found to be associated with improved post-
chemoradiation survival from the time of definitive treatment or postoperative survival. 
Conclusion: Salvage lung resection for recurrent lung cancer following 
definitive chemoradiation therapy is feasible and is associated with 
postoperative survival and complication rates that are reasonable. 
Keywords: lung cancer, salvage surgery, definitive chemoradiotherapy
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P3.03-020 Outcomes of Concurrent Chemoradiotherapy in Elderly Patients 
with Stage III Non-Small Cell Lung Cancer Seok Ho Lee1, Seung Heon Lee1, Ho-Jin 
Heo1, Kihoon Sung1, Kyu Chan Lee1, Sung Hwan Jung2, Jeong Woong Park2, Eun Kyung 
Cho3, Hee Kyung Ahn3 1Radiation Oncology, Gachon University Gil Medical Center, Incheon/
Korea, 2Internal Medicine, Gachon University Gil Medical Center, Incheon/Korea, 3Division of 
Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
Center, Incheon/Korea
Background: The aim of this study was to assess the outcomes of concurrent 
chemoradiotherapy(CCRT) in elderly patients with stage III non-small cell lung 
cancer(NSCLC), focusing on the survival outcomes, prognostic factors and toxicities. 
Methods: From January 2006 to May 2012, 39 elderly patients older than 60 years 
(median 68 years; range 62~78 years) with stage III NSCLC were enrolled in this study. 
Radiotherapy (RT) was administered to the primary tumor and regional lymph nodes 
with concomitant administration of chemotherapy. The total RT dose was 46.8-79 Gy 
in daily 1.8-2.5 Gy fractions (median 66.6 Gy). Overall survival (OS) and progression 
free survival (PFS) were estimated with the Kaplan-Meyer method. Prognostic factors 
(gender, age, smoking, pathology, ECOG performance status, body weight, RT dose 
and tumor response) were analyzed by the log-rank test and Cox regression model. 
Acute toxicities were assessed according to Radiation therapy oncology group(RTOG) 
criteria. Results: The median follow-up period was 18.4 months. The 1, 2 and 3-year 
overall survival(OS) rates were 61.5%, 41.0% and 30.8%, respectively. The 1, 2 and 
3-year progression free survival(PFS) rates were 51.7%, 30.0% and 21.8%, respectively. 
Multivariable analysis showed that ECOG performance status(p=0.002) and tumor 
response(p=0.001) significantly influenced OS. The tumor response(p=0.013) was a 
significant prognostic factor for PFS in multivariable analysis. The grade 3 or higher 
radiation pneumonitis and esophagitis were developed in 9 (23.1%) and 4 (10.3%) 
patients. Neutropenia with grade 3 or higher was developed in 8 patients (20.8%). 
Conclusion: Survival (OS and PFS) of elderly patients with stage III NSCLC treated with 
CCRT is significantly affected by tumor response. However, the survival outcomes for 
elderly patients with stage III NSCLC treated with CCRT showed comparable results 
with previous reports. The CCRT related toxicity such as pneumonitis and neutropenia 
were relatively higher. These results means that CCRT is effective in increasing survival, 
however, the careful selection of elderly NSCLC patients for CCRT is also required. 
Keywords: Elderly patients, Non-small cell lung cancer, Chemoradiotherapy
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P3.03-021 Neoadjuvant Chemotherapy for Locally Advanced Non-Small Cell 
Lung Cancer (NSCLC) Patients Taku Nakagawa1, Yoshihiro Minamiya2, Hajime Saito2, 
Kazuhiro Imai2, Hayato Konno2, Satoshi Kudo1, Yoshitaro Saito2, Nobuyasu Kurihara2, 
Shinnosuke Watanabe1 1General Thoracic Surgery, Omagari Kosei Medical Center, Daisen, 
Akita/Japan, 2Thoracic Surgery, Akita University Graduate School of Medicine, Akita/Japan
Background: Neoadjuvant chemotherapy (NAC) has gained popularity in recent years, 
becoming a standard treatment for locally advanced non-small cell lung cancer (NSCLC) 
to improve resectability and downstage nodal disease, which have clear impacts on 
profile of erlotinib intercalated with gemcitabine/cisplatin as neoadjuvant treatment in 
stage IIIA N2 NSCLC pts. Methods: Patients with untreated stage IIIA bulky N2 NSCLC 
and ECOG PS 0/1 were enrolled to received up to 2 cycles of gemcitabine 1,000 mg/
m2 on days 1 and 8 and cisplatin 75 mg/m2 on day 1 or carboplatin AUC=5 d1, followed 
by oral erlotinib (150 mg, once a day) on days 15 to 28 as neoadjuvant therapy. A repeat 
computed tomography (CT) scan evaluated the response after induction therapy and 
eligible patients would undergo surgical resection. The primary endpoint was ORR 
which was reported in 2013 WCLC. The secondary endpoints included pCR, resection 
rate, DFS (disease free survival) and OS (overall survival), safety, QoL and biomarker 
analyses. Results: Between March 2011 and December 2012, a total of 39 patients (29 
male, median age 59.0 years; range 34.0 to 74.0 years) were enrolled in the study, in 
which 36 patients ( 92.3%) had completed 2-cycle erlotinib neoadjuvant treatment. For 
pathologic type, 13 pts were adenocarcinoma, 18 pts were squamous carcinoma, and 
8 pts were other types. One patient withdrew from the study and one patient was lost 
in the follow-up. Twenty-two (56.4%, 22/39) patients underwent surgical resection after 
erlotinib neoadjuvant treatment. Till Jan 15, 2015, the median follow up duration was 24.4 
mo (range 5.5 to 43.7 mo). To the cut-off date, 22 patients (56.4%) died. The median 
OS for total 39 patients was 29.0 mo (Figure 1A, range 3.4 to 43.7 mo). The median OS 
for those no surgery pts was 17.0 mo (range 6.1 to 39.8 mo) while the median OS is not 
matured ye for those pts who received surgery (Figure 1B).
Conclusion: Neoadjuvant erlotinib intercalated with gemcitabine/cisplatin brought 
clinical benefits by extending overall survival for stage IIIA N2 NSCLC pts. 
Keywords: intercalated chemotherapy, IIIA N2 NSCLC, Erlotinib, noadjuvant treatment
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P3.03-018 Intercalated TKI and Chemotherapy Induction in EGFR mt+ NSCLC 
Stage IIIA and IIIB: 3 Cases with Complete Remission in Mediastinal Lymph 
Nodes Frank Griesinger1, Anne C. Lueers1, Markus Falk2, Imme Conradi1, Michael 
Reinhardt3, Alexander Kluge4, Kay Wilborn5, Regina Prenzel6, Douglas Scriba7, R.-P. 
Henke8, Wilfried E.E. Eberhardt9, Cora Hallas2, Markus Tiemann2 1Oncology, Pius-
Hospital, Oldenburg/Germany, 2Haematopathology Hamburg, Hamburg/Germany, 3Nuclear 
Medicine, Pius-Hospital, Oldenburg/Germany, 4Diagnostic Radiology, Pius-Hospital, 
Oldenburg/Germany, 5Department of Radiation Oncology, Pius-Hospital, Oldenburg/
Germany, 6Pulmonary Medicine, Pius-Hospital, Oldenburg/Germany, 7Thoracic Surgery, 
Pius-Hospital, Oldenburg/Germany, 8Pathology Oldenburg, Oldenburg/Germany, 9University 
Hospital Essen, West German Cancer Centre, Ruhrlandklinik, University Duisburg-Essen, 
Essen/Germany
Background: EGFR TKI treatment is standard of care in patients with metastasized NSCLC 
carrying an activating EGFR mutation. However, induction concepts in locally advanced 
NSCLC with EGFR mutation including TKI have not been studied extensively. Recently 
new focus has been shed on intercalated regimens of chemotherapy and TKI, showing 
improved PFS as well as OS. This concept was used as induction regimen in 3 patients 
with activating EGFR mutation in stages IIIA and IIIB. Methods: Patients were diagnosed 
and worked up according to standard imaging, histology and immunohistology methods. 
EGFR, KRAS, BRAF, ALK and P53 mutation analysis were performed with standard 
procedures as described by Halbfass et al. 2013. Remission induction was measured 
by RECIST 1.1, regression grading by Junker criteria. Results: 2 female never smokers 
(pt #1 and 3), 62 and 59 y.o. and 1 male light smoker (pt#2) (5 packyear), 58 y.o . were 
diagnosed with with TTF1+ adenocarcinoma of the lung, 2 with exon 21 L858R (#2,3) 
and 1 with Exon 19 deletion (#1). All patients carried a p53 mutation, exon 6 (#2,3), exon 
8 (#1). Tumor stage was T (extension to mediastinal pleura) N2 (2R, 4R) M0, IIIA4 (#1), 
T2aN3(4L,7,2R)M0 IIIB (#2) and T2N3M0. Induction therapy was started with erlotinib 
150 mg/die p.o. days -12 to -1 (#1,2) and gefitinib (#3) in order to prove responsiveness 
of the tumor to EGFR-TKI. On day 0 partial response or no progression was achieved in all 
3 patients. Therapy was continued with 3 cycles of docetaxel 75 mg/m2 d1 and cisplatin 
50 mg/m2 d1 and 2 qd22 in combination with erlotinib d4-19 (#1), 1 cycle of docetaxel and 
cisplatin followed by 2 cycles of paclitaxel and carboplatin (#2) and switch from erlotinib 
to gefitinib with cycle 2 (#2) because of diarrhea) and 3 cycles of docetaxel and cisplatin 
with gefinitib 250 mg d4-19 (#3). PR was was achieved after 2 cycles in all patients. All 
three patients were resected and regression grade IIB was remarked in mediastinal lymph 
nodes (#1-3), regression IIA was remarked in the primary tumor in 2 patients (#2,3), 
regression grade III in 1 patient (#1). All three patients received adjuvant radiotherapy. 
Patients #1 and 3 are in CR, patient 2 developed one isolated CNS metastasis which has 
been stereotactically irradiated. No additional therapy, including TKI was administered 
postoperatively. Conclusion: Intercalated TKI treatment is a promising treatment 
choice in patients with EGFR mt+ locally advanced NSCLC. A phase II trial (NeoIntercal) 
trial is currently under way in 9 German centers in stages II and III using gefitinib in 
combination with induction taxane based chemotherapy, supported by ASTRA Zeneca. 
Keywords: Intercalated therapy
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Patients received four cycles of S-1 (80 mg/m2/day for 2 weeks, followed by 2 weeks’ 
rest) plus carboplatin (area under the curve 5, day 1) followed by S-1 (80 mg/m2/day 
for 2 weeks, followed by 1 week’s rest). Patients unable to continue S-1 plus carboplatin 
because of severe toxicity converted to single-agent S-1 maintenance. The duration of 
adjuvant chemotherapy was 10 months in both situations. The primary endpoint was 
feasibility, defined as the proportion of patients who completed four cycles of S-1 plus 
carboplatin and single-agent S-1 maintenance for 10 months. The treatment-completion 
rate was determined and treatment was considered feasible if the lower 90% confidence 
interval (CI) was ≥50%. Results:
Eighty-nine patients were enrolled, of whom 87 were eligible and assessable. 
Seventy-eight patients (89.7%) completed four cycles of S-1 plus carboplatin and 
55 (63.2%) completed the following S-1 maintenance therapy for a total of 10 
months. The treatment-completion rate was 63.2% (90% CI: 54.4–71.2%), indicating 
feasibility. There were no treatment-related deaths. Grade 3/4 toxicities included 
neutropenia (11.5%), thrombocytopenia (10.3%), and anorexia (2.3%). The 2-year 
relapse-free survival rate was 59.8%. Conclusion: We concluded that novel adjuvant 
chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy 
with S-1 was feasible and tolerable in patients with completely-resected NSCLC. 
Keywords: Non-small-cell lung cancer, adjuvant chemotherapy, S-1, maintenance therapy
POSTER SESSION/ TREATMENT OF LOCOREGIONAL DISEASE – NSCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.03-023 Phase III Study of Accelerated Hypofraction in CCRT of Unresectable 
Stage III NSCLC: Interim Analysis of KROG 0903 Sung-Ja Ahn1, Kwan-Ho Cho2, 
Young-Chul Kim3, In-Jae Oh3, Jae-Uk Jeong1, Sung Ho Moon4, Jin Hee Kim5, Mee Sun 
Yoon1, Joo Young Song1, Taek-Keun Nam1 1Radiation Oncology, Chonnam National 
University Hwasun Hospital, Jeonnam/Korea, 2Radiation Oncology, National Cancer Center, 
Ilsan/Korea, 3Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun 
Hospital, Jeonnam/Korea, 4National Cancer Center, Goyang/Korea, 5Keimyung University, 
School of Medicine, Taegu/Korea
Background: KROG 0301 prospective phase I & II study of the modified hypofractionation 
using concomitant boost to the gross tumor volume (GTV) simultaneously in the patients 
with unresectable NSCLC showed outstanding results comparing to the previous ones. 
So, we designed phase III prospective clinical trial comparing it with the standard 2 
Gy fractionation. Methods: Eligibility criteria were histologically proven unresectable 
stage III NSCLC determined by thoracic surgeon and more than one lesion measurable 
with CT scan according to the criteria of RECIST (version 1.1). Exclusion criteria were 
supraclavicular nodal metastasis, superior vena cava syndrome, atelectasia obscuring 
GTV contouring, and disease suspected to extend the major vessels and bronchus and 
to be at the risk of hemorrhage after concurrent chemoradiation (CCRT). In conventional 
fractionated RT group (Arm-1), a dose of 2Gy was delivered daily to the PTV and total 
cumulative dose was 44Gy to the PTV in 22 fractions and field was reduced and 2Gy was 
delivered to GTV and proceeded to 60Gy to the GTV in 30 fractions. In hypofractionated 
RT group (Arm-2), a dose of 1.8Gy was delivered daily to the PTV with a synchronous boost 
of 0.6Gy to the GTV to bring its daily dose to 2.4Gy per fraction. Total cumulative doses 
were 60Gy to the GTV and 45Gy to PTV in 25 fractions over 5 weeks. All patients received 
concurrent weekly chemotherapy consisting of paclitaxel first (50mg/m2intravenously 
over 1 hour) and cisplatin (20mg/m2 intravenously over 1 hour) on days 1,8,15,22,29, 
and (36). Chemotherapy was performed before radiotherapy in a day. Dose modification 
of chemotherapy was guided according to the severity of toxicity. Results: One-hundred 
twelve patients who were followed more than 6 months after completion of planned 
treatment were included in this analysis. Median F-U was 14 months. Median age was 67 
years(45-75) and male to female was 112/8. Stage IIIA was 81(72%) and IIIB 31(28%). Sixty 
and fifty-two patients were allocated in Arm-1 and 2, respectively. Patient’s characteristics 
prognosis. Potential disadvantages are increased morbidity and/or mortality after 
surgery and risk of progression of disease that could have been initially resected. The 
purpose of this study was to evaluate outcomes in a series of patients with locally 
advanced NSCLC receiving NAC followed by surgery. Methods: A total of 12 patients 
(66.7% males; median age, 71 years) affected by NSCLC in clinical stage IIA-IIIB 
underwent platinum-based NAC followed by surgery between 2008 and 2014. The clinical 
stage was IIA in 3 patients, IIIA in 8 (4 of which were IIIAN2), and IIIB in 1. Histology was 
adenocarcinoma in 8, squamous cell carcinoma in 3, and adenosquamous carcinoma in 
1. Results: All patients received platinum-based chemotherapy (median, 4 cycles). The 
NAC regimen was weekly paclitaxel-carboplatin in 6 patients, pemetrexed-carboplatin 
in 3, paclitaxel-carboplatin-bevacizumab in 2, and gemcitabine-cisplatin in 1. Radiologic 
response to NAC was complete in 1 patient (8.3%), partial in 8 (66.7%) and stable 
disease in 3 (25.0%). Overall response rate was 75.0% (95% confidence interval, 51-
100%). Grade 3 or 4 hematological toxicities were common, including neutropenia (50%) 
and anemia (8.3%), but were transient and manageable. Non-hematological toxicities 
were moderate and no treatment-related deaths were encountered. Eleven patients 
(91.7%) underwent complete surgical resection after induction. Surgical procedures 
comprised lobectomy in 10 patients, bilobectomy in 1 and pneumonectomy in 1. No 
severe intraoperative complications or 30-/90-day mortality were seen. At pathological 
evaluation, 8 patients (66.7%) showed downstaging of disease, with complete in 1 
(8.3%), major in 3 (25.0%) and minor in 7 (58.3%). With a median follow-up of 12.7 
months (range, 5.2-50.8 months), the 1-year relapse-free survival rate was 56.6%. Four 
of the 12 patients developed metastasis (at 4.7, 6.0, 8.4, and 9.2 months), and 2 patients 
died at 14.7 and 23.9 months. Conclusion: NAC using platinum-based chemotherapy 
with new-generation cytotoxic agents for locally advanced NSCLC seems justified by 
low morbidity and mortality, good response rates, and high resectability. Although 
the evidence level for induction chemotherapy is low, incorporation of chemotherapy 
and surgery will greatly impact strategies for future lung cancer treatment. 
Keywords: neoadjuvant chemotherapy, Locally advanced NSCLC, Platinum, NAC
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P3.03-022 Feasibility of Adjuvant Therapy with S-1 plus Carboplatin Followed 
by Maintenance Therapy with S-1 for Resected Non-Small-Cell Lung Cancer 
Norihito Okumura1, Makoto Sonobe2, Kazunori Okabe3, Hiroshige Nakamura4, 
Masafumi Kataoka5, Motohiro Yamashita6, Masao Nakata7, Kazuhiko Kataoka8, Yoshinori 
Yamashita9, Junichi Soh10, Hiroshige Yoshioka1, Katsuyuki Hotta10, Keitaro Matsuo11, 
Junichi Sakamoto12, Shinichi Toyooka10, Hiroshi Date2 1Kurashiki Central Hospital, 
Kurashiki/Japan, 2Kyoto University Graduate School of Medicine, Kyoto/Japan, 3Yamaguchi 
Ube Medical Center, Ube/Japan, 4Tottori University Faculty of Medicine, Yonago/
Japan, 5Okayama Saiseikai General Hospital, Okayama/Japan, 6Shikoku Cancer Center, 
Matsuyama/Japan, 7Kawasaki Medical School, Kurashiki/Japan, 8Iwakuni Clinical Center, 
Iwakuni/Japan, 9Kure Medical Center/Chugoku Cancer Center, Hiroshima/Japan, 10Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama/
Japan, 11Kyushu University Faculty of Medical Sciences, Fukuoka/Japan, 12Tokai Central 
Hospital, Kakamigahara/Japan
Background: The prognosis of patients with locally-advanced stages (II or IIIA) non-small-
cell lung cancer (NSCLC) is unsatisfactory, even after complete resection, and the 5-year 
survival rate is <50%, indicating the need for further improvements in postoperative 
survival. This multicenter study (the Setouchi Lung Cancer Group Study 0701) aimed to 
evaluate the feasibility of novel adjuvant chemotherapy with S-1 plus carboplatin followed 
by single-agent, long-term maintenance with S-1 in patients with completely-resected 
stage II–IIIA NSCLC. Methods:
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radiotherapy, but usually asymptomatic or mild. Sometimes, however, it is fulminant and 
fatal. We reviewed clinical characteristics of fatal and near fatal form of radiation lung injury 
after lung cancer treatment. Methods: We retrospectively reviewed medical records of 
patients with lung cancer who received radiation on thorax greater than 50 Gy from 
January 2006 to December 2014, and clinical, radiologic, and pathologic characteristics 
were assessed. Results: Three hundred forty two patients were received thoracic 
radiation greater than 50 Gy. Radiation lung injury was observed in 284 patients(74.3%), 
and in 177 patients(62.3%) those lung injury was asymptomatic and mild fibrosis confined 
in directly radiated lung field. Fatal and near fatal radiation pneumonitis were developed in 
39 patients(11.4%), of them 25 patients(7.3%) died of respiratory failure. In 25 patients, 
13 patients(52.0%) had pre-existing interstitial lung disease, 16 patients(64.0%) 
received chemotherapy concurrently. All the fatal lung injuries were extensive 
consolidation and ground glass opacity out of radiation field. Conclusion: Radiation 
lung injury is usually mild and asymptomatic, however extensive radiation pneumonitis 
out of radiation field is fatal and near fatal. Concurrent chemoradiation and pre-
existing interstitial lung disease were risk factors of this fulminant lung injury. 
Keywords: Radiation pneumonitis, interstitial lung disease
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P3.03-026 Analysis of Clinical and Dosimetric Factors Influencing Radiation-
Induced Lung Injury in Patients with Lung Cancer Han Shuiyun1, Feiying Gu1, Gang 
Lin1, Xiaojiang Sun1, Yuezhen Wang1, Zhun Wang1, Qingren Lin1, Denghu Weng1, Yaping 
Xu1, Weimin Mao2 1Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou/
China, 2Department of Thoracic Surgery, Zhejiang Cancer Hospital, Zhejiang/China
Background: Dose escalation of thoracic radiation is limited by the occurrence of 
radiation-induced lung injury (RILI). This study investigated the clinical and dosimetric 
factors influencing RILI in lung-cancer patients receiving chemoradiotherapy. Methods: A 
retrospective analysis was carried out on 161 patients with non-small-cell or small-
cell lung cancer (NSCLC and SCLC, respectively), who underwent chemoradiotherapy 
between April 2010 and May 2011 with a median follow-up time of 545 days (range: 
39–1453). Chemotherapy regimens were based on the histological type (squamous 
cell carcinoma, adenocarcinoma, or SCLC), and radiotherapy was delivered in 1.8–3.0 
Gy fractions, once daily, to a total of 39–66 Gy (median, 60). Univariate analysis was 
performed to analyze clinical and dosimetric factors associated with RILI. Multivariate 
analysis using logistic regression identified independent risk factors correlated to 
RILI. Results: The incidence of symptomatic RILI (≥grade 2) was 31.7%. Univariate 
analysis showed that V5, V20, and mean lung dose (MLD) were significantly associated 
with RILI incidence (P=0.029, 0.048, and 0.041, respectively). The association was not 
statistically significant for histological type (NSCLC vs. SCLC, P = .092) or radiation 
technology (IMRT vs. 3DCRT, P = .095). Multivariate analysis identified MLD as an 
independent risk factor for symptomatic RILI (OR=1.249, 95%CI=1.055–1.48, P= .01). 
The incidence of bilateral RILI in cases where the tumor was located unilaterally was 
22.7% (32/141) and all dosimetric-parameter values were higher (P< .05) for bilateral 
versus ipsilateral injury, but only for grade-1 (low) RILI. The RILI grade was higher in 
cases of ipsilateral lung injury than in bilateral cases (Mann-Whitney U test, z=8.216, P< 
.001). Conclusion: The dosimetric parameter, MLD, was found to be an independent 
predictive factor for RILI. Contralateral injury does not seem to be correlated with 
increased RILI grade under the condition of conventional radiotherapy treatment planning. 
Keywords: radiation induced lung injury, lung cancer, mean lung dose
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P3.03-027 Lung Cancer: Doses to Mediastinal Structures Can Be Reduced 
with Volumetric Modulated Arc Therapy and Deep Inspiration Breath-Hold 
Radiotherapy Gitte F. Persson1, Jonas S. Rydhög1, Marianne C. Aznar1, Maja V. 
Maraldo1, Lotte Nygård1, Junia Costa2, Anne K. Berthelsen2, Lena Specht1, Mirjana 
Josipovic1 1Department of Oncology, Rigshospitalet Copenhagen University Hospital, 
Copenhagen/Denmark, 2Department of Clinical Physiology, Nuclear Medicine and Pet, 
Rigshospitalet Copenhagen University Hospital, Copenhagen/Denmark
Background: When thoracic radiotherapy (RT) doses are escalated, toxicity from 
mediastinal structures are a limiting factor (Cannon et al. JCO 2013). In this study we 
examined, if deep inspiration breath-hold (DIBH) combined with volumetric modulated arc 
therapy (VMAT) can decrease the dose to lungs, heart, central bronchi and esophagus 
compared to free breathing (FB) RT. Methods: 17 patients with stage III NSCLC were CT 
scanned in both FB (4DCT) and visually guided voluntary DIBH before radical RT. Lungs, 
heart, central bronchi, trachea, esophagus and heart subvolumes (coronary arteries 
and valves) were contoured. Three dimensional conformal (3DC) and VMAT plans were 
computed on FB and DIBH images. VMAT plans were optimized using constraints for 
target and lungs. DIBH plans were compared to FB plans. Friedman signed rank test with 
post-hoc Nemenyi test was applied. Results: GTV sizes were slightly smaller in DIBH 
(mean 119 vs. 132 ml, p=0.01). Lung volume increased in DIBH by median 60% (range 
35-108%, p<0.0001) compared to FB. Median and range of dose parameters are listed in 
the table together with Friedman signed rank test p-values. Mean lung dose was in DIBH 
reduced with a median 3.2 Gy (p=0.002) with 3DC and 3.5 Gy (p<0.001) with VMAT. DIBH 
alone did not significantly alter heart, esophagus and trachea-bronchial dose parameters, 
but VMAT did. The largest differences were found between FB 3DC and DIBH VMAT. Mean 
doses to coronary arteries, tricuspid and pulmonary valves were significantly reduced 
with DIBH VMAT compared to FB 3DC (P=0.002-0.04). No differences were found for 
aortic and mitral valves.
were evenly distributed between two groups. Overall survival, local progression free, 
and disease progression free survival of all patients was median 30 months, 15months, 
and 12 months, respectively. Two- and 3-year survival rates were 53.6% vs. 54.1% 
and 50.4% vs. 44.6% in Arm-1 and Arm-2 (p=0.95), respectively. Two-year local tumor 
control rates were 58.3% and 50.0% (p=0.977) and 2-year progression free survival 
rates were 41.4% and 34.2% (p=0.704) in Arm-1 and Arm-2, respectively. Radiation 
esophagitis (≥ grade 2) was 15(25%) and 10(20%) and radiation pneumonitis (≥ grade 
2) was 8(13.3%) and 7(13.5%) in Arm-1 and Arm-2, respectively. Conclusion: Interim 
analysis did not show any statistically significant toxicity or survival differences between 
two groups. This on-going clinical study needs to continue for the confirmative results. 
Keywords: Unresectable stage III, non-small cell lung cancer, Hypofractionation, 
Concurrent Chemoradiation
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P3.03-024 Efficacy of 18 F-FDG PET/CT as Response Predictor in Locally 
Advanced Non-Small Cell Lung Cancer Soumyajit Roy1, Sushmita Pathy1, Rakesh 
Kumar2, Bidhu K. Mohanti1, Vinod Raina3, Anand Jaiswal4, Sameer Taywade2, Arun 
Malhotra2, Sanjay Thulkar5, Anant Mohan6, Sandeep Mathur7, Digamber Behera4 
1Radiation Oncology, All India Institute of Medical Sciences, New Delhi/India, 2Nuclear 
Medicine, All India Institute of Medical Sciences, New Delhi/India, 3Medical Oncology, All 
India Institute of Medical Sciences, New Delhi/India, 4Pulmonary Medicine, LRS Institute 
of TB and Respiratory Diseases, New Delhi/India, 5Radiology, All India Institute of Medical 
Sciences, New Delhi/India, 6Pulmonary Medicine, All India Institute of Medical Sciences, New 
Delhi/India, 7Pathology, All India Institute of Medical Sciences, New Delhi/India
Background: The study was aimed to assess the role of 18F-FDG PET/CT in response 
assessment of patients with locally advanced non-small cell lung cancer (NSCLC) and 
in evaluating the predictive value of metabolic response for progression-free survival 
(PFS) and overall survival (OS). Methods: Thirty patients of locally advanced NSCLC 
were enrolled in this randomized controlled study and were allocated to one of the two 
treatment arms. Patients in Arm A (n=15) received neoadjuvant chemotherapy (NACT) 
and external beam radiotherapy (EBRT) while arm B (n=15) received NACT and EBRT 
with concomitant chemotherapy. 18F-FDG PET/CT was carried out at baseline and 
after 6-weeks of completion of intended treatment. Pre and post-treatment maximum 
standardized uptake value (SUVmax) was noted. A reduction of SUVmax> 50% (∆SUVmax) 
were considered to be metabolic responders (MR) and ≤ 50% as non-responders (MNR). 
The difference in SUVmax parameters were compared by Wilcoxon signed rank test and 
Mann-Whitney U test for paired and unpaired samples. The significance of difference 
in the number of MR and MNR between two arms was computed using Fisher’s exact 
test. Survival time was estimated by Kaplan–Meier survival analysis. Survival pattern 
was compared using the log-rank test. Factors which had p value <0.25 in univariate 
analysis were subjected to multivariate analysis using Cox regression analysis. Statistical 
analysis was carried out using Stata software version 12.0. Results: Twenty one patients 
completed the intended treatment. The median pre and post-treatment SUVmax were 14, 
6.4 for arm A and 15.3, 3.5 for arm B. There was no statistically significant difference 
between pre and post treatment SUVmax among the two treatment arms. Significant 
decrease in SUVmax was observed in both arms (median ∆SUVmax of 50% and 74% 
in arm A and B; p=0.618). Twelve patients achieved metabolic response. Metabolic 
response rate in arm A and B was 50% and 64% respectively (p=0.783). At median 
follow-up of 18.98 months the median PFS and OS of the MR were 22.31, 24.73 months 
and of MNR were 7.83, 8.26 months The Cox proportional hazard ratio for PFS and OS 
in MNR group was 2.33 (95% confidence interval i.e. C.I: 0.78-6.91) and 2.12 (95% C.I: 
0.65-6.97). No significant difference in OS and PFS was observed between MR and MNR 
subpopulation of two arms (table-1). 
Group Median PFS (in months) 
P value (Log 
rank test) 
Median OS (in 
months) 
P value (Log 
rank test) 
Total cohort: 17.02 (95% C.I:7.44-22.31) - 24.73 - 
MR: MNR: 22.31 7.83 0.09 24.73 8.26 0.12 
Arm A Arm B 18.7 9.12 0.59 24.73 15.4 0.27 
MR of Arm A MR 
of arm B 10.5 22.3 0.34 
15.4 Not 
achieved 0.27 
MNR of arm A 
MNR of Arm B 7.44 7.83 0.71 7.47 8.26 0.71 
 
Conclusion: PET/CT distinguishes responders to treatment based on metabolic activity 
in patients with locally advanced NSCLC, but did not provide any prognostic significance. 
Keywords: locally advanced NSCLC; 18F-FDG PET/CT; response assessment; SUVmax
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P3.03-025 Fatal and near Fatal Radiation Lung Injury after Lung Cancer 
Treatment Choonhee Son1, Mee Sook Roh2, Soo-Jung Um2 1Pulmonology, Dong-A 
University Hospital, Busan/Korea, 2Dong-A University Hospital, Busan/Korea
Background: Radiotherapy is important, and potentially curative method of treatment 
in lung cancer. Radiation pneumonitis and fibrosis is very frequent complication of 
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P3.03-029 No Inferior Outcomes after Stereotactic Radiotherapy for 
Stage I and II NSCLC Compared with Surgery Elisabeth A. Kastelijn1, Sherif El 
Sharouni2, Frederik Hofman3, Bart Van Putte3, Evelyn Monninkhof4, Marco Van Vulpen2, 
Franz Schramel1 1Department of Pulmonology, St. Antonius Hospital, Nieuwegein/
Netherlands, 2Department of Radiotherapy, University Medical Centre Utrecht, Utrecht/
Netherlands, 3Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein/
Netherlands, 4Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht/
Netherlands
Background: Surgical resection is the treatment of fi rst choice for patients who are 
diagnosed with stage I and II non-small cell lung cancer (NSCLC). However, last years, 
stereotactic body radiotherapy (SBRT) has shown to be a good alternative treatment, 
especially for the elderly or for patients with a poor pulmonary function. We compared 
the overall survival (OS), progression free survival (PFS) and locoregional and 
distant recurrence between patients with stage I and II NSCLC treated with SBRT or 
surgery. Methods: Patients who were diagnosed with stage I and II NSCLC between 
2008 and 2011 and treated with SBRT or surgery were included. Crude survival and 
recurrence rates in both groups were evaluated and compared by Kaplan-Meier survival 
and Cox proportional hazard analyses. Since the selection of treatment is infl uenced 
by patients characteristics, we used the propensity score method to account for this 
bias. Propensity scores were estimated by a logistic regression model that included 
treatment as dependent variable and age, gender, performance status, FEV1, DLCO, 
nodule diameter and clinical TNM classifi cation as independent variable. The propensity 
score was added as covariate to Cox proportional hazard analyses to adjust the outcome 
for patient characteristics. Results: The cohort treated with SBRT and surgery consisted 
of 53 and 175 patients, respectively. Before adjustment for the propensity score, the 
OS at 1 and 3 years after SBRT was 87% and 43% and after surgery 89% and 70% 
(HR = 2.42, 95% CI 1.65 – 3.56; p = 0.0001). The PFS at 1 and 3 years was 72% and 
39% after SBRT and 80% and 60% after surgery (HR = 2.07; 95% CI 1.43 – 2.99; p 
= 0.0001). The locoregional recurrence rates at 1 year after SBRT and surgery were 
94% and 95% and at 3 years for both 85% (HR = 1.43 ; 95% CI = 0.60 – 3.43; p = 
0.42). The distant recurrence rates at 1 and 3 years after SBRT were 73% and 62% 
and after surgery 88% and 74% (HR = 1.67; 95% CI = 0.96 – 3.92; p = 0.07). After 
adjustment for the propensity score, the OS and PFS after SBRT were not signifi cantly 
different compared with surgery (HR = 1.71, 95% CI 0.87 – 3.35; p = 0.12 respectively 
HR = 1.56; 95% CI 0.83 – 2.93; p = 0.17). The locoregional and distant recurrence 
rates between SBRT and surgery were also not signifi cantly different (HR = 2.11; 
95% CI = 0.56 – 7.75; p = 0.26 respectively HR = 1.24; 95% CI = 0.48 – 3.20; p = 
0.65). Conclusion: This study shows that, after adjustment for the propensity score, 
the OS, PFS and recurrence rates after SBRT are not inferior compared with surgery 
in patients with stage I and II NSCLC. Although, we used the propensity score to 
reduce the effects of confounding by indication, randomized clinical trials are desired. 
Due to the lack of these trials, a thorough discussion of the patient individual merits 
and drawbacks of surgery and SBRT should be the cornerstone of the treatment. 
Keywords: NSCLC, stereotactic radiotherapy, Surgery, outcome
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P3.03-030 Evaluation of the Functional Heart Condition During Radiotherapy 
for Lung Cancer Yury Ragulin1, Vladimir Parshin2, Elena Kozlova2, Nina 
Dvuchsherstnova2 1Thoracic Department, Medical Radiological Research Center, Obninsk/
Russian Federation, 2Diagnostic Department, Medical Radiological Research Center, 
Obninsk/Russian Federation
Background: Alterations in cardiac function appearing immediately during radiation 
therapy for lung cancer are insuffi ciently studied. It is necessary to continue studying 
alterations in left ventricular systolic and diastolic function arising during radiotherapy 
for lung cancer to prevent other complications. We aimed to study the functional state 
of the left ventricle during radiotherapy for lung cancer. Methods: The study included 
39 patients with lung cancer. Irradiation was performed with a total radiation dose (TRD) 
of 60 Gy and a single radiation dose (SRD) of 1+1.5 Gy delivered from two different 
treatment fi elds. Initial echocardiographic examinations were carried out before starting 
radiotherapy in order to assess the functional state of the heart. Subsequently, the 
patients were followed up during radiotherapy with TRD of 20 Gy, 40 Gy, and 60 Gy. The 
following parameters were evaluated: left ventricular end diastolic volume (LVEDV), left 
ventricular end systolic volume (LVESV), stroke volume (SV), ejection fraction (EF), ratio 
of early and late diastolic fi lling rates of the left ventricle (E/A), motion rate of the lateral 
part of the fi brous ring of the mitral valve in early diastole (Еа), motion rate of the lateral 
part of the fi brous ring of the mitral valve in late diastole (Аа), ratio of motion rates 
of the lateral part of the fi brous ring of the mitral valve in early and late diastole (Еа/
Аа). Results: At dose 20 Gy, left ventricular end diastolic volume decreased by 13%, 
and at TRD of 60 Gy – by 20%. At TRD of 20 Gy, left ventricular end systolic volume was 
altered by 9%, and at TRD of 60 Gy – by 14%. At TRD of 20 Gy, stroke volume decreased 
by 16%, and at TRD of 60 Gy – by 32% compared to the initial level. At TRD of 20 Gy, the 
ejection fraction decreased by 9 %, and at TRD of 60 Gy – by 23%. The parameters of 
left ventricular diastolic function were found to be reduced as well. At TRD of 20 Gy, the 
ratio of fi lling rates of the left ventricle in early and late diastole decreased by 4% and at 
TRD of 60 Gy – by 18%. At TRD of 20 Gy, the motion rate of the lateral part of the fi brous 
ring of the mitral valve in early diastole decreased by 10% and at TRD of 60 Gy – by 
20%. At TRD of 20 Gy, the ratio of motion rates of the lateral part of the fi brous ring of 
the mitral valve in early and late diastoles decreased by 12%, and at TRD of 60 Gy – by 
21%. Thus, an increase in radiation dose led to a decrease in left ventricular systolic and 
diastolic function. Conclusion: Radiation therapy for lung cancer signifi cantly alters left 
 
Conclusion: DIBH VMAT decreased the estimated mean doses to heart, lungs, esophagus 
and bronchii compared to FB 3DC. Possibly, the dose to these structures could be 
further reduced, had the mediastinal structures been included in the VMAT optimization 
process. Combining DIBH and VMAT may facilitate dose escalation to target volumes or 
subvolumes, without decreasing mediastinal toxicity compared to current standard, FB RT. 
Keywords: Breathhold, VMAT, Radiotherapy
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P3.03-028 High Dose Rate (HDR) Dual Intraluminal Brachytherapy Catheter in 
Treatment of Bilateral Endobronchial Tumor Progression: A Case Report
Larry Ladi1, John Grecula2, Eric Allan2, Shaheen Islam1 1Pulmonary, Allergy, Critical Care, 
and Sleep Medicine, The Ohio State University-Wexner Medical Center, Columbus/OH/United 
States of America, 2Radiation Oncology, The Ohio State University-Wexner Medical Center, 
Columbus/United States of America
Background: While radiation therapy is used for locoregional disease with a curative 
intent, the use of brachytherapy is one method of delivering a higher radiation dose 
to endobronchial tumor while sparing the surrounding normal tissues. Although 
commonly done with a single catheter we report on the simultaneous use of 
dual HDR-intraluminal brachytherapy catheters Methods: CASE PRESENTATION:
We report a case of a 71-year-old gentleman with history of squamous cell carcinoma of left 
lung, status post left upper lobe resection in March, 2012. He developed biopsy proven,left 
mainstem recurrence in April, 2014 which was treated with concurrent chemoradiation 
(63 Gy/ 35 tx). In January, 2015, he was referred to interventional pulmonary clinic for 
bronchoscopy revealing extension of tumor involving carina and proximal 2 cm of both 
left and right mainstem bronchi (Fig.1) Biopsy demonstrated squamous cell carcinoma. 
He underwent rigid bronchoscopy with tumor debulking using Nd:YAG laser. He was than 
referred to radiation oncology for HDR-brachytherapy. Since both main stem bronchi were 
involved a decision was made to place two catheter to radiate both sides simultaneously. 
The patient was intubated with an 8.0 endotracheal tube and two brachytherapy 
catheters were placed into the left and right mainstem bronchus respectively under 
general anesthesia (Fig.2). The length and patency of the catheters were manually 
checked. The guidewire was removed from the catheters and replaced with the dummy 
source cables (Fig.3). A dose plan was then created to irradiate the proximal 5 cm of 
both the right and left mainstem bronchi and carina with a dose of 750cGy prescribed 
at 1 cm from the source. The computer was programmed to irradiate the above area 
(Fig.4). The catheters were connected to the high dose rate afterloader. A dose of 750 
cGy at 1 cm from the source was delivered over actual time 466.2 seconds with the high 
activity (4.33 Ci) Ir-192 source (nominal treatment time = 201.6 seconds). Two additional 
weekly treatments of 750 cGy to the above area is planned. Results: DISCUSSION:
Central airway obstruction worsens the quality of life in lung cancer patients. When 
surgical resection is not plausible, HDR-brachytherapy is effective in palliating dyspnea. 
Hennequin C, et al treated 106 patients with endobronchial lung cancer with HDR-
bachytherapy which consisted of six fractions of 5 or 7 Gy, who were not eligible for 
surgery or external beam radiotherapy, and had relapse after surgery or external beam 
radiotherapy or respiratory insuffi ciency. The histologic response rate, evaluated at 3 
months after HDR-brachytherapy, was 59.4% [1]. In our patient, given the bilaterality 
of tumor progression, routine HDR-intraluminal brachytherapy would have required 
our patient to undergo unilateral treatment separately in multiple sessions and may 
have resulted in overlap of the brachytherapy isodoses. By planning the bilateral 
HDR-intraluminal brachytherapy catheters simultaneous, the risk of future overlap is 
avoided, and the overall treatment interval is reduced in half Conclusion: CONCLUSION:
Here we demonstrate the concomitant use of two intraluminal brachytherapy 
catheters placed in separate bronchi decreased the overall treatment 
interval. Future studies need to be conducted to evaluate effi cacy. 
Keywords: lung cancer, brachytherapy
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In addition to delivering evidence-based, weighted therapy recommendations, OEA™ 
Lung provides care pathways for management of toxicities for each treatment modality 
(surgery, radiation, and medical oncology). Results: The OEA™ Lung application 
supports three core functions: 1) dynamic patient summary assimilating complete 
(structured and unstructured) data to show demographics, labs, genotype, treatment 
history, and previous treatment responses; 2) weighted evidence-based, multimodality 
treatment options, with recommendations based on literature support which is provided, 
along with screening for relevant trials; 3) care pathway advisories, to manage treatment 
related toxicities for each modality. Further, this product improves quality of care by 
optimizing outcomes with access to trials and care pathways. Conclusion: The OEA™ 
application for lung is a cognitive expert system designed to assimilate multidisciplinary 
recommendations for care and management of lung cancer patients based on current 
consensus guidelines and expert recommendations from a quaternary referral cancer 
center to the community practice setting. By democratizing knowledge from our 
specialty cancer center, we have taken steps toward achieving an important goal of 
ending cancer for all, by providing global access to optimal cancer care for patients with 
this disease. Further evaluation of outcomes following implementation are warranted. 
Keywords: NSCLC, Multidisciplinary Care, Cognitive Computing, care pathways
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P3.03-033 Management of Clinical T3-4 Locally Advanced Non-Small-Cell 
Lung Cancer Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro 
Miyazaki, Daisuke Taniguchi, Katsunori Takagi, Tomohiro Obata, Koichiro Shimoyama, 
Takeshi Nagayasu Surgical Oncology, Nagasaki University, Nagasaki/Japan
Background: Several studies of trimodality therapy for locally advanced lung cancer 
invvasing neighboring structures including SST were reported. They resulted in high 
rates of pathological complete response and better survival than previous reports. The 
aim of this study was to retrospectively review our experience of patients for clinical 
T3-T4 lung cancer. Methods: Between January 2000 and March 2014, 52 patients 
underwent surgical complete resection for locally advanced clinical T3-T4 non-small cell 
lung cancer. Also, we are conducting a phase II trial from 2011 to evaluate induction 
chemoradiotherapy using cisplatin and TS-1 combined concurrent radiotherapy (40Gy) 
followed by surgery would improve the survival of these patients. The extent of chest wall 
involvement was limited to the parietal pleura, pm1 (T3 in the same lobe) and pm2 (T4 in 
another lobe beyond the interlobe) were excluded in this study. Patients were divided into 
three groups. In the initial surgery group (IS group, n=35), patients underwent surgery 
without induction therapy. In the chemotherapy group (CT group, n=4), patients were 
received chemotherapy followed by surgery, and in chemoradiotehrapy group (CRT group, 
n=13), patient were received chemoradiotherapy followed by surgery. Results: The 
median age was 64 years old (range, 41-83). Patients with T3 were in 42 (chest wall: 
n=30, pericardium: n=5, diaphragm: n=4, main bronchus: n=3 ), and with T4 were in 
10 (left atrium: n=2, carina: n=2, vertebra: n=2, esophagus: n=1, subclavian artery: 
n=1, superior vena cava: n=1, mediastinal fat: n=1), respectively. The histological types 
included 21 squamous cell carcinoma, 16 adenocarcinoma, 4 large cell carcinoma, 4 
pleomorphic carcinoma, and 7 other types. All patients underwent complete resection. 
The 3- and 5-year overall survival rate was 61.5% and 17.5%, respectively in this series. 
The 3-and 5-year survival rate in patients with T3 was 65.3%, 20.8%, while that with T4 
was 48.0%, 0%, respectively. There was no significant difference in survival rate between 
them (p=0.1454). The prognosis in the N0 disease was significant better than N1-2 
disease (p=0.0073). Multivariate analysis showed N0 disease was independent factor of 
a favorable prognosis (p=0.046). In the CRT group, patients with T3 disease was in 9, and 
T4 in 4. Induction therapy was completed in all 13 candidates (100%), and 5 (38%) had 
a complete response, 8(62%) had a partial response in the pathological examinations. 
The 3-year survival rate in the CRT group was 69.2%. The prognosis in the CRT group 
was better than the IS plus CT group, but there was no significant difference between the 
group. Although there were no locoregional recurrences after surgery in the CRT group, 
4 patients experienced major postoperative complications and 1 patient who underwent 
combined resection of both chest wall and superior vena cava with reconstruction by 
artificial materials died of septic shock. Conclusion: Multimodality therapy consisted 
of 2 cycle chemotherapy with concurrent 40 Gy of radiation for clinical T3-4 locally 
advanced lung cancer showed be feasible and good local control. However, the criteria 
for selecting patients should be mature, especially patients using artificial material. 
Keywords: locally advanced non-small cell lung cancer, Surgery, induction therapy
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P3.03-034 Utility of Surveillance Imaging in Detection of Recurrence in 
Treated Stage III NSCLC Patients Omid S. Tehrani1, Antoinette Wozniak2, Peter 
Paximadis2, Laura Mantha2, Judith Abrams2, Ann G. Schwartz2, Michele L. Cote2, Gerold 
Bepler2, Shirish Gadgeel2 1University of California San Francisco, Fresno/CA/United States 
of America, 2Wayne State University/Karmanos Cancer Institute, Detroit/MI/United States of 
America
Background: About a third of newly diagnosed NSCLC patients have stage III disease at 
diagnosis, of whom, a quarter achieve long term survival. The current recommendation 
of National Comprehensive Cancer Network (NCCN) for surveillance following 
completion of therapy is to perform CT scan of the chest every 6-12 months for 2 
years. However, it is unclear if strategy of surveillance scans is superior in detecting 
recurrences as compared to the strategy of scans done for symptoms suggestive 
of disease progression. We conducted a retrospective analysis of stage III NSCLC at 
our institution to estimate the rate of detection of recurrence in scans performed for 
symptomatic worsening, in patients on surveillance scans. Methods: This study is a 
ventricular systolic and diastolic function. Increased radiation doses cause the growth in 
the number of altered parameters. Keywords: echocardiography, lung cancer, 
Radiotherapy
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P3.03-031 Predictors of Radiation Pneumonitis and Associated Changes of 
Pulmonary Function After Definitive Concurrent Chemoradiotherapy in NSCLC 
Jae-Sung Kim1, Young Hee Park2 1Radiation Oncology, Seoul National University Bundang 
Hospital, Seongnam/Korea, 2Radiation Oncology, Seoul National University Hospital, Seoul/
Korea
Background: To evaluate the predictive factors of radiation pneumonitis (RP) and 
associated changes of pulmonary function after definitive concurrent chemoradiotherapy 
(CCRT) in patients with NSCLC Methods: Medical records of 61 patients with NSCLC who 
received definitive CCRT at Seoul National University Bundang Hospital were retrospectively 
reviewed. Dose volumetric parameters, clinical factors, pulmonary function test (PFT) 
data were analyzed. RP was graded according to the Common Terminology Criteria for 
Adverse Events v3.0. Percentage of lung volume that received a dose of 10 Gy or more 
(V10), 20 Gy or more (V20), 30 Gy or more (V30), mean lung dose (MLD) were analyzed 
for potential dose volumetric (DV) parameters. PFT changes were calculated as the 
difference between pre-RT and post-RT values compared to the pre-RT values at 3, 6, 12 
months after RT. Tumor location was categorized two groups, upper (including middle) and 
lower lobe. Results: The overall and progression-free survival time were 21.9 month and 
10.6 months. Twenty-three patients (38%) developed grade≥2 RP. Among clinical factors, 
underlying chronic obstructive pulmonary disease was associated with RP (p=0.050) but 
not with grade ≥2 RP (p=0.871). Tumor located at lower lobe was associated with grade 
≥2 RP (p=0.002). Among the DV parameters, only MLD > 15 Gy was associated with 
grade ≥2 RP (p=0.009). There were statistically significant decreases in PFT values at 
all points compared with pre-RT values. MLD was associated with magnitude of forced 
vital capacity (FVC) changes at 6/12 months (p=0.006/0.016) and forced expiratory 
volume in 1 s (FEV1) changes at 6 months (p=0.005). V10 and V20 were associated 
with FVC changes at 12 months (p=0.048/0.025) and V30 was associated with diffusion 
capacity for carbon monoxide changes at 6 months (p=0.023). Conclusion: MLD > 
15 Gy and lower lobe tumor were predictors of grade ≥2 RP. Pulmonary functions were 
decreased after CCRT and the magnitude of change was associated with DV parameters. 
Keywords: Non-small cell lung cancer, Radiation pneumonitis, Dose volumetric 
parameter, Pulmonary function
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P3.03-032 MD Anderson Oncology Expert Advisor™: A Cognitive Clinical 
Decision Support Tool for Evidence-Based Multi-Disciplinary Lung Cancer Care 
Mara B. Antonoff1, George R. Simon2, Kathryn A. Gold2, Sunil Patel3, Daniel 
Gomez4, Renata Ferrarotto2, Joshua Allen5, Rick Stevens6, Fernando J. Suarez 
Saiz7, Mitch Berger8, Garrett Walsh1, Mark Mynhier9, Rob High10, Andy Futreal11, 
Stephen Hahn4, Stephen Swisher1, John V. Heymach2, Lynda Chin11, Utmdacc Oea™ 
System Development Team11, Quynh-Nhu Nguyen4, Emily Roarty1 1Thoracic and 
Cardiovascular Surgery, UT MD Anderson Cancer Center, Houston/TX/United States of 
America, 2Thoracic Medical Oncology, MD Anderson Cancer Center, Houston/TX/United States 
of America, 3General Medical Oncology, MD Anderson Cancer Center, Katy/TX/United States 
of America, 4Radiation Oncology, UT MD Anderson Cancer Center, Houston/United States of 
America, 5Ibm Watson, Raleigh-Durham/United States of America, 6Ibm Watson, Burlington/VT/
United States of America, 7Ibm Canada, Toronto/ON/Canada, 8Price Waterhouse Coopers Llp, 
Atlanta/GA/United States of America, 9Price Waterhouse Coopers Llp, Irvine/CA/United States 
of America, 10Ibm Watson, Austin/TX/United States of America,11Genomic Medicine, UT MD 
Anderson Cancer Center, Houston/TX/United States of America
Background: The majority of patients diagnosed with non-small cell lung cancer (NSCLC) 
receive care in the community setting with limited access to multidisciplinary management 
common in tertiary care centers. The availability of genomics allows tailored treatments 
for patients; and with novel, rapidly emerging therapeutic options, it is challenging 
for busy clinicians to maintain familiarity with current therapy recommendations. 
Therefore, to empower practicing oncologists in community settings to offer the optimal 
management at the first intervention, we have developed the MD Anderson Oncology 
Expert Advisor™ (OEA) application for multi-disciplinary management of lung cancer 
patients. As the first multi-disciplinary solution for providing comprehensive management 
of lung cancer, the objective of OEA™ Lung is to leverage cognitive analytics on vast and 
ever evolving clinical care information and patient big data to disseminate knowledge and 
expertise, thus enabling physicians to provide evidence-based care and management 
tailored for the individual patient, similar to consulting an expert. Further, we aimed to 
create a system for sharing knowledge from more experienced experts to provide care 
pathways and management recommendations for physicians globally. Methods: Using 
cognitive computing, our cancer center partnered with IBM Watson to develop an 
expert system designed to provide physicians with the tools needed to process high-
volume patient and medical information and to stay up-to-date with the latest treatment 
and management options, so that they can make the best evidence-based treatment 
decisions for their lung cancer patients. The OEA™ application for lung was built 
upon core capabilities of the OEA™ applications for leukemia and molecular/targeted 
therapies. Experts in multiple disciplines including thoracic surgery, medical oncology, 
and radiation oncology met regularly to design and provide specialized input to the IBM 
technical team in an agile development cycle. This system was powered to utilize both 
structured and unstructured data from validated sources; to thoroughly evaluate and 
stage patients; and to offer eligible clinical trials and personalized therapeutic options. 
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from FDG PET/CT for stage III NSCLC. Methods: This study included 61 patients with 
unresectable stage III NSCLC treated with concurrent thoracic radiotherapy (63Gy) given 
with cisplatin and etoposide. 18F-FDG PET/CT scans were obtained from all patients 
within 45 days before treatment. The prognostic value of SUVmax of the primary tumors 
were analyzed with univariate Cox regression. Survival was estimated using the Kaplan–
Meier method Results: The median age of the patients was 56 years (range 40–71). 
The median follow-up time was 20 months (range 1.4–81 months). The median SUVmax 
of the tumor (15.0) was decided as the cutoff value, and the impact of the SUVmax 
on survival was statistically evaluated according to this cutoff value. There was no a 
statistically signifi cant difference in overall survival (OS) between the low (≤15) and high 
(>15) SUVmax groups (p = 0.006) upon univariate analysis (p=0.403). Conclusion: SUV 
max of the primary tumor did not predicted overall survival in patients with 
unresectable stage III NSCLC treated with concurrent chemotherapy and radiotherapy 
Keywords: SUV, PET/CT, lung cancer, Prognosis
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P3.03-037 High Pretreatment Neutrophil-Lymphocyte Ratio: A Poor Prognostic 
Factor for Stage III Non-Small Cell Lung Cancer Patients Ahmet T. Sumbul1, 
Celal Batmacı2, Edip Ucar2, Fatih Kose1, Ali M. Sedef1, Berna Yildirim3, Huseyin 
Mertsoylu1, Ahmet Sezer1, Ozgur Ozyilkan1 1Medical Oncology, Baskent University, Adana,/
Turkey, 2Mustafa Kemal University, Hatay/Turkey, 3Radiation Oncology, Baskent University, 
Adana,/Turkey
Background: Smoldering infl ammation induced by tumor tissue form cytokine enrich 
environment which increase tumor growth potential signifi cantly. Neutrophil-Lymphocyte 
ratio (N/L) has been reported as a valuable indicator for tumor induced systemic 
infl ammation in literature. With this study, we aimed to evaluate potential prognostic 
role of pretreatment N/L ratio in locally advanced NSCLC patients those who were 
treated with curative chemoradiotherapy. Methods: Stage III 97 NSCLC patients were 
included into this study. Demographic characteristics of patients and well defi ned clinic 
and histopathological prognostic factors of their tumors were recorded. There is no 
clear delineated cut off value for N/L ratio in literature; fi rst, we performed ROC curve 
statistical analysis. Our statistical analysis showed cut off level of 4.26 ED with high 
sensitivity and specifi ty. We used Kaplan-Meier survival curve and log-rank test (p<0.05) 
for survival analysis. Results:
Median age was 58 years old (range 39-75), and 87 (89.7%) of the patients were men. 
ECOG performance score was 0-1 in 93 patients (95.9%). Squamous histology, most 
common histology, was diagnosed in 46 patients (47.4%). Number of Stage IIIA and IIIB 
patients 41(42.3%) and were 56 (57.7%), respectively. Objective response rate (CR+PR) 
and clinical benefi t rate (CR+PR+SD) were 75.3% and 83.5%, respectively. Median 
follow-up time was 23.8 months (range 0.9-60). Median PFS and OS were 10.3 ([(95%CIs), 
9.2-11.5) and 17.8 months ([(95%CIs), 11.4-24.4]. When we evaluate 61 (62.8%) patients 
those who relapsed, distant and local relapse rate were found as 57.1 and 42.9 %, 
respectively. When the patients were grouped through N/L ratio, below (group a) or 
upper (group b) the cut-off value (4.26 ED), there was a statistically signifi cant difference 
between these groups, group a and group b, PFS and OS; 15.2 vs 8.1, 34 vs 23 months, 
respectively (p<0.005). Conclusion: Prognostic and predictive markers are major tools 
for oncologist to make decision making process. With this study, our results proved that 
pretreatment N/L ratio, marker for the systemic infl ammation, may be used as a 
prognostic marker for the local advanced stage III NSCLC patients. 
Keywords: neutrophil/lymphocyte ratio, infl ammation, prognosis, lung cancer
single institutional, retrospective, review utilizing the Karmanos Cancer Institute lung 
cancer database established in 2010. Inclusion criteria: stage III lung cancer patients 
who had completed therapy and who were treated between 2011 and 2013. Exclusion 
criteria: inadequate documentation and those who were not eligible for treatment 
based on clinician or patient preference. Patients were followed until progression or 
last assessment. The primary objective was to estimate the percentage of patients 
who had documented tumor recurrence on a surveillance scan. Results: Fifty four 
patients met the eligibility criteria. Mean age was 61 years (40-80), 34% were males; 
44% were Caucasians and 39% were African-Americans; 85% were current or former 
smokers. Histology at diagnosis was adenocarcinoma in 67% and squamous cell in 
31%, the remaining were large cell and poorly differentiated. Thirty-seven (69%) patients 
received chemotherapy and radiation, 12 (22%) received surgery with chemotherapy and 
radiation, and 5 (9%) received surgery and chemotherapy. The median follow up following 
completion of treatment was 18 months. Eighteen (33%) patients have had disease 
recurrence, with 11 (20%) recurrences within 1 year following completion of therapy. 
Of all 18 patients with recurrences, 17 (98%) were detected on surveillance scans. 
Only 1 (2%; 95% CI: 0-10%) recurrence was detected on scans obtained for worsening 
symptoms. Conclusion: In this retrospective analysis in stage III NSCLC patients who had 
completed therapy, except one case, all of the recurrences were detected on surveillance 
scans, strongly suggesting that routine surveillance scans provide clinical utility. 
Keywords: Stage-III NSCLC, lung cancer, follow up imaging, follow up post treatment
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P3.03-035 Unclear Clinical Course and Treatment Options for Clear Cell Lung 
Cancer: A Case Series Muhammad K. Riaz, David Mosko, Jiang Wang, Nagla A. Karim
University of Cincinnati Medical Center, Cincinnati/OH/United States of America
Background: Clear cell lung cancer (CCLC) is an extremely rare variant of lung tumors 
which was fi rst described by Liebow and Castleman in 1963. It has vague natural history 
with slight female predominance and is most often seen in elderly. The clear appearance 
results from intracellular accumulation of glycogen in absence of mucus production. 
Because of the rarity of this disease, clinical course and treatment options are not well 
established. Here we describe a case series of 4 patients of clear cell adenocarcinoma 
and highlight these aspects. Methods: We reviewed the charts, pathological diagnosis 
and imaging studies of 4 rare cases of clear cell adenocarcinoma of the lung that were 
encountered over the past 5 years at the University of Cincinnati Medical Center. Case1:
61 yo F smoker presented with new onset hemoptysis and unintentional 
weight loss. CT scan revealed 7.2cm lung mass with endobronchial extension. 
This was followed by biopsy and the pathology revealed poorly differentiated 
CCLC. She was started on defi nitive chemoradiotherapy but, just after a 
month of completing treatment, she developed brain metastasis. Case2:
52 yo F smoker had workup for unintentional weight loss and CT scan revealed 
1.4cm spiculated nodule. She underwent Video-assisted thoracoscopic surgery 
(VATS) and pathology confi rmed high grade CCLC without lymphovascular 
or perineural invasion. She was managed conservatively. Case3:
71 yo F smoker had CT chest which showed a 2.2cm nodule. Because FNA was 
equivocal she underwent VATS and pathology showed clear cell adenocarcinoma 
without evidence of metastasis. No adjuvant therapy was offered. Case4:
74 yo F with history of Orthotopic heart transplantation had a CT scan which incidentally 
showed 4cm nodule which turned out to be an adenocarcinoma on biopsy. She 
underwent VATS and pathology was consistent with clear cell adenocarcinoma without 
evidence of infi ltration. Her post-op course was complicated by infection and she passed 
away. Results: Clear cell features are cytologic changes that occur in association with 
adenocarcinoma or large cell carcinoma per WHO classifi cation. Our 4 cases were all 
clear cell adenocarcinoma of the lung confi rmed by immunohistochemistry. Immunostains 
were positive for CAM5.2, TTF-1 and CK7 and negative for CK20, p63, S-100 and PAX-
8. Case1 and case2 highlights the lack of established treatment guidelines for CCLC. 
Currently, same chemotherapy regimens are used as for non-clear cell adenocarcinoma. 
One study reported KRAS as driver mutation, which, if established, could lead to future 
therapeutic options. Case3 showed that small biopsies could be insuffi cient for diagnosis 
of CCLC. Case4 questions if these lesions could be followed without surgery in high-
risk patients to avoid unnecessary morbidity and mortality. Finally, clear cell carcinoma 
of renal, endometrium and ovarian origin should be considered before making the fi nal 
diagnosis of CCLC. Conclusion: CCLC is a rare tumor and more studies are needed to 
establish management and guidelines. Genetic mutations could be potential therapeutic 
targets. Risks and benefi ts of treatment should be considered in high-risk patients. 
Keywords: Clear cell, Adenocarcinoma, lung cancer
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P3.03-036 PET for Prognostic Assessment in Patients with Unresectable Stage 
III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy 
Ufuk Yilmaz1, Zehra Asuk2, Hakan Koparal3, Engin Ozbilek3, Esra Korkmaz4, Burcu 
Yalcın1, Hasan Yilmaz4 1Pulmonary Medicine, Izmir, Dr. Suat Seren Chest Disease and 
Surgery Training and Research Hospital, Izmir/Turkey, 2Pulmonary Medicine, Abant Izzet 
Baysal University School of Medicine, Bolu/Turkey, 3Nuclear Medicine, Izmir, Dr. Suat 
Seren Chest Disease and Surgery Training and Research Hospital, Izmir/Turkey, 4Radiation 
Oncology, Izmir, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, 
Izmir/Turkey
Background: Concurrent chemoradiotherapy is the standard of care for locally 
advanced, unresectable non-small cell lung carcinoma(NSCLC). The study purpose 
was to assess the prognostic value of maximum standardized uptake values (SUV max) 
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biomarker in exosomal RNA transcripts isolated from patient plasma. We determined 
the variant-specific expression profile of EML4-ALK fusion transcripts in a cohort of 
NSCLC patients with high sensitivity and specificity. We observed high concordance of 
the qPCR-based plasma results with FISH-based tissue information. Conclusion: Liquid 
biopsies represent a low-risk and viable approach to testing for predictive cancer 
markers in NSCLC patients. Here, we demonstrate the capability of our validated 
diagnostic test to determine expression of rare EML4-ALK fusion transcripts in plasma 
as a sensitive alternative to repeat biopsy. Monitoring discrete EML4-ALK fusion variants 
would enable effective personalized treatment and has clear clinical application. 
Keywords: EML4-ALK, liquid biopsy, RT-qPCR, extracellular vesicles
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P3.04-002 Correlation of ALK Status Between FISH and Immunohistochemistry 
in Lung Cancer: A Multicenter Study of 738 Cases in Argentina 
Maria Jose Labanca1, Pablo D. Roitman1, Erica Rojas Bilbao2, Lina Marino3, Gabriel 
Casas4, Mercedes L. Dalurzo1, Paola X. De La Iglesia1 1Pathology, Hospital Italiano 
de Buenos Aires, Ciudad Autonoma de Buenos Aires/Argentina, 2Pathology, Instituto 
de Oncología Angel Roffo Y Hospital Alemán, Ciudad Autónoma de Buenos Aires/
Argentina, 3Pathology, Instituto de Oncología Angel Roffo, Ciudad Autónoma de Buenos 
Aires/Argentina, 4Pathology, Hospital Alemán, Ciudad Autónoma de Buenos Aires/Argentina
Background: Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements 
are infrequent alterations in lung cancer occurring in approximately 3-6% of non small 
cell lung carcinomas (NSCLC). ALK status is an important predictive factor in NSCLC, 
as ALK rearranged tumors have shown sensitivity to Crizotinib treatment. Even 
though FISH remains the gold standard for assessment of ALK status, it bears some 
disadvantages such as availability, need for trained personnel and difficult evaluation 
in some cases. Currently, this tool is the only approved diagnostic test by the FDA to 
detect ALK rearrangement. Detection of ALK protein by immunohistochemistry (IHC) is 
a much more affordable and widespread method. The use of new clones and highly 
sensitive methods have improved the sensitivity, specificity and predictive values of 
IHC in the assessment of ALK status. Methods: We compared ALK rearrangement in 
738 consecutive cases from three Reference center’s surgical pathology laboratories 
(Hospital Italiano de Buenos Aires, Instituto de Oncología Angel H. Roffo and Hospital 
Alemán). They were evaluated by FISH and ultra sensitive IHC. FISH was performed on 
unstained 4 um formalin-fixed paraffin embedded tumor tissue sections using an ALK 
break-apart probe set (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe; 
Abbott Molecular) and paraffin pretreatment IV reagent kit (Vysis, Abbott Molecular). 
Assays were performed following the manufacturer’s instructions. Positive and negative 
controls were present in each run. Sections were analyzed by a trained observer under 
a fluorescence microscope, using appropriate filters. Cases were considered ALK-FISH 
positive if ≥15% tumor cells showed split red and green signals (separation of 2 diameters 
or more) and/or single red signals. IHC was performed on an automated Benchmark 
XT slide stainers, using Ventana anti-ALK D5F3 monoclonal antibody on previously 
deparaffinized 4um tissue sections. For detection, OptiView DAB IHC Detection Kit 
and OptiView amplification Kit (Ventana, AZ) was used. Positive and negative controls 
were present in each run. IHC staining results were interpreted as either negative 
(weak or no staining present) or positive (strong granular cytoplasmic staining in tumor 
cells). Results: Of 738 cases, 709 were FISH negative and 29 FISH positive (prevalence 
of ALK rearranged cases 3.92%). Of FISH negative cases, two cases had IHC positive 
results, and 29 out of 29 FISH positive cases were also IHC positive. For IHC testing, 
sensitivity was 100%, specificity was 99,71% with a positive predictive value of 93,54% 
and a negative predictive value of 100%. Conclusion: Our results show that IHC has a 
high sensitivity and specificity to detect ALK rearrangements. Discordant results were 
unusual, agreeing with the values  reported in the literature. While several studies have 
shown good response to crizotinib in cases with negative FISH and positive IHC, larger 
studies are needed to validate this association. So far, international guidelines have 
accepted the use of properly validated IHC as a screening tool in assessing ALK status. 
Keywords: Non small cell lung carcinomas (NSCLC), Fluorescence in situ hybridization 
(FISH), Anaplastic lymphoma receptor tyrosine kinase (ALK), Immunohistochemistry 
(IHC)
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P3.04-003 Novel Fusion Protein ALK-MPRIP Exhibits ALK Activation and 
Sensitivity to Crizotinib Namrata Shah, Kristina Teso, Katie Zilli, Smitha Menon 
Hematology/Oncology, Medical College of Wisconsin, Milwaukee/WI/United States of 
America
Background: Rearrangement of the ALK gene is an important therapeutic pathway in 
NSCLC. EML4 is the partner gene in the vast majority of ALK driven cancers, with other 
variants rarely reported. The clinical characteristics and sensitivity to ALK targeted 
agents in patients with non-EML4 variants are unknown. Methods: We report a patient 
case with a novel fusion of ALK-MPRIP (myosin phosphatase-Rho-interacting protein 
gene). A 49-year-old Caucasian female with less than 10 pack-year smoking history 
presented with chest pain and dyspnea on exertion. Chest x-ray showed mild CHF. An 
echocardiogram demonstrated a large pericardial effusion with tamponade physiology. 
She underwent a pericardial window with cytology of the pericardial fluid demonstrating 
adenocarcinoma, positive for TTF1 and napsin, consistent with lung primary. CT imaging 
revealed cervical and mediastinal adenopathy, bilateral pleural effusions, small lung 
nodules. She was staged as TxN3M1a. She was negative for EGFR and ALK by FISH. Tissue 
was sent for next generation sequencing due to her light smoking history, which revealed 
a never before characterized ALK-MPRIP fusion. As the functional significance of this 
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P3.03-038 A Multi-Center Trial Comparing Standard 22-Gauge and 22-Gauge 
Bibevel (ProCore) Needles for Endobronchial Ultrasound Nichole T. Tanner1, 
Paul Nietert2, Jason Akulian3, Lonny Yarmus4, Jack Yang5, Leslie Dodd6, Peter B. Illei7, 
Arnold Schwartz8, Gerard Silvestri1 1Medicine, Medical University of South Carolina, 
Charleston/SC/United States of America, 2Public Health Sciences, Medical University of 
South Carolina, Charleston/SC/United States of America, 3University of North Carolina, 
Chapel Hill/NC/United States of America, 4Johns Hopkins University, Baltimore/MD/
United States of America, 5Pathology, Medical University of South Carolina, Charleston/
SC/United States of America, 6Pathology, University of North Carolina, Chapel Hill/NC/
United States of America, 7Pathology, Johns Hopkins University, Baltimore/United States of 
America, 8Pathology, George Washington University, Washington Dc/DC/United States of 
America
Background: Endobronchial ultrasound fine needle aspiration (EBUS-FNA) is 
recommended as the first tissue sampling procedure for the staging and diagnosis of 
known or suspected lung cancer. With the advent of targeted agents for lung cancer 
therapy, there is an increasing demand to extend EBUS-FNA samples for molecular 
testing. While it has been shown to be adequate for EGFR mutational analysis in 77-
96% of samples, as new discoveries are made the challenge is to obtain enough quality 
tissue via EBUS-FNA. Bibevel (ProCore) needle technology used during endoscopic 
ultrasound (EUS) procedures has been shown to provide larger samples of tissue for 
histologic diagnosis of gastrointestinal malignancies. This same needle technology 
may also provide more tissue during EBUS to allow for better histologic and molecular 
analysis than standard EBUS-FNA. The goal of this study is to determine the utility of the 
22-gauge (G) ProCore EBUS needle by comparing it to standard single bevel 22G EBUS 
needles. Methods: This multicenter randomized trial will enroll 200 patients with known 
or suspected lung cancer during standard of care diagnostic/staging EBUS. A maximum 
of two lymph nodes (pathologic in size (>1cm) and/or hypermetabolic on PET/CT) will be 
included in the comparison. A total of 8 passes will be taken from each node (4 from the 
bibevel needle, 4 from standard) and cell blocks compared by a blinded pathologist . The 
primary outcome is tumor cells per mm2. Descriptive statistics will be used to characterize 
the study subjects and their outcomes with the 2 different needles. For the within-subject 
(i.e. between needle) comparisons of tumor quantity and ability to perform commercially 
available immunohistochemical stains and mutational analysis, non-parametric Wilcoxon 
signed rank tests will be used. Since cell block quality will be quantified as simply which 
needle’s sample provided the better sample, the non-parametric sign test will be used. All 
hypothesis testing will be 2-sided, using an alpha level of 0.05 Results: Forty-one patients 
from three centers have been enrolled, with 48 lymph nodes sampled. There is an even 
gender distribution (22 (54%) male, 19 (46%) female). The majority are non-Hispanic 
white (n=30, 73%). 22 patients have (54%) have a malignant diagnosis, 12 (30%) a benign 
diagnosis, and 2 (5%) have been non-diagnostic. Minor complications include bleeding 
at the site in 7 (17%). There have been no major complications. Conclusion: Data for 
the primary outcomes have yet to be analyzed, however the trial design is feasible 
and thus far the use of two separate needles during EBUS has shown to be safe. 
Keywords: endobronchial ultrasound, molecular analysis, tissue aquisition
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P3.04-001 Exosomal RNA Based Liquid Biopsy Detection of EML4-ALK in 
Plasma from NSCLC Patients Kay Brinkmann1, David P. Carbone2, Daniel Enderle1, 
Tina Koestler1, Stefan Bentink1, Jennifer Emenegger1, Alexandra Spiel1, Romy Mueller1, 
Vince O’Neill3, Johan Skog3, Mikkel Noerholm1 1Exosome Diagnostics Gmbh, Martinsried/
Germany, 2The Ohio State University Medical Center, Columbus/OH/United States of 
America, 3Exosome Diagnostics Inc., Ma/MA/United States of America
Background: Molecular profiling to direct targeted therapy has revolutionized cancer 
treatment. For instance, the tailored therapy of NSCLC patients carrying somatic EML4-
ALK rearrangements with ALK inhibitors has shown to be associated with substantial 
clinical response. A prerequisite of this approach is highly sensitive and specific 
diagnostics to detect and monitor the prognostic biomarker. Today’s tissue-based 
diagnostics like FISH are limited by complications of biopsy and technical challenges. 
Therefore, biomarker assessment in plasma circulation would be a valuable alternative 
to tissue based testing and provide a simple new option for identifying and monitoring 
EML4-ALK positive NSCLC patients. We previously demonstrated the feasibility of 
detecting EML4-ALK fusion transcripts in 6 plasma samples from patients known to be 
positive by tissue FISH testing (the gold standard). Here we present more comprehensive 
performance characteristics of this diagnostic test analyzing the exosomal expression 
of EML4-ALK in plasma of NSCLC patients. Methods: We developed a diagnostic test to 
monitor the expression of EML4-ALK fusion transcripts in low-volume plasma samples 
of lung cancer patients. The Exosome Diagnostics ALK assay comprises column-based 
isolation of total vesicular RNA from 0.5 – 2.0 ml patient plasma, followed by discrete 
detection of EML4-ALK variants v1, v2 and v3 via qPCR. Assay quality is confirmed by 
inclusion of internal and external controls. Following validation on both synthetic and 
human samples, we monitored variant-specific expression of EML4-ALK in a cohort of more 
than 20 plasma samples from NSCLC patients. The data was analyzed for concordance 
with time-matched tissue and aligned with patient’s response data. Results: Applying 
our diagnostic test for EML4-ALK fusion variants, we were able to identify the predictive 
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P3.04-004 Utility of Cytology Specimens for ALK Fusion Detected by qRT-
PCR in Patients of Advanced Non Small Cell Lung Cancer Yan Wang1, Guanghui 
Gao2, Yayi He2, Xuefei Li2, Chao Zhao2, Chunyan Wu2, Shengxiang Ren2, Caicun Zhou2 
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School 
of Medicine, Shanghai/China, 2Shanghai Pulmonary Hospital, Tongji University School of 
Medicine, Shanghai/China
Background: Tumor tissue is the essential specimen for anaplastic lymphoma kinase 
(ALK) rearrangements detection by the methods of fluorescence in situ hybridization 
assay(FISH) and immunohistochemistry(IHC). However, a lot of patients could just 
provide cytological samples but not tumor tissue in clinical practice. The aim of this study 
was to evaluate the feasibility of cytology as an alternative specimen for ALK detection 
in patients with advanced non small cell lung cancer (NSCLC). Methods: Advanced 
NSCLC patients with cytology specimens or tumor tissue who had their ALK fusion status 
detected by qRT-PCR in Shanghai Pulmonary Hospital, Tongji University were included 
into this analysis. The efficacy was evaluated in those with ALK fusion and treated with 
crizotinib. Results: From December 10th 2010 to March 20th 2015, 1386 patients 
entered into this study with 1144 cytology specimens and 242 tumor tissue. Among 
them, 110 of 1144(9.6%) patients were ALK qRT-PCR positive using cytology specimens 
to perform detection and 26 of 242(10.7%) patients with tumor tissue were ALK fusion 
positive. Totally, 69 patients received the treatment of crizotinib. The overall response 
rate (ORR) of the 50 patients with cytology specimens was 62.0%, which was similar as 
52.6% in 19 patients with tissue (p=0.479). Median progression free survival (mPFS) was 
8.3 months (95% CI 6.91-9.75) in the cytology specimens group, which was also similar 
as 5.2 months (95% CI 2.58-7.82) (p=0.604) in the tissue group. Conclusion: Cytology 
specimens showed a high feasibility to perform ALK fusion status detection by qRT-
PCR and a similar response to ALK inhibitor as tissue specimens, which might be 
regarded as alternative specimens for ALK detection in patients of advanced NSCLC. 
Keywords: qRT-PCR, NSCLC, ALK, cytology specimens
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P3.04-005 Discrepancies between ALK FISH and Capture Based NGS Test 
NEOplus and Clinical Outcome with ALK TKI Therapy Rafal Dziadziuszko1, 
Martin Reck2, Sylvie Lantuejoul3, Frank Griesinger4, Federico Cappuzzo5, Wilfried 
E.E. Eberhardt6, Markus Tiemann7, Roopika Menon8, Lukas C. Heukamp8, Johannes 
Heuckmann8 1Medical University of Gdansk, Gdansk/Poland, 2Lungenclinic Grosshansdorf, 
Grosshansdorf/Germany, 3CHU de Grenoble, Grenoble/France, 4Pius-Hospital Oldenburg, 
Oldenburg/Germany, 5Istituto Toscano Tumori, Livorno/Italy, 6University Hospital Essen, 
West German Cancer Centre, Ruhrlandklinik, University Duisburg-Essen, Essen/Germany, 
7Haematopathology Hamburg, Hamburg/Germany, 8Neo New Oncology, Cologne/Germany
Background: Research in recent years has unraveled several gene fusions driving 
tumor development in lung cancer. Especially adenocarcinomas of the lung harboring 
ALK and ROS1 gene fusions exhibit striking sensitivity to ALK and ROS1 kinase 
inhibitors respectively, translating to dramatic responses in the clinic. Several different 
technologies are available to detect aberrant genomic structures. The most frequently 
used technologies include fluorescent in situ hybridization (FISH), currently considered 
as the “gold standard”, immunohistochemistry (IHC), RT-PCR based approaches and 
hybrid capture based NGS sequencing. Methods: Here, we describe a selection of 
tumor samples showing discrepant results between fluorescent in situ hybridization and 
hybrid capture based NGS sequencing. These included samples with positive FISH but 
negative NEOplus as well as negative FISH and positive NEOplus results. In addition, 
we used response data of targeted therapies to evaluate the true genetic phenotype 
of the tumor. Results: Overall, several lung adenocarcinomas showed discrepant 
results when FISH and NEOplus data were compared. First, one sample was tested 
positive for ALK rearrangement using FISH which was not confirmed using NEOplus. 
In line with this finding, the tumor did not respond to ALK TKI treatment. Second, a 
total of 4 cases were fusion negative by FISH but positive by NEOplus. Three out of 
4 ALK positive cases showed clinical response to ALK kinase inhibition, the clinical 
results for case number 4 are pending. Interestingly, one of these responding tumors 
was also negative for ALK expression using IHC. Conclusion: In summary, we describe 
a selection of tumor samples with discrepant results for fusion detecting using FISH 
and NEOplus. Overall, in all of the cases for which clinical response data was available, 
tumor sensitivity was in line with the initial diagnosis generated by the NEOplus assay. 
Keywords: ALK, FISH, NGS, outcome
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-006 ALK Immunohistochemistry in NSCLC: Evaluation of Performance 
of D5F3-IHC without Using Automated Ventana System Deepali Jain1, Kirti Jangra1, 
Prabhat Malik2, Mehar C. Sharma1 1Pathology, All India Institute of Medical Sciences, New 
Delhi/India, 2Medical Oncology, All India Institute of Medical Sciences, New Delhi/India
Background: Since the advent of targeted therapy, molecular testing for common 
mutations has become vital in the diagnostic algorithm of non- small cell lung 
cancer (NSCLCs). ALK-EML4 fusion is a rare abnormality detected in 3–13% patients 
of adenocarcinomas (ADC). Although Fluorescent In-Situ Hybridization (FISH) is a 
gold standard technique for detection of ALK rearrangement, it is expensive, time-
consuming and requires specialized equipment and expertise for interpretation. 
Immunohistochemistry (IHC) with ALK rearrangement-specific antibodies is considered 
as a more economical method for routine diagnostic practice. Ultrasensitive automated 
alteration was unknown, she continued Carboplatin/Pemetrexed/Bevacizumab therapy 
for 4 cycles followed by 6 cycles of maintenance Pemetrexed/Bevacizumab before 
documented progression. She was subsequently started on Crizotinib. Results: Two 
months after starting Crizotinib, CT scans demonstrated decreased lung nodules, 
lymphadenopathy and improved interstitial thickening. After 5 months of treatment CT 
scans demonstrated new ground glass opacities with increasing bilateral interlobular 
septal thickening concerning for either Crizotinib-induced lung toxicity or lymphangitic 
carcinomatosis. Bronchoscopy with transbronchial biopsy demonstrated lymphangitic 
spread suggestive of progression on Crizotinib within 6 months of therapy. The average 
PFS of Crizotinib treated EML4-ALK translocated patients is 7.7 months.
 
Conclusion: ALK-MPRIP is a novel fusion gene causing ALK activation. Our patient responded 
to Crizotinib but had a shorter than average PFS compared to EML4-ALK mutated patients. 
Keywords: non-small cell lung cancer, novel ALK fusion, crizotinib
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analysis showed that younger age (p= 0.0143) and female preponderance (p=0.0251) 
were statistically significant in the ALK positive subset. A specific predilection towards 
morphology could not be established. Acinar subtype constituted the majority of 
all subtypes 8/16 (50%) Conclusion: Increased frequency of ALK positivity in lung 
adenocarcinoma (7.96%) was noted in comparison to earlier published data .ALK 
D5F3 assessment by IHC may prove to be a cost effective alternative for analysis 
Keywords: ALK,FISH,Immunohistochemistry ,Lung
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P3.04-008 Detection of EML4-ALK Fusion Gene by Using Nested Long-
Ranged Polymerase Chain Reaction Shinnosuke Takemoto1, Hiroaki Senju1, Yoichi 
Nakamura1, Hiroshi Gyotoku1, Takaya Ikeda2, Hiroyuki Yamaguchi1, Takeshi Kitazaki3, 
Katsumi Nakatomi1, Minoru Fukuda4, Junji Tsurutani5, Kazuhiro Tsukamoto6, Shigeru 
Kohno1 1Second Department of Internal Medicine, Nagasaki University Hospital, Nagasaki 
City/Japan, 2Division of Respiratory Medicine, Sasebo City General Hospital, Sasebo/
Japan, 3Division of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, 
Nagasaki/Japan, 4Clinical Oncology Center, Nagasaki University Hospital, Nagasaki/
Japan, 5Department of Medical Oncology, Kinki University, Sayamashi/Japan, 6Department of 
Pharmacotherapeutics, Unit of Medical Pharmacy, Nagasaki University, Nagasaki City/Japan
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm 
microtubule-associated protein-like 4 (EML4) was identified in Non-small cell lung 
cancer (NSCLC). ALK tyrosine kinase inhibitors were proved to be superior to standard 
chemotherapies and it is important to detect EML4-ALK fusion gene accurately. 
Reverse transcriptase-polymerase chain reaction (RT-PCR), Fluorescence in situ 
hybridization (FISH) and Immunohistochemical (IHC) stain are performed clinically to 
detect the fusion gene. However, there are discrepancies among these methods for 
detection of EML4-ALK fusion gene and the best detection method remain unknown. 
The purpose of this study was to evaluate the new method for detection of the EML4-
ALK fusion gene. Methods: The combination of nested polymerase chain reaction (PCR) 
and ｌong-ranged PCR (Nested long-ranged PCR) was used to detect EML4-ALK fusion 
gene. Genomic deoxyribonucleic acid (gDNA) was extracted from EML4-ALK positive 
lung cancer cell lines (NCI-H2228,NCI-H3122,ALKSFA8). It was verified whether the 
fusion gene was amplified. We evaluated the sensitivity of Nested long-ranged PCR 
for EML4-ALK fusion gene in various ratios. It was confirmed whether the amplification 
products were EML4-ALK fusion gene by using PCR direct Sequencing. Results: EML4-
ALK fusion genes were detectable successfully in each of EML4-ALK positive lung cancer 
cell lines.NCI-H3122 had EML4-ALK variant 1. ALK-SFA8 and NCI-H2228 had EML4-
ALK variant 3a/b. One fusion gene in the presence of 1×102 wild type genes was 
detectable in each cell line. Each PCR product was confirmed by sequencing from both 
ends. Conclusion: In this study, we were able to detect the fusion gene in vitro by Nested 
long-ranged PCR. This may become a new diagnostic method for EML4-ALK fusion gene. 
Keywords: genomic DNA, PCR, EML4-ALK, NSCLC
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P3.04-009 Evaluation of RT-PCR Methodology for ALK Assessment in 
Patients with NSCLC in Europe: Results from the ETOP Lungscape Project Igor 
Letovanec1, Solange Peters2, Zoi Tsourti3, Stephen P. Finn4, Alex Soltermann5, Lukas 
Bubendorf6, Ernst-Jan M. Speel7, Antonio Marchetti8, Daisuke Nonaka9, Henrik Hager10, 
Miguel Martorell11, Kim Monkhorst12, Aleksandra Sejda13, Richard Cheney14, Irene 
Sansano15, Eric K. Verbeken16, Verena Tischler17, Spasenija Savic18, Alessia Di Lorito8, 
Maria Consuelo Calabuig19, Enriqueta Felip20, Alex Adjei21, Arne Warth22, Paul Baas23, 
Peter Meldgaard24, Fiona Blackhall25, Anne-Marie Dingemans26, Hendrik Dienemann27, 
Rafal Dziadziuszko28, Johan Vansteenkiste29, Rosita Kammler30, Urania Dafni31, Keith 
Kerr32, Erik Thunnissen33, Rolf Stahel34 1Co-First Author, Department of Pathology, Centre 
Hospitalier Universitaire Vaudois - Chuv, Lausanne/Switzerland, 2Co-First Author, Department 
of Oncology, Etop and Centre Hospitalier Universitaire Vaudois (Chuv), Lausanne/
Switzerland,3Frontier Science Foundation-Hellas, Athens/Greece, 4Department of Pathology, 
University of Dublin, Trinity College and St. James’S Hospital, Dublin/Ireland, 5Institute of 
Surgical Pathology, University Hospital Zurich, Zurich/Switzerland, 6Institute of Pathology, 
University Hospital Basel, Basel/Switzerland, 7Department of Pathology, Maastricht 
University Medical Centre, Maastricht/Netherlands, 8Anatomia Patologica, Ospedale 
Clinicizzato, Chieti/Italy, 9The Christie Hospital and Institute of Cancer Sciences University 
of Manchester, Manchester/United Kingdom, 10Department of Pathology, Aarhus University 
Hospital, Aarhus/Denmark, 11Department of Pathology, Consorcio Hospital General 
Universitario, Valencia/Spain,12Department of Pathology, Netherlands Cancer Institute, 
Amsterdam/Netherlands, 13Department of Pathology, Medical University of Gdansk, Gdansk/
Poland, 14Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, 
Buffalo/NY/United States of America, 15Department of Pathology, Hospital Universitari 
Vall D’Hebron, Barcelona/Spain, 16Department of Pathology, University Hospital Leuven, 
Leuven/Belgium, 17Institute of Clinical Pathology, University Hospital Zurich, Zurich/
Switzerland, 18Insitute of Pathology, University Hospital Basel, Basel/Switzerland, 19Consorcio 
Hospital General Universitario, Valencia/Spain, 20Vall D’Hebron University Hospital and Vall 
D’Hebron Institute of Oncology (Vhio), Barcelona/Spain, 21Medicine, Roswell Park Cancer 
Institute, Buffalo/NY/United States of America, 22Department of Pathology, University 
Hospital Heidelberg, Heidelberg/Germany, 23Department of Thoracic Oncology, Netherlands 
Cancer Institute, Amsterdam/Netherlands, 24Department of Oncology, Aarhus University 
Hospital, Aarhus C/Denmark, 25Manchester University and the Christie NHS Foundation Trust, 
Manchester/United Kingdom, 26Department of Pulmonary Diseases, Maastricht University 
Medical Center, Maastricht/Netherlands, 27Department of Thoracic Surgery, Thoraxklinik 
at University of Heidelberg and TLRC, Heidelberg/Germany, 28Department of Oncology 
and Radiotherapy, Medical University of Gdansk, Gdansk/Poland, 29Respiratory Oncology, 
Ventana D5F3-IHC revealed a very high correlation with FISH and approved by China 
FDA for targeted therapy; however, the automated IHC apparatus are not widely used 
in most general laboratories. In this study, we evaluated performance of ALK IHC using 
manual semiquantitative method in a cohort of 133 adenocarcinomas, to achieve the 
frequency of ALK positivity in Indian patients and correlation with automated Ventana 
D5F3-IHC. Methods: We tested 133 cases of primary lung ADCs, which were negative 
for EGFR mutation, for ALKrearrangement by D5F3-IHC.Thirty three of them were tested 
by both automated Ventana (D5F3) and manual methods (Cell Signaling Technology, 
Danvers, MA, USA). The intensity of cytoplasmic staining was classified as 0 (negative) or 
1+/2+/3+ (weak/medium/strong). Binary score of positive (strong granular cytoplasmic 
staining in any percentage of tumor cells) and negative (absence of strong granular 
cytoplasmic staining) was used for Ventana IHC which was taken as gold standard. A 
comparison analysis and clinicopathological features were recorded. Results: Male to 
female ratio of the patient population was 2.3:1. ALK rearrangement was positive in 10 
(7.5%) cases, out of which 7 were men and 50% were non- smokers. Median age for all 
ADCs was 55 years and for ALK rearrangement positive cases was 47 years. Three of 
10 ALK IHC positive cases showed signet ring cell morphology. On comparison, all cases 
positive by Ventana (10 cases) (Figure 1A) showed positive results by manual method. 
Six cases showed 3+ (Figure1B) whereas 2+ (Three cases) and 1+ (one case) staining 
intensity was observed. The latter 4 cases were positive by FISH. All negative cases by 
Ventana system were negative by manual method.
  
Conclusion: Mutation specific IHC serves as a rapid tool for detection 
of ALK rearrangement in low resource settings. Manual IHC is equally effective in 
detection of ALK rearranged cases as automated methods. IHC positive cases may 
subsequently be analyzed by FISH thus reducing the cost of automated systems. 
Keywords: NSCLC, ALK immunohistochemistry, Ventana, automated IHC
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P3.04-007 EML4/ALK Status in Lung Cancer - A 2 Year Experience from 
a Tertiary Care Cancer Centre in India Sudha S. Murthy1, Senthil J. Rajappa2, 
Sandhya D. Gundimeda1, Krishna M. Mallavarapu2, Santa Ayyagari2, K V. Raju3, 
Thamineedi S. Rao3, Daphne Fonseca1, Veeraiah Koppula4 1Pathology & Laboratory 
Medicine, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad/
India, 2Medical Oncology, Basavatarakam Indo American Cancer Hospital & Research 
Institute, Hyderabad/India, 3Surgical Oncology, Basavatarakam Indo American Cancer 
Hospital & Research Institute, Hyderabad/India, 4Diagnostic Radiology, Basavatarakam Indo 
American Cancer Hospital & Research Institute, Hyderabad/India
Background: Detection of EML4-ALK rearrangement in lung cancers has influenced the 
diagnosis and management of a subset of patients with advanced adenocarcinoma. It 
has become pertinent that all ethnic groups are evaluated for ALK status. Since there is 
only one published study of EML4/ALK status ( Desai et al, 2013) from India, we sought 
to analyse the frequency of ALK positivity and correlation of this gene rearrangement 
with different parameters (age, gender and morphologic subtypes etc.). Methods: A 
retrospective analysis of data on ALK gene rearrangement status in lung cancer patients 
from the archives of the Department of Pathology & Laboratory Medicine was done over 
a period of 2 years( between March 2013 to March 2015) as per the ASCO / CAP/ IASLC 
guidelines 2013. Majority of the assays were done by Fluorescence in situ hybridization 
(FISH) using the Vysis ALK Breakapart rearrangement probe ( Abbott Molecular Inc). 
Immunohistochemistry was done with ALK D5F3 clone (Ventana). The morphology 
was reviewed by two pathologists trained in pulmonary pathology. Statistical analysis 
was performed to assess the impact of age, gender and morphologic subtypes on 
ALK positivity. Results: Of the 217 cases of adenocarcinoma of lung diagnosed in 
the Pathology department, 16 patients were excluded from the study. Two hundred 
and one patients underwent assay for ALK gene rearrangement. The assay was done 
by FISH in 181 patients(90%) and IHC in 20 patients(9.95%). The male to female ratio 
was 1.25:1. The tissue submitted for analysis comprised of lung tissue in 138 patients 
(68.7 %) and tissue from metastatic sites in 63 patients (31.34%). The most common 
metastatic siteswere lymph nodes 30 (47.61) and skeletal metastases 10 (15.87%). Of 
these, ALK was positive in 16 cases (7.96%) and negative in 185 patients( 92.03% ). 
All cases detected to be positive for ALK by either method (FISH/IHC) were confirmed 
by the other methodology inhouse.The major morphologic subtypes included acinar 
predominant 99 (49.25%),solid predominant 36 (17.91%),mucinous 16 (7.96%) and 
lepidic predominant 15(7.46%). Of the 99 (47.76%) cases, TTF 1 expression was seen in 
89 cases (92.07%). ALK positivity was seen in 10 female patients (62.5%) as opposed 
to 79(42.7%) females lacking ALK rearrangement. ALK positive patients were younger 
( median 41 years) among females when compared to ALK negative women ( median 
54.5 years). ALK positive males were also younger( median 50 years) when compared 
to negative cases (median 60 years). Stratifying the ALK status in relation to age 
groups in increments of 10 years showed that 68.7% of the ALK positive patients were 
below the age of fifty years when compared to 27% of ALK negative cases. Statistical 
S694 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-011 A Validation Study for the Use of ROS-1 Immunohistochemistry 
in Screening for ROS-1 Translocations in Lung Cancer Patrizia Viola1, Manisha 
Maurya2, James Croud1, Jana Gazdova2, Nadia Suleman1, Eric Lim3, Sanjay Popat4, 
Alexandra Rice1, Angeles Montero Fernandez1, David Gonzalez De Castro2, Andrew G. 
Nicholson5 1Histopathology, Royal Brompton Hospital, London/United Kingdom, 2Centre 
for Molecular Pathology, Royal Marsedn Hospital, Sutton/United Kingdom, 3Department 
of Thoracic Surgery, Royal Brompton and Harefield NHS Trust, London/United 
Kingdom, 4Medical Oncology, Royal Marsden Hospital, London/United Kingdom, 5Pathology, 
Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, 
London/United Kingdom
Background: ROS-1 translocations are a rare genetic abnormality in lung cancers 
that, when identified, are a target for personalised therapy. The current test of choice is 
FISH, although with a rate of no more than 1-2%, screening using FISH is an expensive 
proposition. A further possibility is using immunohistochemistry (IHC) as a screening tool 
and commercial antibodies are now available that identify the ROS-1 protein in tumour 
cells. We present our data in undertaking a validation study for potential diagnostic 
usage. Methods: Given the relative rarity of the translocation and the fact the most 
driver mutations occur in isolation, a test cohort of cases was selected from patients 
recruited to phase 1 of the Cancer Research UK-Stratified Medicine Project (CRUK-
SMP), who were identified as negative for EGFR, KRAS and/or BRAF mutations, as well 
as ALK translocations. Negative cases were then screened with an antibody for ROS-1 
(D4D6, Cell Signalling, 1 in 300 dilution) and scored as negative, weakly positive or 
moderately positive, along with the percentage of positive cells. Cases were then sent 
for FISH analysis for the ROS-1 translocation, with a cut-off of > or = to15%, and the 
sensitivity and specificity of positive staining for ROS-1 was generated. Results: From 
170 patients recruited from our institution into CRUK-SMP phase 1, a total of 103 patients 
were wild type for the above mutations (90 for all 4 genetic abnormalities. 9 further 
cases had failed tests for one and 4 for two mutations (6 carcinoids, 38 squamous 
cell carcinomas, 5 small cell carcinoma, 2 adenosquamous carcinoma, 1 pleomorphic 
carcinoma, 3 large cell carcinoma, 2 large cell neuroendocrine cell carcinoma, 7 non-
small cell carcinoma (on biopsy) and 39 adenocarcinomas). 39 cases were tested 
(adenocarcinoma = 37, adenosquamous carcinoma = 2) with FISH, and one case 
was positive (78% positive cells). FISH testing was negative in 35 cases with scores 
of 1-8%, and three cases failed. The one positive case was positive on IHC (>90% of 
cells, moderate staining). In the 35 cases negative for FISH, four cases showed variable 
positivity on IHC (20, 40,50, 90%, moderate staining) and five cases showed weak focal 
staining (<5, <5, 10, 20, 30%, weak staining). The remainder were negative on IHC. 
All non-adenocarcinomas were negative on IHC. Several cases show positive staining 
of entrapped background pneumocytes and alveolar macrophages, making scoring 
problematic in some adenocarcinomas. Conclusion: Moderate staining for ROS-1 
using IHC, independent of percentage positive cells, showed high sensitivity (100%) for 
tumours that contained a high level of translocated cells. However, specificity was at 
best 50%, even if a cut-off of 50% positive cells was applied. Pathologists also need 
to be aware of background staining so cases are not interpreted as false positives. 
Keywords: lung cancer, ROS-1 immunohistochemistry, FISH, ROS-1 translocations
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P3.04-012 Transition of HSP90-Dependent Client Proteins in ALK Rearranged 
Non-Small Cell Lung Cancer Ryohei Yoshida, Shunsuke Okumura, Takaaki Sasaki, 
Yoshinobu Ohsaki Asahikawa Medical University, Asahikawa/Japan
Background: Heat Shock Protein (HSP) 90 is one of the major intracellular 
molecular chaperones, the protein expression is increased in the cell stress 
conditions, is one of the proteins most present in the cytoplasm in normal condition. 
HSP90 plays a role for the correct folding of proteins in the correct conformation, 
and function by interacting with various intracellular proteins. The client proteins 
that interact with HSP90 contains many important role signaling molecules for cell 
proliferation and differentiation, such as protein kinase and steroid hormone receptors. 
Luminespib (AUY922) is a specific HSP90 inhibitor bound to the ATP-binding pocket, 
leading inactivation, destabilization and degradation of HSP90-dependent client protein. 
In Non-small cell lung cancer, ALK rearranged cancers are reported as highly sensitive 
to luminespib, which supposed to ALK fusion proteins are the client proteins of HSP90. 
By comparing the expression changes in intracellular proteins after treatment of 
luminespib, we determined the significant pathways in the ALK rearranged cancer 
cells both sensitive to ALK tyrosine kinase inhibitors (TKIs) and resistant to ALK-TKIs. 
 
Methods: HSP90 inhibitor luminespib (AUY922, Novartis Pharm.) and ALK-TKIs, alectinib 
(CH5424802, Chugai Pharm.) and were used in this study. Alectinib resistant cell lines were 
established by exposing increased dose of alectinib to ALK rearranged H3122 cell line (AFR). 
To study the protein expression screening after treatment of luminespib, protein lysate 
from H3122 and AFR with or without luminespib were collected, and submitted for 
mass-spectrometry using iTRAQ. We also determined the protein expression of HSP90-
dependent client protein and signaling proteins by Western Blotting. Results: The 
iTRAQ data analysis and protein identifications were done with ProteinPilot version 
4.5. We observed 1118 proteins/peptides in each cell lines. At first we focused on 
changes in the protein expression of HSP family after treatment of luminespib. The 
HSP90A after treatment of luminespib was increased in H3122 and the HSP90B after 
treatment of luminespib was decreased in AFR. The protein expression of HSP70 
after treatment of luminespib was increased in H3122 and in AFR. These results 
suggested that the role of HSP90-dependent client proteins have changed in ALK-TKIs 
acquired resistant cells. Secondly, we studied the HSP90-dependent client proteins by 
University Hospital Ku Leuven, Leuven/Belgium, 30Translational Research Coordination, Etop 
Coordinating Office, Bern/Switzerland, 31Frontier Science Foundation-Hellas & University of 
Athens, Athens/Greece, 32Department of Pathology, Aberdeen Royal Infirmary, Aberdeen/
United Kingdom, 33Department of Pathology, VU University Medical Center,, Amsterdam/
Netherlands, 34Laboratory of Molecular Oncology, Clinic of Oncology, Etop and University 
Hospital Zurich, Zurich/Switzerland
Background: ALK rearrangement is documented in 2%-7% of NSCLC, depending on 
the population studied and detection method used. Although the reverse transcriptase-
polymerase chain reaction (RT-PCR) was the first used and published method, 
fluorescence in situ hybridization (FISH) has become the primary standard diagnostic 
method. Recently, immunohistochemistry (IHC) has also proven to be a reproducible, 
faster and sensitive technique. This is one of the first studies concurrently comparing 
all three techniques in resected lung adenocarcinomas from the large ETOP Lungscape 
cohort. Methods: 95 cases from the ETOP Lungscape iBiobank, selected based on 
any degree of IHC staining (clone 5A4 antibody, Novocastra, UK), were examined by 
ALK FISH (Abbott Molecular, Inc.; Blackhall, JCO 2014) and central RT-PCR. For the 
latter, formalin-fixed, paraffin-embedded (FFPE) unstained slides were collected from 
participating centers. Slides were de-paraffinized, Toluidine Blue stained, and tumors 
macro-dissected. Tissue digestion and RNA extraction were performed (Qiagen 
RNeasy FFPE Kit). Using primers described in the literature covering most of ALK 
known translocations, RT-PCR (Superscript One-Step RT-PCR with Platinum Taq – 40 
loops) was performed, followed by capillary electrophoresis in two separate mixes. 
Co-amplification of B-actin was done to validate the procedure and RNA quality. All 
tests were duplicated. Results: 76 of 95 RT-PCR had adequate RNA quality (B-actin 
co-amplification present). Among these, 18 were FISH positive, 16 were RT-PCR positive, 
including EML4-ALK V3a/b in 7, V1 in 5, V2 in one, and undetermined variants in 3 cases. 
53 of 54 FISH negative cases were also RT-PCR negative (98%). 15 of 18 FISH positives 
harbored a translocation by RT-PCR (83%). Among the 4 discrepant cases, 2 FISH+/
RT-PCR- cases had IHC H-scores of 180 and 260, and 98.3% and 95% of rearranged 
cells by FISH, probably corresponding to variants not covered by the RT-PCR. One had 
an IHC H-score of 5, and 16% cells rearranged on FISH, most probably corresponding 
to a FISH false positive case. The last had an IHC H-score of 200, 13% rearranged cells 
by FISH, and, thus is defined as a false negative FISH result. Provided IHC is defined 
as positive by an H-score above 120, all but one case (H-Score 20, FISH and RT-PCR 
positive) gave concordant results by a combination of FISH and RT-PCR. Overall, using 
as true negative or true positive the concordant result of two of the methods, the third 
method is characterized by high specificity and sensitivity with corresponding values 
of 100/98/100% and 94/94/89% for IHC/FISH/RT-PCR, respectively. Conclusion: RT-
PCR is a very good tool for sorting discordant IHC/FISH cases, however, we do not 
recommend using this technique as single method due to the lower sensitivity of RT-PCR, 
as not all variants are covered, and also due to the limitations with RNA preservation. 
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P3.04-010 EML4-ALK Fusion Detected by qRT-PCR Confers Similar Response 
to Crizotinib as Detected by FISH in Patients with Advanced NSCLC Shengxiang 
Ren1, Yan Wang2, Guanghui Gao1, Xuefei Li3, Chao Zhao4, Chunxia Su5, Xiaoxia Chen3, 
Yayi He5, Caicun Zhou6 1Oncology, Shanghai Pulmonary Hospital, Tongji University School of 
Medicine, Tongji University Cancer Institute, Shanghai/China, 2Shanghai Pulmonay Hospital, 
Shanghai/China, 3Lung Cancer and Immunity Laboratory, Shanghai Pulmonary Hospital, 
Tongji University; Tongji University Medical School Pulmonary Cancer Institute, Shanghai/
China, 4Medical Oncology, Shanghai Pulmonary Hospital, Shanghai/China, 5Shanghai 
Pulmonary Hospital, Shanghai/China, 6Department of Medical Oncology, Shanghai 
Pulmonary Hospital, Tongji University School of Medicine, Shanghai/China
Background: Quantitative reverse transcriptase polymerase chain reaction assay 
(qRT-PCR) has been proved to have high sensitivity and specificity to detect anaplastic 
lymphoma kinase (ALK) rearrangements. The aim of this study was to investigate the 
response to crizotinib in patients of advanced non-small-cell lung cancer (NSCLC) with 
ALK rearrangements detected by qRT-PCR. Methods: Patients with advanced NSCLC 
who had their ALK rearrangement status detected by qRT-PCR were included in this 
analysis. The utility of qRT-PCR and fluorescence in situ hybridization assay (FISH) 
were compared in patients who were treated with crizotinib based on their positive ALK 
rearrangements. Results: 1010 patients were included in this study. Among them, 104 
patients were ALK qRT-PCR positive and 53 of them received crizotinib treatment. Among 
255 tumors simultaneously analyzed by FISH and RT-PCR, the latter successfully detected 
all the 25 tumors with arrangements, including two cases which were missed by FISH. 
The overall response rate (ORR) and median progression free survival (mPFS) of the 53 
patients with ALK rearrangements who received crizotinib treatment were 60.4% (95%CI, 
47.2-73.6) and 8.4 months (95% CI 6.75-10.05) respectively, which were similar to the 21 
patients detected by FISH with ORR of 57.1% (95% CI 33.3-76.2) (p=0.799) and mPFS of 
7.4 months (95% CI 4.43-10.38) (p=0.833) after crizotinib treatment. Interestingly, there 
were 2 patients responded to crizotinib had their ALK rearrangement detected by qRT-PCR 
but not FISH. Conclusion: qRT-PCR should be considered as an alternative assay to detect 
ALK fusion oncogene in NSCLC patients who might be benefit from crizotinib treatment. 
Keywords: ALK, RT-PCR, FISH, NSCLC
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P3.04-015 Immunohistochemistry With 3 ALK Antibodies and Thymidylate 
Synthase Evaluation of FISH-Positive ALK-Rearranged Lung Adenocarcinomas 
Paolo Bironzo1, Valentina Monica1, Paolo Graziano2, Luisella Righi1, Evaristo Maiello3, 
Marcello Tiseo4, Maria R. Migliorino5, Lucio Buffoni6, Fausto Barbieri7, Alessandra 
Lombardi8, Giulio Rossi9, Silvia Novello1 1University of Turin, Department of Oncology, 
Turin/Italy, 2Unit of Pathology, Scientific Institute for Research and Health Care “Casa Sollievo 
Della Sofferenza”, S. Giovanni Rotondo/Italy, 3Oncology Unit, Scientific Institute for Research 
and Health Care “Casa Sollievo Della Sofferenza”, S. Giovanni Rotondo/Italy, 4Medical 
Oncology Unit, University Hospital of Parma, Parma/Italy, 51St Oncological Pulmonary Unit, 
San Camillo-Forlanini High Specialization Hospitals, Rome/Italy, 6Medical Oncology, Città 
Della Salute E Della Scienza - Molinette Hospital, Turin/Italy, 7Department of Oncology, 
University Hospital Policlinico of Modena, Modena/Italy, 816Th Oncological Pulmonary Unit, 
San Camillo-Forlanini High Specialization Hospitals, Rome/Italy, 9Unit of Pathology, University 
Hospital Policlinico of Modena, Modena/Italy
Background: ALK-rearranged lung tumors represent approximately 2-7% of all Non-Small-
Cell Lung Cancers (NSCLCs). Young age, never/light smoking habit, adenocarcinoma 
(ADK) histology and good response to chemotherapy with pemetrexed characterize ALK-
positive patients (pts). Current treatment strategies in this molecular setting are based 
on ALK-kinase inhibition with small molecules including first (crizotinib/CZT) and second 
generation TKIs. The FDA-approved companion diagnostic test for CZT treatment is the 
Vysis break-apart FISH probe, but several works support the immunohistochemistry 
(IHC) as a sensitive and specific test. The European Medical Agency (EMA) recently 
approved CZT for second-line treatment of ALK-rearranged NSCLC as detected by “an 
accurate and validated ALK assay”, thus endorsing IHC for eligibility purposes. Here, we 
retrospectively assessed ALK status in 28 pts with known FISH-positive ALK-rearranged 
NSCLC performing IHC with 3 different antibodies in order to assess their diagnostic 
accuracy as compared to the FISH assay. Moreover, we evaluated thymidylate synthase 
(TS) expression using real-time polymerase chain reaction (RT-PCR) given the conflicting 
literature data on pemetrexed sensitivity in those tumors. As a secondary end point we 
will compare molecular and clinical outcomes. Methods: FISH was performed with Vysis 
break-apart FISH probe. IHC was performed with 3 different antibodies: ALK1 (DAKO), 5A4 
(Novocastra) and D5F3 (Ventana/Cell Signaling Technology). For ALK1 and 5A4 an IHC 
scoring value between 0+ and 3+ was used, as previously proposed, while a positive or 
negative score was used with D5F3 and Ventana KIT. TS gene expression was measured 
through Real Time PCR, TaqMan method. Results: 28 specimens of ALK-rearranged 
ADK diagnosed between 2010 and 2013 from 7 different Italian Oncology Centres were 
evaluated. Pts median age at diagnosis was 55 (range: 25-78), 9 pts were female. 25/28 
(89.3%) specimens were D5F3 positive. 13/28 (46.4%) had 5A4 3+ positivity, 12 (42.8%) 
showed 2+ positivity while the remaining 3 were negative. 3/28 specimens (10.7%) had 
ALK1 3+ score, 9 (32.1%) 2+, 13 (46.5%) 1+ and the remaining 3 (10.7%) were negative. 
Among the 3 FISH-positive and IHC-negative cases, 2 pts underwent CZT treatment, 
both progressing within 2 weeks and with low percentage of rearranged tumor cells at 
FISH testing (16-20%) When considering 3+ and 2+ scores as positive, 12 specimens 
(42.8%) resulted to be positive with all the 3 antibodies, while score 1+ was observed 
only with ALK1 in 13 (46.4%). Only 3 cases resulted strongly positive with all clones. TS 
gene expression median value on 25 cases was 6.27 (range 2,8-14-94). 65% of cases 
had low expression as compared to a population of ALK-negative lung ADK (personal 
data). Conclusion: IHC proved to be a reliable tool to diagnose ALK-rearranged lung 
tumors, especially with D5F3 and 5A4 antibodies. As the two IHC negative and FISH 
positive patients who received CZT didn’t respond to treatment, IHC should be used 
as screening tool or a confirmatory test in case of low-rearranged FISH-positive cases. 
TS expression appeared to be lower in ALK-positive lung tumors as compared to ALK-
negative lung ADK. Further comparisons between clinical and molecular data are ongoing. 
Keywords: FISH, Immunohistochemistry, Thymidilate Synthase, ALK
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P3.04-016 EML4-ALK Fusion in a NSCLC Patient Detected by High Sensitivity 
Circulating Tumor DNA Assay Empowers Targeted Therapy Decisions 
Nisha Mohindra1, Becky Nagy2, Bahram Kermani2, Stefanie Mortimer2, Richard B. 
Lanman2, Helmy Eltoukhy2, Amir A. Talasaz2, Jyoti Patel1 1Medical Oncology, Robert H. 
Lurie Comprehensive Cancer Center of Northwestern University, Chicago/IL/United States of 
America, 2Guardant Health, Inc, Redwood City/CA/United States of America
Background: The National Comprehensive Cancer Network (NCCN) non-small cell lung 
cancer (NSCLC) guidelines recommend genomic testing of seven genes in order to 
determine appropriate targeted therapy, including fusions in the anaplastic lymphoma 
kinase (ALK) gene which may be highly responsive to matched therapies. Tissue-based 
approaches to determine the tumor’s genetic status are often hampered by patient 
intolerance to repeat biopsy or insufficient tissue. Novel digital sequencing technology of 
plasma cell free circulating tumor DNA (ctDNA) allows assessment of these biomarkers 
without an invasive tissue biopsy. Methods: A 58 year-old woman was diagnosed with 
metastatic lung adenocarcinoma with bone predominant metastatic disease in February 
2013. Despite histologic confirmation of adenocarcinoma, tissue was insufficient 
for genotyping despite multiple attempts at biopsy. She was treated empirically with 
carboplatin/pemetrexed with initial response, suffered from symptomatic progression 
in bone and underwent cell free circulating tumor DNA testing. Assessment of ctDNA 
levels using a comprehensive 68-gene digital sequencingTM panel (Guardant360) with 
high sensitivity (detection of single nucleotid variants, focal gene amplifications in 16 
intracellular pathway analysis. We suggested that the focal adhesion pathway such as 
paxilin/crkⅡrevealed significant HSP90-dependent client proteins. Conclusion: The 
focal adhesion molecules are one of the significant signaling pathways in the ALK 
rearranged NSCLC both sensitive and resistant to ALK-TKIs, and that proteins in 
the focal adhesion pathway could be a potential target of a ALK-rearranged NSCLC. 
Keywords: HSP90 inhibitor, Resistance, mass spectrometry, ALK-rearranged NSCLC
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-013 Clinicopathological Data’s of Advanced NSCLC Patients with ROS1 
Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY 
Buge Oz1, Sebnem Batur1, Yesim Eralp2, Serap Hasturk3, Fulden Yumuk4, Ozcan Yıldız5, 
Aziz Karaoglu6 1Pathology, Istanbul Univercity Cerrahpasa Medical Faculty, Istanbul/
Turkey, 2Medical Oncology, Istanbul Univercity Oncology Institute, Istanbul/Turkey, 3Medical 
Oncology, Yedikule Chest Disease and Chest Surgery Education and Research Hospital, 
Istanbul/Turkey, 4Medical Oncology, Marmara Univercity Hospital, Istanbul/Turkey, 5Medical 
Oncology, Medipol University Hospital, Istanbul/Turkey, 6Medical Oncology, Dokuz Eylul 
Univercity, Izmir/Turkey
Background: The ROS1 oncogene encodes an orphan receptor tyrosine kinase related 
to anaplastic lymphoma kinase (ALK), leukocyte receptor tyrosine kinase, and members 
of the insulin receptor family. Chromosomal rearrangement of ROS1 occurs in a variety 
of human cancers, including non-small cell lung cancer (NSCLC). Crizotinib (XALKORI®) 
is , first-in-class, small molecule tyrosine kinase inhibitor of ALK, ROS1, and c-MET. It has 
been approved in several countries for the treatment of advanced ALK-positive NSCLC. A 
global phase I study of crizotinib includes expansion cohorts for patients with molecularly 
defined tumors, including a cohort of patients with advanced NSCLC harboring ROS1 
fusions. Methods:Between January 2014 and January 2015, a total of 542 patients 
with advanced NSCLC was enrolled. They were all negative for EGFR mutation and also 
ALK rearrangement. All of the cases of ROS1 rearrangement were identified through 
a break-apart ROS1 fluorescence in-situ hybridization (FISH) assay together with 
immunohistocemical ROS1 (D4D6 clone) positivity. Treatment All patients received at 
least one prior line of standard therapy for advanced NSCLC. After that Crizotinib was 
administered orally at the standard dose of 250 mg twice daily in continuous 28-day 
cycles. Results: ROS1 rearrangements were found in 5 cases of 542 lung cancer samples, 
the total incidence was 0,9%. All the tumors of the positive cases were adenocarcinoma. 
The ROS-1 rearrangements were more frequent in female patients (80%) than male ones. 
They were all young patients median age 39 years old. The majority of patients had never 
smoked (60%) and the others were light-smoker. The first patient has been receiving 
Crizotinib therapy for thirteen months and all patients are still alive. Two patients (40%) 
achieved a complete response, 2 patients (40%) achieved a partial response. Last 
patient was started Crizotinib therapy in the March of 2015. Conclusion: Patients 
with ROS1-positive NSCLC have similar demographic characteristics to those with ALK-
positive NSCLC. ROS1 rearrangement test is recommended for all patients whose tumors 
were negative EGFR and ALK. ROS1 rearrangement defines a second molecular subset of 
NSCLC for which crizotinib is a highly active treatment. This is the first report presenting 
clinico-pathological data of the patients harboring ROS1 rearrangement in TURKEY. 
Keywords: ros1 rearrangement, nonsmall cell lung cancer, crizotinib treatment
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P3.04-014 High concordance of ALK fusion between primary tumor and paired 
metastatic lymph node in patients with adenocarcinoma Likun Hou, Chunyan Wu 
Department of Pathology in Shanghai Pulmonary Hospital, Tongji University Shcool of 
Medicine Shanghai China, Shanghai/China
Background: Anaplastic lymphoma kinase gene (ALK) rearrangement represents a novel 
oncogenic gene in NSCLC patients which show response to crizotinib, an ALK inhibitor. 
Lung cancer is a heterogeneous tumor. It remains unclear whether ALK rearrangement 
was distributed heterogeneously in tumor from different anatomic site of the same 
patient. To address this issue, we compared the concordance of ALK gene fusion status 
between primary tumor and paired lymphatic metastasis. Meanwhile, we evaluated the 
effectiveness of crizotinib treatment of advanced NSCLC patients with ALK rearrangement 
detected on biopsy or cytology from primary tumors or metastatic lymph nodes by RT-
PCR. Methods: A total of 101 NSCLC patients with metastatic lymph nodes by surgical 
resection were enrolled from September 2013 to Auguast 2014, including 33 patients 
with N1 and N2 lymphatic metastasis. We performed immuohistochemical(IHC) staining 
for the ALK protein with Ventana D5F3 antibody on primary tumor and paired metastatic 
lymph nodes. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to 
confirm ALK fusion status. Discordance of ALK fusion gene status between primary 
tumor and paired metastatic lymph nodes was further confirmed by fluorescence in Situ 
hybridization (FISH). Progression-free survival (PFS) was evaluated in 13 ALK positive 
advanced adenocarcinoma patients with crizotinib treatment including 7 patients who 
harbored ALK rearrangement detected on primary tumor and 6 patients detected on 
metastatic lymph nodes. Results: The concordance rate of ALK rearrangement between 
primary tumor and paired metastatic lymph nodes was 98%. ALK fusion gene status 
between different groups of metastatic lymph nodes in the same patient showed totally 
concordant. PFS (11.1 months) was similar in patients with ALK rearrangement detected 
on primary tumor and patients (PFS, 10.8 months, P=0.2) detected on metastatic lymph 
nodes by RT-PCR. Conclusion: The current results indicated that ALK rearrangement 
showed a high concordance between primary tumor and lymphatic metastasis and 
successfully predict response to ALK inhibitor. RT-PCR detecting ALK rearrangement 
on biopsy or cytology with limited tissue from primary tumors and metastatic lymph 
nodes can be important for ALK inhibitor treatment in advanced NSCLC patients. 
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drivers has led to a better understanding of lung cancer and the development of very 
active targeted therapies. ALK rearrangements have been identifi ed as oncogenic drivers 
for a subgroup of lung adenocarcinoma. The clinical benefi t gained by targeted therapies 
has led to transition from a standardized therapeutic approach to a personalized 
approach based on molecular tumor characteristics in current clinical practice.
Keywords: NSCLC, IHC, EML4-ALK
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P3.04-019 A Retrospective Analysis of Frequency of ALK Gene Rearrangement 
in Saudi Lung Patients Fouad H. Al Dayel1, Hamad Al Husaini2, Shamayel Mohammed1, 
Asma Tulbah1, Khawla Al Kuraya3 1Pathology and Laboratory Medicine, King Faisal 
Specialist Hospital and Research Centre, Riyadh/Saudi Arabia, 2Oncology, King Faisal 
Specialist Hospital and Research Centre, Riyadh/Saudi Arabia, 3Research Centre, King Faisal 
Specialist Hospital and Research Centre, Riyadh/Saudi Arabia
Background: Lung carcinoma represents 2.6% of cancer seen at King Faisal Specialist 
Hospital and Research Centre (KFSH&RC) and 4.5% of cancers in Saudi Arabia as per 
Saudi Cancer Registry. EML4-ALK re-arrangements are found to play an oncogenic driver 
role in lung adenocarcinoma tumor genesis in 3-6% of cases. ALK gene rearrangement 
testing can identify patients with adenocarcinoma who are sensitive to ALK kinase 
inhibitors. However, no data are available on the prevalence of ALK rearrangements 
changes in Middle Eastern population. Therefore, we carried out this study to evaluate 
the prevalence of ALK gene rearrangements in lung adenocarcinoma of Saudi 
patients. Methods: ALK gene rearrangements were studied using fl uorescence in situ 
hybridization (FISH) on 97 adenocarcinoma samples utilizing tissue microarray format. 
ALK gene rearrangements tested using break-apart probes from Vysis (Abott Molecular, 
Il, USA). Results: One hundred ninety eight (198) lung adenocarcinoma cases were 
evaluated. Eleven (11) cases exhibited ALK gene rearrangement (5.5%). Seven (7) of these 
cases were metastatic lung adenocarcinoma (stage IV). Mean age of the patient is 51 
years (21-79 years). History of smoking was available on only four (4) cases (2 smokers 
and 2 non-smokers). All cases were moderately to poorly differentiated adenocarcinoma. 
None of our cases showed signet cells or abundant intracellular mucin. Conclusion: The 
fi ndings of this retrospective study show that the incidence of ALK gene rearrangements 
positive adenocarcinoma in Saudi patients is 5.5%. This is similar to the published data. 
Keywords: ALK rearrangement, FISH, lung tumors, Adenocarcinoma
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P3.04-020 ALK Rearrangements Epidemiology in Latin America (CLICaP) 
Oscar Arrieta Rodriguez1, Andrés F. Cardona2, Guillermo Bramuglia3, Graciela Cruz-
Rico1, Claudio Martin4, Alejandro Aviles-Salas5, Luis Corrales6, Omar Castillo7, Hernan 
Carranza2, Erica Rojas Bilbao8, Carlos A. Vargas2, Leonardo Rojas9, Hernán Lupera10, 
Horacio Astudillo11 1Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina 
Personalizada, National Cancer Institute, Mexico City/Mexico, 2Clinical and Translational 
Oncology Group, Foundation for Clinical and Applied Cancer Research - Ficmac, Bogotá/
Colombia, 3Argenomics, Buenos Aires/Argentina, 4Clinical Oncology, Instituto Fleming, 
Buenos Aires/Argentina, 5Pathology, National Cancer Institute, Mexico, Df/Mexico, 6Clinical 
Oncology, Hospital San Juan de Dios, San José/Costa Rica, 7Oncology, Hospital Santa Fe, 
Panama, Panama/Panama, 8Pathology, Instituto de Oncología Angel Roffo Y Hospital Alemán, 
Ciudad Autónoma de Buenos Aires/Argentina, 9Centro Javeriano de Oncología, Hospital 
Universitario San Ignacio, Bogotá/Colombia, 10Medical Oncology, Hospital Metropolitano, 
Quito/Ecuador, 11Laboratory of Translational Cancer Research and Cellular Therapy, 
Oncology Hospital,, Medical Center Xxi Century, Mexican Institute of Social Security (Imss), 
Mexico/Mexico
Background: Latin American countries are heterogeneous in terms of lung cancer 
incidence, ethnicity, and exposure to potential carcinogens. The discovery of the 
echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase 
(EML4-ALK) translocation as an oncogenic driver has led to the development of 
novel therapies with activity in vitro and in the clinic. In this study we evaluated the 
frequency and clinical characteristics of ALK rearrangements in six Latin-American 
genes, EGFR indels and fusions in ALK, ROS1, RET and NTRK1) in 87%+ of advanced cancer 
patients) and ultra-high specifi city (>99.9999%) was performed on a blood sample from 
the patient. Results: Analysis of the patient’s ctDNA revealed an EML4-ALK fusion at 
0.06% mutant allele fraction, which is equivalent to a single mutant molecule in a 10 
mL tube of blood. This result was repeated in a second tube of blood, and two DNA 
fragments with the EML4-ALK fusion breakpoint were found. The patient also had a 
single nucleotide variant (R386G) in the AR gene at 0.25% and JAK2 V617F variant at 
0.93% concentration. Crizotinib therapy was initiated on the basis of the EML4-ALK fusion 
and clinical improvement has already been noted. Repeat ctDNA measurements are 
planned and will be correlated with clinical response parameters based on RECIST 
criteria and protein-based tumor marker levels. This information will be reported at 
the time of presentation. Conclusion: To our knowledge, this is the fi rst case report 
of EML4-ALK fusion identifi ed in the clinical setting via biopsy-free circulating tumor 
DNA analysis. With single molecule sensitivity, this simple blood test was able to 
identify a therapeutic option in a patient who was unable to undergo tissue-based NGS. 
Keywords: EML4-ALK, personalized medicine, cell free DNA, Circulating Tumor DNA
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P3.04-017 Acinar Subtype of Lung Adenocarcinoma Is Signifi cantly Related 
to EML4-ALK Translocation in Eastern European Patients Bojan Zaric, Branislav 
Perin, Vladimir Stojsic, Milana Panjkovic, Dragana Tegeltija, Vanesa Stepanov, Tomi 
Kovacevic Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, 
Faculty of Medicine, University of Novi Sad, Sremska Kamenica/Serbia
Background: The incidence of echinoderm microtubule-associated protein-like4-
anaplastic lymphoma kinase (EML4-ALK) translocation among surgically treated patients 
with adenocarcinoma of the lung of the Eastern European ethnicity is underreported. The 
aim of this trial was the determination of EML4-ALK translocation frequency in investigated 
population, and the evaluation of correlations between lung adenocarcinoma subtype 
and clinical characteristics with mutation status. Methods: This was a prospective 
trial which included 195 patients with adenocarcinoma of the lung who underwent 
surgical treatment. ALK mutation screening was performed by immunohistochemistry 
(IHC). IHC scores of 2+ and 3+ were regarded as positive. Confi rmatory FISH was 
performed in all IHC positive and in 2:1 ratio in negative patients. Results: Overall 
ALK mutation rate established by IHC was 6.2%, while FISH confi rmed rate of 5.1%. 
The FISH confi rmed ALK positivity in 7.6% Hungarians, 5.5% Serbians, and 6.6% 
Slovakians. Acinar subtype of adenocarcinoma of the lung was signifi cantly (p=0.02) 
related to EML4-ALK positive mutation status. Most of the patients were males 
(56.9%), smokers (50.8%), or former smokers (28.7%) with acinar (55.4%) or solid 
(35.9%) adenocarcinoma of the lung. Sensitivity and specifi city of IHC were 100% and 
98.9% respectively. Conclusion: ALK mutation rate in surgically treated patients with 
adenocarcinoma of the lung was found to be 6.2% by IHC and 5.1% by FISH. Acinar subtype 
of the adenocarcinoma of the lung was signifi cantly related to ALK positive mutation. 
Keywords: adenocarcinoma of the lung; anaplastic lymphoma kinase (ALK); EML4-ALK 
translocation; non-small cell
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P3.04-018 Expression of Protein Kinase EML4-ALK Gene in Non-Small Cell 
Lung Cancer (NSCLC) in a University Hospital of Reference in Latin America 
Luz F. Sua1, Liliana Fernandez2, Carlos A. Muñoz3, Juan G. Restrepo4 1Department of 
Pathology and Laboratory Medicine and Phd Biomedical Sciences, Fundacion Valle Del Lili, 
Universidad ICESI, Cali/Colombia, 2Interventional Pulmonology, Fundacion Valle Del Lili, 
Universidad ICESI, Cali/Colombia, 3Medical Research, Fundacion Valle Del Lili, Universidad 
ICESI, Cali/Colombia, 4Hemato-Oncology Clinic, Fundacion Valle Del Lili, Universidad ICESI, 
Cali/Colombia
Background: Lung cancer, the leading cause of cancer deaths worldwide, exists in two 
distinct entities: small and non-small cell lung cancer, representing 85% of lung cancers, 
and generally presents at diagnosis with locally advanced or metastatic disease. The rare 
genetic changes, anaplastic lymphoma kinase (ALK) gene rearrangements, most often 
consisting in a chromosome 2 inversion leading to a fusion with the echinoderm 
microtubule-associated protein like 4 (EML4) gene, results in the abnormal expression 
and activation of this tyrosine kinase in the cytoplasm of cancer cells. This rearrangement 
occurs in 2–5% of NSCLC, predominantly in young patients (50 years or younger), in non-
smokers or former smokers with adenocarcinoma. This aberration most commonly 
occurs independent of EGFR and KRAS gene mutations. Inmunohistochemical analysis is 
a cost-effective alternative for the detection of ALK gene rearrangements and recent 
guidelines from the College of American Pathologists, International Association of the 
Study of Lung Cancer, and The Association for Molecular Pathology supports the use of 
IHC screening as long as it has been appropriately validated. Methods:Between 
November 2014 and March 2015, 20 tumor samples were obtained in the Fundacion Valle 
del Lili, Cali-Colombia. The Ventana anti-ALK (D5F3) assay was performed using OptiView 
DAB IHC detection kit and OptiView Amplifi cation Kit, with external controls rated with 
positive and negative cell lines (H2228 and CALU-3 respectively), with appropriate 
expression. Results: We analyzed samples from 20 patients with NSCLC using 
immunohistochemistry. We found tumor cells in 100% of the samples. The average age 
was 62.8 years ± SD, 45% (9) women and 55% (11) men. The protein kinase expression 
of EML4-ALK gene was found in 20% of the cases (4),which included 3 females. Thirteen 
cases were adenocarcinoma and fourteen patients were diagnosed in stage IV. Fourteen 
of twenty patients received chemotherapy. At this time in our hospital began the Phase 
Three study of the molecule specifi c for this tumor rearrangement. The mortality in this 
group of patients was 3 of 20. Conclusion: Knowledge of cancer biology and oncogenic 
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for TCGA are representative of the overall selected lung cancer samples. Methods: We 
analyzed the JHU cohort using TCGA’s shipment qualification reports in addition to our 
biospecimen data pre-selected for TCGA. Specimens with at least 60% tumor qualified 
for TCGA and those that disqualified were because of lack of RNA. Specimens that 
were not eligible for shipment had less than 60% tumor. Results: There is a trend in 
older specimens being disqualified throughout the TCGA shipments. In contrast, those 
specimens that were cut but deemed ineligible to be sent to TCGA tended to be older, 
male, adenocarcinoma (p=0.003), and earlier stage (p=0.010) than those that were 
actually shipped. The majority of the specimens that were shipped were sent during 
shipment 1 (p<0.001) and the proportion of specimens sent were older (long surgery to 
cut duration) than younger comparing specimens with durations of 0 years, 1-10 years, 
and 11-21 years (p<0.001).
 
 
Conclusion: Our data suggests that older specimens were the most likely to be disqualified 
when shipped to the TCGA as well as those that were not sent but were cut for shipment. Future 
research should focus on developing more advanced technology that will allow the inclusion 
of a wide range of specimens that do not exclude a large part of the lung cancer population. 
Keywords: biospecimen, lung cancer, TCGA
countries. Methods: A total of 2799 biopsies of advanced NSCLC patients from 6 
countries of Latin America (Argentina, Colombia, Costa Rica, Panama, Ecuador, and 
Mexico) were evaluated by the method fluorescence in situ hybridization (FISH) for 
detection of ALK-rearrangements. Demographic and clinicopathologic characteristics 
were analyzed. Results: The FISH analyses showed positive ALK fusion gene 
status in 6.55% (181/2761) of the total sample from all participating countries. 
ALK+ for each country was a follows: Argentina 6.08% (105/1726), Colombia 
4.83% (10/207), Costa Rica 4.83% (2/49), Mexico 8.57% (64/746), and Panama 
0% (0/33). Ecuador only used immunohistochemistry for ALK detection rearrangement; 
therefore, these samples were excluded from FISH technique analysis. Conclusion: The 
frequency of ALK rearrangement in Latin America is higher than previously reported for 
the Caucasian and Japanese populations. In addition, there is significant continental 
variability. Until now, FISH for ALK testing is not widely available in Latin America due 
to its high cost, time-consumption and result interpretation. There is an increased 
need to develop a common platform for genomic evaluation in developing countries. 
Keywords: Non-small-cell lung cancer, Rearrangements ALK, FISH, Latin America
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P3.04-021 Mutation Profiling by Targeted Next-Generation Sequencing for 
Diagnostics and Patient Cohort Screening in FFPE NSCLC Samples Linnea La 
Fleur1, Lotte Moens1, Elin Falk-Sörqvist1, Magnus Sundström1, Johanna S.M. Mattsson1, 
Hirsh Koyi2, Eva Branden2, Hans Brunnström3, Simon Ekman1, Martin Sandelin4, Johan 
Isaksson2, Karin Jirström3, Patrick Micke1, Mats Nilsson5, Johan Botling1 1Department of 
Immunology, Genetics and Pathology, Uppsala University, Uppsala/Sweden, 2Department 
of Respiratory Medicine, Gävle Hospital, Gävle/Sweden, 3Department of Clinical Sciences 
Lund, Division of Oncology and Pathology, Lund University, Lund/Sweden, 4Department of 
Medical Sciences, Uppsala University, Uppsala/Sweden, 5Department of Biochemistry and 
Biophysics, Stockholm University, Stockholm/Sweden
Background: Recent discovery of the landscape of somatic mutations in non-small cell 
lung cancer (NSCLC), and introduction of new therapeutics have raised the demands 
for multiplex mutation assays. In exploratory research, mutation profiling has largely 
been performed on fresh-frozen tissue from surgical specimens. However, for patients 
with advanced disease the assays need to be adapted to small formalin-fixed paraffin 
embedded (FFPE) biopsies and cytology preparations. Targeted next-generation 
sequencing (NGS) techniques are now being developed to address these challenges and 
have now reached the point where they are more cost efficient than previously used 
methods, hence there is a need to optimize and validate these techniques to determine 
if they are robust enough to work in clinical diagnostics. Methods: Here we have 
developed and evaluated Haloplex gene panels in comparison to pyrosequencing and 
quantitative PCR(qPCR), i.e. the current standard methods for molecular diagnostics of 
solid tumours in Sweden. The target enrichment was focused on short DNA fragments 
and included independent capture of complementary strands, “two strand capture”, to 
address fragmentation and base damage induced by formalin fixation. The panels include 
all exons of 18-32 genes (for lung cancer and other solid tumors respectively) with 
known clinical relevance. Seventy-one clinical samples (NSCLC, colorectal carcinoma 
and melanoma), with known mutational status of hotspots in KRAS, BRAF, NRAS, PIK3CA 
and EGFR, were selected for analysis. DNA was prepared from FFPE tissues and used for 
library preparation using the panels and subsequently sequenced on an Illumina MiSeq 
instrument. Results: A complete concordance was seen between the previously defined 
pyrosequencing and qPCR genotypes and the corresponding variants detected using 
the gene panels. Both point mutations and smaller indels (<25bp) could be detected 
by this technique using an in-house bioinformatic pipeline. False positive FFPE-induced 
mutation artefacts could reliably be identified by the two-strand filter. The technical 
sensitivity of mutation detection was determined to 2%, and we have decided to use 
a 5% variant allele frequency threshold for clinical reporting. In addition, clonality and 
subclonality could be discovered in patients with complex tumour disease (mixed or 
multiple tumour lesions) by analysis of the mutation patterns. An extended 85 gene 
panel has also been designed to screen for mutations in NSCLC patient cohorts for 
clinical molecular research. Conclusion: We believe that the established lung cancer 
gene panels for targeted enrichment and NGS can replace pyrosequencing and qPCR for 
molecular diagnostics in NSCLC, and will be useful for screening of unselected population-
based prospective and retrospective lung cancer patient cohorts in clinical research. 
Keywords: target enrichment, formalin-fixed paraffin embedded, next-generation 
sequencing, non-small cell lung cancer
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P3.04-022 The Johns Hopkins University TCGA Experience Candace Griffin1, 
Beverly Lee2, Kristen Rodgers1, Andrew Yang1, Vincent Battafarano1, Craig Hooker1, 
Alicia Hulbert2, Peter B. Illei3, Dante Trusty3, James Shin3, Richard Battafarano1, Daniela 
Molena1, Stephen Yang1, Malcolm Brock1 1Department of Thoracic Surgery, Johns Hopkins 
University School of Medicine, Baltimore/MD/United States of America, 2Department 
of Oncology, Johns Hopkins Medical Institution, Baltimore/MD/United States of 
America, 3Department of Pathology, Johns Hopkins University, Baltimore/United States of 
America
Background: The Cancer Genome Atlas (TCGA) is a genomic mapping effort that 
characterizes and analyzes the major types of cancer. Specimens have to meet strict 
tissue criteria to become eligible for shipment to TCGA and used for genomic analysis. 
Johns Hopkins University (JHU) is a part of the TCGA network and we have sent numerous 
biospecimens for analysis. Our experience is catalogued over 3 different shipments and 
may be unique only to JHU. This paper will analyze if the JHU samples that have qualified 
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DNA sample pairs were used as template for PGM AmpliSeq and MiSeq TSCA library 
preparation, followed by NGS. A subset of DNA sample pairs were also analyzed for 
copy number using the nanoString nCounter system. Results: DNA yields and fragment 
lengths were substantially higher for truXtract samples as compared to DNeasy when 
measured by picogreen quantitation and Bioanalyzer electrophoresis (Figure 1). A higher 
degree of successful advanced molecular diagnostic test results was also observed for 
the truXtract DNA samples, especially for the Illumina NGS system (improved clustering 
and coverage) and nCounter platform (improved counts) that prefer longer fragment 
lengths than Ion Torrent NGS.
Figure 1: 2100 Bioanalyzer traces of DNA prepared from three lung cancer FFPE 
samples; DNeasy (left) and TruXtract (right). Conclusion: FFPE tumor samples 
prepared using the truXtract FFPE DNA isolation kit provides an efficient system for 
generating high quality DNA samples from even the most difficult lung cancer specimens. 
The combination of improved yield and fragment size measured for nearly every sample 
tested suggests that even smaller biopsies can now be collected for advanced diagnostic 
testing.  
Keywords: DNA extraction, molecular diagnostics, FFPE tissue, NGS
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P3.04-026 Reflex Testing of EGFR and ALK in Non-Squamous Non-Small Cell 
Lung Cancer Jonan Z.-E. Tan1, Whee-Sze Ong2, Daniel S.-W. Tan3, Angela Takano4, Tony 
Kiat-Hon Lim4, Kian-Sing Chan4, Lynette Lin-Ean Oon4, Alvin Soon-Tiong Lim4, Amit Jain5, 
Chee-Keong Toh5, Mei-Kim Ang5, Quan-Sing Ng5, Ravindran Kanesvaran5, Anantham 
Devanand6, Chong-Hee Lim7, Tina Puay-Theng Koh8, Wan-Teck Lim5, Eng Huat Tan5 
1Bristol University, Bristol/United Kingdom, 2Division of Clinical Trials and Epidemiological 
Sciences, National Cancer Centre, Singapore, Singapore/Singapore, 3National Cancer 
Centre, Singapore, Singapore/Singapore, 4Pathology, Singapore General Hospital, 
Singapore/Singapore, 5Medical Oncology, National Cancer Centre, Singapore, Singapore/
Singapore, 6Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore/
Singapore, 7Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore/
Singapore, 8Surgical Oncology, National Cancer Centre, Singapore, Singapore/Singapore
Background: Reflex molecular testing has affirmed the paradigm shift in the 
classification of tumors by genetic profile, in addition to conventional histopathology. 
It plays a critical role in identifying actionable targets and prompt allocation of patients 
to the appropriate treatment. We sought to compare the clinical characteristics and 
treatment outcomes between patients with genetic alterations against wild-type (WT) 
tumors for both EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) to 
examine the impact of reflex testing which was recently implemented in the National 
Cancer Centre Singapore. Methods: We analyzed all NSCLC patients diagnosed between 
Jan 2010 and Mar 2014 from a prospective database maintained by the Lung Cancer 
Consortium Singapore. Patients underwent reflex Sanger-based EGFR analysis from 2010 
and ALK-FISH analysis from 2012. These analyses were undertaken upon histological 
diagnosis, regardless of the AJCC stage at presentation. Clinical characteristics of 
the mutant and WT groups were compared using chi-squared and Mann Whitney U 
tests. Overall survival(OS) was estimated using Kaplan-Meier method. Survivals were 
compared using log-rank test, and prognostic factors were determined using multivariate 
cox regression. Results: The overall EGFR mutation rate in our cohort (n=1308) was 
51.4%. The corresponding rates in adenocarcinoma and non-adenocarcinoma groups 
were 52.5% and 34.9% respectively. EGFR mutants were more prevalent among females, 
never-smokers, and less symptomatic. A higher proportion had better ECOG status, well 
to moderately differentiated histology, more sites of distant metastases especially in 
the lungs and bones, presented with Stage IV, , and received more lines of palliative 
treatment (all p<0.05). The median OS(months) for the mutant group was 24.8 versus 
13.3 for the WT group (p<0.001). Prognostic factors included ethnicity, smoking status, 
stage, histology, number of symptoms, ECOG status, number of metastatic sites, 
treatment intention and EGFR tyrosine kinase inhibitor (TKI) treatment (all p<0.02). The 
overall ALK alteration rate (n=405) was 12.6%, 12.4% in adenocarcinoma and 15.2% in 
non-adenocarcinoma. Contrary to prior reports, there were no differences in gender, 
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P3.04-023 Exosomes and Their Potential for Detection of Lung Cancer Birgitte 
Sandfeld Paulsen1, Kristine R. Jakobsen1, Rikke Bæk2, Peter Meldgaard3, Kim Varming2, 
Malene Jørgensen2, Boe S. Sorensen1 1Dept. of Clinical Biochemistry, Aarhus University 
Hospital, Aarhus C/Denmark, 2Dept of Immunology, Aalborg University Hospital, Aalborg/
Denmark, 3Dept. of Oncology, Aarhus University Hospital, Aarhus C/Denmark
Background: A recent study showed that advanced lung adenocarcinoma patients 
have a distinct exosomal protein-profile compared to a matched group without cancer 
(Jakobsen et al., 2015, JEV). To improve the overall survival, it is however crucial to 
develop tools capable of detecting early stages of lung cancer as well. In addition, it is 
unsettled if different histologic subclasses result in distinct exosomal protein profiles. The 
aim of this study is to explore the potential of using exosomal proteins as biomarkers in 
lung cancer patients of all stages and of different histology histology. Methods: Plasma 
was isolated from patients suspected of having lung cancer. Patients diagnosed to be 
cancer free were defined as controls. Based on previous experiments a panel of 47 
antibodies were selected for exosome-capture using a highly sensitive extracellular 
vesicle protein array (EV Array). 10 µl unpurified plasma was applied to the EV Array and 
captured exosomes were visualised by binding of biotin-conjugated CD9, CD63 and CD81 
antibodies. The information from all 47 markers was investigated by multivariate analysis 
by partial least squares discriminant analysis (PLS-DA). Results: The study included 
504 patients; 153 control patients and 351 patients with NSCLC (adenocarcinoma 70%, 
squamous cell 24%, other 6%). 51% had locally advanced or advanced disease and 49% 
had local disease. Multivariate analysis produced a combined marker model separating 
cancer patients from controls regardless of stage and histology. Area under the curve 
(AUC) was for each stage: I: 0.74 (0.68-0.82), II: 0.68 (0.57-0.79), III: 0.77 (0.62-0.91) and 
IV 0.79 (0.73-0.83). For all stages AUC was 0.755, CI (0.72-0.81) with sensitivity 0.70 and 
specificity 0.66. The accuracy of the test was 0.69. Conclusion: We demonstrate that the 
EV array is able to lung cancer in advanced as well as low stages regardless of histology. 
Keywords: exosomes, EV Array, NSCLC
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P3.04-024 Lung Adenocarcinoma with Neuroendocrine Feature Revealed by 
Transcriptome Profiling Takeshi Fujiwara, Yuichi Ishikawa Japanese Foundation for 
Cancer Research, Tokyo/Japan
Background: Although our previous transcriptomic analyses revealed that a 
subgroup in lung adenocarcinoma with a neuroendocrine feature exhibits poor 
prognosis, the link of the phenotype with patient outcomes has been limited only to 
two populations derived from a Japanese and a US institution. Here we performed 
additional transcriptomic profiling analyses to elucidate whether our method was useful 
also to other populations. Methods: Seven independent web-based datasets of lung 
adenocarcinoma, either on expression microarrays or on an RNA-seq platform, were 
examined. The expression level of the ASCL1 geneset (100 probes closely correlated 
with ASCL1 expression) was used to define the neuroendocrine character based on the 
method we previously reported. Subtyping was performed by consensus clustering with 
non-negative matrix factorization. Correlation of overall survival was analyzed with the 
Kaplan-Meier method. Results: The neuroendocrine subtype was identified from each of 
seven independent cohorts with 45, 90, 117, 183,196, 443 and 548 lung adenocarcinoma 
samples. Among them, three datasets showed statistically significant association with 
patient survival (p<0.05). The neuroendocrine subtype was inversely correlated with 
expression of ubiquitination genes. Somatic mutations identified in the neuroendocrine 
subtype with the TCGA data were common ones such as TP53, STK11 and KRAS. 
Conclusion: Transcriptomic profiling partially reproduced the neuroendocrine 
subtype in lung adenocarcinoma samples derived from the independent datasets. 
Keywords: transcriptome
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P3.04-025 DNA Extraction of Lung Cancer Samples for Advanced Diagnostic 
Testing Jeffrey Conroy1, Hanchun T. Defedericis1, Angela Stout2, Kiersten Marie 
Miles2, Blake C. Burgher1, Antonios Papanicolau-Sengos1, Carl D. Morrison1 1Center 
for Personalized Medicine, Roswell Park Cancer Institute, Buffalo/NY/United States of 
America, 2Molecular Pathology, Roswell Park Cancer Institute, Buffalo/NY/United States of 
America
Background: Tumor specimens are routinely formalin fixed and paraffin embedded 
(FFPE) prior to histologic evaluation. This process preserves the morphology and cellular 
features required for proper staining and microscopic review. However, this practice 
presents numerous challenges for the extraction of high quality DNA for advanced 
diagnostic testing that include nanoString and Next-Generation Sequencing (NGS) 
technologies. An extraction process that consistently produces sufficient DNA yield and 
fragment size from these difficult but most precious tissue samples is a requirement for 
any Molecular Pathology laboratory utilizing these platforms. The data presented here 
will compare the quantity and quality of DNA extracted using two methods, QIAGEN and 
Covaris, and success of downstream testing. Methods: FFPE tumor samples from a 
variety of tumor types, including lung, were macro-dissected using 14-guage needles, 
with 1 core extracted using the Covaris truXtract FFPE DNA isolation method and the 
other matched core using the QIAGEN DNeasy tissue kit. All samples were processed 
using manufacturer’s recommended instructions. DNA metrics were measured 
using Qubit (picogreen) and NanoDrop for yield and purity, followed by fragment 
size estimation on a 2100 BioAnalyzer (Agilent Technologies). A subset of matched 
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P3.04-028 Defining the Molecular Profile of Non-Small Cell Lung Carcinoma 
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Diana E. Aguilar-Leon2, Guadalupe Canchola-Aguilar2, Laura García-Alanís2, María De 
Los Angeles Ibarra-Meneses2, Gabriel Herrera-Maya2, Raquel Gerson-Cwilich3, Alberto 
Villalobos Prieto3, Carlos Ortiz Hidalgo2 1Molecular Pathology Laboratory, The American 
British Cowdray Medical Center, Mexico City/Mexico, 2Molecular Pathology Laboratory, 
The American British Cowdray Medical Center, Mexico/Mexico, 3Cancer Center Oncology 
Department, The American British Cowdray Medical Center, Mexico/Mexico
Background: Molecular characterization of lung cancer is of paramount importance. 
Although genetic drivers such as EGFR,KRAS and ALK mutation are routine, they represent 
30-40% of all mutations identified. The relative frequency vary according to the population 
studied and scarce data exist on Mexican population. The aim of the study is to describe 
the clinicopathologic characteristics and molecular profile of the population of NSCLC 
patients studied in a recent molecular pathology laboratory. Methods: Cases diagnosed 
with NSCLC from January 2012 to March 2015 seen at the department of surgical and 
molecular pathology of TheAmerican-BritishCowdrayMedical Center in Mexico City were 
retrieved. Medical records were reviewed for data on clinicopathologic characteristics 
(age, sex, biopsy site, histological parameters, and mutational status of EGFR, KRAS 
and ALK. DNA extraction was done using QIAampDNAFFPE Tissue Kit(Qiagen). EGFR 
and KRAS determination was performed using scorpion-ARMS technique(Therascreen/
Qiagen) in Rotor-GeneQThermalcycler(Qiagen). ALK rearrangement was determined 
using ALK-LSI probes(Abbott Molecular), and evaluated with OlympusBX53 fluorescence 
microscope. All the procedures were carried out according to manufacturer 
instructions. Results: 90 cases were retrieved, 77(85.6%) adenocarcinoma, 6(6.7%) 
squamous cell carcinoma, 3(3.3%)large cell carcinoma and 4(4.4%) mixed cells types 
(2 adenosquamous carcinoma, 1 adenocarcinoma with neuroendocrine component, and 
1 sarcomatoid carcinoma). Histologic subclassification showed predominant acinar in 
56%, solid 20%, lepidic 15%, and 9% micropapillary pattern. Lung biopsies were the 
tissue specimen in 58 cases(64.4), metastatic site in 28(31.1)(lymph node 9, bone 8, 
pleura 3, skin 2, soft tissue 2, mediastinal tumor 1, ovary 1, parotid 1 and CNS 1), and 
non-specified 4(4.5%). Demographic variables and mutational status of EGFR/KRAS/ALK 
are shown in table 1
.
 
Conclusion: We corroborate in our population the higher frequency of 
diagnosis age, and smoking status between fusion and WT groups. The percentage of ALK 
fusion among Malays was higher (26.3% vs 7.9%; p=0.031). While ALK fusion had more 
lines of palliative treatment than WT, there was no significant difference in OS between 
both groups. Prognostic factors include gender, ethnicity, ECOG status, treatment intent, 
and number of palliative treatment and metastatic sites (all p<0.02). Conclusion: This 
study demonstrated significant differences in clinical features, management and 
subsequent response to treatment between genetically altered and WT patients for 
both EGFR and ALK profiles, reiterating the importance of reflex testing in patient 
management. While significant survival benefit was demonstrated with EGFR TKI therapy 
in EGFR cohort, this was not demonstrated for the ALK cohort, which can be attributed 
to the relative lack of access to ALK TKI (93% treated with EGFR TKI compared to 46.6% 
treated with ALK TKI). Finally, the considerable rate of EGFR and ALK mutations in non-
adenocarcinoma groups reflects the need to extend reflex testing to these patient 
groups, and not just in patients with adenocarcinoma or adenocarcinoma components. 
Keywords: Reflex testing, EGFR mutations, ALK fusion
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P3.04-027 Targeted next Generation Sequencing in Lung Cancer: Genomic 
Oncology in Daily Practice Deepa Rangachari1, Paul Vanderlaan2, Xiuning Le3, Erik 
Folch4, Michael S. Kent5, Sidhartha P. Gangadharan6, Adnan Majid4, Richard L. Haspel2, 
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Beth Israel Deaconess Medical Center, Boston/United States of America, 4Department of 
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Background: Tumor genotyping using single gene assays (SGAs) is a standard approach 
in the management of advanced NSCLC. We evaluated how therapeutic decision-making 
was altered by the introduction of next generation sequencing (NGS) into routine clinical 
practice. Methods: Clinicopathologic data, tumor genotype, and clinical decisions were 
retrospectively compiled over 6 months following introduction of NGS assay use at our 
institution. Results: 82 tumors were genotyped: 75 by SGAs, 7 by NGS alone, and 22 
by SGAs and NGS. SGAs identified 10 EGFR-mutated, 3 ALK-rearranged, and 21 KRAS-
mutated tumors. Sequential testing with SGAs followed by NGS was more common for 
patients with EGFR/ALK/KRAS-negative tumors (22/29 or 75.9%) and adenocarcinomas 
(ACs) (21/22 or 95.5%). Most EGFR/ALK/KRAS-negative tumors were sent for NGS 
(21/35 or 60%). Of 17 ACs, 10 harbored abnormalities in a known driver oncogene (1-
EGFR, 2-ERBB2, 1-ROS1, 1-RET, 2-MET, 2-KRAS and 1-MAP2K1). Primary NGS was used 
mainly in squamous cell cancers (SCCAs) (6/7 or 85.7%). In 7 SCCAs, 1 sample had a 
driver aberration (FGFR1); 6 had other genomic events (all with TP53 mutations). NGS 
was successful in 24/29 (82.7%) tumors overall. There was a trend toward increased 
assay failure in those samples undergoing sequential SGAs followed by NGS as compared 
to primary NGS alone. All patients with EGFR-mutated or ALK-rearranged tumors received 
approved tyrosine kinase inhibitors (TKIs) or were consented for clinical trials. Clinical 
decisions were impacted by NGS results in 8/17 (47.0%) ACs (trial consideration in 6, off-
label TKI use in 2). Therapeutic decisions were influenced by NGS results in 0/7 SCCAs 
(p=0.0538 when compared to ACs). Actionable therapeutic targets were significantly 
more frequent in patients with a ≤15 pack-year tobacco history vs. those with >15 
pack-years of tobacco use (17/27 or 62.9% vs. 3/42 or 7.1%, respectively; p<0.0001). 
Only 1/9 (11%) of oncologists demonstrated a detailed understanding of the genomic 
technologies being used.
Conclusion: Targeted NGS can identify a significant number of driver events in lung 
ACs—particularly in never/light smokers—for which targeted therapies are available or 
in development. However, for SCCAs, NGS results are less likely to alter standard 
practice, barring participation in biomarker-driven studies. Future research into the cost 
effectiveness and optimal use of NGS in NSCLC is warranted, as well as continued efforts 
to improve provider awareness and application of genomic technologies. 
Keywords: lung cancer, EGFR, ALK, next generation sequencing
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when taken from large central tumors. Of 14 image guided biopsies that were returned 
because of inadequate tumor tissue, only two had complications: one with bleeding and 
the other with pneumothorax. Both tumors were peripheral. Of three bronchoscopical 
biopsies that were returned due to inadequate tumor tissue, one was complicated by 
major bleeding, in another the patient was very restless during the procedure. The last 
was uncomplicated. Conclusion: Our results show that the quality of image guided 
biopsies taken by more experienced physicians is better than those taken by doctors 
with less experience. For small peripheral tumors, the frequency of non-analyzable 
samples were higher than for large central tumors taken by image guided biopsy. 
Keywords: EGFR mutation, Pathology, lung cancer
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P3.04-031 Combining CT Texture Analysis with Semantic Imaging Descriptions 
for the Radiogenomic Detection of EGFR and KRAS Mutations in NSCLC 
James Sorensen1, Jeremy Erasmus Jr1, Girish Shroff1, Arvind Rao1, Francesco Stingo1, 
Laurence Court1, Kathryn A. Gold2, Jack Lee3, John V. Heymach4, Stephen Swisher5, 
Myrna Godoy1 1Thoracic Radiology, University of Texas MD Anderson Cancer Center, 
Houston/United States of America, 2Thoracic/Head & Neck Medical Oncology, University 
of Texas MD Anderson Cancer Center, Houston/TX/United States of America,3Biostatistics, 
MD Anderson, Houston/TX/United States of America, 4Thoracic/Head and Neck 
Medical Oncology, MD Anderson, Houston/TX/United States of America, 5Thoracic and 
Cardiovascular Surgery, MD Anderson, Houston/AL/United States of America
Background: Existing literature suggests quantitative texture features derived from CT 
imaging can differentiate tumor genotypes and phenotypes. We combined CT texture 
analysis with semantic imaging descriptions provided by radiologists, and evaluated their 
ability to identify EGFR and KRAS mutation status in NSCLC. Methods: We retrospectively 
reviewed CT images from 628 patients from the GEMINI (Genomic Marker-Guided Therapy 
Initiative) cohort. Included were NSCLC patients whose biopsies included genetic testing 
for EGFR or KRAS mutations, and who underwent contrast-enhanced CT imaging within 
90 days of biopsy. Excluded were patients who had undergone therapy or biopsy of their 
primary tumor before imaging, or whose tumors weren’t segmentable. All CT images 
were contrast-enhanced, with body kernel reconstruction, and slice thicknesses of 
1.25-5mm. Tumor segmentation was done in 3DSlicer (Harvard University, Cambridge 
MA) using a semi-automatic segmentation algorithm. Image pre-processing and 
textural feature extraction was performed using IBEX (MDACC, Houston TX). Semantic 
descriptions of the tumors were recorded by a thoracic radiology fellow and a board-
certified thoracic radiologist in consensus. For each patient a set of textural features 
was calculated, based on the GreyLevel Co-Occurrence Matrix, Run-Length Matrix, 
voxel intensity histogram, and geometric properties of the tumor. Feature selection was 
based on existing literature, prior research experience, and excluded those features 
previously found to be poorly reproducible in lung tissue. These were combined with 
semantic descriptions (e.g. presence or absence of features such as spiculations, air 
bronchograms, and pleural effusions), for a total of 51 textural and geometric features, 
and 11 semantic features. When available, the SUVmax for the tumor was also included. 
To detect correlations with genetic mutations, these features were combined to train 
a Random Forest machine learning algorithm. This algorithm output a prediction for 
the mutation status of each tumor, and the predictive accuracy was assessed based 
on 10-fold cross-validation. Results:Included were 121 patients, 113 tested for KRAS 
mutations (26 positive) and 118 tested for EGFR mutations (31 positive). Maximum tumor 
dimensions ranged from 1.2–15.5cm (mean 5.6cm). Individual semantic features found 
to correlate with mutation status included tumor cavitation, pleural effusion, presence 
of ground glass opacity, and the nature of tumor margins (all p-values <0.05). Used 
collectively in a Random Forest classifier, textural features alone showed a sensitivity and 
specificity for KRAS detection of 50% and 81% respectively, with 74% overall accuracy. 
This increased modestly to a sensitivity and specificity of 50% and 84% respectively 
when semantic features were added, with accuracy increasing to 77%. For EGFR 
detection, textural features had sensitivity and specificity of 48% and 77% respectively, 
giving 69% accuracy. Detection of EGFR did not improve with inclusion of semantic 
features. Conclusion: Texture analysis correctly identified EGFR and KRAS mutation 
status in most patients. Although some semantic features correlated with mutation status, 
when combined with textural features they provided little or no improvement in predictive 
accuracy. One possible explanation is that textural features may already be capturing the 
information contained in the semantic features. Our results suggest oncogenic drivers of 
NSCLC are associated with distinct imaging features that can be detected radiographically. 
Keywords: CT, radiogenomics, texture, NSCLC
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
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Terashima2, Hiroyasu Kaneda1, Hidetoshi Hayashi1, Kaoru Tanaka1, Tsutomu Iwasa1, 
Takeshi Yoshida1, Takayuki Takahama1, Kazuto Nishio2, Kazuhiko Nakagawa1 
1Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama/Japan, 2Department 
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Background: The identification of driver mutations, such as epidermal growth factor 
receptor (EGFR) and anaplastic lymphoma kinase (ALK), have already been successfully 
translated into clinical practice. The clinical implementation of genomic profiling 
for NSCLC with high-throughput and multiplex genotyping tests is thus warranted 
in order to prioritize appropriate therapies for individual patients. Methods: The 
present study has recruited lung cancer patients at Kinki University Hospital from June 
2013. To screen patients with lung cancer for genetic alterations relevant to novel 
EGFR mutation in female patients, with a percentage between Caucasian 
and Asian populations. KRAS is the most frequent mutation and mutually 
exclusive with EGFR and ALK. Triple negative cases represent half of NSCLC. 
Keywords: non-small cell lung cancer, EGFR/KRAS/ALK, demography, Mexican 
population
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Yang2, Yoo Jin Jung4, Sae Bom Lee4, Yun Ho Kim4, In Kyu Park1, Chang Hyun Kang1, 
Yeul Hong Kim3, Jeong-Sun Seong5, Young Tae Kim1 1Thoracic and Cardiovascular 
Surgery, Seoul National University Hospital, Seoul/Korea, 2Macrogen, Seoul/Korea, 3Cancer 
Research Institute, Korea University, Seoul/Korea, 4Cancer Research Institute, Seoul National 
University, Seoul/Korea,5Genomic Medicine Institute (Gmi), Seoul National University, Seoul/
Korea
Background: Recent development of next generation sequencing technologies enabled 
the accumulation of a lot of information about genomic variants in cancer. However, the 
price of whole genome / exome sequencing is still high to be used as a diagnostic testing 
for treatment decision-making. Methods: To develop a clinically useful diagnostic kit, we 
designed a lung cancer diagnostics (LCDx) panel to discover all coding mutations on 42 
genes, MET exon14 skipping and fusion genes involving 4 genes (ALK, RET, ROS1 and AXL). 
The performance of the panel was tested by using 100 lung cancer tissues and compared 
the results to those of three different diagnostic platforms, including Sanger sequencing, 
Ion AmpliSeq Cancer Hotspot Panel (Thermo-Life Technologies) and fluorescence in situ 
hybridization (FISH). Results: For the detection of EGFR and KRAS mutations, LCDx panel 
showed 100% sensitivity and specificity. For fusion discovery, the specificity reached 
93% but the sensitivity was only 35%, which suggested a novel design of fusion detection 
method should be addressed for future development.
EML4-ALK
FISH+ FISH-
LCDx+ 8 8 Sensitivity 42.1%
LCDx- 11 62 Specificity 88.6%
KIF5B-RET
FISH+ FISH-
LCDx+ 1 2 Sensitivity 14.3%
LCDx- 6 78 Specificity 97.5%
 
 
Conclusion: In our result, we confirmed all the lung cancer mutations currently being 
examined by multiple clinical assays could be identified by one target sequencing 
method more accurately and conveniently using LCDx. Our results suggest that, with 
improvement of fusion discovery, cancer panel such as our LCDx panel, can be used for 
clinical diagnostics and treatment decision making of non-small cell lung cancer patients. 
Keywords: mutation, fusion, Adenocarcinoma, cancer panel
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P3.04-030 Are Experienced Physicians More Likely to Acquire Adequate 
Tissue Material for EGFR-Testing? Janna Berg1, Pål Suhrke1, Lars Fjellbirkeland2, Odd 
Terje Brustugun3, Åslaug Helland3 1Dept. of Medicine, Vestfold Hospital Trust, Tønsberg/
Norway, 2Dept.Of Pulmonology, Oslo University Hospital-Rikshospitalet, Oslo/Norway, 3Dept 
of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo/Norway
Background: Epidermal Growth Factor Receptor (EGFR) mutation testing is now 
recommended practice for non-squamous non-small cell lung cancer. The patients with 
activating EGFR mutations are eligible for targeted personalized treatment offering better 
survival and quality of life, often with low toxicity. However, little is known about how the 
physician’s level of experience influences the quality of samples taken for EGFR-analysis 
and if complicated interventions result in more inadequate samples. We therefore 
performed a retrospective analysis on correlation between doctors’ experience and 
tissue quality at a moderately-sized community hospital. Methods: The Norwegian Lung 
Cancer Group (NLCG) recommended EGFR- testing of all patients with non-small cell lung 
carcinoma from June 2010. In March 2013 squamous cell carcinomas were excluded. 
Basic demographic data, sample type, test results and procedure related complications 
were recorded for the period June 2010 to December 2013, and the level of experience 
(measured as inexperienced physicians having less than 10 procedures per year) of 
the involved physicians was recorded. Results: Material was sent for EGFR analysis 
for 256 of the 304 eligible patients diagnosed in the period. For a total of 34 patients 
(13%) the first biopsy was not analyzed at department of molecular pathology due to 
inadequate tumor material. The tissue collected by experienced physicians was sufficient 
for EGFR analyses in 91-97.2% (median 93%), compared to 50-90% (median 86.7%) 
for the less experienced physicians. For image supervised biopsies, non-analyzable 
samples were more frequent when puncturing small (<3 cm) peripheral tumors than 
S701Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-034 Molecular Subtyping in Advanced Non-Small Cell Lung Cancer, a 
Minimally Invasive Strategy with Small Volume Fine Needle Aspirates 
Kristopher Hansen1, Lance Miller2, Travis Dotson3, Christina Bellinger3, Graham 
Parks4, James Cappellari4, Hollins Clark5, Clifford Howard5, Britt Bolemon6, William J. 
Petty6, Lou Craddock2, Jimmy Ruiz6 1Internal Medicine, Wake Forest University School 
of Medicine, Winston-Salem/NC/United States of America, 2Cancer Biology, Wake Forest 
University School of Medicine, Winston-Salem/NC/United States of America, 3Pulmonary 
Medicine, Wake Forest University School of Medicine, Winston-Salem/NC/United States of 
America, 4Pathology, Wake Forest University School of Medicine, Winston-Salem/NC/United 
States of America, 5Interventional Radiology, Wake Forest University School of Medicine, 
Winston-Salem/NC/United States of America, 6Oncology and Hematology, Wake Forest 
University School of Medicine, Winston-Salem/NC/United States of America
Background: Lung cancer is the leading cause of cancer related deaths worldwide. Non-
small cell lung cancer (NSCLC) accounts for the vast majority representing approximately 
85-90% of cases. NSCLC is further divided into histological subtypes including 
adenocarcinoma (AC) and squamous cell (SCC). Significant treatment implications 
exist according to histological classification which can be difficult due to scarcity of 
tissue or poor cellular differentiation. Patients often present with advanced disease thus 
making small volume, minimally invasive biopsy techniques ideal. Small volume biopsies, 
however, present an inherent challenge in obtaining sufficient amounts of high quality 
cancer cell-specific genomic material for testing and diagnostics. Here we tested the RNA 
yields from several minimally invasive techniques. We utilized two separate platforms to 
test a previously determined adeno-squam signature. We hypothesized that RNA yields 
would be sufficient for molecular histologic classification from a single needle biopsy. 
We sought to compare the yields of small volume biopsy techniques to RNA extracted 
from larger volume fresh frozen surgical specimens. Methods: Forty-eight individuals 
with suspected lung cancer underwent diagnostic biopsy with the standard approaches 
utilizing trans-thoracic needle biopsy (n=22) and transbronchial needle aspiration 
(n=26). RNA was extracted from a single pass specimen after the diagnostic biopsies 
were obtained (multiple passes). The total mass (ug), RNA integrity number (RIN) and 
% mass equal to or above 300 base pairs were recorded for all specimens. Statistical 
t-test analysis was performed on subgroups with focus on yield and quality. RNA from 
both FNA specimens as well as fresh frozen surgical specimens (n=44) obtained from 
a tumor bank at our institution were analyzed using Nanostring technology with the 
previously identified specific gene panel (A/S signature) obtained on the Quantigene 
platform. Results: Histological classification of FNA samples included adenocarcinoma 
(n=24), squamous cell (n=16) and NSC-NOS (n=8). Mean values for all FNA specimens 
included total mass of 1.58 ug, RIN of 4.0, and 85.4% mass equal to or above 300 
base pairs. Fresh frozen surgical specimens including adenocarcinoma (n=21) and 
squamous cell (n=23) underwent successful RNA isolation with mean total mass of 
45.2 ug, RIN of 6.1, and 68.8% mass equal to or above 300 base pairs. Differential 
histological gene expression occurred for both FNA and fresh frozen surgical specimens 
on the Nanostring platform. Conclusion: RNA isolation from NSCLC related small 
volume tissue biopsies is possible among several minimally invasive FNA techniques. 
Small volume tissue biopsy RNA yields are a sufficient means for molecular analysis 
and histological subtyping. We have successfully validated differential histological 
expression on two separate platforms from both single pass FNA techniques and frozen 
tumor samples. Given the increasing prevalence of such techniques and evolution 
of molecular analysis this may prove to be a powerful research and diagnostic tool. 
Keywords: NSCLC, Fine Needle Aspirates, Genetic Expression Analysis, Molecular 
Subtyping
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P3.04-035 Genetic Heterogeneity of Actionable Genes between Primary and 
Metastatic Tumor in Lung Adenocarcinoma Eun Young Kim, Eun Na Cho, Ji An 
Hwang, Yoon Soo Chang Division of Pulmonology, Department of Internal Medicine, Yonsei 
University College of Medicine, Seoul/Korea
Background: Because procedures obtaining lung cancer tissues involve high probability 
of critical complication, biopsies are usually done at a site of easy access. Authors 
questioned whether genetic information obtained at one biopsy site represent that of 
other lesion and is sufficient for therapeutic decision. Methods: Forty-one matched 
non-small cell lung cancer (NSCLC) samples of primary tumor and metastatic lymph 
node (L/N) were randomly selected from institutional tissue archives. non-synonymous 
mutation and ins-del of 16 genes that contain actionable mutations, intron 2 deletion 
polymorphism of Bcl2-like11, and copy number variation (CNV) of MET and FGFR1 were 
analyzed by NGS based technique. Results:A total 251 mutations, including 217 non-
synonymous mutations, 30 deletions, and 4 insertions were discovered in this study. 
There were higher chances to discover non-synonymous mutations in the primary tumor 
than in the metastatic L/N (140 (64.5 %) vs. 77 (35.5%)). In the primary tumor, 106 G>A: 
C>T transitions (75.7%) out of 140 non-synonymous mutation were detected, whereas in 
the metastatic L/N 44 (57.1%) out of 77 were discovered, showing decrease of G>A: C>T 
transition in the L/N metastatic lesion. The proportion of C>G: G>C and C>T: G>A was 
80.7% in the primary tumor and 67.5% in the metastatic L/N, showing APOBEC activity 
in the metastatic L/N was not prominent in this study model. When the mutation profile 
between primary and metastatic lesion were compared, 28 out of 41 (68.3%) cases 
showed identical mutation profiles whereas 13 (31.7%) showed discrepancy. Fifty out of 
82 tested samples showed CNV of either FGFR1 or MET and 24 out of 41 cases showed 
discrepancy of copy numbers of tested genes between primary tumor and metastatic 
L/N. Conclusion: The genetic heterogeneity between the primary tumor and lymph node 
metastatic lesions are significant findings to consider when designing a therapeutic plan 
molecular-targeted therapeutics, we have applied a Ion AmpliSeq RNA Fusion Lung 
Cancer Research Panel to detect known fusion transcripts such as ALK, ROS1, RET, 
and NTRK1 rearrangements simultaneously in a RNA sample obtained from FFPE lung 
cancer tissues. Deep sequencing was also performed using the Ion AmpliSeq Colon 
and Lung Cancer Panel. There were two co-primary endpoints for this study. First, 
we assessed the percentage of patients with additional therapy options uncovered 
by detecting potentially actionable genetic alterations. Second, we evaluated the 
percentage of patients who actually received genotype-directed therapy. Results: From 
June 2013, one hundred ten patient tumor samples were sequenced with these assays, 
and 104 (95%) patients received the results of Ion AmpliSeq Colon and Lung Cancer 
Panel and 106 (96%) patients received the results of the Ion AmpliSeq RNA Fusion 
Lung Cancer Research Panel with a >90% success rate for genotyping. An actionable 
driver alteration was detected in 43 (39%) of tumors from patients, leading to use 
of a targeted therapy in 23 (21%). Conclusion: Multiplexed genomic testing can aid 
physicians in matching patients with targeted treatments and appropriate clinical trials. 
Keywords: lung cancer, NGS, Driver mutation
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P3.04-033 Screening for Driver Mutations in Caucasian Patients with Central 
Nervous System Metastases of Non-Small-Cell Lung Cancer  
Marcin Nicoś1, Bożena Jarosz2, Tomasz Powrózek1, Pawel Krawczyk3, Marek Sawicki4, 
Justyna Szumiłło5, Tomasz Trojanowski2, Janusz Milanowski1 
1Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin/
Poland, 2Pathological Laboratory, Department of Neurosurgery and Pediatric Neurosurgery, 
Medical University of Lublin, Lublin/Poland, 3Laboratory of Immunology and Genetics, 
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 
Lublin/Poland, 4Department of Thoracic Surgery, Medical University of Lublin, Lublin/
Poland, 5Department of Pathomorphology, Medical University of Lublin, Lublin/Poland
Background: The knowledge about molecular profile of advanced NSCLC may increase 
the possibility and effectiveness of cancer treatment. According to data of LCMC, 
FNN and CRUK, driver mutations are reported in 50-60% of non-small cell lung cancer 
(NSCLC) patients, especially in adenocarcinoma subtype. Unfortunately, we have limited 
information concerning the incidence of driver mutations in metastatic lesions of NSCLC. 
The main aim of the study was characterize the molecular background of central nervous 
system (CNS) metastatic lesions of NSCLC. It was performed by estimation the frequency 
of selected driver mutations in Caucasian chemotherapy and molecularly targeted 
therapy naïve patients. Methods: The studied group included 145 patients (45 females, 
100 males, age: 60±8,8 years) with CNS metastases of NSCLC.The studied group 
included 80 adenocarcinomas, 29 squamous-cell carcinomas, 22 large-cell carcinomas 
and 14 not otherwise specified patients. 36 patients were non-smokers. In 30 patients 
the material was simultaneously available from primary and metastatic NSCLC tumors. 
The molecular profile of driver mutations was determined in EGFR, KRAS, NRAS, BRAF, 
PIK3CA, HER2, and DDR2 genes. Mutations were screened in DNA isolated from formalin-
fixed paraffin-embedded tissue samples using the quantitative real-time PCR technique 
with commercially available molecular kits. The driver mutations presence was confirmed 
by DNA sequencing, multiple single-strand conformation polymorphism (MSCCP) and 
other PCR techniques. Results: The driver mutations were identified in 52/145 (36%) of 
patients with CNS metastases (Fig.1), significantly more frequent in adenocarcinoma (p= 
0.05, χ2= 3.817), patients and non-smokers (p= 0.004, χ2= 8.131). Only one patient 
had doublet mutations in DDR2 and KRAS genes. In corresponding primary tumors we 
detected 10/30 (33%) mutations in KRAS gene (7/30, 23%) and EGFR gene (3/30, 10%). 
However, 5 KRAS mutations were identified both in primary and metastatic lesions, while 
1 mutation was detected only in primary tumor and 1 mutation - only in the metastatic 
tumor. Conclusion: Analysis of molecular profile confirmed assumptions that driver 
mutations could be detected both in primary and CNS metastatic tumors of NSCLC. 
Therefore, both primary and metastatic tumor samples could be considered as a 
representative for molecular testing in patients with metastatic cancer.
 
 
Keywords: NSCLC, CNS-metastases, driver mutations
S702 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-038 Molecular Topography of Early-Stage Lung Adenocarcinomas 
Esther Conde1, Barbara Angulo1, Rebeca Martinez1, Luis Madrigal2, Luis Jimenez2, 
Elena Piñeiro-Yañez3, Fatima Al-Shahrour3, Victor Reyes4, Susana Hernandez1, Fernando 
Lopez-Rios1 1Pathology-Laboratorio de Dianas Terapeuticas, Hospital Universitario Hm 
Sanchinarro, Madrid/Spain, 2Thoracic Surgery, Hospital Universitario Hm Sanchinarro, 
Madrid/Spain, 3Translational Bioinformatics Unit, Cnio, Madrid/Spain, 4Pathology-Laboratorio 
de Dianas Terapeuticas, Hospital Universitario Hm Puerta Del Sur, Madrid/Spain
Background: Intratumor heterogeneity may have implications for targeted therapies. 
Despite the well known morphologic intratumor heterogeneity of lung adenocarcinomas 
(ACs), the heterogeneity of druggable alterations throughout individual primary tumors 
is still controversial and has remained poorly defined. The purpose of our work was 
to comprehensively characterize histological intratumor heterogeneity in primary lung 
ACs. Methods: A total of 83 consecutive patients with stage I-IIIA primary lung AC who 
underwent surgery at HM Sanchinarro University Hospital were considered. All tumors 
were always included in toto for histological analysis, regardless of size, by the same 
pathologists. We carefully reviewed all slides to identify and quantify (with the help of digital 
pathology, [iScan, Ventana Medical Systems, USA]) the different histological patterns 
according to the revised International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification of lung 
ACs. Every pattern from each specimen was macrodissected, and a new paraffin block per 
pattern was constructed. Afterwards, we performed targeted next-generation sequencing 
(Ion AmpliSeqTM Cancer Hotspot Panel v2, Life Technologies, USA) to detect actionable 
somatic mutations and copy number variations (CNVs) in 50 genes in every different 
histological pattern of each tumor. The raw data were processed using the RUbioSeq and 
MuTect softwares. After a filtering process, the detected variants were then annotated 
with the Ensembl Variant Effect Predictor. The annotations were used to compute a 
variant score and rank the mutations according to their clinical significance. Results: All 
83 tumors were primary invasive ACs. Detailed histological analysis revealed that 63 
tumors (76%) had more than one histological pattern. Among them, 52 (82,5%) exhibited 
two patterns, and 11 (17,5%) showed three components. An initial pilot study of 20 cases 
showed that 45% of the tumors had heterogeneous results regarding the presence 
of somatic mutations and CNVs between different histological patterns within a given 
tumor. We observed intratumor heterogeneity predominantly regarding the mutational 
status of several genes (e.g. 2 out of 11 TP53 mutated tumors, 1 out of 6 KRAS positive 
tumors, 1 out of 3 STK11 mutated cases, and 3 out of 3 CDKN2A mutated tumors). 
Solid patterns accumulated more molecular alterations than other patterns, and also 
showed events not present in other components (i.e. CDKN2A or NOTCH1 mutations, 
copy number gain of ALK, HER2, FGFR2 or NOTCH1). RET and GNAS mutations were 
exclusively observed in papillary patterns. EGFR and HER2 mutations were not 
heterogeneous. Conclusion: In early stage lung ACs there is a significant degree of 
intratumor heterogeneity. Our preliminary results indicated a trend towards a high 
somatic events rate in solid patterns. The comprehensive approach presented herein 
links routine pathology practice with targeted clinical molecular annotation of lung ACs. 
Therefore, it could be used prospectively to assess the implications of studying single 
tumor regions. Acknowledgements This study was partially funded by Instituto de Salud 
Carlos III (ISCIII), Fondo de Investigaciones Sanitarias (FIS) [Fondos FEDER, Plan Nacional 
de I+D+I 2008-2011 (PI11-02866) and Plan Estatal de I+D+I 2013-2016 (PI14-01176)]. 
Keywords: lung adenocarcinoma, Heterogeneity, next generation sequencing, 
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P3.04-039 Characterization of RNA Splicing Factor Mutations in Lung 
Adenocarcinoma Peter S. Choi, Angela N. Brooks, Matthew Meyerson Medical 
Oncology, Dana-Farber Cancer Institute, Boston/United States of America
Background: Large-scale genomic surveys of lung adenocarcinoma have revealed 
unexpected mutations in RNA splicing factors such as U2AF1 and RBM10, and it remains 
unknown how changes in splicing are involved in promoting cancer. Somatic alterations 
in the RNA-binding protein RBM10 occur at a frequency of approximately 7% and consist 
predominantly of loss-of-function mutations. In this study, we sought to investigate the 
functional impact of RBM10 mutations in lung cancer. Methods: RBM10 mutant non-
small cell lung cancer (NSCLC) cell lines were identified by analysis of Cancer Cell Line 
Encyclopedia gene expression data and Sanger sequencing of RBM10 coding exons. 
Ectopic expression of wildtype RBM10 or a control protein (BFP) was induced using 
the tetracycline-regulatory system. RNA–sequencing and JuncBASE software were 
used to identify differentially spliced transcripts between RBM10 wildtype and mutant 
cells. Changes in individual splicing events were validated by RT-PCR. Results: We 
have identified several NSCLC cell lines harboring loss-of-function mutations in RBM10. 
Restoring expression of wildtype RBM10 in these RBM10 -mutant cell lines resulted in 
significant growth suppression and inhibition of anchorage-independent growth. These 
phenotypic effects were associated with a variety of splicing changes and expression 
of wildtype RBM10 frequently increased skipping of cassette exons. Expression 
of RBM10 variants with either deletion of an RNA recognition motif (RRM), or containing 
a cancer-associated missense mutation in the RRM, were significantly diminished in their 
ability to promote exon skipping and suppress cellular proliferation. Conclusion: Our 
results suggest that RBM10 functions as a novel tumor suppressor in lung adenocarcinoma 
through its effects on RNA splicing. Further work is needed to better understand how 
changes in specific splicing events may be directly contributing to lung tumorigenesis. 
Keywords: RNA splicing, splice factor mutations, RBM10
from a result of one site inspection. A large prospective study is needed to evaluate 
the impact of genetic heterogeneity on the clinical outcome of NSCLC patients. 
Keywords: co-mutation, next generation sequencing, copy number variation, lung 
adenocarcinoma
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P3.04-036 Rare Discrepancies in a Driving Gene Alteration within 
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Su1, Fang-Ping Xu2, Hao-Ran Zhai3, Xu-Chao Zhang1, Xue-Ning Yang1, Zhi-Yong Chen1, 
Zhi-Hong Chen1, Wei Li3, Song Dong1, Qing Zhou1, Jin-Ji Yang1, Yi-Long Wu4 1Department 
of Pulmonary Oncology; Guangdong General Hospital & Guangdong Academy of Medical 
Sciences, Guangzhou/China, 2Department of Pathology and Laboratory Medicine; 
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of 
Medical Sciences, Guangzhou/China, 3Department of Pulmonary Oncology; Guangdong 
General Hospital & Guangdong Academy of Medical Sciences; Southern Medical University, 
Guangzhou/China,4Guangdong General Hospital & Guangdong Academy of Medical 
Sciences, Guangzhgou/China
Background: Most lung adenocarcinomas consist of a mixture of histological subtypes 
among which driving gene mutations occurred with different frequencies. However, little 
is known about intratumoral heterogeneity within histologically heterogeneous primary 
lung cancers. Investigating key driver genes in respective morphological pattern is crucial 
to clinical practice and personalized treatment. Methods: Morphologically different 
tumor areas within the same surgically resected primary tumors were extracted from 
tissue sections and the gene status in each growth pattern was analyzed. Driving genes, 
epidermal growth factor receptor (EGFR ), KRAS, and rearrangements in echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), were 
assessed by assays of different sensitivity. Results: Seventy-nine consecutive, surgically 
resected, adenocarcinomas or adeno-squamouse cell carcinomas harboring a driving 
gene mutation or rearrangement (EGFR, n = 65; KARS, n = 10; EML4-ALK, n = 4) were 
selected. For EGFR mutations in adenocarcinomas, ITH occurred in 13.3% (8/60) as 
determined by direct sequencing, but in only 1.7% (1/60) by ARMS(P= 0.016). A consistent 
intratumoral EGFR mutation status was found within 5 histologically heterogeneous 
adeno-squamous cell carcinomas, as shown with ARMS. ITH among KRAS mutations 
were detected in 20% (2/10) of regions examined by direct sequencing ,whereas a 
consistent status (10/10) was obtained with HRM. There were no discrepancies in EML4-
ALK rearrangements according to FISH for four tumors. Conclusion: Rare ITHs deriving 
from EGFR/KRAS/EML4-ALK alterations within histologically heterogeneous primary 
lung adenocarcinomas were found with methods of high sensitivity. Discrepancies 
might be due to the abundance of cells harboring driving gene and detection assays. 
Keywords: Intratumor heterogeneity, Epidermal growth factor receptor, KRAS/EML4-
ALK, lung cancer
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P3.04-037 Prevalence of NRG1 fusions in Caucasian NSCLC patients 
determined by fluorescence in situ hybridisation Andreas H. Scheel1, Katja 
Schmitz2, Lea Wilsberg2, Rieke N. Fischer3, Sabine Merkelbach-Bruse1, Elke Binot1, 
Dennis Plenker4, Jürgen Wolf3, Koji Tsuta5, Takashi Kohno6, Roman K. Thomas4, 
Hans-Ulrich Schildhaus2, Reinhard Büttner1 1Institute of Pathology, University Hospital 
of Cologne, Cologne/Germany, 2Pathology, University Hospital Göttingen, Göttingen/
Germany, 3Lung Cancer Group Cologne, Department I of Internal Medicine, University 
Hospital of Cologne, Cologne/Germany, 4Department of Translational Genomics, Center for 
Integrated Oncology Cologne/Bonn, University of Cologne, Cologne/Germany, 5Pathology, 
National Cancer Center Hospital, Tokyo/Japan, 6Genome Biology, National Cancer Center 
Research Institute, Tokyo/Japan
Background: Fusions of the gene Neuregulin1 (NRG1) have been described to activate 
PI3K-AKT signaling in NSCLC via NRG1 overexpression and binding to Her2/Neu-
Her3. NRG1 fusions were detected in pulmonary mucinous adenocarcinoma of Asian non-
smokers lacking other known oncogenic driver mutations. The incidence in such patients 
has been described to be between 17.6% (6/34) and 44.4% (4/9). NRG1 fusions might 
be targeted by Her2/Her3-inhibitors and clinical trials are planned. Here we describe 
for the first time the systematic analysis of NRG1 in Caucasian patients by Fluorescence 
in situ hybridization (FISH). Methods: A ZytoLight®-based FISH assay (ZytoVision, 
Bremerhaven, Germany) was developed and verified on nine published clinical cases 
with known NRG1 fusions. A total of 160 Caucasian NSCLC patients were screened. 
25 of the cases were mucinous adenocarcinoma lacking a known oncogenic driver 
mutation as determined by deep-sequencing and FISH tests. 135 cases were pulmonary 
adenocarcinoma of various subtypes including 35 cases that lacked a driver mutation 
and 100 cases that were EGFR, ALK and ROS1 wildtype. The smoking-status was not 
evaluated. Statistics were calculated using R 3.1.0 . Results: The NRG1 fusions in the 
published cases were easily detected by the FISH assay. However, none of the screened 
cases harbored a NRG1 fusion. The result is significant compared to published reference 
values of 17.6% (p=0.041) and 44.4% (p<0.001). The theoretical maximum incidence 
of NRG1 fusions among Caucasian NSCLC patients not stratified by smoking-status 
was calculated to be <16.6% for mucinous adenocarcinomas lacking driver mutations, 
<7.5% for adenocarcinoma of all morphological subtypes lacking driver mutations 
and <3% for EGFR, ALK, ROS1 negative pulmonary adenocarcinoma (95% confidence 
intervals). Conclusion: FISH is a suitable technique to screen for NRG1 fusions in pulmonary 
adenocarcinoma. Among 160 Caucasian patients including 25 mucinous carcinomas 
lacking a driver mutation none were NRG1 positive. Thus, the incidence among Caucasian 
patients appears to be low and should be evaluated in studies of large NSCLC cohorts. 
Keywords: fusion gene, NRG1, FISH, Mucinous Adenocarcinoma
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Caroline Caramella2, Silvia Rosellini3, Charlotte Leduc4, Francesco Facchinetti1, Eva 
Haspinger1, Charles Ferte1, Stefan Michiels3, Jean C. Soria1, Benjamin Besse1 
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Background: The quantitative assessment of heterogeneity in tumor images through 
Texture Analysis is an emerging tool that can potentially provide a non-invasive prognostic 
biomarker. We investigated if Texture Analysis parameters derived from contrast-
enhanced CT (CTTA) were associated with EGFR/ALK status and have a prognostic value 
in NSCLC patients treated with tyrosine-kinase inhibitors. Methods: The CT images of 
patients with EGFR mutated or ALK rearranged advanced NSCLC treated with tyrosine-
kinase inhibitors were retrospectively reviewed. CTTA using the filtration-histogram 
method was applied to the region of interest (ROI) in the primary tumor of the enhanced-
CT by two independent operators to examine the inter-individual reproducibility. A 
wilcoxon test was used to correlate CTTA with EGFR / ALK status and a Cox model 
to evaluate the prognostic value of CTTA for overall survival. A p-value cutoff of 0.01 
was used to adjust for multiple testing. Results: CTTA parameters were evaluated in 
CT scan from 68 patients recruited in 2 centers between 2008 and 2013, of them, 
80.9% (n=55) were EGFR mutated and 19.1 % (n=13) ALK+ NSCLC, 48.5% received 
treatment with gefitinib (n=33), 33.8% with erlotinib (n=23) and 17.7% with crizotinib 
(n=12). The CTTA measures were highly reproducible between the 2 operators as 
indicated by Bland-Altman plots and correlation values. The skewness of the distribution 
was significantly different between EGFR mutated and ALK+ tumors for coarse texture 
with spatial filter value 3.3 (p= 0.002), filter value 2.8 (p=0.001) and medium texture 
with spatial filter value 2.2 (p=0.004). The median follow-up time was 35 months; 39 
deaths occurred. The A unit increase in skewness in coarse texture (2.8 spatial filter) 
was significantly associated with better survival with an univariate cox analysis (HR: 
0.36 [0.2-0.69] p=0.002). A multivariate analysis adjusted by prognostic factors (PS, 
lymphocyte count, hepatic and adrenal metastasis) indicate a similar trend for better 
survival (HR: 0.40 [0.2-0.8] p=0.01). Conclusion: CTTA parameters were reproducible 
between the 2 operators. The skewness was significantly different between EGFR 
mutated and ALK rearranged advanced NSCLC and may have a prognostic value. 
Keywords: Texture analysis, non small cell lung cancer, EGFR mutated, ALK rearranged, 
computed tomography
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P3.04-043 Driver Mutations in Non-Small Cell Lung Cancer in Western 
Pennsylvania: Prevalence and Barriers to Testing Rohit Rao1, Zachary D. Otaibi2, 
Blair Jobe3, Ali Zaidi3, Rodney Landreneau3, Gene G. Finley1 1Medical Oncology and 
Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh/PA/United States of 
America, 2Internal Medicine and Esophageal and Lung Institute, Allegheny Health Network, 
Pittsburgh/PA/United States of America,3Esophageal and Lung Institute, Allegheny Health 
Network, Pittsburgh/United States of America
Background: EGFR gene mutations and EML4-ALK rearrangements are key therapeutic 
targets in nonsquamous non-small cell lung carcinoma (nsNSCLC). Therapy targeted 
towards these mutations has been shown to improve tumor response, progression-free 
survival, and quality of life. Current guidelines recommend testing all advanced (Stage IIIB 
and IV) nsNSCLC patients for these genetic aberrations. Despite this recommendation, 
not all patients eligible for mutation analysis are tested. In our institution, preliminary 
observations suggest the percentage of patients being tested and the frequency of 
driver mutations are significantly lower compared to published data. The purpose of the 
study was to review tumor registry data in order to determine the rate of testing and the 
frequency of driver mutations in Western Pennsylvania. Our secondary aim was to evaluate 
whether biopsy size impacts the frequency of EGFR and ALK testing. Methods: From the 
tumor registry, 167 cases of advanced nsNSCLC were identified (2011-2013). The testing 
rates for driver mutations, frequency of driver mutations, and the tissue procurement 
technique were determined by individual chart review. Surgical specimens, core biopsies, 
and large volume thoracentesis specimens were categorized as large tissue biopsies and 
samples obtained by fine needle aspiration, bronchial washing, and bronchial brushing 
were considered small tissue biopsies. Using a Chi-square analysis, mutation testing 
rates were compared between the large and small biopsy groups. Frequency of driver 
mutations was determined, excluding unknown or inadequate samples. Results: Of the 
167 cases, there were 120 (71.9%) large and 47 (28.1%) small biopsy specimens. 61 
(50.8%) large sample biopsies and 17 (36.2%) small sample biopsies were submitted for 
EGFR analysis. 39 (32.5%) large sample biopsies and 10 (21.3%) small sample biopsies 
were tested for ALK rearrangements. It was found that large tissue biopsies were more 
likely to be analyzed for EGFR mutations and ALK rearrangements although the results 
did not reach statistical significance (p=0.088 and p=0.150, respectively). Across 
all samples, a total of 7 EGFR mutations and 0 ALK rearrangements were identified 
representing a frequency of 10.0% and 0.0% respectively. Conclusion: Despite current 
guidelines for testing driver mutations in advanced nsNSCLC, we are testing less than 50% 
of our patients. There are several barriers that continue to thwart this recommendation, 
including failure to integrate driver mutation testing into routine pathology practice 
(i.e., reflex testing), lack of care coordination with relevant clinical specialties beyond 
medical oncology and pathology, and insufficient tissue obtained from biopsy. More 
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P3.04-040 Comparison of Histology with Genome-Wide Copy Number Profiling 
in Patients with Metachronous or Synchronous Tumors Erik Thunnissen1, Julien 
Vincenten1, Hf Van Essen1, Nicole Bulkmans1, Katrien Grunberg1, Egbert Smit2, Birgit 
Witte3, Bauke Ylstra1 1Department of Pathology, VU University Medical Center,, Amsterdam/
Netherlands, 2Dept. of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam/
Netherlands, 3Department of Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam/Netherlands
Background: Multiple synchronous and metachronous lung tumors are frequently 
encountered in patients with lung cancer. In addition, tumors of head and neck 
(usually squamous cell carcinoma) have a chance for a second primary malignancy in 
the lung. For treatment purposes it is important to know whether tumors are related 
(clonal = metastases) or not (multiple primaries). Histopathological comparison of the 
synchronous or metachronous tumors has been associated with molecular analysis. The 
purpose of this study is to examine the value of histopathological scoring with genome-
wide copy number profiling for determination of clonality. Methods: From cases in which 
array CGH for clonality analysis performed between 2006 and 2012 were selected 
if at least one intrathoracic tumor was present. In the first years genome-wide copy 
number profiling was performed with arrayCGH and later with shallow sequencing. 
Results of the genome-wide copy number profiling were compared to histological 
(sub)typing. Results: 100 tumor pairs from 59 patients were examined. 32 pairs 
were discovered simultaneously (synchronous), the other 68 were metachronous. The 
histopathological diagnosis was similar in 74 cases (74%). genome-wide copy number 
profiling revealed evidence for clonality in 55% of the pairs, no-clonality in 28% and was 
undetermined in 17%. Comparing of histology with genome-wide copy number profiling 
revealed concordancy in 54 pairs ( 74%; 44 clonal en 10 non-clonal). In 18 of the 62 
pairs where histology was similar the genome-wide copy number profiling revealed a 
non-clonal pattern. In 11 out of 21 pairs where histology differed between the pairs, 
genome-wide copy number profiling revealed a clonal pattern. Thus histology was 
not prognostic in 29/83 pairs (35%). Conclusion: For the determination of clonality 
in lung cancer histological examination is discordant with genome-wide copy number 
profiling in 35% of the comparisons. As histology is a poor predictor of clonality, 
genome-wide copy number profiling is preferred for clonality analysis between tumors. 
Keywords: multiple primary tumors*lung*molecular analysis*histology
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P3.04-041 Identification of the Functional Significance of Mutations in Lung 
Cancer Using the Novel Precision Cancer Analysis System Nir Peled1, Gabi 
Tarcic2, Mariusz Adamek3, Naama Barabash-Katzir2, Zohar Barabash2, Shlomo Yaakobi2, 
Eli Besser2, Hani Nevo2, Michael Vidne2, Yaniv Tocker2, Damian Czyzewski3, Yakov 
Fellig4, Karen Meir4, Keith Mostov5, Erez Chimovits6, Yoram Altschuler2 1Tel Aviv University 
Sackler School of Medicine, Tel Aviv/Israel, 2Novellusdx, Jerusalem/Israel, 3Medical 
University of Silesia, Zabrze/Poland, 4Hadassah-Hebrew-University-Medical-Center, 
Jerusalem/Israel, 5University of California School of Medicine, San Francisco/CA/United 
States of America, 6Orbimed, Herzliya/Israel
Background: Mounting evidence indicates that growth of pathologically identical lung 
cancers in each individual patient is fueled by different sets of driving mutations. The 
need to identify these drivers stems from the recognized necessity for tailoring therapy 
and scheduling future surveillance. This personalized medical approach has been 
shown to result in better treatment outcomes. We present a novel Precision Cancer 
Analysis system (PCAS) capable of identifying activated signaling pathways by means 
of a transfected cell-based fluorescent reporter assay yielding a quantitative output of 
particular pathway activation levels. Being a functional platform PCAS reveals activated 
pathways regardless of the type of mutation behind it, i.e. whether it is already a known 
mutation or a variant of unknown significance (VOUS) mutation. Methods: In 10 patients 
with lung cancer next generation sequencing (NGS) was employed to sequence a set of 
37 genes relevant in lung carcinogenesis. These genes were sequenced with 90 -100 % 
coverage. According to the prevalence of mutations in the analyzed cohort 3 major genes 
were selected for the current study: EGFR, PIK3CA and KRAS. These genes were then 
mapped to their major signaling pathways, and the reporters that best account for their 
activation were selected. Four major signaling pathways were found to be relevant for 
these genes‐ MAPK, STAT, NFkB and AKT. Results: In analyzed samples of 10 patients 
14 mutations were identified, among them 3 in the tested genes: 2 in KRAS and 1 
complex mutation in EGFR. The remaining mutations were found in STK11, CDKN2A, NF1, 
RB1 and TP53 genes. Of mutations found in KRAS 1 was known mutation (K117N) and 1 
was VOUS (G60R). The former caused activation via MAPK/ERK but not via AKT pathway. 
The latter, never so far reported in cancer, significantly activated both pathways: MAPK/
ERK and AKT. Interestingly the VOUS KRAS mutation was identified in carcinoid, whereas 
2 carcinoid samples from other individuals displayed no mutations in the 37-gene panel. 
Additionally, 1 VOUS in RB1 and 2 mutations in STK11 were found to be associated with 
cancer cells aggressiveness evidenced by vessel and nerve tissue invasion. Measuring 
the functional mechanism behind known mutations and VOUS provides another layer of 
critical information to the physician. Conclusion: The study produced a comprehensive 
delineation of the oncogenic activity of each patients’ individual mutations demonstrating 
the ability of the PCAS to:
• Accurately deliver comparable actionable information as found by NGS
• Functionally characterize mutations annotated as VOUS.
• Monitor oncogenic activity of signaling pathways induced by different mutations and 
mutation-combinations enabling informed treatment decisions.
S704 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Some are minor, e.g. for EGFR mutation testing real-time PCR is used in all countries, 
direct sequencing in 5, and other methods are used in addition in only 2 countries. Up 
to one-quarter of samples are inadequate for testing. For ALK testing, IHC followed 
by FISH and/or FISH alone are currently used in all 7 countries with responses; in 
Israel, other methods including DNA sequencing are also used. However, some of the 
differences are quite large, such as the proportion of eligible patients tested for EGFR 
mutations and ALK rearrangements, and the proportion of NSCLC patients discussed 
at multidisciplinary tumor boards. There is also wide variation in funding sources for 
EGFR and ALK testing. Conclusion: NSCLC molecular testing is available in all Central 
and Eastern European countries participating in this survey. For the future, ensuring 
adequate NSCLC samples, solving sustainable financing of molecular testing and 
enabling wide access of eligible patients to molecular testing resulting in raising the 
number of patients reviewed by multidisciplinary boards are among the key challenges. 
Keywords: NSCLC, molecular testing
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P3.04-046 Prevalence of ROS1, HER2, and BRAF Alterations in a Cohort of 
Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (P) Triple Negative 
(TN) Teresa Morán1, Enric Carcereny1, Josefa Terrasa2, Raquel Marse2, Ana Estival1, 
Monica Guillot2, Laia Vila1, Maria De Los Llanos Gil1, Max Hardy-Weber1, Iris Teruel1 
1Medical Oncology, Catalan Institute of Oncology-Hospital Germans Trias I Pujol, Badalona/
Spain, 2Medical Oncology, Hospital Universitari Son Espases, Palma de Mallorca/Spain
Background: During the last years, new predictive and less frequent biomarkers have 
emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) 
and BRAF mutations (BRAFm). We analyze retrospectively the frequency, clinical and 
tumor characteristics of NSCLC p TN( EGFR, KRAS and ALK wild-type). Methods: The 
study included data from all consecutive non-squamous and non-smokers squamous 
TN advanced NSCLC p diagnosed at our hospital from December 2008 to July 
2014 Results: 101 p were included. The table below summarizes p characteristics. ROS1t 
were found in 4.9% p and were found more in female gender (100%), non-smokers(100%), 
stage IV (100%), adenocarcinoma histology (100%) and p had more lung metastasis(50% 
vs 34.2%), brain metastasis (50%vs 38.5%) and pleural/pericardial effusions (50% vs 
12.8%). HER2m was found in 1 p (1.25%). Female, non-smoker and adenocarcinoma 
histology. BRAFm were found in 2 p ( 3.2%), one male and one female, smokers and 
adenocarcinoma histology. Valid results range from 85.6% to 96.2% for biopsy samples 
and from 78.2% to 81.4% for citology samples.
TO-
TAL(N101) ROS1(N81) BRAF(N80) HER2(N80)
Mean 
age 61 58 63 63
Gender Male Female
65(64,3%) 
36(35,6%)
57(70,3%) 
24(29,6%)
52 (65%) 
28(35%)
52(65%) 
28(35%)
Smok-
ing 
history
Current 
Former 
Never
38(37,6%) 
41(40,5%) 
22(21,7%)
32(39,5%) 
37(45,6%) 
12(14,8%)
33(41,2%) 
31(38,7%) 
16(20%)
33(41,2%) 
31(38,7%) 
16(20%)
Histol-
ogy
Adeno-
carci-
noma 
Squa-
mous 
NOS LCC
88(87,1%) 
5(4,9%) 
6(5,9%) 
2(1,9%)
72(88,8%) 
3(3,7%) 
6(7,4%) 0
71(88,7%) 
2(2,5%) 
5(6,2%) 
2(2,5%)
71(88,7%) 
2(2,5%) 5(6,2%) 
2(2,5%)
Sample CItology Biopsy
29(28,7%) 
72(71,2%)
27(33,3%) 
54(66,6%)
23 (28,7%) 
57 (71,2%)
23 (28,7%) 57 
(71,2%)
Site 
metas-
tasis
Lung 
Bone 
Brain 
Liver
33(32,6%) 
28(27,7%) 
30(29,7%) 
9(8,9%)
28(34,5%) 
21(25,9%) 
25(30,8%) 
5(6,1%)
25(31,2%) 
22(27,5%) 
27(33,7%) 
7(8,7%)
25(31,2%) 
22(27,5%) 
27(33,7%) 
7(8,7%)
 
Conclusion: ROS1t, HER2m and BRAFm have emerged as targetable 
oncogenic drivers in NSCLC. Although the prevalence is low (1%–2%), 
could be increased selecting by clinical and molecular characteristics. 
Citology samples could be useful to detect these molecular alterations. 
Keywords: ROS1 translocation, HER2 mutations, BRAF mutations, molecular alterations
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-047 Prospective Study of Molecular Markers in Patients with Advanced 
Lung Adenocarcinoma in CEMIC. Argentina Gonzalo Recondo1, Valeria Denninhoff2, 
Gonzalo Recondo Jr1, Constanza Lorente2, Martin Greco1, Maria T. Cuello2, Maximo 
De La Vega1, Enrique A. Diaz Canton1, Mariana Dos Santos2, Florencia Perazzo1, 
Silvana Nieto2, Jorge Nazar3, Matias Lescano3, Alejandro Garcia2, Pablo Rodriguez4, 
Shigeru Kozima5, Alejandra Avagnina2 1Medical Oncology, Cemic, Buenos Aires/
Argentina, 2Pathology, Cemic, Buenos Aires/Argentina, 3Thoracic Surgery, Cemic, Buenos 
Aires/Argentina, 4Neumonology, Cemic, Buenos Aires/Argentina, 5Imaging, Cemic, Buenos 
Aires/Argentina
importantly, these trends are not isolated to our institution and reflect a significant 
challenge within the oncology community. In the coming months, we will be initiating a 
Lean Six Sigma approach to modify our current clinical practice and improve our testing 
rate. In addition, we have begun using a blood based assay (liquid biopsy) to interrogate 
advanced nsNSCLC for driver mutations. We have also demonstrated that the frequency 
of driver mutations in Western Pennsylvania is lower than published data. Accession 
of additional patients to this data set continues and a final analysis will be presented. 
Keywords: testing rate, non-small cell lung cancer, EGFR, EML4-ALK
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P3.04-044 EGFR and ALK Status Influence Health Utility and Global Quality 
of Life Scores in Patients with Metastatic Lung Cancer Catherine Labbe1, Erin 
Stewart1, Catherine Brown1, Andrea Perez Cosio1, Ashlee Vennettilli1, Devalben Patel1, 
Nicholas Cheng1, Mindy Liang1, Gursharan Gill1, Yvonne Leung1, Hiten Naik1, Nicole 
Mittmann2, Natasha Leighl1, Ronald Feld1, Penelope Bradbury1, Frances Shepherd1, 
Doris Howell1, Geoffrey Liu1 1Princess Margaret Cancer Centre, Toronto/Canada, 2Health 
Outcomes and Pharmacoeconomics (Hope) Research Centre, Sunnybrook Research Institute, 
Toronto/ON/Canada
Background: EGFR mutations and EML4-ALK rearrangements play important roles 
in prognosis and response to treatment. While extending survival is a main goal of 
treatment, improving symptoms, well-being, and quality of life is an equally important 
priority. Methods: At Princess Margaret Cancer Centre, a cross-sectional study evaluated 
224 outpatients with metastatic lung cancer who completed demographic and EQ5D-3L 
questionnaires generating health utility scores (HUS, 0-1) and a visual analogue scale 
(VAS) slider (0-100). Patients rated their ECOG performance status (0-4), and described 
their health over the last month from 1 (excellent) to 5 (poor). Results were correlated 
with clinical and demographic data. Our objective was to compare HUS and global quality 
of life by mutational status. Patients with EGFR mutations and ALK rearrangements 
were enriched through targeted enrolment, while patients with neither alteration were 
selected randomly from the same outpatient clinics. Results: 94 patients (42%) had 
an EGFR mutation, 23 (10%) an ALK rearrangement and 107 (48%) had neither (“wildtype”) 
in their tumor. Participation rate was 87%. Characteristics of the populations were as 
expected, with higher rates of never smokers in patients with EGFR or ALK alterations 
(p<0.0001), greater proportion of Asians (p=0.0004), and higher proportion of 
adenocarcinoma (p<0.0001). Current systemic treatment differed among groups, as 
the majority of patients with driver mutations were receiving targeted agents at the time 
of assessment (77% EGFR and 65% ALK vs 7% wildtype). Conversely, wildtype patients 
were more likely on chemotherapy (6% vs 17% vs 38%) or not on treatment (17% vs 17% 
vs 47%, p<0.0001). Patients filled questionnaires on average 25 months after initial 
diagnosis of lung cancer. Patients with EGFR mutations (97%) or ALK rearrangements 
(100%) were more often ECOG performance status 0-1 at the time of diagnosis of 
stage IV disease than wildtype individuals (86%, p=0.02). For quality of life analysis, 
we regrouped the patients with EGFR/ALK alterations (n=117). Their mean HUS was 
better than for wildtype patients (0.80 vs 0.71, p=0.0003), their mean VAS slider was 
higher (66.9 vs 60.8, p=0.0381) and their mean self-rated ECOG scores was better 
(0.90 vs 1.26, p=0.022). Conclusion: In a clinical population, patients with metastatic 
lung cancer harboring EGFR and ALKalterations report superior HUS and global quality 
of life scores when compared with patients without these molecular changes, during 
the course of their therapy. This is reflected in higher proportion of patients on active 
therapy, particularly with molecularly targeted agents, and with improved self-reported 
performance scores. Health utility values used in economic analyses of metastatic 
lung cancer patients in clinical practice should be specific for different mutations. 
Keywords: health utility scores, metastatic lung cancer, EGFR mutation, ALK 
rearrangement
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P3.04-045 Insights into NSCLC Molecular Testing in Central and Eastern 
European Countries Ales Ryska1, Peter Berzinec2, Tanja Cufer3, Rafal Dziadziuszko4, 
Maya Gottfried5, Włodzimierz Olszewski6, Buge Oz7, Lukas Plank8, Jozsef Timar9 
1Fingerland Institute of Pathology, Hradec Králové/Czech Republic, 2Oncology, 
Specialised Hospital of St Zoerardus Zobor, Nitra/Slovak Republic, 3University Clinic 
Golnik, Ljubljana/Slovenia, 4Medical University of Gdansk, Gdansk/Poland, 5Meir Medical 
Center, Kfar Saba/Israel, 6Institute of Oncology, Warsaw/Poland, 7Cerrahpasa Medical 
Faculty, Istanbul/Turkey, 8Comenius University Jessenius Medical Faculty, Martin/Slovak 
Republic, 9Semmelweis University, Budapest/Hungary
Background: Information is lacking about molecular testing practices for NSCLC 
in Central and Eastern Europe; identification of the challenges for personalized lung 
cancer treatment within this region might facilitate strategies to overcome these and 
to improve patient care. Methods: A Working Group of oncologists, pulmonologists 
and pathologists from Central and Eastern Europe was established in order to get more 
information about NSCLC molecular testing used in these countries, technologies, 
patient selection, availability and other questions, and to raise greater awareness of 
the current issues around personalized medicine for lung cancer in this region. As a 
first step, a questionnaire including 37 questions about issues connected with NSCLC 
molecular testing and other aspects of NSCLC management was distributed in 2014 
to 59 specialists in different areas of NSCLC, including epidemiologists, oncologists, 
pulmonologists and pathologists. Results: In all, 25 experts from 9 countries (Bulgaria, 
Croatia, Czech Republic, Hungary, Israel, Poland, Slovakia, Slovenia, Turkey) responded. 
The responses show that there are some differences between the countries in the region 
and also between centers within countries with regard to NSCLC molecular testing. 
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detected ALK and ROS1 fusions by multiplex RT-PCR, and all fusions positive were verified 
by direct sequencing. The relationship between HER-2 mutations and clincopathological 
features and the prognostic effect of its status on disease free survival (DFS) were 
analyzed. Results: 21 of 398 (5.3%) harbored HER-2 mutations; 7.6% of 278 samples 
with triple-negative lung adenocarcinoma ( EGFR-, ALK-, ROS1-) were found to have HER-
2 mutations. 17 samples (81.0%) were A775_G776insYVMA, two with G776>VC, one with 
V777_G778insGSP and the last one with 2340_2341ins12 in-frame insertions of exon 20. 
59 of 398 (14.8%) were positive of HER-2 expression. No association was found between 
HER-2 mutations and expression, only two patients coexisted the positive in mutation 
and expression. There was no statistically significant difference in age, sex, smoking 
history, and pathological stage between patients with HER-2 mutations and those 
with negative patients. The DFS of patients with HER-2 mutations have no significant 
difference compared with those patients with negative mutations. Conclusion: 5.3% 
of Chinese lung adenocarcinoma with wild-type EGFR harbored HER-
2 mutations. The HER-2 mutations had no association with HER-2 expression. 
Keywords: lung adenocarcinoma, HER-2 mutation, HER-2 overexpression, EGFR mutation
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P3.04-050 Detection of PIK3CA Mutations, including a Novel Mutation of 
V344G in Exon 4, in Metastatic NSCLC: A Retrospective Study of 139 FNA 
Cases Derek B. Allison, Mohammed T. Lilo, Susan Geddes, Ming-Tseh Lin, Edward 
Gabrielson, Frederic Askin, Qing Kay Li Pathology, Johns Hopkins Medical Institutions, 
Baltimore/MD/United States of America
Background: Several molecular alterations of PIK3CA (phosphatidylinositol-4,5-
biphosphate 3-kinases, catalytic subunit alpha) signaling pathways have been detected 
in primary non-small cell lung carcinoma (NSCLC). These include genomic amplifications 
of the regulatory subunit p85 and the catalytic subunit p110 alpha, as well as mutations 
of the helical binding domain on exon 9 and the catalytic subunit on exon 20. A mutation 
in the PIK3CA gene is a much rarer event than amplification in NSCLCs (approximately 
2% in primary NSCLCs). The clinical significance of PIK3CA mutations in carcinoma 
is still not fully understood and is controversial. For example, some have suggested 
that PIK3CA mutations are associated with a favorable prognosis in breast cancer, 
while others have found PIK3CA mutations to be associated with a poor prognosis 
in primary lung cancers. Additionally, PIK3CA alterations have been associated 
with EGFR, KRAS and AKTmutations in primary NSCLC. In this study, we have collected 
FNA specimens of metastatic NSCLCs, investigated PIK3CA mutations, and correlated 
the findings with other molecular results. Methods: We identified 139 fine needle 
aspiration (FNA) cases of metastatic NSCLC with targeted next-generation sequencing 
(NGS) analyses of AKT, BRAF, EGFR, ERBB2, KRAS, NRAS, and PIK3CA genes, as well as 
testing for ALK gene rearrangements by fluorescence in situ hybridization (FISH) at the 
Johns Hopkins Medical Institute. Results:
Age Sex Location Diag-nosis
PIK3CAMuta-
tion (exon #) EGFR Mutation
BRAF-
Muta-
tion
KRAS-
Mutation
63 F LN ADC R88Q (1) (-) V600E (-)
69 M LN ADC V344G(4)
E709A
(-) (-)
G719C
53 F PL ADC V344G(4)
T790M
(-) (-)E746_
A750del
68 M LN NS-CLC E542K(9) (-) (-) (-)
58 M PL ADC E542K (9)
T790M
(-) (-)
L747_A750de-
linsP
S768_
V769delinsIL 
(S768I + 
V769L)
55 F Pelvic Bone SqCC E545K(9) (-) (-) (-)
74 F LN ADC P539R(9) (-) (-) G12C
60 M PR ADC H1047R(20)
T790M
(-) (-)L858R
K860I
 
LN: Lymph node; PL: Pleural fluid; PR Peritoneal fluid. (-): not 
detected. Conclusion: PIK3CA mutation was detected in 5.8% of metastatic NSCLCs. 
The majority of the mutations were located on exon 9 or exon 20; however, a rare 
mutation in exon 1 was seen in one case. Further, a novel mutation, to our knowledge, 
for NSCLC was detected (V344G) in exon 4 in two cases. Among PIK3CA mutations, 
50.0%, 12.5%, and 12% were associated with EGFR, BRAF, and KRAS mutations, 
Background: Lung Cancer is the first cause of cancer related death in Argentina being 
Adenocarcinoma the most frequent histology. The incidence of EGFR mutations is 13% 
but there isn’t data regarding other molecular abnormalities. The objective is to study the 
prevalence of EGFR, BRAF and KRAS mutations together with ALK and MET overexpression 
in consecutive adult patients with advanced lung adenocarcinoma. Methods: Pts with 
tumor biopsy and candidates for treatment who consented were included. Specific sites 
regarding each gene were analyzed with PCR and Sanger sequencing: KRAS exon2 
(G12V/S/D/A/C/R, G13D, V14X, G15X); EGFR exons 18 (G719C/S/A, V689M, E709K/Q, 
S720P), 19 (deletions and insetions 746-759), 20 (T790M, D700_N771, V769L, 
S768I,V765A, T783A) and 21 (L858R,L884Q, G863D,N826S, A839T, K864R) and BRAF 
exon 15 (V600E, D594M,N709K/Q and S720P) and 11 . IH for ALK was performed with 
5A4 Mo Ab and CMET with C-12-sc-10 Mo Ab. CMET 2+/3+ and ALK 3+ were considered 
positive, ALK positive samples were confirmed by FISH. Results: From May 2012 to 
December 2014 119 patients signed the informed consent, 107 pts with at least one 
mutational and/or IH analysis were included and 12 pts were excluded due to other 
histologies or inadequate material. Median age was 63 years (32-82), male/female 
61/46, smoker/former/never 37 (34%)/50 (47%)/20 (19%). Complete mutational and 
IH analysis was performed in 85 pts(79,5 %), 3 had incomplete analysis (3,75 %) , and 
19 only IH (17,75%). Complete molecular testing was achieved in 90% of surgical and 
36% of imaging guided biopsies. KRAS was mutated in 18/85 pts (21%): 12 in codon 
12 and 6 in codon 13. EGFR was mutated in 15 pts (15%), 11 (13%) harbored EGFR tki 
responding mutations: 1 exon 18 (E709K), 1 exon 20 (V765A), 4 in exon 21 (3 L858R 
and 1 G863D) and 5 have exon 19 deletions. Exon 20 insertions (D770_N771 and 
V774_c775) conferring EGFR tki resistance were detected in 2 patients (2%). One BRAF 
mutations were detected in exon 11 (G469A). ALK IH was 3+ in 2/107 (2%) and CMET 
were positive in 57 % (43% 2+ and 14% 3+) of 106 samples tested. In the 85 patiens 
where all test were performed the prevalence of KRAS mutations was 21 %, EGFR 15 %, 
BRAF 1,2 % and ALK 2,4 %. Conclusion: The molecular analysis of multiple molecular 
markers in lung adenocarcinoma in an academic center in Argetnina is feasible. The 
amount of tumor obtained from non surgical biopsies is frequently inadequate for 
full evaluation by this methods. The prevalence of BRAF, KRAS, EGFR mutations 
and ALK IHC is similar to larger series in other western countries 
Keywords: Adenoarcinoma, Molecular analysis.
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P3.04-048 Rare Gene Mutations in Japanese Surgically Resected Non-Small-
Cell Lung Cancer Patients Teppei Nishii1, Tomoyuki Yokose2, Yohei Miyagi3, Yataro 
Daigo4, Tomohiko Matsuzaki1, Masashi Nagata1, Tetsuya Isaka1, Hideyuki Furumoto1, 
Hiroyuki Ito1, Saki Manabe1, Shuji Murakami1, Tetsuro Kondo1, Haruhiro Saito1, Kouzo 
Yamada1, Munetaka Masuda5, Haruhiko Nakayama1 1Department of Thoracic Oncology, 
Kanagawa Cancer Center, Yokohama/Japan, 2Department of Pathology, Kanagawa Cancer 
Center Hospital, Yokohama/Japan, 3Molecular Pathology and Genetics Division, Kanagawa 
Cancer Center, Yokohama/Japan, 4Department of Medical Oncology and Cancer Center, 
Shiga University of Medical Science Hospital, Otsu/Japan, 5Department of Surgery, 
Yokohama City University Graduate School of Medicine, Yokohama/Japan
Background: Driver gene mutations except for EGFR are rare in Japanese population. In 
this study, we investigated EGFR, KRAS, BRAF and PIK-3 mutations in surgically resected 
non-small-cell lung cancer (NSCLC). Methods: A total of 388 consecutive patients with 
NSCLC who underwent complete tumor resection in our hospital from 2006 through 
2008 were studied retrospectively. Formalin-fixed, paraffin-embedded tissue sections 
were used to isolate DNA from carcinoma lesions. Mutational analyses of EGFR, KRAS, 
BRAF and PIK-3 were performed by loop-hybrid mobility shift assay, a highly sensitive 
polymerase chain reaction-based method. Results: We identified 185 EGFR mutations 
(47.7%), 33 KRAS mutations (8.5%), 3 BRAF mutations (0.77%), and 4 PIK-3 mutations 
(1.03%). In patients with BRAF mutation, all three patients were adenocarcinomas and 
smokers. There was no mutual mutation with EGFR and KRAS. PIK-3 mutations include 2 
adenocarcinomas and 2 squamous cell carcinomas. Three of 4 patients were smoker. 
We found one PIK-3 and EGFR double mutation case. Conclusion: In Japanese surgically 
resected NSCLC, there are a lot of EGFR mutations, but there was little KRAS mutation. 
Although new molecular targeted therapy is expected, BRAF and PIK-3 mutations were 
very rare. Highly smoking rate in patients with KRAS and BRAF mutations was not different 
from past reports, but we could not find other clinical characteristics. Histopathologically, 
correlation between PIK-3 mutation and small cell carcinoma is attracting attention 
recently. In this study, histological types of cases with PIK-3 mutation were various. 
Keywords: PIK-3, Non-small-cell lung cancer, BRAF
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P3.04-049 HER-2 Mutations in Chinese Lung Adenocarcinoma Patients 
with Negative EGFR Mutations Caicun Zhou1, Xuefei Li2, Chao Zhao2, Shengxiang 
Ren1, Chunxia Su1 1Department of Medical Oncology, Shanghai Pulmonary Hospital, 
Tongji University; Tongji University Medical School Pulmonary Cancer Institute, Shanghai/
China, 2Lung Cancer and Immunity Laboratory, Shanghai Pulmonary Hospital, Tongji 
University; Tongji University Medical School Pulmonary Cancer Institute, Shanghai/China
Background: To determine the prevalence and clinicopathological features of epidermal 
growth factor receptor 2 (HER-2) mutations in Chinese lung adenocarcinoma patients 
with negative EGFR mutations. Methods: Formalin-fixed and paraffin-embedded (FFPE) 
tissue sections from 398 lung adenocarcinoma patients with wild-type EGFR were 
screened for HER-2 mutations by amplification refractory mutation system (ARMS) assay 
and all HER-2 mutations were validated by direct sequencing. The protein expression of 
HER-2 was evaluated by immunohistochemistry (IHC). Of the 398 samples, 331 were also 
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determine how best to identify specifi c validated treatment targets, and to determine 
mutation load in clinical samples. Methods: We extracted DNA from 0.6 mm tissue 
cores selected both from tumor rich regions of paraffi n blocks and normal lung tissue. 
DNA quality was assessed by Bioanalyzer and Qbit testing. A sequencing library was 
prepared using the Agilent Sure Select XT5 (v5) library kit. DNA was sequenced using 
an Illumina Hiseq 2500 ultrahigh throughput sequencing system. We used two fl ow cells 
for each of 4 samples to obtain a high level of coverage and to determine the effect of 
reducing coverage on mutation detection by computational methods. We used the DNA 
from non-tumoral regions to identify genomic polymorphisms and to then compile lists of 
mutations that were suspected of have a deleterious effect on the host. As a control, we 
tested DNA from each tumor by a clinically validated multiplexed panel (Illumina True Site 
panel). We compared our sequencing results with the TCGA database for the respective 
tumors. Results: DNA yield was 13 and 17 micrograms for the SCC and adenocarcinoma 
respectively. After shearing to 200 base pairs and library preparation, excellent quality 
DNA was obtained for sequencing. All of the mutations detected by Miseq analysis were 
detected by WES. Several mutations identifi ed by WES have not been documented in 
TCGA. The mutations of the two tumors are sumarized below, including mutation load.
WES Mutations SCC Adenocarcinoma
Nonsynonomous SNV 247 51
Stopgain SNV 16 1
Fs deletion 10 1
Non-fs substitution 9 7
Fs insertion 2 2
Non-fs deletion 1 3
Non-fs insertion 1 0
Stoploss SNV 1 0
Splice region abnormality 9 0
Not present in TCGA 37 7
Present in TCGA 265 59
Mutations detected by Miseq TP53 (p.G245R) EGFR exon19 del CTNNB1 (p.S45C)
Total (Mutation Load) 302 66
Conclusion: This study confi rms that WES is feasible on FFPE tissue and that 
the two tumors sequenced fall into the two categories, high and low mutation 
loads. The mutations identifi ed include several that have not previously 
been reported. All mutations identifi ed by high coverage clinical platforms 
were also detected by WES. WES may be suitbable for clinical application. 
Keywords: next generation sequencing, Mutation load, Whole exome sequencing (WES), 
Sequencing archival tissue
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-053 SPECTAlung: Screening Patients with Thoracic Tumors for Effi cient 
Clinical Trial Access Benjamin Besse1, Jessica Menis2, Julien Adam3, Thierry 
Berghmans4, Tanja Cufer5, Rafal Dziadziuszko6, Enriqueta Felip7, Stephen P. Finn8, 
Ludovic Lacroix3, Julien Mazières9, Peter Melgaard10, Silvia Novello11, Solange Peters12, 
Sanjay Popat13, Martin Reck14, Egbert Smit15, Johan Vansteenkiste16, Baktiar Hasan17, 
Jonathan Steuve18, Emilie Varin18, Denis Lacombe18, Rolf Stahel19 1Gustave Roussy 
Cancer Campus, Villejuif/France, 2Medical Department, Eortc Headquarters, Brussels/
Belgium, 3Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, 
Villejuif/France, 4Intensive Care and Thoracic Oncology, Institut Jules Bordet, Brussels/
Belgium, 5Medical Faculty, University Clinic Golnik, Lubjana/Slovenia, 6Department 
of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk/Poland, 7Vall 
D’Hebron University Hospital and Vall D’Hebron Institute of Oncology (Vhio), Barcelona/
Spain, 8University of Dublin, Trinity College and St. James’S Hospital, Dublin/Ireland, 9Hôpital 
Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse/France, 10Medical Oncology, 
Aarhus University Hospital, Aarhus/Denmark, 11Department of Oncology, University of Turin, 
Aou San Luigi, Orbassano/Italy, 12Department of Oncology, Centre Hospitalier Universitaire 
Vaudois (Chuv), Lausanne/Switzerland, 13Department of Medicine - Lung, Royal Marsden 
NHS Foundation Trust, Surrey/United Kingdom, 14Lungclinic Grosshansdorf, Grosshansdorf/
Germany, 15VU University Medical Center,, Amsterdam/Netherlands, 16Department of 
Pneumology University Hospital Gasthuisberg, Kul Leuven, Leuven/Belgium, 17Statistical 
Department, Eortc Headquarters, Brussels/Belgium, 18Eortc Headquarters, Brussels/
Belgium, 19University Hospital Zürich, Zurich/Switzerland
Background: The identifi cation of molecular alteration and its targeting has completely 
changed the treatment and prognosis of lung cancer. However, designing and implementing 
clinical trials in small subsets of patients with a particular molecular alteration is challenging 
because of lack of uniform screening program. Across Europe, screening for molecular 
alterations is center or country dependent and, generally limited to a small subset of genes.
SPECTAlung is the fi rst European standardized, quality-assured molecular screening 
program of the European Organization for the Research and Treatment of Cancer 
(EORTC) in collaboration with the European Thoracic Oncology Platform (ETOP) to 
respectively. In contrast to primary NSCLC, we did not fi nd any metastatic cases 
to contain both PIK3CA and AKT mutations. The unique role of PIK3CA mutation in 
metastatic NSCLC and its clinical implications need to be further investigated. 
Keywords: metastatic non-small cell lung cancer, molecular testing, PIK3CA mutation, 
fi ne needle aspiration
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P3.04-051 Molecular Testing on Cell Blocks Formed From Bronchial Brush 
Tip Washing Asha Bonney1, Michael Christie2, Anne Beaty2, Louis B. Irving1, Daniel 
P. Steinfort1 1Respiratory Medicine, Royal Melbourne Hospital, Melbourne/VIC/
Australia, 2Anatomical Pathology, Royal Melbourne Hospital, Melbourne/VIC/Australia
Background: With the rapid growth of genotype guided targeted therapies, molecular 
testing is increasingly important for the routine work up in lung cancer. This testing is 
traditionally performed on biopsy specimens. Bronchoscopy is commonly performed 
for diagnosis of suspected lung cancer; and multiple sampling modalities are often 
combined to maximize diagnostic yield. Bronchial brushings are frequently reported to 
have the highest sensitivity, though the cytology smears generated from these brushings 
are rarely used for molecular analysis. The aim of this study was to assess the feasibility 
and accuracy of molecular testing performed on cell blocks (CB) formed from a brush 
tip wash (BTW). Methods: We retrospectively reviewed molecular testing performed on 
CB from BTW in patients undergoing investigation of peripheral lung lesions between 
January 2014 and March 2015. During bronchoscopy, brushings were performed and 
smears created. Following this, the brush tip was then washed in normal saline. This was 
repeated each time the peripheral lesion was sampled with the bronchial cytology brush. 
The fl uid from the BTW was then processed into a formalin fi xed paraffi n embedded CB. 
Patients were included in the study cohort if molecular testing was attempted on the CB 
created from BTW. The CB specimens underwent molecular testing targeting regions on 
BRAF (exon 15), KRAS (exon 2,3,4), NRAS (exon 2,3,4), PIK3CA (exon 9. 20) and EGFR 
(exon 18, 19, 20, 21) genes by amplicon-based parallel sequencing using an Illumina 
MiSeq. Results: There were 22 patients in whom BTW CB was subjected to molecular 
testing. Results are summarized in fi gure 1
.  
Figure 1. Results of molecular analysis In fi fteen cases (68%) a CB was generated, and 
was successfully subject to molecular testing. Fourteen of these were adenocarcinomas, 
in which the frequency of detecting a mutation in any of the fi ve assayed genes was 
57% (8/14). This is similar to previous reports of molecular testing on adenocarcinoma 
from other sampling modalities, and suggests that BTW CB generally contain adequate 
tumour cells for testing. In seven cases, there was no diagnosis obtained from 
transbronchial lung biopsy, meaning BTW was the sole specimen available for molecular 
testing. Conclusion: Our results demonstrate that molecular studies can successfully be 
performed on cell blocks obtained from brush tip wash and that this may be the only sample 
that has adequate material for analysis. We suggest that brush tip washings be routinely 
created during bronchoscopy to maximize the likelihood of successful molecular testing. 
Keywords: molecular testing, brush tip wash, cell block, lung cancer
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P3.04-052 Next Generation Exome Sequencing of Archival Lung Cancer 
Resection Specimens Chad M. Vanderbilt1, Kenneth Jones2, Mark W. Geraci3, Bifeng 
Gao3, John Mitchell4, Michael Weyant4, Wilbur A. Franklin1 1Department of Pathology, 
University of Colorado Som, Aurora/United States of America, 2Biochemistry and Molecular 
Genetics, University of Colorado Som, Aurora/CO/United States of America, 3Department of 
Medicine, University of Colorado Som, Aurora/CO/United States of America, 4Department of 
Surgery, University of Colorado Som, Aurora/CO/United States of America
Background: Genetic testing of non-small cell lung cancer has grown rapidly in recent 
years to accommodate expansion of the number of agents with molecular targets. 
Whole exome sequencing (WES) has been proposed as a method to comprehensively 
assess tumor mutation status that could replace current piecemeal approaches to 
predictive testing. The feasibility of WES for formalin fi xed paraffi n embedded (FFPE) 
clinical samples has recently been documented. However, several issues remain to 
be resolved before this platform can be adopted for routine clinical use. The purpose 
of the present study is to evaluate tissue coring as a method for obtaining DNA from 
FFPE tumor tissue, to assess the gene coverage of libraries prepared from FFPE, to 
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expression but also structural variants such as alternative splicing, fusion products or 
mutations. The full utilization of the multi-level information will facilitate personalized 
medicine. Although single nucleotide mutations (SNVs) can be more easily identified 
from RNA-seq, intermediate insertions/deletions (indels) exert significant bioinformatics 
challenges as RNA-seq data is much more complex as a result splicing and most RNA-
seq alignment programs do not align reads with gap well and variant callers designed 
for DNA-seq are not adequate for RNA-seq, which leaves most of important indels 
undetected. Methods: We evaluated commonly used RNA-seq analysis programs TopHat, 
BWA, BWA-MEM, STAR, and GSNAP along with single sample variant and paired tumor/
normal somatic mutation callers GATK, VarScan, MuTect, JointSNVmix, SomaticSniper 
in a set of lung adenocarcinomas with known single nucleotide and indel (from 15 to 19 
bases) mutations from exome-seq data. We aimed to develop highly sensitive and specific 
strategies for both single nucleotide and longer indel mutations that are important to 
clinical actions. Results: The alignment is the critical step for longer indel identification 
and the evaluated programs had a wide range of sensitivity to map sequence reads with 
indels, ranging from not at all (TopHat with either Bowtie 1 or 2) to a decent number 
of reads mapped if sequence reads are long (GSNAP). The sensitivity was significantly 
impacted by sequence lengths (50bp vs 100bp) or if gapped alignment was explicitly 
used. When sufficient reads with indels were aligned, most variant calling programs 
were able to detect the indels with varied sensitivities except MuTect which only single 
nucleotide mutations were reported. Specificity was highly filtering criteria dependent. 
We implemented and recommended different strategies for the indel detection 
depending upon which alignment program was used. For TopHat alignment, unmapped 
reads were realigned with BWA-MEM; alignments from STAR or GSNAP were further 
processed following RNA-seq variant detection best practice. With these strategies, we 
demonstrated high accuracy in SNV or somatic mutation detections in RNA-seq data 
compared with exome-seq data and known mutations validated from other technologies 
in lung adenocarcinoma datasets. With the information, a more comprehensive genomic 
aberration characterization can be made to each individual tumor for clinical decision 
making. Conclusion: With careful modifications and customization to bioinformatics 
algorithms, RNA-seq data can be reliably used for both single nucleotide and long 
indel detection that can be used for treatment selection and outcome prediction. 
Keywords: Bioinformatics, RNA sequencing, long insertion deletion, EGFR
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P3.04-056 Some Lung Cancer Patients End up without an EGFR-Mutation 
Analysis Janna Berg1, Pål Suhrke1, Lars Fjellbirkeland2, Odd Terje Brustugun3, 
Åslaug Helland3 1Dept. of Medicine, Vestfold Hospital Trust, Tønsberg/Norway, 2Dept.
Of Pulmonology, Oslo University Hospital-Rikshospitalet, Oslo/Norway, 3Dept of Oncology, 
3Oslo University Hospital-Radiumhospitalet, Oslo/Norway
Background: Lung cancer patients with activating mutations in the EGFR-gene are eligible 
for targeted therapy with tyrosine kinase inhibitors, and clinicians strive for acquiring 
enough tumor tissue for the needed diagnostic analyses. However, not all patients have 
an EGFR-test, and little is known about the subsequent steps for patients with inadequate 
first biopsy. Methods: Data on the diagnostic work-up on all NSCLC patients eligible for 
EGFR-testing was collected at a medium-sized Norwegian hospital for the period June 
2010 to December 2013. For samples without successful EGFR-mutation results, we 
recorded possible explanations. Results: Material was sent for EGFR analysis for 256 of 
the 304 eligible patients diagnosed in the period. For a total of 34 patients (13%) the first 
biopsy was not analyzed at the department of molecular pathology due to inadequate 
tumor material. Of these 34 patients, 23 (65%) had no new sample submitted for analysis. 
13 of the 23 (57%) were in stage IV, and of these, three did not want active treatment 
and one was not a candidate for active treatment because of poor general condition. One 
patient was not  re-biopsied due to rapid disease progression. Eigth patients were for no 
obvious reason never considered for re-biopsies, including a younger patient who had 
brain metastases at the time of diagnosis, but who lived for 19 months after diagnosis. 
One of the 11 sent was diagnosed with activating EGFR mutation in the second sample 
sent for analyses. For patients with rejected samples, EGFR results were available 
after 17 - 69 days (median 38) from rejection of the first sampling. Conclusion: For 
65% of the rejected samples, no new samples were submitted for analysis. 57% 
of the patients with no new sample taken, were in stage IV. When a new biopsy was 
planned, our study shows that EGFR results from the new sampling were available after 
median 38 days. For this patient group, with poor prognosis and often rapid disease 
progression, one should strive for a new sampling and a quicker turn-around time. 
Keywords: Pathology, lung cancer, EGFR mutation
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P3.04-057 Pyrosequencing VS NGS KRAS and EGFR Mutation Detection:  
A Head to Head Comparison in Lung Adenocarcinomas Antonios Papanicolau-
Sengos, Jeffrey Conroy, Hanchun T. Defedericis, Carl D. Morrison Pathology, Roswell 
Park Cancer Institute, Buffalo/United States of America
Background: Pyrosequencing is a popular method for detecting actionable somatic 
mutations. Most labs use pyrosequencing at an analytical sensitivity of 10%, potentially 
missing actionable mutations that have a low variant allele frequency (VAF) due to low 
neoplastic nuclear content or due to neoplastic heterogeneity. Furthermore, the cost-
effectiveness of pyrosequencing rapidly decreases when numerous hotspots are 
interrogated simultaneously and scaleability is limited. Next-generation sequencing 
(NGS) is scaleable and has the capacity to detect mutations at VAFs less than 10%. 
The goals of this study were to perform NGS on a series of KRAS and EGFR cases 
that were “mutation negative” but had suspicious pyrosequencing peaks which were 
facilitate clinical trial access for patients with thoracic tumors. It is expected to test 
500 to 1000 patients each year with the overall goal of offering patients clinical trials 
with targeted agents. Methods: Patients sign the informed consent for their tumor 
tissue to be collected, centralized and processed according to defined international 
quality control standards at Gustave Roussy Biobank (Villejuif, France). Next Generation 
Sequencing (NGS) is performed at Sanger Institute (Cambridge, UK) where a panel of 
about 360 genes is analyzed for mutation, rearrangements and gene copy number. 
Eligible patients will be those having a pathological diagnosis of any thoracic 
tumor (lung cancer, malignant pleural mesothelioma and thymic malignancies) at 
any stage of disease, availability of tumor tissue, age at least 18 years, PS 0-2, life 
expectancy > 3 months, no active malignancy in the 5 years before study entry 
and absence of any exclusion criteria that may prevent inclusion into clinical trials. 
A molecular report will be released to the investigator highlighting identified 
molecular alterations and also the trials for which the patients might be eligible. 
The study has been submitted to ethical committees of 15 selected highly specialized 
and qualified thoracic centres in 12 countries in Europe. EORTC and ETOP will promote 
the implementation of clinical trials in molecularly selected groups of patients at the 
SPECTAlung centers. SPECTAlung offers innovative and attractive models of collaboration 
with commercial and research organizations, by improving patient access to novel 
therapeutic clinical trial and support the development of personalized medicine. Clinical 
trial registry number NCT02214134. Results: Not applicable Conclusion: Not applicable 
Keywords: clinical trial, biomarker, thoracic tumor, Screening
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P3.04-054 Validation of PTEN and c-MET Status in Small Biopsy Material 
and Cytology for Pulmonary Adenocarcinoma Dimple Pandya, Achim Jungbluth, 
Natasha Rekhtman, Andre Moreira Pathology, Memorial Sloan-Kettering Cancer Center, 
New York/NY/United States of America
Background: Targeted therapy in lung cancer is an expanding field. Molecular 
alterations in phosphatase and tensin homolog (PTEN) and c-MET (mesenchymal 
epithelial transition proto-oncogene) are potential therapeutic targets. Loss of PTEN 
expression has been associated with activation of PIK3CA/AKT/mTOR pathway and is 
associated with sensitivity to mTOR inhibitors. Amplification or overexpression of c-MET 
is associated with resistance to tyrosine kinase inhibitors and/or poor prognosis. Both 
PTEN and c-MET can be detected by immunohistochemistry. In this study we evaluated 
the concordance rate of both antibodies in biopsy material and subsequent excision of 
the same tumor, since small biopsy and cytology material are the only tissue available 
for diagnosis in patients with advanced stage. In addition since biopsy material is 
collected in different fixatives, we also compared the antibody expression in alcohol 
versus formalin fixed tumors. Methods:Pathology database was queried for concurrent 
biopsy and surgical specimens from 12/2010-7/2014. Surgical core biopsies (n=44) and 
cytology aspiration biopsies (n=10) with surgical specimens were reviewed to evaluate 
tumor histology and specimen cellularity. In addition, 8 cases of NSCLC were scrapped 
and collected in formalin and alcohol fixative. Immunohistochemistry with PTEN 
antibody (clone 138G6) and c-MET antibody (clone sp44) were performed according 
to manufactures’ instruction following a rigorous validation using positive and negative 
controls. PTEN staining was evaluated for complete loss of expression or retention 
(any cytoplasmic or nuclear stain). c-MET staining was evaluated for the intensityand 
extent of the staining. Positivity is defined as a strong membranous staining (2-3+) in 
more than 50% of the tumor cells. Results: There was a 90% (19/21) concordance 
for PTEN expression between biopsy and resection (k=0.76). 6 cases showed loss 
of expression in the biopsy, among these cases 2 were classified as retained PTEN 
in the excision. In both cases the excision specimen had partial loss of PTEN. Partial 
loss of PTEN was seen in 3 other cases with retained PTEN in biopsy. There is a 95.2% 
(20/21) concordance in c-MET staining (k=0.89). In the discrepant case, the biopsy 
was deemed positive (2+ > 50% of tumor cells), with a negative excision (1+ >70% of 
tumor cells). For the cases that were fixed in alcohol and formalin there was a 62% (5/8) 
concordance for PTEN (k=0.37). 3 cases showed loss of expression in alcohol fixed 
tissue but retention in formalin fixed material. There was a 37% (3/8) concordance for 
c-MET between the two fixatives (k=0.21). In the 5 discordant cases, c-MET expression 
was interpreted as negative in alcohol fixed but was considered positive in formalin 
fixed tissue due to variability in the intensity of staining. Conclusion: Despite a good 
correlation between biopsy and resection for both markers, our results show there is 
a greater possibility of discrepant results for PTEN than c-MET because of geographic 
heterogenetic of expression and scoring criteria. The type of fixative (alcohol vs. 
formalin) is associated with variability in antibody expression. Therefore evaluation 
of PTEN and c-MET staining in biopsy material and alcohol fixed tissue should be 
interpreted with caution, especially when designing clinical trials for potential therapy. 
Keywords: c-Met, Immunohistochemistry, Adenocarcinoma, PTEN
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P3.04-055 Accurate Strategies to Detect Clinical Important Long Indels from 
RNA-Seq Data: EGFR as Example Zhifu Sun1, Naresh Prodduturi1, Aditya Bhagwate1, 
Jinsung Jang2, Jin Jen2, Ping Yang1, Jean-Pierre Kocher1 1Health Sciences Research, Mayo 
Clinic, Rochester/MN/United States of America, 2Medical Genome Facility, Mayo Clinic, 
Rochester/United States of America
Background: Somatic mutations are driver for tumor development and tumor 
characteristics that can be used for diagnosis and targeted therapy. These mutations 
are mostly detected from tumor DNA. As dynamic molecules of gene activities, 
transcriptome by RNA-seq is increasingly popular, which not only measures gene 
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(cobas® EGFR Mutation Test, Roche), all negative were than tested for KRAS mutations 
(cobas® KRAS Mutation Test, Roche), and double negative samples were than tested 
for ALK mutation using immunohistochemistry (IHC) (clone D5F3, Ventana). Results: Out 
of 387 samples 57 had EGFR mutation (14.72%). Most common mutation was exon 19 
deletion (23/57, 40.35%), while 8/57 (14.04%) had two simultaneous mutations. KRAS 
mutations were present in 158 samples out of 330 samples that were tested (47.88%). 
ALK immunohistochemistry was performed on 172 double negative samples, resulting 
in 12 positive cases (6.98%). When calculating with the whole cohort, we had 14.72% 
of EGFR positive cases, 40.82% with KRAS mutations and 3.10% of ALK IHC positive 
cases. Conclusion:gene changes rates in EGFR and ALG gene are in Croatian lung 
cancer patients in concordance with previously reported rates in Caucasian population, 
while KRAS rates are higher than previously reported. For the first time, rates of genetic 
changes are reported for representative sample of purely Caucasian Croatian population. 
Keywords: EGFR, ALK, KRAS, Croatia
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P3.04-060 Non Small Cell Lung Cancer in Women: Identification of Molecular 
Biomarkers Towards Sex Specific Tailored Treatments Tiziana Vavala, Valentina 
Monica, Marco Lo Iacono, Teresa Mele, Elisa Gobbini, Luisella Righi, Mauro Papotti, 
Giorgio V.V. Scagliotti, Silvia Novello Department of Oncology - University of Turin, Thoracic 
Oncology Unit, Orbassano/Italy
Background: Lung cancer is the leading cause of cancer mortality in both men and 
women in more developed countries, with a four-fold increase in lung cancer in women 
in US over the past 30 years. This was confirmed in Europe where, in the last 5 years, 
lung cancer mortality fell in men (−6%) and increased in women (+7%). Several studies 
documented sex differences in lung cancer in terms of clinical presentation, survival, 
pathological patterns and treatment related toxicities; younger age at diagnosis, higher 
frequency of adenocarcinoma histology, different metabolism of tobacco-related 
carcinogens, differential gene expression are commonly seen in women. Furthermore, 
previous studies showed in female gender the expression of functional aromatase 
enzyme in lung tumor tissues as well as the interaction between Estrogen Receptors 
(ERs) and Epidermal Growth factor Receptor (EGFR) pathways in lung cancer cells. 
The aim of this study is to collect a prospective series of advanced stage non small 
cell lung cancers (NSCLC), to identify, through the Next Generation Sequencing (NGS) 
technology, potential gender sex differences of selected tumor-associated genes, 
assessing their both mutational status and gene expression levels. Methods: One 
hundred patients, including 50 women and 50 men, with newly diagnosed stage IV 
NSCLC will be prospectively enrolled. Smoking history, clinical and anamnestical data will 
be collected for all patients. Female patients will also provide obstetrical-gynecological 
anamnesis, while men will provide urological one, if present. Formalin fixed, paraffin 
embedded diagnostic sample of each patient will be collected and sectioned to obtain: 
a DNA genomic library to define the mutational profile of a selected panel including 
50 tumor-associated genes, a mRNA library to obtain gene expression levels of the 
corresponding transcripts and protein expression of estrogen receptor Beta (ERß) and 
DNA repair enzyme ERCC1. Immunohistochemistry reaction, for both ERCC1 and ERβ, 
will be scored according to the H-score method. NGS analyses will be performed by 
means of the Ion Torrent Personal Genome Machine (PGM, Life Technologies, Grand 
Island, NE). Tumor tissues will be tested with commercial library kits: Ion AmpliSeq 
Cancer Hotspot Panel v.2 to investigate 50 cancer-associated genes and significant gene 
variations will be further confirmed using Sanger Sequencing method; Ion AmpliSeq™ 
RNA Cancer Panel to define also gene expression of the same 50 cancer-associated 
genes (Life Technologies). Correlations among mutational profile, transcriptional pattern, 
protein levels and clinico-pathological characteristics will be assessed. Results: Not 
Applicable Conclusion: Lung cancer incidence in women is increasing worldwide and 
genetic predisposition, sex hormones or specific molecular features could all account 
for the clinical differences observed between females and males. Up to the current 
date, the clinical approach to lung cancer treatment does not rely on gender. The 
identification of differential status of specific biomarkers can deepen knowledge on 
the molecular basis of this disease, guiding clinicians towards sex-based treatments. 
Keywords: NSCLC, Women, Gender differences, lung cancer
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P3.04-061 Thoracic Oncology Clinic: Our First 200 Cases, San Jose, Costa 
Rica Raquel Rojas Vigott, Luis Ugalde Gamboa, Luis Corrales-Rodríguez 
Oncology, CCSS, Cartago/Costa Rica
Background: Lung Cancer has been gaining interest in our country, because there is 
a higher number of cases and the capacity to make diagnosis and give opportunities 
of treatment t the patiens. As we give opportunities of treatment to th patients.As we 
realized, this is a complex pathology, and heterogeneous disease. For that reason, we 
decided three years ago, to orgnize a multidisciplinary approach for lung cancer patients 
and to obtain our own statistis. Methods: We reviewed 200 cases (files) and followed the 
patients during the last 3 years. (Retrospective study) Results: We attended 200 cases 
with teh diagnosis of lung cancer. The average age was 63 years old. 62% of patients 
were female. 68% patients had an adenocarcinoma histology, 17% squamus cell and 
10% Small Cell Lung cancer. 59% of patients were people who used to smoke, 41% never 
smoke. 69% were patients inn stage IV disease, 16% stage III (A,B) and 15% Stage I. 
From patients in stage IV, 73% received some medical treatment. We tested 100 patients 
who hat adenocarcinoma for EGFR mutation. 26% of the patients with adenocarcinoma 
had EGFR (+) ; 53% exon 19, 7% exon 20 and 34% exon 21. 9 patients have received 
treatment with Erlotinib. 6 of them have accomplished al least 10 months of PFS, and 
insufficient for a definite determination, and to review EGFR exon 19 deletion cases that 
were detected by NGS but missed by pyrosequencing. Methods: All the KRAS and EGFR 
pyrosequencing runs performed at Roswell Park Cancer Institute between July 2011 and 
November 2014 were manually reviewed. All actionable KRAS and EGFR variants that 
were found at a VAF of 4% or more and less than 10% and had remnant DNA were 
tested by a dual MiSeq/PGM platform NGS pipeline with a 3.6% VAF analytic sensitivity 
for FFPE tissues. We also included EGFR exon 19 cases that had discrepant findings 
between NGS and pyrosequencing. Results: Six lung adenocarcinomas with suspicious 
KRAS pyrograms were reviewed. By NGS, 4/6 were found to have activating codon 12 
and 13 KRAS mutations (NGS VAF range 6-14%). Twelve lung adenocarcinomas with 
suspicious EGFR pyrograms or discrepant EGFR exon 19 pyrosequencing/NGS results 
were reviewed. By NGS, 4/12 were found to have actionable mutations, including 3 
exon 19 deletions (NGS VAF range 5-24%) and 2 T790M resistance mutations (NGS 
VAF range 4-5%). Conclusion: Pyrosequencing lacks the analytic sensitivity to detect 
actionable KRAS and EGFR mutations with very low VAF and can entirely miss EGFR exon 
19 deletions, even at a high VAF. NGS and can be optimized to detect single nucleotide 
alterations with a VAF less than 5% and can reliably detect EGFR exon 19 deletions. 
The capabilities of NGS can translate into improved clinical validity and clinical utility. 
Keywords: NGS, pyrosequencing, EGFR, KRAS
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P3.04-058 Is Targeted next Generation Sequencing Superior to Older Methods 
at Identifying Actionable Mutations in Selected NSCLC Patients? Wendy Cooper1, 
Spiridoula Kraitsek2, Christina Selinger1, Thang Tran1, Maija Kohonen-Corish3, Steven 
Kao4, Sandra O’Toole1, Bing Yu2 1Tissue Pathology and Diagnostic Oncology, Royal Prince 
Alfred Hospital, Camperdown/NSW/Australia, 2Medical Genomics, Royal Prince Alfred 
Hospital, Camperdown/NSW/Australia, 3Kinghorn Cancer Centre and Garvan Institute of 
Medical Research, Darlinghurst/NSW/Australia, 4Medical Oncology, Chris O’Brien Lifehouse, 
Sydney/NSW/Australia
Background: Mutation testing for clinically actionable somatic mutations is standard of 
care for patients with lung adenocarcinoma. Multiplex cancer panels that simultaneously 
assess for a range of possible mutations are available for next generation sequencing 
(NGS) platforms covering a wider range of genes than previously available, but it 
is uncertain if these provide more clinically useful information than older multiplex 
systems. Methods: We undertook targeted next generation sequencing (NGS) of 
paraffin embedded tumour tissue from a cohort of 13 never smokers and 18 unselected 
patients who underwent surgical resection of lung adenocarcinoma using the Truseq 
Amplicon Cancer Panel that assesses hot spots in 48 genes using the Illumina platform. 
Control normal tissue was obtained from non-involved lymph nodes or normal lung 
parenchyma obtained from the resection specimens. Results were compared to 
those obtained using OncoCarta™ v1.0 panel that assesses hot spots in 19 genes 
using mass spectrometry. Results: 3 of the samples from the never smokers were 
unsuitable for NGS analysis as they failed quality control. Of the 10 samples that 
could be assessed, 6 (60%) had EGFRmutations (3 L858R and 3 exon 19 deletions), 1 
(10%) had a KRAS G12D mutation and 5 (50%) had T53 mutations (3 in association with 
an EGFR mutation). Other mutations identified were ATM, PTEN and PDGFRA mutations in 
one of the patients that also had an EGFR mutation. All of the EGFR and KRAS mutations 
were also identified using the OncoCarta™ panel. Of the 3 samples that could not 
be assessed by NGS, 1 had an exon 19 deletion in EGFR and 1 had a BRAF V600M 
mutation. In the unselected patient population all of the samples passed quality 
control and were suitable for both NGS and mass spectrometry. Using NGS, 
10/18 (55.6%) had a KRAS mutation, 3 (16.7%) had an EGFR mutation, 7 (38.9%) 
had aTP53 mutation, 2 (11.1%) had PIK3CA mutations and 1 (5.6%) each had a BRAF 
AF, ERBB4, MET, HRAS, STK11, HRAS, PDGFRA, CTNNB1, NOTCH1 or SMARCB1 mutation. 
Using the OncoCarta™ panel, all of the EGFR and KRAS mutations were identified along 
with only 1 of the PIK3CA mutations. The BRAF G469S mutation was not identified by 
mass spectrometry. Conclusion: NGS using a targeted cancer panel identifies more 
mutations than older generation multiplex mutation testing but has a higher failure 
rate. In the never-smoker patient group, no additional clinically actionable mutations 
were identified by NGS that were not found by the OncoCarta™ panel. In patient 
populations with a high rate of EGFR mutations, such as never smokers, there may not 
be much advantage to using more expensive broader NGS cancer mutation panels. 
Keywords: next generation sequencing, never-smoker, lung adenocarcinoma, mutation
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P3.04-059 Non-Small Cell Lung Cancer Mutation Analysis in Purely Caucasian 
Croatian Population Marko Jakopovic1, Luka Brcic2, Marija Misic3, Fran Seiwerth1, 
Gordana Drpa1, Branka Cucevic1, Sanja Plestina1, Suzana Kukulj1, Mihovil Roglic1, Silvana 
Smojver-Jezek1, Nabil Chalfe1, Sven Seiwerth3, Zoran Janevski1, Miroslav Samarzija1 
1University Hospital Centre Zagreb, Zagreb/Croatia, 2Institute of Pathology, Medical 
University Graz, Graz/Austria, 3Department for Pathology, Zagreb Medical School, Zagreb/
Croatia
Background: Molecular profiling in lung cancer patients is crucial before starting 
treatment. Driver mutations in EGFR and ALK genes are targets for tyrosine kinase 
inhibitors. Mutation rate in domain of EGFR, ALK and KRAS genes varies between 
populations of lung cancer patients. The aim of the study was to analyze rates of 
mutation in these genes in purely Caucasian Croatian population. Methods: Reflex 
testing was performed on all non-squamous NSCLC in a period of 6 months, regardless 
of staging and received therapy. There were altogether 387 patients with adequate 
(histological and cytological) material for testing. EGFR mutations were tested first 
S709Copyright © 2015 by the International Association for the Study of Lung Cancer
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P3.04-064 A 24h-Single Highthroughput Assay to Identify ALK or ROS-1 
Gene Fusions and EGFR Mutations in DNA from FFPE Tumor Samples or Free 
Circulating DNA Raphael Saffroy1, Jean-François Morere2, Nelly Bosselut1, Pasquale 
Innominato2, Catherine Guettier3, Antoinette Lemoine1 1Oncogenetics, Aphp Hups Paul 
Brousse Hospital, Villejuif/France, 2Medical Oncology, Hôpital Paul Brousse, Villejuif/
France, 3Pathology, Aphp Hups Paul Brousse Hospital, Villejuif/France
Background: The diagnosis of metastatic lung adenocarcinoma to decide tyrosine kinase 
inhibitors (TKI) targeting either EGFR mutations or ALK or ROS translocations requires 
the combination of several techniques and different biological or pathological expertises. 
These are DNA sequence analysis, immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH) that are performed independently and require time and DNA materials. 
Importantly, to our knowledge no diagnostic can be performed on extracted DNA from 
FFPE tumors for the identification of ALK or ROS translocations except FISH. FISH is 
considered as the gold standard technique for gene translocations but time-consumable 
and not applicable to highthoughput diagnosis. Some unsuccessful attempts have been 
made using RNA extracted from FFPE. Methods: We have developed and patented an 
assay using the i-plex technology and mass spectrometry detection (Sequenom-Agena 
Bioscience, CA, USA) allowing the concomitant identification of 20 targeted EGFR exon 
18-21 gene sequence abnormalities as well as variants of EML4-ALK (variants 1-2-3a-3b) 
or ROS1-SLC34A2/EZR/CD74 gene fusions on extracted DNA samples in a single 24h 
experiment. DNA has been extracted eitherfrom either FFPE tumor samples or plasma 
free circulating DNA. Results: DNA samples from 6 different patient can be analyzed 
on the same 96 wells-assay (more if a 384 well-assay). As low as 16ng DNA per sample 
from FFPE biopsies (10 slices) or plama can be used. We have applied this new panel to 
a cohort of 90 lung adenocarcinoma samples positive for EGFR mutations (n=30), ALK 
(n=30) or ROS (n=30) translocations; one third being extracted DNA from circulating 
plasma samples. The limit of detection of the assay is as low as 1 to 5% depending on 
the gene abnormality. When compared to IHC (EML4-ALK 5A4 clone; ROS1 D4D6 clone, 
Cell Signalling) / FISH techniques (Vysis LSI ALK Break Apart Rearrangement Probe Kit, 
Abbott; ROS1 Split FISH Probe, Abnova), the specificity of the identification of ALK or ROS 
gene rearrangements is 97%. Conclusion: In conclusion, we have developed a promising 
and performant assay based on an innovative methodology that we have patented for 
the identification in a single experiment of both gene mutations and gene translocations 
using very low amounts of DNA extracted from FFPE tumor biopsies or plasma samples. 
Keywords: FFPE tumor or free circulating DNA, Diagnostics, ALK or ROS rearrangments 
on extracted DNA, highthroughput assay
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P3.04-065 Use of next Generation Sequencing to Distinguish Origin of Poorly 
Differentiated Carcinomas in the Lung from Carcinomas in Other Organs 
Jens B. Sørensen1, Morten Grauslund2, Linea Melchior2, Edyta Urbanska1, Eric 
Santoni-Rugiu2 1Dept. Oncology, Finsen Centre/National University Hospital, Copenhagen, 
Copenhagen/Denmark, 2Pathology, National University Hospital, Copenhagen, Copenhagen/
Denmark
Background: Next generation sequencing (NGS) is a molecular analysis for 
concomitantly assessing several genes for mutations and other abnormalities. Thus, 
NGS can diminish costs and labour time compared to multiple analyses for individual 
mutations in Non Small Cell Lung Cancer (NSCLC), such as EGFR, ALK or ROS1 mutations. 
Another important use may be in diagnostic cases, in which it may be difficult to establish 
whether a tumor is a primary NSCLC, or represents a metastasis from another organ. 
Molecular[EMU1] events in every compared sample are assessed in order to find a possible 
gene constellation matching best the primary origin of the disease. This study describes 
experience with NGS used in this differential diagnostic process Methods: The NGS 
was performed on genomic DNA purified from formalin-fixed paraffin-embedded tumor 
tissue using the Ion Torrent PGM NGS sequenator and the Ion AmpliSeq Cancer Hotspot 
Panel version 2 covering the most common hotspot mutations in 50 cancer relevant 
genes. The sensitivity is 5% tumor cell nuclei and >500 reads for each amplicon was 
obtained. Results: The use of NGS technique as differential diagnostic tool is exemplified 
in a 77 year male who in 2010 had left renal R0 resection due to papillary urothelial 
cancer. In January 2015 he subsequently had right lung upper lobectomy for a 22-mm 
tumor (primary pulmonary adenocarcinoma, CK7- and TTF1-positive, no EGFR- and ALK-
mutations) and right lower lobe wedge resection of a 33 mm tumor (undifferentiated 
carcinoma of uncertain origin, CK7-positive, TTF1-negative). The clinical dilemma was 
concerning the possible postoperative treatment indication for this patient. Regarding 
these two lung tumours as an entire disease, it will be T4N0 and thus IIIA stage of NSCLC 
with strong indication for adjuvant treatment, despite of the age and one-kidney status. 
However, if these two resected lung tumours represent different cancers, the tumour in 
the upper lobe will be staged as IB (T2aN0) and possible benefit of adjuvant chemotherapy 
for this patient will be limited. NGS showed that each of these three tumors had one unique 
hotspot mutation, i.e. the urological tumor had BRAF mutation (c.1405_1406GG>TC, 
p.G469S), the right lung upper lobe tumor had KRAS mutation (c.35G>C, p.G12A), and 
the right lower lobe tumor had HRAS mutation (c.182A>G, p.Q61R). Thus, the theoretic 
possibility that the right lower lobe tumor was a metastasis from the urological tumor was 
not supported and the patient accordingly not considered as having metastatic relapse 
of the urological cancer, but two primary NSCLCs. Thus, the results did not provide a 
justification to recommend the adjuvant treatment for this patient. A series of NGS uses 
in the differential diagnostic process will be presented. Conclusion: NGS can examine 
simultaneously several DNA abnormalities such as EGFR mutations, ALK- and ROS1-
rearrangements, which all are of interest for treatment possibilities of NSCLC. 
However, in patients with NSCLC and a carcinoma in another organ, NGS may also be 
least 1.5 years of OS. Conclusion: We understand taht lung cancer is a complex disease 
and we are getting our first results of the multidisciplinary work in our hospital. We are so 
motivated to continue working in this paticular cancer and to understand the profile of our 
patients. The majority of our patients are in stage IV, nevertheless tha major part of them 
have the opportunity to receive some medical treatment. Testing for EGFR is now a routine 
exam, and the analisys of new targets (ALK) is our concern.In Costa Rica the incidence 
of EGFR positive is around 26%. We are analizing actual data in relation to OS and PFS. 
Keywords: Lung Cancer, Costa Rica, EGFR, 200 cases
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P3.04-062 Application of Molecular Detection of Lung Cancer in Developing 
Countries Aimin Zang, Youchao Jia, Yanhong Shang Department of Oncology, Affiliated 
Hospital of Hebei University, Baoding/China
Background: The era of personalized medicine of non-small cell lung cancer (NSCLC) has 
arrived. Gene detection plays a key role in the decision of clinical treatment for patients with 
adenocarcinoma at least. Access to those tests is still very limited in the developing countries, 
such as quality control, expenditure/cost and popularization. Methods: Individualized 
treatment of lung cancer, application of molecular detection in developing countries 
and challenges that high-quality molecular detection faces were all retrospectively 
reviewed. Results: The strategies certainly vary from country to country due to the 
differences of national conditions in developing countries. Individualized treatment based 
on molecular detection kits and targeted drugs has been a reality, and the subtypes 
of lung adenocarcinoma will emerge rapidly. Conclusion: Molecular epidemiology data 
generated by developing countries, as well as application of their emerging scientific 
and technologic capacities to generate and validate novel biomarkers and diagnostic 
kits, will certainly contribute to better treatment of patients with lung cancer worldwide. 
Keywords: carcinoma; non-small cell lung cancer; genes; developing countries
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P3.04-063 The Mutational Landscape of Pulmonary Premalignancy in the 
Context of Lung Adenocarcinoma Kostyantyn Krysan1, Linh Tran1, Atsuko Seki2, 
Tonya Walser1, Avrum Spira3, Michael Fishbein2, W. Dean Wallace4, Steven M. Dubinett1 
1Medicine, David Geffen School of Medicine at UCLA, Los Angeles/CA/United States of 
America, 2Pathology, David Geffen School of Medicine at UCLA, Los Angeles/CA/United 
States of America, 3Boston University, Boston/United States of America, 4Pathology, David 
Geffen School of Medicine at UCLA, Los Angeles/United States of America
Background: While genomic alterations in lung cancer are being actively investigated, 
the early mutational events that occur within the pulmonary field of cancerization that 
subsequently drive early carcinogenesis are poorly understood. As a result, the clinical 
importance of premalignant lesions remains enigmatic. Epithelial cells in the field of 
lung injury can give rise to distinct premalignant lesions that may bear unique genetic 
aberrations. A subset of these lesions may progress to invasive cancer, however the 
mutational landscape that may predict progression has not been determined. In the 
present study we performed whole exome DNA sequencing to measure the incidence 
of somatic DNA alterations in matched sets of primary tumor, premalignant lesions 
and adjacent normal lung tissues. Methods: FFPE tissue blocks from 41 patients were 
obtained from the UCLA Lung Cancer SPORE Tissue Repository. The following regions 
were dissected from distal airways utilizing Laser Capture Microdissection: a) normal 
airway epithelial cells (1-3 regions), b) premalignant atypical adenomatous hyperplasia 
(AAH, 2-4 regions), c) adenocarcinoma in situ (AIS, 1-3 regions) and, d) adenocarcinoma 
(ADC, 1-3 regions). DNA was extracted and sequencing libraries were constructed 
followed by exome capture. Sequencing was performed on an Illumina HiSeq2000 with a 
mean coverage of ~50x per base. Results: Data analysis included analyses for germline 
and somatic variants, loss of heterozygosity and copy number alternations. Within each 
case, position-specific missense and nonsense mutations were compared. Different 
cases were compared for the mutations at a gene-specific level. Mutations found only 
in AAH lesions were defined as premalignant, in ADC as malignant, and in both AAH 
and ADC as progression-associated mutations. The analysis demonstrated that AAH 
lesions from the same patient often have different mutational profiles. We identified novel 
recurring progression-associated mutations in 33 genes, most of which have not been 
previously described as key drivers for lung cancer. Interestingly, recurring mutations 
were found in genes involved in calcium signaling and extracellular matrix/receptor 
interaction. The data was compared to the TCGA and COSMIC databases. Among 
affected proteins, only 3% overlapped with the COSMIC and approximately 6% with the 
TCGA database. Interestingly, all of the mutations overlapping with the COSMIC, were 
found to be common mutations in AAH. Furthermore, pathways affected by the mutated 
genes were identified utilizing Gene Ontology and pathways from the KEGG, Biocarta or 
Reactome databases. The observation that few genes mutated in both AAH and ADC are 
known as key drivers, indicates that: a) progression-associated mutations might facilitate 
malignant transformation by mutated key driver(s), or b) a combination of two or more 
progression-associated mutations that are not oncogenic alone, might drive malignant 
transformation. These hypotheses will be further tested by mapping progression- 
and malignant-associated genes in the context of pathways. Conclusion: Our 
data indicate that premalignant lesions from the same patient may have different 
mutational profiles. This inter-lesion heterogeneity suggests that a progression-
associated mutational landscape could be defined in longitudinal studies of pulmonary 
premalignancy. These results could help identify targets for the development of targeted 
chemopreventive strategies for lung cancer. Supported by EDRN (U01CA152751-AS). 
Keywords: Somatic mutations, Premalignancy, progression, Whole exome sequencing
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P3.04-067 Inflammatory Cytokines Are Associated with the Development of 
Fatigue in Patients with NSCLC Treated with Definitive Radiotherapy 
Shulian Wang1, Jeff Campbell2, Ramses Sadek2, Paul Stanton3, Jing Zhao4, Ping 
Ye5, Matthew Stenmark6, Martha M. Matuszak7, James Hayman7, Randall Ten Haken 
Haken6, Theodore S. Lawrence7, Feng-Ming (Spring) Kong8 1Department of Radiation 
Oncology, Georgia Regents University, Cancer Hospital and Institute, Chinese Academy 
of Medical Sciences and Peking Union Medical College, Augusta/GA/United States of 
America, 2Department of Biostatistics and Epidemiolog, Gru Cancer Research Center 
and Medical College of Georgia, Augusta/GA/United States of America, 3Department of 
Radiation Oncology, Gru Cancer Research Center and Medical College of Georgia, Augusta/
United States of America, 4Georgia Regents University, Augusta/GA/United States of 
America, 5Gru-Cancer Center, Georgia Regents University, Augusta/GA/United States of 
America, 6Department of Radiation Oncology, University of Michigan Health System, Ann 
Arbor/United States of America, 7University of Michigan, Ann Arbor/AL/United States 
of America, 8Department of Radiation Oncology, Gru Cancer Center/Medical College of 
Georgia, Georgia Regents University, Augusta/GA/United States of America
Background: Fatigue is one of the most common symptoms in cancer patients at 
baseline and or treatment which affects cancer patients’ quality of life. This study is 
to evaluate the association of inflammatory cytokines with the development of fatigue 
in patients with NSCLC treated with definitive radiation therapy (RT). Methods: 109 
patients with stage I-IIINSCLC and ECOG 0-2 treated with definitive RT from prospective 
studies were included. The median age was 66 years (range 43-85), and 84 patients 
(77.1%) had stage IIIdisease. The median RT dose was 70 Gy (range 34-87.9) at 1.8~2.9 
Gy/fx for 103 patients and 6 (5.5%) received stereotactic body RT (SBRT) to a total 
dose of 50-55Gy at 10-11 Gy/fx. Seventy-six (69.7%) received concurrent and 31 (28.4%) 
consolidated chemotherapy. Thirty inflammatory, pro-inflammatory, immunomodulation 
cytokines were measured in plasma samples before RT, using ELISA. Fatigue was 
evaluated and scored according to CTCAE 3.0 before, 2, 4, 6 weeks during- and 3, 6, 9, 
12, 18, 24 months after RT. The fatigue scores from all time points are averaged for each 
person to create a composite score, which is the endpoint of this analysis. Spearman’s 
rho test was used to check the association of cytokine levels and other clinical factors 
with fatigue.  The p-value of the cytokines are adjusted using the Benjamini-Hochberg 
procedure. Results: 109 patients had fatigue information available before, 2, 4 and 6 
weeks during RT, and 106, 101, 98, 97, 92 and 88 had fatigue information available at 
3, 6, 9, 12, 18, 24 months after RT, respectively. The incidence of grade 1-3 fatigue 
was 37.6% before RT, 52.3%, 60.6%, 65.1% at 2, 4, 6 weeks during RT, and 62.3%, 
50.5%, 33.7%, 28.9%, 14.1%, 13.6% at 3, 6, 9, 12, 18, 24 months after RT, respectively. 
Grade 3 fatigue was rare, less than 1% and no grade 4-5 fatigue occurred. Among 
30 cytokines, IL-10 (p=0.019) and IP-10 (p=0.054) were significantly associated with 
fatigue. Lower level of IL-10 and higher level of IP-10 were associated with less fatigue 
score. SBRT (p=0.002), and consolidated chemotherapy (p=0.049) were significantly 
associated with fatigue. Patients treated with SBRT had lower fatigue score, but those 
with consolidated chemotherapy had higher fatigue score. IL-10 was not related with the 
use of SBRT (p=0.26) or consolidated chemotherapy (p=0.11). IP-10 was not related 
with the use of consolidated chemotherapy (p=0.76), but it is significantly related with 
the use of SBRT (p=0.01) and SBRT individuals had higher IP-10 levels. By excluding the 
6 SBRT patients, IP-10 was significantly associated with fatigue for non-SBRT patients 
(p=0.02). Age (p=0.09), gender (p=0.59), histology (p=0.56), ECOG (p=0.16), weight 
loss (p=0.85), COPD (p=0.16), smoking (p=0.99), stage (p=0.89), biological equivalent 
RT dose for non-SBRT patients (p=0.12), and concurrent chemotherapy (p=0.59), were 
not associated with fatigue. Conclusion: For patients with NSCLC treated with definitive 
RT, fatigue increases during RT and decreases over time after completion of RT, with 
peak severity at 6 weeks during RT. Plasma level of IL-10 and IP-10 before RT, SBRT 
and consolidated chemotherapy play important roles in the development of fatigue. 
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P3.04-068 A Genetic Variation in a microRNA Target Site of ETS2 Gene Is 
Associated with Clinical Outcome of Chemotherapy in Non-Small Cell Lung 
Cancer Shin Yup Lee1, Mi Jeong Hong2, Jin Eun Choi2, Chengcheng Jin2, Sook Kyung 
Do2, Deuk Kju Jung2, Hyo-Gyoung Kang2, Seung Soo Yoo1, Jae Yong Park1 1Internal 
Medicine, School of Medicine, Kyungpook National University, Daegu/Korea, 2Biochemistry 
and Cell Biology, School of Medicine, Kyungpook National University, Daegu/Korea
Background: Genetic polymorphisms in miRNAs or their target sites may affect 
miRNA-mRNA interactions, leading to altered expression of target genes. Recently, 
crosslinking, ligation, and sequencing of hybrids (CLASH) provided direct observation of 
transcriptome-wide miRNA-target pairs. The present study was performed to investigate 
the association of single nucleotide polymorphisms (SNPs) located in the miRNA 
target sites, which were experimentally verified by CLASH, with the clinical outcome 
of chemotherapy in advanced non–small cell lung cancer (NSCLC). Methods: Ninety 
eight SNPs in miRNA target sites of cancer related genes were selected from 18,500 
miRNA:target interactions in CLASH data, and investigated in 384 advanced NSCLC 
patients who received first-line paclitaxel-cisplatin chemotherapy, using a sequenom 
mass spectrometry-based genotype assay. Results: Of the 98 SNPs analyzed, 17 SNPs 
were significantly associated with the clinical outcome after chemotherapy. Among 
these, ANAPC1 rs3814026C>T, ETS2 rs461155A>G, and SORBS1 rs7081076C>A 
were found to be associated with both chemotherapy response and survival. Notably, 
the relative expression level of ETS2 was significantly associated with rs461155A>G 
genotypes in both tumor and paired normal lung tissues (Ptrend = 4 x 10-7, and 
0.0003, respectively). Conclusion: These findings suggest that the three SNPs, 
a valuable diagnostic tool for distinguishing poorly differentiated primary NSCLC from 
metastasis derived from another organ. A series of such cases will be presented. 
Keywords: next generation sequencing, non small cell lung cancer, poorly differentiated 
carcinoma, differential diagnoses
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P3.04-066 Overexpression of KIF23 Predicts Clinical Outcome in Primary 
Lung Cancer Patients Tatsuya Kato1, Hironobu Wada1, Priya Patel1, Daiyoon Lee1, 
Spencer Hu1, Kentaro Hirohashi1, Takahiro Nakajima1, Mitsuhito Kaji2, Kichizo Kaga3, 
Yoshiro Matsui3, Ming S. Tsao4, Kazuhiro Yasufuku1 1Division of Thoracic Surgery, Toronto 
General Hospital, University Health Network, Toronto/ON/Canada, 2Department of Thoracic 
Surgery, Sapporo Minami-Sanjo Hospital, Sapporo/Japan, 3Department of Cardiovascular 
and Thoracic Surgery, Hokkaido University, Sapporo/Japan, 4Departments of Laboratory 
Medicine and Pathobiology, University of Toronto, University Health Network, Toronto/
Canada
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. 
To improve the survival rate, it is important to examine or analyze metastatic lymph 
node samples taken from advanced lung cancer patients, especially using minimally 
invasive techniques like endobronchial ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA). We have been attempting to isolate potential molecular targets 
for lung cancer by analyzing expression profiles of our microarray and various types 
of database. Throughout these screenings, we identified kinesin family member 23 
(KIF23) as a promising molecular target gene for the treatment of lung cancer. High-
level expression of KIF23, a member of microtubule-dependent molecular motors that 
transport organelles within cells and move chromosomes during cell division, has been 
observed in a variety of human malignancies. The aims of the present study were to 
observe the expression of KIF23 in human lung cancer, examine the role of KIF23 in 
lung cancer cell growth and/or survival by small interfering RNA experiments, and 
explore its clinicopathologic significance and evaluate KIF23 expression as a prognostic 
marker. Methods:Quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
analysis was performed to detect the expression of KIF23 mRNA using metastatic lymph 
nodes from patients with advanced lung cancer obtained by EBUS-TBNA and normal 
human organs. A role of KIF23 in cancer cell growth and/or survival was examined 
by small interfering RNA experiments. A total of 341 lung cancers were analyzed 
immunohistochemically on tissue microarrays to examine the expression of KIF23 protein 
in archival lung cancer samples and its clinicopathologic significance. Results: KIF23 
transcript was extremely higher in the great majority of metastatic lymph nodes from 
advanced lung cancers with higher frequency compared with the average expression 
of normal lung tissues as determined by quantitative RT-PCR. KIF23 was more highly 
expressed only in the testis and the thymus compared to other human organs. Inhibiting 
KIF23 expression effectively suppressed non-small cell lung cancer (NSCLC) cell growth, 
and KIF23 siRNA-treated lung cancer cells more frequently exhibited large cell bodies 
with two or more nuclei. High-level KIF23 expression was observed in 67.7% of the 341 
cases, and this only correlated with pathological T classification (P=0.0269). Lung 
adenocarcinoma patients with tumors displaying a high-level of KIF23 expression was 
also identified as an independent prognostic factor by multivariate analysis (P=0.0042).
 
Conclusion: KIF23 not only provides additional prognostic information for surgical 
treatment of lung cancer, but may also be a novel therapeutic target for these patients. 
Keywords: kinesin motor protein, prognostic factor, lung cancer, KIF23 (MKLP1)
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among clinical stages II-IV (P = 0.830), stages T2-4 (P = 0.575), stages N1-3 (P = 
0.669), and stage M1 (P = 0.849) groups, respectively. Subsequently, Cox regression 
analysis was performed to define serum LN-γ2 as an independent prognostic indicator 
in the all-stage NSCLC cases (N = 370, univariate, P = 0.035; multivariate, P = 0.007). 
Worthy of note, however, in the multivariate analysis on those more advanced cases 
(stage II-IV), no statistical significance was observed on the serum levels of Ln-γ2 (N = 
298, P = 0.234). Conclusion: In summary, our study suggests circulating LN-γ2 to be a 
promising diagnostic biomarker for early-stage NSCLC and an effective indicator of tumor 
progression. It is proposed that circulating LN-γ2 might be important and applicable 
for the prognosis of early-stage NSCLC patients, rather than that of advanced cases. 
Keywords: Laminin gamma2, Circulating, Early prognosis, Non-small-cell lung cancer
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P3.04-071 High Id1 Expression in Lung Cancer: A Favorable Predictor after 
Adjuvant Chemotherapy Yu-Jen Cheng1, Jen-Wei Tsai2, Shyng-Shiou F. Yuan3 
1Surgery, E-Da Cancer Treatment Hospital, Kaohsiung/Taiwan, 2Pathology, E-Da Hospital, 
Kaohsiung/Taiwan, 3Obstetric and Gynecology, Kaohsiung Medical University Hosiptal, 
Kaohsiung/Taiwan
Background: Overexpression of Id family proteins inhibits cell differentiation and 
enhances cell proliferation and invasiveness. An elevated Id1 expression was observed in 
lung cancer cell lines as well as lung cancer tissues. Nude mice study further confirmed 
an increased tumor growth in Id1-overexpressing cells and a decreased tumor growth in 
Id1-knockdowned cells. Id1 protein may provide a pivot role in non-small cell lung cancer 
(NSCLC) development. Methods: Effects of Id1 expression on cytotoxicity of paclitaxel 
and cisplatin, and the mechanisms underlying these effects, were analyzed in A549, 
H460 and H520 cells in vitro. The influence of Id1 expression on xenograft lung tumor 
growth was investigated in nude mice, following treatment with paclitaxel and cisplatin. 
Eighty-three surgically-treated NSCLC patients receiving adjuvant paclitaxel and cisplatin 
were included for clinical analysis. Id1 expression in tumor and normal lung tissues was 
examined by immunohistochemistry, and associations for Id1 with clinicopathological 
characteristics and patient survival were assessed using Cox regression models and 
Kaplan Meier survival curves. Results: NSCLC cells with high Id1 protein expression 
were observed to be vulnerable to the treatment of paclitaxel and cisplatin. In the 
nude mice xenograft model, the tumor growth was reduced to a large degree in the 
Id1-overexpressing group upon treatment with paclitaxel and cisplatin. There were 60 
patients with adenocarcinoma (Ade) and 23 patients with squamous cell carcinoma 
(SqCC). After surgery followed by adjuvant chemotherapy, the Ade patients with high 
Id1 expression had an increased disease free survival (DFS) and overall survival (OS) 
compared to the patients with low Id1, whereas there was no difference in DFS or 
OS for SqCC patients. The pooled trends of DFS and OS were similar to those of the 
analyses for Ade patients only. Conclusion: In summary, our current data suggest that 
Id1, a generally negative prognostic factor, predicts a favorable prognosis in the cases 
of surgically treated NSCLC patients receiving the definitive adjuvant chemotherapy. 
Keywords: non-small cell lung cancer, Id1 protein, paclitaxel, adjuvant chemotherapy
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P3.04-072 Overexpression of CADM1 Is Associated with Poor Prognosis in 
Small Cell Lung Cancer Shinji Kikuchi1, Yuko Minami2, Yusuke Saeki1, Masatoshi 
Yamaoka1, Naohiro Kobayashi1, Yukinobu Goto1, Mitsuaki Sakai1, Masataka Onizuka1, 
Hideo Ichimura1, Yukio Sato1 1Department of Surgery (Thoracic Surgery), University 
of Tsukuba, Tsukuba Ibaraki/Japan, 2Department of Diagnostic Pathology, University of 
Tsukuba, Tsukuba Ibaraki/Japan
Background: CADM1, a member of the immunoglobulin superfamily cell adhesion 
molecules, acts as a tumor suppressor in a various cancers, including non-small cell 
lung cancer (NSCLC). In contrast, CADM1 also acts as an oncoprotein that promotes 
invasion in ATL and small cell lung cancer (SCLC) cells. Here, we investigate the possible 
association of CADM1 expression and splicing variant with the clinical characteristics of 
surgically treated patients with primary lung cancer. Methods: Expression and splicing 
variant of CADM1 was examined by RT-PCR, Western blotting, immunohistochemistry, 
and SSCP, respectively. We studied splicing variant of CADM1 in 5 primary NSCLC 
tumors and a primary SCLC tumor, as well as 16 SCLC and 10 NSCLC cell lines. 
Immunohistochemical expression of CADM1 was analyzed in 34 primary SCLC tumors 
and 25 primary NSCLC tumors. Statistical analysis was performed to determine 
significant predictor for overall survival and recurrence-free survival. Results: Western 
blotting and RT-PCR analyses have revealed that CADM1 is significantly expressed in 11 
of 14 SCLC cells growing in suspension cultures but in neither of 2 SCLC cells showing 
attached growth to plastic dishes, suggesting that CADM1 is involved in anchorage-
independent growth in SCLC. Then, we demonstrate that SCLC expresses a unique 
splicing variant of CADM1 (variant 8/9) containing additional extracellular fragments 
corresponding to exon 9 in addition to variant 8, a common isoform in epithelia. Variant 
8/9 of CADM1 is almost exclusively observed in SCLC and testis, although this variant 
protein localizes along the membrane and shows similar cell aggregation activity 
to variant 8. Interestingly, both variant 8/9 and variant 8 of CADM1 show enhanced 
tumorigenicity in nude mice when transfected into SBC5, a SCLC cell lacking CADM1. 
Inversely, suppression of CADM1 expression by shRNA reduced spheroid-like cell 
aggregation of NCI-H69, a SCLC cell expressing a high amount of CADM1. These findings 
suggest that CADM1 enhances the malignant features of SCLC, as is observed in ATL. 
Immunohistochemistry demonstrates that CADM1 is strongly expressed in 24 of 34 
(71%) SCLC and 2 of 25 (8%) NSCLC, weakly expressed in 7of 34 (21%) SCLC and 10 of 
25 (40%) NSCLC, and negative in 3 of 34 (9%) SCLC and 7 of 16 (44%). In NSCLC, loss of 
especially ETS2rs461155A>G, could be used as biomarkers predicting the response 
and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. 
Keywords: NSCLC, chemotherapy, miRNA target site, polymorphism
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P3.04-069 Exportin-5 (XPO5) in Lung Adenocarcinoma: A New Biomarker 
of Invasion in Pathology Specimens Amy M. Coffey1, Pierre P. Massion2, Charles 
A. Powell3, Yong Zou2, Jun Zhu3, Seungyeul Yoo3, Alain C. Borczuk4 1Department of 
Pathology and Cell Biology, Columbia University Medical Center, New York/United States 
of America, 2Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram 
Cancer Center, Nashville/TN/United States of America, 3Icahn School of Medicine at Mount 
Sinai, New York/NY/United States of America, 4Department of Pathology and Laboratory 
Medicine, Weill Cornell Medical College, New York/NY/United States of America
Background: The WHO/IASLC classification of lung adenocarcinoma (LADC) emphasizes 
the distinction of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma 
(MIA) from their invasive counterparts. The distinction between lepidic-pattern lesions, 
in particular AIS/MIA and lepidic-predominant adenocarcinoma (LPA), is difficult in small 
biopsies and cytology specimens. Currently, there are no biomarkers of lung invasion 
in this setting. Methods: The WHO/IASLC classification of LADC was used for all 
components of this study. Gene expression (GE) data from 58 LADC samples including 
33 samples of AIS/MIA and LPA identified two predominant clusters of 553 differentially 
expressed genes (p<0.01, FDR<0.06). The 317 genes upregulated in LPA localized to 
6 regions on chromosomes 1, 2, 6 and 17 (Gene Set Enrichment Analysis). Expression 
data was compared to copy number (CN) data of AIS/MIA and LPA pooled from a re-
annotated Cancer Genome Atlas data set along with prior annotated Affy 6.0 SNP array 
data (total 1086 LADC samples including 43 AIS/MIA and 26 LPA). Two regions (6p and 
17q) contained genes with increased expression and CN increase in LPA. TheXPO5 gene 
at 6p21 was selected for further study. Immunohistochemistry (IHC) for the XPO5 protein 
product Exportin-5 (XPO5, Sigma-Aldrich, St. Louis, USA) was performed on 686 lung 
cancers (NSCLC), on tissue microarrays and read independently by two pathologists. 
Nuclear (N) and cytoplasmic (C) positivity was scored for intensity (0-3) and percentage; 
an H-score was calculated for each (0-300, N-score and C-score). A total score (T-score) 
was calculated from the sum of the N-and C-scores (0 to 600). Statistical analysis was 
performed using the independent-samples Kruskal-Wallis test and pairwise analysis. Cox 
regression was used for survival analysis (continuous variable and quartile regressions), 
as well as Kaplan-Meier curves, logrank statistic. Results: XPO5 at 6p21 showed 
upregulation in LPAs by CN, GE and IHC. High XPO5 IHC T-scores correlated with CN, 
with a median T-score of 300 in tumors with CN gain vs. 50 in tumors without gain. 
High T-scores were seen in the following invasive patterns of NSCLCs as compared to 
AIS/MIA: acinar-ADC, solid-ADC, papillary-ADC, large cell carcinoma and squamous cell 
carcinoma; mean T-scores ranged from 144.7-251.4 in these groups vs. 48.3 and 72.1 
in AIS and MIA, respectively. Importantly, T-scores correlated with overall survival for 
all-stage (n=686) and stage I (n=307) analyses, with higher scores predicting inferior 
survival. While IHC scores did not show statistically significant staining in LPA as 
compared to AIS/MIA, a qualitative difference was noted in some cases with acquisition 
of cytoplasmic positivity in the invasive component of LPAs. Conclusion: XPO5 is 
a candidate biomarker of invasion in LADC. GE and CN data along with IHC staining 
patterns in 686 NSCLC samples show upregulation of XPO5 in invasive tumors and in 
tumors with poor survival. In addition to its application in small biopsies, this marker 
may be of particular use in cytology specimens, where there is significant morphologic 
overlap between lepidic-pattern tumors and well-differentiated invasive patterns of LADC. 
Keywords: lung adenocarcinoma, XPO5, Exportin-5, Pathology
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P3.04-070 Early Prognostic Significance of Circulating Laminin γ2-Chain 
Fragment in Non-Small-Cell Lung Cancer Yu Teng, Wentao Yue, Li Ma, Xiaoting 
Zhao, Lina Zhang, Yue Wang, Meng Gu Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing/China
Background: Laminin γ2-chain (LN-γ2), a distinctive subunit of heterotrimeric 
laminin-332, is frequently up-regulated in various types of carcinomas, and is of great 
importance in the biological processes including cell migration and tumor invasion. 
Despite of this, the status of circulating LN-γ2 fragment in lung cancer patients is still 
uncertain. Methods: In this study, serum samples from 538 all-stage (stage I-IV) patients 
of non-small-cell lung cancer (NSCLC) and 94 age-matched normal volunteers were 
determined by enzyme-linked immunosorbent assay. Data were statistically analyzed 
in combination with clinicopathological information. Results: Compared to the normal 
controls, serum LN-γ2 concentration is drastically increased in NSCLC patients (P < 
0.001), even in early cases of stage I patients (P < 0.001). Furthermore, our data 
suggested that serum LN-γ2 level was in close correlation to male gender (P < 0.001) and 
smoking status (P < 0.001) with a higher positive rate relative to each counterpart, but 
was not significant between adenocarcinoma and squamous cell carcinoma histologies 
(P = 0.879). We also found that circulating LN-γ2 could reflect the progression of lung 
cancer with higher serum levels or positive rates in higher tumor-node-metastasis (TNM) 
stages. Survival analysis on 370 eligible patients who underwent a follow-up examination 
up to 4 years indicated that patients of serum LN-γ2 positive group survived markedly 
shorter compared with those in the negative group (P = 0.028), and it was especially the 
case for clinical stage I (N = 72, P < 0.001) and stage T1 (N = 67, P = 0.001), even for 
stage N0 patients (N = 148, P = 0.038), which all represent groups of early cases. As 
for the patients of advanced stages, however, it was not the case that the overall survival 
rates between LN-γ2 positive and negative patients were not significantly different 
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score may be candidates for adjuvant therapy to reduce cancer related mortality. 
Keywords: recurrence, proliferation, 46-gene, stage IB
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P3.04-075 The Biological and Clinical Significance of Alpha-1 Antitrypsin in 
Non-Small Cell Lung Cancer Adam Szpechcinski1, Joanna Chorostowska-Wynimko1, 
Renata Langfort2, Emilia Debek1, Wlodzimierz Kupis3, Piotr Rudzinski3, Jolanta Zaleska4, 
Beata Poplawska-Wisniewska1, Radoslaw Struniawski1, Dorota Giedronowicz2, Tadeusz 
Orlowski3, Kazimierz Roszkowski-Sliz4 1Department of Genetics and Clinical Immunology, 
National Institute of Tuberculosis and Lung Diseases, Warsaw/Poland, 2Department 
of Pathomorphology, National Institute of Tuberculosis and Lung Diseases, Warsaw/
Poland, 3Department of Thoracic Surgery, National Institute of Tuberculosis and Lung 
Diseases, Warsaw/Poland, 4Iii Department of Lung Diseases, National Institute of 
Tuberculosis and Lung Diseases, Warsaw/Poland
Background: Lung cancer progression is generally associated with extensive tissue 
remodeling to provide a suitable environment for tumor growth, invasion and metastasis, 
and it is known that proteinases expressed by cancer cells and/or host cells play a 
key role in this process. However, the biological role of alpha-1 antitrypsin (AAT) in 
lung carcinogenesis is not clear. Methods: Serum and FFPE tissue samples from 206 
NSCLC patients (stages I-IV) were analyzed for AAT and CRP blood concentration, AAT 
phenotype and AAT protein expression in tumor cells. Reference groups consisted 
of 183 PiMM COPD patients and 23 PiMM patients with benign lung nodules (positive 
chest radiograph). Results: Only 10/206 (5%) NSCLC patients carried deficient AAT 
allele (mean AAT blood concentration 150 mg/dl). In the PiMM NSCLC patients mean 
AAT serum concentration (195.5 mg/dl) was significantly higher than in the PiMM COPD 
group (171 mg/dl) and the patients with benign lung nodules (154 mg/dl; p<0.0001). 
AAT concentration was significantly higher in SQC type (202 mg/dl) than ADC (175 mg/
dl; p<0.029) patients, and in advanced (IIIb-IV, 247 mg/dl) versus early stage disease 
(I-IIIa, 190 mg/dl, p<0.0001). The AAT levels significantly correlated with CRP (R=0.6; 
p<0.0001), however CRP level did not differentiate NSCLC from COPD. Importantly, 
the strong AAT expression observed in tumor tissue was positively associated with the 
higher AAT blood levels, while weak or no AAT expression directly correlated with the 
lower AAT blood levels. Conclusion: Our results evidenced that local production of AAT 
by tumor cells significantly contribute to high levels of AAT in blood of NSCLC patients 
reflecting an active role of this anti-protease in lung carcinogenesis. The study is on-going. 
Keywords: non-small cell lung cancer (NSCLC), serum concentration by nephelometry, 
AAT expression in lung cancer FFPE tissue by IHC, alpha-1 antitrypsin (AAT)
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P3.04-076 The Crux of Molecular Prognostications in NSCLC: An Optimized 
Biomarker Panel Fails to Outperform Clinical Parameters Dijana Djureinovic1, 
Marianna Grinberg2, Johanna Sofia Margareta Mattsson1, Karolina Edlund3, Jörg 
Rahnenführer2, Jan Hengstler3, Linnea La Fleur1, Simon Ekman1, Hans Brunnström4, 
Hirsh Koyi5, Eva Brandén5, Mats Lambe6, Karin Jirström4, Fredrik Pontén1, Johan 
Botling1, Patrick Micke1 1Department of Immunology, Genetics and Pathology, Uppsala 
University, Uppsala/Sweden, 2Department of Statistics, Tu Dortmund University, Dortmund/
Germany, 3Leibniz Research Centre for Working Environment and Human Factors, Tu 
Dortmund University, Dortmund/Germany, 4Division of Pathology, Lund University, Lund 
University, Lund/Sweden, 5Dept. of Pneumology, Gävle Hospital, Gävle/Sweden, 6Regional 
Cancer Center Uppsala-Örebro, Regional Cancer Center Uppsala-Örebro, Uppsala/Sweden
Background: The best known prognostic factors for non-small cell lung cancer (NSCLC) 
patients are age, tumor stage and performance status. Numerous proteins have been 
analyzed to improve the traditional prognostication. Even though some proteins have 
shown prognostic value, the performance is not sufficient to be introduced in the clinical 
routine. The aim of this study was to generate a prognostic classifier based on proteins 
that previously have shown reproducible prognostic value and represent different 
aspects of tumorigenesis. Methods: The selection of proteins was based on literature 
search, meta-analysis of gene expression data sets and availability of reliable antibodies 
towards these proteins. Finally, five proteins (Ki67, EZH2, SLC2A1, TTF1 and CADM1) 
were chosen and analyzed by immunohistochemistry on tissue microarrays comprising 
NSCLC tissue patients (n=673), divided into a training and a validation cohort. For each 
patient, one score was obtained for each of the five antibodies, integrating the staining 
intensity and the fraction of stained tumor cells. Analyses were performed using all 
possible combinations of proteins and tested with or without clinical parameters. The 
C-index was used to develop the best prediction model on a training cohort (n=326) and 
the model was subsequently validated in the validation cohort (n=347). Results: All five 
proteins showed a significant prognostic impact in the univariate and the multivariate 
Cox analyses. Using a combination of the protein scores, the model was then fitted 
to provide the best prognostic performance (C-index=0.60). This did, however, not 
outperform the use of clinical parameters alone (C-index=0.62). The same was true when 
the analyses were performed separately for the adenocarcinoma (C-index=0.60) and the 
squamous cell carcinoma subgroup, respectively (C-index=0.60). More importantly, the 
addition of protein data to the clinical information (C-index=0.62) did not improve the 
prognostic value of the clinical parameters alone (C-index=0.60). To substantiate the 
results of our test cohort, we transferred the best prognostic model for all NSCLC, only 
adenocarcinomas and only squamous cell carcinomas respectively to a validation cohort. 
Again, all proteins showed prognostic relevance in the univariate analysis but did not 
perform better, alone or in combination, than the clinical parameters. Conclusion: Here 
we have performed a comprehensive analysis in order to obtain the best survival 
prediction model by using clinical parameters and the expression of five proteins. 
CADM1 expression was preferentially observed in heavy smokers (smoking index ≥ 800). 
In SCLC, overexpression of CADM1 was significantly associated with poor prognosis 
in surgical patients. Conclusion: SCLC represents high recurrence rates and poor 
clinical outcome. Surgical treatment can achieve satisfactory results in selected cases. 
Overexpression of CADM1 could be an indicator of poor prognosis and could influence 
the decision for adjuvant therapy or follow up intervals in surgical patients with SCLC. 
Keywords: CADM1, SCLC, splicing variant
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P3.04-073 CXCR4 Expression Is Associated with Poor Survival in Early, 
Resected NSCLC Shannon Otsuka1, Alexander Klimowicz1, Karen Kopciuk1, Michelle 
Dean1, Yukun Zhang2, Don Morris1, D. G. Bebb1 1Tom Baker Cancer Centre/University of 
Calgary, Calgary/Canada, 2University of Calgary, Calgary/AB/Canada
Background: CXCR4, a G protein coupled chemokine receptor, and its ligand, stromal 
cell derived factor-1 (SDF-1), play a critical role in organ specific tumor metastasis. 
In vitro, CXCR4 expression has been shown to correlate with migration, invasion and 
adhesion in various cancer cell lines including lung, breast and colon, among others. 
In clinical studies, patients whose tumors exhibit high CXCR4 expression tend to have 
a poorer clinical outcome. We previously demonstrated that high expression of CXCR4 
by quantitative IHC in a cohort of 170 stage IV NSCLC specimens was associated 
with significantly decreased overall survival, particularly in the female patients. 
We subsequently investigated whether CXCR4 also conferred a poorer prognosis 
in our early stage NSCLC patients with resected disease, to validate our previous 
findings. Methods: After ethical approval was obtained, demographic details, clinical 
variables and outcome data were gathered on patients diagnosed at the Tom Baker 
Cancer Centre (TBCC) from 2003 to 2006. Formalin-fixed paraffin embedded tumor 
specimens were obtained from those patients diagnosed with resected stage I, II or III 
NSCLC and tissue micro arrays (TMAs) were generated. CXCR4 expression in NSCLC cells 
was analyzed by immunohistochemistry using anti CXCR4 mAb and the HistoRx PM-2000 
platform, then correlated with clinical outcome. Statistical analysis was performed using 
the Kaplan-Meier method, multivariate analysis and a multi-state model to account for the 
competing risks of disease free and overall survival. Results: Of 1502 patients diagnosed 
with NSCLC at the TBCC in 2003-2006, 166 had resected (pneumonectomy, lobectomy 
or wedge resection) stage I (63%), II (30.7%) or III (9.6%) disease. 37.3% of the patients 
received adjuvant treatment (combined chemoradiotherapy or radical radiotherapy 
alone) after their surgery. 46.4% of the patients were still alive at the time of analysis. 
The mean CXCR4 AQUA scores were significantly lower for the early stage patients than 
those obtained for the advanced stage IV patients (1715.90 vs 2512.44 p< 0.0001). High 
CXCR4 expression was associated with worse overall survival (p = 0.026) but had no 
significant effect on disease free survival after resection (p = 0.376). Subgroup analysis 
showed no significant differences between genders in the association between high 
CXCR4 expression and clinical outcome. Conclusion: CXCR4 is expressed in early stage 
resected NSCLC tumors and appears to increase significantly from stage I-III to stage IV 
NSCLC. High CXCR4 expression is associated with significantly poorer overall survival in 
early stage resected patients, validating our previous findings in stage IV NSCLC using 
the same method. CXCR4 does not seem to be associated with disease free survival in 
this cohort of patients, nor does there seem to be any association between gender and 
the effect of CXCR4 on poor outcome unlike that seen in our stage IV NSCLC patients. 
Keywords: NSCLC, CXCR4, survival, resected
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P3.04-074 Prognostic Multi-Gene Molecular Assay Might Improve Identification 
of Pathologic Stage IB Lung Adenocarcinoma Patients at Risk for Recurrence 
Daniel Oh1, Kraig Yager2, Brent Evans2, Jonathan Nelson2, Alison Sibley2, Thaylon 
Davis2, Kristen Rushton2, Kathryn A. Kolquist2, John Kidd2, Anne-Renee Hartman2 1Keck 
School Ofmedicine, University of Southern California, Los Angeles/CA/United States of 
America, 2Myriad Genetic Laboratories, Inc., Salt Lake City/UT/United States of America
Background: Adjuvant chemotherapy improves survival for some patients with NSCLC 
and is recommended for consideration by NCCN guidelines for pathologic stage IB 
patients presenting certain high risk features. A validated, 46-gene RNA expression 
assay has been shown to stratify lung cancer specific, post-resection mortality risk in 
pathologic stage I and II NSCLC adenocarcinoma independently of pathologic staging 
and high risk features. The aim of this study was to compare Stage IB patient risk as 
assessed by cell cycle progression (CCP) and prognostic score, a combination of CCP 
score and pathologic stage, versus NCCN high risk features. Methods: Formalin-fixed 
paraffin-embedded surgical tumor samples from 92 stage IB lung adenocarcinoma 
patients, who underwent definitive surgical treatment and complete lymph node 
evaluation, were stratified to high or low risk groups by analysis of the molecular assay 
and the remaining NCCN high risk features of wedge resection, tumor size >4 cm, poorly 
differentiated tumor, lymphovascular invasion, and visceral pleural invasion. Results: Of 
the 92 Stage IB patients, 63 (68.5%) were designated high risk by the 46-gene molecular 
assay. Of these molecularly designated high risk patients, 5 (7.9%) presented no NCCN 
high risk features, 23 (36.5%) presented only 1 high risk feature, 22 (34.9%) presented 
2 high risk features, 11 (17.5%) presented 3 high risk features, and 2 (3.2%) presented 4 
high risk features. No patients presented with all 5 high risk features. Conclusion: This 
study demonstrates that a validated measure of recurrence in Stage IB adenocarcinoma 
patients can identify high risk patients that would have been otherwise designated as low 
risk according to pathological features. Significantly, in the Stage IB population, prognostic 
score provide quantitative risk information above that captured by current NCCN high 
risk features. Patients with resected Stage I lung adenocarcinoma and a high prognostic 
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P3.04-078 Adverse Effect of Smoking on the Intratumoral Expression of 
Thymidylate Synthase in Lung Cancer Shugo Uematsu1, Akihiko Kitami1, Takashi 
Suzuki1, Shoko Hayashi1, Kosuke Suzuki1, Ryosuke Usuda1, Yoshito Kamio1, Naoya 
Himuro2, Yuri Tomita2, Daisuke Kataoka2, Shigeru Yamamoto2, Mitsutaka Kadokura2 
1Respiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama/
Japan, 2Chest Surgery, Showa University School of Medicine, Tokyo/Japan
Background: Cigarette smoke is a risk factor for lung cancer. A recent study showed 
that lung tumors exhibited distinct epidemiological, clinical, pathological, and molecular 
features depending on the smoking status. Thymidylate synthase (TS) is an essential 
enzyme for de novo DNA synthesis. TS expression has been associated with the 
proliferative activity of cancer cells, and low TS expression was be associated with better 
outcomes for non-small cell lung cancer patients treated with TS-targeted drugs. The aim 
of the present study was to investigate the relationship between TS expression in lung 
cancer and the smoking status. Methods:
 
 
 
The subjects were 113 patients who underwent surgical resection of lung cancer in at 
one of our three hospitals. Table 1 shows the patient’s clinical and pathological 
characteristics accoding to the smoking status. We measured the intratumoral mRNA 
expression for TS, in manually microdissected tumor specimens using RT-PCR, and we 
normalized the values considering the gene for to β-actin as the reference. We analyzed 
the expression level of TS considering the cumulative dose of smoking in a patient’s life. 
Results: 
 
Table 2 shows the relationship between TS expression and the smoking dose. 
Among smokers, the median of smoking dose was 45 pack-years in patients with 
adenocarcinoma (Ad) and 50 pack-years in squamous cell carcinoma (Sq). TS expression 
was significantly higher in patients with Sq than in those with Ad (p = 0.0153). Among 
smokers with Ad, TS expression was significantly higher in patients with a smoking 
status of more than 45 pack-years compared to those with a smoking status of less 
than 45 pack-years (p = 0.0187). Conclusion: Our results indicate that it may be 
possible to predict high TS levels in patients with Ad by considering smoking dose. 
Keywords: Thymidylate Synthase, smoking dose, non-small cell lung cancer, predictive 
factor
Although we chose strict criteria for protein marker selection, the prognostic power 
of these proteins was inferior to the traditional clinical parameters. Our findings 
question the general concept of using protein markers for prognostication in NSCLC 
but stress the value of careful assessment of traditional parameters in clinical practice. 
Keywords: NSCLC;prognostication;IHC;protein panel;
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1Hematology/Oncology, Uams, Little Rock/AR/United States of America, 2Department of 
Biostatistics, University of Arkansas for Medical Sciences, Little Rock/AR/United States 
of America, 3Environmental and Occupational Health, University of Arkansas for Medical 
Sciences, Little Rock/AR/United States of America, 4Department of Pathology, University of 
Arkansas for Medical Sciences, Little Rock/AR/United States of America, 5Internal Medicine/
Pulmonary, Uams, Little Rock/AR/United States of America
Background: Non-small cell lung cancer (NSCLC) has a high mortality. TNM staging 
has prognostic implications, but there is a paucity of biomarkers to predict prognosis. 
The aim of this study was to evaluate the metabolomic profiles of mediastinal and hilar 
lymph nodes of NSCLC patients and to determine the prognostic implications of different 
metabolites. Methods: Endobronchial ultrasound-guided fine needle aspirates of hilar 
and mediastinal nodes from patients with NSCLC were collected from January 2011 to 
February 2013. Metabolomic profiles were generated using liquid chromatography mass 
spectrometry. Electronic medical records were reviewed for histologic diagnoses and 
survival status. T-testing was used to compare metabolite differences between groups. 
Metabolites dichotomized at their median values were assessed for prognostic potential 
via Cox regressions. P<0.05 was regarded as statistically significant. Results: A total of 
79 lymph node aspirates were collected. 50 were positive for NSCLC, 13 were negative 
for NSCLC in patients with biopsy-proven NSCLC at the primary site, and 16 were from 
patients with non-malignant lung disease. The histologic subtypes of patients with NSCLC 
were 38 (60.3%) adenocarcinoma (AD) and 25 (39.7%) squamous cell carcinoma (SCC). 
TNM staging for the patients with NSCLC was as follows: 8 (12.7%) stage I, 10 (15.9%) 
stage II, 23 (36.5%) III, and 22 (34.9%) IV. Concentrations of alanine, alpha-ketoglutarate, 
glutathione (reduced and oxidized states), homocysteine, malate, melatonin, malonyl-
carnitine, S-adenosyl homocysteine, and S-adenosylmethionine were statistically 
significantly higher in NSCLC patients than in patients with benign disease. In contrast, 
citruline, cysteine, glutamine, isoleucine, L-carnitine, leucine, ornithine, tryptophan, and 
valine were lower in the NSCLC group than in the benign group. Metabolite concentrations 
were different for different cancer sub-types; SCC patients had a 4.92-fold higher 
concentration of succinate than AD (p<0.0001), whereas AD had a 1.52-fold higher 
concentration of homocysteine than SCC (p=0.041). Elevated concentrations of the 
following metabolites were associated with shorter overall survival: melatonin (HR=2.24, 
95% CI: 1.27-3.97; p=0.0057) Figure 1, malate (HR=1.91, 95% CI: 1.08-3.35; p=0.025), 
cystathionine (HR=1.84, 95% CI: 1.03-3.28; p=0.039), and glutamate (HR=1.77, 95% 
CI: 1.01-3.09; p=0.045).
  
Conclusion: Metabolomic data demonstrate differences between different 
NSCLC subtypes. In addition, metabolomic data may have prognostic potential 
that is independent from that associated with TNM stage. Metabolites 
associated with worsened prognosis offer an avenue for research; they 
may allow us to identify specific pathways that correlate with prognosis. 
Keywords: Metabolomic profile, mediastinal lymph nodes, prognostic factor, non-small 
cell lung cancer
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P3.04-081 Molecular Evidence of Viral DNA in Non-Small Cell Lung Cancer 
(NSCLC) and Normal Lung Lary A. Robinson1, Crystal J. Jaing2, Anna R. Giuliano3, 
Christine M. Pierce Campbell3, Sean J. Yoder4, Jamie K. Teer5, Scott J. Antonia1 
1Thoracic Oncology, Moffitt Cancer Center, Tampa/FL/United States of 
America, 2Biosciences and Biotechnology, Lawrence Livermore National Laboratory, 
Livermore, Ca/United States of America, 3Department of Epidemiology, Moffitt Cancer 
Center, Tampa/FL/United States of America, 4Molecular Genomics Core, Moffitt Cancer 
Center, Tampa/FL/United States of America, 5Biostatistics and Bioinformatics, Moffitt Cancer 
Center, Tampa/FL/United States of America
Background: Although 20% of human cancers are caused by infections, only 
suspicion exists for a microbial cause of lung cancer. This study investigated potential 
infectious agents in the etiology of non-small cell lung cancer (NSCLC) in both frozen 
tumor of the major cell types and non-neoplastic lung using several molecular 
methods. Methods: Nucleic acids were extracted from 30 frozen NSCLC [10 squamous 
cell (SCC), 10 adenocarcinomas (ADC), 10 bronchioloalveolar (BAC)] and 10 non-
neoplastic lung tissue specimens. All specimens were screened for microbial DNA on 
a pan-microbial detection array containing 135,000 DNA probes and controls to detect 
all sequenced viral and bacterial pathogen species. Additionally, SCC specimens were 
evaluated by PCR for the presence of 27 subtypes of human papillomavirus (HPV) 
and an independent panel of 17 known or suspected oncoviruses. Results: RESULTS: 
Using the pan-microbial microarray, several species of retroviral DNA were observed in 
100% of SCC, 60% of ADC, and 10% of BAC (Table 1). Among the SCC specimens, HPV 
DNA was found in 60%, with 30% containing one or more high-risk HPV types, but the 
oncovirus panel was negative. No consistent viral DNA was detected in non-neoplastic 
lung specimens by the pan-microbial microarray.
Lung 
cancer 
cell type
HPV 
(human 
papillo-
mavirus, 
type 57)
HBV 
(hepatitis 
B virus)
HTLV-2 
(human 
T- lym-
photropic 
virus 2), a 
Delta-ret-
rovirus
Bovine 
leukemia 
virus (a 
Delta-ret-
rovirus, 
similar to 
HTLV-1)
Y53 
Sarcoma 
virus (an 
Alpha-ret-
rovirus)
STLV-1, 
2, or 6 
(simian 
T-cell 
leukemia 
viruses, 
Delta-ret-
roviruses)
Squa-
mous 
cell ca. 
n=10
6 (60%) 9 (90%) 7 (70%) 8 (80%) 0 8 (80%)
Adeno-
ca. n=10 1 (10%) 2 (20%) 0 0 6 (60%) 1 (10%)
Bronchi-
oloalve-
olar ca. 
n=10
0 0 0 0 1 (10%) 0
Normal 
lung, 
n=10
0 0 0 0 0 0
 
Table 1. Viral DNA Found in Human Lung Cancer Specimens: Pan-Microbial Array 
Results Conclusion: High-risk HPV types were detected in many squamous cell lung 
cancers and, retroviral DNA was found in the majority of NSCLC but not in non-neoplastic 
lung. Of the 24 naturally-occurring animal cancers with a known etiology including lung 
adenocarcinoma in sheep, all are induced by retroviruses. Results from this initial discovery 
trial encourage further study of the viral contribution to human lung oncogenesis. 
Keywords: lung cancer, virus, DNA, carcinogenesis
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P3.04-082 Activation of JAK1 Confers Poor Prognosis in Chinese Patients 
with Lung Adenocarcinoma Dan Liu1, Yi Huang2, Weimin Li1 1Respiratory Medicine 
Department, West China Hospital of Sichuan University, Chengdu/China, 2Clinical Laboratory 
Department, Sichuan Academy of Medical Sciences and Sichuan Provincial People’S 
Hospital, Chengdu/China
Background: Janus kinase 1 (JAK1) has been reported to activate the JAK/STAT cascade 
in non-small cell lung cancers (NSCLC), among which most lung adenocarcinoma (ADCC) is 
associated with somatic epidermal growth factor receptor (EGFR) tyrosine kinase mutations. 
STAT3 is considered to be one of both JAK1 and EGFR downstream pathways promoting 
oncogenesis. However, the association between JAK1 activation, EGFR mutations and their 
prognostic value on NSCLC remains unclear. This study explored relations between the 
activated form, p-JAK1 and prognosis in patients with NSCLC and EGFR mutations status 
with ADCC subjects. Methods: a cohort of 142 resected primary NSCLC cases including 74 
ADCC and 68 squamous carcinoma (SqCC) were collected and analyzed, p-JAK1 expression 
was determined by immunohistolchemical (IHC) assay. EGFR FISH status was analyzed in 74 
ADCC subjects. The prognostic significances of p-JAK1 and EGFR expression status were 
evaluated with univariate and multivariate survival analysis. Results: Compared with normal 
lung tissues, p-JAK1 expression level significantly increased in NSCLC (P=0.000). Positive 
p-JAK1 expression indicated poor prognosis in NSCLC, especially in early stage subjects 
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P3.04-079 A Panel of Genetic Polymorphism Can Predict Prognosis in Lung 
Cancer Shin Yup Lee1, Jin Eun Choi2, Eungbae Lee3, Seung Soo Yoo1, Jae Yong Park2 
1Internal Medicine, School of Medicine, Kyungpook National University, Daegu/
Korea, 2Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, 
Daegu/Korea, 3Thoracic Surgery, Kyungpook National University Medical Center, Daegu/
Korea
Background: This study was conducted to investigate whether a panel of 8 genetic 
polymorphisms can predict the prognosis of patients with early stage non-small cell lung 
cancer (NSCLC) after surgical resection. Methods: We selected 8 single nucleotide 
polymorphisms (SNPs) which have been associated with the prognosis of lung cancer 
patients after surgery in our previous studies. A total of 814 patients with early stage 
NSCLC who underwent curative surgical resection were enrolled. The association of the 8 
SNPs with overall survival (OS) and disease-free survival (DFS) was analyzed. Results: The 
8 SNPs (CD3EAP rs967591, TNFRSF10B rs1047266, AKT1 rs3803300, C3 
rs2287845,  HOMER2 rs1256428, GNB2L1rs3756585, ADAMTSL3 rs11259927, 
and CD3D rs3181259) were significantly associated with OS and/or DFS. Combining 
those 8 SNPs, we designed a prognostic index to predict the prognosis of patients. 
According to relative risk of death, a score value was assigned to each genotype 
of the SNPs in the genetic model which best explains the association between 
genotypes and prognosis for each SNP. When we categorized the patients into 
two groups based on the prognostic index, high risk group was significantly 
associated with worse OS and DFS compared to low risk group (aHR for OS = 
2.21, 95% CI = 1.69-2.88, P = 8.0 x 10-9, and aHR for DFS = 1.58, 95% CI = 1.29-
1.94, P = 1.0 x 10-5). Conclusion: Prognostic index using 8 genetic polymorphisms 
may be useful for the prognostication of patients with surgically resected NSCLC. 
Keywords: Cancer-Related Gene polymorphism, Lung cancer survival
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P3.04-080 Combination of BMI and OLR1 in Prognosis Prediction of Patients 
with Squamous Non-Small Cell Lung Cancer Shanshan Jiang1, Long Jiang2, 
Jianchuan Xia1 1Sun Yat-Sen University Cancer Center, Guangzhou/China, 2Department 
of Surgery, University of California, San Francisco (Ucsf), San Francisco/United States of 
America
Background: Lung cancer, especially non-small cell lung cancer (NSCLC), represents 
enormous challenges in continuously achieving treatment improvements. Besides 
cancer, obesity is becoming more and more prevalent. Obesity is increasingly recognized 
as a major risk factor for several types of common cancers. Significant mechanisms 
overlap in the pathobiology of obesity and tumorigenesis. One of these mechanisms 
involves oxidized low density lipoprotein receptor 1 (OLR1), as link between obesity 
and cancer. Additionally, body mass index (BMI) has been widely used in exploiting 
the role of obesity on a series of diseases, including cancer. Significantly, squamous 
NSCLC revealed to be divergent clinical and molecular phenotypes compared with non-
squamous NSCLC. Methods: Chart review was performed on 1286 consecutive patients 
who suffered from squamous NSCLC with between November 2004 and March 2008. 
131 of the 1286 patients were enrolled in the final analysis. These 131 patients were 
randomly assigned (2:1) centrally by computer into training group (n=87) and validation 
group (n=44). BMI was calculated as follow: BMI (kg/m2) = weight (kg)/height (m2). 
Surgically resected or biopsied specimens were fixed in formalin and embedded in 
paraffin for routine histopathological diagnosis and immunohistochemical analysis. 
Then, PFS was defined as the time from the first documentation to the time of tumor 
progression or death. The total OLR1 immunostaining score was calculated as the sum of 
the positively stained tumor cells and staining intensity. OLR1 immunostaining score and 
BMI were assessed by Fisher’s linear discriminant analysis to discriminate if progression-
free survival (PFS) would exceeding 2 years. Results: The mean follow-up for survivors 
as of December 2014 was 47.23 months. Mean PFS was 724 days and the overall 1-, 
2- and 3-year PFS rates were 87.8%, 47.3% and 39.7%, respectively. OLR1 expressed 
on tumor cells. There was no significant difference between the training (n=87) and 
validation (n=44) cohorts (P > 0.1). The clinical classifying model was described by 
the following equation: Y = -5.811 + 1.285 ×OLR1 immunostaining score + 0.152 ×BMI 
(eigenvalue 1.272, canonical correlation 0.748, P < 0.001). Group centroids for PFS 
<= 2 years and PFS > 2 years were 0.914 and - 1.359, respectively. Next, a cut score 
halfway between the two centroids was determined: cut score= (−1.359 + 0.914)/2 = 
-0.2225. For the training set of 87 leave-one-out-cross-validated cases, 49 of 52 PFS > 2 
years (94.2% sensitivity) and 30 of 35 PFS <= 2 years (85.7% specificity) were correctly 
classified with an overall accuracy of 90.8% (79 of 87) and an area under the curve (AUC) 
of 0.938. In the validation set, survival prediction for 40 of the 44 patients (90.9%) with 
an AUC of 0.979was achieved. Conclusion: The analysis of combination of BMI and OLR1 
could effectively and reproducibly classify patients with squamous NCSLC according 
to their PFS. Further prospective validation in larger independent cohorts of patients 
with similar or different regimens is warranted to fully assess its predictive power. 
However, the combinational model offers a novel tool for survival prediction and could 
provide a framework for future individualized therapy in patients with squamous NCSLC. 
Keywords: Squamous non-small cell lung cancer, Oxidized low density lipoprotein 
receptor 1, Body mass index, Prediction model
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P3.04-084 Analytical Validation of a Proliferation-Based Molecular Signature 
Used as a Prognostic Marker in Early Stage Lung Adenocarcinoma 
M Bryan Warf1, Placede G. Fosso1, Elisha Hughes1, Michael Perry1, Krystal Brown2, Julia 
E. Reid1, Kathryn A. Kolquist2, Susanne Wagner1, Alexander Gutin1, Benjamin Roa1 
1Myriad Genetics, Inc., Salt Lake City/UT/United States of America, 2Myriad Genetic 
Laboratories, Inc., Salt Lake City/UT/United States of America
Background: We have developed a gene expression signature that provides prognostic 
information for patients with early stage lung adenocarcinoma that would benefit from 
adjuvant chemotherapy. This signature uses quantitative reverse transcription PCR to 
measure RNA expression of 31 cell-cycle progression (CCP) genes normalized to 15 
housekeeping genes to provide a quantitative CCP score. The signature can identify 
aggressive early stage tumors that might be suitable for post-surgical therapy. The 
aim of these studies was to validate the analytical performance of the CCP gene 
signature. Methods: The analytical performance of the CCP gene signature was evaluated 
using formalin-fixed, paraffin-embedded lung resections by assessing parameters such 
as precision, dynamic range, and RNA input requirements. Results: The signature had a 
standard deviation (SD) of 0.06 score units, which is 1% of the clinical range of scores. 
The dynamic range of CCP scores in this signature was from -13 and 14 score units. The 
average amplicon efficiencies for target and housekeeper genes were comparable at 
107% and 105%, respectively. All but one amplicon had a SD <0.5 CT. The gene signature 
reproducibly generated a consistent CCP score with RNA input concentrations between 
0.12 and 62.5 ng/µL, which is considerably larger than the concentration ranges used 
for clinical testing (2–40 ng/µL). Conclusion: These studies demonstrate that the gene 
signature is robust and reproducible, making it suitable for use in a clinical setting. 
Keywords: Gene Expression, Cell-Cycle Progression, quantitative RT-PCR, Early Stage 
Lung Adenocarcinoma
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P3.04-085 Anti-Glycan Antibody Profiling in De-Novo Stage IV Non-Small Cell 
Lung Cancer: A Pilot Study Nagashree Seetharamu1, Marko Vuskovic2, Abraham 
Chachoua3, Geraldine Brusca-Augello4, Anna-Maria Barbuti5, Jennifer E. Thomson5, 
Ingrid Gills5, Jordan Preiss5, Sasha Joseph3, Hilary Ma3, William N. Rom6, Margaret E. 
Huflejt5 1Medical Oncology, Hofstra Northshore-Lij School of Medicine, New Hyde Park/NY/
United States of America, 2Department of Computer Science, San Diego State University, 
San Diego/CA/United States of America, 3Department of Medical Oncology, New York 
University Langone Medical Center, New York/United States of America, 4Department of 
Radiology, New York University Langone Medical Center, New York/NY/United States of 
America, 5Department of Cardiothoracic Surgery, New York University Langone Medical 
Center, New York/NY/United States of America, 6Division of Pulmonary Medicine, New York 
University School of Medicine, New York/NY/United States of America
Background: NSCLC is a heterogeneous disease with marked molecular and genomic 
variability that usually presents in advanced stage. Aberrant glycosylation occurs early 
during malignant transformation producing tumor-associated carbohydrate antigens 
(TACAs). Immune response to TACAs can be evaluated by immunoprofiling serum anti-
glycan antibodies (AGAs) using printed glycan arrays (PGA), a new biomarker-discovery 
platform. Control and stage I NSCLC immunoprofiles were evaluated in a parallel study 
involving 70 subjects with high risk for developing lung cancer enrolled in low-dose CT 
lung cancer screening trial, 20 of who subsequently developed stage I NSCLC and a 
putative signature for early stage NSCLC has been obtained. The objective of this study 
was to obtain a putative signature of de-novo stage IV NSCLC patients using serum AGA 
immunoprofiles. Methods: 18 patients were enrolled in this prospective study. Data 
collected included demographics, tumor histology, EGFR mutational status, and cancer 
treatment details. Blood sample was collected at each visit. Response was assessed 
after every two cycles of first-line chemotherapy regimen by a radiologist using RECIST 
1.1 and the best overall response and time-to-progression (TTP) were recorded. 
Patients were dichotomized as “good” or “poor” responders by median TTP. AGAs were 
immunoprofiled in 30 microliters of serum using PGA with 382 glycans. The raw PGA 
data were screened to remove glycans with critically low signal intensities, low Intra-array 
Correlation Coefficient (ICC) and high coefficient of variation (CV) of on-slide replicates. 
The raw data were normalized with intra-slide linear normalization, and log-transformed. 
The putative glycan signature was obtained by our novel Compound ImmunoRuler (CIR) 
algorithm based on bootstrap aggregation of multiple signatures derived from correlation-
(T1+T2, N0+N1, stage I + stage II) (All P<0.05). (P=0.001).
p-JAK1 is an independent predictor for poor prognosis (P=0.022). Further analysis 
showed that significance existed only in ADCC cases but not in SqCC. Survival time for 
p-JAK1(+)/EGFR(+) subjects was drastically shortened than the other 3 combinations 
 
Conclusion: Our results provided clinical evidence that activation of JAK1 
is an independent prognostic factor in early stage NSCLC, especially in 
ADCC. EGFR and p-JAK1 combination could be a new target for selecting 
individual therapy strategies and predicting therapeutic effect for NSCLC. 
Keywords: NSCLC, JAK1, EGFR, Prognosis
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P3.04-083 FGFR1, 2 and 3 Expression in Early Stage Non-Small-Cell Lung 
Cancer Willemijn Engelsman-Theelen1, Michel V.D. Heuvel1, Stefan Willems2, Lorenza 
Mittempergher3, Astrid J. Bosma3, Dennis D. Peters4, Hans J. Blaauwgeers5, Eva J. 
Japenga6, Carel J. Van Noesel7, Rene Bernards3 1Thoracic Oncology, NKI-AVL, Amsterdam/
Netherlands, 2Pathology, Umcu, Utrecht/Netherlands, 3Division of Molecular Carcinogenesis, 
NKI-AVL, Amsterdam/Netherlands, 4Molecular Pathology, NKI-AVL, Amsterdam/
Netherlands, 5Pathology, Olvg, Amsterdam/Netherlands, 6Pulmonology, Olvg, Amsterdam/
Netherlands, 7Pathology, Academic Medical Center, Amsterdam/Netherlands
Background: The aim of this study was to identify the protein expression levels of 
Fibroblast Growth Factor Receptors (FGFR) 1, 2 and 3 in early-stage non-small-cell lung 
carcinoma (NSCLC). Additionally, we performed a screen to define the frequency of 
FGFR3-TACC3 translocation and FGFR3 amplification. Methods: Archived tissue from 653 
NSCLC samples (adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell 
carcinoma (LCC)) was analyzed with immunohistochemistry (IHC) for expression of FGFR1, 
2 and 3. Expression levels of FGFR1, 2 and 3 were then correlated with clinicopathological 
features. The presence of FGFR3-TACC3 translocation was detected with RT-PCR and 
FGFR3 amplification was detected with FISH. Results: High protein expression of FGFR1, 
2 and 3 was shown in 65 (10.5%), 78 (12.9%) and 20 (3.2%) of NSCLC tumor samples, 
respectively. Expression of FGFR1 was associated with light smoking (p = 0.007), AC (p 
< 0.000) and worse overall survival (p < 0.04). Expression of FGFR2 was associated with 
female sex (p < 0.001), younger age (p = 0.01) and AC (p < 0.000). Expression of FGFR3 
was associated with male sex (p = 0.047), older patients (p = 0.01) and SCC (p < 0.000). 
FGFR3-TACC3 fusion was shown in 2.8% (6/210). In 45 FGFR3 IHC positive samples, 
two samples were FGFR3 amplified (4.4%) and one showed gain (2.2%). Conclusion: We 
show that FGFR1, 2 and 3 proteins are expressed in a significant number of NSCLC and 
identify some of the underlying molecular mechanisms. FGFR1 (but not FGFR2 and 3) 
protein overexpression is correlated with significant worse overall survival. FGFR1, 2 and 
3 protein overexpression may become a new target of treatment in patients with NSCLC. 
Keywords: FGFR3-TACC3, FGFR, NSCLC, IHC
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P3.04-087 NUT Expression in Surgically Treated Small Cell, Non-Small Cell 
and Carcinoid Tumors of the Lung Marius Lund-Iversen1, Krystyna K. Groholt1, Odd 
Terje Brustugun2, Elin Borgen1 1Pathology, Oslo University Hospital, Radiumhospitalet, 
Oslo/Norway, 2Oncology, Oslo University Hosital,The Norwegian Radium Hospital, Oslo/
Norwa, Oslo/Norway
Background: NUT midline carcinoma (NMT) is a rare, highly aggressive carcinoma 
defined by rearrangement of nuclear protein gene in testis (NUT) on chromosome 15; in 
most cases to bromodomain-containing protein 4 (BRD4) on chromosome 19. Although 
the majority of cases occur in midline structures above the diaphragm there are reports 
regarding cases in non-midline solid organs. There is an increased need to identify 
tumors with targetable mutations, and NUT-BRD4 translocations are potential goals for 
bromodomain and extra terminal (BET) inhibitors. The putative incidence among lung 
carcinomas low, but the true incidence is unknown. Methods: In a tissue micro array 
(TMA) set we investigated samples from 483 surgically resected lung tumors for the 
expression of the NUT protein using immunohistochemistry with monoclonal anti-NUT 
antibody (clone C52B1, Cell Signaling). 278 were adenocarcinomas, 140 squamous cell 
carcinomas, 30 large cell carcinomas, 7 small cell carcinoma, 18 carcinoid tumours and 
10 carcinoma not otherwise specified. The median age were 66.3 [33.9 – 87.0], 247 were 
males and 236 were females. Testis and two previously confirmed NMT served as positive 
controls. Lymph nodes and normal lung tissue served as negative controls. Results: The 
positive controls had distinct nuclear staining without any unspecific background. 
The negative controls and all tumours were completely negative for the anti-NUT 
staining. Conclusion: We did not find any NUT expression in the investigated set of 
tumors. The golden standard for showing NUT rearrangement are fluorescence in situ 
hybridization (FISH), but the sensitivity and specificity for immunohistochemistry are 
high, 87% and 100% respectively (Haack et al. Am J Surg Pathol 2010). Although we 
cannot exclude a minority to be false negative, NUT translocations does not seem to 
be a relevant differential diagnostic issue in unselected early stage lung carcinomas. 
Keywords: Pathology, NUT midline carcinoma, Predictive testing, Diagnostics
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P3.04-088 Matrix Proteoglycans Gene Expression Predicts Lung Cancer 
Patients Outcome Maristela P. Rangel1, Tabatha Prieto2, Eloisa R. Olivieri3, Dirce 
M. Carraro3, Vera L. Capelozzi4 1Pathology, Faculty of Medicine; University of Sao Paulo, 
São Paulo/Brazil, 2Pathology, Faculty of Medicine, University of Sao Paulo, São Paulo/
Brazil, 3Pathology, Ac Camargo Cancer Center, São Paulo/Brazil, 4Pathology, Faculdade de 
Medicina Da Usp, São Paulo/Brazil
Background: The relationship between the extracellular matrix (ECM) components and 
cancer cells have an important role on cancer development and progression. Between 
the most important molecules present on the ECM are the glycosaminoglycans(GAGs) 
and their respective proteoglycans (PGs). Studies have reported that they have different 
behaviours when in the presence of malignant tissues.The aim of this study was to 
analyse PGs gene expression in normal and tumoral areas of patients with lung cancer 
(LC) and to explore its association with GAGs concentration. Methods: Eighty-seven lung 
specimens were evaluated. Biglycan, glypican, perlecan, syndecan and versican gene 
expression were analysed by qRT-PCR and sulfated GAG chains(heparan, dermatan and 
chondroitin sulfate - HS, DS and CS)were obtained after incubation with a proteolytic 
enzyme.GAGs were precipitated with ethanol and the pellet was centrifugated, dried and 
dissolved in DNAse(5 l/mg).The different types of sulfated GAGs and their concentration 
in the lung samples were identified after gel electrophoresis in diaminopropane buffer. 
Statistical analyses included ANOVA, Paired-samples T Test, Spearman correlation, and 
logistic regression. Results: A significant increase of biglycan was found in tumor tissue 
compared to normal (52.30 ± 21.2 vs 11.28 ± 3.77; p=0.04). A significant association 
was found between biglycan vs glypican (R= 0.64; P<0.01), biglycan vs perlecan (R=0.70; 
P<0.01) and biglycan vs versican (R=0.68; P<0.01). Univariate analysis demonstrated 
that high expression of tumoral biglycan significantly related to squamous cell carcinoma 
histologic type (P=0.02) and death (P=0.03). Equally significant was the association 
between high syndecan expression, tobacco history (P<0.01) and tumoral recurrence 
(P=0.04). Logistic regression analysis controlled for age, gender, Tstage, Nstage, 
histologic types and proteoglycans expression showed that higher biglycan expression 
was and independent predictor of death [OR= 1.44 (0.88-2.36)]. Those with higher relative 
expression of biglycan had a high risk for death. In addition, we found that biglycan and 
glypican gene expression related significantly to tumoral heparan sulphate concentration 
in tumoral tissue (R=0.38; P=0.04 and R=0.41; P=0.03). Conclusion: Different 
expression of PGs in lung cancer samples, its relationship with histologic types and 
death suggest a possible role of these PGs in this malignancy, but more importantly 
provide a potential biomolecular marker to predict outcome.The correlation between 
the histologic types and the expression of biglycan provide a possible role of this PG on 
the development of tumor agressiveness considering that one of its functions is to bind 
itself to growth factors and regulate their action. Moreover, the relationship between 
heparan sulphate concentration, biglycan and glypican gene expression might indicate 
what sort of PGs are produced by tumoral tissue considering that heparan sulphate is the 
GAG chain in these PGs. Further studies are needed to determine whether or not these 
PGs gene expression are able to be predict prognosis and tumoral aggressiveness. 
Keywords: proteoglycans, lung cancer outcome, extracellular matrix, biglycan
adjusted Wilcoxon ranking using projections based on multivariate logistic regression. 
The training of CIR was performed on the baseline immunoprofiles of de novo stage IV 
samples with control immunoprofiles from the screening trial. Results: Study population 
included 11 males and 7 females. Mean age was 62 years (range 47-80). 15 patients 
(83%) had adenocarcinoma, two squamous, and one poorly differentiated. Two had 
EGFR mutation. Most common regimen was platinum/pemetrexed (n=14) followed by 
platinum/gemcitabine (n=2) and erlotinib (n=2). One patient had a complete response 
(CR); 6 PR and 4 had stable disease while 7 progressed. The median TTP was 140 
days (41-387). For PGA data analyses, 278 glycans with ICC>80% were used for 
downstream analysis which delivered 3 glycans-based putative signature of Stage IV de 
novo NSCLC with AUC value 0.956; specificity 86%, and sensitivity 88.9%. Glycans in 
signatures of stage I and de-novo stage IV NSCLC were distinctly different. When 
immunoprofiles of stage IV NSCLC were projected on stage I ImmunoRuler, 13 out 
of 18 (72%) stage IV patients were accurately recognized as malignant. AGA binding 
to 4 glycans was significantly different between the sub-groups of “poor” vs. “good” 
responders. Conclusion: Uniquely different serum AGA-signatures of early stage 
and de novo stage IV lung cancer may provide basis for minimally-invasive test for early 
detection of risk for these malignancies and for better understanding their underlying 
pathologies. Further study in a larger population should help validate these findings. 
Keywords: non-small cell lung cancer, anti-glycan antibody profiling, ImmunoRuler
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P3.04-086 REQUITE: Validating Predictive Models and Biomarkers of RT 
Toxicity to Reduce Side Effects and Improve QOL Dirk De Ruysscher1, David 
Azria2, Jenny Chang-Claude3, Susan Davidson4, Alison Dunning5, Philippe Lambin6, Barry 
Rosenstein7, Chris Talbot8, Hubert Thierens9, Riccardo Valdagni10, Ana Vega11, Catharine 
West12 1Experimental Radiation Oncology, Ku Leuven, Leuven/Belgium, 2Radiation Oncology, 
University of Montpellier, Montpellier/France, 3Radiation Oncology, 3German Cancer 
Research Centre (Dkfz), Heidelberg/Germany, 4The Christie Hospital NHS Trust, Manchester/
United Kingdom, 5University of Cambridge, Cambridge/United Kingdom, 6Department of 
Radiation Oncology (Maastro), Grow-School for Oncology and Developmental Biology, 
Maastricht University Medical Centre, Maastricht/Netherlands, 77Mount Sinai School of 
Medicine, New York, New York/AL/United States of America, 8University of Leicester, 
Leicester/United Kingdom, 9Universiteit Gent, Gent/Belgium, 10Fondazione Irccs Istituto 
Nazionale Dei Tumori, Milano/Italy, 11Fundación Pública Galega Medicina Xenómica, Santiago 
de Compostela/Spain, 12University of Manchester, Manchester/United Kingdom
Background: Recently the first replicated genetic associations for radiotherapy-induced 
adverse reactions were reported. These should improve the power of toxicity prediction 
models, opening the way to an optimised radiotherapy delivery and interventions to 
alleviate the side effects. The European Union funded REQUITE consortium aims to 
validate known predictors of adverse reactions and to develop statistical models 
resulting in clinically useful models. The focus of the project is on breast, prostate and 
lung cancer. As the barrier to clinical impact is the lack of validated statistical models 
incorporating genetic predictors, and the barrier to validation is the lack of standardised 
data collection, the main objectives of the REQUITE project are the following:
• Perform a multi-centre cohort study collecting blood samples, epidemiology and 
treatment data, longitudinal side effect and quality of life (QOL) data (before and 
after treatment: years 1 and 2 for breast and prostate cancer; with additional 3 and 
6 month timepoints for lung cancer).
• Produce a centralized database and biobank of DNA for 5300 patients.
• Validate published biomarkers of radiosensitivity.
• Validate clinical predictors of radiotherapy toxicity in breast, prostate and lung 
cancer and incorporate biomarker data.
• Design interventional trials to reduce long-term side effects.
• Provide a resource for dissemination and exploitation to the radiotherapy 
community.
Methods: The central activity of the project is a multi-centre, observational study 
organized through WP2. Enrolment will proceed for two years in nine centres (eight in 
Europe and one in the United States), with another two years of follow-up. The primary 
endpoints are change in breast appearance at two years (breast), rectal bleeding at two 
years (prostate) and pneumonitis at 6 months (lung). An integrated study database is 
designed. Blood samples are collected before radiotherapy. Tracking, biobanking and 
DNA extraction is handled in WP3. Validation of biomarkers (genetic markers and apoptosis 
assays) as predictive factors is carried out in WP4. Some clinical factors have suggested 
predictive value for radiotherapy side effects, but there is no consensus. In WP5 these 
will be validated in existing cohorts. Finally, in WP6, predictive models will be used to 
design clinical interventional trials and produce protocols that seek to lower radiotherapy 
side effects, in those individuals at high risk of developing them, without affecting tumour 
control. Patient advocates will play an essential role in this effort. Results: Standardised 
data collection forms were generated. Questionnaires for collecting patient reported 
toxicity according to Common Toxicity Criteria for Adverse Events were developed in 
different languages. These forms and questionnaires are available at http://www.requite.
eu/. A centralised database for electronic data capture and storage was developed. 
Ethical approval for the observational study was obtained in all centres. More than 
1300 patients were enrolled in the REQUITE study to this date. Conclusion: Centralised 
collection of standardised data and biobanking is practical for lung cancer patients 
undergoing radiotherapy in routine clinical practice in a multi-centre, multi-national setting. 
Keywords: radiotherapy toxicity, biomarkers, predictive models, multi-centre cohort 
study
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P3.04-091 Expression of Cytoplasmic ECT2 as a New Prognostic Marker for 
Early-Stage Lung Adenocarcinoma Yoshihiko Murata1, Zeinab Kosibaty2, Yuko 
Minami3, Masayuki Noguchi3 1Department of Pathology, Univerysity of Tsukuba Hospital, 
Tsukuba-Shi, Ibaraki/Japan, 2Grad. Sch. of Comprehensive Human Sciences, University 
of Tsukuba, Tsukuba-Shi, Ibaraki/Japan, 3Faculty of Medicine, Department of Pathology, 
Univerysity of Tsukuba, Tsukuba/Japan
Background: We have examined genetic abnormalities in early-stage lung 
adenocarcinoma (LAd) using array-comparative genomic hybridization (array-CGH) 
and found that ECT2 amplification and overexpression can be a new prognostic marker 
(Cancer Science, 2014). In normal cells, ECT2 is localized in the nucleus, and its 
function is associated with cytokinesis. In cancer cells, however, ECT2 is thought to 
exist in the cytoplasm as well as the nucleus. In the cytoplasm, ECT2 is reported to 
bind to PKCi-Par6a and activate the Rac1 and MAPK pathway. Therefore, cytoplasmic 
ECT2 is thought to be associated with tumor growth and invasion. In the present study, 
we examined the clinicopathological implication of cytoplasmic ECT2 in terms of 
patient outcome, and also the biological significance of cytoplasmic ECT2 using lung 
adenocarcinoma cell lines. Methods: To examine the clinicopathological implication of 
cytoplasmic ECT2, 66 cases of various types of lung adenocarcinoma were examined 
using immunohistochemistry (IHC). Nine lung adenocarcinoma cell lines – A549, Calu-
3, HCC827, LC-2/ad, NCI-H23, NCI-H1650, NCI-H1975, PC-9 and RERF-LC-KJ – were 
genetically examined for ECT2 amplification using FISH and for intracellular localization 
of ECT2 by Western blotting. Results: Overexpression of ECT2 in the nucleus was closely 
associated with the MIB-1 index (r=0.76) and was a strong prognostic factor of lung 
adenocarcinoma (OS; P=0.0096, DFS; P=0.019). On the other hand, cytoplasmic ECT2 
was also associated with patient outcome (OS; P=0.02, DFS; P=0.023). Two of the nine 
lung adenocarcinoma cell lines, Calu-3 and A549, expressed ECT2 in the cytoplasm as 
well as the nucleus.
 
Conclusion: Cytoplasmic ECT2 is a prognostic factor of lung adenocarcinoma, and 
some lung adenocarcinoma cell lines show localization of ECT2 in the cytoplasm as well 
as the nucleus.
Keywords: Cytoplasmic ECT2, lung adenocarcinoma, prognostic marker, 
Immunohistochemistry
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P3.04-092 HNF4α Is a Marker for Invasive Mucinous Adenocarcinoma (IMA) 
and a Prognostic Factor in Stage I Lung Adenocarcinoma (LADC) 
Takashi Eguchi1, Kyuichi Kadota2, Charles Leduc3, Natasha Rekhtman3, Andre Moreira3, 
David R. Jones1, Prasad S. Adusumilli4 1Thoracic Service, Department of Surgery, Memorial 
Sloan Kettering Cancer Center, New York/NY/United States of America, 2Department 
of Diagnostic Pathology, Kagawa University, Kagawa/Japan, 3Department of Pathology, 
Memorial Sloan Kettering Cancer Center, New York/NY/United States of America, 4Thoracic 
Service and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York/
NY/United States of America
Background: According to the 2015 WHO classification, invasive LADC with prominent 
apical intra-cytoplasmic mucin and small basally oriented nuclei, formerly referred to as 
mucinous bronchioloalveolar carcinoma, is classified as IMA. Hepatocyte nuclear factor 
4 alpha (HNF4α) is a recently recognized marker for IMA although it is also infrequently 
positive for other subtypes of LADC. However, the prognostic significance of HNF4α is 
not known. We investigated the frequency of HNF4α expression in IMA as well as non-IMA 
subtypes, and the prognostic significance of HNF4α in Stage I LADC. Methods: Slides 
from patients with therapy-naive, surgically resected solitary stage I LADC (1995-2009) 
were subtyped according to the 2015 WHO classification. Tissue microarrays were 
constructed from each tumor (n=793), and stained for HNF4α. HNF4α expression 
intensity (0-3) and distribution (1, 1%-50%; 2, 51%-100%) were summed into a total score 
(0-5) and dichotomized as negative (score <2) or positive (score ≥2). Comparisons were 
made with TTF-1 expression. Recurrence-free probability (RFP) was estimated using 
the Kaplan-Meier method, and multivariate analyses were performed using the Cox 
proportional hazards model. Results: 32 cases were identified as IMA. Of all LADC, HNF4α 
was positive in 68 cases (9%) including72% (n = 23) of IMA, 6% (n = 45) of tumors with non-
IMA subtypes (P < 0.001). Among non-IMA subtypes, HNF4α was positive in 6% of lepidic, 
4% of papillary, 2% of micropapillary, 7% of solid, and 29% of colloid tumors. HNF4α was 
positive in 12% of KRAS mutant tumors while it was negative in all EGFR mutant tumors (P 
< 0.001). HNF4α was more frequently positive in TTF-1 negative tumors (40%) than TTF-
1 positive tumors (5%; P < 0.001). The RFP for patients with HNF4α-positive tumors was 
significantly lower than that for patients with HNF4α-negative tumors (P = 0.002) in the 
entire cohort. This finding was confirmed in subgroup analysis of patients with non-IMA 
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P3.04-089 Prospective Use of Prognostic Molecular Assay Identifies Patients 
at Risk for Recurrence and Changes Clinical Management in Early-Stage 
NSCLC Gavitt A. Woodard1, Johannes R. Kratz1, Matthew A. Gubens2, Thierry Marie 
Jahan2, Kirk Jones3, Pierre Theodore1, Jasleen Kukreja1, Michael Mann1, David Jablons1 
1Thoracic Surgery, University of California, San Francisco/CA/United States of 
America, 2Medicine (Oncology), University of California San Francisco Medical Center, San 
Francisco/United States of America, 3Pathology, University of California San Francisco 
Medical Center, San Francisco/CA/United States of America
Background: Adjuvant chemotherapy recommendations depend on identification 
of early-stage non-small-cell lung cancer (NSCLC) patients at high-risk of recurrence. 
Current National Comprehensive Cancer Network (NCCN) guidelines use certain 
clinicopathologic features to make this recommendation for stage Ib-IIa patients. An 
internationally validated, 14-gene expression assay has been shown retrospectively 
to better stratify mortality risk in non-squamous NSCLC than conventional 
staging. Methods: Following up on a previously reported cohort of 52 patients, 
prospective molecular risk-stratification by the 14-gene test was performed in 66 
patients with a mean follow up of 20.7 ±14.1 months. Disease-free survival and lung 
cancer mortality rates were compared between high- and low-risk patients by both 
molecular risk-stratification and NCCN “high-risk” characteristics. Results: Patients 
with low-, intermediate-, and high-risk based on molecular testing had recurrence rates 
of 4%, 8%, and 28% (p=.031, Fisher’s exact test) and lung cancer mortalities of 0%, 
0%, and 16% (p=.039), respectively. Molecular high-risk was associated with shorter 
disease-free survival (p=.043, Kaplan-Meier log-rank). Molecular risk assessment was 
discordant from NCCN “high-risk” features in 15 of 25 stage Ib-IIa patients (60%). NCCN 
criteria failed to significantly predict either recurrence or mortality with recurrence rates 
of 8% and 23% (p=.077, Fisher’s exact test) and lung cancer related mortality of 3% 
and 12% (p=.165) among patients with NCCN low- and high-risk features respectively. 
Molecular high-risk scores changed adjuvant chemotherapy recommendations 
in 3 of 10 (30%) patients who otherwise did not meet NCCN criteria for adjuvant 
chemotherapy. Conclusion: This study demonstrates that prospective application of 
a 14-gene prognostic assay significantly predicts differences in disease-free survival. 
This prognostic information differs from NCCN high-risk clinicopathologic features 
and has clinical utility in better informing adjuvant chemotherapy recommendations. 
Keywords: Recurrence predictors, Prognostic molecular assay, adjuvant chemotherapy, 
Genetic signature
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P3.04-090 Association of Nuclear Expression of RAR Beta and YY1 with 
Prognosis in Advance Non-Small Cell Lung Cancer Saé Muñiz-Hernández1, Sara 
Huerta-Yepez2, Laura-Alejandra Ramírez-Tirado1, Alejandro Aviles-Salas3, Altagracia 
Maldonado2, Daniel Hernández-Cueto2, Norma Hernández-Pedro1, Oscar Arrieta 
Rodriguez4 1Laboratory of Experimental Oncology, National Cancer Institute, Mexico, Df/
Mexico, 2Hospital Infantil de Mexico “Federico Gómez”, Mexico, Df/Mexico, 3Pathology, 
National Cancer Institute, Mexico, Df/Mexico, 4Laboratory of Experimental Oncology and 
Thoracic Oncology Unit, National Institute of Cancer, Mexico City/Mexico
Background: Lung cancer is the most common cause of cancer-related death worldwide 
and it is responsible for approximately 1.4 million deceases per year. In Mexico, the NSCLC 
cause more than 6,697 deaths annually. Approximately, 85% of all lung cancer corresponds 
to NSCLC and unfortunately at diagnosis 60% patients have advanced unresectable 
disease with a very poor prognosis. The standard of care treatment for advanced disease 
is platinum-based doublet chemotherapy, this present an objective response rates of 19% 
to 37% with a 7 to 10 months of median survival. The identification of molecular alteration 
in NSCLC has transformed the clinical management of this disease, increasing the survival 
and improves the response in patients. The genetic alterations affect a common group of 
oncogenic signaling pathways such as retinoid receptors (RR) and yin and yang 1 (YY1) 
resulting in lung cancer development and progression. The nuclear RR may play a critical 
role in the process of lung carcinogenesis. In NSCLC, reduction in the levels of mRNA 
RARβ and RARα have associated with lack of response to treatment and progression. 
As the same manner, YY1 is a key regulator of multiple signaling pathways involved in 
differentiation, replication, cellular proliferation and oncogenic transformation. The role of 
YY1 in development of cancer depend upon the context in which it binds. It could activate 
a variety of oncoproteins attenuates the stability of the tumor suppressor such as p53 or 
mediates the activation of genes with tumor-suppressive functions. The aim of this study 
was to analyze the expression of RARα, RARβ and YY1 and its relationship with overall 
survival in patients with advanced NSCLC. Methods: This was an observational study, 
where patients with advanced NSCLC at the National Cancer Institute of Mexico City from 
July 2005 to December 2011 were enrolled. The expression of RARα, RARβ and YY1, was 
determinate with immunohistochemistry by mean digital pathology and analyzed by Image-
Pro Plus. Results: Eighty-five patients were included for the analysis. The mean and standard 
deviation of the nuclei expression of RARα, RARβ and YY1 were (106.7±97), (14±13) 
and (13±12). Patients with a high RARβ total expression have a better ECOG 0-1 vs 2-3 
performance status (92.9 vs 74.4%). Non-smokers had a high nuclei expression of YY1 (61.9 
vs <40.5%) and better median OS 15.6 (4.5-26.7 months). Nuclei expression of RAR-β was 
associated with the nuclei expression of YY-1 (R2 = 0.28; p-Value <0.0001). Also, the higher 
nuclei expression of RARβ was associated with a higher OS (27.5 vs 8.7 months) in both, 
the univariate analysis and multivariate analysis (p=0.016; p=0.037). Conclusion: The 
nuclei expression of both RARβ and YY1, could be used as biomarkers to NSCLC 
prognosis, specifically YY1 predicted a better response in patient that had never smoke. 
Keywords: RETINOIC ACID RECEPTOR BETA, YING-YANG 1, ADVANCE NON-SMALL CELL 
LUNG CANCER, Biomarkers
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with rpS6 interference (all P < 0.05). Furthermore, upstream overexpression or 
knockdown of Akt2, rather than Akt1 or Akt3, resulted in striking hyperphosphorylation 
or dephosphorylation of mTOR, p70S6K and rpS6 (all P < 0.05). These might be the 
underlying mechanisms in which rpS6 overactivation promotes the development of 
NSCLC. Conclusion: Hyperphosphorylation of rpS6, probably regulated by the Akt2/
mTOR/p70S6K signaling pathway, is closely relevant to the progression of NSCLC 
and it might be served as a promising therapeutic target for NSCLC treatment. 
Keywords: non-small cell lung cancer (NSCLC), Hyperphosphorylation, survival, 
Ribosomal protein S6 (rpS6)
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P3.04-095 Intensity Expression of DOK2 as a Prognostic Marker in Patients 
with Advanced Stage of Lung Adenocarcinoma Huang-Chih Chang1, Yung-Che 
Chen1, Chang-Chun Hsiao2, Meng-Chih Lin1 1Division of Pulmonary and Critical Care 
Medicine, Department of Internal Medicine,, Kaohsiung Chang Gung Memorial Hospital and 
Chang Gung University College of Medicine, Kaohsiung/Taiwan, 2Graduate Institute of Clinical 
Medical Sciences,, Chang Gung University College of Medicine, Kaohsiung/Taiwan
Background: DOK family is an adaptor proteins that function in feedback loops to 
modulate tyrosine kinase signaling, including epidermal growth factor receptor, c-Kit and 
platelet-derived growth factor receptor. Our previous study has shown that DOK2 was 
up-regulated in PBMC of NSCLC patients, and partially reversed after chemotherapy. We 
speculated that DOK2 levels in tumor tissue may be used to predict outcome of non-small 
cell lung cancer. The aim of this study is to determine the significance of DOK2 in advanced 
stage of lung adenocarcinoma. Methods: We retrospectively reviewed the data of 87 
advanced stage of lung adenocarcinoma patients from Kaohsiung Chang Gung Memorial 
Hospital, Taiwan between Jan 2008 and Dec 2009. Tumor tissue was analyzed for DOK2 
protein expressions detected via immunohistochemistry and specimens were classified 
into high or low DOK2 expression groups. Correlation with survival and clinicopathological 
parameters were undertaken. Results: DOK2 expression was confirmed in the advanced 
stage of lung adenocarcinoma tissue. Considerable differences in the protein expression 
were noted among the lung adenocarcinoma tissue. Patients were classified to high 
intensity DOK2 stained expression (n=53, 60.9%) or low intensity stained DOK2 
expression (n=34, 39.1%), There were no significant correlation was found between DOK2 
expression and clinicopathologic factor such as TNM stage, tumor size, performance 
status, comorbidity and treatment. Patients with low intensity DOK2 expression were 
significant and independent determinants of poor progressive free survival (9.5ms vs 
4.3ms, P= 0.018) and overall survival (19.9ms vs 6.8ms, P= 0.013). Conclusion: Our 
study suggests the potential usefulness of DOK2 as a clinical marker for evaluating 
the advanced stage of lung adenocarcinoma progression and prognostic value. 
Prospective survey and mechanism studies are needed for further confirmation. 
Keywords: DOK2, non small cell lung cancer, biomarker
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P3.04-096 A Feasibility Pilot Study Testing Six DNA Methylation Markers to 
Improve Detection of Malignant Pleural Effusions in Lung Cancer 
Joshua A. Boys, Stephanie G. Worrell, Mihaela Campan, Victoria A. Scala, James M. 
Tatum, Jeffrey A. Hagen, Ite Laird-Offringa, Daniel S. Oh Department of Surgery, Norris 
Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 
Los Angeles/CA/United States of America
Background: Patients presenting with pleural effusion and suspected primary lung 
cancer raise suspicion for pleural metastasis. Accurate diagnosis is critical; metastatic 
pleural effusion indicates stage IV disease with significantly different treatment and 
prognosis. Currently diagnosis is obtained by cytology, however the mean sensitivity 
of cytology is only 60%. Lung cancer-specific DNA methylation markers may improve 
sensitivity. Here we determine whether six previously identified DNA methylation markers 
can detect malignancy in pleural effusions of lung cancer patients. Methods: Pleural 
effusions were collected from one small cell lung cancer (SCLC), 5 non-small cell 
lung cancer (NSCLC) and 3 patients with benign conditions not suspicious for cancer, 
presenting to USC Keck Hospital and Los Angeles County Hospital (June 2013 to March 
2015). The 6 lung cancer patients underwent drainage and pleural fluid cytology. Samples 
were centrifuged (3000g, 10 minutes) to remove cellular material. DNA was extracted 
from 1 ml of pleural fluid and bisulfite converted. MethyLight was used to quantitate 
the methylation levels of the markers. The preliminary specificity and sensitivity were 
calculated. Results: Percent of methylated reference (PMR, a measure of methylation 
levels compared to enzymatically fully methylated DNA) is shown in Table 1. Markers 
LuCa-1 and LuCa-2 had 100% sensitivity and 100% specificity (Table 2). Two patients 
(5 and 6) had negative cytology but positive malignancy based on markers. Pathologic 
confirmation of malignant involvement of the pleura was obtained in both cases, one with 
a different cytology specimen and the other by thoracoscopic exploration.
subtypes (P = 0.009). In multivariate analysis, HNF4α was an independent prognostic 
factor for recurrence (HR=1.61, 95%CI =1.27-2.02, p<0.001). Conclusion:HNF4α 
expression was significantly associated with IMA histology, negative EGFR mutation 
status, and TTF-1 negativity. Furthermore HNF4α was also expressed infrequently 
in non-IMA subtypes, however in these patients it was a significant prognostic factor. 
Keywords: invasive mucinous adenocarcinoma, HNF4-alpha, lung adenocarcinoma, 
prognostic marker
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P3.04-093 Neutrophil/Lymphocyte Ratios Inversely Related to Weight Change, 
Overall Survival; ALI Inversely Related to OS in NSCLC Pts. Marta Batus1, Jason 
Macklis2, Mary Fidler3, Sanjib Basu4, Jeffrey A. Borgia4, Mohammed Azeem3, David 
Sher3, Philip Bonomi4 1Hematology, Oncology and Cell Therapy, Rush University Medical 
Center, Chicago/AL/United States of America, 2Rush University Medical Center, Chicago/
AL/United States of America, 3Rush University Medical Center, Chicago/United States of 
America, 4Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago/
United States of America
Background: A high neutrophil/lymphocyte ratio (NLR) at baseline and at follow-
up is associated with shorter survival in cancer patients and may be a surrogate for 
ongoing inflammation which is implicated in promoting cancer cachexia and tumor 
progression. The objective of this study is to explore potential relationships between 
OS, serial weights, and serial NLRs and ALI (Advanced Lung cancer Inflammatory) index 
in advanced NSCLC patients receiving chemotherapy. Methods: 139 stage III/IV NSCLC 
pts were treated with first-line platinum doublets from June, 2011 to August, 2012. NLR 
and body weight were recorded at baseline, 6, and 12 weeks from initiation of therapy 
and correlated with OS. The association between NLR and OS was assessed using 
Cox PH analysis, and the association between NLR and weight change was assessed 
using a simple regression analysis. ALI index was defined as BMI (Body Mass Index) x 
(Albumin)/NLR. ALI was calculated at baseline, 6, and 12 weeks from initiation of therapy 
and correlated with OS for some pts. Results: 139 pts with median age 68, PS 0-1/2 
= 83/17%, male/ female = 48%/52%. NLR at baseline median 3.6, range 0.1898 to 
30.910; at 6wks median 3.11, range 0.2703 to 42.11; at 12wks median 3.52 range 
0.2147 to 42.93. Increase in the NLR at baseline, 6, and 12 weeks were associated 
with a decrease in OS (baseline HR 1.06, p < 0.001; 6 wks HR 1.07, p = 0.001; 12wks 
HR 1.05, p < 0.001). The effect of NLR on hazard is multiplicative (i.e. a change of 5 in 
baseline NLR results in a HR of 1.065). Initial weight and NLR were negatively correlated 
(cor = -0.267, p = 0.001), and weight change and NLR were also negatively correlated 
at 12wks (cor = -0.371, p < 0.001; weight change -13.17kg to +16.61kg, median 
-0.5kg, mean -0.89kg). 96, 93 and 84 pts had ALI score available at baseline, 6wks, 
and 12 wks respectively. 38 pts with baseline ALI score <= 18 had significantly lower 
OS (median OS=9.63 mos) compared to 58 pts with ALI > 18 (median not reached, p 
= 0.001). 41 pts with 6 week ALI <= 18 had significantly lower OS (median OS=11.4 
mos) compared to 52 pts with ALI > 18 (median not reached, p = 0.03). 30 pts with 12 
week ALI <= 18 had significantly lower OS (median OS=9 mos) compared to 54 pts with 
ALI > 18 (median not reached, p < 0.001). Conclusion: High baseline and progressive 
increase in NLRs are associated with inferior OS and weight loss in advanced NSCLC 
patients. In addition to having prognostic significance, these observations suggest 
that studying molecular mediators of cachexia/inflammation and their relationships to 
tumor progression may identify new therapeutic targets in the large subset of NSCLC 
patients who have cancer cachexia. We also confirmed findings by Jafri at all 2013, that 
ALI score <=18 is associated with lower OS at any time before or during treatment. 
Keywords: NEUTROPHIL, inflammation, Cachexia, lung cancer
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P3.04-094 Hyperphosphorylation of Ribosomal Protein S6 Predicts 
Unfavorable Clinical Survival in Non-Small Cell Lung Cancer Bojiang Chen, 
Weimin Li Department of Respiratory Medicine, China Hospital of Sichuan University, 
Chengdu/China
Background: Ribosomal protein S6 (rpS6), a component of the 40S ribosomal subunit, 
is involved in multiple cellular bioactivities. However, its clinicopathological significance 
in non-small cell lung cancer (NSCLC) is poorly understood. Methods:Expressions 
of total rpS6 (t-rpS6) and phosphorylated rpS6 (Ser235/236, p-rpS6) were detected 
immunohistochemically in 316 NSCLC tissues and 82 adjacent controls, followed by 
statistical evaluation of the relationship between proteins expressions and patients’ 
survivals to identify their prognostic values. Cytological experiments with overexpressing 
or silencing rpS6 by lentivirus in human bronchial epithelial (HBE) or NSCLC cell lines 
were performed to explore potential mechanisms by which rpS6 affects the clinical 
development of NSCLC. Additionally, RNA interference for Akt1, Akt2 and Akt3 were 
performed as well to investigate the upstream regulation of rpS6. Results: Positive 
rates of t-rpS6 and p-rpS6 were both significantly increased in NSCLC tissues, compared 
with controls (82.9% vs 62.2% for t-rpS6; 52.2% vs 22.0% for p-rpS6; both P < 0.001). 
However, only hyperphosphorylation of rpS6, expressed as either elevated p-rpS6 alone 
or the ratio of p-rpS6 to t-rpS6 (p-rpS6/t-rpS6) no less than 0.67, was greatly associated 
with the unfavorable survival of NSCLC patients, especially for cases at stage I (all P < 
0.001). The independent adverse prognostic value of hyperphosphorylated rpS6 was 
confirmed by multivariate Cox regression analysis (hazard ratios for elevated p-rpS6 
alone and p-rpS6/t-rpS6 no less than 0.67 were 2.403, 4.311 respectively, both P < 
0.001). Overexpression or knockdown of rpS6, along with parallel alterations of p-rpS6, 
led to increased or decreased cells proliferations respectively, which were dependent 
on redistributions of cell cycles (all P < 0.05). Cells migration and invasion also changed 
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P3.04-098 Bis Expression in Patients with Surgically Resected Lung Cancer 
and Its Clinical Significance Chang Dong Yeo1, Seung Joon Kim2 1Uijeongbu St. 
Mary’S Hospital, Uijeongbu/Korea, 2Department of Internal Medicine, The Catholic University 
of Korea, Seoul/Korea
Background: Bis, also known as BAG3, has been identified as a Bcl-2-interacting protein 
that enhances cellular anti-apoptotic activity. It is involved in cellular differentiation, 
angiogenesis, migration, and invasion in various tumors. The purpose of this study was 
to investigate the Bis expression pattern, and the clinical significance thereof, in patients 
with resected lung cancer. Methods: We studied 121 lung cancer patients who underwent 
curative surgical resection. Patient clinicopathological characteristics were reviewed 
retrospectively from medical records, including tumor recurrence and survival. The 
expression of Bis protein in lung cancer tissues was evaluated by immunohistochemical 
staining and was assessed using a four-tiered intensity score system (negative, weak, 
moderate, strong). Enhanced Bis expression at the periphery of a tumor facing the 
adjacent non-tumor region was referred as ‘marginal activity.’ Results: Although Bis 
expression was higher in squamous cell carcinoma than in adenocarcinoma, marginal 
activity was higher in adenocarcinoma than in squamous cell carcinoma. All of the small 
cell carcinomas and lung cancer with neuroendocrine differentiation examined were 
negative for Bis expression. Compared with stage I lung cancer, patients with stage II and 
IIIA lung cancer exhibited higher Bis protein levels in lung tissues. Recurrence and survival 
rates did not differ significantly according to Bis expression intensity score or marginal 
activity. Conclusion: Our study demonstrated that Bis expression differed according to 
the histological type and pathological stage of the lung cancer. Further studies are needed 
to assess its use as a biomarker and its role in the molecular pathogenesis of lung cancer. 
Keywords: Bis, lung cancer
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P3.04-099 Proteome Signatures with Prognostic Impact Distinguish Non-
Small Cell Lung Cancer Histology Subtypes and Metabolic States Wen Zhang1, 
Shingo Sakashita2, Paul Taylor3, Jiefei Tong3, Nhu-An Pham2, Vladimir Ignatchenko2, 
Melania Pintilie2, Thomas Kislinger2, Ming S. Tsao2, Michael Moran3 1University of Toronto, 
Toronto/Canada, 2Princess Margaret Cancer Centre, Toronto/ON/Canada, 3The Hospital for 
Sick Children Research Institute, Toronto/ON/Canada
Background: We showed that the ability to establish a primary tumorderived xenograft 
(PDX) is an independent predictor of shorter disease-free survival in early stage non-
small cell lung carcinoma (NSCLC). Hence, NSCLC engraftment may select for critical, 
aggressive aspects of the cancer phenotype linked to disease progression. More 
recently we reported dramatic remodeling of NSCLC proteomes not predicted by 
genomics analyses, and which distinguish between the major histological subtypes of 
NSCLC. Herein we report details on NSCLC proteome remodeling as a major determinant 
of the expression of the metabolism proteome, engraftment, and related to patient 
outcome. Methods: Omics platforms were used to comprehensively characterize 
the genomes and proteomes of non-engrafting, engrafting, and derived PDX tumors 
associated with NSCLC. To facilitate proteome quantification by mass spectrometry, 
tumor samples were spiked with stable-isotope-labeled proteomes from a mixture of 
representative NSCLC cell lines as an internal standard. Results: Proteome remodeling 
in NSCLC is extensive and largely unpredicted by gene copy number variation, and not 
highly correlated with mRNA-based expression. Analysis of the proteomes of cognate 
engrafting primary and PDX tumor pairs revealed signatures comprising sets of 
metabolism proteins that distinguished between the major histological subtypes, and 
which were particularly highly recapitulated in PDX tumors. Interrogation of The Cancer 
Genome Atlas showed that the genes encoding the highly recapitulated metabolism 
protein signatures are for the most part not highly mutated in cancers. However, when 
the signature-encoding genes are considered as a singular polygene, then patients with 
mutations are recognized as having significantly different overall survival compared 
to patients without mutations. The proteomes of non-engrafting NSCLC tumors 
were generally more similar to normal lung than were engrafting tumor proteomes. 
Hence, proteome remodeling affects metabolic states associated with NSCLC 
outcome. Conclusion: NSCLC is characterized by significant proteome remodeling 
that is invisible to genomics platforms. The proteomes of engrafting and non-engrafting 
NSCLC primary tumors are different, suggesting the potential to develop proteome 
signatures as prognostic biomarkers. Moreover, proteome signatures associated with 
PDX engraftment and poor outcome may be a source of new drivers and targets in NSCLC. 
Keywords: non-small cell lung cancer, proteomics, Metabolism, Prognosis
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P3.04-100 Chaperonin (HSP60) and Annexin 2 Are Candidate Biomarkers for 
Early Diagnosis of Non Small Cell Lung Carcinoma Ismail Agababaoglu, Banu 
Demir, Pınar Ercetin, Ayca Pamukoglu, Safiye Aktas, Zekiye Altun, Atila Akkoclu 
Dokuz Eylul University Faculty of Medicine, Izmir/Turkey
Background: Lung cancer is responsible of 12.4% and 17.6% of all newly diagnosed 
cancer cases and mortality due to cancer respectively and 5-year survival rate despite 
all improved treatment options is 15%. This survival rate reaches 66% in the Stage 1 and 
surgically treated patients. Early diagnosis which could not be definitely and commonly 
achieved yet is extremely critical in obtaining high survival rate in this disease. For this 
reason; proteomic differences were evaluated using MALDI TOF/TOF mass spectrometry 
in the subgroups of lung adenocarcinoma and squamous cell carcinoma. Methods: Fresh 
 
Table 2 DNA Methylation Marker Sensitivity & Specificity
Marker Sensitivity Specificity
LuCa-1 100% 100%
LuCa-2 100% 100%
LuCa-3 100% 67%
LuCa-4 100% 33%
LuCa-5 100% 33%
LuCa-6 100% 33%
 
Conclusion: This pilot study indicates that DNA methylation markers can detect 
lung cancer in pleural effusions, potentially with sensitivity and specificity that 
exceed routine cytology. Further analysis of these 6 markers, used separately or 
in combination as a multiplexed panel to detect pleural malignancy is warranted. 
Keywords: lung cancer, malignant pleural effusion, DNA methylation, Detection
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P3.04-097 Expression of GM2 Activator Protein as a Potential Biomarker 
for Lung Cancer Laddawan Pottprommanee1, Kongsak Boonyapranai2, Padchanee 
Sangthong1, Busyamas Chewaskulyong3, Shui-Tein Chen4, Lalida Shank5 1Of Chemistry, 
Chiangmai University, Chiangmai/Thailand, 2Department of Science, Nakornrathasima 
College, Nakornratchasima/Thailand, 3Of Medicine, Chiang Mai University, Chiang Mai/
Thailand, 4Department of Biological Chemistry, National Taiwan University, Taipei/
Taiwan, 5Department of Chemistry, Chiangmai University, Chiangmai/Thailand
Background: Lung cancer is a leading cause of cancer-related worldwide. Finding 
effective biomarkers for early diagnosis would be useful for potential curative treatment. 
GM2activator protein (GM2AP) is a glycoprotein acting as a cofactor for gangliosideGM2 
degradation. GM2AP also associated with the changing levels of ganglioside which has 
role in tumor invasion, progression and metastases. This study aims to investigate and 
validate the potential of GM2AP as a lung cancer biomarker. Methods: The study was 
done from September 2011 to June 2013. Serum and urine samples were obtained from 
lung cancers patients and healthy volunteers from Thailand and Taiwan. The expression 
level of GM2AP was using two-dimensional gel electrophoresi (2-DE), Western blotting 
and enzyme linked immunosorbine ent assay (ELISA). This studly was approved by 
the local research ethics committee . Statistical analysis was performed using SPSS 
version 17.0. Paired samples t-test and one-way analysis of variance (ANOVA) were 
used to analyze in different groups. A confidential level of 95% (P<0.05) was consider 
statistically significant. Results: Thailand data There were total 48 lung cancer patients 
(male 33, female 15) and 44 healthy volunteers . The mean age of study cases and 
controlled group were 53.3 years (range 2-74) and 42.1 years (range 25-74) respectively. 
The mean of GM2AP level in lung cancer patiens was 1.60+/-1.21 ng/mL, whereas in 
healthy controls the levels was 0.21+/-0.14 ng/mLThe expression levels of urine and 
serum GM2AP were significantly increased when compared to those from healthy 
controls (P<0.05). The urine GM2AP level of lung cancer patients was 7.62+/-1.06 fold 
on the median. Moreover the urinary GM2AP level in the male patients (1.16+/-1.07 ng/
mL) was higher than in female patients (1.13 +/-1.05 ng/mL). According to histologic 
subtype, the urinary GM2AP level measured in patents with adenocarinoma, small cell 
carcinoma and sqaumous cell carcinoma were 1.25+/-1.12, 1.48+/-1.35 and 2.27+/-
2.20 ng.ml, respectively. From ROC curve of urinary GM2AP showed sensitivity of 
90.91% and specificity of 91.67%.The expression levels of GM2AP of all patiens were 
included in the statistical analysis and significant correlation (P<0.05) was found with 
histology cancer types, whereas gender and pathological stage were not correlated. 
Taiwan data There were 133 lung cancer patients (male 60,female 73) with a mean age 
of 62 (range 30-81 years). The mean urinary GM2AP level in lung cancer patients was 
1.46+/-1.55 ng/mL where as in controlled group was 0.18+/-0.19 ng/mL. There was a 
8.03 +/- 1.36 fold increase of GM2AP level in urine and a 5.41+/-0.73 ng/mL. increase in 
the serum compared to the controlled group. From ROC curve provides 88.46% sensivity 
and 85.71% specificity in urine G2AP. The mean seum GM2AP level was 0.92+/- 0.27 and 
controlled group was 0.17+/-0.07 ng/mL. The ROC curve from serum G2AP provides 
100% sensitivity and 82.71% specificity. No difference was shown in urinary or serum 
GM2AP levels when stratified by gender, smoking status , EGFR status or histology 
subtypes except for the pathology stage. Conclusion: Our data suggest that the 
GM2AP may be useflul as a biomarker for early diagnostic and prognostic in lung cancer. 
Keywords: GM2 activator protein, lung cancer, biomarker
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after therapy. These results were then correlated with routinely performed computed 
tomographies at 6 weeks and 3 months after the last treatment. Results: Twenty three 
patients developed radiologic signs of RILD but only three of them developed symptoms. 
The mean CCL18 levels, for the whole group of patients, were, before treatment, 110 ng/
ml (standard deviation, SD: 53) and at the end of treatment 85 ng/ml (SD: 73). During 
the first (6 weeks after treatment) and second follow-up (3 months after treatment) the 
mean CCL18 levels were 93 ng/ml (SD: 57) and 104 ng/ml (SD: 49), respectively. The 
CCL18 concentrations in serum were not significantly elevated in the group of patients 
who developed a RILD. The mean CCL18 levels, at six weeks and three months after 
treatment, were in the RILD-group 94 ng/ml (SD: 62) and 104 ng/ml (SD: 61) and in 
the non-RILD-group 93 ng/ml (SD: 54) and 103 ng/ml (SD: 39). Furthermore there 
was no statistical significant correlation between CCL18 levels or decreasing serum 
CCL18 concentrations and RILD, fibrosis, tumor volume, T-stage, histology, adjuvant 
therapy, dosimetric parameters such as V20, response after treatment and overall 
survival. Conclusion: These findings do not suggest that the chemokine CCL18 is 
involved in the development of RILD in patients undergoing radiotherapy for chest tumors. 
Keywords: CCL18, RILD, Radiotherapy
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P3.04-103 Evaluation of the TGF Beta Superfamily Member Activin-A as a 
Novel Circulating Prognostic Marker in Lung Cancer Mir A. Hoda1, Anita Rozsas1, 
Thomas Klikovits1, Elisabeth Lang2, Zoltan Lohinai3, Yawen Dong1, Paul Stockhammer1, 
Judit Ozsvar1, Barbara Dekan1, Marko Jakopovic4, Miroslav Samarzija4, Walter Berger5, 
Walter Klepetko1, Balazs Dome1, Balazs Hegedus1, Michael Grusch2, Viktoria Laszlo1 
1Division of Thoracic Surgery, Medical University Vienna, Vienna/Austria, 2Institute of 
Cancer Research, Medical University Vienna, Vienna/Austria, 3Tumor Biology, National 
Koranyi Institute of Pulmonology, Budapest/Hungary, 4Department for Pulmonary Diseases, 
University Center Zagreb, Zagreb/Croatia, 5Institute of Cancer Research, Vienna/Austria
Background: Identification of biomarkers that can facilitate early detection and 
therapeutic decision making in lung cancer (LC) is urgently needed. Growth factors of 
the activin family are deregulated in a number of malignancies including thoracic tumors. 
Recent studies provided data regarding the tumor tissue expression levels of activin-A 
in lung adenocarcinoma (ADC): High activin-A expression was associated with poor 
prognosis, enhanced metastasis and shorter progression-free survival in stage I ADC. 
Since activin-A is secreted to the circulation and can be detected in plasma, this study 
aims to determine, for the first time, the value of circulating activin-A as a biomarker in LC 
patients. Methods: Plasma samples from patients with small cell lung cancer (SCLC, n= 
79), ADC (n=87) and squamous cell carcinoma (n=36) were collected between 2009 and 
2013 at the time of diagnosis or before surgical resection. Additional samples, serving 
as age- and sex-matched controls, consisted of individuals without malignancies (n=66). 
Measurement of samples was performed using the Quantikine activin-A Elisa kit (R&D 
Systems) and all statistical analyses were performed using the PASW Statistics 20.0 
package and GraphPad Prism 6.0. Results: Mean plasma activin-A levels (PAL) (pg/ml) 
were the following: 628,8±38,42 (ADC, range: 112,4-1875), 613,5±68,22 (SCC, range: 
194-2076), 771±77,06 (SCLC, range: 174,1-3627) and 433,3±16,27 (controls, range: 
194,1-808,8). A gender-related variation in the PAL of controls (female (n=31, mean PAL 
469,5±24,54 (range 212,95-808,79)) vs. male (n=35; mean PAL 401,3±20,49 (range 
194,1-759,02)), p= 0.0319) was observed. PAL was significantly increased in patients 
with ADC (p=0.0009), SCC (p=0.0061) and SCLC (p<0.0001) compared to controls. 
There was no difference in PAL with regard to patients´ age, gender, BMI, smoking status 
or other co-morbidities in all 3 LC types. A significant TNM stage-dependent increase 
of PAL was observed in all 3 LC types. PAL was elevated in T3 SCC, in T4 ADC and in 
T3 and T4 SCLC. PAL was also clearly associated with N status and metastatic disease 
in all 3 LC types. Importantly, in case of SCLC, PAL was associated with extensive 
disease and showed metastatic site specificity. In ADC patients, elevated PAL was 
associated with significantly worse overall survival (OS) (p<0.0001). Of note, in locally 
advanced ADC, elevated PAL also proved to be a significant negative prognosticator 
(p=0.048). Moreover, elevated PAL was associated with a poor OS in SCLC patients 
(p=0.0009). Multivariate analysis revealed that PAL was an independent prognostic 
factor in ADC and SCLC patients. Survival and multivariate analysis data of the SCC 
cohort will be presented at the conference. ROC curve analysis showed an AUC of 
0.691 in SCLC and an AUC of 0,657 in ADC for PAL. Conclusion: Our findings suggest 
that PAL is significantly elevated in a disease stage-dependent manner in LC patients. 
Moreover, elevated PAL is associated with poor prognosis in ADC and SCLC patients. 
Keywords: SCLC, biomarker, growth factor, NSCLC
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P3.04-104 Radiation Pneumonitis: Assessment by Inflammation Imaging with 
Tc-99m HMPAO - Clinical Trial in Progress Hadyn Williams1, Jing Zhao2, Zonglin 
Hao2, Feng-Ming (Spring) Kong3 1Department of Radiology, Gru Cancer Center/Medical 
College of Georgia, Georgia Regents University, Augusta/GA/United States of America, 2Gru-
Cancer Center, Medical College of Georgia, Georgia Regents University, Augusta/GA/United 
States of America, 3Department of Radiation Oncology, Gru Cancer Center/Medical College 
of Georgia, Georgia Regents University, Augusta/United States of America
Background: Background: Over 60% of patients with non-small-cell lung carcinoma 
(NSCLC) require radiation treatment, with an overall cure rate < 10-15% and moderate 
toxicity in 10-30% of treated patients. While high-dose radiation improves survival, 
concern over radiation-induced toxicities including radiation pneumonitis (RP) have 
limited its use. Predicting probability of tumor control and lung toxicity offers a promising 
strategy for individualized radiation therapy (RT), such as giving higher dose radiation to 
tissue samples of 36 malignant cases involving 83.3% (n=30) male and 16.7% (n=6) 
female patients were distributed into two groups as early and end stage lung cancer 
and each group were composed of subgroups including 18 squamous cell carcinoma 
(9 early stage cases, 9 end stage cases) and 18 adenocarcinoma cases (9 early stage 
cases, 9 end stage cases). Of the malignant cases, 41.7%, 7.3%, 44.4% and 5.6% were 
at Stage 1, Stage 2, Stage 3 and Stage 4, respectively. 50.0% (n=18) and 50.0% (n=18) 
were classified as early and final stage cases, respectively. The fresh tissues obtained 
from the tumoral and matched normal sites after surgical intervention. The differences 
in protein expression levels were determined by comparing proteomic changes in the 
tumoral tissues with normal tissues in each patient. The results obtained following 
two dimensional gel electrophoresis and MALDI TOF/TOF mass spectrometry were 
detected with respect to differences in protein densities of the subgroups identified by 
Decodon two dimensional gel analysis system. Results: In the subgroups of advanced 
stage adenocarcinoma; tumoral tissue revealed differences in expression of 2 proteins 
compared with normal parenchymal tissue. Of those; difference in protein expression 
in HSP60 (heat shock protein 60) was found statistically significant (p=0.0001). 
On the other side, subgroups of early and advanced stage squamous cell carcinoma 
revealed differences in expression of 20 particular proteins. Of those, increased 
protein expression level of only annexin-2 protein was found statistically significant 
(p=0.002). No significant difference was detected in early and advanced stage protein 
expressions of the tumoral tissues in the subgroups of adenocarcinoma and squamous 
cell carcinoma. Conclusion: n the light of these results; we conclude that with respect 
to early diagnosis of lung cancer that HSP60 and annexin-2 proteins are the important 
biomarkers in the subgroups of adenocarcinoma and squamous cell carcinoma. We also 
consider that these two proteins are molecules which may provide critical contribution in 
evaluation of prognosis, metastatic potential, response to treatment and in establishment 
of differential diagnosis between adenocarcinoma and squamous cell carcinoma. 
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P3.04-101 Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 
in Lung Adenocarcinoma: Correlations and Prognostic Significance Hisao Imai1, 
Kyoichi Kaira2, Tomohiro Yazawa3, Akira Shimizu4, Toshiteru Nagashima3, Yoichi Ohtaki3, 
Takayuki Asao2, Koichi Minato1, Tetsunari Oyama5, Izumi Takeyoshi3, Kimihiro Shimizu3 
1Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma/
Japan, 2Oncology Clinical Development, Gunma University Graduate School of Medicine, 
Gunma/Japan, 3Department of Thoracic and Visceral Organ Surgery, Gunma University 
Graduate School of Medicine, Gunma/Japan, 4Department of Dermatology, Gunma University 
Graduate School of Medicine, Gunma/Japan, 5Department of Diagnostic Pathology, Gunma 
University Graduate School of Medicine, Gunma/Japan
Background: Endoplasmic Reticulum (ER) Stress Sensor, BiP/glucose-related protein 
78 (GRP78) is an important member of the heat shock protein family 70 (HSPs70) 
that plays an essential role in the tumor growth and progression. It is localized to the 
endoplasmic reticulum. Although GRP78/BiP is highly expressed in various cancer 
cells, the clinicopathological significance of its expression in non-small cell lung cancer 
(NSCLC) remains unclear. The aim of the present study was to investigate the expression 
of the GRP78/BiP in patients with lung adenocarcinoma. Methods: Two hundred and 
twenty patients with surgically resected lung adenocarcinoma were evaluated as one 
institutional cohort. Tumor sections were stained by immunohistochemistry for GRP78/
BiP, PERK, Ki-67, p-mTOR, and CD34 to assess the microvessel density. The correlation 
between GRP78/BiP and the other factors was assessed using the Spearman correlation 
analysis. Results: GRP78/BiP was highly expressed in 41% of patients, and was 
significantly associated with pleural invasion, lymphatic permeation, vascular invasion, cell 
proliferation, and p-mTOR phosphorylation. Multivaritate analysis confirmed that GRP78/
BiP expression was an independent factor for predicting poor progression-free survival 
and overall survival in patients with stage I disease. Conclusion: The increased GRP78/
BiP expression is an independent prognostic factor for early stage lung adenocarcinoma 
patients. Our study suggests that the expression of GRP78/BiP as ER stress marker 
plays a crucial role in the pathogenesis and development of lung adenocarcinoma. 
Keywords: Endoplasmic reticulum stress, Glucose-related protein 78, 
Immunohistochemistry, non-small cell lung cancer
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P3.04-102 CC Chemokine Ligand 18 as a Biomarker for the Prediction of 
Radiation Induced Lung Disease (RILD) Eleni Gkika1, Sonja Adebahr1, Tanja Schimek-
Jasch1, Antje Prasse2, Gernot Zissel3, Anca-Ligia Grosu1, Ursula Nestle1 1Radiation 
Therapy, University Medical Center Freiburg, Freiburg/Germany, 2Pneumology, Hannover 
Medical School, Hannover/Germany, 3Pneumology, University Medical Center Freiburg, 
Freiburg/Germany
Background: In patients with fibrosing lung disease the CC Chemokine Ligand 18 (CCL18) 
is abundantly produced by alveolar macrophages and its concentration is increased in 
various inflammatory and fibrotic lung diseases. In this study we aimed to analyze the 
role of CCL18 as a prognostic biomarker for the development of radiation induced lung 
disease (RILD) after thoracic irradiation. Methods: Between August 2011 and February 
2012, 60 patients were enrolled prospectively in the study. Forty-six patients were 
treated for lung cancer, thirteen had an esophageal cancer and one a thymoma. Patients 
were treated either with conventionally fractionated (n=47) or hypo-fractionated (n=13) 
radiotherapy. The CCL18 levels in serum were quantified with ELISA (enzyme-linked 
immunosorbent assay) at predefined time points; before treatment, after 30 Gy, after 60 
Gy (for conventional fractionation), at 6 weeks after completion of treatment and 3 months 
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50%). We also investigated the relationship between stromal SPARC reactivity and tumor 
response to nab -paclitaxel using small or surgical specimens obtained from advanced 
or recurrent lung cancer patients. Results: One hundred forty-five patients (72.5%) 
showed positive staining for stromal SPARC immunohistochemistry. The positivity of 
immunostaining was significantly higher in patients with Brinkman index (B.I) ≧ 400 
(80/98, 82%) compared with in those with < 400 (65/102, 64%) (p = 0.01), in squamous 
cell carcinoma (26/29, 90%) compared with adenocarcinoma (107/155, 69%) (p = 0.03), 
and in vessel invasion positive (45/53, 85%) compared with vessel invasion negative 
(95/140, 68%) (p = 0.03). In contrast, positive staining of cytoplasmic or nucleus 
SPARC in cancer cells was rare (5 cases). We found that patients in stage I with high 
SPARC stromal reactivity had significantly shorter survival than patients with low SPARC 
stromal reactivity (log-rank p = 0.05). We also found that patients with high expression 
of stromal SPARC in small specimens such as TBLB or surgical specimens tend to 
response to nab -paclitaxel. Conclusion: Positive immunostaining of the stromal SPARC 
was more frequently observed in male smokers with squamous cell carcinoma , and good 
tumor response to nab -paclitaxel was correlated with high stromal SPARC reactivity. 
SPARC is a possible useful predictive marker for selecting nab -paclitaxel treatment. 
Keywords: SPARC, nab-paclitaxel, predictive marker, Squamous cell carcinoma
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P3.04-106 ATG7-Dependent Autophagy May Not Be Involved in Prognosis of 
Human NSCLC Shaoxing Sun, Zhihao Wang, Fang Tang, Chunxu Yang, Conghua Xie 
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, 
Wuhan/China
Background: Autophagy, one of two major intracellular degradation pathways, plays 
a critical role in energy homeostasis and the quality control of macromolecules and 
intracellular organelles. Autophagy plays a role in the various stages of tumorigenesis. 
However, the role of autophagy in cancer seems complex. Autophagy confers both pro- and 
anti-tumourigenic roles, depending on the cellular and environmental context. Autophagy 
related gene 7 (ATG7) is an essential autophagy gene. Previous studies showed that ATG7-
dependent autophagy represses early oncogenesis but accelerating tumour progression 
in mouse lung cancer models. However, the expression of ATG7 and its correlation with 
prognosis of human lung cancer have not been reported. Methods: In Cohort 1, we 
analyzed 41 patients with non-small-cell-lung cancer who had undergone surgery from 
June 2013 through December 2013. Expression levels of ATG7 in the tumor tissues and 
the adjacent normal tissues were examined by immunohistochemistry. We then sought to 
find the relationship between the expression of ATG7 and the overall survival of NSCLC. 
In Cohort 2, we screened surgery sample library in Department of pathology, Zhongnan 
Hospital of Wuhan University for NSCLC patients sample from 2010 to 2011. None of the 
patients underwent radiotherapy or chemotherapy before surgery. Tissue samples of 
76 included patients were obtained with the assistant of work staff in that department. 
Baseline characteristics were collected mainly by consulting archived medical records and 
the same staging system was referred to anew classify stage. Follow-up was completed 
within 2 months mainly through telephone contact. 13 patients were excluded from this 
study because of contact loss. The samples of the rest with a median age of 60 (range 37-
79) were submitted for further immunohistochemical analysis and survival data analysis 
were conducted. Immunohistochemistry was performed by a well-trained pathological 
technicist. Results: In Cohort 1, ATG7 protein was detected mainly in the cytoplasm of 
tumor cells. Positive staining was identified in 26 (63.4%) tumor tissue samples while 
only 9 (9.8%) normal lung tissue samples were considered as positive. Chi-square test 
revealed a significant difference (p<0.01). In Cohort 2, Patients with no ATG7 expression 
had a median survival time of 17.5 months (95%CI, 11.9-23.1 months) while patients 
with positive ATG7 expression had the same survival time of 17.5 months (95% CI, 11.3-
23.7 months). No significant difference was noticed (p=0.199). Conclusion: Differential 
expression of ATG7 between cancer cells and normal tissues indicates that ATG7 is 
related to early oncogenesis of NSCLC. However, different from the results obstained 
from mouse models, ATG7 expression is not correlated with prognosis of human NSCLC. 
Keywords: Immunohistochemistry, Autophagy, ATG7, Prognosis
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-107 MicroRNA Expression in Epithelial and Stromal Components of 
Early-Stage Non-Small Cell Lung Tumors Santosh K. Patnaik1, Reema Mallick2, Eric 
Kannisto1, Wiam Bshara3, Sai Yendamuri1 1Thoracic Surgery, Roswell Park Cancer Institute, 
Buffalo/United States of America, 2University of Minnesota, Minneapolis/MN/United States of 
America, 3Pathology, Roswell Park Cancer Institute, Buffalo/United States of America
Background: MicroRNAs are ultra-short, non-coding RNAs that play important roles in 
the biology of lung cancer. In addition, biomarker utility of lung cancer tumor microRNAs 
for diagnosis, histological sub-typing, prognosis and prediction of response to therapy has 
been demonstrated in a large number of studies. Like all tumors, those of non-small cell lung 
cancer contain both cancerous epithelial and non-cancerous stromal cells. To facilitate our 
understanding of the role of microRNAs in lung cancer biology as well as their application 
as biomarkers, we examined microRNA expression in epithelial and stromal components 
of early-stage non-small cell lung tumors. Methods: Laser capture microdissection of 8 
µm-thick, hematoxylin-eosin-stained sections of formalin-fixed specimens was used to 
separately collect epithelial and stromal components of 77 resected pathologic stage 
I non-small cell lung cancer tumors. Total RNA was extracted from the dissectates with 
the Norgen Biotek® FFPE Tissue RNA Isolation kit and quantified with Ribogreen™ assay 
(Invitrogen®). MiRCURY™ microarrays (Exiqon®) with locked nucleic acid hybridization 
probes were used to quantify microRNAs in 350 ng of each RNA isolate. For validating the 
microarray data, 10 microRNAs in the RNA isolates were also quantified using Taqman™ 
resistant tumors when probability of toxicity is low, improving the therapeutic ratio. 
Technetium-99m (Tc-99m) hexamethylpropylene amine oxime (HMPAO) imaging is an 
established method for evaluation of brain perfusion, tissue inflammation, infection, and 
abscess localization. Tc-99m HMPAO, a lipophilic biogenic amine that easily crosses the 
cell membrane into the endothelial cytoplasm, is a sensitive indicator of endothelial cell 
damage and microvascular injury, penetrating into the alveolar macrophage reflecting 
impaired alveolar integrity proportional to inflammation and lung toxicity. Once 
intracellular, it is retained by conversion to hydrophilic nondiffusable form mediated by 
glutathione oxidation/reduction within the epithelial lining and bronchoalveolar cell, and 
has been used for non-invasive detection of lung injury proportional to severity. We used 
Tc-99m HMPAO scintigraphy to semiquantitatively document the presence and severity 
of lung toxicity in 4 patients undergoing RT for NSCLC. Methods: Methods: Four patients 
with NSCLC (3 Stage IIIB receiving concurrent RT and carboplatin/paclitaxel 
chemotherapy, 1 Stage IB RT alone) underwent lung computed tomography (CT), positron 
emission tomography (PET)/CT with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG), 
ventilation (V)/perfusion (Q) lung imaging with Tc-99m diethylene triamine pentaacetic 
acid/Tc-99m macroaggregated albumin, and inflammation imaging with Tc-99m HMPAO; 
at baseline prior to treatment, during RT after 36-50 Gray, and at 3 months following 
radiation completion. Results: Results: All patients had matching V/Q lung abnormalities 
in the areas of tumor and RT, and tumor-positive baseline FDG PET/CT imaging that 
showed response to therapy. Three patients without RP had HMPAO imaging that 
mimicked Q lung imaging on all 3 sequential imaging studies. No patient experienced RP 
during RT, while one patient experienced grade 1 RP at 3 months, showing progressive 
increase in HMPAO inflammatory uptake in adjacent lung from baseline to during-RT to 3 
months post-RT imaging, not appreciated on FDG PET/CT imaging (Figure 1). 
Conclusion: Conclusion: Tc-99m HMPAO nuclear imaging may provide more sensitive 
evaluation of the presence and severity of RP. In this case, uptake on during-RT imaging 
predated, predicted, and confirmed development of grade 1 RP at 3 months. 
 
Keywords: radiation toxicity, Radiation pneumonitis, molecular imaging, glutathione
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P3.04-105 SPARC, a Possible Predictive Marker to Albumin-Bound Paclitaxel 
(Nab-Paclitaxel) in Non-Small Cell Lung Cancer Kazutoshi Komiya1, Tomomi 
Nakamura1, Hironori Sadamatsu1, Chiho Nakashima1, Koichiro Takahashi1, Hitomi 
Umeguchi2, Naomi Kobayashi1, Akemi Sato1, Yuji Takeda1, Shinya Kimura1, Naoko 
Sueoka-Aragane1 1Saga University, Saga/Japan, 2Japanese Red Cross Karatsu Hospital, 
Karatsu/Japan
Background: Anti-cancer agents to lung squamous cell carcinoma are limited compared 
to adenocarcinoma, and most novel therapeutic agents including molecular targeted 
therapy are indicated for adenocarcinoma not squamous cell carcinoma. Recently, it 
is reported that carboplatin plus albumin-bound paclitaxel (nab -paclitaxel) as first-
line therapy in patients with advanced non-small cell lung cancer demonstrated a 
significantly higher overall response rate than carboplatin plus solvent-based paclitaxel 
(33% vs 25%, p=0.005) and in patients with squamous histology compared to non-
squamous (41% vs 24%, p＜0.001) . Secreted protein acidic and rich in cysteine 
(SPARC) plays a crucial role in cell growth and angiogenesis through an interaction 
with extracellular matrix or cytokines. SPARC bound to albumin and they co-localized 
in cancer tissues, suggesting that SPARC plays an important role on higher tumor 
uptake of nab -paclitaxel. Expression of SPARC was correlated with prognosis in breast 
cancers and high SPARC stromal reactivity was correlated with tumor response to nab -
paclitaxel in pancreatic cancers. nab -paclitaxel showed a good tumor response to lung 
squamous cell carcinoma, which is one of the most difficult cancers to be treated. In 
this study, we investigated the possibility of SPARC as a predictive marker for nab -
paclitaxel. Methods: We studied the stromal SPARC reactivity and the association with 
clinicopathological characteristics in 200 non-small cell lung cancers using custom 
tissue microarray fabricated in our laboratory by immunohistochemical staining. SPARC 
stromal reactivity was defined as the percentage of reactive stromal area among the 
optical fields and scored as － ( less than 10%), ＋ (10%<, 50%≧) or ＋＋ (more than 
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237 (57%) were female. According to ethnicity, 357 pts were Caucasian (86%), 37 African-
American (9%) and 21 Asian (5%); 140 pts were classified as never-smokers (34%), 37 
(9%) as light-smokers (≤ 10 packs/year.) and 238 (57%) as current smokers (> 10 packs/
year). EGFR activating mutations were identified in 103 out of 417 samples (24.7%). 
Among patients harboring EGFR mutations, median survival, in months (m), according to 
ECOG performance status was: 25.1m for ECOG 0, 19.5m for ECOG 1, 10.5m for ECOG 
2, 5.9m for ECOG 3, and <1m for ECOG 4. Among patients with wild-type EGFR, median 
survival, in months, according to ECOG was: 112.8m for ECOG 0, 20.1m for ECOG 1, 
8.8m for ECOG 2, 5.7m for ECOG 3, and 2m for ECOG 4. Among those pts with stage IV 
adenocarcinoma and ECOG-PS 0-1, with a median follow-up of 12 months, the median 
overall survival rate was 16.3 months for pts harboring EGFR-activating mutations, and 
14.5 months for those with EGFR-wild-type tumors (HR 0.99, p=0.93, 95%CI 0.73-1.33). 
On multivariate analysis, ECOG-PS > 1 increased 1.59 times the risk of death (HR 1.59, 
95%CI 1.41-1.78) regardless of EGFR-mutational status. Conclusion: Our data has 
validated ECOG performance status as a prognostic factor in this Brazilian population of 
pulmonary adenocarcinoma pts, independent of EGFR mutational status. As a practical 
and reproducible scale, ECOG remains a valuable tool to guide clinical decisions and 
estimate cancer patients´ prognosis, even with the advent of Tyrosine kinase inhibitors. 
Keywords: pulmonary adenocarcinoma, lung cancer, EGFR, ECOG
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P3.04-110 PTPRH Hypomethylation as a Prognostic Factor in Non-Small Cell 
Lung Cancer Takashi Sato1, Kenzo Soejima1, Eri Arai2, Junko Hamamoto1, Hiroyuki 
Yasuda1, Daisuke Arai1, Kota Ishioka1, Keiko Ohgino1, Katsuhiko Naoki1, Takashi Kohno3, 
Koji Tsuta4, Shun-Ichi Watanabe5, Yae Kanai2, Tomoko Betsuyaku1 1Pulmonary Medicine, 
Keio University School of Medicine, Tokyo/Japan, 2Molecular Pathology, National Cancer 
Center Research Institute, Tokyo/Japan, 3Genome Biology, National Cancer Center Research 
Institute, Tokyo/Japan, 4Pathology, National Cancer Center Hospital, Tokyo/Japan, 5Thoracic 
Surgery, National Cancer Center Hospital, Tokyo/Japan
Background: Tyrosine phosphorylation is an important signaling mechanism in cancer. 
PTPRH is a receptor-type protein tyrosine phosphatase thought to be a potential regulator 
of tumorigenesis. The aim of this study is to clarify the significance ofPTPRH expression 
and its regulation by DNA methylation in non-small cell lung cancer (NSCLC), especially 
in lung adenocarcinoma. Methods: PTPRH mRNA expression was examined in 89 NSCLC 
and corresponding non-cancerous tissues. The correlation between DNA methylation 
and PTPRH gene expression was investigated in another cohort that consisted of 145 
patients with lung adnocarcinoma. Gene regulation by DNA methylation was assessed 
using a DNA methylation inhibitor. Statistic analysis was performed to clarify whether 
the DNA methylation status of PTPRH is a prognostic factor for patients with lung 
adenocarcinoma. Results: PTPRH mRNA expression was significantly up-regulated in 
NSCLC. PTPRHDNA methylation was reduced in lung ademocarcinomas and inversely 
correlated with mRNA expression. 5-aza-2’-deoxycytidine treatment of lung cancer cell 
lines with low PTPRH expression, restored mRNA PTPRH expression levels. Furthermore, 
low PTPRH methylation was associated with shorter recurrence-free survival (P < 0.0002) 
and overall survival (P < 0.0001). Multivariate analysis revealed that PTPRH DNA 
methylation was an independent prognostic factor (P < 0.01). Conclusion: We 
confirmed that PTPRH is overexpressed in NSCLC. In addition, we determined that 
hypomethylation of PTPRH is a poor prognostic factor in lung adenocarcinoma. 
Keywords: non-small cell lung cancer, PTPRH, DNA methylation, prognostic factor
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P3.04-111 Gene Polymorphisms in Thoracic Tumors Receiving Cisplatin-
Pemetrexed Nicolas Simon1, Eric Dansin2, Brigitte Baldeyrou3, Marie-Christine Etienne-
Grimaldi4, Gérard Milano4, Jean-François Goossens1, Christine Bobin-Dubigeon5, Sophie 
Salingue3, Radj Gervais6, Hélène Senellart5, Amélie Lansiaux7, Samuel Meignan8 
1University of Lille, Lille/France, 2Département de Cancérologie Générale, Centre Oscar 
Lambret, Lille/France, 3Centre Oscar Lambret, Lille/France, 4Centre Antoine Lacassagne, 
Nice/France, 5Institut Du Cancer de L’Ouest, Nantes/France,6Centre François Baclesse, 
Caen/France, 7Institut Catholique de Lille, Lille/France, 8Tumorigenesis and Resistance To 
Treatment Unit - Inserm U908, Lille/France
Background: Chemotherary combining cisplatin and the multitarget antifolate 
pemetrexed (ALIMTA®) is widely used in mesothelioma and metastatic non-squamous 
non-small cell lung cancer (n-sq NSCLC). Thymidylate synthase (TYMS) expression is 
recognized as a predictive marker of pemetrexed efficacy. Polymorphisms in TYMS and 
Excision repair cross-complementing (ERCC) genes have been associated with decreased 
tumour response to pemetrexed, and 5-10 Methylenetetrahydrofolate reductase (MTHFR) 
polymorphisms have been linked to increased toxicity to pemetrexed. The objective of this 
pilot study was to examine the feasibility and usefulness of testing gene polymorphisms 
for predicting pharmacodynamics of cisplatin-pemetrexed. Methods: This ancillary 
study (ALIMESO trial) was conducted on 21 patients (mean age 61, 15 men, 6 women) 
with malignant pleural mesothelioma (8 epithelioid, 2 sarcomatoid, 2 biphasic, 1 
desmoplastic) or n-sq NSCLC (3 adenocarcinoma, 5 large-cell carcinoma) treated by 
cisplatin (75 mg/m2) plus pemetrexed (500 mg/m2) for 6 cycles (day 1 = day 22). 
Response to treatment was evaluated after 3 cycles (RECIST criteria). Toxicity was 
recorded according to CTC-AE classification. Gene polymorphisms were analyzed in 
all patients (blood DNA). TYMS polymorphisms in 5’UTR (28 bp repeats rs34743033 
along with G>C mutation on 3R allele, rs11540151) were analyzed by PCR-RFLP and 6 
bp deletion in 3’UTR (rs11280056) by PCR-electrophoresis. MTHFR C677T (rs1801133) 
and A1298C (rs1801131) were analyzed by sequencing. ERCC1 AAT118AAC (rs11615), 
ERCC2 Lys751Gln (rs13181), GSTP1 Ile105Val (rs1695) and Ala114Val (rs1138272) 
microRNA reverse transcription (RT) -PCR assays (ABI®). Results: Microdissection was 
performed for 35 adenocarcinoma, 16 bronchioloalveolar carcinoma and 26 squamous 
cell carcinoma tumors. Of the 1936 human mature microRNAs detectable with the 
microarray platform, 595 (31%) were identified as expressed and reliably quantified 
among the RNA samples. Microarray-based quantification of 10 microRNAs in the 
samples was validated by RT-PCR. Significant differences for microRNA expression 
between tumor epithelia and stroma, and between cancer of different histologies 
was noted. Conclusion: Our study provides information on microRNA expression 
in epithelial and stromal components of early-stage non-small cell lung tumors. 
Keywords: microRNA, tumor stroma, biomarker, NSCLC
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P3.04-108 Differential Cellular and Molecular Response to Ablative Radiation 
in Non-Small Cell Lung Cancer Based on Molecular Subtype Ayman Oweida1, 
Zeinab Sharifi1, Mojgan Ebrahimi2, Richard Fraser2, Siham Sabri1, Russell Ruo3, Jan 
Seuntjens3, Bassam Abdulkarim4 1Centre for Translational Biology, Research Institute of the 
Mcgill University Health Centre, Montreal/QC/Canada, 2Department of Pathology, Montreal 
General Hospital, Montreal/QC/Canada, 3Medical Physics Unit, Montreal General Hospital, 
Montreal/QC/Canada, 4Division of Radiation Oncology, Montreal General Hospital, Montreal/
QC/Canada
Background: Ablative radiotherapy (ART) is increasingly used in the management and 
treatment of early-stage inoperable non-small cell lung cancer (NSCLC). Clinical studies 
show response rates of 80-90% in NSCLC patients treated with ART. However, the 
cellular and molecular determinants of the response to ART have not been investigated 
and recent analysis of patterns of failure in patients treated with ART show increased 
distant metastatic recurrence. Methods: Human NSCLC adenocarcinoma cell lines with 
different molecular subtypes (EGFR, K-RAS and p53 status) were chosen for this study 
including, A549, HCC827 and H1975 cells. To assess the cellular response to ART, several 
cellular assays were used after exposure to a single dose of 12Gy. Western blotting was 
performed to analyze expression and phosphorylation levels of molecular determinants 
involved in proliferation and invasion after exposure to ART. An In vivo study was performed 
using a novel orthotopic primary NSCLC animal model. When lung tumors reached a size 
of 0.2 cm3, animals were treated with a dose of 34Gy using a Varian Novalis system 
equipped with cone-beam CT for accurate positioning. Treated animals were sacrificed at 
10days, 30days and 60days after treatment and assessed for the presence of local and 
distant metastasis. In addition, immunohistochemistry was performed to assess tumor 
markers for proliferation, invasiveness, and metastasis. Results: Our results show that 
ART significantly reduced cell proliferation compared to FRT in A549 cells only. HCC827 
and H1975 cells were equally inhibited by ablative and fractionated radiation. In A549 
cells, ART significantly increased the invasive phenotype of the cells while in HCC827 
and H1975 cell invasion was significantly reduced compared to FRT. Molecular analysis 
of proteins involved in invasion and migration revealed that ART upregulated c-MET 
expression in A549 cells without inducing epithelial-to-mesenchymal transition (EMT). 
In tumor-bearing rats, 50% had complete response, 25% partial response and 25% had 
local progression or distant metastasis after 34Gy. Consistent with in-vitro data, the 
tumor invasive profile was independent of EMT. Conclusion: Our results demonstrate 
that there is a differential response to ablative and fractionated radiation that is cell-
type dependent. A549 cells exposed to ablative doses acquired a pro-invasive and 
migratory phenotype, which was independent of EMT. These findings can have significant 
implications for NSCLC patients undergoing ART and underscore the importance of 
understanding the underlying biology for effective disease management and treatment. 
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P3.04-109 Validating ECOG Performance Status as a Prognostic Factor in 
Brazilian Patients with Pulmonary Adenocarcinoma Rafael C. Bitton1, Luiz G.C.A. 
De Lima2, Felipe S.R. Roitberg1, Cristiane Mesquita1, Renata E. Martins1, Cheng T. Yen1, 
Ricardo M. Terra3, Evandro S. Mello2, Gilberto De Castro Jr1 1Medical Oncology, Instituto 
Do Câncer Do Estado de São Paulo - Icesp, Sao Paulo/Brazil, 2Pathology, Instituto Do Câncer 
Do Estado de São Paulo - Icesp, Sao Paulo/Brazil, 3Thoracic Surgery, Instituto Do Câncer Do 
Estado de São Paulo - Icesp, Sao Paulo/Brazil
Background: ECOG performance status scale (ECOG) is a score used in clinical practice 
to estimate cancer patients´ functionality, and its value as a prognostic factor has 
been extensively demonstrated. Patients (pts) harboring EGFR mutations have been 
experiencing substantial improvements in their functionality and ECOG after receiving 
targeted therapies with tyrosine kinase inhibitors (TKIs). Recently, with the availability of 
TKIs for the treatment of pts harboring EGFR mutations, a treatment capable of inducing 
marked improvements in patients´ functionality, it is pertinent to access the prognostic 
value of ECOG (at the moment of the diagnosis of cancer) for these pts. In this scenario, we 
aimed to validate ECOG as a prognostic factor in a population of Brazilian pts with pulmonary 
adenocarcinoma, including those harboring EGFR mutations who received treatment with 
TKIs. Methods: This is a retrospective, uniinstitutional study of all consecutively tested 
tissue samples from 417 pts diagnosed with pulmonary adenocarcinoma treated at our 
Institution. All samples were formalin-fixed and paraffin-embedded. Tumor areas were 
selected and macrodissected, followed by whole DNA extraction and amplification by 
PCR. EGFR genotyping was performed through DNA sequencing (exons 18, 19, 20 and 
21) by Sanger´s methodology. Pts were treated according to their clinician´s choice: 
TKIs (Erlotinib or Gefitinib) were available for pts harboring EGFR mutations, and those 
harboring wild type EGFR were treated with chemotherapy. Results: 417 pts had tumor 
samples genotyped between Aug/2011 and Sep/2015. Median age was 62 y (17-91), and 
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using Cox regression to assess independent patient characteristics associated with OS, 
and included in the model all variables with p < 0.05 on univariate analysis. All analysis 
were considered statistically significant when p < 0.05. Results: A total of 170 patients 
were included in the study. Median age was 63.4 years, 54.1% were male, 80.6% had 
adenocarcinoma, 17.6% had mutated EGFR, 47.6% were former smoker, and 78.2% had 
ECOG ≤ 1. Median NLR was 4.6. NLR > 4.6 was associated with SNC metastasis. Median 
follow-up time was 19.64 months and median overall survival was 13.7 months. Patients 
with NLR > 4.6 had a worse survival. OS was 22.27 months versus 7.03 months (p < 
0.001) for patients with NLR ≤ 4.6 and NLR > 4.6, respectively. In multivariate analysis, 
the NLR remained as an independent prognostic factor for worse OS after adjusting 
for sex, histology, tumor size and performance status. Conclusion: Elevated NLR at 
diagnosis is an independent predictor of poor OS in patients with advanced NSCLC 
Keywords: metastatic, Neutrophil to lymphocyte ratio, prognostic marker, non-small 
cell lung cancer
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P3.04-114 IASLC and WHO 2004 Grading System as Prognostic Factors in 
492 Cases of Pulmonary Adenocarcinoma Luca Ampollini1, Letizia Gnetti2, Matteo 
Goldoni3, Carlotta Rossi2, Luigi Rolli1, Michela Solinas1, Luigi Ventura1, Marcello Tiseo4, 
Michele Rusca1, Antonio Mutti3, Paolo Carbognani1, Enrico Maria Silini2 1Thoracic Surgery, 
University of Parma, Parma/Italy, 2Pathology, University of Parma, Parma/Italy, 3Departement 
of Clinical and Experimental Medicine, University of Parma, Parma/Italy, 4Medical Oncology, 
University Hospital of Parma, Parma/Italy
Background: Primary aim of the study was to evaluate the prognostic value of 
the IASLC grading system and the WHO 2004 classification on a consecutive series 
of resected primary pulmonary adenocarcinomas. Secondary aim was to identify 
new prognostic histological features. Methods: All consecutive patients undergoing 
radical resection with a pathological diagnosis of primary lung adenocarcinoma 
were considered. All histological slides were reviewed for the study. Tumor-specific 
survival was considered as primary outcome. Statistical analysis included Kaplan-
Meyer analysis and Cox regression to identify variables with significant Hazard Ratios 
(HR). Results: 492 patients were considered between January 2002 and December 
2013. 67.7% were male, mean age was 67.4 years, mean follow-up was 55 months. 
In a first multivariate Cox Regression Model the WHO 2004 grading was considered; 
gender [males vs females HR=1.7 95% CI (1.2-2.3), p=0.002], stage (p-trend <0.001), 
lymphoplasmacellular infiltrate [yes vs no HR=0.5 95% CI (0.3-0.8), p=0.001], and 
WHO 2004 grade (p-trend = 0.002) were independent prognostic factors of survival. 
In a second model the IASLC grading was considered; gender [HR=1.7 95% CI (1.2-
2.4), p=0.002], stage (p-trend<0.001), lymphoplasmacellular infiltrate [HR=0.5 95% 
CI (0.3-0.8), p=0.001], and combined grading score according to Sica (p-trend=0.011) 
were maintained as independent prognostic factors. Conclusion: Tumor grading 
was an independent prognostic factor of survival in patients with adenocarcinoma 
undergoing lung resection both considering IASLC and WHO 2004 classifications. 
Lymphoplasmacellular infiltrate was significantly and favorably related to survival. 
Keywords: Tumour grading, IASLC grading system, WHO 2004 classification, pulmonary 
adenocarcinoma
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P3.04-115 A New Prognostic Index in Chinese Patients With Metastatic Non-
Small Cell Lung Cancer Receiving First-Line Chemotherapy Hui Yu1, Jialei Wang1, 
Fang Liu2, Benoît Sansas3, Xavier Preville3, Xianghua Wu1, Xia Meng2, Jianhua Chang1, 
Romain Micol3 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
Shanghai/China, 2Institut Merieux Laboratory, Fudan University Shanghai Cancer Center, 
Shanghai/China, 3Transgene S.A., Illkirch-Graffenstaden Cedex/France
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths 
worldwide. Platinum-based duplet therapy is current standard first-line therapy for 
metastatic NSCLC although its influence on overall survival is modest. The response 
to chemotherapy and prognosis of patients with metastatic NSCLC is variable due to 
the heterogeneity. The purpose of the present study was to develop a new prognostic 
index to predict the clinical outcome of patients with metastatic NSCLC and then 
improve the clinical management for these patients. Methods: This prospective single-
institutional study included 70 patients with metastatic NSCLC receiving platinum-
based first-line chemotherapy. Plasma levels of 27 cytokines before chemotherapy 
were measured using multiplex immune assays. Receiver operating characteristics 
(ROC) curves were adopted to select the cut-off values for survival and chemotherapy 
response analyses. The Kaplan–Meier method, univariate and multivariate Cox 
regression analyses were used to evaluate the associations between each cytokine, 
ratio or clinical variable and progression-free survival (PFS) and overall survival (OS). 
Prognostic index (PI) was calculated by parameters estimates and PI subgroups were 
created using tertiles. The performance of the PI was calculated using PSEP method 
and validated by a bootstrap approach. Results: Five variables were identified as 
statistical significant independent prognostic factors by multivariate Cox model: three 
cytokines/cytokine ratios including IP-10/Eotaxin (HR, 1.578; P=0.018), MCP-1 (HR, 
1.138; P=0.032) and MIP-1a (HR, 0.464; P=0.007) as well as CRP (HR, 5.948; P<0.001) 
and histology (HR, 5.372; P<0.001). Using these five variables, a new PI was developed 
to distinguish the patients into high-risk group and low-risk group according to the 
outcome (P<0.001). Internal validation showed that the mean optimism over 1000 
iterations was 0.17 and an unbiased estimate of PSEP was 0.40. Conclusion: The new 
PI including cytokine and clinical variables can efficiently predict the survival outcome 
of patients with metastatic NSCLC. This finding may serve as the basis for further 
were analyzed by PCR-RFLP. Results: 13 patients (62%) were evaluable for response (8 
patients not assessable due to either no chemo or <3 cycles). ORR was 46% (6PR, no 
CR) and DCR was 100%. 20 patients (95%) were evaluable for toxicity. 78 chemotherapy-
related adverse events were reported with 17 (22%) grade 3/4 (2 anemia, 7 neutropenia, 
5 thrombocytopenia, 1 renal failure, 1 asthenia, 1 nausea). There was no toxic death. 
Chemotherapy was stopped after 3 cycles for 2 patients. Homozygous and heterozygous 
deletion in 3’UTR of TYMS was observed in 1 and 9 patients, respectively. For TYMS 
5’UTR, 13 patients belong to class 2 (2R/2R, 2R/3RC or 3RC/3RC), 6 belong to class 3 
(2R/3RG or 3RG/3RC) and one belong to class 4 (3RG/3RG). Other genotypes were as 
follows. GSTP1 codon 105: 10 Ile/Val and 4 Val/Val; GSTP1 codon 114: 1 Ala/Val; ERCC1 
codon 118: 10 C/T and 4 C/C; ERCC2 codon 751: 12 Lys/Gln and one Gln/Gln; MTHFR 
C677T: 10 C/T and 3 T/T; MTHFR A1298C: 8 A/C and 3 C/C. There was no correlation 
between any gene polymorphisms and response or G3-4 toxicity. Of note, among the 
6 patients homozygous for rare MTHFR alleles (i.e. 677TT or 1298CC), 4 exhibited a 
high-grade (grade 3/4) haematological toxicity. Conclusion: Present results suggest 
that gene polymorpshism analysis is feasible in the context of pharmacodynamics 
predictivity. From this limited number of patients, a trend was observed between MTHFR 
genotype and haematological toxicity. These preliminary data need to be confirmed 
on a larger set of patients with thoracic tumors treated by cisplatin/pemetrexed. 
Keywords: pharmacogenetics, Lung cancers, Cisplatin, pemetrexed
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P3.04-112 Repeated Observation of Immune Gene Sets Enrichment in 
Women with Non-Small Cell Lung Cancer Jhajaira Araujo1, Joseph A. Pinto1, Zaida 
Morante2, Alfredo Aguilar2, Silvia Neciosup2, Luis Mas2, Henry Gomez2, Carlos Vallejos2 
1Basic and Translational Research, Oncosalud, Lima/Peru, 2Medical Oncology Department, 
Oncosalud, Lima/Peru
Background: There are different patterns of lung cancer (LC) characteristics between 
men and women. Females tend to present LC at a younger age and with more advanced 
stages than males; however, the prognostic is better in women. In despite of the great 
advances in the knowledge of the genomic landscape of lung cancer, it is not explored 
the molecular differences regarding to gender. Our aim was to evaluate differentially 
enriched gene sets between women and men. Methods: We evaluated 05 public 
databases containing gene expression values from NSCLC patients: GSE50081 (HG-
U133_Plus_2; n=81 samples), GSE47115 (Illumina HumanHT-12 WG-DASL V4.0 R2; 16 
samples), GSE10072 (HG-U133A; n=71 samples), GSE32863 (Illumina HumanWG-6 v3.0; 
116 samples), GSE7670 (HG-U133A; n=52 samples). In each dataset, expression levels 
were log2 transformed and median centered. We performed the Gene Set Enrichment 
Analysis (GSEA) to find differences between the two genders. Each dataset was analyzed 
individually. Since the smoking status is the main confounding factor, datasets were 
divided in cohorts of smokers and non-smokers (and healthy tissues by smoking status 
when it was included in the dataset). Cases with unknown smoking status and former 
smokers were excluded from the analysis. We use the Gene ontology biological process 
terms to find similar enriched pathways between cohorts, 1454 gene sets named by 
gene ontology terms were examined. We consider a gene set enriched when at least a 
cohort had a p-value<0.05 and also the observation was repeated in other datasets with 
a p-values <0.08 (statistical trends). Results: The analysis showed repeated observation 
of immune genes enrichment in women; defense response to virus was enriched in four 
data sets; cytokine biosynthetic process, innate immune response, positive regulation of 
cytokine biosynthetic process, regulation of cytokine biosynthetic process and response 
to other organism were enriched in three dataset; adaptive immune response, B cell 
activation, cellular defense response, chemokine activity, innate immune response, 
interferon gamma biosynthetic process, interleukin 8 production and others were 
enriched in at least two data sets. On the other hand, aminoacid transport, cellular protein 
catabolic process, maintenance of protein localization, regulation of GTPase activity, 
regulation of protein polymerization, regulation of Rho GTPase cctivity and others were 
enriched in three datasets in men. Conclusion: The analysis of global gene expression 
showed that Immune genes sets are frequently enriched in women compared to men. 
Differences on enrichment pathways between men and women should be deeply explored. 
Keywords: non-small cell lung cancer, GSEA, smoking status, Immune genes
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P3.04-113 Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis as a Prognostic 
Marker in Patients with Stage IV Non-Small Cell Lung Cancer Eliza D. Ricardo1, 
Alexandre A.B.A. Da Costa2, Vladmir C.C. De Lima1 1Clinical Oncology, A.C. Camargo 
Cancer Center, São Paulo/Brazil, 2Cinical Oncology, Ac Camargo Cancer Center, Sao Paulo/
Brazil
Background: Systemic inflammation has been linked with cancer development, cancer 
cachexia and poor outcome. Neutrophil to lymphocyte ratio (NLR), an index of systemic 
inflammation, has been associated with worse survival for many types of cancer. The aim 
of this study is to investigate the clinical significance of the blood NLR as a prognostic 
factor in non-small cell lung cancer (NSCLC) patients. Methods: We retrospectively 
reviewed the medical charts of patients with metastatic NSCLC, diagnosed between Jan 
1st 2011 and July 30th 2014, from a single Brazilian institution. Data on prognostic factors 
such as histology, gender, performance status, comorbidities and type of treatment 
were collected. The baseline NLR was assessed just before chemotherapy treatment 
initiation. NLR was defined as the ratio between the absolute neutrophil and lymphocyte 
counts. Associations between clinical variables and NLR were tested with Chi-square or 
exact Fisher´s test. Overall survival (OS) was calculated by the Kaplan–Meier method. 
Curves were compared using the log-rank test. Multivariate analysis was performed 
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P3.04-118 Expression of TS and DPD in Primary Lung Cancer Takayuki Shiina, 
Takao Sakaizawa, Hiroyuki Agatsuma, Takashi Eguchi, Gaku Saito, Akira Hyogotani, 
Masayuki Toishi, Kazuo Yoshida Thoracic Surgery, Shinshu University Hospital, Matsumoto/
Japan
Background: Chemotherapy with 5-fluorouracil (5-FU) preparations is widely used to 
treat gastrointestinal cancer, head and neck cancer, and breast cancer. 5-FU acts by 
inhibiting thymidylate synthase (TS), the rate-controlling enzyme of pyrimidine synthesis, 
and its anticancer activity is related to the rate of TS inhibition in gastrointestinal cancer 
and other tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme 
for the catabolism and inactivation 5-FU. As one biochemical modulation strategy, uracil–
tegafur (UFT) has been developed to improve the bioavailability of 5-FU by inhibiting 
DPD. Expression levels of TS and DPD in resected lung cancer samples are generally 
determined quantitatively by reverse-transcription polymerase chain reaction (RT-PCR) 
or qualitatively by immunohistochemical analysis. However, no study has employed 
enzyme-linked immunosorbent assay (ELISA) to measure TS and DPD expression in 
lung cancer, although this technique is often used for gastrointestinal, colorectal, 
and breast cancers. Methods: From April 2004 through December 2007, we studied 
tissue samples from 168 of 280 patients with primary lung cancer in which both TS 
and DPD could be measured. TS and DPD in normal and tumor tissues were quantified 
by ELISA and compared according to expression level, gender, histological type, and 
clinicopathological characteristics. Patient Characteristics: Of the 168 patients, 110 
were men (65.4%), and 58 were women (34.6%). The median age was 69.6 (range, 35-
89) years; 107 patients were former or current smokers and 61 were nonsmokers.The 
pathologic disease stage was IA in 59 patients, IB in 34, IIA in 8, IIB in 23, IIIA in 33, 
IIIB in 7, and IV in 4. The patients with stage IV disease had brain metastasis. The most 
common histological type was adenocarcinoma (107 cases), followed by squamous 
cell carcinoma (39), adenosquamous carcinoma (2), large cell carcinoma (9), small 
cell carcinoma (5), pleomorphic carcinoma (3), and carcinoid (3). Results: Expression 
levels of TS and DPD were significantly higher in lung cancer tissue than in noncancerous 
tissue. As for patient characteristics, TS expression in tumors was significantly lower 
in women and nonsmokers. According to histological type, tumor TS expression was 
significantly lower in adenocarcinoma and squamous cell carcinoma than in other types 
of lung cancer, whereas DPD expression did not differ significantly among histological 
types. Median tumor TS expression was significantly lower in well-differentiated tumors 
than in moderately/poorly-differentiated tumors. Among patients with adenocarcinoma 
(n=107), median tumor TS expression was significantly lower in women and nonsmokers. 
Conclusion: The present study suggested that tumor TS and DPD levels are useful 
predictors of chemosensitivity to UFT in patients with primary lung cancer who receive 
postoperative adjuvant chemotherapy. The expression level of TS in tumors may be 
useful for selecting postoperative treatment for individual patients with lung cancer, 
particularly those who are women or nonsmokers or who have adenocarcinoma. 
Keywords: lung cancer, Thymidylate Synthase, Dihydropyrimidine Dehydrogenase
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P3.04-119 The Decreased Serum Dopamine Level Is Associated with Poor 
Prognosis in Non-Small Cell Lung Cancer and Contributes to Cancer Cell 
Stemness Xiaoyuan Wu, Bin Zhang, Wei Zhao Central Laboratory, Nanjing Chest Hospital, 
Nanjing/China
Background: Lung cancer ranks the first cancer related mortality worldwide. 
Dysregulation of dopamine-related pathways have been implicated in tumor 
development/angiogenesis. Methods: In this study, we detected dopamine in 63 non-
small cell lung cancer (NSCLC) patients, and 70 healthy control serum by Elisa kit. 
The associations between serum dopamine level with patient’s prognosis and survival 
were analyzed by SPSS 17.0 statistical software. Add dopamine into NSCLC cancer 
cell medium and FACS detected the effects on cancer cells stemness. Results: The 
serum dopamine level is significantly down-regulated in NSCLC samples, compared 
to the healthy control (P < 0.0001). In addition, low level of serum dopamine was 
correlated with tumor size (P = 0.0207) and N stage (P = 0.007). Kaplan-Meier 
analysis indicated that patients with low serum dopamine had a poor overall survival 
(P = 0.0144). Additional dopamine inhibited the stemness and proliferation of NSCLC 
cell line A549. Conclusion: Our data indicates that dopamine negatively regulates 
NSCLC cell stemness and might be a novel therapeutic target in NSCLC patients. 
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P3.04-120 Quantitative Immunofluorescence Based Expression Analysis 
in NSCLC Reveals Nuclear EZH2 as Poor Prognostic Biomarker Vamsidhar 
Velcheti1, Sijin Wen2, Kurt Schalper3, Veronique Neumeister4, Hashim Abbas1, Wei 
Zhang2, Lihong Yin1, Patrick C. Ma2 1Cleveland Clinic, Pepper Pike/United States of 
America, 2Mary Babb Randolph Cancer Center., West Virginia University., Morgantown/
United States of America, 3Pathology, Yale University, New Haven/CT/United States of 
America, 4Pathology, Yale University, New Haven/United States of America
Background: EZH2 is a histone-lysine N-methyltransferase enzyme and the key 
functional enzymatic component of the polycomb repressive complex 2 (PRC2), which 
is a crucial epigenetic regulator in cancer cell survival. EZH2 methylates histone 3 at 
lysine 27 (H3K27me/me2/me3) and has been associated with the heterochromatin 
state, transcriptional repression and activation, hematopoiesis, development, and 
development of biomarkers for the prognosis and treatment of metastatic NSCLC. 
Keywords: clinical factors, non-small cell lung cancer, prognostic index, cytokines
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P3.04-116 Prognostic Role of fox-p3 Positive T-Regulatory Cells in Curatively 
Resected NSCLC Other than Stage IA Fatih Kose1, Ayberk Besen1, Alper 
Findikcioglu2, Tuba Canbolat3, Yurday Ozdemir3, Ali M. Sedef1, Huseyin Mertsoylu1, 
Ahmet T. Sumbul1, Ozgur Ozyilkan1, Huseyin Abali1 1Medical Oncology, Baskent University, 
Adana,/Turkey, 2Thoracic Surgery, Baskent University, Adana,/Turkey, 3Baskent University, 
Adana,/Turkey
Background: Curative surgical excision accompanied by adjuvan chemotherapy for 
those stage II, III and high risk stage IB patients for completely resected early stage 
Non-small cell lung cancer is the widely accepted. However, over 50 % of cases in this 
early stage group recur and die after this aggressive treatment strategy. Currently used 
prognostic markers are imperfect to estimate the patients with high risk of relapse. 
Biologic agents which increase the immune system activity recently approved in the 
treatment of advanced NSCLC. Main aim of this study is to explore the prognostic role 
T-regulatory cells, which has essential role in decreasing effect of cytotoxic cells on 
tumor tissue, in early stage NSCLC. Methods: A total 48 patients those who were 
resected with R0 resection in baskent university between 2005-2009. Stage IA patients 
were excluded. İmmunohistochemical staining made on the parffin embedded tissue. 
Kaplan meier survival curve and log-rank test used for the stattistical evaluation. The 
values of p below the <0.05 was accepted as statistical signifcant. Results: A total 
48 patients, 40 (83.3%) male and 8 (16.7%) female, were included. ECOG 0, 1, 2 scale 
were found in 32(66.7%), 14(29.2%), and 2 (4.2%) patients, accordingly. Mean follow-
up time for whole group was 49 months (6-128). Adjuvant chemotherapy were given 
to 16 patients (33.3%) at physician discretion. There were 21(43.8%), 14(29.2%), 
and 13 (27.2%) patients with stage of IB, II, and III, respectively. Grade 0, 1, 2, 3 IHC 
staining intensity for CD 3 and FOX-P3 were found in 0-25 (52.1%), 11(22.9%)-21(43.8%), 
16(33.3%)-2(4.2%), and 21(43.8%)-0 patients, respectively. We build a risk score based 
on the rate of FOXP3/CD3 grades. Low risk, intermediate risk, and high risk score 
were detected in 22 (45.8%), 17 (35.4%), and 9 (18.8%) patients, respectively. Disease 
relapse rate were 88.9, 76.5, and 18.8% in high, intermediate, and low risk group. 
(p:0.005). Disease free survival and overall survival were 30 (14.7-45.6) and 49 months 
(20.6-77.7). In univariate analyses, ECOG performance (p=0.025) scale, pathological 
stage (p=0.029), and grade of FOX-P3 (p=0,032) had statistically significant effects 
on disease free survival (DFS). In univariate analyses, ECOG performance (p=0.008) 
scale, pathological stage (p=0.03), and IHC staining intensity of FOX-P3 (p=0,018) had 
statistically significant effects on overall survival (OS). The statistical analysis failed 
to show statistically significant effects of formed risk groups (p>0.005) on DFS and 
OS. Conclusion: In conclusion, results of the present study showed that increase the IHC 
staining of T-reg cells in tumor tissue significantly related with tumor relapse (higher the 
intensity-higher the relapse rate). Univariate analysis showed that IHC staining intensity 
had negative prognostic factor and statistically significant effect on both DFS and OS. 
Keywords: lung cancer, Tregulatory cell, prognosis,
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P3.04-117 Clinical Characteristics and Survival Outcome of Non-Small Cell 
Lung Cancer According to Age Young Sik Park1, Sun Mi Choi2, Jinwoo Lee2, Chang-
Hoon Lee2, Sang-Min Lee2, Jae-Joon Yim2, Chul-Gyu Yoo2, Sung Koo Han2, Young Tae 
Kim2, Dae Seog Heo2, Young Whan Kim2 1Internal Medicine, Seoul National University 
Hospital, Seoul/Korea, 2Seoul National University Hospital, Seoul/Korea
Background: Clinical characteristics of non-small cell lung cancer (NSCLC) in young 
age are different from those of older patients. The aim of this study was to compare 
the survival according to age with adjustment for major confounding factors including 
major drugable mutations (EGFR and ALK). Methods: From June 2011 to December 
2014, 1860 consecutive newly diagnosed NSCLC patients were recruited. Among 
them, we divided 4 groups according to age; group I (age<40), group II (40≤age<60), 
group III (60≤age<80), and group IV (age>80). We compared survival using 3 
different Cox proportional hazard model; unadjusted model, model 1 (adjusted for 
sex, smoking, BMI, ECOG performance status, histology of adenocarcinoma, initial 
stage), and model 2 (model 1 + drugable mutations). Results: Among 1860 patients, 
mean age was 66.1 years old, and 64.7% was male. Never smokers were 38.0% and 
adenocarcinoma observed in 62.0%. EGFR and ALK mutations were detected in 40.3% 
and 5.1%, respectively. The numbers of patients were 29 in group I, 436 in group 
II, 1276 in group III, and 119 in group IV. In Cox proportional hazard model, survival 
differences between age groups were significant in unadjusted model and model 1. 
But after adjustment for drugable mutations (model 2), the survival difference was 
not significant. Conclusion: Survival on NSCLC in young age was not different from 
that older patients, after adjustment for sex, smoking, BMI, ECOG performance status, 
histology of adenocarcinoma, initial stage and major drugable mutations (EGFR and ALK). 
Keywords: age, NSCLC, survival
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P3.04-121 Testicular Orphan Receptor 4 (TR4) Is a Marker for Metastasis and 
Poor Prognosis in Non-Small Cell Lung Cancer That Drives the EMT Phenotype 
Liyi Zhang, Jianzhi Zhang, Yuanyuan Ma Department of Thoracic Surgery Ii, Peking 
University Cancer Hospital & Institute, Beijing/China
Background: Aberrant expression of Testicular orphan receptor 4 (TR4) has been shown 
to regulate biologic processes around solid tumors. However, it is not clear the role of 
TR4 in prognosis for non small cell lung cancer (NSCLC) patients and the development 
of NSCLC cells. Methods: Immunohistochemical was used to evaluate the correlation 
between TR4 expression and clinicolpathological characteristics in 35 paired of tumor 
and counterpart normal tissues and 291 cases of specimens. Knock-down assay was 
performed to suppress the TR4 expression level. Transwell and colony formation assays 
were done to investigate metastatic and proliferative abilities. Quantitative real-time PCR 
, western blotting and immunofluorescence staining were carried out to analyze the EMT 
phenotype. Results: Immunohistochemical evaluation of clinical samples disclosed most 
of the lung cancer tissues were positive for TR4, while weakly positive or negative for TR4 
expression in the counterpart normal tissues. Moreover, higher levels of TR4 expression 
were significantly associated with higher lymph node metastases, TNM stages, tumor 
thrombus in vana and poor prognosis with significant difference. We observed that 
downregulation of TR4 with stable cell transfection significantly reduced the proliferation, 
invasive and metastatic abilities of NSCLC cell lines A549 and PC-9. In addition, aberrant 
TR4 expression could modulate the expression levels of several epithelial-to-mesenchymal 
transition (EMT) related markers. Conclusion: Collectively, our results show TR4 
expression in NSCLC samples is significantly associated with poor clinicopathological 
features and an important role in metastatic capacity of NSCLC cells by EMT regulation. 
Keywords: Testicular orphan receptor 4, Prognosis, metastasis, EMT
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P3.04-122 The Prognostic Significance of Galectin-3 Expression in Non-Small 
Cell Lung Carcinoma Saraswati Pokharel1, Sharmeen Mansoor1, Umesh Sharma2, 
Richard Cheney3 1Pathology, Roswell Park Cancer Institute, Buffalo/United States of 
America, 2Cardiology, University of Buffalo, Buffalo/AL/United States of America, 3Pathology, 
Roswell Park Cancer Institute, Buffalo/AL/United States of America
Background: Galectin-3 (gal-3) is a beta-galactoside binding protein expressed by 
various cells and is overexpressed in several malignancies, including lung cancer. 
Preclinical cancer models have shown gal-3 to be associated with tumor cell 
transformation, invasive behavior, and metastasis. The role of gal-3 in lung cancer has 
not been well studied. The aim of this study is to examine the prognostic significance 
of gal-3 overexpression in non-small cell lung carcinoma (NSCLC). Methods: Using 
pathology archives from our cancer center, tissue microarray (TMA) were constructed 
of 248 resected NSCLC and matching normal lung tissue. Gal-3 protein expression was 
assessed by immunohistochemical analysis (IHC). The staining pattern of triplicate tumor 
cores spread in to 3 TMAs were scored semi- quantitatively as: 0, negative, 1 weak, 
2, moderate, and 3 strong. Average score was calculated and the score up to 1 was 
regarded as low expression and 2 and 3 were regarded as high expression. One or 
less cores were available for 24 cases and they were excluded from the study. The 
association between gal-3 score and 5-year survival, nodal metastasis, and cancer stage 
were analyzed using chi-square test. Results: Of the 224 patients included, 217 were 
squamous cell carcinoma and 7 were other types of NSCLC. Normal lung tissues had 
mean gal-3 score of 0 (median score 0, range 0-2). Tumor samples had mean gal-3 score 
of 2 (range 0-3) with 62% of the samples having gal-3 score of ≥ 2. In this data set, high 
gal-3 score was associated with less than 5-year survival rate (p=0.04) but not associated 
with nodal metastasis, nor higher stage (stage II-IV) in NSCLC patients. Conclusion: Gal-
3 expression is increased in more than 60% of NSCLC, particularly squamous cell 
carcinoma. Higher gal-3 protein expression is associated with poorer prognosis in this 
cohort. Larger studies are necessary to evaluate gal-3 as prognostic factor in NSCLC. 
Keywords: Galectin-3, lung cancer, survival
POSTER SESSION/ BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-17:00
P3.04-123 Serum and Pleural Fluid VEGF Levels in Advanced NSCLC 
Ioannis Gkiozos, Sofia Tsagouli, Andriani Charpidou, Dimitra Grapsa, Elias Kainis, 
Christina Gratziou, Konstantinos Syrigos University of Athens, Athens/Greece
Background: Although most previous studies have suggested that higher pretreatment 
serum vascular endothelial factor (VEGF) levels may be associated with reduced survival 
in patients with non-small cell lung cancer (NSCLC), the independent prognostic value of 
this biomarker remains largely controversial. The primary aim of this study was to 
evaluate the prognostic significance of pretreatment serum and pleural fluid VEGF levels 
in NSCLC patients presenting with malignant pleural effusion (MPE). Methods: Forty 
consecutive newly diagnosed NSCLC patients with MPE at presentation but without 
distant metastases were prospectively enrolled. Serum and pleural fluid VEGF levels were 
assayed by enzyme-linked immunoassay (ELISA). ROC curve analysis was used to 
determine the optimal cut-off value for serum VEGF to discriminate between patients and 
healthy subjects. Serum and pleural fluid VEGF levels were correlated with standard 
clinicopathological parameters, including gender, age, smoking history, performance 
cell differentiation. Activating EZH2 mutations has been identified in lymphoma, 
and EZH2 overexpression has recently been reported in solid tumors including 
melanoma, breast, prostate, and lung cancer. Inhibition of EZH2 is a promising 
therapeutic strategy and a number of EZH2 targeting drugs are currently in clinical 
development. Methods: Multiplexed QIF assay was used to evaluate EZH2 expression 
using monoclonal antibody (clone D2C9, cell signaling technology) against human EZH2, 
and cytokeratin (AE1/AE3, Dako) in a retrospective cohort of 298 stages I-IV NSCLC 
represented in tissue microarray (TMA) format. H3122 NSCLC xenografts and control 
patient samples were used to determine staining specificity and optimal titer. The 
association between EZH2 level, clinico-pathological characteristics and survival were 
studied. The classification and regression tree (CART) analysis was used to determine 
the optimal cutoff of EZH2 expression to predict survival. Kaplan-Meier and log-rank 
test were used in statistical analysis of overall survival. Chi-square test was used for 
clinic-pathologic correlation statistical analysis. Results: EZH2 protein was detected 
predominantly in the tumor compartment with nuclear staining pattern. A high EZH2 
level was detected in 82% of cases and was correlated with active smoking (92% vs. 
64%, P=0.005) and squamous cell histology (94% vs 76%, P=0.013) (Table 1). Elevated 
tumor nuclear EZH2 expression was significantly associated with worse survival (median 
survival 53 vs. 104 months; log-rank P=0.002) (Figure 1).
Table 1: Clinical Correlations of EZH2 expression in NSCLC
EZH2.in.Nu-
clear.AQUA.
Norm> 570
Chi-square 
test
All (%) No (%) Yes (%) p-value
Age
<70 120 (56.1) 22(18) 98(82) 0.864
≥70 94 (43.9) 19(20) 75(80)
Gender
Female 130 (60.7) 25(19) 105(81) 0.885
Male 84 (39.3) 16(19) 68(81)
Tobacco.
history
Current 
Smoker 49 (22.9) 4(8) 45(92) 0.005
Former 113 (52.8) 21(19) 92(81)
Never 39 (18.2) 14(36) 25(64)
unknown 13 (6.1)
Histology
Adenocarci-
noma 134 (62.6) 32(24) 102(76) 0.013
Others 26 (12.1) 6(23) 20(77)
Squamous 
Cell 54 (25.3) 3(6) 51(94)
Tumor Size
<3cm 115 (53.7) 23(20) 92(80) 0.778
≥3cm 97(45.3) 17(18) 80(82)
unknown 2 (1)
 Conclusion: Our study shows that high nuclear EZH2 protein expression is a poor prognostic 
biomarker in NSCLC, and is correlated with smoking status and squamous cell histology. 
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Results:
 
Enhanced trimethylation of H3K27me3 was correlated with longer OS and better 
prognosis (P<0.05). Both univariate and multivariate analyses indicated that H3K27me3 
level was a significant and independent predictor of better survival (hazard ratio, 0.187; 
95% confidence interval, 0.066-0.531, P=0.002). Furthermore, H3K27me3 expression 
was positively correlated with DNA methylation level at CCGG sites while reversely 
related to EZH2 expression (P<0.05) Conclusion: H3K27me3 level defines unrecognized 
subgroups of NSCLC patients with distinct epigenetic phenotype and clinical outcome, 
and can probably be used as a novel predictor for better prognosis in NSCLC patients. 
Keywords: non-small cell lung cancer, H3K27me3, epigenetics, EZH2, DNA methylation
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P3.04-125 Cytokine Profiles in Non-Small Cell Lung Cancer Patients 
Undergoing Palliative Thoracic Radiotherapy; Predictor of Response? 
Hanne A. Eide1, Ann R. Halvorsen1, Anne Fåne2, Jon A. Kyte2, Odd Terje Brustugun3, 
Åslaug Helland4 1Department of Cancer Genetics, Oslo University Hospital - the Norwegian 
Radium Hospital, Oslo/Norway, 2Departement for Cell Therapy, Oslo University Hospital - 
the Norwegian Radium Hospital, Oslo/Norway, 3Department of Oncology, Oslo University 
Hospital-The Norwegian Radium Hospital, Oslo/Norway, 4Department of Oncology, The 
Norwegian Radium Hospital, Oslo/Norwa, Oslo/Norway
Background: A majority of patients with non-small cell lung cancer are diagnosed in 
later stages of disease where no curative treatment is currently available. The prognosis 
for these patients is poor. Median survival from diagnosis in stage IV is approximately 9 
months. Many patients will benefit from external radiotherapy to the thorax for alleviation 
of symptoms due to advanced lung cancer. Despite adequate radiotherapy, however, 
many tumors progress locally in the radiation field. Here, we investigate whether the 
kinetics of cytokines in serum can be utilized as predictors for tumor response to 
radiotherapy and/or predictors of lung toxicity. Methods: Patients with histologically 
confirmed non-small cell lung cancer, eligible for palliative radiotherapy to the hilus-
mediastinum, were included in a randomized phase II clinical trial; the ThoRaT-study. 
Patients were randomised to 1 of 2 study arms undergoing thoracic radiotherapy, 3 Gy 
status (PS), histological type of tumor and treatment response. The prognostic value of 
each variable for overall survival (OS) and progression-free survival (PFS) was assessed 
by Cox regression analysis. Results: The median serum VEGF levels were significantly 
higher in patients as compared to healthy controls (p<0.001), while the optimal cut-off of 
serum VEGF was 375 pg/ml, with a sensitivity and specificity of 76.9% and 98.0%, 
respectively. Serum VEGF more than 375 pg/ml, pleural fluid VEGF over the median value 
and the presence of progressive disease, were all significantly associated with reduced 
OS and PFS, both in univariate and multivariate analysis (Figures 1 and 2). A statistically 
significant correlation was also observed between serum and pleural fluid VEGF levels 
(p<0.001).
 
Conclusion: Our results suggest that increased pretreatment serum and 
pleural fluid levels of VEGF may be independent predictors of a worse survival in 
advanced-stage NSCLC patients. Furthermore, pretreatment serum VEGF levels 
may be useful in discriminating between NSCLC patients and healthy subjects. 
Keywords: vascular endothelial growth factor, non-small cell lung cancer, pleural fluid, 
serum
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P3.04-124 High Expression of Trimethylated Histone H3 at Lysine 27 Predicts 
Better Prognosis in Non-Small Cell Lung Cancer Xiaohui Chen1, Ning Song2, 
Keitaro Matsumoto3, Takeshi Nagayasu3, Hayashi Tomayoshi4, Mingang Ying1, Takehiko 
Koji2 1Thoracic Surgery, Fujian Provincial Cancer Hospital, Fuzhou/China, 2Department of 
Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, 
Nagasaki, Japan, Nagasaki/Japan, 3Division of Surgical Oncology, Department of 
Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Science, 
Nagasaki, Nagasaki/Japan, 4Department of Pathology, Nagasaki University Hospital, 
Nagasaki, Nagasaki/Japan
Background: Lung cancer is still the leading cause of cancer death in both sexes 
throughout the world. The alterations in epigenomes such as DNA methylation and 
histone modifications play pivotal roles in carcinogenesis. It has been reported that DNA 
methylation level and global histone modification patterns may be possible predictors of 
cancer recurrence and prognosis in a large variety of cancer entities. One such repressive 
modification, the trimethylation of lysine 27 on histone H3 (H3K27me3), seemed to be 
an epigenetic label mediating gene silencing; and a mark for de novo DNA methylation in 
cancer cells by recruitment of DNA methyltransferase (DNMTs) , contributing to tumor 
progression through suppression of a certain gene expression. In fact, many recent 
studies have revealed that H3K27me3 may be involved in the characterization of various 
types of human cancers, excluding NSCLC. Interestingly, reports of H3K27me3 levels 
in different cancer samples are somewhat contradictory. It’s demonstrated that low 
H3K27me3 levels predicted poor outcome in breast, ovarian and pancreatic cancers 
while high levels predicted poor outcome in hepatocellular carcinoma and esophageal 
squamous cell carcinoma. Moreover, H3K27 methylation is catalyzed by its specific 
methyltransferase, EZH2. Overexpression of EZH2 was also found in a variety of cancers, 
resulting in worse clinical outcome. Although many reports on the role of H3K27me3 in 
carcinogenesis were available, its carcinogenic role in NSCLC and how it interacts with 
EZH2 and DNA methylation remain unclear. Methods: Expressions of H3K27me3 and 
its methyltransferase, enhancer of zeste homolog 2 (EZH2) together with proliferating 
cell nuclear antigen (PCNA) were evaluated by immunohistochemistry in normal lung 
tissue (n=5) and resected NSCLC patients (n=42). In addition, the specificity of antibody 
for H3K27me3 were testified by western blotting. The optimal cut-point of H3K27me3 
expression for prognosis was determined by the X-tile program. The prognostic 
significance was determined by means of Kaplan-Meier survival estimates and log-rank 
tests. 
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P3.04-128 Does the Amount of Malignant Pleural Effusion Affect the Survival 
in Patients with Non-Small Cell Lung Cancer? Shota Nakamura, Toshiki Okasaka, 
Koji Kawaguchi, Takayuki Fukui, Koichi Fukumoto, Kohei Yokoi Thoracic Surgery, Nagoya 
University, Nagoya/Japan
Background: Malignant pleuritis in non-small cell lung cancer (NSCLC) is uniformly 
classified as M1a/stage IV disease according to the 7th TNM classification irrespective of 
its amount of malignant pleural effusion (MPE) and is considered as an incurable disease 
condition. Although it has been reported that small amount of MPE might be an early phase of 
malignant pleuritis, its clinical relevance has rarely been studied. Therefore, we examined 
an impact of the amount of MPE on the survival in patients with NSCLC. Methods: Sixty 
NSCLC patients with malignant pleuritis were treated in our institution between 2005 
and 2012. By the amount of MPE on chest high resolution computed tomography (HRCT) 
scans, the patients were classified into the three groups: no MPE (E0, n=21), small 
amount of MPE (<1.0 cm thick on HRCT) (E1, n=19), and large amount of MPE (≥1.0 cm 
thick on HRCT) (E2, n=20). Clinicopathological factors including the amount of MPE were 
investigated for the association between the amount of MPE with the survival regardless 
of the treatment. Results: The E2 group correlated significantly with shorter survival than 
did the E0 and the E1 groups (median survival time, 16, 31 and 20 months, respectively; 
log-rank P<.01), but there was no significant difference between the E0 and E1 groups. 
In the univariate analysis, the amount of MPE (E0 + E1 vs E2), histopathological type 
(adenocarcinoma vs others), treatment (chemotherapy or surgery vs best supportive 
care) and EGFR mutation (positive vs negative) were significant prognostic factors. 
After full adjustment with other variables, the amount of MPE, histopathological type 
and EGFR mutation remained as significant prognostic factors. Conclusion: The amount 
of MPE in NSCLC might be an important prognostic factor and affect the patients’ 
survivals. We suppose the present TNM classification, which uniformly define MPE as 
M1a/IV status irrespective of the amount of MPE, is necessary to be reconsidered. 
Keywords: non-small cell lung cancer, TNM classification, malignant pleural effusion, 
malignant pleuritis
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P3.04-129 Prognostic Factors and Biomarkers in Large Cell Carcinoma and 
Neuroendocrine Tumors of the Lung in the Thai Population 
Phannin Tiraswasdichai1, Narumol Trachu1, Noppadol Larbcharoensub2, Nanamon 
Monnamo1, Kiattipong Kamprerasart2, Ekaphop Sirachainan1, Thanyanan 
Reungwetwattana1 1Department of Medicine, Ramathibodi Hospital, Bangkok/
Thailand, 2Department of Pathology, Ramathibodi Hospital, Bangkok/Thailand
Background: There are limited data on prognostic factors and biomarkers of large 
cell carcinoma and neuroendocrine tumors of the lung (LCC/NETs) due to decreasing 
prevalence and the lack of large epidemiological studies. This study describes the natural 
history and clinical behavior of the disease including exploration of molecular alterations 
of LCC/NETs in the Thai population. Methods: Patients who had a diagnosis of LCC/ NETs 
of the lung from January 2000 to August 2014 were identified from the tumor registry 
of Ramathibodi Hospital. Data on the natural history and clinical behavior of the disease 
were collected. The association and predictive ability of patient and tumor characteristics 
with overall survival (OS) and recurrence-free survival (RFS) outcomes were examined, 
respectively. In 46 patients with adequate tumor tissue, Ki-67, neuroendocrine markers, 
CD117, HER-2, PDL-1, ALK, and IGF1-R were evaluated by immunohistochemistry staining 
(IHC). In addition, EGFR, PIK3CA and BRAF V600E mutations were evaluated by real time 
PCR. Results: Medical records of 191 patients were reviewed. OS rates at 1 year for 
small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC) and LCC were 39.7%, 
63.6% and 32.6%, respectively. The RFS rates at 1 year for SCLC, NEC and LCC were 
25.4%, 10.6% and 14.0%, respectively. There were 3 significant factors predicting for 
better survival outcomes. These included age, ECOG performance status, and receiving 
chemotherapy. There was no difference in Ki-67 expression between the SCLC and LCC/
NEC groups. In the molecular analysis, 10.8% of patients expressed ALK, 41.3% expressed 
CD117 (c-KIT), 23.9% expressed PDL1, and 78.3% expressed IGF1-R. In the mutational 
analysis, 4.9% of patients had a PIK3CA mutation, and 9.8% had an EGFR mutation. 19 
out of 46 patients (41.3%) who had positive CD117 expression had better 1-year survival 
rate than the negative group (68.4% vs 29.6%, P=0.018). No c-kit mutation was found 
in exons 9 and 11
.
x 10, with or without the addition of erlotinib concomitant with radiotherapy treatment. 
Side effects were recorded and graded according to CTC version 4.0. Clinical response 
in the radiation field was evaluated by CT or PET-CT scans. Blood serum was sampled at 
different time points; prior to treatment, at mid-therapy, at the end of therapy and 6 week 
following treatment completion. Multiplex immunoassays were used to measure serum 
concentration of 52 cytokines and 9 MMPs on all collected samples. Serum samples from 
COPD patients were included as controls. Results: Cytokine analyses of serum samples 
are ongoing and have to date been performed on 43 non-small cell lung cancer patients. 
Pre-treatment and follow up CT/PET-CT scans are currently under revision. Preliminary 
investigations show considerable variation in cytokine patterns between the patients 
and between different time points for some of the cytokines. Analyses of possible 
predictors for radiotherapy response and toxicity, as well as comparison with normal 
controls are currently ongoing and will be presented. Conclusion: We hypothesize that 
pre-treatment cytokine values and/or kinetics of concentration changes may provide 
information on the probability of clinical response and side effects from radiotherapy. 
Keywords: cytokines, non-small cell lung cancer, Radiotherapy
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P3.04-126 Expression of Notch1 and Notch2 in Xuanwei Female Patients with 
Lung Cancer and Its Clinical Significance Yunchao Huang, Huatao Niu, Guangqiang 
Zhao, Yujie Lei Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, 
Kunming/China
Background: To explore the expression of Notch1 and Notch2 in Xuanwei female 
patients with lung cancer and its clinical significance. Methods: The expression of 
Notch1 and Notch2 in the cancer tissue and distant normal tissue from 54 Xuanwei 
female patients with lung cancer was detected using immunohistochemical SP 
method. By combining with the clinicopathological characteristics and follow-up files, 
the functions of Notch1 and Notch2 in Xuanwei female patients with lung cancer for 
pathological and prognostic assessment were investigated. Results: Both Notch-1 and 
Notch-2 proteins were mainly expressed in cytoplasm. The positive rates of Notch-1 
and Notch-2 expression in the lung cancer tissue of Xuanwei females were dramatically 
higher than in distant normal tissue (P<0.05). There was statistical significance by 
comparison to the expression of Notch-1 and Notch-2 in patients with different clinical 
stagings, differentiated degrees and presence or absence of lymph node metastasis 
(P<0.05). The expression of Notch-1 and Notch-2 proteins was positively correlated 
in Xuanwei female patients with lung cancer. Conclusion: The expression of Notch-1 
and Notch-2 proteins goes up abnormally in the lung cancer tissue of Xuanwei females, 
and their expression levels combined with clinical staging has a certain clinical 
significance for prognostic assessment in Xuanwei female patients with lung cancer. 
Keywords: Notch1; Notch2; Female; Lung cancer, Xuanwei
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P3.04-127 Correlation Between ApoA-I and Prognosis of Advanced NSCLC 
Patients Chong Bai, Hui Shi, Qin Y. Sun, Yu C. Dong Respiratory Department, Changhai 
Hospital, Shanghai/China
Background: To investigate the correlation between apolipoprotein A-I(ApoA-I)
and clinicopathological features, as well as the effect of ApoA-I on the prognosis 
of advanced non-small cell lung cancer (NSCLC) patients. Methods: Retrospective 
analysis was performed for 117 cases with histologically confirmed IIIB and IV stage 
NSCLC patients in Changhai Hospital from January 2009 to December 2014. All 
patients were classified into two groups based on the value of baseline serum ApoA-I 
before treatment. The relationship between ApoA-I and clinicopathological features 
was studied. Univariate and multivariate analyses were performed to assess the 
prognostic effect of ApoA-I. Results: All patients were divided into two groups: low 
serum ApoA-I levels before treatment (≤1.2g/L, n=50,42.7%) and high serum ApoA-I 
levels before treatment (>1.2g/L, n=67,57.3%).ApoA-I was correlated with greatest 
tumor diameter（P=0.013), clinical stage(P=0.012),serum C-reactive protein before 
treatment（P=0.018),serum albumin(P<0.0001)and ECOG PS(P=0.024).The median 
survival time of low and high ApoA-I levels patients were10.1months and15.1 months, 
respectively,which indicated a statistically significant difference (χ2=7.027,P=0.008) 
between the two groups.Univariate analysis showed that smoking status（P=0.029), 
serum C-reactive protein before treatment（P=0.024),serum albumin（P=0.013),clinical 
stage(P=0.014),N stage（P=0.037）,ECOG PS（P=0.001)and serum ApoA-I levels 
before treatment（P=0.008).Multivariate analysis by using COX regression identified 
serum C-reactive protein before treatment（HR1.650，P=0.033),clinical stage（HR2.165
，P=0.001), ECOG PS（HR0.451,P=0.008)and serum ApoA-I levels before 
treatment（HR0.487,P=0.005) as independent prognostic factors of all the patients.In 
addition, stratified analysis showed that the one-year survival rate of the low ApoA-I group 
was lower than that of the high ApoA-I group with or without distant metastasis, and 
the differences were statistically significant （χ2=12.053，P=0.001). Conclusion: An 
decreased serum ApoA-I levels before treatment indicates poor prognosis in advanced 
NSCLC patients. ApoA-I could be a potential biological marker for advanced NSCLC patients. 
Keywords: apolipoprotein A-I, Prognosis, non-small cell lung cancer
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Table 2.GSTM1/T1/*105/*114 Genotype Distributions in Lung Cancer and Control 
Cases
Genotypes Lung cancer
Lung 
cancer Control Control p
n % n %
GSTP1 
Ile105Val AA 169 48,1 56 54,4
GSTP1 
Ile105Val AG 158 45,0 39 37,9 0,437
GSTP1 
Ile105Val GG 24 6,8 8 7,7
GSTP1 
Ala114Val CC 289 82,3 88 85,4
GSTP1 
Ala114Val CT 60 17,1 15 14,6 0,610
GSTP1 
Ala114Val TT 2 0,6 0 0,0
GSTM1 (+) 187 53,3 52 50,5 0,654
(-) 164 46,7 51 49,5
GSTT1 (+) 253 72,1 75 72,8 1,00
(-) 98 27,9 28 27,2
Total 351 100,0 103 100,0
 
 
Conclusion: In order to the most frequent lung cancer type is adenocarcinoma in world 
wide, our study indicate that epidermoid carcinoma was the most frequent type in our 
country. Recent studies showed that GST genes are expressed at human epitelial tissues 
including lungs. GST gene expressions are overexpressed expecially tumor tissues. Our 
results indicate that GST polymorphisims may play an important role at tumor pathogenesis. 
Therefore GSTP1 Ile105Val and Ala114Val functional polymorphisims’ mutant genotypes 
are more relevant for Squamous cell and Undifferentiated carcinoma pathogenesis. 
Keywords: lung cancer, GST genes, polymorphisim
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P3.04-131 Relationship between Peripheral Basophil Count and Non Small Cell 
Lung Cancer Abhishek Kumar1, Michael Maroules2 1Hematology and Oncology, Saint 
Joseph’S Regional Medical Center, Paterson/NJ/United States of America, 2Hematology and 
Oncology, Saint Joseph’S Regional Medical Center, Paterson/United States of America
Background: Lung cancer is the second most common cancer diagnosed in men and 
women after prostate and breast respectively. Basophils are the novel targets in cancer 
directed immunotherapy. We propose to study co-relationship between absolute counts 
of peripheral basophils in patients with NSCLC. Methods: The study was conducted at 
651 bedded tertiary care teaching hospital in Northern New Jersey, USA. The protocol 
was classified as “exempt” by the hospital’s institutional review board. The study included 
561 patients with a primary diagnosis of NSCLC registered with the hospital’s tumor 
registry from January 2001 to June 2011. Medical records were reviewed for these 
patients and Age, sex, race, WBC count, absolute basophilic count, histological type 
and TNM staging of all patients was noted at the time of diagnosis. The exclusion criteria 
were: 1. Patients whose biopsy reports were unavailable in the medical records or 2. 
Patients whose TNM Stage or Absolute Basophil Counts were unavailable at the time of 
diagnosis or 3. 18 years or less in age at the time of diagnosis. Data analysis was done 
using Microsoft Office Excel, 2007. Results: Mean age for the diagnosis was 67.6±11.1 
year. Adenocarcinoma (49.1%) was the most common diagnosis followed SCC (40.9%). 
Caucasians (61%) were more commonly diagnosed adenocarcinoma and SCC then 
African Americans (25.7%) & other races (13.2%). Males (64.2%) were more commonly 
diagnosed than females. Most of the cancers were diagnosed in the late stages (Stage 
III; 25.7% & Stage IV; 32.9%) accounting for 58.6% of the tumor burden. Mean White 
blood cell (WBC) count was 9.34±5.56 (*103/mm3). There were no statistically significant 
differences noticed in WBC counts based on histology for Adenocarcinoma: 8.66±4.16 
(p=0.103) and SCC: 9.71±5.69 (p=0.453) except other cancers: 11.20±9.26 
(p=0.046). Mean peripheral basophil count (PBC) was 0.0959±0.099 (*103/mm3). 
Based on histological types, there were no statistically significant differences noticed in 
PBC counts for Adenocarcinoma: 0.0897±0.0851 (p=0.418) and SCC: 0.0961±0.1048 
(p=0.976) other cancers: 0.1253±0.1283 (p=0.06). Further, we assumed PBC of 
stage1 as baseline for all the cancers subtypes and compared PBC with stage II, III & 
IV using student t-test (table 2). There was no statistical difference between PBC with 
any stages and histological subtypes. With the p-value trending towards significance 
in other cancers group. Mean PBC was statistically higher for the Undifferentiated 
cancers (p= 0.0359; 95% CI ±0.048). NSCLC weakly correlated with absolute basophils 
(Adjusted R2 = -0.000228, p = 0.70). Median interval change did not vary significantly 
between stages of adenocarcinoma and SCC (Kruskal-Wallis p value: 0.8702, 0.5798 
respectively). Conclusion: Though, the study was unable to demonstrate any relationship 
between peripheral basophil count and adenocarcinoma or SCC of lung. But surprisingly, 
there is a positive relationship between Undifferenciated lung cancer and PBC. But 
Conclusion: Our study provided strong evidence for clinical features (age, ECOG 
performance status, receiving chemotherapy) as prognostic factors for LCC/NETs of the 
lung. CD117 expression is a useful biomarker to predict OS. While earlier studies with 
Imatinib in both SCLC and NSCLC were negative, further mechanistic studies in the role 
of CD117 in LCC/NETs may yield therapeutic insights. Finally, larger studies to further 
explore the molecular alterations of LCC/NETs of the lung are needed. 
Keywords: neuroendocrine tumor of the lung, small cell lung cancer, large cell carcinoma, 
large cell neuroendocrine carcinoma
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P3.04-130 Frequency of GST Polymorphisms in Lung Cancer and Healthy 
Individuals from Turkey Kemal C. Tertemiz1, Esra Ataman2, Erkan Kaytankaş3, 
Mahafarin Maralani3, Ferah Ece4, Aykut Çilli5, Elif Yılmazer Uçar6, Pınar Mutlu7, 
Abdurrahman Şenyiğit8, Yılmaz Bülbül9, Ülkü Yılmaz10, Celal Karlıkaya11, Meftun Uysal12, 
Ayfer Ülgenalp13, Derya Erçal13, Atila Akkoclu1 1Department of Pulmonary Medicine, Dokuz 
Eylul University Faculty of Medicine, Izmir/Turkey, 2Department of Medical Genetics, Dokuz 
Eylul University Faculty of Medicine, Izmir/Turkey, 3Department of Moleculary Medicine, 
Dokuz Eylul University Faculty of Medicine, Izmir/Turkey, 4Department of Pulmonary 
Medicine, Liv Hospital Ulus, Istanbul/Turkey, 5Department of Pulmonary Medicine, Akdeniz 
University Faculty of Medicine, Antalya/Turkey, 6Department of Pulmonary Medicine, Ataturk 
University Faculty of Medicine, Erzurum/Turkey, 7Department of Pulmonary Medicine, 
Çanakkale Çan Public Hospital, Çanakkale/Turkey, 8Department of Pulmonary Medicine, 
Dicle University Faculty of Medicine, Diyarbakır/Turkey, 9Department of Pulmonary 
Medicine, Karadeniz Technical University Faculty of Medicine, Trabzon/Turkey, 10Department 
of Pulmonary Medicine, Ankara Atatürk Training and Research Hospital, Ankara/
Turkey, 11Department of Pulmonary Medicine, Trakya University Faculty of Medicine, Edirne/
Turkey, 12Department of Pulmonary Medicine, Ondokuz Mayıs University Faculty of Medicine, 
Samsun/Turkey, 13Department of Medical Genetics and Moleculary Medicine, Dokuz Eylul 
University Faculty of Medicine, Izmir/Turkey
Background: Glutathione S-transferases play an important role in detoxification of a 
wide range of human carcinogens. Functional polymorphisms have been identified in the 
GSTM1, GSTT1, GSTP1 genes, which may alter the risk of lung cancer among individuals 
exposed to coal, wood, and biomass smoke, and cooking oil fumes. Methods: We 
have evaluated the association between the GSTM1, GSTT1, GSTP1 Ile105Val and 
GSTP1 Ala114Val polymorphisms and lung cancer risk. All genotypes were detected by 
reverse hibridization method. Demographics datas, genotypes and allele frequencies 
are evaluated. Results: Prospectively 351 lung cancer and 103 control cases included 
to the study from 7 centers in Turkey. Mean age was 60 years and 76.4% of them were 
male. Subgroups of the cases are shown in table 1. All genotypes of four polymorphisms 
are found similar between the cancer and control group (table 2). Although we found 
no statisticaly significant correlation between the polymorphisms and occupational risk, 
smoke cessation, living area, biomass exposure and familial cancer history (p>0,05). 
GSTP1 *105 and *114 compaund heterozygote genotypes increase the lung cancer risk 
approximately 2,5 folds (OR=2,463;p=0,051). Moreover GST *105 and *114 compaund 
heterozygote genotypes increase squamous cell cancer risk 3 folds (OR=2,992;p=0,028 ) 
and undiferantial carcinoma risk 4 folds (OR=4.015;p=0.016). Table 1.Lung cancer 
subgroups
n %
Squamous cell carcinoma 133 37,9
Adenocarsinoma 98 27,9
Undifferentiated carcinoma 55 15,7
Small cell carcinoma 47 13,4
Large cell carcinoma 10 2,8
Adenosquamous carcinoma 8 2,3
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P3.04-134 Cancer-Specific Production of N-Acetylaspartate via NAT8L 
Overexpression in Non-Small Cell Lung Cancer and its Potential as a Biomarker 
Tzu-Fang Lou1, Deepa Sethuraman2, Patrick Dospoy3, Pallevi Srivastva1, Hyun Seok 
Kim4, Joongsoo Kim5, Xiaotu Ma6, Pei-Hsuan Chen7, Kenneth E. Huffman8, Robin E. 
Frink8, Jill E. Larsen9, Cheryl Lewis10, Sang-Won Um11, Duk-Hwan Kim12, Jung-Mo Ahn5, 
Ralph J. Deberardinis7, Michael A. White13, John D. Minna8, Hyuntae Yoo14 
1Departments of Molecular and Cell Biology and Center for Systems Biology, University 
of Texas, Richardson/TX/United States of America, 2Bioengineering and Center for 
Systems Biology, University of Texas, Richardson/TX/United States of America, 3Hamon 
Center for Therapeutic Oncology Research, University of Texas, Richardson/TX/United 
States of America, 4Severance Biomedical Science Institute, Yonsei University College 
of Medicine, Seoul/Korea, 5Departments of Chemistry, University of Texas, Richardson/
TX/United States of America, 6Department of Computational Biology, St Jude Children’S 
Research Hospital, Memphis/TN/United States of America, 7Children’S Medical Center 
Research Institute, University of Texas Southwestern Medical Center, Dallas/TX/United 
States of America, 8Hamon Center for Therapeutic Oncology Research, University of 
Texas Southwestern Medical Center, Dallas/TX/United States of America, 9Department 
of Genetics and Computational Biology, Qimr Berghofer Medical Research, Brisbane/
ACT/Australia, 10Department of Pathology, University of Texas Southwestern Medical 
Center, Dallas/TX/United States of America, 11Division of Pulmonary and Critical Care 
Medicine, Samsung Medical Center, Seoul/Korea, 12Department of Molecular Cell 
Biology, Sungkyunkwan University School of Medicine, Seoul/Korea, 13Department of 
Cell Biology, University of Texas Southwestern Medical Center, Dallas/TX/United States 
of America, 14Departments of Molecular and Cell Biology, Bioengineering and Center for 
Systems Biology, University of Texas, Richardson/TX/United States of America
Background: Lung cancer is the leading cause of cancer death worldwide, leading to 
1.6 million deaths every year. The majority of lung cancer cases are diagnosed in late 
stages, and early-stage detection and treatment are now known to reduce mortality 
rates, as recently reported for non-invasive screening with low-dose CT (LDCT) scan. 
Currently, LDCT screening is recommended only for the high-risk population of smokers 
over 55 years of age. This limitation is due to high false positive rates (96.4%) as well 
as risks of radiation exposure in LDCT. For better screening methods, recent studies 
have attempted to use diverse biological fluid samples from patients for finding new 
lung cancer biomarkers. Unlike diagnostic biomarkers that are required to have high 
sensitivity for clinical application, screening biomarkers must have high specificity 
(i.e. low false positive rates) in order to avoid a large number of people without lung 
cancer from undergoing invasive or costly procedures for confirmation. Among 
recent studies on new lung cancer biomarkers, only one small-scale study identified 
a panel of blood microRNAs with cancer-specificity higher than 99%. Methods: In 
order to expedite the discovery of candidates for cancer-specific metabolites in lung 
cancer, we exploited a unique system of a non-small cell lung cancer (NSCLC) cell line 
and a line of immortalized bronchial epithelial cells derived from the same patient, 
HCC4017 and HBEC30KT, for the initial discovery. After molecular characterization, 
we validated the selected candidate’s cancer specificity in additional NSCLC cell 
lines and NSCLC tumors. The mechanistic basis of this cancer specificity was further 
investigated with NSCLC cell lines, and its clinical potential as a circulating biomarker 
of lung cancer was evaluated with selected blood samples from lung cancer patients. 
Results: Among several metabolites with significant cancer/normal differences, we 
identified a unique metabolic compound, N-acetylaspartate (NAA) in cancer cells ¾ 
undetectable in normal lung epithelium. NAA’s cancer-specific detection was validated 
in additional cancer and control lung cells as well as selected NSCLC patient tumors and 
control tissues. NAA’s cancer-specificity was further supported in our analysis of NAA 
synthetase (gene symbol: NAT8L) gene expression levels in The Cancer Genome Atlas: 
elevated NAT8L expression in approximately 40% of adenocarcinoma and squamous 
cell carcinoma cases (N=577), with minimal expression in all non-malignant lung tissues 
(N=74). We then showed that NAT8L is functionally involved in NAA production of NSCLC 
cells through siRNA-mediated suppression of NAT8L, which caused selective reduction 
of intracellular and secreted NAA. Our cell culture experiments also indicated that NAA 
biosynthesis in NSCLC cells depends on glutamine availability. For preliminary evaluation 
of NAA’s clinical potential as a circulating biomarker, we developed a sensitive NAA 
blood assay and found that NAA blood levels were elevated in approximately 40% of 
NSCLC patients (N=13) in comparison with age-matched healthy controls (N=21) among 
individuals aged 55 years or younger. Conclusion: Taken together, these results indicate 
that NAA is produced specifically in NSCLC tumors through NAT8L overexpression and 
its extracellular secretion can be detected in blood.
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P3.05-001 The Role of Big Tobacco in the Creation of the Expanding Epidemic 
of Smoking-Related Adenocarcinoma of the Lung Gary Strauss1, Alejandro 
Moreno-Koehler2, Matthew Finkelman3 1Hematology/Oncology, Tufts Medical Center, 
Boston/MA/United States of America, 2Tufts Medical Center, Boston/MA/United States of 
America, 3Tufts University School of Dental Medicine, Boston/MA/United States of America
Background: In 1950, when the relationship between cigarette smoking and lung cancer 
was definitively demonstrated, adenocarcinoma of the lung comprised approximately 5% 
of lung cancers and appeared to be unrelated to smoking. Subsequently, the incidence 
to translate this result in clinical significance will be difficult as absolute PBC may be 
very small. The mean age of diagnosis and male sex being predominantly affected 
corroborates with the current literature. We recommend further studies to compare 
the PBC in NSCLC patients with age, gender and ethnicity matched population controls 
Keywords: basophill count, non small cell lung cancer, peripheral basophill count, 
cancer immunotherapy
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P3.04-132 Expression of nm23 and CD44v6 Proteins in Non-Small Cell Lung 
Cancer and Their Clinical Significance Patiguli Aerxiding, Guoqing Zhang, Ling Ma 
First Department of Medical Oncology, Cancer Hospital Affiliated To Xinjiang Medical 
University, Urumqi/China
Background: To investigate the expression of nm23 and CD44v6 proteins in non-
small cell lung cancer (NSCLC) and their clinical significance. Methods: The expression 
of nm23 and CD44v6 proteins was detected in 58 NSCLC samples using two-step 
immunohistochemistry. Results: The overall positive rate of nm23 was 87.9% (51/58), 
and significant difference was presented between T1～T2 groups and T3～T4 groups 
(P<0.05). The overall positive rate of CD44v6 was 55.2% (32/58), in which that 
of squamous cell carcinoma was dramatically higher than that of adenocarcinoma 
(85.7% vs. 24%, P<0.05). The positive rate of moderately-differentiated group 
was higher than that of poorly-differentiated group (71.9% vs. 44.4%,P<0.05). The 
expression of nm23 and CD44v6 was not associated with pTNM staging, lymph 
node metastasis and survival rate (P>0.05). Conclusion: The expression of nm23 
and CD44v6 proteins is correlated with the tumor size (T), pathological types and 
differentiated degrees of NSCLC instead of pTNM staging and lymph node metastasis. 
Keywords: genes; nm23, non-small cell lung cancer; gene expression; antigens; CD44
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P3.04-133 ADAM9 and EGFR Correlated With Lymph Node Metastasis Predicts 
Worse Prognosis in Surgically Resected Non-Small Cell Lung Cancer Jun 
Zhang1, Ning Chen2, Juan Qi3, Baosen Zhou1, Xueshan Qiu1 1China Medical University Lung 
Cancer Center, The First Hospital of China Medical University, Shenyang/China, 2Department 
of Logistic Management, College of Economics and Management, Liaoning University 
of Traditional Chinese Medicine, Shenyang/China, 3Department of Molecular Targeted 
Therapeutics, The First Hospital of China Medical University, Shenyang/China
Background: Recently we first reported that a disintegrin and metalloproteinase-9 
(ADAM9) was highly expressed in resected non-small cell lung cancer (NSCLC), correlated 
with lymph node metastasis, shorterned survival time. ADAM9 has been known of being 
able to enhance the expression of epidermal growth factor receptor (EGFR) pathway, 
here, we investigate the expression of EGFR in surgically resected NSCLC, to elucidate 
the relationship between EGFR expression and lymph node metastasis, prognosis, 
and further evaluate the consistence of ADAM9 expression and EGFR expression, and 
their significance as novel biomarkers in molecular staging, predicting the prognosis 
for surgically resected NSCLC. Methods: One hundred and six cases of completely 
resected stage Ⅰ, Ⅱ and Ⅲ NSCLC with mediastinal N2 lymph nodes dissected were 
immunohistochemically analyzed for EGFR and ADAM9 protein expression. Survival 
analysis was conducted to assess the significance of EGFR and ADAM9 expression and the 
relationship with other clinicopathological characteristics. Results: Of the 106 NSCLC, 
49 were stage Ⅰ, 16 stage Ⅱ and 41 stage Ⅲ; 60.4% was found with EGFR protein 
highly expressed (EGFR+), significantly higher when compared with normal control lung 
tissues (P=0.000). The EGFR+ rate in stage Ⅱ and Ⅲ NSCLC was 73.7%, significantly 
higher than 44.9% in stage Ⅰ (P=0.003). Stratified, EGFR+ rates in N1 and N2 cases was 
72.0%, significantly higher than 50.0% in N0 NSCLC (P=0.021); the difference between 
EGFR+ rates in T factor groups was not statistically significant (P>0.05). The overall 
5-year survival rate was 55.7% for this group of 106 completely resected NSCLC. The 
5-year survival rate in EGFR low expression (EGFR-) group (42 cases) was 74.9%, however, 
the 5-year survival rate was sharply decreased to 43.2% in EGFR+ group (64 cases) 
(P=0.001). For ADAM9, the ADAM9+ rates in stage Ⅱ and Ⅲ NSCLC was significantly 
higher than in stage Ⅰ (P=0.013). Stratified, ADAM9+ rates in N1 and N2 cases was 
significantly higher than in N0 NSCLC (P=0.040). The difference between ADAM9+ rates 
in T factor groups was not statistically significant (P>0.05). The 5-year survival rate in 
ADAM9+ group was statistically lower than in ADAM9- group (P=0.040). EGFR expression 
was revealed correlated positively and significantly with ADAM9 expression in this group 
of surgically resected NSCLC (Pearson r=0.275, P=0.004). Conclusion: This report 
for the first time revealed the relationship of expression of EGFR and ADAM9 protein in 
human lung cancer tissues. EGFR and ADAM9 are highly expressed in human resected 
NSCLC, correlated with lymph node metastasis and pTNM stage; highly expressed 
EGFR and ADAM9 predicts worse prognosis, suggesting that EGFR and ADAM9 are 
useful molecular staging biomarkers, and prognostic biomarkers for NSCLC. EGFR and 
ADAM9 may also become useful predictive biomarkers helping decide if postoperative 
chemo-radiation therapy should be selected or not. (This study was partly supported by 
grants from the Education Department of Liaoning Province, China, No. 20060991; the 
Nature Science Foundation of Liaoning Province, China, No.20102285; and the Fund 
for Scientific Research of The First Hospital of China Medical University, No.FSFH1210). 
Keywords: EGFR, molecular stage, Prognosis, ADAM9
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contained questions about beliefs, orientation, knowledge, understanding and attitudes 
about Lung Cancer Diagnosis and incidences. In addition, questions assessing the 
variables of the Health Belief Model and health motivations also were included. The data 
were obtained during face-to-face interviews in the primary language of the participating 
people. The interviews were translated into English Results: Out of the 1500 men who 
participated, only 10% of the participants knew about lung cancer, 5% had undergone 
at least one Lung Cancer Diagnosis during their lives, and 85% were not aware of the 
disease. There was little or no access to treatment even at early detection in these rural 
areas thereby causing vulnerability to loss of life. Majority of these men (95%) said they 
knew little or nothing about lung cancer. While 10% of the men said detecting cancer 
early was important, only 5% reported that cancer could be cured. Age, education, 
or mother tongue showed no statistically significant relationship with the lung health 
practice scores. However, proficiency with the English language (p = 0.009) and number 
of years exposed to awareness and education (p = 0.009) had a significant relationship 
with the lung health practice scores. The significant explanatory factor for the variable 
lung health practices was a cue to action (p = 0.009) Conclusion: The level of awareness 
and treatment access to lung cancer amongst Nigeria’s rural men is extremely low 
thereby making them not to engage in screening and/or detection practices. This 
alarming situation calls for urgent intervention of medical/health organizations to provide 
immediate lung cancer awareness, diagnosis and care so as to reduce incidences or 
threat at early detection. Tobacco which is known as a major cause of cancer (90%) 
is widely used by these rural men thereby making them so vulnerable. Awareness 
is suggested while providing smoking cessation for smokers who intend to quit 
Keywords: lung cancer, tobacco, Smoking Cessation, lung cancer diagnosis
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P3.05-004 Lung Cancer Perception and Treatment Access Among Rural 
Smokers in Northern Nigeria Emmanuel Odiase Epidemiology, University of Ibadan, 
Abuja/Nigeria
Background: Despite alarming evidences of the damages smoking causes to health 
which includes lung cancer. A large number of rural populaces in disadvantaged regions 
still have little or no knowledge about lung cancer which is a major disease caused by 
smoking. Methods: We organized a community tobacco awareness program in four 
states in northern Nigeria. An interview guide was designed mainly for this purpose 
in which 1200 rural/illiterate smokers, male and female, aged 45 and over who had 
smoked for at least 15 years took part in. The interview guide contained questions 
about year of smoking initiation, number of sticks smoked daily, number of years as 
smoker. It also contained questions about the knowledge of smoking damage and/or 
lung cancer perception. In addition, questions assessing the variables of the Health Belief 
Model and health motivations also were included. The data were obtained during face-
to-face interviews in the primary language of the participating people. The interviews 
were translated into English. Results: All together, 15% of the participants agreed that 
smoking was dangerous to their health. Only 5% had heard about lung cancer and 4% 
had undergone at least one Lung Cancer Diagnosis during their lives. There was little 
or no access to treatment even at early detection in these rural areas thereby causing 
vulnerability to loss of life. 15% of these rural smokers said detecting cancer early was 
important, only 3% reported that cancer could be cured. Age, education, or mother 
tongue showed no statistically significant relationship with the lung health practice scores. 
However, proficiency with the English language (p = 0.009) and number of years exposed 
to awareness and education (p = 0.009) had a significant relationship with the lung health 
practice scores. The significant explanatory factor for the variable lung health practices 
was a cue to action (p = 0.009). Conclusion: The level of awareness, perception of lung 
cancer and treatment access among rural and illiterate smokers in northern Nigeria is 
unacceptably low thereby making them not to engage in screening and/or detection 
practices. This alarming situation calls for urgent intervention of not-for-profit advocacy 
groups, tobacco-related medical/health organizations to provide immediate lung cancer 
awareness, diagnosis and care so as to reduce incidences or threat at early detection. 
Keywords: lung cancer, nigeria, rural, tobacco
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P3.05-005 Trends in Lung Cancer Survival in Middle East and Africa, 1995-
2009 Zoubida Zaidi1, Mokhtar Hamdi Cherif2 1Epidemiology, University Hospital of Setif, 
Setif/Algeria, 2University Hospital of Setif, Setif/Algeria
Background: Lung cancer is the most common cancer in men and the third most 
common in women. Tobacco smoking, including second-hand smoke, is the predominant 
cause of lung cancer worldwide. Screening for lung cancer is under development. It 
is one of the most aggressive human cancers, with a 5-year overall survival of 10-
15%. Methods: Individual lung tumour records were submitted by 11 population-based 
cancer registries, 03 in Arab countries in Middle East (Jordan, Saoudi Arabia and 
Qatar) and 08 in Africa (Algeria, Lybia, Tunisia, Mali, Mauritius, Nigeria, South Africa 
and Gambia) for 6535 adults (15-99 years) diagnosed during 1995-2009 and followed 
up to 31 December 2009 . Estimated five-year net survival, adjusted for background 
mortality by single year of age, sex, calendar year in each country . Results: Age 
standardised five year net survival was generaly low in the range 10-20% for most 
geographical areas both in the developed and developing world. Survival was very 
low less than 10% (only 02% in Lybia). Conclusion: Surveillance of cancer survival 
is seen as important by national and international agencies, cancer patient advocacy 
groups, departments of health and research agencies. Cancer survival research is 
being used to formulate cancer control strategies to prioritise cancer control measures 
and to evaluate both the effectiveness and cost-effectiveness of those strategies. 
of lung adenocarcinoma increased sharply, and became strongly related to smoking. 
Utilizing SEER data on 419,941 lung cancers diagnosed between 1973 and 2011, 
we demonstrate that adenocarcinoma now comprises 55% of all lung cancers in the 
US. Adenocarcinoma rose in conjunction cigarette design changes introduced by the 
Tobacco Industry beginning in the 1950s in response to mounting evidence that smoking 
caused other forms of lung cancer. The objective of this abstract is to address how 
actions of Big Tobacco were primarily responsible for the rise of adenocarcinoma of 
the lung. Methods: Because SEER contains no information about cigarette smoking, 
other sources were utilized to correlate changing histology to time trends in smoking 
prevalence, the changing cigarette, and Tobacco Industry actions. These include internal 
Tobacco Industry documents, historical documents describing Tobacco Industry actions, 
several Surgeon General Reports, NCI Monograph #13, and the verdict of Civil Action No. 
99-2496: “United States versus Phillip Morris et al.” Results: Mounting evidence from 
population-based epidemiological analyses, the 1953 mouse painting experiments, and 
extensive press reporting created a crisis for the Tobacco Industry, as smoking rates 
temporarily dropped in the early/mid 1950s. While the Tobacco Industry consistently 
denied the evidence, they introduced filters and low yield cigarettes, inferring that 
modifications in cigarette design were safer. Indeed, many public health professionals 
believed that there would be some benefit from these changes insofar as compensation 
by smokers would be incomplete. Moreover, numerous epidemiologic studies appeared 
to support that filtered and low yield cigarettes conferred a lower lung cancer risk. Indeed, 
the 1981 Surgeon General Report on “The Changing Cigarette” concluded that individuals 
unable to quit should switch to filtered and low tar cigarettes. It was not until the analysis 
of Brown & Williamson internal documents in 1994 and other previously secret Tobacco 
Industry documents after the Master Settlement Agreement in the 1998 that it became 
abundantly clear regarding the extent to which the Tobacco Industry had knowingly 
deceived both the public and federal government about the safety of cigarette design 
changes for decades. Conclusion: Big Tobacco intentionally and extensively deceived 
the public during the second half of the 20th century. Trends in the rising incidence of 
adenocarcinoma of the lung correlate with the wide-scale adoption by smokers of filtered 
and low-yield cigarettes. Actions of Big Tobacco were predominantly responsible for the 
current epidemic of smoking-related lung adenocarcinoma.
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P3.05-002 Heterogeneity of Metformin Response for Lung Cancer 
Chemoprevention Michael Asiedu1, Matthew Barron1, Marie Christine Aubry2, Dennis 
Wigle3 1Thoracic Surgery, Mayo Clinic, Rochester/United States of America, 2Mayo Clinic, 
Rochester/MN/United States of America, 3Thoracic Surgery, Mayo Clinic, Rochester/MN/
United States of America
Background: Squamous cell carcinoma accounts for about 25-30% of all non-small cell 
lung cancers. Metformin is a drug commonly prescribed as first-line treatment for type-
2 diabetes, with some evidence showing that the drug can also act directly on cancer 
cells. Recent observational studies and meta-analysis show that diabetic patients who 
are long term users of metformin have lower risk for breast cancer and that metformin 
use lowered cancer development in the liver and lung. The goal of this study was to 
determine metformin response in different cell lines and different cellular contexts, and 
to use that information to work towards the generation of a metformin “sensitivity index” 
that could be used guide individualized chemoprevention. Methods: We performed cell 
survival analysis to assess differences in the sensitivity of patient-derived fibroblast cells 
and squamous cancer cell lines exposed to metformin. We also evaluated metformin 
response of Nkx2.1 positive lung progenitor cells that were differentiated from induced 
pluripotent stem (iPS) cells to identify differences for cells in different cellular contexts. 
Gene expression profiling and DNA sequencing analyses were performed to identify 
genes, pathways and genomic alterations that mediate metformin response in order to 
generate a “sensitivity index” for predicting metformin response. Results: Cell survival 
analysis showed that different cell lines respond differently to metformin, and cells of 
identical genotypes in a variety of differentiated states or cellular contexts also show 
differential response to metformin. Gene expression profiling of metformin treated cells 
identified eight differentially expressed gene including ADH1B, TMEM161B, CPED1, 
SNAI2, FOXF1 and DLGAP1 that may mediate metformin response. Exome sequencing 
and analysis identified unique single nucleotide variants (SNV) in TRAF3IP3, DMBT1, 
RIT2, SERPINB2, PIK3R2 that were present in all non-responders but absent in all 
responders. SNVs and indels present in all responders but absent in all non-responders 
included those in GRK7, SMARCA5, CTSB, CHD4, PLCB2, ZADH2, RPLP2, CLASP2, 
NEDD4, DNAH17, CPXCR1, LDHD and CLTC. Conclusion: Differences in response 
to metformin treatment across a variety of cell lines and cellular contexts suggest 
heterogeneity that may be patient-specific. A list of differentially expressed genes and 
genetic mutations can be used as a metformin “sensitivity index” to stratify patients into 
metformin responders and non-responders and guide individualized chemoprevention. 
Keywords: metformin, sensitivity, squamous cell cancer
POSTER SESSION/ PREVENTION AND TOBACCO CONTROL 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.05-003 Beliefs, Attitudes and Treatment Access to Lung Cancer amongst 
Nigeria Rural Men Malcolm O. Tagbarha Public Health, University of Abuja, Abuja/
Nigeria
Background: Evidences of lung cancer cases from scientific researches have being on 
the rise in the last few decades and tobacco which is a major risk factor causes about 
90% of cancer diagnosed around the world. The need to reduce this scourge has become 
more important Methods: An interview guide was designed specifically for these studies 
in which 1500 rural men in Nigeria most of which were age 35 and over took part in. It 
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(47%; n=289) and as an inpatient in a Hospital, Clinic or Medical Center (44.2%; n=272). 
No significant differences were found between place of death and gender. Regarding 
the marital status, 47% (n=289) were married (women (36.8%) men (52%); p< 0.05), 
15.6% (n=96) were divorced, 14.3% (n=88) had never married, and 23% (n=141) were 
widowed (women (36.3%) men (16.4%); p<0.05). Conclusion: The majority patient who 
die from lung cancer have important comorbidities that need to be addressed during 
the disease, die at home or as inpatients, and are not married. Given these findings, 
a strong support network may be important for the patient who has lung cancer. 
Keywords: mortality, multiple causes, place of death, underlying cause
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P3.05-008 Lung Cancer, Burden of Disease, Puerto Rico 2000-2010 
Juan C. Orengo1, Felipe Arbelaez2, Cecile Marques-Goyco2, Homero Monsanto2, Vivian 
Green3 1Medical Department, Merck & Co, Carolina/Puerto Rico, 2Medical Affairs, Merck & 
Co, Carolina/Puerto Rico, 3Public Health, Ponce Health Sciences University, Ponce/Puerto 
Rico
Background: The Annual Percent Change (APC) of lung cancer mortality has decreased 
from 1987 until 2010 by 1.5% for men and 1.1% for women, representing 13.8% and 
9.7% of all cancer deaths among men and women for the period 2006-2010, respectively 
(Puerto Rico Cancer Registry, last issue from 2011). Objectives: The objectives were to: 
a) estimate both Years of Potential Life Lost (YPLL) and Potentially Productive Years of 
Life Lost (PPYLL) for lung cancer in Puerto Rico (2000-2010) by gender; b) estimate the 
Average Years of Life Lost (AYLL) by gender; c) estimate the cost associated with YPLL by 
gender. Methods: Mortality data from the National Center for Health Statistics for Puerto 
Rico (2000 and 2010) was analyzed. An upper limit of 80 years was established for the 
YPLL, in accordance with WHO guidelines. The YPLL was divided by the total deaths in 
each year to calculate the Average Years of Life Lost (AYLL). The PPYLL was calculated 
by setting an interval from 16 to 65 years (Puerto Rico Labor Department). The method 
of willingness to pay, using three times the GDP per capita in 2010 (US$82,353)
(Puerto Rico Planning Board), with a discount rate of 3% and an annual increase of 1%, 
was used to calculate the economic cost. Results: In 2010, the YPLL for lung cancer 
represented a total of 6,311 years, 11.2% of YPLL for all cancer types, while in 2010 
it represented a total of 5,893 years, 10.6 % of YPLL for all cancer types. The YPLL 
for men in 2000 accounted for 4,301 years (71.5% of YPLL for lung cancer) whereas 
in 2010 it accounted for 3,843 years (65.2% of YPLL for lung cancer). For women in 
2000, the YPLL accounted for 2,010 years (28.5% of YPLL for lung cancer) while in 
2010 it accounted for 2,050 years (34.8% of YPLL for lung cancer). The YPLL for both 
genders decreased 6.6% in the period 2000-2010. The AYLL for men in 2000 and 2010 
was 13.5 years and 12.4 years, respectively, and for women 14.4 years and 15.2 years, 
respectively. The PPYLL in 2000 was 1,085 years for men and 479 years for women, 
whereas in in 2010 it was 776 years for men and 589 years for women. The economic 
cost (willingness to pay) associated to YPLL for men was $287.6 million and $261.5 
million for 2000 and 2010, respectively, and for women it was $134.5 million and $134.4 
million for 2000 and 2010, respectively. Conclusion: The YPLL has remained stable 
for women and decreased for men from 2000 to 2010 and the PPYLL has decreased 
for men when compared to women. Lung cancer deaths occur in younger women than 
men. The financial burden associated with women has remained constant while for men it 
has decreased. These findings suggest that lung cancer continues to be a public health 
problem with substantial burden of disease among men and women in Puerto Rico. 
Keywords: burden of disease, mortality, Years of Potential Life Lost, willingness to pay
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P3.05-009 Tobacco Consumption in Cancer Patients from Colombia’s Coffee 
Zone Paula Londno1, Jaime A. Echeverri F2, Jose W. Martinez1, Felipe Parrado1, Carolina 
Angel1, Dahiana Gallego1, German A. Moreno1 1Oncologos Del Occidente S.A., Pereira/
Colombia, 2Pulmonary Medicine, Oncologos Del Occidente, Pereira/Colombia
Background: The General Surgeon has been reporting the similarities of the addiction 
magnitude of nicotine, heroin and cocaine. The criteria for diagnosis of dependency to 
nicotine have been established by the DSM-IV which includes impulsivity for consumption, 
lack of control despite the negative effects of smoking, and a high motivation to consume 
above other activities that can be done instead. Other elements of diagnosis are signs 
of physical dependency and tolerance which demands an increase in consumption. The 
effects of nicotine have been related to the fact that inhalation of nicotine by a large body 
surface such as the lungs, which is dissolved at a high pH fluid, which is transported from 
the lungs to the heart and quickly reaches the brain. The high rate of absorption and 
large amount of nicotine is concentrated in the brain are the two causes that generate 
dependency. Smoking also affects the processes of tissue repair and states that the 
mortality among current smokers is 2 to 3 times as high as that among persons who 
never smoked. We evaluate cigarette smoking in cancer patients “Colombia’s Coffee 
Zone” Methods: Oncologos del Occidente has clinics for the attention of cancer patients 
throughout “Colombia’s Coffee Zone” conformed by Caldas, Quindio and Risaralda states. 
Inhabited by 4.8% of the national population and during 2004, 4340 cancer patients had 
their first medical appointment. We measured cigarette consumption with surveys and 
validated tests and the level of dependency to tobacco of these new patients through 
a systematic sampling Results: The prevalence of cigarette consumption through 
life was 44.6% (IC95% 37.0-52.5) in 168 tested patients; former smokers consumed an 
average of 0.7 cigarette packs per year during 21.6 years. Current smokers consume 
an average of 0.67 cigarette packs per year during 42 years. The 61% of these patients 
wait until 30 minutes to consume their first cigarette of day, after they get up from 
bed. The 38% of the current smokers do not like to avoid the first cigarette of the day. 
Keywords: Cancer Registry, tobacco, mortality, Cancer Survival
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P3.05-006 Tobacco Control and the Trend of Lung Cancer Histology in Taiwan, 
1994-2011 Yung-Hung Luo1, Chun-Ming Tsai2, Yu-Chin Lee2, Jacqueline Whang-
Peng3, Yuh-Min Chen2 1Chest Medicine Division of Medicine Department, Fenglin Branch/
Department of Chest Medicine, Taipei Veterans General Hospital, Taipei/Taiwan, 2Department 
of Chest Medicine, Taipei Veterans General Hospital, Taipei/Taiwan, 3Taipei Cancer Center, 
Taipei Medical University, Taipei/Taiwan
Background: Tobacco control policies in Taiwan have resulted in substantial declines 
in smoking prevalence and cigarette consumption. The ingredients of cigarettes have 
changed under government regulations. The changing epidemiology of lung cancer 
has also been observed in recent years. In this study, the lung cancer incidence 
and trend of histological types after the initiation of tobacco control policies were 
evaluated. Methods: We examined the data from Taiwan Cancer Registry to evaluate lung 
cancer incidence rates and frequencies of different histological type. The information of 
tobacco control and smoking prevalence from Health Promotion Administration and Food 
and Drug Administration in Taiwan were analyzed to identify the relation between tobacco 
control and lung cancer trend. Results: In total, 135073 individuals were diagnosed with 
lung cancer from 1994 to 2011 in Taiwan. The age-standardized incidence rate (ASIR) of 
all lung cancer patients increased significantly (22.3 per 105 in 1994 to 34.04 in 2011), 
and the average annual percentage change (AAPC) was 2.6 [95% confidence interval 
(CI): 2-3.2, p < 0.0001]. The ASIR of female lung cancer patients (13.82 per 105 in 1994 
to 24.79 in 2011, AAPC 3.6, 95% CI: 2.8-4.5, p < 0.001) rose more rapidly than that of 
male patients (30.11 per 105 in 1994 to 44.21 in 2011, AAPC 2.4, 95% CI: 1.8-3, p < 
0.0001). Adult (≥18y/o) and male smoking prevalence decreased gradually (29.1% in 
1994 to 19.1% in 2011, 54.8% to 33.5%, respectively) after the initiation of Tobacco 
Hazards Prevention Act in 1997. In addition, tobacco health welfare surcharge was 
gradually increased by the government, and adult smoking prevalence also decreased at 
the same time. However, female smoking prevalence remained relatively low level during 
the study period (3.3% in 1994 to 4.4% in 2011), so no obvious decline was observed. 
Therefore, decreased male smoking prevalence may contribute to the lower AAPC in 
male population than in females. The upper limit of tar and nicotine in each cigarette 
were gradually reduced under government regulations (tar: 15mg/cigarette in 2001 to 
10 in 2009; nicotine: 1.5 mg/cigarette in 2001 to 1 in 2009), and there was a decline in 
average contents of tar and nicotine in each cigarette during study period. The increasing 
proportion of adenocarcinoma (45.5% in 1995 to 60.3% in 2011) and decreasing 
proportion of squamous cell carcinoma (SCC) (32.6% in 1995 to 19.1% in 2011) were 
observed during study period. The correlation coefficient (CC) between the content of 
tar per cigarette and proportion of SCC was 0.988 (p < 0.001). The CC between the 
content of nicotine per cigarette and proportion of adenocarcinoma was -0.942 (p < 
0.001). The changes in the composition of cigarette may have influence on the trend 
of lung cancer histology. Conclusion: Tobacco control policies have led to reduction 
in adult smoking prevalence, but failed to decrease the overall lung cancer incidence. 
However, they may reduce the ascending rate of lung cancer incidence. The changing 
trend of lung cancer histology may be affected by the different composition of cigarettes. 
Keywords: lung cancer, Tobacco Control, cigarette
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P3.05-007 Lung Cancer and Multiple Causes of Death, Puerto Rico, 2010 
Juan C. Orengo1, Cecile Marques-Goyco2, Felipe Arbelaez2, Homero Monsanto2, Vivian 
Green3 1Medical Department, Merck & Co, Carolina/Puerto Rico, 2Medical Affairs, Merck & 
Co, Carolina/Puerto Rico, 3Public Health, Ponce Health Sciences University, Ponce/Puerto 
Rico
Background: In 2010, 615 people died from lung cancer in Puerto Rico, representing 
11.8% of all deaths from cancer and 2.1% of all causes of death. Objectives: The 
objectives were to: a) determine the underlying cause of death; b) determine the 
prevalence of conditions reported; c) determine the place of death; and d) determine 
the marital status as a proxy of network support; all the previous objectives were 
analyzed by gender. Methods: The Mortality Multiple Cause-of-Death Public Use Record 
from the National Center for Health Statistics for Puerto Rico (2010) was analyzed. The 
variables analyzed were: sex, age, place of death (Hospital, Clinic or Medical Center 
– Inpatient; Hospital, Clinic or Medical Center - Outpatient or admitted to Emergency 
Room; Hospital, Clinic or Medical Center - Dead on Arrival; Decedent’s home; Hospice 
facility; Nursing home/long term care; Other; Place of death unknown), marital status 
(divorced, married, never married, widowed, marital status unknown), underlying cause, 
number of condition and condition. Relative and absolute frequencies were calculated; 
and for the gender comparisons, T-test, Chi square and OR were used. Results: The 
underlying most frequent cause of death (610 deaths, 99.2%) was the malignant 
neoplasm of unspecified part of bronchus or lung (ICD-10 code C34.9), four deaths 
(0.6%) were attributed to primary metastatic malignant neoplasm involving the trachea 
(ICD-10 code C33) and another death (0.2%) was from malignant neoplasm of upper lobe, 
bronchus or lung. More than 68% of deaths presented 3 or less conditions (including the 
underlying condition). The most prevalent conditions were: diseases of the circulatory 
system (67.3%; women (68%) and men (67%)), diseases of respiratory system (48.4%; 
women (46.3%) and men (49.5%)), other malignant neoplasm (13.9%; women (17.4%) 
and men (12.1%)), diabetes (11.7%; women (12.9%) and men (11.1%)), and zoonotic and 
bacterial infections (10.2%). More men (67.3%; n=414) than women (32.7%; n=201) 
died from lung cancer. A great majority of the deaths were in individuals 65 years and 
older (86.4%; n= 530). The most frequent places of death were in the decedent’s home 
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P3.05-012 Hookah Smoke Mediates Cancer-Associated Alterations in Normal 
Human Respiratory Epithelial Cells Yin Xiong1, Sichuan Xi1, Jigui Shan2, Mary 
Zhang1, Saïd Azoury1, Julie A Hong1, David S. Schrump1 1Tgib, Nci/Ccr/Nih, Bethesda/MD/
United States of America, 2National Cancer Institute, Frederick, Frederick/MD/United States 
of America
Background: Cigarette smoking is the leading cause of lung cancers worldwide, and 
numerous countries have initiated public health programs to curtail cigarette abuse. 
Although hookah tobacco is perceived to be a safe alternative to cigarettes, the 
effects of hookah smoke in human respiratory epithelial cells and lung cancer cells 
are currently unknown. The present study was undertaken to examine if hookah smoke 
mediates cancer-associated alterations in normal respiratory epithelia and lung cancer 
cells. Methods: Human small airway epithelial cells (SAEC), cdk4/hTERT-immortalized 
human bronchial epithelial cells (HBEC) and lung cancer cells (Calu-6 and A549) were 
cultured in normal media in the presence or absence of waterpipe condensates (WPC) 
or cigarette smoke condensates (CSC) under relevant exposure conditions. MTS, 
quantitative RT-PCR and western blot techniques were used to examine the effects 
of hookah smoke on cell proliferation, mRNA/ microRNA expression and the histone 
code relative to those induced by cigarette smoke. Results: Five day WPC exposures 
mediated variable effects in cultured respiratory epithelia and lung cancer cells. In 
SAEC and HBEC, WPC mediated dose-dependent growth inhibition. In Calu-6 cells, 
low dose WPC (0.1mg/ml and 0.5mg/ml) enhanced proliferation, whereas higher 
concentrations of WPC (1.0mg/ml and 2.0mg/ml) inhibited growth. High concentrations 
of WPC (2.0mg/ml) inhibited proliferation of A549 cells. Similar to CSC, WPC 
decreased H4K16Ac and H4K20Me3 levels in SAEC and HBEC. In addition, like CSC, 
WPC increased miR-31 and decreased miR-487b expression in SAEC, HBEC and lung 
cancer cells. Furthermore, WPC increased expression of Cyp1b1 in SAEC cells, enhanced 
expression of ABCG2, Lin28B, Myc, SALL4, CTCF, JARID2 and Cyp1a1 in HBEC cells, up-
regulated ABCG2 and Cyp1a1 in Calu-6 lung cancer cells, and induced dose-dependent 
up-regulation of Cyp1a1 and Cyp1b1 in A549 lung cancer cells. WPC exposure significantly 
decreased expression of Dkk-1 in HBEC and Calu-6 cells. Cigarette smoke induced 
similar changes in these cells. Conclusion: These preliminary findings demonstrate that 
hookah smoke mediates cancer-associated alterations in human respiratory epithelial 
cells, and suggest that waterpipe tobacco is not a safe alternative to cigarettes. 
Keywords: Normal Respiratory Epithelial Cells, Cancer-Associated Alterations, lung 
cancer, Hookah Smoke
SESSION: POSTER SESSION/ SCREENING 
AND EARLY DETECTION 
WEDNESDAY, SEPTEMBER 9, 2015
POSTER SESSION/ SCREENING AND EARLY DETECTION 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.06-001 Clinico-Pathological Profile of Lung Cancer at New AIIMS Hospital in 
Eastern India Prasanta R. Mohapatra1, Sourin Bhuniya1, Manoj K. Panigrahi1, Susama 
Patra2, Pritinanda Mishra2, Saroj K. Das Majumdar3, Gourahari Pradhan1, Priyadarshini 
Behera1, Anupam Dey4 1Pulmonary Medicine, All India Institute of Medical Sciences, 
Bhubaneswar/India, 2Pathology, All India Institute of Medical Sciences, Bhubaneswar/
India, 3Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar/
India, 4General Medicine, All India Institute of Medical Sciences, Bhubaneswar/India
Background: Lung cancer is one of the commonest cancers worldwide. The pathological 
profile varies among different geographical regions. In India squamous cell carcinoma or 
adenocarcinoma has been reported as the common histological type in all the series. Odisha 
is socioeconomically behind some states of India. There is no epidemiological published 
data on lung cancer from this part of the country. The aim of the study was to analyse 
the epidemiological, clinical and pathological profile of lung cancer patients at a newly 
established tertiary level Government hospital in Odisha. Methods: We analysed 87 lung 
cancer cases registered at our centre over a period of initial 18 months in the department 
of Pulmonary Medicine of this newly opened Government Institution. They were evaluated 
for their epidemiological, clinical and pathological profiles. The data were recorded in 
Excel spreadsheets and subjected to appropriate statistical analysis. Results:Average 
age was 57 years with a male: female ratio of 2.6:1. About 48% of patients were 
smokers. Non-small cell lung cancer (NSCLC) was the predominant pathological variant 
in about 92 % and small cell lung cancer (SCLC) in only 3% of the cases. Among the 
patients with NSCLC, adenocarcinoma was the commonest histological subtype after 
the pathology review. Conclusion: Adenocarcinoma now be the commonest histological 
subtype. Prevalence of lung cancer among non-smokers is also high in the eastern 
part of India. Most of the patients present at an advanced stage with poor outcome, 
probably due to lack of awareness and limited resources in this part of the country. 
Keywords: epidemiology, India, lung cancer, Odisha
The 50% smokes even when they fill ill and stay in bed, meanwhile the 16.7% of the 
patients want to smoke “right now”; the 22.2% feel less depressed and tired when they 
smoke. Conclusion: There is a high frequency of consumption among these cancer 
patients who also present high levels of dependence; this is why they require support to quit 
smoking tobacco. The pharmacological effects of nicotine must be medically evaluated. 
We propose a clinic to support these patients in the cessation of tobacco consumption. 
Keywords: Cigarette smoking; Knowledge; Behaviors; Cancer; Prevention
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P3.05-010 Incidence and Survival of Lung Cancer at Oncosalud: Dynamic 
Cohort Study Alfredo Aguilar1, Claudio J. Flores1, Luis Mas1, Gustavo Sarria2, Luis 
Pinillos2, Carlos Vallejos1 1Oncosalud - Auna, Lima/Peru, 2Radioncología - Auna, Lima/Peru
Background: Lung cancer is the most common malignancy in many countries and 
regions; it represents the first cause of death in the world and the fourth cause of death 
in the Peruvian population. The incidence of lung cancer in a population affiliated with 
a prepaid system is important for the implementation of prevention programs. The 
arm of study was to determinate the incidence rate of lung cancer in a population of 
affiliates and the survival rate of patients treated in a private institution (ONCOSALUD 
- AUNA). Methods: In a study of dynamic cohort, the incidence of lung cancer was 
evaluated in a population of affiliates to ONCOSALUD - AUNA between 2008–2013 (n 
= 1’096,140). Overall survival (OS) was evaluated in patients treated in ONCOSALUD 
- AUNA between 2000-2005 (n = 241). The incidence rate was calculated based on 
new cases/persons-year of observation. The OS was calculated according to Kaplan-
Meier method. Results: The median age was 33 years and 55.7% were women. A total 
of 2’611,438.3 persons-year of observation was produced and 394 affiliates were 
diagnosed with lung cancer. The median age at diagnosis was 70 years. The standardized 
incidence rate by age was 7.9 per 100,000 persons-year (6.5 and 10.0 in women and 
men per 100,000 persons-year, respectively) and 74 years cumulative risk was 1.0% (0.8 
and 1.2% in women and men, respectively). For survival assessment, the median age was 
69 years, 39.4% were women and 76.4% had advanced disease (CS III: 18.3% and CS 
IV: 58.1%). With a 10.6 years follow-up, the median survival was 7.5 months. The OS rate 
at 2, 5 and 10-years was 24.3%, 16.4% and 12.9%, not showing significant difference 
in relation to sex (p=0.687), age (<60 vs. > 60 years: p=0.116) and shows significant 
difference according clinical stage (CS I-II vs. III-IV: p <0.001). Conclusion: The incidence 
rate of lung cancer in our population is lower than reported by the IARC for the Peruvian 
population. The survival rate at 2, 5 and 10-years is similar to reported for other series.
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P3.05-011 Tumour Microenvironment: A Potential Role for Curcumin in Lung 
Cancer Chemoprevention Jagdish N. Mahale, Gintare Smagurauskaite, Karen Brown, 
Lynne Howells Department of Cancer Studies, University of Leicester, Leicester/United 
Kingdom
Background: Recent studies have shown that the tumour microenvironment plays 
a crucial role in regulating tumor progression and cell migration. This is of particular 
importance in diseases such as lung cancer, which exhibit dense stroma. Cell-cell 
interactions and the effect that drugs have upon them can be investigated via use of 
in vitro 3D organotypic co-culture models. Curcumin, a naturally occurring polyphenol, 
is reported to exhibit strong anti-inflammatory, antioxidant, anti-proliferative and 
chemopreventive activity. An organotypic co-culture model representative of a tertiary 
prevention model system was used to study lung cancer tumour-stroma interactions and 
to investigate anti-invasive properties of curcumin. Fibroblast-secreted HGF is reported 
to stimulate invasion and migration of tumour cells by activation of the cMet pathway. 
In this study we also determined the potential for curcumin to elicit chemopreventive 
efficacy via disruption of this pro-proliferative c-Met signalling axis. Methods: A549 
lung adenocarcinoma cells and MRC5 normal human lung fibroblasts were used for the 
study. For air-interface organotypic co-culture, a gel matrix consisting of matrigel and 
rat tail collagen was embedded with MRC5 fibroblasts and a combination of A549 and 
MRC5 fibroblasts seeded on to the gel. The gel was then placed onto a metal grid in a 
6-well plate. Curcumin-containing media was added to the well so that it just touched 
the bottom of the gel. After 12 days, gels were processed for formalin fixation and 
paraffin embedding (FFPE). The objectives were as follows: i) to evaluate invasiveness 
of A549 cells in the absence of fibroblasts; ii) to determine the effect of differing ratios 
of A549:fibroblasts on invasion; iii) to determine the effect of curcumin treatment 
on invasion of A549 cells. For HGF estimation, MRC5 fibroblasts were treated with a 
single dose of curcumin at concentrations ranging from 0 to 5µM. On day 6, media 
was collected and analysed for determination of HGF levels using ELISA. Results: The 
IC50 value of curcumin for A549 and MRC5 was found to be 4.7±0.8µM and 1.5±0.3µM 
respectively. In the absence of MRC5 fibroblasts in co-culture, A549 cells did not invade. 
Five different ratios of A549:MRC5 (1:5, 1:2, 1:1, 2:1 and 5:1) were used to determine 
effect on invasion. The 1:5 ratio showed maximum invasion whereas 5:1 showed minimal 
or no invasion. Organotypics (1:5 ratio) were treated with curcumin concentrations 
ranging from 0µM to 5µM. Curcumin treatment significantly inhibited invasion of A549 
cells by 24.39±8.39% in organotypic co-cultures. HGF ELISA on curcumin treated MRC5 
media revealed that curcumin significantly inhibited HGF secretion by 67.87±5.96% when 
adjusted for cell number, at concentration as low as 0.25µM. Conclusion: A549 cells 
require the presence of fibroblasts to invade in the organotypic co-culture model, and 
invasive index increases with increasing ratio of fibroblasts. Intervention with curcumin in 
contact with fibroblasts only, suggested that this is sufficient to inhibit invasion of A549. 
The potential mechanism for this may be via the ability of curcumin to inhibit paracrine 
signalling networks between the two cell types, which impinge on the cMet signalling axis. 
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has shown a lung cancer mortality reduction. In the Mayo Lung Project, however, CXR 
screening produced a significant survival advantage which was not attributable to 
overdiagnosis or other screening biases (JCO 20:1973-83; 2002). The lung portion of 
the Prostate Lung Colon Ovary (PLCO) Cancer Screening Trial reported no lung cancer 
mortality reduction with CXR versus no screening, and it is considered to be a negative 
trial. The National Lung Screening Trial (NLST) was the first lung cancer screening RPT 
to report a mortality reduction comparing CT to CXR, but lacked an unscreened control. 
Survival from these trials has not been reported. Methods: To compare effectiveness of 
CXR and CT versus no screening, we calculated mortality, survival, and stage distribution 
in an intent-to screen analysis of PLCO and NLST data. Only lung cancers diagnosed 
within 7 years of randomization in PLCO were considered to match the median 6.7 years 
follow-up in NLST. Kaplan-Meier survival was compared by the log-rank test. Incidence, 
mortality, and stage distribution were compared with Fisher’s exact test. All p-values are 
two-sided. Results: In PLCO, 154,897 participants were randomized to either four annual 
CXRs over 3 years or to no screening. Within 7 years of randomization, 1072 and 1022 
lung cancers were diagnosed, respectively (RR=1.05; 95%CI 0.96-1.14; p=0.271). 5-year 
survival was 27% and 18% (p<0.001). Mortality analysis revealed 764 and 811 lung cancer 
deaths in CXR and control groups (RR=0.94; 95%CI 0.85-1.04, p=0.244). The CXR group 
had significantly more stage IA cancers (RR 1.70; 95%CI 1.33 – 2.16; p<0.001) and 
fewer advanced stage IIIB and IV cancers (RR=0.87; 95%CI 0.76 – 0.99; p=0.044). NLST 
randomized 53,452 participants to either three annual CTs or CXRs over 2 years. There 
were 1089 and 969 lung cancers in the CT and CXR groups respectively (RR=1.12; 95%CI 
1.03-1.22; p=0.007). 5-year survival was 49% and 33% (p<0.001). Mortality comparisons 
revealed 449 and 528 lung cancer deaths in the CT and CXR groups (RR=0.850; 95%CI 
0.751-0.964, p=0.012). There were significantly more stage IA cancers (RR 2.16; 95%CI 
1.82 – 2.56; p<0.001) and fewer advanced stage IIIB and IV cancers in the CT versus 
CXR groups (RR=0.74; 95%CI 0.63 – 0.87; p<0.001). Conclusion: Based upon similar 
lung cancer incidence, improved survival, and a more favorable stage distribution 
(particularly a reduction in the number of advanced cancers) in PLCO, CXR screening 
is superior to no screening, and overdiagnosis does not account for this advantage. 
While CXR screening is superior to no screening, CT is more efficacious than CXR in 
NLST. As CT is more expensive, has a higher false positive rate, and is more likely to 
detect overdiagnosed cancers than CXR, CXR may still be cost-effective compared to CT. 
Accordingly, a cost-effectiveness analysis employing NLST and PLCO data is ongoing. 
Keywords: Screening, lung cancer
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P3.06-004 Update in the Surgical Outcomes in a Large Clinical Low-Dose 
Computed Tomographic Lung Cancer Screening Program Christina Williamson1, 
Bryan Walker2, Shawn Regis3, Paul J. Hesketh4, Andrea Mckee3, Carla Lamb5, Sebastian 
Flacke6, Christoph Wald7, Brady Mckee8 1Thoracic and Cardiovascular Surgery, Lahey 
Hospital and Medical Center, Burlington/MA/United States of America, 2Tufts University 
Medical School, Boston/United States of America, 3Radiation Oncology, Lahey Hospital 
and Medical Center, Burlington/MA/United States of America, 4Medical Oncology, Lahey 
Hospital and Medical Center, Burlington/United States of America, 5Pulmonary Medicine, 
Lahey Hospital and Medical Center, Burlington/United States of America, 6Lahey Hospital 
and Medical Center, Burlington/MA/United States of America, 7Diagnostic Radiology, 
Lahey Hospital and Medical Center, Burlington/MA/United States of America, 8Diagnostic 
Radiology, Lahey Hospital and Medical Center, Burlington/United States of America
Background: Lung Cancer screening with low-dose computed tomography (LDCT) 
has been shown to reduce lung cancer mortality in high-risk individuals. Critics raise 
concern over the potential for unnecessary surgical procedures for benign disease 
as a result of screening. We have up-dated our surgical outsomes in a large clinical 
lung cancer screening program to assess the number of surgical procedures done 
for benign disease. Methods: We retrospectively reviewed our surgical outcomes 
of consecutive individuals who underwent LDCT lung cancer screening from January 
2012 through March 2015 using a prospectively collected database. All patients 
met the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening 
Guidelines high risk criteria. Results: There were 2,043 screened individuals during 
this interval with clinical follow-up at Lahey Hospital and Medical Center. Thirty-
nine of the 2.043 (1.9%) had surgery. Twenty-eight (72%) had lung cancer, 25/28 
(89%) had early stage and 3/28 (11%) had advanced stage lung cancers. Four 
(10%) had non-lung cancer malignancies. Seven of thirty-nine (18%) were found to 
have benign disease. There were no in hospital or 30 day mortalities in those who 
had surgery and only one (2.56%) major surgical complication. Conclusion: The 
incidence of surgical intervention for non-lung cancer diagnosis was low (0.56%) 
and is comparable to the rate reported in the National Lung Cancer Screening Tria; 
(0.62%). Surgical intervention for benign disease was rare (0.34%) in our experience. 
Keywords: lung cancer screening, surgical outcomes
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P3.06-005 Attitudes and Beliefs Toward Lung Cancer Screening Among Older 
Smokers Janine K. Cataldo Physiological Nursing, University of California, San Francisco, 
San Francisco/CA/United States of America
Background: Lung cancer (LC) is the leading cause of cancer in the U.S. with 85% caused 
by smoking. There is recent strong evidence that LC mortality is decreased by 20% with 
low-dose computed tomography (LDCT) screening for healthy individuals with an elevated 
risk for lung cancer. Previous studies have shown that those at higher risk (i.e., older 
smokers) are less interested in being screened despite awareness of risk. Methods: The 
aims for this study were, among older smokers: 1) Identify the demographics, smoking 
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P3.06-002 Favourable Stage-Shift Limited to Screening Participants 
with COPD in a Biomarker Sub-Study of the National Lung Screening Trial 
(NLST) Robert Young1, Caroline Chiles2, Raewyn J. Hopkins1, Fenghai Duan3, Greg D. 
Gamble1, Denise R. Aberle4 1University of Auckland, Auckland/New Zealand, 2Wake Forest 
University Baptist Medical Center, Winston-Salem/AL/United States of America, 3Department 
of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, 
Providence, Rhode Island, Providence/United States of America, 4Department of Radiological 
Sciences, David Geffen School of Medicine at UCLA, Los Angeles/CA/United States of 
America
Background: Based on a 20% reduction in lung cancer deaths in participants of the 
National Lung Screening Trial (NLST), CT screening for lung cancer is now widely 
recommended in the US. However concerns remain regarding the cost-benefits of 
screening due to overall low detection rates, over-diagnosis and high false-positive rates. 
Using the spirometric data available from the ACRIN-biomarker sub-study of the NLST 
(n=18,714), we examined the effect of Chronic Obstrucitve Pulmonary Disease (COPD) 
status on lung cancer detection in the NLST screening participants. Specifically we 
compared lung cancer incidence, histology and stage shift in those with and without 
COPD based on baseline pre-bronchodilator spirometry. Methods: Baseline spirometry 
results were available for 18,475 (99%) of the total cohort of 18,714, (6,436 with COPD 
and 12,039 with no COPD). Spirometry results were available for 758 (99%) of the 768 
histology-confirmed lung cancer cases diagnosed over the 7 year follow-up period. After 
lung cancer cases were sub-grouped by spirometry-defined COPD (GOLD 1-4, n=401) 
and no baseline COPD (n=357) it was possible to compare the number of cancers, 
histology and stage according to screening arm. Differences in lung cancer incidence 
rates were compared by incident rate ratios, while prevalence, histology and stage shift, 
were compared by chi-square frequency tables. Results: In this NLST-ACRIN Biomarker 
sub-study, we found the demographic variables were comparable to those from the full 
NLST study. Regardless of screening interval, we found the lung cancer incidence was 2 
fold greater in those with COPD compared to no COPD (P<0.0001). In those with COPD, 
we found a signficant reduction in adenocarcinomas and bronchioloalveolar carcinomas. 
After stratification by COPD status, when comparing CT versus CXR screening arms, we 
found no excess lung cancers and comparable lung cancer histology. However, a 
clinically significant stage shift favouring increased early stage (+17) and reduced late 
stage cancers (-23) was found (P=0.05). In contrast, in cancer cases with no COPD, we 
found an 18% excess of lung cancers in the CT arm (+29) which were of a BAC/AC 
histology. After correction for this overdiagnosis from these excess cancers, the stage 
shift no longer favoured early stage over late stage.
 
Conclusion: These data suggest that in those with COPD at baseline, CT screening 
(vs CXR) was associated with no excess cancers, no histology shift but a clinically 
significant stage shift favouring early over late stage cancers. In those with 
no COPD, CT was associated with excess cancers and a marginal stage shift. 
Keywords: National Lung Screening Trial, COPD, overdiagnosis, stage shift
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P3.06-003 Effectiveness of Lung Cancer Screening Comparing Computed 
Tomography (CT) to Chest X-Ray (CXR) to No Screening in PLCO and NLST 
Randomized Trials John Paul E. Flores1, Alejandro Moreno-Koehler2, Matthew 
Finkelman3, Jaime Caro4, Gary Strauss1 1Hematology/Oncology, Tufts Medical Center, 
Boston/MA/United States of America, 2Tufts Medical Center, Boston/MA/United States 
of America, 3Tufts University School of Dental Medicine, Boston/MA/United States of 
America, 4Mcgill University, Montreal/QC/Canada
Background: We sought to estimate the relative effectiveness of CT and CXR versus 
no screening in the context of a comparative cost-effectiveness analysis of lung cancer 
screening. CXR is considered ineffective because no randomized population trial (RPT) 
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P3.06-007 Discovery and Validation of Potential Glycoprotein Biomarkers in 
the Airway Fluid to Improve the Detection of Lung Cancer from Benign Lung 
Nodule Qing Kay K. Li1, Edward Gabrielson2, Frederic Askin2, Daniel W. Chen2, Hui 
Zhang2 1Pathology, The Johns Hopkins Medical Institutions, Baltimore/United States of 
America, 2Pathology, Johns Hopkins Medical Institutions, Baltimore/United States of America
Background: Recent clinical screening trials using highly sensitive low-dose computed 
tomography (LDCT) demonstrated an increased detection proportion of stage I lung 
cancers and improved overall survival of lung cancer patients as the result of early 
detection. However, lung cancer screening trials also showed high repeat screening 
rates and false-positive rates causing unnecessary second-line invasive procedures 
and surgery. New strategies are still needed to improve the specifi city of lung cancer 
screening. The airway fl uid, bronchoalveolar lavage (BAL), is commonly used for the 
evaluation of lung nodules and diagnosis of lung cancers. Proteins in the BAL fl uid 
may serve as potential biomarkers for cancer detection. In this study, we examined 
the protein profi le, particularly the signature of glycoprotein in normal and lung cancer 
patients. Methods: We collected BAL fl uid after cellular components were harvested for 
cytological examination in the cytology laboratory. Protein profi le and N -glycoproteins 
were analyzed using the solid-phase extraction of N -glycoprotein (SPEG) and liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Sixteen BAL samples, 
including four cases each of benign lung disease, adenocarcinoma (ADC), squamous cell 
carcinoma (SqCC), and small cell carcinoma (SCLC), were analyzed. Results: A total of 
1013 unique peptides from 457 glycoproteins were identifi ed and quatifi ed. Among them, 
286 proteins were identifi ed in BAL of ADC, 363 in squamous cell carcinoma (SqCC), 
298 in SCLC and 330 in benign BALs. In addition to common proteins found in all groups, 
we identifi ed 113 unique proteins that were differentially expresssed in benign disease, 
ADC, SqCC and SCLC, respectively. The levels of Napsin A, periostin, Galectin-3-binding 
protein (G3-BP) and myeloperoxidase (MPO) in cancer and benign BALs were further 
validated using independently collected BAL specimens by ELISA assays (Table 1).
history, knowledge, and attitude factors associated with willingness to have a CT scan 
and 2) Provide a predictive model of factors to explain willingness to have a CT scan. This 
was a cross-sectional national survey study with 549 older adult (≥ 45 years) current and 
former smokers (≤ 2 years quit). Results: There were no signifi cant differences between 
current and former smokers on all variables. After controlling for age, gender, ethnicity, 
income and education, all perception and belief variables signifi cantly associated with 
agreement to have a LDCT scan were included in a logistic regression analysis to develop 
a predictive model for agreement to have a LDCT scan.
 
 
Conclusion: Older smokers are interested in LC screening and overall, their attitudes 
are positive. Eleven variables had a signifi cant association with the decision to have 
a CT scan. In the fi nal model, four beliefs were signifi cant predictors of whether older 
smokers would agree to a scan. The strongest predictor was “believes that early 
detection of LC will result in a good prognosis,” followed by perception of accuracy, 
belief that they are at high risk for LC, and belief it will decrease worry about 
LC. An effort needs to be made to improve smokers’ knowledge of the potential 
benefi ts and risks when they are making decisions about participation in screening. 
Keywords: older smokers, Screening
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P3.06-006 Extent of Progression for Small Cancers in a Screening Program 
Even with Proper Follow-Up Ricardo S. Avila1, Artit Jirapatnakul2, David F. Yankelevitz2
1Accumetra, Rexford/NY/United States of America, 2Radiology, Icahn School of Medicine at 
Mount Sinai, New York/United States of America
Background: Current guidelines for repeat CT imaging of small nodules detected during 
screening are a function of the size and consistency of the nodules and the round it was 
detected. They attempt to balance the frequency with which a change would genuinely 
occur (i.e. the frequency with which a nodule of a given size is a cancer) with the ability 
to actually measure the change should it have occurred. Recently the American College 
of Radiology has established a new set of guidelines for this purpose called LungRads. 
This study analyzes the change in nodule volumes and doubling times for small nodules 
if the LungRads guidelines are followed. Methods: The LungRads protocol focuses on 
providing categories for nodules based on their degree of suspiciousness and provides 
suggestions for follow-up. They also provide criteria so as to determine when growth 
is genuine —that is, the change in size is beyond what could have occurred solely as a 
result of measurement error. Genuine growth defi ned as increase in diameter of >1.5 
mm. For purposes of estimating change in nodule volume and doubling times associated 
with them, we used the time intervals in LungRads for follow-up and derived the doubling 
times necessary for a nodule to reach the defi nitional growth threshold. We assumed a 
spherical model for the nodules and used a simple exponential growth rate. We focused 
on solid nodules where the range of growth rates is known to be large and they are most 
accurately measured. Results: For LungRads Category 2, where 6 month follow up CT 
is recommended, in order for a 4 mm nodule to grow suffi ciently so as to pass the size 
threshold where change could be detected, it would need to have a doubling time faster 
than 129 days, anything slower would not achieve the necessary size change and it would 
only then be rescanned 6 months later at an annual repeat scan and it would then potentially 
reach a size of 8.0 mm. For category 4A, LungRads recommends repeat scanning in 3 
months. According to the protocol, a 6 mm nodule would need a doubling time of 92 days 
for detection otherwise at one year it will reach a size of 15.1 mm. Conclusion: The change 
threshold for growth and time intervals between scans can have serious consequences 
downstream in terms of how large a tumor might become before it can reliably be 
diagnosed. The ability to better defi ne the threshold for when change has occurred will 
always be benefi cial as it will allow not only the very fast growing tumors to be diagnosed 
but those with more typical doubling times as well. The LungRads protocol keeps the 
smallest size category of tumors from growing beyond 15 mm when workup is initiated. 
Keywords: Lung-RADS, growth rate, CT
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examinations and bone scintigraphy every 3 months for 12 months. Progression of 
bone metastases during the follow-up period was defined as when the number of bone 
metastases as assessed by bone scintigraphy had increased from the previous follow-
up measurement. The optimal cut-off value of sNTx levels indicative of progression of 
bone metastasis was evaluated by performing a receiver operating characteristic (ROC) 
curve analysis. In this ROC analysis, we evaluated the change rate of sNTx per month. 
The change rate per month was defined as “The change rate of sNTx between at the 
minimum levels of NTx and at the worsening bone metastasis / the number of month 
from the minimum levels of sNTx to the worsening bone metastasis’’ Results: Twenty 
patients were enrolled between June and December 2010. The sNTx concentration 
at baseline was 19.8 ± 5.8 nmol bone collagen equivalents (nM BCE)/L. In the 16 
patients receiving ZA, the levels of sNTx showed a significant decrease after the first 
month of treatment (baseline vs. 1 month of treatment: 21.3 ± 5.5 vs. 13.6 ± 2.7 
nM BCE/L; p < 0.01). During the follow-up period, 13 of the patients treated with ZA 
experienced worsening bone metastasis. There were statistically significant differences 
in the levels of sNTx at baseline (20.3 ± 4.8 nM BCE/L), at the lowest levels after the 
administration of ZA (11.8 ± 2.9 nM BCE/L vs. baseline; p < 0.001), and at the point of 
measurable disease progression (14.1 ± 4.6 nM BCE/L vs. baseline; p < 0.05). In the 
ROC analysis, the optimal change rate of sNTx per month was 4.0% (sensitivity: 53.8%, 
specificity: 100%, area under the curve = 0.564). Conclusion: The administration of ZA 
significantly decreased the levels of sNTx within one month of the initiation of therapy. 
However, the levels of sNTx was slightly elevated when the bone metastasis has been 
aggravated during ZA treatment. The serial measurements of sNTx might prove to be 
useful in selecting drug treatment and evaluating drug efficacy for bone metastasis. 
Keywords: bone metastasis, lung cancer, NTx, cross-linked N-telopeptide of type I 
collagen
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P3.06-010 The Performance of a Novel Amino Acid Multivariate Index for 
Detecting Lung Cancer: A Case Control Study in Korea Kye Yonng Lee1, Hee 
Joung Kim1, Seung Hun Jang2, Jeong Seon Ryu3, Jeong Eun Lee4, Young Chul Kim5, 
Min Ki Lee6, Tae Won Jang7, Shin Yup Lee8, Hidehiro Nakamura9, Natsumi Nishikata9, 
Maiko Mori9, Yasushi Noguchi9, Hiroshi Miyano9 1Internal Medicine, Konkuk University 
Medical Center, Seoul/Korea, 2Internal Medicine, Hallym University Sacred Heart Hospital, 
Anyang/Korea, 3Internal Medicine, Inha University Hospital, Inchoen/Korea, 4Internal 
Medicine, Choongnam National University Hospital and Cancer Research Institute, Deajon/
Korea, 5Internal Medicine, Chonnam National University Medical School, Hwasun Hospital, 
Hwasun/Korea, 6Pusan National University Hospital, Pusan/Korea, 7Kosin University Medical 
College, Pusan/Korea, 8Kyungpook National University Hospital, Daegu/Korea, 9Institute for 
Innovation, Ajinomoto Co. Inc., Kawasaki/Japan
Background: Previous studies have shown that plasma free amino acid (PFAA) profiles 
are altered in cancer patients compared with healthy controls. A multivariate index 
based on PFAAs was generated from a Japanese dataset and has been previously 
demonstrated to be clinically valuable for discriminating patients in the early stages of 
lung cancer. However, it remains unclear whether similar PFAA profile changes occur 
in cancer patients from other populations. Therefore, this study aimed to validate the 
performance of this index in discriminating lung cancer patients from controls in the 
Korean population. Methods: Samples were collected from a total of 142 Korean 
subjects (72 lung cancer/70 controls) for this study. PFAAs were quantified by high-
performance liquid chromatography-electrospray ionization-mass spectrometry, and 
the clinical performance characteristics of the amino acid multivariate index were 
evaluated across cancer stages and histological types. Results: The concentrations 
of several PFAAs were significantly decreased in the Korean lung cancer patients 
compared with the controls. Significant decreases in threonine, citrulline, histidine 
and tryptophan and increases in proline, isoleucine, phenylalanine and ornithine were 
observed, which are similar to the PFAA changes reported by a previous Japanese 
study. The area under the receiver-operator characteristic curve (AUC of the ROC) for 
the index was 0.80, and similar performances were demonstrated for the different 
histological types. Conclusion: These results suggest that the amino acid multivariate 
index previously developed from a Japanese dataset has the potential to aid in the 
early detection of lung cancers of different histological types in Korean patients. 
Keywords: plasma free amino acid, lung cancer, Early Detection
Table1. Detection of Proteins in BAL from lung cancer and benign lung disease by ELISA 
assays.
Protein Benign* (n=7)
ADC* 
(n=18)
SqCC* 
(n=9)
SCLC* 
(n=6) Sensitivity (%) Specificity (%) PPV (%) NPV (%) P value
Napsin A 55±39 295±104 102±34 50±28 83.3 66.7 88.2 57.1 <0.05
Periostin 255±104 4002±218 3496±1765 1772±1119 73.68 71.43 87.5 50.0 <0.05
G3-BP 168±29 290±70 240±65 132±65 47.4 11.8% 69.2 23.1 >0.05
MPO 3227±2948 0.08±0.03 1.6±0.7 0.1±0.06 33.3 100 100 83.3 <0.05**
 
 
*protein concentration was expressed as ng/mg total BAL protein.* for benign 
lesions. Conclusion: Our study demonstrates that potential protein biomarkers in BAL fluid 
can be identified and quantified. They have the potential to improve the specificity of lung 
screening tests and to reduce unnecessary surgery in patients with benign lung nodules. 
Keywords: improve detection specificity, BAL fluid, protein biomarkers, lung cancer
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P3.06-008 Meta-Analysis Criteria Used to Rank Biomarkers for Validation 
Testing: What Works? Brad Rikke1, Murry Wynes1, Leslie Rozeboom1, Anna E. Barón2, 
Fred R. Hirsch1 1Division of Medical Oncology, University of Colorado Anschutz Medical 
Campus, Aurora/CO/United States of America, 2Department of Biostatistics and Informatics, 
Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora/
CO/United States of America
Background: Hundreds of biomarkers are being developed for the screening and 
early detection of lung cancer. The vast majority, however, even after extensive internal 
validation, will likely fail during external validation. For biomarkers to reach the clinic, 
therefore, it’s imperative that external validation studies focus on the most promising 
candidates. Towards this end, various strategies have been proposed to rank order and 
prioritize biomarker candidates. These strategies range from simple, highly intuitive 
ideas to highly sophisticated statistical analyses. To our knowledge, however, none of 
these strategies has itself been validated externally, which is an important consideration 
given that each strategy involves making subjective decisions. Here we conducted an 
independent validation test to assess the performance of the “vote-counting strategy”, 
a straightforward, commonly used strategy that ranks biomarkers on the basis of three 
highly intuitive criteria: the number of supporting studies in the literature, the combined 
sample size in the supporting studies, and the average fold change difference associated 
with the biomarker. Methods: We obtained vote-counting biomarker rankings from two 
recent meta-analyses that together surveyed over 180 miRNAs reported to distinguish 
lung tumor tissue from normal. We compared the rankings of 50 top candidates and 22 
unranked miRNAs to our RT-qPCR results obtained from 45 tumor-normal pairs. We tested 
for a statistically significant Pearson correlation (r) between biomarker performance and 
the rankings according to each of the three ranking criteria. Results: We found that 
the number of supporting studies in the literature was indeed a statistically significant 
predictor of biomarker performance (r = 0.44, n = 50, p = .0006). Our results also 
suggested that markers supported by two studies in the literature had approximately a 
50% chance of being confirmed, markers supported by 3 studies about a 67% chance, 
and markers supported by 6 studies about a 90% chance. Our unranked markers showed 
only a 5% chance of being confirmed. At the same time, we found that the combined 
sample size in the supporting studies was not a predictor of biomarker performance 
(r = 0.11, n = 50, p = 0.29). We also found that the mean fold change associated with 
each biomarker was not a predictor (r = 0.12, n = 47, p = 0.22) because large fold-
change differences were also associated with large amounts of variability between 
studies. Conclusion: Considering that vote counting has obvious limitations (such as 
selection bias, not counting negative votes, and the variation in how different studies 
define significance) counting the number of supporting studies in the literature appears 
to work remarkably well for ranking biomarker candidates. On the other hand, using total 
sample size or mean fold change in the supporting studies to rank biomarker candidates 
appears to provide little, if any, added value. Our results also indicate a need for external 
validation testing of the current strategies being used to rank biomarkers across studies. 
Keywords: miRNA, microRNA, validation testing, biomarkers, meta-analysis, lung cancer
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P3.06-009 Evaluation of Bone Metastasis Using Serial Measurements of Serum 
NTx in Patients with Lung Cancer: A Prospective Study Takayuki Shiroyama1, 
Motohiro Tamiya1, Shinya Tokunaga2, Hideaki Okada2, Hidekazu Suzuki1, Norio 
Okamoto1, Naoko Morishita1, Natsuko Miyamoto2, Koichi Taira2, Haruko Daga2, Koji 
Takeda2, Tomonori Hirashima1 1Department of Thoracic Malignancy, Osaka Prefectural 
Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic 
Diseases, Habikino/Japan, 2Clinical Oncology, Osaka City General Hospital, Osaka/Japan
Background: The bone resorption biomarkers cross-linked N-telopeptide of type 
I collagen (NTx) have been shown to aid in the diagnosis of metastatic bone disease 
from lung cancer (MBDLC). Patients with MBDLC are often treated with zoledronic 
acid (ZA). ZA reduces the levels of NTx and also lowers the risk of skeletal adverse 
events in patients with MBDLC. Methods: Patients with MBDLC at initial diagnosis 
were included in this study. Serum NTx (sNTx) was measured once a month using the 
OSTEOMARKTM sNTx assay (Alere Medical). MBDLC was assessed by monthly physical 
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P3.06-013 VOC Breath Testing in Squamous Cell Carcinoma (SCC) of Lung 
and Larynx Shows Distinct Profiles Each of Which Relate to Tumour Burden 
David Fielding1, Mark Davis1, Michael Brown1, Annette Dent2, Graham Dickie3, 
Julienne Agnew4, Robert Hodge4 1Thoracic Medicine, Royal Brisbane and Womens 
Hospital, Brisbane/Australia, 2Thoracic Medicine, The Prince Charles Hospital, Brisbane/
QLD/Australia, 3Radiation Oncology, Royal Brisbane and Womens Hospital, Brisbane/
Australia, 4Surgery, Royal Brisbane and Womens Hospital, Brisbane/Australia
Background: Early studies of volatile organic compound (VOC) testing in lung cancer 
suggested similar profiles for all stages of lung cancer, raising the possibility that in-
situ cancer might be detectable by VOC profiling. It was hypothesized that a metabolic 
predisposition to cancer was being detected in VOC profiles, rather than VOCs arising 
from tumour bulk. In situ SCC can be detected in lung as well as the larynx allowing 
VOC profiles to be compared to advanced cancer. Because many lung cancer patients 
can develop Larynx cancer (and vice versa) profiling to determine the possibility of VOC 
testing in post treatment surveillance could provide useful data. Methods: Prospective 
pilot study. Breath samples were collected using the E-Nose Cyranose ®per 
established protocols prior to biopsy. Data were reduced to principal components for 
canonical discriminant analysis to determine differences between groups. Accuracy 
(CVV) was calculated using leave one out cross validation. All cases and controls had 
autofluorescence or Narrow Band Imaging bronchoscopy or microlaryngoscopy as well 
as CT chest. Histological confirmation was obtained. Control patients had negative larynx 
and bronchus on scopes. All patients had a smoking history. Results: Patients were as 
follows:
Bronchus Larynx
N Age M/F Current smokers N Age M/F
Current 
smokers
In situ 8 67±9 6/2 0 10 61±10 9/1 4
Ad-
vanced 10 71±6 7/3 5 10 65±9 10/0 4
Control 10 63±9 7/3 2 10 62±10 9/1 4
 
Factor analysis p values for advanced cancer compared to control were 0.05 for 
larynx and 0.08, NS for bronchus. Values for in situ for both sites compared to control 
were NS, but were significant when compared to advanced cancer (0.04 and 0.009 
respectively). Advanced cancer of larynx compared to bronchus showed p=0.001, CVV 
80%. Conclusion: These results suggest that VOC signal as measured by eNose relates 
to tumour bulk as opposed to a systemic metabolic predisposition to cancer, (which 
might have allowed in situ cancer to be detected). Whilst the inability to detect in situ 
SCC was disappointing, the clear differences between VOC profiles for advanced cancer 
suggest the Squamous cell carcinoma has different metabolic profiles in the 2 sites, and 
further study may allow development of VOC breath testing for surveillance of bronchial 
SCC after larynx cancer. It suggests that whereas SCC arises in the aerodigestive 
tract “field” there are different inputs into the tumour development at each site. 
Keywords: Breath testing, In situ Carcinoma, volatile organic compounds, Squamous 
cell carcinoma
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P3.06-014 Onset of Silicosis among Sandstone Mine Workers in Rural 
Rajasthan, India Absar Ahmad Public Health, International Institute for Population 
Sciences,Mumbai, Mumbai/India
Background: There are about 3 million workers at high potential risk of silica exposure in 
India and around 17 lakh in mining industry.But unofficialy figure for Rajasthan alone, over 
2.5 million that are engaged in unorganized mine sector. The problem of silicosis is much 
more severe in the unorganized sector of industries like slate pencil cutting, stone cutting, 
and agate industry.The flaw here is because most industries belonging to the unorganized 
sector do not fall under the purview of Factories Act and Mines Act. Methods: Present 
study used the data from published report of detection of Silicosis by National Institute 
for Miner’s health an autonomous Institute under Ministry of Mines, Government of India. 
ARAVALI a NGO based in Jaipur arranged for medical investigations (through Dang Vikas 
Sansthan (DVS), Karauli based voluntary organization, one of the ARAVALI‟s field host 
organization since 2008), of persons which had the history of work in stone mines. 
That included detailed work history, respiratory symptoms, history of treatment, chest 
radiography, sputum examination and pulmonary function test. The medical records 
evaluated by three specialists experienced in the evaluation of chest radiographs as per 
ILO classifications of radiographs for Pneumoconiosis, 2000. The report has published in 
three different time, first were in 2011 (101 miners), second 2014 (314 miners) and third 
2014 (157 miners). These reports cover stone miner from two districts of Rajasthan, 
named Karauli (first two reports) and Dhaulpur (third report). Reports include around 18 
villages from Dhaulpur and 38 villages from Karauli. Thirty-four X-ray qualities were poor, 
and nine has no history of mining were not clinically evaluated for Silicosis. So, total 529 
mine worker were clinically assessed for silicosis as per ILO classification of radiographs 
by the Institute. Cox regression is used for exploring the relationship between the 
onsets of silicosis among mine workers. Results: Bivariate analysis of the study shows 
that 58 % of the mine workers those diagnosed for silicosis were previously treated for TB. 
TB treatment, working duration in mines (16-30 years) and (30+ years) were found to be risk 
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P3.06-011 Unique Combination of 6 Circulating microRNAs for Early Detection 
of Lung Cancer Ann R. Halvorsen1, Maria M. Bjaanæs1, Are Holm2, Nils Bolstad3, Luis 
Rubio4, Juan C. Peñalver5, José Cervera6, Julia C. Mojarrieta7, Jose A. López-Guerrero4, 
Odd Terje Brustugun8, Åslaug Helland9 1Department of Cancer Genetics, Oslo University 
Hospital Radiumhospitalet, Oslo/Norway, 2Department of Respiratory Medicine, Oslo 
University Hospital Rikshospitalet, Oslo/Norway, 3Department of Medical Biochemistry, 
Oslo University Hospital Radiumhospitalet, Oslo/Norway, 4Laboratory of Molecular Biology, 
Fundación Instituto Valenciano de Oncología, Valencia/Spain, 5Department of Thoracic 
Surgery, Fundación Instituto Valenciano de Oncología, Valencia/Spain, 6Department of 
Radiology, Fundación Instituto Valenciano de Oncología, Valencia/Spain, 7Department of 
Pathology, Fundación Instituto Valenciano de Oncología, Valencia/Spain, 82Department 
of Oncology, Oslo University Hosital,The Norwegian Radium Hospital, Oslo/Norwa, Oslo/
Norway, 9Department of Oncology, The Norwegian Radium Hospital, Oslo/Norwa, Oslo/
Norway
Background: Worlwide, lung cancer is the primary cause of cancer death. Today 75% of 
patients are diagnosed in a locally advanced or metastatic inoperable stage, and a new 
tool for early detection of lung cancer is urgently needed in order to improve the outcome. 
Circulating microRNAs have emerged as stable, non-invasive and promising biomarkers 
for diagnosis, prognostication and prediction in cancer. The purpose of this study was 
to identify circulating microRNAs for detection of early stage lung cancer, capable of 
discriminating lung cancer patients from those with chronic obstructive pulmonary 
disease (COPD) and healthy normal individuals. Methods: We profiled the expression of 
756 unique microRNAs in sera from 38 patients with NSCLC, 16 patients suffering from 
COPD and 16 healthy volunteers, to explore the potential of the microRNAs as diagnostic 
biomarkers. For validation of our results, we analyzed serum from an independent 
cohort of high-risk individuals enrolled in the IELCAP screening trial (n=161) using RT-
qPCR Results: Focusing on microRNAs upregulated in sera from lung cancer patients, 
we identified a unique set of 6 microRNAs with significantly higher abundance compared 
with sera from COPD patients and healthy normals. Validation of the 6-miR signature 
demonstrated a sensitivity of 86% and specificity of 79.3% Conclusion: Considering their 
accessibility and stability, circulating microRNAs can be a diagnostic tool for clinicians 
in the future, and may lead to increased fraction of lung cancers diagnosed in an early 
curative stage. The 6-miR signature may be a basis for a screening study and can easily be 
implemented in the clinic to identify those who should be further examined for lung cancer 
Keywords: screening study, circulating microRNA, Early Detection, diagnostic biomarker
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P3.06-012 cfDNA in Lung Cancer Patients and People with High Risk of LC 
Exposed to Environmental Pollution Marta Adonis1, Carolina Tamayo2, Ulises Urzua2, 
Marco Chahuan3, Veronica Rosana Miranda4, Monica Campos3, Alcides Zambrano5, 
Hugo Benitez5, Pedro Marin5, Lionel Gil2 1Cetecancer, ICBM, University of Chile, Santiago/
Chile, 2Cetecancer, University of Chile, Santiago/Chile, 3Adult Pulmonary, Hospital San Borja 
Arriarán, Santiago/Chile, 4Hospital Barros Lucos Trudeau, Santiago/Chile, 5Hospital Regional 
de Antofagasta, Antofagasta/Chile
Background: In Chile, Lung Cancer (LC) has the second high mortality rate/100,000 
for cancer, after to stomach cancer. During 2012, in the country the LC incidence for 
male was 17.1 with a mortality of 17.0, while for female the incidence was a 10.2, with 
a mortality of 8.8. In the same period, the Antofagasta region (North of Chile) showed 
a rate mortality of 31.6 for both gender, with a rate of 44.2 and 17.4, for men and 
women, respectively. According to this point of view, early detection and screening 
are imperative in order to increase survive to 5 years. Non invasive biomarkers, as 
complementary tools, might contribute with the early diagnosis of LC. In this context, 
free-circulating DNA (fcDNA) levels have been described as a potential tool to detect 
in comparison with controls. Methods: Volunteers enrolled, were classified as LC free 
subjects (C), Pre Neoplastic Lesions (PNL) and Lung Cancer (LC), according to results 
of Quantitative Automatic Cytology (QAC) in sputum specimen, DR70 tumor marker, and 
Auto fluorescence Bronchoscopy (AFB). Free circulating DNA (fcDNA) was isolated from 
serum of the three groups of volunteers, quantified by qPCR and amplified. The amplified 
fcDNA was co-hybridized against genomic DNA from total blood, using microarray-
HGC. Results: The LC patients showed significantly higher levels of fcDNA (average, 16,13 
ng/mL) than volunteers cancer free (CF) (p < 0.01) (average 2,692 ng/mL) and with Pre 
neoplastic Lesions (PNL) (p < 0.001) (average 1,961 ng/mL). Additionally, four recurrent 
and significant deletions were detected in 2p, 7q, 11q and 17p of LC volunteers. Non 
significant alterations were detected in PNL. Genes located in segments with CNAs were 
related in immune response, xenobiotic metabolism and oxidative phosphorilation and 
associated to , cell proliferation, cell cycle regulation, apoptosis, differentiation and cellular 
adhesion and migration, all functions relevant to neoplastic progression. Conclusion: . In 
conclusion; fcDNA levels were significantly associated to LC but not to PNL related to LC, 
fcDNA concentration could be a non invasive and complementary tool to diagnosis of LC, 
molecular characteristic of fcDNA suggest that its might be used as biomarker associated 
to malignancy of LC, as a non invasive and complementary tool for the diagnosis of 
LC. Supported by INNOVA CORFO Chile: Grants 07CN13B48 and 11IDL2-10634. 
Keywords: Early Detection, GENOMIC MARKERS, fcDNA, lung cancer
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Fig. 2:
 
 
Conclusion: Vascular invasion has previously been demonstrated to result in upstaging 
and a poorer prognosis. Critical to the workup, then, is not only diagnostic pathology, 
but also rapid and accurate staging and a decision regarding appropriateness of surgical 
resection. We believe our case illustrates that with the synergistic use of convex or 
radial endobronchial ultrasound during initial bronchoscopy, vascular invasion may be 
accurately confirmed resulting in improved decisions in patient care.
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P3.06-017 The Search for Cancer: Procedures in High Risk Patients: Elevated 
Cardiac Risk in Patients Undergoing Bronchoscopy Dipaben Modi1, Tina Dudney2, 
J. F. Turner2 1Department of Medicine, University of Tennessee Graduate School of Medicine, 
Knoxville/United States of America, 2Department of Medicine, University of Tennessee 
Graduate School of Medicine, Knoxville/TN/United States of America
Background: There has been an increased utilization of tomographic imaging to aid 
in the acute evaluation of patients with chest complaints and in high-risk patients to 
screen for lung cancer with the recently reported National Lung Screening Trial (NLST). 
In particular, utilization of CT-angiograms in the emergency room may, increasingly, 
identify patients presenting with concurrent cardiac injury and imaging abnormalities 
concerning for lung cancer. Methods: We present the case of a 75 year old male with 
chest pain and a non-resolving pulmonary infiltrate concerning for lung cancer. Although 
the chest pain was felt to be secondary to the pulmonary abnormality, evaluation by the 
bronchoscopy and anesthesia services revealed severe hypertension and an elevated 
troponin. The procedure was cancelled and cardiology was consulted with cardiac 
evaluation, control of blood pressure, and subsequent bronchoscopy. Results: Although 
review of the literature revealed extensive study of preoperative risk stratification for 
surgery there was a paucity of studies regarding the performance of bronchoscopy in 
factors for Silicosis. The corresponding adjusted hazard ratios were 1.299(95 % C.I. 0.895, 
1.886), 5.605(95% C.I. 3.485, 9.016) and 3.689(95% C.I. 2.73, 4.984). By age 40, maximum 
miners get silicosis found in life table analysis. Conclusion:Sandstone miners affected with 
silicosis but getting treatment of TB. After 15 years of work in mine, miners get affected 
with silicosis and by age 65 all miner get affected with silicosis if he continued to work. 
Keywords: Sandstone mine, Silicosis, Karauli, Mine worker
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P3.06-015 Is the Development of Primary Lung Adenocarcinoma Simply Due 
To ‘Bad Luck’? Maria Elena Cufari1, Chiara Proli1, Manraj Phull1, Anna Allan2, Hilgardt 
Raubenheimer1, May Al Sahaf2, Nizar Asadi2, Periklis Perikleous1, Hemangi Chavan2, 
Lynn Shedden1, Zakiyah Niwaz3, Giulia Luciano2, Maria Leung4, Andre Kubler1, Andrew G. 
Nicholson5, Patrizia Viola6, Vladimir Anikin2, Emma Beddow2, Niall Mcgonigle2, Michael 
Dusmet1, Simon Jordan1, George Ladas1, Eric Lim1 1Department of Thoracic Surgery, 
Royal Brompton and Harefield NHS Trust, London/United Kingdom, 2Thoracic Surgery, Royal 
Brompton and Harefield NHS Trust, London/United Kingdom, 3Clinical Outcomes Analyst - 
Lung Division, Royal Brompton and Harefield NHS Trust, London/United Kingdom, 4Thoracic 
Surgery, Royal Brompton Hospital, London/United Kingdom, 5Department of Histopathology, 
Royal Brompton and Harefield NHS Trust, London/United Kingdom,6Histopathology, Royal 
Brompton Hospital, London/United Kingdom
Background: Recently, Tomasetti and Vogelstein proposed that the variation in cancer 
risk among tissue is explained by the number of stem cell division, and this was widely 
interpreted as “bad luck” due to random mutations arising during DNA replication in normal 
non-cancerous stem cells. Smoking is widely considered as the main aetiological risk 
factor for the lung cancer and the aim of our study is to evaluate the hypothesis comparing 
the differences in proportions of the two main histological subtypes in smokers and 
never smokers in a patients with early stage primary lung cancer to determine the impact 
of smoking on the development of squamous and adenocarcinoma. Methods: Data were 
retrospectively analysed from a prospectively collated database at our institution over a 
7 year period. Histological data were extracted and compared for the two main historical 
subtypes of squamous and adenocarcinoma (subtyped according to the new IASLC 
adenocarcinoma classification). Frequencies were compared using Fishers exact or Chi 
square tests as appropriate to the data. Results: A total of 2170 patients underwent 
surgical resection for lung cancer at our institution from March 2008 to November 2014 
of which 436 (20%) patients were never smokers. The mean age (SD) was 66 (12) years 
and 48% were female. The relative proportion of patients with squamous carcinoma was 
significantly different between smokers 323 (27.0%) and never-smokers 16 (5.7%) with 
P <0.001 with a risk ratio of 4.70 (95% CI 2.9 to 7.6). However the relative proportions 
between patients with adenocarcinoma were similar between smokers 578 (48.3%) and 
never-smokers (54.4%) P=0.06 with a risk ratio of 0.89 (0.79 to 1.00). Conclusion: Our 
results suggest that smoking remains an important aetiological risk factor for the 
development of primary lung squamous cell carcinoma. For adenocarcinoma, the 
relative proportions between smokers and never-smokers were similar (in fact lower for 
smokers) supporting Tomasetti and Vogelstein hypothesis of random mutations arising 
during DNA replication in normal non-cancerous stem cells– or simply put as “bad luck”. 
Keywords: smoking history, adenocarcinoma, spontaneous mutations
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P3.06-016 Upstaging of Lung Cancer - Use of Endobronchial Ultrasound in the 
Prediction of T4 Disease J. F. Turner1, Scott Parrish2, Robert Browning2 1Department 
of Medicine, University of Tennessee Graduate School of Medicine, Knoxville/TN/United 
States of America, 2Pulmonary, Walter Reed National Military Medical Center, Bethesda/MD/
United States of America
Background: There has been an increased utilization of radial and convex probe 
endobronchial ultrasound with application in the nodal staging of the mediastinum for 
bronchogenic carcinoma. Prior work has demonstrated that vascular invasion (Vi) is 
associated with upstaging and a worsened prognosis in those patients with non-small 
cell carcinoma. Utilization of endobronchial ultrasound has been promulgated to improve 
the sensitivity of transbronchial needle aspiration (TBNA), but also to avoid vascular 
puncture. As such, imaging of the pulmonary vasculature is routinely performed and 
may allow insight and confirmation of CT imaging of vascular invasion. Methods: We 
present the case of a patient presenting with scant hemoptysis where the CT scan was 
interpreted as possible invasion of the right pulmonary artery (Fig 1). The literature was 
reviewed as to the effect of vascular invasion on upstaging patients with lung cancer 
and he underwent a diagnostic procedure. Results: Bronchoscopy and endobronchial 
ultrasound were performed to allow nodal TBNA to permit pathologic diagnosis and 
staging of the patient’s identified lung mass. During the procedure, ultrasound of the 
pulmonary vasculature revealed extensive invasion and mass effect from the central 
tumor mass (Fig 2). Using these synergistic techniques, the patient was upstaged to T4 
and was referred for consultation with medical and radiation oncology. Fig. 1:
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Table 1. Lung cancer deaths with non-solid nodules in NLST database
Case Any NS nodules
Size of 
largest 
NS
Multiple/
solitary
Stage/Cell-
type Comments
128534 Y 29 x 19
Solitary 
NS Solitary 
solid
IIIA/Squamous 
cell
Large solid nod-
ule (57 x 52)
134088 Y 27 x 20
Multiple 
NS Multiple 
solid
IV/Small-cell
212718 Y 26 x 26 Multiple NS Multiple PS IV/BAC
Cancer reported 
in all lobes
116279 Y 5 x 4 Solitary NS IV/Carcinoma NOS
NS nodule 
appears stable 
over 3 years
126576 Y
Multiple 
NS Solitary 
solid
IA/Adeno-mixed Growing solid nodule, 15 mm
117025 N Multiple solid IV/Adeno NOS
208792 N Solitary solid
IIIA/Squamous 
cell
218307 N Solitary solid
IIIA/Squamous 
cell
 
 
*ns-nonsolid; ps-part-solid Conclusion: It seems unlikely that within the NLST, 
there were cases of lung cancer specific death that were attributable to cancers 
manifesting as a solitary or dominant nonsolid nodule. This lends further support 
that lung cancers manifesting as nonsolid nodules have an indolent course. 
Keywords: non-solid, ground glass, mortality, CT
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P3.06-020 CT-Guided Percutaneous Fine Needle Biopsy for Small Lung Tumor 
(≤ 2cm) and Diffficult Pulmonary Lesions Jun Zhang, Xueshan Qiu China Medical 
University Lung Cancer Center, The First Hospital of China Medical University, Shenyang/
China
Background: lung cancer is increasing rapidly in China. There are more and more 
peripheral small lung cancer (≤2cm) was found. CT-guided percutaneous fine needle 
biopsy becomes first of choice for pathological diagnosis of peripheral small lung tumor 
(≤2cm) and some central pulmonary lesions which could not be pathologically diagnosed 
by fiberoptic bronchoscopy. We developed CT-guided percutaneous fine needle biopsy 
(CT-NB) for detecting early stage lung cancer (size ≤2cm peripheral small lung cancer) 
since 1992. We discuss typical cases here. Methods: Case1: Man, aged 52, right lower 
lobe 1.5cm ball tumor, no typical malignant sign; unwilling to undergo surgery due to 
years’ coronary heart disease; CT-NB was performed and lung adenocarcinoma was 
diagnosed. Case2: Man, aged 63, right upper lobe 1.2cm ball tumor, with cardiopulmonary 
dysfunction; CT-NB was performed and found some inflammatory cells, but no malignant 
tumor cells found. Case3: Man, aged 40, heavy smoker, cough and blood-tinged sputum 
for one month, left lower lobe 3.5cm irregular mass, regional and subcarinal lymph node 
swollen, clinically progressed rapidly, suspected small-cell lung cancer (SCLC), T2N2M0; 
at least pneumonectomy was needed if want resected; CT-NB was performed and non-
small cell lung cancer (NSCLC) was diagnosed, and SCLC was excluded. Results: For Case 
1: right lower lobe resection and lymph node dissection was performed, postoperative 
diagnosis was adeno-squamous cell carcinoma, 1.5X1.3X1.3cm, lymph node negative, 
pT1N0M0 Stage I, early stage lung cancer. He was alive healthily more than five years 
postoperatively. For Case 2: considered as a benign disease; carefully follow-up for 
more than 5 years, no malignant sign. For Case 3: left pneumonectomy and lymph node 
dissection was performed; postoperative diagnosis was squamous cell carcinoma; 
pulmonary ligament lymph node positive, others negative, pT2N2M0 StageIIIA; radiation 
followed. He was alive healthily more than five years postoperatively. Conclusion: CT-
NB is a very useful diagnostic method for peripheral small lung tumor (≤2cm) and 
some central pulmonary lesions with fiberoptic bronchoscopy failed. CT-NB could 
be used to confirm the diagnosis of lung cancer, to help make decision for surgically 
resection, to help cure more early stage lung cancer patients, to help improve the 
prognosis of lung cancer treatment. CT-NB could also be used to exclude lung cancer 
diagnosis, to avoid unnecessary surgery, especially for those aged, cardiopulmonary 
dysfunction, high risk patients. CT-NB could be used to confirm the pathological type 
of lung cancer before treatment applied, to help distinguish SCLC from NSCLC, to help 
select the best choice of treatment modality of chemotherapy and radiation according 
to patient’s age, cardiopulmonary function status, pathological type, and gene types. 
Keywords: fine needle, small lung cancer, biopsy, CT guided
the setting of hypertension and possible silent ischemia, particularly in patients with 
concurrent elevated troponin levels. We use this case to review the current literature 
and propose recommendations in the setting of cardiac ischemia with a rapid pathway 
for evaluation and treatment to allow needed bronchoscopic diagnostic procedures. 
Conclusion: Bronchoscopy in patients with hypertension or chest pain, particularly 
in the setting of elevated troponins, is poorly studied and may result in an increased 
risk of silent ischemia. Consideration for additional cardiac evaluation or peri-operative 
use of beta-blockers is warranted. Additionally, prospective studies to determine the 
incidence of silent ischemia in patients, such as presented, should be considered. 
Keywords: lung cancer, cardiac risk, bronchoscopy
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P3.06-018 Quick Radiological Course of Lung Cancer Mimicking Pulmonary 
Tuberculosis Nesrin Ocal1, Deniz Dogan1, Gurhan Taskin2, Canturk Tasci1, Hayati Bilgic1 
1Chest Diseases, Gulhane Military Medical Faculty, Ankara/Turkey, 2Intensive Care Unit, 
Gulhane Military Medical Faculty, Ankara/Turkey
Background: Cavitary lung lesions are primarily due to pulmonary tuberculosis 
but they also can be associated with other etiologies such as lung malignancies, 
fungal infections. To exclude tuberculosis with ARB tests when these kind of lesions 
detected, is a generally accepted clinical approach. Rapid radiological progression 
in cavitary lesions are usually interpreted as tuberculosis while a slower progression 
is expected in malignancies. Methods: ‘not applicable’ Results: We presented this 
rare case because of a rapid radiological progression in a patient with lung cancer. 
Sixty-six year old male was admitted to our clinic with cough, weight loss, fever and 
fatigue. ARB test was planned and nonspecific antibiotherapy was started because of 
the cavitary lesions in left upper lobe on CT which was performed in another centre one 
week before admission to our clinic. ARB test was negative and control CT was planned. 
CT revealed prominent progression of the lesions. Although tuberculosis was the initial 
diagnosis because of this rapid progression diagnostic bronchoscopy was performed. 
Endobronchial lesion in the left upper lobe was detected and pathological examination 
revealed squamous cell lung cancer. Conclusion: Although cavitary lesions can be 
observed in lung cancer, such a rapid progression as observed in our case suggests 
infections, especially pulmonary tuberculosis rather than malignancies. We presented 
this case to be useful for the clinicians in cavitary lung lesion assessment process. 
Keywords: cavity, lung cancer, tuberculosis, mimicking
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P3.06-019 Lung Cancer Deaths in the NLST Attributed to Nonsolid Nodules 
Rowena Yip1, Artit Jirapatnakul1, Minxia Hu2, Dongming Xu1, Claudia I. Henschke1, David 
F. Yankelevitz1 1Radiology, Icahn School of Medicine at Mount Sinai, New York/United States 
of America, 2Department of Diagnostic Ultrasound, Beijing Tongren Hospital, Beijing/China
Background: There has been increasing awareness of the more indolent course of 
cancers manifesting in nonsolid nodules, especially among those where the nodule is 
solitary or dominant. There have been reports of virtually 100% cure rates upon resection 
and most recently, the recommendation from the ACR in their Lung-RADS screening 
guidelines is for those nonsolid nodules less than 2 centimeters to be followed by annual 
screening without additional evaluation. In order to further evaluate the aggressiveness 
of these types of cancers in the screening setting, we determined how frequently they 
were the cause of death (COD) within the NLST. Methods: We searched the NLST 
database to identify all participants who had a diagnosis of lung cancer after a positive 
result on CT screening and whose death was attributed to lung cancer by the NLST 
endpoint verification process. Among them, 28 participants had at least one nonsolid 
nodule identified on CT in a screening round. Among these, all cases where the nonsolid 
nodule could not identified in the study year the cancer was first identified (cancyr) or 
in the location of the confirmed lung cancer were excluded. All images associated with 
the remaining 8 cases were downloaded from The Cancer Imaging Archive (TCIA) using 
the NLST Query Tool and reviewed by three radiologists (DY, DX, MH) to assess nodule 
consistency and location. Results: Among the 8 cases reviewed by the radiologists, only 
5 cases had at least one nonsolid nodule. The remaining three cases had no CT evidence 
of a non-solid nodule (Table 1). Among the 5 cases with nonsolid nodules, 2 cases had 
another large solid nodule (average diameter of 54.5mm and 15 mm) in the same lobe 
which was the probable lung cancer that was the cause of death. In another case, the 
nodule was less than 5 mm in diameter and stable for 3 years, and in another the cause of 
death was small cell carcinoma which is not known to manifest as a nonsolid cancer. One 
case manifested on baseline scan with multiple nonsolid and part-solid nodules which all 
grew on successive annual scans.
S739Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
248.6 ml. Only 8 patients (8%) Has oncologic diagnosis in pleural effusion; 40 patients 
(40%) with diagnosis in pleural tissue including 37 patients (37%) cáncer diagnosis and 
3 patients (3%) tuberculousis. The rest 52 patients (52%) only mesothelial reaction in 
first thoracocentesis. From the 100 patients 60% do not return to confirm diagnosis or 
to reevaluate at 2 weeks with chest X ray and to explain first pathologic result arguing 
not having time, no money and no necesary if the first one was no cancer. Results: The 
present study shows how only in 8% can get in an oncologic diagnosis in pleural liquid in a 
thoracic reference hospital, on the other hand patients that had a complete protocol with 
a CT scan after thoracocentesis, and surgical intervention with thoracoscopy and pleural 
biopsy we can achieve an oncologic diagnosis in 29%, in patients with clinical features 
and risk factors for lung cancer. 29 patients that underwent single port thoracoscopy 
were previously rated for cardiovascular risk by a cardiologist, and for respiratory hazard 
by a pulmonologist. Surgical time varied from 1 to 2 hours, hospital stay was 2 to 5 
days, those patients that persisted with high output from thoracic catheter tunneled were 
treated ambulatory and weekly consultation until chest tube withdrawal. Conclusion: Our 
study shows how a patient with a massive pleural effusion, with clinical data and risk 
factors for lung cancer, can get an oncological diagnosis by single port thoracoscopy 
as initial approach, with surgical staging, giving a quick resolution, and in selected 
cases offer a palliative treatment by a thoracic catheter tunneled and chemical 
pleurodesis, if indicated after making serial samples for histological study. Offering a 
resolutive treatment and a prompt diagnosis in a pathology that is increasing and with no 
satisfaying results in developing countries were a strict follow in many cases is no posible 
Keywords: lung cancer, pleural effusion, thoracoscopy, thoracic tunneled catheter
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P3.06-024 Follow-Up Recommendation Compliance in a Clinical CT Lung 
Screening Program Sama Alshora1, Brady Mckee1, Shawn Regis2, Christopher Bolus3, 
Andrea Mckee2, Robert French1, Sebastian Flacke1 1Radiology, Lahey Hospital & Medical 
Center, Burlington/MA/United States of America, 2Radiation Oncology, Lahey Hospital & 
Medical Center, Burlington/MA/United States of America, 3Radiology, Beverly Hospital, 
Beverly/MA/United States of America
Background: The efficacy and cost-effectiveness of CT lung screening will in part 
depend on patient compliance with CT lung screening exam recommendations. However, 
rates of patient compliance and the reasons for non-compliance have not been widely 
reported for clinical CT lung screening programs. Methods: We retrospectively 
assessed the rate of patient compliance with exam follow-up recommendations in our 
CT lung screening program. All patients evaluated fulfilled the NCCN high-risk criteria for 
lung cancer screening and underwent screening between 1/12/2012 and 6/12/2013. 
Screened patients referred from outside our institution were excluded due to limited 
followup. Patients with negative, benign, or probably benign results were recommended 
to have a repeat screening exam in 6-12 months. Patients with suspicious findings 
were recommended to undergo a pulmonary consultation. To be considered compliant, 
patients had to be no more than 90 days past due for their next recommended exam 
or clinical evaluation as of 9/12/2014. Patients who died, were diagnosed with cancer, 
exceeded the program age limit, or became otherwise ineligible for additional screening 
were considered adherent. Compliance rates were assessed across multiple factors 
including sex, age, smoking history, baseline exam result, and NCCN high-risk group 
status. Results: 901 high-risk patients from our institution underwent a baseline CT 
lung screening exam between 1/12/2012 and 6/12/2013. 772/901 (85.7%) were 
compliant as of 9/12/2014. 155/901 (17.2%) were non-compliant during the study 
interval of which 26 (16.8%) returned to screening compliance by 9/12/2014. The 
most common reasons for non-compliance were refusal to undergo the follow-up 
exam (66.7%), inability to contact the patient (20.9%), and patient inability to obtain 
a followup order from their physician (7.8%). 23/901 (2.6%) were discharged for 
reasons other than non-compliance. Subgroup analysis demonstrated a statistically 
significant increase in screening compliance among female patients (p = 0.035) 
and among those patients 65-73 years old (p=0.040). Conclusion: High rates of 
compliance with CT lung screening recommendations are achievable in clinical practice. 
Keywords: compliance, CT lung screening, Follow-up recommendation
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P3.06-025 Electromagnetic Navigation Bronchoscopy in the Evaluation of Lung 
Lesions: The Carolinas Medical Center Experience Jaspal Singh1, Shay Hatfield2, 
Oshauna Morgan1, John D. Doty3 1Charlotte Medical Clinic-Pulmonary Division, Carolinas 
Medical Center, Charlotte/NC/United States of America, 2Medical Education, Carolinas 
Healthcare System, Charlotte/AL/United States of America, 3Thoracic Oncology, Levine 
Cancer Institute, Charlotte/NC/United States of America
Background: Electromagnetic Navigation Bronchoscopy (ENB) is a relatively new 
minimally invasive bronchoscopic procedure that can be used to diagnose lung cancer, 
allowing bronchoscopists to (1) navigate towards peripheral lung lesions unreachable by a 
traditional bronchoscope, and (2) to utilize tools that can potentially obtain tissue samples 
large enough to perform advanced diagnostic and molecular testing. Here we share the 
experience of ENB at a large community-based hospital, aiming to better understand 
the diagnostic ability of ENB as well as possibly identify success factors for the biopsy 
methodology. Methods: Between September, 2012 and June, 2014, ENB was utilized in 
138 cases to diagnose pulmonary lesions. Retrospective chart review was performed 
to access patient personal demographic information and disease-specific information. 
True positive diagnostic procedures were defined as those with a pathologically 
confirmed cancer diagnosis. True negative procedures were defined as those in which 
the lesions were not cancerous and had either resolved on radiological follow-up or have 
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P3.06-021 Lung Cancer Presented with Neurological Symptoms and 
Diagnosed after Brain Surgery Nesrin Ocal, Deniz Dogan, Seval I. Ozan, Canturk 
Tasci, Seyfettin Gumus, Ergun Ucar, Omer Deniz, Ergun Tozkoparan, Hayati Bilgic 
Chest Diseases, Gulhane Military Medical Faculty, Ankara/Turkey
Background: Lung cancer is still one of the the most important and common mortality 
cause. Although, the presentation and course of the disease differ with the cell type, 
usually typical symptoms are seen. The most common symptoms include fatigue, weight 
loss, shortness of breath, and chest pain. These symptoms especially in smoking patients 
suggest lung cancer first. But in some cases paraneoplastic syndromes and symptoms of 
other systems caused by diffusing cancer come forward. Such findings are most common 
in small cell lung cancers (SCLC) among lung cancers. Because early metastasis and 
paraneoplastic syndromes SCLC can have very different clinical presentations. Methods: To 
emphasize this issue, we present a case of SCLC having only neurological signs. 
Results: 60 years old male patient with a history of 70 pack years smoking, admitted to 
neurology clinic with vertigo, headache, nausea, and changes in consciousness. Because 
of the tumoral lesion in the left cerebellum seen in brain computed tomography, he was 
referred to brain surgery. Although, a preoperative thorax tomography revealed a mass 
lesion in left lung, he was operated for palliation of neurological symptoms and pathological 
diagnosis. Intraoperative frozen sampling diagnosed as small cell lung cancer. Patient 
is still followed by our department and radiation oncology. Conclusion: We present 
this case as a reminder of lung malignancies can be met by different presentations. 
Keywords: barin metastasis, lung cancer, neurological, Surgery
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P3.06-022 Huge Dilatation of the Azygos Vein (Aneurysms of the Azygos 
Vein). University Hospital ‘Shefqet Ndroqi’ Thorax Surgery Service Fadil 
Gradica1, Lutfi Lisha1, Dhimitraq Argjiri2, Alma Cani3, Fahri Kokici3, Dorjan Bozaxhiu4, 
Albert Leka5, Silvana Bala2, Loreta Karaulli2, Flora L. Gradica6 1Thorax Surgery, 
University Hospital’Shefqet Ndroqi”, Al/Albania, 2Pnemology, University Hospital”Shefqet 
Ndroqi”, Al/Albania, 3Anestesiology Reanimacion, University Hospital”Shefqet Ndroqi”, 
Al/Albania, 4Visceral Surgery, University Hospital’Shefqet Ndroqi”, Al/Albania, 5Imagery, 
University Hospital”Shefqet Ndroqi”, Al/Albania, 6Farmacy, Farmacy “Gradica”, Al/Albania
Background: Huge dilatacion of the azygos vein (Aneurysms of the azygos vein) are 
rare and can sometimes mimic a paratracheal or posterior mediastinal mass. It is 
important to confirm the diagnosis with radiologic tools before performing invasive 
procedures, which carry the risk of hemorrhage. The usual diagnosis of a mediastinal 
mass by mediastinoscopy or percutaneous fine-needle aspiration or biopsy is very 
hazardous if there is a venous varix. Noninvasive thoracic CT scanning is a safe 
and better choice for diagnosis Methods: Here, we present a case in a 46-year-old 
symptomatic patient of an increasing azygos vein aneurysm that mimicked a growing 
paratracheal mass and posterior mediastinal mass. Review of images obtained 
using various modalities, including contrast CT scanner with out dynamic magnetic 
resonance image (MRI), revealed that the image findings were suggestive of azygos 
vein huge dilatation of the azigos vein ( aneurysm). Results: Using this method, an 
exact diagnosis can be reached without resorting to invasive procedures or with 
mini-invassiv thorax surgery.The main causes of a dilated azygos vein include portal 
vein hypertension, obstruction of the superior vena cava, hypertension in the right-
heart chamber, Budd-Chiari syndrome, hypervascular tumor draining into the azygos 
system, posttraumatic pseudoaneurysm, kinking of the aorta, and pregnancy. In some 
cases, no definitive cause is found. Conclusion: We report a case of azygos vein varix 
mimicking a mediastinal mass in a patient with flebotrombosis of right femoral vena. 
Keywords: Azygos vein aneurysm, dynamic MRI, growing paratracheal or posterior 
mediastinal mass
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P3.06-023 Optimizing Lung Cancer, Utility of Early Thoracoscopy vs 
Thoracocentesis Emmanuel Peña Gómez Portugal1, Leticia S. Nieto2, Francisco G. 
Ramirez3, Salomon S. Ortiz4, Ruben C. Mendez4, Jorge O. Ortiz5, Francina B. Morales6, 
Enrique O. Lopez7, Erick A. Neri8 1Thoracic Surgery, Pachuca General Hospital, Pachuca 
Hidalgo/Mexico, 2Anestesia, La Raza Medical Center, Mexico/Mexico, 3General Surgery, 
Pachuca General Hospital, Pachuca/Mexico, 4Surgery, Pachuca General Hospital, Pachuca/
Mexico,5Oncologuy, Pachuca General Hospital, Pachuca/Mexico, 6Thoracic Surgery, National 
Institute of Nutricion, Mexico/Mexico, 7Pulmonary Medicine, Escandon Medical Hospital, 
Mexico/Mexico, 8Pathology, Pachuca General Hospital, Pachuca Hidalgo/Mexico
Background: INTRODUCTION Prospective study from the work group in thoracic 
oncology in Hidalgo Mexico Lung cancer Still first cause of dead for cancer in wordlwide. 
Diagnosis, prevalence and therapeutic approach apperece directly with their clinic 
manifestation and deppends on economic an sociocultural patients behave. Being a 
non cover pathology by the State the patient has to pay all management and doctors 
visit. Eventhough hospital structure Methods: Retrospective study from january 2012 
to december 2014 in Mexico including patients from public attendance and private all of 
them with autorized consecent We include 100 patients with massive pleural effusion, 
lung cancer risk factors like age more tan 50 years old, tabacco use with approximatly 
30 annual package, Wood smoke 100 hr / year, work activity in mines, construction, 
masonry, or asbestos fibers at home or work. Sample include 54 male and 46 female. 
Diagnostic Thoracocentesis was done in all 100 patients with an amount of pleural 
effusion with range between 2.5 ml to 2500ml, aspect yellow to hematic an average of 
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the first 2 years, it remained consequential up to 6 years after surgery (Figure 2). 
 
 
Conclusion: Stage IIIA NSCLC patients had significantly higher risk of recurrence and this 
risk was continued to 6 years after surgery. SqCC patients had tended to recur earlier. 
Surveillance strategies may need to account for stage- and histology-specific differences. 
Keywords: recurrence, non-small cell lung cancer
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P3.06-028 Risk Factors of Brain Metastases in Completely Resected Stage 
IIIA(N2) Pulmonary Adenocarcinomas Qin Zhang, Xiaolong Fu Radiation Oncology, 
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China
Background: Previous studies show that adenocarcinomas is the main high risk factor of 
brain metastases (BM) in NSCLC, and 90% of BM developes in 3 years. In patients with 
completely resected stage IIIA(N2) pulmonary adenocarcinomas, we aimed to identify the 
risk factors of BM as the first site of failure in 3 years on the basis of the new lung 
adenocarcinoma classification and molecular biology information. Methods: Patients 
with IIIA(N2) pulmonary adenocarcinomas, who had undergone radical surgery in our 
hospital from January 2005 to July 2012 were retrospectively reviewed. We observed the 
correlation among clinical factors, the new lung adenocarcinoma classification, lymph 
node status, microenvironmental factors, gene mutation status and BM to find out the risk 
factors of BM. DNA of EGFR and KRAS was extracted and purified from primary tumors 
embedded in paraffin blocks. KRAS and EGFR mutation analyses were performed by using 
DNA sequencing. Main outcome measure was BM as the first site of failure in 3 years.The 
cumulative incidence of BM as the first site of failure were determined using the Kaplan–
Meier analyiss. The log-rank test was used for univariate analysis, and Cox regression was 
used for multivariate analysis. Results: 179 patients with completely resected stage 
IIIA(N2) pulmonary adenocarcinomas were included in this study. EGFR and KRAS 
mutations were found in tumors 41.3% and 11.7%, respectively. The most common EGFR 
mutations were deletions in exon 19 and the p.L858R point mutation in exon 21. The most 
common KRAS mutations were G-T or G-C point mutation in codon 12. Brain was the most 
common site of distant failure as the first failure, and 93.3% BM developed in 3 years after 
the complete resection. Multivariate analysis showed that the extra-capsular 
extension（ECE）, cN2 and KRAS mutations were significantly associated with the high risk 
of BM as the initial site of failure in 3 years, while EGFR 19 exon mutations were the low 
risk of BM. The risk of BM in patients with KRAS mutations were significantly higher than 
patients with EGFR 19 exon mutations or other EGFR mutaions (P=0.018).
been stable over a period of 1 year. We assessed diagnostic yield percentages, lesion 
characteristics such as size and location, histological and staging characteristics of 
the tumor, outcomes of diagnostic tools, and size-tool correlation. Results: The ENB 
System carried an overall diagnostic yield of 75% with a sensitivity was 71.8% and 
specificity of 100%. 79% represented true positive results and 21% false negatives. Of 
the True Positives, 93% were non-small cell of which 73.6% were adenocarcinoma or 
had adenocarcinoma features. Of the latter, 82.1% of the adenocarcinomas diagnosed 
had enough tissue in the biopsy specimen for molecular testing. Of the negative results, 
23% were later proven within 3-4 months of the initial biopsy and 77% after 3-4 months. 
The majority of cases attempted were stage I and II, with more success with lesions of 
larger tumor volume (greater than 500 mm2). Of the four tools used for biopsy sampling: 
lavage, brush, fine needle aspiration (FNA) and forceps, the brush had the highest 
true value percentage at 82.6%, followed by forceps at 80.7%. Lesions located in the 
right lung produced a greater percentage of true diagnoses with the right middle lobe 
giving an 87.5% yield while having the lowest percentage of false diagnoses at 12.5%. 
Risks for the procedure was 3.6% with 4 patients having pneumothorax and 1 patient 
with hemorrhage requiring intervention Conclusion: ENB can be successfully used to 
diagnose lung cancer in a community setting with a minimally invasive approach, and do 
so with reasonable accuracy and minimal risk. Moreover, tissue yields from this procedure 
were sufficient in over 80% of adenocarcinoma cases for molecular testing. Success 
factors include greater lesion size and the deployment of multiple diagnostic tools to 
enhance diagnostic yield. Further study is needed to determine other success factors. 
Keywords: nodules, bronchoscopy, navigation, Molecular
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P3.06-026 Gene Expression Signature to Predict Early Development of Brain 
Metastasis in Lung Adenocarcinoma Oscar Arrieta Rodriguez1, Alette Ortega 
Gomez2, Claudia Rangel3, Camilo Molina Romero1, Eleazar O. Macedo1, Jorge Negueb1, 
David Saavedra1, Alfredo Hidalgo4, Gabriela Mercado4, Rogelio Hernandez Pando5 
1Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina Personalizada, 
National Cancer Institute, Mexico City/Mexico, 2Medicina Traslacional, National Cancer 
Institute, Mexico City/Mexico, 3Genomica Computacional, Instituto Nacional de Medicina 
Genomica, Mexico City/Mexico, 4Instituto Nacional de Medicina Genomica, Mexico City/
Mexico, 5Patologia Experimental, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador 
Zubiran, Mexico City/Mexico
Background: Advances in systemic treatment have substantially improved the overall 
survival of advanced lung adenocarcinoma patients, and risk of brain metastases(BM) is 
higher. The survival of patients with symptomatic BM is poor. The identification of NSCLC 
patients with a high risk of developing BM would enable pre-emptive intervention to improve 
the outcome. Methods: A total of 53 biopsies of primary lung tumor adenocarcinoma 
stage IV treatment-naïve were analyzed for gene expression profiling using Affymetrix 
HuGene 1.0 ST and were processed in R using Bioconductor libraries. All patients were 
evaluated with brain MRI at diagnosis with a 3-month follow-up for BM development. 
Patients were classified into two groups: early-BM( < 6 months) and late-BM( > 6 months). 
A second independent cohort of 55 patients was analyzed to validate the gene expression 
signature (ClinicalTrials.gov: NCT00862173). Results: Samples were classified as early-
BM(17) and late-BM(6), the remainder 30 never developed BM. Significant changes 
in gene expression of about100 genes were found. Eleven highly significant genes 
(B-stat > 12) were associated with process of cell-migrationCNN3(down-reg.) and 
adhesionCDH10(up-reg); anti-apoptosisBAG1(up-reg); immunological evasionSSX2(up-
reg) and RAET1E(up-reg); signaling pathways related to RAS gene RAB9A(up-reg) 
and RAPGEF5(down-reg); mRNA-tRNA translocationDUS2L(up-reg); methylation 
controlNOC2L(up-reg); and members of the EGFR family EPGN(up-reg) and IGFR, 
IGF2BP1(up-reg). Conclusion: We describe an 11-gene signature that may predict the risk 
of BM which has the potential to classify patients and evaluate screening strategies that 
would facilitate pre-emptive interventional trials such as prophylactic cranial irradiation. 
Keywords: NSCLC, Expression Signature, brain metastases
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P3.06-027 Stage and Histology Specific Differences in Patterns of Recurrence 
in Early Stage and Locally Advanced Non-Small Cell Lung Cancer 
Hideaki Kojima, Yoshiyuki Yasuura, Hiroyuki Kayata, Reiko Shimizu, Tomohiro Maniwa, 
Shoji Takahashi, Mitsuhiro Isaka, Yasuhisa Ohde Division of Thoracic Surgery, Shizuoka 
Cancer Center, Shizuoka/Japan
Background: Various guidelines have proposed continuous surveillance for non-small 
cell lung cancer (NSCLC) after curative therapy. Yet the optimal postoperative surveillance 
strategy remains unclear. Methods: Patients who underwent complete resection for 
stage I-IIIA NSCLC were analyzed. Complete resection was defined as lobectomy and 
lobe-specific systematic nodal resection or more. We compared patterns of recurrence 
in patients with histology and early stage vs locally advanced NSCLC. Results: From 
2002 to 2010, 745 patients were identified. 106 of 625 patients (17%) with stage I-II 
NSCLC and 74 of 120 patients (62%) with stage IIIA NSCLC developed recurrences. Local 
recurrences were significantly frequent in stage IIIA patients (45 [61%] vs 29 [27%] for 
stage I-II patients), whereas distant recurrences were about the same frequency in stage 
I-II and IIIA patients (91 [86%] vs 64 [86%]). Approximately 90% of recurrences had 
occurred within 3 years after surgery and recurrence rate within first year was significantly 
higher in stage IIIA patients (51 [69%] vs 52 [49%] for stage I-II patients; p=0.008). 
Squamous cell carcinoma (SqCC) patients had tendency to relapse earlier than non-SqCC 
patients (Figure 1). In particular, all recurrences in stage IIIA-SqCC patients had occurred 
within first 2 years . Although the risk of recurrence in stage IIIA patients was highest in 
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death was monitored by assessing cell viability (by nigrosin staining), PARP cleavage 
(by Western blot), chromatin condensation and phosphatidylserine flip (by fluorescence 
microscopy). Results: Decreased proliferation was observed in the high (C4) but not 
the low RBM5 (T2) expressing subline, compared to either the parental GLC20 cells or 
the empty vector control subline. Increased cisplatin-mediated cell death, observed 
as PARP cleavage, was observed in both T2 and C4, compared to either the parental 
GLC20 cells or the empty vector control subline. Fluorescence microscopy results will be 
presented. Conclusion: These results suggest that the loss of RBM5 expression in SCLC 
cells leads to increased proliferation and survival of SCLC cells. We hope to demonstrate 
the potential role of RBM5 as a predictive marker for cisplatin sensitivity in SCLC. 
Keywords: small cell lung cancer, RBM5, apoptosis, biomarker
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P3.07-003 A Phase Ib/II Trial of Doxorubicin with Ganetespib, a Novel Hsp90 
Inhibitor, in Advanced Solid Tumors, with Dose Expansion in Small Cell Lung 
Cancer Deepa Subramaniam, Jillian Thompson, Jenna Kramer, Hongkun Wang, 
Giuseppe Giaccone Medical Oncology, Georgetown University, Washington/United States 
of America
Background: Relapsed/refractory small cell lung cancer (RR-SCLC) has a poor 
prognosis with median overall survival of only 2-3 months. Objective responses to single 
agent newer chemotherapy agents range from 14-29%. One of the key mechanisms for 
the development of acquired resistance of cancer cells to chemotherapy is the induction 
of a heat shock response. Over-expression of Hsp90 and its co-chaperones in tumor cells 
results in up-regulation of ATP-dependent transporters such as ABCG2 and RLIP76. Such 
transporters act as drug-efflux pumps for chemotherapeutic agents including doxorubicin, 
thus mediating drug resistance. Ganetespib, a next generation Hsp90 inhibitor devoid of 
liver and ocular toxicities that limit other agents in its class, is now in phase 3 evaluation 
in NSCLC. Targeting Hsp90, ganetespib affects multiple drug resistance pathways. 
We recently demonstrated in vitro and in vivo that the addition of ganetespib (G) to 
doxorubicin (D) can indeed overcome drug resistance (Lai et al., Oncogene 2014). The 
primary objective of this clinical study is to determine the maximum tolerated dose 
and the recommended Phase II dose (RP2D) of G + D in subjects with advanced solid 
tumors. The secondary objectives are to determine the dose limiting toxicities (DLTs) 
and to assess if there is preliminary evidence of activity for the combination of G + D 
in RR- SCLC by determining the objective response rate and response duration. We will 
also aim to establish conditionally reprogrammed cancer cell lines from tumor tissue in 
subjects with RR-SCLC to allow ex-vivo molecular characterization and drug sensitivity 
testing. Methods: The dose escalation phase will follow a standard 3+3 dose escalation 
scheme with 2 dose levels of G administered weekly on Days 1, 8 of a 21-day cycle, in 
combination with fixed dose D at 50 mg/m2 on Day 1. After 4-6 cycles of the combination, 
continuation of single agent G is permitted in patients deriving clinical benefit. The RP2D 
determined at the end of the dose escalation phase will be used to conduct a dose 
expansion study in subjects with RR-SCLC. Key inclusion criteria are refractory solid 
tumors (in dose escalation phase) and RR-SCLC (in dose expansion phase), age >18 
years, ECOG PS 0-1, adequate organ/marrow function. Key exclusion criteria include 
LVEF < 50%, lifetime cumulative doxorubicin dose >150 mg/m2, untreated, symptomatic 
brain metastases, serious cardiac illness, QTc >470 msec, strong inhibitors or inducers 
of CYP 3A4 or 2C19. DLTs are defined as grade 4 hematologic toxicities or > grade 3 non-
hematologic toxicities including hypersensitivity reactions despite pre-medication and 
nausea, vomiting and diarrhea despite maximal medical therapy. Response assessment 
will be done using RECIST 1.1. Results: Clinical Trial Status: A total of 6 subjects 
have been enrolled thus far. With no DLTs observed in 5 subjects who have crossed 
the DLT evaluation period, the trial continues enrollment. Conclusion: Not applicable 
Keywords: small cell lung cancer, Hsp-90 inhibitor, ganetespib, chemoresistance
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P3.07-004 Clinical Impact of Post-Progression Survival for Overall Survival 
in Patients with Sensitive Relapse of Small Cell Lung Cancer Yosuke Miura1, 
Hisao Imai1, Reiko Yoshino2, Sakae Fujimoto1, Kyoichi Kaira3, Noriaki Sunaga4, Yoshio 
Tomizawa2, Koichi Minato1, Takeshi Hisada5, Ryusei Saito2, Masanobu Yamada5 
1Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota/
Japan, 2Department of Respiratory Medicine, National Hospital Organization Nishigunma 
National Hospital, Shibukawa/Japan, 3Oncology Clinical Development, Gunma University 
Graduate School of Medicine, Maebashi/Japan, 4Oncology Center, Gunma University 
Hospital, Maebashi/Japan, 5Department of Medicine and Molecular Science, Gunma 
University Graduate School of Medicine, Maebashi/Japan
Background: The effect of second-line chemotherapy on overall survival (OS) 
might be confounded by subsequent therapies in patients with sensitive relapse of 
small cell lung cancer (SCLC). But there is no research in this viewpoint. Therefore, 
we aimed to determine the relationships between progression-free survival (PFS), 
post-progression survival (PPS) and OS after second-line chemotherapy in this 
population. Methods: Between January 1999 and November 2013, seventy-seven 
patients with sensitive relapse of SCLC who had received second-line chemotherapy 
following first-line platinum doublet chemotherapy were analyzed. We retrospectively 
collected individual data at Gunma Prefectural Cancer Center and National Hospital 
Organization Nishigunma National Hospital from medical records, and evaluated patient 
characteristics, treatment data, tumor shrinkage, PFS, PPS and OS. Results: The 
median follow-up time was 13.1 months (range 2.3-80.8 months). The response rate, 
the disease control rate, median PFS and median OS were 58.4%, 93.5%, 5.1 months 
and 13.7 months, respectively. The relationships of PFS, PPS and tumor shrinkage with 
 
Conclusion: In patients with completely resected stage IIIA(N2) pulmonary 
adenocarcinomas, ECE, cN2 and KRAS mutations were independent high risk 
factors for BM as the initial failure in 3 years. The EGFR 19 exon mutation may 
be a protective factor of BM. The new lung adenocarcinoma classification and 
tumor microenvironment were not statistically significant factors in our series. 
Keywords: EGFR, KRAS, pulmonary adenocarcinomas, brain metastases
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P3.07-001 Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Small-
Cell Lung Cancer (SCLC): A Single Center Experience Birgitta I. Hiddinga1, Karen 
Zwaenepoel2, Christian Rolfo3, Patrick Pauwels2, Jan P. Van Meerbeeck1 1Thoracic 
Oncology, Antwerp University Hospital, Edegem - Antwerp/Belgium, 2Pathology, Antwerp 
University Hospital, Edegem - Antwerp/Belgium, 3Phase I Unit Medical Oncology, Antwerp 
University Hospital, Edegem - Antwerp/Belgium
Background: In small-cell lung cancer little is known about harboring an ALK translocation 
[1, 2]. The aim of this study was to investigate the prevalence of ALK expression and 
rearrangement in patients with SCLC. Methods: In this retrospective series, archival 
tissue from 17 treatment naïve patients with SCLC and neuroendocrine tumors was 
analyzed to detect ALK expression by immunohistochemistry (IHC) in all samples. Cut-off 
value for positivity was similar as in non-small-cell lung cancer (NSCLC): focally strong 
staining of the tumor cells Fluorescent in-situ hybridization (FISH) with Vysis LSI ALK probe 
was performed in the IHC positive cases [3]. The ALK FISH positive cases were submitted 
for exome sequencing (NGS) (Illumina MiseQ). Results: Of the 17 patients 9 were male 
and 8 female. Of these 17 patients 12 had a SCLC, 3 a neuroendocrine tumor, and 2 a 
neuroendocrine carcinoma. Three specimens could not be analyzed. Six of 17 specimens 
were ALK IHC positive, of which one neuroendocrine tumor, one neuroendocrine carcinoma 
and 4 of the SCLC. Conclusion: The IHC expression of ALK suggests a possible role of ALK-
TKI in the treatment of SCLC. Mature FISH and NGS data will be presented at the meeting. 
Keywords: small-cell lung carcinoma, neuroendocrine carcinoma, ALK IHC, ALK FISH
POSTER SESSION/ SMALL CELL LUNG CANCER 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.07-002 RBM5 Expression Correlates with Decreased Proliferation 
and Increased Cisplatin-Mediated Apoptosis Justin Roy1, Sarah Hunt1, Leslie 
Sutherland2 1Chemistry and Biochemistry, Laurentian University, Sudbury/ON/
Canada, 2Advanced Medical Reseach Institute of Canada, Sudbury/ON/Canada
Background: Lung cancer is the leading cause of cancer-related deaths in 
Canada, for both men and women. Small cell lung cancer (SCLC) is one subtype 
of lung cancer, and accounts for 15-20% of lung cancer incidence. SCLC is 
an aggressive cancer and commonly develops resistance to drugs used to 
treat it, including platinum-based agents such as cisplatin. RBM5 is a lung 
cancer tumour suppressor gene that is generally downregulated in lung cancer, and deleted 
in some. RBM5 is an RNA-binding protein that has the ability to regulate the cell cycle and 
modulate apoptosis. We hypothesize that reintroduction of RBM5 into an RBM5-null SCLC 
cell will result in decreased cell proliferation and increased apoptotic-like cell death in the 
presence of cisplatin. Methods: A SCLC cell line with an endogenous RBM5 homozygous 
deletion, and two previously established stable GLC20 sublines (T2 and C4) that express 
different levels of RBM5, were used for in vitro mechanistic studies. Proliferation changes 
were monitored using an MTT assay and a cell counting assay. Cisplatin-induced cell 
S742 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
a poor prognosis with response rates (ORR) of 5-20%, progression-free survival (PFS) 
of 2-4 months and overall survival of 6-10 months. Topotecan is the standard therapy 
for these patients. Methods: Open label study, 132 patients, (1:1 randomization) to 
receive either aldoxorubicin (230 mg/m2, IV infusion, Day 1, every 3 weeks) or topotecan 
(either 1.5 mg/m2/day IV, Days 1-5, every 3 weeks or 4 mg/m2 IV infusion on Days 
1, 8, and 15 every 28 days). Key inclusions: confirmed SCLC, relapsed or refractory 
to ≥ 1 prior chemo, ECOG 0-2, measurable tumor (RECIST 1.1). Key exclusions: 
>375 mg/m2 prior doxorubicin, prior topotecan, active CNS mets, lab abnormalities 
(ANC <1500/mm3, platelets <100,000/mm3, Hgb <9 gm/dL, LFTs > 3 or 5x ULN), 
serious myocardial dysfunction, anion gap >16 meq/L or arterial blood pH < 7.30. 
Key stratifications: relapse < 90 days versus > 90 days; ECOG 0-1 versus 2. Primary 
endpoint: PFS (analysis after 110 events); assume PFS for topotecan = 3.5 months, 
aldoxorubicin = 6.5 months. Secondary endpoints: OS (analysis after 110 deaths; 
assumes OS for topotecan = 6 months, aldoxorubicin = 8 months), ORR, disease control 
rate, adverse events, tolerability, lab abnormalities. Study sites: Up to 40 sites in the 
US, Hungary, Spain, and Italy.  Results: Not applicable. Conclusion: Not applicable. 
Keywords: SCLC, small cell lung cancer, Aldoxorubicin
POSTER SESSION/ SMALL CELL LUNG CANCER 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.07-007 Clinical Effect Observation of Compound Kushen Injection 
Combined with EP Regimen Chemotherapy for Small Cell Lung Cancer (SCLC) 
Feng S. Yun1, Zhang Yao2, Li C. Yuan1 1Thoracic Surgery, Second Part of the First Affiliated 
Hospital of Jilin University, Changchun/China, 2Thoracic Surgery, The First Affiliated Hospital 
of Jilin University, Changchun/China
Background: To observe the clinical efficacy of Compound Kushen Injection combined with 
EP regimen chemotherapy for the treatment of small cell lung cancer SCLC). Methods: 98 
cases of small cell lung cancer patients were chosen and randomly divided into 
experimental group and control group. 49 patients in experimental group were treatment 
with Compound Kushen Injection combined with EP regimen chemotherapy. 49 patients 
in control group received EP regimen chemotherapy alone. Both groups were repeated 
every 4 weeks and 3 cycles. All patients completed efficacy evaluation after treatment 3 
cycles. Results: There was no significant difference in short-term effect between the two 
groups( P＞0.05). The gastrointestinal reactions(represented as vomiting, anepithymia and 
diarrhea) and bone marrow depression(the toxicity on hemoglobin, leukocyte and 
platelet) in experimental group were alleviated compared with those in control 
group. There was significant difference between the two groups (P＜0.05). The median 
survival time was 462d in experimental group while 268d in control group( P＜0.05). 
KPS score after chemotherapy in all experiment groups was significantly higher than 
that in control group( P＜0.05). Conclusion: Compound Kushen Injection combine with 
EP regimen chemotherapy shows precise therapeutic effect on SCLC, reducing adverse 
drug reactions, increasing median survival time and improving the life quality of patients. 
Keywords: Compound Kushen Injection, chemotherapy, SCLC, EP
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P3.07-008 Phase Ib/II Study of Pembrolizumab plus Chemotherapy in 
Advanced Cancer: Results of Lung Cancer Patients Receiving ≥ 1 Prior Line of 
Therapy Glen J. Weiss, Heather Barndt, Lisa Blaydorn, Ashish Sangal, Vivek Khemka 
Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear/AZ/
United States of America
Background: Pembrolizumab (pembro) is a selective anti-PD-1 antibody that blocks the 
interaction between programmed death-1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumor 
cells. We report safety and clinical activity of pembro combined with chemotherapy in 
patients with advanced small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC) progressing after ≥ 1 line of chemotherapy (NCT02331251). Methods: Patients 
were treated with pembro 2 mg/kg on day 1 every 21 days with either irinotecan on day 
1 every 21 days or gemcitabine with or without vinorelbine on days 1 and 8 every 21 
days until progression or toxicity. Eligibility included at least 1 measurable tumor lesion, 
Karnofsky Performance Status (KPS) of 70-100%, and adequate organ function. Tumors 
were assessed every 3 cycles using RECIST 1.1 and immune-related response criteria 
(irRC) and unconfirmed best overall response (BOR) was evaluated. Results: Eight lung 
cancer patients have been enrolled at the time of submission. Median age was 52.5 
(range 33-74) and median KPS was 80%. Histology was adenocarcinoma (62.5%), 
including one with an EGFR T790M mutation and three SCLC (37.5%). One SCLC patient 
is on pembro plus gemcitabine 1,000 mg/m2, one NSCLC patient is on gemcitabine 
1,000 mg/m2 and vinorelbine 25 mg/m2, and the remaining six patients were treated 
with irinotecan 250-300 mg/m2. Two NSCLC had prior exposure to nivolumab for ≥ 2 
months. The maximum tolerated dose (MTD) was exceeded for irinotecan 300 mg/m2, 
and subsequently all patients receiving irinotecan are currently dosed at 250 mg/m2. 
Any grade drug-related treatment adverse events (AEs) occurred in 88% of patients; the 
most common (n>1) were skin rash, fatigue, diarrhea, anorexia, and extremity edema. 
No infusion-related reactions were observed. Dose limiting toxicities (DLTs) with pembro 
plus irinotecan were fatigue and nausea/vomiting. DLT with gemcitabine and vinorelbine 
was hypoxia. No grade 3 AEs were observed thus far with pembro plus gemcitabine. Five 
patients are currently evaluable for BOR. Two of two SCLC on pembro plus irinotecan 
have partial response as BOR and continue on study. One NSCLC patient on pembro 
plus gemcitabine and vinorelbine had stable disease, and two NSCLC patients had PD 
as BOR. Conclusion: In patients with previously treated SCLC and NSCLC, pembro 
plus chemotherapy appears to be safe to administer with a toxicity profile similar to 
the individual components of the regimen utilized. Establishment of the recommended 
phase 2 dose is ongoing for these treatment arms. Since the median follow-up is ~2 
OS were analyzed at the individual level. Spearman rank correlation analysis and linear 
regression analysis showed that PPS was strongly correlated with OS (r = 0.91, p < 
0.01, R 2= 0.96), PFS was moderately correlated with OS (r = 0.58, p < 0.01, R2 = 0.28), 
and tumor shrinkage was weakly correlated with OS (r = 0.34, p < 0.01, R2 = 0.12). Using 
multivariate Cox proportional hazards model with a stepwise regression procedure to 
explore prognostic factors for PPS, the number of regimens after progression beyond 
second-line chemotherapy and performance status (PS) at the beginning of third-line 
treatment were both significantly associated with PPS (p < 0.01). Conclusion: PPS 
has more impact for OS than PFS in patients with sensitive relapse of SCLC. Moreover, 
this study suggests that subsequent treatment and PS after disease progression 
following second-line chemotherapy may be important factors that influence OS. 
Keywords: sensitive relapse, post-progression survival, retrospective analysis, small 
cell lung cancer
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P3.07-005 Maintenance Irinotecan Therapy in Extensive Disease Small Cell 
Lung Cancer: A Feasibility Study Shoichiro Yamamoto1, Shigeki Umemura2, Yukio 
Hosomi3, Atsushi Horiike4, Noboru Yamamoto5, Hiroyasu Kaneda6, Takashi Seto7, Shogo 
Nomura8, Naoyuki Nogami1, Koichi Goto2, Tomohide Tamura5, Yuichiro Ohe5 
1Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama/
Japan, 2Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa/
Japan, 3Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan 
Cancer and Infectious Diseases Center Komagome Hospital, Tokyo/Japan, 4Department of 
Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer 
Research, Tokyo/Japan, 5Department of Thoracic Oncology, National Cancer Center 
Hospital, Tokyo/Japan, 6Department of Medical Oncology, Kinki University Faculty of 
Medicine, Osaka-Sayama/Japan, 7Department of Thoracic Oncology, National Kyushu Cancer 
Center, Fukuoka/Japan,8Center for Research Administration and Support, National Cancer 
Center, Tokyo/Japan
Background: We performed a feasibility study of maintenance irinotecan therapy in 
patients with extensive disease small cell lung cancer (ED-SCLC) who responded to the 
induction irinotecan plus cisplatin (IP) therapy. Methods: The eligibility criteria included 
pts with ED-SCLC who responded to four cycles of induction IP therapy, ECOG 
performance status (PS) of 0 to 1, age of 20 to 70 years and adequate organ functions. 
Pts received irinotecan monotherapy at 60 mg/m2 on days 1, 8 and 15 of a 28-day 
cycles until disease progression. The primary endpoint was the proportion of treatment 
success (TS) at 6 months. Using a binomial design, a lower activity level (p0) of 0.25 and 
a target activity level (p1) of 0.50, the preplanned accrual of 28 patients was sufficient 
(alpha, 0.10 and power, 0.90). Results: Between August 2012 and August 2013, 22 pts 
were enrolled. However, accrual was discontinued because of the three grade 3 
pneumonitis events (3 of 22 patients, 13.6%). Patient characteristics of the 22 eligible 
pts were as follows; the median age was 65 (54-70) years; 12 pts had a PS of 0, and 16 
pts were male. The median number of cycles delivered was four (range, 1–31). Four of 22 
(18.2%) patients achieved TS at 6 months. Median progression free survival and overall 
survival from the start of the maintenance irinotecan therapy were 3.2 months and 15.9 
months, respectively. Grade ≥3 toxicities included neutropenia (4.5%), hyponatremia 
(4.5%), pneumonitis (13.6%) and cholangitis (4.5%). No treatment-related deaths 
occurred.
 
Conclusion: This trial was early terminated due to the unexpected toxicity, 
but maintenance irinotecan therapy was still active for a subset of ED-SCLC. 
Keywords: irinotecan, maintenance, pneumonitis, small cell lung cancer
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P3.07-006 Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/
Refractory Small Cell Lung Cancer Shanta Chawla1, Scott Wieland2 1Cytrx 
Corporation, Los Angeles/United States of America, 2Cytrx Corporation, Los Angeles/CA/
United States of America
Background: Aldoxorubicin is a novel prodrug that binds to albumin in the circulation. 
Doxorubicin is cleaved in low pH environments, allowing administration of 3.5-4-fold 
higher doses than standard doxorubicin and 10-fold greater cumulative doses. Patients 
with metastatic small cell lung cancer (SCLC) who have failed prior chemotherapies have 
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prolongation of survival and Quality of Life benefits in Relapsed Small Cell Lung Cancer. 
Keywords: Metronomic chemotherapy, Recurrent, SCLC
POSTER SESSION/ SMALL CELL LUNG CANCER 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.07-011 Profilattic Cranial Irradiation (PCI) Following Toracic CHT-RT for 
Small Cell Lung Cancer: Retrospective Analysis of 182 Consecutive Patients 
Alessio Bruni1, Vieri Scotti2, Gabriele Simontacchi2, Katia Ferrari3, Biancaluisa 
Lanfranchi1, Laura Rubino1, Daniele Scartoni2, Ilaria Furfaro2, Carla De Luca Cardillo2, 
Filippo Bertoni1 1Radiotherapy Unit, -Aou Policlinico of Modena, Modena/Italy, 2Oncology 
Department-Radiation Oncology Unit, Aou Careggi, Florence/Italy, 3Pneumology Unit, Aou 
Careggi, Florence/Italy
Background: The role of PCI in the management of Small Cell Lung Cancer (SCLC) pts is 
still debated. Several studies showed its effectiveness in terms of progression (PFS) and 
metastasis free survival (MFS), but advantages for overall survival (OS) are not always 
reported. The aim of our analysis is to retrospectively evaluate the current clinical impact 
of PCI in patients affected by SCLC. Methods: From April 1989 to May 2014 a total of 182 
pts with SCLC underwent radical concomitant or sequential CHT-RT on thoracic disease 
+/- PCI in two different Italian Institutions. Thirty-eight pts were female, while 144 were 
male. Mean and median age were respectively 62.6 (range 38-86) and 63 years. Only 5 pts 
had “extended disease”, while the other 177 had T1-T4 N0-N2 limited stage SCLC. Seven 
pts underwent surgery followed by adjuvant CHT-RT on mediastinal nodes while 8 pts 
didn’t received any RT for primary disease; the remaining 167 pts received concomitant/
sequential CHT-RT with radical intent. After receiving CHT or CHT-RT for thoracic disease, 
66/182 pts received PCI, while 118/182 pts underwent regular clinical/radiological follow 
up. Most of patients were routinary followed in out-patient clinic every three months and 
they were also submitted to neurocognitive questionnaires. All PCIs were planned using 
opposite lateral fields with 2D technique or virtual off-line simulation; all pts received 
25-30 Gy in 10 fractions within two weeks. Three- and 5-year OS,PFS and Brain mts 
free survival (BrMFS) were analyzed; univariate and multivariate analysis (using Kaplan 
Meier and Cox Regression tests) were performed due to identify patient, tumor and/or 
treatment related prognostic factors Results: : We retrospectively analyzed our cohort 
of patients using Kaplan Meier curves for survival and Cox regression tests for univariate 
and multivariate analysis. At a mean follow up of 32 months, no difference in terms of 
OS, PFS and brMFS was found comparing population referring to the 2 different centers. 
In the analyzed population 3- and 5-year OS were respectively 28.2 and 18.4%, while 
PFS were 22.4 and 18.9 respectively. Finally 3- and 5-year BrMFS were 56.3 and 50.2%. 
By multivariate analysis PCI and clinical response to primary thoracic treatment remain 
as independent variables being protective in terms of OS, PFS and BrMFS. Concomitant 
CHT-RT and RT on thoracic disease are positive factors just for PFS (respectively with 
p<0.014 and p<0.025). No G3 or G4 acute/late toxicities were found. Conclusion: PCI 
after primary thoracic CHT-RT with radical intent was confirmed as a “treatment-key” 
in the management of SCLC having also an optimal toxicity profile. Our data confirmed 
that PCI will be encouraged in all fit patients due to its potential benefit in terms of OS, 
PFS and BrMFS. Pts with Limited Stage SCLC having experienced a good response to 
primary CHT-RT treatment on thoracic disease seems to be the optimal candidate to PCI. 
Keywords: PCI, SCLC, concomitant CHT-RT, toxicity
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P3.07-012 Hiperfracctioned Radiochemotherapy in Small Cell Lung Cancer, a 
Monoinstutional Experience Begoña Taboada Valladares1, Patricia Calvo Crespo2, 
Antonio Gomez Caamaño2, Martin Lazaro Quintela3 1Radiation Oncology, Clinic 
University Hospital of Santiago de Compostela, Santiago de Compostela/Spain, 2Radiation 
Oncology, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela/
Spain, 3Medical Oncology, University Hospital of Figo, Figo/Spain
Background: To evaluate our experience in radical radiochemotherapy (RCT) twice 
daily in limited disease small cell lung cancer (SCLC) in term of effectiveness and 
toxicity. Methods: A retrospective review was performed to determine the local 
recurrence and survival rates for patients with SCLC localized disease undergoing RCT 
according Turrisi regimen between October 2004 and August 2014. All patients were 
treated with 3DRT, with a median dose of 45 Gy (150cGy twice daily), combined with 
chemotherapy based in cisplatinum-VP16. 73% received preventive cranial irradiation 
(ICP). 22% of patients underwent induction QT based in platinum-VP16. The primary 
objective was overall survival (OS); secondary objectives were progression free survival 
(PFS), local progression free survival (LPFS) and toxicity. OS was analized with Kaplan-
Meier test. Results: 44 elegible patients were recruited (82% male, median age 62, with 
good performance status). The clinical stage was 89% E.III and 11% E.II. At a median follow-
up of 18 months, the median OS was 21 months (95%CI: 16.3-25.4) and median PFS was 
12.6 months (95%CI: 10.2-15). OS at 2 and 5 years were 38.6% and 24.8% respectively. 
LPFS was 14 months (95%CI: 10.5 -17.6) and systemic progression free survival was 14.2 
(95%CI:10.1-18.2). During the RCT we reported anaemia (2%G3), neutropenia (7%G3, 
16%G4), esophagitis (2%G3), dyspnea (2%G2), pneumonitis (7%G2). Induction QT did 
not improve the OS and PFS. Conclusion: In our experience radical radiochemotherapy 
twice daily is a feasible treatment option for small cell lung cancer, showing long-term 
survival with no inferiority results compared with the published and acceptable toxicities. 
Keywords: SCLC, toxicity, HIPERFRACTIONATED
months, updated results including any new lung cancer patients enrolled, median 
progression-free survival (PFS), and overall survival will be presented at the WCLC. 
Keywords: Immunotherapy, chemotherapy, lung cancer, phase i
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P3.07-009 The Retrospective Analysis of Nab-Paclitaxel Regimens for 
Relapsed Small Cell Lung Cancer Patients Yujiro Naito1, Akihiro Tamiya1, Motohiro 
Tamiya2, Kyoichi Okishio3, Masaki Kanazu1, Sayoko Tokura1, Naoki Omachi1, Nobuhiko 
Saijo1, Yohei Kimura1, Hidekazu Suzuki2, Norio Okamoto2, Naoko Morisita2, Takayuki 
Shiroyama2, Masanari Hamaguchi2, Tomonori Hirashima2, Shinji Atagi3 1Department 
of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 
Osaka/Japan, 2Department of Thoracic Malignancy, Osaka Prefectural Medical Center for 
Respiratory and Allergic Diseases, Osaka/Japan,3Department of Thoracic Oncology, National 
Hospital Organization Kinki-Chuo Chest Medical Center, Osaka/Japan
Background: Although small cell lung cancer (SCLC) is initially chemo sensitive, most 
patients rapidly relapse. Prognosis of late line treatment for relapsed SCLC patients is 
generally poor. The efficacy of paclitaxel regimens for relapsed SCLC patients has been 
reported in some articles. But no specific study has been reported to our knowledge, 
about nab-paclitaxel administration for relapsed SCLC patients. Methods: By using the 
database of two hospitals, we underwent a retrospective analysis to evaluate the efficacy 
and safety of nab-paclitaxel regimens for relapsed SCLC patients. The data of patient 
characteristics, treatment efficacy and adverse events were collected from the medical 
records. Results: Fourteen patients (3 women and 11 men) with relapsed SCLC were 
administered weekly nab-paclitaxel or carboplatin plus nab-paclitaxel between February 
2013 and July 2014 in our hospitals. The median age was 71 years old. Eight patients had 
comorbid pulmonary disease (5 had interstitial lung disease, 2 had chronic obstructive 
pulmonary disease, and 1 had both diseases). Five patients were administered nab-
paclitaxel regimen as second line chemotherapy, five patients were as third line and four 
patients were as fourth or fifth line. Five patients achieved partial response, and four 
patients had stable disease. The response rate was 36%, and disease control rate was 
64%. Most common toxicities were hematological adverse events such as neutrophil count 
and anemia. Severe neutropenia (Grade 3 or 4) appeared to some patients, but all patients 
were restored by treatment. The main non-hematologic adverse events were neurotoxicity 
and constipation, and these events were mild. Conclusion: The administration of 
nab-paclitaxel regimens to highly treated patients with relapsed SCLC demonstrated 
modest response rate and disease control rate. All adverse events were manageable, 
so that nab-paclitaxel regimens were well tolerated. Further clinical trial to evaluate the 
efficacy and safety of nab-paclitaxel regimens for relapsed SCLC patients is warranted. 
Keywords: nab-paclitaxel, small cell lung cancer
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P3.07-010 Phase II Trial of metronomic Temozolomide and Topotecan in 
patients with relapsed and/or refractory Small Cell Lung Cancer. Gouri Shankar 
Bhattacharyya1, Purvish M. Parikh2, Ghanashyam Biswas3, Shailesh A. Bondarde4, 
Hemant Malhotra5, Amish Vora6, K Govindbabu7, Anantbhushan A.B. Ranade8 
1Medical Oncology, Fortis Hospital, Kolkata/India, 2Icon-Aro, Mumbai/India, 3Sparsh Hospital 
and Critical Care, Bhubaneshwar/India, 4Shatabdi Super Specialty Hospital, Nashik/
India, 5Medical Oncology, Sms Medical College Hospital, Jaipur/India, 6Max Healthcare, 
Gurgaon/India, 7Kidwai Memorial Institute of Oncology, Bangalore/India, 8Deenanath 
Mangeshkar Hospital, Pune/India
Background: The prognosis of recurrent or refractory small cell carcinoma of lung is 
poor with conventional therapies; one of the issues is the presence of brain metastasis. 
Topotecan is a topo-isomerase inhibitor with very good penetration to CNS system. 
The efficacy of topotecan in metronomic doses over a period of time is extremely well 
tolerated and effective. Topotecan is an approved drug for recurrent or refractory small 
cell carcinoma of lung. Temozolomide in metronomic dosing or in repeated small dosing 
can be an effective alternative to conventional dosing without the side-effects and has 
been shown to be effective in Neuro-endocrine tumors and Small Cell Carcinoma of 
Lung shows neuro-endocrine differentiation as well as the presence of unmethylated 
MGMT. Methods: This is a two arm Open Label Single Institute Phase II Study reviewed 
and approved by Institutional Review Board. Written Informed Consent was obtained from 
all patients. The study was conducted to find the safety and efficacy of this regime. All 
patients had recurrent small cell lung cancer that was sensitive or refractory to first 
line platinum therapy. Patients with brain mets were eligible. All patients had to have 
minimal functional reserves; had to be greater than the age of 18 years; Karnofsky 
scale > 60. Response evaluation by RECIST criteria Version 1.1 was used. Patients were 
treated with Topotecan 1mg per day along with Temozolomide 20mg in morning and in 
the evening, no food allowed 1hr before and 1hr after. The comparator arm was oral 
topotecan at standard dosage of 2.3mg/m2 in Day 1 to Day 5. Patients were evaluated 
for toxicity every 3 weeks and for efficacy after every 12 weeks. There were 21 patients 
in each arm. Palliative medication and Best Supportive Care was offered to both the 
groups. Results: In the experimental arm vs comparator arm, response rate was as 
follows: · Complete response – 9.5% vs 0% · Partial response – 33.3% vs 23.8% · Stable 
disease in – 38.1% vs 28.6% Median Survival time was 38 weeks vs 25.9 weeks in the Intent 
to Treat population arm. (Log rank P=0.0104). Quality of Life had slower deterioration 
in patients with metronomic chemotherapy. Principal toxicities seen were mainly 
hematological toxicity in the standard arm 33% vs 4%; Grade IV thrombocytopenia in 7% 
vs 4%; Grade III/IV anemia in 25% vs 10%; Infection Grade III/IV in 16% vs 6%; Vomiting 
6% vs 1%; Diarrhea 6% vs 0%; Dyspnea 9% vs 4%. Pain 6% vs 4%; Toxic death occurred 
in 6% in comparator arm. Conclusion: Metronomic Chemotherapy is associated with 
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P3.07-015 Final Report of Phase I/II Study of Induction Carboplatin and 
Irinotecan Followed by TRT for Elderly Patients with LD-SCLC: TORG 0604 
Terufumi Kato1, Yuki Misumi2, Hiroaki Okamoto3, Katsuhiko Naoki4, Yukio Hosomi5, 
Noriyuki Masuda6, Koichi Minato7, Takuma Yokoyama8, Kazuma Kishi9, Masanori 
Nishikawa10, Fumihiro Oshita11, Nobuhiko Seki12, Isao Goto13, Koshiro Watanabe14 
1Kanagawa Cardiovascular and Respiratory Center, Yokohama/Japan, 2Department of 
Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizens Hospital, 
Yokohama/Japan, 3Department of Palliative Medicine, Yokohama Municipal Citizen’S Hospital, 
Yokohama-Shi/Japan, 4Pulmonary Medicine, Keio University School of Medicine, Tokyo/
Japan, 5Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan 
Cancer and Infectious Diseases Center Komagome Hospital, Tokyo/Japan, 6Dept. of 
Respiratory Medicine, Kitasato University School of Medicine, Kanagawa/Japan, 7Department 
of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma/Japan, 8Kyorin University 
Hospital, Mitaka/Japan, 9Department of Respiratory Medicine, Respiratory Center,, 
Toranomon Hospital, Tokyo/Japan, 10Department of Respiratory Medicine, Fujisawa City 
Hospital, Fujisawa/Japan, 11Department of Thoracic Oncology, Kanagawa Cancer Center, 
Yokohama/Japan, 12Dept. of Medical Oncology, Teikyo University School of Medicine, Tokyo/
Japan, 13Division of Internal Medicine（Ⅰ）, Osaka Medical College Hospital, Takatsuki/
Japan, 14Thoracic Oncology Research Group, Yokohama/Japan
Background: In elderly patients with LD-SCLC, the role of irinotecan has been unclear 
and the timing of TRT combined with chemo-therapy has not been fully evaluated. 
Furthermore, no standard treatment has been established for them. We report a phase I/
II trial of induction chemotherapy of carboplatin and irinotecan followed by sequential TRT 
in this population. Methods: Patients with untreated, measurable LD-SCLC >70 years 
with performance status (PS) 0 to 2 and adequate organ function were eligible. Treatment 
consisted of induction with carboplatin on day 1 and irinotecan on days 1 and 8 every 
21 days for four cycles. TRT of 54Gy in 27 fractions was then administered sequentially. 
Carboplatin dose was escalated from AUC of 4 to 5 (Levels 1 and 2, respectively) with 
a fixed dose of irinotecan at 50 mg/m2. The primary objective of the phase II portion 
was evaluation of efficacy. Results: A total of 41 patients were enrolled [median age 75 
years, range 70-86 years; 31 male, 10 female; PS 0/1/2: 22/18/1]. At Level 1 (n=6), 
one patient experienced dose-limiting toxicity (DLT) as Grade 3 hypertension. At Level 
2 (n=6), two patients experienced DLT as Grade 4 thrombocytopenia. Therefore, level 
1 was chosen as the recommended dose. The phase II trial was then expanded by 35 
patients in the level 1 based on the Simon minimax design. In all cohorts, the median 
chemotherapy cycle was 4 (1/2/3/4 courses administered as 4/2/2/33); median 
radiation dose was 54Gy (range 36-60). Toxicities were generally mild, as expected. 
Gr 3/4 leukopenia and thrombocytopenia were both observed in six (15%) patients. No 
Gr 3/4 diarrhea or esophagitis was noted. Although Gr 3 febrile neutropenia and Gr 3 
pneumonitis were seen in two patients each, no treatment-related deaths occurred. There 
were five complete responses and 32 partial responses, for a response rate of 90%. With 
median follow-up of 80.4 months (n=41), median progression-free and overall survival 
times were 11.2 and 27.1 months, respectively. Conclusion: Induction chemotherapy 
with carboplatin plus irinotecan followed by sequential TRT was well tolerated and highly 
effective in elderly patients with LD-SCLC. Further confirmatory studies are warranted. 
Keywords: TORG, irinotecan, Limited Stage Small Cell Lung Cancer, thoracic radiotherapy
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P3.07-016 Survival of Patients with N3 Lymph Node Disease in a Cohort 
with Limited Disease Small-Cell Lung Cancer Receiving Concurrent 
Chemoradiotherapy Christine D. Valan1, Tarje O. Halvorsen1, Nina Levin2, Roy 
M. Bremnes3, Paal F. Brunsvig4, Øystein Fløtten5, Odd Terje Brustugun6, Stein H. 
Sundstrøm2, Bjørn H. Grønberg1 1The European Palliative Care Research Centre and the 
Cancer Clinic, Norwegian University of Science and Technology and St. Olavs Hospital - 
Trondheim University Hospital, Trondheim/Norway, 2The Cancer Clinic, St. Olavs Hospital 
- Trondheim University Hospital, Trondheim/Norway, 3Department of Oncology, University 
Hospital of North Norway and the Arctic University of Norway, Tromsoe/Norway, 4Dept 
of Oncology, Oslo University Hospital - Radiumhospitalet, Oslo/Norway, 5Department 
of Pulmonology, Haukeland University Hospital and University of Bergen, Bergen/
Norway, 6Department of Oncology, Oslo University Hosital,The Norwegian Radium Hospital, 
Oslo/Norwa, Oslo/Norway
Background: Treatment of small-cell lung cancer depends on the extent of disease. 
Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended if all lesions 
can be included in a radiotherapy field (limited disease – “LD”), while patients with more 
advanced disease (extensive disease – “ED”) receive chemotherapy alone. LD is defined 
as confined to one hemithorax, but some have excluded patients with contralateral 
hilar and supraclavicular lymph node metastases (LNM). When the latest revision of 
TNM was published, it was recommended that N3-disease should be considered as 
LD with the possible exception of supraclavicular LNM – and that TNM-stage should 
be reported in clinical trials of LD SCLC to further explore this. We assessed extent 
of disease according to TNM v7 in patients from a randomized phase II trial comparing 
two schedules of TRT in LD SCLC (n=157) and investigated whether N3-disease was a 
negative prognostic factor; and whether there were survival-differences between the 
different N3-subcategories. Methods: Patients received four courses of cisplatin plus 
etoposide and were randomized to receive concurrent thoracic radiotherapy of either 
45 Gy/30 fractions (twice-daily) or 42 Gy/15 fractions (once daily). Responders were 
offered prophylactic cranial irradiation of 30 Gy/15 fractions. Extent of disease was 
assessed from CT scans obtained three weeks before chemotherapy commenced. 
N3-disease was categorized according to contralateral supraclavicular, ipsilateral 
supraclavicular, contralateral hilar and contralateral mediastinal LNM. Weight loss was 
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P3.07-013 A Retrospective Analysis of Adjuvant Chemotherapy in Patients with 
Completely Resected SCLC Yosuke Tamura, Yasuhito Fujisaka, Takahito Nakamura, 
Hiroyuki Tsuji, Ninso Matsunaga, Tetsufumi Kawaguchi, Masashi Imanishi, Syuhei 
Yoshida, Keiji Miyoshi, Soichiro Ikeda, Isao Goto, Toshiaki Hanafusa Division of Internal 
Medicine（Ⅰ）, Osaka Medical College Hospital, Takatsuki/Japan
Background: Several clinical studies have demonstrated the efficacy and safety of the 
adjuvant chemotherapy for patients with small cell lung cancer (SCLC) , particularly in 
patients with stage Ⅰ disease. But it is unclear which chemotherapy regimen is the most 
efficacious for SCLC patients who underwent surgery, due to the rarity. The objective of 
this study was to analyze the efficacy and safety of adjuvant chemotherapy for patients 
with SCLC retrospectively. Methods: From January 2002 to September 2014, we 
retrospectively analyzed the clinical data of 23 patients with SCLC who received surgery 
in our institute. Seventeen patients received adjuvant chemotherapy. Six patients was 
observed with no chemotherapy after surgery, due to old age or poor condition（n=4）, 
patient refusal（n=1）, early post-operative relapse（n=1）. Results: The chemotherapy 
regimens were cisplatin and etoposide（PE）in 8 patients, and carboplatin and etoposide 
（CE） in 9 patients. Median time from surgery to starting chemothetapy was 1.5 
months, and median follow-up time was 39.5 months. 12 pts （70%） received full 
cycles of chemotherapy. The recurrence was observed in 2 of 8 pts who received 
PE therapy and 2 of 9 patients who received CE therapy in April 2015. The median 
recurrence free survival (RFS) of patients who received adjuvant chemotherapy was not 
reached, and the RFS of patients with no chemotherapy was 7.62 months（Log-rank test 
P value 0.0007）. No treatment related death was observed. Conclusion: The adjuvant 
chemotherapy for patients with small cell lung cancer may be safe and efficatious. 
Keywords: SCLC surgery adjuvant-chemotherapy
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P3.07-014 Associations between Comorbidity, Treatment Toxicity and 
Overall Survival in Limited Disease Small-Cell Lung Cancer (LD-SCLC) Bjørn 
H. Grønberg1, Stein H. Sundstrøm2, Øystein Fløtten3, Odd Terje Brustugun4, Paal 
F. Brunsvig5, Roy M. Bremnes6, Stein Kaasa1, Tarje O. Halvorsen1 1The European 
Palliative Care Research Centre and the Cancer Clinic, Norwegian University of Science 
and Technology and St. Olavs Hospital - Trondheim University Hospital, Trondheim/
Norway, 2The Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim/
Norway, 3Department of Pulmonology, University of Bergen and Haukeland University 
Hospital, Bergen/Norway, 4Dept of Oncology, University of Oslo and Oslo University 
Hospital, Radiumhospitalet, Oslo/Norway, 5Dept of Oncology, Oslo University Hospital, 
Radiumhospitalet, Oslo/Norway, 6Department of Oncology, Uit the Arctic University of 
Norway and University Hospital of North Norway, Tromsø/Norway
Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is the 
recommended treatment of LD-SCLC. The treatment often causes severe toxicity. 
Many patients have comorbidity due to old age and smoking, and it is unclear whether 
these patients tolerate and benefit from the treatment as much as more fit patients. 
Studies have shown that comorbidity is a negative prognostic factor in many cancers 
(including lung cancer), but this has not been investigated in LD-SCLC patients receiving 
chemo-radiotherapy. We investigated whether comorbidity was a prognostic factor or 
associated with severe toxicity in a randomized trial comparing two schedules of TRT in 
LD-SCLC (n=157). Methods: Patients received four courses of cisplatin plus etoposide 
and were randomized to receive concurrent TRT of either 45 Gy/30 fractions (twice 
daily) or 42 Gy/15 fractions (once daily). Responders were offered prophylactic cranial 
irradiation of 30 Gy/15 fractions. The Charlson Comorbidity Index (CCI) was used to 
assess comorbidity from hospital medical records. The CCI rates common conditions 
associated with increased 1-year mortality with scores of 1, 2, 3 or 6 based on severity 
- and a total score (“CCI-score”) is calculated. Toxicity was assessed using the CTCAE 
v3.0. We adjusted for treatment arm and established baseline prognostic factors in lung 
cancer (gender, stage of disease, appetite loss, weight-loss, age and performance status 
(PS) in the multivariate analyses. Results: 157 patients were analyzed (100%). Median 
age was 63 years, 52% were men, 16% had PS 2, 72% stage III, 30% weight-loss >5% last 
3 months and 46% received twice-daily TRT. The most common grade 3-4 toxicities were 
pneumonitis (n=4; 3%); esophagitis (n=50; 32%) and neutropenic infections (n=64; 
41%). 4 patients (3%) died from pneumonitis. 63 patients (40%) had CCI-score 0; 54 
(34%) CCI-score 1; 23 (15%) CCI-score 2; 13 (8%) CCI-score 3; 3 (2%) CCI-score 4 and 
1 patient had CCI-score 5 (1%). Most common comorbidities were chronic obstructive 
pulmonary disease (n=60, 38%), peptic ulcer disease (n=19, 12%), previous myocardial 
infarction (n=17, 11%) and diabetes (n=17, 11%). Median overall survival (OS) for the 
whole population was 22.7 months. There were no significant associations between 
CCI-score and median OS in univariate (CCI-score 0: 30.6 months; CCI-score 1: 15.1 
months; CCI-score 2: 23.0 months; CCI-score 3: 23.0 months and CCI-score 4-5: 9.3 
months, p=0.18) or multivariate analyses (HR: 0.97; 95% CI 0.79 – 1.18, p=0.74). 
Patients with comorbidity had a shorter survival than others in the univariate (CCI-
score 0: 30.6 months, CCI-score ≥1: 18.8 months, p=0.047), but not in the multivariate 
analysis (HR: 1.27; 95% CI 0.82–1.98, p=0.29). Patients with comorbidity did not 
experience significantly more grade 3-4 pneumonitis (CCI-score 0: 3%, CCI-score ≥1: 
2%, p=1.0), esophagitis (CCI-score 0: 38%, CCI-score ≥1: 28%, p=0.17), neutropenic 
infections (CCI-score 0: 41%, CCI-score ≥1: 40%, p=0.92) or deaths from pneumonitis 
(CCI-score 0: 2%, CCI-score ≥1: 3%, p=0.65). There were no other significant 
associations between CCI-scores and overall survival or toxicity. Conclusion: LD-
SCLC patients with comorbidity had similar survival and toxicity as others, suggesting 
that they should be offered similar treatment as those without comorbidity. 
Keywords: Limited disease small-cell lung cancer, Comorbidity, survival, toxicity
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disease (N=26); Chemotherapy alone: N=19 (73%),1 year PFS was 6.8% and 1 year OS 
was 9.1%, Sequential chemotherapy and radiation: N=7 (17%), 1 year PFS was 28.6% 
and 1 year OS was 53.6% (P=0.075). There were no survivors at 5 years in subjects 
with extensive stage disease irrespective of whether chemotherapy alone was used or 
sequential chemotherapy and radiation. In subjects with limited stage disease 9, (42.85%) 
received prophylactic cranial irradiation Conclusion: Subjects with limited stage disease 
who received concurrent chemo-radiation showed a better overall survival as compared 
to those who received sequential chemo-radiation. Subjects with extensive stage disease 
who underwent sequential chemo-radiation did not show any statistically significant 
improvement in overall survival as compared to those who received only chemotherapy. 
Concurrent chemo-radiation should be the preferred treatment approach in limited stage 
SCLC in spite of the significant increase in costs and side effect profile even in developing 
countries. Sequential chemo-radiation may not show any added advantage in extensive 
stage SCLC especially considering the added side effects as well as the burden on resources 
Keywords: SCLC, survival, India, retrospective analysis
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P3.08-001 Hippo Pathway Dysregulation in Mesothelioma Cells Yoshitaka Sekido 
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya/Japan
Background: Malignant mesothelioma (MM) is a highly aggressive tumor caused 
by asbestos exposure after a long latency. The neurofibromatosis type 2 (NF2) tumor 
suppressor gene is mutated in around 50% of MM cases, and encodes Merlin that 
regulates the Hippo tumor-suppressive signaling pathway. We previously reported 
occasional genetic or epigenetic alteration in the LATS2 and AJUBA genes in MMs, which 
encode components of the Hippo pathway. The LATS2 inactivation was shown to lead to 
constitutive activation of YAP, a prooncogenic protein and transcriptional coactivator, 
which enhances multiple cell cycle regulation genes including cyclin D1 (CCDN1). To 
further delineate the exact inactivation mechanism of this pathway and the roles of 
YAP in the development of MM, we established immortalized mesothelial cell lines and 
transduced YAP to determine whether or not YAP can confer the malignant phenotypes 
to these cells. Methods: Using retroviral transduction of HPV16 E6/E7 and hTERT genes, 
immortalized human omental mesothelial cell lines (HOMCs) were established. Three 
sublines (HOMC-B1, A4, and D4) with different morphologies were cloned by limiting 
dilution from the pool of immortalized cells. Retrovirus expression vectors of wild-
type YAP (YAPwt) and mutant YAP (YAPS127A) were also synthesized. After retroviral 
infection of YAP expression vectors, transplantation of immortalized mesothelial cells 
was performed subcutaneously or intra-thoracically into nude mice. Results: We 
established immortalized mesothelial cell lines (HOMC) by transduction of HPV-E6/E7 
and hTERT, and examined whether YAP activation induces malignant phenotypes in the 
cells. We found that transduction of both wild-type (YAPwt) and constitutively active-type 
(YAPS127A) YAP, but not other cell cycle-promoting genes including CCDN1 and FOXM1, 
enhanced HOMC-cell proliferation in vitro. We also tested whether or not YAP-transduced 
HOMC cells showed enhanced tumorigenicity in vivo after inoculation into nude mice 
subcutaneously or intrathoracically. We found that YAPwt- and YAPS172A- induced tumors 
which displayed more aggressive phenotypes. Meanwhile, we also transduced YAP 
vectors into normal mesothelial cells but they were shown to be unable to immortalize 
them. Conclusion: YAP activation is frequently observed in MM cells. Although 
enforced expression of YAPwt or YAPS127Awas insufficient to immortalize primary 
human mesothelial cells, the present study provides evidence for the crucial role of the 
disrupted Hippo pathway-activated YAP axis in the initiation of mesothelioma in vivo. 
Keywords: tumorigenesis, NF2, Mesothelioma, YAP
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P3.08-002 Nanodiamonds-Conjugated Chemotherapeutic Agent Induces Cell 
Cycle Arrest and Apoptosis of Human Malignant Pleural Mesothelioma Cell 
Lines Bashir M. Mohamed1, Gareth Clarke2, Kieran Crosbie-Staunton1, Steven G. Gray1 
1Department of Clinical Medicine, Trinity College Dublin, and St James’S Hospital, Dublin/
Ireland, 2Clinical Medicine Department, Trinity College Dublin and St James` S Hospital, 
Dublin/Ireland
Background: The use of nanomaterials-based therapeutic systems is rapidly growing and 
covering a several biomedical applications such as detection, diagnosis and treatment. 
Recently, nanodiamonds (NDs) have been demonstrated to have great potential as a 
multimodal imaging/therapy platform. NDs enhance the ability of the drug to cross the 
cell membrane, increase intracellular drug delivery to the cancer cells, improve treatment 
efficacy, and decrease toxicity to normal cells or tissues. NDs are attractive for use in 
drug delivery because of their rich surface chemistry, advantageous size, and ability 
to act as transmembrane carriers. NDs have also been shown to enhance therapeutic 
efficacy of doxorubicin (DOX), particularly in treating murine liver and mammary tumor 
models, and lung metastasis of breast cancer. Yet, nothing similar has been done to 
translate ND-DOX systems to other cancers such as malignant pleural mesothelioma 
(MPM). In our study, we aimed to investigate the efficacy of ND-conjugated DOX on MPM 
cell lines. Methods: Bare, uncoated nanodiamonds were pegylated and functionalised 
with DOX. NDs/Dox were washed three times then re-suspended in water. Nanoparticle 
Tracking Analysis (NTA), FTIR and PL spectroscopy and TEM imaging were performed to 
defined as weight loss >5% the last 3 months prior to enrolment. Results: 150/157 
patients were analysed (96%). Median age was 63 (40-85); 51% were men; 15% had 
PS 2 and 46% received twice-daily TRT. 1% had stage I disease; 14% stage II; and 84% 
stage III. Median overall survival (OS) for stage I: not reached, stage II: 41.1 months, and 
stage III: 20.9 months (p=0.022). 17% had N0-disease; 5% N1-disease; 30% N2-disease; 
and 47% had N3-disease. Among those with N3-involvement, 40 % had contralateral 
mediastinal LNM, 16% contralateral hilar LNM, and 17% supraclavicular LNM (13% 
ipsilateral and 7% contralateral supraclavicular LNM). 43% had LNM to more than one N3-
station. Patients with N3-disease had inferior survival compared with N0-2 disease (18.0 
vs. 33.7 months; p<0.001). All subcategories of N3 had inferior median OS compared 
with N0-2 disease (median 33.7 months): contralateral mediastinal LNM (18.0 months; 
p=0.022), contralateral hilar (19.8 months; p=0.021), supraclavicular LNM (15.1; 
p=0.003) [ipsilateral supraclavicular LNM (15.1 months; p=0.009) and contralateral 
supraclavicular LNM (13.8 months; p=0.007)]. There were no significant differences 
in median OS between the different N3-categories (p=0.84). Multivariate analyses 
adjusting for established prognostic factors in lung cancer (gender, age, PS, weight-loss 
and appetite loss) and treatment showed that N3-disease (HR 2.30; 95% CI=1.51-3.48; 
p<0.001), supraclavicular LNM (HR 1.67; 95% CI=1.01-2.77; p=0.046) and contralateral 
mediastinal LNM (HR 2.34; 95 % CI = 1.55-3.51; p<0.001) remained significant 
prognostic factors. Conclusion: Patients with N3-disease had inferior OS to those with 
N0-2 disease. All subcategories of N3 had inferior OS in the univariate analyses, while 
supraclavicular and contralateral mediastinal LNM remained significant in the multivariate 
analyses. Patients with supraclavicular LNM had similar OS as other N3 subcategories. 
Keywords: Prognostic factors, N3 disease, TNM stage, small-cell lung cancer
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P3.07-017 The Prognostic Factors in the Elderly Patients with Small Cell Lung 
Cancer: A Retrospective Analysis from a Single Cancer Institute Hui Zhu, Sujing 
Liu, Hongbo Guo, Huihui Li, Yan Zhang, Li Kong, Jinming Yu Shandong Cancer Hospital 
and Institute, Jinan,Shandong Province/China
Background: We conducted a retrospective study to evaluate the prognostic factors 
of elderly patients with small cell lung cancer (SCLC). Methods: The records of elderly 
patients (≥65 years) with histologically-proven SCLC were reviewed. The patients’ 
information including demographic, clinical and laboratory parameters, staging status 
on the VALG staging system, and treatment modalities were registered. Univariate 
and multivariate survival analysis was performed by the Kaplan-Meier method and 
Cox proportional hazards model, respectively. Results: Between January 2004 and 
December 2012, 247 elderly patients with SCLC were analyzed, 129 patients initially 
presented with limited stage and 118 with extensive disease. The median age of the 
patients was 70.7 (range 65–83). The median follow-up period for all patients was 22.0 
months (range, 1.0–84.0 months) and 39.9 months for surviving patients (range, 4.7–
84.0 months). The overall median survival time (MST) was 17.3 months, and the 2-y and 
3-y OS rates were 36.3% and 22.7%, respectively. The MST, 2-y and 3-y OS rates were 
22 months, 45.0% and 30.5% in patients with limited stage, versus 13.4months, 26.5% 
and 13.7% in patients having extensive diseases, respectively. The the median PFS, 
2-year and 3-year PFS rates were 10.0 months, 23.5% and 18.3% for the whole group, 
respectively. The median PFS , the 2-year and 3-year PFS rates were 13.0 months, 31.6% 
and 25.7%, respectively in the LD-SCLC group; and those of the ED-SCLC group were 
8.2 months, 13.3% and 7.6%, respectively. Multivariate analysis revealed that disease 
extent (HR=3.034; p＜0.001) and the number of chemotherapy cycles (HR=0.486; 
p=0.003) were independent prognostic factors for the OS. Conclusion: Positive 
treatment was necessary to the elderly SCLC patients with good performance 
status. Fit elderly patients with SCLC could achieve a relatively prolonged survival. 
Keywords: small cell lung cancer, Elderly patients, survival, prognosis factor
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P3.07-018 Outcomes in Small Cell Lung Cancer in India: A 15 Year 
Retrospective Analysis Navile A. Murali1, T.G Sagar2, Trivadi Ganesan2, Krishna 
Rathinam2, Rejiv Rajendranath2, Prashanth Ganesan2, R Swaminathan2, Venkatraman 
Radhakrishnan2 1Medical Oncology, Cancer Institute (Wia), Chennai/India, 2Medical 
Oncology, Cancer Institute(Wia), Chennai/India
Background: Small Cell Lung Cancer has a aggressive clinical course and poor outcomes. 
Role of multi modality therapy and prophylactic cranial irradiation have been established 
in the last two decades. There is a paucity of studies on survival in SCLC in India and to 
our knowledge till date; only one study has been published from India. The current study 
is a retrospective review of outcomes in patients with SCLC in India Methods: All newly 
diagnosed small cell lung cancer cases from 2000 through 2014 who received treatment 
at Cancer Institute (WIA),Chennai were identified and clinical data from their hospital 
records, noted. The influence of various pretreatment factors on survival was investigated 
using Kaplan-Meier plots and Cox multivariate regression model. Only subjects who 
received intravenous chemotherapy were included in the analysis. Results: Forty seven 
subjects were included, 39 (83%) were males. Age distribution: Less than 50 years – 
16 (34%), 50-59 years - 16 (34%),> 60 years – 15 (32%). Limited Stage: 21 (44.6%) 
and extensive stage: 26 (55.4%). Treatment outcomes in Limited stage disease (N=21): 
Sequential chemotherapy and radiation: N=11 (52.38%), median PFS was 8 months, 1 
year OS was 72.9% (P<0.001) and 5 year OS was 0%. Concurrent chemotherapy and 
radiation: N=10 (47.62%), median PFS was 10 months, 1 year OS was 78.8% and 5 year 
OS was 26.3% (P<0.001). The improvement in overall survival when subjects received 
concurrent chemotherapy and radiation as compared to sequential chemotherapy and 
radiation was statistically significant (P<0.001). Treatment outcomes in Extensive stage 
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lung cancer or sarcomas or benign pleuritis show similar patterns. Therefore, we try 
to make differential diagnosis when we suspect pleural mesothelioma by chest CT. 
Keywords: Pleural mesothelioma, Radiological features, Histological type, Pleural rind
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P3.08-005 Mesothelioma Diagnostic Panel Using Remote Digital Diagnostic 
System in Japan Kouki Inai1, Takumi Kishimoto2 1Pathology, Pathological Diagnostic 
Center Inc., Hiroshima/Japan, 2Asbestos Study Center, Okayama Rosai Hospital, Okayama/
Japan
Background: The pathological diagnosis as mesothelioma is difficult even if 
experienced pathologists do. Also the diagnosis of imaging including CT has no 
conclusive evidences as mesothelioma. Accordingly comprehensive diagnosis based on 
discussion by several pathologists and/or radiologists is necessary. However most of 
diagnostic specialists are too busy to have a meeting at designated date and venue. 
New remote diaignostic system will solve those problems and the accurate diagnosis 
as mesothelioma can be made. Methods: The remote pathological diagnosis consists 
of scanning of tissue slide by scanning equipment (NanoZoomer®), transmission of the 
digital data to cloud system (Google) by Internet. We have developed a new system 
named “LOOKREC” including pathological data and imaging data (chest X-P,CT and so 
on). The pathologists and radiologists as a member of special diagnostic group obtain a 
special account and access to the data on cloud by Internet. The diagnotic opinions made 
by individuals are entered into the discussion sheet and the organizer will decide a final 
diagnosis including whether mesothelioma or not, which type of mesothelioma, based 
on individual diagnostic opinions. Results: In Japan, the annual number of occurrence 
of mesothelioma is over 1200. The compensation or relief system for mesothelioma 
patients has been established ten years ago, and the accurate diagnosis is always 
required for adequate management of those systems. The number of mesothelioma 
showing diagnostic problems is about 10% of all mesothelioma cases. The cases with 
some difficulties of differentiation between early epithelioid mesothelioma vs reactive 
mesothelial hyperplasia, pleuritis, localized methelioma vs lung cancer will be presented 
and the points of differential diagnosis will be discussed. Conclusion: The new remote 
diagnostic system using Internet has been developed. It is expected that diagnostic 
accuracy will be improved when the observation of pathological findings as well as imaging 
and effective disccussion on the web will be done by pathologists and radiologists. 
Keywords: Mesothelioma, Accurate diagnosis, Remote digital pathology, Imaging 
diagnosis
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P3.08-006 NF2 Mutations in Malignant Pleural Mesothelioma Synchronous 
with Acoustic Neuroma: Disease-Causing Mutation or Chance Effect? 
Hitomi Kamiya1, Takashi Nakano1, Kozo Kuribayashi1, Taiichiro Otsuki1, Miki Honda1, 
Eriko Masachika1, Koji Mikami1, Takayuki Terada1, Yoshitaka Sekido2, Seiki Hasegawa3, 
Tohru Tsujimura4 1Division of Respiratory Medicine,Department of Internal Medicine, Hyogo 
College of Medcine, Nishinomiya, Hyogo/Japan, 2Division of Molecular Oncology, Aichi 
Cancer Center Research Institute, Nagoya/Japan, 3Department of Thoracic Surgery, Hyogo 
College of Medicine, Nishinomiya, Hyogo/Japan, 4Department of Molecular Pathology, Hyogo 
College of Medcine, Nishinomiya, Hyogo/Japan
Background: Patients with neurofibromatosis type 2 (NF2) are predisposed to 
schwannomas and meningiomas. Somatic NF2 mutation has also been reported in patients 
with sporadic schwannomas and a variety of cancers. In particular, approximately 35–40% 
of patients with malignant pleural mesothelioma (MPM) carry inactivating mutations of NF2. 
In addition to NF2, BRCA1-associated protein-1 (BAP-1) has also been identified as a key 
genetic alteration in mesothelioma. Recently, a new familial cancer syndrome associated 
with germline mutations in BAP1 was proposed, which includes MPM, ocular melanoma, and 
other cancers. However, NF2 mutations do not usually cause mesothelioma synchronous 
with schwannoma. We here report two cases of MPM synchronous with vestibular 
schwannomas and analytical finding on NF2 mutations Methods: Case 1 was a 65-year-
old man with epithelioid MPM. A unilateral acoustic neuroma was resected in 2010 because 
the patient experienced progressive hearing loss in the right ear since 2000. In April 2012, 
right pleural fluid was detected on chest X-ray and a thoracoscopical examination was 
performed. Epithelioid MPM was diagnosed pathologically. Case 2 was a 72-year-old 
man with epithelioid MPM synchronous with unilateral acoustic neurinoma. The patient 
presented with DOE and hearing loss in the left ear that had progressed over the past month. 
Chest X-ray showed pleural effusion, and a biopsied specimen with thoracoscopy revealed 
epithelioid MPM. Brain MRI and CT showed a mass that was highly suspected to be acoustic 
neurinoma between the left cerebellopontine angle and the opening of the internal acoustic 
meatus. We performed whole-exome sequencing on DNA in tumor tissue and blood and 
immunohistochemical analysis of NF2 gene encoding protein merlin. Results: Both patients 
were diagnosed with synchronous acoustic neurinoma and epithelioid MPM. NF2 gene 
mutations were identified in both tumors of MPM and acoustic neurinoma in Case 1. And in 
Case 2, diagnosis of acoustic neurinoma was depended on typical findings of brain MRI/
CT, for which surgical resection was not performed because of advanced stage of MPM. 
Tumor tissue of MPM in Case 2 showed positive result of NF2 mutation. Both patients 
had a history of asbestos exposure. Conclusion: Although the role of NF2 mutation 
as a possible disease-causing mutation in MPM and synchronous occurrence with 
schwannoma remain unclear, both cases showed the possible role of NF2 mutation 
in asbestos-related neoplasm. We will show the pedigree of the patients’ families. 
Keywords: Malignant pleural mesotelioma (MPM), NF2 mutation, BRCA1-associated 
protein-1 (BAP-1)
characterise the functionalisation. Human MPM cell lines such as REN and NCl-H2373 
and human lung carcinoma cell line (NCl-H226) were used. LP-9 cell line, which resembles 
normal human mesothelial cells, was used as control. All cells were cultured and exposed 
to NDs, NDs/DOX or DOX alone. Cell cycle, cell viability, lysosomal mass/pH changes 
and mitochondrial membrane potential were examined using immunofluorescent 
staining techniques and data were collected and analysed with high content screening 
tools such as Cytell and IN Cell Investigator software. Results: Significant alterations 
of the examined biological markers were detected in human MPM cell lines such (REN 
and NCl-H2373) and human lung carcinoma cells (H226), while a slight changes were 
seen in the LP-9 cells. Interestingly, the MPM cells showed greater responses to NDs/
DOX versus DOX alone. Conclusion: Our study demonstrates that NDs loaded with DOX 
exert significant inhibitory activities of human MPM cell lines and at concentrations that 
have minimal effects on normal pleura. Thus, ND-conjugated chemotherapy represents 
a promising, biocompatible strategy for enhancing chemotherapy efficacy and safety. 
Keywords: Nanodiamonds, malignant pleural mesothelioma, Doxorubicin
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P3.08-003 Incidence and Management of Malignant Pleural Mesothelioma 
Related Empyema Abdelrahman M. Abdelrahman1, Rabab Gaffar2, Hoda Baki2, 
Ahmed Elbastaweesy2, Fatma Aboulkasem2 1Surgery, National Cancer Institute, Cairo/
Egypt, 2National Cancer Institute, Cairo/Egypt
Background: Empyema in relation to malignant pleural mesothelioma is a serious 
complication that may stop or delay the planned treatment. It may be secondary to 
surgery or non surgical , both are difficult to treat and are challenging to the thoracic 
surgeon as patients are usually too ill to tolerate therapy. Methods: We retrospectively 
reviewed the data of 443 patients with mesothelioma referred to the National Cancer 
Institute, Cairo between 2004 -2013. Extra pleural pnuemonectomy (EPP) was performed 
in 93 patients and radical pleurectomy / decortication in 12 . The remaining 338 patients 
received palliative chemotherapy or best supportive care. The frequency of empyema 
among those patients was 5.86% (26 cases). Full history and clinical examination was 
done for all patients, culture from the chest tube and or sputum culture was ordered for 
all, Computed tomography of the chest was done to evaluate empyema in all patients 
and bronchoscopy and biopsy to exclude stump recurrence was requested for patients 
with empyema secondary to EPP. Results: There were 23 males and 3 females , the 
right side was affected in 17 patients. Of the 338 patients with non operative therapy, 
17(5%) developed empyema , 5 following repeated tapping of effusion ,8 with prolonged 
chest tube insertion and 4 after pleurodesis. Palliative pleurectomy was possible in 4 
patients and was successful in 2. The remaining 13 patients were treated with second 
chest tube and repeated cavity irrigation with diluted bovidon iodine, 5 of them were 
improved within 2-3 weeks. Empyema secondary to EPP developed in 8 patients, 2 had 
early post operative empyema, one with stump dehiscence and one secondary to tube 
thoracostomy in the post pneumonectomy space. Surgery was successful in both. Of 
the remaining 6 patients, 5 had delayed bronchial stump fistula 1-3 years post pleuro 
pneumonectomy, All were re explored. Two patients were cured, the remaining 4 died 
from persistent sepsis. The last patient had infected mesh 3 years after surgery and was 
treated by re surgery and mesh removal. We had one patient with empyema following 
radical pleurectomy/ decortication due to residual space, wound depridement was done 
and the procedure was successful. Conclusion: Treatment of mesothelioma patients with 
empyema is challenging, every patient should be and evaluated and treated separately. 
In spite of high failure rate with surgery, it’s considered the only treatment option, great 
effort by high volume thoracic surgeon should be offered to this group of patients. 
Keywords: mesothelioma, empyema, incidence , management
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P3.08-004 The Evaluation of Radiological Features for Pleural Mesothelioma 
Takumi Kishimoto Asbestos Study Center, Okayama Rosai Hospital, Okayama/Japan
Background: The differences of radiological features for pleural mesothelioma from 
other diseases such as lung cancer and sarcomas or pleuritis et al. is not evaluated 
and the also the difference of features among the histological manufestation is also 
not clear. Methods: Four hundred and twenty four cases of pleural mesothelioma who 
were clinically diagnosed, were evaluated. The chest CT which patients first visited to 
hospital were classified into 7 category such as 1)uni-mass formation, 2)pleural rind, 3)
slight thickening of pleura, 4)thickening of mediastinal pleura, 5)pleural effusion without 
pleural changes, 6)multi-mass formation and 7)specific type. Furthermore, evidence 
of pleural effusion and the radiological patterns of the histological differences were 
evaluated. Results: The number of mesothelioma who were definitely diagnosed was 
383 cases and 51 cases were not diagnosed mesothelioma but lung cancer, sarcoma 
or pleuritis or benign asbestos pleurisy et al. were diagnosed histologically. For 
mesothelioma cases, 230(60.1%) cases showed epithelioid histology, 62 cases(16.2%) 
biohasic type and 86 cases(22.5%) were sarcomatoid type and 5 cases(1.3%) were 
specific type and 89.6% showed pleural effusion. For the radiological patterns for 
383 cases, pleural rind pattern occupied 42.2% and multi-mass formation 14.1%, 
pleural effusion without pleural changes 12.9% and uni-mass formation occupied 
8.6%. As for the histological features, biphasic type showed only 2 cases(2.9%) uni-
mass formation and 13.2% showed thickening of mediastinal pleura and sarcomatoid 
type only 4.4% showed pleural effusion without pleural changes.  Other 51 cases 
who were not diagnosed mesothelioma such as lung cancer et al. showed 30.9% of 
uni-mass formation, pleural rind 21.8% and pleural effusion without pleural changes 
18.2%. And 80.4% of them showed pleural effusion. Conclusion: Pleural mesothelioma 
shows various types of radiological manifestation and also other diseases such as 
S747Copyright © 2015 by the International Association for the Study of Lung Cancer
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continue to assess this compound by other methodologies to confirm its potential utility 
in the treatment of MPM. Conclusion: KAT5, a lysine acetyltransferase associated with 
cisplatin resistance in cancer is significantly altered in MPM. A small molecule inhibitor 
of this protein shows significant anti-proliferative effects in MPM cell lines. Targeting 
this protein may have important future implications for the management of MPM. 
Keywords: Tip60, Kat5, MG 149, lysine acetyltransferase
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P3.08-009 Diagnostic Efficacy of Electron Microscopy to Distinguish between 
Pleural Mesothelioma and Lung Adenocarcinoma in Pleural Effusion Cytology  
Oscar Arrieta Rodriguez1, Hugo Domínguez-Malagón2, Ana M. Cano-Valdez2, Carlos E. 
González-Carrillo2, Yelitza E. Campos-Salgado1, Mariana Lopez-Mejia1 1Unidad Funcional 
de Oncología Torácica Y Laboratorio de Medicina Personalizada, National Cancer Institute, 
Mexico City/Mexico, 2Pathology, National Cancer Institute, Mexico City/Mexico
Background: Mesothelioma is a mesodermic tumor localized in the pleura in 70-90% of 
the presentations. In most cases the diagnosis is made by computed tomography-guided 
biopsy or thoracoscopy. Characteristically mesothelioma includes papillary structures 
which make it difficult to distinguish from adenocarcinoma on hematoxylin and eosin 
stain, making this entity its main differential diagnosis. Immunohistochemical studies 
in biopsy specimens aids in the obtaining of a precise diagnosis. Notwithstanding it is 
often difficult to distinguish between both entities, in which case, electron microscopy is 
the gold standard as it allows to observe the abundant long thin microvilli (characteristic 
of the mesothelium) in tumor cells. Sometimes patients have only pleural effusion 
cytology which makes the diagnosis more challenging. Methods: Twenty-five pleural 
effusion cytology samples were studied to evaluate electron microscopy and its 
efficacy for diagnosis, as well as by immunohistochemistry for the diagnosis of either 
lung adenocarcinoma or mesothelioma. Results: Five pleural effusion samples with 
the histological diagnosis of mesothelioma and twenty with the histological diagnosis 
of adenocarcinoma, all with confirmed biopsies by immunohistochemistry. Of the five 
pleural effusion samples with histological diagnosis of mesothelioma, cytology in 
electron microscopy showed morphological characteristics of mesothelioma (long thin 
microvilli, dense junctions, desmosomes and tonofilaments ) in two samples (40%), and 
three were acellular (60%). Of the twenty pleural effusion samples with histologically 
confirmed diagnosis of adenocarcinoma (short microvilli, secretory vacuoles and 
intracytoplasmic lumens), eight were confirmed by electron microscopy (40%), eleven 
were acellular (55%), and one showed reactive mesothelium (5%). Conclusion: Pleural 
effusion cytology by electron microscopy showed that cells maintained their 
morphological features, either of mesothelioma or of lung adenocarcinoma, and can help 
in the diagnosis; however this is limited to the presence of cells in the pleural effusion 
Keywords: Mesothelioma, lung adenocarcinoma, electron microscopy
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P3.08-010 Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma 
- Czech Experience Vitezslav Kolek1, Libor Havel2, Milos Pesek3, Frantisek Salajka4, 
Leona Koubkova5, Jaromir Roubec6, Jana Skrickova7, Dimka Sixtova8, Karel Hejduk9, 
Zbynek Bortlicek9 1Respiratory Medicine, University Hospital, Olomouc/Czech Republic, 2P 
Neumology and Thoracic Oncology, Municipal Hospital, Prague/Czech Republic, 3Pulmonary 
Medicine, University Hospital, Plzen/Czech Republic, 4University Hospital, Hradev 
Kralove/Czech Republic, 5Pulmonary Medicine, University Hospital,, Praha/Czech 
Republic, 6Pulmonary Medicine, University Hospital, Ostrava/Czech Republic, 7Pulmonary 
Medicine, University Hospital, Brno/Czech Republic,8Pulmonary Medicine, Memorial 
Thomayer Hospital, Praha/Czech Republic, 9Biostatistics, Iba Institute, Brno/Czech Republic
Background: Malignant Pleural Mesotelioma (MPM) is a tumour with extremely 
unfavourable prognosis. Early diagnostic is rarely possible and chemotherapy has 
limited value in prolongation of survival. Pemetrexed with platinum is the standard 
1st line chemotherapy. In the Czech Republic, the incidence of MPM is influenced mostly 
by former industry processing asbestos for roofs, other parts of buildings and isolation 
materials. Any work with asbetos is prohibited in the mean time. Methods: Treatment 
with pemetrexed and cisplatin was evaluated in a prospective study. Data of consecutive 
patients from 9 centers were prospectively collected from January 2008 till February 
2015. Altogether 181 patients (47 women, 134 men) were evaluated. Mean age was 
62 years, 71 pts were non smokers, 47 smokers, 61 ex smokers. Professional/ non-
professional exposure was reported in 44/ 18 pts. Histology: 119 epithelial, 20 mixed, 12 
sarcomatoid, not specified in 30 pts, TNM st.: I/II/III/IV in 19/32/48/78 pts, not assessed 
in 4 pts, PS: 0/1/2 in 39/130/12 pts. Results: Median of treatment was 18.5 weeks. 
Most frequent side effects (Gr 3, 4): leucopenia in 22, neutropenia in 15, anaemia in 15, 
trombocytopenia in 6, nausea/vomiting in 19, fatigue in 8 pts. Therapeutic response: CR in 
5, PR in 47, SD 85, PD in 21 pts, overall disease control was 75.6 %. The median of overall 
survival (OS) was 19.8 months (16.2; 23.4), 1 year survival 67.9% (48.3; 71.5). Median of 
progression free survival (PFS) was 9.1 months (7.6; 10.7). Differences of survival were 
compared according to sex, smoking history, age, PS, TNM stage, treatment associated 
AE occurrence, type of exposure and histology. Significantly different results were 
achieved according to PS,TNM, exposure, AE and histology. Conclusion: Treatment of 
MPM with pemetrexed and cisplatinum in routine practice is effective and well tolerated. 
Prognosis is still poor and it is influenced by several clinical markers. Longer survival 
can be expected in PS 0, TNM I/II, unknown asbestos exposure, epitheloid histology 
and no treatment associated AE. Supported by national grant IGA MZ ČR NT/13569 
Keywords: Mesothelioma, prognostic markers, survival
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P3.08-007 Fibulin-3: A Potential Prognostic Biomarker in Malignant Pleural 
Mesothelioma? Michaela B. Kirschner1, Emily Pulford2, Mir A. Hoda3, Anita Rozsas3, 
Kim Griggs2, J James B. Edelman4, Steven Kao5, Rebecca Hyland1, Yawen Dong3, 
Viktoria Laszlo3, Thomas Klikovits3, Marko Jakopovic6, Michael Vallely4, Michael Grusch7, 
Balazs Hegedus3, Balazs Dome3, Walter Klepetko3, Nico Van Zandwijk1, Sonja Klebe2, 
Glen Reid1 1Asbestos Diseases Research Institute, Sydney/NSW/Australia, 2Anatomical 
Pathology, Flinders University, Adelaide/SA/Australia, 3Division of Thoracic Surgery, 
Medical University Vienna, Vienna/Austria, 4Cardiothoracic Surgical Unit, Royal Prince Alfred 
Hospital, Sydney/ACT/Australia, 5Medical Oncology, Chris O’Brien Lifehouse, Sydney/
Australia, 6University Hospital Centre Zagreb, Zagreb/Croatia, 7Institute of Cancer Research, 
Medical University Vienna, Vienna/Austria
Background: Malignant pleural mesothelioma (MPM) is a highly aggressive asbestos-
induced cancer arising from the mesothelium lining the thoracic cavities. The definitive 
diagnosis of MPM in most instances depends on the availability of a biopsy. A number of 
biomarkers have been proposed to assist in making the MPM diagnosis but none of them 
has yet reached the accuracy required for routine clinical use. Among the candidates 
is the secreted extracellular glycoprotein Fibulin-3 (FBLN3) (Pass et al, NEJM 2012; 
367(15)). In this study, we have further investigated the potential of FBLN3 to serve as 
a biomarker for MPM. Methods: Cellular and secreted FBLN3 was measured (ELISA) 
in MPM and normal mesothelial cell lines, plasma of xenograft tumour-bearing mice, 
plasma from two independent series of MPM and non-MPM patients, and in malignant 
and non-malignant pleural effusions. The diagnostic and prognostic potential of FBLN3 
was assessed by receiver operating characteristics curve analysis and the Kaplan-Meier 
method, respectively. Results: FBLN3 levels were significantly higher in MPM cells than 
in mesothelial cells, with a strong correlation between secreted and cellular levels. 
Human FBLN3 was also detectable in the plasma of tumour-bearing mice, suggesting 
that MPM cells were the origin of circulating FBLN3. Plasma FBLN3 levels found in MPM 
patients were lower than previously reported (Pass et al, NEJM 2012; 367(15)), but 
were comparable to those appearing in subsequent validation studies (Creaney et al, 
Thorax 2014; 69(10), Corradi et al, Anticancer Res 2013; 33(12)). Plasma FBLN3 was 
significantly elevated in MPM patients from a Sydney cohort, but far less in a Vienna cohort 
and the diagnostic accuracy of FBLN3 was insufficient in both cohorts [63%, (95%CI: 
50.1-76.4) and 56% (95%CI: 41.5-71.0), respectively]. FBLN3 levels found in pleural 
effusions were comparable to those reported in previous studies, but the difference 
between cases and controls did not reach significance. In our series low levels of pleural 
effusion FBLN3 were again associated (p=0.002) with prolonged survival. In multivariate 
analysis taking histological subtype, age and gender into account FBLN3 remained 
significant with a hazard ratio of 9.92 (95%CI: 2.14–45.93). Conclusion: FBLN3 is 
overexpressed in MPM cell lines and may point to a potential oncogenic role for this 
protein. In contrast to the initial report linking FBLN3 to diagnosis in MPM, the levels 
of FBLN3 measured in plasma and pleural fluid of our series of MPM patients lacked 
diagnostic accuracy. However, the potential prognostic value of FBLN3 levels measured 
in pleural fluid was confirmed and in line with previous validation studies. These data 
underline the importance of validation studies for newly proposed biomarkers. 
Keywords: Mesothelioma, biomarker, Prognosis, Fibulin-3
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P3.08-008 Tip60 (KAT5) May Be a Candidate for Therapeutic Targeting in 
Malignant Pleural Mesothelioma Sian Cregan1, Lauren Mcdonagh2, Yun Gao3, Martin 
P. Barr1, Kenneth J. O’Byrne4, Stephen P. Finn5, Sinead Cuffe6, Steven G. Gray1 
1Thoracic Oncology Research Group, Trinity College Dublin/St. James’S Hospital, 
Dublin/Ireland, 2Thoracic Oncology Research Group, Trinity College Dublin, Dublin/
Ireland, 3Department of Oncology, Aerospace Central Clinical Medical College of Peking 
University, Beijing/China, 4Cancer and Ageing Research Program, Princess Alexandra 
Hospital and Queensland University of Technology, Brisbane/Australia, 5Department 
of Pathology, University of Dublin, Trinity College and St. James’S Hospital, Dublin/
Ireland, 6Hope Department, St.James’S Hospital, Dublin/Ireland
Background: Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the 
pleura. The most well established risk factor for this disease is exposure to asbestos. The 
current standard of care for patients suffering from MPM is a combination of cisplatin and 
pemetrexed (or alternatively cisplatin and raltitrexed). Most patients however, die within 
24 months of diagnosis. New therapies are therefore urgently required for this disease. 
KAT5 (also known as Tip60) is the catalytic subunit of the NuA4 histone acetyltransferase 
complex which is involved in transcriptional activation of select genes. This complex may 
be required for the activation of transcriptional programs associated with oncogene and 
proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest 
and replicative senescence, apoptosis, and DNA repair. KAT5 has also been linked with 
the development of cisplatin resistance. KAT5 may therefore be a significant element 
in MPM with respect to responses to cisplatin based therapy and could represent a 
novel candidate target for intervention. Methods: KAT5 has 4 variant mRNAs. Primers 
were designed to distinguish between all variants, and a panel of MPM cell lines was 
screened for KAT5 expression by RT-PCR. Levels of KAT5 were subsequently examined in 
a cohort of snap-frozen patient samples isolated at surgery comprising benign, epithelial, 
biphasic, and sarcomatoid histologies by RT-PCR. The effects of a small molecule inhibitor 
of KAT5 (MG-149) on cellular proliferation were examined. Results: Semi-quantitative 
densitometric analysis showed that the expression of KAT5 is dramatically increased in 
MPM for all mRNA variants. When separated according to histological subtype, significant 
differences were also observed between the various histologies. A small molecule inhibitor 
of KAT5 exists and treatment of cells with this small molecule inhibitor (MG-149) resulted 
in a significant inhibition of cellular proliferation (p < 0.001) in the NCI-H226 cell line. We 
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P3.08-013 Twenty-Four Cases of Malignant Pleural Mesothelioma in Iwakuni, 
Japan Ryosuke Hirai1, Shoichi Kuyama2, Takahiro Umeno2, Daisuke Nojima2, Toshio 
Shiotani3, Ryujiro Sugimoto3, Kazuhiko Kataoka3 1NHO Iwakuni Medical Center, Iwakuni 
City/Japan, 2Department of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni/
Japan, 3Department of Thoracic Surgery, NHO Iwakuni Medical Center, Iwakuni/Japan
Background: Asbestos had been stopped to use in Japan since the late 1970s. 
Asbestos exposure will increase the risk of mesothelioma and the interval between 
initial exposure and subsequent biological consequences is assumed more than 
40 years. Iwakuni is part of the Seto Inland Sea industrial area and one of the 
oldest petrochemical industrial complexes in Japan is located. The incidence of 
mesotheliomas is expected to rise over the next decade. Treatment for mesothelioma 
includes surgery, chemotherapy, radiation therapy and their combination. Recently, 
cisplatin in conjunction with pemetrexed has shown advantageous results in reducing 
tumors, but pleural mesothelioma is still incurable fatal disease except specific case. 
In this study, we reviewed the clinical features of 26 patients with malignant pleural 
mesotelioma treated in our institute. Methods: Between January 2006 and December 
2014, 26 patients were histologically diagnosed as malignant pleural mesotelioma. 
Retrospective review was performed and demographic, clinical, pathologic, treatment 
and survival data were collected. Overall survival were estimated by the Kaplan-Meier 
analysis. Surgery includes two patients treated by trimodality therapy (chemotherapy 
+ extrapleural pneumonectomy + radiation therapy) and a patient treated by 
pleurectomy combined with hyperthermic therapy. Other four patients were treated 
by extrapleural pneumonectomy alone. Results: In the studied population,21 of 26 
patients were male.the mean age of diagnosis was 72y. Each number of histological 
subtypes(epithelial,sarcomatoid and biphasic) were 15,6,and 5.The number of patients 
who treated with surgery were 8,with chemotherapy were 17 and best supportive care 
was 1. The median survival time of the 27 malignant pleural mesotelioma patients was 
13.4 months. According to histological subtypes,the MTS of epithelial,sarcomatoid 
and biphasic were 21.4 months,6.5 months and 11.6 months The MTS of surgery and 
chemotherapy were 21.4 months and 13.2 months.One year survival rate were 85.7% 
and 47.6%. The MTS of the patients with and without pleural plaque were 13.4 months 
and 15.0 months. Female gender, epithelial subtypes, treatment of surgery and patients 
without pleural plaque showed relatively favorable outcome. Conclusion: Because of 
the appearance of effecrive chemotherapies,such as Pemetrexed sodium hydrate,better 
survival has been observed in patients treated by chemotherapy. However, long-term 
survival was seen only in patients treated by surgery. Surgery allows us to accurately 
stage patients and provide data that may be useful in better patient stratification. Surgery 
should be selected for the operable patients with c-stage I-II and epithelial disease. We have 
to detect malignant pleural mesothelioma in early stage and treat in appropriate means. 
Keywords: malignant pleural mesothelioma, Retrospective review
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.08-014 COMMAND: A Phase 2 Randomized, Double-Blind, Study 
of Defactinib (VS-6063) as Maintenance Therapy in Malignant Pleural 
Mesothelioma Hedy Lee Kindler1, Dean A. Fennell2, Paul Baas3, Lee M. Krug4, 
Marjorie G. Zauderer5, Anna K. Nowak6, Richard J. Gralla7, Takashi Nakano8, Marcelyne 
Joseney-Antoine9, Anne Poli9, Mitchell Keegan10, Joanna Horobin9 1Section of 
Hematology/Oncology, University of Chicago, Chicago/IL/United States of America, 2Mrc 
Toxicology Unit, University of Leicester & Leicester University Hospitals, Leicester/
United Kingdom, 3The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, 
Amsterdam/Netherlands, 4Medicine/Thoracic Oncology, Mskcc, New York/United 
States of America, 5Medicine/Thoracic Oncology, Mskcc, New York/NY/United States of 
America, 6School of Medicine and Pharmacology, University of Western Australia, Perth/
WA/Australia, 7Department of Medicine, Jacobi Medical Center - Albert Einstein College of 
Medicine, Bronx/NY/United States of America, 8Department of Respiratory Medcine, Hyogo 
College of Medcine, Nishinomiya , Hyogo/Japan, 9Verastem, Boston/MA/United States of 
America, 10Verastem, Boston/United States of America
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor in the pleural 
lining of the lung. Median OS with frontline chemotherapy of pemetrexed/cisplatin (pem/
cis) is ~12 months. There is no established second line therapy. Pem/cis has been shown 
to enrich cancer stem cells (CSCs) in tumors. Focal adhesion kinase (FAK) inhibitors 
have been found to decrease CSCs in mesothelioma models. The use of a FAK inhibitor 
in a maintenance setting after frontline chemotherapy may therefore extend survival of 
MPM patients. Furthermore, approximately 40% of MPM tumors exhibit disruption of the 
NF2 tumor suppressor gene by mutation and/or deletion resulting in lack of expression 
of functional merlin protein. Mesothelioma cell lines that lack merlin are more sensitive 
to FAK inhibitors than those with wild type merlin. This Phase 2 study will determine if 
defactinib (VS-6063), an oral inhibitor of FAK, provides superior clinical benefit compared 
with placebo as maintenance treatment in patients with MPM following frontline pem/
platinum therapy. Methods: COMMAND is a multinational, randomized, double-blind, 
placebo-controlled trial. Approximately 370 patients with PR or SD following ≥4 cycles of 
frontline pem/platinum therapy will be enrolled. Patients will receive defactinib 400 mg 
BID or matched placebo. Randomization will be stratified by merlin status, as determined 
by immunohistochemistry. Primary endpoints include OS and PFS. An adaptive 
enrichment design at the interim analysis (projected to occur in Q2 2015) may restrict 
patients to those with low merlin protein expression if greater benefit is observed among 
this subpopulation. Secondary endpoints include patient-reported outcomes, objective 
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P3.08-011 Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in 
a Phase Ib Trial in Patients with Advanced Mesothelioma Anish Thomas1, Raffit 
Hassan1, Manish Patel2, John Nemunaitis3, Jaafar Bennouna4, John Powderly5, Matthew 
H. Taylor6, Marcis Bajars7, Anja Von Heydebreck8, James L. Gulley1 1National Cancer 
Institute, National Institutes of Health, Bethesda/MD/United States of America, 2Sarah 
Cannon Research Institute/Florida Cancer Specialists, Sarasota/FL/United States of 
America, 3Mary Crowley Cancer Research Centers, Dallas/TX/United States of America, 4Ico 
- Site René Gauducheau, Saint Herblain/France, 5Carolina Biooncology Institute, Huntersville/
NC/United States of America, 6Oregon Health & Science University, Knight Cancer 
Institute, Portland/OR/United States of America, 7Global Research and Early Development 
- Immunooncology, Emd Serono, Inc., Billerica/MA/United States of America, 8R&D Global 
Biostatistics, Merck Kgaa, Darmstadt/Germany
Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key 
therapeutic targets in the reactivation of the immune response against multiple cancers. 
Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently being 
investigated in clinical trials. The phase Ib study (NCT01772004) is an open-label, parallel 
group expansion trial in patients with metastatic or locally advanced solid tumors that 
includes a cohort of patients with advanced, unresectable mesothelioma. Methods: This 
trial cohort is enrolling patients with histologically or cytologically confirmed unresectable 
mesothelioma (pleural or peritoneal) that has progressed after treatment with either 
a platinum-pemetrexed–containing regimen or a platinum-based regimen followed by 
pemetrexed (or vice versa). Eligible patients must have available tumor archival material 
or fresh biopsy, and an ECOG performance status of 0 or 1 at trial entry, and disease 
with at least 1 measurable lesion that has not been irradiated. Exclusion criteria include 
prior therapy with immune checkpoint drugs, a known history of autoimmune disease, 
or recent anticancer treatment (within the 28 days prior to study start). Up to 50 eligible 
patients will receive avelumab at 10 mg/kg as an infusion Q2W. Treatment will continue 
until disease progression, unacceptable toxicity, or any criterion for withdrawal occurs. 
Treatment may be continued despite progression according to RECIST 1.1 if the patient’s 
clinical status is stable and, according to investigator opinion, there is no need to start 
salvage therapy. The primary objective of the trial is to assess the safety and tolerability 
of avelumab. Select secondary objectives include: assessment of best overall response 
(BOR) and progression-free survival (PFS) according to RECIST 1.1; assessment of 
immune-related BOR and immune-related PFS (using the modified Immune-Related 
Response Criteria); and assessment of overall survival. Association between tumor PD-
L1 expression and efficacy will be evaluated. Changes in soluble factors and immune 
cell profiling will be characterized and immunomonitoring will occur at each visit. Tumor 
assessments will be performed every 6 weeks until progression. Tumor tissue from 
the most recent biopsy or surgical specimen will be collected prior to the initiation of 
trial treatment, and fresh biopsies may be optionally collected on day 43 and at the 
end-of-treatment visit. At each visit during the treatment phase, adverse events will be 
assessed and graded according to NCI-CTCAE v4.0. Enrollment in this study began in 
September 2014. *Proposed INN. Results: not applicable Conclusion: not applicable 
Keywords: Mesothelioma, PD-L1, MSB0010718C, avelumab
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P3.08-012 Renal Safety of Sustained Pemetrexed/Platinum Treatment for 
Advanced Malignant Mesothelioma Meinolf Karthaus1, K Tagizadeh2 
1Hematology and Oncology, Klinikum Neuperlach, Munich/Germany, 2Hematology and 
Oncology, Evkb, Bielefeld/Germany
Background: Advanded malignant peritoneal mesothelioma (AbM) is a rare and 
aggressive neoplasm. The natural course of the disease is different from pleural 
mesothelioma. The optimal ctx duration for AbM remains undetermined. Ctx of AbM is 
commonly reported case by case. Efficacy of Pemetrexed (Pem)+cisplatinum (DDP) ctx 
has been demonstrated previously. A major obstacle to sustained Pem/DDP for AbM is 
renal safety beside neurotoxicity. At present, there are sparse data regarding renal safety 
in AbM pts receiving sustained ctx >6 cycles of Pem+platinum. Methods: We evaluated 
long-term renal safety of Pem (500 mg/m2)+DDP (75 mg/m2) in AbM prospectively. 
Ctx was given on d1 and repeated on d22 until disease progression or toxicity. Pts 
with impairment of renal function (Crea-Cl <60 ml/min) switched to carboplatin AUC5 
(carbo). Pem ctx was stopped with a decline of Crea-Cl <45 ml/min. The trial was in 
accordance with the local ethics. Folic acid 400 µg po/d and vitamin B12 1000 µg i.m. 
qw 9 wks was administered to prevent severe AE. All pts received best supportive care 
with pre and post hydration as well as antiemetics including 5-HT3 antagonists and 
dexamethasone according to local standard of care. Study endpoints were long term 
renal safety in patients receiving sustained therapy of Pem + DDP followed by carbo 
and/or Pem-mono. Results: Between 2002 and 2014 staging revealed AbM in 19 pts. 
Initial ctx was Pem/DDP in 18 pts, except one who died prior to Tx. Ctx with Pem was 
given a mean of 12 cycles (range 1 to 37) with a mean of 259 d(range 21 to 1151). 
Mean dose of DDP was 678 mg(range 130 to 1335). Mean S-Crea(Crea-Cl) was 0,79 
mg/dl(113 ml/min) prior and 0,95 mg/dl(97,4 ml/min) at the end of Pem/DDP. Pem/
DDP was administered >6 cycles in 8 pts up to a max. of 10 cyles. DDP was stopped 
due to a decline in S-Crea in 6 out of 18 pts (33%). Renal tox was the reason for DDP 
cessation in all pts with >6 cycles, except 1. Five pts switched then to carbo due to renal 
tox with S-Crea(Crea-Cl) of 1,1 mg/dl(83 ml/min) prior and 1,2 mg/dl(79 ml/min) at the 
end of Pem/carbo. No renal toxicity was observed in those 4 pts with Pem-mono (max 
10 cycles) subsequently after platinum ctx with S-Crea(Crea-Cl) prior 1,25 mg/dl(69 
ml/min) and 1,14 mg/dl(72,5 ml/min) respectively. Conclusion: Sustained treatment 
for AbM is feasible but limited by renal tox of DDP, while subsequent Pem +/- carbo did 
not lead to additional deterioration of renal function, allowing sustained ctx for AbM. 
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P3.08-017 Quality of Life Impact and Adverse Events after Pleurodesis in 
Patients with Recurrent Malignant Pleural Effusion Ricardo M. Terra, Priscila 
B. Costa, Pedro N. Araujo, Jose D. Andrade-Neto, Benoit J. Bibas, Paulo M. Pêgo-
Fernandes Thoracic Surgery, University of São Paulo, São Paulo/Brazil
Background: Even though pleurodesis is the gold-standard procedure to manage 
recurrent malignant pleural effusion (RMPE), little is known of its impact on the quality 
of life (QOL), adverse events, and systemic inflammatory consequences. Our main 
objective was to evaluate the impact of pleurodesis on the QOL of patients with RMPE 
and the adverse events related to the procedure. The secondary objectives were to 
evaluate systemic consequences of pleurodesis and to identify predictors of QOL 
improvement after pleurodesis. Methods: Retrospective study including data from 
patients who underwent pleurodesis from 2005 to 2014 at our Institution. QOL was 
measured through WHOQoL-Bref instrument, pain visual analog scale, and British Medical 
Research Council dyspnea scale. Adverse events were systematically registered and 
classified according to the NCI–CTCAEV.4.0. Blood tests were collected before, 2, 5, 
and 10 days after the pleurodesis. To compare continuous variables we used paired-T 
test or Wilcoxon test. To find predictors we built linear regression models. We considered 
as significant tests which p<0.05. Results: 257 patients (77% female) with mean age 
of 69 years-old(± 13.01) were included. The most frequent primary malignancies were 
breast cancer (56%) and lung cancer (25%). The sclerosing agents used were talc 
(38%), silver nitrate (36%), and iodopovidone (25%). Clinical recurrence was observed 
in 8% of the patients and mean survival was 8 months. The physical domain of QOL 
as well as pain and dyspnea scores were the most abnormal results at baseline and 
were also the variables which improved the most 30 days after the procedure 
(p<0.001 for all 3 parameters). Female gender, low pleural fluid lymphocytes count, 
and the use of silver nitrate were associated with QOL improvement. Adverse events 
occurred in 43% of the patients, and in 16.3% we observed severe events (Grade 3 
or higher). Hypoxia, renal failure, and pain were the most frequent. We observed 
significant variation in the following blood tests: C-Reactive Protein (rise), hemoglobin 
(decrease), platelets (rise), alkaline phosphatase (rise). Conclusion:Pleurodesis is 
associated with improvement of the QOL of patients with RMPE; nevertheless, it is 
also associated with high number of adverse events and systemic metabolic effects. 
Keywords: pleurodesis, quality of life, malignant pleural effusion
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P3.08-018 Clinical and Pathologic Characteristics of Bronchial Carcinoid 
Tumors: A Single Institution Review Robert A. Ramirez1, David T. Beyer1, Anne E. 
Diebold1, Maria M. Chester1, Yi-Zarn Wang1, John P. Boudreaux1, Eugene A. Woltering2, 
Ann-Porter Uhlhorn2, Pam Ryan2, Richard J. Campeau1, Lowell B. Anthony3 
1Neuroendocrine Tumor Program, Ochsner Medical Center - Kenner, Kenner/LA/United 
States of America, 2Neuroendocrine Tumor Program, Ochsner Medical Center - Kenner, 
Kenner/United States of America, 3University of Kentucky Medical Center, Lexington/United 
States of America
Background: Typical and atypical carcinoids represent about 2% of all lung tumors. 
Unlike most lung tumors, survival of patients with typical bronchial carcinoids is generally 
long but and is dependent on stage. We report the findings from the Ochsner/Louisiana 
State University (LSU) Neuroendocrine Tumor (NET) Program. Methods: A database with 
all patients who were seen at the Ochsner/LSU NET Program was queried for all bronchial 
NET patients. We included those who had confirmed pathological bronchial carcinoid and 
those who had at least one visit to our clinic. Typical and atypical bronchial carcinoids 
were defined by most recent WHO classification. Excluded were patients with large 
and small cell NETs, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, and 
inaccessible patient records. Results: One-hundred sixty-nine patients were included 
from January 1996 - March 2015. The mean age at diagnosis was 53 (range 12-92). 
There were 154 (91%) Caucasian, 10 (6%) African-American, and 5 (3%) other. Females 
represented 67% of all patients. 51% percent (86/169) were well differentiated, 12% 
(21/169) were moderately differentiated. Eighty-five percent and fifty-three percent were 
positive on PET and octreotide scanning, respectively. One-hundred fifty-five patients had 
adequate staging information. Overall survival and survival by stage and differentiation 
status is shown below. There was a statistically significant difference in survival by Ki-67 
index.
response and safety and tolerability. The study is currently enrolling across 15 countries. 
Clinical trial: NCT01870609. Results: Not applicable Conclusion: Not applicable 
Keywords: Cancer Stem Cells, Mesothelioma
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P3.08-015 Naftopidil Is Effective in the Treatment of Malignant Pleural 
Mesothelioma Koji Mikami1, Kozo Kuribayashi1, Ryuji Ieki1, Takayuki Terada1, Taiichiro 
Otsuki1, Hitomi Kamiya1, Eriko Masachika1, Akinobu Gotoh2, Tomoyuki Nishizaki3, 
Takashi Nakano1 1Division of Respiratory Medicine,Department of Internal Medicine, Hyogo 
College of Medcine, Nishinomiya, Hyogo/Japan, 2Laboratory of Cell and Gene Therapy, 
Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiya,Hyogo/
Japan, 3Department of Physiology, Hyogo College of Medcine, Nishinomiya, Hyogo/Japan
Background: Naftopidil, an antagonist of the α1A/1D-adrenoceptor, was developed as a 
drug for the treatment of benign prostate hyperplasia and hypertension, and has recently 
been shown to exert antitumor activity in a variety of cancers. We previously discovered 
that naftopidil induces apoptosis of malignant pleural mesothelioma (MPM) cells in an 
α1-adrenoceptor-independent manner, as this was not reproducible using other α1-
adrenoceptor-inhibitors such as prazosin. The present study was conducted to assess 
whether naftopidil is useful for the treatment of MPM. Methods: Cell viability of cultured 
NCI-H2052 human cells was evaluated using MTT. TUNEL staining was performed to 
detect in situ DNA fragmentation as a marker of apoptosis using an in situ apoptosis 
detection kit. Caspase activity was measured using a caspase fluorometric assay kit. 
NCI-H2052 cells were treated with naftopidil (100 µmol/L) and were subcutaneously 
inoculated into the right flank of BALB/c-nu/nu mice under pentobarbital-induced 
general anesthesia. Naftopidil was diluted with a physiological salt solution and injected 
intraperitoneally twice a week, starting 1 week after inoculation; the salt solution alone 
was used in control mice. The longer (L) and shorter (S) lengths of the induced tumors 
were measured using calipers, and tumor volume (V) was calculated according to the 
following equation: V = (L × S2) × 1/2. Results: Naftopidil reduced NCI-H2052 cell viability 
in a concentration-dependent manner and significantly increased the number of TUNEL-
positive NCI-H2052 cells compared to untreated cells. Naftopidil activated caspase-3 
and -8, but not caspase-9. Naftopidil did not affect the expression of FasL protein in 
NCI-H2052 cells. Notably, however, it did significantly increase the concentrations of 
extracellular FasL protein in a bell-shaped, time-dependent manner. Intraperitoneal 
injection of naftopidil significantly inhibited NCI-H2052 xenograft tumor growth compared 
to tumors in control mice. All mice injected with naftopidil survived 8 weeks after the first 
injection, and the drug had no effect on their mean weight. Conclusion: The results 
of the present study suggest that naftopidil induces apoptosis of NCI-H2052 cells 
by stimulating the secretion of FasL, a ligand of the death receptor Fas. This in turn 
activates caspase-8 and the effector caspase-3, leading to the inhibition of NCI-H2052 
xenograft tumor growth in vivo. This supports the concept that naftopidil could be 
developed as a therapeutic agent for the treatment of malignant pleural mesothelioma. 
Keywords: Cancer therapy, Naftopidil, FasL, malignant pleural mesothelioma
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P3.08-016 Role of Pro-Inflammatory Cells in Development of Mesothelioma 
Tatyana Chernova1, Fiona Murphy1, Xiao Ming Sun1, Sara Galavotti1, Stefano Grosso1, 
David Dinsdale1, Jonathan Bennett2, Apostolos Nakas2, Martin Bushell1, Anne E. 
Willis1, Marion Macfarlane1 1Toxicology Unit, Medical Research Council, Leicester/United 
Kingdom, 2Glenfield Hospital, Uhl NHS Trust, Leicester/United Kingdom
Background: Malignant mesothelioma is an aggressive tumour of the pleura or 
peritoneum and strongly related to asbestos exposure. Malignant pleural mesothelioma 
is the most common and occurs with a latency of up to 40 years. Long pathogenic fibres 
fail to clear through the lymph system and are retained in the pleura of the exposed 
individuals. During the long latency period, mesothelial cells remain exposed to paracrine 
signalling from inflammatory cells recruited to the fibre-retaining areas. However, the 
mechanism of malignant transformation is not well understood. Several studies have 
identified changes in defined signalling pathways in mesothelial and stromal cells, but 
the relationship between different cell types has not been explored. Methods: To 
examine the pro-oncogenic role(s) of different cell populations, the effect of primary 
fibroblasts from human mesotheliomas and fibre-activated macrophages on cellular 
signalling in normal untransformed mesothelial cells was monitored using imaging and 
immunoblotting techniques. Results: Paracrine signalling from activated fibroblasts or 
macrophages increased the levels of proliferation and motility in normal mesothelial 
cell cultures. Activation of pro-oncogenic signalling was demonstrated in the cultures 
subjected to ‘cross-talk’ with pro-inflammatory cells, including ‘horizontal transfer’ 
from activated fibroblasts. Normal mesothelial cells, co-cultured or treated with 
conditioned media from fibre-activated macrophages, also displayed signs of epithelial-
to-mesenchymal transition. The levels of growth modulators and survival rates were also 
altered in these cells. Conclusion: Thus, non-mesothelial cells instigate pro-oncogenic 
alterations in cellular signalling in target mesothelial cells. Further integral examination of 
the aberrant signalling pathways, especially at early stages of neoplasia, will provide new 
insights into the mechanisms underlying malignant transformation of the mesothelium. 
Keywords: Mesothelioma, inflammation, oncogenesis, macrophage
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chemoradiation group, all patients underwent CT imaging at one month follow-up. Among 
these patients, 7 had progressive disease (PD), 5 had stable disease (SD), and 4 had 
partial response (PR). The six-month survival rate was 12.5%. In the chemoablation 
group at one-month follow-up, 12 patients had SD and 3 patients had PR and the six-
month survival rate was 46.6%. Conclusion: Our results suggest that chemoablation 
therapy as salvage treatment after post-radiotherapy relapse is efficacious and safe. 
Keywords: mediastinal nodal metastasis, radiation therapy, chemical ablation
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P3.08-020 Clinicopathological Features of Primary Intra-Thoracic Follicular 
Dendritic Cell Sarcomas Patrizia Viola1, Katherine Vroobel2, Simon Jordan3, Andrew 
Wotherspoon2, Andrew G. Nicholson4 1Histopathology, Royal Brompton Hospital, London/
United Kingdom, 2Pathology, Royal Marsden Hospital, London/United Kingdom, 3Department 
of Thoracic Surgery, Royal Brompton and Harefield NHS Trust, London/United 
Kingdom,4Pathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart 
and Lung Institute, London/United Kingdom
Background: Follicular dendritic cell sarcoma (FDCS) is defined in the WHO as a neoplastic 
proliferation of spindle/ovoid cells with morphological and immunohistochemical 
features of follicular dendritic cells. It is a rare tumour with no clear aetiology, often 
misdiagnosed and difficult to characterise. Occasionally it occurs in association with 
the hyaline-vascular type of Castleman disease which, in such cases, is considered 
its precursor lesion. Most cases are reported in lymph nodes, however several cases 
with extranodal presentation have been described. Despite the fact that metastasis are 
common in the lung, only 7 cases have been reported as primary pulmonary FDCS. 
Surgical excision with chemotherapy is the treatment of choice giving transient, partial 
response in some cases. We report our experience within the last 15 years of 6 cases 
of FDCS arising in the mediastinum and in the lung. Methods: The study included 7 
patients referred to Royal Brompton Hospital between 2001 and 2014 with a diagnosis 
of FDCS. Criteria for inclusion were morphological and immunohistochemical: fascicles/
whorls of spindle to ovid cells with features resambling follicular dendritic cells and the 
expression of one or more specific markers (CD21, CD23 and CD35). We performed 
a broad immunohistochemical panel and we looked for the presence of Castleman’s 
disease and the type of inflammatory infiltrate in the background. Clinical information 
were obtained from hospital records and clinicians. Results: After review, we identified 
6 cases consistent with the diagnosis of FDCS, four males and two females between 
25 and 61 years old. One case was excluded because of equivocal expression of 
specific markers. Three patients presented with a mediastinal mass and one having 
two recurrences within the study period. Two patients presented with a lung mass and 
one with a radiological pleurally based mass infiltrating the lung and chest wall. Clinical 
presentation was mainly with cough and chest pain due to the location of the tumour.
Histologically all cases showed an atypical spindle cell proliferation with storiform 
pattern within a mixed inflammatory stroma. Mitotic rate was generally low except in case 
of recurrences. In three cases Castleman’s features were present in the background.
Five out 6 cases (83.3%) expressed CD21, CD35, p53 and cyclin D1, 3 cases (50%) 
expressed CD35, S100, lysozyme and bcl2 and 2 cases (33.3%) expressed KP1, PGM1, 
CD45, CD4, CD30 and bcl6. All were negative for keratins. Four cases (66.7%) were 
initially misdiagnosed as pleomorphic malignant tumour.Background showed a variably 
amount of B and T cells, with T cells expressing CD4 and PD1. Follow up data were 
available for 4 patients: one died after 5 years, 2 were alive with no recurrence after 
one year and one is alive after 8 years and two recurrences. Conclusion: FDCS is a rare 
tumour and should be considered in cases with a malingant spindle cells proliferation 
negative for the most common markers. Our series also showed Cyclin D1 expression 
in this tumour which has not previously been reported. This may raise the possibility 
for a new more effective therapeutic approach but further studies are needed. 
Keywords: Castleman disease, Cyclin D1, Follicular dendritic cell sarcoma
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P3.08-021 Bronchopulmonary Carcinoid: A Developing Nation Cancer Center’s 
Perspective Sunil Kumar1, Ashish Jakhetiya1, Palaniappan Ramanathan2, Durgatosh 
Pandey1, Svs Deo1, Nootan Shukla1 1Surgical Oncology, All India Institute of Medical 
Sciences, New Delhi, New Delhi/India, 2Surgical Oncology, All India Institute of Medical 
Sciences, New Delhi/India
Background: Bronchopulmonary carcinoids are low grade malignant tumours and 
increased incidence has been noticed worldwide. Our aim was to study preoperative 
characteristics, surgical approaches and outcome in bronchopulmonary carcinoid 
patients treated at a institutional cancer center. Methods: Twenty patients with 
bronchopulmonary carcinoids were surgically treated at department of surgical 
oncology, IRCH, AIIMS between December 2006 and December 2014. Preoperative 
variables, postoperative outcome and histopathological features were analyzed 
retrospectively. All patients underwent a detailed clinical evaluation followed by CECT 
of chest and bronchoscopy with biopsy of the suspicious lesion. After preoperative 
optimization, all patients were treated with upfront surgery. Adjuvant chemotherapy 
was given in patients with lymph nodal metastasis. Patients were followed up at three 
monthly interval with Clinical examination, chest X ray and serum chromogranin in cases 
of suspected recurrence. Because of cost factors Dotanoc scans were done only in 
cases with radiological suspicion of recurrence. Results: Patient’s median age was 
40 years (range 18-62 years). All patients were symptomatic and median duration of 
symptoms before presentation was 18 months (range 6-72 months). Eight patients 
were treated with antitubercular drugs after presumptive diagnosis outside based on 
symptoms and Xrays. All the patients had lobar or main bronchial involvement which 
Overall Survival
N Median 5-year 10-year
169 243 months 88% 74%
Survival by AJCC 7 Stage
N 5-year 10-year
I* 65 98% 91%
II* 23 95% 87%
III* 27 84% 66%
IV 40 73% 49%
Survival by Differentiation Status
Median 5-year 10-year
Well (n=86) 243 88% 81%
Moderate (n=21) 119 80% 42%
Survival by Typical/Atypical
Median 5-year 10-year
Typical (n=109) 243 months 89% 80%
Atypical (46) 126 months 84% 59%
* 
A and B stages are grouped
  
Conclusion: Overall, patients with bronchial carcinoids experience high 5 and 10-year 
survival rates. As expected, there were significant survival differences between nodal status, 
differentiation status and typical versus atypical. Interestingly, there was a statistically 
significant difference in survival between low, low-intermediate and high-intermediate 
Ki-67 values. Our analysis showed that survival rates were much better for Ki-67 index 
value ranges from 0-2% versus >2-10% versus >10-20%. As with gastroenteropancreatic 
NETs, Ki-67 index could become a valuable prognostic indicator for bronchial carcinoids. 
Keywords: carcinoid, survival, neuroendocrine, Ki-67
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P3.08-019 Chemical Ablation Therapy of Recurrent Mediastinal Metastasis 
Xinglu Xu Department of Oncology, Pingyi Branch of Qilu Hospital; Shandong University, 
Pingyi, Shandong China;/China
Background: To evaluate the treatment of post-radiotherapy recurrent mediastinal 
nodal metastasis. Methods: Post-radiotherapy thoracic cancer patients with mediastinal 
lymph node recurrence were enrolled in this study. Patients were randomized into 
the Radiation (+/- Chemotherapy) or the chemoablation group. Patients randomized 
to the chemoradiotherapy group received additional radiotherapy, second-line 
chemotherapy, or both. Patients randomized to the chemoablation group received 
CT-guided percutaneous chemical ablation. Clinical remission was assessed at one 
month by contrast CT. Reirradiation dose ranged from 2200-3600 cGy depending 
on dose limiting constraints in consideration of prior radiotherapy dose. The RECIST 
criteria were used in the evaluation of response to therapy. The median length of 
follow-up is six months. Results: Thirty-one patients were enrolled in the study. In the 
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nodal metastasis. The overall survival curve from second lung resection is shown in the 
figure (Kaplan-Meier curve, log-rank test). The 5-year overall survival rate was 46.2%, 
and the 5-year disease-free survival rate was 44.1%. Three out of 4 cases who underwent 
lung resection three times died within a year after the operation. 
 
Conclusion: A second lung resection seems to be feasible, while a third may 
not. Precise evaluation of metastatic lesions in other organs before operation 
and systemic therapy for preventing multiple metastases may be important. 
Keywords: metastatic lung cancer, colorectal carcinoma, multiple time resection
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P3.08-024 A Rare Cause of Pancoast Syndrome Aleksander Mani1, Lucy 
Cogswell2, Kathleen Swalwell1, Fiona Macleod3, Nick Athanasou4, Dionisios Stavroulias1 
1Thoracic Surgery, John Radcliffe Hospital, Oxford/United Kingdom, 2Plastic Surgery, John 
Radcliffe Hospital, Oxford/United Kingdom, 3Radiology Department, John Radcliffe Hospital, 
Oxford/United Kingdom, 4Histopathology Department, John Radcliffe Hospital, Oxford/United 
Kingdom
Background: Alveolar soft part sarcoma (ASPS) is a rare tumour that was initially 
described by Christopherson et al. in 1952. It accounts for 0.5 - 1% of all soft tissue 
sarcomas. It most commonly presents in the 15 - 35 year age group with slightly higher 
incidence in females than males by a ratio of 3:2. Methods: We describe a case of a 55-
year old woman who had a right mastectomy, adjuvant chemotherapy and radiotherapy 
3 years prior to her presentation to our service with a left sided supraclavicular mass 
that was causing shoulder pain and left upper limb paraesthesia. The patient did not 
present Horner’s syndrome. Results: Preoperative PET-CT showed a 5.8 x 4.5 x 5.5cm 
mass, moderately FDG avid (SUVmax 6.7), arising from the 1st rib. An MRI of the brachial 
plexus showed no vertebral body involvement, no vessel infiltration, but suspicion of left 
T1 nerve sheath involvement (Fig 1.). The patient underwent a CT-guided biopsy that 
classified the lesion as sarcoma. After being discussed at the local sarcoma MDT the 
patient underwent en-block complete resection of the tumour and of the posterior part 
of the first rib. Histology showed morphology typical of an ASPS which had arisen from 
the first rib and extended into the overlying soft tissues. There was nuclear expression 
of TFE3 and the (PAS+) tumour cells also unusually expressed CD68 and HMB45 as well 
as vimentin and NSE.
was detected on bronchoscopy and biopsy. Ninteen patients underwent complete 
pulmonary resection with mediastinal nodal dissection and surgical approach included 
eight pneumonectomies, four bilobectomies, five lobectomies, two sleeve resections. 
After a median follow up of 15 months, all patients were alive with no local recurrence or 
distant metastasis. On Histopathology all the resections margins were free of tumor and 
lymph nodal involvement was found in one patient. Conclusion: Delayed presentation 
and misdiagnosis are major concern in our scenario because of high prevalence of 
tuberculosis and despite a small number of cases our study emphasises the need for 
early bronchoscopy in patients with persistent symptoms. Aggressive surgical resection 
with technical approach of lung preservation may provide optimal survival results 
Keywords: bronchopulmonary carcinoid, surgery, developing nation
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P3.08-022 Atypical Presentation of a Malignant Cardiac Tumor Ionela Erhan1, 
Stefan Dumitrache-Rujinski2, Dragos Zaharia3, Adriana Iliesiu4, Horatiu Moldovan5, 
Miron Bogdan6, Diana Leonte1, Tuberiu Nanea7 1„Marius Nasta” Institute of Pulmonology, 
Bucharest, Romania, Bucharest/Romania, 2„Carol Davila” University of Medicine and 
Pharmacy, Bucharest, Romania, „Marius Nasta” Institute of Pulmonology, Bucharest, 
Romania, Bucharest/Romania, 3Carol Davila” University of Medicine and Pharmacy, 
Bucharest, Romania, „Marius Nasta” Institute of Pulmonology, Bucharest, Romania, 
Bucharest/Romania, 4„Prof. Dr. Traian Burghele” Clinical Hospital of Urology, Department of 
Internal Medicine, Bucharest, Romania, „Carol Davila” University of Medicine and Pharmacy, 
Bucharest, Romania, Bucharest/Romania, 5„Carol Davila” University of Medicine and 
Pharmacy, Bucharest, Romania,„Prof. Cc Iliescu” Emergency Institute of Cardiovascular 
Diseases”, Bucharest, Romania, Bucharest/Romania, 6Carol Davila” University of Medicine 
and Pharmacy, Bucharest, Romania ,„Marius Nasta” Institute of Pulmonology, Bucharest, 
Romania, Bucharest/Romania, 7„Prof. Dr. Traian Burghele” Clinical Hospital of Urology, 
Department of Internal Medicine, Bucharest, Romania, „Carol Davila” University of Medicine 
and Pharmacy, Bucharest, Romania, Bucharest/Romania
Background: primary cardiac tumors are very rare pathological entities with an 
incidence (autopsy and surgical biopsies reports) ranging between 0,3% - 0,7 %. 
The main histopathological type of primary malignant cardiac tumors is represented 
by angiosarcoma, usually located within right atrium. The diagnosis may be delayed 
due to nonspecific symptomatology. Most cases are presenting with metastases 
to the lung in the moment of diagnosis and a median survival is less than one year 
(between 6 and 11 months). Methods: not applicable Results: Case report: we 
present the case of a non-smoker 19-year-old man, with right atrial angiosarcoma, with 
pericardial involvement and difuse limphohaematogenous pulmonary metastasis. The 
symptomatology consisted in: cough, difuse chest pain, progressive dyspnea, night 
swets, low grade fever and hemoptoic sputum. Chest X-ray revealed a diffuse micro 
nodular pattern, a resting pulseoxymetry with mild hypoxemia, no ECG abnormalities. 
No abnormalities on the clinical examination. The differential diagnosis included mainly: 
miliary tuberculosis (high incidence of tuberculosis in Romania) and Pneumocystosis. 
Bronchoalveolar lavage shows no fast acid bacilli, no Pneumocystis cysts, no neoplastic 
cells and HIV was negative. No inflammatory syndrome, normal WBC, no anemia and 
normal biochemistry. According to this data we decided to start antituberculous 
treatment and the patient was programed for thoracic CT scan. The clinical status 
rapidly deteriorated with worsening of dyspnea, respiratory failure and hypotension. 
Chest X-ray revealed enlargement of cardiac opacity and on ECG a micro voltage with 
an alternance in the QRS complex was identified. An echocardiography was performed 
in emergency and a massive mass of tissue occupying almost the entire right atrium 
with pericardial invasion and cardiac tamponed was identified. A median sternotomy 
with pericardial drainage , pericardial and tumor biopsy where performed. The 
patient died one week later with palliative care. The autopsy showed a right massive 
atrium tumor with myocardium, epicardium, and papillary muscle invasion, difuse 
lung nodular and micronodular metastases. The hystopatological / immunochemistry 
exam diagnosed a moderately differentiated angiosarcoma expressing CD 34, CD31. 
Conclusions: Tardive diagnoses of a massive right atrium angiosarcoma with bilateral 
pulmonary metastasis. Particularity of the case: rare cardiac malignant tumor 
revealed by respiratory symptoms dues to diffuse pulmonary micronodular metastases 
Keywords: primary malignant cardiac tumor, angiosarcoma, lung metastases
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P3.08-023 Evaluation of Multiple Time Resection of Lung Metastases from 
Colorectal Cancer Kokichi Miyamoto, Masafumi Kataoka, Toshinori Ohara, Yoshihiro 
Akazai, Yasuki Nitta, Masanobu Maruyama, Hironobu Kawamoto Okayama Saiseikai 
General Hospital, Okayama/Japan
Background: Surgical resection of lung metastasis from colorectal cancer is beneficial 
for improving the prognosis of patients when no other metastatic lesions exist. However, 
the efficiency of multiple time resection of lung metastases has not yet been established. 
We investigated the characteristics and prognosis of multi-time lung resection cases 
in order to identify the appropriate indication for this procedure. Methods: Ninety-
nine patients underwent resection of lung metastases from colorectal cancer between 
1993 and 2013 at our institute. Among these patients, we investigated 26 cases who 
underwent lung resection more than twice. Results: With regard to the initial stage of 
disease, one case was stage I, 4 were stage II, 15 were stage III, and 6 were stage 
IV. Twenty-two patients underwent lung resection twice, and 4 patients underwent 
lung resection three times. The median follow-up time was 85 months (range, 36–215 
months). Twelve cases died of colorectal cancer recurrence. Eight cases died due to 
metastases to multiple organs including the liver, lymph nodes, and lung. Two cases died 
of multiple lung metastases, one died of liver metastasis, and one died of mediastinal 
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P3.08-027 Teratoid Wilms’ Tumor of the Mediastinum in an Adult Konstantinos 
Syrigos1, Ioannis Gkiozos1, Dimitra Grapsa1, Frosso Konstantinou1, Penelope 
Korkolopoulou1, Ioannis Ntanasis-Stathopoulos2, Emmanouil Merikas1, Maria 
Triantafyllou1 1University of Athens, Athens/Greece, 2Oncology, University of Athens, 
Athens/Greece
Background: Teratoid Wilms’ tumor is an uncommon histologic variant of 
nephroblastoma, which is mainly characterized by a predominance of heterologous 
components within the tumor mass, and typically located in the kidney. Extrarenal forms of 
this neoplasm are extremely rare and have been previously described almost exclusively 
in pediatric patients. Methods: We herein describe the clinical, imaging, histological 
and immunohistochemical features of a mediastinal teratoid Wilms’ tumor in a 63-year 
old female. Diagnosis was established following surgical resection and histopathological 
evaluation of the tumor specimen, along with documentation of complete absence of a 
primary renal lesion. Results: Microscopic examination of representative tumor sections 
showed the typical WT architecture consisting of blastemal, mesenchymal and epithelial 
components (fig.1). More than 50% of the tumor’s volume was occupied by a variety of 
heterologous elements. Immunohistochemistry showed positive staining of the epithelial 
tumor cells for pankeratin (fig.2a), while the blastematous component stained positive 
for CD56 (fig.2b), CD99 (fig.2c) and WT1 (fig.2d). The patient received one preoperative 
course of carboplatin etoposide, as well as eight and four postoperative courses 
of carboplatin-etoposide and cyclophosphamide-doxorubicin, respectively. Disease 
progression was noted 15 months following administration of the first chemotherapy 
cycle, and the patient died 23 months after her initial presentation.
 
Conclusion: Identification of the typical triphasic WT histology along with a predominant 
heterologous differentiation –but without evidence of unequivocal heterotopic 
organogenesis- as well as documentation of complete absence of a primary renal 
neoplasm, are all required to establish the diagnosis of this extremely rare tumor. 
Keywords: mediastinum, teratoid, Wilms’ tumor, extrarenal
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P3.08-028 Primary Large Cell Neuroendocrine Carcinoma of the Mediastinum 
Luigi Ventura1, Letizia Gnetti2, Luigi Rolli1, Michela Solinas1, Livia Ruffini3, Paolo 
Carbognani1, Enrico Maria Silini2, Michele Rusca1, Luca Ampollini1 1Thoracic Surgery, 
University Hospital of Parma, Parma/Italy, 2Pathology, University of Parma, Parma/
Italy, 3Nuclear Medicine, University Hospital of Parma, Parma/Italy
Background: to present a rare case of primary neuroendocrine carcinoma of the 
mediastinum treated by multimodal therapy. Methods: a 50-year-old man, non-smoker, 
with unremarkable past medical history, presented for asthenia, dyspnea and sub-sternal 
discomfort. A chest CT-scan showed a huge mass of 10,7x5,5x9,5cm in the anterosuperior 
mediastinum. The mass seems infiltrate both brachiocephalic veins, the superior vena 
cava, pericardium and both lungs (Fig.1a/b). PET-CT showed an intense hyperactivity of 
the mediastinal mass. CT-guided needle biopsy allows diagnosis of neuroendocrine 
carcinoma. After multisciplinary discussion, a multimodal approach was planned. The 
patient underwent 4 cycles of chemotherapy with cisplatin and gemcitabine. Since chest 
CT-scan showed a reduction of the tumor (7,4x5,6x9cm), a surgical resection was 
proposed.
 
Conclusion: Cases of primary intraosseous ASPS are rare. To our knowledge this is the 
second description in the medical literature of an ASPS arising in a rib causing Pancoast 
syndrome. Chemotherapy and radiation have not proven beneficial in the treatment of 
ASPS, although new drug trials are ongoing. Even with en bloc surgical excision and 
adjuvant therapy, 5-year overall survival ranges from 20% for patients with metastatic 
disease to 88% for patients with local disease only at the time of presentation. 
Keywords: Pancoast syndrome, alveolar soft part sarcoma, Surgical resection
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P3.08-025 Clinical and Radiographic Manifestation of PPNHL in Chinese 
Patients: Differentiation of MALT Type and DLBCL Type Yinan Yao1, Shan Lu1, Yan 
Xu2, Guangdie Yang1, Junjun Chen1, Hequan Li1, Jianying Zhou1 1Respiratory Diseases, The 
First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou/China, 2Intensive 
Care Unit, The Second Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou/China
Background: Primary pulmonary non-Hodgkin’s lymphoma (PPNHL) is a rare extranodal 
lymphoid neoplasm with few reports of Chinese patients. This study aims to analyze the 
demographic data, clinical features and radiographic presentation of Chinese PPNHL 
patients to obtain useful information for early diagnosis and differential diagnosis. 
Methods: A retrospective review of primary pulmonary non-Hodgkin’s lymphoma 
diagnosed at our hospital from February 2007 to April 2014 was performed. Results: This 
study included 34 PPNHL patients, comprising of 25 cases of mucosa-associated 
lymphoid tissue (MALT) lymphoma and 9 cases of diffuse large B-cell lymphomas 
(DLBCL). Cough and expectoration were the most common symptoms, accounting 
for 57.9% of the patients with symptoms. Nodules, masses and consolidations 
were the most frequent radiologic abnormalities and right lung is often involved. 
Pericardial effusion and bronchial abnormalities were found only in DLBCL cases. 
CT-guided percutaneous transthoracic biopsy was performed in most of the patients 
(73.5%) for diagnosis. Conclusion: The clinical features of PPNHL lack specificity. 
Imaging findings indicated that DLBCL patients tend to have an elevated incidence of 
pericardial effusion and bronchial abnormalities than MALT types. These discoveries 
provide assistance for the early diagnosis and differential diagnosis of these subtypes. 
Keywords: PPNHL, MALT, DLBCL, differentiation
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P3.08-026 Various Clinical Features in Lung Cancer, Dharmais National 
Cancer Hospital (NCH), Jakarta Fariha Ramadhaniah1, Pradnya S. Rahayu2, Evlina 
S. Sinuraya2 1Research and Development Department, Dharmais National Cancer Centre, 
Jakarta/Indonesia, 2Research and Development, Dharmais National Cancer Centre, Jakarta/
Indonesia
Background: Lungs are the respiratory system that resides in the bottom of the 
chest cavity adjacent to the heart and mediastinum. Based on Jakarta Population-
Based Cancer Registry 2005-2007, the incidence of lung cancer is ranked first in men 
and fourth in women. The frequency of lung cancer in Dharmais 1993-2007 is 4.29 % 
ranks third of all cancer incidence. Methods: Cross-sectional study began in 1993-
2007. Inclusion criteria are patients newly diagnosed of lung cancer microscopically, 
inside or outside Dharmais. Classification using the WHO-ICD-O3. Determination of 
the sample with a precision formula with a total sample is 231. Results: Distribution 
by gender, 79.65% in males and 20.35% in women, higher in the age group 
above 59 years (52.72% male and 53.19% female). Conclusion: There are 14 
variations of the main clinical features in men and 13 in women . The most common 
clinical picture of both men and women are cough, pain, and shortness of breath. 
Keywords: lung cancer, cancer registration, clinical features
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Conclusion: mid-term survival was achieved after aggressive multimodal therapy. 
Keywords: Neuroendocrine tumor, Surgery, mediastinum
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.08-029 Benign Metastatizing Leiomyoma of the Uterus: 2 New Cases Gunnar 
N. Hillerdal, Ocar Grundberg Pulmonary Diseases, Karolinska Hospital, Stockholm/Sweden
Background: Middle-aged and older women can present with dyspnoea and multiple 
well-demarcated rounded compact lesions of the lungs in different sizes, some very 
big. Investigation reveals no primary tumor but many years earlier an hysterectomi has 
been performed due to a big myoma, which was classified as benign. Biopsies of the 
lesions show the same picture. This is a very rare findings but we here present two 
cases seen recently by us. Methods: Two women with large probable metastases of the 
lungs were investigated. Results: Case 1: An exsmoking 74-year old woman was referred 
because of dyspnoea and pulmonary infiltrates. She had two lesions, one on each side 
approximately 2 cm in diameter. Laboratory tests normal .PET showed only minimal 
uptake. Needle puncture revealed leiomymatous cells with very low proliferation. Further 
questioning revealed that in 2008, an hysterectomy was performed because of a very 
large myoma, which was benign. Re-investigation of the myoma and of the biopsy from 
the lung lesion showed the same picture, and there were no signs of malignancy. Case 
2: A neversmoking 68-year old woman was referred because of cough and pulmonary 
infiltrates. Multiple rounded lesions were seen on X-ray. Biopsy showed benign cells. 
In 1986 -29 years earlier - an hysterectomy had been performed because of pressure 
symptoms and a very large benign myoma was found. Conclusion: The diagnosis of 
“Benign metastasizing leiomyoma of the uterus” was established in the two cases. 
The name is an oxymoron; from the clinical view it must be regarded as a low-grade 
malignant leiomyosarcoma. Since its first description in 1939, around 100 case reports 
have been published. In rare cases, metastases in other organs than the lungs can also 
be found. Progression is usually extremely slow, no other organs are involved, and the 
main symptom is a slowly progressive dyspnoea, The prognosis in the short run (years) 
is very good, and specific treatment is lacking. If very big, surgical removal of lesions 
should be considered. We will just follow these patients since they have no symptoms. 
Keywords: pulmonary metastases, leiomyoma
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P3.08-030 Bronchoscopic Diagnosis of Esophageal Carcinoma Mimicking Lung 
Cancer Deniz Dogan1, Nesrin Ocal1, Gurhan Taskin2, Canturk Tasci1, Ergun Tozkoparan1, 
Hayati Bilgic1 1Chest Diseases, Gulhane Military Medical Faculty, Ankara/Turkey, 2Intensive 
Care Unit, Gulhane Military Medical Faculty, Ankara/Turkey
Background: Esophageal cancers are usually determined by examining the etiology 
of symptoms. Diagnosis in people without symptoms is rare and usually incidental. 
Although the most common symptom of esophageal cancer is dysphagia, in some cases 
clinical presentation can be different or misleading. Nevertheless, most esophageal 
 
Results: a median sternotomy was performed. On exploration, both lungs were 
marginally infiltrated. The pericardium was partially excised; the left anonymous vein 
was almost totally invaded by the tumor. The right anonymous vein was infiltrated at 
the confluence with the superior vena cava. After total caval clamping (clamping time: 
27’), a partial section and reconstruction with bovine pericardium was performed 
(Fig.1c). The patient was discharged uneventfully on postoperative-day 9. The patient 
underwent 25 sessions of adjuvant radiotherapy. Currently, he’s free of disease after 
30 months. Macroscopically the mass measured 9x8x3cm, looks whitish with tense-
elastic consistency. Microscopically it showed clusters of small uniform cells, sometimes 
with cuboidal morphology, with nuclear pleomorphism and small nucleoli, arranged in 
trabeculae, nests and lobules and immersed in a hyaline stroma with foci of necrosis 
(Fig.2a). Perineural and vascular invasion were present. Immunohistochemistry 
showed the tumor cells were positive for chromogranin (Fig.2c), synaptophysin 
(Fig.2d), cytokeratins and negative for TTF1, FAP, PSA. The proliferation index Ki-67 
was 10% (Fig.2b). Considering the radiological, morphological and immunophenotypic 
characteristics, the diagnosis was consistent with primary neuroendocrine carcinoma 
of the mediastinum. 
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the reason why arm No. 3 enables good operability and ability to reach remote lesions, 
such as in the apex, diaphragm, or costophrenic angle. Moreover, between the space 
of the camera-arm and arm No. 3 make enough working space than using arm No. 1 to 
avoid conflict between arms. This use of the da Vinci S ® arms should be helpful in robotic 
procedures for thoracic surgeons in manipulating the da Vinci S ® instrument arms. 
Our recent experience has taught us that arm No. 3 is extremely useful when used as 
the main arm instead of arm No. 1. This idea should facilitate the da Vinci S®-assisted 
thoracic surgery procedures as a new effective application of robot-arm No. 3. 
Keywords: Thymoma, da Vinci® Surgical System, Robot arm, Robotic surgery
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.08-033 Expression of Excision Repair Cross-Complementation Group 1 and 
Class III β-Tubulin in Thymic Carcinoma Katsuhiro Okuda, Ayumi Suzuki, Tsutomu 
Tatematsu, Hiroshi Haneda, Satoru Moriyama, Motoki Yano, Risa Oda, Ryoichi Nakanishi 
Dept. Oncology, Immunology and Surgery, Nagoya City University Graduate School of 
Medical Sciences, Nagoya/Japan
Background: Thymic carcinoma is a rare mediastinum malignant tumor based on thymic 
epithelial cells. The complete surgical resection is considered as a best treatment for 
thymic carcinoma. However, except completely resected cases, the effective therapy 
has not been established for the advanced or relapsed thymic carcinoma. The expression 
of excision repair cross-complementation group 1 (ERCC1) and class Ⅲ β-tubulin 
(TUBB3) protein are respectively expected as an indicator for the anticancer activity 
of the platinum-based and taxane-based chemotherapy. Methods: We examined the 
expression of ERCC1 and TUBB3 protein in 40 thymic carcinoma patients who underwent 
either the surgical resection or the core-needle biopsy. We also evaluated the expression 
of ERCC1 and TUBB3 protein in 50 patients who underwent the curative resection for the 
non-small cell lung cancer (NSCLC). We investigated whether the expression of ERCC1 
and TUBB3 protein were associated with some overall survival and clinic-pathological 
factors of thymic carcinoma patients. Results: The expression of ERCC1 and TUBB3 
protein were positive in eight cases (20%) in thymic carcinoma patients. ERCC1 was 
expressed in twenty-one cases (42%), while TUBB3 was in twenty-seven cases (54%) in 
the fifty NSCLC patients. In all thymic carcinoma cases, the 3 year-survival was 67.3%. 
Only complete resection was associated with the better prognosis (p=0.0341). Other 
clinico-pathological factors including the expression of ERCC1 and TUBB3 protein 
showed no effect on the overall survival. Conclusion: High expression of ERCC1 and 
TUBB3 might be associated with resistance to the platinum-based and taxane-based 
chemotherapy. Our results suggest a possibility of better antitumor effects of the 
platinum-based and taxane-based chemotherapy on the thymic carcinoma patients. 
Keywords: ERCC1, TUBB3, chemotherapy, Thymic carcinoma
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P3.08-034 Chemotherapy and Radiotherapy in the Treatment of Malignant 
Thymomas after Subtotal Resection - Escalation of Toxicity Jan Stejskal1, Martina 
Kubecová2, Dana Dvořáková3, Vít Ulrych1, Jaroslav Vaňásek1 1Radiation Oncology, 
Regional Hospital Pardubice, Pardubice/Czech Republic, 2Radiation Oncology, Charles 
University Hospital, Prague/Czech Republic, 3Medical Oncology, Hospital Náchod, Náchod/
Czech Republic
Background: Malignant thymomas are rare tumours. The optimal therapy after subtotal 
resection is still controversial. Patients with locally advanced stages and postoperative 
residual tumours have a high risk of tumor recurrence. Adjuvant therapy using 
chemotherapy and/or radiotherapy brings contradictory results and this treatment can 
be limited by escalation of toxicity. Methods: Between 1994 and 2012 we assessed 
and retrospectively analysed a total of 36 patients. All patients underwent subtotal 
resection to various extent. Sixteen patients (44%) were treated with the standard 
adjuvant radiotherapy (RT) only (group A). In group B, twenty patients (56%) were treated 
with the sequence of chemotherapy (CT) and conformal radiotherapy (3D-CRT). The 
CT regimens consisted of doxorubicin + cisplatin + cyclophosphamide ± vincristine). 
The planned doses of 3D-CRT ranged from 50 to 60 Gy. Both of them, acute toxicities 
(acute eosophagitis-AE, radiation pneumonitis-RP) and late toxicities (lung fibrosis-
LF, heart failure-HF), were classified according to CTC v 3.0. The manifestations of 
RP were softened by oxygenotherapy, antibiotics, corticoids and pentoxifylline (PTX). 
Pentoxifylline (400 mg) was administered orally tid in patients with severe manifestation 
of RP grade 3/4. Results: The median age at the time of diagnosis was 56 (range, 
38 – 75 years). By Masaoka staging system, 8 patients were stage II (24%) and 28 
stage III (76%). The number of applied CT regimens ranged from 4 to 8 cycles. The 
median 3D-CRT dose was 55.8 Gy (range, 43.2 – 66.6 Gy). Thirty-eight percent of all 
patients (14/36) had myastenia gravis. AE of grade 1/2 was observed in 1 (6%) and 
2 (10%) patients and grade 3/4 in 2 (13%) and 3 (15%) patients in groups A vs B. 
RP of grade 1/2 was observed in 5 (31%) and 10 (50%) patients in groups A and B, 
respectively. RP of grade 3/4 was observed in 2 (13%) and 9 (45%) patients in groups 
A vs B. Median time to recover RP grade 3/4 was 4.7 months in patients without PTX 
vs 2.6 months in patients using PTX. Radiographic changes of partial LF was observed 
in 3 (19%) and 8 (40%) patients in groups A and B, respectively. HF was diagnosed 
only in one of twenty patients (5%) in group B. In this patient degenerative and fibrosis 
changes of the heart were observed, which resulted in non-congenital aortic valvular 
stenosis 31 months after 3D-CRT and CT. The patient is still alive with OOS 77 months 
since the time of the diagnosis. A better local control of the disease was observed in 
group B where the median time to tumor progression was 49 months in comparison 
with 21 months in group A (p=0.0001). Five-year survival rates were 43.7% (7/16) and 
85% (17/20) in group A vs group B, respectively (p=0.0001). Conclusion: Intensive 
cancers do not cause symptoms until they have reached an advanced stage. Here, we 
present an esophageal cancer case which suggests pulmonary malignancy with the 
clinical presentation. Methods: ‘not applicable’ Results: 68-year-old male admitted our 
clinic with loss of appetite, weight loss and chest pain complaints. He had a smoking 
history of 30 packs/year. He was using LABA + ICS because of COPD. He told that 
his complaints had started 6 months before and gradually progressed. Because of 
the bilateraly suspicious hilar enlargement in chest X-ray, thorax CT examination was 
performed. In thorax CT, a conglomerate lesion, extending from subcarinal area to the 
posterior aspect of trachea, was observed. A clear distinction of lymphadenopathy/soft 
tissue could not be made. Diagnostic EBUS (endobronchial ultrasound) was performed 
to the patient under general anesthesia. During the process, a lesion protruded into 
the tracheal lumen with irregular surface was observed and biopsy was taken from this 
area. Also, EBUS guided biopsies were taken from the soft tissue lesions observed in 
thorax CT. In PET-CT of the patient, which was performed after this procedure, increased 
focal FDG uptake (SUWmax: 27.1) in the relevant field was observed without increased 
uptake elsewhere. Histopathological evaluations of these biopsies have been reported 
as esophageal squamous cell carcinoma. Subsequently, endoscopy was performed 
by gastroenterologists. In the course ofˈd(y)oαoriNG endoscopy process, an ulcerated 
lesion, 1.5 cm in diameter and obstructing approximately 1/3 of the lumen, was observed 
on esophageal Z line at 44th cm from the incisors. The results of the biopsies taken 
from this area were also reported as esophageal squamous cell carcinoma. Thereafter, 
the patient was referred to Medical Oncology Department for oncologic treatment 
and follow-up. Conclusion: We shared this case in terms of being an informative 
example for local metastasis of esophageal malignancies presented with pulmonary 
symptoms which must be considered in differential diagnosis of intrathoracic masses. 
Keywords: bronchoscopy, esophageal carcinoma, thoracic mass, mimicking
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P3.08-031 Endobronchial Spread of Malignant Melanoma to Lungs, a Case with 
Original Images Nesrin Ocal1, Canturk Tasci1, Gurhan Taskin2, Deniz Dogan1, Levent 
Yamanel2 1Chest Diseases, Gulhane Military Medical Faculty, Ankara/Turkey, 2Intensive Care 
Unit, Gulhane Military Medical Faculty, Ankara/Turkey
Background: Malignant melanoma, result of malignant transformation of melanocytes, 
metastasis mainly to regional lymph nodes, skeletal, and nervous systems. However, 
malignant melanoma can also metastasis to lung either. These metastases usually 
reach the lungs by tumor emboli to pulmonary arteries. Endobronchial spread of 
malignant melanoma to lungs diagnosed by bronchoscopy cases have limited number 
in literature. Here we share a malignant melanoma case spread endobronchially. 
Methods: ‘not applicable’ Results: 62 years old male patient known to have malignant 
melanoma, was accepted to intensive care unit with respiratory distress and was 
intubated. In first evalution of his HRCT, consolidation and pleural effusion, constitute 
with large part of left lung’s atelectasis and less pleural effusion and partial atelectasis 
of neighbor parenchyma in right lung were seen. For both possible endobronchial 
metastasis causing airway obstruction and tumoral infiltration of parenchyma, 
bronchoscopy was performed through the endotracheal tube. Airway visualization 
revealed edema of the left main bronchus, concentrically significantly narrowed upper 
lobe, but segments were visible. Left lower lobe input was narrowed and segments 
were not visible. In entrance of left upper lobe there was an endobronchial lesion in 
brown- black color and slightly bulging form the mucosa like nevus. Transbronchial biopsy 
was taken from this nevus like formed lesion and left lung upper lobe apicoposterior. 
Both samples were reported as malignant melanoma by pathologist. Conclusion: We 
shared this case as an example of rare appearance of malignant melanoma with original 
images. We believe that this case report would be helpfull in terms of clinical practice. 
Keywords: metastasis, bronchoscopy, endobronchial, malignant melanoma
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P3.08-032 Maximizing Use of Robot-Arms in the Robot-Assisted Thoracic 
Surgery Naohiro Kajiwara, Yoshihisa Shimada, Sachio Maehara, Keishi Otani, Junichi 
Maeda, Koichi Yoshida, Yasufumi Kato, Masaru Hagiwara, Masatoshi Kakihana, Tatsuo 
Ohira, Norihiko Ikeda Surgery, Tokyo Medical University, Tokyo/Japan
Background: We have previously reported on the importance of appropriate robot-arm 
settings and replacement of instrument-ports in robot-assisted thoracic surgery. Because 
the thoracic cavity requires a large space to access all lesions in various areas of the 
thoracic cavity from the apex to the diaphragm and mediastinum and the chest wall. 
Moreover it can be difficult manipulate the da Vinci® Surgical System (Intuitive Surgical, 
Inc., Sunnyvale, CA) using only arms No. 1 and No. 2 depending on the tumor location. In 
this report, we show how robot-arm No. 3 can be used with maximum effectiveness in the 
da Vinci®-assisted thoracic surgery. Methods: Robot-arm No. 3 of the da Vinci® Surgical 
System was usually positioned on the same side of arm No. 2, and sometimes it was used 
as an assistant arm to avoid conflict with other arms in our previous report. We describe 
new effective application of robot-arm No. 3 for the da Vinci S®-assisted thoracic surgery. 
A 62-year-old man had an anterior mediastinal tumor suspected to be non-invasive 
thymoma. Instead of arm No. 1, arm No. 3 was placed in the 6th intercostal in the mid-
axillary line inserted from reverse the side, rotating it behind the body of the da Vinci® 
Surgical System. Results: Robotic surgery enables access to tumors located throughout 
in the thoracic cavity. The time required for the da Vinci S ® -setting was 12 minutes and the 
console-time (the da Vinci S ®working time) was 75 minutes. Thymectomy was performed 
successfully, and the amount of bleeding was 68 ml, and there were no complications. 
The pathological findings were thymoma, Masaoka stage II. Conclusion: Arm No. 3 has 
wider range of motion than other arms because it has one more additional joint. That is 
S755Copyright © 2015 by the International Association for the Study of Lung Cancer
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P3.08-037 Management of Thymic Neoplasm: Egyptian NCI Experience 
Hala A. Shokralla1, Ahmed E. Fathalla1, Ismail A. Mourad2 1Medical Oncology, National 
Cancer Institute, Garden City Cairo/Egypt, 2Surgical Oncology, National Cancer Institute, 
Garden City Cairo/Egypt
Background: Thymic tumors are rare entity with little information regarding outcomes 
after therapy with curative intent. We undertook a prospective analysis of all patients who 
underwent resection of thymic tumors at NCI hospitals. The optimal treatment includes 
surgical resection, chemotherapy, and radiotherapy.It is relatively uncommon(10%) but 
are highly aggressive. Methods: From 2008 to 2014, 13 patients (8 men, 5 women) 
underwent surgical resection of thymic tumor at a mean age of 47 years. Patient 
demographics, extent of surgical resection, and outcomes were compiled. Demographic 
variables, use of chemotherapy or radiotherapy, perioperative variables, recurrence 
rates, and long-term survival were analyzed retrospectively. The Masaoka stage and 
tumor diameter were recorded along with other variables that potentially influenced 
survival such tumor grade, site &number of metastatic disease. Results: The distribution 
of Masaoka stages at presentation was I in 6 (47%), II in 3 (23%), III in 1 (7%), and IV 
in 3 (23%). Neoadjuvant chemotherapy was administered to 3 patients (23%) whose 
tumors were deemed to be more locally invasive, two of them received neoadjuvant 
concomittant chemo-radiotherapy. Of the 13 patients in the surgical cohort, 8 (61.5%) 
were men. Mean age was 47 years (range: 21 to 58 years). No patient demonstrated an 
associated immunologic disorder such as myasthenia gravis. In all patients pathologic 
confirmation of thymic tumor was by CT giuded fine needle aspiration/biopsy as part of 
the diagnostic workup. Preoperatively, 3 of 13 patients (23%) received chemotherapy 
and 2 (15.5%) received radiotherapy. The decision to administer chemotherapy or 
radiotherapy preoperatively was individualized in each patient and based on the extent 
of tumor invasion. Complete tumor resection with pathologically confirmed negative 
resection margins (R0) was achieved in 12 patients (92.3%). The other 1 patient had 
microscopic residual disease (R1). Masaoka stage was I in 6 (47%), II in 3 (23%), III 
in 1(7%), and IV in 3 (23%). The most common approach to surgical resection was 
sternotomy, used in 11 patients (84.5%). Mean tumor size was 9.5 cm (range: 4.5 to 16 
cm) for the 13 patients. Pulmonary wedge resection was done for only 2 cases,pleural 
resection 5 cases& lobectomy in only 1. No perioperative deaths occurred nor patients 
required tracheostomy for postoperative respiratory failure. The two patients who had 
unilateral phrenic nerve resection as part of their operation none of these patients 
underwent a diaphragmatic plication early in the postoperative course to improve 
respiratory insufficiency. Four patients received adjuvant chemotherapy or radiotherapy 
or both. Of those whose tumors were completely resected, 1 patient experienced a local 
recurrence. SurvivalMean length of survival in the entire group was 22.7 months (range: 
14 to 36 months). At the last follow-up, 8 patients (61.5%) were alive without disease, 
1 (7.5%) was alive with disease, and 4(31%) had died. Conclusion: Thymic tumor are 
amenable to surgical therapy, With increased use of computed tomography imaging, 
patients with early-stage disease are being identified more frequently, complete surgical 
resection appears to have favorable cure rates in these patients. Patients with locally 
advanced disease can experience long-term survival with a multimodality approach. 
Keywords: thymic -tumor-egypt-NCI
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P3.08-038 Targetable Cancer-Associated Antigens for Immunotherapy in 
Malignant Pleural Mesothelioma (MPM) - Mesothelin, CA125 and WT-1 Hideki 
Ujiie1, Takashi Eguchi1, Marissa Mayor2, Kyuichi Kadota3, William D. Travis4, David R. 
Jones1, Michel Sadelain5, Prasad S. Adusumilli2 1Thoracic Service, Department of Surgery, 
Memorial Sloan Kettering Cancer Center, New York/NY/United States of America, 2Thoracic 
Service and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York/
NY/United States of America, 3Department of Diagnostic Pathology, Kagawa University, 
Kagawa/Japan, 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New 
York/NY/United States of America, 5Center for Cell Engineering, Memorial Sloan Kettering 
Cancer Center, New York/NY/United States of America
Background: Mesothelin (MSLN), CA125 (also know as mucin-16, MUC16) and WT-1 are 
cancer-associated antigens currently under investigation as targets for tumor-specific 
immunotherapy, based on published observations that antigen-specific immune 
responses to these antigens prolong survival. In solid malignancies, we (Clin Cancer 
Res 2012, 2013) and others have published the role of MSLN in promoting tumor 
aggressiveness. Additionally, MSLN has been demonstrated to interact with CA125 in 
promoting invasion and metastasis, resulting in poor clinical outcomes. In this study, we 
investigated the individual and correlative expressions of MSLN, CA125 and WT-1 in both 
epithelioid and non-epithelioid MPMs. Methods: All available H&E-stained slides from 
patients who were diagnosed with MPM (1989-2010) were reviewed; tumors were 
classified according to the WHO classification. We constructed tissue microarrays (6 
tumor cores/tumor) from 273 patients (epithelioid=224; non-epithelioid, including 
biphasic and sarcomatoid =49). MSLN, CA125, and WT-1 immunohistochemistry were 
performed, and total scores for each antigen were determined by assessing the 
combined intensity and distribution of the antigen expression. Results: Epithelioid MPMs 
demonstrated positive MSLN expression in 92% of patient samples (73% high-moderate 
expression), CA125 expression in 72% (19% high-moderate), and WT-1 in 94% (63% high-
moderate) (Fig.1A). Triple positive antigen expression was recognized in 68% of patients; 
co-expression of two antigens was demonstrated in 23% of epithelioid MPMs (Fig.1B). In 
non-epithelioid MPMs, MSLN, CA125, and WT-1 were positive in 57% (16% high-moderate), 
33% (2% high-moderate), and 98% (43% high-moderate) of patient tumors, respectively. 
Triple and double antigen co-expression were demonstrated in 29% and 33% of non-
epithelioid MPMs, respectively. Only 1% of epithelioid and 2% of non-epithelioid MPMs 
postoperative treatment leads to an improvement of the local control of this disease. 
The escalated acute toxicity, especially radiation pneumonitis, was not too serious 
and could be reduced with the benefit by application of pentoxifylline. Manifestation 
of late toxicities, predominantly lung fibrosis and heart failure, was acceptable. 
Keywords: Radiotherapy, Thymoma, toxicity, chemotherapy
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P3.08-035 Impact of Histological Subtypes on Clinical Outcome of Thymoma 
Ahmed El Bastawisy1, Maha Yahia1, Mohamed Rahouma2, Omnia Abo Elazm3, Mai 
Gad4, Jaylan Ahmed5 1Medical Oncology, National Cancer Institute, Cairo University, Cairo/
Egypt, 2Surgical Oncology, National Cancer Institute, Cairo University, Cairo/Egypt, 3Medical 
Biostatistics, National Cancer Institute, Cairo University, Cairo/Egypt, 4Pathology, National 
Cancer Institute, Cairo University, Cairo/Egypt, 5Clinical Pharmacy, National Cancer Institute, 
Cairo University, Cairo/Egypt
Background: Thymoma is a rare tumor with heterogeneous clinical outcome. We aim 
to assess if there is an arbitrary cutoff point of clinical significance to the histological 
subtypes of Thymoma Methods: this is a retrospective study including all eligible 
patients with Thymoma presenting to National cancer institute, Cairo University during 
the period from 2008 to 2015. Patients were divided in to two groups according to 
histological subtypes, first group: included patients with histological subtypes 
(AB+B1+B2) whereas second group included patients with histological subtypes (B3+C+ 
Thymic carcinoma). Endpoints were to compare the two groups with regard to clinical 
response to chemotherapy, progression free survival (PFS) and overall survival (OS) 
with concordance to standard clinicopathological factors. Results: 26 patients were 
included in the study with 69% in the first group (mean age = 45.44 years± 14.1 SD) 
versus 21% in the second group ( mean age=41.63 ± 12.53 SD).Regarding clinical 
response to chemotherapy, 11.1% in the first group showed progressive disease as 
compared to 37.5% in the second group (p=0.51). Median PFS for all thymoma patients 
was 43.1 months (median ±SD = 43.1± 20.8). there was a trend towards better PFS 
in the first group where 2 years PFS in the first group was 68.4% versus 43.8 in the 
second group, p value= 0.09. Median OS for all thymoma patients was 76.7 months, 
(median ± SD = 76.7±29.8). 2 years OS was 72.6% in the first group versus 43.8 in 
the second group. (P- Value=0.24). Conclusion: although numerically better there was 
no statistically significant difference between the first and second groups with regard 
to clinical outcome. Collaborative studies including larger sample size are warranted. 
Keywords: Clinical outcome, Histological subtypes, Thymoma
POSTER SESSION/ THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES 
WEDNESDAY, SEPTEMBER 9, 2015 - 09:30-16:30
P3.08-036 Stepwise Surgical Approach for Advanced Stage Thymoma 
Using Minimally Invasive Techniques Jos Maessen1, Marlies Keijzers1, Monique 
Hochstenbag2, Annemarie Dingemans2, M Abdulhamid3, Marc Debaets1 1Cardiothoracic 
Surgery, Maastricht University Medical Centre, Maastricht/Netherlands, 2Pulmonolgy, 
Maastricht University Medical Centre, Maastricht/Netherlands, 3Pathology, Maastricht 
University Medical Centre, Maastricht/Netherlands
Background: Complete surgical resection is the best prognostic factor for thymomas. 
In advanced stage thymomas a complete surgical resection may require mutilating 
approaches, may not be performed because of anticipated technical difficulties or may 
just be considered not achievable. Methods: Retrospective analysis of patient files 
from April 2004 till March 2015 showed 239 patients who underwent a thymectomy in 
Maastricht University Medical Center. 15 patients (6.3%) underwent thymoma resection 
for Masaoka-Koga advanced stage III or IV. In all cases minimally invasive techniques 
were employed in patients-tailored stepwise treatment approaches. Results: A 66 
years old male presented with a mediastinal mass with suspected invasion of the 
brachiocephalic vein and the ascending aorta (figure 1). Biopsy showed thymoma type 
B2/B3. Resection through sternotomy in a referral hospital was abrogated as invasion of 
the sternum was found. After the attempted resection the patient received chemotherapy 
(cisplatin-etoposid) however, the thymoma did not respond. In a multidisciplinary setting 
we decided on a bilateral robotic-assisted dissection and if successful, subsequent 
sternotomy for final removal of the giant mass. Minimally invasive dissection was 
started from the right side. With the help of the 10x magnification of the robot camera, 
the thymoma was freed from the sternum, the phrenic nerve and the major vessels. 
Macroscopic invasion of the pericardium and the brachiocephalic vein necessitated 
resection of the pericardium (12 x 4 cm) and the vein (3 cm). Complete inspection 
using the 30 degree robotic camera of both the right and left thoracic cavity revealed 
the absence of pleural metastasis, and no invasion of the phrenic nerve or the lung in 
the left thoracic cavity. An additional left-sided approach was therefore cancelled and 
sternotomy was performed to remove the specimen. Lymph nodes from the positions 
4,5,6,7,10,11 as well as from the subclavicular area, were harvested. Pathological 
examination showed a thymic carcinoma/thymoma type B3, Masaoka-Koga stage III, and 
confirmed a R0 resection. All lymphnodes were negative for metastasis. Postoperatively, 
the patient was temporarily treated with an elastic sleeve because of oedema 
of the left arm. As of the histology of the tumor, the patient received postoperative 
radiotherapy. Conclusion: Complete surgical resection in advanced stage thymomas is 
be possible using a stepwise surgical approach including minimally invasive techniques. 
Keywords: Advanced stage, robotic, Thymoma
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of obstruction, type of stent and tumor histology were considered predictors for mortality.
The median survival was analyzed by Kaplan-Meier curve. Prognostic factors of 
mortality were analyzed by Cox regression. Results: We included 42 patients (25M / 
17F) with a mean age of 54 + 11 years, that underwent 68 endoscopic procedures. 
The most common histologic types were lung cancer (n = 15; 36%), esophagus 
(n = 11; 26%) and cystic adenoid carcinoma (n = 8; 19%). Twenty-fi ve stents were 
placed. The silicone Y stent was the most common (n=14;56%). Eleven percent 
of patients required a tracheostomy. Complications occurred in 37.5% of cases; 
pneumonia (n = 10; 15%) and stent obstruction (n = 6; 9%) were the most frequent.
The median survival was 221 days. The 30-day mortality was 14%, and overall 
mortality 40%. The predictors of mortality by Cox regression were re-intervention 
procedures (HR 5.9; p <0.001; 95% CI 2:25 to 15:45), mechanical ventilation 
before the procedure (HR 7:38; p = 0.015; 95% CI: 1.46- 37) and tumor hystology 
(HR: .23; p <0.001; 95% CI: .11 - .47). Individuals with esophageal cancer had 
a signifi cant lower median survival, when compared with lung cancer and cystic 
adenoid carcinoma (94 vs 166 vs 346 days; p=0.002). Conclusion: The morbidity 
and mortality of patients submitted to endoscopic treatment of neoplastic airway 
obstruction is not negligible. Reintervention procedures, mechanical ventilation 
prior to treatment and tumor histology were signifi cant predictors of mortality. 
Keywords: survival, mortality, Airway obstruction, Cancer
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P3.11-003 Contribution of the Comprehensive Geriatric Assessment on 
Management of the Cancer Theraphy in Elderly Patients Melike Sanem Erdas Umut, 
Ülkü Yılmaz, Derya Özaydın Kızılgöz, Tuba Inal Cengiz, Irem Şerifoğlu, Yurdanur Erdoğan 
Ankara Ataturk Chest Disease and Surgery Education Training Hospital, Ankara/Turkey
Background: Lung cancer is getting more common and important especially in 6th-7th 
decade. Several recently published studies showed that eveluating the elderly patients 
with only Eastern Cooperative Oncology Group (ECOG) to manage the treatment is not 
eough. It is needed to consider this elderly group of patients precisely. In our study 
we aim to search the the clinical value of the comprehensive geriatric assessment 
of the elderly patients as a a parameter that can be used to guide the treatment 
decision. Methods: In our study 65 years old and over newly diagnosed 74 lung cancer 
patients in our hospital from April 2013 to April 2014 were included. In order to evaluate 
the comprehensive geriatric assessment, we applied the activities of daily living (ADL’s), 
instrumental activities of daily living ( IADLs), mini-mental test, mini-nutritional test, 
Yesavage depression scale and Charlson comorbidity index . Receiving treatment and 
the survival were assessed with 6 other tests and ECOG in single and multi variable 
analysis. Results: Men were 94.6 % of all patients. In this group 6.8% in small cell 
carsinoma, 90.5% in non-small cell carsinoma, 2.7 % in malignant epithelial tumour were 
diagnosed. According to ADL’s 86.5 % was independent and 13.5 % was semi-dependent 
as well as to IADLs 60.8 % was independent, 20.3 % semi-dependent and 18.9 % was 
dependent. %12.2 of the patients had malnutrition, %56.7 had malnutrition risk. The data 
provided that 54 % of all patients had severe dementia and 17.6 % has mild dementia. 
According to Yesavade depression scale 13.5% of patients were developed depression. 
Charlson comorbidity index provided the data that 2 % of patients had very high risk 
probability, 5% high risk, 42.5 % moderate, 25% low risk probability. It is found signifi cant 
the relationship between the receiving treatment and results of ADL’s, IADLs, mini-mental 
test, Yesavage depression scale, and ECOG as well as ADL’s, IADLs, mini-mental test, 
Yesavage depression scale, ECOG and mini-nutritional test and the survival in single 
variable analysis (p<0,05). In order to consider which test will have more prominent 
role to receive the treatment ,multivariable analysis was performed and only IADLs 
was found signifi cant as a determining factor for receiving or not receiving treatment 
(p=0,003). Yesavage depression scale was found more effi cient to fi nd out the factors 
affecting the survival in multivariable comparison analysis (p=0,011). Conclusion: The 
study published by Maione and collegues evaluating the relationship between functional 
status, comorbidity, life quality and the survival in 566 advanced stage non-small cell 
cancer patients showed that patients with beter IADLs ( p= 0.04) have better survival as 
similarly obtained from our study. Buccheri and his group reported the data from 133 
heterogeneous bronchogenic cancer patients developed depression,have a worse survival 
comparing with the patients having no depression. The results of our study indicates 
that assessing with ECOG is not enough for considering the treatment,but how CGA is 
important to consider it as well. Improving the life quality and the survival of the advanced 
stage elderly patients with cancer, future research requires a more wide population 
Keywords: lung cancer, comprehensive geriatric assessment, management of treatment 
in olds
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P3.11-004 Promising Effect of Olanzapine on Chemotherapy-Induced Nausea 
and Vomiting Uncontrolled with Conventional Antiemetic Therapy
Masafumi Sata1, Akimasa Sekine1, Terufumi Kato1, Ayako Takigami2, Masashi Bando2, 
Yukihiko Sugiyama2 1Respiratory Medicine, Kanagawa Cardiovascular and Respiratory 
Center, Yokohama City/Japan, 2Respiratory Medicine, Jichi Medical University Hospital, 
Simotsuke City/Japan
Background: Chemotherapy-induced nausea and vomiting (CINV) is still a major 
adverse effect especially for patients treated with highly emetogenic chemotherapy 
(HEC). In clinical practice, 5-HT3 receptor antagonist, NK-1 receptor antagonist, and 
corticosteroids are widely used to alleviate emetic episodes during chemotherapy. With 
those drugs, acute-nausea and vomiting is successfully manageable. However, late-onset 
nausea and vomiting is sometimes diffi cult to be controlled and therefore, the promising 
demonstrated absence of expression of all three antigens: MSLN, CA125, and WT-1.
 
Conclusion: Our observation from a large cohort of MPM patients inclusive of all 
histological subtypes demonstrating greater than 98% positive expression of at 
least one of the three cancer-associated antigens in epithelioid and non-epithelioid 
MPMs, with strong antigen expression and high frequency of double and triple antigen 
expression, provides rationale to develop targeted therapies to these cancer-associated 
antigens for the treatment of MPM patients We are initiaiting a phase I clinical trial 
(NCT02414269) of mesothelin-targeted T-cell therapy for MPM patients at our center. 
Keywords: Mesothelin, CA125, WT-1, Mesothelioma, Antigen Expression, Immunotherapy
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P3.11-001 Hypertension Associated with Venous Thromboembolism in Patients 
with Lung Cancer Yuhui Zhang, Yuanhua Yang, Lirong Liang, Webhui Chen, Zhenguo 
Zhai, Lijuan Guo, Chen Wang Beijing Chao-Yang Hospital, Capital Medical University, 
Beijing/China
Background: Patients with lung cancer are at increased risk of venous 
thromboembolism (VTE). Patient-related factors may help estimate an individual’s risk 
for VTE. Cardiovascular disease (CVD) risk factors increase the risk of arterial embolism, 
but it is less clear whether these factors increase the risk of VTE associated with lung 
cancer.We evaluated associations between major CVD risk factors and the occurrence 
of VTE in lung cancer patients using data from the Lung Cancer and Thrombosis Study 
conducted by the China VTE Study Group. Methods: A total of 632 hospitalized patients 
with newly diagnosed lung cancer were screened for VTE, and their major CVD risk 
factors were assessed at the baseline examination. Additionally, VTE diagnoses within 
the three months prior to recruitment were reviewed. Results: Eighty-six of the 632 
(13.6%) experienced a VTE event, and 7.8%, 3.3%, and 16.6% of the patients also 
experienced diabetes, dyslipidemia and hypertension, respectively. Hypertension was 
more frequent in patients with VTE than in those without VTE (24.4% vs. 15.4%, P=0.04). 
Multivariate logistic regression analysis, including age, sex, smoking, body mass index, 
diabetes, dyslipidemia, hypertension and white blood cell count, found that hypertension 
(odds ratio [OR] 1.8; 95% CI 1.0-3.3; P=0.041) and leukocytosis (OR 2.7; 95% CI 1.5-
4.8; P=0.001) were signifi cantly associated with VTE in different tumor histology 
models and that hypertension (OR 1.9; 95% CI 1.1-3.4; P=0.029) and leukocytosis (OR 
2.7; 95% CI 1.5-4.7; P=0.001) were also signifi cantly associated with VTE in different 
tumor stage models. Leukocytosis was linearly associated with hypertension and VTE 
(Pfor trend = 0.006), and the ORs for VTE increased with leukocytosis (all P for trend 
< 0.05). Conclusion: Hypertension was associated with the risk of VTE in patients with 
newly diagnosed lung cancer, which may be mediated by the presence of infl ammation. 
Keywords: lung cancer, venous thromboembolism, risk factors
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P3.11-002 Survival and Predictors of Mortality in Patients Submitted to 
Endoscopic Treatment of Malignant Airway Obstruction Benoit J. Bibas, Oswaldo 
G. Junior, Ricardo M. Terra, Helio Minamoto, Paulo F.G. Cardoso, Mauro F. Tamagno, 
Paulo M. Pêgo-Fernandes Thoracic Surgery, University of São Paulo, São Paulo/Brazil
Background: Neoplastic obstruction of the airways occurs in about 30% of lung neoplasms, 
and is often associated woth end-stage, or advanced disease. Nonetheless, endoscopic 
treatment of the obstruction may improve quality of life and survival in selected patients. 
The primary objective is to evaluate the median survival and the predictors of mortality 
in patients undergoing endoscopic treatment of neoplastic airway obstruction. The 
secondary objective is to evaluate the morbidity of the procedure. Methods: Retrospective 
study, from January 2010 to December 2014. All data was collected until February 
2015. We included patients with neoplastic obstruction of the trachea and bronchi, that 
underwent endoscopic treatment. Procedures were performed in the operating room 
under general anesthesia, through rigid bronchoscopy or suspension laryngoscopy.
Age, sex, neoadjuant chemo-radiotherapy, adjuvant chemo-radiotherapy, ECOG status, ASA 
status, urgent procedures, need for mechanical ventilation, reintervention procedures, site 
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(26.4% vs. 10.3%; p<0.0001). Comorbid pulmonary disease was strongly associated 
with development of pneumonia (OR=4.52, 95%CI: 4.30-4.74) and occurred more often 
in the lung cancer patients (52.1% vs. 24.0%; p<0.0001). With or without pulmonary 
disease as a comorbidity, lung cancer patients were more likely to have pneumonia than 
other solid tumor types (with – 36.0% vs. 22.8%, p<0.0001) (without – 16.1% vs. 6.4%, 
p<0.0001). Conclusion: Lung cancer patients presenting with febrile neutropenia are 
older, have more comorbidities, have a higher incidence of comorbid pulmonary disease, 
and are more likely to have pneumonia. These factors may help explain their higher 
mortality. In order to reduce the mortality of chemotherapy in lung cancer patients, 
careful pretreatment assessment and optimal supportive care during therapy are critical. 
Keywords: Infection, Comorbidity, mortality, Neutropenia
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P3.11-007 How Fit Are Lung Cancer Patients? An Observational Study of Co-
Morbidities and Physiology Matthew Evison, Stuart Britton, Haider Al-Najjar, Philip 
Crosbie, Richard Booton Manchester Thoracic Oncology Centre, University Hospital of 
South Manchester, Manchester/United Kingdom
Background: Co-morbidity is a key factor in determining prognosis and defining 
treatment in lung cancer. In the face of an ageing population and increasing prevalence of 
chronic medical conditions, lung cancer physicians will need to develop robust systems 
and services to ensure appropriate optimisation of co-morbidities during the diagnosis 
and staging pathway. The aim of this study was to provide a detailed description of co-
morbidities and physiology in a UK lung cancer population. Methods: Prospective data 
was collected on all newly diagnosed lung cancer patients at the University Hospital 
South Manchester from November 2014 and February 2015. UHSM is a regional lung 
cancer centre and diagnoses over 200 lung cancers per year. Co-morbidities were 
assessed using the Charlson co-morbidity index. Performance status, MRC Dyspnoea 
Scale, BMI and physiological parameters for the cardiorespiratory and renal systems 
were also measured. Results: 73 patients were diagnosed with lung cancer in the study 
period. Mean age was 70 years and 35 (48%) were male. 37 (51%) had radiological 
evidence of emphysema on staging CT of the thorax. Co-morbidities and physiological 
parameters for the patient cohort are presented in tables 1 & 2.
Table 1: Charlson Co-morbidity Index
n = 73 n (%)
0 9 (12%)
1-2 26 (37%)
3-4 16 (22%)
5-6 12 (16%)
≥7 10 (14%)
Chronic pulmonary disease 27 (37%)
Myocardial Infarction 14 (19%)
Cerebrovascular disease 13 (18%)
Diabetes without end-organ damage 10 (14%)
Congestive cardiac failure 7 (10%)
Peripheral vascular disease 7 (10%)
Moderate-severe CKD 5 (7%)
Dementia 3 (4%)
Diabetes with end-organ damage 3 (4%)
Connective tissue disease 3 (4%)
Chronic liver disease 2 (3%)
Lymphoma 1 (1%)
drugs is needed. Olanzapine is an antipsychotic agent which is approved for schizophrenia 
and bipolar disorder in Japan. Recently, the combination therapy with olanzapine and the 
conventional anti-emetic drugs has been reported highly effective to prevent late-onset 
CIMV after HEC. However, it remains unclear whether olanzapine is really effective for 
patients who develop acute- or late-onset CIMV after HEC. Methods: All consecutive 
patients, who were treated with HEC and olanzapine at Jichi Medical University Hospital 
from January 2014 to December 2014, were included. “Antimetic Response” was 
defined as the absence of nausea and vomitting, no use of breakthrough antiemetic 
medications, or increased dietary intake (≧50%). The details of clinical information were 
reviewed from the medical records . Results: Among 18 patients treated with HEC and 
olanzapine as antimetic medication, 11 were males and 7 were females, with a median 
age of 60.5 years (42-74 years). Primary tumors were non-small cell lung cancer in 11 
cases, small cell lung cancer in 5, malignant mesothelioma in one case, and embryonal 
carcinoma in one case. Olanzapine was used for preventing CINV in 8 patients with the 
previous experience of late-onset CINV and in 2 patients without, for treating late-onset 
CINV in 6 patients and acute onset CINV in 2 patients. “Antiemetic response” has been 
observed in 15 patients (83.3%). Among 8 patients previously experiencing late-onset 
CINV, “Antimetic response” was obtained in 7 patients(87.5%). Conclusion: Our results 
strongly suggest the olanzapine provides an additional effect on CINV uncontrolled 
with conventional antiemetic therapy, regardless of whether CINV is acute or chronic. 
Keywords: olanzapine, highly emetogenc chemotherapy, chemotherapy-induced nausea 
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P3.11-005 Symptom Distress, Anxiety and Depression in Patients with NSCLC 
Undergoing Adjuvant Chemotherapy after VATS Lobectomy Hao Wang1, Xiaoxia 
Jiang2 1Thoracic Surgery, Shanghai Zhongshan Hospital, China/China, 2Thoracic Surgery, 
Shanghai Punan Hospital, Shanghai/China
Background: The aim of this study was to investigate the symptom distress, anxiety 
and depression in patients with NSCLC undergoing adjuvant chemotherapy after 
VATS lobectomy. Methods: A total of 62 patients undergoing adjuvant chemotherapy 
from January 2013 to December 2014 after VATS lobectomy were enrolled. The M.D. 
Anderson Symptom Inventory (MDASI) and the Hospital Anxiety and Depression Scale 
(HADS) were used to assess the patients, symptom distress, anxiety and depression 
condition. Results: The patients averagely scored 3.02 points in symptom items, and 
2.58 points in interference items, with the scores being positively correlated with 
anxiety and depression respectively (P<0.01 for both). The patients mainly reported 
symptoms of alopecia, lack of appetite, dyspnea, etc. Conclusion: Symptom 
distress is commonly seen in patients with NSCLC undergoing adjuvant chemotherapy 
after VATS lobectomy. And symptom distress, anxiety and depression react 
upon each another. Therefore physicians should pay more attention to these 
patients, mental state and guide them to rationally release their emotions. 
Keywords: VATs lobectomy, adjuvant chemotherapy, symptom distress
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P3.11-006 An Analysis of Factors Associated with in Hospital Mortality in Lung 
Cancer Chemotherapy Patients with Neutropenia Julia Cupp1, Eva Culakova2, 
Marek Poniewierski3, David Dale4, Gary Lyman2, Jeffrey Crawford1 1Medicine, Duke 
University Medical Center, Durham/NC/United States of America, 2Fred Hutchinson Cancer 
Research Center, Seattle/WA/United States of America, 3Fred Hutchinson Cancer Research 
Center, Seattle/United States of America,4University of Washington, Seattle/WA/United 
States of America
Background: Febrile neutropenia is considered a severe complication of cancer 
chemotherapy, and one for which lung cancer is frequently associated with higher mortality 
rates than other solid tumors. The focus of this analysis was to identify risk factors most 
associated with in-hospital mortality and to describe their impact on mortality in patients 
with lung cancer. Methods: Hospitalization data from the University Health Consortium 
database inclusive of the years 2004-2012 from 239 US medical centers were analyzed. 
The study population included all adult patients with solid tumors who had neutropenia. 
Cancer type, presence of neutropenia, comorbidities, and further subgroups were based 
on ICD-9-CM codes. The primary study outcome was in-hospital mortality in lung cancer 
patients vs. other solid tumors. Further analysis concentrated on comparisons of the 
two groups with respect to number and type of comorbidities, occurrence of sepsis, 
pneumonia, or any infection, and ICU stay and influence of these factors on mortality. 
Differences between the groups were compared using chi-square test. Results: The 
analysis was based on 61,086 adult patients, including 11,111 lung cancer patients and 
49,975 patients with other solid tumors. Overall 4290 (7.0%) patients died. Lung cancer 
was the tumor type associated with highest mortality (11.2%, compared with other solid 
tumors, 6.1%; p <0.0001) Lung cancer patients were older: 50% of lung cancer patients 
were over age 65, compared to 31.6% of patients with other solid tumors (p<0.0001). 
Lung cancer patients were more likely to have multiple (≥2) comorbidities than patients 
with other solid tumors (57.3% vs. 37.3% p<0.0001). The risk of mortality was directly 
related to the number of comorbidities (ranging from mortality risk of 0.9% for patients 
with 0 comorbidities to 35.2% for patients with 5 or more). The comorbidity-mortality 
relationship was observed in lung cancer patients as well as patients with other solid 
tumors, and the association persisted after adjusting for multiple covariates, including 
age. Even independent of number of comorbidities and age, lung cancer patients had 
higher mortality (Odds Ratio (OR)=1.38, 95%CI: 1.28-1.48). Four risk factors for mortality 
in addition to number of comorbidities were identified: pneumonia, sepsis, any documented 
infection, and ICU stay. Pneumonia occurred more commonly in the lung cancer patients 
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P3.11-009 Lung Cancer in Nepal: Five Years Review from a Tertiary Cancer 
Center of Nepal Rashmey Pun1, Madan K. Piya2, Sandhya Chapagain2 1Clinical Oncolgy, 
National Hospital and Cancer Research Center, Kathmandu/Nepal, 2Clinical Oncology, 
National Hospital and Cancer Research Center, Kathmandu/Nepal
Background: Lung cancer is the leading cause of cancer related morbidity and 
mortality in both the sexes in Nepal. It accounts for 15.4 % of total cancer as per hospital 
based Cancer Registry in Nepal. The purpose of this study was to review the patient 
characteristics and sociocultural factors and their influences in lung cancer cases 
presenting to the National Hospital and Cancer Research Center of Nepal. Methods: A 
retrospective cross-sectional study was done for the lung cancer cases from January 
2009 to May 2014. 72 cases were identified by searching through inpatient records at 
the National Cancer Hospital but only 43 cases were selected for the analysis purpose 
due to lack of complete data in other remaining cases. Mean age, gender, ethnicity, 
locality, smoking habits, histological cell types and staging of the lung cancer patients at 
the initial presentation time were evaluated. Data were analyzed using SPSS statistical 
software. Results: The highest incidence of lung cancer is seen between 61-80 years 
of age (62.7%). There was no significant difference between the number of cases 
among male (51.16%) and female (48.83%). Majority of cases were from central part 
of the country near capital city (76.7%) whereas eastern and the entire western regions 
contributed to 7.1% and 16.2% cases respectively which clearly shows the lack of 
easy accessibility among patient for treatment at tertiary cancer center. People from 
Newar (39.5%) and Chettri (30.2%) ethnic origin were among the group with highest 
incidence of lung cancer in our study. 79.06% were smoker than compared to 20.93% 
who were non-smokers. 76.47% of patient started smoking at age between 10-20 years. 
85.29% of the patients consumed local brand cigarettes which has either poor filter or 
no filter at all. 88.37% of the patients were diagnosed with Non Squamous lung Cancer 
(NSCLC) and 11.62% were diagnosed with Small Cell lung Cancer(SCLC). In NSCLC 
majority had squamous cell carcinoma (68.42%) and adenocarcinoma (31.57%). 86.84% 
of the patients were diagnosed with advanced stage III/IV lung cancer at the time of 
presentation to the hospital which shows significant delay in getting early diagnosis 
and treatment in majority of patient with the lung cancer. Conclusion: Because of 
the negligence for the simple cough patient tend to come to see the doctors late. 
The other reason for late presentation (stage III and IV) being the terrain and lack of 
diagnostic facilities in many parts of the country. Other important aspect of late 
presentation is treating the lung lesions as Pulmonary TB by the general physicians 
because of TB being one of the most common pulmonary diseases in the country. 
Such a study in larger scale would be beneficial for the implementation of awareness 
campaign, early detection, and treatment of the disease at the possible early stage. 
Keywords: Lung cancer,, awareness, sociocultural factors, Staging
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P3.11-010 Palliative Surgical Resection for Infection Superimposed on 
Malignancy Erica Blustein1, Konstantinos Arnaoutakis2, Matthew Steliga3 1Thoracic 
Surgery, University of Arkansas, Little Rock/AR/United States of America, 2Winthrop P. 
Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock/United 
States of America, 3Winthrop P. Rockefeller Cancer Institute, University of Arkansas for 
Medical Sciences, Little Rock/AR/United States of America
Background: Typically, resection of non-small cell lung cancer (NSCLC) is done solely 
for curative intent. Rarely, a patient may benefit from aggressive palliative resection when 
non-oncologic conditions pose a greater threat to health and quality of life. A 59 year 
old man with cT3N1M1 NSCLC suffered from fevers, and relentless cough productive 
of copious foul sputum secondary to tumor necrosis and abscess (Fig. 1). Infectious 
symptoms worsened despite intravenous antibiotics. Clinical staging also suggested 
adrenal metastasis.
Table 2: Fitness and physiological parameters
PS 0-1 45 (62%)
PS 2-4 28 (38%)
MRC Dyspnoea Scale 1-2 38 (52%)
MRC Dyspnoea Scale 3-5 35 (48%)
BMI <20 17 (23%)
BMI 20-30 34 (47%)
BMI >30 22 (30%)
FEV1 % predicted, mean 77.1 ±26.7
FEV1:FVC 62.1 ±14.6
DLCO % predicted, mean 72.0 ±21.2
Shuttle walk distance, metres, mean 366 ±154
Lowest O2 sats during shuttle, %, mean 92 ±4.1
Peak VO2 % predicted, mean 71.7 ±17.8
Estimated glomerular filtration rate 75.4 ±18.9
Revised cardiac index ≥3 9 (12%)
 
Conclusion: Chronic respiratory disease and disability is a major component of co-
morbidity and physiological impairment in lung cancer patients. Cardiovascular disease 
and abnormalities in BMI are also highly prevalent. These results inform the need for rapid 
and reliable access to prehabilitation and dietetic services, robust cardiorespiratory 
physiological testing and specialist cardiovascular teams for all lung cancer physicians. 
Keywords: lung cancer, Co-morbidities
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P3.11-008 An Assessment of the Frequency of Palliative Procedures in 
Thoracic Surgery Gabriel Arevalo, Richard Freeman Thoracic Surgery, St Vincent 
Hospital, Indianapolis/United States of America
Background: Palliative care is a medical specialty focused on improving the quality of 
life of patients and their families with life threatening illness by preventing or relieving 
suffering. An assessment of a thoracic surgery service was performed to identify the 
scope and frequency of care that was considered palliative and any implications the 
findings might have on the current thoracic surgery residency curriculum. Methods: A 
retrospective review of a prospectively collected database of general thoracic surgery 
procedures performed over a five year period at a single institution was performed. 
Procedures considered palliative were reviewed for demographics, diagnoses, 
palliative prognosis score, treatment, morbidity, operative mortality and survival. 
Excluded were referrals from thoracic surgery to other specialties for palliative 
procedures. Results: During the study period, 3842 procedures were performed 
of which 884 (23%) were palliative. Indications included pleural and/or pericardial 
effusion, dysphagia, hemoptysis, tracheobronchial obstruction, bronchopleural fistula 
and tracheoesophageal fistula. The majority was related to a malignancy. Only 127 
patients (14%) had a palliative care assessment prior to thoracic surgery consultation. 
Mean survival following thoracic surgery intervention was 110 days for patients with 
malignancy. Conclusion: This investigation found that thoracic surgeons commonly 
care for patients when the intention is palliation. The majority of these patients have 
an associated malignancy, a poor performance status and a significantly decreased 
survival compared to the general population. Thoracic surgeons should be familiar with 
the concepts of palliative care and consideration should be given to expanding exposure 
to the principles of palliative care in the cardiothoracic residency training curriculum. 
Keywords: palliative thoracic surgery,
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Results: The patient tolerated resection very well, and was home without complication 
in 8 days. Infectious symptoms promptly cleared. He underwent six cycles of carboplatin 
and paclitaxel, without significant toxicity. CT and bone scan revealed no evidence of 
disease 18 months post-resection. Conclusion: In some NSCLC patients whose greatest 
threat to health and quality of life is related to complications such as lung abscess, 
focusing on clearing the infection rather than strictly adhering to oncologic curative 
intent criteria may improve quality of life, alleviate symptoms and improve survival. In 
this particular case, the patient had a relentless cough of putrid sputum and fevers. 
He was not a candidate for curative resection due to adrenal metastasis and positive 
pleural cytology. A palliative resection could be justified, as his symptoms were 
severe, potentially able to be resolved with surgery, and no other treatment options 
were available. Following resection, the infection cleared, and symptoms resolved. He 
then tolerated chemotherapy with a favorable response and over 18 month survival. 
Keywords: Surgery, Palliative, quality of life
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P3.11-011 Mesenchymal Thoracic Neoplasma Presenting as a 
Thromboembolism Ana Laura Ortega Granados, Nuria Cárdenas Quesada, Natalia 
Luque Caro, Tamara Díaz Redondo, Capilla De La Torre Cabrera, Yéssica Plata 
Fernández, Francisco José García Verdejo, Irene González Cebrián, Pedro Sánchez 
Rovira Medical Oncology, Complejo Hospitalario de Jaén, Jaen/Spain
Background: In the screening of the possible etiology of pulmonary embolism rule out 
the presence of an occult neoplasia. Tumors more often associated with thrombotic 
phenomena are lung, pancreas and colon. The pulmonary artery sarcoma is a rare entity 
and its clinical diagnosis is complex. Methods: We report a case of a non-smoker 71 
years old woman. In 1999 suffers first episode of thrombophlebitis. Since then presents 
several episodes of DVT in the lower limbs so it was anticoagulated with acenocumarol. 
In October 2014 she was admitted due to costalgia and fever and suspected diagnosis of 
pneumonia. She told a 3 months history of asthenia and progressive edema of the lower 
limbs. It is performed thoracic CT, with a massive pulmonary thromboembolism. The 
doppler sonography of lower limb show a chronic thrombosis. After clinical stabilization 
she was put under rivaroxaban. At 15th admission day, she starts with dyspnea with 
chest discomfort, and respiratory failure was found. In an urgent CT was shown a 
progression of the known embolism. Being a massive thrombosis refractory to treatment 
and progressive elevation of pulmonary pressure, surgeon was consulted, and is was 
performed a thromboendarterectomy and a pulmonary artery homograft replacement. In 
the pathology report, is reported a intermediate-grade sarcoma, suggestive of intramural 
primary origin and intimal type intimal grade. In January 2015 CT shows progression 
of local disease, and is discussed in the tumor board, considering unresectability of 
disesase, and it is proposed to start palliative chemotherapy Results: The pulmonary 
artery sarcoma is a rare disease, since its first description in 1923, there have been 
documented 200 cases. It can be classified according to their location relative to 
the vessel wall, or by histologic subtype. Usually located in the main pulmonary 
artery, diagnosis and complications arise from its intraluminal extension. Up to 50% 
of cases have pulmonary and mediastinal metastases at diagnosis and distant 
metastases in 16-19% It is an entity with very similar clinical and radiological features 
a thromboembolism, a fact that probably contribute to underdiagnosis. The symptoms 
are dyspnea (72-100%), chest pain (35-45%) and hemoptysis (15-24%), weight loss 
(21%), asthenia (10%) and fever (8%). The prognosis is poor, with survival reported 
between 6 months and 2 years (median 17 months) The treatment of choice is surgical 
approach, by pulmonary endarterectomy, lobectomy or pneumonectomy, with or without 
reconstruction of the pulmonary artery. In most cases R0 resection is not achieved. 
The role of radiotherapy (RT) and chemotherapy (CT) is not yet well defined. Regarding 
chemotherapy schedules, it have been used traditionally active drugs for the treatment 
of sarcomas Conclusion: The pulmonary artery sarcoma is a rare disease that should 
be suspected in patients with progressive or refractory pulmonary thromboembolism. 
Keywords: sarcoma, thromboembolism, pulmonary artery
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P3.11-012 Improving Clinical Trial Awareness in NSCLC: Pilot Testing a Novel 
Healthcare IT Platform for Incorporating Education at the Point of Care 
Joshua Bauml1, Victoria Sherry1, Jun Mao1, Susan Q. Li1, Jessica Rearden2, William 
Dudley3, Karen Hammelef4, Carrie T. Stricker4, Corey J. Langer1 1Abramson Cancer Center 
at the University of Pennsylvania, Philadelphia/PA/United States of America, 2University 
of Pennsylvania School of Nursing, Philadelphia/PA/United States of America, 3Piedmont 
Research Strategies, Inc, Greensboro/NC/United States of America, 4On Q Health, Inc, Bay 
Harbor/FL/United States of America
Background: Cancer clinical trial (CCT) participation is critical to improving the care 
of patients with Non-Small Cell Lung Cancer (NSCLC), yet low participation in CCTs 
persists. Little is known about the specific barriers to CCT participation among patients 
with NSCLC. The On Q Care Planning System (CPS) is an electronic tablet based 
platform adapted to address potential barriers to CCT participation through algorithm-
driven identification of and education about patient specific CCTs at the point of care. 
The primary objectives of this study were to 1) characterize knowledge, attitudes and 
beliefs about CCTs among patients with NSCLC and their providers and 2) evaluate 
the impact of the CPS on CCT participation. Methods: We performed a multi-site pilot 
implementation project of CPS as a clinical decision support and patient education tool. 
Patients were eligible if they had recurrent/metastatic NSCLC. The CPS contained clinical 
trial eligibility criteria for many CCTs in NSCLC open at the primary research site, as well 
as selected CCTs from surrounding cancer centers. Study aims were evaluated using 
 
Methods: Cytology of pleural fluid was positive and right upper lobectomy revealed 
pT3N1 poorly differentiated squamous cell carcinoma. The specimen opened ex vivo was 
consistent with necrosis and abscess (Fig. 2).
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patient and provider self-report surveys. Knowledge, attitudes and beliefs about CCTs 
for both patient’s and provider’s was captured through self-assessment surveys, using 
a combination of true/false questions and 1-5 Likert scale measures where 5 indicated 
highest level of agreement. Effect of CPS on CCT enrollment was measured by rate of 
enrollment in CCTs following the intervention, compared to historical rates of NSCLC 
CCT participation at our institution. Results: From April 2015 through July 2015, 9 
providers (medical oncologists and nurse practitioners) and 79 patients with recurrent/
metastatic NSCLC have been enrolled from 2 participating cancer centers. While 
providers reported being aware of open CCTs (mean score (m)=4.6), they felt that lack 
of adequate information about CCTs (m=3.0) and having time to review eligibility (m=2.6) 
were key barriers to CCT enrollment. Patients agreed that there were both the personal 
(m=3.7) and societal (m=4.1) benefits of CCTs. Similar to providers, key barriers to 
CCT participation for patients centered around lack of knowledge (concern about not 
knowing what drug they would receive (m=3.5) and that CCT agents would be too toxic 
(m=3.2)). Of the patients enrolled, 22 were at a point of new treatment or change in 
treatment and thus evaluable for rate of CCT referral and enrollment. In this subgroup, 21 
(95.5%) received care plans with CCT recommendations. Following the study intervention 
visit, 8 (36.4%) of evaluable patients enrolled in a clinical trial. This compares favorably 
both with historical rates at our institution, where 13.8% of treatment eligible patients 
with lung cancer have been enrolled in CCTs, and with national averages which are less 
than 5%. Conclusion: CCT enrollment is critical to advancing the treatment of NSCLC, 
yet CCT enrollment in NSCLC remains low. For both providers and patients, the lack 
of readily accessible information about clinical trial eligibility and protocol details is a 
major barrier to CCT enrollment. The CPS is specifically designed to address these 
barriers. Indeed, in this pilot study, we showed a promising rate of CCT accrual with 
the use of the CPS. These findings should be validated in larger, randomized studies. 
Keywords: clinical trial enrollment, Technology, Attitudes and Beliefs, Patient Education
